FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Cao, YW
   Li, YX
   Zhang, N
   Hu, JM
   Yin, L
   Pan, ZM
   Li, YC
   Du, XM
   Zhang, WJ
   Li, F
AF Cao, Yuwen
   Li, Yixiao
   Zhang, Na
   Hu, Jianming
   Yin, Liang
   Pan, Zemin
   Li, Yucong
   Du, Xiaoming
   Zhang, Wenjie
   Li, Feng
TI Quantitative DNA hypomethylation of ligand Jagged1 and receptor Notch1
   signifies occurrence and progression of breast carcinoma
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Jagged1; Notch1; methylation; expression; occurrence; progression;
   breast cancer
ID PROGNOSTIC-SIGNIFICANCE; EPIGENETIC REGULATION; METHYLATION PATTERNS;
   CANCER; EXPRESSION; JAG1; METASTASIS; CLEAVAGE; PATHWAY; GENES
AB Methylation alterations of Jagged1 and Notch1 genes have been reported in non-tumor lesions and a few cancers. However, methylation profiles of Jagged1 promoter and Notch1 exon25 in breast cancer and matched normal tissue and the association of methylation with clinicopathological characteristics still remain unclear. To explore the potential effects of aberrant DNA methylation of Jagged1 and Notch1 on occurrence and progression of breast cancer, we detected the quantitative DNA methylation of Jagged1 and Notch1 in 73 breast cancer (BC) and 20 adjacent normal breast tissues (ANBT) by using MassARRAY spectrometry. The methylation level of overall and majority individual CpG sites of the two genes were synergistically significantly lower in BC than in ANBT. The overall hypomethylation of the two genes, particularly of Jagged1 CpG_8.9.10 and Notch1 CpG_14.15.16 in primary tumors, were markedly associated with lymph node metastasis, advanced stage and high grade. The protein expressions of the both genes were examined by immunohistochemical staining in same cohorts. The expression was significantly inverse correlation with methylation. The two proteins in primary tumor were synergistically upregulated and dramatically related to lymph node metastasis, advanced stage and high grade. Our findings suggest that the synergetic hypomethylation of Jagged1 and Notch1 genes, especially of Jagged1 CpG_8.9.10 and Notch1 CpG_14.15.16, may involve tumorigenesis and development of breast cancer. The negative relationship between methylation and expression indicates methylation role for expression regulation. The synergetic overexpression of the two proteins further indicates the effects on occurrence and progression of breast cancer.
C1 [Cao, Yuwen; Li, Yixiao; Zhang, Na; Hu, Jianming; Li, Yucong; Du, Xiaoming; Zhang, Wenjie; Li, Feng] Shihezi Univ, Sch Med, Dept Pathol, Shihezi 832000, Xinjiang, Peoples R China.
   [Cao, Yuwen; Li, Yixiao; Zhang, Na; Hu, Jianming; Li, Yucong; Du, Xiaoming; Zhang, Wenjie; Li, Feng] Shihezi Univ, Minist Educ, Key Lab Xinjiang Endem & Ethn Dis, Shihezi 832000, Xinjiang, Peoples R China.
   [Yin, Liang] Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Endocrinol & Metab, Shihezi 832000, Xinjiang, Peoples R China.
   [Pan, Zemin] Shihezi Univ, Sch Med, Dept Biochem & Mol Biol, Shihezi 832000, Xinjiang, Peoples R China.
C3 Shihezi University; Shihezi University; Shihezi University; Shihezi
   University
RP Li, F (通讯作者)，Shihezi Univ, Sch Med, Dept Pathol, Shihezi 832000, Xinjiang, Peoples R China.
EM fengli7855@126.com
RI Zemin, Pan/R-3238-2019; Zhang, Wenjie/O-5336-2014
FU Natural Science Foundation of China [81260301]; First Affiliated
   Hospital of Shihezi University School
FX This work was supported in part by the Natural Science Foundation of
   China (No. 81260301) and The First Affiliated Hospital of Shihezi
   University School.
CR Acharyya S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012479
   Artavanis T, 1995, SCIENCE, V268, P225
   Brait M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070878
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Cao YW, 2015, KAOHSIUNG J MED SCI, V31, P70, DOI 10.1016/j.kjms.2014.11.008
   Cao YW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0097-2
   Cortese R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026002
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Cowling VH, 2010, ONCOGENE, V29, P930, DOI 10.1038/onc.2009.368
   Cui XB, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-20
   Cui ZL, 2013, INT J IMMUNOPATH PH, V26, P371, DOI 10.1177/039463201302600210
   Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785
   Edge S.B., 2010, AJCC cancer staging manual, V649
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Felician G, 2014, CIRC RES, V115, P636, DOI 10.1161/CIRCRESAHA.115.304517
   Fu Y, 2014, ONCOTARGET, V5, P6701, DOI 10.18632/oncotarget.2239
   Fujiwara S, 2014, ONCOTARGET, V5, P3919, DOI 10.18632/oncotarget.2002
   Ganapathi SK, 2014, BRIT J CANCER, V111, P1581, DOI 10.1038/bjc.2014.477
   Gao S, 2007, J ORAL PATHOL MED, V36, P173, DOI 10.1111/j.1600-0714.2007.00520.x
   Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0
   Kuang SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061807
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lakhani S.R., WHO Classification of Tumours of the Breast, VFourth
   Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485
   Bellido ML, 2010, BIOL REPROD, V82, P745, DOI 10.1095/biolreprod.109.082271
   Moarii M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103986
   Piazzi G, 2011, ONCOTARGET, V2, P1291
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Rauen T, 2012, J BIOL CHEM, V287, P42525, DOI 10.1074/jbc.M112.425371
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3
   Reister S, 2011, STEM CELLS DEV, V20, P1687, DOI 10.1089/scd.2010.0418
   Shargh SA, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0250-y
   Tang YP, 2012, ANTICANCER RES, V32, P4861
   Terragni J, 2014, EPIGENETICS-US, V9, P842, DOI 10.4161/epi.28597
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Uekusa S, 2014, INT J ONCOL, V44, P1669, DOI 10.3892/ijo.2014.2340
   van Breda SG., 2014, Arch Toxicol
   Wang Yong-chuan, 2012, Cancer Biology Medicine, V9, P128, DOI 10.3969/j.issn.2095-3941.2012.02.009
   Zhang Na, 2011, Chinese Journal of Pathology, V40, P324, DOI 10.3760/cma.j.issn.0529-5807.2011.05.009
NR 40
TC 6
Z9 8
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2015
VL 5
IS 5
BP 1621
EP U61
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CN3YJ
UT WOS:000358364200005
PM 26175933
DA 2025-01-12
ER

PT J
AU Li, CH
   Tang, LP
   Zhao, LJ
   Li, LL
   Xiao, Q
   Luo, XR
   Peng, WY
   Ren, GS
   Tao, Q
   Xiang, TX
AF Li, Chunhong
   Tang, Liping
   Zhao, Lijuan
   Li, Lili
   Xiao, Qian
   Luo, Xinrong
   Peng, Weiyan
   Ren, Guosheng
   Tao, Qian
   Xiang, Tingxiu
TI OPCML is frequently methylated in human colorectal cancer and its
   restored expression reverses EMT via downregulation of smad signaling
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Tumor suppressor; OPCML; methylation; cancer
ID EPITHELIAL OVARIAN-CANCER; CPG ISLAND METHYLATION; TUMOR-SUPPRESSOR;
   BREAST-CANCER; GENE; RECEPTOR; CHROMOSOME-11; DECITABINE; CARCINOMA;
   GROWTH
AB Emerging evidence has indicated that the expression of OPCML gene is frequently altered in a variety of cancers. We previously demonstrated that the OPCML gene is a target of epigenetic inactivation and its gene product exhibits tumor-suppressive properties. However, little is known regarding the effects and mechanisms of OPCML in colon cancer. We show that the loss or downregulation of OPCML is associated with its promoter hypermethylation. Methylation of the OPCML promoter was detected in all tumors and tumor-adjacent tissues, but lower methylation in normal colon tissues. The drug-induced release of epigenetic silencing was able to restore OPCML expression and the re-expression led to the suppression of cell growth. Furthermore, the increase in OPCML expression reversed a partial epithelial-to-mesenchymal (EMT)-like transition. Cell migration and invasiveness were also inhibited in response to OPCML upregulation. These actions were mediated through the inactivation of TGF beta-Smad signaling pathways. In addition, OPCML expression was associated with two upstream nuclear receptors (ERRa and RORa). Altogether, our study reveals OPCML as a potential tumor suppressor gene epigenetically silenced in colon cancer. Our study will help to elucidate the anti-invasive mechanisms of OPCML and establish new chemotherapeutic strategies for human colon cancer.
C1 [Li, Chunhong; Zhao, Lijuan; Xiao, Qian; Luo, Xinrong; Peng, Weiyan; Ren, Guosheng; Tao, Qian; Xiang, Tingxiu] Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing 400016, Peoples R China.
   [Tang, Liping] Chongqing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Chongqing 400016, Peoples R China.
   [Li, Chunhong; Ren, Guosheng] Chongqing Med Univ, Affiliated Hosp 1, Dept Endocrine & Breast Surg, Chongqing 400016, Peoples R China.
   [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Dept Clin Oncol, Canc Epigenet Lab, Hong Kong, Hong Kong, Peoples R China.
   [Li, Lili; Tao, Qian] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.
   [Li, Lili; Tao, Qian] CUHK Shenzhen Res Inst, Hong Kong, Hong Kong, Peoples R China.
C3 Chongqing Medical University; Chongqing Medical University; Chongqing
   Medical University; Chinese University of Hong Kong; Chinese University
   of Hong Kong; CUHK Shenzhen Research Institute
RP Xiang, TX (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Mol Oncol & Epigenet Lab, Chongqing 400016, Peoples R China.
EM qtao@clo.cuhk.edu.hk; xiangtx1@gmail.com
RI xiao, qian/IWM-0785-2023; Xiang, Tingxiu/E-6157-2016; Tao,
   Qian/T-4743-2018; Li, Lili/Q-5750-2018
OI Tao, Qian/0000-0001-5383-4808; Li, Lili/0000-0002-0292-5889
FU National Natural Science Foundation [81372238, 81000907, 31171243,
   81372898, 81172582]; Chinese University of Hong Kong
FX This study was supported by grants from National Natural Science
   Foundation (#81372238, #81000907, #31171243, #81372898, #81172582) and
   the Chinese University of Hong Kong.
CR Chen H, 2007, EUR J GYNAECOL ONCOL, V28, P464
   Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990
   Duarte-Pereira S, 2011, EUR J CANCER, V47, P1106, DOI 10.1016/j.ejca.2010.12.025
   Hackanson B, 2014, RECENT RESULTS CANC, V201, P269, DOI 10.1007/978-3-642-54490-3_18
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Kolligs FT, 2013, INTERNIST, V54, P797, DOI 10.1007/s00108-012-3237-9
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Liang WH, 2013, J THORAC DIS, V5, P726, DOI 10.3978/j.issn.2072-1439.2013.12.32
   Lu DS, 2001, CANCER RES, V61, P6755
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Mckie AB, 2012, CANCER DISCOV, V2, P156, DOI 10.1158/2159-8290.CD-11-0256
   McNeish IA, 2004, GENE THER, V11, P497, DOI 10.1038/sj.gt.3302238
   Mei FC, 2005, FASEB J, V19, P497, DOI 10.1096/fj.05-4586fje
   Moon JW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-4
   Pain M, 2014, EUR RESPIR REV, V23, P118, DOI 10.1183/09059180.00004413
   Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872
   Reed JE, 2007, NEUROPATH APPL NEURO, V33, P77, DOI 10.1111/j.1365-2990.2006.00786.x
   Sellar GC, 2003, NAT GENET, V34, P337, DOI 10.1038/ng1183
   SHARK KB, 1995, GENE, V155, P213, DOI 10.1016/0378-1119(94)00830-L
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Tang YR, 2013, WORLD J GASTROENTERO, V19, P1466, DOI 10.3748/wjg.v19.i9.1466
   Tao Q, 2002, HUM MOL GENET, V11, P2091, DOI 10.1093/hmg/11.18.2091
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Uzawa K, 1996, INT J CANCER, V67, P510, DOI 10.1002/(SICI)1097-0215(19960807)67:4<510::AID-IJC8>3.3.CO;2-R
   Wang J, 2010, CELL PROLIFERAT, V43, P103, DOI 10.1111/j.1365-2184.2009.00659.x
   Wang YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034921
   Winczyk K, 2002, TUMOR BIOL, V23, P298, DOI 10.1159/000068569
   Ye F, 2008, CANCER INVEST, V26, P569, DOI 10.1080/07357900701837044
   Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399
   Yun HY, 2014, HAEMATOLOGICA, V99, P1456, DOI 10.3324/haematol.2013.101386
NR 30
TC 32
Z9 35
U1 0
U2 10
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2015
VL 5
IS 5
BP 1635
EP U76
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CN3YJ
UT WOS:000358364200006
PM 26175934
DA 2025-01-12
ER

PT J
AU Cao, YW
   Li, YX
   Zhang, N
   Hu, JM
   Yin, L
   Pan, ZM
   Li, YC
   Du, XM
   Zhang, WJ
   Li, F
AF Cao, Yuwen
   Li, Yixiao
   Zhang, Na
   Hu, Jianming
   Yin, Liang
   Pan, Zemin
   Li, Yucong
   Du, Xiaoming
   Zhang, Wenjie
   Li, Feng
TI Quantitative DNA hypomethylation of ligand Jagged1 and receptor Notch1
   signifies occurrence and progression of breast carcinoma
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Jagged1; Notch1; methylation; expression; occurrence; progression;
   breast cancer
ID PROGNOSTIC-SIGNIFICANCE; EPIGENETIC REGULATION; METHYLATION PATTERNS;
   CANCER; EXPRESSION; JAG1; METASTASIS; CLEAVAGE; PATHWAY; GENES
AB Methylation alterations of Jagged1 and Notch1 genes have been reported in non-tumor lesions and a few cancers. However, methylation profiles of Jagged1 promoter and Notch1 exon25 in breast cancer and matched normal tissue and the association of methylation with clinicopathological characteristics still remain unclear. To explore the potential effects of aberrant DNA methylation of Jagged1 and Notch1 on occurrence and progression of breast cancer, we detected the quantitative DNA methylation of Jagged1 and Notch1 in 73 breast cancer (BC) and 20 adjacent normal breast tissues (ANBT) by using MassARRAY spectrometry. The methylation level of overall and majority individual CpG sites of the two genes were synergistically significantly lower in BC than in ANBT. The overall hypomethylation of the two genes, particularly of Jagged1 CpG_8.9.10 and Notch1 CpG_14.15.16 in primary tumors, were markedly associated with lymph node metastasis, advanced stage and high grade. The protein expressions of the both genes were examined by immunohistochemical staining in same cohorts. The expression was significantly inverse correlation with methylation. The two proteins in primary tumor were synergistically upregulated and dramatically related to lymph node metastasis, advanced stage and high grade. Our findings suggest that the synergetic hypomethylation of Jagged1 and Notch1 genes, especially of Jagged1 CpG_8.9.10 and Notch1 CpG_14.15.16, may involve tumorigenesis and development of breast cancer. The negative relationship between methylation and expression indicates methylation role for expression regulation. The synergetic overexpression of the two proteins further indicates the effects on occurrence and progression of breast cancer.
C1 [Cao, Yuwen; Li, Yixiao; Zhang, Na; Hu, Jianming; Li, Yucong; Du, Xiaoming; Zhang, Wenjie; Li, Feng] Shihezi Univ, Sch Med, Dept Pathol, Shihezi 832002, Xinjiang, Peoples R China.
   [Cao, Yuwen; Li, Yixiao; Zhang, Na; Hu, Jianming; Li, Yucong; Du, Xiaoming; Zhang, Wenjie; Li, Feng] Shihezi Univ, Sch Med, Key Lab Xinjiang Endem & Ethn Dis, Minist Educ, Shihezi 832002, Xinjiang, Peoples R China.
   [Yin, Liang] Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Endocrinol & Metab, Shihezi 832000, Xinjiang, Peoples R China.
   [Pan, Zemin] Shihezi Univ, Sch Med, Dept Biochem & Mol Biol, Shihezi 832000, Xinjiang, Peoples R China.
C3 Shihezi University; Shihezi University; Shihezi University; Shihezi
   University
RP Li, F (通讯作者)，Shihezi Univ, Sch Med, Dept Pathol, North 4th Rd, Shihezi 832002, Xinjiang, Peoples R China.
EM feng-li7855@126.com
RI Zhang, Wenjie/O-5336-2014; Zemin, Pan/R-3238-2019
FU Natural Science Foundation of China [81260301]; First Affiliated
   Hospital of Shihezi University School
FX This work was supported in part by the Natural Science Foundation of
   China (No. 81260301) and The First Affiliated Hospital of Shihezi
   University School.
CR Acharyya S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012479
   ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513
   Brait M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070878
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Cao YW, 2015, KAOHSIUNG J MED SCI, V31, P70, DOI 10.1016/j.kjms.2014.11.008
   Cao YW, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0097-2
   Cortese R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026002
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Cowling VH, 2010, ONCOGENE, V29, P930, DOI 10.1038/onc.2009.368
   Cui XB, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-20
   Cui ZL, 2013, INT J IMMUNOPATH PH, V26, P371, DOI 10.1177/039463201302600210
   Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Felician G, 2014, CIRC RES, V115, P636, DOI 10.1161/CIRCRESAHA.115.304517
   Fu Y, 2014, ONCOTARGET, V5, P6701, DOI 10.18632/oncotarget.2239
   Fujiwara S, 2014, ONCOTARGET, V5, P3919, DOI 10.18632/oncotarget.2002
   Ganapathi SK, 2014, BRIT J CANCER, V111, P1581, DOI 10.1038/bjc.2014.477
   Gao S, 2007, J ORAL PATHOL MED, V36, P173, DOI 10.1111/j.1600-0714.2007.00520.x
   Kiaris H, 2004, AM J PATHOL, V165, P695, DOI 10.1016/S0002-9440(10)63333-0
   Kuang SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061807
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lakhani Sunil R., 2012, WHO CLASSIFICATION T, V4th, P13
   Leshchenko VV, 2010, BLOOD, V116, P1025, DOI 10.1182/blood-2009-12-257485
   Bellido ML, 2010, BIOL REPROD, V82, P745, DOI 10.1095/biolreprod.109.082271
   Moarii M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103986
   Piazzi G, 2011, ONCOTARGET, V2, P1291
   Radpour R, 2008, MOL CANCER RES, V6, P1702, DOI 10.1158/1541-7786.MCR-08-0262
   Rauen T, 2012, J BIOL CHEM, V287, P42525, DOI 10.1074/jbc.M112.425371
   Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069
   Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3
   Reister S, 2011, STEM CELLS DEV, V20, P1687, DOI 10.1089/scd.2010.0418
   Shargh SA, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0250-y
   Stephen B, 2010, EDGE AJCC CANC STAGI, V7th, P100
   Tang YP, 2012, ANTICANCER RES, V32, P4861
   Terragni J, 2014, EPIGENETICS-US, V9, P842, DOI 10.4161/epi.28597
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Uekusa S, 2014, INT J ONCOL, V44, P1669, DOI 10.3892/ijo.2014.2340
   van Breda SG., 2014, Arch Toxicol
   Wang Yong-chuan, 2012, Cancer Biology Medicine, V9, P128, DOI 10.3969/j.issn.2095-3941.2012.02.009
   Zhang Na, 2011, Chinese Journal of Pathology, V40, P324, DOI 10.3760/cma.j.issn.0529-5807.2011.05.009
NR 40
TC 7
Z9 9
U1 0
U2 8
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2015
VL 5
IS 6
BP 1897
EP +
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CN3YK
UT WOS:000358364300004
PM 26269752
DA 2025-01-12
ER

PT J
AU Li, JJ
   Zhang, T
   Yang, FF
   He, Y
   Dai, FJ
   Gao, D
   Chen, YH
   Liu, MY
   Yi, ZF
AF Li, Jingjie
   Zhang, Tao
   Yang, Feifei
   He, Yuan
   Dai, Fujun
   Gao, Dan
   Chen, Yihua
   Liu, Mingyao
   Yi, Zhengfang
TI Inhibition of breast cancer progression by a novel histone deacetylase
   inhibitor, LW479, by down-regulating EGFR expression
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; CELL-CYCLE ARREST; GENE-TRANSCRIPTION;
   HYDROXAMIC ACID; CONCISE GUIDE; PHASE-II; MECHANISMS; THERAPY;
   PHARMACOLOGY; ACETYLATION
AB Background and PurposeCompounds targeting epigenetic events of tumours are likely to be an important addition to anticancer therapy. Histone deacetylase inhibitors (HDACI) have emerged as a promising novel class for therapeutic interventions associated with cancer, and many of them are currently in clinical investigation. Here, we assessed a novel hydroxamate-based HDACI, LW479, in breast cancer progression and explored its underlying mechanism(s).
   Experimental ApproachLW479 was identified using the HDACI screening kit. Western blot and flow cytometry were used to analyse the biological effects of LW479 as a novel HDACI. The effects of LW479 were assessed in mouse models of spontaneous and experimental breast cancer. Co-immunoprecipitation, immunofluorescent staining and chromatin immunoprecipitation assays along with immunohistochemical analysis, were used to elucidate the molecular basis of the actions of LW479.
   Key ResultsLW479 was identified as a novel HDACI and showed marked cytotoxicity and induced apoptosis, as well as cell cycle arrest, in a panel of breast cancer cell lines. Intraperitoneal injections of LW479 markedly suppressed breast tumour growth and pulmonary metastasis in nude mice. LW479 also decreased levels of EGF receptors (EGFR) by blocking the binding of the transcription factor Sp1 and HDAC1 to the EGFR promoter region.
   Conclusions and ImplicationsOur data have elucidated the mechanisms underlying the inhibition by LW479 of tumour growth and metastasis, in models of breast cancer with aberrant EGFR expression. LW479 could be a candidate drug for breast cancer prevention.
C1 [Li, Jingjie; Zhang, Tao; Yang, Feifei; He, Yuan; Dai, Fujun; Gao, Dan; Chen, Yihua; Liu, Mingyao; Yi, Zhengfang] E China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
   [Li, Jingjie; Zhang, Tao; Yang, Feifei; He, Yuan; Dai, Fujun; Gao, Dan; Chen, Yihua; Liu, Mingyao; Yi, Zhengfang] E China Normal Univ, Sch Life Sci, Shanghai 200241, Peoples R China.
   [Zhang, Tao] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 1, Dept Orthoped, Shanghai, Peoples R China.
   [Liu, Mingyao] Texas A&M Univ, Ctr Canc & Stem Cell Biol, Inst Biosci & Technol, Houston, TX USA.
C3 East China Normal University; East China Normal University; Shanghai
   Jiao Tong University; Texas A&M University System
RP Yi, ZF (通讯作者)，E China Normal Univ, Inst Biomed Sci, 500 Dongchuan Rd, Shanghai 200241, Peoples R China.
EM yhchen@bio.ecnu.edu.cn; mliu@ibt.tamhsc.edu; zfyi@bio.ecnu.edu.cn
RI ; Chen, Yihua/A-4323-2013
OI Li, Jingjie/0000-0001-8164-0250; Liu, Mingyao/0000-0001-7339-5048; Chen,
   Yihua/0000-0003-1733-7980
FU Major State Basic Research Development Program of China [2015CB910400,
   2012CB910401]; National Natural Science Foundation of China [81472788,
   81272463, 81202407, 81330049]; National Major Scientific and
   Technological Special Project for 'Significant New Drugs Development'
   [2013ZX09507001]; Shanghai Municipal Education Commission [13zz034]
FX This study was partially supported by Major State Basic Research
   Development Program of China (2015CB910400, 2012CB910401), National
   Natural Science Foundation of China (81472788, 81272463, 81202407,
   81330049), National Major Scientific and Technological Special Project
   for 'Significant New Drugs Development' (2013ZX09507001) and Innovation
   Program of Shanghai Municipal Education Commission (13zz034).
CR Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1676, DOI 10.1111/bph.12449
   Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1797, DOI 10.1111/bph.12451
   ALTENBURG B C, 1976, Experimental Cell Research, V102, P223
   Arnesen T, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001074
   Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048
   Baselga J, 2002, ANN ONCOL, V13, P8, DOI 10.1093/annonc/mdf092
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bots M, 2009, CLIN CANCER RES, V15, P3970, DOI 10.1158/1078-0432.CCR-08-2786
   Brandt B, 2006, CLIN CANCER RES, V12, P7252, DOI 10.1158/1078-0432.CCR-06-0626
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579
   Chen CJ, 2008, EUR J PHARMACOL, V591, P36, DOI 10.1016/j.ejphar.2008.06.041
   Chou CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018087
   Corkery B, 2009, ANN ONCOL, V20, P862, DOI 10.1093/annonc/mdn710
   Dai FJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052162
   Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108
   Dong YM, 2010, CARCINOGENESIS, V31, P2097, DOI 10.1093/carcin/bgq167
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Gediya LK, 2005, J MED CHEM, V48, P5047, DOI 10.1021/jm058214k
   GINSBURG E, 1973, P NATL ACAD SCI USA, V70, P2457, DOI 10.1073/pnas.70.8.2457
   Glaser KB, 2002, MOL CANCER THER, V1, P759
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100
   Kilkenny C., 2010, BRIT J PHARMACOL, V160, P1577, DOI [10.1111/j.1476-5381.2010.00872.x, DOI 10.1111/j.1476-5381.2010.00872.x, DOI 10.1111/J.1476-5381.2010.00872.X]
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lee MJ, 2012, CELL, V149, P780, DOI 10.1016/j.cell.2012.03.031
   Liu WQ, 2005, CANCER RES, V65, P46
   Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010
   Lu ZM, 2001, MOL CELL BIOL, V21, P4016, DOI 10.1128/MCB.21.12.4016-4031.2001
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9
   McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mottet D, 2007, CIRC RES, V101, P1237, DOI 10.1161/CIRCRESAHA.107.149377
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nishi H, 2002, CANCER RES, V62, P827
   Ombrato Luigi, 2014, Critical Reviews in Oncogenesis, V19, P349
   Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143
   Pitteri SJ, 2010, CANCER RES, V70, P8598, DOI 10.1158/0008-5472.CAN-10-1676
   Pulukuri SMK, 2007, J BIOL CHEM, V282, P35594, DOI 10.1074/jbc.M705867200
   Rössig L, 2002, CIRC RES, V91, P837, DOI 10.1161/01.RES.0000037983.07158.B1
   Sasakawa Y, 2003, BIOCHEM PHARMACOL, V66, P897, DOI 10.1016/S0006-2952(03)00411-8
   Schrump DS, 2009, CLIN CANCER RES, V15, P3947, DOI 10.1158/1078-0432.CCR-08-2787
   Su GH, 2000, CANCER RES, V60, P3137
   Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Torigoe T, 2005, J BIOL CHEM, V280, P1179, DOI 10.1074/jbc.M410499200
   Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659
   Varshochi R, 2005, J BIOL CHEM, V280, P3185, DOI 10.1074/jbc.M408063200
   Waby JS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-275
   Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Zhang T, 2014, NEOPLASIA, V16, P665, DOI 10.1016/j.neo.2014.07.009
   Zhang T, 2012, BREAST CANCER RES TR, V135, P445, DOI 10.1007/s10549-012-2175-5
   Zhang YJ, 2011, J MED CHEM, V54, P5532, DOI 10.1021/jm200577a
   Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5
NR 57
TC 13
Z9 14
U1 0
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
EI 1476-5381
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD AUG
PY 2015
VL 172
IS 15
BP 3817
EP 3830
DI 10.1111/bph.13165
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CM8LN
UT WOS:000357952500010
PM 25884486
OA Green Published, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Bae, JH
   Kang, MJ
   Yang, KM
   Kim, TO
   Yi, JM
AF Bae, Jin-Han
   Kang, Myoung Joo
   Yang, Kwang-Mo
   Kim, Tae-Oh
   Yi, Joo Mi
TI Epigenetically silenced microRNAs in gastric cancer: Functional analysis
   and identification of their target genes
SO ONCOLOGY REPORTS
LA English
DT Article
DE DNA methylation; 5-aza-2 '-deoxycytidine; microRNA; gastric cancer;
   tumor-suppressive effect
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; TUMOR-SUPPRESSOR; DNA METHYLATION;
   CELL-PROLIFERATION; DOWN-REGULATION; BREAST-CANCER; EXPRESSION;
   PROGRESSION; GROWTH; ACTIVATION
AB microRNAs (miRNAs), which are small non-coding RNA molecules, can participate in diverse biological functions and act as oncogenes or tumor suppressors by inhibiting target gene expression. The alteration of miRNA expression is observed in many types of human cancers and has been implicated in carcinogenesis. Since miRNAs have been known to be downregulated in most cancer types, there is growing evidence that several miRNAs are downregulated by DNA hypermethylation. Here, we determined that MIR219.2, MIR663B and MIR1237 were transcriptionally silenced by DNA hypermethylation in human gastric cancer cell lines. Moreover, we demonstrated the functional roles of these epigenetically silenced miRNAs by ectopically expressing them in gastric cancer cells, which caused the suppression of growth and proliferation. In addition, wound closure, cell migration, and invasion were significantly reduced in AGS cells following transfection with MIR219.2, MIR663B or MIR1237 mimics. Notably, epithelial-to-mesenchymal transition (EMT)-associated proteins were decreased in response to ectopic expression of these miRNAs, supporting the notion that these miRNAs have a tumor-suppressive effect in gastric cancer. We finally predicted the targets of these miRNAs and identified several candidate genes, the expression levels of which were significantly downregulated by ectopic expression of MIR219.2, MIR663B or MIR1237 mimics in the gastric cancer cell lines. Our study provides strong evidence that these miRNAs are transcriptionally regulated by DNA methylation in gastric cancer and have tumor-suppressive roles by decreasing the mesenchymal traits in cancer as well as by targeting cancer-associated genes.
C1 [Bae, Jin-Han; Yang, Kwang-Mo; Yi, Joo Mi] DIRAMS, Res Ctr, Busan 619953, South Korea.
   [Kang, Myoung Joo; Kim, Tae-Oh] Inje Univ, Dept Internal Med, Haeundae Paik Hosp, Busan 612896, South Korea.
C3 Korea Institute of Radiological & Medical Sciences; Inje University
RP Yi, JM (通讯作者)，DIRAMS, Res Ctr, Busan 619953, South Korea.
EM kto0440@paik.ac.kr; jmyi@dirams.re.kr
RI Kim, Hyung/J-5451-2012
OI Bae, Jin-Han/0000-0003-1859-1825; Kang, Myoung Joo/0000-0002-4334-4028
FU National R&D Program through the Dongnam Institute of Radiological and
   Medical Sciences (DIRAMS) - Ministry of Science, ICT and Future Planning
   (MSIP) of the Korean government [50591-2015]
FX This study was supported by the National R&D Program (nos. 50591-2015)
   through the Dongnam Institute of Radiological and Medical Sciences
   (DIRAMS) funded by the Ministry of Science, ICT and Future Planning
   (MSIP) of the Korean government.
CR Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Begnami MD, 2011, J CLIN ONCOL, V29, P3030, DOI 10.1200/JCO.2010.33.6313
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gong JA, 2014, CARCINOGENESIS, V35, P497, DOI 10.1093/carcin/bgt337
   Hayashi M, 2008, CLIN CANCER RES, V14, P7843, DOI 10.1158/1078-0432.CCR-08-1064
   He J, 2012, EMBO REP, V13, P1116, DOI 10.1038/embor.2012.162
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kim JG, 2014, EPIGENETICS-US, V9, P1018, DOI 10.4161/epi.29007
   Lei HZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060369
   Leone V, 2011, J CLIN ENDOCR METAB, V96, pE1388, DOI 10.1210/jc.2011-0345
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Mraz M, 2012, EXPERT REV HEMATOL, V5, P579, DOI [10.1586/EHM.12.54, 10.1586/ehm.12.54]
   Nakamura T, 2007, P NATL ACAD SCI USA, V104, P10980, DOI 10.1073/pnas.0704559104
   Oshimo Y, 2003, INT J ONCOL, V23, P1663
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Takano Y, 1999, J PATHOL, V189, P194
   Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Ushijima T, 2006, J GASTROENTEROL, V41, P401, DOI 10.1007/s00535-006-1846-6
   Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293
   Yan HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020628
   Yan X, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-220
   Yoon SO, 2011, HUM PATHOL, V42, P1391, DOI 10.1016/j.humpath.2010.12.010
   Zhang L, 2013, CANCER LETT, V332, P94, DOI 10.1016/j.canlet.2013.01.023
NR 39
TC 4
Z9 5
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD AUG
PY 2015
VL 34
IS 2
BP 1017
EP 1026
DI 10.3892/or.2015.4036
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CM8QB
UT WOS:000357965600057
PM 26043902
OA Bronze
DA 2025-01-12
ER

PT J
AU Shen, KK
   Xie, JL
   Wang, H
   Zhang, H
   Yu, MY
   Lu, FF
   Tan, HS
   Xu, HX
AF Shen, Kaikai
   Xie, Jianling
   Wang, Hua
   Zhang, Hong
   Yu, Mengyuan
   Lu, Fangfang
   Tan, Hongsheng
   Xu, Hongxi
TI Cambogin Induces Caspase-Independent Apoptosis through the ROS/JNK
   Pathway and Epigenetic Regulation in Breast Cancer Cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID POLYCYCLIC POLYPRENYLATED ACYLPHLOROGLUCINOLS; ACTIVATING TRANSCRIPTION
   FACTOR-2; SIGNALING PATHWAY; OBLONGIFOLIN C; COMPOUND; GROWTH;
   PROTEOMICS; CHEMISTRY; STRESS; DEATH
AB Cambogin is a polycyclic polyprenylated acylphoroglucinol (PPAP) from the Garcinia genus, which has been used traditionally for cancer treatment across Southeastern Asia. In this study, we found that cambogin inhibited breast cancer cell proliferation and induced cell apoptosis in vitro. Cambogin induced the activation of the caspase-independent mitochondrial apoptotic pathway, as indicated by an increase in the ratio of Bax/Bcl-2 and the nuclear translocation of apoptosis inducing factor (AIF). Two-dimensional gel electrophoresis and mass spectrometry revealed that the expression of proteins involving in the radical oxygen species (ROS) pathway was among the most affected upon cambogin treatment. Cambogin enhanced cellular ROS production, and induced the activation of the ASK1-MKK4/MKK7-JNK/SAPK signaling pathway. Pretreatment with ROS scavenger N-acetylcysteine (NAC), an antioxidant, or the JNK inhibitor SP600125 was able to restore cell viability in the presence of cambogin. Importantly, cambogin treatment led to the activation of activating transcription factor-2 (ATF-2) and the trimethylation of histone H3K9 in the activator protein 1 (AP-1) binding region of the Bcl-2 gene promoter. Finally, cambogin exhibited a potential antitumor effect in MCF-7 breast cancer xenografts without apparent toxicity. Taken in conjunction, the present study indicates that cambogin can induce breast adenocarcinoma cell apoptosis and therefore represents therapeutic potential for cancer treatment. (C)2015 AACR.
C1 [Shen, Kaikai; Zhang, Hong; Yu, Mengyuan; Lu, Fangfang; Tan, Hongsheng; Xu, Hongxi] Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China.
   [Xie, Jianling] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia.
   [Xie, Jianling] Univ Southampton, Ctr Biol Sci, Southampton, Hants, England.
   [Wang, Hua] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; South Australian
   Health & Medical Research Institute (SAHMRI); University of Southampton;
   Chinese University of Hong Kong
RP Xu, HX (通讯作者)，Shanghai Univ Tradit Chinese Med, Sch Pharmacol, 1200 Cailun Rd, Shanghai 201203, Peoples R China.
EM xuhongxi88@gmail.com
RI tan, Hongsheng/AAD-5830-2020; Xu, Hongxi/AAC-2799-2020; Zhang,
   Hong/AAD-5927-2020; Shen, Kaikai/AAD-9970-2019; Xie,
   Jianling/N-1877-2014
OI Xu, Hongxi/0000-0001-6238-4511; Xie, Jianling/0000-0002-0588-8016; Tan,
   Hongsheng/0000-0003-0921-5481
FU Foundation of Shanghai University of Traditional Chinese Medicine
   [2012JW05]; National Natural Science Foundation of China [81303266,
   81303188]; Natural Science and Technology Foundation for Distinguished
   Young Scholars of Shanghai [13ZR1462000]; Chen Guang Foundation of
   Shanghai Ministry of Education [13CG46]; Ministry of Education of
   Shanghai [ZZszy13058]; Shanghai Higher Education Institutions
   [ZYX-CXYJ-012, 085]
FX This work was supported financially by the Foundation of Shanghai
   University of Traditional Chinese Medicine (2012JW05 to K. Shen),
   National Natural Science Foundation of China (81303266 to K. Shen;
   81303188 to H. Zhang), Natural Science and Technology Foundation for
   Distinguished Young Scholars of Shanghai (13ZR1462000 to K. Shen), Chen
   Guang Foundation of Shanghai Ministry of Education (13CG46 to K. Shen),
   Science Foundation for the Excellent Youth Scholars of Ministry of
   Education of Shanghai (ZZszy13058 to K. Shen), and 085 Special Project
   for the Priority Academic Program Development of Shanghai Higher
   Education Institutions (ZYX-CXYJ-012 to H.Xu).
CR Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103
   Armstrong JS, 2002, CELL DEATH DIFFER, V9, P252, DOI 10.1038/sj.cdd.4400959
   Beenken S W, 2002, Minerva Chir, V57, P437
   Chen JM, 2004, CLIN CANCER RES, V10, P7703, DOI 10.1158/1078-0432.CCR-04-1130
   Chien CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099729
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Feng C, 2012, INT J CANCER, V131, P1445, DOI 10.1002/ijc.27365
   Fu WM, 2012, APOPTOSIS, V17, P842, DOI 10.1007/s10495-012-0729-y
   Fu Wen-wei, 2014, Yaoxue Xuebao, V49, P166
   Gozdecka M, 2012, BIOCHEM SOC T, V40, P230, DOI 10.1042/BST20110630
   GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jo GH, 2014, INT J ONCOL, V45, P1497, DOI 10.3892/ijo.2014.2536
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kan WLT, 2013, INT J CANCER, V132, P707, DOI 10.1002/ijc.27694
   Kello M, 2014, MOLECULES, V19, P10877, DOI 10.3390/molecules190810877
   KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33
   Lao YZ, 2014, J ETHNOPHARMACOL, V155, P1, DOI 10.1016/j.jep.2014.05.022
   Lao YZ, 2014, AUTOPHAGY, V10, P736, DOI 10.4161/auto.28034
   Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610
   Liang T, 2014, INT J MOL SCI, V15, P15754, DOI 10.3390/ijms150915754
   Lindsay J, 2011, BBA-MOL CELL RES, V1813, P532, DOI 10.1016/j.bbamcr.2010.10.017
   Ma Q, 2007, J CELL BIOCHEM, V101, P477, DOI 10.1002/jcb.21198
   McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656
   Newman DJ, 2012, J NAT PROD, V75, P311, DOI 10.1021/np200906s
   Palit S, 2015, J CELL PHYSIOL, V230, P1729, DOI 10.1002/jcp.24818
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Richard JA, 2012, ANGEW CHEM INT EDIT, V51, P4536, DOI 10.1002/anie.201103873
   Saleh A, 2008, GENE, V423, P43, DOI 10.1016/j.gene.2008.06.022
   Simpkins NS, 2013, CHEM COMMUN, V49, P1042, DOI 10.1039/c2cc37914g
   Solary E, 1996, EUR RESPIR J, V9, P1293, DOI 10.1183/09031936.96.09061293
   Stearns V, 2007, CANCER INVEST, V25, P659, DOI 10.1080/07357900701719234
   Surakasula A, 2014, J RES PHARM PRACT, V3, P12, DOI 10.4103/2279-042X.132704
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Tao M, 2011, BREAST CANCER RES TR, V129, P247, DOI 10.1007/s10549-011-1512-4
   Tian Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021370
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Vriz S, 2014, CURR TOP DEV BIOL, V108, P121, DOI 10.1016/B978-0-12-391498-9.00002-4
   Wu CC, 2013, ANTIOXID REDOX SIGN, V19, P546, DOI 10.1089/ars.2012.4905
   Xiong SB, 2014, PROTEIN CELL, V5, P737, DOI 10.1007/s13238-014-0089-1
   Zhang H, 2014, J NAT PROD, V77, P1700, DOI 10.1021/np5003498
NR 42
TC 35
Z9 39
U1 0
U2 27
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD JUL
PY 2015
VL 14
IS 7
BP 1738
EP 1749
DI 10.1158/1535-7163.MCT-14-1048
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CM9UZ
UT WOS:000358055900021
PM 25976678
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Licciardello, MP
   Müllner, MK
   Dürnberger, G
   Kerzendorfer, C
   Boidol, B
   Trefzer, C
   Sdelci, S
   Berg, T
   Penz, T
   Schuster, M
   Bock, C
   Kralovics, R
   Superti-Furga, G
   Colinge, J
   Nijman, SM
   Kubicek, S
AF Licciardello, M. P.
   Muellner, M. K.
   Duernberger, G.
   Kerzendorfer, C.
   Boidol, B.
   Trefzer, C.
   Sdelci, S.
   Berg, T.
   Penz, T.
   Schuster, M.
   Bock, C.
   Kralovics, R.
   Superti-Furga, G.
   Colinge, J.
   Nijman, S. M.
   Kubicek, S.
TI NOTCH1 activation in breast cancer confers sensitivity to inhibition of
   SUMOylation
SO ONCOGENE
LA English
DT Article
ID PATHWAY; TUMORS; SUMO; UBC9; IDENTIFICATION; GENERATION; LEUKEMIA;
   EFFICACY; REVEALS; PROTEIN
AB Breast cancer is genetically heterogeneous, and recent studies have underlined a prominent contribution of epigenetics to the development of this disease. To uncover new synthetic lethalities with known breast cancer oncogenes, we screened an epigenome-focused short hairpin RNA library on a panel of engineered breast epithelial cell lines. Here we report a selective interaction between the NOTCH1 signaling pathway and the SUMOylation cascade. Knockdown of the E2-conjugating enzyme UBC9 (UBE2I) as well as inhibition of the E1-activating complex SAE1/UBA2 using ginkgolic acid impairs the growth of NOTCH1-activated breast epithelial cells. We show that upon inhibition of SUMOylation NOTCH1-activated cells proceed slower through the cell cycle and ultimately enter apoptosis. Mechanistically, activation of NOTCH1 signaling depletes the pool of unconjugated small ubiquitin-like modifier 1 (SUMO1) and SUMO2/3 leading to increased sensitivity to perturbation of the SUMOylation cascade. Depletion of unconjugated SUMO correlates with sensitivity to inhibition of SUMOylation also in patient-derived breast cancer cell lines with constitutive NOTCH pathway activation. Our investigation suggests that SUMOylation cascade inhibitors should be further explored as targeted treatment for NOTCH-driven breast cancer.
C1 [Licciardello, M. P.; Muellner, M. K.; Duernberger, G.; Kerzendorfer, C.; Boidol, B.; Trefzer, C.; Sdelci, S.; Berg, T.; Penz, T.; Schuster, M.; Bock, C.; Kralovics, R.; Superti-Furga, G.; Colinge, J.; Nijman, S. M.; Kubicek, S.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1090 Vienna, Austria.
   [Boidol, B.; Kubicek, S.] Austrian Acad Sci, CeMM Res Ctr Mol Med, Christian Doppler Lab Chem Epigenet & Antiinfect, A-1090 Vienna, Austria.
C3 Austrian Academy of Sciences; CeMM Research Center for Molecular
   Medicine of the Austrian Academy of Sciences; Austrian Academy of
   Sciences; CeMM Research Center for Molecular Medicine of the Austrian
   Academy of Sciences
RP Kubicek, S (通讯作者)，Austrian Acad Sci, CeMM Res Ctr Mol Med, Lazarettgasse 14 AKH BT 25-3, A-1090 Vienna, Austria.
EM skubicek@cemm.oeaw.ac.at
RI Colinge, Jacques/Z-2613-2019; Superti-Furga, Giulio/AAE-5681-2019;
   Muellner, Markus/HNS-3544-2023; Bock, Christoph/AAE-7618-2019; Kubicek,
   Stefan/C-2089-2017; Superti-Furga, Giulio/F-4755-2015; Colinge,
   Jacques/D-1578-2017; Jessen-Trefzer, Claudia/E-3710-2019; Sdelci,
   Sara/S-2243-2018
OI Kubicek, Stefan/0000-0003-0855-8343; Superti-Furga,
   Giulio/0000-0002-0570-1768; Kralovics, Robert/0000-0002-6997-8539;
   Colinge, Jacques/0000-0003-2466-4824; Jessen-Trefzer,
   Claudia/0000-0003-4216-8189; Schuster, Michael/0000-0003-2975-8969;
   Bock, Christoph/0000-0001-6091-3088; Licciardello,
   Marco/0000-0003-3197-4855; Nijman, Sebastian/0000-0003-0464-6661;
   Sdelci, Sara/0000-0003-1330-4364
FU Marie Curie Career Integration Grant; Austrian Federal Ministry of
   Science, Research and Economy; National Foundation for Research,
   Technology and Development
FX We thank John Doench, Serena Silver and David E Root (Broad Institute of
   MIT and Harvard) for shRNA tools and screening protocols; Johannes
   Bigenzahn (CeMM) for providing the pMSCV-StrepHA-GW-hPGK-Bla vector; and
   Erika Schirghuber (CeMM) and Berend Snijder (CeMM) for critically
   reading the manuscript. SK acknowledges support by a Marie Curie Career
   Integration Grant, the Austrian Federal Ministry of Science, Research
   and Economy and the National Foundation for Research, Technology and
   Development.
CR Aifantis I, 2008, NAT REV IMMUNOL, V8, P380, DOI 10.1038/nri2304
   Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677
   Andersson ER, 2014, NAT REV DRUG DISCOV, V13, P359, DOI 10.1038/nrd4252
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Falk R, 2012, METHODS, V58, P69, DOI 10.1016/j.ymeth.2012.07.008
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Fukuda I, 2009, CHEM BIOL, V16, P133, DOI 10.1016/j.chembiol.2009.01.009
   Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293
   Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012
   JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0
   Johnson DG, 2013, CELL, V152, P685, DOI 10.1016/j.cell.2013.01.017
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117
   Kessler JD, 2011, SCIENCE, V335, P348
   Knipscheer P, 2008, MOL CELL, V31, P371, DOI 10.1016/j.molcel.2008.05.022
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Mair B, 2014, TRENDS PHARMACOL SCI, V35, P136, DOI 10.1016/j.tips.2014.01.001
   Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224
   Maxmen A, 2012, NATURE, V485, pS50, DOI 10.1038/485S50a
   Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107
   Mo YY, 2005, ONCOGENE, V24, P2677, DOI 10.1038/sj.onc.1208210
   Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543
   Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040
   Moschos SJ, 2007, ONCOGENE, V26, P4216, DOI 10.1038/sj.onc.1210216
   Muellner MK, 2011, NAT CHEM BIOL, V7, P787, DOI 10.1038/nchembio.695
   Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798
   Nijman SMB, 2011, FEBS LETT, V585, P1, DOI 10.1016/j.febslet.2010.11.024
   Pfander B, 2005, NATURE, V436, P428, DOI 10.1038/nature03665
   Purow B, 2012, ADV EXP MED BIOL, V727, P305, DOI 10.1007/978-1-4614-0899-4_23
   Radtke F, 2010, IMMUNITY, V32, P14, DOI 10.1016/j.immuni.2010.01.004
   Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035
   Rao SS, 2009, CANCER RES, V69, P3060, DOI 10.1158/0008-5472.CAN-08-4295
   Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580
   Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200
   Shilo Y, 2003, P NATL ACAD SCI USA, V100, P13225, DOI 10.1073/pnas.1735528100
   Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719
   Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096
   Whitfield ML, 2000, MOL CELL BIOL, V20, P4188, DOI 10.1128/MCB.20.12.4188-4198.2000
NR 49
TC 38
Z9 41
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JUL
PY 2015
VL 34
IS 29
BP 3780
EP 3790
DI 10.1038/onc.2014.319
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA CM9BV
UT WOS:000358001600004
PM 25263445
OA Bronze
DA 2025-01-12
ER

PT J
AU Neri, F
   Dettori, D
   Incarnato, D
   Krepelova, A
   Rapelli, S
   Maldotti, M
   Parlato, C
   Paliogiannis, P
   Oliviero, S
AF Neri, F.
   Dettori, D.
   Incarnato, D.
   Krepelova, A.
   Rapelli, S.
   Maldotti, M.
   Parlato, C.
   Paliogiannis, P.
   Oliviero, S.
TI TET1 is a tumour suppressor that inhibits colon cancer growth by
   derepressing inhibitors of the WNT pathway
SO ONCOGENE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; LARGE GENE LISTS; DNA METHYLATION; EPIGENETIC
   INACTIVATION; BREAST-CANCER; MAMMALIAN DEVELOPMENT; COLORECTAL-CANCER;
   POTENTIAL ROLES; 5-HYDROXYMETHYLCYTOSINE; MUTATIONS
AB Ten eleven translocation (TET) enzymes catalyse the oxidative reactions of 5-methylcytosine (5mC) to promote the demethylation process. The reaction intermediate 5-hydroxymethylcytosine (5hmC) has been shown to be abundant in embryonic stem cells and tissues but strongly depleted in human cancers. Genetic mutations of TET2 gene were associated with leukaemia, whereas TET1 downregulation has been shown to promote malignancy in breast cancer. Here we report that TET1 is downregulated in colon tumours from the initial stage. TET1 silencing in primary epithelial colon cells increase their cellular proliferation while its re-expression in colon cancer cells inhibits their proliferation and the growth of tumour xenografts even at later stages. We found that TET1 binds to the promoter of the DKK gene inhibitors of the WNT signalling to maintain them hypomethylated. Downregulation of TET1 during colon cancer initiation leads to repression, by DNA methylation, the promoters of the inhibitors of the WNT pathway resulting in a constitutive activation of the WNT pathway. Thus the DNA hydroxymethylation mediated by TET1 controlling the WNT signalling is a key player of tumour growth. These results provide new insights for understanding how tumours escape cellular controls.
C1 [Neri, F.; Dettori, D.; Incarnato, D.; Krepelova, A.; Rapelli, S.; Maldotti, M.; Parlato, C.; Oliviero, S.] Human Genet Fdn HuGeF, Epigenet, Turin, Italy.
   [Incarnato, D.; Krepelova, A.; Rapelli, S.] Univ Siena, Dipartimento Biotecnol Chim & Farm, I-53100 Siena, Italy.
   [Paliogiannis, P.] Univ Sassari, Dipartimento Sci Chirurg Microchirurg & Med, I-07100 Sassari, Italy.
   [Oliviero, S.] Univ Turin, Dipartimento Sci Vita & Biol Sistemi, Turin, Italy.
C3 University of Siena; University of Sassari; University of Turin
RP Oliviero, S (通讯作者)，Human Genet Fdn, Epigenet, Via Nizza52, I-10126 Turin, Italy.
EM salvatore.oliviero@hugef-torino.org
RI oliviero, salvatore/R-6657-2019; Paliogiannis, Panagiotis/M-6870-2016;
   neri, francesco/A-3321-2014
OI Maldotti, Mara/0000-0002-3299-9053; PARLATO,
   CATERINA/0000-0001-5304-3117; neri, francesco/0000-0003-3903-1974;
   oliviero, salvatore/0000-0002-3405-765X; Incarnato,
   Danny/0000-0003-3944-2327; Krepelova, Anna/0000-0002-2775-1336;
   Paliogiannis, Panagiotis/0000-0001-5485-6056
FU Associazione Italiana Ricerca sul Cancro (AIRC) [IG 2011/11982]
FX This work was supported by the Associazione Italiana Ricerca sul Cancro
   (AIRC) IG 2011/11982. We thank Carola Ponzetto and Riccardo Taulli for
   the critical reading of the manuscript.
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Bacher U, 2010, ANN HEMATOL, V89, P643, DOI 10.1007/s00277-010-0920-6
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Evellin S, 2013, MOL CELL BIOL, V33, P1198, DOI 10.1128/MCB.01054-12
   Feltus FA, 2003, P NATL ACAD SCI USA, V100, P12253, DOI 10.1073/pnas.2037852100
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Haffner MC, 2011, ONCOTARGET, V2, P627
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Incarnato D, 2013, NUCLEIC ACIDS RES, V41, P8421, DOI 10.1093/nar/gkt629
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Ivanov M, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r83
   Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116
   Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kallin EM, 2012, MOL CELL, V48, P266, DOI 10.1016/j.molcel.2012.08.007
   Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kosmider O, 2009, BLOOD, V114, P3285, DOI 10.1182/blood-2009-04-215814
   Krepelova A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088933
   Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x
   Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033
   Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946
   Maiti A, 2011, J BIOL CHEM, V286, P35334, DOI 10.1074/jbc.C111.284620
   Neri F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-8-r91
   Neri F, 2013, CELL, V155, P121, DOI 10.1016/j.cell.2013.08.056
   Neri F, 2012, MOL CELL BIOL, V32, P840, DOI 10.1128/MCB.06148-11
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pfeifer GP, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-10
   Prensner JR, 2011, NAT MED, V17, P291, DOI 10.1038/nm0311-291
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Rhee JK, 2013, NUCLEIC ACIDS RES, V41, P8464, DOI 10.1093/nar/gkt643
   Saint-Martin C, 2009, BLOOD, V114, P1628, DOI 10.1182/blood-2009-01-197525
   Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Song SJ, 2013, CELL STEM CELL, V13, P87, DOI 10.1016/j.stem.2013.06.003
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tefferi A, 2009, LEUKEMIA, V23, P905, DOI 10.1038/leu.2009.47
   Teng IW, 2011, CANCER RES, V71, P4653, DOI 10.1158/0008-5472.CAN-10-3418
   Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Xu GL, 1999, NATURE, V402, P187, DOI 10.1038/46052
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
NR 49
TC 149
Z9 162
U1 1
U2 41
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD AUG 6
PY 2015
VL 34
IS 32
BP 4168
EP 4176
DI 10.1038/onc.2014.356
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA CO5LE
UT WOS:000359199800003
PM 25362856
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Rafique, S
   Thomas, JS
   Sproul, D
   Bickmore, WA
AF Rafique, Sehrish
   Thomas, Jeremy S.
   Sproul, Duncan
   Bickmore, Wendy A.
TI Estrogen-induced chromatin decondensation and nuclear re-organization
   linked to regional epigenetic regulation in breast cancer
SO GENOME BIOLOGY
LA English
DT Article
ID ENDOCRINE RESISTANCE; TOPOLOGICAL DOMAINS; RECEPTOR FUNCTION; GENE
   ACTIVATION; CELL-LINES; EXPRESSION; GENOME; ORGANIZATION; DISTINCT;
   ABERRATIONS
AB Background: Epigenetic changes are being increasingly recognized as a prominent feature of cancer. This occurs not only at individual genes, but also over larger chromosomal domains. To investigate this, we set out to identify large chromosomal domains of epigenetic dysregulation in breast cancers.
   Results: We identify large regions of coordinate down-regulation of gene expression, and other regions of coordinate activation, in breast cancers and show that these regions are linked to tumor subtype. In particular we show that a group of coordinately regulated regions are expressed in luminal, estrogen-receptor positive breast tumors and cell lines. For one of these regions of coordinate gene activation, we show that regional epigenetic regulation is accompanied by visible unfolding of large-scale chromatin structure and a repositioning of the region within the nucleus. In MCF7 cells, we show that this depends on the presence of estrogen.
   Conclusions: Our data suggest that the liganded estrogen receptor is linked to long-range changes in higher-order chromatin organization and epigenetic dysregulation in cancer. This may suggest that as well as drugs targeting histone modifications, it will be valuable to investigate the inhibition of protein complexes involved in chromatin folding in cancer cells.
C1 [Rafique, Sehrish; Sproul, Duncan; Bickmore, Wendy A.] Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Rafique, Sehrish; Thomas, Jeremy S.; Sproul, Duncan] Univ Edinburgh, Western Gen Hosp, Edinburgh Breakthrough Res Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Rafique, Sehrish; Thomas, Jeremy S.; Sproul, Duncan] Univ Edinburgh, Western Gen Hosp, Edinburgh Canc Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.
C3 University of Edinburgh; University of Edinburgh; University of
   Edinburgh
RP Sproul, D (通讯作者)，Univ Edinburgh, Inst Genet & Mol Med, MRC Human Genet Unit, Crewe Rd South, Edinburgh EH4 2XU, Midlothian, Scotland.
EM Duncan.Sproul@igmm.ed.ac.uk; Wendy.Bickmore@igmm.ed.ac.uk
RI Bickmore, Wendy/C-7314-2013
FU Medical Research Council; Breakthrough Breast Cancer; Breast Cancer
   campaign; European Research Council [249956]; MRC [MC_PC_U127527202]
   Funding Source: UKRI; European Research Council (ERC) [249956] Funding
   Source: European Research Council (ERC)
FX The authors declare that they have no competing interests. SR was funded
   by a PhD studentship from the Medical Research Council and by
   Breakthrough Breast Cancer. DS is funded by Breast Cancer campaign and
   the Medical Research Council. WAB is funded by the Medical Research
   Council and European Research Council Advanced Grant 249956.
CR Akhtar W, 2013, CELL, V154, P914, DOI 10.1016/j.cell.2013.07.018
   Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006
   Bickmore WA, 2013, CELL, V152, P1270, DOI 10.1016/j.cell.2013.02.001
   Boyle S, 2001, HUM MOL GENET, V10, P211, DOI 10.1093/hmg/10.3.211
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Chambeyron S, 2004, GENE DEV, V18, P1119, DOI 10.1101/gad.292104
   Chen DT, 2010, BREAST CANCER RES TR, V119, P335, DOI 10.1007/s10549-009-0344-y
   Chen W, 2011, SEMIN CELL DEV BIOL, V22, P749, DOI 10.1016/j.semcdb.2011.07.026
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Dallosso AR, 2012, ONCOGENE, V31, P4409, DOI 10.1038/onc.2011.609
   Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Eskeland R, 2010, MOL CELL, V38, P452, DOI 10.1016/j.molcel.2010.02.032
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gavrilov AA, NUCL ACIDS RES
   Ghanbarian AT, 2015, MOL BIOL EVOL, V32, P1748, DOI 10.1093/molbev/msv053
   Guglielmi B, 2013, MOL CELL, V51, P480, DOI 10.1016/j.molcel.2013.08.009
   Harewood L, 2010, GENOME RES, V20, P554, DOI 10.1101/gr.103622.109
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Javierre BM, 2011, MOL CANCER RES, V9, P1139, DOI 10.1158/1541-7786.MCR-10-0515
   Jönsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596
   Karp G, 2007, CANCER LETT, V246, P173, DOI 10.1016/j.canlet.2006.02.012
   Kulartz M, 2003, BIOCHEM BIOPH RES CO, V305, P412, DOI 10.1016/S0006-291X(03)00773-3
   Le Dily F, 2014, GENE DEV, V28, P2151, DOI 10.1101/gad.241422.114
   Letourneau A, 2014, NATURE, V508, P345, DOI 10.1038/nature13200
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Meaburn KJ, 2009, J CELL BIOL, V187, P801, DOI 10.1083/jcb.200909127
   Morey C, 2007, DEVELOPMENT, V134, P909, DOI 10.1242/dev.02779
   Morrison G, 2014, BREAST CANCER RES TR, V144, P263, DOI 10.1007/s10549-014-2878-x
   MULLICK A, 1990, CANCER RES, V50, P333
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nolen LD, 2013, HUM MOL GENET, V22, P4180, DOI 10.1093/hmg/ddt265
   Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002
   Park JH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-82
   Patel NS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003614
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotgia F, 2012, CELL CYCLE, V11, P4390, DOI 10.4161/cc.22777
   Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688
   Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923
   Takizawa T, 2008, CELL, V135, P9, DOI 10.1016/j.cell.2008.09.026
   Therizols P, 2014, SCIENCE, V346, P1238, DOI 10.1126/science.1259587
   Timp W, NAT REV CANC
   Vallot C, 2015, ONCOGENE, V34, P741, DOI 10.1038/onc.2013.604
   Vallot C, 2011, JNCI-J NATL CANCER I, V103, P47, DOI 10.1093/jnci/djq470
   van de Wiel MA, 2007, BIOINFORMATICS, V23, P892, DOI 10.1093/bioinformatics/btm030
   Vogel MJ, 2006, GENOME RES, V16, P1493, DOI 10.1101/gr.5391806
   Williamson I, 2014, GENE DEV, V28, P2778, DOI 10.1101/gad.251694.114
   Zhang XS, 2012, P NATL ACAD SCI USA, V109, P13331, DOI 10.1073/pnas.1203280109
NR 58
TC 36
Z9 40
U1 0
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-6906
EI 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD AUG 3
PY 2015
VL 16
AR 145
DI 10.1186/s13059-015-0719-9
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CO9YV
UT WOS:000359533800001
PM 26235388
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Barrow, TM
   Barault, L
   Ellsworth, RE
   Harris, HR
   Binder, AM
   Valente, AL
   Shriver, CD
   Michels, KB
AF Barrow, Timothy M.
   Barault, Ludovic
   Ellsworth, Rachel E.
   Harris, Holly R.
   Binder, Alexandra M.
   Valente, Allyson L.
   Shriver, Craig D.
   Michels, Karin B.
TI Aberrant methylation of imprinted genes is associated with negative
   hormone receptor status in invasive breast cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE DNA methylation; genomic imprinting; pyrosequencing; breast cancer;
   hormone receptor
ID DNA METHYLATION; COLORECTAL-CANCER; OVARIAN-CANCER; PROMOTER
   METHYLATION; GESTATIONAL-AGE; FREQUENT LOSS; HUMAN GRB10; IGF2;
   EXPRESSION; ESTROGEN
AB Epigenetic regulation of imprinted genes enables monoallelic expression according to parental origin, and its disruption is implicated in many cancers and developmental disorders. The expression of hormone receptors is significant in breast cancer because they are indicators of cancer cell growth rate and determine response to endocrine therapies. We investigated the frequency of aberrant events and variation in DNA methylation at nine imprinted sites in invasive breast cancer and examined the association with estrogen and progesterone receptor status. Breast tissue and blood from patients with invasive breast cancer (n=38) and benign breast disease (n=30) were compared with those from healthy individuals (n=36), matched with the cancer patients by age at diagnosis, ethnicity, body mass index, menopausal status and familial history of cancer. DNA methylation and allele-specific expression were analyzed by pyrosequencing. Tumor-specific methylation changes at IGF2 DMR2 were observed in 59% of cancer patients, IGF2 DMR0 in 38%, DIRAS3 DMR in 36%, GRB10 ICR in 23%, PEG3 DMR in 21%, MEST ICR in 19%, H19 ICR in 18%, KvDMR in 8% and SNRPN/SNURF ICR in 4%. Variation in methylation was significantly greater in breast tissue from cancer patients compared with that in healthy individuals and benign breast disease. Aberrant methylation of three or more sites was significantly associated with negative estrogen-alpha (Fisher's exact test, p=0.02) and progesterone-A (p=0.02) receptor status. Aberrant events and increased variation in imprinted gene DNA methylation, therefore, seem to be frequent in invasive breast cancer and are associated with negative estrogen and progesterone receptor status, without loss of monoallelic expression.
   What's new? Epigenetic regulation of imprinted genes enables monoallelic expression according to parental origin, and its disruption is implicated in many cancers. Elucidating the relationship between imprinted genes and hormone receptor status in breast cancer may provide insight into tumorigenesis and potential prognostic factors. This is the first study to identify an association between the aberrant DNA methylation of imprinted genes and negative status of the estrogen and progesterone receptors in breast cancer. Variation in methylation increases from normal tissue to benign disease to cancer. Epigenetic disruption of imprinted genes may play an important role in the development of different breast cancer subtypes.
C1 [Barrow, Timothy M.; Barault, Ludovic; Harris, Holly R.; Binder, Alexandra M.; Michels, Karin B.] Harvard Univ, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Sch Med,Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA.
   [Barrow, Timothy M.; Michels, Karin B.] Univ Med Ctr Freiburg, Inst Prevent & Canc Epidemiol, Freiburg, Germany.
   [Ellsworth, Rachel E.] Henry M Jackson Fdn Adv Mil Med, Clin Breast Care Project, Windber, PA USA.
   [Valente, Allyson L.] Windber Res Inst, Clin Breast Care Project, Windber, PA USA.
   [Shriver, Craig D.] Walter Reed Natl Mil Med Ctr, Clin Breast Care Project, Bethesda, MD USA.
   [Michels, Karin B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Brigham & Women's Hospital;
   University of Freiburg; Henry M. Jackson Foundation for the Advancement
   of Military Medicine, Inc; Windber Research Institute; Walter Reed
   National Military Medical Center; Harvard University; Harvard T.H. Chan
   School of Public Health
RP Michels, KB (通讯作者)，Harvard Univ, Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Sch Med,Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA.
EM kmichels@research.bwh.harvard.edu
RI Harris, Holly/AAK-6844-2020; Binder, Alexandra/JCP-1962-2023; Barault,
   Ludovic/J-2472-2016
OI Barault, Ludovic/0000-0001-5227-5047; Barrow,
   Timothy/0000-0003-4551-3857
FU National Cancer Institute, National Institutes of Health, Department of
   Health and Human Services [R03CA143967]; Breast Cancer Research
   Foundation
FX Grant sponsor: National Cancer Institute, National Institutes of Health,
   Department of Health and Human Services; Grant number: R03CA143967;
   Grant sponsor: Breast Cancer Research Foundation
CR Alvi MA, 2013, CLIN CANCER RES, V19, P878, DOI 10.1158/1078-0432.CCR-12-2880
   Baba Y, 2010, GASTROENTEROLOGY, V139, P1855, DOI 10.1053/j.gastro.2010.07.050
   Barault L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055896
   Barbaux S, 2012, EPIGENETICS-US, V7, P1079, DOI 10.4161/epi.21495
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bentzon N, 2008, INT J CANCER, V122, P1089, DOI 10.1002/ijc.22892
   Blagitko N, 2000, HUM MOL GENET, V9, P1587, DOI 10.1093/hmg/9.11.1587
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Cerrato F, 2008, HUM MOL GENET, V17, P1427, DOI 10.1093/hmg/ddn031
   Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z
   Chik F, 2014, CARCINOGENESIS, V35, P138, DOI 10.1093/carcin/bgt284
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Cui HM, 2002, CANCER RES, V62, P6442
   Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9
   Dalai I, 2007, NEOPLASIA, V9, P181, DOI 10.1593/neo.06838
   Dowdy SC, 2005, GYNECOL ONCOL, V99, P126, DOI 10.1016/j.ygyno.2005.05.036
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Feinberg AP, 2010, P NATL ACAD SCI USA, V107, P1757, DOI 10.1073/pnas.0906183107
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Feng WW, 2008, CANCER-AM CANCER SOC, V112, P1489, DOI 10.1002/cncr.23323
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Guo L, 2008, DEV BIOL, V320, P79, DOI 10.1016/j.ydbio.2008.04.025
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hartmann LC, 2005, NEW ENGL J MED, V353, P229, DOI 10.1056/NEJMoa044383
   Heaphy CM, 2006, INT J CANCER, V119, P108, DOI 10.1002/ijc.21815
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Kamikihara T, 2005, INT J CANCER, V115, P690, DOI 10.1002/ijc.20971
   KONDO M, 1995, ONCOGENE, V10, P1193
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Li Y, 2008, EXP MOL PATHOL, V84, P234, DOI 10.1016/j.yexmp.2008.03.013
   Lin D, 2011, J INT MED RES, V39, P1870, DOI 10.1177/147323001103900530
   McCann AH, 1996, HUM MOL GENET, V5, P1123, DOI 10.1093/hmg/5.8.1123
   Murphy SK, 2006, MOL CANCER RES, V4, P283, DOI 10.1158/1541-7786.MCR-05-0138
   Novakovic B, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-529
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Prabhu JS, 2012, TUMOR BIOL, V33, P315, DOI 10.1007/s13277-012-0343-1
   Rabinovitz S, 2012, P NATL ACAD SCI USA, V109, P7403, DOI 10.1073/pnas.1116661109
   Rodriguez BAT, 2011, CARCINOGENESIS, V32, P812, DOI 10.1093/carcin/bgr017
   Shetty PJ, 2011, J CANCER RES CLIN, V137, P339, DOI 10.1007/s00432-010-0890-z
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Takeo C, 2009, ENDOCR J, V56, P113, DOI 10.1507/endocrj.K08E-220
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Tian FL, 2012, MOL MED REP, V5, P1536, DOI 10.3892/mmr.2012.833
   Weaver JR, 2010, MOL CELL BIOL, V30, P3916, DOI 10.1128/MCB.01278-09
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Woodfine K, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-1
   Yoshihashi H, 2000, AM J HUM GENET, V67, P476, DOI 10.1086/302997
   Zhang XF, 2012, MOL BIOL REP, V39, P8621, DOI 10.1007/s11033-012-1716-7
NR 49
TC 25
Z9 35
U1 0
U2 35
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD AUG 1
PY 2015
VL 137
IS 3
BP 537
EP 547
DI 10.1002/ijc.29419
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CI3HS
UT WOS:000354639200005
PM 25560175
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Krautkramer, KA
   Reiter, L
   Denu, JM
   Dowell, JA
AF Krautkramer, Kimberly A.
   Reiter, Lukas
   Denu, John M.
   Dowell, James A.
TI Quantification of SAHA-Dependent Changes in Histone Modifications Using
   Data-Independent Acquisition Mass Spectrometry
SO JOURNAL OF PROTEOME RESEARCH
LA English
DT Article
DE Histone PTM; mass spectrometry; data-independent acquisition; DIA;
   epigenetics; proteomics; SAHA; acetylation; methylation
ID H4 LYSINE 16; TOP-DOWN; POSTTRANSLATIONAL MODIFICATIONS; TARGETED
   PROTEOMICS; HIGH-RESOLUTION; ACETYLATION; ANTIBODIES; REVEALS;
   VALIDATION; PATTERNS
AB Histone post-translational modifications (PTMs) are important regulators of chromatin structure and gene expression. Quantitative analysis of histone PTMs by mass spectrometry remains extremely challenging due to the complex and combinatorial nature of histone PTMs. The most commonly used mass spectrometry-based method for high-throughput histone PTM analysis is data-dependent acquisition (DDA). However, stochastic precursor selection and dependence on MS1 ions for quantification impede comprehensive interrogation of histone PTM states using DDA methods. To overcome these limitations, we utilized a data-independent acquisition (DIA) workflow that provides superior run-to-run consistency and postacquisition flexibility in comparison to DDA methods. In addition, we developed a novel DIA-based methodology to quantify isobaric, co-eluting histone peptides that lack unique MS2 transitions. Our method enabled deconvolution and quantification of histone PTMs that are otherwise refractory to quantitation, including the heavily acetylated tail of histone H4. Using this workflow, we investigated the effects of the histone deacetylase inhibitor SAHA (suberoylanilide hydroxamic acid) on the global histone PTM state of human breast cancer MCF7 cells. A total of 62 unique histone PTMs were quantified, revealing novel SAHA-induced changes in acetylation and methylation of histones H3 and H4.
C1 [Krautkramer, Kimberly A.; Denu, John M.; Dowell, James A.] Univ Wisconsin, Dept Biomol Chem, Madison, WI 53715 USA.
   [Krautkramer, Kimberly A.; Denu, John M.; Dowell, James A.] Univ Wisconsin, Wisconsin Inst Discovery, Madison, WI 53715 USA.
   [Krautkramer, Kimberly A.] Univ Wisconsin, Med Scientist Training Program, Madison, WI 53715 USA.
   [Reiter, Lukas] BiognoSYS AG, CH-8952 Schlieren, Switzerland.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Denu, JM (通讯作者)，Univ Wisconsin, Dept Biomol Chem, Madison, WI 53715 USA.
EM jmdenu@wisc.edu; jadowell@wisc.edu
RI Krautkramer, Kimberly/AAR-7014-2020
OI Krautkramer, Kimberly/0000-0002-9227-0977
FU NIH [GM059785-15/P250VA]; Molecular and Applied Nutrition Training
   Program (NIH) [5T32DK007665-22]; University of Wisconsin Medical
   Scientist Training Program (NIH) [5T32GM008692-15]
FX We thank the EpiMotif Group for support in establishing the workflow.
   The authors acknowledge the support of NIH grant GM059785-15/P250VA.
   K.A. Krautkramer is supported by the Molecular and Applied Nutrition
   Training Program (NIH grant 5T32DK007665-22) and the University of
   Wisconsin Medical Scientist Training Program (NIH grant
   5T32GM008692-15).
CR Bern M, 2010, ANAL CHEM, V82, P833, DOI 10.1021/ac901801b
   Bernhardt OM, 2012, 60 AM SOC MASS SPECT
   Britton LMP, 2011, EXPERT REV PROTEOMIC, V8, P631, DOI [10.1586/EPR.11.47, 10.1586/epr.11.47]
   Bruderer R, 2015, MOL CELL PROTEOMICS, V14, P1400, DOI 10.1074/mcp.M114.044305
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Dang WW, 2009, NATURE, V459, P802, DOI 10.1038/nature08085
   Distler U, 2014, NAT METHODS, V11, P167, DOI [10.1038/NMETH.2767, 10.1038/nmeth.2767]
   Escher C, 2012, PROTEOMICS, V12, P1111, DOI 10.1002/pmic.201100463
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Fuchs SM, 2011, CURR BIOL, V21, P53, DOI 10.1016/j.cub.2010.11.058
   Gillet LC, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.016717
   Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07
   Hattori T, 2013, NAT METHODS, V10, P992, DOI 10.1038/nmeth.2605
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Keller A, 2015, MOL CELL PROTEOMICS, V14, P1411, DOI 10.1074/mcp.O114.044917
   Lander ES, 2011, NATURE, V470, P187, DOI 10.1038/nature09792
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Law KP, 2013, EXPERT REV PROTEOMIC, V10, P551, DOI 10.1586/14789450.2013.858022
   Lin S, 2014, MOL CELL PROTEOMICS, V13, P2450, DOI 10.1074/mcp.O113.036459
   Lin S, 2012, METHOD ENZYMOL, V512, P3, DOI 10.1016/B978-0-12-391940-3.00001-9
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Moradian A, 2014, PROTEOMICS, V14, P489, DOI 10.1002/pmic.201300256
   Munster PN, 2001, CANCER RES, V61, P8492
   Nicklay JJ, 2009, J BIOL CHEM, V284, P1075, DOI 10.1074/jbc.M807274200
   Nishikori S, 2012, J MOL BIOL, V424, P391, DOI 10.1016/j.jmb.2012.09.022
   Ntai I, 2014, ANAL CHEM, V86, P4961, DOI 10.1021/ac500395k
   Peach SE, 2012, MOL CELL PROTEOMICS, V11, P128, DOI 10.1074/mcp.M111.015941
   Pesavento JJ, 2008, J BIOL CHEM, V283, P14927, DOI 10.1074/jbc.M709796200
   Peterson AC, 2012, MOL CELL PROTEOMICS, V11, P1475, DOI 10.1074/mcp.O112.020131
   Picotti P, 2010, NAT METHODS, V7, P43, DOI [10.1038/NMETH.1408, 10.1038/nmeth.1408]
   Reiter L, 2011, NAT METHODS, V8, P430, DOI [10.1038/NMETH.1584, 10.1038/nmeth.1584]
   Rudomin EL, 2009, J PROTEOME RES, V8, P3154, DOI 10.1021/pr801017a
   Sidoli S, 2015, MOL CELL PROTEOMICS, V14, P2420, DOI 10.1074/mcp.O114.046102
   Tsou CC, 2015, NAT METHODS, V12, P258, DOI [10.1038/NMETH.3255, 10.1038/nmeth.3255]
   Venable JD, 2004, NAT METHODS, V1, P39, DOI 10.1038/NMETH705
   Wu Q, 2013, J PROTEOME RES, V12, P4064, DOI 10.1021/pr4004079
   Xu GF, 2014, J PROTEOME RES, V13, P4211, DOI 10.1021/pr500497e
NR 38
TC 43
Z9 47
U1 0
U2 30
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1535-3893
EI 1535-3907
J9 J PROTEOME RES
JI J. Proteome Res.
PD AUG
PY 2015
VL 14
IS 8
BP 3252
EP 3262
DI 10.1021/acs.jproteome.5b00245
PG 11
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CO8DA
UT WOS:000359394000020
PM 26120868
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kwon, YJ
   Petrie, K
   Leibovitch, BA
   Zeng, L
   Mezei, M
   Howell, L
   Gil, V
   Christova, R
   Bansal, N
   Yang, S
   Sharma, R
   Ariztia, EV
   Frankum, J
   Brough, R
   Sbirkov, Y
   Ashworth, A
   Lord, CJ
   Zelent, A
   Farias, E
   Zhou, MM
   Waxman, S
AF Kwon, Yeon-Jin
   Petrie, Kevin
   Leibovitch, Boris A.
   Zeng, Lei
   Mezei, Mihaly
   Howell, Louise
   Gil, Veronica
   Christova, Rossitza
   Bansal, Nidhi
   Yang, Shuai
   Sharma, Rajal
   Ariztia, Edgardo V.
   Frankum, Jessica
   Brough, Rachel
   Sbirkov, Yordan
   Ashworth, Alan
   Lord, Christopher J.
   Zelent, Arthur
   Farias, Eduardo
   Zhou, Ming-Ming
   Waxman, Samuel
TI Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel
   Therapeutic Strategy in Triple-Negative Breast Cancer
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR-ALPHA; INDUCIBLE
   EARLY GENE; MACROCYCLIC LACTONES; TRANSCRIPTIONAL REPRESSION;
   STEM-CELLS; E-CADHERIN; COMPLEX; EXPRESSION; SURVIVAL
AB Triple-negative breast cancers (TNBC) lacking estrogen, progesterone, and HER2 receptors account for 10% to 20% of breast cancer and are indicative of poor prognosis. The development of effective treatment strategies therefore represents a pressing unmet clinical need. We previously identified a molecularly targeted approach to target aberrant epigenetics of TNBC using a peptide corresponding to the SIN3 interaction domain (SID) of MAD. SID peptide selectively blocked binding of SID-containing proteins to the paired a-helix (PAH2) domain of SIN3, resulting in epigenetic and transcriptional modulation of genes associated with epithelial-mesenchymal transition (EMT). To find small molecule inhibitor (SMI) mimetics of SID peptide, we performed an in silico screen for PAH2 domain-binding compounds. This led to the identification of the avermectin macrocyclic lactone derivatives selamectin and ivermectin (Mectizan) as candidate compounds. Both selamectin and ivermectin phenocopied the effects of SID peptide to block SIN3-PAH2 interaction with MAD, induce expression of CDH1 and ESR1, and restore tamoxifen sensitivity in MDA-MB-231 human and MMTV-Myc mouse TNBC cells in vitro. Treatment with selamectin or ivermectin led to transcriptional modulation of genes associated with EMT and maintenance of a cancer stem cell phenotype in TNBC cells. This resulted in impairment of clonogenic self-renewal in vitro and inhibition of tumor growth and metastasis in vivo. Underlining the potential of avermectins in TNBC, pathway analysis revealed that selamectin also modulated the expression of therapeutically targetable genes. Consistent with this, an unbiased drug screen in TNBC cells identified selamectin-induced sensitization to a number of drugs, including those targeting modulated genes.
C1 [Kwon, Yeon-Jin; Leibovitch, Boris A.; Bansal, Nidhi; Ariztia, Edgardo V.; Farias, Eduardo; Waxman, Samuel] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Div Hematol & Oncol, New York, NY 10029 USA.
   [Petrie, Kevin; Howell, Louise; Gil, Veronica; Christova, Rossitza; Frankum, Jessica; Brough, Rachel; Sbirkov, Yordan; Ashworth, Alan; Lord, Christopher J.; Zelent, Arthur] Inst Canc Res, London SW3 6JB, England.
   [Zeng, Lei; Mezei, Mihaly; Yang, Shuai; Sharma, Rajal; Zhou, Ming-Ming] Icahn Sch Med Mt Sinai, Struct & Chem Biol, New York, NY 10029 USA.
   [Zelent, Arthur] Univ Miami, Div Hematooncol, Sylvester Comprehens Canc Ctr, Miami, FL USA.
C3 Icahn School of Medicine at Mount Sinai; University of London; Institute
   of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Icahn
   School of Medicine at Mount Sinai; University of Miami
RP Waxman, S (通讯作者)，Icahn Sch Med Mt Sinai, Tisch Canc Inst, One Gustave L Levy Pl, New York, NY 10029 USA.
EM Samuel.waxman@mssm.edu
RI Bansal, Nidhi/R-1462-2016; Sbirkov, Yordan/GSM-6746-2022; Zelent,
   Arthur/B-3532-2009; Lord, Christopher/B-3295-2012; Petrie,
   Kevin/I-7115-2015
OI Leibovitch, Boris/0000-0001-6771-5906; Lord,
   Christopher/0000-0002-3226-0515; Sbirkov, Yordan/0000-0002-6554-3773;
   Petrie, Kevin/0000-0002-9805-9152; Bansal, Nidhi/0000-0001-6502-3930;
   Zelent, Arthur/0000-0002-7968-9888
FU NCI [1R01CA158121-01]; Samuel Waxman Cancer Research Foundation;
   Chemotherapy Foundation grants; Leukaemia and Lymphoma Research (LLR) UK
   Specialist Programme Grant [11046]; LLR Gordon Piller Fellowship
   [10053]; AICR Project Grant [11-0301]
FX This work was funded by NCI 1R01CA158121-01, Samuel Waxman Cancer
   Research Foundation, and Chemotherapy Foundation grants. K. Petrie and
   L. Howell were supported by a Leukaemia and Lymphoma Research (LLR) UK
   Specialist Programme Grant (11046). Y. Sbirkov was supported a LLR
   Gordon Piller Fellowship (10053). V. Gil was supported by an AICR
   Project Grant (11-0301).
CR Al-Lazikani B, 2012, NAT BIOTECHNOL, V30, P679, DOI 10.1038/nbt.2284
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Ayer DE, 1996, MOL CELL BIOL, V16, P5772
   Bajrami I, 2012, EMBO MOL MED, V4, P1087, DOI 10.1002/emmm.201201250
   Balch C, 2013, ADV EXP MED BIOL, V754, P285, DOI 10.1007/978-1-4419-9967-2_14
   Baltus GA, 2009, J BIOL CHEM, V284, P6998, DOI 10.1074/jbc.M807670200
   Boeke J, 2000, J BIOL CHEM, V275, P34963, DOI 10.1074/jbc.M005929200
   Bosch A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3247
   Brubaker K, 2000, CELL, V103, P655, DOI 10.1016/S0092-8674(00)00168-9
   CLORE GM, 1994, METHOD ENZYMOL, V239, P349
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Davison Z, 2011, NEOPLASIA, V13, P504, DOI 10.1593/neo.101590
   Ellison-Zelski SJ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-263
   Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09
   Farias EF, 2010, P NATL ACAD SCI USA, V107, P11811, DOI 10.1073/pnas.1006737107
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Galliher AJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1524
   Geiman TM, 2004, NUCLEIC ACIDS RES, V32, P2716, DOI 10.1093/nar/gkh589
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Gordon V, 2013, CLIN CANCER RES, V19, P3738, DOI 10.1158/1078-0432.CCR-12-0274
   Griffin J, 2005, J VET PHARMACOL THER, V28, P257, DOI 10.1111/j.1365-2885.2005.00655.x
   Grzenda A, 2009, BBA-GENE REGUL MECH, V1789, P443, DOI 10.1016/j.bbagrm.2009.05.007
   Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524
   Ishii Y, 2006, JNCI-J NATL CANCER I, V98, P1238, DOI 10.1093/jnci/djj334
   Jacob A, 2013, J CELL SCI, V126, P4647, DOI 10.1242/jcs.126573
   Jelinic P, 2011, MOL CELL BIOL, V31, P54, DOI 10.1128/MCB.00840-10
   Jenkins DE, 2005, BREAST CANCER RES, V7, pR444, DOI 10.1186/bcr1026
   Johnsen SA, 2002, ONCOGENE, V21, P5783, DOI 10.1038/sj.onc.1205681
   Johnsen SA, 2002, J CELL BIOCHEM, V87, P233, DOI 10.1002/jcb.10299
   Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005
   Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kokoz YM, 1999, BIOSCIENCE REP, V19, P535, DOI 10.1023/A:1020262811459
   Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091
   Lespine A, 2009, CURR DRUG METAB, V10, P272, DOI 10.2174/138920009787846297
   Li K, 2014, ONCOTARGETS THER, V7, P1083, DOI 10.2147/OTT.S64759
   Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Mealey KL, 2001, PHARMACOGENETICS, V11, P727, DOI 10.1097/00008571-200111000-00012
   Melotti A, 2014, EMBO MOL MED, V6, P1263, DOI 10.15252/emmm.201404084
   Mezei M, 2010, SOURCE CODE BIOL MED, V5, DOI 10.1186/1751-0473-5-2
   Mitra D, 2011, J BIOL CHEM, V286, P40531, DOI 10.1074/jbc.M111.304865
   Monteiro P, 2013, J CELL BIOL, V203, P1063, DOI 10.1083/jcb.201306162
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Nolan TJ, 2012, CURR PHARM BIOTECHNO, V13, P1078
   PACQUE M, 1990, LANCET, V336, P1486, DOI 10.1016/0140-6736(90)93187-T
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Sánchez-Tilló E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102
   Seguin L, 2014, NAT CELL BIOL, V16, P457, DOI 10.1038/ncb2953
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Shaw FL, 2012, J MAMMARY GLAND BIOL, V17, P111, DOI 10.1007/s10911-012-9255-3
   Silverstein RA, 2005, CURR GENET, V47, P1, DOI 10.1007/s00294-004-0541-5
   Söderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947
   STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thylefors B, 2008, ANN TROP MED PARASIT, V102, P39, DOI 10.1179/136485908X337481
   Tomao F, 2015, ONCOTARGETS THER, V8, P177, DOI 10.2147/OTT.S67673
   Viré E, 2014, MOL CELL, V53, P806, DOI 10.1016/j.molcel.2014.01.029
   Weigelt B, 2010, J PATHOL, V220, P263, DOI 10.1002/path.2648
   Yamamoto S, 2014, CANCER CELL, V25, P762, DOI 10.1016/j.ccr.2014.04.024
   Yang CC, 2012, CURR PHARM BIOTECHNO, V13, P999, DOI 10.2174/138920112800399059
   Zsoldos Z, 2007, J MOL GRAPH MODEL, V26, P198, DOI 10.1016/j.jmgm.2006.06.002
NR 67
TC 64
Z9 71
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG
PY 2015
VL 14
IS 8
BP 1824
EP 1836
DI 10.1158/1535-7163.MCT-14-0980-T
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CO7FI
UT WOS:000359324600006
PM 26078298
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Schech, A
   Kazi, A
   Yu, S
   Shah, P
   Sabnis, G
AF Schech, Amanda
   Kazi, Armina
   Yu, Stephen
   Shah, Preeti
   Sabnis, Gauri
TI Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells
   in Triple-Negative Breast Cancer Cells
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; DRUG-RESISTANCE;
   E-CADHERIN; METASTASIS; IDENTIFICATION; EXPRESSION; MARKER; GROWTH; EMT
AB Mortality following breast cancer diagnosis is mainly due to the development of distant metastasis. To escape from the primary site, tumor cells undergo the epithelial-to-mesenchymal transition (EMT), which helps them acquire a more motile and invasive phenotype. In our previous study, we showed that class I selective HDAC inhibitor entinostat reverses the EMT phenotype through reversal of epigenetic repression of E-cadherin. Recent evidence suggests that a subset of cells within a breast tumor may drive the metastatic outgrowth following escape from the primary site. These cells, termed tumor-initiating cells (TIC), represent a great threat to overall prognosis. They are critical in terms of drug resistance and tumor initiation at metastatic sites. Acquisition of EMT traits has also been shown to impart TIC phenotype to the cells, making EMT a "dual-threat" for prognosis. In the current study, we show that entinostat treatment can reduce the percentage of TIC cells from triple-negative breast cancer (TNBC) cells. Entinostat treatment was able to reduce the CD44high/CD24low cell population, ALDH-1 activity, as well as protein and mRNA expression of known TIC markers such as Bmi-1, Nanog, and Oct-4. Next, we inoculated MDA-MB-231 cells transfected with firefly luciferase (231/Luc) in mammary fat pad of NSG mice. The mice were then treated with entinostat (2.5 mg/kg/d), and tumor development and formation of metastasis were assessed by bioluminescence imaging. Treatment with entinostat significantly reduced tumor formation at the primary site as well as lung metastasis. As such, entinostat may help prevent development of distant metastasis.
C1 [Schech, Amanda; Kazi, Armina; Yu, Stephen; Shah, Preeti; Sabnis, Gauri] Univ Maryland, Dept Pharmacol, Sch Med, Baltimore, MD 21201 USA.
   [Schech, Amanda; Kazi, Armina; Yu, Stephen; Shah, Preeti; Sabnis, Gauri] Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD USA.
   [Kazi, Armina] Loyola Univ Maryland, Dept Biol, Baltimore, MD USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University System of Maryland; University of Maryland Baltimore; Loyola
   University Maryland
RP Sabnis, G (通讯作者)，Univ Maryland, Dept Pharmacol & Expt Therapeut, Sch Med, 685 West Baltimore St,HSF-1 580-1, Baltimore, MD 21201 USA.
EM gsabnis@som.umaryland.edu
OI Sabnis, Gauri/0000-0001-8703-9394
FU Susan G. Komen for the Cure [KG10037]; DOD-BCRP [BC1039031]
FX This work was supported by grants to G. Sabnis (KG10037) from Susan G.
   Komen for the Cure and to A. Kazi (BC1039031) from DOD-BCRP.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bisso A, 2013, CELL CYCLE, V12, P1679, DOI 10.4161/cc.24757
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Brown KA, 2004, BREAST CANCER RES, V6, pR215, DOI 10.1186/bcr778
   Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9
   Debeb BG, 2012, STEM CELLS, V30, P2366, DOI 10.1002/stem.1219
   Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Giudice FS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058672
   Hay ED, 1995, ACTA ANAT, V154, P8
   Iorns E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047995
   Ji DB, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-86
   Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989
   Kim M, 2002, CLIN CANCER RES, V8, P22
   Kong XG, 2006, MOL CELL BIOL, V26, P2019, DOI 10.1128/MCB.26.6.2019-2028.2006
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Morimoto K, 2009, CANCER SCI, V100, P1062, DOI 10.1111/j.1349-7006.2009.01151.x
   Naldini A, 2012, ANTI-CANCER AGENT ME, V12, P407, DOI 10.2174/187152012800228706
   Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Sabnis G, 2009, CANCER RES, V69, P1416, DOI 10.1158/0008-5472.CAN-08-0857
   Sabnis GJ, 2013, MOL CANCER THER, V12, P2804, DOI 10.1158/1535-7163.MCT-13-0345
   Sabnis GJ, 2011, CANCER RES, V71, P1893, DOI 10.1158/0008-5472.CAN-10-2458
   Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Shah P, 2014, BREAST CANCER RES TR, V143, P99, DOI 10.1007/s10549-013-2784-7
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Song LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025454
   Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946
   Tran DD, 2011, MOL CANCER RES, V9, P1644, DOI 10.1158/1541-7786.MCR-11-0371
   van Horssen R, 2012, BREAST CANCER RES TR, V136, P365, DOI 10.1007/s10549-012-2261-8
   Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
NR 33
TC 78
Z9 86
U1 1
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD AUG
PY 2015
VL 14
IS 8
BP 1848
EP 1857
DI 10.1158/1535-7163.MCT-14-0778
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CO7FI
UT WOS:000359324600008
PM 26037781
OA Bronze, Green Submitted
DA 2025-01-12
ER

PT J
AU Huston, A
   Arrowsmith, CH
   Knapp, S
   Schapira, M
AF Huston, Andrea
   Arrowsmith, Cheryl H.
   Knapp, Stefan
   Schapira, Matthieu
TI Probing the epigenome
SO NATURE CHEMICAL BIOLOGY
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; METHYLTRANSFERASE ACTIVITY; CHEMICAL PROBE;
   BREAST-CANCER; IN-VIVO; INHIBITION; LEUKEMIA; BROMODOMAINS; EXPRESSION;
   INDUCTION
AB Epigenetic chemical probes are having a strong impact in biological discovery and target validation. Systematic coverage of emerging epigenetic target classes with these potent, selective, cell-active chemical tools will profoundly influence understanding of the human biology and pathology of chromatin-templated mechanisms.
C1 [Huston, Andrea; Arrowsmith, Cheryl H.; Schapira, Matthieu] Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada.
   [Arrowsmith, Cheryl H.] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Arrowsmith, Cheryl H.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   [Knapp, Stefan] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
   [Knapp, Stefan] Univ Oxford, Target Discovery Inst, Oxford, England.
   [Knapp, Stefan] Univ Oxford, Struct Genom Consortium, Oxford, England.
   [Knapp, Stefan] Goethe Univ Frankfurt, Inst Pharmaceut Chem, D-60054 Frankfurt, Germany.
   [Schapira, Matthieu] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada.
C3 University of Toronto; Structural Genomics Consortium; University of
   Toronto; University Health Network Toronto; Princess Margaret Cancer
   Centre; University of Toronto; University of Oxford; University of
   Oxford; University of Oxford; Goethe University Frankfurt; University of
   Toronto
RP Huston, A (通讯作者)，Univ Toronto, Struct Genom Consortium, Toronto, ON, Canada.
EM knapp@pharmchem.uni-frankfurt.de; matthieu.schapira@utoronto.ca
RI Knapp, Stefan/AAG-2347-2019
OI Knapp, Stefan/0000-0001-5995-6494; Arrowsmith,
   Cheryl/0000-0002-4971-3250
FU Wellcome Trust [106169] Funding Source: Medline
CR Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Baldwin RM, 2015, ONCOTARGET, V6, P3013, DOI 10.18632/oncotarget.3072
   Bitler BG, 2015, NAT MED, V21, P231, DOI 10.1038/nm.3799
   Borkin D, 2015, CANCER CELL, V27, P589, DOI 10.1016/j.ccell.2015.02.016
   Bunnage ME, 2013, NAT CHEM BIOL, V9, P195, DOI 10.1038/nchembio.1197
   Cao F, 2014, MOL CELL, V53, P247, DOI 10.1016/j.molcel.2013.12.001
   Chan-Penebre E, 2015, NAT CHEM BIOL, V11, P432, DOI [10.1038/NCHEMBIO.1810, 10.1038/nchembio.1810]
   Chen CW, 2015, NAT MED, V21, P335, DOI 10.1038/nm.3832
   Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108
   Copeland RA, 2013, CLIN CANCER RES, V19, P6344, DOI 10.1158/1078-0432.CCR-13-0223
   Edwards AM, 2011, NATURE, V470, P163, DOI 10.1038/470163a
   Fedorov O, 2010, NAT CHEM BIOL, V6, P166, DOI 10.1038/nchembio.297
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Frye SV, 2010, NAT CHEM BIOL, V6, P159, DOI 10.1038/nchembio.296
   Gibaja V, 2016, ONCOGENE, V35, P558, DOI 10.1038/onc.2015.114
   Grebien F, 2015, NAT CHEM BIOL, V11, P571, DOI [10.1038/NCHEMBIO.1859, 10.1038/nchembio.1859]
   James LI, 2013, NAT CHEM BIOL, V9, P184, DOI [10.1038/nchembio.1157, 10.1038/NCHEMBIO.1157]
   Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108
   Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830
   Meyer TE, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001045
   Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589
   Schones DE, 2014, EPIGENET CHROMATIN, V7, DOI 10.1186/1756-8935-7-23
   Shi Y, 2008, CELL STEM CELL, V3, P568, DOI 10.1016/j.stem.2008.10.004
   Shi Y, 2008, CELL STEM CELL, V2, P525, DOI 10.1016/j.stem.2008.05.011
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229
   Xhemalce B, 2012, CELL, V151, P278, DOI 10.1016/j.cell.2012.08.041
   Yao RS, 2014, CANCER RES, V74, P5656, DOI 10.1158/0008-5472.CAN-14-0800
   Yu H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.28
NR 30
TC 35
Z9 38
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1552-4450
EI 1552-4469
J9 NAT CHEM BIOL
JI Nat. Chem. Biol.
PD AUG
PY 2015
VL 11
IS 8
BP 542
EP 545
DI 10.1038/nchembio.1871
PG 4
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CN2MJ
UT WOS:000358255300004
PM 26196765
DA 2025-01-12
ER

PT J
AU El-Awady, RA
   Hersi, F
   Al-Tunaiji, H
   Saleh, EM
   Abdel-Wahab, AHA
   Al Homssi, A
   Suhail, M
   El-Serafi, A
   Al-Tel, T
AF El-Awady, Raafat A.
   Hersi, Fatema
   Al-Tunaiji, Hala
   Saleh, Ekram M.
   Abdel-Wahab, Abdel-Hady A.
   Al Homssi, Amer
   Suhail, Mousa
   El-Serafi, Ahmed
   Al-Tel, Taleb
TI Epigenetics and miRNA as predictive markers and targets for lung cancer
   chemotherapy
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE doxorubicin; epigenetics; HDAC; miRNA; trichostatin A; 5-aza-2
   '-deoxycytidine
ID BREAST-CANCER; DNA METHYLATION; ANTICANCER DRUGS; TRICHOSTATIN-A;
   CELL-DEATH; EXPRESSION; DOXORUBICIN; CHEMORESISTANCE; SENSITIVITY;
   ACTIVATION
AB Lung cancer cells show inherent and acquired resistance to chemotherapy. The lack of good predictive markers/novel targets and the incomplete understanding of the mechanisms of resistance limit the success of lung cancer response to chemotherapy. In the present study, we used an isogenic pair of lung adenocarcinoma cell lines; A549 (wild-type) and A549DOX11 (doxorubicin resistant) to study the role of epigenetics and miRNA in resistance/response of non-small cell lung cancer (NSCLC) cells to doxorubicin. Our results demonstrate differential expression of epigenetic markers whereby the level of HDACs 1, 2, 3 and4, DNA methyltransferase, acetylated H2B and acetylated H3 were lower in A549DOX11 compared to A549 cells. Fourteen miRNAs were dys-regulated in A549DOX11 cells compared to A549 cells, of these 14 miRNAs, 4 (has-mir-1973, 494, 4286 and 29b-3p) have shown 2.99 - 4.44 fold increase in their expression. This was associated with reduced apoptosis and higher resistance of A549DOX11cells to doxorubicin and etoposide. Sequential treatment with the epigenetic modifiers trichostatin A or 5-aza-2'-deoxycytidine followed by doxorubicin resulted in: (i) enhanced sensitivity of both cell lines to doxorubicin especially at low concentrations, (ii) enhanced doxorubicin-induced DNA damage in both cell lines, (iii) dysregulation of some miRNAs in A549 cells. In conclusion, A549DOX11 cells resistant to DNA damaging drugs have epigenetic profile and miRNA expression different from the sensitive cells. Moreover, epigenetic modifiers may reverse the resistance of certain NSCLC cells to DNA damaging agents by enhancing induction of DNA damage. This may open the door for using epigenetic profile/miRNA expression of some cancer cells as resistance markers/targets to improve response of resistant cells to doxorubicin and for the use of combination doxorubicin/epigenetic modifiers to reduce doxorubicin toxicity.
C1 [El-Awady, Raafat A.; Al-Tel, Taleb] Univ Sharjah, Coll Pharm, Sharjah, U Arab Emirates.
   [El-Awady, Raafat A.; Hersi, Fatema; Al-Tunaiji, Hala; Al-Tel, Taleb] Univ Sharjah, Sharjah Inst Med Res, Sharjah, U Arab Emirates.
   [El-Awady, Raafat A.; Saleh, Ekram M.; Abdel-Wahab, Abdel-Hady A.] Cairo Univ, Natl Canc Inst, Dept Canc Biol, Pharmacol Unit, Cairo, Egypt.
   [El-Awady, Raafat A.; Saleh, Ekram M.; Abdel-Wahab, Abdel-Hady A.] Cairo Univ, Natl Canc Inst, Dept Canc Biol, Clin Biochem Unit, Cairo, Egypt.
   [El-Awady, Raafat A.; Saleh, Ekram M.; Abdel-Wahab, Abdel-Hady A.] Cairo Univ, Natl Canc Inst, Dept Canc Biol, Mol Biol Unit, Cairo, Egypt.
   [El-Awady, Raafat A.; Al Homssi, Amer; Suhail, Mousa; El-Serafi, Ahmed] Univ Sharjah, Coll Med, Sharjah, U Arab Emirates.
   [El-Serafi, Ahmed] Suez Canal Univ, Coll Med, Ismaileya, Egypt.
C3 University of Sharjah; University of Sharjah; Egyptian Knowledge Bank
   (EKB); Cairo University; National Cancer Institute - Egypt; Egyptian
   Knowledge Bank (EKB); Cairo University; National Cancer Institute -
   Egypt; Egyptian Knowledge Bank (EKB); Cairo University; National Cancer
   Institute - Egypt; University of Sharjah; Egyptian Knowledge Bank (EKB);
   Suez Canal University
RP El-Awady, RA (通讯作者)，Univ Sharjah, Coll Pharm, Sharjah, U Arab Emirates.
EM relawady@sharjah.ac.ae
RI Al-tel, Taleb/L-3689-2019; Elserafy, Ahmed/U-4246-2019
OI AlTel, Taleb/0000-0003-4914-9677; El-Serafi, Ahmed/0000-0001-5394-9082;
   Hersi, Fatema/0000-0002-7122-4779
FU KEF-HOLDING-FAIZAL; Shabana Foundation; Boehringer Ingelheim
   Pharmaceutical company
FX This work was supported by the KEF-HOLDING-FAIZAL and Shabana Foundation
   and the Boehringer Ingelheim Pharmaceutical company.
CR [Anonymous], J CLIN BIOINFORMATIC
   Bao LL, 2012, AM J PATHOL, V180, P2490, DOI 10.1016/j.ajpath.2012.02.024
   Basile V, 2006, J BIOL CHEM, V281, P2347, DOI 10.1074/jbc.M507712200
   Calcagno AM, 2008, BRIT J CANCER, V98, P1515, DOI 10.1038/sj.bjc.6604334
   Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022
   Dong ZY, 2014, INT J ONCOL, V45, P978, DOI 10.3892/ijo.2014.2486
   El-Awady RA, 2011, TOXICOL APPL PHARM, V255, P271, DOI 10.1016/j.taap.2011.06.019
   Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465
   Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024
   Hajji N, 2008, ONCOGENE, V27, P3134, DOI 10.1038/sj.onc.1210976
   Heller G, 2012, CLIN CANCER RES, V18, P1619, DOI 10.1158/1078-0432.CCR-11-2450
   Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266
   Li LH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104203
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Newbold A, 2014, ONCOGENE, V33, P5415, DOI 10.1038/onc.2013.482
   Pang B, 2013, NAT COMM, V4, P1
   Pronzato P, 2011, LUNG CANCER, V34, P57
   Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Romano G, 2012, P NATL ACAD SCI USA, V109, P16570, DOI 10.1073/pnas.1207917109
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Saleh EM, 2012, CANCER BIOL THER, V13, P1058, DOI 10.4161/cbt.21078
   Singhal SS, 2006, FEBS LETT, V580, P2258, DOI 10.1016/j.febslet.2006.03.038
   TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9
   Tsuchiya Y, 2006, CANCER RES, V66, P9090, DOI 10.1158/0008-5472.CAN-06-1403
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Vijayaraghavalu S, 2013, MOL PHARMACEUT, V10, P337, DOI 10.1021/mp3004622
   Yang F, 2014, BBA-REV CANCER, V1845, P84, DOI 10.1016/j.bbcan.2013.12.002
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhao AH, 2012, J GENET GENOMICS, V39, P29, DOI 10.1016/j.jgg.2011.12.003
   Zhou RP, 2014, ASIAN PAC J CANCER P, V15, P1241, DOI 10.7314/APJCP.2014.15.3.1241
   Zhu XL, 2012, ACTA BIOCH BIOPH SIN, V44, P519, DOI 10.1093/abbs/gms026
NR 32
TC 44
Z9 48
U1 0
U2 19
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JUL
PY 2015
VL 16
IS 7
BP 1056
EP 1070
DI 10.1080/15384047.2015.1046023
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CM5AW
UT WOS:000357699300008
PM 25962089
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Cal, S
   López-Otín, C
AF Cal, Santiago
   Lopez-Otin, Carlos
TI ADAMTS proteases and cancer
SO MATRIX BIOLOGY
LA English
DT Article
DE Disintegrin; Metalloprotease; Thrombospondin; Tumorigenesis; Tumor
   microenvironment
ID BREAST-CANCER; MATRIX METALLOPROTEINASES; PROTEOLYTIC CLEAVAGE;
   TUMOR-SUPPRESSOR; EXPRESSION; FAMILY; METHYLATION; DISINTEGRIN; CLONING;
   GROWTH
AB ADAMTSs (A disintegrin and metalloprotease domains with thrombospondins motifs) are complex extracellular proteases that have been related to both oncogenic and tumor-protective functions. These enzymes can be secreted by cancer and stromal cells and may contribute to modify the tumor microenvironment by multiple mechanisms. Thus, ADAMTSs can cleave or interact with a wide range of extracellular matrix components or regulatory factors, and therefore affect cell adhesion, migration, proliferation and angiogenesis. The balance of protumor versus antitumor effects of ADAMTSs may depend on the nature of their substrates or interacting-partners upon secretion from the cell. Moreover, different ADAMTS genes have been found overexpressed, mutated or epigenetically silenced in tumors from different origins, suggesting the direct impact of these metalloproteases in cancer development. However, despite the important advances on the tumor biology of ADAMTSs in recent years, more mechanistic and functional studies are necessary to fully understand how these proteases can influence tumor microenvironment to potentiate cancer growth or to induce tumor regression. This review outlines current and emerging connections between ADAMTSs and cancer. (C) 2015 Published by Elsevier BM.
C1 [Cal, Santiago; Lopez-Otin, Carlos] Univ Oviedo, Dept Bioquim & Biol Mol, IUOPA, E-33006 Oviedo, Asturias, Spain.
C3 University of Oviedo; Instituto Universitario de Oncologia de Asturias
RP Cal, S (通讯作者)，Univ Oviedo, Dept Bioquim & Biol Mol, C Femando Bongera S-N, E-33006 Oviedo, Asturias, Spain.
EM santical@uniovi.es
RI Lopez-Otin, Carlos/AAB-2106-2020
OI Lopez-Otin, Carlos/0000-0001-6964-1904
FU Instituto de Salud Carlos III (Ministerio de Economia y Competitividad,
   Spain) [PI11/00371]; Ministerio de Economia y Competitividad, Spain
   [SAF2011-23089]; FP7 (MicroEnviMet); Banco Santander through its
   Santander Universities Global Division
FX This work was supported by grant PI11/00371 from the Instituto de Salud
   Carlos III (Ministerio de Economia y Competitividad, Spain) to S. Cal,
   and SAF2011-23089 (Ministerio de Economia y Competitividad, Spain) and
   FP7 (MicroEnviMet) to C. Lopez-Otin. The authors apologize to
   investigators whose work could not be cited due to space limitations.
   C.L-O. is an Investigator of the Botin Foundation supported by Banco
   Santander through its Santander Universities Global Division.
CR Al Nakouzi N, 2012, NEOPLASIA, V14, P376, DOI 10.1593/neo.12308
   Apte SS, 2004, INT J BIOCHEM CELL B, V36, P981, DOI 10.1016/j.biocel.2004.01.014
   Baird BN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067054
   Beristain AG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018473
   Bondeson J, 2008, CLIN EXP RHEUMATOL, V26, P139
   Cal S, 2002, GENE, V283, P49, DOI 10.1016/S0378-1119(01)00861-7
   Casal C, 2010, CANCER RES, V70, P4676, DOI 10.1158/0008-5472.CAN-09-4197
   Choi GCG, 2014, MOL CANCER RES, V12, P228, DOI 10.1158/1541-7786.MCR-13-0195
   Choi JE, 2008, CANCER GENET CYTOGEN, V187, P80, DOI 10.1016/j.cancergencyto.2008.08.001
   COLIGE A, 1995, J BIOL CHEM, V270, P16724, DOI 10.1074/jbc.270.28.16724
   Colige A, 2004, J INVEST DERMATOL, V123, P656, DOI 10.1111/j.0022-202X.2004.23406.x
   Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200
   Coussens LM, 1996, CHEM BIOL, V3, P895, DOI 10.1016/S1074-5521(96)90178-7
   Dagoneau N, 2004, AM J HUM GENET, V75, P801, DOI 10.1086/425231
   Demircan K, 2009, HEAD NECK-J SCI SPEC, V31, P793, DOI 10.1002/hed.21045
   Du W, 2013, ONCOGENE, V32, P3319, DOI 10.1038/onc.2012.359
   El Hour M, 2010, ONCOGENE, V29, P3025, DOI 10.1038/onc.2010.49
   Esselens C, 2010, J BIOL CHEM, V285, P2463, DOI 10.1074/jbc.M109.055129
   Fernandes RJ, 2001, J BIOL CHEM, V276, P31502, DOI 10.1074/jbc.M103466200
   Filou S, 2013, BIOCHIMIE, V95, P725, DOI 10.1016/j.biochi.2012.10.022
   Fontanil T, 2014, ONCOTARGET, V5, P1253, DOI 10.18632/oncotarget.1690
   Freitas VM, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-2
   Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001
   Held-Feindt J, 2006, INT J CANCER, V118, P55, DOI 10.1002/ijc.21258
   Hu B, 2008, J BIOL CHEM, V283, P24848, DOI 10.1074/jbc.M801433200
   Inagaki J, 2014, EXP CELL RES, V323, P263, DOI 10.1016/j.yexcr.2014.03.002
   Iruela-Arispe ML, 2003, ANN NY ACAD SCI, V995, P183, DOI 10.1111/j.1749-6632.2003.tb03221.x
   Jin H, 2007, ONCOGENE, V26, P7490, DOI 10.1038/sj.onc.1210559
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Kelwick R, 2015, INT J CANCER, V136, pE14, DOI 10.1002/ijc.29129
   Kim YH, 2011, ANN SURG ONCOL, V18, P2338, DOI 10.1245/s10434-011-1573-y
   Koo BH, 2002, THROMB RES, V105, P471, DOI 10.1016/S0049-3848(02)00053-1
   Kuno K, 1997, J BIOL CHEM, V272, P556, DOI 10.1074/jbc.272.1.556
   Lee NV, 2005, J BIOL CHEM, V280, P34796, DOI 10.1074/jbc.M506980200
   Levy GG, 2001, NATURE, V413, P488, DOI 10.1038/35097008
   Li Z, 2010, MED ONCOL, V27, P998, DOI 10.1007/s12032-009-9323-8
   Lind GE, 2006, CELL ONCOL, V28, P259
   Liu YJ, 2006, ONCOGENE, V25, P2452, DOI 10.1038/sj.onc.1209287
   Llamazares M, 2003, J BIOL CHEM, V278, P13382, DOI 10.1074/jbc.M211900200
   Llamazares M, 2007, J CELL SCI, V120, P3544, DOI 10.1242/jcs.005751
   Lu X, 2009, GENE DEV, V23, P1882, DOI 10.1101/gad.1824809
   Masui T, 2001, CLIN CANCER RES, V7, P3437
   Minn AJ, 2005, J CLIN INVEST, V115, P44, DOI 10.1172/JCI200522320
   Minobe K, 2010, INT J ONCOL, V37, P569, DOI 10.3892/ijo_00000706
   Moncada-Pazos A, 2009, J CELL SCI, V122, P2906, DOI 10.1242/jcs.050468
   Morales J, 2009, AM J HUM GENET, V85, P558, DOI 10.1016/j.ajhg.2009.09.011
   Nakada M, 2005, ACTA NEUROPATHOL, V110, P239, DOI 10.1007/s00401-005-1032-6
   Noël A, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00140
   Obaya AJ, 2012, CANCER LETT, V325, P132, DOI 10.1016/j.canlet.2012.06.019
   Peng L, 2013, MOL MED REP, V7, P1055, DOI 10.3892/mmr.2013.1291
   Porter S, 2004, CLIN CANCER RES, V10, P2429, DOI 10.1158/1078-0432.CCR-0398-3
   Porter S, 2006, INT J CANCER, V118, P1241, DOI 10.1002/ijc.21476
   Porter S, 2005, BIOCHEM J, V386, P15, DOI 10.1042/BJ20040424
   Rao N, 2013, INT J CANCER, V133, P294, DOI 10.1002/ijc.28037
   Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054
   Ricciardelli C, 2011, AM J PATHOL, V179, P3075, DOI 10.1016/j.ajpath.2011.08.021
   Rocks N, 2008, BIOCHIMIE, V90, P369, DOI 10.1016/j.biochi.2007.08.008
   Rodríguez-Rodero S, 2013, J CLIN ENDOCR METAB, V98, P2811, DOI 10.1210/jc.2012-3566
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Somerville RPT, 2003, J BIOL CHEM, V278, P9503, DOI 10.1074/jbc.M211009200
   Suga A, 2006, DEV BIOL, V295, P26, DOI 10.1016/j.ydbio.2006.02.041
   Sulzmaier FJ, 2013, CANCER RES, V73, P6099, DOI 10.1158/0008-5472.CAN-13-1087
   Tan ID, 2013, INT J CANCER, V133, P2263, DOI 10.1002/ijc.28127
   Timpl R, 2003, NAT REV MOL CELL BIO, V4, P479, DOI 10.1038/nrm1130
   Tortorella MD, 1999, SCIENCE, V284, P1664, DOI 10.1126/science.284.5420.1664
   Tyan SW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035128
   Viapiano MS, 2008, J NEURO-ONCOL, V88, P261, DOI 10.1007/s11060-008-9575-8
   Viloria CG, 2009, CANCER RES, V69, P4926, DOI 10.1158/0008-5472.CAN-08-4155
   Wang D, 2011, DIGEST DIS SCI, V56, P3281, DOI 10.1007/s10620-011-1723-x
   Wang WM, 2003, J BIOL CHEM, V278, P19549, DOI 10.1074/jbc.M300767200
   Wei XM, 2010, MOL CANCER RES, V8, P1513, DOI 10.1158/1541-7786.MCR-10-0262
   Yi CH, 2007, AM J PATHOL, V170, P1535, DOI 10.2353/ajpath.2007.060478
   Yi JM, 2013, CLIN CANCER RES, V19, P6544, DOI 10.1158/1078-0432.CCR-12-3224
NR 73
TC 116
Z9 116
U1 0
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0945-053X
EI 1569-1802
J9 MATRIX BIOL
JI Matrix Biol.
PD MAY-JUL
PY 2015
VL 44-46
SI SI
BP 77
EP 85
DI 10.1016/j.matbio.2015.01.013
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CL8MT
UT WOS:000357229500010
PM 25636539
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Calmon, MF
   Jeschke, J
   Zhang, W
   Dhir, M
   Siebenkäs, C
   Herrera, A
   Tsai, HC
   O'Hagan, HM
   Pappou, EP
   Hooker, CM
   Fu, T
   Schuebel, KE
   Gabrielson, E
   Rahal, P
   Herman, JG
   Baylin, SB
   Ahuja, N
AF Calmon, Marilia Freitas
   Jeschke, Jana
   Zhang, Wei
   Dhir, Mashaal
   Siebenkaes, Cornelia
   Herrera, Alexander
   Tsai, Hsing-Chen
   O'Hagan, Heather M.
   Pappou, Emmanouil P.
   Hooker, Craig M.
   Fu, Tao
   Schuebel, Kornel E.
   Gabrielson, Edward
   Rahal, Paula
   Herman, James G.
   Baylin, Stephen B.
   Ahuja, Nita
TI Epigenetic silencing of neurofilament genes promotes an aggressive
   phenotype in breast cancer
SO EPIGENETICS
LA English
DT Article
DE breast cancer; DNA methylation; NEFH; NEFL; NEFM; TCGA
ID DNA HYPERMETHYLATION; COLORECTAL-CANCER; INTERMEDIATE-FILAMENTS; HISTONE
   MODIFICATIONS; CELL CARCINOMA; METHYLATION; HETEROZYGOSITY;
   INACTIVATION; EXPRESSION; BIOMARKERS
AB Neurofilament heavy polypeptide (NEFH) has recently been identified as a candidate DNA hypermethylated gene within the functional breast cancer hypermethylome. NEFH exists in a complex with neurofilament medium polypeptide (NEFM) and neurofilament light polypeptide (NEFL) to form neurofilaments, which are structural components of the cytoskeleton in mature neurons. Recent studies reported the deregulation of these proteins in several malignancies, suggesting that neurofilaments may have a role in other cell types as well. Using a comprehensive approach, we studied the epigenetic inactivation of neurofilament genes in breast cancer and the functional significance of this event. We report that DNA methylation-associated silencing of NEFH, NEFL, and NEFM in breast cancer is frequent, cancer-specific, and correlates with clinical features of disease progression. DNA methylation-mediated inactivation of these genes occurs also in multiple other cancer histologies including pancreas, gastric, and colon. Restoration of NEFH function, the major subunit of the neurofilament complex, reduces proliferation and growth of breast cancer cells and arrests them in Go/G1 phase of the cell cycle along with a reduction in migration and invasion. These findings suggest that DNA methylation-mediated silencing of the neurofilament genes NEFH, NEFM, and NEFL are frequent events that may contribute to the progression of breast cancer and possibly other malignancies.
C1 [Calmon, Marilia Freitas; Rahal, Paula] Univ Sao Paulo State, Dept Biol, Sao Paulo, Brazil.
   [Calmon, Marilia Freitas; Jeschke, Jana; Dhir, Mashaal; Siebenkaes, Cornelia; Herrera, Alexander; Pappou, Emmanouil P.; Fu, Tao; Ahuja, Nita] Johns Hopkins Univ, Dept Surg, Baltimore, MD USA.
   [Calmon, Marilia Freitas; Jeschke, Jana; Zhang, Wei; Tsai, Hsing-Chen; O'Hagan, Heather M.; Hooker, Craig M.; Schuebel, Kornel E.; Herman, James G.; Baylin, Stephen B.; Ahuja, Nita] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21205 USA.
   [Jeschke, Jana] Univ Libre Bruxelles, Lab Canc Epigenet, Fac Med, Brussels, Belgium.
   [Gabrielson, Edward] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA.
   [Ahuja, Nita] Johns Hopkins Univ, Dept Urol, Baltimore, MD USA.
C3 Universidade Estadual Paulista; Johns Hopkins University; Johns Hopkins
   University; Universite Libre de Bruxelles; Johns Hopkins University;
   Johns Hopkins University
RP Baylin, SB (通讯作者)，Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21205 USA.
EM sbaylin@jhmi.edu; nahuja@jhmi.edu
RI zhang, wei/A-7015-2011; Calmon, Marilia/H-3150-2012; Tsai,
   Hsing-Chen/AAE-7530-2021; O'Hagan, Heather/AAF-5385-2020; Rahal,
   Paula/D-3871-2012
OI Tsai, Hsing-Chen/0000-0002-7057-9084; Calmon,
   Marilia/0000-0001-5203-0103; O'Hagan, Heather/0000-0001-9750-5088; Dhir,
   Mashaal/0000-0002-1426-1098; Rahal, Paula/0000-0001-5693-6148; Jeschke,
   Jana/0000-0002-6047-2558
FU NIH; Susan G. Komen Foundation; Mary Kay Foundation; American College of
   Surgeons/Society of University Surgeons; German Academic Exchange
   Service (DAAD); NCI
FX This study was supported by the NIH, Susan G. Komen Foundation, Mary Kay
   Foundation, American College of Surgeons/Society of University Surgeons,
   German Academic Exchange Service (DAAD), Dr. Jost Henkel Stiftung and
   the Mentored Patient-Oriented Research Career Development Award from NCI
   (K23).
CR Alholle A, 2013, EPIGENETICS-US, V8, P1198, DOI 10.4161/epi.26266
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Clements EG, 2012, NUCLEIC ACIDS RES, V40, P4334, DOI 10.1093/nar/gks031
   Dedeurwaerder S, 2014, BRIEF BIOINFORM, V15, P929, DOI 10.1093/bib/bbt054
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Dubrowinskaja N, 2014, CANCER MED-US, V3, P300, DOI 10.1002/cam4.181
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   EMI M, 1992, CANCER RES, V52, P5368
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fahrner JA, 2002, CANCER RES, V62, P7213
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Glöckner SC, 2009, CANCER RES, V69, P4691, DOI 10.1158/0008-5472.CAN-08-0142
   Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   HOFFMAN PN, 1984, J CELL BIOL, V99, P705, DOI 10.1083/jcb.99.2.705
   Huang ZQ, 2014, J ORAL PATHOL MED, V43, P191, DOI 10.1111/jop.12109
   Jeschke J, 2013, CLIN CANCER RES, V19, P3201, DOI 10.1158/1078-0432.CCR-12-3751
   Jeschke J, 2012, EPIGENETICS-US, V7, P701, DOI 10.4161/epi.20445
   Kim MS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009003
   Kizildag S, 2008, J BUON, V13, P533
   Kudo LC, 2010, HUM MOL GENET, V19, P3233, DOI 10.1093/hmg/ddq232
   Li XQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031146
   Liang JY, 2003, CELL CYCLE, V2, P339, DOI 10.4161/cc.2.4.433
   LIEM RKH, 1978, J CELL BIOL, V79, P637, DOI 10.1083/jcb.79.3.637
   Mersiyanova IV, 2000, AM J HUM GENET, V67, P37, DOI 10.1086/302962
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Ohm JE, 2007, CELL CYCLE, V6, P1040, DOI 10.4161/cc.6.9.4210
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015
   Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Skvortsova V, 2004, EUR J HUM GENET, V12, P241, DOI 10.1038/sj.ejhg.5201144
   STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113
   Thijssen PE, 2013, EPIGENETICS-US, V8, P512, DOI 10.4161/epi.24450
   VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047
   Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.3.CO;2-B
   Yi JM, 2011, CLIN CANCER RES, V17, P1535, DOI 10.1158/1078-0432.CCR-10-2509
   Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349
NR 44
TC 31
Z9 32
U1 0
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JUL 3
PY 2015
VL 10
IS 7
BP 622
EP 632
DI 10.1080/15592294.2015.1050173
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CL4WM
UT WOS:000356957200006
PM 25985363
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Umbreit, C
   Erben, P
   Faber, A
   Hofheinz, RD
   Aderhold, C
   Weiss, C
   Hoermann, K
   Wenzel, A
   Schultz, JD
AF Umbreit, Claudia
   Erben, Philipp
   Faber, Anne
   Hofheinz, Ralf-Dieter
   Aderhold, Christoph
   Weiss, Christel
   Hoermann, Karl
   Wenzel, Angela
   Schultz, Johannes David
TI MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive
   Squamous Cell Carcinoma in Therapeutic EGFR Inhibition <i>In Vitro</i>
SO ANTICANCER RESEARCH
LA English
DT Article
DE gefitinib; lapatinib; MMP9; cyclin D1; beta-catenin; epithelial growth
   factor receptor (EGFR); head and neck squamous cancer cells (HNSCC);
   epithelial-mesenchymal transition (EMT); mesenchymal-epithelial
   transition (MET); human papillomavirus (HPV)
ID EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-RECEPTOR;
   HUMAN-PAPILLOMAVIRUS; MATRIX METALLOPROTEINASES; OROPHARYNGEAL CANCER;
   BREAST-CANCER; NECK-CANCER; HEAD; EXPRESSION; HPV
AB Background/Aim: In the United States 53,640 new cases of head and neck cancer were estimated in 2013. Over 95% of these cases were evaluated as squamous cell carcinoma (SCC). At present, smoking, drinking alcohol, chewing betel and infection with high-risk types of human papilloma virus (HPV) are classified as risk factors of oropharyngeal squamous cancer cell carcinoma (OPSCC). It could be suggested that patients with HPV-positive OPSCC have a better response to chemoradiotherapy than patients without. In many studies, there was observed an inverse correlation between epithelial growth factor receptor (EGFR) expression and HPV status in p16-positive SCC. Therefore, it is of great clinical interest to specify the phenotype of cancer cells in order to further individualize treatment modalities. The aim of the study was to investigate the expression pattern of specific markers in p16-positive SCC cells after stimulation with lapatinib and gefitinib. Materials and Methods: We incubated p16-positive CERV196 cells with lapatinib and gefitinib (2 mu g/ml) and after 5, 24 and 96 h determined E-cadherin, vimentin, matrix metalloproteinase-9 (MMP9), cyclin D1 and beta-catenin by immunocytochemistry, enzyme-linked immunosorbent assay and quantitative polymerase chain reaction (PCR). Results: We found an increase of E-cadherin and a decrease of vimentin in unstimulated cells. We detected an alteration of expression of vimentin and E-cadherin level after treatment with lapatinib and gefitinib. We demonstrated a statistically significant lapatinib- and gefitinib-induced repression of cyclin D1, MMP9 and beta-catenin in CERV196 cells dependent on incubation time. Conclusion: Cyclin D1 and MMP9 expression profiles may represent an early measure of sensitivity and level of response to lapatinib and gefitinib. The presented cell culture model is, therefore, well-suited for further study of epigenetic regulation of molecular targeted-therapy by EGFR inhibition and prevention of mesenchymal transition in p16-positive SCC cells.
C1 [Umbreit, Claudia; Faber, Anne; Aderhold, Christoph; Hoermann, Karl; Wenzel, Angela; Schultz, Johannes David] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany.
   [Erben, Philipp] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Dept Urol, Mannheim, Germany.
   [Hofheinz, Ralf-Dieter] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Dept Hematol & Oncol, Mannheim, Germany.
   [Weiss, Christel] Heidelberg Univ, Med Fac Mannheim, Univ Med Ctr Mannheim, Inst Med Stat & Biometry, Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls
   University Heidelberg
RP Umbreit, C (通讯作者)，Univ Hosp Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM claudia.umbreit@web.de
RI Erben, Philipp/AAR-4908-2020; Erben, Philipp/JHU-4920-2023
OI Erben, Philipp/0000-0002-8279-7636
CR Al Moustafa Ala-Eddin, 2012, Front Biosci (Schol Ed), V4, P671
   Al-Azri AR, 2013, ORAL DIS, V19, P347, DOI 10.1111/odi.12023
   [Anonymous], EUR ARCH OTORHINOLAR
   Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509
   Burris HA, 2004, ONCOLOGIST, V9, P10, DOI 10.1634/theoncologist.9-suppl_3-10
   Dalianis T, 2014, PRESSE MED, V43, pE429, DOI 10.1016/j.lpm.2014.08.010
   de Andrés MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054957
   Denaro N, 2014, ONCOLOGY-BASEL, V86, P212, DOI 10.1159/000357712
   Dorsey K, 2013, DRUGS, V73, P315, DOI 10.1007/s40265-013-0025-3
   Erjala K, 2006, CLIN CANCER RES, V12, P4103, DOI 10.1158/1078-0432.CCR-05-2404
   Fan LZ, 2007, MOL BIOL CELL, V18, P1083, DOI 10.1091/mbc.E06-07-0602
   Folgueras AR, 2004, INT J DEV BIOL, V48, P411, DOI 10.1387/ijdb.041811af
   Fumagalli I, 2015, ONCOTARGETS THER, V8, P335, DOI 10.2147/OTT.S68235
   Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709
   Guo F, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-19
   Hay ED, 2005, DEV DYNAM, V233, P706, DOI 10.1002/dvdy.20345
   Huang SH, 2013, MED ORAL PATOL ORAL, V18, pE233, DOI 10.4317/medoral.18772
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Kim SH, 2006, CELL MOL LIFE SCI, V63, P930, DOI 10.1007/s00018-005-5561-x
   Klussmann JP, 2009, HNO, V57, P113, DOI 10.1007/s00106-008-1867-y
   Krisanaprakornkit Suttichai, 2012, ISRN Oncol, V2012, P681469, DOI 10.5402/2012/681469
   Kumar B, 2008, J CLIN ONCOL, V26, P3128, DOI 10.1200/JCO.2007.12.7662
   La Monica S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078656
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018
   Li W, 2004, HEAD NECK-J SCI SPEC, V26, P1, DOI 10.1002/hed.10335
   Li Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094508
   Martins VL, 2013, CELL TISSUE RES, V351, P255, DOI 10.1007/s00441-012-1410-z
   Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24
   Masuda M, 1996, CANCER, V78, P390
   Narayanan R, 2012, INT J ONCOL, V40, P13, DOI 10.3892/ijo.2011.1211
   O-charoenrat P, 1999, CLIN EXP METASTAS, V17, P631, DOI 10.1023/A:1006751016860
   O-charoenrat P, 2000, CANCER RES, V60, P1121
   O'Neill F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-41
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Reimers N, 2007, INT J CANCER, V120, P1731, DOI 10.1002/ijc.22355
   Ren BM, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-55
   Richter P, 2011, J ORAL PATHOL MED, V40, P46, DOI 10.1111/j.1600-0714.2010.00936.x
   Rodrigues IS, 2013, BRIT J CANCER, V109, P184, DOI 10.1038/bjc.2013.273
   Saawarn S, 2012, SCI WORLD J, DOI 10.1100/2012/978327
   Sidransky David, 1995, Current Opinion in Oncology, V7, P229, DOI 10.1097/00001622-199505000-00007
   Sudhoff HH, 2011, EUR ARCH OTO-RHINO-L, V268, P1541, DOI 10.1007/s00405-011-1714-8
   Sun Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031093
   Tamamura R, 2013, ACTA HISTOCHEM, V115, P113, DOI 10.1016/j.acthis.2012.05.001
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Umbreit C, 2014, ANTICANCER RES, V34, P7061
   Wang H, 2014, INT J CLIN EXP PATHO, V7, P264
   Wheeler S, 2012, CLIN CANCER RES, V18, P2278, DOI 10.1158/1078-0432.CCR-11-1593
   Xie M, 2012, J CELL BIOCHEM, V113, P1501, DOI 10.1002/jcb.24019
   Yang ZC, 2013, MOL MED REP, V8, P1663, DOI 10.3892/mmr.2013.1728
   Yoo SB, 2013, ANN SURG ONCOL, V20, pS545, DOI 10.1245/s10434-013-2970-1
   Zhao YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093210
NR 52
TC 3
Z9 4
U1 0
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JUL
PY 2015
VL 35
IS 7
BP 3801
EP 3810
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CL6YV
UT WOS:000357116400009
PM 26124325
DA 2025-01-12
ER

PT J
AU Klinke, OK
   Mizani, T
   Baldwin, G
   Bancel, B
   Devouassoux-Shisheboran, M
   Scoazec, JY
   Bringuier, PP
   Feederle, R
   Jauch, A
   Hinderhofer, K
   Taniere, P
   Delecluse, HJ
AF Klinke, Olaf Karl
   Mizani, Tuba
   Baldwin, Gouri
   Bancel, Brigitte
   Devouassoux-Shisheboran, Mojgan
   Scoazec, Jean-Yves
   Bringuier, Pierre-Paul
   Feederle, Regina
   Jauch, Anna
   Hinderhofer, Katrin
   Taniere, Philippe
   Delecluse, Henri-Jacques
TI KIT Mutation and Loss of 14q May Be Sufficient for the Development of
   Clinically Symptomatic Very Low-Risk GIST
SO PLOS ONE
LA English
DT Article
ID GASTROINTESTINAL STROMAL TUMORS; OF-FUNCTION MUTATIONS; SUPPRESSOR GENE
   LOCI; BREAST-CANCER RISK; SUCCINATE-DEHYDROGENASE; FREQUENT LOSS;
   VARIANT; FAMILY; DOMAIN; BRCA2
AB The aim of this study was to determine the minimal set of genetic alterations required for the development of a very low risk clinically symptomatic gastro-intestinal stromal tumour within the stomach wall. We studied the genome of a very low-risk gastric gastro-intestinal stromal tumour by whole-genome sequencing, comparative genomic hybridisation and methylation profiling. The studied tumour harboured two typical genomic lesions: loss of the long arm of chromosome 14 and an activating mutation in exon 11 of KIT. Besides these genetic lesions, only two point mutations that may affect tumour progression were identified: A frame-shift deletion in RNF146 and a missense mutation in a zinc finger of ZNF407. Whilst the frame-shift deletion in RNF146 seemed to be restricted to this particular tumour, a similar yet germline mutation in ZNF407 was found in a panel of 52 gastro-intestinal stromal tumours from different anatomical sites and different categories. Germline polymorphisms in the mitotic checkpoint proteins Aurora kinase A and BUB1 kinase B may have furthered tumour growth. The epigenetic profile of the tumour matches that of other KIT-mutant tumours. We have identified mutations in three genes and loss of the long arm of chromosome 14 as the so far minimal set of genetic abnormalities sufficient for the development of a very low risk clinically symptomatic gastric stromal tumour.
C1 [Klinke, Olaf Karl; Mizani, Tuba; Feederle, Regina; Delecluse, Henri-Jacques] German Canc Res Ctr DKFZ Unit F100, Heidelberg, Germany.
   [Klinke, Olaf Karl; Mizani, Tuba; Feederle, Regina; Delecluse, Henri-Jacques] Inserm Unit U1074, Heidelberg, Germany.
   [Baldwin, Gouri; Taniere, Philippe] Trust Queen Elizabeth Hosp Birmingham, NHS Fdn, Histopathol Cellular Pathol Univ Hosp Birmingh, Edgbaston Birmingham B15 2WB, England.
   [Bancel, Brigitte; Devouassoux-Shisheboran, Mojgan] Hop Croix Rousse, Serv Anat & Cytol Pathol, F-69317 Lyon 04, France.
   [Scoazec, Jean-Yves; Bringuier, Pierre-Paul] Hop Edouard Herriot, Serv Anat Pathol, F-69437 Lyon 03, France.
   [Jauch, Anna; Hinderhofer, Katrin] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU Lyon; CHU
   Lyon; Ruprecht Karls University Heidelberg
RP Delecluse, HJ (通讯作者)，German Canc Res Ctr DKFZ Unit F100, Heidelberg, Germany.
EM H.Delecluse@dkfz-heidelberg.de
OI Feederle, Regina/0000-0002-3981-367X; Delecluse,
   Henri-Jacques/0000-0002-1744-6274
FU Birmingham Science City - Experimental Medicine Network of Excellence
   project
FX The authors gratefully acknowledge the contribution to this study made
   by the University of Birmingham's Human Biomaterials Resource Centre,
   which has been supported through Birmingham Science City - Experimental
   Medicine Network of Excellence project. HJD is the director of Inserm
   unit U1074,
   http://www.grand-est.inserm.fr/rubriques/l-inserm-grand-est/organisation
   /structures-de-recherche/heidelberg/annexes/unite-inserm-1074.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Andrabi SA, 2011, NAT MED, V17, P692, DOI 10.1038/nm.2387
   [Anonymous], 2001, TRANSFORMATION E COL
   [Anonymous], ONCOTARGET
   AU HC, 1995, GENE, V159, P249, DOI 10.1016/0378-1119(95)00162-Y
   Bandera CA, 1997, CANCER RES, V57, P513
   Beghini A, 2001, CANCER, V92, P657, DOI 10.1002/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Blay JY, 2012, ANN ONCOL, V23, P49, DOI 10.1093/annonc/mds252
   Borrego S, 2003, AM J HUM GENET, V72, P88, DOI 10.1086/345466
   Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688
   Corless CL, 2011, NAT REV CANCER, V11, P865, DOI 10.1038/nrc3143
   Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   El-Rifai W, 2000, GENE CHROMOSOME CANC, V27, P387, DOI 10.1002/(SICI)1098-2264(200004)27:4<387::AID-GCC8>3.0.CO;2-C
   Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085
   Filippova GN, 2002, CANCER RES, V62, P48
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Gao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085377
   Gill AJ, 2010, AM J SURG PATHOL, V34, P636, DOI 10.1097/PAS.0b013e3181d6150d
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Healey CS, 2000, NAT GENET, V26, P362, DOI 10.1038/81691
   Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Irusta PM, 1998, EMBO J, V17, P6912, DOI 10.1093/emboj/17.23.6912
   Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108
   Joensuu H, 2013, LANCET, V382, P973, DOI 10.1016/S0140-6736(13)60106-3
   Jones DTW, 2013, NAT GENET, V45, P927, DOI 10.1038/ng.2682
   Killian JK, 2013, CANCER DISCOV, V3, P648, DOI 10.1158/2159-8290.CD-13-0092
   Kroeger N, 2013, CANCER-AM CANCER SOC, V119, P1547, DOI 10.1002/cncr.27947
   Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113
   Lesueur F, 2006, CANCER RES, V66, P1177, DOI 10.1158/0008-5472.CAN-05-2995
   Liu XM, 2011, HUM MUTAT, V32, P894, DOI 10.1002/humu.21517
   Maher ER, 2002, HUM MOL GENET, V11, P2347, DOI 10.1093/hmg/11.20.2347
   Menon AG, 1997, ONCOGENE, V14, P611, DOI 10.1038/sj.onc.1200853
   Miettinen M, 2006, ARCH PATHOL LAB MED, V130, P1466
   Miettinen M, 2011, AM J SURG PATHOL, V35, P1712, DOI 10.1097/PAS.0b013e3182260752
   Miranda C, 2012, CLIN CANCER RES, V18, P1769, DOI 10.1158/1078-0432.CCR-11-2230
   Monzon FA, 2011, MODERN PATHOL, V24, P1470, DOI 10.1038/modpathol.2011.107
   Nakai N, 2008, J PATHOL, V214, P302, DOI 10.1002/path.2296
   Nannini M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-685
   Okamoto Y, 2012, GUT, V61, P392, DOI 10.1136/gut.2011.241034
   Palli D, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-170
   Pantaleo MA, 2011, J NATL CANCER I, V103, P983, DOI 10.1093/jnci/djr130
   Rubió-Casadevall J, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0474-0
   Schoppmann SF, 2013, CLIN CANCER RES, V19, P5329, DOI 10.1158/1078-0432.CCR-12-3863
   Shen HB, 2005, ONCOL REP, V13, P355
   Spurdle AB, 2002, CANCER EPIDEM BIOMAR, V11, P413
   Stubbs L, 2011, SUBCELL BIOCHEM, V52, P75, DOI 10.1007/978-90-481-9069-0_4
   TAKAYAMA H, 1992, ONCOGENE, V7, P1185
   Tarn C, 2005, CLIN CANCER RES, V11, P3668, DOI 10.1158/1078-0432.CCR-04-2515
   Terheyden P, 2010, J INVEST DERMATOL, V130, P314, DOI 10.1038/jid.2009.197
   Theobald M, 1999, GENE CHROMOSOME CANC, V26, P40, DOI 10.1002/(SICI)1098-2264(199909)26:1<40::AID-GCC6>3.3.CO;2-N
   Ylipää A, 2011, CANCER-AM CANCER SOC, V117, P380, DOI 10.1002/cncr.25594
   YOUNG J, 1993, ONCOGENE, V8, P671
NR 55
TC 5
Z9 5
U1 1
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 23
PY 2015
VL 10
IS 6
AR e0130149
DI 10.1371/journal.pone.0130149
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CL4DD
UT WOS:000356901900031
PM 26102504
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Conway, K
   Edmiston, SN
   Tse, CK
   Bryant, C
   Kuan, PF
   Hair, BY
   Parrish, EA
   May, R
   Swift-Scanlan, T
AF Conway, Kathleen
   Edmiston, Sharon N.
   Tse, Chiu-Kit
   Bryant, Christopher
   Kuan, Pei Fen
   Hair, Brionna Y.
   Parrish, Eloise A.
   May, Ryan
   Swift-Scanlan, Theresa
TI Racial Variation in Breast Tumor Promoter Methylation in the Carolina
   Breast Cancer Study
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID RECEPTOR TYROSINE KINASE; DNA METHYLATION; AFRICAN-AMERICAN; CYTOSINE
   MODIFICATIONS; MOLECULAR PORTRAITS; COMPLEX TRAITS; SURVIVAL; GENOME;
   WOMEN; GENE
AB Background: African American (AA) women are diagnosed with more advanced breast cancers and have worse survival than white women, but a comprehensive understanding of the basis for this disparity remains unclear. Analysis of DNA methylation, an epigenetic mechanism that can regulate gene expression, could help to explain racial differences in breast tumor clinical biology and outcomes.
   Methods: DNA methylation was evaluated at 1,287 CpGs in the promoters of cancer-related genes in 517 breast tumors of AA (n = 216) or non-AA (n = 301) cases in the Carolina Breast Cancer Study (CBCS).
   Results: Multivariable linear regression analysis of all tumors, controlling for age, menopausal status, stage, intrinsic subtype, and multiple comparisons [false discovery rate (FDR)], identified seven CpG probes that showed significant (adjusted P < 0.05) differential methylation between AAs and non-AAs. Stratified analyses detected an additional four CpG probes differing by race within hormone receptor-negative (HR-) tumors. Genes differentially methylated by race included DSC2, KCNK4, GSTM1, AXL, DNAJC15, HBII-52, TUSC3, and TES; the methylation state of several of these genes may be associated with worse survival in AAs. TCGA breast tumor data confirmed the differential methylation by race and negative correlations with expression for most of these genes. Several loci also showed racial differences in methylation in peripheral blood leukocytes (PBL) from CBCS cases, indicating that these variations were not necessarily tumor-specific.
   Conclusions: Racial differences in the methylation of cancer-related genes are detectable in both tumors and PBLs from breast cancer cases.
   Impact: Epigenetic variation could contribute to differences in breast tumor development and outcomes between AAs and non-AAs. (C)2015 AACR.
C1 [Conway, Kathleen; Tse, Chiu-Kit; Hair, Brionna Y.] Univ N Carolina, Dept Epidemiol, Sch Publ Hlth, Chapel Hill, NC 27599 USA.
   [Conway, Kathleen; Edmiston, Sharon N.; Parrish, Eloise A.; Swift-Scanlan, Theresa] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Bryant, Christopher] Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA.
   [Kuan, Pei Fen] SUNY Stony Brook, Dept Appl Math & Stat, Stony Brook, NY 11794 USA.
   [May, Ryan] EMMES Corp, Rockville, MD USA.
   [Swift-Scanlan, Theresa] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   State University of New York (SUNY) System; Stony Brook University;
   Emmes Corporation; University of North Carolina; University of North
   Carolina Chapel Hill
RP Conway, K (通讯作者)，Univ N Carolina, Dept Epidemiol, Campus Box 7435, Chapel Hill, NC 27599 USA.
EM kconway@med.unc.edu
RI Kuan, Pei Fen/GRX-4622-2022
FU Susan G. Komen Foundation [KG081397]; University Cancer Research Fund of
   North Carolina; National Cancer Institute Specialized Program of
   Research Excellence (SPORE) in Breast Cancer [NIH/NCI P50-CA58223]
FX This research was supported by grants to K. Conway from Susan G. Komen
   Foundation (grant #KG081397) and from the University Cancer Research
   Fund of North Carolina. The CBCS was also funded by the University
   Cancer Research Fund of North Carolina and the National Cancer Institute
   Specialized Program of Research Excellence (SPORE) in Breast Cancer
   (NIH/NCI P50-CA58223).
CR Adkins RM, 2011, BIRTH DEFECTS RES A, V91, P728, DOI 10.1002/bdra.20770
   Ambrosone CB, 2014, ONCOTARGET, V5, P237, DOI 10.18632/oncotarget.1599
   Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Barnholtz-Sloan JS, 2010, CARCINOGENESIS, V31, P1417, DOI 10.1093/carcin/bgq128
   BELL DA, 1993, J NATL CANCER I, V85, P1159, DOI 10.1093/jnci/85.14.1159
   Breton CV, 2011, EPIGENETICS-US, V6, P895, DOI 10.4161/epi.6.7.15768
   Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Choufani S, 2011, GENOME RES, V21, P465, DOI 10.1101/gr.111922.110
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   Culhane AC, 2009, CANCER RES, V69, P7480, DOI 10.1158/0008-5472.CAN-08-3350
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang WK, 2010, HUM PATHOL, V41, P1456, DOI 10.1016/j.humpath.2010.04.003
   Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107
   Hamidov Z, 2011, J CLIN PATHOL, V64, P990, DOI 10.1136/jclinpath-2011-200099
   Herman JG, 2005, COLD SH Q B, V70, P329, DOI 10.1101/sqb.2005.70.036
   Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koestler DC, 2013, EPIGENETICS-US, V8, P816, DOI 10.4161/epi.25430
   Kwabi-Addo B, 2010, CLIN CANCER RES, V16, P3539, DOI 10.1158/1078-0432.CCR-09-3342
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Maskarinec G, 2011, WOMENS HEALTH, V7, P677, DOI [10.2217/whe.11.67, 10.2217/WHE.11.67]
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Moen EL, 2013, GENETICS, V194, P987, DOI 10.1534/genetics.113.151381
   Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046
   NEWMAN B, 1995, BREAST CANCER RES TR, V35, P51, DOI 10.1007/BF00694745
   O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pils D, 2013, CANCER-AM CANCER SOC, V119, P946, DOI 10.1002/cncr.27850
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Shavers VL, 2002, JNCI-J NATL CANCER I, V94, P334
   Shoemaker R, 2010, GENOME RES, V20, P883, DOI 10.1101/gr.104695.109
   Smigal C, 2006, CA-CANCER J CLIN, V56, P168, DOI 10.3322/canjclin.56.3.168
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Thomas NE, 2014, PIGM CELL MELANOMA R, V27, P1097, DOI 10.1111/pcmr.12289
   Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433
   Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103
   Wang SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037928
   Wedderburn, 1974, BIOMETRIKA, V61, P439
   Xu SJ, 1998, J BIOL CHEM, V273, P3517, DOI 10.1074/jbc.273.6.3517
   Zhang X, 2014, HUM MOL GENET, V23, P5893, DOI 10.1093/hmg/ddu313
   Zhu J, 2012, CANCER SCI, V103, P2092, DOI 10.1111/cas.12020
NR 48
TC 39
Z9 43
U1 0
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUN
PY 2015
VL 24
IS 6
BP 921
EP 930
DI 10.1158/1055-9965.EPI-14-1228
PG 10
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA CM1FB
UT WOS:000357425200005
PM 25809865
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Mileo, AM
   Di Venere, D
   Abbruzzese, C
   Miccadei, S
AF Mileo, Anna Maria
   Di Venere, Donato
   Abbruzzese, Claudia
   Miccadei, Stefania
TI Long Term Exposure to Polyphenols of Artichoke (<i>Cynara scolymus</i>
   L.) Exerts Induction of Senescence Driven Growth Arrest in the MDA-MB231
   Human Breast Cancer Cell Line
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID ONCOGENE-INDUCED SENESCENCE; FERULIC ACID; TEA POLYPHENOLS; MOLECULAR
   PATHWAYS; CAFFEIC ACID; TUMOR-GROWTH; CHEMOPREVENTION; ANTICANCER;
   PHYTOCHEMICALS; RESVERATROL
AB Polyphenolic extracts from the edible part of artichoke (Cynara scolymus L.) have been shown to be potential chemopreventive and anticancer dietary compounds. High doses of polyphenolic extracts (AEs) induce apoptosis and decrease the invasive potential of the human breast cancer cell line, MDA-MB231. However, the molecular mechanism underlying AEs antiproliferative effects is not completely understood. We demonstrate that chronic and low doses of AEs treatment at sublethal concentrations suppress human breast cancer cell growth via a caspases-independent mechanism. Furthermore, AEs exposure induces a significant increase of senescence-associated beta-galactosidase (SA-beta-gal) staining and upregulation of tumour suppressor genes, p16(INK4a) and p21(Cip1/Waf1) in MDA-MB231 cells. AEs treatment leads to epigenetic alterations in cancer cells, modulating DNA hypomethylation and lysine acetylation levels in total proteins. Cell growth arrest correlates with increased reactive oxygen species (ROS) production in AEs treated breast cancer cells. Inhibition of ROS generation by N-acetylcysteine (NAC) attenuates the antiproliferative effect. These findings demonstrate that chronic AEs treatment inhibits breast cancer cell growth via the induction of premature senescence through epigenetic and ROS-mediated mechanisms. Our results suggest that artichoke polyphenols could be a promising dietary tool either in cancer chemoprevention or/and in cancer treatment as a nonconventional, adjuvant therapy.
C1 [Mileo, Anna Maria; Abbruzzese, Claudia; Miccadei, Stefania] Regina Elena Inst Canc Res, I-00144 Rome, Italy.
   [Di Venere, Donato] CNR, ISPA, I-70126 Bari, Italy.
C3 IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena;
   Consiglio Nazionale delle Ricerche (CNR); Istituto Scienze delle
   Produzioni Alimentari (ISPA-CNR)
RP Miccadei, S (通讯作者)，Regina Elena Inst Canc Res, Via Elio Chianesi 53, I-00144 Rome, Italy.
EM miccadei@ifo.it
RI abbruzzese, claudia/U-7576-2017; Di Venere, Donato/O-1252-2015; Mileo,
   Anna Maria/J-3667-2016; miccadei, stefania/J-2640-2017
OI abbruzzese, claudia/0000-0003-3301-9421; Di Venere,
   Donato/0000-0003-4397-4959; Mileo, Anna Maria/0000-0002-1970-3297;
   miccadei, stefania/0000-0001-8890-6998
FU Lega Italiana per la Lotta contro i Tumori (LILT) [08/12/C/73]
FX The authors thank Dr. Marco Giorgio Paggi (Regina Elena National Cancer
   Institute) for his helpful comments and advice. The authors acknowledge
   Ms. Tania Merlino for her grammatical suggestions for the English paper.
   The Contract grant sponsor is Lega Italiana per la Lotta contro i Tumori
   (LILT), Contract Grant no. 08/12/C/73.
CR Acosta JC, 2012, TRENDS CELL BIOL, V22, P211, DOI 10.1016/j.tcb.2011.11.006
   [Anonymous], BIOTECHNOLOGY ADV
   Ayissi VBO, 2014, MOL NUTR FOOD RES, V58, P22, DOI 10.1002/mnfr.201300195
   Azzini E, 2007, BRIT J NUTR, V97, P963, DOI 10.1017/S0007114507617218
   Baskaran N, 2010, EUR J PHARMACOL, V637, P22, DOI 10.1016/j.ejphar.2010.03.054
   Bennecke M, 2010, CANCER CELL, V18, P135, DOI 10.1016/j.ccr.2010.06.013
   Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841
   Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164
   Conte M, 2012, CLIN CANCER RES, V18, P5526, DOI 10.1158/1078-0432.CCR-12-2037
   Darvesh AS, 2013, NUTR CANCER, V65, P329, DOI 10.1080/01635581.2013.767367
   de Kok TMCM, 2010, MOL NUTR FOOD RES, V54, P208, DOI 10.1002/mnfr.200900288
   Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dong AL, 2011, J PHARMACOL EXP THER, V339, P238, DOI 10.1124/jpet.111.181081
   Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Gerhauser C, 2013, TOP CURR CHEM, V329, P73, DOI 10.1007/128_2012_360
   Gewirtz DA, 2008, BIOCHEM PHARMACOL, V76, P947, DOI 10.1016/j.bcp.2008.06.024
   González-Vallinas M, 2013, NUTR REV, V71, P585, DOI 10.1111/nure.12051
   Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002
   Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988
   Hanau C, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-2
   Hemaiswarya S, 2013, PHYTOMEDICINE, V20, P151, DOI 10.1016/j.phymed.2012.10.009
   Henning SM, 2013, EPIGENOMICS-UK, V5, P729, DOI 10.2217/epi.13.57
   Iriti M, 2013, NUTRIENTS, V5, P2564, DOI 10.3390/nu5072564
   Janicke B, 2011, NUTR CANCER, V63, P611, DOI 10.1080/01635581.2011.538486
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Karthikeyan S, 2011, TOXICOL IN VITRO, V25, P1366, DOI 10.1016/j.tiv.2011.05.007
   Khan HY, 2012, CURR DRUG TARGETS, V13, P1738
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Kristiansen S, 2014, CRIT REV CL LAB SCI, V51, P149, DOI 10.3109/10408363.2014.893279
   Lee HS, 2014, CANCER LETT, V342, P275, DOI 10.1016/j.canlet.2012.01.021
   Lee M, 2014, BMB REP, V47, P51, DOI 10.5483/BMBRep.2014.47.2.005
   Lee WJ, 2006, CARCINOGENESIS, V27, P269, DOI 10.1093/carcin/bgi206
   Li YB, 2013, PHARMACOL REP, V65, P700, DOI 10.1016/S1734-1140(13)71048-X
   LLeonart ME, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-3
   Longo VD, 2010, TRENDS PHARMACOL SCI, V31, P89, DOI 10.1016/j.tips.2009.11.004
   Luo HM, 2013, INT J ONCOL, V43, P1999, DOI 10.3892/ijo.2013.2141
   Luo HM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060065
   Mancuso C, 2014, FOOD CHEM TOXICOL, V65, P185, DOI 10.1016/j.fct.2013.12.024
   McLarty J, 2009, CANCER PREV RES, V2, P673, DOI 10.1158/1940-6207.CAPR-08-0167
   Miccadei S, 2008, NUTR CANCER, V60, P276, DOI 10.1080/01635580801891583
   Mileo AM, 2012, J CELL PHYSIOL, V227, P3301, DOI 10.1002/jcp.24029
   Mummaneni P, 2014, PHARMACOTHERAPY, V34, P495, DOI 10.1002/phar.1408
   Namasivayam N, 2011, ANN NY ACAD SCI, V1215, P60, DOI 10.1111/j.1749-6632.2010.05873.x
   Nebbioso A, 2012, MOL ONCOL, V6, P657, DOI 10.1016/j.molonc.2012.09.004
   Norat T, 2014, CANCER TREAT RES, V159, P35, DOI 10.1007/978-3-642-38007-5_3
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P275, DOI 10.1159/000334585
   Papazoglu C, 2007, J PATHOL, V211, P124, DOI 10.1002/path.2086
   Petiwala SM, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00029
   Quitschke WW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039568
   Roninson IB, 2003, CANCER RES, V63, P2705
   Roy N, 2013, CANCER BIOL THER, V14, P108, DOI 10.4161/cbt.22631
   Scott E, 2012, MOL NUTR FOOD RES, V56, P7, DOI 10.1002/mnfr.201100400
   Shanafelt TD, 2013, CANCER-AM CANCER SOC, V119, P363, DOI 10.1002/cncr.27719
   Shankar S, 2013, PHARMACOL THERAPEUT, V138, P1, DOI 10.1016/j.pharmthera.2012.11.002
   Shu LM, 2010, CANCER METAST REV, V29, P483, DOI 10.1007/s10555-010-9239-y
   Sin S, 2012, INT J ONCOL, V41, P1669, DOI 10.3892/ijo.2012.1604
   Tan AC, 2011, NUTR CANCER, V63, P495, DOI 10.1080/01635581.2011.538953
   Teiten MH, 2013, MOL NUTR FOOD RES, V57, P1619, DOI 10.1002/mnfr.201300201
   Thakur VS, 2014, AAPS J, V16, P151, DOI 10.1208/s12248-013-9548-5
   Wang PW, 2014, J NUTR BIOCHEM, V25, P73, DOI 10.1016/j.jnutbio.2013.09.005
   Wellen KE, 2012, NAT REV MOL CELL BIO, V13, P270, DOI 10.1038/nrm3305
   Yang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070627
   Zamin LL, 2009, CANCER SCI, V100, P1655, DOI 10.1111/j.1349-7006.2009.01215.x
NR 65
TC 40
Z9 41
U1 1
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2015
VL 2015
AR 363827
DI 10.1155/2015/363827
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CL8DF
UT WOS:000357201800001
PM 26180585
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Hwang, KA
   Choi, KC
AF Hwang, Kyung-A
   Choi, Kyung-Chul
TI Anticarcinogenic Effects of Dietary Phytoestrogens and Their
   Chemopreventive Mechanisms
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID PROSTATE-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; COLONY-STIMULATING
   FACTOR; SOY ISOFLAVONE GENISTEIN; TUMOR-SUPPRESSOR GENES; FACTOR-I
   RECEPTOR; BREAST-CANCER; DOWN-REGULATION; CYCLE ARREST; KINASE
   INHIBITORS
AB Phytoestrogens are phenolic compounds derived from plants and exert an estrogenic as well as an antiestrogenic effect and also various biological efficacies. Chemopreventive properties of phytoestrogens has emerged from epidemiological observations indicating that the incidence of some cancers including breast and prostate cancers is much lower in Asian people, who consume significantly higher amounts of phytoestrogens than Western people. There are 4 main classes of phytoestrogens: isoflavones, stilbenes, coumestans, and lignans. Currently, resveratrol is recognized as another major phytoestrogen present in grape and red wine and has been studied in many biological studies. Phytoestrogens have biologically diverse profitabilities and advantages such as low cytotoxicity to patients, lack of side effects in clinical trials, and pronounced benefits in a combined therapy. In this review, we highlighted the effects of genistein, daidzein, and resveratrol in relation with their anticarcinogenic activity. A lot of in vitro and in vivo results on their chemopreventive properties were presented along with the underlying mechanisms. Besides well-known mechanisms such as antioxidant property and apoptosis, newly elucidated anticarcinogenic modes of action including epigenetic modifications and topoisomerase inhibition have been provided to examine the possibility of phytoestrogens as promising reagents for cancer chemoprevention and/or treatment and to suggest the importance of plant-based diet of phytoestrogens.
C1 [Hwang, Kyung-A; Choi, Kyung-Chul] Chungbuk Natl Univ, Coll Vet Med, Lab Biochem & Immunol, Cheongju 361763, Chungbuk, South Korea.
C3 Chungbuk National University
RP Choi, KC (通讯作者)，Chungbuk Natl Univ, Coll Vet Med, Lab Vet Biochem & Immunol, Cheongju 361763, Chungbuk, South Korea.
EM kchoi@cbu.ac.kr
RI Choi, Kyung-Chul/AHC-2282-2022
FU National Research Foundation of Korea (NRF) - Ministry of Education,
   Science and Technology (MEST) of the Republic of Korea
   [2014R1A1A2055295]
FX This work was supported by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science and Technology (MEST) of the Republic of Korea
   (2014R1A1A2055295).
CR Adlercreutz H, 2002, J STEROID BIOCHEM, V83, P113, DOI 10.1016/S0960-0760(02)00273-X
   Adlercreutz M, 1998, BAILLIERE CLIN ENDOC, V12, P605, DOI 10.1016/S0950-351X(98)80007-4
   AKIMARU K, 1992, ARCH BIOCHEM BIOPHYS, V298, P703, DOI 10.1016/0003-9861(92)90469-D
   Androutsopoulos VP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082487
   Arai Y, 2000, J Epidemiol, V10, P127
   Athar M, 2007, TOXICOL APPL PHARM, V224, P274, DOI 10.1016/j.taap.2006.12.025
   Athar M, 2009, ARCH BIOCHEM BIOPHYS, V486, P95, DOI 10.1016/j.abb.2009.01.018
   Baarine M, 2011, GENES NUTR, V6, P161, DOI 10.1007/s12263-011-0232-z
   Banerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Benitez DA, 2007, J ANDROL, V28, P282, DOI 10.2164/jandrol.106.000968
   Bhuva HA, 2010, J MOL GRAPH MODEL, V29, P32, DOI 10.1016/j.jmgm.2010.04.003
   Carter LG, 2014, ENDOCR-RELAT CANCER, V21, pR209, DOI 10.1530/ERC-13-0171
   Chakraborty S, 2013, BMC STRUCT BIOL, V13, DOI 10.1186/1472-6807-13-27
   Charalambous C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-238
   Chen FP, 2014, CLIMACTERIC, V17, P385, DOI 10.3109/13697137.2013.869671
   Choi EJ, 2008, ARCH PHARM RES, V31, P1115, DOI 10.1007/s12272-001-1277-3
   Choi EJ, 2008, PHYTOMEDICINE, V15, P683, DOI 10.1016/j.phymed.2008.04.006
   Chun YJ, 1999, BIOCHEM BIOPH RES CO, V262, P20, DOI 10.1006/bbrc.1999.1152
   Cimino S, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/632959
   Connolly JM, 1997, NUTR CANCER, V29, P48, DOI 10.1080/01635589709514601
   Constantinou AI, 2001, NUTR CANCER, V41, P75, DOI 10.1207/S15327914NC41-1&2_10
   Day JK, 2002, J NUTR, V132, p2419S, DOI 10.1093/jn/132.8.2419S
   DEAN NM, 1989, BIOCHEM BIOPH RES CO, V165, P795, DOI 10.1016/S0006-291X(89)80036-1
   Dong X, 2013, FOOD CHEM, V141, P1923, DOI 10.1016/j.foodchem.2013.04.109
   Dong X, 2012, FOOD CHEM, V135, P1643, DOI 10.1016/j.foodchem.2012.06.023
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Farina HG, 2006, ONCOL REP, V16, P885
   da Costa DCF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048746
   Gercel-Taylor C, 2004, ANTICANCER RES, V24, P795
   GEWIRTZ DA, 1991, BIOCHEM PHARMACOL, V42, P2253, DOI 10.1016/0006-2952(91)90227-V
   Guo JM, 2004, FOOD CHEM TOXICOL, V42, P1641, DOI 10.1016/j.fct.2004.06.001
   Guo JM, 2004, WORLD J GASTROENTERO, V10, P860
   Guo LY, 2010, CANCER BIOTHER RADIO, V25, P471, DOI 10.1089/cbr.2009.0724
   Gupta SC, 2011, ANN NY ACAD SCI, V1215, P150, DOI 10.1111/j.1749-6632.2010.05852.x
   Hwang KA, 2013, INT J ONCOL, V42, P733, DOI 10.3892/ijo.2012.1719
   Hwang KA, 2013, TOXICOL APPL PHARM, V272, P637, DOI 10.1016/j.taap.2013.07.027
   Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218
   Jin S, 2010, ANN ONCOL, V21, P263, DOI 10.1093/annonc/mdp499
   Jin ZM, 2002, J NUTR, V132, P3186, DOI 10.1093/jn/131.10.3186
   JING YK, 1993, ANTICANCER RES, V13, P1049
   Kang NH, 2013, FOOD CHEM TOXICOL, V59, P373, DOI 10.1016/j.fct.2013.06.029
   Kang NH, 2012, MOL MED REP, V6, P151, DOI 10.3892/mmr.2012.887
   Kang XM, 2010, CAN MED ASSOC J, V182, P1857, DOI 10.1503/cmaj.091298
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Lamartiniere CA, 2002, J NUTR, V132, p552S, DOI 10.1093/jn/132.3.552S
   Lee J, 2012, NUTR CANCER, V64, P153, DOI 10.1080/01635581.2012.630161
   Leiro J, 2005, INT IMMUNOPHARMACOL, V5, P393, DOI 10.1016/j.intimp.2004.10.006
   Li K, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0068157, 10.1371/journal.pone.0084171, 10.1371/journal.pone.0057542]
   Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Lindahl G, 2011, CANCER RES, V71, P51, DOI 10.1158/0008-5472.CAN-10-2289
   Liu MM, 2012, ANTI-CANCER AGENT ME, V12, P1306
   Magee PJ, 2011, P NUTR SOC, V70, P10, DOI 10.1017/S0029665110003940
   Magee PJ, 2004, BRIT J NUTR, V91, P513, DOI 10.1079/BJN20031075
   Mahmoud AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078479
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Marcsek ZL, 2007, CELL BIOL INT, V31, P1214, DOI 10.1016/j.cellbi.2007.01.039
   Mason JK, 2014, APPL PHYSIOL NUTR ME, V39, P663, DOI 10.1139/apnm-2013-0420
   Mishra R, 2011, FOOD CHEM TOXICOL, V49, P434, DOI 10.1016/j.fct.2010.11.020
   Mizushina Y, 2013, INT J ONCOL, V43, P1117, DOI 10.3892/ijo.2013.2032
   Moon YJ, 2006, TOXICOL IN VITRO, V20, P187, DOI 10.1016/j.tiv.2005.06.048
   Murrill WB, 1996, CARCINOGENESIS, V17, P1451, DOI 10.1093/carcin/17.7.1451
   Pelekanou V, 2011, INT J DEV BIOL, V55, P869, DOI 10.1387/ijdb.113369vp
   Perabo FGE, 2008, PROSTATE CANCER P D, V11, P6, DOI 10.1038/sj.pcan.4501000
   PETERSON G, 1995, J NUTR, V125, pS784, DOI 10.1093/jn/125.suppl_3.784S
   PETERSON G, 1991, BIOCHEM BIOPH RES CO, V179, P661, DOI 10.1016/0006-291X(91)91423-A
   PIONTEK M, 1993, ANTICANCER RES, V13, P2119
   Ratan HL, 2002, UROL ONCOL, V7, P223, DOI 10.1016/S1078-1439(02)00194-1
   Reagan-Shaw S, 2008, PHOTOCHEM PHOTOBIOL, V84, P415, DOI 10.1111/j.1751-1097.2007.00279.x
   Russo P, 2012, CURR MED CHEM, V19, P5287, DOI 10.2174/092986712803833272
   Sasamura H, 2002, BRIT J CANCER, V86, P768, DOI 10.1038/sj.bjc.6600152
   Setchell KDR, 2002, J NUTR, V132, P3577, DOI 10.1093/jn/132.12.3577
   Shao Zhimin, 2000, Zhonghua Zhongliu Zazhi, V22, P362
   Shu XO, 2009, JAMA-J AM MED ASSOC, V302, P2437, DOI 10.1001/jama.2009.1783
   Singh AV, 2006, CANCER RES, V66, P1851, DOI 10.1158/0008-5472.CAN-05-1332
   Singh-Gupta V, 2010, PHARM RES-DORDR, V27, P1115, DOI 10.1007/s11095-010-0107-9
   Sirtori CR, 2005, ANN MED, V37, P423, DOI 10.1080/07853890510044586
   Song KB, 2006, J NUTR, V136, P1347, DOI 10.1093/jn/136.5.1347
   Sugiyama Y, 2013, ASIAN PAC J CANCER P, V14, P1, DOI 10.7314/APJCP.2013.14.1.1
   Suzuki K, 2002, INT J CANCER, V99, P846, DOI 10.1002/ijc.10428
   Szliszka E, 2011, ONCOL REP, V26, P533, DOI 10.3892/or.2011.1332
   Tang HY, 2006, MOL CANCER THER, V5, P2034, DOI 10.1158/1535-7163.MCT-06-0216
   TANIMURA M, 1992, BIOCHEM PHARMACOL, V44, P1045, DOI 10.1016/0006-2952(92)90366-Q
   Ulasli SS, 2013, ASIAN PAC J CANCER P, V14, P6159, DOI 10.7314/APJCP.2013.14.10.6159
   URSIN G, 1994, CANCER SURV, V20, P241
   Van Poppel Hendrik, 2011, Cancer Manag Res, V3, P91, DOI 10.2147/CMR.S18503
   Virk-Baker MK, 2010, PLANTA MED, V76, P1132, DOI 10.1055/s-0030-1250074
   Wei HC, 1998, CARCINOGENESIS, V19, P1509, DOI 10.1093/carcin/19.8.1509
   WEI HC, 1993, NUTR CANCER, V20, P1, DOI 10.1080/01635589309514265
   Whitten PL, 2001, ENVIRON HEALTH PERSP, V109, P5, DOI 10.2307/3434842
   Wietrzyk J, 2005, ANTICANCER RES, V25, P2357
   Yin HT, 2013, ASIAN PAC J CANCER P, V14, P1703, DOI 10.7314/APJCP.2013.14.3.1703
   Zhao R, 2009, NUTR CANCER, V61, P397, DOI 10.1080/01635580802582751
   Zheng W, 2012, J CLIN BIOCHEM NUTR, V51, P61, DOI 10.3164/jcbn.11-54
   Zhou NJ, 2009, INT J MOL SCI, V10, P3255, DOI 10.3390/ijms10073255
NR 97
TC 37
Z9 41
U1 0
U2 56
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PD JUL 4
PY 2015
VL 67
IS 5
BP 796
EP 803
DI 10.1080/01635581.2015.1040516
PG 8
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA CL5SJ
UT WOS:000357020600009
PM 25996655
DA 2025-01-12
ER

PT J
AU Wu, F
   Lv, TM
   Chen, G
   Ye, HJ
   Wu, W
   Li, G
   Zhi, FC
AF Wu, Fang
   Lv, Tianmin
   Chen, Gang
   Ye, Huajun
   Wu, Wei
   Li, Gang
   Zhi, Fa-Chao
TI Epigenetic silencing of DUSP9 induces the proliferation of human gastric
   cancer by activating JNK signaling
SO ONCOLOGY REPORTS
LA English
DT Article
DE DNA methylation; DUSP9; gastric cancer; proliferation; JNK signaling
ID KINASE PHOSPHATASES MKPS; DECREASED EXPRESSION; DNA METHYLATION;
   BREAST-CANCER; INHIBITOR; PATHWAYS
AB Dual-specificity phosphatase 9 (DUSP9) is a strong negative regulator of transcription factor activating kinases (ERK, JNK and p38) in the mitogen-activated protein kinase (MAPK) pathways. The aim of this study was to examine the CpG island methylation status of DUSP9 using bisulfite sequencing PCR (BSP) in gastric cancer (GC). The investigation was conducted on 30 clinical GC samples and selected corresponding tumor-free normal gastric mucosa tissues, using BSP for the determination of the promoter methylation status. The methylation status of the tumor samples was compared to the corresponding tumor-free samples. DUSP9 was silenced by promoter region hypermethylation and G2/M phase arrest was induced by DUSP9 in the MKN-1 GC cell line. MKN-1 proliferation was suppressed by DUSP9 by inhibiting c-Jun, which was induced by JNK signaling. The expression levels of CCND1, c-Jun, CDK4 and CDK6 were upregulated while p21 was downregulated by DUSP9 in MKN-1 cells. However, DUSP9-induced resulted in the regulation of the levels of cycle-related molecules, whivh were inhibited when the JNK inhibitor 5P600125 was added. In conclusion, DUSP9 was frequently methylated in human GC and the expression of DUSP9 is silenced by promoter region hypermethylation.
C1 [Wu, Fang; Zhi, Fa-Chao] Southern Med Univ, Guangdong Prov Key Lab Gastroenterol, Dept Gastroenterol, Nanfang Hosp, Guangzhou 510515, Guangdong, Peoples R China.
   [Wu, Fang; Ye, Huajun; Wu, Wei] Wenzhou Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
   [Lv, Tianmin] Huzhou Teachers Coll, Sch Med, Dept Nursing, Huzhou, Zhejiang, Peoples R China.
   [Chen, Gang] Wenzhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
   [Li, Gang] Wenzhou Med Univ, Dept Chemoradiat Oncol, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Southern Medical University - China; Wenzhou Medical University; Huzhou
   University; Wenzhou Medical University; Wenzhou Medical University
RP Li, G (通讯作者)，Wenzhou Med Univ, Dept Chemoradiat Oncol, Affiliated Hosp 1, 2 Fuxue Rd, Wenzhou 325000, Zhejiang, Peoples R China.
EM gangliwmu@163.com; zfcfimmu@163.com
FU Medicine and Health grant from Wenzhou Bureau of Science and Technology
   [Y20140281]
FX This study was supported by the Medicine and Health grant from Wenzhou
   Bureau of Science and Technology (grant no. Y20140281). The authors
   thank Ming Li (Sun Yat-Sen University Cancer Center, Guangzhou, People's
   Republic of China) and Liang Wang (Zhejiang University, Hangzhou,
   Zhejiang, People's Republic of China) for technical support.
CR Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Berlier JL, 2015, STEM CELLS, V33, P211, DOI 10.1002/stem.1831
   Bernardo-Faura M, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003795
   Caunt CJ, 2013, FEBS J, V280, P489, DOI 10.1111/j.1742-4658.2012.08716.x
   Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031005
   Chen P, 2012, ONCOL REP, V28, P2149, DOI 10.3892/or.2012.2030
   Chen Z, 2014, EXP THER MED, V8, P1253, DOI 10.3892/etm.2014.1905
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Dong HW, 2013, ARCH TOXICOL, V87, P1797, DOI 10.1007/s00204-013-1041-5
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623
   Guerrero-Preston R, 2014, ONCOL REP, V32, P505, DOI 10.3892/or.2014.3262
   Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jenner S, 2015, PATHOL ONCOL RES, V21, P123, DOI 10.1007/s12253-014-9797-3
   Keyse SM, 2008, CANCER METAST REV, V27, P253, DOI 10.1007/s10555-008-9123-1
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu G, 2014, ONCOL REP, V32, P581, DOI 10.3892/or.2014.3224
   Liu JX, 2013, J GASTROINTEST SURG, V17, P756, DOI 10.1007/s11605-013-2138-0
   Liu YG, 2007, CANCER RES, V67, P10711, DOI 10.1158/0008-5472.CAN-07-1968
   Minning C, 2014, INT J ONCOL, V45, P1959, DOI 10.3892/ijo.2014.2625
   Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141
   Palau A, 2014, EPIGENETICS-US, V9, P468, DOI 10.4161/epi.27759
   Park GB, 2014, INT J ONCOL, V44, P977, DOI 10.3892/ijo.2014.2252
   Venerito M, 2014, HELICOBACTER, V19, P32, DOI 10.1111/hel.12164
   Vizoso M, 2013, EPIGENETICS-US, V8, P998, DOI 10.4161/epi.25856
   Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694
   Wu GS, 2007, CANCER METAST REV, V26, P579, DOI 10.1007/s10555-007-9079-6
   Wu S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-413
   Wu WKK, 2010, CANCER LETT, V295, P144, DOI 10.1016/j.canlet.2010.04.025
NR 31
TC 22
Z9 26
U1 0
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUL
PY 2015
VL 34
IS 1
BP 121
EP 128
DI 10.3892/or.2015.3998
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CL0PR
UT WOS:000356645100014
PM 25998184
OA Bronze
DA 2025-01-12
ER

PT J
AU Song, YZ
   Han, FJ
   Liu, M
   Xia, CC
   Shi, WY
   Dong, LH
AF Song, Yu-Zhe
   Han, Fu-Jun
   Liu, Min
   Xia, Cheng-Cheng
   Shi, Wei-Yan
   Dong, Li-Hua
TI Association between Single Nucleotide Polymorphisms in XRCC3 and
   Radiation-Induced Adverse Effects on Normal Tissue: A Meta-Analysis
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BREAST-CANCER RISK; DOUBLE-STRAND BREAKS;
   DNA-REPAIR; THR241MET POLYMORPHISM; GENETIC POLYMORPHISMS;
   HEPATOCELLULAR-CARCINOMA; ERECTILE DYSFUNCTION; EPIGENETIC FEATURES;
   PROTEIN-KINASE
AB The X-ray repair cross-complementing group 3 (XRCC3) protein plays an important role in the repair of DNA double-strand breaks. The relationship between XRCC3 polymorphisms and the risk of radiation-induced adverse effects on normal tissue remains inconclusive. Thus, we performed a meta-analysis to elucidate the association between XRCC3 polymorphisms and radiation-induced adverse effects on normal tissue. All eligible studies up to December 2014 were identified through a search of the PubMed, Embase and Web of Science databases. Seventeen studies involving 656 cases and 2193 controls were ultimately included in this meta-analysis. The pooled odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were calculated to evaluate the association between XRCC3 polymorphisms and the risk of radiation-induced normal tissue adverse effects. We found that the XRCC3 p.Thr241Met (rs861539) polymorphism was significantly associated with early adverse effects induced by radiotherapy (OR = 1.99, 95% CI: 1.31-3.01, P = 0.001). A positive association lacking statistical significance with late adverse effects was also identified (OR = 1.28, 95% CI: 0.97-1.68, P = 0.08). In addition, the rs861539 polymorphism was significantly correlated with a higher risk of adverse effects induced by head and neck area irradiation (OR = 2.41, 95% CI: 1.49-3.89, p = 0.0003) and breast irradiation (OR = 1.41, 95% CI: 1.02-1.95, p = 0.04), whereas the correlation was not significant for lung irradiation or pelvic irradiation. Furthermore, XRCC3 rs1799794 polymorphism may have a protective effect against late adverse effects induced by radiotherapy (OR = 0.47, 95% CI: 0.26-0.86, P = 0.01). Well-designed large-scale clinical studies are required to further validate our results.
C1 [Song, Yu-Zhe; Liu, Min; Xia, Cheng-Cheng; Shi, Wei-Yan; Dong, Li-Hua] Jilin Univ, Hosp 1, Dept Radiat Oncol, Changchun 130023, Jilin, Peoples R China.
   [Han, Fu-Jun] Jilin Univ, Hosp 1, Ctr Canc, Changchun 130023, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Dong, LH (通讯作者)，Jilin Univ, Hosp 1, Dept Radiat Oncol, Changchun 130023, Jilin, Peoples R China.
EM songyz37@126.com
CR Allen C, 2002, P NATL ACAD SCI USA, V99, P3758, DOI 10.1073/pnas.052545899
   Alsbeih G, 2010, RADIAT RES, V173, P505, DOI 10.1667/RR1769.1
   Alsner J, 2008, SEMIN RADIAT ONCOL, V18, P126, DOI 10.1016/j.semradonc.2007.10.004
   Andreassen CN, 2012, RADIOTHER ONCOL, V105, P337, DOI 10.1016/j.radonc.2012.11.004
   Andreassen CN, 2003, RADIOTHER ONCOL, V69, P127, DOI 10.1016/j.radonc.2003.09.010
   Andreassen CN, 2002, RADIOTHER ONCOL, V64, P131, DOI 10.1016/S0167-8140(02)00154-8
   Andreassen CN, 2005, ACTA ONCOL, V44, P801, DOI 10.1080/02841860500374513
   Araujo FD, 2002, ONCOGENE, V21, P4176, DOI 10.1038/sj.onc.1205539
   Azria D, 2008, CLIN CANCER RES, V14, P6284, DOI 10.1158/1078-0432.CCR-08-0700
   Barnett GC, 2014, RADIOTHER ONCOL, V111, P178, DOI 10.1016/j.radonc.2014.02.012
   Barnett GC, 2012, LANCET ONCOL, V13, P65, DOI 10.1016/S1470-2045(11)70302-3
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Bentzen SM, 2003, SEMIN RADIAT ONCOL, V13, P189, DOI 10.1016/S1053-4296(03)00036-5
   Bourguignon MH, 2005, EUR J NUCL MED MOL I, V32, P351, DOI 10.1007/s00259-004-1731-6
   Bourguignon MH, 2005, EUR J NUCL MED MOL I, V32, P229, DOI 10.1007/s00259-004-1730-7
   Brenneman MA, 2002, MOL CELL, V10, P387, DOI 10.1016/S1097-2765(02)00595-6
   Burri RJ, 2008, RADIAT RES, V170, P49, DOI 10.1667/RR1219.1
   Chang-Claude J, 2009, BRIT J CANCER, V100, P1680, DOI 10.1038/sj.bjc.6605036
   Cheuk IWY, 2014, MOL CLIN ONCOL, V2, P553, DOI 10.3892/mco.2014.276
   De Ruyck K, 2005, INT J RADIAT ONCOL, V62, P1140, DOI 10.1016/j.ijrobp.2004.12.027
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365
   Du L, 2014, TUMOR BIOL, V35, P1371, DOI 10.1007/s13277-013-1187-z
   Duan CY, 2013, TUMOR BIOL, V34, P2827, DOI 10.1007/s13277-013-0841-9
   Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Fachal L, 2014, NAT GENET, V46, P891, DOI 10.1038/ng.3020
   Fachal L, 2012, RADIOTHER ONCOL, V105, P321, DOI 10.1016/j.radonc.2012.09.013
   Fahmideh MA, 2014, NEURO-ONCOLOGY, V16, P807, DOI 10.1093/neuonc/nou003
   Falvo E, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-7
   Falvo E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-291
   Fang F, 2011, MED ONCOL, V28, P999, DOI 10.1007/s12032-010-9591-3
   Fernet M, 2004, DNA REPAIR, V3, P1237, DOI 10.1016/j.dnarep.2004.03.019
   Ghazali N, 2012, ORAL ONCOL, V48, P1090, DOI 10.1016/j.oraloncology.2012.08.002
   Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9
   He XF, 2012, MOL BIOL REP, V39, P5125, DOI 10.1007/s11033-011-1308-y
   Higgins J, 2022, Cochrane Handbook for Systematic Reviews of Interventions
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Ho AY, 2006, INT J RADIAT ONCOL, V65, P646, DOI 10.1016/j.ijrobp.2006.03.006
   Jackson SP, 2002, CARCINOGENESIS, V23, P687, DOI 10.1093/carcin/23.5.687
   Kerns SL, 2013, RADIOTHER ONCOL, V107, P372, DOI 10.1016/j.radonc.2013.05.001
   Kerns SL, 2013, J UROLOGY, V190, P102, DOI 10.1016/j.juro.2013.01.096
   Kerns SL, 2013, INT J RADIAT ONCOL, V85, pE21, DOI 10.1016/j.ijrobp.2012.08.003
   Kerns SL, 2010, INT J RADIAT ONCOL, V78, P1292, DOI 10.1016/j.ijrobp.2010.07.036
   Kühne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384
   LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602
   Liang HJ, 2013, ASIAN PAC J CANCER P, V14, P4243, DOI 10.7314/APJCP.2013.14.7.4243
   Liu L, 2013, MOL BIOL REP, V40, P3943, DOI 10.1007/s11033-012-2471-5
   Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7
   Liu Y, 2015, J CELL PHYSIOL, V230, P1094, DOI 10.1002/jcp.24841
   Ma QT, 2014, TUMOR BIOL, V35, P1473, DOI 10.1007/s13277-013-1203-3
   Mangoni M, 2011, INT J RADIAT ONCOL, V81, P52, DOI 10.1016/j.ijrobp.2010.04.023
   MANTEL N, 1959, JNCI-J NATL CANCER I, V22, P719
   Mao CF, 2014, ASIAN PAC J CANCER P, V15, P6613, DOI 10.7314/APJCP.2014.15.16.6613
   Matullo G, 2001, CARCINOGENESIS, V22, P1437, DOI 10.1093/carcin/22.9.1437
   Peng QL, 2014, TUMOR BIOL, V35, P1933, DOI 10.1007/s13277-013-1259-0
   Popanda O, 2006, CANCER EPIDEM BIOMAR, V15, P1048, DOI 10.1158/1055-9965.EPI-06-0046
   Pratesi N, 2011, RADIOTHER ONCOL, V99, P356, DOI 10.1016/j.radonc.2011.05.062
   Qin LY, 2013, ASIAN PAC J CANCER P, V14, P6703, DOI 10.7314/APJCP.2013.14.11.6703
   Qiu MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077005
   Raabe A, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-65
   Rosenstein BS, 2014, INT J RADIAT ONCOL, V89, P709, DOI 10.1016/j.ijrobp.2014.03.009
   ROTH DB, 1985, P NATL ACAD SCI USA, V82, P3355, DOI 10.1073/pnas.82.10.3355
   Rübe CE, 2008, INT J RADIAT ONCOL, V72, P1180, DOI 10.1016/j.ijrobp.2008.07.017
   Sakano S, 2010, PHARMACOGENOMICS, V11, P1377, DOI 10.2217/PGS.10.106
   Shen MR, 1998, CANCER RES, V58, P604
   Shen XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069553
   Sterpone S, 2010, J CANCER RES CLIN, V136, P631, DOI 10.1007/s00432-010-0791-1
   Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4
   Tucker SL, 2013, INT J RADIAT ONCOL, V85, P251, DOI 10.1016/j.ijrobp.2012.02.021
   Wang Z, 2014, TUMOR BIOL, V35, P1589, DOI 10.1007/s13277-013-1219-8
   Wang ZZ, 2013, TUMOR BIOL, V34, P1421, DOI 10.1007/s13277-012-0639-1
   Werbrouck J, 2009, INT J RADIAT ONCOL, V73, P1187, DOI 10.1016/j.ijrobp.2008.08.073
   Wu D, 2013, TUMOR BIOL, V34, P3865, DOI 10.1007/s13277-013-0973-y
   Yin M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020055
   Zou Y, 2014, JPN J CLIN ONCOL, V44, P241, DOI 10.1093/jjco/hyt202
NR 76
TC 20
Z9 21
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 19
PY 2015
VL 10
IS 6
AR e0130388
DI 10.1371/journal.pone.0130388
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CL3FE
UT WOS:000356835000111
PM 26091483
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Himmetoglu, S
   Guven, MF
   Bilsel, N
   Dincer, Y
AF Himmetoglu, S.
   Guven, M. F.
   Bilsel, N.
   Dincer, Y.
TI DNA damage in children with scoliosis following X-ray exposure
SO MINERVA PEDIATRICA
LA English
DT Article
DE X-rays; Diagnosis; Glutathione peroxidase; 8-Hydroxydeoxyguanosine;
   Scoliosis; Superoxide dismutase
ID OXIDATIVE STRESS; BREAST-CANCER; EPIGENETIC ALTERATIONS; MEDICAL
   RADIATION; IN-VIVO; APOPTOSIS; P53; CARCINOGENESIS; INACTIVATION;
   RADIOGRAPHY
AB Aim. It has been suggested that cancer incidence is high in subjects with scoliosis who are relatively more often exposed to X-ray for diagnosis and follow-up. X-ray is a kind of ionizing radiation and leads to formation of oxygen free radicals which are capable of damage to DNA, thus altered gen expression and mutation. p53 tumor suppressor gene plays a crucial role in the damage response. It controls the checkpoint of cell cycle and redirects the cell metabolism to either repair of damaged DNA or apoptosis as response to DNA damage. The aim of the present study was to examine serum levels of 8-Hydroxydeoxyguanosine (8-OHdG), a strongly mutagenic product of oxidative DNA damage, p53, superoxide dismutase (SOD) and glutathione peroxidase (G-Px), as antioxidant activity, in children with scoliosis who had got whole spine radiograph two times during the last year.
   Methods. A total of 31 children with adolescent idiopathic scoliosis and 21 age-matched healthy children were included in the study. Serum levels of 8-OHdG and p53 were measured with ELISA kits. SOD and G-Px activities were determined with spectrophotometric assays.
   Results. Serum levels of 8-OHdG and p53 were found to be higher (P<0.001 and P<0.01, respectively), SOD activity was found to be lower (P<0.001) in the children with scoliosis as compared to age-matched controls. There was no significant difference between the groups for G-Px activity.
   Conclusion. Our data show that X-ray exposure causes increased 8-OHdG level, and decreased SOD activity, which both may reflect a tumor promoting condition. Increased p53 level may be interpreted as a compensatory effort of cell to X-ray mediated DNA damage.
C1 [Himmetoglu, S.] Biruni Univ, Fac Hlth Sci, Dept Nutr & Dietet, Biruni, Turkey.
   [Guven, M. F.; Bilsel, N.] Istanbul Univ, Cerrahpasa Med Fac, Dept Orthopedia Orthopaed & Traumatol, Istanbul, Turkey.
   [Dincer, Y.] Istanbul Univ, Cerrahpasa Med Fac, Dept Biochem, Istanbul, Turkey.
C3 Biruni University; Istanbul University; Istanbul University -
   Cerrahpasa; Istanbul University; Istanbul University - Cerrahpasa
RP Dincer, Y (通讯作者)，Dere Sok Umut Ap 11-44 Sahrayicedid, Istanbul, Turkey.
EM yldz.dincer@gmail.com
RI Guven, Mehmet/AAD-3743-2021; Dincer, Yildiz/C-9529-2019
OI GUVEN, MEHMET/0000-0002-8749-1708; Dincer, Yildiz/0000-0002-8393-7901;
   Guven, Mehmet Fatih/0000-0003-2598-0503
FU Istanbul University [UDP-17342]
FX This work was supported by The Research Fund of Istanbul University
   (Project number: UDP-17342)
CR Baliga MS, 2008, MOL NUTR FOOD RES, V52, P1300, DOI 10.1002/mnfr.200800020
   Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020
   Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev
   Dastych M, 2002, BIOL TRACE ELEM RES, V89, P105, DOI 10.1385/BTER:89:2:105
   di Masi A, 2006, MUTAT RES-FUND MOL M, V594, P49, DOI 10.1016/j.mrfmmm.2005.07.014
   Doody MM, 2000, SPINE, V25, P2052
   DUTKOWSKY JP, 1990, J PEDIATR ORTHOPED, V10, P532
   Eccles LJ, 2011, MUTAT RES-FUND MOL M, V711, P134, DOI 10.1016/j.mrfmmm.2010.11.003
   Eccles LJ, 2011, MUTAT RES, V711, P134
   Franco R, 2009, MUTAT RES-GEN TOX EN, V674, P3, DOI 10.1016/j.mrgentox.2008.11.012
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Grzelak A, 2000, SCAND J CLIN LAB INV, V60, P253, DOI 10.1080/003655100750046413
   Haegele AD, 1998, CARCINOGENESIS, V19, P1319, DOI 10.1093/carcin/19.7.1319
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   Hill DA, 2002, CANCER CAUSE CONTROL, V13, P711, DOI 10.1023/A:1020201106117
   HOFFMAN DA, 1989, JNCI-J NATL CANCER I, V81, P1307, DOI 10.1093/jnci/81.17.1307
   Huerta JM, 2004, FREE RADICAL RES, V38, P1215, DOI 10.1080/10715760400017269
   Kim GJ, 2006, MUTAGENESIS, V21, P361, DOI 10.1093/mutage/gel048
   Klaunig JE, 2010, TOXICOL PATHOL, V38, P96, DOI 10.1177/0192623309356453
   Koturbash I, 2008, INT J RADIAT ONCOL, V70, P554, DOI 10.1016/j.ijrobp.2007.09.039
   Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194
   Leach JK, 2001, CANCER RES, V61, P3894
   Manda K, 2007, J PINEAL RES, V42, P386, DOI 10.1111/j.1600-079X.2007.00432.x
   Nakano H, 2007, INT J RADIAT ONCOL, V68, P883, DOI 10.1016/j.ijrobp.2007.03.007
   Ortenzi V, 2011, MUTAT RES-GEN TOX EN, V726, P29, DOI 10.1016/j.mrgentox.2011.07.013
   RAO PS, 1984, INVEST RADIOL, V19, P58, DOI 10.1097/00004424-198401000-00014
   Ron E, 2003, HEALTH PHYS, V85, P47, DOI 10.1097/00004032-200307000-00011
   Ronckers CM, 2005, BREAST CANCER RES, V7, P21, DOI 10.1186/bcr970
   Ronckers CM, 2008, CANCER EPIDEM BIOMAR, V17, P3
   Rush JWE, 2003, CLIN BIOCHEM, V36, P345, DOI 10.1016/S0009-9120(03)00039-0
   Sasano N, 2010, CANCER LETT, V293, P52, DOI 10.1016/j.canlet.2009.12.020
   Starr ME, 2011, FREE RADICAL BIO MED, V50, P371, DOI 10.1016/j.freeradbiomed.2010.11.013
   Tudek B, 2010, AM J TRANSL RES, V2, P254
   Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009
   Ziech D, 2011, MUTAT RES-FUND MOL M, V711, P167, DOI 10.1016/j.mrfmmm.2011.02.015
NR 35
TC 17
Z9 18
U1 0
U2 10
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0026-4946
EI 1827-1715
J9 MINERVA PEDIATR
JI Minerva Pediat.
PD JUN
PY 2015
VL 67
IS 3
BP 245
EP 249
PG 5
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA CL4FF
UT WOS:000356907300005
PM 25941131
DA 2025-01-12
ER

PT J
AU Toi, M
   Masuda, N
   Ishiguro, H
   Saji, S
   Ohno, S
   Chow, LWC
AF Toi, Masakazu
   Masuda, Norikazu
   Ishiguro, Hiroshi
   Saji, Shigehira
   Ohno, Shinji
   Chow, Louis W. C.
TI Development of breast cancer therapy: biomarker-driven and
   response-guided approaches in a neoadjuvant setting
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
LA English
DT Article
DE CDK; HER2; mTOR; Neoadjuvant chemotherapy; PARP
AB A therapeutic strategy, biomarker-driven and response-guided approach has been investigated in cancer therapy where the treatment targets heterogeneous and unstable disease. Neoadjuvant chemotherapy, for instance, is indicated based on tumor stage and subtype and its therapeutic outcomes like pathological responses are associated with the long-term prognostic probability in subgroups such as hormone receptor (HR) negative and HR-positive patients with high-grade cancers. Therefore, it would be reasonable to consider a treatment plan according to the short-time response in the stratified subgroups. It is also applicable for new therapy development, and in fact many clinical trials are under investigation in the post-neoadjuvant setting. In order to increase the therapeutic efficacy, it is recognized as necessary to incorporate biomarkers that enable us to classify conventional subtypes further including genetic mutations and epigenetic phenotypes into the planning of treatment. It is also crucial to analyze tumor biology particularly tumor evolution in the metastasis and the clonal selection by the treatment in these clinical settings.
C1 [Toi, Masakazu] Kyoto Univ, Grad Sch Med, Kyoto Univ Hosp, Breast Canc Unit,Breast Surg,Dept Surg, Kyoto 6068507, Japan.
   [Masuda, Norikazu] Osaka Natl Hosp, Natl Hosp Org, Breast Oncol, Dept Surg, Osaka, Japan.
   [Ishiguro, Hiroshi] Kyoto Univ, Outpatient Oncol Unit, Ctr Canc, Kyoto Univ Hosp, Kyoto 6068507, Japan.
   [Saji, Shigehira] Kyoto Univ, Grad Sch Med, Dept Target Therapy Oncol, Kyoto 6068507, Japan.
   [Ohno, Shinji] Kyushu Natl Canc Ctr, Div Breast Oncol, Fukuoka, Japan.
   [Chow, Louis W. C.] Macau Univ Sci & Technol, Appl Res Med & Hlth, Macau, Peoples R China.
C3 Kyoto University; Osaka National Hospital; Kyoto University; Kyoto
   University; Macau University of Science & Technology
RP Toi, M (通讯作者)，Kyoto Univ, Grad Sch Med, Dept Surg, Breast Surg,Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM toi@kuhp.kyoto-u.ac.jp
RI MASUDA, NORIKAZU/AAM-2417-2021
CR Cortazar P, 2014, LANCET
   Freidlin B, 2014, NAT REV CLIN ONCOL, V11, P81, DOI 10.1038/nrclinonc.2013.218
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krop I, 2014, CLIN CANCER RES, V20, P15, DOI 10.1158/1078-0432.CCR-13-0541
   Loi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053292
   Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753
   Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
NR 9
TC 2
Z9 2
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0393-6155
EI 1724-6008
J9 INT J BIOL MARKER
JI Int. J. Biol. Markers
PD APR-JUN
PY 2015
VL 30
IS 2
BP E252
EP E253
DI 10.5301/jbm.5000136
PG 2
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA CL0XS
UT WOS:000356667000013
PM 25684439
OA Bronze
DA 2025-01-12
ER

PT J
AU Oldfors, CH
   Dios, DG
   Linder, A
   Visuttijai, K
   Samuelson, E
   Karlsson, S
   Nilsson, S
   Behboudi, A
AF Oldfors, Carola Hedberg
   Dios, Diego Garcia
   Linder, Anna
   Visuttijai, Kittichate
   Samuelson, Emma
   Karlsson, Sandra
   Nilsson, Staffan
   Behboudi, Afrouz
TI Analysis of an independent tumor suppressor locus telomeric to
   <i>Tp53</i> suggested <i>Inpp5k</i> and <i>Myo1c</i> as novel tumor
   suppressor gene candidates in this region
SO BMC GENETICS
LA English
DT Article
DE Endometrial carcinoma; 17p13.3; RNO10q24-q25; Tp53; Hic1; Inpp5k; Skip;
   Myo1c
ID ADAPTER PROTEIN CRK; SPONTANEOUS ENDOMETRIAL ADENOCARCINOMAS; HUMAN
   LUNG-CANCER; BDII RAT MODEL; GLUT4 TRANSLOCATION; BREAST-CANCER; RENAL
   TUMORS; DISTAL; HETEROZYGOSITY; CARCINOMA
AB Background: Several reports indicate a commonly deleted chromosomal region independent from, and distal to the TP53 locus in a variety of human tumors. In a previous study, we reported a similar finding in a rat tumor model for endometrial carcinoma (EC) and through developing a deletion map, narrowed the candidate region to 700 kb, harboring 19 genes. In the present work real-time qPCR analysis, Western blot, semi-quantitative qPCR, sequencing, promoter methylation analysis, and epigenetic gene expression restoration analyses (5-aza-2'-deoxycytidine and/or trichostatin A treatments) were used to analyze the 19 genes located within the candidate region in a panel of experimental tumors compared to control samples.
   Results: Real-time qPCR analysis suggested Hic1 (hypermethylated in cancer 1), Inpp5k (inositol polyphosphate-5-phosphatase K; a.k.a. Skip, skeletal muscle and kidney enriched inositol phosphatase) and Myo1c (myosin 1c) as the best targets for the observed deletions. No mutation in coding sequences of these genes was detected, hence the observed low expression levels suggest a haploinsufficient mode of function for these potential tumor suppressor genes. Both Inpp5k and Myo1c were down regulated at mRNA and/or protein levels, which could be rescued in gene expression restoration assays. This could not be shown for Hic1.
   Conclusion: Innp5k and Myo1c were identified as the best targets for the deletions in the region. INPP5K and MYO1C are located adjacent to each other within the reported independent region of tumor suppressor activity located at chromosome arm 17p distal to TP53 in human tumors. There is no earlier report on the potential tumor suppressor activity of INPP5K and MYO1C, however, overlapping roles in phosphoinositide (PI) 3-kinase/Akt signaling, known to be vital for the cell growth and survival, are reported for both. Moreover, there are reports on tumor suppressor activity of other members of the gene families that INPP5K and MYO1C belong to. Functional significance of these two candidate tumor suppressor genes in cancerogenesis pathways remains to be investigated.
C1 [Oldfors, Carola Hedberg; Dios, Diego Garcia; Linder, Anna; Visuttijai, Kittichate; Samuelson, Emma] Univ Gothenburg, Sahlgrenska Acad, Dept Med & Clin Genet, SE-40530 Gothenburg, Sweden.
   [Visuttijai, Kittichate; Karlsson, Sandra; Behboudi, Afrouz] Univ Skovde, Sch Biosci, Tumor Biol Res Grp, SE-54128 Skovde, Sweden.
   [Nilsson, Staffan] Chalmers, Inst Stat Math, SE-41296 Gothenburg, Sweden.
C3 University of Gothenburg; University of Skovde; Chalmers University of
   Technology
RP Behboudi, A (通讯作者)，Univ Skovde, Sch Biosci, Tumor Biol Res Grp, SE-54128 Skovde, Sweden.
EM afrouz.behboudi@his.se
RI Visuttijai, Kittichate/S-4927-2019; Behboudi, Afrouz/KQU-4824-2024
OI Linder, Anna/0000-0002-9444-1346; Nilsson, Staffan/0000-0003-4748-0446;
   Behboudi, Afrouz/0000-0003-2525-3752; Visuttijai,
   Kittichate/0000-0002-4800-8533; Karlsson, Sandra/0000-0002-6364-3850
FU Royal Swedish Academy of Sciences [FOA07L575-A, FOA08H-185]; Royal
   Physiographic Society in Lund (Nilsson-Ehle Foundation) [24900, 24538];
   Swedish Society of Medicine [2009-22226]; Gunvor and Ivan Svensson
   Foundation; Wilhelm and Martina Lundgren Foundation [339, 324];
   Ake-Wieberg Foundation [946217602]; Assar Gabrielsson Research
   Foundation for Clinical Cancer Research [FB 08-11, FB 08-23];
   Sahlgrenska University Hospital Foundation [ALFGBG-24451]; Knowledge
   Foundation [HOG12, 20120311]
FX This work was supported by: Royal Swedish Academy of Sciences [grant
   number FOA07L575-A and FOA08H-185], Royal Physiographic Society in Lund
   (Nilsson-Ehle Foundation) [grant number 24900 and 24538], Swedish
   Society of Medicine [grant number 2009-22226], Gunvor and Ivan Svensson
   Foundation, Wilhelm and Martina Lundgren Foundation [grant number 339
   and 324], Ake-Wieberg Foundation [grant number 946217602], Assar
   Gabrielsson Research Foundation for Clinical Cancer Research [grant
   number FB 08-11 and FB 08-23], Sahlgrenska University Hospital
   Foundation [grant number ALFGBG-24451], The Knowledge Foundation [HOG12,
   20120311].
CR Astle MV, 2006, IUBMB LIFE, V58, P451, DOI 10.1080/15216540600871159
   Beckmann MW, 1997, J MOL MED, V75, P429, DOI 10.1007/s001090050128
   Behboudi A, 2001, GENE CHROMOSOME CANC, V32, P330, DOI 10.1002/gcc.1198
   Behboudi A, 2000, RAT GENOME, V6, P77
   Bond LM, 2013, CELL SIGNAL, V25, P229, DOI 10.1016/j.cellsig.2012.09.026
   Bose A, 2002, NATURE, V420, P821, DOI 10.1038/nature01246
   Bova GS, 1996, WORLD J UROL, V14, P338
   Brandstaetter H, 2012, J CELL SCI, V125, P1991, DOI 10.1242/jcs.097212
   Caren H, 2007, BRIT J CANCER, V97, P1416, DOI 10.1038/sj.bjc.6604032
   Chen L, 2007, INT J CANCER, V120, P292, DOI 10.1002/ijc.22165
   DEERBERG F, 1987, JNCI-J NATL CANCER I, V78, P1245
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Guan XY, 2003, CANCER GENET CYTOGEN, V140, P45, DOI 10.1016/S0165-4608(02)00654-4
   Hamta A, 2005, CANCER GENET CYTOGEN, V159, P123, DOI 10.1016/j.cancergencyto.2004.09.022
   Helou K, 2001, CANCER GENET CYTOGEN, V127, P118, DOI 10.1016/S0165-4608(00)00435-0
   Hokanson DE, 2006, P NATL ACAD SCI USA, V103, P3118, DOI 10.1073/pnas.0505685103
   Holman GD, 2008, CELL METAB, V8, P344, DOI 10.1016/j.cmet.2008.10.006
   Ijuin T, 2003, MOL CELL BIOL, V23, P1209, DOI 10.1128/MCB.23.4.1209-1220.2003
   KANEKO Y, 1991, CANCER RES, V51, P5937
   KASPAREITRITTINGHAUSEN J, 1987, Z VERSUCHSTIERKD, V30, P209
   KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1
   Kobashigawa Y, 2007, NAT STRUCT MOL BIOL, V14, P503, DOI 10.1038/nsmb1241
   Konishi H, 2003, ONCOGENE, V22, P1892, DOI 10.1038/sj.onc.1206304
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   MAKOS M, 1993, CANCER RES, V53, P2719
   Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0
   Nishihara H, 2002, CANCER LETT, V180, P55, DOI 10.1016/S0304-3835(01)00763-7
   Nishioka M, 2002, P NATL ACAD SCI USA, V99, P12269, DOI 10.1073/pnas.192445899
   Nordlander C, 2005, CANCER GENET CYTOGEN, V156, P158, DOI 10.1016/j.cancergencyto.2004.05.001
   Nordlander C, 2007, INT J CANCER, V120, P1472, DOI 10.1002/ijc.22533
   Oh H, 2013, INT J BIOL SCI, V9, P778, DOI 10.7150/ijbs.6459
   Roncuzzi L, 2005, ONCOL REP, V14, P471
   Roshani L, 2001, INT J CANCER, V94, P795, DOI 10.1002/ijc.1553
   Roshani L, 2005, CANCER GENET CYTOGEN, V158, P137, DOI 10.1016/j.cancergencyto.2004.08.034
   Samuelson E, 2009, ENDOCR-RELAT CANCER, V16, P99, DOI 10.1677/ERC-08-0185
   Sarkar C, 2003, CANCER GENET CYTOGEN, V144, P156, DOI 10.1016/S0165-4608(02)00937-8
   Sterkers Y, 1998, BLOOD, V91, P616, DOI 10.1182/blood.V91.2.616.616_616_622
   Taki T, 2005, ONCOGENE, V24, P5191, DOI 10.1038/sj.onc.1208711
   Wang L, 2007, BIOCHEM BIOPH RES CO, V362, P976, DOI 10.1016/j.bbrc.2007.08.106
   Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584
   Yip MF, 2008, CELL METAB, V8, P384, DOI 10.1016/j.cmet.2008.09.011
NR 42
TC 18
Z9 19
U1 0
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2156
J9 BMC GENET
JI BMC Genet.
PD JUL 14
PY 2015
VL 16
AR 80
DI 10.1186/s12863-015-0238-4
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CM7EG
UT WOS:000357852600001
PM 26170120
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Deb, M
   Sengupta, D
   Rath, SK
   Kar, S
   Parbin, S
   Shilpi, A
   Pradhan, N
   Bhutia, SK
   Roy, S
   Patra, SK
AF Deb, Moonmoon
   Sengupta, Dipta
   Rath, Sandip Kumar
   Kar, Swayamsiddha
   Parbin, Sabnam
   Shilpi, Arunima
   Pradhan, Nibedita
   Bhutia, Sujit Kumar
   Roy, Subhendu
   Patra, Samir Kumar
TI Clusterin gene is predominantly regulated by histone modifications in
   human colon cancer and ectopic expression of the nuclear isoform induces
   cell death
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Clusterin; Colon cancer; DNA methylation; Histone Modifications
ID EPITHELIAL-MESENCHYMAL TRANSITION; DNA METHYLTRANSFERASE;
   S-ADENOSYLMETHIONINE; BREAST-CANCER; METHYLATION; APOPTOSIS;
   DEACETYLASE; CHROMATIN; HYPERMETHYLATION; PROGRESSION
AB Clusterin (CLU) is an important glycoprotein involved in various cellular functions. Different reports have mentioned that the two isoforms of CLU; secretary (sCLU) and nuclear (nCLU) have opposite (paradoxical) roles in cancer development. sCLU provides pro-survival signal, whereas nCLU is involved in pro-apoptotic signaling. However, the molecular mechanism of CLU gene regulation is not clear as of yet. We hypothesize that CLU gene is regulated by DNA methylation and histone modifications and clusterin plays an important role in colon cancer. To evaluate the hypothesis, we investigated CLU expression in colon cancer tissues and DNA methylation and histone modification status of CLU gene promoter. It is apparent from immonohistology data that both benign and cancerous (primary and metastasis) formalin fixed paraffin embedded (FFPE) tissue samples exhibit CLU expression. However and interestingly only noncancerous tissue samples show nCLU expression. Ectopic expression of nCLU either by epigenetic modulators or by nCLU transfection is responsible for colon cancer cell death. To clarify the molecular mechanisms for regulation of expression of CLU isoforms, we have analyzed DNA methylation and histone modifications, such as histone H3K9me3, H3K27me3, H3K4me3, and H3K9AcS10P patterns around the CLU promoter. There is no remarkable change in the DNA methylation status upon treatment of the cells by AZA, TSA and SAM. Our findings clearly show that promoter histone H3K9me3 and H3K27me3 marks are elevated in comparison to H3K4me3 and H3K9AcS10P marks in colon cancer cell lines. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Deb, Moonmoon; Sengupta, Dipta; Rath, Sandip Kumar; Kar, Swayamsiddha; Parbin, Sabnam; Shilpi, Arunima; Pradhan, Nibedita; Bhutia, Sujit Kumar; Patra, Samir Kumar] Natl Inst Technol, Dept Life Sci, Rourkela 769008, Odisha, India.
   [Roy, Subhendu] Drs Tribedi & Roy Diagnost Lab, Kolkata 700016, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Rourkela
RP Patra, SK (通讯作者)，Natl Inst Technol, Dept Life Sci, Rourkela 769008, Odisha, India.
EM samirp@nitrkl.ac.in
RI PATRA, Samir/AAS-6639-2020; rath, sandip/ABB-9460-2021; Shilpi,
   Arunima/AAF-7221-2019; Sengupta, Dipta/H-3707-2019
OI PATRA, SAMIR/0000-0001-5641-1835; rath, sandip/0000-0003-4589-4039;
   Sengupta, Dipta/0000-0002-7836-4774; Bhutia, Sujit
   Kumar/0000-0003-0962-3354
FU NIT-Rourkela under the Institute Research Scheme; DST, Govt. of India
FX M. Deb, D. Sengupta, S. Kar, A. Shilpi and S.K. Rath are thankful to
   NIT-Rourkela for granting their fellowships under the Institute Research
   Scheme. S. Parbin is thankful to DST, Govt. of India for the INSPIRE
   fellowship.
CR Allan RS, 2012, NATURE, V487, P249, DOI 10.1038/nature11173
   Bhutia SK, 2012, J CELL PHYSIOL, V227, P1805, DOI 10.1002/jcp.22904
   Bonacini M., 2014, BIOCHIM BIOPHYS, V1849, P44
   BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x
   Chen MJ, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/415231
   Clark AM, 1997, J ANDROL, V18, P257
   Deb M, 2014, CELL MOL LIFE SCI, V71, P3439, DOI 10.1007/s00018-014-1605-4
   Derks S, 2009, CARCINOGENESIS, V30, P1041, DOI 10.1093/carcin/bgp073
   Dia VP, 2010, CANCER LETT, V295, P44, DOI 10.1016/j.canlet.2010.02.010
   Finzi L, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-92
   Flanagan L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-107
   Fox-Walsh K, 2010, DEV CELL, V18, P336, DOI 10.1016/j.devcel.2010.03.002
   Habold C, 2008, J CELL MOL MED, V12, P607, DOI 10.1111/j.1582-4934.2007.00136.x
   Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8
   Kevans D, 2009, CANCER EPIDEM BIOMAR, V18, P393, DOI 10.1158/1055-9965.EPI-08-0302
   Kim N, 2012, J CELL PHYSIOL, V227, P1157, DOI 10.1002/jcp.22836
   Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052
   Leskov KS, 2003, J BIOL CHEM, V278, P11590, DOI 10.1074/jbc.M209233200
   Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295
   Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208
   Lund P, 2006, ONCOGENE, V25, P4890, DOI 10.1038/sj.onc.1209502
   Luo J, 2010, INT J BIOL SCI, V6, P784
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Niu ZH, 2013, EUR REV MED PHARMACO, V17, P1337
   Ostapkowicz A, 2006, MOL CANCER THER, V5, P238, DOI 10.1158/1535-7163.MCT-05-0226
   Paglin S, 2001, CANCER RES, V61, P439
   Parbin S, 2014, J HISTOCHEM CYTOCHEM, V62, P11, DOI 10.1369/0022155413506582
   Park J, 2014, MOL CELLS, V37, P178, DOI 10.14348/molcells.2014.2349
   Patra A, 2011, CLIN EPIGENETICS, V2, P339, DOI 10.1007/s13148-010-0019-x
   Patra SK, 2008, EXP CELL RES, V314, P1193, DOI 10.1016/j.yexcr.2008.01.012
   Patra SK, 2011, CLIN EPIGENETICS, V2, P27, DOI 10.1007/s13148-010-0016-0
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Pucci S, 2004, ONCOGENE, V23, P2298, DOI 10.1038/sj.onc.1207404
   Radziwon-Balicka A, 2014, CARCINOGENESIS, V35, P324, DOI 10.1093/carcin/bgt332
   Rajendran P, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-68
   Rauhala HE, 2008, INT J CANCER, V123, P1601, DOI 10.1002/ijc.23658
   Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Seervi M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.90
   Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779
   Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Sims RJ, 2007, MOL CELL, V28, P665, DOI 10.1016/j.molcel.2007.11.010
   Suganuma T, 2011, ANNU REV BIOCHEM, V80, P473, DOI 10.1146/annurev-biochem-061809-175347
   Takeuchi A, 2014, MOL CELL ENDOCRINOL, V384, P117, DOI 10.1016/j.mce.2014.01.012
   Thorne JL, 2012, NUCLEIC ACIDS RES, V40, P7676, DOI 10.1093/nar/gks509
   Toné S, 2007, EXP CELL RES, V313, P3635, DOI 10.1016/j.yexcr.2007.06.018
   Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9
   Wang C, 2012, INT J BIOCHEM CELL B, V44, P2308, DOI 10.1016/j.biocel.2012.09.012
   WONG P, 1994, EUR J BIOCHEM, V221, P917, DOI 10.1111/j.1432-1033.1994.tb18807.x
   Wong VKW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.217
   Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907
   Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291
   Zhou CL, 2006, INT J ONCOL, V29, P269
   Zhou HL, 2014, NUCLEIC ACIDS RES, V42, P701, DOI 10.1093/nar/gkt875
NR 60
TC 34
Z9 36
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD AUG
PY 2015
VL 1852
IS 8
BP 1630
EP 1645
DI 10.1016/j.bbadis.2015.04.021
PG 16
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA CK9HB
UT WOS:000356550100007
PM 25917404
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhao, M
   Ma, L
   Liu, Yn
   Qu, H
AF Zhao, Min
   Ma, Lei
   Liu, Yining
   Qu, Hong
TI Pedican: an online gene resource for pediatric cancers with literature
   evidence
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BIRTH-WEIGHT; BREAST-CANCER; METABOLIC PATHWAYS; CHILDHOOD-CANCER; RISK;
   GENOME; NOTCH; EPIDEMIOLOGY; EXPRESSION; DISEASES
AB Pediatric cancer (PC), that is cancer occurring in children, is the leading cause of death among children worldwide, with an incidence of 175,000 per year. Elucidating the genetic abnormalities and underlying cellular mechanisms may provide less toxic curative treatments. Therefore, it is important to understand the pathology of pediatric cancer at the genetic, genomic and epigenetic level. To unveil the cellular complexity of PC, we have developed a database of pediatric cancers (Pedican), the first literature-based pediatric gene data resource by comprehensive literature curation and data integration. In the current release, Pedican contains 735 human genes, 88 gene fusion and 24 chromosome abnormal events curated from 2245 PubMed abstracts. Pedican provides detailed annotations for each gene, such as Entrez gene information, involved pathways, protein-protein interactions, mutations, gene expression, methylation sites, TF regulation, and post-translational modification. Additionally Pedican has a user-friendly web interface, which allows sophisticated text query, sequence searches, and browsing by highlighted literature evidence and hundreds of cancer types. Overall, our curated pediatric cancer-related gene list maps the genomic and cellular landscape for various pediatric cancers, providing a valuable resource for further experiment design.
C1 [Zhao, Min; Ma, Lei; Liu, Yining; Qu, Hong] Peking Univ, Coll Life Sci, Ctr Bioinformat, State Key Lab Prot & Plant Gene Res, Beijing 100871, Peoples R China.
C3 Peking University
RP Qu, H (通讯作者)，Peking Univ, Coll Life Sci, Ctr Bioinformat, State Key Lab Prot & Plant Gene Res, Beijing 100871, Peoples R China.
EM quh@mail.cbi.pku.edu.cn
RI Ma, Lei/AEI-0577-2022; Zhao, Min/J-6588-2019
OI Zhao, Min/0000-0001-5498-3434; liu, yining/0000-0001-5768-2039
FU National Natural Science Foundation of China [31171270]
FX This work was supported by the National Natural Science Foundation of
   China (No. 31171270).
CR Acland A, 2013, NUCLEIC ACIDS RES, V41, pD8, DOI [10.1093/nar/gks1189, 10.1093/nar/gkq1172, 10.1093/nar/gkx1095]
   Aerts S, 2006, NAT BIOTECHNOL, V24, P537, DOI 10.1038/nbt1203
   Ahlgren M, 2003, INT J CANCER, V107, P997, DOI 10.1002/ijc.11481
   Allenspach EJ, 2002, CANCER BIOL THER, V1, P466, DOI 10.4161/cbt.1.5.159
   Barabási AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Becker KG, 2004, NAT GENET, V36, P431, DOI 10.1038/ng0504-431
   Berardini TZ, 2010, NUCLEIC ACIDS RES, V38, pD331, DOI 10.1093/nar/gkp1018
   Cerami Ethan G, 2011, Nucleic Acids Res, V39, pD685, DOI 10.1093/nar/gkq1039
   Chemaitilly W, 2014, NAT REV ENDOCRINOL, V10, P320, DOI 10.1038/nrendo.2014.50
   Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018
   Downing JR, 2012, NAT GENET, V44, P619, DOI 10.1038/ng.2287
   Du P, 2009, BIOINFORMATICS, V25, pI63, DOI 10.1093/bioinformatics/btp193
   Flicek P, 2011, NUCLEIC ACIDS RES, V39, pD800, DOI 10.1093/nar/gkq1064
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gatta G, 2014, LANCET ONCOL, V15, P35, DOI 10.1016/S1470-2045(13)70548-5
   Goldstein M, 2007, GENE CHROMOSOME CANC, V46, P1028, DOI 10.1002/gcc.20489
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Johnson CH., 2007, The 2007 Multiple Primary and Histology Coding Rules
   Kaijser M, 2003, BRIT J CANCER, V89, P1664, DOI 10.1038/sj.bjc.6601357
   Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882
   Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896
   Karp PD, 2005, NUCLEIC ACIDS RES, V33, P6083, DOI 10.1093/nar/gki892
   Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288
   Kruger M, 2014, PEDIATR BLOOD CANCER, V61, P587, DOI 10.1002/pbc.24845
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Lahmann PH, 2004, BRIT J CANCER, V91, P1666, DOI 10.1038/sj.bjc.6602203
   Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855
   Magrane M, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar009
   Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381
   Matthews L, 2009, NUCLEIC ACIDS RES, V37, pD619, DOI 10.1093/nar/gkn863
   Melbye M, 1999, BRIT J CANCER, V80, P609, DOI 10.1038/sj.bjc.6690399
   Mellemkjær L, 2003, CANCER CAUSE CONTROL, V14, P61, DOI 10.1023/A:1022570305704
   Ortiz-Padilla C, 2013, ONCOGENE, V32, P2696, DOI 10.1038/onc.2012.271
   Osborne JD, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-S1-S6
   Rooney B, 2001, WESTERN J MED, V174, P385, DOI 10.1136/ewjm.174.6.385
   Ross JA, 2006, CANCER EPIDEM BIOMAR, V15, P1, DOI 10.1158/1055-9965.EPI-05-0923
   Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653
   Schaefer KL, 2002, VIRCHOWS ARCH, V440, P476, DOI 10.1007/s00428-001-0558-9
   Seiden-Long I, 2008, CARCINOGENESIS, V29, P647, DOI 10.1093/carcin/bgn009
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Stiller CA, 2004, ONCOGENE, V23, P6429, DOI 10.1038/sj.onc.1207717
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403
   Vatten LJ, 2002, BRIT J CANCER, V86, P89, DOI 10.1038/sj.bjc.6600011
   Ward E, 2014, CA-CANCER J CLIN, V64, P83, DOI 10.3322/caac.21219
   Xie C, 2011, NUCLEIC ACIDS RES, V39, pW316, DOI 10.1093/nar/gkr483
   Zhao M, 2013, SCI CHINA LIFE SCI, V56, P1086, DOI 10.1007/s11427-013-4573-2
   Zhao M, 2011, SCI CHINA LIFE SCI, V54, P60, DOI 10.1007/s11427-010-4125-y
   Zhao M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-S4-S13
   Zhao M, 2009, CELL RES, V19, P793, DOI 10.1038/cr.2009.61
NR 51
TC 6
Z9 6
U1 0
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 15
PY 2015
VL 5
AR 11435
DI 10.1038/srep11435
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CK8RH
UT WOS:000356505300001
PM 26073932
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Price, RJ
   Lillycrop, KA
   Burdge, GC
AF Price, R. Jordan
   Lillycrop, Karen A.
   Burdge, Graham C.
TI Folic acid supplementation in vitro induces cell type-specific changes
   in BRCA1 and BRCA 2 mRNA expression, but does not alter DNA methylation
   of their promoters or DNA repair
SO NUTRITION RESEARCH
LA English
DT Article
DE BRCA; Folic acid; Cancer; Gene expression; DNA methylation; DNA repair
ID SPORADIC BREAST-CANCER; COLORECTAL ADENOMAS; GENE-EXPRESSION; RISK;
   FORTIFICATION; FOLATE; SERUM; PROTEIN; WOMEN; EPIGENETICS
AB Dietary supplementation with folic acid (FA) has been shown to induce opposing effects on cancer-related outcomes. The mechanism underlying such heterogeneity is unclear. We hypothesized that FA supplementation induces changes in breast cancer-associated (BRCA) genes 1 and 2 expression and function through altered epigenetic regulation in a cell type-dependent manner. We investigated the effect of treating normal and cancer cells with physiologically relevant FA concentrations on the mRNA and protein expression, capacity for DNA repair, and DNA methylation of BRCA1 and BRCA2. FA treatment induced dose-related increases in BRCA1 mRNA expression in HepG2, Huh-7D12, Hs578T, and JURKAT and in BRCA2 in HepG2, Hs578T, MCF7, and MDA-MB-157 cells. FA did not affect the corresponding normal cells or on any of the ovarian cell lines. Folic acid induced increased BRCA1 protein expression in Hs578T, but not HepG2 cells, whereas BRCA2 protein levels were undetectable. FA treatment did not alter DNA repair in liver-derived cells, whereas there were transient effects on breast-derived cells. There was no effect of FA treatment on BRCA1 or BRCA2 DNA methylation, although there was some variation in the methylation of specific CpG loci between some cell lines. Overall, these findings show that the effects of FA on BRCA-related outcomes differ between cells lines, but the biological consequences of induced changes in BRCA expression appear to be at most limited. (C) 2015 The Authors. Published by Elsevier Inc.
C1 [Price, R. Jordan; Burdge, Graham C.] Univ Southampton, Fac Med, Acad Unit Human Hlth & Dev, Southampton SO16 6YD, Hants, England.
   [Lillycrop, Karen A.] Univ Southampton, Fac Nat & Environm Sci, Ctr Biol Sci, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton
RP Burdge, GC (通讯作者)，Univ Southampton, Fac Med, Acad Unit Human Hlth & Dev, Southampton Gen Hosp,Inst Dev Sci Bldg MP887, Tremona Rd, Southampton SO16 6YD, Hants, England.
EM g.c.burdge@soton.ac.uk
RI Lillycrop, Karen/O-3322-2013; Burdge, Graham/A-2370-2014
OI Lillycrop, Karen/0000-0001-7350-5489; Burdge,
   Graham/0000-0002-7665-2967; Price, R. Jordan/0000-0003-0930-3246
FU World Cancer Research Fund UK (WCRF UK) [2011/42]
FX This work was supported by an award (2011/42) by the World Cancer
   Research Fund UK (WCRF UK) to GCB and KAL.
CR Anderson OS, 2012, J NUTR BIOCHEM, V23, P853, DOI 10.1016/j.jnutbio.2012.03.003
   Atlas E, 2000, ONCOGENE, V19, P1933, DOI 10.1038/sj.onc.1203516
   Atlas E, 2001, ONCOGENE, V20, P7110, DOI 10.1038/sj.onc.1204890
   Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Boilson A, 2012, AM J CLIN NUTR, V96, P613, DOI 10.3945/ajcn.111.026633
   Bradbury KE, 2014, J NUTR, V144, P68, DOI 10.3945/jn.113.182105
   BUNIN GR, 1993, NEW ENGL J MED, V329, P536, DOI 10.1056/NEJM199308193290804
   Burdge GC, 2009, BRIT J NUTR, V101, P619, DOI 10.1017/S0007114508145883
   Catteau A, 2002, SEMIN CANCER BIOL, V12, P359, DOI 10.1016/S1044-579X(02)00056-1
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chan KYK, 2002, CANCER RES, V62, P4151
   Charles MA, 2012, EPIGENETICS-US, V7, P689, DOI 10.4161/epi.20461
   Cikos S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-113
   Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351
   Cucer N, 2008, J GENET, V87, P155, DOI 10.1007/s12041-008-0023-5
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   French AE, 2003, CLIN PHARMACOL THER, V74, P288, DOI 10.1016/S0009-9236(03)00200-5
   Friedenson Bernard, 2005, MedGenMed, V7, P60
   Gao QY, 2013, CANCER PREV RES, V6, P744, DOI 10.1158/1940-6207.CAPR-13-0013
   Hirsch S, 2009, EUR J GASTROEN HEPAT, V21, P346, DOI 10.1097/MEG.0b013e328306ccdb
   Hoile SP, 2013, J NUTR BIOCHEM, V24, P1213, DOI 10.1016/j.jnutbio.2012.09.005
   Ingrosso D, 2003, LANCET, V361, P1693, DOI 10.1016/S0140-6736(03)13372-7
   Jaszewski R, 2008, WORLD J GASTROENTERO, V14, P4492, DOI 10.3748/wjg.14.4492
   Jin W, 2008, J BIOL CHEM, V283, P29671, DOI 10.1074/jbc.M802785200
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   KANEKO Y, 1995, CANCER LETT, V91, P11, DOI 10.1016/0304-3835(95)03709-6
   Kelly P, 1997, AM J CLIN NUTR, V65, P1790, DOI 10.1093/ajcn/65.6.1790
   Kelly P, 1996, ANAL BIOCHEM, V238, P179, DOI 10.1006/abio.1996.0272
   Kim YI, 2008, CANCER EPIDEM BIOMAR, V17, P2220, DOI 10.1158/1055-9965.EPI-07-2557
   Kotsopoulos J, 2008, J NUTR, V138, P703, DOI 10.1093/jn/138.4.703
   Lemay M, 1999, BIOTECHNIQUES, V27, P846, DOI 10.2144/99274pf01
   Logan RFA, 2008, GASTROENTEROLOGY, V134, P29, DOI 10.1053/j.gastro.2007.10.014
   Mason JB, 2007, CANCER EPIDEM BIOMAR, V16, P1325, DOI 10.1158/1055-9965.EPI-07-0329
   Mathers JC, 2009, GENES NUTR, V4, P173, DOI 10.1007/s12263-009-0126-5
   McKay JA, 2004, BIOCHEM SOC T, V32, P1006, DOI 10.1042/BST0321006
   Mckay JA, 2008, BRIT J NUTR, V99, P550, DOI 10.1017/S0007114507819131
   Mungall AJ, 2003, NATURE, V425, P805, DOI 10.1038/nature02055
   Olshan AF, 2002, EPIDEMIOLOGY, V13, P575, DOI 10.1097/00001648-200209000-00014
   Qin XH, 2013, INT J CANCER, V133, P1033, DOI 10.1002/ijc.28038
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Rice JC, 2000, NUCLEIC ACIDS RES, V28, P3233, DOI 10.1093/nar/28.17.3233
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Rodway HA, 2004, BIOCHEM J, V382, P83, DOI 10.1042/BJ20040107
   Rothbart SB, 2012, NAT STRUCT MOL BIOL, V19, P1155, DOI 10.1038/nsmb.2391
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Stidley CA, 2010, CANCER RES, V70, P568, DOI 10.1158/0008-5472.CAN-09-3410
   Sweeney MR, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-41
   Szaumkessel M, 2011, INT J ONCOL, V39, P505, DOI 10.3892/ijo.2011.1039
   Tam C, 2012, OBSTET GYNECOL INT, V2012, DOI 10.1155/2012/485179
   Terry P, 2002, INT J CANCER, V97, P864, DOI 10.1002/ijc.10138
   Tripathi MK, 2005, J BIOL CHEM, V280, P17163, DOI 10.1074/jbc.M501375200
   Tsiatis AC, 2010, J MOL DIAGN, V12, P425, DOI 10.2353/jmoldx.2010.090188
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Vineis P, 2011, EPIGENETICS-US, V6, P195, DOI 10.4161/epi.6.2.13573
   von Arnim CAF, 2013, NUTR J, V12, DOI 10.1186/1475-2891-12-148
   Wald DS, 2001, ARCH INTERN MED, V161, P695, DOI 10.1001/archinte.161.5.695
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029
   Wolff GL, 1998, FASEB J, V12, P949, DOI 10.1096/fasebj.12.11.949
   Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200
   Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Zhang SMM, 2008, JAMA-J AM MED ASSOC, V300, P2012, DOI 10.1001/jama.2008.555
NR 66
TC 14
Z9 16
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD JUN
PY 2015
VL 35
IS 6
BP 532
EP 544
DI 10.1016/j.nutres.2015.04.009
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA CL0PA
UT WOS:000356643400009
PM 25960189
OA Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Ford, DJ
   Dingwall, AK
AF Ford, David J.
   Dingwall, Andrew K.
TI The cancer COMPASS: navigating the functions of MLL complexes in cancer
SO CANCER GENETICS
LA English
DT Article
DE Epigenetics; enhancers; chromatin; lysine methyltransferase; COMPASS
   complex
ID B-VIRUS DNA; MUTATIONAL LANDSCAPE; HISTONE METHYLTRANSFERASE; SOMATIC
   MUTATIONS; BREAST-CANCER; WHOLE-GENOME; GENE-EXPRESSION; COACTIVATOR
   COMPLEX; RECURRENT MUTATIONS; FREQUENT MUTATIONS
AB The mixed-lineage leukemia family of histone methyltransferases (MLL1-4, or KMT2A-D) were previously linked to cancer through the founding member, MLL1/KMT2A, which is often involved in translocation-associated gene fusion events in childhood leukemias. However, in recent years, a multitude of tumor exome sequencing studies have revealed that orthologues MLL3/KMT2C and MLL2/KMT2D are mutated in a significant percentage of a large variety of malignancies, particularly solid tumors. These unexpected findings necessitate a deeper inspection into the activities and functional differences between the MLL/KMT2 family members. This review provides an overview of this protein family and its relation to cancers, focusing on the recent links between MLL3/KMT2C and MLL2/4/KMT2D and their potential roles as tumor suppressors in an assortment of cell types.
C1 [Ford, David J.; Dingwall, Andrew K.] Loyola Univ Chicago, Stritch Sch Med, Mol Biol & Biochem Grad Program, Maywood, IL 60153 USA.
   [Dingwall, Andrew K.] Loyola Univ Chicago, Stritch Sch Med, Oncol Res Inst, Maywood, IL USA.
   [Dingwall, Andrew K.] Loyola Univ Chicago, Stritch Sch Med, Dept Pathol, Maywood, IL USA.
C3 Loyola University Chicago; Loyola University Chicago; Loyola University
   Chicago
RP Dingwall, AK (通讯作者)，Loyola Univ Chicago, Stritch Sch Med, Mol Biol & Biochem Grad Program, Maywood, IL 60153 USA.
EM adingwall@luc.edu
FU Direct For Biological Sciences; Div Of Molecular and Cellular Bioscience
   [1413331] Funding Source: National Science Foundation
CR Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923
   Ahn SM, 2014, HEPATOLOGY, V60, P1972, DOI 10.1002/hep.27198
   Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039
   Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Antonson P, 2003, MOL CELL BIOL, V23, P1260, DOI 10.1128/MCB.23.4.1260-1268.2003
   Ardehali MB, 2011, EMBO J, V30, P2817, DOI 10.1038/emboj.2011.194
   Ashktorab H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008879
   Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021
   Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065
   Ballabio Erica, 2012, Cancers (Basel), V4, P904, DOI 10.3390/cancers4030904
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279
   Barron DA, 2014, CLIN TRANSL MED, V3, DOI 10.1186/2001-1326-3-25
   Bea S, 2013, P NATL ACAD SCI USA, V110, P18250, DOI 10.1073/pnas.1314608110
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bhan A, 2014, J MOL BIOL, V426, P3426, DOI 10.1016/j.jmb.2014.07.025
   Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547
   Bögershausen N, 2013, CLIN GENET, V83, P201, DOI 10.1111/cge.12051
   Bögershausen N, 2013, CLIN GENET, V83, P212, DOI 10.1111/cge.12050
   Bokinni Y, 2012, J HUM GENET, V57, P223, DOI 10.1038/jhg.2012.28
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Buck MJ, 2014, ONCOGENE, V33, P4961, DOI 10.1038/onc.2013.455
   Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chang PY, 2010, J MOL BIOL, V400, P137, DOI 10.1016/j.jmb.2010.05.005
   Chauhan C, 2013, DEV BIOL, V380, P185, DOI 10.1016/j.ydbio.2013.05.018
   Chauhan C, 2012, DEVELOPMENT, V139, P1997, DOI 10.1242/dev.076687
   Chen C, 2014, CANCER CELL, V25, P652, DOI 10.1016/j.ccr.2014.03.016
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200
   Chung YR, 2012, INT J HEMATOL, V96, P413, DOI 10.1007/s12185-012-1181-z
   Copur Ö, 2013, DEVELOPMENT, V140, P3478, DOI 10.1242/dev.097204
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dolnik A, 2012, BLOOD, V120, pE83, DOI 10.1182/blood-2011-12-401471
   Dubuc AM, 2013, ACTA NEUROPATHOL, V125, P373, DOI 10.1007/s00401-012-1070-9
   Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ernst P, 2004, DEV CELL, V6, P437, DOI 10.1016/S1534-5807(04)00061-9
   Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291
   Fukuda K, 2004, BRIT J CANCER, V91, P1543, DOI 10.1038/sj.bjc.6602187
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076
   Gardner KE, 2011, J MOL BIOL, V409, P36, DOI 10.1016/j.jmb.2011.01.040
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Glaser S, 2006, DEVELOPMENT, V133, P1423, DOI 10.1242/dev.02302
   Gonzalez-Perez A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r106
   Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Green MR, 2013, BLOOD, V121, P1604, DOI 10.1182/blood-2012-09-457283
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Guo CC, 2013, ONCOTARGET, V4, P2144, DOI 10.18632/oncotarget.1555
   Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109
   Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798
   Guo GW, 2012, NAT GENET, V44, P17, DOI 10.1038/ng.1014
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Hao CC, 2015, CANCER LETT, V357, P179, DOI 10.1016/j.canlet.2014.11.024
   Herz HM, 2014, MOL CELL, V53, P859, DOI 10.1016/j.molcel.2014.02.033
   Herz HM, 2013, TRENDS BIOCHEM SCI, V38, P621, DOI 10.1016/j.tibs.2013.09.004
   Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112
   Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13
   Hu DQ, 2013, NAT STRUCT MOL BIOL, V20, P1093, DOI 10.1038/nsmb.2653
   Huether R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4630
   Huntsman DG, 1999, ONCOGENE, V18, P7975, DOI 10.1038/sj.onc.1203291
   Ibragimova I, 2014, EPIGENETICS-US, V9, P760, DOI 10.4161/epi.28078
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06
   Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740
   Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284
   Jones S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6006
   Kanchi KL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4156
   Kanda H, 2013, MOL CELL BIOL, V33, P1702, DOI 10.1128/MCB.01585-12
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kim DS, 2014, ADV DIFFER EQU-NY, DOI 10.1186/1687-1847-2014-4
   Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896
   Kleefstra T, 2012, AM J HUM GENET, V91, P73, DOI 10.1016/j.ajhg.2012.05.003
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359
   Kuang SQ, 2002, J BIOL CHEM, V277, P45356, DOI 10.1074/jbc.C200509200
   Kusch T, 2012, TRANSCR-AUSTIN, V3, P310, DOI 10.4161/trns.21911
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Lee JH, 2007, J BIOL CHEM, V282, P13419, DOI 10.1074/jbc.M609809200
   Lee J, 2009, P NATL ACAD SCI USA, V106, P8513, DOI 10.1073/pnas.0902873106
   Lee J, 2008, P NATL ACAD SCI USA, V105, P19229, DOI 10.1073/pnas.0810100105
   Lee JE, 2013, ELIFE, V2, DOI 10.7554/eLife.01503
   Lee S, 2006, P NATL ACAD SCI USA, V103, P15392, DOI 10.1073/pnas.0607313103
   Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li B, 2014, GENET MOL RES, V13, P7513, DOI 10.4238/2014.September.12.18
   Li BE, 2014, EXP HEMATOL, V42, P995, DOI 10.1016/j.exphem.2014.09.006
   Li B, 2013, ASIAN PAC J CANCER P, V14, P4239, DOI 10.7314/APJCP.2013.14.7.4239
   Li TG, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001349
   Li WD, 2013, BLOOD, V121, P1478, DOI 10.1182/blood-2012-12-470559
   Lindberg J, 2013, EUR UROL, V63, P702, DOI 10.1016/j.eururo.2012.11.053
   Lindqvist CM, 2015, HUM MUTAT, V36, P118, DOI 10.1002/humu.22719
   Liu JN, 2012, EXP HEMATOL, V40, P487, DOI 10.1016/j.exphem.2012.01.017
   Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015
   Lubitz S, 2007, MOL BIOL CELL, V18, P2356, DOI 10.1091/mbc.E06-11-1060
   Mahajan MA, 2004, MOL CELL BIOL, V24, P4994, DOI 10.1128/MCB.24.11.4994-5004.2004
   Mahajan Muktar A, 2008, Nucl Recept Signal, V6, pe002, DOI 10.1621/nrs.06002
   Mar BG, 2012, LEUKEMIA, V26, P1881, DOI 10.1038/leu.2012.56
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Martin D, 2014, ONCOTARGET, V5, P8906, DOI 10.18632/oncotarget.2417
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Miyake N, 2013, AM J MED GENET A, V161, P2234, DOI 10.1002/ajmg.a.36072
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Mohan M, 2011, MOL CELL BIOL, V31, P4310, DOI 10.1128/MCB.06092-11
   Moreira AL, 2015, J THORAC ONCOL, V10, P373, DOI 10.1097/JTO.0000000000000397
   Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nickerson ML, 2014, CLIN CANCER RES, V20, P4935, DOI 10.1158/1078-0432.CCR-14-0330
   Ntziachristos P, 2014, NATURE, V514, P513, DOI 10.1038/nature13605
   Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018
   O'Meara E, 2014, GENE CHROMOSOME CANC, V53, P991, DOI 10.1002/gcc.22208
   Oh H, 2014, CELL REP, V8, P448, DOI 10.1016/j.celrep.2014.06.017
   Okosun J, 2014, NAT GENET, V46, P176, DOI 10.1038/ng.2856
   Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273
   Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008
   Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056
   Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004
   Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396
   Pickering CR, 2014, CLIN CANCER RES, V20, P6582, DOI 10.1158/1078-0432.CCR-14-1768
   Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329
   Qing Y, 2014, ELIFE, V3, DOI 10.7554/eLife.02564
   Rabello DD, 2013, INT J ONCOL, V43, P653, DOI 10.3892/ijo.2013.1981
   Ren J, 2009, CELL RES, V19, P271, DOI 10.1038/cr.2009.6
   Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213
   Rocha-Viegas L, 2014, MOL CELL BIOL, V34, P3765, DOI 10.1128/MCB.00839-14
   Ross JS, 2014, J CLIN PATHOL, V67, P772, DOI 10.1136/jclinpath-2014-202447
   Ruault M, 2002, GENE, V284, P73, DOI 10.1016/S0378-1119(02)00392-X
   Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405
   Saigo K, 2008, HUM MUTAT, V29, P703, DOI 10.1002/humu.20701
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Sedkov Y, 2003, NATURE, V426, P78, DOI 10.1038/nature02080
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shen YQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-470
   Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100
   Shin N, 2011, INT J CANCER, V128, P2872, DOI 10.1002/ijc.25641
   Shinsky SA, 2014, J MOL BIOL, V426, P2283, DOI 10.1016/j.jmb.2014.03.011
   Simon JA, 2002, CURR OPIN GENET DEV, V12, P210, DOI 10.1016/S0959-437X(02)00288-5
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Somervaille TCP, 2010, INT J HEMATOL, V91, P735, DOI 10.1007/s12185-010-0579-8
   Song YM, 2014, NATURE, V509, P91, DOI 10.1038/nature13176
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130
   Tamori A, 2005, AM J GASTROENTEROL, V100, P1748, DOI 10.1111/j.1572-0241.2005.41914.x
   Tarayrah L, 2013, DEVELOPMENT, V140, P1014, DOI 10.1242/dev.089433
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Valekunja UK, 2013, P NATL ACAD SCI USA, V110, P1554, DOI 10.1073/pnas.1214168110
   Van der Meulen J, 2014, EPIGENETICS-US, V9, P658, DOI 10.4161/epi.28298
   van Nuland R, 2013, MOL CELL BIOL, V33, P2067, DOI 10.1128/MCB.01742-12
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524
   Wang PF, 2009, MOL CELL BIOL, V29, P6074, DOI 10.1128/MCB.00924-09
   Wang XX, 2011, PATHOL ONCOL RES, V17, P429, DOI 10.1007/s12253-010-9316-0
   Wang Y, 2014, GENOMICS, V103, P222, DOI 10.1016/j.ygeno.2014.02.002
   Wang ZJ, 2013, ACS APPL MATER INTER, V5, P2013, DOI 10.1021/am3028553
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006
   Wu Min, 2011, Chin J Cancer, V30, P240
   Yagi H, 1998, BLOOD, V92, P108, DOI 10.1182/blood.V92.1.108.413k11_108_117
   Yin SY, 2014, SCI REP-UK, V4, DOI 10.1038/srep06036
   YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0
   Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246
   ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735
NR 177
TC 110
Z9 121
U1 1
U2 36
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 2210-7762
EI 2210-7770
J9 CANCER GENET-NY
JI Cancer Genet.
PD MAY
PY 2015
VL 208
IS 5
BP 178
EP 191
DI 10.1016/j.cancergen.2015.01.005
PG 14
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CL0PO
UT WOS:000356644800003
PM 25794446
DA 2025-01-12
ER

PT J
AU Downs, B
   Wang, SM
AF Downs, Bradley
   Wang, San Ming
TI Epigenetic changes in <i>BRCA1</i>-mutated familial breast cancer
SO CANCER GENETICS
LA English
DT Article
DE BRCA1; familial breast cancer; germline mutation; epigenetic alteration;
   autosomal dominant
ID PROMOTER METHYLATION; DNA METHYLATION; GENE FAMILY; BRCA1;
   SUSCEPTIBILITY; PROTEIN; MICRORNA-155; MUTATIONS; CLONING; CELLS
AB Familial breast cancer occurs in about 10% of breast cancer cases. Germ line mutation in BRCA1 is the most penetrant predisposition for the disease. Mutated BRCA1 leads to disease by causing genome instability via multiple mechanisms including epigenetic changes. This review summarizes recent progress in studying the correlation between BRCA1 predisposition and epigenetic alterations in BRCA1-type familial breast cancer.
C1 [Downs, Bradley; Wang, San Ming] Univ Nebraska Med Ctr, Coll Med, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.
C3 University of Nebraska System; University of Nebraska Medical Center
RP Wang, SM (通讯作者)，Univ Nebraska Med Ctr, Coll Med, Dept Genet Cell Biol & Anat, Omaha, NE 68198 USA.
EM sanming.wang@unmc.edu
RI , san ming wang/ABG-4910-2020
FU Fred & Pamela Buffett Cancer Center; University of Nebraska Medical
   Center; National Institutes of Health [1R21CA180008]
FX The study was supported by a pilot grant from Fred & Pamela Buffett
   Cancer Center, University of Nebraska Medical Center, and a National
   Institutes of Health grant 1R21CA180008 (SMW). The funding bodies play
   no role in design, collection, analysis, or interpretation of data.
CR Aapola U, 2000, GENOMICS, V65, P293, DOI 10.1006/geno.2000.6168
   Anjum S, 2014, GENOME MED, V6, DOI 10.1186/gm567
   Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6
   Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Archey WB, 2002, ONCOGENE, V21, P7034, DOI 10.1038/sj.onc.1205844
   Babar IA, 2012, P NATL ACAD SCI USA, V109, pE1695, DOI 10.1073/pnas.1201516109
   Berg AO, 2005, ANN INTERN MED, V143, P355, DOI 10.7326/0003-4819-143-5-200509060-00011
   Bernardino T, 1997, CANCER GENET CYTOGEN, V97, P83, DOI 10.1016/S0165-4608(96)00385-8
   BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3
   Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459
   Cheng CK, 2005, J CANC RES, P1916
   Couch FJ, 2014, SCIENCE, V343, P1466, DOI 10.1126/science.1251827
   Esteller M, 2001, CANCER RES, V61, P3225
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Li X, 2014, P NATL ACAD SCI USA, V111, P7096, DOI 10.1073/pnas.1324036111
   Mattiske S, 2012, CANCER EPIDEM BIOMAR, V21, P1236, DOI 10.1158/1055-9965.EPI-12-0173
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Okano M, 1998, NAT GENET, V19, P219, DOI 10.1038/890
   Pang D, 2012, MED ONCOL, V29, P1561, DOI 10.1007/s12032-011-0100-0
   Park SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100429
   Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5
   Ren J, 2014, CURR PHARM DESIGN, V20, P1857, DOI 10.2174/13816128113199990529
   Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398
   Sharma Priyanka, 2014, J Cancer Ther Res, V3, P1, DOI 10.7243/2049-7962-3-2
   Shukla V, 2010, CELL RES, V20, P1201, DOI 10.1038/cr.2010.128
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Stratton MR, 2008, NAT GENET, V40, P17, DOI 10.1038/ng.2007.53
   Suijkerbuijk KPM, 2008, ANN ONCOL, V19, P1870, DOI 10.1093/annonc/mdn409
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Vasilatos SN, 2009, CANCER EPIDEM BIOMAR, V18, P901, DOI 10.1158/1055-9965.EPI-08-0875
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7
   Wu L, 2013, BREAST CANCER RES TR, V142, P619, DOI 10.1007/s10549-013-2774-9
   Xie SP, 1999, GENE, V236, P87, DOI 10.1016/S0378-1119(99)00252-8
   Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983
   Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049
   YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287
   YOSHIMURA A, 1995, EMBO J, V14, P2816, DOI 10.1002/j.1460-2075.1995.tb07281.x
NR 41
TC 14
Z9 16
U1 2
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2210-7762
EI 2210-7770
J9 CANCER GENET-NY
JI Cancer Genet.
PD MAY
PY 2015
VL 208
IS 5
BP 237
EP 240
DI 10.1016/j.cancergen.2015.02.001
PG 4
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CL0PO
UT WOS:000356644800009
PM 25800897
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhao, Y
   Hu, JY
   Li, RG
   Song, J
   Kang, YJ
   Liu, S
   Zhang, DW
AF Zhao, Yue
   Hu, Jinyue
   Li, Rongguo
   Song, Jian
   Kang, Yujuan
   Liu, Si
   Zhang, Dongwei
TI Ehanced NK cell adoptive antitumor effects against breast cancer in
   vitro via blockade of the transforming growth factor-β signaling pathway
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE transforming growth factor-beta; natural killer cells; breast cancer;
   adoptive immunotherapy
ID IMMUNE-RESPONSE; TARGET; NKG2D
AB Natural killer (NK) cells have great potential for improving cancer immunotherapy. Adoptive NK cell transfer, an adoptive immunotherapy, represents a promising nontoxic anticancer therapy. However, existing data indicate that tumor cells can effectively escape NK cell-mediated apoptosis through immunosuppressive effects in the tumor microenvironment, and the therapeutic activity of adoptive NK cell transfer is not as efficient as anticipated. Transforming growth factor-beta (TGF-beta ) is a potent immunosuppressant. Genetic and epigenetic events that occur during mammary tumorigenesis circumvent the tumor-suppressing activity of TGF-beta, thereby permitting late-stage breast cancer cells to acquire an invasive and metastatic phenotype in response to TGF-beta. To block the TGF-beta signaling pathway, NK cells were genetically modified with a dominant-negative TGF-beta type II receptor by optimizing electroporation using the Amaxa Nucleofector system. These genetically modified NK cells were insensitive to TGF-beta and resisted the suppressive effect of TGF-beta on MCF-7 breast cancer cells in vitro. Our results demonstrate that blocking the TGF-beta signaling pathway to modulate the tumor microenvironment can improve the antitumor activity of adoptive NK cells in vitro, thereby providing a new rationale for the treatment of breast cancer.
C1 [Zhao, Yue; Li, Rongguo; Song, Jian; Kang, Yujuan; Liu, Si; Zhang, Dongwei] Harbin Med Univ, Affiliated Hosp 2, Dept Gen Surg, Harbin 150086, Peoples R China.
   [Hu, Jinyue] Third Hosp Zhengzhou, Dept Breast & Thyroid Surg, Zhengzhou, Peoples R China.
C3 Harbin Medical University
RP Zhang, DW (通讯作者)，Harbin Med Univ, Affiliated Hosp 2, Dept Gen Surg, 246 Xuefu Rd, Harbin 150086, Peoples R China.
EM mugong0@163.com
FU Heilongjiang Province of Science and Technology [D201273]; Harbin
   Science and Technology Bureau [2012RFQS064]
FX This work was supported by the Heilongjiang Province of Science and
   Technology (grant D201273), and Harbin Science and Technology Bureau
   (grant 2012RFQS064).
CR Biron CA, 2001, CURR OPIN IMMUNOL, V13, P458, DOI 10.1016/S0952-7915(00)00241-7
   Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029
   Crane CA, 2010, NEURO-ONCOLOGY, V12, P7, DOI 10.1093/neuonc/nop009
   de Souza AP, 2009, EXPERT REV ANTICANC, V9, P1317, DOI 10.1586/ERA.09.88
   Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4
   Domschke C, 2009, CANCER RES, V69, P8420, DOI 10.1158/0008-5472.CAN-09-1627
   Friese MA, 2004, CANCER RES, V64, P7596, DOI 10.1158/0008-5472.CAN-04-1627
   Hallett WHD, 2006, SEMIN CANCER BIOL, V16, P367, DOI 10.1016/j.semcancer.2006.07.003
   He Dandan, 2010, CHINA CANC, V19, P108
   Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021
   Herberman RB, 2002, SEMIN ONCOL, V29, P27, DOI 10.1053/sonc.2002.33079
   Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Kelly RJ, 2010, J IMMUNOTOXICOL, V7, P15, DOI 10.3109/15476910903389920
   Lee JC, 2004, J IMMUNOL, V172, P7335, DOI 10.4049/jimmunol.172.12.7335
   Lee MY, 2008, CELL CYCLE, V7, P2705, DOI 10.4161/cc.7.17.6551
   Massagué J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705
   Massagué J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033
   Ngo MC, 2011, HUM MOL GENET, V20, pR93, DOI 10.1093/hmg/ddr102
   Papamichail M, 2004, CANCER IMMUNOL IMMUN, V53, P176, DOI 10.1007/s00262-003-0478-4
   Polat MF, 2003, SURG TODAY, V33, P655, DOI 10.1007/s00595-002-2563-2
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Runyan CE, 2009, J BIOL CHEM, V284, P25181, DOI 10.1074/jbc.M109.032847
   Tian M, 2009, FUTURE ONCOL, V5, P259, DOI 10.2217/14796694.5.2.259
   Wallace A, 2008, CLIN CANCER RES, V14, P3966, DOI 10.1158/1078-0432.CCR-08-0356
   Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157
NR 26
TC 37
Z9 40
U1 0
U2 6
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 1553
EP 1559
DI 10.2147/OTT.S82616
PG 7
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA CK9WC
UT WOS:000356589200002
PM 26124672
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Tsuchiya, M
   Giuliani, A
   Hashimoto, M
   Erenpreisa, J
   Yoshikawa, K
AF Tsuchiya, Masa
   Giuliani, Alessandro
   Hashimoto, Midori
   Erenpreisa, Jekaterina
   Yoshikawa, Kenichi
TI Emergent Self-Organized Criticality in Gene Expression Dynamics:
   Temporal Development of Global Phase Transition Revealed in a Cancer
   Cell Line
SO PLOS ONE
LA English
DT Article
ID NETWORKS; NORMALIZATION; EPIGENETICS; HYPOTHESIS; RANGE
AB Background
   The underlying mechanism of dynamic control of the genome-wide expression is a fundamental issue in bioscience. We addressed it in terms of phase transition by a systemic approach based on both density analysis and characteristics of temporal fluctuation for the time-course mRNA expression in differentiating MCF-7 breast cancer cells.
   Methodology
   In a recent work, we suggested criticality as an essential aspect of dynamic control of genome-wide gene expression. Criticality was evident by a unimodal-bimodal transition through flattened unimodal expression profile. The flatness on the transition suggests the existence of a critical transition at which up- and down-regulated expression is balanced. Mean field (averaging) behavior of mRNAs based on the temporal expression changes reveals a sandpile type of transition in the flattened profile. Furthermore, around the transition, a self-similar unimodal-bimodal transition of the whole expression occurs in the density profile of an ensemble of mRNA expression. These singular and scaling behaviors identify the transition as the expression phase transition driven by self-organized criticality (SOC).
   Principal Findings
   Emergent properties of SOC through a mean field approach are revealed: i) SOC, as a form of genomic phase transition, consolidates distinct critical states of expression, ii) Coupling of coherent stochastic oscillations between critical states on different time-scales gives rise to SOC, and iii) Specific gene clusters (barcode genes) ranging in size from kbp to Mbp reveal similar SOC to genome-wide mRNA expression and ON-OFF synchronization to critical states. This suggests that the cooperative gene regulation of topological genome sub-units is mediated by the coherent phase transitions of megadomain-scaled conformations between compact and swollen chromatin states.
   Conclusion and Significance
   In summary, our study provides not only a systemic method to demonstrate SOC in whole-genome expression, but also introduces novel, physically grounded concepts for a breakthrough in the study of biological regulation.
C1 [Tsuchiya, Masa] Keio Univ, Sch Media & Governance, Syst Biol Program, Fujisawa, Kanagawa, Japan.
   [Giuliani, Alessandro] Ist Super Sanit, Environm & Hlth Dept, Rome, Italy.
   [Hashimoto, Midori] Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Chiba, Japan.
   [Erenpreisa, Jekaterina] Latvian Biomed Res & Study Ctr, Riga, Latvia.
   [Yoshikawa, Kenichi] Doshisha Univ, Fac Life & Med Sci, Kyotanabe, Japan.
C3 Keio University; Istituto Superiore di Sanita (ISS); University of
   Tokyo; Latvian Biomedical Research & Study Centre; Doshisha University
RP Tsuchiya, M (通讯作者)，Keio Univ, Sch Media & Governance, Syst Biol Program, Fujisawa, Kanagawa, Japan.
EM tsuchiya.masa@gmail.com; alessandro.giuliani@iss.it;
   keyoshik@mail.doshisha.ac.jp
RI Giuliani, Alessandro/AAF-1740-2020; Yoshikawa, Kenichi/N-1867-2019;
   Giuliani, Alessandro/K-7589-2016; Yoshikawa, Kenichi/L-4774-2016
OI Giuliani, Alessandro/0000-0002-4640-804X; Yoshikawa,
   Kenichi/0000-0002-2751-7136
FU Japan Society for the Promotion of Science (KAKENHI) [15H02121,
   2510301]; European Social Fund, Latvia [1DP/1.1.1.2/APIA/VIAA/037]
FX This study was supported in part by Japan Society for the Promotion of
   Science (Grants-in-Aid, KAKENHI: Nos. 15H02121 and 2510301) and by
   European Social Fund (grant Nr 1DP/1.1.1.2/APIA/VIAA/037), Latvia.
CR [Anonymous], 2014, Molecular Biology of the Cell: Sixth International Student Edition
   [Anonymous], 2014, Criticality in Neural Systems
   [Anonymous], 1957, STRATEGY GENES
   [Anonymous], 1974, The Physics of Liquid Crystals
   [Anonymous], 1955, MATH BIOPHYS, DOI DOI 10.1007/BF02477753
   Bachmann M., 2014, THERMODYNAMICS STAT
   BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364
   BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381
   Barbieri M, 2012, P NATL ACAD SCI USA, V109, P16173, DOI 10.1073/pnas.1204799109
   BEEBE KR, 1987, ANAL CHEM, V59, pA1007, DOI 10.1021/ac00144a725
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bornfleth H, 1999, BIOPHYS J, V77, P2871, DOI 10.1016/S0006-3495(99)77119-5
   Censi F, 2011, IEEE T BIO-MED ENG, V58, P2943, DOI 10.1109/TBME.2011.2150747
   Cremer T, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003889
   Csermely P, 2013, PHARMACOL THERAPEUT, V138, P333, DOI 10.1016/j.pharmthera.2013.01.016
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223
   Gibcus JH, 2013, MOL CELL, V49, P773, DOI 10.1016/j.molcel.2013.02.011
   Ginzburg V. L., 2009, ZH EKSP TEOR FIZ, P113, DOI [DOI 10.1007/978-3-540-68008-6_4, 10.1007/978-3-540-68008-6_4, DOI 10.1016/B978-0-08-010586-4.50035-3]
   Giuliani A, 2014, ADV SYST BIO, V3, P3
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Huang S, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128701
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Izhikevich EM., 2006, SCHOLARPEDIA, V1, P1349, DOI [DOI 10.4249/SCHOLARPEDIA.1349, 10.4249/scholarpedia.1349]
   Jensen H. J., 1998, Self-Organized Criticality: Emergent Complex Behavior in Physical and Biological Systems
   Kauffman S.A., 1993, The Origins of Order
   Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101
   Koren A, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-164
   Landau L.D, 1937, Zh. Eksp. Teor. Fiz, V11, P545, DOI [10.1016/B978-0-08-010586-4.50034-1, DOI 10.1038/138840A0]
   Laue T, 2011, NAT CHEM BIOL, V7, P331, DOI 10.1038/nchembio.575
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Markovic D, 2014, PHYS REP, V536, P41, DOI 10.1016/j.physrep.2013.11.002
   McClintick JN, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-49
   Mirkin SM, 2001, ENCYCLOPEDIA OF LIFE
   Nagano T, 2013, NATURE, V502, P59, DOI 10.1038/nature12593
   Ohlsson R, 2001, TRENDS GENET, V17, P520, DOI 10.1016/S0168-9525(01)02366-6
   Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891
   Rosenfeld S, 2011, GENE REGUL SYST BIO, V5, P27, DOI 10.4137/GRSB.S6804
   Saeki Y, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-545
   Sexton T, 2009, SEMIN CELL DEV BIOL, V20, P849, DOI 10.1016/j.semcdb.2009.06.004
   Shew WL, 2009, J NEUROSCI, V29, P15595, DOI 10.1523/JNEUROSCI.3864-09.2009
   Shu GP, 2003, COMP FUNCT GENOM, V4, P287, DOI 10.1002/cfg.290
   Swain PS, 2002, P NATL ACAD SCI USA, V99, P12795, DOI 10.1073/pnas.162041399
   Takagi S, 1999, LANGMUIR, V15, P4143, DOI 10.1021/la981158o
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takenaka Y, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.031905
   Tompa P, 2011, PROTEIN SCI, V20, P2074, DOI 10.1002/pro.747
   Tsuchiya M., 2012, Proceedings of the 2012 ICME International Conference on Complex Medical Engineering (CME), P744, DOI 10.1109/ICCME.2012.6275649
   Tsuchiya M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097411
   Tsuchiya M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012116
   Tsuchiya M, 2009, PHYSICA A, V388, P1738, DOI 10.1016/j.physa.2008.12.030
   Tsuchiya M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004905
   Van Bortle K, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-5-r82
   WEINBERG AM, 1982, INTERDISCIPL SCI REV, V7, P47, DOI 10.1179/030801882789801322
   Wendt KS, 2008, NATURE, V451, P796, DOI 10.1038/nature06634
   Yamanaka S, 2009, NATURE, V460, P49, DOI 10.1038/nature08180
   Yasar F, 2005, INT J MOD PHYS C, V16, P427, DOI 10.1142/S0129183105007224
   Yoshikawa K, 1999, CHEM PHYS LETT, V303, P10, DOI 10.1016/S0009-2614(99)00203-1
   Yoshikawa K, 2002, J BIOL PHYS, V28, P701, DOI 10.1023/A:1021251125101
   Yoshikawa K., 2002, PHARM PERSPECTIVES N, P137
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Zhu J, 2013, CELL, V152, P642, DOI 10.1016/j.cell.2012.12.033
   [No title captured]
   [No title captured]
NR 64
TC 32
Z9 32
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2015
VL 10
IS 6
AR e0128565
DI 10.1371/journal.pone.0128565
PG 33
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CK3FB
UT WOS:000356100900025
PM 26067993
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Yamaguchi, T
   Mukai, H
   Yamashita, S
   Fujii, S
   Ushijima, T
AF Yamaguchi, Takeshi
   Mukai, Hirofumi
   Yamashita, Satoshi
   Fujii, Satoshi
   Ushijima, Toshikazu
TI Comprehensive DNA Methylation and Extensive Mutation Analyses of
   HER2-Positive Breast Cancer
SO ONCOLOGY
LA English
DT Article
DE Breast cancer; Epigenome; Gene mutation; HER2; Ki-67; Neoadjuvant
   chemotherapy; Next-generation sequencer; Trastuzumab
ID MONOCLONAL-ANTIBODY; CHEMOTHERAPY; TRASTUZUMAB; EXPRESSION; RECEPTOR;
   FORMALIN; EFFICACY; REVEAL; IMPACT; SAFETY
AB Objective: Resistance to trastuzumab is a problem that remains to be solved in HER2-positive breast cancer. We aimed to characterize profiles of genetic and epigenetic alterations in cancer-related pathways in HER2-positive breast cancers, using biopsy tissue samples obtained from patients enrolled in a prospective neoadjuvant clinical trial. Methods: HER2-positive breast cancer tissue samples were collected and processed with the PAXgene Tissue System. A total of 24 breast cancers were analyzed. Genetic alterations of 409 cancer-related genes were analyzed by a bench-top next-generation sequencer. DNA methylation statuses were analyzed by a bead array with 485,512 probes. Results: The WNT pathway was potentially activated by aberrant methylation of its negative regulators, such as DKK3 and SFRP1, in 9 breast cancers. The AKT/mTOR pathway was activated by mutations of PIK3CA in 5 breast cancers. The Notch pathway was potentially activated by mutations of NOTCH1 and NOTCH2 in 4 breast cancers. The p53 pathway was inactivated by mutations of TP53 in 13 breast cancers and potentially by aberrant methylation of its downstream genes in 10 breast cancers. Cell adhesion was affected by mutations of CDH1 in 1 breast cancer. Conclusion: Genes involved in cancer-related pathways were frequently affected not only by genetic but also by epigenetic alterations in HER2-positive breast cancer. (C) 2015 S. Karger AG, Basel
C1 [Yamaguchi, Takeshi] Musashino Red Cross Hosp, Dept Med Oncol, Tokyo, Japan.
   [Yamashita, Satoshi; Ushijima, Toshikazu] Natl Canc Ctr, Res Inst, Div Epigen, Tokyo 104, Japan.
   [Mukai, Hirofumi] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, Kashiwa, Chiba 2778577, Japan.
   [Fujii, Satoshi] Natl Canc Ctr Hosp East, Div Pathol, Res Ctr Innovat Oncol, Kashiwa, Chiba 2778577, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan; National
   Cancer Center - Japan
RP Mukai, H (通讯作者)，Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan.
EM hrmukai@east.ncc.go.jp
RI Yamashita, Satoshi/KLD-0817-2024; Ushijima, Toshikazu/AAP-5742-2021
OI Ushijima, Toshikazu/0000-0003-3405-7817; Yamashita,
   Satoshi/0000-0002-8609-5797
CR Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Belloni B, 2013, J CLIN PATHOL, V66, P124, DOI 10.1136/jclinpath-2012-200983
   Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639
   Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Groelz D, 2013, EXP MOL PATHOL, V94, P188, DOI 10.1016/j.yexmp.2012.07.002
   Gullapalli RR, 2012, CLIN LAB MED, V32, P585, DOI 10.1016/j.cll.2012.07.005
   Jensen JD, 2012, ANN ONCOL, V23, P2034, DOI 10.1093/annonc/mdr546
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kikuyama M, 2012, CANCER LETT, V322, P204, DOI 10.1016/j.canlet.2012.03.016
   Kim JG, 2013, CANCER LETT, V330, P33, DOI 10.1016/j.canlet.2012.11.022
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Moja L, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006243.pub2
   Perez EA, 2013, J CLIN ONCOL, V31, P2115, DOI 10.1200/JCO.2012.42.2642
   Ruan WJ, 2007, CANCER BIOL THER, V6, P354, DOI 10.4161/cbt.6.3.3702
   Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134
   Shigematsu Y, 2012, ONCOL LETT, V4, P268, DOI 10.3892/ol.2012.708
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Staff S, 2013, J CLIN PATHOL, V66, P807, DOI 10.1136/jclinpath-2012-201283
   Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719
   Yamaguchi T, 2012, JPN J CLIN ONCOL, V42, P1211, DOI 10.1093/jjco/hys161
   Yamashita S, 2009, DNA RES, V16, P275, DOI 10.1093/dnares/dsp017
   Yoda Y, 2015, GASTRIC CANCER, V18, P65, DOI 10.1007/s10120-014-0348-0
   Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267
NR 28
TC 17
Z9 25
U1 1
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-2414
EI 1423-0232
J9 ONCOLOGY-BASEL
JI Oncology
PY 2015
VL 88
IS 6
BP 377
EP 384
DI 10.1159/000369904
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CJ6XM
UT WOS:000355638500008
PM 25591616
DA 2025-01-12
ER

PT J
AU Chiaradonna, F
   Barozzi, I
   Miccolo, C
   Bucci, G
   Palorini, R
   Fornasari, L
   Botrugno, OA
   Pruneri, G
   Masullo, M
   Passafaro, A
   Galimberti, VE
   Fantin, VR
   Richon, VM
   Pece, S
   Viale, G
   Di Fiore, PP
   Draetta, G
   Pelicci, PG
   Minucci, S
   Chiocca, S
AF Chiaradonna, Ferdinando
   Barozzi, Iros
   Miccolo, Claudia
   Bucci, Gabriele
   Palorini, Roberta
   Fornasari, Lorenzo
   Botrugno, Oronza A.
   Pruneri, Giancarlo
   Masullo, Michele
   Passafaro, Alfonso
   Galimberti, Viviana E.
   Fantin, Valeria R.
   Richon, Victoria M.
   Pece, Salvatore
   Viale, Giuseppe
   Di Fiore, Pier Paolo
   Draetta, Giulio
   Pelicci, Pier Giuseppe
   Minucci, Saverio
   Chiocca, Susanna
TI Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast
   Cancer
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; T-CELL LYMPHOMA; OXIDATIVE STRESS;
   GASTRIC-CANCER; HELA-CELLS; EXPRESSION; SAHA; METABOLISM; RESISTANCE;
   PROGNOSIS
AB Aims: Vorinostat (suberoylanilide hydroxamic acid; SAHA) is a histone deacetylase inhibitor (HDACi) approved in the clinics for the treatment of T-cell lymphoma and with the potential to be effective also in breast cancer. We investigated the responsiveness to SAHA in human breast primary tumors and cancer cell lines. Results: We observed a differential response to drug treatment in both human breast primary tumors and cancer cell lines. Gene expression analysis of the breast cancer cell lines revealed that genes involved in cell adhesion and redox pathways, especially glutathione metabolism, were differentially expressed in the cell lines resistant to SAHA compared with the sensitive ones, indicating their possible association with drug resistance mechanisms. Notably, such an association was also observed in breast primary tumors. Indeed, addition of buthionine sulfoximine (BSO), a compound capable of depleting cellular glutathione, significantly enhanced the cytotoxicity of SAHA in both breast cancer cell lines and primary breast tumors. Innovation: We identify and validate transcriptional differences in genes involved in redox pathways, which include potential predictive markers of sensitivity to SAHA. Conclusion: In breast cancer, it could be relevant to evaluate the expression of antioxidant genes that may favor tumor resistance as a factor to consider for potential clinical application and treatment with epigenetic drugs (HDACis). Antioxid. Redox Signal. 23, 15-29.
C1 [Chiaradonna, Ferdinando; Palorini, Roberta] Univ Milano Bicocca, Dept Biotechnol & Biosci, Milan, Italy.
   [Chiaradonna, Ferdinando; Palorini, Roberta] SYSBIO Ctr Syst Biol, Milan, Italy.
   [Barozzi, Iros; Miccolo, Claudia; Bucci, Gabriele; Fornasari, Lorenzo; Botrugno, Oronza A.; Passafaro, Alfonso; Pece, Salvatore; Di Fiore, Pier Paolo; Pelicci, Pier Giuseppe; Minucci, Saverio; Chiocca, Susanna] European Inst Oncol, Dept Expt Oncol, Milan, Italy.
   [Pruneri, Giancarlo; Masullo, Michele; Viale, Giuseppe] European Inst Oncol, Dept Pathol, Milan, Italy.
   [Galimberti, Viviana E.] European Inst Oncol, Dept Surg, Milan, Italy.
   [Fantin, Valeria R.] Pfizer Global Res & Dev, Oncol Res Unit, La Jolla, CA USA.
   [Richon, Victoria M.] Sanofi Oncol, Cambridge, MA USA.
   [Draetta, Giulio] Univ Texas Hlth Sci Ctr Houston, Ctr Sci, Inst Appl Canc, Houston, TX 77030 USA.
   [Minucci, Saverio] Univ Milan, Dept Biosci, Milan, Italy.
C3 University of Milano-Bicocca; IRCCS European Institute of Oncology
   (IEO); IRCCS European Institute of Oncology (IEO); IRCCS European
   Institute of Oncology (IEO); Pfizer; University of Texas System;
   University of Texas Health Science Center Houston; University of Milan
RP Minucci, S (通讯作者)，European Inst Oncol, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.
EM susanna.chiocca@ieo.eu; saverio.minucci@ieo.eu
RI Barozzi, Iros/GLQ-8907-2022; Miccolo, Claudia/AAR-8386-2020; GALIMBERTI,
   Viviana/AAS-3963-2020; Viale, Giuseppe/AAE-8921-2019; Minucci,
   Saverio/J-9669-2012; Di Fiore, Pier/K-2130-2012; Pece,
   Salvatore/B-9609-2013; Pelicci, Pier/AAL-6572-2020; Chiocca,
   Susanna/AAC-8863-2019; Pruneri, Giancarlo/AAC-7767-2022; Chiaradonna,
   Ferdinando/K-4959-2016; Botrugno, Oronza Antonietta/P-2065-2017; Bucci,
   Gabriele/H-3002-2014
OI Pruneri, Giancarlo/0000-0002-7963-7172; Barozzi,
   Iros/0000-0003-0690-3473; Chiaradonna, Ferdinando/0000-0001-8529-2732;
   Botrugno, Oronza Antonietta/0000-0002-2568-9815; Chiocca,
   Susanna/0000-0002-9721-0850; PELICCI, PIER GIUSEPPE/0000-0002-5076-2316;
   Minucci, Saverio/0000-0001-5678-536X; Bucci,
   Gabriele/0000-0001-9838-7204
FU Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.); Italian
   Ministry of Health; SysBioNet; MIUR; Italian Government (FAR); Umberto
   Veronesi Foundation
FX This work was supported by grants from Associazione Italiana per la
   Ricerca sul Cancro (A.I.R.C.) to S.C., S.M., and F.C. and from the
   Italian Ministry of Health. F.C. has also been partially supported by
   SysBioNet, an MIUR grant for the Italian Roadmap of ESFRI
   Infrastructures and from the Italian Government (FAR). I.B. is supported
   by an Umberto Veronesi Foundation fellowship (F.U.V.). R.P. has been
   supported by fellowships of SysBioNet. The authors wish to thank Merck
   for the financial support during the first part of their studies.
CR Alcarraz-Vizán G, 2010, METABOLOMICS, V6, P229, DOI 10.1007/s11306-009-0192-0
   Altucci L, 2009, EUR J CANCER, V45, P1137, DOI 10.1016/j.ejca.2009.03.001
   Amoêdo ND, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022264
   BARD S, 1986, BRIT J CANCER, V53, P637, DOI 10.1038/bjc.1986.107
   Basu HS, 2011, CANCER CHEMOTH PHARM, V67, P705, DOI 10.1007/s00280-010-1364-3
   Botta D, 2008, DRUG METAB REV, V40, P465, DOI [10.1080/03602530802186587, 10.1080/03602530802186587 ]
   Brocker C, 2011, CHEM-BIOL INTERACT, V191, P269, DOI 10.1016/j.cbi.2011.02.016
   Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299
   Carlisi D, 2015, J CELL PHYSIOL, V230, P1276, DOI 10.1002/jcp.24863
   Chiaradonna F, 2015, ANTIOXID REDOX SIGN, V23, P30, DOI 10.1089/ars.2014.5854
   Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187
   Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412
   Corti A, 2010, ANTICANCER RES, V30, P1169
   Cossarizza A, 2009, NAT PROTOC, V4, P1790, DOI 10.1038/nprot.2009.189
   Cui XJ, 2005, J CLIN ONCOL, V23, P7721, DOI 10.1200/JCO.2005.09.004
   Dali-Youcef N, 2007, ANN MED, V39, P335, DOI 10.1080/07853890701408194
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Erejuwa OO, 2013, OXID MED CELL LONGEV, V2013, DOI 10.1155/2013/931251
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Gabrielson M, 2013, ONCOL REP, V29, P1268, DOI 10.3892/or.2013.2247
   Grant C, 2010, EXPERT REV ANTICANC, V10, P997, DOI [10.1586/era.10.88, 10.1586/ERA.10.88]
   Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Hu YM, 2010, BLOOD, V116, P2732, DOI 10.1182/blood-2009-11-256354
   Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963
   Kanehisa M, 2014, NUCLEIC ACIDS RES, V42, pD199, DOI 10.1093/nar/gkt1076
   Kitamura T, 2015, BIOCHEM J, V465, P79, DOI 10.1042/BJ20140624
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Komatsu S, 2013, BIOCHEM BIOPH RES CO, V437, P41, DOI 10.1016/j.bbrc.2013.06.032
   Li YS, 2014, HUM MOL GENET, V23, P5378, DOI 10.1093/hmg/ddu256
   Meimaridou E, 2012, NAT GENET, V44, P740, DOI 10.1038/ng.2299
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   Minamiya Y, 2011, LUNG CANCER, V74, P300, DOI 10.1016/j.lungcan.2011.02.019
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Moser MA, 2014, CHROMOSOMA, V123, P67, DOI 10.1007/s00412-013-0441-x
   Nguyen VD, 2011, J MOL BIOL, V406, P503, DOI 10.1016/j.jmb.2010.12.039
   ODwyer PJ, 1996, J CLIN ONCOL, V14, P249, DOI 10.1200/JCO.1996.14.1.249
   Park S, 2015, CELL STRESS CHAPERON, V20, P149, DOI 10.1007/s12192-014-0533-4
   Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140
   Pellatt AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080554
   Petruccelli LA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020987
   Polyak K, 2014, NATURE, V508, P52, DOI 10.1038/508052a
   Poole RM, 2014, DRUGS, V74, P1543, DOI 10.1007/s40265-014-0275-8
   Rangwala S, 2012, FUTURE MED CHEM, V4, P471, DOI [10.4155/fmc.12.6, 10.4155/FMC.12.6]
   Ronzoni S, 2005, CYTOM PART A, V66A, P52, DOI 10.1002/cyto.a.20151
   Rosato RR, 2005, EXPERT OPIN THER TAR, V9, P809, DOI 10.1517/14728222.9.4.809
   ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H
   Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598
   RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475
   Santoro F, 2013, BLOOD, V121, P3459, DOI 10.1182/blood-2012-10-461988
   SCHULZ GE, 1978, NATURE, V273, P120, DOI 10.1038/273120a0
   Segré CV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/690848
   Spiegel S, 2012, ONCOGENE, V31, P537, DOI 10.1038/onc.2011.267
   Stearns V, 2013, CLIN CANCER RES, V19, P4008, DOI 10.1158/1078-0432.CCR-13-0033
   Tabas-Madrid D, 2012, NUCLEIC ACIDS RES, V40, pW478, DOI 10.1093/nar/gks402
   Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697
   Thakkar Arvind D, 2010, Biomark Cancer, V2, P1, DOI 10.4137/BIC.S3793
   Tina E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-350
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940
   Wang F, 2014, BREAST CANCER RES TR, V147, P203, DOI 10.1007/s10549-014-3068-6
   Wang QJ, 2010, SCIENCE, V327, P1004, DOI 10.1126/science.1179687
   Wardell SE, 2009, MOL ENDOCRINOL, V23, P388, DOI 10.1210/me.2008-0179
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990
   Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Wolf IML, 2014, SCI REP-UK, V4, DOI 10.1038/srep06226
   Xiao WS, 2013, FREE RADICAL BIO MED, V65, P70, DOI 10.1016/j.freeradbiomed.2013.06.010
   Yang XJ, 2008, NAT REV MOL CELL BIO, V9, P206, DOI 10.1038/nrm2346
   You BR, 2013, MOL BIOL REP, V40, P3807, DOI 10.1007/s11033-012-2459-1
   You BR, 2013, INT J ONCOL, V42, P359, DOI 10.3892/ijo.2012.1705
   Zhang CL, 2005, J INVEST DERMATOL, V125, P1045, DOI 10.1111/j.0022-202X.2005.23925.x
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689
   Zhu Y, 2014, ONCOGENE, V33, P1527, DOI 10.1038/onc.2013.104
   Zhuo P, 2009, BBA-GEN SUBJECTS, V1790, P1546, DOI 10.1016/j.bbagen.2009.03.004
NR 76
TC 11
Z9 11
U1 0
U2 13
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUL 1
PY 2015
VL 23
IS 1
BP 15
EP 29
DI 10.1089/ars.2014.6189
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA CV0ZH
UT WOS:000363982100002
PM 25897982
OA Green Published
DA 2025-01-12
ER

PT J
AU Ding, MH
   Wang, Z
   Jiang, L
   Fu, HL
   Gao, J
   Lin, XB
   Zhang, CL
   Liu, ZY
   Shi, YF
   Qiu, GZ
   Ma, Y
   Cui, DX
   Hu, GH
   Jin, WL
AF Ding, Mao-Hua
   Wang, Zhen
   Jiang, Lei
   Fu, Hua-Lin
   Gao, Jie
   Lin, Xian-Bin
   Zhang, Chun-Lei
   Liu, Zhen-Yang
   Shi, Yi-Fei
   Qiu, Guan-Zhong
   Ma, Yue
   Cui, Da-Xiang
   Hu, Guo-Han
   Jin, Wei-Lin
TI The transducible TAT-RIZ1-PR protein exerts histone methyltransferase
   activity and tumor-suppressive functions in human malignant meningiomas
SO BIOMATERIALS
LA English
DT Article
DE Meningioma; RIZ1; PR domain; TAT protein transduction; Histone
   methyltransferase; Tumor suppressor
ID DNA METHYLATION; PR DOMAIN; C-MYC; RETINOBLASTOMA PROTEIN;
   BREAST-CANCER; CELL-CYCLE; RIZ1; GENE; EXPRESSION; GROWTH
AB Malignant meningiomas are a rare meningioma subtype and tend to have post-surgical recurrence. Significant endeavors have been taken to identify functional therapeutic targets to halt the growth of this aggressive cancer. We have recently discovered that RIZ1 is downregulated in high-grade meningiomas, and RIZ1 overexpression inhibits proliferation while promoting cell apoptosis of the IOMM-Lee malignant meningioma cell line. In this report, we show that the N-terminal PR domain of RIZ1 alone possessed growth-inhibitory activity and anticancer activity in primary human meningioma cells. Interestingly, the effects seem to be dependent on differential RIZ1 protein levels. Transducible TAT-RIZ1-PR protein could also inhibit meningioma tumor growth in nude mice models. We further demonstrate that PR protein exerts histone methyltransferase activity. A microarray analysis of TAT-RIZ1-PR-treated human malignant meningioma cells reveals 969 differentially expressed genes and 848 alternative splicing exons. Moreover, c-Myc and TXNIP, two putative downstream targets of H3K9 methylation, may be involved in regulating RIZ1 tumor-suppressive effects. The reciprocal relationship between RIZ1 and c-Myc was then validated in primary meningioma cells and human tumor samples. These findings provide insights into RIZ1 tumor suppression mechanisms and suggest that TAT-RIZ1-PR protein is a potential new epigenetic therapeutic agent for advanced meningiomas. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Ding, Mao-Hua; Jiang, Lei; Lin, Xian-Bin; Qiu, Guan-Zhong; Hu, Guo-Han] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China.
   [Wang, Zhen; Fu, Hua-Lin; Zhang, Chun-Lei; Ma, Yue; Cui, Da-Xiang; Jin, Wei-Lin] Shanghai Jiao Tong Univ, Key Lab Thin Film & Microfabricat Technol, Sch Elect Informat & Elect Engn,Minist Educ, Inst Nano Biomed & Engn,Dept Instrument Sci & Eng, Shanghai 200240, Peoples R China.
   [Wang, Zhen; Gao, Jie; Shi, Yi-Fei; Jin, Wei-Lin] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China.
   [Liu, Zhen-Yang] Gen Hosp Beijing Mil Reg, Affiliated Bayi Brain Hosp, Beijing 100700, Peoples R China.
C3 Naval Medical University; Shanghai Jiao Tong University; Shanghai Jiao
   Tong University; Seventh Medical Center of Chinese PLA General Hospital
RP Jin, WL (通讯作者)，Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China.
EM huguohan6504@sina.com; weilinjin@yahoo.com
RI jiang, lei/IWE-1124-2023; Liu, Zhenyang/JXN-5786-2024; Jin,
   Wei-Lin/A-8355-2013; Qiu, Guan-Zhong/P-6976-2017
OI Jin, Wei-Lin/0000-0001-8011-2405; Qiu, Guan-Zhong/0000-0003-2534-0426
FU National Natural Science Foundation of China [81272801, 81372717,
   81172398]; Shanghai "Science and Technology Innovation Action Plan"
   Basic Research Key Project [12JC1411200]; National Key Basic Research
   Program of China ("973" Project) [2010CB933901]; China Post-doctoral
   Science Foundation [2013M542473]
FX This work was supported by National Natural Science Foundation of China
   (Nos. 81272801, 81372717 and 81172398), Shanghai "Science and Technology
   Innovation Action Plan" Basic Research Key Project (No. 12JC1411200),
   National Key Basic Research Program of China ("973" Project)
   (2010CB933901) and China Post-doctoral Science Foundation (No.
   2013M542473).
CR Abu Shadat NM, 2010, CANCER INVEST, V28, P806, DOI 10.3109/07357907.2010.494323
   Baia GS, 2006, J NEURO-ONCOL, V78, P113, DOI 10.1007/s11060-005-9076-y
   Baudino TA, 2002, GENE DEV, V16, P2530, DOI 10.1101/gad.1024602
   Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186
   Becker-Hapak M, 2003, CURR PROTOC CELL BIO
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   BUYSE IM, 1995, P NATL ACAD SCI USA, V92, P4467, DOI 10.1073/pnas.92.10.4467
   Carling T, 2004, MOL CELL BIOL, V24, P7032, DOI 10.1128/MCB.24.16.7032-7042.2004
   Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497
   Congdon LM, 2014, NUCLEIC ACIDS RES, V42, P3580, DOI 10.1093/nar/gkt1377
   Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014
   Derunes C, 2005, BIOCHEM BIOPH RES CO, V333, P925, DOI 10.1016/j.bbrc.2005.05.190
   Du Y, 2001, CANCER RES, V61, P8094
   Geli J, 2005, INT J ONCOL, V26, P1385
   He LS, 1998, CANCER RES, V58, P4238
   He SH, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.10.FOCUS13360
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   HUANG S, 1994, CELL, V78, P9, DOI 10.1016/0092-8674(94)90565-7
   Jensen RL, 1998, NEUROSURGERY, V42, P130, DOI 10.1097/00006123-199801000-00027
   Jensen RL, 2001, SURG NEUROL, V55, P275, DOI 10.1016/S0090-3019(01)00444-X
   Jiang GL, 2001, CANCER RES, V61, P1796
   Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F
   Kim KC, 2003, CANCER RES, V63, P7619
   Kishida Y, 2012, CARCINOGENESIS, V33, P436, DOI 10.1093/carcin/bgr260
   Lal G, 2006, CANCER, V107, P2752, DOI 10.1002/cncr.22325
   Liu LM, 1997, J BIOL CHEM, V272, P2984, DOI 10.1074/jbc.272.5.2984
   Liu ZY, 2013, ONCOGENE, V32, P1216, DOI 10.1038/onc.2012.155
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P547, DOI 10.1007/s00401-007-0278-6
   Ma Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057865
   Maiuri F, 2007, J NEURO-ONCOL, V82, P63, DOI 10.1007/s11060-005-9078-9
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mi YJ, 2012, CELL DEATH DIFFER, V19, P1175, DOI 10.1038/cdd.2011.206
   Nagashima G, 2001, CLIN NEUROL NEUROSUR, V103, P13, DOI 10.1016/S0303-8467(00)00119-0
   Oue N, 2006, CANCER-AM CANCER SOC, V106, P1250, DOI 10.1002/cncr.21754
   Pastural E, 2007, ONCOGENE, V26, P1586, DOI 10.1038/sj.onc.1209959
   Perrone L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.42
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Püttmann S, 2005, LAB INVEST, V85, P1163, DOI 10.1038/labinvest.3700307
   Riemenschneider MJ, 2006, LANCET NEUROL, V5, P1045, DOI 10.1016/S1474-4422(06)70625-1
   Shen Y, 2011, MOL THER, V19, P903, DOI 10.1038/mt.2010.283
   Shin KH, 2008, BIOCHEM BIOPH RES CO, V372, P880, DOI 10.1016/j.bbrc.2008.05.175
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360
   Soussain C, 2009, LANCET, V374, P1639, DOI 10.1016/S0140-6736(09)61299-X
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   Sun WP, 2011, INT J MED SCI, V8, P161, DOI 10.7150/ijms.8.161
   Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011
   Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608
   Wang Q, 2008, ANESTHESIOLOGY, V108, P1071, DOI 10.1097/ALN.0b013e318173f66b
   Wang XT, 2013, PHYTOMEDICINE, V20, P1330, DOI 10.1016/j.phymed.2013.07.010
   Wen PY, 2010, J NEURO-ONCOL, V99, P365, DOI 10.1007/s11060-010-0349-8
   Wiencke JK, 2008, ONCOGENE, V27, P2412, DOI 10.1038/sj.onc.1210895
   Yoshihara E, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1127
   Zaher A, 2013, WORLD NEUROSURG, V80, P549, DOI 10.1016/j.wneu.2013.07.001
   Zhang CJ, 2010, J HEPATOL, V53, P889, DOI 10.1016/j.jhep.2010.05.012
   Zhang LY, 2007, MOL CANCER THER, V6, P1661, DOI 10.1158/1535-7163.MCT-06-0653
   Zhang X, 2012, ACTA BIOCH BIOPH SIN, V44, P14, DOI 10.1093/abbs/gmr100
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 58
TC 15
Z9 16
U1 0
U2 25
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2015
VL 56
BP 165
EP 178
DI 10.1016/j.biomaterials.2015.03.058
PG 14
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA CI8SI
UT WOS:000355041600017
PM 25934289
DA 2025-01-12
ER

PT J
AU Cho, MH
   Park, JH
   Choi, HJ
   Park, MK
   Won, HY
   Park, YJ
   Lee, CH
   Oh, SH
   Song, YS
   Kim, HS
   Oh, YH
   Lee, JY
   Kong, G
AF Cho, Min-Hyung
   Park, Ji-Hye
   Choi, Hee-Joo
   Park, Mi-Kyung
   Won, Hee-Young
   Park, Yeon-Ji
   Lee, Chang Hoon
   Oh, Seung-Hyun
   Song, Young-Soo
   Kim, Hyun Sung
   Oh, Young-Ha
   Lee, Jeong-Yeon
   Kong, Gu
TI DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress
   <i>CDH1</i> transcription factors in breast cancer progression
SO NATURE COMMUNICATIONS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; H3K79 METHYLATION; STEM-CELLS; C-MYC;
   SELF-RENEWAL; RECRUITMENT; LEUKEMIA; LINKS; PROLIFERATION; INHIBITION
AB DOT1L has emerged as an anticancer target for MLL-associated leukaemias; however, its functional role in solid tumours is largely unknown. Here we identify that DOT1L cooperates with c-Myc and p300 acetyltransferase to epigenetically activate epithelial-mesenchymal transition (EMT) regulators in breast cancer progression. DOT1L recognizes SNAIL, ZEB1 and ZEB2 promoters via interacting with the c-Myc-p300 complex and facilitates lysine-79 methylation and acetylation towards histone H3, leading to the dissociation of HDAC1 and DNMT1 in the regions. The upregulation of these EMT regulators by the DOT1L-c-Myc-p300 complex enhances EMT-induced breast cancer stem cell (CSC)-like properties. Furthermore, in vivo orthotopic xenograft models show that DOT1L is required for malignant transformation of breast epithelial cells and breast tumour initiation and metastasis. Clinically, DOT1L expression is associated with poorer survival and aggressiveness of breast cancers. Collectively, we suggest that cooperative effect of DOT1L and c-Myc-p300 is critical for acquisition of aggressive phenotype of breast cancer by promoting EMT/CSC.
C1 [Cho, Min-Hyung; Choi, Hee-Joo; Won, Hee-Young; Park, Yeon-Ji; Song, Young-Soo; Kim, Hyun Sung; Oh, Young-Ha; Kong, Gu] Hanyang Univ, Dept Pathol, Coll Med, Seoul 133791, South Korea.
   [Park, Ji-Hye; Lee, Jeong-Yeon; Kong, Gu] Hanyang Univ, IBBR, Seoul 133791, South Korea.
   [Park, Mi-Kyung; Lee, Chang Hoon] Dongguk Univ, Coll Pharm, Seoul 100715, South Korea.
   [Oh, Seung-Hyun] Gachon Univ, Coll Pharm, Inchon 405840, South Korea.
C3 Hanyang University; Hanyang University; Dongguk University; Gachon
   University
RP Lee, JY (通讯作者)，Hanyang Univ, IBBR, Seoul 133791, South Korea.
EM jy2jy2@hanyang.ac.kr; gkong@hanyang.ac.kr
RI Park, Mi-Kyung/J-9643-2017; Song, Youngsoo/GVU-9301-2022; Oh,
   Seung/AAN-6744-2021; Kim, Sung/I-2997-2017
OI Choi, Hee-Joo/0000-0001-6432-8193
FU National Research Foundation of Korea (NRF) - Korean government
   [2010-0020879]
FX This study was supported by the National Research Foundation of Korea
   (NRF) funded by the Korean government (No. 2010-0020879).
CR Amatangelo MD, 2012, CARCINOGENESIS, V33, P1965, DOI 10.1093/carcin/bgs227
   Nguyen AT, 2011, GENE DEV, V25, P1345, DOI 10.1101/gad.2057811
   Bedford DC, 2010, EPIGENETICS-US, V5, P9, DOI 10.4161/epi.5.1.10449
   Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010
   Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509
   Chang MJ, 2010, CANCER RES, V70, P10234, DOI 10.1158/0008-5472.CAN-10-3294
   Cho KB, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013
   Daigle SR, 2013, BLOOD, V122, P1017, DOI 10.1182/blood-2013-04-497644
   Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Guccione E, 2006, NAT CELL BIOL, V8, P764, DOI 10.1038/ncb1434
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kenneth NS, 2007, P NATL ACAD SCI USA, V104, P14917, DOI 10.1073/pnas.0702909104
   Kim SK, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.384057
   Kim W, 2012, J BIOL CHEM, V287, P5588, DOI 10.1074/jbc.M111.328138
   Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001
   Kurland JF, 2008, CANCER RES, V68, P3624, DOI 10.1158/0008-5472.CAN-07-6552
   Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53
   Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514
   Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200
   Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020
   Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395
   Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821
   Wakeman TP, 2012, EMBO J, V31, P2169, DOI 10.1038/emboj.2012.50
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364
   Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
   Yu M, 2009, GENE DEV, V23, P1737, DOI 10.1101/gad.1809309
   Zhang L, 2014, ONCOTARGET, V5, P10665, DOI 10.18632/oncotarget.2496
NR 39
TC 154
Z9 168
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUL
PY 2015
VL 6
AR 7821
DI 10.1038/ncomms8821
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CO0RV
UT WOS:000358860900001
PM 26199140
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Treviño, LS
   Wang, Q
   Walker, CL
AF Trevino, Lindsey S.
   Wang, Quan
   Walker, Cheryl L.
TI Hypothesis: Activation of rapid signaling by environmental estrogens and
   epigenetic reprogramming in breast cancer
SO REPRODUCTIVE TOXICOLOGY
LA English
DT Article
DE Breast cancer; Epigenetics; Environmental estrogens; Histone modifiers
ID BISPHENOL-A ALTERS; IN-UTERO EXPOSURE; MAMMARY-GLAND DEVELOPMENT;
   INFLAMMATORY RESPONSES; DEVELOPMENTAL ORIGINS; ENDOCRINE DISRUPTORS;
   NONGENOMIC PATHWAY; EPITHELIAL-CELLS; DNA METHYLATION; RECEPTOR
AB Environmental and lifestyle factors are considered significant components of the increasing breast cancer risk in the last 50 years. Specifically, exposure to environmental endocrine disrupting compounds is correlated with cancer susceptibility in a variety of tissues. In both human and rodent models, the exposure to ubiquitous environmental estrogens during early life has been shown to disrupt normal mammary development and cause permanent adverse effects. Recent studies indicate that environmental estrogens not only have the ability to disrupt estrogen receptor (ER) signaling, but can also reprogram the epigenome by altering DNA and histone methylation through rapid, nongenomic ER actions. We have observed xenoestrogen-mediated activation of several nongenomic signaling pathways and have identified a target for epigenetic reprogramming in MCF-7 breast cancer cells. These observations, in addition to data from the literature, support the hypothesis that activation of rapid signaling by environmental estrogens can lead to epigenetic reprogramming and contribute to the progression of breast cancer. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Trevino, Lindsey S.; Wang, Quan; Walker, Cheryl L.] Texas A&M Hlth Sci Ctr, Ctr Translat Canc Res, Inst Biosci & Technol, Houston, TX USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center
RP Walker, CL (通讯作者)，2121 W Holcombe Blvd, Houston, TX 77030 USA.
EM cwalker@ibt.tamhsc.edu
FU Cancer Prevention Research Institute of Texas (CPRIT) [RP120855];
   National Institutes of Health [RC2 ES018789-02, R01 ES008263-14]
FX C.L.W. is supported by grants from the Cancer Prevention Research
   Institute of Texas (CPRIT; RP120855), and the National Institutes of
   Health (RC2 ES018789-02 and R01 ES008263-14).
CR [Anonymous], 2013, Breast cancer and the environment: prioritizing prevention
   Baba A, 2011, NAT CELL BIOL, V13, P668, DOI 10.1038/ncb2228
   Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x
   Barker DJP, 2012, PUBLIC HEALTH, V126, P185, DOI 10.1016/j.puhe.2011.11.014
   Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148
   Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105
   Bredfeldt TG, 2010, MOL ENDOCRINOL, V24, P993, DOI 10.1210/me.2009-0438
   Brody JG, 2007, CANCER-AM CANCER SOC, V109, P2667, DOI 10.1002/cncr.22655
   Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753
   Cogliano VJ, 2011, JNCI-J NATL CANCER I, V103, P1827, DOI 10.1093/jnci/djr483
   DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dong B, 2010, BIOCHEM PHARMACOL, V79, P487, DOI 10.1016/j.bcp.2009.08.031
   Fénichel P, 2012, HUM REPROD, V27, P983, DOI 10.1093/humrep/der451
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Fujisawa Y, 2011, BIOL CHEM, V392, P897, DOI 10.1515/BC.2011.087
   Greathouse KL, 2008, REPROD SCI, V15, P765, DOI 10.1177/1933719108322440
   Greathouse KL, 2012, MOL CANCER RES, V10, P546, DOI 10.1158/1541-7786.MCR-11-0605
   Hammes SR, 2011, ENDOCRINOLOGY, V152, P4489, DOI 10.1210/en.2011-1470
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Hoover RN, 2011, NEW ENGL J MED, V365, P1304, DOI 10.1056/NEJMoa1013961
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Kawazu M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017830
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Knower KC, 2014, ENDOCR-RELAT CANCER, V21, pT33, DOI 10.1530/ERC-13-0513
   Lamartiniere CA, 2011, HORM MOL BIOL CLIN I, V5, P45, DOI 10.1515/HMBCI.2010.075
   Li W, 2010, BIOL CHEM, V391, P1205, DOI 10.1515/BC.2010.126
   Li W, 2008, BIOCHEMISTRY-US, V47, P13997, DOI 10.1021/bi801913w
   Macon MB, 2013, J MAMMARY GLAND BIOL, V18, P43, DOI 10.1007/s10911-013-9275-7
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Matsumura F, 2009, BIOCHEM PHARMACOL, V77, P608, DOI 10.1016/j.bcp.2008.10.013
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Pedram A, 2007, J BIOL CHEM, V282, P22278, DOI 10.1074/jbc.M611877200
   Pedram A, 2014, DEV CELL, V29, P482, DOI 10.1016/j.devcel.2014.04.016
   Plachot C, 2004, EXP CELL RES, V298, P122, DOI 10.1016/j.yexcr.2004.04.024
   Prins GS, 2014, ENDOCRINOLOGY, V155, P805, DOI 10.1210/en.2013-1955
   Qin XY, 2012, CANCER BIOL THER, V13, P296, DOI 10.4161/cbt.18942
   Rudel RA, 2014, ENVIRON HEALTH PERSP, V122, P881, DOI 10.1289/ehp.1307455
   Schmidt CW, 2012, ENVIRON HEALTH PERSP, V120, pA60, DOI 10.1289/ehp.120-a60a
   Sciullo EM, 2009, CHEMOSPHERE, V74, P1531, DOI 10.1016/j.chemosphere.2008.11.010
   Shanle EK, 2011, CHEM RES TOXICOL, V24, P6, DOI 10.1021/tx100231n
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Sinha S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-84
   Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b
   Tilghman SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032754
   Treviño LS, 2013, TRENDS ENDOCRIN MET, V24, P515, DOI 10.1016/j.tem.2013.05.008
   Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631
   Turnbull C, 2008, ANNU REV GENOM HUM G, V9, P321, DOI 10.1146/annurev.genom.9.081307.164339
   Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561
   Verloop J, 2010, CANCER CAUSE CONTROL, V21, P999, DOI 10.1007/s10552-010-9526-5
   Wadia PR, 2007, ENVIRON HEALTH PERSP, V115, P592, DOI 10.1289/ehp.9640
   Walker CL, 2012, NAT REV CANCER, V12, P479, DOI 10.1038/nrc3220
   Weng YI, 2010, TOXICOL APPL PHARM, V248, P111, DOI 10.1016/j.taap.2010.07.014
   Wong RLY, 2013, CLIN CANCER RES, V19, P3732, DOI 10.1158/1078-0432.CCR-13-0021
NR 58
TC 32
Z9 38
U1 0
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0890-6238
J9 REPROD TOXICOL
JI Reprod. Toxicol.
PD JUL
PY 2015
VL 54
SI SI
BP 136
EP 140
DI 10.1016/j.reprotox.2014.12.014
PG 5
WC Reproductive Biology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Reproductive Biology; Toxicology
GA CK7GR
UT WOS:000356401300017
PM 25554384
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Bian, YJ
   Lei, Y
   Wang, CM
   Wang, J
   Wang, LN
   Liu, LL
   Liu, LX
   Gao, XJ
   Li, QZ
AF Bian, Yanjie
   Lei, Yu
   Wang, Chunmei
   Wang, Jie
   Wang, Lina
   Liu, Lili
   Liu, Lixin
   Gao, Xuejun
   Li, Qingzhang
TI Epigenetic Regulation of miR-29s Affects the Lactation Activity of Dairy
   Cow Mammary Epithelial Cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID MILK PROTEIN-SYNTHESIS; ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION; DNA
   METHYLATION; GLUCOSE TRANSPORTERS; SECRETORY ACTIVATION; MICRORNA
   EXPRESSION; GLAND DEVELOPMENT; BREAST-CANCER; CASEIN GENE
AB Milk is important for human nutrition, and enhanced milk quality has become a major selection criterion for the genetic improvement of livestock. Epigenetic modifications have been shown to be involved in mammary gland development; but the mechanisms underlying their effects remain unknown. MicroRNAs are involved in the regulation of milk synthesis and in mammary gland development. Our study is the first to investigate the roles of miR-29s and epigenetic regulation in dairy cow mammary epithelial cells (DCMECs). Our results show that miR-29s regulate the DNA methylation level by inversely targeting both DNMT3A and DNMT3B in DCMECs. The inhibition of miR-29s caused global DNA hypermethylation and increased the methylation levels of the promoters of important lactation-related genes, including casein alpha s1 (CSN1S1), E74-like factor 5 (ElF5), peroxisome proliferator-activated receptor gamma (PPAR), sterol regulatory element binding protein-1 (SREBP1), and glucose transporter 1 (GLUT1). The inhibition of miR-29s reduced the secretion of lactoprotein, triglycerides (TG) and lactose by DCMECs. Moreover, the treatment of DCMECs with 5-aza-2-deoxycytidine (5-Aza-dC) decreased the methylation levels of the miR-29b promoter and increased the expression of miR-29b. The link between miR-29s and DNMT3A/3B enhances our understanding of the roles of miRNAs in mammary gland function, and our data will inform more experimentally oriented studies to identify new mechanisms of regulating lactation. We present new insights regarding the epigenetic regulation of lactation performance. Improved understanding of the molecular basis of lactation will aid in the development of strategies for optimizing milk quality in dairy cows and modifying the lactation performance of offspring. J. Cell. Physiol. 230: 2152-2163, 2015. (c) 2015 Wiley Periodicals, Inc.
C1 [Bian, Yanjie; Lei, Yu; Wang, Lina; Li, Qingzhang] Northeast Agr Univ, Res Dept Lactat Biol & Regulat Mammary Gland Func, Harbin 150030, Peoples R China.
   [Wang, Chunmei; Wang, Jie; Liu, Lili; Liu, Lixin; Gao, Xuejun; Li, Qingzhang] Northeast Agr Univ, Key Lab Dairy Sci, Minist Educ, Harbin 150030, Peoples R China.
C3 Northeast Agricultural University - China; Northeast Agricultural
   University - China
RP Li, QZ (通讯作者)，Northeast Agr Univ, Res Dept Lactat Biol & Regulat Mammary Gland Func, Key Lab Dairy Sci, Minist Educ, Harbin 150030, Peoples R China.
EM qzli@neau.edu.cn
RI Wang, Chunmei/CAJ-1421-2022
FU Major State Basic Research Development Program of China [2011CB100804];
   National Natural Science Foundation of China [31072103]
FX Contract grant sponsor: Major State Basic Research Development Program
   of China;Contract grant number: 2011CB100804.Contract grant sponsor:
   National Natural Science Foundation of China;Contract grant number:
   31072103.
CR Anderson SM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1653
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bobe G, 2009, J DAIRY SCI, V92, P197, DOI 10.3168/jds.2008-1252
   CAMPS M, 1994, ENDOCRINOLOGY, V134, P924, DOI 10.1210/en.134.2.924
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Choi YS, 2009, DEV BIOL, V329, P227, DOI 10.1016/j.ydbio.2009.02.032
   Ehara T, 2012, DIABETES, V61, P2442, DOI 10.2337/db11-1834
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022
   Handel AE, 2010, TRENDS MOL MED, V16, P7, DOI 10.1016/j.molmed.2009.11.003
   Heck JML, 2009, J DAIRY SCI, V92, P1192, DOI 10.3168/jds.2008-1208
   Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005
   Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S
   JOHNSON ML, 1983, J BIOL CHEM, V258, P805
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Lee HJ, 2011, STEM CELLS, V29, P1611, DOI 10.1002/stem.706
   Li HM, 2012, MOLECULES, V17, P12037, DOI 10.3390/molecules171012037
   Liu ZF, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1156
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Macheda ML, 2003, CELL TISSUE RES, V311, P91, DOI 10.1007/s00441-002-0661-5
   Mueller E, 2002, J BIOL CHEM, V277, P41925, DOI 10.1074/jbc.M206950200
   Ng RK, 2008, NAT CELL BIOL, V10, P1280, DOI 10.1038/ncb1786
   Noer A, 2006, MOL BIOL CELL, V17, P3543, DOI 10.1091/mbc.E06-04-0322
   Noonan EJ, 2009, ONCOGENE, V28, P1714, DOI 10.1038/onc.2009.19
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Rhoads RE, 2007, J MAMMARY GLAND BIOL, V12, P283, DOI 10.1007/s10911-007-9058-0
   Rijnkels M, 2010, J MAMMARY GLAND BIOL, V15, P85, DOI 10.1007/s10911-010-9170-4
   Santos SJ, 2009, J STEROID BIOCHEM, V115, P161, DOI 10.1016/j.jsbmb.2009.04.001
   Silveri L, 2006, REPROD NUTR DEV, V46, P549, DOI 10.1051/rnd:2006026
   Singh K, 2010, J MAMMARY GLAND BIOL, V15, P101, DOI 10.1007/s10911-010-9164-2
   THOMPSON MD, 1985, CANCER RES, V45, P1291
   TRAURIG HH, 1967, ANAT REC, V159, P239, DOI 10.1002/ar.1091590213
   Vanselow J, 2006, J MOL ENDOCRINOL, V37, P463, DOI 10.1677/jme.1.02131
   Walker AK, 2011, CELL, V147, P840, DOI 10.1016/j.cell.2011.09.045
   Walker AK, 2010, GENE DEV, V24, P1403, DOI 10.1101/gad.1901210
   Wang C, 2011, MOL CELL BIOCHEM, V352, P197, DOI 10.1007/s11010-011-0755-z
   Wang ZR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102118
   Wright JA, 2010, J MAMMARY GLAND BIOL, V15, P213, DOI 10.1007/s10911-010-9183-z
   Yang ZR, 2013, BIOCHEM BIOPH RES CO, V434, P143, DOI 10.1016/j.bbrc.2013.03.054
   Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147
   Zhao K, 2010, CELL BIOL INT, V34, P717, DOI 10.1042/CBI20100023
NR 43
TC 67
Z9 75
U1 1
U2 62
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD SEP
PY 2015
VL 230
IS 9
BP 2152
EP 2163
DI 10.1002/jcp.24944
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CJ1HD
UT WOS:000355233700016
PM 25656908
DA 2025-01-12
ER

PT J
AU Karahan, G
   Sayar, N
   Gozum, G
   Bozkurt, B
   Konu, O
   Yulug, IG
AF Karahan, Gurbet
   Sayar, Nilufer
   Gozum, Gokcen
   Bozkurt, Betul
   Konu, Ozlen
   Yulug, Isik G.
TI Relative expression of rRNA transcripts and 45S rDNA promoter
   methylation status are dysregulated in tumors in comparison with
   matched-normal tissues in breast cancer
SO ONCOLOGY REPORTS
LA English
DT Article
DE epigenetics; DNA methylation; ribosomal DNA; ribosomal RNA expression;
   breast cancer
ID TATA-BINDING PROTEIN; DNA METHYLATION; SNORNA U50; EPIGENETIC
   REGULATION; GENE-EXPRESSION; HYPERMETHYLATION; CELLS; NORMALIZATION
AB Ribosomal RNA (rRNA) expression, one of the most important factors regulating ribosome production, is primarily controlled by a CG-rich 45S rDNA promoter. However, the DNA methylation state of the 45S rDNA promoter, as well as its effect on rRNA gene expression in types of human cancers is controversial. In the present study we analyzed the methylation status of the rDNA promoter (-380 to +53 bp) as well as associated rRNA expression levels in breast cancer cell lines and breast tumor-normal tissue pairs. We found that the aforementioned regulatory region was extensively methylated (74-96%) in all cell lines and in 68% (13/19 tumor-normal pairs) of the tumors. Expression levels of rRNA transcripts 18S, 28S, 5.8S and 45S external transcribed spacer (45S ETS) greatly varied in the breast cancer cell lines regardless of their methylation status. Analyses of rRNA transcript expression levels in the breast tumor and normal matched tissues showed no significant difference when normalized with TBP. On the other hand, using the geometric mean of the rRNA expression values (GM-rRNA) as reference enabled us to identify significant changes in the relative expression of rRNAs in the tissue samples. We propose GM-rRNA normalization as a novel strategy to analyze expression differences between rRNA transcripts. Accordingly, the 18S rRNA/GM-rRNA ratio was significantly higher whereas the 5.8S rRNA/GM-rRNA ratio was significantly lower in breast tumor samples than this ratio in the matched normal samples. Moreover, the 18S rRNA/GM-rRNA ratio was negatively correlated with the 45S rDNA promoter methylation level in the normal breast tissue samples, yet not in the breast tumors. Significant correlations observed between the expression levels of rRNA transcripts in the normal samples were lost in the tumor samples. We showed that the expression of rRNA transcripts may not be based solely on promoter methylation. Carcinogenesis may cause dysregulation of the correlation between spliced rRNA expression levels, possibly due to changes in rRNA processing, which requires further investigation.
C1 [Karahan, Gurbet; Sayar, Nilufer; Gozum, Gokcen; Konu, Ozlen; Yulug, Isik G.] Bilkent Univ, Dept Mol Biol & Genet, Fac Sci, TR-06800 Ankara, Turkey.
   [Bozkurt, Betul] Ankara Numune Res & Teaching Hosp, Dept Gen Surg, TR-06100 Ankara, Turkey.
C3 Ihsan Dogramaci Bilkent University; Ankara Numune Training & Research
   Hospital
RP Yulug, IG (通讯作者)，Bilkent Univ, Dept Mol Biol & Genet, Fac Sci, TR-06800 Ankara, Turkey.
EM yulug@fen.bilkent.edu.tr
OI Sayar Atasoy, Nilufer/0000-0002-3247-613X; Gozum,
   Gokcen/0000-0002-8650-0078; Yulug, Isik/0000-0002-7577-2502
FU Scientific and Technical Research Council of Turkey (TUBITAK)
   [TBAG-107T181]
FX The present study was supported by the Scientific and Technical Research
   Council of Turkey (TUBITAK) (grant no. TBAG-107T181). We thank Dr Daniel
   Press for the English editing of the manuscript.
CR Bacalini MG, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-361
   Ballestar E, 2008, ADV GENET, V61, P247, DOI 10.1016/S0065-2660(07)00009-0
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Brown SE, 2008, CELL CYCLE, V7, P382, DOI 10.4161/cc.7.3.5283
   Brown SE, 2007, MOL CELL BIOL, V27, P4938, DOI 10.1128/MCB.01880-06
   Chan MWY, 2005, CLIN CANCER RES, V11, P7376, DOI 10.1158/1078-0432.CCR-05-1100
   CLOS J, 1986, P NATL ACAD SCI USA, V83, P604, DOI 10.1073/pnas.83.3.604
   COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F
   de Kok JB, 2005, LAB INVEST, V85, P154, DOI 10.1038/labinvest.3700208
   Dez C, 2004, CURR OPIN MICROBIOL, V7, P631, DOI 10.1016/j.mib.2004.10.007
   Dong XY, 2008, HUM MOL GENET, V17, P1031, DOI 10.1093/hmg/ddm375
   Dong XY, 2009, J GENET GENOMICS, V36, P447, DOI 10.1016/S1673-8527(08)60134-4
   EDEN S, 1994, CURR OPIN GENET DEV, V4, P255, DOI 10.1016/S0959-437X(05)80052-8
   Egner JR., 2010, JAMA-J AM MED ASSOC, V304, P1726, DOI [DOI 10.1001/JAMA.2010.1525, 10.1001/jama.2010.1525]
   EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Ferlay J., 2013, GLOBOCAN 2012 CANC I
   Gagnon-Kugler T, 2009, MOL CELL, V35, P414, DOI 10.1016/j.molcel.2009.07.008
   Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200
   Ghulam MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078265
   Gray TA, 1999, P NATL ACAD SCI USA, V96, P5616, DOI 10.1073/pnas.96.10.5616
   Guo CM, 2013, CLIN TRANSL ONCOL, V15, P167, DOI 10.1007/s12094-012-0924-x
   Guo CM, 2013, CLIN CHIM ACTA, V417, P39, DOI 10.1016/j.cca.2012.12.012
   Gur-Dedeoglu B, 2009, ONCOL RES, V17, P353, DOI 10.3727/096504009788428460
   HALTINER MM, 1986, MOL CELL BIOL, V6, P227, DOI 10.1128/MCB.6.1.227
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jia F, 2013, PLANT MOL BIOL, V81, P447, DOI 10.1007/s11103-013-0015-6
   Karpinets TV, 2005, CARCINOGENESIS, V26, P1323, DOI 10.1093/carcin/bgi079
   Kiss T, 2006, COLD SPRING HARB SYM, V71, P407, DOI 10.1101/sqb.2006.71.025
   Kobayashi T, 2008, BIOESSAYS, V30, P267, DOI 10.1002/bies.20723
   Kobayashi T, 2014, P JPN ACAD B-PHYS, V90, P119, DOI 10.2183/pjab.90.119
   Kochanek S, 1996, FEBS LETT, V388, P192, DOI 10.1016/0014-5793(96)00506-6
   Kumaki Y, 2008, NUCLEIC ACIDS RES, V36, pW170, DOI 10.1093/nar/gkn294
   Lalloo F, 2012, CLIN GENET, V82, P105, DOI 10.1111/j.1399-0004.2012.01859.x
   LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3
   Li Steven Shoei-Lung, 2010, World J Stem Cells, V2, P97, DOI 10.4252/wjsc.v2.i4.97
   MACLEOD D, 1983, NATURE, V306, P200, DOI 10.1038/306200a0
   MCKNIGHT SL, 1976, CELL, V8, P305, DOI 10.1016/0092-8674(76)90014-3
   Mourtada-Maarabouni M, 2009, ONCOGENE, V28, P195, DOI 10.1038/onc.2008.373
   Muangsub T, 2014, GENE, V553, P31, DOI 10.1016/j.gene.2014.09.060
   Nafee TM, 2008, BJOG-INT J OBSTET GY, V115, P158, DOI 10.1111/j.1471-0528.2007.01528.x
   Németh A, 2008, EMBO J, V27, P1255, DOI 10.1038/emboj.2008.57
   Oakes CC, 2003, P NATL ACAD SCI USA, V100, P1775, DOI 10.1073/pnas.0437971100
   Pacilli A, 2013, INT J MOL SCI, V14, P14923, DOI 10.3390/ijms140714923
   Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283
   Peng JC, 2007, NAT CELL BIOL, V9, P25, DOI 10.1038/ncb1514
   Powell MA, 2002, CANCER-AM CANCER SOC, V94, P2941, DOI 10.1002/cncr.10559
   Raval A, 2012, BLOOD, V120, P4812, DOI 10.1182/blood-2012-04-423111
   Richards EJ, 2002, CELL, V108, P489, DOI 10.1016/S0092-8674(02)00644-X
   Russell J, 2005, TRENDS BIOCHEM SCI, V30, P87, DOI 10.1016/j.tibs.2004.12.008
   Salozhin SV, 2005, BIOCHEMISTRY-MOSCOW+, V70, P525, DOI 10.1007/s10541-005-0146-8
   SCHMICKEL RD, 1973, PEDIATR RES, V7, P5, DOI 10.1203/00006450-197301000-00002
   SENTENAC A, 1985, CRC CR REV BIOCH MOL, V18, P31, DOI 10.3109/10409238509082539
   SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6
   Tanaka R, 2000, GENES CELLS, V5, P277, DOI 10.1046/j.1365-2443.2000.00325.x
   Terns M, 2006, COLD SPRING HARB SYM, V71, P395, DOI 10.1101/sqb.2006.71.034
   TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4
   Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1
   Uemura M, 2012, ONCOGENE, V31, P1254, DOI 10.1038/onc.2011.319
   Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261
   Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7
   WORTON RG, 1988, SCIENCE, V239, P64, DOI 10.1126/science.3336775
   Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955
NR 65
TC 18
Z9 19
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JUN
PY 2015
VL 33
IS 6
BP 3131
EP 3145
DI 10.3892/or.2015.3940
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CI8YX
UT WOS:000355058700059
PM 25962577
OA Bronze
DA 2025-01-12
ER

PT J
AU Wang, L
   Liu, JL
   Yu, L
   Liu, XX
   Wu, HM
   Lei, FY
   Wu, S
   Wang, X
AF Wang, Lan
   Liu, Jun-Ling
   Yu, Liang
   Liu, Xiang-Xia
   Wu, Hong-Mei
   Lei, Fang-Yong
   Wu, Shu
   Wang, Xi
TI Downregulated miR-45 Inhibits the G1-S Phase Transition by Targeting
   Bmi-1 in Breast Cancer
SO MEDICINE
LA English
DT Article
ID GROWTH-FACTOR INDEPENDENCE-1; ELEVATED GENE-1 AEG-1; CELL-PROLIFERATION;
   EXPRESSION PATTERNS; PROSTATE-CANCER; STEM-CELLS; C-MYC; PROGRESSION;
   CARCINOMA; SUPPRESSES
AB Bmi-1 (B cell-specific Moloney murine leukemia virus integration site 1) is upregulated in breast cancer and was involved in many malignant progressions of breast cells, including cell proliferation, stem cell pluripotency, and cancer initiation. However, the epigenetic regulatory mechanism of Bmi-1 in breast cancer remains unclear.
   After analysis of the ArrayExpress dataset GSE45666, we comparatively detected the expression levels of miR-495 in 9 examined breast cancer cell lines, normal breast epithelial cells and 8 pairs of fresh clinical tumor samples. Furthermore, to evaluate the effect of miR-495 on the progression of breast cancer, MCF-7 andMDA-MB-231 were transduced to stably overexpress miR-495. The 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay, colony formation assays, 5-Bromo-2-deoxyUridine labeling and immunofluorescence, anchorage-independent growth ability assay, flow cytometry analysis, and luciferase assays were used to test the effect of miR-495 in MCF-7 and MDA-MB-231 cells in vitro. Xenografted tumor model was also used to evaluate the effect of miR-495 in breast cancer.
   Herein, we found that miR-495, a predicted regulator of Bmi-1, was frequently downregulated in malignant cells and tissues of breast. Upregulation of miR-495 significantly suppressed breast cancer cell proliferation and tumorigenicity via G1-S arrest. Further analysis revealed that miR-495 targeted Bmi-1 through its 30 untranslated region. Moreover, Bmi-1 could neutralize the suppressive effect of miR-495 on cell proliferation and tumorigenicity of breast cancer in vivo.
   These data suggested that miR-495 could inhibit the G1-S phase transition that leads to proliferation and tumorigenicity inhibition by targeting and suppressing Bmi-1 in breast cancer.
C1 [Wang, Lan; Wu, Hong-Mei] Guangdong Pharmaceut Univ, Sch Basic Courses, Dept Pathogen Biol & Immunol, Guangzhou 510006, Guangdong, Peoples R China.
   [Liu, Jun-Ling] Sun Yat Sen Univ, Ctr Canc, Dept Med Oncol, Guangzhou 510275, Guangdong, Peoples R China.
   [Yu, Liang] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc & Breast Surg, Guangzhou 510275, Guangdong, Peoples R China.
   [Liu, Xiang-Xia] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Plast Surg, Guangzhou 510275, Guangdong, Peoples R China.
   [Lei, Fang-Yong; Wu, Shu] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China.
   [Wang, Xi] Sun Yat Sen Univ, Ctr Canc, Dept Expt Res, State Key Lab Oncol Southern China, Guangzhou 510275, Guangdong, Peoples R China.
C3 Guangdong Pharmaceutical University; Sun Yat Sen University; Sun Yat Sen
   University; Sun Yat Sen University; State Key Lab Oncology South China;
   Sun Yat Sen University; State Key Lab Oncology South China
RP Wang, L (通讯作者)，Guangdong Pharmaceut Univ, Sch Basic Courses, Dept Pathogen Biol & Immunol, Guangzhou 510006, Guangdong, Peoples R China.
EM wanglan3435@hotmail.com; 1272908565@qq.com
RI Lei, Yang/AAE-5089-2019
FU National Natural Science Foundation of China [81201677, 81201548,
   81201546, 81171892]
FX This study was supported by the National Natural Science Foundation of
   China (Grants: 81201677, 81201548, 81201546 and 81171892).
CR Abd El Hafez A, 2014, ANN DIAGN PATHOL, V18, P58, DOI 10.1016/j.anndiagpath.2013.11.004
   Becker M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004230
   Cao MH, 2014, PROTEIN CELL, V5, P862, DOI 10.1007/s13238-014-0088-2
   Chen SM, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-87
   Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882
   Choy B, 2012, BMC GASTROENTEROL, V12, DOI 10.1186/1471-230X-12-146
   Cui JG, 2014, J CELL BIOCHEM, V115, P1033, DOI 10.1002/jcb.24754
   Drukker L, 2013, J RECEPT SIG TRANSD, V33, P359, DOI 10.3109/10799893.2013.838785
   Dwivedi PP, 2007, J STEROID BIOCHEM, V103, P742, DOI 10.1016/j.jsbmb.2006.12.014
   Emdad L, 2009, P NATL ACAD SCI USA, V106, P21300, DOI 10.1073/pnas.0910936106
   Formosa A., 2013, Oncogene
   Fraser PE, 2004, GENE EXPR PATTERNS, V5, P23, DOI 10.1016/j.modgep.2004.06.011
   Goel HL, 2012, CANCER DISCOV, V2, P906, DOI 10.1158/2159-8290.CD-12-0085
   Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10
   Harirchi I, 2012, ASIAN PAC J CANCER P, V13, P3927, DOI 10.7314/APJCP.2012.13.8.3927
   Häyry V, 2008, NEUROPATH APPL NEURO, V34, P555, DOI 10.1111/j.1365-2990.2008.00949.x
   Hu J, 2012, LUNG CANCER, V77, P593, DOI 10.1016/j.lungcan.2012.05.112
   Huang M, 2010, ACTA HAEMATOL-BASEL, V123, P1, DOI 10.1159/000253856
   Hwang-Verslues WW, 2011, ONCOGENE, V30, P2463, DOI 10.1038/onc.2010.618
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678
   Jeon HY, 2010, GENE EXPR PATTERNS, V10, P361, DOI 10.1016/j.gep.2010.08.004
   Jiang LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055527
   Jin J, 2014, AGING CELL
   Jin M, 2014, CANCER RES, V74, P4183, DOI 10.1158/0008-5472.CAN-14-0404
   Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008-5472.CAN-04-0633
   Kim BM, 2012, BIOCHEM BIOPH RES CO, V426, P183, DOI 10.1016/j.bbrc.2012.08.058
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Li HP, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-196
   Li J, 2014, CELL SIGNAL, V26, P724, DOI 10.1016/j.cellsig.2013.12.013
   Li XL, 2013, INT J ONCOL, V43, P793, DOI 10.3892/ijo.2013.1992
   Li ZR, 2012, CANCER LETT, V323, P41, DOI 10.1016/j.canlet.2012.03.029
   Lin C, 2015, ONCOGENE, V34, P332, DOI 10.1038/onc.2013.559
   Lin HX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015797
   Luo M, 2011, ACTA OBSTET GYN SCAN, V90, P737, DOI 10.1111/j.1600-0412.2011.01102.x
   Ma LH, 2013, ANN DIAGN PATHOL, V17, P327, DOI 10.1016/j.anndiagpath.2013.03.002
   Ma YF, 2013, BIOCHEM BIOPH RES CO, V441, P958, DOI 10.1016/j.bbrc.2013.11.010
   Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477
   Okui G, 2013, J CELL BIOCHEM, V114, P2039, DOI 10.1002/jcb.24545
   Palacios F., 2014, Leukemia
   Parvathi MVS, 2013, TUMOR BIOL, V34, P3807, DOI 10.1007/s13277-013-0965-y
   Pathmanathan N, 2013, J CLIN PATHOL, V66, P512, DOI 10.1136/jclinpath-2012-201085
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Qiao B, 2013, EXP MOL PATHOL, V95, P57, DOI 10.1016/j.yexmp.2013.05.004
   Sestak I, 2015, CURR OPIN OBSTET GYN, V27, P92, DOI 10.1097/GCO.0000000000000153
   Shair KHY, 2007, PLOS PATHOG, V3, P1669, DOI 10.1371/journal.ppat.0030166
   Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094
   Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374
   Song LB, 2010, J PATHOL, V222, P227, DOI 10.1002/path.2751
   Song LQ, 2014, J CELL BIOCHEM, V115, P1234, DOI 10.1002/jcb.24665
   Subramanian M, 2014, J CELL BIOCH
   Tu X, 2014, J PATHOL
   Vickers AJ, 2010, BMC MED INFORM DECIS, V10, DOI 10.1186/1472-6947-10-34
   Wang HB, 2013, FEBS J, V280, P2929, DOI 10.1111/febs.12299
   Wang YM, 2013, CELL REP, V4, P99, DOI 10.1016/j.celrep.2013.05.027
   Xie Q, 2014, NEUROPATHOLOGY
   Xu KW, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000294
   Yu Q, 2013, ASIAN PAC J CANCER P, V14, P6569, DOI 10.7314/APJCP.2013.14.11.6569
   Yu XY, 2014, STEM CELLS DEV, V23, P576, DOI 10.1089/scd.2013.0308
   Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40
   Zhou XC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096718
   Zhu C, 2014, UROL ONCOL-SEMIN ORI, V32, DOI 10.1016/j.urolonc.2012.11.013
NR 62
TC 26
Z9 31
U1 0
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD MAY
PY 2015
VL 94
IS 21
AR e718
DI 10.1097/MD.0000000000000718
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CJ1ZQ
UT WOS:000355284100003
PM 26020378
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Citro, S
   Miccolo, C
   Meloni, L
   Chiocca, S
AF Citro, Simona
   Miccolo, Claudia
   Meloni, Laura
   Chiocca, Susanna
TI PI3K/mTOR mediate mitogen-dependent HDAC1 phosphorylation in breast
   cancer: a novel regulation of estrogen receptor expression
SO JOURNAL OF MOLECULAR CELL BIOLOGY
LA English
DT Article
DE breast cancer; estrogen receptor; HDAC1/mTOR/PI3K/S6K1
ID HISTONE DEACETYLASES; GENE-EXPRESSION; SODIUM-BUTYRATE; S6 KINASE;
   C-MYC; ALPHA; PROTEIN; ACTIVATION; TRANSCRIPTION; INHIBITION
AB Histone deacetylase 1(HDAC1) is an important epigenetic controller involved in transcriptional regulation through modification of chromatin structure. Genetic and epigenetic changes and deregulation of signal transduction pathways have been implicated in the development of breast cancer. Downregulation of estrogen receptor alpha (ER alpha) expression is one of the mechanisms behind the acquisition of endocrine resistance. Sustained and increased hormone and growth factor receptor signaling in breast cancer cells contribute to resistance to endocrine therapy. Both HDACs and the PI3K/mTOR signaling pathway are becoming promising targets in breast cancer, reversing also acquired hormone resistance. Here we show how mitogens, activating the PI3K/mTOR pathway, trigger the phosphorylation of HDAC1 in breast cancer cells, which is completely dependent on the activity of the p70 S6 kinase (S6K1). Our findings show that S6K1, overexpressed in many breast cancers, controls HDAC1-dependent transcriptional regulation of ER alpha levels upon mitogenic stimuli, controlling HDAC1 recruitment to the ER alpha promoter. Furthermore, cell treatment with both mTOR and HDACs inhibitors shows an additive effect in inhibiting breast cancer proliferation. This confirms the novel cross-talk between the HDAC1 and PI3K pathways with clinical implications towards the treatment of this malignant disease.
C1 [Citro, Simona; Miccolo, Claudia; Meloni, Laura; Chiocca, Susanna] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy.
C3 IRCCS European Institute of Oncology (IEO)
RP Citro, S (通讯作者)，European Inst Oncol, Dept Expt Oncol, IFOM IEO Campus,Via Adamello 16, I-20139 Milan, Italy.
EM simona.citro@ieo.eu; susanna.chiocca@ieo.eu
RI Citro, Simona/K-4994-2016; Chiocca, Susanna/AAC-8863-2019; Miccolo,
   Claudia/AAR-8386-2020
OI citro, simona/0000-0003-3561-1824; Chiocca, Susanna/0000-0002-9721-0850
FU Associazione Italiana per la Ricerca sul Cancro [AIRC IG5732, AIRC
   IG12075]; Fondazione Umberto Veronesi (FUV)
FX This work was supported by grants from Associazione Italiana per la
   Ricerca sul Cancro to S.C. (AIRC IG5732, AIRC IG12075). S.Ci. was
   supported by a fellowship from Fondazione Umberto Veronesi (FUV).
CR Bärlund M, 2000, J NATL CANCER I, V92, P1252, DOI 10.1093/jnci/92.15.1252
   BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977
   Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786
   Chang SB, 2007, J SURG RES, V138, P37, DOI 10.1016/j.jss.2006.07.003
   Citro S, 2013, J MOL CELL BIOL, V5, P416, DOI 10.1093/jmcb/mjt032
   Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594
   Cuisset L, 1997, J BIOL CHEM, V272, P24148, DOI 10.1074/jbc.272.39.24148
   DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035
   Dillon RL, 2007, ONCOGENE, V26, P1338, DOI 10.1038/sj.onc.1210202
   Duong V, 2006, ONCOGENE, V25, P1799, DOI 10.1038/sj.onc.1209102
   Fedele P, 2012, CRIT REV ONCOL HEMAT, V84, P243, DOI 10.1016/j.critrevonc.2012.03.004
   Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542
   Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601
   Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200
   Kang HJ, 2014, CANCER RES, V74, P1484, DOI 10.1158/0008-5472.CAN-13-2020
   Kidder BL, 2012, NUCLEIC ACIDS RES, V40, P2925, DOI 10.1093/nar/gkr1151
   Kim EK, 2011, BREAST CANCER RES TR, V126, P93, DOI 10.1007/s10549-010-1315-z
   Kostyniuk CL, 2002, ONCOGENE, V21, P6340, DOI 10.1038/sj.onc.1205787
   Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907
   Lallemand F, 1996, BIOCHEM BIOPH RES CO, V229, P163, DOI 10.1006/bbrc.1996.1774
   Li YM, 2010, CANCER RES, V70, P646, DOI 10.1158/0008-5472.CAN-09-1924
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Margueron R, 2004, BIOCHEM PHARMACOL, V68, P1239, DOI 10.1016/j.bcp.2004.04.031
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298
   Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043
   Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200
   POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x
   Qiu Y, 2006, MOL CELL, V22, P669, DOI 10.1016/j.molcel.2006.04.019
   Segré CV, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/690848
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Smith CL, 2008, BIOESSAYS, V30, P15, DOI 10.1002/bies.20687
   Spiegel S, 2012, ONCOGENE, V31, P537, DOI 10.1038/onc.2011.267
   Stoica A, 2000, J CELL BIOCHEM, V76, P605, DOI 10.1002/(SICI)1097-4644(20000315)76:4<605::AID-JCB9>3.0.CO;2-T
   Stoica A, 2000, J ENDOCRINOL, V165, P371, DOI 10.1677/joe.0.1650371
   van der Hage JA, 2004, BRIT J CANCER, V90, P1543, DOI 10.1038/sj.bjc.6601741
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Yamaguchi T, 2010, GENE DEV, V24, P455, DOI 10.1101/gad.552310
   Yang XW, 2000, CANCER RES, V60, P6890
   Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06
NR 41
TC 32
Z9 41
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1674-2788
EI 1759-4685
J9 J MOL CELL BIOL
JI J. Mol. Cell Biol.
PD APR
PY 2015
VL 7
IS 2
BP 132
EP 142
DI 10.1093/jmcb/mjv021
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CJ1GO
UT WOS:000355232100005
PM 25801958
OA Bronze
DA 2025-01-12
ER

PT J
AU Gao, YF
   Tollefsbol, TO
AF Gao, Yifeng
   Tollefsbol, Trygve O.
TI Impact of Epigenetic Dietary Components on Cancer through Histone
   Modifications
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Cancer; dietary components; epigenetics; gene expression; histone
   modifications; phytochemicals
ID CELL-CYCLE ARREST; TUMOR-SUPPRESSOR GENES; PROTEIN-ARGININE
   METHYLTRANSFERASE; PROTEASOME-DEPENDENT MECHANISM; DEACETYLASE
   INHIBITORS; IN-VIVO; PHENYLHEXYL ISOTHIOCYANATE; DNA METHYLATION;
   BREAST-CANCER; DIALLYL DISULFIDE
AB Epigenetics, the study of heritable changes in gene expression without modifying the nucleotide sequence, is among the most important topics in medicinal chemistry and cancer prevention and therapy. Among those changes, DNA methylation and histone modification have been shown to be associated with various types of cancers in a number of ways, many of which are regulated by dietary components that are mostly found in plants. Although mechanisms of nutrient components affecting histone acetylation/deacetylation in cancer are widely studied, how those natural compounds affect cancer through other histone modifications, such as methylation, phosphorylation and ubiquitylation, is rarely reviewed. Thus, this review article discusses impacts on histone acetylation as well as other histone modifications by nutrient components, such as genistein, resveratrol, curcumin, epigallocatechin-3-gallate (EGCG), 3,3'-diindolylmethane (DIM), diallyl disulfide, garcinol, procyanidin B3, quercetin, sulforaphane and other isothiocyanates that have been recently reported in vivo as well as in various types of cancer cell lines.
C1 [Gao, Yifeng; Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Ctr Hlth Aging, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Nutr Obes Res Ctr, Birmingham, AL 35294 USA.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Comprehens Diabet Ctr, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Tollefsbol, TO (通讯作者)，CH175,1300 Univ Blvd, Birmingham, AL 35294 USA.
EM trygve@uab.edu
RI yifeng, gao/KLZ-1190-2024
FU NIH [CA178441]; American Institute for Cancer Research
FX This work was supported in part by grants from the NIH (CA178441) and
   the American Institute for Cancer Research. We also thank Bidisha Paul
   for helpful reading of this manuscript.
CR Abdulla Arian, 2013, J Biochem Pharmacol Res, V1, P56
   Acharya MR, 2005, MOL PHARMACOL, V68, P917, DOI 10.1124/mol.105.014167
   Aggarwal BB, 2009, TRENDS PHARMACOL SCI, V30, P85, DOI 10.1016/j.tips.2008.11.002
   Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007
   Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036
   Alves RC, 2010, J AGR FOOD CHEM, V58, P3002, DOI 10.1021/jf9039205
   Groh IAM, 2013, J NUTR METAB, V2013, DOI 10.1155/2013/821082
   Bacon JR, 2003, CARCINOGENESIS, V24, P1903, DOI 10.1093/carcin/bgg157
   Balasubramanian S, 2011, MOL PHARMACOL, V80, P870, DOI 10.1124/mol.111.072363
   Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P51163, DOI 10.1074/jbc.M409024200
   Balasubramanyam K, 2004, J BIOL CHEM, V279, P33716, DOI 10.1074/jbc.M402839200
   Bannister AJ, 2005, NATURE, V436, P1103, DOI 10.1038/nature04048
   BARNES S, 1995, J NUTR, V125, pS777, DOI 10.1093/jn/125.3_Suppl.777S
   Basak S, 2008, MOL CANCER THER, V7, P3195, DOI 10.1158/1535-7163.MCT-08-0617
   Batra S, 2010, MOL CANCER THER, V9, P1596, DOI 10.1158/1535-7163.MCT-09-1146
   Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060
   Beaver LM, 2012, TOXICOL APPL PHARM, V263, P345, DOI 10.1016/j.taap.2012.07.007
   Beklemisheva AA, 2006, ANTICANCER RES, V26, P1225
   Benavides A, 2006, J PHARMACEUT BIOMED, V40, P639, DOI 10.1016/j.jpba.2005.10.004
   Bhamre S, 2009, PROSTATE, V69, P181, DOI 10.1002/pros.20869
   Bhasin M, 2006, J COMPUT BIOL, V13, P102, DOI 10.1089/cmb.2006.13.102
   Bin Hong Y, 2009, EXP MOL MED, V41, P151, DOI 10.3858/emm.2009.41.3.018
   Bourguignon LYW, 2009, J BIOL CHEM, V284, P2657, DOI 10.1074/jbc.M806708200
   Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200
   Brinkmann H, 2001, J BIOL CHEM, V276, P22491, DOI 10.1074/jbc.M100206200
   Bryant CS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-47
   Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174
   Chen Z, 2010, EPIGENOMICS-UK, V2, P551, DOI 10.2217/EPI.10.31
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Choi KC, 2011, BIOCHEM J, V433, P235, DOI 10.1042/BJ20100980
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Choudhuri S, 2010, TOXICOL APPL PHARM, V245, P378, DOI 10.1016/j.taap.2010.03.022
   Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171
   Chu WF, 2009, ORAL ONCOL, V45, P998, DOI 10.1016/j.oraloncology.2009.05.641
   Clarke JD, 2008, CANCER LETT, V269, P291, DOI 10.1016/j.canlet.2008.04.018
   Clarke JD, 2011, MOL NUTR FOOD RES, V55, P999, DOI 10.1002/mnfr.201000547
   Clarke Nicole, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404008488
   Collins HM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-37
   Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z
   Dashwood RH, 2006, CARCINOGENESIS, V27, P344, DOI 10.1093/carcin/bgi253
   Dashwood RH, 2008, NUTR REV, V66, pS36, DOI 10.1111/j.1753-4887.2008.00065.x
   Dashwood RH, 2007, SEMIN CANCER BIOL, V17, P363, DOI 10.1016/j.semcancer.2007.04.001
   Davis CD, 2007, NUTR REV, V65, P88, DOI 10.1301/nr.2007.feb.88-94
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Desai D, 2010, BIOORG MED CHEM LETT, V20, P2044, DOI 10.1016/j.bmcl.2009.07.068
   Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227
   Dinkova-Kostova AT, 2007, CANCER EPIDEM BIOMAR, V16, P847, DOI 10.1158/1055-9965.EPI-06-0934
   Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Drobic B, 2006, EXP SUPPL, V96, P25
   Druesne N, 2004, CARCINOGENESIS, V25, P1227, DOI 10.1093/carcin/bgh123
   Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6
   Fimognari C, 2008, CURR MED CHEM, V15, P440, DOI 10.2174/092986708783503168
   Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fu SQ, 2010, CANCER-AM CANCER SOC, V116, P4670, DOI 10.1002/cncr.25414
   Fujiki R, 2011, NATURE, V480, P557, DOI 10.1038/nature10656
   Furumai R, 2001, P NATL ACAD SCI USA, V98, P87, DOI 10.1073/pnas.011405598
   Ganesan A, 2009, CURR CANCER DRUG TAR, V9, P963, DOI 10.2174/156800909790192428
   Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585
   Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536
   Gibbons RJ, 2005, HUM MOL GENET, V14, pR85, DOI 10.1093/hmg/ddi106
   Gibbs A, 2009, P NATL ACAD SCI USA, V106, P16663, DOI 10.1073/pnas.0908908106
   Goel A, 2010, NUTR CANCER, V62, P919, DOI 10.1080/01635581.2010.509835
   Goulet AC, 2007, CANCER BIOL THER, V6, P494, DOI 10.4161/cbt.6.4.3813
   GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Gu XL, 1999, J AGR FOOD CHEM, V47, P3223, DOI 10.1021/jf981211e
   Gupta SC, 2011, NAT PROD REP, V28, P1937, DOI 10.1039/c1np00051a
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Hartley JL, 2000, GENOME RES, V10, P1788, DOI 10.1101/gr.143000
   Hede K, 2006, J NATL CANCER I, V98, P377, DOI 10.1093/jnci/djj120
   Herman-Antosiewicz A, 2007, MOL CANCER THER, V6, P1673, DOI 10.1158/1535-7163.MCT-06-0807
   Ho E, 2011, ADV NUTR, V2, P497, DOI 10.3945/an.111.001032
   Ho E, 2009, J NUTR, V139, P2393, DOI 10.3945/jn.109.113332
   Hrabeta J, 2014, BIOMED PAP, V158, P161, DOI 10.5507/bp.2013.085
   Hu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064362
   Jackson SJT, 2004, J NUTR, V134, P2229, DOI 10.1093/jn/134.9.2229
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jiang SH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-48
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kamimura A, 2002, EXP DERMATOL, V11, P532, DOI 10.1034/j.1600-0625.2002.110606.x
   Karelia N, 2010, BIOORG MED CHEM LETT, V20, P6816, DOI 10.1016/j.bmcl.2010.08.113
   Kaufman P B, 1997, J Altern Complement Med, V3, P7, DOI 10.1089/acm.1997.3.7
   Kensler TW, 2005, CANCER EPIDEM BIOMAR, V14, P2605, DOI 10.1158/1055-9965.EPI-05-0368
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110
   Kim JE, 2008, EXP MOL MED, V40, P514, DOI 10.3858/emm.2008.40.5.514
   Kim YS, 2005, J NUTR BIOCHEM, V16, P65, DOI 10.1016/j.jnutbio.2004.10.007
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Kortenhorst MSQ, 2006, CELL ONCOL, V28, P191
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252
   Lambert JD, 2003, J NUTR, V133, p3262S, DOI 10.1093/jn/133.10.3262S
   Lao Christopher D, 2006, BMC Complement Altern Med, V6, P10, DOI 10.1186/1472-6882-6-10
   Lee KK, 2007, NAT REV MOL CELL BIO, V8, P284, DOI 10.1038/nrm2145
   Lee SJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-144
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Lemire M, 2010, SCI TOTAL ENVIRON, V408, P4076, DOI 10.1016/j.scitotenv.2010.05.022
   Li GX, 2010, CARCINOGENESIS, V31, P902, DOI 10.1093/carcin/bgq039
   Li GM, 2013, CANCER PREV RES, V6, P27, DOI 10.1158/1940-6207.CAPR-12-0349
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YM, 2010, CANCER RES, V70, P646, DOI 10.1158/0008-5472.CAN-09-1924
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Li YY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055108, 10.1371/journal.pone.0052093, 10.1371/journal.pone.0063648, 10.1371/journal.pone.0077685, 10.1371/journal.pone.0062036, 10.1371/journal.pone.0054369, 10.1371/journal.pone.0066567, 10.1371/journal.pone.0071994]
   Lin JK, 1999, BIOCHEM PHARMACOL, V58, P911, DOI 10.1016/S0006-2952(99)00112-4
   Lin YW, 2011, CANCER INVEST, V29, P187, DOI 10.3109/07357907.2010.512605
   Lu QY, 2008, J HEMATOL ONCOL, V1, DOI 10.1186/1756-8722-1-6
   Lubas WA, 1997, J BIOL CHEM, V272, P9316
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Maheshwari RK, 2006, LIFE SCI, V78, P2081, DOI 10.1016/j.lfs.2005.12.007
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Marks PA, 2005, EXPERT OPIN INV DRUG, V14, P1497, DOI 10.1517/13543784.14.12.1497
   Martin SL, 2013, CURR MED CHEM, V20, P4050
   McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128
   McKitrick TR, 2010, SEMIN IMMUNOL, V22, P34, DOI 10.1016/j.smim.2009.12.001
   McLaughlin F, 2004, BIOCHEM PHARMACOL, V68, P1139, DOI 10.1016/j.bcp.2004.05.034
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Meeran SM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0011-5
   Mork CN, 2005, CURR PHARM DESIGN, V11, P1091, DOI 10.2174/1381612053507567
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Mottet D, 2008, CLIN EXP METASTAS, V25, P183, DOI 10.1007/s10585-007-9131-5
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2006, CURR DRUG TARGETS, V7, P443, DOI 10.2174/138945006776359467
   Myzak MC, 2006, CANCER LETT, V233, P208, DOI 10.1016/j.canlet.2005.02.033
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Myzak MC, 2007, EXP BIOL MED, V232, P227
   Myzak MC, 2006, MOL CARCINOGEN, V45, P443, DOI 10.1002/mc.20224
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502
   Nian H, 2009, ENVIRON MOL MUTAGEN, V50, P213, DOI 10.1002/em.20454
   Ogryzko VV, 2001, CELL MOL LIFE SCI, V58, P683, DOI 10.1007/PL00000892
   Ong TP, 2011, J NUTRIGENET NUTRIGE, V4, P275, DOI 10.1159/000334585
   Pal S, 2007, J CELL PHYSIOL, V213, P306, DOI 10.1002/jcp.21180
   Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6
   Pham TX, 2012, NUTRIENTS, V4, P1868, DOI 10.3390/nu4121868
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Podhorecka M, 2011, ANN HEMATOL, V90, P173, DOI 10.1007/s00277-010-1045-7
   Pong RC, 2006, CANCER RES, V66, P8822, DOI 10.1158/0008-5472.CAN-05-4672
   Quinde-Axtell Z, 2006, J AGR FOOD CHEM, V54, P9978, DOI 10.1021/jf060974w
   Rajendran P, 2013, EPIGENETICS-US, V8, P612, DOI 10.4161/epi.24710
   Rajendran P, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-68
   Rajendran P, 2011, CRIT REV BIOCHEM MOL, V46, P181, DOI 10.3109/10409238.2011.557713
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Rogan EG, 2006, IN VIVO, V20, P221
   Rosato RR, 2003, CANCER BIOL THER, V2, P30
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Roy M, 2014, ASIAN PAC J CANCER P, V15, P1403, DOI 10.7314/APJCP.2014.15.3.1403
   Sasaki K, 2012, J CHROMATOGR B, V903, P171, DOI 10.1016/j.jchromb.2012.07.017
   Sauve AA, 2006, ANNU REV BIOCHEM, V75, P435, DOI 10.1146/annurev.biochem.74.082803.133500
   Sawan C, 2010, ADV GENET, V70, P57, DOI [10.1016/S0065-2660(10)70003-1, 10.1016/B978-0-12-380866-0.60003-4]
   Scuto A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.159
   Shah S, 2012, CANCER RES, V72, P1248, DOI 10.1158/0008-5472.CAN-11-0943
   Shapiro TA, 2006, NUTR CANCER, V55, P53, DOI 10.1207/s15327914nc5501_7
   Sharma RA, 2005, EUR J CANCER, V41, P1955, DOI 10.1016/j.ejca.2005.05.009
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shu LM, 2011, AAPS J, V13, P606, DOI 10.1208/s12248-011-9300-y
   Singh SV, 2004, J BIOL CHEM, V279, P25813, DOI 10.1074/jbc.M313538200
   Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Su SJ, 2005, BIOCHEM PHARMACOL, V69, P307, DOI 10.1016/j.bcp.2004.09.025
   Taddei A, 2005, EMBO REP, V6, P520, DOI 10.1038/sj.embor.7400441
   Telang U, 2009, EXP BIOL MED, V234, P287, DOI 10.3181/0808-RM-241
   Thakur VS, 2012, INT J ONCOL, V41, P353, DOI 10.3892/ijo.2012.1449
   Tochio N, 2006, STRUCTURE, V14, P457, DOI 10.1016/j.str.2005.12.004
   Trapp J, 2006, CURR DRUG TARGETS, V7, P1553, DOI 10.2174/1389450110607011553
   Trievel RC, 2002, CELL, V111, P91, DOI 10.1016/S0092-8674(02)01000-0
   Venturelli S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073097
   Verdin E, 2004, METHOD ENZYMOL, V377, P180
   Verdin E, 2003, TRENDS GENET, V19, P286, DOI 10.1016/S0168-9525(03)00073-8
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wang BS, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/431081
   Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040955
   Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001
   Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165
   Wood A, 2004, ADV PROTEIN CHEM, V67, P201
   Xiang N, 2008, CARCINOGENESIS, V29, P2175, DOI 10.1093/carcin/bgn179
   Xiao XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022934
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yuan H, 2013, BIOPOLYMERS, V99, P98, DOI 10.1002/bip.22128
   Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615
   Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509
   ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399
   Zhang YK, 2011, EPIGENETICS-US, V6, P888, DOI 10.4161/epi.6.7.16315
   Zhao J, 2006, ACTA PHARMACOL SIN, V27, P1459, DOI 10.1111/j.1745-7254.2006.00433.x
   Zou Y, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-36
NR 194
TC 32
Z9 37
U1 1
U2 33
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2015
VL 22
IS 17
BP 2051
EP 2064
DI 10.2174/0929867322666150420102641
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA CJ1CX
UT WOS:000355220700003
PM 25891109
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Pal, B
   Chen, YS
   Bert, A
   Hu, YF
   Sheridan, JM
   Beck, T
   Shi, W
   Satterley, K
   Jamieson, P
   Goodall, GJ
   Lindeman, GJ
   Smyth, GK
   Visvader, JE
AF Pal, Bhupinder
   Chen, Yunshun
   Bert, Andrew
   Hu, Yifang
   Sheridan, Julie M.
   Beck, Tamara
   Shi, Wei
   Satterley, Keith
   Jamieson, Paul
   Goodall, Gregory J.
   Lindeman, Geoffrey J.
   Smyth, Gordon K.
   Visvader, Jane E.
TI Integration of microRNA signatures of distinct mammary epithelial cell
   types with their gene expression and epigenetic portraits
SO BREAST CANCER RESEARCH
LA English
DT Article
ID CANCER STEM-CELLS; BREAST-CANCER; MESENCHYMAL TRANSITION;
   ESTROGEN-RECEPTOR; MIR-200 FAMILY; SELF-RENEWAL; DIFFERENTIATION;
   TARGETS; SUBPOPULATIONS; REGULATOR
AB Introduction: MicroRNAs (miRNAs) have been implicated in governing lineage specification and differentiation in multiple organs; however, little is known about their specific roles in mammopoiesis. We have determined the global miRNA expression profiles of functionally distinct epithelial subpopulations in mouse and human mammary tissue, and compared these to their cognate transcriptomes and epigenomes. Finally, the human miRNA signatures were used to interrogate the different subtypes of breast cancer, with a view to determining miRNA networks deregulated during oncogenesis.
   Methods: RNA from sorted mouse and human mammary cell subpopulations was subjected to miRNA expression analysis using the TaqMan MicroRNA Array. Differentially expressed (DE) miRNAs were correlated with gene expression and histone methylation profiles. Analysis of miRNA signatures of the intrinsic subtypes of breast cancer in The Cancer Genome Atlas (TCGA) database versus those of normal human epithelial subpopulations was performed.
   Results: Unique miRNA signatures characterized each subset (mammary stem cell (MaSC)/basal, luminal progenitor, mature luminal, stromal), with a high degree of conservation across species. Comparison of miRNA and transcriptome profiles for the epithelial subtypes revealed an inverse relationship and pinpointed key developmental genes. Interestingly, expression of the primate-specific miRNA cluster (19q13.4) was found to be restricted to the MaSC/basal subset. Comparative analysis of miRNA signatures with H3 lysine modification maps of the different epithelial subsets revealed a tight correlation between active or repressive marks for the top DE miRNAs, including derepression of miRNAs in Ezh2-deficient cellular subsets. Interrogation of TCGA-identified miRNA profiles with the miRNA signatures of different human subsets revealed specific relationships.
   Conclusions: The derivation of global miRNA expression profiles for the different mammary subpopulations provides a comprehensive resource for understanding the interplay between miRNA networks and target gene expression. These data have highlighted lineage-specific miRNAs and potential miRNA-mRNA networks, some of which are disrupted in neoplasia. Furthermore, our findings suggest that key developmental miRNAs are regulated by global changes in histone modification, thus linking the mammary epigenome with genome-wide changes in the expression of genes and miRNAs. Comparative miRNA signature analyses between normal breast epithelial cells and breast tumors confirmed an important linkage between luminal progenitor cells and basal-like tumors.
C1 [Pal, Bhupinder; Sheridan, Julie M.; Beck, Tamara; Jamieson, Paul; Lindeman, Geoffrey J.; Visvader, Jane E.] Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia.
   [Pal, Bhupinder; Chen, Yunshun; Sheridan, Julie M.; Beck, Tamara; Jamieson, Paul; Visvader, Jane E.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia.
   [Chen, Yunshun; Hu, Yifang; Shi, Wei; Satterley, Keith; Smyth, Gordon K.] Walter & Eliza Hall Inst Med Res, Bioinformat Div, Parkville, Vic 3052, Australia.
   [Bert, Andrew; Goodall, Gregory J.] SA Pathol, Ctr Canc Biol, Adelaide, SA 5000, Australia.
   [Bert, Andrew; Goodall, Gregory J.] Univ S Australia, Adelaide, SA 5000, Australia.
   [Shi, Wei] Univ Melbourne, Dept Comp & Informat Syst, Parkville, Vic 3010, Australia.
   [Goodall, Gregory J.] Univ Adelaide, Sch Med, Adelaide, SA 5005, Australia.
   [Goodall, Gregory J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.
   [Lindeman, Geoffrey J.] Univ Melbourne, Dept Med, Parkville, Vic 3010, Australia.
   [Lindeman, Geoffrey J.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3010, Australia.
   [Smyth, Gordon K.] Univ Melbourne, Dept Math & Stat, Parkville, Vic 3010, Australia.
C3 Walter & Eliza Hall Institute; University of Melbourne; Walter & Eliza
   Hall Institute; SA Pathology; Centre for Cancer Biology; University of
   South Australia; University of Melbourne; University of Adelaide;
   University of Adelaide; University of Melbourne; Melbourne Health; Royal
   Melbourne Hospital; University of Melbourne
RP Visvader, JE (通讯作者)，Walter & Eliza Hall Inst Med Res, ACRF Stem Cells & Canc Div, Parkville, Vic 3052, Australia.
EM visvader@wehi.edu.au
RI Pal, Bhupinder/AAF-4011-2020; Shi, Wei/AGU-0524-2022; Smyth,
   Gordon/B-5276-2008
OI Chen, Yunshun/0000-0003-4911-5653; Lindeman,
   Geoffrey/0000-0001-9386-2416; Smyth, Gordon/0000-0001-9221-2892; Pal,
   Bhupinder/0000-0002-3684-4331; Sheridan, Julie/0000-0002-1478-3662;
   Beck, Tamara/0000-0002-1125-1871; Bert, Andrew/0000-0003-3876-1537;
   Goodall, Gregory/0000-0003-1294-0692; Shi, Wei/0000-0003-1182-7735
FU Victorian Cancer Agency (VCA); Australian National Health and Medical
   Research Council (NHMRC) [461221, 490037, 1008440, 1016701, 1054618];
   NHMRC IRIISS; Victorian State Government through VCA of Victorian Breast
   Cancer Research Consortium and Operational Infrastructure Support;
   Australian Cancer Research Foundation; Cancer Council SA Project Grant
   [626956]; NHMRC Peter Doherty Fellowship; VCA Early Career Seed
   [ECSG13035]; NHMRC Fellowship [1058892, 1026191, 1078730]; Australia
   Fellowship
FX We are very grateful to C Perou and K Hoadley for supplying PAM50
   subtypes for the TCGA breast cancer samples, and F Vaillant for expert
   advice on sorting. Human breast tissue samples used in this project were
   provided by the Victorian Cancer Biobank, which is supported by the
   Victorian Cancer Agency (VCA). This work was supported by the Australian
   National Health and Medical Research Council (NHMRC) grants #461221,
   #490037, #1008440, #1016701, #1054618; NHMRC IRIISS; the Victorian State
   Government through VCA funding of the Victorian Breast Cancer Research
   Consortium and Operational Infrastructure Support; the Australian Cancer
   Research Foundation; Cancer Council SA Project Grant 626956. BP was
   supported by a NHMRC Peter Doherty Fellowship and VCA Early Career Seed
   Grant (#ECSG13035), GKS, GJG and GJL by NHMRC Fellowships (#1058892,
   #1026191 and #1078730, respectively) and JEV by an Australia Fellowship.
CR [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11
   Avril-Sassen S, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-548
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Bockhorn J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2393
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Bu PC, 2013, CELL STEM CELL, V12, P602, DOI 10.1016/j.stem.2013.03.002
   Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297
   Deng L, 2014, CANCER RES, V74, P6648, DOI 10.1158/0008-5472.CAN-13-3710
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Ding XM, 2013, J BIOL CHEM, V288, P10241, DOI 10.1074/jbc.M112.443655
   Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791
   Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462
   Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102
   Fu NY, 2015, NAT CELL BIOL, V17, P365, DOI 10.1038/ncb3117
   Gangaraju VK, 2009, NAT REV MOL CELL BIO, V10, P116, DOI 10.1038/nrm2621
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hu RX, 2014, FASEB J, V28, P2347, DOI 10.1096/fj.13-247247
   Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591
   Kim J, 2014, CANCER RES, V74, P1541, DOI 10.1158/0008-5472.CAN-13-1449
   Knezevic J, 2015, ONCOGENE, V34, P5997, DOI 10.1038/onc.2015.48
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Laurent LC, 2008, STEM CELLS, V26, P1506, DOI 10.1634/stemcells.2007-1081
   Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69
   Li J, 2013, J CELL PHYSIOL, V228, P2324, DOI 10.1002/jcp.24402
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Lin S, 2010, COMPUT BIOL CHEM, V34, P232, DOI 10.1016/j.compbiolchem.2010.08.001
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Llobet-Navas D, 2014, GENE DEV, V28, P765, DOI 10.1101/gad.237404.114
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24
   McCarthy DJ, 2012, NUCLEIC ACIDS RES, V40, P4288, DOI 10.1093/nar/gks042
   Mulrane L, 2013, CANCER RES, V73, P6554, DOI 10.1158/0008-5472.CAN-13-1841
   Noguer-Dance M, 2010, HUM MOL GENET, V19, P3566, DOI 10.1093/hmg/ddq272
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Pérez-Rivas LG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091884
   Pietersen AM, 2008, CURR BIOL, V18, P1094, DOI 10.1016/j.cub.2008.06.070
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Robinson MD, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-r25
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Sleeman KE, 2007, J CELL BIOL, V176, P19, DOI 10.1083/jcb.200604065
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345
   Suzuki H, 2011, CANCER RES, V71, P5646, DOI 10.1158/0008-5472.CAN-11-1076
   Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777
   Verdoodt B, 2013, INT J ONCOL, V43, P307, DOI 10.3892/ijo.2013.1915
   Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114
   Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114
   Wang YL, 2009, J CELL PHYSIOL, V218, P251, DOI 10.1002/jcp.21607
   Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401
   Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642
   Yoo KH, 2014, DEV BIOL, V395, P245, DOI 10.1016/j.ydbio.2014.09.012
   Zaragosi LE, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-r64
   Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020
   Zhang JP, 2014, ONCOGENE, V33, P4069, DOI 10.1038/onc.2013.369
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
NR 78
TC 28
Z9 32
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD JUN 18
PY 2015
VL 17
AR 85
DI 10.1186/s13058-015-0585-0
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CM3CT
UT WOS:000357560000001
PM 26080807
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Hair, BY
   Xu, ZL
   Kirk, EL
   Harlid, S
   Sandhu, R
   Robinson, WR
   Wu, MC
   Olshan, AF
   Conway, K
   Taylor, JA
   Troester, MA
AF Hair, Brionna Y.
   Xu, Zongli
   Kirk, Erin L.
   Harlid, Sophia
   Sandhu, Rupninder
   Robinson, Whitney R.
   Wu, Michael C.
   Olshan, Andrew F.
   Conway, Kathleen
   Taylor, Jack A.
   Troester, Melissa A.
TI Body mass index associated with genome-wide methylation in breast tissue
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Obesity; Methylation; Breast cancer; BMI; Epigenetics
ID DEMONSTRATE FIELD CANCERIZATION; DNA METHYLATION; AROMATASE-ACTIVITY;
   CANCER-RISK; OBESITY; EXPRESSION; RECEPTOR; SUBTYPES; HYPERMETHYLATION;
   INTERLEUKIN-6
AB Gene expression studies indicate that body mass index (BMI) is associated with molecular pathways involved in inflammation, insulin-like growth factor activation, and other carcinogenic processes in breast tissue. The goal of this study was to determine whether BMI is associated with gene methylation in breast tissue and to identify pathways that are commonly methylated in association with high BMI. Epigenome-wide methylation profiles were determined using the Illumina HumanMethylation450 BeadChip array in the non-diseased breast tissue of 81 women undergoing breast surgery between 2009 and 2013 at the University of North Carolina Hospitals. Multivariable, robust linear regression was performed to identify methylation sites associated with BMI at a false discovery rate q value < 0.05. Gene expression microarray data was used to identify which of the BMI-associated methylation sites also showed correlation with gene expression. Gene set enrichment analysis was conducted to assess which pathways were enriched among the BMI-associated methylation sites. Of the 431,568 methylation sites analyzed, 2573 were associated with BMI (q value < 0.05), 57 % of which showed an inverse correlation with BMI. Pathways enriched among the 2573 probe sites included those involved in inflammation, insulin receptor signaling, and leptin signaling. We were able to map 1251 of the BMI-associated methylation sites to gene expression data, and, of these, 226 (18 %) showed substantial correlations with gene expression. Our results suggest that BMI is associated with genome-wide methylation in non-diseased breast tissue and may influence epigenetic pathways involved in inflammatory and other carcinogenic processes.
C1 [Hair, Brionna Y.; Kirk, Erin L.; Robinson, Whitney R.; Olshan, Andrew F.; Conway, Kathleen; Troester, Melissa A.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Xu, Zongli; Harlid, Sophia; Taylor, Jack A.] NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA.
   [Xu, Zongli; Harlid, Sophia; Taylor, Jack A.] NIEHS, Epigen & Stem Cell Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
   [Sandhu, Rupninder; Robinson, Whitney R.; Conway, Kathleen] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Wu, Michael C.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS); University of North Carolina; University of North Carolina
   Chapel Hill; Fred Hutchinson Cancer Center
RP Hair, BY (通讯作者)，Univ N Carolina, Dept Epidemiol, CB 7435,2101 McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.
EM bhair@email.unc.edu
RI taylor, jack/C-7154-2019; Harlid, Sophia/AAJ-5809-2021; Wu, Michael
   C./X-5084-2019
OI Robinson, Whitney/0000-0003-4009-0488; xu, zongli/0000-0002-9034-8902;
   Wu, Michael C./0000-0002-3357-6570; taylor, jack/0000-0001-5303-6398
FU National Cancer Institute Specialized Program of Research Excellence
   (SPORE) in Breast Cancer [NIH/NCI P50-CA58223]; National Cancer
   Institute/National Institute of Environmental Health Sciences Breast
   Cancer and the Environment Research Program [U01 - ES019472]; Intramural
   Research Program of the NIH, National Institute of Environmental Health
   Sciences [ZIA-ES049032-18, ZIA-ES049033-18]; National Cancer Institute
   [K01-CA172717-01]
FX This research was funded, in part, by the National Cancer Institute
   Specialized Program of Research Excellence (SPORE) in Breast Cancer
   (NIH/NCI P50-CA58223), the National Cancer Institute/National Institute
   of Environmental Health Sciences Breast Cancer and the Environment
   Research Program (U01 - ES019472), and the Intramural Research Program
   of the NIH, National Institute of Environmental Health Sciences
   (ZIA-ES049032-18, ZIA-ES049033-18). WRR was supported by the National
   Cancer Institute (K01-CA172717-01).
CR Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   [Anonymous], NCBI NEWS        SEP
   Antuna-Puente B, 2008, DIABETES METAB, V34, P2, DOI 10.1016/j.diabet.2007.09.004
   Byun Jung S, 2013, Int J Cell Biol, V2013, P647975, DOI 10.1155/2013/647975
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Carmichael AR, 2006, BJOG-INT J OBSTET GY, V113, P1160, DOI 10.1111/j.1471-0528.2006.01021.x
   Carmichael AR, 2004, BREAST, V13, P85, DOI 10.1016/j.breast.2003.03.001
   Casbas-Hernandez P, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3476
   Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Creighton CJ, 2012, BREAST CANCER RES TR, V132, P993, DOI 10.1007/s10549-011-1595-y
   Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   Enger SM, 2000, CANCER EPIDEM BIOMAR, V9, P681
   Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023
   Gaudet MM, 2011, BREAST CANCER RES TR, V130, P587, DOI 10.1007/s10549-011-1616-x
   Heaphy CM, 2006, INT J CANCER, V119, P108, DOI 10.1002/ijc.21815
   Heaphy CM, 2009, BREAST CANCER RES TR, V118, P229, DOI 10.1007/s10549-009-0504-0
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kitawaki J, 1999, MOL HUM REPROD, V5, P708, DOI 10.1093/molehr/5.8.708
   Knüpfer H, 2007, BREAST CANCER RES TR, V102, P129, DOI 10.1007/s10549-006-9328-3
   Lorincz AM, 2006, ENDOCR-RELAT CANCER, V13, P279, DOI 10.1677/erc.1.00729
   Magoffin D A, 1999, Ginekol Pol, V70, P1
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantovani A, 2007, BREAST, V16, pS27, DOI 10.1016/j.breast.2007.07.013
   Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6
   Parrizas M, 1997, J BIOL CHEM, V272, P154
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Phipps AI, 2012, ANN EPIDEMIOL, V22, P340, DOI 10.1016/j.annepidem.2012.02.002
   Price EM, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-4
   Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006
   Ritte R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3186
   Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Singh A, 1999, ENDOCR-RELAT CANCER, V6, P139, DOI 10.1677/erc.0.0060139
   Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Suga K, 2001, JPN J CANCER RES, V92, P127, DOI 10.1111/j.1349-7006.2001.tb01074.x
   Sun XZ, 2012, BREAST CANCER RES TR, V131, P1003, DOI 10.1007/s10549-011-1789-3
   Sundaram S, 2013, BREAST CANCER RES TR, V142, P489, DOI 10.1007/s10549-013-2741-5
   Tao MH, 2011, AM J CLIN NUTR, V94, P831, DOI 10.3945/ajcn.110.009365
   Trujillo KA, 2011, INT J CANCER, V129, P1310, DOI 10.1002/ijc.25788
   Wu MC, 2009, STAT METHODS MED RES, V18, P577, DOI 10.1177/0962280209351925
   Xu ZL, 2014, CARCINOGENESIS, V35, P356, DOI 10.1093/carcin/bgt391
   Yang XR, 2011, JNCI-J NATL CANCER I, V103, P250, DOI 10.1093/jnci/djq526
   Zhao Y, 1996, MOL ENDOCRINOL, V10, P1350, DOI 10.1210/me.10.11.1350
NR 49
TC 23
Z9 27
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2015
VL 151
IS 2
BP 453
EP 463
DI 10.1007/s10549-015-3401-8
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CI1JC
UT WOS:000354499200023
PM 25953686
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Thummuri, D
   Kumar, S
   Surapaneni, SK
   Tikoo, K
AF Thummuri, Dinesh
   Kumar, Sandeep
   Surapaneni, Sunil Kumar
   Tikoo, Kulbhushan
TI Epigenetic regulation of protein tyrosine phosphatase PTPN12 in
   triple-negative breast cancer
SO LIFE SCIENCES
LA English
DT Article
DE Triple-negative breast cancer; Hypomethylation; Epigenetics and DNA
   methylation
ID PROMOTER HYPERMETHYLATION; ESTROGEN-RECEPTOR; TUMOR-SUPPRESSOR;
   EXPRESSION; CELLS; CARCINOMA; METHYLATION; PATTERNS; GROWTH;
   CYTOTOXICITY
AB Aims: The present study showed that the expression of PTPN12 is epigenetically regulated. 5-Azacytidine (5-Azac), a DNA hypomethylating agent, significantly increased the expression of PTPN12 at low concentrations (1 mu M and 2.5 mu M) and decreased the expression of PTPN12 at 5 mu M in the MDA-MB-231 and BT-549 triple-negative breast cancer cell lines.
   Main methods: Human MCF-7, MDA-MB-231 and BT-549 cells were exposed to different concentrations of 5-Azac for 24 and 48 h. RT-PCR was performed to determine the mRNA expression of PTPN12, E-cadherin and miRNA-124. Western blotting was performed to assess the protein expression of various proteins, including PTPN12, E-cadherin, DNMT and PARP.
   Key findings: 5-Azac, a DNA hypomethylating agent, significantly increased the expression of PTPN12 at low concentrations (I mu M and 2.5 mu M) and decreased PTPN12 expression at 5 mu M. We provide the first evidence that PTPN12 expression is epigenetically regulated and that it is up-regulated at a lower dose of a DNMT1 inhibitor in MDA-MB-231 and BT-549 cells. Interestingly, the levels of miRNA-124 were increased only at 5 mu M, the concentration at which PTPN12 expression was suppressed.
   Significance: To the best of our knowledge, this is the first report that highlights the therapeutic potential of low-dose 5-Azac for the treatment of TNBC. Therefore, 5-Azac, an agent that has already been tested in acute myeloid leukemia, may be more effective at lower doses for the treatment of triple-negative breast cancer. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Thummuri, Dinesh; Kumar, Sandeep; Surapaneni, Sunil Kumar; Tikoo, Kulbhushan] Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Mohali 160062, Punjab, India.
C3 National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali)
RP Tikoo, K (通讯作者)，Natl Inst Pharmaceut Educ & Res, Dept Pharmacol & Toxicol, Mohali 160062, Punjab, India.
EM tikoo.k@gmail.com
RI Kumar, Sandeep/ABB-3236-2020; Thummuri, Dinesh/Q-2252-2019; Thummuri,
   Dinesh/M-6263-2016
OI Tikoo, Kulbhushan/0000-0003-3061-9739; SURAPANENI, SUNIL
   KUMAR/0000-0002-1121-1511; Thummuri, Dinesh/0000-0002-6027-0999
CR Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Cao X, 2012, ANN THORAC SURG, V93, P1674, DOI 10.1016/j.athoracsur.2011.12.056
   Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1
   Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Ferguson-Smith AC, 2001, SCIENCE, V293, P1086, DOI 10.1126/science.1064020
   Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246
   Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664
   Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jacob ST, 2005, CANCER GENE THER, V12, P665, DOI 10.1038/sj.cgt.7700828
   Kabra Dhiraj G, 2009, Biochim Biophys Acta, V1792, P574, DOI 10.1016/j.bbadis.2009.03.003
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kashiwagi S, 2010, BRIT J CANCER, V103, P249, DOI 10.1038/sj.bjc.6605735
   Kenny FS, 2001, BREAST CANCER RES TR, V65, P135, DOI 10.1023/A:1006469627067
   Kiziltepe T, 2007, MOL CANCER THER, V6, P1718, DOI 10.1158/1535-7163.MCT-07-0010
   Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330
   Mayer EL, 2009, BREAST CANCER RES TR, V117, P615, DOI 10.1007/s10549-009-0366-5
   Meiners S, 1998, ONCOGENE, V16, P9, DOI 10.1038/sj.onc.1201486
   Midland AA, 2012, CELL RES, V22, P620, DOI 10.1038/cr.2012.25
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Morris GJ, 2007, CANCER-AM CANCER SOC, V110, P876, DOI 10.1002/cncr.22836
   Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101
   Nass SJ, 2000, CANCER RES, V60, P4346
   Östman A, 2001, TRENDS CELL BIOL, V11, P258, DOI 10.1016/S0962-8924(01)01990-0
   Östman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837
   Overbergh L, 2003, J Biomol Tech, V14, P33
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Rajaii F, 2014, INVEST OPHTH VIS SCI, V55, P6178, DOI 10.1167/iovs.14-13933
   Ramaswamy B, 2009, MOL ENDOCRINOL, V23, P176, DOI 10.1210/me.2008-0211
   Reeder-Hayes Katherine E, 2010, Breast Dis, V32, P123, DOI 10.3233/BD-2010-0310
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Saunders LR, 2010, AGING-US, V2, P415, DOI 10.18632/aging.100176
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Sun T., 2003, CELL, V144, P703
   TEIXEIRA C, 1995, CANCER RES, V55, P3902
   Trapasso F, 2004, CARCINOGENESIS, V25, P2107, DOI 10.1093/carcin/bgh224
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   van Doorn R, 2005, J CLIN ONCOL, V23, P3886, DOI 10.1200/JCO.2005.11.353
   Yang L, 2011, ONCOGENE, V30, P4437, DOI 10.1038/onc.2011.145
NR 46
TC 15
Z9 19
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0024-3205
EI 1879-0631
J9 LIFE SCI
JI Life Sci.
PD JUN 1
PY 2015
VL 130
BP 73
EP 80
DI 10.1016/j.lfs.2015.03.016
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA CI4XC
UT WOS:000354756200011
PM 25817229
DA 2025-01-12
ER

PT J
AU Li, Y
   Melnikov, AA
   Levenson, V
   Guerra, E
   Simeone, P
   Alberti, S
   Deng, YP
AF Li, Yan
   Melnikov, Anatoliy A.
   Levenson, Victor
   Guerra, Emanuela
   Simeone, Pasquale
   Alberti, Saverio
   Deng, Youping
TI A seven-gene CpG-island methylation panel predicts breast cancer
   progression
SO BMC CANCER
LA English
DT Article
DE Breast cancer; DNA methylation; Microarray; Metastatic relapse;
   Prognostic indicators
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; P53
   GENE-MUTATIONS; DNA METHYLATION; PROMOTER HYPERMETHYLATION;
   PROTEIN-KINASE; EPIGENETIC INACTIVATION; COLORECTAL-CANCER; GERMLINE
   EPIMUTATION; PROGNOSTIC-FACTORS
AB Background: DNA methylation regulates gene expression, through the inhibition/activation of gene transcription of methylated/unmethylated genes. Hence, DNA methylation profiling can capture pivotal features of gene expression in cancer tissues from patients at the time of diagnosis. In this work, we analyzed a breast cancer case series, to identify DNA methylation determinants of metastatic versus non-metastatic tumors.
   Methods: CpG-island methylation was evaluated on a 56-gene cancer-specific biomarker microarray in metastatic versus non-metastatic breast cancers in a multi-institutional case series of 123 breast cancer patients. Global statistical modeling and unsupervised hierarchical clustering were applied to identify a multi-gene binary classifier with high sensitivity and specificity. Network analysis was utilized to quantify the connectivity of the identified genes.
   Results: Seven genes (BRCA1, DAPK1, MSH2, CDKN2A, PGR, PRKCDBP, RANKL) were found informative for prognosis of metastatic diffusion and were used to calculate classifier accuracy versus the entire data-set. Individual-gene performances showed sensitivities of 63-79 %, 53-84 % specificities, positive predictive values of 59-83 % and negative predictive values of 63-80 %. When modelled together, these seven genes reached a sensitivity of 93 %, 100 % specificity, a positive predictive value of 100 % and a negative predictive value of 93 %, with high statistical power. Unsupervised hierarchical clustering independently confirmed these findings, in close agreement with the accuracy measurements. Network analyses indicated tight interrelationship between the identified genes, suggesting this to be a functionally-coordinated module, linked to breast cancer progression.
   Conclusions: Our findings identify CpG-island methylation profiles with deep impact on clinical outcome, paving the way for use as novel prognostic assays in clinical settings.
C1 [Li, Yan; Deng, Youping] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
   [Melnikov, Anatoliy A.; Levenson, Victor] US Biomarkers Inc, Buffalo, IL 60089 USA.
   [Guerra, Emanuela; Simeone, Pasquale; Alberti, Saverio] Univ G dAnnunzio, CeSI, Unit Canc Pathol, I-66100 Chieti, Italy.
   [Alberti, Saverio] Univ G DAnnunzio, Unit Physiol & Physiopathol, Dept Neurosci Imaging & Clin Sci, I-66100 Chieti, Italy.
C3 Rush University; G d'Annunzio University of Chieti-Pescara; G d'Annunzio
   University of Chieti-Pescara
RP Alberti, S (通讯作者)，Univ G dAnnunzio, CeSI, Unit Canc Pathol, Via L Polacchi 11, I-66100 Chieti, Italy.
EM s.alberti@unich.it
RI Guerra, Emanuela/HOF-2772-2023; Simeone, Pasquale/K-7549-2016; Alberti,
   Saverio/M-4511-2014
OI Deng, Youping/0000-0002-5951-8213; Simeone,
   Pasquale/0000-0003-4430-480X; Guerra, Emanuela/0000-0002-7091-8621;
   Alberti, Saverio/0000-0002-4647-6042
FU Oncoxx Biotech; Compagnia di San Paolo; Fondazione CARIChieti; Italian
   Ministries for the University and Research, Development and Health
   (RicOncol) [RBNE0157EH, SCN_00558, MI01_00424, RF-EMR-2006-361866]
FX We thank C.A. Beltrami, C. Di Loreto, E. Bianchini and B. Murer for help
   with the cancer pathology analyses. We gratefully acknowledge the
   support of Oncoxx Biotech, Compagnia di San Paolo, Fondazione
   CARIChieti, and the Italian Ministries for the University and Research
   (RBNE0157EH, SCN_00558), Development (MI01_00424) and Health (RicOncol
   RF-EMR-2006-361866).
CR Abe O, 1998, LANCET, V352, P930
   Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103
   ALBERTI S, 1994, P NATL ACAD SCI USA, V91, P5833, DOI 10.1073/pnas.91.13.5833
   ALBERTI S, 1988, P NATL ACAD SCI USA, V85, P8391, DOI 10.1073/pnas.85.22.8391
   ALBERTI S, 1990, NUCLEIC ACIDS RES, V18, P351, DOI 10.1093/nar/18.2.351
   Ambrogi F, 2006, CLIN CANCER RES, V12, P781, DOI 10.1158/1078-0432.CCR-05-0763
   Ambrogi F, 2013, CANC CLIN ONCOL, V2, P41
   Ambrogi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096993
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Biganzoli E, 2010, CURR BREAST CANCER R, V2, P96, DOI 10.1007/s12609-010-0013-5
   Biganzoli E, 2011, JPN J CLIN ONCOL, V41, P172, DOI 10.1093/jjco/hyq227
   Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1
   Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681
   Bonasera V, 2007, BIOTECHNIQUES, V43, P173, DOI 10.2144/000112500
   Boultwood J, 2007, BRIT J HAEMATOL, V138, P3, DOI 10.1111/j.1365-2141.2007.06604.x
   Carén H, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-66
   Carter SL, 2012, NAT BIOTECHNOL, V30, P413, DOI 10.1038/nbt.2203
   Castrilli G, 2001, J ORAL PATHOL MED, V30, P305, DOI 10.1034/j.1600-0714.2001.300508.x
   Chan KYK, 2002, CANCER RES, V62, P4151
   Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866
   Chim CS, 2002, HEMATOL ONCOL, V20, P167, DOI 10.1002/hon.694
   Cimoli G, 2004, BBA-REV CANCER, V1705, P103, DOI 10.1016/j.bbcan.2004.10.001
   Delgado-Calle J, 2012, EPIGENETICS-US, V7, P83, DOI 10.4161/epi.7.1.18753
   Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]
   Denissenko MF, 1997, P NATL ACAD SCI USA, V94, P3893, DOI 10.1073/pnas.94.8.3893
   DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4
   Duncan JA, 1998, J CLIN PATHOL-MOL PA, V51, P237, DOI 10.1136/mp.51.5.237
   Dunn JR, 2004, BRIT J CANCER, V91, P1149, DOI 10.1038/sj.bjc.6602107
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834
   Gonzalez-Gomez P, 2003, ONCOL REP, V10, P1031
   Guo MZ, 2014, DISCOV MED, V17, P67
   Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205
   Hammarsund M, 2004, FEBS LETT, V556, P75, DOI 10.1016/S0014-5793(03)01371-1
   Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953
   He XM, 2008, NUCLEIC ACIDS RES, V36, pD836, DOI 10.1093/nar/gkm730
   Hitchins MP, 2013, FAM CANCER, V12, P189, DOI 10.1007/s10689-013-9613-3
   Illingworth RS, 2009, FEBS LETT
   Jones DH, 2006, NATURE, V440, P692, DOI 10.1038/nature04524
   Kazianis S, 2000, CARCINOGENESIS, V21, P599, DOI 10.1093/carcin/21.4.599
   Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003
   Kiss NB, 2008, ENDOCR-RELAT CANCER, V15, P609, DOI 10.1677/ERC-07-0285
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kondo T, 2009, LAB INVEST, V89, P791, DOI 10.1038/labinvest.2009.50
   Kroeger H, 2008, BLOOD, V112, P1366, DOI 10.1182/blood-2007-11-126227
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee JH, 2011, CLIN CANCER RES, V17, P7551, DOI 10.1158/1078-0432.CCR-11-1026
   Lee KH, 2011, LANGENBECK ARCH SURG, V396, P1017, DOI 10.1007/s00423-011-0812-9
   Levenson VV, 2011, EXPERT REV MOL DIAGN, V11, P807, DOI [10.1586/erm.11.74, 10.1586/ERM.11.74]
   Li YH, 2014, TUMOR BIOL, V35, P5869, DOI [10.1007/s13277-014-1777-4, 10.1007/s13277-013-1573-6]
   Liggett T, 2010, CANCER-AM CANCER SOC, V116, P1674, DOI 10.1002/cncr.24893
   Lou-Qian Zhang, 2013, PLoS One, V8, pe54970, DOI 10.1371/journal.pone.0054970
   Martinez R, 2009, EPIGENETICS-US, V4, P255, DOI 10.4161/epi.9130
   Martínez-Chantar ML, 2008, HEPATOLOGY, V47, P1191, DOI 10.1002/hep.22159
   Matsuda Y, 2006, MED MOL MORPHOL, V39, P169, DOI 10.1007/s00795-006-0339-2
   McCoy Marcia L, 2003, Reprod Biol Endocrinol, V1, P72, DOI 10.1186/1477-7827-1-72
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Mellon I, 1996, SCIENCE, V272, P557, DOI 10.1126/science.272.5261.557
   Melnikov AA, 2008, J MOL DIAGN, V10, P93, DOI 10.2353/jmoldx.2008.070077
   Melson J, 2014, INT J CANCER, V134, P2656, DOI 10.1002/ijc.28593
   Michie AM, 2010, FEBS J, V277, P74, DOI 10.1111/j.1742-4658.2009.07414.x
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Moutinho C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt322
   Nasr AF, 2003, ONCOGENE, V22, P1668, DOI 10.1038/sj.onc.1206248
   Oncofem P., 1992, FEDERAZIONE MED, V9, P11
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Park HL, 2008, INT J CANCER, V122, P2498, DOI 10.1002/ijc.23434
   Pitsikas P, 2007, MUTAGENESIS, V22, P235, DOI 10.1093/mutage/gem008
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Querzoli P, 2006, CLIN CANCER RES, V12, P6696, DOI 10.1158/1078-0432.CCR-06-0569
   Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043
   Rosas SLB, 2001, CANCER RES, V61, P939
   Rossi D, 2003, BRIT J HAEMATOL, V123, P475, DOI 10.1046/j.1365-2141.2003.04644.x
   Rzepecka IK, 2012, CANCER GENET-NY, V205, P94, DOI 10.1016/j.cancergen.2011.12.005
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Scholz C, 2005, ANN HEMATOL, V84, P236, DOI 10.1007/s00277-004-0969-1
   Schramek D, 2010, NATURE, V468, P98, DOI 10.1038/nature09387
   Sharma Priyanka, 2014, J Cancer Ther Res, V3, P1, DOI 10.7243/2049-7962-3-2
   SIDRANSKY D, 1992, CANCER RES, V52, P2984
   SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505
   Silverstein MJ, 1999, NEW ENGL J MED, V340, P1455, DOI 10.1056/NEJM199905133401902
   Simeone P, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12047
   Simeone P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103030
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stone A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040466
   Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342
   Tada Y, 2002, CANCER RES, V62, P4048
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Tellez CS, 2009, MELANOMA RES, V19, P146, DOI 10.1097/CMR.0b013e32832b274e
   Wang B, 2009, GENE DEV, V23, P729, DOI 10.1101/gad.1770309
   Wang C, 2004, J PATHOL, V202, P215, DOI 10.1002/path.1507
   Wang CX, 2014, ASIAN PAC J CANCER P, V15, P355, DOI 10.7314/APJCP.2014.15.1.355
   Wang C, 2014, NAT BIOTECHNOL, V32, P926, DOI 10.1038/nbt.3001
   Wang YQ, 2013, J OBSTET GYNAECOL RE, V39, P549, DOI 10.1111/j.1447-0756.2012.01979.x
   Wen XZ, 2006, ONCOGENE, V25, P2666, DOI 10.1038/sj.onc.1209297
   WOLD LE, 1995, MAYO CLIN PROC, V70, P678, DOI 10.4065/70.7.678
   Wolf I, 2007, BREAST CANCER RES TR, V105, P139, DOI 10.1007/s10549-006-9440-4
   Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4
   Xu XL, 2001, CANCER RES, V61, P7943
   Yang HJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-212
   Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x
   Yuan LQ, 2014, BBA-MOL CELL RES, V1843, P1834, DOI 10.1016/j.bbamcr.2014.05.010
   Zöchbauer-Müller S, 2005, ONCOGENE, V24, P6249, DOI 10.1038/sj.onc.1208775
NR 103
TC 24
Z9 31
U1 0
U2 17
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 19
PY 2015
VL 15
AR 417
DI 10.1186/s12885-015-1412-9
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CI6AZ
UT WOS:000354842300001
PM 25986046
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Vaca-Paniagua, F
   Alvarez-Gomez, RM
   Maldonado-Martínez, HA
   Pérez-Plasencia, C
   Fragoso-Ontiveros, V
   Lasa-Gonsebatt, F
   Herrera, LA
   Cantú, D
   Bargallo-Rocha, E
   Mohar, A
   Durand, G
   Forey, N
   Voegele, C
   Vallée, M
   Le Calvez-Kelm, F
   McKay, J
   Ardin, M
   Villar, S
   Zavadil, J
   Olivier, M
AF Vaca-Paniagua, Felipe
   Maria Alvarez-Gomez, Rosa
   Aquiles Maldonado-Martinez, Hector
   Perez-Plasencia, Carlos
   Fragoso-Ontiveros, Veronica
   Lasa-Gonsebatt, Federico
   Alonso Herrera, Luis
   Cantu, David
   Bargallo-Rocha, Enrique
   Mohar, Alejandro
   Durand, Geoffroy
   Forey, Nathalie
   Voegele, Catherine
   Vallee, Maxime
   Le Calvez-Kelm, Florence
   McKay, James
   Ardin, Maude
   Villar, Stephanie
   Zavadil, Jiri
   Olivier, Magali
TI Revealing the Molecular Portrait of Triple Negative Breast Tumors in an
   Understudied Population through Omics Analysis of Formalin-Fixed and
   Paraffin-Embedded Tissues
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; HOMOLOGOUS RECOMBINATION; MUTATIONAL PROCESSES;
   MICRORNA EXPRESSION; CANCER SUBTYPES; GENOME; SURVIVAL; BRCA1; P53;
   MUTAGENESIS
AB Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen receptor, progesterone receptor and human epidermal receptor 2, is an aggressive form of breast cancer that is more prevalent in certain populations, in particular in low-and middle-income regions. The detailed molecular features of TNBC in these regions remain unexplored as samples are mostly accessible as formalin-fixed paraffin embedded (FFPE) archived tissues, a challenging material for advanced genomic and transcriptomic studies. Using dedicated reagents and analysis pipelines, we performed whole exome sequencing and miRNA and mRNA profiling of 12 FFPE tumor tissues collected from pathological archives in Mexico. Sequencing analyses of the tumor tissues and their blood pairs identified TP53 and RB1 genes as the most frequently mutated genes, with a somatic mutation load of 1.7 mutations/exome Mb on average. Transcriptional analyses revealed an overexpression of growth-promoting signals (EGFR, PDGFR, VEGF, PIK3CA, FOXM1), a repression of cell cycle control pathways (TP53, RB1), a deregulation of DNA-repair pathways, and alterations in epigenetic modifiers through miRNA: mRNA network de-regulation. The molecular programs identified were typical of those described in basal-like tumors in other populations. This work demonstrates the feasibility of using archived clinical samples for advanced integrated genomics analyses. It thus opens up opportunities for investigating molecular features of tumors from regions where only FFPE tissues are available, allowing retrospective studies on the search for treatment strategies or on the exploration of the geographic diversity of breast cancer.
C1 [Vaca-Paniagua, Felipe; Ardin, Maude; Villar, Stephanie; Zavadil, Jiri; Olivier, Magali] Int Agcy Res Canc, Grp Mol Mech & Biomarkers, F-69372 Lyon, France.
   [Durand, Geoffroy; Forey, Nathalie; Voegele, Catherine; Vallee, Maxime; Le Calvez-Kelm, Florence; McKay, James] Int Agcy Res Canc, Grp Genet Canc Susceptibil, F-69372 Lyon, France.
   [Vaca-Paniagua, Felipe; Perez-Plasencia, Carlos; Fragoso-Ontiveros, Veronica] Inst Nacl Cancerol, Subdirecc Invest Basica, Mexico City, DF, Mexico.
   [Vaca-Paniagua, Felipe; Perez-Plasencia, Carlos] Univ Nacl Autonoma Mexico, FES Iztacala, Unidad Biomed, Mexico City 04510, DF, Mexico.
   [Maria Alvarez-Gomez, Rosa; Perez-Plasencia, Carlos; Fragoso-Ontiveros, Veronica] Inst Nacl Cancerol, Unidad Genom & Secuenciac Masiva UGESEM, Mexico City, DF, Mexico.
   [Aquiles Maldonado-Martinez, Hector] Inst Nacl Cancerol, Dept Patol Mol, Mexico City, DF, Mexico.
   [Lasa-Gonsebatt, Federico; Mohar, Alejandro] Inst Nacl Cancerol, Dept Epidemiol, Mexico City, DF, Mexico.
   [Alonso Herrera, Luis; Cantu, David] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Inst Nacl Cancerol, Unidad Invest Biomed Canc, Mexico City 04510, DF, Mexico.
   [Bargallo-Rocha, Enrique] Inst Nacl Cancerol, Dept Tumores Mamarios, Mexico City, DF, Mexico.
C3 World Health Organization; International Agency for Research on Cancer
   (IARC); World Health Organization; International Agency for Research on
   Cancer (IARC); Instituto Nacional de Cancerologia (INCAN); Universidad
   Nacional Autonoma de Mexico; Instituto Nacional de Cancerologia (INCAN);
   Instituto Nacional de Cancerologia (INCAN); Instituto Nacional de
   Cancerologia (INCAN); Universidad Nacional Autonoma de Mexico; Instituto
   Nacional de Cancerologia (INCAN); Instituto Nacional de Cancerologia
   (INCAN)
RP Vaca-Paniagua, F (通讯作者)，Int Agcy Res Canc, Grp Mol Mech & Biomarkers, 150 Cours Albert Thomas, F-69372 Lyon, France.
EM felipe.vaca@gmail.com; OlivierM@iarc.fr
RI Zavadil, Jiri/ABG-1780-2020; Vaca, Felipe/ISW-8557-2023; Herrera,
   Luis/GOV-3311-2022; Perez-Plasencia, Carlos/P-2372-2019; Cantu-de Leon,
   David/P-7930-2017; OLIVIER, Magali/G-3728-2010
OI Cantu-de Leon, David/0000-0002-0229-7931; Villar,
   Stephanie/0009-0005-1502-670X; Perez-Plasencia,
   Carlos/0000-0002-8593-8211; OLIVIER, Magali/0000-0002-8202-342X;
   Zavadil, Jiri/0000-0003-0640-5562; Le Calvez-Kelm,
   Florence/0000-0003-0063-5068; Vaca Paniagua, Felipe/0000-0002-2200-9706;
   Vallee, Maxime/0000-0002-3616-9508
FU International Agency for Research on Cancer; European Commission;
   CONACyT [169082]
FX This work was undertaken during the tenure of a Postdoctoral Fellowship
   from the International Agency for Research on Cancer, partially
   supported by the European Commission FP7 Marie Curie
   Actions-People-Co-funding of regional, national and international
   programs (COFUND). FV was supported by CONACyT 169082.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Amirikia KC, 2011, CANCER-AM CANCER SOC, V117, P2747, DOI 10.1002/cncr.25862
   April C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008162
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701
   Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881
   Burstein MD, 2014, CLIN CANC RES
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Cascione L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055910
   Cline MS, 2007, NAT PROTOC, V2, P2366, DOI 10.1038/nprot.2007.324
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Craig DW, 2013, MOL CANCER THER, V12, P104, DOI 10.1158/1535-7163.MCT-12-0781
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136
   Goswami RS, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-47
   Hall JS, 2012, BRIT J CANCER, V107, P684, DOI 10.1038/bjc.2012.294
   Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028
   Holstege H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-654
   Hui ABY, 2009, LAB INVEST, V89, P597, DOI 10.1038/labinvest.2009.12
   Huo DZ, 2009, J CLIN ONCOL, V27, P4515, DOI 10.1200/JCO.2008.19.6873
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lara-Medina F, 2011, CANCER-AM CANCER SOC, V117, P3658, DOI 10.1002/cncr.25961
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Lu HM, 2007, NUCLEIC ACIDS RES, V35, P7160, DOI 10.1093/nar/gkm732
   Lund MJ, 2009, BREAST CANCER RES TR, V113, P357, DOI 10.1007/s10549-008-9926-3
   Ly M, 2011, B CANCER, V98, P797, DOI 10.1684/bdc.2011.1392
   Maia AT, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2458
   Meng XB, 2007, J BIOL CHEM, V282, P1570, DOI 10.1074/jbc.M607520200
   Morris JH, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-436
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Podo F, 2010, MOL ONCOL, V4, P209, DOI 10.1016/j.molonc.2010.04.006
   Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678
   Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397
   Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702
   Schweiger MR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005548
   Sfakianos GP, 2013, GYNECOL ONCOL, V129, P159, DOI 10.1016/j.ygyno.2012.12.030
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Stead LA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2242
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stevens KN, 2013, CANCER RES, V73, P2025, DOI 10.1158/0008-5472.CAN-12-1699
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tian S, 2010, BIOCHEM BIOPH RES CO, V396, P435, DOI 10.1016/j.bbrc.2010.04.112
   Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wagle N, 2012, CANCER DISCOV, V2, P82, DOI 10.1158/2159-8290.CD-11-0184
   Xi YG, 2007, RNA, V13, P1668, DOI 10.1261/rna.642907
   Xu H, 2014, CLIN CHEM, V60, P122, DOI 10.1373/clinchem.2013.207167
   Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107
NR 53
TC 15
Z9 17
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2015
VL 10
IS 5
AR e0126762
DI 10.1371/journal.pone.0126762
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CI1YY
UT WOS:000354542500145
PM 25961742
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Perrigue, PM
   Silva, ME
   Warden, CD
   Feng, NL
   Reid, MA
   Mota, DJ
   Joseph, LP
   Tian, YI
   Glackin, CA
   Gutova, M
   Najbauer, J
   Aboody, KS
   Barish, ME
AF Perrigue, Patrick M.
   Silva, Michael E.
   Warden, Charles D.
   Feng, Nathan L.
   Reid, Michael A.
   Mota, Daniel J.
   Joseph, Lauren P.
   Tian, Yangzi Isabel
   Glackin, Carlotta A.
   Gutova, Margarita
   Najbauer, Joseph
   Aboody, Karen S.
   Barish, Michael E.
TI The Histone Demethylase Jumonji Coordinates Cellular Senescence
   Including Secretion of Neural Stem Cell-Attracting Cytokines
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID JMJD3 CONTRIBUTES; TUMOR SUPPRESSION; GENE-EXPRESSION;
   CHROMATIN-STRUCTURE; EPIGENETIC CONTROL; INK4A-ARF LOCUS; BREAST-CANCER;
   RNA-SEQ; IN-VIVO; PHENOTYPE
AB Jumonji domain-containing protein 3 (JMJD3/KDM6B) demethylates lysine 27 on histone H3 (H3K27me3), a repressive epigenetic mark controlling chromatin organization and cellular senescence. To better understand the functional consequences of JMJD3its expression was investigated in brain tumor cells. Querying patient expression profile databases confirmed JMJD3 overexpression in high-grade glioma. Immunochemical staining of two glioma cell lines, U251 and U87, indicated intrinsic differences in JMJD3 expression levels that were reflected in changes in cell phenotype and variations associated with cellular senescence, including senescence-associated beta-galactosidase (SA-beta-gal) activity and the senescence-associated secretory phenotype (SASP). Overexpressing wild-type JMJD3 (JMJD3wt) activated SASP-associated genes, enhanced SA-beta-gal activity, and induced nuclear blebbing. Conversely, overexpression of a catalytically inactive dominant negative mutant JMJD3 (JMJD3mut) increased proliferation. In addition, a large number of transcripts were identified by RNA-seq as altered in JMJD3 overexpressing cells, including cancer-and inflammation-related transcripts as defined by Ingenuity Pathway Analysis. These results suggest that expression of the SASP in the context of cancer undermines normal tissue homeostasis and contributes to tumorigenesis and tumor progression. These studies are therapeutically relevant because inflammatory cytokines have been linked to homing of neural stem cells and other stem cells to tumor loci.
   Implications: This glioma study brings together actions of a normal epigenetic mechanism (JMJD3 activity) with dysfunctional activation of senescence-related processes, including secretion of SASP proinflammatory cytokines and stem cell tropism toward tumors.
C1 [Perrigue, Patrick M.; Silva, Michael E.; Feng, Nathan L.; Reid, Michael A.; Mota, Daniel J.; Joseph, Lauren P.; Tian, Yangzi Isabel; Glackin, Carlotta A.; Gutova, Margarita; Najbauer, Joseph; Aboody, Karen S.; Barish, Michael E.] City Hope Beckman Res Inst & Med Ctr, Dept Neurosci, Duarte, CA USA.
   [Perrigue, Patrick M.; Reid, Michael A.] City Hope Beckman Res Inst & Med Ctr, Irell & Manella Grad Sch Biol Sci, Duarte, CA USA.
   [Warden, Charles D.] City Hope Beckman Res Inst & Med Ctr, Bioinformat Core Facil, Duarte, CA USA.
   [Aboody, Karen S.] City Hope Beckman Res Inst & Med Ctr, Div Neurosurg, Duarte, CA USA.
RP Barish, ME (通讯作者)，City Hope Natl Med Ctr, Beckman Res Inst, Dept Neurosci, 1500 E Duarte Rd, Duarte, CA 91010 USA.
EM mbarish@coh.org
OI Reid, Michael/0000-0001-6222-9538; Mota, Daniel/0000-0002-3415-2892;
   Warden, Charles/0000-0002-1827-4486; Perrigue,
   Patrick/0000-0001-6501-118X
FU California Institute of Regenerative Medicine [DR1-01421]; National
   Cancer Institute [P30 CA033572]; Rosalinde and Arthur Gilbert
   Foundation; STOP Cancer
FX This work was supported by funding from the California Institute of
   Regenerative Medicine (DR1-01421), the National Cancer Institute (P30
   CA033572), The Rosalinde and Arthur Gilbert Foundation, and STOP Cancer.
CR Aboody K, 2011, NEURON, V70, P597, DOI 10.1016/j.neuron.2011.05.007
   Adams PD, 2007, GENE, V397, P84, DOI 10.1016/j.gene.2007.04.020
   Agarwal S, 2011, CURR PHARM DESIGN, V17, P2793, DOI 10.2174/138161211797440186
   Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Agherbi H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005622
   Anders HJ, 2014, TRENDS MOL MED, V20, P154, DOI 10.1016/j.molmed.2013.12.002
   Angrisano T, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-172
   [Anonymous], 2013, R: A language and environment for statistical computing
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Burtner CR, 2010, NAT REV MOL CELL BIO, V11, P567, DOI 10.1038/nrm2944
   Cakouros D, 2010, J CELL BIOCHEM, V110, P1288, DOI 10.1002/jcb.22651
   Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003
   Carnero Amancio, 2013, Methods Mol Biol, V965, P63, DOI 10.1007/978-1-62703-239-1_4
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Coppé JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071
   Coppé JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Davalos AR, 2010, CANCER METAST REV, V29, P273, DOI 10.1007/s10555-010-9220-9
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   De Santa F, 2009, EMBO J, V28, P3341, DOI 10.1038/emboj.2009.271
   Dechat T, 2008, GENE DEV, V22, P832, DOI 10.1101/gad.1652708
   Deng X, BRAVO BIOMARKE UNPUB
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Duesberg P, 2007, SCI AM, V296, P52, DOI 10.1038/scientificamerican0507-52
   Dundr M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000711
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452
   Funayama R, 2007, CHROMOSOMA, V116, P431, DOI 10.1007/s00412-007-0115-7
   Graham L, 2007, NAT PROTOC, V2, P2439, DOI 10.1038/nprot.2007.304
   Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307
   Gutova M, 2008, STEM CELLS, V26, P1406, DOI 10.1634/stemcells.2008-0141
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Ishii M, 2009, BLOOD, V114, P3244, DOI 10.1182/blood-2009-04-217620
   Ivanov A, 2013, J CELL BIOL, V202, P129, DOI 10.1083/jcb.201212110
   Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476
   Kendall SE, 2008, STEM CELLS, V26, P1575, DOI 10.1634/stemcells.2007-0887
   Kortlever RM, 2006, CELL CYCLE, V5, P2697, DOI 10.4161/cc.5.23.3510
   Kosar M, 2011, CELL CYCLE, V10, P457, DOI 10.4161/cc.10.3.14707
   Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560
   Liu BH, 2005, NAT MED, V11, P780, DOI 10.1038/nm1266
   Mah LJ, 2010, EPIGENETICS-US, V5, P129, DOI 10.4161/epi.5.2.11080
   Martinez-Garcia E, 2010, NAT GENET, V42, P100, DOI 10.1038/ng0210-100
   Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Najbauer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035150
   Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008-5472.CAN-11-3386
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   Porter KR, 2010, NEURO-ONCOLOGY, V12, P520, DOI 10.1093/neuonc/nop066
   Pruitt KD, 2012, NUCLEIC ACIDS RES, V40, pD130, DOI 10.1093/nar/gkr1079
   Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Salminen A, 2014, J MOL MED, V92, P1035, DOI 10.1007/s00109-014-1182-x
   Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006
   Samuel JM, 2008, CYTOKINE, V42, P256, DOI 10.1016/j.cyto.2008.02.008
   Scaffidi P, 2006, SCIENCE, V312, P1059, DOI 10.1126/science.1127168
   Schmidt NO, 2005, NEOPLASIA, V7, P623, DOI 10.1593/neo.04781
   Shaw T, 2009, EMBO REP, V10, P881, DOI 10.1038/embor.2009.102
   Shumaker DK, 2006, P NATL ACAD SCI USA, V103, P8703, DOI 10.1073/pnas.0602569103
   Stewart S, 2009, P NATL ACAD SCI USA, V106, P19889, DOI 10.1073/pnas.0904132106
   Sun Ji-Yong, 2003, Ai Zheng, V22, P225
   Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Warden CD, 2014, INT J COMPUT BIOINFO, V2, P285
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Xing Y, 2006, NUCLEIC ACIDS RES, V34, P3150, DOI 10.1093/nar/gkl396
   Zhang RG, 2007, CELL CYCLE, V6, P784, DOI 10.4161/cc.6.7.4079
   Zhao DH, 2012, STEM CELLS, V30, P314, DOI 10.1002/stem.784
   Zhao DH, 2008, MOL CANCER RES, V6, P1819, DOI 10.1158/1541-7786.MCR-08-0146
   Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430
NR 77
TC 43
Z9 48
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD APR
PY 2015
VL 13
IS 4
BP 636
EP 650
DI 10.1158/1541-7786.MCR-13-0268
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CI5PY
UT WOS:000354812000005
PM 25652587
OA Green Submitted, Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Desai, MA
   Webb, HD
   Sinanan, LM
   Scarsdale, JN
   Walavalkar, NM
   Ginder, GD
   Williams, DC
AF Desai, Megha A.
   Webb, Heather D.
   Sinanan, Leander M.
   Scarsdale, J. Neel
   Walavalkar, Ninad M.
   Ginder, Gordon D.
   Williams, David C., Jr.
TI An intrinsically disordered region of methyl-CpG binding domain protein
   2 (MBD2) recruits the histone deacetylase core of the NuRD complex
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID MOLECULAR RECOGNITION FEATURES; PROSTASIN SERINE-PROTEASE; COILED-COIL
   INTERACTION; N-TERMINAL DOMAIN; EPIGENETIC MECHANISMS; DNA; CANCER;
   TRANSCRIPTION; COMPONENTS; SUPPRESSOR
AB The MBD2-NuRD (Nucleosome Remodeling and Deacetylase) complex is an epigenetic reader of DNA methylation that regulates genes involved in normal development and neoplastic diseases. To delineate the architecture and functional interactions of the MBD2-NuRD complex, we previously solved the structures of MBD2 bound to methylated DNA and a coiled-coil interaction between MBD2 and p66 alpha that recruits the CHD4 nucleosome remodeling protein to the complex. The work presented here identifies novel structural and functional features of a previously uncharacterized domain of MBD2 (MBD2(IDR)). Biophysical analyses show that the MBD2(IDR) is an intrinsically disordered region (IDR). However, despite this inherent disorder, MBD2(IDR) increases the overall binding affinity of MBD2 for methylated DNA. MBD2(IDR) also recruits the histone deacetylase core components (RbAp48, HDAC2 and MTA2) of NuRD through a critical contact region requiring two contiguous amino acid residues, Arg(286) and Leu(287). Mutating these residues abrogates interaction of MBD2 with the histone deacetylase core and impairs the ability of MBD2 to repress the methylated tumor suppressor gene PRSS8 in MDA-MB-435 breast cancer cells. These findings expand our knowledge of the multi-dimensional interactions of the MBD2-NuRD complex that govern its function.
C1 [Desai, Megha A.; Ginder, Gordon D.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA 23298 USA.
   [Desai, Megha A.; Webb, Heather D.; Scarsdale, J. Neel; Ginder, Gordon D.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23298 USA.
   [Webb, Heather D.] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA 23298 USA.
   [Sinanan, Leander M.; Walavalkar, Ninad M.; Williams, David C., Jr.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
   [Scarsdale, J. Neel] Virginia Commonwealth Univ, Inst Struct Biol & Drug Design, Ctr Study Biol Complex, Richmond, VA 23298 USA.
   [Ginder, Gordon D.] Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA 23298 USA.
   [Ginder, Gordon D.] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Richmond, VA 23298 USA.
C3 Virginia Commonwealth University; Virginia Commonwealth University;
   Virginia Commonwealth University; University of North Carolina;
   University of North Carolina Chapel Hill; Virginia Commonwealth
   University; Virginia Commonwealth University; Virginia Commonwealth
   University
RP Williams, DC (通讯作者)，Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
EM gdginder@vcu.edu; david_willjr@med.unc.edu
FU NIH [R01 GM098624, R01 DK029902, 5R01GM098264-3]; NCI Cancer Center Core
   Support Grant [P30 CA016059]
FX NIH R01 GM098624 [to D.C.W.]; NIH R01 DK029902 [to G.D.G]. NMR data were
   acquired using NMR instrumentation in the VCU Massey Cancer Center
   Structural Biology Core [NCI Cancer Center Core Support Grant P30
   CA016059, in part]; Surface plasmon resonance data were acquired in the
   VCU Massey Cancer Center Flow Cytometry Core [NCI Cancer Center Core
   Support Grant P30 CA016059, in part]. Funding for open access charge:
   NIH [5R01GM098264-3].
CR Adams VH, 2007, J BIOL CHEM, V282, P15057, DOI 10.1074/jbc.M700855200
   Alqarni SSM, 2014, J BIOL CHEM, V289, P21844, DOI 10.1074/jbc.M114.558940
   Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999
   Berger J, 2007, MOL CELL BIOL, V27, P4049, DOI 10.1128/MCB.02023-06
   BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163
   Brackertz M, 2006, NUCLEIC ACIDS RES, V34, P397, DOI 10.1093/nar/gkj437
   Cai ML, 2003, J BIOL CHEM, V278, P25191, DOI 10.1074/jbc.M302677200
   Chen LM, 2001, PROSTATE, V48, P93, DOI 10.1002/pros.1085
   Chen LM, 2002, INT J CANCER, V97, P323, DOI 10.1002/ijc.1601
   Cramer JM, 2014, J BIOL CHEM, V289, P1294, DOI 10.1074/jbc.M113.512236
   Dawson R, 2003, J MOL BIOL, V332, P1131, DOI 10.1016/j.jmb.2003.08.008
   DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809
   Dunker AK, 2005, FEBS J, V272, P5129, DOI 10.1111/j.1742-4658.2005.04948.x
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feng Q, 2001, GENE DEV, V15, P827
   Fraga MF, 2003, NUCLEIC ACIDS RES, V31, P1765, DOI 10.1093/nar/gkg249
   Fuxreiter M, 2012, ADV EXP MED BIOL, V725, P1, DOI 10.1007/978-1-4614-0659-4_1
   Fuxreiter M, 2012, MOL BIOSYST, V8, P168, DOI 10.1039/c1mb05234a
   Ghosh RP, 2010, BIOCHEMISTRY-US, V49, P4395, DOI 10.1021/bi9019753
   Gnanapragasam MN, 2011, P NATL ACAD SCI USA, V108, P7487, DOI 10.1073/pnas.1015341108
   Hameed UFS, 2014, SCI REP-UK, V4, DOI 10.1038/srep04896
   Hammoudeh DI, 2009, J AM CHEM SOC, V131, P7390, DOI 10.1021/ja900616b
   Hashimoto H, 2012, NUCLEIC ACIDS RES, V40, P4841, DOI 10.1093/nar/gks155
   Haynes C, 2006, PLOS COMPUT BIOL, V2, P890, DOI 10.1371/journal.pcbi.0020100
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Illingworth RS, 2009, FEBS LETT, V583, P1713, DOI 10.1016/j.febslet.2009.04.012
   Jiang CL, 2004, J BIOL CHEM, V279, P52456, DOI 10.1074/jbc.M409149200
   Jiang CL, 2002, GENOMICS, V80, P621, DOI 10.1006/geno.2002.7001
   Jin SG, 2005, J BIOL CHEM, V280, P12700, DOI 10.1074/jbc.M413492200
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kim JK, 2009, CELL MOL LIFE SCI, V66, P596, DOI 10.1007/s00018-008-8432-4
   Kingston R.E., 2003, CURR PROTOC CELL BIO, V19
   Kjaergaard M, 2011, J BIOMOL NMR, V50, P157, DOI 10.1007/s10858-011-9508-2
   Kloet SL, 2015, FEBS J, V282, P1774, DOI 10.1111/febs.12972
   Kransdorf EP, 2006, BLOOD, V108, P2836, DOI 10.1182/blood-2006-04-016394
   Krishnan N, 2014, NAT CHEM BIOL, V10, P558, DOI [10.1038/NCHEMBIO.1528, 10.1038/nchembio.1528]
   Kumita JR, 2000, P NATL ACAD SCI USA, V97, P3803, DOI 10.1073/pnas.97.8.3803
   Lebowitz J, 2002, PROTEIN SCI, V11, P2067, DOI 10.1110/ps.0207702
   Li, 1999, Genome Inform Ser Workshop Genome Inform, V10, P30
   Lopez-Serra L, 2008, ONCOGENE, V27, P3556, DOI 10.1038/sj.onc.1211022
   Lu Y, 2014, CELL STEM CELL, V15, P92, DOI 10.1016/j.stem.2014.04.002
   Magdinier F, 2001, P NATL ACAD SCI USA, V98, P4990, DOI 10.1073/pnas.101617298
   Markley JL, 1998, J BIOMOL NMR, V12, P1, DOI 10.1023/A:1008290618449
   MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3
   Mian OY, 2011, MOL CANCER RES, V9, P1152, DOI 10.1158/1541-7786.MCR-11-0252
   Millard CJ, 2013, MOL CELL, V51, P57, DOI 10.1016/j.molcel.2013.05.020
   Mohan A, 2006, J MOL BIOL, V362, P1043, DOI 10.1016/j.jmb.2006.07.087
   Myung JK, 2013, J CLIN INVEST, V123, P2948, DOI 10.1172/JCI66398
   Patil A, 2006, FEBS LETT, V580, P2041, DOI 10.1016/j.febslet.2006.03.003
   PONTIUS BW, 1993, TRENDS BIOCHEM SCI, V18, P181, DOI 10.1016/0968-0004(93)90111-Y
   Romero, 1997, Genome Inform Ser Workshop Genome Inform, V8, P110
   Rupon JW, 2011, BLOOD CELL MOL DIS, V46, P212, DOI 10.1016/j.bcmd.2011.01.001
   Rupon JW, 2006, P NATL ACAD SCI USA, V103, P6617, DOI 10.1073/pnas.0509322103
   Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200
   Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155
   Scarsdale JN, 2011, NUCLEIC ACIDS RES, V39, P6741, DOI 10.1093/nar/gkr262
   Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0
   Singal R, 2002, J BIOL CHEM, V277, P1897, DOI 10.1074/jbc.M105580200
   Smits AH, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks941
   Stefanska B, 2013, CARCINOGENESIS, V34, P2738, DOI 10.1093/carcin/bgt273
   Straussman R, 2009, NAT STRUCT MOL BIOL, V16, P564, DOI 10.1038/nsmb.1594
   Tompa P, 2012, TRENDS BIOCHEM SCI, V37, P509, DOI 10.1016/j.tibs.2012.08.004
   Tóth G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087133
   Uversky VN, 2011, INT J BIOCHEM CELL B, V43, P1090, DOI 10.1016/j.biocel.2011.04.001
   Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200
   Vacic V, 2007, J PROTEOME RES, V6, P2351, DOI 10.1021/pr0701411
   Vranken WF, 2005, PROTEINS, V59, P687, DOI 10.1002/prot.20449
   Walavalkar NM, 2014, NUCLEIC ACIDS RES, V42, P11218, DOI 10.1093/nar/gku782
   Walavalkar NM, 2013, J BIOL CHEM, V288, P3419, DOI 10.1074/jbc.M112.431346
   Wells M, 2008, P NATL ACAD SCI USA, V105, P5762, DOI 10.1073/pnas.0801353105
   Yu SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008579
NR 71
TC 52
Z9 64
U1 0
U2 16
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD MAR 31
PY 2015
VL 43
IS 6
BP 3100
EP 3113
DI 10.1093/nar/gkv168
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CI4LD
UT WOS:000354719300018
PM 25753662
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Su, Y
   Subedee, A
   Bloushtain-Qimron, N
   Savova, V
   Krzystanek, M
   Li, L
   Marusyk, A
   Tabassum, DP
   Zak, A
   Flacker, MJ
   Li, M
   Lin, JJ
   Sukumar, S
   Suzuki, H
   Long, H
   Szallasi, Z
   Gimelbrant, A
   Maruyama, R
   Polyak, K
AF Su, Ying
   Subedee, Ashim
   Bloushtain-Qimron, Noga
   Savova, Virginia
   Krzystanek, Marcin
   Li, Lewyn
   Marusyk, Andriy
   Tabassum, Doris P.
   Zak, Alexander
   Flacker, Mary Jo
   Li, Mei
   Lin, Jessica J.
   Sukumar, Saraswati
   Suzuki, Hiromu
   Long, Henry
   Szallasi, Zoltan
   Gimelbrant, Alexander
   Maruyama, Reo
   Polyak, Kornelia
TI Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast
   Cancer
SO CELL REPORTS
LA English
DT Article
ID TRANSCRIPTION FACTORS; TUMOR SUBTYPE; IDENTIFICATION; GENES;
   PROGENITORS; POPULATION; EXTINCTION; EXPRESSION; PHENOTYPE; EVOLUTION
AB Basal-like and luminal breast tumors have distinct clinical behavior and molecular profiles, yet the underlying mechanisms are poorly defined. To interrogate processes that determine these distinct phenotypes and their inheritance pattern, we generated somatic cell fusions and performed integrated genetic and epigenetic (DNA methylation and chromatin) profiling. We found that the basal-like trait is generally dominant and is largely defined by epigenetic repression of luminal transcription factors. Definition of super-enhancers highlighted a core program common in luminal cells but a high degree of heterogeneity in basal-like breast cancers that correlates with clinical outcome. We also found that protein extracts of basal-like cells are sufficient to induce a luminal-to-basal phenotypic switch, implying a trigger of basal-like autoregulatory circuits. We determined that KDM6A might be required for luminal-basal fusions, and we identified EN1, TBX18, and TCF4 as candidate transcriptional regulators of the luminal-to-basal switch. Our findings highlight the remarkable epigenetic plasticity of breast cancer cells.
C1 [Su, Ying; Subedee, Ashim; Bloushtain-Qimron, Noga; Marusyk, Andriy; Tabassum, Doris P.; Li, Mei; Lin, Jessica J.; Maruyama, Reo; Polyak, Kornelia] Dana Farber Canc Inst Boston, Dept Med Oncol, Boston, MA 02215 USA.
   [Savova, Virginia; Zak, Alexander; Gimelbrant, Alexander] Dana Farber Canc Inst Boston, Dept Canc Biol, Boston, MA 02215 USA.
   [Li, Lewyn; Long, Henry] Dana Farber Canc Inst Boston, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
   [Su, Ying; Marusyk, Andriy; Lin, Jessica J.; Maruyama, Reo; Polyak, Kornelia] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
   [Su, Ying; Marusyk, Andriy; Lin, Jessica J.; Maruyama, Reo; Polyak, Kornelia] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Savova, Virginia; Gimelbrant, Alexander] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
   [Subedee, Ashim; Tabassum, Doris P.; Polyak, Kornelia] Harvard Univ, Sch Med, BBS Program, Boston, MA 02115 USA.
   [Krzystanek, Marcin; Szallasi, Zoltan] Tech Univ Denmark, Dept Syst Biol, DK-2800 Kongens Lyngby, Denmark.
   [Flacker, Mary Jo; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Baltimore, MD 21231 USA.
   [Suzuki, Hiromu; Maruyama, Reo] Sapporo Med Univ, Sch Med,Sapporo, Dept Mol Biol, Sapporo, Hokkaido 0608556, Japan.
   [Szallasi, Zoltan] Childrens Hosp, Boston, MA 02115 USA.
   [Polyak, Kornelia] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
   [Polyak, Kornelia] Broad Inst, Cambridge, MA 02138 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer
   Institute; Harvard University; Brigham & Women's Hospital; Harvard
   University; Harvard Medical School; Harvard University; Harvard Medical
   School; Harvard University; Harvard Medical School; Technical University
   of Denmark; Johns Hopkins University; Sapporo Medical University;
   Harvard University; Boston Children's Hospital; Harvard University;
   Harvard University; Massachusetts Institute of Technology (MIT); Broad
   Institute
RP Maruyama, R (通讯作者)，Dana Farber Canc Inst Boston, Dept Med Oncol, Boston, MA 02215 USA.
EM reomaru@sapmed.ac.jp; kornelia_polyak@dfci.harvard.edu
RI Lin, Jessica/U-3020-2019; Polyak, Kornelia/ACJ-5837-2022
OI Szallasi, Zoltan/0000-0001-5395-7509; Lin, Jessica/0000-0001-7373-3916;
   Su, Ying/0000-0003-0462-3865; Subedee, Ashim/0000-0002-1208-5182;
   Krzystanek, Marcin/0000-0002-5920-2147; Gimelbrant,
   Alexander/0000-0001-6986-0285
FU US Army Congressionally Directed Research Program [BC084006, BC134001,
   BC087579]; Danish Cancer Society; Susan G. Komen Foundation; Kraeftens
   Bekaempelse
FX We thank members of our laboratories for their critical reading of this
   manuscript and useful discussions and the Cytogenetics Core of
   Dana-Farber Harvard Cancer Center (P30 CA006516) for the SKY studies.
   This work was supported by the US Army Congressionally Directed Research
   Program BC084006 and BC134001 (K.P.) and BC087579 (A.M.), Kraeftens
   Bekaempelse, the Danish Cancer Society (M.K.), and the Susan G. Komen
   Foundation (R.M. and Y.S.).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Beltran AS, 2014, ONCOGENE, V33, P4767, DOI 10.1038/onc.2013.422
   Choudhury S, 2013, CELL STEM CELL, V13, P117, DOI 10.1016/j.stem.2013.05.004
   Collas P, 2006, STEM CELL REV, V2, P309, DOI 10.1007/BF02698058
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629
   Egli D, 2008, NAT REV MOL CELL BIO, V9, P505, DOI 10.1038/nrm2439
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105
   MacDougall JR, 2000, J CELL SCI, V113, P409
   Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
   Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Takeichi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057829
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Vaz-Luis I, 2014, J CLIN ONCOL, V32, P2142, DOI 10.1200/JCO.2013.53.1608
   Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781
   Whyte WA, 2013, CELL, V153, P307, DOI 10.1016/j.cell.2013.03.035
NR 39
TC 56
Z9 62
U1 1
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JUN 16
PY 2015
VL 11
IS 10
BP 1549
EP 1563
DI 10.1016/j.celrep.2015.05.011
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CK6XM
UT WOS:000356372100007
PM 26051943
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Park, SB
   Kim, B
   Bae, H
   Lee, H
   Lee, S
   Choi, EH
   Kim, SJ
AF Park, Sung-Bin
   Kim, Byungtak
   Bae, Hansol
   Lee, Hyunkyung
   Lee, Seungyeon
   Choi, Eun H.
   Kim, Sun Jung
TI Differential Epigenetic Effects of Atmospheric Cold Plasma on MCF-7 and
   MDA-MB-231 Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; OXIDATIVE STRESS; OVARIAN-CANCER; APOPTOSIS; THERAPY;
   GENES; CARCINOGENESIS; METASTASIS; EXPRESSION; PROMOTER
AB Cold atmospheric plasma (plasma) has emerged as a novel tool for a cancer treatment option, having been successfully applied to a few types of cancer cells, as well as tissues. However, to date, no studies have been performed to examine the effect of plasma on epigenetic alterations, including CpG methylation. In this study, the effects of plasma on DNA methylation changes in breast cancer cells were examined by treating cultured MCF-7 and MDA-MB-231 cells, representing estrogen-positive and estrogen-negative cancer cells, respectively, with plasma. A pyrosequencing analysis of Alu indicated that a specific CpG site was induced to be hypomethylated from 23.4 to 20.3% (p < 0.05) by plasma treatment in the estrogen-negative MDA-MB-231 cells only. A genome-wide methylation analysis identified "cellular movement, connective tissue development and function, tissue development" and "cell-to-cell signaling and interaction, cell death and survival, cellular development" as the top networks. Of the two cell types, the MDA-MB-231 cells underwent a higher rate of apoptosis and a decreased proliferation rate upon plasma treatment. Taken together, these results indicate that plasma induces epigenetic and cellular changes in a cell type-specific manner, suggesting that a careful screening of target cells and tissues is necessary for the potential application of plasma as a cancer treatment option.
C1 [Park, Sung-Bin; Kim, Byungtak; Bae, Hansol; Lee, Hyunkyung; Lee, Seungyeon; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
   [Choi, Eun H.] Kwangwoon Univ, Plasma Biosci Res Ctr, Seoul, South Korea.
C3 Dongguk University; Kwangwoon University
RP Kim, SJ (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Goyang, South Korea.
EM sunjungk@dongguk.edu
RI Bae, Hansol/AGH-4590-2022; Choi, Eun/AFN-9488-2022; kim, sun/T-1013-2019
OI Choi, Eun Ha/0000-0001-5385-1878
FU National Research Foundation of Korea [NRF-2012R1A1A2040830,
   NRF-2010-0027963]
FX Funding was provided by National Research Foundation of Korea
   (www.nrf.re.kr) grants NRF-2012R1A1A2040830 and NRF-2010-0027963. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Alpay M, 2015, BREAST CANCER RES TR, V151, P75, DOI 10.1007/s10549-015-3368-5
   Arndt S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079325
   Arndt S, 2013, EXP DERMATOL, V22, P284, DOI 10.1111/exd.12127
   Aypar U, 2011, MUTAT RES-FUND MOL M, V707, P24, DOI 10.1016/j.mrfmmm.2010.12.003
   Bekeschus S, 2014, FREE RADICAL RES, V48, P542, DOI 10.3109/10715762.2014.892937
   Chalitchagorn K, 2004, ONCOGENE, V23, P8841, DOI 10.1038/sj.onc.1208137
   Chang JW, 2014, ARCH BIOCHEM BIOPHYS, V545, P133, DOI 10.1016/j.abb.2014.01.022
   Cui Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002990
   Deferme L, 2015, TOXICOL IN VITRO, V29, P845, DOI 10.1016/j.tiv.2015.03.007
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Geiger TR, 2007, CANCER RES, V67, P6221, DOI 10.1158/0008-5472.CAN-07-0121
   Goetz W, 2011, RADIAT RES, V175, P575, DOI 10.1667/RR2390.1
   Guerrero-Preston R, 2014, INT J MOL MED, V34, P941, DOI 10.3892/ijmm.2014.1849
   Hu JM, 2014, EPIGENETICS-US, V9, P1366, DOI 10.4161/15592294.2014.969625
   Huoh YS, 2014, BIOCHEMISTRY-US, V53, P4946, DOI 10.1021/bi5005156
   Ishaq M, 2014, INT J CANCER, V134, P1517, DOI 10.1002/ijc.28323
   Jha P, 2014, NEURO-ONCOLOGY, V16, P1607, DOI 10.1093/neuonc/nou113
   Keidar M, 2011, BRIT J CANCER, V105, P1295, DOI 10.1038/bjc.2011.386
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Kim JY, 2010, SMALL, V6, P1474, DOI 10.1002/smll.201000480
   KOCHANEK S, 1993, EMBO J, V12, P1141, DOI 10.1002/j.1460-2075.1993.tb05755.x
   Köritzer J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064498
   Lahtz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044858
   Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062
   Lee HS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005260
   Liebmann J, 2011, NITRIC OXIDE-BIOL CH, V24, P8, DOI 10.1016/j.niox.2010.09.005
   Ma YH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091947
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Partecke LI, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-473
   Pawlowski KM, 2013, VET RES COMMUN, V37, P123, DOI 10.1007/s11259-013-9554-1
   Pickeral OK, 2000, GENOME RES, V10, P411, DOI 10.1101/gr.10.4.411
   Saka M, 2010, J NEUROSURG, V113, P270, DOI 10.3171/2009.9.JNS09708
   Thiyagarajan M, 2014, BIOTECHNOL BIOENG, V111, P565, DOI 10.1002/bit.25114
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214
   Utsumi F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081576
   Wang M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073741
   Woloszynska-Read A, 2008, CLIN CANCER RES, V14, P3283, DOI 10.1158/1078-0432.CCR-07-5279
   Wu QH, 2015, CURR DRUG TARGETS, V16, P13, DOI 10.2174/1389450116666150113121054
   Yan PS, 2003, CANCER RES, V63, P6178
   Ye S, 2014, MUTAT RES-GEN TOX EN, V773, P34, DOI 10.1016/j.mrgentox.2014.08.004
   Zhou F, 2014, CLIN CHEM LAB MED, V52, P735, DOI 10.1515/cclm-2013-0736
NR 42
TC 60
Z9 63
U1 0
U2 24
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2015
VL 10
IS 6
AR e0129931
DI 10.1371/journal.pone.0129931
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CJ7TC
UT WOS:000355701600103
PM 26042423
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Ganai, SA
   Kalladi, SM
   Mahadevan, V
AF Ganai, Shabir Ahmad
   Kalladi, Shashwath Malli
   Mahadevan, Vijayalakshmi
TI HDAC inhibition through valproic acid modulates the methylation profiles
   in human embryonic kidney cells
SO JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS
LA English
DT Article
DE human embryonic kidney cells; histone deacetylase inhibitor; molecular
   mechanics-generalised born surface area; valproic acid;
   immunofluorescence; developmental kinases
ID HISTONE DEACETYLASE INHIBITORS; AGGRESSIVE BREAST-CANCER;
   PROTEIN-KINASE-C; CHROMATIN-STRUCTURE; STEM-CELLS; DEVELOPMENTAL
   REGULATORS; EPITHELIAL-CELLS; GENE-EXPRESSION; POLYCOMB; EZH2
AB Post-translational modifications on the tails of core and linker histones dictate transcription and have vital roles in disease and development. Acetylation and deacetylation events enabled by histone acetyl transferases and histone deacetylases (HDACs) on the chromatin milieu are intricately involved in gene regulation. Inhibition of HDACs is emerging as a powerful strategy in regenerative therapy, transplantation, development and in nuclear reprogramming events. Valproic acid (VPA), belonging to the short-chain fatty acid group of HDAC inhibitors, modulates the epigenome altering gene expression profiles across cell lines. This work attempts to explore the methylation profiles triggered by VPA treatment on human embryonic kidney cells (HEK 293) through a biochemical and computational approach. VPA treatment (for 48 h) has been observed to hypermethylate lysine 4 on the core histone H3 and confers a hypomethylation status of H3 lysine 27 in HEK 293 cells leaving the nuclear area and nuclear contour unaltered. Our structural docking and Binding Free Energy (BFE) calculations establish an active role for VPA in inhibiting the demethylase JARID1A (Jumonji, AT Rich Interactive Domain 1A) and the methyl-transferase EZH2 (Enhancer of Zeste Homologue 2). This work has also proven that VPA can inhibit the activity of proteins like GSK3 beta and PKC beta II involved in developmental disorders. This work establishes a dynamic correlation between histone methylation events and HDAC inhibition and may define newer epigenetic strategies for treating neurodevelopmental and oncological disorders.
C1 [Ganai, Shabir Ahmad; Kalladi, Shashwath Malli; Mahadevan, Vijayalakshmi] SASTRA Univ, Sch Chem & Biotechnol, Ctr Nanotechnol & Adv Biomat, Thanjavur 613401, India.
   [Mahadevan, Vijayalakshmi] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur 613401, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA);
   Shanmugha Arts, Science, Technology & Research Academy (SASTRA)
RP Mahadevan, V (通讯作者)，SASTRA Univ, Sch Chem & Biotechnol, Ctr Nanotechnol & Adv Biomat, Thanjavur 613401, India.
EM mviji@sastra.edu
RI Ganai, Ahmad/R-9527-2019
OI ganai, shabir ahmad/0000-0002-4668-8248; Mahadevan,
   Vijayalakshmi/0000-0003-1102-9979; Malli Kalladi,
   Shashwath/0000-0002-0191-3632
CR Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bártová E, 2005, J CELL SCI, V118, P5035, DOI 10.1242/jcs.02621
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Brilli LL, 2013, PEDIATR NEPHROL, V28, P1909, DOI 10.1007/s00467-012-2320-8
   Buch I, 2010, BIOCHEMISTRY-US, V49, P10890, DOI 10.1021/bi100822q
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chen CS, 1997, SCIENCE, V276, P1425, DOI 10.1126/science.276.5317.1425
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Consalvi S, 2011, MOL MED, V17, P457, DOI 10.2119/molmed.2011.00049
   Cunliffe VT, 2008, CURR OPIN GENET DEV, V18, P404, DOI 10.1016/j.gde.2008.10.001
   De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Ezhkova E, 2011, GENE DEV, V25, P485, DOI 10.1101/gad.2019811
   Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503
   Fiskus W, 2009, BLOOD, V114, P2733, DOI 10.1182/blood-2009-03-213496
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Grodsky N, 2006, BIOCHEMISTRY-US, V45, P13970, DOI 10.1021/bi061128h
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Hertzog R. G., 2009, THERAPEUTICS PHARM C, VXIII, P154
   Holler C, 2009, BLOOD, V113, P2791, DOI 10.1182/blood-2008-06-160713
   Hu ED, 2003, J PHARMACOL EXP THER, V307, P720, DOI 10.1124/jpet.103.055541
   Huang PH, 2011, MOL PHARMACOL, V79, P197, DOI 10.1124/mol.110.067702
   Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870
   Johannessen CU, 2003, CNS DRUG REV, V9, P199
   Karagiannis TC, 2006, EPIGENETICS-US, V1, P121, DOI 10.4161/epi.1.3.3328
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H
   Le Beyec J, 2007, EXP CELL RES, V313, P3066, DOI 10.1016/j.yexcr.2007.04.022
   Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Legube G, 2003, EMBO REP, V4, P944, DOI 10.1038/sj.embor.embor941
   LigPrep, 2012, SCHROD VERS 2 5
   Liu SZ, 2008, MOL CANCER THER, V7, P1751, DOI 10.1158/1535-7163.MCT-07-0560
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Luo Jia, 2012, Front Biol (Beijing), V7, P212
   Lyne PD, 2006, J MED CHEM, V49, P4805, DOI 10.1021/jm060522a
   Mannironi C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086002
   Marchion DC, 2005, CANCER RES, V65, P3815, DOI 10.1158/0008-5472.CAN-04-2478
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Marinova Z, 2011, NEUROPHARMACOLOGY, V60, P1109, DOI 10.1016/j.neuropharm.2010.09.022
   Martín-Sánchez E, 2011, BRIT J HAEMATOL, V152, P352, DOI 10.1111/j.1365-2141.2010.08401.x
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Milutinovic S, 2007, CARCINOGENESIS, V28, P560, DOI 10.1093/carcin/bgl167
   Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088
   Nightingale KP, 2007, J BIOL CHEM, V282, P4408, DOI 10.1074/jbc.M606773200
   Nowak SJ, 2004, TRENDS GENET, V20, P214, DOI 10.1016/j.tig.2004.02.007
   Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200
   Raman JD, 2005, CLIN CANCER RES, V11, P8570, DOI 10.1158/1078-0432.CCR-05-1047
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945
   Salam NK, 2009, J CHEM INF MODEL, V49, P2356, DOI 10.1021/ci900212v
   Sayegh J, 2013, J BIOL CHEM, V288, P9408, DOI 10.1074/jbc.M112.419861
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Spina E, 2004, EPILEPTIC DISORD, V6, P57
   Spittaels K, 2002, NEUROSCIENCE, V113, P797, DOI 10.1016/S0306-4522(02)00236-1
   Sproul D, 2005, NAT REV GENET, V6, P775, DOI 10.1038/nrg1688
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vergani L, 2004, INT J BIOCHEM CELL B, V36, P1447, DOI 10.1016/j.biocel.2003.11.015
   Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Way KJ, 2001, DIABETIC MED, V18, P945, DOI 10.1046/j.0742-3071.2001.00638.x
   Weake VM, 2008, MOL CELL, V29, P653, DOI 10.1016/j.molcel.2008.02.014
   Wu C, 1997, J BIOL CHEM, V272, P28171, DOI 10.1074/jbc.272.45.28171
   Yang XJ, 2007, ONCOGENE, V26, P5310, DOI 10.1038/sj.onc.1210599
   Yildirim E, 2003, NEUROSCI LETT, V345, P141, DOI 10.1016/S0304-3940(03)00490-7
   Zhang KL, 2004, PROTEOMICS, V4, P3765, DOI 10.1002/pmic.200400819
   Zhao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052698
NR 73
TC 18
Z9 21
U1 0
U2 39
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0739-1102
EI 1538-0254
J9 J BIOMOL STRUCT DYN
JI J. Biomol. Struct. Dyn.
PD JUN 3
PY 2015
VL 33
IS 6
BP 1185
EP 1197
DI 10.1080/07391102.2014.938247
PG 13
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CE3VR
UT WOS:000351758200004
PM 25012937
DA 2025-01-12
ER

PT J
AU Locke, WJ
   Zotenko, E
   Stirzaker, C
   Robinson, MD
   Hinshelwood, RA
   Stone, A
   Reddel, RR
   Huschtscha, LI
   Clark, SJ
AF Locke, Warwick J.
   Zotenko, Elena
   Stirzaker, Clare
   Robinson, Mark D.
   Hinshelwood, Rebecca A.
   Stone, Andrew
   Reddel, Roger R.
   Huschtscha, Lily I.
   Clark, Susan J.
TI Coordinated epigenetic remodelling of transcriptional networks occurs
   during early breast carcinogenesis
SO CLINICAL EPIGENETICS
LA English
DT Article
DE DNA methylation; Methylome; Epigenetics; Basal breast cancer; Epigenome
   sequencing; Biomarker
ID MAMMARY EPITHELIAL-CELLS; ARYL-HYDROCARBON RECEPTOR; DNA METHYLATION;
   PROMOTER HYPERMETHYLATION; EMBRYONIC STEM; CANCER GENOME; EXPRESSION;
   TARGETS; GROWTH; HYPOMETHYLATION
AB Background: Dysregulation of the epigenome is a common event in malignancy; however, deciphering the earliest cancer-associated epigenetic events remains a challenge. Cancer epigenome studies to date have primarily utilised cancer cell lines or clinical samples, where it is difficult to identify the initial epigenetic lesions from those that occur over time. Here, we analysed the epigenome of human mammary epithelial cells (HMEC) and a matched variant cell population (vHMEC) that have spontaneously escaped senescence and undergone partial carcinogenic transformation. Using this model of basal-like breast carcinogenesis, we provide striking new insights into the very first epigenetic changes that occur during the initial stages of malignancy.
   Results: The first phase of malignancy is defined by coordinated changes in the epigenome. At the chromatin level, this is embodied in long-range epigenetic deregulation, which involves the concomitant but atypical acquisition or loss of active and repressive histone modifications across large regional blocks. Changes in DNA methylation also occurs in a highly coordinated manner. We identified differentially methylated regions (DMRs) in the very earliest passages of vHMECs. Notably, we find that differential methylation targets loci regulated by key transcription factors including p53, AHR and E2F family members suggesting that epigenetic deregulation of transcription factor binding is a key event in breast carcinogenesis. Interestingly, DMRs identified in vHMEC are extensively methylated in breast cancer, with hypermethylation frequently encroaching into neighbouring regions. A subset of vHMEC DMRs exhibited a strong basal-like cancer specific hypermethylation.
   Conclusions: Here, we generated epigenome-wide maps of the earliest phase of breast malignancy and show long-range epigenetic deregulation and coordinated DNA hypermethylation targets loci regulated by key transcription factors. These findings support a model where induction of breast cancer occurs through epigenetic disruption of transcription factor binding leading to deregulation of cancer-associated transcriptional networks. With their stability and very early occurrence, vHMECs hypermethylated loci could serve as excellent biomarkers for the initial detection of basal breast cancer.
C1 [Locke, Warwick J.; Zotenko, Elena; Stirzaker, Clare; Hinshelwood, Rebecca A.; Stone, Andrew; Clark, Susan J.] Garvan Inst Med Res, Genom & Epigenet Div, Epigenet Res Lab, Darlinghurst, NSW 2010, Australia.
   [Locke, Warwick J.; Zotenko, Elena; Stirzaker, Clare; Stone, Andrew; Clark, Susan J.] Univ New S Wales, St Vincents Hosp, Fac Med, St Vincents Clin Sch, Victoria, NSW 2010, Australia.
   [Robinson, Mark D.] Univ Zurich, Swiss Inst Bioinformat, Zurich, Switzerland.
   [Robinson, Mark D.] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland.
   [Hinshelwood, Rebecca A.] Westmead Hosp, Crown Princess Mary Canc Ctr Westmead, Sydney West Canc Trials Ctr, Westmead, NSW 2145, Australia.
   [Reddel, Roger R.; Huschtscha, Lily I.] Childrens Med Res Inst, Canc Res Unit, Westmead, NSW 2145, Australia.
   [Reddel, Roger R.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
C3 Garvan Institute of Medical Research; NSW Health; St Vincents Hospital
   Sydney; University of New South Wales Sydney; Swiss Institute of
   Bioinformatics; University of Zurich; University of Zurich; NSW Health;
   Westmead Hospital; University of Sydney; Children's Medical Research
   Institute - Australia; University of Sydney
RP Clark, SJ (通讯作者)，Garvan Inst Med Res, Genom & Epigenet Div, Epigenet Res Lab, 384 Victoria St, Darlinghurst, NSW 2010, Australia.
EM s.clark@garvan.org.au
RI Reddel, Roger/A-6635-2014; Robinson, Mark/A-6432-2015; Clark,
   Susan/B-2272-2008; Locke, Warwick/G-3152-2017
OI Stirzaker, Clare/0000-0001-5601-3140; Robinson,
   Mark/0000-0002-3048-5518; Clark, Susan/0000-0001-5925-5030; Locke,
   Warwick/0000-0002-9281-0363
FU National Breast Cancer Foundation of Australia [DS-09-06]; National
   Health and Medical Research Council [1011447, 1063559, 1070881]; New
   South Wales Cancer Council [PG11-08]; National Health and Medical
   Research Council of Australia [1070881] Funding Source: NHMRC
FX All work was performed using funding from the following grants,
   scholarships and fellowships; National Breast Cancer Foundation of
   Australia Postgraduate Research Scholarship #DS-09-06 (WJL,
   http://www.nbcf.org.au/), National Breast Cancer Foundation of Australia
   Collaborative Grant entitled 'Novel strategies for prediction and
   control of advanced breast cancer via nanoscaled epigenetic-based
   biosensors' (SJL, http://www.nbcf.org.au/), National Health and Medical
   Research Council Project grant #1011447 (SJL https://www.nhmrc.gov.au/),
   National Health and Medical Research Council Fellowship #1063559 (SJL
   https://www.nhmrc.gov.au/), National Health and Medical Research Council
   Project Grant #1070881 (LIH, RRR https://www.nhmrc.gov.au/), New South
   Wales Cancer Council Program Grant #PG11-08 (RRR
   http://www.cancercouncil.com.au/).
CR [Anonymous], MOL CARCINOGENESIS
   [Anonymous], EUROPEAN J IMMUNOL
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bengtsson H., 2008, aroma. affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory
   Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006
   Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Brenner AJ, 1998, ONCOGENE, V17, P199, DOI 10.1038/sj.onc.1201919
   Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Daskalos A, 2009, INT J CANCER, V124, P81, DOI 10.1002/ijc.23849
   Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457
   Dvinge H, 2009, BIOINFORMATICS, V25, P3325, DOI 10.1093/bioinformatics/btp578
   Easwaran H, 2012, GENOME RES, V22, P837, DOI 10.1101/gr.131169.111
   Foster SA, 1998, MOL CELL BIOL, V18, P1793, DOI 10.1128/MCB.18.4.1793
   Frauenstein K, 2013, CELL DEATH DIFFER, V20, P1425, DOI 10.1038/cdd.2013.102
   HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435
   HAYASHI S, 1995, CARCINOGENESIS, V16, P1403, DOI 10.1093/carcin/16.6.1403
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hinshelwood RA, 2007, CANCER RES, V67, P11517, DOI 10.1158/0008-5472.CAN-07-1284
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Huschtscha LI, 1998, CANCER RES, V58, P3508
   Huschtscha LI, 2009, J CELL SCI, V122, P2989, DOI 10.1242/jcs.044107
   Jackson M, 2004, MOL CELL BIOL, V24, P8862, DOI 10.1128/MCB.24.20.8862-8871.2004
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kornegoor R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3220
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Locke WJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3237
   Meyer LR, 2013, NUCLEIC ACIDS RES, V41, pD64, DOI 10.1093/nar/gks1048
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   O'Donnell EF, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.549
   Papoutsis AJ, 2012, J NUTR BIOCHEM, V23, P1324, DOI 10.1016/j.jnutbio.2011.08.001
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pei LR, 2012, EPIGENETICS-US, V7, P567, DOI 10.4161/epi.20237
   Prada D, 2012, MUTAT RES-FUND MOL M, V729, P100, DOI 10.1016/j.mrfmmm.2011.10.007
   Ray SS, 2004, J BIOL CHEM, V279, P27187, DOI 10.1074/jbc.M402771200
   Robinson MD, 2008, BIOSTATISTICS, V9, P321, DOI 10.1093/biostatistics/kxm030
   Robinson MD, 2007, BIOINFORMATICS, V23, P2881, DOI 10.1093/bioinformatics/btm453
   Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110
   Robinson MD, 2010, EPIGENOMICS-UK, V2, P587, DOI 10.2217/EPI.10.36
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Saito R, 2014, HORM CANCER-US, V5, P11, DOI 10.1007/s12672-013-0160-z
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sorlie T, 2010, LANCET ONCOL, V11, P719, DOI 10.1016/S1470-2045(10)70174-1
   Spizzo R, 2010, CELL DEATH DIFFER, V17, P246, DOI 10.1038/cdd.2009.117
   Stampfer M., 1985, Journal of Tissue Culture Methods, V9, P107
   Statham AL, 2010, BIOINFORMATICS, V26, P1662, DOI 10.1093/bioinformatics/btq247
   Stone A, 2013, MOL CANCER THER, V12, P1874, DOI 10.1158/1535-7163.MCT-13-0012
   Stone A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040466
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tian YN, 2003, J BIOL CHEM, V278, P44041, DOI 10.1074/jbc.M306443200
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   van Roon EH, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-2
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Vidal LJP, 2010, MOL CANCER RES, V8, P444, DOI 10.1158/1541-7786.MCR-09-0368
   Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431
   Wang C, 2014, CARCINOGENESIS, V35, P703, DOI 10.1093/carcin/bgt356
   Wang K, 2013, CANCER LETT, V340, P63, DOI 10.1016/j.canlet.2013.06.026
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
NR 67
TC 25
Z9 27
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD MAY 1
PY 2015
VL 7
AR 52
DI 10.1186/s13148-015-0086-0
PG 15
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CH5OD
UT WOS:000354084300001
PM 25960784
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Hussain, I
   Bhan, A
   Ansari, KI
   Deb, P
   Bobzean, SAM
   Perrotti, LI
   Mandal, SS
AF Hussain, Imran
   Bhan, Arunoday
   Ansari, Khairul I.
   Deb, Paromita
   Bobzean, Samara A. M.
   Perrotti, Linda I.
   Mandal, Subhrangsu S.
TI Bisphenol-A induces expression of HOXC6, an estrogen-regulated
   homeobox-containing gene associated with breast cancer
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
LA English
DT Article
DE HOXC6 expression; Estrogen-receptors; Bisphenol A; Endocrine disruption;
   Epigenetics; Mixed lineage leukemia (MLL)
ID RANGE CHROMATIN INTERACTIONS; NUCLEOTIDE SPACER SEQUENCE; MAMMARY-GLAND
   DEVELOPMENT; MLL HISTONE METHYLASES; ELEMENT HALF-SITES; RESPONSE
   ELEMENT; RECEPTOR-ALPHA; IN-VIVO; IMMUNOCYTOCHEMICAL DETECTION;
   TUMOR-GROWTH
AB HOXC6 is a homeobox-containing gene associated with mammary gland development and is overexpressed in variety of cancers including breast and prostate cancers. Here, we have examined the expression of HOXC6 in breast cancer tissue, investigated its transcriptional regulation via estradiol (E2) and bisphenol-A (BPA, an estrogenic endocrine disruptor) in vitro and in vivo. We observed that HOXC6 is differentially over-expressed in breast cancer tissue. E2 induces HOXC6 expression in cultured breast cancer cells and in mammary glands of Sprague Dawley rats. HOXC6 expression is also induced upon exposure to BPA both in vitro and in vivo. Estrogen-receptor-alpha (ER alpha) and ER-coregulators such as MLL-histone methylases are bound to the HOXC6 promoter upon exposure to E2 or BPA and that resulted in increased histone H3K4-trimethylation, histone acetylation, and recruitment of RNA polymerase II at the HOXC6 promoter. HOXC6 overexpression induces expression of tumor growth factors and facilitates growth 3D-colony formation, indicating its potential roles in tumor growth. Our studies demonstrate that HOXC6, which is a critical player in mammary gland development, is upregulated in multiple cases of breast cancer, and is transcriptionally regulated by E2 and BPA, in vitro and in vivo. Published by Elsevier B.V.
C1 [Hussain, Imran; Bhan, Arunoday; Ansari, Khairul I.; Deb, Paromita; Mandal, Subhrangsu S.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
   [Bobzean, Samara A. M.; Perrotti, Linda I.] Univ Texas Arlington, Dept Psychol, Arlington, TX 76019 USA.
C3 University of Texas System; University of Texas Arlington; University of
   Texas System; University of Texas Arlington
RP Mandal, SS (通讯作者)，Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
EM smandal@uta.edu
RI Ansari, Khairul/C-9791-2011; bhan, arunoday/F-1066-2011
OI Hussain, Imran/0000-0003-1563-7656; Perrotti, Linda/0000-0002-6297-2572;
   Mandal, Subhrangsu/0000-0001-8495-9881
FU NIH [1R15 ES019129-01]
FX We thank all the Mandal and Perrotti lab members for helpful
   discussions. Research in Mandal laboratory is supported by grant from
   NIH (1R15 ES019129-01).
CR Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052
   Alexander T, 2009, ANNU REV CELL DEV BI, V25, P431, DOI 10.1146/annurev.cellbio.042308.113423
   Anderson I, 2000, BIOCHEMISTRY-US, V39, P3842, DOI 10.1021/bi9924516
   [Anonymous], 1996, BIOCHEM J
   Ansari AZ, 2011, CELL, V147, P1220, DOI 10.1016/j.cell.2011.11.046
   Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352
   Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263
   Ansari KI, 2008, BBA-GENE REGUL MECH, V1779, P66, DOI 10.1016/j.bbagrm.2007.11.006
   Ansari KI, 2013, MOL ENDOCRINOL, V27, P92, DOI 10.1210/me.2012-1147
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t
   Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x
   Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x
   Ansari KI, 2009, FEBS J, V276, P3299, DOI 10.1111/j.1742-4658.2009.07055.x
   Ansari KI, 2009, J INORG BIOCHEM, V103, P818, DOI 10.1016/j.jinorgbio.2009.02.004
   Ansari KI, 2009, FRONT BIOSCI-LANDMRK, V14, P3483, DOI 10.2741/3466
   Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003
   Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148
   Bhan A, 2014, J MOL BIOL, V426, P3426, DOI 10.1016/j.jmb.2014.07.025
   Bhan A, 2014, CHEMMEDCHEM, V9, P1932, DOI 10.1002/cmdc.201300534
   Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002
   Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022
   Bijl J, 1996, BLOOD, V87, P1737, DOI 10.1182/blood.V87.5.1737.bloodjournal8751737
   Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138
   Bobzean SAM, 2014, BRAIN RES BULL, V103, P49, DOI 10.1016/j.brainresbull.2014.02.002
   Bodey B, 2000, ANTICANCER RES, V20, P3281
   Bodey B, 2000, ANTICANCER RES, V20, P1769
   Bodey B, 2000, ANTICANCER RES, V20, P2711
   Bodey B, 2000, ANTICANCER RES, V20, P2717
   Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200
   CASTRONOVO V, 1994, BIOCHEM PHARMACOL, V47, P137, DOI 10.1016/0006-2952(94)90447-2
   Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525
   Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Eilam-Stock T, 2012, BEHAV NEUROSCI, V126, P175, DOI 10.1037/a0025959
   Ernst P, 2004, CURR BIOL, V14, P2063, DOI 10.1016/j.cub.2004.11.012
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   FRIEDMANN Y, 1994, CANCER RES, V54, P5981
   Fujiki K, 2008, GASTROENTEROLOGY, V135, P907, DOI 10.1053/j.gastro.2008.06.034
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Fullwood MJ, 2009, J CELL BIOCHEM, V107, P30, DOI 10.1002/jcb.22116
   Fullwood MJ, 2009, GENOME RES, V19, P521, DOI 10.1101/gr.074906.107
   Garcia-Gasca A, 2000, DEV DYNAM, V219, P261, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1048>3.0.CO;2-3
   Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111
   Grishina IB, 2005, DEV BIOL, V288, P334, DOI 10.1016/j.ydbio.2005.08.018
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005
   Holwerda Sjoerd, 2012, Frontiers in Genetics, V3, P217, DOI 10.3389/fgene.2012.00217
   Hueber SD, 2008, BIOESSAYS, V30, P965, DOI 10.1002/bies.20823
   Inagaki T, 2012, ENDOCRINOLOGY, V153, P3357, DOI 10.1210/en.2012-1121
   Jiang SM, 2006, MOL ENDOCRINOL, V20, P311, DOI 10.1210/me.2005-0100
   JONES FS, 1993, P NATL ACAD SCI USA, V90, P6557, DOI 10.1073/pnas.90.14.6557
   Kasiri S, 2013, RSC ADV, V3, P3260, DOI 10.1039/c2ra22006g
   Kelly ZL, 2011, J OVARIAN RES, V4, DOI 10.1186/1757-2215-4-16
   Klinge CM, 1998, MOL CELL ENDOCRINOL, V143, P79, DOI 10.1016/S0303-7207(98)00130-0
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Lappin Terence R J, 2006, Ulster Med J, V75, P23
   Lee S, 2006, P NATL ACAD SCI USA, V103, P15392, DOI 10.1073/pnas.0607313103
   Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455
   Lin YS, 2007, DEVELOPMENT, V134, P723, DOI 10.1242/dev.02765
   Liu MH, 2014, MOL CELL ENDOCRINOL, V382, P624, DOI 10.1016/j.mce.2013.09.019
   Lopez D, 2002, ENDOCRINOLOGY, V143, P2155, DOI 10.1210/en.143.6.2155
   MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633
   Makiyama K, 2005, ONCOL REP, V13, P673
   Mallo M, 2013, DEVELOPMENT, V140, P3951, DOI 10.1242/dev.068346
   Mandal SS, 2010, FASEB J, V24
   Mandal SS, 2010, FEBS J, V277, P1789, DOI 10.1111/j.1742-4658.2010.07605.x
   Maroulakou IG, 2003, ANTICANCER RES, V23, P2101
   McCabe CD, 2008, CANCER RES, V68, P1988, DOI 10.1158/0008-5472.CAN-07-5843
   Miller GJ, 2003, CANCER RES, V63, P5879
   Mishra BP, 2009, FEBS J, V276, P1629, DOI 10.1111/j.1742-4658.2009.06895.x
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Moon SM, 2012, J BIOL CHEM, V287, P35678, DOI 10.1074/jbc.M112.361675
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81
   Nunes Fabio Daumas, 2003, Pesqui Odontol Bras, V17, P94
   Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369
   Ramachandran S, 2005, ONCOGENE, V24, P188, DOI 10.1038/sj.onc.1207906
   Rhoads Kim, 2005, Lymphatic Research and Biology, V3, P240, DOI 10.1089/lrb.2005.3.240
   Ricort JM, 2002, J BIOL CHEM, V277, P19448, DOI 10.1074/jbc.M200439200
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   Shibata H, 1997, RECENT PROG HORM RES, V52, P141
   Shrestha B, 2012, FEBS J, V279, P3715, DOI 10.1111/j.1742-4658.2012.08733.x
   Shu FJ, 2010, J STEROID BIOCHEM, V120, P172, DOI 10.1016/j.jsbmb.2010.04.009
   Sidell N, 2011, J STEROID BIOCHEM, V124, P121, DOI 10.1016/j.jsbmb.2011.02.003
   Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com
   Stender JD, 2007, MOL ENDOCRINOL, V21, P2112, DOI 10.1210/me.2006-0474
   Takahashi Y, 2004, EXP CELL RES, V293, P144, DOI 10.1016/j.yexcr.2003.09.024
   Theodorou V, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2470
   Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561
   Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010
   VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251
   Velghe AI, 2014, ONCOGENE, V33, P2568, DOI 10.1038/onc.2013.218
   Vinarskaja Anna, 2011, Cancers (Basel), V3, P3714, DOI 10.3390/cancers3043714
   Washington W, 2001, IN VITRO MOL TOXICOL, V14, P43, DOI 10.1089/109793301316882531
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Yamashita T, 2006, INT J ONCOL, V28, P931
   YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0
   Zhang XR, 2007, J CELL MOL MED, V11, P299, DOI 10.1111/j.1582-4934.2007.00020.x
NR 103
TC 47
Z9 52
U1 0
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-9399
EI 0006-3002
J9 BBA-GENE REGUL MECH
JI Biochim. Biophys. Acta-Gene Regul. Mech.
PD JUN
PY 2015
VL 1849
IS 6
BP 697
EP 708
DI 10.1016/j.bbagrm.2015.02.003
PG 12
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CK0KY
UT WOS:000355895300011
PM 25725483
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Chang, CC
   Wu, MJ
   Yang, JY
   Camarillo, IG
   Chang, CJ
AF Chang, Chao-Ching
   Wu, Meng-Ju
   Yang, Jer-Yen
   Camarillo, Ignacio G.
   Chang, Chun-Ju
TI Leptin-STAT3-G9a Signaling Promotes Obesity-Mediated Breast Cancer
   Progression
SO CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; STEM-CELLS; MAMMARY TUMORIGENESIS;
   LEPTIN; STAT3; ACTIVATION; EXPRESSION; REPRESSION; SURVIVAL; EVALUATE
AB Obesity has been linked to breast cancer progression but the underlying mechanisms remain obscure. Here we report how leptin, an obesity-associated adipokine, regulates a transcriptional pathway to silence a genetic program of epithelial homeostasis in breast cancer stem-like cells (CSC) that promotes malignant progression. Using genome-wide ChIP-seq and RNA expression profiling, we defined a role for activated STAT3 and G9a histone methyltransferase in epigenetic silencing of miR-200c, which promotes the formation of breast CSCs defined by elevated cell surface levels of the leptin receptor (OBRhi). Inhibiting the STAT3/G9a pathway restored expression of miR-200c, which in turn reversed the CSC phenotype to a more differentiated epithelial phenotype. In a rat model of breast cancer driven by diet-induced obesity, STAT3 blockade suppressed the CSC-like OBRhi population and abrogated tumor progression. Together, our results show how targeting STAT3-G9a signaling regulates CSC plasticity during obesity-related breast cancer progression, suggesting a novel therapeutic paradigm to suppress CSC pools and limit breast malignancy. (C)2015 AACR.
C1 [Wu, Meng-Ju; Yang, Jer-Yen; Chang, Chun-Ju] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47906 USA.
   [Chang, Chao-Ching; Wu, Meng-Ju; Yang, Jer-Yen; Camarillo, Ignacio G.; Chang, Chun-Ju] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47906 USA.
   [Camarillo, Ignacio G.] Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University; Purdue University System; Purdue University
RP Chang, CJ (通讯作者)，Purdue Univ, 625 Harrison St, W Lafayette, IN 47906 USA.
EM chunjuchang@purdue.edu
RI Wu, Meng-Ju/AAY-9410-2021; yan, jie/HNJ-0097-2023
OI Wu, Meng-Ju/0000-0001-6847-7065; Chang, Chunju/0000-0003-2887-9603
FU Women's Global Health Institute-Mildred Elizabeth Edmundson Research
   Grant; Walther Cancer Foundation-Obesity and Cancer Pilot Grant;
   American Cancer Society IRG Junior Investigator Award [58-006-53];
   Showalter Research Scholar Grant [206793];  [P30 CA023168]
FX This study was supported by Women's Global Health Institute-Mildred
   Elizabeth Edmundson Research Grant (C.-J. Chang), Walther Cancer
   Foundation-Obesity and Cancer Pilot Grant (I.G. Camarillo and C-J.
   Chang), American Cancer Society IRG Junior Investigator Award
   (#58-006-53 to C.-J. Chang), Showalter Research Scholar Grant (#206793
   to C.-J. Chang), and P30 CA023168 to the Purdue University Center for
   Cancer Research in support of the use of facilities
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423
   Camarillo IG, 2001, J ENDOCRINOL, V171, P85, DOI 10.1677/joe.0.1710085
   Chan MM, 2005, CARCINOGENESIS, V26, P1343, DOI 10.1093/carcin/bgi100
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Cleary MP, 2009, ENDOCRINOLOGY, V150, P2537, DOI 10.1210/en.2009-0070
   Demark-Wahnefried W, 2012, CANCER EPIDEM BIOMAR, V21, P1244, DOI 10.1158/1055-9965.EPI-12-0485
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Farooqi IS, 2005, ANNU REV MED, V56, P443, DOI 10.1146/annurev.med.56.062904.144924
   Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673
   Ghibaudi L, 2002, OBES RES, V10, P956, DOI 10.1038/oby.2002.130
   Grossmann ME, 2012, BIOCHIMIE, V94, P2164, DOI 10.1016/j.biochi.2012.06.013
   Hu X, 2002, J NATL CANCER I, V94, P1704, DOI 10.1093/jnci/94.22.1704
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X
   Le TT, 2007, MOL IMAGING, V6, P205, DOI 10.2310/7290.2007.00018
   Ligibel J, 2011, ONCOLOGY-NY, V25, P994
   Mandal M, 2011, NAT IMMUNOL, V12, P1212, DOI 10.1038/ni.2136
   Park J, 2011, ENDOCR-RELAT CANCER, V18, pC25, DOI 10.1530/ERC-11-0163
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109
   Rankinen T, 2006, OBESITY, V14, P529, DOI 10.1038/oby.2006.71
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   RUSSO J, 1990, LAB INVEST, V62, P244
   Salameh TS, 2013, INT J CANCER, V132, P288, DOI 10.1002/ijc.27672
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shinkai Y, 2011, GENE DEV, V25, P781, DOI 10.1101/gad.2027411
   Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104
   Speakman J, 2007, OBES REV, V8, P55, DOI 10.1111/j.1467-789X.2007.00319.x
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wallace J, 2000, ILAR J, V41, P87
   Yan D, 2012, J BIOL CHEM, V287, P8598, DOI 10.1074/jbc.M111.322800
   Zheng Q, 2011, ENDOCR-RELAT CANCER, V18, P491, DOI 10.1530/ERC-11-0102
NR 33
TC 92
Z9 106
U1 0
U2 24
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2015
VL 75
IS 11
BP 2375
EP 2386
DI 10.1158/0008-5472.CAN-14-3076
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CL9XX
UT WOS:000357333500025
PM 25840984
OA Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Ma, JF
   Guo, XB
   Zhang, SJ
   Liu, HC
   Lu, J
   Dong, ZM
   Liu, KD
   Ming, L
AF Ma, Junfen
   Guo, Xiaobing
   Zhang, Shijie
   Liu, Hongchun
   Lu, Jing
   Dong, Ziming
   Liu, Kangdong
   Ming, Liang
TI Trichostatin A, a histone deacetylase inhibitor, suppresses
   proliferation and promotes apoptosis of esophageal squamous cell lines
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE histone deacetylase inhibitor; trichostatin A; esophageal squamous cell
   carcinoma; apoptosis
ID CANCER; CYCLE; ACETYLATION; EXPRESSION; INDUCTION; ARREST; HDACS
AB Histone deacetylase (HDAC)-mediated epigenetic modification plays crucial roles in numerous biological processes, including cell cycle regulation, cell proliferation and apoptosis. HDAC inhibitors demonstrate antitumor effects in various cancers, including glioblastoma and breast cancer. HDAC inhibitors are therefore promising antitumor drugs for these tumors. The tumorigenesis and development of esophageal squamous cell carcinoma (ESCC) involve genetic and epigenetic mechanisms. However, the effects of the HDAC inhibitor on ESCC are not fully investigated. In the present study, ESCC cells were treated with trichostatin A (TSA) and its antitumor effects and related mechanisms were investigated. The results indicated that TSA suppressed the proliferation of ESCCs and caused G1 phase arrest by inducing the expression of p21 and p27. TSA also induced cell apoptosis by enhancing the expression of pro-apoptotic protein Bax and decreasing the expression of anti-apoptotic protein Bcl-2. Furthermore, TSA inhibited the expression of phosphatidylinositol-3-kinase (PI3K) and reduced the phosphorylation of Akt and extracellular signal-regulated kinase (ERK)1/2 in EC9706 and EC1 cell lines. High levels of acetylated histone H4 were detected in TSA-treated ESCC cell lines. Overall, these results indicate that TSA suppresses ESCC cell growth by inhibiting the activation of the PI3K/Akt and ERK1/2 pathways. TSA also promotes cell apoptosis through epigenetic regulation of the expression of apoptosis-related protein.
C1 [Ma, Junfen; Guo, Xiaobing; Zhang, Shijie; Liu, Hongchun; Ming, Liang] Zhengzhou Univ, Affiliated Hosp 1, Dept Clin Lab, Zhengzhou 450052, Henan, Peoples R China.
   [Lu, Jing; Dong, Ziming; Liu, Kangdong] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.
C3 Zhengzhou University; Zhengzhou University
RP Liu, KD (通讯作者)，Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, 100 Kexue Ave, Zhengzhou 450001, Henan, Peoples R China.
EM kdliu@zzu.edu.cn; mingliang@zzu.edu.cn
RI Zhang, Shijie/AAW-7058-2021
FU National Basic Research Program of China [2012CB933300]; Natural Science
   Foundation of the Henan Province of China [12B310023, 81372269,
   13HASTIT022, 12B310022]
FX This study was supported by the National Basic Research Program of China
   (grant no. 2012CB933300), the Natural Science Foundation of the Henan
   Province of China (grant nos. 12B310023 and 81372269) and the Natural
   Science Foundation of the Henan province of China (grant nos.
   13HASTIT022 and 12B310022).
CR Abbas A, 2008, EPIGENETICS-US, V3, P300, DOI 10.4161/epi.3.6.7273
   Aguero MF, 2005, CANCER RES, V65, P3364, DOI 10.1158/0008-5472.CAN-04-2429
   Bonfils C, 2008, EXPERT OPIN DRUG DIS, V3, P1041, DOI 10.1517/17460441.3.9.1041
   Cai Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-57
   Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200
   Chen X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.416
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Ellis L, 2010, PHARMACEUTICALS, V3, P2441, DOI 10.3390/ph3082441
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Gérard C, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00413
   Häcker S, 2011, ONCOGENE, V30, P2275, DOI 10.1038/onc.2010.599
   Hoshino I, 2010, SURG TODAY, V40, P809, DOI 10.1007/s00595-010-4300-6
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Jurkin J, 2011, CELL CYCLE, V10, P406, DOI 10.4161/cc.10.3.14712
   Liu Bin, 2012, Sheng Wu Yi Xue Gong Cheng Xue Za Zhi, V29, P1221
   Marson CM, 2009, ANTI-CANCER AGENT ME, V9, P661, DOI 10.2174/187152009788679976
   Meng FL, 2013, INT J ONCOL, V43, P495, DOI 10.3892/ijo.2013.1960
   Minsky BD, 2002, J CLIN ONCOL, V20, P1167, DOI 10.1200/JCO.20.5.1167
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1
   Noureen N, 2010, CANCER CHEMOTH PHARM, V66, P625, DOI 10.1007/s00280-010-1324-y
   Queiroz AB, 2010, ANTICANCER RES, V30, P2799
   Reichert N, 2012, CELL MOL LIFE SCI, V69, P2173, DOI 10.1007/s00018-012-0921-9
   Rezaei PF, 2012, FOOD CHEM TOXICOL, V50, P1054, DOI 10.1016/j.fct.2011.11.012
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Spiegel S, 2012, ONCOGENE, V31, P537, DOI 10.1038/onc.2011.267
   Stein C, 2012, NUCLEIC ACIDS RES, V40, P9522, DOI 10.1093/nar/gks767
   Tula-Sanchez AA, 2013, CANCER BIOL THER, V14, P949, DOI 10.4161/cbt.25941
   Ueki N, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3735
   Wang CG, 2001, FRONT BIOSCI-LANDMRK, V6, pD610, DOI 10.2741/1wang1
   Ward CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062610
   Watson JA, 2010, J CELL MOL MED, V14, P1668, DOI 10.1111/j.1582-4934.2009.00835.x
   Wilson PM, 2013, INVEST NEW DRUG, V31, P845, DOI 10.1007/s10637-012-9914-7
   Yagi Y, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-149
   You BR, 2013, INT J ONCOL, V42, P359, DOI 10.3892/ijo.2012.1705
   Zhang J, 2011, GASTROENTEROLOGY, V141, P50, DOI 10.1053/j.gastro.2011.05.010
   Zhu HW, 2013, MOL CLIN ONCOL, V1, P1009, DOI 10.3892/mco.2013.161
NR 37
TC 39
Z9 45
U1 0
U2 23
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JUN
PY 2015
VL 11
IS 6
BP 4525
EP 4531
DI 10.3892/mmr.2015.3268
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CJ4ZL
UT WOS:000355497100075
PM 25634603
OA hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Jeschke, J
   Collignon, E
   Fuks, F
AF Jeschke, Jana
   Collignon, Evelyne
   Fuks, Francois
TI DNA methylome profiling beyond promoters - taking an epigenetic snapshot
   of the breast tumor microenvironment
SO FEBS JOURNAL
LA English
DT Article
DE breast cancer; cell frequency; cell identity; cell-lineage specificity;
   clinical outcome; DNA methylation; prognosis; tumor immune response;
   tumor microenvironment; tumor-infiltrating lymphocytes
ID REGULATORY T-CELLS; INFILTRATING LYMPHOCYTES; METHYLATION ANALYSIS; CPG
   ISLANDS; CANCER; GENE; GENOME; HYPOMETHYLATION; CHEMOTHERAPY;
   FIBROBLASTS
AB Breast cancer, one of the most common and deadliest malignancies in developed countries, is a remarkably heterogeneous disease, which is clinically reflected by patients who display similar pathological features but respond differently to treatments. In the search for mediators of responsiveness, the tumor microenvironment (TME), in particular tumor-associated immune cells, has been pushed into the spotlight as it has become clear that the TME is an active component of breast cancer disease that affects clinical outcomes. Thus, the characterization of the TME in terms of cell identities and their frequencies has generated a great deal of interest. The common methods currently used for this purpose are either limited in accuracy or application, and DNA methylation has recently been proposed as an alternative approach. The aim of this review is to discuss DNA methylation profiling beyond promoters as a potential clinical tool for TME characterization and cell typing within tumors. With respect to this, we review the role of DNA methylation in breast cancer and cell-lineage specification, as well as inform about the composition and clinical relevance of the TME.
C1 [Jeschke, Jana; Collignon, Evelyne; Fuks, Francois] Univ Libre Bruxelles, Lab Canc Epigenet, B-1070 Brussels, Belgium.
C3 Universite Libre de Bruxelles
RP Fuks, F (通讯作者)，Univ Libre Bruxelles, Lab Canc Epigenet, Fac Med, CP 614,Bldg GE,5th Floor,808 Route Lennik, B-1070 Brussels, Belgium.
EM ffuks@ulb.ac.be
RI Fuks, Francois/HJY-8201-2023
OI Collignon, Evelyne/0000-0001-7617-5905; Jeschke,
   Jana/0000-0002-6047-2558
FU F.N.R.S; Televie; Interuniversity Attraction Poles [IAPP7/03]; CEAction
   de Recherche Concertee (AUWB); l'Oreal; UNESCO
FX We apologize to the many authors whose work is not cited in this review
   due to space constraints. This work was supported by grants from the
   F.N.R.S and Televie, the Interuniversity Attraction Poles (IAPP7/03) and
   the CEAction de Recherche Concertee (AUWB-2010-2015 ULB-No 7). F.F. is a
   FNRS Senior Research Associate, J.J. a FNRS Postdoctoral Researcher and
   EC is funded by the program 'For Women in Science' from l'Oreal and
   UNESCO.
CR AALTOMAA S, 1992, EUR J CANCER, V28A, P859, DOI 10.1016/0959-8049(92)90134-N
   Accomando WP, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r50
   Ambrosone CB, 2014, ONCOTARGET, V5, P237, DOI 10.18632/oncotarget.1599
   Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782
   Baron U, 2006, EPIGENETICS-US, V1, P55, DOI 10.4161/epi.1.1.2643
   Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Berdasco M, 2011, STEM CELL RES THER, V2, DOI 10.1186/scrt83
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Bochet L, 2011, BIOCHEM BIOPH RES CO, V411, P102, DOI 10.1016/j.bbrc.2011.06.101
   Bos PD, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3005283
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Chua W, 2011, BRIT J CANCER, V104, P1288, DOI 10.1038/bjc.2011.100
   Clark C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050233
   Cornen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081843
   Costa FF, 2006, CANCER GENET CYTOGEN, V165, P135, DOI 10.1016/j.cancergencyto.2005.07.023
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Day TK, 2013, ENDOCR-RELAT CANCER, V20, pR215, DOI 10.1530/ERC-13-0204
   de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014
   Deaton AM, 2011, GENOME RES, V21, P1074, DOI 10.1101/gr.118703.110
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Delpu Y, 2013, INT J MOL SCI, V14, P15029, DOI 10.3390/ijms140715029
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Doherty R, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00126
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
   Fumagalli C, 2012, BREAST CANCER RES TR, V134, P131, DOI 10.1007/s10549-011-1945-9
   Ginno PA, 2013, GENOME RES, V23, P1590, DOI 10.1101/gr.158436.113
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Huh JI, 2005, ONCOGENE, V24, P790, DOI 10.1038/sj.onc.1208221
   Hunt BG, 2013, INTEGR COMP BIOL, V53, P319, DOI 10.1093/icb/ict003
   Ito Y, 2008, HUM MOL GENET, V17, P2633, DOI 10.1093/hmg/ddn163
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koester B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029889
   Koestler DC, 2013, EPIGENETICS-US, V8, P816, DOI 10.4161/epi.25430
   Konkel MK, 2010, SEMIN CANCER BIOL, V20, P211, DOI 10.1016/j.semcancer.2010.03.001
   Kulis M, 2013, BBA-GENE REGUL MECH, V1829, P1161, DOI 10.1016/j.bbagrm.2013.08.001
   Lança T, 2012, ONCOIMMUNOLOGY, V1, P717, DOI 10.4161/onci.20068
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Lu LG, 2012, BREAST CANCER RES TR, V136, P875, DOI 10.1007/s10549-012-2314-z
   Lucas S, 2012, INT J CANCER, V130, P1960, DOI 10.1002/ijc.26198
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901
   Muenst S, 2013, BREAST CANCER RES TR, V139, P667, DOI 10.1007/s10549-013-2581-3
   Murata H, 2005, CANCER LETT, V223, P143, DOI 10.1016/j.canlet.2004.09.039
   Ndlovu MN, 2011, TRENDS BIOCHEM SCI, V36, P381, DOI 10.1016/j.tibs.2011.03.002
   Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052299
   Östman A, 2009, CURR OPIN GENET DEV, V19, P67, DOI 10.1016/j.gde.2009.01.003
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Pakneshan P, 2005, CURR CANCER DRUG TAR, V5, P471, DOI 10.2174/156800905774574011
   Paredes J, 2005, CLIN CANCER RES, V11, P5869, DOI 10.1158/1078-0432.CCR-05-0059
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Pontiggia O, 2012, BREAST CANCER RES TR, V133, P459, DOI 10.1007/s10549-011-1766-x
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Reddington JP, 2013, BIOCHEM J, V451, P13, DOI 10.1042/BJ20121585
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Ross JP, 2010, EPIGENOMICS-UK, V2, P245, DOI 10.2217/EPI.10.2
   Schlesinger F, 2013, GENOME RES, V23, P1601, DOI 10.1101/gr.157271.113
   Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206
   Schmidt M, 2012, CLIN CANCER RES, V18, P2695, DOI 10.1158/1078-0432.CCR-11-2210
   Sehouli J, 2011, EPIGENETICS-US, V6, P236, DOI 10.4161/epi.6.2.13755
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Sharma G, 2010, CLIN BIOCHEM, V43, P373, DOI 10.1016/j.clinbiochem.2009.10.009
   Shekhar MPV, 2007, AM J PATHOL, V170, P1546, DOI 10.2353/ajpath.2007.061004
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Shetty Preetha J, 2011, Breast Dis, V33, P27, DOI 10.3233/BD-2010-0312
   Shetty PJ, 2011, J CANCER RES CLIN, V137, P339, DOI 10.1007/s00432-010-0890-z
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Sorensen AL, 2010, STEM CELLS DEV, V19, P1257, DOI 10.1089/scd.2009.0309
   Stone A, 2013, MOL CANCER THER, V12, P1874, DOI 10.1158/1535-7163.MCT-13-0012
   Swift-Scanlan T, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-5
   Taylor CR, 2006, HISTOPATHOLOGY, V49, P411, DOI 10.1111/j.1365-2559.2006.02513.x
   Tchou J, 2012, ADV PHARMACOL, V65, P45, DOI 10.1016/B978-0-12-397927-8.00003-8
   Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157
   Thomas RM, 2012, J BIOL CHEM, V287, P25049, DOI 10.1074/jbc.M112.351916
   van Hoesel AQ, 2012, BREAST CANCER RES TR, V134, P1103, DOI 10.1007/s10549-012-2038-0
   Vinson C, 2012, EPIGENOMICS-UK, V4, P655, DOI [10.2217/EPI.12.55, 10.2217/epi.12.55]
   Wang L, 2012, MOL MED REP, V6, P904, DOI 10.3892/mmr.2012.1001
   West NR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3072
   Whiteside TL, 2012, SEMIN CANCER BIOL, V22, P327, DOI 10.1016/j.semcancer.2012.03.004
   Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361
   Yamashita M, 2012, BREAST CANCER-TOKYO, V19, P170, DOI 10.1007/s12282-010-0234-5
   Yeo S, 2007, BIOCHEM BIOPH RES CO, V359, P536, DOI 10.1016/j.bbrc.2007.05.120
NR 108
TC 22
Z9 24
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD MAY
PY 2015
VL 282
IS 9
SI SI
BP 1801
EP 1814
DI 10.1111/febs.13125
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CH4TS
UT WOS:000354026400017
PM 25331982
OA Bronze
DA 2025-01-12
ER

PT J
AU Wen, HC
   Chuu, CP
   Chen, CY
   Shiah, SG
   Kung, HJ
   King, KL
   Su, LC
   Chang, SC
   Chang, CH
AF Wen, Hui-Chin
   Chuu, Chih-Pin
   Chen, Chen-Yu
   Shiah, Shine-Gwo
   Kung, Hsing-Jien
   King, Kuang-Liang
   Su, Liang-Chen
   Chang, Shi-Chuan
   Chang, Chung-Ho
TI Elevation of Soluble Guanylate Cyclase Suppresses Proliferation and
   Survival of Human Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID OXIDE SYNTHASE ACTIVITY; NITRIC-OXIDE; BRADYKININ RECEPTORS; EXPRESSION;
   EPIGENETICS; INHIBITOR; APOPTOSIS
AB Nitric oxide (NO) is an essential signaling molecule in biological systems. Soluble guanylate cyclase (sGC), composing of alpha 1 and beta 1 subunit, is the receptor for NO. Using radioimmunoassay, we discovered that activation of sGC by treatment with bradykinin or sodium nitroprusside (SNP) is impaired in MCF-7 and MDA-MB-231 breast cancer cells as compared to normal breast epithelial 184A1 cells. The 184A1 cells expressed both sGC alpha 1 and sGC beta 1 mRNAs. However, levels of sGC beta 1 mRNAs were relatively lower in MCF-7 cells while both mRNA of sGC subunits were absent in MDA-MB-231 cells. Treatment with DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine (5-aza-dC) increased mRNA levels of both sGC alpha 1 and sGC beta 1 in MDA-MB-231 cells but only sGC beta 1 mRNAs in MCF-7 cells. The 5-aza-dC treatment increased the SNP-induced cGMP production in MCF-7 and MDA-MB-231, but not in 184A1 cells. Bisulfite sequencing revealed that the promoter of sGCa1 in MDA-MB-231 cells and promoter of sGC beta 1 in MCF-7 cells were methylated. Promoter hypermethylation of sGC alpha 1 and sGC beta 1 was found in 1 out of 10 breast cancer patients. Over-expression of both sGC subunits in MDA-MB-231 cells induced apoptosis and growth inhibition in vitro as well as reduced tumor incidence and tumor growth rate of MDA-MB-231 xenografts in nude mice. Elevation of sGC reduced protein abundance of Bcl-2, Bcl-xL, Cdc2, Cdc25A, Cyclin B1, Cyclin D1, Cdk6, c-Myc, and Skp2 while increased protein expression of p53. Our study demonstrated that down-regulation of sGC, partially due to promoter methylation, provides growth and survival advantage in human breast cancer cells.
C1 [Wen, Hui-Chin; Chuu, Chih-Pin; Chen, Chen-Yu; Su, Liang-Chen; Chang, Chung-Ho] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan, Miaoli County, Taiwan.
   [Shiah, Shine-Gwo] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan, Miaoli County, Taiwan.
   [Kung, Hsing-Jien] Natl Hlth Res Inst, Inst Mol & Genom Med, Zhunan, Miaoli County, Taiwan.
   [King, Kuang-Liang] Taipei Vet Gen Hosp, Dept Surg, Div Gen Surg, Taipei, Taiwan.
   [Chang, Shi-Chuan] Taipei Vet Gen Hosp, Chest Dept, Taipei, Taiwan.
   [Chang, Shi-Chuan] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei 112, Taiwan.
   [Chang, Chung-Ho] China Med Univ, Grad Inst Basic Med Sci, PhD Program Aging, Taichung, Taiwan.
C3 National Health Research Institutes - Taiwan; National Health Research
   Institutes - Taiwan; National Health Research Institutes - Taiwan;
   Taipei Veterans General Hospital; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; China Medical University
   Taiwan
RP Chang, SC (通讯作者)，Taipei Vet Gen Hosp, Chest Dept, Taipei, Taiwan.
EM scchang@vghtpe.gov.tw; changch@nhri.org.tw
RI Shiah, Shine-Gwo/D-2087-2010; Chung, Chi-Hsiang/AAY-3386-2021; liu,
   yichen/GVT-6262-2022; Kung, Hsing-Jien/C-7651-2013; Chang,
   Chung-Ho/B-1068-2010; Chuu, Chih-Pin/N-6697-2019
FU National Health Research Institutes, Taiwan [CS-103-PP-03,
   CA-103-SP-01]; National Science Council, Taiwan [NSC
   95-2314-B-309-007-MY3, NSC 95-2314-B-309-003-MY3]; Ministry of Science
   and Technology, Taiwan [MOST 103-2325-B-400-001]; Micro-Western Array
   core facility, sequencing core facility, and cell sorting core facility
   of National Health Research Institutes
FX This study was supported by CS-103-PP-03 and CA-103-SP-01 (National
   Health Research Institutes, Taiwan) and NSC 95-2314-B-309-007-MY3 and
   NSC 95-2314-B-309-003-MY3 (National Science Council, Taiwan) for CHC;
   MOST 103-2325-B-400-001 (Ministry of Science and Technology, Taiwan) in
   Taiwan for CPC. The authors are thankful for the support from the
   Micro-Western Array core facility, sequencing core facility, and cell
   sorting core facility of National Health Research Institutes. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Akazawa Y, 2010, J HEPATOL, V52, P586, DOI 10.1016/j.jhep.2010.01.003
   ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203
   Blaukat A, 2003, ANDROLOGIA, V35, P17, DOI 10.1046/j.1439-0272.2003.00533.x
   BRAUGHLER JM, 1979, P NATL ACAD SCI USA, V76, P219, DOI 10.1073/pnas.76.1.219
   Cai J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095974
   Chen ZJ, 2004, HYPERTENSION, V44, P963, DOI 10.1161/01.HYP.0000145859.94894.23
   Chen ZJ, 2002, CANCER LETT, V177, P181, DOI 10.1016/S0304-3835(01)00788-1
   Chuu CP, 2012, CANCER PREV RES, V5, P788, DOI 10.1158/1940-6207.CAPR-12-0004-T
   Chuu CP, 2011, CANCER SCI, V102, P2022, DOI 10.1111/j.1349-7006.2011.02043.x
   Conran N, 2004, BRIT J HAEMATOL, V124, P547, DOI 10.1111/j.1365-2141.2004.04810.x
   Derbyshire ER, 2012, ANNU REV BIOCHEM, V81, P533, DOI 10.1146/annurev-biochem-050410-100030
   Fukumura D, 2006, NAT REV CANCER, V6, P521, DOI 10.1038/nrc1910
   GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Guh JH, 1998, MOL PHARMACOL, V53, P467, DOI 10.1124/mol.53.3.467
   Hall JM, 1997, GEN PHARMACOL, V28, P1, DOI 10.1016/S0306-3623(96)00174-7
   Haramis G, 2008, BRIT J PHARMACOL, V155, P804, DOI 10.1038/bjp.2008.312
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   IGNARRO LJ, 1982, P NATL ACAD SCI-BIOL, V79, P2870, DOI 10.1073/pnas.79.9.2870
   Jeannin JF, 2008, NITRIC OXIDE-BIOL CH, V19, P158, DOI 10.1016/j.niox.2008.04.024
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lin CY, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063936, 10.1371/journal.pone.0065734, 10.1371/journal.pone.0076885]
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MONCADA S, 1991, PHARMACOL REV, V43, P109
   Morbidelli L, 1996, AM J PHYSIOL-HEART C, V270, pH411, DOI 10.1152/ajpheart.1996.270.1.H411
   Moreau ME, 2005, J PHARMACOL SCI, V99, P6, DOI 10.1254/jphs.SRJ05001X
   Mujoo K, 2010, NITRIC OXIDE-BIOL CH, V22, P43, DOI 10.1016/j.niox.2009.11.007
   Murad F, 2006, NEW ENGL J MED, V355, P2003, DOI 10.1056/NEJMsa063904
   NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6
   Olson SY, 2008, NITRIC OXIDE-BIOL CH, V19, P170, DOI 10.1016/j.niox.2008.04.005
   Parrella P, 2010, BREAST CARE, V5, P66, DOI 10.1159/000309138
   Pervin S, 2008, NITRIC OXIDE-BIOL CH, V19, P103, DOI 10.1016/j.niox.2008.04.016
   Pervin S, 2010, CURR PHARM DESIGN, V16, P451, DOI 10.2174/138161210790232130
   Regoli D, 1996, REGUL PEPTIDES, V65, P83, DOI 10.1016/0167-0115(96)00076-6
   Sen S, 2013, FREE RADICAL BIO MED, V57, P210, DOI 10.1016/j.freeradbiomed.2012.10.545
   THOMSEN LL, 1995, BRIT J CANCER, V72, P41, DOI 10.1038/bjc.1995.274
   Tse GMK, 2005, J CLIN PATHOL, V58, P600, DOI 10.1136/jcp.2004.023028
   Vakkala M, 2000, CLIN CANCER RES, V6, P2408
   Vetter M, 2003, HYPERTENSION, V41, P1136, DOI 10.1161/01.HYP.0000068201.48340.3B
   Walter U., 1989, REV PHYSIOL BIOCH P, V113, P41
   Yang CM, 1999, CELL SIGNAL, V11, P853, DOI 10.1016/S0898-6568(99)00056-X
   Yang SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058100
NR 42
TC 36
Z9 38
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 30
PY 2015
VL 10
IS 4
AR e0125518
DI 10.1371/journal.pone.0125518
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CH0MA
UT WOS:000353713100096
PM 25928539
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Tang, D
   Sun, BM
   Yu, HY
   Yang, ZD
   Zhu, L
AF Tang, Dan
   Sun, Baomu
   Yu, Hongyu
   Yang, Zhengde
   Zhu, Liang
TI Tumor-Suppressing Effect of MiR-4458 on Human Hepatocellular Carcinoma
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE Hepatocellular carcinoma; Apoptosis; Micro-RNAs
ID MICRORNA EXPRESSION; HEPATITIS-B; CANCER; LIVER; TARGET; IDENTIFICATION;
   PROLIFERATION; PROGNOSIS; APOPTOSIS; DELIVERY
AB Background: Besides multiple genetic and epigenetic changes of protein coding genes in hepatocellular carcinoma (HCC), growing evidence indicate that deregulation of miRNAs contribute to HCC development by influencing cell growth, apoptosis, migration, or invasion. IKBKE is amplified and over-expressed in a large percentage of human breast tumors and identified as an oncogene of human breast tumor. Microarray analysis showed that miR-4458 was down-regulated in HCC tissues. Methods: The level of miR-4458 was up-regulated by miR-4458 mimics transfection, or down-regulated by miR-4458 ASO transfection. Cell proliferation was assayed by MTT analysis. MiRNAs and mRNA expression were assayed by qRT-PCR. These potential targeted genes of miR-4458 were predicted by bioinformatic algorithms. Dual luciferase reporter assay system was used to analyze the interaction between miR-4458 and IKBKE. IKBKE protein level was assayed by Western blot. The role of miR-4458 or IKBKE in the survival of HCC patients were revealed by Kaplan-Meier plot of overall survival. Results: Lower miR-4458 expression level or higher IKBKE level in HCC tissues correlated with worse prognosis of HCC patients. Overexpression of miR-4458 inhibited the HCC cells growth and vice versa. MiR-4458 played its role via targeting 3'UTR of IKBKE. Conclusions: MiR-4458 or IKBKE may be potential predictors of HCC prognosis. Restoration of miR-4458 or inhibition of IKBKE could be a prospective therapeutic approach for HCC. Copyright (C) 2015 S. Karger AG, Basel
C1 [Tang, Dan; Yang, Zhengde] Chinese PLA 89 Hosp, Dept Gastroenterol, Weifang, Peoples R China.
   [Sun, Baomu] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Integrated Chinese Tradit & Western Med, Shanghai 200003, Peoples R China.
   [Zhu, Liang] Second Mil Med Univ, Changzheng Hosp, Dept Gastroenterol, Shanghai 200003, Peoples R China.
   [Yu, Hongyu] Second Mil Med Univ, Changzheng Hosp, Dept Pathol, Shanghai 200003, Peoples R China.
C3 Naval Medical University; Naval Medical University; Naval Medical
   University
RP Zhu, L (通讯作者)，Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Gastroenterol, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
EM 13792670038@163.com; CZZHULIANG2013@126.com
CR Ahmed Faruque, 2008, Prev Chronic Dis, V5, pA74
   Alexiou P, 2010, NUCLEIC ACIDS RES, V38, pD137, DOI 10.1093/nar/gkp888
   Arbuthnot P, 2009, CURR GENE THER, V9, P91, DOI 10.2174/156652309787909517
   Bendoraite A, 2010, GYNECOL ONCOL, V116, P117, DOI 10.1016/j.ygyno.2009.08.009
   Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   Braconi C, 2008, HEPATOLOGY, V47, P1807, DOI 10.1002/hep.22326
   Budhu A, 2008, HEPATOLOGY, V47, P897, DOI 10.1002/hep.22160
   Coronnello C, 2013, NUCLEIC ACIDS RES, V41, pW159, DOI 10.1093/nar/gkt379
   Coulouarn C, 2009, ONCOGENE, V28, P3526, DOI 10.1038/onc.2009.211
   El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061
   Gramantieri L, 2007, CANCER RES, V67, P6092, DOI 10.1158/0008-5472.CAN-06-4607
   Gramantieri L, 2008, J CELL MOL MED, V12, P2189, DOI 10.1111/j.1582-4934.2008.00533.x
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Guo JP, 2011, J BIOL CHEM, V286, P37389, DOI 10.1074/jbc.M111.287433
   Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001
   Hou WM, 2014, ONCOL LETT, V8, P1249, DOI 10.3892/ol.2014.2253
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282
   Ji JF, 2009, HEPATOLOGY, V50, P472, DOI 10.1002/hep.22989
   John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264
   Kim SI, 2007, MOL THER, V15, P1145, DOI 10.1038/sj.mt.6300168
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li D, 2011, J BIOL CHEM, V286, P36677, DOI 10.1074/jbc.M111.270561
   Liu C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.161
   Liu C, 2011, LEUKEMIA, V25, P1516, DOI 10.1038/leu.2011.113
   Liu C, 2011, INT J BIOL SCI, V7, P221, DOI 10.7150/ijbs.7.221
   Llovet JM, 2005, J GASTROENTEROL, V40, P225, DOI 10.1007/s00535-005-1566-3
   Lu J, 2013, EPIGENETICS-US, V8, P571, DOI 10.4161/epi.24626
   Ma QP, 2013, INT J BIOL SCI, V9, P680, DOI 10.7150/ijbs.6623
   Megraw M, 2007, NUCLEIC ACIDS RES, V35, pD149, DOI 10.1093/nar/gkl904
   Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283
   Murakami Y, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-99
   Nishina K, 2008, MOL THER, V16, P734, DOI 10.1038/mt.2008.14
   Song GS, 2010, HEPATOLOGY, V51, P1735, DOI 10.1002/hep.23547
   Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886
   Ura S, 2009, HEPATOLOGY, V49, P1098, DOI 10.1002/hep.22749
   Wang B, 2009, HEPATOLOGY, V50, P1152, DOI 10.1002/hep.23100
   Wang G, 2015, GENET TEST MOL BIOMA, V19, P30, DOI 10.1089/gtmb.2014.0245
   Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200
   Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666
   Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380
   Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919
   Yin JH, 2013, J CLIN ONCOL, V31, P3647, DOI 10.1200/JCO.2012.48.5896
   Zhou BR, 2013, INT J BIOL SCI, V9, P743, DOI 10.7150/ijbs.5345
NR 48
TC 28
Z9 31
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 35
IS 5
BP 1797
EP 1807
DI 10.1159/000373991
PG 11
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CH0MG
UT WOS:000353713900012
PM 25833000
OA gold
DA 2025-01-12
ER

PT J
AU Roessler, J
   Ammerpohl, O
   Gutwein, J
   Steinemann, D
   Schlegelberger, B
   Weyer, V
   Sariyar, M
   Geffers, R
   Arnold, N
   Schmutzler, R
   Bartram, CR
   Heinrich, T
   Abbas, M
   Antonopoulos, W
   Schipper, E
   Hasemeier, B
   Kreipe, H
   Lehmann, U
AF Roessler, Jessica
   Ammerpohl, Ole
   Gutwein, Jana
   Steinemann, Doris
   Schlegelberger, Brigitte
   Weyer, Veronika
   Sariyar, Murat
   Geffers, Robert
   Arnold, Norbert
   Schmutzler, Rita
   Bartram, Claus R.
   Heinrich, Tilman
   Abbas, Mahmoud
   Antonopoulos, Wiebke
   Schipper, Elisa
   Hasemeier, Britta
   Kreipe, Hans
   Lehmann, Ulrich
TI The CpG island methylator phenotype in breast cancer is associated with
   the lobular subtype
SO EPIGENOMICS
LA English
DT Article
DE breast cancer; CpG island methylator phenotype; DNA methylation;
   epigenetics; lobular breast cancer
ID DNA METHYLATION; EPIGENETIC INACTIVATION; IDH2 MUTATIONS; CELL-LINE;
   IN-SITU; CARCINOMA; GENES; HYPERMETHYLATION; ARRAY; EXPRESSION
AB Background: Aberrations in DNA methylation patterns are well-described in human malignancies. However, the existence of the 'CpG island methylator phenotype' (CIMP) in human breast cancer is still controversial. Materials & methods: Illumina's HumanMethylation 450K BeadChip was used to analyze genome-wide DNA methylation patterns. Chromosomal abnormalities were determined by array-based CGH. Results: Invasive lobular breast carcinomas exhibit the highest number of differentially methylated CpG sites and a strong inverse correlation of aberrant DNA hypermethylation and copy number alterations. Nine differentially methylated regions within seven genes discriminating the investigated subgroups were identified and validated in an independent validation cohort and correlated to a better relapse-free survival. Conclusion: These results depict a clear difference between genetically and epigenetically unstable breast carcinomas indicating different ways of tumor progression and/or initiation, which strongly supports the association of CIMP with the lobular subtype and provide new options for detection and therapy.
C1 [Roessler, Jessica; Abbas, Mahmoud; Antonopoulos, Wiebke; Schipper, Elisa; Hasemeier, Britta; Kreipe, Hans; Lehmann, Ulrich] Hannover Med Sch, Inst Pathol, D-30625 Hannover, Germany.
   [Ammerpohl, Ole; Gutwein, Jana] Univ Kiel, Inst Human Genet, Kiel, Germany.
   [Ammerpohl, Ole; Gutwein, Jana; Arnold, Norbert] Univ Hosp Schleswig Holstein, Kiel, Germany.
   [Steinemann, Doris; Schlegelberger, Brigitte] Med Sch Hanover, Inst Human Genet, Hannover, NH, Germany.
   [Weyer, Veronika; Sariyar, Murat] Johannes Gutenberg Univ Mainz, Med Ctr, Inst Med Biostat Epidemiol & Informat, D-55122 Mainz, Germany.
   [Sariyar, Murat] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany.
   [Geffers, Robert] Helmholtz Ctr Infect Res, Inst Genome Analyt, Braunschweig, Germany.
   [Arnold, Norbert] Univ Kiel, Dept Gynecol & Obstet, Kiel, Germany.
   [Schmutzler, Rita] Univ Cologne, Dept Gynecol & Obstet, CIO, Ctr Familial Breast & Ovarian Canc, D-50931 Cologne, Germany.
   [Bartram, Claus R.] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany.
   [Heinrich, Tilman] Univ Wurzburg, Dept Human Genet, Bioctr, Wurzburg, Germany.
C3 Hannover Medical School; University of Kiel; University of Kiel;
   Schleswig Holstein University Hospital; Johannes Gutenberg University of
   Mainz; Berlin Institute of Health; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz
   Association; Helmholtz-Center for Infection Research; University of
   Kiel; University of Cologne; Ruprecht Karls University Heidelberg;
   University of Wurzburg
RP Lehmann, U (通讯作者)，Hannover Med Sch, Inst Pathol, Carl Neuber Str 1, D-30625 Hannover, Germany.
EM lehmann.ulrich@mh-hannover.de
RI Ammerpohl, Ole/G-2691-2010; Arnold, Norbert/E-3012-2010; Weyer-Elberich,
   Veronika/AAB-8993-2020
OI Abbas, Mahmoud/0000-0002-1025-9089
FU Lower Saxony Israel foundation
FX This study was funded in part by the Lower Saxony Israel foundation. The
   authors have no other relevant affiliations or financial involvement
   with any organization or entity with a financial interest in or
   financial conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Ackland ML, 2001, EXP CELL RES, V263, P14, DOI 10.1006/excr.2000.5106
   Anwar SL, 2013, INT J CANCER, V133, P660, DOI 10.1002/ijc.28068
   Arps DP, 2013, BREAST CANCER RES TR, V138, P719, DOI 10.1007/s10549-013-2493-2
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bertucci F, 2008, ONCOGENE, V27, P5359, DOI 10.1038/onc.2008.158
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Chen XM, 2013, LIVER INT, V33, P476, DOI 10.1111/liv.12097
   Chen XD, 2012, INT J CANCER, V130, P1607, DOI 10.1002/ijc.26171
   Christgen M, 2009, J PATHOL, V217, P620, DOI 10.1002/path.2495
   Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658
   Coppersmith D, 1999, DATA MIN KNOWL DISC, V3, P197, DOI 10.1023/A:1009869804967
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015
   Fleischer T, 2014, GENOME BIOL, V15, DOI [10.1186/s13059-014-0435-x, 10.1186/PREACCEPT-2333349012841587]
   Ghayad SE, 2009, J MOL ENDOCRINOL, V42, P87, DOI 10.1677/JME-08-0076
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Ha GH, 2013, CANCER LETT, V336, P24, DOI 10.1016/j.canlet.2013.04.022
   Hagiwara K, 2012, GENE CHROMOSOME CANC, V51, P1024, DOI 10.1002/gcc.21985
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Horlings HM, 2013, BREAST CANCER RES TR, V142, P257, DOI 10.1007/s10549-013-2740-6
   Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499
   Hughes LAE, 2013, CANCER RES, V73, P5858, DOI 10.1158/0008-5472.CAN-12-4306
   Hughes LAE, 2012, BBA-REV CANCER, V1825, P77, DOI 10.1016/j.bbcan.2011.10.005
   Huiping C, 1999, BRIT J CANCER, V81, P1103, DOI 10.1038/sj.bjc.6690815
   Inokawa Y, 2013, ONCOTARGETS THER, V6, P1417, DOI 10.2147/OTT.S51913
   Jönsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Kang M, 2013, INT J MOL MED, V32, P51, DOI 10.3892/ijmm.2013.1384
   Kilaru V, 2012, EPIGENETICS-US, V7, P225, DOI 10.4161/epi.7.3.19284
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kozlowska J, 2012, TUMOR BIOL, V33, P1015, DOI 10.1007/s13277-012-0334-2
   Krop I, 2003, CANCER RES, V63, P2024
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lehmann U, 2002, CANCER RES, V62, P6634
   Li CI, 2005, BRIT J CANCER, V93, P1046, DOI 10.1038/sj.bjc.6602787
   Loman N, 2001, JNCI-J NATL CANCER I, V93, P1215, DOI 10.1093/jnci/93.16.1215
   Lu CY, 2013, GENE CHROMOSOME CANC, V52, P636, DOI 10.1002/gcc.22059
   Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.3.CO;2-X
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004
   Petrova DT, 2008, CLIN BIOCHEM, V41, P1224, DOI 10.1016/j.clinbiochem.2008.07.012
   Ponder BAJ, 2000, BRIT J CANCER, V83, P1301
   Rauch T, 2006, CANCER RES, V66, P7939, DOI 10.1158/0008-5472.CAN-06-1888
   Ricketts CJ, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-16
   Roessler Jessica, 2012, BMC Res Notes, V5, P210, DOI 10.1186/1756-0500-5-210
   Shen CY, 2000, CANCER RES, V60, P3884
   Shih HA, 2002, J CLIN ONCOL, V20, P994, DOI 10.1200/JCO.20.4.994
   Takagi D, 2013, CANCER SCI, V104, P563, DOI 10.1111/cas.12115
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Van der Auwera I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012616
   Waddell N, 2010, BREAST CANCER RES TR, V123, P661, DOI 10.1007/s10549-009-0653-1
   Wang D, 2012, BIOINFORMATICS, V28, P729, DOI 10.1093/bioinformatics/bts013
   Wessels LFA, 2002, CANCER RES, V62, P7110
   WHITEHEAD RH, 1983, JNCI-J NATL CANCER I, V70, P649
   Wong KY, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-16
   Yerushalmi R, 2009, ANN ONCOL, V20, P1763, DOI 10.1093/annonc/mdp245
   Yu XC, 2013, GENE, V532, P87, DOI 10.1016/j.gene.2013.09.048
NR 67
TC 24
Z9 25
U1 1
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PY 2015
VL 7
IS 2
BP 187
EP 199
DI 10.2217/EPI.14.74
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CH5TF
UT WOS:000354097500007
PM 25347269
OA hybrid
DA 2025-01-12
ER

PT J
AU Cappetta, M
   Berdasco, M
   Hochmann, J
   Bonilla, C
   Sans, M
   Hidalgo, PC
   Artagaveytia, N
   Kittles, R
   Martínez, M
   Esteller, M
   Bertoni, B
AF Cappetta, Monica
   Berdasco, Maria
   Hochmann, Jimena
   Bonilla, Carolina
   Sans, Monica
   Hidalgo, Pedro C.
   Artagaveytia, Nora
   Kittles, Rick
   Martinez, Miguel
   Esteller, Manel
   Bertoni, Bernardo
TI Effect of genetic ancestry on leukocyte global DNA methylation in cancer
   patients
SO BMC CANCER
LA English
DT Article
DE Genetic ancestry; DNA methylation; Admixture; Cancer
ID PERIPHERAL-BLOOD; RISK; HYPOMETHYLATION; ASSOCIATION; BIOMARKER;
   MELANOMA; ORIGINS
AB Background: The study of genetic variants alone is not enough to explain a complex disease like cancer. Alterations in DNA methylation patterns have been associated with different types of tumor. In order to detect markers of susceptibility for the development of cutaneous melanoma and breast cancer in the Uruguayan population, we integrated genetic and epigenetic information of patients and controls.
   Methods: We performed two case-control studies that included 49 individuals with sporadic cutaneous melanoma and 73 unaffected controls, and 179 women with sporadic breast cancer and 209 women controls. We determined the level of global leukocyte DNA methylation using relative quantification of 5mdC by HPLC, and we compared methylation levels between cases and controls with nonparametric statistical tests. Since the Uruguayan population is admixed and both melanoma and breast cancer have very high incidences in Uruguay compared to other populations, we examined whether individual ancestry influences global leucocyte DNA methylation status. We carried out a correlation analysis between the percentage of African, European and Native American individual ancestries, determined using 59 ancestry informative markers, and global DNA methylation in all participants.
   Results: We detected global DNA hypomethylation in leukocytes of melanoma and breast cancer patients compared with healthy controls (p < 0.001). Additionally, we found a negative correlation between African ancestry and global DNA methylation in cancer patients (p < 0.005).
   Conclusions: These results support the potential use of global DNA methylation as a biomarker for cancer risk. In addition, our findings suggest that the ancestral genome structure generated by the admixture process influences DNA methylation patterns, and underscore the importance of considering genetic ancestry as a modifying factor in epigenetic association studies in admixed populations such as Latino ones.
C1 [Cappetta, Monica; Hochmann, Jimena; Bertoni, Bernardo] Univ Republica, Fac Med, Dept Genet, Montevideo, Uruguay.
   [Berdasco, Maria; Esteller, Manel] Hosp LLobregat, Bellvitge Biomed Res Inst IDIBELL, Cancer Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
   [Bonilla, Carolina] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England.
   [Sans, Monica; Hidalgo, Pedro C.] Univ Republica, Fac Humanidades & Ciencias Educ, Dept Biol Anthropol, Montevideo, Uruguay.
   [Hidalgo, Pedro C.] Univ Republ, Ctr Univ Tacuarembo, Tacuarembo, Uruguay.
   [Artagaveytia, Nora] Univ Republica, Fac Med, Dept Basico Med, Montevideo, Uruguay.
   [Kittles, Rick] Univ Arizona, Dept Surg & Publ Hlth, Tucson, AZ USA.
   [Martinez, Miguel] Univ Republica, Hosp Clin Manuel Quintela, Catedra Dermatol, Montevideo, Uruguay.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain.
   [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain.
C3 Universidad de la Republica, Uruguay; Institut d'Investigacio Biomedica
   de Bellvitge (IDIBELL); University of Barcelona; University of Bristol;
   Universidad de la Republica, Uruguay; Universidad de la Republica,
   Uruguay; Universidad de la Republica, Uruguay; University of Arizona;
   Universidad de la Republica, Uruguay; University of Barcelona; ICREA
RP Bertoni, B (通讯作者)，Univ Republica, Fac Med, Dept Genet, Montevideo, Uruguay.
EM bbertoni@fmed.edu.uy
RI Cappetta, Mónica/H-4154-2019; Hidalgo, Pedro/L-4632-2014; Bonilla,
   Carolina/U-9263-2018; Esteller, Manel/L-5956-2014
OI Bonilla, Carolina/0000-0002-9972-6383; Cappetta,
   Monica/0000-0003-2015-0156; Esteller, Manel/0000-0003-4490-6093;
   Bertoni, Bernardo/0000-0002-9418-2911
FU Comision Honoraria de Lucha contra el Cancer (CHLCC); Comision Sectorial
   de Investigacion Cientifica (CSIC-UDELAR); Programa de Desarrollo de las
   Ciencias Basicas (PEDECIBA); ICREA Funding Source: Custom
FX This work was supported by Comision Honoraria de Lucha contra el Cancer
   (CHLCC), Comision Sectorial de Investigacion Cientifica (CSIC-UDELAR)
   and Programa de Desarrollo de las Ciencias Basicas (PEDECIBA).
CR Adkins RM, 2011, BIRTH DEFECTS RES A, V91, P728, DOI 10.1002/bdra.20770
   Altshuler DM, 2010, NATURE, V467, P52, DOI 10.1038/nature09298
   [Anonymous], INT J HUM GENET, DOI DOI 10.1080/09723757.2005.11885929
   [Anonymous], MELANOMA RES S1
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Berdasco Maria, 2009, V507, P23, DOI 10.1007/978-1-59745-522-0_2
   Bonilla C, 2015, BMC WOMENS HEALTH, V15, DOI 10.1186/s12905-015-0171-8
   Breiman L, 1984, Classification and Regression Trees
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Das PM, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-28
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Falush D, 2007, MOL ECOL NOTES, V7, P574, DOI 10.1111/j.1471-8286.2007.01758.x
   Fejerman L, 2012, HUM MOL GENET, V21, P1907, DOI 10.1093/hmg/ddr617
   Fejerman L, 2010, CANCER EPIDEM BIOMAR, V19, P1074, DOI 10.1158/1055-9965.EPI-09-1193
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Fraser HB, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-2-r8
   Fuke C, 2004, ANN HUM GENET, V68, P196, DOI 10.1046/j.1529-8817.2004.00081.x
   Garbe C, 2009, CLIN DERMATOL, V27, P3, DOI 10.1016/j.clindermatol.2008.09.001
   Gibbs JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000952
   Heyn H, 2013, GENOME RES, V23, P1363, DOI 10.1101/gr.154187.112
   Hyland PL, 2013, MELANOMA RES, V23, P55, DOI 10.1097/CMR.0b013e32835adc51
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kok RM, 2007, CLIN CHEM LAB MED, V45, P903, DOI 10.1515/CCLM.2007.137
   Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717
   Li L, 2012, J EPIDEMIOL, V22, P384, DOI 10.2188/jea.JE20120003
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Luiz OC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036348
   Ma HM, 2009, EUR J MASS SPECTROM, V15, P555, DOI 10.1255/ejms.1007
   Mohammed Sulma I, 2012, Methods Mol Biol, V863, P395, DOI 10.1007/978-1-61779-612-8_25
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Raats M. M., 1992, Food Quality and Preference, V3, P89, DOI 10.1016/0950-3293(91)90028-D
   Sans M, 1997, HUM BIOL, V69, P161
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Wang SP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037928
   Winkler CA, 2010, ANNU REV GENOM HUM G, V11, P65, DOI 10.1146/annurev-genom-082509-141523
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Zhang DD, 2010, AM J HUM GENET, V86, P411, DOI 10.1016/j.ajhg.2010.02.005
   Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
   Zhu ZZ, 2011, CANCER CAUSE CONTROL, V22, P437, DOI 10.1007/s10552-010-9715-2
NR 43
TC 21
Z9 20
U1 1
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 27
PY 2015
VL 15
AR 434
DI 10.1186/s12885-015-1461-0
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CJ0LZ
UT WOS:000355169000004
PM 26012346
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pangeni, RP
   Channathodiyil, P
   Huen, DS
   Eagles, LW
   Johal, BK
   Pasha, D
   Hadjistephanou, N
   Nevell, O
   Davies, CL
   Adewumi, AI
   Khanom, H
   Samra, IS
   Buzatto, VC
   Chandrasekaran, P
   Shinawi, T
   Dawson, TP
   Ashton, KM
   Davis, C
   Brodbelt, AR
   Jenkinson, MD
   Bièche, I
   Latif, F
   Darling, JL
   Warr, TJ
   Morris, MR
AF Pangeni, Rajendra P.
   Channathodiyil, Prasanna
   Huen, David S.
   Eagles, Lawrence W.
   Johal, Balraj K.
   Pasha, Dawar
   Hadjistephanou, Natasa
   Nevell, Oliver
   Davies, Claire L.
   Adewumi, Ayobami I.
   Khanom, Hamida
   Samra, Ikroop S.
   Buzatto, Vanessa C.
   Chandrasekaran, Preethi
   Shinawi, Thoraia
   Dawson, Timothy P.
   Ashton, Katherine M.
   Davis, Charles
   Brodbelt, Andrew R.
   Jenkinson, Michael D.
   Bieche, Ivan
   Latif, Farida
   Darling, John L.
   Warr, Tracy J.
   Morris, Mark R.
TI The <i>GALNT9</i>, <i>BNC1</i> and <i>CCDC8</i> genes are frequently
   epigenetically dysregulated in breast tumours that metastasise to the
   brain
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Breast; Brain; Metastasis; DNA methylation; Epigenetic; Tumour
   suppressor
ID CARCINOMA IN-SITU; CANCER METASTASIS; INDEPENDENT GROWTH; EXPRESSION
   PATTERN; PROSTATE-CANCER; MUC1 EMA; CELLS; IDENTIFICATION; METHYLATION;
   BASONUCLIN
AB Background: Tumour metastasis to the brain is a common and deadly development in certain cancers; 18-30 % of breast tumours metastasise to the brain. The contribution that gene silencing through epigenetic mechanisms plays in these metastatic tumours is not well understood.
   Results: We have carried out a bioinformatic screen of genome-wide breast tumour methylation data available at The Cancer Genome Atlas (TCGA) and a broad literature review to identify candidate genes that may contribute to breast to brain metastasis (BBM). This analysis identified 82 candidates. We investigated the methylation status of these genes using Combined Bisulfite and Restriction Analysis (CoBRA) and identified 21 genes frequently methylated in BBM. We have identified three genes, GALNT9, CCDC8 and BNC1, that were frequently methylated (55, 73 and 71 %, respectively) and silenced in BBM and infrequently methylated in primary breast tumours. CCDC8 was commonly methylated in brain metastases and their associated primary tumours whereas GALNT9 and BNC1 were methylated and silenced only in brain metastases, but not in the associated primary breast tumours from individual patients. This suggests differing roles for these genes in the evolution of metastatic tumours; CCDC8 methylation occurs at an early stage of metastatic evolution whereas methylation of GANLT9 and BNC1 occurs at a later stage of tumour evolution. Knockdown of these genes by RNAi resulted in a significant increase in the migratory and invasive potential of breast cancer cell lines.
   Conclusions: These findings indicate that GALNT9 (an initiator of O-glycosylation), CCDC8 (a regulator of microtubule dynamics) and BNC1 (a transcription factor with a broad range of targets) may play a role in the progression of primary breast tumours to brain metastases. These genes may be useful as prognostic markers and their products may provide novel therapeutic targets.
C1 [Pangeni, Rajendra P.; Channathodiyil, Prasanna; Eagles, Lawrence W.; Darling, John L.; Warr, Tracy J.; Morris, Mark R.] Wolverhampton Univ, Brain Tumour Res Ctr, Wolverhampton WV1 1DJ, W Midlands, England.
   [Huen, David S.; Johal, Balraj K.; Pasha, Dawar; Hadjistephanou, Natasa; Nevell, Oliver; Davies, Claire L.; Adewumi, Ayobami I.; Khanom, Hamida; Samra, Ikroop S.; Buzatto, Vanessa C.; Chandrasekaran, Preethi] Wolverhampton Univ, Sch Biol Chem & Forens Sci, Wolverhampton WV1 1DJ, W Midlands, England.
   [Shinawi, Thoraia] Univ Birmingham, Ctr Rare Dis & Personalised Med, Sch Clin & Expt Med, Birmingham, W Midlands, England.
   [Dawson, Timothy P.; Ashton, Katherine M.; Davis, Charles] Royal Preston Hosp, Lancashire Teaching Hosp NHS Fdn Trust, Dept Neurosci, Preston, Lancs, England.
   [Brodbelt, Andrew R.; Jenkinson, Michael D.] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England.
   [Bieche, Ivan] Inst Curie, Dept Genet, Paris, France.
C3 University of Wolverhampton; University of Wolverhampton; University of
   Birmingham; Royal Preston Hospital; Walton Centre; UNICANCER; Universite
   PSL; Institut Curie
RP Morris, MR (通讯作者)，Wolverhampton Univ, Brain Tumour Res Ctr, Wolverhampton WV1 1DJ, W Midlands, England.
EM morrismr@wlv.ac.uk
RI Wen, Patrick/AAE-3776-2022; Morris, Mark/C-6413-2008; Huen,
   David/F-3676-2014; Bieche, Ivan/O-7399-2017
OI Davies, Claire/0000-0002-5735-944X; Huen, David/0000-0002-9900-2297;
   Shinawi, Thoraia/0000-0003-4429-8040; Bieche, Ivan/0000-0002-2430-5429;
   Morris, Mark/0000-0002-0700-355X; Jenkinson, Michael/0000-0003-4587-2139
FU Sidney Driscol Neuroscience Foundation
FX We would like to thank the Sidney Driscol Neuroscience Foundation for
   supporting this research by funding the BTNW research tissue bank.
CR Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Akira S, 2000, ONCOGENE, V19, P2607, DOI 10.1038/sj.onc.1203478
   Berois N, 2013, CLIN CHEM, V59, P225, DOI 10.1373/clinchem.2012.192328
   Bragulla HH, 2009, J ANAT, V214, P516, DOI 10.1111/j.1469-7580.2009.01066.x
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Brockhausen I, 2006, EMBO REP, V7, P599, DOI 10.1038/sj.embor.7400705
   Burstein HJ, 2012, J CLIN ONCOL, V30, P684, DOI 10.1200/JCO.2011.40.1455
   Carrio M, 2005, CANCER RES, V65, P7177, DOI 10.1158/0008-5472.CAN-04-1717
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chen JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080266
   Chen YM, 2004, J CEREBR BLOOD F MET, V24, P1280, DOI 10.1097/01.WCB.0000141770.09022.AB
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Cock-Rada A, 2013, BIOL CELL, V105, P73, DOI 10.1111/boc.201200029
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   de Roos MAJ, 2007, HISTOPATHOLOGY, V51, P227, DOI 10.1111/j.1365-2559.2007.02754.x
   Devaney JM, 2013, PROSTATE CANCER P D, V16, P292, DOI 10.1038/pcan.2013.21
   Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752
   Eichler AF, 2011, NAT REV CLIN ONCOL, V8, P344, DOI 10.1038/nrclinonc.2011.58
   Feuerborn A, ONCOGENE
   Gavrilovic IT, 2005, J NEURO-ONCOL, V75, P5, DOI 10.1007/s11060-004-8093-6
   Ghosh SK, 2013, CLIN BREAST CANCER, V13, P109, DOI 10.1016/j.clbc.2012.09.016
   Gori S, 2007, ONCOLOGIST, V12, P766, DOI 10.1634/theoncologist.12-7-766
   Guo LX, 2011, AM J PATHOL, V178, P2357, DOI 10.1016/j.ajpath.2011.01.047
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022
   Hanson D, 2011, AM J HUM GENET, V89, P148, DOI 10.1016/j.ajhg.2011.05.028
   HAYES DF, 1991, J CLIN ONCOL, V9, P1113, DOI 10.1200/JCO.1991.9.7.1113
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hill VK, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-51
   Huber C, 2005, NAT GENET, V37, P1119, DOI 10.1038/ng1628
   Huber C, 2011, BEST PRACT RES CL EN, V25, P143, DOI 10.1016/j.beem.2010.08.015
   Huber C, 2009, EUR J HUM GENET, V17, P395, DOI 10.1038/ejhg.2008.200
   Jenkinson MD, 2011, EUR J CANCER, V47, P649, DOI 10.1016/j.ejca.2010.11.033
   Jin LJ, 2013, CANCER RES, V73, P2884, DOI 10.1158/0008-5472.CAN-12-2162
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kennecke HF, 2007, ANN ONCOL, V18, P45, DOI 10.1093/annonc/mdl334
   Kim YR, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-124
   Klein CA, 2003, ADV CANCER RES, V89, P35, DOI 10.1016/S0065-230X(03)01002-9
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Li X, 2012, GLYCOBIOLOGY, V22, P602, DOI 10.1093/glycob/cwr179
   Li Z, MOL CELL
   Lim E, 2012, ONCOLOGY-NY, V26, P688
   Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82
   Ma J, 2006, DEVELOPMENT, V133, P2053, DOI 10.1242/dev.02371
   Magin TM, 2007, EXP CELL RES, V313, P2021, DOI 10.1016/j.yexcr.2007.03.005
   Majid S, 2012, CANCER RES, V72, P6435, DOI 10.1158/0008-5472.CAN-12-2181
   Maksimova N, 2007, J MED GENET, V44, P772, DOI 10.1136/jmg.2007.051979
   Metzger O, 2011, CRIT REV ONCOL HEMAT, V77, P21, DOI 10.1016/j.critrevonc.2010.01.011
   MILLER R, 1982, BIOMETRICS, V38, P1011, DOI 10.2307/2529881
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mizuno H, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-18
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Mundy GR, 2002, NAT REV CANCER, V2, P584, DOI 10.1038/nrc867
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048
   Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x
   Osler ME, 2006, DEV DYNAM, V235, P586, DOI 10.1002/dvdy.20688
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Pantel K, 2008, NAT REV CANCER, V8, P329, DOI 10.1038/nrc2375
   Park BK, 2007, NAT MED, V13, P62, DOI 10.1038/nm1519
   Patra SK, 2009, BIOCHEMISTRY-MOSCOW+, V74, P613, DOI 10.1134/S0006297909060042
   Pellegrino L, 2013, NUCLEIC ACIDS RES, V41, P5400, DOI 10.1093/nar/gkt245
   PEREY L, 1992, CANCER RES, V52, P6365
   Raman J, 2012, GLYCOBIOLOGY, V22, P768, DOI 10.1093/glycob/cwr183
   ROSEN H, 1995, MOL ENDOCRINOL, V9, P1621, DOI 10.1210/me.9.11.1621
   Ryberg M, 2005, BREAST CANCER RES TR, V91, P217, DOI 10.1007/s10549-005-0323-x
   Safran M, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq020
   Sanna G, 2007, ANTICANCER RES, V27, P2865
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Shimomura Y, 2010, J INVEST DERMATOL, V130, P892, DOI 10.1038/jid.2009.341
   Shinya Toba MT, 2000, BIOCHIM BIOPHYS ACTA, V1493, P264
   Soffietti R, 2002, J NEUROL, V249, P1357, DOI 10.1007/s00415-002-0870-6
   Soffietti R, 2008, CURR OPIN ONCOL, V20, P676, DOI 10.1097/CCO.0b013e32831186fe
   Sperduto PW, 2010, INT J RADIAT ONCOL, V77, P655, DOI 10.1016/j.ijrobp.2009.08.025
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Strehl S, 1998, GENOMICS, V53, P81, DOI 10.1006/geno.1998.5467
   SUGARBAKER ED, 1952, CANCER, V5, P606, DOI 10.1002/1097-0142(195205)5:3<606::AID-CNCR2820050324>3.0.CO;2-U
   Symmans W F., 2010, Breast Cancer Research, DOI DOI 10.1186/BCR2489
   Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801
   Tosoni A, 2008, CRIT REV ONCOL HEMAT, V68, P212, DOI 10.1016/j.critrevonc.2008.04.004
   Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x
   Tuupanen S, 2014, BRIT J CANCER, V111, P1657, DOI 10.1038/bjc.2014.429
   van der Vegt B, 2007, HISTOPATHOLOGY, V51, P322, DOI 10.1111/j.1365-2559.2007.02757.x
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Veeck J, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-217
   Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8
   Wang JW, 2006, BIOCHEM BIOPH RES CO, V348, P1261, DOI 10.1016/j.bbrc.2006.07.198
   Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Weil RJ, 2005, AM J PATHOL, V167, P913, DOI 10.1016/S0002-9440(10)61180-7
   Yan J, 2014, MOL CELL, V54, P791, DOI 10.1016/j.molcel.2014.03.047
   Yi JM, 2013, CLIN CANCER RES, V19, P6544, DOI 10.1158/1078-0432.CCR-12-3224
   Zaman MS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050203
   Zhang SL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000902
   Zhang XHF, 2013, CLIN CANCER RES, V19, P6389, DOI 10.1158/1078-0432.CCR-13-0838
   Zhang Y, 2003, J BIOL CHEM, V278, P573, DOI 10.1074/jbc.M203094200
NR 103
TC 72
Z9 78
U1 1
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD MAY 27
PY 2015
VL 7
AR 57
DI 10.1186/s13148-015-0089-x
PG 17
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CK2JI
UT WOS:000356036200001
PM 26052355
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Shilpi, A
   Parbin, S
   Sengupta, D
   Kar, S
   Deb, M
   Rath, SK
   Pradhan, N
   Rakshit, M
   Patra, SK
AF Shilpi, Arunima
   Parbin, Sabnam
   Sengupta, Dipta
   Kar, Swayamsiddha
   Deb, Moonmoon
   Rath, Sandip Kumar
   Pradhan, Nibedita
   Rakshit, Madhumita
   Patra, Samir Kumar
TI Mechanisms of DNA methyltransferase-inhibitor interactions: Procyanidin
   B2 shows new promise for therapeutic intervention of cancer
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE DNA methyltransferases; Cancer; Procyanidin B2; Molecular docking;
   Simulation; DNMT activity assay
ID HIGH-THROUGHPUT; HUMAN BREAST; METHYLATION; DOCKING; DISCOVERY;
   PATHWAYS; LIGAND
AB DNA methyltransferases (DNMTs) is a key epigenetic enzyme for pharmacological manipulation and is employed in cancer reprogramming. During past few years multiple strategies have been implemented to excavate epigenetic compounds targeting DNMTs. In light of the emerging concept of chemoinformatics, molecular docking and simulation studies have been employed to accelerate the development of DNMT inhibitors. Among the DNMT inhibitors known till date, epigallocathechin-3-gallate (EGCG) was identified to be effective in reducing DNMT activity. However, the broad spectrum of EGCG to other diseases and variable target enzymes offers some limitations. In view of this, 32 EGCG analogues were screened at S-Adnosyl-L-homocysteine (SAH) binding pocket of DNMTs and procyanidin B2-3, 3'-di-O-gallate (procyanidin B2) was obtained as potent inhibitor having medicinally relevant chemical space. Further, in vitro analysis demonstrates the efficiency of procyanidin B2 in attenuating DNMT activity at IC50 of 6.88 +/- 0.647 mu M and subsequently enhancing the expression of DNMT target genes, E-cadherin, Maspin and BRCA1. Moreover, the toxic property of procyanidin B2 towards triple negative breast cancer cells to normal cells offers platform for pre-clinical trial and an insight to the treatment of cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Shilpi, Arunima; Parbin, Sabnam; Sengupta, Dipta; Kar, Swayamsiddha; Deb, Moonmoon; Rath, Sandip Kumar; Pradhan, Nibedita; Rakshit, Madhumita; Patra, Samir Kumar] Natl Inst Technol, Dept Life Sci, Biochem & Mol Biol Grp, Epigenet & Canc Res Lab, Rourkela 769008, Odisha, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Rourkela
RP Patra, SK (通讯作者)，Natl Inst Technol, Dept Life Sci, Biochem & Mol Biol Grp, Epigenet & Canc Res Lab, Rourkela 769008, Odisha, India.
EM samirp@nitrkl.ac.in
RI Shilpi, Arunima/AAF-7221-2019; rath, sandip/ABB-9460-2021; PATRA,
   Samir/AAS-6639-2020; Sengupta, Dipta/H-3707-2019
OI rath, sandip/0000-0003-4589-4039; Sengupta, Dipta/0000-0002-7836-4774;
   PATRA, SAMIR/0000-0001-5641-1835
FU NIT-Rourkela under the Institute Research Scheme; DST, Govt. of India;
   NIT-Rourkela
FX A. Shilpi, D. Sengupta, S. Kar, M. Deb and S. K. Rath are thankful to
   NIT-Rourkela for granting those fellowships under the Institute Research
   Scheme. S. Parbin and N. Pradhan is thankful to DST, Govt. of India for
   INSPIRE fellowship. M Rakshit is thankful to NIT-Rourkela for granting
   her postdoctoral research associate position and fellowship. We are
   thankful to Professor Tapash C. Ghosh, Bose Institute, Kolkata for
   helping us for using and analysis with discovery Studio. We would also
   like to acknowledge Dr. Vinod Devraji who helped with application
   manuals of Schrodinger software.
CR Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkw1099, 10.1093/nar/gkh131]
   Arce C, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-10
   Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649
   Barlow DP, 2011, ANNU REV GENET, V45, P379, DOI 10.1146/annurev-genet-110410-132459
   Ben Gacem R, 2012, HUM PATHOL, V43, P1731, DOI 10.1016/j.humpath.2011.12.022
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Bestor TH, 1998, CIBA F SYMP, V214, P187
   Beumer JH, 2008, CANCER CHEMOTH PHARM, V62, P363, DOI 10.1007/s00280-007-0603-8
   Bock C, 2012, NAT REV GENET, V13, P705, DOI 10.1038/nrg3273
   Brooksbank C, 2005, NUCLEIC ACIDS RES, V33, pD46, DOI 10.1093/nar/gki026
   Cheng XD, 2008, STRUCTURE, V16, P341, DOI 10.1016/j.str.2008.01.004
   Dinicola S, 2010, BRIT J NUTR, V104, P824, DOI 10.1017/S0007114510001522
   Fang MZ, 2003, CANCER RES, V63, P7563
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Hou TJ, 2011, J CHEM INF MODEL, V51, P69, DOI 10.1021/ci100275a
   Hurtubise A, 2004, ANTI-CANCER DRUG, V15, P161, DOI 10.1097/01.cad.0000113334.52071.97
   Isakovic L, 2009, BIOORG MED CHEM LETT, V19, P2742, DOI 10.1016/j.bmcl.2009.03.132
   ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235
   Jagadeesh S, 2007, BIOCHEM BIOPH RES CO, V362, P212, DOI 10.1016/j.bbrc.2007.08.005
   Jia D, 2007, NATURE, V449, P248, DOI 10.1038/nature06146
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kar S, 2012, EPIGENETICS-US, V7, P994, DOI 10.4161/epi.21568
   Kaur M, 2009, J NUTR, V139, p1806S, DOI 10.3945/jn.109.106864
   Kollman PA, 2000, ACCOUNTS CHEM RES, V33, P889, DOI 10.1021/ar000033j
   Lee BH, 2005, J BIOL CHEM, V280, P40749, DOI 10.1074/jbc.M505593200
   Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684
   Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B
   Nass SJ, 2000, CANCER RES, V60, P4346
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Patra A, 2011, CLIN EPIGENETICS, V2, P339, DOI 10.1007/s13148-010-0019-x
   Patra SK, 2009, BIOCHEMISTRY-MOSCOW+, V74, P613, DOI 10.1134/S0006297909060042
   Patra SK, 2008, FEBS J, V275, P5217, DOI 10.1111/j.1742-4658.2008.06658.x
   Patra SK, 2008, CANCER METAST REV, V27, P315, DOI 10.1007/s10555-008-9118-y
   Patra SK, 2008, EXP CELL RES, V314, P1193, DOI 10.1016/j.yexcr.2008.01.012
   Patra SK, 2011, CLIN EPIGENETICS, V2, P27, DOI 10.1007/s13148-010-0016-0
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Pronk S, 2013, BIOINFORMATICS, V29, P845, DOI 10.1093/bioinformatics/btt055
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Robertson KD, 2000, NAT REV GENET, V1, P11, DOI 10.1038/35049533
   Saavedra OM, 2009, BIOORG MED CHEM LETT, V19, P2747, DOI 10.1016/j.bmcl.2009.03.113
   SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993
   Schüttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679
   Song JK, 2011, SCIENCE, V331, P1036, DOI 10.1126/science.1195380
   SORM F, 1964, EXPERIENTIA, V20, P202, DOI 10.1007/BF02135399
   Suzuki T, 2010, BIOORG MED CHEM LETT, V20, P1124, DOI 10.1016/j.bmcl.2009.12.016
   Takeshita K, 2011, P NATL ACAD SCI USA, V108, P9055, DOI 10.1073/pnas.1019629108
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Tsui V, 2001, BIOPOLYMERS, V56, P275, DOI 10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E
   Venkatachalam CM, 2003, J MOL GRAPH MODEL, V21, P289, DOI 10.1016/S1093-3263(02)00164-X
   Villar-Garea A, 2003, CANCER RES, V63, P4984
   Wu GS, 2003, J COMPUT CHEM, V24, P1549, DOI 10.1002/jcc.10306
   Yoo J, 2012, ADV PROTEIN CHEM STR, V87, P219, DOI 10.1016/B978-0-12-398312-1.00008-1
   Yoo J, 2011, J COMPUT AID MOL DES, V25, P555, DOI 10.1007/s10822-011-9441-1
NR 58
TC 38
Z9 46
U1 2
U2 46
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD MAY 25
PY 2015
VL 233
BP 122
EP 138
DI 10.1016/j.cbi.2015.03.022
PG 17
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA CH6IF
UT WOS:000354139600013
PM 25839702
DA 2025-01-12
ER

PT J
AU Ding, MY
   Zhang, H
   Li, Z
   Wang, CL
   Chen, JM
   Shi, LY
   Xu, DK
   Gao, Y
AF Ding, Muyang
   Zhang, Hang
   Li, Zhen
   Wang, Cuili
   Chen, Jasmine
   Shi, Liyun
   Xu, Dakang
   Gao, Yane
TI The polycomb group protein enhancer of zeste 2 is a novel therapeutic
   target for cervical cancer
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Article
DE cervical cancer; epithelial-mesenchymal transition; enhancer of zeste 2
   inhibitor; xenografts
ID EZH2 EXPRESSION; BREAST-CANCER; IDENTIFICATION; METASTASIS;
   METHYLTRANSFERASE; PROLIFERATION; EPIGENETICS; INHIBITORS; PROSTATE;
   PATHWAY
AB Enhancer of zeste 2 (EZH2), a polycomb histone methyltransferase, is overexpressed in various cancers, including cervical cancer. Gene expression analysis revealed that increased expression of EZH2 is associated with cervical cancer progression, particularly the progression to invasive squamous cell carcinoma. Enhancer of zeste 2 is known to trimethylate lysine 27 on histone H3, leading to gene silencing that contributes to the progression of tumours into a more aggressive form of cancer. However, the specific molecular mechanisms by which EZH2 contributes to the development of cervical cancer remain largely unknown. Recently, an EZH2 inhibitor was reported to selectively inhibit trimethylated lysine 27 on histone H3 and to reactivate silenced genes in cancer cells. In this study, we found that GSK343 (a specific inhibitor of EZH2 methyltransferase) induces phenotypic reprogramming of cancer cells from mesenchymal to epithelial cells, reducing proliferation and cell motility and blocking the invasion of cervical cancer cell lines both in vitro and in vivo. Treatment with the EZH2 inhibitor led to increased levels of the epithelial marker E-cadherin and decreased levels of mesenchymal markers such as N-cadherin and vimentin. The observed reprogramming is associated with restrained cervical cancer progression and provides direct evidence in support of EZH2 as a therapeutic target.
C1 [Ding, Muyang; Gao, Yane] Xi An Jiao Tong Univ, Sch Med, Dept Obstet & Gynecol, Affiliated Hosp 2, Xian 710004, Peoples R China.
   [Zhang, Hang; Wang, Cuili; Shi, Liyun] Hangzhou Normal Univ, Sch Med, Dept Basic Med Sci, Key Lab Immunol & Mol Med, Hangzhou 311121, Zhejiang, Peoples R China.
   [Li, Zhen; Xu, Dakang] Hangzhou Normal Univ, Sch Med, Inst Ageing Res, Hangzhou 311121, Zhejiang, Peoples R China.
   [Chen, Jasmine] MIMR PHI Inst Med Res, Melbourne, Vic, Australia.
C3 Xi'an Jiaotong University; Hangzhou Normal University; Hangzhou Normal
   University; Prince Henry's Institute of Medical Research
RP Gao, Y (通讯作者)，Xi An Jiao Tong Univ, Sch Med, Dept Obstet & Gynecol, Affiliated Hosp 2, Xian 710004, Peoples R China.
EM dakang.xu@monash.edu; yanegao@163.com
FU National Natural Science Foundation of China [81273247, 81472655]
FX This work was supported by the National Natural Science Foundation of
   China (81273247 and 81472655). The authors have no conflicts of
   interests to disclose.
CR Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chinaranagari S, 2014, ONCOTARGET, V5, P7172, DOI 10.18632/oncotarget.2262
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Falkenberg KJ, 2014, NAT REV DRUG DISCOV, V13, P673, DOI 10.1038/nrd4360
   Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118
   He LR, 2010, INT J CANCER, V127, P138, DOI 10.1002/ijc.25031
   Holland D, 2008, CANCER RES, V68, P9964, DOI 10.1158/0008-5472.CAN-08-1134
   Li ZW, 2013, ONCOTARGET, V4, P2532, DOI 10.18632/oncotarget.1503
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Scotto L, 2008, GENE CHROMOSOME CANC, V47, P755, DOI 10.1002/gcc.20577
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Verma SK, 2012, ACS MED CHEM LETT, V3, P1091, DOI 10.1021/ml3003346
   Xu BW, 2015, BLOOD, V125, P346, DOI 10.1182/blood-2014-06-581082
   Xu DK, 2009, IMMUNITY, V30, P802, DOI 10.1016/j.immuni.2009.04.013
   Yuan W, 2012, SCIENCE, V337, P971, DOI 10.1126/science.1225237
   Yuan XL, 2013, CANCER RES, V73, P3625, DOI 10.1158/0008-5472.CAN-12-3879
   Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056
NR 25
TC 22
Z9 28
U1 0
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD MAY
PY 2015
VL 42
IS 5
BP 458
EP 464
DI 10.1111/1440-1681.12382
PG 7
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA CG6KT
UT WOS:000353410100004
PM 25739318
OA Bronze
DA 2025-01-12
ER

PT J
AU Gold, B
   Cankovic, M
   Furtado, LV
   Meier, F
   Gocke, CD
AF Gold, Bert
   Cankovic, Milena
   Furtado, Larissa V.
   Meier, Frederick
   Gocke, Christopher D.
TI Do Circulating Tumor Cells, Exosomes, and Circulating Tumor Nucleic
   Acids Have Clinical Utility? <i>A Report of the Association for
   Molecular Pathology</i>
SO JOURNAL OF MOLECULAR DIAGNOSTICS
LA English
DT Article
ID METASTATIC BREAST-CANCER; K-RAS MUTATIONS; PRIMARY COLORECTAL CANCERS;
   SERUM MICRORNA EXPRESSION; RESISTANT PROSTATE-CANCER; LUNG-CANCER;
   PLASMA DNA; PERIPHERAL-BLOOD; MICROSATELLITE ALTERATIONS; PROMOTER
   HYPERMETHYLATION
AB Diagnosing and screening for tumors through noninvasive means represent an important paradigm shift in precision medicine. In contrast to tissue biopsy, detection of circulating tumor cells (CTCs) and circulating tumor nucleic acids provides a minimally invasive method for predictive and prognostic marker detection. This allows early and serial assessment of metastatic disease, including follow-up during remission, characterization of treatment effects, and clonal evolution. Isolation and characterization of CTCs and circulating tumor DNA (ctDNA) are likely to improve cancer diagnosis, treatment, and minimal residual disease monitoring. However, more trials are required to validate the clinical utility of precise molecular markers for a variety of tumor types. This review focuses on the clinical utility of CTCs and ctDNA testing in patients with solid tumors, including somatic and epigenetic alterations that can be detected. A comparison of methods used to isolate and detect CTCs and some of the intricacies of the characterization of the ctDNA are also provided.
C1 [Gold, Bert; Cankovic, Milena; Furtado, Larissa V.; Meier, Frederick; Gocke, Christopher D.] Circulating Tumor Cells Working Grp, Clin Practice Comm, Associat Mol Pathol, Bethesda, MD USA.
   [Gold, Bert] NIH, Ctr Canc Res, Frederick, MD 21702 USA.
   [Cankovic, Milena; Meier, Frederick] Henry Ford Hosp, Dept Pathol, Detroit, MI 48202 USA.
   [Furtado, Larissa V.] Univ Chicago, Med Ctr, Dept Pathol, Chicago, IL 60637 USA.
   [Gocke, Christopher D.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Henry Ford Health System; Henry Ford Hospital; University of
   Chicago; University of Chicago Medical Center; Johns Hopkins University
RP Gold, B (通讯作者)，NIH, Ctr Canc Res, 1050 Boyles St, Frederick, MD 21702 USA.
EM bert.gold@nih.gov
RI Gold, Bert/HKN-0089-2023
FU Association for Molecular Pathology; Intramural Research Program of the
   National Cancer Institute, NIH
FX Supported in part by the Association for Molecular Pathology and the
   Intramural Research Program of the National Cancer Institute, NIH.
CR Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378
   Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Antolovic D, 2010, BMC BIOTECHNOL, V10, DOI 10.1186/1472-6750-10-35
   Bang C, 2012, INT J BIOCHEM CELL B, V44, P2060, DOI 10.1016/j.biocel.2012.08.007
   Bazan V, 2006, ANN ONCOL, V17, pVII84, DOI 10.1093/annonc/mdl958
   Bearzatto A, 2002, CLIN CANCER RES, V8, P3782
   Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627
   Beerenwinkel N, 2007, PLOS COMPUT BIOL, V3, P2239, DOI 10.1371/journal.pcbi.0030225
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Benlloch S, 2006, CLIN LUNG CANCER, V8, P140, DOI 10.3816/CLC.2006.n.043
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Bidard FC, 2013, CANCER METAST REV, V32, P179, DOI 10.1007/s10555-012-9398-0
   Brábek J, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-22
   Bremnes RM, 2005, LUNG CANCER, V49, P1, DOI 10.1016/j.lungcan.2004.12.008
   Britton KM, 2012, CANCER LETT, V323, P97, DOI 10.1016/j.canlet.2012.03.041
   Bruhn N, 2000, ANN NY ACAD SCI, V906, P72
   Camussi G, 2010, KIDNEY INT, V78, P838, DOI 10.1038/ki.2010.278
   Castells A, 1999, J CLIN ONCOL, V17, P578, DOI 10.1200/JCO.1999.17.2.578
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chen KC, 2012, ANAL BIOCHEM, V429, P116, DOI 10.1016/j.ab.2012.07.007
   Chen XQ, 1996, NAT MED, V2, P1033
   Chen YP, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.067003
   Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551
   Chiu RWK, 2001, CLIN CHEM, V47, P1607
   Church TR, 2014, GUT, V63, P317, DOI 10.1136/gutjnl-2012-304149
   Clawson GA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041052
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Cristofanilli M, 2007, CLIN BREAST CANCER, V7, P471, DOI 10.3816/CBC.2007.n.004
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Del Monte U, 2009, CELL CYCLE, V8, P505, DOI 10.4161/cc.8.3.7608
   Deng G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-456
   deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808
   Diamond E, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00131
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Doyen J, 2012, CRIT REV ONCOL HEMAT, V81, P241, DOI 10.1016/j.critrevonc.2011.05.004
   Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037
   DURBIN PW, 1967, CANCER RES, V27, P1341
   El Messaoudi S, 2013, CLIN CHIM ACTA, V424, P222, DOI 10.1016/j.cca.2013.05.022
   El Mustapha Bahassi., 2013, J. Mol. Biomark. Diagn. 05, P157, DOI DOI 10.4172/2155-9929.1000157
   Ellinger J, 2008, PROSTATE, V68, P42, DOI 10.1002/pros.20651
   Ellinger J, 2009, J UROLOGY, V182, P324, DOI 10.1016/j.juro.2009.02.106
   EMLEN W, 1984, CLIN EXP IMMUNOL, V56, P185
   Esteller M, 1999, CANCER RES, V59, P67
   Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001
   Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726
   FOURNIE GJ, 1995, CANCER LETT, V91, P221, DOI 10.1016/0304-3835(95)03742-F
   Freidin MB, 2014, LUNG CANCER, V85, P182, DOI 10.1016/j.lungcan.2014.05.017
   Friberg S, 1997, J SURG ONCOL, V65, P284, DOI 10.1002/(SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2
   Fujiwara Y, 1999, CANCER RES, V59, P1567
   Gahan Peter B., 2012, Infectious Disorders - Drug Targets, V12, P360
   García JM, 2008, RNA, V14, P1424, DOI 10.1261/rna.755908
   García-Olmo D, 2001, ANN NY ACAD SCI, V945, P265
   García-Olmo DC, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-8
   Gautschi O, 2007, CANCER LETT, V254, P265, DOI 10.1016/j.canlet.2007.03.008
   Gautschi O, 2004, J CLIN ONCOL, V22, P4157, DOI 10.1200/JCO.2004.11.123
   Giacona MB, 1998, PANCREAS, V17, P89, DOI 10.1097/00006676-199807000-00012
   Giovannetti E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049145
   Gocke CD, 2000, LEUKEMIA LYMPHOMA, V39, P165, DOI 10.3109/10428190009053551
   Gocke CD, 2000, ANN NY ACAD SCI, V906, P44
   Godfrey AC, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3428
   Goldkorn A, 2014, J CLIN ONCOL, V32, P1136, DOI 10.1200/JCO.2013.51.7417
   Gormally E, 2004, INT J CANCER, V111, P746, DOI 10.1002/ijc.20327
   Gossett DR, 2010, ANAL BIOANAL CHEM, V397, P3249, DOI 10.1007/s00216-010-3721-9
   Grady WM, 2001, CANCER RES, V61, P900
   Gröger CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051136
   Grützmann R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003759
   Guo JA, 2010, J CANCER RES CLIN, V136, P1341, DOI 10.1007/s00432-010-0785-z
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harb W, 2013, TRANSL ONCOL, V6, P528, DOI 10.1593/tlo.13367
   Hastings ML, 2012, METHODS, V58, P144, DOI 10.1016/j.ymeth.2012.07.026
   Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm477
   Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140
   Hibi K, 2001, INT J CANCER, V94, P429, DOI 10.1002/ijc.1480
   Holdenrieder S, 2005, CLIN CHEM, V51, P1544, DOI 10.1373/clinchem.2005.049320
   Holmgren L, 1999, BLOOD, V93, P3956, DOI 10.1182/blood.V93.11.3956.411k05_3956_3963
   Hou HW, 2013, SCI REP-UK, V3, DOI 10.1038/srep01259
   Hsieh JS, 2005, AM SURGEON, V71, P336
   Ito T, 2003, ONCOL REP, V10, P1937
   Jahr S, 2001, CANCER RES, V61, P1659
   Jiao L, 2007, PANCREAS, V34, P55, DOI 10.1097/01.mpa.0000246665.68869.d4
   Kadam SK, 2012, J MOL DIAGN, V14, P346, DOI 10.1016/j.jmoldx.2012.03.001
   Kamande JW, 2013, ANAL CHEM, V85, P9092, DOI 10.1021/ac401720k
   Karabacak NM, 2014, NAT PROTOC, V9, P694, DOI 10.1038/nprot.2014.044
   Katsuda T, 2014, PROTEOMICS, V14, P412, DOI 10.1002/pmic.201300389
   Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221
   Khoja L, 2012, BRIT J CANCER, V106, P508, DOI 10.1038/bjc.2011.545
   Khoja L, 2013, J INVEST DERMATOL, V133, P1582, DOI 10.1038/jid.2012.468
   Kimura H, 2006, BRIT J CANCER, V95, P1390, DOI 10.1038/sj.bjc.6603428
   Kinde I, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3004952
   Kinde I, 2011, P NATL ACAD SCI USA, V108, P9530, DOI 10.1073/pnas.1105422108
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kölble K, 1999, LAB INVEST, V79, P1145
   Kopreski MS, 1999, CLIN CANCER RES, V5, P1961
   Kopreski MS, 2000, J NATL CANCER I, V92, P918, DOI 10.1093/jnci/92.11.918
   Kopreski MS, 1997, BRIT J CANCER, V76, P1293, DOI 10.1038/bjc.1997.551
   KRAMER RH, 1984, JNCI-J NATL CANCER I, V72, P889
   Kratzke RA, 1996, CANCER RES, V56, P3415
   Kristensen LS, 2009, CLIN CHEM, V55, P1471, DOI 10.1373/clinchem.2008.121962
   Lauschke H, 2001, CANCER DETECT PREV, V25, P55
   Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x
   Leary RJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004742
   Lecomte T, 2010, GASTROEN CLIN BIOL, V34, P662, DOI 10.1016/j.gcb.2009.04.015
   Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526
   Lee TH, 2001, TRANSFUSION, V41, P276, DOI 10.1046/j.1537-2995.2001.41020276.x
   LEON SA, 1977, J RHEUMATOL, V4, P139
   LEON SA, 1977, CANCER RES, V37, P646
   Leung WK, 2005, AM J GASTROENTEROL, V100, P2274, DOI 10.1111/j.1572-0241.2005.50412.x
   Liggett T, 2010, CANCER-AM CANCER SOC, V116, P1674, DOI 10.1002/cncr.24893
   Ligthart ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067148
   Lilleberg SL, 2004, ANN NY ACAD SCI, V1022, P250, DOI 10.1196/annals.1318.039
   LIOTTA LA, 1991, CANCER RES, V51, pS5054
   Liu Y, 2003, CARCINOGENESIS, V24, P1897, DOI 10.1093/carcin/bgg169
   Lo YMD, 1999, AM J HUM GENET, V64, P218, DOI 10.1086/302205
   Lo YMD, 1997, LANCET, V350, P485, DOI 10.1016/S0140-6736(97)02174-0
   Loberg RD, 2004, NEOPLASIA, V6, P302, DOI 10.1593/neo.03484
   Lorger M, 2010, AM J PATHOL, V176, P2958, DOI 10.2353/ajpath.2010.090838
   Lustberg Maryam, 2012, Recent Results Cancer Res, V195, P97, DOI 10.1007/978-3-642-28160-0_9
   Ma YC, 2013, TECHNOL CANCER RES T, V12, P295, DOI 10.7785/tcrt.2012.500328
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   Maire F, 2002, BRIT J CANCER, V87, P551, DOI 10.1038/sj.bjc.6600475
   MANDEL P, 1948, CR SOC BIOL, V142, P241
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Mayall F, 1998, J CLIN PATHOL, V51, P611, DOI 10.1136/jcp.51.8.611
   Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9
   Millner LM, 2013, ANN CLIN LAB SCI, V43, P295
   Miranda E, 2013, CANCER-AM CANCER SOC, V119, P266, DOI 10.1002/cncr.27722
   Mirza S, 2012, ANN SURG ONCOL, V19, P3107, DOI 10.1245/s10434-012-2323-5
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Miyamoto DT, 2012, CANCER DISCOV, V2, P995, DOI 10.1158/2159-8290.CD-12-0222
   Muralidharan-Chari V, 2010, J CELL SCI, V123, P1603, DOI 10.1242/jcs.064386
   Mussolin L, 2013, J CANCER, V4, P323, DOI 10.7150/jca.6226
   Nadal R, 2013, EXPERT REV MOL DIAGN, V13, P295, DOI [10.1586/ERM.13.7, 10.1586/erm.13.7]
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   NAKAGAWA K, 1995, ONCOGENE, V11, P1843
   Napirei M, 2009, FEBS J, V276, P1059, DOI 10.1111/j.1742-4658.2008.06849.x
   Nawroz H, 1996, NAT MED, V2, P1035, DOI 10.1038/nm0996-1035
   Ng CSH, 2002, J SURG ONCOL, V79, P101, DOI 10.1002/jso.10046
   Ng EKO, 2002, CLIN CHEM, V48, P1212
   Nguyen HCN, 2013, PROSTATE, V73, P346, DOI 10.1002/pros.22572
   Ntouroupi TG, 2008, BRIT J CANCER, V99, P789, DOI 10.1038/sj.bjc.6604545
   Olmos D, 2012, LANCET ONCOL, V13, P1114, DOI 10.1016/S1470-2045(12)70372-8
   Orozco AF, 2010, CYTOM PART A, V77A, P502, DOI 10.1002/cyto.a.20886
   Page K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077963
   Palmisano WA, 2000, CANCER RES, V60, P5954
   Panteleakou Z, 2009, MOL MED, V15, P101, DOI 10.2119/molmed.2008.00116
   Parkinson DR, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-138
   Pavese JM, 2010, CANCER METAST REV, V29, P465, DOI 10.1007/s10555-010-9238-z
   Polzer B, 2014, EMBO MOL MED, V6, P1371, DOI 10.15252/emmm.201404033
   Powell AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033788
   Pucciarelli S, 2012, ANN SURG ONCOL, V19, P3089, DOI 10.1245/s10434-012-2272-z
   Qiu SW, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-10
   Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006
   Raimondi C, 2014, ONCOTARGETS THER, V7, P619, DOI 10.2147/OTT.S46200
   Ramirez JL, 2005, J CLIN ONCOL, V23, P9105, DOI 10.1200/JCO.2005.02.2905
   Redis RS, 2012, PHARMACOL THERAPEUT, V136, P169, DOI 10.1016/j.pharmthera.2012.08.003
   Revenfeld ALS, 2014, CLIN THER, V36, P830, DOI 10.1016/j.clinthera.2014.05.008
   Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695
   Ross JS, 2009, AM J CLIN PATHOL, V132, P237, DOI 10.1309/AJCPJI7DEOLKCS6F
   Ross RW, 2012, LANCET ONCOL, V13, P1105, DOI 10.1016/S1470-2045(12)70263-2
   Roth C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-4
   Ryan BM, 2003, GUT, V52, P101, DOI 10.1136/gut.52.1.101
   Sakaizawa K, 2012, BRIT J CANCER, V106, P939, DOI 10.1038/bjc.2012.12
   Salnikov AV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046391
   Salvianti F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049843
   Sanchez-Cespedes M, 1998, ANN ONCOL, V9, P113, DOI 10.1023/A:1008230331221
   Saucedo-Zeni N, 2012, INT J ONCOL, V41, P1241, DOI 10.3892/ijo.2012.1557
   Schrauder MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029770
   Schwarzenbach H, 2011, MOL BIOSYST, V7, P2848, DOI 10.1039/c1mb05197k
   SHAPIRO B, 1983, CANCER-AM CANCER SOC, V51, P2116, DOI 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S
   Shetty S, 2012, INT J HEMATOL, V95, P274, DOI 10.1007/s12185-012-1021-1
   Shinozaki M, 2007, CLIN CANCER RES, V13, P2068, DOI 10.1158/1078-0432.CCR-06-2120
   Silva J, 2011, EUR RESPIR J, V37, P617, DOI 10.1183/09031936.00029610
   Silva JM, 1999, BRIT J CANCER, V80, P1262, DOI 10.1038/sj.bjc.6690495
   Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Smerage JB, 2014, J CLIN ONCOL, V32, P3483, DOI 10.1200/JCO.2014.56.2561
   SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67
   Sozzi G, 1999, CLIN CANCER RES, V5, P2689
   Sozzi G, 2003, J CLIN ONCOL, V21, P3902, DOI 10.1200/JCO.2003.02.006
   Sozzi G, 2001, CANCER RES, V61, P4675
   Stott SL, 2010, P NATL ACAD SCI USA, V107, P18392, DOI 10.1073/pnas.1012539107
   Strauss R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016186
   Stroun M, 2000, ANN NY ACAD SCI, V906, P161
   Sturgeon SR, 2012, EPIGENETICS-US, V7, P1258, DOI 10.4161/epi.22220
   Sung SY, 2007, CURR PROB CANCER, V31, P36, DOI 10.1016/j.currproblcancer.2006.12.002
   Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103
   Tänzer M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009061
   Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033
   Theodor L, 1999, DIGEST DIS SCI, V44, P2014, DOI 10.1023/A:1026618317716
   Théry C, 2009, NAT REV IMMUNOL, V9, P581, DOI 10.1038/nri2567
   Tian TH, 2011, INTEGR BIOL-UK, V3, P17, DOI 10.1039/c0ib00046a
   Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222
   To EWH, 2003, CLIN CANCER RES, V9, P3254
   Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416
   Trevisiol C, 2006, INT J BIOL MARKER, V21, P223, DOI 10.1177/172460080602100405
   Tveito S, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2922
   Umetani N, 2006, CLIN CHEM, V52, P1062, DOI 10.1373/clinchem.2006.068577
   Usiaková Z, 2014, IN VIVO, V28, P605
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   van Schooneveld E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3127
   Vermaat JS, 2012, CLIN CANCER RES, V18, P688, DOI 10.1158/1078-0432.CCR-11-1965
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Vona G, 2000, AM J PATHOL, V156, P57, DOI 10.1016/S0002-9440(10)64706-2
   Wallner M, 2006, CLIN CANCER RES, V12, P7347, DOI 10.1158/1078-0432.CCR-06-1264
   Wang JY, 2004, WORLD J SURG, V28, P721, DOI 10.1007/s00268-004-7366-8
   Wang SH, 2010, CLIN CANCER RES, V16, P1324, DOI 10.1158/1078-0432.CCR-09-2672
   Wang Y, 2013, CANCER RES, V73, P4801, DOI 10.1158/0008-5472.CAN-12-3273
   Warren JD, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-133
   Williams C, 2014, CELL RES, V24, P766, DOI 10.1038/cr.2014.44
   Williams SCP, 2013, P NATL ACAD SCI USA, V110, P4861, DOI 10.1073/pnas.1304186110
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yang CH, 2013, INT J CANCER, V132, P116, DOI 10.1002/ijc.27657
   Yu M, 2011, J CELL BIOL, V192, P373, DOI 10.1083/jcb.201010021
   Zhou J, 2012, SEMIN ONCOL, V39, P440, DOI 10.1053/j.seminoncol.2012.05.013
   Ziegler A, 2002, CANCER TREAT REV, V28, P255, DOI 10.1016/S0305-7372(02)00077-4
NR 221
TC 153
Z9 175
U1 1
U2 69
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1525-1578
EI 1943-7811
J9 J MOL DIAGN
JI J. Mol. Diagn.
PD MAY
PY 2015
VL 17
IS 3
BP 209
EP 224
DI 10.1016/j.jmoldx.2015.02.001
PG 16
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA CH2GO
UT WOS:000353843900001
PM 25908243
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Martin-Doyle, W
   Kwiatkowski, DJ
AF Martin-Doyle, William
   Kwiatkowski, David J.
TI Molecular Biology of Bladder Cancer
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Bladder cancer; Urothelial carcinoma; Mutations; Somatic copy number
   alterations; Cell cycle; Epigenetics; Molecular subtypes
ID TRANSITIONAL-CELL CARCINOMA; CHROMOSOMAL IMBALANCES; WHOLE-GENOME; TUMOR
   GRADE; P53 GENE; MUTATIONS; IDENTIFICATION; STAGE; EXPRESSION; FGFR3
AB Classic as well as more recent large-scale genomic analyses have uncovered multiple genes and pathways important for bladder cancer development. Genes involved in cell-cycle control, chromatin regulation, and receptor tyrosine and PI3 kinase-mammalian target of rapamycin signaling pathways are commonly mutated in muscle-invasive bladder cancer. Expression-based analyses have identified distinct types of bladder cancer that are similar to subsets of breast cancer, and have prognostic and therapeutic significance. These observations are leading to novel therapeutic approaches in bladder cancer, providing optimism for therapeutic progress.
C1 [Martin-Doyle, William; Kwiatkowski, David J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
C3 Harvard University; Harvard Medical School; Brigham & Women's Hospital
RP Kwiatkowski, DJ (通讯作者)，Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, 1 Blackfan Circle,Room 6-213, Boston, MA 02115 USA.
EM dk@rics.bwh.harvard.edu
RI Kwiatkowski, David/AHE-5017-2022
CR Balbás-Martínez C, 2013, NAT GENET, V45, P1464, DOI 10.1038/ng.2799
   Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177
   Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615
   Cazier JB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4756
   CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F
   Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009
   Cote RJ, 1998, CANCER RES, V58, P1090
   Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111
   ESRIG D, 1993, AM J PATHOL, V143, P1389
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Goebell PJ, 2010, UROL ONCOL-SEMIN ORI, V28, P409, DOI 10.1016/j.urolonc.2010.04.003
   Greulich H, 2012, P NATL ACAD SCI USA, V109, P14476, DOI 10.1073/pnas.1203201109
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Guo GW, 2013, NAT GENET, V45, P1459, DOI 10.1038/ng.2798
   Höglund M, 2001, CANCER RES, V61, P8241
   Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854
   Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260
   Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344
   Jaiswal BS, 2014, CANCER CELL, V25, P543, DOI 10.1016/j.ccr.2014.03.030
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   KALLIONIEMI A, 1995, GENE CHROMOSOME CANC, V12, P213, DOI 10.1002/gcc.2870120309
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Knowles MA, 2008, INT J CLIN ONCOL, V13, P287, DOI 10.1007/s10147-008-0812-0
   Lehmann AR, 2001, GENE DEV, V15, P15, DOI 10.1101/gad.859501
   López-Knowles E, 2006, CANCER RES, V66, P7401, DOI 10.1158/0008-5472.CAN-06-1182
   Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024
   PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0
   Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898
   Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970
   Richter J, 1998, AM J PATHOL, V153, P1615, DOI 10.1016/S0002-9440(10)65750-1
   Richter J, 1997, CANCER RES, V57, P2860
   Roberts SA, 2012, MOL CELL, V46, P424, DOI 10.1016/j.molcel.2012.03.030
   Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105
   SIDRANSKY D, 1991, SCIENCE, V252, P706, DOI 10.1126/science.2024123
   Simon R, 1998, J PATHOL, V185, P345
   Singh D, 2012, SCIENCE, V337, P1231, DOI 10.1126/science.1220834
   Sjödahl G, 2013, AM J PATHOL, V183, P681, DOI 10.1016/j.ajpath.2013.05.013
   Sjödahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T
   Solomon DA, 2013, NAT GENET, V45, P1428, DOI 10.1038/ng.2800
   Takata R, 2005, CLIN CANCER RES, V11, P2625, DOI 10.1158/1078-0432.CCR-04-1988
   Taylor CF, 2014, HUM MOL GENET, V23, P1964, DOI 10.1093/hmg/ddt589
   TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628
   United States Food and Drug Administration, 2014, HEM ONC CANC APPR SA
   Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623
   VOORTER C, 1995, AM J PATHOL, V146, P1341
   Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486
   WILLIAMSON MP, 1995, HUM MOL GENET, V4, P1569, DOI 10.1093/hmg/4.9.1569
   XU HJ, 1993, INT J CANCER, V53, P781, DOI 10.1002/ijc.2910530513
   Zhou JBA, 2011, INT J BIOCHEM CELL B, V43, P1668, DOI 10.1016/j.biocel.2011.09.005
NR 51
TC 28
Z9 29
U1 0
U2 18
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD APR
PY 2015
VL 29
IS 2
BP 191
EP +
DI 10.1016/j.hoc.2014.10.002
PG 14
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA CG6RL
UT WOS:000353430000004
PM 25836928
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Orgueira, AM
AF Mosquera Orgueira, Adrian
TI Hidden among the crowd: differential DNA methylation-expression
   correlations in cancer occur at important oncogenic pathways
SO FRONTIERS IN GENETICS
LA English
DT Article
ID NONCODING RNA HOTAIR; STEM-CELLS; LUNG ADENOCARCINOMA; G-QUADRUPLEXES;
   CTCF-BINDING; PROMOTER; CHROMATIN; PATTERNS; DOMAINS; GENES
AB DNA methylation is a frequent epigenetic mechanism that participates in transcriptional repression. Variations in DNA methylation with respect to gene expression are constant, and, for unknown reasons, some genes with highly methylated promoters are sometimes overexpressed. In this study we have analyzed the expression and methylation patterns of thousands of genes in five groups of cancer and normal tissue samples in order to determine local and genome-wide differences. We observed significant changes in global methylation-expression correlation in all the neoplasms, which suggests that differential correlation events are frequent in cancer. A focused analysis in the breast cancer cohort identified 1662 genes whose correlation varies significantly between normal and cancerous breast, but whose DNA methylation and gene expression patterns do not change substantially. These genes were enriched in cancer-related pathways and repressive chromatin features across various model cell lines, such as PRC2 binding and H3K27me3 marks. Substantial changes in methylation-expression correlation indicate that these genes are subject to epigenetic remodeling, where the differential activity of other factors break the expected relationship between both variables. Our findings suggest a complex regulatory landscape where a redistribution of local and large-scale chromatin repressive domains at differentially correlated genes (DCGs) creates epigenetic hotspots that modulate cancer-specific gene expression.
RP Orgueira, AM (通讯作者)，Meson do Vento 56, Ordes 15689, A Coruna, Spain.
EM adrian.mosquera@live.com
CR Abelson P., 1995, Statistics as principled argument
   Agarwal T, 2014, BIOCHEMISTRY-US, V53, P3711, DOI 10.1021/bi401451q
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bae W. K., 2014, MOL CARCINOG, DOI [10.1002/mc.22188, DOI 10.1002/MC.22188.[]
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Blumenthal RD, 2005, CANCER RES, V65, P8809, DOI 10.1158/0008-5472.CAN-05-0420
   Bork S, 2010, AGING CELL, V9, P54, DOI 10.1111/j.1474-9726.2009.00535.x
   Boros J, 2014, MOL CELL BIOL, V34, P3662, DOI 10.1128/MCB.00205-14
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Cerami Ethan G, 2011, Nucleic Acids Res, V39, pD685, DOI 10.1093/nar/gkq1039
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Core Team R, 2012, R LANG ENV STAT COMP
   Creelan BC, 2013, J IMMUNOTHER, V36, P442, DOI 10.1097/CJI.0b013e3182a80237
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Durinck S, 2009, NAT PROTOC, V4, P1184, DOI 10.1038/nprot.2009.97
   Fakhr MG, 2013, GENET RES INT, V2013, DOI 10.1155/2013/317569
   Fertig EJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078127
   Gieni RS, 2009, BIOCHEM CELL BIOL, V87, P711, DOI 10.1139/O09-057
   Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111
   Goodwin LD, 2006, J EXP EDUC, V74, P251, DOI 10.3200/jexe.74.3.249-266
   Govindan SV, 2009, CLIN CANCER RES, V15, P6052, DOI 10.1158/1078-0432.CCR-09-0586
   Guibert S, 2012, EPIGENETICS-US, V7, P361, DOI 10.4161/epi.19487
   Guillaumet-Adkins A, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-4
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Halder R, 2010, MOL BIOSYST, V6, P2439, DOI 10.1039/c0mb00009d
   Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Houseman EA, 2009, BIOINFORMATICS, V25, P1999, DOI 10.1093/bioinformatics/btp364
   HUANG THM, 1995, DIAGN MOL PATHOL, V4, P66
   Huppert JL, 2007, NUCLEIC ACIDS RES, V35, P406, DOI 10.1093/nar/gkl1057
   Jirtle L. J., 1997, GENEIMPRINT GENEIMPR
   Jjingo D, 2012, ONCOTARGET, V3, P462, DOI 10.18632/oncotarget.497
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Jones P, 2014, BIOINFORMATICS, V30, P1236, DOI 10.1093/bioinformatics/btu031
   Kanduri M, 2013, EPIGENETICS-US, V8, P1280, DOI 10.4161/epi.26546
   Kanehisa Minoru, 2013, Methods Mol Biol, V939, P263, DOI 10.1007/978-1-62703-107-3_17
   Kemp CJ, 2014, CELL REP, V7, P1020, DOI 10.1016/j.celrep.2014.04.004
   Kim YJ, 2013, INT J CANCER, V133, P1135, DOI 10.1002/ijc.28121
   Klipp E., 2009, Systems Biology: A Textbook
   Kresse SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048262
   Li T, 2014, HUM MOL GENET, V23, P117, DOI 10.1093/hmg/ddt405
   Liu QY, 2014, FEBS J, V281, P2713, DOI 10.1111/febs.12816
   Liu ZG, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0592-x
   Lou SK, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0408-0
   McEntyre J, 2001, CAN MED ASSOC J, V164, P1317
   Moran AE, 2013, CURR OPIN IMMUNOL, V25, P230, DOI 10.1016/j.coi.2013.01.004
   Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009
   Mudholkar G. S., 2006, ENCY STAT SCI
   Myers L., 2004, Encyclopedia of Statistical Sciences, V12, DOI [10.1002/0471667196.ess5050, DOI 10.1002/0471667196.ESS5050.PUB2]
   Rakhmilevich AL, 2012, INT REV IMMUNOL, V31, P267, DOI 10.3109/08830185.2012.698337
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Sandve GK, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-12-r121
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Schroeder DI, 2011, GENOME RES, V21, P1583, DOI 10.1101/gr.119131.110
   Selamat SA, 2012, GENOME RES, V22, P1197, DOI 10.1101/gr.132662.111
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Sorensen KP, 2013, BREAST CANCER RES TR, V142, P529, DOI 10.1007/s10549-013-2776-7
   Suzuki K, 2013, J CLIN ONCOL, V31, P490, DOI 10.1200/JCO.2012.45.2052
   Szulwach KE, 2014, BIOESSAYS, V36, P107, DOI 10.1002/bies.201300090
   Tabas-Madrid D, 2012, NUCLEIC ACIDS RES, V40, pW478, DOI 10.1093/nar/gks402
   Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Urosevic J, 2014, NAT CELL BIOL, V16, P685, DOI 10.1038/ncb2977
   VanderKraats ND, 2013, NUCLEIC ACIDS RES, V41, P6816, DOI 10.1093/nar/gkt482
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Wagner JR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r37
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wang YJ, 2011, BIOSCIENCE REP, V31, P109, DOI 10.1042/BSR20100033
   Wen B, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-566
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3
   Wood SN, 2011, J ROY STAT SOC B, V73, P3, DOI 10.1111/j.1467-9868.2010.00749.x
   Wu XD, 2008, NUCLEIC ACIDS RES, V36, P3590, DOI 10.1093/nar/gkn243
   Yu W, 2009, CANCER GENET CYTOGEN, V193, P29, DOI 10.1016/j.cancergencyto.2009.03.017
   Zhang H, 2011, J CELL BIOL, V193, P475, DOI 10.1083/jcb.201101021
   Zheng CG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021146
NR 81
TC 11
Z9 11
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD MAY 13
PY 2015
VL 6
AR 163
DI 10.3382/fgene.2015.00163
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA CP1JV
UT WOS:000359633000001
PM 26029238
DA 2025-01-12
ER

PT J
AU Szmida, E
   Karpinski, P
   Leszczynski, P
   Sedziak, T
   Kielan, W
   Ostasiewicz, P
   Sasiadek, MM
AF Szmida, Elzbieta
   Karpinski, Pawel
   Leszczynski, Przemyslaw
   Sedziak, Tomasz
   Kielan, Wojciech
   Ostasiewicz, Pawel
   Sasiadek, Maria M.
TI Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer
SO JOURNAL OF APPLIED GENETICS
LA English
DT Article
DE Colorectal; Methylation; Illumina 27k; ERBB; PKCB
ID CPG ISLAND HYPERMETHYLATION; C BETA-II; DNA METHYLATION; BREAST-CANCER;
   COLON-CANCER; LUNG-CANCER; EXPRESSION; AMPLIFICATION; ENZASTAURIN;
   INHIBITOR
AB The ErbB signalling network plays a crucial role in the growth and progression of several cancers, including colorectal cancer (CRC), and includes potentially drug-targetable genes. Oncogenic activation of the ErbB pathway by mutations and focal amplifications have emerged recently as an important predictive marker of the prognosis of CRC patients. However, in contrast to genetic events, little is known about epigenetic alternations of ErbB-associated genes and their impact on gene expression. Genome-wide methylation in sporadic CRCs (n = 12) paired with adjacent normal tissues have been previously analysed by Illumina Infinium HumanMethylation27 (HM27) at 27,578 CpG sites. For confirmation of our initial genome-wide analysis, we used a published HM27 dataset (GSE25062). Subsequently, CpG island methylation of selected ErbB pathway-associated genes was assessed on 233 CRC samples using methylation-sensitive polymerase chain reaction (MS-PCR) and analysed along with various genetic factors associated with CRC [epigenotype, BRAF and KRAS mutations, microsatellite instability (MSI)]. Methylation and expression integration was performed using published datasets including 25 pairs of CRC and normal colon tissues (GSE25062 and GSE25070), and confirmed with real-time PCR. Our previous microarray-based genome-wide DNA methylation analysis of 12 CRCs revealed that four ErbB-associated genes (PIK3CD, PKCI', ERBB4, ) were differentially methylated in CRCs. This was further confirmed by statistical re-analysis of an HM27 dataset (GSE25062). Frequent methylation at these loci in tumours was subsequently confirmed by MS-PCR (63 %, 43 %, 43 % and 92 %, respectively). Hypermethylation of PKCI' associated with KRAS mutation (p = 0.04), whereas hypermethylation of ERBB4 associated with high-methylation epigenotypes (HME), BRAF mutation and MSI (p = 0.001, 0.002 and 0.0002, respectively). One of the four analysed genes (PKCI') was significantly downregulated in CRC tissue, as revealed by real-time PCR and re-analysis of the GSE25062 and GSE25070 datasets. After careful re-analysis of published methylation and expression data, we conclude that methylation of ERBB4, PAK7 and PIK3CD has no functional role in CRC carcinogenesis. In contrast, methylation seems to have a potential impact on the biology of colorectal tumours by negatively modulating the expression of PKCI'. Importantly, the relationship between DNA methylation of PKCI' and gene expression may warrant further attention in the context of colon cancer chemoprevention and anti-cancer therapy.
C1 [Szmida, Elzbieta; Karpinski, Pawel; Leszczynski, Przemyslaw; Sasiadek, Maria M.] Wroclaw Med Univ, Dept Genet, PL-50368 Wroclaw, Poland.
   [Sedziak, Tomasz] Lower Silesian Oncol Ctr, Dept Surg Oncol 1, Wroclaw, Poland.
   [Kielan, Wojciech] Wroclaw Med Univ, Dept Gen & Oncol Surg 2, PL-50368 Wroclaw, Poland.
   [Ostasiewicz, Pawel] Wroclaw Med Univ, Dept Pathol, PL-50368 Wroclaw, Poland.
C3 Wroclaw Medical University; Wroclaw Medical University; Wroclaw Medical
   University
RP Szmida, E (通讯作者)，Wroclaw Med Univ, Dept Genet, Ul Marcinkowskiego 1, PL-50368 Wroclaw, Poland.
EM e.szmida@gmail.com
RI Ostasiewicz, Pawel/JVO-5036-2024; Karpinski, Pawel/LQJ-4449-2024
OI Sasiadek, Maria/0000-0002-7599-7074; Karpinski,
   Pawel/0000-0003-3885-694X; Leszczynski, Przemyslaw/0000-0002-4181-4997;
   Szmida, Elzbieta/0000-0003-3108-0165
FU State Committee for Scientific Research, Polish Ministry of Scientific
   Research and Information Technology [N N401 601438/2010-2013]
FX This study was supported by a grant from the State Committee for
   Scientific Research, Polish Ministry of Scientific Research and
   Information Technology no. N N401 601438/2010-2013.
CR Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340
   Blazejczyk M., 2007, FlexArray: A statistical data analysis software for gene expression microarrays
   Buhard O, 2006, J CLIN ONCOL, V24, P241, DOI 10.1200/JCO.2005.02.7227
   Das PM, 2010, ONCOGENE, V29, P5214, DOI 10.1038/onc.2010.271
   Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885
   Enroth S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-450
   Fellows I, 2012, J STAT SOFTW, V49, P1
   Furnari MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061321
   Glimelius B, 2010, ANN ONCOL, V21, P1020, DOI 10.1093/annonc/mdp521
   Gökmen-Polar Y, 2001, CANCER RES, V61, P1375
   Graff JR, 2005, CANCER RES, V65, P7462, DOI 10.1158/0008-5472.CAN-05-0071
   Gu J, 2013, FEBS J, V280, P46, DOI 10.1111/febs.12048
   Hagiwara K, 2012, GENE CHROMOSOME CANC, V51, P1024, DOI 10.1002/gcc.21985
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hoque MO, 2010, J THORAC ONCOL, V5, P1887, DOI 10.1097/JTO.0b013e3181f77a53
   Karpinski P, 2012, MOL CARCINOGEN, V51, P1003, DOI 10.1002/mc.20871
   Kilaru V, 2012, EPIGENETICS-US, V7, P225, DOI 10.4161/epi.7.3.19284
   Kok K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005145
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Laczmanska I, 2013, J HUM GENET, V58, P11, DOI 10.1038/jhg.2012.119
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337
   Montero AJ, 2006, CANCER BIOL THER, V5, P1494, DOI 10.4161/cbt.5.11.3299
   PETRANGELI E, 1995, BRIT J CANCER, V72, P973, DOI 10.1038/bjc.1995.444
   RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991
   Sapio MR, 2006, EUR J ENDOCRINOL, V154, P341, DOI 10.1530/eje.1.02072
   SAUTER G, 1993, CANCER RES, V53, P2199
   Sawyer C, 2003, CANCER RES, V63, P1667
   Scartozzi M, 2011, BRIT J CANCER, V104, P1786, DOI 10.1038/bjc.2011.161
   Skog M, 2011, BRIT J CANCER, V105, P1346, DOI 10.1038/bjc.2011.297
   Spalding AC, 2008, TRANSL ONCOL, V1, P195, DOI 10.1593/tlo.08151
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Tzenaki N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00040
   van Vlodrop IJH, 2011, CLIN CANCER RES, V17, P4225, DOI 10.1158/1078-0432.CCR-10-3394
   Wu WKK, 2009, ANTICANCER RES, V29, P229
   Xu YM, 2012, GENOME RES, V22, P283, DOI 10.1101/gr.122788.111
   Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Zhang HT, 2007, J CLIN INVEST, V117, P2051, DOI 10.1172/JCI32278
NR 39
TC 15
Z9 15
U1 1
U2 7
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1234-1983
EI 2190-3883
J9 J APPL GENET
JI J. Appl. Genetics
PD MAY
PY 2015
VL 56
IS 2
BP 185
EP 192
DI 10.1007/s13353-014-0253-6
PG 8
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CG3XM
UT WOS:000353212900005
PM 25366420
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Rodrigues, MF
   Carvalho, É
   Pezzuto, P
   Rumjanek, FD
   Amoêdo, ND
AF Rodrigues, Mariana Figueiredo
   Carvalho, Erika
   Pezzuto, Paula
   Rumjanek, Franklin David
   Amoedo, Nivea Dias
TI Reciprocal Modulation of Histone Deacetylase Inhibitors Sodium Butyrate
   and Trichostatin A on the Energy Metabolism of Breast Cancer Cells
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE BREAST CANCER; MITOCHONDRIAL PHYSIOLOGY; SODIUM BUTYRATE; TRICHOSTATIN A
ID ATP-CITRATE LYASE; ACETYLATION; DEHYDROGENASE; COMBINATION; MECHANISMS;
   EXPRESSION; SURVIVAL; LACTATE; TARGETS; GROWTH
AB Tumor cells display different bioenergetic profiles when compared to normal cells. In the present work we showed metabolic reprogramming by means of inhibitors of histone deacetylase (HDACis), sodium butyrate and trichostatin A in breast cancer cells representing different stages of aggressiveness and metabolic profile. When testing the effect of NaB and TSA on viability of cells, it was shown that non-tumorigenic MCF-10A cells were less affected by increasing doses of the drugs than the tumorigenic, hormone dependent, tightly cohesive MCF-7, T-47D and the highly metastatic triple-negative MDA-MB 231 cells. T-47D cells were the most sensitive to treatment with both, NaB and TSA. Experiments measuring anchorage-independent growth of tumor cells showed that MCF-7, T-47D, and MDA-MB-231 cells were equally sensitive to the treatment with NaB. The NaB induced an attenuation of glycolysis, reflected by a decrease in lactate release in MCF-7 and T47D lines. Pyruvate kinase activity was significantly enhanced by NaB in MDA-MB-231 cells only. In contrast, the inhibitor enhanced lactate dehydrogenase activity specifically in T-47 D cells. Glucose-6-phosphate dehydrogenase activity was shown to be differentially modulated by NaB in the cell lines investigated: the enzyme was inhibited in MCF-7 cells, whereas in T-47D and MDA-MB-231 cells, G6PDH was activated. NaB and TSA were able to significantly increase the oxygen consumption by MDA-MB-231 and T-47D cells. Collectively the results show that epigenetic changes associated to acetylation of proteins in general affect the energy metabolism in all cancer cell lines and that mitochondria may occupy a central role in metastasis. J. Cell. Biochem. 116: 797-808, 2015. (C) 2014 Wiley Periodicals, Inc.
C1 [Rodrigues, Mariana Figueiredo; Carvalho, Erika; Rumjanek, Franklin David; Amoedo, Nivea Dias] Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo De Meis, Ilha Fundao, BR-21941590 Rio De Janeiro, Brazil.
   [Pezzuto, Paula] Univ Fed Rio de Janeiro, Inst Biol, Ilha Fundao, Dept Genet, BR-21941590 Rio De Janeiro, Brazil.
C3 Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de
   Janeiro
RP Amoêdo, ND (通讯作者)，Univ Fed Rio de Janeiro, Inst Bioquim Med Leopoldo De Meis, Ilha Fundao, Ave Carlos Chagas Filho 373 BLE 22, BR-21941590 Rio De Janeiro, Brazil.
EM amoedo@bioqmed.ufrj.br
FU CAPES; FAPERJ; FAF-ONCO; INCT/CNPq-Cancer [573806/2008-0]
FX Grant sponsor: CAPES; Grant sponsor: FAPERJ; Grant sponsor: FAF-ONCO;
   Grant sponsor: INCT/CNPq-Cancer; Grant number: 573806/2008-0.
CR Amoedo ND, 2013, BIOSCIENCE REP, V15, P33
   Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Coller HA, 2014, AM J PATHOL, V184, P4, DOI 10.1016/j.ajpath.2013.07.035
   Falchook GS, 2013, INVEST NEW DRUG, V31, P1192, DOI 10.1007/s10637-013-0003-3
   Gonçalves P, 2013, CURR DRUG METAB, V14, P994
   Grant C, 2010, EXPERT REV ANTICANC, V10, P997, DOI [10.1586/era.10.88, 10.1586/ERA.10.88]
   Guan KL, 2011, TRENDS BIOCHEM SCI, V36, P108, DOI 10.1016/j.tibs.2010.09.003
   HAMILTON SD, 1984, CLIN CHEM, V30, P226
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hitchiler MJ, 2008, FREE RADICAL BIO MED, V45, P1573, DOI 10.1016/j.freeradbiomed.2008.09.005
   Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889
   Hutter E, 2004, BIOCHEM J, V380, P919, DOI 10.1042/BJ20040095
   Kaufman JL, 2013, CL LYMPH MYELOM LEUK, V13, P370, DOI 10.1016/j.clml.2013.03.016
   Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026
   Lee JH, 2012, ADV CANCER RES, V116, P39, DOI 10.1016/B978-0-12-394387-3.00002-1
   Li TT, 2014, J BIOL CHEM, V289, P3775, DOI 10.1074/jbc.M113.531640
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mariadason John M, 2014, ANTIOXID REDOX SIGN, DOI [10.1089/ars.2014.5863, DOI 10.1089/ARS.2014.5863.]
   Moreno-Sánchez R, 2014, INT J BIOCHEM CELL B, V50, P10, DOI 10.1016/j.biocel.2014.01.025
   Moreno-Sánchez R, 2012, J CELL BIOCHEM, V113, P1692, DOI 10.1002/jcb.24039
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Owens KM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023846
   Sastre-Serra J, 2013, INT J BIOCHEM CELL B, V45, P1509, DOI 10.1016/j.biocel.2013.04.007
   SKEHAN P, 1990, JNCI-J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107
   Sun SJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091610
   Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102
   Wang YP, 2014, EMBO J, V33, P1304, DOI 10.1002/embj.201387224
   Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097
   Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620
   Zaidi N, 2012, CANCER RES, V72, P3709, DOI 10.1158/0008-5472.CAN-11-4112
   Zhao D, 2013, CANCER CELL, V23, P464, DOI 10.1016/j.ccr.2013.02.005
NR 33
TC 32
Z9 34
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD MAY
PY 2015
VL 116
IS 5
BP 797
EP 808
DI 10.1002/jcb.25036
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CF8ND
UT WOS:000352817300012
PM 25510910
DA 2025-01-12
ER

PT J
AU Baldan, F
   Mio, C
   Lavarone, E
   Di Loreto, C
   Puglisi, F
   Damante, G
   Puppin, C
AF Baldan, Federica
   Mio, Catia
   Lavarone, Elisa
   Di Loreto, Carla
   Puglisi, Fabio
   Damante, Giuseppe
   Puppin, Cinzia
TI Epigenetic bivalent marking is permissive to the synergy of HDAC and
   PARP inhibitors on <i>TXNIP</i> expression in breast cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE HDAC; PARP1; epigenetics; cell proliferation
ID THIOREDOXIN-INTERACTING PROTEIN; HISTONE DEACETYLASE INHIBITION; BINDING
   PROTEIN-2; COMBINATION; GROWTH; LINES; GENE; PJ34
AB Studies on stem cell differentiation led to the identification of paused genes, characterized by the contemporary presence of both activator and repressor epigenetic markers (bivalent marking). TXNIP is an oncosuppressor gene the expression of which was reduced in breast cancer. In the present study, we evaluated whether the concept of epigenetic bivalent marking can be applied to TXNIP gene in breast cancer cells. Using chromatin immunoprecipitation (ChIP), three histone modifications were investigated: two associated with transcriptional activation, lysines 9-14 acetylation of H3 histone (H3K9K14ac) and lysine 4 trimethylation of H3 histone (H3K4me3), and one associated with transcriptional silencing, lysine 27 trimethylation of H3 histone (H3K27me3). According to the bivalent marking model, TXNIP gene appears to be paused in MDA157 cells (markers of active and repressed transcription are present), but are definitively silenced in MDA468 cells (presence of only markers of transcription repression). This was proven by evaluating TXNIP mRNA and protein levels after the treatment of cell lines with a histone deacetylase inhibitor (SAHA) and a poly-ADPribose polymerases inhibitor (PJ34). In MDA157 cells, SAHA and PJ34 showed a synergistic effect: a large increment was observed in TXNIP mRNA and protein levels. By contrast, in MDA468 cells, synergy between the two compounds was not observed. Therefore, the pausing epigenetic signature was permissive for synergy between SAHA and PJ34 on TXNIP gene expression. The synergy between SAHA and PJ34 on TXNIP expression was associated with variation in cell viability and apoptosis. In MDA157 cells, but not in MDA468 cells, combined treatment of SAHA and PJ34 induced a decrease in cell viability and an increase of apoptosis. Thus, our data support the hypothesis that TXNIP is an effective target for the treatment of breast cancer.
C1 [Baldan, Federica; Mio, Catia; Lavarone, Elisa; Di Loreto, Carla; Damante, Giuseppe; Puppin, Cinzia] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy.
   [Di Loreto, Carla] Univ Hosp S Maria della Misericordia Udine, Inst Pathol Anat, Udine, Italy.
   [Puglisi, Fabio] Univ Hosp S Maria della Misericordia Udine, Dept Oncol, Udine, Italy.
   [Damante, Giuseppe] Univ Hosp S Maria della Misericordia Udine, Inst Med Genet, Udine, Italy.
C3 University of Udine; Hospital Santa Maria della Misericordia; Hospital
   Santa Maria della Misericordia; Hospital Santa Maria della Misericordia
RP Damante, G (通讯作者)，Dipartimento Sci Med & Biol, Piazza Kolbe 4, I-33100 Udine, Italy.
EM giuseppe.damante@uniud.it
RI Lavarone, Elisa/I-4853-2012; Baldan, Federica/AAK-6349-2021; mio,
   catia/AAW-1604-2021; Damante, Giuseppe/AAC-5200-2022; Puglisi,
   Fabio/N-3863-2017; Baldan, Federica/B-5977-2016
OI Puglisi, Fabio/0000-0003-0573-4938; Baldan,
   Federica/0000-0003-1164-1316; Damante, Giuseppe/0000-0003-2312-4009;
   mio, catia/0000-0002-6245-8266
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 10296]
FX This study is funded by grants to GD from Associazione Italiana per la
   Ricerca sul Cancro (AIRC) (project no. IG 10296).
CR Baldan F, 2014, MOL BIOL REP, V41, P5257, DOI 10.1007/s11033-014-3397-x
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299
   Cadenas C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2599
   Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307
   Chen Alice, 2011, Chin J Cancer, V30, P463, DOI 10.5732/cjc.011.10111
   Chen KS, 1994, BIOCHIM BIOPHYS ACTA, V1219, P1226
   Chu BF, 2013, CANCER CHEMOTH PHARM, V71, P115, DOI 10.1007/s00280-012-1986-8
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Elgort Marc G, 2010, Genes Cancer, V1, P893, DOI 10.1177/1947601910389604
   Falchook GS, 2013, INVEST NEW DRUG, V31, P1192, DOI 10.1007/s10637-013-0003-3
   Frullanti E, 2012, INT J CANCER, V131, pE643, DOI 10.1002/ijc.27426
   Füllgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121
   Jasek E, 2014, ANTICANCER RES, V34, P1849
   Kaimul AM, 2007, FREE RADICAL BIO MED, V43, P861, DOI 10.1016/j.freeradbiomed.2007.05.032
   Ku WL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077944
   Lavarone E, 2013, MOL CELL ENDOCRINOL, V365, P1, DOI 10.1016/j.mce.2012.08.019
   Lee JM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju089
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Nishizawa K, 2011, CARCINOGENESIS, V32, P1459, DOI 10.1093/carcin/bgr137
   Patwari P, 2009, J BIOL CHEM, V284, P24996, DOI 10.1074/jbc.M109.018093
   Russo D, 2011, J MOL ENDOCRINOL, V46, pR73, DOI 10.1530/JME-10-0150
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Spindel ON, 2012, ANTIOXID REDOX SIGN, V16, P587, DOI 10.1089/ars.2011.4137
   Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102
   Yamaguchi F, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-468
   Zhou JB, 2013, MITOCHONDRION, V13, P163, DOI 10.1016/j.mito.2012.06.004
   Zhou JBA, 2011, INT J BIOCHEM CELL B, V43, P1668, DOI 10.1016/j.biocel.2011.09.005
NR 28
TC 15
Z9 16
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2015
VL 33
IS 5
BP 2199
EP 2206
DI 10.3892/or.2015.3873
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CG3LE
UT WOS:000353180900014
PM 25812606
OA Bronze
DA 2025-01-12
ER

PT J
AU Muñoz-Rodríguez, JL
   Vrba, L
   Futscher, BW
   Hu, CC
   Komenaka, IK
   Meza-Montenegro, MM
   Gutierrez-Millan, LE
   Daneri-Navarro, A
   Thompson, PA
   Martinez, ME
AF Munoz-Rodriguez, Jose L.
   Vrba, Lukas
   Futscher, Bernard W.
   Hu, Chengcheng
   Komenaka, Ian K.
   Mercedes Meza-Montenegro, Maria
   Enrique Gutierrez-Millan, Luis
   Daneri-Navarro, Adrian
   Thompson, Patricia A.
   Martinez, Maria Elena
TI Differentially Expressed MicroRNAs in Postpartum Breast Cancer in
   Hispanic Women
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; TRANSIENT INCREASE; PREGNANCY; RISK; GENE; AGE;
   INACTIVATION; PROGRESSION; METASTASIS; SIGNATURE
AB The risk of breast cancer transiently increases immediately following pregnancy; peaking between 3-7 years. The biology that underlies this risk window and the effect on the natural history of the disease is unknown. MicroRNAs (miRNAs) are small non-coding RNAs that have been shown to be dysregulated in breast cancer. We conducted miRNA profiling of 56 tumors from a case series of multiparous Hispanic women and assessed the pattern of expression by time since last full-term pregnancy. A data-driven splitting analysis on the pattern of 355 miRNAs separated the case series into two groups: a) an early group representing women diagnosed with breast cancer <= 5.2 years postpartum (n = 12), and b) a late group representing women diagnosed with breast cancer >= 5.3 years postpartum (n = 44). We identified 15 miRNAs with significant differential expression between the early and late postpartum groups; 60% of these miRNAs are encoded on the X chromosome. Ten miRNAs had a two-fold or higher difference in expression with miR-138, miR-660, miR-31, miR-135b, miR-17, miR-454, and miR-934 overexpressed in the early versus the late group; while miR-892a, miR-199a-5p, and miR-542-5p were underexpressed in the early versus the late postpartum group. The DNA methylation of three out of five tested miRNAs (miR-31, miR-135b, and miR-138) was lower in the early versus late postpartum group, and negatively correlated with miRNA expression. Here we show that miRNAs are differentially expressed and differentially methylated between tumors of the early versus late postpartum, suggesting that potential differences in epigenetic dysfunction may be operative in postpartum breast cancers.
C1 [Munoz-Rodriguez, Jose L.; Vrba, Lukas; Futscher, Bernard W.] Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA.
   [Munoz-Rodriguez, Jose L.; Futscher, Bernard W.] Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA.
   [Hu, Chengcheng] Univ Arizona, Dept Epidemiol & Biostat, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA.
   [Komenaka, Ian K.] Maricopa Cty Gen Hosp, Dept Surg, Phoenix, AZ USA.
   [Mercedes Meza-Montenegro, Maria] Inst Tecnol Sonora, Obregon, Mexico.
   [Enrique Gutierrez-Millan, Luis] Univ Sonora, Dept Invest Cient & Tecnol, Hermosillo 83000, Sonora, Mexico.
   [Daneri-Navarro, Adrian] Univ Guadalajara, Dept Fisiol, Ctr Univ Ciencias Salud, Guadalajara 44430, Jalisco, Mexico.
   [Thompson, Patricia A.] Univ Arizona, Dept Cellular & Mol Med, Tucson, AZ USA.
   [Martinez, Maria Elena] Univ Calif San Diego, Dept Family & Prevent Med, La Jolla, CA 92093 USA.
C3 University of Arizona; University of Arizona; University of Arizona;
   Maricopa County General Hospital; Universidad de Sonora; Universidad de
   Guadalajara; University of Arizona; University of California System;
   University of California San Diego
RP Futscher, BW (通讯作者)，Univ Arizona, Ctr Canc, Tucson, AZ 85721 USA.
EM bfutscher@uacc.arizona.edu
RI Hu, Chengcheng/A-8391-2017; Komenaka, Ian/ABC-5161-2021; Vrba,
   Lukas/J-9268-2015; Daneri-Navarro, Adrian/C-1935-2013; Munoz Rodriguez,
   Jose Manuel/A-7323-2016
OI Vrba, Lukas/0000-0003-3042-6275; Daneri-Navarro,
   Adrian/0000-0002-8206-749X; Meza-Montenegro, Maria
   Mercedes/0000-0002-1199-9310; Munoz Rodriguez, Jose
   Manuel/0000-0002-4688-6420; Hu, Chengcheng/0000-0001-8525-0356;
   Thompson, Patricia/0009-0007-3799-0334
FU National Cancer Institute [3U01CA153086-01, 3U01CA153086-02S1]
FX The project described was supported by Grant Number 3U01CA153086-01 from
   the National Cancer Institute. JLMR also received support under the
   Research Supplements to Promote Diversity in Health-Related Research
   Program, Grant Number 3U01CA153086-02S1 from the National Cancer
   Institute. The content of this study is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Cancer Institute or the National Institutes of Health. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Albrektsen G, 2005, BRIT J CANCER, V92, P167, DOI 10.1038/sj.bjc.6602302
   ALBREKTSEN G, 1995, BRIT J CANCER, V72, P480, DOI 10.1038/bjc.1995.359
   Ambros V, 2003, RNA, V9, P277, DOI 10.1261/rna.2183803
   [Anonymous], 2012, CANC FACTS FIG HISP
   [Anonymous], BREAST CANC FACTS
   [Anonymous], STAT BIOL HEALTH
   [Anonymous], 2014, IARC CANC BASE
   Arigoni M, 2013, AM J PATHOL, V182, P2058, DOI 10.1016/j.ajpath.2013.02.046
   Aure MR, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r126
   Ben Gacem R, 2014, TUMOR BIOL, V35, P4047, DOI 10.1007/s13277-013-1530-4
   Berletch JB, 2011, HUM GENET, V130, P237, DOI 10.1007/s00439-011-1011-z
   Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018
   Caldas C, 2005, NAT MED, V11, P712, DOI 10.1038/nm0705-712
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Callihan EB, 2013, BREAST CANCER RES TR, V138, P549, DOI 10.1007/s10549-013-2437-x
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Chaligné R, 2014, FEBS LETT, V588, P2514, DOI 10.1016/j.febslet.2014.06.023
   Chie WC, 2000, AM J EPIDEMIOL, V151, P715, DOI 10.1093/oxfordjournals.aje.a010266
   Demicheli R, 2007, CANCER-AM CANCER SOC, V110, P1880, DOI 10.1002/cncr.22998
   Friend KE, 2012, AM SURGEON, V78, P819
   Fury Wen, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5531
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267
   Guo L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/782490
   Jinda S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3633
   Key TJ, 2001, LANCET ONCOL, V2, P133, DOI 10.1016/S1470-2045(00)00254-0
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102
   Laurila EM, 2013, GENE CHROMOSOME CANC, V52, P1103, DOI 10.1002/gcc.22107
   Lee YC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052979
   Liu Q, 2002, CANCER CAUSE CONTROL, V13, P299, DOI 10.1023/A:1015287208222
   Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566
   Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Luo DY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-57
   Lyons TR, 2009, J MAMMARY GLAND BIOL, V14, P87, DOI 10.1007/s10911-009-9119-7
   Martinez ME., 2010, Health, V2, P1040, DOI DOI 10.4236/HEALTH.2010.29153
   Morita S, 2012, INT J MOL SCI, V13, P8259, DOI 10.3390/ijms13078259
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Novak P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052299
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484
   R Core Team, 2014, R LANG ENV STAT COMP
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Risendal B, 2008, CANCER CAUSE CONTROL, V19, P1349, DOI 10.1007/s10552-008-9206-x
   Schaap-Oziemlak AM, 2010, STEM CELLS DEV, V19, P877, DOI 10.1089/scd.2009.0112
   Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398
   Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Yuan JH, 2003, CANCER RES, V63, P4174
NR 55
TC 27
Z9 28
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 13
PY 2015
VL 10
IS 4
AR e0124340
DI 10.1371/journal.pone.0124340
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CF8XK
UT WOS:000352845100251
PM 25875827
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Felts, SJ
   Van Keulen, VP
   Hansen, MJ
   Bell, MP
   Allen, K
   Belachew, AA
   Vile, RG
   Cunningham, JM
   Hoskin, TL
   Pankratz, VS
   Pease, LR
AF Felts, Sara J.
   Van Keulen, Virginia P.
   Hansen, Michael J.
   Bell, Michael P.
   Allen, Kathleen
   Belachew, Alem A.
   Vile, Richard G.
   Cunningham, Julie M.
   Hoskin, Tanya L.
   Pankratz, V. Shane
   Pease, Larry R.
TI Widespread Non-Canonical Epigenetic Modifications in MMTV-NeuT Breast
   Cancer
SO NEOPLASIA
LA English
DT Article
ID MAMMARY-TUMORS; MOUSE MODELS; MUTATIONAL PROCESSES; METHYLATION;
   THERAPY; HETEROZYGOSITY; HETEROGENEITY; AMPLIFICATION; SIGNATURES;
   VACCINE
AB Breast tumors in (FVB x BALB-NeuT) F1 mice have characteristic loss of chromosome 4 and sporadic loss or gain of other chromosomes. We employed the Illumina GoldenGate genotyping platform to quantitate loss of heterozygosity (LOH) across the genome of primary tumors, revealing strong biases favoring chromosome 4 alleles from the FVB parent. While allelic bias was not observed on other chromosomes, many tumors showed concerted LOH (C-LOH) of all alleles of one or the other parent on sporadic chromosomes, a pattern consistent with cytogenetic observations. Surprisingly, comparison of LOH in tumor samples relative to normal unaffected tissues from these animals revealed significant variegated (stochastic) deviations from heterozygosity (V-LOH) in every tumor genome. Sequence analysis showed expected changes in the allelic frequency of single nucleotide polymorphisms (SNPs) in cases of C-LOH. However, no evidence of LOH due to mutations, small deletions, or gene conversion at the affected SNPs or surrounding DNA was found at loci with V-LOH. Postulating an epigenetic mechanism contributing to V-LOH, we tested whether methylation of template DNA impacts allele detection efficiency using synthetic oligonucleotide templates in an assay mimicking the GoldenGate genotyping format. Methylated templates were systematically over-scored, suggesting that the observed patterns of V-LOH may represent extensive epigenetic DNA modifications across the tumor genomes. As most of the SNPs queried do not contain standard (CpG) methylation targets, we propose that widespread, non-canonical DNA modifications occur during Her2/neuT-driven tumorigenesis.
C1 [Felts, Sara J.; Van Keulen, Virginia P.; Hansen, Michael J.; Bell, Michael P.; Allen, Kathleen; Belachew, Alem A.; Vile, Richard G.; Pease, Larry R.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA.
   [Vile, Richard G.] Mayo Clin, Coll Med, Dept Mol Med, Rochester, MN 55905 USA.
   [Cunningham, Julie M.] Mayo Clin, Coll Med, Dept Lab Med, Rochester, MN 55905 USA.
   [Pease, Larry R.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA.
C3 Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic
RP Pease, LR (通讯作者)，Mayo Clin, Coll Med, Dept Immunol, 200 First St SW, Rochester, MN 55905 USA.
EM pease.larry@mayo.edu
RI Cunningham, Julie/KII-0320-2024
FU Mayo Clinic Cancer Center [CA15083]
FX SKY and cytogenetic analyses were provided by Darlene Knutson and
   Patricia T. Greipp in the Mayo Cytogenetics Core. Additional technical
   support from the Genotyping and Molecular Biology cores (supported by
   the Mayo Clinic Cancer Center CA15083) is appreciated.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Alexandrov LB, 2013, CELL REP, V3, P246, DOI 10.1016/j.celrep.2012.12.008
   Andrechek ER, 2010, J MOL MED, V88, P1095, DOI 10.1007/s00109-010-0644-z
   Bacolod MD, 2009, CANCER RES, V69, P723, DOI 10.1158/0008-5472.CAN-08-3543
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   Chi M, 2011, MELANOMA RES, V21, P165, DOI 10.1097/CMR.0b013e328346554d
   Cool M, 2006, GENE CHROMOSOME CANC, V45, P191, DOI 10.1002/gcc.20276
   Cool M, 1999, CANCER RES, V59, P2438
   Draube A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018801
   Dutt A, 2007, CURR OPIN ONCOL, V19, P43, DOI 10.1097/CCO.0b013e328011a8c1
   Ellsworth RE, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-297
   Florescu A, 2011, CURR ONCOL, V18, pE9
   Gendler SJ, 2001, TRENDS MOL MED, V7, P471, DOI 10.1016/S1471-4914(01)02124-4
   Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298
   Guo JU, 2014, NAT NEUROSCI, V17, P215, DOI 10.1038/nn.3607
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Jin BL, 2012, CELL REP, V2, P1411, DOI 10.1016/j.celrep.2012.10.017
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   López CMR, 2010, ANAL CHEM, V82, P9100, DOI 10.1021/ac1024057
   Montagna C, 2002, ONCOGENE, V21, P890, DOI 10.1038/sj.onc.1205146
   Nava-Parada P, 2007, CANCER RES, V67, P1326, DOI 10.1158/0008-5472.CAN-06-3290
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Novak P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052299
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Nowsheen S, 2014, CANCER LETT, V342, P213, DOI 10.1016/j.canlet.2012.05.015
   Padilla-Nash HM, 2012, GENE CHROMOSOME CANC, V51, P353, DOI 10.1002/gcc.21921
   Quaglino Elena, 2008, Curr Protoc Immunol, VChapter 20, DOI 10.1002/0471142735.im2009s82
   Ritland SR, 1997, CANCER RES, V57, P3520
   Stroud H, 2014, NAT STRUCT MOL BIOL, V21, P64, DOI 10.1038/nsmb.2735
   Ursini-Siegel J, 2007, NAT REV CANCER, V7, P389, DOI 10.1038/nrc2127
   Varghese S, 2007, CANCER RES, V67, P9371, DOI 10.1158/0008-5472.CAN-07-0674
   Weaver ZA, 1999, GENE CHROMOSOME CANC, V25, P251, DOI 10.1002/(SICI)1098-2264(199907)25:3<251::AID-GCC7>3.3.CO;2-V
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 34
TC 3
Z9 4
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1476-5586
J9 NEOPLASIA
JI Neoplasia
PD APR
PY 2015
VL 17
IS 4
BP 348
EP 357
DI 10.1016/j.neo.2015.02.006
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CG9HV
UT WOS:000353626700003
PM 25925377
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Nagarajan, S
   Benito, E
   Fischer, A
   Johnsen, SA
AF Nagarajan, Sankari
   Benito, Eva
   Fischer, Andre
   Johnsen, Steven A.
TI H4K12ac is regulated by estrogen receptor-alpha and is associated with
   BRD4 function and inducible transcription
SO ONCOTARGET
LA English
DT Article
DE Histone acetylation; bromodomain; estrogen; epigenetics; chromatin
ID RNA-POLYMERASE-II; HISTONE DEACETYLASE INHIBITOR; BET BROMODOMAIN
   INHIBITION; H2B MONOUBIQUITINATION; MEDIATED TRANSCRIPTION; ER-ALPHA;
   P-TEFB; ACETYLATION; ACTIVATION; BINDING
AB Hormone-dependent gene expression requires dynamic and coordinated epigenetic changes. Estrogen receptor-positive (ER+) breast cancer is particularly dependent upon extensive chromatin remodeling and changes in histone modifications for the induction of hormone-responsive gene expression. Our previous studies established an important role of bromodomain-containing protein-4 (BRD4) in promoting estrogen-regulated transcription and proliferation of ER+ breast cancer cells. Here, we investigated the association between genome-wide occupancy of histone H4 acetylation at lysine 12 (H4K12ac) and BRD4 in the context of estrogen-induced transcription. Similar to BRD4, we observed that H4K12ac occupancy increases near the transcription start sites (TSS) of estrogen-induced genes as well as at distal ERa binding sites in an estrogen-dependent manner. Interestingly, H4K12ac occupancy highly correlates with BRD4 binding and enhancer RNA production on ERa-positive enhancers. Consistent with an importance in estrogen-induced gene transcription, H4K12ac occupancy globally increased in ER-positive cells relative to ER-negative cells and these levels were further increased by estrogen treatment in an ERa-dependent manner. Together, these findings reveal a strong correlation between H4K12ac and BRD4 occupancy with estrogen-dependent gene transcription and further suggest that modulators of H4K12ac and BRD4 may serve as new therapeutic targets for hormone-dependent cancers.
C1 [Nagarajan, Sankari; Johnsen, Steven A.] Univ Med Ctr Gottingen, Dept Gen Visceral & Pediat Surg, Gottingen, Germany.
   [Benito, Eva; Fischer, Andre] Univ Med Ctr Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany.
   [Fischer, Andre] German Ctr Neurodegenerat Dis DZNE Gottingen, Res Grp Epigenet Neurodegenerat Dis, Gottingen, Germany.
C3 University of Gottingen; UNIVERSITY GOTTINGEN HOSPITAL; Helmholtz
   Association; German Center for Neurodegenerative Diseases (DZNE)
RP Johnsen, SA (通讯作者)，Univ Med Ctr Gottingen, Dept Gen Visceral & Pediat Surg, Gottingen, Germany.
EM steven.johnsen@med.uni-goettingen.de
RI Fischer, Andre/AAU-7487-2021; Johnsen, Steven/AAX-2322-2020; Benito,
   Eva/AAN-9604-2020; Nagarajan, Sankari/ACC-0438-2022
OI Benito, Eva/0000-0003-0094-0257; Johnsen, Steven/0000-0003-1198-5805;
   Fischer, Andre/0000-0001-8546-1161
FU German Academic Exchange Service (DAAD); Deutsche Krebshilfe [109088,
   111600]
FX The authors acknowledge W. Xie, Z. Najafova and T. Hossan for scientific
   discussions and suggestions. We would also like to thank U. Bedi and Z.
   Najafova for providing raw data for sequencing of H3K27ac in MCF10A
   cells. This work was funded by the German Academic Exchange Service
   (DAAD) (to S.N.) and the Deutsche Krebshilfe (109088 and 111600 to
   S.A.J.).
CR ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786
   Alsarraj J, 2011, CANCER RES, V71, P3121, DOI 10.1158/0008-5472.CAN-10-4417
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Asangani IA, 2014, NATURE, V510, P278, DOI 10.1038/nature13229
   Bedi U, 2014, ONCOGENE, P1
   Belikov S, 2012, EXP CELL RES, V318, P61, DOI 10.1016/j.yexcr.2011.09.016
   Bhadury J, 2014, P NATL ACAD SCI USA, V111, pE2721, DOI 10.1073/pnas.1406722111
   Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638
   Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003
   Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a
   Devaiah BN, 2012, P NATL ACAD SCI USA, V109, P6927, DOI 10.1073/pnas.1120422109
   ECKERT RL, 1984, ENDOCRINOLOGY, V114, P629, DOI 10.1210/endo-114-2-629
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Feng Q, 2014, CELL RES, V24, P809, DOI 10.1038/cr.2014.71
   Fierz B, 2011, NAT CHEM BIOL, V7, P113, DOI 10.1038/NCHEMBIO.501
   Fiskus W, 2014, MOL CANCER THER, V13, P1142, DOI 10.1158/1535-7163.MCT-13-0770
   Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Johnsen SA, 2012, FEBS LETT, V586, P1592, DOI 10.1016/j.febslet.2012.04.002
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Jung M, 2014, J BIOL CHEM, V289, P9304, DOI 10.1074/jbc.M113.523019
   Kaikkonen MU, 2013, MOL CELL, V51, P310, DOI 10.1016/j.molcel.2013.07.010
   Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6
   Kanno T, 2014, NAT STRUCT MOL BIOL
   Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103
   Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022
   Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]
   Li WB, 2013, NATURE, V498, P516, DOI 10.1038/nature12210
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485
   Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810
   Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Métivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626
   Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021
   Pavri R, 2006, CELL, V125, P703, DOI 10.1016/j.cell.2006.04.029
   Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200
   Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108
   Prenzel T, 2011, CANCER RES, V71, P1
   Ramirez F, 2014, NUCLEIC ACIDS RES
   Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599
   Sun JM, 2001, J BIOL CHEM, V276, P49435, DOI 10.1074/jbc.M108364200
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Voss TC, 2014, NAT REV GENET, V15, P69, DOI 10.1038/nrg3623
   WAKELING AE, 1992, J STEROID BIOCHEM, V43, P173, DOI 10.1016/0960-0760(92)90204-V
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8
   Yang ZY, 2005, MOL CELL, V19, P535, DOI 10.1016/j.molcel.2005.06.029
   Zhang WS, 2012, J BIOL CHEM, V287, P43137, DOI 10.1074/jbc.M112.413047
   Zippo A, 2009, CELL, V138, P1122, DOI 10.1016/j.cell.2009.07.031
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 67
TC 24
Z9 33
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 30
PY 2015
VL 6
IS 9
BP 7305
EP 7317
DI 10.18632/oncotarget.3439
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CF8GI
UT WOS:000352793800060
PM 25788266
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Sakane, C
   Ohta, H
   Shidoji, Y
AF Sakane, Chiharu
   Ohta, Hiromichi
   Shidoji, Yoshihiro
TI Measurement of lysine-specific demethylase-1 activity in the nuclear
   extracts by flow-injection based time-of-flight mass spectrometry
SO JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION
LA English
DT Article
DE lysine-specific demethylase 1; time-of-flight mass spectrometry;
   consecutive reactions; epigenetics
ID HISTONE DEMETHYLASE; HIGH-THROUGHPUT; LSD1; INHIBITION; CELLS; ASSAY;
   ACID
AB Lysine-specific demethylase 1 (LSD1/KDM1A), a histone-modifying enzyme, is upregulated in many cancers, especially in neuroblastoma, breast cancer and hepatoma. We have established a simple method to measure LSD1 activity using a synthetic N-terminal 21-mer peptide of histone H3, which is dimethylated at Lys-4 (H3K4me2). After the enzyme reaction, a substrate of H3K4me2 and two demethylated products, H3K4me1 and H3K4me0, were quantitatively determined by flow injection time-of-flight mass spectrometry (FI-TOF/MS). By using recombinant human LSD1, a nonlinear fitting simulation of the data obtained by FI-TOF/MS produced typical consecutive-reaction kinetics. Apparent K-m and k(cat) values of hLSD1 for the first and second demethylation reactions were found to be in the range of reported values. Tranylcypromine was shown to inhibit LSD1 activity with an IC50 of 6.9 mu M for the first demethylation reaction and 5.8 mu M for the second demethylation reaction. The FI-TOF/MS assay revealed that the endogenous LSD1 activity was higher in the nuclear extracts of SH-SY5Y cells than in He La or PC-3 cells, and this is in accordance with the immunoblotting data using an anti-LSD1 antibody. A simple, straightforward FI-TOF/MS assay is described to efficiently measure LSD1 activity in the nuclear extracts of cultured cells.
C1 [Sakane, Chiharu; Shidoji, Yoshihiro] Nagasaki Univ, Grad Sch Human Hlth Sci, Mol & Cellular Biol, Nagoya, Nagasaki 8512195, Japan.
   [Ohta, Hiromichi] Nagasaki Univ, Sasebo, Nagasaki 8588580, Japan.
C3 Nagasaki University; Nagasaki University
RP Shidoji, Y (通讯作者)，Nagasaki Univ, Grad Sch Human Hlth Sci, Mol & Cellular Biol, 1-1-1 Manabino, Nagoya, Nagasaki 8512195, Japan.
EM shidoji@sun.ac.jp
FU Project Research Fund of University of Nagasaki, Japan
FX This work was financially supported by the research fund, Project
   Research Fund of the University of Nagasaki, Japan.
CR Abdulla Arian, 2013, J Biochem Pharmacol Res, V1, P56
   Benelkebir H, 2011, BIOORGAN MED CHEM, V19, P3709, DOI 10.1016/j.bmc.2011.02.017
   Blair LP, 2011, EPIGENETICS-US, V6, P491, DOI 10.4161/epi.6.4.14531
   Campbell RM, 2014, J CLIN INVEST, V124, P64, DOI 10.1172/JCI71605
   Chen XH, 2006, J AM CHEM SOC, V128, P12520, DOI 10.1021/ja063676o
   Ciccone DN, 2009, NATURE, V461, P415, DOI 10.1038/nature08315
   Cui SAY, 2011, MOL CELL BIOL, V31, P3298, DOI 10.1128/MCB.05310-11
   Forneris F, 2005, FEBS LETT, V579, P2203, DOI 10.1016/j.febslet.2005.03.015
   Forneris F, 2005, J BIOL CHEM, V280, P41360, DOI 10.1074/jbc.M509549200
   Forneris F, 2009, FEBS J, V276, P4304, DOI 10.1111/j.1742-4658.2009.07142.x
   Fuhrer T, 2011, ANAL CHEM, V83, P7074, DOI 10.1021/ac201267k
   Karytinos A, 2009, J BIOL CHEM, V284, P17775, DOI 10.1074/jbc.M109.003087
   Kaur P, 2013, NUTR REV, V71, P441, DOI 10.1111/nure.12030
   Lee MG, 2006, CHEM BIOL, V13, P563, DOI 10.1016/j.chembiol.2006.05.004
   Mimasu S, 2008, BIOCHEM BIOPH RES CO, V366, P15, DOI 10.1016/j.bbrc.2007.11.066
   Plant M, 2011, ANAL BIOCHEM, V419, P217, DOI 10.1016/j.ab.2011.07.002
   Sakane C, 2014, BIOCHEM BIOPH RES CO, V444, P24, DOI 10.1016/j.bbrc.2013.12.144
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Tsukada Y., 2010, COLD SPRING HARB PRO, V2010
   Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033
   Wang CH, 2012, ASSAY DRUG DEV TECHN, V10, P179, DOI 10.1089/adt.2011.0395
   Willmann D, 2012, INT J CANCER, V131, P2704, DOI 10.1002/ijc.27555
NR 25
TC 2
Z9 2
U1 1
U2 5
PU JOURNAL CLINICAL BIOCHEMISTRY & NUTRITION
PI KYOTO
PA KYOTO PREFECTURAL UNIV MED, GRAD SCH MEDICAL SCIENCE, DEPT MOLECULAR
   GASTROENTEROLOGY & HEPATOLOGY, KYOTO, 602-8566, JAPAN
SN 0912-0009
EI 1880-5086
J9 J CLIN BIOCHEM NUTR
JI J. Clin. Biochem. Nutr.
PD MAR 1
PY 2015
VL 56
IS 2
BP 123
EP 131
DI 10.3164/jcbn.14-99
PG 9
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA CG6TE
UT WOS:000353434500007
PM 25759518
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Kurbel, S
   Dmitrovic, B
   Marjanovic, K
   Kristek, B
AF Kurbel, Sven
   Dmitrovic, Branko
   Marjanovic, Ksenija
   Kristek, Branka
TI Testing tumor type dependent relations between expression of ER and PR
   with Ki-67 values in a single series of 1180 invasive ductal cancer
   patients
SO PERIODICUM BIOLOGORUM
LA English
DT Article
ID ESTROGEN-RECEPTOR GENE; HUMAN BREAST-CANCER; PROGESTERONE-RECEPTOR;
   MEDROXYPROGESTERONE ACETATE; TAMOXIFEN; MODEL; RISK; CARCINOMA; THERAPY;
   LESIONS
AB Background: Model of cancer-associated epigenetic changes (Kurbel S. Tumour Biol. 2013;34:2011-7) proposes that dysfunctional estrogen receptors (ER), unable to adequately express progesterone receptors (PgR), beside in the ER(+)PgR(-) breast cancers might also be present in ER(+)PgR(+) tumors showing weak PgR expression.
   Methods: In 1180 patients with invasive ductal cancers, ER and PgR positivity were semiquantitatively classified in four groups: "0" means no positive cells; "1+" <10% positive cells; "2+" 11-30% positive cells; and "3+" 31-100% positive cells. Tumors were divided in breast cancer types.
   Results: Among patients older than 54, LuminalA andB1 tumors were frequently ER3+ (p<0.01), while PgR(3+) tumors were more common among Luminal A patients younger than 55 (p=0.034), suggesting that in older Luminal A or B1 patients, high ER and low PgR expression is common. Among Luminal B2 patients, ER and PgR expression did not depend much on age or on their Ki-67 values.
   The model predicted share of dysfunctional ERs was 732% (for Luminal A), 11.26% (B1), 12.62% (B2 & Ki-67<=20%) and 14.73% (B2 er Ki-67>20%). The predicted values matched well with the found shares of ER(3+)PgR(1+) tumors within these three types (p>0.10).
   Conclusions: The results support heterogeneity among ER(+)PgR(+) tumors. Future studies of ER+PgR+ phenotype variants are required since hypothetical dysfunctional ERs in some ER(+)PgR(+) breast cancer patients might alter their endocrine treatment outcomes.
C1 [Kurbel, Sven] Sch Med, Dept Internal Med, Osijek, Croatia.
   [Dmitrovic, Branko; Marjanovic, Ksenija] Sch Med, Dept Pathol & Forens Med, Osijek, Croatia.
   [Kristek, Branka] Sch Med, Dept Radiol, Osijek, Croatia.
RP Kristek, B (通讯作者)，Sch Med, J Huttlera 4, Osijek 31000, Croatia.
EM kristek.branka@kbo.hr
RI Dmitrovic, Branko/AAP-4365-2020
OI Dmitrovic, Branko/0000-0002-5797-8013
CR Althuis MD, 2003, CANCER CAUSE CONTROL, V14, P151, DOI 10.1023/A:1023006000760
   American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, 2010, J CLIN ONCOL, V28, P2784
   BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43
   Boyd MT, 1996, BREAST CANCER RES TR, V37, P243, DOI 10.1007/BF01806506
   Britton JA, 2002, AM J EPIDEMIOL, V156, P507, DOI 10.1093/aje/kwf065
   CLARK GM, 1984, J CLIN ONCOL, V2, P1102, DOI 10.1200/JCO.1984.2.10.1102
   CLASSEN S, 1993, J STEROID BIOCHEM, V45, P315, DOI 10.1016/0960-0760(93)90348-Z
   Cuzick J, 2003, LANCET, V361, P296, DOI 10.1016/S0140-6736(03)12342-2
   HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742
   JACQUEMIER JD, 1990, BREAST CANCER RES TR, V15, P109, DOI 10.1007/BF01810783
   Keshgegian AA, 1996, ARCH PATHOL LAB MED, V120, P970
   Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37
   Kurbel S, 2014, THEOR BIOL MED MODEL, V11, DOI 10.1186/1742-4682-11-29
   Kurbel S, 2013, TUMOR BIOL, V34, P2011, DOI 10.1007/s13277-013-0809-9
   Kurbel S, 2012, THEOR BIOL MED MODEL, V9, DOI 10.1186/1742-4682-9-35
   Kurbel S, 2012, INT J BIOL MARKER, V27, pE167, DOI 10.5301/JBM.2012.9313
   Li CI, 2001, J NATL CANCER I, V93, P1008, DOI 10.1093/jnci/93.13.1008
   Lo SS, 2004, BEST PRACT RES CL EN, V18, P97, DOI 10.1016/S1521-690X(03)00043-5
   LUNDGREN S, 1987, ANTICANCER RES, V7, P119
   Major MA, 2003, CANCER NURS, V26, p10S
   Mies C, 1996, DIAGN MOL PATHOL, V5, P39, DOI 10.1097/00019606-199603000-00007
   Naccarato AG, 2000, VIRCHOWS ARCH, V436, P431, DOI 10.1007/s004280050470
   NOGUCHI S, 1989, JPN J CANCER RES, V80, P244, DOI 10.1111/j.1349-7006.1989.tb02300.x
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pujol P, 1998, CANCER-AM CANCER SOC, V83, P698, DOI 10.1002/(SICI)1097-0142(19980815)83:4<698::AID-CNCR10>3.0.CO;2-N
   Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1
   Vereide AB, 2006, GYNECOL ONCOL, V101, P214, DOI 10.1016/j.ygyno.2005.10.030
   WALKER KJ, 1991, BRIT J CANCER, V64, P764, DOI 10.1038/bjc.1991.395
   ZELENIUCH-JACQUOTTE A, 1995, CANCER EPIDEM BIOMAR, V4, P857
NR 29
TC 1
Z9 2
U1 0
U2 5
PU PERIODICUM BIOLOGORUM
PI ZAGREB
PA HRVATSKO PRIRODOSLOVNO DRUSTVO ILICA 16/111, 41000 ZAGREB, CROATIA
SN 0031-5362
J9 PERIOD BIOL
JI Period. Biol.
PD DEC
PY 2014
VL 116
IS 4
BP 417
EP 424
PG 8
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA CG6SF
UT WOS:000353432000014
DA 2025-01-12
ER

PT J
AU Loginov, VI
   Dmitriev, AA
   Senchenko, VN
   Pronina, IV
   Khodyrev, DS
   Kudryavtseva, AV
   Krasnov, GS
   Gerashchenko, GV
   Chashchina, LI
   Kazubskaya, TP
   Kondratieva, TT
   Chashchina, LI
   Kazubskaya, TP
   Kondratieva, TT
   Lerman, MI
   Angeloni, D
   Braga, EA
   Kashuba, VI
AF Loginov, Vitaly I.
   Dmitriev, Alexey A.
   Senchenko, Vera N.
   Pronina, Irina V.
   Khodyrev, Dmitry S.
   Kudryavtseva, Anna V.
   Krasnov, George S.
   Gerashchenko, Ganna V.
   Chashchina, Larisa I.
   Kazubskaya, Tatiana P.
   Kondratieva, Tatiana T.
   Chashchina, Larisa I.
   Kazubskaya, Tatiana P.
   Kondratieva, Tatiana T.
   Lerman, Michael I.
   Angeloni, Debora
   Braga, Eleonora A.
   Kashuba, Vladimir I.
TI Tumor Suppressor Function of the <i>SEMA3B</i> Gene in Human Lung and
   Renal Cancers
SO PLOS ONE
LA English
DT Article
ID HUMAN-CHROMOSOME 3P21.3; CARCINOMA CELL-LINE; SEMAPHORIN 3B;
   GASTRIC-CANCER; BREAST-CANCER; PROMOTER HYPERMETHYLATION; EPIGENETIC
   INACTIVATION; HOMOZYGOUS DELETION; ALLELE LOSS; EXPRESSION
AB The SEMA3B gene is located in the 3p21.3 LUCA region, which is frequently affected in different types of cancer. The objective of our study was to expand our knowledge of the SEMA3B gene as a tumor suppressor and the mechanisms of its inactivation. In this study, several experimental approaches were used: tumor growth analyses and apoptosis assays in vitro and in SCID mice, expression and methylation assays and other. With the use of the small cell lung cancer cell line U2020 we confirmed the function of SEMA3B as a tumor suppressor, and showed that the suppression can be realized through the induction of apoptosis and, possibly, associated with the inhibition of angiogenesis. In addition, for the first time, high methylation frequencies have been observed in both intronic (32-39%) and promoter (44-52%) CpG-islands in 38 non-small cell lung carcinomas, including 16 squamous cell carcinomas (SCC) and 22 adenocarcinomas (ADC), and in 83 clear cell renal cell carcinomas (ccRCC). Correlations between the methylation frequencies of the promoter and the intronic CpG-islands of SEMA3B with tumor stage and grade have been revealed for SCC, ADC and ccRCC. The association between the decrease of the SEMA3B mRNA level and hypermethylation of the promoter and the intronic CpG-islands has been estimated in renal primary tumors (P < 0.01). Using qPCR, we observed on the average 10- and 14-fold decrease of the SEMA3B mRNA level in SCC and ADC, respectively, and a 4-fold decrease in ccRCC. The frequency of this effect was high in both lung (92-95%) and renal (84%) tumor samples. Moreover, we showed a clear difference (P < 0.05) of the SEMA3B relative mRNA levels in ADC with and without lymph node metastases. We conclude that aberrant expression and methylation of SEMA3B could be suggested as markers of lung and renal cancer progression.
C1 [Loginov, Vitaly I.; Pronina, Irina V.; Braga, Eleonora A.] Russian Acad Med Sci, Inst Gen Pathol & Pathophysiol, Lab Pathogen & Transcript, Moscow 125315, Russia.
   [Loginov, Vitaly I.; Pronina, Irina V.; Braga, Eleonora A.] Russian Acad Med Sci, Med Genet Res Ctr, Lab Mol Genet Complex Inherited Dis, Moscow 115478, Russia.
   [Dmitriev, Alexey A.; Senchenko, Vera N.; Kudryavtseva, Anna V.; Krasnov, George S.] Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Struct & Funct Genom, Moscow 119991, Russia.
   [Dmitriev, Alexey A.; Kudryavtseva, Anna V.] Minist Healthcare Russian Federat, PA Herzen Moscow Canc Res Inst, Dept Pathomorphol, Moscow 125284, Russia.
   [Khodyrev, Dmitry S.] Fed Med & Biol Agcy Russia, Fed Res Clin Ctr, Genet Lab, Moscow 115682, Russia.
   [Krasnov, George S.] Russian Acad Med Sci, Mechnikov Res Inst Vaccines & Sera, Biotechnol Lab, Moscow 105064, Russia.
   [Gerashchenko, Ganna V.; Chashchina, Larisa I.; Kashuba, Vladimir I.] Natl Acad Sci Ukraine, Inst Mol Biol & Genet, Dept Mol Oncogenet, UA-03680 Kiev, Ukraine.
   [Kazubskaya, Tatiana P.; Kondratieva, Tatiana T.] Russian Acad Med Sci, NN Blokhin Canc Res Ctr, Res Inst Clin Oncol, Moscow 115478, Russia.
   [Lerman, Michael I.] Affina Biotechnol, Sci Board, Stamford, CT 06902 USA.
   [Angeloni, Debora] Scuola Super Sant Anna, Inst Life Sci, I-56127 Pisa, Italy.
   [Angeloni, Debora] CNR, Inst Clin Physiol, I-56124 Pisa, Italy.
   [Angeloni, Debora] Ist Toscano Tumori, I-56124 Pisa, Italy.
   [Braga, Eleonora A.] Russian Acad Sci, Inst Biochem Phys, Lab Post Genom Mol Genet Res, Moscow 119334, Russia.
   [Kashuba, Vladimir I.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden.
C3 Russian Academy of Medical Sciences; Institute of General Pathology &
   Pathophysiology, RAMS; Research Centre for Medical Genetics; Russian
   Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt
   Institute of Molecular Biology, RAS; Russian Academy of Medical
   Sciences; Research Institute of Vaccines and Sera Mechnikov, RAMS;
   National Academy of Sciences Ukraine; Institute of Molecular Biology &
   Genetics of NASU; Russian Academy of Medical Sciences; N.N. Blokhin
   Russian Cancer Research Center; Scuola Superiore Sant'Anna; Consiglio
   Nazionale delle Ricerche (CNR); Istituto di Fisiologia Clinica
   (IFC-CNR); ISPRO Istituto per lo studio, la prevenzione e la rete
   oncologica; Russian Academy of Sciences; Emanuel Institute of
   Biochemical Physics; Karolinska Institutet
RP Senchenko, VN (通讯作者)，Russian Acad Sci, Engelhardt Inst Mol Biol, Lab Struct & Funct Genom, Moscow 119991, Russia.
EM versen@eimb.ru
RI Khodyrev, Dmitriy/M-7237-2014; Braga, Eleonora/P-5574-2016; Krasnov,
   George/E-6529-2014; Senchenko, Vera/C-8992-2014; Kashuba,
   Vladimir/AAO-7742-2020; Gerashchenko, Ganna/AAO-7703-2020; Карпухин,
   Александр/J-2337-2018; Kudryavtseva, Anna/C-9032-2014; Pronina,
   Irina/G-3951-2014; Dmitriev, Alexey/D-6109-2011; Gerashchenko,
   Ganna/N-3797-2017; Kashuba, Vladimir/N-3732-2017; Krasnov,
   George/Q-2591-2017
OI Angeloni, Debora/0000-0002-3850-5392; Kudryavtseva,
   Anna/0000-0002-3722-8207; Pronina, Irina/0000-0002-0423-7801; Pavlovna,
   Tatiana/0000-0001-5856-0017; Dmitriev, Alexey/0000-0002-6827-9584;
   Gerashchenko, Ganna/0000-0002-4700-5736; Braga,
   Eleonora/0000-0001-5188-4094; Hodyrev, Dmitrii/0000-0001-6518-8305;
   Kashuba, Vladimir/0000-0001-9416-8282; Krasnov,
   George/0000-0002-6493-8378
FU Russian Foundation for Basic Research [13-04-00828a, 13-04-02072a,
   14-04-32084 mol_a]; Istituto Toscano Tumori [28.12.07-6888]; CNR-RAS
   Joint Projects; RAS Presidium Program "Molecular and Cellular Biology";
   Ministry of Education and Science of the Russian Federation
   [14.604.21.0117, RFMEFI60414X0117, 14.621.21.0001, RFMEFI62114X0001]
FX This work was supported by grants 13-04-00828a, 13-04-02072a, and
   14-04-32084 mol_a from the Russian Foundation for Basic Research; grant
   28.12.07-6888 from Istituto Toscano Tumori; a grant from CNR-RAS Joint
   Projects 2008-2010; the grant from RAS Presidium Program "Molecular and
   Cellular Biology"; contracts 14.604.21.0117 (project's unique identifier
   RFMEFI60414X0117) and 14.621.21.0001 (project's unique identifier
   RFMEFI62114X0001) from the Ministry of Education and Science of the
   Russian Federation. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449
   Angeloni Debora, 2007, Briefings in Functional Genomics & Proteomics, V6, P19, DOI 10.1093/bfgp/elm007
   Angeloni D, 2006, GENE CHROMOSOME CANC, V45, P676, DOI 10.1002/gcc.20332
   Basile JR, 2006, P NATL ACAD SCI USA, V103, P9017, DOI 10.1073/pnas.0508825103
   Bender RJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061788
   Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522
   Bielenberg DR, 2007, CANCER METAST REV, V26, P421, DOI 10.1007/s10555-007-9097-4
   Bielenberg DR, 2004, J CLIN INVEST, V114, P1260, DOI 10.1172/JCI200421378
   Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101
   Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601
   Chakraborty G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033633
   Chen RP, 2014, ONCOL REP, V31, P1211, DOI 10.3892/or.2014.2972
   De Lange R, 2003, ANTICANCER RES, V23, P187
   Dorfman DM, 1998, AM J PATHOL, V153, P255, DOI 10.1016/S0002-9440(10)65566-6
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   Eble J., 2004, WHO CLASSIFICATION T
   Gaur P, 2009, CLIN CANCER RES, V15, P6763, DOI 10.1158/1078-0432.CCR-09-1810
   Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200
   Heppell-Parton AC, 1999, CANCER GENET CYTOGEN, V108, P110, DOI 10.1016/S0165-4608(98)00130-7
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547
   Ito M, 2005, CANCER LETT, V225, P131, DOI 10.1016/j.canlet.2004.10.041
   Janssen BJC, 2012, NAT STRUCT MOL BIOL, V19, P1293, DOI 10.1038/nsmb.2416
   Ji Lin, 2005, Future Oncol, V1, P79, DOI 10.1517/14796694.1.1.79
   Joseph D, 2010, MOL CANCER THER, V9, P499, DOI 10.1158/1535-7163.MCT-09-0664
   Kigel B, 2011, BLOOD, V118, P4285, DOI 10.1182/blood-2011-03-341388
   Klimov EA, 2013, FOLIA BIOL-PRAGUE, V59, P204
   Krasnov GS, 2011, MOL BIOL+, V45, P211, DOI 10.1134/S0026893311020129
   Kuroki T, 2003, CANCER RES, V63, P3352
   Lerman MI, 2000, CANCER RES, V60, P6116
   Li JF, 1999, FEBS LETT, V451, P289, DOI 10.1016/S0014-5793(99)00598-0
   Li K, 2013, NEOPLASMA, V60, P683, DOI 10.4149/neo_2013_087
   Lu TP, 2010, CANCER EPIDEM BIOMAR, V19, P2590, DOI 10.1158/1055-9965.EPI-10-0332
   LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L
   Ma Y, 2008, BLOOD, V111, P2339, DOI 10.1182/blood-2007-09-112128
   Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233
   Miyato H, 2012, CANCER SCI, V103, P1961, DOI 10.1111/cas.12003
   MURATA Y, 1994, HUM MOL GENET, V3, P1341, DOI 10.1093/hmg/3.8.1341
   Nair PN, 2007, CANCER GENET CYTOGEN, V174, P100, DOI 10.1016/j.cancergencyto.2006.11.017
   Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404
   Neufeld G, 2007, ADV EXP MED BIOL, V600, P118
   Osada R, 2006, HUM PATHOL, V37, P1414, DOI 10.1016/j.humpath.2006.04.031
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   Prando ED, 2011, EPIGENETICS-US, V6, P1413, DOI 10.4161/epi.6.12.18271
   Pronina IV, 2009, MOL BIOL+, V43, P403, DOI 10.1134/S002689330903008X
   Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283
   Rehman M, 2013, SEMIN CELL DEV BIOL, V24, P179, DOI 10.1016/j.semcdb.2012.10.005
   Riquelme E, 2007, CANCER LETT, V250, P100, DOI 10.1016/j.canlet.2006.09.019
   Rolny C, 2008, J EXP MED, V205, P1155, DOI 10.1084/jem.20072509
   Sabag AD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042912
   Senchenko V, 2003, ONCOGENE, V22, P2984, DOI 10.1038/sj.onc.1206429
   Senchenko VN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015612
   Senchenko VN, 2004, ONCOGENE, V23, P5719, DOI 10.1038/sj.onc.1207760
   Shimizu A, 2008, J BIOL CHEM, V283, P27230, DOI 10.1074/jbc.M804520200
   Sobin L.H., 2009, UICC: TNM classification of malignant tumors, V7th
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Travis WD, 2004, WHO CLASSIFICATION
   Tse C, 2002, CANCER RES, V62, P542
   Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408
   Wang K, 2013, ONCOL REP, V29, P1175, DOI 10.3892/or.2012.2213
   Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823
   Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835
NR 63
TC 38
Z9 45
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 11
PY 2015
VL 10
IS 5
AR e0123369
DI 10.1371/journal.pone.0123369
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CI1YY
UT WOS:000354542500006
PM 25961819
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Deb, G
   Thakur, VS
   Limaye, AM
   Gupta, S
AF Deb, Gauri
   Thakur, Vijay S.
   Limaye, Anil M.
   Gupta, Sanjay
TI Epigenetic Induction of Tissue Inhibitor of Matrix Metalloproteinase-3
   by Green Tea Polyphenols in Breast Cancer Cells
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE breast cancer; tissue inhibitors of matrix metalloproteinase-3; green
   tea polyphenols; invasion; metastasis; enhancer of zeste homolog 2;
   histone deacetylases
ID PROSTATE-CANCER; EPIGALLOCATECHIN-3-GALLATE EGCG; ZESTE HOMOLOG-2;
   TUMOR-GROWTH; INVASION; METASTASIS; METHYLATION; EXPRESSION; GENE;
   CARCINOMA
AB Aberrant epigenetic silencing of the tissue inhibitor of matrix metalloproteinase-3 (TIMP-3) gene that negatively regulates matrix metalloproteinases (MMPs) activity has been implicated in the pathogenesis and metastasis of breast cancer. In the present study, we demonstrate that green tea polyphenols (GTP) and its major constituent, epigallocatechin-3-gallate (EGCG) mediate epigenetic induction of TIMP-3 levels and play a key role in suppressing invasiveness and gelatinolytic activity of MMP-2 and MMP-9 in breast cancer cells. Treatment of MCF-7 and MDA-MB-231 breast cancer cells with 20 mu M EGCG and 10 mu g/mL GTP for 72h significantly induces TIMP-3 mRNA and protein levels. Interestingly, investigations into the molecular mechanism revealed that TIMP-3 repression in breast cancer cells is mediated by epigenetic silencing mechanism(s) involving increased activity of the enhancer of zeste homolog 2 (EZH2) and class I histone deacetylases (HDACs), independent of promoter DNA hypermethylation. Treatment of breast cancer cells with GTP and EGCG significantly reduced EZH2 and class I HDAC protein levels. Furthermore, transcriptional activation of TIMP-3 was found to be associated with decreased EZH2 localization and H3K27 trimethylation enrichment at the TIMP-3 promoter with a concomitant increase in histone H3K9/18 acetylation. Our findings highlight TIMP-3 induction as a key epigenetic event modulated by GTPs in restoring the MMP:TIMP balance to delay breast cancer progression and invasion. (c) 2014 Wiley Periodicals, Inc.
C1 [Deb, Gauri; Thakur, Vijay S.; Gupta, Sanjay] Case Western Reserve Univ, Dept Urol, Cleveland, OH 44106 USA.
   [Deb, Gauri; Limaye, Anil M.] Indian Inst Technol, Dept Biotechnol, Gauhati, Assam, India.
   [Thakur, Vijay S.; Gupta, Sanjay] Univ Hosp Case Med Ctr, Dept Urol, Cleveland, OH USA.
   [Gupta, Sanjay] Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA.
   [Gupta, Sanjay] Case Comprehens Canc Ctr, Div Gen Med Sci, Cleveland, OH USA.
C3 University System of Ohio; Case Western Reserve University; Indian
   Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati; University System of Ohio; Case Western
   Reserve University; Case Western Reserve University Hospital; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University
RP Gupta, S (通讯作者)，Case Western Reserve Univ, Dept Urol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
RI Deb, Gauri/T-8429-2019
OI Gupta, Sanjay/0000-0002-9492-3249
FU United States Public Health Service [RO1CA115491, RO1CA108512,
   R21109424]; Indian Institute of Technology, Guwahati; Department of
   Science and Technology, Government of India [SR/FT/LS-028/2009]; Indian
   Council of Medical Research, Government of India [5/7/773/12-RCH]
FX Grant sponsor: United States Public Health Service; Grant numbers:
   RO1CA115491; RO1CA108512; R21109424; Grant sponsor: Indian Institute of
   Technology, Guwahati; Grant sponsor: Department of Science and
   Technology, Government of India; Grant number: SR/FT/LS-028/2009; Grant
   sponsor: Indian Council of Medical Research, Government of India; Grant
   number: 5/7/773/12-RCH
CR Bachman KE, 1999, CANCER RES, V59, P798
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Balasubramanian S, 2010, CARCINOGENESIS, V31, P496, DOI 10.1093/carcin/bgp314
   Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374
   BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401
   Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x
   Braicu C, 2013, J DRUG TARGET, V21, P250, DOI 10.3109/1061186X.2012.740673
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Chambers AF, 1997, J NATL CANCER I, V89, P1260, DOI 10.1093/jnci/89.17.1260
   Choudhury SR, 2011, CARCINOGENESIS, V32, P1525, DOI 10.1093/carcin/bgr171
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Cruz-Munoz W, 2008, CRIT REV CL LAB SCI, V45, P291, DOI [10.1080/10408360801973244, 10.1080/10408360801973244 ]
   Deb G, 2013, EPIGENETICS-US, V8, P464, DOI 10.4161/epi.24532
   DECLERCK YA, 1992, CANCER RES, V52, P701
   Deng XY, 2006, EUR J CANCER, V42, P3267, DOI 10.1016/j.ejca.2006.07.003
   Dreosti IE, 1997, CRIT REV FOOD SCI, V37, P761, DOI 10.1080/10408399709527801
   Fang JM, 2000, P NATL ACAD SCI USA, V97, P3884, DOI 10.1073/pnas.97.8.3884
   Fang MZ, 2003, CANCER RES, V63, P7563
   Farabegoli F, 2011, BIOSCIENCE REP, V31, P99, DOI 10.1042/BSR20090143
   Friedl P, 2008, CANCER RES, V68, P7247, DOI 10.1158/0008-5472.CAN-08-0784
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Imren S, 1996, CANCER RES, V56, P2891
   Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kato K, 2008, BRIT J CANCER, V99, P647, DOI 10.1038/sj.bjc.6604521
   Kavanagh KT, 2001, J CELL BIOCHEM, V82, P387, DOI 10.1002/jcb.1164
   KHOKHA R, 1992, J NATL CANCER I, V84, P1017, DOI 10.1093/jnci/84.13.1017
   KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186
   Komashko Vitalina M, 2010, Epigenetics, V5, P229
   LIOTTA LA, 1980, NATURE, V284, P67, DOI 10.1038/284067a0
   Lui ELH, 2005, BIOMED PHARMACOTHER, V59, pS363, DOI 10.1016/S0753-3322(05)80079-4
   Mylona E, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1607
   Paz MF, 2003, CANCER RES, V63, P1114
   Schor SL, 2001, BREAST CANCER RES, V3, P373, DOI 10.1186/bcr325
   Sen T, 2010, ANTI-CANCER DRUG, V21, P632, DOI 10.1097/CAD.0b013e32833a4385
   Sen T, 2009, LIFE SCI, V84, P194, DOI 10.1016/j.lfs.2008.11.018
   Shin YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030393
   Shinojima T, 2012, EPIGENETICS-US, V7, P1279, DOI 10.4161/epi.22333
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Singer CF, 2002, BREAST CANCER RES TR, V72, P69, DOI 10.1023/A:1014918512569
   Stearns V, 2007, CANCER INVEST, V25, P659, DOI 10.1080/07357900701719234
   STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541
   Stuart EC, 2010, ONCOL REP, V24, P779, DOI 10.3892/or_00000921
   Takafuji V, 2007, ONCOGENE, V26, P6361, DOI 10.1038/sj.onc.1210463
   Thakur VS, 2012, CURR PHARM BIOTECHNO, V13, P191
   Thakur VS, 2012, CARCINOGENESIS, V33, P377, DOI 10.1093/carcin/bgr277
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   Wang MS, 1997, ONCOGENE, V14, P2767, DOI 10.1038/sj.onc.1201245
   Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8<1676::AID-CNCR38>3.3.CO;2-F
   Wu AH, 2003, INT J CANCER, V106, P574, DOI 10.1002/ijc.11259
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Zhang L, 2010, CANCER GENE THER, V17, P171, DOI 10.1038/cgt.2009.59
   Zhang M, 2007, CARCINOGENESIS, V28, P1074, DOI 10.1093/carcin/bgl252
NR 53
TC 85
Z9 95
U1 0
U2 57
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD JUN
PY 2015
VL 54
IS 6
BP 485
EP 499
DI 10.1002/mc.22121
PG 15
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA CF8ML
UT WOS:000352814800007
PM 24481780
DA 2025-01-12
ER

PT J
AU Sinha, S
   Shukla, S
   Khan, S
   Tollefsbol, TO
   Meeran, SM
AF Sinha, Sonam
   Shukla, Samriddhi
   Khan, Sajid
   Tollefsbol, Trygve O.
   Meeran, Syed M.
TI Epigenetic reactivation of p21<SUP>CIP1/WAF1</SUP> and KLOTHO by a
   combination of bioactive dietary supplements is partially ERα-dependent
   in ERα-negative human breast cancer cells
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Green tea; Sulforaphane; Estrogen receptor; Tumor suppressor genes;
   Epigenetics; Breast cancer
ID TUMOR-SUPPRESSOR GENES; HISTONE DEACETYLASE INHIBITORS; DNA METHYLATION;
   TEA POLYPHENOL; CYCLE ARREST; IN-VIVO; SULFORAPHANE; EXPRESSION;
   APOPTOSIS; GROWTH
AB Available treatment strategies against estrogen receptor (ER)-negative breast cancer patients are limited due to their poor response to hormonal therapy. We have shown previously that the combinations of green tea polyphenols (GTPs), a dietary DNA methyltransferase inhibitor, and sulforaphane (SFN), a dietary histone deacetylase inhibitor, reactivate ER alpha expression in ER alpha-negative MDA-MB-231 cells. Here, we investigated the functional significance of ERa reactivation in the reactivation of silenced tumor suppressor genes (TSGs) in ER alpha-negative human breast cancer cells. We found that the treatment of MDA-MB-231 cells with the combinations of GTPs and SFN leads to the reactivation of silenced TSGs such as p21(CIP1/WAF1) and KLOTHO through active chromatin modifications. Further, GTPs- and SFN-mediated reactivation of TSGs was, at least in part, dependent on ERa reactivation in ERa-negative MDA-MB-231 cells. Collectively, our findings suggest that a novel combination of bioactive dietary supplements could further be explored as an effective therapeutic option against hormonal refractory breast cancer. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Sinha, Sonam; Shukla, Samriddhi; Khan, Sajid; Meeran, Syed M.] CSIR, Cent Drug Res Inst, Lab Canc Epigenet, Div Endocrinol, Lucknow 226031, Uttar Pradesh, India.
   [Tollefsbol, Trygve O.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
   [Meeran, Syed M.] Acad Sci & Innovat Res AcSIR, New Delhi, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Central Drug Research Institute (CDRI); University of Alabama System;
   University of Alabama Birmingham; Academy of Scientific & Innovative
   Research (AcSIR)
RP Meeran, SM (通讯作者)，CSIR, Cent Drug Res Inst, Lab Canc Epigenet, Div Endocrinol, Jankipuram Extn,Sect 10,Sitapur Rd, Lucknow 226031, Uttar Pradesh, India.
EM s.musthapa@cdri.res.in
RI Shukla, Samriddhi/AAF-1876-2021; Meeran, Syed/AAG-2157-2020; Khan,
   Sajid/AAR-8954-2020
OI Shukla, Samriddhi/0000-0002-3771-4184; Sajid, Khan/0000-0003-1331-8846;
   sinha, sonam/0000-0002-6996-0611
FU Science and Engineering Research Board [SR/FT/LS-80/2011]; Department of
   Biotechnology-Twinning Programme, New Delhi, India
   [BCIL/NER-BPMC/2013/722]; CSIR-EpiHeD-Network Scheme [BSC0118]; NCI [ROI
   CA178441]; American Institute for Cancer Research [316184]; Council of
   Scientific and Industrial Research (CSIR), India
FX This work was supported with funds from the Science and Engineering
   Research Board (SR/FT/LS-80/2011), Department of Biotechnology-Twinning
   Programme (BCIL/NER-BPMC/2013/722), New Delhi, India and
   CSIR-EpiHeD-Network Scheme (BSC0118) to SMM. Part of this work was also
   supported from grants by the NCI (ROI CA178441) and the American
   Institute for Cancer Research (316184) to TOT. SS and SK are thankful
   for Senior Research fellowship grants from the Council of Scientific and
   Industrial Research (CSIR), India. CSIR-CDRI communication number-8930.
CR Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881
   Boisvert FM, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.011429
   Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130
   Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528
   Chang J, 2000, CLIN CANCER RES, V6, P616
   Chen HP, 2013, J ONCOL, V2013, DOI 10.1155/2013/872957
   Chen HP, 2013, EXP CELL RES, V319, P697, DOI 10.1016/j.yexcr.2012.12.026
   Chew YC, 2012, J BIOL CHEM, V287, P16168, DOI 10.1074/jbc.M111.305292
   Cornago M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.412
   Dashwood RH, 2007, SEMIN CANCER BIOL, V17, P363, DOI 10.1016/j.semcancer.2007.04.001
   Doi S, 2011, J BIOL CHEM, V286, P8655, DOI 10.1074/jbc.M110.174037
   Fang MZ, 2003, CANCER RES, V63, P7563
   de Oliveira JMPF, 2014, NUTR CANCER, V66, P325, DOI 10.1080/01635581.2014.864777
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261
   Jackson SJT, 2004, CARCINOGENESIS, V25, P219, DOI 10.1093/carcin/bgg192
   Jackson SJT, 2004, J NUTR, V134, P2229, DOI 10.1093/jn/134.9.2229
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971
   Kuzumaki T, 1998, BIOCHEM BIOPH RES CO, V251, P291, DOI 10.1006/bbrc.1998.9462
   Lee J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-109
   Li YY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-9
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Majid S, 2008, CANCER RES, V68, P2736, DOI 10.1158/0008-5472.CAN-07-2290
   Mandal S, 2010, J CELL PHYSIOL, V224, P28, DOI 10.1002/jcp.22078
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Meeran SM, 2008, FRONT BIOSCI-LANDMRK, V13, P2191, DOI 10.2741/2834
   Mukhtar H, 2000, AM J CLIN NUTR, V71, p1698S, DOI 10.1093/ajcn/71.6.1698S
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Myzak MC, 2006, FASEB J, V20, P506, DOI 10.1096/fj.05-4785fje
   Myzak MC, 2007, EXP BIOL MED, V232, P227
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Pan J, 2011, TUMOR BIOL, V32, P729, DOI 10.1007/s13277-011-0174-5
   Park HS, 2014, FOOD CHEM TOXICOL, V64, P157, DOI 10.1016/j.fct.2013.11.034
   Pollak M, 2008, NAT REV CANCER, V8, P915, DOI 10.1038/nrc2536
   Reed SI, 2003, NAT REV MOL CELL BIO, V4, P855, DOI 10.1038/nrm1246
   Rubinek T, 2012, BREAST CANCER RES TR, V133, P649, DOI 10.1007/s10549-011-1824-4
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Suppipat K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051251
   Timmel M Anne, 2013, Chem Res Toxicol, V26, P622, DOI 10.1021/tx4000667
   Wang LJ, 2011, AM J CANCER RES, V1, P111
   Wolf I, 2008, ONCOGENE, V27, P7094, DOI 10.1038/onc.2008.292
   Wu DS, 2013, ONCOL REP, V30, P2969, DOI 10.3892/or.2013.2734
   Xie B, 2013, PATHOL ONCOL RES, V19, P611, DOI 10.1007/s12253-013-9663-8
   Xu WS, 2005, CANCER RES, V65, P7832, DOI 10.1158/0008-5472.CAN-04-4608
   Yang XW, 2001, CANCER RES, V61, P7025
   Yavari K, 2010, INT J COLORECTAL DIS, V25, P9, DOI 10.1007/s00384-009-0783-2
   Yee D, 2006, BRIT J CANCER, V94, P465, DOI 10.1038/sj.bjc.6602963
NR 53
TC 39
Z9 41
U1 0
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
EI 1872-8057
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD MAY 5
PY 2015
VL 406
IS C
BP 102
EP 114
DI 10.1016/j.mce.2015.02.020
PG 13
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA CG2HF
UT WOS:000353094800011
PM 25725373
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Nordström, L
   Andersson, E
   Kuci, V
   Gustavsson, E
   Holm, K
   Ringnér, M
   Guldberg, P
   Ek, S
AF Nordstrom, Lena
   Andersson, Elin
   Kuci, Venera
   Gustavsson, Elin
   Holm, Karolina
   Ringner, Markus
   Guldberg, Per
   Ek, Sara
TI DNA methylation and histone modifications regulate SOX11 expression in
   lymphoid and solid cancer cells
SO BMC CANCER
LA English
DT Article
DE SOX11; DNA methylation; H3K27; Epigenetic regulation
ID TRANSCRIPTION FACTOR SOX11; HUMAN BREAST-CANCER; PROMOTER METHYLATION;
   DIFFERENTIAL EXPRESSION; NUCLEAR EXPRESSION; HDAC INHIBITORS;
   STEM-CELLS; DEACETYLASE; GENES; SUBSETS
AB Background: The neural transcription factor SOX11 is present at specific stages during embryo development with a very restricted expression in adult tissue, indicating precise regulation of transcription. SOX11 is strongly up-regulated in some malignancies and have a functional role in tumorgenesis. With the aim to explore differences in epigenetic regulation of SOX11 expression in normal versus neoplastic cells, we investigated methylation and histone modifications related to the SOX11 promoter and the possibility to induce re-expression using histone deacetylase (HDAC) or EZH2 inhibitors.
   Methods: The epigenetic regulation of SOX11 was investigated in distinct non-malignant cell populations (n = 7) and neoplastic cell-lines (n = 42) of different cellular origins. DNA methylation was assessed using bisulfite sequencing, methylation-specific melting curve analysis, MethyLight and pyrosequencing. The presence of H3K27me3 was assessed using ChIP-qPCR. The HDAC inhibitors Vorinostat and trichostatin A were used to induce SOX11 in cell lines with no endogenous expression.
   Results: The SOX11 promoter shows a low degree of methylation and strong enrichment of H3K27me3 in non-malignant differentiated cells, independent of cellular origin. Cancers of the B-cell lineage are strongly marked by de novo methylation at the SOX11 promoter in SOX11 non-expressing cells, while solid cancer entities display a more varying degree of SOX11 promoter methylation. The silencing mark H3K27me3 was generally present at the SOX11 promoter in non-expressing cells, and an increased enrichment was observed in cancer cells with a low degree of SOX11 methylation compared to cells with dense methylation. Finally, we demonstrate that the HDAC inhibitors (vorinostat and trichostatin A) induce SOX11 expression in cancer cells with low levels of SOX11 methylation.
   Conclusions: We show that SOX11 is strongly marked by repressive histone marks in non-malignant cells. In contrast, SOX11 regulation in neoplastic tissues is more complex involving both DNA methylation and histone modifications. The possibility to re-express SOX11 in non-methylated tissue is of clinical relevance, and was successfully achieved in cell lines with low levels of SOX11 methylation. In breast cancer patients, methylation of the SOX11 promoter was shown to correlate with estrogen receptor status, suggesting that SOX11 may be functionally re-expressed during treatment with HDAC inhibitors in specific patient subgroups.
C1 [Nordstrom, Lena; Kuci, Venera; Gustavsson, Elin; Ek, Sara] Lund Univ, CREATE Hlth, Dept Immunotechnol, Lund, Sweden.
   [Andersson, Elin; Guldberg, Per] Danish Canc Soc Res Ctr, Copenhagen, Denmark.
   [Holm, Karolina; Ringner, Markus] Lund Univ, Skane Univ Hosp, Dept Pathol & Oncol, Clin Sci, Lund, Sweden.
C3 Lund University; Danish Cancer Society; Lund University; Skane
   University Hospital
RP Ek, S (通讯作者)，Lund Univ, CREATE Hlth, Dept Immunotechnol, Lund, Sweden.
EM sara.ek@immun.lth.se
RI Ringnér, Markus/G-3641-2011; Ek, Sara/E-8018-2015
OI Ringner, Markus/0000-0001-5469-8940; Ek, Sara/0000-0002-1388-4912; Kuci
   Emruli, Venera/0000-0002-9527-0809
FU Lund Institute of Technology (LTH); Cancerfonden; Vetenskapsradet;
   Crafoord foundation; BioCARE - a strategic program for Cancer Research
   at Lund University; BioCARE - a strategic program for Cancer Research at
   Gothenburg University; CREATE Health
FX The study was supported by the Lund Institute of Technology (LTH),
   Cancerfonden, Vetenskapsradet, Crafoord foundation, BioCARE - a
   strategic program for Cancer Research at Lund and Gothenburg
   Universities and CREATE Health.
CR Arzenani MK, 2011, MOL CELL BIOL, V31, P4119, DOI 10.1128/MCB.01304-10
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bock C, 2005, BIOINFORMATICS, V21, P4067, DOI 10.1093/bioinformatics/bti652
   Brennana DJ, 2009, EUR J CANCER, V45, P1510, DOI 10.1016/j.ejca.2009.01.028
   Vegliante MC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021382
   Chung W, 2011, CANCER EPIDEM BIOMAR, V20, P1483, DOI 10.1158/1055-9965.EPI-11-0067
   Culmes M, 2013, EUR J CELL BIOL, V92, P70, DOI 10.1016/j.ejcb.2012.11.001
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Dictor M, 2009, HAEMATOL-HEMATOL J, V94, P1563, DOI 10.3324/haematol.2009.008474
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162
   Ek S, 2008, BLOOD, V111, P800, DOI 10.1182/blood-2007-06-093401
   Fernàndez V, 2010, CANCER RES, V70, P1408, DOI 10.1158/0008-5472.CAN-09-3419
   Glaser KB, 2003, MOL CANCER THER, V2, P151
   Gustavsson E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-187
   Issa JPJ, 2005, NAT REV DRUG DISCOV, V4, P275, DOI 10.1038/nrd1698
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792
   Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719
   Kiefer JC, 2007, DEV DYNAM, V236, P2356, DOI 10.1002/dvdy.21218
   Korkolopoulou P, 2013, BRIT J CANCER, V108, P2142, DOI 10.1038/bjc.2013.176
   LaBonte MJ, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-67
   Lefebvre V, 2007, INT J BIOCHEM CELL B, V39, P2195, DOI 10.1016/j.biocel.2007.05.019
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Navarro A, 2012, CANCER RES, V72, P5307, DOI 10.1158/0008-5472.CAN-12-1615
   Nordström L, 2014, BRIT J HAEMATOL, V166, P98, DOI 10.1111/bjh.12854
   Nordström L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-269
   Nygren L, 2012, BLOOD, V119, P4215, DOI 10.1182/blood-2011-12-400580
   Ou JN, 2007, BIOCHEM PHARMACOL, V73, P1297, DOI 10.1016/j.bcp.2006.12.032
   Penzo-Méndez AI, 2010, INT J BIOCHEM CELL B, V42, P425, DOI 10.1016/j.biocel.2009.07.018
   Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Riising EM, 2014, MOL CELL, V55, P347, DOI 10.1016/j.molcel.2014.06.005
   Rohde C, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn083
   Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Svechnikova I, 2008, INT J ONCOL, V32, P821
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Trinh BN, 2001, METHODS, V25, P456, DOI 10.1006/meth.2001.1268
   VanLint C, 1996, GENE EXPRESSION, V5, P245
   Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang X, 2008, BRIT J HAEMATOL, V143, P248, DOI 10.1111/j.1365-2141.2008.07329.x
   Wang Y, 2013, DEV DYNAM, V242, P638, DOI 10.1002/dvdy.23962
   Wasik AM, 2013, SCI REP-UK, V3, DOI [10.1038/srep01400, 10.1038/srep02007]
   Weigle B, 2005, ONCOL REP, V13, P139
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Worm J, 2001, CLIN CHEM, V47, P1183
   Wu LP, 2008, MOL CELL BIOL, V28, P3219, DOI 10.1128/MCB.01516-07
   Zhang S, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-109
   Zhou Q, 2008, MOL CANCER RES, V6, P873, DOI 10.1158/1541-7786.MCR-07-0330
   Zvelebil M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3403
NR 57
TC 17
Z9 21
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 12
PY 2015
VL 15
AR 273
DI 10.1186/s12885-015-1208-y
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CG3UA
UT WOS:000353203900001
PM 25880212
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Teschendorff, AE
   Li, LL
   Yang, Z
AF Teschendorff, Andrew E.
   Li, Linlin
   Yang, Zhen
TI Denoising perturbation signatures reveal an actionable AKT-signaling
   gene module underlying a poor clinical outcome in endocrine-treated ER
   plus breast cancer
SO GENOME BIOLOGY
LA English
DT Article
ID EPIGENETIC INACTIVATION; TAMOXIFEN RESISTANCE; DRUG-SENSITIVITY;
   MUTATION STATUS; EXPRESSION; PATHWAY; TUMOR; METASTASIS; PROLIFERATION;
   INFORMATION
AB Background: Databases of perturbation gene expression signatures and drug sensitivity provide a powerful framework to develop personalized medicine approaches, by helping to identify actionable genomic markers and subgroups of patients who may benefit from targeted treatments.
   Results: Here we use a perturbation expression signature database encompassing perturbations of over 90 cancer genes, in combination with a large breast cancer expression dataset and a novel statistical denoising algorithm, to help discern cancer perturbations driving most of the variation in breast cancer gene expression. Clustering estrogen receptor positive cancers over the perturbation activity scores recapitulates known luminal subtypes. Analysis of individual activity scores enables identification of a novel cancer subtype, defined by a 31-gene AKT-signaling module. Specifically, we show that activation of this module correlates with a poor prognosis in over 900 endocrine-treated breast cancers, a result we validate in two independent cohorts. Importantly, breast cancer cell lines with high activity of the module respond preferentially to PI3K/AKT/mTOR inhibitors, a result we also validate in two independent datasets. We find that at least 34% of the downregulated AKT module genes are either mediators of apoptosis or have tumor suppressor functions.
   Conclusions: The statistical framework advocated here could be used to identify gene modules that correlate with prognosis and sensitivity to alternative treatments. We propose a randomized clinical trial to test whether the 31-gene AKT module could be used to identify estrogen receptor positive breast cancer patients who may benefit from therapy targeting the PI3K/AKT/mTOR signaling axis.
C1 [Teschendorff, Andrew E.; Li, Linlin; Yang, Zhen] Chinese Acad Sci, CAS Key Lab Computat Biol, Max Planck Partner Inst Computat Biol, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China.
   [Teschendorff, Andrew E.] UCL, UCL Canc Inst, Stat Canc Genom, London WC1E 6BT, England.
C3 Chinese Academy of Sciences; Max Planck Society; University of London;
   University College London
RP Teschendorff, AE (通讯作者)，Chinese Acad Sci, CAS Key Lab Computat Biol, Max Planck Partner Inst Computat Biol, Shanghai Inst Biol Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.
EM andrew@picb.ac.cn
RI Teschendorff, Andrew/AFP-1816-2022; Li, Linlin/M-8350-2014; Yang,
   Zhiquan/JDW-7325-2023
FU Chinese Academy of Sciences; Max-Planck Gesellschaft; Shanghai Institute
   for Biological Sciences
FX LL, YZ and AET are supported by the Chinese Academy of Sciences,
   Shanghai Institute for Biological Sciences and the Max-Planck
   Gesellschaft.
CR Arthur LM, 2014, BREAST CANCER RES TR, V147, P211, DOI 10.1007/s10549-014-3080-x
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Beck AH, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002875
   Beelen K, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3606
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Chang JT, 2009, MOL CELL, V34, P104, DOI 10.1016/j.molcel.2009.02.030
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Correa TCS, 2006, J CELL BIOCHEM, V99, P156, DOI 10.1002/jcb.20917
   Creixell P, 2012, NAT BIOTECHNOL, V30, P842, DOI 10.1038/nbt.2345
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Daemen A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r110
   Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222
   Domínguez-Monzón G, 2009, INT J DEV NEUROSCI, V27, P305, DOI 10.1016/j.ijdevneu.2009.03.009
   Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004
   Dubsky P, 2013, BRIT J CANCER, V109, P2959, DOI 10.1038/bjc.2013.671
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Filipits M, 2011, CLIN CANCER RES, V17, P6012, DOI 10.1158/1078-0432.CCR-11-0926
   Frigola J, 2005, ONCOGENE, V24, P7320, DOI 10.1038/sj.onc.1208883
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073
   Gobeil S, 2008, GENE DEV, V22, P2932, DOI 10.1101/gad.1714608
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Huang J, 2010, J CLIN INVEST, V120, P223, DOI 10.1172/JCI38012
   Jiang Z, 2011, HUM PATHOL, V42, P361, DOI 10.1016/j.humpath.2010.03.009
   Jiao Y, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-403
   Jordan NJ, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3604
   Kilinc D, 2012, DNA CELL BIOL, V31, P826, DOI 10.1089/dna.2011.1431
   Kim JW, 2009, INT J CANCER, V124, P734, DOI 10.1002/ijc.23972
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Loi S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053292
   Ma YF, 2013, BIOCHEM BIOPH RES CO, V441, P958, DOI 10.1016/j.bbrc.2013.11.010
   Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Pagès F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416
   Polyak K, 2014, NAT MED, V20, P344, DOI 10.1038/nm.3518
   Ring A, 2014, ENDOCR-RELAT CANCER, V11, P643
   Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6
   Sabine VS, 2014, J CLIN ONCOL, V32, P2951, DOI 10.1200/JCO.2013.53.8272
   Smyth Gordon K, 2003, Methods Mol Biol, V224, P111
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387
   Teschendorff AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r101
   Teschendorff AE, 2006, BIOINFORMATICS, V22, P2269, DOI 10.1093/bioinformatics/btl174
   Teschendorff AE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-604
   Venet D, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002240
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wang HH, 2012, FEBS J, V279, P3652, DOI 10.1111/j.1742-4658.2012.08726.x
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Yu K, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000129
   Zarco N, 2012, APOPTOSIS, V17, P627, DOI 10.1007/s10495-011-0696-8
   Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2
NR 56
TC 7
Z9 7
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PD APR 2
PY 2015
VL 16
AR 61
DI 10.1186/s13059-015-0630-4
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CG1CV
UT WOS:000353011500001
PM 25886003
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Zhu, X
   Shan, L
   Wang, F
   Wang, J
   Wang, F
   Shen, G
   Liu, X
   Wang, B
   Yuan, Y
   Ying, J
   Yang, H
AF Zhu, X.
   Shan, L.
   Wang, F.
   Wang, J.
   Wang, F.
   Shen, G.
   Liu, X.
   Wang, B.
   Yuan, Y.
   Ying, J.
   Yang, H.
TI Hypermethylation of <i>BRCA1</i> gene: implication for prognostic
   biomarker and therapeutic target in sporadic primary triple-negative
   breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE BRCA1; Promoter methylation; Triple-negative breast cancer; Prognosis
ID BASAL-LIKE SUBTYPE; PROMOTER METHYLATION; POLY(ADP-RIBOSE) POLYMERASE;
   DNA-REPAIR; SENSITIVITY; INACTIVATION; PHENOTYPE; EVENTS
AB Paraffin sections from 239 cases of surgical resected mammary gland carcinomas were assessed to determine the role of BRCA1 gene methylation in sporadic triple-negative breast cancer and to evaluate the relationship between BRCA1 gene methylation and clinicopathologic features of triple-negative breast cancer in the National Cancer Center, China. Diagnostic tissues collected from patients received mastectomy in the National Cancer Center from January 1, 1999 to December 31, 2008 were reviewed. Tissue microarrays were constructed using 239 triple-negative breast cancer cases and stained with estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, cytokeratin 5/6, and epidermal growth factor receptor. Methylation status of the BRCA1 promoter was measured by methylation-specific PCR and analyzed against clinicopathologic characteristics, subtypes, and prognosis using standard statistical methods. Among the 239 triple-negative breast cancer cases, 137 (57.3 %) showed methylation of the BRCA1. According to the immunohistochemistry results, triple-negative breast cancer cases were classified into basal-like breast cancer (60.7 %) and non-basal-like breast cancer (39.3 %). The frequency of BRCA1 methylation was significantly higher in basal-like breast cancer subtype (71.7 %) than the non-basal subtype (35.1 %). Thus, BRCA1 methylation is statistically significantly correlated with basal-like breast cancer subtype (p < 0.001). Multivariate analyses further showed that BRCA1 promoter methylation is an independently predictor of overall survival (p = 0.023; HR 2.32; 95 % CI 1.12-4.81) and disease-free survival (p = 0.022; HR 2.36; 95 % CI 1.13-4.90) in triple-negative breast cancer. Here we demonstrated that epigenetic alteration of key tumor suppressor gene can be a promising biomarker for the prognosis of triple-negative breast cancer/basal-like breast cancer. Specifically our finding revealed that BRCA1 methylation is closely associated with a significant decrease in overall survival and disease-free survival, highlighting BRCA1 promoter methylation as promising and powerful biomarkers for effect and better prognosis of DNA damaging agents for triple-negative breast cancer/basal-like breast cancer.
C1 [Zhu, X.; Shan, L.; Wang, J.; Shen, G.; Liu, X.; Wang, B.; Yuan, Y.; Ying, J.; Yang, H.] Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst & Hosp, Dept Pathol, Beijing 100021, Peoples R China.
   [Wang, F.] CapitalBio Corp, Beijing, Peoples R China.
   [Wang, F.] Yantai Yuhuangding Hosp, Dept Pathol, Yantai, Shandong, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Cancer Institute & Hospital - CAMS; Peking Union Medical College
RP Ying, J (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll, Canc Inst & Hosp, Dept Pathol, Beijing 100021, Peoples R China.
EM jmying@cicams.ac.cn; doctoryanghongying@aliyun.com
CR [Anonymous], GENES CHROMOSOMES CA
   [Anonymous], GENES CHROMOSOMES CA
   Bal A, 2012, VIRCHOWS ARCH, V461, P305, DOI 10.1007/s00428-012-1286-z
   Banerjee S, 2006, J CLIN PATHOL, V59, P729, DOI 10.1136/jcp.2005.033043
   Ben Gacem R, 2012, CANCER EPIDEMIOL, V36, P190, DOI 10.1016/j.canep.2011.09.001
   Birkbak NJ, 2012, CANCER DISCOV, V2, P366, DOI 10.1158/2159-8290.CD-11-0206
   Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050
   Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389
   Ignatov T, 2013, BREAST CANCER RES TR, V141, P205, DOI 10.1007/s10549-013-2693-9
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Joosse SA, 2011, GENE CHROMOSOME CANC, V50, P71, DOI 10.1002/gcc.20833
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Kennedy RD, 2002, LANCET, V360, P1007, DOI 10.1016/S0140-6736(02)11087-7
   Kim MJ, 2006, HUM PATHOL, V37, P1217, DOI 10.1016/j.humpath.2006.04.015
   Kriege M, 2009, J CLIN ONCOL, V27, P3764, DOI 10.1200/JCO.2008.19.9067
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Pang D, 2012, MED ONCOL, V29, P1561, DOI 10.1007/s12032-011-0100-0
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Peshkin Beth N, 2010, Breast Dis, V32, P25, DOI 10.3233/BD-2010-0306
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Samouëlian V, 2004, CANCER CHEMOTH PHARM, V54, P497, DOI 10.1007/s00280-004-0843-9
   Santarosa M, 2012, CANCER METAST REV, V31, P131, DOI 10.1007/s10555-011-9336-6
   Sharma Priyanka, 2014, J Cancer Ther Res, V3, P1, DOI 10.7243/2049-7962-3-2
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Singh AK, 2011, EUR J CANCER PREV, V20, P478, DOI 10.1097/CEJ.0b013e32834761a6
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Turner N, 2005, CURR OPIN PHARMACOL, V5, P388, DOI 10.1016/j.coph.2005.03.006
   Wu L, 2013, BREAST CANCER RES TR, V142, P619, DOI 10.1007/s10549-013-2774-9
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Xu Y, 2013, ANN ONCOL, V24, P1498, DOI 10.1093/annonc/mdt011
NR 36
TC 52
Z9 56
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2015
VL 150
IS 3
BP 479
EP 486
DI 10.1007/s10549-015-3338-y
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CF1GW
UT WOS:000352293600003
PM 25783183
DA 2025-01-12
ER

PT J
AU Krishnan, SR
   Nair, BC
   Sareddy, GR
   Roy, SS
   Natarajan, M
   Suzuki, T
   Peng, Y
   Raj, G
   Vadlamudi, RK
AF Krishnan, Samaya R.
   Nair, Binoj C.
   Sareddy, Gangadhara R.
   Roy, Sudipa Saha
   Natarajan, Mohan
   Suzuki, Takayoshi
   Peng, Yan
   Raj, Ganesh
   Vadlamudi, Ratna K.
TI Novel role of PELP1 in regulating chemotherapy response in mutant
   p53-expressing triple negative breast cancer cells
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE PELP1; p53; DNA damage response; Oncogene; Coregulator; E2F1; TNBC
ID DNA-DAMAGE; ONCOGENIC FUNCTIONS; P53; E2F1; APOPTOSIS; PHOSPHORYLATION;
   TRANSCRIPTION; EXPRESSION; IDENTIFICATION; METASTASIS
AB Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, occurs in younger women and is associated with poor prognosis. Gain-of-function mutations in TP53 are a frequent occurrence in TNBC and have been demonstrated to repress apoptosis and up-regulate cell cycle progression. Even though TNBC responds to initial chemotherapy, resistance to chemotherapy develops and is a major clinical problem. Tumor recurrence eventually occurs and most patients die from their disease. An urgent need exists to identify molecular-targeted therapies that can enhance chemotherapy response. In the present study, we report that targeting PELP1, an oncogenic co-regulator molecule, could enhance the chemotherapeutic response of TNBC through the inhibition of cell cycle progression and activation of apoptosis. We demonstrate that PELP1 interacts with MTp53, regulates its recruitment, and alters epigenetic marks at the target gene promoters. PELP1 knockdown reduced MTp53 target gene expression, resulting in decreased cell survival and increased apoptosis upon genotoxic stress. Mechanistic studies revealed that PELP1 depletion contributes to increased stability of E2F1, a transcription factor that regulates both cell cycle and apoptosis in a context-dependent manner. Further, PELP1 regulates E2F1 stability in a KDM1A-dependent manner, and PELP1 phosphorylation at the S1033 residue plays an important role in mediating its oncogenic functions in TNBC cells. Accordingly, depletion of PELP1 increased the expression of E2F1 target genes and reduced TNBC cell survival in response to genotoxic agents. PELP1 phosphorylation was significantly greater in the TNBC tumors than in the other subtypes of breast cancer and in the normal tissues. These findings suggest that PELP1 is an important molecular target in TNBC, and that PELP1-targeted therapies may enhance response to chemotherapies.
C1 [Krishnan, Samaya R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Krishnan, Samaya R.; Nair, Binoj C.; Sareddy, Gangadhara R.; Roy, Sudipa Saha; Vadlamudi, Ratna K.] Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
   [Natarajan, Mohan] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
   [Suzuki, Takayoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Sakyo Ku, Kyoto 6060823, Japan.
   [Peng, Yan] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   [Raj, Ganesh] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA.
   [Vadlamudi, Ratna K.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio; Kyoto Prefectural University
   of Medicine; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; Cancer Therapy &
   Research Center; University of Texas System; University of Texas Health
   Science Center at San Antonio
RP Vadlamudi, RK (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM vadlamudi@uthscsa.edu
RI Nair, Binoj/A-1936-2012
FU NIH/NCI [CA095681]; CPRIT [DP150096, RP140105]; Cancer Therapy and
   Research Center at the University of Texas Health Science Center at San
   Antonio through the NCI Cancer Center Support Grant [P30CA054174-17]
FX This study was supported by the NIH/NCI Grant CA095681 (RKV); CPRIT
   grant DP150096 (RKV; GR); CPRIT pre-doctoral fellow ship grant RP140105
   (SK); CPRIT postdoctoral fellowship grant RP140105 (GRS); and the Cancer
   Therapy and Research Center at the University of Texas Health Science
   Center at San Antonio through the NCI Cancer Center Support Grant
   P30CA054174-17.
CR Bararia D, 2008, LEUKEMIA, V22, P800, DOI 10.1038/sj.leu.2405101
   BARTEK J, 1990, ONCOGENE, V5, P893
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Bertheau P, 2013, BREAST, V22, pS27, DOI 10.1016/j.breast.2013.07.005
   Boohaker RJ, 2013, RADIOTHER ONCOL, V108, P403, DOI 10.1016/j.radonc.2013.06.017
   Bossi G, 2006, ONCOGENE, V25, P304, DOI 10.1038/sj.onc.1209026
   DeGregori J, 2006, CURR MOL MED, V6, P739
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Di AS, 2006, CANCER CELL, V10, P191
   Dobes P, 2014, ONCOL REP, V32, P1695, DOI 10.3892/or.2014.3346
   Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575
   Girard BJ, 2014, MOL CELL ENDOCRINOL, V382, P642, DOI 10.1016/j.mce.2013.07.031
   Gonugunta VK, 2014, ENDOCR-RELAT CANCER, V21, pT79, DOI 10.1530/ERC-13-0502
   Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9
   Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335
   Lin WC, 2001, GENE DEV, V15, P1833
   Mann M, 2013, CARCINOGENESIS, V34, P1468, DOI 10.1093/carcin/bgt091
   Mann Monica, 2011, Cancers (Basel), V3, P1691, DOI 10.3390/cancers3021691
   Nair BC, 2014, CELL DEATH DIFFER, V21, P1409, DOI 10.1038/cdd.2014.55
   Nair BC, 2010, CANCER RES, V70, P7166, DOI 10.1158/0008-5472.CAN-10-0628
   Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62
   NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0
   Oren M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001107
   Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998
   Phillips AC, 2001, APOPTOSIS, V6, P173, DOI 10.1023/A:1011332625740
   Roy S, 2012, MOL CANCER RES, V10, P25, DOI 10.1158/1541-7786.MCR-11-0456
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000
   Sun MN, 2012, J MOL CELL BIOL, V4, P304, DOI 10.1093/jmcb/mjs048
   Tonsing-Carter E, 2013, CANCER RES, V279, P8627
   Ueda R, 2009, J AM CHEM SOC, V131, P17536, DOI 10.1021/ja907055q
   Wright JD, 2007, J BIOSCIENCES, V32, P827, DOI 10.1007/s12038-007-0083-3
   Xie Q, 2011, J RECEPT SIG TRANSD, V31, P139, DOI 10.3109/10799893.2011.552914
   Xu J, 2011, NAT CHEM BIOL, V7, P285, DOI 10.1038/nchembio.546
NR 39
TC 23
Z9 28
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2015
VL 150
IS 3
BP 487
EP 499
DI 10.1007/s10549-015-3339-x
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CF1GW
UT WOS:000352293600004
PM 25788226
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Delgado-Cruzata, L
   Zhang, WF
   McDonald, JA
   Tsai, WY
   Valdovinos, C
   Falci, L
   Wang, Q
   Crew, KD
   Santella, RM
   Hershman, DL
   Greenlee, H
AF Delgado-Cruzata, Lissette
   Zhang, Wenfei
   McDonald, Jasmine A.
   Tsai, Wei Yann
   Valdovinos, Cristina
   Falci, Laura
   Wang, Qiao
   Crew, Katherine D.
   Santella, Regina M.
   Hershman, Dawn L.
   Greenlee, Heather
TI Dietary Modifications, Weight Loss, and Changes in Metabolic Markers
   Affect Global DNA Methylation in Hispanic, African American, and
   Afro-Caribbean Breast Cancer Survivors
SO JOURNAL OF NUTRITION
LA English
DT Article
DE weight loss; epigenetics; LINE-1; Sat2; LUMA
ID PHYSICAL-ACTIVITY; INSULIN-RESISTANCE; BLOOD-CELLS; PATTERNS; GLUCOSE;
   WOMEN; HYPOMETHYLATION; EPIGENOMICS; LINE-1; GENES
AB Background: Lower levels of global DNA methylation in tissue and blood have been associated with increased cancer risk. Conversely, cross-sectional analyses of healthier lifestyle patterns have been associated with higher levels of global DNA methylation.
   Objective: In this trial, we explored the associations between changes in lifestyle modifications (diet, weight loss), metabolic markers, and global epigenetic biomarkers in white blood cells.
   Methods: Study participants were Hispanic, African American, and Afro-Caribbean overweight and sedentary female breast cancer survivors (n=24) who participated in a larger randomized, crossover, pilot study of a 6-mo weight loss intervention and who had available blood specimens. Anthropometric measures, a food-frequency questionnaire, and peripheral blood were collected at baseline, 6 mo, and 12 mo. Plasma samples were analyzed for metabolic markers (insulin, glucose). We measured DNA methylation of long interspersed nucleotide element 1 (LINE-1) and satellite 2 by pyrosequencing and MethyLight, respectively, and global DNA methylation by the luminometric methylation assay (LUMA).
   Results: DNA methylation of LINE-1 was statistically significantly elevated at 6 mo [75.5% vs. 78.5% (P< 0.0001)] and 12 mo [75.5% vs. 77.7% (P< 0.0001)], compared to baseline. Over a 12-mo period, changes in percentage body fat and plasma glucose concentrations were positively associated with LINE-1 DNA methylation (beta = 0.19, P= 0.001) and LUMA DNA methylation levels (beta = 0.24, P= 0.02), respectively. Similarly, 12-mo changes in dietary measures such as vegetable (beta = 0.009, P= 0.048), protein (beta = 0.04, P= 0.001), and total caloric (beta = 0.05, P = 0.01) intake were positively associated with changes in LUMA DNA methylation, as was intake of fruit positively associated with changes in LINE-1 DNA methylation (beta = 0.004, P= 0.02).
   Conclusions: Our hypothesis-generating results suggest that lifestyle modifications may be associated with changes in global DNA methylation detectable at 6 and 12 mo. These biomarkers may be useful intermediate biomarkers to use in future intervention trials. This trial was registered at clinicaltrials.gov as NCT00811824.
C1 [Delgado-Cruzata, Lissette; Wang, Qiao; Santella, Regina M.] Columbia Univ Coll Phys & Surg, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA.
   [Zhang, Wenfei; Tsai, Wei Yann] Columbia Univ Coll Phys & Surg, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA.
   [McDonald, Jasmine A.; Valdovinos, Cristina; Falci, Laura; Crew, Katherine D.; Hershman, Dawn L.; Greenlee, Heather] Columbia Univ Coll Phys & Surg, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA.
   [Crew, Katherine D.; Santella, Regina M.; Hershman, Dawn L.; Greenlee, Heather] Columbia Univ Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA.
   [Crew, Katherine D.; Hershman, Dawn L.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA.
   [Delgado-Cruzata, Lissette] CUNY John Jay Coll Criminal Justice, Dept Sci, New York, NY 10019 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University; Columbia University; City University of New York (CUNY)
   System; John Jay College of Criminal Justice (CUNY)
RP Greenlee, H (通讯作者)，Columbia Univ Coll Phys & Surg, Mailman Sch Publ Hlth, Dept Epidemiol, 630 W 168th St, New York, NY 10032 USA.
EM hg2120@columbia.edu
RI Hershman, Dawn/AAG-2114-2020; McDonald, Jasmine/L-4249-2019
OI Delgado-Cruzata, Lissette/0000-0002-2884-0234; McDonald,
   Jasmine/0000-0002-8270-8074
FU NCI [R25 CA094061-0851, T32 CA09529, K23 CA141052]; Gateway for Cancer
   Research; Women At Risk; Susan G. Komen Foundati; National Center for
   Research Resources, a component of the NIH [UL1 RR024156]; NIH Roadmap
   for Medical Research [P30 CA013696, P30 ES009089]
FX Supported by NCI R25 CA094061-0851 (LD-C), T32 CA09529 (JAM), K23
   CA141052 (HG), Gateway for Cancer Research (HG), Women At Risk (HG), the
   Susan G. Komen Foundation (DLH), and grant UL1 RR024156 from the
   National Center for Research Resources, a component of the NIH and NIH
   Roadmap for Medical Research, P30 CA013696, and P30 ES009089.
CR Ainsworth BE, 2000, MED SCI SPORT EXER, V32, P1327, DOI 10.1097/00005768-200007000-00022
   Martínez JA, 2014, ADV NUTR, V5, P71, DOI 10.3945/an.113.004705
   Aslibekyan S, 2014, J NUTR, V144, P425, DOI 10.3945/jn.113.187203
   Barres R, 2011, AM J CLIN NUTR, V93, p897S, DOI 10.3945/ajcn.110.001933
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Block G, 1990, Epidemiology, V1, P58, DOI 10.1097/00001648-199001000-00013
   Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995
   Bouchard L, 2010, DIABETES CARE, V33, P2436, DOI 10.2337/dc10-1024
   Chen J, 2010, ADV GENET, V71, P237, DOI [10.1016/S0065-2660(10)71009-9, 10.1016/B978-0-12-380864-6.00008-0]
   Chiang EPI, 2009, J CLIN ENDOCR METAB, V94, P1017, DOI 10.1210/jc.2008-2038
   Deneberg S, 2010, LEUKEMIA, V24, P932, DOI 10.1038/leu.2010.41
   Fazzari MJ, 2004, NAT REV GENET, V5, P446, DOI 10.1038/nrg1349
   Figueiredo JC, 2009, CANCER EPIDEM BIOMAR, V18, P1041, DOI 10.1158/1055-9965.EPI-08-0926
   Greenlee HA, 2013, OBESITY, V21, P65, DOI 10.1002/oby.20245
   Hillemacher T, 2008, EUR NEUROPSYCHOPHARM, V18, P295, DOI 10.1016/j.euroneuro.2007.12.005
   Holmes MD, 2005, JAMA-J AM MED ASSOC, V293, P2479, DOI 10.1001/jama.293.20.2479
   Holmes MD, 1999, CANCER, V86, P826, DOI 10.1002/(SICI)1097-0142(19990901)86:5<826::AID-CNCR19>3.0.CO;2-0
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lee JJ, 2008, INT J ONCOL, V33, P861, DOI 10.3892/ijo_00000074
   Luttropp K, 2013, SCAND J CLIN LAB INV, V73, P184, DOI 10.3109/00365513.2012.743166
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Pearce MS, 2012, INT J EPIDEMIOL, V41, P210, DOI 10.1093/ije/dys020
   Pierce JP, 2007, J CLIN ONCOL, V25, P2345, DOI 10.1200/JCO.2006.08.6819
   Pilsner JR, 2007, AM J CLIN NUTR, V86, P1179, DOI 10.1093/ajcn/86.4.1179
   Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P1466, DOI 10.1289/ehp.0800497
   Pirola L, 2011, GENOME RES, V21, P1601, DOI 10.1101/gr.116095.110
   Piyathilake CJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054544
   Pulte D, 2012, ANN ONCOL, V23, P2428, DOI 10.1093/annonc/mds023
   Rock CL, 2005, J CLIN ONCOL, V23, P6631, DOI 10.1200/JCO.2005.19.505
   Rock CL, 2002, J CLIN ONCOL, V20, P3302, DOI 10.1200/JCO.2002.03.008
   Romermann D, 2007, Verh Dtsch Ges Pathol, V91, P338
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Scoccianti C, 2011, EPIGENETICS-US, V6, P1114, DOI 10.4161/epi.6.9.16515
   Skowronski K, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12400
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Toyota M, 2010, ADV GENET, V70, P309, DOI [10.1016/S0065-2660(10)70011-0, 10.1016/B978-0-12-380866-0.60011-3]
   Ulrich CM, 2012, EPIGENETICS-US, V7, P1020, DOI 10.4161/epi.21464
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   White AJ, 2013, EUR J CANCER, V49, P2199, DOI 10.1016/j.ejca.2013.02.013
   Wilhelm CS, 2010, CLIN CANCER RES, V16, P1682, DOI 10.1158/1078-0432.CCR-09-2983
   Wright RO, 2010, ENVIRON HEALTH PERSP, V118, P790, DOI 10.1289/ehp.0901429
   Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391
   Xing CH, 2010, CHEM-BIOL INTERACT, V184, P306, DOI 10.1016/j.cbi.2009.12.028
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Zhang FF, 2011, J NUTR, V141, P1165, DOI 10.3945/jn.110.134536
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
   Zhao JY, 2012, DIABETES, V61, P542, DOI 10.2337/db11-1048
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 54
TC 52
Z9 54
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0022-3166
EI 1541-6100
J9 J NUTR
JI J. Nutr.
PD APR
PY 2015
VL 145
IS 4
BP 783
EP 790
DI 10.3945/jn.114.202853
PG 8
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA CE9RG
UT WOS:000352180500016
PM 25833781
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Papoutsis, AJ
   Selmin, OI
   Borg, JL
   Romagnolo, DF
AF Papoutsis, Andreas J.
   Selmin, Ornella I.
   Borg, Jamie L.
   Romagnolo, Donato F.
TI Gestational Exposure to the AhR Agonist
   2,3,7,8-Tetrachlorodibenzo-<i>p</i>-dioxin Induces BRCA-1 Promoter
   Hypermethylation and Reduces BRCA-1 Expression in Mammary Tissue of Rat
   Offspring: Preventive Effects of Resveratrol
SO MOLECULAR CARCINOGENESIS
LA English
DT Article
DE epigenetics; BRCA-1; mammary carcinogenesis; aromatic hydrocarbon
   receptor; resveratrol
ID ARYL-HYDROCARBON RECEPTOR; SPORADIC BREAST-CANCER; DNA METHYLATION;
   BINDING-PROTEIN; IN-UTERO; GLAND DIFFERENTIATION; NUCLEAR TRANSLOCATOR;
   GENE-EXPRESSION; DIOXIN EXPOSURE; PRENATAL TCDD
AB Studies with murine models suggest that maternal exposure to aromatic hydrocarbon receptor (AhR) agonists may impair mammary gland differentiation and increase the susceptibility to mammary carcinogenesis in offspring. However, the molecular mechanisms responsible for these perturbations remain largely unknown. Previously, we reported that the AhR agonists 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced CpG methylation of the breast cancer-1 (BRCA-1) gene and reduced BRCA-1 expression in breast cancer cell lines. Based on the information both the human and rat BRCA-1 genes harbor xenobiotic responsive elements (XRE = 5'-GCGTG-3'), which are binding targets for the AhR, we extended our studies to the analysis of offspring of pregnant Sprague-Dawley rats treated during gestation with TCDD alone or in combination with the dietary AhR antagonist resveratrol (Res). We report that the in utero exposure to TCDD increased the number of terminal end buds (TEB) and reduced BRCA-1 expression in mammary tissue of offspring. The treatment with TCDD induced occupancy of the BRCA-1 promoter by DNA methyltransferase-1 (DNMT-1), CpG methylation of the BRCA1 promoter, and expression of cyclin D1 and cyclin-dependent kinase-4 (CDK4). These changes were partially overridden by pre-exposure to Res, which stimulated the expression of the AhR repressor (AhRR) and its recruitment to the BRCA-1 gene. These findings point to maternal exposure to AhR agonists as a risk factor for breast cancer in offspring through epigenetic inhibition of BRCA-1 expression, whereas dietary antagonists of the AhR may exert protective effects. (C) 2013 Wiley Periodicals, Inc.
C1 Univ Arizona, Dept Nutr Sci, Tucson, AZ USA.
   [Romagnolo, Donato F.] Univ Arizona, Arizona Canc Ctr, Tucson, AZ USA.
C3 University of Arizona; University of Arizona; Arizona Center Cancer Care
RP Romagnolo, DF (通讯作者)，Univ Arizona, Dept Nutr Sci, Nutr Sci, 303 Shantz Bldg, Tucson, AZ 85721 USA.
RI Selmin, Ornella/ABC-8971-2020
FU US ARMY Medical Research and Materiel Command [DAMD 10-1-0215]; American
   Institute for Cancer Research [10A058]; Arizona Cancer Center Support
   Grant [P30CA23074]
FX Grant sponsor: US ARMY Medical Research and Materiel Command; Grant
   number: DAMD 10-1-0215; Grant sponsor: The American Institute for Cancer
   Research; Grant number: 10A058; Grant sponsor: The Arizona Cancer Center
   Support Grant; Grant number: P30CA23074
CR Banerjee S, 2002, CANCER RES, V62, P4945
   Bennett LM, 1999, MAMM GENOME, V10, P19, DOI 10.1007/s003359900935
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Botelho GGK, 2009, ARCH ENVIRON CON TOX, V57, P785, DOI 10.1007/s00244-009-9385-9
   Bourque SL, 2012, PLACENTA, V33, P449, DOI 10.1016/j.placenta.2012.01.012
   Brown NM, 1998, CARCINOGENESIS, V19, P1623, DOI 10.1093/carcin/19.9.1623
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Clouaire T, 2010, NUCLEIC ACIDS RES, V38, P4620, DOI 10.1093/nar/gkq228
   Daniel JM, 2002, NUCLEIC ACIDS RES, V30, P2911, DOI 10.1093/nar/gkf398
   Denison MS, 2003, ANNU REV PHARMACOL, V43, P309, DOI 10.1146/annurev.pharmtox.43.100901.135828
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evans BR, 2008, MOL PHARMACOL, V73, P387, DOI 10.1124/mol.107.040204
   Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Gehm BD, 2004, J STEROID BIOCHEM, V88, P223, DOI 10.1016/j.jsbmb.2003.12.002
   Hahn ME, 2009, BIOCHEM PHARMACOL, V77, P485, DOI 10.1016/j.bcp.2008.09.016
   Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619
   Hushka LJ, 1998, TOXICOL APPL PHARM, V152, P200, DOI 10.1006/taap.1998.8508
   Iba MM, 2000, BIOCHEM PHARMACOL, V59, P1147, DOI 10.1016/S0006-2952(99)00415-3
   Jang JY, 2008, EUR J PHARMACOL, V591, P280, DOI 10.1016/j.ejphar.2008.05.033
   Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256
   Jenkins S, 2007, REPROD TOXICOL, V23, P391, DOI 10.1016/j.reprotox.2006.10.004
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Lamartiniere CA, 2002, J MAMMARY GLAND BIOL, V7, P67, DOI 10.1023/A:1015722507237
   Leijs MM, 2008, CHEMOSPHERE, V73, P999, DOI 10.1016/j.chemosphere.2008.05.053
   Levy-Lahad E, 2007, BRIT J CANCER, V96, P11, DOI 10.1038/sj.bjc.6603535
   Lewis BC, 2001, TOXICOL SCI, V62, P46, DOI 10.1093/toxsci/62.1.46
   Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105
   Lopes EC, 2008, CANCER RES, V68, P7258, DOI 10.1158/0008-5472.CAN-08-0344
   MacPherson L, 2010, CANCER LETT, V299, P119, DOI 10.1016/j.canlet.2010.08.010
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Mora R., 2011, Educacion Comunicacion Tecnologia, V10, P1
   Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557
   Papoutsis AJ, 2012, J NUTR BIOCHEM, V23, P1324, DOI 10.1016/j.jnutbio.2011.08.001
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   Russo J, 1996, BREAST CANCER RES TR, V39, P7, DOI 10.1007/BF01806074
   Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x
   RUSSO J, 1980, AM J PATHOL, V100, P497
   Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043
   Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145
   Singh CK, 2011, MOL NUTR FOOD RES, V55, P1186, DOI 10.1002/mnfr.201000457
   Singh NP, 2011, MOL NUTR FOOD RES, V55, P209, DOI 10.1002/mnfr.201000206
   Stejskalova L, 2011, TOXICOL SCI, V123, P26, DOI 10.1093/toxsci/kfr150
   Suter M, 2010, METABOLISM, V59, P1481, DOI 10.1016/j.metabol.2010.01.013
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   Trombino AF, 2000, BREAST CANCER RES TR, V63, P117, DOI 10.1023/A:1006443104670
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Vorderstrasse BA, 2004, TOXICOL SCI, V78, P248, DOI 10.1093/toxsci/kfh062
   Williams LD, 2009, FOOD CHEM TOXICOL, V47, P2170, DOI 10.1016/j.fct.2009.06.002
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743
   Yang XH, 2008, J CELL BIOCHEM, V104, P402, DOI 10.1002/jcb.21630
   Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008
   Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012
   Zudaire E, 2008, J CLIN INVEST, V118, P640, DOI 10.1172/JCI30024
NR 59
TC 59
Z9 66
U1 0
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0899-1987
EI 1098-2744
J9 MOL CARCINOGEN
JI Mol. Carcinog.
PD APR
PY 2015
VL 54
IS 4
BP 261
EP 269
DI 10.1002/mc.22095
PG 9
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA CE9GJ
UT WOS:000352151800002
PM 24136580
DA 2025-01-12
ER

PT J
AU Teplyuk, NM
   Uhlmann, EJ
   Wong, AHK
   Karmali, P
   Basu, M
   Gabriely, G
   Jain, A
   Wang, Y
   Chiocca, EA
   Stephens, R
   Marcusson, E
   Yi, M
   Krichevsky, AM
AF Teplyuk, Nadiya M.
   Uhlmann, Erik J.
   Wong, Andus Hon-Kit
   Karmali, Priya
   Basu, Meenakshi
   Gabriely, Galina
   Jain, Anant
   Wang, Yang
   Chiocca, E. Antonio
   Stephens, Robert
   Marcusson, Eric
   Yi, Ming
   Krichevsky, Anna M.
TI MicroRNA-10b inhibition reduces E2F1-mediated transcription and
   miR-15/16 activity in glioblastoma
SO ONCOTARGET
LA English
DT Article
DE miR-10b; E2F1 transcription; p21; glioblastoma; cell cycle
ID CANCER-CELL-PROLIFERATION; HUMAN GLIOMA-CELLS; MIR-B-10 EXPRESSION;
   GENE-EXPRESSION; BREAST-CANCER; BRAIN-TUMORS; INVASION; PROTEIN;
   PROMOTES; APOPTOSIS
AB MicroRNA-10b (miR-10b) is commonly elevated in glioblastoma (GBM), while not expressed in normal brain tissues. Targeted inhibition of miR-10b has pleiotropic effects on GBM derived cell lines, it reduces GBM growth in animal models, but does not affect normal neurons and astrocytes. This data raises the possibility of developing miR-10b-targeting GBM therapy. However, the mechanisms contributing to miR-10b-mediated glioma cell survival and proliferation are unexplored. We found that inhibition of miR-10b has distinct effects on specific glioma cell lines. In cells expressing high levels of tumor suppressor p21WAF1/Cip1, it represses E2F1-mediated transcription, leading to down-regulation of multiple E2F1 target genes encoding for S-phase specific proteins, epigenetic modulators, and miRNAs (e.g. miR-15/16), and thereby stalling progression through the S-phase of cell cycle. Subsequently, miR-15/16 activities are reduced and many of their direct targets are de-repressed, including ubiquitin ligase FBXW7 that destabilizes Cyclin E. Conversely, GBM cells expressing low p21 level, or after p21 knock-down, exhibit weaker or no E2F1 response to miR-10b inhibition. Comparative analysis of The Cancer Genome Atlas revealed a strong correlation between miR-10b and multiple E2F target genes in GBM and low-grade glioma. Taken together, these findings indicate that miR-10b regulates E2F1-mediated transcription in GBM, in a p21-dependent fashion.
C1 [Teplyuk, Nadiya M.; Uhlmann, Erik J.; Wong, Andus Hon-Kit; Basu, Meenakshi; Gabriely, Galina; Jain, Anant; Wang, Yang; Krichevsky, Anna M.] Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Karmali, Priya; Marcusson, Eric] Regulus Therapeut Inc, San Diego, CA USA.
   [Chiocca, E. Antonio] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA.
   [Stephens, Robert; Yi, Ming] Leidos Biomed Res Inc, Canc Res & Technol Program, Frederick Natl Lab Canc Res, Frederick, MD USA.
C3 Harvard University; Harvard Medical School; Brigham & Women's Hospital;
   Isis Pharmaceuticals Inc; Harvard University; Brigham & Women's
   Hospital; Harvard Medical School; National Institutes of Health (NIH) -
   USA; NIH National Cancer Institute (NCI); Frederick National Laboratory
   for Cancer Research
RP Krichevsky, AM (通讯作者)，Harvard Univ, Sch Med, Dept Neurol, Brigham & Womens Hosp, Boston, MA 02115 USA.
EM akrichevsky@rics.bwh.harvard.edu
RI Kretz-Remy, Carole/J-7850-2019; Wang, Yang/HCG-9543-2022
OI Yi, Ming/0000-0001-9098-1364; Wang, Yang/0000-0003-0842-2446;
   Krichevsky, Anna/0000-0002-5080-5507; Basu Shrivastava,
   Meenakshi/0000-0003-3992-4684; Marcusson, Eric/0000-0002-0504-8674
FU NIH/NCI [RO1CA138734]; Sontag Foundation Distinguished Scientist Award;
   National Brain Tumor Society; Brain Science Foundation
FX This work was supported by NIH/NCI grant RO1CA138734, Sontag Foundation
   Distinguished Scientist Award, grants from National Brain Tumor Society
   (to AMK), and Brain Science Foundation (to AMK, NMT, and EJU).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Aqeilan RI, 2010, CELL DEATH DIFFER, V17, P215, DOI 10.1038/cdd.2009.69
   Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880
   Bottoni A, 2005, J CELL PHYSIOL, V204, P280, DOI 10.1002/jcp.20282
   Calin GA, 2008, P NATL ACAD SCI USA, V105, P5166, DOI 10.1073/pnas.0800121105
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Crea F, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-265
   Delavaine L, 1999, ONCOGENE, V18, P5381, DOI 10.1038/sj.onc.1202923
   Dong CG, 2012, INT J ONCOL, V41, P1005, DOI 10.3892/ijo.2012.1542
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Gabriely G, 2011, AUTOPHAGY, V7, P1384, DOI 10.4161/auto.7.11.17371
   Gabriely G, 2011, CANCER RES, V71, P3563, DOI 10.1158/0008-5472.CAN-10-3568
   Garcia DM, 2011, NAT STRUCT MOL BIOL, V18, P1139, DOI 10.1038/nsmb.2115
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Gu ZD, 2007, BIOCHEM BIOPH RES CO, V354, P992, DOI 10.1016/j.bbrc.2007.01.080
   Guessous F, 2013, J NEURO-ONCOL, V112, P153, DOI 10.1007/s11060-013-1047-0
   Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009
   Hagedorn M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-9
   HARPER JW, 1993, CELL, V75, P805
   Inwald EC, 2013, BREAST CANCER RES TR, V139, P539, DOI 10.1007/s10549-013-2560-8
   Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026
   Jin Q, 2011, CHINESE MED J-PEKING, V124, P2584, DOI 10.3760/cma.j.issn.0366-6999.2011.17.004
   JUNG JM, 1995, ONCOGENE, V11, P2021
   Kayaselçuk F, 2002, J NEURO-ONCOL, V57, P115, DOI 10.1023/A:1015739130208
   Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008
   Korkolopoulou P, 1998, ACTA NEUROPATHOL, V95, P617, DOI 10.1007/s004010050848
   Lang MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036248
   Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005
   Li QJ, 2012, TUMOR BIOL, V33, P1455, DOI 10.1007/s13277-012-0396-1
   Lin J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.134
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Liu Y, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-41
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Malzkorn B, 2010, BRAIN PATHOL, V20, P539, DOI 10.1111/j.1750-3639.2009.00328.x
   McCall CM, 2013, AM J SURG PATHOL, V37, P1671, DOI 10.1097/PAS.0000000000000089
   Mussnich P, 2013, MOL ONCOL, V7, P531, DOI 10.1016/j.molonc.2013.01.002
   Nakata K, 2011, SURGERY, V150, P916, DOI 10.1016/j.surg.2011.06.017
   Nakayama I, 2013, INT J ONCOL, V43, P63, DOI 10.3892/ijo.2013.1935
   Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1
   Nourry C, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-20
   Ofir M, 2011, MOL CANCER RES, V9, P440, DOI 10.1158/1541-7786.MCR-10-0344
   Ouyang H, 2014, ONCOGENE, V33, P4664, DOI 10.1038/onc.2013.405
   Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013
   Rao SAM, 2010, MODERN PATHOL, V23, P1404, DOI 10.1038/modpathol.2010.135
   Sasayama T, 2009, INT J CANCER, V125, P1407, DOI 10.1002/ijc.24522
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Skalsky RL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024248
   Sun LQ, 2004, GENE DEV, V18, P1035, DOI 10.1101/gad.1176104
   Sun XJ, 2013, ASIAN PAC J CANCER P, V14, P5533, DOI 10.7314/APJCP.2013.14.9.5533
   Suvà ML, 2009, CANCER RES, V69, P9211, DOI 10.1158/0008-5472.CAN-09-1622
   Teplyuk NM, 2012, NEURO-ONCOLOGY, V14, P689, DOI 10.1093/neuonc/nos074
   van Leuken R, 2008, BBA-REV CANCER, V1786, P49, DOI 10.1016/j.bbcan.2008.05.002
   Wang KH, 2011, J BIOL CHEM, V286, P9468, DOI 10.1074/jbc.M110.178335
   Wang YY, 2013, HUM PATHOL, V44, P1278, DOI 10.1016/j.humpath.2012.10.014
   Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   Yi M, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-200
NR 58
TC 41
Z9 46
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 28
PY 2015
VL 6
IS 6
BP 3770
EP 3783
DI 10.18632/oncotarget.3009
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CF6WB
UT WOS:000352696200027
PM 25738367
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Bihani, T
   Ezell, SA
   Ladd, B
   Grosskurth, SE
   Mazzola, AM
   Pietras, M
   Reimer, C
   Zinda, M
   Fawell, S
   D'Cruz, CM
AF Bihani, Teeru
   Ezell, Scott A.
   Ladd, Brendon
   Grosskurth, Shaun E.
   Mazzola, Anne Marie
   Pietras, Mark
   Reimer, Corinne
   Zinda, Michael
   Fawell, Stephen
   D'Cruz, Celina M.
TI Resistance to everolimus driven by epigenetic regulation of MYC in ER
   plus breast cancers
SO ONCOTARGET
LA English
DT Article
DE everolimus; resistance; mTOR; MYC; BRD4
ID SELECTIVE-INHIBITION; AROMATASE INHIBITOR; EXPRESSION ANALYSIS;
   AROMATIZATION; TRANSCRIPTION; EXEMESTANE; SIGNATURES; DATABASE
AB Acquired resistance to PI3K/mTOR/Akt pathway inhibitors is often associated with compensatory feedback loops involving the activation of oncogenes. Here, we have generated everolimus resistance in ER+ breast cancer cells and in long-term estrogen deprived (LTED) models that mimic progression on anti-estrogens. This allowed us to uncover MYC as a driver of mTOR inhibitor resistance. We demonstrate that both everolimus resistance and acute treatment of everolimus can lead to the upregulation of MYC mRNA, protein expression and, consequently, the enrichment of MYC signatures as revealed by RNA sequencing data. Depletion of MYC resulted in resensitization to everolimus, confirming its functional importance in this setting. Furthermore, ChIP assays demonstrate that MYC upregulation in the everolimus resistant lines is mediated by increased association of the BRD4 transcription factor with the MYC gene. Finally, JQ1, a BRD4 inhibitor combined with everolimus exhibited increased tumor growth inhibition in 3D Matrigel models and an in vivo xenograft model. These data suggest that MYC plays an important role in mediating resistance to everolimus in ER+ and ER+/LTED models. Furthermore, given the regulation of MYC by BRD4 in this setting, these data have implications for increased therapeutic potential of combining epigenetic agents with mTOR inhibitors to effectively downregulate otherwise difficult to target transcription factors such as MYC.
C1 [Bihani, Teeru; Ezell, Scott A.; Ladd, Brendon; Grosskurth, Shaun E.; Mazzola, Anne Marie; Pietras, Mark; Reimer, Corinne; Zinda, Michael; Fawell, Stephen; D'Cruz, Celina M.] AstraZeneca, R&D Boston, Waltham, MA 02451 USA.
C3 AstraZeneca
RP D'Cruz, CM (通讯作者)，AstraZeneca, R&D Boston, Waltham, MA 02451 USA.
EM celina.dcruz@astrazeneca.com
OI Ladd, Brendon/0009-0007-4322-0360; Mazzola, Anne
   Marie/0000-0003-3300-0245
CR Allred DC, 2004, BREAST CANCER RES, V6, P240, DOI 10.1186/bcr938
   Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510
   [Anonymous], 2014, Cell research
   Arabi A, 2005, NAT CELL BIOL, V7, P303, DOI 10.1038/ncb1225
   Balakumaran BS, 2009, CANCER RES, V69, P7803, DOI 10.1158/0008-5472.CAN-09-0910
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Black JC, 2013, CELL, V154, P541, DOI 10.1016/j.cell.2013.06.051
   Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260
   Culhane AC, 2012, NUCLEIC ACIDS RES, V40, pD1060, DOI 10.1093/nar/gkr901
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   DEMERS LM, 1994, BREAST CANCER RES TR, V30, P95, DOI 10.1007/BF00682744
   Ezell SA, 2014, ONCOTARGET, V5, P4990, DOI 10.18632/oncotarget.2071
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Geisler J, 1998, CLIN CANCER RES, V4, P2089
   Geisler J, 1996, BRIT J CANCER, V74, P1286, DOI 10.1038/bjc.1996.531
   Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124
   Lebwohl D, 2013, ANN NY ACAD SCI, V1291, P14, DOI 10.1111/nyas.12122
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567
   Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680
   ODOREKR E., 2014, AACR ANN M
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Piccart M., 2014, ANN ONCOL
   Pourdehnada M, 2013, P NATL ACAD SCI USA, V110, P11988, DOI 10.1073/pnas.1310230110
   Robinson MD, 2008, BIOSTATISTICS, V9, P321, DOI 10.1093/biostatistics/kxm030
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Toh PPC, 2013, HUM MOL GENET, V22, P5237, DOI 10.1093/hmg/ddt381
   Tolani B, 2014, ONCOGENE, V33, P2928, DOI 10.1038/onc.2013.242
   WAKELING AE, 1991, CANCER RES, V51, P3867
   Yardley DA, 2013, ADV THER, V30, P870, DOI 10.1007/s12325-013-0060-1
   Ziauddin MF, 2014, CANC METASTASIS REV
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 35
TC 49
Z9 56
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 10
PY 2015
VL 6
IS 4
BP 2407
EP 2420
DI 10.18632/oncotarget.2964
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CF6UL
UT WOS:000352691800037
PM 25537515
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Shenker, NS
   Flower, KJ
   Wilhelm-Benartzi, CS
   Dai, W
   Bell, E
   Gore, E
   El Bahrawy, M
   Weaver, G
   Brown, R
   Flanagan, JM
AF Shenker, Natalie S.
   Flower, Kirsty J.
   Wilhelm-Benartzi, Charlotte S.
   Dai, Wei
   Bell, Emma
   Gore, Edmund
   El Bahrawy, Mona
   Weaver, Gillian
   Brown, Robert
   Flanagan, James M.
TI Transcriptional implications of intragenic DNA methylation in the
   oestrogen receptor alpha gene in breast cancer cells and tissues
SO BMC CANCER
LA English
DT Article
DE Intragenic; DNA methylation; Breast cancer; ESR1; Breast epithelial
   cells; Breast cancer campaign tissue bank; Breast milk
ID EXPRESSION; HYPOMETHYLATION; DIFFERENTIATION; UNCOVERS; PATTERNS;
   HISTORY
AB Background: DNA methylation variability regions (MVRs) across the oestrogen receptor alpha (ESR1) gene have been identified in peripheral blood cells from breast cancer patients and healthy individuals. In contrast to promoter methylation, gene body methylation may be important in maintaining active transcription. This study aimed to assess MVRs in ESR1 in breast cancer cell lines, tumour biopsies and exfoliated epithelial cells from expressed breast milk (EBM), to determine their significance for ESR1 transcription.
   Methods: DNA methylation levels in eight MVRs across ESR1 were assessed by pyrosequencing bisulphite-converted DNA from three oestrogen receptor (ER)-positive and three ER-negative breast cancer cell lines. DNA methylation and expression were assessed following treatment with DAC (1 mu M), or DMSO (controls). ESR1 methylation levels were also assayed in DNA from 155 invasive ductal carcinoma biopsies provided by the Breast Cancer Campaign Tissue Bank, and validated with DNA methylation profiles from the TCGA breast tumours (n = 356 ER-pos, n = 109 ER-neg). DNA methylation was profiled in exfoliated breast epithelial cells from EBM using the Illumina 450 K (n = 36) and pyrosequencing in a further 53 donor samples. ESR1 mRNA levels were measured by qRT-PCR.
   Results: We show that ER-positive cell lines had unmethylated ESR1 promoter regions and highly methylated intragenic regions (median, 80.45%) while ER-negative cells had methylated promoters and lower intragenic methylation levels (median, 38.62%). DAC treatment increased ESR1 expression in ER-negative cells, but significantly reduced methylation and expression of ESR1 in ER-positive cells. The ESR1 promoter was unmethylated in breast tumour biopsies with high levels of intragenic methylation, independent of ER status. However, ESR1 methylation in the strongly ER-positive EBM DNA samples were very similar to ER-positive tumour cell lines.
   Conclusion: DAC treatment inhibited ESR1 transcription in cells with an unmethylated ESR1 promoter and reduced intragenic DNA methylation. Intragenic methylation levels correlated with ESR1 expression in homogenous cell populations (cell lines and exfoliated primary breast epithelial cells), but not in heterogeneous tumour biopsies, highlighting the significant differences between the in vivo tumour microenvironment and individual homogenous cell types. These findings emphasise the need for care when choosing material for epigenetic research and highlights the presence of aberrant intragenic methylation levels in tumour tissue.
C1 [Shenker, Natalie S.; Flower, Kirsty J.; Wilhelm-Benartzi, Charlotte S.; Dai, Wei; Bell, Emma; Gore, Edmund; El Bahrawy, Mona; Brown, Robert; Flanagan, James M.] Univ London Imperial Coll Sci Technol & Med, Div Canc, Dept Surg & Canc, Epigenet Unit, London W12 0NN, England.
   [Weaver, Gillian] Queen Charlotte & Chelsea Hosp, Milk Bank, London, England.
C3 Imperial College London; Imperial College London
RP Flanagan, JM (通讯作者)，Univ London Imperial Coll Sci Technol & Med, Div Canc, Dept Surg & Canc, Epigenet Unit, 4th Floor IRDB,Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
EM j.flanagan@imperial.ac.uk
RI Dai, Wei/T-8889-2019; Shenker, Natalie/ABX-1855-2022
OI Dai, Wei/0000-0002-5558-0685; Gore, Edmund/0000-0001-9506-336X; Brown,
   Robert/0000-0001-7960-5755; Bell, Emma/0000-0003-4103-3741; Shenker,
   Natalie/0000-0002-8067-1079; Wilhelm-Benartzi,
   Charlotte/0000-0003-4927-6158; Flanagan, James/0000-0003-4955-1383
FU Breast Cancer Campaign Scientific Fellowship; Medical Research Council
   (MRC UK) doctoral scholarship; Breast Cancer Campaign; CRUK programme
   [A13086]; National Institute for Health Research (NIHR) Biomedical
   Research Centre based at Imperial College Healthcare NHS Trust; Imperial
   College London
FX The authors would like to thank all of the breast cancer patients who
   donated to the Breast Cancer Campaign Tissue Bank and the breast milk
   donors to the QCCH Milk Bank. We would also like to thank the SERV
   volunteers for collecting and Jennifer Sangalang for processing milk
   samples donated to the Milk Bank. JMF is funded by a Breast Cancer
   Campaign Scientific Fellowship and NSS is funded by a Medical Research
   Council (MRC UK) doctoral scholarship. This work was funded by Breast
   Cancer Campaign and supported by CRUK programme grant A13086 and the
   National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Imperial College Healthcare NHS Trust and Imperial College
   London. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health.
CR Aran D, 2011, HUM MOL GENET, V20, P670, DOI 10.1093/hmg/ddq513
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Benson JR, 2009, LANCET, V373, P1463, DOI 10.1016/S0140-6736(09)60316-0
   Blattler A, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0469-0
   Brenet F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014524
   Carey LA, 2010, CLIN BREAST CANCER, V10, P188, DOI 10.3816/CBC.2010.n.026
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Cleator SJ, 2009, CLIN BREAST CANCER, V9, pS6, DOI 10.3816/CBC.2009.s.001
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Ehrlich M, 2013, EPIGENOMICS-UK, V5, P553, DOI 10.2217/epi.13.43
   Faupel-Badger JM, 2013, JNCI-J NATL CANCER I, V105, P166, DOI 10.1093/jnci/djs505
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Gur-Dedeoglu B, 2009, ONCOL RES, V17, P353, DOI 10.3727/096504009788428460
   Hassiotou F, 2013, J HUM LACT, V29, P171, DOI 10.1177/0890334413477242
   Heijmans BT, 2012, INT J EPIDEMIOL, V41, P74, DOI 10.1093/ije/dyr225
   Huang ZQ, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00131
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kanai Y, 2010, CANCER SCI, V101, P36, DOI 10.1111/j.1349-7006.2009.01383.x
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Kulis M, 2013, BBA-GENE REGUL MECH, V1829, P1161, DOI 10.1016/j.bbagrm.2013.08.001
   Lorincz MC, 2004, NAT STRUCT MOL BIOL, V11, P1068, DOI 10.1038/nsmb840
   Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200
   Malousi A, 2012, MOL GENET GENOMICS, V287, P631, DOI 10.1007/s00438-012-0703-y
   Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Michels KB, 2010, EXP GERONTOL, V45, P297, DOI 10.1016/j.exger.2009.12.011
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Nathan D, 2002, J MOL BIOL, V316, P7, DOI 10.1006/jmbi.2001.5247
   Ooi SKT, 2008, CELL, V133, P1145, DOI 10.1016/j.cell.2008.06.009
   Pleyer L, 2015, DRUG METAB REV, P1
   Royo JL, 2007, NAT PROTOC, V2, P1734, DOI 10.1038/nprot.2007.244
   Schor IE, 2013, EMBO J, V32, P2264, DOI 10.1038/emboj.2013.167
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127
   Tost J, 2010, MOL BIOTECHNOL, V44, P71, DOI 10.1007/s12033-009-9216-2
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Velicescu M, 2002, CANCER RES, V62, P2378
   Wild L, 2010, BBA-REV CANCER, V1806, P50, DOI 10.1016/j.bbcan.2010.03.003
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Zemach A, 2010, P NATL ACAD SCI USA, V107, P18729, DOI 10.1073/pnas.1009695107
   Zemach A, 2010, CURR BIOL, V20, pR780, DOI 10.1016/j.cub.2010.07.007
   Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366
   Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929
NR 50
TC 16
Z9 18
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 1
PY 2015
VL 15
AR 337
DI 10.1186/s12885-015-1335-5
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CH6RV
UT WOS:000354164700003
PM 25927974
OA Green Published, Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Lu, JC
   Song, GH
   Tang, QL
   Zou, CY
   Han, F
   Zhao, ZQ
   Yong, BC
   Yin, JQ
   Xu, HY
   Xie, XB
   Kang, TB
   Lam, YL
   Yang, HL
   Shen, JN
   Wang, J
AF Lu, Jinchang
   Song, Guohui
   Tang, Qinglian
   Zou, Changye
   Han, Feng
   Zhao, Zhiqiang
   Yong, Bicheng
   Yin, Junqiang
   Xu, Huaiyuan
   Xie, Xianbiao
   Kang, Tiebang
   Lam, YingLee
   Yang, Hulling
   Shen, Jingnan
   Wang, Jin
TI <i>IRX1</i> hypomethylation promotes osteosarcoma metastasis via
   induction of CXCL14/NF-κB signaling
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID SUPPRESSES TUMOR-GROWTH; CELLS IN-VITRO; DNA METHYLATION; BREAST-CANCER;
   PROSTATE-CANCER; GENE-EXPRESSION; C-FLIP; VIVO; CARCINOMA; DEMETHYLATION
AB Osteosarcoma is a common malignant bone tumor with a propensity to metastasize to the lungs. Epigenetic abnormalities have been demonstrated to underlie osteosarcoma development; however, the epigenetic mechanisms that are involved in metastasis are not yet clear. Here, we analyzed 2 syngeneic primary human osteosarcoma cell lines that exhibit disparate metastatic potential for differences in epigenetic modifications and expression. Using methylated DNA immunoprecipitation (MeDIP) and microarray expression analysis to screen for metastasis-associated genes, we identified Iroquois homeobox 1 (IRX1). In both human osteosarcoma cell lines and clinical osteosarcoma tissues, IRX1 overexpression was strongly associated with hypomethylation of its own promoter. Furthermore, experimental modulation of IRX1 in osteosarcoma cell lines profoundly altered metastatic activity, including migration, invasion, and resistance to anoikis in vitro, and influenced lung metastasis in murine models. These prometastatic effects of IRX1 were mediated by upregulation of CXCL14/NF-kappa B signaling. In serum from osteosarcoma patients, the presence of IRX1 hypomethylation in circulating tumor DNA reduced lung metastasis free survival. Together, these results identify IRX1 as a prometastatic gene, implicate IRX1 hypomethylation as a potential molecular marker for lung metastasis, and suggest that epigenetic reversion of IRX1 activation may be beneficial for controlling osteosarcoma metastasis.
C1 [Lu, Jinchang; Song, Guohui; Tang, Qinglian; Zou, Changye; Zhao, Zhiqiang; Yong, Bicheng; Yin, Junqiang; Xu, Huaiyuan; Xie, Xianbiao; Shen, Jingnan; Wang, Jin] Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.
   [Han, Feng; Lam, YingLee] Univ Hong Kong, Dept Orthopaed & Traumatol, Div Gen Orthopaed & Oncol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
   [Yong, Bicheng] Guangzhou Women & Childrens Hosp, Dept Pediat Orthoped, Guangzhou, Guangdong, Peoples R China.
   [Kang, Tiebang] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou 510080, Guangdong, Peoples R China.
   [Yang, Hulling] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Pathophysiol, Guangzhou 510080, Guangdong, Peoples R China.
C3 Sun Yat Sen University; University of Hong Kong; State Key Lab Oncology
   South China; Sun Yat Sen University; Sun Yat Sen University
RP Wang, J (通讯作者)，Sun Yat Sen Univ, Dept Musculoskeletal Oncol, Affiliated Hosp 1, 58 Zhongshan Rd 2, Guangzhou 510080, Guangdong, Peoples R China.
EM 2004wjhf@163.com
RI han, feng/KBB-3356-2024; Song, Guohui/AAD-9259-2022; Wang,
   He/JCO-3900-2023
OI Kang, Tiebang/0000-0001-8805-4174
FU National Natural Science Foundation of China [81272940, 81472507,
   81001194]; Sun Yat-Sen University [13yk2d08]; PhD Program Foundation of
   the Ministry of Education of China [20130171110062]; Sun Yat-Sen
   University Clinical Research 5010 Program [2012002]
FX This research was supported by the National Natural Science Foundation
   of China (81272940 and 81472507, to Jin Wang and 81001194, to Changye
   Zou); a Talent Grant from Sun Yat-Sen University (13yk2d08, to Jin
   Wang); the PhD Program Foundation of the Ministry of Education of China
   (20130171110062, to Jin Wang); and the Sun Yat-Sen University Clinical
   Research 5010 Program (2012002, to Jin Wang). We thank J. Zhao (Sun
   Yat-Sen University) for expert technical assistance.
CR Adamowicz M, 2006, GENE CHROMOSOME CANC, V45, P829, DOI 10.1002/gcc.20343
   Al-Romaih K, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-14
   Al-Romaih K, 2008, NEOPLASIA, V10, P471, DOI 10.1593/neo.08174
   Alix-Panabières C, 2012, ANNU REV MED, V63, P199, DOI 10.1146/annurev-med-062310-094219
   Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010
   [Anonymous], ASIAN WOMEN
   [Anonymous], 2012, International Journal of Cell Biology
   Asaka SI, 2006, SURG TODAY, V36, P793, DOI 10.1007/s00595-006-3261-2
   Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388
   Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029
   Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509
   Bilioni A, 2005, P NATL ACAD SCI USA, V102, P14671, DOI 10.1073/pnas.0502480102
   Bosch-Presegue Laia, 2011, Genes Cancer, V2, P648, DOI 10.1177/1947601911417862
   Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200
   Cavodeassi F, 2001, DEVELOPMENT, V128, P2847
   Delle Chiaie R, 2002, AM J CLIN NUTR, V76, p1172S, DOI 10.1093/ajcn/76.5.1172S
   Detich N, 2003, J BIOL CHEM, V278, P20812, DOI 10.1074/jbc.M211813200
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Frederick MJ, 2000, AM J PATHOL, V156, P1937, DOI 10.1016/S0002-9440(10)65067-5
   Guo X, 2010, ONCOGENE, V29, P3908, DOI 10.1038/onc.2010.143
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Nguyen HH, 2012, HUM MOL GENET, V21, P2076, DOI 10.1093/hmg/dds025
   Hromas R, 1999, BIOCHEM BIOPH RES CO, V255, P703, DOI 10.1006/bbrc.1999.0257
   Itoh M, 2002, DEVELOPMENT, V129, P2317
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lu Jinchang, 2013, Nan Fang Yi Ke Da Xue Xue Bao, V33, P798
   Luu HH, 2005, CLIN EXP METASTAS, V22, P319, DOI 10.1007/s10585-005-0365-9
   Mato JM, 2007, HEPATOLOGY, V45, P1306, DOI 10.1002/hep.21650
   Matsumoto K, 2004, NAT NEUROSCI, V7, P605, DOI 10.1038/nn1249
   Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001
   Miller NH, 2006, AM J MED GENET A, V140A, P1059, DOI 10.1002/ajmg.a.31211
   Müller HM, 2004, ANN NY ACAD SCI, V1022, P44, DOI 10.1196/annals.1318.008
   Myrthue A, 2008, CLIN CANCER RES, V14, P3562, DOI 10.1158/1078-0432.CCR-07-4649
   Najm WI, 2004, BMC MUSCULOSKEL DIS, V5, DOI 10.1186/1471-2474-5-6
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   O'Dea E, 2009, WIRES SYST BIOL MED, V1, P107, DOI 10.1002/wsbm.30
   Oler G, 2008, CLIN CANCER RES, V14, P4735, DOI 10.1158/1078-0432.CCR-07-4372
   Ozawa S, 2006, BIOCHEM BIOPH RES CO, V348, P406, DOI 10.1016/j.bbrc.2006.07.070
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Pelicano H, 2009, CANCER RES, V69, P2375, DOI 10.1158/0008-5472.CAN-08-3359
   Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096
   RAZIN A, 1980, SCIENCE, V210, P604, DOI 10.1126/science.6254144
   RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991
   Robbs BK, 2008, MOL CELL BIOL, V28, P7168, DOI 10.1128/MCB.00256-08
   Rodenhiser DI, 2009, CLIN EXP METASTAS, V26, P5, DOI 10.1007/s10585-008-9166-2
   Safa A. R., 2012, Experimental Oncology, V34, P176
   Schwarze SR, 2005, PROSTATE, V64, P67, DOI 10.1002/pros.20215
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Selvarajah S, 2007, CANCER GENET CYTOGEN, V179, P52, DOI 10.1016/j.cancergencyto.2007.08.003
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Siegel HJ, 2008, EXPERT REV ANTICANC, V8, P1257, DOI 10.1586/14737140.8.8.1257
   Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029
   Su Y, 2011, ONCOGENE, V30, P3907, DOI 10.1038/onc.2011.97
   Su YX, 2009, CLIN EXP METASTAS, V26, P599, DOI 10.1007/s10585-009-9259-6
   Sun XQ, 2010, CANCER METAST REV, V29, P709, DOI 10.1007/s10555-010-9256-x
   Tan PX, 2012, BIOCHEM BIOPH RES CO, V419, P801, DOI 10.1016/j.bbrc.2012.02.110
   Tang QL, 2012, JNCI-J NATL CANCER I, V104, P749, DOI 10.1093/jnci/djs210
   Tang QL, 2011, CANCER LETT, V311, P113, DOI 10.1016/j.canlet.2011.07.016
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Wente MN, 2008, CANC LETT, V259, P209
   Xu C, 2007, PROSTATE, V67, P1621, DOI 10.1002/pros.20655
   Zeng J, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-6
   Zhao ZQ, 2014, CANCER LETT, V342, P150, DOI 10.1016/j.canlet.2013.08.042
   Zou CY, 2008, ACTA PHARMACOL SIN, V29, P325, DOI 10.1111/j.1745-7254.2008.00756.x
   Zülch A, 2001, MECH DEVELOP, V106, P159, DOI 10.1016/S0925-4773(01)00411-7
NR 69
TC 103
Z9 116
U1 0
U2 33
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2015
VL 125
IS 5
BP 1839
EP 1856
DI 10.1172/JCI78437
PG 18
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CH5JK
UT WOS:000354071700010
PM 25822025
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Westcott, JM
   Prechtl, AM
   Maine, EA
   Gang, TT
   Esparza, MA
   Sun, H
   Zhou, YY
   Xie, Y
   Pearson, GW
AF Westcott, Jill M.
   Prechtl, Amanda M.
   Maine, Erin A.
   Gang, Tuyen T.
   Esparza, Matthew A.
   Sun, Han
   Zhou, Yunyun
   Xie, Yang
   Pearson, Gray W.
TI An epigenetically distinct breast cancer cell subpopulation promotes
   collective invasion
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION SIGNATURE; IN-SITU;
   CLAUDIN-LOW; TUMOR; MIGRATION; HETEROGENEITY; IDENTIFICATION;
   METASTASIS; ACTIVATION
AB Tumor cells can engage in a process called collective invasion, in which cohesive groups of cells invade through interstitial tissue. Here, we identified an epigenetically distinct subpopulation of breast tumor cells that have an enhanced capacity to collectively invade. Analysis of spheroid invasion in an organotypic culture.system revealed that these "trailblazer" cells are capable of initiating collective invasion and promote non-trailblazer cell invasion, indicating a commensal relationship among subpopulations within heterogenous tumors. Canonical mesenchymal markers were not sufficient to distinguish trailblazer cells from non-trailblazer cells, suggesting that defining the molecular underpinnings of the trailblazer phenotype could reveal collective invasion-specific mechanisms. Functional analysis determined that DOCK10, ITGA11, DAB2, PDFGRA, VASN, PPAP2B, and LPAR1 are highly expressed in trailblazer cells and required to initiate collective invasion, with DOCK10 essential for metastasis. In patients with triple-negative breast cancer, expression of these 7 genes correlated with poor outcome. Together, our results indicate that spontaneous conversion of the epigenetic state in a subpopulation of cells can promote a transition from in situ to invasive growth through induction of a cooperative form of collective invasion and suggest that therapeutic inhibition of trailblazer cell invasion may help prevent metastasis.
C1 [Westcott, Jill M.; Prechtl, Amanda M.; Maine, Erin A.; Gang, Tuyen T.; Esparza, Matthew A.; Xie, Yang; Pearson, Gray W.] Univ Texas SW Med Ctr Dallas, Harold C Simmons Canc Ctr, UTSW, Dallas, TX 75390 USA.
   [Sun, Han; Zhou, Yunyun; Xie, Yang] Univ Texas SW Med Ctr Dallas, Quantitat Biomed Res Ctr, UTSW, Dallas, TX 75390 USA.
   [Sun, Han; Zhou, Yunyun; Xie, Yang] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, UTSW, Dallas, TX 75390 USA.
   [Pearson, Gray W.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, UTSW, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; University of
   Texas System; University of Texas Southwestern Medical Center Dallas
RP Pearson, GW (通讯作者)，Univ Texas SW Med Ctr Dallas, Harold C Simmons Canc Ctr, 6001 Forest Pk Rd, Dallas, TX 75390 USA.
EM gray.pearson@utsouthwestern.edu
RI Zhou, Yunyun/P-1792-2017
OI Dang, Tuyen/0000-0003-4836-8819; Esparza, Matthew/0000-0001-5277-0398
FU NIH [1RO1CA155241, 5RO1CA152301, 5T32CA124334]; Cancer Prevention
   Research Institute of Texas [RP101251, RP10496]; Mary Kay Foundation;
   UTSW
FX This work was supported by NIH grants 1RO1CA155241 (to G.W. Pearson),
   5RO1CA152301 (to Y. Xie), and 5T32CA124334 (to A.M. Prechtl and M.A.
   Esparza); Cancer Prevention Research Institute of Texas grants RP101251
   (to Y. Xie) and RP10496 (to T.T. Dang); the Mary Kay Foundation (to G.W.
   Pearson); and UTSW institutional support funds (to G.W. Pearson). We
   thank Abhijit Bugde and Kate Phelps in the UTSW Live Cell Imaging
   Facility for microscopy support.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Almendro V, 2014, CANCER RES, V74, P1338, DOI 10.1158/0008-5472.CAN-13-2357-T
   Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923
   Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Bianco A, 2007, NATURE, V448, P362, DOI 10.1038/nature05965
   Bissell MJ, 2002, DIFFERENTIATION, V70, P537, DOI 10.1046/j.1432-0436.2002.700907.x
   Bookout Angie L, 2006, Curr Protoc Mol Biol, VChapter 15, DOI 10.1002/0471142727.mb1508s73
   Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324
   Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301
   Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021
   Celià-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218
   Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978
   Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029
   Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   Dang TT, 2011, CANCER RES, V71, P6857, DOI 10.1158/0008-5472.CAN-11-1818
   DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927
   FRIEDL P, 1995, CANCER RES, V55, P4557
   Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016
   Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720
   Gadea G, 2008, CURR BIOL, V18, P1456, DOI 10.1016/j.cub.2008.08.053
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1
   Jacob LS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001225
   Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103
   Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Padrick SB, 2010, ANNU REV BIOCHEM, V79, P707, DOI 10.1146/annurev.biochem.77.060407.135452
   Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724
   Pasic L, 2011, GENE DEV, V25, P1641, DOI 10.1101/gad.2025611
   Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534
   Polyak Kornelia, 2010, Journal of the National Cancer Institute Monographs, P210, DOI 10.1093/jncimonographs/lgq019
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Rorth P, 2012, EMBO REP, V13, P984, DOI 10.1038/embor.2012.149
   Rorth P, 2009, ANNU REV CELL DEV BI, V25, P407, DOI 10.1146/annurev.cellbio.042308.113231
   Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043
   Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041
   Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100
   Singh DK, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.22
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007
   Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136
   Wolf K, 2007, NAT CELL BIOL, V9, P893, DOI 10.1038/ncb1616
   Xian W, 2005, J CELL BIOL, V171, P663, DOI 10.1083/jcb.200505098
   Xie Y, 2011, CLIN CANCER RES, V17, P5705, DOI 10.1158/1078-0432.CCR-11-0196
   Xie Y, 2009, BIOINFORMATICS, V25, P751, DOI 10.1093/bioinformatics/btp040
   Yu XZ, 2012, J CELL BIOL, V199, P527, DOI 10.1083/jcb.201203025
NR 64
TC 131
Z9 155
U1 0
U2 18
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD MAY
PY 2015
VL 125
IS 5
BP 1927
EP 1943
DI 10.1172/JCI77767
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CH5JK
UT WOS:000354071700016
PM 25844900
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU De La Cruz-Hernandez, E
   Medina-Franco, JL
   Trujillo, J
   Chavez-Blanco, A
   Dominguez-Gomez, G
   Perez-Cardenas, E
   Gonzalez-Fierro, A
   Taja-Chayeb, L
   Dueñas-Gonzalez, A
AF De La Cruz-Hernandez, Erick
   Luis Medina-Franco, Jose
   Trujillo, Jaenai
   Chavez-Blanco, Alma
   Dominguez-Gomez, Guadalupe
   Perez-Cardenas, Enrique
   Gonzalez-Fierro, Aurora
   Taja-Chayeb, Lucia
   Duenas-Gonzalez, Alfonso
TI Ribavirin as a tri-targeted antitumor repositioned drug
SO ONCOLOGY REPORTS
LA English
DT Article
DE ribavirin; drug repositioning; EZH2; eIF4E; inosine 5 '-phosphate
   dehydrogenase; cancer
ID HISTONE METHYLTRANSFERASE; IMP DEHYDROGENASE; BREAST-CANCER; EZH2;
   EXPRESSION; SIMILARITY; CELLS; TRANSFORMATION; PROLIFERATION; MECHANISMS
AB The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5'-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2). A computational searching revealed that ribavirin has a high structural similarity to 3-deazaneplanocin A (DZNep). The growth inhibitory effects of ribavirin as well as its effects upon epigenetic enzymes were evaluated in various cancer cell lines. siRNA assays were used to downregulate eIF4E, EZH2 and IMPDH to determine the contribution of these targets to the growth inhibitory effects of ribavirin. Ribavirin decreased EZH2 expression, inhibited histone methyltransferase activity and decreased H3K27 trimethylation. Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin. The results showed that ribavirin inhibits these cancer targets and should thus be studied for cancer therapy.
C1 [De La Cruz-Hernandez, Erick] Juarez Autonomous Univ Tabasco, Multidisciplinary Acad Div Comalcalco, Villahermosa, Mexico.
   [Luis Medina-Franco, Jose] Univ Nacl Autonoma Mexico, Dept Pharm, Fac Chem, Mexico City, DF, Mexico.
   [Trujillo, Jaenai; Chavez-Blanco, Alma; Dominguez-Gomez, Guadalupe; Perez-Cardenas, Enrique; Gonzalez-Fierro, Aurora; Taja-Chayeb, Lucia] Natl Canc Inst Mexico, Basic Res Div, Mexico City, DF, Mexico.
   [Duenas-Gonzalez, Alfonso] Univ Nacl Autonoma Mexico, Biomed Res Inst, Natl Canc Inst Mexico, Mexico City, DF, Mexico.
   [Duenas-Gonzalez, Alfonso] ISSEMyM Canc Ctr Toluca, Toluca, Mexico.
C3 Universidad Juarez Autonoma de Tabasco; Universidad Nacional Autonoma de
   Mexico; Universidad Nacional Autonoma de Mexico
RP Dueñas-Gonzalez, A (通讯作者)，Unidad Invest Biomed Canc, San Fernando 22, Mexico City 14080, DF, Mexico.
EM alfonso_duenasg@yahoo.com
RI De la Cruz-Hernandez, Erick/E-1487-2019; Perez-Cardenas,
   Enrique/JPW-9339-2023; Medina-Franco, Jose L./AAJ-1633-2020
OI Perez-Cardenas, Enrique/0000-0002-4896-4111; Dominguez-Gomez,
   Guadalupe/0000-0003-3906-4493; Medina-Franco, Jose
   L./0000-0003-4940-1107
FU Fonsec CONACyT [161915]; UNAM PAPIIT [IT206611]
FX This study was supported by Fonsec CONACyT grant 161915, and UNAM PAPIIT
   grant IT206611.
CR [Anonymous], MOL OP ENV MOE VERS
   Assouline S, 2009, BLOOD, V114, P257, DOI 10.1182/blood-2009-02-205153
   Bender A, 2004, ORG BIOMOL CHEM, V2, P3204, DOI 10.1039/b409813g
   Borden KLB, 2010, LEUKEMIA LYMPHOMA, V51, P1805, DOI 10.3109/10428194.2010.496506
   Chan SL, 2010, J CHEM INF MODEL, V50, P1724, DOI 10.1021/ci100227h
   Chen LQ, 2007, CURR OPIN DRUG DISC, V10, P403
   CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7
   Dueñas-González A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-82
   ITOH O, 1989, CANCER RES, V49, P996
   JACKSON RC, 1975, NATURE, V256, P331, DOI 10.1038/256331a0
   Kentsis A, 2004, P NATL ACAD SCI USA, V101, P18105, DOI 10.1073/pnas.0406927102
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kökény S, 2009, ANTICANCER RES, V29, P1971
   Kosaka T, 2013, CANCER SCI, V104, P1017, DOI 10.1111/cas.12183
   Lee JK, 2013, BIOCHEM BIOPH RES CO, V438, P647, DOI 10.1016/j.bbrc.2013.07.128
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   Medina-Franco JL, 2013, DRUG DISCOV TODAY, V18, P495, DOI 10.1016/j.drudis.2013.01.008
   Medina-Franco JL, 2012, J CHEM INF MODEL, V52, P2485, DOI 10.1021/ci300362x
   Miranda TB, 2009, MOL CANCER THER, V8, P1579, DOI 10.1158/1535-7163.MCT-09-0013
   NAGAI M, 1991, CANCER RES, V51, P3886
   Pettersson F, 2011, CLIN CANCER RES, V17, P2874, DOI 10.1158/1078-0432.CCR-10-2334
   Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213
   Ryan RJH, 2012, SCIENCE, V336, P1513, DOI 10.1126/science.1223730
   SCHEIDEL LM, 1987, VIROLOGY, V158, P1, DOI 10.1016/0042-6822(87)90230-3
   Shepherd J, 2007, HEALTH TECHNOL ASSES, V11, P1
   Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343
   SIDWELL RW, 1979, PHARMACOL THERAPEUT, V6, P123, DOI 10.1016/0163-7258(79)90058-5
   Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524
   Willett P, 1998, J CHEM INF COMP SCI, V38, P983, DOI 10.1021/ci9800211
   Willett P, 2006, DRUG DISCOV TODAY, V11, P1046, DOI 10.1016/j.drudis.2006.10.005
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Zagni C, 2013, CURR MED CHEM, V20, P167, DOI 10.2174/092986713804806667
   Zimmermann A, 1996, ADV ENZYME REGUL, V36, P75, DOI 10.1016/0065-2571(95)00012-7
NR 37
TC 38
Z9 42
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAY
PY 2015
VL 33
IS 5
BP 2384
EP 2392
DI 10.3892/or.2015.3816
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CG3LE
UT WOS:000353180900036
PM 25738706
OA Bronze
DA 2025-01-12
ER

PT J
AU Mao, YY
   Fu, AA
   Hoffman, AE
   Jacobs, DI
   Jin, M
   Chen, K
   Zhu, Y
AF Mao, Yingying
   Fu, Alan
   Hoffman, Aaron E.
   Jacobs, Daniel I.
   Jin, Mingjuan
   Chen, Kun
   Zhu, Yong
TI The circadian gene <i>CRY2</i> is associated with breast cancer
   aggressiveness possibly via epigenomic modifications
SO TUMOR BIOLOGY
LA English
DT Article
DE CRY2; Breast cancer; Biomarker; DNA methylation; Network analysis
ID MICROARRAY ANALYSIS; CRYPTOCHROME 2; STEM-CELLS; EXPRESSION;
   PROGRESSION; CD44; CARCINOMAS; ACTIVATION; PATHWAYS; PROTEIN
AB Although the role of core circadian gene cryptochrome 2 (CRY2) in breast tumorigenesis has been demonstrated, the correlations of CRY2 with clinical parameters in breast cancer patients and its involvement in epigenetic processes such as DNA methylation remain relatively unexplored. In the current study, we first queried the Oncomine database and the Gene Expression-Based Outcome for Breast Cancer Online (GOBO) database to identify associations between CRY2 expression levels and clinical parameters in breast cancer patients. We then silenced CRY2 in vitro and performed a genome-wide methylation array to determine the epigenetic impact of CRY2 silencing. The Ingenuity Pathway Analysis software was used to further explore the genes exhibiting altered methylation identified using the array. We found that CRY2 was frequently down-regulated in breast cancer tissue compared to adjacent normal tissue or breast tissue from healthy controls. Lower CRY2 expression was associated with estrogen receptor (ER)-negativity (P < 0.0001), higher tumor grade (P < 0.0001), and shorter overall survival time in breast cancer patients (HR = 1.44, 95 % confidence interval (CI) 1.09-1.91). Genome-wide methylation analysis showed that a total of 515 CpG sites were hypermethylated following CRY2 knockdown, while 730 sites were hypomethylated. The pathway analysis revealed several cancer-relevant networks with genes exhibiting significantly altered methylation following CRY2 silencing. These findings suggest that the core circadian gene CRY2 is associated with breast cancer progression and prognosis, and that knockdown of CRY2 causes the epigenetic dysregulation of genes involved in cancer-relevant pathways, which provide further evidence supporting a role of the circadian system in breast tumorigenesis.
C1 [Mao, Yingying; Fu, Alan; Jacobs, Daniel I.; Zhu, Yong] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
   [Mao, Yingying; Jin, Mingjuan; Chen, Kun] Zhejiang Univ, Dept Epidemiol & Hlth Stat, Sch Publ Hlth, Hangzhou 310003, Zhejiang, Peoples R China.
   [Hoffman, Aaron E.] Tulane Sch Publ Hlth, Dept Epidemiol, New Orleans, LA USA.
   [Hoffman, Aaron E.] Trop Med & Tulane Canc Ctr, New Orleans, LA USA.
   [Zhu, Yong] Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou, Zhejiang, Peoples R China.
C3 Yale University; Zhejiang University; Tulane University; Zhejiang
   Chinese Medical University
RP Zhu, Y (通讯作者)，Zhejiang Chinese Med Univ, Coll Basic Med Sci, Hangzhou, Zhejiang, Peoples R China.
EM yong.zhu@yale.edu
RI Mao, Yingying/Q-9996-2018
OI Mao, Yingying/0000-0003-3644-9160
FU National Institutes of Environmental Health Sciences (NIEHS) [ES018915]
FX This work was supported by the National Institutes of Environmental
   Health Sciences (NIEHS) grant ES018915.
CR Bourguignon LYW, 2010, J BIOL CHEM, V285, P36721, DOI 10.1074/jbc.M110.162305
   Bourguignon LYW, 2003, J BIOL CHEM, V278, P29420, DOI 10.1074/jbc.M301885200
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072
   Gauger MA, 2005, CANCER RES, V65, P6828, DOI 10.1158/0008-5472.CAN-05-1119
   Glück S, 2012, BREAST CANCER RES TR, V132, P781, DOI 10.1007/s10549-011-1412-7
   Hoffman AE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-110
   Hoffman AE, 2010, CANCER PREV RES, V3, P539, DOI 10.1158/1940-6207.CAPR-09-0127
   Hoffman AE, 2009, CANCER RES, V69, P3605, DOI 10.1158/0008-5472.CAN-08-4572
   Kai K, 2010, BREAST CANCER-TOKYO, V17, P80, DOI 10.1007/s12282-009-0176-y
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kondratov RV, 2007, CURR TOP DEV BIOL, V78, P173, DOI 10.1016/S0070-2153(06)78005-X
   Louderbough JMV, 2011, MOL CANCER RES, V9, P1573, DOI 10.1158/1541-7786.MCR-11-0156
   Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
   Marhaba R, 2004, J MOL HISTOL, V35, P211
   McCain Jack, 2006, Biotechnol Healthc, V3, P46
   Orian-Rousseau W, 2007, MOL BIOL CELL, V18, P76, DOI 10.1091/mbc.E06-08-0674
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   Ünsal-Kaçmaz K, 2005, MOL CELL BIOL, V25, P3109, DOI 10.1128/MCB.25.8.3109-3116.2005
   Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002
   vanderSpek PJ, 1996, GENOMICS, V37, P177, DOI 10.1006/geno.1996.0539
   Xiang Shulin, 2008, J Circadian Rhythms, V6, P4, DOI 10.1186/1740-3391-6-4
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
   Zhu Y, 2009, CANCER RES, V69, P9315, DOI 10.1158/0008-5472.CAN-09-0648
NR 32
TC 27
Z9 29
U1 0
U2 17
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2015
VL 36
IS 5
BP 3533
EP 3539
DI 10.1007/s13277-014-2989-3
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CJ0WK
UT WOS:000355199800047
PM 25740058
DA 2025-01-12
ER

PT J
AU Merry, CR
   McMahon, S
   Thompson, CL
   Miskimen, KLS
   Harris, LN
   Khalil, AM
AF Merry, Callie R.
   McMahon, Sarah
   Thompson, Cheryl L.
   Miskimen, Kristy L. S.
   Harris, Lyndsay N.
   Khalil, Ahmad M.
TI Integrative transcriptome-wide analyses reveal critical HER2-regulated
   mRNAs and lincRNAs in HER2+breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; HER2; Gene expression; lincRNAs; RNA-seq; Genome-wide
ID LONG NONCODING RNA; GENE-EXPRESSION; CHROMATIN; DIFFERENTIATION;
   MECHANISMS; COMPLEXES; EVOLUTION; DISEASE; SEQ
AB Breast cancer is a major health problem affecting millions of women worldwide. Over 200,000 new cases are diagnosed annually in the USA, with approximately 40,000 of these cases resulting in death. HER2-positive (HER2+) breast tumors, representing 20-30 % of early-stage breast cancer diagnoses, are characterized by the amplification of the HER2 gene. However, the critical genes and pathways that become affected by HER2 amplification in humans are yet to be specifically identified. Furthermore, it is yet to be determined if HER2 amplification also affects the expression of long intervening non-coding (linc)RNAs, which are involved in the epigenetic regulation of gene expression. We examined changes in gene expression by next generation RNA sequencing in human tumors pre- and post- HER2 inhibition by trastuzumab in vivo, and changes in gene expression in response to HER2 knock down in cell culture models. We integrated our results with gene expression analysis of HER2+ tumors vs matched normal tissue from The Cancer Genome Atlas. The integrative analyses of these datasets led to the identification of a small set of mRNAs, and the associated biological pathways that become deregulated by HER2 amplification. Furthermore, our analyses identified three lincRNAs that become deregulated in response to HER2 amplification both in vitro and in vivo. Our results should provide the foundation for functional studies of these candidate mRNAs and lincRNAs to further our understanding of how HER2 amplification results in tumorigenesis. Also, the identified lincRNAs could potentially open the door for future RNA-based biomarkers and therapeutics in HER2+ breast cancer.
C1 [Merry, Callie R.; McMahon, Sarah; Khalil, Ahmad M.] Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
   [Merry, Callie R.; McMahon, Sarah; Khalil, Ahmad M.] Case Western Reserve Univ, Dept Genome Sci, Cleveland, OH 44106 USA.
   [Merry, Callie R.; Khalil, Ahmad M.] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA.
   [Thompson, Cheryl L.; Miskimen, Kristy L. S.; Harris, Lyndsay N.; Khalil, Ahmad M.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA.
   [Thompson, Cheryl L.] Case Western Reserve Univ, Dept Family Med, Cleveland, OH 44106 USA.
   [Thompson, Cheryl L.] Case Western Reserve Univ, Dept Community Hlth, Cleveland, OH 44106 USA.
   [Harris, Lyndsay N.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University; University System of Ohio; Case
   Western Reserve University; University System of Ohio; Case Western
   Reserve University; University System of Ohio; Case Western Reserve
   University; University System of Ohio; Case Western Reserve University
RP Khalil, AM (通讯作者)，Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA.
EM dr.ahmad.khalil@gmail.com
CR Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Clark MB, 2011, SEMIN CELL DEV BIOL, V22, P366, DOI 10.1016/j.semcdb.2011.01.001
   Dinger ME, 2009, NUCLEIC ACIDS RES, V37, pD122, DOI 10.1093/nar/gkn617
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Iyer M.K., 2015, Nature Genetics
   Jiang J, 2013, NATURE, V500, P296, DOI 10.1038/nature12394
   Kaneko S, 2014, MOL CELL, V53, P290, DOI 10.1016/j.molcel.2013.11.012
   Khalil AM, 2011, SEMIN CELL DEV BIOL, V22, P359, DOI 10.1016/j.semcdb.2011.02.016
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   Kretz M, 2012, GENE DEV, V26, P338, DOI 10.1101/gad.182121.111
   Le XF, 2005, J BIOL CHEM, V280, P2092, DOI 10.1074/jbc.M403080200
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loewer S, 2010, NAT GENET, V42, P1113, DOI 10.1038/ng.710
   Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459
   Mitri Zahi, 2012, Chemother Res Pract, V2012, P743193, DOI 10.1155/2012/743193
   Moran VA, 2012, NUCLEIC ACIDS RES, V40, P6391, DOI 10.1093/nar/gks296
   Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722
   Moskalev EA, 2012, GENE CHROMOSOME CANC, V51, P105, DOI 10.1002/gcc.20943
   Mustafi D, 2013, HUM MOL GENET, V22, P2992, DOI 10.1093/hmg/ddt156
   Niland Courtney N., 2012, Frontiers in Genetics, V3, P25, DOI 10.3389/fgene.2012.00025
   Putluri N, 2014, NEOPLASIA, V16, P390, DOI 10.1016/j.neo.2014.05.007
   Qureshi IA, 2010, BRAIN RES, V1338, P20, DOI 10.1016/j.brainres.2010.03.110
   Sauvageau M, 2013, ELIFE, V2, DOI 10.7554/eLife.01749
   Sendur MA, 2012, ASIAN PAC J CANCER P, V13, P5929
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Ulitsky I, 2011, CELL, V147, P1537, DOI 10.1016/j.cell.2011.11.055
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764
   Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y
   Yildirim E, 2013, CELL, V152, P727, DOI 10.1016/j.cell.2013.01.034
NR 47
TC 14
Z9 16
U1 0
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2015
VL 150
IS 2
BP 321
EP 334
DI 10.1007/s10549-015-3327-1
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CE9ZL
UT WOS:000352202200009
PM 25749757
DA 2025-01-12
ER

PT J
AU Chaligné, R
   Popova, T
   Mendoza-Parra, MA
   Saleem, MAM
   Gentien, D
   Ban, K
   Piolot, T
   Leroy, O
   Mariani, O
   Gronemeyer, H
   Vincent-Salomon, A
   Stern, MH
   Heard, E
AF Chaligne, Ronan
   Popova, Tatiana
   Mendoza-Parra, Marco-Antonio
   Saleem, Mohamed-Ashick M.
   Gentien, David
   Ban, Kristen
   Piolot, Tristan
   Leroy, Olivier
   Mariani, Odette
   Gronemeyer, Hinrich
   Vincent-Salomon, Anne
   Stern, Marc-Henri
   Heard, Edith
TI The inactive X chromosome is epigenetically unstable and
   transcriptionally labile in breast cancer
SO GENOME RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; XIST RNA; HISTONE DEACETYLASES; BARR BODY;
   FACULTATIVE HETEROCHROMATIN; DNA METHYLATION; EXPRESSION; BRCA1; GENE;
   HDAC3
AB Disappearance of the Barr body is considered a hallmark of cancer, although whether this corresponds to genetic loss or to epigenetic instability and transcriptional reactivation is unclear. Here we show that breast tumors and cell lines frequently display major epigenetic instability of the inactive X chromosome, with highly abnormal 3D nuclear organization and global perturbations of heterochromatin, including gain of euchromatic marks and aberrant distributions of repressive marks such as H3K27me3 and promoter DNA methylation. Genome-wide profiling of chromatin and transcription reveal modified epigenomic landscapes in cancer cells and a significant degree of aberrant gene activity from the inactive X chromosome, including several genes involved in cancer promotion. We demonstrate that many of these genes are aberrantly reactivated in primary breast tumors, and we further demonstrate that epigenetic instability of the inactive X can lead to perturbed dosage of X-linked factors. Taken together, our study provides the first integrated analysis of the inactive X chromosome in the context of breast cancer and establishes that epigenetic erosion of the inactive X can lead to the disappearance of the Barr body in breast cancer cells. This work offers new insights and opens up the possibility of exploiting the inactive X chromosome as an epigenetic biomarker at the molecular and cytological levels in cancer.
C1 [Chaligne, Ronan; Popova, Tatiana; Gentien, David; Ban, Kristen; Piolot, Tristan; Leroy, Olivier; Vincent-Salomon, Anne; Stern, Marc-Henri; Heard, Edith] Inst Curie, Ctr Rech, F-75248 Paris 05, France.
   [Chaligne, Ronan; Ban, Kristen; Heard, Edith] Inst Curie, CNRS, Unite Mixte Rech 3215, F-75248 Paris 05, France.
   [Chaligne, Ronan; Ban, Kristen; Heard, Edith] Inst Curie, INSERM, U934, F-75248 Paris 05, France.
   [Chaligne, Ronan; Ban, Kristen; Vincent-Salomon, Anne; Heard, Edith] UMR3215, Equipe Labellisee Ligue Canc, F-75248 Paris 05, France.
   [Popova, Tatiana; Vincent-Salomon, Anne; Stern, Marc-Henri] Inst Curie, INSERM, U830, F-75248 Paris 05, France.
   [Mendoza-Parra, Marco-Antonio; Saleem, Mohamed-Ashick M.; Gronemeyer, Hinrich] Univ Strasbourg, INSERM, CNRS,U964,UMR 7104, Equipe Labellisee Ligue Canc,Inst Genet & Biol Mo, F-67404 Illkirch Graffenstaden, France.
   [Gentien, David; Mariani, Odette; Vincent-Salomon, Anne; Stern, Marc-Henri] Inst Curie, Dept Tumor Biol, F-75248 Paris 05, France.
   [Piolot, Tristan; Leroy, Olivier] Inst Curie, Plate Forme Imagerie Cellulaire & Tissulaire BDD, F-75248 Paris 05, France.
C3 UNICANCER; Universite PSL; Institut Curie; Centre National de la
   Recherche Scientifique (CNRS); UNICANCER; Universite PSL; Institut
   Curie; Universite PSL; UNICANCER; Institut Curie; Centre National de la
   Recherche Scientifique (CNRS); Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite PSL; UNICANCER; Institut Curie;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; UNICANCER; Universite PSL; Institut
   Curie; UNICANCER; Universite PSL; Institut Curie
RP Heard, E (通讯作者)，Inst Curie, Ctr Rech, F-75248 Paris 05, France.
EM hg@igbmc.fr; Anne.Salomon@curie.fr; marc-henri.stern@curie.fr;
   Edith.Heard@curie.fr
RI Heard, Edith/D-7197-2017; Popova, Tatiana/P-6112-2017; Gentien,
   David/O-9356-2019; Stern, Marc-Henri/A-2728-2011; Gronemeyer,
   Hinrich/G-6240-2011
OI Chaligne, Ronan/0000-0001-5788-5848; Mendoza-Parra, Marco
   Antonio/0000-0002-1809-1727; Stern, Marc-Henri/0000-0002-8100-2272;
   Gronemeyer, Hinrich/0000-0001-9454-2449; Chaligne,
   Ronan/0000-0003-4332-3291
FU l'Association pour la Recherche sur le Cancer (ARC); FRM; Equipe
   labellisee "La Ligue Contre Le Cancer"; EU FP7 MODHEP EU, IDEX Idex PSL
   [259743, ANR-10-IDEX-0001-02]; Labex DEEP [ANR-11-LBX-0044]; ERC
   Advanced Investigator Award [250367]; AVIESAN-ITMOCancer-INCa grant
   "Epigenomicsofbreast cancer"; Agence Nationale de la Recherche
   [ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02]; Ligue Contre le Cancer;
   SATT Conectus Alsace; Institut Nationale du Cancer; European Research
   Council (ERC) [250367] Funding Source: European Research Council (ERC)
FX We would like to thank all members of the Heard team for helpful
   discussions and in particular Julie Chaumeil and Simao da Rocha for
   critical reading of the manuscript. We would also like to thank Michel
   Wassef and Raphael Margueron for discussions and feedback on this work.
   Support is gratefully acknowledged from l'Association pour la Recherche
   sur le Cancer (ARC) (post-doctoral fellowship to R.C.); FRM (Equipe FRM
   to E.H. from 2006-2009); Equipe labellisee "La Ligue Contre Le Cancer"
   (Equipe Labellisee to E.H. since 2011); EU FP7 MODHEP EU Grant no.
   259743 (to E.H.); Labex DEEP (ANR-11-LBX-0044) part of the IDEX Idex PSL
   (ANR-10-IDEX-0001-02 PSL); and ERC Advanced Investigator Award no.
   250367. This work was also supported by the AVIESAN-ITMOCancer-INCa
   grant "Epigenomicsofbreast cancer" (E.H., H.G., and M.-H.S.). Work in
   the laboratory of H.G. was supported by the Agence Nationale de la
   Recherche (ANR-10-LABX-0030-INRT and ANR-10-IDEX-0002-02), the Ligue
   Contre le Cancer (H.G.; Equipe Labellisee), SATT Conectus Alsace, and
   the Institut Nationale du Cancer. The authors greatly acknowledge the
   PICT-IBiSA@BDD (UMR3215/U934) Imaging facility of the Institut Curie,
   the cytometry platform of the Institut Curie, and the "Centre de
   Ressources Biologiques" for access to the tumor materials.
CR Agrelo R, 2010, EMBO MOL MED, V2, P6, DOI 10.1002/emmm.200900053
   Azoulay S, 2005, MODERN PATHOL, V18, P1623, DOI 10.1038/modpathol.3800483
   BARR M L, 1957, Proc Can Cancer Conf, V2, P3
   Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787
   Carone DM, 2013, SEMIN CANCER BIOL, V23, P99, DOI 10.1016/j.semcancer.2012.06.008
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Chadwick BP, 2004, P NATL ACAD SCI USA, V101, P17450, DOI 10.1073/pnas.0408021101
   Chadwick BP, 2007, CHROMOSOMA, V116, P147, DOI 10.1007/s00412-006-0085-1
   Chaumeil J, 2002, CYTOGENET GENOME RES, V99, P75, DOI 10.1159/000071577
   Chaumeil J, 2006, GENE DEV, V20, P2223, DOI 10.1101/gad.380906
   Chaumeil Julie, 2008, V463, P297, DOI 10.1007/978-1-59745-406-3_18
   Chow JC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000604
   Chow JC, 2010, CELL, V141, P956, DOI 10.1016/j.cell.2010.04.042
   Clemson CM, 2006, P NATL ACAD SCI USA, V103, P7688, DOI 10.1073/pnas.0601069103
   Cotton AM, 2014, HUM MOL GENET, V23, P1211, DOI 10.1093/hmg/ddt513
   Cotton AM, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r122
   Csankovszki G, 2001, J CELL BIOL, V153, P773, DOI 10.1083/jcb.153.4.773
   Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Filippova GN, 2005, DEV CELL, V8, P31, DOI 10.1016/j.devcel.2004.10.018
   Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8
   Gendrel AV, 2013, MOL CELL BIOL, V33, P3150, DOI 10.1128/MCB.00145-13
   Gimelbrant A, 2007, SCIENCE, V318, P1136, DOI 10.1126/science.1148910
   Grigoriadis A, 2009, P NATL ACAD SCI USA, V106, P13493, DOI 10.1073/pnas.0906840106
   Heard E, 2001, CELL, V107, P727, DOI 10.1016/S0092-8674(01)00598-0
   Huang KC, 2002, MOL CANCER THER, V1, P769
   Huang S, 1997, J CELL BIOL, V137, P965, DOI 10.1083/jcb.137.5.965
   Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808
   Keohane AM, 1996, DEV BIOL, V180, P618, DOI 10.1006/dbio.1996.0333
   Kim HC, 2010, CELL MOL LIFE SCI, V67, P3499, DOI 10.1007/s00018-010-0388-5
   Kucera KS, 2011, HUM MOL GENET, V20, P3964, DOI 10.1093/hmg/ddr315
   López-Soto A, 2009, ONCOGENE, V28, P2370, DOI 10.1038/onc.2009.117
   LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0
   Maenner S, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000276
   Marks H, 2009, GENOME RES, V19, P1361, DOI 10.1101/gr.092643.109
   Miao LJ, 2014, TUMOR BIOL, V35, P7097, DOI 10.1007/s13277-014-1961-6
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Nakagawa M, 2007, ONCOL REP, V18, P769
   O'Donovan PJ, 2010, CARCINOGENESIS, V31, P961, DOI 10.1093/carcin/bgq069
   Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684
   Okamoto I, 2011, NATURE, V472, P370, DOI 10.1038/nature09872
   Pageau GJ, 2007, NAT REV CANCER, V7, P628, DOI 10.1038/nrc2172
   Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   PERRY M, 1972, BRIT J SURG, V59, P731, DOI 10.1002/bjs.1800590912
   Plath K, 2004, J CELL BIOL, V167, P1025, DOI 10.1083/jcb.200409026
   Popova T, 2012, CANCER RES, V72, P5454, DOI 10.1158/0008-5472.CAN-12-1470
   Popova T, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r128
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Silver DP, 2007, CELL, V128, P991, DOI 10.1016/j.cell.2007.02.025
   Simon MD, 2013, NATURE, V504, P465, DOI 10.1038/nature12719
   Sirchia SM, 2005, CANCER RES, V65, P2139, DOI 10.1158/0008-5472.CAN-04-3465
   SMETHURST M, 1981, J ENDOCRINOL INVEST, V4, P455, DOI 10.1007/BF03348311
   Spatz A, 2004, NAT REV CANCER, V4, P617, DOI 10.1038/nrc1413
   Splinter E, 2011, GENE DEV, V25, P1371, DOI 10.1101/gad.633311
   Spurling CC, 2008, MOL CARCINOGEN, V47, P137, DOI 10.1002/mc.20373
   Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876
   Vincent-Salomon A, 2007, CANCER RES, V67, P5134, DOI 10.1158/0008-5472.CAN-07-0465
   Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820
   Xiao CY, 2007, CELL, V128, P977, DOI 10.1016/j.cell.2007.01.034
   Yildirim E, 2013, CELL, V152, P727, DOI 10.1016/j.cell.2013.01.034
   Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733
   Zink D, 2004, NAT REV CANCER, V4, P677, DOI 10.1038/nrc1430
NR 72
TC 95
Z9 107
U1 0
U2 37
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD APR
PY 2015
VL 25
IS 4
BP 488
EP 503
DI 10.1101/gr.185926.114
PG 16
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA CE9BU
UT WOS:000352139200004
PM 25653311
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Nye, MD
   Hoyo, C
   Murphy, SK
AF Nye, Monica D.
   Hoyo, Cathrine
   Murphy, Susan K.
TI <i>In vitro</i> lead exposure changes DNA methylation and expression of
   <i>IGF2</i> and <i>PEG1</i>/<i>MEST</i>
SO TOXICOLOGY IN VITRO
LA English
DT Article
DE DNA methylation; Epigenetics; Insulin-like growth factor 2 (IGF2);
   Paternally expressed gene 1/mesoderm specific transcript (PEG1/MEST);
   Lead acetate; Bisulfite pyrosequencing
ID GROWTH-FACTOR-II; PRENATAL EXPOSURE; BREAST-CANCER; DUTCH FAMINE;
   DISEASE; CONSEQUENCES; EPIGENETICS; NUTRITION; CHILDREN; REGIONS
AB Epigenetic processes, such as changes in DNA methylation, likely mediate the link between environmental exposures in utero and altered gene expression. Differentially methylated regions (DMRs) that regulate imprinted genes may be especially vulnerable to environmental exposures since imprinting is established and maintained largely through DNA methylation, resulting in expression from only one parental chromosome. We used the human embryonic kidney cell line, HEK-293, to investigate the effects of exposure to physiologically relevant doses of lead acetate (Pb) on the methylation status of nine imprinted gene DMRs. We assessed mean methylation after seventy-two hours of Pb exposure (0-25 mu g/dL) using bisulfite pyrosequencing. The PEG1/MEST and IGF2 DMRs had maximum methylation decreases of 9.6% (20 mu g/dL; p <0.005) and 3.8% (25 mu g/dL; p < 0.005), respectively. Changes at the MEG3 DMRs had a maximum decrease in methylation of 2.9% (MEG3) and 1.8% (MEG3-IG) at 5 mu g/dL, Pb, but were not statistically significant. The H19, NNAT, PEG3, PLAGL1, and SGCE/PEG10 DMRs showed a less than 0.5% change in methylation, across the dose range used, and were deemed non-responsive to Pb in our model. Pb exposure below reportable/actionable levels increased expression of PEG1/MEST concomitant with decreased methylation. These results suggest that Pb exposure can stably alter the regulatory capacity of multiple imprinted DMRs. (c) 2015 Elsevier Ltd. All rights reserved.
C1 [Nye, Monica D.; Murphy, Susan K.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27708 USA.
   [Nye, Monica D.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Hoyo, Cathrine] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA.
C3 Duke University; University of North Carolina; University of North
   Carolina Chapel Hill; North Carolina State University
RP Murphy, SK (通讯作者)，Duke Univ, Dept Obstet & Gynecol, Box 91012, Durham, NC 27708 USA.
EM mnye@email.unc.edu; choyo@ncsu.edu; susan.murphy@duke.edu
RI Murphy, Susan/R-3903-2019
OI Hoyo, Cathrine/0000-0002-2466-8617; Murphy, Susan/0000-0001-8298-7272
FU NIH [R25CA057726, R01DK085173, R01ES016772, P01ES022831]; US EPA
   [RD-83543701]
FX This work was supported by NIH Grants R25CA057726, R01DK085173,
   R01ES016772, P01ES022831 and by US EPA Grant RD-83543701. The content is
   solely the responsibility of the authors and does not necessarily
   represent the official views of the NIH or the US EPA.
CR BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237
   Boffetta P, 2011, OCCUP ENVIRON MED, V68, P723, DOI 10.1136/oem.2010.056341
   Canfield RL, 2003, CHILD NEUROPSYCHOL, V9, P35, DOI 10.1076/chin.9.1.35.14496
   Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848
   Cecil KM, 2008, PLOS MED, V5, P741, DOI 10.1371/journal.pmed.0050112
   Coolen MW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025590
   Cui HM, 2001, CANCER RES, V61, P4947
   Cui HM, 2002, CANCER RES, V62, P6442
   Davies W, 2005, NAT GENET, V37, P625, DOI 10.1038/ng1577
   Dekel B, 2006, CANCER RES, V66, P6040, DOI 10.1158/0008-5472.CAN-05-4528
   Elias SG, 2004, JNCI-J NATL CANCER I, V96, P539, DOI 10.1093/jnci/djh087
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292
   Godfrey K M, 2001, Public Health Nutr, V4, P611
   Hackett JA, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2011.0328
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Heijmans BT, 2009, EPIGENETICS-US, V4, P526, DOI 10.4161/epi.4.8.10265
   Hochberg Z, 2011, ENDOCR REV, V32, P159, DOI 10.1210/er.2009-0039
   Hogg K, 2012, CLIN PHARMACOL THER, V92, P716, DOI 10.1038/clpt.2012.141
   Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154
   Hoyo C, 2011, EPIGENETICS-US, V6, P928, DOI 10.4161/epi.6.7.16263
   Hoyo C, 2009, J EPIDEMIOL COMMUN H, V63, P683, DOI 10.1136/jech.2009.090803
   Isles AR, 2000, TRENDS COGN SCI, V4, P309, DOI 10.1016/S1364-6613(00)01504-7
   Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412
   Kyle UG, 2006, CURR OPIN CLIN NUTR, V9, P388, DOI 10.1097/01.mco.0000232898.74415.42
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Li YP, 2010, DIABETES, V59, P2400, DOI 10.2337/db10-0385
   Liu Y, 2012, INT J NONLIN SCI NUM, V13, P1
   LUCAS A, 1994, ARCH DIS CHILD, V71, P288, DOI 10.1136/adc.71.4.288
   Martorell R, 2010, J NUTR, V140, P411, DOI 10.3945/jn.109.114504
   Mathers JC, 2007, FORUM NUTR, V60, P42, DOI 10.1159/000107066
   Murphy SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040924
   Murphy SK, 2012, GENE, V494, P36, DOI 10.1016/j.gene.2011.11.062
   Myers JP, 2009, ENVIRON HEALTH PERSP, V117, P1652, DOI 10.1289/ehp.0900887
   NEEDLEMAN HL, 1989, AM J PUBLIC HEALTH, V79, P643, DOI 10.2105/AJPH.79.5.643
   Nigg JT, 2008, BIOL PSYCHIAT, V63, P325, DOI 10.1016/j.biopsych.2007.07.013
   Nonomura N, 1997, CANCER RES, V57, P2575
   Nye MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056325
   Oda H, 1998, INT J CANCER, V75, P343, DOI 10.1002/(SICI)1097-0215(19980130)75:3<343::AID-IJC3>3.3.CO;2-A
   Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564
   Pedersen IS, 1999, CANCER RES, V59, P5449
   Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P1466, DOI 10.1289/ehp.0800497
   Ravelli ACJ, 1999, AM J CLIN NUTR, V70, P811
   Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9
   Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554
   Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595
   Santos F, 2004, REPRODUCTION, V127, P643, DOI 10.1530/rep.1.00221
   Schug TT, 2011, J STEROID BIOCHEM, V127, P204, DOI 10.1016/j.jsbmb.2011.08.007
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Skaar DA, 2012, ILAR J, V53, P341, DOI 10.1093/ilar.53.3-4.341
   Surkan PJ, 2007, NEUROTOXICOLOGY, V28, P1170, DOI 10.1016/j.neuro.2007.07.007
   Timmermans S, 2009, BRIT J NUTR, V102, P777, DOI 10.1017/S0007114509288994
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   Victora CG, 2008, LANCET, V371, P340, DOI 10.1016/S0140-6736(07)61692-4
   Vidal AC, 2014, CLIN TRANSL ONCOL, V16, P266, DOI 10.1007/s12094-013-1067-4
   Woodfine K, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-1
NR 56
TC 17
Z9 28
U1 0
U2 17
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-2333
EI 1879-3177
J9 TOXICOL IN VITRO
JI Toxicol. Vitro
PD APR
PY 2015
VL 29
IS 3
BP 544
EP 550
DI 10.1016/j.tiv.2015.01.002
PG 7
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA CE7VN
UT WOS:000352050100014
PM 25596546
OA Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Mazumdar, S
   Arendt, LM
   Phillips, S
   Sedic, M
   Kuperwasser, C
   Gill, G
AF Mazumdar, Sohini
   Arendt, Lisa M.
   Phillips, Sarah
   Sedic, Maja
   Kuperwasser, Charlotte
   Gill, Grace
TI CoREST1 Promotes Tumor Formation and Tumor Stroma Interactions in a
   Mouse Model of Breast Cancer
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1;
   EPITHELIAL-MESENCHYMAL TRANSITION; DEMETHYLASE 1; HISTONE DEMETHYLASE;
   GENE-EXPRESSION; STEM-CELLS; LSD1; MACROPHAGES; COMPLEX
AB Regulators of chromatin structure and gene expression contribute to tumor formation and progression. The co-repressor CoREST1 regulates the localization and activity of associated histone modifying enzymes including lysine specific demethylase 1 (LSD1) and histone deacetylase 1 (HDAC1). Although several CoREST1 associated proteins have been reported to enhance breast cancer progression, the role of CoREST1 in breast cancer is currently unclear. Here we report that knockdown of CoREST1 in the basal-type breast cancer cell line, MDA-MB-231, led to significantly reduced incidence and diminished size of tumors compared to controls in mouse xenograft studies. Notably, CoREST1-depleted cells gave rise to tumors with a marked decrease in angiogenesis. CoREST1 knockdown led to a decrease in secreted angiogenic and inflammatory factors, and mRNA analysis suggests that CoREST1 promotes expression of genes related to angiogenesis and inflammation including VEGF-A and CCL2. CoREST1 knockdown decreased the ability of MDA-MB-231 conditioned media to promote endothelial cell tube formation and migration. Further, tumors derived from CoREST1-depleted cells had reduced macrophage infiltration and the secretome of CoREST1 knockdown cells was deficient in promoting macrophage migration and macrophage-mediated angiogenesis. Taken together, these findings reveal that the epigenetic regulator CoREST1 promotes tumorigenesis in a breast cancer model at least in part through regulation of gene expression patterns in tumor cells that have profound non-cell autonomous effects on endothelial and inflammatory cells in the tumor microenvironment.
C1 [Mazumdar, Sohini; Arendt, Lisa M.; Phillips, Sarah; Sedic, Maja; Kuperwasser, Charlotte; Gill, Grace] Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA.
   [Mazumdar, Sohini; Phillips, Sarah] Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Genet Program, Boston, MA 02111 USA.
   [Sedic, Maja] Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Cellular Mol & Dev Biol Program, Boston, MA 02111 USA.
   [Arendt, Lisa M.; Phillips, Sarah; Sedic, Maja; Kuperwasser, Charlotte] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA USA.
C3 Tufts University; Tufts University; Tufts University; Tufts Medical
   Center
RP Gill, G (通讯作者)，Tufts Univ, Sackler Sch Grad Biomed Sci, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA.
EM Grace.Gill@tufts.edu
RI Phillips, Sarah/GNP-0430-2022
OI Arendt, Lisa/0000-0002-7954-3635; Gill, Grace/0009-0007-2384-6016
FU Sackler Families Fund for Collaborative Cancer Biology Research Award;
   Breast Cancer Research Foundation; National Institutes of
   Health/National Cancer Institute [CA125554, CA170851]
FX Funding: This work was supported by a Sackler Families Fund for
   Collaborative Cancer Biology Research Award (G.G. and S.M.), the Breast
   Cancer Research Foundation (C.K.), and the National Institutes of
   Health/National Cancer Institute Awards CA125554 and CA170851 (C.K.).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andrés ME, 1999, P NATL ACAD SCI USA, V96, P9873, DOI 10.1073/pnas.96.17.9873
   Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926
   Ballas N, 2001, NEURON, V31, P353, DOI 10.1016/S0896-6273(01)00371-3
   Barrios AP, 2014, MOL CELL BIOL, V34, P2760, DOI 10.1128/MCB.00083-14
   Cai CM, 2014, CELL REP, V9, P1618, DOI 10.1016/j.celrep.2014.11.008
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Domanitskaya E, 2012, J CELL SCI, V125, P399, DOI 10.1242/jcs.089797
   DVORAK HF, 1986, NEW ENGL J MED, V315, P1650
   Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008
   Ferrari-Amorotti G, 2014, NEOPLASIA, V16, P1047, DOI 10.1016/j.neo.2014.10.006
   Foekens JA, 2001, CANCER RES, V61, P5407
   Gasparini G, 1997, J NATL CANCER I, V89, P139, DOI 10.1093/jnci/89.2.139
   Gocke CB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003255
   Gordillo GM, 2004, AM J PHYSIOL-CELL PH, V287, pC866, DOI 10.1152/ajpcell.00238.2003
   Guo CQ, 2013, VASC CELL, V5, DOI 10.1186/2045-824X-5-20
   Hakimi MA, 2002, P NATL ACAD SCI USA, V99, P7420, DOI 10.1073/pnas.112008599
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   Humphrey GW, 2001, J BIOL CHEM, V276, P6817, DOI 10.1074/jbc.M007372200
   Jian OY, 2009, MOL CELL, V34, P145, DOI 10.1016/j.molcel.2009.03.013
   Jin LH, 2013, BIOCHEM J, V449, P459, DOI 10.1042/BJ20121360
   Kang FW, 2012, ONCOL REP, V28, P193, DOI 10.3892/or.2012.1784
   Kashyap V, 2013, MOL ONCOL, V7, P555, DOI 10.1016/j.molonc.2013.01.003
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Komohara Y, 2012, CANCER SCI, V103, P2165, DOI 10.1111/cas.12015
   LaMarca HL, 2010, STEM CELLS, V28, P535, DOI 10.1002/stem.297
   Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Linderholm B, 2000, J CLIN ONCOL, V18, P1423, DOI 10.1200/JCO.2000.18.7.1423
   Liu CY, 2013, LAB INVEST, V93, P844, DOI 10.1038/labinvest.2013.69
   Lv T, 2009, PLOS ONE, V7
   Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3
   Meier K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002676
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020
   Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112
   Pollock JA, 2012, ACS CHEM BIOL, V7, P1221, DOI 10.1021/cb300108c
   Porta C, 2007, ADV EXP MED BIOL, V604, P67, DOI 10.1007/978-0-387-69116-9_5
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40
   Saleque S, 2007, MOL CELL, V27, P562, DOI 10.1016/j.molcel.2007.06.039
   Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735
   Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13
   Shi YJ, 2005, MOL CELL, V19, P857, DOI 10.1016/j.molcel.2005.08.027
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shima DT, 1996, J BIOL CHEM, V271, P3877, DOI 10.1074/jbc.271.7.3877
   Stamatovic SM, 2006, J IMMUNOL, V177, P2651, DOI 10.4049/jimmunol.177.4.2651
   Thillainadesan G, 2008, MOL CELL BIOL, V28, P6066, DOI 10.1128/MCB.00246-08
   Toney LM, 2000, NAT IMMUNOL, V1, P214, DOI 10.1038/79749
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Upadhyay G, 2014, P NATL ACAD SCI USA, V111, P8071, DOI 10.1073/pnas.1404292111
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281
   Yang P, 2011, STEM CELLS, V29, P791, DOI 10.1002/stem.634
   You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454
   Zhu QS, 2012, AMINO ACIDS, V42, P887, DOI 10.1007/s00726-011-1004-1
NR 62
TC 8
Z9 8
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 20
PY 2015
VL 10
IS 3
AR e0121281
DI 10.1371/journal.pone.0121281
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CE8HY
UT WOS:000352083900120
PM 25793264
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU de Oca, RM
   Gurard-Levin, ZA
   Berger, F
   Rehman, H
   Martel, E
   Corpet, A
   de Koning, L
   Vassias, I
   Wilson, LOW
   Meseure, D
   Reyal, F
   Savignoni, A
   Asselain, B
   Sastre-Garauk, X
   Almouzni, G
AF de Oca, Rocio Montes
   Gurard-Levin, Zachary A.
   Berger, Frederique
   Rehman, Haniya
   Martel, Elise
   Corpet, Armelle
   de Koning, Leanne
   Vassias, Isabelle
   Wilson, Laurence O. W.
   Meseure, Didier
   Reyal, Fabien
   Savignoni, Alexia
   Asselain, Bernard
   Sastre-Garauk, Xavier
   Almouzni, Genevieve
TI The histone chaperone HJURP is a new independent prognostic marker for
   luminal A breast carcinoma
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Chromatin; Epigenetics; Biomarkers; Prognosis; MKI67; CENP-A
ID CENTROMERE PROTEIN-A; GENE-EXPRESSION PROFILES; CELL-CYCLE; CANCER
   CLASSIFICATION; PROSTATE-CANCER; CENP-A; PROLIFERATION; OVEREXPRESSION;
   RECURRENCE; PREDICTION
AB Background: Breast cancer is a heterogeneous disease with different molecular subtypes that have varying responses to therapy. An ongoing challenge in breast cancer research is to distinguish high-risk patients from good prognosis patients. This is particularly difficult in the low-grade, ER-positive luminal A tumors, where robust diagnostic tools to aid clinical treatment decisions are lacking. Recent data implicating chromatin regulators in cancer initiation and progression offers a promising avenue to develop new tools to help guide clinical decisions.
   Methods: Here we exploit a published transcriptome dataset and an independent validation cohort to correlate the mRNA expression of selected chromatin regulators with respect to the four intrinsic breast cancer molecular subtypes. We then perform univariate and multivariate analyses to compare the prognostic value of a panel of chromatin regulators to Ki67, a currently utilized proliferation marker.
   Results: Unsupervised hierarchical clustering revealed a gene cluster containing several histone chaperones and histone variants highly-expressed in the proliferative subtypes (basal-like, HER2-positive, luminal B) but not in the luminal A subtype. Several chromatin regulators, including the histone chaperones CAF-1 (subunits p150 and p60), ASF1b, and HJURP, and the centromeric histone variant CENP-A, associated with local and metastatic relapse and poor patient outcome. Importantly, we find that HJURP can discriminate favorable and unfavorable outcome within the luminal A subtype, outperforming the currently utilized proliferation marker Ki67, as an independent prognostic marker for luminal A patients.
   Conclusions: The integration of chromatin regulators as clinical biomarkers, in particular the histone chaperone HJURP, will help guide patient substratification and treatment options for low-risk luminal A breast carcinoma patients. (c) 2014 Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.
C1 [de Oca, Rocio Montes; Gurard-Levin, Zachary A.; Rehman, Haniya; Corpet, Armelle; de Koning, Leanne; Vassias, Isabelle; Wilson, Laurence O. W.; Almouzni, Genevieve] Inst Curie, Ctr Rech, F-75248 Paris, France.
   [de Oca, Rocio Montes; Gurard-Levin, Zachary A.; Rehman, Haniya; Corpet, Armelle; de Koning, Leanne; Vassias, Isabelle; Wilson, Laurence O. W.; Almouzni, Genevieve] CNRS, UMR3664, F-75248 Paris, France.
   [de Oca, Rocio Montes; Gurard-Levin, Zachary A.; Rehman, Haniya; Corpet, Armelle; de Koning, Leanne; Vassias, Isabelle; Wilson, Laurence O. W.; Almouzni, Genevieve] Equipe Labellisee Ligue Canc, UMR3664, F-75248 Paris, France.
   [de Oca, Rocio Montes; Gurard-Levin, Zachary A.; Rehman, Haniya; Corpet, Armelle; de Koning, Leanne; Vassias, Isabelle; Wilson, Laurence O. W.; Almouzni, Genevieve] UPMC, UMR3664, F-75248 Paris, France.
   [de Oca, Rocio Montes; Gurard-Levin, Zachary A.; Berger, Frederique; Rehman, Haniya; Corpet, Armelle; de Koning, Leanne; Vassias, Isabelle; Wilson, Laurence O. W.; Almouzni, Genevieve] Univ Paris 04, PSL, F-75230 Paris 05, France.
   [Berger, Frederique; Savignoni, Alexia; Asselain, Bernard] Inst Curie, U900, F-75248 Paris, France.
   [Berger, Frederique; Savignoni, Alexia; Asselain, Bernard] Mines ParisTech, INSERM, U900, F-75248 Paris, France.
   [Berger, Frederique; Savignoni, Alexia; Asselain, Bernard] Inst Curie, Dept Biostat, F-75248 Paris, France.
   [Martel, Elise; Meseure, Didier] Inst Curie, Invest Pathol Platform, F-75248 Paris, France.
   [Reyal, Fabien] Inst Curie, Dept Surg, F-75248 Paris, France.
   [Sastre-Garauk, Xavier] Inst Curie, Dept Pathol, F-75248 Paris, France.
C3 UNICANCER; Universite PSL; Institut Curie; Centre National de la
   Recherche Scientifique (CNRS); CNRS - National Institute for Biology
   (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Sorbonne Universite; Centre
   National de la Recherche Scientifique (CNRS); CNRS - National Institute
   for Biology (INSB); Sorbonne Universite; Universite PSL; UNICANCER;
   Institut Curie; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite PSL; MINES ParisTech; UNICANCER; Institut
   Curie; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UNICANCER; Universite PSL; Institut Curie; UNICANCER;
   Universite PSL; Institut Curie; UNICANCER; Universite PSL; Institut
   Curie; UNICANCER; Universite PSL; Institut Curie
RP Almouzni, G (通讯作者)，Inst Curie, Ctr Rech, F-75248 Paris, France.
EM Rocio.Montes-De-Oca@curie.fr; zachary.gurard-levin@curie.fr;
   frederique.-berger@curie.fr; haniya.rehman@gmail.com;
   elise.martel@curie.fr; armelle.corpet@univ-lyon1.fr;
   Leanne.De-Koning@curie.fr; isabelle.vassias@curie.fr;
   laurence.wilson@curie.fr; didier.meseure@curie.fr;
   fabien.reyal@curie.fr; alexia.savignoni@curie.fr;
   bemard.asselain@curie.fr; xavier.sastre@curie.fr;
   Genevieve.Almouzni@curie.fr
RI Wilson, Laurence/B-4362-2019; Almouzni, Genevieve/ABG-1029-2021; Corpet,
   Armelle/GLT-6199-2022; BERGER, Frederique/A-8893-2008
OI BERGER, Frederique/0000-0002-3251-4060; Sastre-Garau,
   Xavier/0000-0001-5992-2083; Meseure, Didier/0000-0001-6730-6686; Corpet,
   Armelle/0000-0002-2126-5783
FU la Ligue Nationale contre le Cancer (Equipe labellisee Ligue); European
   Commission Network of Excellence EpiGeneSys [HEALTH-F4-2010-257082]; ERC
   [2009-AdG_20090506]; European Commission [FP7_HEALTH-2010-259743]; ANR
   "ChromaTin" [ANR-10-BLAN-1326-03, ANR-11-LABX-0044_DEEP,
   ANR-10-IDEX-0001-02 PSL*]; ANR "CHAPINHIB" [ANR-12-BSV5-0022-02];
   Aviesan-ITMO Cancer Project "Epigenomics of breast cancer"; Agence
   Nationale de la Recherche (ANR) [ANR-10-BLAN-1326, ANR-12-BSV5-0022,
   ANR-11-LABX-0044] Funding Source: Agence Nationale de la Recherche (ANR)
FX This work was supported by la Ligue Nationale contre le Cancer (Equipe
   labellisee Ligue and a postdoctoral fellowship to R.M. and Z.G.L.), the
   European Commission Network of Excellence EpiGeneSys
   (HEALTH-F4-2010-257082), ERC Advanced Grant 2009-AdG_20090506
   "Eccentric", the European Commission large-scale integrating Project
   FP7_HEALTH-2010-259743 "MODHEP", ANR "ChromaTin" ANR-10-BLAN-1326-03,
   ANR-11-LABX-0044_DEEP and ANR-10-IDEX-0001-02 PSL*, ANR "CHAPINHIB"
   ANR-12-BSV5-0022-02 and Aviesan-ITMO Cancer Project "Epigenomics of
   breast cancer".
CR Abascal F, 2013, MOL BIOL EVOL, V30, P1853, DOI 10.1093/molbev/mst086
   Amato A, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-119
   Avvakumov N, 2011, MOL CELL, V41, P502, DOI 10.1016/j.molcel.2011.02.013
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Berry DA, 2006, JAMA-J AM MED ASSOC, V295, P1658, DOI 10.1001/jama.295.14.1658
   Boyarchuk E, 2014, J CELL SCI, V127, P3347, DOI 10.1242/jcs.148189
   Boyarchuk E, 2011, CURR OPIN CELL BIOL, V23, P266, DOI 10.1016/j.ceb.2011.03.006
   Castellini P, 2014, HUM PATHOL, V45, P745, DOI 10.1016/j.humpath.2013.10.034
   Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
   Chia SK, 2012, CLIN CANCER RES, V18, P4465, DOI 10.1158/1078-0432.CCR-12-0286
   Cobleigh MA, 2005, CLIN CANCER RES, V11, P8623, DOI 10.1158/1078-0432.CCR-05-0735
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Corpet A, 2011, EMBO J, V30, P480, DOI 10.1038/emboj.2010.335
   COX DR, 1972, J R STAT SOC B, V34, P187
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   de Cremoux P, 2004, ENDOCR-RELAT CANCER, V11, P489, DOI 10.1677/erc.1.00808
   de Tayrac M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073332
   Dunleavy EM, 2009, CELL, V137, P485, DOI 10.1016/j.cell.2009.02.040
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Filipescu D, 2013, TRENDS GENET, V29, P630, DOI 10.1016/j.tig.2013.06.002
   Foltz DR, 2009, CELL, V137, P472, DOI 10.1016/j.cell.2009.02.039
   Gerdes J, 1990, Semin Cancer Biol, V1, P199
   GERDES J, 1983, INT J CANCER, V31, P13, DOI 10.1002/ijc.2910310104
   Geyer FC, 2009, INT J SURG PATHOL, V17, P285, DOI 10.1177/1066896908328577
   Giaginis C, 2010, HISTOL HISTOPATHOL, V25, P351, DOI 10.14670/HH-25.351
   Gu XM, 2014, PATHOL RES PRACT, V210, P228, DOI 10.1016/j.prp.2013.12.007
   Gurard-Levin Zachary A, 2014, F1000Prime Rep, V6, P76, DOI 10.12703/P6-76
   Gurard-Levin ZA, 2014, ANNU REV BIOCHEM, V83, P487, DOI 10.1146/annurev-biochem-060713-035536
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Harbeck N, 2014, CANCER TREAT REV, V40, P434, DOI 10.1016/j.ctrv.2013.09.014
   Hu Z, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2487
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Kato T, 2007, CANCER RES, V67, P8544, DOI 10.1158/0008-5472.CAN-07-1307
   Lacoste N, 2014, MOL CELL, V53, P631, DOI 10.1016/j.molcel.2014.01.018
   Li QY, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-474
   Li Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017794
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Maisonneuve P, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3679
   McGovern SL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3181
   Mishra PK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002303
   Mullan PB, 2007, CELL MOL LIFE SCI, V64, P3219, DOI 10.1007/s00018-007-7389-z
   Nielsen T, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-177
   O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Patani N, 2013, INT J CANCER, V133, P1, DOI 10.1002/ijc.27997
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Piccart-Gebhart MJ, 2011, ONCOLOGIST, V16, P40, DOI 10.1634/theoncologist.2011-S1-40
   Polley MYC, 2013, JNCI-J NATL CANCER I, V105, P1897, DOI 10.1093/jnci/djt306
   Polo SE, 2006, CURR OPIN GENET DEV, V16, P104, DOI 10.1016/j.gde.2006.02.011
   Polo SE, 2004, CANCER RES, V64, P2371, DOI 10.1158/0008-5472.CAN-03-2893
   Qiu JJ, 2013, TUMOR BIOL, V34, P2971, DOI 10.1007/s13277-013-0860-6
   Rajput Ashish B, 2011, Cancers (Basel), V3, P4212, DOI 10.3390/cancers3044212
   Ray-Gallet D, 2011, MOL CELL, V44, P928, DOI 10.1016/j.molcel.2011.12.006
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Reyal F, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2192
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Schmidt M, 2009, ANN ONCOL, V20, P258, DOI 10.1093/annonc/mdn590
   Schnitt SJ, 2010, INT J SURG PATHOL, V18, p162S, DOI 10.1177/1066896910370771
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Servant Nicolas, 2010, BMC Res Notes, V3, P277, DOI 10.1186/1756-0500-3-277
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100
   Svotelis A, 2010, CELL CYCLE, V9, P364, DOI 10.4161/cc.9.2.10465
   Tabachnick, 2013, Using multivariate statistics, V6th
   Tian S, 2010, BIOMARK INSIGHTS, V5, P129, DOI 10.4137/BMI.S6184
   Tobin NP, 2014, MOL ONCOL, V8, P741, DOI 10.1016/j.molonc.2014.02.007
   Tomonaga T, 2003, CANCER RES, V63, P3511
   Tsourlakis MC, 2013, HUM PATHOL, V44, P1789, DOI 10.1016/j.humpath.2013.01.022
   Valente V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062200
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z
   Varga Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037379
   Weigelt B, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2734
   Wirapati P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2124
   Wu Q, 2012, LUNG CANCER, V77, P407, DOI 10.1016/j.lungcan.2012.04.007
NR 78
TC 62
Z9 67
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD MAR
PY 2015
VL 9
IS 3
BP 657
EP 674
DI 10.1016/j.molonc.2014.11.002
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CE7SX
UT WOS:000352043200009
PM 25497280
OA Green Published
DA 2025-01-12
ER

PT J
AU Ong, CC
   Gierke, S
   Pitt, C
   Sagolla, M
   Cheng, CK
   Zhou, W
   Jubb, AM
   Strickland, L
   Schmidt, M
   Duron, SG
   Campbell, DA
   Zheng, W
   Dehdashti, S
   Shen, M
   Yang, NR
   Behnke, ML
   Huang, WW
   Mckew, JC
   Chernoff, J
   Forrest, WF
   Haverty, PM
   Chin, SF
   Rakha, EA
   Green, AR
   Ellis, IO
   Caldas, C
   O'Brien, T
   Friedman, LS
   Koeppen, H
   Rudolph, J
   Hoeflich, KP
AF Ong, Christy C.
   Gierke, Sarah
   Pitt, Cameron
   Sagolla, Meredith
   Cheng, Christine K.
   Zhou, Wei
   Jubb, Adrian M.
   Strickland, Laura
   Schmidt, Maike
   Duron, Sergio G.
   Campbell, David A.
   Zheng, Wei
   Dehdashti, Seameen
   Shen, Min
   Yang, Nora
   Behnke, Mark L.
   Huang, Wenwei
   Mckew, John C.
   Chernoff, Jonathan
   Forrest, William F.
   Haverty, Peter M.
   Chin, Suet-Feung
   Rakha, Emad A.
   Green, Andrew R.
   Ellis, Ian O.
   Caldas, Carlos
   O'Brien, Thomas
   Friedman, Lori S.
   Koeppen, Hartmut
   Rudolph, Joachim
   Hoeflich, Klaus P.
TI Small molecule inhibition of group I p21-activated kinases in breast
   cancer induces apoptosis and potentiates the activity of microtubule
   stabilizing agents
SO BREAST CANCER RESEARCH
LA English
DT Article
ID PAK1; RAS; PHOSPHORYLATION; FAMILY; TARGET
AB Introduction: Breast cancer, the most common cause of cancer-related deaths worldwide among women, is a molecularly and clinically heterogeneous disease. Extensive genetic and epigenetic profiling of breast tumors has recently revealed novel putative driver genes, including p21-activated kinase (PAK) 1. PAK1 is a serine/threonine kinase downstream of small GTP-binding proteins, Rac1 and Cdc42, and is an integral component of growth factor signaling networks and cellular functions fundamental to tumorigenesis.
   Methods: PAK1 dysregulation (copy number gain, mRNA and protein expression) was evaluated in two cohorts of breast cancer tissues (n = 980 and 1,108). A novel small molecule inhibitor, FRAX1036, and RNA interference were used to examine PAK1 loss of function and combination with docetaxel in vitro. Mechanism of action for the therapeutic combination, both cellular and molecular, was assessed via time-lapse microscopy and immunoblotting.
   Results: We demonstrate that focal genomic amplification and overexpression of PAK1 are associated with poor clinical outcome in the luminal subtype of breast cancer (P = 1.29 x 10(-4) and P = 0.015, respectively). Given the role for PAK1 in regulating cytoskeletal organization, we hypothesized that combination of PAK1 inhibition with taxane treatment could be combined to further interfere with microtubule dynamics and cell survival. Consistent with this, administration of docetaxel with either a novel small molecule inhibitor of group I PAKs, FRAX1036, or PAK1 small interfering RNA oligonucleotides dramatically altered signaling to cytoskeletal-associated proteins, such as stathmin, and induced microtubule disorganization and cellular apoptosis. Live-cell imaging revealed that the duration of mitotic arrest mediated by docetaxel was significantly reduced in the presence of FRAX1036, and this was associated with increased kinetics of apoptosis.
   Conclusions: Taken together, these findings further support PAK1 as a potential target in breast cancer and suggest combination with taxanes as a viable strategy to increase anti-tumor efficacy.
C1 [Ong, Christy C.; Pitt, Cameron; Cheng, Christine K.; Zhou, Wei; O'Brien, Thomas; Friedman, Lori S.; Hoeflich, Klaus P.] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA.
   [Gierke, Sarah; Sagolla, Meredith; Jubb, Adrian M.; Koeppen, Hartmut] Genentech Inc, Dept Pathol, San Francisco, CA 94080 USA.
   [Strickland, Laura; Schmidt, Maike] Genentech Inc, Dept Diagnost, San Francisco, CA 94080 USA.
   [Duron, Sergio G.; Campbell, David A.] Afraxis, La Jolla, CA USA.
   [Dehdashti, Seameen; Shen, Min; Yang, Nora; Behnke, Mark L.; Huang, Wenwei; Mckew, John C.] Natl Ctr Adv Translat Sci, Bethesda, MD USA.
   [Chernoff, Jonathan] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
   [Forrest, William F.] Genentech Inc, Dept Biostat, San Francisco, CA 94080 USA.
   [Haverty, Peter M.] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA.
   [Chin, Suet-Feung; Caldas, Carlos] Univ Cambridge, Canc Res UK, Cambridge, England.
   [Rakha, Emad A.; Green, Andrew R.; Ellis, Ian O.] Univ Nottingham, Sch Med, Div Canc & Stem Cells, Histopathol, Nottingham, England.
   [Rakha, Emad A.; Green, Andrew R.; Ellis, Ian O.] Univ Nottingham Hosp, Nottingham NG7 2UH, England.
   [Rudolph, Joachim] Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech; National Institutes of Health (NIH) - USA; NIH National
   Center for Advancing Translational Sciences (NCATS); Fox Chase Cancer
   Center; Roche Holding; Genentech; Roche Holding; Genentech; CRUK
   Cambridge Institute; Cancer Research UK; University of Cambridge;
   University of Nottingham; University of Nottingham; Roche Holding;
   Genentech
RP Rudolph, J (通讯作者)，Genentech Inc, Discovery Chem, San Francisco, CA 94080 USA.
EM rudolph.joachim@gene.com; klaushoeflich@hotmail.com
RI Huang, Wenwei/AFO-1997-2022; Rakha, Emad/Q-5554-2019; Green,
   Andrew/AAF-1991-2020; Ellis, Ian/JJF-5555-2023; Chernoff,
   Jonathan/I-7631-2014; Zheng, Wei/J-8889-2014; Caldas, Carlos/U-7250-2019
OI Chernoff, Jonathan/0000-0002-4803-7836; Sanders,
   Laura/0009-0008-8045-4331; Schmidt, Maike/0000-0001-9062-1828; Rakha,
   Emad/0000-0002-5009-5525; Gierke, Sarah/0000-0002-0364-1220; O'Brien,
   Thomas/0000-0002-9161-8070; Zheng, Wei/0000-0003-1034-0757; Caldas,
   Carlos/0000-0003-3547-1489; Ellis, Ian/0000-0001-5292-8474; Green,
   Andrew/0000-0002-0488-5913; chin, suet-feung/0000-0001-5697-1082
FU Genentech
FX CCO, SG, CKC, MSa, WZho, AMJ, LS, MSc, WFF, PMH, TOB, LSF, HK and JR own
   stock in Hoffmann-La Roche. KPH is a shareholder of Blueprint Medicines.
   DAC and SGD own shares in Afraxis. CC receives research funding from
   Genentech and is a member of the Scientific Advisory Board at
   AstraZeneca. CP, WZhe, SD, MS, NY, MLB, WH, JCM, JC, SFC, EAR, ARG and
   IOE declare that they have no competing interests.
CR Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965
   Arias-Romero LE, 2013, CANCER RES, V73, P3671, DOI 10.1158/0008-5472.CAN-12-4453
   Banerjee M, 2002, CURR BIOL, V12, P1233, DOI 10.1016/S0960-9822(02)00956-9
   Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7
   Chow HY, 2012, CANCER RES, V72, P5966, DOI 10.1158/0008-5472.CAN-12-2246
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834
   Gnad F, 2013, MOL CELL PROTEOMICS, V12, P2070, DOI 10.1074/mcp.M112.027052
   Greenman CD, 2010, BIOSTATISTICS, V11, P164, DOI 10.1093/biostatistics/kxp045
   Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185
   Licciulli S, 2013, J BIOL CHEM, V288, P29105, DOI 10.1074/jbc.M113.510933
   McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004
   Ong CC, 2013, JNCI-J NATL CANCER I, V105, P606, DOI 10.1093/jnci/djt054
   Ong CC, 2011, ONCOTARGET, V2, P491
   Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108
   Pakala SB, 2012, J BIOL CHEM, V287, P40560, DOI 10.1074/jbc.M112.399576
   QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0
   R Core Team, 2017, R: A language and environment for statistical computing
   Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645
   Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103
   Rubin CI, 2004, J CELL BIOCHEM, V93, P242, DOI 10.1002/jcb.20187
   Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405
   Rudolph J, 2015, J MED CHEM, V58, P111, DOI 10.1021/jm501613q
   Shrestha Y, 2012, ONCOGENE, V31, P3397, DOI 10.1038/onc.2011.515
   Stengel KR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037317
   Vadlamudi RK, 2005, MOL CELL BIOL, V25, P3726, DOI 10.1128/MCB.25.9.3726-3736.2005
   Vadlamudi RK, 2004, CANCER CELL, V5, P575, DOI 10.1016/j.ccr.2004.05.022
   Wang RA, 2006, ONCOGENE, V25, P2931, DOI 10.1038/sj.onc.1209309
   Whale A, 2011, FRONT BIOSCI-LANDMRK, V16, P849, DOI 10.2741/3724
   Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200
   Ye Diana Zi, 2012, Cell Logist, V2, P105
NR 31
TC 54
Z9 58
U1 1
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD APR 23
PY 2015
VL 17
AR 59
DI 10.1186/s13058-015-0564-5
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CI9LR
UT WOS:000355092100001
PM 25902869
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Mayor, R
   Izquierdo-Bouldstridge, A
   Millán-Ariño, L
   Bustillos, A
   Sampaio, C
   Luque, N
   Jordan, A
AF Mayor, Regina
   Izquierdo-Bouldstridge, Andrea
   Millan-Arino, Lluis
   Bustillos, Alberto
   Sampaio, Cristina
   Luque, Neus
   Jordan, Albert
TI Genome Distribution of Replication-independent Histone H1 Variants Shows
   H1.0 Associated with Nucleolar Domains and H1X Associated with RNA
   Polymerase II-enriched Regions
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
DE Chromatin; Epigenetics; Histone; Nucleolus; RNA Polymerase II; H1; 0;
   H1X; Histone H1; Variants
ID NUCLEAR LAMINA INTERACTIONS; DNA METHYLATION; GENE-EXPRESSION;
   BREAST-CANCER; CHROMOSOME TERRITORIES; CHROMATIN-STRUCTURE; HUMAN-CELLS;
   IN-VIVO; TRANSCRIPTION; PHOSPHORYLATION
AB Background: There are seven histone H1 variants in somatic mammalian cells, two of which are replication-independent, H1.0 and H1X. Results: In breast cancer cells, H1.0 is enriched at nucleolus-associated domains, whereas H1X is associated with RNA polymerase II-enriched regions. Conclusion: Most H1 variants show great redundancy across the genome, but there is also some specificity. Significance: Some H1 variants may have specific functions.
   Unlike core histones, the linker histone H1 family is more evolutionarily diverse, and many organisms have multiple H1 variants or subtypes. In mammals, the H1 family includes seven somatic H1 variants; H1.1 to H1.5 are expressed in a replication-dependent manner, whereas H1.0 and H1X are replication-independent. Using ChIP-sequencing data and cell fractionation, we have compared the genomic distribution of H1.0 and H1X in human breast cancer cells, in which we previously observed differential distribution of H1.2 compared with the other subtypes. We have found H1.0 to be enriched at nucleolus-associated DNA repeats and chromatin domains, whereas H1X is associated with coding regions, RNA polymerase II-enriched regions, and hypomethylated CpG islands. Further, H1X accumulates within constitutive or included exons and retained introns and toward the 3 end of expressed genes. Inducible H1X knockdown does not affect cell proliferation but dysregulates a subset of genes related to cell movement and transport. In H1X-depleted cells, the promoters of up-regulated genes are not occupied specifically by this variant, have a lower than average H1 content, and, unexpectedly, do not form an H1 valley upon induction. We conclude that H1 variants are not distributed evenly across the genome and may participate with some specificity in chromatin domain organization or gene regulation.
C1 [Mayor, Regina; Izquierdo-Bouldstridge, Andrea; Millan-Arino, Lluis; Bustillos, Alberto; Sampaio, Cristina; Luque, Neus; Jordan, Albert] CSIC, IBMB, E-08028 Barcelona, Catalonia, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de Biologia Molecular de Barcelona (IBMB)
RP Jordan, A (通讯作者)，CSIC, IBMB, C Baldiri Reixac 4, E-08028 Barcelona, Catalonia, Spain.
EM albert.jordan@ibmb.csic.es
RI jordan, albert/ABC-8229-2020; Bustillos, Alberto/AAQ-5390-2021; jordan,
   albert/K-4678-2014
OI Bustillos, Alcides/0000-0002-4409-8113; Luque, Neus/0000-0001-6546-7259;
   Izquierdo Bouldstridge, Andrea/0000-0001-6169-936X; Sampaio,
   Cristina/0000-0002-2974-210X; jordan, albert/0000-0002-3970-8693
FU Spanish Ministry of Science and Innovation (MICINN); European Regional
   Development Fund [BFU2011-23057]; Generalitat de Catalunya
   [2009-SGR-1222]; Consejo Superior de Investigaciones Cientificas-MICINN;
   MICINN
FX This work was supported by funding from the Spanish Ministry of Science
   and Innovation (MICINN), European Regional Development Fund Grant
   BFU2011-23057, and Generalitat de Catalunya Grant 2009-SGR-1222.
   Recipient of a Tecnico de Apoyo contract from Consejo Superior de
   Investigaciones Cientificas-MICINN. Recipient of a Formacion de Personal
   Universitario predoctoral fellowship from MICINN.
CR Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9
   Ballaré C, 2013, MOL CELL, V49, P67, DOI 10.1016/j.molcel.2012.10.019
   Bednar J, 1998, P NATL ACAD SCI USA, V95, P14173, DOI 10.1073/pnas.95.24.14173
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Braunschweig U, 2013, CELL, V152, P1252, DOI 10.1016/j.cell.2013.02.034
   Cao Kaixiang, 2013, PLoS Genet, V9, pe1003417, DOI 10.1371/journal.pgen.1003417
   Daujat S, 2005, J BIOL CHEM, V280, P38090, DOI 10.1074/jbc.C500229200
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028
   Fan YH, 2001, MOL CELL BIOL, V21, P7933, DOI 10.1128/MCB.21.23.7933-7943.2001
   Ferreira J, 1997, J CELL BIOL, V139, P1597, DOI 10.1083/jcb.139.7.1597
   Acuña LIG, 2013, WIRES RNA, V4, P77, DOI 10.1002/wrna.1142
   GORKA C, 1993, EXP CELL RES, V205, P152, DOI 10.1006/excr.1993.1069
   Guelen L, 2008, NATURE, V453, P948, DOI 10.1038/nature06947
   Hale TK, 2006, MOL CELL, V22, P693, DOI 10.1016/j.molcel.2006.04.016
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Happel N, 2005, BIOL CHEM, V386, P541, DOI 10.1515/BC.2005.064
   Happel N, 2009, GENE, V431, P1, DOI 10.1016/j.gene.2008.11.003
   Hergeth SP, 2011, J CELL SCI, V124, P1623, DOI 10.1242/jcs.084947
   Hnilicová J, 2011, NUCLEUS-PHILA, V2, P182, DOI 10.4161/nucl.2.3.15876
   Hödl M, 2012, CURR BIOL, V22, P2253, DOI 10.1016/j.cub.2012.10.008
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Izzo A, 2008, BIOL CHEM, V389, P333, DOI 10.1515/BC.2008.037
   Izzo A, 2013, CELL REP, V3, P2142, DOI 10.1016/j.celrep.2013.05.003
   Jarboui MA, 2011, MOL IMMUNOL, V49, P441, DOI 10.1016/j.molimm.2011.09.005
   Jurka J, 2005, CYTOGENET GENOME RES, V110, P462, DOI 10.1159/000084979
   Kalashnikova AA, 2013, NUCLEIC ACIDS RES, V41, P4026, DOI 10.1093/nar/gkt104
   Kamieniarz K, 2012, GENE DEV, V26, P797, DOI 10.1101/gad.182014.111
   Kim K, 2012, ONCOGENE, V31, P4290, DOI 10.1038/onc.2011.605
   Kim KJ, 2013, BIOMIMETIC ROBOTIC ARTIFICIAL MUSCLES, P1
   Kolasinska-Zwierz P, 2009, NAT GENET, V41, P376, DOI 10.1038/ng.322
   Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039
   Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096
   LENNOX RW, 1983, J BIOL CHEM, V258, P262
   Lin QC, 2004, J BIOL CHEM, V279, P23525, DOI 10.1074/jbc.M400925200
   Maunakea AK, 2013, CELL RES, V23, P1256, DOI 10.1038/cr.2013.110
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Medrzycki M, 2012, FRONT BIOSCI-LANDMRK, V17, P396, DOI 10.2741/3934
   Meergans T, 1997, DNA CELL BIOL, V16, P1041, DOI 10.1089/dna.1997.16.1041
   Millán-Ariño L, 2014, NUCLEIC ACIDS RES, V42, P4474, DOI 10.1093/nar/gku079
   Nègre N, 2011, NATURE, V471, P527, DOI 10.1038/nature09990
   Németh A, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000889
   Orthaus S, 2009, NUCLEIC ACIDS RES, V37, P3391, DOI 10.1093/nar/gkp199
   Parseghian MH, 2000, CHROMOSOME RES, V8, P405, DOI 10.1023/A:1009262819961
   Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289
   PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275
   Peric-Hupkes D, 2010, MOL CELL, V38, P603, DOI 10.1016/j.molcel.2010.03.016
   PINA B, 1987, EUR J BIOCHEM, V164, P71, DOI 10.1111/j.1432-1033.1987.tb10994.x
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Sadoni N, 1999, J CELL BIOL, V146, P1211, DOI 10.1083/jcb.146.6.1211
   Sancho M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000227
   Sato S, 2012, PATHOL INT, V62, P84, DOI 10.1111/j.1440-1827.2011.02755.x
   Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Stoldt S, 2007, BIOL CELL, V99, P541, DOI 10.1042/BC20060117
   Takata H, 2007, FEBS LETT, V581, P3783, DOI 10.1016/j.febslet.2007.06.076
   Telu KH, 2013, J PROTEOME RES, V12, P3317, DOI 10.1021/pr400143x
   Terme JM, 2014, FEBS LETT, V588, P2353, DOI 10.1016/j.febslet.2014.05.035
   Terme JM, 2011, J BIOL CHEM, V286, P35347, DOI 10.1074/jbc.M111.281923
   Th'ng JPH, 2005, J BIOL CHEM, V280, P27809, DOI 10.1074/jbc.M501627200
   THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403
   Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486
   TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x
   van Koningsbruggen S, 2010, MOL BIOL CELL, V21, P3735, DOI 10.1091/mbc.E10-06-0508
   VanderKraats ND, 2013, NUCLEIC ACIDS RES, V41, P6816, DOI 10.1093/nar/gkt482
   Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031
   Weiss T, 2010, EPIGENET CHROMATIN, V3, DOI 10.1186/1756-8935-3-7
   Wiznerowicz M, 2003, J VIROL, V77, P8957, DOI 10.1128/JVI.77.16.8957-8951.2003
   Yamamoto T, 1996, GENE, V173, P281, DOI 10.1016/0378-1119(96)00020-0
   Yang SM, 2013, P NATL ACAD SCI USA, V110, P1708, DOI 10.1073/pnas.1213266110
   Zentner GE, 2011, NUCLEIC ACIDS RES, V39, P4949, DOI 10.1093/nar/gkq1326
   Zhang HS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004202
   Zhang YZ, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002691
   Zheng YP, 2010, J CELL BIOL, V189, P407, DOI 10.1083/jcb.201001148
NR 78
TC 54
Z9 55
U1 0
U2 10
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 20
PY 2015
VL 290
IS 12
BP 7474
EP 7491
DI 10.1074/jbc.M114.617324
PG 18
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CE2AC
UT WOS:000351613600016
PM 25645921
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, SJ
   Yu, SY
   Yoon, HJ
   Lee, SY
   Youn, JP
   Hwang, SY
AF Kim, Seung Jun
   Yu, So-Yeon
   Yoon, Hyo-Jung
   Lee, Seung Yong
   Youn, Jong-Phil
   Hwang, Seung Yong
TI Epigenetic Regulation of miR-22 in a BPA-exposed Human Hepatoma Cell
SO BIOCHIP JOURNAL
LA English
DT Article
DE Methylation; MicroRNA; Gene expression; Toxicogenomics; Microarray; BPA
ID ESTROGEN-RECEPTOR-ALPHA; N-TERMINAL KINASE; GENE-EXPRESSION;
   BISPHENOL-A; MESSENGER-RNA; BREAST-CANCER; PROTEIN; MICRORNAS; PATHWAY;
   RAT
AB Bisphenol A (BPA), an widely used environmental chemical, is encircled to human life. However, we generally do not know whether or not it can cause negative health effects. One of the representative epigenetic changes that inhibit gene expression is DNA methylation, which has been very well studied in association with cancer and development. Gene function is changed by DNA methylation; however, its genetic code does not change. Our study hypothesized that a post-transcriptional change in DNA occurs due to exposure to BPA. These changes then cause regulation of microRNA and gene expression. To identify these successional regulations, we conducted microarraybased assays. For validation, also we conducted bisulfite sequencing, quantitative real-time PCR, miRNA inhibitor assay, and Western blotting. We found 1,751 hypo-methylation changed regions, and several micro- RNA had included methylated-regions. miR-22 was also hypomethylated (chr17:1563947-1564031) by BPA-exposure, and expression of miR-22 was up-regulated in an miRNA array and real-time PCR. miR- 22 has been reported to inhibit estrogen signaling by direct targeting of the estrogen receptor alpha mRNA. Taking notice of this point, we analyzed gene expression profiles that included its predicted targets. In the present study, we found the cause of hypomethylation of miR-22 and negative regulation of its apoptosisrelated target gene expression by BPA-exposure. These results suggests that BPA can alter sequential genomic appearances in HepG2 cells, a potentially affection of BPA toxicity. Also, the results of our study support that toxicology study need to integrated analysis of array-based assays for help in understanding of the molecular action of environmental toxicants.
C1 [Yu, So-Yeon; Hwang, Seung Yong] Hanyang Univ, Dept Biochem, Ansan, Gyeonggi Do, South Korea.
   [Kim, Seung Jun; Yu, So-Yeon; Yoon, Hyo-Jung; Lee, Seung Yong; Youn, Jong-Phil; Hwang, Seung Yong] BioCore Co Ltd, GenoLifeCare Div, Seoul, South Korea.
C3 Hanyang University
RP Hwang, SY (通讯作者)，Hanyang Univ, Dept Biochem, Ansan, Gyeonggi Do, South Korea.
EM syhwang@hanyang.ac.kr
FU Korea Ministry of Environment as a "Converging technology project"
FX This subject was supported by the Korea Ministry of Environment as a
   "Converging technology project".
CR Adams BD, 2007, MOL ENDOCRINOL, V21, P1132, DOI 10.1210/me.2007-0022
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178
   Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Chou FI, 2009, APPL RADIAT ISOTOPES, V67, pS105, DOI 10.1016/j.apradiso.2009.03.025
   Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687
   Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104
   Donald S, 2002, CANCER RES, V62, P4256
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Gabai VL, 2000, MOL CELL BIOL, V20, P6826, DOI 10.1128/MCB.20.18.6826-6836.2000
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022
   Hanet N, 2008, STEROIDS, V73, P1242, DOI 10.1016/j.steroids.2008.06.005
   Heinloth AN, 2004, TOXICOL SCI, V80, P193, DOI 10.1093/toxsci/kfh145
   Kim SJ, 2009, MOL CELL TOXICOL, V5, P310
   Kim SJ, 2009, BIOCHIP J, V3, P293
   Kol S, 1999, MOL CELL ENDOCRINOL, V149, P115, DOI 10.1016/S0303-7207(98)00260-3
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MIKOL YB, 1983, CARCINOGENESIS, V4, P1619, DOI 10.1093/carcin/4.12.1619
   Nuwaysir EF, 1999, MOL CARCINOGEN, V24, P153, DOI 10.1002/(SICI)1098-2744(199903)24:3<153::AID-MC1>3.0.CO;2-P
   O'Connor JC, 2003, PURE APPL CHEM, V75, P2099, DOI 10.1351/pac200375112099
   Okada H, 2008, ENVIRON HEALTH PERSP, V116, P32, DOI 10.1289/ehp.10587
   Pandey DP, 2009, MOL CELL BIOL, V29, P3783, DOI 10.1128/MCB.01875-08
   Park K, 2010, CHEMOSPHERE, V79, P934, DOI 10.1016/j.chemosphere.2010.03.002
   Revankar CM, 2004, J BIOL CHEM, V279, P24578, DOI 10.1074/jbc.M402121200
   Richter CA, 2007, ENVIRON HEALTH PERSP, V115, P902, DOI 10.1289/ehp.9804
   Salehi AH, 2002, J BIOL CHEM, V277, P48043, DOI 10.1074/jbc.M205324200
   Soung YH, 2003, ONCOGENE, V22, P8048, DOI 10.1038/sj.onc.1206727
   Yu MC, 2008, J GASTROEN HEPATOL, V23, pS92, DOI 10.1111/j.1440-1746.2007.05293.x
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
   Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929
NR 34
TC 12
Z9 12
U1 0
U2 18
PU KOREAN BIOCHIP SOCIETY-KBCS
PI SEOUL
PA KOREA SCI & TECHNOL CENT, #310, 635-4, YEOGSAM-DONG, KANGNAM-GU, SEOUL,
   135-703, SOUTH KOREA
SN 1976-0280
EI 2092-7843
J9 BIOCHIP J
JI BioChip J.
PD MAR
PY 2015
VL 9
IS 1
BP 76
EP 84
DI 10.1007/s13206-014-9110-2
PG 9
WC Biochemical Research Methods; Chemistry, Analytical; Nanoscience &
   Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Science & Technology -
   Other Topics
GA CE5KN
UT WOS:000351872700010
DA 2025-01-12
ER

PT J
AU Hair, BY
   Troester, MA
   Edmiston, SN
   Parrish, EA
   Robinson, WR
   Wu, MC
   Olshan, AF
   Swift-Scanlan, T
   Conway, K
AF Hair, Brionna Y.
   Troester, Melissa A.
   Edmiston, Sharon N.
   Parrish, Eloise A.
   Robinson, Whitney R.
   Wu, Michael C.
   Olshan, Andrew F.
   Swift-Scanlan, Theresa
   Conway, Kathleen
TI Body Mass Index Is Associated with Gene Methylation in Estrogen
   Receptor-Positive Breast Tumors
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOMIC DNA METHYLATION; 3BP2 ADAPTER PROTEIN; CANCER RISK; BINDING
   PROTEIN-6; PHYSICAL-ACTIVITY; OBESITY; WEIGHT; PREMENOPAUSAL;
   EXPRESSION; RELEVANCE
AB Background: Although obesity is associated with breast cancer incidence and prognosis, the underlying mechanisms are poorly understood. Identification of obesity-associated epigenetic changes in breast tissue may advance mechanistic understanding of breast cancer initiation and progression. The goal of this study, therefore, was to investigate associations between obesity and gene methylation in breast tumors.
   Methods: Using the Illumina GoldenGate Cancer I Panel, we estimated the association between body mass index (BMI) and gene methylation in 345 breast tumor samples from phase I of the Carolina Breast Cancer Study, a population-based case-control study. Multivariable linear regression was used to identify sites that were differentially methylated by BMI. Stratification by tumor estrogen receptor (ER) status was also conducted.
   Results: In the majority of the 935 probes analyzed (87%), the average beta value increased with obesity (BMI >= 30). Obesity was significantly associated with differential methylation (FDR q < 0.05) in just two gene loci in breast tumor tissue overall and in 21 loci among ER-positive tumors. Obesity was associated with methylation of genes that function in immune response, cell growth, and DNA repair.
   Conclusions: Obesity is associated with altered methylation overall, and with hypermethylation among ER-positive tumors in particular, suggesting that obesity may influence the methylation of genes with known relevance to cancer. Some of these differences in methylation by obese status may influence levels of gene expression within breast cells.
   Impact: If our results are validated, obesity-associated methylation sites could serve as targets for prevention and treatment research. (c) 2015 AACR.
C1 [Hair, Brionna Y.; Troester, Melissa A.; Robinson, Whitney R.; Olshan, Andrew F.; Conway, Kathleen] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
   [Edmiston, Sharon N.; Parrish, Eloise A.; Swift-Scanlan, Theresa; Conway, Kathleen] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
   [Wu, Michael C.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
   [Swift-Scanlan, Theresa] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina; University of North Carolina Chapel Hill;
   Fred Hutchinson Cancer Center; University of North Carolina; University
   of North Carolina Chapel Hill
RP Hair, BY (通讯作者)，Univ N Carolina, Dept Epidemiol, CB 7435,2101 McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.
EM bhair@email.unc.edu
RI Wu, Michael C./X-5084-2019
OI Wu, Michael C./0000-0002-3357-6570; Robinson,
   Whitney/0000-0003-4009-0488
FU University Cancer Research Fund of North Carolina; National Cancer
   Institute Specialized Program of Research Excellence (SPORE) in Breast
   Cancer [NIH/NCI P50-CA58223]; Lineberger Comprehensive Cancer Center
   Core Grant [NIH/NCI P30-CA16086]; Susan G. Komen for the Cure
   [KG081397]; National Cancer Institute [1K01CA172717-01]; National Cancer
   Institute/National Institute of Environmental Health Sciences Breast
   Cancer and the Environment Research Program [U01-ES019472]
FX This research was funded, in part, by the University Cancer Research
   Fund of North Carolina, the National Cancer Institute Specialized
   Program of Research Excellence (SPORE) in Breast Cancer (NIH/NCI
   P50-CA58223), the Lineberger Comprehensive Cancer Center Core Grant
   (NIH/NCI P30-CA16086). Support for K. Conway was provided by a grant
   from Susan G. Komen for the Cure (#KG081397). Support for W.R. Robinson
   was provided by the National Cancer Institute (1K01CA172717-01). Support
   for M.A. Troester was provided by the National Cancer Institute/National
   Institute of Environmental Health Sciences Breast Cancer and the
   Environment Research Program (U01-ES019472).
CR [Anonymous], NUCL ACIDS RES
   Bach LA, 2013, CLIN SCI, V124, P215, DOI 10.1042/CS20120343
   Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   Carmichael AR, 2006, BJOG-INT J OBSTET GY, V113, P1160, DOI 10.1111/j.1471-0528.2006.01021.x
   Carmichael AR, 2004, BREAST, V13, P85, DOI 10.1016/j.breast.2003.03.001
   Chen G, 2007, MOL CELL BIOL, V27, P3109, DOI 10.1128/MCB.01014-06
   Chen G, 2012, J IMMUNOL, V189, P2138, DOI 10.4049/jimmunol.1103184
   Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164
   Conway K, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0450-6
   de la Fuente MA, 2006, MOL CELL BIOL, V26, P5214, DOI 10.1128/MCB.00087-06
   Deckert M, 2006, ADV EXP MED BIOL, V584, P107
   Dick KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4
   Enger SM, 2000, CANCER EPIDEM BIOMAR, V9, P681
   Fang M, 2011, CANCER-AM CANCER SOC, V117, P2024, DOI 10.1002/cncr.25770
   Feinberg AP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001262
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Gorber SC, 2007, OBES REV, V8, P307, DOI 10.1111/j.1467-789X.2007.00347.x
   Howe LR, 2013, CLIN CANCER RES, V19, P6074, DOI 10.1158/1078-0432.CCR-12-2603
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Kaulsay KK, 1999, EUR J ENDOCRINOL, V140, P164, DOI 10.1530/eje.0.1400164
   Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131
   Koestler DC, 2012, CANCER EPIDEM BIOMAR, V21, P1293, DOI 10.1158/1055-9965.EPI-12-0361
   Lake RJ, 2013, MECH AGEING DEV, V134, P202, DOI 10.1016/j.mad.2013.02.004
   Loi S, 2005, CANCER EPIDEM BIOMAR, V14, P1686, DOI 10.1158/1055-9965.EPI-05-0042
   Moorman PG, 1999, ANN EPIDEMIOL, V9, P188, DOI 10.1016/S1047-2797(98)00057-X
   Naushad SM, 2014, MOL CELL BIOCHEM, V392, P273, DOI 10.1007/s11010-014-2037-z
   Pazaitou-Panayiotou K, 2007, EUR J ENDOCRINOL, V156, P187, DOI 10.1530/EJE-06-0611
   Piyathilake C, 2011, CANCER EPIDEM BIOMAR, V20, P719, DOI 10.1158/1055-9965.EPI-11-0094
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Shukla U, 2009, J BIOL CHEM, V284, P33719, DOI 10.1074/jbc.M109.049999
   Smid M, 2011, BREAST CANCER RES TR, V128, P23, DOI 10.1007/s10549-010-1026-5
   Suga K, 2001, JPN J CANCER RES, V92, P127, DOI 10.1111/j.1349-7006.2001.tb01074.x
   Sun XZ, 2012, BREAST CANCER RES TR, V131, P1003, DOI 10.1007/s10549-011-1789-3
   Tao MH, 2011, AM J CLIN NUTR, V94, P831, DOI 10.3945/ajcn.110.009365
   Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   URSIN G, 1995, EPIDEMIOLOGY, V6, P137, DOI 10.1097/00001648-199503000-00009
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   White KK, 2012, INT J CANCER, V131, pE705, DOI 10.1002/ijc.27373
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Xu XJ, 2013, EPIGENETICS-US, V8, P522, DOI 10.4161/epi.24506
   Yang XR, 2011, JNCI-J NATL CANCER I, V103, P250, DOI 10.1093/jnci/djq526
   Zhang FF, 2011, EPIGENETICS-US, V6, P623, DOI 10.4161/epi.6.5.15335
   Zhang FF, 2011, EPIGENETICS-US, V6, P293, DOI 10.4161/epi.6.3.14378
NR 49
TC 22
Z9 24
U1 0
U2 7
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD MAR
PY 2015
VL 24
IS 3
BP 580
EP 586
DI 10.1158/1055-9965.EPI-14-1017
PG 7
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA CE6NC
UT WOS:000351953100014
PM 25583948
OA Green Submitted, Green Accepted, hybrid
DA 2025-01-12
ER

PT J
AU Liu, T
   Qin, WX
   Hou, LC
   Huang, YY
AF Liu, Te
   Qin, Wenxing
   Hou, Lengchen
   Huang, Yongyi
TI MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells
   development via suppression of the LKB1-p53-p21/WAF1 pathway
SO TUMOR BIOLOGY
LA English
DT Article
DE Ovarian cancer; Cancer stem cells; LKB1-p53-p21/WAF1 pathway;
   MicroRNA-17; Proliferation; Tumorigenicity
ID INITIATING CELLS; TUMOR-METASTASIS; BREAST-CANCER; LKB1; EXPRESSION;
   IDENTIFICATION; ACTIVATION; RESISTANCE; P53
AB The mechanism underlying the development of human ovarian cancer is poorly understood. The liver kinase protein, LKB1, is hypothesized to play a pivotal role in tumor cell proliferation and invasion capacity through regulation of p53 and p21/WAF1 expression. Previous studies suggest LKB1 may, in turn, be regulated by microRNA-17. Here, we examined the role of miR-17 in the expression of LKB1 and the downstream effects on proliferation and invasion capacity of normal ovarian cancer cells (OCCs) and ovarian stem cells. In this study, both the mRNA and protein expression levels of LKB1, p53, and p21 decreased in OCCs following transfection with a miR-17 expression plasmid. MiR-17 expression affected cell cycle regulation and stimulated the proliferation and invasion capacity of OCCs in vitro. ChIP assays indicated that the binding efficiency of p53 to the p21/WAF1 gene promoter was much lower in miR-17 transfected OCCs than in OCCs transfected with a mutated miR-17. Co-immunoprecipitation and western blotting showed significantly lower levels of p53 and p53 Ser15-pho in the miR-17 transfected OCCs as compared to the mutant miR-17 transfected OCCs. Xenograft experiments confirmed that suppression of tumor growth in vivo occurred in the absence of functional miR-17. These findings suggest that mature miR-17 expression may have an important role in the pathogenesis of human ovarian tumors through its interference with the LKB1-p53-p21/WAF1 pathway expression by epigenetic modification. These findings are of potential importance in the identification of novel therapeutic targets in human ovarian cancer.
C1 [Liu, Te; Hou, Lengchen] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.
   [Qin, Wenxing] Second Mil Med Univ, Shanghai Changzheng Hosp, Dept Med Oncol, Shanghai 200070, Peoples R China.
   [Liu, Te] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Shanghai Geriatr Inst Chinese Med, Shanghai 200031, Peoples R China.
   [Huang, Yongyi] Univ Sud Toulon Var, Lab PROTEE, F-83957 La Garde, France.
C3 Tongji University; Naval Medical University; Shanghai University of
   Traditional Chinese Medicine
RP Liu, T (通讯作者)，Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China.
EM liutelt@163.com
FU National Natural Science Foundation of China [81202811]; China
   Postdoctoral Science Foundation [2014 M550250]; Shanghai Municipal
   Health Bureau [20124320]
FX This work was supported by a grant from the National Natural Science
   Foundation of China (No. 81202811) and project funded by the China
   Postdoctoral Science Foundation (No. 2014 M550250) and Shanghai
   Municipal Health Bureau Fund (No. 20124320) to Te Liu.
CR Andersson E, 2012, CANCER IMMUNOL IMMUN, V61, P1243, DOI 10.1007/s00262-012-1201-0
   Brown KA, 2011, J STEROID BIOCHEM, V127, P439, DOI 10.1016/j.jsbmb.2011.06.005
   Cao YH, 2011, EMBO J, V30, P2083, DOI 10.1038/emboj.2011.116
   Chen H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041574
   Cheng WW, 2012, FEBS J, V279, P2047, DOI 10.1111/j.1742-4658.2012.08589.x
   Denison FC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028306
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595
   Gurumurthy S, 2010, NATURE, V468, P659, DOI 10.1038/nature09572
   Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296
   Krock B, 2011, CELL METAB, V13, P8, DOI 10.1016/j.cmet.2010.12.015
   Lee CG, 2012, GASTROENTEROLOGY, V142, P1206, DOI 10.1053/j.gastro.2012.01.007
   Liang XY, 2010, CANCER BIOL THER, V9, P156, DOI 10.4161/cbt.9.2.10452
   Liu T, 2012, ACTA BIOCH BIOPH SIN, V44, P197, DOI 10.1093/abbs/gmr127
   Liu T, 2010, ONCOL REP, V23, P1277, DOI 10.3892/or_00000761
   Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048
   Lützner N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042166
   Lützner N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032590
   Nakada D, 2010, NATURE, V468, P653, DOI 10.1038/nature09571
   Ollila S, 2011, J MOL CELL BIOL, V3, P330, DOI 10.1093/jmcb/mjr016
   Qin WX, 2013, FEBS LETT, V587, P1434, DOI 10.1016/j.febslet.2013.03.023
   Rubatt JM, 2012, GYNECOL ONCOL, V125, P421, DOI 10.1016/j.ygyno.2012.01.008
   Shen DZ, 2013, ASIAN PAC J TROP MED, V6, P493, DOI 10.1016/S1995-7645(13)60081-4
   Shen Y, 2013, CELL BIOL INT, V37, P1114, DOI 10.1002/cbin.10139
   Udd L, 2011, FAM CANCER, V10, P425, DOI 10.1007/s10689-011-9441-2
   Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034
   Veeranki S, 2011, DEV BIOL, V360, P351, DOI 10.1016/j.ydbio.2011.10.006
   Wei CJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041118
   Wu SY, 2013, STRAHLENTHER ONKOL, V189, P675, DOI 10.1007/s00066-013-0347-9
   Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107
   Zeng PY, 2006, CANCER RES, V66, P10701, DOI 10.1158/0008-5472.CAN-06-0999
   Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364
NR 32
TC 26
Z9 30
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2015
VL 36
IS 3
BP 1881
EP 1893
DI 10.1007/s13277-014-2790-3
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CE5OC
UT WOS:000351884000063
PM 25510663
DA 2025-01-12
ER

PT J
AU Koumangoye, RB
   Andl, T
   Taubenslag, KJ
   Zilberman, ST
   Taylor, CJ
   Loomans, HA
   Andl, CD
AF Koumangoye, Rainelli B.
   Andl, Thomas
   Taubenslag, Kenneth J.
   Zilberman, Steven T.
   Taylor, Chase J.
   Loomans, Holli A.
   Andl, Claudia D.
TI SOX4 interacts with EZH2 and HDAC3 to suppress microRNA-31 in invasive
   esophageal cancer cells
SO MOLECULAR CANCER
LA English
DT Article
DE Esophageal cancer; Oncogene; MicroRNA; miR-31; EZH2; SOX4; HDAC3;
   Epigenetics
ID GROUP PROTEIN EZH2; BREAST-CANCER; NEOPLASTIC TRANSFORMATION;
   MESENCHYMAL TRANSITION; TRANSCRIPTION FACTORS; MIR-200 FAMILY;
   E-CADHERIN; EXPRESSION; MIR-31; ADENOCARCINOMA
AB Background: Tumor metastasis is responsible for 90% of cancer-related deaths. Recently, a strong link between microRNA dysregulation and human cancers has been established. However, the molecular mechanisms through which microRNAs regulate metastasis and cancer progression remain unclear.
   Methods: We analyzed the reciprocal expression regulation of miR-31 and SOX4 in esophageal squamous and adenocarcinoma cell lines by qRT-PCR and Western blotting using overexpression and shRNA knock-down approaches. Furthermore, methylation studies were used to assess epigenetic regulation of expression. Functionally, we determined the cellular consequences using migration and invasion assays, as well as proliferation assays. Immunoprecipitation and ChIP were used to identify complex formation of SOX4 and co-repressor components.
   Results: Here, we report that SOX4 promotes esophageal tumor cell proliferation and invasion by silencing miR-31 via activation and stabilization of a co-repressor complex with EZH2 and HDAC3. We demonstrate that miR-31 is significantly decreased in invasive esophageal cancer cells, while upregulation of miR-31 inhibits growth, migration and invasion of esophageal adenocarcinoma (EAC) and squamous cell carcinoma (ESCC) cell lines. miR-31, in turn, targets SOX4 for degradation by directly binding to its 3'-UTR. Additionally, miR-31 regulates EZH2 and HDAC3 indirectly. SOX4, EZH2 and HDAC3 levels inversely correlate with miR-31 expression in ESCC cell lines. Ectopic expression of miR-31 in ESCC and EAC cell lines leads to down regulation of SOX4, EZH2 and HDAC3. Conversely, pharmacologic and genetic inhibition of SOX4 and EZH2 restore miR-31 expression. We show that SOX4, EZH2 and HDAC3 form a co-repressor complex that binds to the miR-31 promoter, repressing miR-31 through an epigenetic mark by H3K27me3 and by histone acetylation. Clinically, when compared to normal adjacent tissues, esophageal tumor samples show upregulation of SOX4, EZH2, and HDAC3, and EZH2 expression is significantly increased in metastatic ESCC tissues.
   Conclusions: Thus, we identified a novel molecular mechanism by which the SOX4, EZH2 and miR-31 circuit promotes tumor progression and potential therapeutic targets for invasive esophageal carcinomas.
C1 [Koumangoye, Rainelli B.; Taubenslag, Kenneth J.; Zilberman, Steven T.; Taylor, Chase J.; Andl, Claudia D.] Dept Surg, Nashville, TN 37232 USA.
   [Andl, Thomas] Dept Med, Div Dermatol, Nashville, TN 37232 USA.
   [Loomans, Holli A.; Andl, Claudia D.] Dept Canc Biol, Nashville, TN 37232 USA.
   [Andl, Claudia D.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Med Ctr, Nashville, TN 37232 USA.
   [Andl, Claudia D.] Vanderbilt Univ, Vanderbilt Digest Dis Ctr, Med Ctr, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University
RP Andl, CD (通讯作者)，Dept Surg, 2213 Garland Ave 10445 MRB 4, Nashville, TN 37232 USA.
EM claudia.andl@vanderbilt.edu
OI Andl, Thomas/0000-0002-5555-468X; Loomans-Kropp,
   Holli/0000-0002-9681-8725
FU National Institute of Health [DK94900, DK091491]; Vanderbilt Ingram
   Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research
   Center [P30 DK058404]; National Center for Research Resources [UL1
   RR024975-01]; National Center for Advancing Translational Sciences [2
   UL1 TR000445-06]
FX This work was supported by the National Institute of Health (DK94900,
   DK091491). The use of Research Cores is supported by the Vanderbilt
   Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease
   Research Center (P30 DK058404). Further support is from the National
   Center for Research Resources, Grant UL1 RR024975-01, and is now at the
   National Center for Advancing Translational Sciences, Grant 2 UL1
   TR000445-06. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the NIH. We would
   like to thank Drs. Jeff Franklin and Christine Eischen for critical
   discussion of the manuscript.
CR Andl CD, 2010, NEOPLASIA, V12, P485, DOI 10.1593/neo.10216
   Asangani IA, 2012, ONCOTARGET, V3, P1011, DOI 10.18632/oncotarget.622
   Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5
   Bandrés E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29
   Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008
   Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chen Z, 2013, CANCER-AM CANCER SOC, V119, P1985, DOI 10.1002/cncr.28002
   Creighton CJ, 2010, CANCER RES, V70, P1906, DOI 10.1158/0008-5472.CAN-09-3875
   Deneault E, 2009, CELL, V137, P369, DOI 10.1016/j.cell.2009.03.026
   Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162
   Fuse M, 2012, J HUM GENET, V57, P691, DOI 10.1038/jhg.2012.95
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111
   Hötte GJ, 2012, RADIAT RES, V177, P272, DOI 10.1667/RR2776.1
   Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kobielak K, 2007, P NATL ACAD SCI USA, V104, P10063, DOI 10.1073/pnas.0703004104
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004
   Leidner RS, 2012, GENE CHROMOSOME CANC, V51, P473, DOI 10.1002/gcc.21934
   Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968
   Lin RJ, 2012, J SURG ONCOL, V105, P175, DOI 10.1002/jso.22066
   Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291
   Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lynam-Lennon N, 2012, J MOL MED, V90, P1449, DOI 10.1007/s00109-012-0924-x
   NISHIHIRA T, 1993, J CANCER RES CLIN, V119, P441, DOI 10.1007/BF01215923
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101
   Saad R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064463
   Sakai NS, 2013, SEMIN CANCER BIOL, V23, P512, DOI 10.1016/j.semcancer.2013.08.005
   Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415
   Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   SHIMADA Y, 1992, CANCER, V69, P277, DOI 10.1002/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Tantin D, 2013, JOVE-J VIS EXP, DOI 10.3791/50064
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Vervoort SJ, 2013, ONCOGENE, V32, P3397, DOI 10.1038/onc.2012.506
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang TF, 2011, CLIN SCI, V121, P437, DOI 10.1042/CS20110207
   Zhang XW, 2012, CANCER CELL, V22, P506, DOI 10.1016/j.ccr.2012.09.003
NR 53
TC 106
Z9 114
U1 0
U2 13
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD FEB 3
PY 2015
VL 14
AR 24
DI 10.1186/s12943-014-0284-y
PG 16
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA CE7CF
UT WOS:000351993900001
PM 25644061
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Swellam, M
   Abdelmaksoud, MDE
   Mahmoud, MS
   Ramadan, A
   Abdel-Moneem, W
   Hefny, MM
AF Swellam, Menha
   Abdelmaksoud, Mohamed D. E.
   Mahmoud, Magda Sayed
   Ramadan, Amal
   Abdel-Moneem, Walid
   Hefny, Mona M.
TI Aberrant Methylation of <i>APC</i> and <i>RARβ<sub>2</sub></i> Genes in
   Breast Cancer Patients
SO IUBMB LIFE
LA English
DT Article
DE DNA methylation; breast cancer; early diagnosis RAR(2); APC
ID PROMOTER HYPERMETHYLATION; LUNG-CANCER; SERUM DNA; TUMOR; PLASMA; URINE;
   HYPOMETHYLATION; FLUID
AB Changes in the status of DNA methylation are one of the most common molecular alterations in human neoplasia. We aimed to identify epigenetic molecular markers in serum for early detection of breast cancer. Authors analyzed retrospectively the methylation status of RAR(2) and APC genes in serum samples from 121 breast cancer patients, 79 patients with benign breast diseases, and 66 healthy volunteers using methylation-specific PCR. The methylated APC and RAR(2) were significantly higher in breast cancer patients (93.4%, 95.6%) than benign (7.8%, 14.5%) but not detected in healthy volunteers (0%) at (P<0.0001). Both methylated genes showed no significant difference among clinicopathological factors apart from triple negative breast cancer patients as all of them ((2)=7.4, P=0.007) reported to be methylated RAR(2) genes. Both methylated genes were detected in all grades and stages. Both sensitivities and specificities of the methylated genes for breast cancer detection were superior to traditional tumor markers in detection of breast cancer, early stage, low grade tumors, and triple negative breast cancer patients. Thus methylated APC and RAR(2) genes might be valuable serum-based molecular markers for early detection of breast cancer. (c) 2015 IUBMB Life, 67(1):61-68, 2015
C1 [Swellam, Menha; Abdelmaksoud, Mohamed D. E.; Mahmoud, Magda Sayed; Ramadan, Amal] Natl Res Ctr, Genet Engn & Biotechnol Res Div, Dept Biochem, Giza 12622, Egypt.
   [Abdel-Moneem, Walid] Ain Shams Univ, Fac Med, Deptartment Radiat Oncol & Nucl Med, Cairo, Egypt.
   [Hefny, Mona M.] Ain Shams Univ, Fac Med, Dept Biochem, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); National Research Centre (NRC); Egyptian
   Knowledge Bank (EKB); Ain Shams University; Egyptian Knowledge Bank
   (EKB); Ain Shams University
RP Swellam, M (通讯作者)，Natl Res Ctr, Genet Engn & Biotechnol Res Div, Dept Biochem, El Bohouth St, Giza 12622, Egypt.
EM menha_m_swellam@yahoo.com
RI Swellam, Menha/AAM-8789-2020
OI mahmoud, magda sayed/0000-0002-9914-8739; Abd El-Maksoud, Mohamed
   .D.E/0000-0002-6535-5668; Ramadan, Amal/0000-0001-9158-9559
CR Ahrendt SA, 1999, JNCI-J NATL CANCER I, V91, P332, DOI 10.1093/jnci/91.4.332
   Bae Young Kyung, 2005, Cancer Res Treat, V37, P233, DOI 10.4143/crt.2005.37.4.233
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   CHIOU HC, 1994, NUCLEIC ACIDS RES, V22, P5439, DOI 10.1093/nar/22.24.5439
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   COUCH FJ, 2001, METABOLIC MOL BASIS, P999
   Eissa S, 2011, CANCER EPIDEM BIOMAR, V20, P1657, DOI 10.1158/1055-9965.EPI-11-0237
   Esteller M, 1999, CANCER RES, V59, P67
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Greene FL, 2008, CA-CANCER J CLIN, V58, P180, DOI 10.3322/CA.2008.0001
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Kawasaki H., 2013, Per Med Univ., V2, P20, DOI [10.1016/j.pmu.2013.04.007, DOI 10.1016/J.PMU.2013.04.007]
   Krassenstein R, 2004, CLIN CANCER RES, V10, P28, DOI 10.1158/1078-0432.CCR-0410-3
   Omar S, 2003, East Mediterr Health J, V9, P448
   Papadopoulou E, 2006, ANN NY ACAD SCI, V1075, P235, DOI 10.1196/annals.1368.032
   ROBBINS P, 1995, HUM PATHOL, V26, P873, DOI 10.1016/0046-8177(95)90010-1
   Sambrook J., 2001, MOL CLONING LAB MANU, V5, P14
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Seifert HH, 2007, EXP MOL PATHOL, V82, P292, DOI 10.1016/j.yexmp.2006.08.002
   Swift-Scanlan T, 2011, CANCER BIOL THER, V11, P853, DOI 10.4161/cbt.11.10.15177
   Virmani AK, 2001, CLIN CANCER RES, V7, P1998
   Wong IHN, 1999, CANCER RES, V59, P71
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 25
TC 33
Z9 35
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD JAN
PY 2015
VL 67
IS 1
BP 61
EP 68
DI 10.1002/iub.1346
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CE4BU
UT WOS:000351776600009
PM 25684670
OA Bronze
DA 2025-01-12
ER

PT J
AU He, D
   Zhang, YW
   Zhang, NN
   Zhou, L
   Chen, JN
   Jiang, Y
   Shao, CK
AF He, Dan
   Zhang, Yi-wang
   Zhang, Na-na
   Zhou, Lu
   Chen, Jian-ning
   Jiang, Ye
   Shao, Chun-kui
TI Aberrant gene promoter methylation of <i>p16</i>, <i>FHIT</i>,
   <i>CRBP1</i>, <i>WWOX</i>, and <i>DLC</i>-<i>1</i> in Epstein-Barr
   virus-associated gastric carcinomas
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Epstein-Barr virus-associated gastric carcinoma; Methylation; p16; FHIT;
   CRBP1; WWOX; DLC-1
ID SQUAMOUS-CELL CARCINOMA; CPG-ISLAND METHYLATION; TUMOR-SUPPRESSOR GENE;
   DNA METHYLATION; CLINICOPATHOLOGICAL FEATURES; BREAST-CANCER;
   MICROSATELLITE INSTABILITY; HEPATOCELLULAR-CARCINOMA; EPIGENETIC
   ALTERATIONS; PROTEIN EXPRESSION
AB Alterations in global DNA methylation and specific regulatory gene methylation are frequently found in cancer, but the significance of these epigenetic changes in EBV-associated gastric carcinoma (EBVaGC) remains unclear. We evaluated global DNA methylation status in 49 EBVaGC and 45 EBV-negative gastric carcinoma (EBVnGC) tissue samples and cell lines by 5-methylcytosine immunohistochemical staining and methylation quantification. We determined promoter methylation status and protein expression for the p16, FHIT, CRBP1, WWOX, and DLC-1 genes in tissues and studied the correlation between CpG island methylator phenotype (CIMP) class and clinicopathological characteristics. Changes in gene methylation and mRNA expression in EBVaGC cell line SNU-719 and in EBVnGC cell lines SGC-7901, BGC-823, and AGS were assessed after treatment with 5-aza-2'-deoxycytidine (5-aza-dC), trichostatin A (TSA), or a combination of both, by methylation-specific PCR and quantitative real-time RT-PCR. Global genomic DNA hypomethylation was more pronounced in EBVnGC than in EBVaGC. Promoter methylation of all five genes was more frequent in EBVaGC than in EBVnGC (p < 0.05). p16 and FHIT methylation was reversely correlated with protein expression in EBVaGC. Most (41/49) EBVaGC exhibited CIMP-high (CIMP-H), and the prognosis of CIMP-H patients was significantly worse than that of CIMP-low (p = 0.027) and CIMP-none (p = 0.003) patients. Treatment with 5-aza-dC and/or TSA induced upregulation of RNA expression of all five genes in SNU-719; meanwhile, individual gene expression increased in EBVnGC cell lines. In summary, EBV-induced hypermethylation of p16, FHIT, CRBP1, WWOX, and DLC-1 may contribute to EBVaGC development. Demethylation therapy may represent a novel therapeutic strategy for EBVaGC.
C1 [He, Dan; Zhang, Yi-wang; Zhang, Na-na; Zhou, Lu; Chen, Jian-ning; Jiang, Ye; Shao, Chun-kui] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, Guangzhou 510630, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Shao, CK (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 3, Dept Pathol, 600 Tianhe Rd, Guangzhou 510630, Guangdong, Peoples R China.
EM chunkuishao2011@163.com
RI Zhang, Ruiyan/HHC-5329-2022; Zhang, Juan/GRX-2638-2022
FU National Natural Science Foundation of China [81272553]; Guangdong
   Natural Science Foundation [S2012020010898]; Guangdong Province, China;
   Guangzhou Science and Technology Project, Guangdong Province, China
   [2011J4100106]
FX This study was supported by National Natural Science Foundation of China
   (No. 81272553), Guangdong Natural Science Foundation (No.
   S2012020010898), Guangdong Province, China, and Guangzhou Science and
   Technology Project (No. 2011J4100106), Guangdong Province, China.
CR Akiba S, 2008, CANCER SCI, V99, P195, DOI 10.1111/j.1349-7006.2007.00674.x
   Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451
   Cavusoglu AC, 2010, NEOPLASMA, V57, P465, DOI 10.4149/neo_2010_05_465
   Chang MS, 2006, CLIN CANCER RES, V12, P2995, DOI 10.1158/1078-0432.CCR-05-1601
   Chang MS, 2003, J PATHOL, V199, P447, DOI 10.1002/path.1302
   Chen JN, 2010, J MED VIROL, V82, P658, DOI 10.1002/jmv.21731
   Chong JM, 2003, CANCER SCI, V94, P76, DOI 10.1111/j.1349-7006.2003.tb01355.x
   Dumon KR, 2001, CANCER RES, V61, P4827
   Esteller M, 2002, CANCER RES, V62, P5902
   Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102
   Leal MF, 2007, WORLD J GASTROENTERO, V13, P2568, DOI 10.3748/wjg.v13.i18.2568
   Goldberg M, 2006, BRIT J DERMATOL, V155, P1154, DOI 10.1111/j.1365-2133.2006.07433.x
   Gopisetty G, 2006, MOL IMMUNOL, V43, P1729, DOI 10.1016/j.molimm.2005.11.010
   Guo W, 2013, ENVIRON MOL MUTAGEN, V54, P112, DOI 10.1002/em.21748
   He Dan, 2010, Chin J Cancer, V29, P283
   Hutajulu SH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-48
   Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398
   Jablonowski Z, 2011, ARCH MED SCI, V7, P512, DOI 10.5114/aoms.2011.23421
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Kawano H, 2014, ANN SURG ONCOL, V21, pS696, DOI 10.1245/s10434-014-3818-z
   Kim JH, 2009, ONCOL REP, V21, P1251, DOI 10.3892/or_00000348
   Kim JS, 2004, CARCINOGENESIS, V25, P2165, DOI 10.1093/carcin/bgh217
   Kim NR, 2005, J KOREAN MED SCI, V20, P636, DOI 10.3346/jkms.2005.20.4.636
   Kim TY, 2003, ONCOGENE, V22, P3943, DOI 10.1038/sj.onc.1206573
   Koriyama C, 2004, ONCOLOGY-BASEL, V67, P81, DOI 10.1159/000080290
   Kuppumbatti YS, 2000, J NATL CANCER I, V92, P475, DOI 10.1093/jnci/92.6.475
   Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096
   Kusano M, 2006, CANCER-AM CANCER SOC, V106, P1467, DOI 10.1002/cncr.21789
   Lee HS, 2004, CLIN CANCER RES, V10, P1698, DOI 10.1158/1078-0432.CCR-1122-3
   Lee JH, 2009, J GASTROEN HEPATOL, V24, P354, DOI 10.1111/j.1440-1746.2009.05775.x
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Maruyama R, 2002, CLIN CANCER RES, V8, P514
   Matsusaka K, 2011, CANCER RES, V71, P7187, DOI 10.1158/0008-5472.CAN-11-1349
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Nagai H, 1999, DNA Res, V6, P219, DOI 10.1093/dnares/6.4.219
   Nakayama S, 2009, BRIT J CANCER, V100, P1438, DOI 10.1038/sj.bjc.6604986
   Ogino S, 2008, INT J CANCER, V122, P2767, DOI 10.1002/ijc.23470
   Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034
   Peralta R, 2010, J CANCER RES CLIN, V136, P931, DOI 10.1007/s00432-009-0735-9
   Piyathilake CJ, 2001, HUM PATHOL, V32, P856, DOI 10.1053/hupa.2001.26471
   Plaumann M, 2003, J CANCER RES CLIN, V129, P349, DOI 10.1007/s00432-003-0440-z
   Qin HR, 2006, CANCER RES, V66, P6477, DOI 10.1158/0008-5472.CAN-06-0956
   Richards KL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004941
   Ryan Julie L, 2010, Infect Agent Cancer, V5, P27, DOI 10.1186/1750-9378-5-27
   Sakuma K, 2004, INT J CANCER, V112, P273, DOI 10.1002/ijc.20420
   Alves MKS, 2011, PATHOBIOLOGY, V78, P266, DOI 10.1159/000329475
   SHIBATA D, 1992, AM J PATHOL, V140, P769
   Shim YH, 2000, LAB INVEST, V80, P689, DOI 10.1038/labinvest.3780072
   Shutoh M, 2005, CANCER-AM CANCER SOC, V104, P1609, DOI 10.1002/cncr.21392
   Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M
   Sudo M, 2004, INT J CANCER, V109, P194, DOI 10.1002/ijc.11701
   Suzuki M, 2006, CANCER LETT, V242, P222, DOI 10.1016/j.canlet.2005.11.002
   Toyota M, 1999, CANCER RES, V59, P5438
   Tripathi SC, 2012, MODERN PATHOL, V25, P14, DOI 10.1038/modpathol.2011.145
   Uozaki H, 2008, INT J CLIN EXP PATHO, V1, P198
   Ushiku T, 2007, INT J CANCER, V120, P60, DOI 10.1002/ijc.22275
   van Rees BP, 2002, AM J PATHOL, V161, P1207, DOI 10.1016/S0002-9440(10)64397-0
   de Castro SV, 2012, REV ESP ENFERM DIG, V104, P111, DOI 10.4321/s1130-01082012000300002
   Wong CM, 2003, CANCER RES, V63, P7646
   Xiao YP, 2005, WORLD J GASTROENTERO, V11, P3212, DOI 10.3748/wjg.v11.i21.3212
   Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452
   Zhang B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028882
   Zhang P, 2012, MOL MED REP, V6, P121, DOI 10.3892/mmr.2012.860
   Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246
NR 64
TC 62
Z9 70
U1 0
U2 8
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD APR
PY 2015
VL 32
IS 4
AR 92
DI 10.1007/s12032-015-0525-y
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CE0DG
UT WOS:000351474100006
PM 25720522
DA 2025-01-12
ER

PT J
AU Raha, P
   Thomas, S
   Thurn, KT
   Park, J
   Munster, PN
AF Raha, Paromita
   Thomas, Scott
   Thurn, K. Ted
   Park, Jeenah
   Munster, Pamela N.
TI Combined histone deacetylase inhibition and tamoxifen induces apoptosis
   in tamoxifen- resistant breast cancer models, by reversing Bcl-2
   overexpression
SO BREAST CANCER RESEARCH
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; PHASE-II; C-MYC;
   PROGESTERONE-RECEPTOR; THERAPY; ACTIVATION; MECHANISMS; GROWTH; CELLS
AB Introduction: The emergence of hormone therapy resistance, despite continued expression of the estrogen receptor ( ER), is a major challenge to curing breast cancer. Recent clinical studies suggest that epigenetic modulation by histone deacetylase ( HDAC) inhibitors reverses hormone therapy resistance. However, little is known about epigenetic modulation of the ER during acquired hormone resistance. Our recent phase II study demonstrated that HDAC inhibitors re- sensitize hormone therapy- resistant tumors to the anti- estrogen tamoxifen. In this study, we sought to understand the mechanism behind the efficacy of this combination. Methods: We generated cell lines resistant to tamoxifen, named TAMRM and TAMRT, by continuous exposure of ER- positive MCF7 and T47D cells, respectively to 4- hydroxy tamoxifen for over 12 months. HDAC inhibition, along with pharmacological and genetic manipulation of key survival pathways, including ER and Bcl- 2, were used to characterize these resistant models. Results: The TAMRM cells displayed decreased sensitivity to tamoxifen, fulvestrant and estrogen deprivation. Consistent with previous models, ER expression was retained and the gene harbored no mutations. Compared to parental MCF7 cells, ER expression in TAMRM was elevated, while progesterone receptor ( PGR) was lost. Sensitivity of ER to ligands was greatly reduced and classic ER response genes were suppressed. This model conveyed tamoxifen resistance through transcriptional upregulation of Bcl- 2 and c- Myc, and downregulation of the cell cycle checkpoint protein p21, manifesting in accelerated growth and reduced cell death. Similar to TAMRM cells, the TAMRT cell line exhibited substantially decreased tamoxifen sensitivity, increased ER and Bcl- 2 expression and significantly reduced PGR expression. Treatment with HDAC inhibitors reversed the altered transcriptional events and reestablished the sensitivity of the ER to tamoxifen resulting in substantial Bcl- 2 downregulation, growth arrest and apoptosis. Selective inhibition of Bcl- 2 mirrored these effects in presence of an HDAC inhibitor. Conclusions: Our model implicates elevated ER and Bcl- 2 as key drivers of anti- estrogen resistance, which can be reversed by epigenetic modulation through HDAC inhibition.
C1 [Raha, Paromita; Thomas, Scott; Thurn, K. Ted; Park, Jeenah; Munster, Pamela N.] Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, San Francisco, CA 94115 USA.
C3 University of California System; University of California San Francisco
RP Munster, PN (通讯作者)，Univ Calif San Francisco, Dept Med, Div Hematol & Oncol, 1600 Div St,Room A722,Box 1770, San Francisco, CA 94115 USA.
EM pmunster@medicine.ucsf.edu
RI Thomas, Scott/AAF-2683-2020; Raha, Paromita/AAJ-1559-2020
OI Raha, Paromita/0000-0002-6941-1495
CR Adamo V, 2007, ANN ONCOL, V18, P53, DOI 10.1093/annonc/mdm225
   BADIA E, 1994, CANCER RES, V54, P5860
   Bergan RC, 1999, CLIN CANCER RES, V5, P2366
   Biçaku E, 2008, CANCER RES, V68, P1513, DOI 10.1158/0008-5472.CAN-07-2822
   BRUNNER N, 1993, CANCER RES, V53, P3229
   de Leeuw R, 2013, ONCOGENE, V32, P3543, DOI 10.1038/onc.2012.361
   DEFAZIO A, 1992, J BIOL CHEM, V267, P18008
   Dong LA, 1999, J BIOL CHEM, V274, P32099, DOI 10.1074/jbc.274.45.32099
   DUBIK D, 1988, J BIOL CHEM, V263, P12705
   Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Gutierrez MC, 2005, J CLIN ONCOL, V23, P2469, DOI 10.1200/JCO.2005.01.172
   HELLEMANS P, 1995, BRIT J CANCER, V72, P354, DOI 10.1038/bjc.1995.338
   Hirokawa Y, 2005, CANCER BIOL THER, V4, P956, DOI 10.4161/cbt.4.9.1911
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   JOHNSTON SRD, 1995, CANCER RES, V55, P3331
   JOHNSTON SRD, 1994, EUR J CANCER, V30A, P1663, DOI 10.1016/0959-8049(94)00327-2
   Kim YH, 2003, BIOCHEM PHARMACOL, V66, P1779, DOI 10.1016/S0006-2952(03)00545-8
   Kurebayashi Junichi, 2003, Breast Cancer, V10, P112, DOI 10.1007/BF02967635
   Mandal S, 2010, J CELL PHYSIOL, V224, P28, DOI 10.1002/jcp.22078
   Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707
   Matthews GM, 2012, ADV CANCER RES, V116, P165, DOI 10.1016/B978-0-12-394387-3.00005-7
   Miller TW, 2011, CLIN CANCER RES, V17, P2024, DOI 10.1158/1078-0432.CCR-10-2567
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   NAWATA H, 1981, J BIOL CHEM, V256, P6895
   NAWATA H, 1981, J BIOL CHEM, V256, P5016
   Ocker M, 2007, INT J BIOCHEM CELL B, V39, P1367, DOI 10.1016/j.biocel.2007.03.001
   Oie S, 2013, BIOCHEM BIOPH RES CO, V432, P236, DOI 10.1016/j.bbrc.2013.02.007
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629
   Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Planas-Silva MD, 2007, EXP MOL PATHOL, V82, P85, DOI 10.1016/j.yexmp.2006.09.001
   Plotkin A, 2014, BREAST CANCER RES TR, V147, P249, DOI 10.1007/s10549-014-3093-5
   Raha P, 2011, EPIGENOMICS-UK, V3, P451, DOI [10.2217/epi.11.72, 10.2217/EPI.11.72]
   Raisova M, 2002, FEBS LETT, V516, P47, DOI 10.1016/S0014-5793(02)02472-9
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Silvestrini R, 1996, J CLIN ONCOL, V14, P1604, DOI 10.1200/JCO.1996.14.5.1604
   Stone A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040466
   Strasser A, 2011, EMBO J, V30, P3667, DOI 10.1038/emboj.2011.307
   Thomas S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068973
   Thomas S, 2011, BREAST CANCER RES TR, V130, P437, DOI 10.1007/s10549-011-1364-y
   Thrane S, 2013, BREAST CANCER RES TR, V139, P71, DOI 10.1007/s10549-013-2485-2
   Thurn KT, 2011, FUTURE ONCOL, V7, P263, DOI [10.2217/fon.11.2, 10.2217/FON.11.2]
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   TRUMP DL, 1992, JNCI-J NATL CANCER I, V84, P1811, DOI 10.1093/jnci/84.23.1811
   Vaillant F, 2013, CANCER CELL, V24, P120, DOI 10.1016/j.ccr.2013.06.002
   Wang CY, 2011, MOL ENDOCRINOL, V25, P1527, DOI 10.1210/me.2011-1037
   Wang Y, 2012, J CHEMOTHERAPY, V24, P348, DOI 10.1179/1973947812Y.0000000049
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Yardley DA, 2013, J CLIN ONCOL, V31, P2128, DOI 10.1200/JCO.2012.43.7251
NR 52
TC 74
Z9 83
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PD FEB 25
PY 2015
VL 17
AR 26
DI 10.1186/s13058-015-0533-z
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CE3LO
UT WOS:000351728100001
PM 25848915
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Lin, IH
   Chen, DT
   Chang, YF
   Lee, YL
   Su, CH
   Cheng, C
   Tsai, YC
   Ng, SC
   Chen, HT
   Lee, MC
   Chen, HW
   Suen, SH
   Chen, YC
   Liu, TT
   Chang, CH
   Hsu, MT
AF Lin, I-Hsuan
   Chen, Dow-Tien
   Chang, Yi-Feng
   Lee, Yu-Ling
   Su, Chia-Hsin
   Cheng, Ching
   Tsai, Yi-Chien
   Ng, Swee-Chuan
   Chen, Hsiao-Tan
   Lee, Mei-Chen
   Chen, Hong-Wei
   Suen, Shih-Hui
   Chen, Yu-Cheng
   Liu, Tze-Tze
   Chang, Chuan-Hsiung
   Hsu, Ming-Ta
TI Hierarchical Clustering of Breast Cancer Methylomes Revealed
   Differentially Methylated and Expressed Breast Cancer Genes
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; DECREASED EXPRESSION; ABERRANT EXPRESSION; RECEPTOR
   STATUS; X-INACTIVATION; HYPOMETHYLATION; TRANSCRIPTION; PLURIPOTENT;
   INSIGHTS; EPIGENOMICS
AB Oncogenic transformation of normal cells often involves epigenetic alterations, including histone modification and DNA methylation. We conducted whole-genome bisulfite sequencing to determine the DNA methylomes of normal breast, fibroadenoma, invasive ductal carcinomas and MCF7. The emergence, disappearance, expansion and contraction of kilobase-sized hypomethylated regions (HMRs) and the hypomethylation of the megabasesized partially methylated domains (PMDs) are the major forms of methylation changes observed in breast tumor samples. Hierarchical clustering of HMR revealed tumor-specific hypermethylated clusters and differential methylated enhancers specific to normal or breast cancer cell lines. Joint analysis of gene expression and DNA methylation data of normal breast and breast cancer cells identified differentially methylated and expressed genes associated with breast and/ or ovarian cancers in cancer-specific HMR clusters. Furthermore, aberrant patterns of X-chromosome inactivation (XCI) was found in breast cancer cell lines as well as breast tumor samples in the TCGA BRCA (breast invasive carcinoma) dataset. They were characterized with differentially hypermethylated XIST promoter, reduced expression of XIST, and over-expression of hypomethylated X-linked genes. High expressions of these genes were significantly associated with lower survival rates in breast cancer patients. Comprehensive analysis of the normal and breast tumor methylomes suggests selective targeting of DNA methylation changes during breast cancer progression. The weak causal relationship between DNA methylation and gene expression observed in this study is evident of more complex role of DNA methylation in the regulation of gene expression in human epigenetics that deserves further investigation.
C1 [Lin, I-Hsuan; Chen, Dow-Tien; Ng, Swee-Chuan; Chen, Hsiao-Tan; Lee, Mei-Chen; Chen, Hong-Wei; Suen, Shih-Hui; Chen, Yu-Cheng; Liu, Tze-Tze; Hsu, Ming-Ta] Natl Yang Ming Univ, VGH YM Genome Ctr, Taipei 112, Taiwan.
   [Lin, I-Hsuan; Lee, Yu-Ling; Su, Chia-Hsin; Cheng, Ching; Tsai, Yi-Chien; Hsu, Ming-Ta] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Chang, Chuan-Hsiung] Natl Yang Ming Univ, Ctr Syst & Synthet Biol, Taipei 112, Taiwan.
   [Chang, Yi-Feng; Chang, Chuan-Hsiung] Natl Yang Ming Univ, Inst Biomed Informat, Taipei 112, Taiwan.
C3 National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University
RP Hsu, MT (通讯作者)，Natl Yang Ming Univ, VGH YM Genome Ctr, Taipei 112, Taiwan.
EM mth@ym.edu.tw
RI Chang, Ian/U-3571-2019; chen, yu-cheng/IQT-1648-2023; Chen,
   Hongwei/AAN-2868-2020; Chen, Tim/W-7970-2019; Liu, Scott/AAC-7891-2021;
   Lin, I-Hsuan/N-6501-2013
OI Lee, Yu-Ling/0000-0003-1897-9918; Lin, I-Hsuan/0000-0002-6207-1299;
   Chang, Ian/0000-0001-5840-2051
FU Ministry of Education, Taiwan; National Core Facility Program for
   Biotechnology, Taiwan [NSC 102-2319-B-010-001]; National Research
   Program for Biopharmaceuticals, Taiwan [NSC 102-2325-B-492-001];
   National Center for High-performance Computing of National Applied
   Research Laboratories, Taiwan
FX This work was supported by Aim for the Top University Plan from the
   Ministry of Education, Taiwan. The authors acknowledge the
   High-throughput Genome Analysis Core Facility of National Core Facility
   Program for Biotechnology, Taiwan (NSC 102-2319-B-010-001), for their
   sequencing services. The authors also thank the National Research
   Program for Biopharmaceuticals, Taiwan (NSC 102-2325-B-492-001) and
   National Center for High-performance Computing of National Applied
   Research Laboratories, Taiwan for providing computational and storage
   resources. The funders had no role in study design, data collection and
   analysis, decision to publish or preparation of the manuscript.
CR Anguera MC, 2012, CELL STEM CELL, V11, P75, DOI 10.1016/j.stem.2012.03.008
   Araujo FD, 1999, J BIOL CHEM, V274, P9335, DOI 10.1074/jbc.274.14.9335
   Avraham A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091805
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chalamalasetty RB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1381
   Chaligné R, 2014, FEBS LETT, V588, P2514, DOI 10.1016/j.febslet.2014.06.023
   Cohen J., 1988, STAT POWER ANAL BEHA, DOI 10.4324/9780203771587
   Davies MN, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r43
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Futscher BW, 2004, NEOPLASIA, V6, P380, DOI 10.1593/neo.04115
   Gupta A, 2003, CANCER RES, V63, P664
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356
   Han LL, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-52
   Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hovestadt V, 2014, NATURE, V510, P537, DOI 10.1038/nature13268
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Illingworth R, 2008, PLOS BIOL, V6, P37, DOI 10.1371/journal.pbio.0060022
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kuchiba A, 2014, BRIT J CANCER, V110, P2765, DOI 10.1038/bjc.2014.223
   Kundaje A, ASSESSMENT CHI UNPUB
   Kundaje A, REPROD MEASURE UNPUB
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Li H., 2013, arXiv, P1303, DOI DOI 10.48550/ARXIV.1303.3997
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Li YR, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000533
   Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009
   Locke WJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3237
   Lung HL, 2005, ONCOGENE, V24, P6525, DOI 10.1038/sj.onc.1208812
   Marzese DM, 2014, HUM MOL GENET, V23, P226, DOI 10.1093/hmg/ddt420
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Molaro A, 2011, CELL, V146, P1028, DOI 10.1016/j.cell.2011.08.016
   Park YJ, 2011, PROG DRUG RES, V67, P25, DOI 10.1007/978-3-7643-8989-5_2
   Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Reyngold M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103896
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Schlesinger F, 2013, GENOME RES, V23, P1601, DOI 10.1101/gr.157271.113
   Shann YJ, 2008, GENOME RES, V18, P791, DOI 10.1101/gr.070961.107
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Song Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081148
   Sproul D, 2013, BRIEF FUNCT GENOMICS, V12, P174, DOI 10.1093/bfgp/els063
   Stirzaker C, 2014, TRENDS GENET, V30, P75, DOI 10.1016/j.tig.2013.11.004
   Taberlay PC, 2014, GENOME RES, DOI [10.1101/gr.174730.114, DOI 10.1101/GR.174730.114]
   Thakur A, 2007, MOL CANCER RES, V5, P171, DOI 10.1158/1541-7786.MCR-06-0071
   Tsai Yi-Chien, 2011, Cancers (Basel), V3, P1996, DOI 10.3390/cancers3021996
   Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391
   Wang CY, 2012, BREAST CANCER RES TR, V134, P101, DOI 10.1007/s10549-011-1925-0
   Wang CY, 2011, MOL ENDOCRINOL, V25, P1527, DOI 10.1210/me.2011-1037
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Wutz A, 2000, MOL CELL, V5, P695, DOI 10.1016/S1097-2765(00)80248-8
   Yamashita K, 2013, INT J MOL SCI, V14, P23231, DOI 10.3390/ijms141223231
   Yu YP, 2013, AM J PATHOL, V183, P1960, DOI 10.1016/j.ajpath.2013.08.018
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhang YC, 2013, MOL BIOL EVOL, V30, P2588, DOI 10.1093/molbev/mst148
   Zhao H, 2014, BIOINFORMATICS, V30, P1006, DOI 10.1093/bioinformatics/btt730
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 75
TC 27
Z9 30
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 23
PY 2015
VL 10
IS 2
AR e0118453
DI 10.1371/journal.pone.0118453
PG 30
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC9BI
UT WOS:000350662100182
PM 25706888
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Romagnolo, APG
   Romagnolo, DF
   Selmin, OI
AF Romagnolo, Alberto P. G.
   Romagnolo, Donato F.
   Selmin, Ornella I.
TI BRCA1 as Target for Breast Cancer Prevention and Therapy
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Breast Cancer; BRCA1; diet; gene regulation; prevention; therapy
ID ARYL-HYDROCARBON RECEPTOR; BRCA1-DEFICIENT MAMMARY-TUMORS; CELL-CYCLE
   KINETICS; PPAR-GAMMA AGONIST; ESTROGEN-RECEPTOR; DNA METHYLATION;
   SPORADIC BREAST; CPG METHYLATION; MESSENGER-RNA; PROMOTER
   HYPERMETHYLATION
AB The Breast Cancer 1 protein (BRCA1) is a tumor suppressor involved in basic cellular functions necessary for cell replication and DNA synthesis, but reduced expression of BRCA1, due to mutations or epigenetic inactivation, leads to impaired mammary gland differentiation and increased risk of breast cancer development. Although BRCA1 acts as a tumor suppressor and is present in all cells, where it is essential for the maintenance of the genome integrity, it is still not clear why mutations in the BRCA1 gene predispose to breast and ovarian, but not to other types of cancer. In the first part of this review, we briefly discuss the function and regulation of the BRCA1 protein, including its role associated with familial and sporadic breast cancer. The second part is an overview of the therapeutic compounds used for breast cancer treatment targeting BRCA1, and the natural food components that hold potential preventive effect against those types of breast cancer in which BRCA1 expression is either reduced or lacking. Further studies elucidating the interactions between dietary compounds and cellular pathways, involved in regulation of BRCA1 expression, are necessary for the development of strategies that may successfully prevent or treat breast cancer.
C1 [Romagnolo, Alberto P. G.; Romagnolo, Donato F.; Selmin, Ornella I.] Univ Arizona, Ctr Canc, Tucson, AZ 85724 USA.
   [Romagnolo, Donato F.; Selmin, Ornella I.] Univ Arizona, Dept Nutr Sci, Tucson, AZ 85724 USA.
C3 University of Arizona; University of Arizona
RP Selmin, OI (通讯作者)，Univ Arizona, Ctr Canc, 1515 N Campbell,Room 3999A, Tucson, AZ 85724 USA.
EM selmin@u.arizona.edu
RI Selmin, Ornella/ABC-8971-2020
FU U.S. ARMY Medical Research and Materiel Command [DAMD 10-1-0215];
   American Institute for Cancer Research [10A058]; Arizona Cancer Center
   [P30CA23074]
FX This manuscript was supported by U.S. ARMY Medical Research and Materiel
   Command (DAMD 10-1-0215), The American Institute for Cancer Research
   (10A058), and the Arizona Cancer Center Support Grant P30CA23074.
CR [Anonymous], MOL CARCINOG
   Ashworth A, 2004, NAT CELL BIOL, V6, P916, DOI 10.1038/ncb1004-916
   Auriol E, 2005, NUCLEIC ACIDS RES, V33, P4243, DOI 10.1093/nar/gki729
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105
   Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   BUZDAR AU, 1982, CANCER-AM CANCER SOC, V50, P1708, DOI 10.1002/1097-0142(19821101)50:9<1708::AID-CNCR2820500909>3.0.CO;2-8
   Cabanes A, 2004, CARCINOGENESIS, V25, P741, DOI 10.1093/carcin/bgh065
   Caruso JA, 1999, BIOCHEM PHARMACOL, V58, P1395, DOI 10.1016/S0006-2952(99)00225-7
   Chapman JR, 2012, MOL CELL, V47, P497, DOI 10.1016/j.molcel.2012.07.029
   Chatterjee R, 2012, BBA-GENE REGUL MECH, V1819, P763, DOI 10.1016/j.bbagrm.2012.02.014
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   COS S, 1991, J PINEAL RES, V10, P36, DOI 10.1111/j.1600-079X.1991.tb00007.x
   Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9
   Daidone MG, 2002, J CLIN ONCOL, V20, P3752, DOI 10.1200/JCO.2002.99.116
   Daley JM, 2014, MOL CELL BIOL, V34, P1380, DOI 10.1128/MCB.01639-13
   De Assis S, 2006, ANN NY ACAD SCI, V1089, P14, DOI 10.1196/annals.1386.039
   De Siervi A, 2010, CANCER RES, V70, P532, DOI 10.1158/0008-5472.CAN-09-1477
   Degner SC, 2009, J NUTR, V139, P26, DOI 10.3945/jn.108.099259
   Di LJ, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2438
   Di LJ, 2010, NAT STRUCT MOL BIOL, V17, P1406, DOI 10.1038/nsmb.1941
   DiNardo DNM, 2001, ONCOGENE, V20, P5331, DOI 10.1038/sj.onc.1204697
   Drost R, 2014, ONCOGENE, V33, P3753, DOI 10.1038/onc.2013.329
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001
   Fenton SE, 2002, TOXICOL SCI, V67, P63, DOI 10.1093/toxsci/67.1.63
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Gery S, 2005, CLIN CANCER RES, V11, P7243, DOI 10.1158/1078-0432.CCR-05-0231
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Gorski JJ, 2009, CLIN CANCER RES, V15, P1514, DOI 10.1158/1078-0432.CCR-08-0640
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482
   Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064
   Helferich W. G., 2008, Inflammopharmacology, V16, P219, DOI 10.1007/s10787-008-8020-0
   Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089
   Hilakivi-Clarke L, 1999, BRIT J CANCER, V80, P1682, DOI 10.1038/sj.bjc.6690584
   Hilakivi-Clarke L, 1998, MOL CELL BIOCHEM, V188, P5, DOI 10.1023/A:1006827229431
   Hilakivi-Clarke L, 2002, J STEROID BIOCHEM, V80, P163, DOI 10.1016/S0960-0760(01)00184-4
   Hill SM, 2009, INTEGR CANCER THER, V8, P337, DOI 10.1177/1534735409353332
   Hirshfield KM, 2014, CURR OPIN OBSTET GYN, V26, P34, DOI 10.1097/GCO.0000000000000038
   Hockings JK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1987
   Hockings JK, 2006, CANCER RES, V66, P2224, DOI 10.1158/0008-5472.CAN-05-1619
   Hooper K, 1998, ENVIRON HEALTH PERSP, V106, P797, DOI 10.2307/3434123
   Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207
   Jeffy BD, 1999, MOL CARCINOGEN, V26, P100, DOI 10.1002/(SICI)1098-2744(199910)26:2<100::AID-MC5>3.0.CO;2-1
   Jeffy BD, 2005, NEOPLASIA, V7, P873, DOI 10.1593/neo.05256
   Jeffy BD, 2002, CANCER RES, V62, P113
   Jeffy BD, 2000, NEOPLASIA, V2, P460, DOI 10.1038/sj.neo.7900104
   Jensen KA, 2006, MOL PHARMACEUT, V3, P695, DOI 10.1021/mp0600438
   Kang HJ, 2012, TOXICOL LETT, V209, P154, DOI 10.1016/j.toxlet.2011.12.002
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kotsopoulos J, 2014, BRIT J CANCER, V111, P1269, DOI 10.1038/bjc.2014.391
   Kurian AW, 2010, CURR OPIN OBSTET GYN, V22, P72, DOI 10.1097/GCO.0b013e328332dca3
   La Merrill M, 2010, ENVIRON HEALTH PERSP, V118, P596, DOI 10.1289/ehp.0901047
   Lalloo F, 2012, CLIN GENET, V82, P105, DOI 10.1111/j.1399-0004.2012.01859.x
   Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109
   Lewis BC, 2001, TOXICOL SCI, V62, P46, DOI 10.1093/toxsci/62.1.46
   Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369
   Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248
   Malaviya A, 2014, PPAR RES, V2014, DOI 10.1155/2014/439146
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Margalit O, 2012, CANCER PREV RES, V5, P1169, DOI 10.1158/1940-6207.CAPR-12-0365
   Milner, 2010, BIOACTIVE FOOD COMPO
   Miyamoto K, 2002, JPN J CLIN ONCOL, V32, P79, DOI 10.1093/jjco/hyf020
   Moy I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077543
   Nakles RE, 2013, AM J PATHOL, V182, P1976, DOI 10.1016/j.ajpath.2013.02.006
   Nguyen TA, 1999, ARCH BIOCHEM BIOPHYS, V367, P250, DOI 10.1006/abbi.1999.1282
   Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980
   Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683
   Olivo-Marston S.E., 2008, CANCER PREV RES, V1
   Pal T, 2014, ANTI-CANCER AGENT ME, V14, P872, DOI 10.2174/1871520614666140528155118
   Paltsev M, 2013, EPMA J, V4, DOI 10.1186/1878-5085-4-25
   Papoutsis AJ, 2012, J NUTR BIOCHEM, V23, P1324, DOI 10.1016/j.jnutbio.2011.08.001
   Papoutsis AJ, 2010, J NUTR, V140, P1607, DOI 10.3945/jn.110.123422
   PETERSON G, 1993, PROSTATE, V22, P335, DOI 10.1002/pros.2990220408
   Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943
   Piccart MJ, 2001, ANN ONCOL, V12, P1195, DOI 10.1023/A:1012259625746
   Privat M, 2009, BIOCHEM BIOPH RES CO, V379, P785, DOI 10.1016/j.bbrc.2008.12.151
   Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354
   REVICH BA, 2001, GIG SANIT, V6, P6
   Rigakos G, 2012, ONCOLOGIST, V17, P956, DOI 10.1634/theoncologist.2012-0028
   Rishi V, 2010, P NATL ACAD SCI USA, V107, P20311, DOI 10.1073/pnas.1008688107
   Romagnolo D.F., 2014, NUTR EPIGEN IN PRESS, pChapter 13
   Romagnolo DF, 2014, ADV NUTR, V5, P373, DOI 10.3945/an.114.005868
   Romagnolo DF, 2010, NUTR HEALTH SER, P761, DOI 10.1007/978-1-60761-627-6_32
   Rottenberg S, 2008, P NATL ACAD SCI USA, V105, P17079, DOI 10.1073/pnas.0806092105
   Rottenberg S, 2012, CANCER RES, V72, P2350, DOI 10.1158/0008-5472.CAN-11-4201
   Ruffner H, 1999, MOL CELL BIOL, V19, P4843
   Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Shukla V, 2010, CELL RES, V20, P1201, DOI 10.1038/cr.2010.128
   Sieri S, 2008, AM J CLIN NUTR, V88, P1304, DOI 10.3945/ajcn.2008.26090
   Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004
   Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   TATE PH, 1993, CURR OPIN GENET DEV, V3, P226, DOI 10.1016/0959-437X(93)90027-M
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   Wang L, 2013, CELL CYCLE, V12, P3575, DOI 10.4161/cc.26785
   Wang QQ, 2013, ACTA BIOCH BIOPH SIN, V45, P179, DOI 10.1093/abbs/gmt001
   Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011
   Wannous R, 2013, BBA-MOL CELL BIOL L, V1831, P1618, DOI 10.1016/j.bbalip.2013.07.010
   Warner M, 2002, ENVIRON HEALTH PERSP, V110, P625, DOI 10.1289/ehp.02110625
   Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Weiss J, 2003, ACTA PAEDIATR, V92, P467, DOI 10.1111/j.1651-2227.2003.tb00580.x
   Xiang Shulin, 2008, J Circadian Rhythms, V6, P4, DOI 10.1186/1740-3391-6-4
   Xiao X, 2010, CURR CANCER DRUG TAR, V10, P384, DOI 10.2174/156800910791208535
   XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259
   Yao PL, 2014, MOL CANCER THER, V13, P1008, DOI 10.1158/1535-7163.MCT-13-0836
   Yao ZW, 2013, PHARMACOL RES, V70, P139, DOI 10.1016/j.phrs.2013.01.006
   Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008
   Yun MH, 2009, NATURE, V459, P460, DOI 10.1038/nature07955
   Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x
   Zaman MS, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-44
   Zarrizi R., 2014, CANC RES
   Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371
NR 122
TC 47
Z9 53
U1 0
U2 22
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PY 2015
VL 15
IS 1
BP 4
EP 14
PG 11
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA CD6PB
UT WOS:000351210300009
PM 25329591
DA 2025-01-12
ER

PT J
AU Truong, PK
   Lao, TD
   Doan, TPT
   Le, TAH
AF Phuong Kim Truong
   Thuan Duc Lao
   Thao Phuong Thi Doan
   Thuy Ai Huyen Le
TI <i>BRCA1</i> Promoter Hypermethylation Signature for Early Detection of
   Breast Cancer in the Vietnamese Population
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE BRCA1; methylation; bisulfite modification; breast cancer
ID CPG ISLAND METHYLATION; DNA METHYLATION; EXPRESSION; BIOMARKERS;
   PROFILE; SERUM
AB Breast cancer, a leading cause of death among women in most countries worldwide, is rapidly increasing in incidence in Vietnam. One of biomarkers is the disruption of the genetic material including epigenetic changes like DNA methylation. With the aim of finding hypermethylation at CpG islands of promoter of BRCA1 gene, belonged to the tumor suppressor gene family, as the biomarker for breast cancer in Vietnamese population, sensitive methyl specific PCR (MSP) was carried out on 115 samples including 95 breast cancer specimens and 20 normal breast tissues with other diseases which were obtained from Ho Chi Minh City Medical Hospital, Vietnam. The result indicated that the frequency of BRCA1 hypermethylation reached 82.1% in the cases (p<0.001). In addition, the DNA hypermethylation of this candidate gene increased the possibility to be breast cancer with high incidence via calculated odd ratios (p<0.05). In conclusion, hypermethylation of this candidate gene could be used as the promising biomarker application with Vietnamese breast cancer patients.
C1 [Phuong Kim Truong; Thuan Duc Lao; Thuy Ai Huyen Le] Ho Chi Minh City Med & Pharm Univ, Fac Biotechnol, Dept Biotechnol Applicat Med, Ho Chi Minh, Vietnam.
   [Thao Phuong Thi Doan] Fac Med, Dept Pathol Anat, Ho Chi Minh, Vietnam.
RP Le, TAH (通讯作者)，Ho Chi Minh City Med & Pharm Univ, Fac Biotechnol, Dept Biotechnol Applicat Med, Ho Chi Minh, Vietnam.
EM thuy.lha@ou.edu.vn
RI Lao, Thuan/IWD-8612-2023
OI Le, Thuy AI Huyen/0000-0002-4825-3299; Lao, Thuan
   Duc/0000-0002-6459-3058
CR Alsner J, 2000, CLIN CANCER RES, V6, P3923
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2001, CANCER RES, V61, P3225
   Evron E, 2001, CANCER RES, V61, P2782
   Fang WJ, 2012, ASIAN PAC J CANCER P, V13, P1917, DOI 10.7314/APJCP.2012.13.5.1917
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Hsu NC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056256
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Jacot W, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-523
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lan NH, 2013, GLOBAL HEALTH ACTION, V6, P32, DOI 10.3402/gha.v6i0.18872
   Pongtheerat T, 2011, ASIAN PAC J CANCER P, V12, P2731
   Ramezani F, 2012, ASIAN PAC J CANCER P, V13, P451, DOI 10.7314/APJCP.2012.13.2.451
   Tapia T, 2008, EPIGENETICS-US, V3, P157, DOI 10.4161/epi.3.3.6387
   Terada K, 2009, CARCINOGENESIS, V30, P466, DOI 10.1093/carcin/bgp021
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
NR 18
TC 8
Z9 8
U1 0
U2 3
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2014
VL 15
IS 22
BP 9607
EP 9610
DI 10.7314/APJCP.2014.15.22.9607
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CD4ML
UT WOS:000351056900009
PM 25520075
OA gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Glass, K
   Quackenbush, J
   Spentzos, D
   Haibe-Kains, B
   Yuan, GC
AF Glass, Kimberly
   Quackenbush, John
   Spentzos, Dimitrios
   Haibe-Kains, Benjamin
   Yuan, Guo-Cheng
TI A network model for angiogenesis in ovarian cancer
SO BMC BIOINFORMATICS
LA English
DT Article
DE Network modeling; Gene regulation; Regulatory networks; Ovarian cancer;
   Cancer subtypes; Angiogenesis
ID ENDOTHELIAL GROWTH-FACTOR; RECURRENT EPITHELIAL OVARIAN; BREAST-CANCER;
   COOPERATIVE INTERACTION; TRANSCRIPTION FACTOR; EPIGENETIC THERAPY;
   PRIMARY PERITONEAL; RECEPTOR AGONISTS; SMALL MOLECULES; TUMOR-GROWTH
AB Background: We recently identified two robust ovarian cancer subtypes, defined by the expression of genes involved in angiogenesis, with significant differences in clinical outcome. To identify potential regulatory mechanisms that distinguish the subtypes we applied PANDA, a method that uses an integrative approach to model information flow in gene regulatory networks.
   Results: We find distinct differences between networks that are active in the angiogenic and non-angiogenic subtypes, largely defined by a set of key transcription factors that, although previously reported to play a role in angiogenesis, are not strongly differentially-expressed between the subtypes. Our network analysis indicates that these factors are involved in the activation (or repression) of different genes in the two subtypes, resulting in differential expression of their network targets. Mechanisms mediating differences between subtypes include a previously unrecognized pro-angiogenic role for increased genome-wide DNA methylation and complex patterns of combinatorial regulation.
   Conclusions: The models we develop require a shift in our interpretation of the driving factors in biological networks away from the genes themselves and toward their interactions. The observed regulatory changes between subtypes suggest therapeutic interventions that may help in the treatment of ovarian cancer.
C1 [Glass, Kimberly; Quackenbush, John; Yuan, Guo-Cheng] Dana Farber Canc Inst, Boston, MA 02115 USA.
   [Glass, Kimberly; Quackenbush, John; Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
   [Glass, Kimberly] Brigham & Womens Hosp, Boston, MA 02115 USA.
   [Spentzos, Dimitrios] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
   [Haibe-Kains, Benjamin] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Harvard T.H. Chan School of Public Health; Harvard University; Brigham &
   Women's Hospital; Harvard University; Beth Israel Deaconess Medical
   Center; Harvard Medical School; University of Toronto; University Health
   Network Toronto; Princess Margaret Cancer Centre
RP Yuan, GC (通讯作者)，Dana Farber Canc Inst, Boston, MA 02115 USA.
EM gcyuan@jimmy.harvard.edu
RI Chen, Guoping/H-2593-2011; Glass, Kimberly/K-2964-2014; Quackenbush,
   John/JJD-1148-2023; Haibe-Kains, Benjamin/D-3702-2011
OI Quackenbush, John/0000-0002-2702-5879; Haibe-Kains,
   Benjamin/0000-0002-7684-0079; Glass, Kimberly/0000-0003-4394-5779
FU  [R01 HL089438];  [R01 HL111759];  [P01 HL105339]
FX This project has been supported by R01 HL089438, R01 HL111759 and P01
   HL105339. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aghajanian C, 2012, J CLIN ONCOL, V30, P2039, DOI 10.1200/JCO.2012.42.0505
   Ahn KS, 2006, J BIOL CHEM, V281, P19798, DOI 10.1074/jbc.M601162200
   ANTOUN MD, 1993, J NAT PROD, V56, P1423, DOI 10.1021/np50098a030
   Arnaldez FI, 2012, HEMATOL ONCOL CLIN N, V26, P527, DOI 10.1016/j.hoc.2012.01.004
   Aurora AB, 2010, BLOOD, V116, P475, DOI 10.1182/blood-2009-07-232132
   Barabási AL, 2007, NEW ENGL J MED, V357, P404, DOI 10.1056/NEJMe078114
   Beischlag TV, 2004, J BIOL CHEM, V279, P54620, DOI 10.1074/jbc.M410456200
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bentink S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030269
   Bergwerff M, 2000, VIRCHOWS ARCH, V436, P12, DOI 10.1007/PL00008193
   BERTAZZI PA, 1993, EPIDEMIOLOGY, V4, P398, DOI 10.1097/00001648-199309000-00004
   Bobek V, 2004, BIOMED PHARMACOTHER, V58, P213, DOI 10.1016/j.biopha.2003.11.007
   Brown C, 2004, BRIT J PHARMACOL, V141, P233, DOI 10.1038/sj.bjp.0705605
   Brun Yseult F., 2008, Cancer Genomics & Proteomics, V5, P43
   Burger RA, 2007, J CLIN ONCOL, V25, P5165, DOI 10.1200/JCO.2007.11.5345
   Burger RA, 2011, NEW ENGL J MED, V365, P2473, DOI 10.1056/NEJMoa1104390
   Burger RA, 2011, GYNECOL ONCOL, V121, P230, DOI 10.1016/j.ygyno.2010.11.035
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Cannistra SA, 2007, J CLIN ONCOL, V25, P5180, DOI 10.1200/JCO.2007.12.0782
   Card PB, 2005, J MOL BIOL, V353, P664, DOI 10.1016/j.jmb.2005.08.043
   Cardoso R, 2012, PROTEIN SCI, V21, P1885, DOI 10.1002/pro.2172
   Roman AC, 2009, J BIOL CHEM, V284, P25135, DOI 10.1074/jbc.M109.013292
   Carlson EA, 2009, TOXICOL SCI, V112, P257, DOI 10.1093/toxsci/kfp200
   Collinson F, 2013, CLIN CANCER RES, V19, P5227, DOI 10.1158/1078-0432.CCR-13-0489
   Dai FJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052162
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Davison Z, 2011, NEOPLASIA, V13, P504, DOI 10.1593/neo.101590
   Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441
   Do W, 2013, BIOCHEM BIOPH RES CO, V439, P215, DOI 10.1016/j.bbrc.2013.08.057
   Dutta D, 2008, J BIOL CHEM, V283, P25404, DOI 10.1074/jbc.M804349200
   El Gendy MAM, 2012, TOXICOL LETT, V208, P51, DOI 10.1016/j.toxlet.2011.09.030
   El Gendy MAM, 2010, TOXICOL APPL PHARM, V249, P55, DOI 10.1016/j.taap.2010.08.014
   Elvert G, 2003, J BIOL CHEM, V278, P7520, DOI 10.1074/jbc.M211298200
   Emmert-Streib F, 2007, J COMPUT BIOL, V14, P961, DOI 10.1089/cmb.2007.0041
   Evidente A, 2009, PLANTA MED, V75, P501, DOI 10.1055/s-0029-1185340
   Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fracchiolla NS, 2011, TOXICOLOGY, V283, P18, DOI 10.1016/j.tox.2011.01.025
   Fraley C, 2002, J AM STAT ASSOC, V97, P611, DOI 10.1198/016214502760047131
   Fritz WA, 2008, CARCINOGENESIS, V29, P1077, DOI 10.1093/carcin/bgn069
   Ftitz WA, 2009, BIOCHEM PHARMACOL, V77, P1151, DOI 10.1016/j.bcp.2008.12.015
   Garcia VM, 2012, CLIN CANCER RES, V18, P3750, DOI 10.1158/1078-0432.CCR-11-1275
   Gerger A, 2011, CANCER J, V17, P134, DOI 10.1097/PPO.0b013e318212db3c
   Gerotziafas GT, 2007, PATHOPHYSIOL HAEMO T, V36, P204, DOI 10.1159/000175158
   Gershenwald JE, 2001, ONCOGENE, V20, P3363, DOI 10.1038/sj.onc.1204450
   Glass K, 2013, PANDA IMPLEMENTATION
   Glass K., 2013, PLoS One
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hao N, 2011, NUCLEIC ACIDS RES, V39, P3695, DOI 10.1093/nar/gkq1336
   Hartemink Alexander J, 2002, Pac Symp Biocomput, P437
   Hecker M, 2009, BIOSYSTEMS, V96, P86, DOI 10.1016/j.biosystems.2008.12.004
   Hellebrekers DMEI, 2007, BBA-REV CANCER, V1775, P76, DOI 10.1016/j.bbcan.2006.07.003
   Horowitz Neil S, 2011, Clin Ovarian Cancer Other Gynecol Malig, V4, P26
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang KJ, 2012, MED ONCOL, V29, P318, DOI 10.1007/s12032-010-9817-4
   INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Ishimura R, 2009, BIOCHEM PHARMACOL, V77, P660, DOI 10.1016/j.bcp.2008.10.030
   Kang HJ, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.78
   Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971
   Khatun S, 2003, CANCER SCI, V94, P769, DOI 10.1111/j.1349-7006.2003.tb01517.x
   Komiyama T, 2009, J BIOL CHEM, V284, P15729, DOI 10.1074/jbc.M901540200
   Korpelainen EI, 1998, CURR OPIN CELL BIOL, V10, P159, DOI 10.1016/S0955-0674(98)80137-3
   Kumaran GC, 2009, BRIT J CANCER, V100, P1, DOI 10.1038/sj.bjc.6604767
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Lelièvre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5
   Li D, 2002, ONCOGENE, V21, P2805, DOI 10.1038/sj.onc.1205410
   Liao N, 2012, MOLECULES, V17, P3723, DOI 10.3390/molecules17043723
   Liu J, 2011, CURR ONCOL REP, V13, P450, DOI 10.1007/s11912-011-0194-8
   Madsen CV, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-23
   Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110
   Matulonis UA, 2009, J CLIN ONCOL, V27, P5601, DOI 10.1200/JCO.2009.23.2777
   McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059
   Mimura I, 2012, MOL CELL BIOL, V32, P3018, DOI 10.1128/MCB.06643-11
   Moses MA, 1998, CANCER RES, V58, P1395
   Murukesh N, 2010, BRIT J CANCER, V102, P8, DOI 10.1038/sj.bjc.6605483
   Nariai N, 2005, BIOINFORMATICS, V21, P206, DOI 10.1093/bioinformatics/bti1133
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Oron AP, 2008, BIOINFORMATICS, V24, P2586, DOI 10.1093/bioinformatics/btn465
   Papin JA, 2004, TRENDS BIOCHEM SCI, V29, P641, DOI 10.1016/j.tibs.2004.10.001
   PERROTTI D, 1995, MOL CELL BIOL, V15, P6075
   Privalov PL, 1999, J MOL BIOL, V294, P997, DOI 10.1006/jmbi.1999.3285
   Prokhortchouk E, 2008, BBA-MOL CELL RES, V1783, P2167, DOI 10.1016/j.bbamcr.2008.07.015
   Ravasi T, 2010, CELL, V140, P744, DOI 10.1016/j.cell.2010.01.044
   Safe S, 2001, TOXICOL LETT, V120, P1, DOI 10.1016/S0378-4274(01)00301-0
   Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19
   Scheuermann TH, 2009, P NATL ACAD SCI USA, V106, P450, DOI 10.1073/pnas.0808092106
   Schmidlin H, 2008, BLOOD, V112, P1804, DOI 10.1182/blood-2008-01-136440
   Sessa C, 2008, NAT CLIN PRACT ONCOL, V5, P378, DOI 10.1038/ncponc1150
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Silverman EK, 2013, CLIN PHARMACOL THER, V93, P26, DOI 10.1038/clpt.2012.207
   Silverman EK, 2012, DISCOV MED, V14, P143
   Smedley D, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-22
   Spannuth WA, 2008, NAT CLIN PRACT ONCOL, V5, P194, DOI 10.1038/ncponc1051
   Stevens TA, 2006, ONCOGENE, V25, P5426, DOI 10.1038/sj.onc.1209529
   Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16
   Storti P, 2013, LEUKEMIA, V27, P1697, DOI 10.1038/leu.2013.24
   Tanaka M, 1999, DEVELOPMENT, V126, P1269
   Teoh D, 2012, INT J GYNECOL CANCER, V22, P348, DOI 10.1097/IGC.0b013e31823c6efd
   Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196
   Tsai SJ, 2012, BIOCHEM BIOPH RES CO, V425, P462, DOI 10.1016/j.bbrc.2012.07.125
   Veikkola T, 2000, CANCER RES, V60, P203
   Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315
   Webb CF, 2011, MOL CELL BIOL, V31, P1041, DOI 10.1128/MCB.01448-10
   Xu J, 2012, DEV CELL, V23, P796, DOI 10.1016/j.devcel.2012.09.003
   Yang SX, 2008, CLIN CANCER RES, V14, P5893, DOI 10.1158/1078-0432.CCR-07-4762
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472
   Zhang H, 2014, PHYTOMEDICINE, V21, P348, DOI 10.1016/j.phymed.2013.09.007
NR 109
TC 51
Z9 56
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD APR 11
PY 2015
VL 16
AR 115
DI 10.1186/s12859-015-0551-y
PG 17
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA CG5HT
UT WOS:000353322500001
PM 25888305
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Ning, XH
   Shi, ZD
   Liu, X
   Zhang, AL
   Han, L
   Jiang, K
   Kang, CS
   Zhang, QY
AF Ning, Xianghong
   Shi, Zhendong
   Liu, Xi
   Zhang, Anling
   Han, Lei
   Jiang, Kui
   Kang, Chunsheng
   Zhang, Qingyu
TI DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429
   gene and promotes tumor progression
SO CANCER LETTERS
LA English
DT Article
DE Histone modifications; DNA methylation; miR-200; DNMT; EZH2
ID MULTIPLE CPG ISLANDS; GROUP PROTEIN EZH2; DNA METHYLATION; CANCER-CELLS;
   PHARMACOLOGICAL DISRUPTION; COLORECTAL CANCERS; PROSTATE-CANCER;
   DOWN-REGULATION; BREAST-CANCER; EXPRESSION
AB Aberrant expression of the microRNA-200 (miR-200) family has been linked to the occurrence and development of various types of malignant tumors, including hepatocellular carcinoma (HCC), colon cancer and breast cancer. However, little is known about the precise mechanism by which miR-200 expression is downregulated. The intricate relationship between DNA methylation and histone modifications has become a subject of increasing interest. The expression of miR-200 family membersds modified by similar or complementary epigenetic mechanisms in MGC-803 and BGC-823 gastric cancer cells and IJ87 MG glioma cells. Chromatin immunoprecipitation assays revealed that DNA methyltransferase 1 (DNMT1) bound to miR-200b/a/429 promoter regions, indicating an interaction between DNMT1 and the miR200b/a/429 promoter. Furthermore, Co-lmmunoprecipitation (Co-IF) detection showed that DNMT1, together with the PcG protein Enhancer of Zeste homolog 2 (EZH2), a histone methyltransferase, contributed to the transcriptional repression of microRNA-200 family members. Knockdown of EZH2 not only impacted H3K27 trimethylation but also reduced DNMT1 presence on the miR-200b/a/429 promoter. EZH2 appeared to be essential for DNMT1 recruitment to the promoter region. Silencing EZH2 and DNMT1 using drugs or RNA interference dramatically reduced the levels of miR-200b/a/429 expression. Collectively, these results indicated that EZH2 and DNMT1-mediated epigenetic silencing contributed to the progression of gastric cancer and glioblastoma, and therefore represents a novel therapeutic target for malignant tumors. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Ning, Xianghong; Liu, Xi; Jiang, Kui; Zhang, Qingyu] Tianjin Med Univ, Gen Hosp, Dept Gastroenterol, Tianjin 300052, Peoples R China.
   [Shi, Zhendong; Zhang, Anling; Han, Lei; Kang, Chunsheng] Tianjin Med Univ, Gen Hosp, Dept Neurosurg, Tianjin 300052, Peoples R China.
   [Shi, Zhendong] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Breast Canc Prevent 3,Treatment & Res Ctr, Tianjin 300052, Peoples R China.
   [Shi, Zhendong; Zhang, Anling; Han, Lei; Kang, Chunsheng] Tianjin Neurol Inst, Lab Neurooncol, Tianjin, Peoples R China.
   [Shi, Zhendong; Zhang, Anling; Han, Lei; Kang, Chunsheng] Minist Educ, Key Lab Posttrauma Neurorepair & Regenerat Cent N, Tianjin, Peoples R China.
   [Shi, Zhendong; Zhang, Anling; Han, Lei; Kang, Chunsheng] Tianjin Key Lab Injuries Variat & Regenerat Nervo, Tianjin, Peoples R China.
   [Kang, Chunsheng] CGCG, Beijing, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University
RP Kang, CS (通讯作者)，Tianjin Med Univ, Gen Hosp, Dept Neurosurg, 154 An Shan Rd, Tianjin 300052, Peoples R China.
EM kang97061@gmail.com; zhangqy@tijmu.edu.cn
RI Kang, Chunsheng/AAM-5979-2021
OI Kang, Chunsheng/0000-0002-3255-3369
FU National High Technology Research and Development Program 863
   [2014AA021102]; China National Natural Scientific Fund [81372703,
   81172356]; Tianjin Innovation Team Project [TD12-5025]; Tianjin Medical
   University Research Project [2014KYQ08]; Basic and Advanced Technology
   Research Project of Tianjin [10JCZDJC18500]
FX This work was partially supported by the National High Technology
   Research and Development Program 863 (2014AA021102), the China National
   Natural Scientific Fund (81372703 and 81172356), Tianjin Innovation Team
   Project (TD12-5025), Tianjin Medical University Research Project
   (2014KYQ08). Application of Basic and Advanced Technology Research
   Project of Tianjin (10JCZDJC18500).
CR Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Cai MY, 2011, MOL MED, V17, P12, DOI 10.2119/molmed.2010.00103
   Cong NN, 2013, ONCOL REP, V29, P1579, DOI 10.3892/or.2013.2267
   Crea F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-40
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Diaz T, 2014, J SURG ONCOL, V109, P676, DOI 10.1002/jso.23572
   Enkhbaatar Z, 2013, CELL CYCLE, V12, P2100, DOI 10.4161/cc.25142
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2
   He M, 2013, MOL MED REP, V8, P942, DOI 10.3892/mmr.2013.1566
   Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1
   Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867
   Inoue Akiko, 2014, J Pediatr Hematol Oncol, V36, pe322, DOI 10.1097/MPH.0000000000000042
   Kanai Y, 2003, CANCER LETT, V192, P75, DOI 10.1016/S0304-3835(02)00689-4
   Karam JA, 2007, INT J CANCER, V120, P1795, DOI 10.1002/ijc.22405
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6
   Liu WB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.366
   Manavalan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062334
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Men DH, 2014, CANCER EPIDEMIOL, V38, P152, DOI 10.1016/j.canep.2014.01.003
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Nakagawa T, 2005, J UROLOGY, V173, P1767, DOI 10.1097/01.ju.0000154632.11824.4d
   Nakagawa T, 2003, J UROLOGY, V170, P2463, DOI 10.1097/01.ju.0000095919.50869.c9
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Nishihori T, 2014, BIOL BLOOD MARROW TR, V20, P776, DOI 10.1016/j.bbmt.2014.02.008
   Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828
   Peng DF, 2005, CANCER SCI, V96, P403, DOI 10.1111/j.1349-7006.2005.00071.x
   Qian XM, 2012, MOL PHARMACEUT, V9, P2636, DOI 10.1021/mp3002039
   Shi ZD, 2013, CANCER RES, V73, P5519, DOI 10.1158/0008-5472.CAN-13-0280
   Smits M, 2010, ONCOTARGET, V1, P710, DOI 10.18632/oncotarget.205
   So AY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019503
   Soubani O, 2012, CARCINOGENESIS, V33, P1563, DOI 10.1093/carcin/bgs189
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vella S, 2013, INT J MOL SCI, V14, P24154, DOI 10.3390/ijms141224154
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Wu XD, 2008, NUCLEIC ACIDS RES, V36, P3590, DOI 10.1093/nar/gkn243
   Xiao X, 2014, TUMOR BIOL, V35, P3755, DOI 10.1007/s13277-013-1497-1
   Yan HC, 2013, ONCOL LETT, V6, P845, DOI 10.3892/ol.2013.1438
   Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827
NR 43
TC 149
Z9 172
U1 1
U2 53
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 10
PY 2015
VL 359
IS 2
BP 198
EP 205
DI 10.1016/j.canlet.2015.01.005
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CC7AC
UT WOS:000350519100006
PM 25595591
DA 2025-01-12
ER

PT J
AU Perdereau, D
   Cailliau, K
   Browaeys-Poly, E
   Lescuyer, A
   Carré, N
   Benhamed, F
   Goenaga, D
   Burnol, AF
AF Perdereau, Dominique
   Cailliau, Katia
   Browaeys-Poly, Edith
   Lescuyer, Arlette
   Carre, Nadege
   Benhamed, Fadila
   Goenaga, Diana
   Burnol, Anne-Francoise
TI Insulin-induced cell division is controlled by the adaptor Grb14 in a
   Chfr-dependent manner
SO CELLULAR SIGNALLING
LA English
DT Article
DE Cancer; Cell proliferation; Grb14; Insulin signalling
ID MITOTIC CHECKPOINT PROTEIN; DNA-DAMAGE RESPONSE; BREAST-CANCER CELLS;
   EPIGENETIC INACTIVATION; STRESS CHECKPOINT; TUMOR SUPPRESSION;
   XENOPUS-LAEVIS; LUNG-CANCER; CPG ISLAND; KINASE
AB Beyond its key role in the control of energy metabolism, insulin is also an important regulator of cell division and neoplasia. However, the molecular events involved in insulin-driven cell proliferation are not fully elucidated. Here, we show that the ubiquitin ligase Chfr, a checkpoint protein involved in G2/M transition, is a new effector involved in the control of insulin-induced cell proliferation. Chfr is identified as a partner of the molecular adapter Grb14, an inhibitor of insulin signalling. Using mammalian cell lines and the Xenopus oocyte as a model of G2/M transition, we demonstrate that Chfr potentiates the inhibitory effect of Grb14 on insulin-induced cell division. Insulin stimulates Chfr binding to the T220 residue of Grb14. Both Chfr binding site and Grb14 C-ter BPS-SH2 domain, mediating IR binding and inhibition, are required to prevent insulin-induced cell division. Targeted mutagenesis revealed that Chfr ligase activity and phosphorylation of its T39 residue, a target of Akt, are required to potentiate Grb14 inhibitory activity. In the presence of insulin, the binding of Chfr to Grb14 activates its ligase activity, leading to Aurora A and Polo-like kinase degradation and blocking cell division. Collectively, our results show that Chfr and Grb14 collaborate in a negative feedback loop controlling insulin-stimulated cell division. (c) 2015 Elsevier Inc. All rights reserved.
C1 [Perdereau, Dominique; Carre, Nadege; Benhamed, Fadila; Goenaga, Diana; Burnol, Anne-Francoise] Inst Cochin, INSERM, U1016, Paris, France.
   [Perdereau, Dominique; Carre, Nadege; Benhamed, Fadila; Goenaga, Diana; Burnol, Anne-Francoise] CNRS, UMR8104, Paris, France.
   [Perdereau, Dominique; Carre, Nadege; Benhamed, Fadila; Goenaga, Diana; Burnol, Anne-Francoise] Univ Paris 05, Sorbonne Paris Cite, F-75014 Paris, France.
   [Cailliau, Katia; Browaeys-Poly, Edith; Lescuyer, Arlette] Univ Lille 1, Lab Regulat Signaux Div, F-59655 Villeneuve Dascq, France.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS);
   CNRS - National Institute for Biology (INSB); Universite Paris Cite;
   Universite Paris Cite; Universite de Lille
RP Burnol, AF (通讯作者)，Inst Cochin, Endocrinol, Metab, Dept Diabet, 24 Rue Faubourg St Jacques, F-75014 Paris, France.
EM anne-francoise.burnol@inserm.fr
RI Benhamed, Fadila/HPD-1637-2023; Burnol, Anne-Francoise/P-2181-2017
OI Cailliau, Katia/0000-0001-7993-8437; cailliau,
   katia/0000-0003-1772-1034; Rayah Benhamed, Fadila/0000-0003-4905-6585
FU Agence Nationale pour la Recherche [ANR-06-PHYSIO-014-01]; Association
   pour la Recherche sur le Cancer [ARC 3487]; "La Ligue contre le Cancer"
   Comite du Nord [07850]
FX We thank A. Castro for the gift of anti-Xenopus Chfr antibodies, E.
   Shtivelman for the anti-pT39 antibodies, A. Kumagai for anti-Plx1
   antibodies and L. Holt for Grb14 KO MEF. We thank F. Margottin and L.
   Morzyglod for helpful suggestions. These studies were supported by
   grants from the Agence Nationale pour la Recherche
   (ANR-06-PHYSIO-014-01), from the Association pour la Recherche sur le
   Cancer (ARC 3487) and from "La Ligue contre le Cancer" Comite du Nord
   (grant no. 07850).
CR Béréziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200
   BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297
   Burgess A, 2008, ONCOGENE, V27, P5554, DOI 10.1038/onc.2008.167
   Calle EE, 2004, NAT REV CANCER, V4, P579, DOI 10.1038/nrc1408
   Cariou B, 2004, FASEB J, V18, P965, DOI 10.1096/fj.03-0824fje
   Cariou B, 2002, MOL CELL BIOL, V22, P6959, DOI 10.1128/MCB.22.20.6959-6970.2002
   Celton-Morizur S, 2010, CELL CYCLE, V9, P460, DOI 10.4161/cc.9.3.10542
   Corn PG, 2003, CARCINOGENESIS, V24, P47, DOI 10.1093/carcin/24.1.47
   Depetris RS, 2009, NAT STRUCT MOL BIOL, V16, P833, DOI 10.1038/nsmb.1642
   Depetris RS, 2005, MOL CELL, V20, P325, DOI 10.1016/j.molcel.2005.09.001
   Desbuquois B, 2013, FEBS J, V280, P794, DOI 10.1111/febs.12080
   Ditch S, 2012, TRENDS BIOCHEM SCI, V37, P15, DOI 10.1016/j.tibs.2011.10.002
   ELETR M, 1979, SCIENCE, V205, P1397, DOI 10.1126/science.472755
   Erson AE, 2004, MOL CARCINOGEN, V39, P26, DOI 10.1002/mc.10161
   Frank-Vaillant M, 2000, J CELL SCI, V113, P1127
   Fu Z, 2009, J CLIN INVEST, V119, P2714, DOI 10.1172/JCI37405
   Gallagher EJ, 2010, TRENDS ENDOCRIN MET, V21, P610, DOI 10.1016/j.tem.2010.06.007
   Goenaga D, 2009, MOL ENDOCRINOL, V23, P1043, DOI 10.1210/me.2008-0360
   Holt LJ, 2005, BIOCHEM J, V388, P393, DOI 10.1042/BJ20050216
   Kairouz R, 2005, J CELL PHYSIOL, V203, P85, DOI 10.1002/jcp.20199
   Kang DM, 2002, J CELL BIOL, V156, P249, DOI 10.1083/jcb.200108016
   Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026
   KasusJacobi A, 1997, J BIOL CHEM, V272, P17166, DOI 10.1074/jbc.272.27.17166
   Kooner JS, 2011, NAT GENET, V43, P984, DOI 10.1038/ng.921
   Leevers SJ, 2005, CURR OPIN CELL BIOL, V17, P604, DOI 10.1016/j.ceb.2005.09.008
   Löbrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248
   Manning AK, 2012, NAT GENET, V44, P659, DOI 10.1038/ng.2274
   Mariatos G, 2003, CANCER RES, V63, P7185
   Mizuno K, 2002, ONCOGENE, V21, P2328, DOI 10.1038/sj.onc.1205402
   Morris AP, 2012, NAT GENET, V44, P981, DOI 10.1038/ng.2383
   Park JJ, 2006, PHYSIOL GENOMICS, V27, P114, DOI 10.1152/physiolgenomics.00045.2006
   Privette LM, 2007, CANCER RES, V67, P6064, DOI 10.1158/0008-5472.CAN-06-4109
   Privette LM, 2008, TRANSL ONCOL, V1, P57, DOI 10.1593/tlo.08109
   Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262
   Sakai M, 2005, HEPATO-GASTROENTEROL, V52, P1854
   Sanbhnani S, 2012, CELL MOL LIFE SCI, V69, P1669, DOI 10.1007/s00018-011-0892-2
   Satoh A, 2003, CANCER RES, V63, P8606
   Scolnick DM, 2000, NATURE, V406, P430, DOI 10.1038/35019108
   Shibata Y, 2002, CARCINOGENESIS, V23, P1695, DOI 10.1093/carcin/23.10.1695
   Shiloh Y, 2006, TRENDS BIOCHEM SCI, V31, P402, DOI 10.1016/j.tibs.2006.05.004
   Shinde SR, 2013, CELL SIGNAL, V25, P2511, DOI 10.1016/j.cellsig.2013.08.013
   Shtivelman E, 2003, MOL CANCER RES, V1, P959
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Toyota M, 2003, P NATL ACAD SCI USA, V100, P7818, DOI 10.1073/pnas.1337066100
   Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078
   Wu MYW, 2007, EMBO J, V26, P371, DOI 10.1038/sj.emboj.7601487
   Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538
NR 47
TC 3
Z9 3
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD APR
PY 2015
VL 27
IS 4
BP 798
EP 806
DI 10.1016/j.cellsig.2015.01.003
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CD2UG
UT WOS:000350933900007
PM 25578860
DA 2025-01-12
ER

PT J
AU Costa, ET
   Barnabée, GF
   Li, M
   Dias, AAM
   Machado, TR
   Asprino, PF
   Cavalher, FP
   Ferreira, EN
   Inda, MD
   Nagai, MH
   Malnic, B
   Duarte, ML
   Leite, KRM
   de Barros, ACSD
   Carraro, DM
   Chammas, R
   Armelin, HA
   Cavenee, W
   Furnari, F
   Camargo, A
AF Costa, E. T.
   Barnabe, G. F.
   Li, M.
   Dias, A. A. M.
   Machado, T. R.
   Asprino, P. F.
   Cavalher, F. P.
   Ferreira, E. N.
   Inda, M. del Mar
   Nagai, M. H.
   Malnic, B.
   Duarte, M. L.
   Leite, K. R. M.
   de Barros, A. C. S. D.
   Carraro, D. M.
   Chammas, R.
   Armelin, H. A.
   Cavenee, W.
   Furnari, F.
   Camargo, A. A.
TI Intratumoral heterogeneity of ADAM23 promotes tumor growth and
   metastasis through LGI4 and nitric oxide signals
SO ONCOGENE
LA English
DT Article
ID CELL-LINES; EVOLUTION; CANCER; METHYLATION; CARCINOMA; GENE;
   PROGRESSION; EXPRESSION; INTEGRIN; ADHESION
AB Intratumoral heterogeneity (ITH) represents an obstacle for cancer diagnosis and treatment, but little is known about its functional role in cancer progression. The A Desintegrin And Metalloproteinase 23 (ADAM23) gene is epigenetically silenced in different types of tumors, and silencing is often associated with advanced disease and metastasis. Here, we show that invasive breast tumors exhibit significant ADAM23-ITH and that this heterogeneity is critical for tumor growth and metastasis. We demonstrate that while loss of ADAM23 expression enhances invasion, it causes a severe proliferative deficiency and is not itself sufficient to trigger metastasis. Rather, we observed that, in ADAM23-heterotypic environments, ADAM23-negative cells promote tumor growth and metastasis by enhancing the proliferation and invasion of adjacent A23-positive cells through the production of LGI4 (Leucine-rich Glioma Inactivated 4) and nitric oxide (NO). Ablation of LGI4 and NO in A23-negative cells significantly attenuates A23-positive cell proliferation and invasion. Our work denotes a driving role of ADAM23-ITH during disease progression, shifting the malignant phenotype from the cellular to the tissue level. Our findings also provide insights for therapeutic intervention, enforcing the need to ascertain ITH to improve cancer diagnosis and therapy.
C1 [Costa, E. T.; Barnabe, G. F.; Asprino, P. F.; Duarte, M. L.; Camargo, A. A.] Hosp Sirio Libanes, Ctr Mol Oncol, BR-01308060 Sao Paulo, Brazil.
   [Costa, E. T.; Barnabe, G. F.; Machado, T. R.; Asprino, P. F.; Cavalher, F. P.; Duarte, M. L.; Camargo, A. A.] LICR, Sao Paulo, Brazil.
   [Li, M.; Inda, M. del Mar; Cavenee, W.; Furnari, F.] Univ Calif San Diego, LICR, San Diego, CA 92103 USA.
   [Dias, A. A. M.] Univ Fed Minas Gerais, Dept Biol Geral ICB, Belo Horizonte, MG, Brazil.
   [Ferreira, E. N.; Carraro, D. M.] Hosp AC Camargo Fund Antonio Prudente, Ctr Internacl Pesquisa, Sao Paulo, Brazil.
   [Nagai, M. H.; Malnic, B.; Armelin, H. A.] Univ Sao Paulo, Dept Bioquim IQ, Sao Paulo, Brazil.
   [Leite, K. R. M.; Chammas, R.] Univ Sao Paulo, Fac Med, Dept Urol, Sao Paulo, Brazil.
   [de Barros, A. C. S. D.] Hosp Sirio Libanes, Dept Mastol, BR-01308060 Sao Paulo, Brazil.
   [Armelin, H. A.] Inst Butantan, Sao Paulo, Brazil.
C3 University of California System; University of California San Diego;
   Universidade Federal de Minas Gerais; A.C.Camargo Cancer Center;
   Universidade de Sao Paulo; Universidade de Sao Paulo; Instituto Butantan
RP Camargo, A (通讯作者)，Hosp Sirio Libanes, Ctr Mol Oncol, LICR, Rua Cel Nicolau Dos Santos 69, BR-01308060 Sao Paulo, Brazil.
EM aacamargo@mochsl.org.br
RI Barros, Alfredo/M-2525-2017; li, ming/F-3495-2013; Barnabe,
   Gabriela/E-9033-2013; Armelin, Hugo/P-4390-2015; Asprino,
   Paula/AAB-5600-2021; Malnic, Bettina/A-4905-2008; Dias,
   Adriana/B-4974-2014; Aranha Camargo, Anamaria/E-9388-2012; Costa, Erico
   Tosoni/D-5750-2014; Ferreira, Elisa/A-6485-2011; Carraro,
   Dirce/C-9179-2009; Leite, Katia/C-2055-2008; Chammas, Roger/A-8004-2011;
   Lemos Duarte, Mariana/K-6233-2012
OI Cavenee, Webster/0000-0003-3804-9179; Li, Ming/0000-0002-2540-1738;
   Aranha Camargo, Anamaria/0000-0002-6076-9597; Costa, Erico
   Tosoni/0000-0001-7413-4675; Furnari, Frank/0000-0003-1909-4361;
   Ferreira, Elisa/0000-0001-7809-7349; Asprino, Paula/0000-0002-2157-5853;
   Carraro, Dirce/0000-0001-5667-1418; Armelin, Hugo
   A./0000-0001-9557-0804; Leite, Katia/0000-0002-2615-7730; Chammas,
   Roger/0000-0003-0342-8726; Abalen Martins Dias,
   Adriana/0000-0001-9415-3240; Lemos Duarte, Mariana/0000-0002-1611-7102
FU FAPESP [06/60219-2, 07/51194-9, 07/52920-5, 11/50541-2]; LICR
FX We are grateful to Dr Andrew Simpson and Dr Raphael Parmigiani for
   critical reading of this manuscript and to Dr Rodrigo Perez, Dr Alicia
   Kowaltowski, Dr Beatriz Geronymo, Dr Camila Machado, Dr Vilma Martins,
   Dr Tiago dos Santos and Dr Anibal Vercesi for scientific discussions and
   technical assistance. This work was supported by grants from FAPESP
   (06/60219-2, 07/51194-9, 07/52920-5, 11/50541-2) and LICR.
CR Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923
   Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650
   Axelrod R, 2006, P NATL ACAD SCI USA, V103, P13474, DOI 10.1073/pnas.0606053103
   Bermingham JR, 2006, NAT NEUROSCI, V9, P76, DOI 10.1038/nn1598
   Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548
   CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0
   Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457
   Calmon MF, 2007, CANCER GENET CYTOGEN, V173, P31, DOI 10.1016/j.cancergencyto.2006.09.008
   Choi JS, 2009, INT J CANCER, V124, P1258, DOI 10.1002/ijc.24023
   Clark J, 2008, ONCOGENE, V27, P1993, DOI 10.1038/sj.onc.1210843
   Costa FF, 2005, NEUROSCI LETT, V380, P260, DOI 10.1016/j.neulet.2005.01.050
   Costa FF, 2004, ONCOGENE, V23, P1481, DOI 10.1038/sj.onc.1207263
   Cottu PH, 2008, ANN ONCOL, V19, P596, DOI 10.1093/annonc/mdn021
   FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927
   GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343
   Gauthier N, 2004, CARCINOGENESIS, V25, P1559, DOI 10.1093/carcin/bgh158
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Hagihara A, 2004, ONCOGENE, V23, P8705, DOI 10.1038/sj.onc.1207783
   Hu CY, 2011, INT J EXP PATHOL, V92, P333, DOI 10.1111/j.1365-2613.2011.00766.x
   Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510
   Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I
   Kim HA, 2012, BBA-MOL CELL BIOL L, V1821, P914, DOI 10.1016/j.bbalip.2012.02.010
   Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723
   Lampson BL, 2012, CANCER RES, V72, P4472, DOI 10.1158/0008-5472.CAN-12-0057
   Maley CC, 2006, NAT GENET, V38, P468, DOI 10.1038/ng1768
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Michor F, 2010, CANCER PREV RES, V3, P1361, DOI 10.1158/1940-6207.CAPR-10-0234
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Nishino J, 2010, J NEUROSCI, V30, P15228, DOI 10.1523/JNEUROSCI.2286-10.2010
   Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Orucevic A, 1999, INT J CANCER, V81, P889, DOI 10.1002/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2
   Özkaynak E, 2010, J NEUROSCI, V30, P3857, DOI 10.1523/JNEUROSCI.6287-09.2010
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   PRICE JE, 1990, CANCER RES, V50, P717
   Sagane K, 2008, INT J BIOL SCI, V4, P387
   Senechal KR, 2005, HUM MOL GENET, V14, P1613, DOI 10.1093/hmg/ddi169
   Sens-Abuázar C, 2012, TRANSL ONCOL, V5, P113, DOI 10.1593/tlo.11280
   SUZUKI N, 1978, CANCER RES, V38, P3349
   Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217
   Takada H, 2005, ONCOGENE, V24, P8051, DOI 10.1038/sj.onc.1208952
   Takahashi T, 1998, CANCER RES, V58, P5835
   Teixeira MR, 1996, CANCER RES, V56, P855
   Verbisck NV, 2009, CANCER RES, V69, P5546, DOI 10.1158/0008-5472.CAN-08-2976
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Yamada KM, 2007, CELL, V130, P601, DOI 10.1016/j.cell.2007.08.006
   Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336
   Yap TA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003854
NR 49
TC 15
Z9 19
U1 0
U2 27
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 5
PY 2015
VL 34
IS 10
BP 1270
EP 1279
DI 10.1038/onc.2014.70
PG 10
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA CC9JX
UT WOS:000350687100007
PM 24662834
OA Bronze
DA 2025-01-12
ER

PT J
AU Ghoshal, A
   Ghosh, SS
AF Ghoshal, Archita
   Ghosh, Siddhartha Sankar
TI Expression, Purification, and Therapeutic Implications of Recombinant
   sFRP1
SO APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
LA English
DT Article
DE Secreted frizzled-related protein; Wnt; GST tagged; Recombinant protein
   expression; Characterization; Glutathione agarose affinity
   chromatography; Chemotherapeutic drugs; Combination therapy
ID WNT ANTAGONIST SFRP1; GST-FUSION PROTEINS; EPIGENETIC INACTIVATION;
   MONOCLONAL-ANTIBODY; BREAST-CANCER; GENES; IDENTIFICATION; METHYLATION;
   RECEPTOR; GROWTH
AB Secreted frizzled-related proteins (sFRPs) constitute a family of proteins, which impede the Wnt signaling pathway. Upregulation of the Wnt cascade is one of the multiple facets of carcinogenesis. Herein, we report the expression, solubilization, purification, characterization, and anti-cell proliferative activity of a novel recombinant GST-tagged sFRP1 of human origin. sFRP1 was cloned into pGEX-4T2 bacterial expression vector, and the recombinant protein was overexpressed in Escherichia coli BL21 (DE3). It was solubilized from inclusion bodies with N-lauroylsarcosine and Triton X-100, before being purified to homogeneity using glutathione agarose affinity chromatography column. The purified protein was characterized using Western blotting, MALDI TOF-TOF, and circular dichroism spectroscopy analysis. Homology modeling and docking studies revealed that tagging GST with sFRP1 does not change the binding conformation of the cysteine-rich domain and hence, possibly does not alter its function. The novel anti-proliferative activity of GST-sFRP1 was demonstrated in a dose-dependent manner on two cancer cell lines, viz., HeLa (cervical cancer) and MCF-7 (breast cancer). Also, combination therapy of the protein with chemotherapeutic drugs resulted in enhanced anti-cancer activity. This opens up a new avenue in the application of recombinant sFRP1 for cancer therapeutics.
C1 [Ghoshal, Archita; Ghosh, Siddhartha Sankar] Indian Inst Technol Guwahati, Dept Biotechnol, Gauhati 39, Assam, India.
   [Ghosh, Siddhartha Sankar] Indian Inst Technol Guwahati, Ctr Nanotechnol, Gauhati 39, Assam, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT) - Guwahati
RP Ghosh, SS (通讯作者)，Indian Inst Technol Guwahati, Ctr Nanotechnol, Gauhati 39, Assam, India.
EM sghosh@iitg.ernet.in
OI Ghoshal, Archita/0000-0002-9210-3140
FU Department of Biotechnology, Government of India [BT/01/NE/PS/08];
   Department of Electronics and Information Technology, Government of
   India [5(9)/2012-NANO (Vol. II)]
FX This work was supported by the Department of Biotechnology (No.
   BT/01/NE/PS/08) and the Department of Electronics and Information
   Technology, Government of India for financial support (No.
   5(9)/2012-NANO (Vol. II)). The authors acknowledge the aid of the
   Central Instruments Facility (CIF) and the Centre for Nanotechnology,
   IIT Guwahati.
CR Achilonu I, 2014, PROTEIN EXPRES PURIF, V99, P70, DOI 10.1016/j.pep.2014.04.003
   [Anonymous], NUCL ACIDS RES
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Fang Han-lin, 2012, Zhonghua Zhong Liu Za Zhi, V34, P658, DOI 10.3760/cma.j.issn.0253-3766.2012.09.004
   Ferrer-Miralles N, 2009, MICROB CELL FACT, V8, DOI 10.1186/1475-2859-8-17
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Fukui T, 2005, ONCOGENE, V24, P6323, DOI 10.1038/sj.onc.1208777
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Hu ED, 1998, BIOCHEM BIOPH RES CO, V247, P287, DOI 10.1006/bbrc.1998.8784
   JAMES P, 1993, BIOCHEM BIOPH RES CO, V195, P58, DOI 10.1006/bbrc.1993.2009
   Joesting MS, 2005, CANCER RES, V65, P10423, DOI 10.1158/0008-5472.CAN-05-0824
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Lu Da Yong, 2005, BMC Pharmacology, V5, P11, DOI 10.1186/1471-2210-5-11
   Marsit CJ, 2005, CANCER RES, V65, P7081, DOI 10.1158/0008-5472.CAN-05-0267
   Mercado-Pimentel ME, 2002, PROTEIN EXPRES PURIF, V26, P260, DOI 10.1016/S1046-5928(02)00524-7
   Molina MA, 2001, CANCER RES, V61, P4744
   Nojima M, 2007, ONCOGENE, V26, P4699, DOI 10.1038/sj.onc.1210259
   PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T
   Park DW, 2011, BMB REP, V44, P279, DOI 10.5483/BMBRep.2011.44.4.279
   Qu Y, 2013, EUR J CANCER, V49, P3718, DOI 10.1016/j.ejca.2013.07.011
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Rubin JS, 2006, FRONT BIOSCI, V11, P2093, DOI 10.2741/1952
   Saran U, 2012, BMC CELL BIOL, V13, DOI 10.1186/1471-2121-13-25
   Schwanke RC, 2009, INT J BIOL MACROMOL, V45, P97, DOI 10.1016/j.ijbiomac.2009.04.005
   Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takada T, 2004, CANCER SCI, V95, P741, DOI 10.1111/j.1349-7006.2004.tb03255.x
   Tardito S, 2009, J BIOL CHEM, V284, P24306, DOI 10.1074/jbc.M109.026583
   Tsumoto K, 2003, PROTEIN EXPRES PURIF, V28, P1, DOI 10.1016/S1046-5928(02)00641-1
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Yang XD, 1999, CANCER RES, V59, P1236
   Yang ZQ, 2009, INT J CANCER, V125, P1613, DOI 10.1002/ijc.24518
   Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40
   Zhou ZJ, 1998, INT J CANCER, V78, P95, DOI 10.1002/(SICI)1097-0215(19980925)78:1<95::AID-IJC15>3.0.CO;2-4
NR 37
TC 12
Z9 14
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0273-2289
EI 1559-0291
J9 APPL BIOCHEM BIOTECH
JI Appl. Biochem. Biotechnol.
PD FEB
PY 2015
VL 175
IS 4
BP 2087
EP 2103
DI 10.1007/s12010-014-1354-8
PG 17
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology
GA CD2BN
UT WOS:000350878700025
PM 25432334
DA 2025-01-12
ER

PT J
AU Rybicka, A
   Mucha, J
   Majchrzak, K
   Taciak, B
   Hellmen, E
   Motyl, T
   Krol, M
AF Rybicka, A.
   Mucha, J.
   Majchrzak, K.
   Taciak, B.
   Hellmen, E.
   Motyl, T.
   Krol, M.
TI ANALYSIS OF MICRORNA EXPRESSION IN CANINE MAMMARY CANCER STEM-LIKE CELLS
   INDICATES EPIGENETIC REGULATION OF TRANSFORMING GROWTH FACTOR-BETA
   SIGNALING
SO JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
LA English
DT Article
DE cancer stem cells; microRNA; canine mammary cancer; transforming growth
   factor; tumor necrosis factor-beta
ID TUMOR-INITIATING CELLS; SELF-RENEWAL; REFERENCE GENES; LINES;
   TUMORIGENICITY; IDENTIFICATION; INHIBITION; RESISTANCE; CARCINOMA;
   CATENIN
AB Cancer stem cells (CSCs) display both unique self-renewal ability as well as the ability to differentiate into many kinds of cancer cells. They are supposed to be responsible for cancer initiation, recurrence and drug resistance. Despite the fact that a variety of methods are currently employed in order to target CSCs, little is known about the regulation of their phenotype and biology by miRNAs. The aim of our study was to assess miRNA expression in canine mammary cancer stem-like cells (expressing stem cell antigen 1, Sca-1; CD44 and EpCAM) sorted from canine mammary tumour cell lines (CMT-U27, CMT-309 and P114). In order to prove their stem-like phenotype, we conducted a colony formation assay that confirmed their ability to form colonies from a single cell. Profiles of miRNA expression were investigated using Agilent custom-designed microarrays. The results were further validated by real-time rt-PCR analysis of expression of randomly selected miRNAs. Target genes were indicated and analysed using Kioto Encyclopedia of Genes and Genomes (KEGG) and BioCarta databases. The results revealed 24 down-regulated and nine up-regulated miRNAs in cancer stem-like cells compared to differentiated tumour cells. According to KEGG and BioCarta databases, target genes (n=240) of significantly down-regulated miRNAs were involved in transforming growth factor-beta signaling, mitogen-activated protein kinases (MAPK) signaling pathway, anaplastic lymphoma receptor tyrosine kinase (ALK) and peroxisome proliferator-activated receptor gamma, coactivator 1 alpha (PGC1A) pathways. The analysis of single-gene overlapping with different pathways showed that the most important genes were: TGFBR1, TGFBR2, SOS1, CHUK, PDGFRA, SMAD2, MEF2A, MEF2C and MEF2D. All of them are involved in tumor necrosis factor-beta signaling and may indicate its important role in cancer stem cell biology. Increased expression of TGFBR2, SMAD2, MEF2A and MEF2D in canine mammary cancer stem-like cells was further confirmed by real-time-qPCR. The results of our study point at epigenetic differences between cancer stem-like cells and differentiated tumour cells, which may be important not only for veterinary medicine but also for comparative oncology.
C1 [Rybicka, A.; Mucha, J.; Taciak, B.; Motyl, T.; Krol, M.] Warsaw Univ Life Sci, Dept Physiol Sci, Fac Vet Med, Warsaw, Poland.
   [Majchrzak, K.] Warsaw Univ Life Sci, Fac Anim Sci, Dept Anim Environm Biol, Warsaw, Poland.
   [Hellmen, E.] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, Uppsala, Sweden.
C3 Warsaw University of Life Sciences; Warsaw University of Life Sciences;
   Swedish University of Agricultural Sciences
RP Krol, M (通讯作者)，Warsaw Univ Life Sci, Dept Physiol Sci, Fac Vet Med, 159 Nowoursynowska St, Warsaw, Poland.
EM magdalena_krol@sggw.pl
RI ; Krol, Magdalena/A-5554-2019
OI Rybicka, Agata/0000-0002-7749-8850; Taciak,
   Bartlomiej/0000-0003-2623-4860; Majchrzak-Kuligowska,
   Kinga/0000-0002-9504-4588; Krol, Magdalena/0000-0003-0421-5167; Motyl,
   Tomasz/0000-0002-3470-3324; Mucha, Joanna/0000-0001-8322-8155
FU National Science Centre (NCN) [2011/03/B/NZ5/05299]; COST Action [CM
   11106]
FX The authors would like to thank Dr. Alicja Majewska for her excellent
   technical support. This work was supported by the grant no.
   2011/03/B/NZ5/05299 from National Science Centre (NCN) and by COST
   Action CM 11106.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Barh D, 2010, CURR ONCOL, V17, P70
   Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416
   Brinkhof B, 2006, ANAL BIOCHEM, V356, P36, DOI 10.1016/j.ab.2006.06.001
   Butz H, 2012, TRENDS PHARMACOL SCI, V33, P382, DOI 10.1016/j.tips.2012.04.003
   Chiang CH, 2013, BBA-GEN SUBJECTS, V1830, P3067, DOI 10.1016/j.bbagen.2013.01.009
   Chuthapisith S, 2010, SURG ONCOL, V19, P27, DOI 10.1016/j.suronc.2009.01.004
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Etschmann B, 2006, VET PATHOL, V43, P934, DOI 10.1354/vp.43-6-934
   Ferletta M, 2011, INT J DEV BIOL, V55, P791, DOI 10.1387/ijdb.113363mf
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Gal H, 2008, BIOCHEM BIOPH RES CO, V376, P86, DOI 10.1016/j.bbrc.2008.08.107
   Grange C, 2008, NEOPLASIA, V10, P1433, DOI 10.1593/neo.08902
   Harrison H, 2010, CANCER RES, V70, P709, DOI 10.1158/0008-5472.CAN-09-1681
   Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017
   HELLMEN E, 1992, IN VITRO CELL DEV-AN, V28A, P309, DOI 10.1007/BF02877054
   Hellmén E, 2000, BREAST CANCER RES TR, V61, P197, DOI 10.1023/A:1006410020384
   Hu Y, 2014, PLOS ONE, V9
   Korbut E, 2012, J PHYSIOL PHARMACOL, V63, P565
   Król M, 2010, J APPL GENET, V51, P169, DOI 10.1007/BF03195725
   Król M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083995
   Lamb R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067811
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Ma L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2720
   Magalhaes GM, 2013, BMC VET RES, V9, DOI 10.1186/1746-6148-9-205
   Marhaba R, 2008, CURR MOL MED, V8, P784, DOI 10.2174/156652408786733667
   Masri S, 2010, BREAST CANCER RES TR, V124, P89, DOI 10.1007/s10549-009-0716-3
   Michishita M, 2012, VET J, V193, P508, DOI 10.1016/j.tvjl.2012.01.006
   Mulholland DJ, 2009, CANCER RES, V69, P8555, DOI 10.1158/0008-5472.CAN-08-4673
   Pang Lisa Y, 2011, Cancers (Basel), V3, P1744, DOI 10.3390/cancers3021744
   Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schwarzenbacher D, 2013, INT J MOL SCI, V14, P14712, DOI 10.3390/ijms140714712
   Shafee N, 2008, CANCER RES, V68, P3243, DOI 10.1158/0008-5472.CAN-07-5480
   Skidan I, 2014, J PHYSIOL PHARMACOL, V65, P157
   Soltysik K, 2013, J PHYSIOL PHARMACOL, V64, P129
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13
   Tang W, 2014, ONCOGENE, V33, P2629, DOI 10.1038/onc.2013.214
   vanLeeuwen IS, 1996, ANTICANCER RES, V16, P3737
   Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
   Watabe T, 2009, CELL RES, V19, P103, DOI 10.1038/cr.2008.323
   Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855
   Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071
NR 47
TC 24
Z9 26
U1 0
U2 15
PU POLISH PHYSIOLOGICAL SOC
PI GRZEGORZECKA
PA JAGIELLONIAN UNIV SCHOOL MED, INST PHYSIOLOGY, 31-531 KRAKOW, 16
   GRZEGORZECKA, POLAND
SN 0867-5910
J9 J PHYSIOL PHARMACOL
JI J. Physiol. Pharmacol.
PD FEB
PY 2015
VL 66
IS 1
BP 29
EP 37
PG 9
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA CC8KG
UT WOS:000350616600003
PM 25716962
DA 2025-01-12
ER

PT J
AU Jadhav, RR
   Ye, ZQ
   Huang, RL
   Liu, J
   Hsu, PY
   Huang, YW
   Rangel, LB
   Lai, HC
   Roa, JC
   Kirma, NB
   Huang, THM
   Jin, VX
AF Jadhav, Rohit R.
   Ye, Zhenqing
   Huang, Rui-Lan
   Liu, Joseph
   Hsu, Pei-Yin
   Huang, Yi-Wen
   Rangel, Leticia B.
   Lai, Hung-Cheng
   Roa, Juan Carlos
   Kirma, Nameer B.
   Huang, Tim Hui-Ming
   Jin, Victor X.
TI Genome-wide DNA methylation analysis reveals estrogen-mediated
   epigenetic repression of metallothionein-1 gene cluster in breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE DNA methylation; MT1
ID DIFFERENTIAL EXPRESSION; LUNG-CANCER; CELL-LINES; STEM-CELLS;
   IDENTIFICATION; METHYLOME; HYPERMETHYLATION; PROMOTERS; HOTSPOTS;
   REGIONS
AB Background: Recent genome-wide analysis has shown that DNA methylation spans long stretches of chromosome regions consisting of clusters of contiguous CpG islands or gene families. Hypermethylation of various gene clusters has been reported in many types of cancer. In this study, we conducted methyl-binding domain capture (MBDCap) sequencing (MBD-seq) analysis on a breast cancer cohort consisting of 77 patients and 10 normal controls, as well as a panel of 38 breast cancer cell lines.
   Results: Bioinformatics analysis determined seven gene clusters with a significant difference in overall survival (OS) and further revealed a distinct feature that the conservation of a large gene cluster (approximately 70 kb) metallothionein-1 (MT1) among 45 species is much lower than the average of all RefSeq genes. Furthermore, we found that DNA methylation is an important epigenetic regulator contributing to gene repression of MT1 gene cluster in both ER alpha positive (ER alpha+) and ER alpha negative (ER alpha-) breast tumors. In silico analysis revealed much lower gene expression of this cluster in The Cancer Genome Atlas (TCGA) cohort for ER alpha+ tumors. To further investigate the role of estrogen, we conducted 17 beta-estradiol (E2) and demethylating agent 5-aza-2'-deoxycytidine (DAC) treatment in various breast cancer cell types. Cell proliferation and invasion assays suggested MT1F and MT1M may play an anti-oncogenic role in breast cancer.
   Conclusions: Our data suggests that DNA methylation in large contiguous gene clusters can be potential prognostic markers of breast cancer. Further investigation of these clusters revealed that estrogen mediates epigenetic repression of MT1 cluster in ER alpha+ breast cancer cell lines. In all, our studies identify thousands of breast tumor hypermethylated regions for the first time, in particular, discovering seven large contiguous hypermethylated gene clusters.
C1 [Jadhav, Rohit R.; Ye, Zhenqing; Liu, Joseph; Hsu, Pei-Yin; Rangel, Leticia B.; Kirma, Nameer B.; Huang, Tim Hui-Ming; Jin, Victor X.] Univ Texas Hlth Sci Ctr San Antonio, STRF, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA.
   [Huang, Rui-Lan; Lai, Hung-Cheng] Taipei Med Univ, Shuang Ho Hosp, Dept Obstet & Gynecol, New Taipei City 23561, Taiwan.
   [Lai, Hung-Cheng] Taipei Med Univ, Sch Med, Taipei 110, Taiwan.
   [Lai, Hung-Cheng] Tri Serv Gen Hosp, Natl Def Med Ctr, Grad Inst Life Sci, Dept & Grad Inst Biochem, Taipei, Taiwan.
   [Huang, Yi-Wen] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA.
   [Roa, Juan Carlos] Univ La Frontera, Dept Pathol, Temuco, Chile.
   [Rangel, Leticia B.] Univ Fed Espirito Santo, RENORBIO, Hlth Sci Ctr, Dept Pharmaceut Sci,Biotechnol Program, BR-29040090 Vitoria, ES, Brazil.
   [Rangel, Leticia B.] CNPq, Programa Ciencias Sem Fronteiras, Brasilia, DF, Brazil.
   [Kirma, Nameer B.; Huang, Tim Hui-Ming; Jin, Victor X.] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Kirma, Nameer B.; Huang, Tim Hui-Ming; Jin, Victor X.] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas Health Science Center at
   San Antonio; Taipei Medical University; Taipei Medical University;
   National Defense Medical Center; Tri-Service General Hospital; Medical
   College of Wisconsin; Universidad de La Frontera; Universidade Federal
   do Espirito Santo; University of Texas System; University of Texas
   Health Science Center at San Antonio; Cancer Therapy & Research Center;
   University of Texas System; University of Texas Health Science Center at
   San Antonio
RP Huang, THM (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, STRF, Inst Biotechnol, Dept Mol Med, Room 225,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM huangt3@uthscsa.edu; jinv@uthscsa.edu
RI Roa, Juan/K-4749-2014; Rangel, Leticia/E-6241-2018; Ye,
   Zhenqing/ABF-1433-2020; Huang, Yiwen/KPB-2034-2024; Jadhav,
   Rohit/D-2254-2016
OI Huang, Rui Lan/0000-0001-6458-4672; Jadhav, Rohit/0000-0002-2999-6329;
   Roa, Juan Carlos/0000-0001-8313-8774
FU Department of Molecular Medicine at University of Texas Health Science
   Center at San Antonio; National Institutes of Health [U54CA113001, P30
   CA054174]
FX This study was supported by funds from the Department of Molecular
   Medicine at University of Texas Health Science Center at San Antonio
   (VXJ) and by National Institutes of Health [grant numbers: U54CA113001
   to THH, VXJ] and P30 CA054174 (Cancer Center Support Grant).
CR [Anonymous], SCI TRANSL MED
   Antequera F, 2003, CELL MOL LIFE SCI, V60, P1647, DOI 10.1007/s00018-003-3088-6
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Clark SJ, 2007, HUM MOL GENET, V16, pR88, DOI 10.1093/hmg/ddm051
   Cui M, 2009, MOL BIOL REP, V36, P2201, DOI 10.1007/s11033-008-9435-9
   Dallosso AR, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000745
   Flagiello D, 1997, FEBS LETT, V415, P263, DOI 10.1016/S0014-5793(97)01118-6
   Friedline JA, 1998, AM J PATHOL, V152, P23
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hsu PY, 2013, CANCER CELL, V24, P197, DOI 10.1016/j.ccr.2013.07.007
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Hsu YT, 2013, CLIN CANCER RES, V19, P6272, DOI 10.1158/1078-0432.CCR-13-1734
   Huang RL, 2013, EPIGENETICS-US, V8, P624, DOI 10.4161/epi.24816
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Lan X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022226
   Laurent L, 2010, GENOME RES, V20, P320, DOI 10.1101/gr.101907.109
   Lister R, 2011, NATURE, V471, P68, DOI 10.1038/nature09798
   Mao J, 2012, CARCINOGENESIS, V33, P2568, DOI 10.1093/carcin/bgs287
   Marzese DM, 2014, HUM MOL GENET, V23, P226, DOI 10.1093/hmg/ddt420
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Moleirinho A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018487
   Nordlund J, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r105
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Oyama T, 1996, ONCOLOGY, V53, P112
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Rakyan VK, 2008, GENOME RES, V18, P1518, DOI 10.1101/gr.077479.108
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rossi M, 2004, CANCER LETT, V215, P229, DOI 10.1016/j.canlet.2004.05.014
   Sandoval J, 2013, J CLIN ONCOL, V31, P4140, DOI 10.1200/JCO.2012.48.5516
   Shi JF, 2012, BIOCHEM BIOPH RES CO, V427, P47, DOI 10.1016/j.bbrc.2012.08.144
   Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453
   Tai SK, 2003, AM J PATHOL, V163, P2009, DOI 10.1016/S0002-9440(10)63559-6
   Wang LH, 2006, CANCER CELL, V10, P487, DOI 10.1016/j.ccr.2006.09.015
   Wu XW, 2010, CANCER RES, V70, P2718, DOI 10.1158/0008-5472.CAN-09-3631
   Xie W, 2013, CELL, V153, P1134, DOI 10.1016/j.cell.2013.04.022
   Yang YQ, 2012, HISTOL HISTOPATHOL, V27, P217, DOI 10.14670/HH-27.217
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 43
TC 38
Z9 53
U1 0
U2 27
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD FEB 24
PY 2015
VL 7
AR 13
DI 10.1186/s13148-015-0045-9
PG 15
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CC9VX
UT WOS:000350720400001
PM 25763113
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Kim, SE
   Hinoue, T
   Kim, MS
   Sohn, KJ
   Cho, RC
   Cole, PD
   Weisenberger, DJ
   Laird, PW
   Kim, YI
AF Kim, Sung-Eun
   Hinoue, Toshinori
   Kim, Michael S.
   Sohn, Kyoung-Jin
   Cho, Robert C.
   Cole, Peter D.
   Weisenberger, Daniel J.
   Laird, Peter W.
   Kim, Young-In
TI γ-Glutamyl hydrolase modulation significantly influences global and
   gene-specific DNA methylation and gene expression in human colon and
   breast cancer cells
SO GENES AND NUTRITION
LA English
DT Article
DE Folate; gamma-Glutamyl hydrolase (GGH); DNA methylation; Gene
   expression; Colon cancer; Breast cancer
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; SINGLE NUCLEOTIDE POLYMORPHISMS;
   DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDYLATE SYNTHASE;
   COLORECTAL-CANCER; CONFERS RESISTANCE; FOLATE-DEFICIENCY;
   5-FLUOROURACIL; METHOTREXATE; CHEMOTHERAPY
AB gamma-Glutamyl hydrolase (GGH) plays an important role in folate homeostasis by catalyzing hydrolysis of polyglutamylated folate into monoglutamates. Polyglutamylated folates are better substrates for several enzymes involved in the generation of S-adenosylmethionine, the primary methyl group donor, and hence, GGH modulation may affect DNA methylation. DNA methylation is an important epigenetic determinant in gene expression, in the maintenance of DNA integrity and stability, and in chromatin modifications, and aberrant or dysregulation of DNA methylation has been mechanistically linked to the development of human diseases including cancer. Using a recently developed in vitro model of GGH modulation in HCT116 colon and MDA-MB-435 breast cancer cells, we investigated whether GGH modulation would affect global and gene-specific DNA methylation and whether these alterations were associated with significant gene expression changes. In both cell lines, GGH overexpression decreased global DNA methylation and DNA methyltransferase (DNMT) activity, while GGH inhibition increased global DNA methylation and DNMT activity. Epigenomic and gene expression analyses revealed that GGH modulation influenced CpG promoter DNA methylation and gene expression involved in important biological pathways including cell cycle, cellular development, and cellular growth and proliferation. Some of the observed altered gene expression appeared to be regulated by changes in CpG promoter DNA methylation. Our data suggest that the GGH modulation-induced changes in total intracellular folate concentrations and content of long-chain folylpolyglutamates are associated with functionally significant DNA methylation alterations in several important biological pathways.
C1 [Kim, Sung-Eun; Cho, Robert C.; Kim, Young-In] Univ Toronto, Dept Nutr Sci, Toronto, ON M5S 1A8, Canada.
   [Kim, Sung-Eun; Kim, Michael S.; Sohn, Kyoung-Jin; Kim, Young-In] St Michaels Hosp, Keenan Res Ctr Biomed Sci, Toronto, ON M5B 1T8, Canada.
   [Hinoue, Toshinori; Laird, Peter W.] Van Andel Res Inst, Ctr Epigenet, Grand Rapids, MI 49503 USA.
   [Sohn, Kyoung-Jin; Kim, Young-In] Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada.
   [Cole, Peter D.] Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA.
   [Weisenberger, Daniel J.] Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90089 USA.
   [Weisenberger, Daniel J.] Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA.
   [Kim, Young-In] St Michaels Hosp, Div Gastroenterol, Toronto, ON M5B 1W8, Canada.
C3 University of Toronto; University of Toronto; Saint Michaels Hospital
   Toronto; Van Andel Institute; University of Toronto; Yeshiva University;
   Montefiore Medical Center; Albert Einstein College of Medicine;
   University of Southern California; University of Southern California;
   University of Toronto; Saint Michaels Hospital Toronto
RP Kim, SE (通讯作者)，St Michaels Hosp, Keenan Res Ctr Biomed Sci, Room 516,209 Victoria St, Toronto, ON M5B 1T8, Canada.
EM sungeun.kim@alum.utoronto.ca
RI Weisenberger, Daniel/AAA-8314-2020; Kim, Kyu/F-6596-2010; Park,
   Yongsoon/E-6968-2017; LAIRD, PETER W/G-8683-2012
OI JIN, youri/0000-0002-3356-0085; Park, Yongsoon/0000-0001-5110-5716;
   LAIRD, PETER W/0000-0001-9117-3641
FU Canadian Institutes of Health Research [14126]
FX Funding was provided by the Canadian Institutes of Health Research
   (Grant Number 14126 to YIK).
CR AKSOY S, 1994, J BIOL CHEM, V269, P14835
   Assaraf YG, 2007, CANCER METAST REV, V26, P153, DOI 10.1007/s10555-007-9049-z
   Assaraf YG, 2006, DRUG RESIST UPDATE, V9, P227, DOI 10.1016/j.drup.2006.09.001
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Campan Mihhaela, 2009, V507, P325, DOI 10.1007/978-1-59745-522-0_23
   Chave KJ, 2003, GENE, V319, P167, DOI 10.1016/S0378-1119(03)00807-2
   Chen L, 1996, J BIOL CHEM, V271, P13077, DOI 10.1074/jbc.271.22.13077
   Cheng Q, 2004, PHARMACOGENETICS, V14, P557, DOI 10.1097/01.fpc.0000114761.78957.7e
   Cheng Q, 2006, AM J HUM GENET, V79, P264, DOI 10.1086/505645
   Chung JH, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000863
   Dervieux T, 2004, PHARMACOGENETICS, V14, P733, DOI 10.1097/00008571-200411000-00004
   DeVos L, 2008, AM J CLIN NUTR, V88, P1149, DOI 10.1093/ajcn/88.4.1149
   Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200
   Guo XX, 2008, ANTICANCER RES, V28, P9
   Hayashi H, 2009, J CLIN PHARM THER, V34, P355, DOI 10.1111/j.1365-2710.2009.01046.x
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hirsch DS, 2001, J BIOL CHEM, V276, P875, DOI 10.1074/jbc.M007039200
   Hooijberg JH, 2006, CANCER CHEMOTH PHARM, V58, P1, DOI 10.1007/s00280-005-0141-1
   Houshdaran S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009359
   Iacopetta B, 2008, INT J CLIN ONCOL, V13, P498, DOI 10.1007/s10147-008-0854-3
   Jekic B, 2013, EUR J CLIN PHARMACOL, V69, P377, DOI 10.1007/s00228-012-1341-3
   Kawakami K, 2003, CLIN CANCER RES, V9, P5860
   Kawakami K, 2008, BRIT J CANCER, V98, P1555, DOI 10.1038/sj.bjc.6604346
   Kim K, 2008, GYNECOL ONCOL, V111, P509, DOI 10.1016/j.ygyno.2008.08.034
   Kim SE, 2013, BRIT J CANCER, V109, P2175, DOI 10.1038/bjc.2013.579
   Kim YI, 2004, CANCER EPIDEM BIOMAR, V13, P511
   Kim YI, 2005, J NUTR, V135, P2703, DOI 10.1093/jn/135.11.2703
   Kim YI, 2007, MOL NUTR FOOD RES, V51, P267, DOI 10.1002/mnfr.200600191
   Koomdee N, 2012, ASIAN PAC J CANCER P, V13, P3461, DOI 10.7314/APJCP.2012.13.7.3461
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293
   Li En, 2000, P351
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Llombart-Cussac A, 2007, CLIN CANCER RES, V13, P3652, DOI 10.1158/1078-0432.CCR-06-2377
   Ly A, 2012, ANTIOXID REDOX SIGN, V17, P302, DOI 10.1089/ars.2012.4554
   Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065
   MCGUIRE JJ, 1981, MOL CELL BIOCHEM, V38, P19, DOI 10.1007/BF00235686
   Moran RG, 1999, SEMIN ONCOL, V26, P24
   Nakajima TE, 2008, EUR J CANCER, V44, P400, DOI 10.1016/j.ejca.2007.11.010
   Nakamura A, 2011, EXP THER MED, V2, P1097, DOI 10.3892/etm.2011.340
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Oguri T, 2005, LUNG CANCER, V49, P345, DOI 10.1016/j.lungcan.2005.05.003
   Organista-Nava J, 2010, LEUKEMIA RES, V34, P728, DOI 10.1016/j.leukres.2009.11.027
   Owen SA, 2013, PHARMACOGENOMICS J, V13, P227, DOI 10.1038/tpj.2012.7
   Panetta JC, 2002, CLIN CANCER RES, V8, P2423
   Pike BL, 2008, LEUKEMIA, V22, P1035, DOI 10.1038/leu.2008.18
   Pozzi V, 2011, INT J IMMUNOPATH PH, V24, P69, DOI 10.1177/039463201102400109
   Pratt S, 2005, MOL CANCER THER, V4, P855, DOI 10.1158/1535-7163.MCT-04-0291
   Rhee MS, 1999, CANCER CHEMOTH PHARM, V44, P427, DOI 10.1007/s002800051000
   Rots MG, 1999, BLOOD, V93, P1677, DOI 10.1182/blood.V93.5.1677.405a16_1677_1683
   Salonga D, 2000, CLIN CANCER RES, V6, P1322
   Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195
   SHANE B, 1989, VITAM HORM, V45, P263
   Shane B., 2010, Folate in Health and Disease, V2nd, P1
   Shubbar E, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-47
   Silva IH, 2013, GENE, V512, P247, DOI 10.1016/j.gene.2012.10.038
   Smit EF, 2012, ANN ONCOL, V23, P1723, DOI 10.1093/annonc/mdr563
   Sohn KJ, 2004, JNCI-J NATL CANCER I, V96, P134, DOI 10.1093/jnci/djh015
   Spritz RA, 2003, CURR OPIN GENET DEV, V13, P284, DOI 10.1016/S0959-437X(03)00059-5
   Takebe N, 2001, CANCER GENE THER, V8, P966, DOI 10.1038/sj.cgt.7700393
   Titus SA, 2000, J BIOL CHEM, V275, P36811, DOI 10.1074/jbc.M005163200
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   van der Straaten RJHM, 2007, PHARMACOGENOMICS, V8, P141, DOI 10.2217/14622416.8.2.141
   Wang SM, 2014, CANCER CHEMOTH PHARM, V74, P283, DOI 10.1007/s00280-014-2507-8
   Wang WG, 2004, CANCER RES, V64, P8167, DOI 10.1158/0008-5472.CAN-04-0970
   Wernimont SM, 2012, J NUTR, V142, P1272, DOI 10.3945/jn.111.157180
   Wielinga P, 2005, CANCER RES, V65, P4425, DOI 10.1158/0008-5472.CAN-04-2810
   Yajnik CS, 2008, DIABETOLOGIA, V51, P29, DOI 10.1007/s00125-007-0793-y
   Yanagimachi M, 2011, BRIT J CLIN PHARMACO, V71, P237, DOI 10.1111/j.1365-2125.2010.03814.x
   YAO R, 1995, MOL PHARMACOL, V48, P505
   Yoshinare K, 2003, CANCER SCI, V94, P633, DOI 10.1111/j.1349-7006.2003.tb01495.x
NR 71
TC 16
Z9 18
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1555-8932
EI 1865-3499
J9 GENES NUTR
JI Genes Nutr.
PD JAN
PY 2015
VL 10
IS 1
AR 444
DI 10.1007/s12263-014-0444-0
PG 17
WC Genetics & Heredity; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Nutrition & Dietetics
GA CD0HL
UT WOS:000350751300007
PM 25502219
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Tan, EJ
   Kahata, K
   Idås, O
   Thuault, S
   Heldin, CH
   Moustakas, A
AF Tan, E-Jean
   Kahata, Kaoru
   Idas, Oskar
   Thuault, Sylvie
   Heldin, Carl-Henrik
   Moustakas, Aristidis
TI The high mobility group A2 protein epigenetically silences the
   <i>Cdh1</i> gene during epithelial-to-mesenchymal transition
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-BETA; INVASION-SUPPRESSOR GENE; E-CADHERIN EXPRESSION;
   BREAST-CANCER CELLS; TUMOR-SUPPRESSOR; DNA METHYLATION; CHROMATIN STATE;
   CARCINOMA-CELLS; HMGA2; METASTASIS
AB The loss of the tumour suppressor E-cadherin (Cdh1) is a key event during tumourigenesis and epithelial-mesenchymal transition (EMT). Transforming growth factor-beta (TGF beta) triggers EMT by inducing the expression of non-histone chromatin protein High Mobility Group A2 (HMGA2). We have previously shown that HMGA2, together with Smads, regulate a network of EMT-transcription factors (EMT-TFs) like Snail1, Snail2, ZEB1, ZEB2 and Twist1, most of which are well-known repressors of the Cdh1 gene. In this study, we show that the Cdh1 promoter is hypermethylated and epigenetically silenced in our constitutive EMT cell model, whereby HMGA2 is ectopically expressed in mammary epithelial NMuMG cells and these cells are highly motile and invasive. Furthermore, HMGA2 remodels the chromatin to favour binding of de novo DNA methyltransferase 3A (DNMT3A) to the Cdh1 promoter. E-cadherin expression could be restored after treatment with the DNA de-methylating agent 5-aza-2'-deoxycytidine. Here, we describe a new epigenetic role for HMGA2, which follows the actions that HMGA2 initiates via the EMT-TFs, thus achieving sustained silencing of E-cadherin expression and promoting tumour cell invasion.
C1 [Tan, E-Jean; Kahata, Kaoru; Idas, Oskar; Thuault, Sylvie; Heldin, Carl-Henrik; Moustakas, Aristidis] Uppsala Univ, Sci Life Lab, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden.
   [Moustakas, Aristidis] Uppsala Univ, Sci Life Lab, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden.
C3 Ludwig Institute for Cancer Research; Uppsala University; Uppsala
   University
RP Moustakas, A (通讯作者)，Uppsala Univ, Sci Life Lab, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden.
EM aris.moustakas@imbim.uu.se
RI Tan, E-Jean/J-3425-2019
OI Tan, E-Jean/0000-0002-4631-174X; THUAULT, Sylvie/0000-0003-0133-3803
FU Swedish Cancer Society [05 0288, 09 0112, 10 0113]; Marie Curie Research
   Training Network 'EpiPlastCarcinoma' under the European Union FP6
   program [MRTN-2005-005428]; Ludwig Institute for Cancer Research
FX Ludwig Institute for Cancer Research and the Swedish Cancer Society [05
   0288, 09 0112, 10 0113 to A.M.]; Marie Curie Research Training Network
   'EpiPlastCarcinoma' under the European Union FP6 program
   [MRTN-2005-005428 to S.T.]. Funding for open access charge: Swedish
   Cancer Society [05 0288, 09 0112, 10 0113].
CR Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   [Anonymous], NAT REV CANC
   Bergström R, 2010, J BIOL CHEM, V285, P19727, DOI 10.1074/jbc.M109.088385
   Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Deckers M, 2006, CANCER RES, V66, P2202, DOI 10.1158/0008-5472.CAN-05-3560
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Dumont N, 2008, P NATL ACAD SCI USA, V105, P14867, DOI 10.1073/pnas.0807146105
   FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173
   Fusco A, 2007, NAT REV CANCER, V7, P899, DOI 10.1038/nrc2271
   Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5
   Herold M, 2012, DEVELOPMENT, V139, P1045, DOI 10.1242/dev.065268
   Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037
   Ji XD, 1997, CELL GROWTH DIFFER, V8, P773
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kishi Y, 2012, NAT NEUROSCI, V15, P1127, DOI 10.1038/nn.3165
   Kumar MS, 2014, NATURE, V505, P212, DOI 10.1038/nature12785
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Morishita A, 2013, CANCER RES, V73, P4289, DOI 10.1158/0008-5472.CAN-12-3848
   Moustakas A, 2012, SEMIN CANCER BIOL, V22, P446, DOI 10.1016/j.semcancer.2012.04.002
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   Pfannkuche K, 2009, STEM CELL REV REP, V5, P224, DOI 10.1007/s12015-009-9078-9
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tan EJ, 2012, J BIOL CHEM, V287, P7134, DOI 10.1074/jbc.M111.291385
   Tessari MA, 2003, MOL CELL BIOL, V23, P9104, DOI 10.1128/MCB.23.24.9104-9116.2003
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110
   Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200
   van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Winter N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018837
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   Zha L, 2012, MOL CELL BIOCHEM, V364, P243, DOI 10.1007/s11010-012-1224-z
   Zhang Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025168
NR 49
TC 58
Z9 61
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JAN
PY 2015
VL 43
IS 1
BP 162
EP 178
DI 10.1093/nar/gku1293
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CC2XA
UT WOS:000350207100021
PM 25492890
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Nowotarski, SL
   Pachaiyappan, B
   Holshouser, SL
   Kutz, CJ
   Li, YX
   Huang, Y
   Sharma, SK
   Casero, RA
   Woster, PM
AF Nowotarski, Shannon L.
   Pachaiyappan, Boobalan
   Holshouser, Steven L.
   Kutz, Craig J.
   Li, Youxuan
   Huang, Yi
   Sharma, Shiv K.
   Casero, Robert A., Jr.
   Woster, Patrick M.
TI Structure-activity study for (bis)ureidopropyl- and
   (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon
   backbone architectures
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Epigenetics; Histone demethylase; Lysine-specific demethylase 1;
   Oligoamine; Antitumor agent
ID HISTONE LYSINE METHYLATION; DEMETHYLASE 1; EPIGENETIC MODULATORS; INDUCE
   REEXPRESSION; OLIGOAMINE ANALOGS; POLYAMINE ANALOGS; SILENCED GENES;
   MECHANISM; CANCER; TRANS-2-PHENYLCYCLOPROPYLAMINE
AB Methylation at specific histone lysine residues is a critical post-translational modification that alters chromatin architecture, and dysregulated lysine methylation/demethylation is associated with the silencing of tumor suppressor genes. The enzyme lysine-specific demethylase 1 (LSD1) complexed to specific transcription factors catalyzes the oxidative demethylation of mono-and dimethyllysine 4 of histone H3 (H3K4me and H3K4me2, respectively). We have previously reported potent (bis) urea and (bis) thiourea LSD1 inhibitors that increase cellular levels of H3K4me and H3K4me2, promote the re-expression of silenced tumor suppressor genes and suppress tumor growth in vitro. Here we report the design additional (bis) urea and (bis) thiourea LSD1 inhibitors that feature 3-5-3 or 3-6-3 carbon backbone architectures. Three of these compounds displayed single-digit IC50 values in a recombinant LSD1 assay. In addition, compound 6d exhibited an IC50 of 4.2 mu M against the Calu-6 human lung adenocarcinoma line, and 4.8 mu M against the MCF7 breast tumor cell line, in an MTS cell viability assay. Following treatment with 6b-6d, Calu-6 cells exhibited a significant increase in the mRNA expression for the silenced tumor suppressor genes SFRP2, HCAD and p16, and modest increases in GATA4 message. The compounds described in this paper represent the most potent epigenetic modulators in this series, and have potential for use as antitumor agents. (C) 2015 Elsevier Ltd. All rights reserved.
C1 [Pachaiyappan, Boobalan; Holshouser, Steven L.; Kutz, Craig J.; Li, Youxuan; Woster, Patrick M.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA.
   [Nowotarski, Shannon L.; Huang, Yi; Casero, Robert A., Jr.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
   [Sharma, Shiv K.] Wayne State Univ, Eugene Applebaum Coll Pharm, Dept Pharmaceut Sci, Detroit, MI 48202 USA.
C3 Medical University of South Carolina; Johns Hopkins University; Johns
   Hopkins Medicine; Wayne State University
RP Woster, PM (通讯作者)，Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, 70 President St, Charleston, SC 29425 USA.
EM woster@musc.edu
RI Huang, Yi/AAW-7892-2021; Woster, Patrick/A-5604-2010
OI Woster, Patrick/0000-0002-9471-1916; Huang, Yi/0000-0002-9982-117X;
   Casero, Robert/0000-0001-5653-3306
FU NIH/NCI [5RO1 CA149095, CA051085]; Samuel Waxman Cancer Research
   Foundation
FX This work was supported by NIH/NCI grant 5RO1 CA149095 (PMW), CA051085
   (RAC) and the Samuel Waxman Cancer Research Foundation.
CR Bag P, 2014, ANTIVIR RES, V105, P126, DOI 10.1016/j.antiviral.2014.02.007
   Bellevue FH, 1996, BIOORG MED CHEM LETT, V6, P2765, DOI 10.1016/S0960-894X(96)00510-0
   Benelkebir H, 2011, BIOORGAN MED CHEM, V19, P3709, DOI 10.1016/j.bmc.2011.02.017
   BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3
   Bi XD, 2006, BIOORG MED CHEM LETT, V16, P3229, DOI 10.1016/j.bmcl.2006.03.048
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Culhane JC, 2007, CURR OPIN CHEM BIOL, V11, P561, DOI 10.1016/j.cbpa.2007.07.014
   DePrez P., 2008, United States Patent Application, Patent No. 20080125424
   Forneris F, 2007, J BIOL CHEM, V282, P20070, DOI 10.1074/jbc.C700100200
   Gooden DM, 2008, BIOORG MED CHEM LETT, V18, P3047, DOI 10.1016/j.bmcl.2008.01.003
   Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349
   Hazeldine S, 2012, J MED CHEM, V55, P7378, DOI 10.1021/jm3002845
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   Jin LH, 2013, BIOCHEM J, V449, P459, DOI 10.1042/BJ20121360
   Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897
   Keller O., 1985, Org. Syn, V63, P160, DOI DOI 10.15227/ORGSYN.063.0160
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Mimasu S, 2010, BIOCHEMISTRY-US, V49, P6494, DOI 10.1021/bi100299r
   Murray-Stewart T., 2013, AMINO ACIDS
   Ogasawara D, 2013, ANGEW CHEM INT EDIT, V52, P8620, DOI 10.1002/anie.201303999
   Ogasawara D, 2011, BIOORGAN MED CHEM, V19, P3702, DOI 10.1016/j.bmc.2010.12.024
   Ortega-Munoz A., 2011, PCT application, Patent No. [WO 2011035941 A1 20110331, 2011035941]
   Schmidt DMZ, 2007, BIOCHEMISTRY-US, V46, P4408, DOI 10.1021/bi0618621
   Sharma SK, 2012, MEDCHEMCOMM, V3, P14, DOI 10.1039/c1md00220a
   Sharma SK, 2010, J MED CHEM, V53, P5197, DOI 10.1021/jm100217a
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Suzuki T, 2011, J MED CHEM, V54, P8236, DOI 10.1021/jm201048w
   Toyooka S, 2002, CANCER RES, V62, P3382
   Vellore NA, 2013, BMC BIOPHYS, V6, DOI 10.1186/2046-1682-6-15
   Verlinden BK, 2011, J MED CHEM, V54, P6624, DOI 10.1021/jm200463z
   Wu Y, 2012, BIOCHEM J, V442, P693, DOI 10.1042/BJ20111271
NR 35
TC 42
Z9 43
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD APR 1
PY 2015
VL 23
IS 7
BP 1601
EP 1612
DI 10.1016/j.bmc.2015.01.049
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA CD3QV
UT WOS:000350995500025
PM 25725609
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Khan, D
   Dai, R
   Ahmed, SA
AF Khan, Deena
   Dai, Rujuan
   Ahmed, S. Ansar
TI Sex differences and estrogen regulation of miRNAs in lupus, a
   prototypical autoimmune disease
SO CELLULAR IMMUNOLOGY
LA English
DT Article
DE Estrogen; microRNA; Lupus; Sex differences; Autoimmune; Immune
ID POSTTRANSCRIPTIONAL GENE-REGULATION; DNA METHYLTRANSFERASE 1;
   BREAST-CANCER CELLS; T-CELLS; MESSENGER-RNA; X-CHROMOSOME; MICRORNA
   EXPRESSION; IMMUNE-SYSTEM; POSSIBLE MECHANISMS; MOUSE MODEL
AB Unique dysregulated expression patterns of microRNAs (miRNAs) have been reported in many disease conditions including autoimmune diseases such as systemic lupus erythematosus (SLE). We have recently reported that miRNAs are differentially expressed not only between autoimmune and control mice, but also between male and female lupus-prone mice. This important observation is of potential clinical and experimental significance since females have higher incidence, earlier expression or severity of lupus when compared to their male counterparts. Further, estrogen administration to orchiectomized males accelerates the expression of lupus-related miRNAs and induces unique miRNA signature profile. Understanding the basis of altered miRNAs in autoimmune diseases offers a new paradigm to understand autoimmune diseases, including sex-differential susceptibility. In this review, we summarize miRNA biogenesis and function, and focus on miRNA dysregulation in SLE in the context of sexual bias. Furthermore, the effect of estrogen on epigenetic miRNA regulation in relation to SLE is highlighted. (C) 2015 Published by Elsevier Inc.
C1 [Khan, Deena; Dai, Rujuan; Ahmed, S. Ansar] Virginia Tech, Dept Biomed Sci & Pathobiol, VMRCVM, Blacksburg, VA 24060 USA.
C3 Virginia Polytechnic Institute & State University
RP Ahmed, SA (通讯作者)，Dept Biomed Sci & Pathobiol, Duck Pond Dr,Phase 2, Blacksburg, VA 24060 USA.
EM ansrahmd@vt.edu
FU American Autoimmune Related Diseases Association (AARDA); NIH
   [9T350DO1187-06]; Lupus Foundation of America (LFA) Novel Pilot Project
   [208-11-110B-033-918-1]; Alliance for Lupus Research (ALR) [219636];
   Virginia-Maryland Regional College of Veterinary Medicine (VMRCVM)
   Intramural Research Competition Grant [IRC 17385]
FX Studies were supported by American Autoimmune Related Diseases
   Association (AARDA), NIH T35 grant, 9T350DO1187-06, Lupus Foundation of
   America (LFA) Novel Pilot Project (208-11-110B-033-918-1), Alliance for
   Lupus Research (ALR, Award No: 219636), and Virginia-Maryland Regional
   College of Veterinary Medicine (VMRCVM) Intramural Research Competition
   Grant (IRC 17385).
CR Ahmed SA, 2010, SEX HORMONES AND IMMUNITY TO INFECTION, P19, DOI 10.1007/978-3-642-02155-8_2
   AHMED SA, 1990, BAILLIERE CLIN RHEUM, V4, P13, DOI 10.1016/S0950-3579(05)80241-9
   AHMED SA, 1985, AM J PATHOL, V121, P531
   Ahmed SA, 1999, ENVIRON HEALTH PERSP, V107, P681, DOI 10.2307/3434327
   Alevizos I, 2010, AUTOIMMUN REV, V9, P618, DOI 10.1016/j.autrev.2010.05.009
   Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031
   Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028
   Bernstein E, 2003, NAT GENET, V35, P215, DOI 10.1038/ng1253
   Bhat-Nakshatri P, 2009, NUCLEIC ACIDS RES, V37, P4850, DOI 10.1093/nar/gkp500
   Björnström L, 2005, MOL ENDOCRINOL, V19, P833, DOI 10.1210/me.2004-0486
   Brümmer A, 2014, BIOESSAYS, V36, P617, DOI 10.1002/bies.201300104
   Carlsen AL, 2013, ARTHRITIS RHEUM-US, V65, P1324, DOI 10.1002/art.37890
   Carrel L, 2005, NATURE, V434, P400, DOI 10.1038/nature03479
   Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106
   Ceribelli A, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3377
   Cervera R, 2014, AUTOIMMUN REV, V13, P621, DOI 10.1016/j.autrev.2013.11.007
   Cheng C, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-9-r90
   Cheung L, 2009, BMC MOL BIOL, V10, DOI 10.1186/1471-2199-10-13
   Coller J, 2004, ANNU REV BIOCHEM, V73, P861, DOI 10.1146/annurev.biochem.73.011303.074032
   Cui Y, 2013, J AUTOIMMUN, V41, P25, DOI 10.1016/j.jaut.2013.01.008
   Dai RJ, 2013, BIOL SEX DIFFER, V4, DOI 10.1186/2042-6410-4-19
   Dai RJ, 2014, THER CLIN RISK MANAG, V10, P151, DOI 10.2147/TCRM.S33517
   Dai R, 2011, TRANSL RES, V157, P163, DOI 10.1016/j.trsl.2011.01.007
   Dai RJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014302
   Dai RJ, 2008, BLOOD, V112, P4591, DOI 10.1182/blood-2008-04-152488
   de Faria Omar Jr., 2013, Frontiers in Genetics, V3, P311, DOI 10.3389/fgene.2012.00311
   De León-Nava MA, 2009, J STEROID BIOCHEM, V113, P57, DOI 10.1016/j.jsbmb.2008.11.003
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Ding S, 2012, ARTHRITIS RHEUM-US, V64, P2953, DOI 10.1002/art.34505
   Divekar AA, 2011, J IMMUNOL, V186, P924, DOI 10.4049/jimmunol.1002218
   Du CS, 2009, NAT IMMUNOL, V10, P1252, DOI 10.1038/ni.1798
   Durali D, 2003, BLOOD, V102, P4084, DOI 10.1182/blood-2003-02-0518
   Engels BM, 2006, ONCOGENE, V25, P6163, DOI 10.1038/sj.onc.1209909
   Fairweather D, 2008, AM J PATHOL, V173, P600, DOI 10.2353/ajpath.2008.071008
   Fan W, 2012, ARTHRITIS RHEUM-US, V64, P3715, DOI 10.1002/art.34596
   Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023
   Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
   Fulci V, 2010, HUM IMMUNOL, V71, P206, DOI 10.1016/j.humimm.2009.11.008
   García-Ortiz H, 2010, ANN RHEUM DIS, V69, P1861, DOI 10.1136/ard.2009.124313
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023
   Grigoryev YA, 2011, J IMMUNOL, V187, P2233, DOI 10.4049/jimmunol.1101233
   Hai-yan Wang, 2011, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V33, P185, DOI 10.3881/j.issn.1000-503X.2011.02.017
   Helms WS, 2007, J LEUKOCYTE BIOL, V82, P361, DOI 10.1189/jlb.0206120
   Hewagama A, 2013, J AUTOIMMUN, V41, P60, DOI 10.1016/j.jaut.2012.12.006
   Hewagama Anura., 2013, RHEUMATOLOGY CURRENT, V03, DOI [DOI 10.4172/2161-1149.1000118, 10.4172/2161-1149.1000118.]
   Invernizzi P, 2007, ANN NY ACAD SCI, V1110, P57, DOI 10.1196/annals.1423.007
   Invernizzi P, 2009, J AUTOIMMUN, V33, P12, DOI 10.1016/j.jaut.2009.03.005
   Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607
   Kanda N, 1999, J ALLERGY CLIN IMMUN, V103, P282, DOI 10.1016/S0091-6749(99)70503-8
   Kassi E, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/317452
   Khan D, 2012, ADV NEUROIMMUNE BIOL, V3, P73, DOI 10.3233/NIB-2012-012039
   Klein S. La. R. C. W., 2010, SEX HORMONES IMMUNIT
   Klein SL, 2012, ENDOCRINOLOGY, V153, P2544, DOI 10.1210/en.2011-2120
   Klinge CM, 2012, TRENDS ENDOCRIN MET, V23, P223, DOI 10.1016/j.tem.2012.03.002
   Klinge CM, 2009, CURR GENOMICS, V10, P169, DOI 10.2174/138920209788185289
   Koturbash I, 2011, MUTAT RES-GEN TOX EN, V722, P114, DOI 10.1016/j.mrgentox.2010.05.007
   Krützfeldt J, 2006, CELL METAB, V4, P9, DOI 10.1016/j.cmet.2006.05.009
   Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108
   Laffont S., 2014, J IMMUNOL
   Lagos-Quintana M, 2003, RNA, V9, P175, DOI 10.1261/rna.2146903
   Lamason R, 2006, BMC IMMUNOL, V7, DOI 10.1186/1471-2172-7-2
   Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957
   Leng RX, 2011, CYTOKINE GROWTH F R, V22, P141, DOI 10.1016/j.cytogfr.2011.05.002
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Libert C, 2010, NAT REV IMMUNOL, V10, P594, DOI 10.1038/nri2815
   Liu Y, 2011, FEBS LETT, V585, P1963, DOI 10.1016/j.febslet.2011.05.029
   Lu CM, 2011, BLOOD, V117, P4293, DOI 10.1182/blood-2010-12-322503
   Lu H, 2010, CARDIOVASC RES, V86, P410, DOI 10.1093/cvr/cvq010
   Lu Q, 2007, J IMMUNOL, V179, P6352, DOI 10.4049/jimmunol.179.9.6352
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Mani ST, 2006, BRAIN RES, V1067, P43, DOI 10.1016/j.brainres.2005.10.006
   Mellios N, 2012, SCHIZOPHRENIA BULL, V38, P433, DOI 10.1093/schbul/sbq091
   Morgan CP, 2012, BIOL SEX DIFFER, V3, DOI 10.1186/2042-6410-3-22
   Morgan CP, 2011, J NEUROSCI, V31, P11748, DOI 10.1523/JNEUROSCI.1887-11.2011
   Moxley G, 2002, ARTHRITIS RHEUM, V46, P250, DOI 10.1002/1529-0131(200201)46:1<250::AID-ART10064>3.0.CO;2-T
   Mujahid S, 2013, BMC DEV BIOL, V13, DOI 10.1186/1471-213X-13-13
   Murphy S., 2014, Neurochemistry International
   Nothnick WB, 2010, ENDOCRINE, V37, P265, DOI 10.1007/s12020-009-9293-9
   O'Connell RM, 2010, IMMUNITY, V33, P607, DOI 10.1016/j.immuni.2010.09.009
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708
   Okamura K, 2007, CELL, V130, P89, DOI 10.1016/j.cell.2007.06.028
   Olivieri F., 2014, AGING CELL
   Onnis A, 2012, BLOOD CANCER J, V2, DOI 10.1038/bcj.2012.29
   Ozcelik T, 2006, EUR J HUM GENET, V14, P791, DOI 10.1038/sj.ejhg.5201614
   Pak TR, 2013, PFLUG ARCH EUR J PHY, V465, P655, DOI 10.1007/s00424-013-1227-y
   Pan W, 2010, J IMMUNOL, V184, P6773, DOI 10.4049/jimmunol.0904060
   Pandis I, 2012, ANN RHEUM DIS, V71, P1716, DOI 10.1136/annrheumdis-2011-200803
   Paris O, 2012, ONCOGENE, V31, P4196, DOI 10.1038/onc.2011.583
   Parker R, 2004, NAT STRUCT MOL BIOL, V11, P121, DOI 10.1038/nsmb724
   Pinheiro I, 2011, BIOESSAYS, V33, P791, DOI 10.1002/bies.201100047
   Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101
   Qin HH, 2013, AUSTRALAS J DERMATOL, V54, P90, DOI 10.1111/j.1440-0960.2012.00968.x
   Qin HH, 2013, J DERMATOL SCI, V69, P61, DOI 10.1016/j.jdermsci.2012.10.011
   Queirós AM, 2013, INT J CARDIOL, V169, P331, DOI 10.1016/j.ijcard.2013.09.002
   Quintero OL, 2012, J AUTOIMMUN, V38, pJ109, DOI 10.1016/j.jaut.2011.10.003
   Raiche J, 2004, BIOCHEM BIOPH RES CO, V325, P39, DOI 10.1016/j.bbrc.2004.10.002
   Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704
   Ross MT, 2005, NATURE, V434, P325, DOI 10.1038/nature03440
   Rouas R, 2009, EUR J IMMUNOL, V39, P1608, DOI 10.1002/eji.200838509
   ROUBINIAN J, 1979, ARTHRITIS RHEUM, V22, P1162
   ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568
   Ruby JG, 2007, NATURE, V448, P83, DOI 10.1038/nature05983
   Saumet A, 2012, MOL BIOSYST, V8, P3242, DOI 10.1039/c2mb25298h
   Sekigawa I, 2004, LUPUS, V13, P217, DOI 10.1191/0961203304lu1012ed
   Sekigawa I, 2010, CLIN EXP RHEUMATOL, V28, P419
   Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228
   Selvamani A, 2014, CLIN SCI, V127, P77, DOI 10.1042/CS20130565
   Shen N, 2012, NAT REV RHEUMATOL, V8, P701, DOI 10.1038/nrrheum.2012.142
   Shen N, 2010, P NATL ACAD SCI USA, V107, P15838, DOI 10.1073/pnas.1001337107
   Shi H, 2014, J ORAL PATHOL MED
   Shi ZH, 2014, ENDOCRINOLOGY, V155, P1982, DOI 10.1210/en.2013-2046
   Staedel C, 2013, CELL MICROBIOL, V15, P1496, DOI 10.1111/cmi.12159
   Stagakis E, 2011, ANN RHEUM DIS, V70, P1496, DOI 10.1136/ard.2010.139857
   Stamatopoulos B, 2009, BLOOD, V113, P5237, DOI 10.1182/blood-2008-11-189407
   Stittrich AB, 2010, NAT IMMUNOL, V11, P1057, DOI 10.1038/ni.1945
   Straub RH, 2007, ENDOCR REV, V28, P521, DOI 10.1210/er.2007-0001
   Strickland FM, 2012, J AUTOIMMUN, V38, pJ135, DOI 10.1016/j.jaut.2011.11.001
   T. A. D. C. Committee, 2005, PROGR AUT DIS RES
   Tang YJ, 2009, ARTHRITIS RHEUM-US, V60, P1065, DOI 10.1002/art.24436
   Tao S., 2014, BIOCH BIOPHYS RES CO
   Urowitz MB, 2012, ARTHRIT CARE RES, V64, P132, DOI 10.1002/acr.20648
   Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806
   Venkatesh J, 2011, J IMMUNOL, V186, P5304, DOI 10.4049/jimmunol.1000224
   Walker SE, 2011, CLIN REV ALLERG IMMU, V40, P60, DOI 10.1007/s12016-010-8199-x
   Wang G, 2011, LUPUS, V20, P493, DOI 10.1177/0961203310389841
   Wang HL, 2012, TRANSL RES, V160, P198, DOI 10.1016/j.trsl.2012.04.002
   Whitacre CC, 2001, NAT IMMUNOL, V2, P777, DOI 10.1038/ni0901-777
   Wijchers PJ, 2011, TRENDS GENET, V27, P132, DOI 10.1016/j.tig.2011.01.004
   Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003
   Xie T, 2012, J IMMUNOL, V188, P2437, DOI 10.4049/jimmunol.1101070
   Xue F, 2013, GENES IMMUN, V14, P127, DOI 10.1038/gene.2012.58
   Yamagata K, 2009, MOL CELL, V36, P340, DOI 10.1016/j.molcel.2009.08.017
   Yang WB, 2014, ONCOTARGET, V5, P740, DOI 10.18632/oncotarget.1608
   Yang ZH, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-31
   Ying SY, 2010, METHODS MOL BIOL, V629, P203, DOI 10.1007/978-1-60761-657-3_14
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhao S, 2011, ARTHRITIS RHEUM-US, V63, P1376, DOI 10.1002/art.30196
   Zhao X, 2010, ARTHRITIS RHEUM-US, V62, P3425, DOI 10.1002/art.27632
   ZIATS MN, 2013, MOL PSYCHIAT, P37777
NR 143
TC 34
Z9 41
U1 0
U2 27
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0008-8749
EI 1090-2163
J9 CELL IMMUNOL
JI Cell. Immunol.
PD APR
PY 2015
VL 294
IS 2
SI SI
BP 70
EP 79
DI 10.1016/j.cellimm.2015.01.004
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA CE0FV
UT WOS:000351480800003
PM 25619140
DA 2025-01-12
ER

PT J
AU Sever, R
   Brugge, JS
AF Sever, Richard
   Brugge, Joan S.
TI Signal Transduction in Cancer
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID PYRUVATE-KINASE M2; EPITHELIAL-MESENCHYMAL TRANSITIONS; ACUTE
   MYELOID-LEUKEMIA; PAR3 POLARITY PROTEIN; BREAST-CANCER; C-MYC;
   CELL-MIGRATION; TUMOR-GROWTH; DEPENDENT PHOSPHORYLATION; NASOPHARYNGEAL
   CARCINOMA
AB Cancer is driven by genetic and epigenetic alterations that allow cells to overproliferate and escape mechanisms that normally control their survival and migration. Many of these alterations map to signaling pathways that control cell growth and division, cell death, cell fate, and cell motility, and can be placed in the context of distortions of wider signaling networks that fuel cancer progression, such as changes in the tumor microenvironment, angiogenesis, and inflammation. Mutations that convert cellular proto-oncogenes to oncogenes can cause hyper-activation of these signaling pathways, whereas inactivation of tumor suppressors eliminates critical negative regulators of signaling. An examination of the PI3K-Akt and Ras-ERK pathways illustrates how such alterations dysregulate signaling in cancer and produce many of the characteristic features of tumor cells.
C1 [Sever, Richard] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Brugge, Joan S.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
C3 Cold Spring Harbor Laboratory; Harvard University; Harvard Medical
   School
RP Brugge, JS (通讯作者)，Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
EM joan_brugge@hms.harvard.edu
OI Sever, Richard/0000-0001-6478-931X
CR Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485
   Bakan I, 2012, CURR OPIN LIPIDOL, V23, P226, DOI 10.1097/MOL.0b013e328352dd03
   Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281
   Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230
   Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792
   Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200
   Birchmeier W, 1995, EXS, V74, P1
   Burgering BMT, 2003, J LEUKOCYTE BIOL, V73, P689, DOI 10.1189/jlb.1202629
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079
   Castells M, 2012, INT J MOL SCI, V13, P9545, DOI 10.3390/ijms13089545
   Castoria G, 2004, STEROIDS, V69, P517, DOI 10.1016/j.steroids.2004.05.001
   Chin YR, 2011, CELL ADHES MIGR, V5, P211, DOI 10.4161/cam.5.3.15790
   Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667
   Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8
   Collak FK, 2012, J BIOL CHEM, V287, P23698, DOI 10.1074/jbc.M112.358713
   Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217
   Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069
   Devreotes P, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a005959
   Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957
   Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738
   Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306
   Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219
   Duronio RJ, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008904
   Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584
   Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200
   Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029
   Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281
   Giroux S, 2013, BIOORG MED CHEM LETT, V23, P394, DOI 10.1016/j.bmcl.2012.11.037
   Gorgoulis VG, 2010, CURR OPIN CELL BIOL, V22, P816, DOI 10.1016/j.ceb.2010.07.013
   Green DR, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a006080
   Greer C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074641
   Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465
   Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486
   Hamede RK, 2013, J ANIM ECOL, V82, P182, DOI 10.1111/j.1365-2656.2012.02025.x
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Haq S, 2003, P NATL ACAD SCI USA, V100, P4610, DOI 10.1073/pnas.0835895100
   Hardie DG, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006031
   Harrison DA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011205
   Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458
   Harvey KF, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011288
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189
   Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431
   Hölzel M, 2013, NAT REV CANCER, V13, P365, DOI 10.1038/nrc3498
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107
   Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003
   Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004
   Ingham PW, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011221
   Israelsen WJ, 2013, CELL, V155, P397, DOI 10.1016/j.cell.2013.09.025
   Jensen PJ, 2010, J BIOL CHEM, V285, P17673, DOI 10.1074/jbc.M109.079343
   Jeon TI, 2012, TRENDS ENDOCRIN MET, V23, P65, DOI 10.1016/j.tem.2011.10.004
   Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141
   Keely PJ, 2011, J MAMMARY GLAND BIOL, V16, P205, DOI 10.1007/s10911-011-9226-0
   Kim D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009616
   Kim J, 2012, EMBO J, V31, P1279, DOI 10.1038/emboj.2011.491
   Kim JW, 2004, MOL CELL BIOL, V24, P5923, DOI 10.1128/MCB.24.13.5923-5936.2004
   Kopan Raphael, 2012, Cold Spring Harb Perspect Biol, V4, DOI 10.1101/cshperspect.a011213
   Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121
   Kubatka P, 2011, Klin Onkol, V24, P41
   Laplante M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011593
   Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022
   Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026
   Lin JI, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003813
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392
   Liu WJ, 2008, ANTICANCER RES, V28, P3613
   Lu PF, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005058
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054
   Ma L, 2013, FEBS J, V280, P2027, DOI 10.1111/febs.12226
   Mazzone M, 2010, P NATL ACAD SCI USA, V107, P5012, DOI 10.1073/pnas.1000896107
   McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003
   McLaughlin SK, 2013, CANCER CELL, V24, P365, DOI 10.1016/j.ccr.2013.08.004
   Mîinea CP, 2005, BIOCHEM J, V391, P87, DOI 10.1042/BJ20050887
   Miller DM, 2012, CLIN CANCER RES, V18, P5546, DOI 10.1158/1078-0432.CCR-12-0977
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Morris MA, 2009, FUTURE ONCOL, V5, P811, DOI [10.2217/fon.09.53, 10.2217/FON.09.53]
   Morrison DK, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011254
   Münger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9
   Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024
   Murchison EP, 2012, CELL, V148, P780, DOI 10.1016/j.cell.2011.11.065
   Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822
   Nagasaka K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053752
   Nakashima A, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-24
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Newton K, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006049
   Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033
   Novellasdemunt L, 2013, J BIOL CHEM, V288, P10640, DOI 10.1074/jbc.M113.455998
   Nusse R, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011163
   O'Neill E, 2005, CELL CYCLE, V4, P365, DOI 10.4161/cc.4.3.1531
   Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200
   Plas DR, 2005, ONCOGENE, V24, P7435, DOI 10.1038/sj.onc.1209097
   Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8
   Pratilas CA, 2010, CLIN CANCER RES, V16, P3329, DOI 10.1158/1078-0432.CCR-09-3064
   Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161
   Raftopoulou M, 2004, DEV BIOL, V265, P23, DOI 10.1016/j.ydbio.2003.06.003
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Renoir JM, 2013, BIOCHEM PHARMACOL, V85, P449, DOI 10.1016/j.bcp.2012.10.018
   Rhind N, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a005942
   Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023
   Roberts DJ, 2013, J BIOL CHEM, V288, P23798, DOI 10.1074/jbc.M113.482026
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085
   Rössig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001
   Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004
   Ruiz C, 2011, P NATL ACAD SCI USA, V108, P12054, DOI 10.1073/pnas.1104009108
   Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781
   Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800
   Seeger C., 2013, Fields virology, V6th
   Sever R, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016709
   Shaikh S, 1996, HUM GENET, V97, P714
   Shen HM, 2009, APOPTOSIS, V14, P348, DOI 10.1007/s10495-009-0315-0
   Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007
   Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273
   Sulzmaier FJ, 2013, CANCER RES, V73, P6099, DOI 10.1158/0008-5472.CAN-13-1087
   Sutrias-Grau M, 2004, MOL CELL BIOL, V24, P5953, DOI 10.1128/MCB.24.13.5953-5966.2004
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Suzuki S, 2010, P NATL ACAD SCI USA, V107, P7461, DOI 10.1073/pnas.1002459107
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093
   TODA M, 1993, BIOCHEM BIOPH RES CO, V196, P468, DOI 10.1006/bbrc.1993.2273
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Turner SL, 2009, BRIT J BIOMED SCI, V66, P117, DOI 10.1080/09674845.2009.11730257
   Vargas J, 2012, FRONT BIOSCI-LANDMRK, V17, P2616, DOI 10.2741/4074
   Vicente-Manzanares M, 2011, METHODS MOL BIOL, V769, P1, DOI 10.1007/978-1-61779-207-6_1
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Ward PS, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006783
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Weinberg R.A, 2013, The Biology of Cancer
   Wiernan HL, 2007, MOL BIOL CELL, V18, P1437, DOI 10.1091/mbc.E06-07-0593
   Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102
   Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702
   Xu NH, 2012, J ONCOL, V2012, DOI 10.1155/2012/951724
   Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025
   Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663
   Yamada E, 2005, J CELL BIOL, V168, P921, DOI 10.1083/jcb.200408182
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010
NR 150
TC 633
Z9 703
U1 8
U2 84
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD APR
PY 2015
VL 5
IS 4
AR a006098
DI 10.1101/cshperspect.a006098
PG 21
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CJ0VX
UT WOS:000355198300001
PM 25833940
OA Green Published, Bronze
HC Y
HP N
DA 2025-01-12
ER

PT J
AU McConkey, DJ
   Choi, W
   Ochoa, A
   Siefker-Radtke, A
   Czerniak, B
   Dinney, CPN
AF McConkey, David J.
   Choi, Woonyoung
   Ochoa, Andrea
   Siefker-Radtke, Arlene
   Czerniak, Bogdan
   Dinney, Colin P. N.
TI Therapeutic Opportunities in the Intrinsic Subtypes of Muscle-Invasive
   Bladder Cancer
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Urothelial cancer; Basal and luminal; Neoadjuvant chemotherapy
ID PATHOLOGICAL COMPLETE RESPONSE; EPITHELIAL-MESENCHYMAL TRANSITION;
   ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER; UROTHELIAL CARCINOMA;
   GENE-EXPRESSION; URINARY-BLADDER; MOLECULAR CHARACTERIZATION;
   NEOADJUVANT CHEMOTHERAPY; LUMINAL SUBTYPES
AB Recent studies revealed that muscle-invasive bladder cancers segregate into intrinsic basal and luminal subtypes that are similar to those described for breast cancer. Each subtype is enriched with potentially clinically actionable genomic alterations and epigenetic signatures; there are associations between tumor subtype and sensitivity to conventional cisplatin-based chemotherapy. The authors review biological and clinical characteristics of the intrinsic subtypes and describe their implications for the development of conventional and targeted agents. The role that tumor plasticity seems to play in basal and luminal bladder cancer biology and its potential effects on the development of therapeutic resistance is also discussed.
C1 [McConkey, David J.; Choi, Woonyoung; Ochoa, Andrea; Dinney, Colin P. N.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA.
   [McConkey, David J.; Choi, Woonyoung; Ochoa, Andrea] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   [Siefker-Radtke, Arlene] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA.
   [Czerniak, Bogdan] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center
RP McConkey, DJ (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Urol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM dmcconke@mdanderson.org
OI Ochoa, Andrea/0000-0002-8745-8633; Dinney, Colin/0000-0002-8969-711X;
   Siefker-Radtke, Arlene/0000-0002-6328-9599
CR Black PC, 2008, CLIN CANCER RES, V14, P1478, DOI 10.1158/1078-0432.CCR-07-1593
   Blaveri E, 2005, CLIN CANCER RES, V11, P4044, DOI 10.1158/1078-0432.CCR-04-2409
   Byrski T, 2014, BREAST CANCER RES TR, V147, P401, DOI 10.1007/s10549-014-3100-x
   Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420
   Chan KS, 2009, P NATL ACAD SCI USA, V106, P14016, DOI 10.1073/pnas.0906549106
   Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029
   Ching CB, 2011, MODERN PATHOL, V24, P1111, DOI 10.1038/modpathol.2011.69
   Choi W, 2014, NAT REV UROL, V11, P400, DOI 10.1038/nrurol.2014.129
   Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009
   Choi W, 2012, PLOS ONE, V7, P453, DOI 10.1371/journal.pone.0030206
   Cooperberg MR, 2014, EUR UROL
   Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111
   Denkert C, 2010, J CLIN ONCOL, V28, P105, DOI 10.1200/JCO.2009.23.7370
   Dinney CPN, 2014, UROL ONCOL-SEMIN ORI, V32, P1108, DOI 10.1016/j.urolonc.2013.10.021
   Dominick MA, 2006, TOXICOL PATHOL, V34, P903, DOI 10.1080/01926230601072327
   Egerod FL, 2005, BIOMARKERS, V10, P295, DOI 10.1080/13547500500218682
   Egerod FL, 2010, J APPL TOXICOL, V30, P151, DOI 10.1002/jat.1481
   Esserman LJ, 2012, J CLIN ONCOL, V30, P3242, DOI 10.1200/JCO.2011.39.2779
   Esserman LJ, 2012, BREAST CANCER RES TR, V132, P1049, DOI 10.1007/s10549-011-1895-2
   George SK, 2013, TRANSL ONCOL, V6, P244, DOI 10.1593/tlo.13247
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Grossman HB, 2003, NEW ENGL J MED, V349, P859, DOI 10.1056/NEJMoa022148
   Haddad Y, 2009, CLIN CANCER RES, V15, P532, DOI 10.1158/1078-0432.CCR-08-1733
   Ho PL, 2012, NAT REV UROL, V9, P583, DOI 10.1038/nrurol.2012.142
   Ho PL, 2012, CANCER RES, V72, P3135, DOI 10.1158/0008-5472.CAN-11-3195
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049
   Hoffman KL, 2013, HORM CANCER-US, V4, P24, DOI 10.1007/s12672-012-0123-9
   Hsu IW, 2014, ONCOTARGET, V5, P7917, DOI 10.18632/oncotarget.1421
   Hsu I, 2014, CARCINOGENESIS, V35, P651, DOI 10.1093/carcin/bgt348
   Inoue K, 2000, CLIN CANCER RES, V6, P4866
   Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740
   Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344
   Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Karni-Schmidt O, 2011, AM J PATHOL, V178, P1350, DOI 10.1016/j.ajpath.2010.11.061
   Knowles MA, 2009, CANCER METAST REV, V28, P305, DOI 10.1007/s10555-009-9198-3
   Knowles MA, 2008, FUTURE ONCOL, V4, P71, DOI 10.2217/14796694.4.1.71
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lamont FR, 2011, BRIT J CANCER, V104, P75, DOI 10.1038/sj.bjc.6606016
   Lauss M, 2010, CLIN CANCER RES, V16, P4421, DOI 10.1158/1078-0432.CCR-10-0606
   Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104
   Lindgren D, 2010, CANCER RES, V70, P3463, DOI 10.1158/0008-5472.CAN-09-4213
   Lotan Y, 2013, EUR UROL, V64, P465, DOI 10.1016/j.eururo.2013.03.043
   Lozano G, 2007, CURR OPIN GENET DEV, V17, P66, DOI 10.1016/j.gde.2006.12.003
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marquis L, 2012, CANCER BIOL THER, V13, P477, DOI 10.4161/cbt.19590
   McConkey DJ, 2014, EUR UROL, V66, P609, DOI 10.1016/j.eururo.2014.05.006
   Narod SA, 2010, NAT REV CLIN ONCOL, V7, P702, DOI 10.1038/nrclinonc.2010.166
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Powles T, 2014, J CLIN ONCOL S, V32, P5
   Prat A, 2012, NAT REV CLIN ONCOL, V9, P48, DOI 10.1038/nrclinonc.2011.178
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Prowell TM, 2012, NEW ENGL J MED, V366, P2438, DOI 10.1056/NEJMp1205737
   Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970
   Ross JS, 2014, CLIN CANCER RES, V20, P68, DOI 10.1158/1078-0432.CCR-13-1992
   Shah JB, 2011, CLIN CANCER RES, V17, P2608, DOI 10.1158/1078-0432.CCR-10-2770
   Shen SS, 2006, CANCER-AM CANCER SOC, V106, P2610, DOI 10.1002/cncr.21945
   Sjödahl G, 2012, CLIN CANCER RES, V18, P3377, DOI 10.1158/1078-0432.CCR-12-0077-T
   Slaton JW, 2004, J UROLOGY, V171, P570, DOI 10.1097/01.ju.0000108845.91485.20
   Sonpavde G, 2010, LANCET ONCOL, V11, P861, DOI 10.1016/S1470-2045(10)70086-3
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Tran MN, 2013, J BIOL CHEM, V288, P3275, DOI 10.1074/jbc.M112.408104
   Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623
   Van Batavia J, 2014, NAT CELL BIOL, V16, P982, DOI 10.1038/ncb3038
   Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509
   Volkmer JP, 2012, P NATL ACAD SCI USA, V109, P2078, DOI 10.1073/pnas.1120605109
   Wang XY, 2007, CLIN CANCER RES, V13, P953, DOI 10.1158/1078-0432.CCR-06-2167
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Williams SV, 2013, HUM MOL GENET, V22, P795, DOI 10.1093/hmg/dds486
   Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988
   Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017
NR 73
TC 52
Z9 62
U1 0
U2 3
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD APR
PY 2015
VL 29
IS 2
BP 377
EP +
DI 10.1016/j.hoc.2014.11.003
PG 20
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA CG6RL
UT WOS:000353430000017
PM 25836941
DA 2025-01-12
ER

PT J
AU Soubry, A
   Murphy, SK
   Wang, F
   Huang, Z
   Vidal, AC
   Fuemmeler, BF
   Kurtzberg, J
   Murtha, A
   Jirtle, RL
   Schildkraut, JM
   Hoyo, C
AF Soubry, A.
   Murphy, S. K.
   Wang, F.
   Huang, Z.
   Vidal, A. C.
   Fuemmeler, B. F.
   Kurtzberg, J.
   Murtha, A.
   Jirtle, R. L.
   Schildkraut, J. M.
   Hoyo, C.
TI Newborns of obese parents have altered DNA methylation patterns at
   imprinted genes
SO INTERNATIONAL JOURNAL OF OBESITY
LA English
DT Article
ID HIGH-FAT DIET; PRENATAL EXPOSURE; EARLY-LIFE; CELL CARCINOMAS; FAMINE
   EXPOSURE; OVARIAN-CANCER; BREAST-CANCER; DISEASE RISK; BODY-FAT;
   EXPRESSION
AB BACKGROUND: Several epidemiologic studies have demonstrated associations between periconceptional environmental exposures and health status of the offspring in later life. Although these environmentally related effects have been attributed to epigenetic changes, such as DNA methylation shifts at imprinted genes, little is known about the potential effects of maternal and paternal preconceptional overnutrition or obesity.
   OBJECTIVE: We examined parental preconceptional obesity in relation to DNA methylation profiles at multiple human imprinted genes important in normal growth and development, such as: maternally expressed gene 3 (MEG3), mesoderm-specific transcript (MEST), paternally expressed gene 3 (PEG3), pleiomorphic adenoma gene-like 1 (PLAGL1), epsilon sarcoglycan and paternally expressed gene 10 (SGCE/PEG10) and neuronatin (NNAT).
   METHODS: We measured methylation percentages at the differentially methylated regions (DMRs) by bisulfite pyrosequencing in DNA extracted from umbilical cord blood leukocytes of 92 newborns. Preconceptional obesity, defined as BMI >= 30 kg m(-2), was ascertained through standardized questionnaires.
   RESULTS: After adjusting for potential confounders and cluster effects, paternal obesity was significantly associated with lower methylation levels at the MEST (beta = -2.57; s.e. = 0.95; P = 0.008), PEG3 (beta = -1.71; s.e. = 0.61; P = 0.005) and NNAT (beta = -3.59; s.e. = 1.76; P = 0.04) DMRs. Changes related to maternal obesity detected at other loci were as follows: beta-coefficient was +2.58 (s.e. = 1.00; P = 0.01) at the PLAGL1 DMR and -3.42 (s.e. = 1.69; P = 0.04) at the MEG3 DMR.
   CONCLUSION: We found altered methylation outcomes at multiple imprint regulatory regions in children born to obese parents, compared with children born to non-obese parents. In spite of the small sample size, our data suggest a preconceptional influence of parental life-style or overnutrition on the (re) programming of imprint marks during gametogenesis and early development. More specifically, the significant and independent association between paternal obesity and the offspring's methylation status suggests the susceptibility of the developing sperm for environmental insults. The acquired imprint instability may be carried onto the next generation and increase the risk for chronic diseases in adulthood.
C1 [Soubry, A.; Wang, F.; Schildkraut, J. M.] Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC 27710 USA.
   [Soubry, A.] KULeuven, Dept Publ Hlth & Primary Care, Epidemiol Res Grp, Fac Med, Leuven, Belgium.
   [Murphy, S. K.; Huang, Z.] Duke Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Med Ctr, Durham, NC 27710 USA.
   [Vidal, A. C.; Hoyo, C.] Duke Univ, Div Clin & Epidemiol Res & Canc Prevent, Dept Obstet & Gynecol, Med Ctr, Durham, NC 27710 USA.
   [Fuemmeler, B. F.; Schildkraut, J. M.] Duke Univ, Med Ctr, Dept Community & Family Med, Durham, NC 27710 USA.
   [Kurtzberg, J.] Duke Univ, Duke Translat Res Inst, Robertson Cell & Translat Therapy Program, Carolinas Cord Blood Bank,Med Ctr, Durham, NC 27710 USA.
   [Murtha, A.] Duke Univ, Med Ctr, Dept Obstet & Gynecol, Div Maternal & Fetal Med, Durham, NC 27710 USA.
   [Jirtle, R. L.] Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA.
C3 Duke University; KU Leuven; Duke University; Duke University; Duke
   University; Duke University; Duke University; University of Wisconsin
   System; University of Wisconsin Madison
RP Soubry, A (通讯作者)，Duke Univ, Duke Canc Inst, Med Ctr, Durham, NC 27710 USA.
EM adelheid.soubry@hotmail.com
RI Vidal, Adriana/AAG-8944-2021; Murphy, Susan/R-3903-2019; Soubry,
   Adelheid/LWI-5218-2024
OI Fuemmeler, Bernard/0000-0002-3550-0107
FU National Institutes of Health [P30ES011961, R21ES014947, R01ES016772,
   R01DK085173, R25CA126938]; American Cancer Society [ACS-IRG 83-006];
   Fred and Alice Stanback Foundation
FX We are thankful toward the NEST families, voluntarily participating in
   this study. We acknowledge Francine Overcash and Stacy Murray for
   successfully coordinating the study and Rachel Maguire for the data
   management. We also thank the research nurse Tammy Bishop and technical
   assistance from Carole Grenier, Darby Kroyer, Erin Erginer, Cara Davis
   and Allison Barratt for processing the NEST specimens and generation of
   the methylation data. This work was supported by National Institutes of
   Health (P30ES011961, R21ES014947, R01ES016772, R01DK085173 and
   R25CA126938), the American Cancer Society (ACS-IRG 83-006), and the Fred
   and Alice Stanback Foundation.
CR Anderson LM, 2006, NUTRITION, V22, P327, DOI 10.1016/j.nut.2005.09.006
   Barker DJP, 1997, ACTA PAEDIATR, V86, P178
   Basyuk E, 2005, MOL CANCER RES, V3, P483, DOI 10.1158/1541-7786.MCR-05-0019
   Benetatos L, 2011, INT J CANCER, V129, P773, DOI 10.1002/ijc.26052
   Berg JS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026410
   Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933
   Carone BR, 2010, CELL, V143, P1084, DOI 10.1016/j.cell.2010.12.008
   Crespi B, 2008, BIOL REV, V83, P441, DOI 10.1111/j.1469-185X.2008.00050.x
   Cruz-Correa M, 2004, GASTROENTEROLOGY, V126, P964, DOI 10.1053/j.gastro.2003.12.051
   Cruz-Correa M, 2009, EPIGENETICS-US, V4, P114, DOI 10.4161/epi.4.2.7954
   Cui HM, 2002, CANCER RES, V62, P6442
   Cvetkovic D, 2004, GYNECOL ONCOL, V95, P449, DOI 10.1016/j.ygyno.2004.08.051
   Drake AJ, 2010, REPRODUCTION, V140, P387, DOI 10.1530/REP-10-0077
   Dyer JS, 2011, SEMIN REPROD MED, V29, P266, DOI 10.1055/s-0031-1275521
   El Hajj N, 2013, DIABETES, V62, P1320, DOI 10.2337/db12-0289
   el Hajj N, 2013, FERTIL STERIL, V99, P632, DOI 10.1016/j.fertnstert.2012.12.044
   Figueroa-Colon R, 2000, AM J CLIN NUTR, V71, P829, DOI 10.1093/ajcn/71.3.829
   Gabory A, 2009, DEVELOPMENT, V136, P3413, DOI 10.1242/dev.036061
   Ge ZJ, 2013, BIOL REPROD, V88, DOI 10.1095/biolreprod.112.105981
   Gejman R, 2008, J CLIN ENDOCR METAB, V93, P4119, DOI 10.1210/jc.2007-2633
   Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Hoyo C, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-46
   Huang C, 2013, SOC SCI MED, V97, P259, DOI 10.1016/j.socscimed.2012.09.051
   Huang C, 2010, J NUTR, V140, P1874, DOI 10.3945/jn.110.121293
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Kaati G, 2002, EUR J HUM GENET, V10, P682, DOI 10.1038/sj.ejhg.5200859
   Koy S, 2004, HEAD NECK-J SCI SPEC, V26, P338, DOI 10.1002/hed.10386
   Krakowiak P, 2012, PEDIATRICS, V129, pE1121, DOI 10.1542/peds.2011-2583
   Lefebvre L, 1998, NAT GENET, V20, P163, DOI 10.1038/2464
   Loomba R, 2008, GASTROENTEROLOGY, V134, P953, DOI 10.1053/j.gastro.2008.01.037
   Lui JC, 2008, AM J PHYSIOL-REG I, V295, pR189, DOI 10.1152/ajpregu.00182.2008
   Lumey LH, 2009, AM J CLIN NUTR, V89, P1737, DOI 10.3945/ajcn.2008.27038
   Malaspina D, 2001, SCHIZOPHRENIA BULL, V27, P379, DOI 10.1093/oxfordjournals.schbul.a006882
   Murphy SK, 2006, MOL CANCER RES, V4, P283, DOI 10.1158/1541-7786.MCR-05-0138
   Murphy SK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040924
   Murphy SK, 2012, GENE, V494, P36, DOI 10.1016/j.gene.2011.11.062
   Ng SF, 2010, NATURE, V467, P963, DOI 10.1038/nature09491
   Nye MD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056325
   Otsuka S, 2009, P JPN ACAD B-PHYS, V85, P157, DOI 10.2183/pjab.85.157
   Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564
   Painter RC, 2006, AM J CLIN NUTR, V84, P322
   Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055
   RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701
   Rezvani G, 2012, PEDIATR RES, V71, P32, DOI 10.1038/pr.2011.6
   Rodriguez A, 2008, INT J OBESITY, V32, P550, DOI 10.1038/sj.ijo.0803741
   Roseboom TJ, 1999, J HYPERTENS, V17, P325, DOI 10.1097/00004872-199917030-00004
   Soubry A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-2
   Soubry A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-29
   Steegers-Theunissen RP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007845
   STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433
   Stothard KJ, 2009, JAMA-J AM MED ASSOC, V301, P636, DOI 10.1001/jama.2009.113
   Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096
   Sun C, 2013, PEDIATR RES, V73, P523, DOI 10.1038/pr.2013.6
   Takahashi M, 2005, AM J PHYSIOL-ENDOC M, V288, pE117, DOI 10.1152/ajpendo.00244.2004
   Varrault A, 2006, DEV CELL, V11, P711, DOI 10.1016/j.devcel.2006.09.003
   Vidal AC, 2013, INT J OBESITY, V37, P907, DOI 10.1038/ijo.2013.47
   Vrang N, 2010, OBESITY, V18, P1289, DOI 10.1038/oby.2009.361
   Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011
   Wu Q, 2006, OBES REV, V7, P201, DOI 10.1111/j.1467-789X.2006.00232.x
   Zhao J, 2005, J CLIN ENDOCR METAB, V90, P2179, DOI 10.1210/jc.2004-1848
NR 61
TC 215
Z9 243
U1 1
U2 62
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0307-0565
EI 1476-5497
J9 INT J OBESITY
JI Int. J. Obes.
PD APR
PY 2015
VL 39
IS 4
BP 650
EP 657
DI 10.1038/ijo.2013.193
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA CF4XO
UT WOS:000352557500015
PM 24158121
OA Green Published, hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Santos, GC
   da Silva, APA
   Feldman, L
   Ventura, GM
   Vassetzky, Y
   Gallo, CVD
AF Santos, Gilson C., Jr.
   da Silva, Ana P. A.
   Feldman, Lucas
   Ventura, Grasiella M.
   Vassetzky, Yegor
   de Moura Gallo, Claudia V.
TI Epigenetic Modifications, Chromatin Distribution and <i>TP53</i>
   Transcription in a Model of Breast Cancer Progression
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE EPIGENETICS; BREAST CANCER PROGRESSION; 21T CELL LINES; DNA METHYLATION;
   HISTONE ACETYLATION; TP53
ID IN-VITRO MODEL; CELL-LINES; TUMOR PROGRESSION; DNA METHYLATION; PROTEIN;
   METHYLTRANSFERASES; ACETYLATION; EPIGENOME; DISEASE
AB In the present paper we aimed to characterize epigenetic aspects and analyze TP53 transcription in the 21T series, composed of breast cell lines: non-cancerous H16N2; Atypical Ductal Hyperplasia 21PT; Ductal Carcinoma in situ 21NT and Invasive Metastatic Carcinoma 21MT1. We detected a global genomic hypomethylation in 21NT and 21MT1. The histone modification markers analysis showed an important global decrease of the active chromatin mark H4Ac in 21MT1 relative to the other cell lines while the repressive mark H3K9Me3 were not significantly altered. The mRNA levels of DNA methylation and histone modification key enzymes are consistent with the observed genomic hypomethylation and histone hypoacetylation. The expression of DNMT3A/B increased at the initial stages of oncogenesis and the expression of DNMT1 and HAT1 decreased at the advanced stages of breast cancer. Using a confocal immunofluorescent assay, we observed that H4Ac was mostly located at the periphery and the repressive mark H3K9Me3, at the center of 21NT and 21MT1 cells nuclei. TP53 P1 promoter was found to be in an open chromatin state, with a relatively high enrichment of H4Ac and similar TP53 transcription levels in all 21T cell lines. In conclusion, we observed epigenetic alterations (global genome hypomethylation, global hypoacetylation and accumulation of pericentric heterochromatin) in metastatic breast cancer cells of the 21T series. These alterations may act at later stages of breast cancer progression and may not affect TP53 transcription at the P1 promoter. J. Cell. Biochem. 116: 533-541, 2015. (c) 2014 Wiley Periodicals, Inc.
C1 [Santos, Gilson C., Jr.; da Silva, Ana P. A.; Feldman, Lucas; de Moura Gallo, Claudia V.] Univ Estado Rio de Janeiro, Inst Biol Roberto Alcantara Gomes, Dept Genet, BR-20550013 Rio De Janeiro, Brazil.
   [Santos, Gilson C., Jr.; Vassetzky, Yegor] Univ Paris 11, Inst Cancerol Gustave Roussy, CNRS, UMR Signalisat Noyaux & Innovat Cancerol 8126, F-94805 Villejuif, France.
   [Ventura, Grasiella M.] Univ Estado Rio de Janeiro UERJ, Inst Ciencias Biol, Rio De Janeiro, Brazil.
C3 Universidade do Estado do Rio de Janeiro; Centre National de la
   Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Universite
   Paris Saclay; Universidade do Estado do Rio de Janeiro
RP Gallo, CVD (通讯作者)，Univ Estado Rio de Janeiro UERJ, Lab Biol Mol Tumores LBMT, Sala 525-6 Rua Sao Francisco Xavier,524, Rio De Janeiro, RJ, Brazil.
EM cgallo8@yahoo.com
RI Silva, Ana/KHE-5116-2024; Ventura, Grasiella/JWA-1644-2024; Vassetzky,
   Yegor/C-6447-2008
OI Vassetzky, Yegor/0000-0003-3101-7043; da Silva, Ana
   Paula/0000-0002-5050-6419
FU FAPERJ-Brazil; CAPES-COFECUB; Universidade do Estado do Rio de Janeiro
FX Grant sponsor: FAPERJ-Brazil; Grant sponsor: CAPES-COFECUB; Grant
   sponsor: Universidade do Estado do Rio de Janeiro.
CR Akhavan-Niaki H, 2013, CELL BIOCHEM BIOPHYS, V67, P501, DOI 10.1007/s12013-013-9555-2
   Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007
   Badeaux AI, 2013, NAT REV MOL CELL BIO, V14, P211, DOI 10.1038/nrm3545
   BAND V, 1990, CANCER RES, V50, P7351
   BAND V, 1991, EXP BIOL M, P169
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Carone DM, 2013, SEMIN CANCER BIOL, V23, P99, DOI 10.1016/j.semcancer.2012.06.008
   Chakrabarti A, 2012, ANN BIOMED ENG, V40, P2488, DOI 10.1007/s10439-012-0655-8
   DeHart CJ, 2014, MOL CELL PROTEOMICS, V13, P1, DOI 10.1074/mcp.M113.030254
   Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110
   Di Cerbo V, 2013, BRIEF FUNCT GENOMICS, V12, P231, DOI 10.1093/bfgp/els065
   Ethier SP, 1996, J MAMMARY GLAND BIOL, V1, P111, DOI 10.1007/BF02096306
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Halley-Stott RP, 2013, BRIEF FUNCT GENOMICS, V12, P164, DOI 10.1093/bfgp/elt011
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149
   LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969
   Locke WJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3237
   Luo X, 2011, BREAST CANC FOCUS TU, V15, P321, DOI [10.5772/1747, DOI 10.5772/1747]
   Molognoni F, 2011, EPIGENETICS-US, V6, P451, DOI 10.4161/epi.6.4.14917
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008-5472.CAN-07-0877
   Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9
   Schweiger MR, 2013, BRIEF FUNCT GENOMICS, V12, P411, DOI 10.1093/bfgp/elt024
   Souter LH, 2010, LAB INVEST, V90, P1247, DOI 10.1038/labinvest.2010.97
   Stefansson O, 2013, AM J PATHOL, V183, P1
   Suzuki J, 2009, CLIN CANCER RES, V15, P3163, DOI 10.1158/1078-0432.CCR-08-2319
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Yang XH, 2013, J BIOL CHEM, V288, P18271, DOI 10.1074/jbc.M113.473199
   Yuan H, 2013, BIOPOLYMERS, V99, P98, DOI 10.1002/bip.22128
NR 33
TC 9
Z9 9
U1 0
U2 29
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD APR
PY 2015
VL 116
IS 4
BP 533
EP 541
DI 10.1002/jcb.25003
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA CA8IU
UT WOS:000349163000006
PM 25358520
DA 2025-01-12
ER

PT J
AU Burgio, E
   Migliore, L
AF Burgio, Ernesto
   Migliore, Lucia
TI Towards a systemic paradigm in carcinogenesis: linking epigenetics and
   genetics
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Carcinogenesis; Genetics; Epigenetics
ID MYELOID LEUKEMIC-CELLS; SOMATIC MUTATION THEORY; NORMAL MAST-CELLS; DNA
   METHYLATION; BREAST-CANCER; NORMAL DIFFERENTIATION; CHROMOSOME
   TRANSLOCATIONS; TERATOCARCINOMA CELLS; GLOBAL BURDEN; TUMOR STROMA
AB For at least 30 years cancer has been defined as a genetic disease and explained by the so-called somatic mutation theory (SMT), which has dominated the carcinogenesis field. Criticism of the SMT has recently greatly increased, although still not enough to force all SMT supporters to recognize its limits. Various researchers point out that cancer appears to be a complex process concerning a whole tissue; and that genomic mutations, although variably deleterious and unpredictably important in determining the establishment of the neoplastic phenotype, are not the primary origin for a malignant neoplasia. We attempt to describe the inadequacies of the SMT and demonstrate that epigenetics is a more logical cause of carcinogenesis. Many previous models of carcinogenesis fall into two classes: (i) in which some biological changes inside cells alone lead to malignancy; and (ii) requiring changes in stroma/extracellular matrix. We try to make clear that in the (ii) model genomic instability is induced by persistent signals coming from the microenvironment, provoking epigenetic and genetic modifications in tissue stem cells that can lead to cancer. In this perspective, stochastic mutations of DNA are a critical by-product rather then the primary cause of cancer. Indirect support for such model of carcinogenesis comes from the in vitro and vivo experiments showing apparent 'reversion' of cancer phenotypes obtained via physiological factors of cellular differentiation (cytokines and other signaling molecules) or drugs, even if the key mutations are not 'reversed'.
C1 [Burgio, Ernesto] European Canc & Environm Res Inst, Brussels, Belgium.
   [Burgio, Ernesto] Int Soc Doctors Environm, Sci Off, Arezzo, Italy.
   [Migliore, Lucia] Univ Pisa, Div Med Genet, Dept Translat Res & New Technol Med & Surg, I-56126 Pisa, Italy.
C3 University of Pisa
RP Burgio, E (通讯作者)，European Canc & Environm Res Inst, Brussels, Belgium.
EM erburgio@libero.it; lucia.migliore@med.unipi.it
CR Agopian J, 2009, J EXP MED, V206, P1473, DOI 10.1084/jem.20082842
   Andrews PW, 2005, BIOCHEM SOC T, V33, P1526, DOI 10.1042/BST0331526
   [Anonymous], 2007, 1999 2007 CANC INC M
   Askanazy M., 1907, Verh, V11, P39
   Baccarelli A, 2006, CARCINOGENESIS, V27, P2001, DOI 10.1093/carcin/bgl011
   Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100
   Balducci L, 2005, NAT REV CANCER, V5, P655, DOI 10.1038/nrc1675
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bertram John S., 2000, Molecular Aspects of Medicine, V21, P167, DOI 10.1016/S0098-2997(00)00007-8
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Bizzarri M, 2008, ACTA BIOTHEOR, V56, P173, DOI 10.1007/s10441-008-9047-8
   Bleyer A., 2006, Cancer epidemiology in older adolescents and young adults 15 to 29 years of age iIncluding SEER incidence and survival: 1975-2000
   Boland CR, 2005, SEMIN CANCER BIOL, V15, P436, DOI 10.1016/j.semcancer.2005.06.001
   Boveri T, 1902, MEHRPOLIGE MITOSEN A, V35
   Braakhuis BJM, 2003, CANCER RES, V63, P1727
   Briggs D, 2003, BRIT MED BULL, V68, P1, DOI 10.1093/bmb/ldg019
   CHEAH MSC, 1984, JNCI-J NATL CANCER I, V73, P1057
   Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172
   Chen SS, 2009, P NATL ACAD SCI USA, V106, P13433, DOI 10.1073/pnas.0906455106
   Cheung HH, 2009, BIRTH DEFECTS RES C, V87, P335, DOI 10.1002/bdrc.20163
   Cohen AJ, 2005, J TOXICOL ENV HEAL A, V68, P1301, DOI 10.1080/15287390590936166
   COHEN L, 1981, P NATL ACAD SCI-BIOL, V78, P353, DOI 10.1073/pnas.78.1.353
   Cohnheim J., 1875, VIRCHOWS ARCH, V65, P64
   Cohnhein J, 1889, LECT GEN PATHOLOGY
   Croce CM, 2008, NEW ENGL J MED, V358, P502, DOI 10.1056/NEJMra072367
   Cyr AR, 2011, ANTIOXID REDOX SIGN, V15, P551, DOI 10.1089/ars.2010.3492
   Das K, 2008, THEOR BIOL MED MODEL, V5, DOI 10.1186/1742-4682-5-7
   Degos L, 2001, ONCOGENE, V20, P7140, DOI 10.1038/sj.onc.1204763
   Delys L, 2007, ONCOGENE, V26, P7894, DOI 10.1038/sj.onc.1210588
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   Dix D, 2003, MECH AGEING DEV, V124, P323, DOI 10.1016/S0047-6374(02)00113-6
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Duesberg P, 2000, CANCER GENET CYTOGEN, V119, P83, DOI 10.1016/S0165-4608(99)00236-8
   Duesberg P, 2005, CELL ONCOL, V27, P293
   Duesberg P, 2000, CELL MOTIL CYTOSKEL, V47, P81
   Duesberg P, 2006, CONTRIB MICROBIOL, V13, P16, DOI 10.1159/000092963
   Durante F., 1874, ARCH MEMOR OBSERV CH, V11, P217
   Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080
   Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133
   Esteller M, 1999, AM J PATHOL, V155, P1767, DOI 10.1016/S0002-9440(10)65492-2
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   FEINBERG AP, 1983, SCIENCE, V220, P1175, DOI 10.1126/science.6304875
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   FIBACH E, 1972, NATURE-NEW BIOL, V237, P276, DOI 10.1038/newbio237276a0
   FIBACH E, 1973, P NATL ACAD SCI USA, V70, P343, DOI 10.1073/pnas.70.2.343
   Fiegl H, 2006, CANCER RES, V66, P29, DOI 10.1158/0008-5472.CAN-05-2508
   FINKE J, 1992, BLOOD, V80, P459
   Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005
   Gerstein MB, 2007, GENOME RES, V17, P669, DOI 10.1101/gr.6339607
   Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552
   Gilbert SF, 1996, DEV BIOL, V173, P357, DOI 10.1006/dbio.1996.0032
   GINSBURG H, 1963, JNCI-J NATL CANCER I, V31, P1
   GOOTWINE E, 1982, NATURE, V299, P63, DOI 10.1038/299063a0
   Gorbunova V, 2007, NUCLEIC ACIDS RES, V35, P7466, DOI 10.1093/nar/gkm756
   Greaves M, 2005, EARLY HUM DEV, V81, P123, DOI 10.1016/j.earlhumdev.2004.10.004
   Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harris H, 2008, J CELL SCI, V121, P3, DOI [10.1242/jcs.017483, 10.1242/jcs.025742]
   Hauptmann S, 2006, MED HYPOTHESES, V66, P580, DOI 10.1016/j.mehy.2005.08.051
   HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0
   Heng HHQ, 2008, BIOESSAYS, V30, P196, DOI 10.1002/bies.20711
   Heng HHQ, 2007, BIOESSAYS, V29, P783, DOI 10.1002/bies.20610
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herrera LA, 2008, CURR GENOMICS, V9, P43, DOI 10.2174/138920208783884883
   Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718
   Hoover RN, 2000, NEW ENGL J MED, V343, P135, DOI 10.1056/NEJM200007133430210
   Hu M, 2005, NAT GENET, V37, P899, DOI 10.1038/ng1596
   Huang M E, 1989, Haematol Blood Transfus, V32, P88
   ICHIKAWA Y, 1966, P NATL ACAD SCI USA, V56, P488, DOI 10.1073/pnas.56.2.488
   ILLMENSEE K, 1976, P NATL ACAD SCI USA, V73, P549, DOI 10.1073/pnas.73.2.549
   Jelinic P, 2007, J PATHOL, V211, P261, DOI 10.1002/path.2116
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Karpinets TV, 2005, CARCINOGENESIS, V26, P1323, DOI 10.1093/carcin/bgi079
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0
   Klein G, 1981, NATURE, V294, P313, DOI 10.1038/294313a0
   KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820
   Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Kurtulus S, 2011, J IMMUNOL, V186, P5729, DOI 10.4049/jimmunol.1100102
   Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326
   Levin M, 2012, BIOSYSTEMS, V109, P243, DOI 10.1016/j.biosystems.2012.04.005
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241
   LOEB LA, 1991, CANCER RES, V51, P3075
   López-Maury L, 2008, NAT REV GENET, V9, P583, DOI 10.1038/nrg2398
   LOTEM J, 1974, P NATL ACAD SCI USA, V71, P3507, DOI 10.1073/pnas.71.9.3507
   Lotem J, 2002, ONCOGENE, V21, P3284, DOI 10.1038/sj.onc.1205319
   Lotem J, 2002, SEMIN CANCER BIOL, V12, P339, DOI 10.1016/S1044-579X(02)00054-8
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Mack SC, 2014, NATURE, V506, P445, DOI 10.1038/nature13108
   Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223
   MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214
   Mazzocchi F, 2008, EMBO REP, V9, P10, DOI 10.1038/sj.embor.7401147
   Mbeunkui F, 2009, CANCER CHEMOTH PHARM, V63, P571, DOI 10.1007/s00280-008-0881-9
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   Nachman Keeve E, 2011, Open Epidemiol J, V4, P3, DOI 10.2174/1874297101104010003
   NORDLING CO, 1953, BRIT J CANCER, V7, P68, DOI 10.1038/bjc.1953.8
   Nowak D, 2009, BLOOD, V113, P3655, DOI 10.1182/blood-2009-01-198911
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   OLSSON I, 1988, LEUKEMIA, V2, pS16
   PAPAIOANNOU VE, 1978, J EMBRYOL EXP MORPH, V44, P93
   Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232
   PIERCE GB, 1961, CANCER-AM CANCER SOC, V14, P1017, DOI 10.1002/1097-0142(196109/10)14:5<1017::AID-CNCR2820140516>3.0.CO;2-P
   PIERCE GB, 1983, AM J PATHOL, V113, P115
   PLUZNIK DH, 1966, EXP CELL RES, V43, P553, DOI 10.1016/0014-4827(66)90026-7
   PLUZNIK DH, 1965, J CELL COMPAR PHYSL, V66, P319, DOI 10.1002/jcp.1030660309
   POTTER V R, 1978, British Journal of Cancer, V38, P1, DOI 10.1038/bjc.1978.159
   Pritchard-Jones K, 2006, EUR J CANCER, V42, P2183, DOI 10.1016/j.ejca.2006.06.006
   Radisky D, 2001, SEMIN CANCER BIOL, V11, P87, DOI 10.1006/scbi.2000.0360
   Radisky ES, 2007, REV ENDOCR METAB DIS, V8, P279, DOI 10.1007/s11154-007-9037-1
   Redig AJ, 2013, J INTERN MED, V274, P113, DOI 10.1111/joim.12084
   REMAK R, 1854, DEUT KLIN, V6, P70
   Rippert V, 1911, CARCINOM MENSCHEN
   Rippert V, 1904, ARCH PATHOLOGISCHE A, V106, P282
   Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006
   Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495
   SACHS L, 1990, CANCER-AM CANCER SOC, V65, P2196, DOI 10.1002/1097-0142(19900515)65:10<2196::AID-CNCR2820651006>3.0.CO;2-Y
   SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831
   Sachs L, 1996, P NATL ACAD SCI USA, V93, P4742, DOI 10.1073/pnas.93.10.4742
   SACHS L, 1987, PROC R SOC SER B-BIO, V231, P289, DOI 10.1098/rspb.1987.0045
   SACHS L, 1987, CANCER RES, V47, P1981
   SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0
   SACHS L, 1995, ADV CANCER RES, V66, P1, DOI 10.1016/S0065-230X(08)60250-X
   Sachs L, 1982, CANCER SURV, V1, P321
   SAKAI T, 1991, AM J HUM GENET, V48, P880
   SANDER K, 1994, ROUX ARCH DEV BIOL, V203, P295, DOI 10.1007/BF00457799
   Satgé D, 2008, SEMIN CANCER BIOL, V18, P365, DOI 10.1016/j.semcancer.2008.03.020
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   SELL S, 2006, CELL SCI REV, V3, P1742
   Sell S, 2010, AM J PATHOL, V176, P2584, DOI 10.2353/ajpath.2010.091064
   Shapiro JA, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00087
   Shapiro JA, 2013, PHYS LIFE REV, V10, P287, DOI 10.1016/j.plrev.2013.07.001
   Shapiro JA, 2009, ANN NY ACAD SCI, V1178, P6, DOI 10.1111/j.1749-6632.2009.04990.x
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Sonnenschein C, 2000, MOL CARCINOGEN, V29, P205, DOI 10.1002/1098-2744(200012)29:4<205::AID-MC1002>3.0.CO;2-W
   Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087
   Soto AM, 2005, J BIOSCIENCES, V30, P103, DOI 10.1007/BF02705155
   Soto AM, 2008, INT J ANDROL, V31, P288, DOI 10.1111/j.1365-2605.2007.00834.x
   Soto AM, 2008, BASIC CLIN PHARMACOL, V102, P125, DOI 10.1111/j.1742-7843.2007.00165.x
   Spira AI, 2003, CURR OPIN PHARMACOL, V3, P338, DOI 10.1016/S1471-4892(03)00081-X
   Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055
   Sternlicht MD, 1997, CLIN CANCER RES, V3, P1949
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153
   Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194
   Telerman A, 2009, NAT REV CANCER, V9, P206, DOI 10.1038/nrc2589
   Tomás G, 2012, ONCOGENE, V31, P4490, DOI 10.1038/onc.2011.626
   Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2
   Van Regenmortel MHV, 2004, J MOL RECOGNIT, V17, P145, DOI 10.1002/jmr.674
   Vineis P, 2003, CARCINOGENESIS, V24, P1, DOI 10.1093/carcin/24.1.1
   Vineis P, 2009, ANN ONCOL, V20, P205, DOI 10.1093/annonc/mdn596
   Vineis P, 2006, INT J EPIDEMIOL, V35, P1151, DOI 10.1093/ije/dyl185
   Vineis P, 2010, CARCINOGENESIS, V31, P1703, DOI 10.1093/carcin/bgq087
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   WEBB CG, 1984, DEV BIOL, V101, P221, DOI 10.1016/0012-1606(84)90132-5
   Xu WP, 2014, J DIGEST DIS, V15, P159, DOI 10.1111/1751-2980.12122
NR 170
TC 30
Z9 34
U1 1
U2 34
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD APR
PY 2015
VL 42
IS 4
SI SI
BP 777
EP 790
DI 10.1007/s11033-014-3804-3
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CD6BM
UT WOS:000351173600002
PM 25387435
DA 2025-01-12
ER

PT J
AU Pathania, R
   Ramachandran, S
   Elangovan, S
   Padia, R
   Yang, PY
   Cinghu, S
   Veeranan-Karmegam, R
   Arjunan, P
   Gnana-Prakasam, JP
   Sadanand, F
   Pei, LR
   Chang, CS
   Choi, JH
   Shi, HD
   Manicassamy, S
   Prasad, PD
   Sharma, S
   Ganapathy, V
   Jothi, R
   Thangaraju, M
AF Pathania, Rajneesh
   Ramachandran, Sabarish
   Elangovan, Selvakumar
   Padia, Ravi
   Yang, Pengyi
   Cinghu, Senthilkumar
   Veeranan-Karmegam, Rajalakshmi
   Arjunan, Pachiappan
   Gnana-Prakasam, Jaya P.
   Sadanand, Fulzele
   Pei, Lirong
   Chang, Chang-Sheng
   Choi, Jeong-Hyeon
   Shi, Huidong
   Manicassamy, Santhakumar
   Prasad, Puttur D.
   Sharma, Suash
   Ganapathy, Vadivel
   Jothi, Raja
   Thangaraju, Muthusamy
TI DNMT1 is essential for mammary and cancer stem cell maintenance and
   tumorigenesis
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CPG-ISLAND METHYLATION; DNA METHYLATION; HEMATOPOIETIC STEM;
   SELF-RENEWAL; MAMMALIAN DEVELOPMENT; PROGENITOR CELLS; BREAST-CANCER;
   IN-VITRO; GENOME; GENE
AB Mammary stem/progenitor cells (MaSCs) maintain self-renewal of the mammary epithelium during puberty and pregnancy. DNA methylation provides a potential epigenetic mechanism for maintaining cellular memory during self-renewal. Although DNA methyltransferases (DNMTs) are dispensable for embryonic stem cell maintenance, their role in maintaining MaSCs and cancer stem cells (CSCs) in constantly replenishing mammary epithelium is unclear. Here we show that DNMT1 is indispensable for MaSC maintenance. Furthermore, we find that DNMT1 expression is elevated in mammary tumours, and mammary gland-specific DNMT1 deletion protects mice from mammary tumorigenesis by limiting the CSC pool. Through genome-scale methylation studies, we identify ISL1 as a direct DNMT1 target, hypermethylated and downregulated in mammary tumours and CSCs. DNMT inhibition or ISL1 expression in breast cancer cells limits CSC population. Altogether, our studies uncover an essential role for DNMT1 in MaSC and CSC maintenance and identify DNMT1-ISL1 axis as a potential therapeutic target for breast cancer treatment.
C1 [Pathania, Rajneesh; Ramachandran, Sabarish; Elangovan, Selvakumar; Padia, Ravi; Veeranan-Karmegam, Rajalakshmi; Arjunan, Pachiappan; Gnana-Prakasam, Jaya P.; Shi, Huidong; Prasad, Puttur D.; Ganapathy, Vadivel; Thangaraju, Muthusamy] Georgia Regents Univ, Dept Biochem & Mol Biol, Med Coll Georgia, Augusta, GA 30912 USA.
   [Yang, Pengyi; Cinghu, Senthilkumar; Jothi, Raja] NIEHS, Syst Biol Sect, Epigenet & Stem Cell Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
   [Sadanand, Fulzele] Georgia Regents Univ, Dept Orthoped Surg, Med Coll Georgia, Augusta, GA 30912 USA.
   [Pei, Lirong; Chang, Chang-Sheng; Sharma, Suash] Georgia Regents Univ, Dept Pathol, Med Coll Georgia, Augusta, GA 30912 USA.
   [Choi, Jeong-Hyeon] Georgia Regents Univ, Dept Biostat, Med Coll Georgia, Augusta, GA 30912 USA.
   [Choi, Jeong-Hyeon; Shi, Huidong; Manicassamy, Santhakumar; Prasad, Puttur D.; Sharma, Suash; Ganapathy, Vadivel; Thangaraju, Muthusamy] Georgia Regents Univ, Canc Res Ctr, Med Coll Georgia, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; National Institutes of
   Health (NIH) - USA; NIH National Institute of Environmental Health
   Sciences (NIEHS); University System of Georgia; Augusta University;
   University System of Georgia; Augusta University; University System of
   Georgia; Augusta University; University System of Georgia; Augusta
   University
RP Thangaraju, M (通讯作者)，Georgia Regents Univ, Dept Biochem & Mol Biol, Med Coll Georgia, Augusta, GA 30912 USA.
EM mthangaraju@gru.edu
RI Jothi, Raja/G-3780-2015; Sharma, Atul/ISS-2723-2023; Arjunan,
   Pachiappan/AAG-3297-2021; Ramachandran, Sabarish/K-8146-2016; Elangovan,
   Selvakumar/ABB-9558-2021; Pathania, Rajneesh/H-9985-2016; Yang,
   Pengyi/B-1002-2010
OI /0000-0002-4833-1090; Pathania, Rajneesh/0000-0003-0099-3682; S, Dr.
   Selvakumar/0000-0001-9795-3569; Elangovan,
   Selvakumar/0000-0001-9906-5477; Yang, Pengyi/0000-0003-1098-3138;
   Gnana-Prakasam, Jaya P/0000-0003-2259-9213; Shi,
   Huidong/0000-0003-1137-3390
FU National Institute of Health [CA131402]; Department of Defense
   [BC074289]; Georgia Regents University (GRU); Intramural Research
   Program of the NIH, National Institute of Environmental Health Sciences
   [1ZIAES102625]
FX We thank Jeanene Pihkala for Flow sorting and William King for technical
   assistance. This work was supported by grants from the National
   Institute of Health (CA131402), Department of Defense (BC074289) and
   Georgia Regents University (GRU) Intramural Pilot Study grant, Start-up
   and Bridge funds. P.Y., S.C. and R.J. were supported by the Intramural
   Research Program of the NIH, National Institute of Environmental Health
   Sciences (1ZIAES102625).
CR Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027
   BAYLIN SB, 1991, CANCER CELL-MON REV, V3, P383
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bröske AM, 2009, NAT GENET, V41, P1207, DOI 10.1038/ng.463
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Elangovan S, 2014, CANCER RES, V74, P1166, DOI 10.1158/0008-5472.CAN-13-1451
   Elangovan S, 2013, MOL CELL BIOL, V33, P3920, DOI 10.1128/MCB.01702-12
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Gay F, 2000, MOL ENDOCRINOL, V14, P1627, DOI 10.1210/me.14.10.1627
   Gu HC, 2011, NAT PROTOC, V6, P468, DOI 10.1038/nprot.2010.190
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76
   Ho L, 2011, NAT CELL BIOL, V13, P903, DOI 10.1038/ncb2285
   Huang THM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004515
   Jönsson M, 2002, CANCER RES, V62, P409
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   LAIRD PW, 1994, HUM MOL GENET, V3, P1487, DOI 10.1093/hmg/3.suppl_1.1487
   Latini FRM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-11
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Moretti A, 2006, CELL, V127, P1151, DOI 10.1016/j.cell.2006.10.029
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Pei LR, 2012, EPIGENETICS-US, V7, P567, DOI 10.4161/epi.20237
   Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X
   Rios AC, 2014, NATURE, V506, P322, DOI 10.1038/nature12948
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923
   Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7
   Tadokoro Y, 2007, J EXP MED, V204, P715, DOI 10.1084/jem.20060750
   Trowbridge JJ, 2012, GENE DEV, V26, P344, DOI 10.1101/gad.184341.111
   Trowbridge JJ, 2009, CELL STEM CELL, V5, P442, DOI 10.1016/j.stem.2009.08.016
   Tsai CC, 2012, MOL CELL, V47, P169, DOI 10.1016/j.molcel.2012.06.020
   Tsumura A, 2006, GENES CELLS, V11, P805, DOI 10.1111/j.1365-2443.2006.00984.x
   Visvader JE, 2014, GENE DEV, V28, P1143, DOI 10.1101/gad.242511.114
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Zhang WZ, 2013, CANCER CELL, V23, P647, DOI 10.1016/j.ccr.2013.03.012
NR 44
TC 194
Z9 215
U1 2
U2 24
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD APR
PY 2015
VL 6
AR 6910
DI 10.1038/ncomms7910
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CH0IW
UT WOS:000353704100018
PM 25908435
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Karsli-Ceppioglu, S
   Ngollo, M
   Adjakly, M
   Dagdemir, A
   Judes, G
   Lebert, A
   Boiteux, JP
   Penault-LLorca, F
   Bignon, YJ
   Guy, L
   Bernard-Gallon, D
AF Karsli-Ceppioglu, Seher
   Ngollo, Marjolaine
   Adjakly, Mawussi
   Dagdemir, Aslihan
   Judes, Gaelle
   Lebert, Andre
   Boiteux, Jean-Paul
   Penault-LLorca, Frederique
   Bignon, Yves-Jean
   Guy, Laurent
   Bernard-Gallon, Dominique
TI Genome-Wide DNA Methylation Modified by Soy Phytoestrogens: Role for
   Epigenetic Therapeutics in Prostate Cancer?
SO OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY
LA English
DT Article
ID FACTOR-KAPPA-B; CELL-LINES; TELOMERASE ACTIVITY; ANDROGEN RECEPTOR;
   BREAST-CANCER; MICROARRAY ANALYSIS; SEQUENCING REVEALS; CATALYTIC
   SUBUNIT; MITOTIC ARREST; GENISTEIN
AB In prostate cancer, DNA methylation is significantly associated with tumor initiation, progression, and metastasis. Previous studies have suggested that soy phytoestrogens might regulate DNA methylation at individual candidate gene loci and that they play a crucial role as potential therapeutic agents for prostate cancer. The purpose of our study was to examine the modulation effects of phytoestrogens on a genome-wide scale in regards to DNA methylation in prostate cancer. Prostate cancer cell lines DU-145 and LNCaP were treated with 40 mu M of genistein and 110 mu M of daidzein. DNMT inhibitor 5-azacytidine (2 mu M) and the methylating agent budesonide (2 mu M) were used to compare their demethylation/methylation effects with phytoestrogens. The regulatory effects of phytoestrogens on DNA methylation were analyzed by using a methyl-DNA immunoprecipitation method coupled with Human DNA Methylation Microarrays (MeDIP-chip). We observed that the methylation profiles of 58 genes were altered by genistein and daidzein treatments in DU-145 and LNCaP prostate cancer cells. In addition, the methylation frequencies of the MAD1L1, TRAF7, KDM4B, and hTERT genes were remarkably modified by genistein treatment. Our results suggest that the modulation effects of phytoestrogens on DNA methylation essentially lead to inhibition of cell growth and induction of apoptosis. Genome-wide methylation profiling reported here suggests that epigenetic regulation mechanisms and, by extension, epigenetics-driven novel therapeutic candidates warrant further consideration in future "omics" studies of prostate cancer.
C1 [Karsli-Ceppioglu, Seher; Ngollo, Marjolaine; Adjakly, Mawussi; Dagdemir, Aslihan; Judes, Gaelle; Penault-LLorca, Frederique; Bignon, Yves-Jean; Bernard-Gallon, Dominique] Ctr Jean Perrin CBRV, Dept Oncogenet, Clermont Ferrand, France.
   [Karsli-Ceppioglu, Seher; Ngollo, Marjolaine; Adjakly, Mawussi; Dagdemir, Aslihan; Judes, Gaelle; Penault-LLorca, Frederique; Bignon, Yves-Jean; Guy, Laurent; Bernard-Gallon, Dominique] Univ Auvergne, EA ERTICA 4677, Clermont Ferrand, France.
   [Karsli-Ceppioglu, Seher] Marmara Univ, Dept Toxicol, Fac Pharm, Istanbul, Turkey.
   [Lebert, Andre] Univ Blaise Pascal, Pascal Inst, CNRS, UMR 6602, Aubiere, France.
   [Boiteux, Jean-Paul; Guy, Laurent] CHU Gabriel Montpied, Dept Urol, Clermont Ferrand, France.
   [Penault-LLorca, Frederique] Ctr Jean Perrin, Lab Anatomopathol, Clermont Ferrand, France.
C3 Universite Clermont Auvergne (UCA); Marmara University; Centre National
   de la Recherche Scientifique (CNRS); Universite Clermont Auvergne (UCA);
   CNRS - Institute for Engineering & Systems Sciences (INSIS); CHU
   Clermont Ferrand; UNICANCER; Centre Jean Perrin
RP Bignon, YJ (通讯作者)，Ctr Jean Perrin, Dept Oncogenet, 58 Rue Montalembert, F-63000 Clermont Ferrand 01, France.
EM yves-jean.bignon@cjp.fr; dominique.bernard-gallon@cjp.fr
RI Bernard-Gallon, Dominique/L-6079-2015; Karsli-Ceppioglu,
   Seher/JED-4667-2023
OI Bernard-Gallon, Dominique/0000-0003-2931-5340
FU Scientific and Technology Research Council of Turkey [TUBITAK-2219];
   Protema Saglik Hizm. A.S.
FX Seher Karsli-Ceppioglu was supported by The Scientific and Technology
   Research Council of Turkey (TUBITAK-2219) project grants and Aslihan
   Dagdemir was funded by Protema Saglik Hizm. A.S.
CR Adjakly M, 2014, NUTR CANCER, V66, P474, DOI 10.1080/01635581.2014.884236
   Adjakly M, 2011, EPIGENOMICS-UK, V3, P795, DOI [10.2217/EPI.11.103, 10.2217/epi.11.103]
   Akiyama M, 2003, CANCER RES, V63, P18
   Ashour N, 2014, PROSTATE, V74, P1171, DOI 10.1002/pros.22833
   Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081
   Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Beyer S, 2008, J BIOL CHEM, V283, P36542, DOI 10.1074/jbc.M804578200
   Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065
   Chen RH, 1999, MOL BIOL CELL, V10, P2607, DOI 10.1091/mbc.10.8.2607
   Choi YH, 1998, INT J ONCOL, V13, P391
   Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200
   Coe BR, 2006, GENE CHROMOSOME CANC, V45, P11, DOI 10.1002/gcc.20260
   Coffey K, 2013, NUCLEIC ACIDS RES, V41, P4433, DOI 10.1093/nar/gkt106
   Dagdemir A, 2013, EPIGENOMICS-UK, V5, P51, DOI [10.2217/epi.12.74, 10.2217/EPI.12.74]
   Davis JN, 2001, FREE RADICAL BIO MED, V30, P1293, DOI 10.1016/S0891-5849(01)00535-4
   Domingo-Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078-0432.CCR-05-2767
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Gao F, 2014, GENOMICS, V103, P204, DOI 10.1016/j.ygeno.2013.12.006
   Graça I, 2014, ONCOTARGET, V5, P5950, DOI 10.18632/oncotarget.1909
   Guilleret I, 2002, INT J CANCER, V101, P335, DOI 10.1002/ijc.10593
   Herceg Z, 2011, EPIGENETICS-US, V6, P804, DOI 10.4161/epi.6.7.16262
   Hillman GG, 2004, MOL CANCER THER, V3, P1271
   Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326
   Jagadeesh S, 2006, CANCER RES, V66, P2107, DOI 10.1158/0008-5472.CAN-05-2494
   Jarrard DF, 1998, CANCER RES, V58, P5310
   Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015
   Karsli-Ceppioglu S, 2014, EPIGENOMICS-UK, V6, P651, DOI [10.2217/EPI.14.59, 10.2217/epi.14.59]
   Kikuno N, 2008, INT J CANCER, V123, P552, DOI 10.1002/ijc.23590
   KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428
   Kote-Jarai Z, 2013, HUM MOL GENET, V22, P2520, DOI 10.1093/hmg/ddt086
   Kyo S, 2008, CANCER SCI, V99, P1528, DOI 10.1111/j.1349-7006.2008.00878.x
   Li YW, 2005, CANCER RES, V65, P6934, DOI 10.1158/0008-5472.CAN-04-4604
   Liu L, 2004, GENE CHROMOSOME CANC, V41, P26, DOI 10.1002/gcc.20058
   Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9
   Lopatina NG, 2003, BIOCHEM BIOPH RES CO, V306, P650, DOI 10.1016/S0006-291X(03)01033-7
   Luo JH, 2013, AM J PATHOL, V182, P2028, DOI 10.1016/j.ajpath.2013.02.040
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   McCall P, 2012, BRIT J CANCER, V107, P1554, DOI 10.1038/bjc.2012.372
   Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094
   New M, 2012, MOL ONCOL, V6, P637, DOI 10.1016/j.molonc.2012.09.003
   Ngollo M, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-994
   Ngollo M, 2014, EPIGENOMICS-UK, V6, P415, DOI 10.2217/epi.14.34
   Ouchi H, 2005, INT J UROL, V12, P73, DOI 10.1111/j.1442-2042.2004.00973.x
   Phillip CJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-145
   Poole JC, 2001, GENE, V269, P1, DOI 10.1016/S0378-1119(01)00440-1
   Rabiau N, 2010, CANCER EPIDEMIOL, V34, P200, DOI 10.1016/j.canep.2009.12.018
   Regenbrecht CRA, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-49
   Ross JS, 2004, CLIN CANCER RES, V10, P2466, DOI 10.1158/1078-0432.CCR-0543-3
   Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Setlur SR, 2007, CANCER RES, V67, P10296, DOI 10.1158/0008-5472.CAN-07-2173
   Shin KH, 2003, BRIT J CANCER, V89, P1473, DOI 10.1038/sj.bjc.6601291
   Shin S, 2007, BIOCHEM BIOPH RES CO, V359, P742, DOI 10.1016/j.bbrc.2007.05.179
   Takeshima H, 2015, CARCINOGENESIS, V36, P192, DOI 10.1093/carcin/bgu238
   Toedling J, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-221
   Tsukasaki K, 2001, ONCOGENE, V20, P3301, DOI 10.1038/sj.onc.1204421
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   van Die MD, 2014, BJU INT, V113, pE119, DOI 10.1111/bju.12435
   Van Poppel Hendrik, 2011, Cancer Manag Res, V3, P91, DOI 10.2147/CMR.S18503
   Wang LX, 2013, ONCOL REP, V29, P283, DOI 10.3892/or.2012.2121
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Xu LG, 2004, J BIOL CHEM, V279, P17278, DOI 10.1074/jbc.C400063200
   Yu YP, 2013, AM J PATHOL, V183, P1960, DOI 10.1016/j.ajpath.2013.08.018
   Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903
   Zhou JR, 1999, J NUTR, V129, P1628, DOI 10.1093/jn/129.9.1628
   Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396
   Zotti T, 2011, J BIOL CHEM, V286, P22924, DOI 10.1074/jbc.M110.215426
NR 68
TC 26
Z9 31
U1 1
U2 24
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1536-2310
EI 1557-8100
J9 OMICS
JI OMICS
PD APR 1
PY 2015
VL 19
IS 4
BP 209
EP 219
DI 10.1089/omi.2014.0142
PG 11
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CF1FN
UT WOS:000352289400002
PM 25831061
DA 2025-01-12
ER

PT J
AU Cuddington, BP
   Verschoor, M
   Ashkar, A
   Mossman, KL
AF Cuddington, Breanne P.
   Verschoor, Meghan
   Ashkar, Ali
   Mossman, Karen L.
TI Enhanced efficacy with azacytidine and oncolytic BHV-1 in a tolerized
   cotton rat model of breast adenocarcinoma
SO MOLECULAR THERAPY-ONCOLYTICS
LA English
DT Article
ID BOVINE HERPESVIRUS TYPE-1; TUMOR-CELLS; NK CELLS; CANCER; GROWTH;
   EXPRESSION; RESPONSES; PATTERNS; VIRUSES
AB Oncolytic viruses selectively replicate in cancer cells by exploiting biochemical differences between normal and tumor cells. Treatment with epigenetic modifiers such as 5-Azacytidine, a DNA methyltransferase inhibitor, increases the replication and cytotoxicity of oncolytic viruses in vivo and in vitro. The cotton rat is an attractive animal to study oncolytic viruses, as syngeneic models of breast adenocarcinoma and osteosarcoma are well established, and many features of primary and secondary tumor growth recapitulate human disease. Treatment of LCRT breast cancer cells with 5-Azacytidine increases bovine herpesvirus type 1 (BHV-1)-mediated cytotoxicity in vitro, with Chou-Talalay analysis indicating a very strong synergy. In vivo, BHV-1 monotherapy delayed tumor growth but did not improve survival of cotton rats with subcutaneous breast adenocarcinomas. However, combination therapy significantly decreased the incidence of secondary lesions, with enhanced tumor cell clearance and evidence of immune cell infiltration compared to BHV-1 monotherapy. Together, these results warrant further investigation of BHV-1 combination therapy with epigenetic modifiers for the treatment of breast cancer, particularly in the context of the prevention and treatment of secondary lesions.
C1 [Cuddington, Breanne P.; Verschoor, Meghan; Ashkar, Ali; Mossman, Karen L.] McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada.
C3 McMaster University
RP Mossman, KL (通讯作者)，McMaster Univ, Inst Infect Dis Res, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada.
EM mossk@mcmaster.ca
OI Ashkar, Ali/0000-0003-1139-1468
FU Canadian Breast Cancer Foundation; Cancer Research Society; Canadian
   Cancer Society Research Institute
FX We thank Vikram Misra (University of Saskatchewan, Canada), Gunther Keil
   (Friedrich-Loeffler-Institut, Germany) and Clinton Jones (University of
   Nebraska, USA) for reagents and Derek Cummings for technical assistance.
   We would also like to thank Dr. Jean-Claude Cutz (McMaster University,
   Canada) for his help with analyzing lung histology samples. Breanne
   Cuddington was the recipient of a fellowship from the Canadian Breast
   Cancer Foundation. This work was sponsored by operating grants from the
   Cancer Research Society and the Canadian Cancer Society Research
   Institute (formerly the Canadian Breast Cancer Research Alliance). The
   authors acknowledge there are no financial conflicts of interest related
   to this research.
CR Adhya D, 2010, J BIOSCIENCES, V35, P647, DOI 10.1007/s12038-010-0072-9
   Ayala-Breton C, 2014, J VIROL, V88, P8332, DOI 10.1128/JVI.03823-13
   Belinsky SA, 2011, CANCER RES, V71, P454, DOI 10.1158/0008-5472.CAN-10-3184
   Berman AT, 2013, CLIN BREAST CANCER, V13, P88, DOI 10.1016/j.clbc.2012.11.001
   Bridle BW, 2013, MOL THER, V21, P887, DOI 10.1038/mt.2012.265
   Byler S, 2014, ANTICANCER RES, V34, P1071
   Cervantes-García D, 2008, ANN HEPATOL, V7, P34
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Chung SM, 2002, GENE THER, V9, P75, DOI 10.1038/sj.gt.3301620
   Connolly RM, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.AM2013-4666
   Cuddington BP, 2013, CANCER GENE THER, V20, P282, DOI 10.1038/cgt.2013.18
   Cullen BR, 2011, GENE DEV, V25, P1881, DOI 10.1101/gad.17352611
   Diallo JS, 2010, MOL THER, V18, P1123, DOI 10.1038/mt.2010.67
   Disibio G, 2008, ARCH PATHOL LAB MED, V132, P931, DOI 10.1043/1543-2165(2008)132[931:MPOCRF]2.0.CO;2
   Fernandez AF, 2010, ONCOGENE, V29, P1405, DOI 10.1038/onc.2009.517
   Frey AB, 2006, J LEUKOCYTE BIOL, V79, P652, DOI 10.1189/jlb.1105628
   Gang AO, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.14
   Heo J, 2013, NAT MED, V19, P329, DOI 10.1038/nm.3089
   Herold CJ, 1996, EUR RADIOL, V6, P596
   Hushur O, 2004, J VET MED SCI, V66, P453, DOI 10.1292/jvms.66.453
   Jones C, 2010, VET CLIN N AM-FOOD A, V26, P303, DOI 10.1016/j.cvfa.2010.04.007
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kanai R, 2010, FUTURE ONCOL, V6, P619, DOI [10.2217/fon.10.18, 10.2217/FON.10.18]
   Kaufman HL, 2010, ANN SURG ONCOL, V17, P718, DOI 10.1245/s10434-009-0809-6
   Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782
   Liu RB, 2012, CANCER RES, V72, P1964, DOI 10.1158/0008-5472.CAN-11-3208
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Okemoto K, 2013, CLIN CANCER RES, V19, P5952, DOI 10.1158/1078-0432.CCR-12-3588
   Otsuki A, 2008, MOL THER, V16, P1546, DOI 10.1038/mt.2008.155
   Papp Z, 1998, VIRAL IMMUNOL, V11, P79, DOI 10.1089/vim.1998.11.79
   Pesonen S, 2012, CANCER RES, V72, P1621, DOI 10.1158/0008-5472.CAN-11-3001
   Prince G. A., 1994, Animal Welfare Information Center Newsletter, V5, P3
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027355
   Rodrigues R, 2010, CANCER GENE THER, V17, P344, DOI 10.1038/cgt.2009.77
   Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287
   Senzer NN, 2009, J CLIN ONCOL, V27, P5763, DOI 10.1200/JCO.2009.24.3675
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sobol PT, 2011, MOL THER, V19, P335, DOI 10.1038/mt.2010.264
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Tomasi TB, 2006, CANCER IMMUNOL IMMUN, V55, P1159, DOI 10.1007/s00262-006-0164-4
   Toth K, 2005, HUM GENE THER, V16, P139, DOI 10.1089/hum.2005.16.139
   Toth Karoly, 2007, Methods Mol Med, V130, P157
   Vähä-Koskela MJV, 2007, CANCER LETT, V254, P178, DOI 10.1016/j.canlet.2007.02.002
   Wojton J, 2010, CYTOKINE GROWTH F R, V21, P127, DOI 10.1016/j.cytogfr.2010.02.014
   Workenhe ST, 2013, CANCER IMMUNOL RES, V1, P309, DOI 10.1158/2326-6066.CIR-13-0059-T
   Workenhe ST, 2014, MOL THER, V22, P123, DOI 10.1038/mt.2013.238
   Yang XW, 2000, CANCER RES, V60, P6890
   Yu F, 2014, MOL THER, V22, P102, DOI 10.1038/mt.2013.240
   Zeng WG, 2013, ONCOL REP, V29, P2355, DOI 10.3892/or.2013.2359
NR 49
TC 9
Z9 9
U1 0
U2 2
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2372-7705
J9 MOL THER-ONCOLYTICS
JI Mol. Ther.-Oncolytics
PD MAR 25
PY 2015
VL 2
AR 15004
DI 10.1038/mto.2015.4
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EE2SF
UT WOS:000389433800001
PM 27119103
OA Green Published
DA 2025-01-12
ER

PT J
AU Pan, Y
   Niles, LP
AF Pan, Yi
   Niles, Lennard P.
TI Epigenetic mechanisms of melatonin action in human SH-SY5Y neuroblastoma
   cells
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Melatonin MT1 receptor; Phospho-Akt; p300; Histone hyperacetylation;
   Epigenetic
ID ADENYLATE-CYCLASE ACTIVITY; BREAST-CANCER CELLS; GENE-EXPRESSION;
   HISTONE ACETYLATION; TRANSCRIPTIONAL REGULATION; ACETYLTRANSFERASE
   ACTIVITY; AKT-PHOSPHORYLATION; SIGNALING CASCADE; STEM-CELLS; CROSS-TALK
AB We have shown that melatonin induces histone hyperacetylation in vitro and in vivo. To clarify the mechanisms involved, we have now investigated its effects on histone acetylation and signaling pathways in human SH-SY5Y neuroblastoma cells, which express melatonin MT1 receptors. Melatonin caused significant concentration-dependent increases in both histone H3 and H4 acetylation. Blockade of melatonin receptors with luzindole abolished the histone hyperacetylating effect of melatonin, whereas inhibition of MAPK-ERK by PD98059 attenuated but did not block this effect. Melatonin treatment for 24-h decreased the levels of phospho-ERK1/2, but significantly increased Akt phosphorylation and protein expression of the histone acetyltransferase, p300. These findings suggest that the epigenetic effects of melatonin in SH-SY5Y cells are mediated by G protein-coupled MT1 melatonin receptors. Furthermore, upregulation of the histone acetyltransferase/transcriptional co-activator p300, along with phosphorylation of Akt, which is essential for p300 activation, appear to be key mechanisms underlying the epigenetic effects of melatonin. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Pan, Yi; Niles, Lennard P.] McMaster Univ, Fac Hlth Sci, Dept Psychiat & Behav Neurosci, Hamilton, ON L8S 4L8, Canada.
C3 McMaster University
RP Niles, LP (通讯作者)，McMaster Univ, Fac Hlth Sci, Dept Psychiat & Behav Neurosci, HSC-4N77,1280 Main St West, Hamilton, ON L8S 4L8, Canada.
EM niles@mcmaster.ca
FU Canadian Institutes of Health Research (CIHR), Canada
FX This work was supported by a research grant to LPN from the Canadian
   Institutes of Health Research (CIHR), Canada.
CR Agez L, 2007, NEUROSCIENCE, V144, P522, DOI 10.1016/j.neuroscience.2006.09.030
   Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609
   Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Bode Ann M, 2005, Sci STKE, V2005, pre4, DOI 10.1126/stke.2812005re4
   Brouillard F, 2003, J BIOL CHEM, V278, P39509, DOI 10.1074/jbc.M307123200
   Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7
   Carlberg C, 2000, ANN NY ACAD SCI, V917, P387
   Dubocovich ML, 2010, PHARMACOL REV, V62, P343, DOI 10.1124/pr.110.002832
   Faria JA, 2013, AM J PHYSIOL-ENDOC M, V305, pE230, DOI 10.1152/ajpendo.00094.2013
   Hardeland R, 2011, PROG NEUROBIOL, V93, P350, DOI 10.1016/j.pneurobio.2010.12.004
   Hausenloy DJ, 2004, CARDIOVASC RES, V63, P305, DOI 10.1016/j.cardiores.2004.04.011
   Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005
   Kilic Ü, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x
   Koh PO, 2008, J VET MED SCI, V70, P1219, DOI 10.1292/jvms.70.1219
   Kokkola T, 2007, J PINEAL RES, V43, P255, DOI 10.1111/j.1600-079X.2007.00470.x
   Kong PJ, 2008, KOREAN J PHYSIOL PHA, V12, P37, DOI 10.4196/kjpp.2008.12.2.37
   Kopp M, 1997, NEUROSCI LETT, V227, P145, DOI 10.1016/S0304-3940(97)00312-1
   Lardone PJ, 2009, CELL MOL LIFE SCI, V66, P516, DOI 10.1007/s00018-008-8601-5
   Lee SH, 2006, J PINEAL RES, V40, P79, DOI 10.1111/j.1600-079X.2005.00283.x
   Luchetti F, 2010, FASEB J, V24, P3603, DOI 10.1096/fj.10-154450
   Luo RX, 1999, JNCI-J NATL CANCER I, V91, P1288, DOI 10.1093/jnci/91.15.1288
   Masri S, 2010, NAT NEUROSCI, V13, P1324, DOI 10.1038/nn.2668
   McMillan CR, 2007, NEUROSCI LETT, V419, P202, DOI 10.1016/j.neulet.2007.04.029
   Niles LP, 2013, NEUROSCI LETT, V541, P49, DOI 10.1016/j.neulet.2013.01.050
   NILES LP, 1991, BIOCHEM BIOPH RES CO, V178, P786, DOI 10.1016/0006-291X(91)90177-9
   NILES LP, 1990, CELL MOL NEUROBIOL, V10, P553, DOI 10.1007/BF00712848
   Pandi-Perumal SR, 2008, PROG NEUROBIOL, V85, P335, DOI 10.1016/j.pneurobio.2008.04.001
   Park KH, 2011, J PINEAL RES, V51, P187, DOI 10.1111/j.1600-079X.2011.00875.x
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Proietti S, 2011, J PINEAL RES, V50, P150, DOI 10.1111/j.1600-079X.2010.00824.x
   Radio NM, 2006, J PINEAL RES, V40, P332, DOI 10.1111/j.1600-079X.2006.00318.x
   Radogna F, 2009, ANN NY ACAD SCI, V1171, P509, DOI 10.1111/j.1749-6632.2009.04900.x
   Reiter RJ, 2007, ADV MED SCI-POLAND, V52, P11
   Reiter RJ, 2003, ADV EXP MED BIOL, V527, P539
   Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014
   Roy D, 2002, J BIOL CHEM, V277, P251, DOI 10.1074/jbc.M108890200
   Sharma R, 2008, J PINEAL RES, V45, P277, DOI 10.1111/j.1600-079X.2008.00587.x
   Sheikh BN, 2014, CELL TISSUE RES, V356, P553, DOI 10.1007/s00441-014-1835-7
   Shikama N, 2003, EMBO J, V22, P5175, DOI 10.1093/emboj/cdg502
   Soares JM, 2003, J PHARMACOL EXP THER, V306, P694, DOI 10.1124/jpet.103.049916
   Soto-Vega E, 2004, J PINEAL RES, V37, P98, DOI 10.1111/j.1600-079X.2004.00141.x
   Tang YH, 2014, CELL TRANSPLANT, V23, P1279, DOI [10.3727/096368913x667510, 10.3727/096368913X667510]
   Vanecek J, 1998, PHYSIOL REV, V78, P687, DOI 10.1152/physrev.1998.78.3.687
   Verdone L, 2005, BIOCHEM CELL BIOL, V83, P344, DOI 10.1139/o05-041
   Verdone Loredana, 2006, Briefings in Functional Genomics & Proteomics, V5, P209, DOI 10.1093/bfgp/ell028
   von Gall C, 2000, NEUROREPORT, V11, P1803, DOI 10.1097/00001756-200006260-00002
   Wang JS, 2012, J PINEAL RES, V53, P77, DOI 10.1111/j.1600-079X.2012.00973.x
NR 49
TC 18
Z9 18
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD FEB 15
PY 2015
VL 402
IS C
BP 57
EP 63
DI 10.1016/j.mce.2015.01.003
PG 7
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA CC1IG
UT WOS:000350093800007
PM 25578604
DA 2025-01-12
ER

PT J
AU Zheng, L
   Qian, B
   Tian, D
   Tang, T
   Wan, SY
   Wang, L
   Zhu, LX
   Geng, XP
AF Zheng, Lu
   Qian, Bo
   Tian, Duo
   Tang, Tong
   Wan, Shengyun
   Wang, Lei
   Zhu, Lixin
   Geng, Xiaoping
TI FOXA1 positively regulates gene expression by changing gene methylation
   status in human breast cancer MCF-7 cells
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE MCF-7; FOXA1; tumor suppressor gene expression; methylation
ID DNA METHYLTRANSFERASES 1; TRANSCRIPTION FACTORS; CLINICAL-SIGNIFICANCE;
   3B OVEREXPRESSION; STEM-CELLS; TUMORS; ASSOCIATION; PROGNOSIS;
   CARCINOMA; FAMILY
AB Objective: DNA methylation is an important epigenetic modification with tumor suppressor gene silencing in cancer. The mechanisms underlying DNA methylation patterns are still poorly understood. This study aims to evaluate the potential value of FOXA1 for controlling gene CpG island methylation in breast cancer. Methods: FOXA1 was down-regulated by transfection with siRNA and up-regulated by transfection with plasmid in MCF-7 cell lines. The DNA methylation and mRNA levels were examined by qMSP and qRT-PCR. The cell proliferation and apoptosis was detected by MTT and Flow cytometry. Results: Suppression of FOXA1 enhanced the methylation status of DAPK, MGMT, RASSF1A, p53, and depressed mRNA levels of these tumor suppressor genes, whereas over-expression of FOXA1 showed the opposite effects. DNMT1, DNMT3A and DNMT3B mRNA were up-regulated by siRNA knock-down of FOXA1. At the same time, FOXA1 suppression promoted cell growth and inhibited apoptosis. Conclusions: FOXA1 may be associated with methylation of the tumor suppressor genes promoter through changing DNMTs expression. FOXA1 could be a potential demethylation target for prevention and treatment of breast cancer.
C1 [Zheng, Lu; Qian, Bo; Tian, Duo; Tang, Tong; Wan, Shengyun; Wang, Lei; Geng, Xiaoping] Anhui Med Univ, Dept Gen Surg, Hosp 2, Hefei 230601, Anhui, Peoples R China.
   [Zhu, Lixin] Anhui Med Univ, Hosp 1, Cental Lab, Hefei 230022, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University
RP Geng, XP (通讯作者)，Anhui Med Univ, Dept Gen Surg, Hosp 2, Hefei 230601, Anhui, Peoples R China.
EM xiaopinggeng@126.com
RI zheng, lu/GXH-7035-2022; wang, lei/GLV-0075-2022; TANG,
   TONG/KRO-7674-2024
FU Anhui Natural Science Foundation [1308085QH152]
FX This study was supported by Anhui Natural Science Foundation (NO.
   1308085QH152).
CR Alkam Y, 2013, HISTOPATHOLOGY, V63, P713, DOI 10.1111/his.12220
   Belikov S, 2009, MOL CELL BIOL, V29, P5413, DOI 10.1128/MCB.00368-09
   Ben Gacem R, 2012, HUM PATHOL, V43, P1731, DOI 10.1016/j.humpath.2011.12.022
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   Ding WJ, 2008, DIGEST DIS SCI, V53, P2083, DOI 10.1007/s10620-007-0145-2
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 1999, CANCER RES, V59, P793
   Feki A, 2004, CRIT REV ONCOL HEMAT, V52, P103, DOI 10.1016/j.critrevonc.2004.07.002
   Feng J, 2010, TUMOR BIOL, V31, P321, DOI 10.1007/s13277-010-0040-x
   Feng W, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1762
   Foley CJ, 2008, MOL CELL BIOL, V28, P4520, DOI 10.1128/MCB.02011-07
   Franco R, 2008, CANCER LETT, V266, P6, DOI 10.1016/j.canlet.2008.02.026
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Goodman JI, 2002, ANNU REV PHARMACOL, V42, P501, DOI 10.1146/annurev.pharmtox.42.092001.141143
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Hu XL, 2009, MOL CANCER RES, V7, P511, DOI 10.1158/1541-7786.MCR-08-0107
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Katoh M, 2013, CANCER LETT, V328, P198, DOI 10.1016/j.canlet.2012.09.017
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427
   LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416
   Lin L, 2002, CANCER RES, V62, P5273
   Liu L, 2003, MECH AGEING DEV, V124, P989, DOI 10.1016/j.mad.2003.08.001
   Macleod D, 1999, NAT GENET, V23, P139, DOI 10.1038/13767
   Newell-Price J, 2000, TRENDS ENDOCRIN MET, V11, P142, DOI 10.1016/S1043-2760(00)00248-4
   Nucera C, 2009, CLIN CANCER RES, V15, P3680, DOI 10.1158/1078-0432.CCR-08-3155
   Oh BK, 2007, INT J MOL MED, V20, P65
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Rahman MM, 2010, HUM PATHOL, V41, P1069, DOI 10.1016/j.humpath.2010.01.011
   Robbins CM, 2011, GENOME RES, V21, P47, DOI 10.1101/gr.107961.110
   Sekiya S, 2011, NATURE, V475, P390, DOI 10.1038/nature10263
   Sérandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110
   Smale ST, 2010, CURR OPIN GENET DEV, V20, P519, DOI 10.1016/j.gde.2010.06.010
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Tan YJ, 2010, STEM CELLS DEV, V19, P1365, DOI 10.1089/scd.2009.0386
   Thorat MA, 2008, J CLIN PATHOL, V61, P327, DOI 10.1136/jcp.2007.052431
   Tuteja G, 2007, CELL, V130, DOI 10.1016/j.cell.2007.09.005
   Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200
   Wang DYC, 1999, P ROY SOC B-BIOL SCI, V266, P163, DOI 10.1098/rspb.1999.0617
   Williamson EA, 2006, ONCOGENE, V25, P1391, DOI 10.1038/sj.onc.1209170
   Wolf I, 2007, INT J CANCER, V120, P1013, DOI 10.1002/ijc.22389
   Xu J, 2009, GENE DEV, V23, P2824, DOI 10.1101/gad.1861209
NR 46
TC 18
Z9 20
U1 1
U2 7
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 1
BP 96
EP 106
PG 11
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CB7WG
UT WOS:000349838700009
PM 25755696
DA 2025-01-12
ER

PT J
AU Su, HY
   Ma, XD
   Huang, YQ
   Han, HD
   Zou, Y
   Huang, WH
AF Su, Haiyan
   Ma, Xudong
   Huang, Yiqun
   Han, Huidan
   Zou, Yong
   Huang, Wenhua
TI JARID1B deletion induced apoptosis in Jeko-1 and HL-60 cell lines
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE siRNA; JARID1B; histone methylation; MCL; acute leukemia
ID BREAST-CANCER; PROTEIN; PLU-1; GENE; METHYLATION; EXPRESSION;
   REPRESSION; LYSINE-4; TISSUES
AB Aims: To investigate the involvement of JARID1B histone methyltransferase in the epigenetic change of euchromatic promoter in mantle cell lymphoma (MCL) and acute leukemia. Methods: We retrospectively analyzed the protein of JARID1B and tri-methylated histone H3 lysine 4 (H3K4), histone H3 lysine 9 (H3K9), and cyclin D1 and Ki67 in 30 cases of MCL by immunohistochemistry. JARID1B was depleted by small interfering RNA (siRNA), and cell apoptosis and cell proliferation were detected by flow cytometry and MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide], histone tri-methylated H3K4 and histone acetylated H3, H4, cyclin D1, Bcl-2, pro-caspase-3, C-myc were studied by Western blot. Results: We demonstrated that JARID1B was upregulated and histone tri-methylated H3K4 was downregulated in MCL compared to proliferative lymphadenitis, P < 0.05. The expression of histone methylated H3K9 was similar in both. Histone methylation of H3K4 was positively correlated with Ki67 in MCL (Kappa = 0.757, P < 0.05). This study showed that depletion of JARID1B cleavage apoptotic proteins of Bcl-2, procaspase-3, C-myc and resulted in loss cell viability and inducing apoptosis in Jeko-1 and HL-60 cell lines. JARID1B siRNA improved tri-methyl H3K4 and histone acetylated H3 and inhibited cyclin D1, but did not affect histone acetylated H4. Conclusions: This study revealed hyper JARID1B expression and hypo histone H3K4 tri-methylation in MCL. We identify depletion JARID1B as a demethylase which is capable of removing three methyl groups from H3K4 and up-regulating histone acetylation of H3 in both cell lines. Interestingly, depletion of JARID1B inhibits Cyclin D1, which is one of the genes contributes to MCL pathogenesis. JARID1B might be one of therapeutic targets in acute leukemia and MCL.
C1 [Su, Haiyan] Fujian Med Univ, Zhangzhou Affiliated Hosp, Dept Pathol, Zhangzhou 363000, Fujian, Peoples R China.
   [Ma, Xudong; Huang, Yiqun; Han, Huidan; Zou, Yong] Fujian Med Univ, Zhangzhou Affiliated Hosp, Dept Hematol, Zhangzhou 363000, Fujian, Peoples R China.
   [Huang, Wenhua] Southern Med Univ, Sch Basic Med Sci, Guangzhou, Guangdong, Peoples R China.
C3 Fujian Medical University; Fujian Medical University; Southern Medical
   University - China
RP Ma, XD (通讯作者)，Fujian Med Univ, Zhangzhou Affiliated Hosp, Dept Hematol, Zhangzhou 363000, Fujian, Peoples R China.
EM maxudong005@hotmail.com
RI huang, wenhua/AAO-5990-2020
OI huang, wenhua/0000-0003-2382-9180
FU Foundation of Science and Technology of Fujian Medical University,
   Fujian, China [FZS08018]; Science Research Foundation of Ministry of
   Health; United Fujian Provincial Health, and Education Project for
   Tackling the Key Research, P. R. China [WKJ2008-2-55]; Science Research
   Foundation of Fujian Province, P. R. China [2012J01420]; Medical
   Innovations Research Foundation of Fujian Province, P. R. China
   [2012-CX-32]; R & D institutions of Fujain [2012I2004]
FX This work was partly supported by grant-in-aid from the Foundation of
   Science and Technology of Fujian Medical University, Fujian, China (No.
   FZS08018), Science Research Foundation of Ministry of Health, United
   Fujian Provincial Health, and Education Project for Tackling the Key
   Research, P. R. China (WKJ2008-2-55), Science Research Foundation of
   Fujian Province, P. R. China (2012J01420), Medical Innovations Research
   Foundation of Fujian Province, P. R. China (2012-CX-32) and the major
   project funded by R & D institutions of Fujain (2012I2004).
CR Banck MS, 2009, EPIGENETICS-US, V4, P100, DOI 10.4161/epi.4.2.7953
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Engellau J, 2004, VIRCHOWS ARCH, V445, P224, DOI 10.1007/s00428-004-1065-6
   Fujimori Y, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-59
   Gao JH, 2009, AM J CLIN PATHOL, V132, P699, DOI 10.1309/AJCPV8LN5ENMZOVY
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Katzenberger T, 2006, BLOOD, V107, P3407, DOI 10.1182/blood-2005-10-4079
   Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787
   Lahoud MH, 2001, GENOME RES, V11, P1327, DOI 10.1101/gr.168801
   Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004
   Li LXL, 2000, AM J DERMATOPATH, V22, P489, DOI 10.1097/00000372-200012000-00002
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Ma XD, 2006, INT J ONCOL, V28, P1287
   Ma Xu-Dong, 2010, Zhonghua Xue Ye Xue Za Zhi, V31, P523
   Mitra D, 2011, J BIOL CHEM, V286, P40531, DOI 10.1074/jbc.M111.304865
   Roesch A, 2008, INT J CANCER, V122, P1047, DOI 10.1002/ijc.23211
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Sabatini E, 2010, PATHOLOGICA, V102, P83
   Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zhu LY, 2001, BIOCHEMISTRY-US, V40, P9142, DOI 10.1021/bi010476a
NR 26
TC 16
Z9 16
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 1
BP 171
EP 183
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CB7WG
UT WOS:000349838700017
PM 25755704
DA 2025-01-12
ER

PT J
AU Houseman, EA
   Kelsey, KT
   Wiencke, JK
   Marsit, CJ
AF Houseman, E. Andres
   Kelsey, Karl T.
   Wiencke, John K.
   Marsit, Carmen J.
TI Cell-composition effects in the analysis of DNA methylation array data:
   a mathematical perspective
SO BMC BIOINFORMATICS
LA English
DT Article
DE Epigenetics; Epigenome-wide-association; Epigenomics; Immune; Infinium
ID EPIGENOME-WIDE ASSOCIATION; EPIGENETIC CONTROL; IMMUNE-RESPONSE;
   GENE-EXPRESSION; BREAST-CANCER; POLYCOMB; BLOOD; HETEROGENEITY; ALCOHOL;
   MIXTURE
AB Background: The impact of cell-composition effects in analysis of DNA methylation data is now widely appreciated. With the availability of a reference data set consisting of DNA methylation measurements on isolated cell types, it is possible to impute cell proportions and adjust for them, but there is increasing interest in methods that adjust for cell composition effects when reference sets are incomplete or unavailable.
   Results: In this article we present a theoretical basis for one such method, showing that the total effect of a phenotype on DNA methylation can be decomposed into orthogonal components, one representing the effect of phenotype on proportions of major cell types, the other representing either subtle effects in composition or global effects at focused loci, and that it is possible to separate these two types of effects in a finite data set. We demonstrate this principle empirically on nine DNA methylation data sets, showing that the first few principal components generally contain a majority of the information on cell-type present in the data, but that later principal components nevertheless contain information about a small number of loci that may represent more focused associations. We also present a new method for determining the number of linear terms to interpret as cell-mixture effects and demonstrate robustness to the choice of this parameter.
   Conclusions: Taken together, our work demonstrates that reference-free algorithms for cell-mixture adjustment can produce biologically valid results, separating cell-mediated epigenetic effects (i.e. apparent effects arising from differences in cell composition) from those that are not cell mediated, and that in general the interpretation of associations evident from DNA methylation should be carefully considered.
C1 [Houseman, E. Andres] Oregon State Univ, Coll Publ Hlth & Human Sci, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA.
   [Kelsey, Karl T.] Brown Univ, Sch Publ Hlth, Dept Epidemiol, Providence, RI 02912 USA.
   [Wiencke, John K.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA.
   [Wiencke, John K.] Univ Calif San Francisco, Div Epidemiol, San Francisco, CA 94143 USA.
   [Marsit, Carmen J.] Dartmouth Coll, Hitchcock Med Ctr, Dartmouth Med Sch, Dept Community & Family Med, Hanover, NH 03756 USA.
C3 Oregon State University; Brown University; University of California
   System; University of California San Francisco; University of California
   System; University of California San Francisco; Dartmouth College
RP Houseman, EA (通讯作者)，Oregon State Univ, Coll Publ Hlth & Human Sci, Sch Biol & Populat Hlth Sci, Corvallis, OR 97331 USA.
EM andres.houseman@oregonstate.edu
RI Houseman, Eugene Andres/LXW-8656-2024; Kelsey, Karl/I-1252-2014
OI Houseman, Eugene Andres/0000-0003-0703-1830; Marsit,
   Carmen/0000-0003-4566-150X
FU National Institutes for Health [NIMH R01MH094609, NIEHS P01 ES022832,
   R01CA052689, P50CA097257]; EPA [RD83544201]; National Cancer Institute
   [P50CA097257] Funding Source: NIH RePORTER
FX Funding for this work was provided by grants from the National
   Institutes for Health: NIMH R01MH094609 (EAH and CJM), NIEHS P01
   ES022832 (CJM), R01CA052689 (JKW), P50CA097257 (JKW). Funding was also
   provided by EPA grant RD83544201 (CJM).
CR Accomando WP, 2012, CLIN CANCER RES, V18, P6147, DOI 10.1158/1078-0432.CCR-12-1008
   Barker D.J. P., 1992, FETAL INFANT ORIGINS
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Charlton J, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0434-y
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Davis BK, 2011, J IMMUNOL, V186, P1333, DOI 10.4049/jimmunol.1003111
   DeNardo DG, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1746
   Dick KJ, 2014, LANCET, V383, P1990, DOI 10.1016/S0140-6736(13)62674-4
   Falvo JV, 2013, ADV IMMUNOL, V118, P37, DOI 10.1016/B978-0-12-407708-9.00002-9
   Guintivano J, 2013, EPIGENETICS-US, V8, P290, DOI 10.4161/epi.23924
   Hansen J-PFKD, 2014, MINFI TUTORIAL BIOC2
   Hlady RA, 2014, ONCOTARGET, V5, P9425, DOI 10.18632/oncotarget.2444
   Houseman EA, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-365
   Houseman EA, 2014, BIOINFORMATICS, V30, P1431, DOI 10.1093/bioinformatics/btu029
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Jaffe AE, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r31
   Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367
   Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412
   Khavari DA, 2010, CELL CYCLE, V9, P3880, DOI 10.4161/cc.9.19.13385
   Kile ML, 2014, EPIGENETICS-US, V9, P774, DOI 10.4161/epi.28153
   Kim M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009692
   Koestler DC, 2013, ENVIRON HEALTH PERSP, V121, P971, DOI 10.1289/ehp.1205925
   Koestler DC, 2012, CANCER EPIDEM BIOMAR, V21, P1293, DOI 10.1158/1055-9965.EPI-12-0361
   Kolybaba A, 2014, CELL TISSUE RES, V356, P477, DOI 10.1007/s00441-014-1824-x
   Langevin SM, 2014, EPIGENETICS-US, V9, P884, DOI 10.4161/epi.28575
   Langevin SM, 2012, EPIGENETICS-US, V7, P291, DOI 10.4161/epi.7.3.19134
   Lederer SL, 2006, VIROL J, V3, DOI 10.1186/1743-422X-3-98
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Liu YM, 2002, ONCOGENE, V21, P7680, DOI 10.1038/sj.onc.1205883
   Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Marsit CJ, 2011, J CLIN ONCOL, V29, P1133, DOI 10.1200/JCO.2010.31.3577
   Michels KB, 2013, NAT METHODS, V10, P949, DOI 10.1038/nmeth.2632
   Monick MM, 2012, AM J MED GENET B, V159B, P141, DOI 10.1002/ajmg.b.32021
   Nakashima Y, 2007, ARTERIOSCL THROM VAS, V27, P1159, DOI 10.1161/ATVBAHA.106.134080
   Natoli G, 2010, IMMUNITY, V33, P12, DOI 10.1016/j.immuni.2010.07.006
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Simon JA, 2013, MOL CELL, V49, P808, DOI 10.1016/j.molcel.2013.02.013
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   Sung NY, 2007, BRIT J CANCER, V97, P700, DOI 10.1038/sj.bjc.6603893
   Teschendorff AE, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003709
   Teschendorff AE, 2012, BIOINFORMATICS, V28, P1487, DOI 10.1093/bioinformatics/bts170
   Teschendorff AE, 2011, BIOINFORMATICS, V27, P1496, DOI 10.1093/bioinformatics/btr171
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Waldén TB, 2012, AM J PHYSIOL-ENDOC M, V302, pE19, DOI 10.1152/ajpendo.00249.2011
   Yao Y, 2012, CELL RES, V22, P836, DOI 10.1038/cr.2012.56
   Zaina S, 2014, CIRC-CARDIOVASC GENE, V7, P692, DOI 10.1161/CIRCGENETICS.113.000441
   Zheng XQ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0419-x
   Zhou XH, 1996, AM J PATHOL, V149, P359
   Zhuang J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002517
   Zou J, 2014, NAT METHODS, V11, P309, DOI [10.1038/NMETH.2815, 10.1038/nmeth.2815]
   Zouridis H, 2012, SCI TRANSL MED, V4
NR 55
TC 76
Z9 90
U1 1
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD MAR 21
PY 2015
VL 16
AR 95
DI 10.1186/s12859-015-0527-y
PG 16
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA CF3UO
UT WOS:000352474400001
PM 25887114
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Bae, JH
   Kim, JG
   Heo, K
   Yang, K
   Kim, TO
   Yi, JM
AF Bae, Jin-Han
   Kim, Joong-Gook
   Heo, Kyu
   Yang, Kwangmo
   Kim, Tae-Oh
   Yi, Joo Mi
TI Identification of radiation-induced aberrant hypomethylation in colon
   cancer
SO BMC GENOMICS
LA English
DT Article
DE Ionizing radiation; 5-aza-2'-deoxycytidine; DNA hypomethylation;
   Methylation profiling; Gene ontology; Colon cancer
ID DNA METHYLATION; CPG METHYLATION; BREAST-CANCER; CELLS; EXPRESSION;
   TISSUE; PROTEIN; MICE; RADIOSENSITIVITY; TRANSCRIPTION
AB signaling pathways that play critical roles in cell type-specific control of survival or death. IR is a well-known genotoxic agent and human carcinogen that induces cellular damage through direct and indirect mechanisms. However, its impact on epigenetic mechanisms has not been elucidated, and more specifically, little information is available regarding genome-wide DNA methylation changes in cancer cells after IR exposure. Recently, genome-wide DNA methylation profiling technology using the Illumina HumanMethylation450K platform has emerged that allows us to query >450,000 loci within the genome. This improved technology is capable of identifying genome-wide DNA methylation changes in CpG islands and other CpG island-associated regions.
   Results: In this study, we employed this technology to test the hypothesis that exposure to IR not only induces differential DNA methylation patterns at a genome-wide level, but also results in locus-and gene-specific DNA methylation changes. We screened for differential DNA methylation changes in colorectal cancer cells after IR exposure with 2 and 5 Gy. Twenty-nine genes showed radiation-induced hypomethylation in colon cancer cells, and of those, seven genes showed a corresponding increase in gene expression by reverse transcriptase polymerase chain reaction (RT-PCR). In addition, we performed chromatin immunoprecipitation (ChIP) to confirm that the DNA-methyltransferase 1 (DNMT1) level associated with the promoter regions of these genes correlated with their methylation level and gene expression changes. Finally, we used a gene ontology (GO) database to show that a handful of hypomethylated genes induced by IR are associated with a variety of biological pathways related to cancer.
   Conclusion: We identified alterations in global DNA methylation patterns and hypomethylation at specific cancerrelated genes following IR exposure, which suggests that radiation exposure plays a critical role in conferring epigenetic alterations in cancer.
C1 [Bae, Jin-Han; Kim, Joong-Gook; Heo, Kyu; Yang, Kwangmo; Yi, Joo Mi] Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Pusan 619953, South Korea.
   [Yang, Kwangmo] Korea Inst Radiol & Med Sci, Dept Radiat Oncol, Seoul 139709, South Korea.
   [Kim, Tae-Oh] Inje Univ, Dept Internal Med, Haeundae Paik Hosp, Pusan 612896, South Korea.
C3 Korea Institute of Radiological & Medical Sciences; Korea Institute of
   Radiological & Medical Sciences; Inje University
RP Yi, JM (通讯作者)，Dongnam Inst Radiol & Med Sci DIRAMS, Res Ctr, Pusan 619953, South Korea.
EM jmyi@diram.re.kr
RI Kim, Hyung/J-5451-2012; Kim, Byung Joo/ABG-7715-2021
OI Heo, Kyu/0000-0001-8833-4731; Bae, Jin-Han/0000-0003-1859-1825
FU National Research Foundation of Korea (DIRAMS) - Korea government (MSIP)
   [50591-2015]
FX This study was supported by a National Research Foundation of Korea
   (DIRAMS) grant funded by the Korea government (MSIP) (50591-2015). We
   would like to thank Khadijah Mitchell at the Johns Hopkins School of
   Medicine for critical reading of the manuscript and providing language
   help.
CR Amundson SA, 2005, ONCOGENE, V24, P4572, DOI 10.1038/sj.onc.1208653
   Antwih DA, 2013, EPIGENETICS-US, V8, P839, DOI 10.4161/epi.25498
   Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Bodoy S, 2005, J BIOL CHEM, V280, P12002, DOI 10.1074/jbc.M408638200
   Bruni P, 2002, J BIOL CHEM, V277, P35481, DOI 10.1074/jbc.M205227200
   Chaudhry MA, 2012, DNA CELL BIOL, V31, P908, DOI 10.1089/dna.2011.1509
   Dote H, 2005, CLIN CANCER RES, V11, P4571, DOI 10.1158/1078-0432.CCR-05-0050
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fonseca C, 2007, NEW ENGL J MED, V357, P1210, DOI 10.1056/NEJMoa067655
   GOODHEAD DT, 1994, INT J RADIAT BIOL, V65, P7, DOI 10.1080/09553009414550021
   Han K, 2013, GENES GENOM, V35, P265, DOI 10.1007/s13258-013-0095-3
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hofstetter B, 2010, INT J RADIAT ONCOL, V76, P1512, DOI 10.1016/j.ijrobp.2009.10.037
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   KALINICH JF, 1989, RADIAT RES, V117, P185, DOI 10.2307/3577319
   Kim EH, 2010, ONCOGENE, V29, P4725, DOI 10.1038/onc.2010.223
   Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39
   Kim JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105405
   Kim JG, 2014, EPIGENETICS-US, V9, P1018, DOI 10.4161/epi.29007
   Kovalchuk O, 2004, MUTAT RES-FUND MOL M, V548, P75, DOI 10.1016/j.mrfmmm.2003.12.016
   Li YH, 2005, HUM MUTAT, V25, P270, DOI 10.1002/humu.20138
   Loree J, 2006, INT J RADIAT BIOL, V82, P805, DOI 10.1080/09553000600960027
   Mahapatra NR, 2005, J CLIN INVEST, V115, P1942, DOI 10.1172/JCI24354
   Martin V, 1997, J CELL BIOCHEM, V65, P95, DOI 10.1002/(SICI)1097-4644(199704)65:1<95::AID-JCB10>3.0.CO;2-G
   MICHALOWSKY LA, 1987, MOL CELL BIOL, V7, P3076, DOI 10.1128/MCB.7.9.3076
   Nakanishi T, 2001, BIOCHEM BIOPH RES CO, V281, P678, DOI 10.1006/bbrc.2001.4379
   Park WY, 2002, ONCOGENE, V21, P8521, DOI 10.1038/sj.onc.1205977
   Pogribny I, 2004, BIOCHEM BIOPH RES CO, V320, P1253, DOI 10.1016/j.bbrc.2004.06.081
   Poortmans P, 2007, RADIOTHER ONCOL, V84, P84, DOI 10.1016/j.radonc.2007.06.002
   Raiche J, 2004, BIOCHEM BIOPH RES CO, V325, P39, DOI 10.1016/j.bbrc.2004.10.002
   RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9
   Rhee I, 2000, NATURE, V404, P1003, DOI 10.1038/35010000
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Velpula KK, 2013, NEOPLASIA, V15, P192, DOI 10.1593/neo.121334
   Wen G, 2004, AM J HUM GENET, V74, P197, DOI 10.1086/381399
NR 38
TC 23
Z9 27
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD FEB 6
PY 2015
VL 16
AR 56
DI 10.1186/s12864-015-1229-6
PG 12
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA CC2FM
UT WOS:000350160600001
PM 25887185
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Tyagi, T
   Treas, JN
   Mahalingaiah, PKS
   Singh, KP
AF Tyagi, Tulika
   Treas, Justin N.
   Mahalingaiah, Prathap Kumar S.
   Singh, Kamaleshwar P.
TI Potentiation of growth inhibition and epigenetic modulation by
   combination of green tea polyphenol and 5-aza-2'-deoxycytidine in human
   breast cancer cells
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Epigenetic therapy; EGCG; 5-Aza-2 '-deoxycytidine
ID TUMOR-SUPPRESSOR GENES; EPIGALLOCATECHIN GALLATE; DNA METHYLATION;
   (-)-EPIGALLOCATECHIN GALLATE; CARCINOMA-CELLS; CYCLE ARREST; PROMOTER
   HYPERMETHYLATION; RECEPTOR-BINDING; PROSTATE-CANCER; MCF-7 CELLS
AB Epigenetic therapy by DNA demethylating agent 5-aza-2'-deoxycytidine (5-aza 2'dC) is clinically effective in acute myeloid leukemia; however, it has shown limited results in treatment of breast cancer and has significant toxicity to normal cells. Green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG) has anti-cancer and DNA demethylating properties with no significant toxicity toward normal cells. Therefore, the objective of this study was to evaluate the therapeutic efficacy of a combination of non-toxic, low dose of 5-aza 2' dC with EGCG, on growth inhibition of breast cancer cells. Human breast cancer cell lines (MCF-7, MDA-MB 231) and non-tumorigenic MCF-10A breast epithelial cells were treated with either 5-aza 2' dC, EGCG, or their combination for 7 days. Cell growth inhibition was determined by cell count, cell viability, cell cycle, and soft agar assay, whereas genes expression changes were determined by quantitative real-time PCR and/or Western blot analysis. Histone modifications and global DNA methylation changes were determined by Western blot and RAPD-PCR, respectively. The results revealed significantly greater inhibition of growth of breast cancer cells by co-treatment with 5-aza 2' dC and EGCG compared to individual treatments, whereas it has no significant toxicity to MCF-10A cells. This was further confirmed by gene expression analysis. Changes in DNA methylation and histone modifications were also greater in cells with combination treatment. Findings of this study suggest that potentiation of growth inhibition of breast cancer cells by 5-aza 2' dC and EGCG combination treatment, at least in part, is mediated by epigenetic mechanism.
C1 [Tyagi, Tulika; Treas, Justin N.; Mahalingaiah, Prathap Kumar S.; Singh, Kamaleshwar P.] Texas Tech Univ, Inst Environm & Human Hlth TIEHH, Dept Environm Toxicol, Lubbock, TX 79409 USA.
C3 Texas Tech University System; Texas Tech University
RP Singh, KP (通讯作者)，Texas Tech Univ, Inst Environm & Human Hlth TIEHH, Dept Environm Toxicol, Lubbock, TX 79409 USA.
EM kamaleshwar.singh@ttu.edu
RI Singh, Kamaleshwar/AAE-9166-2020
CR Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881
   Ahn WS, 2003, DNA CELL BIOL, V22, P217, DOI 10.1089/104454903321655846
   Aktas O, 2004, J IMMUNOL, V173, P5794, DOI 10.4049/jimmunol.173.9.5794
   Al-Romaih K, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-14
   Bae YK, 2004, CLIN CANCER RES, V10, P5998, DOI 10.1158/1078-0432.CCR-04-0667
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Brown Robert, 2004, Expert Rev Anticancer Ther, V4, P501, DOI 10.1586/14737140.4.4.501
   Chari RVJ, 2008, ACCOUNTS CHEM RES, V41, P98, DOI 10.1021/ar700108g
   Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073
   Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6
   Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7
   Chisholm K, 2004, ANTI-CANCER DRUG, V15, P889, DOI 10.1097/00001813-200410000-00010
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Ciftci K, 2003, J PHARM PHARMACOL, V55, P1135, DOI 10.1211/002235703322277177
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   CORROCHER R, 1986, CANCER-AM CANCER SOC, V58, P1658, DOI 10.1002/1097-0142(19861015)58:8<1658::AID-CNCR2820580814>3.0.CO;2-7
   Dammann R, 2001, CANCER RES, V61, P3105
   Daskalakis M, 2010, RECENT RESULTS CANC, V184, P131, DOI 10.1007/978-3-642-01222-8_10
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Dong ZG, 1997, CANCER RES, V57, P4414
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 1998, ONCOGENE, V17, P2413, DOI 10.1038/sj.onc.1202178
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Fang MZ, 2003, CANCER RES, V63, P7563
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P222, DOI 10.1002/mc.20380
   GUPTA RC, 1984, P NATL ACAD SCI-BIOL, V81, P6943, DOI 10.1073/pnas.81.22.6943
   HORWITZ SB, 1986, ANN NY ACAD SCI, V466, P733, DOI 10.1111/j.1749-6632.1986.tb38455.x
   Hsieh TC, 2008, INT J ONCOL, V33, P851, DOI 10.3892/ijo_00000073
   Hsuuw YD, 2007, ANN NY ACAD SCI, V1095, P428, DOI 10.1196/annals.1397.046
   Huang J, 2011, CURR DRUG TARGETS, V12, P1925, DOI 10.2174/138945011798184155
   Huh SW, 2004, GYNECOL ONCOL, V94, P760, DOI 10.1016/j.ygyno.2004.05.031
   Jabbour E, 2008, CANCER-AM CANCER SOC, V112, P2341, DOI 10.1002/cncr.23463
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Khan N, 2008, CANCER LETT, V269, P269, DOI 10.1016/j.canlet.2008.04.014
   Kondo T, 2002, CANCER LETT, V180, P139, DOI 10.1016/S0304-3835(02)00007-1
   Lambert JD, 2010, ARCH BIOCHEM BIOPHYS, V501, P65, DOI 10.1016/j.abb.2010.06.013
   Lavelle D, 2003, LEUKEMIA RES, V27, P999, DOI 10.1016/S0145-2126(03)00068-7
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Li WG, 2005, LIFE SCI, V76, P1735, DOI 10.1016/j.lfs.2004.09.024
   Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Mittal A, 2004, INT J ONCOL, V24, P703
   Moseley VR, 2013, ANTICANCER RES, V33, P5325
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   O'Driscoll L, 2006, CURR CANCER DRUG TAR, V6, P365, DOI 10.2174/156800906777723958
   Pandey M, 2010, INT J CANCER, V126, P2520, DOI 10.1002/ijc.24988
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Poklar N, 1996, P NATL ACAD SCI USA, V93, P7606, DOI 10.1073/pnas.93.15.7606
   Reiter CEN, 2010, ENDOCRINOLOGY, V151, P103, DOI 10.1210/en.2009-0997
   Rius M, 2012, ONCOGENE, V31, P4257, DOI 10.1038/onc.2011.601
   Roy AM, 2005, MOL CANCER THER, V4, P81
   Shimizu M, 2005, BIOCHEM BIOPH RES CO, V334, P947, DOI 10.1016/j.bbrc.2005.06.182
   Shin DY, 2013, BIOMED PHARMACOTHER, V67, P305, DOI 10.1016/j.biopha.2013.01.004
   Singh BN, 2011, BIOCHEM PHARMACOL, V82, P1807, DOI 10.1016/j.bcp.2011.07.093
   Singh KP, 2014, METHODS MOL BIOL, V1105, P71, DOI 10.1007/978-1-62703-739-6_6
   Stuart EC, 2006, LIFE SCI, V79, P2329, DOI 10.1016/j.lfs.2006.07.036
   Thakur VS, 2012, CURR PHARM BIOTECHNO, V13, P191
   Thangapazham RL, 2007, CANCER LETT, V245, P232, DOI 10.1016/j.canlet.2006.01.027
   Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X
   Townsend PA, 2004, FASEB J, V18, P1612, DOI 10.1096/fj.04-1716fje
   TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B
   Valdez BC, 2010, LEUKEMIA RES, V34, P364, DOI 10.1016/j.leukres.2009.08.014
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   Ververis K, 2012, AM J TRANSL RES, V4, P24
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yang GY, 2000, CARCINOGENESIS, V21, P2035, DOI 10.1093/carcin/21.11.2035
   Yang XH, 2001, CANCER RES, V61, P348
   Yuanyuan L, 2010, MOL CANCER, V9, P274, DOI [10.1186/1476-4598-9-274, DOI 10.1186/1476-4598-9-274]
   Zhu Wei-Guo, 2003, Current Medicinal Chemistry - Anti-Cancer Agents, V3, P187, DOI 10.2174/1568011033482440
NR 74
TC 31
Z9 34
U1 0
U2 30
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD FEB
PY 2015
VL 149
IS 3
BP 655
EP 668
DI 10.1007/s10549-015-3295-5
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CB6UC
UT WOS:000349761200009
PM 25663548
DA 2025-01-12
ER

PT J
AU Zhang, CL
   Zhao, HY
   Li, J
   Liu, HB
   Wang, F
   Wei, YJ
   Su, JZ
   Zhang, DW
   Liu, TF
   Zhang, Y
AF Zhang, Chunlong
   Zhao, Hongyan
   Li, Jie
   Liu, Hongbo
   Wang, Fang
   Wei, Yanjun
   Su, Jianzhong
   Zhang, Dongwei
   Liu, Tiefu
   Zhang, Yan
TI The Identification of Specific Methylation Patterns across Different
   Cancers
SO PLOS ONE
LA English
DT Article
ID MOLECULAR INTERACTION DATABASE; PROTEIN INTERACTION DATABASE;
   BREAST-CANCER; DNA METHYLATION; GASTRIC-CANCER; COLORECTAL-CANCER;
   PROMOTER METHYLATION; EXPRESSION; CELLS; GENES
AB Abnormal DNA methylation is known as playing an important role in the tumorgenesis. It is helpful for distinguishing the specificity of diagnosis and therapeutic targets for cancers based on characteristics of DNA methylation patterns across cancers. High throughput DNA methylation analysis provides the possibility to comprehensively filter the epigenetics diversity across various cancers. We integrated whole-genome methylation data detected in 798 samples from seven cancers. The hierarchical clustering revealed the existence of cancer-specific methylation pattern. Then we identified 331 differentially methylated genes across these cancers, most of which (266) were specifically differential methylation in unique cancer. A DNA methylation correlation network (DMCN) was built based on the methylation correlation between these genes. It was shown the hubs in the DMCN were inclined to cancer-specific genes in seven cancers. Further survival analysis using the part of genes in the DMCN revealed high-risk group and low-risk group were distinguished by seven biomarkers (PCDHB15, WBSCR17, IGF1, GYPC, CYGB, ACTG2, and PRRT1) in breast cancer and eight biomarkers (ZBTB32, OR51B4, CCL8, TMEFF2, SALL3, GPSM1, MAGEA8, and SALL1) in colon cancer, respectively. At last, a protein-protein interaction network was introduced to verify the biological function of differentially methylated genes. It was shown that MAP3K14, PTN, ACVR1 and HCK sharing different DNA methylation and gene expression across cancers were relatively high degree distribution in PPI network. The study suggested that not only the identified cancer-specific genes provided reference for individual treatment but also the relationship across cancers could be explained by differential DNA methylation.
C1 [Zhang, Chunlong; Li, Jie; Liu, Hongbo; Wang, Fang; Wei, Yanjun; Su, Jianzhong; Zhang, Yan] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
   [Zhao, Hongyan; Liu, Tiefu] Harbin Med Univ, Affiliated Hosp 4, Dept Gastroenterol, Harbin, Peoples R China.
   [Zhang, Dongwei] Harbin Med Univ, Affiliated Hosp 2, Dept Gen Surg, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Liu, TF (通讯作者)，Harbin Med Univ, Affiliated Hosp 4, Dept Gastroenterol, Harbin, Peoples R China.
EM liutiefu2014@sina.com; tyozhang@ems.hrbmu.edu.cn
RI zhang, chunlong/KQU-9361-2024; Zhang, Wanju/JRW-7091-2023; Liu,
   Hongbo/M-2162-2015
OI Liu, Hongbo/0000-0002-0733-8616
FU National Natural Science Foundation of China [31371334, 61203262,
   61403112, 61402139]
FX Support was provided by the National Natural Science Foundation of China
   [no. 31371334, 61203262, 61403112, 61402139]. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdel-Magid AF, 2014, ACS MED CHEM LETT, V5, P456, DOI [10.1021/ml500276a, 10.1021/ml5000838]
   Antony P, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-901
   Anwar S, 2000, EUR J SURG ONCOL, V26, P635, DOI 10.1053/ejso.2000.0974
   Aranda B, 2010, NUCLEIC ACIDS RES, V38, pD525, DOI 10.1093/nar/gkp878
   Armendariz BG, 2014, EUR J NEUROSCI
   Asiaf A, 2014, ASIAN PAC J CANCER P, V15, P6397, DOI 10.7314/APJCP.2014.15.15.6397
   Barchitta M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109478
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bernatsky S, 2005, ARTHRITIS RHEUM-US, V52, P1481, DOI 10.1002/art.21029
   Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Choo Kong-Bung, 2011, Malays J Pathol, V33, P61
   Correa Candace R, 2009, Eur J Cancer, V45 Suppl 1, P420, DOI 10.1016/S0959-8049(09)70073-5
   Dallol A, 2003, CANCER RES, V63, P1054
   Daniunaite K, 2014, J UROL
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782
   Delgado-Cruzata L, 2012, EPIGENETICS-US, V7, P868, DOI 10.4161/epi.20830
   Deng JY, 2014, AM J CANCER RES, V4, P518
   Gallagher WM, 2001, FEBS LETT, V489, P59, DOI 10.1016/S0014-5793(00)02389-9
   Ghasemi R, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.31
   Giani C, 1996, J CLIN ENDOCR METAB, V81, P990, DOI 10.1210/jc.81.3.990
   Gokul Gopinathan, 2013, Subcell Biochem, V61, P597, DOI 10.1007/978-94-007-4525-4_26
   Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029
   Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414
   Guardiola M, 2014, ATHEROSCLEROSIS, V237, P528, DOI 10.1016/j.atherosclerosis.2014.10.029
   Guerrero-Setas D, 2013, MODERN PATHOL, V26, P1111, DOI 10.1038/modpathol.2013.32
   Isserlin R, 2011, DATABASE-OXFORD, DOI 10.1093/database/baq037
   Kang C, 2014, WORLD J GASTROENTERO, V20, P6433, DOI 10.3748/wjg.v20.i21.6433
   Kawano H, 2014, ANN SURG ONCOL, V21, pS696, DOI 10.1245/s10434-014-3818-z
   Kiga K, 2014, RNA BIOL
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krupp M, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-53
   Li G, 2013, GENE
   Li YX, 2014, DNA CELL BIOL, V33, P455, DOI 10.1089/dna.2013.2291
   Licata L, 2012, NUCLEIC ACIDS RES, V40, pD857, DOI 10.1093/nar/gkr930
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Litovkin K, 2014, J CANCER RES CLIN, V140, P1849, DOI 10.1007/s00432-014-1738-8
   Liu ZQ, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00194
   Mahon KL, 2014, BR J CANC
   Miura D, 2014, J NIPPON MED SCH, V81, P211, DOI 10.1272/jnms.81.211
   MURRAY TI, 1992, CANCER, V69, P2232, DOI 10.1002/1097-0142(19920501)69:9<2232::AID-CNCR2820690904>3.0.CO;2-0
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nakamura J, 2014, WORLD J GASTROENTERO, V20, P11991, DOI 10.3748/wjg.v20.i34.11991
   Oh JH, 2014, CANCER PREV RES, V7, P585, DOI 10.1158/1940-6207.CAPR-13-0320
   Pagel P, 2005, BIOINFORMATICS, V21, P832, DOI 10.1093/bioinformatics/bti115
   Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803
   Prasad A, 2008, J BIOL CHEM, V283, P26624, DOI 10.1074/jbc.M800679200
   Pu H, 2014, CARCINOGENESIS
   Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108
   Sakoda LC, 2008, CANCER EPIDEM BIOMAR, V17, P1066, DOI 10.1158/1055-9965.EPI-07-2680
   Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086
   Schreiber G, 2010, CURR OPIN CHEM BIOL, V14, P511, DOI 10.1016/j.cbpa.2010.06.165
   Söreide K, 2006, BRIT J SURG, V93, P395, DOI 10.1002/bjs.5328
   Stark C, 2011, NUCLEIC ACIDS RES, V39, pD698, DOI 10.1093/nar/gkq1116
   Sutherland JE, 2003, ANN NY ACAD SCI, V983, P151, DOI 10.1111/j.1749-6632.2003.tb05970.x
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   van den Broek AJ, 2014, EUR J HUM GENET
   Varisli L, 2013, GENET TEST MOL BIOMA, V17, P562, DOI 10.1089/gtmb.2012.0524
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Vastrik I, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-r39
   Vidigal JA, 2014, TRENDS CELL BIOL
   Vivanco I, 2014, BR J CANC
   Wang L, 2014, ACTA BIOCH BIOPHYS S
   Wang WQ, 2010, EXP CELL RES, V316, P2456, DOI 10.1016/j.yexcr.2010.05.027
   Wei Z, 2007, BIOINFORMATICS, V23, P1537, DOI 10.1093/bioinformatics/btm129
   Wu BK, 2014, CELL CYCLE, V13, P3222, DOI 10.4161/15384101.2014.950886
   Wu MC, 2014, EPIGENETICS-US, V9, P318, DOI 10.4161/epi.27119
   Yu XP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-79
NR 69
TC 40
Z9 46
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 16
PY 2015
VL 10
IS 3
AR e0120361
DI 10.1371/journal.pone.0120361
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CD6EY
UT WOS:000351183500166
PM 25774687
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Urrutia, G
   Laurito, S
   Marzese, DM
   Gago, F
   Orozco, J
   Tello, O
   Branham, T
   Campoy, EM
   Roqué, M
AF Urrutia, Guillermo
   Laurito, Sergio
   Marzese, Diego M.
   Gago, Francisco
   Orozco, Javier
   Tello, Olga
   Branham, Teresita
   Campoy, Emanuel M.
   Roque, Maria
TI Epigenetic variations in breast cancer progression to lymph node
   metastasis
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE Breast cancer; Lymph node metastasis; PAX6; DNA methylation
ID PROMOTER HYPERMETHYLATION; METHYLATION; DNA; TUMOR; DISCORDANCE;
   PROFILES; RECEPTOR; GROWTH; EXPRESSION; INVASION
AB Breast cancer is a heterogeneous disease characterized by the accumulation of genetic and epigenetic alterations that contribute to the development of regional and distant metastases. Lymph node metastasis (LNM) status is the single most important prognostic factor. Metastatic cancer cells share common molecular alterations with those of the primary tumor, but in addition, they develop distinct changes that allow the cancer to progress. There is an urgent need for molecular studies which focus on identifying genomic and epigenomic markers that can predict the progression to metastasis. The objective of this study was to identify epigenetic similarities and differences between paired primary breast tumor (PBT) and LNM. We employed Methylation-Specific-MLPA (Multiplex ligation-dependent probe amplification) to assess the methylation status of 33 cancer-related genes in a cohort of 50 paired PBT and LNM specimens. We found that the methylation index, which represents the degree of aberrantly methylated genes in a specimen, was maintained during the progression to LNM. However, some genes presented differential methylation profiles. Interestingly, PAX6 presented a significant negative correlation between paired PBT and LNM (p = 0.03), which indicated a switch from methylated to unmethylated status in the progression from PBT to LNM. We further identified that the methylation status of PAX6 on the identified CpG site functionally affected the expression of PAX6 at the mRNA level. Our study unraveled significant epigenetic changes during the progression from PBT to LNM, which may contribute to improved prognosis, prediction and therapeutic management of metastatic breast cancer patients.
C1 [Urrutia, Guillermo; Laurito, Sergio; Branham, Teresita; Campoy, Emanuel M.; Roque, Maria] IHEM CCT CONICET Mendoza, Mendoza, Argentina.
   [Urrutia, Guillermo; Laurito, Sergio; Branham, Teresita; Campoy, Emanuel M.; Roque, Maria] Natl Univ Cuyo, Mendoza, Argentina.
   [Marzese, Diego M.] Providence St Johns Hlth Ctr, John Wayne Canc Inst, Santa Monica, CA USA.
   [Gago, Francisco; Orozco, Javier] Natl Univ Cuyo, Sch Med, Mendoza, Argentina.
   [Tello, Olga] Natl Univ Cuyo, Sch Dent, Mendoza, Argentina.
C3 University Nacional Cuyo Mendoza; John Wayne Cancer Institute;
   University Nacional Cuyo Mendoza; University Nacional Cuyo Mendoza
RP Roqué, M (通讯作者)，IHEM CCT CONICET Mendoza, Mendoza, Argentina.
EM mroque@mendoza-conicet.gob.ar
RI Marzese, Diego/AAA-3547-2022
OI Campoy, Emanuel/0000-0003-0521-6073; Roque, Maria/0000-0002-9564-1032
FU National University of Cuyo, Mendoza, Argentina; argentine National
   Cancer Institute; Margie and Robert E. Petersen Foundation
FX This work was partially funded by the National University of Cuyo,
   Mendoza, Argentina and the argentine National Cancer Institute. We thank
   to Nellie Nelson for her critical revision of our manuscript. DMM was
   supported by the Margie and Robert E. Petersen Foundation.
CR Alevizos L, 2014, CLIN EXP METASTAS, V31, P511, DOI 10.1007/s10585-014-9645-6
   [Anonymous], CANC MOL BIOL
   Aurilio G, 2014, EUR J CANCER, V50, P277, DOI 10.1016/j.ejca.2013.10.004
   Bergman Y, 2013, NAT STRUCT MOL BIOL, V20, P274, DOI 10.1038/nsmb.2518
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Huang BS, 2013, ONCOL REP, V30, P2263, DOI 10.3892/or.2013.2683
   Ibrahim T, 2013, ONCOLOGY-BASEL, V84, P150, DOI 10.1159/000345795
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Li YW, 2014, DIGEST DIS SCI, V59, P598, DOI 10.1007/s10620-013-2929-x
   Lindner DJ, 2013, MATRIX BIOL, V32, P123, DOI 10.1016/j.matbio.2012.11.010
   Marzese DM, 2012, J MOL DIAGN, V14, P613, DOI 10.1016/j.jmoldx.2012.07.001
   Marzese DM, 2010, MOL CELL PROBE, V24, P271, DOI 10.1016/j.mcp.2010.05.002
   Metge BJ, 2008, CLIN EXP METASTAS, V25, P753, DOI 10.1007/s10585-008-9187-x
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rykova EY, 2008, ANN NY ACAD SCI, V1137, P232, DOI 10.1196/annals.1448.021
   Senkus E, 2013, ANN ONCOL, V24, P7, DOI 10.1093/annonc/mdt284
   Sighoko D, 2014, ONCOLOGIST, V19, P592, DOI 10.1634/theoncologist.2013-0427
   Taback B, 2004, CURR OPIN MOL THER, V6, P273
   Twelves D, 2013, BREAST CANCER RES TR, V139, P341, DOI 10.1007/s10549-013-2544-8
   WALTHER C, 1991, DEVELOPMENT, V113, P1435
   Wang JW, 2013, FEBS LETT, V587, P1779, DOI 10.1016/j.febslet.2013.04.029
   Widschwendter M, 2001, J MAMMARY GLAND BIOL, V6, P193, DOI 10.1023/A:1011360724350
   Yao ZX, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0798-y
   Zhao XT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085738
NR 28
TC 15
Z9 16
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD FEB
PY 2015
VL 32
IS 2
BP 99
EP 110
DI 10.1007/s10585-015-9695-4
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CB3SJ
UT WOS:000349548500001
PM 25628026
DA 2025-01-12
ER

PT J
AU Wang, JQ
   Wu, KJ
AF Wang, Jian-Qiu
   Wu, Kou-Juey
TI Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in
   Cancer: Targets and Therapy
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Epigenetic regulation; hypoxia; epithelial-mesenchymal transition; HIF-1
   alpha; chromatin modifier; co-regulator; target
ID SMALL-MOLECULE INHIBITORS; HIPPEL-LINDAU PROTEIN; E-CADHERIN EXPRESSION;
   INDUCIBLE FACTOR-I; HISTONE DEACETYLASE; PROSTATE-CANCER; BREAST-CANCER;
   HEPATOCELLULAR-CARCINOMA; METHYLTRANSFERASE G9A; H3K4 METHYLATION
AB Intratumoral hypoxia followed by stabilization/activation of hypoxia-inducible factor 1 (HIF-1) and its downstream transcriptional factors, is one of the most important mechanisms inducing epithelial-mesenchymal transition (EMT), which has been widely accepted as a crucial step to generate early stage of tumor metastasis. Accumulating evidence suggests that epigenetic mechanisms play important roles in hypoxia-induced EMT and metastasis. These epigenetic regulations are mediated by various players including chromatin modifiers, transcriptional co-regulators, microRNAs, etc. In this review, we discuss how his tone-modifying enzymes and transcriptional co-regulators regulate EMT under hypoxic conditions. Developed or potential anticancer agents targeting epigenetic molecules regulating hypoxia-induced EMT are also discussed.
C1 [Wang, Jian-Qiu] Hangzhou Normal Univ, Sch Med, Dept Basic Med Sci, Inst Aging Res, Hangzhou 310036, Zhejiang, Peoples R China.
   [Wu, Kou-Juey] China Med Univ, Res Ctr Tumor Med Sci, Grad Inst Canc Biol, Taichung 40402, Taiwan.
C3 Hangzhou Normal University; China Medical University Taiwan
RP Wu, KJ (通讯作者)，China Med Univ, Res Ctr Tumor Med Sci, Grad Inst Canc Biol, Taichung 40402, Taiwan.
EM wukj@mail.cmu.edu.tw
RI Wu, Kou-Juey/P-4654-2015
FU National Natural Science Foundation of China [81301850]; Educational
   Commission of Zhejiang Province of China [Y201328812]; Ministry of
   Science and Technology Summit grant [MOST 103-2745-B-039-001-ASP];
   National Science Council Frontier grant [NSC102-2321-B-010-001];
   Kee-lung Chang-Gang Memorial Hospital [CMRPG2D0031]; National Research
   Program for Biopharmaceuticals [NSC102-2325-B-010-004]; Ministry of
   Education, Aim for the Top University Plan [103AC-T301]; Health and
   welfare surcharge of tobacco products [MOHW103-TD-B-111-02]; National
   Health Research Institutes [NHRI-EX103-10230SI]
FX We apologize to the authors whose work could not be cited due to the
   space constraint of reference citation. We declare no competing
   financial interests. This work was supported in part to J.Q.W. by
   National Natural Science Foundation of China (No. 81301850), Educational
   Commission of Zhejiang Province of China (No. Y201328812), and to K.J.W.
   by Ministry of Science and Technology Summit grant (MOST
   103-2745-B-039-001-ASP), National Science Council Frontier grant
   (NSC102-2321-B-010-001), Kee-lung Chang-Gang Memorial Hospital
   (CMRPG2D0031), National Research Program for Biopharmaceuticals
   (NSC102-2325-B-010-004), a grant from Ministry of Education, Aim for the
   Top University Plan (103AC-T301), a grant from Health and welfare
   surcharge of tobacco products (MOHW103-TD-B-111-02), and National Health
   Research Institutes (NHRI-EX103-10230SI).
CR Abaza MSI, 2014, INT J ONCOL, V44, P105, DOI 10.3892/ijo.2013.2146
   Ang YS, 2011, CELL, V145, P183, DOI 10.1016/j.cell.2011.03.003
   Arzumanyan A, 2012, ONCOGENE, V31, P563, DOI 10.1038/onc.2011.255
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bowers EM, 2010, CHEM BIOL, V17, P471, DOI 10.1016/j.chembiol.2010.03.006
   Bueno MTD, 2013, EPIGENETICS-US, V8, P1162, DOI 10.4161/epi.26112
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chen HB, 2006, CANCER RES, V66, P9009, DOI 10.1158/0008-5472.CAN-06-0101
   Cohen Idan, 2011, Genes Cancer, V2, P631, DOI 10.1177/1947601911417176
   Corn PG, 2003, NAT GENET, V35, P229, DOI 10.1038/ng1254
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Dekker FJ, 2009, DRUG DISCOV TODAY, V14, P942, DOI 10.1016/j.drudis.2009.06.008
   Di Fazio P, 2010, CELL ONCOL, V32, P285, DOI 10.3233/CLO-2010-0511
   Eccleston Alex, 2013, Nature, V502, P461, DOI 10.1038/502461a
   Feng TT, 2014, MED CHEM, V10, P426, DOI 10.2174/15734064113096660068
   Fritzsche FR, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-381
   Fu LN, 2012, CARCINOGENESIS, V33, P1664, DOI 10.1093/carcin/bgs217
   Gilkes DM, 2014, NAT REV CANC
   Grant S, 2007, NAT REV DRUG DISCOV, V6, P21, DOI 10.1038/nrd2227
   Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174/1566524013363537
   Guillemette B, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001354
   Hamada S, 2010, J MED CHEM, V53, P5629, DOI 10.1021/jm1003655
   Heddleston JM, 2012, CELL DEATH DIFFER, V19, P428, DOI 10.1038/cdd.2011.109
   Hojfeldt JW, 2013, NAT REV DRUG DISCOV, V12, P917, DOI 10.1038/nrd4154
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Jiang H, 2011, CELL, V144, P513, DOI 10.1016/j.cell.2011.01.020
   Jung SY, 2005, MOL ENDOCRINOL, V19, P2451, DOI 10.1210/me.2004-0476
   Karagianni P, 2007, ONCOGENE, V26, P5439, DOI 10.1038/sj.onc.1210612
   Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846
   Kiesslich T, 2013, MOL CLIN ONCOL, V1, P3, DOI 10.3892/mco.2012.28
   Kim JG, 2012, BBA-GENE REGUL MECH, V1819, P1200, DOI 10.1016/j.bbagrm.2012.10.001
   Kim T, 2009, CELL, V137, P259, DOI 10.1016/j.cell.2009.02.045
   King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535
   Knutson SK, 2014, MOL CANCER THER, V13, P842, DOI 10.1158/1535-7163.MCT-13-0773
   Knutson SK, 2013, P NATL ACAD SCI USA, V110, P7922, DOI 10.1073/pnas.1303800110
   Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200
   Krieg AJ, 2010, MOL CELL BIOL, V30, P344, DOI 10.1128/MCB.00444-09
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lansigan F, 2010, DRUGS, V70, P273, DOI 10.2165/11532190-000000000-00000
   Lee HT, 2013, ONCOL REP, V30, P1587, DOI 10.3892/or.2013.2635
   Lee JS, 2011, P NATL ACAD SCI USA, V108, P13510, DOI 10.1073/pnas.1106106108
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Liu F, 2011, J MED CHEM, V54, P6139, DOI 10.1021/jm200903z
   Liu M, 2013, J SURG RES, V182, P146, DOI 10.1016/j.jss.2012.07.066
   Lundgren K, 2009, BRIT J CANCER, V101, P1769, DOI 10.1038/sj.bjc.6605369
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mateen S, 2013, J PHARMACOL EXP THER, V345, P206, DOI 10.1124/jpet.113.203471
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Mimasu S, 2010, BIOCHEMISTRY-US, V49, P6494, DOI 10.1021/bi100299r
   Mimeault M, 2013, J CELL MOL MED, V17, P30, DOI 10.1111/jcmm.12004
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054
   Partch CL, 2011, P NATL ACAD SCI USA, V108, P7739, DOI 10.1073/pnas.1101357108
   Pierce RJ, 2012, CURR PHARM DESIGN, V18, P3567, DOI 10.2174/138161212801327248
   Privalsky ML, 2009, J BIOL CHEM, V284, P19554, DOI 10.1074/jbc.M109.007542
   Ruas JL, 2005, J CELL SCI, V118, P301, DOI 10.1242/jcs.01617
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Sarris M, 2014, ONCOGENE, V33, P1207, DOI 10.1038/onc.2013.87
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tsai YP, 2014, INT J CANCER, V134, P249, DOI 10.1002/ijc.28190
   Valente S, 2014, EXPERT OPIN THER PAT, V24, P401, DOI 10.1517/13543776.2014.877446
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035
   Wang YY, 2010, P NATL ACAD SCI USA, V107, P815, DOI 10.1073/pnas.0908967107
   Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049
   Weichert W, 2008, BRIT J CANCER, V98, P604, DOI 10.1038/sj.bjc.6604199
   Wu CY, 2012, TRENDS GENET, V28, P454, DOI 10.1016/j.tig.2012.05.005
   Wu D, 2007, ONCOGENE, V26, P5070, DOI 10.1038/sj.onc.1210316
   Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012
   Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036
   Xenaki G, 2008, ONCOGENE, V27, P5785, DOI 10.1038/onc.2008.192
   Xhemalce B, 2010, GENE DEV, V24, P647, DOI 10.1101/gad.1881710
   Xu JC, 2006, PROSTATE, V66, P1664, DOI 10.1002/pros.20488
   Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364
   Yang H, 2013, MOL CANCER THER, V12, P610, DOI 10.1158/1535-7163.MCT-12-0930
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yang MH, 2008, CELL CYCLE, V7, P2090, DOI 10.4161/cc.7.14.6324
   Zhang HS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004202
   Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027
NR 88
TC 15
Z9 18
U1 0
U2 17
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 10
BP 1272
EP 1278
DI 10.2174/1381612821666141211145610
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CB2NI
UT WOS:000349464100007
PM 25506893
DA 2025-01-12
ER

PT J
AU Toffoli, S
   Bar, I
   Abdel-Sater, F
   Delrée, P
   Hilbert, P
   Cavallin, F
   Moreau, F
   Van Criekinge, W
   Lacroix-Triki, M
   Campone, M
   Martin, AL
   Roché, H
   Machiels, JP
   Carrasco, J
   Canon, JL
AF Toffoli, Sebastien
   Bar, Isabelle
   Abdel-Sater, Fadi
   Delree, Paul
   Hilbert, Pascale
   Cavallin, Frederic
   Moreau, Fabrice
   Van Criekinge, Wim
   Lacroix-Triki, Magali
   Campone, Mario
   Martin, Anne-Laure
   Roche, Henri
   Machiels, Jean-Pascal
   Carrasco, Javier
   Canon, Jean-Luc
TI Identification by array comparative genomic hybridization of a new
   amplicon on chromosome 17q highly recurrent in <i>BRCA1</i> mutated
   triple negative breast cancer
SO BREAST CANCER RESEARCH
LA English
DT Article
ID BASAL-LIKE; MOLECULAR PORTRAITS; OVARIAN-CARCINOMA; COPY NUMBER;
   DNA-DAMAGE; IN-VIVO; TUMORS; METHYLATION; EXPRESSION; GENES
AB Introduction: Triple Negative Breast Cancers (TNBC) represent about 12% to 20% of all breast cancers (BC) and have a worse outcome compared to other BC subtypes. TNBC often show a deficiency in DNA double-strand break repair mechanisms. This is generally related to the inactivation of a repair enzymatic complex involving BRCA1 caused either by genetic mutations, epigenetic modifications or by post-transcriptional regulations. The identification of new molecular biomarkers that would allow the rapid identification of BC presenting a BRCA1 deficiency could be useful to select patients who could benefit from PARP inhibitors, alkylating agents or platinum-based chemotherapy.
   Methods: Genomic DNA from 131 formalin-fixed paraffin-embedded (FFPE) tumors (luminal A and B, HER2+ and triple negative BC) with known BRCA1 mutation status or unscreened for BRCA1 mutation were analysed by array Comparative Genomic Hybridization (array CGH). One highly significant and recurrent gain in the 17q25.3 genomic region was analysed by fluorescent in situ hybridization (FISH). Expression of the genes of the 17q25.3 amplicon was studied using customized Taqman low density arrays and single Taqman assays (Applied Biosystems).
   Results: We identified by array CGH and confirmed by FISH a gain in the 17q25.3 genomic region in 90% of the BRCA1 mutated tumors. This chromosomal gain was present in only 28.6% of the BRCA1 non-mutated TNBC, 26.7% of the unscreened TNBC, 13.6% of the luminal B, 19.0% of the HER2+ and 0% of the luminal A breast cancers. The 17q25.3 gain was also detected in 50% of the TNBC with BRCA1 promoter methylation. Interestingly, BRCA1 promoter methylation was never detected in BRCA1 mutated BC. Gene expression analyses of the 17q25.3 sub-region showed a significant over-expression of 17 genes in BRCA1 mutated TNBC (n = 15) as compared to the BRCA1 non mutated TNBC (n = 13).
   Conclusions: In this study, we have identified by array CGH and confirmed by FISH a recurrent gain in 17q25.3 significantly associated to BRCA1 mutated TNBC. Up-regulated genes in the 17q25.3 amplicon might represent potential therapeutic targets and warrant further investigation.
C1 [Toffoli, Sebastien; Bar, Isabelle] Grand Hop Charleroi, Inst Pathol & Genet, Lab Translat Oncol, B-6041 Gosselies, Belgium.
   [Abdel-Sater, Fadi] Inst Pathol & Genet, Tumor Bank, B-6041 Gosselies, Belgium.
   [Delree, Paul] Inst Pathol & Genet, Dept Pathol, B-6041 Gosselies, Belgium.
   [Hilbert, Pascale; Cavallin, Frederic] Inst Pathol & Genet, Dept Mol Biol, B-6041 Gosselies, Belgium.
   [Moreau, Fabrice; Van Criekinge, Wim] MdxHlth Inc, Irvine, CA 92618 USA.
   [Lacroix-Triki, Magali] Inst Claudius Regaud, Dept Biol & Pathol, F-31052 Toulouse, France.
   [Campone, Mario] Inst Cancerol Ouest Rene Gauducheau, Dept Med Oncol, F-44805 Nantes, France.
   [Martin, Anne-Laure] R&D UNICANCER, F-75654 Paris 13, France.
   [Roche, Henri] Inst Claudius Regaud, Dept Med Oncol, F-31300 Toulouse, France.
   [Machiels, Jean-Pascal] Clin Univ St Luc, Dept Oncol, B-1200 Brussels, Belgium.
   [Carrasco, Javier; Canon, Jean-Luc] Grand Hop Charleroi, Serv Oncol Hematol, B-6000 Charleroi, Belgium.
C3 Grand Hopital De Charleroi; UNICANCER; Institut Claudius Regaud;
   UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER;
   UNICANCER; Institut Claudius Regaud; Universite Catholique Louvain;
   Cliniques Universitaires Saint-Luc; Grand Hopital De Charleroi
RP Toffoli, S (通讯作者)，Grand Hop Charleroi, Inst Pathol & Genet, Lab Translat Oncol, Ave Georges Lemaitre 25, B-6041 Gosselies, Belgium.
EM sebastien.toffoli@ipg.be
RI Roché, Henri/O-9211-2014; Sater, Ali/ABC-2036-2020; bar,
   isabelle/AAQ-7795-2020
OI Van Criekinge, Wim/0000-0003-2971-5539; BAR,
   ISABELLE/0000-0002-6091-9137; abdel-sater, fadi/0000-0003-3590-140X
FU Plan National Cancer - Action 29 (Belgium); PACS08 study (UNICANCER,
   France)
FX This work was financed through the Plan National Cancer - Action 29
   (Belgium) and supported by the PACS08 study (UNICANCER, France).
   Jean-Baptiste Poullet (Stat'Rgy, Naninne, Belgium) built the SVM model.
   We thank Aline Van Maanen and Loic Campione for help with statistical
   analysis. We thank Dr Francois Duhoux for critically reviewing the
   manuscript.
CR Abba MC, 2007, MOL CANCER RES, V5, P881, DOI 10.1158/1541-7786.MCR-07-0055
   Ali AB, 2011, MED ONCOL, V28, P64, DOI 10.1007/s12032-010-9438-y
   Anders CK, 2010, CLIN CANCER RES, V16, P4702, DOI 10.1158/1078-0432.CCR-10-0939
   Bal A, 2012, VIRCHOWS ARCH, V461, P305, DOI 10.1007/s00428-012-1286-z
   Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bermudo R, 2010, ANN NY ACAD SCI, V1210, P17, DOI 10.1111/j.1749-6632.2010.05780.x
   Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360
   Bol GM, 2010, HISTOPATHOLOGY, V57, P363, DOI 10.1111/j.1365-2559.2010.03642.x
   Bosch A, 2010, CANCER TREAT REV, V36, P206, DOI 10.1016/j.ctrv.2009.12.002
   Brockschmidt C, 2008, GUT, V57, P799, DOI 10.1136/gut.2007.123695
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chin LS, 2001, J BIOL CHEM, V276, P7069, DOI 10.1074/jbc.M004129200
   Evans DG, 2011, J MED GENET, V48, P520, DOI 10.1136/jmedgenet-2011-100006
   Gluz O, 2009, ANN ONCOL, V20, P1913, DOI 10.1093/annonc/mdp492
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hirner H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029709
   Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210
   Jönsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570
   Jönsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596
   Joosse SA, 2011, GENE CHROMOSOME CANC, V50, P71, DOI 10.1002/gcc.20833
   Joosse SA, 2009, BREAST CANCER RES TR, V116, P479, DOI 10.1007/s10549-008-0117-z
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koh JLY, 2012, NUCLEIC ACIDS RES, V40, pD957, DOI 10.1093/nar/gkr959
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Leunen K, 2009, HUM MUTAT, V30, P1693, DOI 10.1002/humu.21135
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   MacDonald JR, 2014, NUCLEIC ACIDS RES, V42, pD986, DOI 10.1093/nar/gkt958
   Marchiò C, 2009, J PATHOL, V219, P16, DOI 10.1002/path.2574
   Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321
   Natrajan R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3154
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Paulsen RD, 2009, MOL CELL, V35, P228, DOI 10.1016/j.molcel.2009.06.021
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Robertson L, 2012, BRIT J CANCER, V106, P1234, DOI 10.1038/bjc.2012.31
   Schmidt EE, 2013, NUCLEIC ACIDS RES, V41, pD1021, DOI 10.1093/nar/gks1170
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Slabicki M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000408
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Stefansson OA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2334
   Takazawa Koutarou, 2006, Cancer Genomics & Proteomics, V3, P373
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Tirkkonen M, 1997, CANCER RES, V57, P1222
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Vollebergh MA, 2011, ANN ONCOL, V22, P1561, DOI 10.1093/annonc/mdq624
   Walter-Yohrling J, 2003, CANCER RES, V63, P8939
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wen YH, 2012, BREAST CANCER RES TR, V135, P93, DOI 10.1007/s10549-012-2070-0
   Zweemer RP, 2001, LAB INVEST, V81, P1363, DOI 10.1038/labinvest.3780350
NR 54
TC 29
Z9 30
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1465-542X
EI 1465-5411
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2014
VL 16
IS 6
AR 466
DI 10.1186/s13058-014-0466-y
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CB8NB
UT WOS:000349885800005
PM 25416589
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Li, YS
   Zhang, YP
   Li, SL
   Lu, JP
   Chen, J
   Wang, Y
   Li, YX
   Xu, J
   Li, X
AF Li, Yongsheng
   Zhang, Yunpeng
   Li, Shengli
   Lu, Jianping
   Chen, Juan
   Wang, Yuan
   Li, Yixue
   Xu, Juan
   Li, Xia
TI Genome-wide DNA methylome analysis reveals epigenetically dysregulated
   non-coding RNAs in human breast cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MICRORNA DYSREGULATION; METHYLATION; CHROMATIN; METASTASIS; PROMOTER;
   GENES; HYPERMETHYLATION; TRANSCRIPTS; ANNOTATION; EXPRESSION
AB Despite growing appreciation of the importance of epigenetics in breast cancer, our understanding of epigenetic alterations of non-coding RNAs (ncRNAs) in breast cancer remains limited. Here, we explored the epigenetic patterns of ncRNAs in breast cancers using published sequencing-based methylome data, primarily focusing on the two most commonly studied ncRNA biotypes, long ncRNAs and miRNAs. We observed widely aberrant methylation in the promoters of ncRNAs, and this abnormal methylation was more frequent than that in protein-coding genes. Specifically, intergenic ncRNAs were observed to comprise a majority (51.45% of the lncRNAs and 51.57% of the miRNAs) of the aberrantly methylated ncRNA promoters. Moreover, we summarized five patterns of aberrant ncRNA promoter methylation in the context of genomic CpG islands (CGIs), in which aberrant methylation occurred not only on CGIs, but also in regions flanking CGI and in CGI-lacking promoters. Integration with transcriptional datasets enabled us to determine that the ncRNA promoter methylation events were associated with transcriptional changes. Furthermore, a panel of ncRNAs were identified as biomarkers that discriminated between disease phenotypes. Finally, the potential functions of aberrantly methylated ncRNAs were predicted, suggestiong that ncRNAs and coding genes cooperatively mediate pathway dysregulation during the development and progression of breast cancer.
C1 [Li, Yongsheng; Zhang, Yunpeng; Li, Shengli; Lu, Jianping; Chen, Juan; Wang, Yuan; Li, Yixue; Xu, Juan; Li, Xia] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
   [Li, Yixue] Shanghai Ctr Bioinformat Technol, Shanghai, Peoples R China.
C3 Harbin Medical University; Chinese Academy of Sciences
RP Li, YX (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
EM yxli@sibs.ac.cn; xujuanbiocc@ems.hrbmu.edu.cn; lixia@hrbmu.edu.cn
RI Li, YiXue/JRW-6306-2023; Zhang, Yunpeng/KFA-0488-2024; li,
   xia/HHZ-7468-2022; 陆, 建平/HPB-6780-2023
OI Li, Shengli/0000-0001-5430-303X; Juan, Chen/0000-0002-7959-335X; Xu,
   Juan/0000-0002-3709-4165; Li, Yongsheng/0000-0003-1914-0727
FU National High Technology Research and Development Program of China [863
   Program] [2014AA021102]; National Natural Science Foundation of China
   [91439117, 61473106, 61203264]; China Postdoctoral Science Foundation
   [2014T70364, LBH-Z14134]; Harbin Medical University
FX This work was supported by the National High Technology Research and
   Development Program of China [863 Program, Grant No. 2014AA021102], the
   National Natural Science Foundation of China [Grant Nos. 91439117,
   61473106, and 61203264], the China Postdoctoral Science Foundation
   [Grant No. 2014T70364 and LBH-Z14134] and WeihanYu Youth Science Fund
   Project of Harbin Medical University.
CR Augoff K, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-5
   Aure MR, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-11-r126
   Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Bajic Vladimir B., 2004, In Silico Biology, V4, P109
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Cao W, 2013, INT J GENOMICS, V2013, DOI 10.1155/2013/480534
   Cheng C, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003132
   Cho WCS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-60
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Cui P, 2010, GENOMICS, V96, P259, DOI 10.1016/j.ygeno.2010.07.010
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Dolfi SC, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-20
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084
   Flintoft L, 2013, NAT REV GENET, V14, DOI 10.1038/nrg3561
   Gibbs JR, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000952
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   Guo XL, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks967
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jacobsen A, 2013, NAT STRUCT MOL BIOL, V20, P1325, DOI 10.1038/nsmb.2678
   Jia H, 2010, RNA, V16, P1478, DOI 10.1261/rna.1951310
   Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110
   Koga Y, 2009, GENOME RES, V19, P1462, DOI 10.1101/gr.091447.109
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Liao Q, 2011, NUCLEIC ACIDS RES, V39, P3864, DOI 10.1093/nar/gkq1348
   Lucas JJ, 2004, MOL CANCER RES, V2, P105
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Nie Y, 2013, CANCER SCI, V104, P458, DOI 10.1111/cas.12092
   Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022
   Pic-Taylor A, 2004, MOL CELL BIOL, V24, P10036, DOI 10.1128/MCB.24.22.10036-10046.2004
   Ponjavic J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000617
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Sánchez-Muñoz A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-136
   Shen J, 2012, EPIGENETICS-US, V7, P1230, DOI 10.4161/epi.22140
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Varley KE, 2014, BREAST CANCER RES TR, V146, P287, DOI 10.1007/s10549-014-3019-2
   Vrba L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054398
   Wamstad JA, 2012, CELL, V151, P206, DOI 10.1016/j.cell.2012.07.035
   Wang C, 2011, MOL CELL BIOCHEM, V352, P197, DOI 10.1007/s11010-011-0755-z
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Wu SC, 2010, CELL RES, V20, P1109, DOI 10.1038/cr.2010.114
   Wu WKK, 2010, ONCOGENE, V29, P5761, DOI 10.1038/onc.2010.352
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Zhang LX, 2011, CANCER RES, V71, P645, DOI 10.1158/0008-5472.CAN-10-1910
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
NR 58
TC 39
Z9 42
U1 0
U2 25
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 5
PY 2015
VL 5
AR 8790
DI 10.1038/srep08790
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC6CV
UT WOS:000350453200017
PM 25739977
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Sun, LL
   Wu, JY
   Wu, ZY
   Shen, JH
   Xu, XE
   Chen, B
   Wang, SH
   Li, EM
   Xu, LY
AF Sun, Ling-Ling
   Wu, Jian-Yi
   Wu, Zhi-Yong
   Shen, Jin-Hui
   Xu, Xiu-E
   Chen, Bo
   Wang, Shao-Hong
   Li, En-Min
   Xu, Li-Yan
TI A three-gene signature and clinical outcome in esophageal squamous cell
   carcinoma
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE esophageal squamous cell carcinoma; histone demethylase; gene prognostic
   signature; histopathology
ID ACTIVATED RECEPTOR-GAMMA; EXPRESSION; GASC1; NANOG; GENE;
   IDENTIFICATION; AMPLIFICATION; ASSOCIATION; MORTALITY; PROTEINS
AB It is increasingly apparent that cancer development depends not only on genetic alterations, but also on epigenetic changes involving histone modifications. GASC1, member of the histone demethylases affecting heterochromatin formation and transcriptional repression, has been found to be dysregulation in many types of cancers including breast cancer, prostate cancer, metastatic lung sarcomatoid carcinoma, and leukemia. In this study, we examined the expression of GASC1 and certain GASC1-targeted genes (KLF4, MYC, SOX2, PPARG, MDM2, and NANOG) and identified a three-gene prognostic signature (PPARG, MDM2, and NANOG), using risk scores based on immunohistochemical analyses of 149 tumor specimens from patients with esophageal squamous cell carcinoma (ESCC). The presence of a high-risk three-gene signature in the ESCC tumors was significantly associated with decreased overall survival (OS) of the patients. We validated the predictive value of the three-gene signature in a second independent cohort of 101 patients with ESCC in order to determine whether it had predictive value. The results were similar to those in 149 patients. According to multivariate Cox proportional hazards analyses, the predictive model of a three-gene signature was an independent predictor for OS (p=0.005 in cohort 1, p=0.025 in cohort 2). In addition, ROC analysis indicated that the predictive ability of the three-gene model was more robust than that of a single biomarker. Therefore, our three-gene signature is closely associated with OS among patients with ESCC and may serve as a predictor for the poor prognosis of ESCC patients.
   What's new? Epigenetic alterations that involve modifications to histones are thought to play critical roles in cancer, with effects on processes ranging from tumor development to metastasis. The present investigation focused on the expression of the histone demethylase GASC1 and its gene targets in tumors from patients with esophageal squamous cell carcinoma (ESCC). Using risk scores from immunohistochemical analyses, the authors developed a three-gene prognostic signature involving the genes PPARG, MDM2, and NANOG. The signature was associated with a reduction in overall survival of ESCC patients, suggesting that it is predictive for poor prognosis in ESCC.
C1 [Sun, Ling-Ling; Xu, Xiu-E; Chen, Bo; Xu, Li-Yan] Shantou Univ, Inst Oncol Pathol, Key Lab Mol Biol High Canc Incidence Coastal Chao, Coll Med, Shantou, Guangdong, Peoples R China.
   [Sun, Ling-Ling] Univ South China, Affiliated Shaoyang Hosp, Shaoyang Cent Hosp, Dept Pathol, Shaoyang, Hunan, Peoples R China.
   [Wu, Jian-Yi; Li, En-Min] Shantou Univ, Dept Biochem & Mol Biol, Key Lab Mol Biol High Canc Incidence Coastal Chao, Coll Med, Shantou, Guangdong, Peoples R China.
   [Wu, Zhi-Yong] Sun Yat Sen Univ, Dept Surg Oncol, Shantou Cent Hosp, Affiliated Shantou Hosp, Shantou, Guangdong, Peoples R China.
   [Shen, Jin-Hui; Wang, Shao-Hong] Sun Yat Sen Univ, Affiliated Shantou Hosp, Shantou Cent Hosp, Dept Pathol, Shantou, Guangdong, Peoples R China.
C3 Shantou University; University of South China; Shantou University; Sun
   Yat Sen University; Sun Yat Sen University
RP Xu, LY (通讯作者)，Shantou Univ, Inst Oncol Pathol, Coll Med, 22 Xinling Rd, Shantou 515041, Guangdong, Peoples R China.
EM nmli@stu.edu.cn; lyxu@stu.edu.cn
RI Chen, Bo/GRS-7546-2022
FU National Basic Research Program [2012CB526600]; National High Technology
   Research and Development Program of China [2012AA02A503, 2012AA02A209];
   Natural Science Foundation of China-GuangDong Joint Fund [U0932001,
   U1301227]; National Science Foundation of China [81172264]
FX Grant sponsor: National Basic Research Program; Grant number: 973
   Program No. 2012CB526600; Grant sponsors: National High Technology
   Research and Development Program of China; Grant numbers: 2012AA02A503
   and 2012AA02A209; Grant sponsor: Natural Science Foundation of
   China-GuangDong Joint Fund; Grant numbers: U0932001 and U1301227; Grant
   sponsor: National Science Foundation of China; Grant number: 81172264
CR Alldridge L, 2008, J PROTEOME RES, V7, P1458, DOI 10.1021/pr7007829
   Bussolati B, 2008, FASEB J, V22, P3696, DOI 10.1096/fj.08-102590
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Chen HY, 2007, NEW ENGL J MED, V356, P11, DOI 10.1056/NEJMoa060096
   Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Enzinger PC, 2003, NEW ENGL J MED, V349, P2241, DOI 10.1056/NEJMra035010
   Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432
   Giaginis C, 2009, MED SCI MONITOR, V15, pBR148
   Helias C, 2008, CANCER GENET CYTOGEN, V180, P51, DOI 10.1016/j.cancergencyto.2007.09.010
   Hu N, 2005, CANCER RES, V65, P2542, DOI 10.1158/0008-5472.CAN-04-3247
   Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155
   Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004
   Jiang Y, 2009, J CANCER RES CLIN, V135, P1551, DOI 10.1007/s00432-009-0602-8
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   KATLIC MR, 1990, J THORAC CARDIOV SUR, V99, P929
   Lin YL, 2011, MOL CELL BIOCHEM, V351, P109, DOI 10.1007/s11010-011-0717-5
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Liu TM, 2009, STEM CELLS DEV, V18, P1013, DOI 10.1089/scd.2008.0335
   Lizcano F, 2011, GENET MOL BIOL, V34, P19, DOI 10.1590/S1415-47572010005000105
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   McClatchey AI, 2003, NAT REV CANCER, V3, P877, DOI 10.1038/nrc1213
   Nakamura Y, 2009, PATHOL INT, V59, P288, DOI 10.1111/j.1440-1827.2009.02367.x
   Neumann J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-518
   Ogino S, 2009, GASTROENTEROLOGY, V136, P1242, DOI 10.1053/j.gastro.2008.12.048
   Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1<18::AID-IJC5>3.0.CO;2-M
   Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051
   Rapp UR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006029
   Rayburn E, 2005, CURR CANCER DRUG TAR, V5, P27, DOI 10.2174/1568009053332636
   Suikki HE, 2010, PROSTATE, V70, P889, DOI 10.1002/pros.21123
   Sun LL, 2013, AM J CANCER RES, V3, P509
   Tachibana M, 2008, EUR J CARDIO-THORAC, V34, P427, DOI 10.1016/j.ejcts.2008.04.022
   Theocharis S, 2011, J CANCER RES CLIN, V137, P251, DOI 10.1007/s00432-010-0882-z
   Tiwari N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057329
   Wang JL, 2010, BIOL REPROD, V82, P105, DOI 10.1095/biolreprod.109.078055
   Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174
   Yang ZQ, 2001, JPN J CANCER RES, V92, P423, DOI 10.1111/j.1349-7006.2001.tb01112.x
   Yang ZQ, 2000, CANCER RES, V60, P4735
   Ye F, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-108
   Zhang FR, 2008, J HISTOCHEM CYTOCHEM, V56, P193, DOI 10.1369/jhc.7A7353.2007
   Zhang JY, 2005, BIOCHEM BIOPH RES CO, V338, P1098, DOI 10.1016/j.bbrc.2005.10.071
   Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364
   Zhou W, 2009, BMB REP, V42, P154, DOI 10.5483/BMBRep.2009.42.3.154
NR 43
TC 38
Z9 44
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 15
PY 2015
VL 136
IS 6
BP E569
EP E577
DI 10.1002/ijc.29211
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY6XD
UT WOS:000347705200009
PM 25220908
OA Green Published
DA 2025-01-12
ER

PT J
AU Blei, T
   Soukup, ST
   Schmalbach, K
   Pudenz, M
   Möller, FJ
   Egert, B
   Wörtz, N
   Kurrat, A
   Müller, D
   Vollmer, G
   Gerhäuser, C
   Lehmann, L
   Kulling, SE
   Diel, P
AF Blei, Tina
   Soukup, Sebastian T.
   Schmalbach, Katja
   Pudenz, Maria
   Moeller, Frank Josef
   Egert, Bjoern
   Woertz, Nadine
   Kurrat, Anne
   Mueller, Dennis
   Vollmer, Guenter
   Gerhaeuser, Clarissa
   Lehmann, Leane
   Kulling, Sabine E.
   Diel, Patrick
TI Dose-dependent effects of isoflavone exposure during early lifetime on
   the rat mammary gland: Studies on estrogen sensitivity, isoflavone
   metabolism, and DNA methylation
SO MOLECULAR NUTRITION & FOOD RESEARCH
LA English
DT Article
DE Epigenetics; Isoflavones; Mammary gland; Phase-II metabolism;
   Proliferation
ID BREAST-CANCER RISK; SPRAGUE-DAWLEY RATS; SOY FOOD-INTAKE; IN-UTERO;
   GENISTEIN; CHEMOPREVENTION; PHYTOESTROGENS; HORMONES; PROTEIN; FEMALE
AB Scope: Isoflavone (ISO) exposure during adolescence modulates 17 beta-estradiol (E2) sensitivity of the adult mammary gland. The present study investigated the dose dependency of these effects focusing on proliferation, estrogen receptor dependent and independent gene expression, as well as DNA methylation and ISO metabolism.
   Methods and results: Female Wistar rats were lifelong exposed to an ISO-depleted diet or to diets enriched with a soy ISO extract (ISO-rich diet (IRD)) causing plasma concentrations as observed minimally (IRDlow) and maximally (IRDhigh) in Asian women. The extract was characterized by both phytochemical analysis and E-Screen. Rats were ovariectomized at postnatal day (PND) 80 and treated with E2 from PND94 to 97. In contrast to uterine response, body weight and visceral fat mass were affected by ISO. In the mammary gland, both E2-induced proliferation (proliferating cell nuclear antigen staining) and estrogen receptor activation (progesterone receptor staining) were significantly reduced by IRDhigh but not by IRDlow, which however attenuated Gdf15mRNA expression. DNA methylation analysis revealed significant differences in the promoter regions of Aldhl1, Extl1, and WAP between IRDhigh and ISO-depleted diet.
   Conclusion: Lifelong exposure to ISO results in dose-dependent differential effects on proliferation, gene expression, and DNA methylation in rat mammary glands. Yet, a decrease in estrogen responsiveness was only achieved by IRDhigh.
C1 [Blei, Tina; Kurrat, Anne; Mueller, Dennis; Diel, Patrick] German Sports Univ Cologne, D-50933 Cologne, Germany.
   [Soukup, Sebastian T.; Egert, Bjoern; Kulling, Sabine E.] Max Rubner Inst, Karlsruhe, Germany.
   [Schmalbach, Katja; Woertz, Nadine; Lehmann, Leane] Univ Wurzburg, D-97070 Wurzburg, Germany.
   [Pudenz, Maria; Gerhaeuser, Clarissa] German Canc Res Ctr, Heidelberg, Germany.
   [Moeller, Frank Josef; Vollmer, Guenter] Tech Univ Dresden, D-01062 Dresden, Germany.
C3 German Sport University Cologne; University of Wurzburg; Helmholtz
   Association; German Cancer Research Center (DKFZ); Technische
   Universitat Dresden
RP Diel, P (通讯作者)，German Sports Univ Cologne, Dept Mol & Cellular Sport Med, Sportpk Muengersdorf 6, D-50933 Cologne, Germany.
EM Diel@dshs-koeln.de
OI Gerhauser, Clarissa/0000-0002-5792-3901; Kulling, Sabine
   E./0000-0002-9956-2702; Lehmann, Leane/0000-0002-9990-8718
FU German Research Foundation (DFG) [GE 1049/5-1, KU 1079/10-1, LE
   1329/10-1, VO 410/12-1, DI 716/12-2]
FX The members of the collaborative research project Isocross "Isoflavones:
   Cross-species comparison of metabolism, estrogen sensitivity,
   epigenetics and carcinogenesis" would like to thank the German Research
   Foundation (DFG) for financial support (grants: GE 1049/5-1 (C.G.,
   M.P.); KU 1079/10-1; LE 1329/10-1; VO 410/12-1; DI 716/12-2). We thank
   Marion Piechotta (TiHo, Hannover) for measurement of the serum leptin
   levels, Ute Laudenbach Leschowsky for support in animal experiments, and
   Karin Klimo and Oliver Mucke (DKFZ Heidelberg) for excellent technical
   assistance.
CR Adgent MA, 2012, PAEDIATR PERINAT EP, V26, P163, DOI 10.1111/j.1365-3016.2011.01244.x
   [Anonymous], J NUTR HLTH FOOD SCI
   Arai Y, 2000, J Epidemiol, V10, P127
   Brown NM, 2010, FOOD CHEM TOXICOL, V48, P3042, DOI 10.1016/j.fct.2010.07.042
   CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685
   Delclos KB, 2009, REPROD TOXICOL, V27, P117, DOI 10.1016/j.reprotox.2008.12.005
   Dewi FN, 2013, CANCER PREV RES, V6, P832, DOI 10.1158/1940-6207.CAPR-13-0128
   Dong JY, 2011, BREAST CANCER RES TR, V125, P315, DOI 10.1007/s10549-010-1270-8
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Golub MS, 2008, PEDIATRICS, V121, pS218, DOI 10.1542/peds.2007-1813G
   Guerrero-Bosagna Carlos M., 2008, BMC Physiology, V8, P17, DOI 10.1186/1472-6793-8-17
   Hosoda K, 2011, DRUG METAB DISPOS, V39, P1762, DOI 10.1124/dmd.111.038281
   Huang J, 2011, CURR DRUG TARGETS, V12, P1925, DOI 10.2174/138945011798184155
   Hulka BS, 2001, MATURITAS, V38, P103, DOI 10.1016/S0378-5122(00)00196-1
   Krupenko SA, 2002, CELL GROWTH DIFFER, V13, P227
   Lampe JW, 2003, J NUTR, V133, p956S, DOI 10.1093/jn/133.3.956S
   Lee SA, 2009, AM J CLIN NUTR, V89, P1920, DOI 10.3945/ajcn.2008.27361
   Lehmann L, 2008, CARCINOGENESIS, V29, P363, DOI 10.1093/carcin/bgm235
   Lewis EM, 2002, DRUG CHEM TOXICOL, V25, P437, DOI 10.1081/DCT-120014794
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Limer JL, 2004, BREAST CANCER RES, V6, P119, DOI 10.1186/bcr781
   Lu LJW, 1996, CANCER EPIDEM BIOMAR, V5, P63
   Magee PJ, 2012, CURR OPIN CLIN NUTR, V15, P586, DOI 10.1097/MCO.0b013e328359156f
   Mardon J, 2008, EXP BIOL MED, V233, P229, DOI 10.3181/0707-RM-202
   Messina M, 2006, NUTR CANCER, V55, P1, DOI 10.1207/s15327914nc5501_1
   Messina M, 2009, NUTR CANCER, V61, P792, DOI 10.1080/01635580903285015
   Möller FJ, 2010, TOXICOL LETT, V196, P142, DOI 10.1016/j.toxlet.2010.03.1117
   Molinié B, 2009, DRUG NEWS PERSPECT, V22, P247, DOI 10.1358/dnp.2009.22.5.1378633
   Molzberger AF, 2013, ARCH TOXICOL, V87, P1129, DOI 10.1007/s00204-012-1009-x
   Molzberger AF, 2012, MOL NUTR FOOD RES, V56, P399, DOI 10.1002/mnfr.201100371
   Morito K, 2001, BIOL PHARM BULL, V24, P351, DOI 10.1248/bpb.24.351
   Nagata C, 2014, JPN J CLIN ONCOL, V44, P282, DOI 10.1093/jjco/hyt203
   Nagata C, 2010, J EPIDEMIOL, V20, P83, DOI 10.2188/jea.JE20090181
   National Toxicology Program, 2008, Natl Toxicol Program Tech Rep Ser, P1
   Prasain JK, 2007, MOL PHARMACEUT, V4, P846, DOI 10.1021/mp700116u
   Pudenz M, 2014, NUTRIENTS, V6, P4218, DOI 10.3390/nu6104218
   Ronis MJJ, 2012, ENDOCRINOLOGY, V153, P6021, DOI 10.1210/en.2012-1591
   Rucker R, 2002, J NUTR, V132, P2999, DOI 10.1093/jn/131.10.2999
   Ruttkay-Nedecky B, 2013, INT J MOL SCI, V14, P6044, DOI 10.3390/ijms14036044
   Saad HE, 2011, REPROD TOXICOL, V32, P15, DOI 10.1016/j.reprotox.2011.03.001
   Schneider K, 2004, REGUL TOXICOL PHARM, V39, P334, DOI 10.1016/j.yrtph.2004.03.001
   Shu XO, 2009, JAMA-J AM MED ASSOC, V302, P2437, DOI 10.1001/jama.2009.1783
   SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519
   Soukup ST, 2014, ANAL BIOANAL CHEM, V406, P6007, DOI 10.1007/s00216-014-8034-y
   Stone A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040466
   Strakovsky RS, 2014, TOXICOL SCI, V138, P161, DOI 10.1093/toxsci/kft331
   Su Y, 2009, J NUTR, V139, P945, DOI 10.3945/jn.108.103820
   TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190
   Travis RC, 2008, INT J CANCER, V122, P705, DOI 10.1002/ijc.23141
   Unsicker K, 2013, CYTOKINE GROWTH F R, V24, P373, DOI 10.1016/j.cytogfr.2013.05.003
   van der Velpen V, 2014, EUR J CLIN NUTR, V68, P1141, DOI 10.1038/ejcn.2014.108
   Vandenberg LN, 2012, ENDOCR REV, V33, P378, DOI 10.1210/er.2011-1050
   Velders M, 2012, FASEB J, V26, P1909, DOI 10.1096/fj.11-194779
   Wada K, 2013, INT J CANCER, V133, P952, DOI 10.1002/ijc.28088
   Warri A, 2008, BRIT J CANCER, V98, P1485, DOI 10.1038/sj.bjc.6604321
   Weigt C, 2012, MOL CELL ENDOCRINOL, V351, P227, DOI 10.1016/j.mce.2011.12.013
   Whitsett TG, 2006, EXPERT REV ANTICANC, V6, P1699, DOI 10.1586/14737140.6.12.1699
   Wu AH, 2008, BRIT J CANCER, V98, P9, DOI 10.1038/sj.bjc.6604145
   Yamamoto S, 2001, J NUTR, V131, P2741, DOI 10.1093/jn/131.10.2741
NR 59
TC 23
Z9 25
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1613-4125
EI 1613-4133
J9 MOL NUTR FOOD RES
JI Mol. Nutr. Food Res.
PD FEB
PY 2015
VL 59
IS 2
BP 270
EP 283
DI 10.1002/mnfr.201400480
PG 14
WC Food Science & Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Food Science & Technology
GA CA8HH
UT WOS:000349158100009
PM 25410811
DA 2025-01-12
ER

PT J
AU Nakshatri, H
   Appaiah, HN
   Anjanappa, M
   Gilley, D
   Tanaka, H
   Badve, S
   Crooks, PA
   Mathews, W
   Sweeney, C
   Bhat-Nakshatri, P
AF Nakshatri, H.
   Appaiah, H. N.
   Anjanappa, M.
   Gilley, D.
   Tanaka, H.
   Badve, S.
   Crooks, P. A.
   Mathews, W.
   Sweeney, C.
   Bhat-Nakshatri, P.
TI NF-κB-dependent and -independent epigenetic modulation using the novel
   anti-cancer agent DMAPT
SO CELL DEATH & DISEASE
LA English
DT Article
ID BREAST-CANCER CELLS; GENE-EXPRESSION SIGNATURE; HISTONE H3; LYSINE 36;
   PROTEIN; PARTHENOLIDE; METHYLATION; APOPTOSIS; METHYLTRANSFERASE;
   TRIMETHYLATION
AB The transcription factor nuclear factor-kappaB (NF-kappa B) is constitutively active in several cancers and is a target of therapeutic development. We recently developed dimethylaminoparthenolide (DMAPT), a clinical grade water-soluble analog of parthenolide, as a potent inhibitor of NF-kappa B and demonstrated in vitro and in vivo anti-tumor activities in multiple cancers. In this study, we show DMAPT is an epigenetic modulator functioning in an NF-kappa B-dependent and -independent manner. DMAPT-mediated NF-kappa B inhibition resulted in elevated histone H3K36 trimethylation (H3K36me3), which could be recapitulated through genetic ablation of the p65 subunit of NF-kappa B or inhibitor-of-kappaB alpha super-repressor overexpression. DMAPT treatment and p65 ablation increased the levels of H3K36 trimethylases NSD1 (KMT3B) and SETD2 (KMT3A), suggesting that NF-kappa B directly represses their expression and that lower H3K36me3 is an epigenetic marker of constitutive NF-kappa B activity. Overexpression of a constitutively active p65 subunit of NF-kappa B reduced NSD1 and H3K36me3 levels. NSD1 is essential for DMAPT-induced expression of pro-apoptotic BIM, indicating a functional link between epigenetic modification and gene expression. Interestingly, we observed enhanced H4K20 trimethylation and induction of H4K20 trimethylase KMT5C in DMAPT-treated cells independent of NF-kappa B inhibition. These results add KMT5C to the list NF-kappa B-independent epigenetic targets of parthenolide, which include previously described histone deacetylase 1 (HDAC-1) and DNA methyltransferase 1. As NSD1 and SETD2 are known tumor suppressors and loss of H4K20 trimethylation is an early event in cancer progression, which contributes to genomic instability, we propose DMAPT as a potent pharmacologic agent that can reverse NF-kappa B-dependent and -independent cancer-specific epigenetic abnormalities.
C1 [Nakshatri, H.; Appaiah, H. N.; Anjanappa, M.; Bhat-Nakshatri, P.] Indiana Univ Sch Med, Dept Surg, Indianapolis, IN 46202 USA.
   [Nakshatri, H.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Gilley, D.; Tanaka, H.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Badve, S.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA.
   [Crooks, P. A.] Univ Arkansas, Dept Pharmaceut Sci, Little Rock, AR 72204 USA.
   [Mathews, W.] Leuchemix Inc, Woodside, CA USA.
   [Sweeney, C.] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA.
C3 Indiana University System; Indiana University Bloomington; Indiana
   University System; Indiana University Bloomington; Indiana University
   System; Indiana University Bloomington; Indiana University System;
   Indiana University Bloomington; University of Arkansas System;
   University of Arkansas Fayetteville; University of Arkansas Little Rock;
   Harvard University; Dana-Farber Cancer Institute
RP Nakshatri, H (通讯作者)，Indiana Univ Sch Med, Dept Surg, 980 Walther Hall,West Walnut St C218C, Indianapolis, IN 46202 USA.
EM hnakshat@iupui.edu
RI Tanaka, Hiromi/AAX-3540-2020; Nidumanda, HITESH/B-5744-2015
OI Nakshatri, Harikrishna/0000-0001-8876-0052
FU NIH [CA143994-01A1]; IUPUI Breast Cancer Signature Center initiative
FX We thank Dr. Alex Hoffman for MEFs and Nikail R Collins for technical
   assistance. This work is supported by a grant from NIH CA143994-01A1 to
   HN. IUPUI Breast Cancer Signature Center initiative provided funding for
   establishing prognostic database.
CR Beauchef G, 2012, J BIOL CHEM, V287, P3462, DOI 10.1074/jbc.M111.286443
   Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Benetti R, 2007, J CELL BIOL, V178, P925, DOI 10.1083/jcb.200703081
   Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808
   Czabotar PE, 2014, NAT REV MOL CELL BIO, V15, P49, DOI 10.1038/nrm3722
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Dhawan P, 2002, J LEUKOCYTE BIOL, V72, P9
   Dong J, 2008, GENE DEV, V22, P1159, DOI 10.1101/gad.1657408
   Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Ge R, 2011, CELL DEATH DIFFER, V18, P1184, DOI 10.1038/cdd.2010.185
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gopal YV, 2007, CHEM BIOL, V14, P813, DOI 10.1016/j.chembiol.2007.06.007
   Goswami Chirayu Pankaj, 2013, J Clin Bioinforma, V3, P22, DOI 10.1186/2043-9113-3-22
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hoffmann A, 2003, EMBO J, V22, P5530, DOI 10.1093/emboj/cdg534
   Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kanno R, 2008, CANCER SCI, V99, P1077, DOI 10.1111/j.1349-7006.2008.00797.x
   Kapoor-Vazirani P, 2011, MOL CELL BIOL, V31, P1594, DOI 10.1128/MCB.00524-10
   Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042
   Lin YC, 2009, CELL MICROBIOL, V11, P645, DOI 10.1111/j.1462-5822.2008.01280.x
   Liu ZF, 2009, J PHARMACOL EXP THER, V329, P505, DOI 10.1124/jpet.108.147934
   Lu T, 2009, P NATL ACAD SCI USA, V106, P16339, DOI 10.1073/pnas.0908560106
   Lucio-Eterovic AK, 2010, P NATL ACAD SCI USA, V107, P16952, DOI 10.1073/pnas.1002653107
   Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108
   Modak R, 2012, EPIGENETICS-US, V7, P492, DOI 10.4161/epi.19742
   Mott JL, 2010, J CELL BIOCHEM, V110, P1155, DOI 10.1002/jcb.22630
   Nakshatri H, 2004, ONCOGENE, V23, P7330, DOI 10.1038/sj.onc.1207995
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Nozaki S, 2001, ONCOGENE, V20, P2178, DOI 10.1038/sj.onc.1204292
   Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768
   Price BD, 2013, CELL, V152, P1344, DOI 10.1016/j.cell.2013.02.011
   Riggins RB, 2005, MOL CANCER THER, V4, P33
   Schmidt CK, 2013, CELL, V153, P513, DOI 10.1016/j.cell.2013.04.018
   Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704
   Schuettengruber B, 2007, CELL, V128, P735, DOI 10.1016/j.cell.2007.02.009
   Shanmugam R, 2011, INT J CANCER, V128, P2481, DOI 10.1002/ijc.25587
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Wagner EJ, 2012, NAT REV MOL CELL BIO, V13, P115, DOI 10.1038/nrm3274
   Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608
   Weinstein JN, 2013, NATURE, V504, P381, DOI 10.1038/nature12839
   Xie P, 2008, CELL SIGNAL, V20, P1671, DOI 10.1016/j.cellsig.2008.05.012
   Yuan W, 2011, J BIOL CHEM, V286, P7983, DOI 10.1074/jbc.M110.194027
   Zhou Y, 2005, ENDOCR-RELAT CANCER, V12, pS37, DOI 10.1677/erc.1.00977
NR 55
TC 46
Z9 51
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JAN
PY 2015
VL 6
AR e1608
DI 10.1038/cddis.2014.569
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CA6JZ
UT WOS:000349020500027
PM 25611383
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Aumsuwan, P
   Khan, SI
   Khan, IA
   Avula, B
   Walker, LA
   Helferich, WG
   Katzenellenbogen, BS
   Dasmahapatra, AK
AF Aumsuwan, Pranapda
   Khan, Shabana I.
   Khan, Ikhlas A.
   Avula, Bharathi
   Walker, Larry A.
   Helferich, William G.
   Katzenellenbogen, Benita S.
   Dasmahapatra, Asok K.
TI Evaluation of wild yam (<i>Dioscorea villosa</i>) root extract as a
   potential epigenetic agent in breast cancer cells
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Article
DE Breast cancer; Epigenetics; DNMT; TET; Wild yam; Methylation
ID MESSENGER-RNA STABILITY; MEDAKA ORYZIAS-LATIPES; TUMOR-SUPPRESSOR GENES;
   DNA METHYLATION; NATURAL-PRODUCTS; STEROIDAL SAPONINS;
   5-HYDROXYMETHYLCYTOSINE; METHYLTRANSFERASE; EXPRESSION; 5-METHYLCYTOSINE
AB The present study was designed to evaluate the efficacy of wild yam root extract (WYRE) as a potential demethylating agent using two breast cancer cell lines, MCF-7 (estrogen receptor positive; ER+) and MDA-MB-231 (Estrogen receptor negative; ER-), and a methylated gene, GATA3, as a potential marker of breast cancer development. The cells were treated with WYRE (0-50 mu g/mL) for 72 h and used for viability, mRNA, and methylation analyses. WYRE significantly reduced viability of both cell lines and enhanced mRNA content of GATA3 in a concentration-dependent manner; however, DNMT mRNAs (DNMT1, 3A, 3B) were found to increase significantly only in MDA-MB-231 cells. Global DNA methylation, analyzed as 5'-methyl-2'-deoxycytidine (5-mC) and 5-hydroxymethylcytosine (5-hmC), showed a concentration-dependent enhancement of 5-mC with no alteration in 5-hmC level in MCF-7 cells; however, in MDA-MB-231 cells, in contrast to MCF-7 cells, 5-mC remained unaltered but 5-hmC reduced significantly in all WYRE concentrations (10-50 mu g/mL) used in this study. Since 5-hmC is generated from 5-mC by ten-eleven-translocation (TET) enzymes, analysis of TET mRNAs (TET1, TET2, and TET3) in MDA-MB-231 cells indicated a concentration-dependent reduction in TET1 and induction of TET3; however, TET2 remained unaltered. No alterations in any of the TET mRNAs were found in MCF-7 cells. Methylation analysis of GATA3 promoter at specific locus indicates probable demethylating activity of WYRE in MDA-MB-231 cells. We conclude that activation of GATA3 gene in ER- MDA-MB-231 cells may occur by altering DNA methylation pattern on the promoter region which may be different from the mechanisms operated in ER+ MCF-7 cells.
C1 [Aumsuwan, Pranapda; Khan, Shabana I.; Khan, Ikhlas A.; Avula, Bharathi; Walker, Larry A.; Dasmahapatra, Asok K.] Univ Mississippi, Sch Pharm, Natl Ctr Nat Prod Res, University, MS 38677 USA.
   [Aumsuwan, Pranapda; Walker, Larry A.; Dasmahapatra, Asok K.] Univ Mississippi, Sch Pharm, Dept BioMol Sci, Div Pharmacol, University, MS 38677 USA.
   [Khan, Shabana I.; Khan, Ikhlas A.] Univ Mississippi, Sch Pharm, Dept BioMol Sci, Div Pharmacognosy, University, MS 38677 USA.
   [Walker, Larry A.; Dasmahapatra, Asok K.] Univ Mississippi, Sch Pharm, Inst Canc, University, MS 38677 USA.
   [Helferich, William G.] Univ Illinois, Dept Food Sci & Human Nutr, Urbana, IL 61801 USA.
   [Katzenellenbogen, Benita S.] Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA.
C3 University of Mississippi; University of Mississippi; University of
   Mississippi; University of Mississippi; University of Illinois System;
   University of Illinois Urbana-Champaign; University of Illinois System;
   University of Illinois Urbana-Champaign
RP Dasmahapatra, AK (通讯作者)，Univ Mississippi, Sch Pharm, Inst Canc, Oxford Campus, University, MS 38677 USA.
EM asok@olemiss.edu
RI Khan, Ikhlas/AAA-1490-2020; Khan, Ikhlas/AAA-1829-2020
FU United States Department of Agriculture (USDA), Agriculture Research
   Service [58-6408-2009]; National Center for Complementary and
   Alternative Medicines (NCCAM) [P50AT006268]; Office of Dietary
   Supplements (ODS); National Cancer Institute (NCI)
FX This work was supported in part by the United States Department of
   Agriculture (USDA), Agriculture Research Service Specific Cooperative
   Agreement no 58-6408-2009. This project was made possible by Grant
   Number P50AT006268 (to WGS, IK, and BSK) from the National Center for
   Complementary and Alternative Medicines (NCCAM), the Office of Dietary
   Supplements (ODS) and the National Cancer Institute (NCI). Its contents
   are solely the responsibility of the authors and do not necessarily
   represent the official views of the NCCAM, ODS, NCI or the National
   Institutes of Health.
CR Ali Z, 2013, CARBOHYD RES, V370, P86, DOI 10.1016/j.carres.2012.12.022
   Amatori Stefano, 2010, Genes Cancer, V1, P197, DOI 10.1177/1947601910365081
   ARADHANA A R R, 1992, Indian Journal of Experimental Biology, V30, P367
   Avula B, 2014, PLANTA MED, V80, P321, DOI 10.1055/s-0033-1360330
   Bell DW, 2010, J PATHOL, V220, P231, DOI 10.1002/path.2645
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Butler MS, 2008, NAT PROD REP, V25, P475, DOI 10.1039/b514294f
   Carroll DG, 2006, AM FAM PHYSICIAN, V73, P457
   Chen ML, 2013, CLIN CHEM, V59, P824, DOI 10.1373/clinchem.2012.193938
   Chiang CT, 2007, FEBS LETT, V581, P5735, DOI 10.1016/j.febslet.2007.11.021
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672
   CIHAK A, 1974, CANCER RES, V34, P3003
   Cohen I, 2002, SEMIN ONCOL, V29, P563, DOI 10.1053/sonc.2002.50005
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Cragg GM, 2009, PHYTOCHEM REV, V8, P313, DOI 10.1007/s11101-009-9123-y
   Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z
   Dong SJ, 2007, FOOD CHEM TOXICOL, V45, P2470, DOI 10.1016/j.fct.2007.05.031
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fang SH, 2009, J SURG RES, V157, P290, DOI 10.1016/j.jss.2008.07.015
   Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260
   Ganesan A, 2008, CURR OPIN CHEM BIOL, V12, P306, DOI 10.1016/j.cbpa.2008.03.016
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Hayes PY, 2007, MAGN RESON CHEM, V45, P1001, DOI 10.1002/mrc.2071
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hooker E, 2004, INT J TOXICOL, V23, P49, DOI 10.1080/10915810490499055
   Hu YH, 2008, COMP BIOCHEM PHYS C, V148, P273, DOI 10.1016/j.cbpc.2008.06.006
   Iida A, 2006, GENET RES, V87, P187, DOI 10.1017/S0016672306008184
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jagadeesan J, 2012, J ENVIRON PATHOL TOX, V31, P121, DOI 10.1615/JEnvironPatholToxicolOncol.v31.i2.40
   Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607
   Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c
   Khan SI, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-91
   Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786
   Kudo Y, 2012, CANCER SCI, V103, P670, DOI 10.1111/j.1349-7006.2012.02213.x
   Lambrechts S, 2011, ACTA CLIN BELG, V66, P283, DOI 10.2143/ACB.66.4.2062570
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Licata LA, 2010, BREAST CANCER RES TR, V122, P55, DOI 10.1007/s10549-009-0517-8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lubecka-Pietruszewska K, 2014, EUR J PHARMACOL, V723, P276, DOI 10.1016/j.ejphar.2013.11.021
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   Medina-Franco JL, 2011, MOL DIVERS, V15, P293, DOI 10.1007/s11030-010-9262-5
   Molinski TF, 2009, NAT REV DRUG DISCOV, V8, P69, DOI 10.1038/nrd2487
   Newman DJ, 2008, J MED CHEM, V51, P2589, DOI 10.1021/jm0704090
   Nguyen C, 2013, RADIOGRAPHICS, V33, P763, DOI 10.1148/rg.333125137
   Oakeley EJ, 1999, PHARMACOL THERAPEUT, V84, P389, DOI 10.1016/S0163-7258(99)00043-1
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Park MK, 2009, AM J CHINESE MED, V37, P159, DOI 10.1142/S0192415X09006746
   Peedicayil J, 2006, INDIAN J MED RES, V123, P17
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Sautour M, 2006, BIOCHEM SYST ECOL, V34, P60, DOI 10.1016/j.bse.2005.07.007
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Srivastava S, 2011, CANCER BIOMARK, V9, P41, DOI 10.3233/CBM-2011-0204
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Tominaga N, 2012, ANN ONCOL, V23, P3051, DOI 10.1093/annonc/mds120
   van Duursen MBM, 2013, TOXICOL APPL PHARM, V269, P132, DOI 10.1016/j.taap.2013.03.014
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7
   Wang SC, 2014, J AGR FOOD IN PRESS
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wu MH, 2010, CHEM RES TOXICOL, V23, P1405, DOI 10.1021/tx100205a
   Xie Q, 2014, GENE CHROMOSOME CANC, V53, P422, DOI 10.1002/gcc.22154
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Yoon NK, 2010, HUM PATHOL, V41, P1794, DOI 10.1016/j.humpath.2010.06.010
NR 72
TC 10
Z9 10
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
EI 1543-706X
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD JAN
PY 2015
VL 51
IS 1
BP 59
EP 71
DI 10.1007/s11626-014-9807-5
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA CA6AF
UT WOS:000348989700009
PM 25148825
DA 2025-01-12
ER

PT J
AU Yaswen, P
AF Yaswen, Paul
TI Reinforcing targeted therapeutics with phenotypic stability factors
SO CELL CYCLE
LA English
DT Article
DE cancer therapy; cyclin-dependent kinase (CDK); drug resistance;
   epithelial-mesenchymal transition (EMT); inflammation; Notch; NF-B;
   Ovol; TGF; CSC; cancer stem cell; CDK; cyclin-dependent kinase; EMT;
   epithelial-mesenchymal transition; ER; estrogen receptor; GSI;
   -secretase inhibitor; HER2; Human Epidermal Growth Factor Receptor 2;
   NICD; Notch intracellular domain
ID BREAST-CANCER CELLS; TRASTUZUMAB RESISTANCE; CDK4/6 INHIBITION;
   STEM-CELLS; CYCLIN-E; NOTCH; PROLIFERATION; THERAPY; GROWTH; MECHANISMS
AB Deregulated cell cycle progression can often be traced to intrinsic defects in specific regulatory proteins in cancer cells. Knowledge of these primary defects has led to targeted approaches that exploit the defects and spare normal cells. However, the success of such targeted approaches is still hit-or-miss. Genetic and epigenetic variability inherent in most tumors often results in phenotypic heterogeneity that, in turn, results in de novo or acquired resistance to therapeutic agents. The ability of cells to compensate and adapt to the inhibition of a specific cell cycle mediator is not remarkable. What is novel and of great potential importance is that the ability of cells to exhibit such adaptability varies markedly. Phenotypic stability factors that restrict the ability of cells to undergo epithelial-mesenchymal transitions (EMT) may dictate the success or failure of targeted therapies by interfering with compensatory changes such as deregulation of CDK2 activity. Identification of existing and new agents that induce and maintain phenotypic stability factors will inform and enable synergistic approaches to the eradication of even the most aggressive tumors.
C1 Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
C3 University of California System; University of California Berkeley;
   United States Department of Energy (DOE); Lawrence Berkeley National
   Laboratory
RP Yaswen, P (通讯作者)，Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA.
EM P_Yaswen@lbl.gov
CR Abukhdeir AM, 2008, P NATL ACAD SCI USA, V105, P288, DOI 10.1073/pnas.0710887105
   Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744
   Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677
   Andersen P, 2012, TRENDS CELL BIOL, V22, P257, DOI 10.1016/j.tcb.2012.02.003
   Bazarov AV, 2012, CELL CYCLE, V11, P1008, DOI 10.4161/cc.11.5.19492
   Campos SM, 2003, ONCOLOGY-BASEL, V64, P289, DOI 10.1159/000070284
   CENTRELLA M, 1988, FASEB J, V2, P3066, DOI 10.1096/fasebj.2.15.2903838
   Chen Jianying, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P565, DOI 10.1007/s11596-006-0521-8
   Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049
   Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639
   Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154
   Dickson MA, 2009, CURR ONCOL, V16, P120
   Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025
   Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920
   Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419
   Finn RS, 2014, P AM ASSOC CANC RES, V55, pCT101
   Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380
   Fry DW, 2004, MOL CANCER THER, V3, P1427
   Gangopadhyay S, 2013, CLIN BREAST CANCER, V13, P7, DOI 10.1016/j.clbc.2012.09.017
   Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
   Horiuchi D, 2012, P NATL ACAD SCI USA, V109, pE1019, DOI 10.1073/pnas.1111317109
   Ichikawa A, 2008, HUM CELL, V21, P28, DOI 10.1111/j.1749-0774.2008.00048.x
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000
   Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095912
   Liu F, 2012, MOL CANCER THER, V11, P2138, DOI 10.1158/1535-7163.MCT-12-0562
   LOVE RR, 1989, J CLIN ONCOL, V7, P803, DOI 10.1200/JCO.1989.7.6.803
   Miele L, 2006, CLIN CANCER RES, V12, P1074, DOI 10.1158/1078-0432.CCR-05-2570
   Mittendorf EA, 2010, ONCOGENE, V29, P3896, DOI 10.1038/onc.2010.151
   Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900
   Pandya K, 2011, BRIT J CANCER, V105, P796, DOI 10.1038/bjc.2011.321
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108
   Shi W, 2006, J MAMMARY GLAND BIOL, V11, P41, DOI 10.1007/s10911-006-9011-7
   Singh G, 2010, J BIOL CHEM, V285, P27241, DOI 10.1074/jbc.M110.100438
   Smalley M, 2013, CANCER LETT, V338, P57, DOI 10.1016/j.canlet.2012.04.023
   Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9
   Watanabe K, 2014, DEV CELL, V29, P59, DOI 10.1016/j.devcel.2014.03.006
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
NR 39
TC 17
Z9 20
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD DEC 15
PY 2014
VL 13
IS 24
BP 3818
EP 3822
DI 10.4161/15384101.2014.985071
PG 5
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AZ6KU
UT WOS:000348329600011
PM 25483053
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Mourad, R
   Hsu, PY
   Juan, LR
   Shen, CY
   Koneru, P
   Lin, H
   Liu, YL
   Nephew, K
   Huang, TH
   Li, L
AF Mourad, Raphael
   Hsu, Pei-Yin
   Juan, Liran
   Shen, Changyu
   Koneru, Prasad
   Lin, Hai
   Liu, Yunlong
   Nephew, Kenneth
   Huang, Tim H.
   Li, Lang
TI Estrogen Induces Global Reorganization of Chromatin Structure in Human
   Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID HI-C DATA; GENE-EXPRESSION; CHIP-SEQ; ELEMENTS; ALPHA; ORGANIZATION;
   ARCHITECTURE; PRINCIPLES; TAMOXIFEN; CORRELATE
AB In the cell nucleus, each chromosome is confined to a chromosome territory. This spatial organization of chromosomes plays a crucial role in gene regulation and genome stability. An additional level of organization has been discovered at the chromosome scale: the spatial segregation into open and closed chromatins to form two genome-wide compartments. Although considerable progress has been made in our knowledge of chromatin organization, a fundamental issue remains the understanding of its dynamics, especially in cancer. To address this issue, we performed genome-wide mapping of chromatin interactions (Hi-C) over the time after estrogen stimulation of breast cancer cells. To biologically interpret these interactions, we integrated with estrogen receptor alpha (ER alpha) binding events, gene expression and epigenetic marks. We show that gene-rich chromosomes as well as areas of open and highly transcribed chromatins are rearranged to greater spatial proximity, thus enabling genes to share transcriptional machinery and regulatory elements. At a smaller scale, differentially interacting loci are enriched for cancer proliferation and estrogen-related genes. Moreover, these loci are correlated with higher ERa binding events and gene expression. Taken together these results reveal the role of a hormone - estrogen - on genome organization, and its effect on gene regulation in cancer.
C1 [Mourad, Raphael; Juan, Liran; Koneru, Prasad; Lin, Hai; Liu, Yunlong; Li, Lang] Indiana Univ, Indiana Sch Med, Ctr Computat Biol & Bioinformat, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
   [Shen, Changyu] Indiana Univ, Indiana Sch Med, Ctr Computat Biol & Bioinformat, Dept Biostat, Indianapolis, IN 46202 USA.
   [Hsu, Pei-Yin; Huang, Tim H.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78245 USA.
   [Nephew, Kenneth] Indiana Univ, Lab Ovarian Canc Epigen, Bloomington, IN 47405 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University Bloomington; Indiana University System; Indiana University
   Bloomington; Indiana University Indianapolis; University of Texas
   System; University of Texas Health Science Center at San Antonio;
   Indiana University System; Indiana University Bloomington
RP Li, L (通讯作者)，Indiana Univ, Indiana Sch Med, Ctr Computat Biol & Bioinformat, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
EM lali@iupui.edu
RI Shen, Changyu/E-7519-2016; Lin, Hai/N-3860-2016
FU Integrative Cancer Biology Program (ICBP): Centers for Cancer Systems
   Biology (CCSB);  [NCI- U54 CA113001-07]
FX Funding: This study was funded by NCI- U54 CA113001-07, The Integrative
   Cancer Biology Program (ICBP): Centers for Cancer Systems Biology
   (CCSB). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Barbieri M, 2012, P NATL ACAD SCI USA, V109, P16173, DOI 10.1073/pnas.1204799109
   Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412
   Botta M, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.79
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Cavalli G, 2007, CURR OPIN GENET DEV, V17, P443, DOI 10.1016/j.gde.2007.08.013
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   Cournac A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-436
   Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Dekker J, 2013, NAT REV GENET, V14, P390, DOI 10.1038/nrg3454
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Dostie J, 2006, GENOME RES, V16, P1299, DOI 10.1101/gr.5571506
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fudenberg G, 2012, CURRENT OPINION GENE, V22, P1
   Fudenberg G, 2011, NAT BIOTECHNOL, V29, P1109, DOI 10.1038/nbt.2049
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Gasser SM, 2002, SCIENCE, V296, P1412, DOI 10.1126/science.1067703
   Gerlich D, 2003, CELL, V112, P751, DOI 10.1016/S0092-8674(03)00189-2
   Hagège H, 2007, NAT PROTOC, V2, P1722, DOI 10.1038/nprot.2007.243
   Hampton OA, 2009, GENOME RES, V19, P167, DOI 10.1101/gr.080259.108
   Hsu PY, 2013, CANCER CELL, V24, P197, DOI 10.1016/j.ccr.2013.07.007
   Hsu PY, 2010, GENOME RES, V20, P733, DOI 10.1101/gr.101923.109
   Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668
   Hu M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002893
   Hu M, 2012, BIOINFORMATICS, V28, P3131, DOI 10.1093/bioinformatics/bts570
   Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105
   Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25
   Hübner MR, 2010, ANNU REV BIOPHYS, V39, P471, DOI 10.1146/annurev.biophys.093008.131348
   Imakaev M, 2012, NAT METHODS, V9, P999, DOI [10.1038/NMETH.2148, 10.1038/nmeth.2148]
   Kalhor R, 2012, NAT BIOTECHNOL, V30, P90, DOI 10.1038/nbt.2057
   Kocanova S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000922
   Lan X, 2012, NUCLEIC ACIDS RES, V40, P7690, DOI 10.1093/nar/gks501
   Lanctôt C, 2007, NAT REV GENET, V8, P104, DOI 10.1038/nrg2041
   Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Meaburn KJ, 2007, NATURE, V445, P379, DOI 10.1038/445379a
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Mirny LA, 2011, CHROMOSOME RES, V19, P37, DOI 10.1007/s10577-010-9177-0
   Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002
   Osmanbeyoglu HU, 2013, NUCLEIC ACIDS RES, V41, P8061, DOI 10.1093/nar/gkt586
   Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000
   Putnik M, 2012, BIOCHEM BIOPH RES CO, V426, P26, DOI 10.1016/j.bbrc.2012.08.007
   Rickman DS, 2012, P NATL ACAD SCI USA, V109, P9083, DOI 10.1073/pnas.1112570109
   Ross-Innes CS, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-593
   Rousseau M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-414
   Sabo PJ, 2006, NAT METHODS, V3, P511, DOI 10.1038/NMETH890
   Sabo PJ, 2004, P NATL ACAD SCI USA, V101, P16837, DOI 10.1073/pnas.0407387101
   Sexton T, 2007, NAT STRUCT MOL BIOL, V14, P1049, DOI 10.1038/nsmb1324
   Sexton T, 2012, CELL, V148, P458, DOI 10.1016/j.cell.2012.01.010
   Shavit Y, 2013, BIOINFORMATICS, V29, P1206, DOI 10.1093/bioinformatics/btt120
   Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896
   van Berkum Nynke L, 2010, J Vis Exp, DOI 10.3791/1869
   Wang GH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013798
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Wijchers PJ, 2011, TRENDS GENET, V27, P63, DOI 10.1016/j.tig.2010.11.001
   Yaffe E, 2011, NAT GENET, V43, P1059, DOI 10.1038/ng.947
   Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9
   Zhang XS, 2012, P NATL ACAD SCI USA, V109, P13331, DOI 10.1073/pnas.1203280109
   Zhao Z, 2006, NAT GENET, V38, P1341, DOI 10.1038/ng1891
NR 61
TC 45
Z9 51
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 3
PY 2014
VL 9
IS 12
AR e113354
DI 10.1371/journal.pone.0113354
PG 24
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CA7WS
UT WOS:000349128700024
PM 25470140
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Rose, M
   Schubert, C
   Dierichs, L
   Gaisa, NT
   Heer, M
   Heidenreich, A
   Knüchel, R
   Dahl, E
AF Rose, Michael
   Schubert, Claudia
   Dierichs, Laura
   Gaisa, Nadine T.
   Heer, Matthias
   Heidenreich, Axel
   Knuechel, Ruth
   Dahl, Edgar
TI <i>OASIS</i>/<i>CREB3L1</i> is epigenetically silenced in human bladder
   cancer facilitating tumor cell spreading and migration <i>in vitro</i>
SO EPIGENETICS
LA English
DT Article
DE bladder cancer; HTRA3; OASIS; CREB3L1; promoter methylation; tumor cell
   migration; tumor suppressor gene; ATCC; American Type Culture
   Collection; BMP-2; bone morphogenetic protein 2; CA; California; cDNA;
   copy number desoxyribonucleic acid; CIS; Carcinoma in situ; CREB3L1;
   element binding protein 3-like 1; DAB; 3-3 diaminobenzidine; DAC;
   5-aza-2-deoxycytidine; DNA; desoxyribonucleic acid; EK; ethics
   committee; ER; endoplasmic reticulum; FC; fold change; FFPE; formalin
   fixed paraffin embedded; G1; well differentiated; G2; moderately
   differentiated; G3; poorly differentiated; GAPDH; glyceraldehyde
   3-phosphate dehydrogenase; HCV; Hepatitis C virus; HPV; human papilloma
   virus; HTRA (1-4); high-temperature requirement factor A (1-4); IQR;
   interquartile range; IRS; immunoreactive score; LMU;
   Ludwig-Maximilians-University; M; methylated; MIBC; muscle invasive
   bladder cancer; mRNA; messenger ribo nucleic acid; MSP; methylation
   specific PCR; n; number; NMIBC; non-muscle invasive bladder cancer; ns;
   not significant; NU; normal urothelium; OASIS; old astrocyte
   specifically-induced substance; PCR; polymerase chain reaction; pTa;
   papillary non-invasive tumors; RIP; regulated intramembrane proteolysis;
   RWTH; Rheinisch Westfalisch Technische Hochschule; s; e; m; standard
   error of the margin; SP1; site 1 protease; SP2; site 2 protease; TCGA;
   The Cancer Genome Atlas; TGF-; transforming growth factor beta; TSA;
   trichostatin A; TSS; transcription start site; U; unmethylated; UC;
   urothelial cell cancer; UPR; unfold protein response; USA; United States
   of America; WHO; World Health Organization; WI; Wisconsin
ID UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; TRANSCRIPTION FACTOR;
   BREAST-CANCER; OASIS FAMILY; ER STRESS; EXPRESSION; HTRA3; GENE;
   METHYLATION
AB CREB3L1 has been recently proposed as a novel metastasis suppressor gene in breast cancer. Our current study highlights CREB3L1 expression, regulation, and function in bladder cancer. We demonstrate a significant downregulation of CREB3L1 mRNA expression (n = 64) in primary bladder cancer tissues caused by tumor-specific CREB3L1 promoter hypermethylation (n = 51). Based on pyrosequencing CREB3L1 methylation was shown to be potentially associated with a more aggressive phenotype of bladder cancer. These findings were verified by an independent public data set containing data from 184 bladder tumors. In addition, immunohistochemical evaluation showed that CREB3L1 protein expression is decreased in bladder cancer tissues as well. Interestingly, protein loss is predominately observed in the nuclei of aggressive tumor cells. Based on in vitro models we clearly show that CREB3L1 re-expression mediates suppression of tumor cell migration and colony growth of high grade and invasive bladder cancer cells. The candidate tumor suppressor and TGF- signaling inhibitor HTRA3 was furthermore identified as putative target gene of CREB3L1 in both invasive J82 bladder cells and primary bladder tumors. Hence, our data provide for the first time evidence that the transcription factor CREB3L1 may have an important role as a putative tumor suppressor in bladder cancer.
C1 [Rose, Michael; Schubert, Claudia; Dierichs, Laura; Gaisa, Nadine T.; Heer, Matthias; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
   [Heidenreich, Axel] Rhein Westfal TH Aachen, Dept Urol, Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
EM edahl@ukaachen.de
RI Heidenreich, Axel/L-1015-2013
OI Godfrey, Laura/0000-0003-2393-9881; Gaisa, Nadine/0000-0002-4762-3964
FU START-program of the Medical Faculty of the RWTH Aachen University
   [149/08]
FX This work was supported by the START-program of the Medical Faculty of
   the RWTH Aachen University (grant number: 149/08).
CR Asada R, 2011, J BIOCHEM, V149, P507, DOI 10.1093/jb/mvr041
   Beleford D, 2010, CLIN CANCER RES, V16, P398, DOI 10.1158/1078-0432.CCR-09-1677
   Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153
   Chan CP, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-6
   Chen QY, 2013, J VIROL, V87, P659, DOI 10.1128/JVI.01984-12
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Debelenko LV, 2011, GENE CHROMOSOME CANC, V50, P1054, DOI 10.1002/gcc.20923
   Denard B, 2012, ELIFE, V1, DOI 10.7554/eLife.00090
   Denard B, 2011, CELL HOST MICROBE, V10, P65, DOI 10.1016/j.chom.2011.06.006
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fels DR, 2006, CANCER BIOL THER, V5, P723, DOI 10.4161/cbt.5.7.2967
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Honma Y, 1999, MOL BRAIN RES, V69, P93, DOI 10.1016/S0169-328X(99)00102-3
   Hurst CD, 2014, CANCER CELL, V25, P135, DOI 10.1016/j.ccr.2014.01.026
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kadowaki H, 2013, GENES-BASEL, V4, P306, DOI 10.3390/genes4030306
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310
   Kondo S, 2012, CELL DEATH DIFFER, V19, P1939, DOI 10.1038/cdd.2012.77
   Kondo S, 2011, IUBMB LIFE, V63, P233, DOI 10.1002/iub.433
   Kristiansen G, 2011, J BIOL CHEM, V286, P43417, DOI 10.1074/jbc.M111.227553
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   MASTERS JRW, 1986, CANCER RES, V46, P3630
   Mellor P, 2013, MOL CELL BIOL, V33, P4985, DOI 10.1128/MCB.00959-13
   Mertens F, 2005, LAB INVEST, V85, P408, DOI 10.1038/labinvest.3700230
   Murakami T, 2006, J NEUROCHEM, V96, P1090, DOI 10.1111/j.1471-4159.2005.03596.x
   Murakami T, 2011, BONE, V48, P514, DOI 10.1016/j.bone.2010.10.176
   Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963
   Nie GY, 2003, BIOCHEM J, V371, P39, DOI 10.1042/BJ20021569
   Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403
   Noetzel E, 2010, ONCOGENE, V29, P4814, DOI 10.1038/onc.2010.229
   Omori Y, 2002, BIOCHEM BIOPH RES CO, V293, P470, DOI 10.1016/S0006-291X(02)00253-X
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Rose M, 2014, CARCINOGENESIS, V35, P727, DOI 10.1093/carcin/bgt375
   Saito A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1971
   Schubert SW, 2008, NUCLEIC ACIDS RES, V36, P3834, DOI 10.1093/nar/gkn306
   Singh H, 2010, PLACENTA, V31, P1085, DOI 10.1016/j.placenta.2010.10.003
   Singh H, 2013, J CANCER, V4, P152, DOI 10.7150/jca.5702
   Steenbergen RDM, 2013, J PATHOL, V231, P53, DOI 10.1002/path.4210
   Tocharus J, 2004, DEV GROWTH DIFFER, V46, P257
   Tsutsumi S, 2006, ONCOGENE, V25, P1018, DOI 10.1038/sj.onc.1209139
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Vellanki RN, 2010, ENDOCRINOLOGY, V151, P4146, DOI 10.1210/en.2010-0137
   Wang W., 2014, Biochim Biophys Acta
   Wild PJ, 2005, CLIN CANCER RES, V11, P4415, DOI 10.1158/1078-0432.CCR-05-0259
   Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697
   Yin YX, 2013, TUMOR BIOL, V34, P3611, DOI 10.1007/s13277-013-0942-5
   Zhang CB, 2012, HEPATOLOGY, V55, P1070, DOI 10.1002/hep.24783
   Zhang KZ, 2006, CELL, V124, P587, DOI 10.1016/j.cell.2005.11.040
NR 49
TC 28
Z9 31
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD DEC
PY 2014
VL 9
IS 12
BP 1626
EP 1640
DI 10.4161/15592294.2014.988052
PG 15
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CB1CK
UT WOS:000349364000008
PM 25625847
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Hallberg, AR
   Vorrink, SU
   Hudachek, DR
   Cramer-Morales, K
   Milhem, MM
   Cornell, RA
   Domann, FE
AF Hallberg, Andrea R.
   Vorrink, Sabine U.
   Hudachek, Danielle R.
   Cramer-Morales, Kimberly
   Milhem, Mohammed M.
   Cornell, Robert A.
   Domann, Frederick E.
TI Aberrant CpG methylation of the <i>TFAP2A</i> gene constitutes a
   mechanism for loss of <i>TFAP2A</i> expression in human metastatic
   melanoma
SO EPIGENETICS
LA English
DT Article
DE DNA methylation; epigenetic regulation; gene expression; metastatic
   melanoma; TCGA; The Cancer Genome Atlas; TFAP2A; Transcription Factor
   Activating Enhancer Binding Protein 2 Alpha; qRT-PCR; quantitative
   real-time Reverse Transcription Polymerase Chain Reaction
ID AP-2 TRANSCRIPTION FACTORS; BREAST-CANCER; ROLES; PROGRESSION;
   AP-2-ALPHA; ZEBRAFISH; PHENOTYPE; SKELETAL; DEFECTS; CELLS
AB Metastatic melanoma is a deadly treatment-resistant form of skin cancer whose global incidence is on the rise. During melanocyte transformation and melanoma progression the expression profile of many genes changes. Among these, a gene implicated in several steps of melanocyte development, TFAP2A, is frequently silenced; however, the molecular mechanism of TFAP2A silencing in human melanoma remains unknown. In this study, we measured TFAP2A mRNA expression in primary human melanocytes compared to 11 human melanoma samples by quantitative real-time RT-PCR. In addition, we assessed CpG DNA methylation of the TFAP2A promoter in these samples using bisulfite sequencing. Compared to primary melanocytes, which showed high TFAP2A mRNA expression and no promoter methylation, human melanoma samples showed decreased TFAP2A mRNA expression and increased promoter methylation. We further show that increased CpG methylation correlates with decreased TFAP2A mRNA expression. Using The Cancer Genome Atlas, we further identified TFAP2A as a gene displaying among the most decreased expression in stage 4 melanomas vs. non-stage 4 melanomas, and whose CpG methylation was frequently associated with lack of mRNA expression. Based on our data, we conclude that TFAP2A expression in human melanomas can be silenced by aberrant CpG methylation of the TFAP2A promoter. We have identified aberrant CpG DNA methylation as an epigenetic mark associated with TFAP2A silencing in human melanoma that could have significant implications for the therapy of human melanoma using epigenetic modifying drugs.
C1 [Hallberg, Andrea R.] Univ Iowa, Interdisciplinary Grad Program Mol & Cellular Bio, Grad Coll, Iowa City, IA USA.
   [Vorrink, Sabine U.; Hudachek, Danielle R.; Cramer-Morales, Kimberly; Domann, Frederick E.] Univ Iowa, Dept Radiat Oncol, Carver Coll Med, Iowa City, IA 52242 USA.
   [Hudachek, Danielle R.] Univ Iowa, Grad Coll, Summer Undergrad Res Program, Interdisciplinary Grad Program Mol & Cellular Bio, Iowa City, IA USA.
   [Milhem, Mohammed M.] Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA.
   [Cornell, Robert A.] Univ Iowa, Dept Anat & Cell Biol, Carver Coll Med, Iowa City, IA USA.
C3 University of Iowa; University of Iowa; University of Iowa; University
   of Iowa; University of Iowa
RP Domann, FE (通讯作者)，Univ Iowa, Dept Radiat Oncol, Carver Coll Med, Iowa City, IA 52242 USA.
EM frederick-domann@uiowa.edu
OI Hallberg, Andrea/0000-0002-3252-6547; Cornell,
   Robert/0000-0003-4207-9100; Domann, Frederick/0000-0002-0489-2179;
   Milhem, Mohammed/0000-0003-4663-6824
FU University of Iowa's Melanoma Research Program; NIH Cancer Center [5P30
   086862-14]; NIH [R01 AR062547]; NSF [IOS-114722]; SRP [P42
   ES013661-5110]; Summer Undergraduate Research Program (SURP)
FX This work was also supported in part by The University of Iowa's
   Melanoma Research Program (FED), NIH Cancer Center Support Grant 5P30
   086862-14, and by NIH R01 AR062547 (RAC) and NSF IOS-114722 (RAC). SUV
   received salary support from SRP Training Core P42 ES013661-5110. DRH
   and ARH were supported in part by the Summer Undergraduate Research
   Program (SURP) administered by the Interdisciplinary Graduate Program in
   Molecular and Cellular Biology at The University of Iowa. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Berger AJ, 2005, CANCER RES, V65, P11185, DOI 10.1158/0008-5472.CAN-05-2300
   Brewer S, 2004, DEV BIOL, V267, P135, DOI 10.1016/j.ydbio.2003.10.039
   Douglas DB, 2004, CANCER RES, V64, P1611, DOI 10.1158/0008-5472.CAN-0318-2
   Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246
   Gollob JA, 2006, CLIN CANCER RES, V12, P4619, DOI 10.1158/1078-0432.CCR-06-0883
   Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6
   Huang S, 1998, EMBO J, V17, P4358, DOI 10.1093/emboj/17.15.4358
   Knight RD, 2004, DEV DYNAM, V229, P87, DOI 10.1002/dvdy.10494
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Livingstone E, 2010, EXPERT OPIN INV DRUG, V19, P1439, DOI 10.1517/13543784.2010.527945
   Makhov PB, 2011, CARCINOGENESIS, V32, P1773, DOI 10.1093/carcin/bgr212
   Melnikova VO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012452
   Milunsky JM, 2011, AM J MED GENET A, V155A, P22, DOI 10.1002/ajmg.a.33783
   Nyormoi O, 2003, CLIN EXP METASTAS, V20, P251, DOI 10.1023/A:1022991302172
   O'Brien EK, 2004, DEV BIOL, V265, P246, DOI 10.1016/j.ydbio.2003.09.029
   Penna E, 2013, CANCER RES, V73, P4098, DOI 10.1158/0008-5472.CAN-12-3686
   Solit DB, 2011, NEW ENGL J MED, V364, P772, DOI 10.1056/NEJMcibr1013704
   Tellez C, 2003, J BIOL CHEM, V278, P46632, DOI 10.1074/jbc.M309159200
   Van Otterloo E, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001122
   Wenke AK, 2010, FEBS J, V277, P894, DOI 10.1111/j.1742-4658.2009.07509.x
   Zeng L, 2013, EXP CELL RES, V319, P2282, DOI 10.1016/j.yexcr.2013.06.011
NR 21
TC 28
Z9 33
U1 0
U2 8
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD DEC
PY 2014
VL 9
IS 12
BP 1641
EP 1647
DI 10.4161/15592294.2014.988062
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CB1CK
UT WOS:000349364000009
PM 25625848
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Penzo, M
   Casoli, L
   Pollutri, D
   Sicuro, L
   Ceccarelli, C
   Santini, D
   Taffurelli, M
   Govoni, M
   Brina, D
   Trerè, D
   Montanaro, L
AF Penzo, Marianna
   Casoli, Lucia
   Pollutri, Daniela
   Sicuro, Laura
   Ceccarelli, Claudio
   Santini, Donatella
   Taffurelli, Mario
   Govoni, Marzia
   Brina, Daniela
   Trere, Davide
   Montanaro, Lorenzo
TI JHDM1B expression regulates ribosome biogenesis and cancer cell growth
   in a p53 dependent manner
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; JHDM1B; p38MAPK; p53; ribosome biogenesis
ID NUCLEOLAR PROTEIN; DNA-DAMAGE; C-MYC; RNA; PHOSPHORYLATION; ACTIVATION;
   P38; PROLIFERATION; APOPTOSIS; ARREST
AB Tumors characterized by an intense ribosome biogenesis often display a more aggressive behavior. Ribosomal RNA (rRNA) synthesis is controlled at several levels, including the epigenetic regulation of the condensation of chromatin portions containing rRNA genes. JHDM1B (Jumonji C histone demethylase 1B) is a histone demethylase able to regulate the accessibility of rRNA genes. In this study, we aimed to define the contribution of JHDM1B expression to the features of breast cancer, a tumor type whose behavior is related to the rate of ribosome biogenesis. We show that, in breast cancer-derived cell lines, the increase in rRNA transcription that follows JHDM1B knock-down is mirrored by an augmented cell proliferation only in p53 compromised cells, while p53 competent cells undergo cellular senescence and death. The latter effect appears to be mediated by a p38-dependent phosphorylation of p53, inducing the expression of p15(Ink4b) and p21(Waf1). In breast cancers, lower JHDM1B expression correlates with an increased size of specifically stained nucleolar organized regions, a morphological parameter directly related to the rate of ribosome biogenesis and with a poorer prognosis. In addition, in tumors lacking the controller function of p53, a lower expression of JHDM1B is associated with an increased tumor size at diagnosis. Altogether, our data indicate that epigenetic activation of rDNA genes induced by JHDM1B depletion is associated with a p53-dependent growth arrest, but may promote cancer cell growth when p53 is lacking.
   What's new? Cancer cells divide rapidly, but faster division requires faster growth, so each generation of cells doesn't get ever smaller. Thus, cancer cells must make extra ribosomes to pump out more proteins, meaning they have to speed up transcription of ribosomal DNA. And when cells make less of the enzyme JHDM1B, rDNA transcription does increase. But depending on cell type, the lack of JHDM1B may speed up proliferation, or may instead shut it down. These authors asked why the different biological outcomes? They found that it depends on a p53 pathway: Knocking down JHDM1B only spurs faster proliferation in cells that lack p53. When p53 is functional, getting rid of JHDM1B leads to senescence and death.
C1 [Penzo, Marianna; Casoli, Lucia; Pollutri, Daniela; Sicuro, Laura; Ceccarelli, Claudio; Govoni, Marzia; Trere, Davide; Montanaro, Lorenzo] Univ Bologna, Dept Expt Diagnost & Specialty Med, I-40138 Bologna, Italy.
   [Santini, Donatella] S Orsola Malpighi Univ Hosp, Surg Pathol Unit, Bologna, Italy.
   [Taffurelli, Mario] Univ Bologna, Dept Med & Surg Sci, I-40138 Bologna, Italy.
   [Brina, Daniela] Ist Sci San Raffaele, Div Oncol, Lab Mol Histol & Cell Growth, I-20132 Milan, Italy.
C3 University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di
   Bologna; University of Bologna; Vita-Salute San Raffaele University;
   IRCCS Ospedale San Raffaele
RP Montanaro, L (通讯作者)，Univ Bologna, S Orsola Malpighi Univ Hosp, Dept Expt Diagnost & Specialty Med, Pav 11,Via Massarenti 9, I-40138 Bologna, Italy.
EM lorenzo.montanaro@unibo.it
RI PENZO, MARIANNA/AAC-3264-2021; Trere', Davide/AAC-4725-2021; Santini,
   Donatella/AAO-1490-2021; Taffurelli, Mario/HLP-6179-2023; Montanaro,
   Lorenzo/I-4236-2019; Ceccarelli, Claudio/AAS-6105-2020; POLLUTRI,
   DANIELA/GMW-9654-2022
OI Taffurelli, Mario/0000-0001-9474-995X; govoni,
   marzia/0000-0003-1673-0107; TRERE', DAVIDE/0000-0003-1127-1052;
   Ceccarelli, Claudio/0000-0003-0743-2087; POLLUTRI,
   DANIELA/0000-0002-7895-5128; santini, donatella/0000-0002-1692-6348;
   PENZO, MARIANNA/0000-0002-1738-9767; montanaro,
   lorenzo/0000-0001-9776-9518; Pollutri, Daniela/0000-0003-4531-7258
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-11416];
   Italian Ministry of Education, University and Research PRIN
   [20104AE23N_002]
FX Grant sponsor: Associazione Italiana per la Ricerca sul Cancro (AIRC);
   Grant number: IG-11416; Grant sponsor: Italian Ministry of Education,
   University and Research PRIN; Grant number: 20104AE23N_002
CR Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x
   Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845
   Chédin S, 2007, CELL CYCLE, V6, P11, DOI 10.4161/cc.6.1.3649
   Conlon I, 1999, CELL, V96, P235, DOI 10.1016/S0092-8674(00)80563-2
   Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x
   Donati G, 2011, ONCOGENE, V30, P3274, DOI 10.1038/onc.2011.48
   Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992
   Dussault AA, 2006, BIOL PROCED ONLINE, V8, P1, DOI 10.1251/bpo114
   Frescas D, 2007, NATURE, V450, P309, DOI 10.1038/nature06255
   Gandin V, 2008, NATURE, V455, P684, DOI 10.1038/nature07267
   Gao DM, 2012, LAB INVEST, V92, P200, DOI 10.1038/labinvest.2011.163
   He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499
   He J, 2013, NAT CELL BIOL, V15, P373, DOI 10.1038/ncb2702
   He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Kim HD, 2011, ONCOGENE, V30, P3317, DOI 10.1038/onc.2011.47
   Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200
   Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064
   Ma HH, 2013, MOL BIOL CELL, V24, P1334, DOI 10.1091/mbc.E12-12-0881
   Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje
   Montanaro L, 2006, J PATHOL, V210, P10, DOI 10.1002/path.2023
   Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752
   Montanaro L, 2012, BBA-REV CANCER, V1825, P101, DOI 10.1016/j.bbcan.2011.10.006
   Montanaro L, 2010, CANCER RES, V70, P4767, DOI 10.1158/0008-5472.CAN-09-4024
   Pfau R, 2008, P NATL ACAD SCI USA, V105, P1907, DOI 10.1073/pnas.0711865105
   PLOTON D, 1986, HISTOCHEM J, V18, P5, DOI 10.1007/BF01676192
   RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420
   Rinn JL, 2011, TRENDS CELL BIOL, V21, P344, DOI 10.1016/j.tcb.2011.04.002
   Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015
   Sansone P, 2007, BRIT J CANCER, V96, P1302, DOI 10.1038/sj.bjc.6603723
   Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751
   Sharma Arishya, 2012, Methods Mol Biol, V920, P613, DOI 10.1007/978-1-61779-998-3_40
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581
   Tzatsos A, 2011, J BIOL CHEM, V286, P33061, DOI 10.1074/jbc.M111.257667
   Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005
NR 36
TC 17
Z9 18
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD MAR 1
PY 2015
VL 136
IS 5
BP E272
EP E281
DI 10.1002/ijc.29240
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AW5ZY
UT WOS:000346350500007
PM 25273595
DA 2025-01-12
ER

PT J
AU Salz, T
   Deng, CW
   Pampo, C
   Siemann, D
   Qiu, Y
   Brown, K
   Huang, SM
AF Salz, Tal
   Deng, Changwang
   Pampo, Christine
   Siemann, Dietmar
   Qiu, Yi
   Brown, Kevin
   Huang, Suming
TI Histone Methyltransferase hSETD1A Is a Novel Regulator of Metastasis in
   Breast Cancer
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID H3 LYSINE 4; EPITHELIAL-MESENCHYMAL TRANSITION; MATRIX
   METALLOPROTEINASES MMPS; CELL-PROLIFERATION; HUMAN GENOME; COMPASS
   FAMILY; TARGET GENES; EXPRESSION; METHYLATION; PROGRESSION
AB Epigenetic alteration is a hallmark of all cancers. Such alterations lead to modulation of fundamental cancer-related functions, such as proliferation, migration, and invasion. In particular, methylation of Histone H3 Lysine 4 (H3K4), a histone mark generally associated with transcriptional activation, is altered during progression of several human cancers. While the depletion of H3K4 demethylases promotes breast cancer metastasis, the effect of H3K4 methyltransferases on metastasis is not clear. Nevertheless, gene duplications in the human SETD1A (hSETD1A) H3K4 methyltransferase are present in almost half of breast cancers. Herein, expression analysis determined that hSETD1A is upregulated in multiple metastatic human breast cancer cell lines and clinical tumor specimens. Ablation of hSETD1A in breast cancer cells led to a decrease in migration and invasion in vitro and to a decrease in metastasis in nude mice. Furthermore, a group of matrix metalloproteinases (including MMP2, MMP9, MMP12, MMP13, and MMP17) were identified which were downregulated upon depletion of hSETD1A and demonstrated a decrease in H3K4me3 at their proximal promoters based on chromatin immunoprecipitation analysis. These results provide evidence for a functional and mechanistic link among hSETD1A, MMPs, and metastasis in breast cancer, thereby supporting an oncogenic role for hSETD1A in cancer. (C) 2014 AACR.
C1 [Salz, Tal; Deng, Changwang; Brown, Kevin; Huang, Suming] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.
   [Pampo, Christine; Siemann, Dietmar] Univ Florida, Coll Med, Dept Radiat Oncol, Gainesville, FL 32610 USA.
   [Siemann, Dietmar; Qiu, Yi; Brown, Kevin; Huang, Suming] Univ Florida, Coll Med, UF Hlth Canc Ctr, Gainesville, FL 32610 USA.
   [Qiu, Yi] Univ Florida, Coll Med, Anat & Cell Biol, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida; State University
   System of Florida; University of Florida; State University System of
   Florida; University of Florida
RP Huang, SM (通讯作者)，Univ Florida, Coll Med, 2033 Mowry Rd,CGRC 355, Gainesville, FL 32610 USA.
EM sumingh@ufl.edu
OI Siemann, Dietmar/0000-0002-5190-5761; , Yi/0000-0002-3282-6072
FU NIH [R01HL090589, R01HL091929, R01HL095674]
FX This work was supported by grants from the NIH (R01HL090589 and
   R01HL091929, to S. Huang; and R01HL095674, to Y. Qiu).
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Alford SH, 2012, BREAST CANCER RES TR, V132, P429, DOI 10.1007/s10549-011-1591-2
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   [Anonymous], 2013, Breast Cancer Facts Figures 2013-2014
   Ardehali MB, 2011, EMBO J, V30, P2817, DOI 10.1038/emboj.2011.194
   Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Berdel B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-516
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763
   Chernov Andrei V, 2011, Biomol Concepts, V2, P135
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Ellinger J, 2010, INT J CANCER, V127, P2360, DOI 10.1002/ijc.25250
   Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038
   Enroth S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-450
   Feinberg Andrew P, 2013, Trans Am Clin Climatol Assoc, V124, P84
   Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hallson G, 2012, GENETICS, V190, P91, DOI 10.1534/genetics.111.135863
   He CC, 2012, HUM PATHOL, V43, P1425, DOI 10.1016/j.humpath.2011.11.003
   Hegedüs L, 2008, J CELL PHYSIOL, V216, P480, DOI 10.1002/jcp.21417
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Herz HM, 2012, GENE DEV, V26, P2604, DOI 10.1101/gad.201327.112
   Hu DQ, 2013, MOL CELL BIOL, V33, P4745, DOI 10.1128/MCB.01181-13
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Khanna C, 2005, CARCINOGENESIS, V26, P513, DOI 10.1093/carcin/bgh261
   Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896
   Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877
   Köhrmann A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-188
   Labrie M, 2013, CELL MOL LIFE SCI, V70, P3109, DOI 10.1007/s00018-012-1214-z
   Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052
   Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004
   Li H, 2010, MOL CANCER RES, V8, P1610, DOI 10.1158/1541-7786.MCR-10-0398
   Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Liu CH, 2014, TUMOR BIOL, V35, P6073, DOI 10.1007/s13277-014-1804-5
   Liu YL, 2014, PHARMACOL THERAPEUT, V143, P275, DOI 10.1016/j.pharmthera.2014.03.007
   Mair B, 2014, TRENDS PHARMACOL SCI, V35, P136, DOI 10.1016/j.tips.2014.01.001
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Merdad A, 2014, ANTICANCER RES, V34, P1355
   Newby AC, 2012, VASC PHARMACOL, V56, P232, DOI 10.1016/j.vph.2012.01.007
   Pang J, 2012, BREAST CANCER RES TR, V135, P59, DOI 10.1007/s10549-012-2055-z
   Pujadas E, 2012, CELL, V148, P1123, DOI 10.1016/j.cell.2012.02.045
   Rabello DD, 2013, INT J ONCOL, V43, P653, DOI 10.3892/ijo.2013.1981
   Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Salz T, 2014, CANCER RES, V74, P775, DOI 10.1158/0008-5472.CAN-13-1400
   Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shilatifard A, 2012, ANNU REV BIOCHEM, V81, P65, DOI 10.1146/annurev-biochem-051710-134100
   Tahiliani M, 2007, NATURE, V447, P601, DOI 10.1038/nature05823
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364
   Yang H, 2014, FASEB J, V28, P4265, DOI 10.1096/fj.14-250654
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
NR 64
TC 53
Z9 59
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAR
PY 2015
VL 13
IS 3
BP 461
EP 469
DI 10.1158/1541-7786.MCR-14-0389
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CD6UA
UT WOS:000351223800007
PM 25373480
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Stefansson, OA
   Moran, S
   Gomez, A
   Sayols, S
   Arribas-Jorba, C
   Sandoval, J
   Hilrnarsdottir, H
   Olafsdottir, E
   Tryggvadottir, L
   Jonasson, JG
   Eyfjord, J
   Esteller, M
AF Stefansson, Olafur A.
   Moran, Sebastian
   Gomez, Antonio
   Sayols, Sergi
   Arribas-Jorba, Carlos
   Sandoval, Juan
   Hilrnarsdottir, Holrnfridur
   Olafsdottir, Elinborg
   Tryggvadottir, Laufey
   Jonasson, Jon G.
   Eyfjord, Jorunn
   Esteller, Manel
TI A DNA methylation-based definition of biologically distinct breast
   cancer subtypes
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Breast cancer; DNA methylation; Microarrays; Biological subtypes;
   Prognosis
ID TUMOR-SUPPRESSOR GENE; LANDSCAPE; EXPRESSION; MUTATIONS; ARID1A
AB In cancer, epigenetic states are deregulated and thought to be of significance in cancer development and progression. We explored DNA methylation-based signatures in association with breast cancer subtypes to assess their impact on clinical presentation and patient prognosis. DNA methylation was analyzed using Infinium 450K arrays in 40 tumors and 17 normal breast samples, together with DNA copy number changes and subtype-specific markers by tissue microarrays. The identified methylation signatures were validated against a cohort of 212 tumors annotated for breast cancer subtypes by the PAM50 method (The Cancer Genome Atlas). Selected markers were pyrosequenced in an independent validation cohort of 310 tumors and analyzed with respect to survival, clinical stage and grade. The results demonstrate that DNA methylation patterns linked to the luminal-B subtype are characterized by CpG island promoter methylation events. In contrast, a large fraction of basal-like tumors are characterized by hypomethylation events occurring within the gene body. Based on these hallmark signatures, we defined two DNA methylation-based subtypes, Epi-LumB and Epi-Basal, and show that they are associated with unfavorable clinical parameters and reduced survival. Our data show that distinct mechanisms leading to changes in CpG methylation states are operative in different breast cancer subtypes. Importantly, we show that a few selected proxy markers can be used to detect the distinct DNA methylation-based subtypes thereby providing valuable information on disease prognosis. (c) 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical Societies.
C1 [Stefansson, Olafur A.; Moran, Sebastian; Gomez, Antonio; Sayols, Sergi; Arribas-Jorba, Carlos; Sandoval, Juan; Esteller, Manel] Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program PEBC, Barcelona 08908, Catalonia, Spain.
   [Hilrnarsdottir, Holrnfridur; Eyfjord, Jorunn] Univ Iceland, Fac Med, Canc Res Lab, Reykjavik, Iceland.
   [Olafsdottir, Elinborg; Tryggvadottir, Laufey; Jonasson, Jon G.] Iceland Canc Registry, Reykjavik, Iceland.
   [Jonasson, Jon G.] Landspitali Univ Hosp, Dept Pathol, Reykjavik, Iceland.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain.
   [Esteller, Manel] ICREA, Barcelona, Catalonia, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of
   Iceland; Landspitali National University Hospital; University of
   Barcelona; ICREA
RP Esteller, M (通讯作者)，Hosp Llobregat, Hosp Duran & Reynals, IDIBELL Bellvitge Biomed Res Inst, Canc Epigenet & Biol Program PEBC, Gran Via Hosp 199, Barcelona 08907, Catalonia, Spain.
EM mesteller@idibell.cat
RI sandoval, juan/M-4593-2015; Esteller, Manel/L-5956-2014; Gomez Moruno,
   Antonio/H-7574-2015; Moran, Sebastian/G-5293-2013
OI Sayols, Sergi/0000-0002-3877-4170; Tryggvadottir,
   Laufey/0000-0001-8067-9030; Esteller, Manel/0000-0003-4490-6093;
   Jonasson, Jon G./0000-0002-2635-5032; Gomez Moruno,
   Antonio/0000-0001-5308-981X; Moran, Sebastian/0000-0003-4192-8983;
   sandoval, juan/0000-0002-5100-973X; Hilmarsdottir,
   Holmfridur/0000-0003-1040-8125
FU Icelandic Centre for Research RANNIS; Cellex Foundation; Fundacion
   Sandra Ibarra de Solidaridad frente al Cancer; Junta de Barcelona of the
   Asociacion Espanola Contra el Cancer; Health and Science Departments of
   the Catalan Government (Generalitat de Catalunya); ICREA Funding Source:
   Custom
FX The Icelandic Centre for Research RANNIS (J.E., H.H.), the Cellex
   Foundation (ME), Fundacion Sandra Ibarra de Solidaridad frente al Cancer
   (M.E.), Junta de Barcelona of the Asociacion Espanola Contra el Cancer
   (O.A.S.), and the Health and Science Departments of the Catalan
   Government (Generalitat de Catalunya) (M.E.). M.E. is an ICREA Research
   Professor.
CR Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Chan LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005572
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Diaz-Cruz Edgar S, 2010, Breast Dis, V32, P85, DOI 10.3233/BD-2010-0308
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hortobagyi Gabriel N, 2005, Clin Breast Cancer, V6, P391, DOI 10.3816/CBC.2005.n.043
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   López-Tarruella S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2226
   Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386
   Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou C.M., 2011, COLD SPRING HARB PER, V3
   Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062
   Saal LH, 2008, NAT GENET, V40, P102, DOI 10.1038/ng.2007.39
   Sigurdardottir LG, 2012, ACTA ONCOL, V51, P880, DOI 10.3109/0284186X.2012.698751
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866
   Varley KE, 2013, GENOME RES, V23, P555, DOI 10.1101/gr.147942.112
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Zhao M, 2013, NUCLEIC ACIDS RES, V41, pD970, DOI 10.1093/nar/gks937
NR 33
TC 126
Z9 145
U1 0
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD MAR
PY 2015
VL 9
IS 3
BP 555
EP 568
DI 10.1016/j.molonc.2014.10.012
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CE7SX
UT WOS:000352043200002
PM 25468711
OA Green Published, hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Hassan, HE
   Carlson, S
   Abdallah, I
   Buttolph, T
   Glass, KC
   Fandy, TE
AF Hassan, Hazem E.
   Carlson, Samuel
   Abdallah, Inas
   Buttolph, Thomm
   Glass, Karen C.
   Fandy, Tamer E.
TI Curcumin and Dimethoxycurcumin Induced Epigenetic Changes in Leukemia
   Cells
SO PHARMACEUTICAL RESEARCH
LA English
DT Article
DE curcumin; dimethoxycurcumin; DNA methylation; DNA pyrosequencing;
   histone methylation
ID DNA METHYLTRANSFERASE INHIBITORS; BREAST-CANCER CELLS; HYPOMETHYLATION
   AGENT; HISTONE DEACETYLASE; PANCREATIC-CANCER; GENE-EXPRESSION; CYCLE
   ARREST; KAPPA-B; ANALOGS; METHYLATION
AB Curcumin is an ideal chemopreventive and antitumor agent characterized by poor bioavailability and low stability. The development of synthetic structural analogues like dimethoxycurcumin (DMC) could overcome these drawbacks. In this study we compared the cytotoxicity, metabolism and the epigenetic changes induced by both drugs in leukemia cells.
   Apoptosis and cell cycle analysis were analyzed by flow cytometry. Real-time PCR was used for gene expression analysis. DNA methylation was analyzed by DNA pyrosequencing. The metabolic stability was determined using human pooled liver microsomes. Chromatin Immunoprecipitation was used to quantify histone methylation.
   Clinically relevant concentration of curcumin and DMC were not cytotoxic to leukemia cells and induced G2/M cell cycle arrest. DMC was more metabolically stable than curcumin. Curcumin and DMC were devoid of DNA hypomethylating activity. DMC induced the expression of promoter methylated genes without reversing DNA methylation and increased H3K36me3 mark near the promoter region of hypermethylated genes.
   DMC is a more stable analogue of curcumin that can induce epigenetic changes not induced by curcumin. DMC induced the expression of promoter methylated genes. The combination of DMC with DNA methyltransferase inhibitors could harness their combined induced epigenetic changes for optimal re-expression of epigenetically silenced genes.
C1 [Hassan, Hazem E.; Abdallah, Inas] Univ Maryland, Dept Pharmaceut Sci, Baltimore, MD 21201 USA.
   [Carlson, Samuel; Glass, Karen C.; Fandy, Tamer E.] Albany Coll Pharm, Dept Pharmaceut Sci, Colchester, VT 05446 USA.
   [Buttolph, Thomm] Univ Vermont, Dept Neurol Sci, Burlington, VT USA.
C3 University System of Maryland; University of Maryland Baltimore;
   University of Vermont
RP Fandy, TE (通讯作者)，Albany Coll Pharm, Dept Pharmaceut Sci, Vermont Campus,261 Mt View Dr, Colchester, VT 05446 USA.
EM tamer.fandy@acphs.edu
RI Glass, Karen/AAV-1076-2021; Abdallah, Inas/F-2485-2017
OI Glass, Karen/0000-0002-2761-733X; Abdallah, Inas/0000-0002-4207-0985;
   Carlson, Samuel/0000-0001-9881-4210
FU Scholarship of Discovery Intramural Research Grant Program (SDIRGP) from
   Albany College of Pharmacy; University of Maryland; NIH [NIGMS
   R15GM104865]; COBRE Program of the National Center for Research
   Resources [5 P30 RR032135]; National Institute of General Medical
   Sciences [8 P30 GM 103498]
FX This work was supported by the Scholarship of Discovery Intramural
   Research Grant Program (SDIRGP) from Albany College of Pharmacy to TEF
   and University of Maryland intramural research grant to HH. The work was
   also supported by NIH Grant Numbers NIGMS R15GM104865 to KCG, 5 P30
   RR032135 from the COBRE Program of the National Center for Research
   Resources and 8 P30 GM 103498 from the National Institute of General
   Medical Sciences. Its contents are solely the responsibility of the
   authors and do not necessarily represent the official views of NIH.
CR Brueckner B, 2005, CANCER RES, V65, P6305, DOI 10.1158/0008-5472.CAN-04-2957
   Bukhari SNA, 2013, MED CHEM, V9, P897, DOI 10.2174/1573406411309070002
   Chakraborti S, 2013, BIOCHEMISTRY-US, V52, P7449, DOI 10.1021/bi400734e
   Chen C, 2011, CANCER BIOL THER, V12, P797, DOI 10.4161/cbt.12.9.17671
   Chen WF, 2006, FREE RADICAL BIO MED, V40, P526, DOI 10.1016/j.freeradbiomed.2005.09.008
   Chen Y, 2007, BASIC CLIN PHARMACOL, V101, P427, DOI 10.1111/j.1742-7843.2007.00142.x
   Du LP, 2012, NUTR CANCER, V64, P1228, DOI 10.1080/01635581.2012.717682
   Easwaran HP, 2004, EMBO REP, V5, P1181, DOI 10.1038/sj.embor.7400295
   Fandy TE, 2014, CLIN CANCER RES, V20, P1249, DOI 10.1158/1078-0432.CCR-13-1453
   Fandy TE, 2009, BLOOD, V114, P2764, DOI 10.1182/blood-2009-02-203547
   Fandy TE, 2009, CURR MED CHEM, V16, P2075, DOI 10.2174/092986709788612738
   Gazal M, 2014, EUR J PHARMACOL, V724, P132, DOI 10.1016/j.ejphar.2013.12.028
   Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018
   Khor TO, 2011, BIOCHEM PHARMACOL, V82, P1073, DOI 10.1016/j.bcp.2011.07.065
   Link A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057709
   Liu H, 2014, MOL BIOSYST
   Liu HS, 2011, MOL PHARMACOL, V80, P638, DOI 10.1124/mol.111.072512
   Liu ZF, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1156
   Liu ZF, 2009, BIOORG MED CHEM LETT, V19, P706, DOI 10.1016/j.bmcl.2008.12.041
   Mach CM, 2010, ANTICANCER RES, V30, P811
   Medina-Franco JL, 2011, MOL DIVERS, V15, P293, DOI 10.1007/s11030-010-9262-5
   Migheli F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052501
   Mohr F, 2011, EXP HEMATOL, V39, P272, DOI 10.1016/j.exphem.2010.12.004
   Moiseeva EP, 2007, MOL CANCER THER, V6, P3071, DOI 10.1158/1535-7163.MCT-07-0117
   Nagaraju GP, 2013, CANCER LETT, V341, P195, DOI 10.1016/j.canlet.2013.08.002
   Ou JL, 2013, FEBS J, V280, P5829, DOI 10.1111/febs.12503
   Parashar G, 2012, MOL CELL BIOCHEM, V365, P29, DOI 10.1007/s11010-012-1240-z
   Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040
   Qiu PJ, 2013, BIOORGAN MED CHEM, V21, P5012, DOI 10.1016/j.bmc.2013.06.053
   Raynal NJM, 2012, CANCER RES, V72, P1170, DOI 10.1158/0008-5472.CAN-11-3248
   Sarris M, 2014, ONCOGENE, V33, P1207, DOI 10.1038/onc.2013.87
   Shankar Sharmila, 2007, J Mol Signal, V2, P10, DOI 10.1186/1750-2187-2-10
   Shankar S, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-16
   Shankar S, 2007, CARCINOGENESIS, V28, P1277, DOI 10.1093/carcin/bgm024
   Shehzad A, 2013, BIOFACTORS, V39, P69, DOI 10.1002/biof.1066
   Shu LM, 2011, AAPS J, V13, P606, DOI 10.1208/s12248-011-9300-y
   Srivastava RK, 2007, CELL CYCLE, V6, P2953, DOI 10.4161/cc.6.23.4951
   Sun M, 2008, MOL CANCER THER, V7, P464, DOI 10.1158/1535-7163.MCT-07-2272
   Tamvakopoulos C, 2007, CLIN CANCER RES, V13, P1269, DOI 10.1158/1078-0432.CCR-06-1839
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yang XW, 2000, CANCER RES, V60, P6890
   Yu JH, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0055934, 10.1371/journal.pone.0057564]
NR 43
TC 35
Z9 37
U1 1
U2 15
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0724-8741
EI 1573-904X
J9 PHARM RES-DORDR
JI Pharm. Res.
PD MAR
PY 2015
VL 32
IS 3
BP 863
EP 875
DI 10.1007/s11095-014-1502-4
PG 13
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA CB0ZX
UT WOS:000349357300011
PM 25186441
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Latimer, JJ
   Majekwana, VJ
   Pabón-Padín, YR
   Pimpley, MR
   Grant, SG
AF Latimer, Jean J.
   Majekwana, Vongai J.
   Pabon-Padin, Yashira R.
   Pimpley, Manasi R.
   Grant, Stephen G.
TI Regulation and Disregulation of Mammalian Nucleotide Excision Repair: A
   Pathway to Nongermline Breast Carcinogenesis
SO PHOTOCHEMISTRY AND PHOTOBIOLOGY
LA English
DT Article
ID UNSCHEDULED DNA-SYNTHESIS; CELL-CYCLE CHECKPOINTS; PRIMARY HUMAN
   MAMMARY; XERODERMA-PIGMENTOSUM; DAMAGED DNA; GENOMIC INSTABILITY;
   PYRIMIDINE DIMERS; HUMAN FIBROBLASTS; DEFECTIVE REPAIR; REPLICATION
AB Nucleotide excision repair (NER) is an important modulator of disease, especially in constitutive deficiencies such as the cancer predisposition syndrome Xeroderma pigmentosum. We have found profound variation in NER capacity among normal individuals, between cell-types and during carcinogenesis. NER is a repair system for many types of DNA damage, and therefore many types of genotoxic carcinogenic exposures, including ultraviolet light, products of organic combustion, metals and oxidative stress. Because NER is intimately related to cellular metabolism, requiring components of both the DNA replicative and transcription machinery, it has a narrow range of functional viability. Thus, genes in the NER pathway are expressed at the low levels manifested by, for example, nuclear transcription factors. As NER activity and gene expression vary by cell-type, it is inherently epigenetically regulated. Furthermore, this epigenetic modulation is disregulated during sporadic breast carcinogenesis. Loss of NER is one basis of genomic instability, a required element in cellular transformation, and one that potentially influences response to therapy. In this study, we demonstrate differences in NER capacity in eight adult mouse tissues, and place this result into the context of our previous work on mouse extraembryonic tissues, normal human tissues and sporadic early stage human breast cancer.
C1 [Latimer, Jean J.; Majekwana, Vongai J.; Pabon-Padin, Yashira R.; Pimpley, Manasi R.; Grant, Stephen G.] Nova SE Univ, Coll Pharm, Dept Pharmaceut Sci, Ft Lauderdale, FL 33314 USA.
   [Grant, Stephen G.] Nova SE Univ, Coll Osteopath Med, Publ Hlth Program, Ft Lauderdale, FL 33314 USA.
C3 Nova Southeastern University; Nova Southeastern University
RP Latimer, JJ (通讯作者)，Nova SE Univ, Coll Pharm, Dept Pharmaceut Sci, Ft Lauderdale, FL 33314 USA.
EM jean.latimer@nova.edu
RI ; Grant, Stephen/D-6984-2014
OI Latimer, Jean/0000-0002-4882-5170; Grant, Stephen/0000-0002-9236-0913
FU Ruth Estrin Goldberg Foundation; Nova Southeastern University; National
   Institutes of Health [R29-CA71894]; US Department of Defense
   [DAMD17-00-1-0409, DAMD17-00-1-0651, DAMD17-00-1-0681, DAMD17-00-1-0686,
   W81X-04-1-0685, W81XWH-04-1-0686]; Pennsylvania Department of Health
   [ME-98-205]; Komen or the Cure Awards [DISP0707276, POP99806, POP00998,
   BCTR0403329, DISS00403112]; American Cancer Society [RPG-98-055-01-CCE];
   Glimmer of Hope Foundation [SF01012]; NIH Program [HD26732]; U.S.
   Department of Energy [AC 03-76-SF01012]; National Institute of
   Environmental Health Sciences [5 T32 ES07106]
FX The authors thank Khushbu Thumar, Omar Ibrahim and Homood As Sobeai for
   technical assistance with this study. We would also like to thank
   Michael Hultner, Tariq Nazir, Lisa Flowers, Michael Forlenza, Kelly
   Beaudry-Rodgers, Crystal Kelley, Julie Conte, Jennifer Johnson, Tiffany
   Miles, Jason Dimsdale and Nancy Lalanne for their past contributions to
   this work. The study presented on adult mouse tissues was funded by the
   Ruth Estrin Goldberg Foundation and a President's Faculty Research and
   Development Grant from Nova Southeastern University. Other cited work
   was funded by National Institutes of Health Grant R29-CA71894; US
   Department of Defense Grants DAMD17-00-1-0409, DAMD17-00-1-0651,
   DAMD17-00-1-0681, DAMD17-00-1-0686, W81X-04-1-0685 and W81XWH-04-1-0686;
   Pennsylvania Department of Health Grant ME-98-205; Komen or the Cure
   Awards DISP0707276, POP99806, POP00998, BCTR0403329 and DISS00403112 (to
   Jennifer M. Johnson); American Cancer Society Grant RPG-98-055-01-CCE;
   the Glimmer of Hope Foundation SF01012; NIH Program Project Grant
   HD26732; the U.S. Department of Energy Contract No. AC 03-76-SF01012;
   the National Institute of Environmental Health Sciences Postdoctoral
   Training Grant 5 T32 ES07106.
CR Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030
   Alapetite C, 1997, J INVEST DERMATOL, V108, P154, DOI 10.1111/1523-1747.ep12332692
   ATHAS WF, 1991, CANCER RES, V51, P5786
   Batty DP, 2000, GENE, V241, P193, DOI 10.1016/S0378-1119(99)00489-8
   Biggerstaff Maureen, 2006, Methods Mol Biol, V314, P417
   Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4
   Bradford PT, 2011, J MED GENET, V48, P168, DOI 10.1136/jmg.2010.083022
   Cleaver JE, 2014, P NATL ACAD SCI USA, V111, P13487, DOI 10.1073/pnas.1414135111
   Cleaver JE, 2000, J DERMATOL SCI, V23, P1, DOI 10.1016/S0923-1811(99)00088-2
   CLEAVER JE, 1968, NATURE, V218, P652, DOI 10.1038/218652a0
   Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283
   de Boer J, 1999, BIOCHIMIE, V81, P127, DOI 10.1016/S0300-9084(99)80045-5
   de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453
   DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0
   deVries A, 1997, MOL CARCINOGEN, V19, P46, DOI 10.1002/(SICI)1098-2744(199705)19:1<46::AID-MC7>3.0.CO;2-L
   Dolbeare F, 1996, HISTOCHEM J, V28, P531, DOI 10.1007/BF02331377
   DOWNES CS, 1994, BIOESSAYS, V16, P75, DOI 10.1002/bies.950160112
   FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7
   Foulkes WD, 1995, CLIN INVEST MED, V18, P473
   Fousteri M, 2008, CELL RES, V18, P73, DOI 10.1038/cr.2008.6
   Furda A, 2014, METHODS MOL BIOL, V1105, P419, DOI 10.1007/978-1-62703-739-6_31
   Gospodinov A, 2003, EUR J BIOCHEM, V270, P1000, DOI 10.1046/j.1432-1033.2003.03473.x
   Grant SG, 2000, CLIN GENET, V58, P209, DOI 10.1034/j.1399-0004.2000.580308.x
   Hanawalt P. C., 1983, MANIPULATION EXPRESS, P45
   HART RW, 1974, P NATL ACAD SCI USA, V71, P2169, DOI 10.1073/pnas.71.6.2169
   Hellerstein M, 1999, NAT MED, V5, P83, DOI 10.1038/4772
   Jaspers NGJ, 2007, AM J HUM GENET, V80, P457, DOI 10.1086/512486
   Johansson F, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh154
   Johnson J. M., 2006, THESIS U PITTSBURGH
   Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1
   KATZ EB, 1992, AM J PHYSIOL, V262, pH1867, DOI 10.1152/ajpheart.1992.262.6.H1867
   Köberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3
   Konishi H, 2011, P NATL ACAD SCI USA, V108, P17773, DOI 10.1073/pnas.1110969108
   Lai Jin-Ping, 2013, Acta Neuropathol Commun, V1, P4, DOI 10.1186/2051-5960-1-4
   Latimer J. J., 2000, U. S. Patent, Patent No. [6, 383, 805, 6383805]
   Latimer JJ, 2008, CELL TISSUE RES, V333, P461, DOI 10.1007/s00441-008-0645-1
   Latimer JJ, 2014, METHODS MOL BIOL, V1105, P533, DOI 10.1007/978-1-62703-739-6_37
   Latimer JJ, 2014, METHODS MOL BIOL, V1105, P511, DOI 10.1007/978-1-62703-739-6_36
   Latimer JJ, 2010, P NATL ACAD SCI USA, V107, P21725, DOI 10.1073/pnas.0914772107
   Latimer JJ, 1996, EXP CELL RES, V228, P19, DOI 10.1006/excr.1996.0294
   Latimer JJ, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-26
   Latimer JJ, 2003, EXP CELL RES, V291, P111, DOI 10.1016/S0014-4827(03)00368-9
   Limsirichaikul S, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp023
   Lopez-Saez JF, 1998, HISTOL HISTOPATHOL, V13, P1197, DOI 10.14670/HH-13.1197
   Maddukuri L, 2007, ACTA BIOCHIM POL, V54, P469, DOI 10.18388/abp.2007_3222
   Martelli A, 1997, IN VIVO, V11, P189
   McCarty WJ, 2014, TECHNOLOGY, V2, P67, DOI 10.1142/S2339547814500083
   McCready S, 2014, METHODS MOL BIOL, V1105, P551, DOI 10.1007/978-1-62703-739-6_38
   Menck CFM, 2014, GENET MOL BIOL, V37, P220, DOI 10.1590/S1415-47572014000200008
   MITCHELL DL, 1990, RADIAT RES, V123, P299, DOI 10.2307/3577736
   Morita Y, 2011, J TOXICOL SCI, V36, P515
   Moriwaki SI, 1996, MUTAT RES-DNA REPAIR, V364, P117, DOI 10.1016/0921-8777(96)00029-8
   Nesslany F, 2013, METHODS MOL BIOL, V1044, P373, DOI 10.1007/978-1-62703-529-3_20
   Nouspikel T, 2008, DNA REPAIR, V7, P1155, DOI 10.1016/j.dnarep.2008.03.015
   PAINTER RB, 1969, RADIAT RES, V37, P451, DOI 10.2307/3572686
   PROBST GS, 1981, ENVIRON MUTAGEN, V3, P11, DOI 10.1002/em.2860030103
   Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463
   Robertson AB, 2009, CELL MOL LIFE SCI, V66, P981, DOI 10.1007/s00018-009-8736-z
   Shuck SC, 2008, CELL RES, V18, P64, DOI 10.1038/cr.2008.2
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h
   STEIER H, 1969, Laboratory Practice, V18, P1295
   Tan T, 2002, MOL CELL BIOL, V22, P3247, DOI 10.1128/MCB.22.10.3247-3254.2002
   Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X
   Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002
   Thomas J. C. G., 1981, DNA REPAIR LABORAT B, V1, P277
   van Hoffen A, 2003, TOXICOLOGY, V193, P79, DOI 10.1016/j.tox.2003.06.001
   van Steeg H, 1999, MOL MED TODAY, V5, P86, DOI 10.1016/S1357-4310(98)01394-X
   VANZEELAND AA, 1981, MUTAT RES, V82, P173, DOI 10.1016/0027-5107(81)90148-2
   VIJG J, 1984, MUTAT RES, V132, P129, DOI 10.1016/0167-8817(84)90007-5
   Vincent F, 2001, CYTOMETRY, V45, P96, DOI 10.1002/1097-0320(20011001)45:2<96::AID-CYTO1151>3.0.CO;2-1
   WILLIAMS GM, 1989, MUTAT RES, V221, P263, DOI 10.1016/0165-1110(89)90039-0
   WILLIAMS GM, 1977, CANCER RES, V37, P1845
   Wu M, 2002, NUCLEIC ACIDS RES, V30, P3422, DOI 10.1093/nar/gkf427
   Zsurka G, 2013, IUBMB LIFE, V65, P263, DOI 10.1002/iub.1126
NR 75
TC 6
Z9 8
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0031-8655
EI 1751-1097
J9 PHOTOCHEM PHOTOBIOL
JI Photochem. Photobiol.
PD MAR-APR
PY 2015
VL 91
IS 2
BP 493
EP 500
DI 10.1111/php.12387
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CD5JM
UT WOS:000351123900031
PM 25393451
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ke, J
   Zhao, ZJ
   Hong, SH
   Bai, SM
   He, Z
   Malik, F
   Xu, JH
   Zhou, L
   Chen, WL
   Martin-Trevino, R
   Wu, XJ
   Lan, P
   Yi, YJ
   Ginestier, C
   Ibarra, I
   Shang, L
   McDermott, S
   Luther, T
   Clouthier, SG
   Wicha, MS
   Liu, SL
AF Ke, Jia
   Zhao, Zhiju
   Hong, Su-Hyung
   Bai, Shoumin
   He, Zhen
   Malik, Fayaz
   Xu, Jiahui
   Zhou, Lei
   Chen, Weilong
   Martin-Trevino, Rachel
   Wu, Xiaojian
   Lan, Ping
   Yi, Yongju
   Ginestier, Christophe
   Ibarra, Ingrid
   Shang, Li
   McDermott, Sean
   Luther, Tahra
   Clouthier, Shawn G.
   Wicha, Max S.
   Liu, Suling
TI Role of microRNA221 in regulating normal mammary epithelial hierarchy
   and breast cancer stem-like cells
SO ONCOTARGET
LA English
DT Article
DE miR-221; breast stem-like cells; differentiation; hierarchy
ID ADULT HUMAN BREAST; IN-VITRO; BASAL; SUBPOPULATIONS; PREDICTOR;
   SURVIVAL; SUBTYPES; MIR-221; MARKER; LINES
AB Increasing evidence suggests that lineage specific subpopulations and stem-like cells exist in normal and malignant breast tissues. Epigenetic mechanisms maintaining this hierarchical homeostasis remain to be investigated. In this study, we found the level of microRNA221 (miR-221) was higher in stem-like and myoepithelial cells than in luminal cells isolated from normal and malignant breast tissue. In normal breast cells, over-expression of miR-221 generated more myoepithelial cells whereas knockdown of miR-221 increased luminal cells. Over-expression of miR-221 stimulated stem-like cells in luminal type of cancer and the miR-221 level was correlated with clinical outcome in breast cancer patients. Epithelial-mesenchymal transition (EMT) was induced by overexpression of miR-221 in normal and breast cancer cells. The EMT related gene ATXN1 was found to be a miR-221 target gene regulating breast cell hierarchy. In conclusion, we propose that miR-221 contributes to lineage homeostasis of normal and malignant breast epithelium.
C1 [Ke, Jia; He, Zhen; Wu, Xiaojian; Lan, Ping] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510275, Guangdong, Peoples R China.
   [Zhao, Zhiju; Xu, Jiahui; Zhou, Lei; Chen, Weilong; Liu, Suling] Univ Sci & Technol China, Innovat Ctr Cell Biol, Hefei 230026, Anhui, Peoples R China.
   [Zhao, Zhiju; Xu, Jiahui; Zhou, Lei; Chen, Weilong; Liu, Suling] Univ Sci & Technol China, CAS Key Lab Innate Immun & Chron Dis, Sch Life Sci & Med Ctr, Hefei 230026, Anhui, Peoples R China.
   [Hong, Su-Hyung] Kyungpook Natl Univ, Sch Dent, Dept Oral Microbiol, Daegu, South Korea.
   [Bai, Shoumin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou 510275, Guangdong, Peoples R China.
   [Malik, Fayaz; Martin-Trevino, Rachel; Shang, Li; McDermott, Sean; Luther, Tahra; Clouthier, Shawn G.; Wicha, Max S.] Univ Michigan, Dept Internal Med, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA.
   [Yi, Yongju] Sun Yat Sen Univ, Affiliated Hosp 6, Network Informat Ctr, Guangzhou 510275, Guangdong, Peoples R China.
   [Ginestier, Christophe] Univ Aix Marseille 2, Inst Paoli Calmettes, Inserm UMR891, Ctr Rech Cancerol Marseille,Lab Oncol Mol, Marseille, France.
   [Ibarra, Ingrid] Cold Spring Harbor Lab, Program Genet & Bioinformat, Cold Spring Harbor, NY 11724 USA.
C3 Sun Yat Sen University; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS; Chinese Academy of Sciences;
   University of Science & Technology of China, CAS; Kyungpook National
   University (KNU); Sun Yat Sen University; University of Michigan System;
   University of Michigan; Sun Yat Sen University; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Aix-Marseille Universite;
   UNICANCER; Institut Paoli-Calmette (IPC); Cold Spring Harbor Laboratory
RP Liu, SL (通讯作者)，Univ Sci & Technol China, Innovat Ctr Cell Biol, Hefei 230026, Anhui, Peoples R China.
EM 278494686@qq.com; mwicha@med.umich.edu; suling@ustc.edu.cn
RI Ginestier, Christophe/M-8828-2017; Wicha, Max/AAE-7268-2019; Liu,
   Suling/N-2796-2013; McDermott, Sean/I-2978-2013; lan, ping/T-1708-2017;
   Chen, Weilong/KHC-3480-2024; he, zhen/AFJ-0299-2022; jia,
   ke/GWM-4454-2022; xu, jiahui/KLZ-8859-2024; Zhou, Lei/B-9155-2014
OI Malik, Fayaz/0000-0001-5475-6610; liu, suling/0000-0002-0475-0242;
   Ginestier, Christophe/0000-0002-7477-3837; Zhou, Lei/0000-0003-0417-1168
FU CAS stem cell grant [XDA01040410]; NSFC [81472741, 81322033, 81402091];
   Susan G Komen career catalyst award [KG110316]; Fundamental Research
   Funds for the Central Universities [WK2070000034]; Stand Up 2 Cancer;
   Guangdong Department of Science & Technology Translational Medicine
   Center [2011A080300002]; Kyungpook National University Research Fund;
   National Cancer Institute [P30CA046592] Funding Source: NIH RePORTER
FX We thank Dr. Stephen Ethier for generously providing the breast cancer
   cell lines SUM149 and SUM159. We also thank the University of Michigan
   Flow Cytometry Core, Microarray Core (Joe Washburn and Craig Johnson),
   Vector Core, Molecular Imaging Core, and Pathology Core for invaluable
   assistance. This work was supported by CAS stem cell grant XDA01040410,
   NSFC grants 81472741 and 81322033(S.L.) and 81402091(J.K.), Susan G
   Komen career catalyst award KG110316 and the Fundamental Research Funds
   for the Central Universities WK2070000034(S.L.), Stand Up 2 Cancer (M.W.
   and G.H.), Guangdong Department of Science & Technology Translational
   Medicine Center grant 2011A080300002(P.L.). This Research was also
   supported by Kyungpook National University Research Fund, 2012 (HSH).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bachelard-Cascales E, 2010, STEM CELLS, V28, P1081, DOI 10.1002/stem.435
   Di Leva G, 2010, JNCI-J NATL CANCER I, V102, P706, DOI 10.1093/jnci/djq102
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Eirew P, 2008, NAT MED, V14, P1384, DOI 10.1038/nm.1791
   Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X
   Lee S, 2011, BBA-MOL CELL RES, V1813, P713, DOI 10.1016/j.bbamcr.2011.01.035
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Liu S, 2008, P NATL ACAD SCI USA, V105, P1680, DOI 10.1073/pnas.0711613105
   Liu SL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002751
   Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Moritani S, 2002, MODERN PATHOL, V15, P397, DOI 10.1038/modpathol.3880536
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Park JK, 2011, CANCER RES, V71, P7608, DOI 10.1158/0008-5472.CAN-11-1144
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Rakha EA, 2006, J PATHOL, V208, P495, DOI 10.1002/path.1916
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Sarrio D, 2012, STEM CELLS, V30, P292, DOI 10.1002/stem.791
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   SOULE HD, 1990, CANCER RES, V50, P6075
   Stingl J, 2001, BREAST CANCER RES TR, V67, P93, DOI 10.1023/A:1010615124301
   Stingl J, 1998, DIFFERENTIATION, V63, P201, DOI 10.1046/j.1432-0436.1998.6340201.x
   Tiscornia G, 2006, NAT PROTOC, V1, P241, DOI 10.1038/nprot.2006.37
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229
NR 32
TC 45
Z9 50
U1 4
U2 24
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 28
PY 2015
VL 6
IS 6
BP 3709
EP 3721
DI 10.18632/oncotarget.2888
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CF6WB
UT WOS:000352696200023
PM 25686829
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Moskalev, EA
   Jandaghi, P
   Fallah, M
   Manoochehri, M
   Botla, SK
   Kolychev, OV
   Nikitin, EA
   Bubnov, VV
   Doeberitz, MV
   Strobel, O
   Hackert, T
   Büchler, MW
   Giese, N
   Bauer, A
   Muley, T
   Warth, A
   Schirmacher, P
   Haller, F
   Hoheisel, JD
   Riazalhosseini, Y
AF Moskalev, Evgeny A.
   Jandaghi, Pouria
   Fallah, Mahdi
   Manoochehri, Mehdi
   Botla, Sandeep K.
   Kolychev, Oleg V.
   Nikitin, Evgeny A.
   Bubnov, Vladymyr V.
   Doeberitz, M. von Knebel
   Strobel, Oliver
   Hackert, Thilo
   Buechler, Markus W.
   Giese, Nathalia
   Bauer, Andrea
   Muley, Thomas
   Warth, Arne
   Schirmacher, Peter
   Haller, Florian
   Hoheisel, Joerg D.
   Riazalhosseini, Yasser
TI <i>GHSR</i> DNA hypermethylation is a common epigenetic alteration of
   high diagnostic value in a broad spectrum of cancers
SO ONCOTARGET
LA English
DT Article
DE DNA methylation; Cancer; Diagnosis; GHSR; Epigenetics
ID BREAST-CANCER; METHYLATION; MARKERS; PLASMA
AB Identification of a single molecular trait that is determinant of common malignancies may serve as a powerful diagnostic supplement to cancer type-specific markers. Here, we report a DNA methylation mark that is characteristic of seven studied malignancies, namely cancers of lung, breast, prostate, pancreas, colorectum, glioblastoma and B cell chronic lymphocytic leukaemia (CLL) (n = 137). This mark was defined by substantial hypermethylation at the promoter and first exon of growth hormone secretagouge receptor (GHSR) through bisulfite pyrosequencing. The degree of aberrant methylation was capable of accurate discrimination between cancer and control samples. The highest sensitivity and specificity of cancer detection was achieved for cancers of pancreas, lung, breast and CLL yielding the area under the curve (AUC) values of 1.0000, 0.9952, 0.9800 and 0.9400, respectively. Narrowing to a single CpG site within the gene's promoter or four consecutive CpG units of the highest methylation levels within the first exon improved the detection power. GHSR hypermethylation was detected already at the early stage tumors. The accurate performance of this marker was further replicated in an independent set of pancreatic cancer and control samples (n = 78). These findings support the candidature of GHSR methylation as a highly accurate pan-cancer marker.
C1 [Moskalev, Evgeny A.; Jandaghi, Pouria; Manoochehri, Mehdi; Botla, Sandeep K.; Bauer, Andrea; Hoheisel, Joerg D.; Riazalhosseini, Yasser] Deutsch Krebsforschungszentrum DKFZ, Funct Genome Anal, D-69120 Heidelberg, Germany.
   [Fallah, Mahdi] Deutsch Krebsforschungszentrum DKFZ, Mol Genet Epidemiol, D-69120 Heidelberg, Germany.
   [Kolychev, Oleg V.] Zhukovsky Gagarin Air Force Acad, Mil Training Res Ctr, Voronezh 394064, Russia.
   [Nikitin, Evgeny A.] Natl Res Ctr Haematol, Mol Haematol, Moscow 125167, Russia.
   [Bubnov, Vladymyr V.] Odessa State Med Univ, Dept Genom & Immunol, UA-265026 Odessa, Ukraine.
   [Doeberitz, M. von Knebel] Univ Heidelberg Hosp, Inst Pathol, Dept Appl Tumor Biol, D-69120 Heidelberg, Germany.
   [Strobel, Oliver; Hackert, Thilo; Buechler, Markus W.; Giese, Nathalia] Univ Heidelberg Hosp, Dept Surg, D-69120 Heidelberg, Germany.
   [Muley, Thomas] Heidelberg Univ, Thoraxklin Heidelberg, Translat Res Unit, Heidelberg, Germany.
   [Warth, Arne; Schirmacher, Peter] Univ Heidelberg Hosp, Inst Pathol, D-69120 Heidelberg, Germany.
   [Moskalev, Evgeny A.; Haller, Florian] Univ Erlangen Nurnberg, Diagnost Mol Pathol, Inst Pathol, D-91054 Erlangen, Germany.
   [Muley, Thomas] TLRC H, Dept Translat Pneumol, D-69120 Heidelberg, Germany.
C3 Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz
   Association; German Cancer Research Center (DKFZ); Russian Academy of
   Medical Sciences; National Medical Research Center for Hematology;
   Odessa National Medical University; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls
   University Heidelberg; Ruprecht Karls University Heidelberg; University
   of Erlangen Nuremberg
RP Riazalhosseini, Y (通讯作者)，Dept Human Genet, Montreal, PQ H3A 0G1, Canada.
EM yasser.riazalhosseini@mcgill.ca
RI von Knebel Doeberitz, Magnus/D-2372-2016; Muley, Thomas/AAY-9200-2020;
   Arribas, Francisco/H-5275-2015; Moskalev, Evgeny/A-3050-2012; Buechler,
   Markus/ABE-3716-2022; Fallah, Mahdi/A-8745-2008
OI Strobel, Oliver/0000-0001-5100-8449; Botla, Sandeep/0000-0001-9937-0455;
   Bauer, Andrea/0000-0002-7919-0497; Nikitin, Eugene/0000-0002-2490-1263;
   Fallah, Mahdi/0000-0002-6639-065X; Bubnov, Vladymyr/0000-0002-4940-5223
FU German Federal Ministry of Education and Research (BMBF) as part of the
   NGFN programme [01GS08117]; German Academic Exchange Service (DAAD)
FX This study was supported by the German Federal Ministry of Education and
   Research (BMBF) as part of the NGFN programme (grant number 01GS08117).
   EAM was in part supported by a postdoctoral fellowship of the German
   Academic Exchange Service (DAAD).
CR [Anonymous], 2008, R LANG ENV STAT COMP
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Botla SK, 2012, BREAST CANCER RES TR, V135, P705, DOI 10.1007/s10549-012-2197-z
   Brena RM, 2006, PLOS MED, V3, P2184, DOI 10.1371/journal.pmed.0030479
   Claus R, 2012, J CLIN ONCOL, V30, P2483, DOI 10.1200/JCO.2011.39.3090
   Cuk K, 2013, INT J CANCER, V132, P1602, DOI 10.1002/ijc.27799
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Howlader N., 2011, SEER cancer statistics review, 1975-2008
   Moskalev EA, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr213
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shiotani A, 2013, BRIT J CANCER, V109, P2323, DOI 10.1038/bjc.2013.596
   Sun N, 2013, CLIN CANCER RES, V19, P5136, DOI 10.1158/1078-0432.CCR-13-0046
   Widschwendter M, 2006, CLIN CANCER RES, V12, P7205, DOI 10.1158/1078-0432.CCR-06-2531
NR 14
TC 26
Z9 26
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD FEB 28
PY 2015
VL 6
IS 6
BP 4418
EP 4427
DI 10.18632/oncotarget.2759
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CF6WB
UT WOS:000352696200075
PM 25557172
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Sandhu, R
   Roll, JD
   Rivenbark, AG
   Coleman, WB
AF Sandhu, Rupninder
   Roll, J. Devon
   Rivenbark, Ashley G.
   Coleman, William B.
TI Dysregulation of the Epigenome in Human Breast Cancer Contributions of
   Gene-Specific DNA Hypermethylation to Breast Cancer Pathobiology and
   Targeting the Breast Cancer Methylome for Improved Therapy
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID LUNG-CANCER; BASAL-LIKE; ABERRANT METHYLATION; MOLECULAR PORTRAITS;
   CPG-ISLANDS; EXPRESSION; MICRORNA; SIGNATURE; PROGNOSIS; TUMORS
AB Triple-negative breast cancers (including basal-Like and claudin-low molecular subtypes) represent 20% to 25% of all breast cancers, but disproportionately contribute to breast cancer associated death. We have identified a novel fundamental biological property of triple-negative breast cancers: most triple-negative breast cancers express aberrant DNA hypermethylation due to overexpression of DNA methyttransferase 3b (and hyperactivity of the DNA methyltransferase enzymes). DNA methyltransferase 3b overexpression occurs secondary to Loss of miRNA-mediated post-transcriptional regulation. The resulting hyperactivity of DNA methyltransferase 3b produces concurrent DNA methylation-dependent silencing of numerous critical gene targets (including tumor suppressors and pro-apoptotic genes) and resistance to cytotoxic chemotherapy. This observation presents new opportunities for development of innovative treatment strategies on the basis of the epigenome as a novel therapeutic target in triple-negative breast cancers. Epigenetic therapy represents a new principle in cancer treatment in which restoration of critical molecular pathways occurs secondary to reexpression of silenced genes that encode negative mediators of cancer cell growth.
C1 [Sandhu, Rupninder; Roll, J. Devon; Rivenbark, Ashley G.; Coleman, William B.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Dept Pathol & Lab Med,Curriculum Toxicol,Program, Chapel Hill, NC 27599 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill;
   University of North Carolina School of Medicine
RP Coleman, WB (通讯作者)，Univ N Carolina, Sch Med, Dept Pathol & Lab Med, 515 Brinithous Bullitt Bldg,Campus Box 7525, Chapel Hill, NC 27599 USA.
EM william_coleman@med.unc.edu
FU Susan G. Komen Breast Cancer Foundation [BCTR0100-575]; UNC Lineberger
   Comprehensive Cancer Center grant; University Cancer Research Fund
   grant; University Research Council grant; University of North Carolina
   at Chapel Hill Medical Alumni Endowment Fund grant; American Society for
   Investigative Pathology
FX Supported by Susan G. Komen Breast Cancer Foundation grant BCTR0100-575,
   a UNC Lineberger Comprehensive Cancer Center grant, a University Cancer
   Research Fund grant, a University Research Council grant, and a
   University of North Carolina at Chapel Hill Medical Alumni Endowment
   Fund grant.The ASIP Outstanding Investigator Award is given by the
   American Society for Investigative Pathology to a mid-career
   investigator with demonstrated excellence in research in experimental
   pathology at the time of the award. William B. Coleman, recipient of the
   2013 ASTP Outstanding Investigator Award, delivered a lecture entitled
   Targeting the Epigenome for Improved Treatment of Triple-Negative Breast
   Cancer on April 20, 2013, at the annual meeting of the American Society
   for Investigative Pathology in Boston, MA.
CR Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Aydogdu E, 2012, CARCINOGENESIS, V33, P1502, DOI 10.1093/carcin/bgs161
   Bartel B, 2005, NAT STRUCT MOL BIOL, V12, P569, DOI 10.1038/nsmb0705-569
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baylin S, 2001, Dev Biol (Basel), V106, P85
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D
   Bockhorn J, 2013, BREAST CANCER RES TR, V137, P373, DOI 10.1007/s10549-012-2346-4
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Cascione L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055910
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Chuang JC, 2005, MOL CANCER THER, V4, P1515, DOI 10.1158/1535-7163.MCT-05-0172
   Corcoran C, 2011, CLIN CHEM, V57, P18, DOI 10.1373/clinchem.2010.150730
   Ducasse M, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-60
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Esteller M, 2005, CURR OPIN ONCOL, V17, P55, DOI 10.1097/01.cco.0000147383.04709.10
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6
   FEINBERG AP, 1987, SEMIN SURG ONCOL, V3, P149, DOI 10.1002/ssu.2980030304
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749
   Garzon R, 2009, BLOOD, V114, P5331, DOI 10.1182/blood-2009-03-211938
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Grunau C, 2001, Nucleic Acids Res, V29, pE65, DOI 10.1093/nar/29.13.e65
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   HOTCHKISS RD, 1948, J BIOL CHEM, V175, P315
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jin F, 2005, GYNECOL ONCOL, V96, P531, DOI 10.1016/j.ygyno.2004.10.039
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   LAPEYRE JN, 1979, BIOCHEM BIOPH RES CO, V87, P698, DOI 10.1016/0006-291X(79)92015-1
   Liang G, 2002, CANCER RES, V62, P961
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lyko F, 2005, JNCI-J NATL CANCER I, V97, P1498, DOI 10.1093/jnci/dji311
   Marquez VE, 2005, ANN NY ACAD SCI, V1058, P246, DOI 10.1196/annals.1359.037
   Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Oh DS, 2006, J CLIN ONCOL, V24, P1656, DOI 10.1200/JCO.2005.03.2755
   Paulsen Martina, 2008, P1
   Perreard L, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1399
   Pompeia C, 2004, CANCER RES, V64, P3465, DOI 10.1158/0008-5472.CAN-03-3970
   Rivenbark AG, 2007, EXP MOL PATHOL, V83, P188, DOI 10.1016/j.yexmp.2007.03.008
   Rivenbark AG, 2006, LAB INVEST, V86, P1233, DOI 10.1038/labinvest.3700485
   Rivenbark AG, 2006, EPIGENETICS-US, V1, P32, DOI 10.4161/epi.1.1.2358
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Roll JD, 2013, EXP MOL PATHOL, V95, P276, DOI 10.1016/j.yexmp.2013.09.001
   Sandhu R, 2014, INT J ONCOL, V44, P563, DOI 10.3892/ijo.2013.2197
   Sandhu R, 2012, INT J ONCOL, V41, P721, DOI 10.3892/ijo.2012.1505
   Sandhu R, 2012, BREAST CANCER RES TR, V131, P385, DOI 10.1007/s10549-011-1409-2
   Sato N, 2003, CANCER RES, V63, P3735
   Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105
   Shimamoto T, 2005, LEUKEMIA RES, V29, P653, DOI 10.1016/j.leukres.2004.11.014
   Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Weigelt B, 2005, CANCER RES, V65, P9155, DOI 10.1158/0008-5472.CAN-05-2553
   WEINBERG RA, 1989, CANCER RES, V49, P3713
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Yoo CB, 2004, BIOCHEM SOC T, V32, P910, DOI 10.1042/BST0320910
   Zhang H, 2004, CELL RES, V14, P283, DOI 10.1038/sj.cr.7290229
NR 96
TC 18
Z9 19
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD FEB
PY 2015
VL 185
IS 2
BP 282
EP 292
DI 10.1016/j.ajpath.2014.12.003
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AZ8UH
UT WOS:000348489400001
PM 25541331
DA 2025-01-12
ER

PT J
AU Perotti, A
   Rossi, V
   Mutti, A
   Buschini, A
AF Perotti, Alessio
   Rossi, Valeria
   Mutti, Antonio
   Buschini, Annamaria
TI Methy-sens Comet assay and DNMTs transcriptional analysis as a combined
   approach in epigenotoxicology
SO BIOMARKERS
LA English
DT Article
DE Comet assay; DNMT; epigenotoxicology; methylation
ID CELL GEL-ELECTROPHORESIS; DNA METHYLTRANSFERASE 1; HUMAN CANCER-CELLS;
   IN-VIVO; INDUCED CARCINOGENESIS; BREAST-CANCER; METHYLATION; DAMAGE;
   NICKEL; DECITABINE
AB Epigenotoxicology needs simple and fast tools to assess xenobiotic epigenetic load. This work proposes a comet assay modification designed to detect global methylation changes (Methysens Comet) through enzymatic digestion with two restriction enzymes (HpaII, MspI). In the methylation-sensitive protocol tested for repeatability on A549 cells, nickel chloride induced hypermethylation and decitabine-induced hypomethylation. A concomitant assessment of DNA methyltransferases (DNMTs) genes transcriptional levels has been performed, to implement a multifunctional approach to epigenotoxicology. Methy-sens Comet showed a general good repeatability and sensitivity to methylation changes while DNMTs transcriptional levels granted additional proof of xenobiotic-induced impairment of methylome maintenance.
C1 [Perotti, Alessio; Rossi, Valeria; Buschini, Annamaria] Univ Parma, Dept Life Sci, I-43124 Parma, Italy.
   [Perotti, Alessio; Mutti, Antonio] Univ Parma, Dept Clin & Expt Med, I-43124 Parma, Italy.
C3 University of Parma; University of Parma; University Hospital of Parma
RP Buschini, A (通讯作者)，Univ Parma, Dept Life Sci, Parco Area Sci 11-a, I-43124 Parma, Italy.
EM annamaria.buschini@unipr.it
RI Mutti, Antonio/C-1095-2011; Rossi, Valeria/I-8112-2014; Buschini,
   Annamaria/A-5774-2012
OI Buschini, Annamaria/0000-0002-9877-2767; Perotti,
   Alessio/0000-0003-4215-4166; Mutti, Antonio/0000-0003-2189-3808
CR Alcazar O, 2012, INT J CANCER, V131, P18, DOI 10.1002/ijc.26320
   Beaulieu N, 2002, J BIOL CHEM, V277, P28176, DOI 10.1074/jbc.M204734200
   BRENDLERSCHWAAB SY, 1994, TOXICOL IN VITRO, V8, P1285, DOI 10.1016/0887-2333(94)90122-8
   Brocato J, 2013, CRIT REV TOXICOL, V43, P493, DOI 10.3109/10408444.2013.794769
   COLLINS AR, 1993, CARCINOGENESIS, V14, P1733, DOI 10.1093/carcin/14.9.1733
   Deplus R, 2002, NUCLEIC ACIDS RES, V30, P3831, DOI 10.1093/nar/gkf509
   Duthie SJ, 1997, CARCINOGENESIS, V18, P1709, DOI 10.1093/carcin/18.9.1709
   Ellen TP, 2009, BIOCHEMISTRY-US, V48, P4626, DOI 10.1021/bi900246h
   FLETCHER GG, 1994, ENVIRON HEALTH PERSP, V102, P69, DOI 10.2307/3431766
   Fojtova M, 2007, PHARMACOL RES, V55, P16, DOI 10.1016/j.phrs.2006.09.008
   Fragou D, 2011, TOXICOL MECH METHOD, V21, P343, DOI 10.3109/15376516.2011.557878
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Gichner T, 2009, ISSUES TOXICOL, V5, P98, DOI 10.1039/9781847559746-00098
   Hagemann S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036125
   Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z
   Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154
   Hughes CM, 1996, MOL HUM REPROD, V2, P613, DOI 10.1093/molehr/2.8.613
   Ji WD, 2013, CARCINOGENESIS, V34, P446, DOI 10.1093/carcin/bgs343
   Kastl L, 2010, INT J ONCOL, V36, P1235, DOI 10.3892/ijo_00000607
   Kehrmann J, 2014, IMMUNOLOGY, V142, P384, DOI 10.1111/imm.12261
   Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39
   Li D, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-26
   Li QO, 1997, CARCINOGENESIS, V18, P1035, DOI 10.1093/carcin/18.5.1035
   Li YY, 2012, ENVIRON TOXICOL, V27, P495, DOI 10.1002/tox.20666
   Orta ML, 2009, MUTAGENESIS, V24, P237, DOI 10.1093/mutage/gep002
   Osnes-Ringen O, 2013, ACTA OPHTHALMOL, V91, P652, DOI 10.1111/j.1755-3768.2012.02500.x
   Rojas E, 2000, MUTAT RES-GEN TOX EN, V468, P11, DOI 10.1016/S1383-5718(00)00035-8
   Sasaki YF, 1997, MUTAT RES-GEN TOX EN, V392, P251, DOI 10.1016/S1383-5718(97)00079-X
   Shin DY, 2013, BIOMED PHARMACOTHER, V67, P305, DOI 10.1016/j.biopha.2013.01.004
   SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0
   Smith CA, 2006, COGNITION EMOTION, V20, P1, DOI 10.1080/02699930500465950
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Sun H, 2013, GENES-BASEL, V4, P583, DOI 10.3390/genes4040583
   Szemes M, 2013, HUM MOL GENET, V22, P74, DOI 10.1093/hmg/dds403
   Szeto YT, 2005, MUTAT RES-FUND MOL M, V578, P371, DOI 10.1016/j.mrfmmm.2005.06.014
   Szyf M, 2007, TOXICOL SCI, V100, P7, DOI 10.1093/toxsci/kfm177
   Wasson GR, 2006, J NUTR, V136, P2748, DOI 10.1093/jn/136.11.2748
   Wentzel JF, 2010, ANAL BIOCHEM, V400, P190, DOI 10.1016/j.ab.2010.02.008
NR 39
TC 15
Z9 15
U1 0
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 1354-750X
EI 1366-5804
J9 BIOMARKERS
JI Biomarkers
PD FEB
PY 2015
VL 20
IS 1
BP 64
EP 70
DI 10.3109/1354750X.2014.992813
PG 7
WC Biotechnology & Applied Microbiology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Toxicology
GA AZ7AC
UT WOS:000348369500010
PM 25518886
DA 2025-01-12
ER

PT J
AU Bedi, U
   Scheel, AH
   Hennion, M
   Begus-Nahrmann, Y
   Rüschoff, J
   Johnsen, SA
AF Bedi, U.
   Scheel, A. H.
   Hennion, M.
   Begus-Nahrmann, Y.
   Rueschoff, J.
   Johnsen, S. A.
TI SUPT6H controls estrogen receptor activity and cellular differentiation
   by multiple epigenomic mechanisms
SO ONCOGENE
LA English
DT Article
DE estrogen receptor; breast cancer; differentiation; chromatin
ID HUMAN BREAST-CANCER; GENE-EXPRESSION; HISTONE H2B; TRANSCRIPTIONAL
   ELONGATION; CHROMATIN MODIFICATIONS; HUMAN-CELLS; P-TEFB;
   MONOUBIQUITINATION; SPT6; ALPHA
AB The estrogen receptor alpha (ER alpha) is the central transcriptional regulator of ductal mammary epithelial lineage specification and is an important prognostic marker in human breast cancer. Although antiestrogen therapies are initially highly effective at treating ER alpha-positive tumors, a large number of tumors progress to a refractory, more poorly differentiated phenotype accompanied by reduced survival. A better understanding of the molecular mechanisms involved in the progression from estrogen-dependent to hormone-resistant breast cancer may uncover new targets for treatment and the discovery of new predictive markers. Recent studies have uncovered an important role for transcriptional elongation and chromatin modifications in controlling ER alpha activity and estrogen responsiveness. The human Suppressor of Ty Homologue-6 (SUPT6H) is a histone chaperone that links transcriptional elongation to changes in chromatin structure. We show that SUPT6H is required for estrogen-regulated transcription and the maintenance of chromatin structure in breast cancer cells, possibly in part through interaction with RNF40 and regulation of histone H2B monoubiquitination (H2Bub1). Moreover, we demonstrate that SUPT6H protein levels decrease with malignancy in breast cancer. Consistently, SUPT6H, similar to H2Bub1, is required for cellular differentiation and suppression of the repressive histone mark H3K27me3 on lineage-specific genes. Together, these data identify SUPT6H as a new epigenetic regulator of ER alpha activity and cellular differentiation.
C1 [Bedi, U.; Johnsen, S. A.] Univ Med Ctr Hamburg Eppendorf UKE, Dept Tumor Biol, Ctr Med Expt, D-20251 Hamburg, Germany.
   [Bedi, U.; Hennion, M.; Begus-Nahrmann, Y.; Johnsen, S. A.] Univ Med Ctr Gottingen, Inst Mol Oncol, Gottingen, Germany.
   [Scheel, A. H.; Rueschoff, J.] Inst Pathol Nordhessen, Kassel, Germany.
   [Scheel, A. H.] Univ Med Ctr Gottinngen, Dept Pathol, Ctr Pathol & Forens Med, Gottingen, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Gottingen; UNIVERSITY GOTTINGEN HOSPITAL
RP Johnsen, SA (通讯作者)，Univ Med Ctr Hamburg Eppendorf UKE, Dept Tumor Biol, Ctr Med Expt, D-20251 Hamburg, Germany.
EM sjohnsen@alumni.mayo.edu
RI Johnsen, Steven/AAX-2322-2020
OI Hennion, Magali/0000-0002-0352-2790; Johnsen, Steven/0000-0003-1198-5805
FU Erasmus Mundus External Cooperation Window EURINDIA; Gottingen Graduate
   School for Neurosciences, Biophysics and Molecular Biosciences; Deutsche
   Krebshilfe [109088]; Deutsche Forschungsgemeinschaft [JO 815/3]
FX We thank L Schreiber, J Schiller and CR Schlegel for initial efforts in
   establishing SUPT6H knockdown. UB was supported by doctoral fellowships
   from the Erasmus Mundus External Cooperation Window EURINDIA and the
   Gottingen Graduate School for Neurosciences, Biophysics and Molecular
   Biosciences. This work was supported by grants from the Deutsche
   Krebshilfe (109088) and the Deutsche Forschungsgemeinschaft (JO 815/3)
   to SAJ.
CR Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358
   BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34
   Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Chen SZ, 2012, GENE DEV, V26, P1364, DOI 10.1101/gad.186056.111
   Chen S, 2012, CELL RES, V22, P1402, DOI 10.1038/cr.2012.114
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Diebold ML, 2010, J BIOL CHEM, V285, P38389, DOI 10.1074/jbc.M110.146696
   Egloff S, 2008, TRENDS GENET, V24, P280, DOI 10.1016/j.tig.2008.03.008
   El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fuchs G, 2012, MOL CELL, V46, P662, DOI 10.1016/j.molcel.2012.05.023
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Johnsen S A, 2006, Ernst Schering Found Symp Proc, P1
   Johnsen SA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002860
   Johnsen SA, 2012, FEBS LETT, V586, P1592, DOI 10.1016/j.febslet.2012.04.002
   Kari V, 2011, CELL CYCLE, V10, P3495, DOI 10.4161/cc.10.20.17769
   Karpiuk O, 2012, MOL CELL, V46, P705, DOI 10.1016/j.molcel.2012.05.022
   Ketchart W, 2011, ONCOGENE, V30, P3563, DOI 10.1038/onc.2011.76
   Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37
   Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139
   Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027
   Kininis M, 2009, MOL CELL BIOL, V29, P1123, DOI 10.1128/MCB.00841-08
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Métivier R, 2006, EMBO REP, V7, P161, DOI 10.1038/sj.embor.7400626
   Minsky N, 2008, NAT CELL BIOL, V10, P483, DOI 10.1038/ncb1712
   Ogba N, 2008, CANCER RES, V68, P7015, DOI 10.1158/0008-5472.CAN-08-0814
   Pirngruber J, 2010, ONCOGENE, V29, P2853, DOI 10.1038/onc.2010.42
   Pirngruber J, 2009, CELL CYCLE, V8, P3636, DOI 10.4161/cc.8.22.9890
   Pirngruber J, 2009, EMBO REP, V10, P894, DOI 10.1038/embor.2009.108
   Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Reijm EA, 2011, BREAST CANCER RES TR, V125, P387, DOI 10.1007/s10549-010-0836-9
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shema E, 2008, GENE DEV, V22, P2664, DOI 10.1101/gad.1703008
   Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Wang AHJ, 2013, EMBO J, V32, P1075, DOI 10.1038/emboj.2013.54
   Wittmann BM, 2005, ONCOGENE, V24, P5576, DOI 10.1038/sj.onc.1208728
   Yoh SM, 2007, GENE DEV, V21, P160, DOI 10.1101/gad.1503107
   Zhang F, 2011, MOL CELL, V41, P384, DOI 10.1016/j.molcel.2011.01.024
NR 46
TC 40
Z9 44
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 22
PY 2015
VL 34
IS 4
BP 465
EP 473
DI 10.1038/onc.2013.558
PG 9
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AZ8FU
UT WOS:000348451300007
PM 24441044
DA 2025-01-12
ER

PT J
AU Liu, HX
   Li, XL
   Dong, CF
AF Liu, Hui-xin
   Li, Xiao-li
   Dong, Chen-fang
TI Epigenetic and metabolic regulation of breast cancer stem cells
SO JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B
LA English
DT Article
DE Cancer stem cells (CSCs); Epithelial mesenchymal transition (EMT);
   Epigenetic modification; Metabolic reprogramming; Breast cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; DNA METHYLATION; OXIDATIVE STRESS;
   BETA-CATENIN; MECHANISMS; POLYCOMB; ROLES; TUMORIGENICITY;
   HETEROGENEITY; PLURIPOTENCY
AB Breast cancer has a relatively high mortality rate in women due to recurrence and metastasis. Increasing evidence has identified a rare population of cells with stem cell-like properties in breast cancer. These cells, termed cancer stem cells (CSCs), which have the capacity for self-renewal and differentiation, contribute significantly to tumor progression, recurrence, drug resistance and metastasis. Clarifying the mechanisms regulating breast CSCs has important implications for our understanding of breast cancer progression and therapeutics. A strong connection has been found between breast CSCs and epithelial mesenchymal transition (EMT). In addition, recent studies suggest that the maintenance of the breast CSC phenotype is associated with epigenetic and metabolic regulation. In this review, we focus on recent discoveries about the connection between EMT and CSC, and advances made in understanding the roles and mechanisms of epigenetic and metabolic reprogramming in controlling breast CSC properties.
C1 [Liu, Hui-xin; Li, Xiao-li; Dong, Chen-fang] Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Dong, CF (通讯作者)，Zhejiang Univ, Sch Med, Dept Pathol & Pathophysiol, Hangzhou 310058, Zhejiang, Peoples R China.
EM chenfangdong@zju.edu.cn
RI Li, Yichong/A-3559-2019; Li, xiaofei/GXF-7187-2022
FU Thousand Young Talents Program of China; National Natural Science
   Foundation of China [81472455]; Fundamental Research Funds for the
   Central Universities of China
FX Project supported by the Thousand Young Talents Program of China, the
   National Natural Science Foundation of China (No. 81472455), and the
   Fundamental Research Funds for the Central Universities of China
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Allegrucci C, 2007, HUM MOL GENET, V16, P1253, DOI 10.1093/hmg/ddm074
   Almendro V, 2011, CLIN TRANSL ONCOL, V13, P767, DOI 10.1007/s12094-011-0731-9
   Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036
   Armstrong L, 2010, STEM CELLS, V28, P661, DOI 10.1002/stem.307
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Bowerman B, 2005, SCIENCE, V308, P1119, DOI 10.1126/science.1113356
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344
   Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083
   Facucho-Oliveira JM, 2009, STEM CELL REV REP, V5, P140, DOI 10.1007/s12015-009-9058-0
   Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011
   Gerhard R, 2012, BREAST, V21, P354, DOI 10.1016/j.breast.2012.03.001
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Greene SB, 2010, CURR DRUG TARGETS, V11, P1059
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808
   Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Mallick B, 2011, RNA BIOL, V8, P415, DOI 10.4161/rna.8.3.14497
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   Meyer MJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2449
   Mohn F, 2009, TRENDS GENET, V25, P129, DOI 10.1016/j.tig.2008.12.005
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404
   Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Shah M, 2012, BREAST CANCER-TARGET, V4, P155, DOI 10.2147/BCTT.S26434
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhu SY, 2010, CELL STEM CELL, V7, P651, DOI 10.1016/j.stem.2010.11.015
NR 58
TC 27
Z9 30
U1 2
U2 25
PU ZHEJIANG UNIV PRESS
PI Hangzhou
PA Xixi Campus, Zhejiang University, No. 148 Tianmushan Road, Hangzhou,
   Zhejiang, PEOPLES R CHINA
SN 1673-1581
EI 1862-1783
J9 J ZHEJIANG UNIV-SC B
JI J. Zhejiang Univ.-SCI. B
PD JAN
PY 2015
VL 16
IS 1
BP 10
EP 17
DI 10.1631/jzus.B1400172
PG 8
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Research & Experimental Medicine
GA AZ6QC
UT WOS:000348342800002
PM 25559951
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Jacob, V
   Chernyavskaya, Y
   Chen, XT
   Tan, PS
   Kent, B
   Hoshida, Y
   Sadler, KC
AF Jacob, Vinitha
   Chernyavskaya, Yelena
   Chen, Xintong
   Tan, Poh Seng
   Kent, Brandon
   Hoshida, Yujin
   Sadler, Kirsten C.
TI DNA hypomethylation induces a DNA replication-associated cell cycle
   arrest to block hepatic outgrowth in <i>uhrf1</i> mutant zebrafish
   embryos
SO DEVELOPMENT
LA English
DT Article
DE DNA methylation; DNA replication; Hepatic outgrowth; Liver development;
   UHRF1; Zebrafish
ID HEMI-METHYLATED DNA; TOPOISOMERASE-II-ALPHA; BREAST-CANCER CELLS; SRA
   DOMAIN; METHYLTRANSFERASE DNMT1; LIVER-REGENERATION; MAMMALIAN-CELLS;
   GENE-EXPRESSION; PROTEIN UHRF1; TUDOR DOMAIN
AB UHRF1 (ubiquitin-like, containing PHD and RING finger domains, 1) recruits DNMT1 to hemimethylated DNA during replication and is essential for maintaining DNA methylation. uhrf1 mutant zebrafish have global DNA hypomethylation and display embryonic defects, including a small liver, and they die as larvae. We make the surprising finding that, despite their reduced organ size, uhrf1 mutants express high levels of genes controlling S-phase and have many more cells undergoing DNA replication, as measured by BrdU incorporation. In contrast to wild-type hepatocytes, which are continually dividing during hepatic outgrowth and thus dilute the BrdU label, uhrf1 mutant hepatocytes retain BrdU throughout outgrowth, reflecting cell cycle arrest. Pulse-chase-pulse experiments with BrdU and EdU, and DNA content analysis indicate that uhrf1 mutant cells undergo DNA re-replication and that apoptosis is the fate of many of the re-replicating and arrested hepatocytes. Importantly, the DNA re-replication phenotype and hepatic outgrowth failure are preceded by global loss of DNA methylation. Moreover, uhrf1 mutants are phenocopied by mutation of dnmt1, and Dnmt1 knockdown in uhrf1 mutants enhances their small liver phenotype. Together, these data indicate that unscheduled DNA replication and failed cell cycle progression leading to apoptosis are the mechanisms by which DNA hypomethylation prevents organ expansion in uhrf1 mutants. We propose that cell cycle arrest leading to apoptosis is a strategy that restricts propagation of epigenetically damaged cells during embryogenesis.
C1 [Jacob, Vinitha; Chernyavskaya, Yelena; Chen, Xintong; Tan, Poh Seng; Kent, Brandon; Hoshida, Yujin; Sadler, Kirsten C.] Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, New York, NY 10029 USA.
   [Jacob, Vinitha; Chernyavskaya, Yelena; Kent, Brandon; Sadler, Kirsten C.] Icahn Sch Med Mt Sinai, Dept Dev & Regenerat Biol, New York, NY 10029 USA.
   [Jacob, Vinitha; Kent, Brandon; Hoshida, Yujin; Sadler, Kirsten C.] Icahn Sch Med Mt Sinai, Grad Sch Biomed Sci, New York, NY 10029 USA.
   [Chen, Xintong; Tan, Poh Seng; Hoshida, Yujin] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Liver Canc Program, New York, NY 10029 USA.
   [Tan, Poh Seng] Natl Univ Hlth Syst, Univ Med Cluster, Div Gastroenterol & Hepatol, Singapore, Singapore.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of
   Medicine at Mount Sinai; National University of Singapore
RP Sadler, KC (通讯作者)，Icahn Sch Med Mt Sinai, Dept Med, Div Liver Dis, 1 Gustave L Levy Pl,Box 1020, New York, NY 10029 USA.
EM kirsten.edepli@mssm.edu
RI Hoshida, Yujin/R-7513-2019; Chen, Xintong/I-4800-2019
OI Kent, Brandon/0000-0002-6175-0898; Sadler Edepli,
   Kirsten/0000-0002-1100-4125; Chen, Xintong/0000-0002-2536-165X
FU National Institutes of Health [5R01DK080789, R01DK099558, F30DK094503,
   T32CA078207-14]; European Commission [259744]
FX This work was supported by grants from the National Institutes of Health
   [5R01DK080789 to K.C.S., R01DK099558 to Y.H., F30DK094503 to V.J. and
   T32CA078207-14 to support Y.C.] and the European Commission Framework
   Programme 7 [Heptromic, proposal number 259744 to Y.H.]. Deposited in
   PMC for release after 12 months.
CR Achour M, 2009, BIOCHEM BIOPH RES CO, V390, P523, DOI 10.1016/j.bbrc.2009.09.131
   Amsterdam A, 2004, P NATL ACAD SCI USA, V101, P12792, DOI 10.1073/pnas.0403929101
   Anderson RM, 2009, DEV BIOL, V334, P213, DOI 10.1016/j.ydbio.2009.07.017
   Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x
   Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249
   Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273
   Bashtrykov P, 2014, J BIOL CHEM, V289, P4106, DOI 10.1074/jbc.M113.528893
   Berkyurek AC, 2014, J BIOL CHEM, V289, P379, DOI 10.1074/jbc.M113.523209
   Biniszkiewicz D, 2002, MOL CELL BIOL, V22, P2124, DOI 10.1128/MCB.22.7.2124-2135.2002
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Chen TP, 2007, NAT GENET, V39, P391, DOI 10.1038/ng1982
   Cheng JD, 2013, J BIOL CHEM, V288, P1329, DOI 10.1074/jbc.M112.415398
   Chu J, 2012, MOL BIOL CELL, V23, P59, DOI 10.1091/mbc.E11-06-0487
   Dong PDS, 2007, NAT GENET, V39, P397, DOI 10.1038/ng1961
   Dorn ES, 2011, EPIGENETICS-US, V6, P552, DOI 10.4161/epi.6.5.15082
   Dovey M, 2009, MOL CELL BIOL, V29, P3746, DOI 10.1128/MCB.01684-08
   Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462
   Feng SH, 2010, P NATL ACAD SCI USA, V107, P8689, DOI 10.1073/pnas.1002720107
   Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280
   Hervouet E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011333
   Hopfner R, 2002, ANTICANCER RES, V22, P3165
   Jacob Y, 2010, NATURE, V466, P987, DOI 10.1038/nature09290
   Jégu T, 2013, PLANT PHYSIOL, V161, P1694, DOI 10.1104/pp.112.212357
   Karpf AR, 2005, CANCER RES, V65, P8635, DOI 10.1158/0008-5472.CAN-05-1961
   Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961
   Li XL, 2011, INT J RADIAT BIOL, V87, P263, DOI 10.3109/09553002.2011.530335
   Milutinovic S, 2004, J BIOL CHEM, V279, P27915, DOI 10.1074/jbc.M312823200
   Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200
   Mistry Helena, 2010, Genome Integr, V1, P7, DOI 10.1186/2041-9414-1-7
   Mudbhary R, 2014, CANCER CELL, V25, P196, DOI 10.1016/j.ccr.2014.01.003
   Mudbhary R, 2011, BIRTH DEFECTS RES C, V93, P194, DOI 10.1002/bdrc.20207
   Muto M, 2002, J BIOL CHEM, V277, P34549, DOI 10.1074/jbc.M205189200
   Nishiyama A, 2013, NATURE, V502, P249, DOI 10.1038/nature12488
   Obata Y, 2014, NAT IMMUNOL, V15, P571, DOI 10.1038/ni.2886
   Papait R, 2008, MOL BIOL CELL, V19, P3554, DOI 10.1091/mbc.E07-10-1059
   Qian CM, 2008, J BIOL CHEM, V283, P34490, DOI 10.1074/jbc.C800169200
   Qin WH, 2011, J CELL BIOCHEM, V112, P439, DOI 10.1002/jcb.22998
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152
   Sadler KC, 2007, P NATL ACAD SCI USA, V104, P1570, DOI 10.1073/pnas.0610774104
   Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397
   Stroud H, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002808
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Taylor EM, 2013, NUCLEIC ACIDS RES, V41, P7725, DOI 10.1093/nar/gkt549
   Tien AL, 2011, BIOCHEM J, V435, P175, DOI 10.1042/BJ20100840
   Tittle RK, 2011, DEV BIOL, V350, P50, DOI 10.1016/j.ydbio.2010.11.009
   Truong LN, 2011, J MOL CELL BIOL, V3, P13, DOI 10.1093/jmcb/mjq052
   Unoki M, 2004, ONCOGENE, V23, P7601, DOI 10.1038/sj.onc.1208053
   Unterberger A, 2006, MOL CELL BIOL, V26, P7575, DOI 10.1128/MCB.01887-05
   Vijayaraghavalu S, 2013, MOL PHARMACEUT, V10, P337, DOI 10.1021/mp3004622
   Xie S, 2012, J MOL BIOL, V415, P318, DOI 10.1016/j.jmb.2011.11.012
NR 51
TC 47
Z9 52
U1 0
U2 20
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
   CAMBS, ENGLAND
SN 0950-1991
EI 1477-9129
J9 DEVELOPMENT
JI Development
PD FEB 1
PY 2015
VL 142
IS 3
BP 510
EP 521
DI 10.1242/dev.115980
PG 12
WC Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology
GA AZ5HT
UT WOS:000348251800012
PM 25564650
OA Green Published
DA 2025-01-12
ER

PT J
AU Sepsa, A
   Levidou, G
   Gargalionis, A
   Adamopoulos, C
   Spyropoulou, A
   Dalagiorgou, G
   Thymara, I
   Boviatsis, E
   Themistocleous, MS
   Petraki, K
   Vrettakos, G
   Samaras, V
   Zisakis, A
   Patsouris, E
   Piperi, C
   Korkolopoulou, P
AF Sepsa, Athanasia
   Levidou, Georgia
   Gargalionis, Antonis
   Adamopoulos, Christos
   Spyropoulou, Anastasia
   Dalagiorgou, Georgia
   Thymara, Irene
   Boviatsis, Efstathios
   Themistocleous, Marios S.
   Petraki, Kalliopi
   Vrettakos, George
   Samaras, Vassilis
   Zisakis, Athanassios
   Patsouris, Efstratios
   Piperi, Christina
   Korkolopoulou, Penelope
TI Emerging Role of Linker Histone Variant H1x as a Biomarker with
   Prognostic Value in Astrocytic Gliomas. A Multivariate Analysis
   including Trimethylation of H3K9 and H4K20
SO PLOS ONE
LA English
DT Article
ID ONCOMETABOLITE 2-HYDROXYGLUTARATE; EPIGENETIC CONTROL; BREAST-CANCER;
   IN-VITRO; METHYLATION; DNA; CELLS; DIFFERENTIATION; EXPRESSION; SURVIVAL
AB Although epigenetic alterations play an essential role in gliomagenesis, the relevance of aberrant histone modifications and the respective enzymes has not been clarified. Experimental data implicates histone H3 lysine (K) methyltransferases SETDB1 and SUV39H1 into glioma pathobiology, whereas linker histone variant H1.0 and H4K20me3 reportedly affect prognosis. We investigated the expression of H3K9me3 and its methyltransferases along with H4K20me3 and H1x in 101 astrocytic tumors with regard to clinicopathological characteristics and survival. The effect of SUV39H1 inhibition by chaetocin on the proliferation, colony formation and migration of T98G cells was also examined. SETDB1 and cytoplasmic SUV39H1 levels increased from normal brain through low-grade to high-grade tumors, nuclear SUV39H1 correlating inversely with grade. H3K9me3 immunoreactivity was higher in normal brain showing no association with grade, whereas H1x and H4K20me3 expression was higher in grade 2 than in normal brain or high grades. These expression patterns of H1x, H4K20me3 and H3K9me3 were verified by Western immunoblotting. Chaetocin treatment significantly reduced proliferation, clonogenic potential and migratory ability of T98G cells. H1x was an independent favorable prognosticator in glioblastomas, this effect being validated in an independent set of 66 patients. Diminished nuclear SUV39H1 expression adversely affected survival in univariate analysis. In conclusion, H4K20me3 and H3K9 methyltransferases are differentially implicated in astroglial tumor progression. Deregulation of H1x emerges as a prognostic biomarker.
C1 [Sepsa, Athanasia; Levidou, Georgia; Thymara, Irene; Patsouris, Efstratios; Korkolopoulou, Penelope] Univ Athens, Laikon Gen Hosp, Sch Med, Dept Pathol 1, Athens 11527, Greece.
   [Gargalionis, Antonis; Adamopoulos, Christos; Spyropoulou, Anastasia; Dalagiorgou, Georgia; Piperi, Christina] Univ Athens, Sch Med, Dept Biol Chem, Athens 11527, Greece.
   [Boviatsis, Efstathios; Themistocleous, Marios S.] Univ Athens, Evangelismos Hosp, Sch Med, Dept Neurosurg, Athens 10676, Greece.
   [Petraki, Kalliopi] Metropolitan Hosp, Dept Pathol, Athens 18547, Greece.
   [Vrettakos, George] Metropolitan Hosp, Dept Neurosurg, Athens 18547, Greece.
   [Samaras, Vassilis] Red Cross Hosp, Dept Pathol, Athens 11526, Greece.
   [Zisakis, Athanassios] Red Cross Hosp, Dept Neurosurg, Athens 11526, Greece.
C3 Athens Medical School; National & Kapodistrian University of Athens;
   Laiko General Hospital; Athens Medical School; National & Kapodistrian
   University of Athens; Evangelismos Hospital; National & Kapodistrian
   University of Athens; Athens Medical School
RP Levidou, G (通讯作者)，Univ Athens, Laikon Gen Hosp, Sch Med, Dept Pathol 1, Athens 11527, Greece.
EM glevidou@yahoo.gr
RI Piperi, Christina/AAF-2009-2020; Adamopoulos, Christos/JMQ-6589-2023
OI Adamopoulos, Christos/0000-0001-6323-4216; Piperi,
   Christina/0000-0002-2701-0618; Spyropoulou,
   Anastasia/0000-0001-8599-7740; Themistocleous,
   Marios/0000-0003-3810-8001
CR Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Chen JH, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0513-z
   Chernov AV, 2009, J BIOL CHEM, V284, P12727, DOI 10.1074/jbc.M900273200
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132
   Ellinger J, 2014, UROL INT, V93, P113, DOI 10.1159/000355467
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Estève PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706
   Fan YH, 2005, CELL, V123, P1199, DOI 10.1016/j.cell.2005.10.028
   Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642
   Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gabrovsky N, 2013, ACTA NEUROCHIR, V155, P1437, DOI 10.1007/s00701-013-1802-1
   Gerlitz G, 2010, J CELL SCI, V123, P2207, DOI 10.1242/jcs.058271
   Han XS, 2014, J NEURO-ONCOL, V118, P61, DOI 10.1007/s11060-014-1419-0
   Harshman SW, 2013, NUCLEIC ACIDS RES, V41, P9593, DOI 10.1093/nar/gkt700
   Harvey AC, 2004, MOL MICROBIOL, V53, P771, DOI 10.1111/j.1365-2958.2004.04195.x
   He YL, 2012, ACTA BIOCH BIOPH SIN, V44, P70, DOI 10.1093/abbs/gmr109
   HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230
   Isham CR, 2007, BLOOD, V109, P2579, DOI 10.1182/blood-2006-07-027326
   Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3
   Kreth S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017156
   LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201
   Li FQ, 2011, APPL IMMUNOHISTO M M, V19, P389, DOI 10.1097/PAI.0b013e3182108e2e
   Liu BL, 2010, CANCER EPIDEM BIOMAR, V19, P2888, DOI 10.1158/1055-9965.EPI-10-0454
   Lohmann F, 2010, STEM CELLS, V28, P201, DOI 10.1002/stem.278
   Louis DN., 2007, 2007 WHO CLASSIFICAT
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Luger K, 2006, CHROMOSOME RES, V14, P5, DOI 10.1007/s10577-005-1026-1
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Martin C, 2006, J BIOL CHEM, V281, P8365, DOI 10.1074/jbc.M513425200
   Martinez R, 2010, NEUROBIOL DIS, V39, P40, DOI 10.1016/j.nbd.2009.12.030
   McBryant SJ, 2010, CELL RES, V20, P519, DOI 10.1038/cr.2010.35
   Medrzycki M, 2012, FRONT BIOSCI-LANDMRK, V17, P396, DOI 10.2741/3934
   Metellus P, 2010, ACTA NEUROPATHOL, V120, P719, DOI 10.1007/s00401-010-0777-8
   Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140
   Myung JK, 2012, ONCOL REP, V28, P1639, DOI 10.3892/or.2012.1994
   Patani N, 2011, ANTICANCER RES, V31, P4115
   Rai K, 2006, MOL CELL BIOL, V26, P7077, DOI 10.1128/MCB.00312-06
   Rai K, 2010, J BIOL CHEM, V285, P4110, DOI 10.1074/jbc.M109.073676
   Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2
   Saratsis AM, 2014, ACTA NEUROPATHOL, V127, P881, DOI 10.1007/s00401-013-1218-2
   Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200
   Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043
   Schneider AC, 2011, BJU INT, V108, pE290, DOI 10.1111/j.1464-410X.2011.10203.x
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Spyropoulou A, 2014, NEUROMOL MED, V16, P70, DOI 10.1007/s12017-013-8254-x
   Spyropoulou A, 2013, NEUROMOL MED, V15, P1, DOI 10.1007/s12017-012-8205-y
   Tan SL, 2012, DEVELOPMENT, V139, P3806, DOI 10.1242/dev.082198
   Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869
   Venneti S, 2013, J NEUROPATH EXP NEUR, V72, P298, DOI 10.1097/NEN.0b013e3182898113
   Wang HJ, 2013, ONCOL REP, V30, P2089, DOI 10.3892/or.2013.2706
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yan FT, 2014, CANCER RES, V74, P1752, DOI 10.1158/0008-5472.CAN-13-0884
NR 59
TC 30
Z9 30
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 20
PY 2015
VL 10
IS 1
AR e0115101
DI 10.1371/journal.pone.0115101
PG 22
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AZ4OZ
UT WOS:000348203500008
PM 25602259
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Sun, J
   Wang, J
   He, L
   Lin, Y
   Wu, J
AF Sun, Jin
   Wang, Jian
   He, Lin
   Lin, Yi
   Wu, Ji
TI Knockdown of Polycomb-Group RING Finger 6 Modulates Mouse Male Germ Cell
   Differentiation <i>in Vitro</i>
SO CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
LA English
DT Article
DE PCGF6; Knockdown; Germ cell development
ID HEMATOPOIETIC STEM-CELLS; SELF-RENEWAL; BREAST-CANCER; EXPRESSION; BMI1;
   SPERMATOGENESIS; MICE; TUMORIGENICITY; PROGRESSION; COMPLEXES
AB Background: Polycomb-group RING finger 6 (PCGF6), one of six PCGF homologs, is the core component of the PRC1 complex that plays critical roles in epigenetic transcriptional silencing in higher eukaryotes. However, the biological functions of PCGF6 are unknown. Method: qRT-PCR and Western blot were used to detect the expression profile of PCGF6 in testes. Fluorescent immunohistochemistry was used to examine the cellular localization of PCGF6 protein in testes. Cell proliferation was tested by performing CCK-8 and EdU incorporation assay. Cell cycle and haploid cell population analysis was determined by flow cytometry using propidium iodide DNA staining. Co-immunoprecipitation experiment was conducted using PCGF6 antibody to obtain interacting protein of PCGF6. Luciferase reporter assays were performed to examine the promoter activity of PCGF6 in cells overexpressing OVOL1 and PLZF. Results: PCGF6 was expressed predominantly in meiotic and post-meiotic male germ cells, could negatively regulate the proliferation of GC-2 spd cells, an immortalized mouse spermatogenic cell line, and could modulate the differentiation of GC-2 spd cells in vitro. PCGF6 could indirectly interact with HSPA2, a key factor that is essential for male meiosis, and OVOL1 and PLZF, two key transcription factors that are involved in spermatogenesis, could positively and negatively modulate Pcgf6 promoter activity, respectively. PCGF1, BMI1, and PCGF5 are also highly expressed in mouse testes like PCGF6. Conclusion: PCGF6 may play important roles in male germ cell development. Copyright (C) 2015 S. Karger AG, Basel
C1 [Sun, Jin; Wang, Jian; He, Lin; Wu, Ji] Shanghai Jiao Tong Univ, Bio X Inst, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, Shanghai, Peoples R China.
   [Wu, Ji] Ningxia Med Univ, Minist Educ, Key Lab Fertil Preservat & Maintenance, Ningxia, Peoples R China.
   [Wu, Ji] Shanghai Jiao Tong Univ, Sch Med, Int Peace Matern & Child Hlth Hosp, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; Ningxia Medical University; Shanghai Jiao
   Tong University
RP Wu, J (通讯作者)，Shanghai Jiao Tong Univ, Bio X Inst, 800 Dongchuan Rd, Shanghai, Peoples R China.
EM jiwu@sjtu.edu
RI wu, ji/IAR-8520-2023
FU National Basic Research Program of China [2013CB967401]; National Nature
   Science Foundation of China [81370675, 81200472, 81421061]
FX This work was supported by National Basic Research Program of China
   (grant numbers 2013CB967401; http://www.most.gov.cn) and the National
   Nature Science Foundation of China (grant number 81370675, 81200472 and
   81421061; http://www.nsfc.gov.cn)
CR Akasaka T, 2002, GENES CELLS, V7, P835, DOI 10.1046/j.1365-2443.2002.00565.x
   Aloia L, 2013, DEVELOPMENT, V140, P2525, DOI 10.1242/dev.091553
   BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68
   Brawand D, 2011, NATURE, V478, P343, DOI 10.1038/nature10532
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Chen TP, 2014, NAT REV GENET, V15, P93, DOI 10.1038/nrg3607
   Chiba T, 2010, HEPATOLOGY, V52, P1111, DOI 10.1002/hep.23793
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264
   Filipponi D, 2007, MOL CELL BIOL, V27, P6770, DOI 10.1128/MCB.00479-07
   Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002
   Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030
   Gong YH, 2006, NUCLEIC ACIDS RES, V34, P6158, DOI 10.1093/nar/gkl834
   Hobbs RM, 2010, CELL, V142, P468, DOI 10.1016/j.cell.2010.06.041
   HOFMANN MC, 1994, P NATL ACAD SCI USA, V91, P5533, DOI 10.1073/pnas.91.12.5533
   HOFMANN MC, 1995, DEV GENET, V16, P119, DOI 10.1002/dvg.1020160205
   Kajiume T, 2004, EXP HEMATOL, V32, P571, DOI 10.1016/j.exphem.2004.03.001
   Koeberle A, 2012, FASEB J, V26, P169, DOI 10.1096/fj.11-184879
   Lanzuolo C, 2012, ANNU REV GENET, V46, P561, DOI 10.1146/annurev-genet-110711-155603
   Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570
   Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004
   Li BA, 2005, DEVELOPMENT, V132, P1463, DOI 10.1242/dev.01658
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Martin Perrine J, 2003, Nucl Recept, V1, P6, DOI 10.1186/1478-1336-1-6
   Molofsky AV, 2005, GENE DEV, V19, P1432, DOI 10.1101/gad.1299505
   Niessen HEC, 2009, EPIGENET CHROMATIN, V2, DOI 10.1186/1756-8935-2-10
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Ross K, 2012, BLOOD, V119, P4152, DOI 10.1182/blood-2011-09-382390
   Sangiorgi E, 2008, NAT GENET, V40, P915, DOI 10.1038/ng.165
   Schwartz YB, 2013, NAT REV GENET, V14, P853, DOI 10.1038/nrg3603
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Sun J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075750
   Vandamme J, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.002642
   Won HY, 2012, FASEB J, V26, P5002, DOI 10.1096/fj.12-209247
   Yu QS, 2008, MOL CELL BIOCHEM, V315, P17, DOI 10.1007/s11010-008-9783-8
   Zacharek SJ, 2011, CELL STEM CELL, V9, P272, DOI 10.1016/j.stem.2011.07.007
   Zhang SQ, 2008, MOL CELL ENDOCRINOL, V287, P47, DOI 10.1016/j.mce.2008.01.008
   Zindy F, 2001, MOL CELL BIOL, V21, P3244, DOI 10.1128/MCB.21.9.3244-3255.2001
NR 38
TC 10
Z9 13
U1 0
U2 10
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-8987
EI 1421-9778
J9 CELL PHYSIOL BIOCHEM
JI Cell. Physiol. Biochem.
PY 2015
VL 35
IS 1
BP 339
EP 352
DI 10.1159/000369700
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA AZ2ES
UT WOS:000348048000031
PM 25591775
OA gold
DA 2025-01-12
ER

PT J
AU Delgado-Cruzata, L
   Vin-Raviv, N
   Tehranifar, P
   Flom, J
   Reynolds, D
   Gonzalez, K
   Santella, RM
   Terry, MB
AF Delgado-Cruzata, Lissette
   Vin-Raviv, Neomi
   Tehranifar, Parisa
   Flom, Julie
   Reynolds, Diane
   Gonzalez, Karina
   Santella, Regina M.
   Terry, Mary Beth
TI Correlations in global DNA methylation measures in peripheral blood
   mononuclear cells and granulocytes
SO EPIGENETICS
LA English
DT Article
DE Alu; DNA methylation; LINE-1; LUMA; Sat2; LUMA; Luminometric methylation
   assay; PBMC; peripheral mononuclear cell
ID CANCER FAMILY REGISTRY; NEW-YORK SITE; BREAST-CANCER; SISTERS
   DISCORDANT; PROFILES; EPIGENETICS; ASSOCIATION; LEUKOCYTES; RISK
AB Alterations in global DNA methylation levels have been associated with chronic diseases. Despite the increase in the number of studies measuring markers of global methylation, few have adequately examined within-individual differences by source of DNA and whether within-individual differences by source of DNA differ by age, race and other lifestyle factors. We examined correlations between peripheral mononuclear cell (PBMC) and granulocyte DNA methylation levels measured by the luminometric methylation assay (LUMA), and in LINE-1, Sat2, and Alu by MethyLight and pyrosequencing, in the same individual in 112 women participating in The New York City Multiethnic Breast Cancer Project. Levels of DNA methylation of Sat2 by MethyLight (r = 0.57; P < 0.01) and LINE-1 by pyrosequencing (r = 0.30; P < 0.01) were correlated between PBMC and granulocyte DNA of the same individuals, but LUMA and Alu levels were not. The magnitude of the correlations for Sat2 and LINE-1 varied when stratified by selected demographic and lifestyle factors, although the study sample size limited our comparisons across subgroups. These results lend further support to the importance of considering the source of DNA in epidemiologic studies of white blood cell DNA methylation. Results from studies that combine individuals with different available DNA sources need to be interpreted with caution.
C1 [Delgado-Cruzata, Lissette; Gonzalez, Karina; Santella, Regina M.] Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, Med Ctr, New York, NY 10027 USA.
   [Delgado-Cruzata, Lissette] CUNY John Jay Coll Criminal Justice, Dept Sci, New York, NY 10019 USA.
   [Vin-Raviv, Neomi; Tehranifar, Parisa; Flom, Julie; Terry, Mary Beth] Columbia Univ, Dept Epidemiol, Med Ctr, Mailman Sch Publ Hlth, New York, NY USA.
   [Reynolds, Diane] Long Isl Univ, Sch Nursing, Brooklyn, NY USA.
   [Santella, Regina M.; Terry, Mary Beth] Columbia Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
C3 Columbia University; City University of New York (CUNY) System; John Jay
   College of Criminal Justice (CUNY); Columbia University; Long Island
   University-Brooklyn Campus; Columbia University
RP Delgado-Cruzata, L (通讯作者)，Columbia Univ, Dept Environm Hlth Sci, Mailman Sch Publ Hlth, Med Ctr, New York, NY 10027 USA.
EM ldelgado-cruzata@jjay.cuny.edu
RI Tehranifar, Parisa/P-8221-2016; Vin-Raviv, Neomi/AAL-6384-2021
OI Terry, Mary Beth/0000-0002-4106-5033; Delgado-Cruzata,
   Lissette/0000-0002-2884-0234
FU National Cancer Institute [U54 CA101598]; National Institute of
   Environmental Health Sciences Center Support [ES009089]; post-doctoral
   fellowship from the Environment and Health Fund, Jerusalem, Israel; NCI
   [R25 CA094061-08S1]
FX This work was funded by grants from the National Cancer Institute (U54
   CA101598) and the National Institute of Environmental Health Sciences
   Center Support (ES009089). Neomi Vin-Raviv was partly supported by a
   post-doctoral fellowship from the Environment and Health Fund,
   Jerusalem, Israel; and Lissette Delgado-Cruzata was partly supported by
   NCI R25 CA094061-08S1.
CR Adalsteinsson BT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046705
   Baccarelli A, 2012, CURR OPIN CLIN NUTR, V15, P323, DOI 10.1097/MCO.0b013e328354bf5c
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Delgado-Cruzata L, 2012, EPIGENETICS-US, V7, P868, DOI 10.4161/epi.20830
   Jacoby M, 2012, EPIGENETICS-US, V7, P1421, DOI 10.4161/epi.22845
   Jia EZ, 2005, ACTA PHARMACOL SIN, V26, P1057, DOI 10.1111/j.1745-7254.2005.00169.x
   KOCHANEK S, 1991, P NATL ACAD SCI USA, V88, P5759, DOI 10.1073/pnas.88.13.5759
   Koestler DC, 2013, EPIGENETICS-US, V8, P816, DOI 10.4161/epi.25430
   Lam LL, 2012, P NATL ACAD SCI USA, V109, P17253, DOI 10.1073/pnas.1121249109
   Lumey LH, 2012, INT J EPIDEMIOL, V41, P116, DOI 10.1093/ije/dyr137
   MCCARTHY A, 1988, BRIT J PSYCHIAT, V152, P558, DOI 10.1192/bjp.152.4.558
   Meda F, 2011, CELL MOL IMMUNOL, V8, P226, DOI 10.1038/cmi.2010.78
   Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Shen H, 2013, EPIGENOMICS-UK, V5, P255, DOI [10.2217/EPI.13.18, 10.2217/epi.13.18]
   Shin YO, 2013, CYTOKINE, V61, P364, DOI 10.1016/j.cyto.2012.11.019
   Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490
   Tehranifar P, 2011, CANCER CAUSE CONTROL, V22, P599, DOI 10.1007/s10552-011-9733-8
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Weaver B, 2013, BEHAV RES METHODS, V45, P880, DOI 10.3758/s13428-012-0289-7
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201
   Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   ZEZULKA AV, 1987, POSTGRAD MED J, V63, P257, DOI 10.1136/pgmj.63.738.257
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 28
TC 14
Z9 14
U1 0
U2 6
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD NOV
PY 2014
VL 9
IS 11
BP 1504
EP 1510
DI 10.4161/15592294.2014.983364
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AZ8CI
UT WOS:000348442000008
PM 25482109
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Barrio-Real, L
   Benedetti, LG
   Engel, N
   Tu, YP
   Cho, S
   Sukumar, S
   Kazanietz, MG
AF Barrio-Real, Laura
   Benedetti, Lorena G.
   Engel, Nora
   Tu, Yaping
   Cho, Soonweng
   Sukumar, Saraswati
   Kazanietz, Marcelo G.
TI Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer
   is associated with promoter hypomethylation
SO BREAST CANCER RESEARCH
LA English
DT Article
ID DNA METHYLATION PATTERNS; PROSTATE-CANCER; PHASE-I; EPIGENETIC THERAPY;
   CELL-PROLIFERATION; SPORADIC BREAST; RHO GTPASES; EXPRESSION; GENE;
   DEMETHYLATION
AB Introduction: The Rac-GEF P-REX1 is a key mediator of ErbB signaling in breast cancer recently implicated in mammary tumorigenesis and metastatic dissemination. Although P-REX1 is essentially undetectable in normal human mammary epithelial tissue, this Rac-GEF is markedly upregulated in human breast carcinomas, particularly of the luminal subtype. The mechanisms underlying P-REX1 upregulation in breast cancer are unknown. Toward the goal of dissecting the mechanistic basis of P-REX1 overexpression in breast cancer, in this study we focused on the analysis of methylation of the PREX1 gene promoter.
   Methods: To determine the methylation status of the PREX1 promoter region, we used bisulfite genomic sequencing and pyrosequencing approaches. Re-expression studies in cell lines were carried out by treatment of breast cancer cells with the demethylating agent 5-aza-2'-deoxycitidine. PREX1 gene methylation in different human breast cancer subtypes was analyzed from the TCGA database.
   Results: We found that the human PREX1 gene promoter has a CpG island located between -1.2 kb and +1.4 kb, and that DNA methylation in this region inversely correlates with P-REX1 expression in human breast cancer cell lines. A comprehensive analysis of human breast cancer cell lines and tumors revealed significant hypomethylation of the PREX1 promoter in ER-positive, luminal subtype, whereas hypermethylation occurs in basal-like breast cancer. Treatment of normal MCF-10A or basal-like cancer cells, MDA-MB-231 with the demethylating agent 5-aza-2'-deoxycitidine in combination with the histone deacetylase inhibitor trichostatin A restores P-REX1 levels to those observed in luminal breast cancer cell lines, suggesting that aberrant expression of P-REX1 in luminal breast cancer is a consequence of PREX1 promoter demethylation. Unlike PREX1, the pro-metastatic Rho/Rac-GEF, VAV3, is not regulated by methylation. Notably, PREX1 gene promoter hypomethylation is a prognostic marker of poor patient survival.
   Conclusions: Our study identified for the first time gene promoter hypomethylation as a distinctive subtype-specific mechanism for controlling the expression of a key regulator of Rac-mediated motility and metastasis in breast cancer.
C1 [Barrio-Real, Laura; Benedetti, Lorena G.; Kazanietz, Marcelo G.] Univ Penn, Dept Pharmacol, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Engel, Nora] Temple Univ, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA.
   [Tu, Yaping] Creighton Univ, Dept Pharmacol, Omaha, NE 68178 USA.
   [Cho, Soonweng; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA.
C3 University of Pennsylvania; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); Temple University; Creighton University; Johns
   Hopkins University
RP Kazanietz, MG (通讯作者)，Univ Penn, Dept Pharmacol, Perelman Sch Med, 1256 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM marcelog@upenn.edu
OI Cho, Soonweng/0000-0002-1637-2875
FU NIH [CA139120, GM093066, CA140311]; SKCCC Core Grant [P30 CA006973]; DOD
   [W81XWH-04-1-0595]
FX This work was supported by NIH Grants CA139120 (MGK), GM093066 (NE),
   CA140311 (SC) and SKCCC Core Grant P30 CA006973 and DOD W81XWH-04-1-0595
   (SS).
CR Altundag O, 2004, MED HYPOTHESES, V63, P684, DOI 10.1016/j.mehy.2004.03.017
   [Anonymous], PHARM THER
   Appleton K, 2007, J CLIN ONCOL, V25, P4603, DOI 10.1200/JCO.2007.10.8688
   Barrio-Real L, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003543
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Bustelo XR, 2012, BIOESSAYS, V34, P748, DOI 10.1002/bies.201200041
   Caan BJ, 2014, CANCER EPIDEM BIOMAR, V23, P725, DOI 10.1158/1055-9965.EPI-13-1017
   Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047
   Campbell AD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053982
   Candelaria M, 2007, ANN ONCOL, V18, P1529, DOI 10.1093/annonc/mdm204
   Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962
   Cook DR, 2014, ONCOGENE, V33, P4021, DOI 10.1038/onc.2013.362
   Daemen A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r110
   DuenasGonzalez A, 1997, CANCER, V80, P2100, DOI 10.1002/(SICI)1097-0142(19971201)80:11<2100::AID-CNCR9>3.0.CO;2-#
   Ebi H, 2013, P NATL ACAD SCI USA, V110, P21124, DOI 10.1073/pnas.1314124110
   Ehrlich M, 2013, ADV EXP MED BIOL, V754, P31, DOI 10.1007/978-1-4419-9967-2_2
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fang JY, 1996, J GASTROEN HEPATOL, V11, P1079, DOI 10.1111/j.1440-1746.1996.tb00040.x
   Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9
   Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   George RE, 2010, PEDIATR BLOOD CANCER, V55, P629, DOI 10.1002/pbc.22607
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   HANADA M, 1993, BLOOD, V82, P1820
   Haque R, 2012, CANCER EPIDEM BIOMAR, V21, P1848, DOI 10.1158/1055-9965.EPI-12-0474
   Hellebrekers DMEI, 2007, BBA-REV CANCER, V1775, P76, DOI 10.1016/j.bbcan.2006.07.003
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Hou P, 2012, CELL CYCLE, V11, P286, DOI 10.4161/cc.11.2.18707
   Hwang SL, 2005, ACTA NEUROCHIR, V147, P551, DOI 10.1007/s00701-005-0515-5
   Ignatiadis M, 2013, NAT REV CLIN ONCOL, V10, P494, DOI 10.1038/nrclinonc.2013.124
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jin H, 2011, HUM PATHOL, V42, P541, DOI 10.1016/j.humpath.2010.08.013
   Kamiyama H, 2012, ONCOGENE, V31, P5029, DOI 10.1038/onc.2011.652
   Katz E, 2012, ONCOTARGET, V3, P608
   Kawazu M, 2013, P NATL ACAD SCI USA, V110, P3029, DOI 10.1073/pnas.1216141110
   Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359
   Lane Jane, 2008, Int Semin Surg Oncol, V5, P23, DOI 10.1186/1477-7800-5-23
   Lim HW, 2010, J REPROD DEVELOP, V56, P86, DOI 10.1262/jrd.20247
   Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Marzese DM, 2014, HUM MOL GENET, V23, P226, DOI 10.1093/hmg/ddt420
   Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6
   Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489
   Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340
   Pakneshan P, 2003, FASEB J, V17, P1081, DOI 10.1096/fj.02-0973com
   Pitta CA, 2013, CANCER LETT, V337, P167, DOI 10.1016/j.canlet.2013.05.031
   Plummer R, 2009, CLIN CANCER RES, V15, P3177, DOI 10.1158/1078-0432.CCR-08-2859
   Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30
   R Core Team, 2017, R: A language and environment for statistical computing
   Rodríguez-Rodero S, 2013, J CLIN ENDOCR METAB, V98, P2811, DOI 10.1210/jc.2012-3566
   Rosenmüller T, 2001, J CELL PHYSIOL, V188, P369, DOI 10.1002/jcp.1126
   Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587
   Salhia B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085448
   Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Singh A, 2004, ONCOGENE, V23, P9369, DOI 10.1038/sj.onc.1208182
   Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029
   Stathis A, 2011, CLIN CANCER RES, V17, P1582, DOI 10.1158/1078-0432.CCR-10-1893
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Szyf M, 2008, EXPERT OPIN DRUG DIS, V3, P519, DOI 10.1517/17460441.3.5.519
   de Souza CRT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064420
   von Burstin VA, 2010, MOL PHARMACOL, V78, P325, DOI 10.1124/mol.110.064741
   Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071
   Wang WF, 2013, ACTA PHARMACOL SIN, V34, P1560, DOI 10.1038/aps.2013.163
   Wertheimer E, 2012, CELL SIGNAL, V24, P353, DOI 10.1016/j.cellsig.2011.08.011
   Widschwendter M, 2004, CANCER RES, V64, P4472, DOI 10.1158/0008-5472.CAN-04-0238
   Wild L, 2010, BBA-REV CANCER, V1806, P50, DOI 10.1016/j.bbcan.2010.03.003
   Wong CYA, 2011, J BIOL CHEM, V286, P25813, DOI 10.1074/jbc.M110.211292
   Yang CF, 2006, MOL CELL BIOL, V26, P831, DOI 10.1128/MCB.26.3.831-842.2006
   Yang CF, 2005, J BIOL CHEM, V280, P24363, DOI 10.1074/jbc.M411629200
   Zhang YJ, 2012, WORLD J HEPATOL, V4, P169, DOI [10.4254/wjh.v4.i5.169., 10.4254/wjh.v4.i5.169]
   Zheng M, 2004, AM J PATHOL, V165, P63, DOI 10.1016/S0002-9440(10)63275-0
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
   Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504
NR 85
TC 27
Z9 28
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-5411
EI 1465-542X
J9 BREAST CANCER RES
JI Breast Cancer Res.
PY 2014
VL 16
IS 5
AR 441
DI 10.1186/s13058-014-0441-7
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CA1II
UT WOS:000348665600016
PM 25248717
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhou, X
   Zhu, HQ
   Lu, J
AF Zhou, Xu
   Zhu, Hua-Qiang
   Lu, Jun
TI Regulation of gene expression in HBV- and HCV-related hepatocellular
   carcinoma: integrated GWRS and GWGS analyses
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Hepatocellular carcinoma; hepatitis B virus; hepatitis C virus;
   transcription factor
ID HEPATITIS-C VIRUS; MESSENGER-RNA EXPRESSION; B-VIRUS; CORE PROTEIN;
   BREAST-CANCER; X-PROTEIN; INDUCIBLE FACTOR-1-ALPHA; EPIGENETIC
   REGULATION; GROWTH-FACTOR; RISK-FACTORS
AB Objectives: To explore the molecular mechanism of hepatitis B virus-related and hepatitis C virus-related hepatocellular carcinoma, samples from hepatitis B virus and hepatitis C virus infected patients and the normal were compared, respectively. Methods: In both experiments, genes with high value were selected based on a genome-wide relative significance and genome-wide global significance model. Co-expression network of the selected genes was constructed, and transcription factors in the network were identified. Molecular complex detection algorithm was used to obtain sub-networks. Results: Based on the new model, the top 300 genes were selected. Co-expression network was constructed and transcription factors were identified. We obtained two common genes FCN2 and CXCL14, and two common transcription factors RFX5 and EZH2. In hepatitis B virus experiment, cluster 1 and 3 had the higher value. In cluster 1, ten of the 17 genes and one transcription factor were all reported associated with hepatocellular carcinoma. In cluster 3, transcription factor ESR1 was reported related with hepatocellular carcinoma. In hepatitis C virus experiment, the value of cluster 3 and 4 was higher. In cluster 3, nine genes were reported to play a key role in hepatocellular carcinoma. In cluster 4, there were 5 genes in the 34 genes. To compare the relevance of a node in holding together communicating nodes, centralities based analysis was performed and we obtained some genes with high stress value. Conclusion: The analysis above helped us to understand the pathogenesis of hepatitis B virus and hepatitis C virus associated hepatocellular carcinoma.
C1 [Zhou, Xu; Zhu, Hua-Qiang; Lu, Jun] Shandong Univ, Prov Hosp, Dept Gen Surg, Jinan 250014, Peoples R China.
C3 Shandong University
RP Lu, J (通讯作者)，Shandong Univ, Prov Hosp, Dept Gen Surg, 9677 Jingshi Rd, Jinan 250014, Peoples R China.
EM junlu12345@yeah.net
FU Natural Science Foundation of Shandong Province, China [Y2008C22];
   Excellent Youth Scientist Foundation of Shandong Province, China
   [2007BS03038]
FX This work was supported by Natural Science Foundation of Shandong
   Province, China [Y2008C22] and Excellent Youth Scientist Foundation of
   Shandong Province, China [2007BS03038].
CR Abe M, 2012, HEPATOL RES, V42, P591, DOI 10.1111/j.1872-034X.2011.00953.x
   Arzumanyan A, 2013, NAT REV CANCER, V13, P123, DOI 10.1038/nrc3449
   Barbaria EM, 2009, NEUROBIOL DIS, V33, P448, DOI 10.1016/j.nbd.2008.11.014
   Belloni L, 2009, P NATL ACAD SCI USA, V106, P19975, DOI 10.1073/pnas.0908365106
   Benegiamo G, 2012, DIGEST DIS SCI, V57, P1598, DOI 10.1007/s10620-012-2160-1
   Bonnafe E, 2004, MOL CELL BIOL, V24, P4417, DOI 10.1128/MCB.24.10.4417-4427.2004
   Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chen X, 2006, J DERMATOL SCI, V43, P201, DOI 10.1016/j.jdermsci.2006.05.010
   Cheng ASL, 2011, CANCER RES, V71, P4028, DOI 10.1158/0008-5472.CAN-10-3342
   Chiba T, 2012, INT J CANCER, V130, P2557, DOI 10.1002/ijc.26264
   Chuang SC, 2009, CANCER LETT, V286, P9, DOI 10.1016/j.canlet.2008.10.040
   Dawson JA, 2012, BIOINFORMATICS, V28, P1939, DOI 10.1093/bioinformatics/bts268
   Dawson JA, 2012, BIOMETRICS, V68, P455, DOI 10.1111/j.1541-0420.2011.01688.x
   de Messias-Reason I, 2009, J INFECT DIS, V199, P801, DOI 10.1086/597070
   Deng YB, 2010, CANCER SCI, V101, P1501, DOI 10.1111/j.1349-7006.2010.01549.x
   Furukawa T, 2006, ONCOGENE, V25, P4831, DOI 10.1038/sj.onc.1209494
   Gamucci T, 2013, J CANCER RES CLIN, V139, P853, DOI 10.1007/s00432-013-1388-2
   Gene Ontology Consortium, 2004, Bioinformatics, V32, pD258, DOI [DOI 10.1093/NAR/GKH036, 10.1093/nar/gkh036]
   Gu X, 2012, MOL BIOL REP, V39, P797, DOI 10.1007/s11033-011-0801-7
   Hodo Y, 2013, CLIN CANCER RES, V19, P1827, DOI 10.1158/1078-0432.CCR-12-1641
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang H, 2009, FITOTERAPIA, V80, P448, DOI 10.1016/j.fitote.2009.06.004
   Hummelshoj T, 2005, HUM MOL GENET, V14, P1651, DOI 10.1093/hmg/ddi173
   Hummelshoj T, 2007, MOL IMMUNOL, V44, P401, DOI 10.1016/j.molimm.2006.02.023
   Javadi AA, 2006, IRAN J PUBLIC HEALTH, V35, P33
   Jin YM, 2001, J VIRAL HEPATITIS, V8, P322, DOI 10.1046/j.1365-2893.2001.00308.x
   Jurman G, 2008, BIOINFORMATICS, V24, P258, DOI 10.1093/bioinformatics/btm550
   Kasprzak A, 2008, HEPATOL RES, V38, P1, DOI 10.1111/j.1872-034X.2007.00261.x
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lavanchy D, 2005, J CLIN VIROL, V34, pS1, DOI 10.1016/S1386-6532(05)00384-7
   Lee H, 2013, CANCER LETT, V335, P372, DOI 10.1016/j.canlet.2013.02.057
   Lee SW, 2000, MOL CELL BIOL, V20, P1723, DOI 10.1128/MCB.20.5.1723-1732.2000
   Levrero M, 2009, J HEPATOL, V51, P581, DOI 10.1016/j.jhep.2009.05.022
   [李冰 LI Bing], 2011, [肿瘤, Tumor], V31, P751
   Lim JS, 2012, CANCER LETT, V321, P154, DOI 10.1016/j.canlet.2012.01.044
   Liu WT, 2013, PEERJ, V1, DOI 10.7717/peerj.49
   Luz PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060237
   Ma CH, 2014, EUR REV MED PHARMACO, V18, P431
   MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531
   Marshall A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059459
   Martin ST, 2005, CANCER BIOL THER, V4, P728, DOI 10.4161/cbt.4.7.1802
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Ogata H, 1999, NUCLEIC ACIDS RES, V27, P29, DOI 10.1093/nar/27.1.29
   Ohh M, 2006, CANCER CELL, V10, P95, DOI 10.1016/j.ccr.2006.07.016
   Panchal SC, 1999, INDIAN J BIOCHEM BIO, V36, P429
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rehermann B, 2005, NAT REV IMMUNOL, V5, P215, DOI 10.1038/nri1573
   Rehermann B, 2009, J CLIN INVEST, V119, P1745, DOI 10.1172/JCI39133
   Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106
   Roessler S, 2010, CANCER RES, V70, P10202, DOI 10.1158/0008-5472.CAN-10-2607
   Sanz-Cameno P, 2006, AM J PATHOL, V169, P1215, DOI 10.2353/ajpath.2006.051246
   Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144
   Scanlan MJ, 2002, INT J CANCER, V98, P485, DOI 10.1002/ijc.10276
   Scardoni G, 2012, IN TECH OPEN
   Scholl T, 1997, P NATL ACAD SCI USA, V94, P6330, DOI 10.1073/pnas.94.12.6330
   Shellenberger TD, 2004, CANCER RES, V64, P8262, DOI 10.1158/0008-5472.CAN-04-2056
   Shimo A, 2007, CANCER SCI, V98, P174, DOI 10.1111/j.1349-7006.2006.00381.x
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Sugimoto R, 1998, J BIOL CHEM, V273, P20721, DOI 10.1074/jbc.273.33.20721
   Sun M, 2009, FRONT BIOSCI, V2, P829
   Sun M, 2009, FRONT BIOSCI, V2, P1127
   TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0
   Tong HV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028113
   Toyota M, 2010, ADV GENET, V70, P309, DOI [10.1016/S0065-2660(10)70011-0, 10.1016/B978-0-12-380866-0.60011-3]
   Tsang DPF, 2011, J GASTROEN HEPATOL, V26, P19, DOI 10.1111/j.1440-1746.2010.06447.x
   Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Visser HPJ, 2001, BRIT J HAEMATOL, V112, P950, DOI 10.1046/j.1365-2141.2001.02641.x
   Wang L, 2011, CELL PROLIFERAT, V44, P291, DOI 10.1111/j.1365-2184.2011.00752.x
   Wang SM, 2011, CLIN CANCER RES, V17, P6040, DOI 10.1158/1078-0432.CCR-11-0557
   Wang WL, 2013, CANCER SCI, V104, P1523, DOI 10.1111/cas.12279
   Weng Li, 2012, Zhong Xi Yi Jie He Xue Bao, V10, P406
   Wenjian J, 2013, CHONGQING MED, V20, P021
   Wente MN, 2008, CANCER LETT, V259, P209, DOI 10.1016/j.canlet.2007.10.021
   Wu KM, 2003, J BIOL CHEM, V278, P51673, DOI 10.1074/jbc.M310021200
   Wu KM, 2006, MOL CELL BIOL, V26, P7116, DOI 10.1128/MCB.00268-06
   Wu YH, 2011, BREAST CANCER RES TR, V127, P397, DOI 10.1007/s10549-010-1013-x
   Yang YF, 2009, J VIRAL HEPATITIS, V16, P265, DOI 10.1111/j.1365-2893.2009.01070.x
   Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200
   Young E., 2005, Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases, V6th, P2669
   Zhai Y, 2006, GASTROENTEROLOGY, V130, P2001, DOI 10.1053/j.gastro.2006.02.030
NR 84
TC 4
Z9 5
U1 0
U2 2
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2014
VL 7
IS 11
BP 4038
EP 4050
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AZ6BC
UT WOS:000348302100024
PM 25550913
DA 2025-01-12
ER

PT J
AU Brambert, PR
   Kelpsch, DJ
   Hameed, R
   Desai, CV
   Calafiore, G
   Godley, LA
   Raimondi, SL
AF Brambert, Patrick R.
   Kelpsch, Daniel J.
   Hameed, Rabia
   Desai, Charmi V.
   Calafiore, Gianfranco
   Godley, Lucy A.
   Raimondi, Stacey L.
TI <i>DNMT3B7</i> Expression Promotes Tumor Progression to a More
   Aggressive Phenotype in Breast Cancer Cells
SO PLOS ONE
LA English
DT Article
ID BETA-CATENIN; DNA METHYLTRANSFERASES; METHYLATION; METASTASIS; PATHWAYS;
   SUPPRESSES; INVASION
AB Epigenetic changes, such as DNA methylation, have been shown to promote breast cancer progression. However, the mechanism by which cancer cells acquire and maintain abnormal DNA methylation is not well understood. We have previously identified an aberrant splice form of a DNA methyltransferase, DNMT3B7, expressed in virtually all cancer cell lines but at very low levels in normal cells. Furthermore, aggressive MDA-MB-231 breast cancer cells have been shown to express increased levels of DNMT3B7 compared to poorly invasive MCF-7 cells, indicating that DNMT3B7 may have a role in promoting a more invasive phenotype. Using data gathered from The Cancer Genome Atlas, we show that DNMT3B7 expression is increased in breast cancer patient tissues compared to normal tissue. To determine the mechanism by which DNMT3B7 was functioning in breast cancer cells, two poorly invasive breast cancer cell lines, MCF-7 and T-47D, were stably transfected with a DNMT3B7 expression construct. Expression of DNMT3B7 led to hypermethylation and down-regulation of E-cadherin, altered localization of beta-catenin, as well as increased adhesion turnover, cell proliferation, and anchorage-independent growth. The novel results presented in this study suggest a role for DNMT3B7 in the progression of breast cancer to a more aggressive state and the potential for future development of novel therapeutics.
C1 [Brambert, Patrick R.; Kelpsch, Daniel J.; Hameed, Rabia; Desai, Charmi V.; Calafiore, Gianfranco; Raimondi, Stacey L.] Elmhurst Coll, Dept Biol, Elmhurst, IL 60126 USA.
   [Godley, Lucy A.] Univ Chicago, Dept Med, Hematol Oncol Sect, Chicago, IL 60637 USA.
C3 University of Chicago
RP Raimondi, SL (通讯作者)，Elmhurst Coll, Dept Biol, Elmhurst, IL 60126 USA.
EM raimondis@elmhurst.edu
OI Kelpsch, Daniel/0000-0002-7383-5530; Raimondi,
   Stacey/0000-0001-7667-6814
FU Diana Nicholas Loving Trust; Alfred Koplin; Beta Beta Beta Research
   Foundation; Elmhurst College Biology Department; Elmhurst College Center
   for Scholarship and Teaching/Faculty Development Committee
FX This work was supported by the Diana Nicholas Loving Trust (SLR), Alfred
   Koplin (SLR), Beta Beta Beta Research Foundation (RH), the Elmhurst
   College Biology Department (SLR), and the Elmhurst College Center for
   Scholarship and Teaching/Faculty Development Committee (SLR, PRB, GC).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Azarschab P, 2003, ONCOL REP, V10, P501
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Kelpsch Daniel J., 2012, BIOS, V83, P17
   Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lim SC, 2002, ONCOL REP, V9, P915
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Odero-Marah VA, 2003, CANCER BIOL THER, V2, P398, DOI 10.4161/cbt.2.4.471
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Orsulic S, 1999, J CELL SCI, V112, P1237
   Ostler K, 2007, ONCOGENE, V26, P5553, DOI 10.1038/sj.onc.1210351
   Ostler KR, 2012, CANCER RES, V72, P4714, DOI 10.1158/0008-5472.CAN-12-0886
   Payne SL, 2006, J CELL BIOCHEM, V98, P827, DOI 10.1002/jcb.20792
   Prasad CP, 2007, ONCOLOGY-BASEL, V73, P112, DOI 10.1159/000120999
   Reed KR, 2008, P NATL ACAD SCI USA, V105, P18919, DOI 10.1073/pnas.0805778105
   Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443
   Semba S, 2000, ENDOCR PATHOL, V11, P243, DOI 10.1385/EP:11:3:243
   Shah MY, 2010, CANCER RES, V70, P5840, DOI 10.1158/0008-5472.CAN-10-0847
   Siapati EK, 2011, BRIT J HAEMATOL, V152, P164, DOI 10.1111/j.1365-2141.2010.08471.x
   Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448
   Wheelock MJ, 2008, J CELL SCI, V121, P727, DOI 10.1242/jcs.000455
   Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020
NR 26
TC 14
Z9 16
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 21
PY 2015
VL 10
IS 1
AR e0117310
DI 10.1371/journal.pone.0117310
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AZ4PR
UT WOS:000348205300050
PM 25607950
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Boukhari, A
   Alhosin, M
   Bronner, C
   Sagini, K
   Truchot, C
   Sick, E
   Schini-Kerth, VB
   André, P
   Mély, Y
   Mousli, M
   Gies, JP
AF Boukhari, Abdelaziz
   Alhosin, Mahmoud
   Bronner, Christian
   Sagini, Krizia
   Truchot, Cecile
   Sick, Emilie
   Schini-Kerth, Valerie B.
   Andre, Philippe
   Mely, Yves
   Mousli, Marc
   Gies, Jean-Pierre
TI CD47 Activation-induced UHRF1 Over-expression Is Associated with
   Silencing of Tumor Suppressor Gene <i>p16<SUP>INK4A</SUP></i> in
   Glioblastoma Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Astrocytoma; CD47; NF-kappa B; UHRF1
ID NF-KAPPA-B; HEMI-METHYLATED DNA; BREAST-CANCER; DOWN-REGULATION; SRA
   DOMAIN; ICBP90; APOPTOSIS; BINDING; INHIBITION; TARGET
AB CD47, an integrin-associated protein is over-expressed in several tumors including glioblastomas. Activation of CD47 induces proliferation of human astrocytoma cells but not normal astrocytes via an Akt-dependent way. However, the pathways mediating this process are still unknown. The epigenetic integrator UHRF1 (Ubiquitin-like containing PHD and RING Finger 1) is over-expressed in various cancers and plays a vital role in the silencing of numerous tumor suppressor genes including p16(INK4A), thereby promoting cell proliferation. The aim of the present study was to investigate the role of UHRFI and p16(INK4A) in CD47-induced effects. Herein we showed that activation of CD47 in human astrocytoma cell lines U87 and CCF- STTG1 (Grade IV), up-regulated the expression of UHRFI with subsequent down-regulation of p16(INK4A), thus promoting cell proliferation. Blockage of CD47 using a blocking antibody down-regulated UHRFI expression, accompanied by a re-expression of p16(INK4A), conducting to decreased cell proliferation in both cancer cell lines. Neither CD47 activation nor its blocking has any effect on UHRF1/p16(INK4A) expression in normal human astrocytes. Depletion of CD47 in the U87 cell line resulted in downregulation of UHRFI. We also found that CD47 activated the inflammatory genes IL-6, IL-7 and MCP-1 by a NF-0dependent mechanism in human astrocytoma but not in normal astrocytes. In conclusion, the present findings indicate that CD47 activation increases expression of UHRFI and suggest, for the first time, that CD47 regulates the epigenetic code by targeting UHRFI. This could represent a new pathway towards cell proliferation and metastasis.
C1 [Boukhari, Abdelaziz; Alhosin, Mahmoud; Sagini, Krizia; Truchot, Cecile; Sick, Emilie; Schini-Kerth, Valerie B.; Andre, Philippe; Mely, Yves; Mousli, Marc; Gies, Jean-Pierre] Univ Strasbourg, Lab Biophoton & Pharmacol, CNRS, UMR 7213,Fac Pharm, Illkirch Graffenstaden, France.
   [Bronner, Christian] Univ Strasbourg, Inst Natl Sante & Rech Med, Ctr Natl Rech Sci, Inst Genet & Biol Mol & Cellulaire, Illkirch Graffenstaden, France.
C3 Universites de Strasbourg Etablissements Associes; Universite de
   Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS -
   National Institute for Biology (INSB); Centre National de la Recherche
   Scientifique (CNRS); Universites de Strasbourg Etablissements Associes;
   Universite de Strasbourg; Institut National de la Sante et de la
   Recherche Medicale (Inserm)
RP Gies, JP (通讯作者)，Fac Pharm, Lab Biophoton & Pharmacol, CNRS, UMR 7213, 74 Route Rhin,BP 60024, F-67401 Illkirch Graffenstaden, France.
EM jean-pierre.gies@unistra.fr
RI Naselsky, Pavel/M-4799-2014; Alhosin, Mahmoud/H-8101-2017; BRONNER,
   Christian/R-8488-2016; Mousli, Marc/Q-1722-2017; SAGINI,
   Krizia/Z-1629-2019
OI Alhosin, Mahmoud/0000-0003-2147-1445; BRONNER,
   Christian/0000-0002-3101-9279; Mousli, Marc/0000-0001-9759-6864; SAGINI,
   Krizia/0000-0003-3357-2171
FU Agence Nationale de la Recherche (ANR Fluometadn); Fondation pour la
   Recherche Medicale (FRM) [DCM20111223038]; Ligue contre le Cancer
FX This study was supported by the Agence Nationale de la Recherche (ANR
   Fluometadn), by the Fondation pour la Recherche Medicale (FRM
   DCM20111223038) and Ligue contre le Cancer.
CR Abbady AQ, 2003, ANN NY ACAD SCI, V1010, P300, DOI 10.1196/annals.1299.052
   Achour M, 2008, ONCOGENE, V27, P2187, DOI 10.1038/sj.onc.1210855
   Akca H, 2011, LUNG CANCER, V73, P302, DOI 10.1016/j.lungcan.2011.01.012
   Alhosin M, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-41
   Arima Y, 2004, GENES CELLS, V9, P131, DOI 10.1111/j.1356-9597.2004.00710.x
   Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249
   Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273
   Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238
   Bhat-Nakshatri P, 2002, ONCOGENE, V21, P2066, DOI 10.1038/sj.onc.1205243
   Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Chao MP, 2012, CURR OPIN IMMUNOL, V24, P225, DOI 10.1016/j.coi.2012.01.010
   Chao MP, 2011, CANCER RES, V71, P1374, DOI 10.1158/0008-5472.CAN-10-2238
   Danielsen JMR, 2007, BRIT J HAEMATOL, V138, P756, DOI 10.1111/j.1365-2141.2007.06729.x
   Daskalos A, 2011, CANCER-AM CANCER SOC, V117, P1027, DOI 10.1002/cncr.25531
   Foo SY, 1999, TRENDS GENET, V15, P229
   Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032
   Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029
   Huang WC, 2007, MOL CELL, V26, P75, DOI 10.1016/j.molcel.2007.02.019
   Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046
   Jeanblanc M, 2005, ONCOGENE, V24, P7337, DOI 10.1038/sj.onc.1208878
   Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2
   Johansson U, 2004, SCAND J IMMUNOL, V59, P40, DOI 10.1111/j.0300-9475.2004.01355.x
   Karagianni P, 2008, MOL CELL BIOL, V28, P705, DOI 10.1128/MCB.01598-07
   Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795
   Liu Y, 2001, J BIOL CHEM, V276, P40156, DOI 10.1074/jbc.M104138200
   Lymn JS, 2002, J CELL SCI, V115, P4353, DOI 10.1242/jcs.00119
   Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045
   Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968
   Mayo MW, 2001, METHOD ENZYMOL, V333, P73
   Miyakoshi J, 2000, BRIT J CANCER, V82, P28
   Miyata Y, 2003, CLIN CANCER RES, V9, P1734
   Mousli M, 2003, BRIT J CANCER, V89, P120, DOI 10.1038/sj.bjc.6601068
   Mut M, 2010, TURK NEUROSURG, V20, P277, DOI 10.5137/1019-5149.JTN.3008-10.1
   Nagahara M, 2010, CLIN CANCER RES, V16, P4625, DOI 10.1158/1078-0432.CCR-10-0349
   Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629
   Newton TR, 1999, J BIOL CHEM, V274, P18827, DOI 10.1074/jbc.274.26.18827
   Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239
   Parcellier A, 2008, CELL SIGNAL, V20, P21, DOI 10.1016/j.cellsig.2007.07.010
   Park S, 2009, CANCER RES, V69, P2809, DOI 10.1158/0008-5472.CAN-08-4079
   Patel NM, 2000, ONCOGENE, V19, P4159, DOI 10.1038/sj.onc.1203768
   Russell JS, 2002, CANCER RES, V62, P2318
   Sarfati M, 2008, CURR DRUG TARGETS, V9, P842, DOI 10.2174/138945008785909310
   Sick E, 2011, GLIA, V59, P308, DOI 10.1002/glia.21102
   Sun HZ, 2010, J ENDOCRINOL, V204, P311, DOI 10.1677/JOE-09-0270
   Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5
   Uluçkan Ö, 2009, CANCER RES, V69, P3196, DOI 10.1158/0008-5472.CAN-08-3358
   Wang F, 2012, ANN SURG ONCOL, V19, P2753, DOI 10.1245/s10434-011-2194-1
   Yamagishi N, 1997, INT J RADIAT BIOL, V72, P157, DOI 10.1080/095530097143374
NR 48
TC 50
Z9 52
U1 0
U2 8
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN
PY 2015
VL 35
IS 1
BP 149
EP 157
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY7IY
UT WOS:000347735300019
PM 25550546
DA 2025-01-12
ER

PT J
AU Llanos, AA
   Dumitrescu, RG
   Brasky, TM
   Liu, ZH
   Mason, JB
   Marian, C
   Makambi, KH
   Spear, SL
   Kallakury, BVS
   Freudenheim, JL
   Shields, PG
AF Llanos, Adana A.
   Dumitrescu, Ramona G.
   Brasky, Theodore M.
   Liu, Zhenhua
   Mason, Joel B.
   Marian, Catalin
   Makambi, Kepher H.
   Spear, Scott L.
   Kallakury, Bhaskar V. S.
   Freudenheim, Jo L.
   Shields, Peter G.
TI Relationships among folate, alcohol consumption, gene variants in
   one-carbon metabolism and <i>p16</i> <i><SUP>INK4a</SUP></i> methylation
   and expression in healthy breast tissues
SO CARCINOGENESIS
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; CANCER RISK; PROMOTER METHYLATION;
   POSTMENOPAUSAL WOMEN; CELLULAR SENESCENCE; DIETARY-INTAKE; P16(INK4A)
   EXPRESSION; DNA HYPERMETHYLATION; POLYMORPHISMS; ASSOCIATION
AB Alcohol consumption, breast folate concentration and variation in one-carbon metabolism genes may be determinants of p16 (INK4a) promoter methylation and P16 protein expression in histologically normal breast tissues, and may influence early breast carcinogenic events.p16 (INK4a) is a tumor suppressor gene, frequently hypermethylated in breast cancer; this epigenetic silencing of p16 (INK4a) occurs early in carcinogenesis. The risk factors and functional consequences of p16 (INK4a) methylation are unknown. Alcohol consumption, a breast cancer risk factor, impedes folate metabolism and may thereby alter gene methylation since folate plays a pivotal role in DNA methylation. In a cross-sectional study of 138 women with no history of breast cancer who underwent reduction mammoplasty, we studied breast cancer risk factors, plasma and breast folate concentrations, variation in one-carbon metabolism genes, p16 (INK4a) promoter methylation and P16 protein expression. Logistic regression was used to estimate multivariable-adjusted odds ratios (OR) and 95% confidence intervals (CI). p16 (INK4a) methylation was negatively correlated with P16 expression (r = -0.28; P = 0.002). Alcohol consumption was associated with lower breast folate (P = 0.03), higher p16 (INK4a) promoter methylation (P = 0.007) and less P16 expression (P = 0.002). Higher breast folate concentrations were associated with lower p16 (INK4a) promoter methylation (P = 0.06). Genetic variation in MTRR (rs1801394) and MTHFD1 (rs1950902) was associated with higher p16 (INK4a) promoter methylation (OR = 2.66, 95% CI: 1.11-6.42 and OR = 2.72, 95% CI: 1.12-6.66, respectively), whereas variation in TYMS (rs502396) was associated with less P16 protein expression (OR = 0.22, 95% CI: 0.05-0.99). Given that this is the first study to indicate that alcohol consumption, breast folate and variation in one-carbon metabolism genes are associated with p16 (INK4a) promoter methylation and P16 protein expression in healthy tissues; these findings require replication.
C1 [Llanos, Adana A.] Ohio State Univ, Div Populat Sci, Ctr Comprehens Canc, Columbus, OH 43201 USA.
   [Llanos, Adana A.] Rutgers State Univ, RBHS Sch Publ Hlth, Dept Epidemiol, New Brunswick, NJ 08903 USA.
   [Llanos, Adana A.] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
   [Dumitrescu, Ramona G.] Georgetown Univ, Dept Oncol, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA.
   [Dumitrescu, Ramona G.] Saba Univ, Sch Med, Dept Med Genet & Epidemiol, Basic Sci Program, Saba, Dutch Caribbean, Netherlands.
   [Brasky, Theodore M.; Marian, Catalin; Shields, Peter G.] Ohio State Univ, Coll Med, Div Canc Prevent & Control, Columbus, OH 43210 USA.
   [Liu, Zhenhua; Mason, Joel B.] Tufts Univ, Human Nutr Res Ctr, Boston, MA 02111 USA.
   [Liu, Zhenhua] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Nutr, Amherst, MA 01003 USA.
   [Marian, Catalin] Univ Med & Farm Timisoara, Dept Biochem & Pharmacol, Timisoara, Romania.
   [Makambi, Kepher H.] Georgetown Univ, Dept Biostat Bioinformat & Biomath, Washington, DC 20057 USA.
   [Spear, Scott L.] Georgetown Univ, Dept Plast Surg, Washington, DC 20057 USA.
   [Kallakury, Bhaskar V. S.] Georgetown Univ, Dept Pathol, Washington, DC 20057 USA.
   [Freudenheim, Jo L.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Epidemiol & Environm Hlth, Buffalo, NY 14214 USA.
C3 University System of Ohio; Ohio State University; James Cancer Hospital
   & Solove Research Institute; Rutgers University System; Rutgers
   University New Brunswick; Rutgers University System; Rutgers University
   New Brunswick; Rutgers University Biomedical & Health Sciences; Rutgers
   Cancer Institute of New Jersey; Georgetown University; University System
   of Ohio; Ohio State University; Tufts University; University of
   Massachusetts System; University of Massachusetts Amherst; Victor Babes
   University of Medicine & Pharmacy, Timisoara; Georgetown University;
   Georgetown University; Georgetown University; State University of New
   York (SUNY) System; University at Buffalo, SUNY
RP Shields, PG (通讯作者)，Ohio State Univ, Coll Med, Div Canc Prevent & Control, Columbus, OH 43210 USA.
EM peter.shields@osumc.edu
RI Llanos, Adana/J-8695-2019; Marian, Catalin/KHU-8477-2024; Shields,
   Peter/I-1644-2012; Marian, Catalin/P-2885-2019
OI Marian, Catalin/0000-0002-7749-1384; Freudenheim, Jo/0000-0002-9301-0499
FU Department of Defense, Alcohol Center of Excellence [BC022346]
FX Department of Defense, Alcohol Center of Excellence (BC022346 to
   P.G.S.).
CR ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200
   Arima Y, 2012, INT J CANCER, V130, P2568, DOI 10.1002/ijc.26271
   Baglietto L, 2005, BMJ-BRIT MED J, V331, P807, DOI 10.1136/bmj.38551.446470.06
   Bazarov AV, 2012, CELL CYCLE, V11, P1008, DOI 10.4161/cc.11.5.19492
   Bazarov AV, 2010, AGING CELL, V9, P736, DOI 10.1111/j.1474-9726.2010.00599.x
   Cavusoglu AC, 2010, NEOPLASMA, V57, P465, DOI 10.4149/neo_2010_05_465
   Chen WY, 2011, JAMA-J AM MED ASSOC, V306, P1884, DOI 10.1001/jama.2011.1590
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Coppé JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071
   Dumitrescu RG, 2010, J CELL MOL MED, V14, P1468, DOI 10.1111/j.1582-4934.2009.00924.x
   Egan KM, 1999, CANCER CAUSE CONTROL, V10, P115, DOI 10.1023/A:1008801131831
   Fowler BM, 1998, CANCER EPIDEM BIOMAR, V7, P901
   Friso S, 2002, P NATL ACAD SCI USA, V99, P5606, DOI 10.1073/pnas.062066299
   Han D, 2012, MOL BIOL REP, V39, P805, DOI 10.1007/s11033-011-0802-6
   Holst CR, 2003, CANCER RES, V63, P1596
   HORNE DW, 1988, CLIN CHEM, V34, P2357
   Hu J, 2010, BREAST CANCER RES TR, V124, P779, DOI 10.1007/s10549-010-0892-1
   Kotsopoulos J, 2008, BREAST CANCER RES TR, V112, P585, DOI 10.1007/s10549-008-9895-6
   Kusano AS, 2006, INT J CANCER, V118, P2031, DOI 10.1002/ijc.21588
   LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350
   Li N, 2011, FEBS LETT, V585, P3106, DOI 10.1016/j.febslet.2011.08.044
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Lissowska J, 2007, INT J CANCER, V120, P2696, DOI 10.1002/ijc.22604
   Ma E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-122
   Mason JB, 2005, ALCOHOL, V35, P235, DOI 10.1016/j.alcohol.2005.03.012
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Platek ME, 2009, CANCER EPIDEM BIOMAR, V18, P2453, DOI 10.1158/1055-9965.EPI-09-0159
   Radpour R, 2010, MODERN PATHOL, V23, P763, DOI 10.1038/modpathol.2009.195
   Rayess H, 2012, INT J CANCER, V130, P1715, DOI 10.1002/ijc.27316
   Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909
   Sangrajrang S, 2010, BREAST CANCER RES TR, V123, P885, DOI 10.1007/s10549-010-0804-4
   Sellers TA, 2001, EPIDEMIOLOGY, V12, P420, DOI 10.1097/00001648-200107000-00012
   Shrubsole MJ, 2006, CANCER EPIDEM BIOMAR, V15, P586, DOI 10.1158/1055-9965.EPI-05-0576
   Sperka T, 2012, NAT REV MOL CELL BIO, V13, P579, DOI 10.1038/nrm3420
   Stevens VL, 2007, CANCER EPIDEM BIOMAR, V16, P1140, DOI 10.1158/1055-9965.EPI-06-1037
   Stolzenberg-Solomon RZ, 2006, AM J CLIN NUTR, V83, P895, DOI 10.1093/ajcn/83.4.895
   Sturgeon SR, 2012, EPIGENETICS-US, V7, P1258, DOI 10.4161/epi.22220
   Suzuki T, 2008, CARCINOGENESIS, V29, P356, DOI 10.1093/carcin/bgm295
   Tao MH, 2011, NUTR CANCER, V63, P1143, DOI 10.1080/01635581.2011.605982
   Teng Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055332
   Tjonneland A, 2006, EUR J CLIN NUTR, V60, P280, DOI 10.1038/sj.ejcn.1602313
   Vallian S, 2009, J CANCER RES CLIN, V135, P991, DOI 10.1007/s00432-008-0534-8
   VARELAMOREIRAS G, 1992, J NUTR, V122, P986, DOI 10.1093/jn/122.4.986
   Wang J, 2011, BREAST CANCER RES TR, V128, P203, DOI 10.1007/s10549-010-1314-0
   Weiner AS, 2012, CANCER EPIDEMIOL, V36, pE95, DOI 10.1016/j.canep.2011.11.010
   Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776
   Zhu WZ, 2010, INT J CANCER, V126, P474, DOI 10.1002/ijc.24728
NR 48
TC 13
Z9 14
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2015
VL 36
IS 1
BP 60
EP 67
DI 10.1093/carcin/bgu219
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY9BM
UT WOS:000347844700008
PM 25344837
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Yan, H
   Wu, QL
   Sun, CY
   Ai, LS
   Deng, J
   Zhang, L
   Chen, L
   Chu, ZB
   Tang, B
   Wang, K
   Wu, XF
   Xu, J
   Hu, Y
AF Yan, H.
   Wu, Q-L
   Sun, C-Y
   Ai, L-S
   Deng, J.
   Zhang, L.
   Chen, L.
   Chu, Z-B
   Tang, B.
   Wang, K.
   Wu, X-F
   Xu, J.
   Hu, Y.
TI piRNA-823 contributes to tumorigenesis by regulating <i>de novo</i> DNA
   methylation and angiogenesis in multiple myeloma
SO LEUKEMIA
LA English
DT Article
ID BONE-MARROW ANGIOGENESIS; GROWTH-FACTOR EXPRESSION; SQUAMOUS-CELL
   CARCINOMA; HUMAN GASTRIC-CANCER; NONCODING RNAS; EPIGENETIC
   INACTIVATION; GENE HYPERMETHYLATION; ENDOTHELIAL-CELLS; PROTEIN PIWIL2;
   BREAST-CANCER
AB Aberrant DNA hypermethylation contributes to myelomagenesis by silencing tumor-suppressor genes. Recently, a few reports have suggested that a novel class of small non-coding RNAs, called Piwi-interacting RNAs (piRNAs), may be involved in the epigenetic regulation of cancer. In this study, for the first time we provided evidence that the expression of piRNA-823 was upregulated in multiple myeloma (MM) patients and cell lines, and positively correlated with clinical stage. Silencing piRNA-823 in MM cells induced deregulation of cell cycle regulators and apoptosis-related proteins expression, accompanied by inhibition of tumorigenicity in vitro and in vivo. Moreover, piRNA-823 was directly relevant to de novo DNA methyltransferases, DNMT3A and 3B, in primary CD138-MM cells. The inhibited expression of piRNA-823 in MM cells resulted in marked reduction of DNMT3A and 3B at both mRNA and protein levels, which in turn led to decrease in global DNA methylation and reexpression of methylation-silenced tumor suppressor, p16(INK4A). In addition, piRNA-823 abrogation in MM cells induced reduction of vascular endothelial growth factor secretion, with consequent decreased proangiogenic activity. Altogether, these data support an oncogenic role of piRNA-823 in the biology of MM, providing a rational for the development of piRNA-targeted therapeutic strategies in MM.
C1 [Yan, H.; Wu, Q-L; Sun, C-Y; Ai, L-S; Deng, J.; Zhang, L.; Chen, L.; Chu, Z-B; Tang, B.; Wang, K.; Wu, X-F; Xu, J.; Hu, Y.] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, Wuhan 430022, Peoples R China.
C3 Huazhong University of Science & Technology
RP Hu, Y (通讯作者)，Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Inst Hematol, 1277 Jiefang Dadao, Wuhan 430022, Peoples R China.
EM dr_huyu@126.com
RI Wang, Kang/IAN-8518-2023
OI Wu, Qiuling/0000-0001-6488-5731
FU National Natural Science Funds for Distinguished Young Scholar
   [30825018]; Important New Drug Discovery [2011ZX09302-002]; Scientific
   Research Foundation for the Returned Overseas Chinese Scholars
FX This work was supported by National Natural Science Funds for
   Distinguished Young Scholar (no. 30825018, for YH); Important New Drug
   Discovery (no. 2011ZX09302-002, for YH); Scientific Research Foundation
   for the Returned Overseas Chinese Scholars (no. 02.07.060246, for Q-LW);
   National Natural Sciences Foundation of P. R. China (no. 30500686, for
   Q-LW) and National Natural Sciences Foundation of P. R. China (no.
   81272625, for C-YS). We thank Professor Jun-Ming Guo from Ningbo
   University School of Medicine for proving valuable suggestions about
   qRT-PCR analysis of piRNA-823, as well as Shun-Chang Zhou from
   Department of Experimental Animals, Tongji Medical College, Huazhong
   University of Science and Technology and members of our laboratories for
   stimulating discussion.
CR Amodio N, 2012, ONCOTARGET, V3, P1246
   Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916
   Aravin AA, 2008, MOL CELL, V31, P785, DOI 10.1016/j.molcel.2008.09.003
   Aravin AA, 2008, GENE DEV, V22, P970, DOI 10.1101/gad.1669408
   Aravin AA, 2007, SCIENCE, V316, P744, DOI 10.1126/science.1142612
   Cheng J, 2012, CANCER LETT, V315, P12, DOI 10.1016/j.canlet.2011.10.004
   Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015
   Chi JX, 2011, BIOL DIRECT, V6, DOI 10.1186/1745-6150-6-23
   Chim CS, 2010, CARCINOGENESIS, V31, P745, DOI 10.1093/carcin/bgq033
   Chim CS, 2008, CLIN LYMPHOMA MYELOM, V8, P331, DOI 10.3816/CLM.2008.n.048
   Chim CS, 2007, J CLIN PATHOL, V60, P104, DOI 10.1136/jcp.2006.036715
   Chim CS, 2005, LEUKEMIA, V19, P2352, DOI 10.1038/sj.leu.2403904
   Chim CS, 2003, LEUKEMIA, V17, P2533, DOI 10.1038/sj.leu.2403133
   Chng WJ, 2007, BEST PRACT RES CL HA, V20, P571, DOI 10.1016/j.beha.2007.08.004
   Claudio PP, 2001, CANCER RES, V61, P462
   Cui L, 2011, CLIN BIOCHEM, V44, P1050, DOI 10.1016/j.clinbiochem.2011.06.004
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Galm O, 2004, LEUKEMIA, V18, P1687, DOI 10.1038/sj.leu.2403434
   Gibson SL, 2003, CANCER RES, V63, P742
   Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917
   Greipp PR, 2005, J CLIN ONCOL, V23, P3412, DOI 10.1200/JCO.2005.04.242
   Grivna ST, 2006, GENE DEV, V20, P1709, DOI 10.1101/gad.1434406
   Grochola LF, 2008, BRIT J CANCER, V99, P1083, DOI 10.1038/sj.bjc.6604653
   He W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-426
   Hellebrekers DMEI, 2006, MOL CANCER THER, V5, P467, DOI 10.1158/1535-7163.MCT-05-0417
   Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hu Y, 2007, CANCER GENET CYTOGEN, V178, P1, DOI 10.1016/j.cancergencyto.2007.05.028
   Huang G, 2013, CLIN TRANSL ONCOL, V15, P563, DOI 10.1007/s12094-012-0966-0
   Janic A, 2010, SCIENCE, V330, P1824, DOI 10.1126/science.1195481
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kaiser MF, 2013, BLOOD, V122, P219, DOI 10.1182/blood-2013-03-487884
   Krämer AK, 2002, LEUKEMIA, V16, P1844, DOI 10.1038/sj.leu.2402609
   Kuramochi-Miyagawa S, 2008, GENE DEV, V22, P908, DOI 10.1101/gad.1640708
   Lamorte S, 2012, LEUKEMIA, V26, P1081, DOI 10.1038/leu.2011.290
   Law PTY, 2013, J HEPATOL, V58, P1165, DOI 10.1016/j.jhep.2013.01.032
   Lee JH, 2010, CANCER RES, V70, P4569, DOI 10.1158/0008-5472.CAN-09-2670
   Lee JH, 2006, HUM MOL GENET, V15, P201, DOI 10.1093/hmg/ddi430
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257
   Park G, 2011, ANN HEMATOL, V90, P73, DOI 10.1007/s00277-010-1043-9
   Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005
   Rajkumar SV, 2000, CLIN CANCER RES, V6, P3111
   Ria R, 2004, THROMB HAEMOSTASIS, V92, P1438, DOI 10.1160/TH04-06-0334
   Schulz P, 2008, BRIT J CANCER, V99, P110, DOI 10.1038/sj.bjc.6604457
   Siddiqi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033711
   Siddiqi S, 2012, J CELL BIOCHEM, V113, P373, DOI 10.1002/jcb.23363
   Takeuchi H, 2004, INT J CANCER, V109, P483, DOI 10.1002/ijc.11734
   Vacca A, 2003, HAEMATOLOGICA, V88, P176
   Vacca A, 2001, SEMIN ONCOL, V28, P543, DOI 10.1053/sonc.2001.28604
   Walker BA, 2011, BLOOD, V117, P553, DOI 10.1182/blood-2010-04-279539
   Wang Y, 2012, INT J CLIN EXP PATHO, V5, P315
   Watanabe T, 2011, SCIENCE, V332, P848, DOI 10.1126/science.1203919
   Wong KY, 2011, BLOOD, V118, P5901, DOI 10.1182/blood-2011-06-361022
   Wu P, 2013, BRIT J HAEMATOL, V162, P348, DOI 10.1111/bjh.12394
   Zhang H, 2013, SURG ONCOL, V22, P217, DOI 10.1016/j.suronc.2013.07.001
   Zhou HH, 2010, BIOL CELL, V102, P645, DOI 10.1042/BC20100029
   Zhu D, 2011, CANCER RES, V71, P5859, DOI 10.1158/0008-5472.CAN-11-1157
NR 57
TC 178
Z9 189
U1 1
U2 48
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD JAN
PY 2015
VL 29
IS 1
BP 196
EP 206
DI 10.1038/leu.2014.135
PG 11
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA AY6JX
UT WOS:000347673700021
PM 24732595
DA 2025-01-12
ER

PT J
AU Liu, Q
   Su, PF
   Zhao, SL
   Shyr, Y
AF Liu, Qi
   Su, Pei-Fang
   Zhao, Shilin
   Shyr, Yu
TI Transcriptome-wide signatures of tumor stage in kidney renal clear cell
   carcinoma: connecting copy number variation, methylation and
   transcription factor activity
SO GENOME MEDICINE
LA English
DT Article
ID GENE-EXPRESSION; CANCER PROGRESSION; PROSTATE-CANCER; GASTRIC-CANCER;
   BREAST-CANCER; DNA HYPOMETHYLATION; ENRICHMENT ANALYSIS;
   COLORECTAL-CANCER; BLADDER-CANCER; COLON-CANCER
AB Background: Comparative analysis of expression profiles between early and late stage cancers can help to understand cancer progression and metastasis mechanisms and to predict the clinical aggressiveness of cancer. The observed stage-dependent expression changes can be explained by genetic and epigenetic alterations as well as transcription dysregulation. Unlike genetic and epigenetic alterations, however, activity changes of transcription factors, generally occurring at the post-transcriptional or post-translational level, are hard to detect and quantify.
   Methods: Here we developed a statistical framework to infer the activity changes of transcription factors by simultaneously taking into account the contributions of genetic and epigenetic alterations to mRNA expression variations.
   Results: Applied to kidney renal clear cell carcinoma (KIRC), the model underscored the role of methylation as a significant contributor to stage-dependent expression alterations and identified key transcription factors as potential drivers of cancer progression.
   Conclusions: Integrating copy number, methylation, and transcription factor activity signatures to explain stage-dependent expression alterations presented a precise and comprehensive view on the underlying mechanisms during KIRC progression.
C1 [Liu, Qi; Zhao, Shilin; Shyr, Yu] Vanderbilt Univ, Sch Med, Ctr Quantitat Sci, Nashville, TN 37232 USA.
   [Liu, Qi] Vanderbilt Univ, Sch Med, Dept Biomed Informat, Nashville, TN 37232 USA.
   [Su, Pei-Fang] Natl Cheng Kung Univ, Dept Stat, Tainan 70101, Taiwan.
   [Shyr, Yu] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA.
   [Shyr, Yu] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA.
   [Shyr, Yu] Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China.
C3 Vanderbilt University; Vanderbilt University; National Cheng Kung
   University; Vanderbilt University; Vanderbilt University; Shanghai Jiao
   Tong University
RP Shyr, Y (通讯作者)，Vanderbilt Univ, Sch Med, Ctr Quantitat Sci, Nashville, TN 37232 USA.
EM yu.shyr@vanderbilt.edu
RI Liu, Qi/KLZ-9389-2024; Shyr, Yu/KSM-5348-2024; Zhao,
   Shilin/KLZ-4937-2024
OI Zhao, Shilin/0000-0002-3921-3965; Shyr, Yu/0000-0003-2086-9670
FU National Cancer Institute [U01 CA163056, P30 CA068485, P50 CA098131, P50
   CA090949]
FX The authors wish to thank reviewers for valuable comments and Margot
   Bjoring for editorial work on this manuscript. This work was supported
   by National Cancer Institute grants U01 CA163056, P30 CA068485, P50
   CA098131, and P50 CA090949 (to YS).
CR Aishima S, 2007, HUM PATHOL, V38, P1819, DOI 10.1016/j.humpath.2007.04.016
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Baty F, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-178
   Belaguli NS, 2010, NEOPLASIA, V12, P856, DOI 10.1593/neo.10224
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Boorsma A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003112
   Boulesteix AL, 2005, THEOR BIOL MED MODEL, V2, DOI 10.1186/1742-4682-2-23
   Caldwell JT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068601
   Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111
   Chang DZ, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-15
   Chen J, 2013, CANCER LETT, V330, P217, DOI 10.1016/j.canlet.2012.11.051
   Cheng C, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-225
   Cheng C, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-452
   Cravo M, 1996, GUT, V39, P434, DOI 10.1136/gut.39.3.434
   Cui JA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017819
   Di Vinci A, 2012, TRANSL RES, V160, P355, DOI 10.1016/j.trsl.2012.05.007
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Fransson S, 2013, INT J ONCOL, V42, P609, DOI 10.3892/ijo.2012.1732
   Gao F, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-31
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Huang Y, 2009, EUR UROL, V56, P690, DOI 10.1016/j.eururo.2008.10.014
   Kaiser MF, 2013, BLOOD, V122, P219, DOI 10.1182/blood-2013-03-487884
   Keniry M, 2013, GENE DEV, V27, P916, DOI 10.1101/gad.214049.113
   Khaja ASS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072210
   Kim J, 2012, CELL CYCLE, V11, P1123, DOI 10.4161/cc.11.6.19550
   Kim M, 2012, MOL CANCER RES, V10, P1419, DOI 10.1158/1541-7786.MCR-12-0361
   Kim Tae-Min, 2006, In Silico Biology, V6, P531
   Kinney SRM, 2008, MOL CANCER RES, V6, P1365, DOI 10.1158/1541-7786.MCR-08-0040
   Kinney SRM, 2010, MOL CELL BIOL, V30, P4159, DOI 10.1128/MCB.00235-10
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Liu BY, 2013, J BIOL CHEM, V288, P24581, DOI 10.1074/jbc.M113.467506
   Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100
   Maienschein-Cline M, 2012, BIOINFORMATICS, V28, P206, DOI 10.1093/bioinformatics/btr628
   Muntean AG, 2005, BLOOD, V106, P1223, DOI 10.1182/blood-2005-02-0551
   Oue N, 2006, CANCER-AM CANCER SOC, V106, P1250, DOI 10.1002/cncr.21754
   Panse J, 2008, BRIT J CANCER, V99, P930, DOI 10.1038/sj.bjc.6604621
   Pazienza V, 2012, PPAR RES, V2012, DOI 10.1155/2012/560846
   Pournara I, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-61
   Rahman MA, 2013, CLIN CANCER RES, V19, P3416, DOI 10.1158/1078-0432.CCR-13-0073
   Roven C, 2003, NUCLEIC ACIDS RES, V31, P3487, DOI 10.1093/nar/gkg630
   Salem C, 2000, CANCER RES, V60, P2473
   Scolz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051259
   Setty M, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2012.37
   Shen F, 2013, ONCOL REP, V30, P1355, DOI 10.3892/or.2013.2544
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tanaka K, 2009, INT J CANCER, V124, P1072, DOI 10.1002/ijc.24065
   Thomas A, 2013, CANCER MED-US, V2, P836, DOI 10.1002/cam4.152
   Tsujimoto H, 2010, GASTRIC CANCER, V13, P212, DOI 10.1007/s10120-010-0568-x
   Uchida F, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-321
   Vaquerizas JM, 2009, NAT REV GENET, V10, P252, DOI 10.1038/nrg2538
   Wang J, 2013, NUCLEIC ACIDS RES, V41, pW77, DOI 10.1093/nar/gkt439
   Wang LM, 2012, CHINESE MED J-PEKING, V125, P2151, DOI 10.3760/cma.j.issn.0366-6999.2012.12.013
   Weijts BGMW, 2012, EMBO J, V31, P3871, DOI 10.1038/emboj.2012.231
   Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441
   Yeo ZX, 2009, J COMPUT BIOL, V16, P357, DOI 10.1089/cmb.2008.19TT
   Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhu MZ, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-504
NR 62
TC 9
Z9 12
U1 0
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD DEC 11
PY 2014
VL 6
AR 117
DI 10.1186/s13073-014-0117-z
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AZ3ZW
UT WOS:000348163200001
PM 25648588
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Khushi, M
   Clarke, CL
   Graham, JD
AF Khushi, Matloob
   Clarke, Christine L.
   Graham, J. Dinny
TI Bioinformatic analysis of cis-regulatory interactions between
   progesterone and estrogen receptors in breast cancer
SO PEERJ
LA English
DT Article
DE Transcription factors; Estrogen receptor alpha; Progesterone receptor;
   ER alpha; ESR1; PR; Breast cancer; T47D; BiSA; Genomic region database
ID TRANSCRIPTION FACTOR-BINDING; CHIP-SEQ; ALPHA; FOXA1; PROLIFERATION;
   PROTEINS; REVEALS; SITES
AB Chromatin factors interact with each other in a cell and sequence-specific manner in order to regulate transcription and a wealth of publically available datasets exists describing the genomic locations of these interactions. Our recently published BiSA (Binding Sites Analyser) database contains transcription factor binding locations and epigenetic modifications collected from published studies and provides tools to analyse stored and imported data. Using BiSA we investigated the overlapping cis-regulatory role of estrogen receptor alpha (ER alpha) and progesterone receptor (PR) in the T-47D breast cancer cell line. We found that ER alpha binding sites overlap with a subset of PR binding sites. To investigate further, we re-analysed raw data to remove any biases introduced by the use of distinct tools in the original publications. We identified 22,152 PR and 18,560 ER alpha binding sites (<5% false discovery rate) with 4,358 overlapping regions among the two datasets. BiSA statistical analysis revealed a non-significant overall overlap correlation between the two factors, suggesting that ER alpha and PR are not partner factors and do not require each other for binding to occur. However, Monte Carlo simulation by Binary Interval Search (BITS), Relevant Distance, Absolute Distance, Jaccard and Projection tests by Genometricorr revealed a statistically significant spatial correlation of binding regions on chromosome between the two factors. Motif analysis revealed that the shared binding regions were enriched with binding motifs for ER alpha, PR and a number of other transcription and pioneer factors. Some of these factors are known to co-locate with ER alpha and PR binding. Therefore spatially close proximity of ER alpha binding sites with PR binding sites suggests that ER alpha and PR, in general function independently at the molecular level, but that their activities converge on a specific subset of transcriptional targets.
C1 [Khushi, Matloob; Clarke, Christine L.; Graham, J. Dinny] Univ Sydney, Ctr Canc Res, Sydney Med School Westmead, Westmead Millennium Inst, Sydney, NSW 2006, Australia.
C3 University of Sydney; Westmead Institute for Medical Research
RP Khushi, M (通讯作者)，Childrens Med Res Inst, Bioinformat Unit, Westmead, NSW, Australia.
EM mkhushi@uni.sydney.edu.au
RI Clarke, Christine/B-7127-2009; Khushi, Matloob/H-2725-2019
OI Graham, Dinny/0000-0002-0269-0493; Khushi, Matloob/0000-0001-7792-2327;
   Clarke, Christine/0000-0001-7568-111X
FU Australian Postgraduate Award (APA); Westmead Medical Research
   Foundation (WMRF)
FX MK was previously supported by Australian Postgraduate Award (APA) and
   Westmead Medical Research Foundation (WMRF) Top-Up scholarship. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abdel-Hafiz HA, 2014, J STEROID BIOCHEM, V140, P80, DOI 10.1016/j.jsbmb.2013.12.008
   [Anonymous], ONCOGENE IN PRESS
   Augello MA, 2011, EMBO J, V30, P3885, DOI 10.1038/emboj.2011.340
   Ballaré C, 2013, MOL CELL, V49, P67, DOI 10.1016/j.molcel.2012.10.019
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bernardo GM, 2012, BIOSCIENCE REP, V32, P113, DOI 10.1042/BSR20110046
   Bulger M, 2011, CELL, V144, P327, DOI 10.1016/j.cell.2011.01.024
   Bulun SE, 2014, FERTIL STERIL, V101, P323, DOI 10.1016/j.fertnstert.2013.12.022
   Cadoo KA, 2013, Q J NUCL MED MOL IM, V57, P312
   Calo E, 2013, MOL CELL, V49, P825, DOI 10.1016/j.molcel.2013.01.038
   Cerami EG, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-497
   CHALBOS D, 1982, J CLIN ENDOCR METAB, V55, P276, DOI 10.1210/jcem-55-2-276
   Chikina MD, 2012, BIOINFORMATICS, V28, P607, DOI 10.1093/bioinformatics/bts009
   Clarke CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035859
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   D'Abreo N, 2013, VITAM HORM, V93, P99, DOI 10.1016/B978-0-12-416673-8.00001-0
   Favorov A, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002529
   Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111
   Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86
   Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36
   Gu F, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-170
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hu M, 2010, NUCLEIC ACIDS RES, V38, P2154, DOI 10.1093/nar/gkp1180
   Hurtado A, 2008, NATURE, V456, P663, DOI 10.1038/nature07483
   Hynes NE, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2406
   Ishikawa H, 2010, ENDOCRINOLOGY, V151, P2433, DOI 10.1210/en.2009-1225
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Kalkman S, 2014, AM J CLIN PATHOL, V142, P16, DOI 10.1309/AJCP96YDQSTYBXWU
   Kerpedjiev P, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-100
   Kharchenko PV, 2008, NAT BIOTECHNOL, V26, P1351, DOI 10.1038/nbt.1508
   Khushi M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087301
   Kim JJ, 2013, ENDOCR REV, V34, P130, DOI 10.1210/er.2012-1043
   Kittler R, 2013, CELL REP, V3, P538, DOI 10.1016/j.celrep.2013.01.004
   Ladunga I, 2010, METHODS MOL BIOL, V674, P1, DOI 10.1007/978-1-60761-854-6_1
   Lal G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073953
   Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539
   Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Layer RM, 2013, BIOINFORMATICS, V29, P1, DOI 10.1093/bioinformatics/bts652
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Lunter G, 2011, GENOME RES, V21, P936, DOI 10.1101/gr.111120.110
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   Mesrouze Y, 2014, CHEMBIOCHEM, V15, P537, DOI 10.1002/cbic.201300715
   Motallebipour M, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r129
   Nakshatri H, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001008
   Obiorah IE, 2014, STEROIDS, V90, P60, DOI 10.1016/j.steroids.2014.06.003
   Orr N, 2012, NAT GENET, V44, P1182, DOI 10.1038/ng.2417
   Penault-Llorca F, 2012, ANN ONCOL, V23, P19, DOI 10.1093/annonc/mds190
   Pepke S, 2009, NAT METHODS, V6, pS22, DOI [10.1038/NMETH.1371, 10.1038/nmeth.1371]
   Salehnia M, 2013, INT J FERTIL STERIL, V7, P74
   Schmidt D, 2010, GENOME RES, V20, P578, DOI 10.1101/gr.100479.109
   Shao RJ, 2014, AM J TRANSL RES, V6, P104
   Ström A, 2004, P NATL ACAD SCI USA, V101, P1566, DOI 10.1073/pnas.0308319100
   TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315
   Tsai WW, 2010, NATURE, V468, P927, DOI 10.1038/nature09542
   Wang CY, 2011, MOL ENDOCRINOL, V25, P1527, DOI 10.1210/me.2011-1037
   Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006
   Wang L, 2014, INT J BIOL SCI, V10, P563, DOI 10.7150/ijbs.8579
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Wilbanks EG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011471
   Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807
   Xia Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091770
   Xie W, 2013, CELL, V153, P1134, DOI 10.1016/j.cell.2013.04.022
   Yadav BS, 2014, WORLD J CLIN ONCOL, V5, P125, DOI 10.5306/wjco.v5.i2.125
   Yin P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029021
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 68
TC 10
Z9 11
U1 0
U2 7
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD NOV 18
PY 2014
VL 2
AR e654
DI 10.7717/peerj.654
PG 20
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AY5QG
UT WOS:000347626300002
PM 25426335
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Chen, S
   Chen, JZ
   Zhan, Q
   Zhu, Y
   Chen, H
   Deng, XX
   Hou, ZY
   Shen, BY
   Chen, YL
   Peng, CH
AF Chen, Shi
   Chen, Jiangzhi
   Zhan, Qian
   Zhu, Yi
   Chen, Hao
   Deng, Xiaxing
   Hou, Zhaoyuan
   Shen, Baiyong
   Chen, Yanling
   Peng, Chenghong
TI H2AK119Ub1 and H3K27Me3 in molecular staging for survival prediction of
   patients with pancreatic ductal adenocarcinoma
SO ONCOTARGET
LA English
DT Article
DE histone modification; molecular staging; prognosis; pancreatic cancer
ID COVALENT HISTONE MODIFICATIONS; GROUP PROTEIN EZH2; BREAST-CANCER;
   REPRESSION; PROGNOSIS; PATTERNS; CELLS
AB Polycomb group (PcG) proteins Ring1B and EZH2, which have been characterized as catalyzing the two epigenetic modifications H2AK119 monoubiquitination (H2AK119Ub1) and H3K27 trimethylation (H3K27Me3), are well-known epigenetic silencers implicated in embryonic development and tumorigenesis. However, the status of polycomb-associated histone modifications and their clinical implications in pancreatic cancer remain unclear. Here, we performed immunohistochemistry on tissue microarrays (TMAs) containing 80 pairs of human pancreatic cancer specimens to assess the expression levels of Ring1B, H2AK119Ub1, EZH2, and H3K27Me3 in tumors. More than 50% of the tumor cells showed a high expression of H2AK119Ub1, Ring1B, and EZH2, whereas more than 50% of the tumor cells showed a low level of H3K27Me3. Different expression patterns of H2AK119Ub1 and H3K27Me3 in tumors were negatively correlated (r = -0.247, P = 0.027). Both H2AK119Ub1 and H3K27Me3 independently predicted the clinical prognosis. In particular, a combinatorial pattern of elevated H2AK119Ub1 and decreased H3K27Me3 in tumors was significantly correlated with a poorer prognosis. Furthermore, compared to the tumor, lymph node, metastasis (TNM) staging system, histone modifications can discriminate the survival difference more accurately, especially for patients with stage I or stage II tumors. Simultaneous silencing of Ring1B and EZH2 via shRNA depleted H2AK119Ub1 and H3K27Me3 in the pancreatic cancer cells PanC1 and AsPC1, enhanced HOX gene derepression, and inhibited tumor cell growth in vitro and in tumor xenograft models. These results demonstrated that H2AK119Ub1 and H3K27Me3 cooperate in tumors and are associated with the clinical prognosis in combinatorial patterns. We have proposed that epigenetic modifications may serve as discriminatory biomarkers for molecular staging of pancreatic cancer.
C1 [Chen, Shi; Chen, Jiangzhi; Zhan, Qian; Zhu, Yi; Chen, Hao; Deng, Xiaxing; Shen, Baiyong; Peng, Chenghong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp, Shanghai 200030, Peoples R China.
   [Chen, Jiangzhi; Chen, Yanling] Fujian Med Univ, Dept Hepatobiliary Surg, Union Hosp, Fujian Inst Hepatobiliary Surg, Fuzhou, Peoples R China.
   [Chen, Shi] Fujian Med Univ, Fujian Prov Hosp, Dept Hepatobiliary Surg, Fuzhou, Peoples R China.
   [Hou, Zhaoyuan] Shanghai Jiao Tong Univ, Sch Med, Dept Biochem & Mol Cell Biol, Shanghai Key Lab Tumor Microenvironm & Inflammat, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; Fujian Medical University; Fujian Medical
   University; Fujian Provincial Hospital; Shanghai Jiao Tong University
RP Peng, CH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp, Shanghai 200030, Peoples R China.
EM drchenyl@126.com; chhpeng@188.com
RI Zhang, Jiacheng/HTS-3961-2023; chen, huan/GXZ-8858-2022; chen,
   yanling/GRE-8287-2022; chen, shuai/GXG-9235-2022
OI Peng, Chenghong/0000-0002-5573-7873; Chen, Shi/0000-0002-8207-7479
FU National Science Foundation of China [31170938]; Shanghai Committee of
   Science and Technology [11JC1407800]; Fujian Health Department
   [2013-1-2]
FX We thank Ms. Guiping Li, Xuemei Yang, and Minmin Shi for technical help
   with immunohistochemistry, scoring and imaging; and Yanyan Song for
   statistical analysis. This work was supported by the National Science
   Foundation of China (grant no. 31170938 to C. Peng), the Shanghai
   Committee of Science and Technology (grant no. 11JC1407800 to C. Peng),
   and the Youth Grant of Fujian Health Department (grant no. 2013-1-2 to
   S. Chen).
CR [Anonymous], ONCOTARGET
   Barlesi F, 2007, J CLIN ONCOL, V25, P4358, DOI 10.1200/JCO.2007.11.2599
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Camp RL, 2004, CLIN CANCER RES, V10, P7252, DOI 10.1158/1078-0432.CCR-04-0713
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Cross NCP, 2012, ONCOTARGET, V3, P3
   Dancey CP, 2006, Estatistica Sem Matematica para Psicologia: Usando SPSS para Windows
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Endoh M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002774
   Eschrich S, 2005, J CLIN ONCOL, V23, P3526, DOI 10.1200/JCO.2005.00.695
   Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575
   Hamidi T, 2012, CLIN CANCER RES, V18, P5234, DOI 10.1158/1078-0432.CCR-12-0026
   Hansen KH, 2008, NAT CELL BIOL, V10, P1291, DOI 10.1038/ncb1787
   Hirabayashi Y, 2009, NEURON, V63, P600, DOI 10.1016/j.neuron.2009.08.021
   Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07
   Kim SY, 2006, DEVELOPMENT, V133, P4957, DOI 10.1242/dev.02677
   Kleeff J, 1998, J CLIN INVEST, V102, P1662, DOI 10.1172/JCI4105
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Martínez-Romero C, 2009, J PATHOL, V219, P205, DOI 10.1002/path.2585
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shivers SC, 1998, JAMA-J AM MED ASSOC, V280, P1410, DOI 10.1001/jama.280.16.1410
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Tavares L, 2012, CELL, V148, P664, DOI 10.1016/j.cell.2011.12.029
   Terranova R, 2008, DEV CELL, V15, P668, DOI 10.1016/j.devcel.2008.08.015
   Tzao C, 2009, MODERN PATHOL, V22, P252, DOI 10.1038/modpathol.2008.172
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vidal M, 2009, INT J DEV BIOL, V53, P355, DOI 10.1387/ijdb.082690mv
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
NR 33
TC 26
Z9 33
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 15
PY 2014
VL 5
IS 21
BP 10421
EP 10433
DI 10.18632/oncotarget.2126
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AZ2AL
UT WOS:000348036900017
PM 25431952
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Chinaranagari, S
   Sharma, P
   Chaudhary, J
AF Chinaranagari, Swathi
   Sharma, Pankaj
   Chaudhary, Jaideep
TI EZH2 dependent H3K27me3 is involved in epigenetic silencing of ID4 in
   prostate cancer
SO ONCOTARGET
LA English
DT Article
DE ID4; EZH2; epigenetics; H3K27me3; prostate cancer
ID GROUP PROTEIN EZH2; ABERRANT DNA METHYLATION; TUMOR-SUPPRESSOR GENES;
   PROMOTER METHYLATION; DIFFERENTIATION 4; BREAST-CANCER; CELL-LINES;
   EXPRESSION; ADENOCARCINOMA; REPRESSION
AB Inhibitor of DNA binding/differentiation protein 4 (ID4) is dominant negative helix loop helix transcriptional regulator is epigenetically silenced due to promoter hyper-methylation in many cancers including prostate. However, the underlying mechanism involved in epigenetic silencing of ID4 is not known. Here, we demonstrate that ID4 promoter methylation is initiated by EZH2 dependent trimethylation of histone 3 at lysine 27 (H3K27me3). ID4 expressing (LNCaP) and non-expressing (DU145 and C81) prostate cancer cell lines were used to investigate EZH2, H3K27me3 and DNMT1 enrichment on ID4 promoter by Chromatin immunoprecipitation (ChIP). Enrichment of EZH2, H3K27Me3 and DNMT1 in DU145 and C81 cell lines compared to ID4 expressing LNCaP cell line. Knockdown of EZH2 in DU145 cell line led to re-expression of ID4 and decrease in enrichment of EZH2, H3K27Me3 and DNMT1 demonstrating that ID4 is regulated in an EZH2 dependent manner. ChIP data on prostate cancer tissue specimens and cell lines suggested EZH2 occupancy and H3K27Me3 marks on the ID4 promoter. Collectively, our data indicate a PRC2 dependent mechanism in ID4 promoter silencing in prostate cancer through recruitment of EZH2 and a corresponding increase in H3K27Me3. Increased EZH2 but decreased ID4 expression in prostate cancer strongly supports this model.
C1 [Chinaranagari, Swathi; Sharma, Pankaj; Chaudhary, Jaideep] Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Atlanta, GA 30314 USA.
C3 Clark Atlanta University
RP Chaudhary, J (通讯作者)，Clark Atlanta Univ, Ctr Canc Res & Therapeut Dev, Atlanta, GA 30314 USA.
EM jchaudhary@cau.edu
RI SHARMA, PANKAJ/JVO-4476-2024
FU NIH/NCI [CA128914]; NIH/NCRR/RCMI [G12RR03062]
FX The work was supported by NIH/NCI CA128914 (JC) and in part by
   NIH/NCRR/RCMI G12RR03062.
CR Asirvatham AJ, 2006, PROSTATE, V66, P921, DOI 10.1002/pros.20366
   Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248
   Borinstein SC, 2010, MOL CARCINOGEN, V49, P94, DOI 10.1002/mc.20581
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Carey JP, 2013, ANTICANCER RES, V33, P4271
   Carey JPW, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-173
   Carvalho B, 2012, CELL ONCOL, V35, P53, DOI 10.1007/s13402-011-0065-1
   Castro M, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-86
   Chan ASW, 2003, ONCOGENE, V22, P6946, DOI 10.1038/sj.onc.1206799
   Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551
   Chen SS, 2011, BLOOD, V117, P862, DOI 10.1182/blood-2010-05-284638
   Claus R, 2012, EPIGENETICS-US, V7, P772, DOI 10.4161/epi.20299
   Del Pulgar TG, 2008, INT J ONCOL, V33, P185
   Delcuve GP, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-5
   Fanelli M, 2011, NAT PROTOC, V6, P1905, DOI 10.1038/nprot.2011.406
   Goldman M, 2013, NUCLEIC ACIDS RES, V41, pD949, DOI 10.1093/nar/gks1008
   Gu ZP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044033
   Hagiwara K, 2007, J CLIN EXP HEMATOP, V47, P15, DOI 10.3960/jslrt.47.15
   Hernández-Muñoz I, 2005, MOL CELL BIOL, V25, P11047, DOI 10.1128/MCB.25.24.11047-11058.2005
   Hoffmann MJ, 2007, CANCER BIOL THER, V6, P1403, DOI 10.4161/cbt.6.9.4542
   Hu Hong-Bo, 2010, Zhongguo Dang Dai Er Ke Za Zhi, V12, P940
   Huang JH, 2011, J BIOL CHEM, V286, P44424, DOI 10.1074/jbc.M111.277046
   Karanikolas BDW, 2010, PROSTATE, V70, P675, DOI 10.1002/pros.21112
   Knowell AE, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-161
   Komashko Vitalina M, 2010, Epigenetics, V5, P229
   Kumar A, 2013, ARTERIOSCLEROSIS THR
   Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939
   Liu Fei, 2012, Zhongguo Zhong Xi Yi Jie He Za Zhi, V32, P471
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Martini M, 2013, CANCER-AM CANCER SOC, V119, P1004, DOI 10.1002/cncr.27821
   Noetzel E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-154
   PAGLIUCA A, 1995, GENOMICS, V27, P200, DOI 10.1006/geno.1995.1026
   Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668
   Patel D., 2014, MOL ENDOCRINOL
   Patel K, 2010, NUCLEIC ACIDS RES, V38, P4313, DOI 10.1093/nar/gkq187
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Ruchusatsawat K, 2011, HUM PATHOL, V42, P1878, DOI 10.1016/j.humpath.2011.02.005
   Sellers WR, 2002, CANCER CELL, V2, P349, DOI 10.1016/S1535-6108(02)00187-3
   Sharma P, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-67
   Sharma P, 2012, CANCER MED-US, V1, P187, DOI 10.1002/cam4.19
   Sharma P, 2012, CANCER MED-US, V1, P176, DOI 10.1002/cam4.16
   Shin YJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030393
   Smallwood A, 2007, GENE DEV, V21, P1169, DOI 10.1101/gad.1536807
   Smith E, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-75
   Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387
   Uhm KO, 2008, ONCOL RES, V17, P151, DOI 10.3727/096504008785114110
   Uhm KO, 2009, J KOREAN MED SCI, V24, P493, DOI 10.3346/jkms.2009.24.3.493
   Umetani N, 2004, CLIN CANCER RES, V10, P7475, DOI 10.1158/1078-0432.CCR-04-0689
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vinarskaja A, 2012, WORLD J UROL, V30, P319, DOI 10.1007/s00345-011-0750-8
   Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang H, 2010, LEUKEMIA RES, V34, P598, DOI 10.1016/j.leukres.2009.09.031
   Wang Li-Fang, 2011, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V19, P1388
   Yang YA, 2013, PROTEIN CELL, V4, P331, DOI 10.1007/s13238-013-2093-2
   Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521
NR 59
TC 48
Z9 52
U1 0
U2 12
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 30
PY 2014
VL 5
IS 16
BP 7172
EP 7182
DI 10.18632/oncotarget.2262
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AZ0EX
UT WOS:000347920100053
PM 25115397
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Brunquell, J
   Yuan, J
   Erwin, A
   Westerheide, SD
   Xue, B
AF Brunquell, Jessica
   Yuan, Jia
   Erwin, Aqeela
   Westerheide, Sandy D.
   Xue, Bin
TI DBC1/CCAR2 and CCAR1 Are Largely Disordered Proteins that Have Evolved
   from One Common Ancestor
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID MOLECULAR RECOGNITION FEATURES; PREDICTING INTRINSIC DISORDER;
   SEQUENCE-BASED PREDICTION; BREAST CANCER-1; BINDING; DBC1; REGIONS;
   SIRT1; EVOLUTION; DOMAINS
AB Deleted in breast cancer 1 (DBC1, CCAR2, KIAA1967) is a large, predominantly nuclear, multidomain protein that modulates gene expression by inhibiting several epigenetic modifiers, including the deacetylases SIRT1 and HDAC3, and the methyltransferase SUV39H1. DBC1 shares many highly conserved protein domains with its paralog cell cycle and apoptosis regulator 1 (CCAR1, CARP-1). In this study, we examined the full-length sequential and structural properties of DBC1 and CCAR1 from multiple species and correlated these properties with evolution. Our data shows that the conserved domains shared between DBC1 and CCAR1 have similar domain structures, as well as similar patterns of predicted disorder in less-conserved intrinsically disordered regions. Our analysis indicates similarities between DBC1, CCAR1, and the nematode protein lateral signaling target 3 (LST-3), suggesting that DBC1 and CCAR1 may have evolved from LST-3. Our data also suggests that DBC1 emerged later in evolution than CCAR1. DBC1 contains regions that show less conservation across species as compared to the same regions in CCAR1, suggesting a continuously evolving scenario for DBC1. Overall, this study provides insight into the structure and evolution of DBC1 and CCAR1, which may impact future studies on the biological functions of these proteins.
C1 [Brunquell, Jessica; Yuan, Jia; Erwin, Aqeela; Westerheide, Sandy D.; Xue, Bin] Univ S Florida, Coll Arts & Sci, Dept Cell Biol Microbiol & Mol Biol, Tampa, FL 33620 USA.
C3 State University System of Florida; University of South Florida
RP Westerheide, SD (通讯作者)，Univ S Florida, Coll Arts & Sci, Dept Cell Biol Microbiol & Mol Biol, 4202 East Fowler Ave,ISA 2015, Tampa, FL 33620 USA.
EM swesterheide@usf.edu; binxue@usf.edu
RI xue, bin/E-5617-2011
FU Department of Cell Biology, Microbiology and Molecular Biology and
   College of Arts and Sciences at the University of South Florida
FX This work was supported by start-up grants from the Department of Cell
   Biology, Microbiology and Molecular Biology and College of Arts and
   Sciences at the University of South Florida to Sandy D. Westerheide and
   Bin Xue.
CR Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8
   ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999
   Anantharaman V, 2008, CELL CYCLE, V7, P1467, DOI 10.4161/cc.7.10.5883
   Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6
   Benkert P, 2008, PROTEINS, V71, P261, DOI 10.1002/prot.21715
   Borcherds W, 2013, PROTEINS, V81, P1686, DOI 10.1002/prot.24303
   Brown CJ, 2011, CURR OPIN STRUC BIOL, V21, P441, DOI 10.1016/j.sbi.2011.02.005
   Brown CJ, 2010, MOL BIOL EVOL, V27, P609, DOI 10.1093/molbev/msp277
   Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9
   Camacho C, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-421
   Campen A, 2008, PROTEIN PEPTIDE LETT, V15, P956, DOI 10.2174/092986608785849164
   Chemes LB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047661
   Chen JW, 2006, J PROTEOME RES, V5, P879, DOI 10.1021/pr060048x
   Chen JW, 2006, J PROTEOME RES, V5, P888, DOI 10.1021/pr060049p
   Cheng YG, 2007, BIOCHEMISTRY-US, V46, P13468, DOI 10.1021/bi7012273
   Chini CCS, 2013, BIOCHEM J, V451, P453, DOI 10.1042/BJ20121085
   Chini CCS, 2010, J BIOL CHEM, V285, P40830, DOI 10.1074/jbc.M110.153270
   Daughdrill GW, 2007, J MOL EVOL, V65, P277, DOI 10.1007/s00239-007-9011-2
   Dawson DA, 2007, MOL BIOL EVOL, V24, P1537, DOI 10.1093/molbev/msm071
   De S, 2009, GENOME RES, V19, P785, DOI 10.1101/gr.086165.108
   Deng X, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-436
   Dosztányi Z, 2005, BIOINFORMATICS, V21, P3433, DOI 10.1093/bioinformatics/bti541
   Dunker A K, 2000, Genome Inform Ser Workshop Genome Inform, V11, P161
   Dunker AK, 2005, FEBS J, V272, P5129, DOI 10.1111/j.1742-4658.2005.04948.x
   Dunker AK, 2001, J MOL GRAPH MODEL, V19, P26, DOI 10.1016/S1093-3263(00)00138-8
   Engström PG, 2007, GENOME RES, V17, P1898, DOI 10.1101/gr.6669607
   Ribeiro MF, 2013, CATAL TODAY, V218, P1, DOI 10.1016/j.cattod.2013.10.050
   Gray KA, 2013, NUCLEIC ACIDS RES, V41, pD545, DOI 10.1093/nar/gks1066
   Gypas F, 2013, BIOINFORMATICS, V29, P2517, DOI 10.1093/bioinformatics/btt427
   Hamaguchi M, 2002, P NATL ACAD SCI USA, V99, P13647, DOI 10.1073/pnas.212516099
   He B, 2009, CELL RES, V19, P929, DOI 10.1038/cr.2009.87
   Hegyi H, 2001, GENOME RES, V11, P1632, DOI 10.1101/gr. 183801
   Hsu WL, 2013, PROTEIN SCI, V22, P258, DOI 10.1002/pro.2207
   Hsu WL, 2012, BIOCOMPUT-PAC SYM, P116
   Hubbard BP, 2013, CELL CYCLE, V12, P2233, DOI 10.4161/cc.25268
   Iakoucheva LM, 2002, J MOL BIOL, V323, P573, DOI 10.1016/S0022-2836(02)00969-5
   Ishida T, 2008, BIOINFORMATICS, V24, P1344, DOI 10.1093/bioinformatics/btn195
   Ispolatov I, 2005, NUCLEIC ACIDS RES, V33, P3629, DOI 10.1093/nar/gki678
   Jeong CS, 2012, BIOCOMPUT-PAC SYM, P140
   Källberg M, 2012, NAT PROTOC, V7, P1511, DOI 10.1038/nprot.2012.085
   Kang H, 2011, MOL CELL, V44, P203, DOI 10.1016/j.molcel.2011.07.038
   Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500
   Kim JE, 2009, CELL CYCLE, V8, P2932
   Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001
   Kotta-Loizou I, 2013, BBA-PROTEINS PROTEOM, V1834, P798, DOI 10.1016/j.bbapap.2013.01.006
   Kozlowski LP, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-111
   Li ZY, 2009, J BIOL CHEM, V284, P10361, DOI 10.1074/jbc.M900956200
   Magrane M, 2011, DATABASE-OXFORD, DOI 10.1093/database/bar009
   Mahani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075057
   Malaney P, 2013, SCI REP-UK, V3, DOI 10.1038/srep02035
   Marchler-Bauer A, 2011, NUCLEIC ACIDS RES, V39, pD225, DOI 10.1093/nar/gkq1189
   Mizianty MJ, 2010, BIOINFORMATICS, V26, pi489, DOI 10.1093/bioinformatics/btq373
   Mohan A, 2006, J MOL BIOL, V362, P1043, DOI 10.1016/j.jmb.2006.07.087
   Neukirch S, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.038105
   Nin V, 2012, J BIOL CHEM, V287, P23489, DOI 10.1074/jbc.M112.365874
   Oates ME, 2013, NUCLEIC ACIDS RES, V41, pD508, DOI 10.1093/nar/gks1226
   Obradovic Z, 2003, PROTEINS, V53, P566, DOI 10.1002/prot.10532
   Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P12454, DOI 10.1021/bi050736e
   Oldfield CJ, 2005, BIOCHEMISTRY-US, V44, P1989, DOI 10.1021/bi047993o
   Park SH, 2013, APOPTOSIS, V18, P949, DOI 10.1007/s10495-013-0847-1
   Peng K, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-208
   Peng Kang, 2005, Journal of Bioinformatics and Computational Biology, V3, P35, DOI 10.1142/S0219720005000886
   Peng ZL, 2014, CELL MOL LIFE SCI, V71, P1477, DOI 10.1007/s00018-013-1446-6
   Poyatos JF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r233
   Prilusky J, 2005, BIOINFORMATICS, V21, P3435, DOI 10.1093/bioinformatics/bti537
   Raynes R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054364
   Rishi AK, 2003, J BIOL CHEM, V278, P33422, DOI 10.1074/jbc.M303173200
   Rogozin IB, 2004, BRIEF BIOINFORM, V5, P131, DOI 10.1093/bib/5.2.131
   Romero P, 2001, PROTEINS, V42, P38, DOI 10.1002/1097-0134(20010101)42:1<38::AID-PROT50>3.0.CO;2-3
   Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5
   Schlessinger A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004433
   Söding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408
   Sun XL, 2011, PLANT MOL BIOL, V77, P205, DOI 10.1007/s11103-011-9803-z
   Sundararajan R, 2005, ONCOGENE, V24, P4908, DOI 10.1038/sj.onc.1208681
   Szalkowski AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020488
   Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121
   Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.0.CO;2-7
   Uversky VN, 2005, J MOL RECOGNIT, V18, P343, DOI 10.1002/jmr.747
   Vucetic S, 2003, PROTEINS, V52, P573, DOI 10.1002/prot.10437
   Waterhouse RM, 2013, NUCLEIC ACIDS RES, V41, pD358, DOI 10.1093/nar/gks1116
   Wood M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057354
   Wrabl JO, 2011, BIOPHYS CHEM, V159, P129, DOI 10.1016/j.bpc.2011.05.020
   Xue B, 2013, BBA-PROTEINS PROTEOM, V1834, P725, DOI 10.1016/j.bbapap.2013.01.012
   Xue B, 2012, J BIOMOL STRUCT DYN, V30, P137, DOI 10.1080/07391102.2012.675145
   Xue B, 2012, CELL MOL LIFE SCI, V69, P1211, DOI 10.1007/s00018-011-0859-3
   Xue B, 2012, MOL BIOSYST, V8, P134, DOI 10.1039/c1mb05163f
   Xue B, 2010, INT J MOL SCI, V11, P3725, DOI 10.3390/ijms11103725
   Xue B, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-S1-S1
   Xue B, 2010, BBA-PROTEINS PROTEOM, V1804, P996, DOI 10.1016/j.bbapap.2010.01.011
   Xue B, 2009, FEBS LETT, V583, P1469, DOI 10.1016/j.febslet.2009.03.070
   Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347
   Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515
NR 92
TC 21
Z9 26
U1 0
U2 4
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 418458
DI 10.1155/2014/418458
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AY8OL
UT WOS:000347813000001
PM 25610865
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, HY
   Park, JH
   Won, HY
   Lee, JY
   Kong, G
AF Kim, Hey-Yon
   Park, Ji-Hye
   Won, Hee-Young
   Lee, Jeong-Yeon
   Kong, Gu
TI CBX7 inhibits breast tumorigenicity through DKK-1-mediated suppression
   of the Wnt/β-catenin pathway
SO FASEB JOURNAL
LA English
DT Article
DE polycomb; self-renewal pathway; p300; acetylation
ID POLYCOMB GROUP PROTEINS; STEM-CELLS; CHROMOBOX PROTEIN;
   TUMOR-SUPPRESSOR; CANCER CELLS; SIGNALING PATHWAY; EXPRESSION; GENE;
   DICKKOPF-1; CARCINOMA
AB Polycomb protein chromobox homolog 7 (CBX7) is involved in several biologic processes including stem cell regulation and cancer development, but its roles in breast cancer remain unknown. Here, we demonstrate that CBX7 negatively regulates breast tumor initiation. CD44(+)/CD24(-)/ESA(+) breast stem-like cells showed diminished CBX7 expression. Furthermore, small hairpin RNA-mediated CBX7 knockdown in breast epithelial and cancer cells increased the CD44(+)/CD24(-)/ESA(+) cell population and reinforced in vitro self-renewal and in vivo tumor-initiating ability. Similarly, CBX7 overexpression repressed these effects. We also found that CBX7 inhibits the Wnt/b-catenin/T cell factor pathway by enhancing the expression of Dickkopf-1 (DKK-1), a Wnt antagonist. In particular, CBX7 increased DKK-1 transcription by cooperating with p300 acetyltransferase and subsequently enhancing the histone acetylation of the DKK-1 promoter. Furthermore, pharmacologic inhibition of DKK-1 in CBX7-overexpressing cells showed recovery of Wnt signaling and consequent rescue of the CD44(+)/CD24(-)/ESA(+) cell population. Taken together, these findings indicate that CBX7-mediated epigenetic induction of DKK-1 is crucial for the inhibition of breast tumorigenicity, suggesting that CBX7 could be a potential tumor suppressor in human breast cancer.
C1 [Kim, Hey-Yon; Won, Hee-Young; Kong, Gu] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea.
   [Park, Ji-Hye; Lee, Jeong-Yeon; Kong, Gu] Hanyang Univ, Inst Bioengn & Biopharmaceut Res, Seoul 133791, South Korea.
C3 Hanyang University; Hanyang University
RP Kong, G (通讯作者)，Hanyang Univ, Coll Med, Dept Pathol, 17 Haengdang Dong, Seoul 133791, South Korea.
EM jy2jy2@hanyang.ac.kr; gkong@hanyang.ac.kr
CR Agur Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024225
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Aloia L, 2013, DEVELOPMENT, V140, P2525, DOI 10.1242/dev.091553
   Arima Y, 2012, INT J CANCER, V130, P2568, DOI 10.1002/ijc.26271
   Bafico A, 2001, NAT CELL BIOL, V3, P683, DOI 10.1038/35083081
   Bernard D, 2005, ONCOGENE, V24, P5543, DOI 10.1038/sj.onc.1208735
   Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002
   Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931
   Dees C, 2014, ANN RHEUM DIS, V73, P1232, DOI 10.1136/annrheumdis-2012-203194
   Endoh M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002774
   Federico A, 2009, CANCER RES, V69, P7079, DOI 10.1158/0008-5472.CAN-09-1542
   Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982
   Forzati F, 2012, CELL CYCLE, V11, P1888, DOI 10.4161/cc.20022
   Forzati F, 2012, J CLIN INVEST, V122, P612, DOI 10.1172/JCI58620
   Gil J, 2004, NAT CELL BIOL, V6, P67, DOI 10.1038/ncb1077
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Hinz S, 2008, TUMOR BIOL, V29, P323, DOI 10.1159/000170879
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang ZB, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075007, 10.1371/journal.pone.0070077]
   Hussain M, 2009, CANCER RES, V69, P3570, DOI 10.1158/0008-5472.CAN-08-2807
   Jiang Z, 2010, J GASTROENTEROL, V45, P17, DOI 10.1007/s00535-009-0135-6
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Karamitopoulou E, 2010, EUR J CANCER, V46, P1438, DOI 10.1016/j.ejca.2010.01.033
   Klauke K, 2013, NAT CELL BIOL, V15, P353, DOI 10.1038/ncb2701
   Lamb R, 2013, CELL CYCLE, V12, P2384, DOI 10.4161/cc.25403
   Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53
   Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Liu SL, 2014, STEM CELL REP, V2, P78, DOI 10.1016/j.stemcr.2013.11.009
   Mansueto Gelsomina, 2010, Genes Cancer, V1, P210, DOI 10.1177/1947601910366860
   Min JR, 2003, GENE DEV, V17, P1823, DOI 10.1101/gad.269603
   Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065
   Morey L, 2012, CELL STEM CELL, V10, P47, DOI 10.1016/j.stem.2011.12.006
   Neth P, 2006, STEM CELLS, V24, P1892, DOI 10.1634/stemcells.2005-0503
   O'Loghlen A, 2012, CELL STEM CELL, V10, P33, DOI 10.1016/j.stem.2011.12.004
   Pallante P, 2008, CANCER RES, V68, P6770, DOI 10.1158/0008-5472.CAN-08-0695
   Pallante P, 2010, EUR J CANCER, V46, P2304, DOI 10.1016/j.ejca.2010.05.011
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Rawson JB, 2012, NUTR CANCER, V64, P919, DOI 10.1080/01635581.2012.711418
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84
   Scott CL, 2007, P NATL ACAD SCI USA, V104, P5389, DOI 10.1073/pnas.0608721104
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Vibhakar R, 2007, NEURO-ONCOLOGY, V9, P135, DOI 10.1215/15228517-2006-038
   Wang JL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003769
   Yao H, 2011, EXPERT OPIN THER TAR, V15, P873, DOI 10.1517/14728222.2011.577418
   Zhang XW, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-114
NR 48
TC 57
Z9 62
U1 0
U2 11
PU FEDERATION AMER SOC EXP BIOL
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD JAN
PY 2015
VL 29
IS 1
BP 300
EP 313
DI 10.1096/fj.14-253997
PG 14
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA AY1UX
UT WOS:000347378600028
PM 25351982
DA 2025-01-12
ER

PT J
AU Petrau, C
   Cornic, M
   Bertrand, P
   Maingonnat, C
   Marchand, V
   Picquenot, JM
   Jardin, F
   Clatot, F
AF Petrau, Camille
   Cornic, Marie
   Bertrand, Philippe
   Maingonnat, Catherine
   Marchand, Vinciane
   Picquenot, Jean-Michel
   Jardin, Fabrice
   Clatot, Florian
TI <i>CD70</i>: A Potential Target in Breast Cancer?
SO JOURNAL OF CANCER
LA English
DT Article
DE breast cancer; CD70; DNA methylation; mRNA expression; q-RT-PCR;
   antibody-drug conjugate
ID RENAL-CELL CARCINOMA; THERAPEUTIC TARGET; OVARIAN CARCINOMAS;
   EXPRESSION; IDENTIFICATION; PROGRESSION; AURISTATIN; APOPTOSIS;
   SURVIVAL; IMMUNITY
AB CD70 is a co-stimulatory molecule involved in the immune response and also in cancer development and progression. Recent studies show that high CD70 expression in cancer cells may inhibit the anti-tumor response. Furthermore, CD70 expression has been reported as a predictive marker of resistance to chemotherapy in ovarian cancers. Some in vitro studies have shown that CD70 expression is epigenetically down-regulated through hypermethylation of its promoter during tumoral progression. This study evaluated the level of CD70 expression in surgical samples of breast invasive tumors and determined its correlation with CD70 promoter methylation.
   Twenty "luminal A" and 20 "basal-like" frozen samples from early breast tumors were retrospectively selected. CD70 expression was evaluated by quantitative real-time PCR. Total DNA was bisulfite-treated, and methylation levels of 5 consecutive CG sites present in the proximal region (-464, -421) of the promoter were assessed by pyrosequencing analysis. Statistical analyses were performed using the Mann-Whitney test.
   The median relative CD70 expression level was 0.37 and was significantly higher in the basal-like group (0.78 [0.24-31.7]) compared to the luminal A group (0.25 [0.03-1.83], p=0.0001). The median methylation level was 61%, with no significant difference between the basal-like (63%) and luminal A (58%) groups. No correlation was found between CD70 expression and CD70 methylation level.
   In this study, higher CD70 expression was observed in the basal-like group, but this expression was not related to promoter methylation. The higher expression in the poor-prognosis subgroup of patients makes CD70 a potential target for emerging anti-CD70 therapies.
C1 [Petrau, Camille; Clatot, Florian] Ctr Henri Becquerel, Dept Med Oncol, F-76038 Rouen, France.
   [Cornic, Marie; Picquenot, Jean-Michel] Ctr Henri Becquerel, Dept Pathol, F-76038 Rouen, France.
   [Bertrand, Philippe; Maingonnat, Catherine; Marchand, Vinciane; Picquenot, Jean-Michel; Jardin, Fabrice; Clatot, Florian] Ctr Henri Becquerel, INSERM U918, IRIB, Rouen, France.
C3 UNICANCER; Centre Henri Becquerel; UNICANCER; Centre Henri Becquerel;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UNICANCER; Centre Henri Becquerel
RP Petrau, C (通讯作者)，Ctr Henri Becquerel, Dept Med Oncol, 1 Rue Amiens, F-76038 Rouen, France.
EM camillepetrau@yahoo.fr
RI Clatot, Florian/AAC-1280-2020; Clatot, Florian/K-9146-2017
OI Clatot, Florian/0000-0002-7074-9282
CR Aulwurm S, 2006, INT J CANCER, V118, P1728, DOI 10.1002/ijc.21544
   Bertrand P, 2013, GENE CHROMOSOME CANC, V52, P764, DOI 10.1002/gcc.22072
   BOWMAN MR, 1994, J IMMUNOL, V152, P1756
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Cormary C, 2004, CANCER GENE THER, V11, P497, DOI 10.1038/sj.cgt.7700708
   Douin-Echinard V, 2003, INT IMMUNOL, V15, P359, DOI 10.1093/intimm/dxg038
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Grewal IS, 2008, EXPERT OPIN THER TAR, V12, P341, DOI 10.1517/14728222.12.3.341
   Jilaveanu LB, 2012, HUM PATHOL, V43, P1394, DOI 10.1016/j.humpath.2011.10.014
   Law CL, 2006, CANCER RES, V66, P2328, DOI 10.1158/0008-5472.CAN-05-2883
   Liu NF, 2013, ONCOTARGETS THER, V6, P615, DOI 10.2147/OTT.S44445
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu QJ, 2005, J IMMUNOL, V174, P6212, DOI 10.4049/jimmunol.174.10.6212
   Oflazoglu E, 2008, CLIN CANCER RES, V14, P6171, DOI 10.1158/1078-0432.CCR-08-0916
   PARDOLL DM, 1993, IMMUNOL TODAY, V14, P310, DOI 10.1016/0167-5699(93)90051-L
   Rhee DK, 2008, GENOMICS, V92, P419, DOI 10.1016/j.ygeno.2008.08.005
   Ryan MC, 2010, BRIT J CANCER, V103, P676, DOI 10.1038/sj.bjc.6605816
   Wischhusen J, 2002, CANCER RES, V62, P2592
   Yu SE, 2010, MOL CELLS, V29, P217, DOI 10.1007/s10059-010-0052-9
NR 19
TC 13
Z9 16
U1 0
U2 10
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2014
VL 5
IS 9
BP 761
EP 764
DI 10.7150/jca.10360
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY4OF
UT WOS:000347557400006
PM 25368676
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Connolly, RM
   Leal, JP
   Goetz, MP
   Zhang, Z
   Zhou, XC
   Jacobs, LK
   Mhlanga, J
   O, JH
   Carpenter, J
   Storniolo, AM
   Watkins, S
   Fetting, JH
   Miller, RS
   Sideras, K
   Jeter, SC
   Walsh, B
   Powers, P
   Zorzi, J
   Boughey, JC
   Davidson, NE
   Carey, LA
   Wolff, AC
   Khouri, N
   Gabrielson, E
   Wahl, RL
   Stearns, V
AF Connolly, Roisin M.
   Leal, Jeffrey P.
   Goetz, Matthew P.
   Zhang, Zhe
   Zhou, Xian C.
   Jacobs, Lisa K.
   Mhlanga, Joyce
   O, Joo H.
   Carpenter, John
   Storniolo, Anna Maria
   Watkins, Stanley
   Fetting, John H.
   Miller, Robert S.
   Sideras, Kostandinos
   Jeter, Stacie C.
   Walsh, Bridget
   Powers, Penny
   Zorzi, Jane
   Boughey, Judy C.
   Davidson, Nancy E.
   Carey, Lisa A.
   Wolff, Antonio C.
   Khouri, Nagi
   Gabrielson, Edward
   Wahl, Richard L.
   Stearns, Vered
TI TBCRC 008: Early Change in <SUP>18</SUP>F-FDG Uptake on PET Predicts
   Response to Preoperative Systemic Therapy in Human Epidermal Growth
   Factor Receptor 2-Negative Primary Operable Breast Cancer
SO JOURNAL OF NUCLEAR MEDICINE
LA English
DT Article
DE neoadjuvant; breast cancer; F-18-FDG PET; biomarker; vorinostat
ID PATHOLOGICAL COMPLETE RESPONSE; HISTONE DEACETYLASE INHIBITOR;
   NEOADJUVANT CHEMOTHERAPY; RECOMMENDATIONS; PACLITAXEL; CISPLATIN
AB Epigenetic modifiers, including the histone deacetylase inhibitor vorinostat, may sensitize tumors to chemotherapy and enhance outcomes. We conducted a multicenter randomized phase II neoadjuvant trial of carboplatin and nanoparticle albumin-bound paclitaxel (CP) with vorinostat or placebo in women with stage II/III, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, in which we also examined whether change in maximum standardized uptake values corrected for lean body mass (SULmax) on F-18-FDG PET predicted pathologic complete response (pCR) in breast and axillary lymph nodes. Methods: Participants were randomly assigned to 12 wk of preoperative carboplatin (area under the curve of 2, weekly) and nab-paclitaxel (100 mg/m(2) weekly) with vorinostat (400 mg orally daily, days 1-3 of every 7-d period) or placebo. All patients underwent 18F-FDG PET and research biopsy at baseline and on cycle 1 day 15. The primary endpoint was the pCR rate. Secondary objectives included correlation of change in tumor SULmax on 18F-FDG PET by cycle 1 day 15 with pCR and correlation of baseline and change in Ki-67 with pCR. Results: In an intent-to-treat analysis (n = 62), overall pCR was 27.4% (vorinostat, 25.8%; placebo, 29.0%). In a pooled analysis (n 5 59), we observed a significant difference in median change in SULmax 15 d after initiating preoperative therapy between those achieving pCR versus not (percentage reduction, 63.0% vs. 32.9%; P = 0.003). Patients with 50% or greater reduction in SULmax were more likely to achieve pCR, which remained statistically significant in multivariable analysis including estrogen receptor status (odds ratio, 5.1; 95% confidence interval, 1.3-22.7; P = 0.023). Differences in baseline and change in Ki-67 were not significantly different between those achieving pCR versus not. Conclusion: Preoperative CP with vorinostat or placebo is associated with similar pCR rates. Early change in SULmax on F-18-FDG PET 15 d after the initiation of preoperative therapy has potential in predicting pCR in patients with HER2-negative breast cancer. Future studies will further test F-18-FDG PET as a potential treatment-selection biomarker.
C1 [Connolly, Roisin M.; Zhang, Zhe; Zhou, Xian C.; Jacobs, Lisa K.; Fetting, John H.; Miller, Robert S.; Jeter, Stacie C.; Walsh, Bridget; Powers, Penny; Zorzi, Jane; Wolff, Antonio C.; Khouri, Nagi; Gabrielson, Edward; Wahl, Richard L.; Stearns, Vered] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA.
   [Leal, Jeffrey P.; Mhlanga, Joyce; O, Joo H.; Wahl, Richard L.] Johns Hopkins Sch Med, Div Nucl Med, Baltimore, MD 21287 USA.
   [Goetz, Matthew P.; Sideras, Kostandinos; Boughey, Judy C.] Mayo Clin, Rochester, MN USA.
   [Carpenter, John] Univ Alabama Birmingham, Birmingham, AL USA.
   [Storniolo, Anna Maria] Indiana Univ, Indianapolis, IN 46204 USA.
   [Watkins, Stanley] Anne Arundel Med Ctr, Annapolis, MD USA.
   [Davidson, Nancy E.] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
   [Davidson, Nancy E.] UPMC Canc Ctr, Pittsburgh, PA USA.
   [Carey, Lisa A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins
   University; Johns Hopkins Medicine; Mayo Clinic; University of Alabama
   System; University of Alabama Birmingham; Indiana University System;
   Indiana University Indianapolis; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; University of North
   Carolina; University of North Carolina Chapel Hill
RP Stearns, V (通讯作者)，Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,Room 144, Baltimore, MD 21287 USA.
EM vstearn1@jhmi.edu
RI Goetz, Matthew/AAH-2333-2020; Wolff, Antonio/T-8796-2019; Storniolo,
   Anna/AAB-5399-2022
OI WAHL, RICHARD L./0000-0002-7306-2590; Sideras,
   Kostandinos/0000-0002-4698-2105; Wolff, Antonio/0000-0003-3734-1063;
   Harrington, Jon/0000-0003-1293-5201
FU NCI NIH HHS [P50 CA116201, P50 CA88843, P50 CA088843, P30 CA006973, 3
   P30 CA006973, 5U01CA140204, U01 CA140204] Funding Source: Medline
CR Byrski T, 2014, BREAST CANCER RES TR, V147, P401, DOI 10.1007/s10549-014-3100-x
   Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8
   Dowsett M, 2011, JNCI-J NATL CANCER I, V103, P1656, DOI 10.1093/jnci/djr393
   Duch J, 2012, Q J NUCL MED MOL IM, V56, P291
   Ezzat AA, 2004, BRIT J CANCER, V90, P968, DOI 10.1038/sj.bjc.6601616
   Groheux D, 2012, J NUCL MED, V53, P249, DOI 10.2967/jnumed.111.094045
   Jacene HA, 2006, J NUCL MED, V47, P950
   Jacobs MA, 2011, BREAST CANCER RES TR, V128, P119, DOI 10.1007/s10549-011-1442-1
   Jung SY, 2010, ANN SURG ONCOL, V17, P247, DOI 10.1245/s10434-009-0710-3
   Kim MS, 2003, CANCER RES, V63, P7291
   Kong XN, 2011, EUR J CANCER, V47, P2084, DOI 10.1016/j.ejca.2011.06.014
   Munster PN, 2001, CANCER RES, V61, P8492
   Ramalingam SS, 2007, CLIN CANCER RES, V13, P3605, DOI 10.1158/1078-0432.CCR-07-0162
   Rousseau C, 2011, EUR J NUCL MED MOL I, V38, P1029, DOI 10.1007/s00259-011-1735-y
   Schwarz-Dose J, 2009, J CLIN ONCOL, V27, P535, DOI 10.1200/JCO.2008.17.2650
   Shankar LK, 2006, J NUCL MED, V47, P1059
   Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307
   WAHL RL, 1993, J CLIN ONCOL, V11, P2101, DOI 10.1200/JCO.1993.11.11.2101
   Wang YT, 2012, BREAST CANCER RES TR, V131, P357, DOI 10.1007/s10549-011-1780-z
   Wolff AC, 2008, J CLIN ONCOL, V26, P806, DOI 10.1200/JCO.2007.15.2983
   Wolmark N, 2001, J Natl Cancer Inst Monogr, P96
NR 21
TC 48
Z9 51
U1 0
U2 17
PU SOC NUCLEAR MEDICINE INC
PI RESTON
PA 1850 SAMUEL MORSE DR, RESTON, VA 20190-5316 USA
SN 0161-5505
EI 1535-5667
J9 J NUCL MED
JI J. Nucl. Med.
PD JAN
PY 2015
VL 56
IS 1
BP 31
EP 37
DI 10.2967/jnumed.114.144741
PG 7
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA AX9PG
UT WOS:000347233700025
PM 25476537
OA Bronze, Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Ling, CS
   Yin, KB
   Cun, STW
   Ling, FL
AF Ling, Chua Siang
   Yin, Khoo Boon
   Cun, See Too Wei
   Ling, Few Ling
TI Expression profiling of choline and ethanolamine kinases in MCF7, HCT116
   and HepG2 cells, and the transcriptional regulation by epigenetic
   modification
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE choline kinase; ethanolamine kinase; mRNA expression; quantitative
   real-time PCR; histone deacetylase inhibitor; trichostatin A; epigenetic
   modification
ID HISTONE DEACETYLASE INHIBITOR; CARNITINE PALMITOYLTRANSFERASE-I; TIME
   QUANTITATIVE PCR; GENE-EXPRESSION; TRICHOSTATIN-A; BREAST-CANCER;
   CHOLINE/ETHANOLAMINE KINASE; MULTIPLE-MYELOMA; HEPATOMA-CELLS; ALPHA
AB The function of choline kinase (CK) and ethanolamine kinase (EK) is to catalyse the phosphorylation of choline and ethanolamine, respectively, in order to yield phosphocholine (PCho) and phosphoethanolamine (PEtn). A high expression level of PCho, due to elevated CK activity, has previously been associated with malignant transformation. In the present study, a quantitative polymerase chain reaction was performed to determine the mRNA expression profiles of ck and ek mRNA variants in MCF7 breast, HCT116 colon and HepG2 liver cancer cells. The ck and ek mRNA expression profiles showed that total ck was expressed most abundantly in the HepG2 cells. The HCT116 cells exhibited the highest ck and ek1 mRNA expression levels, whereas the highest ek2 mRNA expression levels were detected in the MCF7 cells. The ck variant had higher mRNA expression levels, as compared with total ck, in both the MCF7 and HCT116 cells. Relatively low ek1 mRNA expression levels were detected, as compared with ek2 in the MCF7 cells; however, this was not observed in the HCT116 and HepG2 cells. Notably, the mRNA expression levels of ck2 were markedly low, as compared with ck1, in all three cancer cell lines. The effects of epigenetic modification on ck and ek mRNA expression, by treatment of the cells with the histone deacetylase inhibitor trichostatin A (TSA), were also investigated. The results of the present study showed that the mRNA expression levels of ck, ck and ek2 were affected by TSA. An increase >8-fold was observed in ek2 mRNA expression upon treatment with TSA, in a concentration- and time-dependent manner. In conclusion, the levels of ck and ek transcript variants in the three cancer cell lines were varied. The effects of TSA treatment on the mRNA expression levels of ck and ek imply that ck and ek mRNA expression may be regulated by epigenetic modification.
C1 [Ling, Chua Siang; Cun, See Too Wei; Ling, Few Ling] Univ Sains Malaysia, Sch Hlth Sci, Kubang Kerian 16150, Kelantan, Malaysia.
   [Yin, Khoo Boon] Univ Sains Malaysia, Inst Res Mol Med, George Town 11800, Malaysia.
C3 Universiti Sains Malaysia; Universiti Sains Malaysia
RP Ling, FL (通讯作者)，Univ Sains Malaysia, Sch Hlth Sci, Kubang Kerian 16150, Kelantan, Malaysia.
EM fewling@usm.my
RI Few, Ling/E-1964-2012; Khoo, Boon/A-9256-2011; See Too, Wei
   Cun/C-9382-2016
OI Khoo, Boon Yin/0000-0003-1915-6606; See Too, Wei Cun/0000-0003-1933-3107
FU Universiti Sains Malaysia [1001/PPSK/813034, 1001/PPSK/815101];
   Institute of Postgraduate Studies, Universiti Sains Malaysia
FX The present study was funded by the Research University Grant (no.
   1001/PPSK/813034, 1001/PPSK/815101) from the Universiti Sains Malaysia.
   Chua Siang Ling was supported by a fellowship from the Institute of
   Postgraduate Studies, Universiti Sains Malaysia. The authors of the
   present study would also like to acknowledge the technical support
   provided by the UPM, Cell Culture and Biomedicine Laboratories, School
   of Health Sciences, Universiti Sains Malaysia.
CR Al-Saffar NMS, 2006, CANCER RES, V66, P427, DOI 10.1158/0008-5472.CAN-05-1338
   Aoyama C, 2004, PROG LIPID RES, V43, P266, DOI 10.1016/j.plipres.2003.12.001
   Aoyama C, 2000, J LIPID RES, V41, P452
   Beloueche-Babari M, 2012, CANCER RES, V72, P990, DOI 10.1158/0008-5472.CAN-11-2688
   Chiba T, 2004, ONCOLOGY-BASEL, V66, P481, DOI 10.1159/000079503
   Chiba T, 2004, J HEPATOL, V41, P436, DOI 10.1016/j.jhep.2004.05.018
   Chini V, 2007, LETT APPL MICROBIOL, V45, P479, DOI 10.1111/j.1472-765X.2007.02208.x
   Chua SL, 2011, CYTOTECHNOLOGY, V63, P645, DOI 10.1007/s10616-011-9383-4
   Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293
   Fu J, 2009, ANAL SCI, V25, P675, DOI 10.2116/analsci.25.675
   Furumai R, 2011, CANCER SCI, V102, P1081, DOI 10.1111/j.1349-7006.2011.01904.x
   Gallego-Ortega D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007819
   Gang HY, 2011, PEDIATR CARDIOL, V32, P263, DOI 10.1007/s00246-011-9893-z
   Glunde K, 2006, PHARMACOGENOMICS, V7, P1109, DOI 10.2217/14622416.7.7.1109
   Gruber J, 2012, FEBS J, V279, P1915, DOI 10.1111/j.1742-4658.2012.08573.x
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19
   Heller G, 2008, CANCER RES, V68, P44, DOI 10.1158/0008-5472.CAN-07-2531
   Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200
   Katz-Brull R, 2002, JNCI-J NATL CANCER I, V94, P1197
   KENNEDY EP, 1957, ANNU REV BIOCHEM, V26, P119, DOI 10.1146/annurev.bi.26.070157.001003
   Kiss Z, 1999, CELL SIGNAL, V11, P149, DOI 10.1016/S0898-6568(98)00057-6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lykidis A, 2001, J BIOL CHEM, V276, P2174, DOI 10.1074/jbc.M008794200
   Marks PA, 2010, BBA-GENE REGUL MECH, V1799, P717, DOI 10.1016/j.bbagrm.2010.05.008
   Meng J, 2012, ONCOL REP, V28, P384, DOI 10.3892/or.2012.1793
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   Nunes MJ, 2010, J NEUROCHEM, V113, P418, DOI 10.1111/j.1471-4159.2010.06612.x
   Pfaffl M. W., 2004, AZ QUANT PCR, P89, DOI DOI 10.1186/1471-2199-11-57
   Ramírez de Molina A, 2007, LANCET ONCOL, V8, P889, DOI 10.1016/S1470-2045(07)70279-6
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Schnur N, 2007, BBA-MOL CELL BIOL L, V1771, P1271, DOI 10.1016/j.bbalip.2007.08.003
   Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430
   Tian Y, 2006, J BIOL CHEM, V281, P28438, DOI 10.1074/jbc.M605861200
   Too WCS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012999
   Wu LP, 2008, MOL CELL BIOL, V28, P3219, DOI 10.1128/MCB.01516-07
   Xenidis N, 2007, ANN ONCOL, V18, P1623, DOI 10.1093/annonc/mdm208
   Yamazaki N, 2000, J BIOL CHEM, V275, P31739, DOI 10.1074/jbc.M006322200
   Yamazaki N, 1997, FEBS LETT, V409, P401, DOI 10.1016/S0014-5793(97)00561-9
   Yang XW, 2001, CANCER RES, V61, P7025
NR 41
TC 8
Z9 9
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2015
VL 11
IS 1
BP 611
EP 618
DI 10.3892/mmr.2014.2707
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AX0OH
UT WOS:000346651100089
PM 25333818
OA Bronze
DA 2025-01-12
ER

PT J
AU Nickel, A
   Stadler, SC
AF Nickel, Annina
   Stadler, Sonja C.
TI Role of epigenetic mechanisms in epithelial-to-mesenchymal transition of
   breast cancer cells
SO TRANSLATIONAL RESEARCH
LA English
DT Article
ID LONG NONCODING RNA; E-CADHERIN EXPRESSION; ESTROGEN-RECEPTOR-ALPHA;
   TUMOR-SUPPRESSOR GENE; GROUP PROTEIN EZH2; PROMOTES METASTATIC
   COLONIZATION; HISTONE DEACETYLASE INHIBITION; TRANSCRIPTION FACTOR
   SNAIL; ACUTE MYELOID-LEUKEMIA; REGULATES E-CADHERIN
AB The epithelial-to-mesenchymal transition (EMT) is a crucial process during normal development that allows dynamic and reversible shifts between epithelial and mesenchymal cell states. Cancer cells take advantage of the complex, interrelated cellular networks that regulate EMT to promote their migratory and invasive capabilities. During the past few years, evidence has accumulated that indicates that genetic mutations and changes to epigenetic mechanisms are key drivers of EMT in cancer cells. Recent studies have begun to shed light on the epigenetic reprogramming in cancer cells that enables them to switch from a noninvasive form to an invasive, metastatic form. The authors review the current knowledge of alterations of epigenetic machinery, including DNA methylation, histone modifications, nucleosome remodeling and expression of microRNAs, associated with EMT and tumor progression of breast cancer cells. Last, existing and upcoming drug therapies targeting epigenetic regulators and their potential benefit for developing novel treatment strategies are discussed.
C1 Leipzig Univ Hosp, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany.
   Univ Leipzig, LIFE Leipzig Res Ctr Civilizat Dis, D-04103 Leipzig, Germany.
C3 Leipzig University; Leipzig University
RP Stadler, SC (通讯作者)，Univ Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Liebigstr 27, D-04103 Leipzig, Germany.
EM Sonja.Stadler@medizin.uni-leipzig.de
FU Leipzig Research Center for Civilization Diseases (LIFE); European
   Union; European Regional Development Fund (ERDF); European Social Fund
   (ESF); Free State of Saxony within the framework of the excellence
   initiative
FX The authors are supported by the Leipzig Research Center for
   Civilization Diseases (LIFE). LIFE is funded by means of the European
   Union, by the European Regional Development Fund (ERDF), by the European
   Social Fund (ESF), and by means of the Free State of Saxony within the
   framework of the excellence initiative.
CR ALLFREY VG, 1964, SCIENCE, V144, P559, DOI 10.1126/science.144.3618.559
   ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Bachman KE, 1999, CANCER RES, V59, P798
   Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Belinsky SA, 2003, CANCER RES, V63, P7089
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Berger SL, 2009, GENE DEV, V23, P781, DOI 10.1101/gad.1787609
   Bergmann JH, 2014, CURR OPIN CELL BIOL, V26, P10, DOI 10.1016/j.ceb.2013.08.005
   Bertone P, 2004, SCIENCE, V306, P2242, DOI 10.1126/science.1103388
   Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D
   Berx G, 2007, CLIN EXP METASTAS, V24, P587, DOI 10.1007/s10585-007-9114-6
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Castanon I, 2002, GENE, V287, P11, DOI 10.1016/S0378-1119(01)00893-9
   Chaffer CL, 2007, CELLS TISSUES ORGANS, V185, P7, DOI 10.1159/000101298
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Collins R, 2010, NUCLEIC ACIDS RES, V38, P3503, DOI 10.1093/nar/gkq081
   Côme C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   DAMSKY CH, 1983, CELL, V34, P455, DOI 10.1016/0092-8674(83)90379-3
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Deng S, 2008, CELL CYCLE, V7, P2643, DOI 10.4161/cc.7.17.6597
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Dobrovic A, 1997, CANCER RES, V57, P3347
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429
   Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946
   Evron E, 2001, CANCER RES, V61, P2782
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Federico M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/475641
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ficz G, 2011, NATURE, V473, P398, DOI 10.1038/nature10008
   Filipowicz W, 2005, CURR OPIN STRUC BIOL, V15, P331, DOI 10.1016/j.sbi.2005.05.006
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Friedman JM, 2009, CELL CYCLE, V8, P2313, DOI 10.4161/cc.8.15.9168
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Fu JJ, 2011, CELL RES, V21, P275, DOI 10.1038/cr.2010.118
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Gardner KE, 2011, J MOL BIOL, V409, P36, DOI 10.1016/j.jmb.2011.01.040
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x
   Grooteclaes ML, 2000, ONCOGENE, V19, P3823, DOI 10.1038/sj.onc.1203721
   Gupta GP, 2007, P NATL ACAD SCI USA, V104, P19506, DOI 10.1073/pnas.0709185104
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hajra KM, 2002, CANCER RES, V62, P1613
   Han ML, 2012, MOL CELL BIOCHEM, V363, P427, DOI 10.1007/s11010-011-1195-5
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hassler MR, 2012, BIOCHIMIE, V94, P2219, DOI 10.1016/j.biochi.2012.05.007
   Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   He L., 2004, NAT REV GENET, V5, P522
   Heaphy CM, 2011, SCIENCE, V333, P425, DOI 10.1126/science.1207313
   HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108
   Huang Y, 2007, P NATL ACAD SCI USA, V104, P8023, DOI 10.1073/pnas.0700720104
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293
   Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058
   Iorio MV, 2011, BREAST, V20, pS63, DOI 10.1016/S0960-9776(11)70297-1
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Jin CY, 2007, GENE DEV, V21, P1519, DOI 10.1101/gad.1547707
   Johnstone RW, 2003, CANCER CELL, V4, P13, DOI 10.1016/S1535-6108(03)00165-X
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kalakonda N, 2008, ONCOGENE, V27, P4293, DOI 10.1038/onc.2008.67
   Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530
   Kaminskas E, 2005, CLIN CANCER RES, V11, P3604, DOI 10.1158/1078-0432.CCR-04-2135
   Kapranov P, 2007, NAT REV GENET, V8, P413, DOI 10.1038/nrg2083
   Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341
   Kaur H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050249
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Koyanagi M, 2005, J BIOL CHEM, V280, P31470, DOI 10.1074/jbc.M504766200
   Kumar R, 2003, CELL, V113, P142, DOI 10.1016/S0092-8674(03)00274-5
   Lapidus RG, 1998, J MAMMARY GLAND BIOL, V3, P85, DOI 10.1023/A:1018778403001
   Lee JS, 2010, CELL, V142, P682, DOI 10.1016/j.cell.2010.08.011
   Lehner A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060359
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Lewis PW, 2010, P NATL ACAD SCI USA, V107, P14075, DOI 10.1073/pnas.1008850107
   Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143
   Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Lujambio A, 2009, CELL CYCLE, V8, P377, DOI 10.4161/cc.8.3.7526
   Luo DY, 2006, LAB INVEST, V86, P591, DOI 10.1038/labinvest.3700415
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, NAT BIOTECHNOL, V28, P341, DOI 10.1038/nbt.1618
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Maass PG, 2014, J MOL MED, V92, P337, DOI 10.1007/s00109-014-1131-8
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mitra D, 2011, J BIOL CHEM, V286, P40531, DOI 10.1074/jbc.M111.304865
   MOLL R, 1993, AM J PATHOL, V143, P1731
   Mongroo Perry S, 2010, Cancer Biol Ther, V10, P219
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Mullany SA, 2011, CLIN CANCER RES, V17, P427, DOI 10.1158/1078-0432.CCR-09-3069
   Nan XS, 1997, CELL, V88, P471, DOI 10.1016/S0092-8674(00)81887-5
   Narkiewicz J, 2009, ONCOL REP, V21, P1529, DOI 10.3892/or_00000385
   Nass SJ, 2000, CANCER RES, V60, P4346
   Nicholson TB, 2009, EPIGENETICS-US, V4, P129, DOI 10.4161/epi.4.3.8443
   Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   OKA H, 1993, CANCER RES, V53, P1696
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434
   Özdag H, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-90
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peinado HC, 2004, INT J DEV BIOL, V48, P365, DOI 10.1387/ijdb.041794hp
   Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131
   Pérez-Moreno MA, 2001, J BIOL CHEM, V276, P27424, DOI 10.1074/jbc.M100827200
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Roesch A, 2005, MODERN PATHOL, V18, P1249, DOI 10.1038/modpathol.3800413
   Sachdeva M, 2010, AM J TRANSL RES, V2, P170
   Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106
   Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340
   Santenard A, 2009, EPIGENETICS-US, V4, P80, DOI 10.4161/epi.4.2.7838
   Sarma K, 2005, NAT REV MOL CELL BIO, V6, P139, DOI 10.1038/nrm1567
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Satijn DPE, 1999, BBA-GENE STRUCT EXPR, V1447, P1, DOI 10.1016/S0167-4781(99)00130-X
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672
   Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200
   Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stadler SC, 2013, P NATL ACAD SCI USA, V110, P11851, DOI 10.1073/pnas.1308362110
   Stadler SC, 2012, SEMIN CANCER BIOL, V22, P404, DOI 10.1016/j.semcancer.2012.06.007
   Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3
   Straussman R, 2009, NAT STRUCT MOL BIOL, V16, P564, DOI 10.1038/nsmb.1594
   Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P
   Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tang J, 2004, J BIOL CHEM, V279, P20369, DOI 10.1074/jbc.M401321200
   Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006
   Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406
   Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699
   Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.3.CO;2-O
   URIA JA, 1994, CANCER RES, V54, P2091
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005
   Wahlestedt C, 2013, NAT REV DRUG DISCOV, V12, P433, DOI 10.1038/nrd4018
   Wang GG, 2007, TRENDS MOL MED, V13, P373, DOI 10.1016/j.molmed.2007.07.004
   Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003
   Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039446
   Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Wilhelm BT, 2008, NATURE, V453, P1239, DOI 10.1038/nature07002
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Wu G, 2012, NAT GENET, V44, P251, DOI 10.1038/ng.1102
   Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Xue YT, 2003, P NATL ACAD SCI USA, V100, P10635, DOI 10.1073/pnas.1937626100
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yan L, 2003, CANCER BIOL THER, V2, P552, DOI 10.4161/cbt.2.5.469
   Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   YOSHIURA K, 1995, P NATL ACAD SCI USA, V92, P7416, DOI 10.1073/pnas.92.16.7416
   You A, 2001, P NATL ACAD SCI USA, V98, P1454, DOI 10.1073/pnas.98.4.1454
   Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498
   Zhang H, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-37
   Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200
   Zilberman D, 2008, NATURE, V456, P125, DOI 10.1038/nature07324
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 255
TC 32
Z9 36
U1 0
U2 20
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1931-5244
EI 1878-1810
J9 TRANSL RES
JI Transl. Res.
PD JAN
PY 2015
VL 165
IS 1
BP 126
EP 142
DI 10.1016/j.trsl.2014.04.001
PG 17
WC Medical Laboratory Technology; Medicine, General & Internal; Medicine,
   Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; General & Internal Medicine; Research &
   Experimental Medicine
GA AX6FC
UT WOS:000347017600013
PM 24768944
DA 2025-01-12
ER

PT J
AU Gordon, JAR
   Montecino, MA
   Aqeilan, RI
   Stein, JL
   Stein, GS
   Lian, JB
AF Gordon, Jonathan A. R.
   Montecino, Martin A.
   Aqeilan, Rami I.
   Stein, Janet L.
   Stein, Gary S.
   Lian, Jane B.
TI Epigenetic Pathways Regulating Bone Homeostasis: Potential Targeting for
   Intervention of Skeletal Disorders
SO CURRENT OSTEOPOROSIS REPORTS
LA English
DT Article
DE Epigenetic marks in bone; DNA methylation; Histone modifications; miRNA;
   Osteoblast regulation; Osteosarcoma miRNAs
ID LONG NONCODING RNAS; MESENCHYMAL STEM-CELLS; WWOX TUMOR-SUPPRESSOR;
   TRANSCRIPTION FACTOR RUNX2; RAT OSTEOCALCIN GENE; HUMAN BREAST-CANCER;
   OSTEOGENIC DIFFERENTIATION; OSTEOBLAST DIFFERENTIATION; DNA METHYLATION;
   MICRORNA BIOGENESIS
AB Epigenetic regulation utilizes different mechanisms to convey heritable traits to progeny cells that are independent of DNA sequence, including DNA silencing, post-translational modifications of histone proteins, and the post-transcriptional modulation of RNA transcript levels by noncoding RNAs. Although long non-coding RNAs have recently emerged as important regulators of gene imprinting, their functions during osteogenesis are as yet unexplored. In contrast, microRNAs (miRNAs) are well characterized for their control of osteogenic and osteoclastic pathways; thus, further defining how gene regulatory networks essential for skeleton functions are coordinated and finely tuned through the activities of miRNAs. Roles of miRNAs are constantly expanding as new studies uncover associations with skeletal disorders. The distinct functions of epigenetic regulators and evidence for integrating their activities to control normal bone gene expression and bone disease will be presented. In addition, potential for using "signature miRNAs" to identify, manage, and therapeutically treat osteosarcoma will be discussed in this review.
C1 [Gordon, Jonathan A. R.; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.] Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.
   [Gordon, Jonathan A. R.; Stein, Janet L.; Stein, Gary S.; Lian, Jane B.] Univ Vermont, Coll Med, Vermont Canc Ctr, Burlington, VT 05405 USA.
   [Montecino, Martin A.] Univ Andres Bello, Ctr Invest Biomed, Santiago, Chile.
   [Montecino, Martin A.] Univ Andres Bello, FONDAP Ctr Genome Regulat, Santiago, Chile.
   [Aqeilan, Rami I.] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Immunol & Canc Res IMRIC, IL-91120 Jerusalem, Israel.
C3 University of Vermont; University of Vermont; Universidad Andres Bello;
   Universidad Andres Bello; Hebrew University of Jerusalem
RP Lian, JB (通讯作者)，Univ Vermont, Coll Med, Dept Biochem, 89 Beaumont Ave, Burlington, VT 05405 USA.
EM jane.lian@uvm.edu
RI Aqeilan, Rami/AAT-7785-2020; Gordon, Jonathan/B-3904-2016
OI Montecino, Martin/0000-0002-6025-0023
FU National Institutes of Health (National Cancer Institute) [P01
   CA082834]; National Institutes of Health (National Institute of Dental
   and Craniofacial Research) [R37 DE012528]; National Institutes of Health
   (National Institute of Arthritis and Musculoskeletal and Skin Diseases)
   [R01 AR039588, P01 AR048818]; US-Israel Binational Science Foundation
   [2011300]; FONDAP [15090007]
FX We thank Jennifer Diaz for manuscript preparation and formatting, and S.
   H. Ralston of the Molecular Medicine Centre and Western General Hospital
   (Edinburgh, UK) and M. L. Johnson of the University of Missouri (Kansas
   City, USA) for their review of the manuscript. The authors acknowledge
   financial support from the National Institutes of Health (National
   Cancer Institute P01 CA082834, National Institute of Dental and
   Craniofacial Research R37 DE012528, National Institute of Arthritis and
   Musculoskeletal and Skin Diseases R01 AR039588 and P01 AR048818), and
   the US-Israel Binational Science Foundation (2011300), and FONDAP
   15090007.
CR Aqeilan RI, 2008, J BIOL CHEM, V283, P21629, DOI 10.1074/jbc.M800855200
   Aslibekyan S, 2015, TRANSL RES, V165, P143, DOI 10.1016/j.trsl.2014.04.004
   Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Baglìo SR, 2013, GENE, V527, P321, DOI 10.1016/j.gene.2013.06.021
   Barter MJ, 2012, OSTEOARTHR CARTILAGE, V20, P339, DOI 10.1016/j.joca.2011.12.012
   Barter MJ, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0353-z
   Berendsen AD, 2014, CELL MOL LIFE SCI, V71, P493, DOI 10.1007/s00018-013-1440-z
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bi CL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/521586
   Bradley EW, 2011, CRIT REV EUKAR GENE, V21, P101
   Brennecke P, 2014, CLIN EXP METASTAS, V31, P339, DOI 10.1007/s10585-013-9632-3
   Browne G, 2014, TRENDS ENDOCRIN MET, V25, P320, DOI 10.1016/j.tem.2014.03.014
   Butler JS, 2012, EPIGENOMICS-UK, V4, P163, DOI [10.2217/EPI.12.3, 10.2217/epi.12.3]
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008
   Chen C, 2014, J BONE MINER RES, V29, P338, DOI 10.1002/jbmr.2032
   Chen Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058104
   Croset M, 2014, MOLECULES, V19, P10115, DOI 10.3390/molecules190710115
   Cruzat F, 2009, BIOCHEMISTRY-US, V48, P7287, DOI 10.1021/bi9004792
   Dasen JS, 2013, CELL REP, V5, P1, DOI 10.1016/j.celrep.2013.09.033
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   de Andrés MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054957
   Del Mare S, 2011, AM J CANCER RES, V1, P585
   Delgado-Calle J, 2013, ARTHRITIS RHEUM-US, V65, P197, DOI 10.1002/art.37753
   Delgado-Calle J, 2012, CURR GENOMICS, V13, P252, DOI 10.2174/138920212800543129
   Deng Y, 2013, BIOMATERIALS, V34, P6717, DOI 10.1016/j.biomaterials.2013.05.042
   Dey BK, 2014, GENE DEV, V28, P491, DOI 10.1101/gad.234419.113
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Dong SW, 2012, BIOCHEM BIOPH RES CO, V418, P587, DOI 10.1016/j.bbrc.2012.01.075
   Ell B, 2014, J BIOL CHEM, V289, P21888, DOI 10.1074/jbc.M114.582866
   Ell B, 2013, CANCER CELL, V24, P542, DOI 10.1016/j.ccr.2013.09.008
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fetahu IS, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00164
   Finnegan EF, 2013, CRIT REV BIOCHEM MOL, V48, P51, DOI 10.3109/10409238.2012.738643
   Flynn RA, 2014, CELL STEM CELL, V14, P752, DOI 10.1016/j.stem.2014.05.014
   Gámez B, 2014, J MOL ENDOCRINOL, V52, pR179, DOI 10.1530/JME-13-0294
   Gámez B, 2013, J BIOL CHEM, V288, P14264, DOI 10.1074/jbc.M112.432104
   Gaur T, 2010, DEV BIOL, V340, P10, DOI 10.1016/j.ydbio.2010.01.008
   Gordon JAR, 2010, MOL CELL BIOL, V30, P3531, DOI 10.1128/MCB.00889-09
   Gromak N, 2012, BIOCHEM SOC T, V40, P759, DOI 10.1042/BST20120023
   Gutiérrez J, 2007, J BIOL CHEM, V282, P9445, DOI 10.1074/jbc.M609847200
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Håkelien AM, 2014, STEM CELLS, V32, P2780, DOI 10.1002/stem.1759
   Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32
   Hashimoto K, 2013, J BIOL CHEM, V288, P10061, DOI 10.1074/jbc.M112.421156
   Hassan MQ, 2007, MOL CELL BIOL, V27, P3337, DOI 10.1128/MCB.01544-06
   Hassan MQ, 2012, J BIOL CHEM, V287, P42084, DOI 10.1074/jbc.M112.377515
   Hassan MQ, 2010, P NATL ACAD SCI USA, V107, P19879, DOI 10.1073/pnas.1007698107
   Hemming S, 2014, STEM CELLS, V32, P802, DOI 10.1002/stem.1573
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288
   Huang S, 2012, STEM CELLS DEV, V21, P2531, DOI 10.1089/scd.2012.0014
   Imagawa K, 2014, ARTHRITIS RHEUMATOL, V66, P3040, DOI 10.1002/art.38774
   Jeffries MA, 2014, ARTHRITIS RHEUMATOL, V66, P2804, DOI 10.1002/art.38762
   Jia J, 2013, FEBS LETT, V587, P3027, DOI 10.1016/j.febslet.2013.07.030
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663
   Kapinas K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3325
   Kawai M, 2012, J INTERN MED, V272, P317, DOI 10.1111/j.1365-2796.2012.02564.x
   Kilpinen H, 2012, HUM MOL GENET, V21, pR24, DOI 10.1093/hmg/dds383
   Kimura H, 2013, J HUM GENET, V58, P439, DOI 10.1038/jhg.2013.66
   Kohli RM, 2013, NATURE, V502, P472, DOI 10.1038/nature12750
   Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375
   Kurek KC, 2010, CANCER RES, V70, P5577, DOI 10.1158/0008-5472.CAN-09-4602
   Lee JT, 2013, CELL, V152, P1308, DOI 10.1016/j.cell.2013.02.016
   Lee JY, 2006, MOL CELLS, V22, P182
   Lehmann U, 2014, CELL TISSUE RES, V356, P657, DOI 10.1007/s00441-014-1793-0
   Lei SF, 2011, J BONE MINER RES, V26, P72, DOI 10.1002/jbmr.186
   Li EQ, 2014, MOL CELL BIOCHEM, V390, P69, DOI 10.1007/s11010-013-1957-3
   Li H, 2009, J CLIN INVEST, V119, P3666, DOI 10.1172/JCI39832
   Li J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.348
   Li LJ, 2013, CELL REP, V5, P3, DOI 10.1016/j.celrep.2013.09.003
   Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105
   Li ZY, 2009, J BIOL CHEM, V284, P15676, DOI 10.1074/jbc.M809787200
   Lian JB, 2012, NAT REV ENDOCRINOL, V8, P212, DOI 10.1038/nrendo.2011.234
   Liang WQ, 2013, FRONT BIOSCI-LANDMRK, V18, P788, DOI 10.2741/4142
   Liao L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.130
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Liu H, 2014, J CELL PHYSIOL, V229, P1494, DOI 10.1002/jcp.24591
   Luetke A, 2014, CANCER TREAT REV, V40, P523, DOI 10.1016/j.ctrv.2013.11.006
   Maire G, 2011, CANCER GENET-NY, V204, P138, DOI 10.1016/j.cancergen.2010.12.012
   Martin J. W., 2011, Sarcoma, V2011, P282745, DOI 10.1155/2011/282745
   Miao JL, 2013, TUMOR BIOL, V34, P2093, DOI 10.1007/s13277-013-0940-7
   Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s
   Montecino M, 2007, BIOCHEM CELL BIOL, V85, P419, DOI 10.1139/O07-070
   Mortus JR, 2014, ADV EXP MED BIOL, V804, P93, DOI 10.1007/978-3-319-04843-7_5
   Murr R, 2010, ADV GENET, V70, P101, DOI [10.1016/S0065-2660(10)70005-5, 10.1016/B978-0-12-380866-0.60005-8]
   Mutsaers AJ, 2014, BONE, V62, P56, DOI 10.1016/j.bone.2014.02.003
   Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028
   Ouyang L, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0340-7
   Paci P, 2014, BMC SYST BIOL, V8, DOI 10.1186/1752-0509-8-83
   Pereira BP, 2009, J CELL PHYSIOL, V221, P778, DOI 10.1002/jcp.21921
   Prosser DE, 2004, TRENDS BIOCHEM SCI, V29, P664, DOI 10.1016/j.tibs.2004.10.005
   Razidlo DF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011492
   Richardson BC, 2014, NAT REV RHEUMATOL, V10, P72, DOI 10.1038/nrrheum.2013.211
   Sadikovic B, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-202
   Sarge KD, 2005, TRENDS BIOCHEM SCI, V30, P605, DOI 10.1016/j.tibs.2005.09.004
   Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175
   Sinha KM, 2010, EMBO J, V29, P68, DOI 10.1038/emboj.2009.332
   Stankov K, 2013, PEDIATRICS, V132, P1112, DOI 10.1542/peds.2013-1652
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Sugatani T, 2013, J CELL BIOCHEM, V114, P1217, DOI 10.1002/jcb.24471
   Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood-2010-10-311415
   Taipaleenmäki H, 2012, EUR J ENDOCRINOL, V166, P359, DOI 10.1530/EJE-11-0646
   van der Deen M, 2012, J BIOL CHEM, V287, P4503, DOI 10.1074/jbc.M111.287771
   van der Eerden BCJ, 2014, ARCH BIOCHEM BIOPHYS, V561, P46, DOI 10.1016/j.abb.2014.04.016
   van Dijk SJ, 2015, INT J OBESITY, V39, P85, DOI 10.1038/ijo.2014.34
   van Wijnen AJ, 2013, CURR OSTEOPOROS REP, V11, P72, DOI 10.1007/s11914-013-0143-6
   Vance KW, 2014, TRENDS GENET, V30, P348, DOI 10.1016/j.tig.2014.06.001
   Vega RB, 2004, CELL, V119, P555, DOI 10.1016/j.cell.2004.10.024
   Villagra A, 2002, J CELL BIOCHEM, V85, P112, DOI 10.1002/jcb.10113
   Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557
   Vrtacnik P, 2014, CLIN CHEM LAB MED, V52, P589, DOI 10.1515/cclm-2013-0770
   Wang J, 2010, DEV CELL, V19, P903, DOI 10.1016/j.devcel.2010.10.022
   Wang XG, 2013, NAT MED, V19, P93, DOI 10.1038/nm.3026
   Wang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034641
   Wu H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-3-r52
   Wu L, 2010, MOL CELL, V38, P465, DOI 10.1016/j.molcel.2010.03.008
   Yang JL, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-56
   Yang L, 2012, J BONE MINER RES, V27, P1598, DOI 10.1002/jbmr.1621
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   Young DW, 2007, NATURE, V445, P442, DOI 10.1038/nature05473
   Young DW, 2005, J CELL BIOCHEM, V94, P720, DOI 10.1002/jcb.20332
   Zaidi SK, 2007, NAT REV CANCER, V7, P454, DOI 10.1038/nrc2149
   Zaidi SK, 2014, CANCER RES, V74, P420, DOI 10.1158/0008-5472.CAN-13-2837
   Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377
   Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108
   Zhou GX, 2013, J INT MED RES, V41, P1, DOI 10.1177/0300060513475959
   Zhou SH, 2013, J STEROID BIOCHEM, V136, P156, DOI 10.1016/j.jsbmb.2012.09.002
   Zhou WY, 2014, DISCOV MED, V17, P301
   Zhou Y, 2014, J STEROID BIOCHEM, V144, P207, DOI 10.1016/j.jsbmb.2013.10.004
   Zhu ED, 2008, J BIOL CHEM, V283, P7361, DOI 10.1074/jbc.M703304200
   Zhu L, 2013, BIOCHEM BIOPH RES CO, V432, P612, DOI 10.1016/j.bbrc.2013.02.036
NR 132
TC 20
Z9 25
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1544-2241
J9 CURR OSTEOPOROS REP
JI Curr. Osteoporos. Rep.
PD DEC
PY 2014
VL 12
IS 4
BP 496
EP 506
DI 10.1007/s11914-014-0240-1
PG 11
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AY0KB
UT WOS:000347284400014
PM 25260661
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Liu, R
   Jacobs, DI
   Hansen, J
   Fu, A
   Stevens, RG
   Zhu, Y
AF Liu, Ran
   Jacobs, Daniel I.
   Hansen, Johnni
   Fu, Alan
   Stevens, Richard G.
   Zhu, Yong
TI Aberrant methylation of <i>miR</i>-<i>34b</i> is associated with
   long-term shiftwork: a potential mechanism for increased breast cancer
   susceptibility
SO CANCER CAUSES & CONTROL
LA English
DT Article
DE Shiftwork; MiR-34b; Breast cancer; MicroRNAs; Methylation
ID TUMOR-SUPPRESSOR NETWORK; CPG ISLAND METHYLATION; DNA METHYLATION;
   COLORECTAL-CANCER; GENE-EXPRESSION; LUNG-CANCER; WORK; P53; MICRORNAS;
   APOPTOSIS
AB Although the evidence linking exposure to light at night (LAN) and breast cancer risk continues to accumulate, the molecular mechanisms driving this association remain to be fully elucidated. We have previously suggested that long-term exposure to LAN through shiftwork may result in dysregulated patterns of methylation genome-wide. In this study, we investigate the link between miR-34b, a miRNA suggested to be an important tumor suppressor, and shiftwork-related breast cancer.
   Methylation states in the miR-34b promoter region were previously compared between 10 female long-term shiftworkers and 10 folate intake- and age-matched female dayworkers participating in the Danish "Diet, Cancer and Health" prospective cohort study. In order to further explore the functional role of miR-34b in breast tumorigenesis, a genome-wide expression microarray was carried out in miR-34b-overexpressed MCF-7 breast cancer cells and the identified transcripts were further analyzed for network and functional interrelatedness using Ingenuity Pathway Analysis software.
   We observed a 49.1 % increase in miR-34b promoter methylation among shiftworkers at a CpG site in this region (p = 0.016). Transfection of the miR-34b mimic in an MCF-7 breast cancer cell line induced differential expression of 230 transcripts that are involved in the interferon-mediated antiviral response as well as apoptotic and antiproliferative gene networks.
   Together, our results suggest that long-term shiftwork may increase the risk of breast cancer via methylation-based suppression of miR-34b and a consequent reduction in immunomediated anti-tumor capacity and support our previous findings that LAN may induce epigenetic alteration of cancer-relevant microRNAs.
C1 [Liu, Ran; Jacobs, Daniel I.; Fu, Alan; Zhu, Yong] Yale Univ, Sch Med, Dept Environm Hlth Sci, New Haven, CT 06520 USA.
   [Liu, Ran] Southeast Univ, Sch Publ Hlth, Key Lab Environm Med Engn, Nanjing 210009, Jiangsu, Peoples R China.
   [Hansen, Johnni] Danish Canc Soc, Inst Canc Epidemiol, Copenhagen, Denmark.
   [Stevens, Richard G.] Univ Connecticut, Ctr Hlth, Farmington, CT 06030 USA.
C3 Yale University; Southeast University - China; Danish Cancer Society;
   University of Connecticut
RP Zhu, Y (通讯作者)，Yale Univ, Sch Med, Dept Environm Hlth Sci, 333 Cedar St, New Haven, CT 06520 USA.
EM yong.zhu@yale.edu
OI Hansen, Johnni/0000-0002-9342-2725
FU National Institutes of Health [ES018915, CA62006]; China Scholarship
   Council (CSC); Danish Cancer Society
FX This work was supported by the National Institutes of Health Grants
   (ES018915 and CA62006). Ran Liu's visit at Yale University was supported
   by the China Scholarship Council (CSC). The Diet, Cancer and Health
   cohort was funded by the Danish Cancer Society.
CR Åkerstedt T, 2003, OCCUP MED-OXFORD, V53, P89, DOI 10.1093/occmed/kqg046
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Boominathan L, 2010, CANCER METAST REV, V29, P613, DOI 10.1007/s10555-010-9257-9
   Calvano SE, 2005, NATURE, V437, P1032, DOI 10.1038/nature03985
   Chen XD, 2012, INT J CANCER, V130, P1607, DOI 10.1002/ijc.26171
   Chudin E, 2006, J COMPUT BIOL, V13, P996, DOI 10.1089/cmb.2006.13.996
   Corney DC, 2007, CANCER RES, V67, P8433, DOI 10.1158/0008-5472.CAN-07-1585
   Costa G, 2010, SCAND J WORK ENV HEA, V36, P163, DOI 10.5271/sjweh.2899
   Davis S, 2001, JNCI-J NATL CANCER I, V93, P1557, DOI 10.1093/jnci/93.20.1557
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Erren Thomas C, 2010, Epidemiol Perspect Innov, V7, P11, DOI 10.1186/1742-5573-7-11
   Hansen J, 2006, CANCER CAUSE CONTROL, V17, P531, DOI 10.1007/s10552-005-9006-5
   Hansen J, 2012, EUR J CANCER, V48, P1722, DOI 10.1016/j.ejca.2011.07.005
   He L, 2007, NAT REV CANCER, V7, P819, DOI 10.1038/nrc2232
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   He XY, 2007, CANCER RES, V67, P11099, DOI 10.1158/0008-5472.CAN-07-2672
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   Hermeking H, 2007, CANCER CELL, V12, P414, DOI 10.1016/j.ccr.2007.10.028
   Jacobs DI, 2013, ENVIRON MOL MUTAGEN, V54, P141, DOI 10.1002/em.21752
   Kalimutho M, 2011, BRIT J CANCER, V104, P1770, DOI 10.1038/bjc.2011.82
   Kasinski AL, 2012, CANCER RES, V72, P5576, DOI 10.1158/0008-5472.CAN-12-2001
   KIRCHHOFF S, 1993, NUCLEIC ACIDS RES, V21, P2881, DOI 10.1093/nar/21.12.2881
   Knutsson A, 2003, OCCUP MED-OXFORD, V53, P103, DOI 10.1093/occmed/kqg048
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Leucci E, 2008, J PATHOL, V216, P440, DOI 10.1002/path.2410
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Ossina NK, 1997, J BIOL CHEM, V272, P16351, DOI 10.1074/jbc.272.26.16351
   Pigazzi M, 2009, CANCER RES, V69, P2471, DOI 10.1158/0008-5472.CAN-08-3404
   Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Reed VA, 2011, AAOHN J, V59, P37, DOI 10.3928/08910162-20101216-01
   Shi FQ, 2013, ENVIRON MOL MUTAGEN, V54, P406, DOI 10.1002/em.21790
   Straif K, 2007, LANCET ONCOL, V8, P1065, DOI 10.1016/S1470-2045(07)70373-X
   Takaoka A, 2003, NATURE, V424, P516, DOI 10.1038/nature01850
   Thomas C, 2010, EUR J EPIDEMIOL, V25, P305, DOI 10.1007/s10654-010-9438-4
   Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   van Mark A, 2010, J OCCUP MED TOXICOL, V5, DOI 10.1186/1745-6673-5-18
   Wang Z, 2011, CANCER BIOL THER, V11, P490, DOI 10.4161/cbt.11.5.14550
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655
   Zhu Y, 2011, CHRONOBIOL INT, V28, P852, DOI 10.3109/07420528.2011.618896
NR 45
TC 17
Z9 22
U1 0
U2 13
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0957-5243
EI 1573-7225
J9 CANCER CAUSE CONTROL
JI Cancer Causes Control
PD FEB
PY 2015
VL 26
IS 2
BP 171
EP 178
DI 10.1007/s10552-014-0494-z
PG 8
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA AZ4IF
UT WOS:000348184100002
PM 25398683
DA 2025-01-12
ER

PT J
AU Kim, JM
   Kang, HJ
   Kim, SY
   Kim, SW
   Shin, IS
   Kim, HR
   Park, MH
   Shin, MG
   Yoon, JH
   Yoon, JS
AF Kim, Jae-Min
   Kang, Hee-Ju
   Kim, Seon-Young
   Kim, Sung-Wan
   Shin, Il-Seon
   Kim, Hye-Ran
   Park, Min-Ho
   Shin, Myung-Geun
   Yoon, Jung-Han
   Yoon, Jin-Sang
TI <i>BDNF</i> PROMOTER METHYLATION ASSOCIATED WITH SUICIDAL IDEATION IN
   PATIENTS WITH BREAST CANCER
SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE
LA English
DT Article
DE breast cancer; suicidality; BDNF; DNA methylation; epigenetics
ID TYROSINE KINASE-B; QUALITY-OF-LIFE; NEUROTROPHIC FACTOR; SEROTONIN
   TRANSPORTER; POSTMORTEM BRAIN; BEHAVIOR; EXPRESSION; DEPRESSION; GENE;
   DIAGNOSIS
AB Objective: Brain-derived neurotrophic factor (BDNF) has been considered a risk factor for suicidality. BDNF secretion is influenced by epigenetic (DNA methylation) and genetic (val66met polymorphism) profiles. We aimed to investigate the independent effects of BDNF promoter methylation status on suicidal ideation as well as the effects of its interaction with the val66met polymorphism in patients with breast cancer. Methods: A total of 279 patients with breast cancer were evaluated 1 week after breast surgery, and 244 (87%) were followed up 1 year later. Suicidal ideation was identified using the item addressing suicidal thoughts on the Beck Depression Inventory. The independent effects of BDNF methylation status on suicidal ideation at two points was investigated using multivariable logistic regression models. The two-way interactive effects of BDNF methylation status and the val66met polymorphism on suicidal ideation were also estimated using the same models. Results: Increased BDNF methylation was significantly associated with suicidal ideation and depression 1 year after breast surgery, and this association was independent of potential covariates, including previous depression, current depressive symptoms, and BDNF genotype. No significant methylation-genotype interactions were found. Conclusions: The BDNF hypothesis and the epigenetic origin of suicidality in patients with breast cancer were supported. BDNF gene methylation status may be a biological marker for suicidality in patients with breast cancer.
C1 [Kim, Jae-Min; Kang, Hee-Ju; Kim, Seon-Young; Kim, Sung-Wan; Shin, Il-Seon; Kim, Hye-Ran; Shin, Myung-Geun; Yoon, Jin-Sang] Chonnam Natl Univ, Sch Med, Gwangju 501746, South Korea.
   [Park, Min-Ho; Yoon, Jung-Han] Chonnam Natl Univ, Hwasun Hosp, Hwasun, South Korea.
C3 Chonnam National University; Chonnam National University
RP Yoon, JS (通讯作者)，Chonnam Natl Univ, Sch Med, Dept Psychiat, 160 Baekseoro, Gwangju 501746, South Korea.
EM jsyoon@chonnam.ac.kr
RI Wan, Kim/AAI-8744-2020; shin, i/JCE-1227-2023; KIM, Jae-Min/S-7637-2019
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [A120051]
FX This work was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (A120051).
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Akechi T, 2004, CANCER, V100, P183, DOI 10.1002/cncr.11890
   [Anonymous], AJCC CANC STAG HDB A
   Beck A, 1979, J CONSULT CLIN PSYCH, V47, P559
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   Bower JE, 2008, J CLIN ONCOL, V26, P768, DOI 10.1200/JCO.2007.14.3248
   Burgess C, 2005, BRIT MED J, V330, P702, DOI 10.1136/bmj.38343.670868.D3
   Chen WG, 2003, SCIENCE, V302, P885, DOI 10.1126/science.1086446
   Davies MN, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r43
   Devlin AM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012201
   Dwivedi Y, 2003, ARCH GEN PSYCHIAT, V60, P804, DOI 10.1001/archpsyc.60.8.804
   Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7
   Ernst C, 2009, ARCH GEN PSYCHIAT, V66, P22, DOI 10.1001/archpsyc.66.1.22
   Fang F, 2012, NEW ENGL J MED, V366, P1310, DOI 10.1056/NEJMoa1110307
   Fu Q, 2002, PSYCHOL MED, V32, P11, DOI 10.1017/S0033291701004846
   Fuchikami M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023881
   Hawton K, 2009, LANCET, V373, P1372, DOI [10.1016/S0140-6736(09)60372-X, 10.1016/S0140-6736(13)62118-2]
   Henningsson S, 2009, BIOL PSYCHIAT, V66, P477, DOI 10.1016/j.biopsych.2009.04.009
   Hochberg Z, 2011, ENDOCR REV, V32, P159, DOI 10.1210/er.2009-0039
   Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677
   Kang HJ, 2013, J AFFECT DISORDERS, V151, P679, DOI 10.1016/j.jad.2013.08.001
   Karege F, 2005, MOL BRAIN RES, V136, P29, DOI 10.1016/j.molbrainres.2004.12.020
   Keller S, 2010, ARCH GEN PSYCHIAT, V67, P258, DOI 10.1001/archgenpsychiatry.2010.9
   Kim JM, 2013, PSYCHO-ONCOLOGY, V22, P2848, DOI 10.1002/pon.3367
   Kim JM, 2013, J PSYCHIATR RES, V47, P1222, DOI 10.1016/j.jpsychires.2013.04.010
   Kim JM, 2013, J AFFECT DISORDERS, V149, P93, DOI 10.1016/j.jad.2013.01.008
   Kim JM, 2012, PSYCHOSOM MED, V74, P8, DOI 10.1097/PSY.0b013e318241530c
   Kim YK, 2007, PROG NEURO-PSYCHOPH, V31, P78, DOI 10.1016/j.pnpbp.2006.06.024
   Kinnally EL, 2010, GENES BRAIN BEHAV, V9, P575, DOI 10.1111/j.1601-183X.2010.00588.x
   Mann JJ, 1998, NAT MED, V4, P25, DOI 10.1038/nm0198-025
   Martinowich K, 2003, SCIENCE, V302, P890, DOI 10.1126/science.1090842
   Mill J, 2007, MOL PSYCHIATR, V12, P799, DOI 10.1038/sj.mp.4001992
   Pandey GN, 2008, INT J NEUROPSYCHOPH, V11, P1047, DOI 10.1017/S1461145708009000
   Pandey GN, 2013, BIPOLAR DISORD, V15, P524, DOI 10.1111/bdi.12089
   Pidsley R, 2011, BIOL PSYCHIAT, V69, P146, DOI 10.1016/j.biopsych.2010.03.029
   Posner K, 2011, AM J PSYCHIAT, V168, P1266, DOI 10.1176/appi.ajp.2011.10111704
   Poulter MO, 2008, BIOL PSYCHIAT, V64, P645, DOI 10.1016/j.biopsych.2008.05.028
   Reeve BB, 2012, CANCER-AM CANCER SOC, V118, P5679, DOI 10.1002/cncr.27578
   Roth TL, 2009, BIOL PSYCHIAT, V65, P760, DOI 10.1016/j.biopsych.2008.11.028
   Schairer C, 2006, JNCI-J NATL CANCER I, V98, P1416, DOI 10.1093/jnci/djj377
   Walker J, 2008, J CLIN ONCOL, V26, P4725, DOI 10.1200/JCO.2007.11.8844
   Zai CC, 2012, INT J NEUROPSYCHOPH, V15, P1037, DOI 10.1017/S1461145711001313
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 43
TC 26
Z9 27
U1 0
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0091-2174
EI 1541-3527
J9 INT J PSYCHIAT MED
JI Int. J. Psychiatr. Med.
PD FEB
PY 2015
VL 49
IS 1
BP 75
EP 94
DI 10.1177/0091217415574439
PG 20
WC Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Psychiatry
GA CG3BB
UT WOS:000353150300006
PM 25838322
DA 2025-01-12
ER

PT J
AU Luzhna, L
   Kutanzi, K
   Kovalchuk, O
AF Luzhna, Lidia
   Kutanzi, Kristy
   Kovalchuk, Olga
TI Gene expression and epigenetic profiles of mammary gland tissue: Insight
   into the differential predisposition of four rat strains to mammary
   gland cancer
SO MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
LA English
DT Article
DE Gene expression profile; Epigenetics; DNA methylation; Histone
   modifications; Mammary cancer; Susceptibility
ID GLUTATHIONE-S-TRANSFERASE; HUMAN-BREAST-CANCER; RENIN-ANGIOTENSIN
   SYSTEM; H3 LYSINE-9 METHYLATION; HISTORICAL CONTROL DATA; DE-NOVO
   METHYLATION; CPG-BINDING PROTEIN; DNA METHYLATION; HISTONE DEACETYLASE;
   PPAR-GAMMA
AB Rats are excellent experimental models for studying breast cancer, but rat strains differ in susceptibility. Among the four strains used in this study, Fischer rats are less susceptible to spontaneous breast cancer, yet they are highly prone to extremely severe metastatic and drug-resistant tumors, in those case where they actually develop the disease. In contrast, Sprague Dawley rats are the most susceptible to spontaneous breast cancer among the strains. ACI rats are highly prone to estrogen-induced cancer. Long-Evans rats are commonly used in mammary gland carcinogenesis studies. The molecular mechanisms of differential breast cancer susceptibility among rat strains are not well understood. Here, gene expression analysis was conducted in the mammary gland tissue of four rat strains - August x Copenhagen Irish (ACD, Long Evans, Fischer-344 and Sprague Dawley - to evaluate possible explanations for the differing breast cancer predispositions. According to the DAVID functional annotation analysis, there were at least eleven, five, and one significantly different pathways, respectively, in Fischer-344, Long-Evans and Sprague Dawley rats, in comparison to ACI rats. Two strains, Fischer-344 and Long-Evans, displayed differential expression in the complement and coagulation cascades, chemokine signaling, PPAR signaling, renin-angiotensin system, ECM-receptor interaction, focal adhesion and glutathione metabolism pathways. The only pathway that was significantly different between the Sprague Dawley and the ACI rats was the ribosome pathway. Our data indicate that general cancer susceptibility and predisposition to the development of aggressive and metastatic cancer are independent genetic conditions. Moreover, we have identified several important differences in the basal epigenetic profile of four rat strains with varying degrees of susceptibility to spontaneous and induced mammary carcinogenesis. (C) 2015 Published by Elsevier B.V.
C1 [Luzhna, Lidia; Kutanzi, Kristy; Kovalchuk, Olga] Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
C3 University of Lethbridge
RP Kovalchuk, O (通讯作者)，Univ Lethbridge, Dept Biol Sci, Lethbridge, AB T1K 3M4, Canada.
EM olga.kovalchuk@uleth.ca
FU Canadian Institutes for Health Research; Alberta Cancer Foundation;
   Canadian Breast Cancer Foundation Grants; Alberta Cancer Foundation
   Graduate Scholarship; Vanier Canada Graduate Scholarship; National
   Science and Engineering Research Council Graduate Scholarship; Queen
   Elizabeth II Graduate Scholarship; Alberta Heritage
FX This work was supported by the Canadian Institutes for Health Research,
   the Alberta Cancer Foundation and the Canadian Breast Cancer Foundation
   Grants to Olga Kovalchuk. Lidia Luzhna is supported by the Alberta
   Cancer Foundation Graduate Scholarship. Kristy Kutanzi was a recipient
   of the Vanier Canada Graduate Scholarship, National Science and
   Engineering Research Council Graduate Scholarship, Queen Elizabeth II
   Graduate Scholarship and the Alberta Heritage for Medical Research
   Scholarship. We are thankful to Rocio Rodriguez-Juarez, Natasha Singh
   and Jody Filkowski for technical assistance.
CR AALTOMAA S, 1993, ANTICANCER RES, V13, P785
   Ager EI, 2008, CARCINOGENESIS, V29, P1675, DOI 10.1093/carcin/bgn171
   Ahmed N, 2005, CLIN EXP METASTAS, V22, P391, DOI 10.1007/s10585-005-1262-y
   Akashi T, 2001, JPN J CANCER RES, V92, P293, DOI 10.1111/j.1349-7006.2001.tb01094.x
   Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139
   Arita K, 2008, NATURE, V455, P818, DOI 10.1038/nature07249
   Bachman AN, 2006, TOXICOL SCI, V91, P393, DOI 10.1093/toxsci/kfj155
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bagnyukova T.V., 2010, MUTAT RES
   Bagnyukovay TV, 2008, CARCINOGENESIS, V29, P638, DOI 10.1093/carcin/bgm303
   Balkwill F, 2004, SEMIN CANCER BIOL, V14, P171, DOI 10.1016/j.semcancer.2003.10.003
   Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147
   BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   BLANKENSTEIN MA, 1977, EUR J CANCER, V13, P1437, DOI 10.1016/0014-2964(77)90158-X
   Boisvert FM, 2007, NAT REV MOL CELL BIO, V8, P574, DOI 10.1038/nrm2184
   BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5
   BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0
   BROERSE JJ, 1985, INT J RADIAT BIOL, V48, P167, DOI 10.1080/09553008514551171
   Bullwinkel J, 2006, J CELL PHYSIOL, V206, P624, DOI 10.1002/jcp.20494
   Carbone R, 2006, MOL CELL BIOL, V26, P1288, DOI 10.1128/MCB.26.4.1288-1296.2006
   Chen T, 2006, CURR TOP MICROBIOL, V301, P179
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   Choi JY, 2006, PHARMACOGENOMICS, V7, P613, DOI 10.2217/14622416.7.4.613
   Clapper ML, 1998, CHEM-BIOL INTERACT, V112, P377, DOI 10.1016/S0009-2797(97)00174-9
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   CROCKER TT, 1977, IN VITRO CELL DEV B, V13, P648
   CUTTS JH, 1964, CANCER RES, V24, P1116
   CYBULSKY MI, 1988, LAB INVEST, V58, P365
   DARDENNE AJ, 1991, J PATHOL, V165, P213, DOI 10.1002/path.1711650304
   Deshayes F, 2005, TRENDS ENDOCRIN MET, V16, P293, DOI 10.1016/j.tem.2005.07.009
   DOEHMER J, 1993, CYTOTECHNOLOGY, V12, P357, DOI 10.1007/BF00744673
   Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746
   DuBois RN, 1998, CARCINOGENESIS, V19, P49, DOI 10.1093/carcin/19.1.49
   DUNNING WF, 1953, CANCER RES, V13, P147
   EDWARDS RL, 1981, J LAB CLIN MED, V98, P917
   Ertel A, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-55
   FLETCHER TM, 1995, J BIOL CHEM, V270, P25359, DOI 10.1074/jbc.270.43.25359
   Freitag M, 2005, CURR OPIN GENET DEV, V15, P191, DOI 10.1016/j.gde.2005.02.003
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Fujita M, 2002, BIOCHEM BIOPH RES CO, V294, P441, DOI 10.1016/S0006-291X(02)00496-5
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   GAMASOSA MA, 1983, BIOCHIM BIOPHYS ACTA, V740, P212, DOI 10.1016/0167-4781(83)90079-9
   GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721
   Gould KA, 2004, GENETICS, V168, P2113, DOI 10.1534/genetics.104.033878
   Gromadzinska J, 1997, NEOPLASMA, V44, P45
   Grubben MJAL, 2001, SCAND J GASTROENTERO, V36, P68, DOI 10.1080/003655201753265479
   Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042
   Hannan KM, 2011, IUBMB LIFE, V63, P79, DOI 10.1002/iub.428
   Harvell DME, 2000, P NATL ACAD SCI USA, V97, P2779, DOI 10.1073/pnas.050569097
   HASEMAN JK, 1989, FUND APPL TOXICOL, V12, P793, DOI 10.1016/0272-0590(89)90011-0
   Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519
   Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491
   He GC, 2002, MOL CELL BIOL, V22, P2965, DOI 10.1128/MCB.22.9.2965-2973.2002
   HENRY JL, 1993, CANCER RES, V53, P1403
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   HOWEEDY AA, 1990, LAB INVEST, V63, P798
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang JX, 2003, MODERN PATHOL, V16, P558, DOI 10.1097/01.MP.0000071842.83169.5A
   Jackson K, 2004, CANCER BIOL THER, V3, P1225, DOI 10.4161/cbt.3.12.1222
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561
   Kauppila S, 1998, J PATHOL, V186, P262, DOI 10.1002/(SICI)1096-9896(1998110)186:3<262::AID-PATH191>3.0.CO;2-3
   KIM YI, 1994, CANCER, V74, P893, DOI 10.1002/1097-0142(19940801)74:3<893::AID-CNCR2820740316>3.0.CO;2-B
   Kimura H, 2003, J BIOL CHEM, V278, P4806, DOI 10.1074/jbc.M209923200
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Köhl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4
   Kovalchuk O, 2007, CELL CYCLE, V6, P2010, DOI 10.4161/cc.6.16.4549
   Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Liang GN, 2004, P NATL ACAD SCI USA, V101, P7357, DOI 10.1073/pnas.0401866101
   Lin CH, 2001, CANCER RES, V61, P4238
   Linhart HG, 2007, GENE DEV, V21, P3110, DOI 10.1101/gad.1594007
   LOCHTER A, 1995, SEMIN CANCER BIOL, V6, P165, DOI 10.1006/scbi.1995.0017
   Loreto M. F., 2000, Pathology and Oncology Research, V6, P301
   Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2
   Ma PP, 2008, DEV BIOL, V319, P110, DOI 10.1016/j.ydbio.2008.04.011
   Malkas LH, 2006, P NATL ACAD SCI USA, V103, P19472, DOI 10.1073/pnas.0604614103
   Mantovani A, 2001, NOVART FDN SYMP, V234, P120
   Markiewski MM, 2008, NAT IMMUNOL, V9, P1225, DOI 10.1038/ni.1655
   Markiewski MM, 2007, TRENDS IMMUNOL, V28, P184, DOI 10.1016/j.it.2007.02.006
   Martin KJ, 1998, MOL MED, V4, P602, DOI 10.1007/BF03401760
   Milsted A, 1998, J HYPERTENS, V16, P823, DOI 10.1097/00004872-199816060-00013
   Miyara H, 1996, JPN J CLIN ONCOL, V26, P1
   Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752
   Morrow CS, 1998, CARCINOGENESIS, V19, P109, DOI 10.1093/carcin/19.1.109
   MOSCOW JA, 1989, MOL PHARMACOL, V36, P22
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Nagano Makoto, 2012, Int J Cell Biol, V2012, P310616, DOI 10.1155/2012/310616
   Nakagawa T, 2005, J UROLOGY, V173, P243, DOI 10.1097/01.ju.0000141577.98902.49
   Nakayam J, 2001, SCIENCE, V292, P110, DOI 10.1126/science.1060118
   Nakayama T, 2001, J BIOCHEM-TOKYO, V129, P491, DOI 10.1093/oxfordjournals.jbchem.a002882
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Niculescu MD, 2002, J NUTR, V132, p2333S, DOI 10.1093/jn/132.8.2333S
   NOBLE RL, 1959, CANCER RES, V19, P1125
   Nuytten M, 2008, ONCOGENE, V27, P1449, DOI 10.1038/sj.onc.1210774
   OKADA M, 1981, BRIT J CANCER, V43, P689, DOI 10.1038/bjc.1981.100
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Ostrand-Rosenberg S, 2008, CURR OPIN GENET DEV, V18, P11, DOI 10.1016/j.gde.2007.12.007
   Perquin M, 2001, J CANCER RES CLIN, V127, P368, DOI 10.1007/s004320000228
   Perra A, 2008, CARCINOGENESIS, V29, P161, DOI 10.1093/carcin/bgm205
   Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Pogribny IP, 2007, J NUTR, V137, p216S, DOI 10.1093/jn/137.1.216S
   Pupilli C, 1999, J AM SOC NEPHROL, V10, P245
   Raaphorst FM, 2003, NEOPLASIA, V5, P481, DOI 10.1016/S1476-5586(03)80032-5
   Raiche J, 2004, BIOCHEM BIOPH RES CO, V325, P39, DOI 10.1016/j.bbrc.2004.10.002
   RAMOS DM, 1990, CANCER RES, V50, P728
   Rauch TA, 2008, P NATL ACAD SCI USA, V105, P252, DOI 10.1073/pnas.0710735105
   REES ED, 1968, CANCER RES, V28, P823
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Rochat B, 2005, CLIN PHARMACOKINET, V44, P349, DOI 10.2165/00003088-200544040-00002
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Rothenburg S, 2001, IMMUNOGENETICS, V52, P231
   Rubin JB, 2009, SEMIN CANCER BIOL, V19, P116, DOI 10.1016/j.semcancer.2008.10.001
   Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015
   Russell JC, 2003, CARDIOVASC RES, V59, P810, DOI 10.1016/S0008-6363(03)00530-3
   Rutkowski MJ, 2010, MOL CANCER RES, V8, P1453, DOI 10.1158/1541-7786.MCR-10-0225
   Saez E, 2004, GENE DEV, V18, P528, DOI 10.1101/gad.1167804
   Saleh EM, 2009, CELL BIOCHEM BIOPHYS, V55, P95, DOI 10.1007/s12013-009-9058-3
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6389
   Schaffer BS, 2006, CANCER RES, V66, P7793, DOI 10.1158/0008-5472.CAN-06-0143
   SHELLABARGER CJ, 1978, JNCI-J NATL CANCER I, V61, P1505
   Shull James D, 2007, Breast Dis, V28, P69
   Shull JD, 2007, MAMM GENOME, V18, P657, DOI 10.1007/s00335-007-9052-2
   Shull JD, 2001, ENDOCRINOLOGY, V142, P5124, DOI 10.1210/en.142.12.5124
   Singer-Sam J., 1993, Experientia Supplementum (Basel), V64, P358
   Stein T, 2010, AM J PATHOL, V177, P2323, DOI 10.2353/ajpath.2010.100209
   Steinmetz KL, 1998, CARCINOGENESIS, V19, P1487, DOI 10.1093/carcin/19.8.1487
   Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005
   STONE JP, 1979, CANCER RES, V39, P773
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Szpirer C, 2007, MAMM GENOME, V18, P817, DOI 10.1007/s00335-007-9073-x
   Szyf M, 2000, ANN NY ACAD SCI, V910, P156
   Szyf Moshe, 2000, Current Drug Targets, V1, P101, DOI 10.2174/1389450003349362
   Tennekes H, 2004, REGUL TOXICOL PHARM, V40, P293, DOI 10.1016/j.yrtph.2004.07.007
   Tennekes H, 2004, REGUL TOXICOL PHARM, V40, P18, DOI 10.1016/j.yrtph.2004.04.003
   Tonini T, 2004, ONCOGENE, V23, P4930, DOI 10.1038/sj.onc.1207608
   Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237
   Townsend DM, 2003, ONCOGENE, V22, P7369, DOI 10.1038/sj.onc.1206940
   Trinh BN, 2002, MOL CELL BIOL, V22, P2906, DOI 10.1128/MCB.22.9.2906-2917.2002
   Tse C, 1998, MOL CELL BIOL, V18, P4629, DOI 10.1128/MCB.18.8.4629
   Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008
   Turker MS, 1997, MUTAT RES-REV MUTAT, V386, P119, DOI 10.1016/S1383-5742(96)00048-8
   Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100
   Ungefroren H, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-18
   van der Hel OL, 2005, CANCER CAUSE CONTROL, V16, P675, DOI 10.1007/s10552-005-1227-0
   Vinson GP, 2012, ENDOCR-RELAT CANCER, V19, pR1, DOI 10.1530/ERC-11-0335
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Vo AT, 2012, OBSTET GYNECOL INT, V2012, DOI 10.1155/2012/602720
   VOGEL HH, 1982, RADIAT RES, V89, P264, DOI 10.2307/3575772
   Walczak R, 2002, J LIPID RES, V43, P177
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506
   WALTON JR, 1975, AGENTS ACTIONS, V5, P69, DOI 10.1007/BF02027163
   Wang XY, 2001, J BIOL CHEM, V276, P12764, DOI 10.1074/jbc.M100501200
   Watts GS, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-47
   Wilkinson J, 1997, P SOC EXP BIOL MED, V216, P192
   Wright AT, 2007, CHEM BIOL, V14, P1043, DOI 10.1016/j.chembiol.2007.08.008
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Zeisel SH, 2008, BRAIN RES, V1237, P5, DOI 10.1016/j.brainres.2008.08.059
NR 172
TC 7
Z9 8
U1 0
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1383-5718
EI 1879-3592
J9 MUTAT RES-GEN TOX EN
JI Mutat. Res. Genet. Toxicol. Environ. Mutagen.
PD FEB
PY 2015
VL 779
BP 39
EP 56
DI 10.1016/j.mrgentox.2014.07.006
PG 18
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA CF6NK
UT WOS:000352673200006
PM 25813725
DA 2025-01-12
ER

PT J
AU Stirzaker, C
   Zotenko, E
   Song, JZ
   Qu, W
   Nair, SS
   Locke, WJ
   Stone, A
   Armstong, NJ
   Robinson, MD
   Dobrovic, A
   Avery-Kiejda, KA
   Peters, KM
   French, JD
   Stein, S
   Korbie, DJ
   Trau, M
   Forbes, JF
   Scott, RJ
   Brown, MA
   Francis, GD
   Clark, SJ
AF Stirzaker, Clare
   Zotenko, Elena
   Song, Jenny Z.
   Qu, Wenjia
   Nair, Shalima S.
   Locke, Warwick J.
   Stone, Andrew
   Armstong, Nicola J.
   Robinson, Mark D.
   Dobrovic, Alexander
   Avery-Kiejda, Kelly A.
   Peters, Kate M.
   French, Juliet D.
   Stein, Sandra
   Korbie, Darren J.
   Trau, Matt
   Forbes, John F.
   Scott, Rodney J.
   Brown, Melissa A.
   Francis, Glenn D.
   Clark, Susan J.
TI Methylome sequencing in triple-negative breast cancer reveals distinct
   methylation clusters with prognostic value
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DNA METHYLATION; TUMOR-SUPPRESSOR; EPIGENETIC INACTIVATION;
   HIGH-THROUGHPUT; GENE SIGNATURE; CPG ISLANDS; EXPRESSION; GENOME;
   HYPERMETHYLATION; SENSITIVITY
AB Epigenetic alterations in the cancer methylome are common in breast cancer and provide novel options for tumour stratification. Here, we perform whole-genome methylation capture sequencing on small amounts of DNA isolated from formalin-fixed, paraffin-embedded tissue from triple-negative breast cancer (TNBC) and matched normal samples. We identify differentially methylated regions (DMRs) enriched with promoters associated with transcription factor binding sites and DNA hypersensitive sites. Importantly, we stratify TNBCs into three distinct methylation clusters associated with better or worse prognosis and identify 17 DMRs that show a strong association with overall survival, including DMRs located in the Wilms tumour 1 (WT1) gene, bi-directional-promoter and antisense WT1-AS. Our data reveal that coordinated hypermethylation can occur in oestrogen receptor-negative disease, and that characterizing the epigenetic framework provides a potential signature to stratify TNBCs. Together, our findings demonstrate the feasibility of profiling the cancer methylome with limited archival tissue to identify regulatory regions associated with cancer.
C1 [Stirzaker, Clare; Zotenko, Elena; Song, Jenny Z.; Qu, Wenjia; Nair, Shalima S.; Locke, Warwick J.; Stone, Andrew; Armstong, Nicola J.; Robinson, Mark D.; Clark, Susan J.] Garvan Inst Med Res, Canc Div, Epigenet Grp, Sydney, NSW 2010, Australia.
   [Stirzaker, Clare; Zotenko, Elena; Nair, Shalima S.; Locke, Warwick J.; Stone, Andrew; Clark, Susan J.] Univ NSW, St Vincents Clin Sch, Sydney, NSW 2010, Australia.
   [Armstong, Nicola J.] Univ Sydney, Sch Math & Stat, Sydney, NSW 2006, Australia.
   [Robinson, Mark D.] Univ Zurich, Swiss Inst Bioinformat, CH-8057 Zurich, Switzerland.
   [Robinson, Mark D.] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland.
   [Dobrovic, Alexander] Olivia Newton John Canc Res Inst, Translat Genom & Epigen Lab, Melbourne, Vic 3084, Australia.
   [Avery-Kiejda, Kelly A.; Scott, Rodney J.] Univ Newcastle, Fac Hlth, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.
   [Peters, Kate M.; French, Juliet D.; Trau, Matt; Brown, Melissa A.] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld 4072, Australia.
   [French, Juliet D.] QIMR Berghofer Med Res Inst, Dept Genet & Computat Biol, Herston, Qld 4029, Australia.
   [Stein, Sandra; Francis, Glenn D.] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
   [Korbie, Darren J.; Trau, Matt; Francis, Glenn D.] Univ Queensland, Australian Inst Bioengn & Nanotechnol, Brisbane, Qld 4072, Australia.
   [Forbes, John F.] Univ Newcastle, Fac Hlth & Med, Sch Med & Publ Hlth, Newcastle, NSW 2305, Australia.
   [Scott, Rodney J.] John Hunter Hosp, Div Mol Med, Hunter Area Pathol Serv, Newcastle, NSW 2305, Australia.
   [Scott, Rodney J.] John Hunter Hosp, Hunter Med Res Inst, Newcastle, NSW 2305, Australia.
C3 Garvan Institute of Medical Research; University of New South Wales
   Sydney; University of Sydney; University of Zurich; Swiss Institute of
   Bioinformatics; University of Zurich; La Trobe University; Olivia
   Newton-John Cancer Research Institute; University of Newcastle;
   University of Queensland; QIMR Berghofer Medical Research Institute;
   Princess Alexandra Hospital; University of Queensland; University of
   Newcastle; John Hunter Hospital; John Hunter Hospital; University of
   Newcastle; Hunter Medical Research Institute
RP Clark, SJ (通讯作者)，Garvan Inst Med Res, Canc Div, Epigenet Grp, Sydney, NSW 2010, Australia.
EM s.clark@garvan.org.au
RI Trau, Matt/E-3944-2015; French, Juliet/AAV-4435-2020; Brown,
   Melissa/F-1451-2010; Clark, Susan/B-2272-2008; Locke,
   Warwick/G-3152-2017; Scott, Rodney/B-2827-2013; Robinson,
   Mark/A-6432-2015
OI French, Juliet/0000-0002-9770-0198; Clark, Susan/0000-0001-5925-5030;
   Peters, Kate/0000-0002-5982-4448; Locke, Warwick/0000-0002-9281-0363;
   Brown, Melissa/0000-0002-2830-9259; Trau, Matt/0000-0001-5516-1280;
   Scott, Rodney/0000-0001-7724-3404; Robinson, Mark/0000-0002-3048-5518;
   Avery-Kiejda, Kelly/0000-0003-2285-9118; Zotenko,
   Elena/0000-0002-0256-3195; Dobrovic, Alexander/0000-0003-3414-112X;
   Stirzaker, Clare/0000-0001-5601-3140
FU National Breast Cancer Foundation (NBCF) program; National Health and
   Medical Research Council [NHMRC1029579]; NHMRC Fellowship; Cancer
   Council Queensland and University of Queensland; National Breast Cancer
   Foundation (NBCF) Australia
FX We thank the Ramaciotti Centre, University of New South Wales (Sydney,
   Australia) for genome sequencing. This work is supported by the National
   Breast Cancer Foundation (NBCF) program and project grants and National
   Health and Medical Research Council (NHMRC1029579) project grant and
   NHMRC Fellowship to S.J.C.M.A.B. is supported by Cancer Council
   Queensland and University of Queensland. J.D.F. is supported by a
   fellowship from the National Breast Cancer Foundation (NBCF) Australia.
CR Blows FM, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000279
   Bruno P, 2012, BIOCHEM BIOPH RES CO, V426, P306, DOI 10.1016/j.bbrc.2012.08.059
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566
   Chimonidou M, 2013, CLIN BIOCHEM, V46, P235, DOI 10.1016/j.clinbiochem.2012.09.015
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662
   Dallosso AR, 2007, RNA, V13, P2287, DOI 10.1261/rna.562907
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Ghoshal K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010338
   Hallett RM, 2012, SCI REP-UK, V2, DOI 10.1038/srep00227
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang RL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041060
   Hughes LAE, 2013, CANCER RES, V73, P5858, DOI 10.1158/0008-5472.CAN-12-4306
   Jatoi I, 2011, J CLIN ONCOL, V29, P2301, DOI 10.1200/JCO.2010.32.3550
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kuhn M, 2008, J STAT SOFTW, V28, P1, DOI 10.18637/jss.v028.i05
   Kuo WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045831
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lleras RA, 2011, AM J PATHOL, V178, P1965, DOI 10.1016/j.ajpath.2011.01.049
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   Mehlen P, 2011, NAT REV CANCER, V11, P188, DOI 10.1038/nrc3005
   Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984
   Mevik BH, 2007, J STAT SOFTW, V18, P1, DOI 10.18637/jss.v018.i02
   Miyoshi Y, 2002, CLIN CANCER RES, V8, P1167
   Monti S, 2003, MACH LEARN, V52, P91, DOI 10.1023/A:1023949509487
   Moorwood K, 1998, J PATHOL, V185, P352, DOI 10.1002/(SICI)1096-9896(199808)185:4<352::AID-PATH119>3.0.CO;2-#
   Nair SS, 2011, EPIGENETICS-US, V6, P34, DOI 10.4161/epi.6.1.13313
   Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404
   Okuda H, 2006, ONCOGENE, V25, P1733, DOI 10.1038/sj.onc.1209200
   Park YH, 2011, ANN ONCOL, V22, P1554, DOI 10.1093/annonc/mdq617
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pilato B, 2013, J HUM GENET, V58, P51, DOI 10.1038/jhg.2012.118
   Rauch T, 2005, LAB INVEST, V85, P1172, DOI 10.1038/labinvest.3700311
   Reinert T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046297
   Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0
   Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035
   Rudd PM, 2001, SCIENCE, V291, P2370, DOI 10.1126/science.291.5512.2370
   Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992
   Severson PL, 2013, EPIGENETICS-US, V8, P1080, DOI 10.4161/epi.25926
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Stone A, 2013, MOL CANCER THER, V12, P1874, DOI 10.1158/1535-7163.MCT-13-0012
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Teschendorff AE, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-8-r157
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Vanaja DK, 2003, CANCER RES, V63, P3877
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Yang L, 2007, LEUKEMIA, V21, P868, DOI 10.1038/sj.leu.2404624
   Yau C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2753
NR 63
TC 138
Z9 171
U1 1
U2 25
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD FEB
PY 2015
VL 6
AR 5899
DI 10.1038/ncomms6899
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CC0OH
UT WOS:000350034800001
PM 25641231
OA gold
DA 2025-01-12
ER

PT J
AU Wu, B
   Cao, XM
   Liang, XZ
   Zhang, XH
   Zhang, W
   Sun, G
   Wang, DW
AF Wu, Bo
   Cao, Xiaoming
   Liang, Xuezhi
   Zhang, Xuhui
   Zhang, Wei
   Sun, Guang
   Wang, Dongwen
TI Epigenetic Regulation of Elf5 Is Associated with Epithelial-Mesenchymal
   Transition in Urothelial Cancer
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; METHYLATION; PROMOTER; CELLS; PLASTICITY; STATES; FATE
AB E74-like factor 5 (Elf5) has been associated with tumor suppression in breast cancer. However, its role in urothelial cancer (UC) is completely unknown. Immunohistochemistry (IHC) and methylation specific PCR (MSP) were done to detect Elf5 expression level and its promoter methylation. Results revealed that low expression of Elf5 on protein and mRNA levels were associated with tumor progression, early relapse and poor survival. In vitro, downregulation of Elf5 can increase epithelial-mesenchymal transition (EMT). Aberrant Elf5 methylation was identified as major mechanism for Elf5 gene silence. Accordingly, restoration of Elf5 by infection or demethylating treatment effectively reversed EMT processes. In conclusion, we identified Elf5 as a novel biomarker of UC on several biological levels and established a causative link between Elf5 and EMT in UC.
C1 [Wu, Bo; Cao, Xiaoming; Liang, Xuezhi; Zhang, Wei; Wang, Dongwen] Shanxi Med Univ, Hosp 1, Dept Urol, Taiyuan, Peoples R China.
   [Zhang, Xuhui; Wang, Dongwen] Shanxi Med Univ, Clin Med Coll 1, Taiyuan, Peoples R China.
   [Sun, Guang] Tianjin Med Univ, Hosp 2, Dept Urol, Tianjin, Peoples R China.
C3 Shanxi Medical University; Shanxi Medical University; Tianjin Medical
   University
RP Wang, DW (通讯作者)，Shanxi Med Univ, Hosp 1, Dept Urol, Taiyuan, Peoples R China.
EM dongwen_shanyi@126.com
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   [Anonymous], CANC RES
   Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607
   Chakrabarti R, 2012, STEM CELLS, V30, P1496, DOI 10.1002/stem.1112
   Donat SM, 2003, UROL CLIN N AM, V30, P765, DOI 10.1016/S0094-0143(03)00060-0
   Escamilla-Hernandez R, 2010, BMC MOL BIOL, V11, DOI 10.1186/1471-2199-11-68
   Hemberger M, 2010, HUM MOL GENET, V19, P2456, DOI 10.1093/hmg/ddq128
   Hilton HN, 2010, MOL ENDOCRINOL, V24, P1380, DOI 10.1210/me.2009-0516
   Kalyuga M, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001461
   Kendrick H, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-591
   Lee HJ, 2011, STEM CELLS, V29, P1611, DOI 10.1002/stem.706
   Li H, 2014, J UROLOGY, V191, P493, DOI 10.1016/j.juro.2013.08.087
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Menzies KK, 2010, FUNCT INTEGR GENOMIC, V10, P87, DOI 10.1007/s10142-009-0140-0
   Ng RK, 2008, NAT CELL BIOL, V10, P1280, DOI 10.1038/ncb1786
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   RUBBEN H, 1988, J UROLOGY, V139, P283, DOI 10.1016/S0022-5347(17)42387-1
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Taddei ML, 2013, CANCER LETT, V341, P80, DOI 10.1016/j.canlet.2013.01.042
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tian J, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.395574
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Villicana P, 2009, BIOMARK MED, V3, P265, DOI 10.2217/BMM.09.23
   Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019
   Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
NR 29
TC 16
Z9 21
U1 1
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 28
PY 2015
VL 10
IS 1
AR e0117510
DI 10.1371/journal.pone.0117510
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CA2IM
UT WOS:000348732100086
PM 25629735
OA Green Published, Green Submitted, gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Bajpe, PK
   Prahallad, A
   Horlings, H
   Nagtegaal, I
   Beijersbergen, R
   Bernards, R
AF Bajpe, P. K.
   Prahallad, A.
   Horlings, H.
   Nagtegaal, I.
   Beijersbergen, R.
   Bernards, R.
TI A chromatin modifier genetic screen identifies SIRT2 as a modulator of
   response to targeted therapies through the regulation of MEK kinase
   activity
SO ONCOGENE
LA English
DT Article
DE SIRT2; drug resistance; chromatin modifiers; genetic screen
ID METASTATIC COLORECTAL-CANCER; FREQUENT MUTATIONS; CELL CARCINOMA; RAS
   MUTATIONS; BREAST-CANCER; CETUXIMAB; RESISTANCE; RECEPTOR; PATHWAY;
   MARKER
AB Resistance to targeted therapies is a major problem in cancer treatment. The epidermal growth factor receptor (EGFR) antibody drugs are effective in a subset of colorectal cancers, but the molecular mechanisms of resistance are understood poorly. Genes involved in epigenetic regulation are frequently deregulated in cancer, raising the possibility that such genes also contribute to drug resistance. Using a focused RNA interference library for genes involved in epigenetic regulation, we identify sirtuin2 (SIRT2), an NAD(+)-dependent deacetylase, as a modulator of the response to EGFR inhibitors in colon and lung cancer. SIRT2 loss also conferred resistance to BRAF and MEK inhibitors in BRAF mutant melanoma and KRAS mutant colon cancers, respectively. These results warrant further investigation into the potential role of SIRT2 in resistance to drugs that act in the receptor tyrosine kinase-RAS-RAF-MEK-ERK signaling pathway.
C1 [Bajpe, P. K.; Prahallad, A.; Horlings, H.; Beijersbergen, R.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, NL-1066 CX Amsterdam, Netherlands.
   [Horlings, H.] Acad Medisch Cent, Dept Pathol, Amsterdam, Netherlands.
   [Nagtegaal, I.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands.
C3 Netherlands Cancer Institute; University of Amsterdam; Academic Medical
   Center Amsterdam; Radboud University Nijmegen
RP Bernards, R (通讯作者)，Netherlands Canc Inst, Div Mol Carcinogenesis, Canc Genom Ctr, 121 Plesmanlaan, NL-1066 CX Amsterdam, Netherlands.
EM r.bernards@nki.nl
RI Nagtegaal, Iris/IXE-0119-2023; Nagtegaal, Iris/A-2448-2014
OI Nagtegaal, Iris/0000-0003-0887-4127; Beijersbergen,
   Roderick/0000-0003-0116-4130; Bernards, Rene/0000-0001-8677-3423
FU Dutch Cancer Society (KWF); European Union [259015]
FX We are grateful to Kees Punt, Sabine Tejpar, Josep Tabernero, Jose
   Jimenez, Adriana Lopez-Doriga Guerra, Ramon Salzar and Loredana
   Vecchione for providing clinical specimen of cetuximab-treated colon
   cancers. We thank Gerrit Hooiger and Marc van de Vijver (AMC, Amsterdam)
   for assistance in staining tissue microarrays and Alberto Bardelli for
   the kind gift of the Difi cells. We thank the NKI Genomics Core
   Facility, especially Iris de Rink, for support. We also thank Chong Sun
   and Sidong Huang for helpful discussions. This work was supported by
   grants from the Dutch Cancer Society (KWF) and the European Union
   Seventh Framework Program COLTHERES project, grant agreement 259015.
CR Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964
   Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Brummelkamp TR, 2006, NAT CHEM BIOL, V2, P202, DOI 10.1038/nchembio774
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Geutjes EJ, 2012, ONCOGENE, V31, P3827, DOI 10.1038/onc.2011.552
   Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035
   Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023
   Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609
   Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333
   Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Liu H, 2009, CANCER BIOL THER, V8, P1204, DOI 10.4161/cbt.8.13.8924
   Marschalek R, 2011, BRIT J HAEMATOL, V152, P141, DOI 10.1111/j.1365-2141.2010.08459.x
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Reisman DN, 2003, CANCER RES, V63, P560
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Samowitz WS, 2000, CANCER EPIDEM BIOMAR, V9, P1193
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433
   Yeung F, ONCOGENE
NR 27
TC 37
Z9 46
U1 1
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 22
PY 2015
VL 34
IS 4
BP 531
EP 536
DI 10.1038/onc.2013.588
PG 6
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AZ8FU
UT WOS:000348451300014
PM 24469059
OA Bronze
DA 2025-01-12
ER

PT J
AU Ekizoglu, S
   Bulut, P
   Karaman, E
   Kilic, E
   Buyru, N
AF Ekizoglu, Seda
   Bulut, Pelin
   Karaman, Emin
   Kilic, Erkan
   Buyru, Nur
TI Epigenetic and Genetic Alterations Affect the WWOX Gene in Head and Neck
   Squamous Cell Carcinoma
SO PLOS ONE
LA English
DT Article
ID GROWTH IN-VITRO; BREAST-CANCER; EXPRESSION; SUPPRESSOR; LUNG; FRA16D;
   INACTIVATION; RESTORATION; PROGRESSION; REVEALS
AB Different types of genetic and epigenetic changes are associated with HNSCC. The molecular mechanisms of HNSCC carcinogenesis are still undergoing intensive investigation. WWOX gene expression is altered in many cancers and in a recent work reduced WWOX expression has been associated with miR-134 expression in HNSCC. In this study we investigated the WWOX messenger RNA expression levels in association with the promoter methylation of the WWOX gene and miR-134 expression levels in 80 HNSCC tumor and non-cancerous tissue samples. Our results show that WWOX expression is down-regulated especially in advanced-stage tumor samples or in tumors with SCC. This down-regulation was associated with methylation of the WWOX promoter region but not with miR-134 expression. There was an inverse correlation between the expression level and promoter methylation. We also analyzed whole exons and exon/intron boundries of the WWOX gene by direct sequencing. In our study group we observed 10 different alterations in the coding sequences and 18 different alterations in the non-coding sequences of the WWOX gene in HNSCC tumor samples. These results indicate that the WWOX gene can be functionally inactivated by promoter methylation, epigenetically or by mutations affecting the sequences coding for the enzymatic domain of the gene, functionally. We conclude that inactivation of WWOX gene contributes to the progression of HNSCC.
C1 [Ekizoglu, Seda; Bulut, Pelin; Buyru, Nur] Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, Istanbul, Turkey.
   [Karaman, Emin; Kilic, Erkan] Istanbul Univ, Cerrahpasa Med Fac, Dept Otorhinolaryngol, Istanbul, Turkey.
C3 Istanbul University - Cerrahpasa; Istanbul University; Istanbul
   University; Istanbul University - Cerrahpasa
RP Buyru, N (通讯作者)，Istanbul Univ, Cerrahpasa Med Fac, Dept Med Biol, Istanbul, Turkey.
EM nbuyru@yahoo.com
RI Buyru, Nur/D-1810-2019
OI Buyru, Nur/0000-0002-6920-1455
CR Abdeen SK, 2011, ONCOGENE, V30, P3900, DOI 10.1038/onc.2011.115
   Aldaz CM, 2014, BBA-REV CANCER, V1846, P188, DOI 10.1016/j.bbcan.2014.06.001
   Aqeilan RI, 2007, CANCER RES, V67, P5606, DOI 10.1158/0008-5472.CAN-07-1081
   Aqeilan RI, 2007, P NATL ACAD SCI USA, V104, P3949, DOI 10.1073/pnas.0609783104
   Aqeilan RI, 2004, CLIN CANCER RES, V10, P3053, DOI 10.1158/1078-0432.CCR-03-0594
   Baykara O, 2010, TUMOR BIOL, V31, P315, DOI 10.1007/s13277-010-0039-3
   Bednarek AK, 2000, CANCER RES, V60, P2140
   Bednarek AK, 2001, CANCER RES, V61, P8068
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Cancemi L, 2011, INT J CANCER, V129, P2816, DOI 10.1002/ijc.25937
   Donati V, 2007, CLIN CANCER RES, V13, P884, DOI 10.1158/1078-0432.CCR-06-2016
   Ekizoglu S, 2012, MED ONCOL, V29, P1529, DOI 10.1007/s12032-011-0080-0
   Fabbri M, 2005, P NATL ACAD SCI USA, V102, P15611, DOI 10.1073/pnas.0505485102
   Gale N., 2005, WHO CLASSIFICATION T, P140
   Gilad Y, 2006, NATURE, V440, P242, DOI 10.1038/nature04559
   Guo W, 2013, MOL CARCINOGEN, V52, P265, DOI 10.1002/mc.21853
   Guo W, 2013, ENVIRON MOL MUTAGEN, V54, P112, DOI 10.1002/em.21748
   Haddad RI, 2008, NEW ENGL J MED, V359, P1143, DOI 10.1056/NEJMra0707975
   Hashibe M, 2009, CANCER EPIDEM BIOMAR, V18, P541, DOI 10.1158/1055-9965.EPI-08-0347
   Iliopoulos D, 2005, ONCOGENE, V24, P1625, DOI 10.1038/sj.onc.1208398
   Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038
   Jenner MW, 2007, BLOOD, V110, P3291, DOI 10.1182/blood-2007-02-075069
   Kuroki T, 2004, CLIN CANCER RES, V10, P2459, DOI 10.1158/1078-0432.CCR-03-0096
   Kuroki T, 2002, CANCER RES, V62, P2258
   Liu CJ, 2014, INT J CANCER, V134, P811, DOI 10.1002/ijc.28358
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nunez M, 2005, BREAST CANCER RES TR, V89, P99, DOI 10.1007/s10549-004-1474-x
   Nunez MI, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-64
   Paige AJW, 2001, P NATL ACAD SCI USA, V98, P11417, DOI 10.1073/pnas.191175898
   Pimenta FJ, 2006, INT J CANCER, V118, P1154, DOI 10.1002/ijc.21446
   Ramos D, 2008, HISTOPATHOLOGY, V52, P831, DOI 10.1111/j.1365-2559.2008.03033.x
   Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Yan HC, 2013, BIOMED REP, V1, P375, DOI 10.3892/br.2013.86
   Yan HC, 2013, ONCOL LETT, V6, P845, DOI 10.3892/ol.2013.1438
NR 35
TC 17
Z9 18
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2015
VL 10
IS 1
AR e0115353
DI 10.1371/journal.pone.0115353
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AZ9UU
UT WOS:000348562900008
PM 25612104
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Zhao, F
   Pan, SL
   Gu, Y
   Guo, SY
   Dai, QC
   Yu, YY
   Zhang, W
AF Zhao, Feng
   Pan, Shengli
   Gu, Yan
   Guo, Shanyu
   Dai, Qiancheng
   Yu, Yingyan
   Zhang, Wei
TI Reactivation of HIC-1 gene by saRNA inhibits clonogenicity and
   invasiveness in breast cancer cells
SO ONCOLOGY LETTERS
LA English
DT Article
DE breast cancer; HIC-1; clonogenicity; cell invasion; saRNA
ID INDUCE TRANSCRIPTIONAL ACTIVATION; TUMOR-SUPPRESSOR GENE; UP-REGULATION;
   CARCINOMA CELL; ALLELIC LOSS; RNA; P21(WAF1/CIP1); EXPRESSION;
   HYPERMETHYLATION; MISREGULATION
AB Hypermethylated in cancer 1 (HIC-1) is a tumor suppressor gene, which is epigenetically silenced in breast cancer. It is known that the loss of HIC-1, caused by promoter hypermethylation, is associated with tumor aggression and poor survival in breast carcinoma. It has been shown that small activating RNA (saRNA) targeting promoter sequences may induce gene re-expression. In the current study, saRNA was used to restore HIC-1 expression, and the effects on colony formation, invasiveness and the cell cycle in breast cancer cells were explored. dsHIC1-2998, an saRNA, exhibited activating efficacy on MCF-7 and MDA-MB-231 cancer cell lines. A clonogenicity assay showed that evident colony inhibition was induced via saRNA-mediated re-expression of HIC-1 in the two cancer cell lines. Reactivation of HIC-1 significantly inhibited cell migration and invasion, resulting in G0/G1 cell cycle arrest in these cell lines. These findings suggest that HIC-1 may be a potential target in gene therapy for the treatment of breast cancer. saRNA may function as a therapeutic option for upregulating tumor suppressor genes in breast cancer.
C1 [Zhao, Feng; Gu, Yan; Guo, Shanyu; Dai, Qiancheng; Zhang, Wei] Shanghai Jiao Tong Univ, Sch Med, Dept Surg, Peoples Hosp 9, Shanghai 200011, Peoples R China.
   [Pan, Shengli; Yu, Yingyan] Shanghai Jiao Tong Univ, Sch Med, Dept Surg, Shanghai Ruijin Hosp, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zhang, W (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Dept Surg, Peoples Hosp 9, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM weizh1518@hotmail.com
RI yu, yingying/GRR-7851-2022; Gu, Yan/AFQ-1163-2022; Zhang,
   Wei/HOF-7252-2023
OI Yu, Yingyan/0000-0002-3585-3252
FU National Natural Science Foundation of China [81172329, 81372644];
   Chinese National High Tech Program [2012AA02A504, 2012AA02A203,
   2011ZX09307-001-05]; Shanghai Excellent Academic Leader Plan
   [11XD1403600]; Shanghai Science and Technology Commission [14ZR1424400]
FX The authors thank Professor Long-Cheng Li, of the Department of Urology,
   Helen Diller Family Comprehensive Cancer Center, University of
   California, USA, for the suggestive instruction for saRNA design. This
   study was supported, in part, by grants from the National Natural
   Science Foundation of China (grant nos. 81172329 and 81372644), the
   Chinese National High Tech Program (grant nos. 2012AA02A504,
   2012AA02A203 and 2011ZX09307-001-05), Shanghai Excellent Academic Leader
   Plan (grant no. 11XD1403600) and Shanghai Science and Technology
   Commission (grant no. 14ZR1424400).
CR Boulay G, 2012, J BIOL CHEM, V287, P5379, DOI 10.1074/jbc.M111.304287
   Brieger J, 2010, ORAL ONCOL, V46, P678, DOI 10.1016/j.oraloncology.2010.06.016
   Chen RB, 2011, J SEX MED, V8, P2773, DOI 10.1111/j.1743-6109.2011.02412.x
   Chen Z, 2008, MOL CANCER THER, V7, P698, DOI 10.1158/1535-7163.MCT-07-2312
   Cheng GC, 2014, CANCER RES, V74, P862, DOI 10.1158/0008-5472.CAN-13-2420
   Dehennaut V, 2013, J BIOL CHEM, V288, P10254, DOI 10.1074/jbc.M112.421610
   Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Hayashi M, 2001, ANTICANCER RES, V21, P535
   Hu J, 2012, BIOCHEM J, V447, P407, DOI 10.1042/BJ20120256
   Huang V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008848
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338
   Kang MR, 2012, CANCER RES, V72, P5069, DOI 10.1158/0008-5472.CAN-12-1871
   Kosaka M, 2012, NUCLEIC ACID THER, V22, P335, DOI 10.1089/nat.2012.0354
   Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103
   Mao QQ, 2008, BIOCHEM BIOPH RES CO, V375, P566, DOI 10.1016/j.bbrc.2008.08.059
   Pan SL, 2013, GENE, V527, P102, DOI 10.1016/j.gene.2013.05.034
   Parrella P, 2005, CANCER LETT, V222, P75, DOI 10.1016/j.canlet.2004.08.026
   Portnoy V, 2011, WIRES RNA, V2, P748, DOI 10.1002/wrna.90
   Qin Q, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-11
   Ren SC, 2013, PROSTATE, V73, P1591, DOI 10.1002/pros.22709
   Rood BR, 2002, CANCER RES, V62, P3794
   Wei JX, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-632
   Wei JX, 2010, CANCER SCI, V101, P1790, DOI 10.1111/j.1349-7006.2010.01594.x
   Wu ZM, 2011, ACTA PHARMACOL SIN, V32, P939, DOI 10.1038/aps.2011.28
   Yang K, 2008, CANCER LETT, V265, P206, DOI 10.1016/j.canlet.2008.02.014
   Zhao F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086486
NR 28
TC 8
Z9 8
U1 0
U2 10
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JAN
PY 2015
VL 9
IS 1
BP 159
EP 164
DI 10.3892/ol.2014.2633
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AX0JH
UT WOS:000346638300027
PM 25435951
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Lo, PHY
   Tanikawa, C
   Katagiri, T
   Nakamura, Y
   Matsuda, K
AF Lo, Paulisally Hau Yi
   Tanikawa, Chizu
   Katagiri, Toyomasa
   Nakamura, Yusuke
   Matsuda, Koichi
TI Identification of novel epigenetically inactivated gene <i>PAMR1</i> in
   breast carcinoma
SO ONCOLOGY REPORTS
LA English
DT Article
DE breast carcinoma; epigenetically inactivated gene; PAMR1; microarray
ID TUMOR-SUPPRESSOR; DNA METHYLATION; EXPRESSION; OVEREXPRESSION;
   INVOLVEMENT; PROTEIN; PROFILES; PATHWAY
AB Development of cancer is a complex process involving multiple genetic and epigenetic alterations. In our microarray analysis of 81 breast carcinoma specimens, we identified peptidase domain containing associated with muscle regeneration 1 (PAMR1) as being frequently suppressed in breast cancer tissues. PAMR1 expression was also reduced in all tested breast cancer cell lines, while PAMR1 was expressed moderately in normal breast tissues and primary mammary epithelial cells. DNA sequencing of the PAMR1 promoter after sodium bisulfite treatment revealed that CpG sites were hypermethylated in the breast cancer tissues and cell lines. PAMR1 expression was restored by 5-aza-2 deoxycytidine treatment, demonstrating that promoter hypermethylation contributed to PAMR1 inactivation in the breast cancer cells. In addition, ectopic expression of PAMR1 markedly suppressed cancer cell growth. In summary, our study identified PAMR1 as a putative tumor suppressor which was frequently inactivated by promoter hypermethylation in breast cancer tissues.
C1 [Lo, Paulisally Hau Yi; Tanikawa, Chizu; Matsuda, Koichi] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Mol Med Lab, Tokyo 1088639, Japan.
   [Katagiri, Toyomasa] Univ Tokushima, Inst Genome Res, Div Genome Med, Tokushima 770, Japan.
   [Nakamura, Yusuke] Univ Chicago, Dept Med, Chicago, IL 60637 USA.
   [Nakamura, Yusuke] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
   [Nakamura, Yusuke] Univ Chicago, Ctr Personalized Therapeut, Chicago, IL 60637 USA.
C3 University of Tokyo; Tokushima University; University of Chicago;
   University of Chicago; University of Chicago
RP Matsuda, K (通讯作者)，Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.
EM koichima@ims.u-tokyo.ac.jp
RI Matsuda, Koichi/D-4597-2011
OI Matsuda, Koichi/0000-0001-7292-2686; Tanikawa, Chizu/0000-0003-4759-4793
FU Grants-in-Aid for Scientific Research [25293168] Funding Source: KAKEN
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Ajiro M, 2009, INT J ONCOL, V35, P673, DOI 10.3892/ijo_00000379
   Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244
   Campo E, 2013, MODERN PATHOL, V26, pS97, DOI 10.1038/modpathol.2012.179
   Cheng CJ, 2009, CANCER RES, V69, P3634, DOI 10.1158/0008-5472.CAN-08-3615
   Clark HF, 2003, GENOME RES, V13, P2265, DOI 10.1101/gr.1293003
   Gao YX, 2011, HUM PATHOL, V42, P1693, DOI 10.1016/j.humpath.2010.12.027
   Hawthorn L, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-460
   Huang Y, 1999, MOL CARCINOGEN, V24, P118, DOI 10.1002/(SICI)1098-2744(199902)24:2<118::AID-MC6>3.0.CO;2-L
   Issa JPJ, 2005, NAT REV DRUG DISCOV, V4, P275, DOI 10.1038/nrd1698
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kim JW, 2010, INT J ONCOL, V37, P861, DOI 10.3892/ijo_00000737
   Kim JW, 2009, CANCER SCI, V100, P1468, DOI 10.1111/j.1349-7006.2009.01209.x
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin JY, 2014, INT J ONCOL, V44, P1490, DOI 10.3892/ijo.2014.2314
   Lin YC, 2014, J CELL SCI, V127, P85, DOI 10.1242/jcs.132779
   Lin YC, 2011, J BIOL CHEM, V286, P27039, DOI 10.1074/jbc.M111.244418
   Medina-Franco JL, 2011, DRUG DISCOV TODAY, V16, P418, DOI 10.1016/j.drudis.2011.02.003
   Nakayama Y, 2004, AM J PATHOL, V164, P1773, DOI 10.1016/S0002-9440(10)63735-2
   Nishidate T, 2004, INT J ONCOL, V25, P797
   Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Schrump DS, 2006, CLIN CANCER RES, V12, P5777, DOI 10.1158/1078-0432.CCR-06-0669
   Shimo A, 2008, CANCER SCI, V99, P62, DOI 10.1111/j.1349-7006.2007.00635.x
   Shimo A, 2007, CANCER SCI, V98, P174, DOI 10.1111/j.1349-7006.2006.00381.x
   Tanikawa C, 2009, ONCOGENE, V28, P3081, DOI 10.1038/onc.2009.154
   Van de Voorde L, 2012, MUTAT RES-REV MUTAT, V751, P304, DOI 10.1016/j.mrrev.2012.06.001
   Yoshimaru T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3443
   Yu ZJ, 2015, MOL CARCINOGEN, V54, P707, DOI 10.1002/mc.22133
NR 29
TC 24
Z9 26
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD JAN
PY 2015
VL 33
IS 1
BP 267
EP 273
DI 10.3892/or.2014.3581
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AX0IN
UT WOS:000346636200033
PM 25370079
OA Bronze
DA 2025-01-12
ER

PT J
AU Deb, M
   Sengupta, D
   Kar, S
   Rath, SK
   Parbin, S
   Shilpi, A
   Roy, S
   Das, G
   Patra, SK
AF Deb, Moonmoon
   Sengupta, Dipta
   Kar, Swayamsiddha
   Rath, Sandip Kumar
   Parbin, Sabnam
   Shilpi, Arunima
   Roy, Subhendu
   Das, Gautam
   Patra, Samir Kumar
TI Elucidation of caveolin 1 both as a tumor suppressor and metastasis
   promoter in light of epigenetic modulators
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; Caveolin-1; DNA methylation; AZA; TSA; SFN; SAM
ID COLORECTAL-CANCER CELLS; BREAST-CANCER; LIPID RAFTS; UP-REGULATION;
   EXPRESSION; GENE; METHYLATION; GROWTH; MICE; RNA
AB Caveolin-1 (CAV1) is an integral part of plasma membrane protein playing a vital role in breast cancer initiation and progression. CAV1 acts both as a tumor suppressor as well as an oncogene, and its activity is thus highly dependent on cellular environment. Keeping this fact in mind, the recent work is designed to reveal the role of CAV1 in inhibiting cancer cell progression in presence of epigenetic modulators like 5-aza-2'-deoxycytidine (AZA), trichostatin A (TSA), S-adenosyl methionine (SAM) and sulforaphane (SFN). Forced expression of CAV1 by AZA, TSA, and SFN is correlated to induction of apoptosis and inhibition of cell migration in breast cancer. In breast cancer along with promoter DNA methylation, other epigenetic mechanisms are also involved in CAV1 expression. These observations clearly provide a new scenario regarding the role of CAV1 in cancer and as a possible therapeutic target in breast cancer.
C1 [Deb, Moonmoon; Sengupta, Dipta; Kar, Swayamsiddha; Rath, Sandip Kumar; Parbin, Sabnam; Shilpi, Arunima; Patra, Samir Kumar] Natl Inst Technol, Dept Life Sci, Biochem & Mol Biol Grp, Epigenet & Canc Res Lab, Rourkela 769008, Odisha, India.
   [Roy, Subhendu] Drs Tribedi & Roy Diagnost Lab, Kolkata 700016, India.
   [Das, Gautam] Calcutta Natl Med Coll, Dept Surg, Kolkata 7000014, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Rourkela
RP Patra, SK (通讯作者)，Natl Inst Technol, Dept Life Sci, Biochem & Mol Biol Grp, Epigenet & Canc Res Lab, Rourkela 769008, Odisha, India.
EM samirp@nitrkl.ac.in
RI rath, sandip/ABB-9460-2021; Shilpi, Arunima/AAF-7221-2019; PATRA,
   Samir/AAS-6639-2020; Sengupta, Dipta/H-3707-2019
OI Sengupta, Dipta/0000-0002-7836-4774; rath, sandip/0000-0003-4589-4039;
   PATRA, SAMIR/0000-0001-5641-1835
CR Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-8
   Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288
   Bachmann N, 2008, CANCER GENET CYTOGEN, V182, P103, DOI 10.1016/j.cancergencyto.2008.01.006
   Bélanger MM, 2003, ANTI-CANCER DRUG, V14, P281, DOI 10.1097/00001813-200304000-00005
   Braasch DA, 2003, BIOCHEMISTRY-US, V42, P7967, DOI 10.1021/bi0343774
   Chanvorachote P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057466
   Chen ST, 2004, INT J MOL MED, V14, P577
   Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#
   Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688
   Du J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035957
   Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107
   Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172
   Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229
   Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X
   Gerlitz G, 2010, J CELL SCI, V123, P2207, DOI 10.1242/jcs.058271
   Gratton JP, 2004, CIRC RES, V94, P1408, DOI 10.1161/01.RES.0000129178.56294.17
   Guendel I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011379
   Ha TK, 2012, CANCER RES, V72, P4097, DOI 10.1158/0008-5472.CAN-12-0448
   Habold C, 2008, J CELL MOL MED, V12, P607, DOI 10.1111/j.1582-4934.2007.00136.x
   Ho CC, 2002, AM J PATHOL, V161, P1647, DOI 10.1016/S0002-9440(10)64442-2
   Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102
   Jacobson K, 2007, NAT CELL BIOL, V9, P7, DOI 10.1038/ncb0107-7
   Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6
   Kim SH, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2562
   Lin MI, 2007, CANCER RES, V67, P2849, DOI 10.1158/0008-5472.CAN-06-4082
   Lin SY, 2004, ANTICANCER RES, V24, P1645
   Luo J, 2010, INT J BIOL SCI, V6, P784
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Migneco G, 2010, CELL CYCLE, V9, P2412, DOI 10.4161/cc.9.12.11989
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366
   Nestl A, 2001, CANCER RES, V61, P1569
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ostapkowicz A, 2006, MOL CANCER THER, V5, P238, DOI 10.1158/1535-7163.MCT-05-0226
   Parbin S, 2014, J HISTOCHEM CYTOCHEM, V62, P11, DOI 10.1369/0022155413506582
   Patra A, 2011, CLIN EPIGENETICS, V2, P339, DOI 10.1007/s13148-010-0019-x
   Patra SK, 2007, ONCOL REP, V17, P1279
   Patra SK, 2008, BBA-REV CANCER, V1785, P182, DOI 10.1016/j.bbcan.2007.11.002
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337
   Razani B, 2001, J BIOL CHEM, V276, P38121
   Rodriguez Luis G., 2004, V294, P23
   Sagara Y, 2004, BRIT J CANCER, V91, P959, DOI 10.1038/sj.bjc.6602029
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schubert W, 2007, AM J PATHOL, V170, P316, DOI 10.2353/ajpath.2007.060687
   Seervi M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.90
   Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052
   Singh KP, 2012, CANCER LETT, V316, P62, DOI 10.1016/j.canlet.2011.10.022
   Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941
   Toné S, 2007, EXP CELL RES, V313, P3635, DOI 10.1016/j.yexcr.2007.06.018
   Tse EYT, 2012, J PATHOL, V226, P645, DOI 10.1002/path.3957
   Yu J, 2006, J CLIN INVEST, V116, P1284, DOI 10.1172/JCI27100
   Zhao YY, 2002, P NATL ACAD SCI USA, V99, P11375, DOI 10.1073/pnas.172360799
   Zhou CL, 2006, INT J ONCOL, V29, P269
NR 54
TC 22
Z9 23
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD DEC
PY 2014
VL 35
IS 12
BP 12031
EP 12047
DI 10.1007/s13277-014-2502-z
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AX3UI
UT WOS:000346863700040
PM 25192721
DA 2025-01-12
ER

PT J
AU Zielske, SP
AF Zielske, Steven P.
TI Epigenetic DNA Methylation in Radiation Biology: On the Field or on the
   Sidelines?
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE EPIGENETICS; RADIATION; METHYLATION; AZACYTIDINE; DECITABINE; ZEBULARINE
ID SQUAMOUS-CELL CARCINOMA; METHYLTRANSFERASE INHIBITORS; BREAST-CANCER;
   IN-VITRO; RADIOSENSITIVITY; 5-AZA-2'-DEOXYCYTIDINE; IRRADIATION; LINES;
   HYPERMETHYLATION; ENHANCEMENT
AB DNA methylation has been studied with regard to chemotherapeutics for a number of years. The radiation field has just begun to look at this in the context of radiotherapy or radiation exposure. So far, the data suggest that radiation induces epigenetic reprogramming which indicates a purposeful response that influences the cell fate or alters the response to future exposure. Further studies may result in discovery of biomarkers for radiotherapy outcome or prediction of the degree of radiation resistance. Past and ongoing development of DNMT1 inhibitors that lead to DNA hypomethylation appear to sensitize many tumor types to radiation and may be an area with long term clinical implications. (C) 2014 The Authors. Journal of Cellular Biochemistry published by Wiley Periodicals, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
C1 Wayne State Univ, Dept Radiat Oncol, Detroit, MI 48201 USA.
C3 Wayne State University
RP Zielske, SP (通讯作者)，Wayne State Univ, Dept Radiat Oncol, 4201 St Antoine Blvd,1D-UHC, Detroit, MI 48201 USA.
EM stevenzielske@aol.com
RI Zielske, Steven/HLQ-2816-2023
OI Zielske, Steven/0000-0001-6893-246X
CR Antwih DA, 2013, EPIGENETICS-US, V8, P839, DOI 10.4161/epi.25498
   Asgatay S, 2014, J MED CHEM, V57, P421, DOI 10.1021/jm401419p
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Brieger J, 2012, INT J MOL MED, V29, P505, DOI 10.3892/ijmm.2011.843
   Bryan JN, 2014, CELL BIOL INT, V38, P187, DOI 10.1002/cbin.10215
   Chen CC, 2013, J BIOL CHEM, V288, P9084, DOI 10.1074/jbc.M112.445585
   Chen CC, 2012, J BIOL CHEM, V287, P33116, DOI 10.1074/jbc.C112.406975
   De Schutter H, 2009, INT J RADIAT ONCOL, V73, P904, DOI 10.1016/j.ijrobp.2008.10.032
   Dote H, 2005, CLIN CANCER RES, V11, P4571, DOI 10.1158/1078-0432.CCR-05-0050
   Halvorsen AR, 2014, INT J CANCER, V135, P2085, DOI 10.1002/ijc.28862
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200
   Hofstetter B, 2010, INT J RADIAT ONCOL, V76, P1512, DOI 10.1016/j.ijrobp.2009.10.037
   Jiang W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093273
   KALINICH JF, 1989, RADIAT RES, V117, P185, DOI 10.2307/3577319
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Kim EH, 2010, ONCOGENE, V29, P4725, DOI 10.1038/onc.2010.223
   Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39
   Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048
   Lahtz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044858
   Lee JC, 2014, INT J RADIAT ONCOL, V88, P1203, DOI 10.1016/j.ijrobp.2013.12.016
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Patties I, 2009, STRAHLENTHER ONKOL, V185, P331, DOI 10.1007/s00066-009-1956-1
   Pogribny I, 2004, BIOCHEM BIOPH RES CO, V320, P1253, DOI 10.1016/j.bbrc.2004.06.081
   Pogrlbny I, 2005, MOL CANCER RES, V3, P553, DOI 10.1158/1541-7786.MCR-05-0074
   Qiu H, 2009, CANCER SCI, V100, P181, DOI 10.1111/j.1349-7006.2008.01004.x
   Rae JM, 2007, BREAST CANCER RES TR, V104, P13, DOI 10.1007/s10549-006-9392-8
   Ren J, 2011, CELL SIGNAL, V23, P1082, DOI 10.1016/j.cellsig.2011.02.003
   Shamma A, 2013, MOL CELL BIOL, V33, P3113, DOI 10.1128/MCB.01597-12
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Stresemann C, 2008, INT J CANCER, V123, P8, DOI 10.1002/ijc.23607
   Tawa R, 1998, J RADIAT RES, V39, P271, DOI 10.1269/jrr.39.271
   Wang JZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090804
   Wang L, 2013, CANCER BIOTHER RADIO, V28, P34, DOI 10.1089/cbr.2012.1170
   Yu W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029450
NR 35
TC 24
Z9 28
U1 1
U2 36
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD FEB
PY 2015
VL 116
IS 2
BP 212
EP 217
DI 10.1002/jcb.24959
PG 6
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AW4QM
UT WOS:000346265700002
PM 25186310
OA Bronze
DA 2025-01-12
ER

PT J
AU Lee, RT
   Yang, PY
   Greenlee, H
   Bauer-Wu, S
   Balneaves, LG
   Zick, S
AF Lee, Richard T.
   Yang, Peiying
   Greenlee, Heather
   Bauer-Wu, Susan
   Balneaves, Lynda G.
   Zick, Suzanna
TI Personalized Integrative Oncology: Targeted Approaches for Optimal
   Outcomes The 11th International Conference of the Society for
   Integrative Oncology
SO INTEGRATIVE CANCER THERAPIES
LA English
DT Article
DE integrative medicine; integrative oncology; personalized medicine;
   complementary and alternative medicine; conference
AB The 11th International Conference of the Society for Integrative Oncology (SIO) brought together more than 300 clinicians, researchers, patients, and advocates to hear and interact with world-leading experts about the latest research in the areas of nutrition, exercise, acupuncture, health services research, meditation, and other integrative disciplines. The conference theme, Personalized Integrative Oncology: Targeted Approaches for Optimal Outcomes, highlighted innovations in personalized medicine and ways this growing field will advance the evolution of individualized integrative cancer care to the next level. This year's conference also featured a clinical track focusing on clinical information for the practicing health care professional. The conference's rigorous schedule included 3 keynotes, 4 plenary sessions, 2 interdisciplinary tumor boards, 5 workshops, 45 concurrent oral sessions, and 106 posters. In addition to the conference theme, keynote and plenary sessions presented topics on stress and cancer, the importance of sleep for cancer patients, epigenetic mechanisms of lifestyle and natural products, recently published Journal of the National Cancer Institute monograph on integrative oncology, SIO's clinical practice guidelines for breast cancer survivors, and a joint session of the American Academy of Hospice and Palliative Medicine and SIO about supportive care and symptom management. This highly successful conference helped further the mission of the SIO to advance evidence-based, comprehensive, integrative health care to improve the lives of people affected by cancer.
C1 [Lee, Richard T.; Yang, Peiying] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Greenlee, Heather] Columbia Univ, New York, NY USA.
   [Bauer-Wu, Susan] Univ Virginia, Charlottesville, VA USA.
   [Balneaves, Lynda G.] Univ Toronto, Princess Margaret Canc Ctr, Toronto, ON, Canada.
   [Zick, Suzanna] Univ Michigan, Ann Arbor, MI 48109 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Columbia
   University; University of Virginia; University of Toronto; University
   Health Network Toronto; Princess Margaret Cancer Centre; University of
   Michigan System; University of Michigan
RP Lee, RT (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, 1515 Holcombe Blvd,Unit 462, Houston, TX 77030 USA.
EM RTLee@mdanderson.org
RI Lee, Richard/AAS-1416-2021; Balneaves, Lynda/AAG-9383-2021
OI Balneaves, Lynda/0000-0002-6535-2096; Lee, Richard/0000-0001-9916-6155
FU National Institutes of Health National Cancer Institute; Office of
   Cancer Complementary and Alternative Medicine [R13CA192731]; Lotte and
   John Hecht Memorial Foundation; Weil Foundation
FX The conference received support from the National Institutes of Health
   National Cancer Institute, Office of Cancer Complementary and
   Alternative Medicine (R13CA192731), the Lotte and John Hecht Memorial
   Foundation, and the Weil Foundation.
CR Bauml Joshua, 2014, Journal of the National Cancer Institute Monographs, P302, DOI 10.1093/jncimonographs/lgu029
   Carlson Linda E., 2014, Journal of the National Cancer Institute Monographs, P308, DOI 10.1093/jncimonographs/lgu034
   Greenlee Heather, 2014, Journal of the National Cancer Institute Monographs, P346, DOI 10.1093/jncimonographs/lgu041
   Johnson Jill R., 2014, Journal of the National Cancer Institute Monographs, P330, DOI 10.1093/jncimonographs/lgu030
NR 4
TC 1
Z9 1
U1 0
U2 33
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1534-7354
EI 1552-695X
J9 INTEGR CANCER THER
JI Integr. Cancer Ther.
PD JAN
PY 2015
VL 14
IS 1
BP 98
EP 105
DI 10.1177/1534735414563603
PG 8
WC Oncology; Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Integrative & Complementary Medicine
GA AW4PK
UT WOS:000346262900011
PM 25505022
OA gold
DA 2025-01-12
ER

PT J
AU Wang, CA
   Drasin, D
   Pham, C
   Jedlicka, P
   Zaberezhnyy, V
   Guney, M
   Li, H
   Nemenoff, R
   Costello, JC
   Tan, AC
   Ford, HL
AF Wang, Chu-An
   Drasin, David
   Pham, Catherine
   Jedlicka, Paul
   Zaberezhnyy, Vadym
   Guney, Michelle
   Li, Howard
   Nemenoff, Raphael
   Costello, James C.
   Tan, Aik-Choon
   Ford, Heide L.
TI Homeoprotein Six2 Promotes Breast Cancer Metastasis via Transcriptional
   and Epigenetic Control of E-Cadherin Expression
SO CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY-CARCINOMA; POOR-PROGNOSIS;
   CELLS; SUPPRESSION; PROSTATE; DISSEMINATION; TUMORIGENESIS; SURVIVAL;
   RENEWAL
AB Misexpression of developmental transcription factors occurs often in human cancers, where embryonic programs may be reinstated in a context that promotes or sustains malignant development. In this study, we report the involvement of the kidney development transcription factor Six2 in the metastatic progression of human breast cancer. We found that Six2 promoted breast cancer metastasis by a novel mechanism involving both transcriptional and epigenetic regulation of E-cadherin. Downregulation of E-cadherin by Six2 was necessary for its ability to increase soft agar growth and in vivo metastasis in an immunocompetent mouse model of breast cancer. Mechanistic investigations showed that Six2 represses E-cadherin expression by upregulating Zeb2, in part, through a microRNA-mediated mechanism and by stimulating promoter methylation of the E-cadherin gene (Cdh1). Clinically, SIX2 expression correlated inversely with CDH1 expression in human breast cancer specimens, corroborating the disease relevance of their interaction. Our findings establish Six2 as a regulator of metastasis in human breast cancers and demonstrate an epigenetic function for SIX family transcription factors in metastatic progression through the regulation of E-cadherin. (C) 2014 AACR.
C1 [Wang, Chu-An; Guney, Michelle; Costello, James C.; Ford, Heide L.] Univ Colorado, Sch Med, Dept Pharmacol, Aurora, CO 80045 USA.
   [Drasin, David; Ford, Heide L.] Univ Colorado, Sch Med, Program Mol Biol, Aurora, CO 80045 USA.
   [Pham, Catherine; Ford, Heide L.] Univ Colorado, Sch Med, Program Canc Biol, Aurora, CO 80045 USA.
   [Jedlicka, Paul] Univ Colorado, Sch Med, Dept Pathol, Aurora, CO 80045 USA.
   [Zaberezhnyy, Vadym; Ford, Heide L.] Univ Colorado, Sch Med, Dept Biochem & Mol Genet, Aurora, CO 80045 USA.
   [Li, Howard; Nemenoff, Raphael] Univ Colorado, Sch Med, Div Renal Dis & Hypertens, Aurora, CO 80045 USA.
   [Tan, Aik-Choon] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus; University of Colorado System; University of Colorado
   Anschutz Medical Campus; University of Colorado System; University of
   Colorado Anschutz Medical Campus; University of Colorado System;
   University of Colorado Anschutz Medical Campus; University of Colorado
   System; University of Colorado Anschutz Medical Campus; University of
   Colorado System; University of Colorado Anschutz Medical Campus
RP Ford, HL (通讯作者)，Univ Colorado, Sch Med, Anschutz Med Campus,RC1 North,Room 6115, Aurora, CO 80045 USA.
EM Heide.Ford@ucdenver.edu
RI Ford, Heide/JXN-4273-2024; Li, Howard/AAM-3544-2021; Tan, Aik
   Choon/A-3135-2011
OI Li, Howard/0000-0002-1230-2941; Tan, Aik Choon/0000-0003-2955-8369;
   Costello, James/0000-0003-3158-9682
FU NCI [R01CA157790, R01CA095277, 1 F31 CA165617]; Department of Defense
   Breast Cancer Research Program [W81ZWH-10-1-0162]; Cancer League of
   Colorado, Inc.; NIH [1R41CA180347]; BDEG (Bioscience Discovery
   Evaluation grant)
FX This work was funded by grants from the NCI (R01CA157790 and
   R01CA095277) to H.L. Ford. C.-A. Wang was funded by a pre-doctoral
   fellowship from the Department of Defense Breast Cancer Research Program
   (W81ZWH-10-1-0162) and a postdoctoral fellowship from the Cancer League
   of Colorado, Inc. D. Drasin was funded from a National Research Service
   Award from the NCI (1 F31 CA165617). H.L. Ford received a commercial
   research STTR grant from NIH 1R41CA180347 and a BDEG (Bioscience
   Discovery Evaluation grant).
CR ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Brodbeck S, 2004, MECH DEVELOP, V121, P1211, DOI 10.1016/j.mod.2004.05.019
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Chinnadurai G, 2007, INT J BIOCHEM CELL B, V39, P1593, DOI 10.1016/j.biocel.2007.01.025
   Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3
   Cieply B, 2013, CANCER RES, V73, P6299, DOI 10.1158/0008-5472.CAN-12-4082
   Coletta RD, 2004, P NATL ACAD SCI USA, V101, P6478, DOI 10.1073/pnas.0401139101
   Day ML, 1999, J BIOL CHEM, V274, P9656, DOI 10.1074/jbc.274.14.9656
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593
   Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Iwanaga R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3219
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Kobayashi A, 2008, CELL STEM CELL, V3, P169, DOI 10.1016/j.stem.2008.05.020
   Liu Y, 2012, MED SCI MONITOR, V18, pBR299, DOI 10.12659/MSM.883262
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   Micalizzi DS, 2009, J CLIN INVEST, V119, P2678, DOI 10.1172/JCI37815
   Mirza S, 2010, MOL CELL BIOCHEM, V342, P101, DOI 10.1007/s11010-010-0473-y
   Mori S, 2009, ONCOGENE, V28, P2796, DOI 10.1038/onc.2009.139
   Murphy AJ, 2012, J PEDIATR SURG, V47, P1239, DOI 10.1016/j.jpedsurg.2012.03.034
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Ono H, 2012, ONCOGENE, V31, P4923, DOI 10.1038/onc.2011.646
   Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Sánchez-Tilló E, 2012, CELL MOL LIFE SCI, V69, P3429, DOI 10.1007/s00018-012-1122-2
   Sanchez-Tilló E, 2011, AM J CANCER RES, V1, P897
   Self M, 2006, EMBO J, V25, P5214, DOI 10.1038/sj.emboj.7601381
   Senanayake U, 2013, HUM PATHOL, V44, P336, DOI 10.1016/j.humpath.2012.05.021
   Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394
   St Croix B, 1998, J CELL BIOL, V142, P557, DOI 10.1083/jcb.142.2.557
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Tsukamoto T, 1999, J BIOL CHEM, V274, P24579, DOI 10.1074/jbc.274.35.24579
   UMBAS R, 1994, CANCER RES, V54, P3929
   van Horssen R, 2012, BREAST CANCER RES TR, V136, P365, DOI 10.1007/s10549-012-2261-8
   Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8
   VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M
   Wang CA, 2012, J CLIN INVEST, V122, P1895, DOI 10.1172/JCI59858
   Wang L, 2013, CANCER BIOTHER RADIO, V28, P34, DOI 10.1089/cbr.2012.1170
   Wendt MK, 2011, MOL BIOL CELL, V22, P2423, DOI 10.1091/mbc.E11-04-0306
   Wijnhoven BPL, 2000, BRIT J SURG, V87, P992, DOI 10.1046/j.1365-2168.2000.01513.x
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
NR 44
TC 50
Z9 55
U1 1
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7357
EP 7370
DI 10.1158/0008-5472.CAN-14-0666
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AW6FC
UT WOS:000346363900021
PM 25348955
OA Bronze, Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Bockhorn, J
   Prat, A
   Chang, YF
   Liu, X
   Huang, SM
   Shang, M
   Nwachukwu, C
   Gomez-Vega, MJ
   Harrell, JC
   Olopade, OI
   Perou, CM
   Liu, HP
AF Bockhorn, Jessica
   Prat, Aleix
   Chang, Ya-Fang
   Liu, Xia
   Huang, Simo
   Shang, Meng
   Nwachukwu, Chika
   Gomez-Vega, Maria J.
   Harrell, J. Chuck
   Olopade, Olufunmilayo I.
   Perou, Charles M.
   Liu, Huiping
TI Differentiation and Loss of Malignant Character of Spontaneous Pulmonary
   Metastases in Patient-Derived Breast Cancer Models
SO CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; MIR-200 FAMILY; PROSTATE-CANCER;
   TUMOR INVASION; MOLECULAR CHARACTERIZATION; REPRESSORS ZEB1; PROTEIN
   EZH2; STEM-CELLS; EXPRESSION; PROGRESSION
AB Patient-derived human-in-mouse xenograft models of breast cancer (PDX models) that exhibit spontaneous lung metastases offer a potentially powerful model of cancer metastasis. In this study, we evaluated the malignant character of lung micrometastases that emerge in such models after orthotopic implantation of human breast tumor cells into the mouse mammary fat pad. Interestingly, relative to the parental primary breast tumors, the lung metastasis (met)-derived mammary tumors exhibited a slower growth rate and a reduced metastatic potential with a more differentiated epithelial status. Epigenetic correlates were determined by gene array analyses. Lung met-derived tumors displayed differential expression of negative regulators of cell proliferation and metabolism and positive regulators of mammary epithelial differentiation. Clinically, this signature correlated with breast tumor subtypes. We identified hsa-miR-138 (miR-138) as a novel regulator of invasion and epithelial-mesenchymal transition in breast cancer cells, acting by directly targeting the polycomb epigenetic regulator EZH2. Mechanistic investigations showed that GATA3 transcriptionally controlled miR-138 levels in lung metastases. Notably, the miR-138 activity signature served as a novel independent prognostic marker for patient survival beyond traditional pathologic variables, intrinsic subtypes, or a proliferation gene signature. Our results highlight the loss of malignant character in some lung micrometastatic lesions and the epigenetic regulation of this phenotype. (C) 2014 AACR.
C1 [Bockhorn, Jessica; Chang, Ya-Fang] Univ Chicago, Ben May Dept Canc Res, Chicago, IL 60637 USA.
   [Bockhorn, Jessica] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA.
   [Prat, Aleix] Vall dHebron Inst Oncol VHIO, Translat Genom Grp, Barcelona, Spain.
   [Prat, Aleix] Univ Barcelona, Dept Med Oncol, Hosp Clin, Barcelona, Spain.
   [Liu, Xia; Huang, Simo; Liu, Huiping] Case Western Reserve Univ, Case Comprehens Canc Ctr, Dept Pathol, Cleveland, OH 44106 USA.
   [Liu, Xia; Huang, Simo; Liu, Huiping] Case Western Reserve Univ, Natl Ctr Regenerat Med, Cleveland, OH 44106 USA.
   [Shang, Meng] IIT, Chicago, IL 60616 USA.
   [Nwachukwu, Chika; Gomez-Vega, Maria J.; Olopade, Olufunmilayo I.] Univ Chicago, Dept Med, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
   [Harrell, J. Chuck; Perou, Charles M.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA.
C3 University of Chicago; Stanford Cancer Institute; Stanford University;
   Vall d'Hebron Institut d'Oncologia (VHIO); University of Barcelona;
   Hospital Clinic de Barcelona; University System of Ohio; Case Western
   Reserve University; University System of Ohio; Case Western Reserve
   University; Illinois Institute of Technology; University of Chicago;
   University of North Carolina; University of North Carolina Chapel Hill
RP Liu, HP (通讯作者)，Case Western Reserve Univ, 2103 Cornell Rd,WRB2-134, Cleveland, OH 44106 USA.
EM hliu@case.edu
RI Huang, Huilin/AAA-8376-2019; Shang, Meng/GVS-6273-2022; Perou,
   Charles/H-9934-2014; Prat, Aleix/P-8561-2014
OI Harrell, J. Chuck/0000-0003-3541-8418; Liu, Huiping/0000-0003-4822-7995;
   Perou, Charles/0000-0001-9827-2247; Prat, Aleix/0000-0003-2377-540X
FU Case Western Reserve University start-up fund; National Cancer Institute
   Paul Calabresi K12 Scholar [1K12CA139160-02, K99/R00 CA160638-02]; Case
   Comprehensive Cancer Center Pilot Project [P30 CA043703-23]; Northern
   Ohio Golf Charities and Foundation
FX This study was supported in part by Case Western Reserve University
   start-up fund, National Cancer Institute Paul Calabresi K12 Scholar
   1K12CA139160-02, K99/R00 CA160638-02, Case Comprehensive Cancer Center
   Pilot Project P30 CA043703-23, and Northern Ohio Golf Charities and
   Foundation (H. Liu).
CR Antonov AV, 2009, NUCLEIC ACIDS RES, V37, pW323, DOI 10.1093/nar/gkp313
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Bockhorn J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2393
   Bockhorn J, 2013, BREAST CANCER RES TR, V137, P373, DOI 10.1007/s10549-012-2346-4
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Di Meglio T, 2013, SCIENCE, V339, P204, DOI 10.1126/science.1229326
   Gravgaard KH, 2012, BREAST CANCER RES TR, V134, P207, DOI 10.1007/s10549-012-1969-9
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guo X, 2009, RNA BIOL, V6, P575, DOI 10.4161/rna.6.5.10079
   Harrell JC, 2014, CLIN EXP METASTAS, V31, P33, DOI 10.1007/s10585-013-9607-4
   Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593
   He L., 2004, NAT REV GENET, V5, P522
   Huang J, 1999, J CELL SCI, V112, P4193
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011
   Leung N, 2008, ONCOGENE, V27, P4943, DOI 10.1038/onc.2008.136
   Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541
   Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mortenson ED, 2013, CLIN CANCER RES, V19, P1476, DOI 10.1158/1078-0432.CCR-12-2522
   Nielsen TO, 2010, CLIN CANCER RES, V16, P5222, DOI 10.1158/1078-0432.CCR-10-1282
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prat A, 2012, BREAST CANCER RES TR, V135, P301, DOI 10.1007/s10549-012-2143-0
   Prat A, 2013, ONCOLOGIST, V18, P123, DOI 10.1634/theoncologist.2012-0397
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Stankic M, 2013, CELL REP, V5, P1228, DOI 10.1016/j.celrep.2013.11.014
   Steinbrecher KA, 2008, J IMMUNOL, V180, P2588, DOI 10.4049/jimmunol.180.4.2588
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
NR 53
TC 37
Z9 48
U1 0
U2 10
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7406
EP 7417
DI 10.1158/0008-5472.CAN-14-1188
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AW6FC
UT WOS:000346363900025
PM 25339353
OA Green Submitted, Green Accepted, Green Published
DA 2025-01-12
ER

PT J
AU Hsiao, YL
   Hsieh, TZ
   Liou, CJ
   Cheng, YH
   Lin, CT
   Chang, CY
   Lai, YS
AF Hsiao, Yen-Ling
   Hsieh, Tai-Zu
   Liou, Chian-Jiun
   Cheng, Yeong-Hsiang
   Lin, Chung-Tien
   Chang, Chi-Yao
   Lai, Yu-Shen
TI Characterization of protein marker expression, tumorigenicity, and
   doxorubicin chemoresistance in two new canine mammary tumor cell lines
SO BMC VETERINARY RESEARCH
LA English
DT Article
DE Canine mammary tumor; Cell line; Heat shock protein 27; Chemoresistance;
   Tumorigenicity
ID HEAT-SHOCK-PROTEIN; HUMAN-BREAST-CANCER; EPITHELIAL-MESENCHYMAL
   TRANSITION; INTERMEDIATE FILAMENTS; HSP27; MODELS; APOPTOSIS;
   IDENTIFICATION; CYTOKERATIN; VIMENTIN
AB Background: Canine mammary tumors (CMTs) are the most common type of cancer found in female dogs. Establishment and evaluation of tumor cell lines can facilitate investigations of the biological mechanisms of cancer. Different cell models are used to investigate genetic, epigenetic, and cellular pathways, cancer progression, and cancer therapeutics. Establishment of new cell models will greatly facilitate research in this field. In the present study, we established and characterized two new CMT cell lines derived from a single CMT.
   Results: We established two cell lines from a single malignant CMT specimen: DTK-E and DTK-SME. Morphologically, the DTK-E cells were large, flat, and epithelial-like, whereas DTK-SME cells were round and epithelial-like. Doubling times were 24 h for DTK-E and 18 h for DTK-SME. On western blots, both cell lines expressed cytokeratin AE1, vimentin, cytokeratin 7 (CK7), and heat shock protein 27 (HSP27). Moreover, investigation of chemoresistance revealed that DTK-SME was more resistant to doxorubicin-induced apoptosis than DTK-E was. After xenotransplantation, both DTK-E and DTK-SME tumors appeared within 14 days, but the average size of DTK-SME tumors was greater than that of DTK-E tumors after 56 days.
   Conclusion: We established two new cell lines from a single CMT, which exhibit significant diversity in cell morphology, protein marker expression, tumorigenicity, and chemoresistance. The results of this study revealed that the DTK-SME cell line was more resistant to doxorubicin-induced apoptosis and exhibited higher tumorigenicity in vivo than the DTK-E cell line. We anticipate that the two novel CMT cell lines established in this study will be useful for investigating the tumorigenesis of mammary carcinomas and for screening anticancer drugs.
C1 [Hsiao, Yen-Ling; Cheng, Yeong-Hsiang; Lai, Yu-Shen] Natl Ilan Univ, Dept Biotechnol & Anim Sci, Yilan, Taiwan.
   [Hsieh, Tai-Zu; Lin, Chung-Tien] Natl Taiwan Univ, Dept & Grad Inst Vet Med, Taipei 10764, Taiwan.
   [Hsieh, Tai-Zu; Chang, Chi-Yao] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
   [Liou, Chian-Jiun] Chang Gung Univ Sci & Technol, Dept Nursing, Taoyuan, Taiwan.
   [Liou, Chian-Jiun] Chang Gung Univ Sci & Technol, Res Ctr Ind Human Ecol, Taoyuan, Taiwan.
C3 National Ilan University; National Taiwan University; Academia Sinica -
   Taiwan; Chang Gung University of Science & Technology; Chang Gung
   University of Science & Technology
RP Chang, CY (通讯作者)，Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
EM ychang@gate.sinica.edu.tw; yslai@niu.edu.tw
FU National Science Council, Taiwan [NSC 91-2320-B-001-049-B,
   94-2815-C-197-013-B]
FX This study was supported by grant nos. NSC 91-2320-B-001-049-B and
   94-2815-C-197-013-B from the National Science Council, Taiwan.
CR BRODEY RS, 1983, J AM ANIM HOSP ASSOC, V19, P61
   Chang CY, 2010, RES VET SCI, V88, P285, DOI 10.1016/j.rvsc.2009.08.006
   Chu PG, 2000, MODERN PATHOL, V13, P962, DOI 10.1038/modpathol.3880175
   CIOCCA DR, 1993, JNCI-J NATL CANCER I, V85, P1558, DOI 10.1093/jnci/85.19.1558
   Ciocca DR, 2005, CELL STRESS CHAPERON, V10, P86, DOI 10.1379/CSC-99r.1
   De Los Monteros AE, 1999, VET PATHOL, V36, P179, DOI 10.1354/vp.36-3-179
   De Maio A, 1999, SHOCK, V11, P1, DOI 10.1097/00024382-199901000-00001
   Devaja O, 1997, EUR J GYNAECOL ONCOL, V18, P16
   Di X, 2009, BIOCHEM PHARMACOL, V77, P1139, DOI 10.1016/j.bcp.2008.12.016
   Díaz-Chávez J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064378
   El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559
   Gazdar AF, 2010, JNCI-J NATL CANCER I, V102, P1310, DOI 10.1093/jnci/djq279
   Grzegrzolka J, 2012, FOLIA HISTOCHEM CYTO, V50, P527, DOI [10.5603/FHC.2012.0074, 10.5603/16717]
   Gudjonsson T, 2005, J MAMMARY GLAND BIOL, V10, P261, DOI 10.1007/s10911-005-9586-4
   GUPTA RK, 1992, CYTOPATHOLOGY, V3, P303, DOI 10.1111/j.1365-2303.1992.tb00052.x
   Hansen RK, 1999, BREAST CANCER RES TR, V56, P187
   Harbaum L, 2011, HISTOPATHOLOGY, V59, P225, DOI 10.1111/j.1365-2559.2011.03694.x
   Havasi A, 2008, J BIOL CHEM, V283, P12305, DOI 10.1074/jbc.M801291200
   HELLMEN E, 1989, VET PATHOL, V26, P420, DOI 10.1177/030098588902600507
   HENDERSON D, 1981, EXP CELL RES, V132, P297, DOI 10.1016/0014-4827(81)90106-3
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Korsching E, 2005, J PATHOL, V206, P451, DOI 10.1002/path.1797
   Lemieux Pierre, 1997, Invasion and Metastasis, V17, P113
   Louzada S, 2012, PLOS ONE, V7, P206, DOI 10.1371/journal.pone.0029923
   LOVE S, 1994, BRIT J CANCER, V69, P743, DOI 10.1038/bjc.1994.140
   MACEWEN EG, 1990, CANCER METAST REV, V9, P125, DOI 10.1007/BF00046339
   MARTIN PM, 1984, CANCER CHEMOTH PHARM, V12, P13
   Misdorp W., 2002, Tumors in domestic animals, P575, DOI 10.1002/9780470376928.ch12
   Morimoto RI, 1997, ESSAYS BIOCHEM, V32, P17
   Nakatsu N, 2005, MOL CANCER THER, V4, P399
   Nieto A, 2000, VET PATHOL, V37, P239, DOI 10.1354/vp.37-3-239
   NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453
   OESTERREICH S, 1993, CANCER RES, V53, P4443
   Pfragner R, 2009, ANTICANCER RES, V29, P1951
   Romanucci M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-171
   RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69
   Ruhe JE, 2007, CANCER RES, V67, P11368, DOI 10.1158/0008-5472.CAN-07-2703
   Shi P, 2008, CHINESE MED J-PEKING, V121, P1975, DOI 10.1097/00029330-200810020-00005
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Thanner F, 2005, ANTICANCER RES, V25, P1649
   TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319
   van Staveren WCG, 2009, BBA-REV CANCER, V1795, P92, DOI 10.1016/j.bbcan.2008.12.004
   Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193
   Wei L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3042
NR 45
TC 7
Z9 9
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1746-6148
J9 BMC VET RES
JI BMC Vet. Res.
PD SEP 30
PY 2014
VL 10
AR 229
DI 10.1186/s12917-014-0229-0
PG 9
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA AX2XM
UT WOS:000346805700001
PM 25267010
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Fleischer, T
   Frigessi, A
   Johnson, KC
   Edvardsen, H
   Touleimat, N
   Klajic, J
   Riis, MLH
   Haakensen, VD
   Wärnberg, F
   Naume, B
   Helland, Å
   Borresen-Dale, AL
   Tost, J
   Christensen, BC
   Kristensen, VN
AF Fleischer, Thomas
   Frigessi, Arnoldo
   Johnson, Kevin C.
   Edvardsen, Hege
   Touleimat, Nizar
   Klajic, Jovana
   Riis, Margit L. H.
   Haakensen, Vilde D.
   Warnberg, Fredrik
   Naume, Bjorn
   Helland, Aslaug
   Borresen-Dale, Anne-Lise
   Tost, Jorg
   Christensen, Brock C.
   Kristensen, Vessela N.
TI Genome-wide DNA methylation profiles in progression to <i>in situ</i>
   and invasive carcinoma of the breast with impact on gene transcription
   and prognosis
SO GENOME BIOLOGY
LA English
DT Article
ID CPG ISLAND METHYLATION; MOLECULAR SUBTYPES; MAMMOGRAPHIC DENSITY;
   CANCER; DISEASE; CARCINOGENESIS; IDENTIFICATION; EXPRESSION; RECEPTOR;
   FREQUENT
AB Background: Ductal carcinoma in situ (DCIS) of the breast is a precursor of invasive breast carcinoma. DNA methylation alterations are thought to be an early event in progression of cancer, and may prove valuable as a tool in clinical decision making and for understanding neoplastic development.
   Results: We generate genome-wide DNA methylation profiles of 285 breast tissue samples representing progression of cancer, and validate methylation changes between normal and DCIS in an independent dataset of 15 normal and 40 DCIS samples. We also validate a prognostic signature on 583 breast cancer samples from The Cancer Genome Atlas. Our analysis reveals that DNA methylation profiles of DCIS are radically altered compared to normal breast tissue, involving more than 5,000 genes. Changes between DCIS and invasive breast carcinoma involve around 1,000 genes. In tumors, DNA methylation is associated with gene expression of almost 3,000 genes, including both negative and positive correlations. A prognostic signature based on methylation level of 18 CpGs is associated with survival of breast cancer patients with invasive tumors, as well as with survival of patients with DCIS and mixed lesions of DCIS and invasive breast carcinoma.
   Conclusions: This work demonstrates that changes in the epigenome occur early in the neoplastic progression, provides evidence for the possible utilization of DNA methylation-based markers of progression in the clinic, and highlights the importance of epigenetic changes in carcinogenesis.
C1 [Fleischer, Thomas; Edvardsen, Hege; Klajic, Jovana; Haakensen, Vilde D.; Helland, Aslaug; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.] OUS Radiumhosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
   [Fleischer, Thomas; Klajic, Jovana; Haakensen, Vilde D.; Borresen-Dale, Anne-Lise; Kristensen, Vessela N.] Univ Oslo, Fac Med, KG Jebsen Ctr Breast Canc Res, Inst Clin Med, N-0318 Oslo, Norway.
   [Frigessi, Arnoldo] Univ Oslo, Oslo Ctr Biostat & Epidemiol, Dept Biostat, N-0424 Oslo, Norway.
   [Frigessi, Arnoldo] Oslo Univ Hosp, Res Support Serv, N-0424 Oslo, Norway.
   [Johnson, Kevin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Sect Biostat & Epidemiol, Hanover, NH 03755 USA.
   [Johnson, Kevin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.
   [Touleimat, Nizar; Tost, Jorg] CEA, Inst Genom, Ctr Natl Genotypage, Lab Epigenet & Environm, F-91000 Evry, France.
   [Klajic, Jovana; Riis, Margit L. H.; Kristensen, Vessela N.] Akershus Univ Hosp, Dept Clin Mol Biol & Lab Sci EpiGen, Div Med, N-1476 Lorenskog, Norway.
   [Riis, Margit L. H.] Akershus Univ Hosp, Dept Surg, N-1478 Lorenskog, Norway.
   [Riis, Margit L. H.] Oslo Univ Hosp, Dept Breast & Endocrine Surg, N-0450 Oslo, Norway.
   [Warnberg, Fredrik] Uppsala Univ, Uppsala Acad Hosp, Dept Surg, SE-75185 Uppsala, Sweden.
   [Naume, Bjorn; Helland, Aslaug] Oslo Univ Hosp, Radiumhosp, Dept Oncol, N-0379 Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; Dartmouth
   College; Dartmouth College; Universite Paris Saclay; CEA; University of
   Oslo; University of Oslo; University of Oslo; Uppsala University;
   Uppsala University Hospital; University of Oslo
RP Kristensen, VN (通讯作者)，OUS Radiumhosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway.
EM v.n.kristensen@medisin.uio.no
RI Christensen, Brock/B-8460-2009; Helland, Aslaug/H-3910-2015; Tost,
   Jorg/H-7129-2019; Fleischer, Thomas/T-8066-2017
OI Frigessi, Arnoldo/0000-0001-7103-7589; Haakensen, Vilde
   Drageset/0000-0003-0864-3628; Helland, Aslaug/0000-0002-5520-0275;
   Warnberg, Fredrik/0000-0002-0130-7296; Tost, Jorg/0000-0002-2683-0817;
   Fleischer, Thomas/0000-0003-0985-8460
FU NFR-Kreft [193387/H10]; K.G. Jebsen Center for breast cancer research,
   DNK: The genetic makeup of breast cancer patients [368039-6260-33220];
   K.G. Jebsen Center [2639032]; NIH [P20GM104416]
FX TF was a PhD fellow at the Faculty of Medicine, University of Oslo. This
   research was supported by NFR-Kreft grant no. 193387/H10, K.G. Jebsen
   Center for breast cancer research, DNK: The genetic makeup of breast
   cancer patients grant no. 368039-6260-33220, HSO: OSBRAC 39346 (OUS
   no.), HSO: The participation of Ahus on the K.G. Jebsen Center grant no.
   2639032, and NIH grant P20GM104416 (BCC).
CR [Anonymous], 2014, A language and environment for statistical computing
   [Anonymous], 2010, EMAP MAP GENE EXPRES
   Bailey CM, 2008, CELL CYCLE, V7, P1925, DOI 10.4161/cc.7.13.6221
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bhagat R, 2012, CELL ONCOL, V35, P473, DOI 10.1007/s13402-012-0106-4
   Bijker N, 2006, J CLIN ONCOL, V24, P3381, DOI 10.1200/JCO.2006.06.1366
   Botti E, 2011, P NATL ACAD SCI USA, V108, P13710, DOI 10.1073/pnas.1110931108
   Bovelstad HM, 2007, BIOINFORMATICS, V23, P2080, DOI 10.1093/bioinformatics/btm305
   Coon Brian G, 2011, Commun Integr Biol, V4, P95, DOI 10.4161/cib.4.1.14129
   De Smaele E, 2011, NEOPLASIA, V13, P374, DOI 10.1593/neo.101630
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dowell JD, 2007, BBA-MOL CELL RES, V1773, P358, DOI 10.1016/j.bbamcr.2006.11.020
   Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Feinberg AP, 2010, P NATL ACAD SCI USA, V107, P1757, DOI 10.1073/pnas.0906183107
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797
   Gao F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054114
   Haakensen VD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2632
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hastie T., 2014, PAMR PAM PREDICTION
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hiraoka N, 2011, GASTROENTEROLOGY, V140, P310, DOI 10.1053/j.gastro.2010.10.009
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Kamalakaran S, 2011, MOL ONCOL, V5, P77, DOI 10.1016/j.molonc.2010.11.002
   Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65
   Kang GH, 2001, CANCER RES, V61, P2847
   Kim SS, 2007, CANCER RES, V67, P9616, DOI 10.1158/0008-5472.CAN-07-0644
   Kishida Y, 2012, CARCINOGENESIS, V33, P436, DOI 10.1093/carcin/bgr260
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443
   Luo YX, 2014, GASTROENTEROLOGY, V147, P418, DOI 10.1053/j.gastro.2014.04.039
   Maekawa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066632
   Maunakea AK, 2010, NATURE, V466, P253, DOI 10.1038/nature09165
   Mishra SK, 2004, ONCOGENE, V23, P4422, DOI 10.1038/sj.onc.1207569
   Morris TJ, 2014, BIOINFORMATICS, V30, P428, DOI 10.1093/bioinformatics/btt684
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Muggerud AA, 2010, MOL ONCOL, V4, P357, DOI 10.1016/j.molonc.2010.06.007
   Naume B, 2007, MOL ONCOL, V1, P160, DOI 10.1016/j.molonc.2007.03.004
   Navarro A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033284
   Oosting J, 2012, QUANTSMOOTH QUANTILE
   Pang JMB, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3420
   Paradis V, 2013, GUT, V62, P911, DOI 10.1136/gutjnl-2012-302091
   Ronneberg JA, 2011, MOL ONCOL, V5, P61, DOI 10.1016/j.molonc.2010.11.004
   Stevens KN, 2012, HUM MOL GENET, V21, P3299, DOI 10.1093/hmg/dds158
   Tao T, 2013, CELL RES, V23, P620, DOI 10.1038/cr.2013.16
   Therneau T., 2013, A package for survival analysis in s
   Tibshirani R, 1996, J ROY STAT SOC B, V58, P267, DOI 10.1111/j.2517-6161.1996.tb02080.x
   Tibshirani R., 2011, samr: SAM: Significance Analysis of Microarrays, DOI DOI 10.1111/j.1365-313x.2011.04514.x
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Touleimat N, EPIGENOMICS
   Tsioras K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082172
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Verschuur-Maes AHJ, 2012, BREAST CANCER RES TR, V136, P705, DOI 10.1007/s10549-012-2301-4
   Yamamoto E, 2012, AM J PATHOL, V181, P1847, DOI 10.1016/j.ajpath.2012.08.007
   Yu J, 2010, ONCOGENE, V29, P6464, DOI 10.1038/onc.2010.370
   Zaoui K, 2010, P NATL ACAD SCI USA, V107, P18517, DOI 10.1073/pnas.1000975107
NR 58
TC 149
Z9 171
U1 0
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1474-760X
J9 GENOME BIOL
JI Genome Biol.
PY 2014
VL 15
IS 8
AR 435
DI 10.1186/s13059-014-0435-x
PG 13
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AW9UU
UT WOS:000346604100016
PM 25146004
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Li, Z
   Lei, HZ
   Luo, M
   Wang, Y
   Dong, L
   Ma, YN
   Liu, CZ
   Song, W
   Wang, F
   Zhang, JW
   Shen, JX
   Yu, J
AF Li, Zheng
   Lei, Huizi
   Luo, Min
   Wang, Yi
   Dong, Lei
   Ma, Yanni
   Liu, Changzheng
   Song, Wei
   Wang, Fang
   Zhang, Junwu
   Shen, Jianxiong
   Yu, Jia
TI DNA methylation downregulated mir-10b acts as a tumor suppressor in
   gastric cancer
SO GASTRIC CANCER
LA English
DT Article
DE Gastric cancer; miR-10b; Tumor suppressor; Methylation
ID BREAST-CANCER; EPIGENETIC REGULATION; MICRORNA EXPRESSION; CELL
   INVASION; METASTASIS; MIGRATION; PROMOTES; TIAM1; INVASIVENESS;
   INVOLVEMENT
AB MicroRNAs act as tumor suppressors or oncogenes. The pathological roles of miRNAs in gastric tumorigenesis are largely unknown. Although miR-10b was identified as an miRNA deregulator expressed in gastric cancer (GC), there also exists some debate on whether miR-10b is acting as tumor suppressor or oncogene in GC.
   Quantitative RT-PCR was employed to investigate the level of miR-10b in GC tissues and matched adjacent normal tissues (n = 100). In vitro cell proliferation, apoptosis assays, cell migration, and invasion assays were performed to elucidate the biological effects of miR-10b. Because silencing of miRNA by promoter CpG island methylation may be an important mechanism in tumorigenesis, GC cells were treated with 5-aza-2'-deoxycytidine and trichostatin A, and expression changes of miR-10b were subsequently examined by quantitative RT-PCR. Furthermore, the methylation status of the CpG island upstream of miR-10b was analyzed by methylation-specific PCR in GC tissues (n = 29).
   We showed here that miR-10b was significantly downregulated in GC cell lines and tissues as demonstrated by quantitative real-time PCR. Overexpression of miR-10b in MGC-803 and HGC-27 dramatically suppressed cell proliferation, migration, invasion, and induced apoptosis. Moreover, we demonstrated that T-cell lymphoma invasion and metastasis (Tiam1) was a target of miR-10b. Furthermore, 5-aza-2'-deoxycytidine and trichostain A increased miR-10b expression, and the methylation level was high in the CpG islands upstream of miR-10b gene.
   Taken together, these findings suggest that miR-10b may function as a novel tumor suppressor and is partially silenced by DNA hypermethylation in GC.
C1 [Li, Zheng; Shen, Jianxiong] Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Orthoped Surg, Beijing 100021, Peoples R China.
   [Li, Zheng; Lei, Huizi; Luo, Min; Dong, Lei; Ma, Yanni; Liu, Changzheng; Song, Wei; Wang, Fang; Zhang, Junwu; Yu, Jia] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Biochem, PUMC, Beijing 100005, Peoples R China.
   [Lei, Huizi] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Pathol, Beijing 100021, Peoples R China.
   [Wang, Yi] Chinese Acad Med Sci, Canc Inst & Hosp, Dept VIP, Beijing 100021, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Peking Union Medical College Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Institute of Basic Medical Sciences -
   CAMS; Chinese Academy of Medical Sciences - Peking Union Medical
   College; Cancer Institute & Hospital - CAMS; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Cancer Institute & Hospital -
   CAMS
RP Shen, JX (通讯作者)，Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Orthoped Surg, Beijing 100021, Peoples R China.
EM shenjianxiong@medmail.com.cn; j-yu@ibms.pumc.edu.cn
RI Dong, Lei/AAA-9495-2020; Shen, Jianxiong/AAH-6200-2019; Pan,
   Yuesong/AAI-6303-2020
OI Dong, Lei/0000-0001-9574-0148
FU National Natural Science Foundation of China [91129716]; Beijing
   Municipal Science & Technology Commission [2010B071]
FX This work was supported by grants from the National Natural Science
   Foundation of China [2012, 91129716, to JY] and the Beijing Municipal
   Science & Technology Commission [2010B071, to JY]. The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   Bandres E, 2009, INT J CANCER, V125, P2737, DOI 10.1002/ijc.24638
   Breving K, 2010, INT J BIOCHEM CELL B, V42, P1316, DOI 10.1016/j.biocel.2009.09.016
   Chai GL, 2010, CANCER SCI, V101, P1997, DOI 10.1111/j.1349-7006.2010.01616.x
   Cullen BR, 2013, NAT IMMUNOL, V14, P205, DOI 10.1038/ni.2537
   Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616
   HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X
   Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464
   Ibrahim SA, 2012, INT J CANCER, V131, pE884, DOI 10.1002/ijc.27629
   Ichikawa D, 2012, GASTROENTEROLOGY, V142, P1074, DOI 10.1053/j.gastro.2012.03.008
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Kim K, 2011, EPIGENETICS-US, V6, P740, DOI 10.4161/epi.6.6.15874
   Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256
   Li G, 2010, CANCER LETT, V299, P29, DOI 10.1016/j.canlet.2010.07.021
   Li QJ, 2012, TUMOR BIOL, V33, P1455, DOI 10.1007/s13277-012-0396-1
   Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497
   Liu Z, 2012, INT J ONCOL, V40, P1553, DOI 10.3892/ijo.2012.1342
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Ma L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2720
   MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0
   Minard ME, 2004, BREAST CANCER RES TR, V84, P21, DOI 10.1023/B:BREA.0000018421.31632.e6
   Moriarty CH, 2010, J BIOL CHEM, V285, P20541, DOI 10.1074/jbc.M110.121012
   Nakata K, 2011, SURGERY, V150, P916, DOI 10.1016/j.surg.2011.06.017
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Phua SLC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025689
   Sasayama T, 2009, INT J CANCER, V125, P1407, DOI 10.1002/ijc.24522
   Shi YL, 2013, CHINESE MED J-PEKING, V126, P640, DOI 10.3760/cma.j.issn.0366-6999.20122167
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Teplyuk NM, 2012, NEURO-ONCOLOGY, V14, P689, DOI 10.1093/neuonc/nos074
   Tian YY, 2010, J BIOL CHEM, V285, P7986, DOI 10.1074/jbc.M109.062877
   Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126
   Walch A, 2008, MODERN PATHOL, V21, P544, DOI 10.1038/modpathol.2008.3
   Wang YY, 2013, HUM PATHOL, V44, P1278, DOI 10.1016/j.humpath.2012.10.014
   Yamamoto H, 2012, WORLD J GASTROENTERO, V18, P2745, DOI 10.3748/wjg.v18.i22.2745
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
NR 35
TC 210
Z9 223
U1 0
U2 75
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1436-3291
EI 1436-3305
J9 GASTRIC CANCER
JI Gastric Cancer
PD JAN
PY 2015
VL 18
IS 1
BP 43
EP 54
DI 10.1007/s10120-014-0340-8
PG 12
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA AW0GF
UT WOS:000345968500005
PM 24481854
OA Bronze
DA 2025-01-12
ER

PT J
AU Rawat, A
   Gopisetty, G
   Thangarajan, R
AF Rawat, Akhilesh
   Gopisetty, Gopal
   Thangarajan, Rajkumar
TI <i>E4BP4</i> is a repressor of epigenetically regulated <i>SOSTDC1</i>
   expression in breast cancer cells
SO CELLULAR ONCOLOGY
LA English
DT Article
DE Breast cancer; SOSTDC1; Epigenetic; Methylation; 5 '-Aza-dC; E4BP4
ID PROMOTER HYPERMETHYLATION; TRANSCRIPTIONAL REPRESSOR; CPG METHYLATION;
   DNA METHYLATION
AB We and others show that SOSTDC1 is down-regulated in breast cancer tissues compared to matched normal tissues. Previously, we found that epigenetic mechanisms underlie the down-regulation of SOSTDC1 in gastric cancer cells. The aim of this study was to assess the putative epigenetic regulation of SOSTDC1 expression in breast cancer cells.
   Microarray-based expression profiling was performed in a series of primary breast cancers and matched normal tissues. Real-time PCR was performed to assess SOSTDC1 and E4BP4 mRNA levels in MCF7, BT549, MBMDA231, T47D (breast cancer) and HEK293T (normal kidney) cell lines. Methylation-specific PCR (MSP) and bisulfite sequencing PCR (BSP) were performed to assess the methylation level of the SOSTDC1 gene promoter, and 5-Aza 2-deoxycytidine (5'-Aza-dC) treatment was used to induce its demethylation. A luciferase assay was used to measure SOSTDC1 promoter activity in vitro. Stable shRNA-mediated knockdown of E4BP4 was carried out in MCF7 cells and confirmed by Western blotting. Finally, MCF7 cell proliferation and survival were measured by MTS assay.
   We found that SOSTDC1 is frequently down-regulated in primary breast cancers (98.2 %) and in all breast cancer cell lines tested. MSP and BSP analyses revealed SOSTC1 promoter hypermethylation at CpG sites. 5'-Aza-dC treatment induced a striking down-regulation of SOSTDC1 gene expression, whereas BSP analysis showed demethylation of its promoter. Subsequent in silico SOSTDC1 promoter analysis indicated the presence of putative transcriptional repressor E4BP4 binding sites, and promoter deletion studies indeed revealed repressor binding regions encompassing these E4BP4 binding sites. Relative quantification of E4BP4 expression showed an inverse correlation to SOSTDC1 expression in the breast cancer cell lines tested. Exogenous over-expression of E4BP4 in HEK-293 and BT549 cells reduced SOSTDC1 expression and its promoter activity, respectively. Stable shRNA-mediated E4BP4 BT549 and MCF7 knock-down cells treated with 5'-Aza-dC exhibited up-regulation of SOSTDC1 expression and a concomitant inhibition of cell proliferation and survival.
   From our results we conclude that the transcriptional repressor E4BP4 plays a role in repressing epigenetically regulated SOSTDC1 expression in breast cancer cells, which can be reverted by E4BP4 silencing.
C1 [Rawat, Akhilesh; Gopisetty, Gopal; Thangarajan, Rajkumar] Canc Inst WIA, Dept Mol Oncol, Chennai 600036, Tamil Nadu, India.
RP Thangarajan, R (通讯作者)，Canc Inst WIA, Dept Mol Oncol, 38,Sardar Patel Rd, Chennai 600036, Tamil Nadu, India.
EM drtrajkumar@gmail.com
RI RAJKUMAR, THANGARAJAN/AAZ-5663-2020; Gopisetty, Gopal/ABB-6470-2020
OI Gopisetty, Gopal/0000-0002-7869-4343
FU Department of Science and Technology, Government of India
FX This study was funded by the Department of Science and Technology,
   Government of India.
CR Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200
   Blish KR, 2008, MOL BIOL CELL, V19, P457, DOI 10.1091/mbc.E07-05-0433
   Clausen KA, 2011, BREAST CANCER RES TR, V129, P737, DOI 10.1007/s10549-010-1261-9
   Cowell IG, 1996, NUCLEIC ACIDS RES, V24, P3607, DOI 10.1093/nar/24.18.3607
   Cowell IG, 2002, BIOESSAYS, V24, P1023, DOI 10.1002/bies.10176
   COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070
   de Groot JS, 2014, CELL ONCOL, V37, P297, DOI 10.1007/s13402-014-0189-1
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Gopal G, 2013, CANCER GENET-NY, V206, P174, DOI 10.1016/j.cancergen.2013.04.005
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Rajkumar T., 2010, CANCER CELL INT, V10, P1475
   Rajkumar T, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-45
   Rawat A, 2013, CELL ONCOL, V36, P459, DOI 10.1007/s13402-013-0150-8
   Tabarestani S, 2014, CELL ONCOL, V37, P107, DOI 10.1007/s13402-013-0165-1
   van Kessel AG, 2014, CELL ONCOL, V37, P155, DOI 10.1007/s13402-014-0177-5
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 17
TC 23
Z9 25
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 2211-3428
EI 2211-3436
J9 CELL ONCOL
JI Cell. Oncol.
PD DEC
PY 2014
VL 37
IS 6
BP 409
EP 419
DI 10.1007/s13402-014-0204-6
PG 11
WC Oncology; Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology; Pathology
GA AW0OZ
UT WOS:000345993800003
PM 25338303
DA 2025-01-12
ER

PT J
AU Han, RF
   Li, K
   Yang, ZS
   Chen, ZG
   Yang, WC
AF Han, Rong-Fei
   Li, Kai
   Yang, Zi-Shan
   Chen, Zhi-Guo
   Yang, Wan-Cai
TI Trichostatin A induces mesenchymal-like morphological change and gene
   expression but inhibits migration and colony formation in human cancer
   cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE TSA; EMT; migration; cancer cells
ID HISTONE DEACETYLASE INHIBITORS; TRANSITION; PROGRESSION; METASTASIS;
   ACTIVATION; CARCINOMA; BREAST; GROWTH; HDAC6
AB Histone deacetylases (HDACs) are enzymes that catalyze the removal of acetyl from lysine residues in histones and other proteins, which results in gene transcriptional repression and subsequent changes in signaling events. HDACs inhibitors (HDACIs) have been used to reverse the aberrant epigenetic changes associated with cancer. However, the effects of HDACIs on epithelial-mesenchymal transition (EMT) in human cancer cells remain unclear. EMT is a fundamental process governing morphogenesis in multicellular organisms and promotes cancer invasion and metastasis. In this study, human cancer cells were treated with the HDAC1 trichostatin A (TSA). TSA was found to induce mesenchymal-like morphological changes in BGC-823 human gastric cancer and MCF-7 breast cancer cells, and increase the expression levels of the mesenchymal markers Vimentin and Twist. However, the expression levels of the epithelial cell marker E-cadherin were also increased in response to TSA treatment, while cell migration was reduced by TSA. Furthermore, TSA decreased cancer cell colony formation in BGC-823 and MCF-7 cells, and led to the deregulation of beta-catenin, a critical signaling molecule involved in EMT. In conclusion, the results suggested that TSA exhibits dual functions in EMT induction and inhibition in human cancer cells, but the detailed mechanisms require further investigation.
C1 [Han, Rong-Fei] Xinxiang Med Univ, Dept Biochem, Xinxiang 453003, Henan, Peoples R China.
   [Li, Kai; Yang, Zi-Shan; Chen, Zhi-Guo; Yang, Wan-Cai] Xinxiang Med Univ, Dept Pathol, Xinxiang 453003, Henan, Peoples R China.
   [Yang, Wan-Cai] Univ Illinois, Dept Pathol, Chicago, IL 60612 USA.
C3 Xinxiang Medical University; Xinxiang Medical University; University of
   Illinois System; University of Illinois Chicago; University of Illinois
   Chicago Hospital
RP Yang, WC (通讯作者)，Xinxiang Med Univ, Dept Pathol, 601 East Jinsui Ave, Xinxiang 453003, Henan, Peoples R China.
EM wyang06@uic.edu
RI jia, xiaolong/HII-6615-2022; Yang, Wancai/O-7655-2019
OI Yang, Wancai/0000-0001-7437-9197
FU Nature Science Foundation of China [91229115, 81272251]; Xinxiang
   Medical University New Faculty Startup Fund
FX This study was supported in part by the Nature Science Foundation of
   China (grant nos. 91229115 and 81272251) and by the Xinxiang Medical
   University New Faculty Startup Fund.
CR Acharya MR, 2005, MOL PHARMACOL, V68, P917, DOI 10.1124/mol.105.014167
   Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001
   Bi XL, 2012, CARCINOGENESIS, V33, P326, DOI 10.1093/carcin/bgr293
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574
   Buchwald M, 2009, CANCER LETT, V280, P160, DOI 10.1016/j.canlet.2009.02.028
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200
   Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011
   Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045045
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Li Y, 2008, J BIOL CHEM, V283, P12686, DOI 10.1074/jbc.C700185200
   Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010
   Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Roth SY, 2001, ANNU REV BIOCHEM, V70, P81, DOI 10.1146/annurev.biochem.70.1.81
   Sahai E, 2007, NAT REV CANCER, V7, P737, DOI 10.1038/nrc2229
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Winer IS, 2006, J BIOL CHEM, V281, P26181, DOI 10.1074/jbc.M604217200
   Yoshikawa M, 2007, J AM SOC NEPHROL, V18, P58, DOI 10.1681/ASN.2005111187
NR 22
TC 15
Z9 15
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2014
VL 10
IS 6
BP 3211
EP 3216
DI 10.3892/mmr.2014.2594
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AU9YM
UT WOS:000345947900063
PM 25269990
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhang, BB
   Guo, XR
   Zhang, JX
   Liu, X
   Zhan, XB
   Li, ZS
AF Zhang, Beibei
   Guo, Xiaorong
   Zhang, Jingxi
   Liu, Xiao
   Zhan, Xianbao
   Li, Zhaoshen
TI MicroRNA-224 is downregulated in mucinous cystic neoplasms of the
   pancreas and may regulate tumorigenesis by targeting Jagged1
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE mucinous cystic neoplasms of pancreas; microRNA-224; Jagged 1;
   tumorigenesis
ID EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; CANCER-CELLS; DUCTAL
   ADENOCARCINOMA; BREAST-CANCER; NOTCH LIGAND; EXPRESSION; PATHWAYS;
   GENES; JAG1
AB The underlying malignancy of mucinous cystic neoplasms (MCNs) of the pancreas most commonly results in patients undergoing surgery. The tumorigenesis of MCNs remains elusive and few studies have investigated the role of specific micro (mi)RNAs in MCNs. The present study focused on the expression of miRNA-224 and its putative target gene Jagged1 (Jag1) to examine its role in tumorigenesis and its suitability as a biomarker for MCNs. Paired tissue samples confirmed by surgical pathology were used to screen the mi RNAs involved in MCNs with miRNA microarrays (n=3), and to verify the differentially expressed miRNAs (n=3) and mRNAs of candidate target genes of miRNAs by quantitative polymerase chain reaction (qPCR; n=8). Immunohistochemistry was conducted to confirm the expression and location of Jag1 in the neoplastic epithelial cells. Luciferase assays were performed. to confirm the direct target gene of miRNA-224. mi RNA microarray analysis revealed that two differentially expressed miRNAs were closely associated with tumorigenesis and pancreatic diseases. The qPCR results revealed that miRNA-224 was more significantly aberrantly expressed and the mRNA expression levels of its putative target gene, Jag1, were upregulated. Strong, diffuse cytoplasmic immunohistochemical labeling of Jag1 with occasional nuclear labeling was detected in the mucinous epithelium. Luciferase reporter activity was significantly reduced by co-transfected miRNA-224 mimics and pMIR-Jag1-wild-type, which suggested that miRNA-224 bound to recognition sites in the 3' untranslated region of its target mRNA, Jag1. In conclusion, miRNA-224 was downregulated in MCNs and may regulate tumorigenesis by targeting Jag1. Further studies investigating the role of miRNAs and functional analysis of epigenetic alterations are required to examine the diagnostic and therapeutic potential of miRNAs in MCNs.
C1 [Zhang, Beibei; Guo, Xiaorong; Zhang, Jingxi; Liu, Xiao; Zhan, Xianbao; Li, Zhaoshen] Second Mil Med Univ, Dept Gastroenterol, Changhai Hosp, Shanghai 200433, Peoples R China.
C3 Naval Medical University
RP Zhan, XB (通讯作者)，Second Mil Med Univ, Dept Gastroenterol, Changhai Hosp, Shanghai 200433, Peoples R China.
EM xianbaozhan@yahoo.com; zhsli@81890.net
RI Zhan, Xianbao/I-4084-2018
OI Zhan, Xianbao/0000-0003-3718-466X
FU Innovation Program of Shanghai Municipal Education Commission [11ZZ72]
FX The study was supported by Innovation Program of Shanghai Municipal
   Education Commission (11ZZ72).
CR Ban J, 2008, CANCER RES, V68, P7100, DOI 10.1158/0008-5472.CAN-07-6145
   Bao B, 2011, CANCER LETT, V307, P26, DOI 10.1016/j.canlet.2011.03.012
   Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901
   Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349
   Crippa S, 2008, ANN SURG, V247, P571, DOI 10.1097/SLA.0b013e31811f4449
   Crippa S, 2010, CLIN GASTROENTEROL H, V8, P213, DOI 10.1016/j.cgh.2009.10.001
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Dickson BC, 2007, MODERN PATHOL, V20, P685, DOI 10.1038/modpathol.3800785
   du Rieu MC, 2010, CLIN CHEM, V56, P603, DOI 10.1373/clinchem.2009.137364
   Fukushima N, 2004, ONCOGENE, V23, P9042, DOI 10.1038/sj.onc.1208117
   Goh BKP, 2006, WORLD J SURG, V30, P2236, DOI 10.1007/s00268-006-0126-1
   Golson ML, 2009, MECH DEVELOP, V126, P687, DOI 10.1016/j.mod.2009.05.005
   Golson ML, 2009, GASTROENTEROLOGY, V136, P1761, DOI 10.1053/j.gastro.2009.01.040
   Grogan JR, 2001, AM J ROENTGENOL, V176, P921, DOI 10.2214/ajr.176.4.1760921
   Habbe N, 2009, CANCER BIOL THER, V8, P340, DOI 10.4161/cbt.8.4.7338
   Izeradjene K, 2007, CANCER CELL, V11, P229, DOI 10.1016/j.ccr.2007.01.017
   Jamieson NB, 2012, CLIN CANCER RES, V18, P534, DOI 10.1158/1078-0432.CCR-11-0679
   Katoh M, 2006, INT J MOL MED, V17, P681
   Kiefel H, 2010, ONCOGENE, V29, P4766, DOI 10.1038/onc.2010.230
   Levy L, 2005, MOL CELL BIOL, V25, P8108, DOI 10.1128/MCB.25.18.8108-8125.2005
   Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797
   Matthaei H, 2011, NAT REV GASTRO HEPAT, V8, P141, DOI 10.1038/nrgastro.2011.2
   Mees ST, 2009, ANN SURG ONCOL, V16, P2339, DOI 10.1245/s10434-009-0531-4
   Pang RTK, 2010, CARCINOGENESIS, V31, P1037, DOI 10.1093/carcin/bgq066
   Prueitt RL, 2008, PROSTATE, V68, P1152, DOI 10.1002/pros.20786
   Remmers N, 2011, CANCER BIOMARK, V9, P421, DOI 10.3233/CBM-2011-0168
   Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106
   Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200
   Sawhney MS, 2009, GASTROINTEST ENDOSC, V69, P1106, DOI 10.1016/j.gie.2008.08.015
   Selcuklu SD, 2012, BIOCHEM BIOPH RES CO, V423, P234, DOI 10.1016/j.bbrc.2012.05.074
   Sorio C, 2005, VIRCHOWS ARCH, V446, P239, DOI 10.1007/s00428-004-1167-1
   Steg AD, 2011, CLIN CANCER RES, V17, P5674, DOI 10.1158/1078-0432.CCR-11-0432
   Szafranska AE, 2008, CLIN CHEM, V54, P1716, DOI 10.1373/clinchem.2008.109603
   TAN MH, 1986, CANCER INVEST, V4, P15, DOI 10.3109/07357908609039823
   Testini M, 2010, WORLD J GASTROENTERO, V16, P5682, DOI 10.3748/wjg.v16.i45.5682
   Vaccaro V, 2011, EXPERT OPIN THER TAR, V15, P1183, DOI 10.1517/14728222.2011.607438
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wang ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020537
   Yao GD, 2010, MOL ENDOCRINOL, V24, P540, DOI 10.1210/me.2009-0432
   Yu J, 2012, CLIN CANCER RES, V18, P981, DOI 10.1158/1078-0432.CCR-11-2347
   Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105
NR 41
TC 4
Z9 4
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD DEC
PY 2014
VL 10
IS 6
BP 3303
EP 3309
DI 10.3892/mmr.2014.2658
PG 7
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AU9YM
UT WOS:000345947900076
PM 25322937
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, D
   Jiao, J
   Zhou, YM
   Wang, XX
AF Li, Da
   Jiao, Jiao
   Zhou, Yi-Ming
   Wang, Xiu-Xia
TI Epigenetic regulation of traf2-and Nck-interacting kinase (TNIK) in
   polycystic ovary syndrome
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE TNIK; PCOS; epigenetic; DNA methylation; histone modifications
ID BRCA1-MUTATED BREAST-CANCER; DNA METHYLATION; CUMULUS CELLS;
   HYPOMETHYLATION; INFLAMMATION; ADIPOSITY; CROSSTALK; GROWTH
AB Emerging evidence has led to considerable interest in the role of Traf2- and Nck-interacting kinase (TNIK) in polycystic ovary syndrome (PCOS) development. However, the epigenetic mechanism regulating TNIK transcription remains largely unknown. Here, we show that (i) TNIK mRNA expression is significantly increased in PCOS ovarian tissues, compared to normal ovarian tissues; (ii) PCOS ovarian tissues exhibit a hypermethylation pattern at the cg10180092 site, (iii) and cg10180092 is the critical site for the transcriptional regulation of TNIK. Mechanistically, hypermethylated cg10180092 site-mediated loss of holocarboxylase synthetase (HLCS)-related H3K9me enrichment activated TNIK transcription in PCOS ovarian tissues. Notably, a substantial body of evidence indicates that DNA hypermethylation is an alternative mechanism for gene inactivation, and a new role for DNA hypermethylation-mediated TNIK activating was observed in this study. This may improve our understanding of divergent transcriptional regulation in the initiation and progression of TNIK-related PCOS.
C1 [Li, Da; Jiao, Jiao; Wang, Xiu-Xia] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang 110004, Peoples R China.
   [Zhou, Yi-Ming] Harvard Univ, Sch Med, Harvard Inst Med, Dept Med,Brigham & Womens Hosp, Boston, MA 02115 USA.
C3 China Medical University; Harvard University; Harvard Medical School;
   Brigham & Women's Hospital
RP Wang, XX (通讯作者)，China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang 110004, Peoples R China.
EM wangxx@sj-hospital.org
RI jiao, jiao/JDD-3955-2023; Wang, Xuemei/GXF-3702-2022
FU Natural Science Foundation of China [81402130]; Doctoral Start-up
   Foundation of Liaoning Province [20141045]
FX This work was supported by the Natural Science Foundation of China (No.
   81402130) and Doctoral Start-up Foundation of Liaoning Province (No.
   20141045).
CR Almario RU, 2015, HORM METAB RES, V47, P152, DOI 10.1055/s-0034-1384521
   Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004
   Coba MP, 2012, J NEUROSCI, V32, P13987, DOI 10.1523/JNEUROSCI.2433-12.2012
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Fuster JJ, 2015, DIABETES, V64, P1235, DOI 10.2337/db14-1164
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
   Huang X, 2013, REPRODUCTION, V145, P597, DOI 10.1530/REP-13-0005
   Insenser M, 2013, MOL CELL ENDOCRINOL, V370, P65, DOI 10.1016/j.mce.2013.02.009
   Jiao X, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-165
   Kim J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110180
   Li D, 2014, ONCOTARGET, V5, P1315, DOI 10.18632/oncotarget.1800
   Li D, 2014, ONCOTARGET, V5, P291, DOI 10.18632/oncotarget.1549
   Li D, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-26
   Moran LJ, 2015, TRENDS ENDOCRIN MET, V26, P136, DOI 10.1016/j.tem.2014.12.003
   Polzikov M, 2012, J ASSIST REPROD GEN, V29, P1141, DOI 10.1007/s10815-012-9827-6
   Qu F, 2012, J MOL MED, V90, P911, DOI 10.1007/s00109-012-0881-4
   Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306
   Stubbs SA, 2007, J CLIN ENDOCR METAB, V92, P4418, DOI 10.1210/jc.2007-0729
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Tan SH, 2014, P NATL ACAD SCI USA, V111, pE5262, DOI 10.1073/pnas.1420463111
   Tanaka SS, 2011, DEV GROWTH DIFFER, V53, P843, DOI 10.1111/j.1440-169X.2011.01292.x
   Teede H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-41
   Villavicencio A, 2007, GYNECOL ONCOL, V104, P290, DOI 10.1016/j.ygyno.2006.09.003
   Wang P, 2014, ENDOCRINOLOGY, V155, P1445, DOI 10.1210/en.2013-1764
   Wang Q, 2012, ENDOCRINOLOGY, V153, P5600, DOI 10.1210/en.2012-1424
   Wang XX, 2014, ONCOTARGET, V5, P6603, DOI 10.18632/oncotarget.2224
   Witchel SF, 2013, FERTIL STERIL, V100, P12, DOI 10.1016/j.fertnstert.2013.05.024
   Wood JR, 2004, J REPROD IMMUNOL, V63, P51, DOI 10.1016/j.jri.2004.01.010
   Yu DH, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.2
   Zhang B, 2013, GENOME RES, V23, P1522, DOI 10.1101/gr.156539.113
NR 30
TC 12
Z9 14
U1 0
U2 9
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2015
VL 7
IS 6
BP 1152
EP 1160
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CN3YI
UT WOS:000358364100015
PM 26279758
DA 2025-01-12
ER

PT J
AU Roura, LC
   Arulkumaran, SS
AF Cabero Roura, Lluis
   Arulkumaran, Sir Sabaratnam
TI Facing the noncommunicable disease (NCD) global epidemic - The battle of
   prevention starts in utero - The FIGO challenge
SO BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY
LA English
DT Article
DE NCDs; fetal programming; epigenetics; FIGO; DOHaD; diabetes mellitus
ID BIRTH-WEIGHT; DEVELOPMENTAL ORIGINS; METABOLIC SYNDROME; SHORT CHILDREN;
   BREAST-CANCER; RISK-FACTOR; CHILDHOOD; CONSEQUENCES; ASSOCIATION;
   PROGRAMS
AB Noncommunicable diseases (NCDs) are responsible for 36 million deaths every year. Of this death toll, nearly 80% (29 million) occur in low-and median-income countries. More than 9 million deaths attributed to NCDs occur in people under 60 years of age. National economies are suffering considerable losses due to premature death or disability to work resulting from heart disease, stroke, and diabetes. The knowledge that in utero and in early childhood certain processes can affect the risk of developing NCDs provides an opportunity to enforce interventions during this critical time, when they may have the greatest effect. Using appropriate protocols, the health-care provider can educate mothers about the risks of certain nutritional and environmental exposures and integrate health promotion on the agenda, as part of the social and economic development. All this could motivate a substantial reduction in the risk of NCDs. Current and future health challenges demand new and changing competencies that should form the basis for education, training, and workforce planning. The International Federation of Gynaecology and Obstetrics (FIGO) is aware of that responsibility and has joined hands with other agencies and organizations that make a considerable effort in providing appropriate prenatal care programs to prevent and treat most of the common preconditioning factors, especially in low-income countries. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Cabero Roura, Lluis] Univ Autonoma Barcelona, Hosp Vall Hebron, E-08193 Barcelona, Spain.
   [Arulkumaran, Sir Sabaratnam] St Georges Univ London, London SW17 0RE, England.
C3 Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   City St Georges, University of London; St Georges University London
RP Roura, LC (通讯作者)，Hosp Valle De Hebron, Passeig Vall Hebron 115, Barcelona 08035, Spain.
EM lcaberor@sego.es
RI Roura, Lluis/O-1209-2015
OI Cabero, Luis/0000-0002-1905-5680
CR Abegunde D, 2006, WORKING PAPER
   Ahlgren M, 2004, NEW ENGL J MED, V351, P1619, DOI 10.1056/NEJMoa040576
   [Anonymous], 2009, 2008 2013 ACTION PLA
   [Anonymous], 2016, Global Status Report on Blood Safety and Availability
   [Anonymous], 2010, Equity, social determinants and public health programmes
   [Anonymous], 2010, COMMITTEE PREVENTING
   [Anonymous], MILL DEV GOALS REP 2
   Azad MB, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6471
   Balbus JM, 2013, LANCET, V381, P3, DOI 10.1016/S0140-6736(12)61609-2
   BARKER DJ, 2000, NIH MONOGRAPH SERIES
   BARKER DJP, 1989, LANCET, V2, P577
   Barker DJP, 2005, HORM RES, V64, P2, DOI 10.1159/000089311
   Barouki R, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-42
   Barth TK, 2010, TRENDS BIOCHEM SCI, V35, P618, DOI 10.1016/j.tibs.2010.05.006
   Berthold Koletzko, 2005, EARLY NUTR ITS LATER
   Bertram CE, 2001, BRIT MED BULL, V60, P103, DOI 10.1093/bmb/60.1.103
   Bloom D.E., 2011, PGDA Working Papers
   Bloomfield FH, 2011, J NEURODEV DISORD, V3, P348, DOI 10.1007/s11689-011-9096-1
   Boney CM, 2005, PEDIATRICS, V115, pE290, DOI 10.1542/peds.2004-1808
   Roura LC, 2011, INT J GYNECOL OBSTET, V115, pS1, DOI 10.1016/S0020-7292(11)00541-8
   Chuang JC, 2007, PEDIATR RES, V61, p24R, DOI 10.1203/pdr.0b013e3180457684
   Cutfield WS, 2002, J CLIN ENDOCR METAB, V87, P235, DOI 10.1210/jc.87.1.235
   de Rooij SR, 2007, AM J CLIN NUTR, V86, P1219, DOI 10.1093/ajcn/86.4.1219
   Fall CHD, 1998, DIABETIC MED, V15, P220, DOI 10.1002/(SICI)1096-9136(199803)15:3<220::AID-DIA544>3.0.CO;2-O
   Fernandez-Twinn DS, 2006, PHYSIOL BEHAV, V88, P234, DOI 10.1016/j.physbeh.2006.05.039
   Godfrey KM, 2007, PEDIATR RES, V61, p5R, DOI 10.1203/pdr.0b013e318045bedb
   Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402
   Hou LF, 2012, INT J EPIDEMIOL, V41, P79, DOI 10.1093/ije/dyr154
   Keeling A, 2011, DIABETES RES CLIN PR, V92, P143, DOI 10.1016/j.diabres.2011.03.024
   Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241
   Li YP, 2011, DIABETES CARE, V34, P1014, DOI 10.2337/dc10-2039
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Martinez VLE., 2008, MED UNIVER, V10, P108
   Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9
   Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055
   Ross M.G., 2012, Obstetrics: Normal and Problem Pregnancies, P83
   Serour GI, 2011, INT J GYNECOL OBSTET, V115, pS48, DOI 10.1016/S0020-7292(11)60014-3
   Silva ID, 2004, BRIT J CANCER, V91, P519, DOI 10.1038/sj.bjc.6601972
   Stuckler D, 2008, MILBANK Q, V86, P273, DOI 10.1111/j.1468-0009.2008.00522.x
   Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490
   United Nations, 2011, NCDS MDGS SUCC SYN
   Vieau D, 2011, WORLD J DIABETES, V2, P133, DOI 10.4239/wjd.v2.i9.133
   *WHO, 2008, CLOSING GAP GENERATI
   World Health Organization, 2005, PREVENTING CHRONIC D
NR 44
TC 23
Z9 26
U1 0
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1521-6934
EI 1532-1932
J9 BEST PRACT RES CL OB
JI Best Pract. Res. Clin. Obstet. Gynaecol.
PD JAN
PY 2015
VL 29
IS 1
BP 5
EP 14
DI 10.1016/j.bpobgyn.2014.04.018
PG 10
WC Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology
GA AZ2XD
UT WOS:000348091800002
PM 25248554
DA 2025-01-12
ER

PT J
AU Flanagan, JM
   Brook, MN
   Orr, N
   Tomczyk, K
   Coulson, P
   Fletcher, O
   Jones, ME
   Schoemaker, MJ
   Ashworth, A
   Swerdlow, A
   Brown, R
   Garcia-Closas, M
AF Flanagan, James M.
   Brook, Mark N.
   Orr, Nick
   Tomczyk, Katarzyna
   Coulson, Penny
   Fletcher, Olivia
   Jones, Michael E.
   Schoemaker, Minouk J.
   Ashworth, Alan
   Swerdlow, Anthony
   Brown, Robert
   Garcia-Closas, Montserrat
TI Temporal Stability and Determinants of White Blood Cell DNA Methylation
   in the Breakthrough Generations Study
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID EPIGENOME-WIDE ASSOCIATION; BREAST-CANCER; EPIGENETIC DRIFT; PROMOTER
   METHYLATION; AGE; BIOMARKER; EXPOSURE; SMOKING; RISK; HYPERMETHYLATION
AB Background: Epigenome-wide association studies (EWAS) using measurements of blood DNA methylation are performed to identify associations of methylation changes with environmental and lifestyle exposures and disease risk. However, little is known about the variation of methylation markers in the population and their stability over time, both important factors in the design and interpretation of EWAS. We aimed to identify stable variable methylated probes (VMP), i.e., markers that are variable in the population, yet stable over time.
   Methods: We estimated the intraclass correlation coefficient (ICC) for each probe on the Illumina 450K methylation array in paired samples collected approximately 6 years apart from 92 participants in the Breakthrough Generations Study. We also evaluated relationships with age, reproductive and hormonal history, weight, alcohol intake, and smoking.
   Results: Approximately 17% of probes had an ICC > 0.50 and were considered stable VMPs (stable-VMPs). Stable-VMPs were enriched for probes located in "shores" bordering CpG islands, and at approximately 1.3 kb downstream from the transcription start site in the transition between the unmethylated promoter and methylated gene body. Both cross-sectional and longitudinal data analyses provided strong evidence for associations between changes in methylation levels and aging. Smoking-related probes at 2q37.1 and AHRR were stable-VMPs and related to time since quitting. We also observed associations between methylation and weight changes.
   Conclusion: Our results provide support for the use of white blood cell DNA methylation as a biomarker of exposure in EWAS.
   Impact: Larger studies, preferably with repeated measures over time, will be required to establish associations between specific probes and exposures. (C) 2014 AACR.
C1 [Flanagan, James M.; Brown, Robert] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London W12 0NN, England.
   [Brook, Mark N.; Coulson, Penny; Jones, Michael E.; Schoemaker, Minouk J.; Swerdlow, Anthony; Garcia-Closas, Montserrat] Inst Canc Res, Div Genet & Epidemiol, London SW3 6JB, England.
   [Orr, Nick; Tomczyk, Katarzyna; Fletcher, Olivia; Ashworth, Alan; Garcia-Closas, Montserrat] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England.
   [Swerdlow, Anthony] Inst Canc Res, Div Breast Canc Res, London SW3 6JB, England.
   [Brown, Robert] Inst Canc Res, Div Med, London SW3 6JB, England.
C3 Imperial College London; Royal Marsden NHS Foundation Trust; University
   of London; Institute of Cancer Research - UK; University of London;
   Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust;
   Royal Marsden NHS Foundation Trust; University of London; Institute of
   Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of
   London; Institute of Cancer Research - UK
RP Flanagan, JM (通讯作者)，Univ London Imperial Coll Sci Technol & Med, 4th Floor IRDB,Hammersmith Campus,Du Cane Rd, London W12 0NN, England.
EM j.flanagan@imperial.ac.uk
RI ; Garcia-Closas, Montserrat/F-3871-2015
OI Brook, Mark/0000-0002-8969-2378; Garcia-Closas,
   Montserrat/0000-0003-1033-2650; Swerdlow, Anthony/0000-0001-5550-4159;
   Jones, Michael/0000-0001-7479-3451; Orr, Nick/0000-0003-2866-942X;
   Flanagan, James/0000-0003-4955-1383; Schoemaker,
   Minouk/0000-0001-8403-2234; Brown, Robert/0000-0001-7960-5755; Fletcher,
   Olivia/0000-0001-9387-7116
FU Breast Cancer Campaign Fellowship; Cancer Research UK Programme
   [A13086]; Breakthrough Breast Cancer Research Centre, The Institute of
   Cancer Research; BGS; NHS
FX J.M. Flanagan is funded by a Breast Cancer Campaign Fellowship and
   Cancer Research UK Programme A13086 (awarded to R. Brown and J.M.
   Flanagan), and M. Garcia-Closas is funded by Breakthrough Breast Cancer
   Research Centre, The Institute of Cancer Research. This work was funded
   by the Breakthrough Breast Cancer Research Centre, The Institute of
   Cancer Research (grant awarded to M. Garcia-Closas), and the BGS
   (awarded to A. Ashworth and A. Swerdlow). This was also funded by NHS to
   the NIHR Institute of Cancer Research/Royal Marsden Hospital Biomedical
   Research Centre.
CR Barrès R, 2012, CELL METAB, V15, P405, DOI 10.1016/j.cmet.2012.01.001
   Bell JT, 2012, PLOS GENET, V8, P189, DOI 10.1371/journal.pgen.1002629
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   Breitling LP, 2011, AM J HUM GENET, V88, P450, DOI 10.1016/j.ajhg.2011.03.003
   Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Brennan Kevin, 2012, Methods Mol Biol, V863, P439, DOI 10.1007/978-1-61779-612-8_27
   Bruniquel D, 2003, NAT IMMUNOL, V4, P235, DOI 10.1038/ni887
   Chiacchiera F, 2013, CELL MOL LIFE SCI, V70, P1495, DOI 10.1007/s00018-013-1293-5
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Croissant Y., 2008, Journal of Statistical Software, V27
   Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Feinberg AP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001262
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Flanagan JM, 2009, HUM MOL GENET, V18, P1332, DOI 10.1093/hmg/ddp033
   Florath I, 2014, HUM MOL GENET, V23, P1186, DOI 10.1093/hmg/ddt531
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Hahn MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018844
   Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   Johansson A, 2013, PLOS ONE, V8
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Joubert BR, 2012, ENVIRON HEALTH PERSP, V120, P1425, DOI 10.1289/ehp.1205412
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Langevin SM, 2012, EPIGENETICS-US, V7, P291, DOI 10.4161/epi.7.3.19134
   Leek JT, 2007, PLOS GENET, V3, P1724, DOI 10.1371/journal.pgen.0030161
   Leek JT, 2008, P NATL ACAD SCI USA, V105, P18718, DOI 10.1073/pnas.0808709105
   Li SF, 2003, ANN NY ACAD SCI, V983, P161, DOI 10.1111/j.1749-6632.2003.tb05971.x
   Marsit CJ, 2011, J CLIN ONCOL, V29, P1133, DOI 10.1200/JCO.2010.31.3577
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Moleres A, 2013, FASEB J, V27, P2504, DOI 10.1096/fj.12-215566
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Philibert RA, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-19
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Relton CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031821
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Shenker NS, 2013, HUM MOL GENET, V22, P843, DOI 10.1093/hmg/dds488
   Stepanow S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017711
   Sun YV, 2013, HUM GENET, V132, P1027, DOI 10.1007/s00439-013-1311-6
   Swerdlow AJ, 2011, BRIT J CANCER, V105, P911, DOI 10.1038/bjc.2011.337
   Teschendorff AE, 2013, HUM MOL GENET, V22, pR7, DOI 10.1093/hmg/ddt375
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Teschendorff AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008274
   Tobi EW, 2009, HUM MOL GENET, V18, P4046, DOI 10.1093/hmg/ddp353
   Wang SC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002698
   West J, 2013, P NATL ACAD SCI USA, V110, P14138, DOI 10.1073/pnas.1307242110
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812
NR 54
TC 51
Z9 53
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JAN
PY 2015
VL 24
IS 1
BP 221
EP 229
DI 10.1158/1055-9965.EPI-14-0767
PG 9
WC Oncology; Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Public, Environmental & Occupational Health
GA AZ1YG
UT WOS:000348030700026
PM 25371448
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Fukagawa, A
   Ishii, H
   Miyazawa, K
   Saitoh, M
AF Fukagawa, Akihiko
   Ishii, Hiroki
   Miyazawa, Keiji
   Saitoh, Masao
TI δEF1 associates with DNMT1 and maintains DNA methylation of the
   E-cadherin promoter in breast cancer cells
SO CANCER MEDICINE
LA English
DT Article
DE Cancer cells; DNA methylation; E-cadherin; EMT; delta EF1
ID EPITHELIAL-MESENCHYMAL TRANSITION; BINDING; COMPLEX; LINES
AB Abnormal DNA methylation at the C-5 position of cytosine (5mC) of CpG dinucleotides is a well-known epigenetic feature of cancer. Levels of E-cadherin, which is regularly expressed in epithelial tissues, are frequently reduced in epithelial tumors due to transcriptional repression, sometimes accompanied by hypermethylation of the promoter region. delta EF1 family proteins (delta EF1/ZEB1 and SIP1/ZEB2), key regulators of the epithelial-mesenchymal transition (EMT), suppress E-cadherin expression at the transcriptional level. We recently showed that levels of mRNAs encoding delta EF1 proteins are regulated reciprocally with E-cadherin level in breast cancer cells. Here, we examined the mechanism underlying downregulation of E-cadherin expression in three basal-type breast cancer cells in which the E-cadherin promoter region is hypermethylated (Hs578T) or moderately methylated (BT549 and MDA-MB-231). Regardless of methylation status, treatment with 5-aza-2'-deoxycytidine (5-aza), which inhibits DNA methyltransferases, had no effect on E-cadherin expression. Knockdown of delta EF1 and SIP1 resulted in recovery of E-cadherin expression in cells lacking hypermethylation, whereas combined treatment with 5-aza synergistically restored E-cadherin expression, especially when the E-cadherin promoter was hypermethylated. Moreover, delta EF1 interacted with DNA methyltransferase 1 (DNMT1) through the Smad-binding domain. Sustained knockdown of delta EF1 family proteins reduced the number of 5mC sites in the E-cadherin promoter region, suggesting that these proteins maintain 5mC through interaction with DNMT1 in breast cancer cells. Thus, delta EF1 family proteins appear to repress expression of E-cadherin during cancer progression, both directly at the transcriptional level and indirectly at the epigenetic level.
C1 [Fukagawa, Akihiko; Ishii, Hiroki; Miyazawa, Keiji; Saitoh, Masao] Univ Yamanashi, Dept Biochem, Chuo Ku, Yamanashi 4093898, Japan.
   [Fukagawa, Akihiko] Univ Yamanashi, Res Training Program Undergrad, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, Yamanashi 4093898, Japan.
C3 University of Yamanashi; University of Yamanashi
RP Saitoh, M (通讯作者)，Univ Yamanashi, Dept Biochem, Interdisciplinary Grad Sch Med & Engn, Chuo Ku, 1110 Shimokato, Yamanashi 4093898, Japan.
EM msaitoh-ind@umin.ac.jp
RI MIYAZAWA, KEIJI/I-9713-2014
FU JSPS KAKENHI [24390419]; Ministry of Education, Culture, Sports, Science
   and Technology of Japan; Grants-in-Aid for Scientific Research
   [24390419] Funding Source: KAKEN
FX This work was supported by JSPS KAKENHI Grant Number 24390419, JSPS
   Core-to-Core Program "Cooperative International Framework in TGF-beta
   Family Signaling", and a research program of the Project for Development
   of Innovative Research on Cancer Therapeutics (P-Direct), Ministry of
   Education, Culture, Sports, Science and Technology of Japan.
CR Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Dhasarathy A, 2008, MUTAT RES-FUND MOL M, V647, P39, DOI 10.1016/j.mrfmmm.2008.07.007
   Espada J, 2011, NUCLEIC ACIDS RES, V39, P9194, DOI 10.1093/nar/gkr658
   Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x
   Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493
   Horiguchi K, 2009, J BIOL CHEM, V284, P245, DOI 10.1074/jbc.M804777200
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Li DQ, 2012, CANCER RES, V72, P387, DOI 10.1158/0008-5472.CAN-11-2345
   Lin YW, 2014, CURR PHARM DESIGN, V20, P1698, DOI 10.2174/13816128113199990512
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073
   Ringner Markus, 2013, Methods Mol Biol, V973, P279, DOI 10.1007/978-1-62703-281-0_18
   Shirakihara T, 2007, MOL BIOL CELL, V18, P3533, DOI 10.1091/mbc.E07-03-0249
   Shirakihara T, 2011, EMBO J, V30, P783, DOI 10.1038/emboj.2010.351
   Singh V, 2013, CURR CANCER DRUG TAR, V13, P379, DOI 10.2174/15680096113139990077
   Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
NR 19
TC 83
Z9 97
U1 0
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD JAN
PY 2015
VL 4
IS 1
BP 125
EP 135
DI 10.1002/cam4.347
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AZ4YH
UT WOS:000348226600015
PM 25315069
OA Green Published
DA 2025-01-12
ER

PT J
AU Kurashige, J
   Mima, K
   Sawada, G
   Takahashi, Y
   Eguchi, H
   Sugimachi, K
   Mori, M
   Yanagihara, K
   Yashiro, M
   Hirakawa, K
   Baba, H
   Mimori, K
AF Kurashige, Junji
   Mima, Kosuke
   Sawada, Genta
   Takahashi, Yusuke
   Eguchi, Hidetoshi
   Sugimachi, Keishi
   Mori, Masaki
   Yanagihara, Kazuyoshi
   Yashiro, Masakazu
   Hirakawa, Kosei
   Baba, Hideo
   Mimori, Koshi
TI Epigenetic modulation and repression of miR-200b by cancer-associated
   fibroblasts contribute to cancer invasion and peritoneal dissemination
   in gastric cancer
SO CARCINOGENESIS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; TGF-BETA; STROMAL
   FIBROBLASTS; COLORECTAL-CANCER; BREAST-CANCER; NUDE-MICE; CARCINOMA;
   PROGRESSION; FAMILY
AB CAFs induced the hypermethylation of the miR-200b promoter regions and reduced miR-200b expression and there was a negative correlation between miR-200b expression in gastric cancer specimens and alpha-smooth muscle actin expression in the stroma of gastric cancer.Cancer-associated fibroblasts (CAFs) have recently been linked to the invasion and metastasis of gastric cancer. In addition, the microRNA (miR)-200 family plays a central role in the regulation of the epithelial-mesenchymal transition process during cancer metastasis, and aberrant DNA methylation is one of the key mechanisms underlying regulation of the miR-200 family. In this study, we clarified whether epigenetic changes of miR-200b by CAFs stimulate cancer invasion and peritoneal dissemination in gastric cancer. We evaluated the relationship between miR-200b and CAFs using a coculture model. In addition, we established a peritoneal metastasis mouse model and investigated the expression and methylation status of miR-200b. We also investigated the expression and methylation status of miR-200b and CAFs expression in primary gastric cancer samples. CAFs (CAF-37 and CAF-50) contributed to epigenetic changes of miR-200b, reduced miR-200b expression and promoted tumor invasion and migration in NUGC3 and OCUM-2M cells in coculture. In the model mice, epigenetic changes of miR-200b were observed in the inoculated high-frequency peritoneal dissemination cells. In the 173 gastric cancer samples, the low miR-200b expression group demonstrated a significantly poorer prognosis compared with the high miR-200b expression group and was associated with peritoneal metastasis. In addition, downregulation of miR-200b in cancer cells was significantly correlated with alpha-smooth muscle actin expression. Our data provide evidence that CAFs reduce miR-200b expression and promote tumor invasion through epigenetic changes of miR-200b in gastric cancer. Thus, CAFs might be a therapeutic target for inhibition of gastric cancer.
C1 [Kurashige, Junji; Mima, Kosuke; Sawada, Genta; Takahashi, Yusuke; Eguchi, Hidetoshi; Sugimachi, Keishi; Mimori, Koshi] Kyushu Univ, Dept Surg, Beppu Hosp, Beppu, Oita 8740838, Japan.
   [Kurashige, Junji; Mima, Kosuke; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, Kumamoto 8608556, Japan.
   [Sawada, Genta; Takahashi, Yusuke; Mori, Masaki] Osaka Univ, Grad Sch Med, Dept Gastroenterol Surg, Suita, Osaka 5650871, Japan.
   [Yanagihara, Kazuyoshi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Translat Res, Kashiwa, Chiba 2778577, Japan.
   [Yashiro, Masakazu; Hirakawa, Kosei] Osaka City Univ, Grad Sch Med, Dept Surg Oncol, Abeno Ku, Osaka 5458585, Japan.
C3 Kyushu University; Kumamoto University; Osaka University; National
   Cancer Center - Japan; Osaka Metropolitan University
RP Mimori, K (通讯作者)，Kyushu Univ, Dept Surg, Beppu Hosp, 4546 Tsurumihara, Beppu, Oita 8740838, Japan.
EM kmimori@beppu.kyushu-u.ac.jp
RI Mori, Masaki/AGA-2440-2022; Sugimachi, Keishi/AGJ-7206-2022
OI Mimori, Koshi/0000-0003-3897-9974
FU MEXT [24008081, 25430111, 25461953, 25861199, 25861200, 24592005,
   21229015]; Funding Program for Next Generation World Leading Researchers
   [LS094]; MEXT 'Systems Cancer Research' [4201]; MEXT Strategic Programs
   on Innovative Research 'Supercomputational Life Science'; RIKEN Advanced
   Institute for Computational Science through the HPCI System Research
   project [hp140230]; Ministry of Health, Labour and Welfare [14524362,
   14525288]; Grants-in-Aid for Scientific Research [25861200, 21229015,
   25461953, 24592005, 25430111, 25861199] Funding Source: KAKEN
FX Grants-in-Aid for Scientific Research of MEXT (24008081, 25430111,
   25461953, 25861199, 25861200, 24592005 and 21229015); Funding Program
   for Next Generation World Leading Researchers (LS094); Grants-in-Aid for
   Scientific Research on Innovative Areas of MEXT 'Systems Cancer
   Research' (4201); The MEXT Strategic Programs on Innovative Research
   'Supercomputational Life Science'. This research used computational
   resources of the K computer provided by the RIKEN Advanced Institute for
   Computational Science through the HPCI System Research project (Project
   ID: hp140230). Computation time was also provided by the Supercomputer
   System, Human Genome Center, Institute of Medical Science, University of
   Tokyo and The OITA Cancer Research Foundation 2014. Grant-in-Aid for
   Scientific Research of Ministry of Health, Labour and Welfare (14524362
   and 14525288).
CR Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925
   Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Fuyuhiro Y, 2012, CANCER SCI, V103, P797, DOI 10.1111/j.1349-7006.2012.02209.x
   Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Grugan KD, 2010, P NATL ACAD SCI USA, V107, P11026, DOI 10.1073/pnas.0914295107
   Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846
   Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714
   Ikeguchi M, 2009, SURG TODAY, V39, P290, DOI 10.1007/s00595-008-3860-1
   Iwaya T, 2012, CARCINOGENESIS, V33, P2391, DOI 10.1093/carcin/bgs288
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Kurashige J, 2012, ANN SURG ONCOL, V19, pS656, DOI 10.1245/s10434-012-2217-6
   Li A, 2010, CANCER RES, V70, P5226, DOI 10.1158/0008-5472.CAN-09-4227
   Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110
   Navab R, 2011, P NATL ACAD SCI USA, V108, P7160, DOI 10.1073/pnas.1014506108
   Neves Rui, 2010, BMC Res Notes, V3, P219, DOI 10.1186/1756-0500-3-219
   Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1
   Okabe H, 2012, INT J CANCER, V131, P2234, DOI 10.1002/ijc.27496
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Sohn BH, 2010, GASTROENTEROLOGY, V138, P1898, DOI 10.1053/j.gastro.2009.12.044
   Takahashi I, 2000, HEPATO-GASTROENTEROL, V47, P1485
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191
   Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567
   van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Xia HP, 2010, J BIOL CHEM, V285, P36995, DOI 10.1074/jbc.M110.133744
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yanagihara K, 2005, CANCER SCI, V96, P323, DOI 10.1111/j.1349-7006.2005.00054.x
   Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x
   Yanagihara K, 2006, CANCER RES, V66, P7532, DOI 10.1158/0008-5472.CAN-05-3259
   YASHIRO M, 1995, BRIT J CANCER, V72, P1200, DOI 10.1038/bjc.1995.486
   Yashiro M, 1996, CLIN EXP METASTAS, V14, P43, DOI 10.1007/BF00157685
   Yashiro M, 2010, CANCER MICROENVIRON, V3, P127, DOI 10.1007/s12307-010-0036-5
   You HN, 2010, HEPATOLOGY, V51, P1635, DOI 10.1002/hep.23544
   Yu J, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-169
   Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
   Zhang Q, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025168
   Zhang YA, 2011, CANCER LETT, V303, P47, DOI 10.1016/j.canlet.2011.01.011
NR 50
TC 75
Z9 79
U1 1
U2 21
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD JAN
PY 2015
VL 36
IS 1
BP 133
EP 141
DI 10.1093/carcin/bgu232
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY9BM
UT WOS:000347844700018
PM 25411357
DA 2025-01-12
ER

PT J
AU Boyko, A
   Riabowol, K
AF Boyko, A.
   Riabowol, K.
TI Defining the minimal peptide sequence of the ING tumour suppressor
   capable of efficiently inducing apoptosis
SO CELL DEATH DISCOVERY
LA English
DT Article
AB The ING1b protein is a type-II tumour suppressor and stoichiometric member of the Sin3 histone deacetylase (HDAC) protein complex in which it acts to target HDAC activity to regulate chromatin structure. Altering ING1 levels by ectopic expression of ING1b in cancer cells promotes apoptosis, whereas altering levels by knockout in normal murine fibroblasts alters sensitivity to doxorubicin-induced apoptosis. We have identified a minimal region of ING1b capable of inducing levels of apoptosis in targeted cells as effectively as full-length ING1b, using transient overexpression of ING1b fragments followed by the Annexin V assay. We observed high levels of apoptosis in 14 of 14 cancer cell lines tested. Infecting triple-negative tumorigenic MDA-MB-468 breast cancer, U2OS or Saos-2 cells at multiplicities of infection (MO's) ranging from 10 to 20 rapidly triggered apoptosis in similar to 80% of infected cells within 48 h. This was not due to the effects of virus, as infection at the same MOI with a control adenovirus expressing GFP was not effective in inducing apoptosis. When used at low MOls, the ING1b fragment showed a cell-killing efficacy that was higher than native, full-length ING1b. Using a doxycycline-regulated inducible p53 expression system demonstrated that apoptosis induced by the ING1b fragment was p53 independent. Given the growing importance of combination therapies, we evaluated whether there was synergism between the ING1b fragment and HDAC inhibitors. Combination treatments with TSA, LBH 589 and SAHA reduced cancer cell survival by 3.9-4.7-fold as compared with single-drug treatment, and resulted in similar to 90% reduction in cell survival. Normalized isobologram analysis confirmed strong synergism between the ING1b fragment and drugs tested. These findings provide support for using ING1b-derived therapeutics as adjuvant treatments in combination with existing epigenetic therapies.
C1 [Boyko, A.; Riabowol, K.] Univ Calgary, Dept Biochem, Calgary, AB, Canada.
   [Boyko, A.; Riabowol, K.] Univ Calgary, Dept Mol Biol, Calgary, AB, Canada.
   [Riabowol, K.] Univ Calgary, Dept Oncol, Calgary, AB, Canada.
C3 University of Calgary; University of Calgary; University of Calgary
RP Riabowol, K (通讯作者)，Univ Calgary, Dept Biochem, Calgary, AB, Canada.
EM karl@ucalgary.ca
CR Abad M, 2007, J BIOL CHEM, V282, P31060, DOI 10.1074/jbc.M701639200
   Berardi P, 2004, CELL MOL LIFE SCI, V61, P2173, DOI 10.1007/s00018-004-4179-8
   Birbach A, 2004, J CELL SCI, V117, P3615, DOI 10.1242/jcs.01224
   Bua DJ, 2013, SCI REP-UK, V3, DOI 10.1038/srep02137
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Cheung KJ, 2002, EXP CELL RES, V279, P291, DOI 10.1006/excr.2002.5610
   Chin MY, 2005, EXP CELL RES, V304, P531, DOI 10.1016/j.yexcr.2004.11.023
   Chou T, 2007, COMPUSYN SOFTWARE DR
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Coles AH, 2008, CANCER RES, V68, P8705, DOI 10.1158/0008-5472.CAN-08-0923
   Coles AH, 2007, CANCER RES, V67, P2054, DOI 10.1158/0008-5472.CAN-06-3558
   Coles AH, 2009, J CELL PHYSIOL, V218, P45, DOI 10.1002/jcp.21583
   Culurgioni S, 2012, J BIOL CHEM, V287, P10876, DOI 10.1074/jbc.M111.330001
   Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007
   Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06
   Garkavtsev I, 1998, NATURE, V391, P295, DOI 10.1038/34675
   Gómez-Cabello D, 2010, CANCER RES, V70, P1866, DOI 10.1158/0008-5472.CAN-09-2088
   Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006
   Guérillon C, 2014, CANCER LETT, V345, P1, DOI 10.1016/j.canlet.2013.11.016
   Han XJ, 2008, NAT CELL BIOL, V10, P1333, DOI 10.1038/ncb1792
   He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   He TC, 2004, Curr Protoc Hum Genet
   Helbing CC, 1997, CANCER RES, V57, P1255
   Kaadige MR, 2006, J BIOL CHEM, V281, P28831, DOI 10.1074/jbc.M605624200
   Kataoka H, 2003, CANCER RES, V63, P5785
   Li N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.22
   Li ZY, 2010, CANCER BIOTHER RADIO, V25, P427, DOI 10.1089/cbr.2010.0778
   Ling C, 2012, CANCER GENE THER, V19, P697, DOI 10.1038/cgt.2012.50
   Pena PV, 2008, J MOL BIOL, V380, P303, DOI 10.1016/j.jmb.2008.04.061
   Schäfer A, 2013, GENE DEV, V27, P261, DOI 10.1101/gad.186916.112
   Scott M, 2001, NUCLEIC ACIDS RES, V29, P2052, DOI 10.1093/nar/29.10.2052
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Shinoura N, 1999, CANCER RES, V59, P5521
   Soliman MA, 2007, TRENDS BIOCHEM SCI, V32, P509, DOI 10.1016/j.tibs.2007.08.006
   Tallen G, 2014, FEBS LETT, V588, P2728, DOI 10.1016/j.febslet.2014.03.011
   Tamannai M, 2010, ONCOL RES, V18, P469, DOI 10.3727/096504010X12704916124828
   Thakur S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043671
   Thalappilly S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021065
   Tran UM, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.15
   Tsang FC, 2003, FEBS LETT, V553, P277, DOI 10.1016/S0014-5793(03)01024-X
   Vieyra D, 2002, CANCER RES, V62, P4445
   Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200
   Xie YF, 2008, CANCER LETT, V271, P105, DOI 10.1016/j.canlet.2008.05.050
   Ythier D, 2008, INT J CANCER, V123, P1483, DOI 10.1002/ijc.23790
   Zhang X, 2005, BIOCHEM BIOPH RES CO, V331, P1032, DOI 10.1016/j.bbrc.2005.04.023
   Zhu JJ, 2006, LIFE SCI, V78, P1469, DOI 10.1016/j.lfs.2005.07.044
NR 47
TC 1
Z9 1
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2058-7716
J9 CELL DEATH DISCOV
JI Cell Death Discov.
PY 2015
VL 1
AR 15048
DI 10.1038/cddiscovery.2015.48
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA VI2FS
UT WOS:000463069500043
PM 27551477
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Murai, F
   Koinuma, D
   Shinozaki-Ushiku, A
   Fukayama, M
   Miyaozono, K
   Ehata, S
AF Murai, Fumihiko
   Koinuma, Daizo
   Shinozaki-Ushiku, Aya
   Fukayama, Masashi
   Miyaozono, Kohei
   Ehata, Shogo
TI EZH2 promotes progression of small cell lung cancer by suppressing the
   TGF-β-Smad-ASCL1 pathway
SO CELL DISCOVERY
LA English
DT Article
DE small cell lung cancer; epigenetics; apoptosis; EZH2; TGF-beta; ASCL1;
   Smad
ID TGF-BETA; II RECEPTOR; BREAST-CANCER; NEUROENDOCRINE DIFFERENTIATION;
   TUMOR-SUPPRESSOR; INACTIVATION; EXPRESSION; GENE; ADENOCARCINOMA;
   CARCINOMA
AB Transforming growth factor-beta (TGF-beta) induces apoptosis in many types of cancer cells and acts as a tumor suppressor. We performed a functional analysis of TGF-beta signaling to identify a molecular mechanism that regulated survival in small cell lung cancer cells. Here, we found low expression of TGF-beta type II receptor (T beta RII) in most small cell lung cancer cells and tissues compared to normal lung epithelial cells and normal lung tissues, respectively. When wild-type T beta RII was overexpressed in small cell lung cancer cells, TGF-beta suppressed cell growth in vitro and tumor formation in vivo through induction of apoptosis. Components of polycomb repressive complex 2, including enhancer of zeste 2 (EZH2), were highly expressed in small cell lung cancer cells; this led to epigenetic silencing of T beta RII expression and suppression of TGF-beta mediated apoptosis. Achaete-scute family bHLH transcription factor 1 (ASCL1; also known as ASH1), a Smad-dependent target of TGF-beta, was found to induce survival in small cell lung cancer cells. Thus, EZH2 promoted small cell lung cancer progression by suppressing the TGF-beta-Smad-ASCL1 pathway.
C1 [Murai, Fumihiko; Koinuma, Daizo; Miyaozono, Kohei; Ehata, Shogo] Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan.
   [Shinozaki-Ushiku, Aya; Fukayama, Masashi] Univ Tokyo, Dept Pathol, Grad Sch Med, Bunkyo Ku, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo
RP Miyaozono, K (通讯作者)，Univ Tokyo, Dept Mol Pathol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo, Japan.
EM miyazono@m.u-tokyo.ac.jp
RI Koinuma, Daizo/Y-8716-2018; Shinozaki-Ushiku, Aya/C-3959-2009
OI Ehata, Shogo/0000-0002-6740-9391; Shinozaki-Ushiku,
   Aya/0000-0002-0196-5643
FU KAKENHI from the Ministry of Education, Culture, Sports, Science and
   Technology (MEXT) of Japan [22112002]; KAKENHI from the Japan Society
   for the Promotion of Science (JSPS) [22700967]; Japan Science and
   Technology Agency; Cell Science Research Foundation; Grants-in-Aid for
   Scientific Research [22112002, 15K08393] Funding Source: KAKEN
FX We thank Yasuyuki Morishita and Kei Sakuma (The University of Tokyo) for
   technical assistance, and Hiroyuki Miyoshi (RIKEN) for providing the
   lentiviral vectors. This work was supported by a KAKENHI Grant-in-Aid
   for scientific research on Innovative Area (Integrative Research on
   Cancer Microenvironment Network; grant number 22112002) from the
   Ministry of Education, Culture, Sports, Science and Technology (MEXT) of
   Japan, a KAKENHI Grant-in-Aid for Young Scientists (B) (grant number
   22700967) from the Japan Society for the Promotion of Science (JSPS)
   (SE), the Strategic Basic Research Program from Japan Science and
   Technology Agency (KM), and a Specific Research Grant from The Cell
   Science Research Foundation (SE). This study was performed in part as a
   research program for the Project for Development of Innovative Research
   on Cancer Therapeutics (P-Direct), MEXT.
CR Anumanthan G, 2005, BRIT J CANCER, V93, P1157, DOI 10.1038/sj.bjc.6602831
   Arase M, 2014, CANCER SCI, V105, P974, DOI 10.1111/cas.12454
   Augustyn A, 2014, P NATL ACAD SCI USA, V111, P14788, DOI 10.1073/pnas.1410419111
   Bierie B, 2006, CYTOKINE GROWTH F R, V17, P29, DOI 10.1016/j.cytogfr.2005.09.006
   Borges M, 1997, NATURE, V386, P852, DOI 10.1038/386852a0
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Calbo J, 2011, CANCER CELL, V19, P244, DOI 10.1016/j.ccr.2010.12.021
   Castro DS, 2011, GENE DEV, V25, P930, DOI 10.1101/gad.627811
   Chowdhury Sanjib, 2009, Mol Cell Pharmacol, V1, P57
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   deJonge RR, 1997, ONCOL RES, V9, P89
   di Sant'Agnese PA, 2001, ANN ONCOL, V12, pS135, DOI 10.1093/annonc/12.suppl_2.S135
   Ehata S, 2007, CANCER RES, V67, P9694, DOI 10.1158/0008-5472.CAN-07-1522
   Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018
   Fujiwara T, 2012, LUNG CANCER, V75, P119, DOI 10.1016/j.lungcan.2011.05.028
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Harris K, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S9633
   Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284
   Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115
   Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089
   Hoshino Y, 2015, AM J PATHOL, V185, P1457, DOI 10.1016/j.ajpath.2015.01.011
   Hougaard S, 1999, BRIT J CANCER, V79, P1005, DOI 10.1038/sj.bjc.6690161
   Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Imayoshi I, 2014, NEURON, V82, P9, DOI 10.1016/j.neuron.2014.03.018
   Isogai E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019297
   Isogaya K, 2014, CELL RES, V24, P994, DOI 10.1038/cr.2014.97
   Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1
   Kawabata KC, 2013, ONCOGENE, V32, P2096, DOI 10.1038/onc.2012.219
   Kim SJ, 2000, CYTOKINE GROWTH F R, V11, P159, DOI 10.1016/S1359-6101(99)00039-8
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koinuma D, 2009, MOL CELL BIOL, V29, P172, DOI 10.1128/MCB.01038-08
   Kosari F, 2014, ONCOGENE, V33, P3776, DOI 10.1038/onc.2013.359
   Lynch MA, 1998, CANCER RES, V58, P4227
   Malkoski SP, 2012, CLIN CANCER RES, V18, P2173, DOI 10.1158/1078-0432.CCR-11-2557
   MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852
   Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9
   Maupin KA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013002
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Meuwissen R, 2003, CANCER CELL, V4, P181, DOI 10.1016/S1535-6108(03)00220-4
   Mizutani A, 2011, J BIOL CHEM, V286, P29848, DOI 10.1074/jbc.M110.217745
   Morikawa M, 2011, NUCLEIC ACIDS RES, V39, P8712, DOI 10.1093/nar/gkr572
   Nishikawa E, 2011, CANCER RES, V71, P6165, DOI 10.1158/0008-5472.CAN-11-1020
   Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004
   Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396
   Rapa I, 2008, MODERN PATHOL, V21, P700, DOI 10.1038/modpathol.2008.39
   Saito RA, 2009, CANCER RES, V69, P2783, DOI 10.1158/0008-5472.CAN-08-3490
   Sato T, 2013, SCI REP-UK, V3, DOI 10.1038/srep01911
   Shida T, 2005, CLIN CANCER RES, V11, P450
   Shirai Y, 2011, AM J PATHOL, V179, P2920, DOI 10.1016/j.ajpath.2011.08.022
   Sriuranpong V, 2002, MOL CELL BIOL, V22, P3129, DOI 10.1128/MCB.22.9.3129-3139.2002
   Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190
   Sutherland KD, 2011, CANCER CELL, V19, P754, DOI 10.1016/j.ccr.2011.04.019
   Tani M, 1997, CARCINOGENESIS, V18, P1119, DOI 10.1093/carcin/18.5.1119
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
NR 59
TC 83
Z9 86
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2056-5968
J9 CELL DISCOV
JI Cell Discov.
PY 2015
VL 1
AR 15026
DI 10.1038/celldisc.2015.26
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA VB1VM
UT WOS:000414776800026
PM 27462425
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wu, YT
   Huang, C
   Meng, XM
   Li, J
AF Wu, Yuting
   Huang, Cheng
   Meng, Xiaoming
   Li, Jun
TI Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications
   in Human Disease
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Cancer; diseases; gene therapy; long noncoding RNA; MALAT1
ID ADENOCARCINOMA TRANSCRIPT 1; CELL LUNG-CANCER; MESSENGER-RNA; LNCRNA
   MALAT1; COLORECTAL-CANCER; POOR-PROGNOSIS; BREAST-CANCER; UP-REGULATION;
   INHIBITS PROLIFERATION; NUCLEAR SPECKLES
AB Genome-wide studies have identified thousands of noncoding RNAs (ncRNAs) with no protein coding capacity. Among them, the long non-coding RNAs (lncRNAs), which are more than 200 nucleotides in length, recently are widely concerned for their crucial role in regulating biological processes and diseases. However, most lncRNAs are expressed at a very low level, and generally exhibit poor primary sequence conservation over evolution. Long non-coding RNA MALAT1 (metastasis-associated lung adenocarcinoma transcript 1), also known as NEAT2 (nuclear-enriched abundant transcript 2), is outstanding among the lncRNA family due to its evolutionarily high conservation and abundant expression throughout diferent mammalian species. Meanwhile, MALAT1 was one of the first lncRNAs that was demonstrated to be associated with a disease, namely non-small cell lung cancer (NSCLC). Subsequently, MALAT1 was identified in multiple types of physiological processes, such as alternative splicing, nuclear organization, epigenetic modulating of gene expression, and so on. Moreover, a growing number of evidences indicated that MALAT1 was also closely related to various pathological processes, ranging from diabetes complications to cancers. In this review, we will make a summary on current understanding of MALAT1 in different physiological or pathophysiological processes and discuss the potential therapeutic applications based on MALAT1 detection and inhibition.
C1 [Wu, Yuting; Huang, Cheng; Meng, Xiaoming; Li, Jun] Anhui Med Univ, Sch Pharm, Hefei 230032, Anhui, Peoples R China.
   [Wu, Yuting; Huang, Cheng; Meng, Xiaoming; Li, Jun] AMU, Inst Liver Dis, Hefei, Peoples R China.
C3 Anhui Medical University
RP Li, J (通讯作者)，Anhui Med Univ, Sch Pharm, Meishan Rd, Hefei 230032, Anhui, Peoples R China.
EM lj@ahmu.edu.cn
FU National Science Foundation of China [81473268, 81273526]; Anhui science
   and technology research projects [1301042212]
FX This project was supported by the National Science Foundation of China
   (No. 81473268, No. 81273526) and Anhui science and technology research
   projects (No. 1301042212).
CR Allen DL, 2011, MED SCI SPORT EXER, V43, P1828, DOI 10.1249/MSS.0b013e3182178bb4
   Argani P, 2005, AM J SURG PATHOL, V29, P230, DOI 10.1097/01.pas.0000146007.54092.37
   Argani P, 2001, AM J PATHOL, V158, P2089, DOI 10.1016/S0002-9440(10)64680-9
   Arita T, 2013, ANTICANCER RES, V33, P3185
   Aune T, 2012, TOXICON, V60, P895, DOI 10.1016/j.toxicon.2012.06.007
   Bernard D, 2010, EMBO J, V29, P3082, DOI 10.1038/emboj.2010.199
   Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023
   Brown JA, 2012, P NATL ACAD SCI USA, V109, P19202, DOI 10.1073/pnas.1217338109
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chaudhry MA, 2014, CANCER BIOTHER RADIO, V29, P135, DOI 10.1089/cbr.2013.1574
   Chaudhry MA, 2013, INT J MOL SCI, V14, P9099, DOI 10.3390/ijms14059099
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Chen H, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0246-7
   Cho SF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-809
   Chojnowski JL, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-308
   Conrad NK, 2014, WIRES RNA, V5, P15, DOI 10.1002/wrna.1194
   Dabovic B, 2002, J CELL BIOL, V156, P227, DOI 10.1083/jcb.200111080
   Davis IJ, 2003, P NATL ACAD SCI USA, V100, P6051, DOI 10.1073/pnas.0931430100
   Dong YQ, 2015, TUMOR BIOL, V36, P1477, DOI 10.1007/s13277-014-2631-4
   Dreyfuss G, 2002, NAT REV MOL CELL BIO, V3, P195, DOI 10.1038/nrm760
   Eissmann M, 2012, RNA BIOL, V9, P1076, DOI 10.4161/rna.21089
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ellison TI, 2008, J INVEST DERMATOL, V128, P2508, DOI 10.1038/jid.2008.131
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fan Y, 2014, CLIN CANCER RES, V20, P1531, DOI 10.1158/1078-0432.CCR-13-1455
   Gibbs RA, 2004, NATURE, V428, P493, DOI 10.1038/nature02426
   Gimpl G, 2001, PHYSIOL REV, V81, P629, DOI 10.1152/physrev.2001.81.2.629
   Guffanti A, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-163
   Guo FJ, 2010, ACTA BIOCH BIOPH SIN, V42, P224, DOI 10.1093/abbs/gmq008
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Han YH, 2013, FEBS LETT, V587, P3875, DOI 10.1016/j.febslet.2013.10.023
   Hangauer MJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003569
   Hong SK, 2009, J BIOL CHEM, V284, P33006, DOI 10.1074/jbc.M109.012591
   Hutchinson JN, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-39
   Jablonowska Dagmara, 2012, Przegl Lek, V69, P740
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383
   Ji Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078700
   Jiang Y, 2014, ONCOL LETT, V7, P2135, DOI 10.3892/ol.2014.1996
   Jiang YJ, 2014, J STEROID BIOCHEM, V144, P87, DOI 10.1016/j.jsbmb.2013.11.018
   Jordan VC, 2011, CANCER PREV RES, V4, P633, DOI 10.1158/1940-6207.CAPR-11-0185
   Joulia D, 2003, EXP CELL RES, V286, P263, DOI 10.1016/S0014-4827(03)00074-0
   Koshimizu T, 2010, LIFE SCI, V86, P455, DOI 10.1016/j.lfs.2010.02.001
   Kovacs G, 1997, J PATHOL, V183, P131, DOI 10.1002/(SICI)1096-9896(199710)183:2<131::AID-PATH931>3.0.CO;2-G
   Kryger R, 2012, ALCOHOL, V46, P629, DOI 10.1016/j.alcohol.2012.04.002
   Kuiper RP, 2003, HUM MOL GENET, V12, P1661, DOI 10.1093/hmg/ddg178
   Kuo IY, 2014, INT J CANCER, V135, P563, DOI 10.1002/ijc.28695
   Kurogi Y, 2014, BIOCHEM BIOPH RES CO, V446, P119, DOI 10.1016/j.bbrc.2014.02.060
   Lai MC, 2012, MED ONCOL, V29, P1810, DOI 10.1007/s12032-011-0004-z
   Leucci E, 2013, SCI REP-UK, V3, DOI 10.1038/srep02535
   Li BZ, 2014, J BIOL CHEM, V289, P29365, DOI 10.1074/jbc.M114.572693
   Li CH, 2013, INT J BIOCHEM CELL B, V45, P1895, DOI 10.1016/j.biocel.2013.05.030
   Lin SR, 2007, ADV EXP MED BIOL, V623, P107, DOI 10.1007/978-0-387-77374-2_7
   Lipovich L, 2012, GENETICS, V192, P1133, DOI 10.1534/genetics.112.145128
   Liu JY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.466
   Liu JH, 2014, ASIAN PAC J CANCER P, V15, P2971, DOI 10.7314/APJCP.2014.15.7.2971
   Liu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035145
   Long JC, 2009, BIOCHEM J, V417, P15, DOI 10.1042/BJ20081501
   Luo JH, 2006, HEPATOLOGY, V44, P1012, DOI 10.1002/hep.21328
   Mathews J, 2013, EXP MOL PATHOL, V95, P319, DOI 10.1016/j.yexmp.2013.09.006
   Michalik KM, 2014, CIRC RES, V114, P1389, DOI 10.1161/CIRCRESAHA.114.303265
   Miyagawa R, 2012, RNA, V18, P738, DOI 10.1261/rna.028639.111
   Mothersill C, 1997, INT J RADIAT BIOL, V71, P421, DOI 10.1080/095530097144030
   NAGASAWA H, 1992, CANCER RES, V52, P6394
   Nakagawa S, 2012, RNA, V18, P1487, DOI 10.1261/rna.033217.112
   Okugawa Y, 2014, CARCINOGENESIS, V35, P2731, DOI 10.1093/carcin/bgu200
   Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442
   Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259
   Pang EJ, 2015, TUMOR BIOL, V36, P2403, DOI 10.1007/s13277-014-2850-8
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0
   Ren SC, 2013, J UROLOGY, V190, P2278, DOI 10.1016/j.juro.2013.07.001
   Ren SC, 2013, EUR J CANCER, V49, P2949, DOI 10.1016/j.ejca.2013.04.026
   Sanford JR, 2009, GENOME RES, V19, P381, DOI 10.1101/gr.082503.108
   Schmidt LH, 2011, J THORAC ONCOL, V6, P1984, DOI 10.1097/JTO.0b013e3182307eac
   Schor IE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048084
   Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367
   Shen LQ, 2015, J NEURO-ONCOL, V121, P101, DOI 10.1007/s11060-014-1613-0
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Skroblin P, 2014, CIRC RES, V115, P607, DOI 10.1161/CIRCRESAHA.114.304839
   Sone M, 2007, J CELL SCI, V120, P2498, DOI 10.1242/jcs.009357
   Sowalsky AG, 2015, MOL CANCER RES, V13, P98, DOI 10.1158/1541-7786.MCR-14-0273
   STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311
   Tan ML, 2009, CANCER BIOL THER, V8, P106, DOI 10.4161/cbt.8.2.7385
   Tee AE, 2014, ONCOTARGET, V5, P1793, DOI 10.18632/oncotarget.1785
   Tollervey JR, 2011, NAT NEUROSCI, V14, P452, DOI 10.1038/nn.2778
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Valdiglesias V, 2013, ECOTOX ENVIRON SAFE, V92, P303, DOI 10.1016/j.ecoenv.2013.03.009
   vandenBerg E, 1997, CANCER GENET CYTOGEN, V95, P103, DOI 10.1016/S0165-4608(96)00289-0
   Vausort M, 2014, CIRC RES, V115, P668, DOI 10.1161/CIRCRESAHA.115.303836
   Wang JY, 2014, CELL SIGNAL, V26, P1048, DOI 10.1016/j.cellsig.2014.01.022
   Wang JQ, 2014, BIOMED PHARMACOTHER, V68, P557, DOI 10.1016/j.biopha.2014.04.007
   Wang XY, 2015, J BIOL CHEM, V290, P3925, DOI 10.1074/jbc.M114.596866
   Watts R, 2014, BIOCHEM CELL BIOL, V92, P226, DOI 10.1139/bcb-2014-0004
   Watts R, 2013, AM J PHYSIOL-CELL PH, V304, pC995, DOI 10.1152/ajpcell.00392.2012
   Wilusz JE, 2012, GENE DEV, V26, P2392, DOI 10.1101/gad.204438.112
   Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909
   Wilusz JE, 2008, CELL, V135, P919, DOI 10.1016/j.cell.2008.10.012
   Wu XS, 2014, CANCER BIOL THER, V15, P806, DOI 10.4161/cbt.28584
   Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007
   Xu YT, 2012, PHARMACOL BIOCHEM BE, V101, P174, DOI 10.1016/j.pbb.2011.12.016
   Yamada K, 2006, CANCER SCI, V97, P106, DOI 10.1111/j.1349-7006.2006.00147.x
   Yan B, 2014, INVEST OPHTH VIS SCI, V55, P941, DOI 10.1167/iovs.13-13221
   Yang F, 2013, FEBS LETT, V587, P3175, DOI 10.1016/j.febslet.2013.07.048
   Yang MH, 2015, BBA-MOL BASIS DIS, V1852, P166, DOI 10.1016/j.bbadis.2014.11.013
   Yang N, 2006, DNA REPAIR, V5, P43, DOI 10.1016/j.dnarep.2005.07.003
   Yao YB, 2012, BIOCHEM BIOPH RES CO, V423, P613, DOI 10.1016/j.bbrc.2012.06.050
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154
   Ying L, 2012, MOL BIOSYST, V8, P2289, DOI 10.1039/c2mb25070e
   Zhang B, 2012, CELL REP, V2, P111, DOI 10.1016/j.celrep.2012.06.003
   Zhang HM, 2015, TUMOR BIOL, V36, P2947, DOI 10.1007/s13277-014-2925-6
   Zhao Y, 2014, CANCER RES, V74, P5103, DOI 10.1158/0008-5472.CAN-14-0427
   Zhao ZY, 2014, BIOCHEM BIOPH RES CO, V445, P388, DOI 10.1016/j.bbrc.2014.02.006
   Zheng HT, 2014, INT J CLIN EXP PATHO, V7, P3174
   Zinser GM, 2002, CARCINOGENESIS, V23, P2103, DOI 10.1093/carcin/23.12.2103
NR 117
TC 92
Z9 108
U1 0
U2 25
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 34
BP 5017
EP 5028
DI 10.2174/1381612821666150724115625
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CV8FR
UT WOS:000364516800009
PM 26205289
DA 2025-01-12
ER

PT J
AU Dinic, J
   Podolski-Renic, A
   Stankovic, T
   Bankovic, J
   Pesic, M
AF Dinic, Jelena
   Podolski-Renic, Ana
   Stankovic, Tijana
   Bankovic, Jasna
   Pesic, Milica
TI New Approaches With Natural Product Drugs for Overcoming Multidrug
   Resistance in Cancer
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Cancer; multidrug resistance; P-glycoprotein; natural product drugs;
   plant secondary metabolites; marine products
ID NF-KAPPA-B; HUMAN P-GLYCOPROTEIN; KAMPO EXTRACT MEDICINES; PHORBOL
   ESTER; BREAST-CANCER; CELL-LINES; APOPTOSIS INDUCTION; PROTEIN-KINASE;
   IN-VITRO; JATROPHANE DITERPENES
AB Resistance to chemotherapeautic drugs is one of the main obstacles to effective cancer treatment. Multidrug resistance (MDR) is defined as resistance to structurally and/or functionally unrelated drugs, and has been extensively investigated for the last three decades. There are two types of MDR: intrinsic and acquired. Tumor microenvironment selection pressure leads to the development of intrinsic MDR, while acquired resistance is a consequence of the administered chemotherapy. A central issue in chemotherapy failure is the existence of heterogeneous populations of cancer cells within one patient and patient-to-patient variability within each type of cancer.
   Numerous genes and pathways contribute to the development of MDR in cancer. Point mutations, gene amplification or other genetic or epigenetic changes all affect biological functions and may lead to the occurrence of MDR phenotype. Similar to the characteristics of cancerogenesis, the main features of MDR include abnormal tumor vasculature, regions of hypoxia, aerobic glycolysis, and a lower susceptibility to apoptosis. In order to achieve a lethal effect on cancer cells, drugs need to reach their intracellular target molecules. The overexpression of the efflux transporter P-glycoprotein (P-gp) in MDR cancer cells leads to decreased uptake of the drug and intracellular drug accumulation, minimising drug-target interactions.
   New agents being or inspired by natural products that sucessfully target these mechanisms are the main subject of this review. Two key approaches in combating MDR in cancer are discussed (i) finding agents that preserve citotoxicity toward MDR cancer cells; (ii) developing compounds that restore the cytotoxic activity of classic anticancer drugs.
C1 [Dinic, Jelena; Podolski-Renic, Ana; Stankovic, Tijana; Bankovic, Jasna; Pesic, Milica] Univ Belgrade, Dept Neurobiol, Inst Biol Res Sinisa Stankovic, Belgrade 11060, Serbia.
C3 University of Belgrade
RP Dinic, J (通讯作者)，Univ Belgrade, Dept Neurobiol, Inst Biol Res Sinisa Stankovic, Despota Stefana 142, Belgrade 11060, Serbia.
EM jelena.dinic@ibiss.bg.ac.rs; camala@ibiss.bg.ac.rs
RI Pešić, Milica/I-4727-2019; Dinic, Jelena/JQV-8913-2023; Stankovic,
   Tijana/F-1228-2016; Podolski-Renic, Ana/AFT-9806-2022
OI Dinic, Jelena/0000-0003-3371-2381; Stankovic,
   Tijana/0000-0001-5623-0612; Podolski-Renic, Ana/0000-0001-7412-3685;
   Pesic, Milica/0000-0002-9045-8239
FU Ministry of Education, Science and Technological Development of the
   Republic of Serbia [III41031]; COST Actions [CM1106, CM1407]
FX The authors acknowledge the support from the Ministry of Education,
   Science and Technological Development of the Republic of Serbia (Grant
   No III41031) and COST Actions CM1106 (Chemical Approaches to Targeting
   Drug Resistance in Cancer Stem Cells) and CM1407 (Challenging organic
   syntheses inspired by nature - from natural products chemistry to drug
   discovery).
CR Abdallah HM, 2015, J ADV RES, V6, P45, DOI 10.1016/j.jare.2014.11.008
   Abraham I, 2012, MAR DRUGS, V10, P2312, DOI 10.3390/md10102312
   Abraham I, 2010, BIOCHEM PHARMACOL, V80, P1497, DOI 10.1016/j.bcp.2010.08.001
   Adhami VM, 2004, MOL CANCER THER, V3, P933
   Adhami VM, 2003, CLIN CANCER RES, V9, P3176
   Afaq F, 2003, ONCOGENE, V22, P1035, DOI 10.1038/sj.onc.1206206
   Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   Aggarwal BB, 2009, EXP BIOL MED, V234, P825, DOI 10.3181/0902-MR-78
   Aggarwal BB, 2009, INT J BIOCHEM CELL B, V41, P40, DOI 10.1016/j.biocel.2008.06.010
   AKIYAMA SI, 1985, SOMAT CELL MOLEC GEN, V11, P117, DOI 10.1007/BF01534700
   Aljancic IS, 2011, J NAT PROD, V74, P1613, DOI 10.1021/np200241c
   Allen JD, 2002, MOL CANCER THER, V1, P417
   Amador ML, 2003, ANN ONCOL, V14, P1607, DOI 10.1093/annonc/mdg443
   Andjelkovic T, 2008, CANCER BIOL THER, V7, P1024, DOI 10.4161/cbt.7.7.6036
   [Anonymous], 2006, PLANT SECONDARY META
   Aoki S, 1998, TETRAHEDRON LETT, V39, P6303, DOI 10.1016/S0040-4039(98)01336-7
   Aoki S, 2001, JPN J CANCER RES, V92, P886, DOI 10.1111/j.1349-7006.2001.tb01177.x
   Awad AB, 2000, J NUTR, V130, P2127, DOI 10.1093/jn/130.9.2127
   Bankovic J, 2013, EXP CELL RES, V319, P1013, DOI 10.1016/j.yexcr.2012.12.017
   Bansal T, 2008, LIFE SCI, V83, P250, DOI 10.1016/j.lfs.2008.06.007
   Banthorpe DV., 1991, METHODS PLANT BIOCH, V7, P1
   Bast A, 2007, CARDIOVASC TOXICOL, V7, P154, DOI 10.1007/s12012-007-0018-0
   Bechinger B, 2006, BBA-BIOMEMBRANES, V1758, P1529, DOI 10.1016/j.bbamem.2006.07.001
   Bednarczyk-Cwynar B, 2015, PHYTOCHEM REV, V14, P203, DOI 10.1007/s11101-014-9353-5
   Beevers CS, 2006, INT J CANCER, V119, P757, DOI 10.1002/ijc.21932
   BERHOW MA, 1994, PHYTOCHEMISTRY, V36, P923, DOI 10.1016/S0031-9422(00)90464-3
   BERHOW MA, 2000, CITRUS LIMONOIDS FUN
   Bisht K, 2010, TOXICOLOGY, V278, P88, DOI 10.1016/j.tox.2009.11.008
   Bisht Savita, 2007, Journal of Nanobiotechnology, V5, P3, DOI 10.1186/1477-3155-5-3
   Borska S, 2010, MOLECULES, V15, P857, DOI 10.3390/molecules15020857
   Brand S, 2006, PLANTA, V224, P413, DOI 10.1007/s00425-006-0228-x
   Brobst DE, 2004, J PHARMACOL EXP THER, V310, P528, DOI 10.1124/jpet.103.064329
   CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679
   Chearwae W, 2006, CANCER CHEMOTH PHARM, V57, P376, DOI 10.1007/s00280-005-0052-1
   Chearwae W, 2004, BIOCHEM PHARMACOL, V68, P2043, DOI 10.1016/j.bcp.2004.07.009
   Chearwae W, 2006, MOL CANCER THER, V5, P1995, DOI 10.1158/1535-7163.MCT-06-0087
   Chen AC, 2004, J NUTR, V134, P1303, DOI 10.1093/jn/134.6.1303
   Chen WY, 2011, INVEST NEW DRUG, V29, P1347, DOI 10.1007/s10637-010-9497-0
   Chen YQ, 2010, PEPTIDES, V31, P1504, DOI 10.1016/j.peptides.2010.05.010
   Chen ZS, 2001, INT J CANCER, V93, P107, DOI 10.1002/ijc.1290
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Choi SU, 1999, ANTICANCER RES, V19, P5229
   Choi SE, 2008, ARCH PHARM RES, V31, P1287, DOI 10.1007/s12272-001-2108-z
   Chun KS, 2003, CARCINOGENESIS, V24, P1515, DOI 10.1093/carcin/bgg107
   Cleary JM, 2010, CURR ONCOL REP, V12, P87, DOI 10.1007/s11912-010-0091-6
   Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831
   Cordell Geoffrey A., 2002, Phytochemistry Reviews, V1, P261, DOI 10.1023/A:1026094701495
   Corea G, 2003, J MED CHEM, V46, P3395, DOI 10.1021/jm030787e
   Corea G, 2009, PHYTOCHEM REV, V8, P431, DOI 10.1007/s11101-009-9126-8
   Cortes J, 2007, ONCOLOGIST, V12, P271, DOI 10.1634/theoncologist.12-3-271
   Cortés-Selva F, 2005, CURR PHARM DESIGN, V11, P3125, DOI 10.2174/1381612054864920
   COTELLE N, 1992, FREE RADICAL BIO MED, V13, P211, DOI 10.1016/0891-5849(92)90017-B
   Crown J, 2000, LANCET, V355, P1176, DOI 10.1016/S0140-6736(00)02074-2
   CUSHMAN M, 1994, J MED CHEM, V37, P3353, DOI 10.1021/jm00046a020
   Dahan A, 2004, EUR J CLIN NUTR, V58, P1, DOI 10.1038/sj.ejcn.1601736
   Davis EM, 2000, TOP CURR CHEM, V209, P53
   DEODHAR SD, 1980, INDIAN J MED RES, V71, P632
   DERRY WB, 1995, BIOCHEMISTRY-US, V34, P2203, DOI 10.1021/bi00007a014
   Dhillon N, 2008, CLIN CANCER RES, V14, P4491, DOI 10.1158/1078-0432.CCR-08-0024
   Di Pietro A, 2002, CELL MOL LIFE SCI, V59, P307, DOI 10.1007/s00018-002-8424-8
   Ding ZH, 2002, BIOCHEM PHARMACOL, V63, P1415, DOI 10.1016/S0006-2952(02)00902-4
   Dinic J, 2015, FITOTERAPIA IN PRESS
   Dinic J, 2014, PLANTA MED, V80, P1088, DOI 10.1055/s-0034-1382993
   Dresser GK, 2003, EUR J CLIN INVEST, V33, P10, DOI 10.1046/j.1365-2362.33.s2.2.x
   Duarte N, 2008, PLANTA MED, V74, P61, DOI 10.1055/s-2007-993765
   Duarte N, 2007, BIOORGAN MED CHEM, V15, P546, DOI 10.1016/j.bmc.2006.09.028
   Eid SY, 2015, PHARM PHARM, P46
   El-Readi MZ, 2013, PHYTOMEDICINE, V20, P282, DOI 10.1016/j.phymed.2012.11.005
   El-Readi MZ, 2010, EUR J PHARMACOL, V626, P139, DOI 10.1016/j.ejphar.2009.09.040
   Evans AM, 2000, THER DRUG MONIT, V22, P131, DOI 10.1097/00007691-200002000-00028
   Faber KN, 2003, ADV DRUG DELIVER REV, V55, P107, DOI 10.1016/S0169-409X(02)00173-4
   Fai Y.M., 2009, Natura proda medica, V2, P77
   Feinshtein V, 2013, PEERJ, V1, DOI 10.7717/peerj.153
   Ferreira MJU, 2005, ANTICANCER RES, V25, P4173
   Fischedick JT, 2013, BIOORGAN MED CHEM, V21, P2618, DOI 10.1016/j.bmc.2013.02.019
   Fu LW, 2001, ANTICANCER RES, V21, P2273
   Galletti E, 2007, CHEMMEDCHEM, V2, P920, DOI 10.1002/cmdc.200600308
   Gershenzon J., 1999, BIOCH PLANT SECONDAR, V2, P222
   GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5
   Guéritte F, 2001, CURR PHARM DESIGN, V7, P1229, DOI 10.2174/1381612013397429
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   Gupta SC, 2012, CLIN EXP PHARMACOL P, V39, P283, DOI 10.1111/j.1440-1681.2011.05648.x
   Haefner B, 2003, DRUG DISCOV TODAY, V8, P536, DOI 10.1016/S1359-6446(03)02713-2
   Hammer MU, 2010, BIOCHEM J, V427, P477, DOI 10.1042/BJ20091607
   Han SS, 2001, CANCER LETT, V164, P119, DOI 10.1016/S0304-3835(01)00378-0
   He L, 2002, ACTA PHARMACOL SIN, V23, P591
   Heng MCY, 2000, BRIT J DERMATOL, V143, P937, DOI 10.1046/j.1365-2133.2000.03767.x
   HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267
   Horie N, 2005, BIOL PHARM BULL, V28, P574, DOI 10.1248/bpb.28.574
   Hsu CH, 2007, ADV EXP MED BIOL, V595, P471
   Hu GP, 2011, MAR DRUGS, V9, P514, DOI 10.3390/md9040514
   Hu YW, 2015, MAR DRUGS, V13, P202, DOI 10.3390/md13010202
   Huang M, 2008, CANCER CHEMOTH PHARM, V62, P1015, DOI 10.1007/s00280-008-0691-0
   HUANG MT, 1994, CANCER RES, V54, P701
   Huang SC, 2005, BIOCHEM PHARMACOL, V69, P221, DOI 10.1016/j.bcp.2004.09.019
   Huang Y, 2005, PHARMACOGENOMICS J, V5, P112, DOI 10.1038/sj.tpj.6500297
   Hunyadi A, 2014, PHYTOCHEM REV, V13, P69, DOI 10.1007/s11101-013-9288-2
   Ioannides C, 2002, XENOBIOTICA, V32, P451, DOI 10.1080/00498250210124147
   Iranshahi Mehrdad, 2014, J Tradit Complement Med, V4, P118, DOI 10.4103/2225-4110.126181
   ISAKOV N, 1993, J IMMUNOL, V150, P1195
   Iwanaga K, 2011, BIOL PHARM BULL, V34, P1246, DOI 10.1248/bpb.34.1246
   Iwanaga K, 2010, DRUG METAB DISPOS, V38, P1286, DOI 10.1124/dmd.110.032847
   Jadranin M, 2013, PHYTOCHEMISTRY, V86, P208, DOI 10.1016/j.phytochem.2012.09.003
   Jain S, 2007, J NAT PROD, V70, P928, DOI 10.1021/np0605889
   Jain S, 2009, J NAT PROD, V72, P1291, DOI 10.1021/np900091y
   Jaiswal AS, 2002, ONCOGENE, V21, P8414, DOI 10.1038/sj.onc.1205947
   Jevtic VV, 2013, J MOL STRUCT, V1040, P216, DOI 10.1016/j.molstruc.2013.03.013
   Johnson WW, 2002, DRUG METAB REV, V87
   Ju-Ichi M, 2005, YAKUGAKU ZASSHI, V125, P231, DOI 10.1248/yakushi.125.231
   Jungeström MB, 2007, CLIN CANCER RES, V13, P1061, DOI 10.1158/1078-0432.CCR-06-1651
   Kaneuchi M, 2003, INT J ONCOL, V22, P159
   Kanzaki A, 2002, MOL CANCER THER, V1, P1327
   Katan MB, 2003, MAYO CLIN PROC, V78, P965, DOI 10.4065/78.8.965
   Kavallaris M, 1997, J CLIN INVEST, V100, P1282, DOI 10.1172/JCI119642
   Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200
   Kim SO, 2004, BIOFACTORS, V21, P27, DOI 10.1002/biof.552210107
   Kim SW, 2003, BIOCHEM PHARMACOL, V65, P75, DOI 10.1016/S0006-2952(02)01446-6
   KIOKA N, 1992, FEBS LETT, V301, P307, DOI 10.1016/0014-5793(92)80263-G
   Kitagawa S, 2004, J PHARM PHARMACOL, V56, P1001, DOI 10.1211/0022357044003
   Korkina L, 2011, MINI-REV MED CHEM, V11, P823, DOI 10.2174/138955711796575489
   Korkina LG, 2007, CELL MOL BIOL, V53, P15, DOI 10.1170/T772
   KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334
   Kumi-Diaka J, 2000, BIOL CELL, V92, P595, DOI 10.1016/S0248-4900(00)01109-6
   Lage H, 2010, PHYTOMEDICINE, V17, P441, DOI 10.1016/j.phymed.2009.07.009
   Lai YC, 2012, PHYTOCHEMISTRY, V73, P84, DOI 10.1016/j.phytochem.2011.02.008
   Lal B, 1999, PHYTOTHER RES, V13, P318, DOI 10.1002/(SICI)1099-1573(199906)13:4<318::AID-PTR445>3.0.CO;2-7
   Lanzotti V, 2014, ANTI-CANCER AGENT ME, V14, P1313, DOI 10.2174/187152061410141111101706
   Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042
   Lee CK, 2010, PHARMACOLOGY, V85, P350, DOI 10.1159/000312690
   Lee MA, 2010, PLANTA MED, V76, P1007, DOI 10.1055/s-0029-1240911
   Lee SH, 2008, MOL CARCINOGEN, V47, P197, DOI 10.1002/mc.20374
   Leite DFP, 2006, PLANTA MED, V72, P1353, DOI 10.1055/s-2006-951708
   Leslie EM, 2001, MOL PHARMACOL, V59, P1171, DOI 10.1124/mol.59.5.1171
   Leuschner C, 2004, CURR PHARM DESIGN, V10, P2299, DOI 10.2174/1381612043383971
   Li L, 2005, CANCER-AM CANCER SOC, V104, P1322, DOI 10.1002/cncr.21300
   Limtrakul P, 2007, MOL CELL BIOCHEM, V296, P85, DOI 10.1007/s11010-006-9302-8
   Lindahl G, 2011, CANCER RES, V71, P51, DOI 10.1158/0008-5472.CAN-10-2289
   Lo AH, 2002, CARCINOGENESIS, V23, P983, DOI 10.1093/carcin/23.6.983
   Lohner K, 1999, BBA-BIOMEMBRANES, V1462, P141, DOI 10.1016/S0005-2736(99)00204-7
   Lu ZQ, 2008, J NAT PROD, V71, P873, DOI 10.1021/np0706163
   Malikova Jana, 2006, Biomedical Papers (Olomouc), V150, P5
   Mann J., 1994, NATURAL PRODUCTS, V1st
   Manno S, 2002, P NATL ACAD SCI USA, V99, P1943, DOI 10.1073/pnas.042688399
   Matsuda H, 1998, BIOORG MED CHEM LETT, V8, P2939, DOI 10.1016/S0960-894X(98)00528-9
   McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004
   Mencherini T, 2013, J AGR FOOD CHEM, V61, P1686, DOI 10.1021/jf302815t
   Mi QW, 2003, ANTICANCER RES, V23, P3607
   Mi QW, 2002, CANCER LETT, V184, P13, DOI 10.1016/S0304-3835(02)00202-1
   Mi QW, 2001, CANCER RES, V61, P4030
   Miglietta A, 2003, CANCER CHEMOTH PHARM, V51, P67, DOI 10.1007/s00280-002-0541-4
   Möller M, 2007, PLANTA MED, V73, P1389, DOI 10.1055/s-2007-990229
   Möller M, 2007, ONCOL REP, V18, P737
   Möller M, 2006, PLANTA MED, V72, P1121, DOI 10.1055/s-2006-941546
   Mojsin M, 2014, FOOD FUNCT, V5, P2564, DOI [10.1039/c4fo00484a, 10.1039/C4FO00484A]
   Molnár J, 2006, CURR PHARM DESIGN, V12, P287, DOI 10.2174/138161206775201893
   Moran AE, 2005, CANCER RES, V65, P1097
   Mosley CA, 2007, ADV EXP MED BIOL, V595, P77
   Mshvildadze V, 2007, PHYTOCHEMISTRY, V68, P2531, DOI 10.1016/j.phytochem.2007.05.018
   Munde T, 2013, PHYTOCHEMISTRY, V91, P165, DOI 10.1016/j.phytochem.2012.02.020
   Muñoz-Martínez F, 2004, CANCER RES, V64, P7130, DOI 10.1158/0008-5472.CAN-04-1005
   Murakami A, 2000, CANCER RES, V60, P5059
   Murakami A, 2000, CARCINOGENESIS, V21, P1843, DOI 10.1093/carcin/21.10.1843
   Nabekura T, 2005, BIOCHEM BIOPH RES CO, V327, P866, DOI 10.1016/j.bbrc.2004.12.081
   Nabekura T, 2008, EUR J PHARMACOL, V600, P45, DOI 10.1016/j.ejphar.2008.10.025
   Nabekura T, 2008, BIOCHEM BIOPH RES CO, V369, P363, DOI 10.1016/j.bbrc.2008.02.026
   Nabekura T, 2010, PHARMACOL RES, V61, P259, DOI 10.1016/j.phrs.2009.11.010
   Nakagawa-Goto K, 2010, J MED CHEM, V53, P6699, DOI 10.1021/jm100846r
   Nebl T, 2002, J BIOL CHEM, V277, P43399, DOI 10.1074/jbc.M205386200
   Newman DJ, 2007, J NAT PROD, V70, P461, DOI 10.1021/np068054v
   Nguyen TTT, 2004, CARCINOGENESIS, V25, P647, DOI 10.1093/carcin/bgh052
   Nobili S, 2012, MED RES REV, V32, P1220, DOI 10.1002/med.20239
   Nobili S, 2009, PHARMACOL RES, V59, P365, DOI 10.1016/j.phrs.2009.01.017
   Nomura M, 2000, CARCINOGENESIS, V21, P1885, DOI 10.1093/carcin/21.10.1885
   Novakovic M, 2014, PHYTOCHEMISTRY, V97, P46, DOI 10.1016/j.phytochem.2013.11.001
   Ohtani H, 2007, PHARM RES, V24, P1936, DOI 10.1007/s11095-007-9320-6
   Park CH, 2005, FEBS LETT, V579, P2965, DOI 10.1016/j.febslet.2005.04.013
   Paszel A, 2011, PHARMACOL REP, V63, P1500, DOI 10.1016/S1734-1140(11)70714-9
   Penson RT, 2004, GYNECOL ONCOL, V93, P98, DOI 10.1016/j.ygyno.2003.11.053
   Pesic M, 2011, FOOD CHEM TOXICOL, V49, P3165, DOI 10.1016/j.fct.2011.09.035
   Podolski-Renic A, 2013, CANCER CHEMOTH PHARM, V72, P683, DOI 10.1007/s00280-013-2247-1
   Podolski-Renic A, 2011, BIOMED PHARMACOTHER, V65, P345, DOI 10.1016/j.biopha.2011.04.015
   Pohl A, 2002, BIOCHEM J, V365, P259, DOI 10.1042/BJ20011880
   Poulose SM, 2005, J NUTR, V135, P870, DOI 10.1093/jn/135.4.870
   Qin XL, 2014, DRUG METAB DISPOS, V42, P193, DOI 10.1124/dmd.113.053892
   Rabindran SK, 2000, CANCER RES, V60, P47
   Rinehart KL, 2000, MED RES REV, V20, P1
   ROEPE PD, 1993, BIOCHEMISTRY-US, V32, P11042, DOI 10.1021/bi00092a014
   RONINSON IB, 1986, P NATL ACAD SCI USA, V83, P4538, DOI 10.1073/pnas.83.12.4538
   Rosenkranz V, 2008, MOLECULES, V13, P2462, DOI 10.3390/molecules13102462
   ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507
   Roy A, 2006, BIOL PHARM BULL, V29, P191, DOI 10.1248/bpb.29.191
   Saarinen NM, 2002, MOL CANCER THER, V1, P869
   Schnabel C, 2011, J ORG CHEM, V76, P512, DOI 10.1021/jo1019738
   Schröder-Borm H, 2005, FEBS LETT, V579, P6128, DOI 10.1016/j.febslet.2005.09.084
   Selway J W, 1986, Prog Clin Biol Res, V213, P521
   Shaikh J, 2009, EUR J PHARM SCI, V37, P223, DOI 10.1016/j.ejps.2009.02.019
   Shen XL, 2006, BIOORGAN MED CHEM, V14, P7138, DOI 10.1016/j.bmc.2006.06.066
   Shen XL, 2012, J PHARM PHARMACOL, V64, P90, DOI 10.1111/j.2042-7158.2011.01378.x
   Shi Z, 2007, CANCER RES, V67, P11012, DOI 10.1158/0008-5472.CAN-07-2686
   Shimizu BI, 2014, FRONT PLANT SCI, V5, DOI 10.3389/fpls.2014.00549
   Shishodia S, 2004, J BIOL CHEM, V279, P47148, DOI 10.1074/jbc.M408093200
   Shishodia S, 2007, ADV EXP MED BIOL, V595, P127
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Shukla S, 2008, EXPERT OPIN DRUG MET, V4, P205, DOI 10.1517/17425255.4.2.205
   Silalahi J, 2002, ASIA PAC J CLIN NUTR, V11, P79, DOI 10.1046/j.1440-6047.2002.00271.x
   SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995
   Singh S, 1996, J IMMUNOL, V157, P4412
   Slanina J, 2014, J NAT PROD, V77, P2255, DOI 10.1021/np500521v
   SMITH CD, 1995, MOL PHARMACOL, V47, P241
   Somerset SM, 2008, NUTR CANCER, V60, P442, DOI 10.1080/01635580802143836
   Spivey AC, 2002, CHEM SOC REV, V31, P43, DOI 10.1039/b000678p
   Stankovic T, 2015, CANC CHEMOT IN PRESS
   STEARNS ME, 1992, CANCER RES, V52, P3776
   Steinbach D, 2002, LEUKEMIA, V16, P1443, DOI 10.1038/sj.leu.2402541
   Stiborova M, 2014, SENSORS-BASEL, V14, P22982, DOI 10.3390/s141222982
   Szakács G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984
   Szakács G, 2008, DRUG DISCOV TODAY, V13, P379, DOI 10.1016/j.drudis.2007.12.010
   Szakács G, 2014, CHEM REV, V114, P5753, DOI 10.1021/cr4006236
   Takanaga H, 2000, J PHARMACOL EXP THER, V293, P230
   Tanaka T, 1997, CARCINOGENESIS, V18, P2155, DOI 10.1093/carcin/18.11.2155
   Tanaka T, 1998, CARCINOGENESIS, V19, P425, DOI 10.1093/carcin/19.3.425
   Tanaka T, 2000, BIOFACTORS, V13, P213, DOI 10.1002/biof.5520130133
   Tang MX, 2007, CANCER SCI, V98, P471, DOI 10.1111/j.1349-7006.2007.00417.x
   Toiyama Y, 2009, CANC THER, V7, P123
   Tung NH, 2010, PLANTA MED, V76, P626, DOI 10.1055/s-0029-1240595
   Tung NH, 2010, BIOORG MED CHEM LETT, V20, P1000, DOI 10.1016/j.bmcl.2009.12.057
   Urquhart BL, 2007, J CLIN PHARMACOL, V47, P566, DOI 10.1177/0091270007299930
   UTSUGI T, 1991, CANCER RES, V51, P3062
   van den Heuvel-Eibrink MM, 2002, LEUKEMIA, V16, P833, DOI 10.1038/sj.leu.2402496
   Vasas A, 2011, J NAT PROD, V74, P1453, DOI 10.1021/np200202h
   Villeneuve DJ, 2006, BREAST CANCER RES TR, V96, P17, DOI 10.1007/s10549-005-9026-6
   Wang HK, 1998, ADV EXP MED BIOL, V439, P191
   WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045
   Wellwood CRL, 2004, J AGR FOOD CHEM, V52, P6101, DOI 10.1021/jf035335p
   Wesolowska O, 2012, J NAT PROD, V75, P1896, DOI 10.1021/np3003468
   Wink M, 2008, CURR DRUG METAB, V9, P996, DOI 10.2174/138920008786927794
   Wu CP, 2005, FEBS J, V272, P4725, DOI 10.1111/j.1742-4658.2005.04888.x
   Yang KH, 2008, BIOSCI TRENDS, V2, P137
   Yang LQ, 2012, BIOPHARM DRUG DISPOS, V33, P425, DOI 10.1002/bdd.1806
   Yu MH, 2013, FOOD CHEM, V136, P1047, DOI 10.1016/j.foodchem.2012.08.085
   Yu MW, 2013, FOOD CHEM, V136, P1130, DOI 10.1016/j.foodchem.2012.09.088
   Yu SW, 2008, MOL CANCER THER, V7, P2609, DOI 10.1158/1535-7163.MCT-07-2400
   Zdarilová A, 2006, CHEM LISTY, V100, P30
   Zewail-Foote M, 1999, J MED CHEM, V42, P2493, DOI 10.1021/jm990241l
   Zhang JW, 2012, DRUG METAB DISPOS, V40, P1900, DOI 10.1124/dmd.112.045187
   Zhang JW, 2010, DRUG METAB DISPOS, V38, P2179, DOI 10.1124/dmd.110.034793
   Zhou LG, 2008, ANTICANCER RES, V28, P1119
   Zhu HJ, 2006, J PHARMACOL EXP THER, V317, P850, DOI 10.1124/jpet.105.098541
   Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121
NR 249
TC 36
Z9 40
U1 2
U2 44
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2015
VL 21
IS 38
BP 5589
EP 5604
DI 10.2174/1381612821666151002113546
PG 16
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CV8GH
UT WOS:000364518900010
PM 26429711
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kang, LH
   Sun, JN
   Wen, X
   Cui, JW
   Wang, GJ
   Hoffman, AR
   Hu, JF
   Li, W
AF Kang, Lihua
   Sun, Jingnan
   Wen, Xue
   Cui, Jiuwei
   Wang, Guanjun
   Hoffman, Andrew R.
   Hu, Ji-Fan
   Li, Wei
TI Aberrant allele-switch imprinting of a novel <i>IGF1R</i> intragenic
   antisense non-coding RNA in breast cancers
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Genomic imprinting; IRAIN; Non-coding RNA; Breast cancer; IGF1R; Allelic
   expression; Gene regulation; DNA methylation
ID FACTOR-II RECEPTOR; GROWTH-FACTOR-I; MYELOID-LEUKEMIA CELLS; INTRONIC
   CPG ISLAND; IGF2R GENE DEPENDS; HEMATOPOIETIC MALIGNANCIES; MONOALLELIC
   EXPRESSION; MONOCLONAL-ANTIBODY; MULTIPLE-MYELOMA; DNA METHYLATION
AB The insulin-like growth factor type I receptor (IGF1R) is frequently dysregulated in breast cancers, yet the molecular mechanisms are unknown. A novel intragenic long non-coding RNA (lncRNA) IRAIN within the IGF1R locus has been recently identified in haematopoietic malignancies using RNA-guided chromatin conformation capture (R3C). In breast cancer tissues, we found that IRAIN lncRNA was transcribed from an intronic promoter in an antisense direction as compared to the IGF1R coding mRNA. Unlike the IGF1R coding RNA, this non-coding RNA was imprinted, with monoallelic expression from the paternal allele. In breast cancer tissues that were informative for single nucleotide polymorphism (SNP) rs8034564, there was an imbalanced expression of the two parental alleles, where the 'G' genotype was favorably imprinted over the 'A' genotype. In breast cancer patients, IRAIN was aberrantly imprinted in both tumours and peripheral blood leucocytes, exhibiting a pattern of allele-switch: the allele expressed in normal tissues was inactivated and the normally imprinted allele was expressed. Epigenetic analysis revealed that there was extensive DNA demethylation of CpG islands in the gene promoter. These data identify IRAIN lncRNA as a novel imprinted gene that is aberrantly regulated in breast cancer. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Kang, Lihua; Sun, Jingnan; Wen, Xue; Cui, Jiuwei; Wang, Guanjun; Hu, Ji-Fan; Li, Wei] Jilin Univ, Affiliated Hosp 1, Stem Cell & Canc Ctr, Changchun 130061, Jilin, Peoples R China.
   [Sun, Jingnan; Hoffman, Andrew R.; Hu, Ji-Fan] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
C3 Jilin University; Stanford University
RP Hu, JF (通讯作者)，Jilin Univ, Affiliated Hosp 1, Stem Cell & Canc Ctr, Changchun 130061, Jilin, Peoples R China.
EM Jifan@stanford.edu; drweili@yahoo.com
RI Hu, Jifan/Q-3003-2019
OI Hoffman, Andrew/0000-0002-0145-1917; HU, Jifan/0000-0002-2174-0361
FU California Institute of Regenerative Medicine (CIRM) [RT2-01942]; Jilin
   International Collaboration Grant [20120720]; National Natural Science
   Foundation of China [81272294, 31430021, 81071920, 81372835]; Key
   Project of Chinese Ministry of Education [311015]; Breast Cancer
   Research Program Idea Award of the Department of Defense [BC102122];
   CDMRP [545342, BC102122] Funding Source: Federal RePORTER
FX This work was supported by California Institute of Regenerative Medicine
   (CIRM) grant (RT2-01942), Jilin International Collaboration Grant
   (#20120720), the National Natural Science Foundation of China grant
   (#81272294, #31430021) to J.F.H; the National Natural Science Foundation
   of China grants (#81071920, #81372835) to W.L.; the grant of Key Project
   of Chinese Ministry of Education (#311015) to C.J.; and grant BC102122
   from the Breast Cancer Research Program Idea Award of the Department of
   Defense to A.R.H.
CR Barlow DP, 1997, EMBO J, V16, P6899, DOI 10.1093/emboj/16.23.6899
   BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0
   BARLOW DP, 1995, SCIENCE, V270, P1610, DOI 10.1126/science.270.5242.1610
   Barok M, 2014, BREAST CANCER RES, V13, pR46
   Blackman DJ, 2006, J CLIN ONCOL, V24, P2170, DOI 10.1200/JCO.2005.05.4734
   Bonora E, 2014, EMBO MOL MED, V6
   Buck E, 2011, EXPERT OPIN INV DRUG, V20, P605, DOI 10.1517/13543784.2011.558501
   Capoluongo E, 2011, AM J PATHOL, V178, P26, DOI 10.1016/j.ajpath.2010.11.004
   Chapuis N, 2010, HAEMATOL-HEMATOL J, V95, P415, DOI 10.3324/haematol.2009.010785
   Chen HL, 2006, EMBO J, V25, P5329, DOI 10.1038/sj.emboj.7601399
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cui HM, 2003, SCIENCE, V299, P1753, DOI 10.1126/science.1080902
   Cui HM, 2002, CANCER RES, V62, P6442
   Esumi S, 2005, NAT GENET, V37, P171, DOI 10.1038/ng1500
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110
   Gallagher EJ, 2010, TRENDS ENDOCRIN MET, V21, P610, DOI 10.1016/j.tem.2010.06.007
   Ge NL, 2000, BLOOD, V96, P2856
   Gimelbrant AA, 2005, J BIOL CHEM, V280, P1354, DOI 10.1074/jbc.M411283200
   Grandage VL, 2005, LEUKEMIA, V19, P586, DOI 10.1038/sj.leu.2403653
   Harbeck N, 2013, BREAST CARE, V8, P49, DOI 10.1159/000346837
   Heidegger I, 2011, CANCER BIOL THER, V11, P701, DOI 10.4161/cbt.11.8.14689
   Hofmann WK, 2002, EXP HEMATOL, V30, P318, DOI 10.1016/S0301-472X(01)00797-4
   Holm TM, 2005, CANCER CELL, V8, P275, DOI 10.1016/j.ccr.2005.09.007
   HOWARD TK, 1993, HUM MOL GENET, V2, P2089, DOI 10.1093/hmg/2.12.2089
   Hu JF, 1998, MOL ENDOCRINOL, V12, P220, DOI 10.1210/me.12.2.220
   Hu JF, 2000, ENDOCRINOLOGY, V141, P4428, DOI 10.1210/en.141.12.4428
   Hu JF, 1999, BIOCHEM BIOPH RES CO, V257, P604, DOI 10.1006/bbrc.1999.0380
   Hu JF, 1996, J BIOL CHEM, V271, P18253, DOI 10.1074/jbc.271.30.18253
   Jones RA, 2009, ONCOGENE, V28, P2152, DOI 10.1038/onc.2009.79
   Karamouzis MV, 2012, CRIT REV ONCOL HEMAT, V84, P8, DOI 10.1016/j.critrevonc.2012.02.010
   Kopsida E, 2011, HORM BEHAV, V59, P375, DOI 10.1016/j.yhbeh.2010.04.005
   Li T, 2008, MOL CELL BIOL, V28, P6473, DOI 10.1128/MCB.00204-08
   Li T, 2014, HUM MOL GENET, V23, P117, DOI 10.1093/hmg/ddt405
   Lin MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044017
   Magklara A, 2011, CELL, V145, P555, DOI 10.1016/j.cell.2011.03.040
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509
   Moreau P, 2011, LEUKEMIA, V25, P872, DOI 10.1038/leu.2011.4
   Nahta R, 2006, NAT CLIN PRACT ONCOL, V3, P269, DOI 10.1038/ncponc0509
   OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0
   OGAWA O, 1993, HUM MOL GENET, V2, P2163, DOI 10.1093/hmg/2.12.2163
   Ozkan EE, 2011, MOL CELL ENDOCRINOL, V344, P1, DOI 10.1016/j.mce.2011.07.002
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Polson ES, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2627
   RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0
   Randhawa GS, 1998, BLOOD, V91, P3144, DOI 10.1182/blood.V91.9.3144.3144_3144_3147
   Rhoades KL, 2000, CURR BIOL, V10, P789, DOI 10.1016/S0960-9822(00)00565-0
   Roppolo D, 2007, EMBO J, V26, P3423, DOI 10.1038/sj.emboj.7601782
   Rowinsky EK, 2011, CURR DRUG TARGETS, V12, P2016
   Seccareccia E, 2012, GROWTH HORM IGF RES, V22, P193, DOI 10.1016/j.ghir.2012.09.003
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Skaar DA, 2012, ILAR J, V53, P341, DOI 10.1093/ilar.53.3-4.341
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Soejima H, 2013, J HUM GENET, V58, P402, DOI 10.1038/jhg.2013.51
   Sohda T, 1998, J HUM GENET, V43, P49, DOI 10.1007/s100380050036
   Sprynski AC, 2010, LEUKEMIA, V24, P1940, DOI 10.1038/leu.2010.192
   Sprynski AC, 2009, BLOOD, V113, P4614, DOI 10.1182/blood-2008-07-170464
   STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R
   Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096
   Sun JN, 2014, NUCLEIC ACIDS RES, V42, P9588, DOI 10.1093/nar/gku549
   Takeda S, 1996, ONCOGENE, V12, P1589
   Tognon CE, 2012, EXPERT OPIN THER TAR, V16, P33, DOI 10.1517/14728222.2011.638626
   Ulaner GA, 2003, HUM MOL GENET, V12, P535, DOI 10.1093/hmg/ddg034
   Wang H, 2014, INT J CANCER, V135, P2783, DOI 10.1002/ijc.28922
   Wutz A, 1998, MOL CELL ENDOCRINOL, V140, P9, DOI 10.1016/S0303-7207(98)00022-7
   Wutz A, 1997, NATURE, V389, P745, DOI 10.1038/39631
   Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429
   Zhang H, 2014, J CELL BIOL, V204, P61, DOI 10.1083/jcb.201304152
   Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268
   Zhang SH, 2014, INT J CANCER, V134, P1583, DOI 10.1002/ijc.28487
NR 71
TC 31
Z9 38
U1 0
U2 33
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JAN
PY 2015
VL 51
IS 2
BP 260
EP 270
DI 10.1016/j.ejca.2014.10.031
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AX3PL
UT WOS:000346851200016
PM 25465188
DA 2025-01-12
ER

PT J
AU Lubecka-Pietruszewska, K
   Kaufman-Szymczyk, A
   Stefanska, B
   Cebula-Obrzut, B
   Smolewski, P
   Fabianowska-Majewska, K
AF Lubecka-Pietruszewska, Katarzyna
   Kaufman-Szymczyk, Agnieszka
   Stefanska, Barbara
   Cebula-Obrzut, Barbara
   Smolewski, Piotr
   Fabianowska-Majewska, Krystyna
TI Sulforaphane Alone and in Combination with Clofarabine Epigenetically
   Regulates the Expression of DNA Methylation-Silenced Tumour Suppressor
   Genes in Human Breast Cancer Cells
SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS
LA English
DT Article
DE Sulforaphane; Epigenetic chemoprevention; Tumour suppressor genes;
   Promoter methylation; Breast cancer
ID RETINOIC ACID; PROMOTER; GROWTH; P53; 5-AZA-2'-DEOXYCYTIDINE;
   COMPONENTS; INHIBITORS; APOPTOSIS; ANALOG; PTEN
AB Background/Aim: Sporadic breast cancer is frequently associated with aberrant DNA methylation patterns that are reversible and responsive to environmental factors, including diet. In the present study, we investigated the effects of sulforaphane (SFN), a phytochemical from cruciferous vegetables, on the methylation and expression of PTEN and RARbeta2 tumour suppressor genes as well as on the expression of regulators of DNA nnethylation reaction, DNMT1, p53, and p21, in MCF-7 and MDA-MB-231 human breast cancer cells with different invasive potential. We also evaluate the role of SFN epigenetic effects in support of therapy with clofarabine (CIF) that was recently shown to modulate the epigenome as well. Methods: Promoter methylation and gene expression were estimated using methylation-sensitive restriction analysis and real-time PCR, respectively. Results: In both MCF-7 and MDA-MB-231 cells, SFN at IC50 (22 and 46 pm, respectively) and a physiologically relevant 10 pm concentration lead to hypomethylation of PTEN and RARbeta2 promoters with concomitant gene upregulation. The combination of SFN and CIF enhances these effects, resulting in an increase in cell growth arrest and apoptosis at a non-invasive breast cancer stage. Conclusions: Our findings provide evidence that SFN activates DNA methylation-silenced tumour suppressor genes in breast cancer cells and may contribute to SFN-mediated support of therapy with an anti-cancer drug, CIF, increasing its applications in solid tumours. (C) 2015 S. Karger AG, Basel
C1 [Lubecka-Pietruszewska, Katarzyna; Kaufman-Szymczyk, Agnieszka; Fabianowska-Majewska, Krystyna] Med Univ Lodz, Dept Biomed Chem, Lodz, Poland.
   [Cebula-Obrzut, Barbara; Smolewski, Piotr] Med Univ Lodz, Dept Expt Haematol, Lodz, Poland.
   [Lubecka-Pietruszewska, Katarzyna; Stefanska, Barbara] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA.
C3 Medical University Lodz; Medical University Lodz; Purdue University
   System; Purdue University
RP Lubecka-Pietruszewska, K (通讯作者)，Purdue Univ, Dept Nutr Sci, 201 South Univ St, W Lafayette, IN 47907 USA.
EM klubecka@purdue.edu
RI Stefańska, Barbara/ABD-1161-2021; Kaufman-Szymczyk,
   Agnieszka/S-9624-2016; Lubecka, Katarzyna/S-9731-2016
OI Cebula-Obrzut, Barbara/0000-0002-2689-7130; Lubecka-Gajewska,
   Katarzyna/0000-0002-4250-0922; Smolewski, Piotr/0000-0003-2700-3343;
   Kaufman-Szymczyk, Agnieszka/0000-0001-6014-7280
FU National Science Centre in Poland [DEC-2011/01/N/NZ2/01697]; Medical
   University of Lodz, Poland [502-03/6-099-01/502-64-007,
   503/6-099-01/503-01]
FX The studies were financed by the National Science Centre in Poland,
   grant No. DEC-2011/01/N/NZ2/01697, and partly by the Medical University
   of Lodz, Poland, grants No. 502-03/6-099-01/502-64-007 and
   503/6-099-01/503-01.
CR Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576
   Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Gerhauser C, 2013, CURR OPIN CLIN NUTR, V16, P405, DOI 10.1097/MCO.0b013e328362014e
   Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375
   Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Jänicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c
   Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172
   Lefebvre B, 2006, MOL ENDOCRINOL, V20, P2109, DOI 10.1210/me.2005-0321
   Lubecka-Pietruszewska K, 2014, EUR J PHARMACOL, V723, P276, DOI 10.1016/j.ejphar.2013.11.021
   Lubecka-Pietruszewska K, 2013, BIOCHEM BIOPH RES CO, V430, P623, DOI 10.1016/j.bbrc.2012.11.103
   Meeran SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037748
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Mongan NP, 2005, MOL CANCER THER, V4, P477
   Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265
   Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326
   Pawlik A, 2013, EUR J NUTR, V52, P1949, DOI 10.1007/s00394-013-0499-5
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pledgie-Tracy A, 2007, MOL CANCER THER, V6, P1013, DOI 10.1158/1535-7163.MCT-06-0494
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Rabbani SA, 2008, NEOPLASIA, V10, P266, DOI 10.1593/neo.07947
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Saramäki A, 2006, NUCLEIC ACIDS RES, V34, P543, DOI 10.1093/nar/gkj460
   Sarkar S, 2011, ANTICANCER RES, V31, P2723
   Stefanska B, 2012, BRIT J PHARMACOL, V167, P279, DOI 10.1111/j.1476-5381.2012.02002.x
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Wong CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086787
   Zhang CY, 2013, BIOCHEM PHARMACOL, V85, P1398, DOI 10.1016/j.bcp.2013.02.010
NR 35
TC 57
Z9 59
U1 1
U2 12
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1661-6499
EI 1661-6758
J9 J NUTRIGENET NUTRIGE
JI J. Nutrigenet. Nutrigenomics
PY 2015
VL 8
IS 2
BP 91
EP 101
DI 10.1159/000439111
PG 11
WC Genetics & Heredity; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Nutrition & Dietetics
GA CT8VF
UT WOS:000363094300004
PM 26372775
OA gold
DA 2025-01-12
ER

PT J
AU Marcato, P
   Dean, CA
   Liu, RZ
   Coy, KM
   Bydoun, M
   Wallace, M
   Clements, D
   Turner, C
   Mathenge, EG
   Gujar, SA
   Giacomantonio, CA
   Mackey, JR
   Godbout, R
   Lee, PWK
AF Marcato, Paola
   Dean, Cheryl A.
   Liu, Rong-Zong
   Coy, Krysta M.
   Bydoun, Moamen
   Wallace, Melissa
   Clements, Derek
   Turner, Colin
   Mathenge, Edward G.
   Gujar, Shashi A.
   Giacomantonio, Carman A.
   Mackey, John R.
   Godbout, Roseline
   Lee, Patrick W. K.
TI Aldehyde dehydrogenase 1A3 influences breast cancer progression via
   differential retinoic acid signaling
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE ALDH1A3; ALDH1A1; Breast cancer; Triple-negative; Retinoic acid
ID STEM-CELLS; GENE-EXPRESSION; HUMAN NEOPLASMS; IDENTIFICATION; PREDICTOR;
   RECEPTOR; MARKER; GROWTH; METHYLATION; ASSOCIATION
AB Aldehyde dehydrogenase (ALDH) 1A enzymes produce retinoic acid (RA), a transcription induction molecule. To investigate if ALDH1A1 or ALDH1A3-mediated RA signaling has an active role in breast cancer tumorigenesis, we performed gene expression and tumor xenograft studies. Analysis of breast patient tumors revealed that high levels of ALDH1A3 correlated with expression of RA-inducible genes with retinoic acid response elements (RAREs), poorer patient survival and triple-negative breast cancers. This suggests a potential link between ALDH1A3 expression and RA signaling especially in aggressive and/or triple-negative breast cancers. In MDA-MB-231, MDA-MB-468 and MDA-MB-435 cells, ALDH1A3 and RA increased expression of RA-inducible genes. Interestingly, ALDH1A3 had opposing effects in tumor xenografts, increasing tumor growth and metastasis of MDA-MB-231 and MDA-MB-435 cells, but decreasing tumor growth of MDA-MB-468 cells. Exogenous RA replaced ALDH1A3 in inducing the same opposing tumor growth and metastasis effects, suggesting that ALDH1A3 mediates these effects by promoting RA signaling. Genome expression analysis revealed that ALDH1A3 induced largely divergent gene expression in MDA-MB-231 and MDA-MB-468 cells which likely resulted in the opposing tumor growth effects. Treatment with DNA methylation inhibitor 5-aza-2'deoxycytidine restored uniform RA-inducibility of RARE-containing HOXA1 and MUC4 in MDA-MB-231 and MDA-MB-468 cells, suggesting that differences in epigenetic modifications contribute to differential ALDH1A3/RA-induced gene expression in breast cancer. In summary, ALDH1A3 induces differential RA signaling in breast cancer cells which affects the rate of breast cancer progression. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Marcato, Paola; Coy, Krysta M.; Bydoun, Moamen; Wallace, Melissa; Clements, Derek; Lee, Patrick W. K.] Dalhousie Univ, Dept Pathol, Halifax, NS B3H 4R2, Canada.
   [Marcato, Paola; Dean, Cheryl A.; Gujar, Shashi A.; Lee, Patrick W. K.] Dalhousie Univ, Dept Microbiol & Immunol, Halifax, NS B3H 4R2, Canada.
   [Liu, Rong-Zong; Mackey, John R.; Godbout, Roseline] Univ Alberta, Dept Oncol, Edmonton, AB, Canada.
   [Turner, Colin; Mathenge, Edward G.; Giacomantonio, Carman A.] Dalhousie Univ, Dept Surg, Halifax, NS B3H 4R2, Canada.
   [Gujar, Shashi A.] IWK Hlth Ctr, Halifax, NS, Canada.
C3 Dalhousie University; Dalhousie University; University of Alberta;
   Dalhousie University; Dalhousie University
RP Marcato, P (通讯作者)，Dalhousie Univ, Dept Pathol, Rm 11F11,5850 Coll St, Halifax, NS B3H 4R2, Canada.
EM paola.marcato@dal.ca; patrick.lee@dal.ca
RI Wallace, Melissa/KFB-2837-2024; Godbout, Roseline/I-4639-2016
OI Liu, Rong-Zong/0000-0001-8625-3188; Clements, Derek/0000-0002-0796-8845;
   Godbout, Roseline/0000-0002-4779-9265; Coyle,
   Krysta/0000-0002-1309-4873; Gujar, Shashi/0000-0002-5427-0829; Marcato,
   Paola/0000-0001-8619-283X
FU Canadian Breast Cancer Foundation (CBCF) Atlantic; Dalhousie Medical
   Research Foundation; Canadian Institutes of Health Research
   [MOP-130304]; CBCF Prairies/NWT
FX This work was completed with funding from following sources. Grant
   funding awarded from the Canadian Breast Cancer Foundation (CBCF)
   Atlantic to PWKL, the Dalhousie Medical Research Foundation to PM and
   CAG, the Canadian Institutes of Health Research (MOP-130304) to PM, and
   the CBCF Prairies/NWT to RG.
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Bachmeier BE, 2008, INT J ONCOL, V33, P1011, DOI 10.3892/ijo_00000089
   Balmer JE, 2002, J LIPID RES, V43, P1773, DOI 10.1194/jlr.R100015-JLR200
   Black William, 2009, Human Genomics, V4, P136
   Bryan M, 2011, INVEST NEW DRUG, V29, P1482, DOI 10.1007/s10637-010-9478-3
   Budd GT, 1998, CLIN CANCER RES, V4, P635
   Chambers AF, 2009, CANCER RES, V69, P5292, DOI 10.1158/0008-5472.CAN-09-1528
   Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630
   Chaturvedi P, 2008, FASEB J, V22, P966, DOI 10.1096/fj.07-9673rev
   Chiesa Matteo Dalla, 2007, Acta Biomed, V78, P204
   Chung JH, 2011, VIRCHOWS ARCH, V459, P201, DOI 10.1007/s00428-011-1079-9
   Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004
   Gagnon I, 2003, BIOCHEM PHARMACOL, V65, P1685, DOI 10.1016/S0006-2952(03)00150-3
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Ginestier C, 2009, CELL CYCLE, V8, P3297, DOI 10.4161/cc.8.20.9761
   Guarnaccia V, 2010, RETINOIC ACID BREAST
   Gudas LJ, 2011, J CELL PHYSIOL, V226, P322, DOI 10.1002/jcp.22417
   Hollestelle A, 2009, CANCER RES, V69, P7893, DOI 10.1158/0008-5472.CAN-09-2396
   HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567
   Jia JP, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-33
   Kang EJ, 2014, NEOPLASMA, V61, P352, DOI 10.4149/neo_2014_045
   Khoury T, 2012, MODERN PATHOL, V25, P388, DOI 10.1038/modpathol.2011.172
   Kim BH, 2009, VIRCHOWS ARCH, V455, P343, DOI 10.1007/s00428-009-0829-4
   Lalevée S, 2011, J BIOL CHEM, V286, P33322, DOI 10.1074/jbc.M111.263681
   Lemay DG, 2006, J LIPID RES, V47, P1583, DOI 10.1194/jlr.M500504-JLR200
   Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127
   Li X, 2012, J THORAC ONCOL, V7, P1235, DOI 10.1097/JTO.0b013e318257cc6d
   Liu RZ, 2011, AM J PATHOL, V178, P997, DOI 10.1016/j.ajpath.2010.11.075
   Liu XX, 2011, P NATL ACAD SCI USA, V108, P774, DOI 10.1073/pnas.1011845108
   Luo YC, 2012, STEM CELLS, V30, P2100, DOI 10.1002/stem.1193
   Makiyama K, 2005, ONCOL REP, V13, P673
   Mao P, 2013, P NATL ACAD SCI USA, V110, P8644, DOI 10.1073/pnas.1221478110
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   Marchitti SA, 2008, EXPERT OPIN DRUG MET, V4, P697, DOI 10.1517/17425255.4.6.697 
   McGrane MM, 2007, J NUTR BIOCHEM, V18, P497, DOI 10.1016/j.jnutbio.2006.10.006
   Moreb JS, 2007, CANCER CHEMOTH PHARM, V59, P127, DOI 10.1007/s00280-006-0233-6
   Morimoto K, 2009, CANCER SCI, V100, P1062, DOI 10.1111/j.1349-7006.2009.01151.x
   Mukhopadhyay P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054455
   Nerlich AG, 2013, ONCOL LETT, V5, P1370, DOI 10.3892/ol.2013.1157
   Neumeister V, 2010, AM J PATHOL, V176, P2131, DOI 10.2353/ajpath.2010.090712
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7
   Pilato B, 2013, J HUM GENET, V58, P51, DOI 10.1038/jhg.2012.118
   Resetkova E, 2010, BREAST CANCER RES TR, V123, P97, DOI 10.1007/s10549-009-0619-3
   Rexer BN, 2001, CANCER RES, V61, P7065
   SCHNEIDER TD, 1990, NUCLEIC ACIDS RES, V18, P6097, DOI 10.1093/nar/18.20.6097
   Schug TT, 2008, P NATL ACAD SCI USA, V105, P7546, DOI 10.1073/pnas.0709981105
   Schug TT, 2007, CELL, V129, P723, DOI 10.1016/j.cell.2007.02.050
   Sima A, 2009, BBA-GEN SUBJECTS, V1790, P1660, DOI 10.1016/j.bbagen.2009.09.004
   Singletary SE, 2002, CLIN CANCER RES, V8, P2835
   Sládek NE, 2002, CANCER CHEMOTH PHARM, V49, P309, DOI 10.1007/s00280-001-0412-4
   Sutton LM, 1997, CANCER CHEMOTH PHARM, V40, P335, DOI 10.1007/s002800050666
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Wardwell-Ozgo J, 2014, ONCOGENE, V33, P1017, DOI 10.1038/onc.2013.30
   Yang ZL, 2013, DIS MARKERS, V2013, P163, DOI 10.1155/2013/187043
   Yeon S, 2012, MODERN PATHOL, V25, P185, DOI 10.1038/modpathol.2011.160
   Yonezawa S, 2008, PROTEOMICS, V8, P3329, DOI 10.1002/pmic.200800040
   Yonezawa S, 2011, PATHOL INT, V61, P697, DOI 10.1111/j.1440-1827.2011.02734.x
   ZHANG RD, 1991, INVAS METAST, V11, P204
   Zhang W, 2013, CANCER LETT, V328, P120, DOI 10.1016/j.canlet.2012.08.033
   Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x
   Zhu Y, 2011, MED ONCOL, V28, pS175, DOI 10.1007/s12032-010-9683-0
NR 62
TC 91
Z9 101
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD JAN
PY 2015
VL 9
IS 1
BP 17
EP 31
DI 10.1016/j.molonc.2014.07.010
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AY9IL
UT WOS:000347863700002
PM 25106087
OA Green Published
DA 2025-01-12
ER

PT J
AU Ma, YF
   Zhang, HL
   Liu, FM
   Wu, ZH
   Lu, SH
   Jin, QH
   Zhao, JL
   Zhong, XH
   Mao, HJ
AF Ma, Yunfei
   Zhang, Honglian
   Liu, Fangming
   Wu, Zhenhua
   Lu, Shaohua
   Jin, Qinghui
   Zhao, Jianlong
   Zhong, Xinhua
   Mao, Hongju
TI Highly sensitive detection of DNA methylation levels by using a quantum
   dot-based FRET method
SO NANOSCALE
LA English
DT Article
ID MAGNETIC NANOPARTICLES; BREAST-CANCER; LUNG-CANCER; NANOCRYSTALS; SITES;
   ASSAY; GENE; PCR; BIOMARKERS; ISLANDS
AB DNA methylation is the most frequently studied epigenetic modification that is strongly involved in genomic stability and cellular plasticity. Aberrant changes in DNA methylation status are ubiquitous in human cancer and the detection of these changes can be informative for cancer diagnosis. Herein, we reported a facile quantum dot-based (QD-based) fluorescence resonance energy transfer (FRET) technique for the detection of DNA methylation. The method relies on methylation-sensitive restriction enzymes for the differential digestion of genomic DNA based on its methylation status. Digested DNA is then subjected to PCR amplification for the incorporation of Alexa Fluor-647 (A647) fluorophores. DNA methylation levels can be detected qualitatively through gel analysis and quantitatively by the signal amplification from QDs to A647 during FRET. Furthermore, the methylation levels of three tumor suppressor genes, PCDHGB6, HOXA9 and RASSF1A, in 20 lung adenocarcinoma and 20 corresponding adjacent nontumorous tissue (NT) samples were measured to verify the feasibility of the QD-based FRET method and a high sensitivity for cancer detection (up to 90%) was achieved. Our QD-based FRET method is a convenient, continuous and high-throughput method, and is expected to be an alternative for detecting DNA methylation as a biomarker for certain human cancers.
C1 [Ma, Yunfei; Zhong, Xinhua] E China Univ Sci & Technol, Inst Appl Chem, Shanghai 200237, Peoples R China.
   [Ma, Yunfei; Zhang, Honglian; Liu, Fangming; Wu, Zhenhua; Jin, Qinghui; Zhao, Jianlong; Mao, Hongju] Chinese Acad Sci, Shanghai Inst Microsyst & Informat Technol, State Key Lab Transducer Technol, Shanghai 200050, Peoples R China.
   [Lu, Shaohua] Fudan Univ, Zhongshan Hosp, Dept Pathol, Shanghai 200032, Peoples R China.
C3 East China University of Science & Technology; Chinese Academy of
   Sciences; Shanghai Institute of Microsystem & Information Technology,
   CAS; Fudan University
RP Zhong, XH (通讯作者)，E China Univ Sci & Technol, Inst Appl Chem, Shanghai 200237, Peoples R China.
EM zhongxh@ecust.edu.cn; hjmao@mail.sim.ac.cn
RI Jin, Qinghui/S-8451-2016; Zhong, Xinhua/Y-5341-2019; Wu,
   Zhenhua/A-7017-2017; fang, leiming/ABV-3279-2022; Zhong,
   Xinhua/HGE-6801-2022
OI Zhong, Xinhua/0000-0002-2062-8773
FU National Basic Research Program of China (973 Program) [2012CB933303];
   National Science Foundation of China [61571429, 61401442, 21275153,
   61006086, 21175043, 21301059]; Science and Technology Commission of
   Shanghai Municipality [12441902600]; Shanghai Clinical Center/Shanghai
   Xuhui Central Hospital, Chinese Academic of Sciences [BRC2012002]
FX This work was supported by Grants from the National Basic Research
   Program of China (973 Program) (No. 2012CB933303), the National Science
   Foundation of China (No. 61571429, 61401442, 21275153, 61006086,
   21175043 and 21301059), Science and Technology Commission of Shanghai
   Municipality (Grant No. 12441902600), Shanghai Clinical Center/Shanghai
   Xuhui Central Hospital, Chinese Academic of Sciences (No. BRC2012002).
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bonanno C, 2007, CLIN CHEM, V53, P2119, DOI 10.1373/clinchem.2007.094011
   Cheow LF, 2015, NAT PROTOC, V10, P619, DOI 10.1038/nprot.2015.041
   Clapp AR, 2006, CHEMPHYSCHEM, V7, P47, DOI 10.1002/cphc.200500217
   Clarke MA, 2012, CANCER EPIDEM BIOMAR, V21, P2125, DOI 10.1158/1055-9965.EPI-12-0905
   Colella S, 2003, BIOTECHNIQUES, V35, P146, DOI 10.2144/03351md01
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Egger G, 2012, EXPERT REV MOL DIAGN, V12, P75, DOI 10.1586/ERM.11.90
   Feng FD, 2008, J AM CHEM SOC, V130, P11338, DOI 10.1021/ja8011963
   Feng FD, 2010, NAT PROTOC, V5, P1255, DOI 10.1038/nprot.2010.79
   Frumkin D, 2011, FORENSIC SCI INT-GEN, V5, P517, DOI 10.1016/j.fsigen.2010.12.001
   Goldman ER, 2004, ANAL CHEM, V76, P684, DOI 10.1021/ac035083r
   Goldman ER, 2005, J AM CHEM SOC, V127, P6744, DOI 10.1021/ja043677l
   Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Hwang SH, 2011, CLIN CHEM LAB MED, V49, P699, DOI 10.1515/CCLM.2011.108
   Jiang GX, 2009, ACS NANO, V3, P4127, DOI 10.1021/nn901324y
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kit AH, 2012, BIOCHIMIE, V94, P2314, DOI 10.1016/j.biochi.2012.07.014
   Lee CM, 2010, NANOTECHNOLOGY, V21, DOI 10.1088/0957-4484/21/28/285102
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Li JJ, 2003, J AM CHEM SOC, V125, P12567, DOI 10.1021/ja0363563
   Li S, 2013, J BIOMED NANOTECHNOL, V9, P1254, DOI 10.1166/jbn.2013.1610
   Li S, 2013, J BIOMED NANOTECHNOL, V9, P689, DOI 10.1166/jbn.2013.1568
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Ma YF, 2014, J MATER CHEM B, V2, P5043, DOI 10.1039/c4tb00458b
   Melnikov AA, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni092
   Mikeska T, 2012, EXPERT REV MOL DIAGN, V12, P473, DOI [10.1586/erm.12.45, 10.1586/ERM.12.45]
   Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112
   Regulacio MD, 2010, ACCOUNTS CHEM RES, V43, P621, DOI 10.1021/ar900242r
   Reiss P, 2009, SMALL, V5, P154, DOI 10.1002/smll.200800841
   Resch-Genger U, 2008, NAT METHODS, V5, P763, DOI 10.1038/NMETH.1248
   Sandoval J, 2013, J CLIN ONCOL, V31, P4140, DOI 10.1200/JCO.2012.48.5516
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Van de Voorde L, 2012, MUTAT RES-REV MUTAT, V751, P304, DOI 10.1016/j.mrrev.2012.06.001
   Wang X, 2010, BIOSENS BIOELECTRON, V25, P1934, DOI 10.1016/j.bios.2010.01.007
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Xie RG, 2005, J AM CHEM SOC, V127, P7480, DOI 10.1021/ja042939g
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yang Q, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2209
   Zhang JY, 2014, ANAL CHEM, V86, P346, DOI 10.1021/ac402720g
NR 43
TC 37
Z9 37
U1 1
U2 139
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 2040-3364
EI 2040-3372
J9 NANOSCALE
JI Nanoscale
PY 2015
VL 7
IS 41
BP 17547
EP 17555
DI 10.1039/c5nr04956c
PG 9
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA CU0BX
UT WOS:000363181600046
PM 26446775
DA 2025-01-12
ER

PT J
AU Okada, T
   Sinha, S
   Esposito, I
   Schiavon, G
   López-Lago, MA
   Su, WJ
   Pratilas, CA
   Abele, C
   Hernandez, JM
   Ohara, M
   Okada, M
   Viale, A
   Heguy, A
   Socci, ND
   Sapino, A
   Seshan, VE
   Long, S
   Inghirami, G
   Rosen, N
   Giancotti, FG
AF Okada, Tomoyo
   Sinha, Surajit
   Esposito, Ilaria
   Schiavon, Gaia
   Lopez-Lago, Miguel A.
   Su, Wenjing
   Pratilas, Christine A.
   Abele, Cristina
   Hernandez, Jonathan M.
   Ohara, Masahiro
   Okada, Morihito
   Viale, Agnes
   Heguy, Adriana
   Socci, Nicholas D.
   Sapino, Anna
   Seshan, Venkatraman E.
   Long, Stephen
   Inghirami, Giorgio
   Rosen, Neal
   Giancotti, Filippo G.
TI The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by
   restraining Ras-MAPK signalling
SO NATURE CELL BIOLOGY
LA English
DT Article
ID HUMAN BREAST-CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; RECEPTOR
   TYROSINE KINASE; GENE-EXPRESSION ANALYSIS; ACTIVATING PROTEIN;
   TUMOR-SUPPRESSOR; EPITHELIAL-CELLS; B-RAF; INDUCED SENESCENCE; EFFECTOR
   DOMAIN
AB We identified the Rho GTPase Rnd1 as a candidate metastasis suppressor in basal-like and triple-negative breast cancer through bioinformatics analysis. Depletion of Rnd1 disrupted epithelial adhesion and polarity, induced epithelial-to-mesenchymal transition, and cooperated with deregulated expression of c-Myc or loss of p53 to cause neoplastic conversion. Mechanistic studies revealed that Rnd1 suppresses Ras signalling by activating the GAP domain of Plexin B1, which inhibits Rap1. Rap1 inhibition in turn led to derepression of p120 Ras-GAP, which was able to inhibit Ras. Inactivation of Rnd1 in mammary epithelial cells induced highly undifferentiated and invasive tumours in mice. Conversely, Rnd1 expression inhibited spontaneous and experimental lung colonization in mouse models of metastasis. Genomic studies indicated that gene deletion in combination with epigenetic silencing or, more rarely, point mutation inactivates RND1 in human breast cancer. These results reveal a previously unappreciated mechanism through which Rnd1 restrains activation of Ras-MAPK signalling and breast tumour initiation and progression.
C1 [Okada, Tomoyo; Sinha, Surajit; Esposito, Ilaria; Schiavon, Gaia; Lopez-Lago, Miguel A.; Su, Wenjing; Giancotti, Filippo G.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst Canc Res, Cell Biol Program, New York, NY 10065 USA.
   [Pratilas, Christine A.; Rosen, Neal] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst Canc Res, Mol Pharmacol & Chem Program, New York, NY 10065 USA.
   [Pratilas, Christine A.] Mem Sloan Kettering Canc Ctr, Mem Hosp, Dept Pediat, New York, NY 10065 USA.
   [Abele, Cristina; Inghirami, Giorgio] Univ Turin, Dept Biomed Sci & Human Oncol, Ctr Expt Med & Res, I-10126 Turin, Italy.
   [Hernandez, Jonathan M.] Mem Sloan Kettering Canc Ctr, Mem Hosp, Dept Surg, New York, NY 10065 USA.
   [Ohara, Masahiro; Okada, Morihito] Hiroshima Univ, Res Inst Radiat Biol & Med, Grad Sch Biomed Sci, Dept Surg Oncol, Hiroshima 7348551, Japan.
   [Viale, Agnes] Mem Sloan Kettering Canc Ctr, Genom Core Facil, New York, NY 10065 USA.
   [Heguy, Adriana] Mem Sloan Kettering Canc Ctr, Geoffrey Beene Translat Oncol Core Facil, New York, NY 10065 USA.
   [Socci, Nicholas D.] Mem Sloan Kettering Canc Ctr, Bioinformat Core Facil, New York, NY 10065 USA.
   [Sapino, Anna] Univ Turin, Ctr Expt Med & Res, Dept Med Sci, I-10126 Turin, Italy.
   [Seshan, Venkatraman E.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, Mem Hosp, New York, NY 10065 USA.
   [Long, Stephen] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst Canc Res, Struct Biol Program, New York, NY 10065 USA.
   [Rosen, Neal] Mem Sloan Kettering Canc Ctr, Mem Hosp, Dept Med, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; Memorial Sloan Kettering Cancer Center; University of Turin;
   Memorial Sloan Kettering Cancer Center; Hiroshima University; Memorial
   Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center;
   Memorial Sloan Kettering Cancer Center; University of Turin; Memorial
   Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center;
   Memorial Sloan Kettering Cancer Center
RP Giancotti, FG (通讯作者)，Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst Canc Res, Cell Biol Program, New York, NY 10065 USA.
EM f-giancotti@ski.mskcc.org
RI SINHA, SURAJIT/AAE-9200-2020; Ohara, Mashiro/AAQ-3488-2020; su,
   wenjing/V-4772-2018; Rosen, Neal/ABF-2677-2020; Heguy,
   Adriana/GPP-3907-2022; Okada, Morihito/H-1495-2019; Sapino,
   Anna/J-4113-2018
OI Sapino, Anna/0000-0003-3542-9571
FU National Institutes of Health [P01 CA094060, P30 CA08748]; Geoffrey
   Beene Cancer Center at MSKCC
FX We thank X. Zhang for advice, reagents, and for sharing the structure of
   the Plexin-GAP-Rap1 complex before its publication, R. A. Weinberg, J.
   S. Brugge, M. Overholtzer, A. Ridley, B. Park, L. Tamagnome, M. Resh, H.
   Djaballah, T. Kataoka, M. Negishi and D. Medina for reagents, K.Manova
   for assistance with confocal microscopy, R. Khanin and G. P. Gupta for
   help with multivariate analysis, M. Buck for comments on the manuscript,
   and members of the Giancotti laboratory for discussions. We thank the
   Geoffrey Beene Translational Oncology Core, the Genomic Core, and the
   HTG Core of MSKCC for technical assistance. This work was supported by
   grants from the National Institutes of Health (P01 CA094060 Project 4 to
   F.G.G. and P30 CA08748 to MSKCC) and the Geoffrey Beene Cancer Center at
   MSKCC.
CR Aguirre AJ, 2004, P NATL ACAD SCI USA, V101, P9067, DOI 10.1073/pnas.0402932101
   Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255
   Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005
   Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Barcellos-Hoff MH, 2000, CANCER RES, V60, P1254
   Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Bretones G, 2011, J BIOL CHEM, V286, P9815, DOI 10.1074/jbc.M110.165977
   Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233
   Chardin P, 2006, NAT REV MOL CELL BIO, V7, P54, DOI 10.1038/nrm1788
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Cichowski K, 2003, GENE DEV, V17, P449, DOI 10.1101/gad.1054703
   Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772
   Courtois-Cox S, 2006, CANCER CELL, V10, P459, DOI 10.1016/j.ccr.2006.10.003
   DANIELSON KG, 1984, P NATL ACAD SCI-BIOL, V81, P3756, DOI 10.1073/pnas.81.12.3756
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219
   Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995
   Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Giancotti FG, 2013, CELL, V155, P750, DOI 10.1016/j.cell.2013.10.029
   Ginestier C, 2006, CLIN CANCER RES, V12, P4533, DOI 10.1158/1078-0432.CCR-05-2339
   Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843
   Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   HATA Y, 1990, J BIOL CHEM, V265, P7104
   Hess KR, 2006, J CLIN ONCOL, V24, P4236, DOI 10.1200/JCO.2006.05.6861
   Huang L, 2010, CURR OPIN GENET DEV, V20, P41, DOI 10.1016/j.gde.2009.12.001
   Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106
   Itoh M, 2007, CANCER RES, V67, P4759, DOI 10.1158/0008-5472.CAN-06-4246
   Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721
   Jönsson G, 2007, GENE CHROMOSOME CANC, V46, P543, DOI 10.1002/gcc.20438
   Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6
   Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006
   McCormack J, 2013, J CELL SCI, V126, P379, DOI 10.1242/jcs.097923
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Mishra S, 2005, CURR BIOL, V15, P366, DOI 10.1016/j.cub.2005.02.022
   Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258
   Oinuma I, 2004, SCIENCE, V305, P862, DOI 10.1126/science.1097545
   Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Rody A, 2007, CLIN CANCER RES, V13, P1115, DOI 10.1158/1078-0432.CCR-06-2433
   Rutherford S, 2005, LAB INVEST, V85, P1076, DOI 10.1038/labinvest.3700314
   Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020
   Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490
   Swiercz JM, 2004, J CELL BIOL, V165, P869, DOI 10.1083/jcb.200312094
   Tamagnone L, 2012, CANCER CELL, V22, P145, DOI 10.1016/j.ccr.2012.06.031
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tong Y, 2008, STRUCTURE, V16, P246, DOI 10.1016/j.str.2007.12.012
   Tong Y, 2007, J BIOL CHEM, V282, P37215, DOI 10.1074/jbc.M703800200
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1
   Wang YX, 2013, ELIFE, V2, DOI 10.7554/eLife.01279
   Wang YX, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002636
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Wennerberg K, 2003, CURR BIOL, V13, P1106, DOI 10.1016/S0960-9822(03)00418-4
   Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104
   Yanagisawa M, 2008, J BIOL CHEM, V283, P18344, DOI 10.1074/jbc.M801192200
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Yao J, 2006, CANCER RES, V66, P4065, DOI 10.1158/0008-5472.CAN-05-4083
   York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451
   Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045
NR 74
TC 95
Z9 103
U1 1
U2 40
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD JAN
PY 2015
VL 17
IS 1
BP 81
EP +
DI 10.1038/ncb3082
PG 44
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AX3ET
UT WOS:000346823900010
PM 25531777
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Sosa, MS
   Parikh, F
   Maia, AG
   Estrada, Y
   Bosch, A
   Bragado, P
   Ekpin, E
   George, A
   Zheng, Y
   Lam, HM
   Morrissey, C
   Chung, CY
   Farias, EF
   Bernstein, E
   Aguirre-Ghiso, JA
AF Sosa, Maria Soledad
   Parikh, Falguni
   Maia, Alexandre Gaspar
   Estrada, Yeriel
   Bosch, Almudena
   Bragado, Paloma
   Ekpin, Esther
   George, Ajish
   Zheng, Yang
   Lam, Hung-Ming
   Morrissey, Colm
   Chung, Chi-Yeh
   Farias, Eduardo F.
   Bernstein, Emily
   Aguirre-Ghiso, Julio A.
TI NR2F1 controls tumour cell dormancy via SOX9-and RARβ-driven quiescence
   programmes
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PROMOTER-TRANSCRIPTION FACTORS; RETINOIC ACID; UROKINASE RECEPTOR;
   GENE-EXPRESSION; EMBRYONIC STEM; BREAST-CANCER; SELF-RENEWAL; GROWTH;
   CARCINOMA; REVEALS
AB Metastases can originate from disseminated tumour cells (DTCs), which may be dormant for years before reactivation. Here we find that the orphan nuclear receptor NR2F1 is epigenetically upregulated in experimental head and neck squamous cell carcinoma (HNSCC) dormancy models and in DTCs from prostate cancer patients carrying dormant disease for 7-18 years. NR2F1-dependent dormancy is recapitulated by a co-treatment with the DNA-demethylating agent 5-Aza-C and retinoic acid across various cancer types. NR2F1-induced quiescence is dependent on SOX9, RAR beta and CDK inhibitors. Intriguingly, NR2F1 induces global chromatin repression and the pluripotency gene NANOG, which contributes to dormancy of DTCs in the bone marrow. When NR2F1 is blocked in vivo, growth arrest or survival of dormant DTCs is interrupted in different organs. We conclude that NR2F1 is a critical node in dormancy induction and maintenance by integrating epigenetic programmes of quiescence and survival in DTCs.
C1 [Sosa, Maria Soledad; Parikh, Falguni; Estrada, Yeriel; Bosch, Almudena; Bragado, Paloma; Ekpin, Esther; George, Ajish; Farias, Eduardo F.; Aguirre-Ghiso, Julio A.] Mt Sinai Sch Med, Dept Med, Div Hematol & Oncol, New York, NY 10029 USA.
   [Parikh, Falguni; Zheng, Yang; Aguirre-Ghiso, Julio A.] Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA.
   [Maia, Alexandre Gaspar; Chung, Chi-Yeh; Bernstein, Emily] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA.
   [Lam, Hung-Ming; Morrissey, Colm] Univ Washington, Dept Urol, Seattle, WA 98195 USA.
   [Farias, Eduardo F.; Bernstein, Emily; Aguirre-Ghiso, Julio A.] Mt Sinai Sch Med, Tisch Canc Inst, New York, NY 10029 USA.
   [Bernstein, Emily; Aguirre-Ghiso, Julio A.] Mt Sinai Sch Med, Black Family Stem Cell Inst, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at
   Mount Sinai; Icahn School of Medicine at Mount Sinai; University of
   Washington; University of Washington Seattle; Icahn School of Medicine
   at Mount Sinai; Icahn School of Medicine at Mount Sinai
RP Aguirre-Ghiso, JA (通讯作者)，Mt Sinai Sch Med, Dept Med, Div Hematol & Oncol, New York, NY 10029 USA.
EM julio.aguirre-ghiso@mssm.edu
RI Domingo, Paloma/A-8679-2015; AguirreGhiso, Julio/KXR-3097-2024;
   Gaspar-Maia, Alexandre/AAY-5416-2020
OI Gaspar-Maia, Alexandre/0000-0001-8528-5575
FU Samuel Waxman Cancer Research Foundation Tumor Dormancy Program;
   NIH/National Cancer Institute [CA109182, CA163131]; NIEHS [ES017146];
   NYSTEM; JJR Foundation; Hirschl/Weill-Caulier Trust Research Award;
   DoD-BCRP [BC100975, BC112380]; NIH ARRA Challenge [RC1 CA144825-0];
   Janssen Research and Development LLC
FX We thank the Bernstein, Farias and Aguirre-Ghiso labs as well as Peter
   Nelson, Robert L Vessella and Lynda Snyder for useful discussions. This
   study was supported by Samuel Waxman Cancer Research Foundation Tumor
   Dormancy Program to J.A.A.-G., E.F.F. and E.B., NIH/National Cancer
   Institute (CA109182, CA163131), NIEHS (ES017146) and NYSTEM to
   J.A.A.-G., JJR Foundation and Hirschl/Weill-Caulier Trust Research Award
   to E.B., DoD-BCRP Grant BC100975 to A.G.M. and DoD-BCRP Grant BC112380
   to M.S.S. NIH RC1 CA144825-0 ARRA Challenge, Janssen Research and
   Development LLC to Peter S Nelson, Robert L. Vessella and Linda Snyder.
CR Adam AP, 2009, CANCER RES, V69, P5664, DOI 10.1158/0008-5472.CAN-08-3820
   Afonja O, 2002, ONCOGENE, V21, P7850, DOI 10.1038/sj.onc.1205985
   Aguirre-Ghiso JA, 2004, CANCER RES, V64, P7336, DOI 10.1158/0008-5472.CAN-04-0113
   Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863
   Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Bosch A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3247
   Bragado P, 2013, NAT CELL BIOL, V15, P1351, DOI 10.1038/ncb2861
   Bragado P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029974
   Chéry L, 2014, ONCOTARGET, V5, P9939, DOI 10.18632/oncotarget.2480
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Drivdahl R, 2004, ONCOGENE, V23, P4584, DOI 10.1038/sj.onc.1207603
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Florenes VA, 1996, ONCOGENE, V13, P2447
   Gaspar-Maia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2582
   Ghiaur G, 2013, P NATL ACAD SCI USA, V110, P16121, DOI 10.1073/pnas.1305937110
   Ghiso JAA, 2002, ONCOGENE, V21, P2513, DOI 10.1038/sj/onc/1205342
   Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89
   Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Hou J, 2012, J THORAC ONCOL, V7, P105, DOI 10.1097/JTO.0b013e3182352a45
   Huang SD, 2009, CANCER CELL, V15, P328, DOI 10.1016/j.ccr.2009.02.023
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010
   Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569
   Lin BZ, 2000, MOL CELL BIOL, V20, P957, DOI 10.1128/MCB.20.3.957-970.2000
   Liu D, 2002, CANCER CELL, V1, P445, DOI 10.1016/S1535-6108(02)00072-7
   Lu XS, 2008, BREAST CANCER RES TR, V108, P191, DOI 10.1007/s10549-007-9596-6
   Marión RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287
   Naka H, 2008, NAT NEUROSCI, V11, P1014, DOI 10.1038/nn.2168
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   OSSOWSKI L, 1983, CELL, V33, P323, DOI 10.1016/0092-8674(83)90414-2
   OSSOWSKI L, 1987, J CELL PHYSIOL, V133, P288, DOI 10.1002/jcp.1041330212
   Purton LE, 2006, J EXP MED, V203, P1283, DOI 10.1084/jem.20052105
   Qiu Y, 1996, J STEROID BIOCHEM, V56, P81, DOI 10.1016/0960-0760(95)00225-1
   QIU YH, 1994, P NATL ACAD SCI USA, V91, P4451, DOI 10.1073/pnas.91.10.4451
   Rada-Iglesias A, 2012, CELL STEM CELL, V11, P633, DOI 10.1016/j.stem.2012.07.006
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Sang LY, 2008, SCIENCE, V321, P1095, DOI 10.1126/science.1155998
   Schewe DM, 2008, P NATL ACAD SCI USA, V105, P10519, DOI 10.1073/pnas.0800939105
   Smits BMG, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003549
   Sosa M. S., CLIN CANC RES, V17, P5850
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Thompson VC, 2012, INT J CANCER, V131, P662, DOI 10.1002/ijc.26414
   Tsai H. C., CANC CELL, V21, P430
   Zhuang Y, 2008, DIFFERENTIATION, V76, P760, DOI 10.1111/j.1432-0436.2007.00258.x
   Zijlstra A, 2002, CANCER RES, V62, P7083
NR 48
TC 244
Z9 275
U1 2
U2 30
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN
PY 2015
VL 6
AR 6170
DI 10.1038/ncomms7170
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CA3US
UT WOS:000348832900001
PM 25636082
OA gold, Green Accepted
DA 2025-01-12
ER

PT J
AU Yan, B
   Guo, Q
   Nan, XX
   Wang, Z
   Yin, Z
   Yi, L
   Wei, YB
   Gao, YL
   Zhou, KQ
   Yang, JR
AF Yan, Bin
   Guo, Qiong
   Nan, Xiao-xin
   Wang, Zhao
   Yin, Zhuo
   Yi, Lu
   Wei, Yong-bao
   Gao, Yun-liang
   Zhou, Ke-qin
   Yang, Jin-rui
TI Micro-ribonucleic acid 29b inhibits cell proliferation and invasion and
   enhances cell apoptosis and chemotherapy effects of cisplatin via
   targeting of DNMT3b and AKT3 in prostate cancer
SO ONCOTARGETS AND THERAPY
LA English
DT Article
DE miRNA-29b; prostate cancer; cell biological behavior; chemosensitivity;
   DNMT3b; AKT3
ID ACUTE MYELOID-LEUKEMIA; MULTIPLE-MYELOMA; DNA METHYLTRANSFERASES;
   MICRORNA-29 FAMILY; BREAST-CANCER; EXPRESSION; MIR-29B; METHYLATION;
   ACTIVATION; MECHANISMS
AB Background: Micro-ribonucleic acids (miRNAs) are crucial regulators in malignant tumors. miRNA-29b (miR-29b) has been identified as a tumor suppressor in prostate cancer (PCa). However, very few studies have investigated the effects of miR-29b in PCa, especially the mechanism and its association with chemotherapy. Our study aimed to explore the role and mechanism of miR-29b in PCa.
   Materials and methods: The expression levels of miR-29b were detected in ten clinical PCa specimens and four different PCa cell lines through quantitative real-time polymerase chain reaction. After miR-29b mimics and inhibitors were successfully transfected into LNCaP, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay was then used to investigate cell proliferation and cisplatin sensitivity of PCa cells. Cell cycle, cell apoptosis, and cell invasion were detected via flow cytometry, annexin V-fluorescein isothiocyanate labeling, and transwell assay, respectively. Based on bioinformatic methods, Western blot analysis, and dual-luciferase reporter assay, novel target genes of miR-29b were identified.
   Results: miR-29b was downregulated in PCa tissues compared with matched adjacent nontumor tissues. In the androgen-independent PCa cell line (LNCaP-AI), the expression of miR-29b was much lower than the androgen-dependent PCa cell line (LNCaP). Subsequent studies showed that forced expression of miR-29b inhibited cell proliferation and cell invasion and induced cell apoptosis in PCa. Upregulation of miR-29b also enhanced the chemosensitivity of PCa cells to cisplatin. Moreover, we identified DNMT3b and AKT3 as novel target genes of miR-29b in PCa.
   Conclusion: Taken together, the results showed that miR-29b plays a tumor-suppressive role in PCa. It inhibits cell biological behavior and enhances the chemotherapy effects of cisplatin through its involvement in epigenetic regulation and PI3K/AKT pathway.
C1 [Yan, Bin; Guo, Qiong; Wang, Zhao; Yin, Zhuo; Yi, Lu; Wei, Yong-bao; Gao, Yun-liang; Zhou, Ke-qin; Yang, Jin-rui] Cent S Univ, Xiangya Hosp 2, Dept Urol, Changsha 410011, Hunan, Peoples R China.
   [Nan, Xiao-xin] Third Changsha Hosp, Dept Urol, Changsha, Hunan, Peoples R China.
C3 Central South University
RP Yang, JR (通讯作者)，Cent S Univ, Xiangya Hosp 2, Dept Urol, Renmin Rd 139, Changsha 410011, Hunan, Peoples R China.
EM guoqiong06@163.com; yangjr06@163.com
RI yin, zhuo/KHZ-8047-2024; Yang, Jinrui/HJP-6768-2023; Yan,
   Bin/G-2803-2013; Wei, Yongbao/ABE-4646-2020
OI Wei, Yongbao/0000-0003-3114-9214
FU Science and Technology Agency of Hunan Province [2013FJ3055]
FX The study was supported by the Science and Technology Agency of Hunan
   Province in 2013 (2013FJ3055).
CR Agarwal S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-99
   Amodio N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.175
   Amodio N, 2012, ONCOTARGET, V3, P1246
   Auyeung VC, 2013, CELL, V152, P844, DOI 10.1016/j.cell.2013.01.031
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Chin YR, 2014, CANCER RES, V74, P964, DOI 10.1158/0008-5472.CAN-13-2175
   Chu ML, 2014, ONCOL REP, V31, P34, DOI 10.3892/or.2013.2810
   Dai FR, 2013, GYNECOL ONCOL, V131, P451, DOI 10.1016/j.ygyno.2013.07.112
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Gong JN, 2014, CELL DEATH DIFFER, V21, P100, DOI 10.1038/cdd.2013.133
   Gravina GL, 2013, ONCOL REP, V29, P1189, DOI 10.3892/or.2012.2192
   Gravina GL, 2011, ENDOCRINOLOGY, V152, P4550, DOI 10.1210/en.2011-1056
   Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831
   Lee SH, 2014, J BIOL CHEM
   Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096
   Mims A, 2013, LEUKEMIA, V27, P871, DOI 10.1038/leu.2012.342
   Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056
   Pandey M, 2014, EXP MOL PATHOL, V96, P61, DOI 10.1016/j.yexmp.2013.12.001
   Pennati M, 2014, BIOCHEM PHARMACOL, V87, P579, DOI 10.1016/j.bcp.2013.12.009
   Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007
   Ru P, 2012, MOL CANCER THER, V11, P1166, DOI 10.1158/1535-7163.MCT-12-0100
   Sasaki T, 2010, BIOCHEM BIOPH RES CO, V399, P79, DOI 10.1016/j.bbrc.2010.07.045
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Slack FJ, 2008, NEW ENGL J MED, V359, P2720, DOI 10.1056/NEJMe0808667
   Steele Robert, 2010, Genes Cancer, V1, P381
   Virtakoivu R, 2012, MOL BIOL CELL, V23, P3357, DOI 10.1091/mbc.E12-03-0213
   Wang J., 2014, ONCOTARGET
   Wang Y, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.79
   Wang Y, 2013, EUR J CELL BIOL, V92, P123, DOI 10.1016/j.ejcb.2012.11.004
   Yamamoto Y, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-135
   Yang SM, 2013, TOXICOLOGY, V306, P162, DOI 10.1016/j.tox.2013.02.014
   Zhang YK, 2011, BIOCHEM BIOPH RES CO, V414, P233, DOI 10.1016/j.bbrc.2011.09.063
   Zhao GY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053906
NR 35
TC 35
Z9 41
U1 0
U2 12
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2015
VL 8
BP 557
EP 565
DI 10.2147/OTT.S76484
PG 9
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA CC3TI
UT WOS:000350272500001
PM 25784815
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Terzi, YK
   Kaya, ÖÖ
   Iseri, ÖD
   Çelik, Z
   Sahin, FI
AF Terzi, Yunus Kasim
   Kaya, Ozge Ozer
   Iseri, Ozlem Darcansoy
   Celik, Zerrin
   Sahin, Feride Iffet
TI Epigallocatechin 3-gallate applications on HT-29 and MCF-7 cell lines
   and evaluation of tumor suppressor gene methylation
SO TURKISH JOURNAL OF BIOLOGY
LA English
DT Article
DE Epigallocatechin 3-gallate; epigenetics; methylation; breast cancer;
   colorectal cancer
ID TEA POLYPHENOL (-)-EPIGALLOCATECHIN-3-GALLATE; BREAST-CANCER; GREEN TEA;
   PROMOTER HYPERMETHYLATION; DNA METHYLATION; INHIBITION; DEMETHYLATION;
   MECHANISMS; PATHWAYS; RECEPTOR
AB Epigallocatechin 3-gallate (EGCG) is an antitumor molecule and shows this activity by binding to the active center of a methyltransferase enzyme (DNMT1). The methylation of DNA sequences of tumor suppressor and DNA repair genes is observed in different stages of carcinogenesis. In this study, we analyzed the effect of EGCG on the methylation status of 25 tumor suppressor genes in cancer cell lines HT-29 and MCF-7. HT-29 and MCF-7 cells were incubated with 10 mu M, 20 mu M, and 50 mu M and 1 mu M, 5 mu M, and 10 mu M EGCG for 48 h, respectively. We found promoter hypermethylation of (1) CDH13, GATA5, and RAR beta genes in MCF-7 cell line and (2) RAR beta, ESR1, PAX6, WT1, CADM1, CHFR, CDH13, and GATA5 genes in HT-29 cell line. However, (3) after EGCG application, no changes in methylation status were detected in our samples. Our results suggest that methylation status of tumor suppressor genes did not change with different EGCG doses.
C1 [Terzi, Yunus Kasim; Kaya, Ozge Ozer; Celik, Zerrin; Sahin, Feride Iffet] Baskent Univ, Fac Med, Dept Med Genet, TR-06490 Ankara, Turkey.
   [Iseri, Ozlem Darcansoy] Baskent Univ, Inst Transplantat & Gene Sci, TR-06490 Ankara, Turkey.
C3 Baskent University; Baskent University
RP Sahin, FI (通讯作者)，Baskent Univ, Fac Med, Dept Med Genet, TR-06490 Ankara, Turkey.
EM feridesahin@hotmail.com
RI özer kaya, özge/ITT-4755-2023; işeri, özlem/AGE-6072-2022; Sahin,
   Feride/AAC-7232-2020; yilmaz celik, zerrin/A-1229-2015; Terzi,
   Yunus/B-4372-2018
OI yilmaz celik, zerrin/0000-0001-9158-220X; Terzi,
   Yunus/0000-0001-5612-9696; Sahin, Feride Iffet/0000-0001-7308-9673
FU Baskent University Institutional Review Board [DA09/21]; Baskent
   University Research Fund
FX This study was approved by the Baskent University Institutional Review
   Board (project no: DA09/21) and supported by the Baskent University
   Research Fund.
CR Alvarez M, 1998, MOL PHARMACOL, V54, P802, DOI 10.1124/mol.54.5.802
   Arai M, 2006, CANCER-AM CANCER SOC, V106, P2514, DOI 10.1002/cncr.21905
   Arends MJ, 2013, APPL IMMUNOHISTO M M, V21, P97, DOI 10.1097/PAI.0b013e31827ea79e
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Brooks J, 2009, CANCER CAUSE CONTROL, V20, P1539, DOI 10.1007/s10552-009-9415-y
   Chen D, 2011, ADV CLIN CHEM, V53, P155, DOI 10.1016/S0065-2423(11)53007-0
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Chung JY, 1999, CANCER RES, V59, P4610
   Chung JY, 2001, FASEB J, V15, P2022, DOI 10.1096/fj.01-0031fje
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Fang MZ, 2003, CANCER RES, V63, P7563
   Gao Z, 2009, ANTICANCER RES, V29, P2025
   Hardy TM, 2011, EPIGENOMICS-UK, V3, P503, DOI [10.2217/EPI.11.71, 10.2217/epi.11.71]
   Hong J, 2002, CANCER RES, V62, P7241
   Hsu YC, 2011, J CELL PHYSIOL, V226, P2721, DOI 10.1002/jcp.22623
   Kars MD, 2006, ANTICANCER RES, V26, P4559
   Kornegoor R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3220
   Lecumberri E, 2013, CLIN NUTR, V32, P894, DOI 10.1016/j.clnu.2013.03.008
   Lee WJ, 2005, MOL PHARMACOL, V68, P1018, DOI 10.1124/mol.104.008367
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Liang YC, 1997, J CELL BIOCHEM, V67, P55, DOI 10.1002/(SICI)1097-4644(19971001)67:1<55::AID-JCB6>3.0.CO;2-V
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Moison C, 2013, FASEB J, V27, P1468, DOI 10.1096/fj.12-210971
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Nyström M, 2009, WORLD J GASTROENTERO, V15, P257, DOI 10.3748/wjg.15.257
   Pandey M, 2010, INT J CANCER, V126, P2520, DOI 10.1002/ijc.24988
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0
   Singh PN, 1998, AM J EPIDEMIOL, V148, P761, DOI 10.1093/oxfordjournals.aje.a009697
   Xiang TX, 2013, CHIN J CANCER, V32, P12, DOI 10.5732/cjc.011.10344
   Xu J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-243
   Zeng L, 2014, FRONT ENDOCRINOL, V5, DOI 10.3389/fendo.2014.00061
   Zhang XB, 2012, J CANCER RES CLIN, V138, P2051, DOI 10.1007/s00432-012-1276-1
   Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223
NR 34
TC 2
Z9 2
U1 0
U2 15
PU Tubitak Scientific & Technological Research Council Turkey
PI ANKARA
PA ATATURK BULVARI NO 221, KAVAKLIDERE, TR-06100 ANKARA, TURKIYE
SN 1300-0152
EI 1303-6092
J9 TURK J BIOL
JI Turk. J. Biol.
PY 2015
VL 39
IS 5
BP 698
EP 704
DI 10.3906/biy-1412-82
PG 7
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA CQ0KZ
UT WOS:000360285900006
OA Bronze
DA 2025-01-12
ER

PT J
AU Antony, P
   Rose, M
   Heidenreich, A
   Knüchel, R
   Gaisa, NT
   Dahl, E
AF Antony, Pia
   Rose, Michael
   Heidenreich, Axel
   Knuechel, Ruth
   Gaisa, Nadine T.
   Dahl, Edgar
TI Epigenetic inactivation of <i>ST6GAL1</i> in human bladder cancer
SO BMC CANCER
LA English
DT Article
DE ST6GAL1; Bladder cancer; DNA methylation; Tumor suppressor
ID METHYLATION PATTERNS; GENE-EXPRESSION; CARCINOMA CELLS; URINARY-BLADDER;
   DEATH RECEPTOR; BREAST-CANCER; COLON; SIALYLATION; PROGRESSION;
   APOPTOSIS
AB Background: Posttranslational protein modifications are known to modulate key biological processes like proliferation and apoptosis. Accumulating evidence shows that ST6GAL1, an enzyme that catalyzes the transfer of sialic acid onto galactose-containing substrates, is aberrantly expressed in various cancers and may affect cell motility and invasion. This is the first study to describe ST6GAL1 expression and regulation in human bladder cancer.
   Methods: ST6GAL1 mRNA expression levels in human cell lines (UROtsa, RT4, RT112 and J82) and tissue samples (n = 15 normal urothelium (NU), n = 13 papillary non-invasive tumors (pTa), n = 12 carcinoma in situ (CIS), n = 26 muscle invasive tumors (p(T2-4))) were assessed using real-time PCR. In addition, ST6GAL1 protein expression was evaluated using immunohistochemistry. Promoter methylation analysis was performed using methylation-specific PCR (MSP) in cell lines (n = 4) and patient samples (n = 23 NU, n = 12 CIS, n = 29 pTa, n = 41 pT2-4). Epigenetic ST6GAL1 gene silencing was confirmed by in vitro demethylation of bladder cell lines. Data were validated by analysis of an independent bladder tumor data set (n = 184) based on The Cancer Genome Atlas (TCGA) portal.
   Results: Semi-quantitative ST6GAL1 real-time PCR expression analysis showed two distinct trends: In muscle-invasive tumors ST6GAL1 expression was downregulation by 2.7-fold, while papillary non-invasive tumors showed an increased ST6GAL1 mRNA expression compared to normal urothelium. ST6GAL1 loss in muscle-invasive tumors was associated with increasing invasiveness. On the protein level, 69.2% (n = 45/ 65) of all tumors showed a weak ST6GAL1 protein staining (IRS = 4) while 25.6% (16/65) exhibited a complete loss (IRS = 0) of ST6GAL1 protein. Tumor-specific DNA methylation of the ST6GAL1 promoter region was frequently found in pT2-4 tumors (53.6% (22/41)), whereas only 13.8% (4/29) of pTa tumors showed ST6GAL1 promoter methylation. Normal urothelium remained unmethylated. Importantly, we significantly revealed an inverse correlation between ST6GAL1 mRNA expression and ST6GAL1 promoter merthylation in primary bladder cancer. These findings were clearly verified by the TCGA public data set and in vitro demethylation assays functionally confirmed ST6GAL1 promoter methylation as a potential regulatory factor for ST6GAL1 gene silencing.
   Conclusions: Our study characterizes for the first time ST6GAL1 expression loss caused by aberrant ST6GAL1 promoter methylation potentially indicating a tumor suppressive role in bladder carcinogenesis.
C1 [Antony, Pia; Rose, Michael; Knuechel, Ruth; Gaisa, Nadine T.; Dahl, Edgar] Rhein Westfal TH Aachen, Inst Pathol, Mol Oncol Grp, D-52074 Aachen, Germany.
   [Heidenreich, Axel] Univ Hosp Aachen, Dept Urol, D-52074 Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University; RWTH Aachen University
   Hospital
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Heidenreich, Axel/L-1015-2013
OI Gaisa, Nadine/0000-0002-4762-3964
FU START-funds of the Medical Faculty of the RWTH Aachen University
   [149/08]
FX The authors are grateful for the support of the study by all staff of
   the Department of Urology University Hospital Aachen providing samples
   and data of patients, and the excellent technical assistance of Sevim
   Alkaya, Roswitha Davtalab and Sonja von Serenyi. This project was funded
   by START-funds of the Medical Faculty of the RWTH Aachen University (NTG
   grant number: 149/08).
CR Al Hussain TO, 2013, ADV ANAT PATHOL, V20, P53, DOI 10.1097/PAP.0b013e31827bd0ec
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bilgrami SM, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-178
   BRESALIER RS, 1990, CANCER RES, V50, P1299
   CAIRNS P, 1991, ONCOGENE, V6, P2305
   Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615
   Castillo-Martin M, 2010, UROL ONCOL-SEMIN ORI, V28, P401, DOI 10.1016/j.urolonc.2009.04.019
   Dall'Olio F, 2014, BBA-GEN SUBJECTS, V1840, P2752, DOI 10.1016/j.bbagen.2014.06.006
   Fleischer T, 2014, INT J CANCER, V134, P2615, DOI 10.1002/ijc.28606
   Friedrich MG, 2005, EUR J CANCER, V41, P2769, DOI 10.1016/j.ejca.2005.07.019
   Goebell PJ, 2010, UROL ONCOL-SEMIN ORI, V28, P409, DOI 10.1016/j.urolonc.2010.04.003
   He F, 2009, CANCER RES, V69, P9413, DOI 10.1158/0008-5472.CAN-09-2158
   Kim WJ, 2009, EXPERT REV MOL DIAGN, V9, P259, DOI 10.1586/ERM.09.5
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin SQ, 2002, EXP CELL RES, V276, P101, DOI 10.1006/excr.2002.5521
   Liu ZY, 2011, J BIOL CHEM, V286, P39654, DOI 10.1074/jbc.M111.276063
   McConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008
   Park JJ, 2012, BIOCHEM PHARMACOL, V83, P849, DOI 10.1016/j.bcp.2012.01.007
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Reuter VE, 1999, UROL CLIN N AM, V26, P481, DOI 10.1016/S0094-0143(05)70196-8
   Sánchez-Carbayo M, 2012, TUMOR BIOL, V33, P347, DOI 10.1007/s13277-011-0310-2
   Schultz MJ, 2012, CANCER METAST REV, V31, P501, DOI 10.1007/s10555-012-9359-7
   Seales EC, 2005, CANCER RES, V65, P4645, DOI 10.1158/0008-5472.CAN-04-3117
   Seales EC, 2003, ONCOGENE, V22, P7137, DOI 10.1038/sj.onc.1206834
   Shaikh FM, 2008, EXP CELL RES, V314, P2941, DOI 10.1016/j.yexcr.2008.07.021
   Swindall AF, 2013, CANCER RES, V73, P2368, DOI 10.1158/0008-5472.CAN-12-3424
   Swindall AF, 2011, J BIOL CHEM, V286, P22982, DOI 10.1074/jbc.M110.211375
   Ushijima T, 2005, NAT REV CANCER, V5, P223, DOI 10.1038/nrc1571
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Wild PJ, 2005, CLIN CANCER RES, V11, P4415, DOI 10.1158/1078-0432.CCR-05-0259
   Wolff EM, 2010, CANCER RES, V70, P8169, DOI 10.1158/0008-5472.CAN-10-1335
   Zhu YT, 2001, BBA-MOL BASIS DIS, V1536, P148, DOI 10.1016/S0925-4439(01)00044-8
   Zhuo Y, 2011, J BIOL CHEM, V286, P5935, DOI 10.1074/jbc.R110.191429
NR 34
TC 39
Z9 46
U1 3
U2 13
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD DEC 2
PY 2014
VL 14
AR 901
DI 10.1186/1471-2407-14-901
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU9TK
UT WOS:000345937300002
PM 25465919
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Meisel, JL
   Hyman, DM
   Garg, K
   Zhou, Q
   Dao, F
   Bisogna, M
   Gao, J
   Schultz, ND
   Grisham, RN
   Phillips, M
   Iasonos, A
   Kauff, ND
   Levine, DA
   Soslow, RA
   Spriggs, DR
AF Meisel, J. L.
   Hyman, D. M.
   Garg, K.
   Zhou, Q.
   Dao, F.
   Bisogna, M.
   Gao, J.
   Schultz, N. D.
   Grisham, R. N.
   Phillips, M.
   Iasonos, A.
   Kauff, N. D.
   Levine, D. A.
   Soslow, R. A.
   Spriggs, D. R.
TI The performance of BRCA1 immunohistochemistry for detecting germline,
   somatic, and epigenetic <i>BRCA1</i> loss in high-grade serous ovarian
   cancer
SO ANNALS OF ONCOLOGY
LA English
DT Article
DE BRCA1; immunohistochemistry; genetic testing; ovarian cancer;
   biomarkers; hypermethylation
ID PROTEIN EXPRESSION; BREAST-CANCER; MUTATIONS; SURVIVAL;
   HYPERMETHYLATION; RESISTANCE; CARCINOMA; PROMOTER; CELLS
AB Background: BRCA1 expression can be lost by a variety of mechanisms including germline or somatic mutation and promotor hypermethylation. Given the potential importance of BRCA1 loss as a predictive and prognostic biomarker in high-grade serous ovarian cancer, we sought to evaluate the utility of BRCA1 immunohistochemistry (IHC) in screening for BRCA1 loss by germline, somatic, and epigenetic mechanisms.
   Patients and methods: Patients with advanced high-grade serous ovarian cancer who had previously undergone germline BRCA1 testing were identified. Samples from each tumor were stained for BRCA1 and reviewed independently by two pathologists blinded to BRCA status. Tumors with abnormal BRCA1 IHC and wild-type germline testing underwent further evaluation for somatic BRCA1 mutations and promoter hypermethylation. McNemar's test was used to determine the association of BRCA1 IHC with germline BRCA1 mutations and BRCA1 loss through any mechanism. Kaplan-Meier methods were used to estimate overall survival (OS), and the log-rank test was used to assess differences between groups.
   Results: Inter-rater reliability between the two pathologists on BRCA IHC interpretation was very good (kappa coefficient 0.865, P = 0.16; McNemar's test). BRCA1 IHC was abnormal in 36% (48/135) of cases. When compared with germline BRCA1 status, BRCA1 IHC had a high negative predictive value (95.4%) but a low positive predictive value (PPV, 52.1%). When accounting for promoter hypermethylation and somatic mutations as alternative methods of BRCA1 loss, the PPV rose to 87.5%. Five-year OS rate was 49.6% [95% confidence interval (CI) 26.3% to 69.3%] for patients with germline BRCA1 mutations, 50.4% (95% CI 27.5% to 69.5%) for germline wild-type BRCA1 and abnormal IHC, and 52.1% (95% CI 38.4% to 64.2%) for germline wild-type BRCA1 and normal IHC (P = 0.92).
   Conclusions: BRCA1 IHC interpretation was a highly reproducible and accurate modality for detecting germline, somatic, or epigenetic mechanisms of BRCA1 loss. These results support further development of BRCA1 IHC as a potential biomarker for BRCA1 loss in high-grade serous ovarian cancer.
C1 [Meisel, J. L.; Hyman, D. M.; Grisham, R. N.; Kauff, N. D.; Spriggs, D. R.] Mem Sloan Kettering Canc Ctr, Gynecol Med Oncol Serv, New York, NY 10065 USA.
   [Hyman, D. M.; Spriggs, D. R.] Mem Sloan Kettering Canc Ctr, Dept Med, 300 East 66th St,Room 1353, New York, NY 10065 USA.
   [Garg, K.; Soslow, R. A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA.
   [Zhou, Q.; Iasonos, A.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
   [Dao, F.; Bisogna, M.; Phillips, M.; Kauff, N. D.; Levine, D. A.] Mem Sloan Kettering Canc Ctr, Gynecol Serv, Dept Surg, New York, NY 10065 USA.
   [Gao, J.; Schultz, N. D.] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA.
   [Kauff, N. D.] Mem Sloan Kettering Canc Ctr, Clin Genet Serv, Dept Med, New York, NY 10065 USA.
   [Hyman, D. M.; Grisham, R. N.; Kauff, N. D.; Levine, D. A.; Soslow, R. A.; Spriggs, D. R.] Weill Cornell Med Coll, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering
   Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan
   Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell
   University; Weill Cornell Medicine
RP Hyman, DM (通讯作者)，Mem Sloan Kettering Canc Ctr, Dept Med, 300 East 66th St,Room 1353, New York, NY 10065 USA.
EM hymand@mskcc.org
RI Wang, Jun/C-8434-2016; Meisel, James/AAP-8371-2020; Schultz,
   Nikolaus/ABE-6347-2020; Gao, Jianjiong/B-5673-2016
OI Soslow, Robert/0000-0002-7269-5898; Gao, Jianjiong/0000-0002-5739-1781;
   Levine, Douglas/0000-0003-1038-8232; Schultz,
   Nikolaus/0000-0002-0131-4904; Kauff, Noah/0000-0001-7242-6156
FU cancer center's core grant [P30 CA008748]; Stand Up to Cancer Dream Team
   Translational Research Grant; Program of the Entertainment Industry
   Foundation [SU2C-AACR-DT0209]; Honorable Tina Brozman Foundation; Be The
   Difference Foundation
FX Funded in part by the cancer center's core grant P30 CA008748. The core
   grant provides funding to institutional cores, such as Biostatistics and
   Pathology, which were used in this study. Also supported in part by a
   Stand Up to Cancer Dream Team Translational Research Grant, a Program of
   the Entertainment Industry Foundation (SU2C-AACR-DT0209), The Honorable
   Tina Brozman Foundation, and Be The Difference Foundation.
CR Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bolton KL, 2012, JAMA-J AM MED ASSOC, V307, P382, DOI 10.1001/jama.2012.20
   Byrne TJ, 2000, ONCOL REP, V7, P949
   Carser JE, 2011, GYNECOL ONCOL, V123, P492, DOI 10.1016/j.ygyno.2011.08.017
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Gallagher DJ, 2011, ANN ONCOL, V22, P1127, DOI 10.1093/annonc/mdq577
   Garg K, 2013, AM J SURG PATHOL, V37, P138, DOI 10.1097/PAS.0b013e31826cabbd
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Gilardini Montani MS, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-95
   Husain A, 1998, CANCER RES, V58, P1120
   Hyman DM, 2012, CANCER-AM CANCER SOC, V118, P3703, DOI 10.1002/cncr.26655
   Ibragimova I, 2011, METHODS MOL BIOL, V780, P277, DOI 10.1007/978-1-61779-270-0_17
   Koppensteiner R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100041
   Min A, 2013, MOL CANCER THER, V12, P865, DOI 10.1158/1535-7163.MCT-12-0950
   Radosa MP, 2011, INT J GYNECOL CANCER, V21, P1399, DOI 10.1097/IGC.0b013e318227c990
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Scheuer L, 2002, J CLIN ONCOL, V20, P1260, DOI 10.1200/JCO.2002.20.5.1260
   Skytte AB, 2011, ACTA OBSTET GYN SCAN, V90, P593, DOI 10.1111/j.1600-0412.2011.01121.x
   Vaz FH, 2007, J HISTOCHEM CYTOCHEM, V55, P1105, DOI 10.1369/jhc.7A7209.2007
   Weberpals JI, 2011, ANN ONCOL, V22, P2403, DOI 10.1093/annonc/mdq770
NR 23
TC 30
Z9 31
U1 0
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD DEC
PY 2014
VL 25
IS 12
BP 2372
EP +
DI 10.1093/annonc/mdu461
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU8DD
UT WOS:000345825800010
PM 25281711
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Karambataki, M
   Malousi, A
   Kouidou, S
AF Karambataki, M.
   Malousi, A.
   Kouidou, S.
TI Risk-associated coding synonymous SNPs in type 2 diabetes and
   neurodegenerative diseases: Genetic silence and the underrated
   association with splicing regulation and epigenetics
SO MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
LA English
DT Article
DE Synonymous SNPs; Splicing regulation; Neurodegenerative diseases; Type 2
   diabetes; Methylation
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; GROWTH-FACTOR-I; RECEPTOR-SIGNALING
   PATHWAY; MESSENGER-RNA STABILITY; DNA METHYLATION; BREAST-CANCER;
   HIGH-RESOLUTION; MUTATIONS; HAPLOTYPE; PROTEIN
AB Single nucleotide polymorphisms (SNPs) are tentatively critical with regard to disease predisposition, but coding synonymous SNPs (sSNPs) are generally considered "neutral". Nevertheless, sSNPs in serine/arginine-rich (SR) and splice-site (SS) exonic splicing enhancers (ESEs) or in exonic CpG methylation targets, could be decisive for splicing, particularly in aging-related conditions, where mis-splicing is frequently observed.
   We presently identified 33 genes T2D-related and 28 related to neurodegenerative diseases, by investigating the impact of the corresponding coding sSNPs on splicing and using gene ontology data and computational tools. Potentially critical (prominent) sSNPs comply with the following criteria: changing the splicing potential of prominent SR-ESEs or of significant SS-ESEs by >1.5 units ( A score), or formation/deletion of ESEs with maximum splicing score. We also noted the formation/disruption of CpGs (tentative methylation sites of epigenetic sSNPs). All disease association studies involving sSNPs are also reported. Only 211670 coding SNPs, mostly epigenetic, reported in 33 T2D-related genes, were found to be prominent coding synonymous. No prominent sSNPs have been recorded in three key T2D-related genes (GCGR, PPARGC1A, IGF1). Similarly, 201366 coding synonymous were identified in ND related genes, mostly epigenetic. Meta-analysis showed that 17 of the above prominent sSNPs were previously investigated in association with various pathological conditions. Three out of four sSNPs (all epigenetic) were associated with T2D and one with NDs (branch site sSNP). Five were associated with other or related pathological conditions. None of the four sSNPs introducing new ESEs was found to be disease-associated. sSNPs introducing smaller A score changes (<1.5) in key proteins (INSR, IRS1, DISCI) were also correlated to pathological conditions.
   This data reveals that genetic variation in splicing-regulatory and particularly CpG sites might be related to disease predisposition and that in-silico analysis is useful for identifying sSNPs, which might be falsely identified as silent or synonymous. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Karambataki, M.; Malousi, A.; Kouidou, S.] Aristotle Univ Thessaloniki, Sch Med, Biol Chem Lab, GR-54006 Thessaloniki, Greece.
C3 Aristotle University of Thessaloniki
RP Kouidou, S (通讯作者)，Aristotle Univ Thessaloniki, Sch Med, Biol Chem Lab, GR-54006 Thessaloniki, Greece.
EM kouidou@auth.gr
RI Malousi, Andigoni/K-3754-2019; Malousi, Andigoni/A-9460-2012
OI Kouidou, Sofia/0000-0002-1934-3260; Malousi,
   Andigoni/0000-0002-1968-7020
FU European Union (European Social Fund - ESF); Greek national funds
   through the Operational Program "Education and Lifelong Learning" of the
   National Strategic Reference Framework (NSRF) - Research Funding
   Program: Heracleitus II
FX This research has been co-financed by the European Union (European
   Social Fund - ESF) and Greek national funds through the Operational
   Program "Education and Lifelong Learning" of the National Strategic
   Reference Framework (NSRF) - Research Funding Program: Heracleitus II.
   Investing in knowledge society through the European Social Fund.
CR AlSaraj F, 2010, IRISH J MED SCI, V179, P269, DOI 10.1007/s11845-010-0462-x
   Andreadis A, 2012, J CELL PHYSIOL, V227, P1220, DOI 10.1002/jcp.22842
   Ban HJ, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-26
   Barroso I, 2005, DIABETIC MED, V22, P517, DOI 10.1111/j.1464-5491.2005.01550.x
   Barroso I, 2003, PLOS BIOL, V1, P41, DOI 10.1371/journal.pbio.0000020
   BenMoyal-Segal L, 2012, NEURODEGENER DIS, V9, P87, DOI 10.1159/000331328
   Bergholdt R, 2005, J MED GENET, V42, P17, DOI 10.1136/jmg.2004.022004
   Blackwood DHR, 2001, AM J HUM GENET, V69, P428, DOI 10.1086/321969
   Blewitt M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017939
   Bodhini D, 2012, DIABETES TECHNOL THE, V14, P696, DOI 10.1089/dia.2012.0009
   Boue S, 2003, BIOESSAYS, V25, P1031, DOI 10.1002/bies.10371
   Capon F, 2004, HUM MOL GENET, V13, P2361, DOI 10.1093/hmg/ddh273
   Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616
   Chamary JV, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-9-r75
   Chen Zi-jiang, 2004, Zhonghua Fu Chan Ke Za Zhi, V39, P582
   Concannon P, 2008, CANCER RES, V68, P6486, DOI 10.1158/0008-5472.CAN-08-0134
   Conti E, 2011, CLIN SCI, V120, P377, DOI 10.1042/CS20100400
   Coppieters N, 2014, NEUROBIOL AGING, V35, P1334, DOI 10.1016/j.neurobiolaging.2013.11.031
   Das SK, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-16
   Davidson CM, 2008, REPROD SCI, V15, P51, DOI 10.1177/1933719107309590
   Sandre-Giovannoli A, 2006, PROG MOLEC, V44, P199
   Desrivières S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001769
   Duan JB, 2003, HUM MOL GENET, V12, P205, DOI 10.1093/hmg/ddg055
   Fedetz M, 2006, TISSUE ANTIGENS, V68, P446, DOI 10.1111/j.1399-0039.2006.00694.x
   Feigelson HS, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2114
   Feng X, 2013, ASIA PAC J CLIN NUTR, V22, P150, DOI 10.6133/apjcn.2013.22.1.09
   Finck BN, 2006, J CLIN INVEST, V116, P615, DOI 10.1172/JCI27794
   Florez JC, 2003, ANNU REV GENOM HUM G, V4, P257, DOI 10.1146/annurev.genom.4.070802.110436
   Fraga MF, 2007, TRENDS GENET, V23, P413, DOI 10.1016/j.tig.2007.05.008
   Freeman H, 2006, HUM MOL GENET, V15, pR202, DOI 10.1093/hmg/ddl191
   Fukushima-Uesaka H, 2006, DRUG METAB PHARMACOK, V21, P337, DOI 10.2133/dmpk.21.337
   Fung KL, 2009, BBA-PROTEINS PROTEOM, V1794, P860, DOI 10.1016/j.bbapap.2009.02.014
   Grymek K, 2009, PHARMACOL REP, V61, P1024, DOI 10.1016/S1734-1140(09)70164-1
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Harrill AH, 2009, GENOME RES, V19, P1507, DOI 10.1101/gr.090241.108
   Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036
   Howarth K, 2009, BMC MED GENET, V10, DOI 10.1186/1471-2350-10-54
   Issa JP, 2014, J CLIN INVEST, V124, P24, DOI 10.1172/JCI69735
   Jamshidi Y, 2007, ATHEROSCLEROSIS, V194, pE26, DOI 10.1016/j.atherosclerosis.2006.12.013
   Jamshidi Y, 2006, DIABETOLOGIA, V49, P2659, DOI 10.1007/s00125-006-0388-z
   Jenkins PJ, 2004, EUR J ENDOCRINOL, V151, pS17, DOI 10.1530/eje.0.151S017
   Jones MR, 2008, FERTIL STERIL, V90, P2298, DOI 10.1016/j.fertnstert.2007.10.079
   Kanthappan R., 2010, ADV BIOSCI BIOTECHNO, V1, P361
   Karambataki M, 2010, NEUROMOL MED, V12, P260, DOI 10.1007/s12017-009-8111-0
   KAUL R, 1994, AM J HUM GENET, V55, P34
   Ke JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033676
   Khan Dilshad H., 2012, Advances in Biological Regulation, V52, P377, DOI 10.1016/j.jbior.2012.04.003
   Kilpeläinen TO, 2008, METABOLISM, V57, P428, DOI 10.1016/j.metabol.2007.10.022
   Kimchi-Sarfaty C, 2007, SCIENCE, V315, P525, DOI 10.1126/science.1135308
   Koolen DA, 2012, NAT GENET, V44, P639, DOI 10.1038/ng.2262
   Kouidou S, 2009, MOL CARCINOGEN, V48, P895, DOI 10.1002/mc.20537
   Laukkanen O, 2005, DIABETES, V54, P2256, DOI 10.2337/diabetes.54.7.2256
   Lee Ken W. K., 2013, Frontiers in Genetics, V4, P132, DOI 10.3389/fgene.2013.00132
   Lee W, 2007, NAT GENET, V39, P1235, DOI 10.1038/ng2117
   Lewis DA, 2010, ONCOGENE, V29, P1475, DOI 10.1038/onc.2009.440
   Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004
   Lista S, 2013, CURR PHARM DESIGN, V19, P6393, DOI 10.2174/13816128113199990370
   Lois S, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-252
   Lu ZX, 2012, WIRES RNA, V3, P581, DOI 10.1002/wrna.120
   Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208
   Malan-Müller S, 2014, GENES BRAIN BEHAV, V13, P52, DOI 10.1111/gbb.12102
   Malousi A, 2008, EPIGENETICS-US, V3, P69, DOI 10.4161/epi.3.2.6066
   Mavrich TN, 2008, NATURE, V453, P358, DOI 10.1038/nature06929
   McCarthy MI, 2004, HUM MOL GENET, V13, pR33, DOI 10.1093/hmg/ddh057
   Meshorer E, 2002, AGING CELL, V1, P10, DOI 10.1046/j.1474-9728.2002.00005.x
   Millan MJ, 2013, NEUROPHARMACOLOGY, V68, P2, DOI 10.1016/j.neuropharm.2012.11.015
   Mills JD, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.030
   Miyake K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066729
   Neuhausen SL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2414
   Park SA, 2011, J CLIN NEUROL, V7, P10, DOI 10.3988/jcn.2011.7.1.10
   Pfister EL, 2009, CURR BIOL, V19, P774, DOI 10.1016/j.cub.2009.03.030
   Pilling LC, 2012, J GERONTOL A-BIOL, V67, P511, DOI 10.1093/gerona/gls091
   Pinney SE, 2010, TRENDS ENDOCRIN MET, V21, P223, DOI 10.1016/j.tem.2009.10.002
   Pleiss JA, 2007, MOL CELL, V27, P928, DOI 10.1016/j.molcel.2007.07.018
   Poulsen P, 2007, PEDIATR RES, V61, p38R, DOI 10.1203/pdr.0b013e31803c7b98
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Qu HQ, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-213
   Raddatz G, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-36
   Rajpathak SN, 2009, DIABETES-METAB RES, V25, P3, DOI 10.1002/dmrr.919
   Richter D, 2012, J PROTEOMICS, V75, P3386, DOI 10.1016/j.jprot.2012.04.036
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Schosser A, 2010, MOL PSYCHIATR, V15, P844, DOI 10.1038/mp.2009.21
   Schumann G, 2008, ARCH GEN PSYCHIAT, V65, P826, DOI 10.1001/archpsyc.65.7.826
   Sesti G., 2001, DIAB METAB RES REV, V17, P303
   Shamma A, 2013, MOL CELL BIOL, V33, P3113, DOI 10.1128/MCB.01597-12
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Sherry ST, 1999, GENOME RES, V9, P677
   Shivaswamy S, 2008, PLOS BIOL, V6, P618, DOI 10.1371/journal.pbio.0060065
   Siegel TN, 2005, MOL CELL BIOL, V25, P9586, DOI 10.1128/MCB.25.21.9586-9594.2005
   Slomko H, 2012, ENDOCRINOLOGY, V153, P1025, DOI 10.1210/en.2011-1759
   Smith TJ, 2010, PHARMACOL REV, V62, P199, DOI 10.1124/pr.109.002469
   Song YQ, 2007, HUM MOL GENET, V16, P2960, DOI 10.1093/hmg/ddm256
   Sorensen H, 2006, DIABETES, V55, P3463, DOI 10.2337/db06-0307
   Soyal S, 2006, DIABETOLOGIA, V49, P1477, DOI 10.1007/s00125-006-0268-6
   Stefan M, 2014, J AUTOIMMUN, V50, P33, DOI 10.1016/j.jaut.2013.10.001
   Stevenson TJ, 2013, P NATL ACAD SCI USA, V110, P16651, DOI 10.1073/pnas.1310643110
   Tang K, 2002, PHARMACOGENETICS, V12, P437, DOI 10.1097/00008571-200208000-00004
   Tsai CJ, 2008, J MOL BIOL, V383, P281, DOI 10.1016/j.jmb.2008.08.012
   Unger RH, 2012, J CLIN INVEST, V122, P4, DOI 10.1172/JCI60016
   Unsal T, 2009, J ASSIST REPROD GEN, V26, P205, DOI 10.1007/s10815-009-9308-8
   Urban JD, 2011, DRUG METAB PHARMACOK, V26, P637, DOI 10.2133/dmpk.DMPK-11-SC-031
   Valouev A, 2008, GENOME RES, V18, P1051, DOI 10.1101/gr.076463.108
   van Bilsen PHJ, 2008, HUM GENE THER, V19, P710, DOI 10.1089/hum.2007.116
   Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795
   Wagner K, 2004, CARCINOGENESIS, V25, P2473, DOI 10.1093/carcin/bgh263
   Wang ZF, 2008, RNA, V14, P802, DOI 10.1261/rna.876308
   Warnecke T, 2009, BIOCHEM SOC T, V37, P756, DOI 10.1042/BST0370756
   Waterland RA, 2007, FASEB J, V21, P3380, DOI 10.1096/fj.07-8229com
   Willer CJ, 2007, DIABETES, V56, P256, DOI 10.2337/db06-0461
   Winder T, 2014, PHARMACOGENOMICS J, V14, P28, DOI 10.1038/tpj.2013.8
   Yan H, 2009, J PHARMACOL EXP THER, V329, P102, DOI 10.1124/jpet.108.147009
   Yang L, 2007, MOL CELL, V27, P861, DOI 10.1016/j.molcel.2007.09.003
   Yokomori N, 1999, DIABETES, V48, P685, DOI 10.2337/diabetes.48.4.685
   Young JI, 2005, P NATL ACAD SCI USA, V102, P17551, DOI 10.1073/pnas.0507856102
   Zaitlen NA, 2005, GENOME RES, V15, P1594, DOI 10.1101/gr.4297805
   Ziv-Gal A, 2013, SLEEP MED, V14, P883, DOI 10.1016/j.sleep.2013.04.007
   Zofková I, 2003, PHYSIOL RES, V52, P657, DOI 10.33549/physiolres.930307
NR 117
TC 13
Z9 13
U1 1
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1386-1964
EI 1873-135X
J9 MUTAT RES-FUND MOL M
JI Mutat. Res.-Fundam. Mol. Mech. Mutagen.
PD DEC
PY 2014
VL 770
BP 85
EP 93
DI 10.1016/j.mrfmmm.2014.09.005
PG 9
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology
GA AU5LC
UT WOS:000345647400011
PM 25771874
DA 2025-01-12
ER

PT J
AU Gong, C
   Qu, SH
   Lv, XB
   Liu, BD
   Tan, WG
   Nie, Y
   Su, FX
   Liu, Q
   Yao, HR
   Song, EW
AF Gong, Chang
   Qu, Shaohua
   Lv, Xiao-Bin
   Liu, Bodu
   Tan, Weige
   Nie, Yan
   Su, Fengxi
   Liu, Qiang
   Yao, Herui
   Song, Erwei
TI BRMS1L suppresses breast cancer metastasis by inducing epigenetic
   silence of FZD10
SO NATURE COMMUNICATIONS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE DEACETYLASE; BETA-CATENIN;
   LUNG-CANCER; EXPRESSION; CARCINOMA; GROWTH; ACETYLTRANSFERASE;
   IDENTIFICATION; FRIZZLED-10
AB BRMS1L (breast cancer metastasis suppressor 1 like, BRMS1-like) is a component of Sin3A-histone deacetylase (HDAC) co-repressor complex that suppresses target gene transcription. Here we show that reduced BRMS1L in breast cancer tissues is associated with metastasis and poor patient survival. Functionally, BRMS1L inhibits breast cancer cells migration and invasion by inhibiting epithelial-mesenchymal transition. These effects are mediated by epigenetic silencing of FZD10, a receptor for Wnt signalling, through HDAC1 recruitment and histone H3K9 deacetylation at the promoter. Consequently, BRMS1L-induced FZD10 silencing inhibits aberrant activation of WNT3-FZD10-beta-catenin signalling. Furthermore, BRMS1L is a target of miR-106b and miR-106b upregulation leads to BRMS1L reduction in breast cancer cells. RNA interference-mediated silencing of BRMS1L expression promotes metastasis of breast cancer xenografts in immunocompromised mice, whereas ectopic BRMS1L expression inhibits metastasis. Therefore, BRMS1L provides an epigenetic regulation of Wnt signalling in breast cancer cells and acts as a breast cancer metastasis suppressor.
C1 [Gong, Chang; Qu, Shaohua; Lv, Xiao-Bin; Liu, Bodu; Tan, Weige; Nie, Yan; Su, Fengxi; Liu, Qiang; Yao, Herui; Song, Erwei] Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.
   [Gong, Chang; Qu, Shaohua; Lv, Xiao-Bin; Liu, Bodu; Tan, Weige; Nie, Yan; Su, Fengxi; Liu, Qiang; Song, Erwei] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Guangdong, Peoples R China.
   [Yao, Herui] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Oncol, Guangzhou 510120, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Song, EW (通讯作者)，Med Res Ctr, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.
EM victorlq@hotmail.com; yaoherui@163.com; songew@mail.sysu.edu.cn
RI Liu, Bodu/AAR-9402-2021; Lv, Xiao-Bin/T-7607-2019; Wang,
   Chengxing/HSH-2963-2023; Liu, Qiang/HHZ-3181-2022; Liu,
   Bodu/G-5222-2016; Liu, Qiang/JAX-9209-2023
OI Liu, Bodu/0000-0003-2097-725X; Liu, Qiang/0000-0002-5451-4862; Yao,
   Herui/0000-0001-5520-6469
FU 973 Projects from Ministry of Science and Technology of China
   [2010CB912800, 2011CB504203]; Natural Science Foundation of China
   [81230060, 81261140373, 81272893, 81102023, 81372819, 81272894,
   81472466]; Specialized Research Fund for the Doctoral Program of Higher
   Education [20120171110075]; Program for New Century Excellent Talents in
   University [NCET-12-0565]; Science Foundation of Guangdong Province
   [S2012030006287]; Guangdong Department of Science & Technology
   Translational Medicine Center grant [2011A080300002]; Guangzhou Science
   and Technology Bureau [2012J2200092, 2014J4100170]; Sun Yat-sen
   University Training Project [11ykpy28, 12ykpy32, 13ykzd14]; Special
   Project on New Drug Innovation of Sun Yat-sen University; Yat-Sen
   Scholarship for Young Scientist and Translational medicine public
   platform of Guangdong Province [4202037]; Key Laboratory of Malignant
   Tumor Gene Regulation and Target Therapy of Guangdong Higher Education
   Institutes, Sun Yat-Sen University [KLB09001]; Key Laboratory of
   Malignant Tumor Molecular Mechanism and Translational Medicine of
   Guangzhou Bureau of Science and Information Technology [163]
FX This work was funded by grants from 973 (2010CB912800, 2011CB504203)
   Projects from Ministry of Science and Technology of China; the Natural
   Science Foundation of China (81230060, 81261140373, 81272893, 81102023,
   81372819, 81272894,81472466); Specialized Research Fund for the Doctoral
   Program of Higher Education (20120171110075); Program for New Century
   Excellent Talents in University (NCET-12-0565); Science Foundation of
   Guangdong Province (S2012030006287), Guangdong Department of Science &
   Technology Translational Medicine Center grant (2011A080300002). Funding
   from Guangzhou Science and Technology Bureau (2012J2200092,
   2014J4100170); Sun Yat-sen University Training Project (11ykpy28,
   12ykpy32, 13ykzd14), Special Project on New Drug Innovation of Sun
   Yat-sen University; Yat-Sen Scholarship for Young Scientist and
   Translational medicine public platform of Guangdong Province (4202037);
   Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene
   Regulation and Target Therapy of Guangdong Higher Education Institutes,
   Sun Yat-Sen University; Grant [2013] 163 from Key Laboratory of
   Malignant Tumor Molecular Mechanism and Translational Medicine of
   Guangzhou Bureau of Science and Information Technology.
CR Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060
   Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0
   Baer C, 2013, CANCER RES, V73, P473, DOI 10.1158/0008-5472.CAN-12-3731
   Balgkouranidou I, 2014, BRIT J CANCER, V110, P2054, DOI 10.1038/bjc.2014.104
   Cai JC, 2013, J CLIN INVEST, V123, P566, DOI 10.1172/JCI65871
   Cai KM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-73
   Castro-Castro A, 2012, EUR J CELL BIOL, V91, P950, DOI 10.1016/j.ejcb.2012.07.001
   Chui X, 1996, BRIT J CANCER, V73, P1233, DOI 10.1038/bjc.1996.236
   Cicek M, 2009, CLIN EXP METASTAS, V26, P229, DOI 10.1007/s10585-009-9235-1
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cui RX, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-376
   Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905
   Das TK, 2013, ONCOGENE, V32, P3184, DOI 10.1038/onc.2012.326
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   De Amicis F, 2011, FASEB J, V25, P3695, DOI 10.1096/fj.10-178871
   Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135
   Edmonds MD, 2009, INT J CANCER, V125, P1778, DOI 10.1002/ijc.24616
   FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8
   Fukukawa C, 2009, ONCOGENE, V28, P1110, DOI 10.1038/onc.2008.467
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Gong C, 2015, ONCOGENE, V34, P84, DOI 10.1038/onc.2013.525
   Hedley BD, 2008, CLIN EXP METASTAS, V25, P727, DOI 10.1007/s10585-008-9184-0
   Hedley BD, 2008, INT J CANCER, V123, P526, DOI 10.1002/ijc.23542
   Heideman MR, 2014, HAEMATOLOGICA, V99, P1292, DOI 10.3324/haematol.2013.092643
   Hunter KW, 2001, CANCER RES, V61, P8866
   Hurst DR, 2011, FEBS LETT, V585, P3185, DOI 10.1016/j.febslet.2011.07.045
   Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559
   Icardi L, 2012, P NATL ACAD SCI USA, V109, P12058, DOI 10.1073/pnas.1206458109
   Jeong H, 2012, HISTOPATHOLOGY, V60, pE87, DOI 10.1111/j.1365-2559.2012.04195.x
   Kirikoshi H, 2001, INT J ONCOL, V19, P767
   Koike J, 1999, BIOCHEM BIOPH RES CO, V262, P39, DOI 10.1006/bbrc.1999.1161
   Li J, 2011, ONCOGENE, V30, P896, DOI 10.1038/onc.2010.470
   Liu Y, 2013, CANCER RES, V73, P1308, DOI 10.1158/0008-5472.CAN-12-2489
   Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780
   Nagayama S, 2009, CANCER SCI, V100, P405, DOI 10.1111/j.1349-7006.2008.01052.x
   Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030
   Nikolaev AY, 2004, BIOCHEM BIOPH RES CO, V323, P1216, DOI 10.1016/j.bbrc.2004.08.227
   Phadke PA, 2008, AM J PATHOL, V172, P809, DOI 10.2353/ajpath.2008.070772
   Poliseno L, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000594
   Samant RS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-6
   Seraj MJ, 2000, CANCER RES, V60, P2764
   Silveira AC, 2009, CANCER LETT, V276, P32, DOI 10.1016/j.canlet.2008.10.024
   Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11
   Terasaki H, 2002, INT J MOL MED, V9, P107
   Thurn KT, 2013, MOL CANCER THER, V12, P2078, DOI 10.1158/1535-7163.MCT-12-1242
   Vaidya KS, 2008, J BIOL CHEM, V283, P28354, DOI 10.1074/jbc.M710068200
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Wend P, 2010, SEMIN CELL DEV BIOL, V21, P855, DOI 10.1016/j.semcdb.2010.09.004
   Xiong YN, 2014, AM J PHYSIOL-REG I, V307, pR608, DOI 10.1152/ajpregu.00085.2014
   Yang JY, 2008, CANCER LETT, V269, P46, DOI 10.1016/j.canlet.2008.04.016
   Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027
   Zhang Y, 2014, CELL BIOCHEM BIOPHYS, V70, P505, DOI 10.1007/s12013-014-9948-x
NR 52
TC 86
Z9 93
U1 0
U2 31
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV
PY 2014
VL 5
AR 5406
DI 10.1038/ncomms6406
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AU5CN
UT WOS:000345624800027
PM 25406648
OA Bronze
DA 2025-01-12
ER

PT J
AU Sanchez-Molina, S
   Estaras, C
   Oliva, JL
   Akizu, N
   Asensio-Juan, E
   Rojas, JM
   Martínez-Balbás, MA
AF Sanchez-Molina, Sara
   Estaras, Conchi
   Luis Oliva, Jose
   Akizu, Naiara
   Asensio-Juan, Elena
   Maria Rojas, Jose
   Martinez-Balbas, Marian A.
TI Regulation of CBP and Tip60 coordinates histone acetylation at local and
   global levels during Ras-induced transformation
SO CARCINOGENESIS
LA English
DT Article
ID CELL-CYCLE MACHINERY; HUMAN BREAST-CANCER; ACETYLTRANSFERASE ACTIVITY;
   TIP60-DEPENDENT ACETYLATION; TRANSCRIPTION FACTOR; SIGNALING PATHWAYS;
   DNA METHYLATION; NIH 3T3-CELLS; P53 PATHWAY; H-RAS
AB Cell transformation is clearly linked to epigenetic changes. However, the role of the histone-modifying enzymes in this process is still poorly understood. In this study, we investigated the contribution of the histone acetyltransferase (HAT) enzymes to Ras-mediated transformation. Our results demonstrated that lysine acetyltransferase 5, also known as Tip60, facilitates histone acetylation of bulk chromatin in Ras-transformed cells. As a consequence, global H4 acetylation (H4K8ac and H4K12ac) increases in Ras-transformed cells, rendering a more decompacted chromatin than in parental cells. Furthermore, low levels of CREB-binding protein (CBP) lead to hypoacetylation of retinoblastoma 1 (Rb1) and cyclin-dependent kinase inhibitor 1B (Cdkn1b or p27Kip1) tumour suppressor gene promoters to facilitate Ras-mediated transformation. In agreement with these data, overexpression of Cbp counteracts Ras transforming capability in a HAT-dependent manner. Altogether our results indicate that CBP and Tip60 coordinate histone acetylation at both local and global levels to facilitate Ras-induced transformation.
C1 [Sanchez-Molina, Sara; Estaras, Conchi; Akizu, Naiara; Asensio-Juan, Elena; Martinez-Balbas, Marian A.] CSIC, Inst Biol Mol Barcelona, Dept Genom Regulat, E-08028 Barcelona, Spain.
   [Luis Oliva, Jose; Maria Rojas, Jose] Inst Salud Carlos III, Unidad Func Invest Enfermedades Cron, Unidad Biol Celular, Madrid 28220, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de Biologia Molecular de Barcelona (IBMB); Instituto de Salud Carlos
   III; Unidad Funcional de Investigacion de Enfermedades Cronicas (UFIEC)
RP Martínez-Balbás, MA (通讯作者)，CSIC, Inst Biol Mol Barcelona, Dept Genom Regulat, Baldiri i Reixac 15-21,Parc Cient Barcelona, E-08028 Barcelona, Spain.
EM mmbbmc@ibmb.csic.es
RI Martinez-Balbas, Marian/HOC-6723-2023; Rojas, José/AAA-3354-2021;
   Estaras, Conchi/S-7935-2016; Sanchez-Molina, Sara/B-2148-2017
OI Estaras, Conchi/0000-0002-2600-5841; ROJAS CABANEROS, JOSE
   MARIA/0000-0002-7547-2825; Sanchez-Molina, Sara/0000-0002-1430-131X;
   Martinez-Balbas, Marian/0000-0003-0173-0964; Asensio Juan,
   Elena/0000-0003-3236-8590
FU Spanish Ministry of Education and Science [BFU2006-01493, BFU2009-11527,
   CSD2006-00049, BFU-2012-34261]; Fundacio La Marato de TV3 [090210];
   Fondation Jerome Lejeune; Spanish Ministry of Education and Science;
   Fondo de Investigaciones Sanitarias-Intrasalud [PI09/0562
   (SAF2006-04247)]; Red Tematica de Investigacion Cooperativa en Cancer
   from Instituto de Salud Carlos III [RD06/0020/0003, RD12/0036/0021]; I3P
   fellowship [I3P-BPD2005]; FPU fellowship; Generalitat de Catalunya
   predoctoral fellowship
FX The Spanish Ministry of Education and Science (BFU2006-01493,
   BFU2009-11527, CSD2006-00049, BFU-2012-34261); Fundacio La Marato de TV3
   (090210); Fondation Jerome Lejeune to MAMB; the Spanish Ministry of
   Education and Science, Fondo de Investigaciones Sanitarias-Intrasalud
   PI09/0562 (SAF2006-04247); Red Tematica de Investigacion Cooperativa en
   Cancer from the Instituto de Salud Carlos III (RD06/0020/0003 and
   RD12/0036/0021 to J.M.R.); I3P fellowship (I3P-BPD2005) to N.A.; a FPU
   fellowship to C.E.; and a Generalitat de Catalunya predoctoral
   fellowship to S.S.-M.
CR Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190
   Akizu N, 2010, DEVELOPMENT, V137, P2915, DOI 10.1242/dev.049395
   Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850
   Asensio-Juan E, 2012, NUCLEIC ACIDS RES, V40, P9429, DOI 10.1093/nar/gks716
   Bachman KE, 2003, CANCER CELL, V3, P89, DOI 10.1016/S1535-6108(02)00234-9
   Bellucci L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054102
   Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371
   Blanco-García N, 2009, J BIOL CHEM, V284, P1343, DOI 10.1074/jbc.M806075200
   Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x
   Cascone I, 2008, EMBO J, V27, P2375, DOI 10.1038/emboj.2008.166
   Ceschin DG, 2011, GENE DEV, V25, P1132, DOI 10.1101/gad.619211
   Chevillard-Briet M, 2002, EMBO J, V21, P5457, DOI 10.1093/emboj/cdf548
   Choi HS, 2005, CANCER RES, V65, P5818, DOI 10.1158/0008-5472.CAN-05-0197
   CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753
   Davie JR, 1999, BIOCHEM CELL BIOL, V77, P265, DOI 10.1139/bcb-77-4-265
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7
   Espino PS, 2006, CANCER RES, V66, P4610, DOI 10.1158/0008-5472.CAN-05-4251
   Estarás C, 2012, DEVELOPMENT, V139, P2681, DOI 10.1242/dev.078345
   Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gevry N, 2007, GENE DEV, V21, P1869, DOI 10.1101/gad.1545707
   Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165
   Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544
   Hosoda H, 2009, MOL BRAIN, V2, DOI 10.1186/1756-6606-2-34
   Jorge B, 2002, J BIOL CHEM, V277, P44171, DOI 10.1074/jbc.M204423200
   Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703
   LAITINEN J, 1990, J CELL BIOL, V111, P9, DOI 10.1083/jcb.111.1.9
   Lee MS, 2013, CELL DEATH DIFFER, V20, P620, DOI 10.1038/cdd.2012.159
   Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200
   Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847
   MACLEOD AR, 1995, J BIOL CHEM, V270, P11327, DOI 10.1074/jbc.270.19.11327
   Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887
   Martínez-Balbás MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886
   Mittnacht S, 1997, CURR BIOL, V7, P219, DOI 10.1016/S0960-9822(97)70094-0
   O'Connor MJ, 1999, J VIROL, V73, P3574
   Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2
   Oliva JL, 2004, J BIOL CHEM, V279, P33480, DOI 10.1074/jbc.M404058200
   Omerovic J, 2007, CELL MOL LIFE SCI, V64, P2575, DOI 10.1007/s00018-007-7133-8
   Park JH, 2010, MOL CELL BIOL, V30, P2750, DOI 10.1128/MCB.00804-09
   Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0
   Puppin C, 2011, BIOCHEM BIOPH RES CO, V411, P679, DOI 10.1016/j.bbrc.2011.06.182
   Reitsma JM, 2011, CELL HOST MICROBE, V9, P103, DOI 10.1016/j.chom.2011.01.006
   RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3
   Sánchez-Molina S, 2006, BIOCHEM J, V398, P215, DOI 10.1042/BJ20060052
   Santos-Rosa H, 2005, EUR J CANCER, V41, P2381, DOI 10.1016/j.ejca.2005.08.010
   Sato S, 1997, ONCOGENE, V14, P3083, DOI 10.1038/sj.onc.1201298
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021
   Trouche D, 1996, NUCLEIC ACIDS RES, V24, P4139, DOI 10.1093/nar/24.21.4139
   Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066
   Valls E, 2005, J BIOL CHEM, V280, P42592, DOI 10.1074/jbc.M507407200
   Valls E, 2003, NUCLEIC ACIDS RES, V31, P3114, DOI 10.1093/nar/gkg418
   Valls E, 2007, NUCLEIC ACIDS RES, V35, P1958, DOI 10.1093/nar/gkl1113
   Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966
NR 58
TC 11
Z9 13
U1 1
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2014
VL 35
IS 10
BP 2194
EP 2202
DI 10.1093/carcin/bgu111
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU8EY
UT WOS:000345830400005
PM 24853677
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Satpathy, S
   Guérillon, C
   Kim, TS
   Bigot, N
   Thakur, S
   Bonni, S
   Riabowol, K
   Pedeux, R
AF Satpathy, Shankha
   Guerillon, Claire
   Kim, Tae-Sun
   Bigot, Nicolas
   Thakur, Satbir
   Bonni, Shirin
   Riabowol, Karl
   Pedeux, Remy
TI SUMOylation of the ING1b tumor suppressor regulates gene transcription
SO CARCINOGENESIS
LA English
DT Article
ID SUMO MODIFICATION; PHD-FINGER; REPRESSES TRANSCRIPTION;
   CELL-PROLIFERATION; BREAST-CANCER; UBIQUITIN; PROTEIN; APOPTOSIS; DNA;
   BINDING
AB The INhibitor of Growth (ING) proteins are encoded as multiple isoforms in five ING genes (ING1-5) and act as type II tumor suppressors. They are growth inhibitory when overexpressed and are frequently mislocalized or downregulated in several forms of cancer. ING1 and ING2 are stoichiometric members of histone deacetylase complexes, whereas ING3-5 are stoichiometric components of different histone acetyltransferase complexes. The INGs target these complexes to histone marks, thus acting as epigenetic regulators. ING proteins affect angiogenesis, apoptosis, DNA repair, metastasis and senescence, but how the proteins themselves are regulated is not yet clear. Here, we find a small ubiquitin-like modification (SUMOylation) of the ING1b protein and identify lysine 193 (K193) as the preferred ING1b SUMO acceptor site. We also show that PIAS4 is the E3 SUMO ligase responsible for ING1b SUMOylation on K193. Sequence alignment reveals that the SUMO consensus site on ING1b contains a phosphorylation-dependent SUMOylation motif (PDSM) and our data indicate that the SUMOylation on K193 is enhanced by the S199D phosphomimic mutant. Using an ING1b protein mutated at the major SUMOylation site (ING1b E195A), we further demonstrate that ING1b SUMOylation regulates the binding of ING1b to the ISG15 and DGCR8 promoters, consequently regulating ISG15 and DGCR8 transcription. These results suggest a role for ING1b SUMOylation in the regulation of gene transcription.
C1 [Satpathy, Shankha; Kim, Tae-Sun; Thakur, Satbir; Bonni, Shirin; Riabowol, Karl] Univ Calgary, Fac Med, Southern Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.
   [Guerillon, Claire; Bigot, Nicolas; Pedeux, Remy] INSERM U917, F-350043 Rennes, France.
   [Guerillon, Claire; Bigot, Nicolas; Pedeux, Remy] Univ Rennes 1, F-350043 Rennes, France.
   [Pedeux, Remy] Etab Francais Sang, F-350043 Rennes, France.
C3 University of Calgary; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Rennes; Universite de Rennes
RP Riabowol, K (通讯作者)，Univ Calgary, Fac Med, Southern Alberta Canc Res Inst, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.
EM karl@ucalgary.ca
RI Guérillon, Claire/I-1010-2014; Kim, Sung/G-4114-2014; PEDEUX,
   Remy/I-2603-2014
OI Guerillon, Claire/0000-0002-1982-6596; PEDEUX, Remy/0000-0002-2553-7934;
   Bigot, Nicolas/0000-0002-4247-0217
CR Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117
   Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X
   Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001
   Binda O, 2008, ONCOGENE, V27, P3384, DOI 10.1038/sj.onc.1211014
   Bischof O, 2006, MOL CELL, V22, P783, DOI 10.1016/j.molcel.2006.05.016
   Chen J, 2013, BRIT J CANCER, V108, P1143, DOI 10.1038/bjc.2013.50
   Cheung KJ, 2001, CANCER RES, V61, P4974
   Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007
   Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06
   Feng XL, 2002, TRENDS CELL BIOL, V12, P532, DOI 10.1016/S0962-8924(02)02391-7
   Galanty Y, 2009, NATURE, V462, P935, DOI 10.1038/nature08657
   Gali H, 2012, NUCLEIC ACIDS RES, V40, P6049, DOI 10.1093/nar/gks256
   Garate M, 2007, FASEB J, V21, P3705, DOI 10.1096/fj.07-8069com
   Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415
   Gómez-Cabello D, 2010, CANCER RES, V70, P1866, DOI 10.1158/0008-5472.CAN-09-2088
   Gomez-del Arco P, 2005, MOL CELL BIOL, V25, P2688
   Gong W, 2006, MOL CELL BIOL, V26, P2947, DOI 10.1128/MCB.26.8.2947-2954.2006
   Guérillon C, 2013, CELL MOL LIFE SCI, V70, P3753, DOI 10.1007/s00018-013-1270-z
   Guo Q, 2011, J BIOL CHEM, V286, P17069, DOI 10.1074/jbc.M111.230961
   HAAS AL, 1987, J BIOL CHEM, V262, P11315
   Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504
   Han XJ, 2008, NAT CELL BIOL, V10, P1333, DOI 10.1038/ncb1792
   He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256
   Hickey CM, 2012, NAT REV MOL CELL BIO, V13, P755, DOI 10.1038/nrm3478
   Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102
   Hsu YHR, 2006, J BIOL CHEM, V281, P33008, DOI 10.1074/jbc.M604380200
   Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012
   Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118
   Kataoka H, 2003, CANCER RES, V63, P5785
   Larrieu D, 2009, EMBO REP, V10, P1168, DOI 10.1038/embor.2009.180
   Lenschow DJ, 2005, J VIROL, V79, P13974, DOI 10.1128/JVI.79.22.13974-13983.2005
   Liu HW, 2012, NUCLEIC ACIDS RES, V40, P10172, DOI 10.1093/nar/gks819
   LOEB KR, 1992, J BIOL CHEM, V267, P7806
   Luo JJ, 2009, GENETICS, V181, P473, DOI 10.1534/genetics.107.080515
   Nagashima M, 2003, ONCOGENE, V22, P343, DOI 10.1038/sj.onc.1206115
   Nagashima M, 2001, P NATL ACAD SCI USA, V98, P9671, DOI 10.1073/pnas.161151798
   Neyret-Kahn H, 2013, GENOME RES, V23, P1563, DOI 10.1101/gr.154872.113
   Okumura A, 2006, P NATL ACAD SCI USA, V103, P1440, DOI 10.1073/pnas.0510518103
   Pena PV, 2008, J MOL BIOL, V380, P303, DOI 10.1016/j.jmb.2008.04.061
   Rajarajacholan UK, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001502
   Rohira AD, 2013, J BIOL CHEM, V288, P19288, DOI 10.1074/jbc.M113.473744
   Satpathy S, 2013, BIOCHEM J, V450, P433, DOI 10.1042/BJ20121632
   Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560
   Scott M, 2001, J CELL SCI, V114, P3455
   Shiseki M, 2003, CANCER RES, V63, P2373
   Suzuki K, 2011, HYBRIDOMA, V30, P239, DOI 10.1089/hyb.2010.0124
   Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905
   Vieyra D, 2002, CANCER RES, V62, P4445
   Wong RPC, 2011, NUCLEIC ACIDS RES, V39, P3632, DOI 10.1093/nar/gkq1337
   Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7
   Ythier D, 2010, ONCOGENE, V29, P5946, DOI 10.1038/onc.2010.325
   Ythier D, 2008, INT J CANCER, V123, P1483, DOI 10.1002/ijc.23790
   Yu LS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060943
NR 53
TC 9
Z9 11
U1 1
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD OCT
PY 2014
VL 35
IS 10
BP 2214
EP 2223
DI 10.1093/carcin/bgu126
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU8EY
UT WOS:000345830400007
PM 24903338
OA Bronze, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Gupta, S
   Jaworska-Bieniek, K
   Narod, SA
   Lubinski, J
   Wojdacz, TK
   Jakubowska, A
AF Gupta, Satish
   Jaworska-Bieniek, Katarzyna
   Narod, Steven A.
   Lubinski, Jan
   Wojdacz, Tomasz K.
   Jakubowska, Anna
TI Methylation of the <i>BRCA1</i> promoter in peripheral blood DNA is
   associated with triple-negative and medullary breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer risk; BRCA1 promoter methylation; Peripheral blood;
   Methylation-sensitive high-resolution melting (MS-HRM)
ID SPORADIC BREAST; PREDICTS SENSITIVITY; EPIGENETIC INACTIVATION;
   ESTROGEN-RECEPTOR; OVARIAN-CANCER; MUTATIONS; EXPRESSION; WOMEN;
   HYPERMETHYLATION; CARCINOMA
AB It has been proposed that methylation signatures in blood-derived DNA may correlate with cancer risk. In this study, we evaluated whether methylation of the promoter region of the BRCA1 gene detectable in DNA from peripheral blood cells is a risk factor for breast cancer, in particular for tumors with pathologic features characteristic for cancers with BRCA1 gene mutations. We conducted a case-control study of 66 breast cancer cases and 36 unaffected controls. Cases were triple-negative or of medullary histology, or both; 30 carried a constitutional BRCA1 mutation and 36 did not carry a mutation. Blood for DNA methylation analysis was taken within three months of diagnosis. Methylation of the promoter of the BRCA1 gene was measured in cases and controls using methylation-sensitive high-resolution melting (MS-HRM). A sample with any detectable level of methylation was considered to be positive. Methylation of the BRCA1 promoter was detected in 15 of 66 cases and in 2 of 36 controls (OR 5.0, p = 0.03). Methylation was present in 15 of 36 women with breast cancer and without germline BRCA1 mutation, but in none of 30 women with breast cancer and a germline mutation (p < 0.01). The association between methylation and breast cancer was restricted to women with no constitutional BRCA1 mutation (OR 12.1, p = 0.0006). Methylation of the promoter of the BRCA1 gene detectable in peripheral blood DNA may be a marker of increased susceptibility to triple-negative or medullary breast cancer.
C1 [Gupta, Satish; Jaworska-Bieniek, Katarzyna; Lubinski, Jan; Jakubowska, Anna] Pomeranian Med Univ, Dept Genet & Pathol, Int Hereditary Canc Ctr, Szczecin, Poland.
   [Gupta, Satish; Jaworska-Bieniek, Katarzyna; Lubinski, Jan] Med Univ Warsaw, Postgrad Sch Mol Med, Warsaw, Poland.
   [Narod, Steven A.] Univ Toronto, Womens Coll Res Inst, Toronto, ON M5G 1N8, Canada.
   [Wojdacz, Tomasz K.] Univ Aarhus, Inst Biomed, Aarhus, Denmark.
   [Wojdacz, Tomasz K.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.
C3 Pomeranian Medical University; Medical University of Warsaw; University
   of Toronto; Womens College Hospital; Aarhus University; Karolinska
   Institutet
RP Narod, SA (通讯作者)，Univ Toronto, Womens Coll Res Inst, 790 Bay St,7th Floor, Toronto, ON M5G 1N8, Canada.
EM steven.narod@wchospital.ca
RI Jakubowska, Anna/O-8050-2014; Narod, Steven/AAA-6112-2022
OI Lubinski, Jan/0000-0003-2931-3003; Wojdacz, Tomasz
   K/0000-0001-6003-2432; Jakubowska, Anna/0000-0002-5650-0501
FU Lundbeck Foundation; Danish Cancer Society; State Committee for
   Scientific Research Grants [PBZ-KBN-042/P05/2001, PBZ-KBN-122/P05/02]
FX TKW would like to thank Lundbeck Foundation and Danish Cancer Society
   for the support of this work. This study was supported by the State
   Committee for Scientific Research Grants: PBZ-KBN-042/P05/2001 and
   PBZ-KBN-122/P05/02
CR Akbari MR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt323
   Al-Moghrabi N, 2011, INT J ONCOL, V39, P129, DOI 10.3892/ijo.2011.1021
   Amirikia KC, 2011, CANCER-AM CANCER SOC, V117, P2747, DOI 10.1002/cncr.25862
   Anjum S, 2014, GENOME MED, V6, DOI 10.1186/gm567
   Armes JE, 1998, CANCER-AM CANCER SOC, V83, P2335, DOI 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N
   Atchley DP, 2008, J CLIN ONCOL, V26, P4282, DOI 10.1200/JCO.2008.16.6231
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509
   Chen Y, 2006, GENET TEST, V10, P281, DOI 10.1089/gte.2006.10.281
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1
   Eisinger F, 1998, CANCER RES, V58, P1588
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061
   Greenup R, 2013, ANN SURG ONCOL, V20, P3254, DOI 10.1245/s10434-013-3205-1
   Hansmann T, 2012, HUM MOL GENET, V21, P4669, DOI 10.1093/hmg/dds308
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Iau PTC, 2004, BREAST CANCER RES TR, V85, P81, DOI 10.1023/B:BREA.0000021049.61839.e5
   Ignatov T, 2013, BREAST CANCER RES TR, V141, P205, DOI 10.1007/s10549-013-2693-9
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   Kontorovich T, 2009, BREAST CANCER RES TR, V116, P195, DOI 10.1007/s10549-008-0121-3
   LAHIRI DK, 1993, BIOCHEM GENET, V31, P321, DOI 10.1007/BF02401826
   Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023
   Lara-Medina F, 2011, CANCER-AM CANCER SOC, V117, P3658, DOI 10.1002/cncr.25961
   Matros E, 2005, BREAST CANCER RES TR, V91, P179, DOI 10.1007/s10549-004-7603-8
   Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775
   Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0
   Rice JC, 2000, CARCINOGENESIS, V21, P1761, DOI 10.1093/carcin/21.9.1761
   Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725
   Seeber L M S, 2012, Methods Mol Biol, V863, P253, DOI 10.1007/978-1-61779-612-8_15
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Szwiec M, 2015, CLIN GENET, V87, P288, DOI 10.1111/cge.12360
   THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Veeck J, 2010, J CLIN ONCOL, V28, pE563, DOI 10.1200/JCO.2010.30.1010
   Wei MJ, 2005, CANCER RES, V65, P10692, DOI 10.1158/0008-5472.CAN-05-1277
   Wilcox CB, 2005, CANCER GENET CYTOGEN, V159, P114, DOI 10.1016/j.cancergencyto.2004.12.017
   Wojdacz TK, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm013
   Wojdacz TK, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-116
   Wojdacz TK, 2011, FUTURE ONCOL, V7, P1451, DOI [10.2217/fon.11.123, 10.2217/FON.11.123]
   Wojdacz Tomasz K, 2008, BMC Res Notes, V1, P54, DOI 10.1186/1756-0500-1-54
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Xu Y, 2013, ANN ONCOL, V24, P1498, DOI 10.1093/annonc/mdt011
NR 47
TC 31
Z9 34
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2014
VL 148
IS 3
BP 615
EP 622
DI 10.1007/s10549-014-3179-0
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU1HC
UT WOS:000345370600015
PM 25376744
DA 2025-01-12
ER

PT J
AU Li, Z
   Ding, Y
   Zhu, YL
   Yin, MX
   Le, XP
   Wang, L
   Yang, Y
   Zhang, QX
AF Li, Zhi
   Ding, Yi
   Zhu, Yunliang
   Yin, Mingxing
   Le, Xiaoping
   Wang, Luo
   Yang, Yang
   Zhang, Qinxian
TI Both gene deletion and promoter hyper-methylation contribute to the
   down-regulation of <i>ZAC/PLAGL1</i> gene in gastric adenocarcinomas: A
   case control study
SO CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; COPY NUMBER VARIATIONS;
   SYSTEMIC-LUPUS-ERYTHEMATOSUS; REAL-TIME PCR; OVARIAN-CANCER;
   BREAST-CANCER; HUMAN GENOME; EXPRESSION; PLAGL1; ZAC1
AB Background and objective: Pleiomorphic adenoma gene-like 1 (PLAGL1, also known as LOT1 and ZAC) is a zinc-finger nuclear transcription factor, which possesses antiproliferative effects and is frequently epigenetically silenced during tumorigenesis. PLAGL1 gene is located on 6q24-25, a chromosomal region that is frequently deleted in various kinds of cancers. Both promoter hyper-methylation and loss of heterozygosity may lead to the down-regulation of PLAGL1 in human somatic cancers. Here we aimed to investigate the abnormalities of PLAGL1 in gastric cancers.
   Methods: We collected 153 case-matched gastric adenocarcinoma (GAC) cases. Quantitative real-time PCR method was applied to evaluate the expression levels as well as gene copy numbers of PLAGL1 in the collected samples. Methylation-specific PCR (MSP) assay was performed to analyze the methylation status of PLAGL1 P1 promoter.
   Results: Decreased expression of PLAGL1 mRNA was observed in GAC tissues, especially in advanced GACs. Copy number decrease of PLAGL1 gene in GACs was observed in 9.15% (19 out of 153) of the GAC samples and was closely correlated with gene expression. Methylation status of PLAGL1 promoter in GAC tissues was higher than in normal controls, which was inversely correlated with the expression levels of PLAGL1 mRNA.
   Conclusion: DNA deletion and promoter hyper-methylation both contribute to the downregulation of PLAGL1 in GACs. (C) 2013 Published by Elsevier Masson SAS.
C1 [Li, Zhi; Ding, Yi; Zhu, Yunliang; Yin, Mingxing; Le, Xiaoping; Zhang, Qinxian] Zhengzhou Univ, Basic Med Coll, Dept Histol & Embryol, Zhengzhou, Henan, Peoples R China.
   [Wang, Luo; Yang, Yang] Shenzhen PKU HKUST, Med Ctr, Biomed Res Inst, Shenzhen, Guangdong, Peoples R China.
C3 Zhengzhou University; Peking University; Hong Kong University of Science
   & Technology
RP Zhang, QX (通讯作者)，Zhengzhou Univ, Basic Med Coll, Dept Histol & Embryol, Zhengzhou, Henan, Peoples R China.
EM qxz53@zzu.deu.cn
RI Gao, xiao ling/GQI-2790-2022; zhu, y/IVU-7833-2023
CR Abdollahi A, 2003, J BIOL CHEM, V278, P6041, DOI 10.1074/jbc.M210361200
   Abdollahi A, 2007, J CELL PHYSIOL, V210, P16, DOI 10.1002/jcp.20835
   Bilanges B, 1999, ONCOGENE, V18, P3979, DOI 10.1038/sj.onc.1202933
   Braggio E, CLIN CANC RES, V17, P4245
   Bubner B, 2004, PLANT CELL REP, V23, P263, DOI 10.1007/s00299-004-0859-y
   Ceulemans S, 2012, METHODS MOL BIOL, V838, P311, DOI 10.1007/978-1-61779-507-7_15
   Cvetkovic D, 2004, GYNECOL ONCOL, V95, P449, DOI 10.1016/j.ygyno.2004.08.051
   D'haene B, 2010, METHODS, V50, P262, DOI 10.1016/j.ymeth.2009.12.007
   Enlund F, 2004, EUR J ORAL SCI, V112, P545, DOI 10.1111/j.1600-0722.2004.00174.x
   Leal MF, 2007, WORLD J GASTROENTERO, V13, P2568, DOI 10.3748/wjg.v13.i18.2568
   Gergics Peter, 2009, Orvosi Hetilap, V150, P2258, DOI 10.1556/OH.2009.28755
   Huang SM, 2001, ONCOGENE, V20, P2134, DOI 10.1038/sj.onc.1204298
   Kallioniemi A, 2008, CURR OPIN BIOTECH, V19, P36, DOI 10.1016/j.copbio.2007.11.004
   Kamikihara T, 2005, INT J CANCER, V115, P690, DOI 10.1002/ijc.20971
   Koy S, 2004, HEAD NECK-J SCI SPEC, V26, P338, DOI 10.1002/hed.10386
   Lambros MBK, 2009, J CLIN PATHOL, V62, P604, DOI 10.1136/jcp.2008.059675
   Liu PY, 2008, MOL CANCER RES, V6, P1204, DOI 10.1158/1541-7786.MCR-08-0123
   Nakazawa Y, 2011, CANCER RES, V71, P1146, DOI 10.1158/0008-5472.CAN-10-2695
   Poulin H, 2005, CANCER LETT, V227, P185, DOI 10.1016/j.canlet.2004.12.007
   Redon R, 2006, NATURE, V444, P444, DOI 10.1038/nature05329
   Rozenfeld-Granot G, 2002, ONCOGENE, V21, P1469, DOI 10.1038/sj.onc.1205218
   Rutherford S, 2006, CANCER LETT, V236, P309, DOI 10.1016/j.canlet.2005.05.049
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shinawi M, 2008, DRUG DISCOV TODAY, V13, P760, DOI 10.1016/j.drudis.2008.06.007
   Theodoropoulou M, 2010, MOL CELL ENDOCRINOL, V326, P60, DOI 10.1016/j.mce.2010.01.033
   Valleley EM, 2007, HUM MOL GENET, V16, P972, DOI 10.1093/hmg/ddm041
   Van Dyck F, 2007, INT J ONCOL, V30, P765
   Wu XM, 2009, SCI CHINA SER C, V52, P560, DOI 10.1007/s11427-009-0078-4
   Yu B, 2010, BRIT J DERMATOL, V163, P935, DOI 10.1111/j.1365-2133.2010.09928.x
   Yu B, 2011, ARTHRITIS RHEUM-US, V63, P3487, DOI 10.1002/art.30595
NR 30
TC 4
Z9 5
U1 0
U2 12
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 2210-7401
EI 2210-741X
J9 CLIN RES HEPATOL GAS
JI Clin. Res. Hepatol. Gastroenterol.
PD DEC
PY 2014
VL 38
IS 6
BP 744
EP 750
DI 10.1016/j.clinre.2013.06.007
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA AU3HI
UT WOS:000345502600018
PM 25091631
DA 2025-01-12
ER

PT J
AU Al-Moghrabi, N
   Nofel, A
   Al-Yousef, N
   Madkhali, S
   Bin Amer, SM
   Alaiya, A
   Shinwari, Z
   Al-Tweigeri, T
   Karakas, B
   Tulbah, A
   Aboussekhra, A
AF Al-Moghrabi, Nisreen
   Nofel, Asmaa
   Al-Yousef, Nujoud
   Madkhali, Safia
   Bin Amer, Suad M.
   Alaiya, Ayodele
   Shinwari, Zakia
   Al-Tweigeri, Taher
   Karakas, Bedri
   Tulbah, Asma
   Aboussekhra, Abdelilah
TI The molecular significance of methylated <i>BRCA1</i> promoter in white
   blood cells of cancer-free females
SO BMC CANCER
LA English
DT Article
DE Breast cancer; BRCA1; Methylation; White blood cells; Gene expression
ID BREAST-CANCER; SPORADIC BREAST; GERMLINE EPIMUTATION; OVARIAN-CANCER;
   EXPRESSION; TUMOR; GENE; DNA; RISK; HYPERMETHYLATION
AB Background: BRCA1 promoter methylation has been detected in DNA from peripheral blood cells of both breast cancer patients and cancer-free females. However, the pathological significance of this epigenetic change in white blood cells (WBC) remains an open question. In this study, we hypothesized that if constitutional BRCA1 methylation reflects an elevated risk for developing breast cancer (BC), WBC that harbor methylated BRCA1 in both cancer-free females and BC patients should exhibit similar molecular changes.
   Methods: BRCA1 promoter methylation was examined by methylation-specific PCR in WBC from 155 breast cancer patients and 143 cancer-free females. The Human Breast Cancer EpiTect Methyl II Signature PCR Array and The Human Breast Cancer RT2 Profiler (TM) PCR Array were used to study the methylation status and the expression profile of several breast cancer-related genes, respectively. In addition, we used label-free MS-based technique to study protein expression in plasma.
   Results: We have shown that 14.2% of BC patients and 9.1% of cancer-free females (carriers) harbored methylated BRCA1 promoter in their WBC. Interestingly, 66.7% of patients harbored methylated BRCA1 promoter in both WBC and tumors. Importantly, we have shown the presence of epigenetic changes in 9 other BC-related genes in WBC of both patients and carriers. Additionally, BRCA1 and 15 other important cancer-related genes were found to be differentially expressed in WBC from patients and carriers as compared to controls. Furthermore, we have shown that the carriers exhibited a unique plasma protein pattern different from those of BC patients and controls, with 10 proteins similarly differentially expressed in patients and carriers as compared to controls.
   Conclusions: The present results suggest the presence of a strong link between aberrant methylation of the BRCA1 promoter in WBC and breast cancer-related molecular changes, which indicate the potential predisposition of the carriers for developing breast cancer. This informs the potential use of the aberrant methylation of BRCA1 promoter in WBC as a powerful non-invasive molecular marker for detecting predisposed individuals at a very early age.
C1 [Al-Moghrabi, Nisreen; Nofel, Asmaa; Al-Yousef, Nujoud; Madkhali, Safia; Bin Amer, Suad M.; Alaiya, Ayodele; Shinwari, Zakia; Al-Tweigeri, Taher; Karakas, Bedri; Tulbah, Asma; Aboussekhra, Abdelilah] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh 11211, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center
RP Al-Moghrabi, N (通讯作者)，King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, POB 3354, Riyadh 11211, Saudi Arabia.
EM nisreen@kfshrc.edu.sa
RI Shinwari, Zabta/W-1882-2019; Aboussekhra, Abdelilah/JCD-8138-2023;
   Karakas, Bedri/KIH-4149-2024; , alaiya/ACA-6311-2022
OI Karakas, Bedri/0000-0002-5893-3212; , alaiya/0000-0003-2124-8550
FU National Comprehensive Plan for Science and Technology [10-BIO1353-20]
FX We are grateful to the patients and controls who participated in this
   study. The help of Zahra breast cancer association in sample collection
   is greatly appreciated. This work was supported by The National
   Comprehensive Plan for Science and Technology. Project number
   10-BIO1353-20.
CR Al-Moghrabi N, 2011, INT J ONCOL, V39, P129, DOI 10.3892/ijo.2011.1021
   Alaiya A, 2014, CANCER GENOM PROTEOM, V11, P39
   Angèle S, 2000, MUTAT RES-REV MUTAT, V462, P167, DOI 10.1016/S1383-5742(00)00034-X
   Arver B, 2000, SEMIN CANCER BIOL, V10, P271, DOI 10.1006/scbi.2000.0325
   Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Butcher DT, 2007, EUR J CANCER, V43, P210, DOI 10.1016/j.ejca.2006.09.002
   Chen JZ, 2007, J CHROMATOGR A, V1162, P117, DOI 10.1016/j.chroma.2007.03.096
   Chong S, 2007, NAT GENET, V39, P574, DOI 10.1038/ng0507-574
   Clarke RA, 1998, J CLIN PATHOL-MOL PA, V51, P224, DOI 10.1136/mp.51.4.224
   Cropley JE, 2008, PHARMACOGENOMICS, V9, P1861, DOI 10.2217/14622416.9.12.1861
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9
   Hansmann T, 2012, HUM MOL GENET, V21, P4669, DOI 10.1093/hmg/dds308
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Honda K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046908
   Horsthemke B, 2007, NAT GENET, V39, P573, DOI 10.1038/ng0507-573b
   Iwamoto T, 2011, BREAST CANCER RES TR, V129, P69, DOI 10.1007/s10549-010-1188-1
   JENSEN RA, 1989, CANCER-AM CANCER SOC, V64, P1977, DOI 10.1002/1097-0142(19891115)64:10<1977::AID-CNCR2820641002>3.0.CO;2-N
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Karakolev, 2011, ONLINE, V26, P89
   Knudson AG, 1996, J CANCER RES CLIN, V122, P135, DOI 10.1007/BF01366952
   Lee SW, 1996, NAT MED, V2, P776, DOI 10.1038/nm0796-776
   Li GZ, 2009, PROTEOMICS, V9, P1696, DOI 10.1002/pmic.200800564
   LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   PEGG AE, 1990, CANCER RES, V50, P6119
   Pejovic T, 2006, CANCER RES, V66, P9017, DOI 10.1158/0008-5472.CAN-06-0222
   Schnarr B, 2000, INT J CANCER, V89, P506, DOI 10.1002/1097-0215(20001120)89:6<506::AID-IJC7>3.0.CO;2-F
   Snell C, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1858
   Srinivasula SM, 2002, J BIOL CHEM, V277, P21119, DOI 10.1074/jbc.C200179200
   Suter CM, 2007, NAT GENET, V39, P573, DOI 10.1038/ng0507-573a
   Tamimi RM, 2011, BREAST CANCER RES TR, V128, P243, DOI 10.1007/s10549-010-1313-1
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Waha A, 1998, INT J CANCER, V78, P306, DOI 10.1002/(SICI)1097-0215(19981029)78:3<306::AID-IJC8>3.0.CO;2-Z
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wetzig A, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-54
   Wojdacz TK, 2011, DIAGN PATHOL, V6, DOI 10.1186/1746-1596-6-116
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
   Wong EM, 2011, CANCER PREV RES, V4, P23, DOI 10.1158/1940-6207.CAPR-10-0212
   Yang R, 1999, MOL CELL BIOL, V19, P2400
NR 43
TC 32
Z9 34
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD NOV 17
PY 2014
VL 14
AR 830
DI 10.1186/1471-2407-14-830
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU5OC
UT WOS:000345655400001
PM 25403427
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Mao, ZJ
   Ma, CF
   Huang, THM
   Chen, YD
   Huang, YF
AF Mao, Zijing
   Ma, Chifeng
   Huang, Tim H-M
   Chen, Yidong
   Huang, Yufei
TI BIMMER: a novel algorithm for detecting differential DNA methylation
   regions from MBDCap-seq data
SO BMC BIOINFORMATICS
LA English
DT Article
ID GENOME-WIDE IDENTIFICATION; BREAST-CANCER; GENE; CDC5L; PROGRESSION;
   INHIBITION; DENSITY
AB DNA methylation is a common epigenetic marker that regulates gene expression. A robust and cost-effective way for measuring whole genome methylation is Methyl-CpG binding domain-based capture followed by sequencing (MBDCap-seq). In this study, we proposed BIMMER, a Hidden Markov Model (HMM) for differential Methylation Regions (DMRs) identification, where HMMs were proposed to model the methylation status in normal and cancer samples in the first layer and another HMM was introduced to model the relationship between differential methylation and methylation statuses in normal and cancer samples. To carry out the prediction for BIMMER, an Expectation-Maximization algorithm was derived. BIMMER was validated on the simulated data and applied to real MBDCap-seq data of normal and cancer samples. BIMMER revealed that 8.83% of the breast cancer genome are differentially methylated and the majority are hypo-methylated in breast cancer.
C1 [Mao, Zijing; Ma, Chifeng] Univ Texas San Antonio, Dept Elect & Comp Engn, San Antonio, TX 78229 USA.
   [Huang, Tim H-M] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA.
   [Chen, Yidong; Huang, Yufei] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
   [Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA.
   [Huang, Tim H-M; Chen, Yidong] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
C3 University of Texas System; University of Texas at San Antonio (UTSA);
   University of Texas System; University of Texas Health Science Center at
   San Antonio; University of Texas System; University of Texas Health
   Science Center at San Antonio; University of Texas System; University of
   Texas Health Science Center at San Antonio; University of Texas System;
   University of Texas Health Science Center at San Antonio; Cancer Therapy
   & Research Center
RP Chen, YD (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA.
EM cheny8@uthscsa.edu; yufei.huang@utsa.edu
RI Huang, Yufei/AAU-2891-2021
FU NSF [CCF-1246073]; Qatar National Research Fund [09-897-3-235]; UTSA
   Computational System Biology Core - National Institute on Minority
   Health and Health Disparities from the National Institutes of Health
   [G12MD007591]
FX Publication of this article has been funded by NSF Grant (CCF-1246073)
   to YH and a Qatar National Research Fund (09-897-3-235) to YH and YC to
   support this project. This work also has been supported by the help of
   UTSA Computational System Biology Core, funded by the National Institute
   on Minority Health and Health Disparities (G12MD007591) from the
   National Institutes of Health.
CR Ajuh P, 2000, EMBO J, V19, P6569, DOI 10.1093/emboj/19.23.6569
   Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681
   Cheung AKL, 2011, P NATL ACAD SCI USA, V108, P8390, DOI 10.1073/pnas.1101747108
   Choi HJ, 2010, BIOCHEM BIOPH RES CO, V400, P396, DOI 10.1016/j.bbrc.2010.08.084
   Ganesh K, 2011, J BIOL CHEM, V286, P17091, DOI 10.1074/jbc.M110.208769
   Groenen PMA, 1998, GENOMICS, V49, P218, DOI 10.1006/geno.1998.5254
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   Hinton GE, 2006, NEURAL COMPUT, V18, P1527, DOI 10.1162/neco.2006.18.7.1527
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Huang Z, 2012, ONCOGENE, V31, P3709, DOI 10.1038/onc.2011.529
   Kharchenko PV, 2008, NAT BIOTECHNOL, V26, P1351, DOI 10.1038/nbt.1508
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Lewin J, 2007, INT J BIOCHEM CELL B, V39, P1539, DOI 10.1016/j.biocel.2007.03.006
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lu XY, 2008, MOL CANCER RES, V6, P937, DOI 10.1158/1541-7786.MCR-07-2115
   Luo RZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085592
   Malentacchi F, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp383
   Mitsui T, 2011, MOL CELL ENDOCRINOL, V345, P68, DOI 10.1016/j.mce.2011.07.021
   Nair NU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039573
   Obazee O, 2013, BREAST CANCER RES TR, V138, P543, DOI 10.1007/s10549-013-2448-7
   Qin ZHS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-369
   Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110
   Seifert M, 2012, BIOINFORMATICS, V28, P2930, DOI 10.1093/bioinformatics/bts562
   Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003
   Taslim C, 2009, BIOINFORMATICS, V25, P2334, DOI 10.1093/bioinformatics/btp384
   Villa-Moruzzi E, 2013, MOL CELL BIOCHEM, V375, P151, DOI 10.1007/s11010-012-1537-y
   Wakefield A, 2013, CANCER RES, V73, P745, DOI 10.1158/0008-5472.CAN-12-1321
   Xu H, 2008, BIOINFORMATICS, V24, P2344, DOI 10.1093/bioinformatics/btn402
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yudkin HL, 1965, CHANNEL STATE TESTIN, V126
   Zhang L.S., 2014, Pathol Oncol Res
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 32
TC 1
Z9 2
U1 1
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2105
J9 BMC BIOINFORMATICS
JI BMC Bioinformatics
PD NOV 6
PY 2014
VL 15
SU 12
AR S6
DI 10.1186/1471-2105-15-S12-S6
PG 12
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Mathematical & Computational Biology
GA AU6AR
UT WOS:000345685000006
PM 25474268
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Yang, YB
   Li, JH
   Zhao, ZX
   Zang, AM
   Jia, YC
   Shang, YH
   Jiao, MJ
AF Yang Yongbin
   Li Jinghua
   Zhao Zhanxue
   Zang Aimin
   Jia Youchao
   Shang Yanhong
   Jiao Manjing
TI TES was epigenetically silenced and suppressed the
   epithelial-mesenchymal transition in breast cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE Breast cancer; The TES gene; Tumor suppressor; Hypermethylation; EMT
ID FOCAL ADHESION PROTEIN; TUMOR-SUPPRESSOR; METHYLATION STATUS;
   DOWN-REGULATION; GENE; REGION; HYPERMETHYLATION; FRA7G; DEMETHYLATION;
   STATISTICS
AB The TES gene was frequently lost in breast cancer, which could inhibit tumor invasion and the formation of distant metastasis. However, the underlying mechanisms remain unknown yet. In the present study, we aimed to investigate how TES was silenced and its roles in EMT-the key step for tumor metastasis. Real-time polymerase chain reaction (PCR) and Western blot were used to detect the mRNA and protein expression of target genes; the status of TES promoter was determined by methylation-specific PCR and subsequently, DNA sequencing. Overexpression or downregulation of TES was achieved by pcDNA3.1-TES or shRNA-TES transfection. Cellular adhesion and migration were investigated by the adhesion and Transwell assays. Morphological changes of breast cancer cells were observed under the optical microscope. The Rho A activity was measured using a commercial kit, and its roles in TES-manipulated EMT were determined by real-time PCR and Western blot. The 42.3 % (33/78) breast cancer tissues presented hypermethylation of the TES gene, whereas only 2 (2.6 %) non-malignant cases were hypermethylated (P < 0.001). Moreover, TES hypermethylation was significantly correlated with larger tumor diameter (P = 0.03) and lympho node metastasis (P = 0.024). In primary cultured breast cancer cells, the demethylation treatment using 5-aza-dC notably restored the expression of TES. In vitro, overexpression of TES enhanced cellular adhesion inhibited migration and suppressed EMT, while downregulation of TES impaired cellular adhesion, promoted migration, and enhanced EMT. TES overexpression also activated the Rho A signal, which is a critical factor for the effects of TES on the EMT procedure. We firstly proved that frequent loss of TES in breast cancer was caused by promoter hypermethylation, which was correlated with poor prognosis. In vitro, TES enhanced cellular adhesion, suppressed tumor migration, and inhibited EMT. Moreover, the Rho A pathway was critical for the effects of TES on EMT, which can be blocked by the Rho A inhibitor. Therefore, we propose restoration of TES as a potent strategy for breast cancer therapy.
C1 [Yang Yongbin; Zhao Zhanxue] Hebei Univ, Hlth Sci Ctr, Baoding 071000, Hebei Province, Peoples R China.
   [Li Jinghua; Zang Aimin; Jia Youchao; Shang Yanhong] Hebei Univ, Affiliated Hosp, Dept Oncol, Baoding 071000, Hebei Province, Peoples R China.
   [Jiao Manjing] Zhuozhou City Hosp, Clin Lab, Zhuozhou 072750, Hebei Province, Peoples R China.
C3 Hebei University; Hebei University
RP Shang, YH (通讯作者)，Hebei Univ, Affiliated Hosp, Dept Oncol, Baoding 071000, Hebei Province, Peoples R China.
EM wxrfdong@gmail.com
RI Li, Jinghua/AGS-4025-2022
FU Hebei University, Administration of Traditional Chinese Medicine of
   Hebei Province, Research Center for Eco-Environmental Sciences of the
   Chinese Academy of Sciences [2012A1002, 2011213, KF2010-17, 2008071]
FX This work was supported by the grants from the Hebei University,
   Administration of Traditional Chinese Medicine of Hebei Province,
   Research Center for Eco-Environmental Sciences of the Chinese Academy of
   Sciences (Nos. 2012A1002,2011213, KF2010-17, and 2008071).
CR Askari M, 2013, MOL CELL BIOCHEM, V382, P19, DOI 10.1007/s11010-013-1696-5
   Hirata BKB, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/513158
   Bastid J, 2012, CANCER METAST REV, V31, P277, DOI 10.1007/s10555-011-9344-6
   Chêne L, 2004, INT J CANCER, V111, P798, DOI 10.1002/ijc.20337
   Choi Jae Duk, 2013, Genomics & Informatics, V11, P164, DOI 10.5808/GI.2013.11.4.164
   Coutts AS, 2003, J CELL SCI, V116, P897, DOI 10.1242/jcs.00278
   Drusco A, 2005, P NATL ACAD SCI USA, V102, P10947, DOI 10.1073/pnas.0504934102
   Garvalov BK, 2003, J CELL BIOL, V161, P33, DOI 10.1083/jcb.200211015
   Griffith E, 2005, CELL MOTIL CYTOSKEL, V60, P140, DOI 10.1002/cm.20052
   Griffith E, 2004, CELL MOTIL CYTOSKEL, V57, P133, DOI 10.1002/cm.10162
   Grünert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175
   Gunduz E, 2009, ARCH OTOLARYNGOL, V135, P254, DOI 10.1001/archoto.2008.560
   Hagrass HA, 2014, MOL BIOL REP, V41, P57, DOI 10.1007/s11033-013-2837-3
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T
   Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Kang HF, 2013, ONCOTARGETS THER, V6, P411, DOI 10.2147/OTT.S43744
   Minafra Luigi, 2012, BMC Res Notes, V5, P343, DOI 10.1186/1756-0500-5-343
   Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805
   Poortmans P, 2013, REP PRACT ONCOL RADI, V18, P345, DOI 10.1016/j.rpor.2013.08.002
   Pulling LC, 2009, CARCINOGENESIS, V30, P2023, DOI 10.1093/carcin/bgp276
   Qiu HF, 2010, CANCER SCI, V101, P1255, DOI 10.1111/j.1349-7006.2010.01497.x
   Rivenbark AG, 2013, AM J PATHOL, V183, P1113, DOI 10.1016/j.ajpath.2013.08.002
   Sarkar S, 2013, EPIGENOMICS-UK, V5, P87, DOI [10.2217/EPI.12.68, 10.2217/epi.12.68]
   Sarti M, 2005, CLIN CANCER RES, V11, P806
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433
   Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0
   Zhu J, 2012, CANCER SCI, V103, P2092, DOI 10.1111/cas.12020
NR 34
TC 6
Z9 7
U1 0
U2 9
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD NOV
PY 2014
VL 35
IS 11
BP 11381
EP 11389
DI 10.1007/s13277-014-2472-1
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU1YJ
UT WOS:000345413100091
PM 25119600
DA 2025-01-12
ER

PT J
AU Rezk, NS
   Shehab, AA
   Abd El-Mageed, AI
   El-Shinawi, M
   El Maraghy, MO
AF Rezk, Nasser Sadek
   Shehab, Abeer Al Sayed
   Abd El-Mageed, Abeer Ibrahim
   El-Shinawi, Mohamed
   El Maraghy, Mohamed Omar
TI Assessment of Methylation of RASSF1A Gene in Circulating Tumor DNA of
   Breast Cancer Patients by Methylation-Specific Polymerase Chain Reaction
SO LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION
LA English
DT Article
AB Background: The aim of the present study was to evaluate the methylation status of RASSF1A tumor suppressor gene in circulating tumor DNA in sera of a group of Egyptian breast cancer patients by methylation-specific PCR. Methods: 50 subjects were included: 36 breast cancer patients and 14 healthy controls. Following breast examination, imaging studies and tissue biopsies (for patients group), CA 15-3 was assessed by electrochemiluminescence and RASSF1A gene methylation status was evaluated by methylation-specific PCR. Results: RASSF1A gene was methylated in 17/36 (47.2%) of patients and in none of the 14 control samples. Heterozygous pattern of RASSF1A gene methylation was detected in 2 patient samples. There was a significant association between tumor stage subgroups and each of CA 15-3 serum levels and RASSF1A gene methylation. Conclusion: RASSF1A gene methylation is a potential epigenetic marker for breast cancer. Further improvement of its screening efficiency might be reached by the use of more than one gene in combination. This gene is a likely candidate for tumor demethylation therapy.
C1 [Rezk, Nasser Sadek; Shehab, Abeer Al Sayed; Abd El-Mageed, Abeer Ibrahim; El Maraghy, Mohamed Omar] Ain Shams Univ, Fac Med, Dept Clin Pathol, Cairo, Egypt.
C3 Egyptian Knowledge Bank (EKB); Ain Shams University
RP Rezk, NS (通讯作者)，Ain Shams Univ, Fac Med, Dept Clin Pathol, Cairo, Egypt.
EM abeeribrahim27@yahoo.com
RI ; El Maraghy, Mohamed/G-3159-2013
OI El-Shinawi, Mohamed/0000-0003-3645-2343; El Maraghy,
   Mohamed/0000-0002-9707-2611
NR 0
TC 1
Z9 1
U1 0
U2 5
PU MARSLAND PRESS
PI LANSING
PA PO BOX 21126, LANSING, MI 48909 USA
SN 1097-8135
J9 LIFE SCI J
JI Life Sci. J.
PY 2013
VL 10
IS 1
BP 1945
EP 1951
PG 7
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA 199MR
UT WOS:000322999200059
DA 2025-01-12
ER

PT J
AU Qian, J
   Chen, XX
   Qian, W
   Yang, J
   Wen, XM
   Ma, JC
   Deng, ZQ
   Qian, Z
   Zhang, YY
   Lin, J
AF Qian, Jun
   Chen, Xing-xing
   Qian, Wei
   Yang, Jing
   Wen, Xiang-mei
   Ma, Ji-chun
   Deng, Zhao-qun
   Qian, Zhen
   Zhang, Ying-ying
   Lin, Jiang
TI Aberrant hypermethylation of <i>CTNNA1</i> gene is associated with
   higher IPSS risk in patients with myelodysplastic syndrome
SO CLINICAL CHEMISTRY AND LABORATORY MEDICINE
LA English
DT Article
DE CTNNA1; methylation; myelodysplastic syndrome
ID ALPHA-CATENIN GENE; E-CADHERIN; PROGNOSTIC VALUE; GAMMA-CATENIN;
   BETA-CATENIN; TUMOR-SUPPRESSOR; BREAST-CANCER; EXPRESSION; EPIGENETICS;
   MOLECULES
AB Background: CTNNA1 gene is a putative tumor suppressor for its roles in inhibiting proliferation and promoting apoptosis. Aberrant expression of CTNNA1 is regulated by epigenetic mechanisms including both promoter methylation and histone deacetylation in hematopoietic malignancies. However, the clinical relevance of CTNNA1 methylation remains rarely known in myelodysplastic syndrome (MDS).
   Methods: We investigated the methylation status of CTNNA1 promoter using methylation-specific PCR (MSP) and analyzed its clinical significance in Chinese MDS patients.
   Results: Aberrant hypermethylation of CTNNA1 gene was identified in 22% (18/83) of the patients. CTNNA1 expression was significantly correlated with promoter methylation status (p<0.05). No significant differences were observed in the age, sex, and blood parameters between patients with and without CTNNA1 hypermethylation (p>0.05). The frequency of CTNNA1 hypermethylation was significantly higher in patients with isolated del(5q) (3/4, 75%) than those with other abnormal karyotypes (4/23, 17%) and also than those with normal karyotypes (11/54, 20%) (p=0.042 and 0.040, respectively). The patients with higher IPSS risks (Int-2/High) had significantly increased incidence of CTNNA1 methylation than those with lower risks (Low/Int-1) (36% vs. 15%, p=0.049). Although the estimated 50% survival time of the CTNNA1-methylated group [median 13 months, 95% confidence interval (CI) 3-22 months] was shorter than that of CTNNA1-unmethylated group (median 24 months, 95% CI 7-41 months), the difference was not statistically significant (p=0.330).
   Conclusions: Our data confirm that aberrant CTNNA1 methylation is a common event and is associated with higher IPSS risk in MDS.
C1 [Qian, Wei; Wen, Xiang-mei; Ma, Ji-chun; Deng, Zhao-qun; Lin, Jiang] Jiangsu Univ, Affiliated Peoples Hosp, Lab Ctr, Zhenjiang 212002, Jiangsu, Peoples R China.
   [Qian, Jun; Chen, Xing-xing; Yang, Jing; Qian, Zhen; Zhang, Ying-ying] Jiangsu Univ, Affiliated Peoples Hosp, Dept Hematol, Zhenjiang 212002, Jiangsu, Peoples R China.
C3 Jiangsu University; Jiangsu University
RP Lin, J (通讯作者)，Jiangsu Univ, Affiliated Peoples Hosp, Lab Ctr, 8 Dianli Rd, Zhenjiang 212002, Jiangsu, Peoples R China.
EM dwqian@yahoo.com; linjiangmail@sina.com
RI Yang, Jing/HZJ-2451-2023; zhang, ying/HPC-0477-2023
FU National Natural Science Foundation of China [81270630, 81172592];
   Science and Technology Special Project in Clinical Medicine of Jiangsu
   Province [BL2012056]; 333 Project of Jiangsu Province [BRA2011085,
   BRA2013136]; Science and Technology Infrastructure Program of Zhenjiang
   [SS2012003]; Social Development Foundation of Zhenjiang [SH2013042,
   SH2013082]; Innovation Project of Graduate Student in Jiangsu Province's
   Ordinary University [CXLX12_0673]; Jiangsu Government Scholarship for
   Overseas Studies
FX This study was supported by National Natural Science Foundation of China
   (81270630, 81172592), Science and Technology Special Project in Clinical
   Medicine of Jiangsu Province (BL2012056), 333 Project of Jiangsu
   Province (BRA2011085, BRA2013136), Science and Technology Infrastructure
   Program of Zhenjiang (SS2012003), Social Development Foundation of
   Zhenjiang (SH2013042, SH2013082), the Innovation Project of Graduate
   Student in Jiangsu Province's Ordinary University (CXLX12_0673), and
   Jiangsu Government Scholarship for Overseas Studies.
CR Aaltomaa S, 2004, ANTICANCER RES, V24, P2407
   [Anonymous], WHO CLASSIFICATION T
   BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb02771.x
   Böhm J, 2000, J CLIN ENDOCR METAB, V85, P4806, DOI 10.1210/jc.85.12.4806
   BOULTWOOD J, 1994, BLOOD, V84, P3253
   Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501
   Desmond JC, 2007, LEUKEMIA, V21, P1026, DOI 10.1038/sj.leu.2404611
   Eisenmann KM, 2009, ONCOGENE, V28, P3429, DOI 10.1038/onc.2009.207
   Endo K, 2000, HUM PATHOL, V31, P558, DOI 10.1053/hp.2000.6683
   Estey EH, 2013, LEUKEMIA, V27, P1803, DOI 10.1038/leu.2013.173
   EWING CM, 1995, CANCER RES, V55, P4813
   Fu CT, 2010, BLOOD, V115, P4715, DOI 10.1182/blood-2009-11-255778
   Greenberg P, 1997, BLOOD, V89, P2079, DOI 10.1182/blood.V89.6.2079
   Griffiths EA, 2010, EPIGENETICS-US, V5, P590, DOI 10.4161/epi.5.7.12558
   Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083
   Horrigan SK, 2000, BLOOD, V95, P2372, DOI 10.1182/blood.V95.7.2372.007k20_2372_2377
   Issa JPJ, 2013, BLOOD, V121, P3811, DOI 10.1182/blood-2013-02-451757
   Itzykson R, 2014, LEUKEMIA, V28, P497, DOI 10.1038/leu.2013.343
   Kashibuchi K, 2007, INT J UROL, V14, P789, DOI 10.1111/j.1442-2042.2007.01830.x
   Lee YC, 2002, J THORAC CARDIOV SUR, V123, P502, DOI 10.1067/mtc.2002.119334
   Lin J, 2012, ANN HEMATOL, V91, P519, DOI 10.1007/s00277-011-1352-7
   Lin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026906
   Liu TX, 2007, NAT MED, V13, P78, DOI 10.1038/nm1512
   MORTON RA, 1993, CANCER RES, V53, P3585
   Nakopoulou L, 2002, HISTOPATHOLOGY, V40, P536, DOI 10.1046/j.1365-2559.2002.01392.x
   Piao HL, 2014, NAT CELL BIOL, V16, P245, DOI 10.1038/ncb2909
   Qian J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045760
   Ropponen KM, 1999, J CLIN PATHOL, V52, P10, DOI 10.1136/jcp.52.1.10
   Saito T, 2000, J PATHOL, V192, P342, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH705>3.0.CO;2-R
   Santini V, 2013, CRIT REV ONCOL HEMAT, V88, P231, DOI 10.1016/j.critrevonc.2013.06.004
   Van Aken E, 2001, VIRCHOWS ARCH, V439, P725, DOI 10.1007/S004280100516
   van Oort IM, 2007, PROSTATE, V67, P1432, DOI 10.1002/pros.20626
   Yang J, 2013, GENET TEST MOL BIOMA, V17, P342, DOI 10.1089/gtmb.2012.0364
   Ye Y, 2009, CANCER RES, V69, P8482, DOI 10.1158/0008-5472.CAN-09-1153
NR 34
TC 5
Z9 6
U1 0
U2 5
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1434-6621
EI 1437-4331
J9 CLIN CHEM LAB MED
JI Clin. Chem. Lab. Med.
PD DEC
PY 2014
VL 52
IS 12
BP 1859
EP 1865
DI 10.1515/cclm-2014-0446
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA AT6BK
UT WOS:000345023500030
PM 25153418
DA 2025-01-12
ER

PT J
AU Matsuba, S
   Niwa, S
   Muraki, K
   Kanatsuka, S
   Nakazono, Y
   Hatano, N
   Fujii, M
   Zhan, P
   Suzuki, T
   Ohya, S
AF Matsuba, Sayo
   Niwa, Satomi
   Muraki, Katsuhiko
   Kanatsuka, Saki
   Nakazono, Yurika
   Hatano, Noriyuki
   Fujii, Masanori
   Zhan, Peng
   Suzuki, Takayoshi
   Ohya, Susumu
TI Downregulation of Ca<SUP>2+</SUP>-Activated Cl<SUP>-</SUP> Channel
   TMEM16A by the Inhibition of Histone Deacetylase in TMEM16A-Expressing
   Cancer Cells
SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
LA English
DT Article
ID K+-CHANNEL; THERAPEUTIC TARGET; DNA METHYLATION; BREAST-CANCER;
   EXPRESSION; HDAC3; ANO1; GENE; PROLIFERATION; ANGIOGENESIS
AB The Ca2+-activated Cl- channel transmembrane proteins with unknown function 16 A (TMEM16A; also known as anoctamin 1 or discovered on gastrointestinal stromal tumor 1) plays an important role in facilitating the cell growth and metastasis of TMEM16A-expressing cancer cells. Histone deacetylase (HDAC) inhibitors (HDACi) are useful agents for cancer therapy, but it remains unclear whether ion channels are epigenetically regulated by them. Using real-time polymerase chain reaction, Western blot analysis, and whole-cell patch-clamp assays, we found a significant decrease in TMEM16A expression and its functional activity was induced by the vorinostat, a pan-HDACi in TMEM16A-expressing human cancer cell lines, the prostatic cancer cell line PC-3, and the breast cancer cell line YMB-1. TMEM16A downregulation was not induced by the chemotherapy drug paclitaxel in either cell type. Pharmacologic blockade of HDAC3 by 1 mu M T247 [N-(2-aminophenyl)-4-[1-(2-thiophen-3-ylethyl)-1H-[1],[2],[3]triazol-4-yl]benzamide], a HDAC3-selective HDACi, elicited a large decrease in TMEM16A expression and functional activity in both cell types, and pharmacologic blockade of HDAC2 by AATB [4-(acetylamino)N-[2-amino-5-(2-thienyl)phenyl]-benzamide; 300 nM] elicited partial inhibition of TMEM16A expression (similar to 40%) in both. Pharmacologic blockade of HDAC1 or HDAC6 did not elicit any significant change in TMEM16A expression, respectively. In addition, inhibition of HDAC3 induced by small interfering RNA elicited a large decrease in TMEM16A transcripts in both cell types. Taken together, in malignancies with a frequent gene amplification of TMEM16A, HDAC3 inhibition may exert suppressive effects on cancer cell viability via downregulation of TMEM16A.
C1 [Matsuba, Sayo; Niwa, Satomi; Kanatsuka, Saki; Nakazono, Yurika; Fujii, Masanori; Ohya, Susumu] Kyoto Pharmaceut Univ, Dept Pharmacol, Div Pathol Sci, Kyoto 6078414, Japan.
   [Muraki, Katsuhiko; Hatano, Noriyuki] Aichi Gakuin Univ, Sch Pharm, Lab Cellular Pharmacol, Nagoya, Aichi 464, Japan.
   [Zhan, Peng; Suzuki, Takayoshi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Kyoto, Japan.
C3 Kyoto Pharmaceutical University; Aichi Gakuin University; Kyoto
   Prefectural University of Medicine
RP Ohya, S (通讯作者)，Kyoto Pharmaceut Univ, Dept Pharmacol, Div Pathol Sci, Yamashina Ku, 5 Misasagi Nakauchi, Kyoto 6078414, Japan.
EM sohya@mb.kyoto-phu.ac.jp
RI Ohya, Susumu/AAB-3618-2020; FUJII, MASANORI/KUD-0922-2024
OI FUJII, MASANORI/0000-0003-2050-4567
FU Japan Society for the Promotion of Science [25460111]; Promotion and
   Mutual Aid Cooperation for Private Schools of Japan (Kyoto
   Pharmaceutical University); Promotion and Mutual Aid Cooperation for
   Private Schools of Japan (Aichi-Gakuin University); Mochida Memorial
   Foundation for Medical and Pharmaceutical Research; Uehara Memorial
   Foundation; Grants-in-Aid for Scientific Research [25460111] Funding
   Source: KAKEN
FX This work was supported by a Grant-in-Aid for Scientific Research from
   the Japan Society for the Promotion of Science (No. 25460111); a
   research grant from the Promotion and Mutual Aid Cooperation for Private
   Schools of Japan (Kyoto Pharmaceutical University and Aichi-Gakuin
   University); Mochida Memorial Foundation for Medical and Pharmaceutical
   Research; and Uehara Memorial Foundation (to S.O.).
CR AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6
   Alenghat T, 2013, NATURE, V504, P153, DOI 10.1038/nature12687
   Ayoub C, 2010, BRIT J CANCER, V103, P715, DOI 10.1038/sj.bjc.6605823
   Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110
   Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518
   Chen XF, 2012, P NATL ACAD SCI USA, V109, pE2865, DOI 10.1073/pnas.1121131109
   Cheong A, 2005, MOL CELL, V20, P45, DOI 10.1016/j.molcel.2005.08.030
   Chini CCS, 2010, J BIOL CHEM, V285, P40830, DOI 10.1074/jbc.M110.153270
   Chou CJ, 2008, J BIOL CHEM, V283, P35402, DOI 10.1074/jbc.M807045200
   Duran C, 2011, ACTA PHARMACOL SIN, V32, P685, DOI 10.1038/aps.2011.48
   Duvvuri U, 2012, CANCER RES, V72, P3270, DOI 10.1158/0008-5472.CAN-12-0475-T
   Ellis L, 2009, CANCER LETT, V280, P145, DOI 10.1016/j.canlet.2008.11.012
   Gui CY, 2004, P NATL ACAD SCI USA, V101, P1241, DOI 10.1073/pnas.0307708100
   Hatano N, 2013, AM J PHYSIOL-CELL PH, V304, pC354, DOI 10.1152/ajpcell.00096.2012
   Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799
   Itoh Y, 2007, J MED CHEM, V50, P5425, DOI 10.1021/jm7009217
   Iwamoto M, 2013, CANCER CHEMOTH PHARM, V72, P493, DOI 10.1007/s00280-013-2220-z
   Jacobsen KS, 2013, PFLUG ARCH EUR J PHY, V465, P1753, DOI 10.1007/s00424-013-1315-z
   Kim HC, 2010, CELL MOL LIFE SCI, V67, P3499, DOI 10.1007/s00018-010-0388-5
   Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507
   Komatsu Y, 2006, ANTICANCER RES, V26, P2029
   Lang F, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0108
   Li JY, 2013, CURR MED CHEM, V20, P1858
   Lin HX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020362
   Liu W, 2012, CANCER LETT, V326, P41, DOI 10.1016/j.canlet.2012.07.015
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   Martin-Trujillo A, 2011, EPIGENETICS-US, V6, P1236, DOI 10.4161/epi.6.10.17654
   Methot JL, 2008, BIOORG MED CHEM LETT, V18, P973, DOI 10.1016/j.bmcl.2007.12.031
   Miao LJ, 2014, TUMOR BIOL, V35, P7097, DOI 10.1007/s13277-014-1961-6
   Minami J, 2014, LEUKEMIA, V28, P680, DOI 10.1038/leu.2013.231
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Munster PN, 2009, BRIT J CANCER, V101, P1044, DOI 10.1038/sj.bjc.6605293
   Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2
   Nwaobi SE, 2014, GLIA, V62, P411, DOI 10.1002/glia.22613
   Ohshiro J, 2014, BIOCHEM BIOPH RES CO, V443, P518, DOI 10.1016/j.bbrc.2013.11.117
   Ohya S, 2013, BRIT J PHARMACOL, V169, P1011, DOI 10.1111/bph.12215
   Ohya S, 2011, J PHARMACOL EXP THER, V338, P528, DOI 10.1124/jpet.111.182782
   Ohya S, 2009, J PHARMACOL SCI, V109, P148, DOI 10.1254/jphs.08208SC
   Pardo LA, 2014, NAT REV CANCER, V14, P39, DOI 10.1038/nrc3635
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Ruiz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043265
   Schroeder BC, 2008, CELL, V134, P1019, DOI 10.1016/j.cell.2008.09.003
   Sheridan JT, 2011, J BIOL CHEM, V286, P1381, DOI 10.1074/jbc.M110.174847
   Suzuki T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068669
   Taylor P, 2012, MOL CANCER THER, V11, P1713, DOI 10.1158/1535-7163.MCT-11-0990
   Uchida H, 2010, NEUROSCIENCE, V166, P1, DOI 10.1016/j.neuroscience.2009.12.021
   Venkatraman A, 2014, HUM MOL GENET, V23, P3733, DOI 10.1093/hmg/ddu081
   Yamazaki D, 2006, J BIOL CHEM, V281, P38430, DOI 10.1074/jbc.M603917200
   Yang M, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00185
   Yang YD, 2008, NATURE, V455, P1210, DOI 10.1038/nature07313
   Zhu J, 2013, BRAIN RES, V1520, P15, DOI 10.1016/j.brainres.2013.04.061
NR 51
TC 35
Z9 38
U1 0
U2 13
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0022-3565
EI 1521-0103
J9 J PHARMACOL EXP THER
JI J. Pharmacol. Exp. Ther.
PD DEC
PY 2014
VL 351
IS 3
BP 510
EP 518
DI 10.1124/jpet.114.217315
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AT9AK
UT WOS:000345219800004
PM 25232193
DA 2025-01-12
ER

PT J
AU Zhang, Q
   Padi, SKR
   Tindall, DJ
   Guo, B
AF Zhang, Q.
   Padi, S. K. R.
   Tindall, D. J.
   Guo, B.
TI Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic
   miR-31
SO CELL DEATH & DISEASE
LA English
DT Article
ID PROSTATE-CANCER PROGRESSION; HISTONE METHYLTRANSFERASE; DOWN-REGULATION;
   ENHANCER-OF-ZESTE-HOMOLOG-2 GENE; ANDROGEN RECEPTOR; CARCINOMA-CELLS;
   GASTRIC-CANCER; BREAST-CANCER; PROLIFERATION; EXPRESSION
AB Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of the polycomb repressive complex 2 and suppresses gene expression by catalyzing histone H3 methylation on lysine 27. EZH2 is overexpressed in metastatic prostate cancer and has been shown to promote cell proliferation and metastasis. Here we show that EZH2 also suppresses prostate cancer apoptosis by coordinating the epigenetic silencing of two proapoptotic microRNAs (miRNA), miR-205 and miR-31. We previously reported that miR-205 promotes apoptosis by targeting antiapoptotic protein Bcl-w and miR-205 is silenced in prostate cancer through promoter methylation. In this study, we found that EZH2 suppresses miR-31 expression by trimethylation of lysine 27 on histone 3 on the miR-31 promoter. SiRNA knockdown of EZH2 increased miR-31 expression and decreased the antiapoptotic protein E2F6 (E2F transcription factor 6) (a target of miR-31), resulting in the sensitization of prostate cancer cells to docetaxel-induced apoptosis. Conversely, overexpression of EZH2 blocked docetaxel-induced apoptosis. We further demonstrated that miR-205 silencing is linked to miR-31 silencing through EZH2. Suppression of miR-205 with an miRNA inhibitor caused an increase of EZH2 protein, which in turn inhibited miR-31 expression. Conversely, overexpression of miR-205 decreased EZH2 protein and increased miR-31 expression. In paired human prostate cancer specimens and adjacent normal tissues, we observed that the decrease of miR-205 expression correlated with EZH2 overexpression and miR-31 silencing. Thus, EZH2 integrates the epigenetic silencing of miR-205 and miR-31 to confer resistance to chemotherapy-induced apoptosis.
C1 [Zhang, Q.; Padi, S. K. R.; Guo, B.] N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Fargo, ND 58108 USA.
   [Tindall, D. J.] Coll Med, Mayo Clin, Dept Urol Biochem & Mol Biol, Rochester, MN 55905 USA.
C3 North Dakota State University Fargo; Mayo Clinic
RP Guo, B (通讯作者)，N Dakota State Univ, Coll Pharm, Dept Pharmaceut Sci, Fargo, ND 58108 USA.
EM Bin.Guo@ndsu.edu
RI Guo, Bin/AAA-2445-2019; Padi, Sathish/L-1587-2019
OI Padi, Sathish K. R./0000-0002-5526-4287; GUO, BIN/0000-0003-3296-9177
FU NIH Grants from the National Center for Research Resources [2P20
   RR015566, P30 GM103332-01]
FX We thank Tao Wang for providing help with real-time PCR studies. This
   publication and the use of the Core Biology Facility were made possible
   by NIH Grants 2P20 RR015566 and P30 GM103332-01 from the National Center
   for Research Resources.
CR Alimova I, 2012, INT J CANCER, V131, P1800, DOI 10.1002/ijc.27455
   Asangani IA, 2012, ONCOTARGET, V3, P1011, DOI 10.18632/oncotarget.622
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Berezovska OP, 2006, CELL CYCLE, V5, P1886
   Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Deb G, 2013, EPIGENETICS-US, V8, P464, DOI 10.4161/epi.24532
   Debes JD, 2003, CANCER RES, V63, P7638
   Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894
   Hermeking H, 2010, CELL DEATH DIFFER, V17, P193, DOI 10.1038/cdd.2009.56
   Holland D, 2008, CANCER RES, V68, P9964, DOI 10.1158/0008-5472.CAN-08-1134
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Koh CM, 2011, ONCOTARGET, V2, P669, DOI 10.18632/oncotarget.327
   Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021
   Li KQ, 2013, INT J MOL SCI, V14, P11981, DOI 10.3390/ijms140611981
   Li X, 2009, BR J HAEMATOL
   Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076
   Ridinger-Saison M, 2013, CELL DEATH DIFFER, V20, P1268, DOI 10.1038/cdd.2013.88
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Velichutina I, 2010, BLOOD, V116, P5247, DOI 10.1182/blood-2010-04-280149
   Verdoodt B, 2013, INT J ONCOL, V43, P307, DOI 10.3892/ijo.2013.1915
   Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683
   Wang YJ, 2014, BRIT J PHARMACOL, V171, P618, DOI 10.1111/bph.12501
   Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162
   Xie LM, 2014, MOL CELL BIOCHEM, V392, P153, DOI 10.1007/s11010-014-2028-0
   Xu YH, 2013, ONCOL REP, V29, P2019, DOI 10.3892/or.2013.2338
   Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015
   Yang WW, 2007, CELL DEATH DIFFER, V14, P807, DOI 10.1038/sj.cdd.4402062
   Yang WW, 2008, MOL BIOL CELL, V19, P3691, DOI 10.1091/mbc.E08-02-0171
   Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018
   Zhang J, 2009, BLOOD, V113, P4586, DOI 10.1182/blood-2008-09-178186
   Zhou JB, 2011, BLOOD, V118, P2830, DOI 10.1182/blood-2010-07-294827
NR 43
TC 72
Z9 77
U1 0
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD OCT
PY 2014
VL 5
AR e1486
DI 10.1038/cddis.2014.454
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AT5PG
UT WOS:000344994000058
PM 25341040
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wu, PC
   Lu, JW
   Yang, JY
   Lin, IH
   Ou, DL
   Lin, YH
   Chou, KH
   Huang, WF
   Wang, WP
   Huang, YL
   Hsu, C
   Lin, LI
   Lin, YM
   Shen, CKJ
   Tzeng, TY
AF Wu, Pei-Chun
   Lu, Jeng-Wei
   Yang, Jer-Yen
   Lin, I-Hsuan
   Ou, Da-Liang
   Lin, Yu-Hsiang
   Chou, Kuan-Hsien
   Huang, Wen-Feng
   Wang, Wan-Ping
   Huang, Yih-Leh
   Hsu, Chiun
   Lin, Liang-In
   Lin, Yueh-Min
   Shen, C. -K. James
   Tzeng, Tsai-Yu
TI H3K9 Histone Methyltransferase, KMT1E/SETDB1, Cooperates with the
   SMAD2/3 Pathway to Suppress Lung Cancer Metastasis
SO CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR-BETA; BREAST-CANCER; ANNEXIN A2; INCREASED EXPRESSION;
   CELL-ADHESION; INVASION; PHOSPHORYLATION; PROGRESSION; PROGNOSIS; SETDB1
AB Aberrant histone methylation is a frequent event during tumor development and progression. KMT1E (also known as SETDB1) is a histone H3K9 methyltransferase that contributes to epigenetic silencing of both oncogenes and tumor suppressor genes in cancer cells. In this report, we demonstrate that KMT1E acts as a metastasis suppressor that is strongly downregulated in highly metastatic lung cancer cells. Restoring KMT1E expression in this setting suppressed filopodia formation, migration, and invasive behavior. Conversely, loss of KMT1E in lung cancer cells with limited metastatic potential promoted migration in vitro and restored metastatic prowess in vivo. Mechanistic investigations indicated that KMT1E cooperates with the TGF beta-regulated complex SMAD2/3 to repress metastasis through ANXA2. Together, our findings defined an essential role for the KMT1E/SMAD2/3 repressor complex in TGF beta-mediated lung cancer metastasis. (C)2014 AACR.
C1 [Wu, Pei-Chun; Lin, I-Hsuan; Lin, Yu-Hsiang; Chou, Kuan-Hsien; Huang, Wen-Feng; Tzeng, Tsai-Yu] Natl Yang Ming Univ, VYM Genome Res Ctr, Taipei 112, Taiwan.
   [Lu, Jeng-Wei; Lin, Liang-In] Natl Taiwan Univ, Dept Clin Lab Sci & Med Biotechnol, Taipei 10764, Taiwan.
   [Yang, Jer-Yen] Purdue Univ, Coll Vet Med, Ctr Canc Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
   [Ou, Da-Liang; Hsu, Chiun] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei 10764, Taiwan.
   [Ou, Da-Liang; Hsu, Chiun] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan.
   [Wang, Wan-Ping] Natl Hlth Res Inst, Inst Cellular & Syst Med, Zhunan, Taiwan.
   [Huang, Yih-Leh] Buddhist Dalin Tzu Chi Hosp, Dept Med Res, Chiayi, Taiwan.
   [Lin, Liang-In] Natl Taiwan Univ Hosp, Dept Lab Med, Taipei, Taiwan.
   [Lin, Yueh-Min] Changhua Christian Hosp, Dept Pathol, Changhua, Taiwan.
   [Shen, C. -K. James] Acad Sinica, Inst Mol Biol, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; National Taiwan University;
   Purdue University System; Purdue University; National Taiwan University;
   National Taiwan University; National Taiwan University Hospital;
   National Health Research Institutes - Taiwan; Buddhist Tzu Chi General
   Hospital; Dalin Tzu Chi Hospital; National Taiwan University; National
   Taiwan University Hospital; Changhua Christian Hospital; Academia Sinica
   - Taiwan
RP Tzeng, TY (通讯作者)，Natl Yang Ming Univ, VYM Genome Res Ctr, Taipei 112, Taiwan.
EM tytzeng@ym.edu.tw
RI Lin, Liang-In/K-4600-2019; shen, Che-Kun/L-1343-2015; yan,
   jie/HNJ-0097-2023; Lin, I-Hsuan/N-6501-2013
OI Lin, I-Hsuan/0000-0002-6207-1299; LIN, LIANG-IN/0000-0002-3561-1093; OU,
   DA-LIANG/0000-0002-8368-1141; Tzeng, Tsai-Yu/0000-0001-7334-6270; Lu,
   Jeng-Wei/0000-0003-2128-2046; Hsu, Chiun/0000-0002-1122-0055
FU NSC [NSC99-2320-B-010-020-MY3]; Ministry of Education, Aim for the Top
   University Plan [100AC-T402, 101AC-T402, 102AC-T402, 103AC-T610];
   American Cancer Society Institutional Research grant; Purdue University
   Center for Cancer Research [IRG 58-006-53]; Purdue startup fund
FX Funding was supported from the NSC (NSC99-2320-B-010-020-MY3) and the
   Ministry of Education, Aim for the Top University Plan (100AC-T402,
   101AC-T402, 102AC-T402, and 103AC-T610; T.-Y. Tzeng). J.-Y. Yang was
   supported by American Cancer Society Institutional Research grant to the
   Purdue University Center for Cancer Research (IRG 58-006-53) and the
   Purdue startup fund.
CR Berry WL, 2013, CANCER RES, V73, P2936, DOI 10.1158/0008-5472.CAN-12-4300
   Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Chou JL, 2010, EXPERT OPIN THER TAR, V14, P1213, DOI 10.1517/14728222.2010.525353
   Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837
   COLE SPC, 1992, BRIT J CANCER, V65, P498, DOI 10.1038/bjc.1992.103
   Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5
   de Graauw M, 2008, MOL CELL BIOL, V28, P1029, DOI 10.1128/MCB.01247-07
   Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117
   Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1
   Ellinger J, 2008, UROLOGY, V71, P161, DOI 10.1016/j.urology.2007.09.056
   Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038
   Fan DNY, 2013, HEPATOLOGY, V57, P637, DOI 10.1002/hep.26083
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Karantza V, 2011, ONCOGENE, V30, P127, DOI 10.1038/onc.2010.456
   Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037
   Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200
   Liu J, 2007, MOL CELL BIOCHEM, V303, P211, DOI 10.1007/s11010-007-9477-7
   Longerich T, 2011, PATHOL RES PRACT, V207, P8, DOI 10.1016/j.prp.2010.09.007
   Morel E, 2009, DEV CELL, V16, P445, DOI 10.1016/j.devcel.2009.01.007
   Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003
   Park YS, 2008, ANN SURG ONCOL, V15, P1968, DOI 10.1245/s10434-008-9927-9
   Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J
   Rescher U, 2008, J CELL SCI, V121, P2177, DOI 10.1242/jcs.028415
   Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100
   Rodriguez-Paredes M, 2014, ONCOGENE, V33, P2807, DOI 10.1038/onc.2013.239
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003
   Shinjo Keiko, 2012, Methods Mol Biol, V863, P221, DOI 10.1007/978-1-61779-612-8_13
   Song JS, 2012, PATHOL INT, V62, P182, DOI 10.1111/j.1440-1827.2011.02776.x
   Sun SS, 2012, J SURG ONCOL, V105, P773, DOI 10.1002/jso.22120
   Tzeng TY, 2007, P NATL ACAD SCI USA, V104, P12691, DOI 10.1073/pnas.0705534104
   Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002
   Wakabayashi Y, 2011, J BIOL CHEM, V286, P35456, DOI 10.1074/jbc.M111.236794
   Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148
   Wang Yu-qing, 2012, Cancer Biology Medicine, V9, P248, DOI 10.7497/j.issn.2095-3941.2012.04.005
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Wu N, 2013, CLIN TRANSL ONCOL, V15, P106, DOI 10.1007/s12094-012-0928-6
   Xing R, 2013, CELL MOL BIOL, V59, P1848, DOI 10.1170/219
   Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271
   Yokoyama Y, 2013, CANCER SCI, V104, P889, DOI 10.1111/cas.12166
   Young LC, 2013, BIOCHEM CELL BIOL, V91, P369, DOI 10.1139/bcb-2012-0054
   Zhang XH, 2012, CLIN TRANSL ONCOL, V14, P634, DOI 10.1007/s12094-012-0855-6
   Zhong LP, 2009, ARCH ORAL BIOL, V54, P17, DOI 10.1016/j.archoralbio.2008.08.006
NR 45
TC 61
Z9 69
U1 0
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD DEC 15
PY 2014
VL 74
IS 24
BP 7333
EP 7343
DI 10.1158/0008-5472.CAN-13-3572
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AW6FC
UT WOS:000346363900019
PM 25477335
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, SK
   Kim, JH
   Yun, SJ
   Kim, WJ
   Kim, SY
AF Kim, Seon-Kyu
   Kim, Jong Hwan
   Yun, Seok-Joong
   Kim, Wun-Jae
   Kim, Seon-Young
TI APPEX: analysis platform for the identification of prognostic gene
   expression signatures in cancer
SO BIOINFORMATICS
LA English
DT Article
ID BREAST-CANCER
AB Because cancer has heterogeneous clinical behaviors due to the progressive accumulation of multiple genetic and epigenetic alterations, the identification of robust molecular signatures for predicting cancer outcome is profoundly important. Here, we introduce the APPEX Web-based analysis platform as a versatile tool for identifying prognostic molecular signatures that predict cancer diversity. We incorporated most of statistical methods for survival analysis and implemented seven survival analysis workflows, including CoxSingle, CoxMulti, IntransSingle, IntransMulti, SuperPC, TimeRoc and multivariate. A total of 236 publicly available datasets were collected, processed and stored to support easy independent validation of prognostic signatures. Two case studies including disease recurrence and bladder cancer progression were described using different combinations of the seven workflows.
C1 [Kim, Seon-Kyu; Kim, Jong Hwan; Kim, Seon-Young] Univ Sci & Technol, Med Genom Res Ctr, Taejon 305806, South Korea.
   [Kim, Seon-Kyu] Univ Sci & Technol, Korean Bioinformat Ctr, Korea Res Inst Biosci & Biotechnol, Taejon 305806, South Korea.
   [Kim, Jong Hwan; Kim, Seon-Young] Univ Sci & Technol, Dept Funct Genom, Taejon 305806, South Korea.
   [Yun, Seok-Joong; Kim, Wun-Jae] Chungbuk Natl Univ, Coll Med, Dept Urol, Cheongju 360100, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungbuk
   National University
RP Kim, SY (通讯作者)，Univ Sci & Technol, Med Genom Res Ctr, Taejon 305806, South Korea.
EM kimsy@kribb.re.kr
RI Kim, Seon-Young/A-7193-2009; Kim, Jae-hyung/J-8504-2012; Kim,
   Seon-Kyu/KBA-0395-2024
OI Kim, Seon-Kyu/0000-0002-4176-5187; Yun, Seok-Joong/0000-0001-7737-4746
FU National Research Foundation of Korea - Ministry of Science, ICT and
   Future Planning [2012M3A9B4027954, 2012M3A9D1054670]; KRIBB Research
   Initiative grant
FX This work was supported by grants from the stem cell (2012M3A9B4027954)
   and genomics (2012M3A9D1054670) program of the National Research
   Foundation of Korea funded by the Ministry of Science, ICT and Future
   Planning and a KRIBB Research Initiative grant.
CR Aguirre-Gamboa R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074250
   Bair E, 2004, PLOS BIOL, V2, P511, DOI 10.1371/journal.pbio.0020108
   Corradi L, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-S12-S10
   COX DR, 1972, J R STAT SOC B, V34, P187
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x
   Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977
   Madden SF, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3444
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
NR 11
TC 7
Z9 8
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD NOV 15
PY 2014
VL 30
IS 22
BP 3284
EP 3286
DI 10.1093/bioinformatics/btu521
PG 3
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA AT2OQ
UT WOS:000344774600025
PM 25091586
OA Bronze
DA 2025-01-12
ER

PT J
AU Rattani, NS
   Swift-Scanlan, T
AF Rattani, Nabila S.
   Swift-Scanlan, Theresa
TI Deconstructing Breast Cancer Heterogeneity: Clinical Implications for
   Women With Basal-Like Tumors
SO ONCOLOGY NURSING FORUM
LA English
DT Article
DE basal-like; breast cancer; risk factors; epigenetic; treatment; BRCA1
ID LONG-TERM SURVIVAL; MOLECULAR PORTRAITS; SUBTYPES; EXPLORATION; CELLS;
   PERSPECTIVES; CHEMOTHERAPY; EPIGENETICS; THERAPY; BENEFIT
AB Purpose/Objectives: To compare and contrast the molecular and environmental factors contributing to basal-like breast cancer and highlight the clinical implications for women with this phenotype.
   Data Sources: CINAHL (R) and PubMed databases, journals, and citation indices were searched using the key word basal-like in combination with breast cancer, epigenetic, treatment, subtype, risk factor, and BRCA1 to synthesize the literature on the multiple underpinnings of basal-like breast cancer.
   Data Synthesis: Research findings related to the molecular foundation of basal-like breast cancer were integrated with knowledge of nongenetic contributing risk factors. Approved therapies and those under development were summarized with the goal of improving understanding for research and practice.
   Conclusions: Of the five subtypes of breast cancer, the basal-like subtype has the shortest survival and poorest prognosis. The development of gene expression assays with epigenetic studies has enabled reliable identification of the basal-like subtype and has shed light on novel therapeutic possibilities. Clinical trials for basal-like breast cancer are underway, and the potential for individualized treatments for women with this subtype show promise.
   Implications for Nursing: The main difficulties with basal-like breast cancer are its aggressive course, treatment refractory nature, and complex biology, all of which pose real challenges for clinical management and patient education. Oncology nurses play a pivotal role in providing holistic care and patient support. Therefore, nurses must understand the complexity of the clinical presentation and the underlying biology of this cancer subtype.
C1 [Rattani, Nabila S.; Swift-Scanlan, Theresa] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA.
C3 University of North Carolina; University of North Carolina Chapel Hill
RP Rattani, NS (通讯作者)，Univ N Carolina, Sch Nursing, Chapel Hill, NC 27515 USA.
EM tswift@unc.edu
FU National Center for Research Resources [KL2RR025746]; Susan G. Komen
   Foundation [KG090180]; Barbara Senich Genomics Innovation Endowment
FX Nabila S. Rattani, BSN, RN, is a recent graduate from the School of
   Nursing and Theresa Swift-Scanlan, PhD, RN, is an assistant professor in
   the School of Nursing, both at the University of North Carolina in
   Chapel Hill. This study was supported, in part, by grants from the
   National Center for Research Resources (No. KL2RR025746), the Susan G.
   Komen Foundation (No. KG090180), and the Barbara Senich Genomics
   Innovation Endowment. Swift-Scanlan can be reached at tswift@unc.edu,
   with copy to editor at ONFEditor@ons.org. (Submitted March 2014.
   Accepted for publication July 7, 2014.)
CR Bardowell SA, 2013, BREAST CANCER RES TR, V142, P365, DOI 10.1007/s10549-013-2738-0
   Bertucci F, 2012, CURR MOL MED, V12, P96, DOI 10.2174/156652412798376134
   Bertucci F, 2008, INT J CANCER, V123, P236, DOI 10.1002/ijc.23518
   Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200
   Binkley JM, 2012, CANCER-AM CANCER SOC, V118, P2207, DOI 10.1002/cncr.27469
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chia SK, 2012, CLIN CANCER RES, V18, P4465, DOI 10.1158/1078-0432.CCR-12-0286
   Coyne E, 2012, EUR J ONCOL NURS, V16, P124, DOI 10.1016/j.ejon.2011.04.013
   Creighton CJ, 2012, BIOL-TARGETS THER, V6, P289, DOI 10.2147/BTT.S29923
   D'Anello L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-300
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Eroles P, 2012, CANCER TREAT REV, V38, P698, DOI 10.1016/j.ctrv.2011.11.005
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Feinberg Andrew P, 2008, JAMA, V299, P1345, DOI 10.1001/jama.299.11.1345
   Florea Ana-Maria, 2011, Cancers (Basel), V3, P1351, DOI 10.3390/cancers3011351
   Goncalves R, 2013, J NATL COMPR CANC NE, V11, P174, DOI 10.6004/jnccn.2013.0025
   Gown AM, 2008, MODERN PATHOL, V21, pS8, DOI 10.1038/modpathol.2008.34
   Gronwald J, 2009, J CLIN ONCOL, V27
   Grushko TA, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.10510
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258
   Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Jiang Z, 2011, CELL CYCLE, V10, P1563, DOI 10.4161/cc.10.10.15703
   Kashiwagi S, 2013, BRIT J SURG, V100, P490, DOI 10.1002/bjs.9021
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kottke T, 2011, NAT MED, V17, P854, DOI 10.1038/nm.2390
   Lee JS, 2010, CANCER BIOL THER, V9, P1017, DOI 10.4161/cbt.9.12.11804
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Litsas G, 2013, CLIN J ONCOL NURS, V17, P332, DOI 10.1188/13.CJON.332-334
   López-Knowles E, 2010, INT J CANCER, V126, P1121, DOI 10.1002/ijc.24831
   Lund MJ, 2009, BREAST CANCER RES TR, V113, P357, DOI 10.1007/s10549-008-9926-3
   Millikan RC, 2008, BREAST CANCER RES TR, V109, P123, DOI 10.1007/s10549-007-9632-6
   Moestue SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3391
   Newton DA, 2006, J BIOL CHEM, V281, P5668, DOI 10.1074/jbc.M509314200
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   O'Brien KM, 2010, CLIN CANCER RES, V16, P6100, DOI 10.1158/1078-0432.CCR-10-1533
   Oliveras-Ferraros C, 2008, INT J ONCOL, V33, P1165, DOI 10.3892/ijo_00000106
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Pedersen AE, 2014, ONCOL NURS FORUM, V41, P77, DOI 10.1188/14.ONF.77-88
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Quinn JE, 2003, CANCER RES, V63, P6221
   Rakha EA, 2008, J CLIN ONCOL, V26, P2568, DOI 10.1200/JCO.2007.13.1748
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rody A, 2007, BREAST, V16, P235, DOI 10.1016/j.breast.2007.02.006
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Schmid-Büchi S, 2013, EUR J ONCOL NURS, V17, P22, DOI 10.1016/j.ejon.2012.02.003
   Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607
   Siziopikou KP, 2007, BREAST, V16, P104, DOI 10.1016/j.breast.2006.09.003
   Sorlie T, 2004, EUR J CANCER, V40, P2667, DOI 10.1016/j.ejca.2004.08.021
   Spittler CA, 2012, ONCOL NURS FORUM, V39, pE425, DOI 10.1188/12.ONF.E425-E433
   Toft DJ, 2011, MOL ENDOCRINOL, V25, P199, DOI 10.1210/me.2010-0164
   Tomaskovic-Crook E, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2416
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   Waddington CH, 2012, INT J EPIDEMIOL, V41, P10, DOI 10.1093/ije/dyr184
   Widakowich C, 2007, ONCOLOGIST, V12, P1443, DOI 10.1634/theoncologist.12-12-1443
   Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002
   Yang XR, 2007, CANCER EPIDEM BIOMAR, V16, P439, DOI 10.1158/1055-9965.EPI-06-0806
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yehiely F, 2006, TRENDS MOL MED, V12, P537, DOI 10.1016/j.molmed.2006.09.004
NR 64
TC 5
Z9 6
U1 1
U2 13
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 0190-535X
EI 1538-0688
J9 ONCOL NURS FORUM
JI Oncol. Nurs. Forum
PD NOV
PY 2014
VL 41
IS 6
BP 639
EP 646
DI 10.1188/14.ONF.639-646
PG 8
WC Oncology; Nursing
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Oncology; Nursing
GA AT2IH
UT WOS:000344757200010
PM 25355019
DA 2025-01-12
ER

PT J
AU Pinto, R
   De Summa, S
   Danza, K
   Popescu, O
   Paradiso, A
   Micale, L
   Merla, G
   Palumbo, O
   Carella, M
   Tommasi, S
AF Pinto, R.
   De Summa, S.
   Danza, K.
   Popescu, O.
   Paradiso, A.
   Micale, L.
   Merla, G.
   Palumbo, O.
   Carella, M.
   Tommasi, S.
TI MicroRNA expression profiling in male and female familial breast cancer
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE familial breast cancer; miRNA; RASSF1A; NORE1A; miR-152; miR-497
ID CELL-PROLIFERATION; HIPPO PATHWAY; RASSF1A; TUMORS; ANGIOGENESIS;
   INACTIVATION; INVASION; MIR-152; KINASES; NORE1
AB Background: Gender-associated epigenetic alterations are poorly investigated in male and female familial breast cancer (fBC). MicroRNAs may contribute to the different biology in men and women particularly related to RASSF1A pathways.
   Methods: Microarray technology was used to evaluate miRNA profile in 24 male and 43 female fBC. Key results were validated using RT-qPCR in an external samples set. In vitro studies were carried out to verify microRNA-target gene interaction.
   Results: Pathway enrichment analysis with the 287 differentially expressed microRNAs revealed several signalling pathways differently regulated in male and female cases. Because we previously hypothesised a peculiar involvement of RASSF1A in male fBC pathogenesis, we focussed on the MAPK and the Hippo signalling pathways that are regulated by RASSF1A. Male miR-152 and miR-497 upregulation and RASSF1A and NORE1A interacting gene downregulation were observed, confirming a possible indirect interaction between miRNAs and the two genes.
   Conclusions: For the first time, a different microRNA expression pattern in male and female fBC has been shown. Moreover, the importance of RASSF1A pathway in male fBC carcinogenesis has been confirmed, highlighting a possible role for miR-152 and miR-497 in controlling MAPK and Hippo signalling pathways, regulated by RASSF1A.
C1 [Pinto, R.; De Summa, S.; Danza, K.; Tommasi, S.] IRCCS Giovanni Paolo II, Mol Genet Lab, I-70124 Bari, Italy.
   [Popescu, O.] IRCCS Giovanni Paolo II, Anatomopathol Unit, I-70124 Bari, Italy.
   [Paradiso, A.] IRCCS Giovanni Paolo II, Expt Med Oncol Unit, I-70124 Bari, Italy.
   [Micale, L.; Merla, G.; Palumbo, O.; Carella, M.] IRCCS Casa Sollievo Sofferenza, Med Genet Unit, San Giovanni Rotondo, FG, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica
   Molecolare (IGM-CNR); IRCCS Casa Sollievo Della Sofferenza
RP Tommasi, S (通讯作者)，IRCCS Giovanni Paolo II, Mol Genet Lab, Viale Orazio Flacco 65, I-70124 Bari, Italy.
EM s.tommasi@oncologico.bari.it
RI paradiso, angelo/J-9457-2018; Danza, Katia/K-3182-2018; merla,
   giuseppe/K-4627-2012; Popescu, Ondina/AAO-9751-2020; Micale,
   Lucia/K-3909-2016; Tommasi, Stefania/J-6732-2012; De Summa,
   Simona/K-2582-2018; PALUMBO, ORAZIO/C-1133-2014; Carella,
   Massimo/A-2804-2014
OI Tommasi, Stefania/0000-0002-2157-2978; Micale,
   Lucia/0000-0003-3604-194X; De Summa, Simona/0000-0001-9607-3754;
   PALUMBO, ORAZIO/0000-0001-6583-3482; Carella,
   Massimo/0000-0002-6830-6829; merla, giuseppe/0000-0001-5078-928X
FU VIRTUALAB [PON 01.01297]
FX We thank Caroline Oakley for manuscript revision. This work was
   supported by PON 01.01297 'VIRTUALAB'. No additional external funding
   was received for this study.
CR Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   Avruch J, 2006, METHOD ENZYMOL, V407, P290, DOI 10.1016/S0076-6879(05)07025-4
   Avruch J, 2012, SEMIN CELL DEV BIOL, V23, P770, DOI 10.1016/j.semcdb.2012.07.002
   Bee C, 2010, J BIOL CHEM, V285, P16258, DOI 10.1074/jbc.M109.081562
   Berta S, 2013, EUR J PHARMACOL, V717, P71, DOI 10.1016/j.ejphar.2013.03.037
   Braconi C, 2010, HEPATOLOGY, V51, P881, DOI 10.1002/hep.23381
   Callari M, 2011, BREAST CANCER RES TR, V127, P601, DOI 10.1007/s10549-010-1015-8
   Chen Y, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-43
   Dumitrescu Ramona G, 2012, Methods Mol Biol, V863, P3, DOI 10.1007/978-1-61779-612-8_1
   Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Fausti Francesca, 2012, Mol Biol Int, V2012, P307628, DOI 10.1155/2012/307628
   Fernandes MS, 2013, INT J CANCER, V132, P251, DOI 10.1002/ijc.27696
   Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780
   Jung HY, 2013, CANCER RES TREAT, V45, P134, DOI 10.4143/crt.2013.45.2.134
   Lee CK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-577
   Lehmann U, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-109
   Li D, 2011, CLIN CANCER RES, V17, P1722, DOI 10.1158/1078-0432.CCR-10-1800
   Liu AM, 2012, BBA-REV CANCER, V1826, P357, DOI 10.1016/j.bbcan.2012.05.006
   Luo QF, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-95
   Melchor L, 2013, HUM GENET, V132, P845, DOI 10.1007/s00439-013-1299-y
   Estal RM, 2013, BREAST CANCER RES TR, V142, P19, DOI 10.1007/s10549-013-2723-7
   Ottini L, 2010, CRIT REV ONCOL HEMAT, V73, P141, DOI 10.1016/j.critrevonc.2009.04.003
   Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299
   Pilato B, 2011, BREAST CANCER RES TR, V125, P651, DOI 10.1007/s10549-010-0861-8
   Pinto R, 2013, J CELL PHYSIOL, V228, P1264, DOI 10.1002/jcp.24281
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Ruddy KJ, 2013, ANN ONCOL, V24, P1434, DOI 10.1093/annonc/mdt025
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Shen L, 2012, EXP THER MED, V3, P475, DOI 10.3892/etm.2011.428
   Tahiri A, 2014, CARCINOGENESIS, V35, P76, DOI 10.1093/carcin/bgt333
   Tanic M, 2013, BRIT J CANCER, V109, P2724, DOI 10.1038/bjc.2013.612
   Tanic M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038847
   Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041
   Wang SH, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-172
   Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049
   Zheng DL, 2012, FEBS LETT, V586, P4165, DOI 10.1016/j.febslet.2012.10.014
   Zheng XG, 2013, CANCER LETT, V329, P146, DOI 10.1016/j.canlet.2012.10.026
   Zhou X, 2012, ONCOL REP, V27, P447, DOI 10.3892/or.2011.1482
NR 39
TC 15
Z9 16
U1 0
U2 11
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD DEC 9
PY 2014
VL 111
IS 12
BP 2361
EP 2368
DI 10.1038/bjc.2014.535
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AW4JJ
UT WOS:000346247000020
PM 25393370
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Yi, SA
   Ryu, HW
   Lee, DH
   Han, JW
   Kwon, SH
AF Yi, Sang Ah
   Ryu, Hyun-Wook
   Lee, Dong Hoon
   Han, Jeung-Whan
   Kwon, So Hee
TI HP1β suppresses metastasis of human cancer cells by decreasing the
   expression and activation of MMP2
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE HP1 beta; MMP2; MT1-MMP; TIMP2; migration; cancer metastasis
ID HETEROCHROMATIN PROTEIN-1 HP1; MATRIX METALLOPROTEINASES; BREAST-CANCER;
   MAMMALIAN-CELLS; GENE-EXPRESSION; ORAL-CANCER; IDENTIFICATION;
   HP1(HS-ALPHA); PROGRESSION; HISTONES
AB Heterochromatin protein 1 (HP 1) is an epigenetic modifier of gene regulation and chromatin packing via binding to trimethylated histone H3 lysine 9 (H3K9). HP1 plays an important role in gene activation as well as gene repression in heterochromatin and euchromatin. However, the role of individual HP1 proteins in human diseases remains elusive. Here, we show that HP1 beta negatively regulates the expression and activation of matrix metallopeptidase (MMP)2, which mediates cancer metastasis by destructing type IV collagen. Reduced HP1 beta expression correlates with the increased level of pro- and active-MMP2 in colon cancer cells. Consistently, HP1 beta knockdown (KD) increased and HP1 beta overexpression decreased the mRNA level of MMP2 and membrane type 1 metallopeptidase (MT1-MMP). Furthermore, cancer cells overexpressing HP1 beta showed impaired migratory ability, whereas HP1 beta-deleted cancer cells had increased migration. HP1 beta negatively regulates MMP2 expression in a transcriptional level and prevents MMP2 activation through reducing the expression of MT1-MMP. These findings shed new light on HP1 beta as a molecular regulator and an efficient therapeutic target of metastatic cancer.
C1 [Yi, Sang Ah; Han, Jeung-Whan] Sungkyunkwan Univ, Sch Pharm, Res Ctr Epigenome Regulat, Suwon 440746, South Korea.
   [Ryu, Hyun-Wook; Lee, Dong Hoon; Kwon, So Hee] Yonsei Univ, Yonsei Inst Pharmaceut Sci, Coll Pharm, Inchon 406840, South Korea.
   [Lee, Dong Hoon] Yonsei Univ, Dept Integrated OMICS Biomed Sci, Seoul 120749, South Korea.
C3 Sungkyunkwan University (SKKU); Yonsei University; Yonsei University
RP Kwon, SH (通讯作者)，Yonsei Univ, Yonsei Inst Pharmaceut Sci, Coll Pharm, 162-1 Songdo Dong, Inchon 406840, South Korea.
EM soheekwon@yonsei.ac.kr
RI Kwon, So/AAG-8971-2020; Yi, Sang/AAV-4181-2021
FU Medical Research Center programs [2012-0009849]; Basic Science Research
   Program through National Research Foundation of Korea (NRF) - Ministry
   of Education, Science and Technology [2012013998]
FX This research was supported by Medical Research Center programs
   (2012-0009849) and the Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education, Science and Technology (2012013998).
CR Ayoub N, 2009, CELL CYCLE, V8, P2945
   De Koning L, 2009, EMBO MOL MED, V1, P178, DOI 10.1002/emmm.200900022
   De Lange R, 2001, ANTICANCER RES, V21, P2329
   Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007
   du Chéné I, 2007, EMBO J, V26, P424, DOI 10.1038/sj.emboj.7601517
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Gupta A, 2014, AGEING RES REV, V13, P65, DOI 10.1016/j.arr.2013.12.001
   Hediger F, 2006, CURR OPIN GENET DEV, V16, P143, DOI 10.1016/j.gde.2006.02.013
   Ikebe T, 1999, CLIN EXP METASTAS, V17, P315, DOI 10.1023/A:1006642428826
   JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862
   Kirschmann DA, 2000, CANCER RES, V60, P3359
   Kwon SH, 2011, BIOESSAYS, V33, P280, DOI 10.1002/bies.201000138
   Kwon S, 2007, GENE DEV, V21, P3381, DOI 10.1101/gad.461107
   Lafleur Marc A, 2003, Expert Rev Mol Med, V5, P1, DOI 10.1017/S1462399403006628
   Lomberk G, 2006, NAT CELL BIOL, V8, P407, DOI 10.1038/ncb1383
   Lukásová E, 2005, J LEUKOCYTE BIOL, V77, P100, DOI 10.1189/jlb.0704388
   McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9
   Minc E, 1999, CHROMOSOMA, V108, P220, DOI 10.1007/s004120050372
   Nielsen AL, 1999, EMBO J, V18, P6385, DOI 10.1093/emboj/18.22.6385
   Nielsen AL, 2001, MOL CELL, V7, P729, DOI 10.1016/S1097-2765(01)00218-0
   Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722
   Nishimura K, 2006, ANTICANCER RES, V26, P4349
   Norwood LE, 2006, J BIOL CHEM, V281, P18668, DOI 10.1074/jbc.M512454200
   Piacentini L, 2003, J CELL BIOL, V161, P707, DOI 10.1083/jcb.200303012
   Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a
   Thomas GT, 1999, ORAL ONCOL, V35, P227, DOI 10.1016/S1368-8375(99)00004-4
   Thomsen R, 2011, MOL CARCINOGEN, V50, P601, DOI 10.1002/mc.20755
   Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329
   Wasenius VM, 2003, CLIN CANCER RES, V9, P68
   Zhang RG, 2007, CELL CYCLE, V6, P784, DOI 10.4161/cc.6.7.4079
NR 30
TC 13
Z9 14
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD DEC
PY 2014
VL 45
IS 6
BP 2541
EP 2548
DI 10.3892/ijo.2014.2646
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AS3TJ
UT WOS:000344200700040
PM 25201136
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, Y
   Xu, Z
   Li, B
   Zhang, ZZ
   Luo, HC
   Wang, YH
   Lu, ZZ
   Wu, XL
AF Li, Yan
   Xu, Zhong
   Li, Bo
   Zhang, Zhengzheng
   Luo, Hongchun
   Wang, Yuanhu
   Lu, Zhizhong
   Wu, Xiaoling
TI Epigenetic silencing of miRNA-9 is correlated with promoter-proximal CpG
   island hypermethylation in gastric cancer <i>in vitro</i> and <i>in
   vivo</i>
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE microRNA; methylation; gastric cancer; animal model
ID MICRORNA EXPRESSION SIGNATURE; HUMAN BREAST-CANCER; DNA METHYLATION;
   COLORECTAL-CANCER; 5-AZA-2'-DEOXYCYTIDINE DECITABINE;
   HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; PROSTATE-CANCER; FIELD
   DEFECT; LUNG-CANCER
AB Silencing of protein-coding tumor suppressor genes (TSGs) by CpG island hypermethylation is a common occurrence in gastric cancer (GC). Here, we examine if tumor suppressor microRNAs (miRNAs) are silenced in a similar manner. Real-time quantitative PCR (RTQ-PCR) was employed to investigate the expression level of four candidate miRNAs in GC tissues (n=30) and cell lines. Basing on RTQ-PCR results and bioinformatics approach, miR-9 was chosen for further study on epigenetic regulation. Bisulfite genomic sequencing PCR (BSP) was performed to assess the methylation status of miR-9 in GC tissues. In both GC cell lines and animal models, demethylation was performed either by treatment with 5-aza-2'-deoxycytidine (5-AZA-CdR) or by siRNA targeting DNMT1. We also analyzed the relationship between miRNAs and several clinicopathological features. Candidate miRNAs (miR-9, miR-433, miR-19b, and miR-370) were found strongly downregulated in GC tissues and cell lines. Their expression was increased following 5-AZA-CdR treatment. CpG island methylation of miR-9 was significantly higher in GC tissues compared to normal controls. After two demethylation treatments, miR-9 methylation degree was significantly decreased and miR-9 expression was obviously restored in GC cells and animal models. Deregulation of miR-9 was positively correlated with tumor lesion size. Three other miRNAs, miR-19b, miR-433, and miR-370 were associated with lymph node metastasis, decreased curvature, and poorly differentiated carcinoma. miR-19b and miR-433 were positively correlated with male gender. Of four candidate miRNAs downregulated in GC, miR-9 is epigenetically regulated by DNA methylation both in vitro and in vivo.
C1 [Li, Yan] Chongqing Canc Inst, Chongqing 400030, Peoples R China.
   [Li, Yan; Wu, Xiaoling] Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Chongqing 400010, Peoples R China.
   [Xu, Zhong] Guiyang Med Univ, Affiliated Peoples Hosp, Guizhou Prov Peoples Hosp, Dept Gastroenterol, Guizhou 550002, Peoples R China.
   [Li, Bo] First People Hosp, Dept Surg, Chongqing 400020, Peoples R China.
   [Zhang, Zhengzheng] Chongqing Med Univ, Childrens Hosp, Dept Gastroenterol, Chongqing 400014, Peoples R China.
   [Luo, Hongchun] Chongqing Med Univ, Affiliated Hosp 2, Dept Infect Dis, Chongqing 400016, Peoples R China.
   [Wang, Yuanhu; Lu, Zhizhong] Chongqing Med Univ, Lab Clin Diagnost, Chongqing 400016, Peoples R China.
C3 Chongqing Medical University; Guizhou Medical University; Chongqing
   Medical University; Chongqing Medical University; Chongqing Medical
   University
RP Wu, XL (通讯作者)，Chongqing Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Chongqing 400010, Peoples R China.
EM xiaolianbei@sina.com
RI Li, Bo/AAA-8968-2020; Xu, Zhong/AAA-8476-2022; luo,
   hongchun/LWH-7042-2024
CR Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101
   Chen QJ, 2011, DIGEST DIS SCI, V56, P2009, DOI 10.1007/s10620-010-1536-3
   Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102
   Costinean S, 2006, P NATL ACAD SCI USA, V103, P7024, DOI 10.1073/pnas.0602266103
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Deng HX, 2013, GENE, V518, P351, DOI 10.1016/j.gene.2012.12.103
   Du YT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-249
   Finnegan EJ, 2003, J CELL SCI, V116, P4689, DOI 10.1242/jcs.00838
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Grady WM, 2008, ONCOGENE, V27, P3880, DOI 10.1038/onc.2008.10
   Guo LH, 2013, INT J MOL SCI, V14, P14171, DOI 10.3390/ijms140714171
   Hashimoto Y, 2010, CARCINOGENESIS, V31, P777, DOI 10.1093/carcin/bgq013
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Langevin SM, 2011, CANCER-AM CANCER SOC, V117, P1454, DOI 10.1002/cncr.25689
   Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251
   Lei HZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060369
   Li P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066782
   Li Y, 2011, WORLD J GASTROENTERO, V17, P1442, DOI 10.3748/wjg.v17.i11.1442
   Li YW, 2012, EPIGENETICS-US, V7, P940, DOI 10.4161/epi.21236
   Li ZJ, 2008, P NATL ACAD SCI USA, V105, P15535, DOI 10.1073/pnas.0808266105
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Luo HC, 2009, CHINESE J CANCER RES, V21, P74, DOI 10.1007/s11670-009-0074-z
   Luo HC, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-82
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Minor J, 2012, ORAL ONCOL, V48, P73, DOI 10.1016/j.oraloncology.2011.11.006
   Momparler RL, 2005, SEMIN ONCOL, V32, P443, DOI 10.1053/j.seminoncol.2005.07.008
   Momparler RL, 2005, SEMIN HEMATOL, V42, pS9, DOI 10.1053/j.seminhematol.2005.05.002
   Motoyama K, 2008, CLIN CANCER RES, V14, P2334, DOI 10.1158/1078-0432.CCR-07-4667
   Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283
   O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677
   Rotkrua P, 2011, INT J CANCER, V129, P2611, DOI 10.1002/ijc.25923
   Schiffgen M, 2013, BIOCHEM BIOPH RES CO, V436, P79, DOI 10.1016/j.bbrc.2013.05.061
   Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121
   Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036
   Suzuki H, 2012, MOL ONCOL, V6, P567, DOI 10.1016/j.molonc.2012.07.007
   Suzuki H, 2010, CARCINOGENESIS, V31, P2066, DOI 10.1093/carcin/bgq203
   Takai Daiya, 2003, In Silico Biology, V3, P235
   Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637
   Tanaka N, 2012, LUNG CANCER, V76, P32, DOI 10.1016/j.lungcan.2011.10.002
   Tanaka T, 2011, ONCOL REP, V26, P1329, DOI 10.3892/or.2011.1401
   Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325
   Tsai KW, 2011, EPIGENETICS-US, V6, P1189, DOI 10.4161/epi.6.10.16535
   Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wada R, 2010, INT J CANCER, V127, P1106, DOI 10.1002/ijc.25126
   Weber B, 2007, CELL CYCLE, V6, P1001, DOI 10.4161/cc.6.9.4209
   Wijnhoven BPL, 2007, BRIT J SURG, V94, P23, DOI 10.1002/bjs.5673
   Yamamoto Eiichiro, 2012, Rinsho Byori, V60, P637
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
   Zhang Y, 2013, ONCOL REP, V30, P1976, DOI 10.3892/or.2013.2633
   Zhang ZY, 2008, LAB INVEST, V88, P1358, DOI 10.1038/labinvest.2008.94
   Zhu A, 2012, MED ONCOL, V29, P2701, DOI 10.1007/s12032-011-0134-3
NR 57
TC 25
Z9 26
U1 0
U2 30
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD DEC
PY 2014
VL 45
IS 6
BP 2576
EP 2586
DI 10.3892/ijo.2014.2667
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AS3TJ
UT WOS:000344200700044
PM 25270964
OA Bronze
DA 2025-01-12
ER

PT J
AU Kiehl, S
   Herkt, SC
   Richter, AM
   Fuhrmann, L
   El-Nikhely, N
   Seeger, W
   Savai, R
   Dammann, RH
AF Kiehl, Steffen
   Herkt, Stefanie C.
   Richter, Antje M.
   Fuhrmann, Liesa
   El-Nikhely, Nefertiti
   Seeger, Werner
   Savai, Rajkumar
   Dammann, Reinhard H.
TI <i>ABCB4</i> is frequently epigenetically silenced in human cancers and
   inhibits tumor growth
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CPG ISLAND METHYLATION; DNA METHYLATION; MDR3 GENE; INTRAHEPATIC
   CHOLESTASIS; DRUG-RESISTANCE; INACTIVATION; CHOLANGITIS; MUTATIONS;
   CIRRHOSIS; WOMEN
AB Epigenetic silencing through promoter hypermethylation is an important hallmark for the inactivation of tumor-related genes in carcinogenesis. Here we identified the ATP-binding cassette sub-family B member 4 (ABCB4) as a novel epigenetically silenced target gene. We investigated the epigenetic regulation of ABCB4 in 26 human lung, breast, skin, liver, head and neck cancer cells lines and in primary cancers by methylation and expression analysis. Hypermethylation of the ABCB4 CpG island promoter occurred in 16 out of 26 (62%) human cancer cell lines. Aberrant methylation of ABCB4 was also revealed in 39% of primary lung cancer and in 20% of head and neck cancer tissues. In 37% of primary lung cancer samples, ABCB4 expression was absent. For breast cancer a significant hypermethylation occurred in tumor tissues (41%) compared to matching normal samples (0%, p = 0.002). Silencing of ABCB4 was reversed by 5-aza-2 '-deoxycytidine and zebularine treatments leading to its reexpression in cancer cells. Overexpression of ABCB4 significantly suppressed colony formation and proliferation of lung cancer cells. Hypermethylation of Abcb4 occurred also in murine cancer, but was not found in normal tissues. Our findings suggest that ABCB4 is a frequently silenced gene in different cancers and it may act tumor suppressivly in lung cancer.
C1 [Kiehl, Steffen; Herkt, Stefanie C.; Richter, Antje M.; Dammann, Reinhard H.] Univ Giessen, Inst Genet, D-35392 Giessen, Germany.
   [Kiehl, Steffen; Herkt, Stefanie C.; Richter, Antje M.; Dammann, Reinhard H.] Marburg Lung Ctr, D-35392 Giessen, Germany.
   [Fuhrmann, Liesa; El-Nikhely, Nefertiti; Seeger, Werner; Savai, Rajkumar] Max Planck Inst Heart & Lung Res, D-61231 Bad Nauheim, Germany.
C3 Justus Liebig University Giessen; Max Planck Society
RP Savai, R (通讯作者)，Univ Giessen, Inst Genet, D-35392 Giessen, Germany.
EM Rajkumar.Savai@mpi-bn.mpg.de; Reinhard.Dammann@gen.bio.uni-giessen.de
OI Seeger, Werner/0000-0003-1946-0894; El-Nikhely,
   Nefertiti/0000-0002-6675-234X
FU LOEWE grant (UGMLC) from the Land Hessen
FX The work was supported by a LOEWE grant (UGMLC) from the Land Hessen.
   This organization had no involvement in the study design, acquisition,
   analysis, data interpretation, writing of the manuscript and in the
   decision to submit the manuscript for publication.
CR Bebek G, 2012, HUM MOL GENET, V21, P1557, DOI 10.1093/hmg/ddr593
   Dammann G, 2011, EPIGENETICS-US, V6, P1454, DOI 10.4161/epi.6.12.18363
   Dammann R, 2005, EUR J CANCER, V41, P1223, DOI 10.1016/j.ejca.2005.02.020
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   De Vree JML, 1998, P NATL ACAD SCI USA, V95, P282, DOI 10.1073/pnas.95.1.282
   Denk GU, 2010, HEPATOL RES, V40, P937, DOI 10.1111/j.1872-034X.2010.00698.x
   Elferink RPJO, 2007, PFLUG ARCH EUR J PHY, V453, P601, DOI 10.1007/s00424-006-0062-9
   Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789
   Floreani A, 2008, DIGEST LIVER DIS, V40, P366, DOI 10.1016/j.dld.2007.10.016
   Gotthardt D, 2008, HEPATOLOGY, V48, P1157, DOI 10.1002/hep.22485
   Helmerl S, 2007, MELANOMA RES, V17, P265, DOI 10.1097/CMR.0b013e3282a7e0b9
   JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9
   LINCKE CR, 1991, J BIOL CHEM, V266, P5303
   MAUAD TH, 1994, AM J PATHOL, V145, P1237
   Momparler RL, 2012, PHARMACEUTICALS, V5, P875, DOI 10.3390/ph5080875
   Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Müllenbach R, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e70
   Oberstadt MC, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-617
   Ren LR, 2007, J HUAZHONG U SCI-MED, V27, P721, DOI 10.1007/s11596-007-0627-7
   Richter AM, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.18
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Rosmorduc O, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-29
   Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107
   Sharma D, 2004, CANCER BIOL THER, V3, P549, DOI 10.4161/cbt.3.6.1041
   SMIT JJM, 1995, BBA-GENE STRUCT EXPR, V1261, P44, DOI 10.1016/0167-4781(94)00214-N
   SOULE HD, 1990, CANCER RES, V50, P6075
   Steinmann K, 2009, ONCOL REP, V22, P1519, DOI 10.3892/or_00000596
   Strunnikova M, 2005, MOL CELL BIOL, V25, P3923, DOI 10.1128/MCB.25.10.3923-3933.2005
   Stutes M, 2007, WORLD J GASTROENTERO, V13, P6465, DOI 10.3748/wjg.13.6465
   Tougeron D, 2012, J HEPATOL, V57, P467, DOI 10.1016/j.jhep.2012.01.025
   Wendum D, 2012, VIRCHOWS ARCH, V460, P291, DOI 10.1007/s00428-012-1202-6
   Zhou L, 2002, J MOL BIOL, V321, P591, DOI 10.1016/S0022-2836(02)00676-9
NR 36
TC 21
Z9 24
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 4
PY 2014
VL 4
AR 6899
DI 10.1038/srep06899
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AS4GF
UT WOS:000344230800002
PM 25367630
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Osmanbeyoglu, HU
   Pelossof, R
   Bromberg, JF
   Leslie, CS
AF Osmanbeyoglu, Hatice U.
   Pelossof, Raphael
   Bromberg, Jacqueline F.
   Leslie, Christina S.
TI Linking signaling pathways to transcriptional programs in breast cancer
SO GENOME RESEARCH
LA English
DT Article
ID PROGNOSTIC-SIGNIFICANCE; REGULATORY NETWORKS; FACTOR ETS-1; EXPRESSION;
   PROTEIN; SURVIVAL; CELLS; RECONSTRUCTION; DOCETAXEL; GROWTH
AB Cancer cells acquire genetic and epigenetic alterations that often lead to dysregulation of oncogenic signal transduction pathways, which in turn alters downstream transcriptional programs. Numerous methods attempt to deduce aberrant signaling pathways in tumors from mRNA data alone, but these pathway analysis approaches remain qualitative and imprecise. In this study, we present a statistical method to link upstream signaling to downstream transcriptional response by exploiting reverse phase protein array (RPPA) and mRNA expression data in The Cancer Genome Atlas (TCGA) breast cancer project. Formally, we use an algorithm called affinity regression to learn an interaction matrix between upstream signal transduction proteins and downstream transcription factors (TFs) that explains target gene expression. The trained model can then predict the TF activity, given a tumor sample's protein expression profile, or infer the signaling protein activity, given a tumor sample's gene expression profile. Breast cancers are comprised of molecularly distinct subtypes that respond differently to pathway-targeted therapies. We trained our model on the TCGA breast cancer data set and identified subtype-specific and common TF regulators of gene expression. We then used the trained tumor model to predict signaling protein activity in a panel of breast cancer cell lines for which gene expression and drug response data was available. Correlations between inferred protein activities and drug responses in breast cancer cell lines grouped several drugs that are clinically used in combination. Finally, inferred protein activity predicted the clinical outcome within the METABRIC Luminal A cohort, identifying high- and low-risk patient groups within this heterogeneous subtype.
C1 [Osmanbeyoglu, Hatice U.; Pelossof, Raphael; Leslie, Christina S.] Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA.
   [Bromberg, Jacqueline F.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
   [Bromberg, Jacqueline F.] Weill Cornell Med Coll, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; Cornell University; Weill Cornell Medicine
RP Leslie, CS (通讯作者)，Mem Sloan Kettering Canc Ctr, Computat Biol Program, New York, NY 10065 USA.
EM cleslie@cbio.mskcc.org
RI Osmanbeyogluhu, Hatice/Q-1822-2019
OI Osmanbeyoglu, Hatice/0000-0002-3175-1777
FU Cancer Research UK; British Columbia Cancer Agency Branch; Starr Cancer
   Consortium; GDAC-B award [U24CA143840]
FX We thank Manu Setty for extensive advice and assistance with the TCGA
   data set. This study makes use of data generated by the Molecular
   Taxonomy of the Breast Cancer International Consortium. Funding for that
   project was provided by Cancer Research UK and the British Columbia
   Cancer Agency Branch. The results published here are in whole or part
   based upon data generated by The Cancer Genome Atlas pilot project
   established by the NCI and NHGRI (accession number: phs000178.v7p6).
   Information about TCGA and the investigators and institutions that
   constitute the TCGA research network can be found at
   http://cancergenome.nih. govt. This work was supported by an award from
   the Starr Cancer Consortium and by GDAC-B award U24CA143840.
CR Akavia UD, 2010, CELL, V143, P1005, DOI 10.1016/j.cell.2010.11.013
   [Anonymous], PACKAGE SURVIVAL A S
   Badve S, 2007, CLIN CANCER RES, V13, P4415, DOI 10.1158/1078-0432.CCR-07-0122
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bartholomeusz C, 2006, ONCOGENE, V25, P79, DOI 10.1038/sj.onc.1209014
   Bartholomeusz C, 2010, CLIN CANCER RES, V16, P1802, DOI 10.1158/1078-0432.CCR-09-1456
   Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
   Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12
   Boutsikou E, 2013, ONCOTARGETS THER, V6, P125, DOI 10.2147/OTT.S42245
   Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8
   Cancello G, 2013, ANN ONCOL, V24, P661, DOI 10.1093/annonc/mds430
   Chakravarty G, 2011, EXP BIOL MED, V236, P145, DOI 10.1258/ebm.2010.010086
   Chakravarty G, 2011, CANCER BIOL THER, V11, P71, DOI 10.4161/cbt.11.1.13952
   Chang HR, 2010, CANCER-AM CANCER SOC, V116, P4227, DOI 10.1002/cncr.25309
   Churchill MEA, 1999, METHOD ENZYMOL, V304, P99
   Ciriello G, 2013, BREAST CANCER RES TR, V141, P409, DOI 10.1007/s10549-013-2699-3
   Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Derry JMJ, 2012, NAT GENET, V44, P127, DOI 10.1038/ng.1089
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Doss S, 2012, LANCET ONCOL, V13, P128, DOI 10.1016/S1470-2045(12)70009-8
   Dydensborg AB, 2009, ONCOGENE, V28, P2634, DOI 10.1038/onc.2009.126
   Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107
   Francis LK, 2006, CLIN CANCER RES, V12, P6826, DOI 10.1158/1078-0432.CCR-06-1331
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Gagliardi PA, 2012, NEOPLASIA, V14, P719, DOI 10.1593/neo.12856
   Gayle SS, 2012, ANTI-CANCER AGENT ME, V12, P151
   Giordano C, 2013, MOL ONCOL, V7, P379, DOI 10.1016/j.molonc.2012.11.002
   Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831
   Haque R, 2012, CANCER EPIDEM BIOMAR, V21, P1848, DOI 10.1158/1055-9965.EPI-12-0474
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Huang SSC, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002887
   Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987
   Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008-5472.CAN-12-3349
   Kashiwagi S, 2013, BRIT J SURG, V100, P490, DOI 10.1002/bjs.9021
   Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375
   Kim HS, 2012, J BREAST CANCER, V15, P401, DOI 10.4048/jbc.2012.15.4.401
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014
   Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011
   Lan A, 2011, NUCLEIC ACIDS RES, V39, pW424, DOI 10.1093/nar/gkr359
   Li J, 2013, NAT METHODS, V10, P1046, DOI [10.1038/nmeth.2650, 10.1038/NMETH.2650]
   Li Q, 2005, J BIOL CHEM, V280, P26922, DOI 10.1074/jbc.M504966200
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Lincoln DW, 2005, FRONT BIOSCI-LANDMRK, V10, P506, DOI 10.2741/1546
   Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735
   Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7
   Matheu A, 2012, CANCER RES, V72, P1301, DOI 10.1158/0008-5472.CAN-11-3660
   Milde-Langosch K, 2003, BREAST CANCER RES TR, V79, P175, DOI 10.1023/A:1023929504884
   Mylona EE, 2006, CANCER DETECT PREV, V30, P111, DOI 10.1016/j.cdp.2006.03.006
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Okui T, 2013, CURR CANCER DRUG TAR, V13, P289, DOI 10.2174/1568009611313030007
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Paweletz CP, 2001, ONCOGENE, V20, P1981, DOI 10.1038/sj.onc.1204265
   Peck AR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3328
   Pegoraro S, 2013, ONCOTARGET, V4, P1293, DOI 10.18632/oncotarget.1136
   Peluso S, 2010, BREAST CARE, V5, P81, DOI 10.1159/000297717
   Prat A, 2013, J CLIN ONCOL, V31, P203, DOI 10.1200/JCO.2012.43.4134
   Robens J, 2010, AM J SURG PATHOL, V34, P1881, DOI 10.1097/PAS.0b013e3181f884e8
   Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Span PN, 2002, ONCOGENE, V21, P8506, DOI 10.1038/sj.onc.1206040
   Switzer CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3319
   Tuncbag N, 2013, J COMPUT BIOL, V20, P124, DOI 10.1089/cmb.2012.0092
   Ueno NT, 2011, J CANCER, V2, P324, DOI 10.7150/jca.2.324
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   Vaske CJ, 2010, BIOINFORMATICS, V26, pi237, DOI 10.1093/bioinformatics/btq182
   von Mering C, 2003, NUCLEIC ACIDS RES, V31, P258, DOI 10.1093/nar/gkg034
   Wang K, 2009, NAT BIOTECHNOL, V27, P829, DOI 10.1038/nbt.1563
   Wilson BJ, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-49
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200
   Yosef N, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.3
   Zahnow CA, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001033
NR 75
TC 47
Z9 53
U1 0
U2 10
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD NOV
PY 2014
VL 24
IS 11
BP 1869
EP 1880
DI 10.1101/gr.173039.114
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA AS7NG
UT WOS:000344442000014
PM 25183703
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Izadi, P
   Noruzinia, M
   Fereidooni, F
   Hosseini, ZM
   Kamali, F
AF Izadi, Pantea
   Noruzinia, Mehrdad
   Fereidooni, Forouzandeh
   Hosseini, Zahra Mostakhdemine
   Kamali, Fatemeh
TI Epigenetic marks in estrogen receptor alpha CpG island correlate with
   some reproductive risk factors in breast cancer
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Breast cancer; Estrogen receptor alpha; Reproductive history; DNA
   methylation; Risk factors
ID WOMEN 20-44 YEARS; HORMONE-RECEPTOR; PROGESTERONE; PREGNANCY;
   METHYLATION; SUBTYPES
AB Reproductive backgrounds, such as age at menarche and menopause, age of first full-term pregnancy (FFTP), number of full-term deliveries and oral contraceptive use are main hormone-related risk factors of breast cancer. It seems that the mentioned factors may affect the risk of breast cancer by enhancing the duration of exposure to estrogen as a potent carcinogen for breast tissue, but the molecular mechanism which links each risk factor to breast cancer is unclear. Estrogen mainly works via its nuclear receptor (ER alpha). As epigenetic alterations such as CpG methylation are potential links between endogenous or exogenous exposures and genome, we hypothesized that hormone-related risk factors may correlate with the epigenetic marks of the ER alpha promoter in breast tumors. In the present study, the CpG methylation status of the ER alpha gene in 99 samples of breast tumors belonged to women with different reproductive histories was evaluated. The reproductive history data were collected from patients. ER alpha CpG methylation was investigated by methylation specific PCR in DNA samples were obtained from the breast tumors. We could show that some of the hormone-related risk factors (early FFTP and increased number of pregnancies) were inversely correlated with epigenetic marks in ER alpha gene in breast tumors. Other hormone-related risk factors such as age of menarche and menopause and oral contraceptive use did not show any association with ER alpha methylation. It seems that pregnancy-related risk factors in comparison with other hormone-related factors work via different mechanism. As ER alpha methylation is a poor prognosis marker in breast tumors, its association with some modifiable reproductive risk factors (FFTP age and numbers of pregnancies) reiterates the importance of programming reproductive life style not only for prevention of breast cancer but also in favoring the prognosis of the affected women. The exact molecular mechanisms of the observed correlation need more investigation in the future.
C1 [Izadi, Pantea] Univ Tehran Med Sci, Sch Med, Dept Med Genet, Tehran, Iran.
   [Noruzinia, Mehrdad] Tarbiat Modares Univ, Sch Med Sci, Dept Med Genet, Tehran, Iran.
   [Fereidooni, Forouzandeh; Hosseini, Zahra Mostakhdemine; Kamali, Fatemeh] Univ Tehran Med Sci, Inst Canc, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tarbiat Modares University;
   Tehran University of Medical Sciences
RP Noruzinia, M (通讯作者)，Tarbiat Modares Univ, Sch Med Sci, Dept Med Genet, Tehran, Iran.
EM noruzinia@modares.ac.ir
OI noruzinia, mehrdad/0000-0002-1325-3758
FU Cancer Institute of Tehran University, for Cancer Research; Tarbiat
   Modares University
FX The authors are deeply grateful to Mr. Ahmad Joulaie for his valuable
   collaboration in gathering reproductive history of the patients.
   Biological materials were provided by the IRAN NATIONAL TUMOR BANK,
   which is funded by Cancer Institute of Tehran University, for Cancer
   Research. This study was supported by Tarbiat Modares University.
CR Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358
   Althuis MD, 2005, INT J EPIDEMIOL, V34, P405, DOI 10.1093/ije/dyh414
   Althuis MD, 2004, CANCER EPIDEM BIOMAR, V13, P1558
   Bernstein L, 2002, J MAMMARY GLAND BIOL, V7, P3, DOI 10.1023/A:1015714305420
   Britton JA, 2002, AM J EPIDEMIOL, V156, P507, DOI 10.1093/aje/kwf065
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Dorgan JF, 1996, CANCER EPIDEM BIOMAR, V5, P533
   Ebrahimi M, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr454
   Fishman J, 1995, ANN NY ACAD SCI, V768, P91, DOI 10.1111/j.1749-6632.1995.tb12113.x
   Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7
   Hayashi S, 2009, CANCER SCI, V100, P1773, DOI 10.1111/j.1349-7006.2009.01243.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Izadi P, 2012, ASIAN PAC J CANCER P, V13, P4113, DOI 10.7314/APJCP.2012.13.8.4113
   Kocdor H, 2009, CELL BIOL INT, V33, P1135, DOI 10.1016/j.cellbi.2009.07.002
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Li CI, 2013, BREAST CANCER RES TR, V137, P579, DOI 10.1007/s10549-012-2365-1
   Ma HY, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1514
   McCredie MRE, 2003, BRIT J CANCER, V89, P1661, DOI 10.1038/sj.bjc.6601293
   Parsa P, 2009, ASIAN PAC J CANCER P, V10, P545
   Rajkumar L, 2001, P NATL ACAD SCI USA, V98, P11755, DOI 10.1073/pnas.201393798
   Russo Irma H., 2007, V174, P111
   Russo J, 2008, CANCER EPIDEM BIOMAR, V17, P51, DOI 10.1158/1055-9965.EPI-07-0678
   Swanson SM, 1997, ANTICANCER RES, V17, P4639
   Tamakoshi K, 2005, CANCER SCI, V96, P57, DOI 10.1111/j.1349-7006.2005.00010.x
   Ursin G, 2005, BRIT J CANCER, V93, P364, DOI 10.1038/sj.bjc.6602712
   Vo AT, 2012, OBSTET GYNECOL INT, V2012, DOI 10.1155/2012/602720
   Yang JH, 1999, CARCINOGENESIS, V20, P623, DOI 10.1093/carcin/20.4.623
NR 27
TC 10
Z9 13
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD NOV
PY 2014
VL 41
IS 11
BP 7607
EP 7612
DI 10.1007/s11033-014-3650-3
PG 6
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AS2HS
UT WOS:000344101300060
PM 25135164
DA 2025-01-12
ER

PT J
AU Xiao, C
   Wang, LL
   Zhu, LF
   Zhang, CP
   Zhou, JH
AF Xiao, Can
   Wang, Lili
   Zhu, Lifang
   Zhang, Chenping
   Zhou, Jianhua
TI Secreted frizzled-related protein 2 is epigenetically silenced and
   functions as a tumor suppressor in oral squamous cell carcinoma
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE oral squamous cell carcinoma; methylation; secreted frizzled-related
   protein 2; Wnt signaling pathway
ID HUMAN GASTRIC-CANCER; BETA-CATENIN; PROMOTER HYPERMETHYLATION;
   HEPATOCELLULAR-CARCINOMA; DECREASED EXPRESSION; COLORECTAL-CANCER; DNA
   METHYLATION; BREAST-CANCER; SFRP2; GENES
AB The role of epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) and its functions in the development of oral squamous cell carcinoma (OSCC) remain to be elucidated. The present study demonstrated that SFRP2 mRNA was detected in 97.96% of tumor-adjacent normal tissues, while its expression was only detected in 16.33% of the tumor samples. In addition, the loss of SFRP2 expression was associated with hypermethylation of its promoter. As expected, the overexpression of SFRP2 in OSCC cell lines (Tca8113) suppressed cell proliferation and arrested the cell cycle in the G1 phase. Overexpression of SFRP2 also effectively repressed tumor growth in xenograft animals. Mechanistic investigations revealed that SFRP2 inhibited the development of OSCC in vitro and in vivo through an increase in the expression levels of glycogen synthase kinase-3 beta and a decrease in the expression level of cyclin D1, a direct read-out gene of active Wnt signaling. In addition, an increase in the expression of beta-catenin was observed in the Tca8113/SFRP2 cells and in the animal models overexpressing SFRP2. Therefore, the results of the present study provide insight into the role of SFRP2 as a functional tumor suppressor in the development of OSCC through inhibition of the Wnt signaling pathway. Further studies on the precise mechanisms underlying the inhibition of Wnt signaling by SFRP2 and its association with 13-catenin are required.
C1 [Xiao, Can; Zhou, Jianhua] Soochow Univ, Sch Publ Hlth, Dept Occupat Med & Environm Hlth, Suzhou 215123, Jiangsu, Peoples R China.
   [Xiao, Can; Wang, Lili; Zhu, Lifang] Soochow Univ, Dept Stomatol, Affiliated Hosp 1, Suzhou 215006, Jiangsu, Peoples R China.
   [Zhang, Chenping] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Stomatol, Shanghai 200011, Peoples R China.
C3 Soochow University - China; Soochow University - China; Shanghai Jiao
   Tong University
RP Zhang, CP (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Stomatol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
EM zhang_cping@163.com
RI Zhu, Lifang/HZL-2956-2023; wang, lili/HDL-7210-2022
CR Cheng YY, 2007, BRIT J CANCER, V97, P895, DOI 10.1038/sj.bjc.6603968
   Chung MT, 2009, GYNECOL ONCOL, V112, P646, DOI 10.1016/j.ygyno.2008.10.026
   Cordeiro-Silva MD, 2012, MOL BIOL REP, V39, P10111, DOI 10.1007/s11033-012-1885-4
   Ebrahimi M, 2008, ORAL ONCOL, V44, P634, DOI 10.1016/j.oraloncology.2007.08.001
   Fu YJ, 2011, INT J CANCER, V129, P1541, DOI 10.1002/ijc.26102
   González-Ramírez I, 2011, ORAL DIS, V17, P771, DOI 10.1111/j.1601-0825.2011.01833.x
   Guo Y, 2011, NEOPLASMA, V58, P110, DOI 10.4149/neo_2011_02_110
   Huang SH, 2013, MED ORAL PATOL ORAL, V18, pE233, DOI 10.4317/medoral.18772
   Jia Y, 2013, J PATHOL, V230, P194, DOI 10.1002/path.4073
   Jost E, 2009, CANCER LETT, V281, P24, DOI 10.1016/j.canlet.2009.02.002
   Kim W, 2013, BIOCHEM J, V450, P9, DOI 10.1042/BJ20121284
   Kinoshita T, 2011, HEPATO-GASTROENTEROL, V58, P1051
   Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32
   Lachenmayer A, 2012, CLIN CANCER RES, V18, P4997, DOI 10.1158/1078-0432.CCR-11-2322
   Lavergne E, 2011, ONCOGENE, V30, P423, DOI 10.1038/onc.2010.432
   Li GH, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0437-z
   Li YY, 2013, BIOCHEM BIOPH RES CO, V438, P402, DOI 10.1016/j.bbrc.2013.07.087
   Marcinkiewicz KM, 2014, EXP CELL RES, V320, P128, DOI 10.1016/j.yexcr.2013.09.011
   Monga SPS, 2011, INT J BIOCHEM CELL B, V43, P1021, DOI 10.1016/j.biocel.2009.09.001
   O'Hurley G, 2011, HISTOPATHOLOGY, V59, P1240, DOI 10.1111/j.1365-2559.2011.04073.x
   Ovchinnikov DA, 2012, TRANSL ONCOL, V5, P321, DOI 10.1593/tlo.12232
   Schütz AK, 2012, FEBS LETT, V586, P1645, DOI 10.1016/j.febslet.2012.04.037
   Sharma Mohit, 2013, J Oral Maxillofac Pathol, V17, P240, DOI 10.4103/0973-029X.119740
   Silva TD, 2013, ONCOL LETT, V6, P1687, DOI 10.3892/ol.2013.1606
   Sun Y, 2013, BIOCHEM BIOPH RES CO, V441, P600, DOI 10.1016/j.bbrc.2013.10.110
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Tsao CM, 2012, HEPATOLOGY, V56, P2277, DOI 10.1002/hep.25933
   Umbreit C, 2013, ANTICANCER RES, V33, P2457
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   von Marschall Z, 2010, BIOCHEM BIOPH RES CO, V400, P299, DOI 10.1016/j.bbrc.2010.08.043
   Webster MR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004114
   Zhang YK, 2011, EXP BIOL MED, V236, P714, DOI 10.1258/ebm.2011.010347
NR 32
TC 20
Z9 20
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2014
VL 10
IS 5
BP 2293
EP 2298
DI 10.3892/mmr.2014.2542
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AS7GB
UT WOS:000344424000010
PM 25189527
OA Green Submitted, Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Lu, HG
   Zhan, W
   Yan, L
   Qin, RY
   Yan, YP
   Yang, ZJ
   Liu, GC
   Li, GQ
   Wang, HF
   Li, XL
   Li, Z
   Gao, L
   Chen, GQ
AF Lu, Hou-Gen
   Zhan, Wang
   Yan, Lin
   Qin, Rui-Ying
   Yan, Yi-Peng
   Yang, Zhen-Jiang
   Liu, Gui-Chao
   Li, Gui-Qin
   Wang, Hai-Feng
   Li, Xing-Liang
   Li, Zhi
   Gao, Lu
   Chen, Guo-Qing
TI TET1 partially mediates HDAC inhibitor-induced suppression of breast
   cancer invasion
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE TET1; HDAC inhibitor; TSA; breast cancer
ID HISTONE DEACETYLASE INHIBITORS; NF-KAPPA-B; CELL INVASION; ANTICANCER
   AGENTS; TRICHOSTATIN-A; DNA-DAMAGE; ER-ALPHA; ACETYLATION; EXPRESSION;
   ACTIVATION
AB Histone deacetylases (HDACs) are important in chromatin remodeling and epigenetic regulation of gene expression. Histone deacetylase inhibitors (HDACi) have highly effective anti-metastatic and anti-angiogenic activity in various types of cancer, while the molecular mechanisms involved in this process are not fully understood. In the present study, trichostatin A (TSA), a HDACi, was found to suppress MCF-7 breast carcinoma cell invasion and upregulate TET1 expression in a dose-dependent manner. TET1, a dioxygenase involved in cytosine demethylation, is downregulated during breast cancer progression. TET1 knockdown in MCF-7 cells facilitates cell invasion, inhibits the expression of tissue inhibitors of metalloproteinase 2/3 (TIMP2/3) and promotes matrix metalloproteinases (MMP) 2/9 transcriptional activity. Importantly, TET1 depletion impaired the inhibitory effect of TSA on breast cancer cell invasion. Together, these results illustrated a mechanism by which TET1 partially mediates HDACi elicited suppression of breast cancer invasion.
C1 [Lu, Hou-Gen; Yan, Lin] Cent Hosp Jingzhou, Dept Orthoped, Jinzhou 434100, Hubei, Peoples R China.
   [Zhan, Wang] Shanghai Changzheng Hosp, Dept Med Oncol, Shanghai 200070, Peoples R China.
   [Qin, Rui-Ying; Yan, Yi-Peng; Yang, Zhen-Jiang; Li, Gui-Qin] Xin Xiang Med Univ, Affiliated Hosp 1, Weihui 453100, Henan, Peoples R China.
   [Liu, Gui-Chao] Orthopaed Hosp Nanyang, Dept Orthoped, Nanyang 473003, Henan, Peoples R China.
   [Wang, Hai-Feng] Shanghai Hengrui Pharmaceut Co, Shanghai 20035, Peoples R China.
   [Li, Xing-Liang; Li, Zhi] Shanghai Xuhai Biol Technol Co Ltd, Shanghai 20032, Peoples R China.
   [Gao, Lu] Northeast Agr Univ, Coll Life Sci, Dept Pharmaceut Biotechnol, Harbin 150030, Heilongjiang, Peoples R China.
   [Chen, Guo-Qing] Shanghai Tongren Hosp Changning, Dept Surg, Shanghai 200050, Peoples R China.
C3 Naval Medical University; Northeast Agricultural University - China;
   Shanghai Jiao Tong University
RP Chen, GQ (通讯作者)，Shanghai Tongren Hosp Changning, Dept Surg, 768 Yuyuan Rd, Shanghai 200050, Peoples R China.
EM cguoqing@yeah.net
RI Yu, Changjiang/AAL-5767-2020; chen, guoqing/KVY-0367-2024
CR ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775
   Asrani K, 2013, MOL CANCER RES, V11, P393, DOI 10.1158/1541-7786.MCR-12-0542
   Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Brochier C, 2013, J NEUROSCI, V33, P8621, DOI 10.1523/JNEUROSCI.5214-12.2013
   Brown SAN, 2010, J BIOL CHEM, V285, P17432, DOI 10.1074/jbc.M110.131979
   Cai FF, 2011, INT J MOL SCI, V12, P4465, DOI 10.3390/ijms12074465
   Cheung WL, 2000, CURR OPIN CELL BIOL, V12, P326, DOI 10.1016/S0955-0674(00)00096-X
   Chik F, 2011, CARCINOGENESIS, V32, P224, DOI 10.1093/carcin/bgq221
   DAVIES B, 1993, CANCER RES, V53, P5365
   Gräff J, 2013, NAT REV NEUROSCI, V14, P97, DOI 10.1038/nrn3427
   Grimaldi C, 2006, EXP CELL RES, V312, P363, DOI 10.1016/j.yexcr.2005.10.024
   Hatziapostolou M, 2011, CELL MOL LIFE SCI, V68, P1681, DOI 10.1007/s00018-010-0624-z
   Henderson C, 2003, J BIOL CHEM, V278, P12579, DOI 10.1074/jbc.M213093200
   Horikoshi M, 2013, CURR PHARM DESIGN, V19, P5019, DOI 10.2174/1381612811319280002
   Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jinga D, 2004, Roum Arch Microbiol Immunol, V63, P141
   Kim SH, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2562
   Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011
   Liu LT, 2003, CANCER RES, V63, P3069
   Liu T, 2006, CANCER TREAT REV, V32, P157, DOI 10.1016/j.ctrv.2005.12.006
   Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4
   Marks Paul A, 2004, Novartis Found Symp, V259, P269
   Mayo MW, 2003, J BIOL CHEM, V278, P18980, DOI 10.1074/jbc.M211695200
   McGarry LC, 2004, ONCOGENE, V23, P5284, DOI 10.1038/sj.onc.1207687
   Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100
   MOHANAM S, 1993, CANCER RES, V53, P4143
   Namdar M, 2010, P NATL ACAD SCI USA, V107, P20003, DOI 10.1073/pnas.1013754107
   Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121
   Sachweh MCC, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.61
   Shao YF, 2004, P NATL ACAD SCI USA, V101, P18030, DOI 10.1073/pnas.0408345102
   Sier CFM, 1996, BRIT J CANCER, V74, P413, DOI 10.1038/bjc.1996.374
   Song J, 2005, APMIS, V113, P264, DOI 10.1111/j.1600-0463.2005.apm_04.x
   Steeg PS, 2003, NAT REV CANCER, V3, P55, DOI 10.1038/nrc967
   Taby R, 2010, CA-CANCER J CLIN, V60, P376, DOI 10.3322/caac.20085
   Tarasenko N, 2008, CLIN EXP METASTAS, V25, P703, DOI 10.1007/s10585-008-9179-x
   Travaglini L, 2009, INT J BIOCHEM CELL B, V41, P225, DOI 10.1016/j.biocel.2008.08.019
   VanLint C, 1996, GENE EXPRESSION, V5, P245
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Williams K, 2011, NATURE, V473, P343, DOI 10.1038/nature10066
   Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67
   Yang XW, 2001, CANCER RES, V61, P7025
NR 43
TC 20
Z9 20
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD NOV
PY 2014
VL 10
IS 5
BP 2595
EP 2600
DI 10.3892/mmr.2014.2517
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AS7GB
UT WOS:000344424000056
PM 25175940
OA Bronze
DA 2025-01-12
ER

PT J
AU Kalamohan, K
   Periasamy, J
   Rao, DB
   Barnabas, GD
   Ponnaiyan, S
   Ganesan, K
AF Kalamohan, Kalaivani
   Periasamy, Jayaprakash
   Rao, Divya Bhaskar
   Barnabas, Georgina D.
   Ponnaiyan, Srigayatri
   Ganesan, Kumaresan
TI Transcriptional coexpression network reveals the involvement of varying
   stem cell features with different dysregulations in different gastric
   cancer subtypes
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Gastric cancer; Intestinal subtype; Diffuse subtype; Mesenchymal stem
   cells; Embryonic stem cells; Notch signaling; Polycomb repression;
   Mesenchymal stem cell differentiation
ID GENE-EXPRESSION SIGNATURE; HUMAN PROSTATE-CANCER; BREAST-CANCER;
   OSTEOBLAST DIFFERENTIATION; MOLECULAR CLASSIFICATION; MESENCHYMAL
   TRANSITION; TUMOR MICROENVIRONMENT; INTEGRATIVE ANALYSIS; STROMAL CELLS;
   IDENTIFICATION
AB Despite the advancements in the cancer therapeutics, gastric cancer ranks as the second most common cancers with high global mortality rate. Integrative functional genomic investigation is a powerful approach to understand the major dysregulations and to identify the potential targets toward the development of targeted therapeutics for various cancers. Intestinal and diffuse type gastric tumors remain the major subtypes and the molecular determinants and drivers of these distinct subtypes remain unidentified. In this investigation, by exploring the network of gene coexpression association in gastric tumors, mRNA expressions of 20,318 genes across 200 gastric tumors were categorized into 21 modules. The genes and the hub genes of the modules show gastric cancer subtype specific expression. The expression patterns of the modules were correlated with intestinal and diffuse subtypes as well as with the differentiation status of gastric tumors. Among these, G1 module has been identified as a major driving force of diffuse type gastric tumors with the features of (i) enriched mesenchymal, mesenchymal stem cell like, and mesenchymal derived multiple lineages, (ii) elevated OCT1 mediated transcription, (iii) involvement of Notch activation, and (iv) reduced polycomb mediated epigenetic repression. G13 module has been identified as key factor in intestinal type gastric tumors and found to have the characteristic features of (i) involvement of embryonic stem cell like properties, Wnt, MYC and E2F mediated transcription programs, and (iii) involvement of polycomb mediated repression. Thus the differential transcription programs, differential epigenetic regulation and varying stem cell features involved in two major subtypes of gastric cancer were delineated by exploring the gene coexpression network. The identified subtype specific dysregulations could be optimally employed in developing subtype specific therapeutic targeting strategies for gastric cancer. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Kalamohan, Kalaivani; Periasamy, Jayaprakash; Rao, Divya Bhaskar; Barnabas, Georgina D.; Ponnaiyan, Srigayatri; Ganesan, Kumaresan] Madurai Kamaraj Univ, Dept Genet, Canc Genet Lab, Ctr Excellence Genom Sci,Sch Biol Sci, Madurai 625021, Tamil Nadu, India.
C3 Madurai Kamaraj University
RP Ganesan, K (通讯作者)，Madurai Kamaraj Univ, Dept Genet, Canc Genet Lab, Ctr Excellence Genom Sci,Sch Biol Sci, Madurai 625021, Tamil Nadu, India.
EM kumar@oncocellomics.org
OI Ganesan, Kumaresan/0000-0003-0533-3181; Ponnaiyan,
   Srigayatri/0000-0001-5511-0918; Kalamohan, Kalavani/0000-0002-9234-5270
FU UGC-Meritorious fellowship; Department of Biotechnology (DBT), Govt. of
   India [BT/PR11625/MED/30/155/2008]
FX UGC-Meritorious fellowship support to Kalaivani Kalamohan is
   acknowledged. The experiments were performed with the research grant
   support from Department of Biotechnology (DBT), Govt. of India, through
   the research grant BT/PR11625/MED/30/155/2008 to Kumaresan Ganesan,
   Madurai Kamaraj University. Instrumentation supports of UGC-CEGS,
   DBT-IPLS, DST-PURSE, UGC-NRCBS, and UGC-CAS programme supported central
   facilities of SBS, MKU are acknowledged.
CR Abdollahi H, 2011, J SURG RES, V165, P112, DOI 10.1016/j.jss.2009.09.057
   Aggarwal A, 2006, CANCER RES, V66, P232, DOI 10.1158/0008-5472.CAN-05-2232
   Akiyama H, 2002, GENE DEV, V16, P2813, DOI 10.1101/gad.1017802
   Alphonso A, 2009, NEOPLASIA, V11, P1264, DOI 10.1593/neo.91302
   Aranda P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007809
   Augsten M, 2010, CANCER MICROENVIRON, V3, P167, DOI 10.1007/s12307-010-0040-9
   Barabási AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bhasin M, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-342
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Calvisi DF, 2005, J HEPATOL, V42, P842, DOI 10.1016/j.jhep.2005.01.029
   Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833
   Cho DY, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002820
   Cho JY, 2011, CLIN CANCER RES, V17, P1850, DOI 10.1158/1078-0432.CCR-10-2180
   Culhane AC, 2010, NUCLEIC ACIDS RES, V38, pD716, DOI 10.1093/nar/gkp1015
   Deng ZL, 2008, FRONT BIOSCI-LANDMRK, V13, P2001, DOI 10.2741/2819
   Dey P, 2011, INDIAN J CANCER, V48, P507, DOI 10.4103/0019-509X.92246
   Ding YB, 2003, WORLD J GASTROENTERO, V9, P1409, DOI 10.3748/wjg.v9.i7.1409
   Doig TN, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-469
   Dreger H, 2012, HYPERTENSION, V60, P1176, DOI 10.1161/HYPERTENSIONAHA.112.191098
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ellinger J, 2012, CANCER INVEST, V30, P92, DOI 10.3109/07357907.2011.636117
   Fiskus W, 2006, MOL CANCER THER, V5, P3096, DOI 10.1158/1535-7163.MCT-06-0418
   Förster S, 2011, MODERN PATHOL, V24, P1390, DOI 10.1038/modpathol.2011.99
   Fredlund E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3236
   Ganesan K, 2008, CANCER RES, V68, P4277, DOI 10.1158/0008-5472.CAN-07-6517
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Ghazalpour A, 2006, PLOS GENET, V2, P1182, DOI 10.1371/journal.pgen.0020130
   Giritharan G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026570
   Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531
   Gotea V, 2008, NUCLEIC ACIDS RES, V36, pW133, DOI 10.1093/nar/gkn300
   Graham TR, 2008, CANCER RES, V68, P2479, DOI 10.1158/0008-5472.CAN-07-2559
   Hamilton JP, 2006, CLIN GASTROENTEROL H, V4, P416, DOI 10.1016/j.cgh.2006.01.019
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Horvath S, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000117
   Hu ZJ, 2008, BRIEF BIOINFORM, V9, P317, DOI 10.1093/bib/bbn020
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Kitadai Y, 2010, CANCER MICROENVIRON, V3, P109, DOI 10.1007/s12307-009-0032-9
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kuijjer ML, 2012, GENE CHROMOSOME CANC, V51, P696, DOI 10.1002/gcc.21956
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31
   Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010
   Levine DM, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r93
   Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Milne AN, 2009, HUM GENET, V126, P615, DOI 10.1007/s00439-009-0722-x
   Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108
   Nagini S, 2012, WORLD J GASTRO ONCOL, V4, P156, DOI 10.4251/wjgo.v4.i7.156
   Ogasawara N, 2006, HISTOPATHOLOGY, V49, P612, DOI 10.1111/j.1365-2559.2006.02560.x
   Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676
   Parsons SJW, 2000, ANAL BIOCHEM, V281, P187, DOI 10.1006/abio.2000.4570
   Periasamy J, 2014, CELL SIGNAL, V26, P880, DOI 10.1016/j.cellsig.2014.01.017
   Ponomarev I, 2012, J NEUROSCI, V32, P1884, DOI 10.1523/JNEUROSCI.3136-11.2012
   Pujana MA, 2007, NAT GENET, V39, P1338, DOI 10.1038/ng.2007.2
   Qi HL, 2003, P NATL ACAD SCI USA, V100, P3305, DOI 10.1073/pnas.0532693100
   Qin Shaopu, 2013, Frontiers in Genetics, V3, P160, DOI 10.3389/fgene.2012.00160
   Ron-Bigger S, 2010, STEM CELLS, V28, P1349, DOI 10.1002/stem.468
   Saikawa Y, 2010, GASTRIC CANCER, V13, P11, DOI 10.1007/s10120-009-0537-4
   Schroeder MP, 2013, GENOME MED, V5, DOI 10.1186/gm413
   Sehn LH, 2012, HEMATOL-AM SOC HEMAT, P402, DOI 10.1182/asheducation-2012.1.402
   Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007
   Shah MA, 2011, CLIN CANCER RES, V17, P2693, DOI 10.1158/1078-0432.CCR-10-2203
   Singh SR, 2013, CANCER LETT, V338, P110, DOI 10.1016/j.canlet.2013.03.035
   Spaeth E, 2008, GENE THER, V15, P730, DOI 10.1038/gt.2008.39
   Stains JP, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-7-222
   Stuart JM, 2003, SCIENCE, V302, P249, DOI 10.1126/science.1087447
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sung SY, 2007, CURR PROB CANCER, V31, P36, DOI 10.1016/j.currproblcancer.2006.12.002
   Tan IB, 2011, GASTROENTEROLOGY, V141, P476, DOI 10.1053/j.gastro.2011.04.042
   Tay ST, 2003, CANCER RES, V63, P3309
   Teschendorff AE, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-604
   Tuxhorn JA, 2002, CLIN CANCER RES, V8, P2912
   Wong DJ, 2008, CELL STEM CELL, V2, P333, DOI 10.1016/j.stem.2008.02.009
   Wu YH, 2013, GUT, V62, P1100, DOI 10.1136/gutjnl-2011-301373
   Yang L, 2011, CANCER LETT, V310, P46, DOI 10.1016/j.canlet.2011.06.003
   Yashiro M, 2010, CANCER MICROENVIRON, V3, P127, DOI 10.1007/s12307-010-0036-5
   Zang ZJ, 2011, CANCER RES, V71, P29, DOI 10.1158/0008-5472.CAN-10-1749
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
   Zhang J, 2010, BMC BIOINFORMATICS, V11, DOI [10.1186/1471-2105-11-S9-S5, 10.1186/1471-2105-11-s9-s5]
   Zhang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.152
   Zhao M, 2010, MOL CARCINOGEN, V49, P923, DOI 10.1002/mc.20675
NR 83
TC 18
Z9 18
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD OCT
PY 2014
VL 8
IS 7
BP 1306
EP 1325
DI 10.1016/j.molonc.2014.04.005
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AS7KK
UT WOS:000344434900014
PM 24917244
OA Green Accepted, Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Bethge, N
   Honne, H
   Andresen, K
   Hilden, V
   Troen, G
   Liestol, K
   Holte, H
   Delabie, J
   Lind, GE
   Smeland, EB
AF Bethge, Nicole
   Honne, Hilde
   Andresen, Kim
   Hilden, Vera
   Troen, Gunhild
   Liestol, Knut
   Holte, Harald
   Delabie, Jan
   Lind, Guro E.
   Smeland, Erlend B.
TI A Gene Panel, Including <i>LRP12</i>, Is Frequently Hypermethylated in
   Major Types of B-Cell Lymphoma
SO PLOS ONE
LA English
DT Article
ID BETA-RECEPTOR-II; PROMOTER HYPERMETHYLATION; DNA METHYLATION;
   E-CADHERIN; BREAST-CANCER; CPG-ISLANDS; EXPRESSION; RESISTANCE;
   MALIGNANCIES; DETERMINANT
AB Epigenetic modifications and DNA methylation in particular, have been recognized as important mechanisms to alter gene expression in malignant cells. Here, we identified candidate genes which were upregulated after an epigenetic treatment of B-cell lymphoma cell lines (Burkitt's lymphoma, BL; Follicular lymphoma, FL; Diffuse large B-cell lymphoma, DLBCL activated B-cell like, ABC; and germinal center like, GCB) and simultaneously expressed at low levels in samples from lymphoma patients. Qualitative methylation analysis of 24 candidate genes in cell lines revealed five methylated genes (BMP7, BMPER, CDH1, DUSP4 and LRP12), which were further subjected to quantitative methylation analysis in clinical samples from 59 lymphoma patients (BL, FL, DLBCL ABC and GCB; and primary mediastinal B-cell lymphoma, PMBL). The genes LRP12 and CDH1 showed the highest methylation frequencies (94% and 92%, respectively). BMPER (58%), DUSP4 (32%) and BMP7 (22%), were also frequently methylated in patient samples. Importantly, all gene promoters were unmethylated in various control samples (CD19+ peripheral blood B cells, peripheral blood mononuclear cells and tonsils) as well as in follicular hyperplasia samples, underscoring a high specificity. The combination of LRP12 and CDH1 methylation could successfully discriminate between the vast majority of the lymphoma and control samples, emphasized by receiver operating characteristic analysis with a c-statistic of 0.999. These two genes represent promising epigenetic markers which may be suitable for monitoring of B-cell lymphoma.
C1 [Bethge, Nicole; Hilden, Vera; Smeland, Erlend B.] Oslo Univ Hosp, Inst Canc Res, Dept Immunol, Oslo, Norway.
   [Bethge, Nicole; Honne, Hilde; Andresen, Kim; Hilden, Vera; Liestol, Knut; Holte, Harald; Lind, Guro E.; Smeland, Erlend B.] Univ Oslo, Ctr Canc Biomed, Oslo, Norway.
   [Honne, Hilde; Andresen, Kim; Lind, Guro E.] Oslo Univ Hosp, Inst Canc Res, Dept Canc Prevent, Oslo, Norway.
   [Troen, Gunhild; Delabie, Jan] Oslo Univ Hosp, Dept Pathol, Oslo, Norway.
   [Liestol, Knut] Univ Oslo, Dept Informat, N-0316 Oslo, Norway.
   [Holte, Harald] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Oncol, Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; University of Oslo; University of Oslo
RP Smeland, EB (通讯作者)，Oslo Univ Hosp, Inst Canc Res, Dept Immunol, Oslo, Norway.
EM ebs@rr-research.no
RI Holte, Harald/AAO-5647-2020; Smeland, Erlend/AAO-3214-2020; Delabie,
   Jan/HSF-1260-2023
OI Delabie, Jan/0000-0001-5023-0689; Lind, Guro
   Elisabeth/0000-0003-4643-9345
FU South-Eastern Norway Regional Health Authority [39232, 39535]; Norwegian
   Cancer Society [33260, PR-2008-0163]; Research Council of Norway through
   its Centres of Excellence funding scheme [179571]
FX This work was supported by grants from the South-Eastern Norway Regional
   Health Authority (ES: no. 39232, funding NB as PhD and GEL: no. 39535),
   and The Norwegian Cancer Society (ES: no. 33260 and GEL: PR-2008-0163).
   In addition, this work was partly supported by the Research Council of
   Norway through its Centres of Excellence funding scheme, project number
   179571. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501
   Amara K, 2008, ANN ONCOL, V19, P1774, DOI 10.1093/annonc/mdn374
   Andresen K, 2012, EPIGENETICS-US, V7, P1249, DOI 10.4161/epi.22191
   Berx G, 2009, COLD SPRING HARBOR P, DOI [10.1101/cshperspect.a0031291, DOI 10.1101/CSHPERSPECT.A0031291]
   Chen G, 2007, BLOOD, V109, P5301, DOI 10.1182/blood-2006-06-032128
   Corn PG, 2000, CLIN CANCER RES, V6, P4243
   Daibata M, 2007, CLIN CANCER RES, V13, P3528, DOI 10.1158/1078-0432.CCR-06-2766
   Dave SS, 2006, NEW ENGL J MED, V354, P2431, DOI 10.1056/NEJMoa055759
   de Carvalho F, 2009, INT J CANCER, V125, P1985, DOI 10.1002/ijc.24431
   De S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003137
   Esteller M, 2002, J NATL CANCER I, V94, P26
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Garnis C, 2004, ONCOGENE, V23, P2582, DOI 10.1038/sj.onc.1207367
   Helbing T, 2010, CARDIOVASC RES, V85, P551, DOI 10.1093/cvr/cvp314
   Herman JG, 1997, CANCER RES, V57, P837
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Huang Q, 2007, LEUKEMIA LYMPHOMA, V48, P1988, DOI 10.1080/10428190701573224
   Ibanez de Caceres I, 2010, ONCOGENE, V29, P1681, DOI 10.1038/onc.2009.454
   Inman GJ, 2011, CURR OPIN GENET DEV, V21, P93, DOI 10.1016/j.gde.2010.12.004
   Iorns E, 2008, CANCER CELL, V13, P91, DOI 10.1016/j.ccr.2008.01.001
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kelley R, 2009, J CELL BIOL, V184, P597, DOI 10.1083/jcb.200808064
   Kron K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004830
   Levy L, 2006, CYTOKINE GROWTH F R, V17, P41, DOI 10.1016/j.cytogfr.2005.09.009
   Melki JR, 2000, BLOOD, V95, P3208
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   O'Riain C, 2009, LEUKEMIA, V23, P1858, DOI 10.1038/leu.2009.114
   Pinto M, 2003, J PATHOL, V200, P32, DOI 10.1002/path.1327
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Shaffer AL, 2002, NAT REV IMMUNOL, V2, P920, DOI 10.1038/nri953
   Shaknovich R, 2010, BLOOD, V116, pE81, DOI 10.1182/blood-2010-05-285320
   Shi HD, 2007, CARCINOGENESIS, V28, P60, DOI 10.1093/carcin/bgl092
   Shivapurkar N, 2010, CURR MOL MED, V10, P123, DOI 10.2174/156652410790963303
   Sudo M, 2004, INT J CANCER, V109, P194, DOI 10.1002/ijc.11701
   Syed N, 2011, CANCER RES, V71, P3317, DOI 10.1158/0008-5472.CAN-10-2048
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Uccella S, 2009, J CLIN PATHOL, V62, P715, DOI 10.1136/jcp.2009.064741
   Waha A, 2010, CANCER RES, V70, P1689, DOI 10.1158/0008-5472.CAN-09-3218
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
NR 42
TC 12
Z9 14
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 16
PY 2014
VL 9
IS 9
AR e104249
DI 10.1371/journal.pone.0104249
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AS5NP
UT WOS:000344317700003
PM 25226156
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Zhang, Y
   Li, Y
   Lin, CW
   Ding, J
   Liao, GQ
   Tang, B
AF Zhang, Yi
   Li, Yang
   Lin, Changwei
   Ding, Jie
   Liao, Guoqing
   Tang, Bo
TI Aberrant Upregulation of 14-3-3σ and EZH2 Expression Serves as an
   Inferior Prognostic Biomarker for Hepatocellular Carcinoma
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; PROTEIN; GENE
AB Hepatocellular carcinoma (HCC) is the fifth most common malignancy in the world. It is of important significance to find biomarkers for the prognostic monitoring of HCC. The 14-3-3 sigma and EZH2 proteins are involved in cell cycle regulation and epigenetic silencing. We herein examined the significance of 14-3-3 sigma and EZH2 in HCC (n = 167) by immunohistochemistry, RT-PCR and qRT-PCR. The correlation between 14-3-3s and EZH2 expression and patients' clinicopathologic features were examined, as was the correlation between 14-3-3 sigma and EZH2 expression and the prognosis of HCC patients. We found that 14-3-3 sigma and EZH2 were highly expressed in HCC (71% and 90%), the expression of EZH2, but not 14-3-3 sigma, is associated with vascular invasion and tumor differentiation (p<0.01). The coexistence of 14-3-3 sigma and EZH2 overexpression is associated with a relatively unfavorable prognosis (p<0.01), suggesting that aberrant upregulation of 14-3-3 sigma and EZH2 expression serves as an inferior prognostic biomarker for HCC.
C1 [Zhang, Yi; Liao, Guoqing] Cent S Univ, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha, Hunan, Peoples R China.
   [Lin, Changwei] Cent S Univ, Xiangya Hosp 3, Dept Gastrointestinal Surg, Changsha, Hunan, Peoples R China.
   [Ding, Jie] Guizhou Prov Peoples Hosp, Dept Gastrointestinal Surg, Guiyang, Peoples R China.
   [Li, Yang; Tang, Bo] Guilin Med Univ, Affiliated Hosp, Dept Hepatobiliary Surg, Guilin, Peoples R China.
C3 Central South University; Central South University; Guilin Medical
   University
RP Liao, GQ (通讯作者)，Cent S Univ, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha, Hunan, Peoples R China.
EM liaoguoqing@medmail.com.cn; dytangbo@163.com
RI Lin, Changwei/HKP-0560-2023
OI Zhang, Yi/0000-0001-9357-1205; Liao, Guo-Qing/0000-0002-5967-0282
FU National Natural Science Foundation of China [81360367]; Science and
   technology research projects focused on universities in Guangxi
   [2013ZD046]; Guangxi Health Department; National Natural Science
   Foundation of Hunan province [08JJ5009, Z2013464]
FX This research was supported by the National Natural Science Foundation
   of China (81360367), Science and technology research projects focused on
   universities in Guangxi (2013ZD046), Guangxi Health Department
   self-funded project, and the National Natural Science Foundation of
   Hunan province (08JJ5009) (Z2013464). The funders participated in study
   design, data collection and analysis.
CR Au SLK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068226
   Bedossa P, 1996, HEPATOLOGY, V24, P289, DOI 10.1002/hep.510240201
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cardoso C, 2000, EUR J HUM GENET, V8, P174, DOI 10.1038/sj.ejhg.5200439
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Gheibi A, 2012, Adv Biomed Res, V1, P80, DOI 10.4103/2277-9175.102990
   Hajósi-Kalcakosz S, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-86
   Iwata N, 2000, ONCOGENE, V19, P5298, DOI 10.1038/sj.onc.1203898
   Kino T, 2005, J VIROL, V79, P2780, DOI 10.1128/JVI.79.5.2780-2787.2005
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199
   Luo J, 2010, MED ONCOL, V27, P791, DOI 10.1007/s12032-009-9287-8
   Okuda K, 2000, J HEPATOL, V32, P225, DOI 10.1016/S0168-8278(00)80428-6
   Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9
   Sasaki M, 2008, LAB INVEST, V88, P873, DOI 10.1038/labinvest.2008.52
   Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Zhou WH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-397
   Zurita M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-217
NR 20
TC 20
Z9 21
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 16
PY 2014
VL 9
IS 9
AR e107251
DI 10.1371/journal.pone.0107251
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AS5NP
UT WOS:000344317700039
PM 25226601
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Grimmer, MR
   Stolzenburg, S
   Ford, E
   Lister, R
   Blancafort, P
   Farnham, PJ
AF Grimmer, Matthew R.
   Stolzenburg, Sabine
   Ford, Ethan
   Lister, Ryan
   Blancafort, Pilar
   Farnham, Peggy J.
TI Analysis of an artificial zinc finger epigenetic modulator: widespread
   binding but limited regulation
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID TRANSCRIPTION FACTORS; HISTONE MODIFICATIONS; GENE-EXPRESSION; HUMAN
   GENOME; DNA ELEMENTS; PROTEINS; CANCER; REACTIVATION; COACTIVATOR;
   DOMAINS
AB Artificial transcription factors (ATFs) and genomic nucleases based on a DNA binding platform consisting of multiple zinc finger domains are currently being developed for clinical applications. However, no genome-wide investigations into their binding specificity have been performed. We have created six-finger ATFs to target two different 18 nt regions of the human SOX2 promoter; each ATF is constructed such that it contains or lacks a super KRAB domain (SKD) that interacts with a complex containing repressive histone methyltransferases. ChIP-seq analysis of the effector-free ATFs in MCF7 breast cancer cells identified thousands of binding sites, mostly in promoter regions; the addition of an SKD domain increased the number of binding sites similar to 5-fold, with a majority of the new sites located outside of promoters. De novo motif analyses suggest that the lack of binding specificity is due to subsets of the finger domains being used for genomic interactions. Although the ATFs display widespread binding, few genes showed expression differences; genes repressed by the ATF-SKD have stronger binding sites and are more enriched for a 12 nt motif. Interestingly, epigenetic analyses indicate that the transcriptional repression caused by the ATF-SKD is not due to changes in active histone modifications.
C1 [Grimmer, Matthew R.; Farnham, Peggy J.] Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
   [Grimmer, Matthew R.] Univ Calif Davis, Davis, CA 95616 USA.
   [Stolzenburg, Sabine; Blancafort, Pilar] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27599 USA.
   [Stolzenburg, Sabine; Blancafort, Pilar] Univ Western Australia, Sch Anat Physiol & Human Biol, Crawley, WA 6009, Australia.
   [Ford, Ethan; Lister, Ryan] Univ Western Australia, Australian Res Council Ctr Excellence Plant Energ, Perth, WA 6009, Australia.
   [Blancafort, Pilar] Harry Perkins Inst Med Res, Canc Epigenet Grp, Nedlands, WA 6008, Australia.
C3 University of Southern California; University of California System;
   University of California Davis; University of North Carolina; University
   of North Carolina Chapel Hill; University of North Carolina School of
   Medicine; University of Western Australia; University of Western
   Australia; Harry Perkins Institute of Medical Research
RP Farnham, PJ (通讯作者)，Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA.
EM pilar.blancafort@uwa.edu.au; pfarnham@usc.edu
RI Blancafort, Pilar/K-9029-2012; Lister, Ryan/B-5168-2012
OI Blancafort, Pilar/0000-0002-3881-7396; Farnham,
   Peggy/0000-0003-4469-7914; Lister, Ryan/0000-0001-6637-7239; Grimmer,
   Matthew/0000-0001-5184-9168
FU National Cancer Institute [P30CA014089]; Australian Research Council
   Future Fellowship [FT130101767, FT120100862]; Cancer Council of Western
   Australia Research Fellowship; National Health and Medical Research
   Council [APP1069830]; National Institutes of Health [R01CA170370,
   R01DA036906, R21HG006761]; National Breast Cancer Foundation Novel
   Concept award [NC-14-024]; Raine Medical Research Foundation; Western
   Australia Centre of Excellence for Computational Systems Biology;
   Australian Research Council [FT120100862] Funding Source: Australian
   Research Council
FX National Cancer Institute [P30CA014089]; Australian Research Council
   Future Fellowship [FT130101767, FT120100862]; Cancer Council of Western
   Australia Research Fellowship; National Health and Medical Research
   Council [APP1069830]; National Institutes of Health [R01CA170370,
   R01DA036906, R21HG006761]; National Breast Cancer Foundation Novel
   Concept award NC-14-024; Raine Medical Research Foundation; Western
   Australia Centre of Excellence for Computational Systems Biology.
   Funding for open access charge: National Institutes of Health
   [R21HG006761].
CR [Anonymous], 2011, PLOS BIOL, DOI DOI 10.1371/JOURNAL.PBIO.1001046
   Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803
   Barde I, 2009, J VIROL, V83, P5574, DOI 10.1128/JVI.00001-09
   Beerli RR, 1998, P NATL ACAD SCI USA, V95, P14628, DOI 10.1073/pnas.95.25.14628
   Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072
   Beltran AS, 2008, MOL CANCER THER, V7, P1080, DOI 10.1158/1535-7163.MCT-07-0526
   Beltran AS, 2011, EPIGENETICS-US, V6, P224, DOI 10.4161/epi.6.2.13700
   Bhakta MS, 2010, METHODS MOL BIOL, V649, P3, DOI 10.1007/978-1-60761-753-2_1
   Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874
   Blahnik KR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017121
   Blahnik KR, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1012
   Chang CJ, 1998, MOL CELL BIOL, V18, P5880, DOI 10.1128/MCB.18.10.5880
   Chen H, 2014, NUCLEIC ACIDS RES, V42, P1563, DOI 10.1093/nar/gkt1019
   Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113
   Dobbelstein M, 2014, NAT REV DRUG DISCOV, V13, P179, DOI 10.1038/nrd4201
   Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   ElrodErickson M, 1996, STRUCTURE, V4, P1171, DOI 10.1016/S0969-2126(96)00125-6
   Farnham PJ, 2009, NAT REV GENET, V10, P605, DOI 10.1038/nrg2636
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Frietze S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r52
   Frietze S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015082
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044
   Gommans WM, 2007, MOL CARCINOGEN, V46, P391, DOI 10.1002/mc.20289
   Grimmer M.R., 2014, EPIGENOMICS IN PRESS
   Groner AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000869
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hsu PD, 2013, NAT BIOTECHNOL, V31, P827, DOI 10.1038/nbt.2647
   Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012
   Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569
   Iyengar S, 2011, MOL CELL BIOL, V31, P1833, DOI 10.1128/MCB.01331-10
   Ji QZ, 2014, NUCLEIC ACIDS RES, V42, P6158, DOI 10.1093/nar/gku243
   Juárez-Moreno K, 2013, EPIGENETICS-US, V8, P164, DOI 10.4161/epi.23503
   Kuscu C, 2014, NAT BIOTECHNOL, V32, P677, DOI 10.1038/nbt.2916
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lara H, 2012, J BIOL CHEM, V287, P29873, DOI 10.1074/jbc.M112.360768
   Lee TI, 2013, CELL, V152, P1237, DOI 10.1016/j.cell.2013.02.014
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li XY, 2014, CURR DRUG TARGETS, V15, P622, DOI 10.2174/1389450115666140306152642
   Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525
   Lovén J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036
   MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509
   Mendenhall EM, 2013, NAT BIOTECHNOL, V31, P1133, DOI 10.1038/nbt.2701
   O'Geen H, 2011, METHODS MOL BIOL, V791, P265, DOI 10.1007/978-1-61779-316-5_20
   Perez-Pinera P, 2013, NAT METHODS, V10, P973, DOI [10.1038/NMETH.2600, 10.1038/nmeth.2600]
   Perez-Pinera P, 2013, NAT METHODS, V10, P239, DOI [10.1038/NMETH.2361, 10.1038/nmeth.2361]
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rambaud J, 2009, J BIOL CHEM, V284, P14147, DOI 10.1074/jbc.M809023200
   Ramirez CL, 2008, NAT METHODS, V5, P374, DOI 10.1038/nmeth0508-374
   Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507
   Rooney JW, 2001, GENE DEV, V15, P3023, DOI 10.1101/gad.937201
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Segal DJ, 2013, ANNU REV GENOM HUM G, V14, P135, DOI 10.1146/annurev-genom-091212-153435
   Segal DJ, 2000, CURR OPIN CHEM BIOL, V4, P34, DOI 10.1016/S1367-5931(99)00048-4
   Segal DJ, 2003, BIOCHEMISTRY-US, V42, P2137, DOI 10.1021/bi026806o
   Sripathy SP, 2006, MOL CELL BIOL, V26, P8623, DOI 10.1128/MCB.00487-06
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Tadepally HD, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-176
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Urnov FD, 2010, NAT REV GENET, V11, P636, DOI 10.1038/nrg2842
   Verschure PJ, 2006, ADV GENET, V56, P163, DOI 10.1016/S0065-2660(06)56005-5
   West AC, 2014, J CLIN INVEST, V124, P30, DOI 10.1172/JCI69738
   Wu XB, 2014, NAT BIOTECHNOL, V32, P670, DOI 10.1038/nbt.2889
   Yang XJ, 2010, TRENDS PHARMACOL SCI, V31, P536, DOI 10.1016/j.tips.2010.08.001
NR 65
TC 50
Z9 59
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD SEP 15
PY 2014
VL 42
IS 16
BP 10856
EP 10868
DI 10.1093/nar/gku708
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AT0TM
UT WOS:000344647700058
PM 25122745
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Dembic, Z
AF Dembic, Zlatko
TI Pharmaco-Therapeutic Challenges in Cancer Biology with Focus on the
   Immune-System Related Risk Factors
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Cancer; immune system; predisposition; inflammation; epigenetics;
   genetics; microRNA
ID BREAST-CANCER; STEM-CELLS; T-CELLS; BRAF INHIBITION; DENDRITIC CELLS;
   FOLLOW-UP; EPIGENETICS; SURVEILLANCE; POLYMORPHISM; METHYLATION
AB Over the past, progress has always been achieved in therapy of various human diseases with the introduction of novel methodologies from basic to clinical research. Recent advances in techniques, especially DNA sequencing and methylation analyses, faster miniaturized proteomics and live cellular stainings, are opening a new era in cancer research. Perhaps the difference this time can be envisaged as the beginning of the long-sought individualization of forthcoming cancer therapies. Cancer has complex genetic susceptibility that is wider than previously thought. Apart from genes encoding six functional capabilities of cancer-independent growth, avoidance of apoptosis, immortalization, multi-drug resistance, neovascularization, and invasiveness - predisposition includes four more factors that promote genome instability, inflammation, deregulation of metabolism as well as evasion of destruction by the immune system. The underlying genetic events, i.e. base-pair DNA mutations, are not the sole factors in cancer development. Additional novel controls of gene expression have been found in the epigenetic machinery, which has been increasingly important in assessing cancer risk in recent years. The predisposing factors, including their regulatory elements, are bona fide potential new targets in prospective cancer pharmacotherapy.
C1 Univ Oslo, Mol Genet Lab, Dept Oral Biol, Fac Dent, N-0316 Oslo, Norway.
C3 University of Oslo
RP Dembic, Z (通讯作者)，Univ Oslo, Mol Genet Lab, Dept Oral Biol, Fac Dent, N-0316 Oslo, Norway.
EM zlatko.dembic@odont.uio.no
RI Dembic, Zlatko/A-1833-2008
OI Dembic, Zlatko/0000-0002-9970-6497
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039
   [Anonymous], 1996, EPIGENETIC MECH GENE
   Bergfeld SA, 2010, CANCER METAST REV, V29, P249, DOI 10.1007/s10555-010-9222-7
   Bindea G, 2010, CURR OPIN IMMUNOL, V22, P215, DOI 10.1016/j.coi.2010.02.006
   Birkeland SA, 2003, TRANSPLANTATION, V76, P153, DOI 10.1097/01.TP.0000072015.08302.E9
   BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209
   Bogen B, 2000, ACTA ONCOL, V39, P783
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   BURNET FM, 1970, PROG EXP TUMOR RES, V13, P1
   Calvisi DF, 2007, J CLIN INVEST, V117, P2713, DOI 10.1172/JCI31457
   Cheung TH, 2012, NATURE, V482, P524, DOI 10.1038/nature10834
   Cho RW, 2008, CURR OPIN GENET DEV, V18, P48, DOI 10.1016/j.gde.2008.01.017
   Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440
   Daniel M, 2012, GENE, V498, P135, DOI 10.1016/j.gene.2012.01.095
   Dembic Z, 2013, SCAND J IMMUNOL, V78, P325, DOI 10.1111/sji.12090
   Dembic Z, 2000, P NATL ACAD SCI USA, V97, P2697, DOI 10.1073/pnas.050579897
   Dembic Z, 2001, BLOOD, V97, P2808, DOI 10.1182/blood.V97.9.2808
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Ferrone C, 2010, J CLIN ONCOL, V28, P4045, DOI 10.1200/JCO.2010.27.9992
   Flanagan JM, 2013, ANN ONCOL, V24, P2813, DOI 10.1093/annonc/mdt370
   Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630
   Fujiwara K, 2015, MOL CARCINOGEN, V54, P178, DOI 10.1002/mc.22085
   GATTI RA, 1971, CANCER-AM CANCER SOC, V28, P89, DOI 10.1002/1097-0142(197107)28:1<89::AID-CNCR2820280117>3.0.CO;2-Q
   Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246
   Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916
   Haffner MC, 2011, ONCOTARGET, V2, P627
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanna JH, 2010, CELL, V143, P508, DOI 10.1016/j.cell.2010.10.008
   Hanson EM, 2009, J IMMUNOL, V183, P937, DOI 10.4049/jimmunol.0804253
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Huang THM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004515
   Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010
   Jakopovic M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00261
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kaarvatn MH, 2012, SCAND J IMMUNOL, V76, P329, DOI 10.1111/j.1365-3083.2012.02736.x
   Kaarvatn MH, 2012, PERIOD BIOL, V114, P497
   Kang HY, 2013, STEM CELL RES THER, V4, DOI 10.1186/1757-6512-4-110
   Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Liu CW, 2013, CLIN CANCER RES, V19, P393, DOI 10.1158/1078-0432.CCR-12-1626
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Ma C, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00133
   Macfarlan TS, 2012, NATURE, V487, P57, DOI 10.1038/nature11244
   Mathers JC, 2010, ADV GENET, V71, P3, DOI [10.1016/S0065-2660(10)71001-4, 10.1016/B978-0-12-380864-6.00001-8]
   Metcalfe K, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g226
   Mougiakakos D, 2010, ADV CANCER RES, V107, P57, DOI 10.1016/S0065-230X(10)07003-X
   Nebert DW, 2002, GENET MED, V4, P62, DOI 10.1097/00125817-200203000-00003
   Nelson BH, 2008, IMMUNOL REV, V222, P101, DOI 10.1111/j.1600-065X.2008.00614.x
   Ostrand-Rosenberg S, 2009, J IMMUNOL, V182, P4499, DOI 10.4049/jimmunol.0802740
   Pagès F, 2010, ONCOGENE, V29, P1093, DOI 10.1038/onc.2009.416
   Perona Rosario, 2006, Clin Transl Oncol, V8, P77, DOI 10.1007/s12094-006-0162-1
   Raica M, 2009, EUR J CANCER, V45, P1924, DOI 10.1016/j.ejca.2009.04.007
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Robinton DA, 2012, NATURE, V481, P295, DOI 10.1038/nature10761
   Rosenberg SA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003634
   Schwarz TF, 2012, J ADOLESCENT HEALTH, V50, P187, DOI 10.1016/j.jadohealth.2011.11.004
   Schweiger MR, 2011, CANCER METAST REV, V30, P199, DOI 10.1007/s10555-011-9278-z
   Shao CB, 2011, CLIN CANCER RES, V17, P4320, DOI 10.1158/1078-0432.CCR-10-2992
   Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343
   Silva TM, 2014, GENET MOL RES, V13, P528, DOI 10.4238/2014.January.21.22
   Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7
   Smyth MJ, 2004, IMMUNOL REV, V202, P275, DOI 10.1111/j.0105-2896.2004.00199.x
   Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755
   Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302
   Strauss DC, 2010, LANCET ONCOL, V11, P790, DOI 10.1016/S1470-2045(10)70024-3
   Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063
   Suijkerbuijk KPM, 2011, ANN ONCOL, V22, P24, DOI 10.1093/annonc/mdq305
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Teng MWL, 2008, J LEUKOCYTE BIOL, V84, P988, DOI 10.1189/jlb.1107774
   Tollefsbol TO, 2014, CANCER TREAT RES, V159, P257, DOI 10.1007/978-3-642-38007-5_15
   Vajdic CM, 2009, INT J CANCER, V125, P1747, DOI 10.1002/ijc.24439
   van Veldhoven K, 2014, CANCER TREAT RES, V159, P241, DOI 10.1007/978-3-642-38007-5_14
   Wang W, 2010, CANCER PREV RES, V3, P16, DOI 10.1158/1940-6207.CAPR-09-0098
   Xing CH, 2013, ENVIRON MOL MUTAGEN, V54, P397, DOI 10.1002/em.21786
   Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936
NR 82
TC 3
Z9 3
U1 0
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2014
VL 20
IS 42
BP 6652
EP 6659
DI 10.2174/1381612820666140826154147
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AS0XD
UT WOS:000343998200011
PM 25341937
DA 2025-01-12
ER

PT J
AU Colón-Bolea, P
   Crespo, P
AF Colon-Bolea, Paula
   Crespo, Piero
TI Lysine methylation in cancer: SMYD3-MAP3K2 teaches us new lessons in the
   Ras-ERK pathway
SO BIOESSAYS
LA English
DT Article
DE cancer; ERK; lysine methylation; lysine methyltransferases; MAP3K2; Ras;
   SMYD3
ID ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; HISTONE METHYLTRANSFERASE;
   BREAST-CANCER; POSTTRANSLATIONAL MODIFICATIONS; CELL PROLIFERATION;
   DEMETHYLASE GENE; PROSTATE-CANCER; SUPPRESSOR GENE; RECEPTOR-ALPHA
AB Lysine methylation has been traditionally associated with histones and epigenetics. Recently, lysine methyltransferases and demethylases - which are involved in methylation of non-histone substrates - have been frequently found deregulated in human tumours. In this realm, a new discovery has unveiled the methyltransferase SMYD3 as an enhancer of Ras-driven cancer. SMYD3 is up-regulated in different types of tumours. SMYD3-mediated methylation of MAP3K2 increases mutant K-Ras-induced activation of ERK1/2. Methylation of MAP3K2 prevents it from binding to the phosphatase PP2A, thereby impeding the impact of this negative regulator on Ras-ERK1/2 signals, leading to the formation of lung and pancreatic adenocarcinomas. Furthermore, depletion of SMYD3 synergises with a MEK inhibitor, currently in clinical trials, to block Ras-driven pancreatic neoplasia. These results underscore the importance of lysine methylation in the regulation of signalling pathways relevant for tumourigenesis and endorse the development of drugs targeting unregulated lysine methylation as therapeutic agents in the struggle against cancer.
C1 [Colon-Bolea, Paula; Crespo, Piero] Univ Cantabria, CSIC, Inst Biomed & Biotecnol Cantabria IBBTEC, E-39005 Santander, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de
   Cantabria; CSIC - Instituto de Biomedicina y Biotecnologia de Cantabria
   (IBBTEC)
RP Crespo, P (通讯作者)，Univ Cantabria, CSIC, Inst Biomed & Biotecnol Cantabria IBBTEC, E-39005 Santander, Spain.
EM crespop@unican.es
RI Crespo, Piero/M-3273-2014
OI Crespo, Piero/0000-0003-2825-7783
FU Spanish Ministry of Economy - Fondos FEDER [BFU2011-23807]; Red Tematica
   de Investigacion Cooperativa en Cancer (RTICC), Spanish Ministry of
   Health [RD/12/0036/0033]
FX PC Lab is supported by grant BFU2011-23807 from the Spanish Ministry of
   Economy - Fondos FEDER and by the Red Tematica de Investigacion
   Cooperativa en Cancer (RTICC) (RD/12/0036/0033), Spanish Ministry of
   Health.
CR Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Black JC, 2013, BIOPOLYMERS, V99, P127, DOI 10.1002/bip.22136
   Calvo F, 2010, BIOESSAYS, V32, P412, DOI 10.1002/bies.200900155
   Chen B, 2005, GENOMICS, V86, P627, DOI 10.1016/j.ygeno.2005.08.012
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Chervona Y, 2012, AM J CANCER RES, V2, P589
   Cho HS, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2074
   Cho HS, 2012, NEOPLASIA, V14, P476, DOI 10.1593/neo.12656
   Choi MC, 2012, MOL CELL, V47, P122, DOI 10.1016/j.molcel.2012.04.025
   Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117
   Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052
   Cuevas BD, 2007, ONCOGENE, V26, P3159, DOI 10.1038/sj.onc.1210409
   Dhayalan A, 2011, CHEM BIOL, V18, P111, DOI 10.1016/j.chembiol.2010.11.014
   Dillon SC, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-8-227
   Donlin LT, 2012, GENE DEV, V26, P114, DOI 10.1101/gad.177758.111
   Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120
   Eichhorn PJA, 2009, BBA-REV CANCER, V1795, P1, DOI 10.1016/j.bbcan.2008.05.005
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Estève PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106
   Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961
   Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6
   Gaedcke J, 2010, GENE CHROMOSOME CANC, V49, P1024, DOI 10.1002/gcc.20811
   Grant JE, 2007, J PROTEOME RES, V6, P2786, DOI 10.1021/pr070013c
   Guerrera IC, 2007, J PROTEOME RES, V6, P2623, DOI 10.1021/pr070078f
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x
   Hamamoto R, 2014, CANCER LETT, V351, P126, DOI 10.1016/j.canlet.2014.05.014
   Hartsough EJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004289
   He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111
   Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751
   Henning SM, 1997, J NUTR, V127, P30, DOI 10.1093/jn/127.1.30
   Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Huq MDM, 2008, J PROTEOME RES, V7, P4538, DOI 10.1021/pr800375z
   Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07
   Jakobsson ME, 2013, J BIOL CHEM, V288, P27752, DOI 10.1074/jbc.M113.483248
   Jura N, 2006, MOL CELL, V21, P679, DOI 10.1016/j.molcel.2006.02.011
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Komatsu S, 2009, CARCINOGENESIS, V30, P1139, DOI 10.1093/carcin/bgp116
   Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Kubota Y, 2011, NAT CELL BIOL, V13, P282, DOI 10.1038/ncb2169
   Kunizaki M, 2007, CANCER RES, V67, P10759, DOI 10.1158/0008-5472.CAN-07-1132
   Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042
   Lanouette S, 2014, MOL SYST BIOL, V10, DOI 10.1002/msb.134974
   Lee JS, 2010, MOL CELL, V39, P71, DOI 10.1016/j.molcel.2010.06.008
   Levy D, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-19
   Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126
   Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107
   Maruyama T, 2010, EMBO J, V29, P2501, DOI 10.1038/emboj.2010.141
   Matallanas D, 2010, CURR OPIN MOL THER, V12, P674
   Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320
   McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109
   Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511
   Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336
   Pless O, 2008, J BIOL CHEM, V283, P26357, DOI 10.1074/jbc.M802132200
   Polevoda B, 2007, MOL MICROBIOL, V65, P590, DOI 10.1111/j.1365-2958.2007.05831.x
   Prickett TD, 2007, MOL CELL BIOL, V27, P4217, DOI 10.1128/MCB.00067-07
   Rathert P, 2008, NAT CHEM BIOL, V4, P344, DOI 10.1038/nchembio.88
   ROBERTS DM, 1986, J BIOL CHEM, V261, P1491
   Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612
   Sarris M, 2014, ONCOGENE, V33, P1207, DOI 10.1038/onc.2013.87
   Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3
   Shanley TP, 2001, J IMMUNOL, V166, P966, DOI 10.4049/jimmunol.166.2.966
   Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012
   Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022
   Takawa M, 2012, CANCER RES, V72, P3217, DOI 10.1158/0008-5472.CAN-11-3701
   TSCHIERSCH B, 1994, EMBO J, V13, P3822, DOI 10.1002/j.1460-2075.1994.tb06693.x
   Uhlik MT, 2004, BIOCHEM CELL BIOL, V82, P658, DOI 10.1139/O04-114
   Van Aller GS, 2012, EPIGENETICS-US, V7, P340, DOI 10.4161/epi.19506
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Vermillion KL, 2014, J CELL BIOL, V204, P95, DOI 10.1083/jcb.201306071
   Wang GG, 2007, NAT CELL BIOL, V9, P804, DOI 10.1038/ncb1608
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Watanabe T, 2011, EUR J CANCER, V47, P1946, DOI 10.1016/j.ejca.2011.03.029
   West LE, 2011, EPIGENOMICS-UK, V3, P361, DOI 10.2217/EPI.11.21
   West LE, 2010, J BIOL CHEM, V285, P37725, DOI 10.1074/jbc.M110.139527
   Wu CC, 2003, NAT BIOTECHNOL, V21, P532, DOI 10.1038/nbt819
   Xie Q, 2012, EMBO REP, V13, P371, DOI 10.1038/embor.2012.25
   Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107
   Yang MH, 2012, P NATL ACAD SCI USA, V109, P10843, DOI 10.1073/pnas.1201487109
   Yeung F, 2014, ONCOGENE IN PRESS, DOI [10.1038/onc.2014.39, DOI 10.1038/ONC.2014.39]
   Zhang X, 2012, ACTA BIOCH BIOPH SIN, V44, P14, DOI 10.1093/abbs/gmr100
   Zhong XW, 2015, HISTOPATHOLOGY, V66, P192, DOI 10.1111/his.12456
   Zou JN, 2009, CANCER LETT, V280, P78, DOI 10.1016/j.canlet.2009.02.015
NR 90
TC 29
Z9 34
U1 0
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0265-9247
EI 1521-1878
J9 BIOESSAYS
JI Bioessays
PD DEC
PY 2014
VL 36
IS 12
BP 1162
EP 1169
DI 10.1002/bies.201400120
PG 8
WC Biochemistry & Molecular Biology; Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics
GA AT4OA
UT WOS:000344918000011
PM 25382779
DA 2025-01-12
ER

PT J
AU Severi, G
   Southey, MC
   English, DR
   Jung, CH
   Lonie, A
   McLean, C
   Tsimiklis, H
   Hopper, JL
   Giles, GG
   Baglietto, L
AF Severi, Gianluca
   Southey, Melissa C.
   English, Dallas R.
   Jung, Chol-hee
   Lonie, Andrew
   McLean, Catriona
   Tsimiklis, Helen
   Hopper, John L.
   Giles, Graham G.
   Baglietto, Laura
TI Epigenome-wide methylation in DNA from peripheral blood as a marker of
   risk for breast cancer
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; DNA methylation; Risk marker; Melbourne Collaborative
   Cohort Study; Peripheral blood
ID COLORECTAL ADENOMA; HYPOMETHYLATION; BIOMARKER; CELLS; ASSOCIATION;
   EPIGENETICS; MICROARRAY; CARCINOMA
AB Aberrant DNA methylation is a key feature of breast carcinoma. We aimed to test the association between breast cancer risk and epigenome-wide methylation in DNA from peripheral blood. Nested case-control study within the prospective Melbourne Collaborative Cohort Study. DNA was extracted from before-diagnosis blood samples (420 incident cases and matched controls). Methylation was measured with the Illumina Infinium Human Methylation 450 BeadChip array. Odds ratio (OR) for epigenome-wide methylation, quantified as the mean beta values across the CpGs, in relation to breast cancer risk were estimated using conditional logistic regression. Overall, the OR for breast cancer was 0.42 (95 % CI 0.20-0.90) for the top versus bottom quartile of epigenome-wide DNA methylation and the OR for a one standard deviation increment was 0.69 (95 % CI 0.50-0.95; test for linear trend, p = 0.02). Epigenome-wide DNA methylation of CpGs within functional promoters was associated with an increased risk, whereas epigenome-wide DNA methylation of genomic regions outside promoters was associated with decreased risk (test for heterogeneity, p = 0.0002). The increased risk associated with epigenome-wide DNA methylation in functional promoters did not vary by time between blood collection and diagnosis, whereas the inverse association with epigenome-wide DNA methylation outside functional promoters was strongest when the interval from blood collection to diagnosis was less than 5 years and weakest for the longest interval. Epigenome-wide methylation in DNA extracted from peripheral blood collected before diagnosis may have potential utility as markers of breast cancer risk and for early detection.
C1 [Severi, Gianluca; English, Dallas R.; Giles, Graham G.; Baglietto, Laura] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic 3004, Australia.
   [Severi, Gianluca; English, Dallas R.; Hopper, John L.; Giles, Graham G.; Baglietto, Laura] Univ Melbourne, Sch Populat & Global Hlth, Ctr Epidemiol & Biostat, Melbourne, Vic, Australia.
   [Severi, Gianluca] Human Genet Fdn, Turin, Italy.
   [Southey, Melissa C.; Tsimiklis, Helen] Univ Melbourne, Dept Pathol, Genet Epidemiol Lab, Melbourne, Vic, Australia.
   [Jung, Chol-hee; Lonie, Andrew] Victorian Life Sci Computat Initiat, Life Sci Computat Ctr, Carlton, Vic 3010, Australia.
   [McLean, Catriona] Alfred Hosp, Dept Pathol, Melbourne, Vic, Australia.
   [McLean, Catriona] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia.
   [Hopper, John L.] Seoul Natl Univ, Seoul, South Korea.
   [Giles, Graham G.] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia.
C3 Cancer Council Victoria; University of Melbourne; University of
   Melbourne; University of Melbourne; Florey Institute of Neuroscience &
   Mental Health; Monash University; Seoul National University (SNU);
   Monash University
RP Baglietto, L (通讯作者)，Canc Council Victoria, Canc Epidemiol Ctr, 615 St Kilda Rd, Melbourne, Vic 3004, Australia.
EM graham.giles@cancervic.org.au; laura.baglietto@cancervic.org.au
RI Jung, Cholhee/S-8670-2019; English, Dallas/AAH-5005-2019; Southey,
   Melissa/CAA-7064-2022; Giles, Graham/LCD-5671-2024; Baglietto,
   Laura/AAB-9051-2019; Severi, Gianluca/H-3774-2018; Lonie,
   Andrew/F-3258-2017
OI McLean, Catriona/0000-0002-0302-5727; Baglietto,
   Laura/0000-0002-8193-7529; Severi, Gianluca/0000-0001-7157-419X; Giles,
   Graham/0000-0003-4946-9099; English, Dallas/0000-0001-7828-8188;
   Southey, Melissa/0000-0002-6313-9005; Lonie, Andrew/0000-0002-2006-3856
FU National Health and Medical Research Council [1011618]; Victorian Breast
   Cancer Research Consortium
FX We would like to express our gratitude to the many thousands of
   Melbourne residents who continue to participate in the Melbourne
   Collaborative Cohort Study, the original investigators, program managers
   and the diligent team who recruited the participants and who continue
   working on follow-up. The methylation measures were conducted by the
   Australian Genome Research Facility (AGRF) in Melbourne. This work was
   supported by grants from the National Health and Medical Research
   Council (Grant number 1011618); and the Victorian Breast Cancer Research
   Consortium.
CR Anjum S, 2014, GENOME MED, V6, DOI 10.1186/gm567
   Brennan K, 2012, CANCER RES, V72, P2304, DOI 10.1158/0008-5472.CAN-11-3157
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Clark C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050233
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Delgado-Cruzata L, 2012, EPIGENETICS-US, V7, P868, DOI 10.4161/epi.20830
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Horard B, 2009, EPIGENETICS-US, V4, P339, DOI 10.4161/epi.4.5.9284
   Horvath S, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r97
   Houseman EA, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-86
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kristiansen S, 2013, INT J BIOL MARKER, V28, P141, DOI [10.5301/JBM.5000009, 10.5301/jbm.5000009]
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lim U, 2008, GASTROENTEROLOGY, V134, P47, DOI 10.1053/j.gastro.2007.10.013
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032
   Phillips T., 2008, NAT ED, V1, P116
   Pufulete M, 2003, GASTROENTEROLOGY, V124, P1240, DOI 10.1016/S0016-5085(03)00279-8
   Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Severi G, 2008, NEW ENGL J MED, V358, P2739
   Shenker N.S., 2012, HUM MOL GENET
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Wu HC, 2012, CARCINOGENESIS, V33, P1340, DOI 10.1093/carcin/bgs160
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Xu ZL, 2013, JNCI-J NATL CANCER I, V105, P694, DOI 10.1093/jnci/djt045
   Zhuang J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002517
NR 37
TC 81
Z9 88
U1 1
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD DEC
PY 2014
VL 148
IS 3
BP 665
EP 673
DI 10.1007/s10549-014-3209-y
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AU1HC
UT WOS:000345370600021
PM 25407397
DA 2025-01-12
ER

PT J
AU Hagrass, HA
   Pasha, HF
   Ali, AM
AF Hagrass, Hoda A.
   Pasha, Heba F.
   Ali, Ahmed M.
TI Estrogen receptor alpha (ERα) promoter methylation status in tumor and
   serum DNA in Egyptian breast cancer patients
SO GENE
LA English
DT Article
DE Estrogen receptor; Methylated polymerase chain reaction; Breast cancer;
   Egypt
ID CPG ISLAND METHYLATION; HYPERMETHYLATION PROFILE; ABERRANT METHYLATION;
   GENE; EXPRESSION; DEMETHYLATION; TAMOXIFEN; RASSF1A; EVENT; BRCA1
AB Background: Status of DNA methylation is one of the most common molecular alterations in human neoplasia. Because it is possible to detect these epigenetic alterations in the bloodstream of patients, we investigated the aberrant DNA methylation status of estrogen receptor alpha (ER alpha) in patient pretherapeutic sera and tissue.
   Materials and methods: In this case control study the patient series consisted of 120 sporadic primary breast cancer cases and 100 patients with benign breast lesion. ER3, ER4, and ER5 primers were used for methylation-specific polymerase chain reaction (MSP) to analyze the CpG methylation of promoter region of ER alpha gene. Correlation between ER3, ER4, and ER5 methylation and clinicopathological characteristics of the patients was investigated.
   Result: The methylation status of ER3, ER4 and ER5 was 65%, 26.7% and 61.7% in tissue respectively and 57.5%, 21.7% and 55.8% in serum respectively. The concordance between tumor and serum DNA methylation was 80%, 72% and 92% for ER3, ER4 and ER5 respectively.
   Conclusions: This study demonstrated the potential utility of serum DNA methylation of ER alpha gene promoter as a non-invasive diagnostic and/or prognostic marker in patients with breast cancer. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Hagrass, Hoda A.] Zagazig Univ, Fac Med, Dept Clin Pathol, Zagazig, Egypt.
   [Pasha, Heba F.] Zagazig Univ, Fac Med, Dept Med Biochem, Zagazig, Egypt.
   [Ali, Ahmed M.] Zagazig Univ, Fac Med, Dept Surg, Zagazig, Egypt.
C3 Egyptian Knowledge Bank (EKB); Zagazig University; Egyptian Knowledge
   Bank (EKB); Zagazig University; Egyptian Knowledge Bank (EKB); Zagazig
   University
RP Pasha, HF (通讯作者)，Zagazig Univ, Fac Med, Dept Med Biochem, Zagazig, Egypt.
EM hebapasha@yahoo.com
RI Pasha, Heba/Y-6005-2019
FU Zagazig University Postgraduate & Research Affairs
FX This work was funded by support of academic research in Zagazig
   University Projects, Zagazig University Postgraduate & Research Affairs.
CR Allam M F, 2012, J Prev Med Hyg, V53, P195
   Anderson E, 2002, BREAST CANCER RES, V4, P197, DOI 10.1186/bcr452
   [Anonymous], CA CANC J CLIN
   Ascenzi Paolo, 2006, Molecular Aspects of Medicine, V27, P299, DOI 10.1016/j.mam.2006.07.001
   Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891
   Dulaimi E, 2004, CLIN CANCER RES, V10, P6189, DOI 10.1158/1078-0432.CCR-04-0597
   Esteller M, 2000, CANCER RES, V60, P4366
   Esteller M, 2001, CANCER RES, V61, P3225
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Hagrass HA, 2014, MOL BIOL REP, V41, P57, DOI 10.1007/s11033-013-2837-3
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Holst CR, 2003, CANCER RES, V63, P1596
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Izadi P, 2012, CELL J, V14, P102
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Lehmann U, 2002, AM J PATHOL, V160, P605, DOI 10.1016/S0002-9440(10)64880-8
   Leu YW, 2004, CANCER RES, V64, P8184, DOI 10.1158/0008-5472.CAN-04-2045
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Mehrotra J, 2004, CLIN CANCER RES, V10, P3104, DOI 10.1158/1078-0432.CCR-03-0118
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mirza S, 2010, CLIN BIOCHEM, V43, P380, DOI 10.1016/j.clinbiochem.2009.11.016
   Moise M, 2013, ROM J MORPHOL EMBRYO, V54, P961
   Nass SJ, 2000, CANCER RES, V60, P4346
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Ramezani F, 2012, ASIAN PAC J CANCER P, V13, P451, DOI 10.7314/APJCP.2012.13.2.451
   Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016
   Salami S, 2003, CLIN BIOCHEM, V36, P247, DOI 10.1016/S0009-9120(03)00007-9
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   Sidransky D, 2002, NAT REV CANCER, V2, P210, DOI 10.1038/nrc755
   Tavassoeli FA, 2003, WHO CLASSIFICATION T, P10
   Wang Rui, 2006, Zhonghua Zhongliu Zazhi, V28, P894
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Yamamoto N, 2012, BREAST CANCER RES TR, V132, P165, DOI 10.1007/s10549-011-1575-2
   Zhao L, 2009, BREAST CANCER RES TR, V117, P253, DOI 10.1007/s10549-008-0192-1
NR 40
TC 15
Z9 15
U1 1
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD NOV 15
PY 2014
VL 552
IS 1
BP 81
EP 86
DI 10.1016/j.gene.2014.09.016
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AR8TH
UT WOS:000343846700011
PM 25218234
DA 2025-01-12
ER

PT J
AU Qin, L
   Dong, ZZ
   Zhang, JT
AF Qin, Li
   Dong, Zizheng
   Zhang, Jian-Ting
TI Reversible Epigenetic Regulation of 14-3-3σ Expression in Acquired
   Gemcitabine Resistance by Uhrf1 and DNA Methyltransferase 1
SO MOLECULAR PHARMACOLOGY
LA English
DT Article
ID CANCER-CELL-SURVIVAL; BREAST-CANCER; RIBONUCLEOTIDE REDUCTASE;
   DRUG-RESISTANCE; MAMMALIAN-CELLS; OVEREXPRESSION; HYPERMETHYLATION;
   IDENTIFICATION; METHYLATION; MECHANISM
AB Although gemcitabine is the most commonly used drug for treating pancreatic cancers, acquired gemcitabine resistance in a substantial number of patients appears to hinder its effectiveness in successful treatment of this dreadful disease. To understand acquired gemcitabine resistance, we generated a gemcitabine-resistant pancreatic cancer cell line using stepwise selection and found that, in addition to the known mechanisms of upregulated expression of ribonucleotide reductase, 14-3-3 sigma expression is dramatically upregulated, and that 14-3-3 sigma overexpression contributes to the acquired resistance to gemcitabine and cross-resistance to cytarabine. We also found that the increased 14-3-3 sigma expression in the gemcitabine-resistant cells is due to demethylation of the 14-3-3 sigma gene during gemcitabine selection, which could be partially reversed with removal of the gemcitabine selection pressure. Most importantly, the reversible methylation/demethylation of the 14-3-3 sigma gene appears to be carried out by DNA methyltransferase 1 under regulation by Uhrf1. These findings suggest that the epigenetic regulation of gene expression may play an important role in gemcitabine resistance, and that epigenetic modification is reversible in response to gemcitabine treatment.
C1 [Qin, Li; Dong, Zizheng; Zhang, Jian-Ting] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46204 USA.
   [Qin, Li; Dong, Zizheng; Zhang, Jian-Ting] Indiana Univ, Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46204 USA.
C3 Indiana University System; Indiana University Indianapolis; Indiana
   University System; Indiana University Indianapolis; Indiana University
   Health; IU Health University Hospital
RP Zhang, JT (通讯作者)，IUSCC, R3-C570,980 W Walnut St, Indianapolis, IN 46202 USA.
EM jianzhan@iu.edu
RI Zhang, Jian-Ting/L-8334-2015
OI Zhang, Jian-Ting/0000-0002-2803-9914
FU National Institutes of Health [R01-CA140582]
FX This work was supported in part by the National Institutes of Health
   [Grant R01-CA140582].
CR Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939
   Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188
   Cokus SJ, 2008, NATURE, V452, P215, DOI 10.1038/nature06745
   Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363
   Dong ZZ, 2009, EXP CELL RES, V315, P1889, DOI 10.1016/j.yexcr.2009.03.009
   Dong ZZ, 2005, NUCLEIC ACIDS RES, V33, P2715, DOI 10.1093/nar/gki569
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Goan YG, 1999, CANCER RES, V59, P4204
   Goffin J, 2002, ANN ONCOL, V13, P1699, DOI 10.1093/annonc/mdf314
   Gray SG, 2012, INT J MOL MED, V30, P1505, DOI 10.3892/ijmm.2012.1138
   Han BG, 2006, MOL CANCER THER, V5, P903, DOI 10.1158/1535-7163.MCT-05-0393
   Han ZY, 2009, ANTICANCER RES, V29, P2009
   Hodgkinson VC, 2012, J PROTEOMICS, V75, P1276, DOI 10.1016/j.jprot.2011.11.005
   Hustinx SR, 2005, CANCER BIOL THER, V4, P596, DOI 10.4161/cbt.4.5.1748
   Kim JK, 2009, NUCLEIC ACIDS RES, V37, P493, DOI 10.1093/nar/gkn961
   Li Zhaomin, 2010, BMC Cancer, V10, P598, DOI 10.1186/1471-2407-10-598
   Li ZM, 2009, AM J TRANSL RES, V1, P326
   Liu HL, 2008, MOL CANCER THER, V7, P263, DOI 10.1158/1535-7163.MCT-07-0445
   Liu Y, 2006, CANCER RES, V66, P3248, DOI 10.1158/0008-5472.CAN-05-3801
   Liu ZQ, 2007, DIFFERENTIATION, V75, P652, DOI 10.1111/j.1432-0436.2007.00165.x
   Maxwell SA, 2009, J BIOL CHEM, V284, P22379, DOI 10.1074/jbc.M109.022418
   Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765
   Neupane D, 2008, CLIN CANCER RES, V14, P7614, DOI 10.1158/1078-0432.CCR-08-1366
   Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200
   Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397
   Subramanian RR, 2001, EXP CELL RES, V271, P142, DOI 10.1006/excr.2001.5376
   Suzuki H, 2000, CANCER RES, V60, P4353
   Voutsadakis IA, 2011, WORLD J GASTRO ONCOL, V3, P153, DOI 10.4251/wjgo.v3.i11.153
   Yang YY, 2007, J BIOL CHEM, V282, P8821, DOI 10.1074/jbc.M700152200
   Yang YY, 2002, J BIOL CHEM, V277, P44268, DOI 10.1074/jbc.M207003200
NR 30
TC 14
Z9 15
U1 0
U2 7
PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA
SN 0026-895X
EI 1521-0111
J9 MOL PHARMACOL
JI Mol. Pharmacol.
PD NOV
PY 2014
VL 86
IS 5
BP 561
EP 569
DI 10.1124/mol.114.092544
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AR9IU
UT WOS:000343888200010
PM 25189999
OA Green Published
DA 2025-01-12
ER

PT J
AU Mahajan, K
   Lawrence, HR
   Lawrence, NJ
   Mahajan, NP
AF Mahajan, Kiran
   Lawrence, Harshani R.
   Lawrence, Nicholas J.
   Mahajan, Nupam P.
TI ACK1 Tyrosine Kinase Interacts with Histone Demethylase KDM3A to
   Regulate the Mammary Tumor Oncogene <i>HOXA1</i>
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SURGICAL ADJUVANT BREAST; BOWEL PROJECT P-1; ANDROGEN RECEPTOR;
   ESTROGEN-RECEPTOR; TAMOXIFEN RESISTANCE; PROSTATE-CANCER; DASATINIB
   BMS-354825; PHOSPHORYLATION; ACTIVATION; MECHANISMS
AB Hormone therapy with the selective estrogen-receptor modulator tamoxifen provides a temporary relief for patients with estrogen receptor alpha (ER)-positive breast cancers. However, a subset of patients exhibiting overexpression of the HER2 receptor tyrosine kinase displays intrinsic resistance to tamoxifen therapy. Therefore, elucidating the mechanisms promoting the estrogen (E-2)-independent ER-regulated gene transcription in tamoxifen-resistant breast tumors is essential to identify new therapeutic avenues to overcome drug resistance and ameliorate poor prognosis. The non-receptor tyrosine kinase, ACK1 (also known as TNK2), has emerged as a major integrator of signaling from various receptor tyrosine kinases including HER2. We have uncovered that heregulin-mediated ACK1 activation promoted ER activity in the presence of tamoxifen, which was significantly down-regulated upon ACK1 knockdown or inhibition of ACK1 by small molecule inhibitors, AIM-100 or Dasatinib. We report that ACK1 phosphorylates the ER co-activator, KDM3A, a H3K9 demethylase, at an evolutionary conserved tyrosine 1114 site in a heregulin-dependent manner, even in the presence of tamoxifen. Consistent with this finding, ACK1 activation resulted in a significant decrease in the deposition of dimethyl H3K9 epigenetic marks. Conversely, inhibition of ACK1 by AIM-100 or Dasatinib restored dimethyl H3K9 methylation marks and caused transcriptional suppression of the ER-regulated gene HOXA1. Thus, by its ability to regulate the epigenetic activity of an ER co-activator KDM3A, ACK1 modulates HOXA1 expression in the absence of E-2, conferring tamoxifen resistance. These data reveal a novel therapeutic option, suppression of ACK1 signaling by AIM-100 or Dasatinib, to mitigate HOXA1 up-regulation in breast cancer patients displaying tamoxifen resistance.
C1 [Mahajan, Kiran; Lawrence, Harshani R.; Lawrence, Nicholas J.; Mahajan, Nupam P.] Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Dept, Tampa, FL 33682 USA.
   [Mahajan, Kiran; Lawrence, Harshani R.; Lawrence, Nicholas J.; Mahajan, Nupam P.] Univ S Florida, Dept Oncol Sci, Coll Med, Tampa, FL 33612 USA.
C3 State University System of Florida; University of South Florida; H Lee
   Moffitt Cancer Center & Research Institute; State University System of
   Florida; University of South Florida
RP Mahajan, K (通讯作者)，Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Dept, 12902 Magnolia Dr, Tampa, FL 33682 USA.
EM kiran.mahajan@moffitt.org; nupam.mahajan@moffitt.org
RI Mahajan, Kiran/ABA-3013-2020
OI Mahajan, Kiran/0000-0001-7192-396X
FU Department of Defense [W81XWH-12-1-0248, W81XWH-14-1-0002,
   W81XWH-14-1-0003]; NCI, National Institutes of Health [1R01CA135328]
FX This work was supported in part by Department of Defense Grant
   W81XWH-12-1-0248 (to K. M.) and by NCI, National Institutes of Health
   Grant 1R01CA135328 and Department of Defense Grants W81XWH-14-1-0002 and
   W81XWH-14-1-0003 (to N. P. M.).
CR BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241
   Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310
   Brock A, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007048
   Buchwald M, 2013, ONCOGENE, V32, P4913, DOI 10.1038/onc.2012.515
   Chen HX, 2003, J MAMMARY GLAND BIOL, V8, P159, DOI 10.1023/A:1025996707117
   Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501
   Clarke R, 2001, PHARMACOL REV, V53, P25
   Fisher B, 2005, JNCI-J NATL CANCER I, V97, P1652, DOI 10.1093/jnci/dji372
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Franklin MC, 2004, CANCER CELL, V5, P317, DOI 10.1016/S1535-6108(04)00083-2
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   GOTTARDIS MM, 1988, CANCER RES, V48, P5183
   Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
   Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750
   Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006
   Hopp TA, 2004, CLIN CANCER RES, V10, P7490, DOI 10.1158/1078-0432.CCR-04-1114
   HOWELL A, 1995, LANCET, V345, P29, DOI 10.1016/S0140-6736(95)91156-1
   Johnston SRD, 1997, ANTI-CANCER DRUG, V8, P911, DOI 10.1097/00001813-199711000-00002
   Li JN, 2010, NAT CHEM BIOL, V6, P291, DOI [10.1038/NCHEMBIO.332, 10.1038/nchembio.332]
   Liu WM, 2002, BIOINFORMATICS, V18, P1593, DOI 10.1093/bioinformatics/18.12.1593
   Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200
   Liu Y, 2010, ONCOGENE, V29, P3208, DOI 10.1038/onc.2010.103
   Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a
   Mahajan K, 2013, CANCER LETT, V338, P185, DOI 10.1016/j.canlet.2013.04.004
   Mahajan K, 2012, NAT STRUCT MOL BIOL, V19, P930, DOI 10.1038/nsmb.2356
   Mahajan K, 2012, J BIOL CHEM, V287, P22112, DOI 10.1074/jbc.M112.357384
   Mahajan K, 2012, J CELL PHYSIOL, V227, P3178, DOI 10.1002/jcp.24065
   Mahajan K, 2012, AM J PATHOL, V180, P1386, DOI 10.1016/j.ajpath.2011.12.028
   Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163
   Mahajan K, 2010, J CELL PHYSIOL, V224, P327, DOI 10.1002/jcp.22162
   Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646
   Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127
   Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Massarweh S, 2007, CLIN CANCER RES, V13, P1950, DOI 10.1158/1078-0432.CCR-06-2540
   Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031
   Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731
   Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620
   Okada Y, 2007, NATURE, V450, P119, DOI 10.1038/nature06236
   Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440
   Robertson SC, 2000, TRENDS GENET, V16, P368, DOI 10.1016/S0168-9525(00)02077-1
   Schittenhelm MM, 2006, CANCER RES, V66, P473, DOI 10.1158/0008-5472.CAN-05-2050
   Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166
   Skorski T, 2002, NAT REV CANCER, V2, P351, DOI 10.1038/nrc799
   Tateishi K, 2009, NATURE, V458, P757, DOI 10.1038/nature07777
   van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102
   VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663
   Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143
   Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027
   Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200
NR 53
TC 49
Z9 57
U1 3
U2 18
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 10
PY 2014
VL 289
IS 41
BP 28179
EP 28191
DI 10.1074/jbc.M114.584425
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AR7NC
UT WOS:000343765400015
PM 25148682
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Zhang, CY
   Zhao, YX
   Xia, RH
   Han, J
   Wang, BS
   Tian, Z
   Wang, LZ
   Hu, YH
   Li, J
AF Zhang, Chun-Ye
   Zhao, Yang-Xing
   Xia, Rong-Hui
   Han, Jing
   Wang, Bing-Shun
   Tian, Zhen
   Wang, Li-Zhen
   Hu, Yu-Hua
   Li, Jiang
TI <i>RASSF1A</i> Promoter Hypermethylation Is a Strong Biomarker of Poor
   Survival in Patients with Salivary Adenoid Cystic Carcinoma in a Chinese
   Population
SO PLOS ONE
LA English
DT Article
ID TUMOR-SUPPRESSOR GENE; DOMAIN FAMILY PROTEIN; HIGH-FREQUENCY;
   CLINICOPATHOLOGICAL ANALYSIS; EPIGENETIC INACTIVATION; BREAST-CANCER;
   CHROMOSOME 3P; LUNG-CANCER; METHYLATION; HEAD
AB In addition to the clinicopathological parameters, molecular biomarkers are becoming increasingly important in the prognostic evaluation of cancer patients. This study aimed to determine the molecular alterations in the RAS association domain family protein1A gene (RASSF1A) in salivary adenoid cystic carcinoma (ACC) and to evaluate the potential of such alterations as prognostic markers. One hundred and sixty-seven ACC tumor tissues and 50 samples of matched normal salivary gland tissues from the same patients were analyzed for RASSF1A promoter methylation status by bisulfite sequencing PCR (BSP) and/or methylation-specific PCR (MSP). Fifty ACC tumor tissues and matched normal salivary gland tissues were analyzed for loss of heterozygosity (LOH) by examining two microsatellite markers (D3S1478, D351621) at 3p21. RASSF1A gene mutations were detected by direct sequencing of all six exons in 50 tumor and normal tissue specimens. Over-all, RASSF1A promoter hypermethylation was detected in 35.3% (59/167) of ACC tissues and was associated with histologically solid tumor pattern (P=0.002) and advanced TNM stage (P=0.014). RASSF1A LOH was observed in 18.0% (9/50 cases, and no somatic mutation of RASSF1A was detected in any cases. RASSF1A promoter methlyation was associated h the poor over-all survival (Log-rank test, P<0.001) and disease-free survival (Log-rank test, P<0.001) and identified as independent predicator of over-all patient survival (P=0.009) and disease-free survival (P<0.001). It was concluded that RASSF1A methylation is involved in the development, differentiation and progression of ACC and is a strong independent biomarker of poor survival in ACC patients in a Chinese population.
C1 [Zhang, Chun-Ye; Xia, Rong-Hui; Han, Jing; Tian, Zhen; Wang, Li-Zhen; Hu, Yu-Hua; Li, Jiang] Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Oral Pathol, Shanghai 200030, Peoples R China.
   [Zhao, Yang-Xing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200030, Peoples R China.
   [Wang, Bing-Shun] Shanghai Jiao Tong Univ, Sch Med, Dept Biostat, Shanghai 200030, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University
RP Li, J (通讯作者)，Shanghai Jiao Tong Univ, Peoples Hosp 9, Sch Med, Dept Oral Pathol, Shanghai 200030, Peoples R China.
EM lijiang182000@126.com
RI Wang, Bingshun/B-8698-2013
OI Wang, Bingshun/0000-0002-0435-2543
FU Natural Science Fund of China [81372910, 81302360]; Research Fund for
   the Doctoral Program of Ministry of Education of China [20120073110085];
   Youth Research Foundation of Shanghai Municipal Health Bureau
   [20134Y057]
FX This work was supported by 1. The Natural Science Fund of China (Nos.
   81372910, 81302360) to JL and CYZ
   (http://isisn.nsfc.gov.cn/egrantindex/funcindex/prjsearch-list); 2. The
   Research Fund for the Doctoral Program of Ministry of Education of China
   (No. 20120073110085) to JL
   (http://www.cutech.edu.cn/cn/zxgz/2012/12/1354173228992896.htm); and 3.
   Youth Research Foundation of Shanghai Municipal Health Bureau
   (20134Y057) (http://www.wsjsw.gov.cn/wsj/index.html). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088
   [Anonymous], BREAST CANC RES TREA
   Buckingham L, 2010, INT J CANCER, V126, P1630, DOI 10.1002/ijc.24896
   Buhmeida A, 2011, ANTICANCER RES, V31, P2975
   Choi CH, 2007, CANCER LETT, V255, P26, DOI 10.1016/j.canlet.2007.03.015
   Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083
   de Fraipont F, 2012, CLIN CANCER RES, V18, P2976, DOI 10.1158/1078-0432.CCR-11-2797
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298
   El-Naggar AK, 2005, PATHOLOGY GENETICS H, P221
   Ellis G L., 2008, AFIP Atlas of Tumor Pathology: Tumors of the Salivary Glands
   Gondivkar SM, 2011, ORAL ONCOL, V47, P231, DOI 10.1016/j.oraloncology.2011.01.009
   Grote HJ, 2006, CANCER CYTOPATHOL, V108, P129, DOI 10.1002/cncr.21717
   Jiang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036780
   Karray-Chouayekh S, 2010, J CANCER RES CLIN, V136, P203, DOI 10.1007/s00432-009-0649-6
   Kim JS, 2012, CLIN GENITOURIN CANC, V10, P114, DOI 10.1016/j.clgc.2011.12.003
   Ku JL, 2011, METHODS MOL BIOL, V791, P23, DOI 10.1007/978-1-61779-316-5_3
   Li J, 2004, ARCH PATHOL LAB MED, V128, P1385
   Li J, 2005, CANCER-AM CANCER SOC, V104, P771, DOI 10.1002/cncr.21215
   Licchesi Julien D. F., 2009, V507, P305, DOI 10.1007/978-1-59745-522-0_22
   Lo KW, 2001, CANCER RES, V61, P3877
   Miranda E, 2006, BRIT J CANCER, V95, P1101, DOI 10.1038/sj.bjc.6603337
   NASCIMENTO AG, 1986, CANCER-AM CANCER SOC, V57, P312, DOI 10.1002/1097-0142(19860115)57:2<312::AID-CNCR2820570220>3.0.CO;2-A
   Ohshima J, 2012, PEDIAT BLOOD CANC
   Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906
   Pan ZG, 2005, CANCER BIOL THER, V4, P1116, DOI 10.4161/cbt.4.10.2023
   Rapidis AD, 2005, ORAL ONCOL, V41, P328, DOI 10.1016/j.oraloncology.2004.12.004
   Reed K, 2010, ANAL BIOCHEM, V397, P96, DOI 10.1016/j.ab.2009.10.021
   Riquelme E, 2007, CANCER LETT, V250, P100, DOI 10.1016/j.canlet.2006.09.019
   Saito K, 2010, CLIN CANCER RES, V16, P2418, DOI 10.1158/1078-0432.CCR-09-2819
   Shen CY, 2012, ORAL ONCOL, V48, P445, DOI 10.1016/j.oraloncology.2011.12.002
   Shinozaki M, 2005, CLIN CANCER RES, V11, P2156, DOI 10.1158/1078-0432.CCR-04-1810
   SPIRO RH, 1979, AM J SURG, V138, P579, DOI 10.1016/0002-9610(79)90423-9
   Tian Z, 2010, INT J ORAL MAX SURG, V39, P235, DOI 10.1016/j.ijom.2009.10.016
   Wang J, 2011, CARCINOGENESIS, V32, P411, DOI 10.1093/carcin/bgq266
   Warnecke PM, 2002, METHODS, V27, P101, DOI 10.1016/S1046-2023(02)00060-9
   Yeo W, 2005, PATHOLOGY, V37, P125, DOI 10.1080/00313020500058623
   Yu MY, 2003, INT J CANCER, V105, P204, DOI 10.1002/ijc.11051
   Zhang CY, 2007, CANCER-AM CANCER SOC, V110, P87, DOI 10.1002/cncr.22758
   Zhang CY, 2013, OR SURG OR MED OR PA, V115, P368, DOI 10.1016/j.oooo.2012.11.018
NR 40
TC 32
Z9 34
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2014
VL 9
IS 10
AR e110159
DI 10.1371/journal.pone.0110159
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AR6ZS
UT WOS:000343730400114
PM 25302792
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Wang, YJ
   He, L
   Yuan, M
   Tsang, WWN
   Hao, L
   Wang, M
   Chow, LWC
   Cheung, MNB
   Liu, Q
   Ng, ELY
   Loo, WTY
   Chow, CYC
   Bai, LJ
   Yang, Z
AF Wang, Yan-jun
   He, Ling
   Yuan, Ming
   Tsang, William W. N.
   Hao, Liang
   Wang, Min
   Chow, Louis W. C.
   Cheung, Mary N. B.
   Liu, Qing
   Ng, Elizabeth L. Y.
   Loo, Wings T. Y.
   Chow, Christopher Y. C.
   Bai, Lan-jun
   Yang, Zheng
TI Epigenetic changes of TIMP-3, GSTP-1 and 14-3-3 sigma genes as
   indication of status of chronic inflammation and cancer
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
LA English
DT Article
DE 14-3-3 sigma; Breast cancer; Chronic periodontitis; DNA methylation;
   Epigenetic changes; GSTP-1; TIMP-3
ID PERIODONTAL-DISEASE; HYPERMETHYLATION; METHYLATION; PATHOGENESIS;
   EXPRESSION; RELEVANCE; GROWTH
AB Objectives: This study aimed to compare the epigenetic changes via hypermethylation status of TIMP-3, GSTP-1 and 14-3-3 sigma genes, between healthy subjects and patients with reversible chronic inflammatory disease, and between healthy subjects and patients with irreversible malignant disease, to highlight the genetic changes that occur in the progression from an inflammatory condition to irreversible genetic changes commonly observed in cancer patients.
   Methods: DNA was extracted from the blood of 680 healthy subjects, and tissues and blood of 110 patients with chronic inflammation disease of the gums, as well as neoplastic tissues of 108 breast cancer patients. Methylation-specific polymerase chain reaction (PCR) for TIMP-3, GSTP-1 and 14-3-3 sigma was performed, and hypermethylation status was analyzed and compared between the 3 groups.
   Results: The hypermethylation frequencies of TIMP-3 and GSTP-1 of reversible chronic inflammatory gum disease and the control group were similar, but both were significantly lower than those for malignant disease patients (p<0.0001). The methylation frequency of 14-3-3 sigma in chronic inflammatory gum disease was higher than in the cancer and control groups (p<0.0001). The methylation of CpG islands in TIMP-3 and GSTP-1 in chronic inflammation patients occurred as frequently as in the control group, but less frequently than in breast cancer patients. However, the epigenetic silencing of 14-3-3 sigma occurred more frequently in the chronic inflammation group than in cancer patients and healthy controls.
   Conclusions: The epigenetic silencing of 14-3-3 sigma might be essential for chronic inflammatory gum disease. The epigenetic changes presented in chronic inflammation patients might demonstrate an irreversible destruction in the tissues or organs similar to cancer.
C1 [Wang, Yan-jun; He, Ling; Yuan, Ming; Bai, Lan-jun] Sichuan Acad Med Sci, Dept Stomatol, Chengdu, Sichuan, Peoples R China.
   [Wang, Yan-jun; He, Ling; Yuan, Ming; Bai, Lan-jun] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
   [Tsang, William W. N.; Loo, Wings T. Y.] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China.
   [Hao, Liang; Wang, Min; Yang, Zheng] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis Prosthodont, Chengdu 610064, Sichuan, Peoples R China.
   [Chow, Louis W. C.] Macau Univ Sci & Technol, Macau, Peoples R China.
   [Chow, Louis W. C.; Cheung, Mary N. B.; Liu, Qing; Ng, Elizabeth L. Y.; Loo, Wings T. Y.; Chow, Christopher Y. C.] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China.
   [Chow, Louis W. C.; Cheung, Mary N. B.; Liu, Qing; Ng, Elizabeth L. Y.; Loo, Wings T. Y.; Chow, Christopher Y. C.] UNIMED Med Inst, Hong Kong, Hong Kong, Peoples R China.
   [Loo, Wings T. Y.] Univ Hong Kong, Fac Dent, Hong Kong, Hong Kong, Peoples R China.
   [Loo, Wings T. Y.] Univ Hong Kong, Sch Chinese Med, Hong Kong, Hong Kong, Peoples R China.
C3 Sichuan Provincial People's Hospital; Sichuan Provincial People's
   Hospital; Hong Kong Polytechnic University; Sichuan University; Macau
   University of Science & Technology; University of Hong Kong; University
   of Hong Kong
RP Loo, WTY (通讯作者)，Org Oncol & Translat Res, 10-F,72 Gloucester Rd, Hong Kong, Hong Kong, Peoples R China.
EM tyloo@hku.hk
RI qing, liu/KPB-1841-2024; Loo, Wings Tjing Yung/AHD-4884-2022
OI Hao, Liang/0000-0001-7207-9131; Tsang, William Wai
   Nam/0000-0002-3549-2346
FU Ministry of Education, Science and Technology Development Center of
   Research Fund for the Doctoral Program of Higher Education, China
   [20100181110059]
FX The study was supported by the Ministry of Education, Science and
   Technology Development Center of Research Fund for the Doctoral Program
   of Higher Education, China 2011-2013 (project number 20100181110059).
CR Airola K, 1998, J HISTOCHEM CYTOCHEM, V46, P437, DOI 10.1177/002215549804600403
   Bäckdahl L, 2009, INT J BIOCHEM CELL B, V41, P176, DOI 10.1016/j.biocel.2008.08.023
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bernardini S, 2004, CLIN CHIM ACTA, V350, P181, DOI 10.1016/j.cccn.2004.07.022
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Bian JH, 1996, CARCINOGENESIS, V17, P1805, DOI 10.1093/carcin/17.9.1805
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Esteller M, 2000, CANCER RES, V60, P129
   Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   Forner L, 2006, J CLIN PERIODONTOL, V33, P401, DOI 10.1111/j.1600-051X.2006.00924.x
   Friedrich MG, 2005, EUR J CANCER, V41, P2769, DOI 10.1016/j.ejca.2005.07.019
   HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Hermeking H, 2003, NAT REV CANCER, V3, P931, DOI 10.1038/nrc1230
   Hujoel PP, 2003, ANN EPIDEMIOL, V13, P312, DOI 10.1016/S1047-2797(02)00425-8
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kang GH, 2003, AM J PATHOL, V163, P1551, DOI 10.1016/S0002-9440(10)63511-0
   Kuper H, 2000, J INTERN MED, V248, P171, DOI 10.1046/j.1365-2796.2000.00742.x
   Loo WTY, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-110
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Michaud DS, 2008, LANCET ONCOL, V9, P550, DOI 10.1016/S1470-2045(08)70106-2
   Michaud DS, 2007, JNCI-J NATL CANCER I, V99, P171, DOI 10.1093/jnci/djk021
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Page RC, 1997, PERIODONTOL 2000, V14, P216, DOI 10.1111/j.1600-0757.1997.tb00199.x
   PAGE RC, 1991, J PERIODONTAL RES, V26, P230, DOI 10.1111/j.1600-0765.1991.tb01649.x
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Samuel T, 2001, J BIOL CHEM, V276, P45201, DOI 10.1074/jbc.M106427200
   SCHOLL SM, 1994, JNCI-J NATL CANCER I, V86, P120, DOI 10.1093/jnci/86.2.120
   Shacter E, 2002, ONCOLOGY-NY, V16, P217
   Söder B, 2011, BREAST CANCER RES TR, V127, P497, DOI 10.1007/s10549-010-1221-4
   Szalmás A, 2009, SEMIN CANCER BIOL, V19, P144, DOI 10.1016/j.semcancer.2009.02.011
   Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123
   Wilson AG, 2008, J PERIODONTOL, V79, P1514, DOI 10.1902/jop.2008.080172
   Wolffe AP, 1999, SCIENCE, V286, P481, DOI 10.1126/science.286.5439.481
NR 37
TC 10
Z9 10
U1 0
U2 12
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0393-6155
EI 1724-6008
J9 INT J BIOL MARKER
JI Int. J. Biol. Markers
PD JUL-SEP
PY 2014
VL 29
IS 3
BP E208
EP E214
DI 10.5301/jbm.5000104
PG 7
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA AR8WH
UT WOS:000343851700004
PM 25041782
DA 2025-01-12
ER

PT J
AU Sangplod, P
   Kanngurn, S
   Boonpipattanapong, T
   Ruangrat, P
   Sangkhathat, S
AF Sangplod, Patcharaporn
   Kanngurn, Samornmas
   Boonpipattanapong, Teeranut
   Ruangrat, Pritsana
   Sangkhathat, Surasak
TI Expression of BMP6 is Associated with its Methylation Status in
   Colorectal Cancer Tissue but Lacks Prognostic Significance
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Colorectal cancers; BMP6; promoter hypermethylation
ID MORPHOGENETIC PROTEIN-6 GENE; BREAST-CANCER; DNA METHYLATION; EPIGENETIC
   REGULATION; PROMOTER METHYLATION; BONE; METASTASES; RESISTANCE;
   CARCINOMA; COLON
AB Background: The study aimed to evaluate the incidence of CpG island promoter methylation of BMP6, a member of the transforming growth factor beta family, in tissue samples from colorectal cancers (CRC) and look for its association with BMP6 expression and clinicopathological correlation. Materials and Methods: Methylation specific PCR for the BMP6 promoter region was performed with 85 frozen tissue samples of CRC and 45 of normal colon. Methylation status of MLH1 was also determined by the same method. Expression of BMP6 was evaluated by immunohistochemistry (IHC), using Allred's scoring system. The methylation status was analyzed against clinical and pathological parameters in CRC. Results: The study revealed BMP6 hypermethylation in 34 of 85 tumor specimens (40%), and 15 out of 45 normal tissue samples from CRC (33%). The incidence of hypermethylation was inversely correlated with IHC score. Allred's scores of 7 or more were correlated with lower frequency of BMP6 hypermethylation (29% compared to 50% in the remaining, p-value 0.049). However, there was no association between hypermethylation status and any clinicopathological parameters. The methylation status of BMP6 was not correlated with that of MLH1, a key methylation determinant in CRC. On survival analysis, there was no significant difference in progress-free survival (PFS) between the cases with and without hypermethylation (2-year PFS 74% and 76%, respectively). Conclusions: CpG island methylation of BMP6 is found in high frequency in CRC and this epigenetic event is associated with suppressed protein expression in the tumor tissue. However, the marker is not associated with tumor progression of the disease.
C1 [Sangplod, Patcharaporn; Ruangrat, Pritsana; Sangkhathat, Surasak] Songkla Univ, Fac Med, Dept Biomed Sci, Songkhla, Thailand.
   [Kanngurn, Samornmas; Boonpipattanapong, Teeranut; Sangkhathat, Surasak] Songkla Univ, Tumor Biol Res Unit, Songkhla, Thailand.
   [Boonpipattanapong, Teeranut; Sangkhathat, Surasak] Songkla Univ, Fac Med, Dept Med, Songkhla, Thailand.
   [Kanngurn, Samornmas] Bumrungrad Int Hosp, Dept Surg Pathol, Bangkok, Thailand.
   [Ruangrat, Pritsana; Sangkhathat, Surasak] Prince Songkla Univ, Excellent Res Lab Canc Mol Biol, Hat Yai, Thailand.
C3 Prince of Songkla University; Prince of Songkla University; Prince of
   Songkla University; Prince of Songkla University
RP Sangkhathat, S (通讯作者)，Songkla Univ, Fac Med, Dept Biomed Sci, Songkhla, Thailand.
EM surasak.sa@psu.ac.th
RI Sangkhathat, Surasak/F-6397-2010
OI Sangkhathat, Surasak/0000-0003-3622-3233
CR Alexander C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004479
   Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244
   Bejrananda T, 2010, CANCER BIOMARK, V8, P35, DOI 10.3233/DMA-2011-0822
   Chaiyapan W, 2013, ASIAN PAC J CANCER P, V14, P329, DOI 10.7314/APJCP.2013.14.1.329
   Choudhury KR, 2010, J HISTOCHEM CYTOCHEM, V58, P95, DOI 10.1369/jhc.2009.953554
   Du J, 2009, CELL RES, V19, P487, DOI 10.1038/cr.2009.34
   Fang WJ, 2012, ASIAN PAC J CANCER P, V13, P1917, DOI 10.7314/APJCP.2012.13.5.1917
   Hebrok M, 2000, DEVELOPMENT, V127, P4905
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Imai N, 2001, PATHOL INT, V51, P643, DOI 10.1046/j.1440-1827.2001.01243.x
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Khuhaprema T, 2008, JPN J CLIN ONCOL, V38, P237, DOI 10.1093/jjco/hyn020
   Kim IY, 2003, CLIN CANCER RES, V9, P6046
   Kim MS, 2010, CANCER METAST REV, V29, P181, DOI 10.1007/s10555-010-9207-6
   Kimura K, 2008, ONCOL REP, V20, P1265, DOI 10.3892/or_00000139
   Kraunz KS, 2005, BRIT J CANCER, V93, P949, DOI 10.1038/sj.bjc.6602790
   Lee GT, 2014, BRIT J CANCER, V110, P1634, DOI 10.1038/bjc.2014.23
   Liu G, 2014, ONCOL REP, V32, P581, DOI 10.3892/or.2014.3224
   Lowery JW, 2010, CYTOKINE GROWTH F R, V21, P287, DOI 10.1016/j.cytogfr.2010.06.001
   Pederson L, 2008, P NATL ACAD SCI USA, V105, P20764, DOI 10.1073/pnas.0805133106
   Perr HA, 1999, BIOL NEONATE, V75, P210, DOI 10.1159/000014097
   Ro TB, 2004, ONCOGENE, V23, P3024, DOI 10.1038/sj.onc.1207386
   Sammons J, 2004, STEM CELLS DEV, V13, P273, DOI 10.1089/154732804323099208
   Spanjol J, 2010, COLLEGIUM ANTROPOL, V34, P119
   Tamada H, 2001, J BONE MINER RES, V16, P487, DOI 10.1359/jbmr.2001.16.3.487
   Taniguchi A, 2008, INT J CANCER, V123, P1824, DOI 10.1002/ijc.23749
   Xiao YT, 2007, BIOCHEM BIOPH RES CO, V362, P550, DOI 10.1016/j.bbrc.2007.08.045
   Yuen HF, 2008, MODERN PATHOL, V21, P1436, DOI 10.1038/modpathol.2008.94
   Zhang M, 2007, J STEROID BIOCHEM, V105, P91, DOI 10.1016/j.jsbmb.2007.01.002
NR 29
TC 6
Z9 6
U1 0
U2 6
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2014
VL 15
IS 17
BP 7091
EP 7095
DI 10.7314/APJCP.2014.15.17.7091
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AR8OA
UT WOS:000343833100016
PM 25227796
OA Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Xing, Z
   Lin, AF
   Li, CL
   Liang, K
   Wang, SY
   Liu, Y
   Park, PK
   Qin, L
   Wei, YK
   Hawke, DH
   Hung, MC
   Lin, CR
   Yang, LQ
AF Xing, Zhen
   Lin, Aifu
   Li, Chunlai
   Liang, Ke
   Wang, Shouyu
   Liu, Yang
   Park, Peter K.
   Qin, Li
   Wei, Yongkun
   Hawke, David H.
   Hung, Mien-Chie
   Lin, Chunru
   Yang, Liuqing
TI IncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine
   Signals
SO CELL
LA English
DT Article
ID BREAST-CANCER METASTASIS; RNA-BINDING PROTEINS; NONCODING RNAS;
   POLYMERASE-II; CITRON KINASE; FHA DOMAIN; HEDGEHOG; MECHANISMS; GENES;
   SNIP1
AB IncRNAs are known to regulate a number of different developmental and tumorigenic processes. Here, we report a role for lncRNA BCAR4 in breast cancer metastasis that is mediated by chemokine-induced binding of BCAR4 to two transcription factors with extended regulatory consequences. BCAR4 binding of SNIP1 and PNUTS in response to CCL21 releases the SNIP1's inhibition of p300-dependent histone acetylation, which in turn enables the BCAR4-recruited PNUTS to bind H3K18ac and relieve inhibition of RNA Pol II via activation of the PP1 phosphatase. This mechanism activates a noncanonical Hedgehog/GLI2 transcriptional program that promotes cell migration. BCAR4 expression correlates with advanced breast cancers, and therapeutic delivery of locked nucleic acids (LNAs) targeting BCAR4 strongly suppresses breast cancer metastasis in mouse models. The findings reveal a disease-relevant lncRNA mechanism consisting of both direct coordinated protein recruitment and indirect regulation of transcription factors.
C1 [Xing, Zhen; Lin, Aifu; Li, Chunlai; Liang, Ke; Wang, Shouyu; Liu, Yang; Park, Peter K.; Wei, Yongkun; Hung, Mien-Chie; Lin, Chunru; Yang, Liuqing] Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Hung, Mien-Chie; Lin, Chunru; Yang, Liuqing] Univ Texas, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA.
   [Yang, Liuqing] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNAs, Houston, TX 77030 USA.
   [Hawke, David H.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
   [Qin, Li] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Hung, Mien-Chie] China Med Univ, Grad Inst Canc Biol, Taichung 404, Taiwan.
   [Hung, Mien-Chie] China Med Univ, Ctr Mol Med, Taichung 404, Taiwan.
C3 University of Texas System; University of Texas System; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; Baylor College of Medicine; China Medical
   University Taiwan; China Medical University Taiwan
RP Lin, CR (通讯作者)，Univ Texas, Grad Sch Biomed Sci, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
EM clin2@mdanderson.org; lyang7@mdanderson.org
RI Yang, Liuqing/HQY-8902-2023; Li, Chunlai/AAI-8839-2021; Hung,
   Mien-Chie/ABD-5911-2021; li, qing/JEF-9044-2023
OI Hung, Mien-Chie/0000-0003-4317-4740; Li, Chunlai/0000-0003-1897-9889;
   Liang, Ke/0009-0002-2078-989X; Hawke, David/0000-0002-6102-7843; Qin,
   Li/0000-0003-0099-4992
FU NIH [4R00DK094981-02, 5R00CA166527-03]; UT Startup grant; UT STARS
   grant; CPRIT award [R1218]
FX We are grateful to Dr. Joan Massague and Dr. Jianming Xu for providing
   the MDA-MB-231 LM2 cell line and D. Aten for assistance with figure
   presentation. We thank the Small Animal Imaging Facility at the MD
   Anderson Cancer Center for assistance in mice imaging. This work was
   supported by an NIH K99/R00 award (4R00DK094981-02), UT Startup and UT
   STARS grants (to C. Lin.), and an NIH K99/R00 award (5R00CA166527-03),
   CPRIT award (R1218), and UT Startup and UT STARS grants (to L.Y.).
CR Carpenter S, 2013, SCIENCE, V341, P789, DOI 10.1126/science.1240925
   Castello A, 2012, CELL, V149, P1393, DOI 10.1016/j.cell.2012.04.031
   Chen DH, 2012, NAT MED, V18, P1511, DOI 10.1038/nm.2940
   Ciurciu A, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003885
   Dias N, 2002, MOL CANCER THER, V1, P347
   Dunaeva M, 2003, J BIOL CHEM, V278, P5116, DOI 10.1074/jbc.M209492200
   Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3
   Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606
   Favoni RE, 2000, PHARMACOL REV, V52, P179
   Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281
   Fujii M, 2006, MOL CELL, V24, P771, DOI 10.1016/j.molcel.2006.11.006
   Gai M, 2011, MOL BIOL CELL, V22, P3768, DOI 10.1091/mbc.E10-12-0952
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Godinho M, 2011, J CELL PHYSIOL, V226, P1741, DOI 10.1002/jcp.22503
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Hui M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3401
   Kakinuma T, 2006, J LEUKOCYTE BIOL, V79, P639, DOI 10.1189/jlb.1105633
   Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200
   Kim RH, 2000, GENE DEV, V14, P1605
   Kim YM, 2003, J BIOL CHEM, V278, P13819, DOI 10.1074/jbc.M209621200
   Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700
   Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140
   Lunde BM, 2007, NAT REV MOL CELL BIO, V8, P479, DOI 10.1038/nrm2178
   Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873
   Maloverjan A, 2010, EXP CELL RES, V316, P627, DOI 10.1016/j.yexcr.2009.10.018
   Meijer D, 2006, MOL CANCER RES, V4, P379, DOI 10.1158/1541-7786.MCR-05-0156
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086
   ten Haaf A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-298
   Thelie A, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-125
   Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608
   Wang X, 2012, ONCOGENE, V31, P187, DOI 10.1038/onc.2011.232
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Washington K, 2002, J BIOL CHEM, V277, P40442, DOI 10.1074/jbc.M205687200
   Yang LQ, 2013, NATURE, V500, P598, DOI 10.1038/nature12451
   Yu B, 2008, P NATL ACAD SCI USA, V105, P10073, DOI 10.1073/pnas.0804218105
NR 38
TC 375
Z9 411
U1 1
U2 110
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
EI 1097-4172
J9 CELL
JI Cell
PD NOV 20
PY 2014
VL 159
IS 5
BP 1110
EP 1125
DI 10.1016/j.cell.2014.10.013
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AU3IP
UT WOS:000345506300022
PM 25416949
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Danza, K
   De Summa, S
   Pilato, B
   Carella, M
   Palumbo, O
   Popescu, O
   Paradiso, A
   Pinto, R
   Tommasi, S
AF Danza, Katia
   De Summa, Simona
   Pilato, Brunella
   Carella, Massimo
   Palumbo, Orazio
   Popescu, Ondina
   Paradiso, Angelo
   Pinto, Rosamaria
   Tommasi, Stefania
TI Combined microRNA and ER expression: a new classifier for familial and
   sporadic breast cancer patients
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Familial breast cancer; miRNA; TNBC; BRCA
ID SIGNATURES; MIRNAS; RESISTANCE; RESOURCE; BRCANESS
AB Background: The role of miRNAs in familial breast cancer (fBC) is poorly investigated as also in the BRCA-like tumors. To identify a specific miRNA expression pattern which could allow a better fBC classification not only based on clinico-pathological and immunophenotypical parameters we analyzed miRNA profile in familial and sporadic samples. Moreover since BRCA1 tumors and sporadic triple negative (TN) breast tumors share similarities regarding clinical outcomes and some histological characteristics, we focused on TN and not TN cases.
   Methods: The sample set included fresh frozen tissue samples, including 39 female fBCs (19 BRCA-related and 20 BRCAX) and 12 male fBC (BRCAX). Moreover, we considered TN and non TN (NTN), 21 BRCA-related and 27 sporadic BCs. MiRNA profiling was performed through GeneChip miRNA v.1.0 Array (Affymetrix). ANOVA, hierarchical and consensus clustering analyses allowed identification of pattern of expression of miRNAs and pathway enrichment analysis, considering validated target genes, was carried out to achieve a deeper biological understanding.
   Results: ANOVA test led to the identification of 53 deregulated miRNAs; hierarchical and consensus clustering of female fBCs (fFBCs) and male fBCs (fMBCs) highlighted the presence of 3 sample clusters named FBC1, FBC2 and FBC3. We found a correlation between ER-status and the three sample clusters. The three clusters are distinct by a different expression of two clusters of miRNAs (CLU1 and CLU2), which resulted to be different in targeted pathways. In particular, CLU1 targets cellular pathways and CLU2 is involved in epigenetic activities. Considering TN and NTN BRCA-related and sporadic tumors, a hierarchical clustering identified two clusters of miRNAs, which were not so different from CLU1 and CLU2, both in miRNA content and targeted pathways.
   Conclusions: Our results highlighted the importance of miRNA regulation to better clarify similarities and differences between familial and sporadic BC groups.
C1 [Danza, Katia; De Summa, Simona; Pilato, Brunella; Paradiso, Angelo; Pinto, Rosamaria; Tommasi, Stefania] Ist Tumori Giovanni Paolo II, IRCCS, Mol Genet Lab, I-70124 Bari, Italy.
   [Carella, Massimo; Palumbo, Orazio] IRCCS Casa Sollievo Sofferenza San Giovanni Roton, Med Genet Unit, Bari, Italy.
   [Popescu, Ondina] Ist Tumori Giovanni Paolo II, IRCCS, Anatomopathol Unit, I-70124 Bari, Italy.
   [Paradiso, Angelo] Ist Tumori Giovanni Paolo II, IRCCS, Expt Med Oncol Unit, I-70124 Bari, Italy.
C3 IRCCS Istituto Tumori Bari Giovanni Paolo II; Consiglio Nazionale delle
   Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Casa
   Sollievo Della Sofferenza; IRCCS Istituto Tumori Bari Giovanni Paolo II;
   IRCCS Istituto Tumori Bari Giovanni Paolo II
RP Tommasi, S (通讯作者)，Ist Tumori Giovanni Paolo II, IRCCS, Mol Genet Lab, Vle Orazio Flacco 65, I-70124 Bari, Italy.
EM s.tommasi@oncologico.bari.it
RI Popescu, Ondina/AAO-9751-2020; Pilato, Brunella/AAH-7365-2020; Danza,
   Katia/K-3182-2018; paradiso, angelo/J-9457-2018; De Summa,
   Simona/K-2582-2018; Carella, Massimo/A-2804-2014; Tommasi,
   Stefania/J-6732-2012; PALUMBO, ORAZIO/C-1133-2014
OI De Summa, Simona/0000-0001-9607-3754; Carella,
   Massimo/0000-0002-6830-6829; Tommasi, Stefania/0000-0002-2157-2978;
   pilato, brunella/0000-0001-6067-3977; PALUMBO,
   ORAZIO/0000-0001-6583-3482
CR [Anonymous], 2003, METRON INT J STAT
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Burgess M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00019
   Cascione L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055910
   Cho EY, 2011, CANCER CHEMOTH PHARM, V68, P753, DOI 10.1007/s00280-010-1548-x
   D'Ippolito E, 2013, INT J MOL SCI, V14, P22202, DOI 10.3390/ijms141122202
   Esteller M., 2011, F1000 BIOL REP, V3, P9
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Esteller Manel, 2011, Genes Cancer, V2, P604, DOI 10.1177/1947601911423096
   Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608
   Fu SW, 2011, J CANCER, V2, P116, DOI 10.7150/jca.2.116
   García-Becerra R, 2013, INT J MOL SCI, V14, P108, DOI 10.3390/ijms14010108
   Guo L, 2013, MOL BIOL REP, V40, P2175, DOI 10.1007/s11033-012-2277-5
   Hill L, 2013, INT J CANCER, V132, P745, DOI 10.1002/ijc.27708
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06
   Hsu SD, 2014, NUCLEIC ACIDS RES, V42, pD78, DOI 10.1093/nar/gkt1266
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Manavathi B, 2013, ENDOCR REV, V34, P1, DOI 10.1210/er.2011-1057
   Melchor L, 2013, HUM GENET, V132, P845, DOI 10.1007/s00439-013-1299-y
   Muggia F, 2014, ANTICANCER RES, V34, P551
   Estal RM, 2013, BREAST CANCER RES TR, V142, P19, DOI 10.1007/s10549-013-2723-7
   Pilato B, 2011, BREAST CANCER RES TR, V125, P651, DOI 10.1007/s10549-010-0861-8
   Pinto R, 2013, J CELL PHYSIOL, V228, P1264, DOI 10.1002/jcp.24281
   Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Tanic M, 2013, BRIT J CANCER, V109, P2724, DOI 10.1038/bjc.2013.612
   Tanic M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038847
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109
   Xiao FF, 2009, NUCLEIC ACIDS RES, V37, pD105, DOI 10.1093/nar/gkn851
   Zhou JC, 2013, ONCOL LETT, V6, P295, DOI 10.3892/ol.2013.1405
   Zhou W, 2014, NAT REV CANCER, V14, P26, DOI 10.1038/nrc3622
NR 38
TC 10
Z9 10
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD NOV 19
PY 2014
VL 12
AR 319
DI 10.1186/s12967-014-0319-6
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AT8TP
UT WOS:000345205100001
PM 25406994
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU El Helou, R
   Wicinski, J
   Guille, A
   Adélaide, J
   Finetti, P
   Bertucci, F
   Chaffanet, M
   Birnbaum, D
   Charafe-Jauffret, E
   Ginestier, C
AF El Helou, Rita
   Wicinski, Julien
   Guille, Arnaud
   Adelaide, Jose
   Finetti, Pascal
   Bertucci, Francois
   Chaffanet, Max
   Birnbaum, Daniel
   Charafe-Jauffret, Emmanuelle
   Ginestier, Christophe
TI Brief Reports: A Distinct DNA Methylation Signature Defines Breast
   Cancer Stem Cells and Predicts Cancer Outcome
SO STEM CELLS
LA English
DT Article
DE Breast cancer; Cancer stem cells; Methylation; Differentiation
ID MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR; DIFFERENTIATION;
   HETEROGENEITY; EXPRESSION; PLASTICITY; CHROMATIN; PATTERNS; COMPLEX
AB Self-renewal and differentiation are two epigenetic programs that regulate stem cells fate. Dysregulation of these two programs leads to the development of cancer stem cells (CSCs). Recent evidence suggests that CSCs are relatively resistant to conventional therapies and responsible for metastasis formation. Deciphering these processes will help understand oncogenesis and allow the development of new targeted therapies. Here, we have used a whole genome promoter microarray to establish the DNA methylation portraits of breast cancer stem cells (bCSCs) and non-bCSCs. A total of 68 differentially methylated regions (DMRs) were more hypomethylated in bCSCs than in non-bCSCs. Using a differentiation assay we demonstrated that DMRs are rapidly hypermethylated within the first 6 hours following induction of CSC differentiation whereas the cells reached the steady-state within 6 days, suggesting that these DMRs are linked to early CSC epigenetic regulation. These DMRs were significantly enriched in genes coding for TGF-beta signaling-related proteins. Interestingly, DMRs hypomethylation was correlated to an overexpression of TGF-beta signaling genes in a series of 109 breast tumors. Moreover, patients with tumors harboring the bCSC DMRs signature had a worse prognosis than those with non-bCSC DMRs signature. Our results show that bCSCs have a distinct DNA methylation landscape with TGF-beta signaling as a key epigenetic regulator of bCSCs differentiation.
C1 [El Helou, Rita; Wicinski, Julien; Guille, Arnaud; Adelaide, Jose; Finetti, Pascal; Bertucci, Francois; Chaffanet, Max; Birnbaum, Daniel; Charafe-Jauffret, Emmanuelle; Ginestier, Christophe] INSERM, CRCM, Equipe Labellisee Ligue Canc, U1068, F-13273 Marseille, France.
   [El Helou, Rita; Wicinski, Julien; Guille, Arnaud; Adelaide, Jose; Finetti, Pascal; Bertucci, Francois; Chaffanet, Max; Birnbaum, Daniel; Charafe-Jauffret, Emmanuelle; Ginestier, Christophe] Inst J Paoli I Calmettes, F-13009 Marseille, France.
   [El Helou, Rita; Wicinski, Julien; Guille, Arnaud; Adelaide, Jose; Finetti, Pascal; Bertucci, Francois; Chaffanet, Max; Birnbaum, Daniel; Charafe-Jauffret, Emmanuelle; Ginestier, Christophe] Aix Marseille Univ, Marseille, France.
   [El Helou, Rita; Wicinski, Julien; Guille, Arnaud; Adelaide, Jose; Finetti, Pascal; Bertucci, Francois; Chaffanet, Max; Birnbaum, Daniel; Charafe-Jauffret, Emmanuelle; Ginestier, Christophe] CNRS, UMR7258, Marseille, France.
C3 Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UNICANCER; Institut Paoli-Calmette (IPC); Aix-Marseille Universite;
   Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Aix-Marseille Universite
RP Ginestier, C (通讯作者)，INSERM, CRCM, Dept Mol Oncol, U1068, 27 Bd Lei Roure,BP 30059, F-13273 Marseille, France.
EM christophe.ginestier@inserm.fr
RI Ginestier, Christophe/M-8828-2017; ADELAIDE, José/O-4390-2017;
   CHAFFANET, Max/AAU-5743-2020; Guille, Arnaud/GZG-1785-2022; Finetti,
   Pascal/O-8669-2017; Charafe-Jauffret, emmanuelle/P-6009-2017
OI Finetti, Pascal/0000-0002-2674-3123; CHAFFANET, Max/0000-0002-2344-1488;
   Ginestier, Christophe/0000-0002-7477-3837; Bertucci,
   Francois/0000-0002-0157-0959; Birnbaum, Daniel/0000-0001-7920-9883;
   Guille, Arnaud/0000-0001-5747-562X; Charafe-Jauffret,
   emmanuelle/0000-0002-0286-1299
FU Inserm; Institut Paoli-Calmettes; SIRIC [INCa-DGOS-Inserm 6038]; IVOIRES
   (INCa-PL-BIO); GEFLUC; Ligue National Contre le Cancer; Ministry of
   Research
FX We thank the Association pour la Recherche contre le Cancer for
   supporting our acquisition of a cell sorter. This study was supported by
   Inserm, Institut Paoli-Calmettes, SIRIC (INCa-DGOS-Inserm 6038), IVOIRES
   (INCa-PL-BIO, 2010), GEFLUC, and grants from the Ligue National Contre
   le Cancer (Label DB). R.H. has been supported by a fellowship from the
   Ministry of Research. Thanks are due to the CRCM flow cytometry core
   facility.
CR Bhola NE, 2013, J CLIN INVEST, V123, P1348, DOI 10.1172/JCI65416
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Bock C, 2012, MOL CELL, V47, P633, DOI 10.1016/j.molcel.2012.06.019
   Bruna A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2039
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Charafe-Jauffret E, 2013, CANCER RES, V73, P7290, DOI 10.1158/0008-5472.CAN-12-4704
   Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Cornen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081843
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
   Hernandez-Vargas H, 2011, EPIGENETICS-US, V6, P429, DOI 10.4161/epi.6.4.14515
   Hodges E, 2011, MOL CELL, V44, P17, DOI 10.1016/j.molcel.2011.08.026
   Ji H, 2010, NATURE, V467, P338, DOI 10.1038/nature09367
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Liu SL, 2010, J CLIN ONCOL, V28, P4006, DOI 10.1200/JCO.2009.27.5388
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Maruyama R, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001369
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Pal B, 2013, CELL REP, V3, P411, DOI 10.1016/j.celrep.2012.12.020
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Salvador MA, 2013, CLIN CANCER RES, V19, P6520, DOI 10.1158/1078-0432.CCR-13-0877
   Thillainadesan G, 2012, MOL CELL, V46, P636, DOI 10.1016/j.molcel.2012.03.027
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
NR 30
TC 28
Z9 30
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD NOV
PY 2014
VL 32
IS 11
BP 3031
EP 3036
DI 10.1002/stem.1792
PG 6
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA AR1BK
UT WOS:000343314400020
PM 25069843
OA Bronze
DA 2025-01-12
ER

PT J
AU Zhang, Y
   Tong, TJ
AF Zhang, Yu
   Tong, Tanjun
TI FOXA1 antagonizes EZH2-mediated CDKN2A repression in carcinogenesis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE FOXA1; EZH2; CDKN2A; Carcinogenesis
ID GENE-EXPRESSION PROFILES; PROSTATE-CANCER; CELLULAR SENESCENCE;
   ESTROGEN-RECEPTOR; TRANSCRIPTION; P16(INK4A); CELLS
AB CDKN2A (p16(INK4a)) is a crucial tumor suppressor involved in many cancers. Our recent investigations revealed that FOXA1 as a forkhead transcription factor mediates CDKN2A activation in cellular senescence. However, the contribution of this axis in carcinogenesis remains unclear. Here, using a comprehensive collection of cancer microarray data, we found FOXA1 is down-regulated in many cancers compared to their normal counterparts and the positive correlation between FOXA1 and CDKN2A could be observed in prostate and breast cancers with lower EZH2 (epigenetic repressor for CDKN2A) expression. Experimentally, epistasis analysis in prostate and breast cancer cells indicated that higher expression of FOXA1 opposes EZH2-mediated CDKN2A repression, as further depletion of FOXA1 reverts the de-silencing of CDKN2A caused by EZH2 inhibition. Concomitantly, EZH2-depletion suppresses cancer cell cycle progression and this regulation is optimized in the presence of FOXA1 and CDKN2A. A further oncogenic transformation assay suggested that overexpression of EZH2 is insufficient to block RAS-induced CDKN2A activation and loss of FOXA1 is mandatory to potentiate EZH2-mediated CDKN2A silencing and to bypass the senescence barrier. Importantly, using an in vitro histone methyltransferase (HMTase) system, we found FOXA1 directly inhibits EZH2's histone methyltransferase activity through its C-terminal histone binding motif. These data support that positive regulation of CDKN2A by FOXA1 counteracts its tumorigenic repression of by EZH2 in cancers. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Zhang, Yu; Tong, Tanjun] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Res Ctr Aging, Beijing 100191, Peoples R China.
C3 Peking University
RP Tong, TJ (通讯作者)，Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.
EM zhang_yu@bjmu.edu.cn; ttj@bjmu.edu.cn
FU National Basic Research Programs of China [81300254]; National Key Basic
   Research Program of China [2013CB530801]
FX We appreciate Dr Masashi Narita (Cancer Research UK, Cambridge Research
   Institute) for providing us the retroviral vector WZL-H-Ras V12,
   pLPC-EZH2 and the empty vectors. This work was supported by Grant
   81300254 (to Y.Z.) from the National Basic Research Programs of China
   and Grant 2013CB530801 from National Key Basic Research Program of
   China.
CR Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003
   Craig C, 1998, ONCOGENE, V16, P265, DOI 10.1038/sj.onc.1201493
   Estilo CL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-11
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263
   Katoh M, 2013, CANCER LETT, V328, P198, DOI 10.1016/j.canlet.2012.09.017
   Li Q, 2013, EMBO J, V32, P858, DOI 10.1038/emboj.2013.35
   Li Z, 2012, CELL, V148, P72, DOI 10.1016/j.cell.2011.11.026
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Mas VR, 2009, MOL MED, V15, P85, DOI 10.2119/molmed.2008.00110
   Nanni S, 2006, MOL CANCER RES, V4, P79, DOI 10.1158/1541-7786.MCR-05-0098
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Storz MN, 2003, J INVEST DERMATOL, V120, P865, DOI 10.1046/j.1523-1747.2003.12142.x
   Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683
   Tamura K, 2007, CANCER RES, V67, P5117, DOI 10.1158/0008-5472.CAN-06-4040
   Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006
   Wang HY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-680
   Wang JY, 2014, ONCOL REP, V31, P1225, DOI 10.3892/or.2014.2982
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
NR 27
TC 24
Z9 25
U1 1
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 10
PY 2014
VL 453
IS 1
BP 172
EP 178
DI 10.1016/j.bbrc.2014.09.092
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AR5OZ
UT WOS:000343634900029
PM 25264199
DA 2025-01-12
ER

PT J
AU Singh, B
   Shoulson, R
   Chatterjee, A
   Ronghe, A
   Bhat, NK
   Dim, DC
   Bhat, HK
AF Singh, Bhupendra
   Shoulson, Rivka
   Chatterjee, Anwesha
   Ronghe, Amruta
   Bhat, Nimee K.
   Dim, Daniel C.
   Bhat, Hari K.
TI Resveratrol inhibits estrogen-induced breast carcinogenesis through
   induction of NRF2-mediated protective pathways
SO CARCINOGENESIS
LA English
DT Article
ID FEMALE ACI RATS; OXIDATIVE DNA-DAMAGE; INDUCED MAMMARY-TUMORS;
   PROSTATE-CANCER; MOLECULAR-MECHANISMS; CELL-PROLIFERATION; INDUCED
   APOPTOSIS; NRF2 EXPRESSION; ANTIOXIDANT; DISEASE
AB The importance of estrogens in the etiology of breast cancer is widely recognized. Estrogen-induced oxidative stress has been implicated in this carcinogenic process. Resveratrol (Res), a natural antioxidant phytoestrogen has chemopreventive effects against a variety of illnesses including cancer. The objective of the present study was to characterize the mechanism(s) of Res-mediated protection against estrogen-induced breast carcinogenesis. Female August Copenhagen Irish rats were treated with 17 beta-estradiol (E2), Res and Res + E2 for 8 months. Cotreatment of rats with Res and E2 inhibited E2-mediated proliferative changes in mammary tissues and significantly increased tumor latency and reduced E2-induced breast tumor development. Resveratrol treatment alone or in combination with E2 significantly upregulated expression of nuclear factor erythroid 2-related factor 2 (NRF2) in mammary tissues. Expression of NRF2-regulated antioxidant genes NQO1, SOD3 and OGG1 that are involved in protection against oxidative DNA damage was increased in Res- and Res + E2-treated mammary tissues. Resveratrol also prevented E2-mediated inhibition of detoxification genes AOX1 and FMO1. Inhibition of E2-mediated alterations in NRF2 promoter methylation and expression of NRF2 targeting miR-93 after Res treatment indicated Res-mediated epigenetic regulation of NRF2 during E2-induced breast carcinogenesis. Resveratrol treatment also induced apoptosis and inhibited E2-mediated increase in DNA damage in mammary tissues. Increased apoptosis and decreased DNA damage, cell migration, colony and mammosphere formation in Res-and Res + E2-treated MCF-10A cells suggested a protective role of Res against E2-induced mammary carcinogenesis. Small-interfering RNA-mediated silencing of NRF2 inhibited Res-mediated preventive effects on the colony and mammosphere formation. Taken together, these results suggest that Res inhibits E2-induced breast carcinogenesis via induction of NRF2-mediated protective pathways.
C1 [Singh, Bhupendra] Univ Alabama Birmingham, Sch Med, Dept Genet, Birmingham, AL 35294 USA.
   [Shoulson, Rivka] Columbia Univ, Inst Comparat Med, New York, NY 10032 USA.
   [Chatterjee, Anwesha; Ronghe, Amruta; Bhat, Nimee K.; Bhat, Hari K.] Univ Missouri, Sch Pharm, Div Pharmacol & Toxicol, Kansas City, MO 64108 USA.
   [Dim, Daniel C.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA.
C3 University of Alabama System; University of Alabama Birmingham; Columbia
   University; University of Missouri System; University of Missouri Kansas
   City; University of Missouri System; University of Missouri Kansas City
RP Bhat, HK (通讯作者)，Univ Missouri, Sch Pharm, Div Pharmacol & Toxicol, 2464 Charlotte St,Room 5251, Kansas City, MO 64108 USA.
EM bhath@umkc.edu
FU National Institutes of Health Grant [CA 109551]; University of Missouri
   Research Board Grant; School of Pharmacy, University of Missouri-Kansas
   City
FX National Institutes of Health Grant (CA 109551); the University of
   Missouri Research Board Grant (H.K.B.); the School of Pharmacy,
   University of Missouri-Kansas City.
CR Alkhalaf M, 2008, ARCH MED RES, V39, P162, DOI 10.1016/j.arcmed.2007.09.003
   Alkhalaf M, 2007, PHARMACOLOGY, V80, P134, DOI 10.1159/000103253
   Ansell PJ, 2005, MOL CELL ENDOCRINOL, V243, P27, DOI 10.1016/j.mce.2005.08.002
   Arnerlöv C, 2001, ANAL CELL PATHOL, V23, P21, DOI 10.1155/2001/430674
   Banerjee S, 2002, CANCER RES, V62, P4945
   Bhat HK, 2003, P NATL ACAD SCI USA, V100, P3913, DOI 10.1073/pnas.0437929100
   Bhat KPL, 2001, CANCER RES, V61, P7456
   Buchon N, 2009, GENE DEV, V23, P2333, DOI 10.1101/gad.1827009
   Carrizzo A, 2013, FOOD CHEM TOXICOL, V61, P215, DOI 10.1016/j.fct.2013.07.021
   Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937
   Chmelarova M, 2013, CLIN TRANSL ONCOL, V15, P160, DOI 10.1007/s12094-012-0894-z
   DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Garvin S, 2006, CANCER LETT, V231, P113, DOI 10.1016/j.canlet.2005.01.031
   Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138
   Haldrup C, 2013, J CLIN ONCOL, V31, P3250, DOI 10.1200/JCO.2012.47.1847
   Havens CG, 2006, MOL CELL BIOL, V26, P4701, DOI 10.1128/MCB.00303-06
   Hochmuth CE, 2011, CELL STEM CELL, V8, P188, DOI 10.1016/j.stem.2010.12.006
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kensler TW, 2010, CARCINOGENESIS, V31, P90, DOI 10.1093/carcin/bgp231
   Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009
   Le Corre L, 2005, MOL NUTR FOOD RES, V49, P462, DOI 10.1002/mnfr.200400094
   Li J, 2005, PHYSIOL GENOMICS, V21, P43, DOI 10.1152/physiolgenomics.00214.2004
   Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101
   Li SA, 2002, J ENDOCRINOL, V175, P297, DOI 10.1677/joe.0.1750297
   Li WG, 2009, MOL CARCINOGEN, V48, P91, DOI 10.1002/mc.20465
   Maeda K, 2012, GENE, V505, P374, DOI 10.1016/j.gene.2012.06.010
   Mense SM, 2008, TOXICOL APPL PHARM, V232, P78, DOI 10.1016/j.taap.2008.06.007
   Mense SM, 2008, ENVIRON HEALTH PERSP, V116, P426, DOI 10.1289/ehp.10538
   Mense SM, 2009, CARCINOGENESIS, V30, P1202, DOI 10.1093/carcin/bgp093
   Niles RM, 2006, J NUTR, V136, P2542, DOI 10.1093/jn/136.10.2542
   NTP (National Toxicology Program), 2002, REP CARC
   Patel KR, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005870
   Reddy NM, 2007, PHYSIOL GENOMICS, V32, P74, DOI 10.1152/physiolgenomics.00126.2007
   Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004
   Sato M, 2003, CANCER LETT, V202, P137, DOI 10.1016/j.canlet.2003.08.016
   Schlachterman A, 2008, TRANSL ONCOL, V1, P19, DOI 10.1593/tlo.07100
   Shull JD, 1997, CARCINOGENESIS, V18, P1595, DOI 10.1093/carcin/18.8.1595
   Singh B, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-253
   Singh B, 2013, CARCINOGENESIS, V34, P1165, DOI 10.1093/carcin/bgt026
   Singh B, 2012, CARCINOGENESIS, V33, P2601, DOI 10.1093/carcin/bgs300
   Singh B, 2012, CARCINOGENESIS, V33, P156, DOI 10.1093/carcin/bgr237
   Singh B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025125
   Singh B, 2010, TOXICOL APPL PHARM, V247, P83, DOI 10.1016/j.taap.2010.06.011
   Singh B, 2009, J BIOCHEM MOL TOXIC, V23, P202, DOI 10.1002/jbt.20281
   Singh KP, 2012, CANCER LETT, V316, P62, DOI 10.1016/j.canlet.2011.10.022
   Sirtori CR, 2005, ANN MED, V37, P423, DOI 10.1080/07853890510044586
   Subramanian L, 2010, CLIN CANCER RES, V16, P5942, DOI 10.1158/1078-0432.CCR-10-1486
   Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684
   Varisli L, 2013, GENET TEST MOL BIOMA, V17, P562, DOI 10.1089/gtmb.2012.0524
   Weroha SJ, 2006, CARCINOGENESIS, V27, P491, DOI 10.1093/carcin/bgi278
   Whitsett Timothy, 2006, J Carcinog, V5, P15, DOI 10.1186/1477-3163-5-15
   Wojcieszynska D, 2012, INT J MOL SCI, V13, P16751, DOI 10.3390/ijms131216751
   Wood LG, 2010, ANTIOXID REDOX SIGN, V13, P1535, DOI 10.1089/ars.2009.3064
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Yu SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008579
   Ziegler DM, 2002, DRUG METAB REV, V34, P503, DOI 10.1081/DMR-120005650
NR 57
TC 127
Z9 135
U1 0
U2 20
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD AUG
PY 2014
VL 35
IS 8
BP 1872
EP 1880
DI 10.1093/carcin/bgu120
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AR2NA
UT WOS:000343423000025
PM 24894866
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Miao, Y
   Wang, L
   Zhang, XP
   Xu, XH
   Jiang, GY
   Fan, CF
   Liu, Y
   Lin, XY
   Yu, JH
   Zhang, Y
   Wang, EH
AF Miao, Yuan
   Wang, Liang
   Zhang, Xiupeng
   Xu, Xiaohan
   Jiang, Guiyang
   Fan, Chuifeng
   Liu, Yang
   Lin, Xuyong
   Yu, Juanhan
   Zhang, Yong
   Wang, Enhua
TI Promoter Methylation-Mediated Silencing of β-Catenin Enhances
   Invasiveness of Non-Small Cell Lung Cancer and Predicts Adverse
   Prognosis
SO PLOS ONE
LA English
DT Article
ID E-CADHERIN; MICROSATELLITE INSTABILITY; DNA METHYLATION; POOR-PROGNOSIS;
   BREAST-CANCER; EXPRESSION; GENES; HYPERMETHYLATION; CARCINOMA;
   SUPPRESSION
AB beta-Catenin plays dual role in adhesion complex formation and the Wnt signaling pathway. Although beta-catenin expression appears to be upregulated and Wnt signaling pathway is activated in the majority of cancers, its expression level seems to be lost in non-small cell lung cancer (NSCLC). We previously reported that the promoter of beta-catenin was hypermethylated in two NSCLC cell lines. In the current study, we expanded our analysis for the methylation status of beta-catenin promoter region and its protein expression in seven NSCLC cell lines and a series of 143 cases of primary human lung cancer with adjacent non-neoplastic tissues. Quantitative methylation specific PCR (qMSP) analysis showed methylation of beta-catenin promoter region in five NSCLC cell lines, with increased beta-catenin protein levels upon 5'-Aza-2'-deoxycytidine (5-aza-dC) treatment. The methylation status in SPC (methylated) and A549 (unmethylated) was confirmed by bisulfite sequencing PCR. 5-Aza-dC treatment inhibited invasiveness of SPC but not A549. Immunofluorescence analysis showed membranous bcatenin expression was lost in SPC and could be re-established by 5-aza-dC, while Wnt3a treatment led to nuclear translocation of b-catenin in both SPC and A549. Dual-luciferase assays indicated that 5-aza-dC treatment caused no significant increase in Wnt signaling activity compared with Wnt3a treatment. The effect of demethylation agent in SPC can be reversed by beta-catenin depletion but not E-cadherin depletion which indicated that the methylation mediated beta-catenin silencing might enhance NSCLC invasion and metastasis in an E-cadherin independent manner. Subsequent immunohistochemistry results further confirmed that beta-catenin promoter hypermethylation correlated with loss of immunoreactive protein expression, positive lymph node metastasis, high TNM stage and poor prognosis. The present study implicates beta-catenin promoter hypermethylation in the mechanism of epigenetic changes underlying NSCLC metastasis and progression, thus indicating the potential of beta-catenin as a novel epigenetic target for the treatment of NSCLC patients.
C1 [Miao, Yuan; Wang, Liang; Zhang, Xiupeng; Jiang, Guiyang; Fan, Chuifeng; Liu, Yang; Lin, Xuyong; Yu, Juanhan; Zhang, Yong; Wang, Enhua] China Med Univ, Dept Pathol, Hosp 1, Shenyang, Peoples R China.
   [Miao, Yuan; Wang, Liang; Zhang, Xiupeng; Jiang, Guiyang; Fan, Chuifeng; Liu, Yang; Lin, Xuyong; Yu, Juanhan; Zhang, Yong; Wang, Enhua] China Med Univ, Coll Basic Med Sci, Shenyang, Peoples R China.
   [Xu, Xiaohan] China Med Univ, Year Program Med 96K 7, Shenyang, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Wang, EH (通讯作者)，China Med Univ, Dept Pathol, Hosp 1, Shenyang, Peoples R China.
EM wangeh@hotmail.com
RI Wang, Liang/AAM-2378-2021; Miao, Yuan/AAG-9754-2021
FU National Natural Science Foundation of China [81000942, 30900562]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81000942 to Yuan Miao and No. 30900562 to Yang
   Liu). The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Capaldo CT, 2007, MOL BIOL CELL, V18, P189, DOI 10.1091/mbc.E06-05-0471
   Cho YH, 2012, BREAST CANCER RES TR, V131, P197, DOI 10.1007/s10549-011-1712-y
   Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017
   Fu YJ, 2011, INT J CANCER, V129, P1541, DOI 10.1002/ijc.26102
   Goldstraw P, 2011, SURG ONCOL CLIN N AM, V20, P655, DOI 10.1016/j.soc.2011.07.005
   Hugh TJ, 1999, INT J CANCER, V82, P504, DOI 10.1002/(SICI)1097-0215(19990812)82:4<504::AID-IJC6>3.0.CO;2-6
   Kase S, 2000, CLIN CANCER RES, V6, P4789
   Königshoff M, 2010, AM J RESP CELL MOL, V42, P21, DOI 10.1165/rcmb.2008-0485TR
   Kümper S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011801
   Kwon MJ, 2013, HUM PATHOL, V44, P1722, DOI 10.1016/j.humpath.2013.03.004
   Liu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087537
   Mareel M, 1996, J CELL BIOCHEM, V61, P524
   Miao Y, 2013, PATHOL ONCOL RES, V19, P281, DOI 10.1007/s12253-012-9580-2
   Miao Y, 2012, FOLIA HISTOCHEM CYTO, V50, P392, DOI [10.5603/FHC.2012.0053, 10.5603/11957]
   Mirabelli-Primdahl L, 1999, CANCER RES, V59, P3346
   Nakata S, 2006, CANCER-AM CANCER SOC, V106, P2190, DOI 10.1002/cncr.21870
   Pirinen RT, 2001, J CLIN PATHOL, V54, P391, DOI 10.1136/jcp.54.5.391
   Retera JMAM, 1998, J CLIN PATHOL, V51, P891, DOI 10.1136/jcp.51.12.891
   Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962
   Salon Caroline, 2005, Future Oncol, V1, P649, DOI 10.2217/14796694.1.5.649
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Takahashi Y, 2008, INT J CANCER, V123, P2315, DOI 10.1002/ijc.23812
   Travis WD, 2004, PATHOLOGY GENETICS T
   Travis WD, 2011, CLIN CHEST MED, V32, P669, DOI 10.1016/j.ccm.2011.08.005
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Vaissiere T, 2009, CANCER RES, V69, P243, DOI 10.1158/0008-5472.CAN-08-2489
   Van Scoyk M, 2008, TRANSL RES, V151, P175, DOI 10.1016/j.trsl.2007.12.011
   Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033
   Yanagawa N, 2003, CANCER SCI, V94, P589, DOI 10.1111/j.1349-7006.2003.tb01487.x
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P249
NR 32
TC 18
Z9 20
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 14
PY 2014
VL 9
IS 11
AR e112258
DI 10.1371/journal.pone.0112258
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AU4DF
UT WOS:000345558500041
PM 25396757
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU Wang, Y
   Peng, Y
   Zhou, YQ
   Zhou, YH
   Zhong, H
AF Wang, Yan
   Peng, Yan
   Zhou, Yingqiong
   Zhou, Yuanhua
   Zhong, Hui
TI The Clinical Value of LRRC3B Gene Expression and Promoter
   Hypermethylation in Breast Carcinomas
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Breast cancer; LRRC3B; Gene expression; Methylation
ID CANCER
AB Epigenetic alteration of tumor suppressor genes by promoter hypermethylation has played a key role in tumorigenesis, which is an important mechanism as indispensable as gene deletion and mutation. LRRC3B is a potential tumor suppressor gene newly discovered; however, the specific biologic function is still unknown. In the present study, we tested the expression levels of LRRC3B by methods associated with immunohistochemistry, Real-Time PCR, and methylation-specific polymerase chain reaction. Results showed that the expression levels were significantly low irrespective of methylation status, suggesting that there were other factors involved in this process. However, the expression profile of LRRC3B had a significant relationship with tissue grade, irrespective of the expressions of PR, CERB-2, VEGF, and Ki67 except in cases of p53 and ER, leading us to a conclusion that the abnormal expression of LRRC3B could serve as a useful marker for diagnosis and prognosis in breast carcinomas.
C1 [Wang, Yan; Peng, Yan; Zhou, Yingqiong; Zhong, Hui] Guangxi Normal Univ, Sch Chem & Chem Engn, State Key Lab Cultivat Base Chem & Mol Engn Med R, Guilin 541004, Guangxi, Peoples R China.
   [Peng, Yan] Guangxi Normal Univ, Lab Med Chem Resources & Mol Engn, Guilin 541004, Guangxi, Peoples R China.
   [Zhou, Yuanhua] Guangxi Normal Univ, Affiliated Hosp, Dept Pathol, Guilin 541004, Guangxi, Peoples R China.
C3 Guangxi Normal University; Guangxi Normal University; Guangxi Normal
   University
RP Peng, Y (通讯作者)，Guangxi Normal Univ, Lab Med Chem Resources & Mol Engn, Guilin 541004, Guangxi, Peoples R China.
EM pengyan630@aliyun.com
RI Peng, Yan/U-8481-2017
FU National Key Basic Research Program of China [2010CB933902]
FX This study was supported by the National Key Basic Research Program of
   China (Grant 2010CB933902).
CR ANDERSEN TI, 1993, BRIT J CANCER, V68, P540, DOI 10.1038/bjc.1993.383
   Jensen EV, 2003, CLIN CANCER RES, V9, P1980
   Kim M, 2008, CANCER RES, V68, P7147, DOI 10.1158/0008-5472.CAN-08-0667
   Olivier M, 2006, CLIN CANCER RES, V12, P1157, DOI 10.1158/1078-0432.CCR-05-1029
   Overgaard J, 2000, ACTA ONCOL, V39, P327, DOI 10.1080/028418600750013096
   Ross JS., 2005, Molecular Oncology of Breast Cancer
   Tian XQ, 2009, SCAND J GASTROENTERO, V44, P79, DOI 10.1080/00365520802400834
   Wu H., 2002, J GUANGDONG MED COLL, V8, P264
   Xu Z. M., 2002, LETT BIOTECHNOLOGY, V13, P187
   Xu Zhou-Min, 2003, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V11, P22
   Xu Zhou-Min, 2003, Zhongguo Shi Yan Xue Ye Xue Za Zhi, V11, P583
NR 11
TC 5
Z9 6
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
EI 1559-0283
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD NOV
PY 2014
VL 70
IS 2
BP 1035
EP 1041
DI 10.1007/s12013-014-0018-1
PG 7
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AQ9DN
UT WOS:000343143500039
PM 24839112
DA 2025-01-12
ER

PT J
AU Wu, AML
   Yang, MD
   Dalvi, P
   Turinsky, AL
   Wang, W
   Butcher, D
   Egan, SE
   Weksberg, R
   Harper, PA
   Ito, S
AF Wu, Alex Man Lai
   Yang, Mingdong
   Dalvi, Pooja
   Turinsky, Andrei L.
   Wang, Wei
   Butcher, Darci
   Egan, Sean E.
   Weksberg, Rosanna
   Harper, Patricia A.
   Ito, Shinya
TI Role of STAT5 and epigenetics in lactation-associated upregulation of
   multidrug transporter ABCG2 in the mammary gland
SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
LA English
DT Article
DE prolactin; lactation; ABCG2; STAT5; epigenetics; drug transporter
ID CANCER-RESISTANCE-PROTEIN; BREAST-CANCER; GENE-EXPRESSION;
   MESSENGER-RNA; PROMOTER METHYLATION; SIGNAL TRANSDUCER; DRUG-RESISTANCE;
   HUMAN GENOME; CASEIN GENE; FACTOR-I
AB The multidrug resistance efflux transporter ATP-binding cassette subfamily G member 2 (ABCG2) is not only overexpressed in certain drug-resistant cancers but is also highly expressed in the mammary gland during lactation, carrying xenobiotics and nutrients into milk. We sought to investigate the molecular mechanisms involved in the upregulation of ABCG2 during lactation. Expression profiling of different mouse Abcg2 mRNA isoforms (E1a, E1b, and E1c) revealed that E1b is predominantly expressed and induced in the lactating mouse mammary gland. Despite this induction, analyses of CpG methylation status and published ChIP-seq datasets reveal that E1b promoter sequences in the virgin gland are already hypomethylated and marked with the open chromatin histone mark H3K4me2. Using a forced-weaning model to shut down lactation, we found that within 24 h there was a significant reduction in Abcg2 mRNA expression and a loss of signal transducer and activator of transcription-5 (STAT5) occupancy at the mouse Abcg2 gene. Luciferase reporter assays further showed that some of these STAT5-binding regions that contained interferon-gamma-activated sequence (GAS) motifs function as an enhancer after prolactin treatment. We conclude that Abcg2 is already poised for expression in the virgin mammary gland and that STAT5 plays an important role in Abcg2 expression during lactation.
C1 [Wu, Alex Man Lai; Yang, Mingdong; Dalvi, Pooja; Ito, Shinya] Hosp Sick Children, Res Inst, Physiol & Expt Med Program, Toronto, ON M5G 1X8, Canada.
   [Butcher, Darci; Weksberg, Rosanna] Hosp Sick Children, Res Inst, Genet & Genome Biol Program, Toronto, ON M5G 1X8, Canada.
   [Wang, Wei; Egan, Sean E.] Hosp Sick Children, Res Inst, Dev & Stem Cell Biol Program, Toronto, ON M5G 1X8, Canada.
   [Turinsky, Andrei L.] Hosp Sick Children, Res Inst, Ctr Computat Med, Toronto, ON M5G 1X8, Canada.
   [Wu, Alex Man Lai; Harper, Patricia A.; Ito, Shinya] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON, Canada.
   [Egan, Sean E.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Weksberg, Rosanna; Ito, Shinya] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada.
   [Weksberg, Rosanna] Univ Toronto, Inst Med Sci, Toronto, ON, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto; Hospital for Sick Children (SickKids); University of
   Toronto; Hospital for Sick Children (SickKids); University of Toronto;
   Hospital for Sick Children (SickKids); University of Toronto; University
   of Toronto; University of Toronto; University of Toronto
RP Ito, S (通讯作者)，Hosp Sick Children, Dept Pediat, Div Clin Pharmacol & Toxicol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM shinya.ito@sickkids.ca
OI Ito, Shinya/0000-0002-4498-3075
FU Grant MOP [13747]; Canada Graduate Scholarship from the Canadian
   Institutes of Health Research
FX This work was supported by Grant MOP 13747 (to S. Ito) and a Canada
   Graduate Scholarship (to A. M. L. Wu) from the Canadian Institutes of
   Health Research.
CR Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Blankenberg Daniel, 2010, Curr Protoc Mol Biol, VChapter 19, DOI 10.1002/0471142727.mb1910s89
   Brisken C, 1999, DEV BIOL, V210, P96, DOI 10.1006/dbio.1999.9271
   Chilton BS, 2005, CURR TOP DEV BIOL, V68, P1, DOI 10.1016/S0070-2153(05)68001-5
   Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036
   Clodfelter KH, 2006, MOL ENDOCRINOL, V20, P1333, DOI 10.1210/me.2005-0489
   Creamer BA, 2010, MOL CELL BIOL, V30, P2957, DOI 10.1128/MCB.00851-09
   Cui JY, 2012, TOXICOL SCI, V127, P592, DOI 10.1093/toxsci/kfs107
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ee PLR, 2004, CANCER RES, V64, P1247, DOI 10.1158/0008-5472.CAN-03-3583
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86
   GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x
   Han Y, 2006, BIOL PHARM BULL, V29, P1032, DOI 10.1248/bpb.29.1032
   Hovey RC, 2003, MOL ENDOCRINOL, V17, P460, DOI 10.1210/me.2002-0214
   Jager Richard, 2008, BMC Res Notes, V1, P29, DOI 10.1186/1756-0500-1-29
   JOHNSON ML, 1983, J BIOL CHEM, V258, P805
   Jonker JW, 2005, NAT MED, V11, P127, DOI 10.1038/nm1186
   Kang K, 2014, MOL CELL BIOL, V34, P464, DOI 10.1128/MCB.00988-13
   Karolchik D, 2014, NUCLEIC ACIDS RES, V42, pD764, DOI 10.1093/nar/gkt1168
   Kibbe WA, 2007, NUCLEIC ACIDS RES, V35, pW43, DOI 10.1093/nar/gkm234
   Krishnamurthy P, 2004, J BIOL CHEM, V279, P24218, DOI 10.1074/jbc.M313599200
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425
   LI S, 1995, MOL CELL BIOL, V15, P2063
   Lin JX, 2012, IMMUNITY, V36, P586, DOI 10.1016/j.immuni.2012.02.017
   Liu T, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r83
   Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179
   Merino G, 2005, MOL PHARMACOL, V67, P1765, DOI 10.1124/mol.105.011080
   Nakanishi T, 2006, CANCER RES, V66, P5007, DOI 10.1158/0008-5472.CAN-05-4572
   Natarajan K, 2012, BIOCHEM PHARMACOL, V83, P1084, DOI 10.1016/j.bcp.2012.01.002
   Natarajan K, 2011, BBA-GENE REGUL MECH, V1809, P295, DOI 10.1016/j.bbagrm.2011.06.004
   Nelson EA, 2006, J BIOL CHEM, V281, P26216, DOI 10.1074/jbc.M605001200
   Neville MC, 2002, J MAMMARY GLAND BIOL, V7, P49, DOI 10.1023/A:1015770423167
   Oakes SR, 2008, J MAMMARY GLAND BIOL, V13, P13, DOI 10.1007/s10911-008-9069-5
   Rijnkels M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053270
   Rijnkels M, 2010, J MAMMARY GLAND BIOL, V15, P85, DOI 10.1007/s10911-010-9170-4
   Robey RW, 2009, ADV DRUG DELIVER REV, V61, P3, DOI 10.1016/j.addr.2008.11.003
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Stacy AE, 2013, MOL PHARMACOL, V84, P655, DOI 10.1124/mol.113.088609
   Tan KP, 2010, MOL PHARMACOL, V78, P175, DOI 10.1124/mol.110.065078
   THOMPSON MD, 1985, CANCER RES, V45, P1291
   To KKW, 2006, MOL CELL BIOL, V26, P8572, DOI 10.1128/MCB.00650-06
   Turner JG, 2006, BLOOD, V108, P3881, DOI 10.1182/blood-2005-10-009084
   van Herwaarden AE, 2007, MOL CELL BIOL, V27, P1247, DOI 10.1128/MCB.01621-06
   Vanselow J, 2006, J MOL ENDOCRINOL, V37, P463, DOI 10.1677/jme.1.02131
   Vlaming MLH, 2009, ADV DRUG DELIVER REV, V61, P14, DOI 10.1016/j.addr.2008.08.007
   Wang H, 2008, MOL PHARMACOL, V73, P845, DOI 10.1124/mol.107.041087
   Watson CJ, 2011, INT J DEV BIOL, V55, P757, DOI 10.1387/ijdb.113414cw
   Woelfle J, 2003, J BIOL CHEM, V278, P51261, DOI 10.1074/jbc.M309486200
   Wu AML, 2013, MOL PHARMACOL, V83, P377, DOI 10.1124/mol.112.082362
   Xu KL, 2012, CANCER CELL, V21, P626, DOI 10.1016/j.ccr.2012.03.041
   Xu R, 2009, J CELL BIOL, V184, P57, DOI 10.1083/jcb.200807021
   Yamaji D, 2013, NUCLEIC ACIDS RES, V41, P1622, DOI 10.1093/nar/gks1310
   Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756
   Zhang J, 1999, J EXP MED, V190, P1297, DOI 10.1084/jem.190.9.1297
   Zhang J, 2003, DEV BIOL, V256, P127, DOI 10.1016/S0012-1606(02)00119-7
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhu BM, 2012, NUCLEIC ACIDS RES, V40, P4461, DOI 10.1093/nar/gks056
   Zong Y, 2006, J BIOL CHEM, V281, P29625, DOI 10.1074/jbc.M606314200
   Zorn E, 2006, BLOOD, V108, P1571, DOI 10.1182/blood-2006-02-004747
NR 62
TC 8
Z9 8
U1 0
U2 9
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0193-1849
EI 1522-1555
J9 AM J PHYSIOL-ENDOC M
JI Am. J. Physiol.-Endocrinol. Metab.
PD OCT 1
PY 2014
VL 307
IS 7
BP E596
EP E610
DI 10.1152/ajpendo.00323.2014
PG 15
WC Endocrinology & Metabolism; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Physiology
GA AR0AB
UT WOS:000343222400007
PM 25117410
DA 2025-01-12
ER

PT J
AU Yao, RS
   Jiang, H
   Ma, YH
   Wang, LP
   Wang, L
   Du, J
   Hou, PF
   Gao, YY
   Zhao, L
   Wang, GN
   Zhang, Y
   Liu, DX
   Huang, BQ
   Lu, J
AF Yao, Ruosi
   Jiang, Hao
   Ma, Yuhui
   Wang, Liping
   Wang, Lin
   Du, Juan
   Hou, Pingfu
   Gao, Yanyan
   Zhao, Li
   Wang, Guannan
   Zhang, Yu
   Liu, Dong-Xu
   Huang, Baiqu
   Lu, Jun
TI PRMT7 Induces Epithelial-to-Mesenchymal Transition and Promotes
   Metastasis in Breast Cancer
SO CANCER RESEARCH
LA English
DT Article
ID PROTEIN ARGININE METHYLTRANSFERASE; TRANSCRIPTION FACTOR YY1; E-CADHERIN
   REPRESSION; TUMOR-METASTASIS; HISTONE MODIFICATIONS; EXPRESSION; SNAIL;
   METHYLATION; CELLS; GENE
AB Epithelial-to-mesenchymal transition (EMT) enables metastasis. E-cadherin loss is a hallmark of EMT, but there remains an incomplete understanding of the epigenetics of this process. The protein arginine methyltransferase PRMT7 functions in various physiologic processes, including mRNA splicing, DNA repair, and neural differentiation, but its possible roles in cancer and metastasis have not been explored. In this report, we show that PRMT7 is expressed at higher levels in breast carcinoma cells and that elevated PRMT7 mediates EMT and metastasis. PRMT7 could inhibit the expression of E-cadherin by binding to its proximal promoter in a manner associated with altered histone methylation, specifically with elevated H4R3me2s and reduced H3K4me3, H3Ac, and H4Ac, which occurred at the E-cadherin promoter upon EMT induction. Moreover, PRMT7 interacted with YY1 and HDAC3 and was essential to link these proteins to the E-cadherin promoter. Silencing PRMT7 restored E-cadherin expression by repressing H4R3me2s and by increasing H3K4me3 and H4Ac, attenuating cell migration and invasion in MDA-MB-231 breast cancer cells. Overall, our results define PRMT7 as an inducer of breast cancer metastasis and present the opportunity for applying PRMT7-targeted therapeutics to treat highly invasive breast cancers. (C) 2014 AACR.
C1 [Yao, Ruosi; Ma, Yuhui; Hou, Pingfu; Zhao, Li; Huang, Baiqu] NE Normal Univ, Key Lab Mol Epigenet, Minist Educ, Changchun 130024, Peoples R China.
   [Jiang, Hao; Wang, Lin; Du, Juan; Gao, Yanyan; Zhang, Yu; Lu, Jun] NE Normal Univ, Inst Cytol & Genet, Changchun 130024, Peoples R China.
   [Wang, Liping] Jilin Univ, China Japan Union Hosp, Dept Pathol, Changchun 130023, Peoples R China.
   [Wang, Guannan] NE Normal Univ, Natl Engn Lab Druggable Gene & Prot Screening, Changchun 130024, Peoples R China.
   [Liu, Dong-Xu] Univ Auckland, Liggins Inst, Auckland 1, New Zealand.
C3 Northeast Normal University - China; Northeast Normal University -
   China; Jilin University; Northeast Normal University - China; University
   of Auckland
RP Lu, J (通讯作者)，NE Normal Univ, Inst Cytol & Genet, 5268 Renmin St, Changchun 130024, Peoples R China.
EM huangbq705@nenu.edu.cn; luj809@nenu.edu.cn
RI zhao, li/HTM-9579-2023
FU National Natural Science Foundation of China [31071149, 31170719,
   31371294, 31100998]; Fundamental Research Funds for the Central
   Universities [12SSXM005]; Research Fund for Doctoral Program of Higher
   Education [20110043110007, 20130043130001]
FX This work was supported by grants from the National Natural Science
   Foundation of China (grants 31071149, 31170719, 31371294, and 31100998),
   the Fundamental Research Funds for the Central Universities (grant
   12SSXM005), and the Research Fund for Doctoral Program of Higher
   Education (grants 20110043110007 and 20130043130001).
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   Baldwin RM, 2012, CELL CYCLE, V11, P4597, DOI 10.4161/cc.22871
   Buhr N, 2008, ELECTROPHORESIS, V29, P2381, DOI 10.1002/elps.200700738
   Campos EI, 2009, ANNU REV GENET, V43, P559, DOI 10.1146/annurev.genet.032608.103928
   Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Girardot M, 2014, NUCLEIC ACIDS RES, V42, P235, DOI 10.1093/nar/gkt884
   Gonsalvez GB, 2008, RNA, V14, P878, DOI 10.1261/rna.940708
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200
   Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001
   Hou ZY, 2008, MOL CELL BIOL, V28, P3198, DOI 10.1128/MCB.01435-07
   Hu L, 2004, ONCOGENE, V23, P298, DOI 10.1038/sj.onc.1206483
   Huang WH, 2008, J VIROL, V82, P7313, DOI 10.1128/JVI.02581-07
   Hulit J, 2007, CANCER RES, V67, P3106, DOI 10.1158/0008-5472.CAN-06-3401
   Jelinic P, 2006, PLOS BIOL, V4, P1910, DOI 10.1371/journal.pbio.0040355
   Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6
   Kanai Y, 1997, INT J CANCER, V71, P355
   Karkhanis V, 2012, J BIOL CHEM, V287, P29801, DOI 10.1074/jbc.M112.378281
   Kim YR, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-197
   Koch CM, 2007, GENOME RES, V17, P691, DOI 10.1101/gr.5704207
   Lee JH, 2005, J BIOL CHEM, V280, P3656, DOI 10.1074/jbc.M405295200
   Limm K, 2013, EUR J CANCER, V49, P1305, DOI 10.1016/j.ejca.2012.11.026
   Lin T, 2010, ONCOGENE, V29, P4896, DOI 10.1038/onc.2010.234
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104
   Nicholas C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074710
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Palmer MB, 2009, MOL CANCER RES, V7, P221, DOI 10.1158/1541-7786.MCR-08-0229
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534
   Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0
   SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Wan MM, 2012, AM J PATHOL, V180, P2120, DOI 10.1016/j.ajpath.2012.01.037
   Wang CC, 2005, ONCOGENE, V24, P4081, DOI 10.1038/sj.onc.1208573
   Wang X, 2008, ONCOGENE, V27, P1894, DOI 10.1038/sj.onc.1210821
   Wang Y, 2013, EXP CELL RES, V319, P160, DOI 10.1016/j.yexcr.2012.07.019
   Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012
   Wu SR, 2013, CANCER RES, V73, P1787, DOI 10.1158/0008-5472.CAN-12-0366
   Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001
   Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045
   Zhao Q, 2009, NAT STRUCT MOL BIOL, V16, P304, DOI 10.1038/nsmb.1568
NR 50
TC 114
Z9 128
U1 0
U2 32
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2014
VL 74
IS 19
BP 5656
EP 5667
DI 10.1158/0008-5472.CAN-14-0800
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AQ8WP
UT WOS:000343118900029
PM 25136067
OA Green Submitted
DA 2025-01-12
ER

PT J
AU de Conti, A
   Tryndyak, V
   Churchwell, MI
   Melnyk, S
   Latendresse, JR
   Muskhelishvili, L
   Beland, FA
   Pogribny, IP
AF de Conti, Aline
   Tryndyak, Volodymyr
   Churchwell, Mona I.
   Melnyk, Stepan
   Latendresse, John R.
   Muskhelishvili, Levan
   Beland, Frederick A.
   Pogribny, Igor P.
TI Genotoxic, epigenetic, and transcriptomic effects of tamoxifen in mouse
   liver
SO TOXICOLOGY
LA English
DT Article
DE Tamoxifen; Mouse; Liver; DNA adducts; Epigenetics; Gene expression
ID INDUCED RAT HEPATOCARCINOGENESIS; ACTIVATED RECEPTOR-GAMMA;
   BREAST-CANCER PATIENTS; NONALCOHOLIC STEATOHEPATITIS; HEPATIC STEATOSIS;
   DNA-ADDUCTS; ENDOMETRIAL CANCER; ADJUVANT TAMOXIFEN; MICE; EXPOSURE
AB Tamoxifen is a non-steroidal anti-estrogenic drug widely used for the treatment and prevention of breast cancer in women; however, there is evidence that tamoxifen is hepatocarcinogenic in rats, but not in mice. Additionally, it has been reported that tamoxifen may cause non-alcoholic fatty liver disease (NAFLD) in humans and experimental animals. The goals of the present study were to (i) investigate the mechanisms of the resistance of mice to tamoxifen-induced hepatocarcinogenesis, and (ii) clarify effects of tamoxifen on NAFLD-associated liver injury. Feeding female WSB/EiJ mice a 420 p.p.m. tamoxifen-containing diet for 12 weeks resulted in an accumulation of tamoxifen-DNA adducts, (E)-alpha-(deoxyguanosin-N-2-yl)-tamoxifen (dG-TAM) and (E)-alpha-(deoxyguanosin-N-2-yl)-N-desmethyltamoxifen (dG-DesMeTAM), in the livers. The levels of hepatic dG-TAM and dG-DesMeTAM DNA adducts in tamoxifen-treated mice were 578 and 340 adducts/108 nucleotides, respectively, while the extent of global DNA and repetitive elements methylation and histone modifications did not differ from the values in control mice. Additionally, there was no biochemical or histopathological evidence of NAFLD-associated liver injury in mice treated with tamoxifen. A transcriptomic analysis of differentially expressed genes demonstrated that tamoxifen caused predominantly down-regulation of hepatic lipid metabolism genes accompanied by a distinct over-expression of the lipocalin 13 (Lcn13) and peroxisome proliferator receptor gamma (Ppar gamma), which may prevent the development of NAFLD. The results of the present study demonstrate that the resistance of mice to tamoxifen-induced liver carcinogenesis may be associated with its ability to induce genotoxic alterations only without affecting the cellular epigenome and an inability of tamoxifen to induce the development of NAFLD. Published by Elsevier Ireland Ltd.
C1 [de Conti, Aline; Tryndyak, Volodymyr; Churchwell, Mona I.; Beland, Frederick A.; Pogribny, Igor P.] Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
   [Melnyk, Stepan] Univ Arkansas Med Sci Hosp, Dept Pediat, Little Rock, AR 72202 USA.
   [Latendresse, John R.; Muskhelishvili, Levan] US FDA, Toxicol Pathol Associates, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA.
C3 US Food & Drug Administration (FDA); University of Arkansas System;
   University of Arkansas Medical Sciences; US Food & Drug Administration
   (FDA)
RP Pogribny, IP (通讯作者)，Natl Ctr Toxicol Res, Div Biochem Toxicol, Jefferson, AR 72079 USA.
EM igor.pogribny@fda.hhs.gov
RI de Conti, Aline/I-1666-2013; Latendresse, John/A-9215-2009
OI Tryndyak, Volodymyr/0000-0002-8319-2954; Beland,
   Frederick/0000-0002-2113-6260
CR Ables GP, 2012, PPAR RES, V2012, DOI 10.1155/2012/912351
   Bagnyukovay TV, 2008, CARCINOGENESIS, V29, P638, DOI 10.1093/carcin/bgm303
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Boocock DJ, 2002, CARCINOGENESIS, V23, P1897, DOI 10.1093/carcin/23.11.1897
   Bruno S, 2005, BMJ-BRIT MED J, V330, P932, DOI 10.1136/bmj.38391.663287.E0
   Chen H, 2004, CARCINOGENESIS, V25, P1779, DOI 10.1093/carcin/bgh161
   Cole LK, 2010, HEPATOLOGY, V52, P1258, DOI 10.1002/hep.23813
   da Costa GG, 2003, CHEM RES TOXICOL, V16, P357, DOI 10.1021/tx020090g
   Davies R, 1997, CANCER RES, V57, P1288
   Derosa Giuseppe, 2012, Curr Mol Pharmacol, V5, P272
   Fang H, 2009, METHODS MOL BIOL, V563, P379, DOI 10.1007/978-1-60761-175-2_20
   FISHER B, 1994, JNCI-J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527
   FitzGerald BE, 1996, CARCINOGENESIS, V17, P2703, DOI 10.1093/carcin/17.12.2703
   GREAVES P, 1993, CANCER RES, V53, P3919
   Huidobro C, 2013, CELL MOL LIFE SCI, V70, P1543, DOI 10.1007/s00018-013-1296-2
   Jones ME, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3206
   Kiyotani K, 2012, DRUG METAB PHARMACOK, V27, P122, DOI 10.2133/dmpk.DMPK-11-RV-084
   Lelliott CJ, 2005, FASEB J, V19, P1108, DOI 10.1096/fj.04-3196com
   Martin EA, 1997, CARCINOGENESIS, V18, P2209, DOI 10.1093/carcin/18.11.2209
   Melnyk S, 2000, CLIN CHEM, V46, P265
   Miyashita T, 2012, J TOXICOL SCI, V37, P931, DOI 10.2131/jts.37.931
   Murata Y, 2000, ONCOL REP, V7, P1299
   Nan YM, 2011, SCAND J GASTROENTERO, V46, P358, DOI 10.3109/00365521.2010.525717
   Oien KA, 1999, LANCET, V353, P36, DOI 10.1016/S0140-6736(05)74872-8
   Paini A, 2011, MUTAGENESIS, V26, P605, DOI 10.1093/mutage/ger022
   Pogribny I, 1999, BIOCHEM BIOPH RES CO, V262, P624, DOI 10.1006/bbrc.1999.1187
   Pogribny IP, 2007, TOXICOL APPL PHARM, V225, P61, DOI 10.1016/j.taap.2007.07.001
   Saphner T, 2009, CANCER-AM CANCER SOC, V115, P3189, DOI 10.1002/cncr.24374
   Sheng L, 2011, J BIOL CHEM, V286, P38128, DOI 10.1074/jbc.M111.256677
   Tryndyak V, 2012, FASEB J, V26, P4592, DOI 10.1096/fj.12-209569
   Tryndyak VP, 2007, MOL CARCINOGEN, V46, P187, DOI 10.1002/mc.20263
   Tryndyak VP, 2006, CARCINOGENESIS, V27, P1713, DOI 10.1093/carcin/bgl050
   Tucker M.J., 1984, SAFETY TESTING NEW D, P125
   Umemoto A, 2001, CHEM RES TOXICOL, V14, P1006, DOI 10.1021/tx010012d
   Zhang F, 2013, CELL MOL LIFE SCI, V70, P259, DOI 10.1007/s00018-012-1046-x
   Zheng H, 2011, EUR J PHARMACOL, V659, P244, DOI 10.1016/j.ejphar.2011.03.033
NR 36
TC 9
Z9 12
U1 1
U2 40
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0300-483X
J9 TOXICOLOGY
JI Toxicology
PD NOV 5
PY 2014
VL 325
BP 12
EP 20
DI 10.1016/j.tox.2014.08.004
PG 9
WC Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Toxicology
GA AR7UO
UT WOS:000343785400002
PM 25123088
DA 2025-01-12
ER

PT J
AU Rodney, NC
   Mulligan, CJ
AF Rodney, Nicole C.
   Mulligan, Connie J.
TI A Biocultural Study of the Effects of Maternal Stress on Mother and
   Newborn Health in the Democratic Republic of Congo
SO AMERICAN JOURNAL OF PHYSICAL ANTHROPOLOGY
LA English
DT Article
DE war; cultural; genetics; bioarchaeology; epigenetics; DRC; DOHaD
ID SEXUAL VIOLENCE; BIRTH-WEIGHT; DEVELOPMENTAL PLASTICITY;
   GLUCOCORTICOID-RECEPTOR; IMMUNE FUNCTION; REPRODUCTIVE HEALTH;
   NATIONWIDE SURVEY; DNA METHYLATION; BREAST-CANCER; ADULT DISEASE
AB The impact of stress on human health is a topic of wide-spread relevance and one that is particularly amenable to multidisciplinary investigation. Stress impacts both our psychological and physical health and, thus, may leave evidence on our psyche, our physical body and our genome. We are interested in the effect of extreme stressors, such as war, on health from the perspective of long-term and multigenerational effects. We integrate sociocultural, biological, and epigenetic data from the war-torn Democratic Republic of Congo (DRC). Between May and August, 2010, we measured sociocultural stress exposure among 25 mother-newborn dyads and we measured health outcomes in newborns. We also collected maternal venous blood, placental tissue, and umbilical cord blood to assay for methylation changes to test for a possible epigenetic mechanism that mediates the effects of stress on health. We provide a qualitative description of the wide range of stress exposures experienced by mothers in our study. As we have shown previously, maternal war stress is strongly associated with newborn birthweight and changes in newborn methylation at the glucocorticoid receptor NR3C1. New results presented here demonstrate that maternal war stress and birthweight are also associated with genome-wide changes in maternal methylation levels. In sum, these results suggest that stress may influence gene expression across a broad spectrum in the individual who directly experiences the stress, i.e., the mother, whereas potential heritable effects in the newborn may be focused on specific genes that are uniquely sensitive to environmental cues. (C) 2014 Wiley Periodicals, Inc.
C1 [Rodney, Nicole C.; Mulligan, Connie J.] Univ Florida, Dept Anthropol, Gainesville, FL 32611 USA.
   [Mulligan, Connie J.] Univ Florida, Genet Inst, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Mulligan, CJ (通讯作者)，Univ Florida, 2033 Mowry Rd,POB 103610, Gainesville, FL 32610 USA.
EM cmulligan@ufl.edu
OI Mulligan, Connie/0000-0002-4360-2402
FU NSF [BCS 1231264]; University of Florida (UF) Clinical and Translational
   Science Institute; UF College of Liberal Arts and Science; UF Research
   Opportunity Seed Fund award; Division Of Behavioral and Cognitive Sci;
   Direct For Social, Behav & Economic Scie [1231264] Funding Source:
   National Science Foundation
FX Grant sponsor: NSF; Grant number: BCS 1231264; Grant sponsors:
   University of Florida (UF) Clinical and Translational Science Institute,
   UF College of Liberal Arts and Science, a UF Research Opportunity Seed
   Fund award to CJM.
CR [Anonymous], 2012, DRC ONGOING FIGHTING
   [Anonymous], 1979, THE ETHNOGRAPHIC INT
   [Anonymous], CHANGES IN BODILY FO
   [Anonymous], AGAINST OUR WILL MEN
   Armelagos GJ, 1978, HEALTH AND THE HUMAN
   Baaz ME, 2010, SIDA WORKING PAPER O
   BARKER DJP, 1990, BRIT MED J, V301, P1111, DOI 10.1136/bmj.301.6761.1111
   Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235
   Bartels S., 2010, J INT WOMENS STUDIES, V11, P37, DOI DOI 10.1186/1752-1505-4-9
   Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725
   Black MC, 2010, THE NATIONAL INTIMAT
   Brunet A, 2001, AM J PSYCHIAT, V158, P1480, DOI 10.1176/appi.ajp.158.9.1480
   Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   Chmurzynska A, 2010, NUTR REV, V68, P87, DOI 10.1111/j.1753-4887.2009.00265.x
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   Chu Kathryn, 2010, Confl Health, V4, P6, DOI 10.1186/1752-1505-4-6
   Clark AL, 2014, AM J PHYS ANTHROPOL, V153, P484, DOI 10.1002/ajpa.22449
   Clark MM, 2005, NARRATIVE, V13, P294, DOI 10.1353/nar.2005.0018
   Coghlan B, 2006, LANCET, V367, P44, DOI 10.1016/S0140-6736(06)67923-3
   Coghlan B, 2009, DISASTER MED PUBLIC, V3, P88, DOI 10.1097/DMP.0b013e3181a6e952
   Cottrell EC, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.019.2009
   EnoughProject, 2008, GETTING SERIOUS ABOU
   Farr K, 2009, GEND ISSUES, V26, P1, DOI 10.1007/s12147-009-9068-x
   Filiberto AC, 2011, EPIGENETICS-US, V6, P566, DOI 10.4161/epi.6.5.15236
   Fowden AL, 2004, REPRODUCTION, V127, P515, DOI 10.1530/rep.1.00033
   Frisancho AR, 1993, HUMAN ADAPTATION AND
   Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473
   Gluckman PD, 2009, LANCET, V373, P1654, DOI 10.1016/S0140-6736(09)60234-8
   Gomes MVM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052570
   Gravlee CC, 2005, AM J HUM BIOL, V17, P195, DOI 10.1002/ajhb.20111
   HACK M, 1995, FUTURE CHILD, V5, P176, DOI 10.2307/1602514
   Handel AE, 2010, TRENDS MOL MED, V16, P7, DOI 10.1016/j.molmed.2009.11.003
   Herbert J, 1997, BRIT MED J, V315, P530, DOI 10.1136/bmj.315.7107.530
   Herbstman JB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072824
   HILLIER L, 1993, SEX ROLES, V29, P629, DOI 10.1007/BF00289209
   Hynes M, 2002, JAMA-J AM MED ASSOC, V288, P595, DOI 10.1001/jama.288.5.595
   Innes KE, 1999, EPIDEMIOLOGY, V10, P153, DOI 10.1097/00001648-199903000-00012
   Iwasaki M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-323
   Kelly HW, 2012, NEW ENGL J MED, V367, P904, DOI 10.1056/NEJMoa1203229
   Kelly J, 2012, GLOB PUBLIC HEALTH, V7, P285, DOI 10.1080/17441692.2011.585344
   Koepke S, 2014, VIOLENCE AGAINST WOM, V20, P446, DOI 10.1177/1077801214528581
   Krebs CP, 2011, J INTERPERS VIOLENCE, V26, P3640, DOI 10.1177/0886260511403759
   Krebs CP, 2009, J AM COLL HEALTH, V57, P639, DOI 10.3200/JACH.57.6.639-649
   Kuchiba A, 2014, BRIT J CANCER, V110, P2765, DOI 10.1038/bjc.2014.223
   Kuzawa CW, 2009, ANNU REV ANTHROPOL, V38, P131, DOI 10.1146/annurev-anthro-091908-164350
   Kuzawa CW, 2009, AM J HUM BIOL, V21, P2, DOI 10.1002/ajhb.20822
   Kuzawa CW, 2005, AM J HUM BIOL, V17, P1, DOI 10.1002/ajhb.20090
   Liao LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027361
   Longombe AO, 2008, REPROD HEALTH MATTER, V16, P132, DOI 10.1016/S0968-8080(08)31350-0
   Matthews SG, 2010, ENDOCRINOLOGY, V151, P7, DOI 10.1210/en.2009-0916
   McDade TW, 2002, MED ANTHROPOL Q, V16, P123, DOI 10.1525/maq.2002.16.2.123
   McGinn T, 2000, INT FAM PLAN PERSPEC, V26, P174, DOI 10.2307/2648255
   McGowan PO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014739
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   Meaney MJ, 2007, TRENDS MOL MED, V13, P269, DOI 10.1016/j.molmed.2007.05.003
   Meger S, 2010, J CONTEMP AFR STUD, V28, P119, DOI 10.1080/02589001003736728
   Miller GE, 2009, P NATL ACAD SCI USA, V106, P14716, DOI 10.1073/pnas.0902971106
   Mulligan CJ, 2012, EPIGENETICS-US, V7, P853, DOI 10.4161/epi.21180
   Nepomnaschy PA, 2007, ANN NY ACAD SCI, V1113, P350, DOI 10.1196/annals.1391.028
   Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52
   Peterman A, 2011, AM J PUBLIC HEALTH, V101, P1060, DOI 10.2105/AJPH.2010.300070
   Pham PN, 2010, J TRAUMA STRESS, V23, P313, DOI 10.1002/jts.20527
   Pike IL, 2005, AM J HUM BIOL, V17, P55, DOI 10.1002/ajhb.20093
   Puechguirbal N, 2003, SIGNS, V28, P1271, DOI 10.1086/368319
   Radtke KM, 2011, TRANSL PSYCHIAT, V1, DOI 10.1038/tp.2011.21
   Rutherford JN, 2009, AM J HUM BIOL, V21, P745, DOI 10.1002/ajhb.20923
   Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55
   Schalinski I, 2011, J TRAUMA STRESS, V24, P235, DOI 10.1002/jts.20631
   Slegh Henny., 2012, Gender Relations, Sexual Violnce and the Effects of Conflict on Women and Men in North Kivu, Eastern Democratic Republic of Congo: Preliminary Results of the International Men and Gender Equality Study (IMAGES)
   Smits Rosan., 2011, INCREASING SECURITY, V17, P1
   Tung TA, 2007, AM J PHYS ANTHROPOL, V133, P941, DOI 10.1002/ajpa.20565
   Uddin M, 2010, P NATL ACAD SCI USA, V107, P9470, DOI 10.1073/pnas.0910794107
   UnitedNationsSecurityCouncil, 2008, TWENTY SIXTH REPORT
   UnitedNationsSecurityCouncil, 2011, REPORT OF THE SECRET
   Van Herp M, 2003, DISASTERS, V27, P141, DOI 10.1111/1467-7717.00225
   VENKATACHALAM PS, 1962, B WORLD HEALTH ORGAN, V26, P193
   Vukojevic V, 2011, INTERNATIONAL CONGRE
   Wadhwa PD, 2001, PAEDIATR PERINAT EP, V15, P17, DOI 10.1046/j.1365-3016.2001.00005.x
   Walker PL, 2001, ANNU REV ANTHROPOL, V30, P573, DOI 10.1146/annurev.anthro.30.1.573
   Whatley MA, 1996, AGGRESS VIOLENT BEH, V1, P81, DOI 10.1016/1359-1789(95)00011-9
   Whatley MA, 2005, J FAM VIOLENCE, V20, P191, DOI 10.1007/s10896-005-3655-8
   YEHUDA R, 1993, BIOL PSYCHIAT, V33, P479, DOI 10.1016/0006-3223(93)90001-T
   Zhao JY, 2012, DIABETES, V61, P542, DOI 10.2337/db11-1048
NR 83
TC 51
Z9 68
U1 0
U2 43
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-9483
EI 1096-8644
J9 AM J PHYS ANTHROPOL
JI Am. J. Phys. Anthropol.
PD OCT
PY 2014
VL 155
IS 2
SI SI
BP 200
EP 209
DI 10.1002/ajpa.22568
PG 10
WC Anthropology; Evolutionary Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Anthropology; Evolutionary Biology
GA AQ5AZ
UT WOS:000342816100004
PM 25043696
DA 2025-01-12
ER

PT J
AU Coradini, D
   Boracchi, P
   Oriana, S
   Biganzoli, E
   Arnbrogi, F
AF Coradini, Danila
   Boracchi, Patrizia
   Oriana, Saro
   Biganzoli, Elia
   Arnbrogi, Federico
TI Differential expression of genes involved in the epigenetic regulation
   of cell identity in normal human mammary cell commitment and
   differentiation
SO CHINESE JOURNAL OF CANCER
LA English
DT Article
DE Mammary epithelial cell identity; epigenetic regulation; maintenance
   proteins; normal bipotent cells; committed luminal progenitors;
   differentiated myoepithelial/luminal cells
ID HUMAN BREAST; RETINOIC ACID; POLYCOMB; MAINTENANCE; PROTEINS; MEMORY
AB The establishment and maintenance of mammary epithelial cell identity depends on the activity of a group of proteins, collectively called maintenance proteins, that act as epigenetic regulators of gene transcription through DNA methylation, histone modification, and chromatin remodeling. Increasing evidence indicates that dysregulation of these crucial proteins may disrupt epithelial cell integrity and trigger breast tumor initiation. Therefore, we explored in silico the expression pattern of a panel of 369 genes known to be involved in the establishment and maintenance of epithelial cell identity and mammary gland remodeling in cell subpopulations isolated from normal human mammary tissue and selectively enriched in their content of bipotent progenitors, committed luminal progenitors, and differentiated myoepithelial or differentiated luminal cells. The results indicated that, compared to bipotent cells, differentiated myoepithelial and luminal subpopulations were both characterized by the differential expression of 4 genes involved in cell identity maintenance: CBX6 and PCGF2, encoding proteins belonging to the Polycomb group, and SMARCD3 and SMARCE1, encoding proteins belonging to the Trithorax group. In addition to these common genes, the myoepithelial phenotype was associated with the differential expression of HDAC1, which encodes histone deacetylase 1, whereas the luminal phenotype was associated with the differential expression of SMARCA4 and HAT1, which encode a Trithorax protein and histone acetylase 1, respectively. The luminal compartment was further characterized by the overexpression of ALDH1A3 and GATA3, and the down-regulation of NOTCH4 and CCNB1, with the latter suggesting a block in cell cycle progression at the G(2) phase. In contrast, myoepithelial differentiation was associated with the overexpression of MYC and the down-regulation of CCNE1, with the latter suggesting a block in cell cycle progression at the G(1) phase.
C1 [Coradini, Danila; Boracchi, Patrizia; Biganzoli, Elia; Arnbrogi, Federico] Univ Milan, Dept Clin Sci & Community Hlth Med Stat Biometry, I-20133 Milan, Italy.
   [Oriana, Saro] Ambrosiana Clin, Senol Ctr, I-20090 Milan, Italy.
C3 University of Milan
RP Coradini, D (通讯作者)，Univ Milan, Dept Clin & Community Hlth Sci Med Stat Biometry, Via Vanzetti 5, I-20133 Milan, Italy.
EM danila.coradini@gmail.com
RI Patrizia, Boracchi/AAB-8851-2019; Biganzoli, Elia/J-1678-2012; Ambrogi,
   Federico/D-4294-2015
OI Ambrogi, Federico/0000-0001-9358-011X; Biganzoli,
   Elia/0000-0003-1202-5873; boracchi, patrizia/0000-0001-8506-2005
CR Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Blakely CM, 2005, DEVELOPMENT, V132, P1147, DOI 10.1242/dev.01655
   Böcker W, 2002, LAB INVEST, V82, P737, DOI 10.1097/01.LAB.0000017371.72714.C5
   Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001
   Brock HW, 2005, DEV DYNAM, V232, P633, DOI 10.1002/dvdy.20298
   Dontu G, 2004, BREAST CANCER RES, V6, pR605, DOI 10.1186/bcr920
   Eirew P, 2012, STEM CELLS, V30, P344, DOI 10.1002/stem.1001
   Ferrari F, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-446
   Hah N, 2010, CANCER RES, V70, P4402, DOI 10.1158/0008-5472.CAN-09-2767
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5
   Johnson CN, 2005, BIOCHEM CELL BIOL, V83, P405, DOI 10.1139/O05-115
   Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Massagué J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094
   Nam HS, 2009, CELL STEM CELL, V5, P515, DOI 10.1016/j.stem.2009.08.017
   Raouf A, 2008, CELL STEM CELL, V3, P109, DOI 10.1016/j.stem.2008.05.018
   Rexer BN, 2001, CANCER RES, V61, P7065
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Suzuki T, 2007, CANCER SCI, V98, P644, DOI 10.1111/j.1349-7006.2007.00444.x
   Umetani N, 2005, ONCOGENE, V24, P4721, DOI 10.1038/sj.onc.1208538
   Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7
   Villadsen R, 2007, J CELL BIOL, V177, P87, DOI 10.1083/jcb.200611114
   Voduc D, 2008, HUM PATHOL, V39, P1431, DOI 10.1016/j.humpath.2008.03.004
   Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005
   Xu Jinhua, 2010, Genes Cancer, V1, P629, DOI 10.1177/1947601910378691
   Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X
NR 29
TC 10
Z9 12
U1 0
U2 8
PU SUN YAT SEN UNIV MED SCI WHO
PI GUANGZHOU
PA 651 DONGFENG RD E, GUANGZHOU, GUANGDONG 510060, PEOPLES R CHINA
SN 1000-467X
EI 1944-446X
J9 CHIN J CANCER
JI Chin. J. Cancer
PD OCT
PY 2014
VL 33
IS 10
BP 501
EP 510
DI 10.5732/cjc.014.10066
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AQ5ZJ
UT WOS:000342886800006
PM 25223915
OA Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Scholpa, NE
   Zhang, X
   Kolli, RT
   Cummings, BS
AF Scholpa, N. E.
   Zhang, X.
   Kolli, R. T.
   Cummings, B. S.
TI Epigenetic Changes in p21 Expression in Renal Cells after Exposure to
   Bromate
SO TOXICOLOGICAL SCIENCES
LA English
DT Article
DE epigenetics; p21; kidney; nephrotoxicity; bromate; water disinfection
   byproducts
ID DISINFECTION BY-PRODUCTS; POTASSIUM BROMATE; DNA METHYLATION;
   DRINKING-WATER; RAT-KIDNEY; PROTEIN EXPRESSION; TRICHOSTATIN-A;
   BREAST-CANCER; TUBULAR CELLS; F344 RATS
AB This study tested the hypothesis that bromate (KBrO3)-induced renal cell death is mediated by epigenetic mechanisms. Global DNA methylation, as assessed by 5-methylcytosine staining, was not changed in normal rat kidney cells treated with acute cytotoxic doses of KBrO3 (100 and 200 ppm), as compared with controls. However, KBrO3 treatment did increase p38, p53 and histone 2AX (H2AX) phosphorylation, and p21 expression. Treatment of cells with inhibitors of DNA methyltransferase (5-azacytidine or 5-Aza) and histone deacetylase (trichostatin A or TSA) in addition to KBrO3 increased cytotoxicity, as compared with cells exposed to KBrO3 alone. 5-Aza and TSA co-treatment did not alter p38 or p53 phosphorylation, but slightly decreased H2AX phosphorylation and significantly decreased p21 expression. We also assessed epigenetic changes in cells treated under sub-chronic conditions with environmentally relevant concentrations of KBrO3. Under these conditions (0-10ppm KBrO3 for up to 18 days), we detected no increases in cell death or DNA damage. In contrast, slight alterations were detected in the phosphorylation of H2AX, p38, and p53. Sub-chronic low-dose KBrO3 treatment also induced a biphasic response in p21 expression, with lower concentrations increasing expression, but higher concentrations decreasing expression. Methylation-specific PCR demonstrated that sub-chronic KBrO3 treatment altered the methylation of cytosine bases in the p21 gene, as compared with controls, correlating to alterations in p21 protein expression. Collectively, these data show the novel finding that KBrO3-induced renal cell death is altered by inhibitors of epigenetic modifying enzymes and that KBrO3 itself induces epigenetic changes in the p21 gene.
C1 [Scholpa, N. E.; Zhang, X.; Kolli, R. T.; Cummings, B. S.] Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
C3 University System of Georgia; University of Georgia
RP Cummings, BS (通讯作者)，Univ Georgia, Dept Pharmaceut & Biomed Sci, Athens, GA 30602 USA.
EM bsc@rx.uga.edu
RI Scholpa, Natalie/JBJ-2816-2023
OI Scholpa, Natalie/0000-0002-1234-5482
FU National Institutes of Health (NIH); National Institute of Biomedical
   Imaging and Bioengineering (NIBIB) [EB08153, EB0116100]; Sloan Graduate
   Minority Fellowship; Interdisciplinary Toxicology Program, University of
   Georgia
FX National Institutes of Health (NIH); National Institute of Biomedical
   Imaging and Bioengineering (NIBIB) (EB08153, EB0116100 to B. S. C.);
   Sloan Graduate Minority Fellowship (to N.E.S.); Interdisciplinary
   Toxicology Program, University of Georgia (to N.E.S., X.Z., R.T.K.).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Abukhdeir Abde M., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000744
   Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166
   Aimiuwu J, 2012, BLOOD, V119, P5229, DOI 10.1182/blood-2011-11-382226
   Arai T, 2002, CARCINOGENESIS, V23, P2005, DOI 10.1093/carcin/23.12.2005
   Arany I, 2008, AM J PHYSIOL-RENAL, V294, pF577, DOI 10.1152/ajprenal.00487.2007
   Askari M, 2013, MOL CELL BIOCHEM, V382, P19, DOI 10.1007/s11010-013-1696-5
   Bull RJ, 2012, TOXICOLOGY, V300, P83, DOI 10.1016/j.tox.2012.06.002
   Bull RJ, 2006, TOXICOLOGY, V221, P135, DOI 10.1016/j.tox.2005.10.007
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   CREUSOT F, 1982, J BIOL CHEM, V257, P2041
   DeAngelo AB, 1998, TOXICOL PATHOL, V26, P587, DOI 10.1177/019262339802600501
   Dong GE, 2010, AM J PHYSIOL-RENAL, V298, pF293, DOI 10.1152/ajprenal.00410.2009
   EPA U. S., 2012, IRIS BROM
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26
   Ge RR, 2001, J BIOCHEM MOL TOXIC, V15, P100, DOI 10.1002/jbt.5
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jiang M, 2008, J PHARMACOL EXP THER, V327, P300, DOI 10.1124/jpet.108.139162
   Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013
   KASAI H, 1987, CARCINOGENESIS, V8, P1959, DOI 10.1093/carcin/8.12.1959
   Kiziltepe T, 2007, MOL CANCER THER, V6, P1718, DOI 10.1158/1535-7163.MCT-07-0010
   Kolisetty N, 2013, ARCH TOXICOL, V87, P1911, DOI 10.1007/s00204-013-1052-2
   Kolisetty N, 2013, TOXICOL APPL PHARM, V272, P391, DOI 10.1016/j.taap.2013.06.018
   KUROKAWA Y, 1990, ENVIRON HEALTH PERSP, V87, P309, DOI 10.2307/3431039
   Kuykendall JR, 2005, ANN PHARMACOTHER, V39, P1700, DOI 10.1345/aph.1E612
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Mathews LA, 2009, DIFFERENTIATION, V78, P1, DOI 10.1016/j.diff.2009.04.002
   Megyesi J, 2001, KIDNEY INT, V60, P2164, DOI 10.1046/j.1523-1755.2001.00044.x
   Nowak G, 2003, AM J PHYSIOL-RENAL, V285, pF440, DOI 10.1152/ajprenal.00233.2002
   Phillips T., 2008, Nat. Educ, V1
   Price PM, 2009, KIDNEY INT, V76, P604, DOI 10.1038/ki.2009.224
   Richardson SD, 2007, MUTAT RES-REV MUTAT, V636, P178, DOI 10.1016/j.mrrev.2007.09.001
   Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291
   Sakao Y, 2011, CLIN EXP NEPHROL, V15, P363, DOI 10.1007/s10157-011-0421-5
   Sedlak DL, 2011, SCIENCE, V331, P42, DOI 10.1126/science.1196397
   Shuo Y., 2003, P NATL ACAD SCI USA, V100, P13225
   Tao LH, 2005, TOXICOL SCI, V87, P344, DOI 10.1093/toxsci/kfi257
   Tikoo K, 2009, TOXICOL LETT, V191, P158, DOI 10.1016/j.toxlet.2009.08.018
   Umemura T, 2006, CANCER SCI, V97, P829, DOI 10.1111/j.1349-7006.2006.00248.x
   Unoki M, 2009, BIOCHEM PHARMACOL, V78, P1279, DOI 10.1016/j.bcp.2009.05.035
   Vaquero Alejandro, 2003, Sci Aging Knowledge Environ, V2003, pRE4, DOI 10.1126/sageke.2003.14.re4
   Vassar D., 2009, GENET ENG BIOTECHNOL, V29
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   VONGUNTEN U, 1994, ENVIRON SCI TECHNOL, V28, P1234, DOI 10.1021/es00056a009
   Wolf DC, 1998, TOXICOL PATHOL, V26, P724, DOI 10.1177/019262339802600602
   Yoon MK, 2012, BIOCHEM SOC T, V40, P981, DOI 10.1042/BST20120092
   YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510
   Yu NF, 2008, CURR MED CHEM, V15, P1350, DOI 10.2174/092986708784567653
   Zhang XL, 2011, TOXICOLOGY, V289, P151, DOI 10.1016/j.tox.2011.08.008
   Zhang XL, 2010, TOXICOLOGY, V269, P13, DOI 10.1016/j.tox.2010.01.002
NR 51
TC 11
Z9 12
U1 0
U2 19
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1096-6080
EI 1096-0929
J9 TOXICOL SCI
JI Toxicol. Sci.
PD OCT
PY 2014
VL 141
IS 2
BP 432
EP 440
DI 10.1093/toxsci/kfu138
PG 9
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA AQ8BD
UT WOS:000343045100013
PM 25015661
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Wang, FL
   Yang, YF
   Fu, ZY
   Xu, N
   Chen, F
   Yin, H
   Lu, X
   Shen, R
   Lu, C
AF Wang, Fengliang
   Yang, Yafang
   Fu, Ziyi
   Xu, Nan
   Chen, Fei
   Yin, Hong
   Lu, Xun
   Shen, Rong
   Lu, Cheng
TI Differential DNA methylation status between breast carcinomatous and
   normal tissues
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE Breast cancer; DNA methylation; Microarray
ID INTERFERON-GAMMA; TUMOR-SUPPRESSOR; RETINOIC ACID; GENE ONTOLOGY;
   GENOMIC DATA; CANCER; PATHWAY; AUTOPHAGY; CELLS; EXPRESSION
AB Breast cancer has been considered to be a multifactorial disease with a wide array of well-characterized gene mutations and chromosomal abnormalities. However, it is becoming evident that the onset or development of breast cancer also depends on epigenetic factors, although the mechanisms have not been fully elucidated. We performed a genome-wide analysis of DNA methylation of breast carcinomatous tissues and paired normal tissues to examine the differences in methylation between them. Methylation-specific polymerase chain reaction (MSP) was used to validate the hypermethylated genes screened out by DNA methylation microarray. We found that hypomethylation and hypermethylation occurred in 2753 and 1795 genes, respectively, in breast carcinomatous tissues. Meanwhile, gene ontology analysis and ingenuity pathway analysis revealed the function and pathway of several genes whose methylation status was altered in breast carcinomatous tissues. In addition, we investigated the promoter methylation status of four genes in breast carcinomatous tissue and paired normal tissues (n = 30) by MSP. Promoter hypermethylation of CRABP1, HOXB13, IFNGR2, and PIK3C3 was found in 37% (11/30), 23% (7/30), 17% (5/30), and 2% (2/30) of the carcinomas, respectively. Mutation of these four important genes was critical to many types of cancer. Our results suggest that DNA methylation mechanisms may be involved in regulating the occurrence and development of breast cancer. (C) 2014 Elsevier Masson SAS. All rights reserved.
C1 [Wang, Fengliang; Fu, Ziyi; Chen, Fei; Yin, Hong; Shen, Rong; Lu, Cheng] Nanjing Med Univ, Nanjing Matern & Child Hlth Care Hosp, Dept Breast Surg, Nanjing, Jiangsu, Peoples R China.
   [Yang, Yafang] Nanjing Med Univ, Affiliated Hosp 2, Dept Radiol, Nanjing, Jiangsu, Peoples R China.
   [Xu, Nan] Nanjing Univ Chinese Med, Clin Med Coll 1, Nanjing, Jiangsu, Peoples R China.
   [Lu, Xun] Jinling High Sch, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing
   University of Chinese Medicine
RP Lu, C (通讯作者)，123 Tianfei Rd, Nanjing 210004, Jiangsu, Peoples R China.
EM xianqu1981@126.com
RI XU, nan/KDP-0628-2024; Fu, Ziyi/ABB-8091-2022
OI Lu, Cheng/0000-0002-0974-9697
FU National Natural Science Foundation of China [81172501]; Medical Science
   and Technology Development Foundation, Nanjing Department of Health
   [QYK10159]
FX Funding source: this study was supported by the National Natural Science
   Foundation of China (81172501) and Key Project of Medical Science and
   Technology Development Foundation, Nanjing Department of Health
   (QYK10159).
CR Abramovich C, 2005, CURR OPIN HEMATOL, V12, P210, DOI 10.1097/01.moh.0000160737.52349.aa
   Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556
   Bergman Y, 2013, NAT STRUCT MOL BIOL, V20, P274, DOI 10.1038/nsmb.2518
   Blaese MA, 2003, INT J RADIAT BIOL, V79, P981, DOI 10.1080/09553000310001632949
   Blake JA, 2012, NUCLEIC ACIDS RES, V40, pD559, DOI 10.1093/nar/gkr1028
   Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848
   Docherty SJ, 2010, METHODS, V52, P255, DOI 10.1016/j.ymeth.2010.06.017
   Draghici S, 2007, GENOME RES, V17, P1537, DOI 10.1101/gr.6202607
   Dupuy D, 2007, NAT BIOTECHNOL, V25, P663, DOI 10.1038/nbt1305
   Edelman MJ, 2005, J CLIN ONCOL, V23, P5774, DOI 10.1200/JCO.2005.14.373
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Edinger AL, 2003, CANCER CELL, V4, P422, DOI 10.1016/S1535-6108(03)00306-4
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Falcon S, 2007, BIOINFORMATICS, V23, P257, DOI 10.1093/bioinformatics/btl567
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2
   Fury Wen, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P5531
   García-Tuñón I, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-158
   HABIF DV, 1995, CANCER INVEST, V13, P165, DOI 10.3109/07357909509011686
   Hayes DF, 2001, J MAMMARY GLAND BIOL, V6, P375, DOI 10.1023/A:1014778713034
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Iimura T, 2007, DEV GROWTH DIFFER, V49, P265, DOI 10.1111/j.1440-169x.2007.00928.x
   Jansen R, 2002, GENOME RES, V12, P37, DOI 10.1101/gr.205602
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030
   Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704
   Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717
   Klionsky DJ, 2005, J CELL SCI, V118, P7, DOI 10.1242/jcs.01620
   Li CY, 2008, BIOINFORMATICS, V24, P1175, DOI 10.1093/bioinformatics/btn081
   Lv Q, 2012, CANCER RES, V72, P3238, DOI 10.1158/0008-5472.CAN-11-3832
   Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039
   Moens CB, 2006, DEV BIOL, V291, P193, DOI 10.1016/j.ydbio.2005.10.032
   Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b
   Pilato B, 2013, J HUM GENET, V58, P51, DOI 10.1038/jhg.2012.118
   Rauch Tibor A., 2009, V507, P65, DOI 10.1007/978-1-59745-522-0_6
   Rauch TA, 2009, P NATL ACAD SCI USA, V106, P671, DOI 10.1073/pnas.0812399106
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Rodriguez BAT, 2008, CARCINOGENESIS, V29, P1459, DOI 10.1093/carcin/bgn115
   Ruiz-Ruiz C, 2000, CANCER RES, V60, P5673
   Sanchez-Cespedes M, 2000, CANCER RES, V60, P892
   Schlitt T, 2003, GENOME RES, V13, P2568, DOI 10.1101/gr.1111403
   SEYMOUR L, 1993, BRIT J CANCER, V68, P352, DOI 10.1038/bjc.1993.339
   SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9
   Spirin V, 2003, P NATL ACAD SCI USA, V100, P12123, DOI 10.1073/pnas.2032324100
   Tanaka K, 2007, ONCOGENE, V26, P6456, DOI 10.1038/sj.onc.1210459
   Wei Z, 2007, BIOINFORMATICS, V23, P1537, DOI 10.1093/bioinformatics/btm129
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
   Yamane A, 2009, INTERNAL MED, V48, P1691, DOI 10.2169/internalmedicine.48.2358
   Yang GF, 2013, ARCH GYNECOL OBSTET, V287, P989, DOI 10.1007/s00404-012-2650-6
   Yi M, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-30
   Zhang JD, 2009, BIOINFORMATICS, V25, P1470, DOI 10.1093/bioinformatics/btp167
   Zhao H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049683
NR 53
TC 14
Z9 17
U1 1
U2 15
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI PARIS
PA 23 RUE LINOIS, 75724 PARIS, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2014
VL 68
IS 6
BP 699
EP 707
DI 10.1016/j.biopha.2014.07.014
PG 9
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AQ3DE
UT WOS:000342668300004
PM 25070394
DA 2025-01-12
ER

PT J
AU Hill, J
   Hodsdon, W
AF Hill, Jacob
   Hodsdon, Wendy
TI <i>In Utero</i> Exposure and Breast Cancer Development: An Epigenetic
   Perspective
SO JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY
LA English
DT Article
DE genetics; epigenetics; oncology; nutrition; toxicology; pregnancy;
   environment
ID GROWTH-FACTOR-I; BISPHENOL-A; CORD BLOOD; MATERNAL DIET; BIRTH SIZE;
   PREGNANCY ESTRIOL; ESTROGEN-LEVELS; MAMMARY-GLAND; FAT INTAKE; RISK
AB The ubiquitous and detrimental disease of breast cancer requires continual research into new and alternative forms of treatment and prevention. The emerging field of epigenetics is beginning to unfold an array of contemporary approaches to reduce the risk and improve the clinical approach to breast cancer. The information contained in this non-systematic review highlights and expands on the estrogen-based model of breast cancer epigenetics to provide an overview of epigenetic alterations induced by nutrition and environmental exposure. The majority of evidence suggests that various sources of excess estrogen correlate to future breast cancer development. In addition, maternal macro- and micronutrient balance appear to play a role in genomic regulation, and preliminary data suggest that specific superfoods, such as blueberries, have a protective epigenetic effect. Identifying the influence of environmental toxicants, hormonal exposure, maternal nutrition, and maternal disease on fetal epigenetics may have potential for development of new therapeutic approaches for the prevention of breast cancer.
C1 [Hill, Jacob; Hodsdon, Wendy] Natl Coll Nat Med, Helfgott Res Inst, Portland, OR 97201 USA.
RP Hill, J (通讯作者)，Natl Coll Nat Med, Helfgott Res Inst, 2220 SW 1st Ave, Portland, OR 97201 USA.
EM jhill5095@gmail.com
CR ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q
   AL MD, 1995, J NUTR, V125, P2822
   BAGHURST PA, 1994, INT J CANCER, V56, P173, DOI 10.1002/ijc.2910560204
   BOYD NF, 1993, BRIT J CANCER, V68, P627, DOI 10.1038/bjc.1993.398
   Caygill CPJ, 1996, BRIT J CANCER, V74, P159, DOI 10.1038/bjc.1996.332
   COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096
   DAVIS DL, 1993, ENVIRON HEALTH PERSP, V101, P372, DOI 10.2307/3431889
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011
   Eden JA, 2010, MATURITAS, V67, P117, DOI 10.1016/j.maturitas.2010.05.005
   Ekbom A, 1997, JNCI-J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71
   EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J
   Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6
   GOLDIN BR, 1986, AM J CLIN NUTR, V44, P945, DOI 10.1093/ajcn/44.6.945
   GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201
   Harigaya A, 1997, J CLIN ENDOCR METAB, V82, P3281, DOI 10.1210/jc.82.10.3281
   HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604
   Hilakivi-Clarke L, 1997, BREAST CANCER RES TR, V46, P199, DOI 10.1023/A:1005983621612
   Hilakivi-Clarke L, 1999, ONCOL REP, V6, P1089
   Hilakivi-Clarke L, 1999, NUTRITION, V15, P392, DOI 10.1016/S0899-9007(99)00029-5
   Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   JAIN M, 1994, J NATL CANCER I, V86, P1390, DOI 10.1093/jnci/86.18.1390
   Kaijser M, 2000, EPIDEMIOLOGY, V11, P315, DOI 10.1097/00001648-200005000-00015
   Keeling JW, 2000, J PATHOL, V191, P449
   KORT WJ, 1987, JNCI-J NATL CANCER I, V79, P593
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   La Merrill M, 2010, ENVIRON HEALTH PERSP, V118, P596, DOI 10.1289/ehp.0901047
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305
   MCFADYEN IR, 1982, BRIT J OBSTET GYNAEC, V89, P994, DOI 10.1111/j.1471-0528.1982.tb04653.x
   Mucci LA, 2003, CANCER CAUSE CONTROL, V14, P311, DOI 10.1023/A:1023966813330
   Nagata C, 2006, CANCER EPIDEM BIOMAR, V15, P1469, DOI 10.1158/1055-9965.EPI-06-0158
   Ong KKL, 1999, J CLIN ENDOCR METAB, V84, P1145, DOI 10.1210/jc.84.3.1145
   Orloff MS, 2013, AM J HUM GENET, V92, P76, DOI 10.1016/j.ajhg.2012.10.021
   Painter RC, 2006, AM J HUM BIOL, V18, P853, DOI 10.1002/ajhb.20564
   Palmer JR, 2006, CANCER EPIDEM BIOMAR, V15, P1509, DOI 10.1158/1055-9965.EPI-06-0109
   Park SK, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1850
   Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3
   Petrocelli T, 2010, BREAST CANCER RES, V3, P356
   Ponti D, 2006, EUR J CANCER, V42, P1219, DOI 10.1016/j.ejca.2006.01.031
   PRITCHARD GA, 1989, BRIT J SURG, V76, P1069, DOI 10.1002/bjs.1800761028
   ROSE DP, 1995, JNCI-J NATL CANCER I, V87, P587, DOI 10.1093/jnci/87.8.587
   Roseboom T, 2006, EARLY HUM DEV, V82, P485, DOI 10.1016/j.earlhumdev.2006.07.001
   Santos F, 2004, REPRODUCTION, V127, P643, DOI 10.1530/rep.1.00221
   Savarese TM, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1674
   Schernhammer ES, 2002, CANCER CAUSE CONTROL, V13, P505, DOI 10.1023/A:1016348425833
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   Silva ID, 2008, PLOS MED, V5, P1372, DOI 10.1371/journal.pmed.0050193
   Sivan E, 2003, J CLIN ENDOCR METAB, V88, P5656, DOI 10.1210/jc.2003-031174
   Skalkidou A, 2003, CANCER EPIDEM BIOMAR, V12, P860
   SMITH CA, 1947, AM J OBSTET GYNECOL, V53, P599, DOI 10.1016/0002-9378(47)90277-9
   Stephansson O, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2481
   Trichopoulos D, 2005, BREAST CANCER RES, V7, P13, DOI 10.1186/bcr966
   TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z
   Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010
   Vatten LJ, 2002, PEDIATRICS, V109, P1131, DOI 10.1542/peds.109.6.1131
   Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4
   WANG HS, 1992, J ENDOCRINOL, V132, P11, DOI 10.1677/joe.0.1320011
   WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0
   Wu AH, 1999, J NATL CANCER I, V91, P529, DOI 10.1093/jnci/91.6.529
   Wu XL, 2009, NUTR RES, V29, P802, DOI 10.1016/j.nutres.2009.10.015
   YUAN JM, 1995, BRIT J CANCER, V71, P1353, DOI 10.1038/bjc.1995.263
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
NR 64
TC 5
Z9 5
U1 0
U2 17
PU BEGELL HOUSE INC
PI DANBURY
PA 50 NORTH ST, DANBURY, CT 06810 USA
SN 0731-8898
EI 2162-6537
J9 J ENVIRON PATHOL TOX
JI J. Environ. Pathol. Toxicol. Oncol.
PY 2014
VL 33
IS 3
BP 239
EP 245
DI 10.1615/JEnvironPatholToxicolOncol.2014011005
PG 7
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA AQ3XP
UT WOS:000342727100006
PM 25272062
DA 2025-01-12
ER

PT J
AU Hopkins, BD
   Parsons, RE
AF Hopkins, Benjamin D.
   Parsons, Ramon E.
TI Molecular Pathways: Intercellular PTEN and the Potential of PTEN
   Restoration Therapy
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TUMOR-SUPPRESSOR PTEN; PHOSPHATASE-ACTIVITY; CELL-MIGRATION; GERMLINE
   MUTATIONS; PROSTATE-CANCER; COWDEN-DISEASE; BREAST-CANCER; GENE; GROWTH;
   ANGIOGENESIS
AB Phosphatase and Tensin homolog deleted on chromosome Ten (PTEN) acts as a tumor suppressor through both PI3K-dependent and - independent mechanisms. Reduced PTEN activity has been shown to affect not only tumor cell proliferation and survival but also the microenvironmental context in which nascent tumors develop. As a result of the multifaceted tumor-suppressive roles of PTEN, tumors evolve by selecting for clones in which PTEN activity is lost. PTEN activity within tumors can be modulated in numerous ways, including direct mutation, epigenetic regulation, and amplification or mutation of other proteins that can regulate or degrade PTEN. These events functionally prevent PTEN protein from acting within tumor cells. Paracrine roles for PTEN gene products (exosomal PTEN and PTEN-L) have recently been identified, through which PTEN gene products produced in one cell are able to enter recipient cells and contribute to PTEN functions. In preclinical models purified PTEN-L protein was able to enter tumor xenografts and downregulate PI3K signaling as well as cause tumor cell death. Here, we review the role of PTEN as a multifaceted tumor suppressor and reflect upon the potential for PTEN restoration therapy. (C) 2014 AACR.
C1 [Hopkins, Benjamin D.; Parsons, Ramon E.] Icahn Sch Med Mt Sinai, Dept Oncol Sci, New York, NY 10029 USA.
C3 Icahn School of Medicine at Mount Sinai
RP Parsons, RE (通讯作者)，Mt Sinai Sch Med, 1 Gustave Levy Pl, New York, NY 10029 USA.
EM Ramon.Parsons@mssm.edu
RI Parsons, Ramon/KFT-2922-2024
OI Parsons, Ramon/0000-0002-6656-3514
FU NCI [R01CA184016, R01CA082783]
FX This work is supported by NCI R01CA184016 and R01CA082783 (to B.D.
   Hopkins and R.E. Parsons).
CR Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556
   Arch EM, 1997, AM J MED GENET, V71, P489, DOI 10.1002/(SICI)1096-8628(19970905)71:4<489::AID-AJMG24>3.3.CO;2-I
   Berger AH, 2011, J PATHOL, V223, P137, DOI 10.1002/path.2800
   Carracedo A, 2011, CANCER RES, V71, P629, DOI 10.1158/0008-5472.CAN-10-2488
   Chen HB, 2011, J NEURO-ONCOL, V104, P155, DOI 10.1007/s11060-010-0492-2
   Dey N, 2008, CANCER RES, V68, P1862, DOI 10.1158/0008-5472.CAN-07-1182
   Dillon LM, 2014, CURR DRUG TARGETS, V15, P65, DOI 10.2174/1389450114666140106100909
   Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569
   Giri D, 1999, HUM PATHOL, V30, P419, DOI 10.1016/S0046-8177(99)90117-X
   Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375
   Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037
   Hopkins BD, 2014, TRENDS BIOCHEM SCI, V39, P183, DOI 10.1016/j.tibs.2014.02.006
   Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907
   Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032
   Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036
   Koul D, 2002, INT J ONCOL, V21, P469
   Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026
   Li DM, 1997, CANCER RES, V57, P2124
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li J, 1998, CANCER RES, V58, P5667
   Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64
   Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183
   Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240
   Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375
   Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333
   Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513
   Pandolfi PP, 2004, NEW ENGL J MED, V351, P2337, DOI 10.1056/NEJMcibr043143
   Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954
   Pilarski R, 2004, J MED GENET, V41, P323, DOI 10.1136/jmg.2004.018036
   Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Pulido R, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005560
   Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084
   Raftopoulou M, 2004, SCIENCE, V303, P1179, DOI 10.1126/science.1092089
   She QB, 2003, CLIN CANCER RES, V9, P4340
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Tian XX, 1999, J NEUROPATH EXP NEUR, V58, P472, DOI 10.1097/00005072-199905000-00006
   Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486
   Wen SH, 2001, P NATL ACAD SCI USA, V98, P4622, DOI 10.1073/pnas.081063798
   Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031
   Zhou XP, 2001, LANCET, V358, P210, DOI 10.1016/S0140-6736(01)05412-5
NR 44
TC 38
Z9 43
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD NOV 1
PY 2014
VL 20
IS 21
BP 5379
EP 5383
DI 10.1158/1078-0432.CCR-13-2661
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AT2IU
UT WOS:000344759100007
PM 25361917
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Mezzanotte, JJ
   Hill, V
   Schmidt, ML
   Shinawi, T
   Tommasi, S
   Krex, D
   Schackert, G
   Pfeifer, GP
   Latif, F
   Clark, GJ
AF Mezzanotte, Jessica J.
   Hill, Victoria
   Schmidt, M. Lee
   Shinawi, Thoraia
   Tommasi, Stella
   Krex, Dietmar
   Schackert, Gabriele
   Pfeifer, Gerd P.
   Latif, Farida
   Clark, Geoffrey J.
TI <i>RASSF6</i> exhibits promoter hypermethylation in metastatic melanoma
   and inhibits invasion in melanoma cells
SO EPIGENETICS
LA English
DT Article
DE brain metastases; invasion; melanoma; MAPK; Ras; RASSF
ID GENE; SUPPRESSOR; RAF; CARCINOGENESIS; EXPRESSION; PROTEIN; KINASE;
   FAMILY; BREAST
AB Brain metastasis is a major contributor to cancer mortality, yet, the genetic changes underlying the development of this capacity remain poorly understood. RASSF proteins are a family of tumor suppressors that often suffer epigenetic inactivation during tumorigenesis. However, their epigenetic status in brain metastases has not been well characterized. We have examined the promoter methylation of the classical RASSF members (RASSF1A-RASSF6) in a panel of metastatic brain tumor samples. RASSF1A and RASSF2 have been shown to undergo promoter methylation at high frequency in primary lung and breast tumors and in brain metastases. Other members exhibited little or no methylation in these tumors. In examining melanoma metastases, however, we found that RASSF6 exhibits the highest frequency of inactivation in melanoma and in melanoma brain metastases. Most melanomas are driven by an activating mutation in B-Raf. Introduction of RASSF6 into a B-Raf(V600E)-containing metastatic melanoma cell line inhibited its ability to invade through collagen and suppressed MAPK pathway activation and AKT. RASSF6 also appears to increase the association of mutant B-Raf and MST1, providing a potential mechanism by which RASSF6 is able to suppress MAPK activation. Thus, we have identified a novel potential role for RASSF6 in melanoma development. Promoter methylation leading to reduced expression of RASSF6 may play an important role in melanoma development and may contribute to brain metastases.
C1 [Mezzanotte, Jessica J.; Schmidt, M. Lee; Clark, Geoffrey J.] Univ Louisville, Dept Biochem Pharmacol, Louisville, KY 40292 USA.
   [Hill, Victoria; Shinawi, Thoraia; Latif, Farida] Univ Birmingham, Sch Clin & Expt Med, Birmingham, W Midlands, England.
   [Krex, Dietmar; Schackert, Gabriele] Tech Univ Dresden, Dept Neurosurg, Univ Hosp Carl Gustav Carus Dresden, D-01062 Dresden, Germany.
   [Tommasi, Stella; Pfeifer, Gerd P.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA USA.
C3 University of Louisville; University of Birmingham; Technische
   Universitat Dresden; Carl Gustav Carus University Hospital; City of
   Hope; Beckman Research Institute of City of Hope
RP Clark, GJ (通讯作者)，Univ Louisville, Dept Biochem Pharmacol, Louisville, KY 40292 USA.
EM latif@bham.ac.uk; gjclar01@louisville.edu
RI Schmidt, Lee/D-7266-2018
OI Shinawi, Thoraia/0000-0003-4429-8040; Mezzanotte Sharpe,
   Jessica/0000-0003-2041-5978; Tommasi, Stella/0000-0001-6897-4985
FU Brown Cancer Center MD/PhD program, University of Louisville; Department
   of Neurosurgery, University Hospital Dresden, Germany; King Abdulaziz
   University, Saudi Arabia
FX The work was funded in part by the Brown Cancer Center MD/PhD program,
   University of Louisville, the Department of Neurosurgery, University
   Hospital Dresden, Germany, and King Abdulaziz University, Saudi Arabia.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Allen NPC, 2007, ONCOGENE, V26, P6203, DOI 10.1038/sj.onc.1210440
   Avruch J, 2006, METHOD ENZYMOL, V407, P290, DOI 10.1016/S0076-6879(05)07025-4
   Cantwell-Dorris ER, 2011, MOL CANCER THER, V10, P385, DOI 10.1158/1535-7163.MCT-10-0799
   Carnahan J, 2010, MOL CANCER THER, V9, P2399, DOI 10.1158/1535-7163.MCT-10-0181
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Djos A, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-40
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065
   Finn L, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-23
   Furuta J, 2004, CANCER SCI, V95, P962, DOI 10.1111/j.1349-7006.2004.tb03184.x
   Goulart Carlos R, 2011, ISRN Surg, V2011, P276908, DOI 10.5402/2011/276908
   Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380
   Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191
   Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566
   Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42
   Ikeda M, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000300
   Iwasa H, 2013, J BIOL CHEM, V288, P30320, DOI 10.1074/jbc.M113.507384
   Lee SJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016180
   Li CL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091332
   Liang SL, 2007, CANCER RES, V67, P5814, DOI 10.1158/0008-5472.CAN-06-4233
   MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068
   Osborne JK, 2012, CELL RES, V22, P14, DOI 10.1038/cr.2011.193
   Reddy KB, 2003, CANCER METAST REV, V22, P395, DOI 10.1023/A:1023781114568
   Regad T, 2013, CELL MOL LIFE SCI, V70, P4055, DOI 10.1007/s00018-013-1324-2
   Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004
   Romano D, 2014, NAT CELL BIOL, V16, P673, DOI 10.1038/ncb2986
   Romano D, 2010, CANCER RES, V70, P1195, DOI 10.1158/0008-5472.CAN-09-3147
   Sullivan RJ, 2013, EUR J CANCER, V49, P1297, DOI 10.1016/j.ejca.2012.11.019
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
   Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112
NR 33
TC 36
Z9 38
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD NOV
PY 2014
VL 9
IS 11
BP 1496
EP 1503
DI 10.4161/15592294.2014.983361
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AZ8CI
UT WOS:000348442000007
PM 25482183
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Shargh, SA
   Sakizli, M
   Khalaj, V
   Movafagh, A
   Yazdi, H
   Hagigatjou, E
   Sayad, A
   Mansouri, N
   Mortazavi-Tabatabaei, SA
   Khorshid, HRK
AF Shargh, Shohreh Alizadeh
   Sakizli, Meral
   Khalaj, Vahid
   Movafagh, Abolfazl
   Yazdi, Hamidreza
   Hagigatjou, Elmira
   Sayad, Aresou
   Mansouri, Neda
   Mortazavi-Tabatabaei, Seyed Abdolreza
   Khorshid, Hamid Reza Khorram
TI Downregulation of E-cadherin expression in breast cancer by promoter
   hypermethylation and its relation with progression and prognosis of
   tumor
SO MEDICAL ONCOLOGY
LA English
DT Article
DE Breast cancer; Methylation; E-cadherin; Progression; Prognosis
ID THERAPEUTIC TARGET; PROTEIN EXPRESSION; GENE; METHYLATION; REGION;
   MECHANISMS; CARCINOMA
AB Breast cancer is the most common cancer in women around the world, and novel prognosis strategies is needed to control more accurate and effective of this malignant disease. Among the latest prognostic markers is E-cadherin, which mediates cell-cell adhesion by associating with catenins. Loss of E-cadherin gene (CDH1) function by genetic or epigenetic alteration leads to tumorigenesis. The aim of our study was to investigate E-cadherin gene promoter methylation in breast cancer, and its correlation with E-cadherin protein expression. Fifty primary breast cancers tissue with ductal type and 50 normal breast sample from the same patients that was located adjacent to tumor region as controls were provided by Imam Reza-based referral and teaching hospital affiliated to Tabriz University of Medical Sciences, Tabriz, Iran. CDH1 promoter region CpG sites methylation and E-cadherin protein expression were determined by bisulfitespecific polymerase chain reaction and Western blot analysis, and the resulting products were sequenced on an ABI automated sequencer for firm conclusion. CDH1 hypermethylation in breast tumor specimen (ductal type) was observed in 94 % (47 of 50) comparing with normal samples methylation, and the significant difference was (p = 0.000). Protein expression in tumor samples tends to diminish with the CDH1 promoter region methylation. In the group of 50 ductal carcinomas cases, most of the cases showing CDH1 hypermethylation correlated inversely with the reduced levels of expression of E-cadherin proteins (95 % of full-methylated tumor samples had no protein expression, and 4.5 % of them had weak expression levels). Possible association was observed between CDH1 methylation and its protein expression (p = 0.000). The results of methylation analysis in promoter region in ten CpG sites (863, 865, 873, 879, 887, 892, 901, 918, 920, and 940) suggested that abnormal CDH1 methylation occurs in high frequencies in ductal breast tumors probably sounds the process of carcinogenesis progression.
C1 [Shargh, Shohreh Alizadeh] Islamic Azad Univ, Med Lab Sci Dept, Midwifery Nursing Inst, Chalous Branch, Chalous, Iran.
   [Sakizli, Meral] Eylul Univ, Dept Med Genet & Biol, Hlth Inst, Izmir, Turkey.
   [Khalaj, Vahid] Pasteur Inst Iran, Dept Biotechnol, Tehran, Iran.
   [Movafagh, Abolfazl; Sayad, Aresou; Mansouri, Neda] Shahid Beheshti Univ Med Sci, Dept Med Genet, Pediat Neurol Res Ctr, Mofid Hosp,Fac Med, Tehran, Iran.
   [Yazdi, Hamidreza] Islamic Azad Univ, Dept Microbiol, Varamin & Pishva Branch, Tehran, Iran.
   [Hagigatjou, Elmira] Islamic Azad Univ, Dept Hort, Karaj Branch, Karaj, Iran.
   [Mortazavi-Tabatabaei, Seyed Abdolreza] Shahid Beheshti Univ Med Sci, Prote Res Ctr, Tehran, Iran.
   [Khorshid, Hamid Reza Khorram] Univ Social Welf & Rehabil Sci, Genet Res Ctr, Tehran, Iran.
C3 Islamic Azad University; Dokuz Eylul University; Pasteur Network;
   Pasteur Institute of Iran; Shahid Beheshti University Medical Sciences;
   Islamic Azad University; Islamic Azad University; Shahid Beheshti
   University Medical Sciences
RP Movafagh, A (通讯作者)，Shahid Beheshti Univ Med Sci, Dept Med Genet, Pediat Neurol Res Ctr, Mofid Hosp,Fac Med, Velenjack St,Kodakyar Ave, Tehran, Iran.
EM movafagh_a@yahoo.com
RI Khorshid, Hamidreza/J-9904-2017; Sayad, Arezou/AAX-1349-2021; khalaj,
   vahid/U-2632-2017
OI khalaj, vahid/0000-0003-1621-6394; movafagh,
   abolfazl/0000-0001-7402-7677
CR Balic M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-358
   Brouckaert O, 2013, ANN ONCOL, V24, P1847, DOI 10.1093/annonc/mdt179
   Brown CJ, 1996, J NATL CANCER I, V88, P480, DOI 10.1093/jnci/88.8.480
   Caldeira JRF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-48
   Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200
   Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179
   Chen ZX, 2005, J CELL BIOCHEM, V95, P902, DOI 10.1002/jcb.20447
   Flanagan JM, 2010, AM J HUM GENET, V86, P420, DOI 10.1016/j.ajhg.2010.02.008
   Fuchs M, 2005, J CELL PHYSIOL, V202, P805, DOI 10.1002/jcp.20192
   Graziano F, 2004, ANN ONCOL, V15, P489, DOI 10.1093/annonc/mdh108
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Kajabova V, 2013, TRANSL ONCOL, V6, P297, DOI 10.1593/tlo.13244
   Kleer CG, 2001, MODERN PATHOL, V14, P458, DOI 10.1038/modpathol.3880334
   Lau MT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059083
   Lee EYHP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003236
   Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991
   Matsumura T, 2001, CLIN CANCER RES, V7, P594
   Nojima D, 2001, MOL CARCINOGEN, V32, P19, DOI 10.1002/mc.1060
   Qiu XM, 2010, EXP THER MED, V1, P519, DOI 10.3892/etm_00000082
   Rauch T, 2005, LAB INVEST, V85, P1172, DOI 10.1038/labinvest.3700311
   Ribeiro LA, 2002, MOL CARCINOGEN, V34, P187, DOI 10.1002/mc.10064
   Sambrook J., 1989, MOL CLONING LAB MANU, P125
   Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167
   Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181
   Tan LW, 2002, CARCINOGENESIS, V23, P231, DOI 10.1093/carcin/23.2.231
   Walker DC, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0703
   Younis LK, 2007, INT J HEALTH SCI-IJH, V1, P43
NR 27
TC 47
Z9 59
U1 1
U2 13
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD NOV
PY 2014
VL 31
IS 11
AR 250
DI 10.1007/s12032-014-0250-y
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AQ8FC
UT WOS:000343058600008
PM 25260805
DA 2025-01-12
ER

PT J
AU Tomasetti, M
   Santarelli, L
   Neuzil, J
   Dong, LF
AF Tomasetti, Marco
   Santarelli, Lory
   Neuzil, Jiri
   Dong, Lanfeng
TI MicroRNA regulation of cancer metabolism: role in tumour suppression
SO MITOCHONDRION
LA English
DT Article
DE MicroRNA; Mitochondria; Tumour suppression; Cancer bioenergetics
ID HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; ATP CITRATE LYASE; BREAST-CANCER;
   GROWTH-FACTOR; DOWN-REGULATION; HEXOKINASE 2; C-MYC; MITOCHONDRIAL
   RESPIRATION; HEPATOCELLULAR-CARCINOMA; THERAPEUTIC TARGETS
AB Mitochondria are critical regulators of cell metabolism; thus, mitochondrial dysfunction is associated with many metabolic disorders, including cancer. Altered metabolism is a common property of cancer cells that exhibit enhanced capacity to 'ferment' glucose to pyruvate and then lactate, even in the presence of sufficient oxygen to support mitochondrial metabolism. Recently, it was reported that microRNAs (miRNAs) regulate important signalling pathways in mitochondria and many of these miRNAs are deregulated in various cancers. Different regulatory mechanisms can control miRNA expression at the genetic or epigenetic level, thus affecting the biogenetic machinery via recruitment of specific transcription factors. Metabolic reprogramming that cancer cells undergo during tumorigenesis offers a wide range of potential targets to impair tumour progression. MiRNAs participate in controlling cancer cell metabolism by regulating the expression of genes whose protein products either directly regulate metabolic machinery or indirectly modulate the expression of metabolic enzymes, serving as master regulators. Thus, modulation of the level of miRNAs may provide a new approach for the treatment of neoplastic diseases. (C) 2014 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Tomasetti, Marco; Santarelli, Lory] Polytech Univ Marche, I-60020 Ancona, Italy.
   [Neuzil, Jiri; Dong, Lanfeng] Griffith Univ, Sch Med Sci, Southport, Qld 4222, Australia.
   [Neuzil, Jiri] Acad Sci Czech Republ, Inst Biotechnol, Prague 14220 4, Czech Republic.
C3 Marche Polytechnic University; Griffith University; Griffith University
   - Gold Coast Campus; Czech Academy of Sciences; Institute of
   Biotechnology of the Czech Academy of Sciences
RP Tomasetti, M (通讯作者)，Polytech Univ Marche, Dept Mol & Clin Sci, I-60020 Ancona, Italy.
EM m.tomasetti@univpm.it; j.neuzil@griffith.edu.au
RI Neuzil, Jiri/H-7204-2014; Santarelli, Lory/AAU-4494-2020; DONG,
   LANFENG/S-8805-2019
OI Dong, Lanfeng/0000-0002-9857-6352; santarelli, lory/0000-0003-1015-7098;
   Tomasetti, Marco/0000-0001-5036-7052
FU National Institute against Occupational Injury Insurance (INAIL);
   Australian Research Council; Czech Science Foundation [P301/10/1937];
   BIOCEV European Regional Development Fund [CZ.1.05/1.1.00/02.0109];
   Cancer Council Queensland Grant
FX This work was supported in part by the by grants from the National
   Institute against Occupational Injury Insurance (INAIL) to L.S. and
   M.T., and Australian Research Council, Cancer Council Queensland Grant
   and the Czech Science Foundation (P301/10/1937) to J.N., and by the
   BIOCEV European Regional Development Fund CZ.1.05/1.1.00/02.0109.
CR Abdollahi A, 2007, J CELL PHYSIOL, V210, P16, DOI 10.1002/jcp.20835
   Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200
   Akinc A, 2008, NAT BIOTECHNOL, V26, P561, DOI 10.1038/nbt1402
   Aschrafi A., 2014, CELL MOL LI IN PRESS
   Bai XY, 2011, J AM SOC NEPHROL, V22, P1252, DOI 10.1681/ASN.2010040367
   Bandiera S, 2013, FREE RADICAL BIO MED, V64, P12, DOI 10.1016/j.freeradbiomed.2013.06.013
   Bandiera S, 2011, J BIOL CHEM, V286, pLE19, DOI 10.1074/jbc.L111.240259
   Bandiera S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020746
   Barrey E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020220
   Bauer DE, 2005, ONCOGENE, V24, P6314, DOI 10.1038/sj.onc.1208773
   Benard G, 2010, BBA-BIOENERGETICS, V1797, P698, DOI 10.1016/j.bbabio.2010.02.030
   Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540
   Bian Z, 2010, CELL RES, V20, P1076, DOI 10.1038/cr.2010.119
   Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068
   Budhu A, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-37
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448
   Chan E, 2011, TRENDS MOL MED, V17, P235, DOI 10.1016/j.molmed.2011.01.008
   Chan SY, 2010, CELL CYCLE, V9, P1072, DOI 10.4161/cc.9.6.11006
   Chan SY, 2009, CELL METAB, V10, P273, DOI 10.1016/j.cmet.2009.08.015
   Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200
   Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715
   Chang SH, 2014, CURR OPIN HEMATOL, V21, P235, DOI 10.1097/MOH.0000000000000040
   Chen J., 2014, CURR MED CH IN PRESS
   Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285
   Chiche J, 2013, ANN ENDOCRINOL-PARIS, V74, P111, DOI 10.1016/j.ando.2013.02.004
   Corsini LR, 2012, EXPERT OPIN THER TAR, V16, pS103, DOI 10.1517/14728222.2011.650632
   Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274
   Das S, 2012, CIRC RES, V110, P1596, DOI 10.1161/CIRCRESAHA.112.267732
   De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI [10.1056/NEJMra1011165, 10.1056/NEJMc1110602]
   de Giorgio A., 2014, ONCOGENE IN PRESS
   De Guire V, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq354
   Demongeot J, 2013, ACTA BIOTHEOR, V61, P367, DOI 10.1007/s10441-013-9190-8
   Devlin C, 2011, IUBMB LIFE, V63, P94, DOI [10.1002/iub.427, 10.1002/iub.00427]
   Doherty JR, 2013, J CLIN INVEST, V123, P3685, DOI 10.1172/JCI69741
   Dong XC, 2008, CELL METAB, V8, P65, DOI 10.1016/j.cmet.2008.06.006
   Dumortier O, 2013, CELL METAB, V18, P312, DOI 10.1016/j.cmet.2013.06.004
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Elstrom RL, 2004, CANCER RES, V64, P3892, DOI 10.1158/0008-5472.CAN-03-2904
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Fang R, 2012, J BIOL CHEM, V287, P23227, DOI 10.1074/jbc.M112.373084
   Favaro E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010345
   Fei X, 2012, FEBS LETT, V586, P392, DOI 10.1016/j.febslet.2012.01.006
   Feng RH, 2010, CANCER LETT, V298, P50, DOI 10.1016/j.canlet.2010.06.004
   Filipp FV, 2012, PIGM CELL MELANOMA R, V25, P375, DOI 10.1111/j.1755-148X.2012.00989.x
   Gameiro PA, 2013, CELL METAB, V17, P372, DOI 10.1016/j.cmet.2013.02.002
   Gao P, 2012, CURR GENE THER, V12, P285, DOI 10.2174/156652312802083620
   Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686
   Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980
   Gibson SL, 2007, CELL CYCLE, V6, P631, DOI 10.4161/cc.6.6.3987
   Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016
   Gregersen LH, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-232
   Gumireddy K, 2008, ANGEW CHEM INT EDIT, V47, P7482, DOI 10.1002/anie.200801555
   Guo CG, 2008, GENE CHROMOSOME CANC, V47, P939, DOI 10.1002/gcc.20596
   Guo S, 2009, MOL CELL BIOL, V29, P5070, DOI 10.1128/MCB.00138-09
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen TF, 2013, BRIT J CANCER, V109, P1243, DOI 10.1038/bjc.2013.448
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008
   Horie T, 2009, BIOCHEM BIOPH RES CO, V389, P315, DOI 10.1016/j.bbrc.2009.08.136
   Huang LE, 2008, CELL DEATH DIFFER, V15, P672, DOI 10.1038/sj.cdd.4402302
   Huang T.H., 2014, ONCOGENE IN PRESS
   Huang X, 2010, TRENDS MOL MED, V16, P230, DOI 10.1016/j.molmed.2010.03.004
   Iorio MV, 2012, CANCER J, V18, P215, DOI 10.1097/PPO.0b013e318250c001
   Izzotti A, 2014, INT J HYG ENVIR HEAL, V217, P601, DOI 10.1016/j.ijheh.2014.01.001
   Izzotti A, 2011, MUTAT RES-FUND MOL M, V717, P9, DOI 10.1016/j.mrfmmm.2010.12.008
   Jeong HJ, 2013, BIOCHEM BIOPH RES CO, V434, P503, DOI 10.1016/j.bbrc.2013.03.104
   Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45
   Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014
   Kharaziha P, 2012, BBA-REV CANCER, V1826, P103, DOI 10.1016/j.bbcan.2012.03.006
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307
   Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200
   Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0
   Kosaka Nobuyoshi, 2013, Frontiers in Genetics, V4, P173, DOI 10.3389/fgene.2013.00173
   Kren BT, 2009, RNA BIOL, V6, P65, DOI 10.4161/rna.6.1.7534
   Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06
   Land SC, 2007, J BIOL CHEM, V282, P20534, DOI 10.1074/jbc.M611782200
   Lei Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007629
   Li N, 2014, BIOCHEM BIOPH RES CO, V444, P611, DOI 10.1016/j.bbrc.2014.01.103
   Li PF, 2012, J CELL BIOCHEM, V113, P1104, DOI 10.1002/jcb.24004
   Locasale JW, 2009, NAT BIOTECHNOL, V27, P916, DOI 10.1038/nbt1009-916
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu J., 2014, CANC LETT IN PRESS
   Mancarelli MM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-172
   Maniataki E, 2005, RNA, V11, P849, DOI 10.1261/rna.2210805
   Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459
   Meng S, 2012, J MOL CELL CARDIOL, V53, P64, DOI 10.1016/j.yjmcc.2012.04.003
   Mercer TR, 2011, CELL, V146, P645, DOI 10.1016/j.cell.2011.06.051
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Mutharasan RK, 2011, AM J PHYSIOL-HEART C, V301, pH1519, DOI 10.1152/ajpheart.01080.2010
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Paltridge JL, 2013, BBA-PROTEINS PROTEOM, V1834, P2233, DOI 10.1016/j.bbapap.2013.03.014
   Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Peschiaroli A, 2013, ONCOGENE, V32, P797, DOI 10.1038/onc.2012.100
   Plummer PN, 2013, CANCER RES, V73, P341, DOI 10.1158/0008-5472.CAN-12-0271
   Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215
   Pothof J, 2009, EMBO J, V28, P2090, DOI 10.1038/emboj.2009.156
   Qin WM, 2009, ACTA BIOCH BIOPH SIN, V41, P618, DOI 10.1093/abbs/gmp049
   Rajpathak SN, 2012, DIABETES, V61, P2248, DOI 10.2337/db11-1488
   Rohwer N, 2013, ONCOGENE, V32, P3569, DOI 10.1038/onc.2012.510
   Rottiers V, 2012, NAT REV MOL CELL BIO, V13, P239, DOI 10.1038/nrm3313
   Ryu HS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017343
   Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098
   Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3
   Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462
   Santarelli L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018232
   Sasahira T, 2012, BRIT J CANCER, V107, P700, DOI 10.1038/bjc.2012.330
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022
   Semenza GL, 2007, BIOCHEM J, V405, P1, DOI 10.1042/BJ20070389
   Shah MY, 2014, WIRES RNA, V5, P537, DOI 10.1002/wrna.1229
   Shah YM, 2014, GASTROENTEROLOGY, V146, P630, DOI 10.1053/j.gastro.2013.12.031
   Sheth SS, 2006, ONCOGENE, V25, P3528, DOI 10.1038/sj.onc.1209394
   Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200
   Shih TC, 2012, J HEPATOL, V57, P584, DOI 10.1016/j.jhep.2012.04.031
   Singh Pankaj K, 2011, Mol Cell Pharmacol, V3, P125
   Soon P, 2013, ENDOCR-RELAT CANCER, V20, pR257, DOI 10.1530/ERC-13-0119
   Sotgia F, 2012, CELL CYCLE, V11, P4390, DOI 10.4161/cc.22777
   Sun X, 2014, INT J ONCOL, V44, P1678, DOI 10.3892/ijo.2014.2321
   Taguchi A, 2008, CANCER RES, V68, P5540, DOI 10.1158/0008-5472.CAN-07-6460
   Tang HB, 2012, FASEB J, V26, P4710, DOI 10.1096/fj.11-197467
   Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837
   Tomasetti M., 2014, ANTIOXID RE IN PRESS
   Tomasetti M, 2014, BBA-GEN SUBJECTS, V1840, P1441, DOI 10.1016/j.bbagen.2013.09.002
   Tomasetti M, 2012, CLIN BIOCHEM, V45, P575, DOI 10.1016/j.clinbiochem.2012.02.009
   Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017
   Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48
   Valis K, 2011, CANCER RES, V71, P946, DOI 10.1158/0008-5472.CAN-10-2203
   Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
   Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002
   Wang YL, 2014, BIOCHEM BIOPH RES CO, V446, P1255, DOI 10.1016/j.bbrc.2014.03.107
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Wheaton WW, 2011, AM J PHYSIOL-CELL PH, V300, pC385, DOI 10.1152/ajpcell.00485.2010
   Wood SL, 2014, CANCER TREAT REV, V40, P558, DOI 10.1016/j.ctrv.2013.10.001
   Yamakuchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020291
   Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang D, 2010, CANCER BIOL THER, V9, P122, DOI 10.4161/cbt.9.2.10379
   Yang YZ, 2013, J CELL BIOCHEM, V114, P967, DOI 10.1002/jcb.24438
   Ye PP, 2014, INT J MED SCI, V11, P17, DOI 10.7150/ijms.7329
   Yeh YM, 2013, INT J CANCER, V133, P867, DOI 10.1002/ijc.28086
   Zeiger AS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037904
   Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001
   Zhang J, 2008, BIOCHEM BIOPH RES CO, V377, P136, DOI 10.1016/j.bbrc.2008.09.089
   Zhang XB, 2011, BBA-MOL CELL RES, V1813, P1978, DOI 10.1016/j.bbamcr.2011.03.010
   Zhang Y, 2013, ONCOL REP, V30, P1976, DOI 10.3892/or.2013.2633
   Zhang Y, 2013, NAT CELL BIOL, V15, P284, DOI 10.1038/ncb2690
   Zhao Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.60
   Zhao YH, 2011, CANCER RES, V71, P4585, DOI 10.1158/0008-5472.CAN-11-0127
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhou S, 2014, BRIT J CANCER, V110, P2479, DOI 10.1038/bjc.2014.220
   Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7
   Zhuang GL, 2012, EMBO J, V31, P3513, DOI 10.1038/emboj.2012.183
NR 154
TC 7
Z9 8
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD NOV
PY 2014
VL 19
SI SI
BP 29
EP 38
DI 10.1016/j.mito.2014.06.004
PN A
PG 10
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA AX0DY
UT WOS:000346624700005
DA 2025-01-12
ER

PT J
AU Zhang, X
   Xiao, DK
   Wang, ZY
   Zou, YX
   Huang, LY
   Lin, WX
   Deng, QH
   Pan, H
   Zhou, JF
   Liang, C
   He, JX
AF Zhang, Xin
   Xiao, Dakai
   Wang, Ziyi
   Zou, Yongxin
   Huang, Liyan
   Lin, Weixuan
   Deng, Qiuhua
   Pan, Hui
   Zhou, Jiangfen
   Liang, Chun
   He, Jianxing
TI MicroRNA-26a/b Regulate DNA Replication Licensing, Tumorigenesis, and
   Prognosis by Targeting CDC6 in Lung Cancer
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; CELL-CYCLE; INITIATION PROTEINS; PROSTATE-CANCER;
   TUMOR-GROWTH; EXPRESSION; EZH2; PROLIFERATION; CARCINOMA; MIR-26A
AB Cancer is characterized by mutations, genome rearrangements, epigenetic changes, and altered gene expression that enhance cell proliferation, invasion, and metastasis. To accommodate deregulated cellular proliferation, many DNA replication-initiation proteins are overexpressed in human cancers. However, the mechanism that represses the expression of these proteins in normal cells and the cellular changes that result in their overexpression are largely unknown. One possible mechanism is through miRNA expression differences. Here, it is demonstrated that miR26a and miR26b inhibit replication licensing and the proliferation, migration, and invasion of lung cancer cells by targeting CDC6. Importantly, miR26a/b expression is significantly decreased in human lung cancer tissue specimens compared with the paired adjacent normal tissues, and miR26a/b downregulation and the consequential upregulation of CDC6 are associated with poorer prognosis of patients with lung cancer. These results indicate that miR26a/b repress replication licensing and tumorigenesis by targeting CDC6.
C1 [Zhang, Xin; Xiao, Dakai; Huang, Liyan; Lin, Weixuan; Deng, Qiuhua; Pan, Hui; Zhou, Jiangfen; He, Jianxing] Guangzhou Med Univ, Affiliated Hosp 1, Dept Cardiothorac Surg, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China.
   [Wang, Ziyi; Zou, Yongxin; Liang, Chun] Guangzhou HKUST Fok Ying Tung Res Inst, Guangzhou, Guangdong, Peoples R China.
   [Wang, Ziyi; Zou, Yongxin; Liang, Chun] Hong Kong Univ Sci & Technol, Div Life Sci, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Ziyi; Zou, Yongxin; Liang, Chun] Hong Kong Univ Sci & Technol, Ctr Canc Res, Hong Kong, Hong Kong, Peoples R China.
C3 State Key Laboratory of Respiratory Disease; Guangzhou Medical
   University; Hong Kong University of Science & Technology; Hong Kong
   University of Science & Technology; Hong Kong University of Science &
   Technology
RP Liang, C (通讯作者)，Hong Kong Univ Sci & Technol, Kowloon, Hong Kong, Peoples R China.
EM bccliang@ust.hk; hejx@vip.163.com
RI wang, jiahui/IXD-1197-2023
OI He, Jianxing/0000-0003-1737-8192
FU National Natural Science Foundation of China [81101681, 31171282];
   Center for Nasopharyngeal Carcinoma Research, Hong Kong [AoE/M-06/08];
   Postdoctoral Fellowship of Guangdong Province, China; Hong Kong Scholars
   Postdoctoral Program [201104631]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81101681, to D. Xiao; 31171282, to C. Liang) and
   Center for Nasopharyngeal Carcinoma Research, Hong Kong (AoE/M-06/08, to
   C. Liang). D. Xiao was supported by Postdoctoral Fellowship of Guangdong
   Province, China, and Y. Zou was supported by the Hong Kong Scholars
   Postdoctoral Program (201104631).
CR Akman BH, 2012, NUCLEIC ACIDS RES, V40, P10679, DOI 10.1093/nar/gks855
   Cai ZG, 2013, CELL BIOL INT, V37, P669, DOI 10.1002/cbin.10087
   Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292
   Dang XM, 2012, CANCER GENET-NY, V205, P113, DOI 10.1016/j.cancergen.2012.01.002
   Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005
   Farazi TA, 2013, ADV EXP MED BIOL, V774, P1, DOI 10.1007/978-94-007-5590-1_1
   Feng DR, 2003, CANCER RES, V63, P7356
   Fernández-Morales B, 2012, CELL CYCLE, V11, P3055, DOI 10.4161/cc.21471
   Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585
   Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173
   Ishimi Y, 2003, EUR J BIOCHEM, V270, P1089, DOI 10.1046/j.1432-1033.2003.03440.x
   Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282
   Ji YH, 2010, FEBS LETT, V584, P961, DOI 10.1016/j.febslet.2010.01.036
   Karakaidos P, 2004, AM J PATHOL, V165, P1351, DOI 10.1016/S0002-9440(10)63393-7
   Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120
   Li J, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-7
   Li JN, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-395
   Liu XX, 2011, FEBS LETT, V585, P1363, DOI 10.1016/j.febslet.2011.04.018
   Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850
   Lv ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067591
   Majid S, 2010, CANCER RES, V70, P2809, DOI 10.1158/0008-5472.CAN-09-4176
   Méndez J, 2003, BIOESSAYS, V25, P1158, DOI 10.1002/bies.10370
   Nishitani H, 2004, FRONT BIOSCI-LANDMRK, V9, P2115
   Ohtani K, 1998, ONCOGENE, V17, P1777, DOI 10.1038/sj.onc.1202105
   Rahbari R, 2011, ANN SURG ONCOL, V18, P1158, DOI 10.1245/s10434-010-1359-7
   Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645
   Sclafani RA, 2007, ANNU REV GENET, V41, P237, DOI 10.1146/annurev.genet.41.110306.130308
   Sideridou M, 2011, J CELL BIOL, V195, P1123, DOI 10.1083/jcb.201108121
   Solomides CC, 2012, ACTA CYTOL, V56, P645, DOI 10.1159/000343473
   Stoeber K, 2001, J CELL SCI, V114, P2027
   Todovov IT, 1998, LAB INVEST, V78, P73
   Williams GH, 1998, P NATL ACAD SCI USA, V95, P14932, DOI 10.1073/pnas.95.25.14932
   Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142
   Wu Z, 2009, NEOPLASIA, V11, P66, DOI 10.1593/neo.81048
   Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603
   Yang X, 2013, HEPATOLOGY, V58, P158, DOI 10.1002/hep.26305
   Zhai Y., 2011, FUNDAMENTAL ASPECTS, P87
   Zhang B, 2011, CARCINOGENESIS, V32, P2, DOI 10.1093/carcin/bgq209
   Zhang KM, 2010, J CELL BIOL, V188, P39, DOI 10.1083/jcb.200904144
   Zhu Y, 2012, NUCLEIC ACIDS RES, V40, P4615, DOI 10.1093/nar/gkr1278
NR 40
TC 61
Z9 66
U1 2
U2 22
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD NOV
PY 2014
VL 12
IS 11
BP 1535
EP 1546
DI 10.1158/1541-7786.MCR-13-0641
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AT7PW
UT WOS:000345131000001
PM 25100863
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Zhang, YH
   Wei, LJ
   Yu, J
   Li, G
   Zhang, XR
   Wang, AL
   He, YJ
   Li, HL
   Yin, DL
AF Zhang, Yuhua
   Wei, Lijing
   Yu, Jin
   Li, Guang
   Zhang, Xiuru
   Wang, Anliu
   He, Yanjiao
   Li, Hongli
   Yin, Deling
TI Targeting of the β6 gene to suppress degradation of ECM via inactivation
   of the MAPK pathway in breast adenocarcinoma cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE breast adenocarcinoma; beta 6 gene; RNA interference; matrix
   metalloproteinase; ERK; neoplasm invasion
ID PROSTATE EPITHELIAL-CELLS; ALPHA-V-BETA-6 INTEGRIN; MATRIX
   METALLOPROTEINASES; TUMOR-GROWTH; EXPRESSION; CANCER; PROLIFERATION;
   SECRETION; METASTASIS; INHIBITION
AB Integrin alpha v beta 6 has emerged as a potential novel target for anticancer and plays a major role in promoting malignant tumor progression. Recent studies indicate that integrin alpha v beta 6 occurs in many cancers. However, whether and how alpha v beta 6 is regulated by genetic and epigenetic mechanisms in breast cancer remain unknown. In the present study, two different short hairpin RNAs (shRNAs) targeting the 136 gene were designed and constructed into pSUPER, respectively, which were transfected into the MCF-7 human breast adenocarcinoma cell line. The beta 6-shRNA stably transfected cells were successfully established, and significant lower levels of alpha v beta 6 mRNA and protein expression were confirmed. Furthermore, inhibition of integrin alpha v beta 6 markedly downregulated the expression of matrix metalloproteinase-9 (MMP-9), matrix metalloproteinase-3 (MMP-3) and urokinase plasminogen activator (uPA) in tumor conditioned medium. Furthermore, beta 6-shRNA-mediated silencing of the alpha v beta 6 gene obviously decreased the expression of ERK1/2. In particular, supression of integrin alpha v beta 6 caused significant downregulation of the degradation of basement membrane type IV collagen secretion via modulation of the plasminogen activation cascade. Our results thus indicate that alpha v beta 6 plays a fundamental role in promoting invasion and growth of breast adenocarcinoma cells. Taken together, this study revealed that targeting of the beta 6 gene by RNA interference (RNAi) could efficiently downregulate alpha v beta 6 expression and suppress the ERK1/2-dependent extracellular matrix degradation in vitro, which is dependent upon inactivation of the mitogen-activated protein kinase (MAPK) pathway. These findings may offer a useful therapeutic approach to block invasion and migration of breast cancer cells.
C1 [Zhang, Yuhua; Yu, Jin; Li, Guang; Zhang, Xiuru; Wang, Anliu; He, Yanjiao; Li, Hongli] Capital Med Univ, Beijing Tiantan Hosp, Dept Pathol, Beijing 100050, Peoples R China.
   [Wei, Lijing] Shandong Prov Hosp, Partment Urol, Jinan 250021, Shandong, Peoples R China.
   [Yin, Deling] E Tennessee State Univ, Dept Pharmacol, Dept Internal Med, James H Quillen Coll Med, Johnson City, TN 37614 USA.
C3 Capital Medical University; Shandong First Medical University & Shandong
   Academy of Medical Sciences; East Tennessee State University
RP Zhang, YH (通讯作者)，Capital Med Univ, Beijing Tiantan Hosp, Dept Pathol, 6 Tiantanxili Rd, Beijing 100050, Peoples R China.
EM yuhuazhang111@aliyun.com
RI Li, Hongli/GNH-4029-2022; xiaoyu, zhang/JXY-7226-2024
FU Youth Science Foundation of Beijing Tiantan Hospital, Capital Medical
   University, P.R. China [ky2008-08]; National Natural Science Foundation
   of China (NSFC) [30300124]
FX This study was supported in part by the Youth Science Foundation of
   Beijing Tiantan Hospital, Capital Medical University, P.R. China (no.
   ky2008-08) and the National Natural Science Foundation of China (NSFC,
   no. 30300124).
CR Agrez M, 1999, INT J CANCER, V81, P90, DOI 10.1002/(SICI)1097-0215(19990331)81:1<90::AID-IJC16>3.0.CO;2-K
   AGREZ M, 1994, J CELL BIOL, V127, P547, DOI 10.1083/jcb.127.2.547
   Ahmed N, 2003, BRIT J CANCER, V89, P374, DOI 10.1038/sj.bjc.6601098
   Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286
   Allen MD, 2014, CLIN CANCER RES, V20, P344, DOI 10.1158/1078-0432.CCR-13-1504
   Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183
   Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06
   Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183
   Blasi F, 2002, NAT REV MOL CELL BIO, V3, P932, DOI 10.1038/nrm977
   BREUSS JM, 1995, J CELL SCI, V108, P2241
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Burkhardt BR, 2006, FEBS LETT, V580, P553, DOI 10.1016/j.febslet.2005.12.068
   Cassoni P, 2006, MOL CANCER RES, V4, P351, DOI 10.1158/1541-7786.MCR-06-0024
   Chen Y, 2006, HYPERTENSION, V47, pE18
   Chu CY, 2008, RNA, V14, P1714, DOI 10.1261/rna.1161908
   Delgado R, 2005, ENFERM INFEC MICR CL, V23, P76
   Devi GR, 2006, CANCER GENE THER, V13, P819, DOI 10.1038/sj.cgt.7700931
   Eberlein C, 2013, ONCOGENE, V32, P4406, DOI 10.1038/onc.2012.460
   Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261
   Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745
   Godier A, 2013, J THROMB HAEMOST, V11, P26, DOI 10.1111/jth.12064
   Gu X, 2002, BRIT J CANCER, V87, P348, DOI 10.1038/sj.bjc.6600480
   Hausner SH, 2009, CANCER RES, V69, P5843, DOI 10.1158/0008-5472.CAN-08-4410
   Hazelbag S, 2007, J PATHOL, V212, P316, DOI 10.1002/path.2168
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kähäri VM, 1999, ANN MED, V31, P34, DOI 10.3109/07853899909019260
   Koul HK, 2013, GENES CANC, V4, P11
   Kundu P, 2006, J BIOL CHEM, V281, P34651, DOI 10.1074/jbc.M604574200
   LIOTTA LA, 1991, CANCER RES, V51, pS5054
   Matters GL, 2009, PANCREAS, V38, pE151, DOI 10.1097/MPA.0b013e3181a66fdc
   McGowan PM, 2008, ANN ONCOL, V19, P1566, DOI 10.1093/annonc/mdn180
   Mungall BA, 2008, ANTIVIR RES, V80, P324, DOI 10.1016/j.antiviral.2008.07.004
   Niu J, 2002, INT J CANCER, V99, P529, DOI 10.1002/ijc.10397
   Niu J, 2001, INT J CANCER, V92, P40, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1157>3.0.CO;2-B
   Stein U, 2008, MOL THER, V16, P178, DOI 10.1038/sj.mt.6300304
   Yoon WH, 2004, CLIN CANCER RES, V10, P4517, DOI 10.1158/1078-0432.CCR-04-0084
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
NR 37
TC 11
Z9 11
U1 0
U2 8
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD NOV
PY 2014
VL 32
IS 5
BP 1787
EP 1795
DI 10.3892/or.2014.3419
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AQ3SO
UT WOS:000342714000004
PM 25176506
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Zhang, HY
   Cai, K
   Wang, J
   Wang, XY
   Cheng, K
   Shi, FF
   Jiang, LW
   Zhang, YX
   Dou, J
AF Zhang, Hongyi
   Cai, Kai
   Wang, Jing
   Wang, Xiaoying
   Cheng, Kai
   Shi, Fangfang
   Jiang, Longwei
   Zhang, Yunxia
   Dou, Jun
TI MiR-7, Inhibited Indirectly by LincRNA HOTAIR, Directly Inhibits SETDB1
   and Reverses the EMT of Breast Cancer Stem Cells by Downregulating the
   STAT3 Pathway
SO STEM CELLS
LA English
DT Article
DE miR-7; Breast cancer stem cells; SETDB1; Epithelial-mesenchymal
   transition; Signal transducers and activators of transcription 3
ID METASTASIS; IDENTIFICATION; ACTIVATION; MICRORNA; MELANOMA; TARGETS;
   GROWTH; LINES; TUMORIGENICITY; SUPPRESSION
AB Epithelial-mesenchymal transition (EMT) contributes to tumor invasion and metastasis in many cancers and correlates highly with the acquisition of cancer stem cell (CSC) characteristics. EMT also correlates with changes in specific microRNAs (miRNAs) that have already been integrated into tumorigenic programs as either oncogenes or tumor suppressor genes. Here, we show that miR-7, which was downregulated in breast CSCs (BCSCs) isolated from the human MCF-7 and MDA-MB-231 cell lines, inhibited cell invasion and metastasis, decreased the BCSC population and partially reversed EMT in MDA-MB-231 cells by directly targeting the oncogene, SETDB1. The conspicuous epigenetic transition induced by miR-7 overexpression was found not only in MDA-MB-231 cells but also in BCSC xenograft tumors. MiR-7 inhibited the metastasis of BCSCs in lungs, kidneys, and adrenal glands of NOD/SCID mice. ChIP-polymerase chain reaction result suggested that the SETDB1 induced STAT3 expression by binding to the promoter of STAT3. MiR-7-mediated downregulation of SETDB1 resulted in the suppression of STAT3, which led to the downregulation of c-myc, twist, and mir-9. In addition, the downregulation of miR-7 in BCSCs may be indirectly attributed to lincRNA HOTAIR by modulating the expression of HoxD10 that promotes the expression of miR-7. These findings demonstrate that miR-7 was a tumor suppressor and that the overexpression of miR-7 might serve as a good strategy for treating highly invasive breast cancer.
C1 [Zhang, Hongyi; Cai, Kai; Wang, Jing; Wang, Xiaoying; Cheng, Kai; Shi, Fangfang; Jiang, Longwei; Zhang, Yunxia; Dou, Jun] Southeast Univ, Sch Med, Dept Pathogen Biol & Immunol, Nanjing 210009, Jiangsu, Peoples R China.
   [Cai, Kai; Jiang, Longwei] Peoples Liberat Army, Hosp Peoples Liberat Army, Ctr Canc, Dept Tumor Bio Therapy, Nanjing, Jiangsu, Peoples R China.
   [Wang, Jing; Zhang, Yunxia] Southeast Univ, Sch Med, Zhongda Hosp, Dept Gynecol & Obstet, Nanjing 210009, Jiangsu, Peoples R China.
   [Cheng, Kai] Nanjing Univ, Sch Med, Nanjing Jinling Hosp, Dept Pathol, Nanjing 210008, Jiangsu, Peoples R China.
   [Shi, Fangfang] Southeast Univ, Zhongda Hosp, Dept Oncol, Nanjing 210009, Jiangsu, Peoples R China.
C3 Southeast University - China; Southeast University - China; Nanjing
   University; Southeast University - China
RP Dou, J (通讯作者)，Southeast Univ, Sch Med, Dept Pathogen Biol & Immunol, Nanjing 210009, Jiangsu, Peoples R China.
EM njdoujun@seu.edu.cn
RI Cai, Kai/JRW-1138-2023; zahng, hongyi/AAT-4909-2021; Dou,
   Jun/HTM-0073-2023
FU National Natural Science Funds [81071769]; Graduate Research and
   Innovation Projects in Jiangsu Province [CXZZ1-0129]
FX This work was supported by the National Natural Science Funds (81071769)
   and Graduate Research and Innovation Projects in Jiangsu Province
   (CXZZ1-0129). We thank Shannon Zhang and Anthony Hightower of Yale
   University for the language editing and correction.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   [Anonymous], CELL MOL BIOL NOISY
   [Anonymous], CANC METASTASIS REV
   Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630
   Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200
   Davis FM, 2014, ONCOGENE, V33, P2307, DOI 10.1038/onc.2013.187
   Dou J, 2007, CELL MOL IMMUNOL, V4, P467
   Dou J, 2010, TUMOR BIOL, V31, P243, DOI 10.1007/s13277-010-0023-y
   Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436
   Foekens JA, 2008, P NATL ACAD SCI USA, V105, P13021, DOI 10.1073/pnas.0803304105
   Fouse SD, 2013, CANCER CELL, V23, P711, DOI 10.1016/j.ccr.2013.05.016
   Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001
   Hughes L, 2008, CLIN EXP METASTAS, V25, P549, DOI 10.1007/s10585-008-9169-z
   Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859
   Kato K, 2000, BBA-GENE STRUCT EXPR, V1493, P91, DOI 10.1016/S0167-4781(00)00168-8
   Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008
   Kong XB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0033381, 10.1371/journal.pone.0041523]
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773
   Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024
   MacGregor S, 2011, NAT GENET, V43, P1114, DOI 10.1038/ng.958
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Marshall J, 2011, METHODS MOL BIOL, V769, P97, DOI 10.1007/978-1-61779-207-6_8
   Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858
   Medema JP, 2013, NAT CELL BIOL, V15, P338, DOI 10.1038/ncb2717
   Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195
   Okuda H, 2013, CANCER RES, V73, P1434, DOI 10.1158/0008-5472.CAN-12-2037
   Oliveras-Ferraros C, 2011, CELL CYCLE, V10, P1144, DOI 10.4161/cc.10.7.15210
   Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109
   Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103
   Rodriguez-Paredes M., 2013, Oncogene, P1
   Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Schriebl K, 2012, TISSUE ENG PT A, V18, P899, DOI [10.1089/ten.tea.2011.0311, 10.1089/ten.TEA.2011.0311]
   Shi SR, 2007, BIOTECH HISTOCHEM, V82, P301, DOI 10.1080/10520290701791763
   Vougier S, 2007, BIOCHEM BIOPH RES CO, V364, P627, DOI 10.1016/j.bbrc.2007.10.044
   Wang HB, 2003, MOL CELL, V12, P475, DOI 10.1016/j.molcel.2003.08.007
   Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444
   Wang Y, 2013, DEV CELL, V25, P69, DOI 10.1016/j.devcel.2013.03.002
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Zhang HY, 2012, J CANCER RES THER, V8, P226, DOI 10.4103/0973-1482.98975
   Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006
NR 47
TC 293
Z9 321
U1 0
U2 69
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD NOV
PY 2014
VL 32
IS 11
BP 2858
EP 2868
DI 10.1002/stem.1795
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA AR1BK
UT WOS:000343314400006
PM 25070049
OA Bronze
DA 2025-01-12
ER

PT J
AU Huertas-Martínez, J
   Rello-Varona, S
   Herrero-Martín, D
   Barrau, I
   García-Monclús, S
   Sáinz-Jaspeado, M
   Lagares-Tena, L
   Núñez-Alvarez, Y
   Mateo-Lozano, S
   Mora, J
   Roma, J
   Toran, N
   Moran, S
   López-Alemany, R
   Gallego, S
   Esteller, M
   Peinado, MA
   del Muro, XG
   Tirado, OM
AF Huertas-Martinez, Juan
   Rello-Varona, Santiago
   Herrero-Martin, David
   Barrau, Ignasi
   Garcia-Monclus, Silvia
   Sainz-Jaspeado, Miguel
   Lagares-Tena, Laura
   Nunez-Alvarez, Yaiza
   Mateo-Lozano, Silvia
   Mora, Jaume
   Roma, Josep
   Toran, Nuria
   Moran, Sebastian
   Lopez-Alemany, Roser
   Gallego, Soledad
   Esteller, Manel
   Peinado, Miguel A.
   Garica del Muro, Xavier
   Tirado, Oscar M.
TI Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and
   negatively regulates tumor growth
SO ONCOTARGET
LA English
DT Article
DE alveolar rhabdomyosarcoma; Caveolin-1; muscular differentiation; 5-AZA-2
   '-deoxycytidine; epigenetics; cell death
ID DNA METHYLATION; BREAST-CANCER; IN-VIVO; GENE; DIFFERENTIATION;
   EXPRESSION; SKELETAL; KINASE; MIGRATION; MUSCLE
AB Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and adolescence. Despite advances in therapy, patients with histological variant of rhabdomyosarcoma known as alveolar rhabdomyosarcoma (ARMS) have a 5-year survival of less than 30%. Caveolin-1 (CAV1), encoding the structural component of cellular caveolae, is a suggested tumor suppressor gene involved in cell signaling. In the present study we report that compared to other forms of rhabdomyosarcoma (RMS) CAV1 expression is either undetectable or very low in ARMS cell lines and tumor samples. DNA methylation analysis of the promoter region and azacytidine-induced re-expression suggest the involvement of epigenetic mechanisms in the silencing of CAV1. Reintroduction of CAV1 in three of these cell lines impairs their clonogenic capacity and promotes features of muscular differentiation. In vitro, CAV1-expressing cells show high expression of Caveolin-3 (CAV3), a muscular differentiation marker. Blockade of MAPK signaling is also observed. In vivo, CAV1-expressing xenografts show growth delay, features of muscular differentiation and increased cell death. In summary, our results suggest that CAV1 could function as a potent tumor suppressor in ARMS tumors. Inhibition of CAV1 function therefore, could contribute to aberrant cell proliferation, leading to ARMS development.
C1 [Huertas-Martinez, Juan; Rello-Varona, Santiago; Herrero-Martin, David; Barrau, Ignasi; Garcia-Monclus, Silvia; Sainz-Jaspeado, Miguel; Lagares-Tena, Laura; Lopez-Alemany, Roser; Garica del Muro, Xavier; Tirado, Oscar M.] Bellvitge Biomed Res Inst IDIBELL, Mol Oncol Lab, Sarcoma Res Grp, Barcelona, Spain.
   [Mateo-Lozano, Silvia; Mora, Jaume] Hosp St Joan de Deu, Dev Tumor Biol Lab, Barcelona, Spain.
   [Roma, Josep; Toran, Nuria; Gallego, Soledad] Hosp Univ Vall dHebron, Biomed Res Unit, Barcelona, Spain.
   [Moran, Sebastian; Esteller, Manel] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Programme PEBC, Barcelona, Spain.
   [Nunez-Alvarez, Yaiza; Peinado, Miguel A.] Inst Med Predict & Personalitzada Canc, Barcelona, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of
   Barcelona; Hospital Universitari Vall d'Hebron; Institut d'Investigacio
   Biomedica de Bellvitge (IDIBELL)
RP Tirado, OM (通讯作者)，Bellvitge Biomed Res Inst IDIBELL, Mol Oncol Lab, Sarcoma Res Grp, Barcelona, Spain.
EM omartinez@idibell.cat
RI Tirado, Oscar/R-9604-2019; Gallego, Soledad/ABI-1334-2020; Peinado,
   Miguel A./A-5591-2008; Lopez-Alemany, Roser/R-3565-2018; Esteller,
   Manel/L-5956-2014; Gallego, Soledad/KFB-5062-2024; Moran,
   Sebastian/G-5293-2013; Rello-Varona, Santi/A-4882-2009
OI Peinado, Miguel A./0000-0002-4090-793X; Lopez-Alemany,
   Roser/0000-0002-0913-0691; Tirado, Oscar M/0000-0002-4666-2822; Roma,
   Josep/0000-0001-7692-6123; Mateo, Silvia/0000-0002-2365-1573; Esteller,
   Manel/0000-0003-4490-6093; Lagares-Tena, Laura/0000-0002-5290-3346;
   Gallego, Soledad/0000-0002-4712-9624; Moran,
   Sebastian/0000-0003-4192-8983; Mora, Jaume/0000-0002-9386-5980;
   Rello-Varona, Santi/0000-0002-7500-5522
FU Asociacion Espanola contra el Cancer-AECC; Asociacion Alba Perez lucha
   contra el cancer infantil; Comissionat per a Universitats i Recerca
   (CUR) from Departament d'Innovacio, Universitats i Empresa (DIUE) de la
   Generalitat de Catalunya i del Fons Social Europeu; FPU fellowship;
   Fondo de Investigaciones Sanitarias-ISCIII [CP06/00151, CES12/021,
   PI11/00038]; Ministerio de Economia y Competitividad [SAF2011-23638]
FX S Rello-Varona is a MarieCurieCOFUND-BeatriuDePinos Researcher (The
   European Union 7th Framework Program for R+D and the Generalitat de
   Catalunya's Department for Economy and Knowledge: Secretary for
   Universities and Research). D Herrero-Martin is funded by Asociacion
   Espanola contra el Cancer-AECC. S Garcia-Monclus is funded by Asociacion
   Alba Perez lucha contra el cancer infantil. L Lagares-Tena is funded by
   the Comissionat per a Universitats i Recerca (CUR) from Departament
   d'Innovacio, Universitats i Empresa (DIUE) de la Generalitat de
   Catalunya i del Fons Social Europeu. Y Nunez-Alvarez is funded by a FPU
   fellowship. This work was funded by the Fondo de Investigaciones
   Sanitarias-ISCIII (CP06/00151; CES12/021; PI11/00038) and Ministerio de
   Economia y Competitividad (SAF2011-23638).
CR Bender F, 2002, BIOL RES, V35, P151
   Boscher C, 2012, ADV EXP MED BIOL, V729, P29, DOI 10.1007/978-1-4614-1222-9_3
   Burgermeister E, 2008, CANCER LETT, V268, P187, DOI 10.1016/j.canlet.2008.03.055
   Cardenas CLL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003291
   Chanvorachote P, 2009, J BIOL CHEM, V284, P28476, DOI 10.1074/jbc.M109.050864
   Chiu WT, 2011, CANCER RES, V71, P4932, DOI 10.1158/0008-5472.CAN-10-4249
   Clark SJ, 2002, ONCOGENE, V21, P5380, DOI 10.1038/sj.onc.1205598
   Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8
   Faggi F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084618
   Finckenstein FG, 2008, ONCOGENE, V27, P2004, DOI 10.1038/sj.onc.1210835
   GarciaCardena G, 1997, J BIOL CHEM, V272, P25437, DOI 10.1074/jbc.272.41.25437
   Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9
   Grande-García A, 2007, J CELL BIOL, V177, P683, DOI 10.1083/jcb.200701006
   Harridge SDR, 2007, EXP PHYSIOL, V92, P783, DOI 10.1113/expphysiol.2006.036525
   Kitamura T, 2007, J CLIN INVEST, V117, P2477, DOI 10.1172/JCI32054
   KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin DH, 2011, J AM SOC NEPHROL, V22, P1087, DOI 10.1681/ASN.2010090927
   Lin SY, 2004, ANTICANCER RES, V24, P1645
   LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755
   MacQuarrie KL, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-7
   Mallona I, 2014, SOURCE CODE FOR BIOL
   Marshall AD, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-25
   Miao LF, 2014, ONCOL LETT, V7, P658, DOI 10.3892/ol.2014.1807
   Murray J, 2011, AM J PHYSIOL-CELL PH, V301, pC630, DOI 10.1152/ajpcell.00033.2011
   Parham DM, 2013, ADV ANAT PATHOL, V20, P387, DOI 10.1097/PAP.0b013e3182a92d0d
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Quann K, 2013, CELL CYCLE, V12, P1510, DOI 10.4161/cc.24497
   Rossi S, 2011, EUR J CANCER, V47, P761, DOI 10.1016/j.ejca.2010.10.018
   Sáinz-Jaspeado M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071449
   Sainz-Jaspeado M, 2011, ONCOTARGET, V2, P305
   Sáinz-Jaspeado M, 2010, MOL CANCER RES, V8, P1489, DOI 10.1158/1541-7786.MCR-10-0060
   Sakai E, 2014, WORLD J GASTROENTERO, V20, P978, DOI 10.3748/wjg.v20.i4.978
   Sarver AL, 2010, LAB INVEST, V90, P753, DOI 10.1038/labinvest.2010.53
   Shi XE, 2014, INT J MOL SCI, V15, P8526, DOI 10.3390/ijms15058526
   Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427
   Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160
   Stefansson OA, 2013, AM J PATHOL, V183, P1052, DOI 10.1016/j.ajpath.2013.04.033
   Volonte D, 2004, FASEB J, V18, P237, DOI 10.1096/fj.04-2215fje
   Weisenberger DJ, 2014, J CLIN INVEST, V124, P17, DOI 10.1172/JCI69740
   Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X
   Williams TM, 2004, J BIOL CHEM, V279, P51630, DOI 10.1074/jbc.M409214200
   Yang SB, 2013, MOL CELL BIOCHEM, V384, P213, DOI 10.1007/s11010-013-1800-x
   Yang W, 2006, CANCER RES, V66, P1320, DOI 10.1158/0008-5472.CAN-05-3060
NR 44
TC 19
Z9 20
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 30
PY 2014
VL 5
IS 20
BP 9744
EP 9755
DI 10.18632/oncotarget.2403
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AZ2AH
UT WOS:000348036500018
PM 25313138
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Hashim, A
   Rizzo, F
   Marchese, G
   Ravo, M
   Tarallo, R
   Nassa, G
   Giurato, G
   Santamaria, G
   Cordella, A
   Cantarella, C
   Weisz, A
AF Hashim, Adnan
   Rizzo, Francesca
   Marchese, Giovanna
   Ravo, Maria
   Tarallo, Roberta
   Nassa, Giovanni
   Giurato, Giorgio
   Santamaria, Gianluca
   Cordella, Angela
   Cantarella, Concita
   Weisz, Alessandro
TI RNA sequencing identifies specific PIWI-interacting small non-coding RNA
   expression patterns in breast cancer
SO ONCOTARGET
LA English
DT Article
DE Breast cancer; PIWI; piRNAs; RNA-sequencing; Small non-coding RNA;
   Estrogen receptor
ID ESTROGEN-RECEPTOR BETA; PIRNA PATHWAY; MICRORNAS; PROTEINS; REVEALS;
   ALPHA; CELLS; SUITE
AB PIWI-interacting small non-coding RNAs (piRNAs) are genetic and epigenetic regulatory factors in germline cells, where they maintain genome stability, are involved in RNA silencing and regulate gene expression. We found that the piRNA biogenesis and effector pathway are present in human breast cancer (BC) cells and, analyzing smallRNA-Seq data generated from BC cell lines and tumor biopsies, we identified >100 BC piRNAs, including some very abundant and/or differentially expressed in mammary epithelial compared to BC cells, where this was influenced by estrogen or estrogen receptor beta, and in cancer respect to normal breast tissues. A search for mRNAs targeted by the BC piRNome revealed that eight piRNAs showing a specific expression pattern in breast tumors target key cancer cell pathways. Evidence of an active piRNA pathway in BC suggests that these small non-coding RNAs do exert transcriptional and post-transcriptional gene regulatory actions also in cancer cells.
C1 [Hashim, Adnan; Rizzo, Francesca; Marchese, Giovanna; Ravo, Maria; Tarallo, Roberta; Nassa, Giovanni; Giurato, Giorgio; Santamaria, Gianluca; Weisz, Alessandro] Univ Salerno, Lab Mol Med & Genom, Fac Med & Surg, I-84081 Baronissi, SA, Italy.
   [Cordella, Angela] Fdn IRCCS SDN, Naples, Italy.
   [Cantarella, Concita] Ctr Ric Orticoltura, Consiglio Ric & Sperimentaz Agr, Pontecagnano, SA, Italy.
   [Weisz, Alessandro] Univ Salerno, Div Mol Pathol & Med Genom, SS Giovanni di Dio & Ruggi dAragona Hosp, I-84100 Salerno, Italy.
C3 University of Salerno; IRCCS Istituto di Ricerca Diagnostica e Nucleare
   (SDN); Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia
   Agraria (CREA); University of Salerno
RP Weisz, A (通讯作者)，Univ Salerno, Lab Mol Med & Genom, Fac Med & Surg, I-84081 Baronissi, SA, Italy.
EM aweisz@unisa.it
RI Hashim, Adnan/Y-8924-2019; SANTAMARIA, Gianluca/ISV-4451-2023; Nassa,
   Giovanni/AAB-2059-2022; Giurato, Giorgio/K-3859-2018; Tarallo,
   Roberta/C-2600-2014; Weisz, Alessandro/A-1317-2014; Rizzo,
   Francesca/K-3057-2016
OI Marchese, Giovanna/0000-0002-9594-0729; SANTAMARIA,
   Gianluca/0000-0001-9284-7492; Giurato, Giorgio/0000-0002-0538-8978;
   Tarallo, Roberta/0000-0001-9668-3632; Weisz,
   Alessandro/0000-0003-0455-2083; Rizzo, Francesca/0000-0003-1783-5015;
   Ravo, Maria/0000-0003-1003-2922; Cordella, Angela/0000-0001-9784-7010
FU Italian Association for Cancer Research [IG-13176]; Italian Ministry for
   Education, University and Research [PRIN 2010LC747T_002, FIRB
   RBFR12W5V5_003]; National Research Council (InterOmics Flagship
   Project); University of Salerno (Fondi FARB); Italian Foundation for
   Cancer Research; Italian Association for Cancer Research
FX The work was supported by: Italian Association for Cancer Research
   (Grant IG-13176), Italian Ministry for Education, University and
   Research (Grant PRIN 2010LC747T_002 to AW and FIRB RBFR12W5V5_003 to
   RT), National Research Council (InterOmics Flagship Project) and
   University of Salerno (Fondi FARB 2012). A.H. is a PhD student of the
   Research Doctorate 'Experimental Physiopathology and Neurosciences' of
   the Second University of Naples. GN is supported by a 'Mario e Valeria
   Rindi' fellowship of the Italian Foundation for Cancer Research and MR
   is supported by a 'Vladimir Ashkenazy' fellowship of the Italian
   Association for Cancer Research.
CR Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   Enright Anton J, 2003, Genome Biol, V5, pR1, DOI 10.1186/gb-2003-5-1-r1
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   Garmire LX, 2012, RNA, V18, P1279, DOI 10.1261/rna.030916.111
   Giurato G, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-362
   Gou LT, 2014, CELL RES, V24, P680, DOI 10.1038/cr.2014.41
   Grober OMV, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-36
   Juliano C, 2011, ANNU REV GENET, V45, P447, DOI 10.1146/annurev-genet-110410-132541
   Khurana JS, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001246
   Lakshmi SS, 2008, NUCLEIC ACIDS RES, V36, pD173, DOI 10.1093/nar/gkm696
   Le Thomas A, 2013, GENE DEV, V27, P390, DOI 10.1101/gad.209841.112
   LIVAK KJ, 1990, GENETICS, V124, P303
   Luteijn MJ, 2013, NAT REV GENET, V14, P523, DOI 10.1038/nrg3495
   Malone CD, 2009, CELL, V137, P522, DOI 10.1016/j.cell.2009.03.040
   Mei YP, 2013, CANCER LETT, V336, P46, DOI 10.1016/j.canlet.2013.04.008
   Nassa G, 2014, MOL CELL PROTEOMICS, V13, P1076, DOI 10.1074/mcp.M113.030403
   Nassa G, 2011, PROTEOMICS, V11, P159, DOI 10.1002/pmic.201000344
   Paris O, 2012, ONCOGENE, V31, P4196, DOI 10.1038/onc.2011.583
   Persson H, 2011, CANCER RES, V71, P78, DOI 10.1158/0008-5472.CAN-10-1869
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Reinhold WC, 2012, CANCER RES, V72, P3499, DOI 10.1158/0008-5472.CAN-12-1370
   Rizzo F, 2014, HEPATOLOGY, V60, P798, DOI 10.1002/hep.27267
   Ross RJ, 2014, NATURE, V505, P353, DOI 10.1038/nature12987
   Rouget C, 2010, NATURE, V467, P1128, DOI 10.1038/nature09465
   Sasaki T, 2003, GENOMICS, V82, P323, DOI 10.1016/S0888-7543(03)00129-0
   Scafoglio C, 2006, J CELL BIOCHEM, V98, P1163, DOI 10.1002/jcb.20820
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Siomi MC, 2011, NAT REV MOL CELL BIO, V12, P246, DOI 10.1038/nrm3089
   Suzuki Ryusuke, 2012, Frontiers in Genetics, V3, P204, DOI 10.3389/fgene.2012.00204
NR 30
TC 126
Z9 142
U1 4
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD OCT 30
PY 2014
VL 5
IS 20
BP 9901
EP 9910
DI 10.18632/oncotarget.2476
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AZ2AH
UT WOS:000348036500030
PM 25313140
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Minning, C
   Mokhtar, NM
   Abdullah, N
   Muhammad, R
   Emran, NA
   Ali, SAM
   Harun, R
   Jamal, R
AF Minning, Chin
   Mokhtar, Norfilza Mohd
   Abdullah, Norlia
   Muhammad, Rohaizak
   Emran, Nor Aina
   Ali, Siti Aishah Md
   Harun, Roslan
   Jamal, Rahman
TI Exploring breast carcinogenesis through integrative genomics and
   epigenomics analyses
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE epigenetics; DNA methylation; gene expression; breast cancer;
   microarray; CpG islands
ID ABERRANT PROMOTER METHYLATION; GENE-EXPRESSION SIGNATURES; PROTEIN
   HDAB2IP GENE; DNA METHYLATION; CANCER; HYPERMETHYLATION; COMMON;
   EPIGENETICS; BIOMARKERS; CHROMATIN
AB There have been many DNA methylation studies on breast cancer which showed various methylation patterns involving tumour suppressor genes and oncogenes but only a few of those studies link the methylation data with gene expression. More data are required especially from the Asian region and to analyse how the epigenome data correlate with the transcriptome. DNA methylation profiling was carried out on 76 fresh frozen primary breast tumour tissues and 25 adjacent non-cancerous breast tissues using the Illumina Infinium HumanMethylation27 Bead Chip. Validation of methylation results was performed on 7 genes using either MS-MLPA or MS-qPCR. Gene expression profiling was done on 15 breast tumours and 5 adjacent non-cancerous breast tissues using the Affymetrix Gene Chip Human Gene 1.0 ST array. The overlapping genes between DNA methylation and gene expression datasets were further mapped to the KEGG database to identify the molecular pathways that linked these genes together. Supervised hierarchical cluster analysis revealed 1,389 hypermethylated CpG sites and 22 hypomethylated CpG sites in cancer compared to the normal samples. Gene expression microarray analysis using a fold-change of at least 1.5 and a false discovery rate (FDR) at P>0.05 identified 404 upregulated and 463 downregulated genes in cancer samples. Integration of both datasets identified 51 genes with hypermethylation with low expression (negative association) and 13 genes with hypermethylation with high expression (positive association). Most of the overlapping genes belong to the focal adhesion and extracellular matrix-receptor interaction that play important roles in breast carcinogenesis. The present study displayed the value of using multiple datasets in the same set of tissues and how the integrative analysis can create a list of well-focused genes as well as to show the correlation between epigenetic changes and gene expression. These gene signatures can help us understand the epigenetic regulation of gene expression and could be potential targets for therapeutic intervention in the future.
C1 [Minning, Chin; Mokhtar, Norfilza Mohd; Jamal, Rahman] Univ Kebangsaan Malaysia, UKM Med Mol Biol Inst, Kuala Lumpur, Malaysia.
   [Mokhtar, Norfilza Mohd] Univ Kebangsaan Malaysia, Fac Med, Dept Physiol, Kuala Lumpur, Malaysia.
   [Abdullah, Norlia; Muhammad, Rohaizak] Univ Kebangsaan Malaysia, Fac Med, Dept Surg, Kuala Lumpur, Malaysia.
   [Ali, Siti Aishah Md] Univ Kebangsaan Malaysia, Fac Med, Dept Pathol, Kuala Lumpur, Malaysia.
   [Harun, Roslan] Univ Kebangsaan Malaysia, Fac Med, Dept Med, Kuala Lumpur, Malaysia.
   [Emran, Nor Aina] Hosp Kuala Lumpur, Dept Surg, Kuala Lumpur, Malaysia.
C3 Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia;
   Universiti Kebangsaan Malaysia; Universiti Kebangsaan Malaysia;
   Universiti Kebangsaan Malaysia
RP Jamal, R (通讯作者)，Univ Kebangsaan Malaysia, UKM Med Mol Biol Inst, Kuala Lumpur, Malaysia.
EM norfilza@ppukm.ukm.edu.my; rahmanj@ppukm.ukm.edu.my
RI Muhammad, Rohaizak/F-6199-2015; Mokhtar, Norfilza/AAK-8196-2020
OI Mokhtar, Norfilza/0000-0002-4863-100X
FU Ministry of Science, Technology and Innovation [07-05-MGI-GMB016]
FX The present study was funded by grant from the Ministry of Science,
   Technology and Innovation (07-05-MGI-GMB016).
CR Beisel C, 2011, NAT REV GENET, V12, P123, DOI 10.1038/nrg2932
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bibikova M, 2009, EPIGENOMICS-UK, V1, P177, DOI 10.2217/EPI.09.14
   Bièche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301
   Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26
   Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8
   Bubnov V., 2012, Experimental Oncology, V34, P370
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Cao XC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056735
   Clark MB, 2012, GENOME RES, V22, P885, DOI 10.1101/gr.131037.111
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Costa FF, 2006, CANCER GENET CYTOGEN, V165, P135, DOI 10.1016/j.cancergencyto.2005.07.023
   Dahl E, 2005, Verh Dtsch Ges Pathol, V89, P169
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   Dohi O, 2010, INT J ONCOL, V36, P85, DOI 10.3892/ijo_00000478
   Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Evron E, 2001, CANCER RES, V61, P2782
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007
   GARVER RI, 1994, CANCER, V74, P1584, DOI 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514>3.0.CO;2-V
   Goyal J, 1998, CANCER RES, V58, P4782
   Henderson DJ, 2006, TRENDS CARDIOVAS MED, V16, P38, DOI 10.1016/j.tcm.2005.11.005
   Heyn H, 2013, CARCINOGENESIS, V34, P102, DOI 10.1093/carcin/bgs321
   Hoang BH, 2004, CANCER RES, V64, P2734, DOI 10.1158/0008-5472.CAN-03-1952
   Huang HE, 2004, CANCER RES, V64, P6840, DOI 10.1158/0008-5472.CAN-04-1762
   Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000
   Jeschke J, 2012, EPIGENETICS-US, V7, P701, DOI 10.4161/epi.20445
   Jimenez-Useche I, 2012, BIOPHYS J, V103, P2502, DOI 10.1016/j.bpj.2012.11.012
   Jones PA, 2005, SEMIN HEMATOL, V42, pS3, DOI 10.1053/j.seminhematol.2005.05.001
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kim MS, 2012, ONCOL REP, V27, P1681, DOI 10.3892/or.2012.1691
   Kioulafa M, 2009, ANN ONCOL, V20, P1020, DOI 10.1093/annonc/mdn733
   Ko CD, 2003, CLIN EXP METASTAS, V20, P593, DOI 10.1023/A:1027323210736
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892
   Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34
   Lo Nigro C, 2012, BRIT J CANCER, V107, P75, DOI 10.1038/bjc.2012.212
   Lo PK, 2006, CANCER BIOL THER, V5, P281, DOI 10.4161/cbt.5.3.2384
   Loss LA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-305
   Mascolo M, 2012, INT J MOL SCI, V13, P2331, DOI 10.3390/ijms13022331
   Mazouni C, 2008, BRIT J CANCER, V99, P68, DOI 10.1038/sj.bjc.6604443
   Mokhtar NM, 2012, CANCER INVEST, V30, P156, DOI 10.3109/07357907.2011.633290
   Novak P, 2008, CANCER RES, V68, P8616, DOI 10.1158/0008-5472.CAN-08-1419
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Perez-Pinera P, 2007, BIOCHEM BIOPH RES CO, V362, P5, DOI 10.1016/j.bbrc.2007.06.050
   Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561
   Rhodes DR, 2009, P NATL ACAD SCI USA, V106, P10284, DOI 10.1073/pnas.0900351106
   Ross DT, 2001, DIS MARKERS, V17, P99, DOI 10.1155/2001/850531
   Sengupta PK, 2003, CANCER RES, V63, P1789
   Sidiropoulos M, 2005, TUMOR BIOL, V26, P324, DOI 10.1159/000089290
   Stein T, 2010, AM J PATHOL, V177, P2323, DOI 10.2353/ajpath.2010.100209
   Summers KM, 2009, GENOMICS, V94, P233, DOI 10.1016/j.ygeno.2009.06.005
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2151
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106
   Yang Binh H, 2004, Asian Pac J Cancer Prev, V5, P96
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Zhang J, 2007, BIOCHEM BIOPH RES CO, V352, P6, DOI 10.1016/j.bbrc.2006.10.141
   Zhang XJ, 2012, J GASTROEN HEPATOL, V27, P1117, DOI 10.1111/j.1440-1746.2011.07049.x
   Zhang XP, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0053995, 10.1371/journal.pone.0057805, 10.1371/journal.pone.0053931]
   Zheng J, 2010, ASIAN PAC J CANCER P, V11, P1817
NR 67
TC 4
Z9 4
U1 1
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD NOV
PY 2014
VL 45
IS 5
BP 1959
EP 1968
DI 10.3892/ijo.2014.2625
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AQ3SN
UT WOS:000342713900020
PM 25175708
OA Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Yeh, CM
   Shay, J
   Zeng, TC
   Chou, JL
   Huang, THM
   Lai, HC
   Chan, MWY
AF Yeh, Chia-Ming
   Shay, Jacqueline
   Zeng, Ting-Chuan
   Chou, Jian-Liang
   Huang, Tim H. -M.
   Lai, Hung-Cheng
   Chan, Michael W. Y.
TI Epigenetic silencing of <i>ARNTL</i>, a circadian gene and potential
   tumor suppressor in ovarian cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE ovarian cancer; epigenetic modifications; ARNTL; circadian clock; tumor
   suppressor
ID GROUP PROTEIN EZH2; CELL LUNG-CANCER; BREAST-CANCER; DNA METHYLATION;
   SHIFT-WORK; CLOCKS; RISK; HYPERMETHYLATION; TRANSCRIPTION; PROGRESSION
AB Ovarian cancer is the fifth leading cause of cancer death and the most deadly gynecological malignancy in women. Epigenetic modifications play an important role in regulating gene transcription. Specifically, aberrant promoter hypermethylation has been implicated as a hallmark of cancer. In order to identify genes that are differentially methylated in ovarian cancer, we performed meDIP-chip in various ovarian cancer cell lines using Agilent 244K CpG island microarray. One of the targets, ARNTL which is a core component of the circadian clock is methylated in a sub-set of ovarian cancer cell lines. Combined bisulfite restriction analysis (COBRA) confirmed the results of the microarray. Additional analysis using ChIP-PCR revealed that promoter of ARNTL is enriched with the repressive histone mark H3K27me3 in CP70 and MCP2 ovarian cancer cells. Treatment with the EZH2 inhibitor (GSK126) significantly restored ARNTL expression in these cells (CP70 and MCP2). Further functional analysis demonstrated that overexpression of ARNTL inhibited cell growth and enhanced chemosensitivity of cisplatin in ovarian cancer cells. Finally, overexpression of ARNTL restored the rhythmic activity of c-MYC in ovarian cancer cells. These results suggested that ARNTL may be a tumor suppressor and is epigenetically silenced in ovarian cancer.
C1 [Yeh, Chia-Ming; Shay, Jacqueline; Zeng, Ting-Chuan; Chou, Jian-Liang; Chan, Michael W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Min Hsiung 621, Chia Yi, Taiwan.
   [Yeh, Chia-Ming; Shay, Jacqueline; Zeng, Ting-Chuan; Chan, Michael W. Y.] Natl Chung Cheng Univ, Inst Mol Biol, Min Hsiung 621, Chia Yi, Taiwan.
   [Huang, Tim H. -M.] Univ Texas Hlth Sci Ctr San Antonio, Inst Biotechnol, Dept Mol Med, San Antonio, TX 78229 USA.
   [Lai, Hung-Cheng] Triserv Gen Hosp, Natl Def Med Ctr, Dept Obstet & Gynecol, Taipei, Taiwan.
   [Lai, Hung-Cheng] Taipei Med Univ, Shuang Ho Hosp, Dept Obstet & Gynecol, New Taipei City, Taiwan.
   [Lai, Hung-Cheng] Taipei Med Univ, Sch Med, Taipei, Taiwan.
C3 National Chung Cheng University; National Chung Cheng University;
   University of Texas System; University of Texas Health Science Center at
   San Antonio; Tri-Service General Hospital; National Defense Medical
   Center; Taipei Medical University; Taipei Medical University
RP Chan, MWY (通讯作者)，Natl Chung Cheng Univ, Dept Life Sci, Room 452,168 Univ Rd, Min Hsiung 621, Chia Yi, Taiwan.
EM biowyc@ccu.edu.tw
RI Lai, Hung/F-6426-2012; 周, 建良/HLV-8728-2023; Chan, Michael/F-9615-2018
OI Chan, Michael/0000-0003-0314-2437; Chan, Michael/0000-0003-1431-322X
FU National Science Council, Taiwan [NSC102-2320-B-194-006]; NCCU
   Interdisciplinary Science grant, National Chung Cheng University, Taiwan
   [103-03]
FX The present study was supported by the research grants from the National
   Science Council, Taiwan (NSC102-2320-B-194-006) and the NCCU
   Interdisciplinary Science grant (103-03), National Chung Cheng
   University, Taiwan.
CR Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Canaple L, 2003, CANCER RES, V63, P7545
   Caslini C, 2006, ONCOGENE, V25, P5446, DOI 10.1038/sj.onc.1209533
   Chan M, 2008, NEOPLASIA, V10, P908, DOI 10.1593/neo.08540
   Chan MWY, 2005, CLIN CANCER RES, V11, P7376, DOI 10.1158/1078-0432.CCR-05-1100
   Chou JL, 2010, LAB INVEST, V90, P414, DOI 10.1038/labinvest.2009.138
   Falcón J, 1999, PROG NEUROBIOL, V58, P121, DOI 10.1016/S0301-0082(98)00078-1
   Fu LN, 2003, NAT REV CANCER, V3, P350, DOI 10.1038/nrc1072
   Fu LN, 2002, CELL, V111, P1055, DOI 10.1016/S0092-8674(02)01223-0
   Gery S, 2007, CLIN CANCER RES, V13, P1399, DOI 10.1158/1078-0432.CCR-06-1730
   Gery S, 2010, CELL CYCLE, V9, P1097, DOI 10.4161/cc.9.6.11046
   Gillan L, 2002, CANCER RES, V62, P5358
   Green CB, 2003, SCIENCE, V301, P319, DOI 10.1126/science.1087824
   Hansen J, 2006, CANCER CAUSE CONTROL, V17, P531, DOI 10.1007/s10552-005-9006-5
   Harrington ME, 2012, J PHYSIOL-LONDON, V590, P5929, DOI 10.1113/jphysiol.2012.245308
   Hoffman AE, 2008, MOL CANCER RES, V6, P1461, DOI 10.1158/1541-7786.MCR-07-2094
   Hsu CM, 2012, TUMOR BIOL, V33, P149, DOI 10.1007/s13277-011-0258-2
   Hunt T, 2007, CELL, V129, P461, DOI 10.1016/j.cell.2007.04.015
   Jung CH, 2013, ONCOL REP, V29, P2109, DOI 10.3892/or.2013.2381
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Leonardi GC, 2012, ONCOL REP, V28, P418, DOI 10.3892/or.2012.1839
   Levin RD, 2005, BRIT J CANCER, V93, P1202, DOI 10.1038/sj.bjc.6602859
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Mullenders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004798
   Paschos GK, 2010, CIRC RES, V106, P833, DOI 10.1161/CIRCRESAHA.109.211706
   Rana Sobia, 2010, J Circadian Rhythms, V8, P3, DOI 10.1186/1740-3391-8-3
   Ripperger JRA, 2006, NAT GENET, V38, P369, DOI 10.1038/ng1738
   Schernhammer ES, 2003, JNCI-J NATL CANCER I, V95, P825, DOI 10.1093/jnci/95.11.825
   Seisenberger S, 2013, CURR OPIN CELL BIOL, V25, P281, DOI 10.1016/j.ceb.2013.02.013
   Sellix MT, 2010, TRENDS ENDOCRIN MET, V21, P628, DOI 10.1016/j.tem.2010.06.002
   Shih MC, 2006, MOL CARCINOGEN, V45, P732, DOI 10.1002/mc.20198
   Stevens RG, 2001, CANCER CAUSE CONTROL, V12, P279, DOI 10.1023/A:1011237000609
   Su HY, 2009, INT J CANCER, V124, P387, DOI 10.1002/ijc.23957
   Takahashi JS, 2008, NAT REV GENET, V9, P764, DOI 10.1038/nrg2430
   Taniguchi H, 2009, CANCER RES, V69, P8447, DOI 10.1158/0008-5472.CAN-09-0551
   Tokunaga H, 2008, ACTA OBSTET GYN SCAN, V87, P1060, DOI 10.1080/00016340802348286
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Yang MY, 2006, CANCER SCI, V97, P1298, DOI 10.1111/j.1349-7006.2006.00331.x
   Yeh KT, 2011, EPIGENETICS-US, V6, P727, DOI 10.4161/epi.6.6.15856
   Yu EA, 2011, AGING-US, V3, P479, DOI 10.18632/aging.100323
   Yu YH, 2003, ANN NY ACAD SCI, V983, P268, DOI 10.1111/j.1749-6632.2003.tb05981.x
NR 42
TC 55
Z9 60
U1 1
U2 11
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD NOV
PY 2014
VL 45
IS 5
BP 2101
EP 2107
DI 10.3892/ijo.2014.2627
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AQ3SN
UT WOS:000342713900036
PM 25175925
OA Bronze
DA 2025-01-12
ER

PT J
AU Jiao, YM
   Widschwendter, M
   Teschendorff, AE
AF Jiao, Yinming
   Widschwendter, Martin
   Teschendorff, Andrew E.
TI A systems-level integrative framework for genome-wide DNA methylation
   and gene expression data identifies differential gene expression modules
   under epigenetic control
SO BIOINFORMATICS
LA English
DT Article
ID ENDOTHELIAL-CELLS; BREAST-CANCER; BLOOD; CLASSIFICATION; VALIDATION;
   CARCINOMA; DISEASES
AB Motivation: There is a growing number of studies generating matched Illumina Infinium HumanMethylation450 and gene expression data, yet there is a corresponding shortage of statistical tools aimed at their integrative analysis. Such integrative tools are important for the discovery of epigenetically regulated gene modules or molecular pathways, which play key roles in cellular differentiation and disease.
   Results: Here, we present a novel functional supervised algorithm, called Functional Epigenetic Modules (FEM), for the integrative analysis of Infinium 450k DNA methylation and matched or unmatched gene expression data. The algorithm identifies gene modules of coordinated differential methylation and differential expression in the context of a human interactome. We validate the FEM algorithm on simulated and real data, demonstrating how it successfully retrieves an epigenetically deregulated gene, previously known to drive endometrial cancer development. Importantly, in the same cancer, FEM identified a novel epigenetically deregulated hotspot, directly upstream of the well-known progesterone receptor tumour suppressor pathway. In the context of cellular differentiation, FEM successfully identifies known endothelial cell subtype-specific gene expression markers, as well as a novel gene module whose overexpression in blood endothelial cells is mediated by DNA hypomethylation. The systems-level integrative framework presented here could be used to identify novel key genes or signalling pathways, which drive cellular differentiation or disease through an underlying epigenetic mechanism.
C1 [Jiao, Yinming; Teschendorff, Andrew E.] Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai 200031, Peoples R China.
   [Widschwendter, Martin] UCL, UCL Elizabeth Garrett Anderson Inst Womens Hlth, Dept Womens Canc, London WC1E 6BT, England.
   [Teschendorff, Andrew E.] UCL, UCL Canc Inst, Stat Genom Grp, London WC1E 6BT, England.
C3 Max Planck Society; Chinese Academy of Sciences; University of London;
   University College London; University of London; University College
   London
RP Teschendorff, AE (通讯作者)，Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, Shanghai 200031, Peoples R China.
EM andrew@picb.ac.cn
RI Teschendorff, Andrew/AFP-1816-2022
OI Widschwendter, Martin/0000-0002-7778-8380
FU Chinese Academy of Sciences; Shanghai Institute for Biological Sciences;
   Max-Planck Gesellschaft
FX Funding: Y.J. and A.E.T. acknowledge support from the Chinese Academy of
   Sciences, the Shanghai Institute for Biological Sciences and the
   Max-Planck Gesellschaft.
CR Aghajanova L, 2009, ENDOCRINOLOGY, V150, P3863, DOI 10.1210/en.2009-0008
   Amatschek S, 2007, BLOOD, V109, P4777, DOI 10.1182/blood-2006-10-053280
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Brönneke S, 2012, ANGIOGENESIS, V15, P317, DOI 10.1007/s10456-012-9264-2
   Cerami EG, 2011, NUCLEIC ACIDS RES, V39, pD685, DOI 10.1093/nar/gkq1039
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Chuang HY, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100180
   Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jones A, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001551
   Lechner M, 2013, GENOME MED, V5, DOI 10.1186/gm419
   Nelson GM, 2007, NEOPLASIA, V9, P1038, DOI 10.1593/neo.07643
   Petronis A, 2010, NATURE, V465, P721, DOI 10.1038/nature09230
   Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000
   Reichardt J, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.016110
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Teschendorff AE, 2012, GENOME MED, V4, DOI 10.1186/gm323
   West J, 2013, SCI REP-UK, V3, DOI 10.1038/srep01630
   Zhuang J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-59
   Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433
NR 22
TC 120
Z9 128
U1 1
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1367-4803
EI 1460-2059
J9 BIOINFORMATICS
JI Bioinformatics
PD AUG 15
PY 2014
VL 30
IS 16
BP 2360
EP 2366
DI 10.1093/bioinformatics/btu316
PG 7
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
   Computer Science, Interdisciplinary Applications; Mathematical &
   Computational Biology; Statistics & Probability
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Computer Science; Mathematical & Computational Biology; Mathematics
GA AQ4EM
UT WOS:000342746000016
PM 24794928
OA Bronze
DA 2025-01-12
ER

PT J
AU Wang, D
   Yang, PN
   Chen, J
   Zhou, XY
   Liu, QJ
   Li, HJ
   Li, CL
AF Wang, Da
   Yang, Peng-Na
   Chen, Jin
   Zhou, Xian-Yao
   Liu, Qiu-Jun
   Li, Hong-Jiang
   Li, Chang-Long
TI Promoter hypermethylation may be an important mechanism of the
   transcriptional inactivation of <i>ARRDC3</i>, <i>GATA5,</i> and
   <i>ELP3</i> in invasive ductal breast carcinoma
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Invasive ductal breast carcinoma; Tumor suppressor gene; Promoter
   hypermethylation; mRNA expression; Transcriptional inactivation
ID ELONGATOR COMPLEX; DNA HYPERMETHYLATION; ABERRANT METHYLATION; CPG
   ISLANDS; PAX GENES; IN-SITU; CANCER; EPIGENETICS; PROGRESSION;
   BIOMARKERS
AB Hypermethylation of promoter CpG islands represents an alternative mechanism to inactivate tumor suppressor genes. This study was to detect promoter methylation status and mRNA expression levels of ARRDC3, ELP3, GATA5, and PAX6, and to explore the association between methylation and expression in invasive ductal carcinomas (IDCs) and matched normal tissues (MNTs) from breast cancer patients. Aberrant gene methylation was observed as follows: ARRDC3 in 38.5 %, ELP3 in 73.1 %, GATA5 in 48.1 %, and PAX6 in 50.0 % of IDCs. mRNA expression of ARRDC3, ELP3, and GATA5 in IDCs showed a lower level than that in MNTs (P < 0.001, P = 0.001 and P < 0.001, respectively). For ARRDC3, both methylated and unmethylated IDCs showed significantly lower expression values compared to MNTs (P = 0.001 and P = 0.007, respectively). For ELP3 and GATA5, methylated tumors only showed significantly lower expression values compared to MNTs (P = 0.001 and P < 0.001, respectively). For ARRDC3 and GATA5, methylation was associated with their less fold change in IDCs (P = 0.049 and P = 0.020, respectively). Methylation of ARRDC3 was significantly associated with grades and lymph node status of IDCs (P = 0.036 and P = 0.002, respectively). Methylation frequency of ELP3 was higher in lymph node positive versus lymph node negative tumors (P = 0.020); whereas methylation frequency of PAX6 was lower in tumors with the ER negative samples (P = 0.025). Our data suggested that promoter hypermethylation may be an important mechanism of the transcriptional inactivation of ARRDC3, GATA5, and ELP3 in IDCs.
C1 [Wang, Da; Chen, Jin; Zhou, Xian-Yao; Liu, Qiu-Jun; Li, Chang-Long] Sichuan Univ, Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu 610041, Sichuan, Peoples R China.
   [Yang, Peng-Na] Sichuan Univ, Key Lab Bioresources & Ecoenvironm, Coll Life Sci, Minist Educ, Chengdu 610065, Sichuan, Peoples R China.
   [Li, Hong-Jiang] Sichuan Univ, Dept Thyroid & Breast Surg, West China Hosp, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Li, CL (通讯作者)，Sichuan Univ, Sch Preclin & Forens Med, Dept Biochem & Mol Biol, 3-17 Renmin South Rd, Chengdu 610041, Sichuan, Peoples R China.
EM 494209395@qq.com; changlongli@scu.edu.cn
RI Hongjiang, Li/AAV-3060-2021
FU National Natural Science Foundation of China [81070452]; National
   Research Foundation for Doctoral Program of Higher Education of China
   [20090181110048]
FX This study was supported by National Natural Science Foundation of
   China; Grant number: 81070452, National Research Foundation for Doctoral
   Program of Higher Education of China, Grant number: 20090181110048.
CR Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Agundez M, 2011, EUR UROL, V60, P131, DOI 10.1016/j.eururo.2011.04.020
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Belinsky SA, 2007, BRIT J CANCER, V96, P1278, DOI 10.1038/sj.bjc.6603721
   Bennett LB, 2009, GENE CHROMOSOME CANC, V48, P828, DOI 10.1002/gcc.20687
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307
   Chen BH, 2012, BIOCHEM J, V446, P89, DOI 10.1042/BJ20111942
   Chen WQ, 2012, CHINESE J CANCER RES, V24, P1, DOI 10.1007/s11670-012-0001-6
   Chmelarová M, 2012, FOLIA BIOL-PRAGUE, V58, P246
   Close P, 2006, MOL CELL, V22, P521, DOI 10.1016/j.molcel.2006.04.017
   Cosialls AM, 2012, EPIGENOMICS-UK, V4, P491, DOI [10.2217/EPI.12.40, 10.2217/epi.12.40]
   Draheim KM, 2010, ONCOGENE, V29, P5032, DOI 10.1038/onc.2010.250
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Furuta J, 2006, CANCER RES, V66, P6080, DOI 10.1158/0008-5472.CAN-06-0157
   Gao J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020954
   Gyobu K, 2011, ANN SURG ONCOL, V18, P1185, DOI 10.1245/s10434-010-1393-5
   Harris J., 2000, DIS BREAST
   Hellebrekers DMEI, 2009, CLIN CANCER RES, V15, P3990, DOI 10.1158/1078-0432.CCR-09-0055
   Hellwinkel OJC, 2008, BJU INT, V101, P753, DOI 10.1111/j.1464-410X.2007.07322.x
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Huang B, 2005, RNA, V11, P424, DOI 10.1261/rna.7247705
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lamy A, 2002, INT J CANCER, V100, P189, DOI 10.1002/ijc.10474
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Levenson VV, 2007, BBA-GEN SUBJECTS, V1770, P847, DOI 10.1016/j.bbagen.2007.01.017
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li Q, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000684
   Lyon CM, 2007, RADIAT RES, V168, P409, DOI 10.1667/RR0825.1
   Mishra DK, 2010, MOL CANCER THER, V9, P33, DOI 10.1158/1535-7163.MCT-09-0486
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Nabhan JF, 2010, EMBO REP, V11, P605, DOI 10.1038/embor.2010.80
   Okada Y, 2010, NATURE, V463, P554, DOI 10.1038/nature08732
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Patwari P, 2012, TRENDS ENDOCRIN MET, V23, P216, DOI 10.1016/j.tem.2012.03.003
   Patwari P, 2011, CELL METAB, V14, P671, DOI 10.1016/j.cmet.2011.08.011
   Peng ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036891
   Peters I, 2011, EUR UROL SUPPL, V10, P106, DOI 10.1016/S1569-9056(11)60273-X
   Rafiq S, 2013, CANCER RES, V73, P1883, DOI 10.1158/0008-5472.CAN-12-3377
   Robson EJD, 2006, NAT REV CANCER, V6, P52, DOI 10.1038/nrc1778
   Singh MK, 2010, J BIOL CHEM, V285, P1765, DOI 10.1074/jbc.M109.038539
   Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039-6109(03)00034-3
   Soung YH, 2014, SCI REP-UK, V4, DOI 10.1038/srep03846
   STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9
   Svejstrup JQ, 2007, CURR OPIN CELL BIOL, V19, P331, DOI 10.1016/j.ceb.2007.04.005
   Yao DM, 2012, CLIN CHIM ACTA, V413, P787, DOI 10.1016/j.cca.2012.01.013
NR 48
TC 22
Z9 28
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD NOV
PY 2014
VL 396
IS 1-2
BP 67
EP 77
DI 10.1007/s11010-014-2143-y
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AP9YL
UT WOS:000342437900008
PM 25148870
DA 2025-01-12
ER

PT J
AU Ghosh, S
   Gu, F
   Wang, CM
   Lin, CL
   Liu, J
   Wang, H
   Ravdin, P
   Hu, YF
   Huang, THM
   Li, R
AF Ghosh, Sagar
   Gu, Fei
   Wang, Chou-Miin
   Lin, Chun-Lin
   Liu, Joseph
   Wang, Howard
   Ravdin, Peter
   Hu, Yanfen
   Huang, Tim H. M.
   Li, Rong
TI Genome-wide DNA methylation profiling reveals parity-associated
   hypermethylation of <i>FOXA1</i>
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Parity; FOXA1; DNA methylation; Breast cancer risk reduction
ID BREAST-CANCER; PREGNANCY; ESTROGEN; RISK; BIRTH; AGE
AB Early pregnancy in women by the age of 20 is known to have a profound effect on reduction of lifelong breast cancer risk as compared to their nulliparous counterparts. Additional pregnancies further enhance the protection against breast cancer development. Nationwide trend of delayed pregnancy may contribute to the recently reported increase in the incidence of advanced breast cancer among young women in this country. The underlying mechanism for the parity-associated reduction of breast cancer risk is not clearly understood. The purpose of the current study is to use whole-genome DNA methylation profiling to explore a potential association between parity and epigenetic changes in breast tissue from women with early parity and nulliparity. Breast tissue was collected from age-matched cancer-free women with early parity (age < 20; n = 15) or nulliparity (n = 13). The methyl-CpG binding domain-based capture-sequencing technology was used for whole-genome DNA methylation profiling. Potential parity-associated hypermethylated genes were further verified by locus-specific pyrosequencing, using an expanded cohort of parous (n = 19) and nulliparous (n = 16) women that included the initial samples used in the global analysis. Our study identified six genes that are hypermethylated in the parous group (P < 0.05). Pyrosequencing confirmed parity-associated hypermethylation at multiple CpG islands of the FOXA1 gene, which encodes a pioneer factor that facilitates chromatin binding of estrogen receptor alpha. Our work identifies several potential methylation biomarkers for parity-associated breast cancer risk assessment. In addition, the results are consistent with the notion that parity-associated epigenetic silencing of FOXA1 contributes to long-term attenuation of the estrogenic impact on breast cancer development.
C1 [Ghosh, Sagar; Gu, Fei; Wang, Chou-Miin; Lin, Chun-Lin; Liu, Joseph; Hu, Yanfen; Huang, Tim H. M.; Li, Rong] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Mol Med, San Antonio, TX 78229 USA.
   [Wang, Howard; Ravdin, Peter] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Med, San Antonio, TX 78229 USA.
C3 Cancer Therapy & Research Center; University of Texas System; University
   of Texas Health Science Center at San Antonio; University of Texas
   System; University of Texas Health Science Center at San Antonio; Cancer
   Therapy & Research Center
RP Li, R (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Mol Med, San Antonio, TX 78229 USA.
EM lir3@uthscsa.edu
RI Lin, Chih-Cheng/IQT-4912-2023
OI Gu, Fei/0000-0002-7725-3909
FU NIH [CA161349, U54 CA113001, CA118578]; Department of Defense Breast
   Cancer Research grant [W81XWH-14-1-0129]; Cancer Therapy and Research
   Center at University of Texas Health Science Center at San Antonio
   [P30CA054174]
FX This work was supported by the NIH grants to R. L. (CA161349) and T. H.
   M. H (U54 CA113001), Y.H. (CA118578), and a Department of Defense Breast
   Cancer Research grant to R. L (W81XWH-14-1-0129). We also thank the
   generous support by the Cancer Therapy and Research Center at University
   of Texas Health Science Center at San Antonio (P30CA054174).
CR Albrektsen G, 2005, BRIT J CANCER, V92, P167, DOI 10.1038/sj.bjc.6602302
   Augello MA, 2011, EMBO J, V30, P3885, DOI 10.1038/emboj.2011.340
   Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279
   Bernardo GM, 2012, BIOSCIENCE REP, V32, P113, DOI 10.1042/BSR20110046
   Britt K, 2007, ENDOCR-RELAT CANCER, V14, P907, DOI 10.1677/ERC-07-0137
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Colditz GA, 2004, JNCI-J NATL CANCER I, V96, P218, DOI 10.1093/jnci/djh025
   Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416
   Deroo BJ, 2006, J CLIN INVEST, V116, P561, DOI 10.1172/JCI27987
   Haricharan S, 2013, ELIFE, V2, DOI 10.7554/eLife.00996
   Huang TT, 2013, CARCINOGENESIS, V34, P1717, DOI 10.1093/carcin/bgt112
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Johnson RH, 2013, JAMA-J AM MED ASSOC, V309, P2435, DOI 10.1001/jama.2013.6464
   Katoh M, 2013, CANCER LETT, V328, P198, DOI 10.1016/j.canlet.2012.09.017
   MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209
   Meier-Abt F, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3419
   Polyak K, 2006, CANCER CELL, V9, P151, DOI 10.1016/j.ccr.2006.02.026
   Russo J, 2005, BREAST CANCER RES, V7, P131, DOI 10.1186/bcr1029
   Russo J, 2006, EUR J CANCER PREV, V15, P306, DOI 10.1097/00008469-200608000-00006
   Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839
   Sivaraman L, 2002, J MAMMARY GLAND BIOL, V7, P77, DOI 10.1023/A:1015774524076
   Siwko SK, 2008, STEM CELLS, V26, P3205, DOI 10.1634/stemcells.2008-0103
   THORDARSON G, 1995, CARCINOGENESIS, V16, P2847, DOI 10.1093/carcin/16.11.2847
   van Agthoven T, 2009, J CLIN ONCOL, V27, P542, DOI 10.1200/JCO.2008.17.1462
   Watters RJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3146
   Wilson AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065678
NR 26
TC 24
Z9 32
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD OCT
PY 2014
VL 147
IS 3
BP 653
EP 659
DI 10.1007/s10549-014-3132-2
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP9XV
UT WOS:000342436200018
PM 25234841
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Lai, J
   Yang, F
   Zhang, WW
   Wang, YR
   Xu, J
   Song, W
   Huang, GC
   Gu, J
   Guan, XX
AF Lai, Jing
   Yang, Fang
   Zhang, Wenwen
   Wang, Yanru
   Xu, Jing
   Song, Wei
   Huang, Guichun
   Gu, Jun
   Guan, Xiaoxiang
TI TAp73 and ΔNp73 Have Opposing Roles in 5-aza-2′-Deoxycytidine-Induced
   Apoptosis in Breast Cancer Cells
SO MOLECULES AND CELLS
LA English
DT Article
DE 5-aza-2 '-deoxycytidine; breast cancer; methylation; p53; p73
ID P53 FAMILY-MEMBER; FEEDBACK LOOP; PROMOTER METHYLATION;
   MYELOID-LEUKEMIA; P73; EXPRESSION; GENE; DNA; DEATH; DIFFERENTIATION
AB The p73 gene contains an extrinsic P1 promoter and an intrinsic P2 promoter, controlling the transcription of the pro-apoptotic TAp73 isoform and the anti-apoptotic Delta Np73 isoform, respectively. The DNA methylation status of both promoters act equally in the epigenetic transcriptional regulation of their relevant isoforms. The aim of this study was to analyze the different effects of these p73 isoforms in 5-aza-2'-deoxycytidine (5-aza-dC)-induced apoptosis in breast cancer cells. We investigated the effects of the DNA demethylation agent, 5-aza-dC, on the T-47D breast cancer cell line, and evaluated the methylation status of the p73 promoters and expression of TAp73 and Delta Np73. Furthermore, we assessed the expression of p53 and p73 isoforms in 5-aza-dC-treated T-47D cells and p53 knockout cells. 5-aza-dC induced significant anti-tumor effects in T-47D cells, including inhibition of cell viability, G1 phase arrest and apoptosis. This was associated with p73 promoter demethylation and a concomitant increase in TAp73 mRNA and protein expression. In contrast, the methylation status of promoter P2 was not associated with Delta Np73 mRNA or protein levels. Furthermore, demethylation of P2 failed to inhibit the expression of Delta Np73 with 5-aza-dC in the p53 knockdown cell model. Our study suggests that demethylation of the P1 and P2 promoters has opposite effects on the expression of p73 isoforms, namely up-regulation of TAp73 and down-regulation of Delta Np73. We also demonstrate that p53 likely contributes to 5-aza-dC-induced Delta Np73 transcriptional inactivation in breast cancer cells.
C1 [Lai, Jing; Wang, Yanru; Song, Wei; Guan, Xiaoxiang] Southern Med Univ, Sch Med, Jinling Hosp, Dept Med Oncol, Guangzhou 510282, Guangdong, Peoples R China.
   [Yang, Fang; Zhang, Wenwen; Xu, Jing; Huang, Guichun; Guan, Xiaoxiang] Nanjing Univ, Jinling Hosp, Dept Med Oncol, Sch Med, Nanjing 210002, Jiangsu, Peoples R China.
   [Gu, Jun] Nanjing Univ, Jinling Hosp, Dept Gen Surg, Sch Med, Nanjing 210002, Jiangsu, Peoples R China.
C3 Southern Medical University - China; Nanjing University; Nanjing
   University
RP Gu, J (通讯作者)，Nanjing Univ, Jinling Hosp, Dept Gen Surg, Sch Med, Nanjing 210002, Jiangsu, Peoples R China.
EM jungunj@163.com; xguan@nju.edu.cn
RI Li, xiaolong/GRS-9148-2022; Wang, yanru/JAX-5241-2023
OI Guan, Xiaoxiang/0000-0001-6145-0046; Zhang, Wenwen/0000-0003-1285-3118
FU National Natural Science Foundation of China [81272252]; Foundation for
   Clinical Medicine Science and Technology Special Project of the Jiangsu
   Province, China [BL2014071]
FX This work was supported by grants from the National Natural Science
   Foundation of China (No. 81272252) and a Foundation for Clinical
   Medicine Science and Technology Special Project of the Jiangsu Province,
   China (No. BL2014071) (to X. G).
CR Daskalos A, 2011, CANCER LETT, V300, P79, DOI 10.1016/j.canlet.2010.09.009
   Gonzalez-Cano L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.224
   Gonzalez-Gomez P, 2004, INT J MOL MED, V13, P93
   Gore Steven D, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS30, DOI 10.1038/ncponc0346
   Griffiths EA, 2010, EPIGENETICS-US, V5, P590, DOI 10.4161/epi.5.7.12558
   Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962
   Han LL, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-52
   Hassler MR, 2012, BIOCHIMIE, V94, P2297, DOI 10.1016/j.biochi.2012.05.029
   Hatzimichael E, 2009, LEUKEMIA RES, V33, P1272, DOI 10.1016/j.leukres.2009.04.009
   HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098
   Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631
   Ishimoto O, 2002, CANCER RES, V62, P636
   Jha AK, 2012, MOL BIOL REP, V39, P9145, DOI 10.1007/s11033-012-1787-5
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584
   Kong WJ, 2005, LARYNGOSCOPE, V115, P1395, DOI 10.1097/01.MLG.0000166708.23673.3A
   Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861
   Moll UM, 2004, MOL CANCER RES, V2, P371
   Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914
   Nakagawa T, 2003, CANCER LETT, V197, P105, DOI 10.1016/S0304-3835(03)00090-9
   Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002
   Ozaki T, 2005, CANCER SCI, V96, P729, DOI 10.1111/j.1349-7006.2005.00116.x
   Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304
   Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Rossi M, 2004, ANN NY ACAD SCI, V1028, P143, DOI 10.1196/annals.1322.015
   Sahu GR, 2005, BIOCHEM BIOPH RES CO, V327, P750, DOI 10.1016/j.bbrc.2004.12.064
   Sato H, 2010, AM J PATHOL, V176, P402, DOI 10.2353/ajpath.2010.090236
   Schmelz K, 2005, INT J CANCER, V114, P683, DOI 10.1002/ijc.20797
   Schübeler D, 2000, MOL CELL BIOL, V20, P9103, DOI 10.1128/MCB.20.24.9103-9112.2000
   Stiewe T, 2002, CANCER RES, V62, P3598
   Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308
   Tophkhane C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043564
   Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630
   Ushiku T, 2007, INT J CANCER, V120, P60, DOI 10.1002/ijc.22275
   Willis AC, 2003, ONCOGENE, V22, P5481, DOI 10.1038/sj.onc.1206505
   Yu J, 2007, CELL DEATH DIFFER, V14, P436, DOI 10.1038/sj.cdd.4402029
NR 37
TC 11
Z9 13
U1 0
U2 8
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD AUG 31
PY 2014
VL 37
IS 8
BP 605
EP 612
DI 10.14348/molcells.2014.0154
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AQ1SO
UT WOS:000342561500006
PM 25134538
OA Green Submitted, hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Halvorsen, AR
   Helland, Å
   Fleischer, T
   Haug, KM
   Alnæs, GIG
   Nebdal, D
   Syljuåsen, RG
   Touleimat, N
   Busato, F
   Tost, J
   Sætersdal, AB
   Borresen-Dale, AL
   Kristensen, V
   Edvardsen, H
AF Halvorsen, Ann Rita
   Helland, Aslaug
   Fleischer, Thomas
   Haug, Karen Marie
   Alnaes, Grethe Irene Grenaker
   Nebdal, Daniel
   Syljuasen, Randi G.
   Touleimat, Nizar
   Busato, Florence
   Tost, Jorg
   Saetersdal, Anna B.
   Borresen-Dale, Anne-Lise
   Kristensen, Vessela
   Edvardsen, Hege
TI Differential DNA methylation analysis of breast cancer reveals the
   impact of immune signaling in radiation therapy
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE irradiation; immune response; methylation; breast cancer; dose dependent
ID IN-VIVO; KAPPA-B; ACTIVATION; PATHWAYS; CELLS; EXPRESSION; APOPTOSIS
AB Radiotherapy (RT) is a central treatment modality for breast cancer patients. The purpose of our study was to investigate the DNA methylation changes in tumors following RT, and to identify epigenetic markers predicting treatment outcome. Paired biopsies from patients with inoperable breast cancer were collected both before irradiation (n = 20) and after receiving 1024 Gray (Gy) (n = 19). DNA methylation analysis was performed by using Illumina Infinium 27K arrays. Fourteen genes were selected for technical validation by pyrosequencing. Eighty-two differentially methylated genes were identified in irradiated (n = 11) versus nonirradiated (n = 19) samples (false discovery rate, FDR = 1.1%). Methylation levels in pathways belonging to the immune system were most altered after RT. Based on methylation levels before irradiation, a panel of five genes (H2AFY, CTSA, LTC4S, IL5RA and RB1) were significantly associated with clinical response (p = 0.041). Furthermore, the degree of methylation changes for 2,516 probes correlated with the given radiation dose. Within the 2,516 probes, an enrichment for pathways involved in cellular immune response, proliferation and apoptosis was identified (FDR < 5%). Here, we observed clear differences in methylation levels induced by radiation, some associated with response to treatment. Our study adds knowledge on the molecular mechanisms behind radiation response.
C1 [Halvorsen, Ann Rita; Helland, Aslaug; Fleischer, Thomas; Haug, Karen Marie; Alnaes, Grethe Irene Grenaker; Nebdal, Daniel; Borresen-Dale, Anne-Lise; Kristensen, Vessela; Edvardsen, Hege] Oslo Univ Hosp, Inst Canc Res, Dept Genet, Oslo, Norway.
   [Helland, Aslaug; Saetersdal, Anna B.] Oslo Univ Hosp, Dept Oncol, Oslo, Norway.
   [Helland, Aslaug] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
   [Fleischer, Thomas; Alnaes, Grethe Irene Grenaker; Tost, Jorg; Borresen-Dale, Anne-Lise; Kristensen, Vessela; Edvardsen, Hege] Univ Oslo, KG Jebsen Ctr Breast Canc Res, Oslo, Norway.
   [Syljuasen, Randi G.] Oslo Univ Hosp, Inst Canc Res, Dept Radiat Biol, Oslo, Norway.
   [Touleimat, Nizar; Busato, Florence; Tost, Jorg] CEA, Inst Genom, Ctr Natl Genotypage, Lab Epigenet & Environm, Evry, France.
   [Kristensen, Vessela] Akershus Univ Hosp, Div Med, Dept Clin Mol Biol EpiGen, Lorenskog, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; University of Oslo; Universite Paris Saclay; CEA; University of
   Oslo
RP Helland, Å (通讯作者)，Oslo Univ Hosp, Inst Canc Res, Dept Genet, Oslo, Norway.
EM ahelland@medisin.uio.no
RI Busato, Fabio/LIC-8043-2024; Tost, Jorg/H-7129-2019; Helland,
   Aslaug/H-3910-2015; Fleischer, Thomas/T-8066-2017
OI Tost, Jorg/0000-0002-2683-0817; Helland, Aslaug/0000-0002-5520-0275;
   Fleischer, Thomas/0000-0003-0985-8460; Nebdal,
   Daniel/0000-0002-9526-1662
FU Stiftelsen Henrik Homans Minde; Eckbos Legat and Stiftelsen Kristian
   Gerhard Jebsen
FX Grant sponsors: Stiftelsen Henrik Homans Minde, Eckbos Legat and
   Stiftelsen Kristian Gerhard Jebsen
CR Anderson R E, 1976, Adv Immunol, V24, P215, DOI 10.1016/S0065-2776(08)60331-4
   [Anonymous], 2010, 83 ICRU
   Aypar U, 2010, MUTAT RES, V707, P24
   Bataller R, 2005, HEPATOLOGY, V41, P1046, DOI 10.1002/hep.20665
   Bourguignon MH, 2005, EUR J NUCL MED MOL I, V32, P229, DOI 10.1007/s00259-004-1730-7
   Campan Mihhaela, 2009, V507, P325, DOI 10.1007/978-1-59745-522-0_23
   Carnevale J, 2012, MOL CELL BIOL, V32, P900, DOI 10.1128/MCB.06286-11
   Chaudhry MA, 2012, DNA CELL BIOL, V31, P908, DOI 10.1089/dna.2011.1509
   Clinicaltrials, 2012, RES DAT
   Demaria S, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00095
   Deorukhkar A, 2010, BIOCHEM PHARMACOL, V80, P1904, DOI 10.1016/j.bcp.2010.06.039
   Duroudier NP, 2009, ALLERGY, V64, P823, DOI 10.1111/j.1398-9995.2009.02015.x
   Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Gujral JS, 2003, HEPATOLOGY, V38, P355, DOI 10.1053/jhep.2003.50341
   Helland Å, 2006, RADIOTHER ONCOL, V80, P230, DOI 10.1016/j.radonc.2006.07.007
   Illumina I, 2011, INF METH ASS
   Johnston CJ, 2011, INT J RADIAT BIOL, V87, P902, DOI 10.3109/09553002.2011.573439
   Kuhmann C, 2011, RADIOTHER ONCOL, V101, P116, DOI 10.1016/j.radonc.2011.05.048
   Li XF, 2012, J BIOL CHEM, V287, P23171, DOI 10.1074/jbc.M112.379412
   Liang K, 2003, MOL CANCER THER, V2, P1113
   Lu TP, 2010, INT J RADIAT ONCOL, V76, P212, DOI 10.1016/j.ijrobp.2009.08.015
   Luzhna L, 2010, BIOCHEM BIOPH RES CO, V392, P113, DOI 10.1016/j.bbrc.2009.12.093
   Ma SM, 2010, INT J RADIAT BIOL, V86, P517, DOI 10.3109/09553001003734592
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Radiation Therapy Oncology Group, 2013, RTOG EORTC LAT RAD M
   Raju U, 2000, INT J RADIAT BIOL, V76, P1045, DOI 10.1080/09553000050111514
   Seyrantepe V, 2008, CIRCULATION, V117, P1973, DOI 10.1161/CIRCULATIONAHA.107.733212
   SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320
   Stone HB, 2003, LANCET ONCOL, V4, P529, DOI 10.1016/S1470-2045(03)01191-4
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Tost J, 2010, MOL BIOTECHNOL, V44, P71, DOI 10.1007/s12033-009-9216-2
   Udayakumar T, 2010, SEMIN RADIAT ONCOL, V20, P258, DOI 10.1016/j.semradonc.2010.05.007
   Verbrugge I, 2012, CANCER RES, V72, P3163, DOI 10.1158/0008-5472.CAN-12-0210
   Wang Y, 2004, CANCER RES, V64, P6240, DOI 10.1158/0008-5472.CAN-04-0591
   Xu C, 2012, FEBS LETT, V586, P3920, DOI 10.1016/j.febslet.2012.09.030
   Zhao WL, 2007, RADIAT RES, V167, P581, DOI 10.1667/RR0814.1
   Zheng JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053711
   Zitvogel L, 2008, J CLIN INVEST, V118, P1991, DOI 10.1172/JCI35180
NR 40
TC 24
Z9 25
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 1
PY 2014
VL 135
IS 9
BP 2085
EP 2095
DI 10.1002/ijc.28862
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP3NU
UT WOS:000341983700014
PM 24658971
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Li, YS
   Li, SL
   Chen, J
   Shao, TT
   Jiang, CJ
   Wang, Y
   Chen, H
   Xu, J
   Li, X
AF Li, Yongsheng
   Li, Shengli
   Chen, Juan
   Shao, Tingting
   Jiang, Chunjie
   Wang, Yuan
   Chen, Hong
   Xu, Juan
   Li, Xia
TI Comparative epigenetic analyses reveal distinct patterns of oncogenic
   pathways activation in breast cancer subtypes
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID DNA METHYLATION; CELL-LINES; HISTONE MODIFICATIONS; CHROMATIN
   MODIFICATIONS; COMPREHENSIVE ANALYSIS; CPG-ISLANDS; EXPRESSION;
   POLYCOMB; GENES; BASAL
AB Breast cancer is a highly heterogeneous disease that is characterized by genetic and epigenetic aberrations; however, our knowledge of epigenetic alterations of breast cancer subtypes remains limited. Here, we portrayed and compared the alterations of six types of histone modifications and DNA methylation between two breast cancer subtypes, luminal and basal. Widespread subtype-specific epigenetic alterations were observed in both subtypes, which preferentially occurred within CpG islands (CGIs) and promoter regions. Specifically, aberrant DNA methylation was mostly located inside CGIs in luminal subtype, whereas in basal subtype it was principally located within CGI shores. Moreover, different types and combinatorial patterns of epigenetic alterations were found to occupy at promoter regions between these two subtypes. And these epigenetic alterations regulated corresponding gene expression in a synergetic way in both subtypes. Functional enrichment analysis highlighted that epigenetically dysregulated genes were significantly involved in the hallmarks of cancers, most of which were subtype specific. Even genes involved in the same hallmarks associated biological processes were affected by various types of epi-modifications in different subtypes. Finally, we revealed distinct patterns of oncogenic pathways activation in different subtypes and provided novel insights into subtype specific therapeutic opportunities. In addition, genes in the key signaling pathways were able to discriminate between disease phenotypes, and subtype-specific progression associated genes were identified. This study presents the aberrant epigenetic patterns of breast cancer subtypes at a genome-wide level, which will be a highly valuable resource for investigations at understanding epigenetic regulation of breast cancer subtypes.
C1 [Li, Yongsheng; Li, Shengli; Chen, Juan; Shao, Tingting; Jiang, Chunjie; Wang, Yuan; Chen, Hong; Xu, Juan; Li, Xia] Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
C3 Harbin Medical University
RP Xu, J (通讯作者)，Harbin Med Univ, Coll Bioinformat Sci & Technol, Harbin, Peoples R China.
EM xujuanbiocc@ems.hrbmu.edu.cn; lixia@hrbmu.edu.cn
RI Jiang, Chunjie/AAU-1775-2020; li, xia/HHZ-7468-2022
OI Juan, Chen/0000-0002-7959-335X; Li, Yongsheng/0000-0003-1914-0727;
   Jiang, Chunjie/0000-0002-3033-092X; Xu, Juan/0000-0002-3709-4165; Chen,
   Hong/0000-0001-8054-7417; Li, Shengli/0000-0001-5430-303X
FU National High Technology Research and Development Program of China (863
   Program) [2014AA021102]; National Program on Key Basic Research Project
   (973 Program) [2014CB910504]; National Natural Science Foundation of
   China [91129710, 61170154, 61203264]; China Postdoctoral Science
   Foundation [2012M520764]
FX This work was supported in part by the National High Technology Research
   and Development Program of China (863 Program, Grant Nos. 2014AA021102),
   the National Program on Key Basic Research Project (973 Program, Grant
   Nos. 2014CB910504), the National Natural Science Foundation of China
   (Grant Nos. 91129710, 61170154 and 61203264), and China Postdoctoral
   Science Foundation (2012M520764).
CR Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Akalin A, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R87, 10.1186/gb-2012-13-10-r87]
   Akalin A, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002781
   Andrews JL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3065
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bayani J, 2007, SEMIN CANCER BIOL, V17, P5, DOI 10.1016/j.semcancer.2006.10.006
   Beardsley DI, 2003, EXP CELL RES, V290, P402, DOI 10.1016/S0014-4827(03)00353-7
   Bediaga NG, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2721
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Charafe-Jauffret E, 2006, ONCOGENE, V25, P2273, DOI 10.1038/sj.onc.1209254
   Cheung M, 2013, CURR CANCER DRUG TAR, V13, P234, DOI 10.2174/1568009611313030002
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dai W, 2013, CLIN CANCER RES, V19, P5788, DOI 10.1158/1078-0432.CCR-13-1217
   Deaton AM, 2011, GENOME RES, V21, P1074, DOI 10.1101/gr.118703.110
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dessau Ram Benny, 2008, Ugeskr Laeger, V170, P328
   Dreszer TR, 2012, NUCLEIC ACIDS RES, V40, pD918, DOI 10.1093/nar/gkr1055
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Falahi F, 2013, MOL CANCER RES, V11, P1029, DOI 10.1158/1541-7786.MCR-12-0567
   Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Karlic R, 2010, P NATL ACAD SCI USA, V107, P2926, DOI 10.1073/pnas.0909344107
   Kim M, 2014, HUM MOL GENET, V23, P657, DOI 10.1093/hmg/ddt453
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li YS, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt1054
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Ling LJ, 2010, CANCER BIOL THER, V10, P1115, DOI 10.4161/cbt.10.11.13431
   Mungamuri SK, 2013, CELL REP, V5, P302, DOI 10.1016/j.celrep.2013.09.009
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Plaisier CL, 2012, GENOME RES, V22, P2302, DOI 10.1101/gr.133991.111
   Polyak Kornelia, 2012, Cancer Cell, V22, P562, DOI 10.1016/j.ccr.2012.06.021
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173
   Sircoulomb F, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-539
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Sun ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017490
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Takai D, 2002, P NATL ACAD SCI USA, V99, P3740, DOI 10.1073/pnas.052410099
   Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wistuba II, 1998, CLIN CANCER RES, V4, P2931
   Xu H, 2008, BIOINFORMATICS, V24, P2344, DOI 10.1093/bioinformatics/btn402
   Yu H, 2008, GENOME RES, V18, P1314, DOI 10.1101/gr.073080.107
   Zaman N, 2013, CELL REP, V5, P216, DOI 10.1016/j.celrep.2013.08.028
   Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5
   Zhou VW, 2011, NAT REV GENET, V12, P7, DOI 10.1038/nrg2905
NR 69
TC 24
Z9 25
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2014
VL 23
IS 20
BP 5378
EP 5393
DI 10.1093/hmg/ddu256
PG 16
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AQ9UO
UT WOS:000343202400007
PM 24871326
OA Bronze
DA 2025-01-12
ER

PT J
AU Bjaanæs, MM
   Halvorsen, AR
   Solberg, S
   Jorgensen, L
   Dragani, TA
   Galvan, A
   Colombo, F
   Anderlini, M
   Pastorino, U
   Kure, E
   Rresen-Dale, ALB
   Brustugun, OT
   Helland, Å
AF Bjaanaes, Maria Moksnes
   Halvorsen, Ann Rita
   Solberg, Steinar
   Jorgensen, Lars
   Dragani, Tommaso A.
   Galvan, Antonella
   Colombo, Francesca
   Anderlini, Marco
   Pastorino, Ugo
   Kure, Elin
   Rresen-Dale, Anne-Lise B.
   Brustugun, Odd Terje
   Helland, Aslaug
TI Unique microRNA-profiles in <i>EGFR</i>-mutated lung adenocarcinomas
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE microRNA; lung cancer; EGFR; survival; KRAS
ID GENE-EXPRESSION; BREAST-CANCER; SURVIVAL; PROGNOSIS; CARCINOMA; STAGE;
   OVEREXPRESSION; IDENTIFICATION; DYSREGULATION; PROGRESSION
AB The findings of mutations and the development of targeted therapies have improved lung cancer management. Still, the prognosis remains poor, and we need to know more about the genetic and epigenetic alterations in lung cancer. MicroRNAs are involved in crucial biological processes like carcinogenesis by regulating gene expression at the post-transcriptional level. In this project, we have studied the microRNA expression of lung adenocarcinomas and corresponding normal lung tissue and correlated the expression with clinical data and EGFR-and KRAS-mutational status. Agilent microarrays have been used, examining microRNA expression in 154 surgically resected lung adenocarcinomas and 20 corresponding normal lung tissue samples. Findings were confirmed by RT-qPCR in the same cohort and in an independent cohort of 103 lung cancer patients. EGFR and KRAS mutation analyses were also performed. 129 microRNAs were significantly differentially expressed in lung adenocarcinomas compared with normal lung tissue, and 17 microRNAs were differentially expressed between EGFR-mutated and EGFR wildtype tumors. We identified microRNAs associated with time to progression. We have identified several aberrantly expressed microRNAs that discriminate lung adenocarcinomas from normal lung tissue, and hence may be potential biomarkers for early detection. We have found microRNAs that are differentially expressed between EGFR-mutated and EGFR wildtype lung adenocarcinomas, suggesting that microRNAs can be used as molecular biomarkers in classification. We hypothesize that microRNA expression can be used as biomarkers for clinical course.
C1 [Bjaanaes, Maria Moksnes; Halvorsen, Ann Rita; Kure, Elin; Rresen-Dale, Anne-Lise B.; Brustugun, Odd Terje; Helland, Aslaug] Norwegian Radium Hosp, Dept Genet, Oslo Univ Hosp, Oslo, Norway.
   [Bjaanaes, Maria Moksnes; Brustugun, Odd Terje; Helland, Aslaug] Norwegian Radium Hosp, Dept Oncol, Oslo Univ Hosp, Oslo, Norway.
   [Solberg, Steinar; Jorgensen, Lars] Univ Oslo, Rikshosp, Oslo Univ Hosp, Dept Cardiothorac Surg, N-0027 Oslo, Norway.
   [Dragani, Tommaso A.; Galvan, Antonella; Colombo, Francesca; Anderlini, Marco] Fdn IRCCS Ist Nazl Tumori, Dept Predict & Prevent Med, Milan, Italy.
   [Pastorino, Ugo] Fdn IRCCS Ist Nazl Tumori, Dept Thorac Surg, Milan, Italy.
   [Rresen-Dale, Anne-Lise B.; Brustugun, Odd Terje; Helland, Aslaug] Univ Oslo, Inst Clin Med, Fac Med, Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; National
   Hospital Norway; Fondazione IRCCS Istituto Nazionale Tumori Milan;
   Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Oslo
RP Helland, Å (通讯作者)，Oslo Univ Hosp, PB 4950 Nydalen, N-0424 Oslo, Norway.
EM ahelland@medisin.uio.no
RI Colombo, Francesca/IAN-5950-2023; Helland, Aslaug/H-3910-2015; Dragani,
   Tommaso A./K-4493-2016; Pastorino, Ugo/C-2712-2017
OI Helland, Aslaug/0000-0002-5520-0275; Colombo,
   Francesca/0000-0003-2015-4317; Dragani, Tommaso A./0000-0001-5915-4598;
   Pastorino, Ugo/0000-0001-9974-7902
FU EUROCAN platform (FP7) [260791]; South-Eastern Norway Regional Health
   Authority
FX Grant sponsor: the EUROCAN platform (FP7); Grant number: 260791; Grant
   sponsor: South-Eastern Norway Regional Health Authority
CR Avraham R, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000876
   Bartels CL, 2010, ANN BIOL CLIN-PARIS, V68, P263, DOI 10.1684/abc.2010.0429
   Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014
   Dacic S, 2010, MODERN PATHOL, V23, P1577, DOI 10.1038/modpathol.2010.152
   Devesa SS, 2005, INT J CANCER, V117, P294, DOI 10.1002/ijc.21183
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Dysvik B, 2001, BIOINFORMATICS, V17, P369, DOI 10.1093/bioinformatics/17.4.369
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Foley NH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-83
   Gao W, 2011, J CANCER RES CLIN, V137, P557, DOI 10.1007/s00432-010-0918-4
   Guan P, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-54
   Hamfjord J, 2011, DIAGN MOL PATHOL, V20, P158, DOI 10.1097/PDM.0b013e31820b49e2
   Helland Å, 2011, J THORAC ONCOL, V6, P947, DOI 10.1097/JTO.0b013e31820db209
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363
   Landi MT, 2010, CLIN CANCER RES, V16, P430, DOI 10.1158/1078-0432.CCR-09-1736
   Lee JW, 2008, CLIN CANCER RES, V14, P2535, DOI 10.1158/1078-0432.CCR-07-1231
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li JH, 2011, GYNECOL ONCOL, V120, P145, DOI 10.1016/j.ygyno.2010.09.009
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lu Y, 2012, CARCINOGENESIS, V33, P1046, DOI 10.1093/carcin/bgs100
   Malhas A, 2010, CELL CYCLE, V9, P531, DOI 10.4161/cc.9.3.10511
   Markou A, 2008, CLIN CHEM, V54, P1696, DOI 10.1373/clinchem.2007.101741
   Meister J, 2010, THESCIENTIFICWORLDJO, V10, P2090, DOI 10.1100/tsw.2010.198
   Momi N, 2014, TRENDS MOL MED, V20, P36, DOI 10.1016/j.molmed.2013.10.005
   Moriya Y, 2012, J HUM GENET, V57, P38, DOI 10.1038/jhg.2011.126
   Nakamoto M, 2005, HUM MOL GENET, V14, P3813, DOI 10.1093/hmg/ddi397
   Nohata N, 2012, ONCOTARGET, V3, P9
   Sagerup CMT, 2011, THORAX, V66, P301, DOI 10.1136/thx.2010.151621
   Saintigny P, 2012, DISCOV MED, V13, P287
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Seike M, 2009, P NATL ACAD SCI USA, V106, P12085, DOI 10.1073/pnas.0905234106
   Shen Y, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0750-1
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109
   Voortman J, 2010, CANCER RES, V70, P8288, DOI 10.1158/0008-5472.CAN-10-1348
   Vosa U, 2011, GENE CHROMOSOME CANC, V50, P812, DOI 10.1002/gcc.20902
   Xu T, 2014, CLIN TRANSL ONCOL, V16, P469, DOI 10.1007/s12094-013-1106-1
   Yan LX, 2008, RNA, V14, P2348, DOI 10.1261/rna.1034808
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Zhang H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081408
   Zhang JG, 2010, CLIN CHIM ACTA, V411, P846, DOI 10.1016/j.cca.2010.02.074
NR 44
TC 55
Z9 57
U1 0
U2 44
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 15
PY 2014
VL 135
IS 8
BP 1812
EP 1821
DI 10.1002/ijc.28828
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AN3YF
UT WOS:000340524100008
PM 24599520
OA hybrid, Green Published
DA 2025-01-12
ER

PT J
AU Pereira, IT
   Ramos, EAS
   Costa, ET
   Camargo, AA
   Manica, GCM
   Klassen, LMB
   Chequin, A
   Braun-Prado, K
   Pedrosa, FD
   Souza, EM
   Costa, FF
   Klassen, G
AF Pereira, Isabela T.
   Ramos, Edneia A. S.
   Costa, Erico T.
   Camargo, Anamaria A.
   Manica, Graciele C. M.
   Klassen, Liliane M. B.
   Chequin, Andressa
   Braun-Prado, Karin
   Pedrosa, Fabio de O.
   Souza, Emanuel M.
   Costa, Fabricio F.
   Klassen, Giseli
TI Fibronectin Affects Transient <i>MMP2</i> Gene Expression through DNA
   Demethylation Changes in Non-Invasive Breast Cancer Cell Lines
SO PLOS ONE
LA English
DT Article
ID MATRIX METALLOPROTEINASES; TUMOR INVASION; METASTASIS; ARCHITECTURE;
   ASSOCIATION; ACTIVATION; ZYMOGRAPHY; SUBSTRATE; MIGRATION; EXPOSURE
AB Metastasis accounts for more than 90% of cancer deaths. Cells from primary solid tumors may invade adjacent tissues and migrate to distant sites where they establish new colonies. The tumor microenvironment is now recognized as an important participant in the signaling that induces cancer cell migration. An essential process for metastasis is extracellular matrix (ECM) degradation by metalloproteases (MMPs), which allows tumor cells to invade local tissues and to reach blood vessels. The members of this protein family include gelatinase A, or MMP-2, which is responsible for the degradation of type IV collagen, the most abundant component of the basal membrane, that separates epithelial cells in the stroma. It is known that fibronectin is capable of promoting the expression of MMP-2 in MCF7 breast cancer cells in culture. In addition, it was already shown that the MMP2 gene expression is regulated by epigenetic mechanisms. In this work, we showed that fibronectin was able to induce MMP2 expression by 30% decrease in its promoter methylation. In addition, a histone marker for an open chromatin conformation was significantly increased. These results indicate a new role for fibronectin in the communication between cancer cells and the ECM, promoting epigenetic modifications.
C1 [Pereira, Isabela T.; Ramos, Edneia A. S.; Manica, Graciele C. M.; Klassen, Liliane M. B.; Chequin, Andressa; Braun-Prado, Karin; Klassen, Giseli] Univ Fed Parana, Dept Basic Pathol, BR-80060000 Curitiba, Parana, Brazil.
   [Costa, Erico T.; Camargo, Anamaria A.] Sirio Libanes Hosp, Ctr Mol Oncol, Ludwig Inst Canc Res, Sao Paulo, Brazil.
   [Pedrosa, Fabio de O.; Souza, Emanuel M.] Univ Fed Parana, Dept Biochem & Mol Biol, BR-80060000 Curitiba, Parana, Brazil.
   [Costa, Fabricio F.] Northwestern Univ, Feinberg Sch Med, Ann & Robert Lurie Childrens Hosp, Canc Biol & Epigen Program,Chicago Res Ctr, Chicago, IL 60611 USA.
   [Costa, Fabricio F.] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA.
C3 Universidade Federal do Parana; Ludwig Institute for Cancer Research;
   Hospital Sirio Libanes; Universidade Federal do Parana; Ann & Robert H.
   Lurie Children's Hospital of Chicago; Northwestern University; Feinberg
   School of Medicine; Northwestern University; Feinberg School of Medicine
RP Klassen, G (通讯作者)，Univ Fed Parana, Dept Basic Pathol, BR-80060000 Curitiba, Parana, Brazil.
EM giseli@ufpr.br
RI Pereira, Isabela/AAW-5731-2021; Braun-Prado, Karin/C-4282-2014; Manica,
   Graciele/AGY-7037-2022; Costa, Fabricio/M-5309-2017; Cavalieri,
   Edneia/Q-9636-2019; Aranha Camargo, Anamaria/E-9388-2012; Souza,
   Emanuel/C-1920-2013; Klassen, Giseli/F-8753-2012; Costa, Erico
   Tosoni/D-5750-2014
OI Aranha Camargo, Anamaria/0000-0002-6076-9597; braun prado,
   Karin/0000-0002-9652-0566; Pereira, Isabela/0000-0001-8951-9965; Souza,
   Emanuel/0000-0003-1546-9218; Klassen, Giseli/0000-0001-5336-6178; More
   Manica, Graciele Cristiane/0000-0003-1735-1336; Costa, Erico
   Tosoni/0000-0001-7413-4675; ASR Cavalieri, Edneia/0000-0002-8855-5988
FU Brazilian Research Council (CNPq) [479211/2012-4]; Coordination of
   Improvement of Higher Education Personnel (CAPES)
FX Brazilian Research Council (CNPq) (process 479211/2012-4) and
   Coordination of Improvement of Higher Education Personnel (CAPES). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR [Anonymous], 2014, EST 2014
   [Anonymous], BIOCH BIOPHYSICA ACT
   [Anonymous], BIOCH BIOPHYSICA ACT
   Artacho-Cordón F, 2012, SURG ONCOL, V21, pE143, DOI 10.1016/j.suronc.2012.06.001
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Carraher CL, 2013, J BIOL CHEM, V288, P14805, DOI 10.1074/jbc.M112.435271
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chernov AV, 2009, J BIOL CHEM, V284, P12727, DOI 10.1074/jbc.M900273200
   Chik F, 2011, CARCINOGENESIS, V32, P224, DOI 10.1093/carcin/bgq221
   Das S, 2008, LIFE SCI, V82, P467, DOI 10.1016/j.lfs.2007.12.013
   Duffy SW, 2005, J MED SCREEN, V12, P128, DOI 10.1258/0969141054855319
   Figueira RCS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-20
   Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555
   Hurtubise A, 2006, CANCER CHEMOTH PHARM, V58, P618, DOI 10.1007/s00280-006-0225-6
   Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1
   Ivascu A, 2007, INT J ONCOL, V31, P1403
   Kagey JD, 2010, MOL CANCER RES, V8, P1048, DOI 10.1158/1541-7786.MCR-10-0189
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775
   KLEINER DE, 1994, ANAL BIOCHEM, V218, P325, DOI 10.1006/abio.1994.1186
   Leber TM, 1997, ANAL BIOCHEM, V249, P24, DOI 10.1006/abio.1997.2170
   Lelièvre SA, 2009, BBA-GEN SUBJECTS, V1790, P925, DOI 10.1016/j.bbagen.2009.03.013
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Malouf GG, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r144
   Mayor R, 2011, EPIGENETICS-US, V6, P1138, DOI 10.4161/epi.6.9.16066
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Meng XN, 2009, BRIT J CANCER, V101, P327, DOI 10.1038/sj.bjc.6605154
   MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021
   Mitra A, 2006, J CANCER RES CLIN, V132, P505, DOI 10.1007/s00432-006-0096-6
   Moroz A, 2013, BIOCHEM BIOPH RES CO, V430, P1319, DOI 10.1016/j.bbrc.2012.12.031
   Ni XJ, 2014, CANCER SCI, V105, P18, DOI 10.1111/cas.12309
   Park J., 2013, ONCOGENE, P1
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379
   Stanton H, 1998, J CELL SCI, V111, P2789
   Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336
   Voigt P, 2013, GENE DEV, V27, P1318, DOI 10.1101/gad.219626.113
   Wan LL, 2013, NAT MED, V19, P1450, DOI 10.1038/nm.3391
NR 42
TC 20
Z9 21
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 10
PY 2014
VL 9
IS 9
AR e105806
DI 10.1371/journal.pone.0105806
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AP4EP
UT WOS:000342030300012
PM 25208219
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Perillo, B
   Di Santi, A
   Cernera, G
   Ombra, MN
   Castoria, G
   Migliaccio, A
AF Perillo, Bruno
   Di Santi, Annalisa
   Cernera, Gustavo
   Ombra, Maria Neve
   Castoria, Gabriella
   Migliaccio, Antimo
TI Nuclear receptor-induced transcription is driven by spatially and timely
   restricted waves of ROS The role of Akt, IKKα, and DNA damage repair
   enzymes
SO NUCLEUS-AUSTIN
LA English
DT Article
DE epigenetic marks; nuclear receptors; estrogen; retinoic acid;
   transcription; Akt; IKK alpha; DNA oxidation; DNA repair; apoptosis
ID BREAST-CANCER CELLS; RETINOIC ACID RECEPTOR; ESTROGEN-RECEPTOR;
   GENE-EXPRESSION; HISTONE MODIFICATIONS; DEPENDENT TRANSCRIPTION;
   ACTIVATION; KINASE; MCF-7; PATHWAYS
AB Gene expression is governed by chromatin mainly through posttranslational modifications at the N-terminal tails of nucleosomal histone proteins. According to the histone code theory, peculiar sets of such modifications (marks) give rise to reproducible final effects on transcription and, very recently, a further level of complexity has been highlighted in binary switches between specific marks at adjacent residues. In particular, disappearance of dimethyl-lysine 9 in histone H3 is faced by phosphorylation of the following serine during activation of gene expression. Demethylation of lysine 9 by the lysine-specific demethylase 1 (LSD1) is a pre-requisite for addition of the phosphoryl mark to serine 10 and an essential step in the transcriptional control by estrogens. It generates a local burst of oxygen reactive species (ROS) that induce oxidation of nearby nucleotides and recruitment of repair enzymes with a consequent formation of single or double stranded nicks on DNA that modify chromatin flexibility in order to allow correct assembly of the transcriptional machinery.
   We describe here the molecular mechanism by which members of the family of nuclear receptors prevent the potential damage to DNA during transcription of target genes elicited by the use of ROS to shape chromatin. The mechanism is based on the presence of phosphorylated serine 10 in histone H3 to prevent unbalanced DNA oxidation waves. We also discuss the opportunities raised by the use of voluntary derangement of this servo system to induce selective death in hormone-responsive transformed cells.
C1 [Perillo, Bruno; Ombra, Maria Neve] Ist Sci Alimentaz, Avellino, Italy.
   [Di Santi, Annalisa; Cernera, Gustavo; Castoria, Gabriella; Migliaccio, Antimo] Univ Naples 2, Dipartimento Biochim Biofis & Patol Gen, Naples, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell'
   Alimentazione (ISA-CNR); Universita della Campania Vanvitelli
RP Perillo, B (通讯作者)，Ist Sci Alimentaz, Avellino, Italy.
EM perillo@unina.it
RI Castoria, Gabriella/I-3349-2019; Migliaccio, Antimo/AAB-3376-2019
OI OMBRA, MARIA NEVE/0000-0002-2437-9276; Cernera,
   Gustavo/0000-0002-1370-9786; Migliaccio, Antimo/0000-0002-4197-2055;
   Perillo, Bruno/0000-0001-8935-0370; Castoria,
   Gabriella/0000-0002-0576-4494
FU Associazione per la Ricerca sul Cancro (AIRC) [IG 11520]
FX This work has been supported by the Associazione per la Ricerca sul
   Cancro (AIRC Grant IG 11520: PI Antimo Migliaccio).
CR Abbondanza C, 2011, EPIGENETICS-US, V6, P979, DOI 10.4161/epi.6.8.16060
   Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x
   Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200
   Ayyanathan K, 2003, GENE DEV, V17, P1855, DOI 10.1101/gad.1102803
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   BROWN AMC, 1984, P NATL ACAD SCI-BIOL, V81, P6344, DOI 10.1073/pnas.81.20.6344
   Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2
   Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5
   Donato LJ, 2005, CANCER RES, V65, P8193, DOI 10.1158/0008-5472.CAN-05-1177
   Fischle W, 2003, NATURE, V425, P475, DOI 10.1038/nature02017
   Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567
   Glass CK, 2000, GENE DEV, V14, P121
   Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735
   Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043
   Li JJ, 2004, P NATL ACAD SCI USA, V101, P18123, DOI 10.1073/pnas.0408273101
   Lonning PE, 2001, BREAST CANCER RES TR, V67, P111, DOI 10.1023/A:1010619225209
   Lösel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Niederreither K, 2008, NAT REV GENET, V9, P541, DOI 10.1038/nrg2340
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Ohashi E, 2009, CANCER RES, V69, P3443, DOI 10.1158/0008-5472.CAN-08-3234
   Ombra MN, 2013, BBA-GENE REGUL MECH, V1829, P480, DOI 10.1016/j.bbagrm.2013.03.003
   Ozes ON, 1999, NATURE, V401, P82
   Pallis AG, 2010, CANCER METAST REV, V29, P677, DOI 10.1007/s10555-010-9258-8
   Park KJ, 2005, MOL CELL, V18, P71, DOI 10.1016/j.molcel.2005.03.006
   Perillo B, 2014, CELL DEATH DIFFER, V21, P1503, DOI 10.1038/cdd.2014.91
   Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131
   Song RXD, 2001, J NATL CANCER I, V93, P1714, DOI 10.1093/jnci/93.22.1714
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Wu RC, 2004, MOL CELL, V15, P937, DOI 10.1016/j.molcel.2004.08.019
   Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776
   Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301
NR 44
TC 17
Z9 17
U1 0
U2 12
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1949-1034
EI 1949-1042
J9 NUCLEUS-AUSTIN
JI Nucleus-Austin
PD SEP-OCT
PY 2014
VL 5
IS 5
BP 482
EP 491
DI 10.4161/nucl.36274
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AP6NJ
UT WOS:000342194200015
PM 25482200
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Abdelmaksoud-Dammak, R
   Miladi-Abdennadher, I
   Saadallah-Kallel, A
   Khabir, A
   Sellami-Boudawara, T
   Frikha, M
   Daoud, J
   Mokdad-Gargouri, R
AF Abdelmaksoud-Dammak, Rania
   Miladi-Abdennadher, Imen
   Saadallah-Kallel, Amena
   Khabir, Abdelmajid
   Sellami-Boudawara, Tahia
   Frikha, Mounir
   Daoud, Jamel
   Mokdad-Gargouri, Raja
TI Downregulation of WIF-1 and Wnt5a in patients with colorectal carcinoma:
   clinical significance
SO TUMOR BIOLOGY
LA English
DT Article
DE Colorectal cancer; CpG methylation; Wnt signaling; Wnt5a; Tumor
   suppressor
ID INHIBITORY FACTOR-I; FREQUENT EPIGENETIC INACTIVATION; ISLAND METHYLATOR
   PHENOTYPE; CELL LUNG-CANCER; SIGNALING PATHWAY; MICROSATELLITE
   INSTABILITY; ABERRANT METHYLATION; BREAST-CANCER; COLON-CANCER; CPG
   ISLANDS
AB Activation of the wingless-type (Wnt) signaling pathway is common in various human cancers including colorectal cancer (CRC). Wnt inhibitory factor-1 (WIF-1) is a secreted antagonist that can bind Wnt ligands and therefore inhibits the Wnt signaling pathway. In this study, we aimed to analyze the expression of two members of Wnt signaling (WIF-1 and Wnt5a) in Tunisian patients with sporadic CRC. WIF-1 was frequently methylated in tumor tissues (87.95 %) compared to normal mucosa (39.54 %) and correlated with distant metastasis and vascular invasion (P = 0.001 and 0.037, respectively). The unmethylated profile of the WIF-1 promoter conferred a benefit to patients in terms of overall survival (P log rank = 0.024). In addition, in the group of patients with methylated WIF-1 promoter, the overall survival rate was significantly prolonged for those with small tumor size (< 5 cm) and absence of distant metastasis (P log rank = 0.007 and 0.036, respectively). Aberrant CpG methylation of the WIF-1 promoter leads to transcriptional silencing of this tumor suppressor gene in tumor tissues (P = 0.001). Furthermore, we showed that the level of Wnt5a mRNA was significantly lower in tumor compared to normal tissues (P = 0.031) and lower still in those showing more aggressive behavior (presence of lymph nodes and advanced TNM stage). Our finding supports that WIF-1 is frequently methylated and that Wnt5a acts as a tumor suppressor gene in CRC. Loss of WIF-1 and Wnt5a functions results in more aggressive behavior of the disease.
C1 [Abdelmaksoud-Dammak, Rania; Miladi-Abdennadher, Imen; Saadallah-Kallel, Amena; Mokdad-Gargouri, Raja] Univ Sfax, Ctr Biotechnol Sfax, Lab Biomass Valorisat & Prod Eukaryot Prot, Sfax 3018, Tunisia.
   [Khabir, Abdelmajid; Sellami-Boudawara, Tahia; Frikha, Mounir; Daoud, Jamel] Ctr Hosp Univ Habib Bourguiba, Sfax 3000, Tunisia.
   [Mokdad-Gargouri, Raja] Ctr Biotechnol Sfax, Sfax 3018, Tunisia.
C3 Centre de Biotechnologie de Sfax; Universite de Sfax; Universite de
   Sfax; Hopital Habib Bourguiba; Universite de Sfax; Centre de
   Biotechnologie de Sfax
RP Mokdad-Gargouri, R (通讯作者)，Ctr Biotechnol Sfax, Sidi Mansour St,BP K 1177, Sfax 3018, Tunisia.
EM raja.gargouri@cbs.rnrt.tn
OI ABDELMAJID, KHABIR/0000-0003-0031-2242
FU Tunisian Ministry of High Education and Scientific Research
FX This work was supported by a grant of the Tunisian Ministry of High
   Education and Scientific Research.
CR Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Bauer M, 2013, PLOS ONE, V18, P11
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Blanc E, 2005, ONCOGENE, V24, P1277, DOI 10.1038/sj.onc.1208255
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Chung DC, 2000, GASTROENTEROLOGY, V119, P854, DOI 10.1053/gast.2000.16507
   Dejmek J, 2005, CANCER RES, V65, P9142, DOI 10.1158/0008-5472.CAN-05-1710
   Fendri A, 2010, CANCER INVEST, V28, P896, DOI 10.3109/07357907.2010.494324
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hsairi Mohamed, 2002, Tunis Med, V80, P57
   Huang CL, 2005, J CLIN ONCOL, V23, P8765, DOI 10.1200/JCO.2005.02.2871
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Kim JH, 2009, VIRCHOWS ARCH, V455, P485, DOI 10.1007/s00428-009-0857-0
   Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782
   Kremenevskaja N, 2005, ONCOGENE, V24, P2144, DOI 10.1038/sj.onc.1208370
   Kühl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x
   Lee BB, 2009, CLIN CANCER RES, V15, P6185, DOI 10.1158/1078-0432.CCR-09-0111
   LEJEUNE S, 1995, CLIN CANCER RES, V1, P215
   Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0
   Li Q, 2012, EPIGENETICS-US, V7, P551, DOI 10.4161/epi.20050
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Miladi-Abdennadher I, 2011, BIOSCIENCE REP, V31, P257, DOI 10.1042/BSR20100023
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Polakis P, 2000, GENE DEV, V14, P1837
   Rawson JB, 2011, BRIT J CANCER, V104, P1906, DOI 10.1038/bjc.2011.165
   Roarty K, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2244
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   Shimizu Y, 2002, GENE CHROMOSOME CANC, V33, P73, DOI 10.1002/gcc.1226
   Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463
   Smith RA, 2006, CA-CANCER J CLIN, V56, P11, DOI 10.3322/canjclin.56.1.11
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Trifa F, 2013, TUMOR BIOL
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Umbhauer M, 2000, EMBO J, V19, P4944, DOI 10.1093/emboj/19.18.4944
   Weeraratna AT, 2002, CANCER CELL, V1, P279, DOI 10.1016/S1535-6108(02)00045-4
   Xu XL, 2004, WORLD J GASTROENTERO, V10, P3441
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
NR 46
TC 18
Z9 19
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2014
VL 35
IS 8
BP 7975
EP 7982
DI 10.1007/s13277-014-2015-9
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP2DU
UT WOS:000341883500089
PM 24833087
DA 2025-01-12
ER

PT J
AU Greenberg, E
   Nemlich, Y
   Markel, G
AF Greenberg, Eyal
   Nemlich, Yael
   Markel, Gal
TI microRNAs in Cancer: Lessons from Melanoma
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Melanoma; microRNAs; cancer; proliferation; cell cycle; invasion;
   migration; immune evasion; drug resistance
ID PROTEIN-KINASE ACTIVATION; DOWN-REGULATION; GROWTH-FACTOR;
   CELL-PROLIFERATION; MALIGNANT-MELANOMA; BREAST-CANCER; TRANSCRIPTION
   FACTOR; MIR-17-92 CLUSTER; DRUG-RESISTANCE; TUMOR-CELLS
AB Melanoma is a high-grade, poorly differentiated malignant tumor of pigment-producing cells (melanocytes), accounting for more than 70% of the skin cancer related deaths. Although new lines of targeted therapy and immunotherapy were introduced lately, durable responses are not common as it is hard to target the elusive metastatic phenotype. microRNAs (miRNAs) are short non-coding RNA molecules that function as specific epigenetic regulators of the transcriptome. miRNAs are involved in a broad spectrum of physiological and pathological processes, including cancer-related functions such as proliferation, cell cycle, migration, invasion, immune evasion and drug resistance. These functions are mostly regulated in melanoma through four molecular deregulated pathways, including the RAS/MAPK pathway, the MITF pathway, the p16INK4A-CDK4-RB pathway and the PI3K-AKT pathway. miRNAs provide a strong platform for delineation of cancer mechanisms. Here we review the diverse roles of miRNAs in melanoma cell biology. Studying miRNA-mediated regulation of aggressive and tumor related features is expected to provide novel mechanistic insights that may pave the way for new diagnostic, prognostic and predictive tools as well as new molecular targets for future therapy.
C1 [Greenberg, Eyal; Nemlich, Yael; Markel, Gal] Chaim Sheba Med Ctr, Ella Inst Melanoma, Ramat Gan, Israel.
   [Greenberg, Eyal; Markel, Gal] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel.
   [Markel, Gal] Chaim Sheba Med Ctr, Talpiot Med Leadership Program, Ramat Gan, Israel.
C3 Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of
   Medicine; Chaim Sheba Medical Center
RP Markel, G (通讯作者)，Chaim Sheba Med Ctr, Canc Res Ctr, Ella Inst Melanoma, IL-52621 Tel Hashomer, Israel.
EM Markel@post.tau.ac.il
CR Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220
   Alla V, 2012, CELL CYCLE, V11, P3067, DOI 10.4161/cc.21476
   Altuvia Y, 2005, NUCLEIC ACIDS RES, V33, P2697, DOI 10.1093/nar/gki567
   [Anonymous], 2012, Surveillance Epidemiology and End Results: Cancer Statistics Review, 1975-2009
   Asangani IA, 2012, ONCOTARGET, V3, P1011, DOI 10.18632/oncotarget.622
   Baffa R, 2009, J PATHOL, V219, P214, DOI 10.1002/path.2586
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bell RE, 2013, J INVEST DERMATOL
   Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912
   Berger MF, 2010, GENOME RES, V20, P413, DOI 10.1101/gr.103697.109
   Bhattacharya A, 2013, ONCOGENE, V32, P3175, DOI 10.1038/onc.2012.324
   Boyle GM, 2011, PIGM CELL MELANOMA R, V24, P525, DOI 10.1111/j.1755-148X.2011.00849.x
   Braig S, 2010, CELL MOL LIFE SCI, V67, P3535, DOI 10.1007/s00018-010-0394-7
   Bueno R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010612
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Capoluongo E, 2011, AM J PATHOL, V178, P26, DOI 10.1016/j.ajpath.2010.11.004
   Caramuta S, 2010, J INVEST DERMATOL, V130, P2062, DOI 10.1038/jid.2010.63
   Chang CC, 2013, ORAL ONCOL
   Chen J, 2013, ONCOGENE, V32, P1330, DOI 10.1038/onc.2012.141
   Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010
   Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061
   Chim SSC, 2008, CLIN CHEM, V54, P482, DOI 10.1373/clinchem.2007.097972
   CLARK WH, 1969, CANCER RES, V29, P705
   Cohen C, 2002, CLIN CANCER RES, V8, P3728
   Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392
   Couts KL, 2013, ONCOGENE, V32, P1959, DOI 10.1038/onc.2012.209
   Creighton CJ, CANC RES, V70, P1906
   Cummins DL, 2006, MAYO CLIN PROC, V81, P500, DOI 10.4065/81.4.500
   Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345
   Dar AA, 2013, JNCI-J NATL CANCER I, V105, P433, DOI 10.1093/jnci/djt003
   Dar AA, 2011, J BIOL CHEM, V286, P16606, DOI 10.1074/jbc.M111.227611
   Das SK, 2010, P NATL ACAD SCI USA, V107, P11948, DOI 10.1073/pnas.0914143107
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   de Snoo FA, 2007, J AM ACAD DERMATOL, V56, P748, DOI 10.1016/j.jaad.2007.01.010
   Deng Y, 2011, INT J BIOL SCI, V7, P133, DOI 10.7150/ijbs.7.133
   DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103
   Dynoodt P, 2013, INT J ONCOL, V42, P1443, DOI 10.3892/ijo.2013.1823
   Elson-Schwab I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013176
   Fan MQ, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-21
   Fan XX, 2010, ACTA BIOCH BIOPH SIN, V42, P318, DOI 10.1093/abbs/gmq026
   Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538
   Felli N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056824
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Friedman EB, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-155
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Garbe C, 2012, EUR J CANCER, V48, P2375, DOI 10.1016/j.ejca.2012.06.013
   Gaziel-Sovran A, 2011, CANCER CELL, V20, P104, DOI 10.1016/j.ccr.2011.05.027
   Giles KM, 2013, BIOCHEM BIOPH RES CO, V430, P706, DOI 10.1016/j.bbrc.2012.11.086
   Gloster HM, 1996, DERMATOL SURG, V22, P217, DOI 10.1111/j.1524-4725.1996.tb00312.x
   Glud M, 2010, MELANOMA RES, V20, P479, DOI 10.1097/CMR.0b013e32833e32a1
   Goswami S, 2010, J BIOL CHEM, V285, P20532, DOI 10.1074/jbc.M110.109298
   Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661
   Greenberg E, 2013, BIOMARKERS
   Greenberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018936
   Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610
   Griffiths-Jones S, NUCL ACIDS RES
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Grignol V, 2011, BRIT J CANCER, V105, P1023, DOI 10.1038/bjc.2011.288
   Haflidadóttir BS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011574
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heinemann A, 2012, CANCER RES, V72, P460, DOI 10.1158/0008-5472.CAN-11-1977
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938
   Hoppe R, 2013, EUROPEAN J CANC
   Huang GX, 2012, CANCER RES, V72, P908, DOI 10.1158/0008-5472.CAN-11-1460
   Hunter MP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003694
   Hwang SJ, 2012, MOL CELLS, V34, P329, DOI 10.1007/s10059-012-0171-6
   Igoucheva O, 2009, BIOCHEM BIOPH RES CO, V379, P790, DOI 10.1016/j.bbrc.2008.12.152
   Ivanov SV, 2010, J BIOL CHEM, V285, P22807, DOI 10.1074/jbc.M110.100354
   Ivry GB, 2006, DERMATOL SURG, V32, P481, DOI 10.1111/j.1524-4725.2006.32101.x
   Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260
   Jemal A, 2013, JNCI-J NATL CANCER I, V105, P175, DOI 10.1093/jnci/djs491
   Jiang CC, 2013, ONCOGENE
   Jiang L, 2012, ACTA HISTOCHEM, V114, P582, DOI 10.1016/j.acthis.2011.11.001
   Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108
   Jukic DM, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-27
   Kanemaru H, 2011, J DERMATOL SCI, V61, P187, DOI 10.1016/j.jdermsci.2010.12.010
   Kang HW, 2012, FEBS LETT, V586, P897, DOI 10.1016/j.febslet.2012.02.020
   Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307
   Karst AM, 2009, INT J CANCER, V124, P494, DOI 10.1002/ijc.23973
   Kirkwood JM, 2008, J CLIN ONCOL, V26, P3445, DOI 10.1200/JCO.2007.14.6423
   Kitago M, 2009, CLIN CANCER RES, V15, P2988, DOI 10.1158/1078-0432.CCR-08-3172
   Kivisaari AK, 2010, BRIT J DERMATOL, V163, P726, DOI 10.1111/j.1365-2133.2010.09924.x
   Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6
   Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Lam LT, 2010, MOL CANCER THER, V9, P2943, DOI 10.1158/1535-7163.MCT-10-0427
   Leidinger P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-262
   Levati L, 2011, PIGM CELL MELANOMA R, V24, P538, DOI 10.1111/j.1755-148X.2011.00857.x
   Levati L, 2009, INT J ONCOL, V35, P393, DOI 10.3892/ijo_00000352
   Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485
   Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291
   Liu NN, 2012, ONCOL REP, V28, P961, DOI 10.3892/or.2012.1905
   Liu SJ, 2012, AM J PATHOL, V181, P1823, DOI 10.1016/j.ajpath.2012.07.009
   Liu SJ, 2012, LAB INVEST, V92, P1084, DOI 10.1038/labinvest.2012.62
   Liu SJ, 2012, J PATHOL, V226, P61, DOI 10.1002/path.2964
   Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098
   Luo CL, 2013, J INVEST DERMATOL, V133, P768, DOI 10.1038/jid.2012.357
   Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547
   Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840
   Mattia G, 2011, PIGM CELL MELANOMA R, V24, P953, DOI 10.1111/j.1755-148X.2011.00881.x
   Mazar J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024922
   Mazar J, 2011, FEBS LETT, V585, P2467, DOI 10.1016/j.febslet.2011.06.025
   Mazar J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013779
   Migliore C, 2008, CANCER RES, V68, P10128, DOI 10.1158/0008-5472.CAN-08-2148
   MIHM MC, 1971, NEW ENGL J MED, V284, P1078, DOI 10.1056/NEJM197105132841907
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Mongaret C, 2011, INT J CANCER, V129, P791, DOI 10.1002/ijc.25746
   Müller DW, 2008, ONCOGENE, V27, P6698, DOI 10.1038/onc.2008.282
   Mueller DW, 2011, INT J CANCER, V129, P1064, DOI 10.1002/ijc.25768
   Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452
   Naeyaert JM, 2003, NEW ENGL J MED, V349, P2233, DOI 10.1056/NEJMcp023017
   Nemlich Y, 2013, J CLIN INVEST, V123, P2703, DOI 10.1172/JCI62980
   Nguyen T, 2011, EPIGENETICS-US, V6, P388, DOI 10.4161/epi.6.3.14056
   Noguchi S, 2013, VET COMP ONCOL, V11, P113, DOI 10.1002/vco.306
   Noguchi S, 2013, J INVEST DERMATOL
   Noguchi S, 2012, J BIOL CHEM, V287, P11769, DOI 10.1074/jbc.M111.325027
   Noguchi S, 2012, J VET MED SCI, V74, P1, DOI 10.1292/jvms.11-0264
   Noman MZ, 2012, CANCER RES, V72, P4629, DOI 10.1158/0008-5472.CAN-12-1383
   Ohashi S, 2011, CANCER BIOL THER, V11, P184, DOI 10.4161/cbt.11.2.14140
   Patino Willmar D, 2008, Adv Dermatol, V24, P59, DOI 10.1016/j.yadr.2008.09.003
   Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769
   Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028
   Penna E, 2011, EMBO J, V30, P1990, DOI 10.1038/emboj.2011.102
   Philippidou D, 2010, CANCER RES, V70, P4163, DOI 10.1158/0008-5472.CAN-09-4512
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Poliseno L, 2012, J INVEST DERMATOL, V132, P1860, DOI 10.1038/jid.2011.451
   Polsky D, 2003, ONCOGENE, V22, P3087, DOI 10.1038/sj.onc.1206449
   Reuland SN, 2013, J INVEST DERMATOL, V133, P1286, DOI 10.1038/jid.2012.400
   Rosenfeld N, 2008, NAT BIOTECHNOL, V26, P462, DOI 10.1038/nbt1392
   Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007
   Saldanha G, 2013, J INVEST DERMATOL, V133, P1381, DOI 10.1038/jid.2012.477
   Satyamoorthy K, 2003, CANCER RES, V63, P756
   Satzger I, 2012, EXP DERMATOL, V21, P509, DOI 10.1111/j.1600-0625.2012.01510.x
   Satzger I, 2010, INT J CANCER, V126, P2553, DOI 10.1002/ijc.24960
   Schultz J, 2008, CELL RES, V18, P549, DOI 10.1038/cr.2008.45
   Segura MF, 2010, CLIN CANCER RES, V16, P1577, DOI 10.1158/1078-0432.CCR-09-2721
   Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645
   Streicher KL, 2012, ONCOGENE, V31, P1558, DOI 10.1038/onc.2011.345
   Toki F, 2005, J CELL PHYSIOL, V202, P839, DOI 10.1002/jcp.20175
   Trang P., ONCOGENE, V27, pS52
   Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245
   Udayakumar D, 2010, SEMIN CUTAN MED SURG, V29, P190, DOI 10.1016/j.sder.2010.06.002
   Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Vella MC, 2004, GENE DEV, V18, P132, DOI 10.1101/gad.1165404
   Wang HF, 2013, ONCOL REP, V30, P520, DOI 10.3892/or.2013.2451
   Wei XM, 2011, NAT GENET, V43, P442, DOI 10.1038/ng.810
   Wellbrock C, 2005, J CELL BIOL, V170, P703, DOI 10.1083/jcb.200505059
   Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498
   Willmore-Payne C, 2005, HUM PATHOL, V36, P486, DOI 10.1016/j.humpath.2005.03.015
   Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228
   Wulfken LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025787
   Xu Y, 2012, BRIT J CANCER, V106, P553, DOI 10.1038/bjc.2011.568
   Yang CH, 2011, J BIOL CHEM, V286, P39172, DOI 10.1074/jbc.M111.285098
   Yang Y, 2010, CANCER GENET CYTOGEN, V200, P127, DOI 10.1016/j.cancergencyto.2010.03.014
   Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107
   Zehavi L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-44
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhang YY, 2010, MED ONCOL, V27, P685, DOI 10.1007/s12032-009-9269-x
NR 169
TC 15
Z9 15
U1 0
U2 8
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2014
VL 20
IS 33
BP 5246
EP 5259
DI 10.2174/1381612820666140128210105
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AP3UU
UT WOS:000342004300002
PM 24479804
DA 2025-01-12
ER

PT J
AU Kar, S
   Sengupta, D
   Deb, M
   Shilpi, A
   Parbin, S
   Rath, SK
   Pradhan, N
   Rakshit, M
   Patra, SK
AF Kar, Swayamsiddha
   Sengupta, Dipta
   Deb, Moonmoon
   Shilpi, Arunima
   Parbin, Sabnam
   Rath, Sandip Kumar
   Pradhan, Nibedita
   Rakshit, Madhumita
   Patra, Samir Kumar
TI Expression profiling of DNA methylation-mediated epigenetic
   gene-silencing factors in breast cancer
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Epigenetics; DNA methylation; DNA methyltransferases; Methyl-CpG-binding
   domain proteins; Gene silencing; Cancer
ID CPG BINDING-PROTEINS; TUMOR-SUPPRESSOR GENES; PROSTATE-CANCER;
   HUMAN-DISEASE; CHROMATIN; METHYLTRANSFERASES; MECHANISMS; PATTERNS;
   TARGETS
AB Background: DNA methylation mediates gene silencing primarily by inducing repressive chromatin architecture via a common theme of interaction involving methyl-CpG binding (MBD) proteins, histone modifying enzymes and chromatin remodelling complexes. Hence, targeted inhibition of MBD protein function is now considered a potential therapeutic alternative for thwarting DNA hypermethylation prompted neoplastic progress. We have analyzed the gene and protein expression level of the principal factors responsible for gene silencing, that is, DNMT and MBD proteins in MCF-7 and MDA-MB-231 breast cancer cell lines after treatment with various epigenetic drugs.
   Results: Our study reveals that the epigenetic modulators affect the expression levels at both transcript and protein levels as well as encourage growth arrest and apoptosis in MCF-7 and MDA-MB-231 cells. AZA, TSA, SFN, and SAM inhibit cell growth in MCF-7 and MDA-MB-231 cell lines in a dose-dependent manner, that is, with increasing concentrations of drugs the cell viability gradually decreases. All the epigenetic modulators promote apoptotic cell death, as is evident form increased chromatin condensation which is a distinct characteristic of apoptotic cells. From FACS analysis, it is also clear that these drugs induce G2-M arrest and apoptosis in breast cancer cells. Further, transcript and protein level expression of MBDs and DNMTs is also affected -after treatment with epigenetic drugs; the level of transcripts/mRNA of MBDs and DNMTs has consistently increased in general. The increase in level of gene expression is substantiated at the protein level also where treated cells show higher expression of DNMT1, DNMT3A, DNMT3B, and MBD proteins in comparison to untreated cells. In case of tissue samples, the expression of different DNMTs is tissue stage-specific. DNMT1 exhibits significantly higher expression in the metastatic stage, whereas, DNMT3A and DNMT3B have higher expression in the primary stage in comparison to the metastatic samples.
   Conclusion: The epigenetic modulators AZA, TSA, SFN, and SAM may provide opportunities for cancer prevention by regulating the components of epigenetic gene-silencing machinery especially DNMTs and MBDs.
C1 [Kar, Swayamsiddha; Sengupta, Dipta; Deb, Moonmoon; Shilpi, Arunima; Parbin, Sabnam; Rath, Sandip Kumar; Pradhan, Nibedita; Rakshit, Madhumita; Patra, Samir Kumar] Natl Inst Technol, Dept Life Sci, Epigenet & Canc Res Lab, Biochem & Mol Biol Grp, Rourkela 769008, Odisha, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Rourkela
RP Patra, SK (通讯作者)，Natl Inst Technol, Dept Life Sci, Epigenet & Canc Res Lab, Biochem & Mol Biol Grp, Rourkela 769008, Odisha, India.
EM samirp@nitrkl.ac.in
RI Sengupta, Dipta/H-3707-2019; Shilpi, Arunima/AAF-7221-2019; rath,
   sandip/ABB-9460-2021; PATRA, Samir/AAS-6639-2020
OI Sengupta, Dipta/0000-0002-7836-4774; PATRA, SAMIR/0000-0001-5641-1835;
   rath, sandip/0000-0003-4589-4039
FU NIT-Rourkela; DST, Govt. of India; Departmental operating grants of LS,
   NIT-Rourkela
FX SK, DS, MD, AS, and SR are thankful to NIT-Rourkela for granting them
   fellowships under the Institute Research Scheme. SP and NP are thankful
   to DST, Govt. of India for INSPIRE fellowship. This research was
   supported in part by Departmental operating grants of LS, NIT-Rourkela.
   We apologize to those whose works and related publications we have not
   been able to discuss and cite due to space limitations.
CR Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Ballestar E, 2002, CARCINOGENESIS, V23, P1103, DOI 10.1093/carcin/23.7.1103
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9
   Clouaire T, 2008, CELL MOL LIFE SCI, V65, P1509, DOI 10.1007/s00018-008-7324-y
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Deb M, 2014, CELL MOL LIFE SCI, V71, P3439, DOI 10.1007/s00018-014-1605-4
   Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110
   Dhasarathy A, 2008, MUTAT RES-FUND MOL M, V647, P39, DOI 10.1016/j.mrfmmm.2008.07.007
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Fatemi M, 2006, J CELL SCI, V119, P3033, DOI 10.1242/jcs.03099
   Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jeltsch A, 2008, NAT STRUCT MOL BIOL, V15, P1003, DOI 10.1038/nsmb1008-1003
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651
   Kar S, 2012, EPIGENETICS-US, V7, P994, DOI 10.4161/epi.21568
   Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008
   Lopez-Serra L, 2008, BRIT J CANCER, V98, P1881, DOI 10.1038/sj.bjc.6604374
   Lopez-Serra L, 2008, ONCOGENE, V27, P3556, DOI 10.1038/sj.onc.1211022
   Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932
   Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143
   McCabe MT, 2009, CLIN CANCER RES, V15, P3927, DOI 10.1158/1078-0432.CCR-08-2784
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Parry Lee, 2011, Genes Cancer, V2, P618, DOI 10.1177/1947601911418499
   Patra A, 2011, CLIN EPIGENETICS, V2, P339, DOI 10.1007/s13148-010-0019-x
   Patra SK, 2009, BIOCHEMISTRY-MOSCOW+, V74, P613, DOI 10.1134/S0006297909060042
   Patra SK, 2011, CLIN EPIGENETICS, V2, P27, DOI 10.1007/s13148-010-0016-0
   Patra SK, 2002, MOL CARCINOGEN, V33, P163, DOI 10.1002/mc.10033
   Patra SK, 2003, BIOCHEM BIOPH RES CO, V302, P759, DOI 10.1016/S0006-291X(03)00253-5
   Patra SK, 2001, BIOCHEM BIOPH RES CO, V287, P705, DOI 10.1006/bbrc.2001.5639
   Rodenhiser D, 2006, CAN MED ASSOC J, V174, P341, DOI 10.1503/cmaj.050774
   Sansom OJ, 2007, NAT CLIN PRACT ONCOL, V4, P305, DOI 10.1038/ncponc0812
   Sasai N, 2009, INT J DEV BIOL, V53, P323, DOI 10.1387/ijdb.082652ns
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Strathdee G, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S1462399402004222
   Toné S, 2007, EXP CELL RES, V313, P3635, DOI 10.1016/j.yexcr.2007.06.018
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Vilain A, 1999, FEBS LETT, V460, P231, DOI 10.1016/S0014-5793(99)01358-7
   Wade PA, 2001, ONCOGENE, V20, P3166, DOI 10.1038/sj.onc.1204340
   Wade PA, 2001, BIOESSAYS, V23, P1131, DOI 10.1002/bies.10008
   Weber M, 2007, CURR OPIN CELL BIOL, V19, P273, DOI 10.1016/j.ceb.2007.04.011
NR 43
TC 53
Z9 57
U1 1
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD OCT 13
PY 2014
VL 6
AR 20
DI 10.1186/1868-7083-6-20
PG 13
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA AX3WG
UT WOS:000346866000001
PM 25478034
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Singh, RK
   Srivastava, A
   Kalaiarasan, P
   Manvati, S
   Chopra, R
   Bamezai, RNK
AF Singh, Rajnish Kumar
   Srivastava, Archita
   Kalaiarasan, Ponnusamy
   Manvati, Siddharth
   Chopra, Rupali
   Bamezai, Rameshwar N. K.
TI mtDNA germ line variation mediated ROS generates retrograde signaling
   and induces pro-cancerous metabolic features
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MITOCHONDRIAL-DNA MUTATIONS; PYRUVATE-KINASE M2; BREAST-CANCER; G10398A
   POLYMORPHISM; MISSENSE MUTATIONS; ESOPHAGEAL CANCER; SPORADIC BREAST;
   GENE-EXPRESSION; DAMAGE RESPONSE; TUMOR-GROWTH
AB mtDNA non-synonymous germ line variation (G10398A; p.A114T) has remained equivocal with least mechanistic understanding in showing an association with cancer. This has necessitated showing in-vitro how an over-expression within mitochondria of either of the variants produces higher intracellular ROS, resulting in differential anchorage dependent and independent growth. Both these features were observed to be relatively higher in ND3:114T variant. An elevated amount of intracellular carbonylated proteins and a reduced activity of a key glycolytic enzyme, Pyruvate kinase M2, along with high glucose uptake and lactate production were other pro-cancerous features observed. The retrograde signaling through surplus ROS was generated by post-ND3 over-expression regulated nuclear gene expression epigenetically, involving selectively the apoptotic-DDR-pathways. The feature of ND3 over-expression, inducing ROS mediated pro-cancerous features in the cells in in vitro, was replicated in a pilot study in a limited number of sporadic breast tumors, suggesting the importance of mitochondrial germ-line variant(s) in enabling the cells to acquire pro-cancerous features.
C1 [Singh, Rajnish Kumar; Srivastava, Archita; Chopra, Rupali; Bamezai, Rameshwar N. K.] Jawaharlal Nehru Univ, Sch Life Sci, Natl Ctr Appl Human Genet, New Delhi 110067, India.
   [Kalaiarasan, Ponnusamy; Manvati, Siddharth] Shri Mata Vaishno Devi Univ, Sch Biotechnol, Katra 182320, Jammu & Kashmir, India.
C3 Jawaharlal Nehru University, New Delhi; Shri Mata Vaishno Devi
   University
RP Bamezai, RNK (通讯作者)，Jawaharlal Nehru Univ, Sch Life Sci, Natl Ctr Appl Human Genet, New Delhi 110067, India.
EM bamezai@hotmail.com
RI ; Ponnusamy, Kalaiarasan/K-4925-2018
OI Bamezai, R.N.K/0000-0002-5128-2859; SINGH, RAJNISH/0000-0001-7414-1170;
   Ponnusamy, Kalaiarasan/0000-0002-4913-2237
FU Council of Scientific and Industrial Research, India
FX R.K.S. was supported by fellowship from Council of Scientific and
   Industrial Research, India.
CR Akhtar K, 2009, J BIOL CHEM, V284, P11971, DOI 10.1074/jbc.M808761200
   Anastasiou D, 2011, SCIENCE, V334, P1278, DOI 10.1126/science.1211485
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arnold RS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/239257
   Bai RK, 2007, CANCER RES, V67, P4687, DOI 10.1158/0008-5472.CAN-06-3554
   Booker LM, 2006, J UROLOGY, V175, P468, DOI 10.1016/S0022-5347(05)00163-1
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Canter JA, 2005, CANCER RES, V65, P8028, DOI 10.1158/0008-5472.CAN-05-1428
   Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604
   Chaudhari AA, 2008, J VET MED SCI, V70, P537, DOI 10.1292/jvms.70.537
   Covarrubias D, 2008, J HUM GENET, V53, P924, DOI 10.1007/s10038-008-0331-x
   Czarnecka AM, 2010, BREAST CANCER RES TR, V121, P511, DOI 10.1007/s10549-009-0358-5
   Darvishi K, 2007, CANCER LETT, V249, P249, DOI 10.1016/j.canlet.2006.09.005
   Dasgupta S, 2008, CANCER RES, V68, P700, DOI 10.1158/0008-5472.CAN-07-5532
   Dhillon VS, 2014, MUTAT RES-REV MUTAT, V759, P1, DOI 10.1016/j.mrrev.2013.09.001
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095
   Galkin A, 2008, J BIOL CHEM, V283, P20907, DOI 10.1074/jbc.M803190200
   Galluzzi L, 2012, CIRC RES, V111, P1198, DOI 10.1161/CIRCRESAHA.112.268946
   Gochhait S, 2008, INT J CANCER, V123, P2580, DOI 10.1002/ijc.23817
   González-Vioque E, 2014, MOL GENET GENOM MED, V2, P107, DOI 10.1002/mgg3.47
   He J, 2012, EMBO REP, V13, P1116, DOI 10.1038/embor.2012.162
   Iqbal MA, 2014, J BIOL CHEM, V289, P8098, DOI 10.1074/jbc.M113.515742
   Iqbal MA, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-72
   Ismail RS, 2000, CANCER RES, V60, P6744
   Janssen AJM, 2007, CLIN CHEM, V53, P729, DOI 10.1373/clinchem.2006.078873
   Juo SHH, 2010, MITOCHONDRION, V10, P294, DOI 10.1016/j.mito.2010.01.001
   Kato T, 2001, J AFFECT DISORDERS, V62, P151, DOI 10.1016/S0165-0327(99)00173-1
   Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128
   Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110
   Lam ET, 2012, CANCER RES, V72, P686, DOI 10.1158/0008-5472.CAN-11-1682
   Larman TC, 2012, P NATL ACAD SCI USA, V109, P14087, DOI 10.1073/pnas.1211502109
   Leslie NR, 2003, EMBO J, V22, P5501, DOI 10.1093/emboj/cdg513
   Li XY, 2011, MITOCHONDRION, V11, P27, DOI 10.1016/j.mito.2010.06.005
   Liu VWS, 2003, HUM MUTAT, V22, P173, DOI 10.1002/humu.10244
   Liu ZC, 2006, ANNU REV GENET, V40, P159, DOI 10.1146/annurev.genet.40.110405.090613
   McMahon S, 2014, CARCINOGENESIS, V35, P1046, DOI 10.1093/carcin/bgu012
   Miki H, 2012, J BIOCHEM, V151, P255, DOI 10.1093/jb/mvs006
   Mittler R, 2011, TRENDS PLANT SCI, V16, P300, DOI 10.1016/j.tplants.2011.03.007
   MORRISON JF, 1954, BIOCHEM J, V58, P685, DOI 10.1042/bj0580685
   Niemi AK, 2005, EUR J HUM GENET, V13, P166, DOI 10.1038/sj.ejhg.5201308
   Nikolaev A. I., 2001, MOL MED REP, V5, P1526
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16
   Ohta S, 2006, ONCOGENE, V25, P4768, DOI 10.1038/sj.onc.1209602
   Pal R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-303
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Pezzotti A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005356
   Segref A, 2014, CELL METAB, V19, P642, DOI 10.1016/j.cmet.2014.01.016
   Torroni A, 1996, GENETICS, V144, P1835
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wallace DC, 2013, J CLIN INVEST, V123, P1405, DOI 10.1172/JCI61398
   Woodson JD, 2008, NAT REV GENET, V9, P383, DOI 10.1038/nrg2348
   Zhang L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/696107
   Zhou SY, 2007, P NATL ACAD SCI USA, V104, P7540, DOI 10.1073/pnas.0610818104
NR 56
TC 23
Z9 23
U1 0
U2 9
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 10
PY 2014
VL 4
AR 6571
DI 10.1038/srep06571
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AQ8NJ
UT WOS:000343082600002
PM 25300428
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Bhan, A
   Hussain, I
   Ansari, KI
   Bobzean, SAM
   Perrotti, LI
   Mandel, SS
AF Bhan, Arunoday
   Hussain, Imran
   Ansari, Khairul I.
   Bobzean, Samara A. M.
   Perrotti, Linda I.
   Mandel, Subhrangsu S.
TI Histone Methyltransferase EZH2 Is Transcriptionally Induced by Estradiol
   as Well as Estrogenic Endocrine Disruptors Bisphenol-A and
   Diethylstilbestrol
SO JOURNAL OF MOLECULAR BIOLOGY
LA English
DT Article
DE EZH2; gene expression; estrogen signaling; endocrine disruptors;
   epigenetics
ID NUCLEAR RECEPTOR COREGULATORS; LONG NONCODING RNA; GROUP PROTEIN
   ENHANCER; ZESTE HOMOLOG-2 EZH2; IN-UTERO EXPOSURE; BREAST-CANCER;
   TUMOR-GROWTH; GENE-EXPRESSION; METHYLASE MLL1; CRITICAL ROLES
AB Enhancer of Zeste homolog 2 (EZH2), a methyltransferase specific to histone 3 lysine 27, is a critical player in gene silencing and is overexpressed in breast cancer. Our studies demonstrate that EZH2 is transcriptionally induced by estradiol in cultured breast cancer cells and in the mammary glands of ovariectomized rats. EZH2 promoter contains multiple functional estrogen-response elements. Estrogen receptors (ERs) and ER coregulators such as mixed lineage leukemia (MLL) histone methylases (MLL2 and MLL3) and histone acetyltransferase CBP/P300 bind to the EZH2 promoter in the presence of estradiol and regulate estradiol-induced EZH2 expression. EZH2 expression is also increased upon exposure to estrogenic endocrine disrupting chemicals (EDCs) such as bisphenol-A (BPA) and diethylstilbestrol (DES). Similar to estradiol, BPA and DES-induced EZH2 expression is coordinated by ERs, MLLs and CBP/P300. In summary, we demonstrate that EZH2 is transcriptionally regulated by estradiol in vitro and in vivo, and its expression is potentially dysregulated upon exposure to estrogenic EDCs. (C) 2014 Published by Elsevier Ltd.
C1 [Bhan, Arunoday; Hussain, Imran; Ansari, Khairul I.; Mandel, Subhrangsu S.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
   [Bobzean, Samara A. M.; Perrotti, Linda I.] Univ Texas Arlington, Dept Psychol, Arlington, TX 76019 USA.
C3 University of Texas System; University of Texas Arlington; University of
   Texas System; University of Texas Arlington
RP Mandel, SS (通讯作者)，Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
EM smandal@uta.edu
RI Ansari, Khairul/C-9791-2011; bhan, arunoday/F-1066-2011
OI Mandal, Subhrangsu/0000-0001-8495-9881; Ansari, Khairul
   I/0000-0002-9564-2107; Perrotti, Linda/0000-0002-6297-2572; Hussain,
   Imran/0000-0003-1563-7656
FU National Institutes of Health [1R15 ES019129-01, 2R15CA113747-02];
   National Science Foundation [0821969]; American Heart Association
   [0765160Y]; Division Of Chemistry; Direct For Mathematical & Physical
   Scien [0821969] Funding Source: National Science Foundation; American
   Heart Association (AHA) [0765160Y] Funding Source: American Heart
   Association (AHA)
FX We thank all the Mandal and Perrotti laboratory members for helpful
   discussions. Research in the Mandal laboratory is supported in part by
   grants from the National Institutes of Health (1R15 ES019129-01 and
   2R15CA113747-02), the National Science Foundation (0821969) and the
   American Heart Association (0765160Y).
CR Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052
   [Anonymous], 2000, UllmannsEncyclopedia of Industrial Chemistry
   Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352
   Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263
   Ansari KI, 2008, BBA-GENE REGUL MECH, V1779, P66, DOI 10.1016/j.bbagrm.2007.11.006
   Ansari KI, 2013, MOL ENDOCRINOL, V27, P92, DOI 10.1210/me.2012-1147
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t
   Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x
   Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x
   Ansari KI, 2009, FEBS J, V276, P3299, DOI 10.1111/j.1742-4658.2009.07055.x
   Ansari KI, 2009, FRONT BIOSCI-LANDMRK, V14, P3483, DOI 10.2741/3466
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bannister AJ, 2000, CURR BIOL, V10, P467, DOI 10.1016/S0960-9822(00)00445-0
   Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0
   Benachour N, 2009, TOXICOL APPL PHARM, V241, P322, DOI 10.1016/j.taap.2009.09.005
   Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148
   Bhan A, 2014, CHEMMEDCHEM
   Bhan A, 2014, J STEROID BIOCHEM, V141, P160, DOI 10.1016/j.jsbmb.2014.02.002
   Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022
   Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138
   Bonasio R, 2010, SCIENCE, V330, P612, DOI 10.1126/science.1191078
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Calle EE, 1996, AM J EPIDEMIOL, V144, P645, DOI 10.1093/oxfordjournals.aje.a008976
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chao HH, 2012, HISTOCHEM CELL BIOL, V137, P249, DOI 10.1007/s00418-011-0894-z
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Crawford BD, 2006, ACS CHEM BIOL, V1, P495, DOI 10.1021/cb600367v
   Croonquist PA, 2005, ONCOGENE, V24, P6269, DOI 10.1038/sj.onc.1208771
   Das J, 2013, BIOORG MED CHEM LETT, V23, P6183, DOI 10.1016/j.bmcl.2013.08.093
   Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109
   Dimri M, 2010, CARCINOGENESIS, V31, P489, DOI 10.1093/carcin/bgp305
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Eilam-Stock T, 2012, BEHAV NEUROSCI, V126, P175, DOI 10.1037/a0025959
   Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621
   Fenichel P, 2013, ANN ENDOCRINOL-PARIS, V74, P211, DOI 10.1016/j.ando.2013.04.002
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Gibert Y, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-4
   Gioiosa L, 2007, HORM BEHAV, V52, P307, DOI 10.1016/j.yhbeh.2007.05.006
   GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201
   Guenther MG, 2005, P NATL ACAD SCI USA, V102, P8603, DOI 10.1073/pnas.0503072102
   Guglielmelli P, 2011, BLOOD, V118, P5227, DOI 10.1182/blood-2011-06-363424
   Hermanson O, 2002, TRENDS ENDOCRIN MET, V13, P55, DOI 10.1016/S1043-2760(01)00527-6
   Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167
   Inagaki T, 2012, ENDOCRINOLOGY, V153, P3357, DOI 10.1210/en.2012-1121
   Kasiri S, 2013, RSC ADV, V3, P3260, DOI 10.1039/c2ra22006g
   Kerppola TK, 2009, TRENDS CELL BIOL, V19, P692, DOI 10.1016/j.tcb.2009.10.001
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Ku M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000242
   Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856
   Lee S, 2006, P NATL ACAD SCI USA, V103, P15392, DOI 10.1073/pnas.0607313103
   Lee S, 2009, MOL ENDOCRINOL, V23, P610, DOI 10.1210/me.2008-0455
   Lemmen JG, 2004, ENVIRON HEALTH PERSP, V112, P1544, DOI 10.1289/ehp.7155
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012
   MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Margueron R, 2009, NATURE, V461, P762, DOI 10.1038/nature08398
   Margueron R, 2008, MOL CELL, V32, P503, DOI 10.1016/j.molcel.2008.11.004
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   McKenna NJ, 2009, MOL ENDOCRINOL, V23, P740, DOI 10.1210/me.2009-0135
   McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Moggs JG, 2001, EMBO REP, V2, P775, DOI 10.1093/embo-reports/kve185
   Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620
   Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10
   Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535
   Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402
   Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Saunders PTK, 1997, ADV EXP MED BIOL, V424, P99
   Shen L, 2013, ONCOTARGETS THER, V6, P321, DOI 10.2147/OTT.S42453
   Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343
   Shrestha B, 2012, FEBS J, V279, P3715, DOI 10.1111/j.1742-4658.2012.08733.x
   Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Sudo T, 2005, BRIT J CANCER, V92, P1754, DOI 10.1038/sj.bjc.6602531
   Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521
   Tremblay GB, 2002, CRIT REV EUKAR GENE, V12, P1, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i1.10
   Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Verma SK, 2013, FUTURE MED CHEM, V5, P1661, DOI 10.4155/fmc.13.136
   Wang CX, 2012, CANCER RES, V72, P315, DOI 10.1158/0008-5472.CAN-11-0961
   Weikert S, 2005, INT J MOL MED, V16, P349
   Xu C, 2010, P NATL ACAD SCI USA, V107, P19266, DOI 10.1073/pnas.1008937107
   Yearley EJ, 2008, J MOL STRUCT, V890, P240, DOI 10.1016/j.molstruc.2008.03.053
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
   Zeidler M, 2006, J MOL HISTOL, V37, P219, DOI 10.1007/s10735-006-9042-9
NR 99
TC 96
Z9 112
U1 1
U2 29
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0022-2836
EI 1089-8638
J9 J MOL BIOL
JI J. Mol. Biol.
PD OCT 9
PY 2014
VL 426
IS 20
SI SI
BP 3426
EP 3441
DI 10.1016/j.jmb.2014.07.025
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AR5IC
UT WOS:000343617400009
PM 25088689
DA 2025-01-12
ER

PT J
AU Shiwarski, DJ
   Shao, CB
   Bill, A
   Kim, J
   Xiao, D
   Bertrand, CA
   Seethala, RS
   Sano, D
   Myers, JN
   Ha, P
   Grandis, J
   Gaither, LA
   Puthenveedu, MA
   Duvvuri, U
AF Shiwarski, Daniel J.
   Shao, Chunbo
   Bill, Anke
   Kim, Jean
   Xiao, Dong
   Bertrand, Carol A.
   Seethala, Raja S.
   Sano, Daisuke
   Myers, Jeffery N.
   Ha, Patrick
   Grandis, Jennifer
   Gaither, L. Alex
   Puthenveedu, Manojkumar A.
   Duvvuri, Umamaheswar
TI To "Grow" or "Go": TMEM16A Expression as a Switch between Tumor Growth
   and Metastasis in SCCHN
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; E-CADHERIN; CELLS;
   CARCINOMA; ANO1; IDENTIFICATION; CONTRIBUTES; PROGRESSION
AB Purpose: Tumor metastasis is the leading cause of death in patients with cancer. However, the mechanisms that underlie metastatic progression remain unclear. We examined TMEM16A (ANO1) expression as a key factor shifting tumors between growth and metastasis.
   Experimental Design: We evaluated 26 pairs of primary and metastatic lymph node (LN) tissue from patients with squamous cell carcinoma of the head and neck (SCCHN) for differential expression of TMEM16A. In addition, we identified mechanisms by which TMEM16A expression influences tumor cell motility via proteomic screens of cell lines and in vivo mouse studies of metastasis.
   Results: Compared with primary tumors, TMEM16A expression decreases in metastatic LNs of patients with SCCHN. Stable reduction of TMEM16A expression enhances cell motility and increases metastases while decreasing tumor proliferation in an orthotopic mouse model. Evaluation of human tumor tissues suggests an epigenetic mechanism for decreasing TMEM16A expression through promoter methylation that correlated with a transition between an epithelial and a mesenchymal phenotype. These effects ofTMEM16A expression on tumor cell size and epithelial-to-mesenchymal transition (EMT) required the amino acid residue serine 970 (S970); however, mutation of S970 to alanine does not disrupt the proliferative advantages of TMEM16A overexpression. Furthermore, S970 mediates the association of TMEM16A with Radixin, an actin-scaffolding protein implicated in EMT.
   Conclusions: Together, our results identify TMEM16A, an eight transmembrane domain Ca2+-activated Cl- channel, as a primary driver of the "Grow" or "Go" model for cancer progression, in which TMEM16A expression acts to balance tumor proliferation and metastasis via its promoter methylation. (C) 2014 AACR.
C1 [Shiwarski, Daniel J.; Kim, Jean; Xiao, Dong; Grandis, Jennifer; Duvvuri, Umamaheswar] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
   [Shiwarski, Daniel J.; Kim, Jean; Xiao, Dong; Grandis, Jennifer; Duvvuri, Umamaheswar] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
   [Shiwarski, Daniel J.; Puthenveedu, Manojkumar A.] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA.
   [Shao, Chunbo; Ha, Patrick] Johns Hopkins Univ, Sch Med, Dept Otolaryngol, Baltimore, MD 21205 USA.
   [Bill, Anke; Gaither, L. Alex] Novartis Inst Biomed Res Inc, Dept Dev & Mol Pathways, Cambridge, MA USA.
   [Bertrand, Carol A.] Univ Pittsburgh, Med Ctr, Dept Cell Biol, Pittsburgh, PA 15213 USA.
   [Seethala, Raja S.] Univ Pittsburgh, Med Ctr, Dept Pathol, Pittsburgh, PA 15213 USA.
   [Sano, Daisuke] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan.
   [Myers, Jeffery N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.
C3 US Department of Veterans Affairs; Veterans Health Administration (VHA);
   VA Pittsburgh Healthcare System; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon
   University; Johns Hopkins University; Novartis; Novartis USA;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Yokohama City University; University
   of Texas System; UTMD Anderson Cancer Center
RP Duvvuri, U (通讯作者)，Univ Pittsburgh, Med Ctr, Suite 500,200 Lothrop St,W948 Biomed Sci Tower, Pittsburgh, PA 15213 USA.
EM duvvuriu@upmc.edu
RI Duvvuri, Umamaheswar/AAN-7973-2020; Shiwarski, Daniel/ABC-9784-2020;
   Sano, Daisuke/R-6591-2018; Puthenveedu, Manojkumar/A-3795-2016
OI Shiwarski, Daniel/0000-0001-6978-303X; Puthenveedu,
   Manojkumar/0000-0002-3177-4231; Bill, Anke/0000-0003-1244-7574
FU Head and Neck Cancer SPORE grant through a Career Development Award
   [P50-CA097190]; Department of Veterans Affairs Biomedical Laboratory
   Science Research and Development RD; PNC Foundation; University of
   Pittsburgh Competitive Medical Research Fund; Department of
   Otolaryngology, University of Pittsburgh School of Medicine
FX This work was supported in part by the Head and Neck Cancer SPORE grant
   (P50-CA097190, to J. Grandis), through a Career Development Award and a
   Pilot Project grant from the Department of Veterans Affairs Biomedical
   Laboratory Science Research and Development R&D (to U. Duvvuri), the PNC
   Foundation, the University of Pittsburgh Competitive Medical Research
   Fund, and start-up funds from the Department of Otolaryngology,
   University of Pittsburgh School of Medicine (to U. Duvvuri).
CR Almaca J, 2009, J BIOL CHEM, V284, P28571, DOI 10.1074/jbc.M109.010074
   Ayoub C, 2010, BRIT J CANCER, V103, P715, DOI 10.1038/sj.bjc.6605823
   Britschgi A, 2013, P NATL ACAD SCI USA, V110, pE1026, DOI 10.1073/pnas.1217072110
   Caputo A, 2008, SCIENCE, V322, P590, DOI 10.1126/science.1163518
   Chao Y, 2012, CANCER MICROENVIRON, V5, P19, DOI 10.1007/s12307-011-0085-4
   Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179
   Duvvuri U, 2012, CANCER RES, V72, P3270, DOI 10.1158/0008-5472.CAN-12-0475-T
   Gil-Henn H, 2013, ONCOGENE, V32, P2622, DOI 10.1038/onc.2012.284
   Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5
   Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799
   Issaq HJ, 2002, BIOCHEM BIOPH RES CO, V292, P587, DOI 10.1006/bbrc.2002.6678
   Jacobsen KS, 2013, PFLUG ARCH EUR J PHY, V465, P1753, DOI 10.1007/s00424-013-1315-z
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675
   Keshamouni VG, 2006, J PROTEOME RES, V5, P1143, DOI 10.1021/pr050455t
   Koppikar P, 2008, CLIN CANCER RES, V14, P7682, DOI 10.1158/1078-0432.CCR-08-1328
   Liu W, 2012, CANCER LETT, V326, P41, DOI 10.1016/j.canlet.2012.07.015
   Mayland MK, 2005, LARYNGOSCOPE, V115, P629, DOI 10.1097/01.mlg.0000161338.54515.b1
   Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Perez-Cornejo P, 2012, P NATL ACAD SCI USA, V109, P10376, DOI 10.1073/pnas.1200174109
   Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1
   Shao CB, 2011, CLIN CANCER RES, V17, P4320, DOI 10.1158/1078-0432.CCR-10-2992
   Simon S, 2013, CANCER RES, V73, P3661, DOI 10.1158/0008-5472.CAN-12-3839
   Teng PN, 2011, J PROTEOME RES, V10, P1333, DOI 10.1021/pr101074p
   Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1
   Zheng L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019390
NR 27
TC 81
Z9 91
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2014
VL 20
IS 17
BP 4673
EP 4688
DI 10.1158/1078-0432.CCR-14-0363
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP1MV
UT WOS:000341835500026
PM 24919570
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Lowe, D
   Raj, K
AF Lowe, Donna
   Raj, Kenneth
TI Premature aging induced by radiation exhibits pro-atherosclerotic
   effects mediated by epigenetic activation of CD44 expression
SO AGING CELL
LA English
DT Article
DE CD44; endothelium; irradiation; inflammation; monocyte adhesion;
   senescence
ID BREAST-CANCER RADIOTHERAPY; ENDOTHELIAL-CELLS; IN-VIVO; SENESCENCE;
   ADHESION; IRRADIATION; DAMAGE; INFLAMMATION; RECRUITMENT; MECHANISMS
AB Age is undoubtedly a major risk factor for heart disease. However, the reason for this is not entirely clear. In the course of our investigation into the mechanism of radiation-induced cardiovascular disease, we made several unexpected findings that inform us on this question. We observed that human coronary endothelial cells, while being able to initiate repair of radiation-induced DNA damage, often fail to complete the repair and become senescent. Such radiation-induced cellular aging occurs through a mutation-independent route. Endothelial cells that aged naturally through replication or as a result of radiation exhibited indistinguishable characteristics. The promoter regions of the CD44 gene in aging endothelial cells become demethylated, and the proteins are highly expressed on the cell surface, making the cells adhesive for monocytes. Adhesion is a cardinal feature that recruits monocytes to the endothelium, allowing them to infiltrate the vessel wall and initiate atherosclerosis. The epigenetic activation of CD44 expression is particularly significant as it causes persistent elevated CD44 protein expression, making senescent endothelial cells chronically adhesive. In addition to understanding why cardiovascular disease increases with age, these observations provide insights into the puzzling association between radiation and cardiovascular disease and highlight the need to consider premature aging as an additional risk of radiation to human health.
C1 [Lowe, Donna; Raj, Kenneth] Publ Hlth England, Biol Effects Dept, Ctr Radiat Chem & Environm Hazards, Didcot OX11 0RQ, Oxon, England.
C3 Public Health England
RP Raj, K (通讯作者)，Publ Hlth England, Biol Effects Dept, Ctr Radiat Chem & Environm Hazards, Didcot OX11 0RQ, Oxon, England.
EM Ken.raj@phe.gov.uk
FU Public Health England through the National Institute for Health Research
   grant [107930]
FX This work was funded by Public Health England through the National
   Institute for Health Research grant No. 107930.
CR Adams MJ, 2003, CRIT REV ONCOL HEMAT, V45, P55, DOI 10.1016/S1040-8428(01)00227-X
   Bendall LJ, 1997, BRIT J HAEMATOL, V98, P828
   Bourguignon LYW, 2006, J BIOL CHEM, V281, P14026, DOI 10.1074/jbc.M507734200
   Brandes RP, 2005, CARDIOVASC RES, V66, P286, DOI 10.1016/j.cardiores.2004.12.027
   COLDENSTANFIELD M, 1994, J IMMUNOL, V153, P5222
   Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455
   Darby S, 2003, BMJ-BRIT MED J, V326, P256
   Ellender M, 2005, RADIAT RES, V163, P552, DOI 10.1667/RR3335
   Erusalimsky JD, 2005, EXP GERONTOL, V40, P634, DOI 10.1016/j.exger.2005.04.010
   Erusalimsky JD, 2009, J APPL PHYSIOL, V106, P326, DOI 10.1152/japplphysiol.91353.2008
   Geng S, 2013, ARCH DERMATOL RES, V305, P35
   Hallahan D, 1996, CANCER RES, V56, P5150
   Hewitt G, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1708
   Hoving S, 2008, INT J RADIAT ONCOL, V71, P848, DOI 10.1016/j.ijrobp.2008.02.031
   Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036
   Johnson P, 2000, BIOCHEM PHARMACOL, V59, P455, DOI 10.1016/S0006-2952(99)00266-X
   Kagara N, 2012, AM J PATHOL, V181, P257, DOI 10.1016/j.ajpath.2012.03.019
   Khaled S, 2012, RADIAT RES, V177, P594, DOI 10.1667/RR2557.1
   Krettek A, 2004, AM J PATHOL, V165, P1571, DOI 10.1016/S0002-9440(10)63414-1
   LIAO HX, 1995, J IMMUNOL, V155, P3938
   Libby P, 2006, AM J CLIN NUTR, V83, p456S
   Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705
   Libby P, 2006, AM J CARDIOL, V98, p3Q, DOI 10.1016/j.amjcard.2006.09.020
   Libby P, 2010, CIRC J, V74, P213, DOI 10.1253/circj.CJ-09-0706
   Little MP, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b4326
   Minamino T, 2002, CIRCULATION, V105, P1541, DOI 10.1161/01.CIR.0000013836.85741.17
   Mone SM, 2004, PEDIATRICS, V113, P1058
   Mun GI, 2010, AM J PHYSIOL-HEART C, V298, pH2102, DOI 10.1152/ajpheart.00835.2009
   Muthna D, 2010, STEM CELLS DEV, V19, P1855, DOI 10.1089/scd.2009.0449
   Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3
   Oostendorp RAJ, 1996, ACTA HAEMATOL-BASEL, V95, P243
   Puré E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3
   REPIN VS, 1984, ATHEROSCLEROSIS, V50, P35, DOI 10.1016/0021-9150(84)90006-6
   ROSS R, 1977, AM J PATHOL, V86, P675
   Roychoudhuri R, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-9
   Seemann I, 2012, RADIOTHER ONCOL, V103, P143, DOI 10.1016/j.radonc.2011.10.011
   Shimizu Y, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5349
   Stewart F. A., 2012, Annals of the ICRP, V41, P72, DOI 10.1016/j.icrp.2012.06.031
   Stewart FA, 2010, RADIAT RES, V174, P865, DOI 10.1667/RR1862.1
   Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2
   Taylor CW, 2008, INT J RADIAT ONCOL, V72, P501, DOI 10.1016/j.ijrobp.2007.12.058
   Taylor CW, 2009, RADIOTHER ONCOL, V90, P127, DOI 10.1016/j.radonc.2008.09.029
   TOKUNAGA O, 1989, AM J PATHOL, V135, P967
   Vasile E, 2001, FASEB J, V15, P458, DOI 10.1096/fj.00-0051com
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
NR 45
TC 73
Z9 77
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD OCT
PY 2014
VL 13
IS 5
BP 900
EP 910
DI 10.1111/acel.12253
PG 11
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA AQ2PY
UT WOS:000342631100014
PM 25059316
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wu, HX
   Tong, SL
   Wu, C
   Wang, WX
AF Wu, Hong-Xue
   Tong, Shi-Lun
   Wu, Chong
   Wang, Wei-Xing
TI <i>HTRA1</i> gene expression in gastric epithelial cells
SO ASIAN PACIFIC JOURNAL OF TROPICAL MEDICINE
LA English
DT Article
DE HtrA1 gene; Gastric epithelial cells; Gastric cancer
ID DNA-DAMAGE RESPONSE; METHYLATION; CHROMATIN; CHEMOTHERAPY
AB Objective: To explore HtrA 1 gene expression and its regulation in human gastric cancers. Methods: The HtrA 1 mRNA levels were examined by QPCR analysis and confirmed its expression with Northern blot analysis. The HtrA1 protein levels in all six gastric epithelial cell lines were investigated by Western blot analysis. Gene copy number was accessed and then sequenced the coding region from each mRNA in all six cell lines. The HtrA1 promoter region DNA methylation status was detected by using bisulfite sequencing analysis. Effect of decitabine and TSA on HTRA1 expression in gastric cancer cell line was determined by RTPCR. Results: HIC analysis indicated that HtrA1 was highly expressed in normal epithelium, but dramatically down regulated in gastric carcinoma tissues and variably expressed in tumor adjacent tissues. HtrA 1 gene expression was dramatically decreased in gastric carcinoma cells compared to non tumorigenic counterparts. The HtrA I gene loss in any of the 4 breast cancer cell lines was not detected. Total 14 CpGs in this region were all methylated in gastric cancer cells, whereas two normal cells, GES-1 and HFI-145, were having several unmethylated cytosines in this region. HtrA1 showed as similar to Mr 44,000, Expression of HtrA1 protein was not observed in any of the four gastric cancer cell lines, BGC-823, MKN-45, SGC-7901 and MKN-28. HtrA1 expression was observed in the HFI-145 and GES-1 cell lines. Conclusions: The epigenetic silencing for HtrA1 gene expression could provide a possible strategy for re activating HtrA1 gene expression in gastric cancer cells, thus facilitating further investigation of Htra1's role in chemotherapy.
C1 [Wu, Hong-Xue; Tong, Shi-Lun; Wu, Chong; Wang, Wei-Xing] Wuhan Univ, Peoples Hosp Affiliated, Gastrointestinal Dept, Wuhan 430060, Hubei, Peoples R China.
C3 Wuhan University
RP Wu, HX (通讯作者)，Wuhan Univ, Peoples Hosp Affiliated, Gastrointestinal Dept, Wuhan 430060, Hubei, Peoples R China.
RI wang, wy/JDD-3603-2023
FU Natural Science and Technology Fund of Hubei Povince [012726334]
FX It is supported by Natural Science and Technology Fund of Hubei Povince
   (012726334).
CR Biran A, 2012, STEM CELLS, V30, P1793, DOI 10.1002/stem.1169
   Catalano V, 2011, HISTOPATHOLOGY, V58, P669, DOI 10.1111/j.1365-2559.2011.03818.x
   Chien J, 2006, J CLIN INVEST, V116, P1994, DOI 10.1172/JCI27698
   Davis CD, 2004, EXP BIOL MED, V229, P988, DOI 10.1177/153537020422901002
   DeWan A, 2006, SCIENCE, V314, P989
   Feinberg AP, 2004, SEMIN CANCER BIOL, V14, P427, DOI 10.1016/j.semcancer.2004.06.005
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Folgueira MAAK, 2005, CLIN CANCER RES, V11, P7434
   Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750
   Grewal SIS, 2003, SCIENCE, V301, P798, DOI 10.1126/science.1086887
   He XP, 2012, INT J CANCER, V130, P1029, DOI 10.1002/ijc.26044
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jin L, 2011, CHIN J GEN SURG, V1, P12
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Karlic R, 2010, P NATL ACAD SCI USA, V107, P2926, DOI 10.1073/pnas.0909344107
   Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   Mullany SA, 2011, CLIN CANCER RES, V17, P427, DOI 10.1158/1078-0432.CCR-09-3069
   Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890
   Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311
   Roberts CWM, 2004, NAT REV CANCER, V4, P133, DOI 10.1038/nrc1273
   Shin DM, 2011, GERONTOLOGY, V57, P76, DOI 10.1159/000281882
   Siersbaek R, 2012, TRENDS ENDOCRIN MET, V23, P56, DOI 10.1016/j.tem.2011.10.001
   Timar J., 2013, CANC GENOMICS MOL CL, P47, DOI [DOI 10.1007/978-94-007-5842-1, 10.1007/978-94-007-5842-1]
   Wang N, 2011, PENNSYLVANIA STATE U
   Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366
   Zhong L, 2012, J XIAN JIAO TONG U M, V33
   Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005
   Zhu F, 2010, HEPATOB PANCREAT DIS, V9, P508
   Zhu WG, 2001, CANCER RES, V61, P1327
   Zupkovitz G, 2006, MOL CELL BIOL, V26, P7913, DOI 10.1128/MCB.01220-06
NR 31
TC 4
Z9 4
U1 0
U2 14
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 1995-7645
EI 2352-4146
J9 ASIAN PAC J TROP MED
JI Asian Pac. J. Trop. Med.
PD OCT
PY 2014
VL 7
IS 10
BP 765
EP 771
DI 10.1016/S1995-7645(14)60133-4
PG 7
WC Public, Environmental & Occupational Health; Tropical Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AN6EN
UT WOS:000340687800003
PM 25129457
OA gold
DA 2025-01-12
ER

PT J
AU Carmona, FJ
   Davalos, V
   Vidal, E
   Gomez, A
   Heyn, H
   Hashimoto, Y
   Vizoso, M
   Martinez-Cardus, A
   Sayols, S
   Ferreira, HJ
   Sánchez-Mut, JV
   Morán, S
   Margel, M
   Castella, E
   Berdasco, M
   Stefansson, OA
   Eyfjord, JE
   Gonzalez-Suarez, E
   Dopazo, J
   Orozco, M
   Gut, IG
   Esteller, M
AF Carmona, F. Javier
   Davalos, Veronica
   Vidal, Enrique
   Gomez, Antonio
   Heyn, Holger
   Hashimoto, Yutaka
   Vizoso, Miguel
   Martinez-Cardus, Anna
   Sayols, Sergi
   Ferreira, Humberto J.
   Sanchez-Mut, Jose V.
   Moran, Sebastian
   Margel, Mireia
   Castella, Eva
   Berdasco, Maria
   Stefansson, Olafur A.
   Eyfjord, Jorunn E.
   Gonzalez-Suarez, Eva
   Dopazo, Joaquin
   Orozco, Modesto
   Gut, Ivo G.
   Esteller, Manel
TI A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal
   Transition
SO CANCER RESEARCH
LA English
DT Article
ID INTEGRIN ALPHA(5); CANCER; METASTASIS; EXPRESSION; SUPPRESSION;
   MICROARRAY; CARCINOMA; PROTEINS; FKBP65; MODEL
AB Epithelial-to-mesenchymal transition (EMT) is a plastic process in which fully differentiated epithelial cells are converted into poorly differentiated, migratory and invasive mesenchymal cells, and it has been related to the metastasis potential of tumors. This is a reversible process and cells can also eventually undergo mesenchymal-to-epithelial transition. The existence of a dynamic EMT process suggests the involvement of epigenetic shifts in the phenotype. Herein, we obtained the DNA methylomes at single-base resolution of Madin-Darby canine kidney cells undergoing EMT and translated the identified differentially methylated regions to human breast cancer cells undergoing a gain of migratory and invasive capabilities associated with the EMT phenotype. We noticed dynamic and reversible changes of DNA methylation, both on promoter sequences and gene-bodies in association with transcription regulation of EMT-related genes. Most importantly, the identified DNA methylation markers of EMT were present in primary mammary tumors in association with the epithelial or the mesenchymal phenotype of the studied breast cancer samples. (C) 2014 AACR.
C1 [Carmona, F. Javier; Davalos, Veronica; Vidal, Enrique; Gomez, Antonio; Heyn, Holger; Hashimoto, Yutaka; Vizoso, Miguel; Martinez-Cardus, Anna; Sayols, Sergi; Ferreira, Humberto J.; Sanchez-Mut, Jose V.; Moran, Sebastian; Berdasco, Maria; Stefansson, Olafur A.; Gonzalez-Suarez, Eva; Esteller, Manel] Hosp Llobregat, Canc Epigenet & Biol Program PEBC, Bellvitge Biomed Res Inst, Barcelona 08908, Spain.
   [Margel, Mireia] Catalan Inst Oncol Badalona, Barcelona, Spain.
   [Castella, Eva] Hosp Badalona Germans Trias & Pujol, Dept Pathol, Badalona, Spain.
   [Eyfjord, Jorunn E.] Univ Iceland, Fac Med, Canc Res Lab, Reykjavik, Iceland.
   [Eyfjord, Jorunn E.] Univ Iceland, Dept Med, Reykjavik, Iceland.
   [Dopazo, Joaquin] CIPF, Dept Bioinformat, Valencia, Spain.
   [Dopazo, Joaquin] CIBER Enfermedades Raras CIBERER, Valencia, Spain.
   [Dopazo, Joaquin] CIPF, Funct Genom Node INB, Valencia, Spain.
   [Orozco, Modesto] IRB Barcelona, Inst Res Biomed, Barcelona, Spain.
   [Orozco, Modesto] Joint IRB BSC Res Program Computat Biol, Barcelona, Spain.
   [Orozco, Modesto] Barcelona Supercomputing Ctr, Barcelona, Spain.
   [Orozco, Modesto] Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain.
   [Gut, Ivo G.] CNAG, Barcelona, Spain.
   [Esteller, Manel] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain.
   [Esteller, Manel] ICREA, Barcelona, Spain.
C3 Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of
   Barcelona; Institut Catala d'Oncologia; Hospital Germans Trias i Pujol;
   University of Iceland; University of Iceland; Prince Felipe Research
   Center; CIBER - Centro de Investigacion Biomedica en Red; CIBERER;
   Prince Felipe Research Center; Barcelona Institute of Science &
   Technology; Institute for Research in Biomedicine - IRB Barcelona;
   Barcelona Institute of Science & Technology; Institute for Research in
   Biomedicine - IRB Barcelona; University of Barcelona; University of
   Barcelona; ICREA
RP Esteller, M (通讯作者)，Hosp Llobregat, Canc Epigenet & Biol Program PEBC, Hosp Duran & Reynals, 3rd Floor,Av Gran Via Hosp 199-203, Barcelona 08908, Spain.
EM mesteller@idibell.cat
RI Hashimoto, Yutaka/B-9821-2017; Vidal, Enrique/J-7118-2015; Gut,
   Ivo/ABF-3188-2020; Dopazo, Joaquin/A-9270-2014; Castellà,
   Eva/K-4140-2017; Martinez, Anna/AAA-4939-2020; Davalos,
   Veronica/AAR-8547-2020; Davalos, Veronica/S-1668-2016; Sanchez-Mut, Jose
   Vicente/A-8651-2019; Gonzalez-Suarez, Eva/L-6298-2014; Gomez Moruno,
   Antonio/H-7574-2015; Esteller, Manel/L-5956-2014; Vidal,
   Enrique/A-9455-2014; Moran, Sebastian/G-5293-2013
OI Sayols, Sergi/0000-0002-3877-4170; Ferreira,
   Humberto/0000-0003-0834-2956; Davalos, Veronica/0000-0003-4077-5137;
   Sanchez-Mut, Jose Vicente/0000-0002-9292-8521; Vizoso,
   Miguel/0000-0002-9992-2851; Gonzalez-Suarez, Eva/0000-0003-0858-8171;
   Gomez Moruno, Antonio/0000-0001-5308-981X; Martinez Cardus,
   Anna/0000-0002-3937-8794; Gut, Ivo/0000-0001-7219-632X; Orozco Lopez,
   Modesto/0000-0002-8608-3278; Esteller, Manel/0000-0003-4490-6093; Vidal,
   Enrique/0000-0002-4217-1807; Moran, Sebastian/0000-0003-4192-8983;
   Margeli Vila, Mireia/0000-0003-3594-4530; Heyn,
   Holger/0000-0002-3276-1889
FU European Research Council [268626-EPINORC]; Cellex Foundation; Sandra
   Ibarra Foundation; Ministry of Economy and Competitiveness
   [SAF2011-22803]; Generalitat de Catalunya; ICREA Funding Source: Custom
FX This work was supported by the European Research Council
   (#268626-EPINORC), Cellex Foundation, Sandra Ibarra Foundation, Ministry
   of Economy and Competitiveness (SAF2011-22803), and Generalitat de
   Catalunya.
CR Andrews J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008665
   Ball MP, 2009, NAT BIOTECHNOL, V27, P361, DOI 10.1038/nbt.1533
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Berdasco Maria, 2009, V507, P23, DOI 10.1007/978-1-59745-522-0_2
   Bernstein BE, 2010, NAT BIOTECHNOL, V28, P1045, DOI 10.1038/nbt1010-1045
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038
   Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   Fernandez AF, 2009, GENOME RES, V19, P438, DOI 10.1101/gr.083550.108
   Forrest MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073169
   Fujita PA, 2011, NUCLEIC ACIDS RES, V39, pD876, DOI 10.1093/nar/gkq963
   GAUSH CR, 1966, P SOC EXP BIOL MED, V122, P931
   Gong JG, 1997, CELL GROWTH DIFFER, V8, P83
   Haider S, 2009, NUCLEIC ACIDS RES, V37, pW23, DOI 10.1093/nar/gkp265
   Hansen KD, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R83, 10.1186/gb-2012-13-10-r83]
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Heyn H, 2012, P NATL ACAD SCI USA, V109, P10522, DOI 10.1073/pnas.1120658109
   Ishikawa Y, 2008, J BIOL CHEM, V283, P31584, DOI 10.1074/jbc.M802535200
   Carmona FJ, 2013, CANCER PREV RES, V6, P656, DOI 10.1158/1940-6207.CAPR-12-0501
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Kulis M, 2012, NAT GENET, V44, P1236, DOI 10.1038/ng.2443
   Li H, 2011, BIOINFORMATICS, V27, P718, DOI 10.1093/bioinformatics/btq671
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Min SW, 2007, P NATL ACAD SCI USA, V104, P3823, DOI 10.1073/pnas.0611725104
   Moreno-Bueno G, 2009, NAT PROTOC, V4, P1591, DOI 10.1038/nprot.2009.152
   Patterson CE, 2005, CELL STRESS CHAPERON, V10, P285, DOI 10.1379/CSC-118R.1
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Qian F, 2005, BIOCHEM BIOPH RES CO, V333, P1269, DOI 10.1016/j.bbrc.2005.06.039
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Quinn MCJ, 2013, INT J ONCOL, V42, P912, DOI 10.3892/ijo.2013.1797
   Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196
   Sarrió D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   Tani N, 2003, BRIT J CANCER, V88, P327, DOI 10.1038/sj.bjc.6600710
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013
   Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410
   Vantyghem SA, 2005, CLIN EXP METASTAS, V22, P351, DOI 10.1007/s10585-005-0745-1
   Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Xu H, 2010, BIOINFORMATICS, V26, P1199, DOI 10.1093/bioinformatics/btq128
   Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
   Zemach A, 2010, SCIENCE, V328, P916, DOI 10.1126/science.1186366
NR 52
TC 56
Z9 63
U1 0
U2 17
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD OCT 1
PY 2014
VL 74
IS 19
BP 5608
EP 5619
DI 10.1158/0008-5472.CAN-13-3659
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AQ8WP
UT WOS:000343118900025
PM 25106427
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Le Dily, F
   Baù, D
   Pohl, A
   Vicent, GP
   Serra, F
   Soronellas, D
   Castellano, G
   Wright, RHG
   Ballare, C
   Filion, G
   Marti-Renom, MA
   Beato, M
AF Le Dily, Francois
   Bau, Davide
   Pohl, Andy
   Vicent, Guillermo P.
   Serra, Francois
   Soronellas, Daniel
   Castellano, Giancarlo
   Wright, Roni H. G.
   Ballare, Cecilia
   Filion, Guillaume
   Marti-Renom, Marc A.
   Beato, Miguel
TI Distinct structural transitions of chromatin topological domains
   correlate with coordinated hormone-induced gene regulation
SO GENES & DEVELOPMENT
LA English
DT Article
DE three-dimensional structure of the genome; gene expression; Hi-C; TADs;
   transcriptional regulation; epigenetic landscape; progesterone receptor
ID ESTROGEN-RECEPTOR; HUMAN GENOME; CHROMOSOME CONFORMATION;
   PROGESTERONE-RECEPTOR; DROSOPHILA GENOME; BREAST-CANCER; HISTONE H1;
   TRANSCRIPTION; ACTIVATION; ORGANIZATION
AB The human genome is segmented into topologically associating domains (TADs), but the role of this conserved organization during transient changes in gene expression is not known. Here we describe the distribution of progestin-induced chromatin modifications and changes in transcriptional activity over TADs in T47D breast cancer cells. Using ChIP-seq (chromatin immunoprecipitation combined with high-throughput sequencing), Hi-C (chromosome capture followed by high-throughput sequencing), and three-dimensional (3D) modeling techniques, we found that the borders of the -2000 TADs in these cells are largely maintained after hormone treatment and that up to 20% of the TADs could be considered as discrete regulatory units where the majority of the genes are either transcriptionally activated or repressed in a coordinated fashion. The epigenetic signatures of the TADs are homogeneously modified by hormones in correlation with the transcriptional changes. Hormone-induced changes in gene activity and chromatin remodeling are accompanied by differential structural changes for activated and repressed TADs, as reflected by specific and opposite changes in the strength of intra-TAD interactions within responsive TADs. Indeed, 3D modeling of the Hi-C data suggested that the structure of TADs was modified upon treatment. The differential responses of TADs to progestins and estrogens suggest that TADs could function as "regulons" to enable spatially proximal genes to be coordinately transcribed in response to hormones.
C1 [Le Dily, Francois; Bau, Davide; Pohl, Andy; Vicent, Guillermo P.; Serra, Francois; Soronellas, Daniel; Castellano, Giancarlo; Wright, Roni H. G.; Ballare, Cecilia; Filion, Guillaume; Marti-Renom, Marc A.; Beato, Miguel] Ctr Regulacio Genom, Gene Regulac Stem Cells & Canc Program, Barcelona 08003, Spain.
   [Le Dily, Francois; Pohl, Andy; Vicent, Guillermo P.; Soronellas, Daniel; Castellano, Giancarlo; Wright, Roni H. G.; Ballare, Cecilia; Filion, Guillaume; Beato, Miguel] Univ Pompeu Fabra, Barcelona 08002, Spain.
   [Le Dily, Francois; Bau, Davide; Serra, Francois; Marti-Renom, Marc A.] Ctr Nacl Anal Genom, Genome Biol Grp, Barcelona 08028, Spain.
   [Castellano, Giancarlo] Univ Barcelona, Hosp Clin, E-08036 Barcelona, Spain.
   [Marti-Renom, Marc A.] Inst Catalana Recerca & Estudis Avancats, Barcelona 08010, Spain.
C3 Barcelona Institute of Science & Technology; Pompeu Fabra University;
   Centre de Regulacio Genomica (CRG); Pompeu Fabra University; University
   of Barcelona; Hospital Clinic de Barcelona; ICREA
RP Beato, M (通讯作者)，Ctr Regulacio Genom, Gene Regulac Stem Cells & Canc Program, Barcelona 08003, Spain.
EM miguel.beato@crg.es
RI Castellano, Giancarlo/AGN-1752-2022; Marti-Renom, Marc/Y-8803-2019;
   Wright, Roni/AAG-5190-2019; Beato, Miguel/B-5564-2015; Marti-Renom, Marc
   A./A-1836-2010; Serra, Francois/A-8789-2011; Filion,
   Guillaume/G-9619-2015; Ballare, Cecilia/F-2593-2016; Vicent, Guillermo
   Pablo/K-5432-2015; Le Dily, Francois/J-9448-2015
OI Wright, Roni/0000-0002-8194-4614; Beato, Miguel/0000-0002-2878-2222;
   Marti-Renom, Marc A./0000-0002-0151-4279; Serra,
   Francois/0000-0003-3895-4742; Filion, Guillaume/0000-0002-3473-1632;
   Ballare, Cecilia/0000-0002-9442-807X; Vicent, Guillermo
   Pablo/0000-0002-0554-2226; Castellano, Giancarlo/0000-0002-5715-7733; Le
   Dily, Francois/0000-0002-8324-7927
FU Spanish Ministry of Economy and Competitiveness (MINECO)
   [BFU2010-19310/BMC]; Human Frontiers Science Program [RGP0044/2011];
   Spanish government [BMC 2003-02902, BMC 2010-15313, CSD2006-00049];
   Catalan government (Agencia de Gestio d'Ajuts Universitaris i de Recerca
   [AGAUR]); Spanish Ministry of Economy and Competitiveness; Centro de
   Excelencia Severo Ochoa;  [SEV-2012-0208]; ICREA Funding Source: Custom
FX We thank the Centre de Regulacio Genomica (CRG) Ultrasequencing Unit and
   Advanced Light Microscopy Unit for technical support, and all members of
   the Chromatin and Gene Expression and Structural Genomic groups for
   helpful discussions. We acknowledge Juan Valcarcel for his helpful
   comments on the manuscript. We also thank Marta Morell and the Genetic
   Causes of Disease group for providing the BAC clones used in this study.
   We thank Ivan Junier for his help and advice in normalizing the Hi-C
   data. We acknowledge financial support from the Spanish Ministry of
   Economy and Competitiveness (MINECO) (BFU2010-19310/BMC) and the Human
   Frontiers Science Program (RGP0044/2011) (to M.A.M.-R.). This work was
   also supported by grants from the Spanish government (BMC 2003-02902,
   BMC 2010-15313, and CSD2006-00049) and the Catalan government (Agencia
   de Gestio d'Ajuts Universitaris i de Recerca [AGAUR]) (to M.B.). We
   acknowledge support of the Spanish Ministry of Economy and
   Competitiveness, 'Centro de Excelencia Severo Ochoa 2013-2017,'
   SEV-2012-0208. F.L.D., G.F., M.A.M-R., and M.B. designed the studies.
   F.L.D. performed Hi-C, FISH, and RNA-seq experiments. G.V., R.H.G.W, and
   C.B. performed ChIP-seq experiments. F.L.D. carried out the data
   analysis with contributions from A.P., D.S., G.C., and G.F., and F.S.,
   D.B., and M.A.M-R. carried out the 3D modelling and analysis. F.S. and
   G.F. designed the TAD boundary algorithm. All of the authors discussed
   the results, and F.L.D., M.A.M-R., and M.B. wrote the manuscript.
CR Ballaré C, 2013, MOL CELL, V49, P67, DOI 10.1016/j.molcel.2012.10.019
   Baù D, 2012, METHODS, V58, P300, DOI 10.1016/j.ymeth.2012.04.004
   Baù D, 2011, NAT STRUCT MOL BIOL, V18, P107, DOI 10.1038/nsmb.1936
   Buttinelli M, 1999, GENETICA, V106, P117, DOI 10.1023/A:1003745315540
   Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794
   Cavalli G, 2007, CURR OPIN GENET DEV, V17, P443, DOI 10.1016/j.gde.2007.08.013
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Dekker J, 2013, NAT REV GENET, V14, P390, DOI 10.1038/nrg3454
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Dostie J, 2006, GENOME RES, V16, P1299, DOI 10.1101/gr.5571506
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   García-Becerra R, 2010, GENE, V458, P37, DOI 10.1016/j.gene.2010.03.007
   Hakim O, 2011, GENOME RES, V21, P697, DOI 10.1101/gr.111153.110
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hou CH, 2012, MOL CELL, V48, P471, DOI 10.1016/j.molcel.2012.08.031
   Imakaev M, 2012, NAT METHODS, V9, P999, DOI [10.1038/NMETH.2148, 10.1038/nmeth.2148]
   Jin F, 2013, NATURE, V503, P290
   Kalhor R, 2012, NAT BIOTECHNOL, V30, P90, DOI 10.1038/nbt.2057
   Kocanova S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000922
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Marco-Sola S, 2012, NAT METHODS, V9, P1185, DOI [10.1038/NMETH.2221, 10.1038/nmeth.2221]
   Mateos-Langerak J, 2009, P NATL ACAD SCI USA, V106, P3812, DOI 10.1073/pnas.0809501106
   Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008
   Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903
   Nora EP, 2013, BIOESSAYS, V35, P818, DOI 10.1002/bies.201300040
   Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049
   Nye AC, 2002, MOL CELL BIOL, V22, P3437, DOI 10.1128/MCB.22.10.3437-3449.2002
   Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192
   Osborne CS, 2004, NAT GENET, V36, P1065, DOI 10.1038/ng1423
   Vicent GP, 2011, GENE DEV, V25, P845, DOI 10.1101/gad.621811
   Routh A, 2008, P NATL ACAD SCI USA, V105, P8872, DOI 10.1073/pnas.0802336105
   Russel D, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001244
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Sexton T, 2012, CELL, V148, P458, DOI 10.1016/j.cell.2012.01.010
   Shen Y, 2012, NATURE, V488, P116, DOI 10.1038/nature11243
   Symmons O, 2014, GENOME RES, V24, P390, DOI 10.1101/gr.163519.113
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   TRUSS M, 1995, EMBO J, V14, P1737, DOI 10.1002/j.1460-2075.1995.tb07163.x
   Vicent GP, 2008, J STEROID BIOCHEM, V109, P344, DOI 10.1016/j.jsbmb.2008.03.015
   Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011
   Vicent GP, 2013, GENE DEV, V27, P1179, DOI 10.1101/gad.215293.113
   Wright RHG, 2012, GENE DEV, V26, P1972, DOI 10.1101/gad.193193.112
   Yadon AN, 2013, MOL CELL, V50, P93, DOI 10.1016/j.molcel.2013.02.005
   Yaffe E, 2011, NAT GENET, V43, P1059, DOI 10.1038/ng.947
NR 45
TC 214
Z9 250
U1 1
U2 30
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD OCT 1
PY 2014
VL 28
IS 19
BP 2151
EP 2162
DI 10.1101/gad.241422.114
PG 12
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA AQ5ZX
UT WOS:000342888200007
PM 25274727
OA Green Submitted, gold, Green Published
DA 2025-01-12
ER

PT J
AU van den Beucken, T
   Koch, E
   Chu, K
   Rupaimoole, R
   Prickaerts, P
   Adriaens, M
   Voncken, JW
   Harris, AL
   Buffa, FM
   Haider, S
   Starmans, MHW
   Yao, CQ
   Ivan, M
   Ivan, C
   Pecot, CV
   Boutros, PC
   Sood, AK
   Koritzinsky, M
   Wouters, BG
AF van den Beucken, Twan
   Koch, Elizabeth
   Chu, Kenneth
   Rupaimoole, Rajesha
   Prickaerts, Peggy
   Adriaens, Michiel
   Voncken, Jan Willem
   Harris, Adrian L.
   Buffa, Francesca M.
   Haider, Syed
   Starmans, Maud H. W.
   Yao, Cindy Q.
   Ivan, Mircea
   Ivan, Cristina
   Pecot, Chad V.
   Boutros, Paul C.
   Sood, Anil K.
   Koritzinsky, Marianne
   Wouters, Bradly G.
TI Hypoxia promotes stem cell phenotypes and poor prognosis through
   epigenetic regulation of DICER
SO NATURE COMMUNICATIONS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; DEMETHYLASE JMJD3 CONTRIBUTES;
   SOMATIC MUTATIONS; INDUCIBLE FACTORS; DOWN-REGULATION; CANCER CELLS;
   EXPRESSION; EZH2; METASTASIS; MICRORNAS
AB MicroRNAs are small regulatory RNAs that post transcriptionally control gene expression. Reduced expression of DICER, the enzyme involved in microRNA processing, is frequently observed in cancer and is associated with poor clinical outcome in various malignancies. Yet, the underlying mechanisms are not well understood. Here we identify tumour hypoxia as a regulator of DICER expression in large cohorts of breast cancer patients. We show that DICER expression is suppressed by hypoxia through an epigenetic mechanism that involves inhibition of oxygen-dependent H3K27me3 demethylases KDM6A/B and results in silencing of the DICER promoter. Subsequently, reduced miRNA processing leads to derepression of the miR-200 target ZEB1, stimulates the epithelial to mesenchymal transition and ultimately results in the acquisition of stem cell phenotypes in human mammary epithelial cells. Our study uncovers a previously unknown relationship between oxygen-sensitive epigenetic regulators, miRNA biogenesis and tumour stem cell phenotypes that may underlie poor outcome in breast cancer.
C1 [van den Beucken, Twan; Koch, Elizabeth; Koritzinsky, Marianne; Wouters, Bradly G.] Princess Margaret Canc Ctr, Toronto, ON M5G IL7, Canada.
   [van den Beucken, Twan; Koch, Elizabeth; Koritzinsky, Marianne; Wouters, Bradly G.] Campbell Family Inst Canc Res, Univ Hlth Network, Toronto, ON M5G IL7, Canada.
   [van den Beucken, Twan; Starmans, Maud H. W.; Wouters, Bradly G.] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol, NL-6200 MD Maastricht, Netherlands.
   [van den Beucken, Twan] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Toxicogen, NL-6200 MD Maastricht, Netherlands.
   [Koch, Elizabeth; Yao, Cindy Q.; Boutros, Paul C.; Wouters, Bradly G.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada.
   [Chu, Kenneth; Starmans, Maud H. W.; Yao, Cindy Q.; Boutros, Paul C.] Ontario Inst Canc Res, Informat & Biocomp Program, Toronto, ON M5G 1L7, Canada.
   [Rupaimoole, Rajesha] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA.
   [Rupaimoole, Rajesha] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
   [Prickaerts, Peggy; Voncken, Jan Willem] Univ Amsterdam, Acad Med Ctr, Heart Failure Res Ctr, Dept Expt Cardiol, NL-1105 AZ Amsterdam, Netherlands.
   [Adriaens, Michiel] Maastricht Univ, BiGCaT, Dept Bioinformat, NL-6200 MD Maastricht, Netherlands.
   [Adriaens, Michiel] Maastricht Univ, BiGCaT, Dept Bioinformat, NL-6200 MD Maastricht, Netherlands.
   [Harris, Adrian L.; Buffa, Francesca M.] John Radcliffe Hosp, Weatherall Inst Mol Med, Canc Res UK Dept Oncol, Oxford OX3 9DS, England.
   [Ivan, Cristina] Indiana Univ, Melvin & Bren Simon Canc Ctr, Dept Med, Indianapolis, IN 46202 USA.
   [Ivan, Cristina; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Non Coding RNAs, Houston, TX 77030 USA.
   [Pecot, Chad V.] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Oncol, Houston, TX 77030 USA.
   [Boutros, Paul C.] Univ Toronto, Dept Pharmacol & Toxicol, Toronto, ON M5S 1A8, Canada.
   [Koritzinsky, Marianne] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A8, Canada.
   [Koritzinsky, Marianne; Wouters, Bradly G.] Univ Toronto, Dept Radiat Oncol, Toronto, ON M5T 1P5, Canada.
   [Wouters, Bradly G.] Ontario Inst Canc Res, Select Therapies Program, Toronto, ON M5G 1L7, Canada.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Toronto; University Health Network
   Toronto; Maastricht University; Maastricht University; University of
   Toronto; University of Toronto; Ontario Institute for Cancer Research;
   University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Amsterdam;
   Academic Medical Center Amsterdam; Maastricht University; Maastricht
   University; University of Oxford; Cancer Research UK; Indiana University
   System; Indiana University Indianapolis; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson
   Cancer Center; University of Toronto; University of Toronto; University
   of Toronto; Ontario Institute for Cancer Research; University of Toronto
RP Wouters, BG (通讯作者)，Princess Margaret Canc Ctr, 101 Coll St,Room 12-310, Toronto, ON M5G IL7, Canada.
EM bradwouters@gmail.com
RI Boutros, Paul/A-1084-2009; Koritzinsky, Marianne/KQU-3089-2024;
   Prickaerts, Peggy/K-7562-2012; Ivan, Mircea/A-8109-2012; Wouters,
   Bradly/T-1525-2017; Rupaimoole, Rajesha/K-3272-2016; Harris,
   Adrian/ABA-3343-2020; Buffa, Francesca M./D-2574-2013
OI Wouters, Bradly/0000-0002-8187-592X; Rupaimoole,
   Rajesha/0000-0002-4795-7921; Boutros, Paul/0000-0003-0553-7520; Harris,
   Adrian/0000-0003-1376-8409; van den Beucken, Twan/0000-0002-2233-7558;
   Ivan, Mircea/0000-0003-3424-6642; Buffa, Francesca
   M./0000-0003-0409-406X; Koritzinsky, Marianne/0000-0003-0547-2480; Ivan,
   Cristina/0000-0002-4848-0168; Adriaens, Michiel/0000-0002-4472-7119
FU Dutch Cancer Society (KWF) [UM 2008-4068]; Ontario Ministry of Health
   and Long Term Care (OMOHLTC); Terry Fox New Frontiers Research Program
   [PPG-1036]; Ontario Institute for Cancer Research; Terry Fox Research
   Institute; Canadian Institute for Health Research (CIHR) [201592]; EU
   [222741]; Government of Ontario; Canadian Breast Cancer Foundation
   (CBCF); Cancer Research UK [CRUK_A11359]; Breast Cancer Research
   Foundation (BCRF); National Institute of Health [U54 151668, P50
   CA083639, UH2 TR000943, R01 CA155332-01]; Cancer Research UK; British
   Columbia Cancer Agency Branch
FX We thank R. Weinberg for providing the HMLER cells. We also thank C.
   Arrowsmith for providing the SGC inhibitors. We thank Alison Casey,
   Milan Ganguly and Trevor Do for advice and technical assistance on the
   immunohistochemical staining in these and other tissue samples. This
   work was financially supported by the Dutch Cancer Society (KWF grant UM
   2008-4068 to B. W.), the Ontario Ministry of Health and Long Term Care
   (OMOHLTC), the Terry Fox New Frontiers Research Program PPG-1036 to B.
   G. W. and M. K.), the Ontario Institute for Cancer Research and Terry
   Fox Research Institute (Stem Cell Program to B. G. W.), the Canadian
   Institute for Health Research (CIHR grant 201592 to B. G. W. and M. K.)
   and the EU 7th framework programme (METOXIA project 222741 to B. G. W.
   and M. K.). The views expressed do not necessarily reflect those of the
   OMOHLTC. This study was conducted with the support of the Ontario
   Institute for Cancer Research to P. C. B. through funding provided by
   the Government of Ontario. E. K. and C.Q.Y. were supported by
   fellowships from the Canadian Breast Cancer Foundation (CBCF). A. L. H.
   was supported by funding from Cancer Research UK (CRUK_A11359) and the
   Breast Cancer Research Foundation (BCRF). A. K. S. was supported by
   funding from the National Institute of Health (U54 151668, P50 CA083639,
   and UH2 TR000943). M. I. was supported by funding from the National
   Institute of Health (R01 CA155332-01). This study makes use of data
   generated by the Molecular Taxonomy of Breast Cancer International
   Consortium<SUP>34</SUP>, which was funded by Cancer Research UK and the
   British Columbia Cancer Agency Branch.
CR Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Amatangelo MD, 2013, CELL CYCLE, V12, P2113, DOI 10.4161/cc.25163
   Banerjee R, 2011, ONCOGENE, V30, P4339, DOI 10.1038/onc.2011.141
   Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bernstein BE, 2007, CELL, V128, P669, DOI 10.1016/j.cell.2007.01.033
   Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Brennan DJ, 2006, CLIN CANCER RES, V12, P6421, DOI 10.1158/1078-0432.CCR-06-0480
   Cairns RA, 2004, CANCER RES, V64, P2054, DOI 10.1158/0008-5472.CAN-03-3196
   Cairns RA, 2001, CANCER RES, V61, P8903
   Chan YC, 2011, J BIOL CHEM, V286, P2047, DOI 10.1074/jbc.M110.158790
   Chaturvedi P, 2013, J CLIN INVEST, V123, P189, DOI 10.1172/JCI64993
   Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Das B, 2008, STEM CELLS, V26, P1818, DOI 10.1634/stemcells.2007-0724
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Fyles A, 2002, J CLIN ONCOL, V20, P680, DOI 10.1200/JCO.2002.20.3.680
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193
   Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002
   Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355
   Ho JJD, 2012, J BIOL CHEM, V287, P29003, DOI 10.1074/jbc.M112.373365
   Hussain SA, 2007, BRIT J CANCER, V96, P104, DOI 10.1038/sj.bjc.6603530
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x
   Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Konze KD, 2013, ACS CHEM BIOL, V8, P1324, DOI [10.1021/cb400133J, 10.1021/cb400133j]
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209
   Levy C, 2010, CELL, V141, P994, DOI 10.1016/j.cell.2010.05.004
   Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018
   Lock FE, 2013, ONCOGENE, V32, P5210, DOI 10.1038/onc.2012.550
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marie-Egyptienne DT, 2013, CANCER LETT, V341, P63, DOI 10.1016/j.canlet.2012.11.019
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Mehta Shaveta, 2011, Journal of the National Cancer Institute Monographs, P71, DOI 10.1093/jncimonographs/lgr027
   Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007
   Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317
   Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785
   Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Okajima M, 2013, ONCOL REP, V29, P2311, DOI 10.3892/or.2013.2401
   Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966
   Pollard PJ, 2008, BIOCHEM J, V416, P387, DOI 10.1042/BJ20081238
   Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202
   Schindl M, 2002, CLIN CANCER RES, V8, P1831
   Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Starmans M. H., RADIOTHER ONCOL, V102, P436
   Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   van den Beucken T, 2009, J BIOL CHEM, V284, P24204, DOI 10.1074/jbc.M109.006510
   van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349
   Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395
   Vaupel P, 2002, Wien Med Wochenschr, V152, P334
   Vaupel P, 2009, ADV EXP MED BIOL, V645, P241, DOI 10.1007/978-0-387-85998-9_36
   Winter SC, 2007, CANCER RES, V67, P3441, DOI 10.1158/0008-5472.CAN-06-3322
   Yan M, 2009, BRIT J CANCER, V101, P1168, DOI 10.1038/sj.bjc.6605287
   Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691
   Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208
NR 71
TC 187
Z9 201
U1 0
U2 43
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT
PY 2014
VL 5
AR 5203
DI 10.1038/ncomms6203
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AS0QL
UT WOS:000343982500002
PM 25351418
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Kong, KA
   Lee, JY
   Oh, JH
   Lee, Y
   Kim, MH
AF Kong, Kyoung-Ah
   Lee, Ji-Yeon
   Oh, Ji Hoon
   Lee, Youra
   Kim, Myoung Hee
TI Akt1 mediates the posterior <i>Hoxc</i> gene expression through
   epigenetic modifications in mouse embryonic fibroblasts
SO BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS
LA English
DT Article
DE Hox gene expression; Epigenetic modification; Akt1; Hdac; Ezh2; Kdm6b
ID HISTONE H3; BREAST-CANCER; DEMETHYLASE; CHROMATIN; METHYLATION;
   LYSINE-27; PROTEIN; EZH2; UTX; CONFORMATION
AB The evolutionarily conserved Hox genes are organized in clusters and expressed colinearly to specify body patterning during embryonic development. Previously, Akt1 has been identified as a putative Hox gene regulator through in silico analysis. Substantial upregulation of consecutive 5' Hoxc genes has been observed when Akt1 is absent in mouse embryonic fibroblast (MEF) cells. In this study, we provide evidence that Akt1 regulates the 5' Hoxc gene expression by epigenetic modifications. Enrichment of histone H3K9 acetylation and a low level of the H3K27me3 mark were detected at the posterior 5' Hoxc loci when Akt1 is absent. A histone deacetylase (HDAC) inhibitor de-repressed 5' Hoxc gene expression when Akt1 is present, and a DNA demethylating reagent synergistically upregulated HDAC-induced 5' Hoxc gene expression. A knockdown study revealed that Hdac6 is mediated in the Hoxc12 repression through direct binding to the transcription start site (TSS) in the presence of Akt1. Co-immunoprecipitation analysis revealed that endogenous Akt1 directly interacted with Hdac6. Furthermore, exogenous Akt1 was enriched at the promoter region of the posterior Hoxc genes such as Hoxc11 and Hoxc12, not the Akt1-independent Hoxc5 and Hoxd10 loci. The regulation of the H3K27me3 mark by Ezh2 and Kdm6b at the 5' Hoxc gene promoter turned out to be Akt1 dependent. Taken together, these results suggest that Akt1 mediates the posterior 5' Hoxc gene expression through epigenetic modification such as histone methylation and acetylation, and partly through a direct binding to the promoter region of the 5' Hoxc genes and/or Hdac6 in mouse embryonic fibroblast cells. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Kong, Kyoung-Ah; Lee, Ji-Yeon; Oh, Ji Hoon; Lee, Youra; Kim, Myoung Hee] Yonsei Univ, Coll Med, Embryol Lab, Dept Anat, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Kim, MH (通讯作者)，Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Dept Anat,Embryol Lab, CPO Box 8044, Seoul 120752, South Korea.
EM mhkim1@yuhs.ac
RI Kim, Tae-Hee/AAN-9079-2021
OI Lee, Ji-Yeon/0000-0002-0670-3095; Oh, Ji Hoon/0000-0001-6619-5515; Kim,
   Myoung Hee/0000-0001-5652-1452
FU Basic Science Research Program through the National Research Foundation
   (NRF) - Ministry of Education, Science and Technology [2010-0026759,
   NRF-2013R1A1A2008399]; Next-Generation BioGreen21 Program of the Rural
   Development Administration [PJ00905601]; Yonsei University College of
   Medicine, Korea [6-2013-0049]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation (NRF) funded by the Ministry of
   Education, Science and Technology (2010-0026759 and
   NRF-2013R1A1A2008399), the Next-Generation BioGreen21 Program of the
   Rural Development Administration (PJ00905601), and partly from a faculty
   research grant (6-2013-0049) of Yonsei University College of Medicine,
   Korea.
CR Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145
   Alexander T, 2009, ANNU REV CELL DEV BI, V25, P431, DOI 10.1146/annurev.cellbio.042308.113423
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Bae SS, 2003, J BIOL CHEM, V278, P49530, DOI 10.1074/jbc.M306782200
   Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103
   Biehs B, 2013, NAT CELL BIOL, V15, P846, DOI 10.1038/ncb2766
   Branciamore S, 2010, P NATL ACAD SCI USA, V107, P15485, DOI 10.1073/pnas.1010506107
   Cha TL, 2005, SCIENCE, V310, P306, DOI 10.1126/science.1118947
   Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525
   Copur Ö, 2013, DEVELOPMENT, V140, P3478, DOI 10.1242/dev.097204
   Daftary GS, 2006, ENDOCR REV, V27, P331, DOI 10.1210/er.2005-0018
   Dasen JS, 2013, CELL REP, V5, P1, DOI 10.1016/j.celrep.2013.09.033
   De Santa F, 2007, CELL, V130, P1083, DOI 10.1016/j.cell.2007.08.019
   Deschamps J, 2005, DEVELOPMENT, V132, P2931, DOI 10.1242/dev.01897
   Estève PO, 2011, NAT STRUCT MOL BIOL, V18, P42, DOI 10.1038/nsmb.1939
   Ferraiuolo MA, 2010, NUCLEIC ACIDS RES, V38, P7472, DOI 10.1093/nar/gkq644
   Fraser J, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-4-r37
   Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009
   He H, 2011, ONCOGENE, V30, P379, DOI 10.1038/onc.2010.484
   Kanduri M, 2013, EPIGENETICS-US, V8, P1280, DOI 10.4161/epi.26546
   Kashyap V, 2011, J BIOL CHEM, V286, P3250, DOI 10.1074/jbc.M110.157545
   Kim YJ, 2011, P NATL ACAD SCI USA, V108, P7391, DOI 10.1073/pnas.1018279108
   Kobrossy L, 2006, J BIOL CHEM, V281, P25926, DOI 10.1074/jbc.M602555200
   Kong KA, 2013, GENE, V513, P287, DOI 10.1016/j.gene.2012.10.034
   Lan F, 2007, NATURE, V449, P689, DOI 10.1038/nature06192
   Lee EY, 2006, ANN NY ACAD SCI, V1090, P182, DOI 10.1196/annals.1378.020
   Lee JT, 2012, SCIENCE, V338, P1435, DOI 10.1126/science.1231776
   Lee S, 2012, DEV CELL, V22, P25, DOI 10.1016/j.devcel.2011.11.009
   Lemons D, 2006, SCIENCE, V313, P1918, DOI 10.1126/science.1132040
   Li LJ, 2013, CELL REP, V5, P3, DOI 10.1016/j.celrep.2013.09.003
   Lim SO, 2008, GASTROENTEROLOGY, V135, P2128, DOI 10.1053/j.gastro.2008.07.027
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Lin RK, 2010, J CLIN INVEST, V120, P521, DOI 10.1172/JCI40706
   Lin WC, 2008, DEV GROWTH DIFFER, V50, P321, DOI [10.1111/j.1440-169x.2008.01041.x, 10.1111/j.1440-169X.2008.01041.x]
   Liu Y, 2013, FEBS LETT, V587, P847, DOI 10.1016/j.febslet.2013.02.023
   Mei CZ, 2010, J CELL BIOCHEM, V111, P158, DOI 10.1002/jcb.22684
   Min H, 2012, INT J BIOL SCI, V8, P802, DOI 10.7150/ijbs.4438
   Morgan R, 2006, TRENDS GENET, V22, P67, DOI 10.1016/j.tig.2005.11.004
   Noordermeer D, 2013, CURR TOP DEV BIOL, V104, P113, DOI 10.1016/B978-0-12-416027-9.00004-8
   Noordermeer D, 2011, SCIENCE, V334, P222, DOI 10.1126/science.1207194
   Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726
   Pindyurin AV, 2012, NUCLEUS-AUSTIN, V3, P118, DOI 10.4161/nucl.19159
   Rastegar M, 2004, MOL CELL BIOL, V24, P8090, DOI 10.1128/MCB.24.18.8090-8103.2004
   Ren GL, 2009, INT J BIOCHEM CELL B, V41, P1094, DOI 10.1016/j.biocel.2008.10.015
   Rousseau M, 2014, NUCLEIC ACIDS RES, V42, P1524, DOI 10.1093/nar/gkt998
   Schorderet P, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003951
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Shahhoseini M, 2013, BIOCHEM CELL BIOL, V91, P116, DOI 10.1139/bcb-2012-0049
   Soshnikova N, 2009, SCIENCE, V324, P1320, DOI 10.1126/science.1171468
   Sun LD, 2007, CELL SIGNAL, V19, P2255, DOI 10.1016/j.cellsig.2007.06.014
   Suzuki K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.195362
   Tabariès S, 2005, MOL CELL BIOL, V25, P1389, DOI 10.1128/MCB.25.4.1389-1401.2005
   Voss AK, 2009, DEV CELL, V17, P674, DOI 10.1016/j.devcel.2009.10.006
   Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819
   Wellik DM, 2009, CURR TOP DEV BIOL, V88, P257, DOI 10.1016/S0070-2153(09)88009-5
   Wu XD, 2008, NUCLEIC ACIDS RES, V36, P3590, DOI 10.1093/nar/gkn243
   Zhang YS, 2012, J ANIM VET ADV, V11, P2469
   Zuo T, 2011, CANCER RES, V71, P1752, DOI 10.1158/0008-5472.CAN-10-3573
NR 58
TC 12
Z9 12
U1 0
U2 16
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1874-9399
EI 1876-4320
J9 BBA-GENE REGUL MECH
JI Biochim. Biophys. Acta-Gene Regul. Mech.
PD SEP
PY 2014
VL 1839
IS 9
BP 793
EP 799
DI 10.1016/j.bbagrm.2014.06.011
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AO4YS
UT WOS:000341347900006
PM 24955524
DA 2025-01-12
ER

PT J
AU Plotkin, A
   Volmar, CH
   Wahlestedt, C
   Ayad, N
   El-Ashry, D
AF Plotkin, Amy
   Volmar, Claude-Henry
   Wahlestedt, Claes
   Ayad, Nagi
   El-Ashry, Dorraya
TI Transcriptional repression of ER through hMAPK dependent histone
   deacetylation by class I HDACs
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; Hormonal status; Histone deacetylase inhibitor; HDAC;
   Estrogen receptor; MAPK; Transcriptional repression
ID BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; ACTIVATED PROTEIN-KINASE;
   GROWTH-FACTOR RECEPTOR; INHIBITOR TRICHOSTATIN; DEPLETED CONDITIONS;
   PROGNOSTIC FACTORS; GENE-EXPRESSION; MCF-7 CELLS; PROGRESSION
AB Anti-estrogen therapies are not effective in ER- breast cancers, thus identifying mechanisms underlying lack of ER expression in ER- breast cancers is imperative. We have previously demonstrated that hyperactivation of MAPK (hMAPK) downstream of overexpressed EGFR or overexpression/amplification of Her2 represses ER protein and mRNA expression. Abrogation of hMAPK in ER- breast cancer cell lines and primary cultures causes re-expression of ER and restoration of anti-estrogen responses. This study was performed to identify mechanisms of hMAPK-induced transcriptional repression of ER. We found that ER promoter activity is significantly reduced in the presence of hMAPK signaling, yet did not identify specific promoter sequences responsible for this repression. We performed an epigenetic compound screen in an ER- breast cancer cell line that expresses hMAPK yet does not exhibit ER promoter hypermethylation. A number of HDAC inhibitors were identified and confirmed to modulate ER expression and estrogen signaling in multiple ER- cell lines and tumor samples lacking ER promoter methylation. siRNA-mediated knockdown of HDACs 1, 2, and 3 reversed the mRNA repression in multiple breast cancer cell lines and primary cultures and ER promoter-associated histone acetylation increased following MAPK inhibition. These data implicate histone deacetylation downstream of hMAPK in the observed ER mRNA repression associated with hMAPK. Importantly, histone deacetylation appears to be a common mechanism in the transcriptional repression of ER between ER- breast cancers with or without ER promoter hypermethylation.
C1 [Plotkin, Amy] Univ Miami, Miller Sch Med, Sheila & David Fuente Grad Program Canc Biol, Miami, FL 33136 USA.
   [Volmar, Claude-Henry; Wahlestedt, Claes; Ayad, Nagi] Univ Miami, Miller Sch Med, Dept Psychiat & Behav Sci, Ctr Therapeut Innovat, Miami, FL 33136 USA.
   [El-Ashry, Dorraya] Univ Miami, Miller Sch Med, Dept Med, Braman Breast Canc Inst,Sylvester Comprehens Canc, Miami, FL 33136 USA.
C3 University of Miami; University of Miami; University of Miami
RP El-Ashry, D (通讯作者)，Univ Miami, Miller Sch Med, Dept Med, Braman Breast Canc Inst,Sylvester Comprehens Canc, 1501 NW 10th Ave,Biomed Res Bldg,Rm 716, Miami, FL 33136 USA.
EM del-ashry@med.miami.edu
RI Volmar, C/AFR-7749-2022
OI Volmar, Claude-Henry/0000-0001-9437-051X
FU National Institutes of Health [NIH 1R01 CA113674, NIH 1R01NS067289];
   NIH; Bankhead Coley Foundation [BC-09BW-04-RC1]; Sylvester Comprehensive
   Cancer Center at the University of Miami Miller School of Medicine
FX This work was supported by grants from the National Institutes of Health
   (NIH 1R01 CA113674 to DEA and NIH 1R01NS067289 to NA), the Bankhead
   Coley Foundation (BC-09BW-04-RC1 to DEA), and by the Sylvester
   Comprehensive Cancer Center at the University of Miami Miller School of
   Medicine (to DEA). We would like to thank the Center for Therapeutic
   Innovation at the University of Miami Miller School of Medicine for the
   use of their epigenetic compound library and laboratory equipment, and
   Laura Parsons and Joeli Brinkman for technical contributions. We would
   also like to thank Drs. Marc Lippman, Zafar Nawaz, and Kerry Burnstein
   of the University of Miami for thoughtful discussion.
CR Alao JP, 2004, CLIN CANCER RES, V10, P8094, DOI 10.1158/1078-0432.CCR-04-1023
   Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047
   Bantscheff M, 2011, NAT BIOTECHNOL, V29, P255, DOI 10.1038/nbt.1759
   Bayliss J, 2007, CLIN CANCER RES, V13, P7029, DOI 10.1158/1078-0432.CCR-07-0587
   Brinkman JA, 2009, J MAMMARY GLAND BIOL, V14, P67, DOI 10.1007/s10911-009-9113-0
   Creighton CJ, 2006, CANCER RES, V66, P3903, DOI 10.1158/0008-5472.CAN-05-4363
   Das PM, 2004, BIOTECHNIQUES, V37, P961, DOI 10.2144/04376RV01
   DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191
   Drews-Elger K, 2014, BREAST CANCER RES TR, V144, P503, DOI 10.1007/s10549-014-2887-9
   ElAshry D, 1997, ONCOGENE, V15, P423, DOI 10.1038/sj.onc.1201198
   FERGUSON AT, 1995, CANCER RES, V55, P2279
   Ferguson BS, 2013, P NATL ACAD SCI USA, V110, P9806, DOI 10.1073/pnas.1301509110
   Holloway JN, 2004, MOL ENDOCRINOL, V18, P1396, DOI 10.1210/me.2004-0048
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   KNIGHT WA, 1977, CANCER RES, V37, P4669
   Krusche CA, 2005, BREAST CANCER RES TR, V90, P15, DOI 10.1007/s10549-004-1668-2
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   LIU YL, 1995, BREAST CANCER RES TR, V34, P97, DOI 10.1007/BF00665783
   MILLER DL, 1994, CELL GROWTH DIFFER, V5, P1263
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Oh AS, 2001, MOL ENDOCRINOL, V15, P1344, DOI 10.1210/me.15.8.1344
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   SAEZ RA, 1989, SEMIN SURG ONCOL, V5, P102, DOI 10.1002/ssu.2980050206
   SAINSBURY JRC, 1985, BRIT J SURG, V72, P186, DOI 10.1002/bjs.1800720309
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Sommer S, 2001, SEMIN CANCER BIOL, V11, P339, DOI 10.1006/scbi.2001.0389
   Stossi F, 2012, ONCOGENE, V31, P1825, DOI 10.1038/onc.2011.370
   Williams KA, 2013, J BIOL CHEM, V288, P33156, DOI 10.1074/jbc.M113.472506
   Winter M, 2013, EMBO J, V32, P3176, DOI 10.1038/emboj.2013.243
   WRIGHT C, 1987, J PATHOL, V153, P325, DOI 10.1002/path.1711530406
   Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001
   Yang XW, 2001, CANCER RES, V61, P7025
   Yi X, 2008, BIOCHEM PHARMACOL, V75, P1697, DOI 10.1016/j.bcp.2007.10.035
   Zhou XB, 2000, P NATL ACAD SCI USA, V97, P14329, DOI 10.1073/pnas.250494697
NR 36
TC 13
Z9 15
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD SEP
PY 2014
VL 147
IS 2
BP 249
EP 263
DI 10.1007/s10549-014-3093-5
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AO6UP
UT WOS:000341487600003
PM 25129342
DA 2025-01-12
ER

PT J
AU Cope, LM
   Fackler, MJ
   Lopez-Bujanda, Z
   Wolff, AC
   Visvanathan, K
   Gray, JW
   Sukumar, S
   Umbricht, CB
AF Cope, Leslie M.
   Fackler, Mary Jo
   Lopez-Bujanda, Zoila
   Wolff, Antonio C.
   Visvanathan, Kala
   Gray, Joe W.
   Sukumar, Saraswati
   Umbricht, Christopher B.
TI Do Breast Cancer Cell Lines Provide a Relevant Model of the Patient
   Tumor Methylome?
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; PROMOTER HYPERMETHYLATION; DRUG DISCOVERY; PREDICTION;
   CHEMOSENSITIVITY; EVOLUTION; PATTERNS; GENOME; GENES
AB It is well documented that tumor cells undergo dramatic genetic and epigenetic changes during initial establishment as cell lines and in subsequent serial passaging, and that the resultant cell lines may have evolved significantly from the primary tumors from which they were derived. This has potential implications due to their widespread use in drug response experiments and studies of genomic function. One approach to optimizing the design of such cell line studies is to identify and use the cell lines that faithfully recapitulate critical features of primary tumors. To evaluate the epigenetic fidelity of breast cancer cell lines in the context of primary tumors, we performed methylation profiling of 55 well-characterized breast cancer cell lines on the Illumina HumanMethylation27 BeadChip platform, and compared them to publicly available methylation profiles of primary breast tumors. We found that the DNA methylation profiles of breast cancer cell lines largely retain the features that characterize primary tumors, although there are crucial differences as well. We describe these similarities and differences between primary tumors and breast cancer cell lines in detail, and develop a quantitative measure of similarity that is used to score each cell line with respect to how faithfully its methylation profile mirrors that of primary tumors.
C1 [Cope, Leslie M.; Fackler, Mary Jo; Lopez-Bujanda, Zoila; Wolff, Antonio C.; Visvanathan, Kala; Sukumar, Saraswati; Umbricht, Christopher B.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Umbricht, Christopher B.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
   [Sukumar, Saraswati; Umbricht, Christopher B.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Visvanathan, Kala] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA.
   [Gray, Joe W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA.
C3 Johns Hopkins University; Johns Hopkins University; Johns Hopkins
   University; Johns Hopkins University; Johns Hopkins Bloomberg School of
   Public Health; Oregon Health & Science University
RP Umbricht, CB (通讯作者)，Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
EM cumbrich@jhmi.edu
RI Gray, Joe/AAX-9549-2020; Wolff, Antonio/T-8796-2019; Visvanathan,
   Kala/AAE-4396-2021; cope, leslie/LTE-4234-2024
OI Wolff, Antonio/0000-0003-3734-1063; Lopez Bujanda,
   Zoila/0000-0001-5729-7309
FU National Institutes of Health (SPORE Program in Breast Cancer) [P50 CA
   88843]; Department of Defense [COE: W81XWH-04-1-0595]; National
   Institutes of Health [P50 CA 58207, P30 CA 82103, U54 CA 112970, U24 CA
   126477, R01 CA 140311]; OHSU Knight Cancer Institute [5P30CA069533-16];
   Susan G. Komen Foundation [SAC110012, IIR KG110094]; National Cancer
   Institute [P30CA082103] Funding Source: NIH RePORTER
FX This work was supported by grants from the National Institutes of Health
   (SPORE Program in Breast Cancer, P50 CA 88843), and the Department of
   Defense (COE: W81XWH-04-1-0595) to SS; by National Institutes of Health
   grants (P50 CA 58207, P30 CA 82103, U54 CA 112970, U24 CA 126477), and
   by the OHSU Knight Cancer Institute (5P30CA069533-16), and by the Susan
   G. Komen Foundation (SAC110012) to JWG; and by the Susan G. Komen
   Foundation (IIR KG110094), and the National Institutes of Health (R01 CA
   140311) to CBU. The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR BAYLIN SB, 2004, NOVART FDN SYMP, V259, P234
   Baylin SB, 2004, NOVARTIS FDN S, V259, P285
   Baylin Stephen B, 2004, Novartis Found Symp, V259, P226
   Cheng F, 2011, J THEOR BIOL, V290, P27, DOI 10.1016/j.jtbi.2011.08.009
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Edwards JR, 2010, GENOME RES, V20, P972, DOI 10.1101/gr.101535.109
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Farmer P, 2005, ONCOGENE, V24, P4660, DOI 10.1038/sj.onc.1208561
   Ferriss JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030550
   Hampton OA, 2009, GENOME RES, V19, P167, DOI 10.1101/gr.080259.108
   Hastie T., 2009, The Elements of Statistical Learning: Data Mining, Inference, and Prediction
   Havaleshko DM, 2007, MOL CANCER THER, V6, P578, DOI 10.1158/1535-7163.MCT-06-0497
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee JS, 2007, CANC BIOL THER, V6
   Maitra A, 2005, NAT GENET, V37, P1099, DOI 10.1038/ng1631
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Schmidt M, 2007, INT J ONCOL, V30, P565
   Smith SC, 2010, CANCER RES, V70, P1753, DOI 10.1158/0008-5472.CAN-09-3562
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Taberlay PC, 2011, PROG DRUG RES, V67, P1, DOI 10.1007/978-3-7643-8989-5_1
   VanderKraats ND, 2013, NUCLEIC ACIDS RES, V41, P6816, DOI 10.1093/nar/gkt482
   WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967
NR 28
TC 16
Z9 20
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 26
PY 2014
VL 9
IS 8
AR e105545
DI 10.1371/journal.pone.0105545
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AO4JK
UT WOS:000341303200037
PM 25157401
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Desai, S
   Ding, MM
   Wang, B
   Lu, ZM
   Zhao, Q
   Shaw, K
   Yung, WKA
   Weinstein, JN
   Tan, M
   Yao, J
AF Desai, Shruti
   Ding, Minming
   Wang, Bin
   Lu, Zhimin
   Zhao, Qi
   Shaw, Kenna
   Yung, W. K. Alfred
   Weinstein, John N.
   Tan, Ming
   Yao, Jun
TI Tissue-specific isoform switch and DNA hypomethylation of the pyruvate
   kinase PKM gene in human cancers
SO ONCOTARGET
LA English
DT Article
DE PKM2; alternative splicing; DNA methylation
ID HYPOXIA-INDUCIBLE FACTOR-1; TUMOR-GROWTH; CELL-METABOLISM;
   BREAST-CANCER; M2; EXPRESSION; TUMORIGENESIS; COACTIVATOR; WARBURG; MYC
AB The M2 isoform of pyruvate kinase (PKM2) plays an important role in aerobic glycolysis and is a mediator of the Warburg effect in tumors. It was previously thought that tumor cells switch expression of PKM from normal tissue-expressed PKM1 to tumor-specific PKM2 via an alternative splicing mechanism. This view was challenged by a recent report demonstrating that PKM2 is already the major PKM isoform expressed in many differentiated normal tissues. Here, through analyses on sixteen tumor types using the cancer genome atlas RNA-Seq and exon array datasets, we confirmed that isoform switch from PKM1 to PKM2 occurred in glioblastomas but not in other tumor types examined. Despite lacking of isoform switches, PKM2 expression was found to be increased in all cancer types examined, and correlated strongly to poor prognosis in head and neck cancers. We further demonstrated that elevated PKM2 expression correlated well with the hypomethylation status of intron 1 of the PKM gene in multiple cancer types, suggesting epigenetic regulation by DNA methylation as a major mechanism in controlling PKM transcription in tumors. Our study suggests that isoform switch of PKM1 to PKM2 in cancers is tissue-specific and targeting PKM2 activity in tumors remains a promising approach for clinical intervention of multiple cancer types.
C1 [Desai, Shruti; Tan, Ming] Univ S Alabama, Dept Cell Biol, Mitchell Canc Inst, Mobile, AL 36688 USA.
   [Desai, Shruti; Tan, Ming] Univ S Alabama, Dept Neurosci, Mitchell Canc Inst, Mobile, AL 36688 USA.
   [Ding, Minming] Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, Div Biostati, Houston, TX USA.
   [Wang, Bin] Univ Texas Houston, Hlth Sci Ctr, Dept Genet, Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
   [Lu, Zhimin; Yung, W. K. Alfred; Yao, Jun] Univ Texas Houston, Hlth Sci Ctr, Dept Neurooncol, Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
   [Zhao, Qi] Johns Hopkins Univ, Ludwig Collaborat Lab, Dept Neurosurg, Baltimore, MD USA.
   [Shaw, Kenna] Univ Texas Houston, Hlth Sci Ctr, Univ Texas MD Anderson Canc Ctr, Dept TCGA Genome Data Anal Ctr, Houston, TX USA.
   [Weinstein, John N.] Univ Texas Houston, Hlth Sci Ctr, Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX USA.
C3 University of South Alabama; University of South Alabama; University of
   Texas System; University of Texas Health Science Center Houston;
   University of Texas School Public Health; University of Texas System;
   UTMD Anderson Cancer Center; University of Texas Health Science Center
   Houston; University of Texas System; University of Texas Health Science
   Center Houston; UTMD Anderson Cancer Center; Johns Hopkins University;
   University of Texas System; University of Texas Health Science Center
   Houston; UTMD Anderson Cancer Center; University of Texas System;
   University of Texas Health Science Center Houston; UTMD Anderson Cancer
   Center
RP Tan, M (通讯作者)，Univ S Alabama, Dept Cell Biol, Mitchell Canc Inst, Mobile, AL 36688 USA.
EM mtan@usouthal.edu; jyao1@mdanderson.org
RI Tan, Ming/ABD-5847-2021; Lu, Zhimin/LZF-0860-2025; Reva,
   Boris/AAB-8932-2022
OI Wang, Bin/0000-0002-3689-6932; Tan, Ming/0000-0003-2007-9898; Weinstein,
   John/0000-0001-9401-6908
FU TCGA grant from NCI/NIH [U24CA143883]; NIH [R01CA149646]; Ludwig
   Institute for Cancer Research
FX This study is supported in part by the TCGA grant U24CA143883 from
   NCI/NIH, NIH Grant R01CA149646, and funds from Ludwig Institute for
   Cancer Research
CR Bluemlein K, 2012, ONCOTARGET, V3, P1356
   Bluemlein K, 2011, ONCOTARGET, V2, P393
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107
   Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Demidenko ZN, 2011, CELL CYCLE, V10, P1557, DOI 10.4161/cc.10.10.15789
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Eigenbrodt E, 1997, ANTICANCER RES, V17, P3153
   Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Jiang P, 2011, NAT CELL BIOL, V13, P310, DOI 10.1038/ncb2172
   Leontieva OV, 2011, AGING-US, V3, P1078, DOI 10.18632/aging.100402
   Lim JY, 2012, WORLD J GASTROENTERO, V18, P4037, DOI 10.3748/wjg.v18.i30.4037
   Lüftner D, 2000, ANTICANCER RES, V20, P5077
   Luo WB, 2011, ONCOTARGET, V2, P551
   Luo WB, 2011, CELL, V145, P732, DOI 10.1016/j.cell.2011.03.054
   Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009
   NOGUCHI T, 1986, J BIOL CHEM, V261, P3807
   Purdom E, 2008, BIOINFORMATICS, V24, P1707, DOI 10.1093/bioinformatics/btn284
   Vander Heiden MG, 2010, BIOCHEM PHARMACOL, V79, P1118, DOI 10.1016/j.bcp.2009.12.003
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wong Nicholas, 2013, Int J Cell Biol, V2013, P242513, DOI 10.1155/2013/242513
   Yang WW, 2012, CELL, V150, P685, DOI 10.1016/j.cell.2012.07.018
   Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598
   Zhan C, 2013, DIS ESOPHAGUS
   Zhao YH, 2009, ONCOGENE, V28, P3689, DOI 10.1038/onc.2009.229
NR 27
TC 115
Z9 127
U1 1
U2 14
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 30
PY 2014
VL 5
IS 18
BP 8202
EP 8210
DI 10.18632/oncotarget.1159
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AZ1YI
UT WOS:000348030900019
PM 24077665
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Reyes, G
   Niederst, M
   Cohen-Katsenelson, K
   Stender, JD
   Kunkel, MT
   Chen, MH
   Brognard, J
   Sierecki, E
   Gao, TY
   Nowak, DG
   Trotman, LC
   Glass, CK
   Newton, AC
AF Reyes, Gloria
   Niederst, Matt
   Cohen-Katsenelson, Ksenya
   Stender, Joshua D.
   Kunkel, Maya T.
   Chen, Muhan
   Brognard, John
   Sierecki, Emma
   Gao, Tianyan
   Nowak, Dawid G.
   Trotman, Lloyd C.
   Glass, Christopher K.
   Newton, Alexandra C.
TI Pleckstrin homology domain leucine-rich repeat protein phosphatases set
   the amplitude of receptor tyrosine kinase output
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
ID HISTONE H3 PHOSPHORYLATION; GROWTH-FACTOR RECEPTOR; HUMAN-BREAST-CANCER;
   COLON-CANCER; PHLPP; CHROMATIN; AKT; ACETYLATION; EPIGENETICS; FEEDBACK
AB Growth factor receptor levels are aberrantly high in diverse cancers, driving the proliferation and survival of tumor cells. Understanding the molecular basis for this aberrant elevation has profound clinical implications. Here we show that the pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP) suppresses receptor tyrosine kinase (RTK) signaling output by a previously unidentified epigenetic mechanism unrelated to its previously described function as the hydrophobic motif phosphatase for the protein kinase AKT, protein kinase C, and S6 kinase. Specifically, we show that nuclear-localized PHLPP suppresses histone phosphorylation and acetylation, in turn suppressing the transcription of diverse growth factor receptors, including the EGF receptor. These data uncover a much broader role for PHLPP in regulation of growth factor signaling beyond its direct inactivation of AKT: By suppressing RTK levels, PHLPP dampens the downstream signaling output of two major oncogenic pathways, the PI3 kinase/AKT and the Rat sarcoma (RAS)/ERK pathways. Our data are consistent with a model in which PHLPP modifies the histone code to control the transcription of RTKs.
C1 [Reyes, Gloria; Niederst, Matt; Cohen-Katsenelson, Ksenya; Kunkel, Maya T.; Brognard, John; Sierecki, Emma; Newton, Alexandra C.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
   [Stender, Joshua D.; Nowak, Dawid G.; Glass, Christopher K.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.
   [Niederst, Matt] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA.
   [Chen, Muhan; Trotman, Lloyd C.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
   [Gao, Tianyan] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   University of California System; University of California San Diego;
   Cold Spring Harbor Laboratory; University of Kentucky
RP Newton, AC (通讯作者)，Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA.
EM anewton@ucsd.edu
RI Brognard, John/T-5099-2019; Sierecki, Emma/I-2920-2019; Glass,
   Christopher/AAI-3933-2021
OI SIERECKI, Emma/0000-0001-9970-868X; Brognard, John/0000-0002-9243-6615
FU University of California at San Diego Graduate Training Program in
   Cellular and Molecular Pharmacology through NIGMS, National Institutes
   of Health (NIH) Institutional Training Grant [T32 GM007752]; NIH
   [CA137050, GM067946]
FX We thank Roger Tsien for the gift of the EGFR kinase activity reporter
   construct and Dr. Frank Furnari for the pcL10A vector for retroviral
   packaging. M.N. was supported in part by the University of California at
   San Diego Graduate Training Program in Cellular and Molecular
   Pharmacology through NIGMS, National Institutes of Health (NIH)
   Institutional Training Grant T32 GM007752. This work was supported by
   NIH Grants CA137050 (to L. C. T.) and GM067946 (to A.C.N.).
CR [Anonymous], COLD SPRING HARB PRO
   Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4
   Banerjee T, 2011, MOL CELL BIOL, V31, P4858, DOI 10.1128/MCB.05631-11
   Bode Ann M, 2005, Sci STKE, V2005, pre4, DOI 10.1126/stke.2812005re4
   Brockmann R, 2007, PLOS COMPUT BIOL, V3, P531, DOI 10.1371/journal.pcbi.0030057
   Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017
   Brognard J, 2009, J BIOL CHEM, V284, P15215, DOI 10.1074/jbc.M901468200
   Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008
   Cai JC, 2013, CANCER RES, V73, P5402, DOI 10.1158/0008-5472.CAN-13-0297
   Campbell RM, 2014, J CLIN INVEST, V124, P64, DOI 10.1172/JCI71605
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008
   Chen MH, 2011, CANCER CELL, V20, P173, DOI 10.1016/j.ccr.2011.07.013
   Cheung P, 2000, MOL CELL, V5, P905, DOI 10.1016/S1097-2765(00)80256-7
   Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5
   Cho KS, 2008, PROSTATE, V68, P803, DOI 10.1002/pros.20743
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Gangula NR, 2013, J BIOL CHEM, V288, P34545, DOI 10.1074/jbc.M113.503383
   Gao T, 2008, J BIOL CHEM, V283, P6300, DOI 10.1074/jbc.M707319200
   Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008
   Goel A, 2003, CANCER RES, V63, P1608
   Hagelkruys Astrid, 2011, Handb Exp Pharmacol, V206, P13, DOI 10.1007/978-3-642-21631-2_2
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Jackson TC, 2013, J PHARMACOL EXP THER, V347, P516, DOI 10.1124/jpet.113.206888
   Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Lau PNI, 2011, P NATL ACAD SCI USA, V108, P2801, DOI 10.1073/pnas.1012798108
   Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450
   Liu JY, 2011, MOL CELL BIOL, V31, P4917, DOI 10.1128/MCB.05799-11
   Lo WS, 2000, MOL CELL, V5, P917, DOI 10.1016/S1097-2765(00)80257-9
   MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C
   Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668
   Mikula M, 2001, EMBO J, V20, P1952, DOI 10.1093/emboj/20.8.1952
   Nitsche C, 2012, GASTROENTEROLOGY, V142, P377, DOI 10.1053/j.gastro.2011.10.026
   O'Neill AK, 2013, FEBS J, V280, P572, DOI 10.1111/j.1742-4658.2012.08537.x
   Ouillette P, 2008, CANCER RES, V68, P1012, DOI 10.1158/0008-5472.CAN-07-3105
   Qiao M, 2007, CANCER RES, V67, P5293, DOI 10.1158/0008-5472.CAN-07-0877
   Qiao M, 2010, MOL CELL, V38, P512, DOI 10.1016/j.molcel.2010.03.017
   Rakha EA, 2006, GENE CHROMOSOME CANC, V45, P527, DOI 10.1002/gcc.20318
   Reardon DA, 2006, ONCOLOGIST, V11, P152, DOI 10.1634/theoncologist.11-2-152
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Ross, 1998, Oncologist, V3, P237
   Rossetto D, 2012, EPIGENETICS-US, V7, P1098, DOI 10.4161/epi.21975
   Sawicka A, 2014, BBA-GENE REGUL MECH, V1839, P711, DOI 10.1016/j.bbagrm.2014.04.013
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Schlomm T, 2007, CLIN CANCER RES, V13, P6579, DOI 10.1158/1078-0432.CCR-07-1257
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Sierecki E, 2014, BIOCHEMISTRY-US, V53, P3971, DOI 10.1021/bi500428j
   Sierecki E, 2010, J MED CHEM, V53, P6899, DOI 10.1021/jm100331d
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003
   Ting AY, 2001, P NATL ACAD SCI USA, V98, P15003, DOI 10.1073/pnas.211564598
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wakeling AE, 2002, CANCER RES, V62, P5749
   Warfel NA, 2012, J BIOL CHEM, V287, P3610, DOI 10.1074/jbc.R111.318675
   Warfel NA, 2011, J BIOL CHEM, V286, P19777, DOI 10.1074/jbc.M111.237081
   Wen YA, 2013, MOL CELL BIOL, V33, P4594, DOI 10.1128/MCB.00695-13
NR 60
TC 28
Z9 29
U1 0
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 23
PY 2014
VL 111
IS 38
BP E3957
EP E3965
DI 10.1073/pnas.1404221111
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AP3PC
UT WOS:000341988200004
PM 25201979
OA Green Published, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Benard, A
   Goossens-Beumer, IJ
   van Hoesel, AQ
   Horati, H
   Putter, H
   Zeestraten, ECM
   van de Velde, CJH
   Kuppen, PJK
AF Benard, Anne
   Goossens-Beumer, Ines J.
   van Hoesel, Anneke Q.
   Horati, Hamed
   Putter, Hein
   Zeestraten, Eliane C. M.
   van de Velde, Cornelis J. H.
   Kuppen, Peter J. K.
TI Prognostic Value of Polycomb Proteins EZH2, BMI1 and SUZ12 and Histone
   Modification H3K27me3 in Colorectal Cancer
SO PLOS ONE
LA English
DT Article
ID CELL LUNG-CANCER; BREAST-CANCER; STEM-CELLS; EXPRESSION; CARCINOMA;
   STAGE; COMPLEXES; SUPPRESSES; APOPTOSIS; PREDICTS
AB Numerous changes in epigenetic mechanisms have been described in various types of tumors. In search for new biomarkers, we investigated the expression of Polycomb-group (PcG) proteins EZH2, BMI1 and SUZ12 and associated histone modification H3K27me3 in colorectal cancer. Nuclear expression of PcG proteins and histone modification H3K27me3 were immunohistochemically (IHC) stained on a tissue microarray (TMA), including 247 tumor tissues and 47 normal tissues, and scored using the semi-automated Ariol system. Tumor tissues showed higher expression of EZH2 (p = 0.05) and H3K27me3 (p<0.001) as compared to their normal counterparts. Combined marker trend analyses indicated that an increase in the number of markers showing high expression was associated with better prognosis. High expression of all four markers in the combined marker analyses was correlated with the best patient survival and the longest recurrence-free survival, with overall survival (p = 0.01, HR 0.42(0.21-0.84)), disease-free survival (p = 0.007, HR 0.23(0.08-0.67) and local recurrence-free survival (p = 0.02, HR 0.30(0.11-0.84)). In conclusion, we found that expression of PcG proteins and H3K27me3 showed prognostic value in our study cohort. Better stratification of patients was obtained by combining the expression data of the investigated biomarkers as compared to the individual markers, underlining the importance of investigating multiple markers simultaneously.
C1 [Benard, Anne; Goossens-Beumer, Ines J.; van Hoesel, Anneke Q.; Horati, Hamed; Zeestraten, Eliane C. M.; van de Velde, Cornelis J. H.; Kuppen, Peter J. K.] Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands.
   [Putter, Hein] Leiden Univ, Med Ctr, Dept Med Stat, Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC
RP Benard, A (通讯作者)，Leiden Univ, Med Ctr, Dept Surg, Leiden, Netherlands.
EM p.j.k.kuppen@lumc.nl
RI van de Velde, Cornelis/AAY-8360-2020; Putter, Hein/C-2244-2018; Kuppen,
   Peter/J-2342-2016
OI Putter, Hein/0000-0001-5395-1422; Kuppen, Peter/0000-0002-0294-3251
CR Allegra E, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-206
   Aloia L, 2013, DEVELOPMENT, V140, P2525, DOI 10.1242/dev.091553
   Behrens C, 2013, CLIN CANCER RES, V19, P6556, DOI 10.1158/1078-0432.CCR-12-3946
   Benard A, 2013, BRIT J CANCER, V109, P3073, DOI 10.1038/bjc.2013.654
   Bender S, 2013, CANCER CELL, V24, P660, DOI 10.1016/j.ccr.2013.10.006
   Benoit YD, 2013, EXP CELL RES, V319, P1463, DOI 10.1016/j.yexcr.2013.04.006
   Chen XH, 2013, INT J ONCOL, V43, P1467, DOI 10.3892/ijo.2013.2062
   Crea F, 2012, ANN ONCOL, V23, P1207, DOI 10.1093/annonc/mdr387
   Cui YJ, 2013, CELL PHYSIOL BIOCHEM, V31, P778, DOI 10.1159/000350095
   de Maat MFG, 2010, CLIN CANCER RES, V16, P2811, DOI 10.1158/1078-0432.CCR-09-2717
   Du JJ, 2010, MED ONCOL, V27, P1273, DOI 10.1007/s12032-009-9373-y
   Edge S.B., 2010, AJCC cancer staging manual, V649
   Fluge O, 2009, BRIT J CANCER, V101, P1282, DOI 10.1038/sj.bjc.6605333
   Gialmanidis IP, 2013, LUNG, V191, P511, DOI 10.1007/s00408-013-9490-4
   Ha SY, 2012, PATHOL RES PRACT, V208, P462, DOI 10.1016/j.prp.2012.05.012
   He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111
   Hinz S, 2008, TUMOR BIOL, V29, P323, DOI 10.1159/000170879
   Hoeben KWJ, 2013, ANN ONCOL, V24, P974, DOI 10.1093/annonc/mds576
   Holm K, 2012, MOL ONCOL, V6, P494, DOI 10.1016/j.molonc.2012.06.002
   Hosogane M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003698
   Li H, 2012, MOL CANCER RES, V10, P1462, DOI 10.1158/1541-7786.MCR-12-0335
   Maertens GN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006380
   Malouf GG, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-12-r144
   Manoranjan B, 2013, STEM CELLS, V31, P1266, DOI 10.1002/stem.1401
   McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678
   Mu ZM, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-70
   Oktaba K, 2008, DEV CELL, V15, P877, DOI 10.1016/j.devcel.2008.10.005
   Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214
   Putter H, 2007, STAT MED, V26, P2389, DOI 10.1002/sim.2712
   Ruan ZP, 2013, INT J ONCOL, V42, P261, DOI 10.3892/ijo.2012.1693
   Siddique HR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0052993
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029
   Tong Q, 2014, J IMMUNOL, V192, P5012, DOI 10.4049/jimmunol.1302943
   van den Broek CBM, 2013, ACTA ONCOL, V52, P941, DOI 10.3109/0284186X.2012.739730
   van Engeland M, 2011, J CLIN ONCOL, V29, P1382, DOI 10.1200/JCO.2010.28.2319
   van Nes JGH, 2011, BREAST CANCER RES TR, V125, P671, DOI 10.1007/s10549-010-0854-7
   Wang CG, 2010, WORLD J GASTROENTERO, V16, P2421, DOI 10.3748/wjg.v16.i19.2421
   Wu ZY, 2013, J NEUROL SCI, V335, P191, DOI 10.1016/j.jns.2013.09.030
   Yonemitsu Y, 2009, HUM PATHOL, V40, P1304, DOI 10.1016/j.humpath.2009.01.017
   Yoshikawa R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-461
   Zeestraten EC, 2013, BR J CANC
NR 42
TC 55
Z9 62
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 22
PY 2014
VL 9
IS 9
AR e108265
DI 10.1371/journal.pone.0108265
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AR6FX
UT WOS:000343679800082
PM 25243792
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Jia, ZH
   Gao, SP
   M'Rabet, N
   De Geyter, C
   Zhang, H
AF Jia, Zanhui
   Gao, Shuping
   M'Rabet, Nadira
   De Geyter, Christian
   Zhang, Hong
TI Sp1 Is Necessary for Gene Activation of Adamts17 by Estrogen
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Adamts17; APOPTOSIS; GENE REGULATION; Sp1; BREAST CANCER
ID BREAST-CANCER; DNA MICROARRAY; RECEPTOR-ALPHA; EXPRESSION;
   TRANSCRIPTION; CELLS; CONTRIBUTES; BACH1
AB Adamts17 is a member of a family of secreted metalloproteinases. In this report, we show that knockdown of Adamts17 expression induces apoptosis and inhibits breast cancer cell growth. Adamts17 expression can rapidly be induced by estrogens. siRNA knockdown of Sp 1 or Myc demonstrated that Sp 1 is required to induce Adamts17 gene expression in response to estrogen. Moreover, reporter assays showed that the proximal promoter and the upstream sequences were not capable of conferring estrogen responsiveness, suggesting that Sp 1 elements may be located in the downstream intronic region. We further demonstrated that Sp 1 and Myc binding in the proximal promoter region contributed to the Adamts17 basal expression. Furthermore, histone deacetylase (HDAC) and methylase inhibitors also induced Adamts17 expression, indicating that epigenetic alterations, such as aberrant HDAC and/or methylation are associated with dysregulated Adamts17 expression. By meta-analysis using Oncomine microarray data, we found that higher Adamts17 expression is found in several human cancer cell subtypes, especially in breast ductal carcinoma. Moreover, we found that there is an inverse correlation between higher Adamts17 expression and patients' survival. Our study suggests that Adamts17 may support breast cancer cell growth and survival. (C) 2014 Wiley Periodicals, Inc.
C1 [Jia, Zanhui; M'Rabet, Nadira; De Geyter, Christian; Zhang, Hong] Univ Basel, Clin Gynecol Endocrinol & Reprod Med, CH-4031 Basel, Switzerland.
   [Jia, Zanhui; M'Rabet, Nadira; De Geyter, Christian; Zhang, Hong] Univ Basel, Dept Biomed, CH-4031 Basel, Switzerland.
   [Jia, Zanhui] Jilin Univ, Hosp 2, Dept Gynecol & Obstet, Changchun 130023, Jilin Province, Peoples R China.
   [Gao, Shuping] Univ Zurich, Dept Surg, CH-8091 Zurich, Switzerland.
C3 University of Basel; University of Basel; Jilin University; University
   of Zurich
RP Zhang, H (通讯作者)，Univ Basel, Clin Gynecol Endocrinol & Reprod Med, Spitalstr 21, CH-4031 Basel, Switzerland.
EM hzhang@uhbs.ch
RI De+Geyter, Christian/ADD-0437-2022
OI Gao, Shuping/0000-0002-7492-6880
FU Repronatal Foundation, Basel; Swiss ESKAS
FX Grant sponsor: Repronatal Foundation, Basel; Grant sponsor: Swiss ESKAS.
CR Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X
   Castellana B, 2012, J CANCER, V3, P175, DOI 10.7150/jca.4120
   Cesari M, 1998, BIOCHEM J, V336, P619, DOI 10.1042/bj3360619
   Duan R, 1998, ENDOCRINOLOGY, V139, P1981, DOI 10.1210/en.139.4.1981
   Farias FHG, 2010, INVEST OPHTH VIS SCI, V51, P4716, DOI 10.1167/iovs.09-5142
   Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
   Itoh Y, 2007, J IMMUNOL, V178, P3059, DOI 10.4049/jimmunol.178.5.3059
   Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401
   Kalaitzidis D, 2005, TRENDS ENDOCRIN MET, V16, P46, DOI 10.1016/j.tem.2005.01.004
   KAMACHI Y, 1990, J VIROL, V64, P4808, DOI 10.1128/JVI.64.10.4808-4819.1990
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905
   Le Goff C, 2011, HUM MOL GENET, V20, pR163, DOI 10.1093/hmg/ddr361
   Leong HY, 2005, MOL ENDOCRINOL, V19, P2930, DOI 10.1210/me.2005-0178
   Levin ER, 2005, MOL ENDOCRINOL, V19, P1951, DOI 10.1210/me.2004-0390
   Li T, 2003, CIRC RES, V93, P1202, DOI 10.1161/01.RES.0000104085.76261.02
   Li Y, 2010, NAT MED, V16, P214, DOI 10.1038/nm.2090
   Lim G, 2011, LEUKEMIA RES, V35, pE106, DOI 10.1016/j.leukres.2011.03.020
   Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222
   Mann Monica, 2011, Cancers (Basel), V3, P1691, DOI 10.3390/cancers3021691
   Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333
   Morales J, 2009, AM J HUM GENET, V85, P558, DOI 10.1016/j.ajhg.2009.09.011
   Overall CM, 2004, BIOL CHEM, V385, P493, DOI 10.1515/BC.2004.058
   Payen G, 2011, J SMALL ANIM PRACT, V52, P401, DOI 10.1111/j.1748-5827.2011.01081.x
   Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003
   Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004
   Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013
   Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13
   Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646
   Sakamoto N, 2010, CANCER SCI, V101, P1038, DOI 10.1111/j.1349-7006.2009.01477.x
   Sarrió D, 2003, INT J CANCER, V106, P208, DOI 10.1002/ijc.11197
   Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55
   Wagstaff L, 2011, FRONT BIOSCI-LANDMRK, V16, P1861, DOI 10.2741/3827
   Warnatz HJ, 2011, J BIOL CHEM, V286, P23521, DOI 10.1074/jbc.M111.220178
   Wei XM, 2010, MOL CANCER RES, V8, P1513, DOI 10.1158/1541-7786.MCR-10-0262
   Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786
NR 39
TC 8
Z9 9
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD OCT
PY 2014
VL 115
IS 10
BP 1829
EP 1839
DI 10.1002/jcb.24855
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AN5XF
UT WOS:000340664800021
PM 24906090
DA 2025-01-12
ER

PT J
AU Winquist, RJ
   Hall, AB
   Eustace, BK
   Furey, BF
AF Winquist, Raymond J.
   Hall, Amy B.
   Eustace, Brenda K.
   Furey, Brinley F.
TI Evaluating the immortal strand hypothesis in cancer stem cells:
   Symmetric/self-renewal as the relevant surrogate marker of
   tumorigenicity
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Article
DE Cancer stem cells; Immortal Strand Hypothesis; Tumorigenicity;
   Asymmetric cell division; Symmetric cell division; Cancer
ID TEMPLATE DNA STRANDS; ASYMMETRIC DIVISION; BREAST-CANCER; SELF-RENEWAL;
   TUMOR-GROWTH; GENE-EXPRESSION; IN-VITRO; SEGREGATION; ID1; PATHWAY
AB Stem cells subserve repair functions for the lifetime of the organism but, as a consequence of this responsibility, are candidate cells for accumulating numerous genetic and/or epigenetic aberrations leading to malignant transformation. However, given the importance of this guardian role, stem cells likely harbor some process for maintaining their precious genetic code such as non-random segregation of chromatid strands as predicted by the Immortal Strand Hypothesis (ISH). Discerning such non-random chromosomal segregation and asymmetric cell division in normal or cancer stem cells has been complicated by methodological shortcomings but also by differing division kinetics amongst tissues and the likelihood that both asymmetric and symmetric cell divisions, dictated by local extrinsic factors, are operant in these cells. Recent data suggest that cancer stem cells demonstrate a higher incidence of symmetric versus asymmetric cell division with both daughter cells retaining self-renewal characteristics, a profile which may underlie poorly differentiated morphology and marked clonal diversity in tumors. Pathways and targets are beginning to emerge which may provide opportunities for preventing such a predilection in cancer stem cells and that will hopefully translate into new classes of chemotherapeutics in oncology. Thus, although the existence of the ISH remains controversial, the shift of cell division dynamics to symmetric random chromosome segregation/self-renewal, which would negate any likelihood of template strand retention, appears to be a surrogate marker for the presence of highly malignant tumorigenic cell populations. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Winquist, Raymond J.; Hall, Amy B.; Eustace, Brenda K.; Furey, Brinley F.] Vertex Pharmaceut Inc, Dept Integrated Biol, Boston, MA 02210 USA.
C3 Vertex Pharmaceuticals
RP Winquist, RJ (通讯作者)，Vertex Pharmaceut Inc, Dept Integrated Biol, 50 Northern Ave, Boston, MA 02210 USA.
EM raymond_winquist@vrtx.com
CR Boman BM, 2007, CLIN PHARMACOL THER, V81, P893, DOI 10.1038/sj.clpt.6100202
   CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0
   Cairns J, 2006, GENETICS, V174, P1069, DOI 10.1534/genetics.104.66886
   Chang KC, 2012, BIOESSAYS, V34, P301, DOI 10.1002/bies.201100090
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Dey-Guha I, 2011, P NATL ACAD SCI USA, V108, P12845, DOI 10.1073/pnas.1109632108
   Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415
   Falconer E, 2013, SEMIN CELL DEV BIOL, V24, P643, DOI 10.1016/j.semcdb.2013.04.005
   Falconer E, 2010, NATURE, V463, P93, DOI 10.1038/nature08644
   Fornasier F, 2012, NATURE
   Fuchs E, 2012, EMBO REP
   Gao X, 2012, CANCER RES, V73, P1481, DOI DOI 10.1158/0008-5472.CAN-12-3429
   Gautschi O, 2008, CANCER RES, V68, P2250, DOI 10.1158/0008-5472.CAN-07-6403
   Hong SY, 2011, J NEUROSCI, V31, P15861, DOI 10.1523/JNEUROSCI.3272-11.2011
   Inoue H., 2014, EMBO J
   Izumi H, 2012, P NATL ACAD SCI USA, V109, P18048, DOI 10.1073/pnas.1205525109
   Januschke J, 2014, SEMIN CELL DEV BIOL
   Kahn M, 2011, FUTURE MED CHEM, V3, P1745, DOI [10.4155/FMC.11.126, 10.4155/fmc.11.126]
   Kajstura J, 2012, CIRC RES, V111, P894, DOI 10.1161/CIRCRESAHA.112.273649
   Kelsom C, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-38
   Kiel MJ, 2007, NATURE, V449, P238, DOI 10.1038/nature06115
   Knoblich JA, 2010, NAT REV MOL CELL BIO, V11, P849, DOI 10.1038/nrm3010
   Lansdorp PM, 2007, CELL, V129, P1244, DOI 10.1016/j.cell.2007.06.017
   Lathia JD, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.80
   Laurenti E, 2012, ANN NY ACAD SCI, V1266, P68, DOI 10.1111/j.1749-6632.2012.06577.x
   Lim YC, 2012, EUR J CANCER, V48, P3310, DOI 10.1016/j.ejca.2012.04.013
   Liu WY, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-139
   Lombardo Y, 2012, P NATL ACAD SCI USA, V109, P16558, DOI 10.1073/pnas.1206268109
   Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956
   Nteliopoulos G, 2012, STEM CELLS DEV, V21, P2565, DOI 10.1089/scd.2011.0467
   O'Brien CA, 2012, CANCER CELL, V21, P777, DOI 10.1016/j.ccr.2012.04.036
   Park JP, 2013, STEM CELLS DEV, V22, P1297, DOI 10.1089/scd.2012.0496
   Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673
   Pine SR, 2010, P NATL ACAD SCI USA, V107, P2195, DOI 10.1073/pnas.0909390107
   Potten CS, 2002, J CELL SCI, V115, P2381
   POTTEN CS, 1978, CELL, V15, P899, DOI 10.1016/0092-8674(78)90274-X
   Qiu M, 2013, CANCER LETT, V328, P261, DOI 10.1016/j.canlet.2012.09.023
   Quyn AJ, 2010, CELL STEM CELL, V6, P175, DOI 10.1016/j.stem.2009.12.007
   Rambhatla L, 2005, CANCER RES, V65, P3155, DOI 10.1158/0008-5472.CAN-04-3161
   Rando TA, 2007, CELL, V129, P1239, DOI 10.1016/j.cell.2007.06.019
   Reizel Y, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002192
   Rodriguez-Pascual J, 2012, INVEST NEW DRUGS
   Ronpirin C, 2012, GENET MOL RES, V11, P3290, DOI 10.4238/2012.September.12.12
   Schenk T, 2012, NAT MED, V18, P605, DOI 10.1038/nm.2661
   Schepers AG, 2012, SCIENCE, V337, P730, DOI 10.1126/science.1224676
   Shinin V, 2006, NAT CELL BIOL, V8, P677, DOI 10.1038/ncb1425
   Simons BD, 2011, CELL, V145, P851, DOI 10.1016/j.cell.2011.05.033
   Snippert HJ, 2010, CELL, V143, P134, DOI 10.1016/j.cell.2010.09.016
   Steinhauser ML, 2012, NATURE, V481, P516, DOI 10.1038/nature10734
   Sugiarto S, 2011, CANCER CELL, V20, P328, DOI 10.1016/j.ccr.2011.08.011
   Tang XH, 2011, ANNU REV PATHOL-MECH, V6, P345, DOI 10.1146/annurev-pathol-011110-130303
   Tran V, 2012, SCIENCE, V338, P679, DOI 10.1126/science.1226028
   Williams SE, 2013, CURR OPIN CELL BIOL, V25, P749, DOI 10.1016/j.ceb.2013.08.003
   Winquist RJ, 2010, CURR OPIN PHARMACOL, V10, P385, DOI 10.1016/j.coph.2010.06.008
   Wu MF, 2007, CELL STEM CELL, V1, P541, DOI 10.1016/j.stem.2007.08.009
   Xin HW, 2012, STEM CELLS, V30, P591, DOI 10.1002/stem.1061
   Xing F, 2013, EMBO MOL MED, V5, P384, DOI 10.1002/emmm.201201623
   Xu ZP, 2014, SCI REP-UK, V4, DOI 10.1038/srep03766
   Yang SY, 2011, J PEPT SCI, V17, P667, DOI 10.1002/psc.1386
   Yu CH, 2013, GENETICS, V193, P85, DOI 10.1534/genetics.112.146233
NR 62
TC 7
Z9 8
U1 0
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD SEP 15
PY 2014
VL 91
IS 2
BP 129
EP 134
DI 10.1016/j.bcp.2014.06.007
PG 6
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AO1KK
UT WOS:000341070800001
PM 24971715
DA 2025-01-12
ER

PT J
AU Zhang, Y
   Liang, J
   Li, Q
AF Zhang, Yu
   Liang, Jing
   Li, Qian
TI Coordinated Regulation of Retinoic Acid Signaling Pathway by KDM5B and
   Polycomb Repressive Complex 2
SO JOURNAL OF CELLULAR BIOCHEMISTRY
LA English
DT Article
DE KDM5B; PRC2; RETINOIC ACID; RAR; HISTONE MODIFICATION
ID HISTONE METHYLTRANSFERASE ACTIVITY; DOMAIN-CONTAINING PROTEINS;
   STEM-CELLS; RESPONSE ELEMENTS; BREAST-CANCER; TARGET GENES;
   DEMETHYLATION; BINDING; PRC2; METHYLATION
AB Polycomb repressive complex 2 (PRC2) is a critical epigenetic regulator in many biological processes, including maintenance of cell identity, stem cell self-renewal, differentiation, and deregulation of PRC2 is often observed in human cancers and diseases. Here we report that KDM5B (PLU-1/JARID1B), a histone lysine demethylase of Jumonji family, associates with PRC2 and colocalizes with PRC2 in nuclear bodies, and their physical association is dependent on direct interaction between KDM5B and the SUZ12 component of PRC2. Interestingly, co-occupancy of KDM5B and PRC2 was evidenced at the conserved cis-regulatory DNA element on retinoic acid (RA) responsive genes. Transcription readout and in vitro pull-down experiments suggest that KDM5B is an essential co-activator, but not a co-repressor, for the RA signaling, and the interface between KDM5B's JMJC domain and retinoic acid receptor alpha (RAR alpha) is crucial for RA-mediated gene expression. Detailed chromatin immunoprecipitation assays addressed the seemingly paradox by revealing a biphasic effect of KDM5B on RA-induced gene activation through decoupled H3K4me3 demethylation and PRC2-antagonizing activities. These results demonstrate that KDM5B and PRC2 regulate RA signaling cascade in a cooperative and orchestrated fashion. (C) 2014 Wiley Periodicals, Inc.
C1 [Zhang, Yu; Liang, Jing; Li, Qian] Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Beijing 100191, Peoples R China.
C3 Peking University
RP Li, Q (通讯作者)，Peking Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China.
EM liang_jing@bjmu.edu.cn; qianli@hsc.pku.edu.cn
RI Liang, Jingyuan/CAH-2002-2022
FU National Natural Science Foundation of China [81300254, 31371301]; China
   Postdoctoral Science Foundation [2013M530491]; Ministry of Science and
   Technology of China [2011CB504204, 2014CB542004]
FX Grant sponsor: National Natural Science Foundation of China; Grant
   numbers: 81300254, 31371301; Grant sponsor: China Postdoctoral Science
   Foundation; Grant number: 2013M530491; Grant sponsor: Ministry of
   Science and Technology of China; Grant numbers: 2011CB504204,
   2014CB542004.
CR Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Cao R, 2004, MOL CELL, V15, P57, DOI 10.1016/j.molcel.2004.06.020
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chen HX, 2007, CANCER RES, V67, P8007, DOI 10.1158/0008-5472.CAN-07-1405
   Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Duester G, 2008, CELL, V134, P921, DOI 10.1016/j.cell.2008.09.002
   Epping MT, 2005, CELL, V122, P835, DOI 10.1016/j.cell.2005.07.003
   Gillespie RF, 2007, J BIOL CHEM, V282, P33421, DOI 10.1074/jbc.M704845200
   Gillespie RF, 2007, J MOL BIOL, V372, P298, DOI 10.1016/j.jmb.2007.06.079
   Glass CK, 2000, GENE DEV, V14, P121
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Kashyap V, 2011, J BIOL CHEM, V286, P3250, DOI 10.1074/jbc.M110.157545
   Kim H, 2009, NUCLEIC ACIDS RES, V37, P2940, DOI 10.1093/nar/gkp149
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945
   Kmita M, 2000, GENE DEV, V14, P198
   Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Lanzuolo C, 2012, ANNU REV GENET, V46, P561, DOI 10.1146/annurev-genet-110711-155603
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Lefebvre P, 2005, VITAM HORM, V70, P199, DOI 10.1016/S0083-6729(05)70007-8
   Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410
   Li Q, 2013, EMBO J, V32, P858, DOI 10.1038/emboj.2013.35
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788
   Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788
   Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002
   Pirrotta V, 2012, CURR OPIN GENET DEV, V22, P101, DOI 10.1016/j.gde.2011.11.004
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0
   Sessa L, 2007, RNA, V13, P223, DOI 10.1261/rna.266707
   Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Simon JA, 2009, NAT REV MOL CELL BIO, V10, P697, DOI 10.1038/nrm2763
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022
   Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338
   Tsukada Y, 2006, NATURE, V439, P811, DOI 10.1038/nature04433
   van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572
   Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zhang Y, 2011, J BIOL CHEM, V286, P42414, DOI 10.1074/jbc.M111.271064
   Zhang Y, 2010, J BIOL CHEM, V285, P28604, DOI 10.1074/jbc.M110.149658
NR 51
TC 22
Z9 27
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0730-2312
EI 1097-4644
J9 J CELL BIOCHEM
JI J. Cell. Biochem.
PD SEP
PY 2014
VL 115
IS 9
BP 1528
EP 1538
DI 10.1002/jcb.24807
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AN5XB
UT WOS:000340664300008
PM 24619877
DA 2025-01-12
ER

PT J
AU Kim, B
   Kang, S
   Jeong, G
   Park, SB
   Kim, SJ
AF Kim, Byungtak
   Kang, Seongeun
   Jeong, Gookjoo
   Park, Sung-Bin
   Kim, Sun Jung
TI Identification and Comparison of Aberrant Key Regulatory Networks in
   Breast, Colon, Liver, Lung, and Stomach Cancers through Methylome
   Database Analysis
SO PLOS ONE
LA English
DT Article
ID METASTASIS SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; DOWN-REGULATION;
   OVARIAN-CANCER; IN-VIVO; METHYLATION; EXPRESSION; PTEN; BRCA1;
   ACTIVATION
AB Aberrant methylation of specific CpG sites at the promoter is widely responsible for genesis and development of various cancer types. Even though the microarray-based methylome analyzing techniques have contributed to the elucidation of the methylation change at the genome-wide level, the identification of key methylation markers or top regulatory networks appearing common in highly incident cancers through comparison analysis is still limited. In this study, we in silico performed the genome-wide methylation analysis on each 10 sets of normal and cancer pairs of five tissues: breast, colon, liver, lung, and stomach. The methylation array covers 27,578 CpG sites, corresponding to 14,495 genes, and significantly hypermethylated or hypomethylated genes in the cancer were collected (FDR adjusted p-value <0.05; methylation difference >0.3). Analysis of the dataset confirmed the methylation of previously known methylation markers and further identified novel methylation markers, such as GPX2, CLDN15, and KL. Cluster analysis using the methylome dataset resulted in a diagram with a bipartite mode distinguishing cancer cells from normal cells regardless of tissue types. The analysis further revealed that breast cancer was closest with lung cancer, whereas it was farthest from colon cancer. Pathway analysis identified that either the "cancer" related network or the "cancer" related bio-function appeared as the highest confidence in all the five cancers, whereas each cancer type represents its tissue-specific gene sets. Our results contribute toward understanding the essential abnormal epigenetic pathways involved in carcinogenesis. Further, the novel methylation markers could be applied to establish markers for cancer prognosis.
C1 [Kim, Byungtak; Kang, Seongeun; Jeong, Gookjoo; Park, Sung-Bin; Kim, Sun Jung] Dongguk Univ Seoul, Dept Life Sci, Seoul, South Korea.
C3 Dongguk University
RP Kim, SJ (通讯作者)，Dongguk Univ Seoul, Dept Life Sci, Seoul, South Korea.
EM sunjungk@dongguk.edu
RI kim, sun/T-1013-2019
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education, Science and Technology
   [NRF-2012R1A1A2040830]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology (NRF-2012R1A1A2040830).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al-Moundhri M S, 2013, Gulf J Oncolog, V1, P45
   Barekati Z, 2010, HUM MOL GENET, V19, P2936, DOI 10.1093/hmg/ddq199
   Buckingham L, 2010, INT J CANCER, V126, P1630, DOI 10.1002/ijc.24896
   Carney Walter P, 2013, Biomark Cancer, V5, P31, DOI 10.4137/BIC.S12389
   Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902
   Chou HL, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-100
   Delgado-Cruzata L, 2013, EPIGENETICS, V9
   Dick FA, 2013, NAT REV MOL CELL BIO, V14, P297, DOI 10.1038/nrm3567
   Dmitriev AA, 2012, EPIGENETICS-US, V7, P502, DOI 10.4161/epi.19801
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   Gu SC, 2011, MOL MED, V17, P48, DOI 10.2119/molmed.2010.00120
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hino R, 2009, CANCER RES, V69, P2766, DOI 10.1158/0008-5472.CAN-08-3070
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Kim JH, 2011, BMB REP, V44, P523, DOI 10.5483/BMBRep.2011.44.8.523
   Kim SJ, 2011, CANCER LETT, V302, P47, DOI 10.1016/j.canlet.2010.12.010
   Lee SJ, 2013, ANN SURG ONCOL
   LeRoy G, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-20
   Liu Y, 2013, J APPL GENET
   Mardin WA, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-549
   Mayor R, 2009, BRIT J CANCER, V100, P1534, DOI 10.1038/sj.bjc.6605045
   Montiel-Duarte C, 2008, LEUKEMIA RES, V32, P709, DOI 10.1016/j.leukres.2007.09.005
   Moya P, 2013, TUMOR BIOL, V34, P471, DOI 10.1007/s13277-012-0572-3
   Müller I, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-297
   Oliveira Andre M, 2005, Am J Clin Pathol, V124 Suppl, pS16
   Patsialou A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3344
   Paul I, 2011, J PATHOL, V224, P564, DOI 10.1002/path.2925
   Sabater L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060438
   Sebova K, 2011, CANCER BIOMARK, V10, P13, DOI 10.3233/CBM-2012-0230
   Seniski GG, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-80
   Stefansson OA, 2011, EPIGENETICS-US, V6, P638, DOI 10.4161/epi.6.5.15667
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang YQ, 2013, J OBSTET GYNAECOL RE, V39, P549, DOI 10.1111/j.1447-0756.2012.01979.x
   Xu Y, 2013, ANN ONCOL, V24, P1498, DOI 10.1093/annonc/mdt011
   Xu Y, 2011, J CELL BIOCHEM, V112, P3440, DOI 10.1002/jcb.23271
   Yin DT, 2012, DISCOV MED, V14, P33
   Yokota J, 2000, CARCINOGENESIS, V21, P497, DOI 10.1093/carcin/21.3.497
   Yun JU, 2011, EMBO J, V30, P4500, DOI 10.1038/emboj.2011.312
NR 39
TC 4
Z9 4
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 19
PY 2014
VL 9
IS 5
AR e97818
DI 10.1371/journal.pone.0097818
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AN9SK
UT WOS:000340948600079
PM 24842468
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Jhala, DV
   Kale, RK
   Singh, RP
AF Jhala, Dhwani V.
   Kale, Raosaheb K.
   Singh, Rana P.
TI Microgravity Alters Cancer Growth and Progression
SO CURRENT CANCER DRUG TARGETS
LA English
DT Article
DE Apoptosis; cancer growth; cell proliferation; cell signalling;
   microgravity
ID THYROID-CARCINOMA CELLS; ESTROGEN-RECEPTOR-ALPHA; ROTATING-WALL VESSEL;
   SIMULATED MICROGRAVITY; EXTRACELLULAR-MATRIX; C-FOS; BREAST-CANCER;
   SPACE-FLIGHT; ENDOTHELIAL-CELLS; GENE-EXPRESSION
AB Study of the process of cancer initiation, growth and progression in altered gravity is of utmost importance considering the health status of researchers visiting in space and future scope of space tourism. Microgravity affects various cells in the body differently; however, the mechanisms of such effects are not understood completely. Therefore, it is imperative to explore various physiological and biochemical processes, particularly those which can influence the process of carcinogenesis. If the changes in physiological or biochemical processes do not revert back to normalcy even after returning from the space to earth, it may lead to various aberrations and morphological changes during the life span. Such changes could lead to pathological conditions including cancer. For example, microgravity is observed to suppress the activity of immune cells, which itself increases the risk of cancer development. It is little known how the microgravity affects cellular and molecular events that determine physiological and biological responses. There is also a possibility of changes in epigenetic signatures during microgravity exposure which remains unexplored. Herein, we have reviewed the effect of microgravity on relevant molecular and biological processes, and how it could influence the course of cancer development. In this regard, we have also highlighted the areas of research that require more attention to bridge the gap of understanding for such biological processes.
C1 [Jhala, Dhwani V.; Kale, Raosaheb K.; Singh, Rana P.] Cent Univ Gujarat, Sch Life Sci, Gandhinagar 382030, India.
   [Kale, Raosaheb K.; Singh, Rana P.] Jawaharlal Nehru Univ, Sch Life Sci, New Delhi 110067, India.
C3 Central University of Gujarat; Jawaharlal Nehru University, New Delhi
RP Singh, RP (通讯作者)，Jawaharlal Nehru Univ, Sch Life Sci, Canc Biol Lab, 104 New Mehrauli Rd, New Delhi 110067, India.
EM ranaps@hotmail.com
RI Singh, Rana/JZT-2038-2024
OI Jhala, Dhwani/0000-0003-3768-7355; Singh, Rana
   Pratap/0000-0003-4261-7044
FU CSIR, New Delhi, India
FX The fellowship support to D.V. Jhala from CSIR, New Delhi, India is
   gratefully acknowledged.
CR ADAMS JC, 1993, DEVELOPMENT, V117, P1183
   [Anonymous], 2002, J GRAVIT PHYSL
   Barr YR, 2007, AVIAT SPACE ENVIR MD, V78, pA26
   Becker JL, 2013, NAT REV CANCER, V13, P315, DOI 10.1038/nrc3507
   BECKER JL, 1993, J CELL BIOCHEM, V51, P283, DOI 10.1002/jcb.240510307
   CARPENTER G, 1979, ANNU REV BIOCHEM, V48, P193, DOI 10.1146/annurev.bi.48.070179.001205
   Carson Daniel D, 2004, Reprod Biol Endocrinol, V2, P1, DOI 10.1186/1477-7827-2-1
   CHAKRABARTY S, 1989, CANCER RES, V49, P2112
   Chiquet M, 2003, MATRIX BIOL, V22, P73, DOI 10.1016/S0945-053X(03)00004-0
   Clejan S, 1996, BIOTECHNOL BIOENG, V50, P587, DOI 10.1002/(SICI)1097-0290(19960605)50:5<587::AID-BIT14>3.3.CO;2-L
   COGOLI A, 1981, ACTA ASTRONAUT, V8, P995, DOI 10.1016/0094-5765(81)90070-9
   Coinu R, 2006, FEBS LETT, V580, P2465, DOI 10.1016/j.febslet.2006.03.078
   De Santo NG, 2005, SEMIN NEPHROL, V25, P379, DOI 10.1016/j.semnephrol.2005.05.006
   DEGROOT RP, 1990, J CELL SCI, V97, P33
   DEGROOT RP, 1991, AVIAT SPACE ENVIR MD, V62, P37
   DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x
   Dias S, 2001, P NATL ACAD SCI USA, V98, P10857, DOI 10.1073/pnas.191117498
   Dias S, 2002, BLOOD, V99, P2179, DOI 10.1182/blood.V99.6.2179
   Dorward A, 1997, J BIOENERG BIOMEMBR, V29, P385, DOI 10.1023/A:1022454932269
   FERRARI S, 1986, MOL CELL BIOL, V6, P3614, DOI 10.1128/MCB.6.11.3614
   FRIEDMAN E, 1984, CANCER RES, V44, P3040
   Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617
   GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305
   Griffith LG, 2006, NAT REV MOL CELL BIO, V7, P211, DOI 10.1038/nrm1858
   Grimm D, 1997, THYROID, V7, P859, DOI 10.1089/thy.1997.7.859
   Grimm D, 2002, FASEB J, V16, P604, DOI 10.1096/fj.01-0673fje
   Grosse J, 2012, FASEB J, V26, P5124, DOI 10.1096/fj.12-215749
   Hagios C, 1998, PHILOS T R SOC B, V353, P857, DOI 10.1098/rstb.1998.0250
   Han ZB, 1999, MUTAT RES-FUND MOL M, V426, P1, DOI 10.1016/S0027-5107(99)00074-3
   Hollander J, 1998, FREE RADICAL BIO MED, V24, P385, DOI 10.1016/S0891-5849(97)00278-5
   Howell GM, 1998, J BIOL CHEM, V273, P9214, DOI 10.1074/jbc.273.15.9214
   Ikenaga M, 2002, J RADIAT RES, V43, pS141
   Imler J L, 1989, Prog Growth Factor Res, V1, P69, DOI 10.1016/0955-2235(89)90001-X
   Infanger M, 2006, CELL TISSUE RES, V324, P267, DOI 10.1007/s00441-005-0142-8
   Ingram M, 1997, IN VITRO CELL DEV-AN, V33, P459
   Jessup JM, 2000, IN VITRO CELL DEV-AN, V36, P367
   Jessup JM, 1997, IN VITRO CELL DEV-AN, V33, P352
   Kalmar B, 2009, ADV DRUG DELIVER REV, V61, P310, DOI 10.1016/j.addr.2009.02.003
   KAWATA M, 1991, CANCER RES, V51, P2655
   Khan SA, 2002, J CELL BIOCHEM, V85, P728, DOI 10.1002/jcb.10170
   Kim MHY, 2006, ADV SPACE RES-SERIES, V37, P1798, DOI 10.1016/j.asr.2006.03.032
   Kossmehl P, 2005, J MOL MED, V83, P626, DOI 10.1007/s00109-005-0642-8
   Kossmehl P, 2003, ENDOCRINOLOGY, V144, P4172, DOI 10.1210/en.2002-0171
   KUMEI Y, 1989, J CELL SCI, V93, P221
   Lelièvre SA, 1998, P NATL ACAD SCI USA, V95, P14711, DOI 10.1073/pnas.95.25.14711
   Leszczyniecka M, 2001, PHARMACOL THERAPEUT, V90, P105, DOI 10.1016/S0163-7258(01)00132-2
   Lindberg U, 2008, SEMIN CANCER BIOL, V18, P2, DOI 10.1016/j.semcancer.2007.10.002
   Liu Yongqing, 2008, Genomics Proteomics & Bioinformatics, V6, P29, DOI 10.1016/S1672-0229(08)60018-2
   Lu N, 2011, CELL SIGNAL, V23, P1473, DOI 10.1016/j.cellsig.2011.04.010
   Marrero B, 2009, IN VITRO CELL DEV-AN, V45, P523, DOI 10.1007/s11626-009-9217-2
   MERKER HJ, 1994, MICROSC RES TECHNIQ, V28, P95, DOI 10.1002/jemt.1070280203
   MINOWADA G, 1995, J CLIN INVEST, V95, P3, DOI 10.1172/JCI117655
   Moes MJA, 2011, MICROGRAVITY SCI TEC, V23, P249, DOI 10.1007/s12217-010-9185-x
   MUKHERJEE BB, 1995, ANN NY ACAD SCI, V760, P201, DOI 10.1111/j.1749-6632.1995.tb44631.x
   MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0
   Nakamura K, 2002, BIOTECHNIQUES, V33, P1068, DOI 10.2144/02335rr02
   NEDERMAN T, 1984, CANCER RES, V44, P3090
   Okaichi K, 2004, J RADIAT RES, V45, P399, DOI 10.1269/jrr.45.399
   Pietsch J, 2013, INT J MOL SCI, V14, P1164, DOI 10.3390/ijms14011164
   Qian AR, 2008, ACTA ASTRONAUT, V63, P947, DOI 10.1016/j.actaastro.2008.01.024
   Razmara A, 2008, J PHARMACOL EXP THER, V325, P782, DOI 10.1124/jpet.107.134072
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   RIJKEN PJ, 1992, ADV SPACE RES-SERIES, V12, P145, DOI 10.1016/0273-1177(92)90277-5
   ROSKELLEY CD, 1994, P NATL ACAD SCI USA, V91, P12378, DOI 10.1073/pnas.91.26.12378
   Sanders AJ, 2010, ANGIOGENESIS, V13, P317, DOI 10.1007/s10456-010-9188-7
   Sasaki N, 2001, CLIN CANCER RES, V7, P4136
   SCHLESSINGER J, 1983, CRC CR REV BIOCH MOL, V14, P93, DOI 10.3109/10409238309102791
   Schnee JM, 2000, CARDIOVASC RES, V46, P264, DOI 10.1016/S0008-6363(00)00044-4
   Stark HJ, 1999, J INVEST DERMATOL, V112, P681, DOI 10.1046/j.1523-1747.1999.00573.x
   StCroix B, 1996, NAT MED, V2, P1204
   Strollo F, 1999, ADV SPACE B, V7, P99, DOI 10.1016/S1569-2574(08)60008-8
   Sytkowski AJ, 2001, IN VITRO CELL DEV-AN, V37, P79
   Taga M, 2006, AVIAT SPACE ENVIR MD, V77, P1113
   Takeda M, 2009, NEUROSCI LETT, V463, P54, DOI 10.1016/j.neulet.2009.07.045
   Testard I, 1996, INT J RADIAT BIOL, V70, P403, DOI 10.1080/095530096144879
   TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2
   Ulbrich C, 2011, CELL PHYSIOL BIOCHEM, V28, P185, DOI 10.1159/000331730
   Vassy J, 2003, ADV SPACE RES-SERIES, V32, P1595, DOI 10.1016/S0273-1177(03)90400-5
   Vassy J., 2001, FASEB Journal, V15, P1104
   VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2
   Vincent L, 2005, ANN BIOMED ENG, V33, P1405, DOI 10.1007/s10439-005-6153-5
   Wang DG, 1998, J CELL PHYSIOL, V177, P387, DOI 10.1002/(SICI)1097-4652(199812)177:3<387::AID-JCP2>3.3.CO;2-C
   Yang C, 2008, ADV SPACE RES, V42, P1898, DOI 10.1016/j.asr.2008.06.017
   Yang TC, 1997, RADIAT RES, V148, pS17, DOI 10.2307/3579712
   Yi ZC, 2009, ADV SPACE RES, V44, P233, DOI 10.1016/j.asr.2009.04.006
   Zheng HX, 2012, ADV SPACE RES, V49, P1432, DOI 10.1016/j.asr.2012.02.020
   Zou LX, 2011, ADV SPACE RES, V48, P390, DOI 10.1016/j.asr.2011.03.022
   Zou LX, 2010, ADV SPACE RES, V46, P1237, DOI 10.1016/j.asr.2010.06.037
NR 88
TC 25
Z9 28
U1 3
U2 28
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0096
EI 1873-5576
J9 CURR CANCER DRUG TAR
JI Curr. Cancer Drug Targets
PY 2014
VL 14
IS 4
BP 394
EP 406
DI 10.2174/1568009614666140407113633
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AN8UL
UT WOS:000340880200007
PM 24720362
DA 2025-01-12
ER

PT J
AU Naipal, KAT
   Verkaik, NS
   Ameziane, N
   van Deurzen, CHM
   ter Brugge, P
   Meijers, M
   Sieuwerts, AM
   Martens, JW
   O'Connor, MJ
   Vrieling, H
   Hoeijmakers, JHJ
   Jonkers, J
   Kanaar, R
   de Winter, JP
   Vreeswijk, MP
   Jager, A
   van Gent, DC
AF Naipal, Kishan A. T.
   Verkaik, Nicole S.
   Ameziane, Najim
   van Deurzen, Carolien H. M.
   ter Brugge, Petra
   Meijers, Matty
   Sieuwerts, Anieta M.
   Martens, John W.
   O'Connor, Mark J.
   Vrieling, Harry
   Hoeijmakers, Jan H. J.
   Jonkers, Jos
   Kanaar, Roland
   de Winter, Johan P.
   Vreeswijk, Maaike P.
   Jager, Agnes
   van Gent, Dik C.
TI Functional <i>Ex Vivo</i> Assay to Select Homologous
   Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID DAMAGE REPAIR PROTEINS; RADIATION-INDUCED FOCI; POLY(ADP-RIBOSE)
   POLYMERASE; DNA-DAMAGE; SYNTHETIC LETHALITY; MUTANT-CELLS; CANCER;
   SENSITIVITY; BRCA1; RESISTANCE
AB Purpose: Poly(ADP-ribose) polymerase (PARP) inhibitors are promising targeted treatment options for hereditary breast tumors with a homologous recombination (HR) deficiency caused by BRCA1 or BRCA2 mutations. However, the functional consequence of BRCA gene mutations is not always known and tumors can be HR deficient for other reasons than BRCA gene mutations. Therefore, we aimed to develop a functional test to determine HR activity in tumor samples to facilitate selection of patients eligible for PARP inhibitor treatment.
   Experimental design: We obtained 54 fresh primary breast tumor samples from patients undergoing surgery. We determined their HR capacity by studying the formation of ionizing radiation induced foci (IRIF) of the HR protein RAD51 after ex vivo irradiation of these organotypic breast tumor samples. Tumors showing impaired RAD51 IRIF formation were subjected to genetic and epigenetic analysis.
   Results: Five of 45 primary breast tumors with sufficient numbers of proliferating tumor cells were RAD51 IRIF formation deficient (11%, 95% CI, 5%-24%). This HR defect was significantly associated with triple-negative breast cancer (OR, 57; 95% CI, 3.9-825; P = 0.003). Twoof five HR-deficient tumors were not caused by mutations in the BRCA genes, but by BRCA1 promoter hypermethylation.
   Conclusion: The functional RAD51 IRIF assay faithfully identifies HR-deficient tumors and has clear advantages over gene sequencing. It is a relatively easy assay that can be performed on biopsy material, making it a powerful tool to select patients with an HR-deficient cancer for PARP inhibitor treatment in the clinic. (C) 2014 AACR.
C1 [Naipal, Kishan A. T.; Verkaik, Nicole S.; Hoeijmakers, Jan H. J.; Kanaar, Roland; van Gent, Dik C.] Erasmus Univ, Med Ctr, Dept Genet, NL-3000 CA Rotterdam, Netherlands.
   [Ameziane, Najim; de Winter, Johan P.] Vrije Univ Amsterdam Med Ctr, Dept Clin Genet, Amsterdam, Netherlands.
   [van Deurzen, Carolien H. M.] Erasmus Univ, Med Ctr, Dept Pathol, NL-3000 CA Rotterdam, Netherlands.
   [ter Brugge, Petra; Jonkers, Jos] Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands.
   [Meijers, Matty; Vrieling, Harry; Vreeswijk, Maaike P.] Leiden Univ, Med Ctr, Dept Toxicogenet, Leiden, Netherlands.
   [Sieuwerts, Anieta M.; Martens, John W.; Jager, Agnes] Erasmus Univ, Med Ctr, Dept Med Oncol, NL-3000 CA Rotterdam, Netherlands.
   [O'Connor, Mark J.] AstraZeneca, iMed Oncol, Macclesfield, Cheshire, England.
   [Kanaar, Roland] Erasmus Univ, Med Ctr, Canc Genom Ctr Netherlands, NL-3000 CA Rotterdam, Netherlands.
   [Kanaar, Roland] Erasmus Univ, Med Ctr, Dept Radiat Oncol, NL-3000 CA Rotterdam, Netherlands.
   [Vreeswijk, Maaike P.] Leiden Univ, Med Ctr, Dept Human Genet, Leiden, Netherlands.
C3 Erasmus University Rotterdam; Erasmus MC; Vrije Universiteit Amsterdam;
   VU UNIVERSITY MEDICAL CENTER; Erasmus University Rotterdam; Erasmus MC;
   Netherlands Cancer Institute; Leiden University - Excl LUMC; Leiden
   University; Leiden University Medical Center (LUMC); Erasmus University
   Rotterdam; Erasmus MC; AstraZeneca; Erasmus University Rotterdam;
   Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Leiden University
   - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC)
RP van Gent, DC (通讯作者)，Erasmus Univ, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands.
EM d.vangent@erasmusmc.nl
RI Hoeijmakers, Jan/AAX-6972-2021; Jonkers, Jos/AAG-3246-2019; jager,
   agnes/V-6381-2017; Vrieling, Harry/ABC-8068-2020
OI Jonkers, Jos/0000-0002-9264-9792; van Gent, Dik C./0000-0003-1473-8148;
   Vrieling, Harry/0000-0002-3034-2664; Naipal, Kishan/0000-0001-8267-8218
FU European Community [HEALTH-F2-2010-259893]; Dutch Cancer Society [EMCR
   2008-4045]
FX The research leading to these results has received funding from the
   European Community's Seventh Framework Programme (FP7/2007-2013) under
   grant agreement No. HEALTH-F2-2010-259893 and from the Dutch Cancer
   Society (grant EMCR 2008-4045 and a Ride for the Roses Cancer Research
   Grant).
CR Abkevich V, 2012, BRIT J CANCER, V107, P1776, DOI 10.1038/bjc.2012.451
   Asakawa H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2486
   Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012
   Campos SM, 2003, ONCOLOGY-BASEL, V64, P289, DOI 10.1159/000070284
   Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399
   Dedes KJ, 2011, CELL CYCLE, V10, P1192, DOI 10.4161/cc.10.8.15273
   DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1
   Drew Y, 2011, JNCI-J NATL CANCER I, V103, P334, DOI 10.1093/jnci/djq509
   Dumay A, 2013, INT J CANCER, V132, P1227, DOI 10.1002/ijc.27767
   Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Garvin S, 2006, CELL TISSUE RES, V325, P245, DOI 10.1007/s00441-006-0159-7
   Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5
   Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560
   Graeser M, 2010, CLIN CANCER RES, V16, P6159, DOI 10.1158/1078-0432.CCR-10-1027
   Hartman AR, 2012, CANCER-AM CANCER SOC, V118, P2787, DOI 10.1002/cncr.26576
   Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001
   Helleday T, 2010, CARCINOGENESIS, V31, P955, DOI 10.1093/carcin/bgq064
   Joosse SA, 2011, GENE CHROMOSOME CANC, V50, P71, DOI 10.1002/gcc.20833
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lips EH, 2013, BRIT J CANCER, V108, P2172, DOI 10.1038/bjc.2013.144
   Lord CJ, 2008, DNA REPAIR, V7, P2010, DOI 10.1016/j.dnarep.2008.08.014
   Madarnas Y, 2008, CANCER TREAT REV, V34, P539, DOI 10.1016/j.ctrv.2008.03.013
   McCabe N, 2006, CANCER RES, V66, P8109, DOI 10.1158/0008-5472.CAN-06-0140
   McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X
   Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041
   Mukhopadhyay A, 2010, CLIN CANCER RES, V16, P2344, DOI 10.1158/1078-0432.CCR-09-2758
   Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Oplustilova L, 2012, CELL CYCLE, V11, P3837, DOI 10.4161/cc.22026
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Petermann E, 2010, MOL CELL, V37, P492, DOI 10.1016/j.molcel.2010.01.021
   Plummer ER, 2006, CURR OPIN PHARMACOL, V6, P364, DOI 10.1016/j.coph.2006.02.004
   Rajan SS, 2014, BREAST CANCER RES TR, V143, P91, DOI 10.1007/s10549-013-2786-5
   Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172
   Sandhu SK, 2013, ANN ONCOL, V24, P1416, DOI 10.1093/annonc/mdt074
   Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Turner NC, 2006, ONCOGENE, V25, P5846, DOI 10.1038/sj.onc.1209876
   Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61
   Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6
   van Veelen LR, 2005, MUTAT RES-FUND MOL M, V574, P34, DOI 10.1016/j.mrfmmm.2005.01.020
   van Veelen LR, 2005, MUTAT RES-FUND MOL M, V574, P22, DOI 10.1016/j.mrfmmm.2005.01.019
   Wang F, 2012, J MOL DIAGN, V14, P22, DOI 10.1016/j.jmoldx.2011.08.002
   Willers H, 2009, MOL CANCER RES, V7, P1304, DOI 10.1158/1541-7786.MCR-09-0149
   Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872
   Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8
NR 50
TC 131
Z9 142
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 15
PY 2014
VL 20
IS 18
BP 4816
EP 4826
DI 10.1158/1078-0432.CCR-14-0571
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP8VX
UT WOS:000342358500011
PM 24963051
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Kumar, S
AF Kumar, Sanjay
TI P53 induction accompanying G2/M arrest upon knockdown of tumor
   suppressor HIC1 in U87MG glioma cells
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Tumor suppressor; HIC1; P53; P21; P27; U87MG; G2/M arrest
ID 17P ALLELIC LOSS; DNA HYPERMETHYLATION; TRANSCRIPTIONAL REPRESSION;
   ASTROCYTIC TUMORS; BREAST-CANCER; GENE; GROWTH;
   HYPERMETHYLATED-IN-CANCER-1; EXPRESSION; CARCINOMA
AB Hypermethylated in cancer 1 (HIC1) is a novel tumor suppressor gene (tsg) frequently silenced by epigenetic modification, predominantly by methylation in different tumors. HIC1 functionally co-operates with p53 in cultured cells as well as in transgenic animals to suppress tumors and has binding site on its promoter. Its over expression often leads to cell cycle arrests. Although HIC1 proven to have role as tsg, its regulation to cell cycle and dependency upon p53 is grossly unknown. In this study, we investigated the role of HIC1 in cell cycle and proliferation of glioma cell line U87MG which has wild type p53, in both serum-containing and serum-deprived medium. Microscopic analysis and MTT assay showed reduced cell number and rate of proliferation upon HIC1 knock down compared to control siRNA (p = 0.025) and untreated cells (p = 0.03) in serum-containing medium and serum-free medium (p = 0.014 vs control siRNA; p = 0.018 vs untreated cells). Cell cycle analysis revealed an arrest at G2/M phase of cell cycle with no demonstrable increase in apoptosis with both medium. An increased expression of p53 concomitant with HIC1 knockdown was observed. Furthermore P21, a p53 responsive gene, along with p27 was significantly increased in comparison with controls. Our results demonstrated an important role of HIC1 for the normal progression of cell cycle, and at molecular level, it could affect the homeostasis of p53 as well as number of cell cycle-related genes, which may or may not be directly linked to p53.
C1 Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Biomol Sci Ctr, Orlando, FL 32816 USA.
C3 State University System of Florida; University of Central Florida
RP Kumar, S (通讯作者)，Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Biomol Sci Ctr, Bld 20,4110 Libra Dr, Orlando, FL 32816 USA.
EM sanjay.kumar@ucf.edu
RI kumar, Sanjay/ITT-3680-2023
FU Council of Scientific and Industrial Research (CSIR), Government of
   India
FX This work was financially supported by the Council of Scientific and
   Industrial Research (CSIR), Government of India for granting senior
   research fellowship. We thank Professor Subrata Sinha, Director,
   National Brain Research Centre, Manesar, Gurgaon for providing
   laboratory support to this work. We are also thankful to Late Mathura
   Prasad, and Jitender Behari Lal for technical support, and Satish Kumar
   for secretarial assistance.
CR [Anonymous], MOL CANC
   ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513
   Chattopadhyay P, 1997, ONCOGENE, V15, P871, DOI 10.1038/sj.onc.1201238
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077
   COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I
   Datta K, 2004, CANCER GENE THER, V11, P525, DOI 10.1038/sj.cgt.7700724
   Fleuriel C, 2009, INT J BIOCHEM CELL B, V41, P26, DOI 10.1016/j.biocel.2008.05.028
   Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Issa JPJ, 1997, CANCER RES, V57, P1678
   Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359
   Kanai Y, 1998, CANCER LETT, V122, P135, DOI 10.1016/S0304-3835(97)00380-7
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Li JP, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-354
   Maki CG, 1996, CANCER RES, V56, P2649
   MAKOS M, 1993, CANCER RES, V53, P2715
   MAKOS M, 1993, CANCER RES, V53, P2719
   MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929
   Manna SK, 2010, J BIOL CHEM, V285, P22318, DOI 10.1074/jbc.M110.131797
   MAXWELL SA, 1994, EXP CELL RES, V214, P67, DOI 10.1006/excr.1994.1234
   Melki JR, 1999, LEUKEMIA, V13, P877, DOI 10.1038/sj.leu.2401401
   MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R
   Mondal AM, 2006, CANCER RES, V66, P10466, DOI 10.1158/0008-5472.CAN-06-0352
   Morton RA, 1996, J UROLOGY, V156, P512, DOI 10.1016/S0022-5347(01)65916-0
   Parrella P, 2005, CANCER LETT, V222, P75, DOI 10.1016/j.canlet.2004.08.026
   Peng XJ, 1998, ENDOCR J, V45, P247, DOI 10.1507/endocrj.45.247
   Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200
   Rood BR, 2002, CANCER RES, V62, P3794
   Sade H, 2004, J BIOL CHEM, V279, P2937, DOI 10.1074/jbc.M309924200
   Sarkar C, 2005, J NEURO-ONCOL, V73, P93, DOI 10.1007/s11060-004-3015-1
   Sarkar Chitra, 2004, Brain Tumor Pathol, V21, P7, DOI 10.1007/BF02482170
   WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570
   Wang X, 2011, MED ONCOL, V28, P1225, DOI 10.1007/s12032-010-9552-x
   Zhang B, 2009, ONCOGENE, V28, P651, DOI 10.1038/onc.2008.419
   Zhang W, 2010, ONCOGENE, V29, P2467, DOI 10.1038/onc.2010.12
NR 37
TC 13
Z9 14
U1 0
U2 18
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD OCT
PY 2014
VL 395
IS 1-2
BP 281
EP 290
DI 10.1007/s11010-014-2137-9
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AN4IC
UT WOS:000340550000027
PM 24992983
DA 2025-01-12
ER

PT J
AU Liu, Y
   Xing, ZB
   Wang, SQ
   Chen, S
   Liu, YK
   Li, YH
   Li, YF
   Wang, YQ
   Lu, Y
   Hu, WN
   Zhang, JH
AF Liu, Yan
   Xing, Zhao-Bin
   Wang, Shu-Qing
   Chen, Su
   Liu, Yan-Kun
   Li, Yu-Hui
   Li, Yu-Feng
   Wang, Ya-Qi
   Lu, Yang
   Hu, Wan-Ning
   Zhang, Jing-Hua
TI MDM2-MOF-H4K16ac axis contributes to tumorigenesis induced by Notch
SO FEBS JOURNAL
LA English
DT Article
DE acetylation; histone modification; MDM2; MOF; Notch
ID HUMAN HEPATOCELLULAR-CARCINOMA; EMBRYONIC STEM-CELLS; BREAST-CANCER;
   HISTONE ACETYLTRANSFERASE; SIGNALING PATHWAY; H4-K16 ACETYLATION;
   DROSOPHILA MOF; LYSINE 56; ACTIVATION; HMOF
AB Identification of the epigenetic mechanisms involved in the transmission of Notch signaling is useful for personalized medicine. We observed that aberrantly high levels of Notch activity resulted in H4K16ac downregulation in hepatocellular carcinoma and breast cancer cell lines and tissues. This downregulated acetylation was a consequence of increased male on the first degradation following the upregulation of full-length murine double minute 2 in different cancer types. We observed that increases in male on the first could attenuate heterogeneity induced by aberrantly high levels of Notch activity. Our results provide new insights into the analysis and treatment of Notch-induced hepatocellular carcinoma and breast cancer.
C1 [Liu, Yan; Xing, Zhao-Bin; Wang, Ya-Qi] Hebei United Univ, Coll Life Sci, Tangshan, Peoples R China.
   [Liu, Yan; Liu, Yan-Kun; Li, Yu-Hui; Li, Yu-Feng; Wang, Ya-Qi; Hu, Wan-Ning; Zhang, Jing-Hua] Tangshan Peoples Hosp, Inst Canc, Cent Lab, Tangshan, Peoples R China.
   [Wang, Shu-Qing] Kailuan Gen Hosp, Dept Nephrol, Tangshan, Hebei, Peoples R China.
   [Chen, Su] Tongji Univ, Sch Life Sci, Shanghai 200092, Peoples R China.
   [Lu, Yang] First Hosp Shi Jia Zhuang City, Shijiazhuang, Peoples R China.
C3 North China University of Science & Technology; Tongji University
RP Liu, Y (通讯作者)，South Jian She Rd 57, Tang Shan 063000, He Bei Province, Peoples R China.
EM wsqlr709@sina.com; zhangjinghuatp1@sina.com
RI Li, Yuhui/O-5321-2015; wang, shuqing/JRX-7812-2023; wang,
   yaqi/HOH-8096-2023
OI xing, zhaobin/0000-0001-6810-4082
FU National Natural Science Foundation of China [81302324]; the Instruction
   Plan of the Science and Technology Research and Development Project of
   Tangshan [13130282z, 13130261a, 13130262a]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81302324) and the Instruction Plan of the Science and
   Technology Research and Development Project of Tangshan (No. 13130282z,
   No. 13130261a, No. 13130262a; Science and Technology Project of Tangshan
   Science and Technology Bureau).
CR Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913
   Buckley NE, 2013, NUCLEIC ACIDS RES, V41, P8601, DOI 10.1093/nar/gkt626
   Cao LL, 2014, INT J ONCOL, V44, P1207, DOI 10.3892/ijo.2014.2266
   Cheng AW, 2013, CELL RES, V23, P1163, DOI 10.1038/cr.2013.122
   Cho SW, 2014, GENOME RES, V24, P132, DOI 10.1101/gr.162339.113
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Dumortier A, 2006, MOL CELL BIOL, V26, P209, DOI 10.1128/MCB.26.1.209-220.2006
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808
   Gao J, 2012, INT J ONCOL, V41, P1773, DOI 10.3892/ijo.2012.1606
   Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07
   Horikoshi Nobuo, 2013, Genome Integr, V4, P3, DOI 10.1186/2041-9414-4-3
   Kapoor-Vazirani P, 2008, CANCER RES, V68, P6810, DOI 10.1158/0008-5472.CAN-08-0141
   Katoh H, 2011, MOL CELL, V44, P770, DOI 10.1016/j.molcel.2011.10.012
   Kim HA, 2012, J CLIN INVEST, V122, P3248, DOI 10.1172/JCI61216
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kwon SY, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000574
   Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704
   Li XZ, 2010, EPIGENETICS-US, V5
   Lim SO, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-83
   Liu M, 2012, MOL CELL, V45, P171, DOI 10.1016/j.molcel.2011.11.018
   Liu N, 2013, ONCOL LETT, V6, P393, DOI 10.3892/ol.2013.1380
   Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847
   Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mittal S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-128
   Neal KC, 2000, BBA-GENE STRUCT EXPR, V1490, P170, DOI 10.1016/S0167-4781(99)00211-0
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823
   Pettersson S, 2013, BIOCHEM J, V450, P523, DOI 10.1042/BJ20121249
   Pfister S, 2008, INT J CANCER, V122, P1207, DOI 10.1002/ijc.23283
   Reedijk M, 2012, ADV EXP MED BIOL, V727, P241, DOI 10.1007/978-1-4614-0899-4_18
   Reister S, 2011, STEM CELLS DEV, V20, P1687, DOI 10.1089/scd.2010.0418
   Robinson PJJ, 2008, J MOL BIOL, V381, P816, DOI 10.1016/j.jmb.2008.04.050
   Ruthenburg AJ, 2011, CELL, V145, P692, DOI 10.1016/j.cell.2011.03.053
   Sánchez-Molina S, 2006, BIOCHEM J, V398, P215, DOI 10.1042/BJ20060052
   Shogren-Knaak M, 2006, SCIENCE, V311, P844, DOI 10.1126/science.1124000
   Speiser J, 2012, INT J SURG PATHOL, V20, P139, DOI 10.1177/1066896911427035
   Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005
   Tschaharganeh DF, 2013, GASTROENTEROLOGY, V144, P1530, DOI 10.1053/j.gastro.2013.02.009
   Vastenhouw NL, 2010, NATURE, V464, P922, DOI 10.1038/nature08866
   Villanueva A, 2012, GASTROENTEROLOGY, V143, P1660, DOI 10.1053/j.gastro.2012.09.002
   Wahlström T, 2013, EXP CELL RES, V319, P3160, DOI 10.1016/j.yexcr.2013.07.004
   Wang F, 2012, ONCOL REP, V27, P1170, DOI 10.3892/or.2012.1620
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Won HY, 2012, FASEB J, V26, P5002, DOI 10.1096/fj.12-209247
   Xie W, 2009, MOL CELL, V33, P417, DOI 10.1016/j.molcel.2009.02.004
   Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174
   Zaidi SK, 2013, J CELL PHYSIOL, V228, P2103, DOI 10.1002/jcp.24387
   Zhou L, 2013, DIGEST DIS SCI, V58, P1016, DOI 10.1007/s10620-012-2434-7
NR 52
TC 11
Z9 13
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD AUG
PY 2014
VL 281
IS 15
BP 3315
EP 3324
DI 10.1111/febs.12863
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AN1PH
UT WOS:000340355300002
PM 24898892
OA Bronze
DA 2025-01-12
ER

PT J
AU Baldan, F
   Lavarone, E
   Di Loreto, C
   Filetti, S
   Russo, D
   Damante, G
   Puppin, C
AF Baldan, Federica
   Lavarone, Elisa
   Di Loreto, Carla
   Filetti, Sebastiano
   Russo, Diego
   Damante, Giuseppe
   Puppin, Cinzia
TI Histone post-translational modifications induced by histone deacetylase
   inhibition in transcriptional control units of <i>NIS</i> gene
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Histone acetylation; Histone methylation; Chromatin immunoprecipitation;
   NIS
ID THYROID-CANCER CELLS; BREAST-CANCER; SODIUM/IODIDE SYMPORTER; IODIDE
   TRANSPORTER; EXPRESSION; CHROMATIN; ACETYLATION; METHYLATION; INDUCTION;
   PATTERNS
AB Histone post-translational modifications (HPTMs) play a major role in control of gene transcription. Among them, histone acetylation and methylation have been extensively investigated. Histone acetylation at different residues is generally associated to active gene transcription. In contrast, histone methylation can be associated either to transcriptional activation or repression, depending primarily on the histone residue that is subjected to the modification. Herein, effects of the histone deacetylase inhibitor SAHA on the sodium-iodide symporter (NIS) gene expression were investigated in breast cancer cells (MDA157 and MDA468). SAHA treatment induces high increase of NIS mRNA levels in MDA468 cells (300-fold), but moderate increase in MDA157 cells (fivefold). Histone H3 HPTMs (acetylation and methylations) on transcriptional units of NIS gene were investigated in these cell lines upon SAHA treatment. Our data indicate that HPTMs, particularly the H3 lysine 27 trimethylation, may operate in contrast to current models that relate epigenetic modifications with transcriptional activity.
C1 [Baldan, Federica; Lavarone, Elisa; Di Loreto, Carla; Damante, Giuseppe; Puppin, Cinzia] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy.
   [Filetti, Sebastiano] Univ Roma La Sapienza, Dept Internal Med & Med Specialties, I-00185 Rome, Italy.
   [Russo, Diego] Magna Graecia Univ Catanzaro, Dept Hlth Sci, Catanzaro, Italy.
   [Damante, Giuseppe] Univ Hosp S Maria della Misericordia, Inst Med Genet, Udine, Italy.
C3 University of Udine; Sapienza University Rome; Magna Graecia University
   of Catanzaro; Hospital Santa Maria della Misericordia
RP Puppin, C (通讯作者)，Univ Udine, Dept Med & Biol Sci, Piazzale Kolbe 4, I-33100 Udine, Italy.
EM cinzia.puppin@uniud.it
RI Baldan, Federica/AAK-6349-2021; Lavarone, Elisa/I-4853-2012; Damante,
   Giuseppe/AAC-5200-2022; Baldan, Federica/B-5977-2016
OI Damante, Giuseppe/0000-0003-2312-4009; Baldan,
   Federica/0000-0003-1164-1316
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG 10296]; MIUR
   [20093WAPYK_003]
FX This work is funded by grants to GD from Associazione Italiana per la
   Ricerca sul Cancro (AIRC) (project no IG 10296) and MIUR
   (20093WAPYK_003).\
CR Akagi T, 2008, BRIT J CANCER, V99, P781, DOI 10.1038/sj.bjc.6604544
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Butler JS, 2012, EPIGENOMICS-UK, V4, P163, DOI [10.2217/EPI.12.3, 10.2217/epi.12.3]
   Cui Peng, 2012, Genomics Proteomics & Bioinformatics, V10, P82, DOI 10.1016/j.gpb.2012.05.007
   Dai G, 1996, NATURE, V379, P458, DOI 10.1038/379458a0
   Fortunati N, 2010, BREAST CANCER RES TR, V124, P667, DOI 10.1007/s10549-010-0789-z
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Hosogane M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003698
   Hou P, 2010, J CLIN ENDOCR METAB, V95, P820, DOI 10.1210/jc.2009-1888
   Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023
   Lavarone E, 2013, MOL CELL ENDOCRINOL, V365, P1, DOI 10.1016/j.mce.2012.08.019
   MacDonald VE, 2009, EPIGENETICS-US, V4, P139, DOI 10.4161/epi.4.3.8484
   Marks PA, 2007, ONCOGENE, V26, P1351, DOI 10.1038/sj.onc.1210204
   Marks PA, 2009, J CELL BIOCHEM, V107, P600, DOI 10.1002/jcb.22185
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Puppin C, 2005, ENDOCRINOLOGY, V146, P3967, DOI 10.1210/en.2005-0128
   Rando OJ, 2007, CURR OPIN GENET DEV, V17, P94, DOI 10.1016/j.gde.2007.02.006
   Renier C, 2009, ANN SURG ONCOL, V16, P962, DOI 10.1245/s10434-008-0280-9
   Ringrose L, 2004, MOL CELL, V16, P641, DOI 10.1016/j.molcel.2004.10.015
   Russo D, 2011, J MOL ENDOCRINOL, V46, pR73, DOI 10.1530/JME-10-0150
   Santos-Rosa H, 2003, MOL CELL, V12, P1325, DOI 10.1016/S1097-2765(03)00438-6
   Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080
   Shilatifard A, 2006, ANNU REV BIOCHEM, V75, P243, DOI 10.1146/annurev.biochem.75.103004.142422
   Sponziello M, 2010, J ENDOCRINOL INVEST, V33, P2, DOI [10.3275/6522, 10.1007/BF03346542]
   Taki K, 2002, MOL ENDOCRINOL, V16, P2266, DOI 10.1210/me.2002-0109
   Tazebay UH, 2000, NAT MED, V6, P871, DOI 10.1038/78630
   Turner BM, 2000, BIOESSAYS, V22, P836, DOI 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.3.CO;2-O
NR 29
TC 8
Z9 8
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD AUG
PY 2014
VL 41
IS 8
BP 5257
EP 5265
DI 10.1007/s11033-014-3397-x
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AM5OY
UT WOS:000339910900041
PM 24844212
DA 2025-01-12
ER

PT J
AU Reyngold, M
   Turcan, S
   Giri, D
   Kannan, K
   Walsh, LA
   Viale, A
   Drobnjak, M
   Vahdat, LT
   Lee, W
   Chan, TA
AF Reyngold, Marsha
   Turcan, Sevin
   Giri, Dilip
   Kannan, Kasthuri
   Walsh, Logan A.
   Viale, Agnes
   Drobnjak, Marija
   Vahdat, Linda T.
   Lee, William
   Chan, Timothy A.
TI Remodeling of the Methylation Landscape in Breast Cancer Metastasis
SO PLOS ONE
LA English
DT Article
ID LYMPH-NODE METASTASES; CLINICAL-IMPLICATIONS; MOLECULAR PORTRAITS; GENE;
   EXPRESSION; PATTERNS; SUBTYPES; NUMBER; TUMORS; HYPERMETHYLATION
AB The development of breast cancer metastasis is accompanied by dynamic transcriptome changes and dramatic alterations in nuclear and chromatin structure. The basis of these changes is incompletely understood. The DNA methylome of primary breast cancers contribute to transcriptomic heterogeneity and different metastatic behavior. Therefore we sought to characterize methylome remodeling during regional metastasis. We profiled the DNA methylome and transcriptome of 44 matched primary breast tumors and regional metastases. Striking subtype-specific patterns of metastasis-associated methylome remodeling were observed, which reflected the molecular heterogeneity of breast cancers. These divergent changes occurred primarily in CpG island (CGI)-poor areas. Regions of methylome reorganization shared by the subtypes were also observed, and we were able to identify a metastasis-specific methylation signature that was present across the breast cancer subclasses. These alterations also occurred outside of CGIs and promoters, including sequences flanking CGIs and intergenic sequences. Integrated analysis of methylation and gene expression identified genes whose expression correlated with metastasis-specific methylation. Together, these findings significantly enhance our understanding of the epigenetic reorganization that occurs during regional breast cancer metastasis across the major breast cancer subtypes and reveal the nature of methylome remodeling during this process.
C1 [Reyngold, Marsha; Turcan, Sevin; Kannan, Kasthuri; Walsh, Logan A.; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
   [Reyngold, Marsha; Chan, Timothy A.] Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA.
   [Giri, Dilip] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA.
   [Viale, Agnes] Mem Sloan Kettering Canc Ctr, Genom Core, New York, NY 10021 USA.
   [Drobnjak, Marija] Mem Sloan Kettering Canc Ctr, Pathol Core, New York, NY 10021 USA.
   [Vahdat, Linda T.] Weill Cornell Med Ctr, Dept Med, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer
   Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering
   Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell
   University; Weill Cornell Medicine
RP Chan, TA (通讯作者)，Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, 1275 York Ave, New York, NY 10021 USA.
EM chant@mskcc.org
RI Chan, Timothy/ABD-5850-2021; Kannan, Kasthuri/A-5403-2013; Turcan,
   Sevin/AAF-1095-2019
OI Vahdat, Linda/0000-0002-3522-7382; Reyngold, Marsha/0000-0001-9475-146X;
   Walsh, Logan/0000-0001-8771-2577; Turcan, Sevin/0000-0002-0885-5607;
   Drobnjak, Marija/0000-0003-0676-4709; Kannan,
   Kasthuri/0000-0002-8479-0657
FU Louis Gerstner Foundation; Elsa U. Pardee Foundation; AVON Foundation;
   STARR Cancer Consortium; Metastasis Research Center; Department of
   Defense Era of Hope Award; NIH [5T32CA160001]
FX This work was supported in part by the Louis Gerstner Foundation
   (T.A.C.); the Elsa U. Pardee Foundation (T.A.C.); the AVON Foundation
   (T.A.C.); the STARR Cancer Consortium (T.A.C., L.T.V.); the Metastasis
   Research Center (T.A.C.), and the Department of Defense Era of Hope
   Award (T.A.C.). S.T. was supported by an NIH T32 grant (5T32CA160001).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989
   Ellsworth RE, 2009, CLIN EXP METASTAS, V26, P205, DOI 10.1007/s10585-008-9232-9
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Feng YM, 2007, BREAST CANCER RES TR, V103, P319, DOI 10.1007/s10549-006-9385-7
   FISHER B, 1983, CANCER-AM CANCER SOC, V52, P1551, DOI 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3
   Frigola J, 2006, NAT GENET, V38, P540, DOI 10.1038/ng1781
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hao XS, 2004, CANCER-AM CANCER SOC, V100, P1110, DOI 10.1002/cncr.20095
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Raddatz G, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003146
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024
   Suzuki M, 2007, MOL ONCOL, V1, P172, DOI 10.1016/j.molonc.2007.03.005
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498
   Venkatraman ES, 2007, BIOINFORMATICS, V23, P657, DOI 10.1093/bioinformatics/btl646
   Weigelt B, 2003, P NATL ACAD SCI USA, V100, P15901, DOI 10.1073/pnas.2634067100
   Weigman VJ, 2012, BREAST CANCER RES TR, V133, P865, DOI 10.1007/s10549-011-1846-y
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239
NR 37
TC 25
Z9 31
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 1
PY 2014
VL 9
IS 8
AR e103896
DI 10.1371/journal.pone.0103896
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AM4JL
UT WOS:000339819800100
PM 25083786
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Skowronki, K
   Andrews, J
   Rodenhiser, DI
   Coomber, BL
AF Skowronki, Karolina
   Andrews, Joseph
   Rodenhiser, David I.
   Coomber, Brenda L.
TI Genome-Wide Analysis in Human Colorectal Cancer Cells Reveals
   Ischemia-Mediated Expression of Motility Genes via DNA Hypomethylation
SO PLOS ONE
LA English
DT Article
ID CPG-BINDING-PROTEIN; PLASMINOGEN-ACTIVATOR; PROSTATE-CANCER; THERAPEUTIC
   IMPLICATIONS; CHROMOSOMAL INSTABILITY; RECEPTOR EXPRESSION;
   GASTRIC-CANCER; BREAST-CANCER; TUMOR HYPOXIA; METHYLATION
AB DNA hypomethylation is an important epigenetic modification found to occur in many different cancer types, leading to the upregulation of previously silenced genes and loss of genomic stability. We previously demonstrated that hypoxia and hypoglycaemia (ischemia), two common micro-environmental changes in solid tumours, decrease DNA methylation through the downregulation of DNMTs in human colorectal cancer cells. Here, we utilized a genome-wide cross-platform approach to identify genes hypomethylated and upregulated by ischemia. Following exposure to hypoxia or hypoglycaemia, methylated DNA from human colorectal cancer cells (HCT116) was immunoprecipitated and analysed with an Affymetrix promoter array. Additionally, RNA was isolated and analysed in parallel with an Affymetrix expression array. Ingenuity pathway analysis software revealed that a significant proportion of the genes hypomethylated and upregulated were involved in cellular movement, including PLAUR and CYR61. A Matrigel invasion assay revealed that indeed HCT116 cells grown in hypoxic or hypoglycaemic conditions have increased mobility capabilities. Confirmation of upregulated expression of cellular movement genes was performed with qPCR. The correlation between ischemia and metastasis is well established in cancer progression, but the molecular mechanisms responsible for this common observation have not been clearly identified. Our novel data suggests that hypoxia and hypoglycaemia may be driving changes in DNA methylation through downregulation of DNMTs. This is the first report to our knowledge that provides an explanation for the increased metastatic potential seen in ischemic cells; i.e. that ischemia could be driving DNA hypomethylation and increasing expression of cellular movement genes.
C1 [Skowronki, Karolina; Coomber, Brenda L.] Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.
   [Andrews, Joseph; Rodenhiser, David I.] Univ Western Ontario, Dept Biochem, London Reg Canc Ctr, London, ON, Canada.
   [Andrews, Joseph; Rodenhiser, David I.] Univ Western Ontario, Dept Oncol, London Reg Canc Ctr, London, ON, Canada.
   [Andrews, Joseph; Rodenhiser, David I.] Univ Western Ontario, Dept Paediat, London Reg Canc Ctr, London, ON, Canada.
   [Andrews, Joseph; Rodenhiser, David I.] Childrens Hlth Res Inst, London, ON, Canada.
C3 University of Guelph; Western University (University of Western
   Ontario); Western University (University of Western Ontario); Western
   University (University of Western Ontario)
RP Coomber, BL (通讯作者)，Univ Guelph, Ontario Vet Coll, Dept Biomed Sci, Guelph, ON N1G 2W1, Canada.
EM bcoomber@uoguelph.ca
FU Canadian Cancer Society Research Institute [020094]
FX This work was funded by a Research Grant # 020094 to BLC and DR from the
   Canadian Cancer Society Research Institute
   (http://www.cancer.ca/research/). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298
   Andrews J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008665
   Avni R, 2011, NMR BIOMED, V24, P569, DOI 10.1002/nbm.1632
   Barrow C, 2006, CLIN CANCER RES, V12, P764, DOI 10.1158/1078-0432.CCR-05-1544
   BESTOR T, 1988, J MOL BIOL, V203, P971, DOI 10.1016/0022-2836(88)90122-2
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3
   Buechler P, 2009, NEOPLASIA, V11, P196, DOI 10.1593/neo.08734
   Cui HM, 2002, CANCER RES, V62, P6442
   DeSmet C, 1996, P NATL ACAD SCI USA, V93, P7149, DOI 10.1073/pnas.93.14.7149
   Draghici S, 2006, TRENDS GENET, V22, P101, DOI 10.1016/j.tig.2005.12.005
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Eskandarpour M, 2009, INT J CANCER, V124, P16, DOI 10.1002/ijc.23876
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   FEINBERG AP, 1988, CANCER RES, V48, P1159
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Frigola J, 2005, HUM MOL GENET, V14, P319, DOI 10.1093/hmg/ddi028
   Fromigue O, 2011, J BONE MINER RES, V26, P1533, DOI 10.1002/jbmr.343
   Fyles A, 2002, J CLIN ONCOL, V20, P680, DOI 10.1200/JCO.2002.20.3.680
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168
   Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C
   Gravina GL, 2013, ONCOL REP, V29, P1189, DOI 10.3892/or.2012.2192
   Gronbaek K, 2007, APMIS, V115, P1039, DOI 10.1111/j.1600-0463.2007.apm_636.xml.x
   Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200
   Haque I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-8
   Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Horiuchi A, 2012, INT J CANC
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Jung EJ, 2005, ANTICANCER RES, V25, P2105
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Kim KH, 2006, WORLD J GASTROENTERO, V12, P5651, DOI 10.3748/wjg.v12.i35.5651
   Kita Y, 2009, EJSO-EUR J SURG ONC, V35, P52, DOI 10.1016/j.ejso.2008.01.025
   Klein R, 2012, REPROD FERT DEVELOP, V24, P482, DOI 10.1071/RD10335
   Krishnamachary B, 2003, CANCER RES, V63, P1138
   Kwon MJ, 2005, FRONT BIOSCI-LANDMRK, V10, P300, DOI 10.2741/1529
   Kwon OH, 2011, BIOCHEM BIOPH RES CO, V406, P539, DOI 10.1016/j.bbrc.2011.02.082
   Laner T, 2005, ONCOL RES, V15, P257, DOI 10.3727/096504005776404607
   Leone G, 2002, HAEMATOLOGICA, V87, P1324
   Liu J, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-261
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764
   Pakneshan P, 2005, CURR CANCER DRUG TAR, V5, P471, DOI 10.2174/156800905774574011
   Phipps KD, 2011, CANCER RES, V71, P6676, DOI 10.1158/0008-5472.CAN-11-1748
   PYKE C, 1995, CANCER RES, V55, P4132
   Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393
   Raghunand N, 2003, BRIT J RADIOL, V76, pS11, DOI 10.1259/bjr/12913493
   Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197
   Shahrzad S, 2007, EPIGENETICS-US, V2, P119, DOI 10.4161/epi.2.2.4613
   Shimozaki K, 2005, J NEUROCHEM, V93, P432, DOI 10.1111/j.1471-4159.2005.03031.x
   Skowronski K, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12400
   Snyder BN, 2011, EUR J CELL BIOL, V90, P376, DOI 10.1016/j.ejcb.2010.11.016
   Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102
   Suzuki S, 1998, GUT, V43, P798, DOI 10.1136/gut.43.6.798
   Takeuchi T, 2011, INT J EXP PATHOL, V92, P79, DOI 10.1111/j.1365-2613.2010.00740.x
   WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136
   Xiao J, 2004, WORLD J GASTROENTERO, V10, P1849
   Xie JJ, 2011, INT J MOL MED, V27, P429, DOI 10.3892/ijmm.2011.603
   Yanagawa N, 2011, ANTICANCER RES, V31, P171
   Yonemura Y, 2000, CLIN CANCER RES, V6, P4234
NR 62
TC 6
Z9 6
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 31
PY 2014
VL 9
IS 7
AR e103243
DI 10.1371/journal.pone.0103243
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AM6EF
UT WOS:000339954800034
PM 25079072
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Li, X
   Chen, C
   Luo, H
   van Velkinburgh, JC
   Ni, B
   Chang, Q
AF Li, Xia
   Chen, Cheng
   Luo, Hui
   van Velkinburgh, Jennifer C.
   Ni, Bing
   Chang, Qing
TI Decreased DNA Methylations at the Progesterone Receptor Promoter A
   Induce Functional Progesterone Withdrawal in Human Parturition
SO REPRODUCTIVE SCIENCES
LA English
DT Article
DE progesterone receptors; myometrium; labor; DNA methylation; DNMT
ID UTERINE ENDOMETRIAL CANCER; CPG HYPERMETHYLATION; BREAST-CANCER; HUMAN
   LABOR; B-ISOFORM; A-ISOFORM; MYOMETRIUM; GENE; TRANSCRIPTION;
   INACTIVATION
AB The functional interaction of progesterone receptor (PR) isoforms PRA and PRB regulates myometrial transition from the resting state to excitation-contraction to initiate parturition. However, the regulatory mechanisms responsible for maintenance and functional alteration of the PRA and PRB expression levels during human pregnancy and term labor, respectively, remain unknown. Therefore, this study was designed to investigate whether and how epigenetic DNA modifications, specifically methylations, at the PRs' promoter regions contribute to the differential expression of PRA and PRB in laboring term myometrium of humans. Comparative analysis of PRA and PRB messenger RNA (mRNA) expression levels and accompanying changes in their promoters' methylation status was carried out using human myometrial samples from women undergoing singleton, term deliveries by cesarean section, either in the absence of labor (designated as NIL for not-in-labor) or in active labor (designated as IL for in labor). The PRA gene expression was shown to be elevated significantly during labor, while PRB gene expression was unaltered, and this differential expression was accompanied by decreased DNA methylation at the PRA promoter and not at the PRB promoter. In addition, labor-related decreased mRNA expression of the DNA methyltransferase (DNMT) family members DNMT1 and DNMT3a was found, however whether the increased expression of DNMTs directly supports the functional withdrawal of progesterone needs further investigation. Collectively, these data indicate that DNA methylation might represent an important epigenetic mechanism of labor-related differential expression of PRs, thereby mediating the biological process of functional PR withdrawal at term for parturition.
C1 [Li, Xia; Chen, Cheng; Luo, Hui; Chang, Qing] Third Mil Med Univ, Southwestern Hosp, Dept Gynecol & Obstet, Chongqing 400038, Peoples R China.
   [van Velkinburgh, Jennifer C.] van Velkinburgh Initiat Collaboratory BioMed Res, Santa Fe, NM USA.
   [Ni, Bing] Third Mil Med Univ, PLA, Inst Immunol, Chongqing 400038, Peoples R China.
C3 Army Medical University; Army Medical University
RP Ni, B (通讯作者)，Third Mil Med Univ, PLA, Inst Immunol, Chongqing 400038, Peoples R China.
EM nibingxi@yahoo.com; cqli99@yahoo.com
RI ; van Velkinburgh, Jennifer/D-7205-2015
OI Ni, Bing/0000-0002-4297-5346; van Velkinburgh,
   Jennifer/0000-0002-4592-2397
FU General Program of National Natural Science Foundation of China
   [30901611]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by a grant from the General Program of National Natural
   Science Foundation of China (No. 30901611).
CR Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581
   Chai SY, 2012, MOL HUM REPROD, V18, P401, DOI 10.1093/molehr/gas012
   CHALBOS D, 1994, J BIOL CHEM, V269, P23007
   Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100
   Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291
   Goldman S, 2007, FRONT BIOSCI-LANDMRK, V12, P634, DOI 10.2741/2088
   Haluska GJ, 2002, J SOC GYNECOL INVEST, V9, P125, DOI 10.1016/S1071-5576(02)00144-2
   Jeltsch A, 2002, CHEMBIOCHEM, V3, P275, DOI 10.1002/1439-7633(20020402)3:4<274::AID-CBIC274>3.0.CO;2-S
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Kar S, 2012, EPIGENETICS-US, V7, P994, DOI 10.4161/epi.21568
   Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887
   Mc Cormack O, 2008, BREAST CANCER RES TR, V111, P45, DOI 10.1007/s10549-007-9757-7
   MCDONNELL DP, 1994, J STEROID BIOCHEM, V48, P425, DOI 10.1016/0960-0760(94)90190-2
   Merlino AA, 2007, J CLIN ENDOCR METAB, V92, P1927, DOI 10.1210/jc.2007-0077
   Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924
   Mesiano S, 2007, SEMIN CELL DEV BIOL, V18, P321, DOI 10.1016/j.semcdb.2007.05.003
   Mesiano S, 2007, SEMIN REPROD MED, V25, P5, DOI 10.1055/s-2006-956771
   Mesiano S, 2011, REPROD SCI, V18, P6, DOI 10.1177/1933719110382922
   Pieber D, 2001, MOL HUM REPROD, V7, P875, DOI 10.1093/molehr/7.9.875
   Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339
   Sasaki M, 2001, CANCER RES, V61, P97
   Sasaki M, 2000, MOL CARCINOGEN, V29, P59, DOI 10.1002/1098-2744(200010)29:2<59::AID-MC2>3.0.CO;2-6
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Scarpin Katherine M, 2009, Nucl Recept Signal, V7, pe009, DOI 10.1621/nrs.07009
   Sheehan PM, 2005, MOL HUM REPROD, V11, P495, DOI 10.1093/molehr/gah201
   Tita ATN, 2009, AM J OBSTET GYNECOL, V200, P219, DOI 10.1016/j.ajog.2008.12.035
   TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   WEN DX, 1994, MOL CELL BIOL, V14, P8356, DOI 10.1128/MCB.14.12.8356
   Xiong YN, 2005, GYNECOL ONCOL, V99, P135, DOI 10.1016/j.ygyno.2005.05.035
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Zakar T, 2007, AM J OBSTET GYNECOL, V196, P289, DOI 10.1016/j.ajog.2006.09.005
NR 32
TC 13
Z9 13
U1 0
U2 13
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1933-7191
EI 1933-7205
J9 REPROD SCI
JI Reprod. Sci.
PD JUL
PY 2014
VL 21
IS 7
BP 898
EP 905
DI 10.1177/1933719113518982
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA AM9KK
UT WOS:000340200300009
PM 24401475
OA Green Published
DA 2025-01-12
ER

PT J
AU Liu, ZJ
   Zhang, J
   Gao, YH
   Pei, LR
   Zhou, J
   Gu, LK
   Zhang, LH
   Zhu, BD
   Hattori, N
   Ji, JF
   Yuasa, Y
   Kim, W
   Ushijima, T
   Shi, HD
   Deng, DJ
AF Liu, Zhaojun
   Zhang, Jun
   Gao, Yanhong
   Pei, Lirong
   Zhou, Jing
   Gu, Liankun
   Zhang, Lianhai
   Zhu, Budong
   Hattori, Naoko
   Ji, Jiafu
   Yuasa, Yasuhito
   Kim, Wooho
   Ushijima, Toshikazu
   Shi, Huidong
   Deng, Dajun
TI Large-Scale Characterization of DNA Methylation Changes in Human Gastric
   Carcinomas with and without Metastasis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID SERUM RESPONSE FACTOR; TUMOR-SUPPRESSOR; BREAST-CANCER; EXPRESSION;
   GENE; IDENTIFICATION; GFR-ALPHA-1; ACTIN; SRF; HYPOMETHYLATION
AB Purpose: Metastasis is the leading cause of death for gastric carcinoma. An epigenetic biomarker panel for predicting gastric carcinoma metastasis could have significant clinical impact on the care of patients with gastric carcinoma. The main purpose of this study is to characterize the methylation differences between gastric carcinomas with and without metastasis.
   Experimental Design: Genome-wide DNA methylation profiles between 4 metastatic and 4 nonmetastatic gastric carcinomas and their surgical margins (SM) were analyzed using methylated-CpG island amplification with microarray. The methylation states of 73 candidate genes were further analyzed in patients with gastric carcinoma in a discovery cohort (n = 108) using denatured high performance liquid chromatography, bisulfite-sequencing, and MethyLight. The predictive values of potential metastasis- methylation biomarkers were validated in cohorts of patients with gastric carcinoma in China (n = 330), Japan (n = 129), and Korea (n = 153).
   Results: The gastric carcinoma genome showed significantly higher proportions of hypomethylation in the promoter and exon-1 regions, as well as increased hypermethylation of intragenic fragments when compared with SMs. Significant differential methylation was validated in the CpG islands of 15 genes (P < 0.05) and confirmed using bisulfite sequencing. These genes included BMP3, BNIP3, CDKN2A, ECEL1, ELK1, GFRA1, HOXD10, KCNH1, PSMD10, PTPRT, SIGIRR, SRF, TBX5, TFPI2, and ZNF382. Methylation changes of GFRA1, SRF, and ZNF382 resulted in up-or downregulation of their transcription. Most importantly, the prevalence of GFRA1, SRF, and ZNF382 methylation alterations was consistently and coordinately associated with gastric carcinoma metastasis and the patients' overall survival throughout discovery and validation cohorts in China, Japan, and Korea.
   Conclusion: Methylation changes of GFRA1, SRF, and ZNF382 may be a potential biomarker set for prediction of gastric carcinoma metastasis. (C) 2014 AACR.
C1 [Liu, Zhaojun; Zhang, Jun; Gao, Yanhong; Zhou, Jing; Gu, Liankun; Deng, Dajun] Peking Univ, Canc Hosp & Inst, Div Etiol, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China.
   [Zhang, Jun] Shihezi Univ, Sch Med, Shihezi, Peoples R China.
   [Pei, Lirong; Shi, Huidong] Georgia Regents Univ, GRU Canc Ctr, Augusta, GA USA.
   [Zhang, Lianhai; Ji, Jiafu] Peking Univ, Canc Hosp & Inst, Dept Surg, Beijing 100142, Peoples R China.
   [Zhu, Budong] Peking Univ, Canc Hosp & Inst, Dept Oncol, Beijing 100142, Peoples R China.
   [Hattori, Naoko; Ushijima, Toshikazu] Natl Canc Ctr, Div Epigenet, Chuo Ku, Tokyo, Japan.
   [Yuasa, Yasuhito] Tokyo Med & Dent Univ, Dept Mol Oncol, Bunkyo Ku, Tokyo, Japan.
   [Kim, Wooho] Seoul Natl Univ, Coll Med, Dept Pathol, Seoul 151, South Korea.
C3 Peking University; Shihezi University; University System of Georgia;
   Augusta University; Peking University; Peking University; National
   Cancer Center - Japan; Institute of Science Tokyo; Tokyo Medical &
   Dental University (TMDU); Seoul National University (SNU)
RP Deng, DJ (通讯作者)，Peking Univ, Canc Hosp & Inst, Fu Cheng Lu 52, Beijing 100142, Peoples R China.
EM hshi@gru.edu; dengdajun@bjmu.edu.cn
RI Hattori, Naoko/IXN-3051-2023; zhao, weiwei/JUU-6585-2023; Ushijima,
   Toshikazu/AAP-5742-2021; Deng, Dajun/D-4605-2009
OI Ushijima, Toshikazu/0000-0003-3405-7817; Shi,
   Huidong/0000-0003-1137-3390; Hattori, Naoko/0000-0002-0901-4869; JI,
   JIAFU/0000-0001-6878-5543; Deng, Dajun/0000-0001-5161-5943
FU Natural Science Foundation of China [30921140311, 31261140372]; National
   Basic Research Program of China (973 Program) [2011CB504201,
   2010CB529300]; U.S. NIH [CA 134304]
FX This work is supported by the Natural Science Foundation of China (A3
   Foresight Program Nos. 30921140311 and 31261140372; to D. Deng), the
   National Basic Research Program of China (973 Program 2011CB504201 and
   2010CB529300; to D. Deng), and the U.S. NIH (grant CA 134304; to H.
   Shi). H. Shi is a Georgia Cancer Coalition Distinguished Cancer Scholar.
CR [Anonymous], METHODS MOL BIOL
   Bennett LB, 2009, GENE CHROMOSOME CANC, V48, P828, DOI 10.1002/gcc.20687
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Busche S, 2010, J CELL SCI, V123, P2803, DOI 10.1242/jcs.061887
   Cacalano G, 1998, NEURON, V21, P53, DOI 10.1016/S0896-6273(00)80514-0
   Cheng YD, 2010, CANCER RES, V70, P6516, DOI 10.1158/0008-5472.CAN-09-4566
   Connelly JT, 2010, NAT CELL BIOL, V12, P711, DOI 10.1038/ncb2074
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785
   Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960
   Deng DJ, 2010, ADV GENET, V71, P125, DOI [10.1016/S0065-2660(10)71005-1, 10.1016/B978-0-12-380864-6.00005-5]
   Deng DJ, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.3.e13
   Devesa SS, 1999, JNCI-J NATL CANCER I, V91, P747, DOI 10.1093/jnci/91.9.747
   Enomoto H, 2004, NEURON, V44, P623, DOI 10.1016/j.neuron.2004.10.032
   Esseghir S, 2006, J PATHOL, V210, P420, DOI 10.1002/path.2071
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Esteller M, 2001, CANCER RES, V61, P3225
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fornari F, 2012, J PATHOL, V227, P275, DOI 10.1002/path.3995
   Frisk T, 2000, EUR J ENDOCRINOL, V142, P643, DOI 10.1530/eje.0.1420643
   Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456
   Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120
   Halachev K, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-10-r96
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hibi K, 2010, ANTICANCER RES, V30, P1205
   Hohenberger P, 2003, LANCET, V362, P305, DOI 10.1016/S0140-6736(03)13975-X
   Iwahashi N, 2002, CANCER, V94, P167, DOI 10.1002/cncr.10169
   Kim JY, 2012, HELICOBACTER, V17, P358, DOI 10.1111/j.1523-5378.2012.00958.x
   Luo DY, 2006, LAB INVEST, V86, P591, DOI 10.1038/labinvest.3700415
   Medjkane S, 2009, NAT CELL BIOL, V11, P257, DOI 10.1038/ncb1833
   Miano JM, 2007, AM J PHYSIOL-CELL PH, V292, pC70, DOI 10.1152/ajpcell.00386.2006
   Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7
   Pattani KM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045534
   Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200
   Shah MA, 2011, CLIN CANCER RES, V17, P2693, DOI 10.1158/1078-0432.CCR-10-2203
   Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181
   Sobin Leslie H, 2003, Semin Surg Oncol, V21, P19, DOI 10.1002/ssu.10017
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Sugita H, 2011, ONCOL REP, V25, P513, DOI 10.3892/or.2010.1085
   Sun Y, 2005, HISTOPATHOLOGY, V46, P505, DOI 10.1111/j.1365-2559.2005.02111.x
   TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2
   Ushijima T, 2004, CANC CELL
   Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084
   Wang D, 2012, GENE, V506, P36, DOI 10.1016/j.gene.2012.06.075
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Wiesenhofer B, 2000, ACTA NEUROPATHOL, V99, P131, DOI 10.1007/PL00007416
   Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225
   Zou HZ, 2007, CANCER EPIDEM BIOMAR, V16, P2686, DOI 10.1158/1055-9965.EPI-07-0518
   Zouridis H, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004504
NR 50
TC 74
Z9 83
U1 2
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD SEP 1
PY 2014
VL 20
IS 17
BP 4598
EP 4612
DI 10.1158/1078-0432.CCR-13-3380
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP1MV
UT WOS:000341835500020
PM 25009298
OA Green Accepted, Green Submitted
DA 2025-01-12
ER

PT J
AU Wang, D
   Li, CL
   Zhang, XM
AF Wang, Da
   Li, Changlong
   Zhang, Xuemei
TI The Promoter Methylation Status and mRNA Expression Levels of
   <i>CTCF</i> and <i>SIRT6</i> in Sporadic Breast Cancer
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID TUMOR-SUPPRESSOR GENES; TRANSCRIPTION FACTOR; EPIGENETIC REGULATION;
   ENHANCER-BLOCKING; DNA METHYLATION; IN-SITU; HYPERMETHYLATION; BINDING;
   BETA; DEACETYLASE
AB Promoter hypermethylation causes gene silencing and is thought to be an early event in carcinogenesis. This study was to detect promoter methylation status and mRNA expression levels of CCCTC-binding factor (CTCF) and sirtuin 6 (SIRT6), and to explore the relationship between methylation and mRNA expression in breast cancer patient samples. Promoter methylation analysis and expression profile analysis of two genes were performed by methylation-specific PCR, bisulfite sequencing PCR, and quantitative real-time PCR in cancer lesions and matched normal tissues. The promoter region of CTCF has not been hypermethylated in all patient samples. In contrast, methylation of SIRT6 gene was present in invasive cancers (93.5%) and matched normal tissues (96.8%) from 62 patients. Promoter hypermethylation of SIRT6 was also observed in ductal carcinoma in situ (three of three) and matched normal tissues (two of three). mRNA expression of CTCF and SIRT6 in invasive tumors showed a lower level than that in paired normal tissues (p = 0.008 and p = 0.030, respectively). The fold change values of CTCF expression were significantly lower in invasive ductal cancer lesions with Ki-67-positive status (p = 0.042). In conclusion, our data showed that the methylation status of CTCF and SIRT6 promoter regions was not statistically different in cancer lesions compared with matched normal tissues. No significant association between promoter methylation status and expression profiles of CTCF and SIRT6 was found in invasive breast cancers.
C1 [Wang, Da; Li, Changlong; Zhang, Xuemei] Sichuan Univ, Sch Preclin & Forens Med, Dept Biochem & Mol Biol, Chengdu 610041, Peoples R China.
C3 Sichuan University
RP Li, CL (通讯作者)，Sichuan Univ, Sch Preclin & Forens Med, Dept Biochem & Mol Biol, 3-17 Renmin South Rd, Chengdu 610041, Peoples R China.
EM changlongli@scu.edu.cn
FU National Natural Science Foundation of China [81070452]; National
   Research Foundation for Doctoral Program of Higher Education of China
   [20090181110048]
FX The authors thank Prof. Bing Wei from the Department of Pathology of
   West China Hospital of SCU for helping in pathological analysis and the
   collection of patients' clinical information. The authors also thank Dr.
   Yue Ma from the Department of Biostatistics of West China School of
   Public Health of SCU for helping in data analysis. This study was
   supported by the National Natural Science Foundation of China, Grant
   number: 81070452 and the National Research Foundation for Doctoral
   Program of Higher Education of China, Grant number: 20090181110048.
CR Alvarez C, 2013, MOL CARCINOGEN, V52, P475, DOI 10.1002/mc.21881
   BANIAHMAD A, 1990, CELL, V61, P505, DOI 10.1016/0092-8674(90)90532-J
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100
   Brooks JD, 1998, CANCER EPIDEM BIOMAR, V7, P531
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Butcher DT, 2004, INT J CANCER, V111, P669, DOI 10.1002/ijc.20324
   Charafe-Jauffret E, 2005, INT J ONCOL, V27, P1307
   Chen WQ, 2012, CHINESE J CANCER RES, V24, P1, DOI 10.1007/s11670-012-0001-6
   De la Rosa-Velázquez IA, 2007, CANCER RES, V67, P2577, DOI 10.1158/0008-5472.CAN-06-2024
   Docquier F, 2005, CANCER RES, V65, P5112, DOI 10.1158/0008-5472.CAN-03-3498
   Egawa C, 2001, JPN J CANCER RES, V92, P624, DOI 10.1111/j.1349-7006.2001.tb01140.x
   ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Filippova GN, 2002, CANCER RES, V62, P48
   Filippova GN, 1996, MOL CELL BIOL, V16, P2802
   Filippova GN, 1998, GENE CHROMOSOME CANC, V22, P26, DOI 10.1002/(SICI)1098-2264(199805)22:1<26::AID-GCC4>3.0.CO;2-9
   Fiorentino FP, 2012, J CELL PHYSIOL, V227, P479, DOI 10.1002/jcp.22780
   Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hou CH, 2008, P NATL ACAD SCI USA, V105, P20398, DOI 10.1073/pnas.0808506106
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Khongkow M, 2013, CARCINOGENESIS, V34, P1476, DOI 10.1093/carcin/bgt098
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Lamy A, 2002, INT J CANCER, V100, P189, DOI 10.1002/ijc.10474
   Lee JS, 2007, VIRCHOWS ARCH, V450, P637, DOI 10.1007/s00428-007-0421-8
   Lerrer B, 2013, EMBO J, V32, P7, DOI 10.1038/emboj.2012.332
   Levenson VV, 2007, BBA-GEN SUBJECTS, V1770, P847, DOI 10.1016/j.bbagen.2007.01.017
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Mostoslavsky R, 2006, CELL, V124, P315, DOI [10.1016/j.cell.2005.11.044, 10.1016/J.CEL.2005.11.044]
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Mulero-Navarro S, 2008, CRIT REV ONCOL HEMAT, V68, P1, DOI 10.1016/j.critrevonc.2008.03.001
   Park SY, 2011, VIRCHOWS ARCH, V458, P73, DOI 10.1007/s00428-010-1013-6
   Peng ZG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036891
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rakha EA, 2004, BRIT J CANCER, V91, P1591, DOI 10.1038/sj.bjc.6602144
   Rasko JEJ, 2001, CANCER RES, V61, P6002
   Recillas-Targa F, 2011, BIOCHEM CELL BIOL, V89, P479, DOI [10.1139/O11-031, 10.1139/o11-031]
   Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Singletary SE, 2003, SURG CLIN N AM, V83, P803, DOI 10.1016/S0039-6109(03)00034-3
   Soto-Reyes E, 2010, ONCOGENE, V29, P2217, DOI 10.1038/onc.2009.509
   Soto-Reyes-Solis E., 2013, J CLIN ONCOL, V31
   Splinter E, 2006, GENE DEV, V20, P2349, DOI 10.1101/gad.399506
   Tiffen JC, 2013, INT J CANCER, V133, P1603, DOI 10.1002/ijc.28184
   Van Meter M, 2011, CELL CYCLE, V10, P3153, DOI 10.4161/cc.10.18.17435
   van Wezel T, 2005, BREAST CANCER RES, V7, pR998, DOI 10.1186/bcr1337
   Vostrov AA, 1997, J BIOL CHEM, V272, P33353, DOI 10.1074/jbc.272.52.33353
   Witcher M, 2009, MOL CELL, V34, P271, DOI 10.1016/j.molcel.2009.04.001
   Yusufzai TM, 2004, MOL CELL, V13, P291, DOI 10.1016/S1097-2765(04)00029-2
   Zwahlen D, 2000, INT J CANCER, V88, P66
NR 54
TC 13
Z9 15
U1 0
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD SEP
PY 2014
VL 33
IS 9
BP 581
EP 590
DI 10.1089/dna.2013.2257
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA AO7BQ
UT WOS:000341507400002
PM 24842653
OA Green Published
DA 2025-01-12
ER

PT J
AU Kolacinska, A
   Morawiec, J
   Pawlowska, Z
   Szemraj, J
   Szymanska, B
   Malachowska, B
   Morawiec, Z
   Morawiec-Sztandera, A
   Pakula, L
   Kubiak, R
   Zawlik, I
AF Kolacinska, Agnieszka
   Morawiec, Jan
   Pawlowska, Zofia
   Szemraj, Janusz
   Szymanska, Bozena
   Malachowska, Beata
   Morawiec, Zbigniew
   Morawiec-Sztandera, Alina
   Pakula, Lukasz
   Kubiak, Robert
   Zawlik, Izabela
TI Association of microRNA-93, 190, 200b and Receptor Status in Core
   Biopsies from Stage III Breast Cancer Patients
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID EXPRESSION; ANGIOGENESIS; LANDSCAPE; MARKERS
AB Oncologists now favor more personalized treatment strategies in breast cancer patients. Gene expression analysis has been widely used, but less is known about epigenetic factors, for example, microRNAs (miRNAs). The aim of this study was to determine the relationship between selected miRNAs and receptor status in core biopsies sampled before preoperative chemotherapy in stage III locally advanced breast cancer (LABC) patients. In 37 LABC core biopsies, three miRNAs per sample were analyzed: hsa-miR-93-5p, hsa-miR-190a, and hsa-miR-200b-3p, and hsa-miR-103a-3p as an endogenous control (TaqMan (R) RT-PCR; Applied Biosystems). Receptor status was determined by a dedicated pathologist. The Mann-Whitney U, Shapiro-Wilk, and Levene's tests were used to compare related samples. Levels of miRNA-93 differed significantly in core biopsies of LABC patients with different expressions of ER (estrogen receptor) and PR (progesterone receptor). Higher levels of miRNA-93 were found in ER-negative (p=0.0027) and PR-negative patients (p=0.0185). Levels of miRNA-190 and 200b did not differ significantly in core biopsies of LABC patients who expressed ER and PR differently (p=0.7727, p=0.9434, p=0.6213, and p=0.1717). Levels of miRNA-93, 190, and 200b were not significantly different in core biopsies of LABC patients with different HER2 (human epidermal growth factor 2) expressions (p=0.8013, p=0.2609, and p=0.3222). The assessment of core biopsy miRNA profiles and receptor-based subtypes may identify new signaling pathways for improved breast cancer classification.
C1 [Kolacinska, Agnieszka; Morawiec, Jan; Morawiec, Zbigniew] Ctr Canc, Dept Surg Oncol, Lodz, Poland.
   [Kolacinska, Agnieszka; Morawiec-Sztandera, Alina] Med Univ Lodz, Dept Head & Neck Canc Surg, PL-93509 Lodz, Poland.
   [Morawiec, Jan] Med Univ Lodz, Dept Gen & Colorectal Surg, PL-93509 Lodz, Poland.
   [Pawlowska, Zofia; Szymanska, Bozena] Med Univ Lodz, Cent Lab, PL-93509 Lodz, Poland.
   [Szemraj, Janusz] Med Univ Lodz, Dept Med Biochem, PL-93509 Lodz, Poland.
   [Malachowska, Beata] Med Univ Lodz, Dept Pediat Oncol Hematol & Diabetol, PL-93509 Lodz, Poland.
   [Pakula, Lukasz] Copernicus Mem Hosp, Dept Anesthesiol, Lodz, Poland.
   [Kubiak, Robert] Med Univ Lodz, Dept Canc Pathol, PL-93509 Lodz, Poland.
   [Zawlik, Izabela] Univ Rzeszow, Dept Med, Dept Med Genet, Inst Nursing & Hlth Sci, Rzeszow, Poland.
C3 Medical University Lodz; Medical University Lodz; Medical University
   Lodz; Medical University Lodz; Medical University Lodz; Medical
   University Lodz; University of Rzeszow
RP Kolacinska, A (通讯作者)，Med Univ Lodz, Dept Head & Neck Canc Surg, Paderewskiego 4, PL-93509 Lodz, Poland.
EM agnieszka.kolacinska@umed.lodz.pl
RI Malachowska, Beata/AAD-7746-2022
OI Szymanska, Bozena/0000-0002-0775-7570; Zawlik,
   Izabela/0000-0001-7992-9100; Kolacinska-Wow,
   Agnieszka/0000-0001-8707-0877; Pawlowska, Zofia/0000-0002-9861-0901
FU National Center of Science [2011/01/B/NZ4/03345, 2012/05/B/NZ5/01852]
FX The study was supported by grants 2011/01/B/NZ4/03345 and
   2012/05/B/NZ5/01852 from the National Center of Science.
CR Almog N., 2013, TRANSCRIPTION, V1, P4
   Almog N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044001
   Anfossi S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083113
   Beatson GT., 1896, LANCET, V148, P104
   BLACK DM, 1993, TRENDS GENET, V9, P22, DOI 10.1016/0168-9525(93)90068-S
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462
   Fang L, 2012, CELL CYCLE, V11, P4352, DOI 10.4161/cc.22670
   Harbeck N, 2014, CANCER TREAT REV, V40, P434, DOI 10.1016/j.ctrv.2013.09.014
   HORWITZ KB, 1975, STEROIDS, V25, P497, DOI 10.1016/0039-128X(75)90027-6
   HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159
   Jensen E.V., 1960, BIOL ACTIVITIES STER, P161
   Kaufmann M, 2013, ARCH GYNECOL OBSTET, V288, P1203, DOI 10.1007/s00404-013-3069-4
   Lehmann U, 2014, CELL TISSUE RES, V356, P657, DOI 10.1007/s00441-014-1793-0
   Li L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087601
   Li X, 2014, ONCOGENE, V33, P4077, DOI 10.1038/onc.2013.370
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Liu SL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002751
   Lowery AJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2257
   Manavalan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062334
   Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583
   McDermott AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087032
   NATALI PG, 1990, INT J CANCER, V45, P457, DOI 10.1002/ijc.2910450314
   Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Peurala H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026122
   ROWELL S, 1994, AM J HUM GENET, V55, P861
   Saber A, 2010, J INVEST SURG, V23, P327, DOI 10.3109/08941939.2010.515289
   Schinzinger A., 1889, VERHANDLUNGEN DTSCH, P28
NR 31
TC 17
Z9 18
U1 0
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD SEP
PY 2014
VL 33
IS 9
BP 624
EP 629
DI 10.1089/dna.2014.2419
PG 6
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA AO7BQ
UT WOS:000341507400007
PM 24865188
OA Green Published
DA 2025-01-12
ER

PT J
AU Kloten, V
   Rose, M
   Kaspar, S
   von Stillfried, S
   Knüchel, R
   Dahl, E
AF Kloten, Vera
   Rose, Michael
   Kaspar, Sophie
   von Stillfried, Saskia
   Knuechel, Ruth
   Dahl, Edgar
TI Epigenetic inactivation of the novel candidate tumor suppressor gene
   <i>ITIH5</i> in colon cancer predicts unfavorable overall survival in
   the CpG island methylator phenotype
SO EPIGENETICS
LA English
DT Article
DE ITIH5; tumor suppressor gene; DNA methylation; CpG island methylator
   phenotype; microsatellite instability; proximal colon
ID URINARY TRYPSIN-INHIBITOR; MICROSATELLITE INSTABILITY;
   COLORECTAL-CANCER; BREAST-CANCER; HEAVY-CHAIN; HYPERMETHYLATION;
   PROFILES; PROMOTER; FEATURES; MARKERS
AB Inter-alpha-trypsin inhibitor heavy chain 5 (ITIH5) is supposed to be involved in extracellular matrix stability and thus may play a key role in the inhibition of tumor progression. The current study is the first to analyze in depth ITIH5 expression as well as its potential clinical and functional impact in colon cancer. Based on 30 tumor and 30 adjacent normal tissues we examined ITIH5 mRNA expression and promoter methylation, whose significance was further validated by independent data sets from The Cancer Genome Atlas (TCGA) platform. In addition, ITIH5 protein expression was evaluated using immunohistochemistry. ITIH5 mRNA expression loss was significantly associated (P < 0.001) with hypermethylation of the ITIH5 promoter in primary colon tumors. In addition, treatment of tumor cell lines with demethylating (DAC) and histone acetylating (TSA) agents induced ITIH5 expression. In line, independent TCGA data revealed a significant expression loss of ITIH5, particularly in the MSI-high and CIMP-positive phenotype concordant with an increased ITIH5 hypermethylation in CIMP-positive colon tumors (P < 0.001). In proximal, i.e., right-sided tumors, abundant ITIH5 expression was associated with longer overall survival (OS, P = 0.049) and the CIMP-positive (P = 0.032) subgroup. Functionally, ITIH5 re-expression mediated a reduced proliferation in HCT116 and CaCo2 cells. In conclusion, our results indicate that ITIH5 is a novel putative tumor suppressor gene in colon cancer with a potential impact in the CIMP-related pathway. ITIH5 may serve as a novel epigenetic-based diagnostic biomarker with further clinical impact for risk stratification of CIMP-positive colon cancer patients.
C1 [Kloten, Vera; Rose, Michael; Kaspar, Sophie; von Stillfried, Saskia; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
C3 RWTH Aachen University
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
EM edahl@ukaachen.de
OI Kaspar, Sophie/0000-0002-0844-6432; von Stillfried,
   Saskia/0000-0002-5260-8494
CR Bae JM, 2011, VIRCHOWS ARCH, V459, P55, DOI 10.1007/s00428-011-1080-3
   Benson AB, 2006, ONCOLOGIST, V11, P973, DOI 10.1634/theoncologist.11-9-973
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Cancer Genome Atlas Network, 2012, Nature (London), V487, P330, DOI 10.1038/nature11252
   Deschoolmeester V, 2010, ONCOLOGIST, V15, P699, DOI 10.1634/theoncologist.2010-0025
   Fink L, 1998, NAT MED, V4, P1329, DOI 10.1038/3327
   Fleisher AS, 2001, ONCOGENE, V20, P329, DOI 10.1038/sj.onc.1204104
   Graziano F, 2003, ANN ONCOL, V14, P1026, DOI 10.1093/annonc/mdg284
   Gröne J, 2011, INT J COLORECTAL DIS, V26, P847, DOI 10.1007/s00384-011-1176-x
   Hamm A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-25
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hawkins N, 2002, GASTROENTEROLOGY, V122, P1376, DOI 10.1053/gast.2002.32997
   Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011
   HUANG L, 1993, J BIOL CHEM, V268, P26725
   Iacopetta B, 2002, INT J CANCER, V101, P403, DOI 10.1002/ijc.10635
   Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jass JR, 1998, GUT, V42, P673, DOI 10.1136/gut.42.5.673
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kapiteijn E, 2001, J PATHOL, V195, P171, DOI 10.1002/path.918
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   KOBAYASHI H, 1995, J BIOL CHEM, V270, P8361, DOI 10.1074/jbc.270.14.8361
   KOBAYASHI H, 1995, INT J CANCER, V63, P455, DOI 10.1002/ijc.2910630326
   Kornmann M, 2008, EJSO-EUR J SURG ONC, V34, P1316, DOI 10.1016/j.ejso.2008.01.019
   Lee S, 2008, ARCH PATHOL LAB MED, V132, P1657, DOI 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2
   Locker GY, 2006, J CLIN ONCOL, V24, P5313, DOI 10.1200/JCO.2006.08.2644
   Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X
   Ogino S, 2006, AM J SURG PATHOL, V30, P1175
   Oing C, 2011, CLIN EPIGENETICS, V2, P419, DOI 10.1007/s13148-011-0043-5
   Peel DJ, 2000, J NATL CANCER I, V92, P1517, DOI 10.1093/jnci/92.18.1517
   Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250
   Rose M, 2014, CARCINOGENESIS, V35, P727, DOI 10.1093/carcin/bgt375
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   van Rijnsoever M, 2003, CLIN CANCER RES, V9, P2898
   van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Veeck J, 2008, Pathologe, V29 Suppl 2, P338, DOI 10.1007/s00292-008-1044-9
   Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   ZWEIG MH, 1993, CLIN CHEM, V39, P561
NR 44
TC 33
Z9 36
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD SEP
PY 2014
VL 9
IS 9
BP 1290
EP 1301
DI 10.4161/epi.32089
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AQ1TP
UT WOS:000342564500011
PM 25093535
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Taberlay, PC
   Statham, AL
   Kelly, TK
   Clark, SJ
   Jones, PA
AF Taberlay, Phillippa C.
   Statham, Aaron L.
   Kelly, Theresa K.
   Clark, Susan J.
   Jones, Peter A.
TI Reconfiguration of nucleosome-depleted regions at distal regulatory
   elements accompanies DNA methylation of enhancers and insulators in
   cancer
SO GENOME RESEARCH
LA English
DT Article
ID HUMAN GENOME; CHROMATIN-STRUCTURE; HIGH-RESOLUTION; EPIGENETIC
   REGULATION; TRANSCRIPTION FACTORS; EUKARYOTIC GENOME; GENE-EXPRESSION;
   CPG ISLAND; IN-VIVO; BINDING
AB It is well established that cancer-associated epigenetic repression occurs concomitant with CpG island hypermethylation and loss of nucleosomes at promoters, but the role of nucleosome occupancy and epigenetic reprogramming at distal regulatory elements in cancer is still poorly understood. Here, we evaluate the scope of global epigenetic alterations at enhancers and insulator elements in prostate and breast cancer cells using simultaneous genome-wide mapping of DNA methylation and nucleosome occupancy (NOMe-seq). We find that the genomic location of nucleosome-depleted regions (NDRs) is mostly cell type specific and preferentially found at enhancers in normal cells. In cancer cells, however, we observe a global reconfiguration of NDRs at distal regulatory elements coupled with a substantial reorganization of the cancer methylome. Aberrant acquisition of nucleosomes at enhancer-associated NDRs is associated with hypermethylation and epigenetic silencing marks, and conversely, loss of nucleosomes with demethylation and epigenetic activation. Remarkably, we show that nucleosomes remain strongly organized and phased at many facultative distal regulatory elements, even in the absence of a NDR as an anchor. Finally, we find that key transcription factor (TF) binding sites also show extensive peripheral nucleosome phasing, suggesting the potential for TFs to organize NDRs genome-wide and contribute to deregulation of cancer epigenomes. Together, our findings suggest that "decommissioning" of NDRs and TFs at distal regulatory elements in cancer cells is accompanied by DNA hypermethylation susceptibility of enhancers and insulator elements, which in turn may contribute to an altered genome-wide architecture and epigenetic deregulation in malignancy.
C1 [Taberlay, Phillippa C.; Statham, Aaron L.; Clark, Susan J.] Garvan Inst Med Res, Canc Program, Darlinghurst, NSW 2010, Australia.
   [Taberlay, Phillippa C.; Kelly, Theresa K.; Jones, Peter A.] Univ So Calif, Dept Biochem, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
   [Taberlay, Phillippa C.; Kelly, Theresa K.; Jones, Peter A.] Univ So Calif, Dept Urol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
   [Taberlay, Phillippa C.; Clark, Susan J.] Univ New S Wales, St Vincents Clin Sch, Fac Med, Darlinghurst, NSW 2010, Australia.
   [Kelly, Theresa K.] Act Motif Inc, Carlsbad, CA 92008 USA.
   [Jones, Peter A.] Van Andel Res Inst, Grand Rapids, MI 49503 USA.
C3 Garvan Institute of Medical Research; University of Southern California;
   University of Southern California; St Vincent's Clinic; University of
   New South Wales Sydney; Van Andel Institute
RP Jones, PA (通讯作者)，Univ So Calif, Dept Biochem, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
EM s.clark@garvan.org.au; p.jones@med.usc.edu
RI Taberlay, Phillippa/C-9616-2010; Clark, Susan/B-2272-2008
OI Taberlay, Phillippa/0000-0002-5298-8730; Clark,
   Susan/0000-0001-5925-5030
FU Cure Cancer Australia Foundation Project [1070613]; NHMRC Project
   [1051757, 1029579]; National Breast Cancer Foundation Program Grant
   (Australia); NTH [R01 CA082422]
FX We thank members of the Clark Laboratory for helpful discussions and
   careful reading of the manuscript. We also thank Yaping Liu and Ben
   Berman for helpful discussions and Charles Nicolet and the USC Epigenome
   Center for sequencing and data generation. S.J.C. is a National Health
   and Medical Research Council (NHMRC) Senior Principal Research Fellow;
   P.C.T. is a Cancer Institute NSW Early Career Development Fellow. This
   work was further supported by Cure Cancer Australia Foundation Project
   Grant no. 1070613, NHMRC Project Grants no. 1051757 and no. 1029579,
   National Breast Cancer Foundation Program Grant (Australia), and NTH R01
   CA082422.
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   ALMEIDA A, 1993, HUM GENET, V91, P538
   Andreu-Vieyra C, 2011, MOL CELL BIOL, V31, P4648, DOI 10.1128/MCB.05934-11
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bernstein BE, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r62
   Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006
   Collings CK, 2013, NUCLEIC ACIDS RES, V41, P2918, DOI 10.1093/nar/gks893
   Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Felle M, 2011, NUCLEIC ACIDS RES, V39, P6956, DOI 10.1093/nar/gkr263
   Field Y, 2009, NAT GENET, V41, P438, DOI 10.1038/ng.324
   Field Y, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000216
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   Gertz J, 2013, MOL CELL, V52, P25, DOI 10.1016/j.molcel.2013.08.037
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Heintzman ND, 2007, CELL MOL LIFE SCI, V64, P386, DOI 10.1007/s00018-006-6295-0
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hinshelwood RA, 2009, HUM MOL GENET, V18, P3098, DOI 10.1093/hmg/ddp251
   Hogan GJ, 2006, PLOS GENET, V2, P1433, DOI 10.1371/journal.pgen.0020158
   Hoose Scott A., 2006, V338, P225
   Hughes AL, 2012, MOL CELL, V48, P5, DOI 10.1016/j.molcel.2012.07.003
   Ioshikhes IP, 2006, NAT GENET, V38, P1210, DOI 10.1038/ng1878
   Jeong S, 2009, MOL CELL BIOL, V29, P5366, DOI 10.1128/MCB.00484-09
   Jessen WJ, 2006, NAT STRUCT MOL BIOL, V13, P256, DOI 10.1038/nsmb1062
   Jessen WJ, 2004, METHODS, V33, P68, DOI 10.1016/j.ymeth.2003.10.025
   Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2
   John S, 2011, NAT GENET, V43, P264, DOI 10.1038/ng.759
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kaplan N, 2009, NATURE, V458, P362, DOI 10.1038/nature07667
   Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112
   Kelly TK, 2011, CELL CYCLE, V10, P370, DOI 10.4161/cc.10.3.14734
   Kelly TK, 2010, MOL CELL, V39, P901, DOI 10.1016/j.molcel.2010.08.026
   Kilgore JA, 2007, METHODS, V41, P320, DOI 10.1016/j.ymeth.2006.08.008
   Kim A, 2007, NUCLEIC ACIDS RES, V35, P5831, DOI 10.1093/nar/gkm620
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lee W, 2007, NAT GENET, V39, P1235, DOI 10.1038/ng2117
   Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014
   Meyer KB, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002165
   Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212
   Oakford PC, 2010, LEUKEMIA RES, V34, P1203, DOI 10.1016/j.leukres.2010.03.029
   PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636
   PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A
   Ross MG, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r51
   Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022
   Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979
   Sharma S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001286
   Shivaswamy S, 2008, PLOS BIOL, V6, P618, DOI 10.1371/journal.pbio.0060065
   Song LY, 2011, GENOME RES, V21, P1757, DOI 10.1101/gr.121541.111
   Stadler MB, 2011, NATURE, V480, P490, DOI 10.1038/nature10716
   Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111
   Struhl K, 2013, NAT STRUCT MOL BIOL, V20, P267, DOI 10.1038/nsmb.2506
   Taberlay PC, 2011, CELL, V147, P1283, DOI 10.1016/j.cell.2011.10.040
   Taberlay PC, 2011, PROG DRUG RES, V67, P1, DOI 10.1007/978-3-7643-8989-5_1
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Valouev A, 2008, GENOME RES, V18, P1051, DOI 10.1101/gr.076463.108
   Visel A, 2007, SEMIN CELL DEV BIOL, V18, P140, DOI 10.1016/j.semcdb.2006.12.014
   Wang H, 2012, GENOME RES, V22, P1680, DOI 10.1101/gr.136101.111
   Wang J, 2012, GENOME RES, V22, P1798, DOI 10.1101/gr.139105.112
   Whitehouse I, 2007, NATURE, V450, P1031, DOI 10.1038/nature06391
   Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917
   Xu M, 1998, NUCLEIC ACIDS RES, V26, P3961, DOI 10.1093/nar/26.17.3961
   You JS, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003459
   You JS, 2011, P NATL ACAD SCI USA, V108, P14497, DOI 10.1073/pnas.1111309108
   Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178
NR 70
TC 143
Z9 167
U1 0
U2 18
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD SEP
PY 2014
VL 24
IS 9
BP 1421
EP 1432
DI 10.1101/gr.163485.113
PG 12
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA AO4BM
UT WOS:000341281200002
PM 24916973
OA hybrid, Green Submitted, Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Bhagat, R
   Kumar, SS
   Vaderhobli, S
   Premalata, CS
   Pallavi, VR
   Ramesh, G
   Krishnamoorthy, L
AF Bhagat, Rahul
   Kumar, Sandeep Sriram
   Vaderhobli, Shilpa
   Premalata, Chennagiri S.
   Pallavi, Venkateshaiah Reddihalli
   Ramesh, Gawari
   Krishnamoorthy, Lakshmi
TI Epigenetic alteration of <i>p16</i> and retinoic acid receptor beta
   genes in the development of epithelial ovarian carcinoma
SO TUMOR BIOLOGY
LA English
DT Article
DE Ovarian carcinoma; p16; RAR-beta; MSP; Gene expression
ID TUMOR-SUPPRESSOR GENES; PROMOTER HYPERMETHYLATION; DNA METHYLATION;
   BREAST-CANCER; HIGH-FREQUENCY; RAR-BETA; EXPRESSION; CELL; INACTIVATION;
   PROGNOSIS
AB Silencing of tumor suppressor and tumor-related genes by promoter hypermethylation is one of the major events in ovarian carcinogenesis. In this study, we analyzed aberrant promoter methylation of p16 and RAR-beta genes in 134 epithelial ovarian carcinomas (EOCs), 23 low malignant potential (LMP) tumors, 26 benign cystadenomas, and 15 normal ovarian tissues. Methylation was investigated by methylation-specific PCR (MSP), and the results were confirmed by bisulfite DNA sequencing. Relative gene expression of p16 and RAR-beta was done using quantitative reverse transcriptase PCR (qRT-PCR) on 51 EOC cases, 9 LMP tumors, and 7 benign cystadenomas with 5 normal ovarian tissues. Aberrant methylation for p16 and RAR-beta was present in 43 % (58/134) and 31 % (41/134) in carcinoma cases, 22 % (05/23) and 52 % (12/23) in LMP tumors, and 42 % (11/26) and 69 % (18/26) in benign cystadenomas. No methylation was observed in any of the normal ovarian tissues. The mRNA expression level of p16 and RAR-beta was significantly downregulated in EOC and LMP tumors than the corresponding normal tissues whereas the expression level was normal in benign cystadenomas for p16 and slightly reduced for RAR-beta. A significant correlation of p16 promoter methylation was observed with reduced gene expression in EOC. For RAR-beta, no significant correlation was observed between promoter methylation and gene expression. Our results suggest that epigenetic alterations of p16 and RAR-beta have an important role in ovarian carcinogenesis and that mechanism along with methylation plays a significant role in downregulation of RAR-beta gene in ovarian cancer.
C1 [Bhagat, Rahul; Kumar, Sandeep Sriram; Vaderhobli, Shilpa; Ramesh, Gawari] Kidwai Mem Inst Oncol, Dept Biochem, Bangalore 560029, Karnataka, India.
   [Premalata, Chennagiri S.] Kidwai Mem Inst Oncol, Dept Pathol, Bangalore 560029, Karnataka, India.
   [Pallavi, Venkateshaiah Reddihalli] Kidwai Mem Inst Oncol, Dept Gynaec Oncol, Bangalore 560029, Karnataka, India.
   [Krishnamoorthy, Lakshmi] Sri Shankara Canc Hosp & Res Ctr, Dept Lab Med, Bangalore 560004, Karnataka, India.
C3 Kidwai Memorial Institute of Oncology; Kidwai Memorial Institute of
   Oncology; Kidwai Memorial Institute of Oncology
RP Krishnamoorthy, L (通讯作者)，Sri Shankara Canc Hosp & Res Ctr, Dept Lab Med, Bangalore 560004, Karnataka, India.
EM rahulbhagat1234@gmail.com; psriramsandeep@gmail.com;
   shilpachadaga@gmail.com; prema_venka@yahoo.co.in;
   drpallaviram123@yahoo.co.in; gdrramesh@gmail.com;
   vkrishlakshmi@gmail.com
OI V, Shilpa/0000-0001-9332-6787
FU Department of Biotechnology, India [BT/PR 13440/MED/30/267/2009]
FX The research work is supported by Department of Biotechnology, India,
   Grant No BT/PR 13440/MED/30/267/2009. We are grateful to Dr V Shanmugam
   (Research Assistant, NIMHANS) for helping with the statistical analysis.
CR [Anonymous], 2013, 3 YEAR REP POP BAS C
   Bammidi LS, 2012, INT J GYNECOL CANCER, V22, P553, DOI 10.1097/IGC.0b013e31823fa90c
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bhagat R, 2012, CELL ONCOL, V35, P473, DOI 10.1007/s13402-012-0106-4
   Björklund P, 2007, J CLIN ENDOCR METAB, V92, P338, DOI 10.1210/jc.2006-1197
   Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176
   Chmelarová M, 2012, FOLIA BIOL-PRAGUE, V58, P246
   COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D
   Fackler MJ, 2003, INT J CANCER, V107, P970, DOI 10.1002/ijc.11508
   Fischer JR, 2006, LUNG CANCER, V54, P109, DOI 10.1016/j.lungcan.2006.06.017
   Fujita M, 1997, INT J CANCER, V74, P148, DOI 10.1002/(SICI)1097-0215(19970422)74:2<148::AID-IJC2>3.3.CO;2-9
   Furlan D, 2006, CLIN CANCER RES, V12, P3329, DOI 10.1158/1078-0432.CCR-05-2679
   Gao Yan-ping, 2007, Zhonghua Fu Chan Ke Za Zhi, V42, P472
   GRUMMER MA, 1994, PEDIATR PULM, V17, P234, DOI 10.1002/ppul.1950170406
   He ML, 2009, PROSTATE, V69, P1643, DOI 10.1002/pros.21013
   Hennessy BT, 2009, LANCET, V374, P1371, DOI 10.1016/S0140-6736(09)61338-6
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Ivanova T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-4
   Jerónimo C, 2004, CLIN CANCER RES, V10, P4010, DOI 10.1158/1078-0432.CCR-03-0643
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kaiser PC, 2005, ANN ONCOL, V16, P1477, DOI 10.1093/annonc/mdi265
   KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
   Katsaros D, 2004, GYNECOL ONCOL, V94, P685, DOI 10.1016/j.ygyno.2004.06.018
   Khodyrev DS, 2008, RUSS J GENET+, V44, P983, DOI 10.1134/S1022795408080139
   Rojas PL, 2009, MED CLIN-BARCELONA, V132, P371, DOI 10.1016/j.medcli.2008.05.022
   Len YW, 2003, CANCER RES, V63, P6110
   Li Min, 2006, Zhonghua Fu Chan Ke Za Zhi, V41, P408
   Liggett WH, 1998, J CLIN ONCOL, V16, P1197, DOI 10.1200/JCO.1998.16.3.1197
   Makarla PB, 2005, CLIN CANCER RES, V11, P5365, DOI 10.1158/1078-0432.CCR-04-2455
   Marchini S, 1997, BRIT J CANCER, V76, P146, DOI 10.1038/bjc.1997.355
   McCluskey LL, 1999, GYNECOL ONCOL, V72, P87, DOI 10.1006/gyno.1998.5235
   MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749
   Milde-Langosch K, 1998, INT J CANCER, V79, P61, DOI 10.1002/(SICI)1097-0215(19980220)79:1<61::AID-IJC12>3.0.CO;2-K
   Nakayama T, 2001, LAB INVEST, V81, P1049, DOI 10.1038/labinvest.3780316
   Niederacher D, 1999, BRIT J CANCER, V80, P1920, DOI 10.1038/sj.bjc.6690621
   NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0
   Ogino S, 2006, J MOL DIAGN, V8, P209, DOI 10.2353/jmoldx.2006.050135
   Ozdemir F, 2012, EXP THER MED, V4, P1092, DOI 10.3892/etm.2012.715
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Parrish R Ryley, 2012, Curr Protoc Neurosci, VChapter 7, DOI 10.1002/0471142301.ns0724s60
   Rocco JW, 2001, EXP CELL RES, V264, P42, DOI 10.1006/excr.2000.5149
   SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Tang DL, 2013, J UROLOGY, V190, P317, DOI 10.1016/j.juro.2013.01.083
   Warnecke PM, 2000, CURR OPIN ONCOL, V12, P68, DOI 10.1097/00001622-200001000-00012
   Wei SH, 2006, CLIN CANCER RES, V12, P2788, DOI 10.1158/1078-0432.CCR-05-1551
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   Wong YF, 1999, CANCER LETT, V136, P231, DOI 10.1016/S0304-3835(98)00327-9
   Yang QF, 2002, J HUM GENET, V47, P453, DOI 10.1007/s100380200064
   Yang QF, 2001, AM J PATHOL, V158, P299, DOI 10.1016/S0002-9440(10)63969-7
   Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X
NR 53
TC 20
Z9 21
U1 0
U2 8
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD SEP
PY 2014
VL 35
IS 9
BP 9069
EP 9078
DI 10.1007/s13277-014-2136-1
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AR5ZQ
UT WOS:000343662000088
PM 24913706
DA 2025-01-12
ER

PT J
AU Wang, XX
   Wei, JZ
   Jiao, J
   Jiang, SY
   Yu, DH
   Li, D
AF Wang, Xiu-Xia
   Wei, Jing-Zan
   Jiao, Jiao
   Jiang, Shu-Yi
   Yu, Da-Hai
   Li, Da
TI Genome-wide DNA methylation and gene expression patterns provide insight
   into polycystic ovary syndrome development
SO ONCOTARGET
LA English
DT Article
DE DNA methylation profiling; expression profiling; epigenetic; PCOS
ID BRCA1-MUTATED BREAST-CANCER; SYNDROME PCOS; WOMEN; SUSCEPTIBILITY;
   PATHOGENESIS; INFLAMMATION; MECHANISM; HEALTH
AB Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders in women. However, the epigenetic mechanism involved in PCOS progression remains largely unknown. Here, combining the DNA methylation profiling together with transcriptome analysis, we showed that (i) there were 7929 differentially methylated CpG sites (beta > 0.1, P < 0.05) and 650 differential transcripts (fold change > 1.5, P < 0.005) in PCOS compared to normal ovaries; (ii) 54 genes were identified with methylated levels that were correlated with gene transcription in PCOS; and (iii) there were less hypermethylated sites, but many more hypomethylated sites residing in CpG islands and N_Shore in PCOS. Among these genes, we identified that several significant pathways, including the type I diabetes mellitus pathway, p53 signaling pathway and NOD-like receptor signaling pathway, and some immune and inflammatory diseases may be highly involved in PCOS development. These results suggested that differences in genome-wide DNA methylation and expression patterns exist between PCOS ovaries and normal ovaries; epigenetic mechanisms may in part be responsible for the different gene expression and PCOS phenotype. All of this may improve our understanding of the basic molecular mechanism underlying the development of PCOS.
C1 [Wang, Xiu-Xia; Wei, Jing-Zan; Jiao, Jiao; Jiang, Shu-Yi; Yu, Da-Hai; Li, Da] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
C3 China Medical University
RP Li, D (通讯作者)，China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
EM wangxx@sj-hospital.org; leeda@ymail.com
RI Wang, Xuemei/GXF-3702-2022
OI Wei, Jingzan/0009-0004-5461-8428
FU Natural Science Foundation of China [81402130]; Doctoral Start-up
   Foundation of Liaoning Province [20141045]
FX This work was supported by the Natural Science Foundation of China (No.
   81402130) and Doctoral Start-up Foundation of Liaoning Province (No.
   20141045). We are grateful to Qi Wang (Shanghai Biotechnology
   Corporation, Shanghai, China) for data analysis.
CR Amato MC, 2014, J CLIN ENDOCR METAB, V99, P203, DOI 10.1210/jc.2013-2669
   Chang J, 2004, FERTIL STERIL, V81, P19, DOI 10.1016/j.fertnstert.2003.10.004
   Corbould A, 2006, DIABETES, V55, P751, DOI 10.2337/diabetes.55.03.06.db05-0453
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Escobar-Morreale HF, 2008, PROTEOM CLIN APPL, V2, P444, DOI 10.1002/prca.200780031
   Goodarzi MO, 2011, NAT REV ENDOCRINOL, V7, P219, DOI 10.1038/nrendo.2010.217
   Hickey TE, 2006, J CLIN ENDOCR METAB, V91, P2789, DOI 10.1210/jc.2006-0069
   Insenser M, 2013, MOL CELL ENDOCRINOL, V370, P65, DOI 10.1016/j.mce.2013.02.009
   Kulis M, 2013, BBA-GENE REGUL MECH, V1829, P1161, DOI 10.1016/j.bbagrm.2013.08.001
   Li D, 2014, ONCOTARGET, V5, P1315, DOI 10.18632/oncotarget.1800
   Li D, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-26
   Li-Byarlay H, 2013, P NATL ACAD SCI USA, V110, P12750, DOI 10.1073/pnas.1310735110
   Louwers YV, 2013, J CLIN ENDOCR METAB, V98, pE2006, DOI 10.1210/jc.2013-2495
   Maurya VK, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-32
   Moran LJ, 2012, REPROD BIOMED ONLINE, V25, P500, DOI 10.1016/j.rbmo.2012.07.013
   Ojeda-Ojeda M, 2013, CURR PHARM DESIGN, V19, P5775, DOI 10.2174/1381612811319320012
   Pepene CE, 2012, GYNECOL ENDOCRINOL, V28, P370, DOI 10.3109/09513590.2011.632792
   Piltonen TT, 2013, J CLIN ENDOCR METAB, V98, P3765, DOI 10.1210/jc.2013-1923
   Prodoehl MJ, 2009, MOL HUM REPROD, V15, P829, DOI 10.1093/molehr/gap072
   Qu F, 2012, J MOL MED, V90, P911, DOI 10.1007/s00109-012-0881-4
   Rosas C, 2010, HUM REPROD, V25, P2870, DOI 10.1093/humrep/deq232
   Schmidt J, 2014, MOL HUM REPROD, V20, P49, DOI 10.1093/molehr/gat051
   Seow KM, 2012, GYNECOL OBSTET INVES, V73, P236, DOI 10.1159/000334175
   Shenker N, 2012, BRIT J CANCER, V106, P248, DOI 10.1038/bjc.2011.550
   Stegh AH, 2012, EXPERT OPIN THER TAR, V16, P67, DOI 10.1517/14728222.2011.643299
   Teede H, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-41
   Villavicencio A, 2009, GYNECOL ONCOL, V115, P102, DOI 10.1016/j.ygyno.2009.06.033
   Wang P, 2014, ENDOCRINOLOGY, V155, P1445, DOI 10.1210/en.2013-1764
   Wen HT, 2013, IMMUNITY, V39, P432, DOI 10.1016/j.immuni.2013.08.037
   Witchel SF, 2013, FERTIL STERIL, V100, P12, DOI 10.1016/j.fertnstert.2013.05.024
NR 30
TC 71
Z9 80
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 30
PY 2014
VL 5
IS 16
BP 6603
EP 6610
DI 10.18632/oncotarget.2224
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AZ0EX
UT WOS:000347920100009
PM 25051372
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Rostas, JW
   Pruitt, HC
   Metge, BJ
   Mitra, A
   Bailey, SK
   Bae, S
   Singh, KP
   Devine, DJ
   Dyess, DL
   Richards, WO
   Tucker, JA
   Shevde, LA
   Samant, RS
AF Rostas, Jack W., III
   Pruitt, Hawley C.
   Metge, Brandon J.
   Mitra, Aparna
   Bailey, Sarah K.
   Bae, Sejong
   Singh, Karan P.
   Devine, Daniel J.
   Dyess, Donna L.
   Richards, William O.
   Tucker, J. Allan
   Shevde, Lalita A.
   Samant, Rajeev S.
TI microRNA-29 negatively regulates EMT regulator N-myc interactor in
   breast cancer
SO MOLECULAR CANCER
LA English
DT Article
DE N-Myc interactor; EMT; Breast cancer; miR-29
ID NMI PROTEIN; METASTASIS; EXPRESSION; PREDICTION; ASSOCIATION;
   OSTEOBLASTS; EPIGENETICS; MIRNAS
AB Background: N-Myc Interactor is an inducible protein whose expression is compromised in advanced stage breast cancer. Downregulation of NMI, a gatekeeper of epithelial phenotype, in breast tumors promotes mesenchymal, invasive and metastatic phenotype of the cancer cells. Thus the mechanisms that regulate expression of NMI are of potential interest for understanding the etiology of breast tumor progression and metastasis.
   Method: Web based prediction algorithms were used to identify miRNAs that potentially target the NMI transcript. Luciferase reporter assays and western blot analysis were used to confirm the ability of miR-29 to target NMI. Quantitive-RT-PCRs were used to examine levels of miR29 and NMI from cell line and patient specimen derived RNA. The functional impact of miR-29 on EMT phenotype was evaluated using transwell migration as well as monitoring 3D matrigel growth morphology. Anti-miRs were used to examine effects of reducing miR-29 levels from cells. Western blots were used to examine changes in GSK3 beta phosphorylation status. The impact on molecular attributes of EMT was evaluated using immunocytochemistry, qRT-PCRs as well as Western blot analyses.
   Results: Invasive, mesenchymal-like breast cancer cell lines showed increased levels of miR-29. Introduction of miR-29 into breast cancer cells (with robust level of NMI) resulted in decreased NMI expression and increased invasion, whereas treatment of cells with high miR-29 and low NMI levels with miR-29 antagonists increased NMI expression and decreased invasion. Assessment of 2D and 3D growth morphologies revealed an EMT promoting effect of miR-29. Analysis of mRNA of NMI and miR-29 from patient derived breast cancer tumors showed a strong, inverse relationship between the expression of NMI and the miR-29. Our studies also revealed that in the absence of NMI, miR-29 expression is upregulated due to unrestricted Wnt/beta-catenin signaling resulting from inactivation of GSK3 beta.
   Conclusion: Aberrant miR-29 expression may account for reduced NMI expression in breast tumors and mesenchymal phenotype of cancer cells that promotes invasive growth. Reduction in NMI levels has a feed-forward impact on miR-29 levels.
C1 [Pruitt, Hawley C.; Metge, Brandon J.; Bailey, Sarah K.; Shevde, Lalita A.; Samant, Rajeev S.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Rostas, Jack W., III; Dyess, Donna L.; Richards, William O.] Univ S Alabama, Dept Surg, Mobile, AL 36688 USA.
   [Mitra, Aparna; Devine, Daniel J.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 36688 USA.
   [Bae, Sejong; Singh, Karan P.] Univ Alabama Birmingham, BBSF Comprehens Canc Ctr, Birmingham, AL 35294 USA.
   [Tucker, J. Allan] Univ S Alabama, Dept Pathol, Mobile, AL 36688 USA.
   [Bae, Sejong; Singh, Karan P.; Shevde, Lalita A.; Samant, Rajeev S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of South Alabama; University of South Alabama; University of
   Alabama System; University of Alabama Birmingham; University of South
   Alabama; University of Alabama System; University of Alabama Birmingham
RP Samant, RS (通讯作者)，Univ Alabama Birmingham, Dept Pathol, WTI 320E,1824 6th Ave South, Birmingham, AL 35294 USA.
EM rsamant@uab.edu
RI ; bae, sejong/JCE-9038-2023
OI Samant, Rajeev/0000-0001-5681-4976; bae, sejong/0000-0001-9982-3223;
   Kammerud, Sarah/0000-0002-4808-1618
FU USPHS [CA140472, CA138850]; American Medical Association Seed Grant;
   Center grant of the National Cancer Institute of the National Institutes
   of Health [P30 CA013148]
FX Grant support: USPHS grants CA140472 (RSS) and CA138850 (LAS).J. Rostas
   is a recipient of the American Medical Association Seed Grant 2011.Drs.
   S. Bae and K.P. Singh's work was partially supported by the Center grant
   of the National Cancer Institute of the National Institutes of Health to
   the University of Alabama at Birmingham Comprehensive Cancer Center (P30
   CA013148)
CR Bannasch D, 1999, ONCOGENE, V18, P6810, DOI 10.1038/sj.onc.1203090
   Bao JX, 1996, ONCOGENE, V12, P2171
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Boggs RM, 2008, MAMM GENOME, V19, P561, DOI 10.1007/s00335-008-9128-7
   Chen GQ, 2010, MED ONCOL, V27, P406, DOI 10.1007/s12032-009-9225-9
   Chou J, 2013, NAT CELL BIOL, V15, P201, DOI 10.1038/ncb2672
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Devine DJ, 2014, ONCOGENE, V33, P2620, DOI 10.1038/onc.2013.215
   Dey N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077425
   Fabian MR, 2010, PROG MOL SUBCELL BIO, V50, P1, DOI 10.1007/978-3-642-03103-8_1
   Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276
   Gebeshuber CA, 2009, EMBO REP, V10, P400, DOI 10.1038/embor.2009.9
   Han YC, 2010, J EXP MED, V207, P475, DOI 10.1084/jem.20090831
   Heyn H, 2012, PANCREAS, V41, P218, DOI 10.1097/MPA.0b013e318224b701
   Huynh KT, 2012, CLIN EXP METASTAS, V29, P747, DOI 10.1007/s10585-012-9491-3
   Incassati A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2723
   Inui M, 2012, CURR OPIN CELL BIOL, V24, P194, DOI 10.1016/j.ceb.2011.11.013
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jiang HS, 2014, ONCOL REP, V31, P1509, DOI 10.3892/or.2014.3036
   John B, 2005, PLOS BIOL, V3, P1328, DOI 10.1371/journal.pbio.0030264
   John Bino, 2006, V342, P101, DOI 10.1385/1-59745-123-1:101
   Kapinas K, 2010, J BIOL CHEM, V285, P25221, DOI 10.1074/jbc.M110.116137
   Kapinas K, 2009, J CELL BIOCHEM, V108, P216, DOI 10.1002/jcb.22243
   Kim JW, 2010, CANCER RES, V70, P4820, DOI 10.1158/0008-5472.CAN-10-0659
   Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200
   Li SG, 2014, TUMOR BIOL, V35, P7693, DOI 10.1007/s13277-014-1975-0
   Li ZP, 2012, MOL BIOL CELL, V23, P4635, DOI 10.1091/mbc.E12-04-0304
   Lovat F, 2011, SEMIN ONCOL, V38, P724, DOI 10.1053/j.seminoncol.2011.08.006
   Mattie MD, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-24
   Menezes ME, 2012, BIOCHEM J, V444, P573, DOI 10.1042/BJ20120205
   Menezes ME, 2012, INT J CANCER, V130, P1477, DOI 10.1002/ijc.26449
   Mitra A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1874
   Mukherjee N, 2012, CANCER SCI, V103, P210, DOI 10.1111/j.1349-7006.2011.02131.x
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Park SY, 2009, NAT STRUCT MOL BIOL, V16, P23, DOI 10.1038/nsmb.1533
   Piao HL, 2012, J MAMMARY GLAND BIOL, V17, P33, DOI 10.1007/s10911-012-9245-5
   Prazeres H, 2011, ONCOGENE, V30, P1302, DOI 10.1038/onc.2010.512
   Rosenbloom KR, 2013, NUCLEIC ACIDS RES, V41, pD56, DOI 10.1093/nar/gks1172
   Santanam U, 2010, P NATL ACAD SCI USA, V107, P12210, DOI 10.1073/pnas.1007186107
   Schlierf B, 2005, J MOL BIOL, V353, P1033, DOI 10.1016/j.jmb.2005.09.013
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Valastyan S, 2012, J MAMMARY GLAND BIOL, V17, P23, DOI 10.1007/s10911-012-9241-9
   Wang C, 2011, MOL CELL BIOCHEM, V352, P197, DOI 10.1007/s11010-011-0755-z
   Wang XW, 2008, BIOINFORMATICS, V24, P325, DOI 10.1093/bioinformatics/btm595
   Wang XW, 2008, RNA, V14, P1012, DOI 10.1261/rna.965408
   Yang HP, 2013, J CLIN INVEST, V123, P285, DOI 10.1172/JCI63861
   Yu ZR, 2012, J MAMMARY GLAND BIOL, V17, P59, DOI 10.1007/s10911-012-9246-4
   Zhang K, 2007, MOL CELL BIOCHEM, V303, P1, DOI 10.1007/s11010-007-9449-y
   Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4
NR 52
TC 66
Z9 71
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD AUG 29
PY 2014
VL 13
AR 200
DI 10.1186/1476-4598-13-200
PG 11
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA AP4AA
UT WOS:000342018000001
PM 25174825
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Sung, HY
   Park, AK
   Ju, W
   Ahn, JH
AF Sung, Hye Youn
   Park, Ae Kyung
   Ju, Woong
   Ahn, Jung-Hyuck
TI Overexpression of Mucin 13 due to Promoter Methylation Promotes
   Aggressive Behavior in Ovarian Cancer Cells
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE Ovarian cancer; mouse xenograft; MUC13; DNA methylation
ID BREAST-CANCER; SURFACE MUCIN; ANTIGEN CA125; EXPRESSION; MUC13; THERAPY;
   GENE
AB Purpose: Recent discoveries suggest that aberrant DNA methylation provides cancer cells with advanced metastatic properties. However, the precise regulatory mechanisms controlling metastasis genes and their role in metastatic transformation are largely unknown. To address epigenetically-regulated gene products involved in ovarian cancer metastasis, we examined the mechanisms regulating mucin 13 (MUC13) expression and its influence on aggressive behaviors of ovarian malignancies. Materials and Methods: We injected SK-OV-3 ovarian cancer cells peritoneally into nude mice to mimic human ovarian tumor metastasis. Overexpression of MUC13 mRNA was detected in metastatic implants from the xenografts by expression microarray analysis and quantitative reverse-transcription polymerase chain reaction (qRT-PCR). The DNA methylation status within the MUC13 promoter region was determined using bisulfite sequencing PCR and quantitative methylation-specific PCR. We evaluated the effects of exogenous MUC13 on cell invasion and migration using in vitro transwell assays. Results: MUC13 mRNA expression was up-regulated, and methylation of specific CpG sites within the promoter was reduced in the metastatic implants relative to those in wild-type SK-OV-3 cells. Addition of a DNA methyltransferase inhibitor to SK-OV-3 cells induced MUC13 expression, thereby implying epigenetic regulation of MUC13 by promoter methylation. MUC13 overexpression increased migration and invasiveness, compared to control cells, suggesting aberrant up-regulation of MUC13 is strongly associated with progression of aggressive behaviors in ovarian cancer. Conclusion: We provide novel evidence for epigenetic regulation of MUC13 in ovarian cancer. We suggest that the DNA methylation status within the MUC13 promoter region may be a potential biomarker of aggressive behavior in ovarian cancer.
C1 [Sung, Hye Youn; Ahn, Jung-Hyuck] Ewha Womans Univ, Sch Med, Dept Biochem, Seoul 158710, South Korea.
   [Ju, Woong] Ewha Womans Univ, Sch Med, Dept Obstet & Gynecol, Seoul 158710, South Korea.
   [Park, Ae Kyung] Sunchon Natl Univ, Coll Pharm, Sunchon, South Korea.
C3 Ewha Womans University; Ewha Womans University; Sunchon National
   University
RP Ahn, JH (通讯作者)，Ewha Womans Univ, Sch Med, Dept Biochem, 1071 Anyangcheon Ro, Seoul 158710, South Korea.
EM goodmorning@ewha.ac.kr; ahnj@ewha.ac.kr
RI Park, Aekyung/JXY-2919-2024
FU Korean Health Technology R&D Project, Ministry of Health & Welfare,
   Republic of Korea [HI12C0050]; RP-Grant of Ewha Womans University
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (HI12C0050) and
   RP-Grant 2011 of Ewha Womans University
CR BROCKHAUSEN I, 1995, EUR J BIOCHEM, V233, P607, DOI 10.1111/j.1432-1033.1995.607_2.x
   Budiu RA, 2011, CANCER IMMUNOL IMMUN, V60, P975, DOI 10.1007/s00262-011-1010-x
   CANNEY PA, 1984, BRIT J CANCER, V50, P765, DOI 10.1038/bjc.1984.254
   Chauhan SC, 2006, MODERN PATHOL, V19, P1386, DOI 10.1038/modpathol.3800646
   Chauhan SC, 2012, MOL CANCER THER, V11, P24, DOI 10.1158/1535-7163.MCT-11-0598
   Chauhan SC, 2009, CANCER RES, V69, P765, DOI 10.1158/0008-5472.CAN-08-0587
   Dong Y, 1997, J PATHOL, V183, P311, DOI 10.1002/(SICI)1096-9896(199711)183:3<311::AID-PATH917>3.0.CO;2-2
   Giuntoli RL, 1998, CANCER RES, V58, P5546
   Gupta BK, 2012, J HISTOCHEM CYTOCHEM, V60, P822, DOI 10.1369/0022155412460678
   Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251
   Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432
   Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105
   Maher DM, 2011, MOL CANCER RES, V9, P531, DOI 10.1158/1541-7786.MCR-10-0443
   Rakha EA, 2005, MODERN PATHOL, V18, P1295, DOI 10.1038/modpathol.3800445
   Ringel Jorg, 2003, Mol Cancer, V2, P9, DOI 10.1186/1476-4598-2-9
   Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005
   Rosen DG, 2005, GYNECOL ONCOL, V99, P267, DOI 10.1016/j.ygyno.2005.06.040
   Shimamura T, 2005, CANCER SCI, V96, P265, DOI 10.1111/j.1349-7006.2005.00043.x
   Singh AP, 2008, LANCET ONCOL, V9, P1076, DOI 10.1016/S1470-2045(08)70277-8
   Walsh MD, 2007, HUM PATHOL, V38, P883, DOI 10.1016/j.humpath.2006.11.020
   Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200
   Yin BWT, 2002, INT J CANCER, V98, P737, DOI 10.1002/ijc.10250
NR 22
TC 14
Z9 15
U1 0
U2 15
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD SEP 1
PY 2014
VL 55
IS 5
BP 1206
EP 1213
DI 10.3349/ymj.2014.55.5.1206
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AM4XY
UT WOS:000339860700005
PM 25048476
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Vladusic, T
   Hrascan, R
   Kruslin, B
   Pecina-Slaus, N
   Perica, K
   Bicanic, A
   Vrhovac, I
   Gamulin, M
   Franekic, J
AF Vladusic, Tomislav
   Hrascan, Reno
   Kruslin, Bozo
   Pecina-Slaus, Nives
   Perica, Kristina
   Bicanic, Anamarija
   Vrhovac, Ivana
   Gamulin, Marija
   Franekic, Jasna
TI Histological Groups of Human Postpubertal Testicular Germ Cell Tumours
   Harbour Different Genetic Alterations
SO ANTICANCER RESEARCH
LA English
DT Article
DE Loss of heterozygosity; microsatellite instability; TGCT; seminomas;
   non-seminomas
ID CARCINOMA IN-SITU; FREQUENT EPIGENETIC INACTIVATION; MICROSATELLITE
   INSTABILITY; SIGNALING PATHWAYS; SUPPRESSOR GENES; GENOME-WIDE; P53;
   EXPRESSION; TESTIS; HETEROZYGOSITY
AB Background: Testicular germ cell tumours are the most common malignancies in young males. Molecular biology studies of these tumours are often contradictory. Two histological groups, seminoma and non-seminoma, differ both morphologically and in malignant behaviour. Although a common cytogenetic feature is seen, namely the amplification of the 12p chromosomal region, the development mechanisms of less aggressive seminomas and more aggressive non-seminomas are unknown. Materials and Methods: Occurrence of structural genetic alterations was analyzed in 18 seminomas and 22 non-seminomas for genes involved in the malignant tumour phenotype: cadherin 1, Type 1, E-cadherin (Epithelial), CDH1; adenomatous polyposis coli, APC; NME/NM23 nucleoside diphosphate kinase I, NME1; tumour protein P53, TP53; cyclin-dependent kinase inhibitor 2A, CDKN2A; retinoblastoma 1, RB1; RAD51 recombinase, RAD51; mutS homolog 2, MSH2; MutL homolog 1, MLH1; breast cancer 1, early onset, BRCA1; BCL2-Associated X Protein, BAX; ATP-Binding Cassette, Sub-Family G (WHITE), Member 2, ABCG2. Genetic alterations, loss of heterozygosity and microsatellite instability, were analyzed using restriction fragment or micro satellite repeat length polymorphisms. Results: A difference in genetic alteration occurrence between seminomas and non-seminomas was observed. Conclusion: Occurrence of genetic alterations correlates with clinical behaviour of these tumours and may indicate that such alterations could occur early in the development of seminomas and non-seminomas.
C1 [Vladusic, Tomislav; Hrascan, Reno; Perica, Kristina; Bicanic, Anamarija; Franekic, Jasna] Univ Zagreb, Fac Food Technol & Biotechnol, Dept Biochem Engn, Zagreb 10000, Croatia.
   [Kruslin, Bozo; Pecina-Slaus, Nives] Univ Zagreb, Sch Med, Zagreb 10000, Croatia.
   [Kruslin, Bozo] Sisters Mercy Univ Hosp, Ljudevit Jurak Dept Pathol, Zagreb, Croatia.
   [Pecina-Slaus, Nives] Croatian Inst Brain Res, Lab Neurooncol, Zagreb, Croatia.
   [Vrhovac, Ivana] Inst Med Res & Occupat Hlth, Zagreb 41000, Croatia.
   [Gamulin, Marija] Rebro Univ Hosp Ctr, Dept Oncol, Zagreb, Croatia.
C3 University of Zagreb; University of Zagreb; Institute for Medical
   Research & Occupational Health (IMROH)
RP Vladusic, T (通讯作者)，Univ Zagreb, Fac Food Technol & Biotechnol, Pierottijeva 6, Zagreb 10000, Croatia.
EM tvladusic@pbf.hr
RI Vladusic, Tomislav/AAC-3987-2022; Vrhovac-Madunic, Ivana/GOH-3447-2022;
   Pecina-Slaus, Nives/A-3942-2008
OI Pecina-Slaus, Nives/0000-0002-3334-7671; Vrhovac Madunic,
   Ivana/0000-0002-4736-0885
FU Ministry of Science and Technology, Republic of Croatia
   [058-0582261-2246]
FX This work was supported by Grant 058-0582261-2246 from the Ministry of
   Science and Technology, Republic of Croatia. The Authors declare that
   they have no conflict of interest.
CR [Anonymous], WHO CLASSIFICATION T
   Bahrami A, 2007, ARCH PATHOL LAB MED, V131, P1267
   Bartkova J, 2003, APMIS, V111, P252, DOI 10.1034/j.1600-0463.2003.1110129.x
   Bergthorsson JT, 2006, CANCER GENET CYTOGEN, V164, P1, DOI 10.1016/j.cancergencyto.2005.06.015
   Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.0.CO;2-S
   Burger H, 1998, INT J RADIAT ONCOL, V41, P415, DOI 10.1016/S0360-3016(98)00065-0
   Carver BS, 2005, ANN SURG ONCOL, V12, P871, DOI 10.1245/ASO.2005.01.013
   Chaubert P, 1997, AM J PATHOL, V151, P859
   Christoph F, 2007, CANCER LETT, V247, P137, DOI 10.1016/j.canlet.2006.03.028
   Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370
   Datta MW, 2001, MODERN PATHOL, V14, P437, DOI 10.1038/modpathol.3880331
   Devouassoux-Shisheboran M, 2001, MOL HUM REPROD, V7, P1099, DOI 10.1093/molehr/7.12.1099
   di Pietro A, 2005, INT J BIOCHEM CELL B, V37, P2437, DOI 10.1016/j.biocel.2005.06.014
   Dieckmann KP, 1999, INT J CANCER, V83, P815, DOI 10.1002/(SICI)1097-0215(19991210)83:6<815::AID-IJC21>3.3.CO;2-Q
   Faulkner SW, 2000, BRIT J CANCER, V83, P729, DOI 10.1054/bjoc.2000.1334
   Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104
   Goddard NC, 2007, INT J ANDROL, V30, P337, DOI 10.1111/j.1365-2605.2007.00769.x
   Gori S, 2005, CRIT REV ONCOL HEMAT, V53, P141, DOI 10.1016/j.critrevonc.2004.05.006
   Guillou L, 1996, AM J PATHOL, V149, P1221
   Heidenreich A, 1998, J UROLOGY, V159, P1725, DOI 10.1097/00005392-199805000-00101
   Heidenreich A, 1998, CANCER, V83, P1002, DOI 10.1002/(SICI)1097-0142(19980901)83:5<1002::AID-CNCR27>3.3.CO;2-F
   Hofree M, 2013, NAT METHODS, V10, P1108, DOI [10.1038/NMETH.2651, 10.1038/nmeth.2651]
   Honecker F, 2004, J PATHOL, V204, P167, DOI 10.1002/path.1614
   Honorio S, 2003, ONCOGENE, V22, P461, DOI 10.1038/sj.onc.1206119
   Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293
   HUDDART RA, 1995, BRIT J CANCER, V72, P642, DOI 10.1038/bjc.1995.387
   Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551
   Koul Sanjay, 2002, Mol Cancer, V1, P8, DOI 10.1186/1476-4598-1-8
   LeBron C, 2011, GENOMICS, V97, P341, DOI 10.1016/j.ygeno.2011.02.011
   Looijenga LHJ, 1999, REV REPROD, V4, P90, DOI 10.1530/ror.0.0040090
   Mayer F, 2002, CANCER RES, V62, P2758
   PENG HQ, 1993, CANCER RES, V53, P3574
   PENG HQ, 1995, CANCER RES, V55, P2871
   Popp G, 2003, SOUTH MED J, V96, P696, DOI 10.1097/01.SMJ.0000052064.60558.9A
   Rothe M, 1999, J PATHOL, V188, P389, DOI 10.1002/(SICI)1096-9896(199908)188:4<389::AID-PATH364>3.0.CO;2-K
   Sesterhenn Isabell A, 2004, Cancer Control, V11, P374
   Sheikine Y, 2012, AM J CANCER RES, V2, P153
   Spencer SL, 2006, PLOS COMPUT BIOL, V2, P939, DOI 10.1371/journal.pcbi.0020108
   Storchova Z, 2004, NAT REV MOL CELL BIO, V5, P45, DOI 10.1038/nrm1276
   Summersgill B, 2001, BRIT J CANCER, V85, P213, DOI 10.1054/bjoc.2001.1889
   Ulbright TM, 2005, MODERN PATHOL, V18, pS61, DOI 10.1038/modpathol.3800310
   Velasco A, 2004, CANCER BIOL THER, V3, P977, DOI 10.4161/cbt.3.10.1135
   Vladusic T, 2010, RADIOL ONCOL, V44, P168, DOI 10.2478/v10019-010-0035-7
   Vladusic T, 2010, PATHOL RES PRACT, V206, P163, DOI 10.1016/j.prp.2009.10.007
   von Eyben FE, 2004, CANCER GENET CYTOGEN, V151, P93, DOI 10.1016/j.cancergencyto.2003.09.008
   Zafarana G, 2002, CANCER RES, V62, P1822
   Zeng XY, 2000, CANCER RES, V60, P6184
NR 47
TC 10
Z9 10
U1 0
U2 4
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD AUG
PY 2014
VL 34
IS 8
BP 4005
EP 4012
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AM3SP
UT WOS:000339773400017
PM 25075023
DA 2025-01-12
ER

PT J
AU Loddo, M
   Andryszkiewicz, J
   Rodriguez-Acebes, S
   Stoeber, K
   Jones, A
   Dafou, D
   Apostolidou, S
   Wollenschlaeger, A
   Widschwendter, M
   Sainsbury, R
   Tudzarova, S
   Williams, GH
AF Loddo, Marco
   Andryszkiewicz, Joanna
   Rodriguez-Acebes, Sara
   Stoeber, Kai
   Jones, Allison
   Dafou, Dimitra
   Apostolidou, Sophia
   Wollenschlaeger, Alex
   Widschwendter, Martin
   Sainsbury, Richard
   Tudzarova, Slavica
   Williams, Gareth Haydn
TI Pregnancy-associated plasma protein A regulates mitosis and is
   epigenetically silenced in breast cancer
SO JOURNAL OF PATHOLOGY
LA English
DT Article
DE breast cancer; mitosis; cell cycle; MitoCheck; epigenetic silencing;
   PAPPA; IGF-1; FoxM1; Foxo3a
ID A PAPP-A; EARLY RECURRENCE; DNA-REPLICATION; IGF-I; PROGRESSION;
   EXPRESSION; REVEALS; INSULIN; BINDING; FOXO3A
AB Aberrant mitosis is a common feature of cancer, yet little is known about the altered genes causing mitotic defects. We screened human tumours for cells with morphological signatures of highly specific mitotic defects previously assigned to candidate genes in a genome-wide RNA interference screen carried out in HeLa cells (www.mitocheck.org). We discovered a striking enrichment of early mitotic configurations indicative of prophase/prometaphase delay in breast cancer. Promoter methylation analysis of MitoCheck candidate genes assigned to the corresponding 'mitotic delay' class linked this defect to epigenetic silencing of the gene encoding pregnancy-associated plasma protein-A (PAPPA), a secreted protease. PAPPA silencing was highly prevalent in precursor lesions and invasive breast cancer. Experimental manipulation of PAPPA protein levels in human mammary epithelial cells and in breast cancer cell lines demonstrates that progression through early mitosis is dependent on PAPPA function, and that breast cancer cells become more invasive after down-regulation of this protease. PAPPA regulates mitotic progression through modulating the IGF-1 signalling pathway resulting in activation of the forkhead transcription factor FoxM1, which drives a transcriptional cluster of essential mitotic genes. Our results show that PAPPA has a critical function in normal cell division and is targeted early in breast cancer development. Copyright (C) 2014 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
C1 [Loddo, Marco; Andryszkiewicz, Joanna; Rodriguez-Acebes, Sara; Stoeber, Kai; Wollenschlaeger, Alex; Sainsbury, Richard; Williams, Gareth Haydn] UCL, UCL Canc Inst, London WC1E 6DD, England.
   [Jones, Allison; Dafou, Dimitra; Apostolidou, Sophia; Widschwendter, Martin] UCL, UCL Elizabeth Garrett Anderson Inst Womens Hlth, Dept Womens Canc, London, England.
   [Tudzarova, Slavica] UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London
RP Williams, GH (通讯作者)，UCL, UCL Canc Inst, Paul OGorman Bldg,72 Huntley St, London WC1E 6DD, England.
EM s.trajkovska@ucl.ac.uk; gareth.williams@ucl.ac.uk
RI Dafou, Dimitra/N-6094-2015; Rodriguez, Sara/AAA-8972-2019; Rodriguez
   Acebes, Sara/K-3670-2014
OI Widschwendter, Martin/0000-0002-7778-8380; Apostolidou,
   Sophia/0000-0003-2659-0451; Dafou, Dimitra/0000-0003-4170-0612;
   Rodriguez Acebes, Sara/0000-0002-9867-7591
FU EU; Fahy Gurteen UK Ltd.
FX We thank M Rashid for technical assistance with immunohistochemistry, E
   Leo for assistance with tissue microdissection and DNA extraction, and P
   Treasure for statistical analyses. We are most grateful to B Neumann, T
   Walter, B Nijmeijer and J Ellenberg, of the Cell Biology and Biophysics
   Unit at EMBL, for sharing their expertise and MitoCheck screening data,
   and we thank all our colleagues in the MitoCheck consortium for
   collaboration. This work was funded by the EU 6th Framework Programme
   Integrated Project 'MitoCheck' and Fahy Gurteen UK Ltd.
CR Boldt HB, 2007, GROWTH HORM IGF RES, V17, P10, DOI 10.1016/j.ghir.2006.11.003
   Boldt HB, 2011, ENDOCRINOLOGY, V152, P1470, DOI 10.1210/en.2010-1095
   BRAMBATI B, 1993, BRIT J OBSTET GYNAEC, V100, P324, DOI 10.1111/j.1471-0528.1993.tb12973.x
   Callahan G, 2003, ONCOGENE, V22, P590, DOI 10.1038/sj.onc.1206171
   Chen BK, 2003, J CLIN ENDOCR METAB, V88, P4465, DOI 10.1210/jc.2003-030193
   Conover CA, 2004, DEVELOPMENT, V131, P1187, DOI 10.1242/dev.00997
   Conover CA, 2007, AGING CELL, V6, P727, DOI 10.1111/j.1474-9726.2007.00328.x
   Conover CA, 2012, TRENDS ENDOCRIN MET, V23, P242, DOI 10.1016/j.tem.2012.02.008
   Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002
   Delpuech O, 2007, MOL CELL BIOL, V27, P4917, DOI 10.1128/MCB.01789-06
   Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457
   Duregon E, 2014, MODERN PATHOL, V27, P1246, DOI 10.1038/modpathol.2013.230
   Gisselsson D, 2005, CELL CYCLE, V4, P1007, DOI 10.4161/cc.4.8.1884
   Kleinberg D, 2008, J MAMMARY GLAND BIOL, V13, P353, DOI 10.1007/s10911-008-9103-7
   KUHAJDA FP, 1985, AM J PATHOL, V121, P342
   KUHAJDA FP, 1985, LAB INVEST, V53, P101
   KULL FC, 1983, J BIOL CHEM, V258, P6561
   Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217
   Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149
   Lénárt P, 2007, CURR BIOL, V17, P304, DOI 10.1016/j.cub.2006.12.046
   Loddo M, 2009, BRIT J CANCER, V100, P959, DOI 10.1038/sj.bjc.6604924
   Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657
   Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200
   Major ML, 2004, MOL CELL BIOL, V24, P2649, DOI 10.1128/MCB.24.7.2649-2661.2004
   Mazerbourg S, 2001, ENDOCRINOLOGY, V142, P5243, DOI 10.1210/en.142.12.5243
   McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805
   Min J, 2012, GLIA, V60, P1684, DOI 10.1002/glia.22387
   Neumann B, 2010, NATURE, V464, P721, DOI 10.1038/nature08869
   Pan H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048799
   Rizki A, 2007, CANCER RES, V67, P11106, DOI 10.1158/0008-5472.CAN-07-2348
   Rodriguez-Acebes S, 2010, AM J PATHOL, V177, P2034, DOI 10.2353/ajpath.2010.100421
   Sanchez-Calderon H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008699
   Strömberg T, 2006, BLOOD, V107, P669, DOI 10.1182/blood-2005-01-0306
   Tanner SJ, 2008, J BONE MINER RES, V23, P655, DOI 10.1359/JBMR.071210
   Tudzarova S, 2010, EMBO J, V29, P3381, DOI 10.1038/emboj.2010.201
   Vincourt JB, 2010, CANCER RES, V70, P4739, DOI 10.1158/0008-5472.CAN-10-0046
   Walter T, 2010, J STRUCT BIOL, V170, P1, DOI 10.1016/j.jsb.2009.10.004
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676
NR 39
TC 25
Z9 27
U1 0
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3417
EI 1096-9896
J9 J PATHOL
JI J. Pathol.
PD AUG
PY 2014
VL 233
IS 4
BP 344
EP 356
DI 10.1002/path.4393
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA AM2EM
UT WOS:000339661900003
PM 24931331
DA 2025-01-12
ER

PT J
AU Montenegro, MF
   Collado-González, MD
   Fernández-Pérez, MP
   Hammouda, MB
   Tolordava, L
   Gamkrelidze, M
   Rodríguez-López, JN
AF Montenegro, Maria F.
   del Mar Collado-Gonzalez, Maria
   Piedad Fernandez-Perez, Maria
   Hammouda, Manel B.
   Tolordava, Lana
   Gamkrelidze, Mariam
   Neptuno Rodriguez-Lopez, Jose
TI Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative
   breast cancer cells
SO BMC CANCER
LA English
DT Article
DE Breast cancer; Oestrogen receptor alpha; E2F1; 4-Hydroxy-tamoxifen;
   Apoptosis
ID TAMOXIFEN SENSITIVITY; ENDOCRINE RESISTANCE; DNA-DAMAGE; CYCLE; E2F1;
   EXPRESSION; INDUCTION; PROLIFERATION; ANTIESTROGENS; METHYLATION
AB Background: Because oestrogen receptor a (ER alpha) regulates E2F1 expression to mediate tamoxifen resistance in ER alpha-positive breast cancer cells, we aimed to define the possible roles of ER alpha and E2F1 in promoting the resistance of ER alpha-negative breast cancer cells to 4-hydroxy-tamoxifen (4OHT).
   Methods: This study utilised conventional techniques to demonstrate the effects of 4OHT on the expression of ER alpha and E2F1 and also examined the individual and combined effects of 4OHT with dipyridamole (DIPY) and 3-O-(3,4,5-trimethoxybenzoyl)-(-)-catechin (TMCG) on the oestrogen-negative MDA-MB-231 breast cancer cell line using viability assays, Hoechst staining, MALDI-TOF mass spectroscopy, and confocal microscopy.
   Results: Despite the ER alpha-negative status of the MDA-MB-231 cells, we observed that 4OHT efficiently up-regulated ER alpha in these cells and that this upregulation promoted E2F1-mediated cell growth. Because E2F1 plays a dual role in cell growth/apoptosis, we designed a therapy incorporating TMCG/DIPY to take advantage of the elevated E2F1 expression in these 4OHT-treated cells. 4OHT enhances the toxicity of TMCG/DIPY in these ER alpha-negative breast cancer cells.
   Conclusions: Because TMCG/DIPY treatment modulates the methylation status/stability of E2F1, the results demonstrate that therapies targeting the epigenetic machinery of cancer cells in the presence of overexpressed E2F1 may result in efficient E2F1-mediated cell death.
C1 [Montenegro, Maria F.; del Mar Collado-Gonzalez, Maria; Piedad Fernandez-Perez, Maria; Hammouda, Manel B.; Neptuno Rodriguez-Lopez, Jose] Univ Murcia, Sch Biol, Dept Biochem & Mol Biol A, E-30100 Murcia, Spain.
   [Tolordava, Lana; Gamkrelidze, Mariam] Agr Univ Georgia, Durmishidze Inst Biochem & Biotechnol, GE-0131 Tbilisi, Georgia.
C3 University of Murcia
RP Montenegro, MF (通讯作者)，Univ Murcia, Sch Biol, Dept Biochem & Mol Biol A, Reg Campus Int Excellence Campus Mare Nostrum, E-30100 Murcia, Spain.
EM fermontenegro@um.es; neptuno@um.es
RI Ben Hammouda, Manel/ADN-7418-2022; Neptuno, Jose/F-5012-2016;
   Montenegro, Maria/AAF-2695-2021; Collado-Gonzalez, Maria del
   Mar/P-6687-2018
OI Ben Hammouda, Manel/0000-0002-6625-7744; Collado-Gonzalez, Maria del
   Mar/0000-0003-3976-8925; Rodriguez-Lopez, Jose
   Neptuno/0000-0001-6863-1173; Montenegro, Maria
   Fernanda/0000-0002-0064-0484; FERNANDEZ PEREZ, MARIA
   PIEDAD/0000-0003-4916-1959
FU Ministerio de Ciencia e Innovacion (MICINN) [SAF2009-12043-C02-01];
   Fundacion Seneca, Region de Murcia (FS-RM) [15230/PI/10]; EU [ERA293514]
FX This work was supported by grants from Ministerio de Ciencia e
   Innovacion (MICINN) (SAF2009-12043-C02-01), Fundacion Seneca, Region de
   Murcia (FS-RM) (15230/PI/10), and EU ERA293514. M. F. M is contracted by
   Fundacion Cientifica de la Asociacion Espanola contra el Cancer
   (FCAECC).
CR Bianco S, 2012, TRANSCR-AUSTIN, V3, P165, DOI 10.4161/trns.20496
   Caldon CE, 2006, J CELL BIOCHEM, V97, P261, DOI 10.1002/jcb.20690
   Cam H, 2003, CANCER CELL, V3, P311, DOI 10.1016/S1535-6108(03)00080-1
   Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697
   Charalambous C, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-238
   Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Dorssers LCJ, 2001, DRUGS, V61, P1721, DOI 10.2165/00003495-200161120-00004
   Droog M, 2013, EUR J PHARMACOL, V717, P47, DOI 10.1016/j.ejphar.2012.11.071
   Ford CE, 2009, P NATL ACAD SCI USA, V106, P3919, DOI 10.1073/pnas.0809516106
   Ford CHJ, 2011, ANTICANCER RES, V31, P521
   GOTTARDIS MM, 1988, CANCER RES, V48, P5183
   Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
   Jiang Q, 2013, FUTURE MED CHEM, V5, P1023, DOI 10.4155/fmc.13.63
   Kim K, 2003, MOL ENDOCRINOL, V17, P804, DOI 10.1210/me.2002-0406
   Kontaki H, 2010, CELL CYCLE, V9, P3836, DOI 10.4161/cc.9.19.13384
   Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006
   Lebedeva G, 2012, BMC SYST BIOL, V6, DOI 10.1186/1752-0509-6-138
   Lewis-Wambi JS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2255
   Lin WC, 2001, GENE DEV, V15, P1833
   Louie MC, 2010, MOL CANCER RES, V8, P343, DOI 10.1158/1541-7786.MCR-09-0395
   Louie MC, 2004, MOL CELL BIOL, V24, P5157, DOI 10.1128/MCB.24.12.5157-5171.2004
   Madeira M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-425
   Martínez-Balbás MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662
   Montenegro MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052231
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   OSBORNE CK, 1983, CANCER RES, V43, P3583
   Pink JJ, 1996, CANCER RES, V56, P2321
   Rochefort H, 2003, ENDOCR-RELAT CANCER, V10, P261, DOI 10.1677/erc.0.0100261
   Sáez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009
   Sáez-Ayala M, 2011, CHEMMEDCHEM, V6, P440, DOI 10.1002/cmdc.201000482
   Samaddar JS, 2008, MOL CANCER THER, V7, P2977, DOI 10.1158/1535-7163.MCT-08-0447
   Sánchez-del-Campo L, 2008, INT J CANCER, V123, P2446, DOI 10.1002/ijc.23813
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   SIPILA PEH, 1993, EUR J CANCER, V29A, P2138, DOI 10.1016/0959-8049(93)90049-L
   SUTHERLAND RL, 1983, CANCER RES, V43, P3998
   Thomas RS, 2008, J MOL ENDOCRINOL, V40, P173, DOI 10.1677/JME-07-0165
   Tian YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017017
   Urist M, 2004, GENE DEV, V18, P3041, DOI 10.1101/gad.1221004
   Wang A, 2005, CANCER RES, V65, P7809, DOI 10.1158/0008-5472.CAN-05-0888
   Yeh WL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060889
   Zhang XT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030174
   Zivadinovic D, 2005, BREAST CANCER RES, V7, pR130, DOI 10.1186/bcr959
NR 44
TC 13
Z9 13
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUL 26
PY 2014
VL 14
AR 539
DI 10.1186/1471-2407-14-539
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AM6JU
UT WOS:000339971500002
PM 25064027
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Lirk, P
   Hollmann, MW
   Fleischer, M
   Weber, NC
   Fiegl, H
AF Lirk, P.
   Hollmann, M. W.
   Fleischer, M.
   Weber, N. C.
   Fiegl, H.
TI Lidocaine and ropivacaine, but not bupivacaine, demethylate
   deoxyribonucleic acid in breast cancer cells <i>in vitro</i>
SO BRITISH JOURNAL OF ANAESTHESIA
LA English
DT Article
DE cancer; demethylation; epigenetics; local anaesthetic; bupivacaine;
   local anaesthetic; lidocaine; local anaesthetic; ropivacaine
ID DNA METHYLATION; LOCAL-ANESTHETICS; COLORECTAL-CANCER; SURGERY;
   INHIBITION; PROCAINE; METASTASIS; RECURRENCE; STRATEGIES; ANALGESIA
AB Lidocaine demethylates deoxyribonucleic acid (DNA) in breast cancer cells. This modification of epigenetic information may be of therapeutic relevance in the perioperative period, because a decrease in methylation can reactivate tumour suppressor genes and inhibit tumour growth. The objectives of this study were to determine the effect of two amide local anaesthetics, ropivacaine and bupivacaine, on methylation in two breast cancer cell lines and to detect whether the combination of lidocaine with the chemotherapy agent 5-aza-2'-deoxycytidine (DAC) would result in additive demethylating effects.
   Breast cancer cell lines BT-20 [oestrogen receptor (ER)-negative] and MCF-7 (ER-positive) were incubated with lidocaine, bupivacaine, and ropivacaine to assess demethylating properties. Then, we tested varying concentrations of lidocaine and DAC to assess whether their demethylating effects were additive. Cell numbers and global methylation status were analysed.
   Lidocaine decreased methylation in BT-20 and MCF-7 cells, ropivacaine decreased methylation in BT-20 cells, and bupivacaine had no demethylating effect. When combined, lidocaine and DAC had additive demethylating effects.
   At clinically relevant doses, lidocaine and ropivacaine exert demethylating effects on specific breast cancer cell lines, but bupivacaine does not. The demethylating effects of lidocaine and DAC are indeed additive.
C1 [Lirk, P.; Hollmann, M. W.; Weber, N. C.] Univ Amsterdam, Acad Med Ctr, Dept Anaesthesiol, NL-1105 AZ Amsterdam, Netherlands.
   [Fleischer, M.; Fiegl, H.] Med Univ Innsbruck, Dept Obstet & Gynaecol, A-6020 Innsbruck, Austria.
C3 University of Amsterdam; Academic Medical Center Amsterdam; Medical
   University of Innsbruck
RP Lirk, P (通讯作者)，Univ Amsterdam, Acad Med Ctr, Dept Anaesthesiol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM p.lirk@amc.uva.nl; heidelinde.fiegl@i-med.ac.at
RI Weber, Nina/CAH-0231-2022; Fiegl, Heidi/K-4445-2017
OI Fiegl, Heidi/0000-0002-1236-6806
FU Dutch Association of Anaesthesiology
FX Supported by the Dutch Association of Anaesthesiology 2012 Young
   Investigator's Grant (to P.L.) and Departmental funds.
CR Alonso DF, 2011, CURR PHARM BIOTECHNO, V12, P1974
   BARANCIK M, 1994, DRUG EXP CLIN RES, V20, P13
   Biki B, 2008, ANESTHESIOLOGY, V109, P180, DOI 10.1097/ALN.0b013e31817f5b73
   BORG T, 1985, ACTA ANAESTH SCAND, V29, P739, DOI 10.1111/j.1399-6576.1985.tb02292.x
   Castellano S, 2008, J MED CHEM, V51, P2321, DOI 10.1021/jm7015705
   Cock-Rada A, 2013, BIOL CELL, V105, P73, DOI 10.1111/boc.201200029
   Coffey JC, 2003, LANCET ONCOL, V4, P760, DOI 10.1016/S1470-2045(03)01282-8
   Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32
   ESPOSITO M, 1990, JNCI-J NATL CANCER I, V82, P677, DOI 10.1093/jnci/82.8.677
   Esteller M, 2003, LANCET ONCOL, V4, P351, DOI 10.1016/S1470-2045(03)01115-X
   Exadaktylos AK, 2006, ANESTHESIOLOGY, V105, P660, DOI 10.1097/00000542-200610000-00008
   Fukuda T, 2003, REGION ANESTH PAIN M, V28, P215, DOI 10.1053/rapm.2003.50131
   Goldoni M, 2007, TOXICOL IN VITRO, V21, P759, DOI 10.1016/j.tiv.2007.03.003
   Gottschalk A, 2010, ANESTHESIOLOGY, V113, P27, DOI 10.1097/ALN.0b013e3181de6d0d
   Jabbour E, 2008, CANCER-AM CANCER SOC, V112, P2341, DOI 10.1002/cncr.23463
   Lirk P, 2012, BRIT J ANAESTH, V109, P200, DOI 10.1093/bja/aes128
   Lirk P, 2008, ANESTH ANALG, V106, P1456, DOI 10.1213/ane.0b013e318168514b
   Liu Z, 2007, CLIN CANCER RES, V13, P2992, DOI 10.1158/1078-0432.CCR-06-2072
   LUOSTARINEN V, 1981, ACTA ANAESTH SCAND, V25, P9, DOI 10.1111/j.1399-6576.1981.tb01596.x
   Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739
   Parson W, 2005, FASEB J, V19, P434, DOI 10.1096/fj.04-3062fje
   Picardi S, 2013, REGION ANESTH PAIN M, V38, P9, DOI 10.1097/AAP.0b013e31827a3cbe
   Piegeler T, 2012, ANESTHESIOLOGY, V117, P548, DOI 10.1097/ALN.0b013e3182661977
   Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554
   Reimer D, 2010, CANCER RES, V70, P4613, DOI 10.1158/0008-5472.CAN-09-3551
   Schlagenhauff B, 2000, MELANOMA RES, V10, P165, DOI 10.1097/00008390-200010020-00009
   Sun YX, 2012, DIS COLON RECTUM, V55, P1183, DOI 10.1097/DCR.0b013e318259bcd8
   Tada M, 2007, HEPATOL INT, V1, P355, DOI 10.1007/s12072-007-9014-5
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Tyzzer EE, 1913, J MED RES, V28, P309
   Villar-Garea A, 2003, CANCER RES, V63, P4984
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wuethrich PY, 2010, ANESTHESIOLOGY, V113, P570, DOI 10.1097/ALN.0b013e3181e4f6ec
NR 33
TC 58
Z9 63
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-0912
EI 1471-6771
J9 BRIT J ANAESTH
JI Br. J. Anaesth.
PD JUL
PY 2014
VL 113
SU 1
SI SI
BP 32
EP 38
DI 10.1093/bja/aeu201
PG 7
WC Anesthesiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anesthesiology
GA AM7LS
UT WOS:000340049300005
PM 24946779
OA Bronze
DA 2025-01-12
ER

PT J
AU Do, SI
   Ko, E
   Kang, SY
   Lee, JE
   Nam, SJ
   Cho, EY
   Kim, DH
AF Do, Sung-Im
   Ko, Eunkyung
   Kang, So Young
   Lee, Jeong Eon
   Nam, Seok Jin
   Cho, Eun Yoon
   Kim, Duk-Hwan
TI Aberrant DNA methylation of integrin α4 in human breast cancer
SO TUMOR BIOLOGY
LA English
DT Article
DE DNA methylation; Integrin; Breast cancer; HER2; MIB1
ID HUMAN GASTRIC-CANCER; EPIGENETIC INACTIVATION; SIGNAL-TRANSDUCTION;
   ADHESION MOLECULES; CELL-ADHESION; HYPERMETHYLATION; METASTASIS;
   EXPRESSION; CARCINOMA; PROMOTER
AB Integrins are cell surface receptors that mediate cell-cell/extracellular interactions and have shown an association with metastasis or transformation in several cancers. However, the correlation between the clinicopathological status of breast cancer and the altered integrin alpha 4 status is not clear. In this study, we investigated DNA methylation of integrin alpha 4 in breast cancer. We retrieved 351 cases of surgically resected breast cancer (290 invasive carcinoma and 61 intraductal carcinoma). Methylation-specific polymerase chain reaction was performed to determine integrin alpha 4 methylation status. Integrin alpha 4 methylation was frequently observed in breast cancer specimens (145/351 cases, 41.3 %). In addition, DNA methylation of integrin alpha 4 showed statistical correlation with HER2 positivity and higher histologic grade (p = 0.001, 0.008 in ductal carcinoma in situ and 0.003 in invasive ductal carcinoma). However, other clinicopathological data such as estrogen receptor, progesterone receptor, metastasis, and TNM status showed no statistical correlation. Moreover, we found that the downregulated expression of integrin alpha 4 in a heavily methylated breast cancer cell line (ZR-75) was restored by treatment with 5-aza-2'deoxycytidine, a DNA methyltransferase inhibitor, implying transcriptional silencing by DNA methylation. We observed that integrin alpha 4 methylation is associated with the histologic grade of tumors and lymph node metastasis. Also, this data supports a previous study that suggested integrin alpha 4 and HER2 are involved in the same signaling pathway. DNA methylation of integrin alpha 4 may be a poor prognostic factor which affects undifferentiated histologic change of breast cancer.
C1 [Do, Sung-Im] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Pathol, Seoul 135710, South Korea.
   [Ko, Eunkyung; Kim, Duk-Hwan] Sungkyunkwan Univ, Sch Med, Dept Mol Cell Biol, Suwon, South Korea.
   [Kang, So Young; Cho, Eun Yoon] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea.
   [Lee, Jeong Eon; Nam, Seok Jin] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Sungkyunkwan University (SKKU); Samsung Medical
   Center; Sungkyunkwan University (SKKU); Samsung Medical Center
RP Cho, EY (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, 50 Ilwon DongKangnam Gu, Seoul 135710, South Korea.
EM eunyoon.cho@gmail.com
RI Lee, Sang/AAG-2448-2019; Kim, Hack-Lyoung/AAL-5038-2020
FU Samsung Biomedical Research Institute [SBRI C-B0-319-2]
FX This study was supported by the Samsung Biomedical Research Institute
   grant, #SBRI C-B0-319-2.
CR Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   CHAN BM, 1992, CELL, V68, P1051, DOI 10.1016/0092-8674(92)90077-P
   Gao YX, 2004, CLIN CHIM ACTA, V349, P173, DOI 10.1016/j.cccn.2004.07.006
   Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334
   Goel A, 2004, INT J CANCER, V112, P754, DOI 10.1002/ijc.20472
   Gonzalo S, 2010, J APPL PHYSIOL, V109, P586, DOI 10.1152/japplphysiol.00238.2010
   Gosslar U, 1996, P NATL ACAD SCI USA, V93, P4821, DOI 10.1073/pnas.93.10.4821
   HAMANN A, 1994, J IMMUNOL, V152, P3282
   Herman JG, 1996, CANCER RES, V56, P722
   Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870
   Holzmann B, 1998, CURR TOP MICROBIOL, V231, P125
   HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S
   Kang SH, 1999, ONCOGENE, V18, P7280, DOI 10.1038/sj.onc.1203146
   Lindsey JC, 2006, INT J CANCER, V118, P346, DOI 10.1002/ijc.21353
   Maruyama R, 2004, CANCER-AM CANCER SOC, V100, P1472, DOI 10.1002/cncr.20144
   Maruyama R, 2004, J THORAC CARDIOV SUR, V127, P1587, DOI 10.1016/j.jtcvs.2004.02.001
   Michetti M, 2000, GASTROENTEROLOGY, V119, P109, DOI 10.1053/gast.2000.8548
   Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83
   Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470
   QIAN F, 1994, CELL, V77, P335, DOI 10.1016/0092-8674(94)90149-X
   Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x
   RINCON J, 1992, INT J CANCER, V51, P452, DOI 10.1002/ijc.2910510319
   Song SH, 2000, INT J CANCER, V87, P236, DOI 10.1002/1097-0215(20000715)87:2<236::AID-IJC14>3.0.CO;2-M
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Uhm KO, 2010, J CANCER RES CLIN, V136, P187, DOI 10.1007/s00432-009-0646-9
   van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417
   Yoon SO, 2006, CANCER RES, V66, P2732, DOI 10.1158/0008-5472.CAN-05-2941
NR 28
TC 7
Z9 9
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2014
VL 35
IS 7
BP 7079
EP 7084
DI 10.1007/s13277-014-1952-7
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AM3EU
UT WOS:000339736300114
PM 24756760
DA 2025-01-12
ER

PT J
AU Yao, J
   Caballero, OL
   Yung, WKA
   Weinstein, JN
   Riggins, GJ
   Strausberg, RL
   Zhao, Q
AF Yao, Jun
   Caballero, Otavia L.
   Yung, W. K. Alfred
   Weinstein, John N.
   Riggins, Gregory J.
   Strausberg, Robert L.
   Zhao, Qi
TI Tumor Subtype-Specific Cancer-Testis Antigens as Potential Biomarkers
   and Immunotherapeutic Targets for Cancers
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID CANCER/TESTIS ANTIGENS; NY-ESO-1 ANTIGEN; DNA METHYLATION; EXPRESSION;
   RESPONSES; MELANOMA; PATTERNS; SURVIVAL; GENES; PREDICTOR
AB Cancer-testis (CT) antigens are potential targets for cancer immunotherapy because of their restricted expression in immune-privileged germ cells and various malignancies. Current application of CT-based immunotherapy has been focused on CT expression-rich tumors such as melanoma and lung cancers. In this study, we surveyed CT expression using The Cancer Genome Atlas (TCGA) datasets for ten common cancer types. We show that CT expression is specific and enriched within certain cancer molecular subtypes. For example, HORMAD1, CXorf61, ACTL8, and PRAME are highly enriched in the basal subtype of breast cancer; MAGE and CSAG are most frequently activated in the magnoid subtype of lung adenocarcinoma; and PRAME is highly upregulated in the ccB subtype of clear cell renal cell carcinoma. Analysis of CT gene expression and DNA methylation indicates that some CTs are regulated epigenetically, whereas others are controlled primarily by tissue-and subtype-specific transcription factors. Our results suggest that although for some CT expression is associated with patient outcome, not many are independent prognostic markers. Thus, CTs with shared expression pattern are heterogeneous molecules with distinct activation modes and functional properties in different cancers and cancer subtypes. These data suggest a cancer subtype-orientated application of CT antigen as biomarkers and immunotherapeutic targets. (C) 2013 AACR.
C1 [Yao, Jun; Yung, W. K. Alfred] Univ Texas Hlth Sci Ctr Houston, Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA.
   [Weinstein, John N.] Univ Texas Hlth Sci Ctr Houston, Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
   [Caballero, Otavia L.; Riggins, Gregory J.; Strausberg, Robert L.; Zhao, Qi] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Ludwig Collaborat Lab, Baltimore, MD 21231 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas Health Science Center Houston; University of Texas System;
   University of Texas Health Science Center Houston; UTMD Anderson Cancer
   Center; Johns Hopkins University
RP Zhao, Q (通讯作者)，Johns Hopkins Univ, Sch Med, 1550 Orleans St, Baltimore, MD 21231 USA.
EM qzhao1@jhmi.edu
RI Yung, W.K./W-5016-2019; Yao, Jun/GXF-4089-2022; Reva,
   Boris/AAB-8932-2022
OI Weinstein, John/0000-0001-9401-6908
FU NCI/NIH [U24CA143883]; Ludwig Institute for Cancer Research
FX This study is supported in part by the TCGA grant U24CA143883 from
   NCI/NIH, and funds from Ludwig Institute for Cancer Research.
CR Adélaide J, 2007, CANCER RES, V67, P11565, DOI 10.1158/0008-5472.CAN-07-2536
   Aprelikova O, 2009, CANCER RES, V69, P616, DOI 10.1158/0008-5472.CAN-08-0811
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Brannon A Rose, 2010, Genes Cancer, V1, P152
   Bricard G, 2005, J IMMUNOL, V174, P1709, DOI 10.4049/jimmunol.174.3.1709
   Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x
   Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222
   De Smet C, 1999, MOL CELL BIOL, V19, P7327
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435
   Grigoriadis A, 2009, P NATL ACAD SCI USA, V106, P13493, DOI 10.1073/pnas.0906840106
   Groeper C, 2007, INT J CANCER, V120, P337, DOI 10.1002/ijc.22309
   Gure AO, 2005, CLIN CANCER RES, V11, P8055, DOI 10.1158/1078-0432.CCR-05-1203
   Jäger D, 2001, J CLIN PATHOL, V54, P669, DOI 10.1136/jcp.54.9.669
   Kim R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-144
   Kimmins S, 2005, NATURE, V434, P583, DOI 10.1038/nature03368
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Konishi J, 2004, ONCOL REP, V11, P1063
   Kurashige T, 2001, CANCER RES, V61, P4671
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Li G, 2004, CANCER IMMUNOL IMMUN, V53, P139, DOI 10.1007/s00262-003-0471-y
   Mischo A, 2006, INT J CANCER, V118, P696, DOI 10.1002/ijc.21352
   Nagao T, 2003, J BIOL CHEM, V278, P10668, DOI 10.1074/jbc.M206104200
   Nishiyama T, 2001, CLIN CANCER RES, V7, P23
   Odunsi K, 2012, P NATL ACAD SCI USA, V109, P5797, DOI 10.1073/pnas.1117208109
   Oi S, 2009, J NEURO-ONCOL, V92, P15, DOI 10.1007/s11060-008-9732-0
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Peikert T, 2006, CANCER RES, V66, P4693, DOI 10.1158/0008-5472.CAN-05-3327
   Freitas MRP, 2013, ONCOTARGET, V4, P636, DOI 10.18632/oncotarget.950
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Robbins PF, 2011, J CLIN ONCOL, V29, P917, DOI 10.1200/JCO.2010.32.2537
   Sakurai T, 2004, J BIOL CHEM, V279, P15505, DOI 10.1074/jbc.M310437200
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Shigematsu Y, 2010, LUNG CANCER, V68, P105, DOI 10.1016/j.lungcan.2009.05.010
   Sigalotti L, 2004, CANCER RES, V64, P9167, DOI 10.1158/0008-5472.CAN-04-1442
   Simpson AJG, 2005, NAT REV CANCER, V5, P615, DOI 10.1038/nrc1669
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Svobodová S, 2011, EUR J CANCER, V47, P460, DOI 10.1016/j.ejca.2010.09.042
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van Duin M, 2011, HAEMATOL-HEMATOL J, V96, P1662, DOI 10.3324/haematol.2010.037978
   Vansteenkiste J, 2013, J CLIN ONCOL, V31, P2396, DOI 10.1200/JCO.2012.43.7103
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   von Boehmer L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021366
   Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530
   Zhao HJ, 2006, PLOS MED, V3, P115, DOI 10.1371/journal.pmed.0030013
   Zhou XC, 2013, JPN J CLIN ONCOL, V43, P243, DOI 10.1093/jjco/hys236
NR 47
TC 83
Z9 95
U1 1
U2 14
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD APR
PY 2014
VL 2
IS 4
BP 371
EP 379
DI 10.1158/2326-6066.CIR-13-0088
PG 9
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA AM7GO
UT WOS:000340033600012
PM 24764584
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Joosse, SA
   Müller, V
   Steinbach, B
   Pantel, K
   Schwarzenbach, H
AF Joosse, S. A.
   Mueller, V.
   Steinbach, B.
   Pantel, K.
   Schwarzenbach, H.
TI Circulating cell-free cancer-testis MAGE-A RNA, BORIS RNA, let-7b and
   miR-202 in the blood of patients with breast cancer and benign breast
   diseases
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE blood serum; cancer-testis antigens; circulating microRNAs; circulating
   RNA; overall survival
ID PROMOTER DEMETHYLATION; MICRORNA BIOGENESIS; TUMOR-CELLS; GENE;
   EXPRESSION; CTCF; ANTIGENS; TARGETS; LINE; DEREPRESSION
AB Background: MAGE-A (melanoma-associated antigen-A) are promising targets for specific immunotherapy and their expression may be induced by the epigenetic factor BORIS.
   Methods: To determine their relevance for breast cancer, we quantified the levels of MAGE-A1, -A2, -A3, -A12 and BORIS mRNA, as well as microRNAs let-7b and miR-202 in pre- and postoperative serum of 102 and 34 breast cancer patients, respectively, and in serum of 26 patients with benign breast diseases and 37 healthy women by real-time PCR. The mean follow-up time of the cancer patients was 6.2 years.
   Results: The serum levels of MAGE-A and BORIS mRNA, as well as let-7b were significantly higher in patients with invasive carcinomas than in patients with benign breast diseases or healthy women (P<0.001), whereas the levels of miR-202 were elevated in both patient cohorts (P<0.001). In uni-and multivariate analyses, high levels of miR-202 significantly correlated with poor overall survival (P = 0.0001). Transfection of breast cancer cells with synthetic microRNAs and their inhibitors showed that let-7b and miR-202 did not affect the protein expression of MAGE-A1.
   Conclusions: Based on their cancer-specific increase in breast cancer patients, circulating MAGE-A and BORIS mRNAs may be further explored for early detection of breast cancer and monitoring of MAGE-directed immunotherapies. Moreover, serum miR-202 is associated with prognosis.
C1 [Joosse, S. A.; Steinbach, B.; Pantel, K.; Schwarzenbach, H.] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany.
   [Mueller, V.] Univ Med Ctr Hamburg Eppendorf, Clin Gynecol, Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Schwarzenbach, H (通讯作者)，Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany.
EM hschwarz@uke.uni-hamburg.de
RI Joosse, Simon/ABC-2470-2020
OI Joosse, Simon A./0000-0002-4296-5615
FU Stiftung fur Pathochemie und Molekulare Diagnostik; Karlsruhe/Hamburg;
   ERC (European Research Council) [ERC-2010 AsG 20100317 DISSECT]
FX We are grateful to the Stiftung fur Pathochemie und Molekulare
   Diagnostik, Karlsruhe/Hamburg, and ERC (European Research Council)
   Advanced Investigator Grant (ERC-2010 AsG 20100317 DISSECT) for
   supporting this work.
CR Bartkowiak K, 2009, J PROTEOME RES, V8, P2004, DOI 10.1021/pr8009758
   Caballero OL, 2009, CANCER SCI, V100, P2014, DOI 10.1111/j.1349-7006.2009.01303.x
   Cookson VJ, 2012, CELL ONCOL, V35, P301, DOI 10.1007/s13402-012-0089-1
   De Smet C, 1999, MOL CELL BIOL, V19, P7327
   DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Hong JA, 2005, CANCER RES, V65, P7763, DOI 10.1158/0008-5472.CAN-05-0823
   Joosse SA, 2012, CLIN CANCER RES, V18, P993, DOI 10.1158/1078-0432.CCR-11-2100
   Jungbluth AA, 2000, INT J CANCER, V85, P460, DOI 10.1002/(SICI)1097-0215(20000215)85:4<460::AID-IJC3>3.3.CO;2-E
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Kwon S, 2005, CANCER-AM CANCER SOC, V104, P251, DOI 10.1002/cncr.21162
   Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699
   Martin-Kleiner I, 2012, EUR J CANCER, V48, P929, DOI 10.1016/j.ejca.2011.09.009
   McShane LM, 2006, BREAST CANCER RES TR, V100, P229, DOI 10.1007/s10549-006-9242-8
   Meek DW, 2012, CANCER LETT, V324, P126, DOI 10.1016/j.canlet.2012.05.011
   Nguyen P, 2008, MOL CELL BIOL, V28, P6720, DOI 10.1128/MCB.00568-08
   Orozco AF, 2010, CYTOM PART A, V77A, P502, DOI 10.1002/cyto.a.20886
   PANTEL K, 1995, JNCI-J NATL CANCER I, V87, P1162, DOI 10.1093/jnci/87.15.1162
   Portnoy V, 2011, WIRES RNA, V2, P748, DOI 10.1002/wrna.90
   Renaud S, 2007, NUCLEIC ACIDS RES, V35, P7372, DOI 10.1093/nar/gkm896
   Renaud S, 2011, NUCLEIC ACIDS RES, V39, P862, DOI 10.1093/nar/gkq827
   Riethdorf S, 2008, PATHOBIOLOGY, V75, P140, DOI 10.1159/000123852
   Sang MX, 2011, VACCINE, V29, P8496, DOI 10.1016/j.vaccine.2011.09.014
   Schrauder MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029770
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Smith IM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004961
   Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9
   Tang ZQ, 2014, INT J CANCER, V134, P306, DOI 10.1002/ijc.28371
   Vatolin S, 2005, CANCER RES, V65, P7751, DOI 10.1158/0008-5472.CAN-05-0858
   Wang YL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044399
   Willipinski-Stapelfeldt B, 2005, CLIN CANCER RES, V11, P8006, DOI 10.1158/1078-0432.CCR-05-0632
   Wischnewski F, 2006, MOL CANCER RES, V4, P339, DOI 10.1158/1541-7786.MCR-05-0229
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Zhao YC, 2011, BREAST CANCER RES TR, V127, P69, DOI 10.1007/s10549-010-0972-2
NR 37
TC 68
Z9 76
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD AUG 26
PY 2014
VL 111
IS 5
BP 909
EP 917
DI 10.1038/bjc.2014.360
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AO7IR
UT WOS:000341527100013
PM 24983365
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Derr, RS
   van Hoesel, AQ
   Benard, A
   Goossens-Beumer, IJ
   Sajet, A
   Dekker-Ensink, NG
   de Kruijf, EM
   Bastiaannet, E
   Smit, VTHBM
   van de Velde, CJH
   Kuppen, PJK
AF Derr, Remco S.
   van Hoesel, Anneke Q.
   Benard, Anne
   Goossens-Beumer, Ines J.
   Sajet, Anita
   Dekker-Ensink, N. Geeske
   de Kruijf, Esther M.
   Bastiaannet, Esther
   Smit, Vincent T. H. B. M.
   van de Velde, Cornelis J. H.
   Kuppen, Peter J. K.
TI High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2
   and SIRT1 in tumor cells correlate with decreased survival and increased
   relapse in breast cancer patients
SO BMC CANCER
LA English
DT Article
DE Biomarkers; Breast cancer; Clinical outcome; Epigenetics; HDAC2;
   Histone-modifying enzymes; LSD1; SIRT1
ID DEMETHYLASE 1; THERAPY; DEACETYLASES; COMPLEX; P53
AB Background: Breast cancer is a heterogeneous disease with a highly variable clinical outcome in which both genetic and epigenetic changes have critical roles. We investigated tumor expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in relation with patient survival and tumor relapse in a retrospective cohort of 460 breast cancer patients. Additionally, we correlated expression levels with tumor differentiation and tumor cell proliferation.
   Methods: Immunohistochemical staining for LSD1, HDAC2 and SIRT1 was performed on tissue microarrays of tumor and corresponding normal formalin-fixed paraffin-embedded tissues from breast cancer patients. Median nuclear expression levels in tumor tissues were used to divide the patients into low and high expression categories. In combined expression analyses, patients were divided into four subgroups: 1, all enzymes below-median; 2, one enzyme above-median; 3, two enzymes above-median; 4, all three enzymes above-median. The Cox proportional hazard model was used for univariate and multivariate survival analyses. The Pearson Chi-square method was used to assess correlation of combined expression levels with tumor cell proliferation and tumor differentiation.
   Results: Expression of LSD1 and SIRT1, but not of HDAC2, was significantly increased in tumor tissues compared to their normal counterparts (both p < 0.001). Multivariate survival analyses identified SIRT1 as independent prognostic factor for relapse-free survival (RFS) with a hazard ratio (HR) of 1.34 (95% CI = 1.04-1.74, p = 0.02). For overall survival (OS), no significant differences were found when the individual enzymes were analyzed. Analyses of combined expression levels of the three histone-modifying enzymes correlated with OS (p = 0.03) and RFS (p = 0.006) with a HR of respectively 1.49 (95% CI = 1.07-2.08) and 1.68 (95% CI = 1.16-2.44) in multivariate analyses and were also related to tumor differentiation (p < 0.001) and tumor cell proliferation (p = 0.002).
   Conclusions: When the combined expression levels were analyzed, high expression of LSD1, HDAC2 and SIRT1 showed shorter patient survival time and shorter time to tumor relapse and correlated with poor tumor differentiation and a high level of tumor cell proliferation. Expression of these histone-modifying enzymes might therefore be involved in breast cancer pathogenesis.
C1 [Derr, Remco S.; van Hoesel, Anneke Q.; Benard, Anne; Goossens-Beumer, Ines J.; Sajet, Anita; Dekker-Ensink, N. Geeske; de Kruijf, Esther M.; Bastiaannet, Esther; van de Velde, Cornelis J. H.; Kuppen, Peter J. K.] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands.
   [Smit, Vincent T. H. B. M.] LUMC, Dept Pathol, Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Leiden University; Leiden University Medical
   Center (LUMC)
RP Kuppen, PJK (通讯作者)，Leiden Univ, Med Ctr, Dept Surg, K6-R,POB 9600, NL-2300 RC Leiden, Netherlands.
EM p.j.k.kuppen@lumc.nl
RI van de Velde, Cornelis/AAY-8360-2020; Smit, Vincent THBM/AAD-1811-2022;
   Kuppen, Peter/J-2342-2016
OI Smit, Vincent THBM/0000-0003-3730-5652; Kuppen,
   Peter/0000-0002-0294-3251
FU Dutch Cancer Society [KWF 2007-3968]
FX We thank Dilesh Kishoendajal for his efforts to optimize the antibodies
   used for the immunohistochemistry. We thank Gerrit-Jan Liefers (LUMC)
   for his clinical input in the study. We would like to thank the Dutch
   Cancer Society (KWF 2007-3968) for funding part of the research
   performed in this study.
CR Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   de Kruijf EM, 2013, BREAST CANCER RES TR, V142, P355, DOI 10.1007/s10549-013-2752-2
   Engels CC, 2013, BREAST CANCER RES TR, V142, P323, DOI 10.1007/s10549-013-2748-y
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271
   Gu HD, 2009, J VIROL, V83, P4376, DOI 10.1128/JVI.02515-08
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harms KL, 2007, CANCER RES, V67, P3145, DOI 10.1158/0008-5472.CAN-06-4397
   Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349
   Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023
   Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Marmé F, 2012, ONKOLOGIE, V35, P28, DOI 10.1159/000334973
   McShane LM, 2005, BRIT J CANCER, V93, P387, DOI 10.1038/sj.bjc.6602678
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   Mulligan P, 2011, MOL CELL, V42, P689, DOI 10.1016/j.molcel.2011.04.020
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nowsheen S, 2012, CANC LETT, V342, P213, DOI DOI 10.1016/J.CANLET.2012.05.015
   Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13
   Sung JY, 2010, CANCER SCI, V101, P1738, DOI 10.1111/j.1349-7006.2010.01573.x
   van Nes JGH, 2011, BREAST CANCER RES TR, V125, P671, DOI 10.1007/s10549-010-0854-7
   Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033
   Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388
NR 26
TC 62
Z9 68
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD AUG 20
PY 2014
VL 14
AR 604
DI 10.1186/1471-2407-14-604
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AN9ZM
UT WOS:000340968200003
PM 25139823
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Fumagalli, C
   Della Pasqua, S
   Bagnardi, V
   Cardillo, A
   Sporchia, A
   Colleoni, M
   Viale, G
   Barberis, M
   Pruneri, G
AF Fumagalli, Caterina
   Della Pasqua, Silvia
   Bagnardi, Vincenzo
   Cardillo, Anna
   Sporchia, Andrea
   Colleoni, Marco
   Viale, Giuseppe
   Barberis, Massimo
   Pruneri, Giancarlo
TI Prevalence and Clinicopathologic Correlates of
   O<SUP>6</SUP>-Methylguanine-DNA Methyltransferase Methylation Status in
   Patients With Triple-Negative Breast Cancer Treated Preoperatively by
   Alkylating Drugs
SO CLINICAL BREAST CANCER
LA English
DT Article
DE DNA repair; Epigenetic alterations; Mammary tumors; Neoadjuvant therapy;
   Prognosis
ID NEOADJUVANT CHEMOTHERAPY; CLINICAL-PRACTICE; PREDICTIVE-VALUE; MGMT;
   TEMOZOLOMIDE; SURVIVAL; THERAPY; REPAIR; INACTIVATION; SENSITIVITY
AB The role of MGMT (O-6-methylguanine-DNA methyltransferase) methylation in predicting the clinical response to neoadjuvant therapy in triple-negative breast cancer (TNBC) was evaluated. MGMT methylation was observed in 80%, 62%, and 29% of patients showing 100%, 99% to 30%, and < 30% tumor reduction, respectively (P = .23). There was no association between MGMT methylation and pathologic complete response. Further studies are warranted for ascertaining the putative clinical role of MGMT in patients with TNBC. Background: Predictive factors of benefit from specific chemotherapy regimens are not currently available in triple-negative breast cancer (TNBC). MGMT (O-6-methylguanine-DNA methyltransferase) controls DNA repair pathways, and its epigenetic silencing is used for predicting the response to the alkylating drug temozolomide in patients with glioma. Materials and Methods: The study population was composed of 84 patients with TNBC treated with alkylating agents and evaluated for clinicopathologic parameters (tumor shrinkage and pathologic complete response [pCR]). MGMT methylation status was assessed in formalin-fixed, paraffin-embedded tumor specimens by pyrosequencing. The samples were categorized as methylated (mean methylation value > 5%), indeterminate (4%-5%), and unmethylated (<= 3%). Results: MGMT methylation status was successfully evaluated in all the cases: 58.3% were methylated; 27.4%, unmethylated; and 14.3%, indeterminate. MGMT methylation was observed in 80%, 62%, and 29% of patients showing a 100%, 99% to 30%, and < 30% tumor reduction, respectively, a trend not achieving statistical significance (P = .23). There was no association between MGMT methylation status and pCR. Conclusion: The present study provided evidence that pyrosequencing performs well for the evaluation of MGMT methylation even in small bioptic samples, suggesting that it could be reliably used in translational studies of preoperative clinical trials. Although there was an association trend between high methylation levels and clinical response to therapy, no statistically significant association with the pCR was found. Further studies in larger series of patients are warranted for ascertaining the putative clinical role of MGMT in patients with TNBC. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Fumagalli, Caterina; Viale, Giuseppe; Barberis, Massimo; Pruneri, Giancarlo] European Inst Oncol, Div Pathol, I-20141 Milan, Italy.
   [Della Pasqua, Silvia; Cardillo, Anna; Sporchia, Andrea; Colleoni, Marco] European Inst Oncol, Div Med Senol, I-20141 Milan, Italy.
   [Bagnardi, Vincenzo] European Inst Oncol, Div Epidemiol & Biostat, I-20141 Milan, Italy.
   [Viale, Giuseppe; Pruneri, Giancarlo] Univ Milan, Sch Med, Milan, Italy.
   [Viale, Giuseppe; Pruneri, Giancarlo] Univ Milano Bicocca, Dept Stat & Quantitat Methods, Milan, Italy.
C3 IRCCS European Institute of Oncology (IEO); IRCCS European Institute of
   Oncology (IEO); IRCCS European Institute of Oncology (IEO); University
   of Milan; University of Milano-Bicocca
RP Pruneri, G (通讯作者)，European Inst Oncol, Div Pathol, Via Ripamonti 435, I-20141 Milan, Italy.
EM giancarlo.pruneri@ieo.it
RI Fumagalli, Caterina/J-1048-2018; Barberis, Massimo/AAL-5446-2020;
   Dellapasqua, Silvia/AAO-7127-2020; Cardillo, Anna/AAN-8234-2020; Viale,
   Giuseppe/AAE-8921-2019; Colleoni, Marco/AAN-8647-2020; Pruneri,
   Giancarlo/AAC-7767-2022
OI Pruneri, Giancarlo/0000-0002-7963-7172; colleoni,
   marco/0000-0002-5743-3013; Fumagalli, Caterina/0000-0001-5417-7985
FU Fondazione Veronesi
FX The study was funded by a grant from Fondazione Veronesi. All authors
   state that they have no conflicts of interest.
CR Adachi J, 2012, J NEURO-ONCOL, V107, P147, DOI 10.1007/s11060-011-0721-3
   Alli E, 2009, CANCER RES, V69, P3589, DOI 10.1158/0008-5472.CAN-08-4016
   Amatu A, 2013, CLIN CANCER RES, V19, P2265, DOI 10.1158/1078-0432.CCR-12-3518
   Branham MT, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.17
   Busch C, 2010, EUR J CANCER, V46, P2127, DOI 10.1016/j.ejca.2010.04.023
   Cankovic M, 2013, J MOL DIAGN, V15, P539, DOI 10.1016/j.jmoldx.2013.05.011
   Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Christians A., PLoS One
   Crown J, 2012, ANN ONCOL, V23, P56, DOI 10.1093/annonc/mds196
   Daniels DS, 2004, NAT STRUCT MOL BIOL, V11, P714, DOI 10.1038/nsmb791
   Dunn J, 2009, BRIT J CANCER, V101, P124, DOI 10.1038/sj.bjc.6605127
   Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901
   Fumagalli C, 2012, BREAST CANCER RES TR, V134, P131, DOI 10.1007/s10549-011-1945-9
   Gerson SL, 2004, NAT REV CANCER, V4, P296, DOI 10.1038/nrc1319
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560
   Irvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034
   Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008
   Kassam F, 2009, CLIN BREAST CANCER, V9, P29, DOI 10.3816/CBC.2009.n.005
   Kulke MH, 2009, CLIN CANCER RES, V15, P338, DOI 10.1158/1078-0432.CCR-08-1476
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Lin NU, 2008, CANCER-AM CANCER SOC, V113, P2638, DOI 10.1002/cncr.23930
   Lin NU, 2012, CANCER-AM CANCER SOC, V118, P5463, DOI 10.1002/cncr.27581
   Nakai K, 2012, CANCER CHEMOTH PHARM, V69, P923, DOI 10.1007/s00280-011-1777-7
   Pogoda K, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0388-4
   Quillien V, 2012, CANCER-AM CANCER SOC, V118, P4201, DOI 10.1002/cncr.27392
   Raguz S, 2013, BIOCHEM PHARMACOL, V85, P186, DOI 10.1016/j.bcp.2012.10.020
   Rodriguez AA, 2010, BREAST CANCER RES TR, V123, P189, DOI 10.1007/s10549-010-0983-z
   Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421
   Schraml P, 2012, ONCOL REP, V28, P654, DOI 10.3892/or.2012.1826
   Srivenugopal KS, 1996, BIOCHEMISTRY-US, V35, P1328, DOI 10.1021/bi9518205
   Tseng LM, 2013, NEOPLASMA, V60, P290, DOI 10.4149/neo_2013_038
   von Minckwitz G, 2012, ANN ONCOL, V23, P35, DOI 10.1093/annonc/mds193
   von Minckwitz G, 2011, BREAST CANCER RES TR, V125, P145, DOI 10.1007/s10549-010-1228-x
   Yagata H, 2011, BREAST CANCER-TOKYO, V18, P165, DOI 10.1007/s12282-011-0254-9
NR 36
TC 9
Z9 10
U1 0
U2 11
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1526-8209
EI 1938-0666
J9 CLIN BREAST CANCER
JI Clin. Breast Cancer
PD AUG
PY 2014
VL 14
IS 4
BP 285
EP 290
DI 10.1016/j.clbc.2014.02.010
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AL9PM
UT WOS:000339473200010
PM 24709436
DA 2025-01-12
ER

PT J
AU Kobori, T
   Harada, S
   Nakamoto, K
   Tokuyama, S
AF Kobori, Takuro
   Harada, Shinichi
   Nakamoto, Kazuo
   Tokuyama, Shogo
TI Mechanisms of P-Glycoprotein Alteration During Anticancer Treatment:
   Role in the Pharmacokinetic and Pharmacological Effects of Various
   Substrate Drugs
SO JOURNAL OF PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE P-glycoprotein; anticancer drug; drug-drug interaction; opioid; cancer
ID CANCER RESISTANCE PROTEIN; BLOOD-BRAIN-BARRIER; ORAL MORPHINE ANALGESIA;
   CENTRAL-NERVOUS-SYSTEM; ERM-FAMILY PROTEINS; HUMAN MDR1 GENE;
   MULTIDRUG-RESISTANCE; BREAST-CANCER; INTESTINAL-ABSORPTION;
   CYTOCHROME-P450 3A4
AB In clinical pharmacotherapy, therapeutic benefits and adverse effects of medicines differ substantially between individuals and are often determined by their blood levels. Critical regulators influencing the pharmacokinetics and pharmacodynamics of drugs include drug transporters and drug-metabolizing enzymes. Among these, we have focused on P-glycoprotein (P-gp), a drug efflux transporter. A growing body of evidence indicates that the expression and functional activity of P-gp are altered under several pathological conditions, by exposure to substrate drugs of P-gp, and by ingestion of certain foods. In this critical review, we discuss the mechanisms by which anticancer drugs, most of which are P-gp substrates, alter the expression and functional activity of P-gp in tumors and normal tissues after chronic treatment. Accumulating evidence shows that various transcription factors, in addition to epigenetic and post-translational factors, modulate P-gp expression, which alters the pharmacokinetics and pharmacological effects of drugs. Therefore, it is important to consider individual patients with regard to drug-taking history, as well as levels of P-gp expression and function, when providing clinical pharmacotherapy.
C1 [Kobori, Takuro; Harada, Shinichi; Nakamoto, Kazuo; Tokuyama, Shogo] Kobe Gakuin Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Chuo Ku, Kobe, Hyogo 6508586, Japan.
C3 Kobe Gakuin University
RP Tokuyama, S (通讯作者)，Kobe Gakuin Univ, Sch Pharmaceut Sci, Dept Clin Pharm, Chuo Ku, 1-1-3 Minatojima, Kobe, Hyogo 6508586, Japan.
EM stoku@pharm.Kobegakuin.ac.jp
RI Kobori, Takuro/AGE-7570-2022
OI Kobori, Takuro/0000-0001-9489-5826
CR Abe T, 2001, GASTROENTEROLOGY, V120, P1689, DOI 10.1053/gast.2001.24804
   Abolhoda A, 1999, CLIN CANCER RES, V5, P3352
   Advani R, 2001, CLIN CANCER RES, V7, P1221
   Allen JD, 2003, CANCER RES, V63, P1339
   Arumugam P, 2013, J GASTROINTEST SURG, V17, P2082, DOI 10.1007/s11605-013-2384-1
   Ayrton A, 2001, XENOBIOTICA, V31, P469, DOI 10.1080/00498250110060969
   Bachmeier C, 2013, J PHARM SCI-US, V102, P3838, DOI 10.1002/jps.23680
   Baker EK, 2004, CANCER BIOL THER, V3, P819, DOI 10.4161/cbt.3.9.1101
   Baker EK, 2003, EXP CELL RES, V290, P177, DOI 10.1016/S0014-4827(03)00342-2
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Bandieri E, 2012, ANN ONCOL, V23, P2016, DOI 10.1093/annonc/mds103
   Benjamin L, 2012, EUR J CANCER, V48, P912, DOI 10.1016/j.ejca.2011.09.019
   Berggren S, 2007, MOL PHARM, V4, P252, DOI 10.1021/mp0600687
   Boote DJ, 1996, J CLIN ONCOL, V14, P610, DOI 10.1200/JCO.1996.14.2.610
   Brambilla D, 2012, INT J CANCER, V130, P2824, DOI 10.1002/ijc.26285
   Bridges JFP, 2012, LUNG CANCER, V77, P224, DOI 10.1016/j.lungcan.2012.01.016
   CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361
   Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795
   Cornwell M M, 1991, Cancer Treat Res, V57, P37
   Dagenais C, 2004, BIOCHEM PHARMACOL, V67, P269, DOI 10.1016/j.bcp.2003.08.027
   De Gregori S, 2012, METAB BRAIN DIS, V27, P1, DOI 10.1007/s11011-011-9274-6
   Deferme S, 2003, J PHARM PHARMACOL, V55, P153, DOI 10.1211/002235702603
   Demeule M, 1999, FEBS LETT, V442, P208, DOI 10.1016/S0014-5793(98)01663-9
   Doran A, 2005, DRUG METAB DISPOS, V33, P165, DOI 10.1124/dmd.104.001230
   Doublier S, 2008, MOL CANCER RES, V6, P1607, DOI 10.1158/1541-7786.MCR-08-0251
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Eyal S, 2006, BRIT J PHARMACOL, V149, P250, DOI 10.1038/sj.bjp.0706830
   Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866
   FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265
   Fracasso PM, 2000, J CLIN ONCOL, V18, P1124, DOI 10.1200/JCO.2000.18.5.1124
   Fujita T, 2005, CLIN CANCER RES, V11, P8837, DOI 10.1158/1078-0432.CCR-05-0945
   Fujita-Hamabe W, 2012, J PHARM PHARMACOL, V64, P496, DOI 10.1111/j.2042-7158.2011.01426.x
   Garcia-Manero G, 2002, CLIN CANCER RES, V8, P1897
   García-Martín E, 2006, PHARMACOGENOMICS, V7, P575, DOI 10.2217/14622416.7.4.575
   Geick A, 2001, J BIOL CHEM, V276, P14581, DOI 10.1074/jbc.M010173200
   GEKELER V, 1988, BIOCHEM BIOPH RES CO, V155, P754, DOI 10.1016/S0006-291X(88)80559-X
   Glare P, 2011, J PEDIAT HEMATOL ONC, V33, pS6, DOI 10.1097/MPH.0b013e3182121a2b
   Greiner B, 1999, J CLIN INVEST, V104, P147, DOI 10.1172/JCI6663
   Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/fmc.12.3, 10.4155/FMC.12.3]
   Halon A, 2013, CELL ONCOL, V36, P181, DOI 10.1007/s13402-013-0125-9
   Hamabe W, 2007, J PHARMACOL SCI, V105, P353, DOI 10.1254/jphs.FP0071287
   Hamabe W, 2006, PHARMACOL BIOCHEM BE, V85, P629, DOI 10.1016/j.pbb.2006.10.018
   Hamman MA, 2001, CLIN PHARMACOL THER, V69, P114, DOI 10.1067/mcp.2001.113697
   Harmsen S, 2009, CANCER CHEMOTH PHARM, V64, P35, DOI 10.1007/s00280-008-0842-3
   Hartz AMS, 2010, MOL PHARMACOL, V77, P715, DOI 10.1124/mol.109.061754
   Hasegawa M, 2011, MOL PHARMACOL, V80, P518, DOI 10.1124/mol.111.071845
   Hassan HE, 2007, J PHARM SCI-US, V96, P2494, DOI 10.1002/jps.20893
   Henthorn TK, 1999, J PHARMACOL EXP THER, V289, P1084
   Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397
   HU XF, 1995, BRIT J CANCER, V71, P931, DOI 10.1038/bjc.1995.180
   Huang Y, 2000, CANCER RES, V60, P4426
   Ieiri I, 2006, EXPERT OPIN DRUG MET, V2, P651, DOI 10.1517/17425255.2.5.651
   Jonker JW, 2000, JNCI-J NATL CANCER I, V92, P1651, DOI 10.1093/jnci/92.20.1651
   JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7
   KANAMARU H, 1989, JNCI-J NATL CANCER I, V81, P844, DOI 10.1093/jnci/81.11.844
   Kano T, 2011, J PHARM SCI-US, V100, P5308, DOI 10.1002/jps.22718
   Kawabata S, 2001, BIOCHEM BIOPH RES CO, V280, P1216, DOI 10.1006/bbrc.2001.4267
   Kerbusch T, 2001, CLIN PHARMACOL THER, V70, P132, DOI 10.1067/mcp.2001.117283
   Kharasch ED, 2004, J CLIN PHARMACOL, V44, P224, DOI 10.1177/0091270003262075
   Kharasch ED, 2003, CLIN PHARMACOL THER, V74, P543, DOI 10.1016/j.clpt.2003.08.011
   Kim SN, 2009, MOL CANCER RES, V7, P735, DOI 10.1158/1541-7786.MCR-08-0296
   Kobori T, 2014, J PHARM SCI-US, V103, P743, DOI 10.1002/jps.23811
   Kobori T, 2013, BIOL PHARM BULL, V36, P1822
   Kobori T, 2013, BIOL PHARM BULL, V36, P1381
   Kobori T, 2013, J PHARM SCI-US, V102, P1670, DOI 10.1002/jps.23503
   Kobori T, 2013, J PHARM SCI-US, V102, P1095, DOI 10.1002/jps.23441
   Kobori T, 2012, EUR J PHARM SCI, V47, P934, DOI 10.1016/j.ejps.2012.08.019
   Kojima H, 2003, J HEPATOL, V39, P693, DOI 10.1016/S0168-8278(03)00410-0
   Kojima H, 2008, J GASTROEN HEPATOL, V23, pE120, DOI 10.1111/j.1440-1746.2007.05109.x
   Lagas JS, 2010, MOL CANCER THER, V9, P319, DOI 10.1158/1535-7163.MCT-09-0663
   Lin JH, 2003, ADV DRUG DELIVER REV, V55, P53, DOI 10.1016/S0169-409X(02)00171-0
   Linnet K, 2008, EUR NEUROPSYCHOPHARM, V18, P157, DOI 10.1016/j.euroneuro.2007.06.003
   Liukas A, 2011, J CLIN PSYCHOPHARM, V31, P302, DOI 10.1097/JCP.0b013e3182189892
   Lötsch J, 2001, CLIN PHARMACOKINET, V40, P485
   Luciani F, 2002, BLOOD, V99, P641, DOI 10.1182/blood.V99.2.641
   Marchetti S, 2008, MOL CANCER THER, V7, P2280, DOI 10.1158/1535-7163.MCT-07-2250
   Marchetti S, 2007, ONCOLOGIST, V12, P927, DOI 10.1634/theoncologist.12-8-927
   Masuda S, 2000, CLIN PHARMACOL THER, V68, P98, DOI 10.1067/mcp.2000.107912
   Mikkaichi Tsuyoshi, 2004, Drug Metab Pharmacokinet, V19, P171, DOI 10.2133/dmpk.19.171
   Miller DS, 2008, PHARMACOL REV, V60, P196, DOI 10.1124/pr.107.07109
   Miller DS, 2010, TRENDS PHARMACOL SCI, V31, P246, DOI 10.1016/j.tips.2010.03.003
   Milne RW, 1996, DRUG METAB REV, V28, P345, DOI 10.3109/03602539608994011
   Mizuno N, 2003, PHARMACOL REV, V55, P425, DOI 10.1124/pr.55.3.1
   Mizuno Naomi, 2002, Drug Metab Pharmacokinet, V17, P93, DOI 10.2133/dmpk.17.93
   Nakagawa M, 1997, J UROLOGY, V157, P1260, DOI 10.1016/S0022-5347(01)64944-9
   Nakano T, 2013, AM J PHYSIOL-GASTR L, V305, pG807, DOI 10.1152/ajpgi.00187.2013
   Nakayama M, 1998, BLOOD, V92, P4296, DOI 10.1182/blood.V92.11.4296.423k25_4296_4307
   Nallani SC, 2004, CANCER CHEMOTH PHARM, V54, P219, DOI 10.1007/s00280-004-0799-9
   Nawa A, 2012, DRUG METAB PHARMACOK, V27, P548, DOI 10.2133/dmpk.DMPK-11-NT-152
   Nawa A, 2011, LIFE SCI, V89, P834, DOI 10.1016/j.lfs.2011.08.019
   Nawa A, 2010, LIFE SCI, V86, P402, DOI 10.1016/j.lfs.2010.01.009
   Oda Y, 1998, CLIN CANCER RES, V4, P2273
   Ogihara T, 2006, DRUG METAB PHARMACOK, V21, P238, DOI 10.2133/dmpk.21.238
   Riganti C, 2006, INT J CANCER, V119, P17, DOI 10.1002/ijc.21832
   Rochat B, 2005, CLIN PHARMACOKINET, V44, P349, DOI 10.2165/00003088-200544040-00002
   Ruddy K, 2009, CA-CANCER J CLIN, V59, P56, DOI 10.3322/caac.20004
   Sachs CW, 1999, BIOCHEM PHARMACOL, V58, P1587, DOI 10.1016/S0006-2952(99)00240-3
   Saglio G, 2010, NEW ENGL J MED, V362, P2251, DOI 10.1056/NEJMoa0912614
   Schinkel AH, 2003, ADV DRUG DELIVER REV, V55, P3, DOI 10.1016/S0169-409X(02)00169-2
   Scotto K W, 2001, Mol Interv, V1, P117
   Shiota K, 2004, CYTOGENET GENOME RES, V105, P325, DOI 10.1159/000078205
   Skarke C, 2003, CLIN PHARMACOL THER, V74, P303, DOI 10.1016/S0009-9236(03)00220-0
   Sparreboom A, 1997, P NATL ACAD SCI USA, V94, P2031, DOI 10.1073/pnas.94.5.2031
   Stadler P, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-279
   Statistics and Information Department, VIT STAT JAP 2013
   Stuurman FE, 2013, CLIN PHARMACOKINET, V52, P399, DOI 10.1007/s40262-013-0040-2
   Suzuki H, 2000, EUR J PHARM SCI, V12, P3, DOI 10.1016/S0928-0987(00)00178-0
   Tada Y, 2002, INT J CANCER, V98, P630, DOI 10.1002/ijc.10246
   Tada Y, 2000, CLIN CANCER RES, V6, P4618
   Tada Y, MOCHIDA CHANGES P GP
   Temel JS, 2010, NEW ENGL J MED, V363, P733, DOI 10.1056/NEJMoa1000678
   Thomas Hilary, 2003, Cancer Control, V10, P159
   Toffoli G, 2004, CLIN PHARMACOKINET, V43, P441, DOI 10.2165/00003088-200443070-00002
   Tokuyama S, 2014, JPN J PHARM HLTH CAR, V40, P193
   UEDA K, 1987, P NATL ACAD SCI USA, V84, P3004, DOI 10.1073/pnas.84.9.3004
   Vlaming MLH, 2009, ADV DRUG DELIVER REV, V61, P14, DOI 10.1016/j.addr.2008.08.007
   Walker LG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-179
   Wang S, 2014, J NEUROL SCI, V338, P71, DOI 10.1016/j.jns.2013.12.019
   Westphal K, 2000, CLIN PHARMACOL THER, V68, P345, DOI 10.1067/mcp.2000.109797
   Wojtal KA, 2006, MOL BIOL CELL, V17, P3638, DOI 10.1091/mbc.E06-03-0230
   Xie RJ, 1999, BRIT J PHARMACOL, V128, P563, DOI 10.1038/sj.bjp.0702804
   Yano K, 2013, J PHARM SCI-US, V102, P2875, DOI 10.1002/jps.23637
   Zhang L, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0052384, 10.1371/journal.pone.0066569]
   Zhang ZG, 2004, MOL PHARMACOL, V66, P395, DOI 10.1124/mol.104.001966
   Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174
NR 126
TC 23
Z9 26
U1 0
U2 14
PU JAPANESE PHARMACOLOGICAL SOC
PI KYOTO
PA EDITORIAL OFF, KANTOHYA BLDG GOKOMACHI-EBISUGAWA NAKAGYO-KU, KYOTO, 604,
   JAPAN
SN 1347-8613
EI 1347-8648
J9 J PHARMACOL SCI
JI J. Pharmacol. Sci.
PD JUL
PY 2014
VL 125
IS 3
BP 242
EP 254
DI 10.1254/jphs.14R01CR
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AL9IS
UT WOS:000339455400002
PM 24989947
OA Bronze
DA 2025-01-12
ER

PT J
AU Yap, YS
   McPherson, JR
   Ong, CK
   Rozen, SG
   Teh, BT
   Lee, ASG
   Callen, DF
AF Yap, Yoon-Sim
   McPherson, John R.
   Ong, Choon-Kiat
   Rozen, Steven G.
   Teh, Bin-Tean
   Lee, Ann S. G.
   Callen, David F.
TI The <i>NF1</i> gene revisited - from bench to bedside
SO ONCOTARGET
LA English
DT Article
DE neurofibromatosis type 1; NF1; neurofibromin; cancer
ID NEUROFIBROMATOSIS TYPE-1 GENE; PHASE-I TRIAL; FARNESYLTRANSFERASE
   INHIBITOR TIPIFARNIB; JUVENILE MYELOMONOCYTIC LEUKEMIA; INTEGRATED
   GENOMIC ANALYSIS; LOSS-OF-HETEROZYGOSITY; NERVE SHEATH TUMORS;
   SOFT-TISSUE SARCOMA; GAP-RELATED DOMAIN; BREAST-CANCER
AB Neurofibromatosis type 1 (NF1) is a relatively common tumour predisposition syndrome related to germline aberrations of NF1, a tumour suppressor gene. The gene product neurofibromin is a negative regulator of the Ras cellular proliferation pathway, and also exerts tumour suppression via other mechanisms.
   Recent next-generation sequencing projects have revealed somatic NF1 aberrations in various sporadic tumours. NF1 plays a critical role in a wide range of tumours. NF1 alterations appear to be associated with resistance to therapy and adverse outcomes in several tumour types.
   Identification of a patient's germline or somatic NF1 aberrations can be challenging, as NF1 is one of the largest human genes, with a myriad of possible mutations. Epigenetic factors may also contribute to inadequate levels of neurofibromin in cancer cells.
   Clinical trials of NF1-based therapeutic approaches are currently limited. Preclinical studies on neurofibromin-deficient malignancies have mainly been on malignant peripheral nerve sheath tumour cell lines or xenografts derived from NF1 patients. However, the emerging recognition of the role of NF1 in sporadic cancers may lead to the development of NF1-based treatments for other tumour types. Improved understanding of the implications of NF1 aberrations is critical for the development of novel therapeutic strategies.
C1 [Yap, Yoon-Sim] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore.
   [Yap, Yoon-Sim] Univ Adelaide, Sch Med, Fac Hlth Sci, Adelaide, SA 5005, Australia.
   [McPherson, John R.; Rozen, Steven G.] Duke Natl Univ Singapore Grad Sch Med, Ctr Computat Biol, Canc & Stem Cell Biol Program, Singapore, Singapore.
   [Ong, Choon-Kiat; Teh, Bin-Tean] Natl Canc Ctr Singapore, Div Med Sci, Lab Canc Epigenome, Singapore, Singapore.
   [Ong, Choon-Kiat; Teh, Bin-Tean] Duke Natl Univ Singapore Grad Med Sch, Div Canc & Stem Cell Biol, Singapore, Singapore.
   [Teh, Bin-Tean] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore 117548, Singapore.
   [Lee, Ann S. G.] Natl Canc Ctr Singapore, Mol Oncol Lab, Div Med Sci, Singapore, Singapore.
   [Lee, Ann S. G.] Duke Natl Univ Singapore Grad Med Sch, Off Clin & Acad Fac Affairs, Singapore, Singapore.
   [Lee, Ann S. G.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore.
   [Callen, David F.] Univ Adelaide, Canc Therapeut Lab, Ctr Personalised Canc Med, Adelaide, SA 5005, Australia.
C3 National Cancer Centre Singapore (NCCS); University of Adelaide;
   National Cancer Centre Singapore (NCCS); National University of
   Singapore; National University of Singapore; National Cancer Centre
   Singapore (NCCS); National University of Singapore; National University
   of Singapore; University of Adelaide
RP Yap, YS (通讯作者)，Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore.
EM Yap.Y.S@nccs.com.sg
RI Callen, David/G-1975-2012; Ong, Choon Kiat/IXN-7059-2023; Lee,
   ann/JFS-5133-2023; Rozen, Steven G./J-5939-2013
OI Callen, David/0000-0002-6189-9991; Ong, Choon Kiat/0000-0001-6402-4288;
   Teh, Bin Tean/0000-0003-1514-1124; Rozen, Steven G./0000-0002-4288-0056;
   Yap, Yoon-Sim/0000-0002-0347-5066
FU SingHealth Foundation Research Grant, Singapore [SHF/FG426S/2009]
FX This work was supported in part by SingHealth Foundation Research Grant,
   Singapore (SHF/FG426S/2009).
CR Ahlquist T, 2008, NEOPLASIA, V10, P680, DOI 10.1593/neo.08312
   ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487
   ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118
   [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007
   Arima Y, 2010, EXP DERMATOL, V19, pE136, DOI 10.1111/j.1600-0625.2009.01017.x
   Ars E, 2000, HUM MOL GENET, V9, P237, DOI 10.1093/hmg/9.2.237
   Babovic-Vuksanovic D, 2006, NEUROLOGY, V67, P1860, DOI 10.1212/01.wnl.0000243231.12248.67
   Babovic-Vuksanovic D, 2007, PEDIATR NEUROL, V36, P293, DOI 10.1016/j.pediatrneurol.2007.01.009
   Balgobind BV, 2008, BLOOD, V111, P4322, DOI 10.1182/blood-2007-06-095075
   BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4
   Banerjee S, 2010, CANCER RES, V70, P1356, DOI 10.1158/0008-5472.CAN-09-2178
   Barkan B, 2006, CLIN CANCER RES, V12, P5533, DOI 10.1158/1078-0432.CCR-06-0792
   Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619
   Bausch B, 2007, J CLIN ENDOCR METAB, V92, P2784, DOI 10.1210/jc.2006-2833
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bhola P, 2010, INT J CANCER, V126, P563, DOI 10.1002/ijc.24783
   BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0
   Boudry-Labis E, 2013, AM J HEMATOL, V88, P306, DOI 10.1002/ajh.23403
   Boyanapalli M, 2006, BIOCHEM BIOPH RES CO, V340, P1200, DOI 10.1016/j.bbrc.2005.12.129
   BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019
   Brems H, 2009, LANCET ONCOL, V10, P508, DOI 10.1016/S1470-2045(09)70033-6
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Brosius S, 2010, J HIST NEUROSCI, V19, P333, DOI 10.1080/09647041003642885
   Brown JA, 2010, J NEUROSCI, V30, P5579, DOI 10.1523/JNEUROSCI.3994-09.2010
   Burnichon N, 2012, HUM MOL GENET, V21, P5397, DOI 10.1093/hmg/dds374
   Cacev T, 2005, GUT, V54, P1129, DOI 10.1136/gut.2004.053348
   Valero MC, 2011, J MOL DIAGN, V13, P113, DOI 10.1016/j.jmoldx.2010.09.002
   CAWKWELL L, 1994, BRIT J CANCER, V70, P813, DOI 10.1038/bjc.1994.404
   CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B
   CAWTHON RM, 1991, GENOMICS, V9, P446, DOI 10.1016/0888-7543(91)90410-G
   Chao RC, 2005, CANCER CELL, V8, P337, DOI 10.1016/j.ccr.2005.08.011
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Choi G, 2012, CANCER RES, V72, P6425, DOI 10.1158/0008-5472.CAN-12-1728
   Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172
   Dai CK, 2012, J CLIN INVEST, V122, P3742, DOI 10.1172/JCI62727
   DANGLOT G, 1995, HUM MOL GENET, V4, P915, DOI 10.1093/hmg/4.5.915
   Dasgupta B, 2003, J NEUROSCI, V23, P8949
   De Bruin E.C, 2014, CANC DISCOV
   De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Dodd RD, 2013, MOL CANCER THER, V12, P1906, DOI 10.1158/1535-7163.MCT-13-0189
   DUCATMAN BS, 1986, CANCER-AM CANCER SOC, V57, P2006, DOI 10.1002/1097-0142(19860515)57:10<2006::AID-CNCR2820571022>3.0.CO;2-6
   Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842
   EASTON DF, 1993, AM J HUM GENET, V53, P305
   Eisenbarth I, 2000, AM J HUM GENET, V66, P393, DOI 10.1086/302747
   Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067
   Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809
   Ferner RE, 2002, CANCER RES, V62, P1573
   Flotho C, 2007, ONCOGENE, V26, P5816, DOI 10.1038/sj.onc.1210361
   GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111
   Gregorian C, 2009, P NATL ACAD SCI USA, V106, P19479, DOI 10.1073/pnas.0910398106
   Griffiths S, 2007, FAM CANCER, V6, P21, DOI 10.1007/s10689-006-9001-3
   Grisart B, 2008, EUR J HUM GENET, V16, P305, DOI 10.1038/sj.ejhg.5201978
   Gupta A, 2003, NEUROLOGY, V60, P130, DOI 10.1212/01.WNL.0000042321.94839.78
   Gutmann DH, 2013, GENOME RES, V23, P431, DOI 10.1101/gr.142604.112
   GUTMANN DH, 1994, GENE CHROMOSOME CANC, V10, P55, DOI 10.1002/gcc.2870100109
   Gutmann DH, 1999, ONCOGENE, V18, P4450, DOI 10.1038/sj.onc.1202829
   Gutmann DH, 1999, ANN NEUROL, V46, P777, DOI 10.1002/1531-8249(199911)46:5<777::AID-ANA15>3.0.CO;2-H
   Gutmann DH, 2002, NEOPLASIA, V4, P279, DOI 10.1038/sj.neo.7900249
   GUTMANN DH, 1995, DEV DYNAM, V202, P302, DOI 10.1002/aja.1002020309
   Haferlach C, 2010, LEUKEMIA, V24, P1065, DOI 10.1038/leu.2010.22
   Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Hirokawa Y, 2007, CANCER LETT, V245, P242, DOI 10.1016/j.canlet.2006.01.018
   Hirokawa Y, 2006, CANCER BIOL THER, V5, P305, DOI 10.4161/cbt.5.3.2404
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Hollstein PE, 2013, CANCER DISCOV, V3, P880, DOI 10.1158/2159-8290.CD-13-0146
   Hsueh YP, 2001, J NEUROSCI, V21, P3764, DOI 10.1523/JNEUROSCI.21-11-03764.2001
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Iyengar TD, 1999, ONCOGENE, V18, P257, DOI 10.1038/sj.onc.1202294
   JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353
   Jakacki RI, 2011, NEUROLOGY, V76, P265, DOI 10.1212/WNL.0b013e318207b031
   Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578
   Johannessen CM, 2005, P NATL ACAD SCI USA, V102, P8573, DOI 10.1073/pnas.0503224102
   Johansson G, 2008, MOL CANCER THER, V7, P1237, DOI 10.1158/1535-7163.MCT-07-2335
   John AM, 2000, J MED GENET, V37, P44, DOI 10.1136/jmg.37.1.44
   JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539
   Kaufmann D, 2002, BIOCHEM BIOPH RES CO, V294, P496, DOI 10.1016/S0006-291X(02)00501-6
   Kim A, 2013, PEDIATR BLOOD CANCER, V60, P396, DOI 10.1002/pbc.24281
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kolquist KA, 2011, CANCER GENET-NY, V204, P603, DOI 10.1016/j.cancergen.2011.10.004
   Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359
   Kweh F, 2009, MOL CARCINOGEN, V48, P1005, DOI 10.1002/mc.20552
   Larizza L, 2009, CURR MOL MED, V9, P634, DOI 10.2174/156652409788488801
   Lasater EA, 2008, HUM MOL GENET, V17, P2336, DOI 10.1093/hmg/ddn134
   Lauchle JO, 2009, NATURE, V461, P411, DOI 10.1038/nature08279
   Laycock-van Spyk Sebastian, 2011, Human Genomics, V5, P623
   Lee J, 2010, CANCER GENET CYTOGEN, V196, P179, DOI 10.1016/j.cancergencyto.2009.09.005
   LEGGETT B, 1995, BRIT J CANCER, V71, P1070, DOI 10.1038/bjc.1995.206
   LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122
   LEGIUS E, 1994, GENE CHROMOSOME CANC, V10, P250, DOI 10.1002/gcc.2870100405
   Lenarduzzi M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053765
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Li HZ, 2002, CANCER RES, V62, P4507
   LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5
   LI Y, 1995, GENOMICS, V25, P9, DOI 10.1016/0888-7543(95)80104-T
   Luijten M, 2000, EUR J HUM GENET, V8, P209, DOI 10.1038/sj.ejhg.5200434
   Maertens O, 2006, HUM MOL GENET, V15, P1015, DOI 10.1093/hmg/ddl016
   Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313
   Mangoura D, 2006, ONCOGENE, V25, P735, DOI 10.1038/sj.onc.1209113
   Mar VJ, 2013, CLIN CANCER RES, V19, P4589, DOI 10.1158/1078-0432.CCR-13-0398
   Marrero D, 2012, J CLIN PATHOL, V65, P419, DOI 10.1136/jclinpath-2011-200569
   MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D
   Martín Y, 2011, EXPERT REV MOL DIAGN, V11, P671, DOI [10.1586/erm.11.52, 10.1586/ERM.11.52]
   Martinsson T, 1997, CANCER GENET CYTOGEN, V95, P183, DOI 10.1016/S0165-4608(96)00259-2
   Mashiach-Farkash E, 2012, ONCOTARGET, V3, P629
   Mattocks C, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011890
   McGillicuddy LT, 2009, CANCER CELL, V16, P44, DOI 10.1016/j.ccr.2009.05.009
   Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108
   Messiaen LM, 2000, HUM MUTAT, V15, P541, DOI 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N
   Misawa Shinichi, 1997, Leukemia (Basingstoke), V11, P533
   Moles KJ, 2012, GENET MED, V14, P508, DOI 10.1038/gim.2011.46
   Mussi C, 2008, CLIN CANCER RES, V14, P4550, DOI 10.1158/1078-0432.CCR-08-0086
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nakamura JL, 2011, CANCER RES, V71, P106, DOI 10.1158/0008-5472.CAN-10-2732
   Nielsen GP, 1999, AM J PATHOL, V155, P1879, DOI 10.1016/S0002-9440(10)65507-1
   NORDLUND M, 1993, J NEUROSCI, V13, P1588
   Ogata H, 2001, CANCER LETT, V172, P159, DOI 10.1016/S0304-3835(01)00648-6
   Origone P, 2003, AM J MED GENET A, V118A, P309, DOI 10.1002/ajmg.a.10167
   Ozawa T, 2005, J BIOL CHEM, V280, P39524, DOI 10.1074/jbc.M503707200
   Packer RJ, 2002, NEUROLOGY, V58, P1461, DOI 10.1212/WNL.58.10.1461
   Parkin B, 2010, CLIN CANCER RES, V16, P4135, DOI 10.1158/1078-0432.CCR-09-2639
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Pasmant E, 2012, J MED GENET, V49, P483, DOI 10.1136/jmedgenet-2012-100978
   Patel AV, 2012, CLIN CANCER RES, V18, P5020, DOI 10.1158/1078-0432.CCR-12-1072
   Patil S, 2012, ONCOLOGIST, V17, P101, DOI 10.1634/theoncologist.2010-0181
   Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864
   Peifer M, 2012, NAT GENET, V44, P1104, DOI 10.1038/ng.2396
   Pemov A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-194
   Petrilli AM, 2013, ONCOTARGET, V4, P2354, DOI 10.18632/oncotarget.1422
   Purandare SM, 1995, GENOMICS, V30, P476, DOI 10.1006/geno.1995.1268
   Rak R, 2014, CELL CYCLE, V13, P1360, DOI 10.4161/cc.28748
   Rasmussen SA, 2000, GENE CHROMOSOME CANC, V28, P425, DOI 10.1002/1098-2264(200008)28:4<425::AID-GCC8>3.3.CO;2-5
   Rasmussen SA, 2000, AM J EPIDEMIOL, V151, P33, DOI 10.1093/oxfordjournals.aje.a010118
   Reinholz MM, 2009, LANCET ONCOL, V10, P267, DOI 10.1016/S1470-2045(09)70063-4
   RICCARDI V M, 1989, Neurofibromatosis, V2, P152
   Robertson KA, 2012, LANCET ONCOL, V13, P1218, DOI 10.1016/S1470-2045(12)70414-X
   Roth TM, 2008, AM J MED GENET A, V146A, P1624, DOI 10.1002/ajmg.a.32301
   Rudin CM, 2012, NAT GENET, V44, P1111, DOI 10.1038/ng.2405
   Sabbagh A, 2013, HUM MUTAT, V34, P1510, DOI 10.1002/humu.22392
   Sangha N, 2008, NEOPLASIA, V10, P1362, DOI 10.1593/neo.08784
   Schroeder RD, 2014, ONCOTARGET, V5, P67, DOI 10.18632/oncotarget.1557
   Sedani A, 2012, HUM GENOMICS, V6, DOI 10.1186/1479-7364-6-23
   See WL, 2012, CANCER RES, V72, P3350, DOI 10.1158/0008-5472.CAN-12-0334
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shapira S, 2007, CELL DEATH DIFFER, V14, P895, DOI 10.1038/sj.cdd.4402057
   Sharif S, 2007, J MED GENET, V44, P481, DOI 10.1136/jmg.2007.049346
   Sharif S, 2006, J CLIN ONCOL, V24, P2570, DOI 10.1200/JCO.2005.03.8349
   Shen R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035236
   SORENSEN SA, 1986, NEW ENGL J MED, V314, P1010, DOI 10.1056/NEJM198604173141603
   Steinemann D, 2010, HAEMATOL-HEMATOL J, V95, P320, DOI 10.3324/haematol.2009.010355
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Stewart W, 2007, FAM CANCER, V6, P147, DOI 10.1007/s10689-006-9002-2
   STILLER CA, 1994, BRIT J CANCER, V70, P969, DOI 10.1038/bjc.1994.431
   Sung L, 2004, J PEDIATR-US, V144, P666, DOI 10.1016/j.jpeds.2004.02.026
   SUZUKI H, 1992, BIOCHEM BIOPH RES CO, V187, P984, DOI 10.1016/0006-291X(92)91294-Z
   Teh BT, 1997, BREAST, V6, P155, DOI 10.1016/S0960-9776(97)90558-0
   Teschendorff AE, 2007, PLOS COMPUT BIOL, V3, P1539, DOI 10.1371/journal.pcbi.0030161
   Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792
   UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4
   Upadhyaya M, 2007, AM J HUM GENET, V80, P140, DOI 10.1086/510781
   Upadhyaya M, 1998, HUM GENET, V102, P591, DOI 10.1007/s004390050746
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   VISKOCHIL D, 1991, MOL CELL BIOL, V11, P906, DOI 10.1128/MCB.11.2.906
   Wagle N, 2012, CANCER DISCOV, V2, P82, DOI 10.1158/2159-8290.CD-11-0184
   Wallace MD, 2012, GENETICS, V192, P385, DOI 10.1534/genetics.112.142802
   WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734
   Wang X, 2012, AM J MED GENET A, V158A, P3061, DOI 10.1002/ajmg.a.35560
   Ward AF, 2012, BLOOD, V120, P3397, DOI 10.1182/blood-2012-05-378596
   Weiss B, 2014, PEDIATR BLOOD CANCER, V61, P982, DOI 10.1002/pbc.24873
   Welander J, 2012, HUM MOL GENET, V21, P5406, DOI 10.1093/hmg/dds402
   Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470
   Widemann BC, 2006, J CLIN ONCOL, V24, P507, DOI 10.1200/JCO.2005.03.8638
   Widemann BC, 2014, NEURO-ONCOLOGY, V16, P707, DOI 10.1093/neuonc/nou004
   Wu M, 2006, ONCOGENE, V25, P2297, DOI 10.1038/sj.onc.1209264
   XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9
   Xu HM, 1997, BRAIN RES, V759, P149, DOI 10.1016/S0006-8993(97)00328-4
   XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411
   Yang FC, 2008, CELL, V135, P437, DOI 10.1016/j.cell.2008.08.041
   Yap YS, 2012, CANCER RES, V72, DOI 10.1158/0008-5472.SABCS12-P3-08-09
   Yu HJ, 2005, HUM MUTAT, V26, P487, DOI 10.1002/humu.20246
   Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725
   Zhu Y, 2002, SCIENCE, V296, P920, DOI 10.1126/science.1068452
   Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004
   Zoller MET, 1997, CANCER-AM CANCER SOC, V79, P2125
   Zou CYY, 2009, MOL CANCER THER, V8, P1157, DOI 10.1158/1535-7163.MCT-08-1008
NR 186
TC 124
Z9 143
U1 1
U2 13
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 15
PY 2014
VL 5
IS 15
BP 5873
EP 5892
DI 10.18632/oncotarget.2194
PG 20
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AZ0EQ
UT WOS:000347919500004
PM 25026295
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Itoh, H
   Iwasaki, M
   Kasuga, Y
   Yokoyama, S
   Onuma, H
   Nishimura, H
   Kusama, R
   Yoshida, T
   Yokoyama, K
   Tsugane, S
AF Itoh, Hiroaki
   Iwasaki, Motoki
   Kasuga, Yoshio
   Yokoyama, Shiro
   Onuma, Hiroshi
   Nishimura, Hideki
   Kusama, Ritsu
   Yoshida, Teruhiko
   Yokoyama, Kazuhito
   Tsugane, Shoichiro
TI Association between serum organochlorines and global methylation level
   of leukocyte DNA among Japanese women: a cross-sectional study
SO SCIENCE OF THE TOTAL ENVIRONMENT
LA English
DT Article
DE Persistent organic pollutants; epidemiology; DNA methylation;
   epigenetics; polychlorinated biphenyl
ID PERSISTENT ORGANIC POLLUTANTS; EPIGENETICS; HYPOMETHYLATION; ASSAY; LUMA
AB While the global methylation level of leukocyte DNA may be a suitable biomarker for cancer risk, the level may be influenced by multiple factors, both environmental and host-related, one of which is exposure to environmental pollutants. To date, three epidemiologic studies have examined associations between serum organochlorine levels and global DNA methylation level, but their findings are not fully consistent, and the associations thus require confirmation in other well-characterized populations. We tested the association between organochlorine exposure and the global DNA methylation level of leukocytes in Japanese women. We conducted a cross-sectional study using the control group of a breast cancer case-control study in Japan. Subjects were 403 Japanese women who provided blood samples. Serum polychlorinated biphenyls (PCBs) and nine pesticiderelated organochlorines were measured by gas chromatography isotope-dilution high-resolution mass spectrometry. Further, global methylation level of peripheral leukocyte DNA among 399 women was measured by luminometric methylation assay. Linear trends in the association between methylation and quartile levels of organochlorines were evaluated by regression coefficients in a multivariable linear regression model. We found significant inverse associations between the global methylation level in leukocyte DNA and many of the organochlorine levels measured. Global methylation level was significantly decreased by 0.33-0.83% per quartile category for serum o, p'-dichlorodiphenyltrichloroethane (o, p'-DDT), p, p'-DDT, p, p'-dichlorodiphenyldichloroethylene, trans-nonachlor, oxychlordane, hexachlorobenzene, beta-hexachlorocyclohexane, PCB17, PCB52/69, PCB74, PCB114, and PCB183. Serum organochlorine levels were inversely associated with the global methylation level of leukocyte DNA in a relatively large sample of Japanese women. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Itoh, Hiroaki; Yokoyama, Kazuhito] Juntendo Univ, Dept Epidemiol & Environm Hlth, Fac Med, Bunkyo Ku, Tokyo 1138421, Japan.
   [Iwasaki, Motoki] Natl Canc Ctr, Div Epidemiol, Res Ctr Canc Prevent & Screening, Chuo Ku, Tokyo 1040045, Japan.
   [Kasuga, Yoshio] Nagano Matsushiro Gen Hosp, Dept Surg, Nagano 3811231, Japan.
   [Yokoyama, Shiro; Onuma, Hiroshi] Nagano Red Cross Hosp, Dept Breast & Thyroid Surg, Nagano 3808582, Japan.
   [Nishimura, Hideki] Nagano Municipal Hosp, Dept Resp Surg & Breast Surg, Nagano 3818551, Japan.
   [Kusama, Ritsu] Hokushin Gen Hosp, Dept Surg, Nagano 3838505, Japan.
   [Yoshida, Teruhiko] Natl Canc Ctr, Res Inst, Div Genet, Chuo Ku, Tokyo 1040045, Japan.
   [Tsugane, Shoichiro] Natl Canc Ctr, Dierctor Res Ctr Canc Prevent & Screening, Chuo Ku, Tokyo 1040045, Japan.
C3 Juntendo University; National Cancer Center - Japan; Nagano Red Cross
   Hospital; National Cancer Center - Japan; National Cancer Center - Japan
RP Iwasaki, M (通讯作者)，Natl Canc Ctr, Div Epidemiol, Res Ctr Canc Prevent & Screening, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM moiwasak@ncc.go.jp
RI Itoh, Hiroaki/AAU-6842-2020; Yoshida, Teruhiko/JGM-7448-2023; Tsugane,
   Shoichiro/A-2424-2015; Yokoyama, Kazuhito/U-3919-2018
OI Itoh, Hiroaki/0000-0001-8441-3934; Yokoyama,
   Kazuhito/0000-0003-3537-5657
FU Ministry of Health, Labour and Welfare of Japan; Program for Promotion
   of Fundamental Studies in Health Sciences of the National Institute of
   Biomedical Innovation (NIBIO); Ministry of Education, Culture, Sports,
   Science, and Technology of Japan [22700934]; Japan Society for the
   Promotion of Science; Foundation for Promotion of Cancer Research in
   Japan; Health and Labour Sciences Research Grant;  [221S0001];
   Grants-in-Aid for Scientific Research [22700934] Funding Source: KAKEN
FX We are deeply grateful to Dr. Hiroe Ono for conducting the DNA
   methylation assay, and Dr. Hiromi Sakamoto for her helpful advice on
   this assay. We also thank Mss. Yoko Odaka and Misuzu Okuyama for
   technical assistance. This study was supported by Grants-in-Aid for the
   Third Term Comprehensive Ten-Year Strategy for Cancer Control and for
   the Research on Applying Health Technology from the Ministry of Health,
   Labour and Welfare of Japan; by the Program for Promotion of Fundamental
   Studies in Health Sciences of the National Institute of Biomedical
   Innovation (NIBIO), by Grants-in-Aid for Scientific Research on
   Innovative Areas (221S0001), and for Young Scientists (B) (22700934)
   from the Ministry of Education, Culture, Sports, Science, and Technology
   of Japan and the Japan Society for the Promotion of Science, and by
   Foundation for Promotion of Cancer Research in Japan. This study was
   also supported by a Health and Labour Sciences Research Grant for
   Research on the Risk of Chemical Substances.
CR Collotta M, 2013, TOXICOLOGY, V307, P35, DOI 10.1016/j.tox.2013.01.017
   Fll, 2002, GUID PLANN EX UPK GR
   Foley DL, 2009, AM J EPIDEMIOL, V169, P389, DOI 10.1093/aje/kwn380
   Gill S.E., 2007, Built Environ, V33, P115, DOI [10.2148/benv.33.1.115, DOI 10.2148/BENV.33.1.115]
   Halsema GEV, 2012, AGR WATER MANAGE, V108, P9
   IARC, 2013, CLASSIFICATION
   Ishihara J, 2006, J EPIDEMIOL, V16, P107, DOI 10.2188/jea.16.107
   Itoh H, 2009, CANCER CAUSE CONTROL, V20, P567, DOI 10.1007/s10552-008-9265-z
   Iwasaki M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-323
   Karimi M, 2006, EPIGENETICS-US, V1, P45
   Karimi M, 2006, EXP CELL RES, V312, P1989, DOI 10.1016/j.yexcr.2006.03.006
   Konishi Y, 2001, ARCH ENVIRON CON TOX, V40, P571, DOI 10.1007/s002440010212
   Konishi Yoshimasa, 2006, Environmental Health and Preventive Medicine, V11, P38, DOI 10.1007/BF02898206
   Lee SK, 2010, ENV HLTH PERSPECT, V118, P370
   Lind L, 2013, ENVIRON INT, V59, P456, DOI 10.1016/j.envint.2013.07.008
   Milbrath MO, 2009, ENVIRON HEALTH PERSP, V117, P417, DOI 10.1289/ehp.11781
   Ono H, 2012, CANCER SCI, V103, P2159, DOI 10.1111/cas.12013
   PHILLIPS DL, 1989, ARCH ENVIRON CON TOX, V18, P495, DOI 10.1007/BF01055015
   Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338
   Sutherland JE, 2003, ANN NY ACAD SCI, V983, P151, DOI 10.1111/j.1749-6632.2003.tb05970.x
   Tsubono Y, 1996, J Epidemiol, V6, P45
   Tsukino H, 2006, SCI TOTAL ENVIRON, V359, P90, DOI 10.1016/j.scitotenv.2005.04.014
   Wilson AS, 2007, BBA-REV CANCER, V1775, P138, DOI 10.1016/j.bbcan.2006.08.007
   Zhang XA, 2011, J MOL ENDOCRINOL, V46, pR11, DOI 10.1677/JME-10-0053
   Zhu ZZ, 2012, INT J EPIDEMIOL, V41, P126, DOI 10.1093/ije/dyq154
NR 25
TC 42
Z9 50
U1 0
U2 18
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0048-9697
EI 1879-1026
J9 SCI TOTAL ENVIRON
JI Sci. Total Environ.
PD AUG 15
PY 2014
VL 490
BP 603
EP 609
DI 10.1016/j.scitotenv.2014.05.035
PG 7
WC Environmental Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Environmental Sciences & Ecology
GA AY0NT
UT WOS:000347293800064
PM 24880549
DA 2025-01-12
ER

PT J
AU Sung, HY
   Choi, EN
   Lyu, D
   Park, AK
   Ju, W
   Ahn, JH
AF Sung, Hye Youn
   Choi, Eun Nam
   Lyu, Dahyun
   Park, Ae Kyung
   Ju, Woong
   Ahn, Jung-Hyuck
TI Aberrant hypomethylation-mediated <i>AGR2</i> overexpression induces an
   aggressive phenotype in ovarian cancer cells
SO ONCOLOGY REPORTS
LA English
DT Article
DE ovarian cancer; metastasis; mouse xenograft; AGR2; DNA methylation
ID PROGNOSTIC-SIGNIFICANCE; ESTROGEN-RECEPTOR; TUMOR-METASTASIS; PROTEIN
   S100A4; BREAST-CANCER; GENE XAG-2; EXPRESSION; INSIGHTS; HAG-2
AB The metastatic properties of cancer cells result from genetic and epigenetic alterations that lead to the abnormal expression of key genes regulating tumor phenotypes. Recent discoveries suggest that aberrant DNA methylation provides cancer cells with advanced metastatic properties; however, the precise regulatory mechanisms controlling metastasis-associated genes and their roles in metastatic transformation are largely unknown. We injected SK-OV-3 human ovarian cancer cells into the perineum of nude mice to generate a mouse model that mimics human ovarian cancer metastasis. We analyzed the mRNA expression and DNA methylation profiles in metastasized tumor tissues in the mice. The pro-oncogenic anterior gradient 2 (AGR2) gene showed increased mRNA expression and hypomethylation at CpG sites in its promoter region in the metastatic tumor tissues compared with the cultured SK-OV-3 cells. We identified crucial cytosine residues at CpG sites in the AGR2 promoter region. Treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine reduced the level of CpG methylation in the AGR2 promoter and increased the level of AGR2 expression. Next, we explored the functional role of AGR2 in the metastatic transformation of SK-OV-3 cells. SK-OV-3 cells overexpressing AGR2 showed increased migratory and invasive activity. Our results indicate that DNA methylation within the AGR2 promoter modulates more aggressive cancer cell phenotypes.
C1 [Sung, Hye Youn; Choi, Eun Nam; Lyu, Dahyun; Ahn, Jung-Hyuck] Ewha Womans Univ, Dept Biochem, Sch Med, Seoul 158710, South Korea.
   [Park, Ae Kyung] Sunchon Natl Univ, Coll Pharm, Jeonnam 540742, South Korea.
   [Ju, Woong] Ewha Womans Univ, Dept Obstet & Gynecol, Sch Med, Seoul 158710, South Korea.
C3 Ewha Womans University; Sunchon National University; Ewha Womans
   University
RP Ahn, JH (通讯作者)，Ewha Womans Univ, Dept Biochem, Sch Med, 911-1 Mok 5 Dong, Seoul 158710, South Korea.
EM goodmorning@ewha.ac.kr; ahnj@ewha.ac.kr
RI Park, Aekyung/JXY-2919-2024
FU Ministry of Health & Welfare, Republic of Korea [HI12C0050]
FX This study was supported by a grant of the Korean Health Technology R&D
   Project, Ministry of Health & Welfare, Republic of Korea (HI12C0050).
CR Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5
   Ai KX, 2008, WORLD J GASTROENTERO, V14, P1931, DOI 10.3748/wjg.14.1931
   Aplin AE, 1998, PHARMACOL REV, V50, P197
   Cheon DJ, 2014, CLIN CANCER RES, V20, P711, DOI 10.1158/1078-0432.CCR-13-1256
   Choi YP, 2012, BIOCHEM BIOPH RES CO, V427, P642, DOI 10.1016/j.bbrc.2012.09.114
   Cock-Rada A, 2013, BIOL CELL, V105, P73, DOI 10.1111/boc.201200029
   Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051
   Feki A, 2009, CRIT REV ONCOL HEMAT, V72, P1, DOI 10.1016/j.critrevonc.2008.12.003
   Fletcher GC, 2003, BRIT J CANCER, V88, P579, DOI 10.1038/sj.bjc.6600740
   Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606
   Hao Y, 2006, GASTROENTEROLOGY, V131, P925, DOI 10.1053/j.gastro.2006.04.026
   Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529
   Howe A, 1998, CURR OPIN CELL BIOL, V10, P220, DOI 10.1016/S0955-0674(98)80144-0
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Jeon BH, 2008, CANCER RES, V68, P1100, DOI 10.1158/0008-5472.CAN-07-2572
   Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432
   Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105
   Naora H, 2005, NAT REV CANCER, V5, P355, DOI 10.1038/nrc1611
   Ninomiya I, 2001, INT J ONCOL, V18, P715
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Rudland PS, 2000, CANCER RES, V60, P1595
   Salama I, 2008, EJSO-EUR J SURG ONC, V34, P357, DOI 10.1016/j.ejso.2007.04.009
   Sale Sanja, 2006, Drug Discov Today Dis Models, V3, P149, DOI 10.1016/j.ddmod.2006.05.006
   Scotton CJ, 2001, CANCER RES, V61, P4961
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1
   Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
NR 28
TC 23
Z9 24
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD AUG 5
PY 2014
VL 32
IS 2
BP 815
EP 820
DI 10.3892/or.2014.3243
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AL1TJ
UT WOS:000338908700047
PM 24920423
OA Bronze
DA 2025-01-12
ER

PT J
AU Zafar, A
   Wu, F
   Hardy, K
   Li, J
   Tu, WJ
   McCuaig, R
   Harris, J
   Khanna, KK
   Attema, J
   Gregory, PA
   Goodall, GJ
   Harrington, K
   Dahlstrom, JE
   Boulding, T
   Madden, R
   Tan, A
   Milburn, PJ
   Rao, S
AF Zafar, Anjum
   Wu, Fan
   Hardy, Kristine
   Li, Jasmine
   Tu, Wen Juan
   McCuaig, Robert
   Harris, Janelle
   Khanna, Kum Kum
   Attema, Joanne
   Gregory, Philip A.
   Goodall, Gregory J.
   Harrington, Kirsti
   Dahlstrom, Jane E.
   Boulding, Tara
   Madden, Rebecca
   Tan, Abel
   Milburn, Peter J.
   Rao, Sudha
TI Chromatinized Protein Kinase C-θ Directly Regulates Inducible Genes in
   Epithelial to Mesenchymal Transition and Breast Cancer Stem Cells
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID NF-KAPPA-B; PKC-THETA; TUMOR PROGRESSION; TRANSCRIPTIONAL ELONGATION;
   MICROARRAY ANALYSIS; NEGATIVE FEEDBACK; T-LYMPHOCYTES; IKK-EPSILON; IL-2
   GENE; CHIP-SEQ
AB Epithelial to mesenchymal transition (EMT) is activated during cancer invasion and metastasis, enriches for cancer stem cells (CSCs), and contributes to therapeutic resistance and disease recurrence. Signal transduction kinases play a pivotal role as chromatin- anchored proteins in eukaryotes. Here we report for the first time that protein kinase C-theta (PKC-theta) promotes EMT by acting as a critical chromatin- anchored switch for inducible genes via transforming growth factor beta (TGF-beta) and the key inflammatory regulatory protein NF-kappa B. Chromatinized PKC-theta exists as an active transcription complex and is required to establish a permissive chromatin state at signature EMT genes. Genome-wide analysis identifies a unique cohort of inducible PKC-theta-sensitive genes that are directly tethered to PKC-theta in the mesenchymal state. Collectively, we show that cross talk between signaling kinases and chromatin is critical for eliciting inducible transcriptional programs that drive mesenchymal differentiation and CSC formation, providing novel mechanisms to target using epigenetic therapy in breast cancer.
C1 [Zafar, Anjum; Wu, Fan; Hardy, Kristine; Li, Jasmine; Tu, Wen Juan; McCuaig, Robert; Boulding, Tara; Madden, Rebecca; Tan, Abel; Rao, Sudha] Univ Canberra, Fac Educ Sci Technol & Math, Canberra, ACT 2601, Australia.
   [Harris, Janelle; Khanna, Kum Kum] Royal Brisbane Hosp, QIMR Berghofer Med Res Inst, Brisbane, Qld 4029, Australia.
   [Attema, Joanne; Gregory, Philip A.; Goodall, Gregory J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.
   [Goodall, Gregory J.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia.
   [Goodall, Gregory J.] Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia.
   [Harrington, Kirsti; Dahlstrom, Jane E.] Canberra Hosp, ACT Pathol, Canberra, ACT, Australia.
   [Dahlstrom, Jane E.] Australian Natl Univ, Sch Med, Canberra, ACT, Australia.
   [Milburn, Peter J.] Australian Natl Univ, JCSMR, ACRF Biomol Resource Facil, Canberra, ACT, Australia.
C3 University of Canberra; Royal Brisbane & Women's Hospital; QIMR
   Berghofer Medical Research Institute; Centre for Cancer Biology; SA
   Pathology; University of Adelaide; University of Adelaide; Australian
   National University; Canberra Hospital; Australian National University;
   Australian National University
RP Rao, S (通讯作者)，Univ Canberra, Fac Educ Sci Technol & Math, Canberra, ACT 2601, Australia.
EM sudha.rao@canberra.edu.au
RI Rao, Sudha/AAW-5192-2020; Khanna, Kum/I-1747-2013; WU, FAN/P-3132-2015;
   Gregory, Philip/F-4089-2013; Hardy, Kristine/D-9985-2011; Dahlstrom,
   Jane/E-4683-2018
OI Dahlstrom, Jane/0000-0001-5608-693X; McCuaig, Robert
   D./0000-0003-0124-4173; Hardy, Kristine/0000-0003-1660-4477; Gregory,
   Philip/0000-0002-0999-0632; Goodall, Gregory/0000-0003-1294-0692; Rao,
   Sudha/0000-0001-9547-947X; Hancock, Janelle/0000-0001-6703-7228; Khanna,
   Kum Kum/0000-0001-8650-5381
FU Endeavor Postgraduate Award [641_2008]; University of Canberra
FX We thank the support of Endeavor Postgraduate Award granted to Anjum
   Zafar (641_2008) and the University of Canberra PDF fellowship scheme.
CR Adli M, 2006, J BIOL CHEM, V281, P26976, DOI 10.1074/jbc.M603133200
   Aguiló JI, 2009, J IMMUNOL, V182, P1972, DOI 10.4049/jimmunol.0801820
   Al-Ejeh F, 2011, CARCINOGENESIS, V32, P650, DOI 10.1093/carcin/bgr028
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Barski A, 2009, GENOME RES, V19, P1742, DOI 10.1101/gr.090951.109
   Belguise K, 2012, ONCOGENE, V31, P4889, DOI 10.1038/onc.2011.659
   Belguise K, 2007, J CLIN INVEST, V117, P4009, DOI 10.1172/JCI32424
   Boehm JS, 2007, CELL, V129, P1065, DOI 10.1016/j.cell.2007.03.052
   Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5
   Browne EP, 2001, J VIROL, V75, P12319, DOI 10.1128/JVI.75.24.12319-12330.2001
   Cairns J, 2011, BIOINFORMATICS, V27, P713, DOI 10.1093/bioinformatics/btq685
   Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473
   Chand S, 2012, CURR PHARM DESIGN, V18, P4725, DOI 10.2174/138161212802651625
   Chen L, 2012, BREAST CANCER RES TR, V136, P129, DOI 10.1007/s10549-012-2246-7
   Cheng JC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034071
   Cho KB, 2010, CANCER LETT, V293, P230, DOI 10.1016/j.canlet.2010.01.013
   Chow CW, 2006, CELL, V127, P887, DOI 10.1016/j.cell.2006.11.015
   Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097
   Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656
   Dean Michael, 2005, Discov Med, V5, P278
   Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10
   Gervasi M, 2012, J CELL BIOL, V196, P589, DOI 10.1083/jcb.201109045
   Giambra V, 2012, NAT MED, V18, P1693, DOI 10.1038/nm.2960
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   He H, 2010, PROSTATE, V70, P1119, DOI 10.1002/pros.21146
   Hecker M, 2013, MOL NEUROBIOL, V48, P737, DOI 10.1007/s12035-013-8463-1
   Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160
   Huang WL, 2012, J THEOR BIOL, V312, P105, DOI 10.1016/j.jtbi.2012.07.027
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   Hwang YP, 2010, BIOCHEM PHARMACOL, V79, P1714, DOI 10.1016/j.bcp.2010.02.003
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Isakov N, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00273
   Jechlinger M, 2003, ONCOGENE, V22, P7155, DOI 10.1038/sj.onc.1206887
   Jimenez JM, 2013, J MED CHEM, V56, P1799, DOI 10.1021/jm301465a
   KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Lee CW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2200
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000
   Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511
   Loyola A, 2006, MOL CELL, V24, P309, DOI 10.1016/j.molcel.2006.08.019
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mao XC, 2009, GENE DEV, V23, P849, DOI 10.1101/gad.1748409
   MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194
   Mattioli I, 2006, J BIOL CHEM, V281, P6175, DOI 10.1074/jbc.M508045200
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   MOOLTEN FL, 1981, CANCER RES, V41, P425
   Moreno R, 2010, NUCLEIC ACIDS RES, V38, P6029, DOI 10.1093/nar/gkq439
   Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev
   Pascual-Ahuir A, 2006, METHODS, V40, P272, DOI 10.1016/j.ymeth.2006.06.007
   Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212
   Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495
   Plasari G, 2009, MOL CELL BIOL, V29, P6006, DOI 10.1128/MCB.01921-08
   Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677
   Proft M, 2006, MOL CELL, V23, P241, DOI 10.1016/j.molcel.2006.05.031
   Rao S, 2003, J IMMUNOL, V170, P3724, DOI 10.4049/jimmunol.170.7.3724
   Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494
   Rashid NU, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-7-r67
   Sana TR, 2005, CYTOKINE, V29, P256, DOI 10.1016/j.cyto.2004.11.003
   Schmitz ML, 2004, CHEMBIOCHEM, V5, P1348, DOI 10.1002/cbic.200400144
   Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610
   Simon JM, 2012, NAT PROTOC, V7, P256, DOI 10.1038/nprot.2011.444
   Sleeman JP, 2011, CELL, V145, DOI 10.1016/j.cell.2011.03.029
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suhasini M, 1999, ONCOGENE, V18, P7360, DOI 10.1038/sj.onc.1203158
   Sun L, 2013, STEM CELLS, V31, P1454, DOI 10.1002/stem.1394
   Sutcliffe EL, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00260
   Sutcliffe EL, 2011, MOL CELL, V41, P704, DOI 10.1016/j.molcel.2011.02.030
   Sutcliffe EL, 2009, MOL CELL BIOL, V29, P1972, DOI 10.1128/MCB.01590-08
   Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   Trushin SA, 2003, MOL CELL BIOL, V23, P7068, DOI 10.1128/MCB.23.19.7068-7081.2003
   Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200
   Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009
   Williams SA, 2006, EMBO J, V25, P139, DOI 10.1038/sj.emboj.7600900
   Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104
   Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299
   Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576
   Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522
   Zanin-Zhorov A, 2010, SCIENCE, V328, P372, DOI 10.1126/science.1186068
   Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111
   Zhang SM, 2013, J BIOL CHEM, V288, P1469, DOI 10.1074/jbc.M112.438341
   Zhang YX, 2008, CANCER RES, V68, P9519, DOI 10.1158/0008-5472.CAN-08-1549
   Zhu LJ, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-237
NR 96
TC 32
Z9 38
U1 0
U2 13
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD AUG
PY 2014
VL 34
IS 16
BP 2961
EP 2980
DI 10.1128/MCB.01693-13
PG 20
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AL8IE
UT WOS:000339381000002
PM 24891615
OA Green Published
DA 2025-01-12
ER

PT J
AU Du, M
   Su, XM
   Zhang, T
   Xing, YJ
AF Du, Min
   Su, Xiao-Mei
   Zhang, Tao
   Xing, Yong-Jun
TI Aberrant promoter DNA methylation inhibits bone morphogenetic protein 2
   expression and contributes to drug resistance in breast cancer
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE DNA methylation; bone morphogenetic protein 2; breast cancer; drug
   resistance
ID CELLS; EPIGENETICS; GENE; BMP4; PROLIFERATION; HIGHLIGHTS; INVASION;
   GROWTH
AB Bone morphogenetic protein 2 (BMP2) is a growth factor that is involved in the development and progression of various types of cancer. However, the epigenetic regulation of the expression of BMP2 and the association between BMP2 expression and drug resistance in breast cancer remains to be elucidated. The present study reported that the expression of BMP2 was significantly decreased in primary breast cancer samples and the MCF-7/ADR breast cancer mulitdrug resistance cell line, which was closely associated with its promoter DNA methylation status. The expression of BMP2 in MCF-7/ADR cells markedly increased when treated with 5-Aza-2'-deoxycytidine. Knockdown of BMP2 by specific small interfering RNA enhanced the chemoresistance of the MCF-7 breast cancer cell line. These findings indicated that epigenetic silencing of BMP2 in breast cancer may be involved in breast cancer progression and drug resistance, and provided a novel prognostic marker and therapeutic strategy for breast cancer.
C1 [Du, Min; Su, Xiao-Mei; Zhang, Tao] PLA Gen Hosp Chengdu Mil Reg, Dept Oncol, Chengdu 610083, Sichuan, Peoples R China.
   [Xing, Yong-Jun] PLA Gen Hosp Chengdu Mil Reg, Affiliated Stomatol Hosp, Chengdu 610083, Sichuan, Peoples R China.
RP Xing, YJ (通讯作者)，PLA Gen Hosp Chengdu Mil Reg, Affiliated Stomatol Hosp, 270 Rongdu Rd, Chengdu 610083, Sichuan, Peoples R China.
EM yongjunxing@gmail.com
CR Alarmo EL, 2007, BREAST CANCER RES TR, V103, P239, DOI 10.1007/s10549-006-9362-1
   Buijs JT, 2010, CURR PHARM DESIGN, V16, P1291
   Clement JH, 2005, INT J ONCOL, V27, P401
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Dagdemir A, 2013, IN VIVO, V27, P1
   Davies Simon R, 2008, J Exp Ther Oncol, V7, P327
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Fu BS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061423
   Ghosh-Choudhury N, 2000, BBA-MOL CELL RES, V1497, P186, DOI 10.1016/S0167-4889(00)00060-4
   Guo D, 2012, MOL CELL BIOCHEM, V363, P179, DOI 10.1007/s11010-011-1170-1
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kanwal R, 2012, CLIN GENET, V81, P303, DOI 10.1111/j.1399-0004.2011.01809.x
   Lian WJ, 2013, ONCOL REP, V30, P193, DOI 10.3892/or.2013.2462
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Pang JMB, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3420
   Raida M, 2005, J CANCER RES CLIN, V131, P741, DOI 10.1007/s00432-005-0024-1
   Rodriguez-Martinez A, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-80
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Slattery ML, 2013, INT J CANCER, V132, P2928, DOI 10.1002/ijc.27960
   Thawani JP, 2010, NEUROSURGERY, V66, P233, DOI 10.1227/01.NEU.0000363722.42097.C2
   Waite KA, 2003, HUM MOL GENET, V12, P679, DOI 10.1093/hmg/ddg069
   Wang K, 2011, J CANCER RES CLIN, V137, P1687, DOI 10.1007/s00432-011-1047-4
   Wen XZ, 2006, ONCOGENE, V25, P2666, DOI 10.1038/sj.onc.1209297
   Ye L, 2010, CANCER SCI, V101, P2137, DOI 10.1111/j.1349-7006.2010.01648.x
   Ye S, 2013, SPINE, V38, pE143, DOI 10.1097/BRS.0b013e31827db4c6
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
NR 28
TC 12
Z9 15
U1 1
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2014
VL 10
IS 2
BP 1051
EP 1055
DI 10.3892/mmr.2014.2276
PG 5
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AL4TL
UT WOS:000339127600072
PM 24866720
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, KC
   Hua, KT
   Lin, YS
   Su, CY
   Ko, JY
   Hsiao, M
   Kuo, ML
   Tan, CT
AF Li, Kai-Chun
   Hua, Kuo-Tai
   Lin, Yi-Shen
   Su, Chia-Yi
   Ko, Jenq-Yuh
   Hsiao, Michael
   Kuo, Min-Liang
   Tan, Ching-Ting
TI Inhibition of G9a induces DUSP4-dependent autophagic cell death in head
   and neck squamous cell carcinoma
SO MOLECULAR CANCER
LA English
DT Article
DE HNSCC; G9a; autophagy; DUSP4; ERK
ID HISTONE LYSINE METHYLTRANSFERASES; DNA METHYLATION; CANCER-CELLS;
   NEGATIVE REGULATION; BREAST-CANCER; BECLIN 1; EXPRESSION; H3K9;
   PHOSPHORYLATION; PROLIFERATION
AB Background: Head and neck squamous cell carcinoma (HNSCC) is a common cancer worldwide. Emerging evidence indicates that alteration of epigenetics might be a key event in HNSCC progression. Abnormal expression of histone methyltransferase G9a, which contributes to transcriptional repression of tumor suppressors, has been implicated in promoting cancerous malignancies. However, its role in HNSCC has not been previously characterized. In this study, we elucidate the function of G9a and its downstream mechanism in HNSCC.
   Methods: We investigated the clinical relevance of G9a in HNSCC using immunohistochemistry (IHC) staining. In vitro cell proliferation and tumorigenesis ability of G9a-manipulated HNSCC cells were examined with MTT assays, clonogenic assays, and soft agar assays. We examined different routes of cell death in HNSCC cells induced by G9a-depletion or enzymatic inhibition by immunoblot, flow cytometry, fluorescent and transmission electron microscopy analysis. Specific targets of G9a were identified by affymetrix microarray and quantitative reverse transcription-polymerase chain reaction (qRT-PCR). Lastly, functions of G9a in vivo were confirmed with a xenograft tumor model.
   Results: G9a expression is positively correlated to proliferation marker Ki-67 and to poor prognosis in HNSCC patients. Genetic or pharmacological inhibition of G9a reduced cell proliferation without inducing necrosis or apoptosis. Instead, autophagic cell death was the major consequence, and our investigation of mechanisms suggested it is mediated via the dual specificity phosphatase-4 (DUSP4) dependent ERK inactivation pathway. An orthotopic tumor model further confirmed the growth inhibiting effect and induction of autophagy that followed suppression of G9a.
   Conclusions: In this study, we provide evidence that G9a confers the survival advantage of HNSCC. Genetic or pharmacological inhibition of G9a induces autophagic cell death; this finding provides a basis for new therapeutic targets for treating HNSCC.
C1 [Li, Kai-Chun; Hua, Kuo-Tai; Lin, Yi-Shen; Kuo, Min-Liang] Natl Taiwan Univ, Coll Med, Grad Inst Toxicol, Taipei 10764, Taiwan.
   [Su, Chia-Yi; Hsiao, Michael] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
   [Ko, Jenq-Yuh; Tan, Ching-Ting] Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan.
   [Ko, Jenq-Yuh; Tan, Ching-Ting] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
   [Kuo, Min-Liang] Natl Taiwan Univ, Coll Life Sci, Grad Inst Biomed Sci, Taipei 10764, Taiwan.
C3 National Taiwan University; Academia Sinica - Taiwan; National Taiwan
   University; National Taiwan University Hospital; National Taiwan
   University; National Taiwan University
RP Tan, CT (通讯作者)，Natl Taiwan Univ Hosp, Dept Otolaryngol, Taipei, Taiwan.
EM tanct5222@ntu.edu.tw
RI Hsiao, Michael/U-6238-2019; Kuo, Min-Liang/C-4872-2009; Su,
   Chia-Yi/L-5378-2016
OI Tan, Ching-Ting/0000-0001-8317-2235; KUO, MIN-LIANG/0000-0002-7139-0144;
   Hsiao, Michael/0000-0001-8529-9213; Su, Chia-Yi/0000-0002-9483-4510;
   Hua, Kuo-Tai/0000-0002-8468-4977
FU NSC [100-2321-B-002-045, 101-2321-B-002-031, 101-2320-B-002-043-MY3,
   102-2321-B-002-025, 102-2321-B-002-076, 101-2911-I-002-303]
FX This work was supported by NSC Grants 100-2321-B-002-045,
   101-2321-B-002-031, 101-2320-B-002-043-MY3, 102-2321-B-002-025 (C.T.
   Tan), 102-2321-B-002-076 and 101-2911-I-002-303 (M.L. Kuo).
CR Arantes LMRB, 2014, ORAL ONCOL, V50, P587, DOI 10.1016/j.oraloncology.2014.02.015
   Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666
   Bagan J, 2010, ORAL ONCOL, V46, P414, DOI 10.1016/j.oraloncology.2010.03.009
   Britson JS, 2009, BIOCHEM BIOPH RES CO, V390, P849, DOI 10.1016/j.bbrc.2009.10.061
   Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540
   Chen MW, 2010, CANCER RES, V70, P7830, DOI 10.1158/0008-5472.CAN-10-0833
   Cho HS, 2011, NEOPLASIA, V13, P676, DOI 10.1593/neo.11512
   de Narvajas AAM, 2013, MOL CELL BIOL, V33, P3983, DOI 10.1128/MCB.00813-13
   Ding J, 2013, CELL METAB, V18, P896, DOI 10.1016/j.cmet.2013.11.004
   Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022
   Dong CF, 2012, J CLIN INVEST, V122, P1469, DOI 10.1172/JCI57349
   Dwivedi N, 2013, CONTEMP CLIN DENT, V4, P7, DOI 10.4103/0976-237X.111586
   Elias J, 2014, BBA-PROTEINS PROTEOM, V1844, P232, DOI 10.1016/j.bbapap.2013.09.019
   Haigentz M, 2012, ORAL ONCOL, V48, P1281, DOI 10.1016/j.oraloncology.2012.05.024
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Kim Y, 2013, AUTOPHAGY, V9, P2126, DOI 10.4161/auto.26308
   Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692
   Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x
   Kondo Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002037
   Kondoh K, 2007, BBA-MOL CELL RES, V1773, P1227, DOI 10.1016/j.bbamcr.2006.12.002
   LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F
   Liu M, 2013, TRANSL ONCOL, V6, P273, DOI 10.1593/tlo.13175
   Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031
   MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587
   Nozawa H, 2006, CANCER SCI, V97, P1115, DOI 10.1111/j.1349-7006.2006.00287.x
   Oh SH, 2012, INT J CANCER, V131, P2253, DOI 10.1002/ijc.27509
   Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200
   Rufini A, 2013, ONCOGENE, V32, P5129, DOI 10.1038/onc.2012.640
   Saigusa S, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0620-x
   Scully C, 2008, ORAL ONCOL, V44, P211, DOI 10.1016/j.oraloncology.2008.01.006
   Shankar SR, 2013, EPIGENETICS-US, V8, P16, DOI 10.4161/epi.23331
   Sieben NLG, 2005, J CLIN ONCOL, V23, P7257, DOI 10.1200/JCO.2005.02.2541
   Son HJ, 2012, MOL CELL BIOL, V32, P3681, DOI 10.1128/MCB.00673-12
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Tachibana M, 2002, GENE DEV, V16, P1779, DOI 10.1101/gad.989402
   Tachibana M, 2008, EMBO J, V27, P2681, DOI 10.1038/emboj.2008.192
   Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013
   Wang LF, 2013, EMBO J, V32, P45, DOI 10.1038/emboj.2012.306
   Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967
   Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15
   Yang Q, 2012, CELL PROLIFERAT, V45, P335, DOI 10.1111/j.1365-2184.2012.00828.x
   Yorimitsu T, 2005, CELL DEATH DIFFER, V12, P1542, DOI 10.1038/sj.cdd.4401765
   Yuan Y, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.191
   Yuan Y, 2012, ACS CHEM BIOL, V7, P1152, DOI 10.1021/cb300139y
   Zhang X, 2003, MOL CELL, V12, P177, DOI 10.1016/S1097-2765(03)00224-7
   Zhao LB, 2014, GENE, V537, P197, DOI 10.1016/j.gene.2014.01.006
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 51
TC 51
Z9 58
U1 0
U2 11
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JUL 15
PY 2014
VL 13
AR 172
DI 10.1186/1476-4598-13-172
PG 14
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA AL7BB
UT WOS:000339286800001
PM 25027955
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Wang, HB
   Gutierrez-Uzquiza, A
   Garg, R
   Barrio-Real, L
   Abera, MB
   Lopez-Haber, C
   Rosemblit, C
   Lu, HS
   Abba, M
   Kazanietz, MG
AF Wang, HongBin
   Gutierrez-Uzquiza, Alvaro
   Garg, Rachana
   Barrio-Real, Laura
   Abera, Mahlet B.
   Lopez-Haber, Cynthia
   Rosemblit, Cinthia
   Lu, Huaisheng
   Abba, Martin
   Kazanietz, Marcelo G.
TI Transcriptional Regulation of Oncogenic Protein Kinase Cε (PKCε) by
   STAT1 and Sp1 Proteins
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID BREAST-CANCER CELLS; GENE-EXPRESSION; CYCLIN D1; ESTROGEN-RECEPTOR;
   OXIDATIVE-STRESS; PROSTATE-CANCER; EPIGENETIC REPRESSION;
   INSULIN-RESISTANCE; DRUG ACTIVITY; GROWTH-FACTOR
AB Overexpression of PKC epsilon, a kinase associated with tumor aggressiveness and widely implicated in malignant transformation and metastasis, is a hallmark of multiple cancers, including mammary, prostate, and lung cancer. To characterize the mechanisms that control PKC epsilon expression and its up-regulation in cancer, we cloned an similar to 1.6-kb promoter segment of the human PKC epsilon gene (PRKCE) that displays elevated transcriptional activity in cancer cells. A comprehensive deletional analysis established two regions rich in Sp1 and STAT1 sites located between -777 and -105 bp (region A) and -921 and -796 bp (region B), respectively, as responsible for the high transcriptional activity observed in cancer cells. A more detailed mutagenesis analysis followed by EMSA and ChIP identified Sp1 sites in positions -668/-659 and -269/-247 as well as STAT1 sites in positions -880/-869 and -793/-782 as the elements responsible for elevated promoter activity in breast cancer cells relative to normal mammary epithelial cells. RNAi silencing of Sp1 and STAT1 in breast cancer cells reduced PKC epsilon mRNA and protein expression, as well as PRKCE promoter activity. Moreover, a strong correlation was found between PKC epsilon and phospho-Ser-727 (active) STAT1 levels in breast cancer cells. Our results may have significant implications for the development of approaches to target PKC epsilon and its effectors in cancer therapeutics.
C1 [Wang, HongBin; Gutierrez-Uzquiza, Alvaro; Garg, Rachana; Barrio-Real, Laura; Abera, Mahlet B.; Lopez-Haber, Cynthia; Rosemblit, Cinthia; Lu, Huaisheng; Kazanietz, Marcelo G.] Univ Penn, Perelman Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.
   [Abba, Martin] Univ Nacl La Plata, Ctr Invest Inmunol Basicas & Aplicadas, RA-1900 La Plata, Argentina.
C3 University of Pennsylvania; National University of La Plata
RP Kazanietz, MG (通讯作者)，Univ Penn, Perelman Sch Med, Dept Pharmacol, 1256 Biomed Res Bldg 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.
EM marcelog@upenn.edu
RI Uzquiza, Alvaro/E-4073-2012; Garg, Rachana/AAQ-9518-2020
OI Lopez Haber, Cynthia/0000-0001-9106-543X; Gutierrez-Uzquiza,
   Alvaro/0000-0002-0446-4131; Abba, Martin/0000-0002-9206-2369; Garg,
   Rachana/0000-0002-7808-1053
FU National Institutes of Health [R01-CA89202]
FX This work was supported, in whole or in part, by National Institutes of
   Health Grant R01-CA89202 (to M. G. K.).
CR Abdelrahim M, 2002, J BIOL CHEM, V277, P28815, DOI 10.1074/jbc.M203828200
   Andl CD, 2004, AM J PHYSIOL-GASTR L, V287, pG1227, DOI 10.1152/ajpgi.00253.2004
   Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604
   Bae KM, 2007, CANCER RES, V67, P6053, DOI 10.1158/0008-5472.CAN-06-4037
   CACACE AM, 1993, ONCOGENE, V8, P2095
   Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428
   Caino MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031714
   Cao YX, 2000, BIOCHEM J, V350, P883, DOI 10.1042/0264-6021:3500883
   Chan SR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3100
   CHEN YY, 1994, ONCOGENE, V9, P2269
   Cheng MB, 2010, CELL SIGNAL, V22, P1206, DOI 10.1016/j.cellsig.2010.03.012
   Churchill EN, 2010, CARDIOVASC RES, V85, P385, DOI 10.1093/cvr/cvp334
   Dann S. G., 2013, ONCOGENE
   Finkenzeller Gunter, 2004, Angiogenesis, V7, P59, DOI 10.1023/B:AGEN.0000037332.66411.f0
   Franci C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058183
   Fryknäs M, 2007, INT J CANCER, V120, P189, DOI 10.1002/ijc.22291
   Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524
   Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925
   Glait C, 2006, EXP CELL RES, V312, P3899, DOI 10.1016/j.yexcr.2006.08.016
   Greenwood C, 2012, J PROTEOMICS, V75, P3031, DOI 10.1016/j.jprot.2011.11.033
   Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110
   Gutiérrez-Uzquiza A, 2012, J BIOL CHEM, V287, P2632, DOI 10.1074/jbc.M111.323709
   Hagiwara K, 2012, GENE CHROMOSOME CANC, V51, P1024, DOI 10.1002/gcc.21985
   Han W, 2013, MOL CARCINOGEN, V52, P959, DOI 10.1002/mc.21936
   Hix LM, 2013, J BIOL CHEM, V288, P11676, DOI 10.1074/jbc.M112.441402
   Ivaska J, 2003, NAT CELL BIOL, V5, P363, DOI 10.1038/ncb957
   Jin HJ, 2011, J BIOL CHEM, V286, P19840, DOI 10.1074/jbc.M110.203687
   Jornayvaz FR, 2012, CELL METAB, V15, P574, DOI 10.1016/j.cmet.2012.03.005
   Kampfer S, 2001, J BIOL CHEM, V276, P42834, DOI 10.1074/jbc.M102047200
   Khodarev NN, 2012, CLIN CANCER RES, V18, P3015, DOI 10.1158/1078-0432.CCR-11-3225
   Khodarev NN, 2004, P NATL ACAD SCI USA, V101, P1714, DOI 10.1073/pnas.0308102100
   Kitazawa S, 1999, J BIOL CHEM, V274, P28787, DOI 10.1074/jbc.274.40.28787
   Körner C, 2013, J BIOL CHEM, V288, P8750, DOI 10.1074/jbc.M112.414128
   Lee AM, 2011, P NATL ACAD SCI USA, V108, P16080, DOI 10.1073/pnas.1106277108
   Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000
   Lopez-Haber C, 2013, MOL PHARMACOL, V83, P1141, DOI 10.1124/mol.112.084293
   Loureiro RMB, 2005, CYTOKINE GROWTH F R, V16, P77, DOI 10.1016/j.cytogfr.2005.01.005
   Magkou C, 2012, HISTOPATHOLOGY, V60, P1125, DOI 10.1111/j.1365-2559.2011.04143.x
   Maor S, 2006, J ENDOCRINOL, V191, P605, DOI 10.1677/joe.1.07016
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Mesquita RFDS, 2014, MOL CELL BIOL, V34, P574, DOI 10.1128/MCB.01098-13
   MISCHAK H, 1993, J BIOL CHEM, V268, P6090
   Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553
   Patterson AJ, 2012, CARDIOVASC RES, V93, P302, DOI 10.1093/cvr/cvr322
   Patterson SG, 2006, ONCOGENE, V25, P6113, DOI 10.1038/sj.onc.1209632
   Perletti GP, 1996, ONCOGENE, V12, P847
   Quann EJ, 2011, NAT IMMUNOL, V12, P647, DOI 10.1038/ni.2033
   Rajski M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029743
   Ramana CV, 2000, ONCOGENE, V19, P2619, DOI 10.1038/sj.onc.1203525
   Rickardson L, 2005, BRIT J CANCER, V93, P483, DOI 10.1038/sj.bjc.6602699
   Rickardson L, 2006, CANCER CHEMOTH PHARM, V58, P749, DOI 10.1007/s00280-006-0216-7
   Salvatori L, 2011, BIOMED PHARMACOTHER, V65, P307, DOI 10.1016/j.biopha.2011.03.007
   SASTRY M, 1993, BIOCHEMISTRY-US, V32, P6588, DOI 10.1021/bi00077a012
   Saurin AT, 2008, NAT CELL BIOL, V10, P891, DOI 10.1038/ncb1749
   Schultz J, 2010, CLIN EXP METASTAS, V27, P133, DOI 10.1007/s10585-010-9310-7
   Shankar E, 2008, ONCOGENE, V27, P3957, DOI 10.1038/onc.2008.39
   Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200
   Su T., 2013, ISRN ONCOL, V2013
   Taminau J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-335
   Verma AK, 2006, MOL CARCINOGEN, V45, P381, DOI 10.1002/mc.20230
   Wang HB, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.227991
   Wang Xiao-Bing, 2007, Ai Zheng, V26, P996
   Wu DF, 2012, J CLIN INVEST, V122, P1306, DOI 10.1172/JCI61934
   Wu DQ, 2002, CANCER RES, V62, P2423
   Xiong FX, 2012, FASEB J, V26, P2753, DOI 10.1096/fj.11-199422
   Xuan YT, 2005, CIRCULATION, V112, P1971, DOI 10.1161/CIRCULATIONAHA.105.561522
   Zannetti A, 2000, CANCER RES, V60, P1546
   Zhang DY, 2010, CELL METAB, V11, P402, DOI 10.1016/j.cmet.2010.03.012
NR 68
TC 28
Z9 30
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD JUL 11
PY 2014
VL 289
IS 28
BP 19823
EP 19838
DI 10.1074/jbc.M114.548446
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AL7PL
UT WOS:000339326800053
PM 24825907
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Calderon, MR
   Verway, M
   Benslama, RO
   Birlea, M
   Bouttier, M
   Dimitrov, V
   Mader, S
   White, JH
AF Calderon, Mario R.
   Verway, Mark
   Benslama, Radia Ouelaa
   Birlea, Mirela
   Bouttier, Manuella
   Dimitrov, Vassil
   Mader, Sylvie
   White, John H.
TI Ligand-dependent corepressor contributes to transcriptional repression
   by C<sub>2</sub>H<sub>2</sub> zinc-finger transcription factor ZBRK1
   through association with KRAB-associated protein-1
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; EMBRYONIC STEM-CELLS; HUMAN BREAST; MCF-7
   CELLS; APOPTOSIS; CHROMATIN; ACTIVATION; FGF-2; GENE; PHOSPHORYLATION
AB We identified a novel interaction between ligand-dependent corepressor (LCoR) and the corepressor KRAB-associated protein-1 (KAP-1). The two form a complex with C2H2 zinc-finger transcription factor ZBRK1 on an intronic binding site in the growth arrest and DNA-damage-inducible alpha (GADD45A) gene and a novel site in the fibroblast growth factor 2 (FGF2) gene. Chromatin at both sites is enriched for histone methyltransferase SETDB1 and histone 3 lysine 9 trimethylation, a repressive epigenetic mark. Depletion of ZBRK1, KAP-1 or LCoR led to elevated GADD45A and FGF2 expression in malignant and non-malignant breast epithelial cells, and caused apoptotic death. Loss of viability could be rescued by simultaneous knockdowns of FGF2 and transcriptional coregulators or by blocking FGF2 function. FGF2 was not concurrently expressed with any of the transcriptional coregulators in breast malignancies, suggesting an inverse correlation between their expression patterns. We propose that ZBRK1, KAP-1 and LCoR form a transcriptional complex that silences gene expression, in particular FGF2, which maintains breast cell viability. Given the broad expression patterns of both LCoR and KAP-1 during development and in the adult, this complex may have several regulatory functions that extend beyond cell survival, mediated by interactions with ZBRK1 or other C2H2 zinc-finger proteins.
C1 [Calderon, Mario R.; Verway, Mark; Bouttier, Manuella; Dimitrov, Vassil; White, John H.] McGill Univ, Dept Physiol, Montreal, PQ, Canada.
   [Benslama, Radia Ouelaa; Mader, Sylvie] Univ Montreal, Dept Biochem, Montreal, PQ H3C 3J7, Canada.
   [Benslama, Radia Ouelaa; Birlea, Mirela; Mader, Sylvie] Univ Montreal, IRIC, Montreal, PQ, Canada.
   [White, John H.] McGill Univ, Dept Med, Montreal, PQ, Canada.
C3 McGill University; Universite de Montreal; Universite de Montreal;
   McGill University
RP White, JH (通讯作者)，McGill Univ, Dept Physiol, Montreal, PQ, Canada.
EM john.white@mcgill.ca
RI white, john/N-9782-2013
OI Calderon, Mario R/0000-0001-6618-1789; MADER, Sylvie/0000-0002-6423-627X
FU Canadian Institute of Health Research (CIHR) [MT-11704]; Natural
   Sciences and Engineering Research Council (NSERC) [RGPGP-2014-00084];
   Fonds de Recherche du Quebec-Sante [FRSQ]; Canadian Institutes of Health
   Research
FX This study was funded by a grant from the Canadian Institute of Health
   Research (CIHR) [Grant number MT-11704] and a grant from the Natural
   Sciences and Engineering Research Council (NSERC) [Grant number
   RGPGP-2014-00084] to J.H.W.; M. V and M. B were supported by doctoral
   and postdoctoral fellowships, respectively, from the Fonds de Recherche
   du Quebec-Sante [FRSQ]. Funding for open access charge: Canadian
   Institutes of Health Research.
CR Ahmed KM, 2010, J BIOL CHEM, V285, P4464, DOI 10.1074/jbc.M109.062265
   BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X
   Birtle Z, 2006, BIOINFORMATICS, V22, P2841, DOI 10.1093/bioinformatics/btl498
   Calderon MR, 2012, J BIOL CHEM, V287, P8662, DOI 10.1074/jbc.M111.311605
   Cammas F, 2000, DEVELOPMENT, V127, P2955
   Chang CW, 2008, BMC MOL BIOL, V9, DOI 10.1186/1471-2199-9-61
   Colomer R, 1997, BRIT J CANCER, V76, P1215, DOI 10.1038/bjc.1997.536
   Cuvillier O, 2001, CELL DEATH DIFFER, V8, P162, DOI 10.1038/sj.cdd.4400793
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Eves EM, 2001, J NEUROSCI, V21, P4996, DOI 10.1523/JNEUROSCI.21-14-04996.2001
   Fenig E, 2002, ONCOL REP, V9, P875
   Fernandes I, 2003, MOL CELL, V11, P139, DOI 10.1016/S1097-2765(03)00014-5
   FRIEDRICHS K, 1993, CANCER, V72, P3641, DOI 10.1002/1097-0142(19931215)72:12<3641::AID-CNCR2820721215>3.0.CO;2-8
   Frietze S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015082
   Furuta S, 2006, CANCER CELL, V10, P13, DOI 10.1016/j.ccr.2006.05.022
   Germain-Desprez D, 2003, J BIOL CHEM, V278, P22367, DOI 10.1074/jbc.M302234200
   Goodarzi AA, 2011, NAT STRUCT MOL BIOL, V18, P831, DOI 10.1038/nsmb.2077
   Groner AC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000869
   Iyengar S, 2011, J BIOL CHEM, V286, P26267, DOI 10.1074/jbc.R111.252569
   Iyengar S, 2011, MOL CELL BIOL, V31, P1833, DOI 10.1128/MCB.01331-10
   Korah RM, 2000, BIOCHEM BIOPH RES CO, V277, P255, DOI 10.1006/bbrc.2000.3655
   Korah RM, 2000, CANCER RES, V60, P733
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   LATCHMAN DS, 1993, INT J EXP PATHOL, V74, P417
   Lee YK, 2007, J BIOL CHEM, V282, P1595, DOI 10.1074/jbc.M606306200
   Liao GL, 2005, J VIROL, V79, P245, DOI 10.1128/JVI.79.1.245-256.2005
   Lin LF, 2010, CANCER RES, V70, P192, DOI 10.1158/0008-5472.CAN-09-2641
   Linda A, 2010, EUR J RADIOL, V75, P178, DOI 10.1016/j.ejrad.2009.04.038
   Liu D, 2001, EUR J CANCER, V37, P268, DOI 10.1016/S0959-8049(00)00392-0
   LUQMANI YA, 1992, BRIT J CANCER, V66, P273, DOI 10.1038/bjc.1992.256
   Maloof P, 1999, BREAST CANCER RES TR, V56, P153
   Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101
   Mooney LM, 2002, BRIT J CANCER, V87, P909, DOI 10.1038/sj.bjc.6600541
   Nishitsuji H, 2012, FEBS LETT, V586, P3562, DOI 10.1016/j.febslet.2012.08.010
   O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089
   Oishi Y, 2008, NAT MED, V14, P656, DOI 10.1038/nm1756
   Palijan A, 2009, J BIOL CHEM, V284, P30275, DOI 10.1074/jbc.M109.051201
   Palijan A, 2009, J BIOL CHEM, V284, P30264, DOI 10.1074/jbc.M109.045526
   Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032
   Schmitt JF, 1996, GROWTH FACTORS, V13, P19, DOI 10.3109/08977199609034564
   Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302
   Seetharam A, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-420
   Semenov DV, 2004, NUCLEOS NUCLEOT NUCL, V23, P831, DOI 10.1081/NCN-200026024
   Shi YJ, 2003, NATURE, V422, P735, DOI 10.1038/nature01550
   Smith E, 2010, MOL CELL, V40, P689, DOI 10.1016/j.molcel.2010.11.031
   SMITH J, 1994, EUR J CANCER, V30A, P496, DOI 10.1016/0959-8049(94)90426-X
   Soufla G, 2006, CANCER LETT, V235, P100, DOI 10.1016/j.canlet.2005.04.022
   Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   White DE, 2006, CANCER RES, V66, P11594, DOI 10.1158/0008-5472.CAN-06-4138
   Wolf D, 2009, NATURE, V458, P1201, DOI 10.1038/nature07844
   Yagami T, 2010, EXP CELL RES, V316, P2278, DOI 10.1016/j.yexcr.2010.03.023
   Yiangou C, 1997, BRIT J CANCER, V75, P28, DOI 10.1038/bjc.1997.5
   Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7
   Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446
NR 56
TC 15
Z9 20
U1 0
U2 17
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PY 2014
VL 42
IS 11
BP 7012
EP 7027
DI 10.1093/nar/gku413
PG 16
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AK9TG
UT WOS:000338769400025
PM 24829459
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Stewart, DJ
   Nunez, MI
   Jelinek, J
   Hong, D
   Gupta, S
   Aldaz, M
   Issa, JP
   Kurzrock, R
   Wistuba, II
AF Stewart, David J.
   Nunez, Maria I.
   Jelinek, Jaroslav
   Hong, David
   Gupta, Sanjay
   Aldaz, Marcelo
   Issa, Jean-Pierre
   Kurzrock, Razelle
   Wistuba, Ignacio I.
TI Impact of decitabine on immunohistochemistry expression of the putative
   tumor suppressor genes FHIT, WWOX, FUS1 and PTEN in clinical tumor
   samples
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Decitabine; FHIT; FUS1; WWOX; PTEN; Tumor suppressor genes; LINE-1
   methylation
ID SQUAMOUS-CELL CARCINOMA; GLOBAL DNA METHYLATION; LUNG-CANCER;
   OVARIAN-CANCER; BREAST-CANCER; EPIGENETIC MODULATION; PROTEIN
   EXPRESSION; HYPERMETHYLATION; ISLAND; PROFILES
AB Background: Since tumor suppressor gene function may be lost through hypermethylation, we assessed whether the demethylating agent decitabine could increase tumor suppressor gene expression clinically. For fragile histidine triad (FHIT), WW domain-containing oxidoreductase (WWOX), fused in sarcoma-1 (FUS1) and phosphatase and tensin homolog (PTEN), immunohistochemistry scores from pre- and post-decitabine tumor biopsies (25 patients) were correlated with methylation of the long interspersed nuclear element-1 (LINE-1) repetitive DNA element (as a surrogate for global DNA methylation) and with tumor regression.
   Results: With negative staining pre-decitabine (score = 0), the number of patients converting to positive staining post-decitabine was 1 of 1 for FHIT, 3 of 6 for WWOX, 2 of 3 for FUS1 and 1 of 10 for PTEN. In tumors with low pre-decitabine tumor suppressor gene scores (<= 150), expression was higher post-treatment in 8 of 8 cases for FHIT (P = 0.014), 7 of 17 for WWOX (P = 0.0547), 7 of 12 for FUS1 (P = 0.0726), and 1 of 16 for PTEN (P = 0.2034). If FHIT, WWOX and FUS1 were considered together, median pre- versus post-decitabine scores were 60 versus 100 (P = 0.0002). Overall, tumor suppressor gene expression change did not correlate with LINE-1 demethylation, although tumors converting from negative to positive had a median decrease in LINE-1 methylation of 24%, compared to 6% in those not converting (P = 0.069). Five of 15 fully evaluable patients had reductions in tumor diameter (range 0.2% to 33.4%). Of these, three had simultaneous increases in three tumor suppressor genes (including the two patients with the greatest tumor regression) compared to 2 of 10 with tumor growth (P = 0.25).
   Conclusions: In tumors with low tumor suppressor gene expression, decitabine may be associated with increased expression of the tumor suppressor genes FHIT, FUS1, and WWOX, but not PTEN.
C1 [Stewart, David J.] Univ Ottawa, Ottawa, ON K1H 8L6, Canada.
   [Nunez, Maria I.; Hong, David; Gupta, Sanjay; Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Jelinek, Jaroslav; Issa, Jean-Pierre] Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA.
   [Aldaz, Marcelo] UT MD Anderson Canc Ctr, Smithville, TX 78957 USA.
   [Kurzrock, Razelle] Univ Calif San Diego, La Jolla, CA 92093 USA.
C3 University of Ottawa; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; UTMD Anderson Cancer Center;
   University of California System; University of California San Diego
RP Stewart, DJ (通讯作者)，Univ Ottawa, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM dstewart@toh.on.ca
RI Aldaz, C./E-7868-2011; Hong, David/HKW-1105-2023; Kurzrock,
   Razelle/AAU-9782-2020; Jelinek, Jaroslav/D-2282-2012
OI Jelinek, Jaroslav/0000-0002-2533-0220; Aldaz, C.
   Marcelo/0000-0002-2453-2939; Gupta, Sanjay/0000-0001-7001-0130; S. Hong,
   David/0000-0001-8721-1609; Issa, Jean-Pierre/0000-0003-2258-5030
FU NIH [UO1 CA062461-10, R21 CA112895-01A1]; Cancer Center Support Grant
   [5-P30 CA16672-32]; Department of Defense [W81XWH-07-1-0306]
FX Supported in part by NIH grants UO1 CA062461-10, R21 CA112895-01A1,
   Cancer Center Support Grant number 5-P30 CA16672-32, and by Department
   of Defense grant number W81XWH-07-1-0306. We would like to thank MD
   Anderson Cancer Center for making funding available for required tumor
   biopsies and would also like to express our appreciation for the help
   and support for this project that we received from the late Dr. Igor
   Espinoza-Delgado while he was at CTEP, NCI.
CR Aqeilan RI, 2007, J CELL PHYSIOL, V212, P307, DOI 10.1002/jcp.21099
   Baykara O, 2010, TUMOR BIOL, V31, P315, DOI 10.1007/s13277-010-0039-3
   Cantor JP, 2007, INT J CANCER, V120, P24, DOI 10.1002/ijc.22073
   Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221
   Cui ZL, 2013, ONCOL REP, V29, P2154, DOI 10.3892/or.2013.2361
   Dayan S, 2013, GENE CHROMOSOME CANC, V52, P823, DOI 10.1002/gcc.22078
   Demokan S, 2013, INT J ONCOL, V42, P1427, DOI 10.3892/ijo.2013.1808
   Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204
   Fu SQ, 2011, CANCER-AM CANCER SOC, V117, P1661, DOI 10.1002/cncr.25701
   Ghoshal K, 2007, DRUG TODAY, V43, P395, DOI 10.1358/dot.2007.43.6.1062666
   Gravina GL, 2009, INT J ONCOL, V35, P1133, DOI 10.3892/ijo_00000429
   Guan YS, 2011, WORLD J GASTROENTERO, V17, P2143, DOI 10.3748/wjg.v17.i16.2143
   Guo W, 2013, MOL CARCINOGEN, V52, P265, DOI 10.1002/mc.21853
   Hesson LB, 2012, BIOL PROCED ONLINE, V14, DOI 10.1186/1480-9222-14-5
   Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037
   Iliopoulos D, 2007, CLIN CANCER RES, V13, P268, DOI 10.1158/1078-0432.CCR-06-2038
   Ishii Hideshi, 2003, J Exp Ther Oncol, V3, P291, DOI 10.1111/j.1533-869X.2003.01101.x
   Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981
   Ji L, 2008, J THORAC ONCOL, V3, P327, DOI 10.1097/JTO.0b013e31816bce65
   Kawaguchi K, 2005, HUM PATHOL, V36, P357, DOI 10.1016/j.humpath.2005.01.017
   Ki Kyung-Do, 2008, J Gynecol Oncol, V19, P117, DOI 10.3802/jgo.2008.19.2.117
   Kim JS, 2006, CANCER RES, V66, P4049, DOI 10.1158/0008-5472.CAN-05-3813
   Kuo LT, 2009, INT J CANCER, V124, P2872, DOI 10.1002/ijc.24303
   Kvasha S, 2008, CANCER LETT, V265, P250, DOI 10.1016/j.canlet.2008.02.036
   Li W, 2010, CANCER BIOL THER, V10, P997, DOI 10.4161/cbt.10.10.13231
   Lu C, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0034833, 10.1371/journal.pone.0038332]
   Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Nunez M, 2005, BREAST CANCER RES TR, V89, P99, DOI 10.1007/s10549-004-1474-x
   Nunez MI, 2006, J MOL HISTOL, V37, P115, DOI 10.1007/s10735-006-9046-5
   Nunez MI, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-64
   Oki Y, 2007, CRIT REV ONCOL HEMAT, V61, P140, DOI 10.1016/j.critrevonc.2006.07.010
   Paluszczak J, 2011, ORAL ONCOL, V47, P104, DOI 10.1016/j.oraloncology.2010.11.006
   Pichiorri F, 2008, FUTURE ONCOL, V4, P815, DOI 10.2217/14796694.4.6.815
   Pluciennik E, 2012, ONCOL REP, V28, P1417, DOI 10.3892/or.2012.1940
   Prando ED, 2011, EPIGENETICS-US, V6, P1413, DOI 10.4161/epi.6.12.18271
   Schönorf T, 2004, CANCER LETT, V207, P215, DOI 10.1016/j.canlet.2003.10.028
   Shetty Preetha J, 2011, Breast Dis, V33, P27, DOI 10.3233/BD-2010-0312
   Si J, 2010, CANCER RES, V70, P6968, DOI 10.1158/0008-5472.CAN-09-4474
   Stephen JK, 2009, INT J GYNECOL PATHOL, V28, P63, DOI 10.1097/PGP.0b013e31817d9c61
   Stewart DJ, 2014, CLIN EPIGENETICS, V6, DOI 10.1186/1868-7083-6-2
   Stewart DJ, 2009, CLIN CANCER RES, V15, P3881, DOI 10.1158/1078-0432.CCR-08-2196
   Swisher SG, 1999, J NATL CANCER I, V91, P763, DOI 10.1093/jnci/91.9.763
   Tamura G, 2004, HISTOL HISTOPATHOL, V19, P221, DOI 10.14670/HH-19.221
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Yang HJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-212
   Yang W, 2012, NEOPLASMA, V59, P216, DOI 10.4149/neo_2012_028
   Yin L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062971
   Yu J, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-29
   Zhang XY, 2013, J GASTROENTEROL, V48, P132, DOI 10.1007/s00535-012-0621-0
   Zöchbauer-Müller S, 2001, CANCER RES, V61, P3581
NR 51
TC 8
Z9 9
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JUL 3
PY 2014
VL 6
AR 13
DI 10.1186/1868-7083-6-13
PG 7
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA AL1JN
UT WOS:000338881800001
PM 25024751
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Masson, AL
   Talseth-Palmer, BA
   Evans, TJ
   Grice, DM
   Hannan, GN
   Scott, RJ
AF Masson, Amy L.
   Talseth-Palmer, Bente A.
   Evans, Tiffany-Jane
   Grice, Desma M.
   Hannan, Garry N.
   Scott, Rodney J.
TI Expanding the genetic basis of copy number variation in familial breast
   cancer
SO HEREDITARY CANCER IN CLINICAL PRACTICE
LA English
DT Article
DE Breast cancer; DNA repair; CNV
ID FHIT GENE; GENOMIC REARRANGEMENTS; ADENOMATOUS POLYPOSIS; PROMOTER
   METHYLATION; TUMOR-SUPPRESSOR; FUNCTIONAL-ROLE; EXPRESSION; GERMLINE;
   DELETION; SUSCEPTIBILITY
AB Introduction: Familial breast cancer (fBC) is generally associated with an early age of diagnosis and a higher frequency of disease among family members. Over the past two decades a number of genes have been identified that are unequivocally associated with breast cancer (BC) risk but there remain a significant proportion of families that cannot be accounted for by these genes. Copy number variants (CNVs) are a form of genetic variation yet to be fully explored for their contribution to fBC. CNVs exert their effects by either being associated with whole or partial gene deletions or duplications and by interrupting epigenetic patterning thereby contributing to disease development. CNV analysis can also be used to identify new genes and loci which may be associated with disease risk.
   Methods: The Affymetrix Cytogenetic Whole Genome 2.7 M (Cyto2.7 M) arrays were used to detect regions of genomic re-arrangement in a cohort of 129 fBC BRCA1/BRCA2 mutation negative patients with a young age of diagnosis (< 50 years) compared to 40 unaffected healthy controls (> 55 years of age).
   Results: CNV analysis revealed the presence of 275 unique rearrangements that were not present in the control population suggestive of their involvement in BC risk. Several CNVs were found that have been previously reported as BC susceptibility genes. This included CNVs in RPA3, NBN (NBS1), MRE11A and CYP19A1 in five unrelated fBC patients suggesting that these genes are involved in BC initiation and/or progression. Of special interest was the identification of WWOX and FHIT rearrangements in three unrelated fBC patients.
   Conclusions: This study has identified a number of CNVs that potentially contribute to BC initiation and/or progression. The identification of CNVs that are associated with known tumour suppressor genes is of special interest that warrants further larger studies to understand their precise role in fBC.
C1 [Masson, Amy L.; Talseth-Palmer, Bente A.; Evans, Tiffany-Jane; Grice, Desma M.; Scott, Rodney J.] Univ Newcastle, Hunter Med Res Inst, Informat Based Med Program, Newcastle, NSW 2305, Australia.
   [Grice, Desma M.; Hannan, Garry N.] CSIRO, Food & Hlth Sci Div, CSIRO Preventat Hlth Flagship & Anim, N Ryde, NSW 2113, Australia.
   [Scott, Rodney J.] John Hunter Hosp, Hunter Area Pathol Serv, Div Mol Med, Newcastle, NSW 2305, Australia.
   [Masson, Amy L.; Talseth-Palmer, Bente A.; Evans, Tiffany-Jane; Scott, Rodney J.] Univ Newcastle, Fac Hlth, Sch Pharm & Biomed Sci, Newcastle, NSW 2308, Australia.
C3 University of Newcastle; Hunter Medical Research Institute; Commonwealth
   Scientific & Industrial Research Organisation (CSIRO); John Hunter
   Hospital; University of Newcastle
RP Scott, RJ (通讯作者)，Univ Newcastle, Hunter Med Res Inst, Informat Based Med Program, Newcastle, NSW 2305, Australia.
EM Rodney.Scott@newcastle.edu.au
RI HANNAN, GARRY/H-8594-2013; Grice, Desma/A-7730-2011; Talseth-Palmer,
   Bente/D-7106-2012; EVANS, TIFFANY-JANE/G-8001-2013; Scott,
   Rodney/B-2827-2013
OI Talseth-Palmer, Bente/0000-0003-0286-7161; Scott,
   Rodney/0000-0001-7724-3404
FU Australian Rotary Health/Rotary District 9650; Commonwealth Scientific
   and Industrial Research Organization (CSIRO); University of Newcastle
   and the Hunter Medical Research Institute
FX This work has been supported by the following funding bodies and
   institutions: Australian Rotary Health/Rotary District 9650, the
   Commonwealth Scientific and Industrial Research Organization (CSIRO),
   the University of Newcastle and the Hunter Medical Research Institute.
   Samples were provided by the Hunter Area Pathology Service and the
   Hunter Community Study.
CR Abdeen SK, 2011, ONCOGENE, V30, P3900, DOI 10.1038/onc.2011.115
   Alonso-Espinaco V, 2011, GENET MED, V13, P155, DOI 10.1097/GIM.0b013e318202e10b
   [Anonymous], 2012, CANC GEN CENS
   [Anonymous], 2013, QUICKCALCS T TEST
   Arun B, 2005, CANCER EPIDEM BIOMAR, V14, P1681, DOI 10.1158/1055-9965.EPI-04-0278
   Bajrami I, 2012, EMBO MOL MED, V4, P1087, DOI 10.1002/emmm.201201250
   Bartkova J, 2008, MOL ONCOL, V2, P296, DOI 10.1016/j.molonc.2008.09.007
   Bianchi F, 2007, CELL CYCLE, V6, P643, DOI 10.4161/cc.6.6.4033
   Campiglio M, 1999, CANCER RES, V59, P3866
   Çeçener G, 2007, TUMORI J, V93, P597
   Chan TL, 2001, ONCOGENE, V20, P2976, DOI 10.1038/sj.onc.1204376
   Chang NS, 2001, J BIOL CHEM, V276, P3361, DOI 10.1074/jbc.M007140200
   Chang XZ, 2008, BREAST CANCER RES TR, V111, P65, DOI 10.1007/s10549-007-9761-y
   Charames GS, 2008, HUM GENET, V124, P535, DOI 10.1007/s00439-008-0579-4
   Clendenning M, 2011, FAM CANCER, V10, P297, DOI 10.1007/s10689-011-9427-0
   D'Antonio M, 2012, NUCLEIC ACIDS RES, V40, pD978, DOI 10.1093/nar/gkr952
   Dellinger AE, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq040
   Delnatte C, 2006, AM J HUM GENET, V78, P1066, DOI 10.1086/504301
   Ekizoglu S, 2012, MED ONCOL, V29, P1529, DOI 10.1007/s12032-011-0080-0
   Eremo AG, 2013, ONCOL REP, V29, P1467, DOI 10.3892/or.2013.2261
   Giarola M, 1999, HUM MUTAT, V13, P116, DOI 10.1002/(SICI)1098-1004(1999)13:2<116::AID-HUMU3>3.0.CO;2-2
   Heikkinen K, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.12.e131
   Hsu HM, 2007, CANCER EPIDEM BIOMAR, V16, P2024, DOI 10.1158/1055-9965.EPI-07-0116
   Iliopoulos D, 2006, CANCER LETT, V232, P27, DOI 10.1016/j.canlet.2005.06.048
   Ismail HMS, 2011, INT J BREAST CANCER, V2011, DOI 10.4061/2011/325947
   Ismail HMS, 2011, MOL CARCINOGEN, V50, P625, DOI 10.1002/mc.20797
   Gracia-Aznarez FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055681
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Krepischi ACV, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3109
   Kuiper RP, 2011, HUM MUTAT, V32, P407, DOI 10.1002/humu.21446
   Lalloo F, 2012, CLIN GENET, V82, P105, DOI 10.1111/j.1399-0004.2012.01859.x
   Li DQ, 2006, EUR J CANCER, V42, P3274, DOI 10.1016/j.ejca.2006.07.008
   Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283
   Lucito R, 2007, CANCER BIOL THER, V6, P1592, DOI 10.4161/cbt.6.10.4725
   Lynch HT, 1999, J MED GENET, V36, P801
   McEvoy M, 2010, INT J EPIDEMIOL, V39, P1452, DOI 10.1093/ije/dyp343
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   MILLER SA, 1988, NUCLEIC ACIDS RES, V0016
   Morak M, 2011, J MED GENET, V48, P513, DOI 10.1136/jmedgenet-2011-100050
   Murata H, 2005, CANCER LETT, V223, P143, DOI 10.1016/j.canlet.2004.09.039
   Naylor TL, 2005, BREAST CANCER RES, V7, pR1186, DOI 10.1186/bcr1356
   Negrini M, 1996, CANCER RES, V56, P3173
   NYSTROMLAHTI M, 1995, NAT MED, V1, P1203, DOI 10.1038/nm1195-1203
   Ong DCT, 2009, ONCOGENE, V28, P4189, DOI 10.1038/onc.2009.266
   Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503
   Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533
   Plaschke J, 2003, J MED GENET, V40, P597, DOI 10.1136/jmg.40.8.597
   Rohlin A, 2011, ONCOGENE, V30, P4977, DOI 10.1038/onc.2011.201
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6389
   Stella A, 2007, CLIN GENET, V71, P130, DOI 10.1111/j.1399-0004.2007.00745.x
   Suehiro Y, 2013, TUMOR BIOL, V34, P947, DOI 10.1007/s13277-012-0630-x
   Tsuang DW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014456
   Van Hattem WA, 2008, GUT, V57, P623, DOI 10.1136/gut.2007.142927
   Vodusek AL, 2011, RADIOL ONCOL, V45, P296, DOI 10.2478/v10019-011-0031-6
   Wong MW, 2011, BREAST CANCER RES TR, V127, P853, DOI 10.1007/s10549-011-1443-0
   Yoshihara K, 2011, GENE CHROMOSOME CANC, V50, P167, DOI 10.1002/gcc.20841
   Yuan SSF, 2012, JNCI-J NATL CANCER I, V104, P1485, DOI 10.1093/jnci/djs355
   Zhang B, 2005, NUCLEIC ACIDS RES, V33, pW741, DOI 10.1093/nar/gki475
   Zhang B, 2011, LANCET ONCOL, V12, P477, DOI 10.1016/S1470-2045(11)70076-6
   Zhang DD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014511
NR 60
TC 12
Z9 13
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1731-2302
EI 1897-4287
J9 HERED CANCER CLIN PR
JI Hered. Cancer Clin. Pract.
PD MAY 24
PY 2014
VL 12
AR 15
DI 10.1186/1897-4287-12-15
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK8HR
UT WOS:000338669000001
PM 24955146
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Xavier, FCA
   Destro, MFDS
   Duarte, CME
   Nunes, FD
AF Aquino Xavier, Flavia Calo
   de Souza Setubal Destro, Maria Fernanda
   Esteves Duarte, Carina Magalhaes
   Nunes, Fabio Daumas
TI Epigenetic repression of <i>HOXB</i> cluster in oral cancer cell lines
SO ARCHIVES OF ORAL BIOLOGY
LA English
DT Article
DE DNA methylation; Epigenetics; Oral cancer; HOX genes
ID HOMEOBOX GENE-EXPRESSION; DE-NOVO METHYLATION; DNA METHYLATION; PROMOTER
   HYPERMETHYLATION; CARCINOMA TISSUES; BREAST-CANCER; CPG ISLANDS;
   OVEREXPRESSION; IDENTIFICATION; PATHWAY
AB Objective: Aberrant DNA methylation is a fundamental transcriptional control mechanism in carcinogenesis. The expression of homeobox genes is usually controlled by an epigenetic mechanism, such as the methylation of CpG islands in the promoter region. The aim of this study was to describe the differential methylation pattern of HOX genes in oral squamous cell carcinoma (OSCC) cell lines and transcript status in a group of hypermethylated and hypomethylated genes.
   Design: Quantitative analysis of DNA methylation was performed on two OSCC cell lines (SCC4 and SCC9) using a method denominated Human Homeobox Genes EpiTect Methyl qPCR Arrays, which allowed fast, precise methylation detection of 24 HOX specific genes without bisulfite conversion.
   Results: Methylation greater than 50% was detected in HOXA11, HOXA6, HOXA7, HOXA9, HOXB1, HOXB2, HOXB3, HOXB4, HOXB5, HOXB6, HOXC8 and HOXD10. Both cell lines demonstrated similar hypermethylation status for eight HOX genes. A similar pattern of promoter hypermethylation and hypomethylation was demonstrated for the HOXB cluster and HOXA cluster, respectively. Moreover, the hypermethylation profile of the HOXB cluster, especially HOXB4, was correlated with decreased transcript expression, which was restored following treatment with 5-aza-2'-deoxycytidine.
   Conclusions: The homeobox methylation profile in OSCC cell lines is consistent with an epigenetic biomarker. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Aquino Xavier, Flavia Calo] Univ Fed Bahia, Sch Dent, Dept Propaedeut, BR-40110150 Salvador, BA, Brazil.
   [Aquino Xavier, Flavia Calo] Univ Fed Bahia, Sch Dent, Integrated Clin, BR-40110150 Salvador, BA, Brazil.
   [de Souza Setubal Destro, Maria Fernanda; Esteves Duarte, Carina Magalhaes; Nunes, Fabio Daumas] Univ Sao Paulo, Dept Estomatol, BR-05508000 Butanta Sao Paulo, SP, Brazil.
C3 Universidade Federal da Bahia; Universidade Federal da Bahia;
   Universidade de Sao Paulo
RP Nunes, FD (通讯作者)，Univ Sao Paulo, Dept Estomatol, Av Prof Lineu Prestes 2227, BR-05508000 Butanta Sao Paulo, SP, Brazil.
EM fadnunes@usp.br
RI Rodrigues, Maria Fernanda/E-7820-2018; Xavier, Flávia/ABB-4632-2020;
   Duarte, Catarina/E-8404-2016; Nunes, Fabio Daumas/B-4543-2011
OI Nunes, Fabio Daumas/0000-0002-7785-6785; Rodrigues, Maria
   Fernanda/0000-0002-3067-9224; Xavier, Flavia/0000-0002-0199-6503
FU Fundacao de Amparo a Pesquisa do Estado de Sao Paulo/FAPESP
   [2010/08720-4, 2009/06521-7]; Fundacao de Amparo a Pesquisa do Estado de
   Sao Paulo (FAPESP) [09/06521-7, 10/08720-4] Funding Source: FAPESP
FX The authors acknowledge the financial support from the Brazilian
   fostering agency Fundacao de Amparo a Pesquisa do Estado de Sao
   Paulo/FAPESP (Grant no. 2010/08720-4 and 2009/06521-7).
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Bach C, 2010, BLOOD, V115, P2910, DOI 10.1182/blood-2009-04-216606
   Cillo C, 2001, J CELL PHYSIOL, V188, P161, DOI 10.1002/jcp.1115
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Destro MFDS, 2010, INT J ONCOL, V36, P141, DOI 10.3892/ijo_00000485
   Di VA, 2012, J CANCER RES CLIN, V138, P35
   Durston AJ, 2011, INT J DEV BIOL, V55, P899, DOI 10.1387/ijdb.113358ad
   Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909
   Ferraiuolo MA, 2010, NUCLEIC ACIDS RES, V38, P7472, DOI 10.1093/nar/gkq644
   Garcia-Fernàndez J, 2005, NAT REV GENET, V6, P881, DOI 10.1038/nrg1723
   Gordon-Keylock SAM, 2010, STEM CELLS DEV, V19, P1687, DOI 10.1089/scd.2009.0467
   Grier DG, 2005, J PATHOL, V205, P154, DOI 10.1002/path.1710
   Guerrero-Preston R, 2011, CANCER PREV RES, V4, P1061, DOI 10.1158/1940-6207.CAPR-11-0006
   Hassan NMM, 2006, ONCOL RES, V16, P217, DOI 10.3727/000000006783981080
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Hwang SH, 2011, CLIN CHEM LAB MED, V49, P699, DOI 10.1515/CCLM.2011.108
   JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Laird PW, 2003, NAT REV CANCER, V3, P253, DOI 10.1038/nrc1045
   Libório TN, 2011, HISTOPATHOLOGY, V58, P225, DOI 10.1111/j.1365-2559.2011.03751.x
   Matizonkas-Antonio LF, 2011, ORAL SURG ORAL MED O, V111, P218, DOI 10.1016/j.tripleo.2010.10.003
   Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Omura Noriyuki, 2008, Proceedings of the American Association for Cancer Research Annual Meeting, V49, P7
   Rakyan VK, 2004, PLOS BIOL, V2, P2170, DOI 10.1371/journal.pbio.0020405
   Rauch T, 2007, P NATL ACAD SCI USA, V104, P5527, DOI 10.1073/pnas.0701059104
   Rodini CO, 2012, INT J ONCOL, V40, P1180, DOI 10.3892/ijo.2011.1321
   Rodríguez-Rodero S, 2013, J CLIN ENDOCR METAB, V98, P2811, DOI 10.1210/jc.2012-3566
   Samuel S, 2005, EUR J CANCER, V41, P2428, DOI 10.1016/j.ejca.2005.08.014
   Shames DS, 2006, PLOS MED, V3, P2244, DOI 10.1371/journal.pmed.0030486
   Shaw R, 2006, INT J ORAL MAX SURG, V35, P101, DOI 10.1016/j.ijom.2005.06.014
   Shiraishi M, 2002, ONCOGENE, V21, P3659, DOI 10.1038/sj.onc.1205453
   Shu Y, 2011, WORLD J GASTROENTERO, V17, P3407, DOI 10.3748/wjg.v17.i29.3407
   Soshnikova N, 2008, BIOESSAYS, V30, P199, DOI 10.1002/bies.20724
   Su PF, 2010, ORAL ONCOL, V46, P734, DOI 10.1016/j.oraloncology.2010.07.002
   Sun M, 2013, P NATL ACAD SCI USA, V110, P9920, DOI 10.1073/pnas.1305172110
   Wajed SA, 2001, ANN SURG, V234, P10, DOI 10.1097/00000658-200107000-00003
   Wang LJ, 2012, MOL MED, V18, P389, DOI 10.2119/molmed.2011.00172
   WILSON V L, 1983, Science (Washington D C), V220, P1055, DOI 10.1126/science.6844925
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
   Zhu F, 2004, J BIOCHEM MOL BIOL, V37, P671
NR 42
TC 30
Z9 32
U1 0
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0003-9969
EI 1879-1506
J9 ARCH ORAL BIOL
JI Arch. Oral Biol.
PD AUG
PY 2014
VL 59
IS 8
BP 783
EP 789
DI 10.1016/j.archoralbio.2014.05.001
PG 7
WC Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine
GA AL0MZ
UT WOS:000338822300003
PM 24859765
DA 2025-01-12
ER

PT J
AU Bai, XS
   Zhang, EK
   Ye, H
   Nandakumar, V
   Wang, Z
   Chen, LH
   Tang, CN
   Li, JH
   Li, HJ
   Zhang, W
   Han, W
   Lou, F
   Zhang, DD
   Sun, H
   Dong, HC
   Zhang, GC
   Liu, ZY
   Dong, ZS
   Guo, BS
   Yan, H
   Yan, CW
   Wang, L
   Su, ZY
   Li, YY
   Jones, L
   Huang, XF
   Chen, SY
   Gao, JL
AF Bai, Xusheng
   Zhang, Enke
   Ye, Hua
   Nandakumar, Vijayalakshmi
   Wang, Zhuo
   Chen, Lihong
   Tang, Chuanning
   Li, Jianhui
   Li, Huijin
   Zhang, Wei
   Han, Wei
   Lou, Feng
   Zhang, Dandan
   Sun, Hong
   Dong, Haichao
   Zhang, Guangchun
   Liu, Zhiyuan
   Dong, Zhishou
   Guo, Baishuai
   Yan, He
   Yan, Chaowei
   Wang, Lu
   Su, Ziyi
   Li, Yangyang
   Jones, Lindsey
   Huang, Xue F.
   Chen, Si-Yi
   Gao, Jinglong
TI PIK3CA and TP53 Gene Mutations in Human Breast Cancer Tumors Frequently
   Detected by Ion Torrent DNA Sequencing
SO PLOS ONE
LA English
DT Article
ID KINASE INHIBITORS; OVARIAN-CANCER; PREVENTION; EXPRESSION; LAPATINIB;
   HER2; P53; REDUCTION; EFFICACY; RECEPTOR
AB Breast cancer is the most common malignancy and the leading cause of cancer deaths in women worldwide. While specific genetic mutations have been linked to 5-10% of breast cancer cases, other environmental and epigenetic factors influence the development and progression of the cancer. Since unique mutations patterns have been observed in individual cancer samples, identification and characterization of the distinctive breast cancer molecular profile is needed to develop more effective target therapies. Until recently, identifying genetic cancer mutations via personalized DNA sequencing was impractical and expensive. The recent technological advancements in next-generation DNA sequencing, such as the semiconductor-based Ion Torrent sequencing platform, has made DNA sequencing cost and time effective with more reliable results. Using the Ion Torrent Ampliseq Cancer Panel, we sequenced 737 loci from 45 cancer-related genes to identify genetic mutations in 105 human breast cancer samples. The sequencing analysis revealed missense mutations in PIK3CA, and TP53 genes in the breast cancer samples of various histologic types. Thus, this study demonstrates the necessity of sequencing individual human cancers in order to develop personalized drugs or combination therapies to effectively target individual, breast cancer-specific mutations.
C1 [Bai, Xusheng; Zhang, Enke; Wang, Zhuo; Chen, Lihong; Li, Jianhui; Li, Huijin; Zhang, Wei; Han, Wei; Gao, Jinglong] Peoples Hosp Shan Xi Prov, Cent Lab, Xian, Peoples R China.
   [Ye, Hua; Tang, Chuanning; Lou, Feng; Zhang, Dandan; Sun, Hong; Dong, Haichao; Zhang, Guangchun; Liu, Zhiyuan; Dong, Zhishou; Guo, Baishuai; Yan, He; Yan, Chaowei; Wang, Lu; Su, Ziyi; Li, Yangyang] San Valley Biotechnol Inc, Beijing, Peoples R China.
   [Jones, Lindsey; Huang, Xue F.; Chen, Si-Yi] Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
C3 University of Southern California
RP Chen, SY (通讯作者)，Univ So Calif, Keck Sch Med, Dept Mol Microbiol & Immunol, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
EM siyichen@usc.edu; gaojinglong126@126.com
RI HUANG, XUEFENG/AIE-2682-2022; chen, siyi/KXR-2904-2024; Su,
   Ziyi/KIJ-8297-2024; Zhang, Guangchun/LNQ-3061-2024; zhang,
   dan-dan/AAR-5085-2020
FU National Natural Science Foundation of China; Wu Jieping Foundation;
   National Institute of Health [R01 CA90427, R01 AI084811]
FX This research was supported by the grants from National Natural Science
   Foundation of China, the Wu Jieping Foundation, and the National
   Institute of Health (R01 CA90427 & R01 AI084811 to SY Chen). The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Alsner J, 2000, CLIN CANCER RES, V6, P3923
   [Anonymous], 2013, GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC cancer base
   Bader AG, 2006, P NATL ACAD SCI USA, V103, P1475, DOI 10.1073/pnas.0510857103
   Beadling C, 2013, J MOL DIAGN, V15, P171, DOI 10.1016/j.jmoldx.2012.09.003
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Bertucci Francois, 2008, J Biol, V7, P6, DOI 10.1186/jbiol67
   Blackburn GL, 2007, AM J CLIN NUTR, V86, p878S, DOI 10.1093/ajcn/86.3.878S
   Brody JG, 2007, CANCER-AM CANCER SOC, V109, P2627, DOI 10.1002/cncr.22656
   Cauley JA, 2001, BREAST CANCER RES TR, V65, P125, DOI 10.1023/A:1006478317173
   Chen WY, 2007, NAT CLIN PRACT ONCOL, V4, P415, DOI 10.1038/ncponc0851
   Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6
   EASTON DF, 1995, AM J HUM GENET, V56, P265
   Etzioni R, 2003, NAT REV CANCER, V3, P243, DOI 10.1038/nrc1041
   Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106
   Fabian CJ, 2007, INT J CLIN PRACT, V61, P2051, DOI 10.1111/j.1742-1241.2007.01587.x
   Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054
   Hadd AG, 2013, J MOL DIAGN, V15, P234, DOI 10.1016/j.jmoldx.2012.11.006
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593
   Langerod A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1675
   Lazzeroni M, 2013, HEMATOL ONCOL CLIN N, V27, P657, DOI 10.1016/j.hoc.2013.05.009
   Levin B, 2012, MOL MED, V18, P1327, DOI 10.2119/molmed.2012.00280
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Montemurro F, 2007, EXPERT OPIN BIOL TH, V7, P257, DOI 10.1517/14712598.7.2.257
   Nakopoulou LL, 1996, J PATHOL, V179, P31, DOI 10.1002/(SICI)1096-9896(199605)179:1<31::AID-PATH523>3.0.CO;2-O
   Nielsen DL, 2013, BREAST, V22, P1, DOI 10.1016/j.breast.2012.09.008
   Obiorah I, 2011, MATURITAS, V70, P315, DOI 10.1016/j.maturitas.2011.09.006
   Perez-Tenorio G, 2007, CLIN CANCER RES, V13, P3577, DOI 10.1158/1078-0432.CCR-06-1609
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628
   Roukos DH, 2012, ANN SURG ONCOL, V19, P3646, DOI 10.1245/s10434-012-2542-9
   Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134
   Singh RR, 2013, J MOL DIAGN, V15, P607, DOI 10.1016/j.jmoldx.2013.05.003
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Toi M, 2009, BRIT J CANCER, V101, P1676, DOI 10.1038/sj.bjc.6605343
   Wooster R, 2003, NEW ENGL J MED, V348, P2339, DOI 10.1056/NEJMra012284
   Xia WL, 2007, CANCER RES, V67, P1170, DOI 10.1158/0008-5472.CAN-06-2101
   Xu Bing-He, 2011, Chin J Cancer, V30, P327
   Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244
NR 39
TC 32
Z9 34
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 11
PY 2014
VL 9
IS 6
AR e99306
DI 10.1371/journal.pone.0099306
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AK7TQ
UT WOS:000338631000074
PM 24918944
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Azam, R
   Ghafouri-Fard, S
   Tabrizi, M
   Modarressi, MH
   Ebrahimzadeh-Vesal, R
   Daneshvar, M
   Mobasheri, MB
   Motevaseli, E
AF Azam, Rosa
   Ghafouri-Fard, Soudeh
   Tabrizi, Mina
   Modarressi, Mohammad-Hossein
   Ebrahimzadeh-Vesal, Reza
   Daneshvar, Maryam
   Mobasheri, Maryam Beigom
   Motevaseli, Elahe
TI <i>Lactobacillus acidophilus</i> and <i>Lactobacillus crispatus</i>
   Culture Supernatants Downregulate Expression of Cancer-testis Genes in
   the MDA-MB-231 Cell Line
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE MDA-MB-231; Lactobacillus acidophilus; Lactobacillus crispatus;
   cancer-testis antigens
ID IN-VITRO; VAGINAL LACTOBACILLI; BACTERIAL VAGINOSIS; BREAST-CANCER;
   RHAMNOSUS GG; GROWTH; TSGA10; WOMEN; IDENTIFICATION; IMMUNOTHERAPY
AB Lactobacilli are probiotics shown to have antitumor activities. In addition, they can regulate gene expression through epigenetic mechanisms. In this study, we aimed to assess anti tumor activities of Lactobacillus acidophilus and Lactobacillus crispatus on the MDA-MB-231 breast cancer cell line. The effects of culture supernatants were determined by MTT [3-(4,5-dimethylthiazol-2-y-2,5-diphenyltetrazolium bromide] assay. Changes in expression of 5 cancer-testis antigens (CTAs), namely AKAP4, ODF4, PIWIL2, RHOXF2 and TSGA10, were analyzed by quantitative real time RT-PCR. The culture supernatants of the 2 lactobacilli inhibited MDA-MB-231 cell proliferation. In addition, transcriptional activity of all mentioned CTAs except AKAP4 was significantly decreased after 24 hour treatment with culture supernatants. This study shows that Lactobacillus acidophilus and Lactobacillus crispatus have antiproliferative activity against MDA-MB-231 cells. In addition, these lactobacilli could decrease transcriptional activity of 4 CTAs. Previous studies have shown that expression of CTAs is epigenetically regulated, so it is possible that lactobacilli cause this expression downregulation through epigenetic mechanisms. As expression of CTAs in cancers is usually associated with higher grades and poor prognosis, downregulation of their expression by lactobacilli may have clinical implications.
C1 [Azam, Rosa; Tabrizi, Mina; Modarressi, Mohammad-Hossein; Ebrahimzadeh-Vesal, Reza; Daneshvar, Maryam] Univ Tehran Med Sci, Dept Med Genet, Tehran, Iran.
   [Motevaseli, Elahe] Univ Tehran Med Sci, Sch Adv Med Technol, Dept Med Biotechnol, Tehran, Iran.
   [Mobasheri, Maryam Beigom] Univ Tehran Med Sci, Canc Res Ctr, Inst Canc, Tehran, Iran.
   [Ghafouri-Fard, Soudeh] Shahid Beheshti Univ Med Sci, Dept Med Genet, Tehran, Iran.
C3 Tehran University of Medical Sciences; Tehran University of Medical
   Sciences; Tehran University of Medical Sciences; Shahid Beheshti
   University Medical Sciences
RP Motevaseli, E (通讯作者)，Univ Tehran Med Sci, Sch Adv Med Technol, Dept Med Biotechnol, Tehran, Iran.
EM e_motevaseli@tums.ac.ir
RI Modarressi, Mohammad/AAL-8377-2020; Ghafouri-Fard, Soudeh/O-7994-2019; ,
   reza/H-4352-2018
OI Modarressi, Mohammad hossein/0000-0003-2763-1964; Ghafouri-Fard,
   Soudeh/0000-0002-0223-499X; , reza/0000-0003-2976-7988
CR Akers SN, 2010, FUTURE ONCOL, V6, P717, DOI 10.2217/FON.10.36
   Dianatpour M, 2012, IRAN RED CRESCENT ME, V14, P719, DOI 10.5812/ircmj.3611
   Ghadimi D, 2012, J LEUKOCYTE BIOL, V92, P895, DOI 10.1189/jlb.0611286
   Ghafouri-Fard S, 2012, ASIAN PAC J CANCER P, V13, P5865, DOI 10.7314/APJCP.2012.13.11.5865
   Ghafouri-Fard S, 2012, ANN SAUDI MED, V32, P256, DOI 10.5144/0256-4947.2012.256
   Ghafouri-Fard S, 2009, ARCH IRAN MED, V12, P395
   Gold MG, 2006, MOL CELL, V24, P383, DOI 10.1016/j.molcel.2006.09.006
   Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105
   Isolauri E, 2001, AM J CLIN NUTR, V73, p1142S
   Kim Y, 2010, LETT APPL MICROBIOL, V51, P123, DOI 10.1111/j.1472-765X.2010.02859.x
   Liu JJ, 2010, INT J CLIN EXP PATHO, V3, P328
   Maroof H, 2012, J CLIN IMMUNOL, V32, P1353, DOI 10.1007/s10875-012-9708-x
   McLean NW, 2000, J MED MICROBIOL, V49, P543, DOI 10.1099/0022-1317-49-6-543
   MEURMAN JH, 1995, EUR J ORAL SCI, V103, P253, DOI 10.1111/j.1600-0722.1995.tb00169.x
   Mobasheri MB, 2007, CANCER DETECT PREV, V31, P296, DOI 10.1016/j.cdp.2007.05.002
   Mobasheri MB, 2006, LEUKEMIA RES, V30, P883, DOI 10.1016/j.leukres.2005.11.012
   Motevaseli E, 2013, IRAN RED CRESCENT ME, V15, P199, DOI 10.5812/ircmj.3533
   Moteyaseli E, 2013, J MED MICROBIOL, V62, P1065, DOI 10.1099/jmm.0.057521-0
   Nakagawa Y, 2001, MOL BIOL CELL, V12, P1687, DOI 10.1091/mbc.12.6.1687
   Oh SJ, 2012, KOREAN J PATHOL, V46, P318, DOI 10.4132/KoreanJPathol.2012.46.4.318
   Orlando A, 2012, NUTR CANCER, V64, P1103, DOI 10.1080/01635581.2012.717676
   Otles Semih, 2003, Asian Pac J Cancer Prev, V4, P369
   Russo F, 2007, NUTR CANCER, V59, P106, DOI 10.1080/01635580701365084
   Saini S, 2013, CANCER GENE THER, V20, P413, DOI 10.1038/cgt.2013.32
   Saini S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057095
   Seifi-Alan M, 2013, ASIAN PAC J CANCER P, V14, P6625, DOI 10.7314/APJCP.2013.14.11.6625
   Shibata-Minoshima F, 2012, INT J ONCOL, V40, P93, DOI 10.3892/ijo.2011.1173
   Vásquez A, 2002, J CLIN MICROBIOL, V40, P2746, DOI 10.1128/JCM.40.8.2746-2749.2002
   Yuan X, 2013, INT J CLIN EXP PATHO, V6, P2651
NR 29
TC 44
Z9 52
U1 2
U2 16
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2014
VL 15
IS 10
BP 4255
EP 4259
DI 10.7314/APJCP.2014.15.10.4255
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK7UY
UT WOS:000338634400025
PM 24935380
OA Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ma, R
   Fredriksson, I
   Karthik, GM
   Winn, G
   Darai-Ramqvist, E
   Bergh, J
   Hartman, J
AF Ma, Ran
   Fredriksson, Irma
   Karthik, Govindasamy-Muralidharan
   Winn, Gregory
   Darai-Ramqvist, Eva
   Bergh, Jonas
   Hartman, Johan
TI Superficial scrapings from breast tumors is a source for biobanking and
   research purposes
SO LABORATORY INVESTIGATION
LA English
DT Article
DE mammary neoplasia; pathology; superficial scrapings; tissue biobanking;
   tumor-initiating cells
ID FRESH-FROZEN TISSUE; ESTROGEN-RECEPTOR-ALPHA; CANCER CELLS;
   EPITHELIAL-CELLS; QUALITY-CONTROL; RNA QUALITY; EXPRESSION; COLLECTION;
   EXTRACTION; CONSENSUS
AB Breast cancer is a unique tumor disease in terms of the stringent requirement of predictive biomarker assessments. As recommended by current international guidelines, the established markers consist of estrogen receptor (ER), progesterone receptor, human epidermal growth factor and Ki67, and are primarily analyzed by immunohistochemistry. However, new diagnostic methods based on microarray or next-generation sequencing on DNA and mRNA level are gaining ground. These analyses require fresh-frozen tumor tissue that is generally not available from tumors <10 mm in diameter, comprising almost 25% of all resected breast cancer at our department. We here present a simple and standardized method to generate material from small tumors without risking the histopathological examination. Furthermore, we show that the quality of this material is sufficient for subsequent analysis on mRNA, DNA, and epigenetic level. We were also able to use this method for isolation and expansion of cancer stem cells from the majority of tumors. Consequently, researches can be provided with clinically relevant material for translational studies. In conclusion, this method opens up a new possibility for usage of valuable fresh tumor material for research purposes, biobanking, and next-generation sequencing.
C1 [Ma, Ran; Karthik, Govindasamy-Muralidharan; Bergh, Jonas; Hartman, Johan] Karolinska Inst, Canc Ctr Karolinska, Dept Oncol, Stockholm, Sweden.
   [Ma, Ran; Karthik, Govindasamy-Muralidharan; Bergh, Jonas; Hartman, Johan] Karolinska Inst, Canc Ctr Karolinska, Dept Pathol, Stockholm, Sweden.
   [Fredriksson, Irma] Karolinska Inst, Dept Mol Med, Stockholm, Sweden.
   [Fredriksson, Irma] Karolinska Inst, Dept Surg, Stockholm, Sweden.
   [Fredriksson, Irma] Karolinska Inst, Dept Breast, Stockholm, Sweden.
   [Fredriksson, Irma] Karolinska Inst, Dept Endocrine Surg, Stockholm, Sweden.
   [Bergh, Jonas] Karolinska Univ Hosp, Radiumhemmet Karolinska Oncol, S-17176 Stockholm, Sweden.
   [Winn, Gregory; Darai-Ramqvist, Eva; Hartman, Johan] Karolinska Univ Hosp, Dept Clin Pathol, S-17176 Stockholm, Sweden.
   [Winn, Gregory; Darai-Ramqvist, Eva; Hartman, Johan] Karolinska Univ Hosp, Dept Cytol, S-17176 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska Institutet; Karolinska Institutet; Karolinska Institutet;
   Karolinska Institutet; Karolinska University Hospital; Karolinska
   Institutet; Karolinska University Hospital; Karolinska Institutet;
   Karolinska University Hospital
RP Hartman, J (通讯作者)，Karolinska Univ Hosp, Dept Clin Pathol, Karolinska Vagen, S-17176 Stockholm, Sweden.
EM johan.hartman@ki.se
RI Fredriksson, Irma/C-6954-2019; Hartman, Johan/N-1406-2015
OI Hartman, Johan/0000-0002-6500-8527; Fredriksson,
   Irma/0000-0001-7811-9317; Bergh, Jonas/0000-0001-5526-1847
FU Swedish Research Council (VR); Breast Cancer Theme Center (BRECT);
   Swedish Cancer Society; research funds at Radiumhemmet; Swedish Society
   for Medical Research (SSMF)
FX We thank Susanne Agartz for the management of patient materials, and
   Simon Sundling for the technical assistance in this study. Swedish
   Research Council (VR), the Breast Cancer Theme Center (BRECT), the
   Swedish Cancer Society, the research funds at Radiumhemmet, Swedish
   Society for Medical Research (SSMF) provided funding for experiments in
   the study.
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Bao WG, 2013, ANN SURG ONCOL, V20, P1737, DOI 10.1245/s10434-012-2440-1
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Bertilsson H, 2010, SCAND J CLIN LAB INV, V70, P45, DOI 10.3109/00365510903540815
   Botling J, 2011, METHODS MOL BIOL, V675, P405, DOI 10.1007/978-1-59745-423-0_25
   Buess M, 2009, NEOPLASIA, V11, P987, DOI 10.1593/neo.09670
   Chen JLY, 2013, CLIN CANCER RES, V19, P5127, DOI 10.1158/1078-0432.CCR-12-3127
   Chin L, 2011, GENE DEV, V25, P534, DOI 10.1101/gad.2017311
   EMERMAN JT, 1990, IN VITRO CELL DEV B, V26, P1186
   Ericsson C, 2006, ACTA ONCOL, V45, P643, DOI 10.1080/02841860600818047
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Giacinti L, 2006, ONCOLOGIST, V11, P1, DOI 10.1634/theoncologist.11-1-1
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106
   Hass R, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-127
   Holley T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050586
   Mager SR, 2007, EUR J CANCER, V43, P828, DOI 10.1016/j.ejca.2007.01.002
   Marsden CG, 2009, METHODS MOL BIOL, V590, P363, DOI 10.1007/978-1-60327-378-7_23
   Mathot L, 2011, CHEM COMMUN, V47, P547, DOI 10.1039/c0cc02248a
   Micke P, 2006, LAB INVEST, V86, P202, DOI 10.1038/labinvest.3700372
   Morente MM, 2006, EUR J CANCER, V42, P2684, DOI 10.1016/j.ejca.2006.04.029
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Wei J, 2012, TUMOR BIOL, V33, P413, DOI 10.1007/s13277-011-0234-x
NR 27
TC 9
Z9 9
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
EI 1530-0307
J9 LAB INVEST
JI Lab. Invest.
PD JUL
PY 2014
VL 94
IS 7
BP 796
EP 805
DI 10.1038/labinvest.2014.65
PG 10
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA AK5TU
UT WOS:000338490100009
PM 24776644
OA Bronze
DA 2025-01-12
ER

PT J
AU Guerrero-Preston, R
   Hadar, T
   Ostrow, KL
   Soudry, E
   Echenique, M
   Ili-Gangas, C
   Pérez, G
   Perez, J
   Brebi-Mieville, P
   Deschamps, J
   Morales, L
   Bayona, M
   Sidransky, D
   Matta, J
AF Guerrero-Preston, Rafael
   Hadar, Tal
   Ostrow, Kimberly Laskie
   Soudry, Ethan
   Echenique, Miguel
   Ili-Gangas, Carmen
   Perez, Gabriela
   Perez, Jimena
   Brebi-Mieville, Priscilla
   Deschamps, Jose
   Morales, Luisa
   Bayona, Manuel
   Sidransky, David
   Matta, Jaime
TI Differential promoter methylation of kinesin family member 1a in plasma
   is associated with breast cancer and DNA repair capacity
SO ONCOLOGY REPORTS
LA English
DT Article
DE epigenetics; epigenetic biomarker panel; breast cancer; KIF1A; OGDHL;
   FKBP4; VGF; MAL promoter methylation; DNA repair capacity
ID CELL LUNG-CANCER; ABERRANT METHYLATION; PARP INHIBITORS; GENES;
   BIOMARKERS; HYPERMETHYLATION; IDENTIFICATION; IMMUNOPHILINS; PRECURSOR;
   MUTATION
AB Methylation alterations of CpG islands, CpG island shores and first exons are key events in the formation and progression of human cancer, and an increasing number of differentially methylated regions and genes have been identified in breast cancer. Recent studies of the breast cancer methylome using deep sequencing and microarray platforms are providing a novel insight on the different roles aberrant methylation plays in molecular subtypes of breast cancer. Accumulating evidence from a subset of studies suggests that promoter methylation of tumor-suppressor genes associated with breast cancer can be quantified in circulating DNA. However, there is a paucity of studies that examine the combined presence of genetic and epigenetic alterations associated with breast cancer using blood-based assays. Dysregulation of DNA repair capacity (DRC) is a genetic risk factor for breast cancer that has been measured in lymphocytes. We isolated plasma DNA from 340 participants in a breast cancer case control project to study promoter methylation levels of five genes previously shown to be associated with breast cancer in frozen tissue and in cell line DNA: MAL, KIF1A, FKBP4, VGF and OGDHL. Methylation of at least one gene was found in 49% of the cases compared to 20% of the controls. Three of the four genes had receiver characteristic operator curve values of >= 0.50: MAL (0.64), KIF1A (0.51) and OGDHL (0.53). KIF1A promoter methylation was associated with breast cancer and inversely associated with DRC. This is the first evidence of a significant association between genetic and epigenetic alterations in breast cancer using blood-based tests. The potential diagnostic utility of these biomarkers and their relevance for breast cancer risk prediction should be examined in larger cohorts.
C1 [Guerrero-Preston, Rafael; Hadar, Tal; Ostrow, Kimberly Laskie; Soudry, Ethan; Ili-Gangas, Carmen; Perez, Gabriela; Perez, Jimena; Brebi-Mieville, Priscilla; Deschamps, Jose; Sidransky, David] Johns Hopkins Sch Med, Dept Otolaryngol, Head & Neck Canc Res Div, Baltimore, MD 21231 USA.
   [Guerrero-Preston, Rafael] Univ Puerto Rico, Sch Med, Dept Obstet & Gynecol, San Juan, PR 00927 USA.
   [Echenique, Miguel] Auxilio Mutuo Hosp, Ctr Canc, San Juan, PR 00919 USA.
   [Ili-Gangas, Carmen; Brebi-Mieville, Priscilla] Univ La Frontera, Sch Med, Mol Pathol Lab, Dept Pathol,CEGIN BIOREN, Temuco, Chile.
   [Morales, Luisa; Matta, Jaime] Ponce Sch Med & Hlth Sci, Dept Pharmacol & Toxicol, Ponce, PR 00732 USA.
   [Bayona, Manuel] Ponce Sch Med & Hlth Sci, Publ Hlth Program, Ponce, PR 00732 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; University of Puerto
   Rico; University of Puerto Rico Medical Sciences Campus; Universidad de
   La Frontera
RP Guerrero-Preston, R (通讯作者)，Johns Hopkins Sch Med, Dept Otolaryngol, Head & Neck Canc Res Div, Canc Res Bldg 2,Room 5N03,1550 Orleans St, Baltimore, MD 21231 USA.
EM rguerre3@jhmi.edu; jmatta@psm.edu
RI Jaffe, Andrew/L-3089-2016; Pérez, Gabriela/GYA-2894-2022; Ili,
   Carmen/H-9389-2016
OI Brebi, Priscilla/0000-0002-3896-146X; Ili, Carmen/0000-0002-4009-4406
FU National Cancer Institute (36) Early Detection Research Network grant
   [U01CA84986]; NCI [K01CA164092, SC1-SA157250-01, 9SC1CA182846-04]; NCI
   Center to Reduce Health Disparities/NIH-MBRS Program [S06 GM008239-20]
FX This study was made possible by the participating volunteers and their
   physicians, which includes the following individuals: R. Barnes, G.
   Bolanos, J. Gonzalez Cruz, J. Laboy, J. Ortiz Rosado, E. Ramirez
   Lizardi, A. Romero, F. Sanchez-Gaetan, A. Torres and S. Santiago-Medina.
   This study was supported in part by the following grant awards: the
   National Cancer Institute (36) Early Detection Research Network grant
   U01CA84986 (to D.S); the NCI K01CA164092 (to R.G-P.) the NCI
   SC1-SA157250-01 and 9SC1CA182846-04 (to J.M); and the NCI Center to
   Reduce Health Disparities/NIH-MBRS Program grant S06 GM008239-20 (to
   J.M.).
CR Berwick M, 2005, J NATL CANCER I, V97, P84, DOI 10.1093/jnci/dji038
   Brait M, 2012, BRIT J CANCER, V106, P414, DOI 10.1038/bjc.2011.468
   Brait M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070878
   Brait M, 2012, EPIGENETICS-US, V7, P710, DOI 10.4161/epi.20524
   Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711
   Curtin N, 2014, BIOCHEM SOC T, V42, P82, DOI 10.1042/BST20130187
   De S, 2009, CANCER RES, V69, P8035, DOI 10.1158/0008-5472.CAN-09-1224
   Demokan S, 2010, INT J CANCER, V127, P2351, DOI 10.1002/ijc.25248
   Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Ferri GL, 2011, J CHEM NEUROANAT, V42, P249, DOI 10.1016/j.jchemneu.2011.05.007
   Forouzanfar MH, 2011, LANCET, V378, P1461, DOI 10.1016/S0140-6736(11)61351-2
   Galigniana MD, 2004, J BIOL CHEM, V279, P22483, DOI 10.1074/jbc.M402223200
   Glendenning J, 2011, BREAST, V20, pS12, DOI 10.1016/S0960-9776(11)70288-0
   Gotzsche PC, 2012, LANCET, V380, P218, DOI 10.1016/S0140-6736(12)61216-1
   Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
   Hoque MO, 2006, J CLIN ONCOL, V24, P4262, DOI 10.1200/JCO.2005.01.3516
   Hoque MO, 2006, JNCI-J NATL CANCER I, V98, P996, DOI 10.1093/jnci/djj265
   Horne HN, 2009, MOL CANCER RES, V7, P199, DOI 10.1158/1541-7786.MCR-08-0314
   Kim GE, 2011, VIRCHOWS ARCH, V459, P383, DOI 10.1007/s00428-011-1143-5
   Lahtz C, 2011, J MOL CELL BIOL, V3, P51, DOI 10.1093/jmcb/mjq053
   Latimer JJ, 2010, P NATL ACAD SCI USA, V107, P21725, DOI 10.1073/pnas.0914772107
   Leary AF, 2012, EUR J CANCER, V48, P61, DOI 10.1016/j.ejca.2011.09.022
   Levi A, 2004, CELL MOL NEUROBIOL, V24, P517, DOI 10.1023/B:CEMN.0000023627.79947.22
   Li L, 2007, DNA REPAIR GENETIC I, P65
   Lin JF, 2007, INT J CANCER, V121, P2596, DOI 10.1002/ijc.23016
   Lind GE, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-85
   Lo KY, 2011, NEUROSCI LETT, V491, P168, DOI 10.1016/j.neulet.2011.01.018
   Matta J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-490
   Matta JL, 2003, J AM ACAD DERMATOL, V49, P433, DOI 10.1067/S0190-9622(03)00918-6
   Morales L, 2013, J EPIDEMIOL GLOB HEA, V3, P205, DOI 10.1016/j.jegh.2013.08.003
   Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214
   Ostrow KL, 2010, CLIN CANCER RES, V16, P3463, DOI 10.1158/1078-0432.CCR-09-3304
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Ramos JM, 2004, CANCER-AM CANCER SOC, V100, P1352, DOI 10.1002/cncr.20135
   Roh JL, 2013, CLIN CANCER RES, V19, P2528, DOI 10.1158/1078-0432.CCR-12-3047
   Rosner B, 2010, FUNDAMENTALS BIOSTAT
   Sen T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048770
   Silva JM, 1999, CANCER RES, V59, P3251
   Suzuki M, 2013, ONCOL REP, V29, P1308, DOI 10.3892/or.2013.2266
   Szklo M., 2006, Epidemiology: Beyond the Basics
   Torres Cintron C.R., Cancer in Puerto Rico
   Ward BK, 1999, BREAST CANCER RES TR, V58, P267
NR 43
TC 40
Z9 43
U1 0
U2 14
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD AUG 5
PY 2014
VL 32
IS 2
BP 505
EP 512
DI 10.3892/or.2014.3262
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AL1TJ
UT WOS:000338908700008
PM 24927296
OA Green Published, hybrid, Green Submitted
DA 2025-01-12
ER

PT J
AU Calvano, CMC
   Calvano-Mendes, DC
   Carvalho, KC
   Maciel, GA
   Ricci, MD
   Torres, AP
   Filassi, JR
   Baracat, EC
AF Cabral Calvano Filho, Carlos Marino
   Calvano-Mendes, Daniele Carvalho
   Carvalho, Katia Candido
   Maciel, Gustavo Arantes
   Ricci, Marcos Desiderio
   Torres, Ana Paula
   Filassi, Jose Roberto
   Baracat, Edmund Chada
TI Triple-negative and luminal A breast tumors: differential expression of
   miR-18a-5p, miR-17-5p, and miR-20a-5p
SO TUMOR BIOLOGY
LA English
DT Article
DE MicroRNA; Breast cancer; FFPE tissue; Triple-negative; Luminal A;
   Cluster miR-17-92
ID ESTROGEN-RECEPTOR-ALPHA; CANCER; MICRORNA; MIGRATION; SURVIVAL; TARGETS;
   GROWTH; ROLES; FOXO1
AB New concepts in epigenetics, microRNAs, and gene expression analysis have significantly enhanced knowledge of cancer pathogenesis over the last decade. MicroRNAs (miRNAs) are a class of non-coding RNAs that regulate gene expression by base pairing with target messenger RNAs (mRNAs), resulting in the repression of translation or the degradation of mRNA. To compare the carcinogenic process in tumors with different prognoses, we used real-time RT-PCR to evaluate the miRNA expression profiles of 24 triple-negative breast invasive ductal carcinoma, 20 luminal A breast invasive ductal carcinoma, and 13 normal breast parenchyma controls. We extracted total RNA from tissues fixed in formol and embedded in paraffin (FFPE). Results revealed the upregulation of miR-96-5p (9.35-fold; p = 0.000115), miR-182-5p (7.75-fold; p = 0.000033), miR-7-5p (6.71-fold; p = 0.015626), and miR-21-5p (6.10-fold; p = 0.000000) in tumors group. In addition, the expression of miR-125b-5p (4.49-fold; p = 0.000000) and miR-205-5p (4.36-fold; p = 0.006098) was downregulated. When the expression profiles of triple-negative and luminal A tumors were compared, there was enhanced expression of miR-17-5p (4.27-fold; p = 0.000664), miR-18a-5p (9.68-fold; p = 0.000545), and miR-20a-5 (4.07-fold; p = 0.001487) in the triple-negative tumors compared with luminal A. These data suggest that there is a similar regulation of certain miRNAs in triple-negative and luminal A tumors. However, it is possible that differences in the expression of miR-17-92 cluster will explain the phenotypic differences between these molecular tumor subtypes.
C1 [Cabral Calvano Filho, Carlos Marino; Calvano-Mendes, Daniele Carvalho; Carvalho, Katia Candido; Maciel, Gustavo Arantes; Baracat, Edmund Chada] Univ Sao Paulo, Fac Med, Lab Ginecol Mol Estrutural LIM 58, Disciplina Ginecol, Sao Paulo, Brazil.
   [Cabral Calvano Filho, Carlos Marino; Calvano-Mendes, Daniele Carvalho; Ricci, Marcos Desiderio; Filassi, Jose Roberto; Baracat, Edmund Chada] Univ Sao Paulo, Fac Med, Setor Mastol, Disciplina Ginecol,ICESP, Sao Paulo, Brazil.
   [Torres, Ana Paula] Fundacao Oncoctr Sao Paulo, Sao Paulo, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo
RP Calvano-Mendes, DC (通讯作者)，Univ Sao Paulo, Fac Med, Setor Mastol, Disciplina Ginecol,ICESP, Rua Dr Arnaldo 455, Sao Paulo, Brazil.
EM dccalvano@hotmail.com
RI Baracat, Edmund/H-3800-2012; Maciel, Gustavo/D-2291-2009; Carvalho,
   Katia/B-9869-2012; RICCI, MARCOS/X-4246-2019; Filassi, José/O-3083-2013
FU Fundacao de Amparo a Pesquisa do Estado de Sao paulo-FAPESP, Sao
   Paulo-SP, Brazil
FX This research was funded by Fundacao de Amparo a Pesquisa do Estado de
   Sao paulo-FAPESP, Sao Paulo-SP, Brazil.
CR Castellano L, 2009, P NATL ACAD SCI USA, V106, P15732, DOI 10.1073/pnas.0906947106
   Chen L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054213
   Cho WCS, 2009, EUR J CANCER, V45, P2197, DOI 10.1016/j.ejca.2009.04.039
   Giles KM, 2013, BIOCHEM BIOPH RES CO, V430, P706, DOI 10.1016/j.bbrc.2012.11.086
   Guo XJ, 2013, CLIN CANCER RES, V19, P4994, DOI 10.1158/1078-0432.CCR-12-3700
   Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427
   Hong L, 2012, GENE, V507, P135, DOI 10.1016/j.gene.2012.07.025
   Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102
   Hutvágner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Jonsdottir K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048692
   Khoshnaw SM, 2009, J CLIN PATHOL, V62, P422, DOI 10.1136/jcp.2008.060681
   Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296
   Kong WQ, 2012, FEBS J, V279, P1252, DOI 10.1111/j.1742-4658.2012.08519.x
   Krishnan K, 2013, RNA, V19, P230, DOI 10.1261/rna.034926.112
   Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241
   Li HL, 2011, BREAST CANCER RES TR, V126, P565, DOI 10.1007/s10549-010-0954-4
   Li JY, 2013, INT J SURG ONCOL, V2013, DOI 10.1155/2013/875078
   Lin HX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015797
   Liu ZJ, 2012, J PATHOL, V228, P204, DOI 10.1002/path.4000
   Lynam-Lennon N, 2009, BIOL REV, V84, P55, DOI 10.1111/j.1469-185X.2008.00061.x
   Mahamodhossen YA, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0653-1
   Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005
   Myatt SS, 2010, CANCER RES, V70, P367, DOI 10.1158/0008-5472.CAN-09-1891
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Niu JX, 2012, J BIOL CHEM, V287, P21783, DOI 10.1074/jbc.M112.355495
   Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173
   Özgün A, 2013, ONKOLOGIE, V36, P115, DOI 10.1159/000348678
   Piovan C, 2012, MOL ONCOL, V6, P458, DOI 10.1016/j.molonc.2012.03.003
   Rothé F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020980
   Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401
   Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827
   Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127
   Toyama T, 2012, JPN J CLIN ONCOL, V42, P256, DOI 10.1093/jjco/hys001
   Voduc KD, 2010, J CLIN ONCOL, V28, P1684, DOI 10.1200/JCO.2009.24.9284
   Weeraratne SD, 2012, ACTA NEUROPATHOL, V123, P539, DOI 10.1007/s00401-012-0969-5
   Yang XL, 2013, NUCLEIC ACIDS RES, V41, P9688, DOI 10.1093/nar/gkt680
   Yoshimoto N, 2011, BREAST CANCER RES TR, V130, P331, DOI 10.1007/s10549-011-1672-2
   Yu ZR, 2008, J CELL BIOL, V182, P509, DOI 10.1083/jcb.200801079
   Yu ZR, 2010, P NATL ACAD SCI USA, V107, P8231, DOI 10.1073/pnas.1002080107
   Zhang Zhen-Wu, 2009, Yichuan, V31, P1094, DOI 10.3724/SP.J.1005.2009.01094
   Zhou M, 2010, J BIOL CHEM, V285, P21496, DOI 10.1074/jbc.M109.083337
NR 43
TC 79
Z9 79
U1 0
U2 24
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD AUG
PY 2014
VL 35
IS 8
BP 7733
EP 7741
DI 10.1007/s13277-014-2025-7
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AP2DU
UT WOS:000341883500061
PM 24810926
DA 2025-01-12
ER

PT J
AU Katz, TA
   Vasilatos, SN
   Harrington, E
   Oesterreich, S
   Davidson, NE
   Huang, Y
AF Katz, Tiffany A.
   Vasilatos, Shauna N.
   Harrington, Emily
   Oesterreich, Steffi
   Davidson, Nancy E.
   Huang, Yi
TI Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA
   methylation and increases sensitivity to DNMT inhibitor-induced
   apoptosis in breast cancer cells
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Breast cancer; LSD2; DNA methylation; DNMT inhibitor; Combination
   therapy; Apoptosis
ID EPIGENETIC REGULATION; EXPRESSION; ESTROGEN; THERAPY; JMJD2B; GENES; H3
AB Increasing evidence suggests that dysfunction of histone lysine demethylase is associated with abnormal chromatin remodeling and gene silencing, contributing to breast tumorigenesis. In silico analysis shows that the newly identified histone demethylase lysine-specific demethylase 2 is highly expressed in breast cancer, especially in invasive tumors. However, it is currently unknown how LSD2 regulates chromatin remodeling and gene expression regulation in breast cancer. Using short hairpin RNA, we stably knocked down LSD2 (LSD2-KD) in MDA-MB-231 breast cancer cells. LSD2-KD led to accumulation of H3K4me1/2 without changing methylation levels of other key histone lysine residues, suggesting that LSD2 acts as a bona fide H3K4 demethylase in breast cancer cells. LSD2-KD resulted in decreased colony formation and attenuated global DNA methylation in MDA-MB-231 cells. Additionally, treatment with the DNMT inhibitor, 5-aza-deoxycytidine (DAC), synergistically increased mRNA expression of aberrantly silenced genes important in breast cancer development, including PR, RAR beta, ER alpha, SFRP1, SFRP2, and E-cadherin in LSD2-KD cells. Furthermore, LSD2-KD cells are more susceptible to cell death than scramble controls, and combined treatment with tranylcypromine, an LSD2 inhibitor, and DAC resulted in synergistic growth inhibition of breast cancer cells. DNMT inhibition by DAC in LSD2-KD cells led to internucleosomal DNA fragmentation, enhanced PARP cleavage and increased sub-G1 apoptotic cell population. These results demonstrate an important role for LSD2 in regulation of DNA methylation and gene silencing in breast cancer, and suggest that inhibition of LSD2 in combination with DNA methyltransferase inhibition represents a novel approach for epigenetic therapy of breast cancer.
C1 [Katz, Tiffany A.; Vasilatos, Shauna N.; Harrington, Emily; Oesterreich, Steffi; Davidson, Nancy E.; Huang, Yi] Univ Pittsburgh, Inst Canc, UPMC Canc Res Pavil, Pittsburgh, PA 15232 USA.
   [Katz, Tiffany A.; Harrington, Emily; Oesterreich, Steffi; Davidson, Nancy E.; Huang, Yi] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA.
   [Katz, Tiffany A.; Vasilatos, Shauna N.; Harrington, Emily; Oesterreich, Steffi; Davidson, Nancy E.; Huang, Yi] Univ Pittsburgh, Womens Canc Res Ctr, Pittsburgh, PA 15232 USA.
   [Huang, Yi] Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); University of
   Pittsburgh; Magee-Womens Research Institute
RP Davidson, NE (通讯作者)，Univ Pittsburgh, Inst Canc, UPMC Canc Res Pavil, Suite 500,5150 Ctr Ave, Pittsburgh, PA 15232 USA.
EM davidsonne@upmc.edu; yih26@pitt.edu
RI Huang, Yi/AAW-7892-2021
OI Huang, Yi/0000-0002-9982-117X
FU Breast Cancer Research Foundation; Samuel Winters Foundation;
   Competitive Medical Research Fund of UPMC;  [P30CA047904]
FX Partially supported by Breast Cancer Research Foundation, Samuel Winters
   Foundation, and Competitive Medical Research Fund of UPMC. These studies
   used the UPCI Genomics Core Facility supported by P30CA047904.
CR Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Ciccone DN, 2009, NATURE, V461, P415, DOI 10.1038/nature08315
   Fang R, 2010, MOL CELL, V39, P222, DOI 10.1016/j.molcel.2010.07.008
   Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206
   Holmes A, 2012, CELL REP, V2, P1513, DOI 10.1016/j.celrep.2012.10.011
   Huang Y, 2003, CLIN CANCER RES, V9, P2769
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Karytinos A, 2009, J BIOL CHEM, V284, P17775, DOI 10.1074/jbc.M109.003087
   Katoh Y, 2007, INT J MOL MED, V20, P269
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481
   Mersin H, 2008, BREAST, V17, P341, DOI 10.1016/j.breast.2007.11.031
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Pathiraja TN, 2011, CLIN CANCER RES, V17, P4177, DOI 10.1158/1078-0432.CCR-10-2950
   Pathiraja TN, 2010, J MAMMARY GLAND BIOL, V15, P35, DOI 10.1007/s10911-010-9166-0
   Seward DJ, 2007, NAT STRUCT MOL BIOL, V14, P240, DOI 10.1038/nsmb1200
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Stearns V, 2007, CANCER INVEST, V25, P659, DOI 10.1080/07357900701719234
   van Essen D, 2010, MOL CELL, V39, P750, DOI 10.1016/j.molcel.2010.08.010
   Vasilatos SN, 2013, CARCINOGENESIS, V34, P1196, DOI 10.1093/carcin/bgt033
   Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268
   Yang Z, 2010, CELL RES, V20, P276, DOI 10.1038/cr.2010.12
   Zhu QS, 2012, AMINO ACIDS, V42, P887, DOI 10.1007/s00726-011-1004-1
NR 29
TC 52
Z9 56
U1 1
U2 26
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUL
PY 2014
VL 146
IS 1
BP 99
EP 108
DI 10.1007/s10549-014-3012-9
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK1ZW
UT WOS:000338219300010
PM 24924415
DA 2025-01-12
ER

PT J
AU Varol, N
   Konac, E
   Onen, IH
   Gurocak, S
   Alp, E
   Yilmaz, A
   Menevse, S
   Sozen, S
AF Varol, Nuray
   Konac, Ece
   Onen, Ilke Hacer
   Gurocak, Serhat
   Alp, Ebru
   Yilmaz, Akin
   Menevse, Sevda
   Sozen, Sinan
TI The Epigenetically Regulated Effects of Wnt Antagonists on the
   Expression of Genes in the Apoptosis Pathway in Human Bladder Cancer
   Cell Line (T24)
SO DNA AND CELL BIOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; CATENIN SIGNALING PATHWAY; BREAST-CANCER;
   BETA-CATENIN; CARCINOMA; TRICHOSTATIN; INACTIVATION; GEMCITABINE;
   CISPLATIN; DEMETHYLATION
AB The epigenetic suppression of Wnt antagonists (sFRPs, DKKs, and WIF-1) causes the activation of both beta-catenin and target genes, which play an important role in cell proliferation, metastasis, and angiogenesis. This study is aimed to investigate, on transcriptional and protein levels, the synergic effects of unaccompanied and/or combined use of 5-aza-2'-deoxycytidine (DAC, 5-aza-dC), trichostatin A (TSA), and gemcitabine + cisplatin chemotherapeutic agents on the apoptotic pathway of human bladder cancer cell line T24. The anti-tumor effects of gemcitabine (0-500 nM), cisplatin (0-10 mu M), DAC (10 mu M), and TSA (300 nM) alone and/or together on T24 cells were determined by WST-1. ELISA method was used to analyze the effects of unaccompanied and combined use of gemcitabine + cisplatin, DAC, and TSA on cell proliferation and determine the cytotoxic and apoptotic dosages at the level of H3 histone acetylation. Methylation-specific PCR was used to evaluate methylation profiles of Wnt antagonist gene (WIF-1). In the case of unaccompanied and/or combined use of specified drugs, the variations in the expression levels of CTNNB1, GSK3 beta, c-MYC, CCND1, CASP-3, CASP-8, CASP-9, BCL2L1, and WIF-1 genes were determined by quantitative real-time PCR. Our results indicate that through inhibition of DNA methylation, expression of beta-catenin and Wnt antagonist re-activation and expressions of canonical Wnt/beta-catenin pathway target genes, c-myc and cyclin D1 (CCND1), have decreased. In addition, DAC, TSA, and gemcitabine + cisplatin combination caused an increase in GSK3 beta mRNA levels, which in turn significantly decreased CCND1 mRNA levels. Moreover, BCL2L1, an anti-apoptotic gene, was downregulated significantly. Meanwhile, both CASP-3 mRNA and active caspase-3 protein levels increased with respect to control (p < 0.01). The results revealed that use of quadruplicate gemcitabine + cisplatin + DAC + TSA combination led to a reduced inhibition of canonical Wnt/beta-catenin pathway and reduced cell proliferation. Our findings may offer a new approach to consider in the treatment of bladder cancer.
C1 [Varol, Nuray; Konac, Ece; Onen, Ilke Hacer; Gurocak, Serhat; Alp, Ebru; Yilmaz, Akin; Menevse, Sevda] Gazi Univ, Fac Med, Dept Med Biol & Genet, TR-06500 Ankara, Turkey.
   [Gurocak, Serhat; Sozen, Sinan] Gazi Univ, Fac Med, Dept Urol, TR-06500 Ankara, Turkey.
C3 Gazi University; Gazi University
RP Konac, E (通讯作者)，Gazi Univ, Fac Med, Dept Med Biol & Genet, TR-06500 Ankara, Turkey.
EM ecemercanoglu@yahoo.com
RI Konac, Ece/AFV-0952-2022; önen, hacer ilke/CAA-8460-2022; YILMAZ,
   AKIN/G-1451-2011
OI YILMAZ, AKIN/0000-0002-4368-0777
FU Scientific and Technological Research Council of Turkey, TUBITAK
   [SBAG-110S137]
FX This study has been supported by the Scientific and Technological
   Research Council of Turkey, TUBITAK (Project No: SBAG-110S137).
CR Ahmad I, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.7
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-8
   Azechi T, 2013, J ATHEROSCLER THROMB, V20, P538, DOI 10.5551/jat.15826
   Charlet J, 2012, BIOCHEM PHARMACOL, V83, P858, DOI 10.1016/j.bcp.2012.01.009
   Costa VL, 2010, EPIGENETICS-US, V5, P343, DOI 10.4161/epi.5.4.11749
   da Silva GN, 2010, EXP BIOL MED, V235, P814, DOI 10.1258/ebm.2010.009322
   Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957
   DiPaola Robert S, 2003, Med Sci Monit, V9, pPI5
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Enokida H, 2008, INT J CLIN ONCOL, V13, P298, DOI 10.1007/s10147-008-0811-1
   Foti SB, 2013, INT J DEV NEUROSCI, V31, P434, DOI 10.1016/j.ijdevneu.2013.03.008
   Gallagher DJ, 2008, CANCER-AM CANCER SOC, V113, P1284, DOI 10.1002/cncr.23692
   Gao Z, 2009, ANTICANCER RES, V29, P2025
   He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511
   Jeon HG, 2011, J UROLOGY, V186, P2084, DOI 10.1016/j.juro.2011.06.053
   Kawakami K, 2009, CANCER RES, V69, P8603, DOI 10.1158/0008-5472.CAN-09-2534
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Li JS, 2010, CANCER BIOL THER, V10, P617, DOI 10.4161/cbt.10.6.12609
   Luo JY, 2007, LAB INVEST, V87, P97, DOI 10.1038/labinvest.3700509
   Luu HH, 2004, CURR CANCER DRUG TAR, V4, P653, DOI 10.2174/1568009043332709
   Naito S, 2010, CLIN CANCER RES, V16, P5124, DOI 10.1158/1078-0432.CCR-10-0275
   Park HJ, 2009, HEARING RES, V257, P53, DOI 10.1016/j.heares.2009.08.001
   Paul S, 2008, NEOPLASMA, V55, P165
   Shang DH, 2008, UROLOGY, V71, P1220, DOI 10.1016/j.urology.2007.11.029
   Shiina H, 2003, CLIN CANCER RES, V9, P2121
   Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Yeh CT, 2011, EVID-BASED COMPL ALT, V2011, P1, DOI 10.1155/2011/750230
   Yoon CY, 2011, J UROLOGY, V185, P1102, DOI 10.1016/j.juro.2010.10.034
   Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560
   Yun SI, 2009, APOPTOSIS, V14, P771, DOI 10.1007/s10495-009-0348-4
NR 36
TC 11
Z9 12
U1 0
U2 11
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1044-5498
EI 1557-7430
J9 DNA CELL BIOL
JI DNA Cell Biol.
PD JUL
PY 2014
VL 33
IS 7
BP 408
EP 417
DI 10.1089/dna.2013.2285
PG 10
WC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Genetics & Heredity
GA AK0WO
UT WOS:000338137100002
PM 24665856
DA 2025-01-12
ER

PT J
AU Pellon-Maison, M
   Montanaro, MA
   Lacunza, E
   Garcia-Fabiani, MB
   Soler-Gerino, MC
   Cattaneo, ER
   Quiroga, IY
   Abba, MC
   Coleman, RA
   Gonzalez-Baro, MR
AF Pellon-Maison, Magali
   Montanaro, Mauro A.
   Lacunza, Ezequiel
   Garcia-Fabiani, Maria B.
   Soler-Gerino, Mercedes C.
   Cattaneo, Elizabeth R.
   Quiroga, Ivana Y.
   Abba, Martin C.
   Coleman, Rosalind A.
   Gonzalez-Baro, Maria R.
TI Glycerol-3-Phosphate Acyltranferase-2 Behaves as a Cancer Testis Gene
   and Promotes Growth and Tumorigenicity of the Breast Cancer MDA-MB-231
   Cell Line
SO PLOS ONE
LA English
DT Article
ID STEM-CELLS; CANCER/TESTIS ANTIGENS; GENOME-WIDE; EXPRESSION;
   OVEREXPRESSION; COEXPRESSION; GPAT2; PIRNA
AB The de novo synthesis of glycerolipids in mammalian cells begins with the acylation of glycerol-3-phosphate, catalyzed by glycerol-3-phosphate acyltransferase (GPAT). GPAT2 is a mitochondrial isoform primarily expressed in testis under physiological conditions. Because it is aberrantly expressed in multiple myeloma, it has been proposed as a novel cancer testis gene. Using a bioinformatics approach, we found that GPAT2 is highly expressed in melanoma, lung, prostate and breast cancer, and we validated GPAT2 expression at the protein level in breast cancer by immunohistochemistry. In this case GPAT2 expression correlated with a higher histological grade. 5-Aza-2' deoxycytidine treatment of human cells lines induced GPAT2 expression suggesting epigenetic regulation of gene expression. In order to evaluate the contribution of GPAT2 to the tumor phenotype, we silenced its expression in MDA-MB-231 cells. GPAT2 knockdown diminished cell proliferation, anchorage independent growth, migration and tumorigenicity, and increased staurosporine-induced apoptosis. In contrast, GPAT2 over-expression increased cell proliferation rate and resistance to staurosporine-induced apoptosis. To understand the functional role of GPAT2, we performed a co-expression analysis in mouse and human testis and found a significant association with semantic terms involved in cell cycle, DNA integrity maintenance, piRNA biogenesis and epigenetic regulation. Overall, these results indicate the GPAT2 would be directly associated with the control of cell proliferation. In conclusion, we confirm GPAT2 as a cancer testis gene and that its expression contributes to the tumor phenotype of MDA-MB-231 cells.
C1 [Pellon-Maison, Magali; Montanaro, Mauro A.; Garcia-Fabiani, Maria B.; Soler-Gerino, Mercedes C.; Cattaneo, Elizabeth R.; Quiroga, Ivana Y.; Gonzalez-Baro, Maria R.] Univ Nacl La Plata, Inst Invest Bioquim La Plata, Consejo Nacl Invest Cient & Tecn, Fac Ciencias Med, La Plata, Buenos Aires, Argentina.
   [Lacunza, Ezequiel; Abba, Martin C.] Univ Nacl La Plata, Ctr Invest Inmunol Basicas & Aplicadas, Fac Ciencias Med, La Plata, Buenos Aires, Argentina.
   [Coleman, Rosalind A.] Univ N Carolina, Dept Nutr, Chapel Hill, NC USA.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   National University of La Plata; National University of La Plata;
   University of North Carolina; University of North Carolina Chapel Hill
RP Gonzalez-Baro, MR (通讯作者)，Univ Nacl La Plata, Inst Invest Bioquim La Plata, Consejo Nacl Invest Cient & Tecn, Fac Ciencias Med, La Plata, Buenos Aires, Argentina.
EM mgbaro@med.unlp.edu.ar
OI Quiroga-Barber, Ivana/0000-0002-6799-0059; Pellon-Maison,
   Magali/0000-0002-7981-5258; Lacunza, Ezequiel/0000-0002-6731-9820; Abba,
   Martin/0000-0002-9206-2369
FU NIH, USA [1R03TW008698, R01DK56598]; PICT [2246 ANPCyT]; UNLP, Argentina
   [M168]
FX This work was supported by NIH Grants 1R03TW008698 (MRGB) and R01DK56598
   (RAC), USA, PICT 2246 ANPCyT and UNLP M168 (MRGB), Argentina. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adler P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-12-r139
   BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331
   BRINKLEY BR, 1980, CANCER RES, V40, P3118
   Cattaneo ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042986
   Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015
   Cheng Yan-Ho, 2011, Spermatogenesis, V1, P209, DOI 10.4161/spmg.1.3.17990
   Chuma S, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2011.0338
   Coletta A, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-11-r104
   Condomines M, 2009, J IMMUNOL, V183, P832, DOI 10.4049/jimmunol.0803298
   Costa FF, 2007, STEM CELLS, V25, P707, DOI 10.1634/stemcells.2006-0469
   Dougherty CJ, 2008, BIOCHEM BIOPH RES CO, V370, P109, DOI 10.1016/j.bbrc.2008.03.040
   Duan ZF, 2003, CLIN CANCER RES, V9, P2778
   Fratta E, 2011, MOL ONCOL, V5, P164, DOI 10.1016/j.molonc.2011.02.001
   Hofmann O, 2008, P NATL ACAD SCI USA, V105, P20422, DOI 10.1073/pnas.0810777105
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Janic A, 2010, SCIENCE, V330, P1824, DOI 10.1126/science.1195481
   Lee HK, 2004, GENOME RES, V14, P1085, DOI 10.1101/gr.1910904
   Lee JH, 2010, CANCER RES, V70, P4569, DOI 10.1158/0008-5472.CAN-09-2670
   Lin ML, 2009, CANCER SCI, V100, P1443, DOI 10.1111/j.1349-7006.2009.01185.x
   Low J, 2010, J BIOMOL SCREEN, V15, P830, DOI 10.1177/1087057110374983
   McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Pek JW, 2011, CELL DIV, V6, DOI 10.1186/1747-1028-6-6
   Scanlan Matthew J, 2004, Cancer Immun, V4, P1
   Scanlan MJ, 2002, IMMUNOL REV, V188, P22, DOI 10.1034/j.1600-065X.2002.18803.x
   Shiromoto Y, 2013, RNA, V19, P803, DOI 10.1261/rna.038521.113
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Wang S, 2007, ARCH BIOCHEM BIOPHYS, V465, P347, DOI 10.1016/j.abb.2007.06.033
   Wendel AA, 2009, BBA-MOL CELL BIOL L, V1791, P501, DOI 10.1016/j.bbalip.2008.10.010
NR 29
TC 34
Z9 39
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 26
PY 2014
VL 9
IS 6
AR e100896
DI 10.1371/journal.pone.0100896
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AK2WP
UT WOS:000338280800079
PM 24967918
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Chen, CY
   Chang, IS
   Hsiung, CA
   Wasserman, WW
AF Chen, Chih-yu
   Chang, I-Shou
   Hsiung, Chao A.
   Wasserman, Wyeth W.
TI On the identification of potential regulatory variants within genome
   wide association candidate SNP sets
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE GWAS; Lung cancer; Regulatory regions; Gene regulation; Transcription
   factor binding site alteration; Enhancer; Topological domains
ID FACTOR-BINDING PROFILES; EMBRYONIC STEM-CELLS; OPEN-ACCESS DATABASE;
   BREAST-CANCER; SEQUENCE VARIATIONS; CHROMATIN; ENHANCERS; TOOL; NETWORK;
   LOCI
AB Background: Genome wide association studies (GWAS) are a population-scale approach to the identification of segments of the genome in which genetic variations may contribute to disease risk. Current methods focus on the discovery of single nucleotide polymorphisms (SNPs) associated with disease traits. As there are many SNPs within identified risk loci, and the majority of these are situated within non-coding regions, a key challenge is to identify and prioritize variants affecting regulatory sequences that are likely to contribute to the phenotype assessed.
   Methods: We focused investigation on SNPs within lung and breast cancer GWAS loci that reached genome-wide significance for potential roles in gene regulation with a specific focus on SNPs likely to disrupt transcription factor binding sites. Within risk loci, the regulatory potential of sub-regions was classified using relevant open chromatin and epigenetic high throughput sequencing data sets from the ENCODE project in available cancer and normal cell lines. Furthermore, transcription factor affinity altering variants were predicted by comparison of position weight matrix scores between disease and reference alleles. Lastly, ChIP-seq data of transcription associated factors and topological domains were included as binding evidence and potential gene target inference.
   Results: The sets of SNPs, including both the disease-associated markers and those in high linkage disequilibrium with them, were significantly over-represented in regulatory sequences of cancer and/or normal cells; however, over-representation was generally not restricted to disease-relevant tissue specific regions. The calculated regulatory potential, allelic binding affinity scores and ChIP-seq binding evidence were the three criteria used to prioritize candidates. Fitting all three criteria, we highlighted breast cancer susceptibility SNPs and a borderline lung cancer relevant SNP located in cancer-specific enhancers overlapping multiple distinct transcription associated factor ChIP-seq binding sites.
   Conclusion: Incorporating high throughput sequencing epigenetic and transcription factor data sets from both cancer and normal cells into cancer genetic studies reveals potential functional SNPs and informs subsequent characterization efforts.
C1 [Chen, Chih-yu; Wasserman, Wyeth W.] Univ British Columbia, Ctr Mol Med & Therapeut, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada.
   [Chen, Chih-yu] Univ British Columbia, Grad Program Bioinformat, Vancouver, BC V5Z 1M9, Canada.
   [Chang, I-Shou] Natl Hlth Res Inst, Natl Inst Canc Res, Zhunan, Taiwan.
   [Hsiung, Chao A.] Natl Hlth Res Inst, Inst Populat Hlth Sci, Div Biostat & Bioinformat, Zhunan, Taiwan.
   [Wasserman, Wyeth W.] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada.
C3 Child & Family Research Institute; University of British Columbia;
   University of British Columbia; National Health Research Institutes -
   Taiwan; National Health Research Institutes - Taiwan; University of
   British Columbia
RP Wasserman, WW (通讯作者)，Univ British Columbia, Ctr Mol Med & Therapeut, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada.
EM wyeth@cmmt.ubc.ca
RI Chen, Chih-yu/AAX-3735-2020; Hsiung, Chao/E-3994-2010; Wasserman,
   Wyeth/I-4866-2015; Chang, I-Shou/D-2084-2010
OI Chen, Chih-yu/0000-0003-4790-0025; Wasserman, Wyeth/0000-0001-6098-6412
FU CIHR IG; NSC-DOIC; Canada's National Sciences and Engineering Research
   Council; Canadian Institutes of Health Research (CIHR) [MOP82875];
   Natural Sciences and Engineering Research Council of Canada (NSERC)
   [15RGPIN355532-10]; Canada Foundation for Innovation; BC Knowledge
   Development Fund; National Institute of General Medical Sciences
   [R01GM084875]; ABC4DE project - Genome Canada and Genome British
   Columbia; WestGrid; Compute Canada Calcul Canada; Taiwan Bioinformatics
   Core [NSC-102-2319-B-400-001]
FX This work was initiated through the Canadian Institutes of Health
   Research 2012 Summer Program in Taiwan, and CYC was partially funded by
   CIHR IG and NSC-DOIC for the duration. CYC was supported by a
   scholarship from Canada's National Sciences and Engineering Research
   Council. The Wasserman laboratory and the work described in this report
   were supported by the Canadian Institutes of Health Research (CIHR):
   MOP82875, and the Natural Sciences and Engineering Research Council of
   Canada (NSERC): 15RGPIN355532-10. The computer systems of the Gene
   Regulation Bioinformatics Laboratory were funded by the Canada
   Foundation for Innovation and the BC Knowledge Development Fund. The
   research was supported by Award Number R01GM084875 from the National
   Institute of General Medical Sciences and the ABC4DE project funded by
   Genome Canada and Genome British Columbia. This research was enabled in
   part by support provided by WestGrid (www.westgrid.ca) and Compute
   Canada Calcul Canada (www.computecanada.ca). Work of ISC was partially
   supported by Taiwan Bioinformatics Core with the grant number
   NSC-102-2319-B-400-001. The content is solely the responsibility of the
   authors and does not necessarily represent the official views of the
   National Institute of General Medical Sciences or the National
   Institutes of Health. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Andersen MC, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.0040005
   Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787
   Barenboim M, 2013, BIOINFORMATICS, V29, P2197, DOI 10.1093/bioinformatics/btt356
   Benos PV, 2002, NUCLEIC ACIDS RES, V30, P4442, DOI 10.1093/nar/gkf578
   Berlivet S, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1004018
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Chen CY, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-152
   Coetzee SG, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks542
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082
   Edwards SL, 2013, AM J HUM GENET, V93, P779, DOI 10.1016/j.ajhg.2013.10.012
   Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101
   Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gerasimova A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054359
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Ghoussaini M, 2012, NAT GENET, V44, P312, DOI 10.1038/ng.1049
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hinrichs AS, 2006, NUCLEIC ACIDS RES, V34, pD590, DOI 10.1093/nar/gkj144
   Hoffman MM, 2012, NAT METHODS, V9, P473, DOI [10.1038/NMETH.1937, 10.1038/nmeth.1937]
   Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564
   Kulakovskiy IV, 2013, NUCLEIC ACIDS RES, V41, pD195, DOI 10.1093/nar/gks1089
   Landi MT, 2009, AM J HUM GENET, V85, P679, DOI 10.1016/j.ajhg.2009.09.012
   Lenhard B, 2002, BIOINFORMATICS, V18, P1135, DOI 10.1093/bioinformatics/18.8.1135
   Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010
   Li MLJ, 2012, NUCLEIC ACIDS RES, V40, pD1047, DOI 10.1093/nar/gkr1182
   Luo ZH, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-3
   Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746
   Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049
   Park YY, 2012, EMBO MOL MED, V4, P52, DOI 10.1002/emmm.201100187
   Paul DS, 2013, GENOME RES, V23, P1130, DOI 10.1101/gr.155127.113
   Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950
   Rhie SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063925
   Rosenbloom KR, 2012, NUCLEIC ACIDS RES, V40, pD912, DOI 10.1093/nar/gkr1012
   Rowan S, 2010, GENE DEV, V24, P980, DOI 10.1101/gad.1890410
   Schaub MA, 2012, GENOME RES, V22, P1748, DOI 10.1101/gr.136127.111
   Servant N, 2012, BIOINFORMATICS, V28, P2843, DOI 10.1093/bioinformatics/bts521
   Spivakov M, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-9-r49
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Teng L, 2011, NUCLEIC ACIDS RES, V39, P7371, DOI 10.1093/nar/gkr476
   Thayanithy V, 2012, BONE, V50, P171, DOI 10.1016/j.bone.2011.10.012
   Uhrmacher S, 2011, LEUKEMIA RES, V35, P1360, DOI 10.1016/j.leukres.2011.04.006
   Visel A, 2009, NATURE, V457, P854, DOI 10.1038/nature07730
   Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917
   Wasserman NF, 2010, GENOME RES, V20, P1191, DOI 10.1101/gr.105361.110
   Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315
   Worsley-Hunt R, 2011, GENOME MED, V3, DOI 10.1186/gm281
   Zhang SP, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0031127, 10.1371/journal.pone.0046853]
   Zhang XY, 2012, GENOME RES, V22, P1437, DOI 10.1101/gr.135665.111
   Zhi QM, 2013, ANTI-CANCER AGENT ME, V13, P270, DOI 10.2174/1871520611313020013
NR 54
TC 37
Z9 43
U1 0
U2 19
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD JUN 11
PY 2014
VL 7
AR 34
DI 10.1186/1755-8794-7-34
PG 15
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AK5LI
UT WOS:000338465700001
PM 24920305
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Tashima, T
   Murata, H
   Kodama, H
AF Tashima, Toshihiko
   Murata, Hiroaki
   Kodama, Hidehiko
TI Design and synthesis of novel and highly-active pan-histone deacetylase
   (pan-HDAC) inhibitors
SO BIOORGANIC & MEDICINAL CHEMISTRY
LA English
DT Article
DE Epigenetics; Histone deacetylase; Histone deacetylase inhibitor; Cancer;
   Carbostyril
ID BREAST-CANCER; DERIVATIVES; OVEREXPRESSION; EXPRESSION; DISEASE
AB Histone deacetylase (HDAC) inhibitions are known to elicit anticancer effects. We designed and synthesized several HDAC inhibitors. Among these compounds, compound 40 exhibited a more than 10-fold stronger inhibitory activity compared with that of suberoylanilide hydroxamic acid (SAHA) against each human HDAC isozyme in vitro (IC50 values of 40: HDAC1, 0.0038 mu M; HDAC2, 0.0082 mu M; HDAC3, 0.015 mu M; HDAC8, 0.0060 mu M; HDAC4, 0.058 mu M; HDAC9, 0.0052 mu M; HDAC6, 0.058 mu M). The dose of the administered HDAC inhibitors that contain hydroxamic acid as the zinc-binding group may be reduced by 40. Because the carbostyril subunit is a time-tested structural component of drugs and biologically active compounds, 40 most likely exhibits good absorption, distribution, metabolism, excretion, and toxicity (ADMET). Thus, compound 40 is expected to be a promising therapeutic agent or chemical tool for the investigation of life process. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Tashima, Toshihiko; Murata, Hiroaki; Kodama, Hidehiko] Nippon Pharmaceut Chem Co Ltd, Higashiosaka, Osaka 5770056, Japan.
RP Tashima, T (通讯作者)，Nippon Pharmaceut Chem Co Ltd, 2-8-18 Chodo, Higashiosaka, Osaka 5770056, Japan.
EM t-tashima@nichiri.co.jp
RI Tashima, Toshihiko/ABD-7891-2021
CR Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674
   Balasubramanian S, 2008, LEUKEMIA, V22, P1026, DOI 10.1038/leu.2008.9
   Berrino R, 2012, J ORG CHEM, V77, P2537, DOI 10.1021/jo202427m
   BRADSHER CK, 1981, J ORG CHEM, V46, P327, DOI 10.1021/jo00315a021
   Cho YS, 2010, J MED CHEM, V53, P2952, DOI 10.1021/jm100007m
   DESS DB, 1991, J AM CHEM SOC, V113, P7277, DOI 10.1021/ja00019a027
   Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324
   Haberland M, 2009, NAT REV GENET, V10, P32, DOI 10.1038/nrg2485
   Hoffmann K, 1999, NUCLEIC ACIDS RES, V27, P2057, DOI 10.1093/nar/27.9.2057
   Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   Müller BM, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-215
   NAKAGAWA K, 1974, J MED CHEM, V17, P529, DOI 10.1021/jm00251a013
   Oehme I, 2009, CLIN CANCER RES, V15, P91, DOI 10.1158/1078-0432.CCR-08-0684
   Oshiro Y, 1998, J MED CHEM, V41, P658, DOI 10.1021/jm940608g
   Paris M, 2008, J MED CHEM, V51, P1505, DOI 10.1021/jm7011408
   Pinto A, 2012, ORG LETT, V14, P2278, DOI 10.1021/ol300707j
   Salmi-Smail C, 2010, J MED CHEM, V53, P3038, DOI 10.1021/jm901358y
   Seefeld MA, 2003, J MED CHEM, V46, P1627, DOI 10.1021/jm0204035
   Suzuki T, 2005, J MED CHEM, V48, P1019, DOI 10.1021/jm049207j
   TAMURA Y, 1970, CHEM IND-LONDON, P1435
   Walker S. K., 2010, PCT Int. Appl., Patent No. 2010141074
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300
NR 28
TC 34
Z9 36
U1 0
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-0896
EI 1464-3391
J9 BIOORGAN MED CHEM
JI Bioorg. Med. Chem.
PD JUL 15
PY 2014
VL 22
IS 14
BP 3720
EP 3731
DI 10.1016/j.bmc.2014.05.001
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry,
   Organic
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry
GA AJ8XJ
UT WOS:000337991100015
PM 24864038
DA 2025-01-12
ER

PT J
AU Li, SY
   Li, R
   Chen, YL
   Xiong, LK
   Wang, HL
   Rong, L
   Luo, RC
AF Li, Shao-ying
   Li, Rong
   Chen, Yu-li
   Xiong, Li-kuang
   Wang, Hui-lin
   Rong, Lei
   Luo, Rong-cheng
TI Aberrant PTPRO methylation in tumor tissues as a potential biomarker
   that predicts clinical outcomes in breast cancer patients
SO BMC GENETICS
LA English
DT Article
DE Protein tyrosine phosphatase receptor-type O (PTPRO); Methylation;
   Breast cancer; Clinical outcome; Biomarker
ID PROTEIN-TYROSINE PHOSPHATASES; RECEPTOR-TYPE-O; BETA MESSENGER-RNA;
   EXPRESSION; HYPERMETHYLATION; GENE; PROMOTER; TRANSFORMATION; CARCINOMA;
   LEUKEMIA
AB Background: Aberrant hypermethylation of gene promoter regions is a primary mechanism by which tumor suppressor genes become inactivated in breast cancer. Epigenetic inactivation of the protein tyrosine phosphatase receptor-type O gene (PTPRO) has been described in several types of cancer.
   Results: We screened primary breast cancer tissues for PTPRO promoter hypermethylation and assessed potential associations with pathological features and patient outcome. We also evaluated its potential as a breast cancer biomarker. PTPRO methylation was observed in 53 of 98 (54%) breast cancer tissues but not in adjacent normal tissue. Among matched peripheral blood samples from breast cancer patients, 33 of 98 (34%) exhibited methylated PTPRO in plasma. In contrast, no methylated PTPRO was observed in normal peripheral blood from 30 healthy individuals. PTPRO methylation was positively associated with lymph node involvement (P = 0.014), poorly differentiated histology (P = 0.037), depth of invasion (P = 0.004), and HER2 amplification (P = 0.001). Multivariate analysis indicated that aberrant PTPRO methylation could serve as an independent predictor for overall survival hazard ratio (HR): 2.7; 95% CI: 1.1-6.2; P = 0.023), especially for patients with HER2-positive (hazard ratio (HR): 7.5; 95% CI: 1.8-31.3; P = 0.006), but not in ER + and PR + subpopulation. In addition, demethylation induced by 5-azacytidine led to gene reactivation in PTPRO-methylated and -silenced breast cancer cell lines.
   Conclusions: Here, we report that tumor PTPRO methylation is a strong prognostic factor in breast cancer. Methylation of PTPRO silences its expression and plays an important role in breast carcinogenesis. The data we present here may provide insight into the development of novel therapies for breast cancer treatment. Additionally, detection of PTPRO methylation in peripheral blood of breast cancer patients may provide a noninvasive means to diagnose and monitor the disease.
C1 [Li, Shao-ying] Baoan Maternal & Child Hlth Hosp, Dept Breast Surg, Shenzhen, Peoples R China.
   [Li, Shao-ying; Li, Rong; Luo, Rong-cheng] Southern Med Univ, TCM Integrated Canc Ctr, Guangzhou 510515, Guangdong, Peoples R China.
   [Chen, Yu-li] Baoan Maternal & Child Hlth Hosp, Dept Womens Hlth, Shenzhen, Peoples R China.
   [Xiong, Li-kuang; Wang, Hui-lin] Baoan Maternal & Child Hlth Hosp, Cent Lab, Shenzhen, Peoples R China.
   [Rong, Lei] ShenZhen Maternal & Child Hlth Hosp, Dept Breast Surg, Shenzhen, Peoples R China.
C3 Southern Medical University - China
RP Li, SY (通讯作者)，Baoan Maternal & Child Hlth Hosp, Dept Breast Surg, Shenzhen, Peoples R China.
EM charlenesyli@126.com
FU Science and Technology Planning Project of Shenzhen China [201103049]
FX We thank Professor Barry Iacopetta from the School of Surgery,
   University of Western Australia for his critical reading of the
   manuscript. We also thank Dr. Qi T. Yan for his gracious gift of cell
   lines. The authors are grateful to Professor Tasneem Motiwala for
   information on primer sequences. This work was supported by the Science
   and Technology Planning Project of Shenzhen China Grant 201103049 (SY
   Li).
CR Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004
   Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018
   Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001
   [Anonymous], TNM CLASSIFICATION M
   Curigliano G, 2007, EXPERT REV ANTICANC, V7, P1225, DOI 10.1586/14737140.7.9.1225
   Dotzlaw H, 1999, CANCER RES, V59, P529
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Emens Leisha A, 2004, Breast Dis, V20, P13
   Fischer EH, 1999, ADV ENZYME REGUL, V39, P359, DOI 10.1016/S0065-2571(98)00014-4
   Gupta S, 2002, FEBS LETT, V532, P61, DOI 10.1016/S0014-5793(02)03628-1
   Henderson BE, 2000, CARCINOGENESIS, V21, P427, DOI 10.1093/carcin/21.3.427
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Hogan LE, 2011, BLOOD, V118, P5218, DOI 10.1182/blood-2011-04-345595
   Hsu SH, 2013, J CELL BIOCHEM, V114, P1810, DOI 10.1002/jcb.24525
   Huang YT, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-245
   Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8
   Iwao K, 2000, INT J CANCER, V88, P733, DOI 10.1002/1097-0215(20001201)88:5<733::AID-IJC8>3.0.CO;2-M
   Jacob ST, 2005, CANCER GENE THER, V12, P665, DOI 10.1038/sj.cgt.7700828
   Jin Z, 2008, INT J CANCER, V123, P2331, DOI 10.1002/ijc.23804
   Jin Z, 2008, CANCER EPIDEM BIOMAR, V17, P111, DOI 10.1158/1055-9965.EPI-07-0407
   Jin Z, 2007, CLIN CANCER RES, V13, P6293, DOI 10.1158/1078-0432.CCR-07-0818
   Laczmanska I, 2011, ACTA BIOCHIM POL, V58, P467
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Liu SL, 2004, ONCOGENE, V23, P1256, DOI 10.1038/sj.onc.1207235
   Motiwala T, 2004, P NATL ACAD SCI USA, V101, P13844, DOI 10.1073/pnas.0405451101
   Motiwala T, 2003, ONCOGENE, V22, P6319, DOI 10.1038/sj.onc.1206750
   Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720
   Motiwala T, 2006, PROG NUCLEIC ACID RE, V81, P297, DOI 10.1016/S0079-6603(06)81008-1
   Motiwala T, 2009, J BIOL CHEM, V284, P455, DOI 10.1074/jbc.M802840200
   Östman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837
   Paulin R, 1998, NUCLEIC ACIDS RES, V26, P5009, DOI 10.1093/nar/26.21.5009
   Ramaswamy B, 2009, MOL ENDOCRINOL, V23, P176, DOI 10.1210/me.2008-0211
   Roger P, 2001, CANCER RES, V61, P2537
   Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4
   Simpson PT, 2005, J PATHOL, V205, P248, DOI 10.1002/path.1691
   Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039
   You YJ, 2012, CANCER LETT, V315, P138, DOI 10.1016/j.canlet.2011.08.032
   Yu M, 2012, MOL CELL BIOL, V32, P3913, DOI 10.1128/MCB.00068-12
   Zheng J, 2000, ANTICANCER RES, V20, P11
NR 40
TC 17
Z9 18
U1 0
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2156
J9 BMC GENET
JI BMC Genet.
PD JUN 11
PY 2014
VL 15
AR 67
DI 10.1186/1471-2156-15-67
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AK1HR
UT WOS:000338166700001
PM 24919593
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Linher-Melville, K
   Singh, G
AF Linher-Melville, Katja
   Singh, Gurmit
TI The transcriptional responsiveness of LKB1 to STAT-mediated signaling is
   differentially modulated by prolactin in human breast cancer cells
SO BMC CANCER
LA English
DT Article
DE Breast cancer; STAT3; STAT5; LKB1; Prolactin; Interleukin 6; Promoter;
   Transcriptional regulation
ID ACTIVATED PROTEIN-KINASE; PEUTZ-JEGHERS-SYNDROME; CYCLIN D1 PROMOTER;
   ESTROGEN-RECEPTOR; EPIGENETIC INACTIVATION; INDUCED EXPRESSION;
   GROWTH-HORMONE; MAMMARY-CANCER; NUCLEAR FACTOR; ENERGY STRESS
AB Background: Liver kinase 1 (LKB1) is an important multi-tasking protein linked with metabolic signaling, also controlling polarity and cytoskeletal rearrangements in diverse cell types including cancer cells. Prolactin (PRL) and Signal transducer and activator of transcription (STAT) proteins have been associated with breast cancer progression. The current investigation examines the effect of PRL and STAT-mediated signaling on the transcriptional regulation of LKB1 expression in human breast cancer cells.
   Methods: MDA-MB-231, MCF-7, and T47D human breast cancer cells, and CHO-K1 cells transiently expressing the PRL receptor (long form), were treated with 100 ng/ml of PRL for 24 hours. A LKB1 promoter-luciferase construct and its truncations were used to assess transcriptional changes in response to specific siRNAs or inhibitors targeting Janus activated kinase 2 (JAK2), STAT3, and STAT5A. Real-time PCR and Western blotting were applied to quantify changes in mRNA and protein levels. Electrophoretic mobility shift (EMSA) and chromatin immunoprecipitation (ChIP) assays were used to examine STAT3 and STAT5A binding to the LKB1 promoter.
   Results: Consistent with increases in mRNA, the LKB1 promoter was up-regulated by PRL in MDA-MB-231 cells, a response that was lost upon distal promoter truncation. A putative GAS element that could provide a STAT binding site mapped to this region, and its mutation decreased PRL-responsiveness. PRL-mediated increases in promoter activity required signaling through STAT3 and STAT5A, also involving JAK2. Both STATs imparted basally repressive effects in MDA-MB-231 cells. PRL increased in vivo binding of STAT3, and more definitively, STAT5A, to the LKB1 promoter region containing the GAS site. In T47D cells, PRL down-regulated LKB1 transcriptional activity, an effect that was reversed upon culture in phenol red-free media. Interleukin 6, a cytokine activating STAT signaling in diverse cell types, also increased LKB1 mRNA levels and promoter activity in MDA-MB-231 cells.
   Conclusions: LKB1 is differentially regulated by PRL at the level of transcription in representative human breast cancer cells. Its promoter is targeted by STAT proteins, and the cellular estrogen receptor status may affect PRL-responsiveness. The hormonal and possibly cytokine-mediated control of LKB1 expression is particularly relevant in aggressive breast cancer cells, potentially promoting survival under energetically unfavorable conditions.
C1 [Linher-Melville, Katja; Singh, Gurmit] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
C3 McMaster University
RP Singh, G (通讯作者)，McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
EM singhg@mcmaster.ca
RI Singh, Gurmit/C-6744-2014
FU Canadian Breast Cancer Foundation (CBCF); Canada Institutes for Health
   Research (CIHR)
FX The authors thank Dr. Eric Seidlitz for proof-reading the manuscript,
   the Canadian Breast Cancer Foundation (CBCF) for providing fellowship
   funding, and Canada Institutes for Health Research (CIHR) for funding
   the research.
CR Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702
   Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604
   Ben-Jonathan N, 2006, TRENDS ENDOCRIN MET, V17, P110, DOI 10.1016/j.tem.2006.02.005
   Ben-Jonathan N, 2002, TRENDS ENDOCRIN MET, V13, P245, DOI 10.1016/S1043-2760(02)00603-3
   Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334
   BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455
   Brandebourg T, 2007, DIABETES OBES METAB, V9, P464, DOI 10.1111/j.1463-1326.2006.00671.x
   Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023
   Brockman JL, 2005, MOL CELL ENDOCRINOL, V239, P45, DOI 10.1016/j.mce.2005.04.006
   Brockman JL, 2002, MOL ENDOCRINOL, V16, P774, DOI 10.1210/me.16.4.774
   Brown KA, 2011, J STEROID BIOCHEM, V127, P439, DOI 10.1016/j.jsbmb.2011.06.005
   Carver KC, 2009, MOL CELL ENDOCRINOL, V307, P1, DOI 10.1016/j.mce.2009.03.014
   Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803
   Clevenger CV, 1998, J ENDOCRINOL, V157, P187, DOI 10.1677/joe.0.1570187
   Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036
   Collares-Buzato CB, 2001, PANCREAS, V23, P177, DOI 10.1097/00006676-200108000-00008
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481
   Ding W, 2010, AFR J BIOTECHNOL, V9, P940
   Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213
   Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227
   Fan DH, 2009, ACTA BIOCH BIOPH SIN, V41, P97, DOI 10.1093/abbs/gmn011
   Fang F, 2009, ENDOCRINOLOGY, V150, P1597, DOI 10.1210/en.2008-1079
   Ferrajoli A, 2007, CANCER RES, V67, P11291, DOI 10.1158/0008-5472.CAN-07-0593
   Frasor J, 2003, TRENDS ENDOCRIN MET, V14, P118, DOI 10.1016/S1043-2760(03)00030-4
   Gill S, 2001, J CLIN PATHOL, V54, P956, DOI 10.1136/jcp.54.12.956
   Ginsburg E, 2013, PROLACTIN
   Ginsburg E, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-678
   Goldhar AS, 2005, MOL CELL ENDOCRINOL, V232, P9, DOI 10.1016/j.mce.2005.01.005
   Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513
   Green Jeremy B A, 2004, Cell Cycle, V3, P12
   Gu L, 2010, ENDOCR-RELAT CANCER, V17, P481, DOI 10.1677/ERC-09-0328
   Harvey PW, 2012, J APPL TOXICOL, V32, P1, DOI 10.1002/jat.1772
   Hezel AF, 2008, MOL CELL BIOL, V28, P2414, DOI 10.1128/MCB.01621-07
   Hogan JC, 2005, DIABETES, V54, P1968, DOI 10.2337/diabetes.54.7.1968
   HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984
   Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5
   Jacob LS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001225
   Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030
   Johnson KJ, 2010, AM J PATHOL, V177, P2971, DOI 10.2353/ajpath.2010.090399
   Leslie K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2725
   Lim EJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033361
   Linher K, 2009, DIFFERENTIATION, V77, P335, DOI 10.1016/j.diff.2008.08.001
   Linher-Melville K, 2012, BIOCHEM BIOPH RES CO, V417, P1063, DOI 10.1016/j.bbrc.2011.12.096
   Linher-Melville K, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-56
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Londesborough A, 2008, DEVELOPMENT, V135, P2331, DOI 10.1242/dev.017038
   Luo GY, 1997, J BIOL CHEM, V272, P26841, DOI 10.1074/jbc.272.43.26841
   Ma YM, 2010, ONCOL REP, V23, P1569, DOI 10.3892/or_00000797
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   Maus MV, 1999, ENDOCRINOLOGY, V140, P5447, DOI 10.1210/en.140.11.5447
   Moon C, 2002, P NATL ACAD SCI USA, V99, P9015, DOI 10.1073/pnas.132131699
   Mukherjee P, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-37
   Nagalingam A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3128
   Nakajima KI, 2009, ASIAN AUSTRAL J ANIM, V22, P788, DOI 10.5713/ajas.2009.80519
   Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292
   O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8
   Ossipova O, 2003, NAT CELL BIOL, V5, P889, DOI 10.1038/ncb1048
   Peck AR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3328
   Phoenix KN, 2009, BREAST CANCER RES TR, V113, P101, DOI 10.1007/s10549-008-9916-5
   RAJENDRAN KG, 1987, BIOCHEM BIOPH RES CO, V142, P724, DOI 10.1016/0006-291X(87)91474-4
   Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555
   Sakamoto K, 2010, ONCOGENE, V29, P5359, DOI 10.1038/onc.2010.274
   Sakamoto K, 2009, CANCER RES, V69, P6642, DOI 10.1158/0008-5472.CAN-09-0746
   SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6
   SCHMITT-NEY M, 1992, P NATL ACAD SCI USA, V89, P3130, DOI 10.1073/pnas.89.7.3130
   SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745
   Sen B, 2012, CLIN CANCER RES, V18, P127, DOI 10.1158/1078-0432.CCR-11-1889
   Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100
   Shen Z, 2002, CLIN CANCER RES, V8, P2085
   Shin J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021492
   Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206
   Sun G, 2011, DIS MODEL MECH, V4, P193, DOI 10.1242/dmm.006833
   Timofeeva OA, 2013, P NATL ACAD SCI USA, V110, P1267, DOI 10.1073/pnas.1211805110
   Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272
   Trott JF, 2012, J ANIM SCI, V90, P1674, DOI 10.2527/jas.2011-4682
   Ueda E, 2006, ENDOCR-RELAT CANCER, V13, P95, DOI 10.1677/erc.1.01076
   WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x
   Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238
   Wang LH, 2005, CELL CYCLE, V4, P242
   White UA, 2007, DIABETES, V56, P1623, DOI 10.2337/db06-1286
   Wu W, 2014, GUT
   Yamamoto T, 2000, FEBS LETT, V486, P143, DOI 10.1016/S0014-5793(00)02296-1
   Yang LX, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-124
   Yin K, 2011, BREAST CANC FOCUSING, P584
   Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103
NR 86
TC 17
Z9 17
U1 3
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD JUN 9
PY 2014
VL 14
AR 415
DI 10.1186/1471-2407-14-415
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK1DV
UT WOS:000338156400001
PM 24913037
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Bacalini, MG
   Pacilli, A
   Giuliani, C
   Penzo, M
   Treré, D
   Pirazzini, C
   Salvioli, S
   Franceschi, C
   Montanaro, L
   Garagnani, P
AF Bacalini, Maria Giulia
   Pacilli, Annalisa
   Giuliani, Cristina
   Penzo, Marianna
   Trere, Davide
   Pirazzini, Chiara
   Salvioli, Stefano
   Franceschi, Claudio
   Montanaro, Lorenzo
   Garagnani, Paolo
TI The nucleolar size is associated to the methylation status of ribosomal
   DNA in breast carcinomas
SO BMC CANCER
LA English
DT Article
ID RNA-POLYMERASE I; CANCER-SPECIFIC ACTIVATION; TRANSCRIPTION MACHINERY;
   GENE-TRANSCRIPTION; CELL-PROLIFERATION; TUMOR PROGRESSION; EMERGING
   TARGET; RDNA LOCI; HYPERMETHYLATION; BIOGENESIS
AB Background: There is a body of evidence that shows a link between tumorigenesis and ribosome biogenesis. The precursor of mature 18S, 28S and 5.8S ribosomal RNAs is transcribed from the ribosomal DNA gene (rDNA), which exists as 300-400 copies in the human diploid genome. Approximately one half of these copies are epigenetically silenced, but the exact role of epigenetic regulation on ribosome biogenesis is not completely understood. In this study we analyzed the methylation profiles of the rDNA promoter and of the 5' regions of 18S and 28S in breast cancer.
   Methods: We analyzed rDNA methylation in 68 breast cancer tissues of which the normal counterpart was partially available (45/68 samples) using the MassARRAY EpiTYPER assay, a sensitive and quantitative method with single base resolution.
   Results: We found that rDNA locus tended to be hypermethylated in tumor compared to matched normal breast tissues and that the DNA methylation level of several CpG units within the rDNA locus was associated to nuclear grade and to nucleolar size of tumor tissues. In addition we identified a subgroup of samples in which large nucleoli were associated with very limited or absent rDNA hypermethylation in tumor respect to matched normal tissue.
   Conclusions: In conclusion, we suggest that rDNA is an important target of epigenetic regulation in breast tumors and that rDNA methylation level is associated to nucleolar size.
C1 [Bacalini, Maria Giulia; Pacilli, Annalisa; Penzo, Marianna; Trere, Davide; Pirazzini, Chiara; Salvioli, Stefano; Franceschi, Claudio; Montanaro, Lorenzo; Garagnani, Paolo] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
   [Bacalini, Maria Giulia; Franceschi, Claudio; Garagnani, Paolo] Personal Genom Srl, Verona, Italy.
   [Bacalini, Maria Giulia; Pirazzini, Chiara; Salvioli, Stefano; Franceschi, Claudio] Univ Bologna, Interdept Ctr L Galvani, Bologna, Italy.
   [Pacilli, Annalisa] Univ Bologna, Ctr Interdipartimentale Ric Canc Giorgio Prodi CI, Bologna, Italy.
   [Giuliani, Cristina] Univ Bologna, Dept Biol Geol & Environm Sci, Bologna, Italy.
   [Garagnani, Paolo] S Orsola Malpighi Polyclin, Appl Biomed Res Ctr, Bologna, Italy.
C3 University of Bologna; University of Bologna; University of Bologna;
   University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di
   Bologna
RP Montanaro, L (通讯作者)，Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy.
EM lorenzo.montanaro@unibo.it; paolo.garagnani2@unibo.it
RI Trere', Davide/AAC-4725-2021; Franceschi, Claudio/L-4484-2017;
   Montanaro, Lorenzo/I-4236-2019; Salvioli, Stefano/K-6663-2016;
   Pirazzini, Chiara/AAD-9318-2021; PENZO, MARIANNA/AAC-3264-2021;
   BACALINI, MARIA GIULIA/K-4931-2016
OI montanaro, lorenzo/0000-0001-9776-9518; PENZO,
   MARIANNA/0000-0002-1738-9767; BACALINI, MARIA
   GIULIA/0000-0003-1618-2673; TRERE', DAVIDE/0000-0003-1127-1052;
   Giuliani, Cristina/0000-0002-5318-6502; Garagnani,
   Paolo/0000-0002-4161-3626
FU Italian Association for Cancer Research [IG-11416]; European Union
   [259679]
FX We thank Vilma Mantovani and Elena Marasco for their technical support
   during experimental procedure of DNA methylation analysis at CRBA
   (Applied Biomedical Research Center, S. Orsola-Malpighi Polyclinic,
   Bologna, Italy). This work was supported by grants from the Italian
   Association for Cancer Research (IG-11416) to L. Montanaro and from
   European Union's Seventh Framework Programme (IDEAL project, 259679) to
   C. Franceschi.
CR BEAHRS OH, 1989, CANCER, V64, P275, DOI 10.1002/1097-0142(19890701)64:1+<275::AID-CNCR2820641320>3.0.CO;2-J
   Beahrs OH, 1989, CANCER, V64, P282
   Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147
   Brown SE, 2008, CELL CYCLE, V7, P382, DOI 10.4161/cc.7.3.5283
   Bywater MJ, 2013, NAT REV CANCER, V13, P299, DOI 10.1038/nrc3496
   Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019
   Chan MWY, 2005, CLIN CANCER RES, V11, P7376, DOI 10.1158/1078-0432.CCR-05-1100
   DANTE R, 1992, J CELL BIOCHEM, V50, P357, DOI 10.1002/jcb.240500404
   Derenzini M, 1998, AM J PATHOL, V152, P1291
   Derenzini M, 2005, J CELL PHYSIOL, V202, P483, DOI 10.1002/jcp.20144
   Derenzini M, 2004, J CLIN PATHOL, V57, P755, DOI 10.1136/jcp.2003.015917
   Derenzini M, 2000, J PATHOL, V191, P181, DOI 10.1002/(SICI)1096-9896(200006)191:2<181::AID-PATH607>3.0.CO;2-V
   Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x
   Drygin D, 2014, DRUG DISCOV TODAY, V19, P259, DOI 10.1016/j.drudis.2013.08.012
   Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728
   Drygin D, 2010, ANNU REV PHARMACOL, V50, P131, DOI 10.1146/annurev.pharmtox.010909.105844
   Espada J, 2007, NUCLEIC ACIDS RES, V35, P2191, DOI 10.1093/nar/gkm118
   Faryna M, 2012, FASEB J, V26, P4937, DOI 10.1096/fj.12-209502
   Garagnani P, 2012, AGING CELL, V11, P1132, DOI 10.1111/acel.12005
   Ghoshal K, 2004, J BIOL CHEM, V279, P6783, DOI 10.1074/jbc.M309393200
   GONZALEZ IL, 1992, NUCLEIC ACIDS RES, V20, P5846, DOI 10.1093/nar/20.21.5846
   Hein N, 2013, TRENDS MOL MED, V19, P643, DOI 10.1016/j.molmed.2013.07.005
   Hernandez-Verdun D, 2006, HISTOCHEM CELL BIOL, V126, P135, DOI 10.1007/s00418-006-0212-3
   Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109
   Kikuyama M, 2012, CANCER LETT, V322, P204, DOI 10.1016/j.canlet.2012.03.016
   Kopp K, 2007, MOL BIOL CELL, V18, P394, DOI 10.1091/mbc.E06-03-0249
   Lempiäinen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002
   Machwe A, 2000, FASEB J, V14, P1715, DOI 10.1096/fj.99-0926com
   Majumder S, 2006, J BIOL CHEM, V281, P22062, DOI 10.1074/jbc.M601155200
   McGowan PO, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002085
   McStay B, 2008, ANNU REV CELL DEV BI, V24, P131, DOI 10.1146/annurev.cellbio.24.110707.175259
   Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752
   Montanaro L, 2013, ONCOTARGETS THER, V6, P909, DOI 10.2147/OTT.S36627
   Montanaro L, 2012, BBA-REV CANCER, V1825, P101, DOI 10.1016/j.bbcan.2011.10.006
   Morita S, 2012, INT J MOL SCI, V13, P8259, DOI 10.3390/ijms13078259
   Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030
   Oakes CC, 2003, P NATL ACAD SCI USA, V100, P1775, DOI 10.1073/pnas.0437971100
   Pietrzak M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022585
   Powell MA, 2002, CANCER-AM CANCER SOC, V94, P2941, DOI 10.1002/cncr.10559
   Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474
   Ruggero D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003477
   Santoro R, 2002, NAT GENET, V32, P393, DOI 10.1038/ng1010
   Schlesinger S, 2009, GENE DEV, V23, P2437, DOI 10.1101/gad.544509
   Schmidt EV, 1999, ONCOGENE, V18, P2988, DOI 10.1038/sj.onc.1202751
   Soares J, 1999, CANCER, V85, P112, DOI 10.1002/(SICI)1097-0142(19990101)85:1<112::AID-CNCR16>3.0.CO;2-T
   Tan BCM, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-57
   Thomas G, 2000, NAT CELL BIOL, V2, pE71, DOI 10.1038/35010581
   Trerè D, 2000, MICRON, V31, P127, DOI 10.1016/S0968-4328(99)00069-4
   Uemura M, 2012, ONCOGENE, V31, P1254, DOI 10.1038/onc.2011.319
   WORTON RG, 1988, SCIENCE, V239, P64, DOI 10.1126/science.3336775
   Yen PS, 2000, BRIT J CANCER, V82, P514, DOI 10.1054/bjoc.1999.0955
NR 51
TC 21
Z9 23
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 22
PY 2014
VL 14
AR 361
DI 10.1186/1471-2407-14-361
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK1AN
UT WOS:000338147600001
PM 24884608
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Huth, L
   Rose, M
   Kloubert, V
   Winkens, W
   Schlensog, M
   Hartmann, A
   Knüchel, R
   Dahl, E
AF Huth, Laura
   Rose, Michael
   Kloubert, Veronika
   Winkens, Wiebke
   Schlensog, Martin
   Hartmann, Arndt
   Knuechel, Ruth
   Dahl, Edgar
TI BDNF Is Associated with SFRP1 Expression in Luminal and Basal-Like
   Breast Cancer Cell Lines and Primary Breast Cancer Tissues: A Novel Role
   in Tumor Suppression?
SO PLOS ONE
LA English
DT Article
ID WNT ANTAGONIST SFRP1; NEUROTROPHIC FACTOR; EPIGENETIC INACTIVATION;
   PATHWAY; GENES; BETA; PROLIFERATION; CONTRIBUTES; RECEPTOR; MAMMARY
AB Secreted frizzled related protein 1 (SFRP1) functions as an important inhibitor of the Wnt pathway and is a known tumor suppressor gene, which is epigenetically silenced in a variety of tumors e. g. in breast cancer. However, it is still unclear how SFRP1 exactly affects the Wnt pathway. Our aim was to decipher SFRP1 involvement in biochemical signaling in dependency of different breast cancer subtypes and to identify novel SFRP1-regulated genes. We generated SFRP1 over-expressing in vitro breast cancer models, reflecting the two major subtypes by using basal-like BT20 and luminal-like HER2-positive SKBR3 cells. DNA microarray expression profiling of these models revealed that SFRP1 expression potentially modulates Bone morphogenetic protein-and Smoothened signaling (p<0.01), in addition to the known impact on Wnt signaling. Importantly, further statistical analysis revealed that in dependency of the cancer subtype model SFRP1 may affect the canonical and non-canonical Wnt pathway (p<0.01), respectively. While SFRP1 re-expression generally mediated distinct patterns of transcriptionally induced or repressed genes in BT20 and SKBR3 cells, brain derived neurotrophic factor (BDNF) was identified as a SFRP1 induced gene in both cell lines. Although BDNF has been postulated as a putative oncogene, the co-regulation with SFRP1 indicates a potential suppressive function in breast cancer. Indeed, a positive correlation between SFRP1 and BDNF protein expression could be shown (p<0.001) in primary breast cancer samples. Moreover, TCGA dataset based analysis clearly underscores that BDNF mRNA is down-regulated in primary breast cancer samples predicting a poor prognosis of these patients. In line, we functionally provide evidence that stable BDNF re-expression in basal-like BT20 breast cancer cells blocks tumor cell proliferation. Hence, our results suggest that BDNF might rather mediate suppressive than promoting function in human breast cancer whose mode of action should be addressed in future studies.
C1 [Huth, Laura; Rose, Michael; Kloubert, Veronika; Winkens, Wiebke; Schlensog, Martin; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
   [Hartmann, Arndt] Univ Hosp, Inst Pathol, Erlangen, Germany.
C3 RWTH Aachen University; University of Erlangen Nuremberg
RP Dahl, E (通讯作者)，Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
EM edahl@ukaachen.de
FU DFG grant [DA329/3-1]
FX This work was supported by DFG grant DA329/3-1. The funders had no role
   in study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aid-Pavlidis T, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-420
   Au CWH, 2009, CANCER LETT, V281, P151, DOI 10.1016/j.canlet.2009.02.025
   Binder DK, 2004, GROWTH FACTORS, V22, P123, DOI 10.1080/08977190410001723308
   Blasco-Gutiérrez MJ, 2007, CANCER INVEST, V25, P405, DOI 10.1080/07357900701206349
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Bronzetti E, 2008, ONCOL REP, V19, P969
   Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346
   Chen BY, 2013, J NEUROSCI RES, V91, P30, DOI 10.1002/jnr.23138
   Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890
   Dahl E, 2006, CLIN CANCER RES, V12, P3950, DOI 10.1158/1078-0432.CCR-05-2090
   Fredlund E, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3236
   Gauger KJ, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-59
   Hu YH, 2008, J NEUROCHEM, V105, P1, DOI 10.1111/j.1471-4159.2008.05237.x
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Huelsken J, 2002, J CELL SCI, V115, P3977, DOI 10.1242/jcs.00089
   Hussein SM, 2003, J BIOL CHEM, V278, P48805, DOI 10.1074/jbc.M305472200
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623
   Klopocki E, 2004, INT J ONCOL, V25, P641
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32
   Labbé E, 2007, CANCER RES, V67, P75, DOI 10.1158/0008-5472.CAN-06-2559
   Lee AY, 2004, ONCOGENE, V23, P6672, DOI 10.1038/sj.onc.1207881
   Li Z, 2007, MOL CANCER THER, V6, P3113, DOI 10.1158/1535-7163.MCT-07-0133
   Massagué J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745
   Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Patani N, 2011, CANCER CELL INT, V11, DOI 10.1186/1475-2867-11-23
   Ricci A, 2001, AM J RESP CELL MOL, V25, P439, DOI 10.1165/ajrcmb.25.4.4470
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Simon R, 2007, CANCER INFORM, V3, P11
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259
   Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330
   ten Haaf A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-298
   Turashvili G, 2006, PATHOBIOLOGY, V73, P213, DOI 10.1159/000098207
   Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890
   Veeck J, 2006, ONCOGENE, V25, P3479, DOI 10.1038/sj.onc.1209386
   Wolfs TGAM, 2008, MOL IMMUNOL, V45, P3268, DOI 10.1016/j.molimm.2008.02.014
   Yang XM, 2012, INT J ONCOL, V41, P1541, DOI 10.3892/ijo.2012.1581
   Yi H, 2012, NEUROREPORT, V23, P189, DOI 10.1097/WNR.0b013e32834fab06
   Yu XH, 2008, CANCER SCI, V99, P543, DOI 10.1111/j.1349-7006.2007.00722.x
NR 44
TC 23
Z9 23
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 18
PY 2014
VL 9
IS 7
AR e102558
DI 10.1371/journal.pone.0102558
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AM1OC
UT WOS:000339615200070
PM 25036590
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Paci, P
   Colombo, T
   Farina, L
AF Paci, Paola
   Colombo, Teresa
   Farina, Lorenzo
TI Computational analysis identifies a sponge interaction network between
   long non-coding RNAs and messenger RNAs in human breast cancer
SO BMC SYSTEMS BIOLOGY
LA English
DT Article
DE Systems biology; Networks analysis; Epigenetics
ID MIR-200 FAMILY; MESENCHYMAL TRANSITION; DOWN-REGULATION; MICRORNA; GENE;
   EXPRESSION; INVASION; ZEB1; MEG3; MECHANISMS
AB Background: Non-coding RNAs (ncRNAs) are emerging as key regulators of many cellular processes in both physiological and pathological states. Moreover, the constant discovery of new non-coding RNA species suggests that the study of their complex functions is still in its very early stages. This variegated class of RNA species encompasses the well-known microRNAs (miRNAs) and themost recently acknowledged long non-coding RNAs (IncRNAs). Interestingly, in the last couple of years, a few studies have shown that some IncRNAs can act as miRNA sponges, i.e. as competing endogenous RNAs (ceRNAs), able to reduce the amount of miRNAs available to target messenger RNAs (mRNAs).
   Results: We propose a computational approach to explore the ability of IncRNAs to act as ceRNAs by protecting mRNAs from miRNA repression. A seed match analysis was performed to validate the underlying regression model. We built normal and cancer networks of miRNA-mediated sponge interactions (MMI-networks) using breast cancer expression data provided by The Cancer Genome Atlas.
   Conclusions: Our study highlights a marked rewiring in the ceRNA program between normal and pathological breast tissue, documented by its "on/off" switch from normal to cancer, and vice-versa. This mutually exclusive activation confers an interesting character to ceRNAs as potential oncosuppressive, or oncogenic, protagonists in cancer. At the heart of this phenomenon is the IncRNA PVT1, as illustrated by both the width of its antagonist mRNAs in normal-MMI-network, and the relevance of the latter in breast cancer. Interestingly, PVT1 revealed a net binding preference towards the mir-200 family as the bone of contention with its rival mRNAs.
C1 [Paci, Paola] CNR, Inst Syst Anal & Comp Sci Antonio Ruberti, I-00185 Rome, Italy.
   [Colombo, Teresa] CNR, Inst Comp Applicat Mauro Picone, I-00185 Rome, Italy.
   [Farina, Lorenzo] Univ Roma La Sapienza, Dept Comp Control & Management Engn, I-00185 Rome, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Analisi dei
   Sistemi ed Informatica "Antonio Ruberti" (IASI-CNR); Consiglio Nazionale
   delle Ricerche (CNR); Istituto per le Applicazioni del Calcolo "Mauro
   Picone" (IAC-CNR); Sapienza University Rome
RP Paci, P (通讯作者)，CNR, Inst Syst Anal & Comp Sci Antonio Ruberti, Viale Manzoni 30, I-00185 Rome, Italy.
EM paola.paci@iasi.cnr.it
RI Colombo, Teresa/P-2959-2018
OI Colombo, Teresa/0000-0003-2415-7507; Farina, Lorenzo/0000-0001-8314-6029
FU SysBioNet, Italian Roadmap Research Infrastructures; Epigenomics
   Flagship Project (Progetto Bandiera Epigenomica) EPIGEN - Italian
   Ministry of Education, University and Research (MIUR); National Research
   Council (CNR)
FX This work was supported by SysBioNet, Italian Roadmap Research
   Infrastructures 2012 and from The Epigenomics Flagship Project (Progetto
   Bandiera Epigenomica) EPIGEN funded by the Italian Ministry of
   Education, University and Research (MIUR) and the National Research
   Council (CNR).
CR Castilla MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047709
   Arbiser JL, 2002, P NATL ACAD SCI USA, V99, P715, DOI 10.1073/pnas.022630199
   Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11
   Balik V, 2013, J NEURO-ONCOL, V112, P1, DOI 10.1007/s11060-012-1038-6
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607
   Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942
   Braconi C, 2011, ONCOGENE, V30, P4750, DOI 10.1038/onc.2011.193
   Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9
   Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chen LF, 2012, J CELL BIOCHEM, V113, P1470, DOI 10.1002/jcb.24074
   Chimge NO, 2013, ONCOGENE, V32, P2121, DOI 10.1038/onc.2012.328
   Costa FF, 2008, GENE, V410, P9, DOI 10.1016/j.gene.2007.12.008
   Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079
   Ellwanger DC, 2011, BIOINFORMATICS, V27, P1346, DOI 10.1093/bioinformatics/btr149
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Franco-Zorrilla JM, 2007, NAT GENET, V39, P1033, DOI 10.1038/ng2079
   Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Grillo G, 2010, NUCLEIC ACIDS RES, V38, pD75, DOI 10.1093/nar/gkp902
   Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017
   Guan YH, 2007, CLIN CANCER RES, V13, P5745, DOI 10.1158/1078-0432.CCR-06-2882
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hodgson G, 2001, NAT GENET, V29, P459, DOI 10.1038/ng771
   Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936
   Janes KA, 2011, CELL CYCLE, V10, P3461, DOI 10.4161/cc.10.20.18029
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Koziol MJ, 2010, CURR OPIN GENET DEV, V20, P142, DOI 10.1016/j.gde.2010.03.003
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liang YJ, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-9
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Liu YN, 2005, ONCOGENE, V24, P8277, DOI 10.1038/sj.onc.1208991
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Manavalan TT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062334
   Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Sumazin P, 2011, CELL, V147, P370, DOI 10.1016/j.cell.2011.09.041
   Wang GY, 2013, P NATL ACAD SCI USA, V110, P2858, DOI 10.1073/pnas.1212769110
   Wang PJ, 2012, J CELL BIOCHEM, V113, P1868, DOI 10.1002/jcb.24055
   Yamano Y, 2008, BIOSCI BIOTECH BIOCH, V72, P1360, DOI 10.1271/bbb.70673
   Yao CX, 2013, RNA BIOL, V10, P465, DOI 10.4161/rna.24370
   Yu Y, 2013, INT J CANCER, V133, P1368, DOI 10.1002/ijc.28151
NR 62
TC 213
Z9 226
U1 0
U2 43
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1752-0509
J9 BMC SYST BIOL
JI BMC Syst. Biol.
PD JUL 17
PY 2014
VL 8
AR 83
DI 10.1186/1752-0509-8-83
PG 15
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA AM1BJ
UT WOS:000339581100001
PM 25033876
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Naushad, SM
   Hussain, T
   Al-Attas, OS
   Prayaga, A
   Digumarti, RR
   Gottumukkala, SR
   Kutala, VK
AF Naushad, Shaik Mohammad
   Hussain, Tajamul
   Al-Attas, Omar S.
   Prayaga, Aruna
   Digumarti, Raghunadha Rao
   Gottumukkala, Suryanarayana Raju
   Kutala, Vijay Kumar
TI Molecular insights into the association of obesity with breast cancer
   risk: relevance to xenobiotic metabolism and CpG island methylation of
   tumor suppressor genes
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE Obesity; Cytochrome P450 1A1; Catechol-O-methyl transferase;
   Ras-association (RalGDS/AF-6) domain family member 1; Breast cancer type
   1 susceptibility protein; BCL2/adenovirus E1B 19 kDa protein-interacting
   protein 3; Extracellular superoxide dismutase; CpG island methylation
ID ONE-CARBON METABOLISM; OXIDATIVE DNA-DAMAGE; PROMOTER METHYLATION;
   BODY-MASS; EXPRESSION; SUBTYPES; IMPACT; SURVIVAL; RASSF1A; BNIP3
AB Obesity, genetic polymorphisms of xenobiotic metabolic pathway, hypermethylation of tumor suppressor genes, and hypomethylation of proapoptotic genes are known to be independent risk factors for breast cancer. The objective of this study is to evaluate the combined effect of these environmental, genetic, and epigenetic risk factors on the susceptibility to breast cancer. PCR-RFLP and multiplex PCR were used for the genetic analysis of six variants of xenobiotic metabolic pathway. Methylation-specific PCR was used for the epigenetic analysis of four genetic loci. Multifactor dimensionality reduction analysis revealed a significant interaction between the body mass index (BMI) and catechol-O-methyl transferase H108L variant alone or in combination with cytochrome P450 (CYP) 1A1m1 variant. Women with "Luminal A" breast cancer phenotype had higher BMI compared to other phenotypes and healthy controls. There was no association between the BMI and tumor grade. The post-menopausal obese women exhibited lower glutathione levels. BMI showed a positive association with the methylation of extracellular superoxide dismutase (r = 0.21, p < 0.05), Ras-association (RalGDS/AF-6) domain family member 1 (RASSF1A) (r = 0.31, p < 0.001), and breast cancer type 1 susceptibility protein (r = 0.19, p < 0.05); and inverse association with methylation of BNIP3 (r = -0.48, p < 0.0001). To conclude based on these results, obesity increases the breast cancer susceptibility by two possible mechanisms: (i) by interacting with xenobiotic genetic polymorphisms in inducing increased oxidative DNA damage and (ii) by altering the methylome of several tumor suppressor genes.
C1 [Naushad, Shaik Mohammad] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur 613401, India.
   [Hussain, Tajamul; Al-Attas, Omar S.] King Saud Univ, Ctr Excellence Biotechnol Res, Riyadh 11451, Saudi Arabia.
   [Prayaga, Aruna] Nizams Inst Med Sci, Dept Pathol, Hyderabad, Andhra Pradesh, India.
   [Digumarti, Raghunadha Rao] Nizams Inst Med Sci, Dept Med Oncol, Hyderabad, Andhra Pradesh, India.
   [Gottumukkala, Suryanarayana Raju] Nizams Inst Med Sci, Dept Surg Oncol, Hyderabad, Andhra Pradesh, India.
   [Kutala, Vijay Kumar] Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad, Andhra Pradesh, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA); King
   Saud University; Nizam's Institute of Medical Sciences; Nizam's
   Institute of Medical Sciences; Nizam's Institute of Medical Sciences;
   Nizam's Institute of Medical Sciences
RP Kutala, VK (通讯作者)，Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad, Andhra Pradesh, India.
EM vijaykutala@gmail.com
RI Digumarti, Raghunadharao/H-4075-2019; Hussain, Tajamul/E-8151-2014;
   Naushad, Shaik Mohammad/C-3094-2012
OI Hussain, Tajamul/0000-0001-7601-1417; Kutala, Vijay
   Kumar/0000-0002-7253-8999; Naushad, Shaik Mohammad/0000-0001-8952-9581;
   Digumarti, Raghunadharao/0000-0003-2876-3475
FU Indian Council of Medical Research (ICMR), New Delhi [5/13/32/2007];
   SASTRA University, Thanjavur, India
FX This work was supported by the grant funded by Indian Council of Medical
   Research (ICMR), New Delhi (Ref No. 5/13/32/2007) and Prof. T. R.
   Rajagopalan Research Fund of SASTRA University, Thanjavur, India.
CR Adachi T, 2004, J ENDOCRINOL, V181, P413, DOI 10.1677/joe.0.1810413
   Apostolou P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/747318
   Biglia N, 2013, GYNECOL ENDOCRINOL, V29, P263, DOI 10.3109/09513590.2012.736559
   Fang QA, 2010, MOL BIOL REP, V37, P2517, DOI 10.1007/s11033-009-9767-0
   FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1
   Ghosh S, 2007, AM J PHYSIOL-ENDOC M, V292, pE246, DOI 10.1152/ajpendo.00242.2006
   Govindaiah V, 2009, CLIN BIOCHEM, V42, P380, DOI 10.1016/j.clinbiochem.2008.12.003
   Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810
   Howard CB, 2003, CELL MOL BIOL, V49, P1057
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Karbownik-Lewinska M, 2012, NEUROENDOCRINOL LETT, V33, P453
   Ko E, 2013, CLIN CANCER RES, V19, P1204, DOI 10.1158/1078-0432.CCR-12-2848
   Korah R, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-87
   Lachman HM, 1996, AM J MED GENET, V67, P468, DOI 10.1002/(SICI)1096-8628(19960920)67:5<468::AID-AJMG5>3.0.CO;2-G
   Lavigne JA, 2001, CANCER RES, V61, P7488
   Leung T, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3574
   Mahadevan B, 2006, MOL CARCINOGEN, V45, P118, DOI 10.1002/mc.20143
   Mohammad NS, 2011, MOL CELL BIOCHEM, V349, P159, DOI 10.1007/s11010-010-0670-8
   Naushad SM, 2014, MOL BIOL REP, V41, P3045, DOI 10.1007/s11033-014-3163-0
   Naushad SM, 2014, CELL BIOCHEM BIOPHYS, V68, P397, DOI 10.1007/s12013-013-9720-7
   Naushad SM, 2012, MOL CARCINOGEN, V51, pE32, DOI 10.1002/mc.21830
   Naushad SM, 2012, MOL CELL BIOCHEM, V361, P189, DOI 10.1007/s11010-011-1103-z
   Naushad SM, 2011, CELL BIOCHEM BIOPHYS, V61, P715, DOI 10.1007/s12013-011-9245-x
   Naushad SM, 2011, MOL BIOL REP, V38, P4893, DOI 10.1007/s11033-010-0631-z
   Pajares B, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3572
   Perng W, 2013, NUTR METAB CARDIOVAS, VS0939-4753, P312
   Peters I, 2007, CANCER EPIDEM BIOMAR, V16, P2526, DOI 10.1158/1055-9965.EPI-07-0203
   Simpson ER, 2013, J MOL ENDOCRINOL, V51, pT51, DOI 10.1530/JME-13-0217
   Song QK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072175
   Szymczak J, 1998, STEROIDS, V63, P319, DOI 10.1016/S0039-128X(98)00019-1
   Taioli E, 1999, CANCER DETECT PREV, V23, P232, DOI 10.1046/j.1525-1500.1999.09912.x
   Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466
   Tao MH, 2011, AM J CLIN NUTR, V94, P831, DOI 10.3945/ajcn.110.009365
   Turkoz FP, 2013, J BUON, V18, P335
   Wang Y, 2000, GENE DEV, V14, P927
NR 35
TC 14
Z9 17
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JUL
PY 2014
VL 392
IS 1-2
BP 273
EP 280
DI 10.1007/s11010-014-2037-z
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AI9EW
UT WOS:000337233900025
PM 24676543
DA 2025-01-12
ER

PT J
AU Jutooru, I
   Guthrie, AS
   Chadalapaka, G
   Pathi, S
   Kim, KH
   Burghardt, R
   Jin, UH
   Safe, S
AF Jutooru, Indira
   Guthrie, Aaron S.
   Chadalapaka, Gayathri
   Pathi, Satya
   Kim, Kyoung Hyun
   Burghardt, Robert
   Jin, Un-Ho
   Safe, Stephen
TI Mechanism of Action of Phenethylisothiocyanate and Other Reactive Oxygen
   Species-Inducing Anticancer Agents
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID BLADDER-CANCER CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR SP1;
   ISOTHIOCYANATE-INDUCED APOPTOSIS; BETA-PHENYLETHYL ISOTHIOCYANATE;
   SPECIFICITY PROTEINS SP; HUMAN GASTRIC-CANCER; BENZYL ISOTHIOCYANATE;
   BREAST-CANCER; TUMOR-GROWTH
AB Reactive oxygen species (ROS)-inducing anticancer agents such as phenethylisothiocyanate (PEITC) activate stress pathways for killing cancer cells. Here we demonstrate that PEITC-induced ROS decreased expression of microRNA 27a (miR-27a)/miR-20a:miR-17-5p and induced miR-regulated ZBTB10/ZBTB4 and ZBTB34 transcriptional repressors, which, in turn, downregulate specificity protein (Sp) transcription factors (TFs) Sp1, Sp3, and Sp4 in pancreatic cancer cells. Decreased expression of miR-27a/miR-20a:miR-17-5p by PEITC-induced ROS is a key step in triggering the miR-ZBTB Sp cascade leading to downregulation of Sp TFs, and this is due to ROS-dependent epigenetic effects associated with genome-wide shifts in repressor complexes, resulting in decreased expression of Myc and the Myc-regulated miRs. Knockdown of Sp1 alone by RNA interference also induced apoptosis and decreased pancreatic cancer cell growth and invasion, indicating that downregulation of Sp transcription factors is an important common mechanism of action for PEITC and other ROS-inducing anticancer agents.
C1 [Jutooru, Indira; Chadalapaka, Gayathri; Pathi, Satya; Safe, Stephen] Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
   [Guthrie, Aaron S.] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.
   [Kim, Kyoung Hyun] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH USA.
   [Burghardt, Robert] Texas A&M Univ, Dept Vet Integrat Biosci, College Stn, TX 77843 USA.
   [Jin, Un-Ho; Safe, Stephen] Texas A&M Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M University System; Texas A&M University College Station; University
   System of Ohio; University of Cincinnati; Texas A&M University System;
   Texas A&M University College Station; Texas A&M University System; Texas
   A&M University College Station; Texas A&M Health Science Center
RP Safe, S (通讯作者)，Texas A&M Univ, Dept Vet Physiol & Pharmacol, College Stn, TX 77843 USA.
EM ssafe@cvm.tamu.edu
RI Burghardt, Robert/AAF-4847-2021
OI Kim, Kyounghyun/0000-0002-7240-2768; Burghardt,
   Robert/0000-0003-1021-8444
FU Public Health Service from the National Institute of Environmental
   Health, National Institutes of Health [P30 ES023512]; Texas AgriLife
   Research
FX Financial support of this work by Public Health Service grant P30
   ES023512 (from the National Institute of Environmental Health, National
   Institutes of Health) and Texas AgriLife Research is gratefully
   acknowledged.
CR Chadalapaka G, 2008, CANCER RES, V68, P5345, DOI 10.1158/0008-5472.CAN-07-6805
   Chadalapaka G, 2012, CARCINOGENESIS, V33, P886, DOI 10.1093/carcin/bgs102
   Chadalapaka G, 2010, MOL CANCER RES, V8, P739, DOI 10.1158/1541-7786.MCR-09-0493
   Chiefari E, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-35
   Chintharlapalli S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-371
   Cohen JH, 2000, JNCI-J NATL CANCER I, V92, P61, DOI 10.1093/jnci/92.1.61
   Engel RH, 2006, FRONT BIOSCI-LANDMRK, V11, P300, DOI 10.2741/1798
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Hosoi Y, 2004, INT J ONCOL, V25, P461
   Jiang NY, 2008, CANCER EPIDEM BIOMAR, V17, P1648, DOI 10.1158/1055-9965.EPI-07-2791
   Jutooru I, 2010, J BIOL CHEM, V285, P25332, DOI 10.1074/jbc.M109.095240
   Jutooru I, 2010, MOL PHARMACOL, V78, P226, DOI 10.1124/mol.110.064451
   Jutooru I, 2010, EXP CELL RES, V316, P2174, DOI 10.1016/j.yexcr.2010.04.027
   Kallifatidis G, 2009, GUT, V58, P949, DOI 10.1136/gut.2008.149039
   Kim JH, 2006, CARCINOGENESIS, V27, P475, DOI 10.1093/carcin/bgi272
   Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193
   Kim K, 2012, ONCOGENE, V31, P1034, DOI 10.1038/onc.2011.296
   Kim SH, 2011, CARCINOGENESIS, V32, P359, DOI 10.1093/carcin/bgq267
   Lai KC, 2010, J AGR FOOD CHEM, V58, P2935, DOI 10.1021/jf9036694
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Lou Z, 2005, CANCER RES, V65, P1007
   Lydon N, 2009, NAT MED, V15, P1153, DOI 10.1038/nm1009-1153
   Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416
   Murillo G, 2001, NUTR CANCER, V41, P17, DOI 10.1207/S15327914NC41-1&2_2
   Nicolás M, 2001, J BIOL CHEM, V276, P22126, DOI 10.1074/jbc.M010740200
   Noratto GD, 2013, MOL NUTR FOOD RES, V57, P1638, DOI 10.1002/mnfr.201200609
   O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012
   Pathi SS, 2011, NUTR CANCER, V63, P1133, DOI 10.1080/01635581.2011.605984
   Pathi SS, 2011, MOL CANCER RES, V9, P195, DOI 10.1158/1541-7786.MCR-10-0363
   Powolny AA, 2010, PHARM RES-DORDR, V27, P2766, DOI 10.1007/s11095-010-0278-4
   Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167
   Sahu RP, 2009, CARCINOGENESIS, V30, P1744, DOI 10.1093/carcin/bgp157
   Sahu RP, 2009, JNCI-J NATL CANCER I, V101, P176, DOI 10.1093/jnci/djn470
   Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015
   Srivastava SK, 2003, CARCINOGENESIS, V24, P1665, DOI 10.1093/carcin/bgg123
   Tang L, 2005, MOL CANCER THER, V4, P1250, DOI 10.1158/1535-7163.MCT-05-0041
   Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   van Haaften G, 2010, GENE DEV, V24, P1, DOI 10.1101/gad.1887110
   Wang LW, 2003, CLIN CANCER RES, V9, P6371
   Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200
   Xiao D, 2006, MOL CANCER THER, V5, P2931, DOI 10.1158/1535-7163.MCT-06-0396
   Xiao D, 2010, J BIOL CHEM, V285, P26558, DOI 10.1074/jbc.M109.063255
   Xu CJ, 2005, ONCOGENE, V24, P4486, DOI 10.1038/sj.onc.1208656
   Yang MD, 2010, ANTICANCER RES, V30, P2135
   Yao JC, 2004, CLIN CANCER RES, V10, P4109, DOI 10.1158/1078-0432.CCR-03-0628
   Zannetti A, 2000, CANCER RES, V60, P1546
NR 47
TC 97
Z9 103
U1 0
U2 9
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUL
PY 2014
VL 34
IS 13
BP 2382
EP 2395
DI 10.1128/MCB.01602-13
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AI9GG
UT WOS:000337239800003
PM 24732804
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Hussey, KM
   Chen, H
   Yang, C
   Park, E
   Hah, N
   Erdjument-Bromage, H
   Tempst, P
   Gamble, MJ
   Kraus, WL
AF Hussey, Kristine M.
   Chen, Hongshan
   Yang, Christine
   Park, Eugene
   Hah, Nasun
   Erdjument-Bromage, Hediye
   Tempst, Paul
   Gamble, Matthew J.
   Kraus, W. Lee
TI The Histone Variant MacroH2A1 Regulates Target Gene Expression in Part
   by Recruiting the Transcriptional Coregulator PELP1
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID GROWTH-FACTOR REGULATION; GLUTAMIC ACID-RICH; POSTTRANSLATIONAL
   MODIFICATIONS; EPIGENETIC REGULATOR; X-CHROMOSOME; PROLINE-RICH;
   CHROMATIN; BINDING; PARP-1; RNA
AB MacroH2A1 is a histone variant harboring an similar to 25-kDa carboxyl-terminal macrodomain. Due to its enrichment on the inactive X chromosome, macroH2A1 was thought to play a role in transcriptional repression. However, recent studies have shown that macroH2A1 occupies autosomal chromatin and regulates genes in a context-specific manner. The macrodomain may play a role in the modulation of gene expression outcomes via physical interactions with effector proteins, which may depend on the ability of the macrodomain to bind NAD(+) metabolite ligands. Here, we identify proline, glutamic acid, and leucine-rich protein 1 (PELP1), a chromatin-associated factor and transcriptional coregulator, as a ligand-independent macrodomain-interacting factor. We used chromatin immunoprecipitation coupled with tiling microarrays (ChIP-chip) to determine the genomic localization of PELP1 in MCF-7 human breast cancer cells. We find that PELP1 genomic localization is highly correlated with that of macroH2A1. Additionally, PELP1 positively correlates with heterochromatic chromatin marks and negatively correlates with active transcription marks, much like macroH2A1. MacroH2A1 specifically recruits PELP1 to the promoters of macroH2A1 target genes, but macroH2A1 occupancy occurs independent of PELP1. This recruitment allows macroH2A1 and PELP1 to cooperatively regulate gene expression outcomes.
C1 [Hussey, Kristine M.; Yang, Christine; Park, Eugene; Hah, Nasun; Gamble, Matthew J.; Kraus, W. Lee] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.
   [Hussey, Kristine M.; Hah, Nasun; Kraus, W. Lee] Cornell Univ, Ithaca, NY USA.
   [Chen, Hongshan; Gamble, Matthew J.] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10467 USA.
   [Erdjument-Bromage, Hediye; Tempst, Paul] Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA.
   [Kraus, W. Lee] Univ Texas SW Med Ctr Dallas, Lab Signaling & Gene Regulat, Cecil H & Ida Green Ctr Reprod Biol Sci, Dallas, TX 75390 USA.
   [Kraus, W. Lee] Univ Texas SW Med Ctr Dallas, Dept Obstet & Gynecol, Basic Res Div, Dallas, TX 75390 USA.
C3 Cornell University; Cornell University; Yeshiva University; Montefiore
   Medical Center; Albert Einstein College of Medicine; Memorial Sloan
   Kettering Cancer Center; University of Texas System; University of Texas
   Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Gamble, MJ (通讯作者)，Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.
EM matthew.gamble@einstein.yu.edu; lee.kraus@utsouthwestern.edu
OI Hah, Nasun/0000-0003-1509-2799; Tempst, Paul/0000-0002-6680-3987;
   Erdjument-Bromage, Hediye/0000-0003-0224-3594
FU NIH/NIDDK [DK069710]; Cornell University's NanoBiotechnology Center (an
   STC Program of the NSF) [ECS-9876771, F32DK079847]; Endocrine Society;
   predoctoral fellowship from the American Heart Association; postdoctoral
   fellowships from the American Heart Association; NIH/NCI [R01CA155232];
   NIH/NCI Cancer Center Support Grant [P30 CA08748]
FX This work was supported by grants from the NIH/NIDDK (DK069710), Cornell
   University's NanoBiotechnology Center (an STC Program of the NSF,
   agreement no. ECS-9876771), and the Endocrine Society to W.L.K., by a
   predoctoral fellowship from the American Heart Association to K.M. H.,
   by postdoctoral fellowships from the American Heart Association and the
   NIH/NIDDK (F32DK079847) and a grant from the NIH/NCI (R01CA155232) to M.
   J. G., and by an NIH/NCI Cancer Center Support Grant (P30 CA08748) to
   P.T.
CR Abbott DW, 2005, J BIOL CHEM, V280, P16437, DOI 10.1074/jbc.M500170200
   Agelopoulos M, 2006, EMBO J, V25, P4843, DOI 10.1038/sj.emboj.7601364
   Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321
   Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9
   Banck MS, 2009, EPIGENETICS-US, V4, P100, DOI 10.4161/epi.4.2.7953
   Barrero MJ, 2013, J BIOL CHEM, V288, P16110, DOI 10.1074/jbc.M113.466144
   Barrero MJ, 2013, CELL REP, V3, P1005, DOI 10.1016/j.celrep.2013.02.029
   Bernstein E, 2008, P NATL ACAD SCI USA, V105, P1533, DOI 10.1073/pnas.0711632105
   Boyle EI, 2004, BIOINFORMATICS, V20, P3710, DOI 10.1093/bioinformatics/bth456
   Brann DW, 2008, MOL CELL ENDOCRINOL, V290, P2, DOI 10.1016/j.mce.2008.04.019
   Buschbeck M, 2009, NAT STRUCT MOL BIOL, V16, P1074, DOI 10.1038/nsmb.1665
   Chakravarthy S, 2005, MOL CELL BIOL, V25, P7616, DOI 10.1128/MCB.25.17.7616-7624.2005
   Changolkar LN, 2008, MOL CELL BIOL, V28, P2059, DOI 10.1128/MCB.01362-07
   Changolkar LN, 2007, MOL CELL BIOL, V27, P2758, DOI 10.1128/MCB.02334-06
   Changolkar LN, 2002, BIOCHEMISTRY-US, V41, P179, DOI 10.1021/bi0157417
   Cheskis BJ, 2008, STEROIDS, V73, P901, DOI 10.1016/j.steroids.2007.12.028
   Choi YB, 2004, J BIOL CHEM, V279, P50930, DOI 10.1074/jbc.M406831200
   Choo JH, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-479
   Chu FX, 2006, MOL CELL PROTEOMICS, V5, P194, DOI 10.1074/mcp.M500285-MCP200
   Cong R, 2014, NUCLEIC ACIDS RES, V42, P181, DOI 10.1093/nar/gkt863
   Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275
   Creppe C, 2012, MOL CELL BIOL, V32, P1442, DOI 10.1128/MCB.06323-11
   Csankovszki G, 1999, NAT GENET, V22, P323, DOI 10.1038/11887
   Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390
   Dimple C, 2008, CANCER RES, V68, P4902, DOI 10.1158/0008-5472.CAN-07-5698
   Dou YL, 2005, CELL, V121, P873, DOI 10.1016/j.cell.2005.04.031
   Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5
   Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136
   Finkbeiner E, 2011, NUCLEUS-PHILA, V2, P527, DOI 10.4161/nucl.2.6.17604
   Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879
   Fu ZM, 2005, J PROTEOME RES, V4, P1583, DOI 10.1021/pr0501158
   Gamble MJ, 2013, NAT STRUCT MOL BIOL, V20, P407, DOI 10.1038/nsmb.2552
   Gamble MJ, 2010, CELL CYCLE, V9, P2568, DOI 10.4161/cc.9.13.12144
   Gamble MJ, 2010, GENE DEV, V24, P21, DOI 10.1101/gad.1876110
   Gaspar-Maia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2582
   Gonugunta VK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021095
   Gottschalk AJ, 2009, P NATL ACAD SCI USA, V106, P13770, DOI 10.1073/pnas.0906920106
   Hernádez-Muñoz I, 2005, P NATL ACAD SCI USA, V102, P7635, DOI 10.1073/pnas.0408918102
   Isabelle M, 2010, PROTEOME SCI, V8, DOI 10.1186/1477-5956-8-22
   Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590
   Karras GI, 2005, EMBO J, V24, P1911, DOI 10.1038/sj.emboj.7600664
   Kashiwaya K, 2010, CANCER RES, V70, P4024, DOI 10.1158/0008-5472.CAN-09-4444
   Kayahara M, 2008, AM J PHYSIOL-ENDOC M, V295, pE1047, DOI 10.1152/ajpendo.90429.2008
   Khan MM, 2006, NEUROENDOCRINOLOGY, V84, P317, DOI 10.1159/000097746
   Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002
   Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07
   Kraus WL, 2009, NAT STRUCT MOL BIOL, V16, P904, DOI 10.1038/nsmb0909-904
   Krishnakumar R, 2008, SCIENCE, V319, P819, DOI 10.1126/science.1149250
   Kustatscher G, 2005, NAT STRUCT MOL BIOL, V12, P624, DOI 10.1038/nsmb956
   Ladurner AG, 2003, MOL CELL, V12, P1, DOI 10.1016/S1097-2765(03)00284-3
   Manavathi B, 2005, CANCER RES, V65, P5571, DOI 10.1158/0008-5472.CAN-04-4664
   Meder VS, 2005, J CELL SCI, V118, P211, DOI 10.1242/jcs.01606
   Mietton F, 2009, MOL CELL BIOL, V29, P150, DOI 10.1128/MCB.00997-08
   Nagpal JK, 2008, MOL CANCER RES, V6, P851, DOI 10.1158/1541-7786.MCR-07-2030
   Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786
   Nair SS, 2007, MOL ENDOCRINOL, V21, P613, DOI 10.1210/me.2006-0269
   Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62
   Novikov L, 2011, MOL CELL BIOL, V31, P4244, DOI 10.1128/MCB.05244-11
   Nusinow DA, 2007, J BIOL CHEM, V282, P12851, DOI 10.1074/jbc.M610502200
   Ouararhni K, 2006, GENE DEV, V20, P3324, DOI 10.1101/gad.396106
   Pasque V, 2012, J CELL SCI, V125, P6094, DOI 10.1242/jcs.113019
   Pasque V, 2011, EMBO J, V30, P2373, DOI 10.1038/emboj.2011.144
   Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837
   Rasmussen TP, 2001, CHROMOSOMA, V110, P411, DOI 10.1007/s004120100158
   Ratnakumar K, 2012, GENE DEV, V26, P433, DOI 10.1101/gad.179416.111
   Reid G, 2009, INT J BIOCHEM CELL B, V41, P155, DOI 10.1016/j.biocel.2008.08.028
   Reynolds A, 2004, NAT BIOTECHNOL, V22, P326, DOI 10.1038/nbt936
   Rosendorff A, 2006, P NATL ACAD SCI USA, V103, P5308, DOI 10.1073/pnas.0601066103
   Singh RR, 2006, J BIOL CHEM, V281, P15394, DOI 10.1074/jbc.M601593200
   Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26
   Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027
   Thambirajah AA, 2009, BIOCHEM CELL BIOL, V87, P7, DOI 10.1139/O08-103
   Timinszky G, 2009, NAT STRUCT MOL BIOL, V16, P923, DOI 10.1038/nsmb.1664
   Turner BM, 2012, TRENDS GENET, V28, P436, DOI 10.1016/j.tig.2012.04.003
   Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272
   van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865
   Volle C, 2014, CURR OPIN GENET DEV, V25, P8, DOI 10.1016/j.gde.2013.11.006
   Winkler GS, 2002, METHODS, V26, P260, DOI 10.1016/S1046-2023(02)00030-0
   Wutz A, 2002, NAT GENET, V30, P167, DOI 10.1038/ng820
NR 79
TC 16
Z9 23
U1 0
U2 12
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
EI 1098-5549
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD JUL
PY 2014
VL 34
IS 13
BP 2437
EP 2449
DI 10.1128/MCB.01315-13
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AI9GG
UT WOS:000337239800007
PM 24752897
OA Green Published
DA 2025-01-12
ER

PT J
AU Lavigne, AC
   Castells, M
   Mermet, J
   Kocanova, S
   Dalvai, M
   Bystricky, K
AF Lavigne, Anne-Claire
   Castells, Magali
   Mermet, Jerome
   Kocanova, Silvia
   Dalvai, Mathieu
   Bystricky, Kerstin
TI Increased macroH2A1.1 Expression Correlates with Poor Survival of
   Triple-Negative Breast Cancer Patients
SO PLOS ONE
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE MACROH2A1; STEM-CELLS;
   MOLECULAR SUBTYPES; CLAUDIN-LOW; METASTASIS; SIGNATURE; GENES; LUNG;
   IDENTIFICATION
AB Purpose: Epithelial-Mesenchymal Transition (EMT) features appear to be key events in development and progression of breast cancer. Epigenetic modifications contribute to the establishment and maintenance of cancer subclasses, as well as to the EMT process. Whether histone variants contribute to these transformations is not known. We investigated the relative expression levels of histone macroH2A1 splice variants and correlated it with breast cancer status/prognosis/types.
   Methods: To detect differential expression of macroH2A1 variant mRNAs in breast cancer cells and tumor samples, we used the following databases: GEO, EMBL-EBI and publisher databases (may-august 2012). We extracted macroH2A1.1/macroH2A1 mRNA ratios and performed correlation studies on intrinsic molecular subclasses of breast cancer and on molecular characteristics of EMT. Associations between molecular and survival data were determined.
   Results: We found increased macroH2A1.1/macroH2A1 mRNA ratios to be associated with the claudin-low intrinsic subtype in breast cancer cell lines. At the molecular level this association translates into a positive correlation between macroH2A1 ratios and molecular characteristics of the EMT process. Moreover, untreated Triple Negative Breast Cancers presenting a high macroH2A1.1 mRNA ratio exhibit a poor outcome.
   Conclusion: These results provide first evidence that macroH2A1.1 could be exploited as an actor in the maintenance of a transient cellular state in EMT progress towards metastatic development of breast tumors.
C1 [Lavigne, Anne-Claire; Castells, Magali; Mermet, Jerome; Kocanova, Silvia; Dalvai, Mathieu; Bystricky, Kerstin] Univ Toulouse, Lab Biol Mol Eucaryote, F-31062 Toulouse, France.
   [Lavigne, Anne-Claire; Castells, Magali; Mermet, Jerome; Kocanova, Silvia; Dalvai, Mathieu; Bystricky, Kerstin] CNRS, LBME, F-31062 Toulouse, France.
C3 Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre
   National de la Recherche Scientifique (CNRS); Universite de Toulouse;
   Universite Toulouse III - Paul Sabatier; Centre National de la Recherche
   Scientifique (CNRS)
RP Lavigne, AC (通讯作者)，Univ Toulouse, Lab Biol Mol Eucaryote, F-31062 Toulouse, France.
EM lavigne@ibcg.biotoul.fr
RI Bystricky, Kerstin/AAA-3003-2020; Lavigne, Anne-Claire/O-8805-2015;
   Bystricky, Kerstin/B-8670-2009
OI Bystricky, Kerstin/0000-0001-6717-3721; Mermet,
   Jerome/0000-0001-8623-7380
FU Institut National du Cancer [TRANSLA11-73]
FX Funding provided by Institut National du Cancer - noTRANSLA11-73
   -URL:http://www.e-cancer.fr/and Fondation pour la Recherche Medicale -
   URL: http://www.frm.org/. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abell AN, 2011, CELL STEM CELL, V8, P525, DOI 10.1016/j.stem.2011.03.008
   Barrero MJ, 2013, J BIOL CHEM
   Barrero MJ, 2013, CELL REP
   Belguise K, 2012, ONCOGENE, V31, P4889, DOI 10.1038/onc.2011.659
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Carmody LC, 2012, J BIOMOL SCREEN, V17, P1204, DOI 10.1177/1087057112458317
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Costanzi C, 1998, NATURE, V393, P599, DOI 10.1038/31275
   Creppe C, 2012, MOL CELL BIOL, V32, P1442, DOI 10.1128/MCB.06323-11
   Dardenne E, 2012, NAT STRUCT MOL BIOL, V19, P1139, DOI 10.1038/nsmb.2390
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Desmedt C, 2008, CLIN CANCER RES, V14, P5158, DOI 10.1158/1078-0432.CCR-07-4756
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Dittmar KA, 2012, MOL CELL BIOL, V32, P1468, DOI 10.1128/MCB.06536-11
   Gaspar-Maia A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2582
   Germain AR, 2012, BIOORG MED CHEM LETT, V22, P3571, DOI 10.1016/j.bmcl.2012.01.035
   Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8
   Kapoor A, 2010, NATURE, V468, P1105, DOI 10.1038/nature09590
   Lapuk A, 2010, MOL CANCER RES, V8, P961, DOI 10.1158/1541-7786.MCR-09-0528
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Loi S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-239
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Novikov L, 2011, MOL CELL BIOL, V31, P4244, DOI 10.1128/MCB.05244-11
   Ocaña OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953
   Pasque V, 2012, J CELL SCI, V125, P6094, DOI 10.1242/jcs.113019
   Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325
   PEHRSON JR, 1992, SCIENCE, V257, P1398
   Pehrson JR, 1997, J CELL BIOCHEM, V65, P107, DOI 10.1002/(SICI)1097-4644(199704)65:1<107::AID-JCB11>3.0.CO;2-H
   Perou CM, 2011, ONCOLOGIST, V16, P61, DOI 10.1634/theoncologist.2011-S1-61
   Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
   Rasmussen TP, 2000, J CELL BIOL, V150, P1189, DOI 10.1083/jcb.150.5.1189
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Rody A, 2007, BREAST, V16, P235, DOI 10.1016/j.breast.2007.02.006
   Rody A, 2007, CLIN CANCER RES, V13, P1115, DOI 10.1158/1078-0432.CCR-06-2433
   Rody A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3035
   Rody A, 2009, EUR J CANCER, V45, P405, DOI 10.1016/j.ejca.2008.10.016
   Ruckhäberle E, 2010, EUR J CANCER, V46, P549, DOI 10.1016/j.ejca.2009.11.020
   Ruckhäberle E, 2008, BREAST CANCER RES TR, V112, P41, DOI 10.1007/s10549-007-9836-9
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Schefe JH, 2006, J MOL MED, V84, P901, DOI 10.1007/s00109-006-0097-6
   Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206
   Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26
   Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027
   Stadler SC, 2012, SEMIN CANC BIOL
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022
   Wang Y, 2012, EXP CELL RES
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Warzecha CC, 2012, SEMIN CANC BIOL
   Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364
   Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019
   Zhang Y, 2009, BREAST CANCER RES TR, V116, P303, DOI 10.1007/s10549-008-0183-2
NR 63
TC 22
Z9 26
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 9
PY 2014
VL 9
IS 6
AR e98930
DI 10.1371/journal.pone.0098930
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI8LF
UT WOS:000337165600027
PM 24911873
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Alevizos, L
   Kataki, A
   Derventzi, A
   Gomatos, I
   Loutraris, C
   Gloustianou, G
   Manouras, A
   Konstadoulakis, MM
   Zografos, G
AF Alevizos, Leonidas
   Kataki, Agapi
   Derventzi, Anastasia
   Gomatos, Ilias
   Loutraris, Christos
   Gloustianou, Georgia
   Manouras, Andreas
   Konstadoulakis, Manousos M.
   Zografos, George
TI Breast cancer nodal metastasis correlates with tumour and lymph node
   methylation profiles of Caveolin-1 and CXCR4
SO CLINICAL & EXPERIMENTAL METASTASIS
LA English
DT Article
DE CXCR4; Caveolin-1; Gene promoter methylation; Breast cancer metastasis
ID PROMOTER HYPERMETHYLATION; SUPPRESSOR GENES; DNA METHYLATION;
   UP-REGULATION; EXPRESSION; INVASION; GROWTH; CELLS; TWIST
AB DNA methylation is the best characterised epigenetic change so far. However, its role in breast cancer metastasis has not as yet been elucidated. The aim of this study was to investigate the differences between the methylation profiles characterising primary tumours and their corresponding positive or negative for metastasis lymph nodes (LN) and correlate these with tumour metastatic potential. Methylation signatures of Caveolin-1, CXCR4, RAR-beta, Cyclin D2 and Twist gene promoters were studied in 30 breast cancer primary lesions and their corresponding metastasis-free and tumour-infiltrated LN with Methylation-Specific PCR. CXCR4 and Caveolin-1 expression was further studied by immunohistochemistry. Tumours were typified by methylation of RAR-beta and hypermethylation of Cyclin-D2 and Twist gene promoters. Tumour patterns were highly conserved in tumour-infiltrated LN. CXCR4 and Caveolin-1 promoter methylation patterns differentiated between node-negative and metastatic tumours. Nodal metastasis was associated with tumour and lymph node profiles of extended methylation of Caveolin-1 and lack of CXCR4 hypermethylation. Immunodetection studies verified CXCR4 and Caveolin-1 hypermethylation as gene silencing mechanism. Absence of Caveolin-1 expression in stromal cells associated with tumour aggressiveness while strong Caveolin-1 expression in tumour cells correlated with decreased 7-year disease-free survival. Methylation-mediated activation of CXCR4 and inactivation of Caveolin-1 was linked with nodal metastasis while intratumoral Caveolin-1 expression heterogeneity correlated with disease progression. This evidence contributes to the better understanding and, thereby, therapeutic management of breast cancer metastasis process.
C1 [Alevizos, Leonidas; Kataki, Agapi; Derventzi, Anastasia; Gomatos, Ilias; Loutraris, Christos; Gloustianou, Georgia; Manouras, Andreas; Konstadoulakis, Manousos M.; Zografos, George] Univ Athens, Athens Med Sch, Hippokrat Hosp Athens, Lab Surg Res,Dept Propaedeut Surg 1, Athens 11527, Greece.
C3 National & Kapodistrian University of Athens
RP Alevizos, L (通讯作者)，Univ Athens, Athens Med Sch, Hippokrat Hosp Athens, Lab Surg Res,Dept Propaedeut Surg 1, 114 Queens Sofia Ave, Athens 11527, Greece.
EM leonalevizos@gmail.com
RI Alevizos, Leonidas/AAF-6637-2020
OI Kataki, Agapi/0009-0008-8930-5383; Alevizos,
   Leonidas/0000-0001-7336-9886; Alexandris, Dimitrios/0000-0002-2296-9360
FU National and Kapodistrian University of Athens, Special Account for
   Research Grants [70/4/8111]
FX This project has been sponsored with funds from the National and
   Kapodistrian University of Athens, Special Account for Research Grants
   (70/4/8111).
CR Barekati Z, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-244
   Borges S, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3460
   Carraway HE, 2009, BREAST CANCER RES TR, V114, P315, DOI 10.1007/s10549-008-0004-7
   Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8
   Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011
   Chen ST, 2004, INT J MOL MED, V14, P577
   De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045
   Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300
   Furusato B, 2010, PATHOL INT, V60, P497, DOI 10.1111/j.1440-1827.2010.02548.x
   Hehlgans S, 2011, AM J CANCER RES, V1, P521
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   Hurst DR, 2011, INT REV CEL MOL BIO, V286, P107, DOI 10.1016/B978-0-12-385859-7.00003-3
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Li Q, 2011, EPIGENETICS-US, V6, P849, DOI 10.4161/epi.6.7.16314
   Lin SY, 2004, ANTICANCER RES, V24, P1645
   Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207
   Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928
   Mori T, 2005, CANCER RES, V65, P1800, DOI 10.1158/0008-5472.CAN-04-3531
   Qian N, 2011, CANCER SCI, V102, P1590, DOI 10.1111/j.1349-7006.2011.01985.x
   Radpour R, 2009, ONCOGENE, V28, P2969, DOI 10.1038/onc.2009.149
   Ramos EAS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029461
   Sato N, 2005, CANCER BIOL THER, V4, P70, DOI 10.4161/cbt.4.1.1378
   Sherif ZA, 2013, CANCER BIOL THER, V14, P29, DOI 10.4161/cbt.22621
   Simpkins SA, 2012, J PATHOL, V227, P490, DOI 10.1002/path.4034
   Sloan EK, 2004, ONCOGENE, V23, P7893, DOI 10.1038/sj.onc.1208062
   Sotgia F, 2009, AM J PATHOL, V174, P746, DOI 10.2353/ajpath.2009.080658
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-r84, 10.1186/gb-2012-13-10-R84]
   Tang DL, 2013, J UROLOGY, V190, P317, DOI 10.1016/j.juro.2013.01.083
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Zhao M, 2013, EXP THER MED, V6, P97, DOI 10.3892/etm.2013.1099
   Zhou J, 2013, BIOCHEM BIOPH RES CO, V433, P207, DOI 10.1016/j.bbrc.2013.02.084
NR 36
TC 22
Z9 23
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0262-0898
EI 1573-7276
J9 CLIN EXP METASTAS
JI Clin. Exp. Metastasis
PD JUN
PY 2014
VL 31
IS 5
BP 511
EP 520
DI 10.1007/s10585-014-9645-6
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI7OL
UT WOS:000337082400002
PM 24590865
DA 2025-01-12
ER

PT J
AU Nesset, KA
   Perri, AM
   Mueller, CR
AF Nesset, Kirsten A.
   Perri, Ami M.
   Mueller, Christopher R.
TI Frequent promoter hypermethylation and expression reduction of the
   glucocorticoid receptor gene in breast tumors
SO EPIGENETICS
LA English
DT Article
DE glucocorticoid receptor; GR; breast cancer; methylation; stress
ID DNA METHYLATION; ESTROGEN-RECEPTOR; CANCER; TISSUE; BRCA1; NR3C1;
   CARCINOMA; MULTIPLE; PATTERNS; STRESS
AB Previous studies have found that expression of the Glucocorticoid Receptor (GR) is altered or reduced in various cancers, while the GR promoter has been shown to be methylated in gastric, lung, and colorectal cancers. Examining a small cohort of matched normal and breast cancer samples we found that GR levels were dramatically reduced in almost all tumors in relation to their normal tissue. The methylation status of the GR promoter was assessed to determine if this observed decrease of expression in breast tumors could be due to epigenetic regulation. While it was not methylated in normal tissue, the GR proximal promoter was methylated in 15% of tumor samples, particularly, but not exclusively, in Estrogen Receptor positive tumors. GR expression in these tumors was particularly low and loss of GR expression was specifically correlated with methylation of the proximal promoter GR B region. Overall, these results show that hypermethylation of the promoter in tumors is a frequent event and suggests that GR may act as a tumor suppressor in breast tissue.
C1 [Nesset, Kirsten A.; Perri, Ami M.; Mueller, Christopher R.] Queens Univ, Dept Biomed & Mol Sci, Dept Pathol & Mol Med, Queens Canc Res Inst, Kingston, ON, Canada.
C3 Queens University - Canada; McMaster University
RP Mueller, CR (通讯作者)，Queens Univ, Dept Biomed & Mol Sci, Dept Pathol & Mol Med, Queens Canc Res Inst, Kingston, ON, Canada.
EM muellerc@queensu.ca
FU Canadian Breast Cancer Foundation (Ontario Chapter)
FX We would like to thank the Canadian Breast Cancer Foundation (Ontario
   Chapter) for supporting this research project through an operating
   grant. We also acknowledge the Ontario Tumour Bank for supplying breast
   cancer patient samples.
CR Antonova L, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2836
   Baylin SB, 2001, HUM MOL GENET, V10, P687, DOI 10.1093/hmg/10.7.687
   Belova L, 2009, BREAST CANCER RES TR, V116, P441, DOI 10.1007/s10549-008-0136-9
   Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Breslin MB, 2001, MOL ENDOCRINOL, V15, P1381, DOI 10.1210/me.15.8.1381
   Buxant F, 2010, APPL IMMUNOHISTO M M, V18, P254, DOI 10.1097/PAI.0b013e3181c10180
   Cao-Lei L, 2011, HUM GENET, V129, P533, DOI 10.1007/s00439-011-0949-1
   Chebotaev D, 2007, MOL CARCINOGEN, V46, P732, DOI 10.1002/mc.20349
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kang GH, 2008, LAB INVEST, V88, P161, DOI 10.1038/labinvest.3700707
   Kay P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024839
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Labonte B, 2012, BIOL PSYCHIAT, V72, P41, DOI 10.1016/j.biopsych.2012.01.034
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Li SY, 2006, CANCER LETT, V237, P272, DOI 10.1016/j.canlet.2005.06.011
   Lien HC, 2006, J PATHOL, V209, P317, DOI 10.1002/path.1982
   Lind GE, 2006, CELL ONCOL, V28, P259
   McGowan PO, 2009, NAT NEUROSCI, V12, P342, DOI 10.1038/nn.2270
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Meyer LR, 2013, NUCLEIC ACIDS RES, V41, pD64, DOI 10.1093/nar/gks1048
   Moutsatsou P, 2008, J CELL MOL MED, V12, P145, DOI 10.1111/j.1582-4934.2007.00177.x
   Mueller CR, 2003, BREAST CANCER RES, V5, P45, DOI 10.1186/bcr557
   Nunez BS, 2002, MOL CELL ENDOCRINOL, V189, P191, DOI 10.1016/S0303-7207(01)00676-1
   Oberlander TF, 2008, EPIGENETICS-US, V3, P97, DOI 10.4161/epi.3.2.6034
   Pan D, 2011, CANCER RES, V71, P6360, DOI 10.1158/0008-5472.CAN-11-0362
   Parrella P, 2004, CLIN CANCER RES, V10, P5349, DOI 10.1158/1078-0432.CCR-04-0555
   Ritter HD, 2012, MOL CANCER RES, V10, P558, DOI 10.1158/1541-7786.MCR-11-0423-T
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Smith RA, 2003, BREAST CANCER RES, V5, DOI 10.1186/bcr556
   Turner JD, 2005, J MOL ENDOCRINOL, V35, P283, DOI 10.1677/jme.1.01822
   Turner JD, 2010, BIOCHEM PHARMACOL, V80, P1860, DOI 10.1016/j.bcp.2010.06.037
   Turner JD, 2008, NUCLEIC ACIDS RES, V36, P7207, DOI 10.1093/nar/gkn897
   Vilasco M, 2011, BREAST CANCER RES TR, V130, P1, DOI 10.1007/s10549-011-1689-6
   Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276
   Wu Q, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-45
NR 37
TC 31
Z9 35
U1 0
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD JUN
PY 2014
VL 9
IS 6
BP 851
EP 859
DI 10.4161/epi.28484
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AI8OR
UT WOS:000337179600009
PM 24622770
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Cao, L
   Gao, H
   Li, P
   Gui, SB
   Zhang, YZ
AF Cao, Lei
   Gao, Hua
   Li, Ping
   Gui, Songbai
   Zhang, Yazhuo
TI The Wnt/β-catenin signaling pathway is involved in the antitumor effect
   of fulvestrant on rat prolactinoma MMQ cells
SO TUMOR BIOLOGY
LA English
DT Article
DE Fulvestrant; beta-Catenin; Estrogen receptor-alpha; Wnt inhibitory
   factor-1; Methylation; SB 216763
ID HUMAN ESTROGEN-RECEPTOR; BETA-CATENIN; BREAST-CANCER; ALPHA;
   INACTIVATION; HYPERPLASIA
AB Although an antiestrogen treatment for estrogen-dependent diseases, such as breast cancers, has been reported, the effect of this endocrine therapy on prolactinomas and its possible mechanism are unclear. This study investigates the antitumor effect of fulvestrant, which is a new estrogen receptor antagonist, on rat prolactinoma MMQ cells and the possible roles of the Wnt/beta-catenin signaling pathway that is involved in this antitumor effect. To investigate the antitumor effect of fulvestrant, the effects of exposure to gradient doses of fulvestrant (0, 0.04, 1, 25, and 625 nM) on the proliferation of cells and the secretion of prolactin (PRL) were studied. Then, the expression levels of the Wnt/beta-catenin signaling pathway-related proteins beta-catenin and Wnt inhibitory factor-1 (WIF-1) were measured to investigate their possible roles in the antitumor effect of fulvestrant. The cells were also treated with decitabine (10 mu M) to investigate the epigenetic mechanism of WIF-1 expression. The proliferation of MMQ cells and the secretion of PRL were suppressed by fulvestrant in a dose-dependent manner (up to 57.0 +/- 3.9 % and 51.2 +/- 4.9 %, respectively). beta-Catenin expression was downregulated and was positively correlated with ER-alpha expression (P < 0.01). As a tumor suppressor, WIF-1 expression was upregulated and was negatively correlated with ER-alpha expression (P < 0.01). Furthermore, WIF-1 expression was upregulated via the hypomethylation of the promoter by decitabine, and cellular proliferation was correspondingly suppressed (37.8 +/- 4.3 %). Antitumor effect of fulvestrant was partially disrupted by SB 216763 via activation of the Wnt/beta-catenin pathway. In conclusion, through the Wnt/beta-catenin signaling pathway, fulvestrant can suppress the proliferation of MMQ cells and the secretion of PRL.
C1 [Cao, Lei; Gao, Hua; Li, Ping; Zhang, Yazhuo] Capital Med Univ, Beijing Neurosurg Inst, Beijing 100050, Peoples R China.
   [Gui, Songbai] Capital Med Univ, Beijing Tiantan Hosp, Beijing 100050, Peoples R China.
C3 Beijing Neurosurgical Institute; Capital Medical University; Capital
   Medical University
RP Zhang, YZ (通讯作者)，Capital Med Univ, Beijing Neurosurg Inst, 6 Tiantan Xili, Beijing 100050, Peoples R China.
EM zyz2004520@yeah.net
RI Cao, Lei/H-3185-2019
FU National Natural Science Foundation of China [81271627, 30971005,
   81072075]; Key Program of the Natural Science Foundation of Beijing
   [7121004]; Ladder Program of the Key Lab in Beijing [Z121107002812031]
FX This work was supported by the National Natural Science Foundation of
   China (81271627, 30971005, and 81072075), the Key Program of the Natural
   Science Foundation of Beijing (7121004), and the Ladder Program of the
   Key Lab in Beijing (Z121107002812031).
CR Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   DAUVOIS S, 1993, J CELL SCI, V106, P1377
   Elston MS, 2008, ENDOCRINOLOGY, V149, P1235, DOI 10.1210/en.2007-0542
   Ergote I, 2006, ANN ONCOL, V17, P200
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Gooren LJG, 1988, J CLIN ENDOCR METAB, V66, P2444
   Gueorguiev M, 2009, PITUITARY, V12, P245, DOI 10.1007/s11102-008-0147-x
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Klibanski A, 2010, NEW ENGL J MED, V362, P1219, DOI 10.1056/NEJMcp0912025
   LEGOFF P, 1994, J BIOL CHEM, V269, P4458
   Li CZ, 2009, NEUROENDOCRINOL LETT, V30, P268
   Liu XR, 2011, MED ONCOL, V28, P608, DOI 10.1007/s12032-010-9476-5
   LLOYD RV, 1983, AM J PATHOL, V113, P198
   Lv HT, 2011, J NEURO-ONCOL, V102, P237, DOI 10.1007/s11060-010-0326-2
   Qian ZR, 2002, MODERN PATHOL, V15, P1357, DOI 10.1097/01.MP.0000039572.75188.1A
   Semba S, 2001, CANCER, V91, P42, DOI 10.1002/1097-0142(20010101)91:1<42::AID-CNCR6>3.0.CO;2-7
   Serri O, 1996, J CLIN ENDOCR METAB, V81, P3177, DOI 10.1210/jc.81.9.3177
   Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344
   Varea O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005153
   WEBSTER J, 1994, NEW ENGL J MED, V331, P904, DOI 10.1056/NEJM199410063311403
   Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200
   Willert K, 2006, GENE DEV, V20, P1394, DOI 10.1101/gad.1424006
   Yang XW, 2001, CANCER RES, V61, P7025
NR 23
TC 13
Z9 14
U1 0
U2 21
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUN
PY 2014
VL 35
IS 6
BP 5121
EP 5127
DI 10.1007/s13277-013-1571-8
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI7RW
UT WOS:000337094900008
PM 24643679
DA 2025-01-12
ER

PT J
AU Deleporte, A
   Paesmans, M
   Garcia, C
   Vandeputte, C
   Lemort, M
   Engelholm, JL
   Hoerner, F
   Aftimos, P
   Awada, A
   Charette, N
   Machiels, G
   Piccart, M
   Flamen, P
   Hendlisz, A
AF Deleporte, Amelie
   Paesmans, Marianne
   Garcia, Camilo
   Vandeputte, Caroline
   Lemort, Marc
   Engelholm, Jean-Luc
   Hoerner, Frederic
   Aftimos, Philippe
   Awada, Ahmad
   Charette, Nicolas
   Machiels, Godelieve
   Piccart, Martine
   Flamen, Patrick
   Hendlisz, Alain
TI <i>Cor</i>relating tumor metabolic progression <i>i</i>ndex measured by
   serial FDG PET-CT, apparent diffusion coefficient measured by magnetic
   resonance imaging (MRI) and blood genomics to patient's <i>o</i>utcome
   in advanced co<i>l</i>orectal c<i>an</i>cer: the CORIOLAN study
SO BMC CANCER
LA English
DT Article
DE Colorectal cancer; Progression rate assessment; FDG-PET; PET/CT
ID METASTATIC BREAST-CANCER; POSITRON-EMISSION-TOMOGRAPHY; 1ST-LINE
   CHEMOTHERAPY; RANDOMIZED-TRIAL; FREE SURVIVAL; RESPONSE RATE; CELLS;
   INTERMITTENT; METAANALYSIS; PREDICTION
AB Background: Metastatic colorectal cancer (mCRC) may present various behaviours that define different courses of tumor evolution. There is presently no available tool designed to assess tumor aggressiveness, despite the fact that this is considered to have a major impact on patient outcome.
   Methods/Design: CORIOLAN is a single-arm prospective interventional non-therapeutic study aiming mainly to assess the natural tumor metabolic progression index (TMPI) measured by serial FDG PET-CT without any intercurrent antitumor therapy as a prognostic factor for overall survival (OS) in patients with mCRC.
   Secondary objectives of the study aim to test the TMPI as a prognostic marker for progression-free survival (PFS), to assess the prognostic value of baseline tumor FDG uptake on PFS and OS, to compare TMPI to classical clinico-biological assessment of prognosis, and to test the prognostic value on OS and PFS of MRI-based apparent diffusion coefficient (ADC) and variation of vADC using voxel-based diffusion maps.
   Additionally, this study intends to identify genomic and epigenetic factors that correlate with progression of tumors and the OS of patients with mCRC. Consequently, this analysis will provide information about the signaling pathways that determine the natural and therapy-free course of the disease. Finally, it would be of great interest to investigate whether in a population of patients with mCRC, for which at present no known effective therapy is available, tumor aggressiveness is related to elevated levels of circulating tumor cells (CTCs) and to patient outcome.
   Discussion: Tumor aggressiveness is one of the major determinants of patient outcome in advanced disease. Despite its importance, supported by findings reported in the literature of extreme outcomes for patients with mCRC treated with chemotherapy, no objective tool allows clinicians to base treatment decisions on this factor. The CORIOLAN study will characterize TMPI using FDG-PET-based metabolic imaging of patients with chemorefractory mCRC during a period of time without treatment. Results will be correlated to other assessment tools like DW-MRI, CTCs and circulating DNA, with the aim to provide usable tools in daily practice and in clinical studies in the future.
C1 [Deleporte, Amelie; Vandeputte, Caroline; Hoerner, Frederic; Aftimos, Philippe; Awada, Ahmad; Charette, Nicolas; Machiels, Godelieve; Piccart, Martine; Hendlisz, Alain] Univ Libre Bruxelles, Dept Med, Inst Jules Bordet, Brussels, Belgium.
   [Paesmans, Marianne] Univ Libre Bruxelles, Inst Jules Bordet, Ctr Data, Brussels, Belgium.
   [Garcia, Camilo; Flamen, Patrick] Univ Libre Bruxelles, Inst Jules Bordet, Dept Nucl Med, Brussels, Belgium.
   [Lemort, Marc; Engelholm, Jean-Luc] Univ Libre Bruxelles, Inst Jules Bordet, Dept Radiol, Brussels, Belgium.
C3 Universite Libre de Bruxelles; Institut Jules Bordet; Universite Libre
   de Bruxelles; Institut Jules Bordet; Universite Libre de Bruxelles;
   Institut Jules Bordet; Universite Catholique Louvain; Cliniques
   Universitaires Saint-Luc; Universite Libre de Bruxelles; Institut Jules
   Bordet
RP Deleporte, A (通讯作者)，Univ Libre Bruxelles, Dept Med, Inst Jules Bordet, Brussels, Belgium.
EM amelie.deleporte@bordet.be
RI AWADA, AHMAD/ABF-1137-2020; Garcia, Camilo/HIZ-5830-2022
OI , AHMAD/0000-0001-7412-9163; hendlisz, alain/0000-0003-2122-1948
FU King Baudouin Foundation; Les Amis de l'Institut Bordet, asbl
FX We would like to thank the King Baudouin Foundation and Les Amis de
   l'Institut Bordet, asbl to the Institut Jules Bordet, who provide
   funding for this study. We also would like to thank the Sponsor, the
   Institut Jules Bordet - Centre des Tumeurs de l'ULB, rue Heger-Bordet,
   1, 1000 Brussels, represented by Dr. D. de Valeriola (Medical Director
   of the Jules Bordet Institute), Mr. P. Goblet (Managing Director Centres
   des Tumeurs de l'ULB), and Dr. A. Hendlisz (Head of Gastroenterology
   Unit).
CR Ackland SP, 2005, BRIT J CANCER, V93, P1236, DOI 10.1038/sj.bjc.6602841
   Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4
   Boellaard R, 2010, EUR J NUCL MED MOL I, V37, P181, DOI 10.1007/s00259-009-1297-4
   Buyse M, 2000, LANCET, V356, P373, DOI 10.1016/S0140-6736(00)02528-9
   Byström P, 2009, ANN ONCOL, V20, P1057, DOI 10.1093/annonc/mdn744
   Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344
   Cohen SJ, 2009, ANN ONCOL, V20, P1223, DOI 10.1093/annonc/mdn786
   Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Cristofanilli M, 2013, NEW ENGL J MED, V369, P93, DOI 10.1056/NEJMc1306040
   DeVries AF, 2003, INT J RADIAT ONCOL, V56, P958, DOI 10.1016/S0360-3016(03)00208-6
   Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102
   Dzik-Jurasz A, 2002, LANCET, V360, P307, DOI 10.1016/S0140-6736(02)09520-X
   Ellingson BM, 2011, J NEURO-ONCOL, V102, P95, DOI 10.1007/s11060-010-0293-7
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   Gambhir SS, 2002, NAT REV CANCER, V2, P683, DOI 10.1038/nrc882
   GLIMELIUS B, 1992, J CLIN ONCOL, V10, P904, DOI 10.1200/JCO.1992.10.6.904
   Grothey A, 2008, J CLIN ONCOL, V26, P183, DOI 10.1200/JCO.2007.13.8099
   Hamstra DA, 2008, J CLIN ONCOL, V26, P3387, DOI 10.1200/JCO.2007.15.2363
   Hamstra DA, 2007, J CLIN ONCOL, V25, P4104, DOI 10.1200/JCO.2007.11.9610
   Hayes DF, 2006, CLIN CANCER RES, V12, P4218, DOI 10.1158/1078-0432.CCR-05-2821
   Hendlisz A, 2012, ANN ONCOL, V23, P1687, DOI 10.1093/annonc/mdr554
   Hendlisz A, 2009, J CLIN ONCOL, V6, P1057
   HIGASHI K, 1993, J NUCL MED, V34, P414
   Johnson KR, 2006, LANCET ONCOL, V7, P741, DOI 10.1016/S1470-2045(06)70800-2
   Labianca R, 2011, ANN ONCOL, V22, P1236, DOI 10.1093/annonc/mdq580
   Louvet C, 2001, CANCER, V91, P2033, DOI 10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J
   Matsusaka S, 2011, CANCER SCI, V102, P1188, DOI 10.1111/j.1349-7006.2011.01926.x
   Maughan TS, 2003, LANCET, V361, P457, DOI 10.1016/S0140-6736(03)12461-0
   McBride DJ, 2010, GENE CHROMOSOME CANC, V49, P1062, DOI 10.1002/gcc.20815
   Morgan VA, 2011, BRIT J RADIOL, V84, P31, DOI 10.1259/bjr/14556365
   Nomura K, 1998, DIGEST SURG, V15, P21, DOI 10.1159/000018581
   Price P, 1995, EUR J CANCER, V31A, P1924, DOI 10.1016/0959-8049(95)00421-1
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Tang PA, 2007, J CLIN ONCOL, V25, P4562, DOI 10.1200/JCO.2006.08.1935
   Theilmann RJ, 2004, NEOPLASIA, V6, P831, DOI 10.1593/neo.03343
   Thoeny HC, 2005, RADIOLOGY, V237, P492, DOI 10.1148/radiol.2372041638
NR 38
TC 1
Z9 1
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 30
PY 2014
VL 14
AR 385
DI 10.1186/1471-2407-14-385
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AJ2ZC
UT WOS:000337533200002
PM 24885112
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Wang, B
   Li, JD
   Sun, M
   Sun, LH
   Zhang, XY
AF Wang, Bin
   Li, Jindong
   Sun, Mei
   Sun, Lihua
   Zhang, Xingyi
TI MiRNA Expression in Breast Cancer Varies with Lymph Node Metastasis and
   Other Clinicopathologic Features
SO IUBMB LIFE
LA English
DT Article
DE breast cancer; microRNAs; microarray; lymph node metastasis; prognosis
ID AXILLARY; MICRORNAS; CARCINOMA; DISSECTION
AB Breast carcinoma is the most common malignant tumor in females, and lymph node (LN) status is one of the most important prognostic factors in patients with breast cancer. MiRNAs have been shown to have important role in oncogenesis, invasion, and metastasis via epigenetic post-transcriptional gene regulation. However, lymphatic metastasis-related miRNAs of breast cancer has not been well documented. The aim of this study was to identify and evaluate miRNAs related to breast cancer LN metastasis and to explore the clinical significance of the differentially expressed miRNAs in patients with breast cancer. The expression of miRNAs in patients with primary breast cancer with LN metastasis and that without LN metastases was compared by miRNA microarray. We further validated the miRNAs (miR-185-5p, miR-339-5p, miR-542-5p, and miR-3923) between LN (n=31) and nonlymph node (NLN; n=42) group using real-time reverse transcriptase polymerase chain reaction. Furthermore, the relationship between miRNA expression and clinical pathological features was analyzed. The miRNA microarray initially identified that eight miRNAs (miR-206, miR-3923, miR-181a, miR-92a, miR-421, miR-339-5p, miR-3196, and miR-29b) were downregulated in LN metastasis group, whereas five miRNAs (miR-542-5p, miR-200a, miR-564, miR-451, miR-30c, miR-200b, miR-191-3p, miR-142-5p, and miR-185-5p) were upregulated in LN group when compared with those in NLN group. In the validation cohort, the expression levels of miR-185-5p and miR-542-5p were significantly expressed higher in LN group (P=0.002 and P=0.001, respectively), and the expression levels of miR-339-5p and miR-3923 were significantly expressed lower in LN group (P=0.001 and P=0.001, respectively). Our results indicate the potential role of miR-185-5p, miR-542-5p, miR-339-5p, and miR-3923 in predicting metastasis to the LN and prognosis in breast cancers. (C) 2014
C1 [Wang, Bin; Li, Jindong; Zhang, Xingyi] Jilin Univ, Hosp 2, Dept Thorac Surg, Changchun 130000, Jilin, Peoples R China.
   [Sun, Mei] Jilin Univ, Hosp 2, Dept Pathol, Changchun 130000, Jilin, Peoples R China.
   [Sun, Lihua] Jilin Univ, Hosp 2, Dept Anesthesiol, Changchun 130000, Jilin, Peoples R China.
C3 Jilin University; Jilin University; Jilin University
RP Zhang, XY (通讯作者)，Jilin Univ, Hosp 2, Dept Thorac Surg, Changchun 130000, Jilin, Peoples R China.
EM binharyida@163.com
FU China Natural Science Foundation [81272472]
FX This study was funded by the China Natural Science Foundation (No.
   81272472).
CR Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   BOOVA RS, 1982, ANN SURG, V196, P642, DOI 10.1097/00000658-198212001-00004
   Bray I, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007850
   CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
   Chen WX, 2013, TUMOR BIOL, V34, P1361, DOI 10.1007/s13277-013-0750-y
   Cox CE, 1998, ONCOLOGY-NY, V12, P1283
   Dees EC, 1997, ANN SURG, V226, P279, DOI 10.1097/00000658-199709000-00007
   Esteller M, 2011, NAT REV GENET, V12, P861, DOI 10.1038/nrg3074
   FISHER ER, 1993, CANCER-AM CANCER SOC, V71, P2141, DOI 10.1002/1097-0142(19930315)71:6+<2141::AID-CNCR2820711603>3.0.CO;2-F
   Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Haffty BG, 1997, J CLIN ONCOL, V15, P691, DOI 10.1200/JCO.1997.15.2.691
   He L., 2004, NAT REV GENET, V5, P522
   HOE AL, 1992, BRIT J SURG, V79, P261, DOI 10.1002/bjs.1800790326
   Jatoi I, 1999, SURG CLIN N AM, V79, P1061, DOI 10.1016/S0039-6109(05)70061-X
   Jatoi I, 2003, LANCET ONCOL, V4, P251, DOI 10.1016/S1470-2045(03)01037-4
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Lerebours F, 2013, INT J CANCER, V133, P1614, DOI 10.1002/ijc.28171
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Mestdagh P, 2010, ONCOGENE, V29, P1394, DOI 10.1038/onc.2009.429
   Mettlin C, 1999, CA-CANCER J CLIN, V49, P138, DOI 10.3322/canjclin.49.3.138
   Pepper MS, 2001, CLIN CANCER RES, V7, P462
   PIGOTT J, 1984, SURG GYNECOL OBSTET, V158, P255
   ROSEN PP, 1993, J CLIN ONCOL, V11, P2090, DOI 10.1200/JCO.1993.11.11.2090
   ROSEN PP, 1983, ANN SURG, V197, P276, DOI 10.1097/00000658-198303000-00006
   Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29
   Tan L. G. L., 2005, SMJ Singapore Medical Journal, V46, P693
   Wu ZS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-542
   Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028
NR 31
TC 61
Z9 64
U1 0
U2 18
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD MAY
PY 2014
VL 66
IS 5
BP 371
EP 377
DI 10.1002/iub.1273
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AJ4DJ
UT WOS:000337620900007
PM 24846313
OA Bronze
DA 2025-01-12
ER

PT J
AU Li, T
   Cai, J
   Ding, H
   Xu, LJ
   Yang, Q
   Wang, ZH
AF Li, Tao
   Cai, Jing
   Ding, Hui
   Xu, Linjuan
   Yang, Qiang
   Wang, Zehua
TI EZH2 participates in malignant biological behavior of epithelial ovarian
   cancer through regulating the expression of BRCA1
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE proliferation; cisplatin resistance; BRCA1; EZH2; migration; cell cycle;
   epithelial ovarian cancer
ID GROUP PROTEIN EZH2; HISTONE METHYLTRANSFERASE EZH2; BREAST-CANCER;
   MESSENGER-RNA; IN-VITRO; POLYCOMB; CELLS; METHYLATION; H3;
   PHOSPHORYLATION
AB Aberrant overexpression of the enhancer of zeste homolog 2 (EZH2), a histone methyltransferase inhibiting targets expression via epigenetic mechanisms, is associated with an invasive phenotype and drug resistance in ovarian cancer. Breast cancer 1 (BRCA1) gene is a well-recognized tumor suppressor, whose downregulation plays a key role in the development of ovarian cancer. In the present study, we found depletion of EZH2 increased BRCA1 protein expression and promoted its nuclear translocation, but decreased BRCA1 mRNA expression. Treatment with the Akt-1 activator insulin-like growth factor-1 (IGF-1) prevented EZH2-induced BRCA1 nuclear/cytoplasmic shuttling. Loss of BRCA1 partially rescued the effects of EZH2 downregulation on proliferation, G(2)/M transition, and migration in ovarian cancer cells. However, in a cisplatin-resistant sub-line of A2780 (A2780/DDP), both EZH2 and BRCA1 were overexpressed compared with parental A2780 cells and depletion of EZH2 reduced BRCA1 expression at both mRNA and protein levels. Downregulation of EZH2 or BRCA1 sensitized A2780/DDP cells to cisplatin, whereas simultaneous inhibition of them only resulted in modest resensitization instead of showing any synergistic effect because EZH2 expression was reactivated when BRCA1 expression was very low. Accordingly, our results suggest the expression of BRCA1 is modulated by EZH2 in epithelial ovarian cancer and BRCA1 is required for the effects of EZH2 downregulation on biological behaviors of tumor cells.
C1 [Li, Tao; Cai, Jing; Ding, Hui; Xu, Linjuan; Yang, Qiang; Wang, Zehua] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China.
C3 Huazhong University of Science & Technology
RP Wang, ZH (通讯作者)，Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Obstet & Gynecol, Wuhan 430074, Peoples R China.
EM zehuawang@163.net
RI Li, Tingting/HKE-0812-2023
FU key Project of Health Department of Hubei Province [JX5A07]
FX This work was supported by JX5A07 from the key Project of Health
   Department of Hubei Province.
CR Baldwin RL, 2000, CANCER RES, V60, P5329
   Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X
   Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333
   CARMICHAEL J, 1987, CANCER RES, V47, P936
   Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200
   Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066
   Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162
   Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3
   Du J, 2012, BREAST CANCER RES TR, V131, P65, DOI 10.1007/s10549-011-1396-3
   Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200
   Gonzalez ME, 2009, ONCOGENE, V28, P843, DOI 10.1038/onc.2008.433
   Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933
   Guo JF, 2011, CANCER SCI, V102, P530, DOI 10.1111/j.1349-7006.2010.01836.x
   Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720
   Hu S, 2010, CANCER BIOL THER, V10, P788, DOI 10.4161/cbt.10.8.12913
   Husain A, 1998, CANCER RES, V58, P1120
   Jelovac D, 2011, CA-CANCER J CLIN, V61, P183, DOI 10.3322/caac.20113
   Khoo Ui-Soon, 2002, Hum Mutat, V19, P307, DOI 10.1002/humu.9015
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kuzmichev A, 2004, MOL CELL, V14, P183, DOI 10.1016/S1097-2765(04)00185-6
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Moss C, 2002, EUR J CANCER, V38, P1701, DOI 10.1016/S0959-8049(02)00161-2
   Müller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5
   Plo I, 2008, CANCER RES, V68, P9404, DOI 10.1158/0008-5472.CAN-08-0861
   Puppe J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2354
   Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B
   Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wang Y, 2008, BIOCHEM BIOPH RES CO, V370, P201, DOI 10.1016/j.bbrc.2008.03.031
   Weikert S, 2005, INT J MOL MED, V16, P349
   Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001
   Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Yasmeen A, 2008, CELL CYCLE, V7, P3781, DOI 10.4161/cc.7.23.6993
   Zeidler M, 2005, NEOPLASIA, V7, P1011, DOI 10.1593/neo.05472
   Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032
NR 39
TC 23
Z9 28
U1 1
U2 19
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD MAR 1
PY 2014
VL 15
IS 3
BP 271
EP 278
DI 10.4161/cbt.27306
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB9TV
UT WOS:000332139500005
PM 24335192
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Dhimolea, E
   Wadia, PR
   Murray, TJ
   Settles, ML
   Treitman, JD
   Sonnenschein, C
   Shioda, T
   Soto, AM
AF Dhimolea, Eugen
   Wadia, Perinaaz R.
   Murray, Tessa J.
   Settles, Matthew L.
   Treitman, Jo D.
   Sonnenschein, Carlos
   Shioda, Toshi
   Soto, Ana M.
TI Prenatal Exposure to BPA Alters the Epigenome of the Rat Mammary Gland
   and Increases the Propensity to Neoplastic Development
SO PLOS ONE
LA English
DT Article
ID IN-UTERO EXPOSURE; BISPHENOL-A ALTERS; PERINATAL EXPOSURE;
   BREAST-CANCER; CARCINOGENESIS; DIETHYLSTILBESTROL; SUSCEPTIBILITY;
   HYPERPLASIAS; DISORDERS; RISK
AB Exposure to environmental estrogens (xenoestrogens) may play a causal role in the increased breast cancer incidence which has been observed in Europe and the US over the last 50 years. The xenoestrogen bisphenol A (BPA) leaches from plastic food/beverage containers and dental materials. Fetal exposure to BPA induces preneoplastic and neoplastic lesions in the adult rat mammary gland. Previous results suggest that BPA acts through the estrogen receptors which are detected exclusively in the mesenchyme during the exposure period by directly altering gene expression, leading to alterations of the reciprocal interactions between mesenchyme and epithelium. This initiates a long sequence of altered morphogenetic events leading to neoplastic transformation. Additionally, BPA induces epigenetic changes in some tissues. To explore this mechanism in the mammary gland, Wistar-Furth rats were exposed subcutaneously via osmotic pumps to vehicle or 250 mu g BPA/kg BW/day, a dose that induced ductal carcinomas in situ. Females exposed from gestational day 9 to postnatal day (PND) 1 were sacrificed at PND4, PND21 and at first estrus after PND50. Genomic DNA (gDNA) was isolated from the mammary tissue and immuno-precipitated using anti-5-methylcytosine antibodies. Detection and quantification of gDNA methylation status using the Nimblegen ChIP array revealed 7412 differentially methylated gDNA segments (out of 58207 segments), with the majority of changes occurring at PND21. Transcriptomal analysis revealed that the majority of gene expression differences between BPA- and vehicle-treated animals were observed later (PND50). BPA exposure resulted in higher levels of pro-activation histone H3K4 trimethylation at the transcriptional initiation site of the alpha-lactalbumin gene at PND4, concomitantly enhancing mRNA expression of this gene. These results show that fetal BPA exposure triggers changes in the postnatal and adult mammary gland epigenome and alters gene expression patterns. These events may contribute to the development of pre-neoplastic and neoplastic lesions that manifest during adulthood.
C1 [Dhimolea, Eugen; Wadia, Perinaaz R.; Murray, Tessa J.; Treitman, Jo D.; Sonnenschein, Carlos; Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.
   [Settles, Matthew L.] Univ Idaho, Inst Bioinformat & Evolutionary Studies, Moscow, ID 83843 USA.
   [Shioda, Toshi] Massachusetts Gen Hosp, MGH Ctr Canc Res, Charlestown, MA USA.
C3 Tufts University; University of Idaho; Harvard University; Massachusetts
   General Hospital
RP Soto, AM (通讯作者)，Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.
EM ana.soto@tufts.edu
RI Settles, Matthew/F-2031-2011
OI Settles, Matthew/0000-0002-3424-1086
FU NIH National Institute of Environmental Health Sciences [ES015182,
   ES018822, ES08314]; Susan G. Komen for Cure [FAS0703860, KG090515];
   ArtBeCause Breast Cancer Foundation
FX This work was funded by NIH National Institute of Environmental Health
   Sciences award numbers ES015182, ES018822, ES08314, (AS), Susan G. Komen
   for Cure (FAS0703860 and KG090515) (TS) and the ArtBeCause Breast Cancer
   Foundation (PW). The content is solely the responsibility of the authors
   and does not necessarily represent the official position of the Centers
   for Disease Control and Prevention, the National Institute of
   Environmental Health Sciences or the National Institutes of Health. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Acevedo N, 2013, ENVIRON HEALTH PERSP, V121, P1040, DOI 10.1289/ehp.1306734
   Ayyanan A, 2011, MOL ENDOCRINOL, V25, P1915, DOI 10.1210/me.2011-1129
   Barker DJP, 2004, ACTA PAEDIATR, V93, P1559, DOI 10.1080/08035250410024772
   Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148
   Biles JE, 1997, J AGR FOOD CHEM, V45, P3541, DOI 10.1021/jf970072i
   BOYLAN ES, 1983, CANCER RES, V43, P4872
   BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   Brotons JA, 1994, ENV HLTH PERSPECT, V103, P608, DOI DOI 10.1289/EHP.95103608
   Cabaton NJ, 2011, ENVIRON HEALTH PERSP, V119, P547, DOI 10.1289/ehp.1002559
   Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753
   Delfosse V, 2012, P NATL ACAD SCI USA, V109, P14930, DOI 10.1073/pnas.1203574109
   Durando M, 2007, ENVIRON HEALTH PERSP, V115, P80, DOI 10.1289/ehp.9282
   Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919
   GRUBBS CJ, 1983, JNCI-J NATL CANCER I, V70, P209
   Guerrero-Bosagna C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013100
   Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795
   Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516
   Honma S, 2002, REPROD TOXICOL, V16, P117, DOI 10.1016/S0890-6238(02)00006-0
   Howdeshell KL, 1999, NATURE, V401, P763, DOI 10.1038/44517
   Iacobuzio-Donahue CA, 2009, ANNU REV PATHOL-MECH, V4, P229, DOI 10.1146/annurev.pathol.3.121806.151442
   Ikezuki Y, 2002, HUM REPROD, V17, P2839, DOI 10.1093/humrep/17.11.2839
   Jenkins S, 2009, ENVIRON HEALTH PERSP, V117, P910, DOI 10.1289/ehp.11751
   Land CE, 2003, RADIAT RES, V160, P707, DOI 10.1667/RR3082
   Lozada KW, 2011, BIOL REPROD, V85, P490, DOI 10.1095/biolreprod.110.090431
   Markey CM, 2002, J STEROID BIOCHEM, V83, P235, DOI 10.1016/S0960-0760(02)00272-8
   Markey CM., 2003, EVOL DEV, V5, P67, DOI [DOI 10.1046/J.1525-142X.2003.03011.X, 10.1046/j.1525-142X.2003.03011.x]
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Murray TJ, 2007, REPROD TOXICOL, V23, P383, DOI 10.1016/j.reprotox.2006.10.002
   Olea N, 1996, ENVIRON HEALTH PERSP, V104, P298, DOI 10.2307/3432888
   Rijnkels M, 2010, J MAMMARY GLAND BIOL, V15, P85, DOI 10.1007/s10911-010-9170-4
   Rubin BS, 2001, ENVIRON HEALTH PERSP, V109, P675, DOI 10.2307/3454783
   Russo IH, 1996, ENVIRON HEALTH PERSP, V104, P938, DOI 10.1289/ehp.96104938
   Sallout B, 2003, J Obstet Gynaecol, V23, P555
   Schönfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703, DOI 10.1289/ehp.021100703
   SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E
   Singh M, 2000, LAB INVEST, V80, P221, DOI 10.1038/labinvest.3780025
   Skakkebaek NE, 1998, APMIS, V106, P3, DOI 10.1111/j.1699-0463.1998.tb01314.x
   Sonnenschein C, 2011, J DEV ORIG HLTH DIS, V2, P9, DOI 10.1017/S2040174411000043
   Sonnenschein C., 1999, SOC CELLS CANC CONTR
   Sonnenschein C, 2011, CANCER RES, V71, P4334, DOI 10.1158/0008-5472.CAN-11-0639
   Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5
   Soto AM, 2011, BIOESSAYS, V33, P332, DOI 10.1002/bies.201100025
   Soto AM, 2010, NAT REV ENDOCRINOL, V6, P364, DOI 10.1038/nrendo.2010.87
   Susiarjo M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003401
   Tharp AP, 2012, P NATL ACAD SCI USA, V109, P8190, DOI 10.1073/pnas.1120488109
   Trichopoulos D, 1990, Epidemiology, V1, P95
   Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561
   Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716
   Vandenberg LN, 2008, REPROD TOXICOL, V26, P210, DOI 10.1016/j.reprotox.2008.09.015
   Wadia PR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063902
   Weinberg RA, 2006, The biology of cancer
   Woodruff TJ, 2011, ENVIRON HEALTH PERSP, V119, P878, DOI 10.1289/ehp.1002727
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
   Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301
   Yaoi T, 2008, BIOCHEM BIOPH RES CO, V376, P563, DOI 10.1016/j.bbrc.2008.09.028
   Ye X, 2008, TALANTA, V76, P865, DOI 10.1016/j.talanta.2008.04.034
NR 57
TC 72
Z9 81
U1 1
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 2
PY 2014
VL 9
IS 7
AR e99800
DI 10.1371/journal.pone.0099800
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AO5BA
UT WOS:000341354100019
PM 24988533
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Moelans, CB
   de Groot, JS
   Pan, XJ
   van der Wall, E
   van Diest, PJ
AF Moelans, Cathy B.
   de Groot, Jolien S.
   Pan, Xiaojuan
   van der Wall, Elsken
   van Diest, Paul J.
TI Clonal intratumor heterogeneity of promoter hypermethylation in breast
   cancer by MS-MLPA
SO MODERN PATHOLOGY
LA English
DT Article
DE breast cancer; heterogeneity; hypermethylation; MS-MLPA
ID TUMOR HETEROGENEITY; METHYLATION; REVEALS
AB Intratumor heterogeneity may lead to sampling bias and may present major challenges to personalized medicine and biomarker development. Despite many studies investigating genetic heterogeneity, epigenetic intratumor heterogeneity of promoter hypermethylation has only rarely been examined in breast cancer. To examine clonal intratumor heterogeneity of promotor hypermethylation, we performed methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) for 24 established tumor-suppressor genes on multiple spatially separated samples obtained from 21 primary breast carcinomas. Multiregion analysis was performed, representing at least two and a maximum of five tumor blocks per patient and four areas per tumor block. Methylation results were heterogeneous at one or more genetic loci between different tumor regions in 95% of breast carcinomas. The most heterogeneous loci in decreasing frequency were RASSF1A (62%), CDKN2B (43%), APC (38%), GSTP1 (33%), CDH13 (24%), DAPK1 (19%), and CDKN1B (5%). Heterogeneity lead to a methylation status change in at least one locus in 65% of the tumors. For most genes, the relative contribution of between-patients and between-block variability to the total variation in methylation results was similar. Regardless of the gene, contribution of within-block variability was of little importance. In conclusion, although most variation in methylation status is present between individual breast cancers, clonal epigenetic heterogeneity is seen within most primary breast carcinomas, indicating that methylation results from a single random sample may not be representative of the whole tumor.
C1 [Moelans, Cathy B.; de Groot, Jolien S.; Pan, Xiaojuan; van der Wall, Elsken; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, NL-3508 GA Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center
RP Moelans, CB (通讯作者)，Univ Med Ctr Utrecht, Dept Pathol, Heidelberglaan 100,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM cmoelans@umcutrecht.nl
OI Moelans, Cathy/0000-0001-9992-8703
CR Aggerholm A, 1999, CANCER RES, V59, P436
   Almendro V, 2011, CLIN TRANSL ONCOL, V13, P767, DOI 10.1007/s12094-011-0731-9
   Aryee MJ, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005211
   Benetkiewicz M, 2006, INT J ONCOL, V29, P935
   Bhawal UK, 2007, ONCOL REP, V18, P817
   Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914
   Diaz-Cano SJ, 2012, INT J MOL SCI, V13, P1951, DOI 10.3390/ijms13021951
   Dopierala J, 2010, INVEST OPHTH VIS SCI, V51, P4898, DOI 10.1167/iovs.09-5004
   Duffy MJ, 2009, EUR J CANCER, V45, P335, DOI 10.1016/j.ejca.2008.12.008
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Kornegoor R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3220
   Korshunova Y, 2008, GENOME RES, V18, P19, DOI 10.1101/gr.6883307
   Matsunoki A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-574
   Moelans CB, 2011, J PATHOL, V225, P222, DOI 10.1002/path.2930
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Rastetter M, 2007, HISTOL HISTOPATHOL, V22, P1005, DOI 10.14670/HH-22.1005
   Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088
   Shibata D, 2012, SCIENCE, V336, P304, DOI 10.1126/science.1222361
   Suijkerbuijk KPM, 2010, ANAL CELL PATHOL, V33, P133, DOI [10.1155/2010/185219, 10.3233/ACP-CLO-2010-0542]
   Trautmann K, 2005, WORLD J GASTROENTERO, V11, P5993, DOI 10.3748/wjg.v11.i38.5993
   van Diest PJ, 2002, BMJ-BRIT MED J, V325, P648, DOI 10.1136/bmj.325.7365.648
   Varley KE, 2009, NUCLEIC ACIDS RES, V37, P4603, DOI 10.1093/nar/gkp457
   Verschuur-Maes AHJ, 2012, BREAST CANCER RES TR, V136, P705, DOI 10.1007/s10549-012-2301-4
   Yap TA, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003854
NR 24
TC 21
Z9 25
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD JUN
PY 2014
VL 27
IS 6
BP 869
EP 874
DI 10.1038/modpathol.2013.207
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AI5CY
UT WOS:000336884200010
PM 24287456
OA Bronze
DA 2025-01-12
ER

PT J
AU Chen, Y
   Mcgee, J
   Chen, XM
   Doman, TN
   Gong, XQ
   Zhang, YY
   Hamm, N
   Ma, XW
   Higgs, RE
   Bhagwat, SV
   Buchanan, S
   Peng, SB
   Staschke, KA
   Yadav, V
   Yue, Y
   Kouros-Mehr, H
AF Chen, Ying
   McGee, Jeremy
   Chen, Xianming
   Doman, Thompson N.
   Gong, Xueqian
   Zhang, Youyan
   Hamm, Nicole
   Ma, Xiwen
   Higgs, Richard E.
   Bhagwat, Shripad V.
   Buchanan, Sean
   Peng, Sheng-Bin
   Staschke, Kirk A.
   Yadav, Vipin
   Yue, Yong
   Kouros-Mehr, Hosein
TI Identification of Druggable Cancer Driver Genes Amplified across TCGA
   Datasets
SO PLOS ONE
LA English
DT Article
ID BREAST-CANCER; GROWTH-FACTOR; AMPLIFICATION; EPIGENETICS; INHIBITORS;
   EXPRESSION; RECEPTOR; PROTEIN; GRB7; AMPK
AB The Cancer Genome Atlas (TCGA) projects have advanced our understanding of the driver mutations, genetic backgrounds, and key pathways activated across cancer types. Analysis of TCGA datasets have mostly focused on somatic mutations and translocations, with less emphasis placed on gene amplifications. Here we describe a bioinformatics screening strategy to identify putative cancer driver genes amplified across TCGA datasets. We carried out GISTIC2 analysis of TCGA datasets spanning 16 cancer subtypes and identified 486 genes that were amplified in two or more datasets. The list was narrowed to 75 cancer-associated genes with potential "druggable'' properties. The majority of the genes were localized to 14 amplicons spread across the genome. To identify potential cancer driver genes, we analyzed gene copy number and mRNA expression data from individual patient samples and identified 42 putative cancer driver genes linked to diverse oncogenic processes. Oncogenic activity was further validated by siRNA/shRNA knockdown and by referencing the Project Achilles datasets. The amplified genes represented a number of gene families, including epigenetic regulators, cell cycle-associated genes, DNA damage response/repair genes, metabolic regulators, and genes linked to the Wnt, Notch, Hedgehog, JAK/STAT, NF-KB and MAPK signaling pathways. Among the 42 putative driver genes were known driver genes, such as EGFR, ERBB2 and PIK3CA. Wild-type KRAS was amplified in several cancer types, and KRAS-amplified cancer cell lines were most sensitive to KRAS shRNA, suggesting that KRAS amplification was an independent oncogenic event. A number of MAP kinase adapters were co-amplified with their receptor tyrosine kinases, such as the FGFR adapter FRS2 and the EGFR family adapters GRB2 and GRB7. The ubiquitin-like ligase DCUN1D1 and the histone methyltransferase NSD3 were also identified as novel putative cancer driver genes. We discuss the patient tailoring implications for existing cancer drug targets and we further discuss potential novel opportunities for drug discovery efforts.
C1 [Chen, Ying; McGee, Jeremy; Chen, Xianming; Doman, Thompson N.; Gong, Xueqian; Zhang, Youyan; Hamm, Nicole; Ma, Xiwen; Higgs, Richard E.; Bhagwat, Shripad V.; Buchanan, Sean; Peng, Sheng-Bin; Staschke, Kirk A.; Yadav, Vipin; Yue, Yong; Kouros-Mehr, Hosein] Eli Lilly & Co, Dept Oncol, Indianapolis, IN 46285 USA.
C3 Eli Lilly
RP Kouros-Mehr, H (通讯作者)，Eli Lilly & Co, Dept Oncol, Indianapolis, IN 46285 USA.
EM kouros.mehr@gmail.com
RI Staschke, Kirk/HGC-5664-2022; Wang, Xiaocheng/HJI-3782-2023
OI Staschke, Kirk/0000-0001-8722-9585
FU Eli Lilly and Company
FX This study was funded by Eli Lilly and Company. The funder provided
   support in the form of salaries for all authors, but did not have any
   additional role in the study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. The specific
   roles of these authors are articulated in the author contributions
   section.
CR Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957
   Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bhargava R, 2005, MODERN PATHOL, V18, P1027, DOI 10.1038/modpathol.3800438
   Birkeland E, 2012, BRIT J CANCER, V107, P1997, DOI 10.1038/bjc.2012.477
   Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806
   Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Dabir S, 2014, INT J CANCER, V134, P1045, DOI 10.1002/ijc.28448
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Franci C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058183
   Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863
   Gibcus JH, 2007, CLIN CANCER RES, V13, P6257, DOI 10.1158/1078-0432.CCR-07-1247
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Herrmann H, 2012, ONCOTARGET, V3, P1588, DOI 10.18632/oncotarget.733
   Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994
   Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kang D, 2013, GENE CHROMOSOME CANC, V52, P126, DOI 10.1002/gcc.22012
   Kim KI, 2009, INT REV CEL MOL BIO, V273, P265, DOI 10.1016/S1937-6448(08)01807-8
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kranenburg O, 2005, BBA-REV CANCER, V1756, P81, DOI 10.1016/j.bbcan.2005.10.001
   Li CL, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-357
   Liang JY, 2013, CANCER RES, V73, P2929, DOI 10.1158/0008-5472.CAN-12-3876
   Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855
   Lucio-Eterovic AK, 2011, TRANSCR-AUSTIN, V2, P158, DOI 10.4161/trns.2.4.16217
   McIntyre A, 2005, CANCER RES, V65, P8085, DOI 10.1158/0008-5472.CAN-05-0471
   Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351
   Morishita M, 2011, BBA-REV CANCER, V1816, P158, DOI 10.1016/j.bbcan.2011.05.004
   Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nencioni A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009024
   Nobusawa S, 2011, NEUROPATHOLOGY, V31, P583, DOI 10.1111/j.1440-1789.2011.01204.x
   Qin CH, 2001, CLIN CANCER RES, V7, P818
   Rabut G, 2008, EMBO REP, V9, P969, DOI 10.1038/embor.2008.183
   Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC
   Rodriguez-Paredes M., 2013, Oncogene, P1
   Rytinki M, 2012, MOL CELL BIOL, V32, P4195, DOI 10.1128/MCB.00753-12
   Saito M, 2012, FEBS LETT, V586, P1708, DOI 10.1016/j.febslet.2012.05.003
   Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771
   Santidrian AF, 2013, J CLIN INVEST, V123, P1068, DOI 10.1172/JCI64264
   Sarkaria I, 2006, CANCER RES, V66, P9437, DOI 10.1158/0008-5472.CAN-06-2074
   Shao DD, 2013, GENOME RES, V23, P665, DOI 10.1101/gr.143586.112
   Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501
   Sundvall M, 2012, J BIOL CHEM, V287, P23216, DOI 10.1074/jbc.M111.335927
   Valtorta E, 2013, INT J CANCER, V133, P1259, DOI 10.1002/ijc.28106
   Vidler LR, 2013, J MED CHEM, V56, P8073, DOI 10.1021/jm4011302
   Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430
   Walch A, 2004, INT J CANCER, V112, P747, DOI 10.1002/ijc.20411
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Yang YL, 2008, GENE CHROMOSOME CANC, V47, P127, DOI 10.1002/gcc.20514
   Zhao YJ, 2013, J MED CHEM, V56, P5553, DOI 10.1021/jm4005708
NR 58
TC 89
Z9 102
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 29
PY 2014
VL 9
IS 5
AR e98293
DI 10.1371/journal.pone.0098293
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI3UR
UT WOS:000336790800032
PM 24874471
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Tsuchiya, M
   Hashimoto, M
   Takenaka, Y
   Motoike, IN
   Yoshikawa, K
AF Tsuchiya, Masa
   Hashimoto, Midori
   Takenaka, Yoshiko
   Motoike, Ikuko N.
   Yoshikawa, Kenichi
TI Global Genetic Response in a Cancer Cell: Self-Organized Coherent
   Expression Dynamics
SO PLOS ONE
LA English
DT Article
ID HIGHER-ORDER STRUCTURE; MOLECULAR-INTERACTIONS; CHROMATIN; DNA; NOISE;
   TRANSITION; DIFFERENTIATION; NORMALIZATION; CHROMOSOMES; SWITCHES
AB Understanding the basic mechanism of the spatio-temporal self-control of genome-wide gene expression engaged with the complex epigenetic molecular assembly is one of major challenges in current biological science. In this study, the genome-wide dynamical profile of gene expression was analyzed for MCF-7 breast cancer cells induced by two distinct ErbB receptor ligands: epidermal growth factor (EGF) and heregulin (HRG), which drive cell proliferation and differentiation, respectively. We focused our attention to elucidate how global genetic responses emerge and to decipher what is an underlying principle for dynamic self-control of genome-wide gene expression. The whole mRNA expression was classified into about a hundred groups according to the root mean square fluctuation (rmsf). These expression groups showed characteristic time-dependent correlations, indicating the existence of collective behaviors on the ensemble of genes with respect to mRNA expression and also to temporal changes in expression. All-or-none responses were observed for HRG and EGF (biphasic statistics) at around 10-20 min. The emergence of time-dependent collective behaviors of expression occurred through bifurcation of a coherent expression state (CES). In the ensemble of mRNA expression, the self-organized CESs reveals distinct characteristic expression domains for biphasic statistics, which exhibits notably the presence of criticality in the expression profile as a route for genomic transition. In time-dependent changes in the expression domains, the dynamics of CES reveals that the temporal development of the characteristic domains is characterized as autonomous bistable switch, which exhibits dynamic criticality (the temporal development of criticality) in the genome-wide coherent expression dynamics. It is expected that elucidation of the biophysical origin for such critical behavior sheds light on the underlying mechanism of the control of whole genome.
C1 [Tsuchiya, Masa] Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.
   [Tsuchiya, Masa] Keio Univ, Sch Media & Governance, Syst Biol Program, Fujisawa, Kanagawa, Japan.
   [Hashimoto, Midori] Univ Tokyo, Grad Sch Frontier Sci, Kashiwa, Chiba, Japan.
   [Takenaka, Yoshiko] Natl Inst Adv Ind Sci & Technol, Nanosyst Res Inst, Tsukuba, Ibaraki, Japan.
   [Motoike, Ikuko N.] Tohoku Univ, Tohoku Med Megabank Org, Sendai, Miyagi 980, Japan.
   [Yoshikawa, Kenichi] Doshisha Univ, Fac Life & Med Sci, Kyotanabe, Japan.
C3 Keio University; Keio University; University of Tokyo; National
   Institute of Advanced Industrial Science & Technology (AIST); Tohoku
   University; Doshisha University
RP Tsuchiya, M (通讯作者)，Keio Univ, Inst Adv Biosci, Tsuruoka, Yamagata, Japan.
EM tsuchiya@ttck.keio.ac.jp; keyoshik@mail.doshisha.ac.jp
RI Yoshikawa, Kenichi/N-1867-2019; Yoshikawa, Kenichi/L-4774-2016
OI Yoshikawa, Kenichi/0000-0002-2751-7136
FU Tsuruoka City; Yamagata prefectural government; GCOE program of Keio
   University; KAKENHI [23240044, 25103012]
FX This study was funded by Tsuruoka City, the Yamagata prefectural
   government, and the GCOE program of Keio University, and was supported
   in part by Grants-in-Aid, KAKENHI (Nos. 23240044 and 25103012). The
   funders had no role in study design, data collection and analysis,
   decision to publish.
CR Akitaya T, 2007, BIOMACROMOLECULES, V8, P273, DOI 10.1021/bm060634j
   Assaf M, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.058102
   Barbieri M, 2012, P NATL ACAD SCI USA, V109, P16173, DOI 10.1073/pnas.1204799109
   Birtwistle MR, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100188
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Chang HH, 2008, NATURE, V453, P544, DOI 10.1038/nature06965
   Chialvo DR, 2010, NAT PHYS, V6, P744, DOI 10.1038/NPHYS1803
   Elowitz MB, 2002, SCIENCE, V297, P1183, DOI 10.1126/science.1070919
   Erenpreisa JA, 1992, P LATVIAN ACAD SCI B, V536, P64
   Felli N, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-85
   Gaspar-Maia A, 2011, NAT REV MOL CELL BIO, V12, P36, DOI 10.1038/nrm3036
   Guenther MG, 2010, CELL STEM CELL, V7, P249, DOI 10.1016/j.stem.2010.06.015
   Hilfinger A, 2011, P NATL ACAD SCI USA, V108, P12167, DOI 10.1073/pnas.1018832108
   Huang S, 2009, DEVELOPMENT, V136, P3853, DOI 10.1242/dev.035139
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Joti Y, 2012, NUCLEUS-PHILA, V3, P404, DOI 10.4161/nucl.21222
   Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kærn M, 2005, NAT REV GENET, V6, P451, DOI 10.1038/nrg1615
   Landau L.D, 1937, Zh. Eksp. Teor. Fiz, V11, P545, DOI [10.1016/B978-0-08-010586-4.50034-1, DOI 10.1038/138840A0]
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Makita N, 1999, FEBS LETT, V460, P333, DOI 10.1016/S0014-5793(99)01368-X
   McClintick JN, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-49
   Mirny LA, 2011, CHROMOSOME RES, V19, P37, DOI 10.1007/s10577-010-9177-0
   Nagahara H, 2010, CHEM PHYS LETT, V494, P88, DOI 10.1016/j.cplett.2010.05.083
   Nagashima T, 2007, J BIOL CHEM, V282, P4045, DOI 10.1074/jbc.M608653200
   Nakakuki T, 2010, CELL, V141, P884, DOI 10.1016/j.cell.2010.03.054
   Newman JRS, 2006, NATURE, V441, P840, DOI 10.1038/nature04785
   Nishino Y, 2012, EMBO J, V31, P1644, DOI 10.1038/emboj.2012.35
   Paulsson J, 2004, NATURE, V427, P415, DOI 10.1038/nature02257
   Radonjic M, 2005, MOL CELL, V18, P171, DOI 10.1016/j.molcel.2005.03.010
   Raj A, 2008, CELL, V135, P216, DOI 10.1016/j.cell.2008.09.050
   Raser JM, 2005, SCIENCE, V309, P2010, DOI 10.1126/science.1105891
   Ryabov Y, 2008, NUCLEIC ACIDS RES, V36, P2756, DOI 10.1093/nar/gkn086
   Saeki Y, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-545
   Shu GP, 2003, COMP FUNCT GENOM, V4, P287, DOI 10.1002/cfg.290
   Sims RJ, 2009, NATURE, V460, P802, DOI 10.1038/460802a
   Snijder B, 2011, NAT REV MOL CELL BIO, V12, P119, DOI 10.1038/nrm3044
   Southern E, 1999, NAT GENET, V21, P5, DOI 10.1038/4429
   Takagi S, 1999, LANGMUIR, V15, P4143, DOI 10.1021/la981158o
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takenaka Y, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.031905
   Tsuchiya M., 2012, Proceedings of the 2012 ICME International Conference on Complex Medical Engineering (CME), P744, DOI 10.1109/ICCME.2012.6275649
   Tsuchiya M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012116
   Tsuchiya M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004905
   Tsumoto K, 1999, BIOPHYS CHEM, V82, P1, DOI 10.1016/S0301-4622(99)00098-8
   Tu Y, 2002, P NATL ACAD SCI USA, V99, P14031, DOI 10.1073/pnas.222164199
   Ueda M, 1996, PHYS REV LETT, V77, P2133, DOI 10.1103/PhysRevLett.77.2133
   YANAGIDA M, 1982, COLD SPRING HARB SYM, V47, P177
   Yoshikawa K, 2002, J BIOL PHYS, V28, P701, DOI 10.1023/A:1021251125101
   Yoshikawa K, 2001, ADV DRUG DELIVER REV, V52, P235, DOI 10.1016/S0169-409X(01)00210-1
   Yoshikawa K, 1996, PHYS REV LETT, V76, P3029, DOI 10.1103/PhysRevLett.76.3029
   Yoshikawa K., 2002, PHARM PERSPECTIVES N, P137
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Zhang L, 2003, NAT BIOTECHNOL, V21, P818, DOI 10.1038/nbt836
   Zinchenko A., 2008, DNA INTERACTIONS POL, P59, DOI [10.1002/9780470286364.ch3, DOI 10.1002/9780470286364.CH3]
NR 56
TC 13
Z9 14
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2014
VL 9
IS 5
AR e97411
DI 10.1371/journal.pone.0097411
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AI3UI
UT WOS:000336789500053
PM 24831017
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Pacini, N
   Borziani, F
AF Pacini, Nicola
   Borziani, Fabio
TI Cancer Stem Cell Theory and the Warburg Effect, Two Sides of the Same
   Coin?
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE cancer; glycolysis; cancer stem cells; Warburg effect; ATP;
   mitochondria; epigenetic modulation; oxidative phosphorylation;
   differentiation; aerobic glycolysis; entropy; free energy; dissipative
   structure; epithelial-mesenchymal transition; cancerogenesis; human
   embryonic stem cells; induced pluripotent stem cells; self renewal
ID MITOCHONDRIAL UNCOUPLING PROTEIN-2; EPITHELIAL-MESENCHYMAL TRANSITION;
   HUMAN-MELANOMA XENOGRAFTS; ACUTE MYELOID-LEUKEMIA; ENERGY-METABOLISM;
   BREAST-CANCER; AEROBIC GLYCOLYSIS; OXIDATIVE STRESS; IN-VITRO;
   MAGNETIC-RESONANCE
AB Over the last 100 years, many studies have been performed to determine the biochemical and histopathological phenomena that mark the origin of neoplasms. At the end of the last century, the leading paradigm, which is currently well rooted, considered the origin of neoplasms to be a set of genetic and/or epigenetic mutations, stochastic and independent in a single cell, or rather, a stochastic monoclonal pattern. However, in the last 20 years, two important areas of research have underlined numerous limitations and incongruities of this pattern, the hypothesis of the so-called cancer stem cell theory and a revaluation of several alterations in metabolic networks that are typical of the neoplastic cell, the so-called Warburg effect. Even if this specific "metabolic sign" has been known for more than 85 years, only in the last few years has it been given more attention; therefore, the so-called Warburg hypothesis has been used in multiple and independent surveys. Based on an accurate analysis of a series of considerations and of biophysical thermodynamic events in the literature, we will demonstrate a homogeneous pattern of the cancer stem cell theory, of the Warburg hypothesis and of the stochastic monoclonal pattern; this pattern could contribute considerably as the first basis of the development of a new uniform theory on the origin of neoplasms. Thus, a new possible epistemological paradigm is represented; this paradigm considers the Warburg effect as a specific "metabolic sign" reflecting the stem origin of the neoplastic cell, where, in this specific metabolic order, an essential reason for the genetic instability that is intrinsic to the neoplastic cell is defined.
C1 [Pacini, Nicola; Borziani, Fabio] Lab Privato Biochim F Pacini, I-89126 Reggio Di Calabria, Italy.
RP Pacini, N (通讯作者)，Lab Privato Biochim F Pacini, Via Trabocchetto 10, I-89126 Reggio Di Calabria, Italy.
EM nicolapacini77@yahoo.it; fabioborziani@tin.it
FU Association Bioprogress Onlus
FX We dedicate all of our modest efforts to the perennial human path
   towards knowledge, Contraria sunt complementa. We also thank the
   non-profit Association Bioprogress Onlus for the support given:
   http://www.associazionebioprogress.org.
CR Abele D, 2002, NATURE, V420, P27, DOI 10.1038/420027a
   Abu Dawud R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039896
   Agathocleous M, 2013, TRENDS CELL BIOL, V23, P484, DOI 10.1016/j.tcb.2013.05.004
   Agathocleous M, 2012, NAT CELL BIOL, V14, P859, DOI 10.1038/ncb2531
   Ahmed N, 2014, MOL ASPECTS MED, V39, P110, DOI 10.1016/j.mam.2013.06.002
   Ahsan H, 2014, CANCER EPIDEM BIOMAR, V23, P658, DOI 10.1158/1055-9965.EPI-13-0340
   Al-Hajj M, 2007, CURR OPIN ONCOL, V19, P61
   Armitage P, 2004, BRIT J CANCER, V91, P1983, DOI 10.1038/sj.bjc.6602297
   Baker SG, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-151
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Balliet RM, 2011, CELL CYCLE, V10, P4065, DOI 10.4161/cc.10.23.18254
   BALUCH S, 1991, BRIT J CANCER, V63, P901, DOI 10.1038/bjc.1991.198
   Banerji CRS, 2013, SCI REP-UK, V3, DOI 10.1038/srep03039
   Banerji CRS, 2013, PHYS REV E, V87, DOI 10.1103/PhysRevE.87.052814
   Bax BE, 1997, BBA-BIOENERGETICS, V1319, P283, DOI 10.1016/S0005-2728(96)00169-7
   Bertram John S., 2000, Molecular Aspects of Medicine, V21, P167, DOI 10.1016/S0098-2997(00)00007-8
   BOITEUX A, 1975, P NATL ACAD SCI USA, V72, P3829, DOI 10.1073/pnas.72.10.3829
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Bradbury DA, 2000, J IMMUNOL METHODS, V240, P79, DOI 10.1016/S0022-1759(00)00178-2
   BRAND K, 1988, EUR J BIOCHEM, V172, P695, DOI 10.1111/j.1432-1033.1988.tb13944.x
   BRASKEN P, 1990, ACTA CHIR SCAND, V156, P565
   Brizel DM, 1997, INT J RADIAT ONCOL, V38, P285, DOI 10.1016/S0360-3016(97)00101-6
   BROWN GC, 1992, BIOCHEM J, V284, P1
   Brown NJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057697
   Buravkova LB, 2013, BBA-GEN SUBJECTS, V1830, P4418, DOI 10.1016/j.bbagen.2013.05.029
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Cairns RA, 2001, CANCER RES, V61, P8903
   Campos B, 2014, J PATHOL, V234, P23, DOI 10.1002/path.4366
   Chen CT, 2008, STEM CELLS, V26, P960, DOI 10.1634/stemcells.2007-0509
   Chen Z, 2007, SCIENCE, V316, P1916, DOI 10.1126/science.1140958
   Cho YM, 2006, BIOCHEM BIOPH RES CO, V348, P1472, DOI 10.1016/j.bbrc.2006.08.020
   Clippinger AJ, 2008, J VIROL, V82, P6798, DOI 10.1128/JVI.00154-08
   COLE MA, 1983, AM J PATHOL, V112, P61
   Cousin W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063528
   Criscuolo F, 2006, BBA-BIOENERGETICS, V1757, P1284, DOI 10.1016/j.bbabio.2006.06.002
   Cukierman E, 2012, CELL ADHES MIGR, V6, P285, DOI 10.4161/cam.20210
   Curtin JC, 2010, ONCOTARGET, V1, P563, DOI 10.18632/oncotarget.191
   D'Agostino DM, 2005, ADV CANCER RES, V94, P87, DOI 10.1016/S0065-230X(05)94003-7
   DALRYMPLE GV, 1969, RADIAT RES, V37, P90, DOI 10.2307/3572754
   Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112
   Daran-Lapujade P, 2007, P NATL ACAD SCI USA, V104, P15753, DOI 10.1073/pnas.0707476104
   Darekar S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042072
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104
   DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032
   DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694
   Dhawan P, 2011, CURR TOP MED CHEM, V11, P1592
   Ding DF, 2013, J INTEGR MED-JIM, V11, P389, DOI 10.3736/jintegrmed2013039
   Duttaroy A, 2003, GENETICS, V165, P2295
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200
   Eguchi Y, 1997, CANCER RES, V57, P1835
   Eguchi Y, 1999, CANCER RES, V59, P2174
   Eigentler TK, 2011, CANCER-AM CANCER SOC, V117, P1697, DOI 10.1002/cncr.25631
   Erol A, 2005, MED HYPOTHESES, V65, P525, DOI 10.1016/j.mehy.2005.03.022
   Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102
   Fanali C, 2014, WORLD J GASTROENTERO, V20, P923, DOI 10.3748/wjg.v20.i4.923
   Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023
   Fliedner SMJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040949
   Folmes CDL, 2011, BIOMARK MED, V5, P715, DOI [10.2217/BMM.11.87, 10.2217/bmm.11.87]
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011
   FORNI E, 1964, Chir Patol Sper, V12, P263
   Frieden BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022085
   Friis RMN, 2009, NUCLEIC ACIDS RES, V37, P3969, DOI 10.1093/nar/gkp270
   FRY DW, 1990, BIOCHEM PHARMACOL, V40, P1981, DOI 10.1016/0006-2952(90)90227-C
   Furth J., 1937, AM J CANC, V31, P276, DOI [DOI 10.1158/AJC.1937.276, 10.1158/ajc.1937.276]
   Gambini J, 2011, ARCH BIOCHEM BIOPHYS, V512, P24, DOI 10.1016/j.abb.2011.04.020
   Ganitkevich V, 2010, J GEN PHYSIOL, V135, P307, DOI 10.1085/jgp.200910332
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   GERSON SL, 1987, CANCER RES, V47, P89
   Goetze K, 2011, INT J ONCOL, V39, P453, DOI 10.3892/ijo.2011.1055
   Goldbeter A, 2013, FEBS LETT, V587, P2778, DOI 10.1016/j.febslet.2013.07.031
   Golinska M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-198
   Gou SM, 2007, PANCREAS, V34, P429, DOI 10.1097/MPA.0b013e318033f9f4
   Graham CH, 1999, INT J CANCER, V80, P617, DOI 10.1002/(SICI)1097-0215(19990209)80:4<617::AID-IJC22>3.0.CO;2-C
   HADLER HI, 1977, J ENVIRON PATHOL TOX, V1, P75
   Hamada S, 2012, BIOCHEM BIOPH RES CO, V421, P349, DOI 10.1016/j.bbrc.2012.04.014
   Harper ME, 2002, FASEB J, V16, P1550, DOI 10.1096/fj.02-0541com
   He J, 2012, CURR MED CHEM, V19, P6050
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Heinrich R, 1999, BIOCHEM SOC T, V27, P294, DOI 10.1042/bst0270294
   HILTON J, 1977, BIOCHEM BIOPH RES CO, V75, P909, DOI 10.1016/0006-291X(77)91468-1
   Hirschhaeuser F, 2011, CANCER RES, V71, P6921, DOI 10.1158/0008-5472.CAN-11-1457
   Hitchler MJ, 2012, FREE RADICAL BIO MED, V53, P2178, DOI 10.1016/j.freeradbiomed.2012.09.028
   Hitchler MJ, 2009, FREE RADICAL BIO MED, V47, P115, DOI 10.1016/j.freeradbiomed.2009.04.010
   Ho JH, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-76
   Hochedlinger K, 2004, GENE DEV, V18, P1875, DOI 10.1101/gad.1213504
   HOFFER FA, 1989, MAGN RESON MED, V11, P202, DOI 10.1002/mrm.1910110208
   Hoffmann RF, 2013, RESP RES, V14, DOI 10.1186/1465-9921-14-97
   Holley AK, 2012, AMINO ACIDS, V42, P139, DOI 10.1007/s00726-010-0600-9
   Houghton J, 2007, SEMIN CANCER BIOL, V17, P191, DOI 10.1016/j.semcancer.2006.04.003
   HOWELL AN, 1978, P NATL ACAD SCI USA, V75, P2358, DOI 10.1073/pnas.75.5.2358
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   INDERLIED CB, 1978, J BACTERIOL, V133, P1282, DOI 10.1128/JB.133.3.1282-1286.1978
   ISRAEL BA, 1987, IN VITRO CELL DEV B, V23, P627
   Jazwinski SM, 2005, GENE, V354, P22, DOI 10.1016/j.gene.2005.03.040
   Jiang Y, 2011, MUTAT RES-GEN TOX EN, V726, P75, DOI 10.1016/j.mrgentox.2011.08.006
   Jonson I, 2013, STEM CELL RES, V11, P1264, DOI 10.1016/j.scr.2013.08.010
   JOYCE RM, 1983, BRIT J CANCER, V48, P385, DOI 10.1038/bjc.1983.203
   Kawahara T, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-178
   Kennedy KM, 2010, FUTURE ONCOL, V6, P127, DOI 10.2217/FON.09.145
   Kenyon J, 2007, NUCLEIC ACIDS RES, V35, P7557, DOI 10.1093/nar/gkm1064
   KIESSLING KH, 1966, Q J STUD ALCOHOL, V27, P189
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501
   Kim S, 2013, TUMOR BIOL, V34, P1699, DOI 10.1007/s13277-013-0707-1
   Klarer AC, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-2
   Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031
   Koike K, 2009, CANCER LETT, V286, P60, DOI 10.1016/j.canlet.2009.04.010
   Kondoh H, 2007, HISTOL HISTOPATHOL, V22, P85, DOI 10.14670/HH-22.85
   Kondoh H, 2007, ANTIOXID REDOX SIGN, V9, P293, DOI 10.1089/ars.2006.1467
   Konopleva M, 2007, CURR DRUG TARGETS, V8, P685, DOI 10.2174/138945007780830827
   Koukourakis MI, 2011, CLIN CANCER RES, V17, P4892, DOI 10.1158/1078-0432.CCR-10-2918
   KOURA M, 1982, GANN, V73, P574
   Kraft CS, 2006, AM J PHYSIOL-CELL PH, V290, pC1119, DOI 10.1152/ajpcell.00463.2005
   Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050
   Kuai XY, 2010, WORLD J GASTROENTERO, V16, P5773, DOI 10.3748/wjg.v16.i45.5773
   Kumar P, 2013, THERIOGENOLOGY, V80, P914, DOI 10.1016/j.theriogenology.2013.07.018
   Kwon HJ, 2013, CELL BIOCHEM FUNCT, V31, P75, DOI 10.1002/cbf.2862
   KYLE JL, 1970, ARCH ENVIRON HEALTH, V21, P492, DOI 10.1080/00039896.1970.10667277
   Lane N, 2010, NATURE, V467, P929, DOI 10.1038/nature09486
   Lang SH, 2009, J PATHOL, V217, P299, DOI 10.1002/path.2478
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Laureti L, 2013, DNA REPAIR, V12, P300, DOI 10.1016/j.dnarep.2013.01.009
   LAVAL F, 1980, P NATL ACAD SCI-BIOL, V77, P2702, DOI 10.1073/pnas.77.5.2702
   LEGNAME AH, 1980, J EMBRYOL EXP MORPH, V59, P175
   Li G, 2012, CHIN J CANCER, V31, P197, DOI 10.5732/cjc.011.10283
   Li L, 2003, CANCER RES, V63, P2733
   Li WJ, 2013, CANCER BIOMARK, V13, P377, DOI 10.3233/CBM-130369
   Lin CC, 2012, SCI REP-UK, V2, DOI 10.1038/srep00785
   Liu G, 2013, ANNU REV PATHOL-MECH, V8, P161, DOI 10.1146/annurev-pathol-020712-163942
   LLAGOSTERA M, 1985, J GEN MICROBIOL, V131, P113
   Loeb LA, 2001, CANCER RES, V61, P3230
   Lonergan T, 2007, MITOCHONDRION, V7, P289, DOI 10.1016/j.mito.2007.05.002
   Lonergan T, 2006, J CELL PHYSIOL, V208, P149, DOI 10.1002/jcp.20641
   Lorico A, 2011, J ONCOL, V2011, DOI 10.1155/2011/135039
   Lu SC, 2012, PHYSIOL REV, V92, P1515, DOI 10.1152/physrev.00047.2011
   Lu WQ, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001326
   Luo LZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030541
   Lynen F, 1942, NATURWISSENSCHAFTEN, V30, P398, DOI 10.1007/BF01475305
   Maglietta R, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-608
   MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773
   Malaguarnera R, 2011, J CLIN ENDOCR METAB, V96, P766, DOI 10.1210/jc.2010-1255
   Martyushev L.M., 2013, ENTROPY, V151, P152
   MASUDA T, 1990, J BIOL CHEM, V265, P20321
   Mato JM, 2011, ALCOHOL CLIN EXP RES, V35, P811, DOI 10.1111/j.1530-0277.2010.01404.x
   Mattiasson G, 2003, NAT MED, V9, P1062, DOI 10.1038/nm903
   MCKINNELL RG, 1969, SCIENCE, V165, P394, DOI 10.1126/science.165.3891.394
   MENYHART J, 1971, ACTA BIOCHIMICA B A, V6, P139
   Miceli MV, 2005, INVEST OPHTH VIS SCI, V46, P1765, DOI 10.1167/iovs.04-1327
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799
   MORLEY A, 1978, LANCET, V2, P9
   MOSS AJ, 1971, BIOPHYS J, V11, P158, DOI 10.1016/S0006-3495(71)86205-7
   Navarro A, 2009, J BIOENERG BIOMEMBR, V41, P517, DOI 10.1007/s10863-009-9250-6
   NAVON G, 1977, P NATL ACAD SCI USA, V74, P87, DOI 10.1073/pnas.74.1.87
   Neary CL, 2010, BIOCHEM BIOPH RES CO, V394, P1075, DOI 10.1016/j.bbrc.2010.03.129
   Nelson TJ, 2011, CLIN PHARMACOL THER, V89, P648, DOI 10.1038/clpt.2010.304
   Nordsmark M, 2000, RADIOTHER ONCOL, V57, P39, DOI 10.1016/S0167-8140(00)00223-1
   Nordsmark M, 1996, INT J RADIAT ONCOL, V35, P701, DOI 10.1016/0360-3016(96)00132-0
   Nouspikel T, 2013, FUTURE ONCOL, V9, P867, DOI [10.2217/FON.13.22, 10.2217/fon.13.22]
   Nowell PC, 2002, SEMIN CANCER BIOL, V12, P261, DOI 10.1016/S1044-579X(02)00012-3
   Nozue M, 1997, J SURG ONCOL, V66, P30, DOI 10.1002/(SICI)1096-9098(199709)66:1<30::AID-JSO7>3.0.CO;2-O
   O'Flaherty JD, 2012, J THORAC ONCOL, V7, P1880, DOI 10.1097/JTO.0b013e31826bfbc6
   OCONNOR RJ, 1950, BRIT J EXP PATHOL, V31, P449
   Okorokov AL, 1999, MOL CELL BIOL, V19, P7501
   Olivotto M, 1984, Toxicol Pathol, V12, P369
   Olovnikov IA, 2009, SEMIN CANCER BIOL, V19, P32, DOI 10.1016/j.semcancer.2008.11.005
   Olsen DR, 1999, MAGN RESON IMAGING, V17, P1049, DOI 10.1016/S0730-725X(99)00032-6
   OZERNYUK ND, 1973, ROUX ARCH DEV BIOL, V172, P66, DOI 10.1007/BF00581885
   Palorini R, 2014, J CELL BIOCHEM, V115, P368, DOI 10.1002/jcb.24671
   Panopoulos AD, 2012, CELL RES, V22, P168, DOI 10.1038/cr.2011.177
   Park JM, 2001, KOREAN J RADIOL, V2, P80, DOI 10.3348/kjr.2001.2.2.80
   Parkin DM, 2006, INT J CANCER, V118, P3030, DOI 10.1002/ijc.21731
   Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32
   Pavanello S, 2013, CANCER EPIDEM BIOMAR, V22, P1722, DOI 10.1158/1055-9965.EPI-13-0118
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Pecqueur C, 2008, FASEB J, V22, P9, DOI 10.1096/fj.07-8945com
   Peitzsch C, 2013, RADIOTHER ONCOL, V108, P378, DOI 10.1016/j.radonc.2013.06.003
   Peláez R, 2009, J BIOL CHEM, V284, P20548, DOI 10.1074/jbc.M109.013730
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Pfeiffer T, 2001, SCIENCE, V292, P504, DOI 10.1126/science.1058079
   PIERCE GB, 1974, AM J PATHOL, V77, P103
   Pokorny J, 2012, Prague Med Rep, V113, P81
   POOLMAN B, 1993, FEMS MICROBIOL REV, V12, P125, DOI 10.1111/j.1574-6976.1993.tb00015.x
   Prigione A, 2010, INT J DEV BIOL, V54, P1729, DOI 10.1387/ijdb.103198ap
   RACKER E, 1976, J CELL PHYSIOL, V89, P697, DOI 10.1002/jcp.1040890429
   RAPAPORT E, 1979, P NATL ACAD SCI USA, V76, P1643, DOI 10.1073/pnas.76.4.1643
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rizwan A, 2013, CLIN CANCER RES, V19, P5158, DOI 10.1158/1078-0432.CCR-12-3300
   Roach JC, 2010, SCIENCE, V328, P636, DOI 10.1126/science.1186802
   Rofstad EK, 1999, INT J RADIAT BIOL, V75, P1377
   ROSS BD, 1988, MAGN RESON MED, V6, P403, DOI 10.1002/mrm.1910060406
   Ruckenstuhl C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004592
   Samudio I, 2008, CANCER RES, V68, P5198, DOI 10.1158/0008-5472.CAN-08-0555
   Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722
   Sanchez-Alvarez R, 2013, CELL CYCLE, V12, P289, DOI 10.4161/cc.23109
   Santin G, 2013, LASER SURG MED, V45, P597, DOI 10.1002/lsm.22182
   Saumet A, 2012, MOL BIOSYST, V8, P3242, DOI 10.1039/c2mb25298h
   SCHMIDT H, 1991, EXP CELL RES, V194, P122, DOI 10.1016/0014-4827(91)90140-P
   Sell S, 2010, AM J PATHOL, V176, P2584, DOI 10.2353/ajpath.2010.091064
   Sen A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054283
   Sengupta A, 2010, J CELL PHYSIOL, V225, P7, DOI 10.1002/jcp.22213
   Sennoune SR, 2004, AM J PHYSIOL-CELL PH, V286, pC1443, DOI 10.1152/ajpcell.00407.2003
   Seppet E, 2009, INT J MOL SCI, V10, P2252, DOI 10.3390/ijms10052252
   Seyfried TN, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-7
   Shen JH, 2011, MOL CELL BIOL, V31, P4902, DOI 10.1128/MCB.05629-11
   Siggins RW, 2008, INT J CLIN EXP MED, V1, P2
   Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759
   SINGER S, 1995, CANCER RES, V55, P5140
   Singh KK, 2005, GENE, V354, P140, DOI 10.1016/j.gene.2005.03.027
   SINGH M, 1974, ARCH BIOCHEM BIOPHYS, V165, P240, DOI 10.1016/0003-9861(74)90160-X
   Singh SK, 2003, CANCER RES, V63, P5821
   Singleton MR, 2003, EMBO J, V22, P4579, DOI 10.1093/emboj/cdg441
   SIVERIO JM, 1985, INT J BIOCHEM, V17, P1015, DOI 10.1016/0020-711X(85)90248-4
   Sloan EK, 2009, AM J PATHOL, V174, P2035, DOI 10.2353/ajpath.2009.080924
   Smith DG, 2013, BIOCHEM SOC T, V41, P664, DOI 10.1042/BST20120352
   Smith-Vikos Thalyana, 2012, Yale Journal of Biology and Medicine, V85, P417
   Sonnenschein C, 2000, MOL CARCINOGEN, V29, P205, DOI 10.1002/1098-2744(200012)29:4<205::AID-MC1002>3.0.CO;2-W
   St John JC, 2005, CLONING STEM CELLS, V7, P141, DOI 10.1089/clo.2005.7.141
   St John J, 2014, BBA-GEN SUBJECTS, V1840, P1345, DOI 10.1016/j.bbagen.2013.10.036
   STACKPOLE CW, 1994, J NATL CANCER I, V86, P361, DOI 10.1093/jnci/86.5.361
   Stringari C, 2012, SCI REP-UK, V2, DOI 10.1038/srep00568
   Sugimura S, 2012, J REPROD DEVELOP, V58, P636, DOI 10.1262/jrd.2012-082
   Sundfor K, 1998, BRIT J CANCER, V78, P822, DOI 10.1038/bjc.1998.586
   Syed M, 2013, TOXICOL IN VITRO, V27, P2135, DOI 10.1016/j.tiv.2013.09.010
   Szanto I, 2005, J PATHOL, V207, P164, DOI 10.1002/path.1824
   Tahanian E, 2011, J INFLAMM RES, V4, P1, DOI 10.2147/JIR.S15880
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Tanori M, 2013, STEM CELLS, V31, P2506, DOI 10.1002/stem.1485
   Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699
   Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817
   TERMONIA Y, 1981, P NATL ACAD SCI-BIOL, V78, P2952, DOI 10.1073/pnas.78.5.2952
   Teschendorff AE, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-104
   THOMAS DC, 1991, J BIOL CHEM, V266, P3744
   Thundathil J, 2005, MOL REPROD DEV, V71, P405, DOI 10.1002/mrd.20260
   Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200
   Trosko JE, 2014, ANAT REC, V297, P161, DOI 10.1002/ar.22793
   Tsuchiya M, 2003, P NATL ACAD SCI USA, V100, P9691, DOI 10.1073/pnas.1633771100
   Van Blerkom J, 2009, SEMIN CELL DEV BIOL, V20, P354, DOI 10.1016/j.semcdb.2008.12.005
   van Horssen R, 2013, CELL MOL LIFE SCI, V70, P2175, DOI 10.1007/s00018-012-1249-1
   Van Remmen H, 2003, PHYSIOL GENOMICS, V16, P29, DOI 10.1152/physiolgenomics.00122.2003
   VANDIJKEN JP, 1993, ANTON LEEUW INT J G, V63, P343, DOI 10.1007/BF00871229
   Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332
   Varum S, 2009, STEM CELL RES, V3, P142, DOI 10.1016/j.scr.2009.07.002
   Varum S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020914
   Vazquez-Martin A, 2013, CELL CYCLE, V12, P207, DOI 10.4161/cc.23352
   Veatch JR, 2009, CELL, V137, P1247, DOI 10.1016/j.cell.2009.04.014
   Veech RL, 1995, INTEGR PHYS BEH SCI, V30, P283, DOI 10.1007/BF02691602
   Veech RL, 2002, IUBMB LIFE, V54, P241, DOI 10.1080/15216540215678
   Végran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828
   Vihersaari T., 1979, ANN SURG, V179, P889
   Vlashi E, 2011, P NATL ACAD SCI USA, V108, P16062, DOI 10.1073/pnas.1106704108
   Walenta S, 2004, SEMIN RADIAT ONCOL, V14, P267, DOI 10.1016/j.semradonc.2004.04.004
   WALES RG, 1986, J REPROD FERTIL, V76, P717, DOI 10.1530/jrf.0.0760717
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wang L, 2007, BLOOD, V110, P3334, DOI 10.1182/blood-2007-01-068122
   WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0
   WANG ZG, 1993, P NATL ACAD SCI USA, V90, P4907, DOI 10.1073/pnas.90.11.4907
   WARBURG O, 1956, SCIENCE, V124, P269
   Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519
   WARBURG O, 1960, H-S Z PHYSIOL CHEM, V321, P252, DOI 10.1515/bchm2.1960.321.1.252
   Watson WH, 2011, BBA-MOL BASIS DIS, V1812, P613, DOI 10.1016/j.bbadis.2011.01.016
   West J, 2012, PHYS REV E, V85, DOI 10.1103/PhysRevE.85.046111
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   Whitaker-Menezes D, 2011, CELL CYCLE, V10, P1772, DOI 10.4161/cc.10.11.15659
   Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153
   WIJKER JE, 1995, BIOPHYS CHEM, V55, P153, DOI 10.1016/0301-4622(94)00148-D
   Wright BK, 2012, BIOPHYS J, V103, pL07, DOI 10.1016/j.bpj.2012.05.038
   Xia T, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/420364
   Xie H, 2009, MOL CANCER THER, V8, P626, DOI 10.1158/1535-7163.MCT-08-1049
   Xie Y, 2013, CELL PHYSIOL BIOCHEM, V31, P473, DOI 10.1159/000350062
   Xu T, 2014, TOXICOL APPL PHARM, V277, P183, DOI 10.1016/j.taap.2014.03.004
   Xun Z, 2012, MECH AGEING DEV, V133, P176, DOI 10.1016/j.mad.2012.01.008
   Yadava N, 2013, J MAMMARY GLAND BIOL, V18, P75, DOI 10.1007/s10911-012-9271-3
   Yang JG, 2007, METHODS, V41, P291, DOI 10.1016/j.ymeth.2006.08.015
   Yang JH, 2008, J BIOL CHEM, V283, P36321, DOI 10.1074/jbc.M804794200
   Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629
   Yoshida Y, 2009, CELL STEM CELL, V5, P237, DOI 10.1016/j.stem.2009.08.001
   YOUNG SD, 1988, P NATL ACAD SCI USA, V85, P9533, DOI 10.1073/pnas.85.24.9533
   YOUNG SD, 1990, JNCI-J NATL CANCER I, V82, P371, DOI 10.1093/jnci/82.5.371
   Zhang GJ, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-173
   Zhang J, 2011, EMBO J, V30, P4860, DOI 10.1038/emboj.2011.401
   Zhang Minjie, 2013, Genomics Proteomics & Bioinformatics, V11, P320, DOI 10.1016/j.gpb.2013.09.006
   Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364
   Zotin AA, 1997, INT J DEV BIOL, V41, P917
NR 284
TC 53
Z9 64
U1 0
U2 33
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2014
VL 15
IS 5
BP 8893
EP 8930
DI 10.3390/ijms15058893
PG 38
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA AI4NJ
UT WOS:000336841800106
PM 24857919
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Bosch, A
   Panoutsopoulou, K
   Corominas, JM
   Gimeno, R
   Moreno-Bueno, G
   Martín-Caballero, J
   Morales, S
   Lobato, T
   Martínez-Romero, C
   Farias, EF
   Mayol, X
   Cano, A
   Hernández-Muñoz, I
AF Bosch, Almudena
   Panoutsopoulou, Konstantina
   Maria Corominas, Josep
   Gimeno, Ramon
   Moreno-Bueno, Gema
   Martin-Caballero, Juan
   Morales, Saleta
   Lobato, Tania
   Martinez-Romero, Carles
   Farias, Eduardo F.
   Mayol, Xavier
   Cano, Amparo
   Hernandez-Munoz, Inmaculada
TI The Polycomb group protein RING1B is overexpressed in ductal breast
   carcinoma and is required to sustain FAK steady state levels in breast
   cancer epithelial cells
SO ONCOTARGET
LA English
DT Article
DE Ring1B; ductal breast carcinoma; Fak; p63; mammary epithelial cell
ID FOCAL ADHESION KINASE; PROGNOSTIC MARKER; GROUP GENES; EXPRESSION;
   BMI-1; P53; METASTASIS; EZH2; PRC1; UBIQUITINATION
AB In early stages of metastasis malignant cells must acquire phenotypic changes to enhance their migratory behavior and their ability to breach the matrix surrounding tumors and blood vessel walls. Epigenetic regulation of gene expression allows the acquisition of these features that, once tumoral cells have escape from the primary tumor, can be reverted. Here we report that the expression of the Polycomb epigenetic repressor Ring1B is enhanced in tumoral cells that invade the stroma in human ductal breast carcinoma and its expression is coincident with that of Fak in these tumors. Ring1B knockdown in breast cancer cell lines revealed that Ring1B is required to sustain Fak expression in basal conditions as well as in Tgf beta-treated cells. Functionally, endogenous Ring1B is required for cell migration and invasion in vitro and for in vivo invasion of the mammary fat pad by tumoral cells. Finally we identify p63 as a target of Ring1B to regulate Fak expression: Ring1B depletion results in enhanced p63 expression, which in turns represses Fak expression. Importantly, Fak downregulation upon Ring1B depletion is dependent on p63 expression. Our findings provide new insights in the biology of the breast carcinoma and open new avenues for breast cancer prognosis and therapy.
C1 [Bosch, Almudena; Panoutsopoulou, Konstantina; Lobato, Tania; Martinez-Romero, Carles; Mayol, Xavier; Hernandez-Munoz, Inmaculada] IMIM Inst Hosp Mar Invest Med, Canc Res Program, Barcelona, Spain.
   [Moreno-Bueno, Gema; Morales, Saleta; Cano, Amparo] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Inst Invest Sanitaria La Paz, Dept Bioquim,Fac Med,CSIC UAM, Madrid, Spain.
   [Martin-Caballero, Juan] Parc Recerca Biomed Barcelona, Lab Anim Units, Barcelona, Spain.
   [Maria Corominas, Josep] Hosp del Mar, Serv Patol, Barcelona, Spain.
   [Gimeno, Ramon] Hosp del Mar, Serv Inmunol, Barcelona, Spain.
C3 Hospital del Mar Research Institute; Consejo Superior de Investigaciones
   Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas
   Alberto Sols (IIBM); Autonomous University of Madrid; Hospital del Mar
   Research Institute; Hospital del Mar; Hospital del Mar Research
   Institute; Hospital del Mar
RP Hernández-Muñoz, I (通讯作者)，IMIM Inst Hosp Mar Invest Med, Canc Res Program, Barcelona, Spain.
EM mhernandez@imim.es
RI Mayol, Xavier/C-1391-2012; Gimeno, Ramon/P-7911-2015; Moreno-Bueno,
   Gema/K-9354-2016
OI Panoutsopoulou, Konstantina/0000-0003-2773-4883; Moreno-Bueno,
   Gema/0000-0002-5030-6687; Mayol, Xavier/0000-0001-7288-195X;
   Martinez-Romero, Carles/0000-0001-8888-7715
FU Spanish Ministry of Science and Innovation/Instituto de Salud Carlos III
   FEDER [PS09/00973]; AGAUR [2009 SGR 1409]
FX The authors are grateful to Sergi Mojal and Oriol Arpi (Department of
   Statistics and Cancer Research Program, respectively, Institut Hospital
   del Mar d'Investigacions Mediques, Barcelona, Spain) and to Dr. Caron de
   Fromentel (INSERM U590, Lyon, France) for Delta Np63 expression vector.
   This work was funded by grants from the Spanish Ministry of Science and
   Innovation/ Instituto de Salud Carlos III FEDER (PS09/00973) and from
   the AGAUR (2009 SGR 1409). IHM is an investigator at the Miguel Servet
   program (Instituto de Salud Carlos III).
CR Agochiya M, 1999, ONCOGENE, V18, P5646, DOI 10.1038/sj.onc.1202957
   Akasaka T, 2001, DEVELOPMENT, V128, P1587
   Bel S, 1998, DEVELOPMENT, V125, P3543
   Boye K, 2010, EUR J CANCER, V46, P2919, DOI 10.1016/j.ejca.2010.07.013
   Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Chervona Y, 2012, AM J CANCER RES, V2, P589
   CIOCCA DR, 1993, J NATL CANCER I, V85, P570, DOI 10.1093/jnci/85.7.570
   Core N, 1997, DEVELOPMENT, V124, P721
   Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Deng BQ, 2010, MOL CELL BIOCHEM, V340, P21, DOI 10.1007/s11010-010-0396-7
   Dumbauld DW, 2010, BIOL CELL, V102, P203, DOI 10.1042/BC20090104
   Gao ZH, 2012, MOL CELL, V45, P344, DOI 10.1016/j.molcel.2012.01.002
   Golubovskaya V, 2004, BBA-GENE STRUCT EXPR, V1678, P111, DOI 10.1016/j.bbaexp.2004.03.002
   Golubovskaya VM, 2008, MOL CARCINOGEN, V47, P373, DOI 10.1002/mc.20395
   Golubovskaya VM, 2009, HISTOL HISTOPATHOL, V24, P503, DOI 10.14670/HH-24.503
   Guo BH, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-10
   Kikuchi N, 2006, CANCER SCI, V97, P1061, DOI 10.1111/j.1349-7006.2006.00295.x
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104
   LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0
   Levrero M, 2000, J CELL SCI, V113, P1661
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Lin YL, 2011, MOL CELL BIOCHEM, V351, P109, DOI 10.1007/s11010-011-0717-5
   Liu JH, 2008, J SURG ONCOL, V97, P267, DOI 10.1002/jso.20934
   Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010
   Mao HP, 2003, J BIOL CHEM, V278, P18214, DOI 10.1074/jbc.M300126200
   Martínez-Romero C, 2009, J PATHOL, V219, P205, DOI 10.1002/path.2585
   Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549
   Moore HM, 2013, BREAST CANCER RES TR, V138, P741, DOI 10.1007/s10549-013-2498-x
   Morey L, 2010, TRENDS BIOCHEM SCI, V35, P323, DOI 10.1016/j.tibs.2010.02.009
   Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359
   Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318
   OWENS LV, 1995, CANCER RES, V55, P2752
   Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214
   Puschendorf M, 2008, NAT GENET, V40, P411, DOI 10.1038/ng.99
   Qin ZK, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-61
   Schoeftner S, 2006, EMBO J, V25, P3110, DOI 10.1038/sj.emboj.7601187
   Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044
   Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094
   Thievessen I, 2013, J CELL BIOL, V202, P163, DOI 10.1083/jcb.201303129
   van der Stoop P, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002235
   van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126
   Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100
   Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985
   Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0
   Yu HX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051239
   Zaaroor-Regev D, 2010, P NATL ACAD SCI USA, V107, P6788, DOI 10.1073/pnas.1003108107
   Zhang XW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-40
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
NR 51
TC 27
Z9 33
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR
PY 2014
VL 5
IS 8
BP 2065
EP 2076
DI 10.18632/oncotarget.1779
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AI6FC
UT WOS:000336965800006
PM 24742605
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Li, D
   Bi, FF
   Chen, NN
   Cao, JM
   Sun, WP
   Zhou, YM
   Cao, C
   Li, CY
   Yang, Q
AF Li, Da
   Bi, Fang-Fang
   Chen, Na-Na
   Cao, Ji-Min
   Sun, Wu-Ping
   Zhou, Yi-Ming
   Cao, Chen
   Li, Chun-Yan
   Yang, Qing
TI Epigenetic repression of phosphatidylethanolamine
   <i>N</i>-methyltransferase (<i>PEMT</i>) in <i>BRCA1</i>-mutated breast
   cancer
SO ONCOTARGET
LA English
DT Article
DE PEMT; DNA methylation; Histone modifications; BRCA1; Breast cancer
ID PROMOTER METHYLATION; DNA METHYLATION; CHOLINE; BRCA1; RISK; METABOLISM;
   RECEPTOR; GENES
AB Phosphatidylethanolamine N-methyltransferase (PEMT) plays a critical role in breast cancer progression. However, the epigenetic mechanism regulating PEMT transcription remains largely unknown. Here, we show that the first promoter-specific transcript 1 is the major PEMT mRNA species, and methylation of the -132 site is a key regulatory element for the PEMT gene in BRCA1-mutated breast cancer. Mechanistically, hypermethylated -132 site-mediated loss of active histone marks H3K9ac and increase of repressive histone marks H3K9me enrichment synergistically inhibited PEMT transcription. Clinicopathological data indicated that a hypermethylated -132 site was associated with histological grade (P = 0.031) and estrogen receptor status (P = 0.004); univariate survival and multivariate analyses demonstrated that lymph node metastasis was an independent and reliable prognostic factor for BRCA1-mutated breast cancer patients. Our findings imply that genetic (e.g., BRCA1 mutation) and epigenetic mechanisms (e.g., DNA methylation and histone modifications) are jointly involved in the malignant progression of PEMT-related breast cancer.
C1 [Li, Da; Bi, Fang-Fang; Yang, Qing] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
   [Chen, Na-Na] Nagoya Univ, Grad Sch Med, Dept Mol Immunol, Nagoya, Aichi 4648601, Japan.
   [Cao, Ji-Min] Chinese Acad Med Sci, Inst Basic Med Sci, Peking Union Med Coll, Dept Physiol & Pathophysiol,Sch Basic Med, Beijing 100730, Peoples R China.
   [Sun, Wu-Ping; Zhou, Yi-Ming] Natl Inst Physiol Sci, Div Cell Signaling, Okazaki, Aichi 444, Japan.
   [Cao, Chen] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing, Peoples R China.
   [Li, Chun-Yan] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Histol & Embryol, Sch Basic Med,Peking Union Med Coll, Beijing 100730, Peoples R China.
C3 China Medical University; Nagoya University; Chinese Academy of Medical
   Sciences - Peking Union Medical College; Peking Union Medical College;
   Institute of Basic Medical Sciences - CAMS; National Institutes of
   Natural Sciences (NINS) - Japan; National Institute for Physiological
   Sciences (NIPS); Chinese People's Liberation Army General Hospital;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Institute of Basic Medical Sciences - CAMS
RP Li, D (通讯作者)，China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang, Peoples R China.
EM leeda@ymail.com
RI li, chunyan/E-7476-2019; Sun, Wuping/A-4492-2015
FU 973 Program of China [2011CB933504]; Natural Science Foundation of China
   [81071072]; Higher Specialized Research Fund for Doctoral Program of
   Ministry of Education of China [20122104110027]
FX This work was supported by the 973 Program of China (No. 2011CB933504),
   Natural Science Foundation of China (No. 81071072) and the Higher
   Specialized Research Fund for Doctoral Program of Ministry of Education
   of China (No. 20122104110027).
CR Amodio N, 2012, ONCOTARGET, V3, P1246
   Beetstra S, 2008, CANCER EPIDEM BIOMAR, V17, P2565, DOI 10.1158/1055-9965.EPI-08-0140
   Bi FF, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-89
   Bochman ML, 2012, NAT REV GENET, V13, P770, DOI 10.1038/nrg3296
   Cao JZ, 2013, CANCER RES, V73, P3326, DOI 10.1158/0008-5472.CAN-12-3055
   Cho K, 2012, CARCINOGENESIS, V33, P1106, DOI 10.1093/carcin/bgs125
   Dacheux E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067313
   Eliyahu G, 2007, INT J CANCER, V120, P1721, DOI 10.1002/ijc.22293
   Fischer LM, 2010, AM J CLIN NUTR, V92, P336, DOI 10.3945/ajcn.2010.29459
   Glunde K, 2004, CANCER RES, V64, P4270, DOI 10.1158/0008-5472.CAN-03-3829
   Hossain MZ, 2013, ONCOTARGET, V4, P298, DOI 10.18632/oncotarget.863
   Imbard A, 2013, CLIN CHEM LAB MED, V51, P683, DOI 10.1515/cclm-2012-0302
   Kristensen LS, 2012, ONCOTARGET, V3, P450, DOI 10.18632/oncotarget.480
   Li D, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-26
   Li D, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-102
   Li D, 2013, J NANOPART RES, V15, DOI 10.1007/s11051-013-1704-4
   Li M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025563
   Dória ML, 2013, J CELL PHYSIOL, V228, P457, DOI 10.1002/jcp.24152
   Morita S, 2010, BIOCHEM J, V432, P387, DOI 10.1042/BJ20100490
   Salvi F, 2013, ARCH BIOCHEM BIOPHYS, V537, P243, DOI 10.1016/j.abb.2013.07.018
   Shin HJ, 2012, AM J ROENTGENOL, V198, pW488, DOI 10.2214/AJR.11.7292
   Shukla V, 2010, CELL RES, V20, P1201, DOI 10.1038/cr.2010.128
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Slattery ML, 2014, INT J CANCER, V134, P629, DOI 10.1002/ijc.28377
   Speirs V, 1998, BRIT J CANCER, V78, P1421, DOI 10.1038/bjc.1998.702
   Stevens KN, 2013, CANCER RES, V73, P2025, DOI 10.1158/0008-5472.CAN-12-1699
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Vance DE, 2013, BBA-MOL CELL BIOL L, V1831, P626, DOI 10.1016/j.bbalip.2012.07.017
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
   Xu XR, 2009, FASEB J, V23, P4022, DOI 10.1096/fj.09-136507
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Zhang CX, 2013, CANCER SCI, V104, P250, DOI 10.1111/cas.12064
NR 32
TC 23
Z9 24
U1 1
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR
PY 2014
VL 5
IS 5
BP 1315
EP 1325
DI 10.18632/oncotarget.1800
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AI6EI
UT WOS:000336963200018
PM 24675476
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Medina-Jaime, AD
   Reyes-Vargas, F
   Martinez-Gaytan, V
   Zambrano-Galvan, G
   Portillo-DelCampo, E
   Burciaga-Nava, JA
   Reyes-Romero, M
   Sifuentes-Alvarez, A
AF Delia Medina-Jaime, Alma
   Reyes-Vargas, Francianella
   Martinez-Gaytan, Victoria
   Zambrano-Galvan, Graciela
   Portillo-DelCampo, Eduardo
   Alberto Burciaga-Nava, Jorge
   Reyes-Romero, Miguel
   Sifuentes-Alvarez, Antonio
TI <i>ESR1</i> and <i>PGR</i> Gene Promoter Methylation and Correlations
   with Estrogen and Progesterone Receptors in Ductal and Lobular Breast
   Cancer
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Biomarkers; breast cancer; estrogen receptors; epigenetics; methylation;
   progesterone receptors
ID CPG ISLAND METHYLATION; DNA; HYPERMETHYLATION
AB The aim of this work was to analyze methylation of the promoter sites of the ESR1 and PGR genes and to determine correlations with immunohistochemical expression of estrogen and progesterone receptors in ductal and lobular breast cancers. An observational, descriptive, molecular study was conducted on 20 ductal and 20 lobular breast cancer samples with immunohistochemical determination of estrogen and progesterone receptor expression. The methylation analysis of ESR1 and PGR promoter sites was carried-out by methylation-specific PCR. For correlation analysis, Kendall's tau coefficient was determined. Positive correlations were found between estrogen and progesterone receptors, estrogen receptor and unmethylated progesterone receptor, progesterone receptor, and unmethylated progesterone receptor. Negative correlations were found between estrogen receptor and methylated progesterone receptor, progesterone receptor and methylated progesterone receptor, methylated and unmethylated estrogen receptor, and methylated and unmethylated progesterone receptor. The results suggest that methylation of promoter sites of ESR1 and PGR is a relatively uncommon event in ductal and lobular breast cancer, and also suggest that the determination of epigenetic states of ESR1 and PGR could represent an alternative or complement to the histopathological expression analysis.
C1 [Delia Medina-Jaime, Alma] Hlth Serv Durango SSD, Durango, Mexico.
   [Reyes-Vargas, Francianella] Minist Hlth Durango SSD, Canc State Ctr, Durango, Mexico.
   [Martinez-Gaytan, Victoria] UMAE 23 IMSS Monterrey, Durango, Mexico.
   [Zambrano-Galvan, Graciela] Fac Dent UJED, Durango, Mexico.
   [Portillo-DelCampo, Eduardo] Espana Autonomous Univ Durango, Durango, Mexico.
   [Alberto Burciaga-Nava, Jorge; Reyes-Romero, Miguel; Sifuentes-Alvarez, Antonio] Fac Med & Nutr UJED, Durango, Mexico.
RP Sifuentes-Alvarez, A (通讯作者)，Fac Med & Nutr UJED, Durango, Mexico.
EM sifual55@hotmail.com
RI Galvan, Graciela/Z-1035-2019
OI Zambrano Galvan, Graciela/0000-0003-4502-4017
CR Allred DC, 2010, MODERN PATHOL, V23, pS52, DOI 10.1038/modpathol.2010.55
   [Anonymous], FREE STAT SOFTWARE V
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Cancer Genome Atlas Network, 2012, NATURE, V4, P49061
   Castoria G, 2010, STEROIDS, V75, P524, DOI 10.1016/j.steroids.2009.10.007
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Goldhirsch A, 2013, ANN ONCOL, V24, P2206, DOI 10.1093/annonc/mdt303
   Hammond MEH, 2010, J CLIN ONCOL, V28, P2784, DOI 10.1200/JCO.2009.25.6529
   Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Knutson TP, 2013, PHARM THER
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Mc Cormack Orla, 2007, Critical Reviews in Oncogenesis, V13, P283
   Parrella P, 2010, BREAST CARE, V5, P66, DOI 10.1159/000309138
   Purdie CA, 2014, BRIT J CANCER, V110, P565, DOI 10.1038/bjc.2013.756
   Radisky DC, 2007, NAT CELL BIOL, V9, P361, DOI 10.1038/ncb0407-361
   Ramezani F, 2012, ASIAN PAC J CANCER P, V13, P451, DOI 10.7314/APJCP.2012.13.2.451
   Renoir JM, 2013, BIOCHEM PHARMACOL, V85, P449, DOI 10.1016/j.bcp.2012.10.018
   Sasaki M, 2001, CANCER RES, V61, P97
   Sturgeon SR, 2012, EPIGENETICS-US, V7, P1258, DOI 10.4161/epi.22220
NR 22
TC 8
Z9 8
U1 0
U2 8
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2014
VL 15
IS 7
BP 3041
EP 3044
DI 10.7314/APJCP.2014.15.7.3041
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI4KQ
UT WOS:000336834500017
PM 24815444
OA gold
DA 2025-01-12
ER

PT J
AU Ge, WS
   Liu, YS
   Chen, T
   Zhang, X
   Lv, LW
   Jin, CY
   Jiang, Y
   Shi, L
   Zhou, YS
AF Ge, Wenshu
   Liu, Yunsong
   Chen, Tong
   Zhang, Xiao
   Lv, Longwei
   Jin, Chanyuan
   Jiang, Yong
   Shi, Lei
   Zhou, Yongsheng
TI The epigenetic promotion of osteogenic differentiation of human
   adipose-derived stem cells by the genetic and chemical blockade of
   histone demethylase LSD1
SO BIOMATERIALS
LA English
DT Article
DE Epigenetic drug; Human adipose-derived stem cells; Histone methylation;
   Osteogenic differentiation; Lysine-specific demethylase 1
ID TRANSCRIPTION FACTOR OSTERIX; STROMAL CELLS; BREAST-CANCER; IN-VIVO;
   TISSUE; METHYLATION; REPRESSION; INHIBITORS; RUNX2; BONE
AB Human adipose-derived stem cells (hASCs) are a highly attractive source in bone tissue engineering. It has become increasingly clear that chromatin regulators play an important role in cell fate determination. However, how osteogenic differentiation of hASCs is controlled by epigenetic mechanisms is not fully understood. Here we use genetic tools and chemical inhibitors to modify the epigenetic program of hASCs and identify lysine-specific demethylase 1 (LSD1), a histone demethylase that specifically catalyzes demethylation of di- and mono- methyl histone H3 lysine 4 (H3K4me2/1), as a key regulator in osteogenic differentiation of hASCs. Specifically, we demonstrated that genetic depletion of LSD1 with lentiviral strategy for gene knockdown promoted osteogenic differentiation of hASCs by cell studies and xenograft assays. At the molecular level, we found that LSD1 regulates osteogenesis-associated genes expression through its histone demethylase activity. Significantly, we demonstrated LSD1 demethylase inhibitors could efficiently block its catalytic activity and epigenetically boost osteogenic differentiation of hASCs. Altogether, our study defined the functional and biological roles of LSD1 and extensively explored the effects of its enzymatic activity in osteogenic differentiation of hASCs. A better understanding of how LSD1 influences on osteogenesis associated epigenetic events will provide new insights into the modulation of hASCs based cell therapy and improve the development of bone tissue engineering with epigenetic intervention. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Ge, Wenshu; Jiang, Yong] Peking Univ, Sch & Hosp Stomatol, Dept Gen Dent 2, Beijing 100081, Peoples R China.
   [Ge, Wenshu; Liu, Yunsong; Chen, Tong; Zhang, Xiao; Lv, Longwei; Jin, Chanyuan; Zhou, Yongsheng] Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, Beijing 100081, Peoples R China.
   [Shi, Lei] Tianjin Med Univ, Dept Biochem & Mol Biol, Tianjin Key Lab Med Epigenet, Tianjin 300070, Peoples R China.
   [Zhou, Yongsheng] Peking Univ, Sch & Hosp Stomatol, Natl Engn Lab Digital & Mat Technol Stomatol, Beijing 100081, Peoples R China.
C3 Peking University; Peking University; Tianjin Medical University; Peking
   University
RP Zhou, YS (通讯作者)，Peking Univ, Sch & Hosp Stomatol, Dept Prosthodont, 22 Zhongguancun South Ave, Beijing 100081, Peoples R China.
EM shilei@tmu.edu.cn; kqzhouysh@hsc.pku.edu.cn
RI Liu, Yunsong/AAS-6801-2020; Zhou, Yanheng/AFX-1820-2022; Lv,
   Longwei/ABA-5055-2020
OI Liu, Yunsong/0000-0001-8364-1898
FU National Natural Science Foundation of China [81200763, 81070809,
   81272284, 91219102]; Program for New Century Excellent Talents (NCET) in
   University from Ministry of Education of China [NCET-13-0934,
   NCET-11-0026]; PKU School of Stomatolgy for talented young
   investigators; National Health and Family Planning Commission of China
FX This work was supported by grants (81200763 to W.G., 81070809 to Y.Z.,
   81272284 and 91219102 to LS) from the National Natural Science
   Foundation of China, grants from Program for New Century Excellent
   Talents (NCET) in University from Ministry of Education of China to LS.
   (NCET-13-0934) and Y.Z. (NCET-11-0026), a grant from PKU School of
   Stomatolgy for talented young investigators to W.G and construction
   program for national key clinical specialty from National Health and
   Family Planning Commission of China.
CR Adamo A, 2011, NAT CELL BIOL, V13, P652, DOI 10.1038/ncb2246
   Ali SA, 2010, P NATL ACAD SCI USA, V107, P4165, DOI 10.1073/pnas.1000620107
   Chen YW, 2012, CRIT REV EUKAR GENE, V22, P53, DOI 10.1615/CritRevEukarGeneExpr.v22.i1.40
   Cho HH, 2005, J CELL BIOCHEM, V96, P533, DOI 10.1002/jcb.20544
   Chung MT, 2013, STEM CELL TRANSL MED, V2, P808, DOI 10.5966/sctm.2012-0183
   De Toni F, 2011, STEM CELLS DEV, V20, P2127, DOI 10.1089/scd.2011.0044
   Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471
   Forneris F, 2008, TRENDS BIOCHEM SCI, V33, P181, DOI 10.1016/j.tibs.2008.01.003
   Foster CT, 2010, MOL CELL BIOL, V30, P4851, DOI 10.1128/MCB.00521-10
   Ge WS, 2011, STEM CELLS, V29, P1112, DOI 10.1002/stem.663
   Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173
   Harrison C, 2013, NAT REV DRUG DISCOV, V12, P188, DOI 10.1038/nrd3961
   Hicok KC, 2004, TISSUE ENG, V10, P371, DOI 10.1089/107632704323061735
   Hong L, 2006, CELLS TISSUES ORGANS, V183, P133, DOI 10.1159/000095987
   Hu XQ, 2013, STEM CELLS DEV, V22, P248, DOI 10.1089/scd.2012.0105
   Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8
   Jensen ED, 2007, CRIT REV EUKAR GENE, V17, P187
   Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570
   Kaiser J, 2010, SCIENCE, V330, P576, DOI [10.1126/science.330.6004.576, 10.1126/science.330.6004.577]
   Kerenyi MA, 2013, ELIFE, V2, DOI 10.7554/eLife.00633
   Lamour V, 2007, J BIOL CHEM, V282, P36240, DOI 10.1074/jbc.M705833200
   Lan F, 2008, CURR OPIN CELL BIOL, V20, P316, DOI 10.1016/j.ceb.2008.03.004
   Levi B, 2011, STEM CELLS DEV, V20, P243, DOI 10.1089/scd.2010.0250
   Levi B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011177
   Liang Y, 2013, MBIO, V4, DOI 10.1128/mBio.00558-12
   Liang Y, 2009, NAT MED, V15, P1312, DOI 10.1038/nm.2051
   Lynch JT, 2012, EXPERT OPIN THER TAR, V16, P1239, DOI 10.1517/14728222.2012.722206
   Maroni P, 2012, BIOCHEM BIOPH RES CO, V428, P271, DOI 10.1016/j.bbrc.2012.10.044
   Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020
   Mosammaparast N, 2010, ANNU REV BIOCHEM, V79, P155, DOI 10.1146/annurev.biochem.78.070907.103946
   Murphy DL, 1998, J NEURAL TRANSM-SUPP, P39
   Murray-Stewart T, 2014, AMINO ACIDS, V46, P585, DOI 10.1007/s00726-013-1485-1
   Neelamegam R, 2012, ACS CHEM NEUROSCI, V3, P120, DOI 10.1021/cn200104y
   Pekowska A, 2011, EMBO J, V30, P4198, DOI 10.1038/emboj.2011.295
   Pollock JA, 2012, ACS CHEM BIOL, V7, P1221, DOI 10.1021/cb300108c
   Qureshi AT, 2013, BIOMATERIALS, V34, P7799, DOI 10.1016/j.biomaterials.2013.07.004
   Rada T, 2009, TISSUE ENG PART B-RE, V15, P113, DOI 10.1089/ten.teb.2008.0423
   Rudolph T, 2013, BIOL CHEM, V394, P1019, DOI 10.1515/hsz-2013-0119
   Shakibaei M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035712
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Sinha KM, 2010, EMBO J, V29, P68, DOI 10.1038/emboj.2009.332
   Tao Y, 2013, J BIOL CHEM, V288, P16430, DOI 10.1074/jbc.M112.446849
   Tapp H, 2009, EXP BIOL MED, V234, P1, DOI [10.3181/0805-MR-170, 10.3181/0805/MR-170]
   Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671
   Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Westendorf JJ, 2006, J CELL BIOCHEM, V98, P54, DOI 10.1002/jcb.20805
   Whyte WA, 2012, NATURE, V482, P221, DOI 10.1038/nature10805
   Williams JS, 2012, AM J HYPERTENS, V25, P812, DOI 10.1038/ajh.2012.43
   Yu LH, 2010, INT J CARDIOL, V139, P166, DOI 10.1016/j.ijcard.2008.10.024
   Yu YY, 2013, BIOCHEM BIOPH RES CO, V437, P192, DOI 10.1016/j.bbrc.2013.05.123
   Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105
NR 56
TC 57
Z9 64
U1 1
U2 77
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD JUL
PY 2014
VL 35
IS 23
BP 6015
EP 6025
DI 10.1016/j.biomaterials.2014.04.055
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA AI8YF
UT WOS:000337212200004
PM 24794925
DA 2025-01-12
ER

PT J
AU Raha, D
   Wilson, TR
   Peng, J
   Peterson, D
   Yue, P
   Evangelista, M
   Wilson, C
   Merchant, M
   Settleman, J
AF Raha, Debasish
   Wilson, Timothy R.
   Peng, Jing
   Peterson, David
   Yue, Peng
   Evangelista, Marie
   Wilson, Catherine
   Merchant, Mark
   Settleman, Jeff
TI The Cancer Stem Cell Marker Aldehyde Dehydrogenase Is Required to
   Maintain a Drug-Tolerant Tumor Cell Subpopulation
SO CANCER RESEARCH
LA English
DT Article
ID BREAST-CANCER; ONCOGENE ADDICTION; OXIDATIVE STRESS; PROSTATE-CANCER;
   RESISTANCE; DISULFIRAM; ASSOCIATION; SPECIFICITY; SENSITIVITY;
   INHIBITION
AB Selective kinase inhibitors have emerged as an important class of cancer therapeutics, and several such drugs are now routinely used to treat advanced-stage disease. However, their clinical benefit is typically short-lived because of the relatively rapid acquisition of drug resistance following treatment response. Accumulating preclinical and clinical data point to a role for a heterogeneous response to treatment within a subpopulation of tumor cells that are intrinsically drug-resistant, such as cancer stem cells. We have previously described an epigenetically determined reversibly drug-tolerant subpopulation of cancer cells that share some properties with cancer stem cells. Here, we define a requirement for the previously established cancer stem cell marker ALDH (aldehyde dehydrogenase) in the maintenance of this drug-tolerant subpopulation. We find that ALDH protects the drug-tolerant subpopulation from the potentially toxic effects of elevated levels of reactive oxygen species (ROS) in these cells, and pharmacologic disruption of ALDH activity leads to accumulation of ROS to toxic levels, consequent DNA damage, and apoptosis specifically within the drug-tolerant subpopulation. Combining ALDH inhibition with other kinase-directed treatments delayed treatment relapse in vitro and in vivo, revealing a novel combination treatment strategy for cancers that might otherwise rapidly relapse following single-agent therapy. (C) 2014 AACR.
C1 [Raha, Debasish; Wilson, Timothy R.; Evangelista, Marie; Wilson, Catherine; Settleman, Jeff] Genentech Inc, Dept Discovery Oncol, San Francisco, CA 94080 USA.
   [Peng, Jing; Peterson, David; Merchant, Mark] Genentech Inc, Dept Translat Oncol, San Francisco, CA 94080 USA.
   [Yue, Peng] Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding;
   Genentech
RP Settleman, J (通讯作者)，Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA.
EM settleman.jeffrey@gene.com
RI Wilson, Catherine/JWB-0289-2024
FU Genentech, Inc.
FX This work was supported by Genentech, Inc., a member of the Roche group.
CR Auvinen P, 2005, HISTOPATHOLOGY, V47, P420, DOI 10.1111/j.1365-2559.2005.02220.x
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Barros GP, 2012, INT J GEOPHYS, V2012, DOI [10.5402/2012/137289, 10.1155/2012/459497]
   Blanpain C, 2011, CELL STEM CELL, V8, P16, DOI 10.1016/j.stem.2010.12.012
   Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200
   Chen D, 2006, CANCER RES, V66, P10425, DOI 10.1158/0008-5472.CAN-06-2126
   Choi J, 1997, BIOCHEM PHARMACOL, V53, P987, DOI 10.1016/S0006-2952(96)00867-2
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016
   DUFOUR P, 1993, BIOTHERAPY, V6, P9, DOI 10.1007/BF01877380
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Keysar SB, 2010, MOL CANCER THER, V9, P2450, DOI 10.1158/1535-7163.MCT-10-0530
   Koppaka V, 2012, PHARMACOL REV, V64, P520, DOI 10.1124/pr.111.005538
   Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259
   Levi BP, 2009, BLOOD, V113, P1670, DOI 10.1182/blood-2008-05-156752
   Liu P, 2013, BRIT J CANCER, V109, P1876, DOI 10.1038/bjc.2013.534
   Marcato P, 2011, CELL CYCLE, V10, P1378, DOI 10.4161/cc.10.9.15486
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X
   Moreb JS, 2007, CANCER CHEMOTH PHARM, V59, P127, DOI 10.1007/s00280-006-0233-6
   Pinheiro J., 2022, nlme: Linear and Nonlinear Mixed Effects Models, R package version 3.1-160
   R Core Team, 2017, R: A language and environment for statistical computing
   Rekha GK, 1997, ADV EXP MED BIOL, V414, P133
   Sauna ZE, 2004, MOL PHARMACOL, V65, P675, DOI 10.1124/mol.65.3.675
   Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372
   Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Singh S, 2013, FREE RADICAL BIO MED, V56, P89, DOI 10.1016/j.freeradbiomed.2012.11.010
   Storms RW, 1999, P NATL ACAD SCI USA, V96, P9118, DOI 10.1073/pnas.96.16.9118
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479
   Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176
   Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096
   Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011
   Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032
   Zhang QZ, 2010, CANCER LETT, V289, P151, DOI 10.1016/j.canlet.2009.08.010
   Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512
NR 40
TC 225
Z9 263
U1 0
U2 30
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUL 1
PY 2014
VL 74
IS 13
BP 3579
EP 3590
DI 10.1158/0008-5472.CAN-13-3456
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK3RF
UT WOS:000338341700020
PM 24812274
OA Green Submitted, Bronze
DA 2025-01-12
ER

PT J
AU Tan, J
   Yang, X
   Jiang, X
   Zhou, J
   Li, Z
   Lee, P
   Li, B
   Robson, P
   Yu, Q
AF Tan, J.
   Yang, X.
   Jiang, X.
   Zhou, J.
   Li, Z.
   Lee, Pl
   Li, B.
   Robson, P.
   Yu, Q.
TI Integrative epigenome analysis identifies a Polycomb-targeted
   differentiation program as a tumor-suppressor event epigenetically
   inactivated in colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; HELIX TRANSCRIPTION FACTOR; PROMOTER DNA
   METHYLATION; GROUP PROTEIN EZH2; PROSTATE-CANCER; GENE-EXPRESSION;
   DEVELOPMENTAL REGULATORS; CHROMATIN PATTERN; RETINOIC ACID;
   BREAST-CANCER
AB Aberrant DNA hypermethylation in human cancer has been associated with Polycomb target genes in embryonic stem (ES) cells, but a functional link of the Polycomb-targeted differentiation program to tumorigenesis remains to be established. Here, through epigenome analysis correlating DNA hypermethylation in colon cancer with ES cell pluripotency and differentiation, we identified a set of DNA hypermethylated genes in cancer cells that are Polycomb targets strongly associated with ES cell differentiation, including HAND1, a developmental regulator. Intriguingly, HAND1 is silenced in over 90% of human primary colorectal tumors, and re-expression of HAND1 in colon cancer cells induces terminal differentiation, inhibits proliferation and prevents xenograft tumor formation. Moreover, hypermethylated HAND1 has a minimum enrichment of EZH2-H3K27me3 in cancer cells, but becomes EZH2 bound and bivalent upon the loss of DNA methylation, suggesting a sequential gene silencing event during oncogenesis. These findings established a functional role of Polycomb-targeted differentiation program as a tumor-suppressor event epigenetically inactivated in human cancer.
C1 [Tan, J.; Yang, X.; Jiang, X.; Li, Z.; Lee, Pl; Robson, P.; Yu, Q.] ASTAR, Genome Inst Singapore, Biopolis 138672, Singapore.
   [Zhou, J.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
   [Li, B.] Shanghai Jiao Tong Univ, Minist Educ, Key Lab Genet Dev & Neuropsychiat Disorders, BioX Inst, Shanghai 200030, Peoples R China.
   [Robson, P.] Natl Univ Singapore, Dept Biol Sci, Singapore 117548, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Genome
   Institute of Singapore (GIS); National University of Singapore; Shanghai
   Jiao Tong University; National University of Singapore
RP Yu, Q (通讯作者)，ASTAR, Genome Inst Singapore, 60 Biopolis St 0201, Biopolis 138672, Singapore.
EM yuq@gis.a-star.edu.sg
RI Robson, Paul/A-3464-2009
OI Yu, Qiang/0000-0003-2132-8278; Robson, Paul/0000-0002-0191-3958
FU Agency for Science, Technology and Research of Singapore
FX We thank Dr. Bert Vogelstein for the HCT116 DKO cells. We thank Zhuang
   Li for performing the microarray hybridization. We thank the Singapore
   Tissue Network for providing the human samples. This work was supported
   by the Agency for Science, Technology and Research of Singapore.
CR Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001
   Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114
   Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   CROSS JC, 1995, DEVELOPMENT, V121, P2513
   Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Gius D, 2004, CANCER CELL, V6, P361, DOI 10.1016/j.ccr.2004.08.029
   Jette C, 2004, J BIOL CHEM, V279, P34397, DOI 10.1074/jbc.M314021200
   Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019
   Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116
   Jones RJ, 2007, J BIOL CHEM, V282, P8317, DOI 10.1074/jbc.M608667200
   Kirmizis A, 2003, MOL CANCER THER, V2, P113
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Martindill DMJ, 2007, NAT CELL BIOL, V9, P1131, DOI 10.1038/ncb1633
   McGarvey KM, 2008, CANCER RES, V68, P5753, DOI 10.1158/0008-5472.CAN-08-0700
   Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157
   Scott IC, 2000, MOL CELL BIOL, V20, P530, DOI 10.1128/MCB.20.2.530-541.2000
   Stingl J, 2007, NAT REV CANCER, V7, P791, DOI 10.1038/nrc2212
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
   Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011
   Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
NR 42
TC 19
Z9 19
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUL
PY 2014
VL 5
AR e1324
DI 10.1038/cddis.2014.283
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AO8XO
UT WOS:000341639300015
PM 25032847
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chao, CH
   Chang, CC
   Wu, MJ
   Ko, HW
   Wang, D
   Hung, MC
   Yang, JY
   Chang, CJ
AF Chao, Chi-Hong
   Chang, Chao-Ching
   Wu, Meng-Ju
   Ko, How-Wen
   Wang, Da
   Hung, Mien-Chie
   Yang, Jer-Yen
   Chang, Chun-Ju
TI MicroRNA-205 signaling regulates mammary stem cell fate and
   tumorigenesis
SO JOURNAL OF CLINICAL INVESTIGATION
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; ESTROGEN-RECEPTOR; BREAST-CANCER;
   NOTCH; MIR-205; GLAND; DIVISIONS; SLUG
AB Dysregulation of epigenetic controls is associated with tumorigenesis in response to microenvironmental stimuli; however, the regulatory pathways involved in epigenetic dysfunction are largely unclear. We have determined that a critical epigenetic regulator, microRNA-205 (miR-205), is repressed by the ligand jagged1, which is secreted from the tumor stroma to promote a cancer-associated stem cell phenotype. Knockdown of miR-205 in mammary epithelial cells promoted epithelial-mesenchymal transition (EMT), disrupted epithelial cell polarity, and enhanced symmetric division to expand the stem cell population. Furthermore, miR-205-deficient mice spontaneously developed mammary lesions, while activation of miR-205 markedly diminished breast cancer sternness. These data provide evidence that links tumor microenvironment and microRNA-dependent regulation to disruption of epithelial polarity and aberrant mammary stem cell division, which in turn leads to an expansion of stem cell population and tumorigenesis. This study elucidates an important role for miR-205 in the regulation of mammary stem cell fate, suggesting a potential therapeutic target for limiting breast cancer genesis.
C1 [Chao, Chi-Hong; Chang, Chao-Ching; Wu, Meng-Ju; Yang, Jer-Yen; Chang, Chun-Ju] Purdue Univ, Coll Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.
   [Chao, Chi-Hong; Chang, Chao-Ching; Wu, Meng-Ju; Yang, Jer-Yen; Chang, Chun-Ju] Purdue Univ, Coll Vet Med, Ctr Canc Res, W Lafayette, IN 47907 USA.
   [Ko, How-Wen; Wang, Da; Hung, Mien-Chie] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Ko, How-Wen; Hung, Mien-Chie] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA.
   [Ko, How-Wen] Chang Gung Univ, Coll Med, Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan.
   [Hung, Mien-Chie] China Med Univ, Ctr Mol Med, Taichung, Taiwan.
   [Hung, Mien-Chie] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan.
C3 Purdue University System; Purdue University; Purdue University System;
   Purdue University; University of Texas System; UTMD Anderson Cancer
   Center; University of Texas System; University of Texas Health Science
   Center Houston; Chang Gung University; Chang Gung Memorial Hospital;
   China Medical University Taiwan; China Medical University Taiwan
RP Chang, CJ (通讯作者)，Purdue Univ, Dept Basic Med Sci, 625 Harrison St, W Lafayette, IN 47907 USA.
EM chunjuchang@purdue.edu
RI Hung, Mien-Chie/ABD-5911-2021; yan, jie/HNJ-0097-2023; Wu,
   Meng-Ju/AAY-9410-2021
OI Chao, Chi-Hong/0000-0001-9890-4902; Chang, Chunju/0000-0003-2887-9603;
   Hung, Mien-Chie/0000-0003-4317-4740; Wu, Meng-Ju/0000-0001-6847-7065
FU Showalter Research Scholar grant [206793]; Purdue University Center for
   Cancer Research [P30 CA023168]; American Cancer Society Institutional
   Research grant [IRG 58-006-53]; CPRIT Graduate Scholar Training Program
   at The University of Texas MD Anderson Cancer Center; National Breast
   Cancer Foundation Inc.; China Medical University Hospital Cancer
   Research Center of Excellence [MOHW103-TD-B-111-03]; Stem Cell and
   Regenerative Medicine Frontier Research [NSC 102-2321-B-039-001]
FX We thank Yava L. Jones-Hall (Department of Comparative Pathobiology,
   Purdue University College of Veterinary Medicine) for her assistance in
   histological examination of the mouse mammary tissue samples. This study
   was supported by a Showalter Research Scholar grant (206793 to C-J.
   Chang); P30 CA023168 to the Purdue University Center for Cancer Research
   in support of the use of facilities; an American Cancer Society
   Institutional Research grant to the Purdue University Center for Cancer
   Research (IRG 58-006-53) in support of the studies led by C.J. Chang and
   J.Y. Yang; the CPRIT Graduate Scholar Training Program at The University
   of Texas MD Anderson Cancer Center (to H.W. Ko); the National Breast
   Cancer Foundation Inc.; the China Medical University Hospital Cancer
   Research Center of Excellence (MOHW103-TD-B-111-03), and the Program for
   Stem Cell and Regenerative Medicine Frontier Research (NSC
   102-2321-B-039-001 to M.C. Hung).
CR Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667
   Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001
   Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632
   Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173
   Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741
   Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048
   Greene SB, 2010, J CELL SCI, V123, P606, DOI 10.1242/jcs.056812
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008
   Haenfler JM, 2012, DEV BIOL, V365, P219, DOI 10.1016/j.ydbio.2012.02.027
   Krause S, 2013, JOVE-J VIS EXP, DOI 10.3791/50692
   Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07
   Lee CW, 2008, CANCER RES, V68, P5273, DOI 10.1158/0008-5472.CAN-07-6673
   Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   Mazur PK, 2010, P NATL ACAD SCI USA, V107, P13438, DOI 10.1073/pnas.1002423107
   Morrison SJ, 2006, NATURE, V441, P1068, DOI 10.1038/nature04956
   Nefedova Y, 2008, BLOOD, V111, P2220, DOI 10.1182/blood-2007-07-102632
   Nguyen D.-A.D., 2000, METHODS MAMMARY GLAN, P259, DOI DOI 10.1007/978-1-4615-4295-723
   Nyfeler Y, 2005, EMBO J, V24, P3504, DOI 10.1038/sj.emboj.7600816
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Piovan C, 2012, MOL ONCOL, V6, P458, DOI 10.1016/j.molonc.2012.03.003
   Qin AY, 2013, EUR J CELL BIOL, V92, P54, DOI 10.1016/j.ejcb.2012.11.002
   Radisky DC, 2007, J CELL BIOCHEM, V101, P830, DOI 10.1002/jcb.21186
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372
   Shih HP, 2012, DEVELOPMENT, V139, P2488, DOI 10.1242/dev.078634
   Siwko SK, 2008, NEOPLASIA, V10, P653, DOI 10.1593/neo.08266
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Stingl J, 2009, J PATHOL, V217, P229, DOI 10.1002/path.2457
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang ZW, 2009, CANCER LETT, V279, P8, DOI 10.1016/j.canlet.2008.09.030
NR 35
TC 94
Z9 105
U1 0
U2 12
PU AMER SOC CLINICAL INVESTIGATION INC
PI ANN ARBOR
PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA
SN 0021-9738
EI 1558-8238
J9 J CLIN INVEST
JI J. Clin. Invest.
PD JUL
PY 2014
VL 124
IS 7
BP 3093
EP 3106
DI 10.1172/JCI73351
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AK8OV
UT WOS:000338688400032
PM 24911147
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Oh, TG
   Bailey, P
   Dray, E
   Smith, AG
   Goode, J
   Eriksson, N
   Funder, JW
   Fuller, PJ
   Simpson, ER
   Tilley, WD
   Leedman, PJ
   Clarke, CL
   Grimmond, S
   Dowhan, DH
   Muscat, GEO
AF Oh, Tae Gyu
   Bailey, Peter
   Dray, Eloise
   Smith, Aaron G.
   Goode, Joel
   Eriksson, Natalie
   Funder, John W.
   Fuller, Peter J.
   Simpson, Evan R.
   Tilley, Wayne D.
   Leedman, Peter J.
   Clarke, Christine L.
   Grimmond, Sean
   Dowhan, Dennis H.
   Muscat, George E. O.
TI PRMT2 and RORγ Expression Are Associated With Breast Cancer Survival
   Outcomes
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID ORPHAN NUCLEAR RECEPTOR; GENE-EXPRESSION; R/BIOCONDUCTOR PACKAGE;
   ARGININE METHYLATION; HOMOLOGOUS RECOMBINATION; MOLECULAR-BASIS;
   IDENTIFICATION; REGULATOR; MODELS; CELLS
AB Protein arginine methyltransferases (PRMTs) methylate arginine residues on histones and target transcription factors that play critical roles in many cellular processes, including gene transcription, mRNA splicing, proliferation, and differentiation. Recent studies have linked PRMT-dependent epigenetic marks and modifications to carcinogenesis and metastasis in cancer. However, the role of PRMT2-dependent signaling in breast cancer remains obscure. We demonstrate PRMT2 mRNA expression was significantly decreased in breast cancer relative to normal breast. Gene expression profiling, Ingenuity and protein-protein interaction network analysis after PRMT2-short interfering RNA transfection into MCF-7 cells, revealed that PRMT2-dependent gene expression is involved in cell-cycle regulation and checkpoint control, chromosomal instability, DNA repair, and carcinogenesis. For example, PRMT2 depletion achieved the following: 1) increased p21 and decreased cyclinD1 expression in (several) breast cancer cell lines, 2) decreased cell migration, 3) induced an increase in nucleotide excision repair and homologous recombination DNA repair, and 4) increased the probability of distance metastasis free survival (DMFS). The expression of PRMT2 and retinoid-related orphan receptor-gamma (ROR gamma) is inversely correlated in estrogen receptor-positive breast cancer and increased ROR gamma expression increases DMFS. Furthermore, we found decreased expression of the PRMT2-dependent signature is significantly associated with increased probability of DMFS. Finally, weighted gene coexpression network analysis demonstrated a significant correlation between PRMT2-dependent genes and cell-cycle checkpoint, kinetochore, and DNA repair circuits. Strikingly, these PRMT2-dependent circuits are correlated with pan-cancer metagene signatures associated with epithelial-mesenchymal transition and chromosomal instability. This study demonstrates the role and significant correlation between a histone methyltransferase (PRMT2)-dependent signature, ROR gamma, the cell-cycle regulation, DNA repair circuits, and breast cancer survival outcomes.
C1 [Oh, Tae Gyu; Bailey, Peter; Goode, Joel; Eriksson, Natalie; Grimmond, Sean; Dowhan, Dennis H.; Muscat, George E. O.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
   [Smith, Aaron G.] Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia.
   [Dray, Eloise] Queensland Univ Technol, Translat Res Inst, Inst Hlth & Biomed Innovat, Brisbane, Qld 4102, Australia.
   [Funder, John W.; Fuller, Peter J.; Simpson, Evan R.] Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia.
   [Tilley, Wayne D.] Univ Adelaide, Sch Med, Dame Roma Mitchell Canc Res Lab, Adelaide, SA 5005, Australia.
   [Leedman, Peter J.] Univ Western Australia, Western Australian Inst Med Res, Perth, WA 6009, Australia.
   [Clarke, Christine L.] Univ Sydney, Sydney Med Sch, Westmead Millennium Inst, Westmead, NSW 2006, Australia.
   [Muscat, George E. O.] Univ Gothenburg, Dept Mol & Clin Med, Wallenberg Lab, S-40530 Gothenburg, Sweden.
C3 University of Queensland; University of Queensland; Queensland
   University of Technology (QUT); University of Queensland; Prince Henry's
   Institute of Medical Research; University of Adelaide; University of
   Western Australia; University of Sydney; Westmead Institute for Medical
   Research; University of Gothenburg
RP Muscat, GEO (通讯作者)，Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.
EM g.muscat@uq.edu.au
RI Dray, Eloise/AAD-5147-2021; Clarke, Christine/B-7127-2009; Leedman,
   Peter/O-4044-2014; Smith, Aaron/A-8329-2010; Dray, Eloise/E-3938-2012;
   Muscat, George/A-6401-2017; Grimmond, Sean/J-5304-2016
OI Dray, Eloise/0000-0001-6793-9838; Smith, Aaron/0000-0003-2937-1713;
   Tilley, Wayne/0000-0003-1893-2626; Bailey, Peter/0000-0002-0857-2041;
   Muscat, George/0000-0002-5829-5695; OH, TAE GYU/0000-0003-3971-6789;
   Clarke, Christine/0000-0001-7568-111X; Grimmond,
   Sean/0000-0002-8102-7998; Oh, Tae Gyu/0000-0002-2756-3546; Fuller,
   Peter/0000-0002-0948-2072
FU University of Queensland; Cancer Council Queensland [1071301]
FX This work was supported by The University of Queensland and the Cancer
   Council Queensland Project Grant 1071301.
CR Aletta JM, 2008, BIOTECHNOL ANN REV, V14, P203, DOI 10.1016/S1387-2656(08)00008-2
   Bedford MT, 2005, MOL CELL, V18, P263, DOI 10.1016/j.molcel.2005.04.003
   Beisser D, 2010, BIOINFORMATICS, V26, P1129, DOI 10.1093/bioinformatics/btq089
   Castro MAA, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-4-r29
   Chand AL, 2010, ENDOCR-RELAT CANCER, V17, P965, DOI 10.1677/ERC-10-0179
   Cheng WY, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1002920
   Chun J, 2013, MOL CELL BIOL, V33, P387, DOI 10.1128/MCB.00465-12
   Coser KR, 2003, P NATL ACAD SCI USA, V100, P13994, DOI 10.1073/pnas.2235866100
   Dai M, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3441
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Doan TB, 2014, MOL ONCOL, V8, P998, DOI 10.1016/j.molonc.2014.03.017
   Dowhan DH, 2012, ENDOCR-RELAT CANCER, V19, P509, DOI 10.1530/ERC-12-0100
   Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609
   Eschenbrenner J, 2011, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00044
   GALEA MH, 1992, BREAST CANCER RES TR, V22, P207, DOI 10.1007/BF01840834
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Haibe-Kains B, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-2-r18
   Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4
   Harrell JC, 2012, BREAST CANCER RES TR, V132, P523, DOI 10.1007/s10549-011-1619-7
   Harrison MJ, 2010, NUCLEIC ACIDS RES, V38, P2201, DOI 10.1093/nar/gkp1203
   Horvath S, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000117
   Iwasaki H, 2010, CIRC RES, V107, P992, DOI 10.1161/CIRCRESAHA.110.225326
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kzhyshkowska J, 2001, BIOCHEM J, V358, P305, DOI 10.1042/0264-6021:3580305
   Lakowski TM, 2009, BIOCHEM J, V421, P253, DOI 10.1042/BJ20090268
   Langfelder P, 2008, BIOINFORMATICS, V24, P719, DOI 10.1093/bioinformatics/btm563
   Lekva T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066927
   Meyer R, 2007, J STEROID BIOCHEM, V107, P1, DOI 10.1016/j.jsbmb.2007.05.006
   Mihaly Z, 2013, BREAST CANC RES TREA, P1
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6
   Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163
   Muscat GEO, 2013, MOL ENDOCRINOL, V27, P350, DOI 10.1210/me.2012-1265
   Myers SA, 2009, MOL CELL ENDOCRINOL, V309, P101, DOI 10.1016/j.mce.2009.05.006
   Neault M, 2012, NUCLEIC ACIDS RES, V40, P9513, DOI 10.1093/nar/gks764
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096
   Phalke S, 2012, NUCLEIC ACIDS RES, V40, P9534, DOI 10.1093/nar/gks858
   Powell SN, 2003, ONCOGENE, V22, P5784, DOI 10.1038/sj.onc.1206678
   Qi C, 2002, J BIOL CHEM, V277, P28624, DOI 10.1074/jbc.M201053200
   Raichur S, 2010, NUCLEIC ACIDS RES, V38, P4296, DOI 10.1093/nar/gkq180
   Razick S, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-405
   Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831
   Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206
   Schröder MS, 2011, BIOINFORMATICS, V27, P3206, DOI 10.1093/bioinformatics/btr511
   Schulltz-Norton JR, 2011, TRENDS ENDOCRIN MET, V22, P124, DOI 10.1016/j.tem.2010.11.005
   Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190
   Shivji MKK, 2004, DNA REPAIR, V3, P835, DOI 10.1016/j.dnarep.2004.03.008
   Smith AG, 2008, J BIOL CHEM, V283, P12564, DOI 10.1074/jbc.M800480200
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   Su XN, 2014, GENE DEV, V28, P622, DOI 10.1101/gad.233239.113
   Sun X, 2013, ONCOL REP, V29, P2079, DOI 10.3892/or.2013.2330
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang X, 2011, BIOINFORMATICS, V27, P879, DOI 10.1093/bioinformatics/btr028
   Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670
   Yang YZ, 2013, NAT REV CANCER, V13, P37, DOI 10.1038/nrc3409
   Yoshimoto T, 2006, EXP CELL RES, V312, P2040, DOI 10.1016/j.yexcr.2006.03.001
   Zhang B, 2005, STAT APPL GENET MOL, V4, DOI 10.2202/1544-6115.1128
   Zhong J, 2012, FEBS J, V279, P316, DOI 10.1111/j.1742-4658.2011.08426.x
NR 59
TC 48
Z9 56
U1 0
U2 15
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUL
PY 2014
VL 28
IS 7
BP 1166
EP 1185
DI 10.1210/me.2013-1403
PG 20
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA AK8SU
UT WOS:000338699100015
PM 24911119
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Guan, DG
   Shao, JF
   Zhao, ZY
   Wang, PW
   Qin, J
   Deng, YP
   Boheler, KR
   Wang, JW
   Yan, B
AF Guan, Daogang
   Shao, Jiaofang
   Zhao, Zhongying
   Wang, Panwen
   Qin, Jing
   Deng, Youping
   Boheler, Kenneth R.
   Wang, Junwen
   Yan, Bin
TI PTHGRN: unraveling post-translational hierarchical gene regulatory
   networks using PPI, ChIP-seq and gene expression data
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID EMBRYONIC STEM-CELLS; TRANSCRIPTION FACTOR; DEVELOPMENTAL REGULATORS;
   MOLECULAR-BASIS; GENOMIC DATA; ER-ALPHA; POLYCOMB; MODEL;
   PHOSPHORYLATION; DIFFERENTIATION
AB Interactions among transcriptional factors (TFs), co-factors and other proteins or enzymes can affect transcriptional regulatory capabilities of eukaryotic organisms. Post-translational modifications (PTMs) cooperate with TFs and epigenetic alterations to constitute a hierarchical complexity in transcriptional gene regulation. While clearly implicated in biological processes, our understanding of these complex regulatory mechanisms is still limited and incomplete. Various online software have been proposed for uncovering transcriptional and epigenetic regulatory networks, however, there is a lack of effective web-based software capable of constructing underlying interactive organizations between post-translational and transcriptional regulatory components. Here, we present an open web server, post-translational hierarchical gene regulatory network (PTHGRN) to unravel relationships among PTMs, TFs, epigenetic modifications and gene expression. PTHGRN utilizes a graphical Gaussian model with partial least squares regression-based methodology, and is able to integrate protein-protein interactions, ChIP-seq and gene expression data and to capture essential regulation features behind high-throughput data. The server provides an integrative platform for users to analyze ready-to-use public high-throughput Omics resources or upload their own data for systems biology study. Users can choose various parameters in the method, build network topologies of interests and dissect their associations with biological functions. Application of the software to stem cell and breast cancer demonstrates that it is an effective tool for understanding regulatory mechanisms in biological complex systems.
C1 [Guan, Daogang; Shao, Jiaofang; Zhao, Zhongying; Yan, Bin] Hong Kong Baptist Univ, Dept Biol, Kowloon, Hong Kong, Peoples R China.
   [Wang, Panwen; Qin, Jing; Wang, Junwen] Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Panwen; Qin, Jing; Wang, Junwen] Univ Hong Kong, HKU SIRI, Hong Kong, Hong Kong, Peoples R China.
   [Deng, Youping] Rush Univ, Med Ctr, Dept Internal Med & Biochem, Chicago, IL 60612 USA.
   [Boheler, Kenneth R.; Yan, Bin] Univ Hong Kong, LKS Fac Med, Stem Cell & Regenerat Med Consortium, Hong Kong, Hong Kong, Peoples R China.
   [Boheler, Kenneth R.; Yan, Bin] Univ Hong Kong, Dept Physiol, Hong Kong, Hong Kong, Peoples R China.
   [Wang, Junwen] Univ Hong Kong, LKS Fac Med, Ctr Genom Sci, Hong Kong, Hong Kong, Peoples R China.
C3 Hong Kong Baptist University; University of Hong Kong; University of
   Hong Kong; Rush University; University of Hong Kong; University of Hong
   Kong; University of Hong Kong
RP Yan, B (通讯作者)，Hong Kong Baptist Univ, Dept Biol, Kowloon, Hong Kong, Peoples R China.
EM bohelerk@hku.hk; junwen@uw.edu; yanbinai6017@gmail.com
RI Zhao, Zhongying/ABF-9458-2021; Qin, Jing/J-9807-2016; Wang,
   Junwen/D-3700-2011
OI Wang, Junwen/0000-0002-4432-4707; Qin, Jing/0000-0002-8327-8846; Deng,
   Youping/0000-0002-5951-8213; Guan, Daogang/0000-0002-3289-1448; Guan,
   Daogang/0000-0003-1414-0189; /0000-0002-2168-3379; Zhao,
   Zhongying/0000-0003-2743-9008
FU Grant of Science Faculty of Hong Kong Baptist University
   [FRG1/13-14/008]; National Nature Science Foundation of China
   [91229105]; Hong Kong Research Grants Council [781511M]; Research Grants
   Council of Hong Kong Theme-based Research Scheme [T13-706/11];
   Collaborative Research Fund of Hong Kong Research Grants Council
   [HKBU5/CRF/11G]
FX Grant of Science Faculty of Hong Kong Baptist University
   [FRG1/13-14/008]; National Nature Science Foundation of China
   [91229105]; Hong Kong Research Grants Council [781511M]; Research Grants
   Council of Hong Kong Theme-based Research Scheme [T13-706/11];
   Collaborative Research Fund of Hong Kong Research Grants Council
   [HKBU5/CRF/11G]. Funding for open access charge: Grant of Science
   Faculty of Hong Kong Baptist University [FRG1/13-14/008]; National
   Nature Science Foundation of China [91229105]; Hong Kong Research Grants
   Council [781511M]; Research Grants Council of Hong Kong Theme-based
   Research Scheme [T13-706/11]; Collaborative Research Fund of Hong Kong
   Research Grants Council [HKBU5/CRF/11G].
CR Anbalagan Muralidharan, 2012, Nucl Recept Signal, V10, pe001, DOI 10.1621/nrs.10001
   Bae SC, 2006, GENE, V366, P58, DOI 10.1016/j.gene.2005.10.017
   Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005
   Bleda M, 2012, NUCLEIC ACIDS RES, V40, pW168, DOI 10.1093/nar/gks573
   Boulesteix AL, 2007, BRIEF BIOINFORM, V8, P32, DOI 10.1093/bib/bb1016
   Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733
   Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6
   Cheng ASL, 2006, MOL CELL, V21, P393, DOI 10.1016/j.molcel.2005.12.016
   Friedländer MR, 2008, NAT BIOTECHNOL, V26, P407, DOI 10.1038/nbt1394
   Furey TS, 2012, NAT REV GENET, V13, P840, DOI 10.1038/nrg3306
   Geeven G, 2012, BIOINFORMATICS, V28, P214, DOI 10.1093/bioinformatics/btr641
   Gioeli D, 2012, MOL CELL ENDOCRINOL, V352, P70, DOI 10.1016/j.mce.2011.07.004
   Guan DG, 2011, RNA BIOL, V8, P1, DOI [10.4161/rna.8.5, 10.4161/rna.8.5.16026]
   Guan DG, 2014, BIOINFORMATICS, V30, P1190, DOI 10.1093/bioinformatics/btt761
   Keenen B, 2009, J CELL PHYSIOL, V219, P1, DOI 10.1002/jcp.21654
   Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466
   Lambertini E, 2008, J CELL PHYSIOL, V216, P101, DOI 10.1002/jcp.21379
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410
   Li JY, 2007, MOL CELL BIOL, V27, P8748, DOI 10.1128/MCB.01380-07
   Li M, 2000, NAT BIOTECHNOL, V18, P1251, DOI 10.1038/82355
   Li MJ, 2010, BIOINFORMATICS, V26, P2897, DOI 10.1093/bioinformatics/btq540
   Li WY, 2012, BIOINFORMATICS, V28, P2458, DOI 10.1093/bioinformatics/bts476
   Li XH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-44
   Linderman GC, 2012, NUCLEIC ACIDS RES, V40, pW152, DOI 10.1093/nar/gks526
   Liu ZP, 2013, IET SYST BIOL, V7, P143, DOI 10.1049/iet-syb.2012.0062
   Ma SS, 2007, GENOME RES, V17, P1614, DOI 10.1101/gr.6911207
   Mann M, 2012, Minerva Ginecol, V64, P75
   Ng HH, 2011, NAT CELL BIOL, V13, P490, DOI 10.1038/ncb0511-490
   Olsen JV, 2013, MOL CELL PROTEOMICS, V12, P3444, DOI 10.1074/mcp.O113.034181
   Pasini D, 2007, MOL CELL BIOL, V27, P3769, DOI 10.1128/MCB.01432-06
   Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788
   Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937
   Qin J, 2011, NUCLEIC ACIDS RES, V39, pW430, DOI 10.1093/nar/gkr332
   Rizzino A, 2009, WIRES SYST BIOL MED, V1, P228, DOI 10.1002/wsbm.12
   Rohila JS, 2006, PLANT J, V46, P1, DOI 10.1111/j.1365-313X.2006.02671.x
   Tang BH, 2012, SCI REP-UK, V2, DOI 10.1038/srep00875
   Tanimura N, 2013, J BIOL CHEM, V288, P5027, DOI 10.1074/jbc.M112.411173
   van den Berg DLC, 2010, CELL STEM CELL, V6, P369, DOI 10.1016/j.stem.2010.02.014
   Walhout AJM, 2001, METHODS, V24, P297, DOI 10.1006/meth.2001.1190
   Wang JG, 2013, SCI REP-UK, V3, DOI 10.1038/srep01097
   Wang K, 2009, NAT BIOTECHNOL, V27, P829, DOI 10.1038/nbt.1563
   Wei Z, 2009, STEM CELLS, V27, P2969, DOI 10.1002/stem.231
   Xu YM, 2012, J PROTEOME RES, V11, P2625, DOI 10.1021/pr201151a
   Yan B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073656
   Zhang L, 2013, BIOSTATISTICS, V14, P708, DOI 10.1093/biostatistics/kxt021
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 47
TC 24
Z9 26
U1 1
U2 27
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUL 1
PY 2014
VL 42
IS W1
BP W130
EP W136
DI 10.1093/nar/gku471
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AM2XN
UT WOS:000339715000023
PM 24875471
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Motevalli, A
   Yasaei, H
   Virmouni, SA
   Slijepcevic, P
   Roberts, T
AF Motevalli, Azadeh
   Yasaei, Hemad
   Virmouni, Sara Anjomani
   Slijepcevic, Predrag
   Roberts, Terry
TI The effect of chemotherapeutic agents on telomere length maintenance in
   breast cancer cell lines
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE Shelterin; Telomere; 5-aza-CdR; TSA; Telomerase
ID BINDING PROTEINS; EXPRESSION; TUMOR; 5-AZA-2'-DEOXYCYTIDINE; GENE; DNA;
   ELONGATION; SHELTERIN; CHROMATIN; SUBUNIT
AB Mammalian telomeric DNA consists of tandem repeats of the sequence TTAGGG associated with a specialized set of proteins, known collectively as Shelterin. These telosomal proteins protect the ends of chromosomes against end-to-end fusion and degradation. Short telomeres in breast cancer cells confer telomere dysfunction and this can be related to Shelterin proteins and their level of expression in breast cancer cell lines. This study investigates whether expression of Shelterin and Shelterin-associated proteins are altered, and influence the protection and maintenance of telomeres, in breast cancer cells. 5-aza-2'-deoxycytidine (5-aza-CdR) and trichostatin A (TSA) were used in an attempt to reactivate the expression of silenced genes. Our studies have shown that Shelterin and Shelterin-associated genes were down-regulated in breast cancer cell lines; this may be due to epigenetic modification of DNA as the promoter region of POT1 was found to be partially methylated. Shelterin genes expression was up-regulated upon treatment of 21NT breast cancer cells with 5-aza-CdR and TSA. The telomere length of treated 21NT cells was measured by q-PCR showed an increase in telomere length at different time points. Our studies have shown that down-regulation of Shelterin genes is partially due to methylation in some epithelial breast cancer cell lines. Removal of epigenetic silencing results in up-regulation of Shelterin and Shelterin-associated genes which can then lead to telomere length elongation and stability.
C1 [Motevalli, Azadeh; Yasaei, Hemad; Virmouni, Sara Anjomani; Slijepcevic, Predrag; Roberts, Terry] Brunel Univ, Sch Hlth Sci & Social Care, Uxbridge UB8 3PH, Middx, England.
C3 Brunel University
RP Roberts, T (通讯作者)，Brunel Univ, Sch Hlth Sci & Social Care, Uxbridge UB8 3PH, Middx, England.
EM Terry.roberts@brunel.ac.uk
RI Yasaei, Hemad/A-6351-2014
CR Autexier C, 2006, ANNU REV BIOCHEM, V75, P493, DOI 10.1146/annurev.biochem.75.103004.142412
   BAND V, 1990, CANCER RES, V50, P7351
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Butler KS, 2012, CANCER MED-US, V1, P165, DOI 10.1002/cam4.14
   Colgin LM, 2003, CURR BIOL, V13, P942, DOI 10.1016/S0960-9822(03)00339-7
   Cookson JC, 2009, EUR J CANCER, V45, P536, DOI 10.1016/j.ejca.2008.11.014
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Drummond DC, 2005, ANNU REV PHARMACOL, V45, P495, DOI 10.1146/annurev.pharmtox.45.120403.095825
   DSOUZA B, 1993, ONCOGENE, V8, P1797
   Garbe JC, 2009, CANCER RES, V69, P7557, DOI 10.1158/0008-5472.CAN-09-0270
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386
   Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6
   HACKETT AJ, 1977, JNCI-J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795
   Holysz H, 2013, TUMOR BIOL, V34, P1371, DOI 10.1007/s13277-013-0757-4
   Hu H, 2010, J CANCER RES CLIN, V136, P1407, DOI 10.1007/s00432-010-0795-x
   KAIGHN ME, 1979, INVEST UROL, V17, P16
   Kong QR, 2014, STEM CELL REV REP, V10, P399, DOI 10.1007/s12015-014-9499-y
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   LASFARGUES EY, 1978, JNCI-J NATL CANCER I, V61, P967
   LASFARGUES EY, 1958, JNCI-J NATL CANCER I, V21, P1131
   Liu Y, 2000, MOL CELL BIOL, V20, P8178, DOI 10.1128/MCB.20.21.8178-8184.2000
   Low KC, 2013, TRENDS BIOCHEM SCI, V38, P426, DOI 10.1016/j.tibs.2013.07.001
   Lu LG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2893
   Lu YM, 2013, PROTEIN CELL, V4, P573, DOI 10.1007/s13238-013-3002-4
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Martínez P, 2010, AGING CELL, V9, P653, DOI 10.1111/j.1474-9726.2010.00596.x
   Meng Chun-Feng, 2008, Ai Zheng, V27, P1251
   Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3
   Mossman D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-366
   O'Callaghan NJ, 2011, BIOL PROCED ONLINE, V13, DOI 10.1186/1480-9222-13-3
   Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350
   Salhab M, 2008, BREAST CANCER RES TR, V109, P35, DOI 10.1007/s10549-007-9622-8
   Saunthararajah Y, 2003, BLOOD, V102, P3865, DOI 10.1182/blood-2003-05-1738
   Schmelz K, 2005, LEUKEMIA, V19, P103, DOI 10.1038/sj.leu.2403552
   Smith S, 1998, SCIENCE, V282, P1484, DOI 10.1126/science.282.5393.1484
   Smogorzewska A, 2004, ANNU REV BIOCHEM, V73, P177, DOI 10.1146/annurev.biochem.73.071403.160049
   SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409
   Sputova Klara, 2013, Genome Integr, V4, P4, DOI 10.1186/2041-9414-4-4
   Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454
   Wyatt HDM, 2010, NUCLEIC ACIDS RES, V38, P5609, DOI 10.1093/nar/gkq370
   Yang Q, 2005, MOL CELL BIOL, V25, P1070, DOI 10.1128/MCB.25.3.1070-1080.2005
   Yang Q, 2007, CANCER RES, V67, P11677, DOI 10.1158/0008-5472.CAN-07-1390
   Zhang GQHFYLF, 2008, J CLIN ONCOL, P304
NR 45
TC 11
Z9 12
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD JUN
PY 2014
VL 145
IS 3
BP 581
EP 591
DI 10.1007/s10549-014-2975-x
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AH9DL
UT WOS:000336441200002
PM 24807106
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Cho, K
   Choi, WS
   Crane, CL
   Park, CS
AF Cho, Kyongshin
   Choi, Woo-Sik
   Crane, Courtney L.
   Park, Chung S.
TI Pubertal supplementation of lipotropes in female rats reduces mammary
   cancer risk by suppressing histone deacetylase 1
SO EUROPEAN JOURNAL OF NUTRITION
LA English
DT Article
DE Lipotropes; Puberty; Breast cancer; Histone deacetylase 1; DNA
   methyltransferase 1
ID FOLIC-ACID; DNA METHYLATION; BREAST-CANCER; FOLATE; EPIGENETICS;
   INHIBITORS; DIET
AB The time from puberty to the first pregnancy is known to be important for a woman's life-time breast cancer risk. Recent studies suggest that epigenetic mechanisms may involve pubertal maturation processes, which can affect the risk of breast cancer in later life. Epigenetic alterations are related to lipotropes (methionine, choline, folate, and vitamin B-12), which are methyl donors and cofactors. However, the effects of pubertal supplementation of lipotropes in breast cancer remain largely unknown.
   Twenty female Sprague-Dawley rats, aged 6 weeks, were divided into two groups and fed a normal control diet or a lipotrope-fortified diet formulated to provide five times basal levels of lipotropes during puberty. All rats were injected intraperitoneally with N-nitroso-N-methylurea at 50 days of age to induce mammary tumors.
   Tumor multiplicity and tumor volume decreased significantly as a result of lipotrope supplementation. Interestingly, quantitative RT-PCR revealed significantly decreased expression of histone deacetylase 1 (Hdac1) and DNA methyltransferase 1 (Dnmt1) genes in tumor tissues of the rats supplemented with lipotrope-fortified diet, suggesting that reduced risk of breast cancer can be attributed, at least in part, to decreased expression of these two genes.
   This study demonstrates that supplementation of lipotrope-fortified diet during puberty suppresses tumor growth, potentially through down-regulating Hdac1 and Dnmt1 gene expression. Our findings suggest that pubertal methyl diet plays an important role in the etiology of breast cancer, and further studies are warranted to develop preventative strategies against breast cancer.
C1 [Cho, Kyongshin; Choi, Woo-Sik; Crane, Courtney L.; Park, Chung S.] N Dakota State Univ, Dept Anim Sci, Fargo, ND 58102 USA.
C3 North Dakota State University Fargo
RP Cho, K (通讯作者)，N Dakota State Univ, Dept Anim Sci, 1300 Albrecht Ave, Fargo, ND 58102 USA.
EM kyongshin.cho@ndsu.edu; c.park@ndsu.edu
FU US National Institutes of Health [1R15CA164768]
FX This work was supported in part by the US National Institutes of Health
   (1R15CA164768). The authors thank Dr Lawrence Mabasa and Ms Kwangbog Cho
   for technical assistance.
CR Bailey SW, 2009, P NATL ACAD SCI USA, V106, P15424, DOI 10.1073/pnas.0902072106
   Burdge GC, 2010, ANNU REV NUTR, V30, P315, DOI 10.1146/annurev.nutr.012809.104751
   Burdge GC, 2009, J NUTR, V139, P1054, DOI 10.3945/jn.109.104653
   Chan MM, 2005, CARCINOGENESIS, V26, P1343, DOI 10.1093/carcin/bgi100
   Cho K, 2012, CARCINOGENESIS, V33, P1106, DOI 10.1093/carcin/bgs125
   Cooney CA, 2002, J NUTR, V132, p2393S
   Ebbing M, 2009, JAMA-J AM MED ASSOC, V302, P2119, DOI 10.1001/jama.2009.1622
   Ericson U, 2007, AM J CLIN NUTR, V86, P434, DOI 10.1093/ajcn/86.2.434
   Fuks F, 2003, J BIOL CHEM, V278, P4035, DOI 10.1074/jbc.M210256200
   Hochberg Z, 2011, ENDOCR REV, V32, P159, DOI 10.1210/er.2009-0039
   Kotsopoulos J, 2008, J NUTR, V138, P703, DOI 10.1093/jn/138.4.703
   Larsson SC, 2007, JNCI-J NATL CANCER I, V99, P64, DOI 10.1093/jnci/djk006
   Lee HS, 2012, CANC LETT, DOI [10.1016/j.bbr.2011.03.031, DOI 10.1016/J.BBR.2011.03.031]
   Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210
   Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779
   Prinz-Langenohl R, 2001, EUR J NUTR, V40, P98, DOI 10.1007/PL00007387
   Selhub J, 2011, BIOFACTORS, V37, P269, DOI 10.1002/biof.173
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Smith AD, 2008, AM J CLIN NUTR, V87, P517
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
NR 21
TC 1
Z9 3
U1 0
U2 2
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1436-6207
EI 1436-6215
J9 EUR J NUTR
JI Eur. J. Nutr.
PD JUN
PY 2014
VL 53
IS 4
BP 1139
EP 1143
DI 10.1007/s00394-013-0626-3
PG 5
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA AI3YL
UT WOS:000336801700015
PM 24276224
DA 2025-01-12
ER

PT J
AU Gao, YY
   Yang, M
   Jiang, Z
   Woda, BA
   Mercurio, AM
   Qin, JJ
   Huang, XL
   Zhang, F
AF Gao, Yuanyuan
   Yang, Michelle
   Jiang, Zhong
   Woda, Bruce A.
   Mercurio, Arthur M.
   Qin, Jianjie
   Huang, Xinli
   Zhang, Feng
TI IMP3 expression is associated with poor outcome and epigenetic
   deregulation in intrahepatic cholangiocarcinoma
SO HUMAN PATHOLOGY
LA English
DT Article
DE IMP3; Intrahepatic; Cholangiocarcinoma; Outcome; Epigenetic; Methylation
ID BINDING PROTEIN-3 EXPRESSION; MESSENGER-RNA; PREDICT METASTASIS;
   MOLECULAR-MARKER; BREAST-CANCER; ADENOCARCINOMA; CARCINOMAS; BIOMARKER;
   SURVIVAL; PROGNOSIS
AB IMP3 is a fetal protein not expressed in normal adult tissues. IMP3 is an oncoprotein and a useful biomarker for a variety of malignancies and is associated with reduced overall survival of a number of them. IMP3 expression and its prognostic value for patients with intrahepatic cholangiocarcinoma (ICC) have not been well investigated. The molecular mechanism underlying IMP3 expression in human cancer cells remains to be elucidated. Here we investigated IMP3 expression in ICC and adjacent nonneoplastic liver in 72 unifocal primary ICCs from a single institute by immunohistochemistry, immunoblotting, and real-time polymerase chain reaction. IMP3 was specifically expressed in cancer cells but not in the surrounding normal tissue, and 59 (82%) of 72 ICCs were IMP3 positive by immunohistochemistry. Among 35 cases with lymphovascular invasion, 26 (74%) showed IMP3 positivity in lymph node metastases. IMP3 expression was significantly correlated with tumor size, pathological grade, metastasis, and clinical stage. Kaplan-Meier analysis demonstrated an inverse correlation between IMP3 expression and overall survival rate. Multivariate analysis revealed that IMP3 was the only risk factor associated with survival. To further explore the mechanism of IMP3 expression in cancers, we identified 2 CpG islands at IMP3 proximal promoter. Interestingly, the IMP3 promoter was almost completely demethylated in ICCs in contrast to densely methylated promoter in normal liver tissues. IMP3 expression is a useful biomarker for ICCs and can provide an independent prognostic value for patients with ICC. To our knoweldge, this is the first direct evidence of epigenetic deregulation of IMP3 in human cancer. (C) 2014 The Authors. Published by Elsevier Inc.
C1 [Gao, Yuanyuan; Qin, Jianjie; Huang, Xinli; Zhang, Feng] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing 210029, Jiangsu, Peoples R China.
   [Gao, Yuanyuan; Qin, Jianjie; Huang, Xinli; Zhang, Feng] Minist Hlth, Key Lab Living Donor Liver Transplantat, Nanjing 210029, Jiangsu, Peoples R China.
   [Gao, Yuanyuan] Changzhou 2nd Peoples Hosp, Changzhou 213000, Jiangsu, Peoples R China.
   [Yang, Michelle; Jiang, Zhong; Woda, Bruce A.] Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA 01605 USA.
   [Mercurio, Arthur M.] Univ Massachusetts, Mem Med Sch, Dept Canc Biol, Worcester, MA 01605 USA.
C3 Nanjing Medical University; University of Massachusetts System;
   University of Massachusetts Worcester; University of Massachusetts
   System; University of Massachusetts Worcester
RP Huang, XL (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM huangxinli@njmu.edu.cn; zhangf@njmu.edu.cn
RI Woda, Bruce/AAS-5898-2020; Gao, Yuanyuan/AAK-9441-2021; wang,
   wei/JYP-7819-2024
FU Key Laboratory of Living Donor Liver Transplantation, Ministry of
   Health, Nanjing, China
FX The authors want to thank The Key Laboratory of Living Donor Liver
   Transplantation, Ministry of Health, Nanjing, China, for their generous
   financial support for this project.
CR Cho SY, 2010, ANN SURG ONCOL, V17, P1823, DOI 10.1245/s10434-010-0938-y
   Chromecki TF, 2012, BJU INT, V110, P63, DOI 10.1111/j.1464-410X.2011.10703.x
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   Edge S.B., 2010, AJCC cancer staging manual, V649
   EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E
   Findeis-Hosey JJ, 2010, HUM PATHOL, V41, P477, DOI 10.1016/j.humpath.2009.10.004
   Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751
   Jeng YM, 2009, BRIT J SURG, V96, P66, DOI 10.1002/bjs.6438
   Jeng YM, 2008, HEPATOLOGY, V48, P1118, DOI 10.1002/hep.22459
   Jiang Z, 2008, CLIN CANCER RES, V14, P5579, DOI 10.1158/1078-0432.CCR-08-0504
   Jiang Z, 2006, LANCET ONCOL, V7, P556, DOI 10.1016/S1470-2045(06)70732-X
   Kono K, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-141
   Levy M, 2010, HUM PATHOL, V41, P1210, DOI 10.1016/j.humpath.2010.01.014
   Li C, 2007, MODERN PATHOL, V20, P1263, DOI 10.1038/modpathol.3800960
   Li CZ, 2007, MODERN PATHOL, V20, P242, DOI 10.1038/modpathol.3800735
   Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200
   Lu D, 2011, AM J SURG PATHOL, V35, P1638, DOI 10.1097/PAS.0b013e31823272d4
   Lu D, 2009, AM J SURG PATHOL, V33, P521, DOI 10.1097/PAS.0b013e31818aada9
   Mueller-Pillasch F, 1999, MECH DEVELOP, V88, P95, DOI 10.1016/S0925-4773(99)00160-4
   Nielsen J, 1999, MOL CELL BIOL, V19, P1262
   Noske A, 2009, INT J GYNECOL PATHOL, V28, P203, DOI 10.1097/PGP.0b013e318189a724
   Patel T, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-10
   Poultsides GA, 2010, SURG CLIN N AM, V90, P817, DOI 10.1016/j.suc.2010.04.011
   Riener MO, 2009, HUM PATHOL, V40, P1377, DOI 10.1016/j.humpath.2009.01.024
   Samanta S, 2012, ONCOGENE, V31, P4689, DOI 10.1038/onc.2011.620
   Samanta S, 2013, J BIOL CHEM, V288, P12569, DOI 10.1074/jbc.C112.442319
   Schaeffer DF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-59
   Sulpice L, 2012, BRIT J SURG, V99, P1711, DOI 10.1002/bjs.8953
   Ueki A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050621
   Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039
   Walter O, 2009, HUM PATHOL, V40, P1528, DOI 10.1016/j.humpath.2009.05.005
   Xu HD, 2007, HUM PATHOL, V38, P555, DOI 10.1016/j.humpath.2006.11.011
   Yantiss RK, 2005, AM J SURG PATHOL, V29, P188, DOI 10.1097/01.pas.0000149688.98333.54
   Yuan RH, 2009, ANN SURG ONCOL, V16, P1711, DOI 10.1245/s10434-009-0446-0
   Zheng WX, 2008, AM J SURG PATHOL, V32, P304, DOI 10.1097/PAS.0b013e3181483ff8
NR 35
TC 31
Z9 34
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0046-8177
EI 1532-8392
J9 HUM PATHOL
JI Hum. Pathol.
PD JUN
PY 2014
VL 45
IS 6
BP 1184
EP 1191
DI 10.1016/j.humpath.2014.01.016
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AI1UG
UT WOS:000336640000009
PM 24745619
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Davies, AH
   Reipas, KM
   Pambid, MR
   Berns, R
   Stratford, AL
   Fotovati, A
   Firmino, N
   Astanehe, A
   Hu, KJ
   Maxwell, C
   Mills, GB
   Dunn, SE
AF Davies, Alastair H.
   Reipas, Kristen M.
   Pambid, Mary Rose
   Berns, Rachel
   Stratford, Anna L.
   Fotovati, Abbas
   Firmino, Natalie
   Astanehe, Arezoo
   Hu, Kaiji
   Maxwell, Christopher
   Mills, Gordon B.
   Dunn, Sandra E.
TI YB-1 Transforms Human Mammary Epithelial Cells Through Chromatin
   Remodeling Leading to the Development of Basal-Like Breast Cancer
SO STEM CELLS
LA English
DT Article
DE Neoplastic cell transformation; Epigenetics; Breast cancer; Cancer stem
   cells; Human mammary epithelial cells; Y-box binding protein-1
ID BOX-BINDING PROTEIN-1; TUMOR-INITIATING CELLS; GROWTH-FACTOR RECEPTOR;
   RIBOSOMAL S6 KINASE; STEM-CELLS; GENE-EXPRESSION; COACTIVATOR P300;
   DRUG-RESISTANCE; H-RAS; TARGET
AB There is growing evidence that cancer-initiation could result from epigenetic changes. Y-box binding protein-1 (YB-1) is a transcription/translation factor that promotes the formation of tumors in transgenic mice; however, the underlying molecular events are not understood. To explore this in a human model system, YB-1 was expressed in mammary epithelial cells under the control of a tetracycline-inducible promoter. The induction of YB-1 promoted phenotypes associated with malignancy in three-dimensional breast acini cultures. This was attributed to YB-1 enhancing the expression and activity of the histone acetyltransferase p300 leading to chromatin remodeling. Specifically, this relaxation of chromatin allowed YB-1 to bind to the BMI1 promoter. The induction of BMI1 engaged the Polycomb complex resulting in histone H2A ubiquitylation and repression of the CDKN2A locus. These events manifested functionally as enhanced self-renewal capacity that occurred in a BMI1-dependent manner. Conversely, p300 inhibition with anacardic acid prevented YB-1 from binding to the BMI1 promoter and thereby subverted self-renewal. Despite these early changes, full malignant transformation was not achieved until RSK2 became overexpressed concomitant with elevated human telomerase reverse transcriptase (hTERT) activity. The YB-1/RSK2/hTERT expressing cells formed tumors in mice that were molecularly subtyped as basal-like breast cancer. We conclude that YB-1 cooperates with p300 to allow BMI1 to over-ride p16(INK4a)-mediated cell cycle arrest enabling self-renewal and the development of aggressive breast tumors.
C1 [Davies, Alastair H.; Reipas, Kristen M.; Pambid, Mary Rose; Berns, Rachel; Stratford, Anna L.; Fotovati, Abbas; Firmino, Natalie; Astanehe, Arezoo; Hu, Kaiji; Maxwell, Christopher; Dunn, Sandra E.] Univ British Columbia, Dept Pediat, Vancouver, BC V5Z 4H4, Canada.
   [Davies, Alastair H.; Reipas, Kristen M.; Pambid, Mary Rose; Berns, Rachel; Stratford, Anna L.; Fotovati, Abbas; Firmino, Natalie; Astanehe, Arezoo; Hu, Kaiji; Maxwell, Christopher; Dunn, Sandra E.] Univ British Columbia, Expt Med Program, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada.
   [Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Div Canc Med, Houston, TX 77030 USA.
C3 University of British Columbia; University of British Columbia; Child &
   Family Research Institute; University of Texas System; UTMD Anderson
   Cancer Center
RP Dunn, SE (通讯作者)，Univ British Columbia, 3082-950 West 28th Ave, Vancouver, BC V5Z 4H4, Canada.
EM sedunn@mail.ubc.ca
RI Firmino, Natalie/JRY-6844-2023; Maxwell, Chris/B-3044-2011; Mills,
   Gordon/L-5416-2014
OI Maxwell, Christopher/0000-0002-0860-4031; Maxwell,
   Christopher/0000-0002-0713-7136
FU Canadian Institutes of Health Research; Child and Family Research
   Institute; Komen Foundation; National Institutes of Health; Frederick
   Banting and Charles Best Doctoral Award
FX We thank Lisa Xu (at the CFRI Flow Core Facility) for technical
   assistance. This work was largely supported by grants from the Canadian
   Institutes of Health Research (to S.E.D.), Child and Family Research
   Institute (to S.E.D.), Komen Foundation (to G.B.M.), and National
   Institutes of Health (to S.E.D. and G.B.M.), with additional support
   from a Frederick Banting and Charles Best Doctoral Award (to A.H.D.).
CR Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Astanehe A, 2009, ONCOGENE, V28, P2406, DOI 10.1038/onc.2009.81
   Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200
   Balko JM, 2013, CANCER RES, V73, P6346, DOI 10.1158/0008-5472.CAN-13-1385
   Balko JM, 2012, NAT MED, V18, P1052, DOI 10.1038/nm.2795
   Bargou RC, 1997, NAT MED, V3, P447, DOI 10.1038/nm0497-447
   Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056
   Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504
   Bhullar J, 2011, IMMUNOGENETICS, V63, P337, DOI 10.1007/s00251-011-0517-9
   Bourguignon LYW, 2009, J BIOL CHEM, V284, P2657, DOI 10.1074/jbc.M806708200
   Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107
   Cappella P, 2014, J BIOMOL SCREEN, V19, P145, DOI 10.1177/1087057113495712
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043
   Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126
   Datta S, 2007, CANCER RES, V67, P10286, DOI 10.1158/0008-5472.CAN-07-1636
   Davies AH, 2011, ONCOGENE, V30, P3649, DOI 10.1038/onc.2011.82
   Dimri GP, 2002, CANCER RES, V62, P4736
   Dumont N, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2457
   Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
   Finkbeiner MR, 2009, ONCOGENE, V28, P1421, DOI 10.1038/onc.2008.485
   Fotovati A, 2011, CANCER RES, V71, P5569, DOI 10.1158/0008-5472.CAN-10-2805
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Fukuda T, 2004, NUCLEIC ACIDS RES, V32, P611, DOI 10.1093/nar/gkh223
   Gastaldi S, 2013, ONCOGENE, V32, P1428, DOI 10.1038/onc.2012.154
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Habibi G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2156
   Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165
   Holst CR, 2003, CANCER RES, V63, P1596
   Imada K, 2013, CLIN CANCER RES, V19, P4638, DOI 10.1158/1078-0432.CCR-12-3705
   Jürchott K, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001231
   Kang SM, 2007, CANCER CELL, V12, P201, DOI 10.1016/j.ccr.2007.08.003
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lasham A, 2012, JNCI-J NATL CANCER I, V104, P133, DOI 10.1093/jnci/djr512
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000
   Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010
   Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Romanov SR, 2001, NATURE, V409, P633, DOI 10.1038/35054579
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stratford AL, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1767
   Stratford AL, 2012, STEM CELLS, V30, P1338, DOI 10.1002/stem.1128
   Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202
   Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590
   To K, 2010, CANCER RES, V70, P2840, DOI 10.1158/0008-5472.CAN-09-3155
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561
   Zhong XM, 2009, J BIOL CHEM, V284, P9168, DOI 10.1074/jbc.M805562200
NR 57
TC 31
Z9 36
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
EI 1549-4918
J9 STEM CELLS
JI Stem Cells
PD JUN
PY 2014
VL 32
IS 6
BP 1437
EP 1450
DI 10.1002/stem.1707
PG 14
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
   Oncology; Cell Biology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA AI3EE
UT WOS:000336741700009
PM 24648416
OA Bronze, Green Accepted
DA 2025-01-12
ER

PT J
AU Gottlieb, B
   Beitel, LK
   Trifiro, M
AF Gottlieb, Bruce
   Beitel, Lenore K.
   Trifiro, Mark
TI Changing genetic paradigms: creating next-generation genetic databases
   as tools to understand the emerging complexities of genotype/phenotype
   relationships
SO HUMAN GENOMICS
LA English
DT Article
DE Human genetic variation; Next-generation sequencing; Genotype to
   phenotype relationships; Next-generation genetic databases
ID DETECTABLE CLONAL MOSAICISM; BREAST-CANCER; PROTEIN INTERACTIONS;
   HETEROGENEITY; MUTATIONS; PHENOTYPE; EVOLUTION; SEQUENCE; PENETRANCE;
   VARIANTS
AB Understanding genotype/phenotype relationships has become more complicated as increasing amounts of inter- and intra-tissue genetic heterogeneity have been revealed through next-generation sequencing and evidence showing that factors such as epigenetic modifications, non-coding RNAs and RNA editing can play an important role in determining phenotype. Such findings have challenged a number of classic genetic assumptions including (i) analysis of genomic sequence obtained from blood is an accurate reflection of the genotype responsible for phenotype expression in an individual; (ii) that significant genetic alterations will be found only in diseased individuals, in germline tissues in inherited diseases, or in specific diseased tissues in somatic diseases such as cancer; and (iii) that mutation rates in putative disease-associated genes solely determine disease phenotypes. With the breakdown of our traditional understanding of genotype to phenotype relationships, it is becoming increasingly apparent that new analytical tools will be required to determine the relationship between genotype and phenotypic expression. To this end, we are proposing that next-generation genetic database (NGDB) platforms be created that include new bioinformatics tools based on algorithms that can evaluate genetic heterogeneity, as well as powerful systems biology analysis tools to actively process and evaluate the vast amounts of both genomic and genomic-modifying information required to reveal the true relationships between genotype and phenotype.
C1 [Gottlieb, Bruce; Beitel, Lenore K.; Trifiro, Mark] Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada.
   [Gottlieb, Bruce; Trifiro, Mark] McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
   [Gottlieb, Bruce; Beitel, Lenore K.; Trifiro, Mark] McGill Univ, Dept Human Genet, Montreal, PQ, Canada.
   [Beitel, Lenore K.; Trifiro, Mark] McGill Univ, Dept Med, Montreal, PQ, Canada.
C3 McGill University; Lady Davis Institute; McGill University; McGill
   University; McGill University
RP Gottlieb, B (通讯作者)，Sir Mortimer B Davis Jewish Hosp, Lady Davis Inst Med Res, 3755 Cote Ste Catherine Rd, Montreal, PQ H3T 1E2, Canada.
EM bruce.gottlieb@mcgill.ca
OI Beitel, Lenore K./0000-0002-2836-5568
FU Weekend to End Breast Cancer Fund of the Segal Cancer Centre of the
   Jewish General Hospital, Montreal, Quebec, Canada
FX The authors acknowledge the support to BG of an operating grant from the
   Weekend to End Breast Cancer Fund of the Segal Cancer Centre of the
   Jewish General Hospital, Montreal, Quebec, Canada.
CR Ahluwalia JK, 2009, BIOESSAYS, V31, P981, DOI 10.1002/bies.200900066
   Ahn SM, 2009, GENOME RES, V19, P1622, DOI 10.1101/gr.092197.109
   Al-Khoury R, 2009, EXPERT OPIN THER TAR, V13, P13, DOI [10.1517/14728220802631876, 10.1517/14728220802631876 ]
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Anderson ARA, 2006, CELL, V127, P905, DOI 10.1016/j.cell.2006.09.042
   [Anonymous], AIDS RES HUM RETR S1
   [Anonymous], AIDS RES HUM RETR S1
   Bashashati A, 2013, J PATHOL, V231, P21, DOI 10.1002/path.4230
   Bertos NR, 2011, J CLIN INVEST, V121, P3789, DOI 10.1172/JCI57100
   Blewitt M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017939
   Civelek M, 2014, NAT REV GENET, V15, P34, DOI 10.1038/nrg3575
   Cooper DN, 2013, HUM GENET, V132, P1077, DOI 10.1007/s00439-013-1331-2
   Costa V, 2013, EUR J HUM GENET, V21, P134, DOI 10.1038/ejhg.2012.129
   Dalgleish R, 2010, GENOME MED, V2, DOI 10.1186/gm145
   Durrant C, 2012, BRIEF BIOINFORM, V13, P135, DOI 10.1093/bib/bbr026
   Erickson RP, 2010, MUTAT RES-REV MUTAT, V705, P96, DOI 10.1016/j.mrrev.2010.04.002
   Evrony GD, 2012, CELL, V151, P483, DOI 10.1016/j.cell.2012.09.035
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Fu JY, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002431
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gottlieb B, 2001, TRENDS GENET, V17, P628, DOI 10.1016/S0168-9525(01)02518-5
   Gottlieb B, 2013, HUM MUTAT, V34, P610, DOI 10.1002/humu.22287
   Gottlieb B, 2012, HUM MUTAT, V33, P887, DOI 10.1002/humu.22046
   Gottlieb B, 2010, HUM GENET, V127, P491, DOI 10.1007/s00439-010-0792-9
   Gottlieb B, 2009, HUM MUTAT, V30, P1043, DOI 10.1002/humu.21046
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Hauptman N, 2013, RADIOL ONCOL, V47, P311, DOI 10.2478/raon-2013-0062
   Howk CL, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00061
   Isakov O, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks228
   Jacobs KB, 2012, NAT GENET, V44, P651, DOI 10.1038/ng.2270
   Khatri P, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002375
   Kuo DS, 2014, HUM MOL GENET, V23, P1709, DOI 10.1093/hmg/ddt560
   Laurie CC, 2012, NAT GENET, V44, P642, DOI 10.1038/ng.2271
   Li MK, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-5-r34
   Li MY, 2011, SCIENCE, V333, P53, DOI 10.1126/science.1207018
   Lindhurst MJ, 2011, NEW ENGL J MED, V365, P611, DOI 10.1056/NEJMoa1104017
   Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653
   MacArthur DG, 2012, SCIENCE, V335, P823, DOI 10.1126/science.1215040
   Moore B, 2011, GENET MED, V13, P210, DOI 10.1097/GIM.0b013e31820ed321
   Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009
   O'Huallachain M, 2012, P NATL ACAD SCI USA, V109, P18018, DOI 10.1073/pnas.1213736109
   Petronis A, 2010, NATURE, V465, P721, DOI 10.1038/nature09230
   Relton CL, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000356
   Robinson PN, 2010, CLIN GENET, V77, P525, DOI 10.1111/j.1399-0004.2010.01436.x
   Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088
   Sale JE, 2009, PHILOS T R SOC B, V364, P595, DOI 10.1098/rstb.2008.0197
   Schmitt MW, 2012, P NATL ACAD SCI USA, V109, P14508, DOI 10.1073/pnas.1208715109
   Schuster-Böckler B, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r9
   Soto AM, 2013, J MAMMARY GLAND BIOL, V18, P199, DOI 10.1007/s10911-013-9293-5
   Taft RJ, 2010, J PATHOL, V220, P126, DOI 10.1002/path.2638
   Yvert G, 2014, TRENDS GENET, V30, P49, DOI 10.1016/j.tig.2013.11.002
   Zaranek AW, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000954
   Zhu TW, 2013, GENE, V529, P80, DOI 10.1016/j.gene.2013.07.079
NR 54
TC 5
Z9 7
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1473-9542
EI 1479-7364
J9 HUM GENOMICS
JI Hum. Genomics
PD MAY 22
PY 2014
VL 8
AR 9
DI 10.1186/1479-7364-8-9
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AI2GL
UT WOS:000336675500001
PM 24885908
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Fortunati, N
   Marano, F
   Bandino, A
   Frairia, R
   Catalano, MG
   Boccuzzi, G
AF Fortunati, Nicoletta
   Marano, Francesca
   Bandino, Andrea
   Frairia, Roberto
   Catalano, Maria Graziella
   Boccuzzi, Giuseppe
TI The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the
   invasive breast cancer cell phenotype
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE E-cadherin; estrogen receptor; DCI; triple-negative breast cancer;
   epigenetic
ID E-CADHERIN EXPRESSION; RECEPTOR-ALPHA ER; MESENCHYMAL TRANSITION;
   DOWN-REGULATION; VALPROIC ACID; RESISTANCE; AGENT; SNAIL; MECHANISMS;
   REPRESSION
AB Triple-negative breast cancer (TNBC) is a very aggressive type of tumour and its aggressiveness is linked to E-cadherin downregulation. In estrogen-sensitive breast cancer, high levels of E-cadherin fit with high levels of ER alpha and MTA3 (a component of the transcription Mi-2/NuRD complex with intrinsic DAC activity). In TNBC the E-cadherin downregulation could be due to epigenetic silencing of the CDH1 gene as well as to the lack of a fully functioning ER alpha-activated pathway. We report that the pan-histone deacetylase inhibitor LBH589, a potent anti-proliferative agent, induced E-cadherin expression on cell membranes of MDA-MB-231 cells (TNBC), determining a reduction of cell invasion and migration. Even though E-cadherin expression in breast cancer is also regulated by estradiol and the ER alpha/MTA3/Snail/Slug pathway, LBH589 is able to increase E-cadherin without affecting the estrogen pathway. In fact, no expression of ER alpha, PR and FoxA1 was observed in MDA-MB-231 cells before and after LBH589 treatment; furthermore, the drug caused an increase in Snail and Slug expression with a concomitant reduction of MTA3 levels. Taking into consideration its anti-proliferative and anti-invasive properties, we suggest the use of LBH589 in aggressive breast cancer refractory to hormonal therapy.
C1 [Fortunati, Nicoletta] AO Citta Salute & Sci Torino, Oncol Endocrinol, I-10126 Turin, Italy.
   [Marano, Francesca; Frairia, Roberto; Catalano, Maria Graziella; Boccuzzi, Giuseppe] Univ Turin, Dept Med Sci, I-10126 Turin, Italy.
   [Bandino, Andrea] Univ Turin, Biochem Sect, Dept Oncol, I-10100 Turin, Italy.
C3 A.O.U. Citta della Salute e della Scienza di Torino; University of
   Turin; University of Turin
RP Fortunati, N (通讯作者)，AO Citta Salute & Sci Torino, Oncol Endocrinol, Via Genova 3, I-10126 Turin, Italy.
EM nfortunati@cittadellasalute.to.it
RI Frairia, Roberto/K-4750-2012; CATALANO, Maria Graziella/J-4320-2016;
   Fortunati, Nicoletta/K-3081-2016
OI CATALANO, Maria Graziella/0000-0002-1170-8245; Fortunati,
   Nicoletta/0000-0001-8069-9621; Frairia, Roberto/0000-0001-9453-772X
CR Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008
   Berry DA, 2005, NEW ENGL J MED, V353, P1784, DOI 10.1056/NEJMoa050518
   Blanco MJ, 2002, ONCOGENE, V21, P3241, DOI 10.1038/sj.onc.1205416
   Cardoso F, 2009, JNCI-J NATL CANCER I, V101, P1174, DOI 10.1093/jnci/djp235
   Catalano MG, 2012, INT J CANCER, V130, P694, DOI 10.1002/ijc.26057
   Cheng CW, 2001, ONCOGENE, V20, P3814, DOI 10.1038/sj.onc.1204505
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Elias AD, 2010, AM J CLIN ONCOL-CANC, V33, P637, DOI 10.1097/COC.0b013e3181b8afcf
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946
   Fearon ER, 2003, CANCER CELL, V3, P307, DOI 10.1016/S1535-6108(03)00087-4
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Fortunati N, 2010, BREAST CANCER RES TR, V124, P667, DOI 10.1007/s10549-010-0789-z
   Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011
   Fortunati N, 2008, CANCER LETT, V259, P156, DOI 10.1016/j.canlet.2007.10.006
   Fujita N, 2003, CELL, V113, P207, DOI 10.1016/S0092-8674(03)00234-4
   Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Göttlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969
   Hajra KM, 1999, ONCOGENE, V18, P7274, DOI 10.1038/sj.onc.1203336
   Hayashi A, 2010, INT J CANCER, V127, P1332, DOI 10.1002/ijc.25151
   Hodges-Gallagher L, 2007, BREAST CANCER RES TR, V105, P297, DOI 10.1007/s10549-006-9459-6
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Katzenellenbogen BS, 2004, SEMIN ONCOL, V31, P28, DOI 10.1053/j.seminoncol.2004.01.004
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kim IA, 2009, RADIOTHER ONCOL, V92, P125, DOI 10.1016/j.radonc.2009.03.008
   Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996
   Maiso P, 2006, CANCER RES, V66, P5781, DOI 10.1158/0008-5472.CAN-05-4186
   Nam JS, 2004, CLIN EXP METASTAS, V21, P49, DOI 10.1023/B:CLIN.0000017180.19881.c1
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1
   Sawan C, 2008, MUTAT RES-FUND MOL M, V642, P1, DOI 10.1016/j.mrfmmm.2008.03.002
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Shao WL, 2010, INT J CANCER, V127, P2199, DOI 10.1002/ijc.25218
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Wong ST, 2009, AM J HEALTH-SYST PH, V66, pS9, DOI 10.2146/ajhp090439
   Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 42
TC 23
Z9 25
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD MAR
PY 2014
VL 44
IS 3
BP 700
EP 708
DI 10.3892/ijo.2013.2218
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI5GZ
UT WOS:000336894900009
PM 24366407
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Susman, S
   Tomuleasa, C
   Fekete, Z
   Pilato, B
   Irimie, A
   Berindan-Neagoe, I
AF Susman, Sergiu
   Tomuleasa, Ciprian
   Fekete, Zsolt
   Pilato, Brunella
   Irimie, Alexandru
   Berindan-Neagoe, Ioana
TI The importance of microRNAs in the stroma-breast cancer cell interplay
SO CANCER BIOMARKERS
LA English
DT Article
DE Breast cancer; tumor microenvironement; microRNA
ID EPITHELIAL-MESENCHYMAL TRANSITION; MAMMARY-GLAND DEVELOPMENT;
   TUMOR-STROMA; STEM-CELLS; CARCINOMA-CELLS; FIBROBLASTS; EXPRESSION;
   METASTASIS; INVASION; TRANSDIFFERENTIATION
AB Breast cancer is one of the most diagnosed cancers in women. Despite outstanding progress over the past few years, breast cancer remains the second leading cause of cancer-related death among women. This fact emphasizes the need for improved diagnostic and prognostic markers, as well as improved understanding of cancer environment, including the crosstalk between epithelial and stromal cells. The tumor microenvironment is paramount in breast cancer progression and dissemination. Accumulating evidence indicates that epigenetic phenomena such as microRNAs are extremely important in cancer homeostasis. Through the improved understanding of the molecular mechanisms involved in the microenvironment-mediated promotion of cancer growth and metastasis, novel targets for therapeutic intervention or early diagnosis may be identified.
C1 [Susman, Sergiu] Oncol Inst Prof Dr Ion Chiricuta, Univ Med & Pharm, Dept Morphol Sci, Cluj Napoca, Romania.
   [Susman, Sergiu; Tomuleasa, Ciprian; Irimie, Alexandru; Berindan-Neagoe, Ioana] Res Ctr Funct Genom Biomed & Translat Med, Cluj Napoca, Romania.
   [Tomuleasa, Ciprian] Johns Hopkins Univ, Sch Med, Dept Internal Med, Baltimore, MD USA.
   [Tomuleasa, Ciprian; Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Dept Immunol, Cluj Napoca, Romania.
   [Fekete, Zsolt] Oncol Inst Prof Dr Ion Chiricuta, Dept Radiotherapy, Cluj Napoca, Romania.
   [Irimie, Alexandru] Oncol Inst Prof Dr Ion Chiricuta, Dept Surg, Cluj Napoca, Romania.
   [Berindan-Neagoe, Ioana] Oncol Inst Prof Dr Ion Chiricuta, Dept Funct Genom, Cluj Napoca, Romania.
   [Pilato, Brunella] Natl Canc Res Ctr, Ist Tumori G Paolo 2, Bari, Italy.
C3 Oncology Institute Prof. Dr. Ion Chiricuta; Iuliu Hatieganu University
   of Medicine & Pharmacy; Johns Hopkins University; Oncology Institute
   Prof. Dr. Ion Chiricuta; Oncology Institute Prof. Dr. Ion Chiricuta;
   Oncology Institute Prof. Dr. Ion Chiricuta; Oncology Institute Prof. Dr.
   Ion Chiricuta; IRCCS Istituto Tumori Bari Giovanni Paolo II
RP Susman, S (通讯作者)，Iuliu Hatieganu Univ Med & Pharm, Dept Morphol Sci, Cluj Napoca, Romania.
EM sergiu.susman@umfcluj.ro
RI Tomuleasa, Ciprian/F-3030-2017; Berindan-Neagoe, Ioana/AAH-9854-2019;
   Fekete, Zsolt/F-2489-2015; Pilato, Brunella/AAH-7365-2020
OI Tomuleasa, Ciprian/0000-0001-5500-1519; Fekete,
   Zsolt/0000-0003-3386-8263; pilato, brunella/0000-0001-6067-3977
FU POSCCE [709/2010]
FX This work was financed by POSCCE 709/2010 grant with the title:
   "Clinical and economic impact of proteom and transcriptom molecular
   profiling in neoadjuvant therapy of triple negative breast cancer
   (BREASTIMPACT)".
CR Aboussekhra A, 2011, INT J DEV BIOL, V55, P841, DOI 10.1387/ijdb.113362aa
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   [Anonymous], PLOS ONE
   [Anonymous], PLOS ONE
   [Anonymous], PLOS ONE
   [Anonymous], CLIN PATHOL
   [Anonymous], PLOS ONE
   Bao B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017850
   Bevilacqua E, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/124704
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Boersma BJ, 2008, INT J CANCER, V122, P1324, DOI 10.1002/ijc.23237
   Brabletz T, 2005, CELLS TISSUES ORGANS, V179, P56, DOI 10.1159/000084509
   Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219
   Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396
   Büssing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Casey T, 2009, BREAST CANCER RES TR, V114, P47, DOI 10.1007/s10549-008-9982-8
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x
   Croce CM, 2005, CELL, V122, P6, DOI 10.1016/j.cell.2005.06.036
   de Kruijf EM, 2011, BREAST CANCER RES TR, V125, P687, DOI 10.1007/s10549-010-0855-6
   Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037
   Dumont N, 2009, CANCER CELL, V16, P3, DOI 10.1016/j.ccr.2009.06.013
   Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109
   Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858
   Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908
   Feller L, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-24
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Guarino M, 2007, INT J BIOCHEM CELL B, V39, P2153, DOI 10.1016/j.biocel.2007.07.011
   Han M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032383
   Hatfield S, 2008, CELL TISSUE RES, V331, P57, DOI 10.1007/s00441-007-0530-3
   Hendrix A, 2011, INT J DEV BIOL, V55, P879, DOI 10.1387/ijdb.113391ah
   Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002
   Horie M, 2012, BIOCHEM BIOPH RES CO, V423, P158, DOI 10.1016/j.bbrc.2012.05.104
   Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111
   Javan H, 2012, EJSO-EUR J SURG ONC, V38, P95, DOI 10.1016/j.ejso.2011.11.005
   Jemal A., 2010, CA-CANCER J CLIN, V5, P277
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kellermann MG, 2008, ORAL ONCOL, V44, P509, DOI 10.1016/j.oraloncology.2007.07.001
   Kharaziha P, 2012, BBA-REV CANCER, V1826, P103, DOI 10.1016/j.bbcan.2012.03.006
   Kim J, 2012, P NATL ACAD SCI USA, V109, P6124, DOI 10.1073/pnas.1203203109
   Kim SJ, 2011, J CONTROL RELEASE, V155, P427, DOI 10.1016/j.jconrel.2011.06.026
   Kong XB, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0033381, 10.1371/journal.pone.0041523]
   LaBarge MA, 2007, STEM CELL REV, V3, P137, DOI 10.1007/s12015-007-0024-4
   Leek RD, 2002, J MAMMARY GLAND BIOL, V7, P177, DOI 10.1023/A:1020304003704
   Leidenius MHK, 2010, ANN SURG ONCOL, V17, P254, DOI 10.1245/s10434-009-0723-y
   Leonardi GC, 2012, INT J ONCOL, V40, P1733, DOI 10.3892/ijo.2012.1408
   Leth-Larsen R, 2012, MOL MED, V18, P1109, DOI 10.2119/molmed.2012.00091
   Liao SJ, 2012, BREAST CANCER RES TR, V133, P853, DOI 10.1007/s10549-011-1844-0
   Lin EY, 2002, J MAMMARY GLAND BIOL, V7, P147, DOI 10.1023/A:1020399802795
   Lin HJL, 2009, BBA-GEN SUBJECTS, V1790, P920, DOI 10.1016/j.bbagen.2008.12.004
   Lin HJL, 2008, CANCER RES, V68, P10257, DOI 10.1158/0008-5472.CAN-08-0288
   Liu SL, 2012, J MAMMARY GLAND BIOL, V17, P15, DOI 10.1007/s10911-012-9242-8
   Louie E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2773
   Martinez-Outschoorn UE, 2011, INT J BIOCHEM CELL B, V43, P1045, DOI 10.1016/j.biocel.2011.01.023
   Mazzocca A, 2011, HEPATOLOGY, V54, P920, DOI 10.1002/hep.24485
   McCready DR, 2004, J NATL CANCER I, V96, P873, DOI 10.1093/jnci/djh142
   Moes M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035440
   Moorman AM, 2012, EJSO-EUR J SURG ONC, V38, P307, DOI 10.1016/j.ejso.2012.01.002
   Morrow M, 2011, LANCET, V378, P1804, DOI 10.1016/S0140-6736(11)61350-0
   Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477
   Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619
   Niu JX, 2012, J BIOL CHEM, V287, P21783, DOI 10.1074/jbc.M112.355495
   Pfeffer SR, 2010, NAT CELL BIOL, V12, P3, DOI 10.1038/ncb0110-3
   Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637
   Radojicic J, 2011, CELL CYCLE, V10, P507, DOI 10.4161/cc.10.3.14754
   Ramachandran S, 2012, WIRES RNA, V3, P286, DOI 10.1002/wrna.115
   Rask L, 2011, APMIS, V119, P663, DOI 10.1111/j.1600-0463.2011.02782.x
   Raviraj V, 2012, CLIN EXP METASTAS, V29, P273, DOI 10.1007/s10585-011-9450-4
   Resetkova E, 2010, BREAST CANCER RES TR, V123, P97, DOI 10.1007/s10549-009-0619-3
   Rhodes LV, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-295
   Sandoval J, 2012, CURR OPIN GENET DEV, V22, P50, DOI 10.1016/j.gde.2012.02.008
   Schulman BRM, 2005, DEV DYNAM, V234, P1046, DOI 10.1002/dvdy.20599
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Sipos F, 2012, WORLD J GASTROENTERO, V18, P601, DOI 10.3748/wjg.v18.i7.601
   Sirica AE, 2011, CURR OPIN GASTROEN, V27, P276, DOI 10.1097/MOG.0b013e32834405c3
   Song B, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-29
   Sotgia F, 2009, AM J PATHOL, V174, P746, DOI 10.2353/ajpath.2009.080658
   Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496
   Terao M, 2011, J BIOL CHEM, V286, P4027, DOI 10.1074/jbc.M110.184994
   Tjomsland V, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/212810
   Tokes AM, 2009, CLIN CANCER RES, V15, P731, DOI 10.1158/1078-0432.CCR-08-1523
   Trimboli AJ, 2009, NATURE, V461, P1084, DOI 10.1038/nature08486
   Tsai YC, 1996, CANCER RES, V56, P402
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Wallace JA, 2011, CANCER RES, V71, P1203, DOI 10.1158/0008-5472.CAN-10-3263
   Williams SA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-250
   Wu ZS, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-51
   Yates C, 2012, ADV EXP MED BIOL, V720, P81, DOI 10.1007/978-1-4614-0254-1_7
   Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103
   Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743
   Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24
NR 94
TC 5
Z9 6
U1 0
U2 10
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2014
VL 14
IS 2-3
BP 137
EP 144
DI 10.3233/CBM-130318
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI3FD
UT WOS:000336745000008
PM 24878814
DA 2025-01-12
ER

PT J
AU Wang, SC
   Lee, TH
   Hsu, CH
   Chang, YJ
   Chang, MS
   Wang, YC
   Ho, YS
   Wen, WC
   Lin, RK
AF Wang, Sheng-Chao
   Lee, Tzong-Huei
   Hsu, Chun-Hua
   Chang, Yu-Jia
   Chang, Man-Shan
   Wang, Yi-Ching
   Ho, Yuan-Soon
   Wen, Wu-Che
   Lin, Ruo-Kai
TI Antroquinonol D, Isolated from <i>Antrodia camphorata</i>, with DNA
   Demethylation and Anticancer Potential
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE breast cancer; DNA methyltransferase; DNA methylation; Antrodia
   camphorata; tumor suppressor genes; cell migration
ID TUMOR-SUPPRESSOR GENES; PROTEIN EXPRESSION; POOR-PROGNOSIS;
   METHYLTRANSFERASE; METHYLATION; DNMT1; HYPERMETHYLATION; EPIGENETICS;
   DECITABINE; TOXICITY
AB DNA methyltransferase 1 (DNMT1) catalyzes DNA methylation and is overexpressed in various human diseases, including cancer. A rational approach to preventing tumorigenesis involves the use of pharmacologic inhibitors of DNA methylation; these inhibitors should reactivate tumor suppressor genes (TSGs) in tumor cells and restore tumor suppressor pathways. Antroquinonol D (3-demethoxyl antroquinonol), a new DNMT1 inhibitor, was isolated from Antrodia camphorata and identified using nuclear magnetic resonance. Antroquinonol D inhibited the growth of MCF7, T47D, and MDA-MB-231 breast cancer cells without harming normal MCF10A and IMR-90 cells. The SRB assay showed that the 50% growth inhibition (GI50) in MCF7, T47D, and MDA-MB-231 breast cancer cells following treatment with antroquinonol D was 8.01, 3.57, and 25.08 mu M, respectively. D-Antroquinonol also inhibited the migratory ability of MDA-MB-231 breast cancer cells in wound healing and Transwell assays. In addition, antroquinonol D inhibited DNMT1 activity, as assessed by the DNMT1 methyltransferase activity assay. As the cofactor SAM level increased, the inhibitory effects of D-antroquinonol on DNMT1 gradually decreased. An enzyme activity assay and molecular modeling revealed that antroquinonol D is bound to the catalytic domain of DNMT1 and competes for the same binding pocket in the DNMT1 enzyme as the cofactor SAM, but does not compete for the binding pocket in the DNMT3B enzyme. An Illumina Methylation 450 K array-based assay and real-time PCR assay revealed that antroquinonol D decreased the methylation status and reactivated the expression of multiple TSGs in MDA-MB-231 breast cancer cells. In conclusion, we showed that antroquinonol D induces DNA demethylation and the recovery of multiple tumor suppressor genes, while inhibiting breast cancer growth and migration potential.
C1 [Wang, Sheng-Chao; Lee, Tzong-Huei; Chang, Man-Shan; Lin, Ruo-Kai] Taipei Med Univ, Grad Inst Pharmacognosy, TW-110 Taipei, Taiwan.
   [Lee, Tzong-Huei; Lin, Ruo-Kai] Taipei Med Univ, PhD Program Clin Drug Discovery Bot Herbs, TW-110 Taipei, Taiwan.
   [Hsu, Chun-Hua] Natl Taiwan Univ, Dept Agr Chem, TW-10617 Taipei, Taiwan.
   [Chang, Yu-Jia] Taipei Med Univ, Grad Inst Clin Med, Coll Med, TW-110 Taipei, Taiwan.
   [Wang, Yi-Ching] Natl Cheng Kung Univ, Dept Pharmacol, TW-701 Tainan, Taiwan.
   [Wang, Yi-Ching] Natl Cheng Kung Univ, Inst Basic Med Sci, TW-701 Tainan, Taiwan.
   [Ho, Yuan-Soon] Taipei Med Univ, Grad Inst Biomed Technol, TW-110 Taipei, Taiwan.
   [Wen, Wu-Che] Golden Biotechnol Corp, TW-110 Taipei, Taiwan.
   [Lin, Ruo-Kai] Taipei Med Univ, Master Program Clin Pharmacogen & Pharmacoprote, TW-110 Taipei, Taiwan.
C3 National Taiwan University; National Cheng Kung University; National
   Cheng Kung University
RP Lin, RK (通讯作者)，Taipei Med Univ, Grad Inst Pharmacognosy, 250 Wu Hsing St Taipei, TW-110 Taipei, Taiwan.
EM linruokai@tmu.edu.tw
RI Yi-Wen, Chen/G-7275-2016; HSU, CHUN-HUA/W-4554-2019; Wang,
   Yi-Ching/J-8702-2019
OI Wang, Yi-Ching/0000-0002-7694-2067; Lee, Tzong-Huei/0000-0001-8036-7563;
   Chang, Yu-Jia/0000-0003-3978-3244; HSU, CHUN-HUA/0000-0002-0008-7383
FU Taipei Medical University [TMU99-AE1-B21]; National Science Council
   (Republic of China) [NSC100-2320-B-038-002, NSC100-2320-B-038-014,
   NSC99-2119-M-002-010]
FX This work was supported in part by grant TMU99-AE1-B21 from the Taipei
   Medical University and grants NSC100-2320-B-038-002,
   NSC100-2320-B-038-014 and NSC99-2119-M-002-010 from the National Science
   Council (Republic of China).
CR Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Bignone PA, 2007, ONCOGENE, V26, P683, DOI 10.1038/sj.onc.1209827
   Castro M, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-86
   Costa E, 2007, EPIGENETICS-US, V2, P29
   De Marzo AM, 1999, CANCER RES, V59, P3855
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Esteller M, 2005, J PATHOL, V205, P172, DOI 10.1002/path.1707
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2
   Ganzinelli M, 2011, EUR J CANCER, V47, P1086, DOI 10.1016/j.ejca.2010.11.029
   Geethangili M., 2011, PLANTA MED, V2011
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   He XP, 2006, WORLD J GASTROENTERO, V12, P6652, DOI 10.3748/wjg.v12.i41.6652
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huey R, 2007, J COMPUT CHEM, V28, P1145, DOI 10.1002/jcc.20634
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Jamaluddin MS, 2007, CLIN CHEM LAB MED, V45, P1660, DOI 10.1515/CCLM.2007.350
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Lee TH, 2007, PLANTA MED, V73, P1412, DOI 10.1055/s-2007-990232
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lin RK, 2007, ANTI-CANCER DRUG, V18, P1157, DOI 10.1097/CAD.0b013e3282a215e9
   Lin RK, 2007, LUNG CANCER, V55, P205, DOI 10.1016/j.lungcan.2006.10.022
   Lübbert M, 2011, J CLIN ONCOL, V29, P1987, DOI 10.1200/JCO.2010.30.9245
   Mastroeni D, 2010, NEUROBIOL AGING, V31, P2025, DOI 10.1016/j.neurobiolaging.2008.12.005
   Medina-Franco JL, 2011, DRUG DISCOV TODAY, V16, P418, DOI 10.1016/j.drudis.2011.02.003
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   MONTO RW, 1969, CANCER RES, V29, P697
   Morris Garrett M, 2008, Curr Protoc Bioinformatics, VChapter 8, DOI 10.1002/0471250953.bi0814s24
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Nakamura N, 2004, J NAT PROD, V67, P46, DOI 10.1021/np030293k
   Nephew KP, 2003, CANCER LETT, V190, P125, DOI 10.1016/S0304-3835(02)00511-6
   Qiu XM, 2014, ONCOL REP, V31, P202, DOI 10.3892/or.2013.2848
   Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a
   Saito Y, 2003, INT J CANCER, V105, P527, DOI 10.1002/ijc.11127
   Sekido Y, 1998, BBA-REV CANCER, V1378, pF21, DOI 10.1016/S0304-419X(98)00010-9
   Stresemann C, 2006, CANCER RES, V66, P2794, DOI 10.1158/0008-5472.CAN-05-2821
   Stricker J, 2010, J BIOMECH, V43, P9, DOI 10.1016/j.jbiomech.2009.09.003
   Tokuoka M, 2010, INT J ONCOL, V37, P1105, DOI 10.3892/ijo_00000762
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Wei PL, 2012, ANN SURG ONCOL, V19, pS572, DOI 10.1245/s10434-011-2055-y
   Yamada S, 2007, ANTICANCER RES, V27, P2269
   Yu CC, 2012, J NUTR BIOCHEM, V23, P900, DOI 10.1016/j.jnutbio.2011.04.015
NR 42
TC 41
Z9 46
U1 0
U2 54
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD JUN 18
PY 2014
VL 62
IS 24
BP 5625
EP 5635
DI 10.1021/jf4056924
PG 11
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Agriculture; Chemistry; Food Science & Technology
GA AJ5KC
UT WOS:000337720100028
PM 24784321
DA 2025-01-12
ER

PT J
AU Chai, SY
   Smith, R
   Fitter, JT
   Mitchell, C
   Pan, X
   Ilicic, M
   Maiti, K
   Zakar, T
   Madsen, G
AF Chai, S. Y.
   Smith, R.
   Fitter, J. T.
   Mitchell, C.
   Pan, X.
   Ilicic, M.
   Maiti, K.
   Zakar, T.
   Madsen, G.
TI Increased progesterone receptor A expression in labouring human
   myometrium is associated with decreased promoter occupancy by the
   histone demethylase JARID1A
SO MOLECULAR HUMAN REPRODUCTION
LA English
DT Article
DE arturition; myometrium; progesterone receptors; epigenetics
ID BREAST-CANCER CELLS; H3 LYSINE 4; B PR-B; ENDOMETRIAL CANCER;
   GENE-EXPRESSION; EPIGENETIC REGULATION; METHYLATION PATTERNS; HUMAN
   PARTURITION; PREGNANT UTERUS; PROSTATE-CANCER
AB Progesterone regulates female reproductive function predominantly through two nuclear progesterone receptors (PRs), PR-A and PR-B. During human parturition myometrial PR expression is altered to favour PR-A, which activates pro-labour genes. We have previously identified histone H3 lysine 4 trimethylation (H3K4me3) as an activator of myometrial PR-A expression at labour. To further elucidate the mechanisms regulating PR isoform expression in the human uterus at labour, we have (i) determined the methylation profile of the cytosine-guanine dinucleotides (CpG) island in the promoter region of the PR gene and (ii) identified the histone-modifying enzymes that target the H3K4me3 mark at the PR promoters in term and preterm human myometrial tissues obtained before and after labour onset. Bisulphite sequencing showed that despite overall low levels of PR CpG island methylation, there was a significant decrease in methylated CpGs with labour in both preterm (P < 0.05) and term (P < 0.01) groups downstream of the PR-B transcription start site. This methylation change was not associated with altered PR-B expression, but may contribute to the increase in PR-A expression with labour. Chromatin immunoprecipitation revealed that the histone methyltransferase, SET and MYND domain-containing protein 3 (SMYD3), bound to the PR gene at significantly higher levels at the PR-A promoter compared with the PR-B promoter (P < 0.010), with no labour-associated changes observed. The H3K4 demethylase, Jumonji AT-rich interactive domain 1A (JARID1A), also bound to the PR-A, but not to the PR-B promoter prior to term labour, and decreased significantly at the onset of labour (P = 0.014), providing a mechanism for the previously reported increase in H3K4me3 level and PR-A expression with labour. Our studies suggest that epigenetic changes mediated by JARID1A, SMYD3 and DNA methylation may be responsible, at least in part, for the functional progesterone withdrawal that precipitates human labour.
C1 [Chai, S. Y.; Smith, R.; Fitter, J. T.; Mitchell, C.; Pan, X.; Ilicic, M.; Maiti, K.; Zakar, T.; Madsen, G.] Univ Newcastle, Hunter Med Res Inst, Mothers & Babies Res Ctr, Newcastle, NSW 2300, Australia.
C3 Hunter Medical Research Institute; University of Newcastle
RP Madsen, G (通讯作者)，Univ Newcastle, Hunter Med Res Inst, Mothers & Babies Res Ctr, Newcastle, NSW 2300, Australia.
EM gemma.madsen@newcastle.edu.au
RI Ilicic, Marina/ABC-2870-2021; Zakar, Tamas/G-7507-2013
OI Zakar, Tamas/0000-0002-1690-1159; Paul, Marina/0000-0002-8647-9213;
   Smith, Roger/0000-0003-4720-0280
FU National Health and Medical Research Council of Australia [631026]; John
   Hunter Hospital Charitable Trust; University of Newcastle, Australia
FX This study was supported by the National Health and Medical Research
   Council of Australia (Project Grant #631026), the John Hunter Hospital
   Charitable Trust and the University of Newcastle, Australia.
CR Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581
   AVRECH OM, 1991, FERTIL STERIL, V56, P385
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499
   Bisits AM, 2005, PLOS COMPUT BIOL, V1, P132, DOI 10.1371/journal.pcbi.0010019
   Chai SY, 2012, MOL HUM REPROD, V18, P401, DOI 10.1093/molehr/gas012
   Challis JRG, 2000, ENDOCR REV, V21, P514, DOI 10.1210/er.21.5.514
   CHWALISZ K, 1995, ANN NY ACAD SCI, V761, P202, DOI 10.1111/j.1749-6632.1995.tb31380.x
   Condon JC, 2003, P NATL ACAD SCI USA, V100, P9518, DOI 10.1073/pnas.1633616100
   CSAPO A, 1956, AM J ANAT, V98, P273, DOI 10.1002/aja.1000980206
   Eissenberg JC, 2010, DEV BIOL, V339, P240, DOI 10.1016/j.ydbio.2009.08.017
   Ferguson AT, 1998, ONCOGENE, V17, P577, DOI 10.1038/sj.onc.1201961
   Gaudet MM, 2009, CANCER EPIDEM BIOMAR, V18, P3036, DOI 10.1158/1055-9965.EPI-09-0678
   Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x
   Hervouet E, 2013, EPIGENETICS-US, V8, P237, DOI 10.4161/epi.23790
   KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x
   Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485
   Kim TH, 2005, NATURE, V436, P876, DOI 10.1038/nature03877
   KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304
   Liu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052703
   Liu ZJ, 2004, FEBS LETT, V567, P327, DOI 10.1016/j.febslet.2004.04.044
   Liu ZJ, 2003, LIFE SCI, V73, P1963, DOI 10.1016/S0024-3205(03)00544-7
   Madsen G, 2004, J CLIN ENDOCR METAB, V89, P1010, DOI 10.1210/jc.2003-031037
   Mc Cormack O, 2008, BREAST CANCER RES TR, V111, P45, DOI 10.1007/s10549-007-9757-7
   Merlino AA, 2007, J CLIN ENDOCR METAB, V92, P1927, DOI 10.1210/jc.2007-0077
   Mesiano S, 2004, J SOC GYNECOL INVEST, V11, P193, DOI 10.1016/j.jsgi.2003.12.004
   Mesiano S, 2002, J CLIN ENDOCR METAB, V87, P2924, DOI 10.1210/jc.87.6.2924
   Miao F, 2005, MOL CELL BIOL, V25, P4650, DOI 10.1128/MCB.25.11.4650-4661.2005
   Neilson JP, 2000, COCHRANE DB SYST REV, V4
   Nie JC, 2010, REPROD SCI, V17, P995, DOI 10.1177/1933719110377118
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Patsialou A, 2005, NUCLEIC ACIDS RES, V33, P66, DOI 10.1093/nar/gki145
   Pieber D, 2001, EUR J PHARMACOL, V427, P7, DOI 10.1016/S0014-2999(01)01189-X
   Ren Y, 2007, CANCER GENET CYTOGEN, V175, P107, DOI 10.1016/j.cancergencyto.2007.02.002
   Renthal NE, 2010, P NATL ACAD SCI USA, V107, P20828, DOI 10.1073/pnas.1008301107
   Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200
   Romero R, 2007, SEMIN REPROD MED, V25, P21, DOI 10.1055/s-2006-956773
   Sasaki M, 2001, CANCER RES, V61, P97
   Sasaki M, 2003, MOL CELL ENDOCRINOL, V202, P201, DOI 10.1016/S0303-7207(03)00084-4
   Sasaki M, 2002, J NATL CANCER I, V94, P384
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076
   Schübeler D, 2004, GENE DEV, V18, P1263, DOI 10.1101/gad.1198204
   Smith R, 2007, NEW ENGL J MED, V356, P271, DOI 10.1056/NEJMra061360
   Stratmann A, 2011, FEBS J, V278, P1458, DOI 10.1111/j.1742-4658.2011.08058.x
   Tan HQ, 2012, J CLIN ENDOCR METAB, V97, pE719, DOI 10.1210/jc.2011-3251
   Tu SJ, 2008, NAT STRUCT MOL BIOL, V15, P419, DOI 10.1038/nsmb.1400
   TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256
   VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244
   Wargon V, 2011, BREAST CANCER RES TR, V126, P319, DOI 10.1007/s10549-010-0908-x
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Williams KC, 2012, P NATL ACAD SCI USA, V109, P7529, DOI 10.1073/pnas.1200650109
   Wu Y, 2006, EPIGENETICS-US, V1, P106, DOI 10.4161/epi.1.2.2766
   Xiong YN, 2005, GYNECOL ONCOL, V99, P135, DOI 10.1016/j.ygyno.2005.05.035
   Yamamoto K, 2011, CANCER SCI, V102, P260, DOI 10.1111/j.1349-7006.2010.01752.x
   Yang J, 2009, ANN NY ACAD SCI, V1177, P185, DOI 10.1111/j.1749-6632.2009.05027.x
   Yokoyama A, 2011, COLD SH Q B, V76, P165, DOI 10.1101/sqb.2011.76.010736
   Zhou X, 2010, CANCER RES, V70, P4214, DOI 10.1158/0008-5472.CAN-09-2942
NR 63
TC 27
Z9 33
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 1460-2407
J9 MOL HUM REPROD
JI Mol. Hum. Reprod.
PD MAY
PY 2014
VL 20
IS 5
BP 442
EP 453
DI 10.1093/molehr/gau005
PG 12
WC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Developmental Biology; Obstetrics & Gynecology; Reproductive Biology
GA AH4IT
UT WOS:000336091300007
PM 24442343
OA Bronze
DA 2025-01-12
ER

PT J
AU Delgado-Cruzata, L
   Wu, HC
   Liao, YY
   Santella, RM
   Terry, MB
AF Delgado-Cruzata, Lissette
   Wu, Hui-Chen
   Liao, Yuyan
   Santella, Regina M.
   Terry, Mary Beth
TI Differences in DNA methylation by extent of breast cancer family history
   in unaffected women
SO EPIGENETICS
LA English
DT Article
DE breast cancer; family history; LINE-1; Sat2; DNA methylation; white
   blood cells
ID NEW-YORK SITE; BLOOD-CELL DNA; SISTERS DISCORDANT; REPAIR CAPACITY;
   HISPANIC WOMEN; NURSES HEALTH; RISK; POPULATION; REGISTRY;
   HYPOMETHYLATION
AB Breast cancer clusters within families but genetic factors identified to date explain only a portion of this clustering. Lower global DNA methylation in white blood cells (WBC) has been associated with increased breast cancer risk. We examined whether WBC DNA methylation varies by extent of breast cancer family history in unaffected women from high-risk breast cancer families. We evaluated DNA methylation levels in LINE-1, Alu and Sat2 in 333 cancer-free female family members of the New York site of the Breast Cancer Family Registry, the minority of which were known BRCA1 or BRCA2 mutation carriers. We used generalized estimated equation models to test for differences in DNA methylation levels by extent of their breast cancer family history after adjusting for age. All unaffected women had at least one sister affected with breast cancer. LINE-1 and Sat2 DNA methylation levels were lower in individuals with 3 or more (3+) first-degree relatives with breast cancer relative to women with only one first-degree relative. For LINE-1, Alu, and Sat2, having 3+ affected first-degree relatives was associated with a decrease of 23.4% (95%CI = -46.8%, 0.1%), 17.9% (95%CI = -39.5%, 3.7%) and 11.4% (95% CI = -20.3%, -2.5%), respectively, relative to individuals with only one affected first-degree relative, but the results were only statistically significant for Sat2. Individuals having an affected mother had 17.9% lower LINE-1 DNA methylation levels (95% CI = -28.8%, -7.1%) when compared with those not having an affected mother. No associations were observed for Alu or Sat2 by maternal breast cancer status. If replicated, these results indicate that lower global WBC DNA methylation levels in families with extensive cancer histories may be one explanation for the clustering of cancers in these families. Family clustering of disease may reflect epigenetic as well as genetic and shared environmental factors.
C1 [Delgado-Cruzata, Lissette; Wu, Hui-Chen; Santella, Regina M.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA.
   [Delgado-Cruzata, Lissette] CUNY, John Jay Coll Criminal Justice, Dept Sci, New York, NY 10021 USA.
   [Wu, Hui-Chen; Liao, Yuyan; Terry, Mary Beth] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
   [Santella, Regina M.; Terry, Mary Beth] Columbia Univ, Med Ctr, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
C3 Columbia University; City University of New York (CUNY) System; Columbia
   University; Columbia University
RP Terry, MB (通讯作者)，Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10027 USA.
EM mt146@columbia.edu
RI Wu, Lisa/JPA-4139-2023
OI Delgado-Cruzata, Lissette/0000-0002-2884-0234; Terry, Mary
   Beth/0000-0002-4106-5033
FU Breast Cancer Research Foundation; NIH [R01CA159868, R01094069];
   National Cancer Institute, National Institutes of Health [RFA-CA-06-503,
   U01 CA69398]
FX We would like to gratefully acknowledge all of the families that
   participate in the New York site of the BCFR. We also would like to
   gratefully acknowledge Ann Johnston Cloud, MPH; Ashley Tsai, MPH, Julie
   Flom, MPH; Jennifer Ferris, MPH; and Irina Gurvich for their dedication
   to the BCFR and for their valuable input and discussion in the
   presentation of these results. This work was supported by an award from
   the Breast Cancer Research Foundation and NIH grants, R01CA159868,
   R01094069, and by the National Cancer Institute, National Institutes of
   Health under RFA-CA-06-503 and through cooperative agreements with
   members of the BCFR and Principal Investigators, including Columbia
   University (U01 CA69398). The content of this manuscript does not
   necessarily reflect the views or policies of the National Cancer
   Institute or any of the collaborating centers in the BCFR, nor does
   mention of trade names, commercial products, or organizations imply
   endorsement by the US Government or the BCFR.
CR Beral V, 2001, LANCET, V358, P1389, DOI 10.1016/S0140-6736(01)06524-2
   Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877
   BONDY ML, 1992, CANCER CAUSE CONTROL, V3, P377, DOI 10.1007/BF00146892
   Boyd Norman F., 2009, V472, P343, DOI 10.1007/978-1-60327-492-0_15
   BUCHANAN AV, 1985, JNCI-J NATL CANCER I, V74, P1199
   Cash HL, 2012, INT J CANCER, V130, P1151, DOI 10.1002/ijc.26098
   Choi JY, 2009, CARCINOGENESIS, V30, P1889, DOI 10.1093/carcin/bgp143
   COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338
   Colditz GA, 2012, BREAST CANCER RES TR, V133, P1097, DOI 10.1007/s10549-012-1985-9
   Delgado-Cruzata L, 2012, EPIGENETICS-US, V7, P868, DOI 10.4161/epi.20830
   Deroo LA, 2013, CARCINOGENE IN PRESS
   Gao Y, 2012, J CANC, V106, P585, DOI 10.1038/bjc.2011.56222173668
   Hou LF, 2010, INT J CANCER, V127, P1866, DOI 10.1002/ijc.25190
   Hsiung DT, 2007, CANCER EPIDEM BIOMAR, V16, P108, DOI 10.1158/1055-9965.EPI-06-0636
   Kennedy DO, 2005, JNCI-J NATL CANCER I, V97, P127, DOI 10.1093/jnci/dji013
   Kile ML, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013730
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Li R, 2001, CANCER CAUSE CONTROL, V12, P747, DOI 10.1023/A:1011285205870
   Lynch HT, 2012, ANN SURG ONCOL, V19, P1723, DOI 10.1245/s10434-012-2256-z
   Michailidou K, 2013, NAT GENET, V45, P353, DOI 10.1038/ng.2563
   Mirabello L, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-77
   Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423
   Ogino S, 2013, JNCI-J NATL CANCER I, V105, P130, DOI 10.1093/jnci/djs482
   Risendal B, 2008, CANCER CAUSE CONTROL, V19, P1349, DOI 10.1007/s10552-008-9206-x
   Rossner P, 2007, J CELL MOL MED, V11, P1138, DOI 10.1111/j.1582-4934.2007.00097.x
   Shen J, 2006, CANCER EPIDEM BIOMAR, V15, P1614, DOI 10.1158/1055-9965.EPI-06-0218
   Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500
   Weisenberger DJ, 2005, NUCLEIC ACIDS RES, V33, P6823, DOI 10.1093/nar/gki987
   Wilhelm CS, 2010, CLIN CANCER RES, V16, P1682, DOI 10.1158/1078-0432.CCR-09-2983
   Wu HC, 2012, CARCINOGENESIS, V33, P1946, DOI 10.1093/carcin/bgs201
   Wu HC, 2011, EPIGENETICS-US, V6, P29, DOI 10.4161/epi.6.1.13393
   Xu XR, 2012, FASEB J, V26, P2657, DOI 10.1096/fj.11-197251
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
   Zhang FF, 2011, J NUTR, V141, P1165, DOI 10.3945/jn.110.134536
   Zipprich J, 2009, CANCER RES, V69, P2966, DOI 10.1158/0008-5472.CAN-08-3418
NR 35
TC 18
Z9 19
U1 0
U2 7
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB 1
PY 2014
VL 9
IS 2
BP 243
EP 248
DI 10.4161/epi.26880
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AB6EK
UT WOS:000331880200008
PM 24172832
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Johnson, KC
   Koestler, DC
   Cheng, C
   Christensen, BC
AF Johnson, Kevin C.
   Koestler, Devin C.
   Cheng, Chao
   Christensen, Brock C.
TI Age-related DNA methylation in normal breast tissue and its relationship
   with invasive breast tumor methylation
SO EPIGENETICS
LA English
DT Article
DE Breast; aging; methylation; normal; array; cancer
ID PROMOTER HYPERMETHYLATION; EPIGENETIC CHANGES; TARGET GENES; CANCER;
   GENOME; EXPRESSION; EPITHELIUM; POLYCOMB; INSULIN; CELLS
AB Age is a key risk factor for breast cancer and epigenetic alterations may contribute to age-related increases in breast cancer risk, though the relation of age-related methylation in normal breast tissues with altered methylation in breast tumors is unclear. We investigated the relation of age with DNA methylation in normal breast tissues genome-wide using two data sets from the Gene Expression Omnibus (GEO) database (GSE32393 and GSE31979). We validated our observations in an independent set of normal breast tissues, examined age-related methylation in normal breast for enrichment of genomic features, and compared age-related methylation in normal tissue with methylation alterations in breast tumors. Between the two array-based methylation data sets, there were 204 CpG loci with significant (P < 0.05) and consistent age-related methylation, 97% of which were increases in methylation. Our validation sets confirmed the direction of age-related DNA methylation changes in all measured regions. Among the 204 age-related CpG loci, we observed a significant enrichment for CpG islands (P = 8.7E-6) and polycomb group protein target genes (P = 0.03). In addition, 24 of the 204 CpGs with age-related methylation in normal breast were significantly differentially methylated between normal and breast tumor tissues. We identified consistent age-related methylation changes in normal breast tissue that are further altered in breast tumors and may represent early events contributing to breast carcinogenesis. This work identifies age-related methylation in normal breast tissue and begins to deconstruct the contribution of aging to epigenetic alterations present in breast tumors.
C1 [Johnson, Kevin C.; Koestler, Devin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Sect Biostat & Epidemiol, Dept Community & Family Med, Hanover, NH 03755 USA.
   [Johnson, Kevin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
   [Cheng, Chao] Geisel Sch Med Dartmouth, Dept Genet, Hanover, NH USA.
C3 Dartmouth College; Dartmouth College; Dartmouth College
RP Christensen, BC (通讯作者)，Geisel Sch Med Dartmouth, Sect Biostat & Epidemiol, Dept Community & Family Med, Hanover, NH 03755 USA.
EM Brock.C.Christensen@dartmouth.edu
RI Christensen, Brock/B-8460-2009; Cheng, Chao-Yang/AAG-9811-2019;
   Koestler, Devin/D-7902-2015
OI Koestler, Devin/0000-0002-0598-0146
FU NIH [P20GM104416, R25CA134286]; American Cancer Society [IRG-82-003-27]
FX This work was supported by NIH grants P20GM104416 (BCC), R25CA134286
   (DCK), and American Cancer Society Research Grant IRG-82-003-27 (CC).
CR Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Benbassat CA, 1997, J CLIN ENDOCR METAB, V82, P1484, DOI 10.1210/jc.82.5.1484
   Benz CC, 2008, NAT REV CANCER, V8, P875, DOI 10.1038/nrc2522
   Boberg DR, 2013, CHEM-BIOL INTERACT, V203, P344, DOI 10.1016/j.cbi.2012.09.020
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Brooksby B, 2006, P NATL ACAD SCI USA, V103, P8828, DOI 10.1073/pnas.0509636103
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Christensen BC, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001043
   Christensen BC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000602
   Edwards BK, 2002, CANCER-AM CANCER SOC, V94, P2766, DOI 10.1002/cncr.10593
   Euhus DM, 2008, CANCER EPIDEM BIOMAR, V17, P1051, DOI 10.1158/1055-9965.EPI-07-2582
   Fackler MJ, 2009, CLIN CANCER RES, V15, P3802, DOI 10.1158/1078-0432.CCR-08-1981
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Hannum G, 2013, MOL CELL, V49, P359, DOI 10.1016/j.molcel.2012.10.016
   Holm K, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2590
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Issa JP, 2003, CLIN IMMUNOL, V109, P103, DOI 10.1016/S1521-6616(03)00203-1
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Junnila RK, 2013, NAT REV ENDOCRINOL, V9, P366, DOI 10.1038/nrendo.2013.67
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kwabi-Addo B, 2007, CLIN CANCER RES, V13, P3796, DOI 10.1158/1078-0432.CCR-07-0085
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Li Z, 2010, MED ONCOL, V27, P998, DOI 10.1007/s12032-009-9323-8
   Liang P, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-231
   Maegawa S, 2010, GENOME RES, V20, P332, DOI 10.1101/gr.096826.109
   Menschikowski M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-576
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Rakyan VK, 2010, GENOME RES, V20, P434, DOI 10.1101/gr.103101.109
   Riener MO, 2008, HUM PATHOL, V39, P1621, DOI 10.1016/j.humpath.2008.02.021
   ROCKE DM, 1993, TECHNOMETRICS, V35, P72, DOI 10.2307/1269291
   Roh JL, 2013, CLIN CANCER RES, V19, P2528, DOI 10.1158/1078-0432.CCR-12-3047
   Schernhammer ES, 2010, GUT, V59, P794, DOI 10.1136/gut.2009.183707
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Shibata-Minoshima F, 2012, INT J ONCOL, V40, P93, DOI 10.3892/ijo.2011.1173
   Squazzo SL, 2006, GENOME RES, V16, P890, DOI 10.1101/gr.5306606
   Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109
   Tlsty TD, 2004, J MAMMARY GLAND BIOL, V9, P263, DOI 10.1023/B:JOMG.0000048773.95897.5f
   Tomii K, 2007, INT J CANCER, V120, P566, DOI 10.1002/ijc.22341
   Waters DL, 2003, J GERONTOL A-BIOL, V58, P648
   Widschwendter M, 2002, ONCOGENE, V21, P5462, DOI 10.1038/sj.onc.1205606
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Zeng L, 2013, EXP CELL RES, V319, P2282, DOI 10.1016/j.yexcr.2013.06.011
   Zhuang J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002517
NR 48
TC 54
Z9 61
U1 0
U2 13
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD FEB 1
PY 2014
VL 9
IS 2
BP 268
EP 275
DI 10.4161/epi.27015
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AB6EK
UT WOS:000331880200011
PM 24196486
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Uimonen, K
   Merikallio, H
   Pääkkö, P
   Harju, T
   Mannermaa, A
   Palvimo, J
   Kosma, VM
   Soini, Y
AF Uimonen, Katri
   Merikallio, Heta
   Paakko, Paavo
   Harju, Terttu
   Mannermaa, Arto
   Palvimo, Jorma
   Kosma, Veli-Matti
   Soini, Ylermi
TI GASC1 expression in lung carcinoma is associated with smoking and
   prognosis of squamous cell carcinoma
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Article
DE GASC1; Epigenetics; Histone demethylase; Lung cancer
ID HISTONE LYSINE METHYLATION; BREAST-CANCER; DEMETHYLASES; GENE; FAMILY
AB GASC1 (gene amplified in squamous cell carcinoma 1) encodes a nuclear protein that epigenetically catalyses the lysine demethylation of histones.
   We investigated the expression of GASC1 in different histological subtypes of lung cancer (n=289). Percentage value of GASC1 immunohistochemical expression was evaluated separately in the nuclei and cytoplasms of epithelial cancer cells. The results were compared with clinicopathologic factors and the smoking history of the patients.
   In lung tumor cells, 38% of nuclei and 54% of the cytoplasms stained positive for GASC1. Adenocarcinomas expressed more GASC1 nuclear (p=0.00011) and cytoplasmic (p=0.00074) positivity than squamous cell carcinoma. Smokers displayed less nuclear and cytoplasmic GASC1 expression than non-smokers (p=0.028 and p=0.036, respectively). Similarly, patients with more cytoplasmic positive staining had fewer pack years (p=0.043). Nuclear GASC1 expression had an impairing effect on survival when all histological lung cancer types were analysed together (p=0.039) and separately in squamous cell lung carcinoma (p=0.016).
   The results reveal that GASC1 expression is higher in adenocarcinoma than squamous cell carcinoma. Smoking decreases GASC1 expression in tumor cells, indicating that tobacco smoke may influence the methylation of histone 3 lysine residues in lung cancer. Nonetheless, nuclear GASC1 predicts a poor prognosis, especially in squamous cell carcinoma.
C1 [Uimonen, Katri; Mannermaa, Arto; Kosma, Veli-Matti; Soini, Ylermi] Univ Eastern Finland, Dept Clin Pathol & Forens Med, Inst Clin Med, FI-70211 Kuopio, Finland.
   [Uimonen, Katri; Mannermaa, Arto; Palvimo, Jorma; Kosma, Veli-Matti; Soini, Ylermi] Canc Ctr Eastern Finland, Kuopio, Finland.
   [Uimonen, Katri; Mannermaa, Arto; Kosma, Veli-Matti; Soini, Ylermi] Kuopio Univ Hosp, Dept Clin Pathol, Imaging Ctr, SF-70210 Kuopio, Finland.
   [Merikallio, Heta; Harju, Terttu] Univ Oulu, Dept Internal Med, Inst Clin Med, Resp Unit,Ctr Excellence Res, SF-90220 Oulu, Finland.
   [Paakko, Paavo] Oulu Univ Hosp, Dept Pathol, Oulu, Finland.
   [Palvimo, Jorma] Univ Eastern Finland, Inst Biomed, FI-70211 Kuopio, Finland.
C3 University of Eastern Finland; Kuopio University Hospital; University of
   Eastern Finland; University of Oulu; University of Oulu; University of
   Eastern Finland
RP Soini, Y (通讯作者)，Univ Eastern Finland, Canc Ctr Eastern Finland, Dept Pathol & Forens Med, Sch Med, POB 1627, FI-70211 Kuopio, Finland.
EM ylermi.soini@uef.fi
RI Merikallio, Heta/GRY-5723-2022
OI Palvimo, Jorma/0000-0003-2373-0578
FU Finnish Anti-Tuberculous Association; Finnish Cancer Society; Cancer
   Center of Eastern Finland; Finnish Academy; KuH and VTR EVO
FX The financial support of Finnish Anti-Tuberculous Association, Finnish
   Cancer Society, Cancer Center of Eastern Finland, Finnish Academy and
   KuH and VTR EVO funding is appreciated.
CR Broeks A, 2011, HUM MOL GENET, V20, P3289, DOI 10.1093/hmg/ddr228
   Canova C, 2009, CANCER RES, V69, P2956, DOI 10.1158/0008-5472.CAN-08-2604
   Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837
   Ishimura A, 2009, BIOCHEM BIOPH RES CO, V389, P366, DOI 10.1016/j.bbrc.2009.08.155
   Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Liu G, 2009, ONCOGENE, V28, P4491, DOI 10.1038/onc.2009.297
   Mitsudomi Tetsuya, 2006, Int J Clin Oncol, V11, P190, DOI 10.1007/s10147-006-0583-4
   Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336
   Pillai RN, 2012, CURR ONCOL REP, V14, P105, DOI 10.1007/s11912-012-0213-4
   Scoccianti C, 2012, EUR RESPIR J, V40, P177, DOI 10.1183/09031936.00097311
   Shi Y, 2007, MOL CELL, V25, P1, DOI 10.1016/j.molcel.2006.12.010
   Shin S, 2007, BIOCHEM BIOPH RES CO, V353, P973, DOI 10.1016/j.bbrc.2006.12.147
   Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101
   Suikki HE, 2010, PROSTATE, V70, P889, DOI 10.1002/pros.21123
   Travis W.D., 2004, TUMOURS LUNG PLEURA
   Wang JL, 2010, BIOL REPROD, V82, P105, DOI 10.1095/biolreprod.109.078055
   Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028
   Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546
   Yang ZQ, 2000, CANCER RES, V60, P4735
NR 20
TC 15
Z9 15
U1 0
U2 6
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
EI 1699-5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD JUN
PY 2014
VL 29
IS 6
BP 797
EP 804
PG 8
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA AH3TX
UT WOS:000336049600012
PM 24371038
DA 2025-01-12
ER

PT J
AU Li, XC
   Xu, Z
   Du, W
   Zhang, ZF
   Wei, YL
   Wang, H
   Zhu, ZY
   Qin, LT
   Wang, L
   Niu, Q
   Zhao, XL
   Girard, L
   Gong, YM
   Ma, ZY
   Sun, BC
   Yao, Z
   Minna, JD
   Terada, LS
   Liu, Z
AF Li, Xichuan
   Xu, Zhao
   Du, Wei
   Zhang, Zhenfa
   Wei, Yiliang
   Wang, Hao
   Zhu, Zhiyan
   Qin, Litao
   Wang, Lin
   Niu, Qing
   Zhao, Xiulan
   Girard, Luc
   Gong, Yimei
   Ma, Zhenyi
   Sun, Baocun
   Yao, Zhi
   Minna, John D.
   Terada, Lance S.
   Liu, Zhe
TI Aiolos Promotes Anchorage Independence by Silencing p66<SUP>Shc</SUP>
   Transcription in Cancer Cells
SO CANCER CELL
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; DNA-BINDING PROTEINS; E-CADHERIN;
   GENE-EXPRESSION; BREAST-CANCER; TUMOR-GROWTH; LUNG-CANCER; IKAROS;
   METASTASIS; ANOIKIS
AB Anchorage of tissue cells to their physical environment is an obligate requirement for survival that is lost in mature hematopoietic and in transformed epithelial cells. Here we find that a lymphocyte lineage-restricted transcription factor, Aiolos, is frequently expressed in lung cancers and predicts markedly reduced patient survival. Aiolos decreases expression of a large set of adhesion-related genes, disrupting cell-cell and cell-matrix interactions. Aiolos also reconfigures chromatin structure within the SHC1 gene, causing isoform-specific silencing of the anchorage reporter p66(Shc) and blocking anoikis in vitro and in vivo. In lung cancer tissues and single cells, p66(Shc)expression inversely correlates with that of Aiolos. Together, these findings suggest that Aiolos functions as an epigenetic driver of lymphocyte mimicry in metastatic epithelial cancers.
C1 [Li, Xichuan; Xu, Zhao; Du, Wei; Wei, Yiliang; Wang, Hao; Zhu, Zhiyan; Qin, Litao; Wang, Lin; Niu, Qing; Ma, Zhenyi; Yao, Zhi; Liu, Zhe] Tianjin Med Univ, Collaborat Innovat Ctr Tianjin Med Epigenet 2011, Tianjin Key Lab Med Epigenet, Dept Immunol Biochem & Mol Biol, Tianjin 300070, Peoples R China.
   [Yao, Zhi; Liu, Zhe] Tianjin Med Univ, Minist Educ, Key Lab Immune Microenvironm & Dis, Tianjin 300070, Peoples R China.
   [Li, Xichuan; Xu, Zhao; Du, Wei; Wei, Yiliang; Wang, Hao; Zhu, Zhiyan; Qin, Litao; Wang, Lin; Niu, Qing; Liu, Zhe] Tianjin Med Univ, Tianjin Res Ctr Basic Med Sci, Lab Epigenet & Tumorigenesis, Tianjin 300070, Peoples R China.
   [Zhao, Xiulan; Sun, Baocun] Tianjin Med Univ, Dept Pathol, Tianjin 300070, Peoples R China.
   [Zhang, Zhenfa] Tianjin Med Univ, Canc Inst & Hosp, Dept Lung Canc Ctr, Tianjin 300060, Peoples R China.
   [Xu, Zhao] Tianjin Med Univ, Hosp 2, Tianjin Inst Cardiol, Tianjin 300211, Peoples R China.
   [Girard, Luc; Minna, John D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA.
   [Gong, Yimei; Terada, Lance S.] Univ Texas SW Med Ctr Dallas, Div Pulm & Crit Care, Dept Internal Med, Dallas, TX 75390 USA.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University; Tianjin Medical University; Tianjin Medical University;
   Tianjin Medical University; University of Texas System; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Southwestern Medical Center Dallas
RP Terada, LS (通讯作者)，Univ Texas SW Med Ctr Dallas, Div Pulm & Crit Care, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM lance.terada@utsouthwestern.edu; zheliu@tmu.edu.cn
RI Minna, John/AAB-1036-2022; Wei, Yiliang/KYO-9121-2024; Du,
   Wei/HZK-9796-2023; Qin, Litao/JCE-3084-2023; Zhao,
   Xiaoshan/GPF-7929-2022
OI Niu, Qing/0000-0002-0410-2616; Terada, Lance/0000-0001-7441-9734
FU Ministry of Science and Technology of China [2014CB910100,
   2009CB918903]; National Natural Science Foundation of China [31371295,
   91019012, 31071128, 81372307, 81071730, 81101546]; Tianjin Municipal
   Science and Technology Commission [11JCZDJC19000, 11JCZDJC18700,
   13JCQNJC10300]; specialized Fund for the Doctoral Program of Higher
   Education [20121202110001]; China Postdoctoral Science Foundation
   [20110490792]; James M. Collins for Biomedical Research; NIH
   [R01-HL067256, R01-HL061897, P50-CA70907]
FX This work was supported by the Ministry of Science and Technology of
   China (grants 2014CB910100 to Z.L. and 2009CB918903 to Z.Y.), the
   National Natural Science Foundation of China (grants 31371295, 91019012,
   and 31071128 to Z.L.; 81372307 and 81071730 to Z.M.; and 81101546 to X.
   L.), the Tianjin Municipal Science and Technology Commission (grants
   11JCZDJC19000 to Z.L., 11JCZDJC18700 to Z.M., and 13JCQNJC10300 to X.
   L.), the specialized Fund for the Doctoral Program of Higher Education
   (grant 20121202110001 to Z.L.), the China Postdoctoral Science
   Foundation (grant 20110490792 to X. L.), and the James M. Collins for
   Biomedical Research and the NIH (grants R01-HL067256 and R01-HL061897 to
   L. S. T. and P50-CA70907 to J.D.M.).
CR Antica M, 2008, BLOOD, V111, P3296, DOI 10.1182/blood-2007-12-125682
   Billot K, 2011, BLOOD, V117, P1917, DOI 10.1182/blood-2010-09-307140
   Billot K, 2010, LEUKEMIA RES, V34, P289, DOI 10.1016/j.leukres.2009.05.016
   Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558
   Caballero R, 2007, J CELL SCI, V120, P2619, DOI 10.1242/jcs.007344
   Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2
   Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013
   Duhamel M, 2008, BLOOD, V111, P3225, DOI 10.1182/blood-2007-09-113191
   Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6
   Fischer B, 2008, REV RECENT CLIN TRIA, V3, P40, DOI 10.2174/157488708783330503
   FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619
   Frisch SM, 2013, J CELL SCI, V126, P21, DOI 10.1242/jcs.120907
   Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011
   Glodek AM, 2003, J EXP MED, V197, P461, DOI 10.1084/jem.20021477
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Holmfeldt L, 2013, NAT GENET, V45, P242, DOI 10.1038/ng.2532
   Hystad ME, 2007, J IMMUNOL, V179, P3662, DOI 10.4049/jimmunol.179.6.3662
   Jackman DM, 2005, LANCET, V366, P1385, DOI 10.1016/S0140-6736(05)67569-1
   Jung MJ, 2013, ONCOGENE, V32, P209, DOI 10.1038/onc.2012.37
   Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139
   Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5
   Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090
   Kumar S, 2011, MOL CELL BIOL, V31, P4036, DOI 10.1128/MCB.01342-10
   Ma SB, 2008, BLOOD, V111, P1396, DOI 10.1182/blood-2007-08-110106
   Ma Z, 2010, ONCOGENE, V29, P5559, DOI 10.1038/onc.2010.326
   Ma Z, 2007, J CELL BIOL, V179, P23, DOI 10.1083/jcb.200706097
   Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365
   Mandal M, 2009, NAT IMMUNOL, V10, P1110, DOI 10.1038/ni.1785
   Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886
   Morgan B, 1997, EMBO J, V16, P2004, DOI 10.1093/emboj/16.8.2004
   Müller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016
   Niebuhr B, 2013, BLOOD, V122, P413, DOI 10.1182/blood-2013-01-480244
   Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938
   Osborne JK, 2013, P NATL ACAD SCI USA, V110, P6524, DOI 10.1073/pnas.1303932110
   PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L
   Quintana FJ, 2012, NAT IMMUNOL, V13, P770, DOI 10.1038/ni.2363
   Rada-Iglesias A, 2011, NATURE, V470, P279, DOI 10.1038/nature09692
   Reynaud D, 2008, NAT IMMUNOL, V9, P927, DOI 10.1038/ni.1626
   Romero F, 1999, EMBO J, V18, P3419, DOI 10.1093/emboj/18.12.3419
   Sung YM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007445
   Thompson EC, 2007, IMMUNITY, V26, P335, DOI 10.1016/j.immuni.2007.02.010
   Timp W, 2013, NAT REV CANCER, V13, P497, DOI 10.1038/nrc3486
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Ventura A, 2002, J BIOL CHEM, V277, P22370, DOI 10.1074/jbc.M200280200
   Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8
   Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6
   Xi G, 2010, J BIOL CHEM, V285, P6937, DOI 10.1074/jbc.M109.069872
NR 49
TC 56
Z9 68
U1 0
U2 45
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD MAY 12
PY 2014
VL 25
IS 5
BP 575
EP 589
DI 10.1016/j.ccr.2014.03.020
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AH3LS
UT WOS:000336025700007
PM 24823637
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Rhie, SK
   Hazelett, DJ
   Coetzee, SG
   Yan, CL
   Noushmehr, H
   Coetzee, GA
AF Rhie, Suhn Kyong
   Hazelett, Dennis J.
   Coetzee, Simon G.
   Yan, Chunli
   Noushmehr, Houtan
   Coetzee, Gerhard A.
TI Nucleosome positioning and histone modifications define relationships
   between regulatory elements and nearby gene expression in breast
   epithelial cells
SO BMC GENOMICS
LA English
DT Article
DE Breast epithelial cells; Epigenetics; Nucleosomes; Enhancers; Promoters;
   Transcription factors; Genes
ID TRANSCRIPTION FACTOR-BINDING; P-CADHERIN; CANCER; ENHANCER; REVEALS;
   P63; INVASION; HETEROCHROMATIN; TRANSITIONS; SUPPRESSOR
AB Background: The precise nature of how cell type specific chromatin structures at enhancer sites affect gene expression is largely unknown. Here we identified cell type specific enhancers coupled with gene expression in two different types of breast epithelial cells, HMEC (normal breast epithelial cells) and MDAMB231 (triple negative breast cancer cell line).
   Results: Enhancers were defined by modified neighboring histones [using chromatin immunoprecipitation followed by sequencing (ChIP-seq)] and nucleosome depletion [using formaldehyde-assisted isolation of regulatory elements followed by sequencing (FAIRE-seq)]. Histone modifications at enhancers were related to the expression levels of nearby genes up to 750 kb away. These expression levels were correlated with enhancer status (poised or active), defined by surrounding histone marks. Furthermore, about fifty percent of poised and active enhancers contained nucleosome-depleted regions. We also identified response element motifs enriched at these enhancer sites that revealed key transcription factors (e.g. TP63) likely involved in regulating breast epithelial enhancer-mediated gene expression. By utilizing expression data, potential target genes of more than 600 active enhancers were identified. These genes were involved in proteolysis, epidermis development, cell adhesion, mitosis, cell cycle, and DNA replication.
   Conclusions: These findings facilitate the understanding of epigenetic regulation specifically, such as the relationships between regulatory elements and gene expression and generally, how breast epithelial cellular phenotypes are determined by cell type specific enhancers.
C1 [Rhie, Suhn Kyong; Hazelett, Dennis J.; Coetzee, Simon G.; Yan, Chunli; Noushmehr, Houtan; Coetzee, Gerhard A.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.
   [Rhie, Suhn Kyong; Hazelett, Dennis J.; Coetzee, Simon G.; Yan, Chunli; Noushmehr, Houtan; Coetzee, Gerhard A.] Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90089 USA.
   [Coetzee, Gerhard A.] Univ So Calif, Keck Sch Med, Dept Urol, Los Angeles, CA 90089 USA.
   [Coetzee, Gerhard A.] Keck Sch Med, USC Norris Canc Ctr, Los Angeles, CA 90089 USA.
C3 University of Southern California; University of Southern California;
   University of Southern California; University of Southern California
RP Coetzee, GA (通讯作者)，Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA.
EM coetzee@usc.edu
RI Coetzee, Gerhard/AAG-8439-2019; Coetzee, Simon Gert/C-1218-2014;
   Noushmehr, Houtan/C-9692-2013
OI Coetzee, Simon Gert/0000-0003-4267-5930; Noushmehr,
   Houtan/0000-0003-4051-8114; Coetzee, Gerhard/0000-0001-8820-8364;
   Hazelett, Dennis/0000-0003-0749-9935; Rhie, Suhn/0000-0002-5522-5296
FU National Institutes of Health [R01 CA136924, T32CA009320]; Genetic
   Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer
   Post-GWAS Initiative
FX The authors thank Charles Nicolet and Zack Ramjan at the USC Epigenome
   Center for library construction and high throughput sequencing. This
   research was supported by the National Institutes of Health [R01
   CA136924 to GAC, T32CA009320 to HN]. The scientific development and
   funding of this project were in part supported by the Genetic
   Associations and Mechanisms in Oncology (GAME-ON): a NCI Cancer
   Post-GWAS Initiative.
CR Arnold CD, 2013, SCIENCE, V339, P1074, DOI 10.1126/science.1232542
   Bantignies F, 2011, TRENDS GENET, V27, P454, DOI 10.1016/j.tig.2011.06.008
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Bedell VM, 2012, NATURE, V491, P114, DOI 10.1038/nature11537
   Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x
   Bragdon B, 2011, CELL SIGNAL, V23, P609, DOI 10.1016/j.cellsig.2010.10.003
   Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688
   Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941
   Chepelev I, 2012, CELL RES, V22, P490, DOI 10.1038/cr.2012.15
   Cho KW, 2006, P NATL ACAD SCI USA, V103, P16788, DOI 10.1073/pnas.0604645103
   Christopher SA, 2002, CANCER RES, V62, P6639
   Collins FS, 2003, NATURE, V422, P835, DOI 10.1038/nature01626
   Creyghton MP, 2010, P NATL ACAD SCI USA, V107, P21931, DOI 10.1073/pnas.1016071107
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   D'Amato NC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045684
   De Rosa L, 2009, J BIOL CHEM, V284, P30574, DOI 10.1074/jbc.M109.049619
   Dekker J, 2006, NAT METHODS, V3, P17, DOI 10.1038/NMETH823
   Ecker JR, 2012, NATURE, V489, P52, DOI 10.1038/489052a
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Eskiw CH, 2010, COLD SH Q B, V75, P501, DOI 10.1101/sqb.2010.75.046
   Fejes AP, 2008, BIOINFORMATICS, V24, P1729, DOI 10.1093/bioinformatics/btn305
   Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Giresi PG, 2007, GENOME RES, V17, P877, DOI 10.1101/gr.5533506
   Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064
   Grewal SIS, 2007, NAT REV GENET, V8, P35, DOI 10.1038/nrg2008
   Guo D, 2012, MOL CELL BIOCHEM, V363, P179, DOI 10.1007/s11010-011-1170-1
   Guttman M, 2010, NAT BIOTECHNOL, V28, P503, DOI 10.1038/nbt.1633
   Ha GH, 2007, CANCER RES, V67, P7155, DOI 10.1158/0008-5472.CAN-06-3392
   Hah N, 2013, GENOME RES, V23, P1210, DOI 10.1101/gr.152306.112
   He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hogan GJ, 2006, PLOS GENET, V2, P1433, DOI 10.1371/journal.pgen.0020158
   Huisinga KL, 2006, CHROMOSOMA, V115, P110, DOI 10.1007/s00412-006-0052-x
   Huntley RP, 2009, DATABASE-OXFORD, DOI 10.1093/database/bap010
   Hutchins JRA, 2010, SCIENCE, V328, P593, DOI 10.1126/science.1181348
   Ivshina AV, 2006, CANCER RES, V66, P10292, DOI 10.1158/0008-5472.CAN-05-4414
   Jia L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000597
   Kalhor R, 2012, NAT BIOTECHNOL, V30, P90, DOI 10.1038/nbt.2057
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Malin J, 2013, NUCLEIC ACIDS RES, V41, P6828, DOI 10.1093/nar/gkt374
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143
   Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888
   Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2
   Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212
   Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957
   Ostrander JH, 2010, CANCER RES, V70, P4759, DOI 10.1158/0008-5472.CAN-09-2572
   PALACIOS J, 1995, AM J PATHOL, V146, P605
   Paredes J, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1774
   Peric-Hupkes D, 2010, COLD SH Q B, V75, P517, DOI 10.1101/sqb.2010.75.014
   Peter AK, 2009, HUM MOL GENET, V18, P318, DOI 10.1093/hmg/ddn358
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Portales-Casamar E, 2010, NUCLEIC ACIDS RES, V38, pD105, DOI 10.1093/nar/gkp950
   Prat A, 2009, NAT MED, V15, P842, DOI 10.1038/nm0809-842
   RASBRIDGE SA, 1993, J PATHOL, V169, P245, DOI 10.1002/path.1711690211
   Rhie SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063925
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rochefort H, 2003, ENDOCR-RELAT CANCER, V10, P261, DOI 10.1677/erc.0.0100261
   Sathyanarayana UG, 2003, CLIN CANCER RES, V9, P6389
   Sheffield NC, 2013, GENOME RES, V23, P777, DOI 10.1101/gr.152140.112
   SHIMOYAMA Y, 1991, CANCER RES, V51, P2185
   Simon JM, 2014, GENOME RES, V24, P241, DOI 10.1101/gr.158253.113
   Song LY, 2011, GENOME RES, V21, P1757, DOI 10.1101/gr.121541.111
   Taberlay PC, 2011, CELL, V147, P1283, DOI 10.1016/j.cell.2011.10.040
   Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P
   TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0
   Terrinoni A, 2013, P NATL ACAD SCI USA, V110, P7300, DOI 10.1073/pnas.1214498110
   Ting MC, 2012, DIS MODEL MECH, V5, P366, DOI 10.1242/dmm.008458
   van Berkum Nynke L, 2010, J Vis Exp, DOI 10.3791/1869
   Wang XH, 2002, J UNIV SCI TECHNOL B, V9, P9
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Westfall MD, 2004, CARCINOGENESIS, V25, P857, DOI 10.1093/carcin/bgh148
   Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0
   Yang A, 2006, MOL CELL, V24, P593, DOI 10.1016/j.molcel.2006.10.018
   Ye T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkq1287
   Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433
   Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111
   Zentner GE, 2012, J BIOL CHEM, V287, P30888, DOI 10.1074/jbc.R111.296491
   Zhang B, 2013, GENOME RES, V23, P917, DOI 10.1101/gr.149674.112
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
   Zhao XS, 2010, P NATL ACAD SCI USA, V107, P14146, DOI 10.1073/pnas.1009030107
   Zhu J, 2013, CELL, V152, P642, DOI 10.1016/j.cell.2012.12.033
NR 89
TC 37
Z9 42
U1 0
U2 20
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD MAY 2
PY 2014
VL 15
AR 331
DI 10.1186/1471-2164-15-331
PG 19
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA AH1FT
UT WOS:000335865900001
PM 24885402
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Shilpa, V
   Bhagat, R
   Premalata, CS
   Pallavi, VR
   Ramesh, G
   Krishnamoorthy, L
AF Shilpa, V.
   Bhagat, Rahul
   Premalata, C. S.
   Pallavi, V. R.
   Ramesh, G.
   Krishnamoorthy, Lakshmi
TI <i>BRCA1</i> promoter hypermethylation and protein expression in ovarian
   carcinoma-an Indian study
SO TUMOR BIOLOGY
LA English
DT Article
DE Ovarian carcinoma; Promoter methylation; BRCA1; Protein expression
ID BREAST-CANCER; SPORADIC BREAST; DNA METHYLATION; MESSENGER-RNA; TUMORS;
   GENE; REGION; TRANSCRIPTION; BORDERLINE; ALLELOTYPE
AB Mounting evidences suggest that aberrant methylation of CpG islands is a major pathway leading to the inactivation of tumour suppressor genes and the development of cancer. The aim of the current study was to examine the prevalence of the promoter hypermethylation and protein expression of the BRCA1 gene in epithelial ovarian carcinoma (EOC) to understand the role of epigenetic silencing in ovarian carcinogenesis. We studied the promoter methylation of the BRCA1 gene by methylation-specific PCR in a cohort of 88 patients with EOC, 14 low malignant potential (LMP) tumours and 20 patients with benign tumours of the ovary. The expression of the BRCA1 protein by immunohistochemical analysis was carried out in a subset of 64 EOCs, 10 LMP tumours, 10 benign tumours and 5 normal ovarian tissues. The frequencies of methylation in EOCs and LMP tumours were 51.2 and 57 %, respectively, significantly higher (p = 0.000 and p = 0.001) in comparison to benign tumours and normal ovarian tissue where no methylation was seen. Expression of BRCA1 was significantly lower in EOCs (p = 0.003). Lack of protein expression correlated with tumour grade and type. The methylation status correlated well with downregulation of BRCA1 expression. Our results clearly demonstrate that hypermethylation of BRCA1 promoter is a frequent event in ovarian cancer. These data support the hypothesis that BRCA1 promoter methylation plays an important role in the functional inactivation of BRCA1. Follow-up clinical data will reveal the impact of BRCA1 methylation on survival.
C1 [Shilpa, V.; Bhagat, Rahul; Ramesh, G.; Krishnamoorthy, Lakshmi] Kidwai Mem Inst Oncol, Dept Biochem, Bangalore 560029, Karnataka, India.
   [Premalata, C. S.] Kidwai Mem Inst Oncol, Dept Pathol, Bangalore 560029, Karnataka, India.
   [Pallavi, V. R.] Kidwai Mem Inst Oncol, Dept Gynaec Oncol, Bangalore 560029, Karnataka, India.
C3 Kidwai Memorial Institute of Oncology; Kidwai Memorial Institute of
   Oncology; Kidwai Memorial Institute of Oncology
RP Krishnamoorthy, L (通讯作者)，Sri Shankara Canc Hosp & Res Ctr, Dept Biochem, 1st Cross, Bangalore 560004, Karnataka, India.
EM shilpachadaga@gmail.com; rahulbhagat1234@gmail.com;
   prema_venka@yahoo.co.in; drpallaviram123@yahoo.co.in;
   gdrramesh@gmail.com; vkrishlakshmi@gmail.com
CR Allred DC, 1998, MODERN PATHOL, V11, P155
   Baldwin RL, 2000, CANCER RES, V60, P5329
   Berger J, 2002, J STEROID BIOCHEM, V80, P1, DOI 10.1016/S0960-0760(01)00179-0
   Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147
   Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9
   Bozzetti C, 2004, INT J GYNECOL OBSTET, V85, P294, DOI 10.1016/j.ijgo.2004.01.002
   CANNISTRA SA, 1993, NEW ENGL J MED, V329, P1550, DOI 10.1056/NEJM199311183292108
   Chan QK, 2005, CLIN CANCER RES, V11, P2156
   CLIBY W, 1993, CANCER RES, V53, P2393
   Dhillon VS, 2004, CLIN CANCER RES, V10, P5537, DOI 10.1158/1078-0432.CCR-04-0228
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15
   Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990
   Jiaze A, 2010, INT J MOL EPIDEMIOL, V1, P1
   Link CJ, 1996, AM J MED, V101, P217, DOI 10.1016/S0002-9343(96)80079-9
   Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630
   Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224
   Pan YM, 2010, SCI RES ESSAYS, V5, P3939
   Pérez-Vallés A, 2001, J CLIN PATHOL, V54, P476, DOI 10.1136/jcp.54.6.476
   Press JZ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-17
   Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086
   SATO T, 1991, CANCER RES, V51, P5118
   Scully RE, 1975, J NATL CANC I MONOGR, V42, P5
   Wang C, 2004, J PATHOL, V202, P215, DOI 10.1002/path.1507
   Weberpals JI, 2011, ANN ONCOL, V22, P2403, DOI 10.1093/annonc/mdq770
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Wilcox CB, 2005, CANCER GENET CYTOGEN, V159, P114, DOI 10.1016/j.cancergencyto.2004.12.017
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259
   Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x
NR 30
TC 13
Z9 14
U1 0
U2 7
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2014
VL 35
IS 5
BP 4277
EP 4284
DI 10.1007/s13277-013-1558-5
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AG9SL
UT WOS:000335759800038
PM 24385383
DA 2025-01-12
ER

PT J
AU Nagy, E
   Gajjar, KB
   Patel, II
   Taylor, S
   Martin-Hirsch, PL
   Stringfellow, HF
   Martin, FL
   Phillips, DH
AF Nagy, E.
   Gajjar, K. B.
   Patel, I. I.
   Taylor, S.
   Martin-Hirsch, P. L.
   Stringfellow, H. F.
   Martin, F. L.
   Phillips, D. H.
TI <i>MGMT</i> promoter hypermethylation and <i>K-RAS</i>, <i>PTEN</i> and
   <i>TP53</i> mutations in tamoxifen-exposed and non-exposed endometrial
   cancer cases
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE tamoxifen; epigenetics; hypermethylation; endometrial cancer; TP53;
   K-RAS; PTEN
ID SPORADIC COLORECTAL-CANCER; TUMOR-SUPPRESSOR GENE; BREAST-CANCER;
   O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; DNA METHYLTRANSFERASE; GERMLINE
   MUTATIONS; METHYLATION; CARCINOMA; FREQUENCY; RISK
AB Background: Tamoxifen has anti-oestrogenic and anti-tumour activity in the breast, but is oestrogenic and carcinogenic in the endometrium. It can induce experimental tumours by both hormonal and DNA-damaging mechanisms, but its carcinogenic mode of action in human endometrium remains unclear.
   Methods: We investigated whether an epigenetic mechanism, involving promoter hypermethylation of the gene for the DNA repair enzyme MGMT (06-methylguanine DNA methyltransferase), was associated with K-RAS, TP53 and PTEN mutations in endometrial tumours from women treated with tamoxifen (TAM, n=30) or unexposed to the drug (EC, n=38).
   Results: There were significant (P<0.05) differences in tumour grade between the TAM and EC groups, with more favourable morphology in the latter. K-RAS mutations, predominantly G >A, occurred in small numbers in both groups. TP53 mutations were of mainly A> G, C>T and indel modifications in both groups, but more frequent in TAM cases. PTEN mutations dominated in EC tumours and were of the type that has large impact on protein function, such as indel or nonsense mutations. These observations alongside the mutational spectrum in PTEN suggest that the malignancies arise from different backgrounds, hence pointing to an effect of tamoxifen. Both groups displayed MGMT promoter hypermethylation. This coincided with mutations more frequently in the TAM (78%) than in the EC (50%) group, even though there were significantly (P<0.05) fewer mutations and methylations in TAM cases.
   Conclusions: Although the difference in coincidence did not reach significance with the current sample size, the findings suggest that epigenetic processes may play a role in the way tamoxifen induces endometrial cancer.
C1 [Nagy, E.; Phillips, D. H.] Kings Coll London, Analyt & Environm Sci Div, London SE1 9NH, England.
   [Gajjar, K. B.; Martin-Hirsch, P. L.; Martin, F. L.] Univ Lancaster, Ctr Biophoton, Lancaster Environm Ctr, Lancaster LA1 4YQ, England.
   [Patel, I. I.] Univ Cambridge, Cavendish Labs, Cambridge CB3 0HE, England.
   [Taylor, S.] Liverpool Womens Hosp NHS Fdn Trust, Dept Gynaecol, Liverpool L8 7SS, Merseyside, England.
   [Martin-Hirsch, P. L.; Stringfellow, H. F.] Lancashire Teaching Hosp NHS Trust, Royal Preston Hosp, Preston PR2 9HT, Lancs, England.
C3 University of London; King's College London; Lancaster University;
   University of Cambridge; Royal Preston Hospital
RP Nagy, E (通讯作者)，Kings Coll London, Analyt & Environm Sci Div, London SE1 9NH, England.
EM eszter.nagy@kcl.ac.uk
RI Martin, Francis/J-4585-2019
OI L Martin, Francis/0000-0001-8562-4944; Phillips,
   David/0000-0001-8509-3485
FU Rosemere Cancer Foundation; Cancer Research UK
FX This work was supported by the Rosemere Cancer Foundation and Cancer
   Research UK. We thank the funding bodies for support throughout this
   project. Hospital and pathology staff who facilitated collection of the
   tissues for the purpose of the study are also thanked.
CR Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922
   Bansal N, 2009, CANCER CONTROL, V16, P8, DOI 10.1177/107327480901600102
   Biron-Shental T, 2003, GYNECOL ONCOL, V90, P382, DOI 10.1016/S0090-8258(03)00276-2
   Brandes JC, 2007, ONCOGENE, V26, P6229, DOI 10.1038/sj.onc.1210433
   Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009
   Chen GP, 2002, J BIOCHEM MOL TOXIC, V16, P279, DOI 10.1002/jbt.10048
   Cheng Zhao-Dong, 2010, Chin J Cancer, V29, P163
   Chetrite GS, 2000, J STEROID BIOCHEM, V72, P23, DOI 10.1016/S0960-0760(00)00040-6
   Cohen Y, 2010, GYNECOL ONCOL, V116, P88, DOI 10.1016/j.ygyno.2009.09.038
   Davies R, 1999, CARCINOGENESIS, V20, P1351, DOI 10.1093/carcin/20.7.1351
   Davis W, 2000, CANCER RES, V60, P2887
   Esteller M, 1999, CANCER RES, V59, P793
   Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371
   Furlan D, 2006, CLIN CANCER RES, V12, P3329, DOI 10.1158/1078-0432.CCR-05-2679
   Hachisuga T, 2005, BRIT J CANCER, V92, P1098, DOI 10.1038/sj.bjc.6602456
   Hachisuga T, 2003, CANCER-AM CANCER SOC, V98, P1890, DOI 10.1002/cncr.11728
   Han JL, 2006, CARCINOGENESIS, V27, P2281, DOI 10.1093/carcin/bgl099
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   HRUBAN RH, 1993, AM J PATHOL, V143, P545
   Jacinto FV, 2007, DNA REPAIR, V6, P1155, DOI 10.1016/j.dnarep.2007.03.013
   Janiec-Jankowska A, 2010, INT J GYNECOL CANCER, V20, P196, DOI 10.1111/IGC.0b013e3181c83675
   Kim SY, 2004, DRUG METAB REV, V36, P199, DOI 10.1081/DMR-120033997
   Koul A, 2002, CANCER, V94, P2369, DOI 10.1002/cncr.10498.abs
   Lax SF, 2000, CANCER-AM CANCER SOC, V88, P814, DOI 10.1002/(SICI)1097-0142(20000215)88:4<814::AID-CNCR12>3.0.CO;2-U
   Liu Fu-Shing, 2007, Taiwan J Obstet Gynecol, V46, P26, DOI 10.1016/S1028-4559(08)60102-3
   MAGRIPLES U, 1993, J CLIN ONCOL, V11, P485, DOI 10.1200/JCO.1993.11.3.485
   MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002
   Nagasaka T, 2008, INT J CANCER, V122, P2429, DOI 10.1002/ijc.23398
   Phillips DH, 2001, CARCINOGENESIS, V22, P839, DOI 10.1093/carcin/22.6.839
   Prasad M, 2005, GYNECOL ONCOL, V96, P25, DOI 10.1016/j.ygyno.2004.08.046
   Rimel BJ, 2009, GYNECOL ONCOL, V112, P224, DOI 10.1016/j.ygyno.2008.08.038
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   Shen LL, 2005, JNCI-J NATL CANCER I, V97, P1330, DOI 10.1093/jnci/dji275
   Singh MN, 2008, TOXICOLOGY, V249, P85, DOI 10.1016/j.tox.2008.04.009
   Singh MN, 2007, CANCER TREAT REV, V33, P91, DOI 10.1016/j.ctrv.2006.09.008
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Teo AKC, 2001, MOL CELL BIOL, V21, P7105, DOI 10.1128/MCB.21.20.7105-7114.2001
   TOGUCHIDA J, 1992, NEW ENGL J MED, V326, P1301, DOI 10.1056/NEJM199205143262001
   Turbiner J, 2008, MODERN PATHOL, V21, P925, DOI 10.1038/modpathol.2008.49
   Utsunomiya H, 2004, CLIN CANCER RES, V10, P5850, DOI 10.1158/1078-0432.CCR-04-0040
   VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1
   Wallén M, 2005, CANCER CHEMOTH PHARM, V55, P343, DOI 10.1007/s00280-004-0923-x
   Williams-Brown MY, 2011, J STEROID BIOCHEM, V126, P78, DOI 10.1016/j.jsbmb.2011.05.001
   Wu CM, 2005, CANCER GENET CYTOGEN, V158, P55, DOI 10.1016/j.cancergencyto.2004.08.030
   Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532
   Yamamoto Kaoru, 2007, Clin Pediatr Endocrinol, V16, P99, DOI 10.1297/cpe.16.99
   Zhang FG, 2000, CHEM RES TOXICOL, V13, P53, DOI 10.1021/tx990145n
NR 47
TC 19
Z9 19
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
EI 1532-1827
J9 BRIT J CANCER
JI Br. J. Cancer
PD JUN 10
PY 2014
VL 110
IS 12
BP 2874
EP 2880
DI 10.1038/bjc.2014.263
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AK1NG
UT WOS:000338181200007
PM 24853176
OA Green Published, hybrid, Green Accepted
DA 2025-01-12
ER

PT J
AU Al-Rayyan, N
   Litchfield, LM
   Ivanova, MM
   Radde, BN
   Cheng, A
   Elbedewy, A
   Klinge, CM
AF Al-Rayyan, Numan
   Litchfield, Lacey M.
   Ivanova, Margarita M.
   Radde, Brandie N.
   Cheng, Alan
   Elbedewy, Ahmed
   Klinge, Carolyn M.
TI 5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression
   in antiestrogen-resistant breast cancer cell lines
SO CANCER LETTERS
LA English
DT Article
DE Breast cancer; Endocrine-resistance; COUP-TFII; Epigenetic modification;
   Estrogen receptor
ID HISTONE DEACETYLASE INHIBITORS; ESTROGEN-RECEPTOR-BETA; DNA METHYLATION;
   HIGH-THROUGHPUT; RESPONSE ELEMENTS; PROGNOSTIC VALUE; TAMOXIFEN;
   PROMOTER; TRANSCRIPTION; ALPHA
AB COUP-TFII is reduced in endocrine-resistant breast cancer cells and is negatively associated with tumor grade. Transient re-expression of COUP-TFII restores antiestrogen sensitivity in resistant LCC2 and LCC9 cells and repression of COUP-TFII results in antiestrogen-resistance in MCF-7 endocrine-sensitive cells. We addressed the hypothesis that reduced COUP-TFII expression in endocrine-resistant breast cancer cells results from epigenetic modification. The NR2F2 gene encoding COUP-TFII includes seven CpG islands, including one in the 5' promoter and one in exon 1. Treatment of LCC2 and LCC9 endocrineresistant breast cancer cells with 5-aza-2'-deoxycytidine (AZA), a DNA methyltransferase (DNMT) inhibitor, +/- trichostatin A (TSA), a histone deacetylase (HDAC) inhibitor, increased COUP-TFII suggesting that the decrease in COUP-TFII is mediated by epigenetic changes. Methylation-specific PCR (MSP) revealed higher methylation of NR2F2 in the first exon in LCC2 and LCC9 cells compared to MCF-7 cells and AZA reduced this methylation. Translational importance is suggested by Cancer Methylome System (CMS) analysis revealing that breast tumors have increased COUP-TFII (NR2F2) promoter and gene methylation versus normal breast. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Al-Rayyan, Numan; Litchfield, Lacey M.; Ivanova, Margarita M.; Radde, Brandie N.; Cheng, Alan; Elbedewy, Ahmed; Klinge, Carolyn M.] Univ Louisville, Ctr Genet & Mol Med, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.
C3 University of Louisville
RP Klinge, CM (通讯作者)，Univ Louisville, Ctr Genet & Mol Med, Sch Med, Dept Biochem & Mol Biol, Louisville, KY 40292 USA.
EM carolyn.klinge@louisville.edu
RI Ivanova, Margarita/AAM-4510-2021; Cheng, Alan/M-9319-2013
OI Ivanova, Margarita/0000-0002-6197-8606; Cheng, Alan/0000-0001-7897-4751;
   Klinge, Carolyn/0000-0002-3358-4378
FU Susan G. Komen for the Cure [KG080365]; NIEHS [T32 ES011564]
FX We thank Dr. Michelle Barati for her review and interpretation of the
   cell images. This work was supported by a grant from Susan G. Komen for
   the Cure KG080365 to C.M.K. L.M.L was supported by a fellowship from
   NIEHS T32 ES011564.
CR Ajabnoor GMA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.139
   Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-40
   BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0
   BRUNNER N, 1993, CANCER RES, V53, P3229
   Brunner N, 1997, CANCER RES, V57, P3486
   BUTLER AJ, 1995, NUCLEIC ACIDS RES, V23, P4143, DOI 10.1093/nar/23.20.4143
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153
   Crawford AC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008604
   Day TK, 2013, ENDOCR-RELAT CANCER, V20, pR215, DOI 10.1530/ERC-13-0204
   Duan L, 2011, J BIOL CHEM, V286, P2864, DOI 10.1074/jbc.M110.143271
   Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666
   Fu JQ, 2010, BREAST CANCER RES TR, V120, P35, DOI 10.1007/s10549-009-0363-8
   Fukazawa H, 2000, CANCER RES, V60, P2104
   Gardner KE, 2011, J MOL BIOL, V409, P36, DOI 10.1016/j.jmb.2011.01.040
   Gnyszka A, 2013, ANTICANCER RES, V33, P2989
   Gonzalez-Malerva L, 2011, P NATL ACAD SCI USA, V108, P2058, DOI 10.1073/pnas.1018157108
   Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664
   Gu F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060980
   He G., 2013, TUMOUR BIOL
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hervouet E, 2013, EPIGENETICS, V8
   Hostetter CL, 2009, CANCER LETT, V275, P178, DOI 10.1016/j.canlet.2008.10.005
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kim HJ, 2011, AM J TRANSL RES, V3, P166
   Kisanga ER, 2004, CLIN CANCER RES, V10, P2336, DOI 10.1158/1078-0432.CCR-03-0538
   Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   Komashko VM, 2010, EPIGENETICS-US, V5
   Lai JC, 2005, INT J CANCER, V117, P974, DOI 10.1002/ijc.21278
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   LIN KT, 1981, J PHARM SCI, V70, P1228, DOI 10.1002/jps.2600701112
   Litchfield LM, 2012, J MOL ENDOCRINOL, V49, pR135, DOI 10.1530/JME-12-0144
   Litchfield LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038278
   Martínez-Iglesias O, 2008, CLIN TRANSL ONCOL, V10, P395, DOI 10.1007/s12094-008-0221-x
   Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V
   Moré E, 2003, J ENDOCRINOL, V176, P83, DOI 10.1677/joe.0.1760083
   Munot K, 2006, HUM PATHOL, V37, P989, DOI 10.1016/j.humpath.2006.04.013
   Muscat GEO, 2013, MOL ENDOCRINOL, V27, P350, DOI 10.1210/me.2012-1265
   Nehra R, 2010, FASEB J, V24, P2040, DOI 10.1096/fj.09-138305
   Pitta CA, 2013, CANCER LETT, V337, P167, DOI 10.1016/j.canlet.2013.05.031
   Pryzbylkowski P, 2008, BREAST CANCER RES TR, V111, P15, DOI 10.1007/s10549-007-9751-0
   Riggs KA, 2006, CANCER RES, V66, P10188, DOI 10.1158/0008-5472.CAN-05-3937
   Ring A, 2004, ENDOCR-RELAT CANCER, V11, P643, DOI 10.1677/erc.1.00776
   Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110
   Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Schultz DJ, 2010, MOL CANCER THER, V9, P594, DOI 10.1158/1535-7163.MCT-09-0978
   Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Singh SB, 2006, SCIENCE, V313, P1438, DOI 10.1126/science.1129577
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Trump BF, 1997, TOXICOL PATHOL, V25, P82, DOI 10.1177/019262339702500116
   Tsai SY, 1997, ENDOCR REV, V18, P229, DOI 10.1210/er.18.2.229
   Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664
   Walkinshaw DR, 2008, CURR ONCOL, V15, P237
   Wen ZH, 2013, ONCOGENE, V32, P160, DOI 10.1038/onc.2012.47
   Wyrebska A., 2013, BASIC CLIN PHARM TOX
   Yang XW, 2001, CANCER RES, V61, P7025
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
   Zou CF, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-22
NR 65
TC 12
Z9 15
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 28
PY 2014
VL 347
IS 1
BP 139
EP 150
DI 10.1016/j.canlet.2014.02.001
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AG5BF
UT WOS:000335433400017
PM 24513177
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Kolacinska, A
   Morawiec, J
   Fendler, W
   Malachowska, B
   Morawiec, Z
   Szemraj, J
   Pawlowska, Z
   Chowdhury, D
   Choi, YE
   Kubiak, R
   Pakula, L
   Zawlik, I
AF Kolacinska, Agnieszka
   Morawiec, Jan
   Fendler, Wojciech
   Malachowska, Beata
   Morawiec, Zbigniew
   Szemraj, Janusz
   Pawlowska, Zofia
   Chowdhury, Dipanjan
   Choi, Young Eun
   Kubiak, Robert
   Pakula, Lukasz
   Zawlik, Izabela
TI Association of microRNAs and pathologic response to preoperative
   chemotherapy in triple negative breast cancer: preliminary report
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Breast cancer; microRNA; Pathologic response
ID CELLS; LANDSCAPE
AB Triple negative breast cancer (TNBC) has caught the attention of oncologists worldwide because of poor prognosis and paucity of targeted therapies. Gene pathways have been widely studied, but less is known about epigenetic factors such as microRNAs (miRNAs) and their role in tailoring an individual systemic and surgical approach for breast cancer patients. The aim of the study was to examine selected miRNAs in TNBC core biopsies sampled before preoperative chemotherapy and the subsequent pathologic response in mastectomy or breast conservation specimens. Prior to treatment, core needle biopsies were collected from 11 female patients with inoperable locally advanced TNBC or large resectable tumors suitable for down-staging. In all 11 TNBC core biopsies we analyzed 19 miRNAs per sample: 512, 190, 200, 346, 148, 449, 203, 577, 93, 126, 423, 129, 193, 182, 136, 135, 191, 122 and 222 (miRCURY LNA (TM) Universal RT microRNA polymerase chain reaction Custom Pick & Mixpanels). The Wilcoxon signed-rank test was used to compare related samples. Ingenuity pathway analysis was used to evaluate potential functional significance of differentially expressed miRNAs. Statistical analysis showed that 3 of 19 miRNAs differed in relation to pathologic response i.e. good versus poor. These differences failed to reach statistical significance, although a trend was observed (p = 0.06). Among these miRNAs, we identified-miR-200b-3p, miR-190a and miR-512-5p. In summary, our results indicate that higher miR-200b-3p, higher miR-190a and lower miR-512-5p expression levels in core biopsies sampled from TNBC patients may be associated with better pathologic response to chemotherapy and the increased feasibility of breast conserving surgery in these patients. Although these results were from a small cohort, they provide an important basis for larger, prospective, multicenter studies to investigate the potential role of miRNAs in neoadjuvant setting.
C1 [Kolacinska, Agnieszka; Morawiec, Jan; Morawiec, Zbigniew] Copernicus Mem Hosp, Dept Surg Oncol, Ctr Canc, PL-93509 Lodz, Poland.
   [Morawiec, Jan] Med Univ Lodz, Dept Gen & Colorectal Surg, PL-90647 Lodz, Poland.
   [Fendler, Wojciech; Malachowska, Beata] Med Univ Lodz, Dept Pediat Oncol Hematol & Diabetol, PL-91738 Lodz, Poland.
   [Szemraj, Janusz] Med Univ Lodz, Dept Med Biochem, PL-92215 Lodz, Poland.
   [Pawlowska, Zofia] Med Univ Lodz, Cent Lab Corelab, PL-92215 Lodz, Poland.
   [Chowdhury, Dipanjan; Choi, Young Eun] Harvard Univ, Dana Farber Canc Inst, Dept Radiat Oncol, Sch Med, Boston, MA 02215 USA.
   [Kubiak, Robert] Med Univ Lodz, Dept Pathol, PL-93513 Lodz, Poland.
   [Pakula, Lukasz] Copernicus Mem Hosp, Dept Anesthesiol, PL-93513 Lodz, Poland.
   [Zawlik, Izabela] Univ Rzeszow, Inst Nursing & Hlth Sci, Dept Med Genet, Dept Med, PL-35959 Rzeszow, Poland.
C3 Medical University Lodz; Medical University Lodz; Medical University
   Lodz; Medical University Lodz; Harvard University; Dana-Farber Cancer
   Institute; Harvard Medical School; Medical University Lodz; University
   of Rzeszow
RP Kolacinska, A (通讯作者)，Copernicus Mem Hosp, Dept Surg Oncol, Ctr Canc, Paderewskiego 4, PL-93509 Lodz, Poland.
EM info@drkolacinska.pl
RI Fendler, Wojciech/AAG-7020-2019; Malachowska, Beata/AAD-7746-2022;
   Fendler, Wojciech/S-9592-2016
OI Fendler, Wojciech/0000-0002-5083-9168; Pawlowska,
   Zofia/0000-0002-9861-0901; Kolacinska-Wow, Agnieszka/0000-0001-8707-0877
FU Ministry of Science and Higher Education, Poland [2011/01/B/NZ4/03345]
FX This study was supported by the grant of the Ministry of Science and
   Higher Education, Poland, 2011/01/B/NZ4/03345.
CR Almog N., 2013, TRANSCRIPTION, V4
   Almog N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044001
   Balic M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-358
   Chan M, 2013, CLIN CANCER RES, V19, P4477, DOI 10.1158/1078-0432.CCR-12-3401
   Dvinge H, 2013, NATURE, V497, P378, DOI 10.1038/nature12108
   Ellis MJ, 2013, CANCER DISCOV, V3, P27, DOI 10.1158/2159-8290.CD-12-0462
   Jung EJ, 2012, CANCER-AM CANCER SOC, V118, P2603, DOI 10.1002/cncr.26565
   Piccart MJ, 2012, ANN ONCOL, V23, P5, DOI 10.1093/annonc/mds186
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Port M, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-52
   Rutnam ZJ, 2012, J CELL SCI, V125, P2075, DOI 10.1242/jcs100818
   Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263
   Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Von Minckwitz G, 2012, ANN ONCOL S, V23, pvi5
   von Minckwitz G, 2013, CLIN CANCER RES, V19, P4521, DOI 10.1158/1078-0432.CCR-12-3628
   von Minckwitz G, 2013, CURR OPIN OBSTET GYN, V25, P66, DOI 10.1097/GCO.0b013e32835c0889
   von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595
NR 18
TC 43
Z9 43
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2014
VL 41
IS 5
BP 2851
EP 2857
DI 10.1007/s11033-014-3140-7
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AG9JC
UT WOS:000335734400017
PM 24469723
OA hybrid, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Akhter, N
   Akhtar, MS
   Ahmad, MM
   Haque, S
   Siddiqui, S
   Hasan, S
   Shukla, N
   Husain, S
AF Akhter, Naseem
   Akhtar, Md Salman
   Ahmad, Md Margoob
   Haque, Shafiul
   Siddiqui, Sarah
   Hasan, Syed Ikramul
   Shukla, Nootan K.
   Husain, Syed Akhtar
TI Association of mutation and hypermethylation of p21 gene with
   susceptibility to breast cancer: a study from north India
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE p21; Breast cancer; North India; Mutation; Hypermethylation
ID KINASE INHIBITOR GENES; CELL-CYCLE ARREST; PROMOTER HYPERMETHYLATION;
   ISLAND METHYLATION; DNA METHYLATION; P16 GENES; POLYMORPHISMS; P53;
   INACTIVATION; BINDING
AB p21 gene located at chromosome 6p21.2 is a possible tumour suppressor gene involved in the pathogenesis of breast cancer. Both genetic and epigenetic alterations in p21 have been implicated in breast carcinoma. In the present study, our main aim was to study the impact of these two kinds of alterations of p21 gene in Indian female breast cancer patients. A total of 150 female breast cancer patients of north India were screened by PCR-SSCP followed by direct sequencing and methylation specific PCR. Mutational screening of p21 gene revealed significant amount of mutations [32.66 % (49/150)] in exon 2, whereas p21 promoter was found hypermethylated in 42 of 150 (28 %) breast cancer patients in our population. The intriguing feature of the study was the G > T transition (GAG > TAG) at codon 107 and the A > C transition (AGC > CGC) at codon 146 possibly rendering p21 completely ineffective in its anti- proliferative activity. Our results suggest a significant association between the mutational and hypermethylation profile of p21 gene. Therefore, we show for the first time that the significant association of p21 mutation and hypermethylation leads to the complete inactivation of p21 gene in Indian female breast cancer patients. Complete silencing of the p21 gene seems to be the result not only of genetic alterations but also of epigenetic modification.
C1 [Akhter, Naseem; Akhtar, Md Salman; Ahmad, Md Margoob; Siddiqui, Sarah; Hasan, Syed Ikramul; Husain, Syed Akhtar] Jamia Millia Islamia, Dept Biotechnol, New Delhi 110025, India.
   [Haque, Shafiul] Univ Helsinki, CDR, Fac Pharm, Helsinki, Finland.
   [Shukla, Nootan K.] All India Inst Med Sci, Dept Surg Oncol, Dr BRA IRCH, New Delhi, India.
C3 Jamia Millia Islamia; University of Helsinki; All India Institute of
   Medical Sciences (AIIMS) New Delhi; DR. B.R.A. Institute Rotary Cancer
   Hospital
RP Husain, S (通讯作者)，Jamia Millia Islamia, Dept Biotechnol, New Delhi 110025, India.
EM akhtarhusain2000@yahoo.com
RI ; Haque, Shafiul/AAN-2946-2020; Akhter, Naseem/ABF-4588-2021
OI ikram, Syed/0000-0002-4997-846X; Haque, Shafiul/0000-0002-2989-121X;
   Akhter, Naseem/0000-0003-2011-0955; Akhtar, Dr. Mohammad
   Salman/0000-0003-0600-2966
FU University Grants Commission, New Delhi, India [34- 219/2008
   (SR)/14.01.2009]
FX The manuscript was thankfully reviewed by Dr. Shaun Cochrane, Ph.D.
   graduate from NIMR, MRC, London. The financial support for this research
   work was provided by the University Grants Commission, New Delhi, India
   under Grant No. F. No. 34- 219/2008 (SR)/14.01.2009
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Abukhdeir AM, 2008, P NATL ACAD SCI USA, V105, P288, DOI 10.1073/pnas.0710887105
   Bahl R, 2000, ONCOGENE, V19, P323, DOI 10.1038/sj.onc.1203325
   Bott SRJ, 2005, PROSTATE CANCER P D, V8, P321, DOI 10.1038/sj.pcan.4500822
   Busia L, 2011, MOL CELL ENDOCRINOL, V333, P37, DOI 10.1016/j.mce.2010.11.034
   Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543
   Cazzalini O, 2010, MUTAT RES-REV MUTAT, V704, P12, DOI 10.1016/j.mrrev.2010.01.009
   Chen B, 2000, CANCER RES, V60, P3290
   CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0
   DEVITT JE, 1967, CAN MED ASSOC J, V97, P1257
   Esteller M, 2000, ONCOGENE, V19, P164, DOI 10.1038/sj.onc.1203227
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Esteller M, 2000, EUR J CANCER, V36, P2294, DOI 10.1016/S0959-8049(00)00303-8
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Facher EA, 1997, CANCER, V79, P2424, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2424::AID-CNCR19>3.0.CO;2-T
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Go JH, 2003, MODERN PATHOL, V16, P752, DOI 10.1097/01.MP.0000081728.21368.85
   Graff JR, 1997, J BIOL CHEM, V272, P22322, DOI 10.1074/jbc.272.35.22322
   Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heinzel PA, 1996, INT J CANCER, V68, P420, DOI 10.1002/(SICI)1097-0215(19961115)68:4<420::AID-IJC3>3.0.CO;2-2
   HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kawasaki T, 1996, INT J CANCER, V68, P501, DOI 10.1002/(SICI)1097-0215(19961115)68:4<501::AID-IJC16>3.0.CO;2-7
   Knappskog S, 2007, INT J CANCER, V121, P908, DOI 10.1002/ijc.22777
   KNUDSON AG, 1975, P NATL ACAD SCI USA, V72, P5116, DOI 10.1073/pnas.72.12.5116
   Milner BJ, 1999, INT J ONCOL, V15, P117
   Mitra S, 2005, INT J CANCER, V117, P786, DOI 10.1002/ijc.21263
   Moreira PR, 2009, J ORAL PATHOL MED, V38, P99, DOI 10.1111/j.1600-0714.2008.00718.x
   MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089
   Naqvi RA, 2008, DNA CELL BIOL, V27, P517, DOI 10.1089/dna.2007.0660
   ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766
   PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Raish M, 2009, TRANSL ONCOL, V2, P264, DOI 10.1593/tlo.09148
   Ralhan R, 2000, CLIN CANCER RES, V6, P2440
   Ressiniotis Thomas, 2005, BMC Ophthalmol, V5, P5, DOI 10.1186/1471-2415-5-5
   Roh JW, 2010, ONCOL RES, V18, P453, DOI 10.3727/096504010X12671222663719
   Roman-Gomez J, 2002, BLOOD, V99, P2291, DOI 10.1182/blood.V99.7.2291
   Sambrook J, 2001, Molecular Cloning: a Laboratory Manual, Vthird
   Shima K, 2011, INT J CANCER, V128, P1080, DOI 10.1002/ijc.25432
   Shin JY, 2000, CANCER RES, V60, P262
   Sjalander A, 1996, HUM HERED, V46, P221, DOI 10.1159/000154357
   Steward BernardW., 2003, WORLD CANC REPORT
   Taghavi N, 2010, ARCH IRAN MED, V13, P235
   Tornesello ML, 2011, BIOMARKERS, V16, P42, DOI 10.3109/1354750X.2010.525664
   WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0
   Wang Z, 2010, CURR CANCER DRUG TAR, V10, P307, DOI 10.2174/156800910791190238
   WATANABE H, 1995, BBA-GENE STRUCT EXPR, V1263, P275, DOI 10.1016/0167-4781(95)00110-3
   Zhu WG, 2003, MOL CELL BIOL, V23, P4056, DOI 10.1128/MCB.23.12.4056-4065.2003
NR 54
TC 12
Z9 13
U1 0
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2014
VL 41
IS 5
BP 2999
EP 3007
DI 10.1007/s11033-014-3159-9
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AG9JC
UT WOS:000335734400033
PM 24464128
DA 2025-01-12
ER

PT J
AU Li, BH
   Ye, ZM
AF Li, Binghao
   Ye, Zhaoming
TI Epigenetic alterations in osteosarcoma: promising targets
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Osteosarcoma; Epigenetics; Combination therapy; Cancer treatment;
   Tumorigenesis
ID TUMOR-SUPPRESSOR GENE; HISTONE DEACETYLASE INHIBITORS; ACTIVE DNA
   DEMETHYLATION; REFRACTORY SOLID TUMORS; MESENCHYMAL STEM-CELLS;
   CANCER-TESTIS ANTIGEN; STUDY-GROUP PROTOCOLS; HUMAN BREAST-CANCER;
   PHASE-I; METASTATIC OSTEOSARCOMA
AB Cancer is being reinterpreted due to recent discoveries related to epigenetic regulation during development, and the importance of epigenetic mechanisms in initiation and progression of cancer has been further highlighted by the recent explosion in medical information. Osteosarcoma is highly genetically unstable, and current therapeutic regimens are subject to chemoresistance and tumor relapse. Understanding the epigenetic mechanisms in the pathogenesis of osteosarcoma will provide novel avenues for cancer therapy. In this review, we examine the epigenetic alterations in gene expression in osteosarcoma, and discuss the utilization of epigenetic regulation therapy in treatment against osteosarcoma.
C1 [Li, Binghao] Zhejiang Univ, Dept Orthopaed, Sch Med, Affiliated Hosp 2, Hangzhou 310008, Zhejiang, Peoples R China.
   [Ye, Zhaoming] Zhejiang Univ, Dept Orthopaed, Ctr Orthopaed Res, Affiliated Hosp 2,Sch Med, Hangzhou 310008, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Ye, ZM (通讯作者)，Zhejiang Univ, Dept Orthopaed, Ctr Orthopaed Res, Affiliated Hosp 2,Sch Med, Hangzhou 310008, Zhejiang, Peoples R China.
EM yezhaominghz@163.com
FU National Natural Science Foundation of China [81172547, 30973444]
FX This work was supported by National Natural Science Foundation of China
   (81172547, 30973444).
CR Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123
   Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379
   Al-Romaih K, 2007, CANCER CELL INT, V7, DOI 10.1186/1475-2867-7-14
   Al-Romaih K, 2008, NEOPLASIA, V10, P471, DOI 10.1593/neo.08174
   Amente S, 2011, NUCLEIC ACIDS RES, V39, P9498, DOI 10.1093/nar/gkr638
   Appleton K, 2007, J CLIN ONCOL, V25, P4603, DOI 10.1200/JCO.2007.10.8688
   Atmaca A, 2007, BRIT J CANCER, V97, P177, DOI 10.1038/sj.bjc.6603851
   Badal V, 2008, CELL CYCLE, V7, P112, DOI 10.4161/cc.7.1.5137
   Bao L, 2011, CANCER IMMUNOL IMMUN, V60, P1299, DOI 10.1007/s00262-011-1037-z
   Benassi MS, 2001, CANCER-AM CANCER SOC, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X
   Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4
   Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105
   Bibikova M, 2008, CELL STEM CELL, V2, P123, DOI 10.1016/j.stem.2008.01.005
   Bielack SS, 2002, J CLIN ONCOL, V20, P776, DOI 10.1200/JCO.20.3.776
   Biermann JS, 2010, J NATL COMPR CANC NE, V8, P688, DOI 10.6004/jnccn.2010.0051
   Blattmann C, 2010, INT J RADIAT ONCOL, V78, P237, DOI 10.1016/j.ijrobp.2010.03.010
   Bradner JE, 2010, NAT CHEM BIOL, V6, P238, DOI 10.1038/NCHEMBIO.313
   Carraway HE, 2007, J CLIN ONCOL, V25, P1955, DOI 10.1200/JCO.2006.09.8293
   Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427
   Chen L, 2013, FEBS LETT, V587, P1366, DOI 10.1016/j.febslet.2013.03.007
   Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011
   Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030
   Cheng JC, 2003, J NATL CANCER I, V95, P399, DOI 10.1093/jnci/95.5.399
   Christiansen AJ, 2011, P NATL ACAD SCI USA, V108, P4141, DOI 10.1073/pnas.1011037108
   Cogdill AP, 2012, SURGERY, V152, pS13, DOI 10.1016/j.surg.2012.05.031
   Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44
   Cruz CR, 2011, CLIN CANCER RES, V17, P7058, DOI 10.1158/1078-0432.CCR-11-1873
   Czekierdowski A, 2006, NEUROENDOCRINOL LETT, V27, P381
   Da CPE, 2011, EPIGENETICS, V6, P1413, DOI [10.4161/epi.6.12.18271, DOI 10.4161/EPI.6.12.18271]
   Das S, 2013, ONCOGENE, V32, P2927, DOI 10.1038/onc.2012.311
   Di Fiore R, 2013, J CELL PHYSIOL, V228, P1676, DOI 10.1002/jcp.24329
   Dokun OY, 2008, INT J CANCER, V123, P2798, DOI 10.1002/ijc.23893
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Duan ZF, 2011, MOL CANCER THER, V10, P1337, DOI 10.1158/1535-7163.MCT-11-0096
   Enders GH, 2009, J CLIN INVEST, V119, P758, DOI 10.1172/JCI38973
   Ettou S, 2012, LEUKEMIA, V26, P2297, DOI 10.1038/leu.2012.152
   Fatemi M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni180
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376
   Fu SQ, 2011, CANCER-AM CANCER SOC, V117, P1661, DOI 10.1002/cncr.25701
   Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976
   Garcia-Manero G, 2011, J CLIN ONCOL, V29, P516, DOI 10.1200/JCO.2010.31.0854
   Gazin C, 2007, NATURE, V449, P1073, DOI 10.1038/nature06251
   Ghanim V, 2012, BLOOD, V119, P4242, DOI 10.1182/blood-2011-09-382770
   Gokgoz N, 2001, CANCER, V92, P2181, DOI 10.1002/1097-0142(20011015)92:8<2181::AID-CNCR1561>3.0.CO;2-3
   Goodyear O, 2010, BLOOD, V116, P1908, DOI 10.1182/blood-2009-11-249474
   Gordon N, 2007, CLIN CANCER RES, V13, P4503, DOI 10.1158/1078-0432.CCR-07-0313
   Graham JS, 2009, EUR J CANCER, V45, P1129, DOI 10.1016/j.ejca.2009.01.003
   Guo JJU, 2011, NAT NEUROSCI, V14, P1345, DOI 10.1038/nn.2900
   Guo JU, 2011, CELL CYCLE, V10, P2662, DOI 10.4161/cc.10.16.17093
   Gupta A, 2003, CANCER RES, V63, P664
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446
   Hassan SE, 2012, CANCER-AM CANCER SOC, V118, P740, DOI 10.1002/cncr.26339
   He CL, 2009, BIOCHEM BIOPH RES CO, V388, P35, DOI 10.1016/j.bbrc.2009.07.101
   Hoffmann MJ, 2005, BIOCHEM CELL BIOL, V83, P296, DOI 10.1139/o05-036
   Hollander MC, 2002, ONCOGENE, V21, P6228, DOI 10.1038/sj.onc.1205774
   Holleran JL, 2005, CLIN CANCER RES, V11, P3862, DOI 10.1158/1078-0432.CCR-04-2406
   Hou P, 2006, CANCER-AM CANCER SOC, V106, P1602, DOI 10.1002/cncr.21762
   Huang GX, 2012, CANCER RES, V72, P908, DOI 10.1158/0008-5472.CAN-11-1460
   Huang GX, 2009, ONCOL RES, V18, P31, DOI 10.3727/096504009789745638
   Imai T, 2003, ONCOGENE, V22, P9231, DOI 10.1038/sj.onc.1207184
   Iwasa H, 2013, J BIOL CHEM, V288, P30320, DOI 10.1074/jbc.M113.507384
   Jacobs JFM, 2007, INT J CANCER, V120, P67, DOI 10.1002/ijc.22118
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Ji F, 2013, BONE, V56, P220, DOI 10.1016/j.bone.2013.05.020
   Jones KB, 2012, CANCER RES, V72, P1865, DOI 10.1158/0008-5472.CAN-11-2663
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kager L, 2003, J CLIN ONCOL, V21, P2011, DOI 10.1200/JCO.2003.08.132
   Kanai Y, 1999, HEPATOLOGY, V29, P703, DOI 10.1002/hep.510290338
   Kansara M, 2009, J CLIN INVEST, V119, P837, DOI 10.1172/JCI37175
   Kantarjian HM, 2007, CANCER-AM CANCER SOC, V109, P1133, DOI 10.1002/cncr.22508
   Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678
   Kleinschmidt MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041446
   Kobayashi Eisuke, 2012, Sarcoma, V2012, P359739, DOI 10.1155/2012/359739
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kovalchuk O, 2010, CARCINOGENESIS, V31, P1882, DOI 10.1093/carcin/bgq119
   Kresse SH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048262
   Lawlor ER, 2012, CLIN CANCER RES, V18, P2768, DOI 10.1158/1078-0432.CCR-11-1921
   Le May N, 2010, MOL CELL, V38, P54, DOI 10.1016/j.molcel.2010.03.004
   Lemaire M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-128
   LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0
   Li SF, 2003, MOL CARCINOGEN, V38, P78, DOI 10.1002/mc.10147
   Li YG, 2013, CARCINOGENESIS, V34, P1601, DOI 10.1093/carcin/bgt065
   Lim S, 2003, ONCOL REP, V10, P897
   Lin JQ, 2009, CLIN CANCER RES, V15, P6241, DOI 10.1158/1078-0432.CCR-09-0567
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Ma DK, 2009, SCIENCE, V323, P1074, DOI 10.1126/science.1166859
   Maire G, 2011, CANCER GENET-NY, V204, P138, DOI 10.1016/j.cancergen.2010.12.012
   Máthé E, 2004, NAT GENET, V36, P117, DOI 10.1038/ng0204-117
   Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389
   Meek DW, 2012, CANCER LETT, V324, P126, DOI 10.1016/j.canlet.2012.05.011
   Mercurio C, 2010, PHARMACOL RES, V62, P18, DOI 10.1016/j.phrs.2010.02.010
   Mitani Y, 2005, J PATHOL, V205, P65, DOI 10.1002/path.1684
   Moolmuang B, 2011, CELL CYCLE, V10, P518, DOI 10.4161/cc.10.3.14756
   Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086
   Niehrs C, 2012, TRENDS CELL BIOL, V22, P220, DOI 10.1016/j.tcb.2012.01.002
   Nosho K, 2009, GASTROENTEROLOGY, V137, P1609, DOI 10.1053/j.gastro.2009.08.002
   Ognjanovic S, 2012, CANCER-AM CANCER SOC, V118, P1387, DOI 10.1002/cncr.26390
   Oh JH, 2006, CLIN ORTHOP RELAT R, P216, DOI 10.1097/01.blo.0000188063.56091.69
   Oki Y, 2007, CANCER, V109, P899, DOI 10.1002/cncr.22470
   Pakos EE, 2004, CLIN CANCER RES, V10, P6208, DOI 10.1158/1078-0432.CCR-04-0246
   Park YB, 2002, CANCER GENET CYTOGEN, V133, P105, DOI 10.1016/S0165-4608(01)00575-1
   Patra SK, 2008, FEBS J, V275, P5217, DOI 10.1111/j.1742-4658.2008.06658.x
   Png KJ, 2011, GENE DEV, V25, P226, DOI 10.1101/gad.1974211
   Pogribny IP, 2010, INT J CANCER, V127, P1785, DOI 10.1002/ijc.25191
   Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2
   Poos K, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003210
   Qiu TZ, 2013, FUTURE ONCOL, V9, P255, DOI [10.2217/FON.12.173, 10.2217/fon.12.173]
   Rao M, 2011, CANCER RES, V71, P4192, DOI 10.1158/0008-5472.CAN-10-2442
   Rathi A, 2003, CLIN CANCER RES, V9, P3674
   Roh MS, 2004, APOPTOSIS, V9, P583, DOI 10.1023/B:APPT.0000038037.68908.6e
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Rubin EM, 2010, MOL CANCER THER, V9, P731, DOI 10.1158/1535-7163.MCT-09-0147
   Sadikovic B, 2009, HUM MOL GENET, V18, P1962, DOI 10.1093/hmg/ddp117
   Sadikovic B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002834
   Samlowski WE, 2005, J CLIN ONCOL, V23, P3897, DOI 10.1200/JCO.2005.06.118
   Savage SA, 2007, CANCER EPIDEM BIOMAR, V16, P1667, DOI 10.1158/1055-9965.EPI-07-0214
   Saxonov S, 2006, P NATL ACAD SCI USA, V103, P1412, DOI 10.1073/pnas.0510310103
   Schomacher L, 2013, EPIGENETICS-US, V8, P679, DOI 10.4161/epi.24977
   Sen GL, 2010, NATURE, V463, P563, DOI 10.1038/nature08683
   Smida J, 2010, CLIN CANCER RES, V16, P4256, DOI 10.1158/1078-0432.CCR-10-0284
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Stewart DJ, 2009, CLIN CANCER RES, V15, P3881, DOI 10.1158/1078-0432.CCR-08-2196
   Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412
   Su JM, 2011, CLIN CANCER RES, V17, P589, DOI 10.1158/1078-0432.CCR-10-0738
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Thaler R, 2013, BIOCHEM PHARMACOL, V85, P173, DOI 10.1016/j.bcp.2012.10.016
   Thaler R, 2011, J BIOL CHEM, V286, P5578, DOI 10.1074/jbc.M110.166181
   Thayanithy V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043720
   Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350
   Velpula KK, 2013, NEOPLASIA, V15, P192, DOI 10.1593/neo.121334
   Wang GG, 2007, TRENDS MOL MED, V13, P373, DOI 10.1016/j.molmed.2007.07.004
   Wang GG, 2007, TRENDS MOL MED, V13, P363, DOI 10.1016/j.molmed.2007.07.003
   Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005
   Wang Y, 2013, MOL CELL BIOCHEM, V384, P105, DOI 10.1007/s11010-013-1786-4
   Watanabe K, 2005, CELL DEATH DIFFER, V12, P10, DOI 10.1038/sj.cdd.4401507
   Widodo N, 2007, J GERONTOL A-BIOL, V62, P246, DOI 10.1093/gerona/62.3.246
   Wild L, 2010, CARCINOGENESIS, V31, P1854, DOI 10.1093/carcin/bgq080
   Wilting RH, 2012, DRUG RESIST UPDATE, V15, P21, DOI 10.1016/j.drup.2012.01.008
   Wittenburg LA, 2010, CLIN CANCER RES, V16, P4832, DOI 10.1158/1078-0432.CCR-10-1238
   Wittenburg LA, 2011, CANCER CHEMOTH PHARM, V67, P83, DOI 10.1007/s00280-010-1287-z
   Wunder JS, 2005, J CLIN ONCOL, V23, P1483, DOI 10.1200/JCO.2005.04.074
   Yamashita S, 2006, CANCER SCI, V97, P64, DOI 10.1111/j.1349-7006.2006.00136.x
   Yang C, 2011, CANCER CHEMOTH PHARM, V67, P439, DOI 10.1007/s00280-010-1344-7
   Yang DF, 2012, J IMMUNOL, V188, P4441, DOI 10.4049/jimmunol.1103035
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Yang QW, 2004, CLIN CANCER RES, V10, P8493, DOI 10.1158/1078-0432.CCR-04-1331
   Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930
   Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611
   Zhang CS, 2008, INT J CANCER, V123, P998, DOI 10.1002/ijc.23650
   Zhang HL, 2013, FASEB J, V27, P232, DOI 10.1096/fj.12-215491
   Zhang RP, 2011, J BIOL CHEM, V286, P41083, DOI 10.1074/jbc.M111.258715
   Zheng JH, 2013, CLIN CANCER RES, V19, P1400, DOI 10.1158/1078-0432.CCR-12-2888
   Zheng ZX, 2012, FASEB J, V26, P449, DOI 10.1096/fj.11-190025
   Zhou X, 2013, BIOCHEM BIOPH RES CO, V437, P653, DOI 10.1016/j.bbrc.2013.07.033
   Zorzi AP, 2013, PEDIATR BLOOD CANCER, V60, P1868, DOI 10.1002/pbc.24694
   Zou CY, 2012, CANCER-AM CANCER SOC, V118, P1845, DOI 10.1002/cncr.26486
NR 158
TC 26
Z9 28
U1 0
U2 15
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD MAY
PY 2014
VL 41
IS 5
BP 3303
EP 3315
DI 10.1007/s11033-014-3193-7
PG 13
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AG9JC
UT WOS:000335734400064
PM 24500341
DA 2025-01-12
ER

PT J
AU Ramalho, EAVF
   Silva, JLQ
   Cartaxo, MFS
   Cavalcanti, CBL
   Rêgo, MJBM
   Oliveira, MBM
   Beltrao, EIC
AF Ramalho, Eduardo A. V. F.
   Silva-Filho, Joao L. Q.
   Cartaxo, Marina F. S.
   Cavalcanti, Carmelita B. L.
   Rego, Moacyr J. B. M.
   Oliveira, Maria B. M.
   Beltrao, Eduardo I. C.
TI Assessment of changes in the <i>brca2</i> and <i>p5</i>3 genes in breast
   invasive ductal carcinoma in northeast Brazil
SO BIOLOGICAL RESEARCH
LA English
DT Article
DE Breast cancer; Epigenetics; Metastasis; Methylation; Polymorphism
ID CODON 72 POLYMORPHISM; CANCER PATIENTS; TP53 MUTATION; RISK;
   ASSOCIATION; METHYLATION; SURVIVAL; ISLANDS
AB Background: BRCA protein interacts with at least 13 different proteins that have been implicated with cancer susceptibility and loss of BRCA function is correlated to sensitivity to DNA crosslinking agents in preclinical models.
   Results: BRCA2 methylation frequency was 44%, p53 Pro22 allele frequency was 32% and heterozygous frequency of Arg/Pro72 genotype was 60% which could be associated as risk factor for metastasis ( p = 0.046 OR = 4.190). Regarding to polymorphism of codon 249 the frequency of Arg249 allele presented 82% which was considered not statistically significant.
   Conclusions: There was not statistical significance to BRCA2 promoter methylation with any parameters chosen. However, our findings suggest that patients who present heterozygous genotype at codon 72 of p53 gene may have a major susceptibility to any type of metastasis and this could serve as potential auxiliary biomarker for poor prognosis.
C1 [Ramalho, Eduardo A. V. F.; Silva-Filho, Joao L. Q.; Cartaxo, Marina F. S.; Cavalcanti, Carmelita B. L.; Rego, Moacyr J. B. M.; Beltrao, Eduardo I. C.] Univ Fed Pernambuco, Keizo Asami Immunopathol Lab, Recife, PE, Brazil.
   [Oliveira, Maria B. M.; Beltrao, Eduardo I. C.] Univ Fed Pernambuco, Dept Biochem, Recife, PE, Brazil.
   [Beltrao, Eduardo I. C.] Univ Fed Pernambuco UFPE, Lab Imunopatol Keizo Asami, BR-50670901 Recife, PE, Brazil.
C3 Universidade Federal de Pernambuco; Universidade Federal de Pernambuco;
   Universidade Federal de Pernambuco
RP Beltrao, EIC (通讯作者)，Univ Fed Pernambuco, Keizo Asami Immunopathol Lab, Recife, PE, Brazil.
EM ebeltrao@hotmail.com
RI Melo de Oliveira, Maria Betânia/HZJ-4146-2023; Rego, Moacyr/I-6782-2013
OI Quirino da Silva Filho, Joao Luiz/0000-0002-4992-6168; Rego,
   Moacyr/0000-0002-1883-6012; Cartaxo, Marina Falcao de
   Souza/0000-0002-8772-9181
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES);
   Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq);
   Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco
   (FACEPE)
FX This research was supported by Coordenacao de Aperfeicoamento de Pessoal
   de Nivel Superior (CAPES); Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) and Fundacao de Amparo a Ciencia e
   Tecnologia do Estado de Pernambuco (FACEPE).
CR Alawadi S, 2011, MED ONCOL, V28, P709, DOI 10.1007/s12032-010-9505-4
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Chirnomas D, 2006, MOL CANCER THER, V5, P952, DOI 10.1158/1535-7163.MCT-05-0493
   Chosdol K, 2002, CURR SCI INDIA, V82, P1253
   Costa KA, 2012, J BIOSCIENCES, V37, P33, DOI 10.1007/s12038-012-9183-9
   Damin APS, 2006, CANCER DETECT PREV, V30, P523, DOI 10.1016/j.cdp.2006.09.007
   Erkko H, 2007, NATURE, V446, P316, DOI 10.1038/nature05609
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Gomez-Lazaro M, 2004, J PHYSIOL BIOCHEM, V60, P287, DOI 10.1007/BF03167075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hussain SP, 2001, CANCER RES, V61, P6350
   Kalemi TG, 2005, CANCER LETT, V222, P57, DOI 10.1016/j.canlet.2004.11.025
   Karran P, 2000, CURR OPIN GENET DEV, V10, P144, DOI 10.1016/S0959-437X(00)00069-1
   Kimbi GC, 2005, J GASTROEN HEPATOL, V20, P1185, DOI 10.1111/j.1440-1746.2005.03951.x
   LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0
   LARSEN F, 1992, GENET ANAL-BIOMOL E, V9, P80, DOI 10.1016/1050-3862(92)90002-M
   Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774
   Nelson HH, 2005, CARCINOGENESIS, V26, P1770, DOI 10.1093/carcin/bgi125
   Nikkilä J, 2009, ONCOGENE, V28, P1843, DOI 10.1038/onc.2009.33
   Nygren AOH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni127
   Orsted DD, 2007, J EXP MED, V204, P1295, DOI 10.1084/jem.20062476
   Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241
   Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495
   Pharoah PDP, 1999, BRIT J CANCER, V80, P1968, DOI 10.1038/sj.bjc.6690628
   Powell SN, 2008, ANTI-CANCER AGENT ME, V8, P448, DOI 10.2174/187152008784220267
   Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959
   Seal S, 2006, NAT GENET, V38, P1239, DOI 10.1038/ng1902
   Shen HB, 2003, J INVEST DERMATOL, V121, P1510, DOI 10.1046/j.1523-1747.2003.12648.x
   Shu KX, 2007, COLLOID SURFACE B, V55, P10, DOI 10.1016/j.colsurfb.2006.11.003
   Solyom S, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003223
   Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428
   Tassone P, 2012, CANC BIOL, V8, P648
   Thomas M, 1999, MOL CELL BIOL, V19, P1092
   Thomas M, 2001, MOL CELL BIOL, V2, P1092
   Tommiska J, 2005, CLIN CANCER RES, V11, P5098, DOI 10.1158/1078-0432.CCR-05-0173
   Tutt A, 2002, TRENDS MOL MED, V8, P571, DOI 10.1016/S1471-4914(02)02434-6
   Venkitaraman AR, 2009, ANNU REV PATHOL-MECH, V4, P461, DOI 10.1146/annurev.pathol.3.121806.151422
   Vijayaraman KP, 2012, ASIAN PAC J CANCER P, V13, P511, DOI 10.7314/APJCP.2012.13.2.511
   Zhuo WL, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-115
NR 39
TC 12
Z9 13
U1 0
U2 6
PU SOC BIOLGIA CHILE
PI SANTIAGO
PA CASILLA 16164, SANTIAGO 9, CHILE
SN 0716-9760
EI 0717-6287
J9 BIOL RES
JI Biol. Res.
PD MAR 26
PY 2014
VL 47
AR 3
DI 10.1186/0717-6287-47-3
PG 7
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA AH0VI
UT WOS:000335838300003
PM 25027116
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Rosik, L
   Niegisch, G
   Fischer, U
   Jung, M
   Schulz, WA
   Hoffmann, MJ
AF Rosik, Lorena
   Niegisch, Guenter
   Fischer, Ute
   Jung, Manfred
   Schulz, Wolfgang Arthur
   Hoffmann, Michele Janine
TI Limited efficacy of specific HDAC6 inhibition in urothelial cancer cells
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE HDAC; HDAC inhibitor; Tubacin; Tubastatin; ST-80; bortezomib; 17-AAG;
   urothelial cancer
ID SUBEROYLANILIDE HYDROXAMIC ACID; ACUTE MYELOID-LEUKEMIA; HISTONE
   DEACETYLASE-6; BLADDER-CANCER; BREAST-CANCER; AGGRESOME FORMATION;
   CHAPERONE FUNCTION; MULTIPLE-MYELOMA; URINARY-BLADDER; PHASE-II
AB Epigenetic modifiers such as histone deacetylases (HDACs) have come into focus as novel drug targets for cancer therapy due to their functional role in tumor progression. Since common pan-HDAC inhibitors have adverse side effects and minor anti-cancer activity against solid tumors, enzyme-specific inhibitors were developed. HDAC6 is especially well-suited for specific inhibition due to its unique domain structure and mode of action and has been suggested to provide an exceptionally suitable target for cancer therapy. However, expression and function of HDACs have been insufficiently studied in urothelial cancers (UC), a disease urgently requiring new therapeutic approaches. The present study sought to evaluate HDAC6 as a target for treatment of urothelial cancers with enzyme-specific inhibitors. We observed moderate HDAC6 overexpression in urothelial cancer tissues and a broad range of expression in urothelial cancer cell lines. In the cell lines Tubacin was the most potent inhibitor, compared with Tubastatin and ST-80, but still active only at high micromolar concentrations. HDAC6 expression levels correlated poorly with sensitivity to enzyme inhibition. Combined treatments with heat shock, HSP90 inhibition by 17-AA G, proteasome inhibition by bortezomib or DNA-damaging agents did not result in significant synergistic effects. Experiments with siRNA-mediated knockdown further underlined that urothelial cancer cells do not critically depend on HDAC6 expression for survival.
C1 [Rosik, Lorena; Niegisch, Guenter; Schulz, Wolfgang Arthur; Hoffmann, Michele Janine] Univ Dusseldorf, Fac Med, Dept Urol, Dusseldorf, Germany.
   [Fischer, Ute] Univ Dusseldorf, Fac Med, Dept Pediat Oncol Hematol & Clin Immunol, Dusseldorf, Germany.
   [Jung, Manfred] Univ Freiburg, Inst Pharmaceut Sci, D-79106 Freiburg, Germany.
   [Jung, Manfred] German Canc Consortium DKTK, Heidelberg, Germany.
   [Jung, Manfred] German Canc Res Ctr, Heidelberg, Germany.
C3 Heinrich Heine University Dusseldorf; Heinrich Heine University
   Dusseldorf; University of Freiburg; Helmholtz Association; German Cancer
   Research Center (DKFZ); Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Niegisch, G (通讯作者)，Univ Dusseldorf, Fac Med, Dept Urol, Dusseldorf, Germany.
EM Guenter.Niegisch@med.uni-duesseldorf.de
RI Hoffmann, Michele/AAL-1028-2020; Schulz, Wolfgang/N-3402-2019; Niegisch,
   Günter/AAX-3069-2021; Jung, Manfred/Q-8029-2016
OI Schulz, Wolfgang/0000-0002-2196-463X; Niegisch,
   Gunter/0000-0001-6929-8691; Jung, Manfred/0000-0002-6361-7716
FU German Research Foundation [NIE 1398/1-1]
FX The study was in part funded by a grant of the German Research
   Foundation to G.N. (NIE 1398/1-1). The authors thank Marija Lenzen for
   experimental support.
CR Ahmad M, 2012, DNA CELL BIOL, V31, pS62, DOI 10.1089/dna.2011.1575
   Arsenault D, 2013, PLOS ONE, V8
   Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Bazzaro M, 2008, CLIN CANCER RES, V14, P7340, DOI 10.1158/1078-0432.CCR-08-0642
   Boyault C, 2007, ONCOGENE, V26, P5468, DOI 10.1038/sj.onc.1210614
   Boyault C, 2007, GENE DEV, V21, P2172, DOI 10.1101/gad.436407
   Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910
   Butler JS, 2012, EPIGENOMICS-UK, V4, P163, DOI [10.2217/EPI.12.3, 10.2217/epi.12.3]
   Butler KV, 2010, J AM CHEM SOC, V132, P10842, DOI 10.1021/ja102758v
   Cabrero JR, 2006, MOL BIOL CELL, V17, P3435, DOI 10.1091/mbc.E06-01-0008
   Chen Y, 2008, CURR OPIN PHARMACOL, V8, P440, DOI 10.1016/j.coph.2008.07.005
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Ding G, 2013, FEBS LETT, V587, P880, DOI 10.1016/j.febslet.2013.02.001
   Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999
   Dyrskjot L, 2004, CANCER RES, V64, P4040, DOI 10.1158/0008-5472.CAN-03-3620
   Dyrskjot L, 2007, FRONT BIOSCI-LANDMRK, V12, P2063, DOI 10.2741/2211
   Gao YS, 2007, MOL CELL BIOL, V27, P8637, DOI 10.1128/MCB.00393-07
   Garg M, 2010, EUR J CANCER, V46, P207, DOI 10.1016/j.ejca.2009.10.020
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Hackanson B, 2012, LEUKEMIA RES, V36, P1055, DOI 10.1016/j.leukres.2012.02.026
   Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100
   Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102
   Hoffmann MJ, 2005, INT J CANCER, V114, P406, DOI 10.1002/ijc.20749
   Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a
   Jung KH, 2012, HEPATOLOGY, V56, P644, DOI 10.1002/hep.25699
   Kaliszczak M, 2013, BRIT J CANCER, V108, P342, DOI 10.1038/bjc.2012.576
   Kaluza D, 2011, EMBO J, V30, P4142, DOI 10.1038/emboj.2011.298
   Kanno K, 2012, ONCOL REP, V28, P867, DOI 10.3892/or.2012.1898
   Kapoor S, 2009, INT J CANCER, V124, P509, DOI 10.1002/ijc.23975
   Karkoulis PK, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-481
   Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5
   Koch A, 2012, CELL ONCOL, V35, P243, DOI 10.1007/s13402-012-0082-8
   Komatsu S, 2013, BIOCHEM BIOPH RES CO, V437, P41, DOI 10.1016/j.bbrc.2013.06.032
   Lafarga V, 2012, EMBO J, V31, P856, DOI 10.1038/emboj.2011.466
   Lee JH, 2013, P NATL ACAD SCI USA, V110, P15704, DOI 10.1073/pnas.1313893110
   Lee JS, 2010, J CLIN ONCOL, V28, P2660, DOI 10.1200/JCO.2009.25.0977
   Li Y, 2013, FEBS J, V280, P775, DOI 10.1111/febs.12079
   Liu YJ, 2012, J BIOL CHEM, V287, P29168, DOI 10.1074/jbc.M112.371120
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079
   Mengual L, 2009, J UROLOGY, V182, P741, DOI 10.1016/j.juro.2009.03.084
   Modesitt SC, 2008, GYNECOL ONCOL, V109, P182, DOI 10.1016/j.ygyno.2008.01.009
   Namdar M, 2010, P NATL ACAD SCI USA, V107, P20003, DOI 10.1073/pnas.1013754107
   Nawrocki ST, 2006, CANCER RES, V66, P3773, DOI 10.1158/0008-5472.CAN-05-2961
   NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O
   Niegisch G, 2013, UROL ONCOL-SEMIN ORI, V31, P1770, DOI 10.1016/j.urolonc.2012.06.015
   Oehme I, 2013, AUTOPHAGY, V9, P2163, DOI 10.4161/auto.26450
   Oehme I, 2013, P NATL ACAD SCI USA, V110, pE2592, DOI 10.1073/pnas.1300113110
   Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236
   Qin HX, 2012, ASIAN PAC J CANCER P, V13, P3367, DOI 10.7314/APJCP.2012.13.7.3367
   Rao R, 2008, BLOOD, V112, P1886, DOI 10.1182/blood-2008-03-143644
   Riolo MT, 2012, J BIOL CHEM, V287, P10885, DOI 10.1074/jbc.M111.308791
   Sakuma T, 2006, INT J ONCOL, V29, P117
   Sanchez-Carbayo M, 2006, J CLIN ONCOL, V24, P778, DOI 10.1200/JCO.2005.03.2375
   Santo L, 2012, BLOOD, V119, P2579, DOI 10.1182/blood-2011-10-387365
   Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110
   Shechter D, 2007, NAT PROTOC, V2, P1445, DOI 10.1038/nprot.2007.202
   Simon D, 2010, HUM MOL GENET, V19, P2015, DOI 10.1093/hmg/ddq083
   Song CL, 2013, J BIOL CHEM, V288, P28021, DOI 10.1074/jbc.M113.498758
   Sternberg CN, 2013, EUR UROL, V63, P58, DOI 10.1016/j.eururo.2012.08.010
   Subramanian C, 2011, NEOPLASIA, V13, P726, DOI 10.1593/neo.11558
   Swiatkowski S, 2003, EXP CELL RES, V282, P48, DOI 10.1006/excr.2002.5647
   Valenzuela-Fernández A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003
   Van Damme M, 2012, EPIGENETICS-US, V7, P1403, DOI 10.4161/epi.22674
   von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757
   Wilting RH, 2010, EMBO J, V29, P2586, DOI 10.1038/emboj.2010.136
   Yu HJ, 2013, HISTOPATHOLOGY, V62, P788, DOI 10.1111/his.12087
   Zhang ZH, 2004, CLIN CANCER RES, V10, P6962, DOI 10.1158/1078-0432.CCR-04-0455
   Zuo QQ, 2012, ONCOL REP, V27, P819, DOI 10.3892/or.2011.1553
NR 69
TC 38
Z9 41
U1 0
U2 10
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JUN
PY 2014
VL 15
IS 6
BP 742
EP 757
DI 10.4161/cbt.28469
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AI8MC
UT WOS:000337169500012
PM 24618845
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Corrales, J
   Fang, X
   Thornton, C
   Mei, W
   Barbazuk, WB
   Duke, M
   Scheffler, BE
   Willett, KL
AF Corrales, J.
   Fang, X.
   Thornton, C.
   Mei, W.
   Barbazuk, W. B.
   Duke, M.
   Scheffler, B. E.
   Willett, K. L.
TI Effects on specific promoter DNA methylation in zebrafish embryos and
   larvae following benzo[a]pyrene exposure
SO COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
LA English
DT Article
DE Benzo[a]pyrene; DNA methylation; Embryo; Larvae; Zebrafish
ID PROSTATE-CANCER; GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA;
   ENVIRONMENTAL CHEMICALS; CYTOCHROME-P450 1B1; DEVELOPMENTAL BASIS;
   BREAST-CANCER; BDNF PROMOTER; HUMAN GENOME; CELL-LINE
AB Benzo[a]pyrene (BaP) is an established carcinogen and reproductive and developmental toxicant. BaP exposure in humans and animals has been linked to infertility and multigenerational health consequences. DNA methylation is the most studied epigenetic mechanism that regulates gene expression, and mapping of methylation patterns has become an important tool for understanding pathologic gene expression events. The goal of this study was to investigate aberrant changes in promoter DNA methylation in zebrafish embryos and larvae following a parental and continued embryonic waterborne BaP exposure. A total of 21 genes known for their role in human diseases were selected to measure percent methylation by multiplex deep sequencing. At 96 hpf (hours post fertilization) compared to 3.3 hpf, dazl, nqo1, sox3, cyp1b1, and gstp1 had higher methylation percentages while c-fos and cdkn1a had decreased CG methylation. BaP exposure significantly reduced egg production and offspring survival. Moreover, BaP decreased global methylation and altered CG, CHH, and CHG methylation both at 33 and 96 hpf. CG methylation changed by 10% or more due to BaP in six genes (c-fos, cdkn1a, dazl, nqo1, nrf2, and sox3) at 3.3 hpf and in ten genes (c-fos, cyp1b1, dazl, gstp1, mlh1, nqo1, pten, p53, sox2, and sox3) at 96 hpf. BaP also induced gene expression of cyp1b1 and gstp1 at 96 hpf which were found to be hypermethylated. Further studies are needed to link aberrant CG, CHH, and CHG methylation to heritable epigenetic consequences associated with disease in later life. (C) 2014 Elsevier Inc All rights reserved.
C1 [Corrales, J.; Thornton, C.; Willett, K. L.] Univ Mississippi, Dept Pharmacol, University, MS 38677 USA.
   [Fang, X.] Univ Florida, Dept Pediat, Gainesville, FL 32610 USA.
   [Mei, W.; Barbazuk, W. B.] Univ Florida, Dept Biol, Gainesville, FL 32669 USA.
   [Barbazuk, W. B.] Univ Florida, Genet Inst, Gainesville, FL 32669 USA.
   [Duke, M.; Scheffler, B. E.] USDA ARS, Stoneville, MS 38776 USA.
C3 University of Mississippi; State University System of Florida;
   University of Florida; State University System of Florida; University of
   Florida; State University System of Florida; University of Florida;
   United States Department of Agriculture (USDA)
RP Willett, KL (通讯作者)，Univ Mississippi, Dept Pharmacol, Box 1848,305 Faser Hall, University, MS 38677 USA.
EM kwillett@olemiss.edu
OI Barbazuk, William/0000-0002-0909-4563; Mei, Wenbin/0000-0002-4838-3034;
   Scheffler, Brian/0000-0003-1968-8952
FU National Institute of Environmental Health Sciences of the National
   Institutes of Health [R21ES019940, R03ES018962]; Technology Transfer
   Award from the South Central Chapter of the Society of Toxicology;
   Graduate Student Council Research Grant from the University of
   Mississippi
FX We wish to thank graduate and undergraduate students Frank Booc, Hallie
   Freyaldenhoven, Mallory White, Daniel Purdy, and Courtney Johnson for
   their critical role in assisting with fish husbandry duties before and
   during the exposure and experimental take-down. Research reported in
   this publication was supported by the National Institute of
   Environmental Health Sciences of the National Institutes of Health under
   award number: R21ES019940 and R03ES018962. It was also partly supported
   by a Technology Transfer Award from the South Central Chapter of the
   Society of Toxicology, and a Graduate Student Council Research Grant
   from the University of Mississippi. The content is solely the
   responsibility of the authors and does not necessarily represent the
   official views of the National Institutes of Health.
CR Abdolmaleky HM, 2005, AM J PHARMACOGENOMIC, V5, P149, DOI 10.2165/00129785-200505030-00002
   Ali Shaukat, 2011, PLoS One, V6, pe20037, DOI 10.1371/journal.pone.0020037
   Andersen IS, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-7-r65
   Archibong AE, 2002, REPROD TOXICOL, V16, P801, DOI 10.1016/S0890-6238(02)00058-8
   Autry AE, 2009, BIOL PSYCHIAT, V66, P812, DOI 10.1016/j.biopsych.2009.08.033
   BARBIERI O, 1986, CANCER RES, V46, P94
   Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129
   Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2
   Bouayed J, 2009, TOXICOLOGY, V259, P97, DOI 10.1016/j.tox.2009.02.010
   Bowes RC, 1996, BIOCHEM PHARMACOL, V52, P587, DOI 10.1016/0006-2952(96)00310-3
   Breton CV, 2012, ENVIRON HEALTH PERSP, V120, P1320, DOI 10.1289/ehp.1104439
   Campión J, 2009, OBES REV, V10, P383, DOI 10.1111/j.1467-789X.2009.00595.x
   Chen CZ, 2012, TOXICOL SCI, V125, P248, DOI 10.1093/toxsci/kfr265
   Choudhuri S, 2010, TOXICOL APPL PHARM, V245, P378, DOI 10.1016/j.taap.2010.03.022
   Corrales J, 2014, AQUAT TOXICOL, V148, P16, DOI 10.1016/j.aquatox.2013.12.028
   D'Addario C, 2012, NEUROPSYCHOPHARMACOL, V37, P1647, DOI 10.1038/npp.2012.10
   de Waard PWJ, 2008, MUTAGENESIS, V23, P67, DOI 10.1093/mutage/gem046
   DiNardo CD, 2013, AM J HEMATOL, V88, P784, DOI 10.1002/ajh.23511
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, HUM MOL GENET, V10, P3001, DOI 10.1093/hmg/10.26.3001
   Fang XF, 2013, COMP BIOCHEM PHYS B, V166, P99, DOI 10.1016/j.cbpb.2013.07.007
   Fang XF, 2013, ENVIRON TOXICOL PHAR, V36, P40, DOI 10.1016/j.etap.2013.02.014
   Farthing CR, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000116
   Feng SH, 2010, P NATL ACAD SCI USA, V107, P8689, DOI 10.1073/pnas.1002720107
   Fuchikami M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023881
   Gaspari L, 2003, MUTAT RES-GEN TOX EN, V535, P155, DOI 10.1016/S1383-5718(02)00297-8
   Habano W, 2009, INT J ONCOL, V34, P1085, DOI 10.3892/ijo_00000235
   Han L, 2008, COMP FUNCT GENOM, DOI 10.1155/2008/565631
   HASS BS, 1993, MUTAT RES, V295, P281, DOI 10.1016/0921-8734(93)90026-Y
   Heindel JJ, 2008, BASIC CLIN PHARMACOL, V102, P76, DOI 10.1111/j.1742-7843.2007.00184.x
   Heindel JJ, 2006, SEMIN REPROD MED, V24, P168, DOI 10.1055/s-2006-944423
   Heller G, 2010, CANCER METAST REV, V29, P95, DOI 10.1007/s10555-010-9203-x
   Hernandez-Vargas H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009749
   HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026
   Hirabayashi Y, 2010, NAT REV NEUROSCI, V11, P377, DOI 10.1038/nrn2810
   Hockley SL, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-260
   Howe K, 2013, NATURE, V496, P498, DOI 10.1038/nature12111
   Ichiyanagi T, 2013, NUCLEIC ACIDS RES, V41, P738, DOI 10.1093/nar/gks1117
   Intarasunanont P, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-31
   Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7
   Keller S, 2010, ARCH GEN PSYCHIAT, V67, P258, DOI 10.1001/archgenpsychiatry.2010.9
   Khor TO, 2011, BIOCHEM PHARMACOL, V82, P1073, DOI 10.1016/j.bcp.2011.07.065
   KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302
   Kisseljova NP, 2005, BIOCHEMISTRY-MOSCOW+, V70, P743, DOI 10.1007/s10541-005-0179-z
   Krausz C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044479
   KRISTENSEN P, 1995, ENVIRON HEALTH PERSP, V103, P588, DOI 10.2307/3432435
   Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167
   Lahtz C, 2011, J MOL CELL BIOL, V3, P51, DOI 10.1093/jmcb/mjq053
   Latimer J.S., 2003, PAHS, P9, DOI [10.1002/0470867132.ch2, DOI 10.1002/0470867132.CH2]
   LeBaron MJ, 2010, MUTAT RES-REV MUTAT, V705, P83, DOI 10.1016/j.mrrev.2010.04.003
   Lees-Murdock DJ, 2008, EPIGENETICS-US, V3, P5, DOI 10.4161/epi.3.1.5553
   LEGRAVEREND C, 1984, TERATOLOGY, V29, P35, DOI 10.1002/tera.1420290106
   Li B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071215
   Li Z, 2012, TOXICOL SCI, V125, P233, DOI 10.1093/toxsci/kfr261
   Lichtenstein AV, 2001, BIOCHEMISTRY-MOSCOW+, V66, P235, DOI 10.1023/A:1010249510906
   Lindeman LC, 2010, INT J DEV BIOL, V54, P803, DOI 10.1387/ijdb.103081ll
   Liu L, 2003, MECH AGEING DEV, V124, P989, DOI 10.1016/j.mad.2003.08.001
   Loo WTY, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-110
   MACKENZIE KM, 1981, BIOL REPROD, V24, P183, DOI 10.1095/biolreprod24.1.183
   Majumdar S, 2011, CURR GENOMICS, V12, P486, DOI 10.2174/138920211797904061
   Manikkam M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046249
   Martin M., 2011, EMBnet.journal, V17, P10, DOI DOI 10.14806/EJ.17.1.200
   Mohamed ESA, 2010, HUM REPROD, V25, P2427, DOI 10.1093/humrep/deq205
   Mohn F, 2008, MOL CELL, V30, P755, DOI 10.1016/j.molcel.2008.05.007
   Muggerud AA, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2466
   Navarro-Costa P, 2010, HUM REPROD, V25, P2647, DOI 10.1093/humrep/deq200
   Popp C, 2010, NATURE, V463, P1101, DOI 10.1038/nature08829
   Pulverer W, 2012, BIOCHIMIE, V94, P2345, DOI 10.1016/j.biochi.2012.06.023
   Qin GH, 2010, INHAL TOXICOL, V22, P322, DOI 10.3109/08958370903341891
   Rengaraj D, 2010, THERIOGENOLOGY, V74, P765, DOI 10.1016/j.theriogenology.2010.04.001
   Richiardi L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068162
   Rousseaux S, 2005, GENE, V345, P139, DOI 10.1016/j.gene.2004.12.004
   Santoriello C, 2012, J CLIN INVEST, V122, P2337, DOI 10.1172/JCI60434
   Sanz LA, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-3-110
   Shirane K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003439
   Singh S, 2012, INT J MOL SCI, V13, P10143, DOI 10.3390/ijms130810143
   Sissung TM, 2006, MOL CANCER RES, V4, P135, DOI 10.1158/1541-7786.MCR-05-0101
   Sui XB, 2012, MOL BIOL REP, V39, P1105, DOI 10.1007/s11033-011-0837-8
   Szyf M, 2009, BBA-GEN SUBJECTS, V1790, P878, DOI 10.1016/j.bbagen.2009.01.009
   Tada M, 2005, J HEPATOL, V42, P511, DOI 10.1016/j.jhep.2004.11.024
   Tokizane T, 2005, CLIN CANCER RES, V11, P5793, DOI 10.1158/1078-0432.CCR-04-2545
   TURUSOV VS, 1990, CANCER LETT, V55, P227, DOI 10.1016/0304-3835(90)90123-F
   Wadjed S.A., 2001, ANN SURG, V234, P10
   WAINFAN E, 1992, CANCER RES, V52, pS2071
   Weaver JR, 2009, MAMM GENOME, V20, P532, DOI 10.1007/s00335-009-9225-2
   Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990
   Weigt S, 2011, TOXICOLOGY, V281, P25, DOI 10.1016/j.tox.2011.01.004
   WISLOCKI PG, 1986, CARCINOGENESIS, V7, P1317, DOI 10.1093/carcin/7.8.1317
   Wong OG, 2010, OBSTET GYNECOL INT, DOI [10.1155/2010/682504, DOI 10.1155/2010/682504]
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Yu SW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008579
   Zeng HW, 2011, J NUTR, V141, P1464, DOI 10.3945/jn.111.140715
   Zenzes MT, 1999, MOL HUM REPROD, V5, P125, DOI 10.1093/molehr/5.2.125
   Zenzes MT, 1998, MOL HUM REPROD, V4, P159, DOI 10.1093/molehr/4.2.159
NR 94
TC 90
Z9 108
U1 2
U2 71
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1532-0456
EI 1878-1659
J9 COMP BIOCHEM PHYS C
JI Comp. Biochem. Physiol. C-Toxicol. Pharmacol.
PD JUN
PY 2014
VL 163
BP 37
EP 46
DI 10.1016/j.cbpc.2014.02.005
PG 10
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Toxicology; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism;
   Toxicology; Zoology
GA AI8YB
UT WOS:000337211800005
PM 24576477
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Rasmussen, PB
   Staller, P
AF Rasmussen, Peter Birk
   Staller, Peter
TI The KDM5 family of histone demethylases as targets in oncology drug
   discovery
SO EPIGENOMICS
LA English
DT Article
DE cancer; enzymatic inhibitors; epigenetics; gene transcription; H3K4
   methylation; histone demethylase; jumonji; oncogenes
ID SMALL-MOLECULE INHIBITORS; TRANSCRIPTIONAL REPRESSION; H3K4 DEMETHYLASE;
   BREAST-CANCER; FUNCTIONAL-ANALYSIS; CPG ISLANDS; BINDING; RBP2; GENE;
   PROTEIN
AB There is growing evidence for a causal role of the KDM5 family of histone demethylases in human cancer. In particular, KDM5A (JARID1A/RBP2) and KDM5B (JARID1B/PLU1) contribute to cancer cell proliferation, reduce the expression of tumor suppressor genes, promote the development of drug tolerance and maintain tumor-initiating cells. KDM5 enzymes remove tri- and di-methylations of lysine 4 of histone H3 - modifications that occur at the start site of transcription in actively transcribed genes. However, the importance of the histone demethylase activity of KDM5 proteins for cancer cells has not been resolved so far. The currently available approaches suppress or remove the targeted proteins and thereby affect their putative functions as structural components and recruitment factors for other chromatin-associated proteins. Therefore, the development of specific enzymatic inhibitors for KDM5 will promote our understanding of the biological role of their catalytic activity and yield potential novel anticancer therapeutics.
C1 [Rasmussen, Peter Birk; Staller, Peter] EpiTherapeut ApS, DK-2200 Copenhagen, Denmark.
RP Staller, P (通讯作者)，EpiTherapeut ApS, Ole MaalOes Vej 3, DK-2200 Copenhagen, Denmark.
EM ps@epitherapeutics.com
CR Adegbola A, 2008, AM J MED GENET A, V146A, P505, DOI 10.1002/ajmg.a.32142
   Akimoto C, 2008, GENES CELLS, V13, P623, DOI 10.1111/j.1365-2443.2008.01193.x
   Albert M, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003461
   Alvares S.M., 2013, AGING CELL
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Barrett A, 2002, INT J CANCER, V101, P581, DOI 10.1002/ijc.10644
   Barrett A, 2007, INT J CANCER, V121, P265, DOI 10.1002/ijc.22673
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012
   Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001
   Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109
   Catchpole S, 2011, INT J ONCOL, V38, P1267, DOI 10.3892/ijo.2011.956
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200
   Chaturvedi CP, 2012, P NATL ACAD SCI USA, V109, P18845, DOI 10.1073/pnas.1213951109
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   Cox BJ, 2010, GENOME RES, V20, P1154, DOI 10.1101/gr.105106.110
   Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672
   Farcas AM, 2012, ELIFE, V1, DOI 10.7554/eLife.00205
   Ge WS, 2011, STEM CELLS, V29, P1112, DOI 10.1002/stem.663
   Ge Z, 2010, FASEB J, V24, P579, DOI 10.1096/fj.09-140087
   Gu BN, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-39
   Hayami S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-59
   He J, 2013, NAT CELL BIOL, V15, P373, DOI 10.1038/ncb2702
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hillringhaus L, 2011, J BIOL CHEM, V286, P41616, DOI 10.1074/jbc.M111.283689
   Hou JL, 2012, AM J TRANSL RES, V4, P247
   Islam ABMMK, 2011, CELL CYCLE, V10, P413, DOI 10.4161/cc.10.3.14705
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Jensen Lars R, 2010, Pathogenetics, V3, P2, DOI 10.1186/1755-8417-3-2
   Jiping Zeng, 2013, J Cell Biochem, V114, P2666, DOI 10.1002/jcb.24613
   King ONF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015535
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Krishnan S, 2013, STRUCTURE, V21, P98, DOI 10.1016/j.str.2012.10.018
   Kruidenier L, 2012, NATURE, V488, P404, DOI 10.1038/nature11262
   Lauberth SM, 2013, CELL, V152, P1021, DOI 10.1016/j.cell.2013.01.052
   Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004
   Li X, 2013, INT J MOL SCI, V14, P7866, DOI 10.3390/ijms14047866
   Liang XM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069784
   Liang Y, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005145
   Liefke R, 2010, GENE DEV, V24, P590, DOI 10.1101/gad.563210
   Liggins Amanda P, 2010, Cancer Immun, V10, P8
   Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108
   Lopez-Bigas N, 2008, MOL CELL, V31, P520, DOI 10.1016/j.molcel.2008.08.004
   Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633
   Ng SS, 2007, NATURE, V448, P87, DOI 10.1038/nature05971
   Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266
   Ohta K, 2013, INT J ONCOL, V42, P1212, DOI 10.3892/ijo.2013.1799
   Outchkourov NS, 2013, CELL REP, V3, P1071, DOI 10.1016/j.celrep.2013.02.030
   Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008
   Pasini D, 2008, GENE DEV, V22, P1345, DOI 10.1101/gad.470008
   Perinchery G, 2000, J UROLOGY, V163, P1339, DOI 10.1016/S0022-5347(05)67774-9
   Pointon JJ, 2011, GENES IMMUN, V12, P395, DOI 10.1038/gene.2011.23
   Pruitt KD, 2014, NUCLEIC ACIDS RES, V42, pD756, DOI 10.1093/nar/gkt1114
   Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Rose NR, 2011, CHEM SOC REV, V40, P4364, DOI 10.1039/c0cs00203h
   Santos C, 2006, EUR J HUM GENET, V14, P583, DOI 10.1038/sj.ejhg.5201608
   Santos-Rebouças CB, 2011, NEUROSCI LETT, V498, P67, DOI 10.1016/j.neulet.2011.04.065
   Sayegh J, 2013, J BIOL CHEM, V288, P9408, DOI 10.1074/jbc.M112.419861
   Schmitz SU, 2011, EMBO J, V30, P4586, DOI 10.1038/emboj.2011.383
   Scibetta AG, 2007, MOL CELL BIOL, V27, P7220, DOI 10.1128/MCB.00274-07
   Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Stratmann A, 2011, FEBS J, V278, P1458, DOI 10.1111/j.1742-4658.2011.08058.x
   Tahiliani M, 2007, NATURE, V447, P601, DOI 10.1038/nature05823
   Tan K, 2003, J BIOL CHEM, V278, P20507, DOI 10.1074/jbc.M301994200
   Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165
   Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535
   Tzschach A, 2006, HUM MUTAT, V27, P389, DOI 10.1002/humu.9420
   Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016
   Vogt T, 1999, LAB INVEST, V79, P1615
   Wagner EK, 2012, BIOCHEMISTRY-US, V51, P8293, DOI 10.1021/bi3009278
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035
   Wang SK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084735
   Woon ECY, 2012, ANGEW CHEM INT EDIT, V51, P1631, DOI 10.1002/anie.201107833
   Wu XD, 2013, MOL CELL, V49, P1134, DOI 10.1016/j.molcel.2013.01.016
   Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815
   Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104
   Xu M, 2013, DEV CELL, V23, P1059
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004
NR 86
TC 85
Z9 92
U1 0
U2 34
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1750-1911
EI 1750-192X
J9 EPIGENOMICS-UK
JI Epigenomics
PD JUN
PY 2014
VL 6
IS 3
BP 277
EP 286
DI 10.2217/EPI.14.14
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AN5YG
UT WOS:000340668300010
PM 25111482
DA 2025-01-12
ER

PT J
AU Thakur, S
   Singla, AK
   Chen, J
   Tran, U
   Yang, Y
   Salazar, C
   Magliocco, A
   Klimowicz, A
   Jirik, F
   Riabowol, K
AF Thakur, Satbir
   Singla, Arvind K.
   Chen, Jie
   Tran, Uyen
   Yang, Yang
   Salazar, Carolina
   Magliocco, Anthony
   Klimowicz, Alexander
   Jirik, Frank
   Riabowol, Karl
TI Reduced ING1 levels in breast cancer promotes metastasis
SO ONCOTARGET
LA English
DT Article
DE ING1; epigenetics; breast cancer; metastasis; survival
ID TUMOR-SUPPRESSOR P33(ING1); DOWN-REGULATION; PHASE-II; EXPRESSION;
   GROWTH; INHIBITOR; CELLS; CARCINOMA; PROTEINS; PROGRESSION
AB INhibitor of Growth 1 (ING1) expression is repressed in breast carcinomas, but its role in breast cancer development and metastasis is unknown. ING1 levels were quantified in >500 patient samples using automated quantitative fluorescence immunohistochemistry, and data were analysed for correlations to patient outcome. Effects of altering ING levels were examined in microarrays and metastasis assays in vitro, and in a mouse metastasis model in vivo. ING1 levels were lower in tumors compared to adjacent normal breast tissue and correlated with tumor size (p=0.019) and distant recurrence (p=0.001) in ER-or Her2+ patients. In these patients ING1 predicted disease-specific and distant metastasis-free survival. Transcriptome analysis showed that the pathway most affected by ING1 was breast cancer (p = 0.0008). Decreasing levels of ING1 increased, and increasing levels decreased, migration and invasion of MDA-MB231 cells in vitro. ING1 overexpression also blocked cancer cell metastasis in vivo and eliminated tumor-induced mortality in mouse models. Our data show that ING1 protein levels are downregulated in breast cancer and for the first time, we show that altering their levels regulates metastasis in vitro and in vivo, which indicates that ING1 may have a therapeutic role for inhibiting metastasis of breast cancer.
C1 [Thakur, Satbir; Singla, Arvind K.; Chen, Jie; Tran, Uyen; Yang, Yang; Salazar, Carolina; Jirik, Frank; Riabowol, Karl] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.
   [Riabowol, Karl] Univ Calgary, Dept Oncol, Calgary, AB, Canada.
   [Magliocco, Anthony] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
   [Klimowicz, Alexander] Tom Baker Canc Clin, Funct Tissue Imaging Unit, Translat Res Lab, Calgary, AB, Canada.
C3 University of Calgary; University of Calgary; H Lee Moffitt Cancer
   Center & Research Institute; State University System of Florida;
   University of South Florida; Tom Baker Cancer Clinic; University of
   Calgary
RP Riabowol, K (通讯作者)，Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.
EM karl@ucalgary.ca
FU Canadian Breast Cancer Foundation; Alberta Innovates-Health Solutions;
   Alberta Cancer Foundation
FX This study was supported by grants to KR from the Canadian Breast Cancer
   Foundation and to KR and FJ from Alberta Innovates-Health Solutions. ST
   is recipient of a Studentship, and JC a Fellowship from the Alberta
   Cancer Foundation. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR [Anonymous], 1997, AJCC cancer staging manual, Vfifth
   Bondareva A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005620
   Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791
   Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304
   Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Feng XL, 2006, MOL CELL BIOL, V26, P9244, DOI 10.1128/MCB.01538-06
   Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329
   Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415
   Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727
   Guo XB, 2011, WORLD J GASTROENTERO, V17, P1895, DOI 10.3748/wjg.v17.i14.1895
   He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256
   Hostetter CL, 2009, CANCER LETT, V275, P178, DOI 10.1016/j.canlet.2008.10.005
   Hung T, 2009, MOL CELL, V33, P248, DOI 10.1016/j.molcel.2008.12.016
   Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652
   Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002
   Li Fengying, 2011, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V25, P986
   Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086
   Liu YL, 2012, J CANCER RES CLIN, V138, P647, DOI 10.1007/s00432-011-1099-5
   Loewith R, 2000, MOL CELL BIOL, V20, P3807, DOI 10.1128/MCB.20.11.3807-3816.2000
   Lu ML, 2012, ONCOL LETT, V4, P47, DOI 10.3892/ol.2012.685
   Luu TH, 2008, CLIN CANCER RES, V14, P7138, DOI 10.1158/1078-0432.CCR-08-0122
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Nouman GS, 2003, J CLIN PATHOL, V56, P507, DOI 10.1136/jcp.56.7.507
   Peinado H, 2004, MOL CELL BIOL, V24, P306, DOI 10.1128/MCB.24.1.306-319.2004
   Peña PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814
   Schäfer A, 2013, GENE DEV, V27, P261, DOI 10.1101/gad.186916.112
   Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Shimada H, 2002, ONCOGENE, V21, P1208, DOI 10.1038/sj.onc.1205176
   Shinoura N, 1999, CANCER RES, V59, P5521
   Smith KT, 2010, CHEM BIOL, V17, P65, DOI 10.1016/j.chembiol.2009.12.010
   Suzuki K, 2011, HYBRIDOMA, V30, P239, DOI 10.1089/hyb.2010.0124
   Tallen G, 2009, ONCOL RES, V18, P95, DOI 10.3727/096504009789954645
   Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107
   Thakur S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043671
   Thalappilly S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021065
   Toyama T, 1999, ONCOGENE, V18, P5187, DOI 10.1038/sj.onc.1202905
   Umbricht CB, 2001, ONCOGENE, V20, P3348, DOI 10.1038/sj.onc.1204438
   Vanharanta S, 2013, NAT MED, V19, P50, DOI 10.1038/nm.3029
   Vieyra D, 2002, CANCER RES, V62, P4445
   Wang QS, 2010, HISTOPATHOLOGY, V57, P271, DOI 10.1111/j.1365-2559.2010.03623.x
   Xie YF, 2008, CANCER LETT, V271, P105, DOI 10.1016/j.canlet.2008.05.050
   Zhang X, 2004, FEBS LETT, V570, P7, DOI 10.1016/j.febslet.2004.06.010
NR 44
TC 12
Z9 14
U1 2
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN
PY 2014
VL 5
IS 12
BP 4244
EP 4256
DI 10.18632/oncotarget.1988
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AL3UM
UT WOS:000339055200023
PM 24962136
OA gold, Green Published, Green Submitted
DA 2025-01-12
ER

PT J
AU Liao, XH
   Li, YQ
   Wang, N
   Zheng, L
   Xing, WJ
   Zhao, DW
   Yan, TB
   Wang, Y
   Liu, LY
   Sun, XG
   Hu, P
   Zhou, H
   Zhang, TC
AF Liao, Xing-Hua
   Li, Yan-Qi
   Wang, Nan
   Zheng, Li
   Xing, Wen-Jing
   Zhao, Dong-Wei
   Yan, Ting-Bao
   Wang, Yue
   Liu, Long-Yue
   Sun, Xue-Guang
   Hu, Peng
   Zhou, Hao
   Zhang, Tong-Cun
TI Re-expression and epigenetic modification of maspin induced apoptosis in
   MCF-7 cells mediated by myocardin
SO CELLULAR SIGNALLING
LA English
DT Article
DE Myocardin; Maspin; Epigenetic modification; Apoptosis
ID MAMMARY EPITHELIAL-CELLS; MESENCHYMAL STEM-CELLS; SERUM RESPONSE FACTOR;
   HUMAN BREAST-CANCER; DNA METHYLATION; GENE-EXPRESSION; HISTONE
   MODIFICATIONS; DIFFERENTIATION; TRANSCRIPTION; THERAPY
AB Breast cancer is the leading cause of cancer death in women worldwide. It is well known that oncogene activation and anti-oncogene inactivation affect the development and progression of breast cancer, but the role of oncogene activation and anti-oncogene inactivation in breast cancer is still not fully understood. We now report that maspin acts as a tumor suppressor gene to induce MCF-7 cell apoptosis. In addition, maspin promoter hypermethylation and histone hypoacetylation lead to silencing of maspin gene expression in MCF-7 cells. Moreover, DNA methyltransferase (DNMT) inhibitor 5-aza-2 '-deoxycytidine (5-aza-dc) and/or the histone deacetylase (HDAC) inhibitor Trichostatin A (TSA) strongly up-regulated the expression of maspin in MCF-7 cells. Notably, myocardin can promote the re-expression of maspin in MCF-7 cells. Luciferase assay shows that myocardin activates the transcription of maspin promoter by CArG box. More importantly, 5-aza-dc/FSA and myocardin synergetically enhance re-expression of maspin and augment maspin-mediated apoptosis in MCF-7 cells. Thus, these data reveal the new insight that myocardin meditates apoptosis in breast cancer through affecting maspin reexpression and epigenetic modification to regulate the development of breast cancer, thereby raising the possibility of its use in breast cancer therapy. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Liao, Xing-Hua; Li, Yan-Qi; Wang, Nan; Zheng, Li; Xing, Wen-Jing; Zhao, Dong-Wei; Yan, Ting-Bao; Wang, Yue; Liu, Long-Yue; Sun, Xue-Guang; Zhou, Hao; Zhang, Tong-Cun] Tianjin Univ Sci & Technol, Coll Biotechnol, Key Lab Ind Fermentat Microbiol, Minist Educ & Tianjin, Tianjin 300457, Peoples R China.
   [Liao, Xing-Hua; Hu, Peng; Zhang, Tong-Cun] Wuhan Univ Sci & Technol, Inst Biol & Med, Wuhan 430000, Peoples R China.
C3 Tianjin University Science & Technology; Wuhan University of Science &
   Technology
RP Wang, N (通讯作者)，Tianjin Univ Sci & Technol, Coll Biotechnol, Tianjin, Peoples R China.
EM wn929@tust.edu.cn; tony@tust.edu.cn
RI li, yanqi/HZM-5831-2023; Wang, Nan/GRY-3150-2022
FU National Natural Science Foundation of China [30970615, 31071126,
   31000343, 31171303, 31171297, 31200955]; Program for Changjiang Scholars
   and Innovative Research Team in University of Ministry of Education of
   the People's Republic of China [IRT1166]; Research Fund for the Doctoral
   Program of Higher Education of China [20111208110001]; Key Project of
   Chinese Ministry of Education [212010]
FX This work was financially supported by the National Natural Science
   Foundation of China (Nos. 30970615, 31071126, 31000343, 31171303,
   31171297, 31200955), Program for Changjiang Scholars and Innovative
   Research Team in University of Ministry of Education of the People's
   Republic of China (IRT1166), Research Fund for the Doctoral Program of
   Higher Education of China (20111208110001) and the Key Project of
   Chinese Ministry of Education (212010).
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Beltran A, 2007, ONCOGENE, V26, P2791, DOI 10.1038/sj.onc.1210072
   Ben Shachar B, 2010, MOL CANCER RES, V8, P363, DOI 10.1158/1541-7786.MCR-09-0137
   Cao DS, 2005, MOL CELL BIOL, V25, P364, DOI 10.1128/MCB.25.1.364-376.2005
   Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7
   Dickson R B, 1988, Cancer Treat Res, V40, P119
   Domann FE, 2000, INT J CANCER, V85, P805, DOI 10.1002/(SICI)1097-0215(20000315)85:6<805::AID-IJC12>3.0.CO;2-5
   Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003
   Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680
   Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Finkel E, 1999, SCIENCE, V286, P2256, DOI 10.1126/science.286.5448.2256
   Futscher BW, 2002, NAT GENET, V31, P175, DOI 10.1038/ng886
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   GRAFF JR, 1995, CANCER RES, V55, P5195
   Hoofnagle M.H., 2003, AM J PHYSIOL-HEART C, V300, P1707
   Jiang N, 2002, ONCOGENE, V21, P4089, DOI 10.1038/sj.onc.1205507
   Kimura Y, 2010, CANCER RES, V70, P501, DOI 10.1158/0008-5472.CAN-09-1469
   Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455
   Kulis M, 2010, ADV GENET, V70, P27, DOI [10.1016/S0065-2660(10)70002-X, 10.1016/B978-0-12-380866-0.60002-2]
   Latha K, 2005, MOL CELL BIOL, V25, P1737, DOI 10.1128/MCB.25.5.1737-1748.2005
   Liu JY, 2004, CANCER RES, V64, P1703, DOI 10.1158/0008-5472.CAN-03-2568
   Maass N, 2002, BIOCHEM BIOPH RES CO, V297, P125, DOI 10.1016/S0006-291X(02)02136-8
   Marx J, 2002, SCIENCE, V295, P1444
   MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686
   Milyavsky M, 2007, CANCER CELL, V11, P133, DOI 10.1016/j.ccr.2006.11.022
   Moiseeva EP, 2007, MOL CANCER THER, V6, P3071, DOI 10.1158/1535-7163.MCT-07-0117
   Oshiro MM, 2003, ONCOGENE, V22, P3624, DOI 10.1038/sj.onc.1206545
   Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669
   Stirzaker C, 1997, CANCER RES, V57, P2229
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Wang DZ, 2001, CELL, V105, P851, DOI 10.1016/S0092-8674(01)00404-4
   Wang N, 2007, J CELL BIOCHEM, V100, P1548, DOI 10.1002/jcb.21139
   Wang N, 2012, IUBMB LIFE, V64, P331, DOI 10.1002/iub.1003
   Yanagawa Masumi, 2012, BMC Res Notes, V5, P376, DOI 10.1186/1756-0500-5-376
   Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09
   Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303
   Zhang M, 1997, CELL GROWTH DIFFER, V8, P179
   ZOU ZQ, 1994, SCIENCE, V263, P526, DOI 10.1126/science.8290962
NR 39
TC 25
Z9 28
U1 0
U2 21
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD JUN
PY 2014
VL 26
IS 6
BP 1335
EP 1346
DI 10.1016/j.cellsig.2014.03.001
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AG0OH
UT WOS:000335114300018
PM 24607789
DA 2025-01-12
ER

PT J
AU Gupta, C
   Kaur, J
   Tikoo, K
AF Gupta, Chanchal
   Kaur, Jasmine
   Tikoo, Kulbhushan
TI Regulation of MDA-MB-231 cell proliferation by GSK-3β involves
   epigenetic modifications under high glucose conditions
SO EXPERIMENTAL CELL RESEARCH
LA English
DT Article
DE Hyperglycemia; GSK-3 beta; Histone H3 phosphorylation; DNA methylation;
   Breast cancer
ID GLYCOGEN-SYNTHASE KINASE-3; WNT SIGNALING PATHWAY;
   EPITHELIAL-MESENCHYMAL TRANSITION; HISTONE H3 PHOSPHORYLATION; HUMAN
   BREAST-CANCER; DNA METHYLATION; SKELETAL-MUSCLE; DIABETES-MELLITUS; CPG
   ISLANDS; CROSS-TALK
AB Hyperglycemia is a critical risk factor for development and progression of breast cancer. We have recently reported that high glucose induces phosphorylation of histone H3 at Ser 10 as well as dephosphorylation of GSK-3 beta at Ser 9 in MDA-MB-231 cells. Here, we elucidate the mechanism underlying hyperglycemia-induced proliferation in MDA-MB-231 breast cancer cells. We provide evidence that hyperglycemia led to increased DNA methylation and DNMT1 expression in MDA-MB-231 cells. High glucose condition led to significant increase in the expression of PCNA, cyclin D1 and decrease in the expression of PTPN 12, p21 and PTEN. It also induced hypermethylation of DNA at the promoter region of PTPN 12, whereas hypomethylation at Vimentin and Snail. Silencing of GSK-3 beta by siRNA prevented histone H3 phosphorylation and reduced DNMT1 expression. We show that chromatin obtained after immunoprecipitation with phospho-histone H3 was hypermethylated under high glucose condition, which indicates a cross-talk between DNA methylation and histone H3 phosphorylation. ChIP-qPCR analysis revealed up-regulation of DNMTI and metastatic genes viz Vimentin, Snail and MMP-7 by phospho-histone H3, which were down-regulated upon GSK-3 beta silencing. To the best of our knowledge, this is the first report which shows that interplay between GSK-3 beta activation, histone H3 phosphorylation and DNA methylation directs proliferation of breast cancer cells. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Gupta, Chanchal; Kaur, Jasmine; Tikoo, Kulbhushan] Natl Inst Pharmaceut Educ & Res, Lab Epigenet & Dis, Dept Pharmacol & Toxicol, Sas Nagar 160062, Punjab, India.
C3 National Institute of Pharmaceutical Education & Research, S.A.S. Nagar
   (Mohali)
RP Tikoo, K (通讯作者)，Natl Inst Pharmaceut Educ & Res, Lab Epigenet & Dis, Dept Pharmacol & Toxicol, Sect 67, Sas Nagar 160062, Punjab, India.
EM tikoo.k@gmail.com
OI Tikoo, Kulbhushan/0000-0003-3061-9739
FU National Institute of Pharmaceutical Education and Research, S.A.S.
   Nagar, Punjab, India
FX The research work was supported by funds granted by National Institute
   of Pharmaceutical Education and Research, S.A.S. Nagar, Punjab, India.
CR Abiola M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008509
   Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2
   Barres R, 2011, AM J CLIN NUTR, V93, p897S, DOI 10.3945/ajcn.110.001933
   Bordonaro M, 2009, VITAM HORM, V80, P563, DOI 10.1016/S0083-6729(08)00619-5
   Boström P, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-348
   Cao Q, 2006, CELL RES, V16, P671, DOI 10.1038/sj.cr.7310078
   Caspi M, 2008, ONCOGENE, V27, P3546, DOI 10.1038/sj.onc.1211026
   Chen Y, 2013, BIOCHEM BIOPH RES CO, V430, P1083, DOI 10.1016/j.bbrc.2012.12.034
   Choi HS, 2005, CANCER RES, V65, P5818, DOI 10.1158/0008-5472.CAN-05-0197
   Choi SW, 2010, ADV NUTR, V1, P8, DOI 10.3945/an.110.1004
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   Ciaraldi TP, 2010, MOL CELL ENDOCRINOL, V315, P153, DOI 10.1016/j.mce.2009.05.020
   De Craene B, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1521
   Dong ZG, 2006, MOL CARCINOGEN, V45, P416, DOI 10.1002/mc.20220
   EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x
   Erdal E, 2005, INT J CANCER, V115, P903, DOI 10.1002/ijc.20972
   Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2
   Fischle W, 2008, GENE DEV, V22, P3375, DOI 10.1101/gad.1759708
   Fuso A., 2012, NEUROBIOL AGING, P1
   Gezgen G, 2012, J BUON, V17, P223
   Gupta C, 2013, J MOL ENDOCRINOL, V51, P119, DOI 10.1530/JME-13-0062
   Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326
   Henriksen EJ, 2010, CURR DIABETES REV, V6, P285, DOI 10.2174/157339910793360888
   Huang THM, 1999, HUM MOL GENET, V8, P459, DOI 10.1093/hmg/8.3.459
   Ip W, 2012, CELL BIOSCI, V2, DOI 10.1186/2045-3701-2-28
   Jacobs Keith M, 2012, Int J Cell Biol, V2012, P930710, DOI 10.1155/2012/930710
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jin T, 2008, MOL ENDOCRINOL, V22, P2383, DOI 10.1210/me.2008-0135
   Jones PA, 1996, CANCER RES, V56, P2463
   Kim M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009692
   Kokkinos MI, 2007, CELLS TISSUES ORGANS, V185, P191, DOI 10.1159/000101320
   Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455
   Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005
   Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045
   Mendez MG, 2010, FASEB J, V24, P1838, DOI 10.1096/fj.09-151639
   Monier K, 2007, J CELL SCI, V120, P101, DOI 10.1242/jcs.03326
   Nikoulina SE, 2002, DIABETES, V51, P2190, DOI 10.2337/diabetes.51.7.2190
   Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642
   Pasco MY, 2010, NEUROBIOL DIS, V38, P425, DOI 10.1016/j.nbd.2010.03.002
   Peng DF, 2006, CARCINOGENESIS, V27, P1160, DOI 10.1093/carcin/bgi361
   Robertson KD, 2005, NAT REV GENET, V6, P597, DOI 10.1038/nrg1655
   Schisano B, 2011, DIABETOLOGIA, V54, P1219, DOI 10.1007/s00125-011-2049-0
   Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041
   Sproul D., 2013, Brief Funct Genomics
   Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Szyf M, 2001, FRONT BIOSCI-LANDMRK, V6, pD599, DOI 10.2741/szyf
   Tikoo K, 2007, FEBS LETT, V581, P1071, DOI 10.1016/j.febslet.2007.02.006
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   Ullmann U, 2008, MOL HUM REPROD, V14, P169, DOI 10.1093/molehr/gan001
   Villarreal-Garza C, 2012, EXP DIABETES RES, DOI 10.1155/2012/732027
   Vrba L, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-486
   Wishart G., 2012, BREAST CANC STAT
   Wolf I, 2005, LANCET ONCOL, V6, P103, DOI 10.1016/S1470-2045(05)01736-5
   Wu AH, 2007, CARCINOGENESIS, V28, P1561, DOI 10.1093/carcin/bgm081
   Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287
   Yu XY, 2012, MOL BIOL REP, V39, P8891, DOI 10.1007/s11033-012-1756-z
   Zhang Y, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-98
NR 60
TC 28
Z9 31
U1 0
U2 12
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4827
EI 1090-2422
J9 EXP CELL RES
JI Exp. Cell Res.
PD MAY 15
PY 2014
VL 324
IS 1
BP 75
EP 83
DI 10.1016/j.yexcr.2014.03.019
PG 9
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AG5WD
UT WOS:000335488500007
PM 24704462
DA 2025-01-12
ER

PT J
AU Stueve, TR
   Wolff, MS
   Pajak, A
   Teitelbaum, SL
   Chen, J
AF Stueve, Theresa Ryan
   Wolff, Mary S.
   Pajak, Ashley
   Teitelbaum, Susan L.
   Chen, Jia
TI <i>CYP19A1</i> promoter methylation in saliva associated with milestones
   of pubertal timing in urban girls
SO BMC PEDIATRICS
LA English
DT Article
DE Aromatase; Methylation; Obesity; PPAR; Puberty
ID POLYCYSTIC-OVARY-SYNDROME; ACTIVATED RECEPTOR-GAMMA; BREAST-CANCER;
   AROMATASE EXPRESSION; PRECOCIOUS PUBARCHE; OBESITY; TISSUE; RISK; BIRTH;
   GENE
AB Background: Childhood obesity and early puberty are intermediate risk factors for later metabolic and reproductive disorders including diabetes, polycystic ovarian syndrome (PCOS), and breast cancer. Atypical methylation patterns in genes related to hormone and adipose metabolism, such as CYP19A1 (aromatase) and PPARG (peroxisome proliferator-activated receptor gamma), are associated with alterations in gene expression which may contribute to pathogenesis of these diseases. If present in early life, it is conceivable similar methylation aberrations may result in hormone perturbations that alter pubertal timing.
   Methods: We used Cox proportional hazard models to investigate whether promoter methylation of CYP19A1 and PPARG, independently or in concert with body weight, was associated with age at breast (B2) or pubic hair development (PH2) when assayed in saliva DNA collected from a cohort of New York City, Black and Hispanic girls (N = 130) enrolled in a study of pubertal timing between 6-8 years of age.
   Results: An inverse association between CYP19A1 methylation and risk of early PH2 was suggested (HR = 0.95, 95% CI = 0.90-1.00, p = 0.05). CYP19A1 methylation also appeared to modify risk of early B2 associated with body weight. Specifically, compared to normal weight girls with ` high' CYP19A1 methylation, significantly increased risk of early B2 was observed in overweight girls with 'low' but not 'high' CYP19A1 methylation (HR = 2.15; 95% CI = 1.23-3.76). However, in formal tests for effect modification, the interaction between body weight and methylation did not reach statistical significance (p for interaction = 0.085). PPARG methylation was not significantly associated with PH2 or B2.
   Conclusions: Though limited by sample size, our findings suggest methylation of CYP19A1, a critical gene in estrogen biosynthesis, may influence timing of breast development in overweight girls. Consistent with emerging reports, these data support the notion that epigenetic marks in surrogate tissues may improve risk prediction when added to standard plasma and anthropometric indicators, and warrant further study.
C1 [Stueve, Theresa Ryan; Wolff, Mary S.; Pajak, Ashley; Teitelbaum, Susan L.; Chen, Jia] Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA.
   [Stueve, Theresa Ryan] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.
C3 Icahn School of Medicine at Mount Sinai; University of Southern
   California
RP Chen, J (通讯作者)，Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY 10029 USA.
EM jia.chen@mssm.edu
OI Stueve, Theresa/0000-0002-0076-4380
FU Breast Cancer and the Environment Research Program (BCERP) [U01ES012771,
   U01ES019454, U01ES019457]; National Institute of Environmental Health
   Sciences (NIEHS); National Cancer Institute (NCI); National Center for
   Research Resources (NCRR) [CSTA-UL1RR029887]; National Institute of
   Environmental Health Sciences [5T32ES013678-07]
FX This project was made possible by the Breast Cancer and the Environment
   Research Program (BCERP) award numbers U01ES012771, U01ES019454 and
   U01ES019457 from the National Institute of Environmental Health Sciences
   (NIEHS) and the National Cancer Institute (NCI), and CSTA-UL1RR029887
   from the National Center for Research Resources (NCRR). Its contents are
   solely the responsibility of the authors and do not necessarily
   represent the official views of the NIEHS or NCI, the National
   Institutes of Health. TRS was supported by a training grant from the
   National Institute of Environmental Health Sciences (NIEHS,
   5T32ES013678-07) while writing the manuscript.
CR Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843
   Biro FM, 2012, J PEDIATR ADOL GYNEC, V25, P289, DOI 10.1016/j.jpag.2012.05.009
   Biro FM, 2010, PEDIATRICS, V126, pE583, DOI 10.1542/peds.2009-3079
   Bremer AA, 2010, METAB SYNDR RELAT D, V8, P375, DOI 10.1089/met.2010.0039
   Bulun SE, 2005, PHARMACOL REV, V57, P359, DOI 10.1124/pr.57.3.6
   BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622
   Bulun SE, 2007, J STEROID BIOCHEM, V106, P81, DOI 10.1016/j.jsbmb.2007.05.027
   Bulun SE, 2012, TRENDS ENDOCRIN MET, V23, P83, DOI 10.1016/j.tem.2011.10.003
   Clyne CD, 2002, J BIOL CHEM, V277, P20591, DOI 10.1074/jbc.M201117200
   Davison KK, 2003, PEDIATRICS, V111, P815, DOI 10.1542/peds.111.4.815
   Demura M, 2008, MOL CELL ENDOCRINOL, V283, P127, DOI 10.1016/j.mce.2007.12.003
   Fujiki K, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-38
   Geisler H, 2003, J STEROID BIOCHEM, V86, P245, DOI 10.1016/S0960-0760(03)00364-9
   Gemma C, 2009, OBESITY, V17, P1032, DOI 10.1038/oby.2008.605
   Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979
   HilakiviClarke L, 1997, P NATL ACAD SCI USA, V94, P9372, DOI 10.1073/pnas.94.17.9372
   Ibáñez L, 2006, PEDIATRICS, V117, P117, DOI 10.1542/peds.2005-0664
   Ibáñez L, 2004, J CLIN ENDOCR METAB, V89, P4331, DOI 10.1210/jc.2004-0463
   Ibáñez L, 2008, J CLIN ENDOCR METAB, V93, P1841, DOI 10.1210/jc.2008-0013
   Janfaza M, 2006, J PEDIATR ENDOCR MET, V19, P901
   Jasik CB, 2008, ANN NY ACAD SCI, V1135, P265, DOI 10.1196/annals.1429.009
   Landrigan P, 2003, ENVIRON HEALTH PERSP, V111, P1678, DOI 10.1289/ehp.5799
   Liu E, 2013, ADIPOCYTE, V2
   Lomniczi A, 2013, NAT NEUROSCI, V16, P281, DOI 10.1038/nn.3319
   Meng L, 2001, CANCER RES, V61, P2250
   Michael MD, 1997, MOL CELL ENDOCRINOL, V134, P147, DOI 10.1016/S0303-7207(97)00178-0
   Morris PG, 2011, CANCER PREV RES, V4, P1021, DOI 10.1158/1940-6207.CAPR-11-0110
   Must A, 2012, J PEDIATR-US, V160, P743, DOI 10.1016/j.jpeds.2011.10.037
   Nader PR, 2006, PEDIATRICS, V118, pE594, DOI 10.1542/peds.2005-2801
   Pancione M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014229
   Qu F, 2012, J MOL MED, V90, P911, DOI 10.1007/s00109-012-0881-4
   Relton CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031821
   Rosenbloom A, 2000, PEDIATRICS, V105, P671
   Rubin GL, 2002, ENDOCRINOLOGY, V143, P2863, DOI 10.1210/en.143.8.2863
   Santen RJ, 2009, ENDOCR REV, V30, P343, DOI 10.1210/er.2008-0016
   Smith JT, 2013, ADV EXP MED BIOL, V784, P275, DOI 10.1007/978-1-4614-6199-9_13
   Subbaramaiah K, 2012, CANCER PREV RES, V5, P1183, DOI 10.1158/1940-6207.CAPR-12-0201
   Subbaramaiah K, 2012, CANCER DISCOV, V2, P356, DOI 10.1158/2159-8290.CD-11-0241
   Tessitore L, 2004, INT J ONCOL, V24, P1529
   Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690
NR 40
TC 14
Z9 15
U1 0
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2431
J9 BMC PEDIATR
JI BMC Pediatr.
PD MAR 20
PY 2014
VL 14
AR 78
DI 10.1186/1471-2431-14-78
PG 7
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA AG4UD
UT WOS:000335414900003
PM 24649863
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Smith, AK
   Conneely, KN
   Pace, TWW
   Mister, D
   Felger, JC
   Kilaru, V
   Akel, MJ
   Vertino, PM
   Miller, AH
   Torres, MA
AF Smith, Alicia K.
   Conneely, Karen N.
   Pace, Thaddeus W. W.
   Mister, Donna
   Felger, Jennifer C.
   Kilaru, Varun
   Akel, Mary J.
   Vertino, Paula M.
   Miller, Andrew H.
   Torres, Mylin A.
TI Epigenetic changes associated with inflammation in breast cancer
   patients treated with chemotherapy
SO BRAIN BEHAVIOR AND IMMUNITY
LA English
DT Article
DE Breast cancer treatment; Epigenetics; Inflammation; Fatigue
ID DNA METHYLATION STATUS; NF-KAPPA-B; CIRCULATING MICRORNAS; PROTEIN
   EXPRESSION; TNF-ALPHA; FATIGUE; MIR-21; ACTIVATION; GENES; CELLS
AB Inflammation has been associated with fatigue during and after various types of breast cancer treatments. We examined whether prior chemotherapy was associated with DNA methylation patterns that could explain persisting inflammation and/or fatigue in women treated for breast cancer. Prior to breast radiation therapy, DNA was extracted from peripheral blood mononuclear cells (PBMCs) of 61 Stage 0-IIIA breast cancer patients who had received partial mastectomy with or without chemotherapy. DNA methylation was assessed at >485,000 CpG sites across the genome along with fatigue and plasma inflammatory markers previously associated with fatigue. Compared to non-chemotherapy-treated, women who had received chemotherapy exhibited significantly decreased methylation at eight CpG sites (p < 1.03 x 10(-7)) including four in exon 11 of transmembrane protein 49 (TMEM49), which demonstrated the largest decreases in methylation. Lower methylation at each identified CpG site was associated with increased plasma soluble tumor necrosis factor receptor 2 (sTNFR2) and interleukin (IL)-6 and mediated the relationship between chemotherapy and increases in these inflammatory biomarkers adjusting for multiple clinical and treatment characteristics. sTNFR2, but not CpG methylation status, was correlated with fatigue. Six months after breast radiation therapy, DNA methylation, inflammatory biomarkers and fatigue assessments were repeated in a subset of subjects (N = 39). Reduced methylation in 4 of the 8 identified CpG sites was still observed in chemotherapy versus non-chemotherapy-treated patients, albeit with some decay indicating the dynamic and potentially reversible nature of the changes. Reduced methylation in these 4 CpG sites also continued to correlate with either increased sTNFR2 or IL-6, but not fatigue. In conclusion, prior chemotherapy treatment was associated with decreased methylation of CpG sites in DNA from PBMCs of breast cancer patients, which correlated with increased inflammatory markers prior to and 6 months after radiation therapy. Persisting epigenetic changes secondary to chemotherapy may be one factor that contributes to inflammation and its consequences including cancer-related fatigue in vulnerable breast cancer patients. (C) 2014 Published by Elsevier Inc.
C1 [Smith, Alicia K.; Felger, Jennifer C.; Kilaru, Varun; Akel, Mary J.; Miller, Andrew H.] Emory Univ, Sch Med, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA.
   [Conneely, Karen N.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA.
   [Mister, Donna; Vertino, Paula M.; Torres, Mylin A.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA.
   [Smith, Alicia K.; Vertino, Paula M.; Miller, Andrew H.; Torres, Mylin A.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
   [Pace, Thaddeus W. W.] Univ Arizona, Coll Nursing, Tucson, AZ 85721 USA.
   [Pace, Thaddeus W. W.] Univ Arizona, Coll Med, Dept Psychiat, Tucson, AZ 85721 USA.
C3 Emory University; Emory University; Emory University; Emory University;
   University of Arizona; University of Arizona
RP Torres, MA (通讯作者)，Emory Univ, Sch Med, Dept Radiat Oncol, 1365 Clifton Rd NE,Bldg A,Rm 1307A, Atlanta, GA 30322 USA.
EM alicia.smith@emory.edu; kconnee@emory.edu; twwpace@email.arizona.edu;
   dmister@emory.edu; jfelger@emory.edu; vkilaru@emory.edu;
   makel@emory.edu; pvertin@emory.edu; amill02@emory.edu; matorre@emory.edu
RI Smith, Alicia/W-6809-2019; Felger, Jennifer/N-3034-2017; Miller,
   Andrew/AFL-5625-2022; Felger, Jennifer/E-1175-2011
OI Felger, Jennifer/0000-0003-4354-2267
FU National Cancer Institute [R21 CA155511]; Cooper Family Foundation
   Breast Cancer Initiative; Winship Cancer Institute of Emory University
   Kennedy Survivorship Pilot Grant Award; NIH/NCI [P30CA138292]
FX This work was supported in part by the National Cancer Institute (R21
   CA155511); The Cooper Family Foundation Breast Cancer Initiative; and
   the Winship Cancer Institute of Emory University Kennedy Survivorship
   Pilot Grant Award. Research reported in this publication was also
   supported in part by the NIH/NCI under award number P30CA138292. The
   content is solely the responsibility of the authors and does not
   necessarily represent the official views of the National Institutes of
   Health.
CR [Anonymous], 2013, NATURE
   Ari F, 2011, CELL BIOCHEM FUNCT, V29, P651, DOI 10.1002/cbf.1801
   Avraham A, 2012, INT J CANCER, V131, pE1166, DOI 10.1002/ijc.27526
   Baker EK, 2005, ONCOGENE, V24, P8061, DOI 10.1038/sj.onc.1208955
   Barfield RT, 2012, BIOINFORMATICS, V28, P1280, DOI 10.1093/bioinformatics/bts124
   Barrès R, 2012, CELL METAB, V15, P405, DOI 10.1016/j.cmet.2012.01.001
   Bower JE, 2011, J CLIN ONCOL, V29, P3517, DOI 10.1200/JCO.2011.36.1154
   Bower JE, 2009, CLIN CANCER RES, V15, P5534, DOI 10.1158/1078-0432.CCR-08-2584
   Bull SJ, 2009, MOL PSYCHIATR, V14, P1095, DOI 10.1038/mp.2008.48
   Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204
   Calcagno AM, 2008, BRIT J CANCER, V98, P1515, DOI 10.1038/sj.bjc.6604334
   Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   D'Anello L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-300
   GEHR G, 1992, J IMMUNOL, V149, P911
   Geinitz H, 2001, INT J RADIAT ONCOL, V51, P691, DOI 10.1016/S0360-3016(01)01657-1
   Giese-Davis J, 2011, J CLIN ONCOL, V29, P413, DOI 10.1200/JCO.2010.28.4455
   HOLM S, 1979, SCAND J STAT, V6, P65
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Jacobsen SC, 2012, DIABETOLOGIA, V55, P3341, DOI 10.1007/s00125-012-2717-8
   Kesler S., 2012, Brain Behav. Immun
   Khalaf H, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-26
   Kilaru V, 2012, EPIGENETICS-US, V7, P225, DOI 10.4161/epi.7.3.19284
   Kumarswamy R, 2011, RNA BIOL, V8, P706, DOI 10.4161/rna.8.5.16154
   Liu LQ, 2012, BRAIN BEHAV IMMUN, V26, P706, DOI 10.1016/j.bbi.2012.02.001
   Lotrich Francis E, 2009, Dialogues Clin Neurosci, V11, P417
   Metzig M, 2011, INT J CANCER, V129, P607, DOI 10.1002/ijc.26124
   Ogawa T, 2012, CELL CYCLE, V11, P1656, DOI 10.4161/cc.20120
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   Papageorgis P, 2010, CANCER RES, V70, P968, DOI 10.1158/0008-5472.CAN-09-1872
   Purcell A, 2010, SUPPORT CARE CANCER, V18, P307, DOI 10.1007/s00520-009-0653-z
   Raison CL, 2009, BIOL PSYCHIAT, V65, P296, DOI 10.1016/j.biopsych.2008.08.010
   Shanmugam M.K., 2012, Subcell Biochem, V61, P627, DOI [10.1007/978-94-007-4525-4_27, DOI 10.1007/978-94-007-4525-4_27]
   Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607
   Sharma G, 2012, TUMOR BIOL, V33, P1837, DOI 10.1007/s13277-012-0443-y
   SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O
   Smith AK, 2012, MOL PSYCHIATR, V17, P781, DOI 10.1038/mp.2011.67
   Sobel M.E., 1982, SOCIOLOGICAL METHODO, P290, DOI DOI 10.2307/270723
   Soltanpour MS, 2013, HEMATOLOGY, V18, P30, DOI 10.1179/1607845412Y.0000000030
   Suzuki M, 2012, CYTOKINE, V58, P344, DOI 10.1016/j.cyto.2012.02.009
   Swisher EM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-48
   TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637
   Tevaarwerk A.J., 2013, J CANC SURVIV
   Torres MA, 2013, CANCER-AM CANCER SOC, V119, P1951, DOI 10.1002/cncr.28003
   Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608
   Wang XS, 2012, BRAIN BEHAV IMMUN, V26, P699, DOI 10.1016/j.bbi.2011.12.007
   Wratten C, 2004, INT J RADIAT ONCOL, V59, P160, DOI 10.1016/j.ijrobp.2003.10.008
   Xu JA, 2011, MOL CARCINOGEN, V50, P136, DOI 10.1002/mc.20712
   Yasuda M, 2010, MOL CARCINOGEN, V49, P837, DOI 10.1002/mc.20660
   Young MR, 2010, MOL INTERV, V10, P76, DOI 10.1124/mi.10.2.5
   Zhong X, 2011, J AM SOC NEPHROL, V22, P1668, DOI 10.1681/ASN.2010111168
NR 50
TC 48
Z9 55
U1 0
U2 18
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0889-1591
EI 1090-2139
J9 BRAIN BEHAV IMMUN
JI Brain Behav. Immun.
PD MAY
PY 2014
VL 38
BP 227
EP 236
DI 10.1016/j.bbi.2014.02.010
PG 10
WC Immunology; Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology; Psychiatry
GA AF8RU
UT WOS:000334984100025
PM 24583204
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Tan, DY
   Tang, PZ
   Huang, JJ
   Zhang, J
   Zhou, WH
   Walker, AM
AF Tan Dunyong
   Tang Peizhi
   Huang Jianjun
   Zhang Jie
   Zhou Weihua
   Walker, Ameae M.
TI Expression of a constitutively active prolactin receptor causes histone
   trimethylation of the p53 gene in breast cancer
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE delta S2 prolactin receptor; breast cancer; enhancer of zeste homolog 2
ID HUMAN PRL RECEPTORS; PROSTATE-CANCER; EPITHELIAL-CELLS; MAMMARY-GLAND;
   EZH2; S179D; INDUCTION; POLYCOMB; MARKER; GROWTH
AB Background Prolactin (PRL) is a pituitary polypeptide hormone characterized by multiple biological actions including stimulation of growth in the prostate and formation of secretory alveoli and stimulation of milk protein gene expression in the mammary gland. PRL exerts its effect by dimerizing its receptor (PRLR) on the plasma membrane and regulating gene expression through the JAK-Stat signal pathway. We have previously described a natural variant of the PRLR in which the S2 subdomain of the extracellular domain is missing (Delta S2). Delta S2 PRLRs are dimerized in the absence of PRL and have constitutive activity in the promotion of breast cancer cell growth. Enhancer of zeste homolog 2 (EZH2), as one of the histone-modifying enzymes, is a key factor regulating gene expression by epigenetic modification. We hypothesized that these constitutive activated Delta S2 PRLRs played a pathogenic role in breast cancer in part through alterations in the expression of EZH2 and the trimethylation of histone 3 on lysine 27 (H3K27Me3).
   Methods In order to verify the clinical significance and to establish the link between Delta S2 PRLR expression and epigenetic change, EZH2, H3K27Me3, and Delta S2 PRLR were detected in both normal and cancerous human breast tissues. Also, overexpression of Delta S2 PRLR in breast epithelial cells was achieved by infection with adenovirus carrying the cDNA. Western blotting and chromatin immunoprecipitation (ChIP assay) and acid histone extraction were applied to detect the expression of EZH2 and the trimethylation of histone 3, respectively.
   Results In breast tissue, higher EZH2 expression and higher H3K27Me3 were found associated with higher Delta S2 expression in breast cancer samples. In breast epithelial cells, overexpression of Delta S2 PRLR increased EZH2 methyltransferase mRNA and protein, induced EZH2 methyltransferase recruitment to chromatin, increased the trimethylation of H3K27Me3, and decreased the expression of p53 gene.
   Conclusions Delta S2 PRLR plays an important pathogenic role in breast cancer through epigenetic modification. Elevated expression of Delta S2 PRLR, achieved by alternate splicing of the pre-mRNA of the full-length form, is a new mechanism contributing to human breast cancer.
C1 [Tan Dunyong; Tang Peizhi; Huang Jianjun; Zhang Jie; Zhou Weihua] Jishou Univ, Coll Med, Inst Med Sci, Affiliated Hosp, Jishou 416000, Hunan, Peoples R China.
   [Walker, Ameae M.] Univ Calif Riverside, Div Biomed Sci, Riverside, CA 92521 USA.
C3 Jishou University; University of California System; University of
   California Riverside
RP Tan, DY (通讯作者)，Jishou Univ, Coll Med, Inst Med Sci, Jishou 416000, Hunan, Peoples R China.
EM naturet2002@yahoo.com
FU National Natural Science Foundation of China [81172497, 81260396];
   Jishou University Research Grant [jsdxkyzz101010]
FX This work was supported by the grants from National Natural Science
   Foundation of China (No. 81172497 and No. 81260396) and Jishou
   University Research Grant (No. jsdxkyzz101010).
CR Akkers RC, 2009, DEV CELL, V17, P425, DOI 10.1016/j.devcel.2009.08.005
   Broutin I, 2010, J BIOL CHEM, V285, P8422, DOI 10.1074/jbc.M109.089128
   Dagvadorj A, 2007, ENDOCRINOLOGY, V148, P3089, DOI 10.1210/en.2006-1761
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Gourdou I, 2004, BIOL REPROD, V70, P718, DOI 10.1095/biolreprod.103.019448
   Haglund F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036448
   Hahn MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018844
   He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474
   Hu ZZ, 1996, J BIOL CHEM, V271, P10242, DOI 10.1074/jbc.271.17.10242
   Johansson EM, 2005, MOL ENDOCRINOL, V19, P992, DOI 10.1210/me.2004-0359
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Lee RCH, 1999, J BIOL CHEM, V274, P10024, DOI 10.1074/jbc.274.15.10024
   Naderi A, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3232
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Stocco C, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.098293
   Tan Dun-Yong, 2012, Sheng Li Ke Xue Jin Zhan, V43, P17
   Tan D, 2008, BIOCHEMISTRY-US, V47, P479, DOI 10.1021/bi7013882
   Tan DY, 2011, CANCER LETT, V310, P101, DOI 10.1016/j.canlet.2011.06.014
   Tan DY, 2005, MOL ENDOCRINOL, V19, P1291, DOI 10.1210/me.2004-0304
   Tan DY, 2009, J MOL ENDOCRINOL, V42, P1
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wu W, 2005, CANCER RES, V65, P7509, DOI 10.1158/0008-5472.CAN-04-3350
   Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59
NR 24
TC 6
Z9 7
U1 0
U2 18
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD MAR 20
PY 2014
VL 127
IS 6
BP 1077
EP 1083
DI 10.3760/cma.j.issn.0366-6999.20140025
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AE9JW
UT WOS:000334325100017
PM 24622438
OA gold
DA 2025-01-12
ER

PT J
AU Roukos, DH
   Baltogiannis, GG
   Katsouras, CS
   Bechlioulis, A
   Naka, KK
   Batsis, C
   Liakakos, T
   Michalis, LK
AF Roukos, Dimitrios H.
   Baltogiannis, Giannis G.
   Katsouras, Christos S.
   Bechlioulis, Aris
   Naka, Katerina K.
   Batsis, Charalambos
   Liakakos, Theodore
   Michalis, Lampros K.
TI Novel Next-Generation Sequencing and Networks-Based Therapeutic Targets:
   Realistic and More Effective Drug Design and Discovery
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Drugs; cancer; cardiovascular disease; genetics; genomics; networks;
   sequencing
ID PROTEIN-PROTEIN INTERACTIONS; METASTATIC COLORECTAL-CANCER; LONG
   NONCODING RNAS; 1ST-LINE TREATMENT; BREAST-CANCER; TRASTUZUMAB
   EMTANSINE; MOLECULAR NETWORKS; BOOLEAN NETWORKS; HUMAN GENOME; LANDSCAPE
AB Reductionist approaches and linear experimentation have expanded our knowledge in biology over the past century and represent till today the basis for the prevention, diagnosis and treatment of all diseases in clinical medicine. However, major diseases still remain incurable. All currently available drugs target a single gene or protein ignoring dynamics of highly complex biomolecular networks driving collectively gene expression and cell's function. No surprise that most of these agents don't cure common multifactorial disorders while available diagnostics and biomarkers are unable to predict tissue-specific cellular reactions to genetic and epigenetic alterations as well as drug effects in individual patients and populations. In this review we discuss latest advances in genome localization of genome-wide association studies variants, whole genome/whole exome data analysis, protein-protein interactions networks databases, and more recent Encyclopedia of DNA Elements (ENCODE) data on regulatory networks including transcription factors-binding sites and gene-gene interactions. In addition challenges for a comprehensive analysis of intracellular signaling pathways network is described. Such analysis, despite genome-scale scarce data and lack of sophisticated methods to predict dynamics of a global hierarchy or 'cloud" of biological networks, appears essential for the discovery of new therapeutic network targets, which could dramatically increase treatment efficacy, while minimizing at the same time major adverse effects. In this review we describe potential and challenges of modern approaches for applying next-generation sequencing and patient's personal whole genome analysis for personalized treatment using available drugs. Additionally, we report why the discovery of next-generation drugs should be shifted from our linear world to motifs-and network-associated disease integrating genome science and dynamics of network biology advances.
C1 [Roukos, Dimitrios H.] Univ Ioannina, Ctr Biosyst & Genom Network Med, GR-45110 Ioannina, Greece.
   [Roukos, Dimitrios H.; Batsis, Charalambos] Univ Ioannina, Sch Med, Dept Surg, GR-45110 Ioannina, Greece.
   [Baltogiannis, Giannis G.; Katsouras, Christos S.; Bechlioulis, Aris; Naka, Katerina K.; Michalis, Lampros K.] Univ Ioannina, Sch Med, Dept Cardiol, GR-45110 Ioannina, Greece.
   [Liakakos, Theodore] Univ Athens, Attikon Univ Hosp, Dept Surg 3, GR-10679 Athens, Greece.
C3 University of Ioannina; University of Ioannina; University of Ioannina;
   University Hospital Attikon
RP Roukos, DH (通讯作者)，Univ Ioannina, Ctr Biosyst & Genom Network Med, GR-45110 Ioannina, Greece.
EM droukos@uoi.gr
RI Naka, Katerina/C-9116-2019; Katsouras, Christos/AAN-5137-2021;
   Bechlioulis, Aris/D-4814-2011; Liakakos, Theodore/A-2779-2011; Ziogas,
   Demosthenes/D-7973-2011
OI Roukos, Dimitrios/0000-0002-6210-5065; Ziogas,
   Demosthenes/0000-0003-2234-8393; Mihalis, Lampros/0000-0001-8834-4462;
   Katsouras, Christos/0000-0001-7638-9217; Liakakos,
   Theodore/0000-0003-2289-6242; Naka, Katerina/0000-0002-9900-9659
CR Alberts B, 2010, SCIENCE, V330, P1724, DOI 10.1126/science.1201826
   Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Assenov Y, 2008, BIOINFORMATICS, V24, P282, DOI 10.1093/bioinformatics/btm554
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Barabási AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918
   Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547
   Boekhout AH, 2011, ONCOLOGIST, V16, P800, DOI 10.1634/theoncologist.2010-0035
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Boon RA, 2013, NATURE          0220
   Bornholdt S, 2008, J R SOC INTERFACE, V5, pS85, DOI 10.1098/rsif.2008.0132.focus
   Brandman O, 2008, SCIENCE, V322, P390, DOI 10.1126/science.1160617
   Brown KR, 2009, BIOINFORMATICS, V25, P3327, DOI 10.1093/bioinformatics/btp595
   Butland G, 2005, NATURE, V433, P531, DOI 10.1038/nature03239
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Chandra N, 2013, EXPERT OPIN DRUG DIS, V8, P7, DOI 10.1517/17460441.2013.741119
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chatraryamontri A, 2007, NUCLEIC ACIDS RES, V35, pD561
   Cheng TMK, 2012, BRIEF FUNCT GENOMICS, V11, P543, DOI 10.1093/bfgp/els025
   Cho WCS, 2013, EXPERT REV ANTICANC, V13, P5, DOI [10.1586/ERA.12.152, 10.1586/era.12.152]
   Chowdhary R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034480
   Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Davidich M, 2008, J THEOR BIOL, V255, P269, DOI 10.1016/j.jtbi.2008.07.020
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Dostie J, 2006, GENOME RES, V16, P1299, DOI 10.1101/gr.5571506
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ewing RM, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100134
   Fabbro D, 2012, METHODS MOL BIOL, V795, P1, DOI 10.1007/978-1-61779-337-0_1
   Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290
   Garcia-Garcia J, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-56
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289
   Goh KI, 2012, BRIEF FUNCT GENOMICS, V11, P533, DOI 10.1093/bfgp/els032
   Gotlib Jason, 2012, Am J Hematol, V87, P903, DOI 10.1002/ajh.23293
   Guttman M, 2012, NATURE, V482, P339, DOI 10.1038/nature10887
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111
   Hickman Graham J., 2009, Journal of Bioinformatics and Computational Biology, V7, P1013, DOI 10.1142/S0219720009004448
   Howald C, 2012, GENOME RES, V22, P1698, DOI 10.1101/gr.134478.111
   Huarte M, 2010, HUM MOL GENET, V19, pR152, DOI 10.1093/hmg/ddq353
   Ideker T, 2001, ANNU REV GENOM HUM G, V2, P343, DOI 10.1146/annurev.genom.2.1.343
   Ideker T, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.99
   Inui M, 2010, NAT REV MOL CELL BIO, V11, P252, DOI 10.1038/nrm2868
   Irwin JJ, 2012, J CHEM INF MODEL, V52, P1757, DOI 10.1021/ci3001277
   Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896
   Kerrien S, NUCL ACIDS RES, V35, pD561
   Kholodenko BN, 2006, NAT REV MOL CELL BIO, V7, P165, DOI 10.1038/nrm1838
   Komurov K, 2012, BIOINFORMATICS, V28, P694, DOI 10.1093/bioinformatics/btr718
   Ku CS, 2013, EXPERT REV MED DEVIC, V10, P1, DOI [10.1586/erd.12.63, 10.1586/ERD.12.63]
   Kühner S, 2009, SCIENCE, V326, P1235, DOI 10.1126/science.1176343
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Kuhn M, 2012, NUCLEIC ACIDS RES, V40, pD876, DOI 10.1093/nar/gkr1011
   Lee SA, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-114
   Li Mulin Jun, 2012, Nucleic Acids Res, V40, pD1047, DOI 10.1093/nar/gkr1182
   Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403
   Mangan S, 2003, P NATL ACAD SCI USA, V100, P11980, DOI 10.1073/pnas.2133841100
   Martin-Castillo B, 2013, CELL CYCLE, V12, P225, DOI 10.4161/cc.23274
   Mattick JS, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000459
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Maurano MT, 2012, SCIENCE, V337, P1190, DOI 10.1126/science.1222794
   Mercer TR, 2008, P NATL ACAD SCI USA, V105, P716, DOI 10.1073/pnas.0706729105
   Mercer TR, 2012, NAT BIOTECHNOL, V30, P99, DOI 10.1038/nbt.2024
   Mewes HW, 1997, NUCLEIC ACIDS RES, V25, P28, DOI 10.1093/nar/25.1.28
   Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nair VS, 2012, JNCI-J NATL CANCER I, V104, P528, DOI 10.1093/jnci/djs027
   Neph S, 2012, CELL, V150, P1274, DOI 10.1016/j.cell.2012.04.040
   Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212
   Parrish JR, 2006, CURR OPIN BIOTECH, V17, P387, DOI 10.1016/j.copbio.2006.06.006
   Pawson T, 2008, FEBS LETT, V582, P1266, DOI 10.1016/j.febslet.2008.02.011
   Perc M, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.0997
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Rask-Andersen M, 2011, NAT REV DRUG DISCOV, V10, P579, DOI 10.1038/nrd3478
   Roukos D, 2013, PHARMACOGENOMICS J, V13, P205, DOI 10.1038/tpj.2012.51
   Roukos DH, 2011, PHARMACOGENOMICS J, V11, P81, DOI 10.1038/tpj.2010.81
   Roukos DH, 2012, EXPERT REV PROTEOMIC, V9, P111, DOI [10.1586/EPR.12.14, 10.1586/epr.12.14]
   Roukos DH, 2011, PHARMACOGENOMICS, V12, P695, DOI [10.2217/PGS.11.28, 10.2217/pgs.11.28]
   Roy S, 2010, SCIENCE, V330, P1787, DOI 10.1126/science.1198374
   Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161
   Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209
   Salwinski L, 2004, NUCLEIC ACIDS RES, V32, pD449, DOI 10.1093/nar/gkh086
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Schaub MA, 2012, GENOME RES, V22, P1748, DOI 10.1101/gr.136127.111
   Scheer Maurice, 2011, Nucleic Acids Res, V39, pD670, DOI 10.1093/nar/gkq1089
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shmulevich I, 2002, BIOINFORMATICS, V18, P261, DOI 10.1093/bioinformatics/18.2.261
   Shoemaker BA, 2007, PLOS COMPUT BIOL, V3, P337, DOI 10.1371/journal.pcbi.0030042
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Smoot ME, 2011, BIOINFORMATICS, V27, P431, DOI 10.1093/bioinformatics/btq675
   Stamatoyannopoulos JA, 2012, GENOME RES, V22, P1602, DOI 10.1101/gr.146506.112
   Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109
   Steg PG, 2012, EUR HEART J, V33, P2569, DOI 10.1093/eurheartj/ehs215
   Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Tarassov K, 2008, SCIENCE, V320, P1465, DOI 10.1126/science.1153878
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Tilgner H, 2012, GENOME RES, V22, P1616, DOI 10.1101/gr.134445.111
   Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915
   Tyson JJ, 2003, CURR OPIN CELL BIOL, V15, P221, DOI 10.1016/S0955-0674(03)00017-6
   Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Vasilescu J, 2006, CURR OPIN BIOTECH, V17, P394, DOI 10.1016/j.copbio.2006.06.008
   Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124
   Vernot B, 2012, GENOME RES, V22, P1689, DOI 10.1101/gr.134890.111
   von Eichborn J, 2011, BIOINFORMATICS, V27, P1725, DOI 10.1093/bioinformatics/btr195
   von Eichborn J, 2011, NUCLEIC ACIDS RES, V39, pD1060, DOI 10.1093/nar/gkq1037
   Wishart DS, 2008, NUCLEIC ACIDS RES, V36, pD901, DOI 10.1093/nar/gkm958
   Wittmann DM, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-98
   Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060
   Zhang QC, 2013, NUCLEIC ACIDS RES, V41, pD828, DOI 10.1093/nar/gks1231
   Zuk O, 2012, P NATL ACAD SCI USA, V109, P1193, DOI 10.1073/pnas.1119675109
NR 116
TC 11
Z9 11
U1 0
U2 23
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JAN
PY 2014
VL 20
IS 1
BP 11
EP 22
DI 10.2174/138161282001140113122438
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AE9CI
UT WOS:000334301200004
PM 23530498
DA 2025-01-12
ER

PT J
AU Xu, X
   Wu, J
   Li, SQ
   Hu, ZH
   Xu, XL
   Zhu, Y
   Liang, Z
   Wang, X
   Lin, YW
   Mao, YQ
   Chen, H
   Luo, JD
   Liu, B
   Zheng, XY
   Xie, LP
AF Xu, Xin
   Wu, Jian
   Li, Shiqi
   Hu, Zhenghui
   Xu, Xianglai
   Zhu, Yi
   Liang, Zhen
   Wang, Xiao
   Lin, Yiwei
   Mao, Yeqing
   Chen, Hong
   Luo, Jindan
   Liu, Ben
   Zheng, Xiangyi
   Xie, Liping
TI Downregulation of microRNA-182-5p contributes to renal cell carcinoma
   proliferation via activating the AKT/FOXO3a signaling pathway
SO MOLECULAR CANCER
LA English
DT Article
DE Renal cell carcinoma; Proliferation; Microrna-182-5p; FLOT1
ID UP-REGULATION; BETA-CATENIN; TRANSCRIPTION FACTORS; BLADDER-CANCER;
   BREAST-CANCER; COLON-CANCER; METASTASIS; EXPRESSION; TARGETS;
   TUMORIGENICITY
AB Background: Emerging evidence has suggested that dysregulation of miR-182-5p may contribute to tumor development and progression in several types of human cancers. However, its role in renal cell carcinoma (RCC) is still unknown.
   Methods: Quantitative RT-PCR was used to quantify miR-182-5p expression in RCC clinical tissues. Bisulfite sequencing PCR was used for DNA methylation analysis. The CCK-8, colony formation, flow cytometry, and a xenograft model were performed. Immunohistochemistry was conducted using the peroxidase and DAB methods. A miR-182-5p target was determined by luciferase reporter assays, quantitative RT-PCR, and Western blotting.
   Results: miR-182-5p is frequently down-regulated in human RCC tissues. Epigenetic modulation may be involved in the regulation of miR-182-5p expression. Enforced expression of miR-182-5p in RCC cells significantly inhibited the proliferation and tumorigenicity in vitro and in vivo. Additionally, overexpression of miR-182-5p induced G1-phase arrest via inhibition of AKT/FOXO3a signaling. Moreover, FLOT1 was confirmed as a target of miR-182-5p. Silencing FLOT1 by small interfering RNAs phenocopied the effects of miR-182-5p overexpression, whereas restoration of FLOT1 in miR-182-5p -overexpressed RCC cells partly reversed the suppressive effects of miR-182-5p.
   Conclusions: These findings highlight an important role for miR-182-5p in the pathogenesis of RCC, and restoration of miR-182-5p could be considered as a potential therapeutic strategy for RCC therapy.
C1 [Xu, Xin; Wu, Jian; Li, Shiqi; Hu, Zhenghui; Xu, Xianglai; Zhu, Yi; Liang, Zhen; Wang, Xiao; Lin, Yiwei; Mao, Yeqing; Chen, Hong; Luo, Jindan; Liu, Ben; Zheng, Xiangyi; Xie, Liping] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Zheng, XY (通讯作者)，Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Urol, Qingchun Rd 79, Hangzhou 310003, Zhejiang, Peoples R China.
EM zheng_xy@zju.edu.cn; xielp@zju.edu.cn
RI zheng, xiangyi/C-3752-2012; Chen, Hong/C-9830-2012
OI Wang, Xiao/0000-0002-8652-8820
FU National Key Clinical Specialty Construction Project of China; Key
   medical disciplines of Zhejiang province; Combination of traditional
   Chinese and Western medicine key disciplines of Zhejiang Province
   [2012-XK-A23]; Health sector scientific research special project
   [201002010]; National Natural Science Foundation of China [81372773,
   81101717]; Scientific Research Fund of Zhejiang Provincial Education
   Department [Y201120149]; Zhejiang Provincial Natural Science Foundation
   of China [Y2110120, LY12H05006]
FX This study was supported by grants from the National Key Clinical
   Specialty Construction Project of China, Key medical disciplines of
   Zhejiang province, Combination of traditional Chinese and Western
   medicine key disciplines of Zhejiang Province (2012-XK-A23), Health
   sector scientific research special project (201002010), National Natural
   Science Foundation of China (Grant No. 81372773 and 81101717),
   Scientific Research Fund of Zhejiang Provincial Education Department
   (Y201120149) and Zhejiang Provincial Natural Science Foundation of China
   (Y2110120 and LY12H05006).
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, NAT REV GENET, V5, P396, DOI 10.1038/nrg1328
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793
   Cekaite L, 2012, NEOPLASIA, V14, P868, DOI 10.1593/neo.121094
   Chen H, 2012, CANCER LETT, V320, P40, DOI 10.1016/j.canlet.2012.01.027
   Chiang CH, 2013, BBA-GEN SUBJECTS, V1830, P3067, DOI 10.1016/j.bbagen.2013.01.009
   Chien CH, 2011, NUCLEIC ACIDS RES, V39, P9345, DOI 10.1093/nar/gkr604
   Chow TFF, 2010, J UROLOGY, V183, P743, DOI 10.1016/j.juro.2009.09.086
   Chow TFF, 2010, CLIN BIOCHEM, V43, P150, DOI 10.1016/j.clinbiochem.2009.07.020
   Doberstein K, 2013, NEOPLASIA, V15, P218, DOI 10.1593/neo.121222
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Hidaka H, 2012, ONCOTARGET, V3, P44
   Hirata H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055502
   Hirata H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051056
   Hirata H, 2012, CARCINOGENESIS, V33, P501, DOI 10.1093/carcin/bgr302
   Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222
   Huang Y, 2009, EJSO-EUR J SURG ONC, V35, P1119, DOI 10.1016/j.ejso.2009.04.010
   Juan D, 2010, UROLOGY, V75, P835, DOI 10.1016/j.urology.2009.10.033
   Jung M, 2009, J CELL MOL MED, V13, P3918, DOI 10.1111/j.1582-4934.2009.00705.x
   Kong WQ, 2012, FEBS J, V279, P1252, DOI 10.1111/j.1742-4658.2012.08519.x
   Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068
   Liu SH, 2013, ANN SURG ONCOL, V20, P1745, DOI 10.1245/s10434-012-2467-3
   Majid S, 2011, CANCER RES, V71, P2611, DOI 10.1158/0008-5472.CAN-10-3666
   Massagué J, 2004, NATURE, V432, P298, DOI 10.1038/nature03094
   Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115
   Motzer RJ, 2000, J UROLOGY, V163, P408, DOI 10.1016/S0022-5347(05)67889-5
   Osanto S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038298
   Pantuck AJ, 2001, J UROLOGY, V166, P1611, DOI 10.1016/S0022-5347(05)65640-6
   Raimondo F, 2008, OPEN PROTEOMICS J, V1, P87, DOI DOI 10.2174/1875039700801010087
   Roy Sanjit K, 2010, J Mol Signal, V5, P10, DOI 10.1186/1750-2187-5-10
   Saini S, 2011, CANCER RES, V71, P6208, DOI 10.1158/0008-5472.CAN-11-0073
   Santo EE, 2013, CANCER RES, V73, P2189, DOI 10.1158/0008-5472.CAN-12-3767
   Song L, 2012, GASTROENTEROLOGY, V143
   Song LB, 2012, J CLIN INVEST, V122, P3563, DOI 10.1172/JCI62339
   Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127
   Tang T, 2013, GYNECOL ONCOL, V129, P199, DOI 10.1016/j.ygyno.2012.12.043
   Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772
   Volonté D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702
   Wang J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-227
   Wang YQ, 2013, J CELL BIOCHEM, V114, P1464, DOI 10.1002/jcb.24488
   Weidinger C, 2011, J CLIN ENDOCR METAB, V96, pE1361, DOI 10.1210/jc.2010-2453
   Xiong P, 2013, NEOPLASMA, V60, P395, DOI 10.4149/neo_2013_051
   Xu X, 2013, MOL CELLS, V36, P62, DOI 10.1007/s10059-013-0044-7
   Yamamura S, 2012, CARCINOGENESIS, V33, P294, DOI 10.1093/carcin/bgr286
   Yan DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040967
   Yi ZJ, 2010, J CANCER RES CLIN, V136, P855, DOI 10.1007/s00432-009-0726-x
   Zhang PF, 2012, J PROTEOMICS, V77, P202, DOI 10.1016/j.jprot.2012.08.021
   Zhang SH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064709
NR 49
TC 100
Z9 107
U1 0
U2 21
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 17
PY 2014
VL 13
AR 109
DI 10.1186/1476-4598-13-109
PG 11
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA AK2JW
UT WOS:000338246400001
PM 24886554
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Pathiraja, TN
   Nayak, SR
   Xi, YX
   Jiang, SM
   Garee, JP
   Edwards, DP
   Lee, AV
   Chen, J
   Shea, MJ
   Santen, RJ
   Gannon, F
   Kangaspeska, S
   Jelinek, J
   Issa, JPJ
   Richer, JK
   Elias, A
   McIlroy, M
   Young, LS
   Davidson, NE
   Schiff, R
   Li, W
   Oesterreich, S
AF Pathiraja, Thushangi N.
   Nayak, Shweta R.
   Xi, Yuanxin
   Jiang, Shiming
   Garee, Jason P.
   Edwards, Dean P.
   Lee, Adrian V.
   Chen, Jian
   Shea, Martin J.
   Santen, Richard J.
   Gannon, Frank
   Kangaspeska, Sara
   Jelinek, Jaroslav
   Issa, Jean-Pierre J.
   Richer, Jennifer K.
   Elias, Anthony
   McIlroy, Marie
   Young, Leonie S.
   Davidson, Nancy E.
   Schiff, Rachel
   Li, Wei
   Oesterreich, Steffi
TI Epigenetic Reprogramming of <i>HOXC10</i> in Endocrine-Resistant Breast
   Cancer
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID GROUP PROTEIN EZH2; ER-ALPHA; ESTROGEN DEPRIVATION; CHROMATIN-STRUCTURE;
   GENE-EXPRESSION; DNA-REPLICATION; MECHANISMS; METHYLATION; CELLS;
   AMPLIFICATION
AB Resistance to aromatase inhibitors (AIs) is a major clinical problem in the treatment of estrogen receptor (ER)positive breast cancer. In two breast cancer cell line models of AI resistance, we identified widespread DNA hyperand hypomethylation, with enrichment for promoter hypermethylation of developmental genes. For the homeobox gene HOXC10, methylation occurred in a CpG shore, which overlapped with a functional ER binding site, causing repression of HOXC10 expression. Although short-term blockade of ER signaling caused relief of HOXC10 repression in both cell lines and breast tumors, it also resulted in concurrent recruitment of EZH2 and increased H3K27me3, ultimately transitioning to increased DNA methylation and silencing of HOXC10. Reduced HOXC10 in vitro and in xenografts resulted in decreased apoptosis and caused antiestrogen resistance. Supporting this, we used paired primary and metastatic breast cancer specimens to show that HOXC10 was reduced in tumors that recurred during AI treatment. We propose a model in which estrogen represses apoptotic and growth-inhibitory genes such as HOXC10, contributing to tumor survival, whereas AIs induce these genes to cause apoptosis and therapeutic benefit, but long-term AI treatment results in permanent repression of these genes via methylation and confers resistance. Therapies aimed at inhibiting AI-induced histone and DNA methylation may be beneficial in blocking or delaying AI resistance.
C1 [Pathiraja, Thushangi N.] Baylor Coll Med, Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA.
   [Pathiraja, Thushangi N.; Jiang, Shiming; Garee, Jason P.; Lee, Adrian V.; Shea, Martin J.; Schiff, Rachel; Oesterreich, Steffi] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
   [Nayak, Shweta R.] Magee Womens Hosp, Ctr Reprod Endocrinol & Infertil, Pittsburgh, PA 15213 USA.
   [Xi, Yuanxin; Edwards, Dean P.; Li, Wei] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Edwards, Dean P.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
   [Edwards, Dean P.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
   [Lee, Adrian V.; Chen, Jian; Davidson, Nancy E.; Oesterreich, Steffi] Univ Pittsburgh, Inst Canc, Womens Canc Res Ctr, Pittsburgh, PA 15213 USA.
   [Lee, Adrian V.; Chen, Jian; Davidson, Nancy E.; Oesterreich, Steffi] Univ Pittsburgh, Ctr Canc, Dept Pharmacol & Chem Biol, Magee Womens Res Inst, Pittsburgh, PA 15213 USA.
   [Santen, Richard J.] Univ Virginia, Hlth Sci Ctr, Charlottesville, VA 22903 USA.
   [Gannon, Frank; Kangaspeska, Sara] European Mol Biol Lab, D-69117 Heidelberg, Germany.
   [Jelinek, Jaroslav; Issa, Jean-Pierre J.] Temple Univ, Fels Inst, Philadelphia, PA 19140 USA.
   [Richer, Jennifer K.; Elias, Anthony] Univ Colorado, Dept Pathol, Denver, CO 80202 USA.
   [Richer, Jennifer K.; Elias, Anthony] Univ Colorado, Dept Med, Denver, CO 80202 USA.
   [McIlroy, Marie; Young, Leonie S.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine; Baylor College of Medicine; Baylor College of Medicine;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Magee-Womens Research Institute;
   University of Virginia; European Molecular Biology Laboratory (EMBL);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple
   University; University of Colorado System; University of Colorado
   Denver; University of Colorado System; University of Colorado Denver;
   University of Colorado Anschutz Medical Campus; Royal College of
   Surgeons - Ireland
RP Oesterreich, S (通讯作者)，Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA.
EM oesterreichs@upmc.edu
RI Gannon, Frank/G-1194-2015; Xing, Puyuan/GMX-3723-2022; Li,
   Wei/A-8544-2009; Jelinek, Jaroslav/O-6876-2019; Young,
   Leonie/D-5631-2012; McIlroy, Marie/D-6110-2012; Jelinek,
   Jaroslav/D-2282-2012
OI Issa, Jean-Pierre/0000-0003-2258-5030; McIlroy,
   Marie/0000-0002-0827-8096; Lee, Adrian/0000-0001-9917-514X; Jelinek,
   Jaroslav/0000-0002-2533-0220; Li, Wei/0000-0001-9931-5990; Young,
   Leonie/0000-0002-4904-0367
FU Alexander von Humboldt Foundation fellowship; U.S. Department of Defense
   (DOD) [DOD 5W81XWH-06-1-0713]; NIH [P30CA125123, P30CA47904, P50CA58183,
   P01CA030195, R01HG007538, R01CA94118, R01CA097213]; Susan G. Komen for
   the Cure Foundation [PG12221410]; EIF/Lee Jeans Breast Cancer Research
   Program; SU2C/Breast Cancer Program; Breast Cancer Research Foundation;
   Pennsylvania Department of Health
FX Funding: This project was in part funded through an Alexander von
   Humboldt Foundation fellowship (to S.O.); a U.S. Department of Defense
   (DOD) predoctoral fellowship DOD 5W81XWH-06-1-0713 (to T.N.P.); NIH
   grants P30CA125123 (to R. S.), P30CA47904 (to N.E.D.), P50CA58183 (to R.
   S.), P01CA030195 (to S.O.), R01HG007538 (to W. L.), R01CA94118 (to A. V.
   L.), and R01CA097213 (to S.O.); Susan G. Komen for the Cure Foundation
   (PG12221410 to R. S.); the EIF/Lee Jeans Breast Cancer Research Program
   (to R. S.); SU2C/Breast Cancer Program (to R. S. and N.E.D.); Breast
   Cancer Research Foundation (to R. S., N.E.D., A. V. L., and S.O.); and
   Pennsylvania Department of Health (S.O. and A. V. L.). The Department
   specifically disclaims responsibility for any analyses, interpretations,
   or conclusions.
CR Abate-Shen C, 2002, NAT REV CANCER, V2, P777, DOI 10.1038/nrc907
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Atkinson SP, 2008, STEM CELLS, V26, P1174, DOI 10.1634/stemcells.2007-0497
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Bautista S, 1998, CLIN CANCER RES, V4, P2925
   Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041
   Cheng ASL, 2008, CANCER RES, V68, P1786, DOI 10.1158/0008-5472.CAN-07-5547
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Falaschi A, 2010, CRIT REV BIOCHEM MOL, V45, P14, DOI 10.3109/10409230903365608
   Foroni C, 2012, CANCER TREAT REV, V38, P689, DOI 10.1016/j.ctrv.2011.11.001
   Harvell DME, 2008, BREAST CANCER RES TR, V112, P475, DOI 10.1007/s10549-008-9897-4
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Jansen MPHM, 2013, CANCER RES, V73, P6632, DOI 10.1158/0008-5472.CAN-13-0704
   Jeng MH, 1998, ENDOCRINOLOGY, V139, P4164, DOI 10.1210/en.139.10.4164
   Johnson WE, 2006, P NATL ACAD SCI USA, V103, P12457, DOI 10.1073/pnas.0601180103
   Jordan VC, 2007, J CLIN ONCOL, V25, P5815, DOI 10.1200/JCO.2007.11.3886
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100
   Lonning PE, 2013, ENDOCR-RELAT CANCER, V20, pR183, DOI 10.1530/ERC-13-0099
   Marchetti L, 2010, NUCLEIC ACIDS RES, V38, P8105, DOI 10.1093/nar/gkq688
   Massarweh S, 2006, CANCER RES, V66, P8266, DOI 10.1158/0008-5472.CAN-05-4045
   Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101
   Miller WR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr2931
   Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713
   Oesterreich S, 2001, CANCER RES, V61, P5771
   Oesterreich S, 2013, NAT GENET, V45, P1415, DOI 10.1038/ng.2831
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pollard SM, 2009, CELL STEM CELL, V5, P571, DOI 10.1016/j.stem.2009.11.006
   Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506
   Shah N, 2013, CANCER RES, V73, P5449, DOI 10.1158/0008-5472.CAN-13-1178
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Vastenhouw NL, 2012, CURR OPIN CELL BIOL, V24, P374, DOI 10.1016/j.ceb.2012.03.009
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186
   Zhai Y, 2007, CANCER RES, V67, P10163, DOI 10.1158/0008-5472.CAN-07-2056
   Zhao LL, 2011, CLIN CANCER RES, V17, P1057, DOI 10.1158/1078-0432.CCR-10-1935
NR 40
TC 71
Z9 83
U1 0
U2 19
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAR 26
PY 2014
VL 6
IS 229
AR 229ra41
DI 10.1126/scitranslmed.3008326
PG 10
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA AE3UR
UT WOS:000333904300005
PM 24670685
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Weissenborn, C
   Ignatov, T
   Ochel, HJ
   Costa, SD
   Zenclussen, AC
   Ignatova, Z
   Ignatov, A
AF Weissenborn, Christine
   Ignatov, Tanja
   Ochel, Hans-Joachim
   Costa, Serban Dan
   Zenclussen, Ana Claudia
   Ignatova, Zoya
   Ignatov, Atanas
TI GPER functions as a tumor suppressor in triple-negative breast cancer
   cells
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE GPER; GPR30; Breast cancer; Tumor suppression; TNBC
ID PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR RECEPTOR; ESTROGEN-RECEPTOR;
   UP-REGULATION; GPR30; OVARIAN; PROLIFERATION; EXPRESSION; SURVIVAL;
   AGONIST
AB The orphan, membrane-bound estrogen receptor (GPER) is expressed at high levels in a large fraction of breast cancer patients and its expression is favorable for patients' survival.
   We investigated the role of GPER as a potential tumor suppressor in triple-negative breast cancer cells MDA-MB-231 and MDA-MB-468 using cell cycle analysis and apoptosis assay. The constitutive activity of GPER was investigated.
   GPER-specific activation with G-1 agonist inhibited breast cancer cell growth in concentration-dependent manner via induction of the cell cycle arrest in G2/M phase, enhanced phosphorylation of histone H3 and caspase-3-mediated apoptosis. Analysis of the methylation status of the GPER promoter in the triple-negative breast cancer cells and in tissues derived from breast cancer patients revealed that GPER amount is regulated by epigenetic mechanisms and GPER expression is inactivated by promoter methylation. Furthermore, GPER expression was induced by stress factors, such as radiation, and GPER amount inversely correlated with the p53 expression level.
   Overall, our results establish the protective role in breast cancer tumorigenesis, and the cell surface expression of GPER makes it an excellent potential therapeutic target for triple-negative breast cancer.
C1 [Weissenborn, Christine; Ignatov, Tanja; Costa, Serban Dan; Ignatov, Atanas] Univ Magdeburg, Dept Obstet & Gynecol, D-39106 Magdeburg, Germany.
   [Weissenborn, Christine; Zenclussen, Ana Claudia] Univ Magdeburg, Dept Expt Obstet & Gynaecol, D-39106 Magdeburg, Germany.
   [Ochel, Hans-Joachim] Univ Magdeburg, Dept Radiotherapy, D-39106 Magdeburg, Germany.
   [Ignatova, Zoya] Univ Potsdam, Dept Biol & Biochem, Potsdam, Germany.
C3 Otto von Guericke University; Otto von Guericke University; Otto von
   Guericke University; University of Potsdam
RP Ignatov, A (通讯作者)，Univ Magdeburg, Dept Obstet & Gynecol, Gerhart Hauptmann Str 35, D-39106 Magdeburg, Germany.
EM atanas.ignatov@gmail.com
RI Zenclussen, Ana/AAE-8760-2020; Zenclussen, Ana Claudia/G-2186-2013
OI Ignatova, Zoya/0000-0002-9478-8825; Zenclussen, Ana
   Claudia/0000-0003-3544-4552
FU Deutsche Krebshilfe
FX This work was supported by Deutsche Krebshilfe.
CR Ahola TM, 2002, ENDOCRINOLOGY, V143, P3376, DOI 10.1210/en.2001-211445
   Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117
   Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909
   Arias-Pulido H, 2010, BREAST CANCER RES TR, V123, P51, DOI 10.1007/s10549-009-0631-7
   Ariazi EA, 2010, CANCER RES, V70, P1184, DOI 10.1158/0008-5472.CAN-09-3068
   Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775
   Chan QKY, 2010, CELL DEATH DIFFER, V17, P1511, DOI 10.1038/cdd.2010.20
   Chimento A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.275
   Choi HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024312
   Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168
   Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069
   Esteller M, 2001, CANCER RES, V61, P3225
   Fan P, 2009, ENDOCRINOLOGY, V150, P2036, DOI 10.1210/en.2008-1195
   Fei PW, 2003, ONCOGENE, V22, P5774, DOI 10.1038/sj.onc.1206677
   Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Filardo EJ, 2002, MOL ENDOCRINOL, V16, P70, DOI 10.1210/me.16.1.70
   Fujiwara S, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-35
   Gao F, 2011, ENDOCRINOLOGY, V152, P1434, DOI 10.1210/en.2010-1368
   Girgert R, 2012, BREAST CANCER RES TR, V134, P199, DOI 10.1007/s10549-012-1968-x
   Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326
   Holm A, 2011, J VASC RES, V48, P327, DOI 10.1159/000322578
   Ignatov A, 2003, BIOCHEM BIOPH RES CO, V311, P329, DOI 10.1016/j.bbrc.2003.10.006
   Ignatov A, 2008, GYNECOL ONCOL, V111, P365, DOI 10.1016/j.ygyno.2008.07.037
   Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1
   Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6
   Ignatov A, 2010, CANCER SCI, V101, P321, DOI 10.1111/j.1349-7006.2009.01397.x
   Ignatov T, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-51
   Ignatov T, 2013, CANCER INVEST, V31, P309, DOI 10.3109/07357907.2013.789901
   Ignatov T, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.07.034
   KASTAN MB, 1991, CANCER RES, V51, P6304
   Kuo Wen-Hung, 2007, Taiwan J Obstet Gynecol, V46, P135, DOI 10.1016/S1028-4559(07)60007-2
   Leblanc K, 2007, INT J ONCOL, V30, P477
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335
   Liu Q, 2009, CHINESE MED J-PEKING, V122, P2763, DOI 10.3760/cma.j.issn.0366-6999.2009.22.017
   Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518
   Schneider BP, 2008, CLIN CANCER RES, V14, P8010, DOI 10.1158/1078-0432.CCR-08-1208
   Schumacher A, 2009, J IMMUNOL, V182, P5488, DOI 10.4049/jimmunol.0803177
   Smith HO, 2009, GYNECOL ONCOL, V114, P465, DOI 10.1016/j.ygyno.2009.05.015
   Smith HO, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2007.01.004
   Sun WP, 2010, J CANCER, V1, P136
   TAM SW, 1994, CANCER RES, V54, P5816
   Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181
   Tu G, 2009, TECHNOL CANCER RES T, V8, P231, DOI 10.1177/153303460900800308
   Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280
   Wang C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.397
   Wang C, 2012, AM J TRANSL RES, V4, P390
NR 50
TC 56
Z9 60
U1 0
U2 28
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD MAY
PY 2014
VL 140
IS 5
BP 713
EP 723
DI 10.1007/s00432-014-1620-8
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AF0WA
UT WOS:000334434000003
PM 24553912
DA 2025-01-12
ER

PT J
AU Liang, RR
   Huang, N
   Li, ZF
   Ji, FP
   Jiang, SW
AF Liang Rongrui
   Huang Na
   Li Zongfang
   Ji Fanpu
   Jiang Shiwen
TI Epigenetic Mechanism Involved in the HBV/HCV-Related Hepatocellular
   Carcinoma Tumorigenesis
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Epigenetic; hepatocellular carcinoma; HBV; HCV; DNA methylation and
   histone modification
ID HEPATITIS-B-VIRUS; CPG ISLAND HYPERMETHYLATION; ABERRANT DNA
   METHYLATION; TUMOR-SUPPRESSOR GENES; STIMULATED CELL-PROLIFERATION;
   E-CADHERIN EXPRESSION; S-TRANSFERASE-PI; X-PROTEIN; DOWN-REGULATION;
   BREAST-CANCER
AB Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection were known to be risk factors for HCC, they were suspected to promote its development by eliciting epigenetic changes. However, the precise gene targets and underlying mechanisms have not been elucidated. Epigenetic regulation of gene expression has emerged as a fundamental aspect of cancer development and progression. The molecular mechanisms of carcinogenesis in hepatocellular carcinoma involve a complex interplay of both genetic and epigenetic factors. DNA methylation, post-translational modifications of histone proteins, chromatin remodeling, and noncoding RNAs are four major types of mechanistic layers in the field of epigenetics. HBV infection could affect methylation on p16(INK4A), GSTP1, CDH1(E-cadherin), RASSF1A, p21(WAF1/CIP1) genes, which may play important roles in the development of HCC. HCV infection was related to aberrant methylation on SOCS-1, Gadd45 beta, MGMT, STAT1 and APC. Other epigenetic alterations included histone proteins, chromatin remodeling, and noncoding RNAs were described in literature. Uncovering the epigenetic alterations of HBV/HCV-induced HCC carcinogenesis could highlight a new strategy for deciphering the mechanism of HCC tumorigenesis and development, as well as a potential diagnostic advantage.
C1 [Liang Rongrui; Huang Na; Li Zongfang] Xi An Jiao Tong Univ, Affiliated Hosp 2, Sch Med, Dept Gen Surg, Xian 710004, Shaanxi Provinc, Peoples R China.
   [Huang Na; Li Zongfang] Xi An Jiao Tong Univ, Engn Res Ctr Biotherapy & Translat Med Shaanxi Pr, Xian 710004, Shaanxi Provinc, Peoples R China.
   [Li Zongfang] Xi An Jiao Tong Univ, Sch Med, Educ Minist, Key Lab Environm & Genes Related Dis, Xian 710004, Shaanxi Provinc, Peoples R China.
   [Ji Fanpu] Xi An Jiao Tong Univ, Affiliated Hosp 2, Coll Med, Dept Infect Dis, Xian 710004, Shaanxi Provinc, Peoples R China.
   [Jiang Shiwen] Mercer Univ, Sch Med, Dept Biomed Sci, Savannah, GA USA.
   [Liang Rongrui] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzohu, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University; Xi'an Jiaotong
   University; Xi'an Jiaotong University; Mercer University; Soochow
   University - China
RP Li, ZF (通讯作者)，Xi An Jiao Tong Univ, Affiliated Hosp 2, Sch Med, Dept Gen Surg, 157,West 5th Rd, Xian 710004, Shaanxi Provinc, Peoples R China.
EM lzf2568@gmail.com
RI Liang, Rongrui/GQY-7360-2022; Zhang, Guowei/HJH-0318-2022
OI Ji, Fanpu/0000-0002-1463-8035
FU program for changjiang Scholars and Innovative Research Team in
   University [PCSIRT:1171]
FX This work was supported by program for changjiang Scholars and
   Innovative Research Team in University (PCSIRT:1171).
CR Agrawal A, 2007, MODERN PATHOL, V20, P711, DOI 10.1038/modpathol.3800822
   Ahmad J, 2011, SEMIN LIVER DIS, V31, P347, DOI 10.1055/s-0031-1297924
   Arai E, 2009, INT J CANCER, V125, P2854, DOI 10.1002/ijc.24708
   Archer KJ, 2010, MOL GENET GENOMICS, V283, P341, DOI 10.1007/s00438-010-0522-y
   Arzumanyan A, 2012, ONCOGENE, V31, P563, DOI 10.1038/onc.2011.255
   Aydemir F, 2012, GENET TEST MOL BIOMA, V16, P335, DOI 10.1089/gtmb.2011.0245
   Balassiano K, 2011, CANCER LETT, V311, P85, DOI 10.1016/j.canlet.2011.06.038
   Bazarov AV, 2012, CELL CYCLE, V11, P1008, DOI 10.4161/cc.11.5.19492
   Belinsky SA, 2004, NAT REV CANCER, V4, P707, DOI 10.1038/nrc1432
   Benegiamo G, 2012, DIGEST DIS SCI, V57, P1598, DOI 10.1007/s10620-012-2160-1
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bock C, 2007, PLOS COMPUT BIOL, V3, P1055, DOI 10.1371/journal.pcbi.0030110
   Brell M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-35
   Calvisi DF, 2006, GASTROENTEROLOGY, V130, P1117, DOI 10.1053/j.gastro.2006.01.006
   Chang H, 2008, EXP MOL PATHOL, V85, P96, DOI 10.1016/j.yexmp.2008.07.001
   Chim CS, 2004, BLOOD, V103, P4630, DOI 10.1182/blood-2003-06-2007
   Christmann M, 2011, BBA-REV CANCER, V1816, P179, DOI 10.1016/j.bbcan.2011.06.002
   Cockerill PN, 2011, FEBS J, V278, P2182, DOI 10.1111/j.1742-4658.2011.08128.x
   Cornellà H, 2011, ALCOHOL CLIN EXP RES, V35, P821, DOI 10.1111/j.1530-0277.2010.01406.x
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Cui HM, 2001, CANCER RES, V61, P4947
   Deng L, 2006, J GEN VIROL, V87, P1703, DOI 10.1099/vir.0.81735-0
   Draht MXG, 2012, EPIGENOMICS-UK, V4, P179, DOI [10.2217/EPI.12.9, 10.2217/epi.12.9]
   Dunn BK, 2003, ANN NY ACAD SCI, V983, P28, DOI 10.1111/j.1749-6632.2003.tb05960.x
   Duong FHT, 2004, GASTROENTEROLOGY, V126, P263, DOI 10.1053/j.gastro.2003.10.076
   Duong FHT, 2010, HEPATOLOGY, V51, P741, DOI 10.1002/hep.23388
   Egger G, 2004, NATURE, V429, P457, DOI 10.1038/nature02625
   Ehrlich M, 2006, ONCOGENE, V25, P2636, DOI 10.1038/sj.onc.1209145
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Feng HX, 2012, FUTURE VIROL, V7, P161, DOI 10.2217/FVL.11.148
   Feng Z, 2012, EXPERT REV MOL DIAGN, V12, P279, DOI [10.1586/ERM.12.19, 10.1586/erm.12.19]
   Ferber MJ, 2003, ONCOGENE, V22, P3813, DOI 10.1038/sj.onc.1206528
   Ferland CL, 2011, NEUROSCIENCE, V174, P104, DOI 10.1016/j.neuroscience.2010.10.077
   Fernandez SV, 2012, INT J ONCOL, V41, P369, DOI 10.3892/ijo.2012.1444
   Foran E, 2010, MOL CANCER RES, V8, P471, DOI 10.1158/1541-7786.MCR-09-0496
   Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108
   Fu VX, 2004, J BIOL CHEM, V279, P52218, DOI 10.1074/jbc.M405015200
   Ganem D, 2004, NEW ENGL J MED, V350, P1118, DOI 10.1056/NEJMra031087
   Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108
   Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006
   Gong Q, 2011, DNA CELL BIOL, V30, P347, DOI 10.1089/dna.2010.1172
   Gozuacik D, 2001, ONCOGENE, V20, P6233, DOI 10.1038/sj.onc.1204835
   Guerrero K, 2012, GYNECOL ONCOL, V125, P720, DOI 10.1016/j.ygyno.2012.03.026
   Higashi H, 2006, ANTICANCER RES, V26, P2143
   Higgs MR, 2010, CANCER RES, V70, P4901, DOI 10.1158/0008-5472.CAN-09-4554
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hofer MJ, 2012, J VIROL, V86, P6932, DOI 10.1128/JVI.07147-11
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hong SM, 2012, CLIN CANCER RES, V18, P700, DOI 10.1158/1078-0432.CCR-11-1718
   Hoque MO, 2009, EXPERT REV MOL DIAGN, V9, P243, DOI 10.1586/ERM.09.10
   Horejs-Hoeck J, 2012, J IMMUNOL, V188, P5319, DOI 10.4049/jimmunol.1101044
   Horikawa I, 2001, J NATL CANCER I, V93, P1171, DOI 10.1093/jnci/93.15.1171
   Hu HZ, 2011, GUT, V60, P710, DOI 10.1136/gut.2010.220020
   Hu ZY, 2006, J VIROL, V80, P1405, DOI 10.1128/JVI.80.3.1405-1413.2006
   Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660
   Hubertus J, 2011, ONCOL REP, V25, P817, DOI 10.3892/or.2010.1113
   Jiang L, 2012, BIOCHEM BIOPH RES CO, V422, P739, DOI 10.1016/j.bbrc.2012.05.072
   Jiang ZS, 2012, GENOME RES, V22, P593, DOI 10.1101/gr.133926.111
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Kasprzak A, 2008, HEPATOL RES, V38, P1, DOI 10.1111/j.1872-034X.2007.00261.x
   Kaur P, 2010, J INFECT DIS, V202, P700, DOI 10.1086/655398
   Khan SI, 2012, CHEM RES TOXICOL, V25, P61, DOI 10.1021/tx200378c
   Kim YS, 2007, GUT LIVER, V1, P1, DOI 10.5009/gnl.2007.1.1.1
   Kirkpatrick KL, 2003, BREAST CANCER RES TR, V77, P277, DOI 10.1023/A:1021849217054
   Ko E, 2008, CANCER LETT, V271, P240, DOI 10.1016/j.canlet.2008.06.009
   Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194
   Lai SL, 2000, CLIN CANCER RES, V6, P3172
   Lambert MP, 2011, J HEPATOL, V54, P705, DOI 10.1016/j.jhep.2010.07.027
   Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589
   Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547
   Lee EJ, 2007, INT J CANCER, V120, P1046, DOI 10.1002/ijc.22394
   Lee HC, 2006, FRONT BIOSCI-LANDMRK, V11, P1901, DOI 10.2741/1933
   Lee H, 2012, P NATL ACAD SCI USA, V109, P7765, DOI 10.1073/pnas.1205132109
   Lee JH, 2010, J BIOL CHEM, V285, P42033, DOI 10.1074/jbc.M110.149831
   Lee S, 2003, AM J PATHOL, V163, P1371, DOI 10.1016/S0002-9440(10)63495-5
   Lee S, 2002, J BIOL CHEM, V277, P8730, DOI 10.1074/jbc.M108025200
   Leibowitz BJ, 2009, J CELL PHYSIOL, V220, P182, DOI 10.1002/jcp.21748
   Li LC, 2005, JNCI-J NATL CANCER I, V97, P103, DOI 10.1093/jnci/dji010
   Li QS, 2009, P NATL ACAD SCI USA, V106, P16410, DOI 10.1073/pnas.0907439106
   Liu WH, 2011, BBA-GENE REGUL MECH, V1809, P678, DOI 10.1016/j.bbagrm.2011.04.008
   Liu Y, 2012, ONCOGENE, V31, P1143, DOI 10.1038/onc.2011.308
   Lo HW, 2004, CANCER RES, V64, P9131, DOI 10.1158/0008-5472.CAN-04-0283
   Lu LG, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2893
   Mas VR, 2009, TRANSPLANTATION, V87, P143, DOI 10.1097/TP.0b013e318191c68d
   Maurer S, 2009, J MOL BIOL, V387, P1261, DOI 10.1016/j.jmb.2009.02.050
   Michaelis KA, 2011, ENDOCRINOLOGY, V152, P3603, DOI 10.1210/en.2011-0109
   Milazzo M, 2011, Minerva Gastroenterol Dietol, V57, P257
   Miura K, 2008, HEPATOLOGY, V48, P1420, DOI 10.1002/hep.22486
   Mochizuki T, 2006, GROWTH HORM IGF RES, V16, P202, DOI 10.1016/j.ghir.2006.05.002
   Moore LE, 2008, LANCET ONCOL, V9, P359, DOI 10.1016/S1470-2045(08)70038-X
   Morrison AJ, 2009, NAT REV MOL CELL BIO, V10, P373, DOI 10.1038/nrm2693
   Morsi MI, 2006, BRIT J BIOMED SCI, V63, P74, DOI 10.1080/09674845.2006.11732724
   Mosley RT, 2012, J VIROL, V86, P6503, DOI 10.1128/JVI.00386-12
   Murphy SK, 2006, MOL CANCER RES, V4, P283, DOI 10.1158/1541-7786.MCR-05-0138
   Nakagawa T, 2005, J UROLOGY, V173, P243, DOI 10.1097/01.ju.0000141577.98902.49
   Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740
   Ng RK, 2004, BIOCHEM BIOPH RES CO, V322, P827, DOI 10.1016/j.bbrc.2004.07.188
   Nishida N, 2008, HEPATOLOGY, V47, P908, DOI 10.1002/hep.22110
   Niu ZS, 2005, WORLD J GASTROENTERO, V11, P4404
   Obermajer N, 2011, BLOOD, V118, P5498, DOI 10.1182/blood-2011-07-365825
   Oh BK, 2006, AM J GASTROENTEROL, V101, P831, DOI 10.1111/j.1572-0241.2006.00532.x
   Okamoto Y, 2012, GUT, V61, P392, DOI 10.1136/gut.2011.241034
   Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
   Ou DL, 2010, CANCER RES, V70, P9309, DOI 10.1158/0008-5472.CAN-10-1033
   Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034
   Park JH, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-82
   Park SH, 2011, J GEN VIROL, V92, P1309, DOI 10.1099/vir.0.029512-0
   Pateras IS, 2006, INT J CANCER, V119, P2546, DOI 10.1002/ijc.22214
   Pohlod-Miller S, 2002, AM J OBSTET GYNECOL, V186, P855, DOI 10.1067/mob.2002.121722
   Prasad ML, 2012, HEAD NECK PATHOL, V6, P184, DOI 10.1007/s12105-011-0319-2
   Qiu WH, 2003, AM J PATHOL, V162, P1961, DOI 10.1016/S0002-9440(10)64329-5
   Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659
   Rosenbaum E, 2012, PROSTATE, V72, P1133, DOI 10.1002/pros.22461
   Ross JP, 2010, EPIGENOMICS-UK, V2, P245, DOI 10.2217/EPI.10.2
   Saelee P, 2010, ASIAN PAC J CANCER P, V11, P1677
   Saha A, 2006, NAT REV MOL CELL BIO, V7, P437, DOI 10.1038/nrm1945
   Sakai M, 2007, BIOCHEM BIOPH RES CO, V357, P575, DOI 10.1016/j.bbrc.2007.03.174
   Sandhu R, 2012, INT J ONCOL, V41, P721, DOI 10.3892/ijo.2012.1505
   Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907
   Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274
   Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y
   Shen J, 2012, HEPATOLOGY, V55, P1799, DOI 10.1002/hep.25569
   Shim YH, 2003, CANCER LETT, V190, P213, DOI 10.1016/S0304-3835(02)00613-4
   Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Stefanska B, 2011, CANCER RES, V71, P5891, DOI 10.1158/0008-5472.CAN-10-3823
   Su H, 2008, MUTAT RES-FUND MOL M, V641, P27, DOI 10.1016/j.mrfmmm.2008.02.005
   Su PF, 2007, INT J CANCER, V121, P1257, DOI 10.1002/ijc.22849
   Tanaka N, 2008, INT J CANCER, V122, P124, DOI 10.1002/ijc.23056
   Tränkenschuh W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013688
   Uehara E, 2003, INT J ONCOL, V23, P693
   Um TH, 2011, J HEPATOL, V54, P939, DOI 10.1016/j.jhep.2010.08.021
   van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003
   Verma M, 2002, LANCET ONCOL, V3, P755, DOI 10.1016/S1470-2045(02)00932-4
   Vu TH, 2003, CANCER RES, V63, P1900
   Wang SJ, 2002, GYNECOL ONCOL, V84, P81, DOI 10.1006/gyno.2001.6483
   Wang X, 2012, TOXICOL SCI, V127, P412, DOI 10.1093/toxsci/kfs106
   Wirtz S, 2010, CARCINOGENESIS, V31, P2111, DOI 10.1093/carcin/bgq174
   Woloszynska-Read A, 2011, CLIN CANCER RES, V17, P2170, DOI 10.1158/1078-0432.CCR-10-2315
   Woo HD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034615
   Xin YR, 2011, EPIGENETICS-US, V6, P1308, DOI 10.4161/epi.6.11.17876
   Xu LX, 2012, GUT, V61, P977, DOI 10.1136/gutjnl-2011-300411
   Xu Y, 2010, ONCOGENE, V29, P4090, DOI 10.1038/onc.2010.159
   Yang B, 2003, AM J PATHOL, V163, P1101, DOI 10.1016/S0002-9440(10)63469-4
   Yang F, 2011, HEPATOLOGY, V54, P1679, DOI 10.1002/hep.24563
   Yang LA, 2010, CANCER BIOL THER, V9, P803, DOI 10.4161/cbt.9.10.11440
   Yang MH, 2009, HEPATOLOGY, V50, P1464, DOI 10.1002/hep.23221
   Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675
   Yu J, 2008, HEPATOLOGY, V48, P508, DOI 10.1002/hep.22343
   Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409
   Yue X, 2011, VIROL J, V8, DOI 10.1186/1743-422X-8-118
   Zeimet AG, 2011, GYNECOL ONCOL, V121, P24, DOI 10.1016/j.ygyno.2010.12.332
   Zhang CH, 2012, J SURG RES, V174, P120, DOI 10.1016/j.jss.2010.10.030
   Zhang JC, 2006, MOL CARCINOGEN, V45, P530, DOI 10.1002/mc.20188
   Zhang J, 2012, INT J CANCER, V130, P1971, DOI 10.1002/ijc.27318
   Zhang XD, 2005, J LAB CLIN MED, V145, P98, DOI 10.1016/j.lab.2004.11.018
   Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008
   Zhao J, 2010, HEPATOLOGY, V51, P142, DOI 10.1002/hep.23247
   Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019
   Zhu R, 2007, PATHOL INT, V57, P328, DOI 10.1111/j.1440-1827.2007.02104.x
   Zhu YZ, 2010, J VIRAL HEPATITIS, V17, P98, DOI 10.1111/j.1365-2893.2009.01156.x
   Zopf S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-386
NR 167
TC 60
Z9 64
U1 0
U2 27
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD APR
PY 2014
VL 20
IS 11
BP 1715
EP 1725
DI 10.2174/13816128113199990533
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AE9FQ
UT WOS:000334311500015
PM 23888939
DA 2025-01-12
ER

PT J
AU Ung, M
   Ma, XT
   Johnson, KC
   Christensen, BC
   Cheng, C
AF Ung, Matthew
   Ma, Xiaotu
   Johnson, Kevin C.
   Christensen, Brock C.
   Cheng, Chao
TI Effect of estrogen receptor α binding on functional DNA methylation in
   breast cancer
SO EPIGENETICS
LA English
DT Article
DE differential gene expression; differential methylation; transcription
   factor; estrogen receptor alpha; breast cancer; DNase I
   hypersensitivity; ChIP-seq
ID GENE-EXPRESSION; HUMAN GENOME; TRANSCRIPTION; PROTEINS; ASSOCIATION;
   POLYCOMB; FAMILY
AB Epigenetic modifications introduce an additional layer of regulation that drastically expands the instructional capability of the human genome. The regulatory consequences of DNA methylation is context dependent; it can induce, enhance, and suppress gene expression, or have no effect on gene regulation. Therefore, it is essential to account for the genomic location of its occurrence and the protein factors it associates with to improve our understanding of its function and effects. Here, we use ENCODE ChIP-seq and DNase I hypersensitivity data, along with large-scale breast cancer genomic data from The Cancer Genome Atlas (TCGA) to computationally dissect the intricacies of DNA methylation in regulation of cancer transcriptomes. In particular, we identified a relationship between estrogen receptor alpha (ER alpha) activity and DNA methylation patterning in breast cancer. We found compelling evidence that methylation status of DNA sequences at ER alpha binding sites is tightly coupled with ER alpha activity. Furthermore, we predicted several transcription factors including FOXA1, GATA1, and SUZ12 to be associated with breast cancer by examining the methylation status of their binding sites in breast cancer. Lastly, we determine that methylated CpGs highly correlated with gene expression are enriched in regions 1kb or more downstream of TSSs, suggesting more significant regulatory roles for CpGs distal to gene TSSs. Our study provides novel insights into the role of ER alpha in breast cancers.
C1 [Ung, Matthew; Cheng, Chao] Geisel Sch Med Dartmouth, Dept Genet, Hanover, NH 03755 USA.
   [Ma, Xiaotu] Univ Texas Dallas, Dept Mol & Cell Biol, Ctr Syst Biol, Dallas, TX 75230 USA.
   [Johnson, Kevin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Sect Biostat & Epidemiol, Dept Community & Family Med, Lebanon, NH USA.
   [Johnson, Kevin C.; Christensen, Brock C.] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH USA.
   [Cheng, Chao] Geisel Sch Med Dartmouth, Inst Quantitat Biomed Sci, Lebanon, NH USA.
   [Cheng, Chao] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH USA.
C3 Dartmouth College; University of Texas System; University of Texas
   Dallas; Dartmouth College; Dartmouth College; Dartmouth College;
   Dartmouth College; Norris Cotton Cancer Center
RP Cheng, C (通讯作者)，Geisel Sch Med Dartmouth, Dept Genet, Hanover, NH 03755 USA.
EM chao.cheng@dartmouth.edu
FU American Cancer Society Research Grant [IRG-82-003-27]; Geisel School of
   Medicine at Dartmouth College
FX This work was supported by the American Cancer Society Research Grant,
   #IRG-82-003-27, and by the start-up funding package provided to C. C. by
   the Geisel School of Medicine at Dartmouth College.
CR Aran D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r21
   Barlow DP, 2011, ANNU REV GENET, V45, P379, DOI 10.1146/annurev-genet-110410-132459
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bediaga N, 2010, BCR 2010, P12
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4
   Choy MK, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-519
   COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975
   Dedeurwaerder S, 2011, EMBO MOL MED, V3, P726, DOI 10.1002/emmm.201100801
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006
   Hartmann O, 2009, CLIN CANCER RES, V15, P315, DOI 10.1158/1078-0432.CCR-08-0166
   Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158
   Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538
   Hill VK, 2011, CANCER RES, V71, P2988, DOI 10.1158/0008-5472.CAN-10-4026
   HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127
   Holm K, 2010, BCR 2010, P12
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Johnson LM, 2007, CURR BIOL, V17, P379, DOI 10.1016/j.cub.2007.01.009
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Li LA, 2010, HUM MOL GENET, V19, P4273, DOI 10.1093/hmg/ddq351
   Margueron R, 2011, NATURE, V469, P343, DOI 10.1038/nature09784
   Martens JWM, 2009, FUTURE ONCOL, V5, P1245, DOI [10.2217/fon.09.89, 10.2217/FON.09.89]
   Martin M, 2012, GENOME MED, V4, DOI 10.1186/gm307
   Meissner A, 2010, NAT BIOTECHNOL, V28, P1079, DOI 10.1038/nbt.1684
   Miranda TB, 2007, J CELL PHYSIOL, V213, P384, DOI 10.1002/jcp.21224
   PIVA R, 1990, BRIT J CANCER, V61, P270, DOI 10.1038/bjc.1990.50
   PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A
   Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501
   Reik W, 2007, NATURE, V447, P425, DOI 10.1038/nature05918
   RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315
   Rottach A, 2010, NUCLEIC ACIDS RES, V38, P1796, DOI 10.1093/nar/gkp1152
   Rozowsky J, 2009, NAT BIOTECHNOL, V27, P66, DOI 10.1038/nbt.1518
   Ruike Y, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-137
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Ulirsch J, 2013, BREAST CANCER RES TR, V137, P383, DOI 10.1007/s10549-012-2353-5
   Watters RJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3146
   Widschwendter M, 2004, CANCER RES, V64, P3807, DOI 10.1158/0008-5472.CAN-03-3852
   Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5
NR 45
TC 25
Z9 30
U1 0
U2 8
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD APR 1
PY 2014
VL 9
IS 4
BP 523
EP 532
DI 10.4161/epi.27688
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AE9DP
UT WOS:000334305100006
PM 24434785
OA Green Published
DA 2025-01-12
ER

PT J
AU Fiano, V
   Trevisan, M
   Trevisan, E
   Senetta, R
   Castiglione, A
   Sacerdote, C
   Gillio-Tos, A
   De Marco, L
   Grasso, C
   Magistrello, M
   Tondat, F
   Rudà, R
   Cassoni, P
   Soffietti, R
   Merletti, F
AF Fiano, Valentina
   Trevisan, Morena
   Trevisan, Elisa
   Senetta, Rebecca
   Castiglione, Anna
   Sacerdote, Carlotta
   Gillio-Tos, Anna
   De Marco, Laura
   Grasso, Chiara
   Magistrello, Michela
   Tondat, Fabrizio
   Ruda, Roberta
   Cassoni, Paola
   Soffietti, Riccardo
   Merletti, Franco
TI MGMT promoter methylation in plasma of glioma patients receiving
   temozolomide
SO JOURNAL OF NEURO-ONCOLOGY
LA English
DT Article
DE Glioma; Plasma DNA; MGMT; Methylation; Temozolomide
ID LOW-GRADE GLIOMAS; NEWLY-DIAGNOSED GLIOBLASTOMA; BREAST-CANCER PATIENTS;
   O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; PROSTATE-CANCER; SERUM DNA;
   QUANTITATIVE DETECTION; ADJUVANT TEMOZOLOMIDE; EPIGENETIC MARKERS;
   PROTEIN EXPRESSION
AB Promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene plays a role in cellular response to alkylating agents. In the present study aimed to: (i) evaluate the concordance between MGMT promoter methylation status in tumor tissue and plasma; (ii) monitor MGMT promoter methylation status in plasma taken before and during temozolomide treatment; (iii) explore the value of MGMT promoter methylation status in plasma as a prognostic/predictive biomarker in glioma patients. We enrolled 58 patients with histologically confirmed glioma at different grades of malignancy. All patients underwent surgical resection and temozolomide treatment. Paraffin-embedded tumor tissue was available for 48 patients. Blood samples were collected from all patients before temozolomide treatment (baseline) and at each MRI examination for a 12-month period. MGMT promoter methylation status was assessed in both sample types by real time PCR with a specific probe. The frequency of MGMT promoter methylation was 60.4 % in tumor tissue and 41.38 % in plasma. MGMT promoter methylation status was concordant in the two sample types (Kappa = 0.75, 95 % confidence interval (CI) 0.57-0.93; p value < 0.001). Overall and progression-free survival were longer in patients with methylated MGMT promoter. Mortality was higher in patients with unmethylated MGMT promoter, whether in tumor tissue [hazard ratio (HR) 2.21; 95 % CI 0.99-4.95] or plasma (HR 2.19; 95 % CI 1.02-4.68). Progression-free survival was shorter in patients with unmethylated MGMT promoter, whether in tissue (HR 2.30; 95 % CI 1.19-4.45) or plasma (HR 1.77; 95 % CI 0.95-3.30). The cumulative incidence of unmethylated MGMT promoter in plasma at baseline was 58 %, and reached virtually 100 % at 12 months. In conclusion MGMT promoter methylation status in tumor tissue and plasma was highly concordant, and both were associated with longer survival, supporting the role of the detection of methylated MGMT promoter in predicting treatment response. However we suggest caution in using plasma as a surrogate of tumor tissue due to possible false-negative results.
C1 [Fiano, Valentina; Trevisan, Morena; Castiglione, Anna; Sacerdote, Carlotta; Gillio-Tos, Anna; De Marco, Laura; Grasso, Chiara; Merletti, Franco] Univ Turin, Unit Canc Epidemiol CERMS, Dept Med Sci, Citta Salute & Sci Hosp, I-10126 Turin, Italy.
   [Trevisan, Elisa; Magistrello, Michela; Ruda, Roberta; Soffietti, Riccardo] Univ Turin, Dept Neurosci, Div Neurooncol, I-10126 Turin, Italy.
   [Trevisan, Morena; Senetta, Rebecca; Magistrello, Michela; Ruda, Roberta; Cassoni, Paola; Soffietti, Riccardo] Citta Salute & Sci Hosp, I-10126 Turin, Italy.
   [Senetta, Rebecca; Cassoni, Paola] Univ Turin, Dept Med Sci, I-10126 Turin, Italy.
   [Tondat, Fabrizio] Citta Salute & Sci Hosp, Lab Pathol CERMS, I-10126 Turin, Italy.
C3 A.O.U. Citta della Salute e della Scienza di Torino; University of
   Turin; University of Turin; A.O.U. Citta della Salute e della Scienza di
   Torino; University of Turin; A.O.U. Citta della Salute e della Scienza
   di Torino
RP Fiano, V (通讯作者)，Univ Turin, Unit Canc Epidemiol CERMS, Dept Med Sci, Citta Salute & Sci Hosp, Via Santena 7, I-10126 Turin, Italy.
EM vfiano@hotmail.com
RI Soffietti, Riccardo/AAA-7965-2022; Sacerdote, Carlotta/K-3611-2018;
   Senetta, Rebecca/IAQ-9688-2023; De Marco, Laura/J-7254-2016; Trevisan,
   Morena/J-9088-2016; Cassoni, Paola/I-8544-2018; Dei Tos,
   Angelo/AAN-3244-2020
OI FIANO, VALENTINA/0000-0001-7978-372X; Sacerdote,
   Carlotta/0000-0002-8008-5096; RUDA', Roberta/0000-0001-9134-1537;
   grasso, chiara celestina/0000-0002-2597-4990; SOFFIETTI,
   Riccardo/0000-0002-9204-7038; Gillio-Tos, Anna/0000-0001-6553-5362
FU Compagnia di San Paolo/Firms; Piedmont Region
FX The study was partially supported by the Compagnia di San Paolo/Firms
   and the Piedmont Region.
CR [Anonymous], 2010, GLOBOCAN 2008 CANC I
   Balaña C, 2003, CLIN CANCER RES, V9, P1461
   Balañá C, 2011, CLIN TRANSL ONCOL, V13, P677, DOI 10.1007/s12094-011-0714-x
   Brandes AA, 2010, NEURO-ONCOLOGY, V12, P283, DOI 10.1093/neuonc/nop050
   Christians A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033449
   Cortese R, 2012, HUM MOL GENET, V21, P3619, DOI 10.1093/hmg/dds192
   Della Puppa A, 2012, J NEURO-ONCOL, V106, P33, DOI 10.1007/s11060-011-0639-9
   Esteller M, 1999, CANCER RES, V59, P793
   Everhard S, 2006, ANN NEUROL, V60, P740, DOI 10.1002/ana.21044
   Felsberg J, 2011, INT J CANCER, V129, P659, DOI 10.1002/ijc.26083
   Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001
   Fujiwara K, 2005, CLIN CANCER RES, V11, P1219
   Grossman SA, 2010, CLIN CANCER RES, V16, P2443, DOI 10.1158/1078-0432.CCR-09-3106
   Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331
   Hoque MO, 2004, CANCER RES, V64, P5511, DOI 10.1158/0008-5472.CAN-04-0799
   Kesari S, 2009, CLIN CANCER RES, V15, P330, DOI 10.1158/1078-0432.CCR-08-0888
   Kwee S, 2012, CTS-CLIN TRANSL SCI, V5, P65, DOI 10.1111/j.1752-8062.2011.00375.x
   Lange CPE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050266
   Lavon I, 2010, NEURO-ONCOLOGY, V12, P173, DOI 10.1093/neuonc/nop041
   Lechapt-Zalcman E, 2012, CANCER-AM CANCER SOC, V118, P4545, DOI 10.1002/cncr.27441
   Lee BB, 2009, CLIN CANCER RES, V15, P6185, DOI 10.1158/1078-0432.CCR-09-0111
   Leu S, 2013, NEURO-ONCOLOGY, V15, P469, DOI 10.1093/neuonc/nos317
   Liggett TE, 2011, INT J CANCER, V128, P492, DOI 10.1002/ijc.25363
   Liu BL, 2010, NEURO-ONCOLOGY, V12, P540, DOI 10.1093/neuonc/nop064
   Ochsenbein AF, 2011, J NEURO-ONCOL, V103, P343, DOI 10.1007/s11060-010-0395-2
   Olson RA, 2011, J NEURO-ONCOL, V105, P325, DOI 10.1007/s11060-011-0594-5
   Ostrow KL, 2010, CLIN CANCER RES, V16, P3463, DOI 10.1158/1078-0432.CCR-09-3304
   Parkinson JF, 2008, J NEURO-ONCOL, V87, P71, DOI 10.1007/s11060-007-9486-0
   Rudà R, 2012, HAND CLINIC, V105, P437, DOI 10.1016/B978-0-444-53502-3.00001-X
   Silber JR, 2012, BBA-REV CANCER, V1826, P71, DOI 10.1016/j.bbcan.2011.12.004
   Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7
   Taback B, 2006, ANN NY ACAD SCI, V1075, P211, DOI 10.1196/annals.1368.029
   Thomas RP, 2013, CLIN PHARMACOL-ADV A, V5, P1, DOI 10.2147/CPAA.S26586
   van der Vaart M, 2010, CLIN BIOCHEM, V43, P26, DOI 10.1016/j.clinbiochem.2009.08.027
   Watanabe R, 2011, BRAIN TUMOR PATHOL, V28, P127, DOI 10.1007/s10014-011-0022-8
   Weller M, 2012, NEURO-ONCOLOGY, V14, P100, DOI 10.1093/neuonc/nos206
   Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805
   Wick W, 2012, LANCET ONCOL, V13, P707, DOI 10.1016/S1470-2045(12)70164-X
   Wick W, 2009, J CLIN ONCOL, V27, P5874, DOI 10.1200/JCO.2009.23.6497
   Wick W, 2009, CURR OPIN NEUROL, V22, P650, DOI 10.1097/WCO.0b013e3283329ce7
   Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972
   Zhang YW, 2011, CANCER LETT, V303, P21, DOI 10.1016/j.canlet.2010.12.011
NR 42
TC 41
Z9 44
U1 1
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-594X
EI 1573-7373
J9 J NEURO-ONCOL
JI J. Neuro-Oncol.
PD APR
PY 2014
VL 117
IS 2
BP 347
EP 357
DI 10.1007/s11060-014-1395-4
PG 11
WC Oncology; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Neurosciences & Neurology
GA AE7NF
UT WOS:000334184100018
PM 24519517
DA 2025-01-12
ER

PT J
AU Hayashi, A
   Morikawa, T
   Kawai, T
   Kume, H
   Ishikawa, S
   Homma, Y
   Fukayama, M
AF Hayashi, Akimasa
   Morikawa, Teppei
   Kawai, Taketo
   Kume, Haruki
   Ishikawa, Shumpei
   Homma, Yukio
   Fukayama, Masashi
TI Clinicopathological and prognostic significance of EZH2 expression in
   upper urinary tract carcinoma
SO VIRCHOWS ARCHIV
LA English
DT Article
DE Urothelial carcinoma; Prognostic biomarker; Epigenetics; Histone
   methyltransferase; Ureter; Renal pelvis
ID POLYCOMB GROUP PROTEIN; RENAL-CELL CARCINOMA; POTENTIAL THERAPEUTIC
   TARGET; AGGRESSIVE BREAST-CANCER; UROTHELIAL CARCINOMA; ZESTE HOMOLOG-2;
   PROSTATE-CANCER; BLADDER-CANCER; ENHANCER-OF-ZESTE-HOMOLOG-2 GENE;
   HISTONE METHYLTRANSFERASE
AB Evidence suggests that overexpression of enhancer of zeste homologue 2 (EZH2) is associated with aggressive behavior in various cancers. However, the clinical, pathological, and prognostic associations of EZH2 expression in the upper urinary tract carcinoma have not been reported. This study aimed to investigate the significance of EZH2 expression in the upper urinary tract carcinoma by immunohistochemical analysis using a tissue microarray. High EZH2 expression was observed in 94 of 171 (55 %) cases and was significantly associated with several adverse prognostic factors, including sessile architecture, high histological grade, presence of lymphovascular invasion, concomitant carcinoma in situ, higher tumor stage, and higher Ki-67 expression (all P < 0.01). EZH2 expression status in primary and metastatic lesions was concordant in all 13 cases examined. Survival analyses were performed using the Kaplan-Meier method and multivariate Cox proportional hazards regression models. High EZH2 expression was significantly associated with a shorter metastasis-free survival (log-rank P = 0.005; multivariate hazard ratio, 1.85; 95 % confidence interval, 0.93-3.71) and cancer-specific survival (log-rank P = 0.006; multivariate hazard ratio, 3.08; 95 % confidence interval, 1.30-7.32) after nephroureterectomy. Our results suggest that EZH2 may serve as a novel prognostic biomarker and a potential therapeutic target in upper urinary tract carcinoma.
C1 [Hayashi, Akimasa; Morikawa, Teppei; Fukayama, Masashi] Univ Tokyo, Dept Pathol, Grad Sch Med, Bunkyo Ku, Tokyo 1130033, Japan.
   [Kawai, Taketo; Kume, Haruki; Homma, Yukio] Univ Tokyo, Dept Urol, Grad Sch Med, Tokyo 1130033, Japan.
   [Ishikawa, Shumpei] Tokyo Med & Dent Univ, Dept Genom Pathol, Med Res Inst, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo; Institute of Science Tokyo;
   Tokyo Medical & Dental University (TMDU)
RP Fukayama, M (通讯作者)，Univ Tokyo, Dept Pathol, Grad Sch Med, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.
EM mfukayama-tky@umin.net
RI Kawai, Taketo/HZL-3053-2023
OI Kawai, Taketo/0000-0002-7279-2874
FU Ichiro Kanehara Foundation for the Promotion of Medical Sciences and
   Medical Care; Japan Society for the Promotion of Science; Grants-in-Aid
   for Scientific Research [25460412] Funding Source: KAKEN
FX This work was supported in part by a research grant from the Ichiro
   Kanehara Foundation for the Promotion of Medical Sciences and Medical
   Care (to T.M.), and a Grant-in-Aid for Scientific Research (C) from the
   Japan Society for the Promotion of Science (to T.M.). We are grateful to
   Yumiko Nagano, Harumi Yamamura, and Kei Sakuma for excellent technical
   support.
CR Arisan S, 2005, UROL INT, V75, P252, DOI 10.1159/000087804
   Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180
   Bryant RJ, 2007, PROSTATE, V67, P547, DOI 10.1002/pros.20550
   Cha EK, 2012, EUR UROL, V61, P818, DOI 10.1016/j.eururo.2012.01.021
   Chen YC, 2007, HEPATOLOGY, V46, P200, DOI 10.1002/hep.21668
   Chowdhury GM, 1996, CANCER, V78, P827, DOI 10.1002/(SICI)1097-0142(19960815)78:4<827::AID-CNCR20>3.0.CO;2-W
   Chromecki TF, 2011, NAT REV UROL, V8, P440, DOI 10.1038/nrurol.2011.96
   Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533
   Crea F, 2012, CANCER METAST REV, V31, P753, DOI 10.1007/s10555-012-9387-3
   Dinney CPN, 2004, CANCER CELL, V6, P111, DOI 10.1016/j.ccr.2004.08.002
   Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002
   Grignon DJ, 2009, MODERN PATHOL, V22, pS60, DOI 10.1038/modpathol.2008.235
   Hinz S, 2008, J CANCER RES CLIN, V134, P331, DOI 10.1007/s00432-007-0288-8
   Hinz S, 2010, WORLD J UROL, V28, P631, DOI 10.1007/s00345-009-0498-6
   Holland D, 2008, CANCER RES, V68, P9964, DOI 10.1158/0008-5472.CAN-08-1134
   Jeon HG, 2010, UROLOGY, V76, pe512
   Joung JY, 2008, UROL INT, V81, P306, DOI 10.1159/000151409
   Kamijima S, 2005, INT J UROL, V12, P941, DOI 10.1111/j.1442-2042.2005.01159.x
   Kidani K, 2009, ORAL ONCOL, V45, P39, DOI 10.1016/j.oraloncology.2008.03.016
   Kikuchi E, 2009, J CLIN ONCOL, V27, P612, DOI 10.1200/JCO.2008.17.2361
   Kitamura H, 2013, VIRCHOWS ARCH, V462, P101, DOI 10.1007/s00428-012-1343-7
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Laitinen S, 2008, INT J CANCER, V122, P595, DOI 10.1002/ijc.23145
   Lughezzani G, 2012, EUR UROL, V62, P100, DOI 10.1016/j.eururo.2012.02.030
   Matsukawa Y, 2006, CANCER SCI, V97, P484, DOI 10.1111/j.1349-7006.2006.00203.x
   McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606
   Mimori K, 2005, EJSO-EUR J SURG ONC, V31, P376, DOI 10.1016/j.ejso.2004.11.001
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Morikawa T, 2007, CLIN CANCER RES, V13, P5703, DOI 10.1158/1078-0432.CCR-07-0603
   Morikawa T, 2010, HISTOPATHOLOGY, V57, P885, DOI 10.1111/j.1365-2559.2010.03725.x
   Raaphorst FM, 2000, J IMMUNOL, V164, P1, DOI 10.4049/jimmunol.164.1.1
   Remzi M, 2011, THER ADV UROL, V3, P69, DOI 10.1177/1756287211403349
   Rhodes DR, 2003, J NATL CANCER I, V95, P661, DOI 10.1093/jnci/95.9.661
   Rouprêt M, 2013, EUR UROL, V63, P1059, DOI 10.1016/j.eururo.2013.03.032
   Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Takawa M, 2011, CANCER SCI, V102, P1298, DOI 10.1111/j.1349-7006.2011.01958.x
   Takeshita F, 2005, P NATL ACAD SCI USA, V102, P12177, DOI 10.1073/pnas.0501753102
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wagener N, 2008, INT J CANCER, V123, P1545, DOI 10.1002/ijc.23683
   Wagener N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-524
   Wan LY, 2013, CLIN TRANSL ONCOL, V15, P132, DOI 10.1007/s12094-012-0897-9
   Wang H, 2012, UROL ONCOL-SEMIN ORI, V30, P428, DOI 10.1016/j.urolonc.2010.09.005
   Weikert S, 2005, INT J MOL MED, V16, P349
   Xiao YT, 2011, INT J BIOCHEM CELL B, V43, P474, DOI 10.1016/j.biocel.2011.01.005
   Zhang YB, 2011, EUR J CANCER CARE, V20, P106, DOI 10.1111/j.1365-2354.2009.01148.x
NR 47
TC 8
Z9 9
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD APR
PY 2014
VL 464
IS 4
BP 463
EP 471
DI 10.1007/s00428-014-1541-6
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AE7JO
UT WOS:000334174000009
PM 24446035
DA 2025-01-12
ER

PT J
AU Li, D
   Bi, FF
   Cao, JM
   Cao, C
   Liu, B
   Yang, Q
AF Li, Da
   Bi, Fang-Fang
   Cao, Ji-Min
   Cao, Chen
   Liu, Bo
   Yang, Qing
TI Regulation of DNA methyltransferase 1 transcription in BRCA1-mutated
   breast cancer: a novel crosstalk between E2F1 motif hypermethylation and
   loss of histone H3 lysine 9 acetylation
SO MOLECULAR CANCER
LA English
DT Article
DE DNMT1; Histone modifications; E2F1; BRCA1; Breast cancer
ID EXPRESSION; METHYLATION; DNMT1; WOMEN; IDENTIFICATION; POLYMORPHISMS;
   MUTATIONS; BRCA1; RISK
AB Background: DNA methyltransferase 1 (DNMT1) plays a critical role in breast cancer progression. However, the epigenetic mechanism regulating DNMT1 expression remains largely unknown.
   Methods: Epigenetic regulation of DNMT1 was assessed in 85 invasive ductal carcinomas from BRCA1 mutation carriers. Association between clinicopathological features and DNMT1 promoter methylation was determined using Fisher's exact test. Univariate analysis of survival was performed using the Kaplan-Meier method. Multivariate Cox regression analysis was performed to identify the independent prognostic factors for overall survival.
   Results: Hypermethylated E2F transcription factor 1 (E2F1) motif is a key regulatory element for the DNMT1 gene in BRCA1 mutated breast cancer. Mechanistically, the abnormal E2F1 motif methylation-mediated loss of active histone H3 lysine 9 acetylation (H3K9ac) and transcription factor E2F1 enrichment synergistically inhibited the transcription of DNMT1. Clinicopathological data indicated that the hypermethylated E2F1 motif was associated with histological grade, lymph node, Ki67 and E-cadherin status; univariate survival and multivariate analyses demonstrated that lymph node metastasis was an independent and reliable prognostic factor for BRCA1-mutated breast cancer patients.
   Conclusions: Our findings imply that genetic (such as BRCA1 mutation) and epigenetic mechanisms (such as DNA methylation, histone modification, transcription factor binding) are jointly involved in the malignant progression of DNMT1-related breast cancer.
C1 [Li, Da; Bi, Fang-Fang; Yang, Qing] China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang 110004, Peoples R China.
   [Li, Da] China Med Univ, Shengjing Hosp, Expt Res Ctr, Shenyang 110004, Peoples R China.
   [Cao, Ji-Min] Chinese Acad Med Sci, Inst Basic Med Sci, Peking Union Med Coll, Sch Basic Med,Dept Physiol & Pathophysiol, Beijing 100005, Peoples R China.
   [Cao, Chen] Chinese Peoples Liberat Army Gen Hosp, Dept Pathol, Beijing 100853, Peoples R China.
   [Liu, Bo] China Med Univ, Hosp 1, Dept Lab Med, Shenyang 110001, Peoples R China.
C3 China Medical University; China Medical University; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College; Institute of Basic Medical Sciences - CAMS; Chinese People's
   Liberation Army General Hospital; China Medical University
RP Li, D (通讯作者)，China Med Univ, Shengjing Hosp, Dept Obstet & Gynecol, Shenyang 110004, Peoples R China.
EM leeda@ymail.com; yangq@sj-hospital.org
FU 973 Program of China [2011CB933504]; Natural Science Foundation of China
   [81071072]; Higher Specialized Research Fund for Doctoral Program of
   Ministry of Education of China [20122104110027]
FX This work was supported by the 973 Program of China (No. 2011CB933504),
   Natural Science Foundation of China (No. 81071072) and the Higher
   Specialized Research Fund for Doctoral Program of Ministry of Education
   of China (No. 20122104110027).
CR Agoston AT, 2005, J BIOL CHEM, V280, P18302, DOI 10.1074/jbc.M501675200
   Bi FF, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/946268
   Bi FF, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-90
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   Gao XA, 2010, CLIN BREAST CANCER, V10, P373, DOI 10.3816/CBC.2010.n.049
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Hershman SG, 2008, NUCLEIC ACIDS RES, V36, P144, DOI 10.1093/nar/gkm986
   Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318
   Jin W, 2010, BREAST CANCER RES TR, V123, P359, DOI 10.1007/s10549-009-0652-2
   Kimura H, 2003, NUCLEIC ACIDS RES, V31, P3101, DOI 10.1093/nar/gkg406
   Kullmann K, 2013, CLIN EPIGENETICS, V5, DOI 10.1186/1868-7083-5-7
   Li D, 2013, BRIT J NUTR, V110, P2156, DOI 10.1017/S0007114513001815
   Magnani L, 2012, EPIGENOMICS-UK, V4, P675, DOI [10.2217/epi.12.64, 10.2217/EPI.12.64]
   McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158
   Meng FX, 2012, EXP PHYSIOL, V97, P730, DOI 10.1113/expphysiol.2011.064204
   Mirza S, 2013, J BREAST CANCER, V16, P23, DOI 10.4048/jbc.2013.16.1.23
   Morris MR, 2010, ONCOGENE, V29, P2104, DOI 10.1038/onc.2009.493
   Pruthi S, 2010, MAYO CLIN PROC, V85, P1111, DOI 10.4065/mcp.2010.0414
   Shukla V, 2010, CELL RES, V20, P1201, DOI 10.1038/cr.2010.128
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Speirs V, 1998, BRIT J CANCER, V78, P1421, DOI 10.1038/bjc.1998.702
   Sun MY, 2012, GENET MOL RES, V11, P4330, DOI 10.4238/2012.September.26.1
   Suter NM, 2004, CANCER EPIDEM BIOMAR, V13, P181, DOI 10.1158/1055-9965.EPI-03-0196
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Xu XM, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-33
   Zhang B, 2013, GENOME RES, V23, P1522, DOI 10.1101/gr.156539.113
NR 27
TC 24
Z9 25
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD FEB 6
PY 2014
VL 13
AR 26
DI 10.1186/1476-4598-13-26
PG 12
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA AF2HM
UT WOS:000334533200001
PM 24502362
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Rashi-Elkeles, S
   Warnatz, HJ
   Elkon, R
   Kupershtein, A
   Chobod, Y
   Paz, A
   Amstislavskiy, V
   Sultan, M
   Safer, H
   Nietfeld, W
   Lehrach, H
   Shamir, R
   Yaspo, ML
   Shiloh, Y
AF Rashi-Elkeles, Sharon
   Warnatz, Hans-Joerg
   Elkon, Ran
   Kupershtein, Ana
   Chobod, Yuliya
   Paz, Arnon
   Amstislavskiy, Vyacheslav
   Sultan, Marc
   Safer, Hershel
   Nietfeld, Wilfried
   Lehrach, Hans
   Shamir, Ron
   Yaspo, Marie-Laure
   Shiloh, Yosef
TI Parallel Profiling of the Transcriptome, Cistrome, and Epigenome in the
   Cellular Response to Ionizing Radiation
SO SCIENCE SIGNALING
LA English
DT Article
ID DNA-DAMAGE RESPONSE; DOUBLE-STRAND BREAKS; GENE-EXPRESSION DATA; LONG
   NONCODING RNAS; CANCER-CELLS; CHIP-SEQ; ATAXIA-TELANGIECTASIA; HISTONE
   MODIFICATIONS; GENOMIC INSTABILITY; MITOTIC CATASTROPHE
AB The DNA damage response (DDR) is a vast signaling network that is robustly activated by DNA double-strand breaks, the critical lesion induced by ionizing radiation (IR). Although much of this response operates at the protein level, a critical component of the network sustains many DDR branches by modulating the cellular transcriptome. Using deep sequencing, we delineated three layers in the transcriptional response to IR in human breast cancer cells: changes in the expression of genes encoding proteins or long noncoding RNAs, alterations in genomic binding by key transcription factors, and dynamics of epigenetic markers of active promoters and enhancers. We identified protein-coding and previously unidentified noncoding genes that were responsive to IR, and demonstrated that IR-induced transcriptional dynamics was mediated largely by the transcription factors p53 and nuclear factor kappa B (NF-kappa B) and was primarily dependent on the kinase ataxia-telangiectasia mutated (ATM). The resultant data set provides a rich resource for understanding a basic, underlying component of a critical cellular stress response.
C1 [Rashi-Elkeles, Sharon; Elkon, Ran; Kupershtein, Ana; Chobod, Yuliya; Paz, Arnon; Shiloh, Yosef] Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, David & Inez Myers Lab Canc Res, IL-69978 Tel Aviv, Israel.
   [Warnatz, Hans-Joerg; Amstislavskiy, Vyacheslav; Sultan, Marc; Nietfeld, Wilfried; Lehrach, Hans; Yaspo, Marie-Laure] Max Planck Inst Mol Genet, Dept Vertebrate Genom, D-14195 Berlin, Germany.
   [Safer, Hershel; Shamir, Ron] Tel Aviv Univ, Blavatnik Sch Comp Sci, IL-69978 Tel Aviv, Israel.
C3 Tel Aviv University; Sackler Faculty of Medicine; Max Planck Society;
   Tel Aviv University
RP Shiloh, Y (通讯作者)，Tel Aviv Univ, Sackler Sch Med, Dept Human Mol Genet & Biochem, David & Inez Myers Lab Canc Res, IL-69978 Tel Aviv, Israel.
EM yossih@post.tau.ac.il
RI Shamir, Ron/E-6514-2011
OI Warnatz, Hans-Jorg/0000-0002-0327-9209; Shamir, Ron/0000-0003-1889-9870
FU European Union [HEALTH-F4-2009-223575, 262055]; Dr. Miriam and Sheldon
   G. Adelson Medical Research Foundation; Max Planck Society; I-CORE
   Program of the Planning and Budgeting Committee; Israel Science
   Foundation [41/11]; Israel Cancer Research Fund
FX This work was supported by research grants from the European Union
   Seventh Framework Program (HEALTH-F4-2009-223575 and 262055-European
   Sequencing and Genotyping Infrastructure), The Dr. Miriam and Sheldon G.
   Adelson Medical Research Foundation, the Max Planck Society, the I-CORE
   Program of the Planning and Budgeting Committee and The Israel Science
   Foundation (Gene Regulation in Complex Human Disease Center, grant no.
   41/11), and The Israel Cancer Research Fund. Y.S. is a Research
   Professor of the Israel Cancer Research Fund.
CR Aksoy O, 2012, GENE DEV, V26, P1546, DOI 10.1101/gad.196238.112
   Alt FW, 2013, CELL, V152, P417, DOI 10.1016/j.cell.2013.01.007
   Amundson SA, 2003, ONCOGENE, V22, P5828, DOI 10.1038/sj.onc.1206681
   Anders S, 2013, NAT PROTOC, V8, P1765, DOI 10.1038/nprot.2013.099
   Aziz K, 2012, PHARMACOL THERAPEUT, V133, P334, DOI 10.1016/j.pharmthera.2011.11.010
   Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28
   Bandyopadhyay S, 2010, SCIENCE, V330, P1385, DOI 10.1126/science.1195618
   Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674
   Bannister AJ, 2011, CELL RES, V21, P381, DOI 10.1038/cr.2011.22
   Basu B, 2012, CURR OPIN ONCOL, V24, P316, DOI 10.1097/CCO.0b013e32835280c6
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Bensimon A, 2011, FEBS LETT, V585, P1625, DOI 10.1016/j.febslet.2011.05.013
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Bieging KT, 2012, TRENDS CELL BIOL, V22, P97, DOI 10.1016/j.tcb.2011.10.006
   Borde V, 2013, CURR OPIN GENET DEV, V23, P147, DOI 10.1016/j.gde.2012.12.002
   Botcheva K, 2011, CELL CYCLE, V10, P4237, DOI 10.4161/cc.10.24.18383
   Busca A, 2012, J BIOL CHEM, V287, P15118, DOI 10.1074/jbc.M111.312660
   Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677
   Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111
   Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019
   Cohen S, 2013, J MOL MED, V91, P357, DOI 10.1007/s00109-012-0946-4
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Dunning MJ, 2007, BIOINFORMATICS, V23, P2183, DOI 10.1093/bioinformatics/btm311
   Eby KG, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-95
   Eriksson D, 2010, TUMOR BIOL, V31, P363, DOI 10.1007/s13277-010-0042-8
   Finn K, 2012, CELL MOL LIFE SCI, V69, P1447, DOI 10.1007/s00018-011-0875-3
   Furey TS, 2012, NAT REV GENET, V13, P840, DOI 10.1038/nrg3306
   Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768
   GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219
   Guénolé A, 2013, MOL CELL, V49, P346, DOI 10.1016/j.molcel.2012.11.023
   He KL, 2002, MOL CELL BIOL, V22, P6034, DOI 10.1128/MCB.22.17.6034-6045.2002
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249
   Jaehnig EJ, 2013, CELL REP, V4, P174, DOI 10.1016/j.celrep.2013.05.041
   Jeppesen DK, 2011, PROG NEUROBIOL, V94, P166, DOI 10.1016/j.pneurobio.2011.04.013
   Ji HK, 2008, NAT BIOTECHNOL, V26, P1293, DOI 10.1038/nbt.1505
   KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2
   KASTAN MB, 1991, CANCER RES, V51, P6304
   Kawase T, 2008, ONCOGENE, V27, P3797, DOI 10.1038/onc.2008.32
   Kawase T, 2009, CELL, V136, P535, DOI 10.1016/j.cell.2008.12.002
   Kim TK, 2010, NATURE, V465, P182, DOI 10.1038/nature09033
   Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Laptenko O, 2011, P NATL ACAD SCI USA, V108, P10385, DOI 10.1073/pnas.1105680108
   LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0
   Linhart C, 2008, GENOME RES, V18, P1180, DOI 10.1101/gr.076117.108
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Loayza-Puch F, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r32
   Lu M, 2013, CANCER CELL, V23, P618, DOI 10.1016/j.ccr.2013.03.013
   McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x
   Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021
   Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504
   Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858
   Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89
   Nili EL, 2010, GENOME RES, V20, P1361, DOI 10.1101/gr.103945.109
   O'Driscoll M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012773
   Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934
   Park PJ, 2009, NAT REV GENET, V10, P669, DOI 10.1038/nrg2641
   Paz A, 2011, NUCLEIC ACIDS RES, V39, pD793, DOI 10.1093/nar/gkq1167
   Pick R, 2006, BIOCHEM BIOPH RES CO, V349, P1329, DOI 10.1016/j.bbrc.2006.08.176
   Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311
   Rashi-Elkeles S, 2006, ONCOGENE, V25, P1584, DOI 10.1038/sj.onc.1209189
   Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017
   Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068
   Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213
   Roos WP, 2013, CANCER LETT, V332, P237, DOI 10.1016/j.canlet.2012.01.007
   Roy L, 2009, ANN I SUPER SANITA, V45, P272
   Sharan R, 2003, BIOINFORMATICS, V19, P1787, DOI 10.1093/bioinformatics/btg232
   Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546
   Sirbu BM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012724
   Sullivan KD, 2012, BBA-REV CANCER, V1825, P229, DOI 10.1016/j.bbcan.2012.01.004
   Sultan M, 2012, BIOCHEM BIOPH RES CO, V422, P643, DOI 10.1016/j.bbrc.2012.05.043
   Surova O, 2013, ONCOGENE, V32, P3789, DOI 10.1038/onc.2012.556
   Thompson LH, 2012, MUTAT RES-REV MUTAT, V751, P158, DOI 10.1016/j.mrrev.2012.06.002
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020
   Ulitsky I, 2010, NAT PROTOC, V5, P303, DOI 10.1038/nprot.2009.230
   Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47
   Vendrell JA, 2007, ONCOGENE, V26, P4656, DOI 10.1038/sj.onc.1210269
   Vijg J, 2013, ANNU REV PHYSIOL, V75, P645, DOI 10.1146/annurev-physiol-030212-183715
   von Stechow L, 2013, ARCH TOXICOL, V87, P1635, DOI 10.1007/s00204-013-1106-5
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Warnatz HJ, 2011, J BIOL CHEM, V286, P23521, DOI 10.1074/jbc.M111.220178
NR 88
TC 50
Z9 54
U1 1
U2 4
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD MAY 13
PY 2014
VL 7
IS 325
AR rs3
DI 10.1126/scisignal.2005032
PG 11
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AH2PY
UT WOS:000335964600004
PM 24825921
OA Green Published
DA 2025-01-12
ER

PT J
AU Iliopoulos, D
AF Iliopoulos, Dimitrios
TI MicroRNA Circuits Regulate the Cancer-Inflammation Link
SO SCIENCE SIGNALING
LA English
DT Article
ID NF-KAPPA-B; INDUCTION
AB Genetic and epigenetic perturbations are required to transform normal cells into cancer cells. Inflammatory signaling pathways are activated in various cancers, linking chronic inflammation to oncogenesis. However, the molecular circuits that result in sustained activation of these inflammatory factors are not yet well understood. In the 28 January 2014 issue of Science Signaling, Xiang et al. identified a microRNA-mediated anti-inflammatory circuit that is repressed epigenetically in receptor-negative breast cancers. A high-throughput screen for signal transducer and activator of transcription 3 (STAT3)-regulated microRNAs revealed microRNA miR-146b as a direct STAT3 target in mammary epithelial cells, but DNA methylation in its promoter area suppressed miR-146b expression in cancer cells. Overexpression of miR-146b suppressed nuclear factor kappa B (NF-kappa B)-dependent expression of IL6 and subsequent STAT3 activation and decreased the STAT3-induced invasiveness and mesenchymal phenotype of breast cancer cells. Overall, this study contributes to our understanding of how inflammation is involved in oncogenic transformation. Further studies could evaluate the therapeutic potential of targeting this circuit in estrogen receptor-negative breast cancers.
C1 Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Syst Biomed, Los Angeles, CA 90095 USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA
RP Iliopoulos, D (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Ctr Syst Biomed, Los Angeles, CA 90095 USA.
EM diliopoulos@mednet.ucla.edu
RI Iliopoulos, Dimitrios/AAE-9106-2019
FU Cancer Research Institute; Leona M. and Harry B. Helmsley Charitable
   Trust
FX This work was supported by the Cancer Research Institute (D.I.) and by
   the Leona M. and Harry B. Helmsley Charitable Trust (D.I.).
CR Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Cowell JK, 2005, CANCER GENET CYTOGEN, V163, P23, DOI 10.1016/j.cancergencyto.2005.04.019
   Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630
   Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245
   Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020
   Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Koukos G, 2013, GASTROENTEROLOGY, V145, P842, DOI 10.1053/j.gastro.2013.07.001
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Ozsolak F, 2008, GENE DEV, V22, P3172, DOI 10.1101/gad.1706508
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Xiang M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004497
NR 13
TC 19
Z9 20
U1 0
U2 10
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD MAR 25
PY 2014
VL 7
IS 318
AR pe8
DI 10.1126/scisignal.2005053
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AD9BD
UT WOS:000333558600002
PM 24667374
DA 2025-01-12
ER

PT J
AU Avraham, A
   Cho, SS
   Uhlmann, R
   Polak, ML
   Sandbank, J
   Karni, T
   Pappo, I
   Halperin, R
   Vaknin, Z
   Sella, A
   Sukumar, S
   Evron, E
AF Avraham, Ayelet
   Cho, Sean Soonweng
   Uhlmann, Ronit
   Polak, Mia Leonov
   Sandbank, Judith
   Karni, Tami
   Pappo, Itzhak
   Halperin, Ruvit
   Vaknin, Zvi
   Sella, Avishay
   Sukumar, Saraswati
   Evron, Ella
TI Tissue Specific DNA Methylation in Normal Human Breast Epithelium and in
   Breast Cancer
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION; TUMOR-SUPPRESSOR; CELLS; TRIM29; ACTIVATION; PATTERNS
AB Cancer is a heterogeneous and tissue-specific disease. Thus, the tissue of origin reflects on the natural history of the disease and dictates the therapeutic approach. It is suggested that tissue differentiation, mediated mostly by epigenetic modifications, could guide tissue-specific susceptibility and protective mechanisms against cancer. Here we studied breast specific methylation in purified normal epithelium and its reflection in breast cancers. We established genome wide methylation profiles of various normal epithelial tissues and identified 110 genes that were differentially methylated in normal breast epithelium. A number of these genes also showed methylation alterations in breast cancers. We elaborated on one of them, TRIM29 (ATDC), and showed that its promoter was hypo-methylated in normal breast epithelium and heavily methylated in other normal epithelial tissues. Moreover, in breast carcinomas methylation increased and expression decreased whereas the reverse was noted for multiple other carcinomas. Interestingly, TRIM29 regulation in breast tumors clustered according to the PAM50 classification. Thus, it was repressed in the estrogen receptor positive tumors, particularly in the more proliferative luminal B subtype. This goes in line with previous reports indicating tumor suppressive activity of TRIM29 in estrogen receptor positive luminal breast cells in contrast to oncogenic function in pancreatic and lung cancers. Overall, these findings emphasize the linkage between breast specific epigenetic regulation and tissue specificity of cancer.
C1 [Avraham, Ayelet; Uhlmann, Ronit; Sella, Avishay; Evron, Ella] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Oncol, Zerifin, Israel.
   [Cho, Sean Soonweng; Sukumar, Saraswati] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
   [Polak, Mia Leonov; Sandbank, Judith] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Pathol, Zerifin, Israel.
   [Karni, Tami; Pappo, Itzhak] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Surg, Zerifin, Israel.
   [Halperin, Ruvit; Vaknin, Zvi] Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Genecol, Zerifin, Israel.
C3 Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Johns
   Hopkins University; Tel Aviv University; Shamir Medical Center (Assaf
   Harofeh); Shamir Medical Center (Assaf Harofeh); Tel Aviv University;
   Tel Aviv University; Shamir Medical Center (Assaf Harofeh)
RP Avraham, A (通讯作者)，Tel Aviv Univ, Assaf Harofeh Med Ctr, Dept Oncol, Zerifin, Israel.
EM ayeleta@asaf.health.gov.il
RI Vaknin, zvi/JBS-7377-2023
OI Evron, Ella/0000-0002-1003-5042; Cho, Soonweng/0000-0002-1637-2875
FU Israeli Cancer Association [20130158]
FX This study was supported by the Israeli Cancer Association grant no.
   20130158. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR [Anonymous], 2012, R LANG ENV STAT COMP
   Avraham A, 2010, EPIGENETICS-US, V5, P41, DOI 10.4161/epi.5.1.10724
   Bloushtain-Qimron N, 2008, P NATL ACAD SCI USA, V105, P14076, DOI 10.1073/pnas.0805206105
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev-biochem-052610-091920
   Chang H, 2009, J CLIN PATHOL, V62, P908, DOI 10.1136/jcp.2009.067298
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ernst T, 2002, AM J PATHOL, V160, P2169, DOI 10.1016/S0002-9440(10)61165-0
   Goldman M, 2013, NUCLEIC ACIDS RES, V41, P29
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139
   Hawkins RD, 2010, CELL STEM CELL, V6, P479, DOI 10.1016/j.stem.2010.03.018
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huggins GS, 2006, CANCER RES, V66, P1384, DOI 10.1158/0008-5472.CAN-05-2715
   Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298
   Ivanov SV, 2013, BRIT J CANCER, V109, P444, DOI 10.1038/bjc.2013.326
   Jandrig B, 2004, ONCOGENE, V23, P9295, DOI 10.1038/sj.onc.1208131
   Klajic J, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-456
   Kosaka Y, 2007, ANN SURG ONCOL, V14, P2543, DOI 10.1245/s10434-007-9461-1
   Liu J, 2012, AM J PATHOL, V180, P839, DOI 10.1016/j.ajpath.2011.10.020
   Myers RM, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001046
   Nacht M, 1999, CANCER RES, V59, P5464
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou C.M., 2011, COLD SPRING HARB PER, V3
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Tollervey JR, 2012, EPIGENETICS-US, V7, P823, DOI 10.4161/epi.21141
   Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018
   Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3
   You JS, 2012, CANCER CELL, V22, P9, DOI 10.1016/j.ccr.2012.06.008
   Yuan ZG, 2010, MOL CELL BIOL, V30, P3004, DOI 10.1128/MCB.01023-09
   Zhang YH, 2012, J BIOL CHEM, V287, P17746, DOI 10.1074/jbc.M112.358143
   Zhou ZY, 2012, J CHIN MED ASSOC, V75, P269, DOI 10.1016/j.jcma.2012.04.015
NR 35
TC 24
Z9 34
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 20
PY 2014
VL 9
IS 3
AR e91805
DI 10.1371/journal.pone.0091805
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AD6FV
UT WOS:000333352800050
PM 24651077
OA Green Published, gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Barciszewska, AM
   Nowak, S
   Naskret-Barciszewska, MZ
AF Barciszewska, Anna-Maria
   Nowak, Stanislaw
   Naskret-Barciszewska, Miroslawa Z.
TI The Degree of Global DNA Hypomethylation in Peripheral Blood Correlates
   with That in Matched Tumor Tissues in Several Neoplasia
SO PLOS ONE
LA English
DT Article
ID METHYLATION; DEMETHYLATION; CANCER; CLASSIFICATION; EPIGENOME; BIOLOGY;
   CELLS
AB There are no good blood and serum biomarkers for detection, follow up, or prognosis of brain tumors. However, they are needed for more detailed tumor classification, better prognosis estimation and selection of an efficient therapeutic strategy. The aim of this study was to use the epigenetic changes in DNA of peripheral blood samples as a molecular marker to diagnose brain tumors as well as other diseases. We have applied a very precise thin-layer chromatography (TLC) analysis of the global amount of 5-methylcytosine (m(5)C) in DNA from brain tumors, colon and breast cancer tissues and peripheral blood samples of the same patients. The m(5)C level in tissue DNA from different brain tumor types, expressed as R coefficient, changes within the range of 0.2-1.6 and overlaps with R of that of blood samples. It negatively correlates with the WHO malignancy grade. The global DNA hypomethylation quantitative measure in blood, demonstrates a big potential for development of non-invasive applications for detection of a low and a high grade brain tumors. We have also used this approach to analyze patients with breast and colon cancers. In all these cases the m(5)C amount in DNA cancer tissue match with data of blood. This study is the first to demonstrate the potential role of global m(5)C content in blood DNA for early detection of brain tumors and others diseases. So, genomic DNA hypomethylation is a promising marker for prognosis of various neoplasms as well as other pathologies.
C1 [Barciszewska, Anna-Maria; Nowak, Stanislaw] Poznan Univ Med Sci, Dept Neurosurg & Neurotraumatol, Poznan, Poland.
   [Naskret-Barciszewska, Miroslawa Z.] Polish Acad Sci, Inst Bioorgan Chem, Poznan, Poland.
C3 Poznan University of Medical Sciences; Polish Academy of Sciences;
   Institute of Bioorganic Chemistry of the Polish Academy of Sciences
RP Barciszewska, AM (通讯作者)，Poznan Univ Med Sci, Dept Neurosurg & Neurotraumatol, Poznan, Poland.
EM abarcisz@man.poznan.pl
RI Barciszewska, Anna-Maria/J-5978-2018
OI Barciszewska, Anna-Maria/0000-0002-7179-1474
FU Polish Ministry of Science and Higher Education [N N401 066338, N N403
   219637]
FX This work was supported within the Polish Ministry of Science and Higher
   Education projects Nr N N401 066338 to AMB and MZNB and Nr N N403 219637
   to AMB, SN and MZNB. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andreoli R, 2011, FREE RADICAL BIO MED, V50, P254, DOI 10.1016/j.freeradbiomed.2010.11.009
   Barciszewska AM, 2007, IUBMB LIFE, V59, P765, DOI 10.1080/15216540701697412
   Barciszewska AM, 2009, THERAPEUTIC RIBONUCLEIC ACIDS IN BRAIN TUMORS, P141, DOI 10.1007/978-3-642-00475-9_7
   Barciszewska MZ, 2007, BIOGERONTOLOGY, V8, P673, DOI 10.1007/s10522-007-9109-3
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Christensen BC, 2011, JNCI-J NATL CANCER I, V103, DOI 10.1093/jnci/djq497
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Fouse SD, 2010, EPIGENOMICS-UK, V2, P105, DOI 10.2217/EPI.09.35
   Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082
   Fueyo J, 2011, ARCH NEUROL-CHICAGO, V68, P303, DOI 10.1001/archneurol.2010.293
   Gong ZZ, 2011, CELL RES, V21, P1649, DOI 10.1038/cr.2011.140
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Iwamoto K, 2011, GENOME RES, V21, P688, DOI 10.1101/gr.112755.110
   Kim MS, 2009, NATURE, V461, P1007, DOI 10.1038/nature08456
   Klug M, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-6-r63
   Langevin SM, 2012, EPIGENETICS-US, V7, P291, DOI 10.4161/epi.7.3.19134
   Louis DN, 2007, ACTA NEUROPATHOL, V114, P547, DOI 10.1007/s00401-007-0278-6
   MILLER SA, 1988, NUCLEIC ACIDS RES, V0016
   Nagarajan RP, 2009, SEMIN CANCER BIOL, V19, P188, DOI 10.1016/j.semcancer.2009.02.005
   Nelson HH, 2011, ENVIRON HEALTH PERSP, V119, P1528, DOI 10.1289/ehp.1103423
   Niedzwiecki MM, 2013, EPIGENETICS-US, V8, P730, DOI 10.4161/epi.25012
   Noushmehr Houtan, 2010, Cancer Cell, V17, P510, DOI 10.1016/j.ccr.2010.03.017
   Rajendran G, 2011, J NEURO-ONCOL, V104, P483, DOI 10.1007/s11060-010-0520-2
   Smolarek I, 2010, MED SCI MONITOR, V16, pCR149
   Stieber D, 2011, EXPERT OPIN THER TAR, V15, P1227, DOI 10.1517/14728222.2011.588211
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Ullah MF, 2009, CANCER TREAT REV, V35, P193, DOI 10.1016/j.ctrv.2008.10.004
   Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020
   Volle CB, 2012, BIOCHEMISTRY-US, V51, P52, DOI 10.1021/bi201552s
   Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060
   Wu SC, 2010, NAT REV MOL CELL BIO, V11, P607, DOI 10.1038/nrm2950
   Zukiel R, 2004, MOL CANCER RES, V2, P196
NR 33
TC 21
Z9 22
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 20
PY 2014
VL 9
IS 3
AR e92599
DI 10.1371/journal.pone.0092599
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AD6FV
UT WOS:000333352800132
PM 24651295
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Mann, M
   Zou, Y
   Chen, YD
   Brann, D
   Vadlamudi, R
AF Mann, Monica
   Zou, Yi
   Chen, Yidong
   Brann, Darrell
   Vadlamudi, Ratna
TI PELP1 oncogenic functions involve alternative splicing via PRIVIT6
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Alternative splicing; Breast cancer; Epigenetics; PELP1; PRMT6
ID ENDOTHELIAL GROWTH-FACTOR; GLUTAMIC-ACID-RICH; BREAST-CANCER; RNA
   HELICASE; PROLINE-RICH; RECEPTOR; PROTEIN; GENE; COACTIVATOR; EXPRESSION
AB Proline-, glutamic acid-, and leucine-rich protein 1 (PELP1) is a proto-oncogene that functions as coactivator of the estrogen receptor and is an independent prognostic predictor of shorter survival of breast cancer patients. The dysregulation of PELP1 in breast cancer has been implicated in oncogenesis, metastasis, and therapy resistance. Although several aspects of PELP1 have been studied, a complete list of PELP1 target genes remains unknown, and the molecular mechanisms of PELP1 mediated oncogenesis remain elusive. In this study, we have performed a whole genome analysis to profile the PELP1 transcriptome by RNA-sequencing and identified 318 genes as PELP1 regulated genes. Pathway analysis revealed that PELP1 modulates several pathways including the molecular mechanisms of cancer, estrogen signaling, and breast cancer progression. Interestingly, RNA-seq analysis also revealed that PELP1 regulates the expression of several genes involved in alternative splicing. Accordingly, the PELP1 regulated genome includes several uniquely spliced isoforms. Mechanistic studies show that PELP1 binds RNA with a preference to poly-C, co-localizes with the splicing factor SC35 at nuclear speckles, and participates in alternative splicing. Further, PELP1 interacts with the arginine methyltransferase PRMT6 and modifies PRMT6 functions. Inhibition of PRMT6 reduced PELP1-mediated estrogen receptor activation, cellular proliferation, and colony formation. PELP1 and PRMT6 are co-recruited to estrogen receptor target genes, PELP1 knockdown affects the enrichment of histone H3R2 di-methylation, and PELP1 and PRMT6 coordinate to regulate the alternative splicing of genes involved in cancer. Collectively, our data suggest that PELP1 oncogenic functions involve alternative splicing leading to the activation of unique pathways that support tumor progression and that the PELP1-PRMT6 axis may be a potential target for breast cancer therapy. (C) 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Mann, Monica] Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
   [Mann, Monica; Vadlamudi, Ratna] Dept Obstet & Gynecol, San Antonio, TX 78229 USA.
   [Zou, Yi; Chen, Yidong; Vadlamudi, Ratna] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
   [Brann, Darrell] Georgia Regents Univ, Inst Mol Med & Genet, Augusta, GA 30912 USA.
C3 Cancer Therapy & Research Center; University of Texas System; University
   of Texas Health Science Center at San Antonio; University System of
   Georgia; Augusta University
RP Vadlamudi, R (通讯作者)，Univ Texas Hlth Sci Ctr San Antonio, Dept Obstet & Gynecol, Div Reprod Res, 7703 Floyd Curl Dr,Mail Code 7836, San Antonio, TX 78229 USA.
EM Mannm3@livemail.uthscsa.edu; zou@uthscsa.edu; cheny8@uthscsa.edu;
   dbrann@gru.edu; vadlamudi@uthscsa.edu
RI zou, yi/HJG-9971-2022
FU UTHSCSA; NIH-NCI [P30 CA54174]; NIH-NIA [P01AG19316]; NIH [CA095681, 1
   F31 CA173909-01A1]
FX We thank Dr. Sujit Nair for the confocal assay and the CD44 minigene
   assay. We thank Dr. Rakesh Kumar for the ERE-CD44 minigene plasmid. We
   thank Lai Zhao and Dawn Garcia at the Next Generation Sequencing Core
   for the RNA sequencing. The confocal images were generated in the Core
   Optical Imaging Facility which is supported by UTHSCSA, NIH-NCI P30
   CA54174 (CTRC at UTHSCSA) and NIH-NIA P01AG19316. This research was
   funded by the NIH CA095681 and NIH 1 F31 CA173909-01A1.
CR Anders S., 2010, HTSEQ ANAL HIGH THRO
   Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106
   Auboeuf D, 2005, MOL CELL BIOL, V25, P5307, DOI 10.1128/MCB.25.13.5307-5316.2005
   Auboeuf D, 2002, SCIENCE, V298, P416, DOI 10.1126/science.1073734
   Balasenthil S, 2003, J BIOL CHEM, V278, P22119, DOI 10.1074/jbc.M212822200
   Castle CD, 2012, MOL BIOL CELL, V23, P716, DOI 10.1091/mbc.E11-06-0530
   Chakravarty D, 2011, CLIN CANCER RES, V17, P2250, DOI 10.1158/1078-0432.CCR-10-2718
   Chakravarty D, 2010, CANCER RES, V70, P4092, DOI 10.1158/0008-5472.CAN-09-3834
   Chen HC, 2002, J BIOL CHEM, V277, P40403, DOI 10.1074/jbc.M206981200
   Cheng DH, 2007, MOL CELL, V25, P71, DOI 10.1016/j.molcel.2006.11.019
   Choi HS, 2009, BIOCHEM BIOPH RES CO, V380, P431, DOI 10.1016/j.bbrc.2009.01.136
   Cortez V, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3229
   Côté J, 2003, MOL BIOL CELL, V14, P274, DOI 10.1091/mbc.E02-08-0484
   Dowhan DH, 2012, ENDOCR-RELAT CANCER, V19, P509, DOI 10.1530/ERC-12-0100
   Finkbeiner E, 2011, EMBO J, V30, P1067, DOI 10.1038/emboj.2011.33
   Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1
   FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0
   Girard BJ, 2014, MOL CELL ENDOCRINOL, V382, P642, DOI 10.1016/j.mce.2013.07.031
   Gonugunta VK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021095
   Gururaj AE, 2007, MOL ENDOCRINOL, V21, P1847, DOI 10.1210/me.2006-0514
   Habashy HO, 2010, BREAST CANCER RES TR, V120, P603, DOI 10.1007/s10549-009-0419-9
   Harrison MJ, 2010, NUCLEIC ACIDS RES, V38, P2201, DOI 10.1093/nar/gkp1203
   Herrmann F, 2004, J BIOL CHEM, V279, P48774, DOI 10.1074/jbc.M407332200
   Ip JY, 2011, GENOME RES, V21, P390, DOI 10.1101/gr.111070.110
   König H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904
   Kornblihtt AR, 2013, NAT REV MOL CELL BIO, V14, P153, DOI 10.1038/nrm3525
   Kramer A, 1996, ANNU REV BIOCHEM, V65, P367, DOI 10.1146/annurev.biochem.65.1.367
   Kumar R, 2009, CLIN CANCER RES, V15, P4123, DOI 10.1158/1078-0432.CCR-08-2347
   Limm K, 2013, EUR J CANCER, V49, P1305, DOI 10.1016/j.ejca.2012.11.026
   Lin SR, 2008, NAT STRUCT MOL BIOL, V15, P819, DOI 10.1038/nsmb.1461
   Mann M, 2013, CARCINOGENESIS, V34, P1468, DOI 10.1093/carcin/bgt091
   Miranda TB, 2005, BIOCHEM BIOPH RES CO, V336, P831, DOI 10.1016/j.bbrc.2005.08.179
   Nair BC, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2929
   Nair BC, 2010, CANCER RES, V70, P7166, DOI 10.1158/0008-5472.CAN-10-0628
   Nair SS, 2004, CANCER RES, V64, P6416, DOI 10.1158/0008-5472.CAN-04-1786
   Nair SS, 2010, EMBO REP, V11, P438, DOI 10.1038/embor.2010.62
   Oesterreich FC, 2010, MOL CELL, V40, P571, DOI 10.1016/j.molcel.2010.11.004
   Rajhans R, 2007, CANCER RES, V67, P5505, DOI 10.1158/0008-5472.CAN-06-3647
   Smith WA, 2004, J BIOL CHEM, V279, P22795, DOI 10.1074/jbc.C300512200
   Tang S., 2004, NUCL ACIDS RES, V32
   TISCHER E, 1991, J BIOL CHEM, V266, P11947
   Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120
   Vadlamudi Ratna K, 2007, Nucl Recept Signal, V5, pe004
   Vadlamudi RK, 2001, J BIOL CHEM, V276, P38272
   Vallabhaneni S, 2011, BREAST CANCER RES TR, V130, P377, DOI 10.1007/s10549-010-1312-2
   Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608
   Wellmann S, 2001, CLIN CHEM, V47, P654
   WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I
   Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786
   Yang L, 2012, MOL ENDOCRINOL, V26, P550, DOI 10.1210/me.2011-1101
   Yoshimatsu M, 2011, INT J CANCER, V128, P562, DOI 10.1002/ijc.25366
NR 51
TC 24
Z9 26
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD MAR
PY 2014
VL 8
IS 2
BP 389
EP 400
DI 10.1016/j.molonc.2013.12.012
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AD8HL
UT WOS:000333507000019
PM 24447537
OA Green Published, Green Accepted
DA 2025-01-12
ER

PT J
AU Ng, EKO
   Li, R
   Shin, VY
   Siu, JM
   Ma, ESK
   Kwong, A
AF Ng, Enders K. O.
   Li, Rufina
   Shin, Vivian Y.
   Siu, Jennifer M.
   Ma, Edmond S. K.
   Kwong, Ava
TI MicroRNA-143 is downregulated in breast cancer and regulates DNA
   methyltransferases 3A in breast cancer cells
SO TUMOR BIOLOGY
LA English
DT Article
DE miR-143; DNMT3A; Breast cancer; Tumor suppressor; PTEN
ID TUMOR-SUPPRESSOR; ABERRANT METHYLATION; PROSTATE-CANCER; EXPRESSION;
   PROGRESSION; PTEN; PROMOTER; GENES; METASTASIS; PROGNOSIS
AB MicroRNAs (miRNAs) are small non-protein-coding RNAs that regulate expression of a wide variety of genes including those involved in cancer development. Here, we investigate the role of miR-143 in breast cancer. In this study, we showed that miR-143 was frequently downregulated in 80 % of breast carcinoma tissues compared to their adjacent noncancerous tissues. Ectopic expression of miR-143 inhibited proliferation and soft agar colony formation of breast cancer cells and also downregulated DNA methyltransferase 3A (DNMT3A) expression on both mRNA and protein levels. Restoration of miR-143 expression in breast cancer cells reduces PTEN hypermethylation and increases TNFRSF10C methylation. DNMT3A was demonstrated to be a direct target of miR-143 by luciferase reporter assay. Furthermore, miR-143 expression was observed to be inversely correlated with DNMT3A mRNA and protein expression in breast cancer tissues. Our findings suggest that miR-143 regulates DNMT3A in breast cancer cells. These findings elucidated a tumor-suppressive role of miR-143 in epigenetic aberration of breast cancer, providing a potential development of miRNA-based treatment for breast cancer.
C1 [Ng, Enders K. O.; Li, Rufina; Shin, Vivian Y.; Siu, Jennifer M.; Kwong, Ava] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China.
   [Ma, Edmond S. K.] Hong Kong Sanat & Hosp, Dept Mol Pathol, Hong Kong, Hong Kong, Peoples R China.
   [Kwong, Ava] Hong Kong Hereditary Breast Canc Family Registry, Hong Kong, Hong Kong, Peoples R China.
   [Kwong, Ava] Univ Hong Kong, Breast Surg Div, Hong Kong, Hong Kong, Peoples R China.
C3 University of Hong Kong; University of Hong Kong
RP Kwong, A (通讯作者)，Univ Hong Kong, Breast Surg Div, Hong Kong, Hong Kong, Peoples R China.
EM akwong@asiabreastregistry.com
RI Yu, Shi-Tong/H-3747-2018; Ma, Shiu Kwan Edmond/AAZ-7637-2021; NG,
   Enders/T-3881-2019; Kwong, Ava/D-8005-2013
OI Kwong, Ava/0000-0002-6968-9489; Ma, Edmond/0000-0002-1259-2205; Shin,
   Vivian Yvonne/0000-0003-1282-7593
CR Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821
   Baranwal S, 2010, INT J CANCER, V126, P1283, DOI 10.1002/ijc.25014
   Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354
   Blenkiron C, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r214
   Bose S, 2002, HUM PATHOL, V33, P405, DOI 10.1053/hupa.2002.124721
   Cai HH, 2011, HEPATOB PANCREAT DIS, V10, P95, DOI 10.1016/S1499-3872(11)60014-3
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779
   Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474
   Cheng Y, 2009, PROSTATE, V69, P327, DOI 10.1002/pros.20882
   Chik F, 2011, CARCINOGENESIS, V32, P224, DOI 10.1093/carcin/bgq221
   Clapé C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Duffy MJ, 1999, ANN CLIN BIOCHEM, V36, P579, DOI 10.1177/000456329903600503
   Gao Q, 2011, P NATL ACAD SCI USA, V108, P18061, DOI 10.1073/pnas.1114946108
   He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Liang GG, 2002, MOL CELL BIOL, V22, P480, DOI 10.1128/MCB.22.2.480-491.2002
   Lin TX, 2009, J UROLOGY, V181, P1372, DOI 10.1016/j.juro.2008.10.149
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Rhei E, 1997, CANCER RES, V57, P3657
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Sandhu Sukhinder K, 2011, Adv Hematol, V2011, P347137, DOI 10.1155/2011/347137
   Schetter AJ, 2008, JAMA-J AM MED ASSOC, V299, P425, DOI 10.1001/jama.299.4.425
   Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220
   Shivapurkar N, 2004, INT J CANCER, V109, P786, DOI 10.1002/ijc.20041
   Tessema M, 2009, CARCINOGENESIS, V30, P1132, DOI 10.1093/carcin/bgp114
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
NR 38
TC 76
Z9 79
U1 0
U2 15
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2014
VL 35
IS 3
BP 2591
EP 2598
DI 10.1007/s13277-013-1341-7
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AD8SQ
UT WOS:000333536300108
PM 24218337
DA 2025-01-12
ER

PT J
AU Jafary, H
   Ahmadian, S
   Soleimani, M
AF Jafary, Hanieh
   Ahmadian, Shahin
   Soleimani, Masoud
TI The enhanced apoptosis and antiproliferative response to combined
   treatment with valproate and nicotinamide in MCF-7 breast cancer cells
SO TUMOR BIOLOGY
LA English
DT Article
DE MCF-7; Histone deacetylase inhibitor; Nicotinamide; Valproate;
   Epigenetic regulation
ID HISTONE DEACETYLASE INHIBITORS; TRANS-RETINOIC ACID; COMBINATION;
   PROLIFERATION; TRICHOSTATIN; EPIGENETICS; THERAPY; EXTRACT; ARREST
AB Acetylation of histone is a major player in epigenetic modifications, resulting in open chromatin structures and, hence, permissive conditions for transcription-factor recruitment to the promoters, followed by initiation of transcription. Histone deacetylase inhibitors arrest cancer cell growth and cause apoptosis with low toxicity thereby constituting a promising treatment for cancer. In this study, we examined the antiproliferative effects of valproate with a combination of nicotinamide in the MCF-7 cell line. MCF-7 was treated with various concentrations of valproate. The MTT assay showed that the viability of MCF-7 cells was inhibited and the cell activity was decreased. Viability percent of valproate and nicotinamide combined treatment cells (28 +/- 2) was 1.78 times increased compared with the valproate-alone (0.5 mM) treated cells (50 +/- 2). Colony formation in soft agar indicated that valproate at 0.3 mM, when used alone, weakly suppressed proliferation of cells (82 +/- 3) and the combination treatment of valproate + nicotinamide strongly suppressed cell proliferation (51 +/- 3). The flow cytometric and microscopic analyses of HDACI combined with treated cells indicated strong apoptosis induction and nuclear morphological alterations greater than those of valproate alone. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) analysis confirmed the efficiency of the HDAC inhibitor combination, revealing the effectively upregulated p16 and p21. Furthermore, to investigate the role of acetyl-histone H3 levels, western blot analyses have been performed and high levels of acetylated histone H3 were detected in valproate- and nicotinamide-treated cells. These results suggest that the combination treatment of valproate with nicotinamide exerts significant antitumor activity and could be a promising therapeutic candidate to treat human breast cancer.
C1 [Jafary, Hanieh; Ahmadian, Shahin] Univ Tehran, Inst Biochem & Biophys, Dept Biochem, Tehran, Iran.
   [Soleimani, Masoud] Tarbiat Modares Univ, Dept Hematol, Fac Med Sci, Tehran, Iran.
   [Soleimani, Masoud] Stem Cell Technol Res Ctr, Dept Stem Cell Biol, Tehran, Iran.
C3 University of Tehran; Tarbiat Modares University
RP Ahmadian, S (通讯作者)，Univ Tehran, Inst Biochem & Biophys, Dept Biochem, POB 13145-1384, Tehran, Iran.
EM ahmadian@ibb.ut.ac.ir; soleim_m@modares.ac.ir
RI Ahmadian, Shahin/Q-7578-2019
OI ahmadian, Shahin/0009-0006-9609-1884
FU Research Council of the University of Tehran; Stem Cell Technology
   Research Center
FX The authors would like to acknowledge the financial support of the
   Research Council of the University of Tehran and the Stem Cell
   Technology Research Center.
CR Adwan L, 2013, PHARMACOL THERAPEUT, V139, P41, DOI 10.1016/j.pharmthera.2013.03.010
   Ageberg M, 2013, AM J TRANSL RES, V5, P170
   Alao JP, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-8
   Azad N, 2013, NAT REV CLIN ONCOL, V10, P256, DOI 10.1038/nrclinonc.2013.42
   Bartels M, 2010, HAEMATOL-HEMATOL J, V95, P1052, DOI 10.3324/haematol.2009.008870
   Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169
   Bouzar AB, 2009, BRIT J HAEMATOL, V144, P41, DOI 10.1111/j.1365-2141.2008.07426.x
   Bozkurt E, 2012, NUTR CANCER, V64, P1245, DOI 10.1080/01635581.2012.719658
   Bug G, 2005, CANCER, V104, P2717, DOI 10.1002/cncr.21589
   Byler TK, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-21
   Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612
   Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037
   Cea M, 2013, CURR PHARM DESIGN, V19, P734, DOI 10.2174/138161213804581945
   Cea M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022739
   Cho YK, 2010, CIRC J, V74, P760, DOI 10.1253/circj.CJ-09-0580
   Ellis L, 2010, PHARMACEUTICALS, V3, P2441, DOI 10.3390/ph3082441
   Ellis L, 2009, MOL CANCER THER, V8, P1409, DOI 10.1158/1535-7163.MCT-08-0860
   Emanuele S, 2008, INT J ONCOL, V33, P637, DOI 10.3892/ijo_00000049
   Federico M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/475641
   Finkel T, 2009, NATURE, V460, P587, DOI 10.1038/nature08197
   Franci G, 2010, EPIGENOMICS-UK, V2, P731, DOI [10.2217/epi.10.62, 10.2217/EPI.10.62]
   Galli M, 2010, CANCER RES, V70, P8, DOI 10.1158/0008-5472.CAN-09-2465
   Hafizi M, 2012, IN VITRO CELL DEV-AN, V48, P562, DOI 10.1007/s11626-012-9546-4
   Hrebackova J, 2010, CURR DRUG TARGETS, V11, P361, DOI 10.2174/138945010790711923
   Hsia DA, 2010, P NATL ACAD SCI USA, V107, P9671, DOI 10.1073/pnas.1000401107
   Jeong JB, 2013, INT IMMUNOPHARMACOL, V16, P184, DOI 10.1016/j.intimp.2013.04.006
   Jung M, 2005, CHEM BIODIVERS, V2, P1452, DOI 10.1002/cbdv.200590118
   Koutsounas I, 2013, WORLD J GASTROENTERO, V19, P1173, DOI 10.3748/wjg.v19.i8.1173
   Koutsounas I, 2013, WORLD J GASTROENTERO, V19, P813, DOI 10.3748/wjg.v19.i6.813
   Kuendgen A, 2005, ANN HEMATOL, V84, P61, DOI 10.1007/s00277-005-0026-8
   Kuendgen A, 2007, CANCER-AM CANCER SOC, V110, P943, DOI 10.1002/cncr.22891
   Morotti A, 2006, CANCER, V106, P1188, DOI 10.1002/cncr.21725
   Noro R, 2010, CANCER SCI, V101, P1424, DOI 10.1111/j.1349-7006.2010.01559.x
   Rezaei PF, 2012, FOOD CHEM TOXICOL, V50, P1054, DOI 10.1016/j.fct.2011.11.012
   Souto JA, 2008, CHEMMEDCHEM, V3, P1435, DOI 10.1002/cmdc.200800096
   Ververis K, 2013, BIOL-TARGETS THER, V7, P47, DOI 10.2147/BTT.S29965
   Ward CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062610
   Zhang Y, 2011, TOXICON, V57, P932, DOI 10.1016/j.toxicon.2011.03.008
NR 38
TC 12
Z9 13
U1 1
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAR
PY 2014
VL 35
IS 3
BP 2701
EP 2710
DI 10.1007/s13277-013-1356-0
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AD8SQ
UT WOS:000333536300122
PM 24213853
DA 2025-01-12
ER

PT J
AU Mohamed, MM
   Sabet, S
   Peng, DF
   Nouh, MA
   El-Shinawi, M
   El-Rifai, W
AF Mohamed, Mona M.
   Sabet, Salwa
   Peng, Dun-Fa
   Nouh, M. Akram
   El-Shinawi, Mohamed
   El-Rifai, Wael
TI Promoter Hypermethylation and Suppression of Glutathione Peroxidase 3
   Are Associated with Inflammatory Breast Carcinogenesis
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID OXIDATIVE STRESS; CANCER; EXPRESSION; METHYLATION; GPX3; MECHANISM;
   SELENIUM; GROWTH; GENES
AB Reactive oxygen species (ROS) play a crucial role in breast cancer initiation, promotion, and progression. Inhibition of antioxidant enzymes that remove ROS was found to accelerate cancer growth. Studies showed that inhibition of glutathione peroxidase-3 (GPX3) was associated with cancer progression. Although the role of GPX3 has been studied in different cancer types, its role in breast cancer and its epigenetic regulation have not yet been investigated. The aim of the present study was to investigate GPX3 expression and epigenetic regulation in carcinoma tissues of breast cancer patients' in comparison to normal breast tissues. Furthermore, we compared GPX3 level of expression and methylation status in aggressive phenotype inflammatory breast cancer (IBC) versus non-IBC invasive ductal carcinoma (IDC). We found that GPX3 mRNA and protein expression levels were downregulated in the carcinoma tissues of IBC compared to non-IBC. However, we did not detect significant correlation between GPX3 and patients' clinical-pathological prosperities. Promoter hypermethylation of GPX3 gene was detected in carcinoma tissues not normal breast tissues. In addition, IBC carcinoma tissues showed a significant increase in the promoter hypermethylation of GPX3 gene compared to non-IBC. Our results propose that downregulation of GPX3 in IBC may play a role in the disease progression.
C1 [Mohamed, Mona M.; Sabet, Salwa] Cairo Univ, Fac Sci, Dept Zool, Giza 12613, Egypt.
   [Peng, Dun-Fa; El-Rifai, Wael] Vanderbilt Univ, Med Ctr, Dept Surg, Nashville, TN 37232 USA.
   [Nouh, M. Akram] Cairo Univ, Natl Canc Inst, Dept Pathol, Giza 12613, Egypt.
   [El-Shinawi, Mohamed] Ain Shams Univ, Fac Med, Dept Gen Surg, Cairo 11566, Egypt.
C3 Egyptian Knowledge Bank (EKB); Cairo University; Vanderbilt University;
   Egyptian Knowledge Bank (EKB); Cairo University; National Cancer
   Institute - Egypt; Egyptian Knowledge Bank (EKB); Ain Shams University
RP Mohamed, MM (通讯作者)，Cairo Univ, Fac Sci, Dept Zool, Giza 12613, Egypt.
EM mmostafa@sci.cu.edu.eg
RI Sabet, Salwa/ADI-4136-2022; Nouh, M Akram/H-9329-2013
OI El-Shinawi, Mohamed/0000-0003-3645-2343; PENG,
   DUNFA/0000-0002-2182-7221; Sabet, Salwa/0000-0002-4097-7866; Nouh, M
   Akram/0000-0003-2720-3986
FU Science and Technology Development Funds (STDF), Egypt [408]; Avon
   Foundation, USA [02-2007-049, 02-2009-085b]
FX This work was supported by Science and Technology Development Funds
   (STDF), Egypt, Grant no. 408 (Wael El-Rifai and Mona M. Mohamed) and
   Avon Foundation, USA (Mona M. Mohamed), Awards nos. 02-2007-049 and
   02-2009-085b.
CR Ambrosone CB, 2000, ANTIOXID REDOX SIGN, V2, P903, DOI 10.1089/ars.2000.2.4-903
   Barrett CW, 2013, CANCER RES, V73, P1245, DOI 10.1158/0008-5472.CAN-12-3150
   BONNIER P, 1995, INT J CANCER, V62, P382, DOI 10.1002/ijc.2910620404
   Brigelius-Flohé R, 2009, BBA-GEN SUBJECTS, V1790, P1555, DOI 10.1016/j.bbagen.2009.03.006
   Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315
   Cejas P, 2007, FREE RADICAL RES, V41, P681, DOI 10.1080/10715760701286167
   Chen BS, 2011, CANCER LETT, V309, P37, DOI 10.1016/j.canlet.2011.05.013
   Christians A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033449
   Falck E, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-46
   FULTON AM, 1992, CARCINOGENESIS, V13, P77, DOI 10.1093/carcin/13.1.77
   Genestie C, 1998, ANTICANCER RES, V18, P571
   Gong Y, 2008, SEMIN ONCOL, V35, P33, DOI 10.1053/j.seminoncol.2007.11.014
   Hasegawa Y, 2002, CANCER LETT, V182, P69, DOI 10.1016/S0304-3835(02)00069-1
   He YL, 2011, DIGEST DIS SCI, V56, P681, DOI 10.1007/s10620-010-1369-0
   Hu YJ, 2003, CANCER RES, V63, P3347
   Hussain S P, 2000, Ann N Y Acad Sci, V919, P79
   Kaiser MF, 2013, BLOOD, V122, P219, DOI 10.1182/blood-2013-03-487884
   Kang Duck-Hee, 2002, AACN Clin Issues, V13, P540, DOI 10.1097/00044067-200211000-00007
   Lee OJ, 2005, NEOPLASIA, V7, P854, DOI 10.1593/neo.05328
   Lo IC, 2005, J BIOMED SCI, V12, P377, DOI 10.1007/s11373-005-1703-2
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mohamed MM., 2013, Journal of Advanced Research, P1
   Mohamed MM, 2014, INT J BIOCHEM CELL B, V46, P138, DOI 10.1016/j.biocel.2013.11.015
   Nouh MA, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-1
   PAWLOWICZ Z, 1991, J TRACE ELEM ELECT H, V5, P275
   Peng DF, 2009, GUT, V58, P5, DOI 10.1136/gut.2007.146290
   Peng DF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046214
   Plak K, 2009, ONCOL REP, V21, P845, DOI 10.3892/or_00000293
   Qu YP, 2013, CLIN CHIM ACTA, V424, P53, DOI 10.1016/j.cca.2013.05.002
   Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467
   Robertson FM, 2010, CA-CANCER J CLIN, V60, P351, DOI 10.3322/caac.20082
   SIPE HJ, 1994, CARCINOGENESIS, V15, P2637, DOI 10.1093/carcin/15.11.2637
   Storz P, 2005, FRONT BIOSCI-LANDMRK, V10, P1881, DOI 10.2741/1667
   Wang JY, 2010, CLIN CHIM ACTA, V411, P1432, DOI 10.1016/j.cca.2010.05.026
   Woolston CM, 2011, INT J RADIAT ONCOL, V79, P1530, DOI 10.1016/j.ijrobp.2010.11.002
   Wu WS, 2006, CANCER METAST REV, V25, P695, DOI 10.1007/s10555-006-9037-8
   Yu YP, 2007, CANCER RES, V67, P8043, DOI 10.1158/0008-5472.CAN-07-0648
   Zhang X, 2010, INT J ONCOL, V36, P405, DOI 10.3892/ijo_00000513
NR 38
TC 47
Z9 51
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PY 2014
VL 2014
AR 787195
DI 10.1155/2014/787195
PG 9
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AE0VD
UT WOS:000333683400001
PM 24790704
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Romano, S
   D'Angelillo, A
   Romano, A
   Nappo, G
   Romano, MF
AF Romano, Simona
   D'Angelillo, Anna
   Romano, Alfredo
   Nappo, Giovanna
   Romano, Maria Fiammetta
TI Cellular and Molecular Background Underlying the Diversity in
   Therapeutic Responses Between Primary Tumours and Metastases
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Cancer therapy; CSC; EMT; genetic and epigenetic modifications;
   metastasis; tumour heterogeneity; Tumour progression
ID CANCER STEM-CELLS; ACUTE MYELOID-LEUKEMIA; BREAST-CANCER; SELF-RENEWAL;
   NATURAL-HISTORY; GROWTH-RATES; PROGRESSION; EXPRESSION; EVOLUTION;
   HETEROGENEITY
AB Metastasis, also called secondary neoplastic disease, is a tumour newly formed in a site different from that of origin, as a consequence of cancer progression and dissemination largely through blood and lymphatic vessels. The ability to form metastases is the main property that distinguishes malignant from benign tumours. Treatments for metastatic cancer are similar in practice to those for primary tumours, but such treatments are mostly palliative; indeed, almost all deaths caused by solid tumours occur in the metastatic phase. Increasing evidence supports the concept that therapies for primary tumours are inadequate to treat metastasis and can even promote formation of metastases, while exerting local growth control. Furthermore, recurrent tumours, which are denoted by increased aggressiveness and therapy resistance in comparison with the primary tumour, have an increased metastatic potential. Genetic modifications occurring during tumour progression lead to substantial differences between the primary and metastatic tumours. This emphasises the importance of designing novel therapies for metastasis. In the last decade, a number of studies have contributed to the understanding of the genetic rearrangements underlying the conversion of cancer cells into the metastasis founder cells. The present article aims at reviewing recent advances in metastasis research and attempts to discuss the reasons for which the therapeutic strategies against primary tumours may not satisfactorily address their metastatic counterparts.
C1 [Romano, Simona; Nappo, Giovanna; Romano, Maria Fiammetta] Univ Naples Federico II, Dept Mol Med & Med Biotechnol, I-80131 Naples, Italy.
   [D'Angelillo, Anna] Univ Naples Federico II, Fac Med & Surg, Dept Adv Biomed Sci, Pathol Sect, Naples, Italy.
   [Romano, Alfredo] Celgene Int Sarl, Boudry, Switzerland.
C3 University of Naples Federico II; University of Naples Federico II;
   Bristol-Myers Squibb; Celgene Corporation
RP Romano, MF (通讯作者)，Univ Naples Federico II, Dept Mol Med & Med Biotechnol, Via Pansini 5, I-80131 Naples, Italy.
EM mariafiammetta.romano@unina.it
OI ROMANO, Maria Fiammetta/0000-0001-5557-7307
FU Italian Association for Cancer Research (AIRC)
FX We thank Italian Association for Cancer Research (AIRC) for supporting
   our cancer research.
CR ABBRUZZESE JL, 1994, J CLIN ONCOL, V12, P1272, DOI 10.1200/JCO.1994.12.6.1272
   Agarwal JR, 2010, ANTI-CANCER AGENT ME, V10, P116, DOI 10.2174/187152010790909344
   Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256
   Akagi H, 2013, GASTRIC CANCER, V16, P100, DOI 10.1007/s10120-012-0153-6
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Albanese I, 2004, BIOCHEM BIOPH RES CO, V325, P784, DOI 10.1016/j.bbrc.2004.10.111
   Almog N, 2010, CANCER LETT, V294, P139, DOI 10.1016/j.canlet.2010.03.004
   Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650
   Baudis M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-226
   Blagosklonny MV, 2006, LEUKEMIA, V20, P385, DOI 10.1038/sj.leu.2404075
   BLANC J, 2013, CURR MED CHEM, V13, P731
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   BROSS IDJ, 1975, J CHRON DIS, V28, P149, DOI 10.1016/0021-9681(75)90003-X
   CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Campoli M, 2010, ADV CANCER RES, V109, P73, DOI 10.1016/B978-0-12-380890-5.00003-X
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638
   Cho RW, 2008, CURR OPIN GENET DEV, V18, P48, DOI 10.1016/j.gde.2008.01.017
   Ciolczyk-Wierzbicka D, 2012, CURR MED CHEM, V19, P145, DOI 10.2174/092986712803414006
   COLLINS VP, 1956, AMER J ROENTGENOL RA, V76, P988
   Cristofanilli M, 2002, NAT REV DRUG DISCOV, V1, P415, DOI 10.1038/nrd819
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Dawood S, 2008, CANCER-AM CANCER SOC, V113, P2422, DOI 10.1002/cncr.23852
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Deepa G, 2012, CURR MED CHEM, V19, P6207
   Diehn M, 2009, SEMIN RADIAT ONCOL, V19, P78, DOI 10.1016/j.semradonc.2008.11.002
   Domingo-Domenech J, 2012, CANCER CELL, V22, P373, DOI 10.1016/j.ccr.2012.07.016
   Eckhardt BL, 2012, NAT REV DRUG DISCOV, V11, P479, DOI 10.1038/nrd2372
   Engel J, 2003, EUR J CANCER, V39, P1794, DOI 10.1016/S0959-8049(03)00422-2
   Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415
   Erez N, 2011, INT J CANCER, V128, P2536, DOI 10.1002/ijc.26032
   Essers MAG, 2009, NATURE, V458, P904, DOI 10.1038/nature07815
   Essers MAG, 2010, MOL ONCOL, V4, P443, DOI 10.1016/j.molonc.2010.06.001
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Frank SA, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001296
   Friberg S, 1997, J SURG ONCOL, V65, P284, DOI 10.1002/(SICI)1096-9098(199708)65:4<284::AID-JSO11>3.0.CO;2-2
   Fuchs E, 2008, COLD SH Q B, V73, P333, DOI 10.1101/sqb.2008.73.032
   Galmozzi E, 2006, CURR MED CHEM, V13, P603, DOI 10.2174/092986706776055661
   Gangemi R, 2009, CURR MED CHEM, V16, P1688, DOI 10.2174/092986709788186147
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gibbs KD, 2012, CELL STEM CELL, V10, P210, DOI 10.1016/j.stem.2012.01.004
   Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246
   Goodison S, 2003, CLIN CANCER RES, V9, P3808
   Gow C-H., 2008, ANN ONCOL, DOI [10.1093/annonc/mdn679, DOI 10.1093/AN-NONC/MDN679]
   Gu W, 2011, CANCER GENE THER, V18, P897, DOI 10.1038/cgt.2011.58
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   He J, 2012, CURR MED CHEM, V19, P6050
   Hoffmann W, 2012, CURR MED CHEM, V19, P5975
   Hoffmann W, 2012, CURR MED CHEM, V19, P5964
   Hüsemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003
   Hunter K, 2006, NAT REV CANCER, V6, P141, DOI 10.1038/nrc1803
   Jin ZH, 2012, MOL IMAGING, V11, P445, DOI 10.2310/7290.2012.00008
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186
   Keck T, 2011, CELL CYCLE, V10, P1715, DOI 10.4161/cc.10.11.15645
   Kiang A., 2012, CURR MED CHEM, V37, P960
   Kim JW, 2004, CANCER LETT, V213, P203, DOI 10.1016/j.canlet.2004.03.042
   Klein CA, 2006, CELL CYCLE, V5, P1788, DOI 10.4161/cc.5.16.3097
   Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627
   Klein G, 1998, ADV CANCER RES, V72, P1
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lo WL, 2012, BIOMATERIALS, V33, P3693, DOI 10.1016/j.biomaterials.2012.01.016
   Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485
   Lugli A, 2010, BRIT J CANCER, V103, P382, DOI 10.1038/sj.bjc.6605762
   Ma J., 2012, MED CHEM, V12, P131
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Nahas G. R., 2012, CURR MED CHEM, V2, P906
   Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Otani Y, 2006, SURGERY, V139, P484, DOI 10.1016/j.surg.2005.08.011
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Pardoll D, 2009, CANCER CELL, V16, P81, DOI 10.1016/j.ccr.2009.07.007
   PEER PGM, 1993, CANCER, V71, P3547, DOI 10.1002/1097-0142(19930601)71:11<3547::AID-CNCR2820711114>3.0.CO;2-C
   Pérez-Caro M, 2006, CURR MED CHEM, V13, P1719, DOI 10.2174/092986706777452533
   Petersson M, 2012, CURR MED CHEM, V19, P5984
   Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620
   Psaila Bethan, 2006, Breast Dis, V26, P65
   Psaila B, 2009, NAT REV CANCER, V9, P285, DOI 10.1038/nrc2621
   Quintana E, 2008, NATURE, V456, P593, DOI 10.1038/nature07567
   QURISHI Y, 2013, CURR MED CHEM, V13, P777
   Romano MF, 2009, CURR OPIN DRUG DISC, V12, P253
   Romano S, 2010, CELL DEATH DIFFER, V17, P145, DOI 10.1038/cdd.2009.115
   Saito Y, 2010, NAT BIOTECHNOL, V28, P275, DOI 10.1038/nbt.1607
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100
   Schubert J, 2011, CELL RES, V21, P705, DOI 10.1038/cr.2011.62
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Shibue T, 2011, SEMIN CANCER BIOL, V21, P99, DOI 10.1016/j.semcancer.2010.12.003
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Singh SR, 2012, CURR MED CHEM, V19, P5965
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Steeg PS, 2008, NAT CLIN PRACT ONCOL, V5, P206, DOI 10.1038/ncponc1066
   Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916
   Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408
   Valastyan S., 2011, CELL, P147
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Wang Y, 2009, CLIN PHARMACOL THER, V86, P167, DOI 10.1038/clpt.2009.64
   Wei P., 2012, CANC LETT, VS0304-3835, P00581
   Weinberg RA, 2008, CARCINOGENESIS, V29, P1092, DOI 10.1093/carcin/bgn104
   Wilson A, 2008, CELL, V135, P1118, DOI 10.1016/j.cell.2008.10.048
   Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Zhao WX, 2012, MOLECULES, V17, P6196, DOI 10.3390/molecules17066196
   Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097
NR 113
TC 3
Z9 4
U1 0
U2 18
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD MAY
PY 2014
VL 21
IS 14
BP 1631
EP 1638
DI 10.2174/09298673113209990225
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AD7FC
UT WOS:000333426700007
PM 23992331
DA 2025-01-12
ER

PT J
AU Wilson-Edell, KA
   Yevtushenko, MA
   Rothschild, DE
   Rogers, AN
   Benz, CC
AF Wilson-Edell, Kathleen A.
   Yevtushenko, Mariya A.
   Rothschild, Daniel E.
   Rogers, Aric N.
   Benz, Christopher C.
TI mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer
   growth by convergent AKT and polysome inhibiting mechanisms
SO BREAST CANCER RESEARCH AND TREATMENT
LA English
DT Article
DE mTOR; HDAC; MLN0128; INK128; Trichostatin A; TSA; Breast cancer; AKT;
   Polysomes; Ribosomes
ID HISTONE DEACETYLASE INHIBITORS; ANTITUMOR-ACTIVITY; MAMMALIAN TARGET;
   IN-VIVO; PATHWAY; ACETYLATION; COMBINATION; EXPRESSION; EVEROLIMUS;
   COMPLEXES
AB Resistance of breast cancers to targeted hormone receptor (HR) or human epidermal growth factor receptor 2 (HER2) inhibitors often occurs through dysregulation of the phosphoinositide 3-kinase, protein kinase B/AKT/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway. Presently, no targeted therapies exist for breast cancers lacking HR and HER2 overexpression, many of which also exhibit PI3K/AKT/mTOR hyper-activation. Resistance of breast cancers to current therapeutics also results, in part, from aberrant epigenetic modifications including protein acetylation regulated by histone deacetylases (HDACs). We show that the investigational drug MLN0128, which inhibits both complexes of mTOR (mTORC1 and mTORC2), and the hydroxamic acid pan-HDAC inhibitor TSA synergistically inhibit the viability of a phenotypically diverse panel of five breast cancer cell lines (HR-/+, HER2-/+). The combination of MLN0128 and TSA induces apoptosis in most breast cancer cell lines tested, but not in the non-malignant MCF-10A mammary epithelial cells. In parallel, the MLN0128/TSA combination reduces phosphorylation of AKT at S473 more than single agents alone and more so in the 5 malignant breast cancer cell lines than in the non-malignant mammary epithelial cells. Examining polysome profiles from one of the most sensitive breast cancer cell lines (SKBR3), we demonstrate that this MLN0128/TSA treatment combination synergistically impairs polysome assembly in conjunction with enhanced inhibition of 4eBP1 phosphorylation at S65. Taken together, these data indicate that the synergistic growth inhibiting consequence of combining a mTORC1/C2 inhibitor like MLN0128 with a pan-HDAC inhibitor like TSA results from their mechanistic convergence onto the PI3K/AKT/mTOR pathway, profoundly inhibiting both AKT S473 and 4eBP1 S65 phosphorylation, reducing polysome formation and cancer cell viability.
C1 [Wilson-Edell, Kathleen A.; Yevtushenko, Mariya A.; Rothschild, Daniel E.; Rogers, Aric N.; Benz, Christopher C.] Buck Inst Res Aging, Novato, CA 94945 USA.
   [Yevtushenko, Mariya A.] Dominican Univ, Master Sci Biol Program, San Rafael, CA USA.
C3 Buck Institute for Research on Aging
RP Wilson-Edell, KA (通讯作者)，Buck Inst Res Aging, 8001 Redwood Blvd, Novato, CA 94945 USA.
EM kwilson@buckinstitute.org; cbenz@buckinstitute.org
RI Rogers, Aric/AAH-2748-2019
FU NIH/NCI [R21-CA155679, R01-CA071468, U24-CA14358]; NIH/NIA
   [T32-AG000266]; Hazel P. Munroe memorial funding
FX This research was supported by NIH/NCI Grants R21-CA155679,
   R01-CA071468, and U24-CA14358; by NIH/NIA T32-AG000266; and by Hazel P.
   Munroe memorial funding to the Buck Institute. The drugs INK0128
   (MLN0128) and GDC0941 were kindly provided by Intellikine
   Pharmaceuticals, Inc.; and we thank Christian Rommel for his
   encouragement and early advice. We are appreciative of technical
   assistance from Ingrid Hanson from the Benz lab and Taki Te Koi (Te Manu
   Whakataki) from the Buck Institute Morphology and Imaging Core. We also
   thank members of the Benz lab for insightful discussions, and Buck
   Institute scientist Patrick Li for assistance with the polysome
   profiling.
CR Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708
   Bali P, 2005, J BIOL CHEM, V280, P26729, DOI 10.1074/jbc.C500186200
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Chen CS, 2005, J BIOL CHEM, V280, P38879, DOI 10.1074/jbc.M505733200
   Cidado J, 2012, J MAMMARY GLAND BIOL, V17, P205, DOI 10.1007/s10911-012-9264-2
   Dong LH, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-53
   Erlich RB, 2012, BRIT J CANCER, V106, P107, DOI 10.1038/bjc.2011.495
   Gökmen-Polar Y, 2012, BREAST CANCER RES TR, V136, P673, DOI 10.1007/s10549-012-2298-8
   Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108
   Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912
   Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021
   Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498
   Janes MR, 2013, LEUKEMIA, V27, P586, DOI 10.1038/leu.2012.276
   Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883
   Nishioka C, 2008, LEUKEMIA, V22, P2159, DOI 10.1038/leu.2008.243
   Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298
   Pérez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126
   Pourdehnada M, 2013, P NATL ACAD SCI USA, V110, P11988, DOI 10.1073/pnas.1310230110
   Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197
   Rogers AN, 2011, CELL METAB, V14, P55, DOI 10.1016/j.cmet.2011.05.010
   Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110
   Scott GK, 2002, MOL CANCER THER, V1, P385
   Shao HJ, 2012, J HEPATOL, V56, P176, DOI 10.1016/j.jhep.2011.07.013
   Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   Tate CR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3192
   Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083
   Verheul HMW, 2008, CLIN CANCER RES, V14, P3589, DOI 10.1158/1078-0432.CCR-07-4306
   Vigushin DM, 2001, CLIN CANCER RES, V7, P971
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wedel S, 2011, LIFE SCI, V88, P418, DOI 10.1016/j.lfs.2010.12.017
   Wilson KA, 2011, MOL CANCER RES, V9, P766, DOI 10.1158/1541-7786.MCR-10-0317
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
NR 36
TC 44
Z9 47
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0167-6806
EI 1573-7217
J9 BREAST CANCER RES TR
JI Breast Cancer Res. Treat.
PD APR
PY 2014
VL 144
IS 2
BP 287
EP 298
DI 10.1007/s10549-014-2877-y
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AD0XY
UT WOS:000332959000008
PM 24562770
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Reyes, D
   Ballaré, C
   Castellano, G
   Soronellas, D
   Bagó, JR
   Blanco, J
   Beato, M
AF Reyes, D.
   Ballare, C.
   Castellano, G.
   Soronellas, D.
   Bago, J. R.
   Blanco, J.
   Beato, M.
TI Activation of mitogen- and stress-activated kinase 1 is required for
   proliferation of breast cancer cells in response to estrogens or
   progestins
SO ONCOGENE
LA English
DT Article
DE breast cancer; xenografts; estrogen receptor; progesterone receptor;
   T47D; hormone signaling
ID NF-KAPPA-B; PROGESTERONE-RECEPTOR; HISTONE H3; GENE-REGULATION;
   PHOSPHORYLATION; PROTEIN; PATHWAY; MSK1; INDUCTION; ESTRADIOL
AB Growth of breast cancers is often dependent on ovarian steroid hormones making the tumors responsive to antagonists of hormone receptors. However, eventually the tumors become hormone independent, raising the need to identify downstream targets for the inhibition of tumor growth. One possibility is to focus on the signaling mechanisms used by ovarian steroid hormones to induce breast cancer cell proliferation. Here we report that the mitogen- and stress-activated kinase 1 (MSK1) could be a potential druggable target. Using the breast cancer cell line T47D, we show that estrogens (E2) and progestins activate MSK1, which forms a complex with the corresponding hormone receptor. Inhibition of MSK1 activity with H89 or its depletion by MSK1 short hairpin RNAs (shRNAs) specifically abrogates cell proliferation in response to E2 or progestins without affecting serum-induced cell proliferation. MSK1 activity is required for the transition from the G1- to the S-phase of the cell cycle and inhibition of MSK1 compromises both estradiol- and progestin-dependent induction of cell cycle genes. ChIP-seq experiments identified binding of MSK1 to progesterone receptor-binding sites associated with hormone-responsive genes. MSK1 recruitment to epigenetically defined enhancer regions supports the need of MSK1 as a chromatin remodeler in hormone-dependent regulation of gene transcription. In agreement with this interpretation, expression of a histone H3 mutated at S10 eliminates the hormonal effect on cell proliferation and on induction of relevant target genes. Finally, we show that E2- or progestin-dependent growth of T47D cells xenografted in immunodefficient mice is inhibited by depletion of MSK1, indicating that our findings are not restricted to cultured cells, and that MSK1 plays an important role for hormone-dependent breast cancer growth in a more physiological context.
C1 [Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Beato, M.] CRG, Barcelona 08003, Spain.
   [Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Beato, M.] UPF, Barcelona, Spain.
   [Bago, J. R.; Blanco, J.] CIBER BBN, CSIC ICCC, Cardiovasc Res Ctr, Barcelona, Spain.
C3 Barcelona Institute of Science & Technology; Pompeu Fabra University;
   Centre de Regulacio Genomica (CRG); Pompeu Fabra University; CIBER -
   Centro de Investigacion Biomedica en Red; CIBERBBN; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies
   Cardiovasculars (ICCC)
RP Beato, M (通讯作者)，CRG, Doctor Aiguader 88, Barcelona 08003, Spain.
EM miguel.beato@crg.eu
RI Castellano, Giancarlo/AGN-1752-2022; Reyes, Diana/A-9441-2017; Ballare,
   Cecilia/F-2593-2016; Blanco, Jeronimo/H-2764-2015; R. BAGO,
   JULI/M-3526-2018; Beato, Miguel/B-5564-2015
OI Castellano, Giancarlo/0000-0002-5715-7733; Reyes,
   Diana/0000-0002-9746-6485; Ballare, Cecilia/0000-0002-9442-807X; Blanco,
   Jeronimo/0000-0003-3765-0640; R. BAGO, JULI/0000-0002-2862-4048; Beato,
   Miguel/0000-0002-2878-2222
FU Spanish government [BMC 2003-02902, 2010-15313, CSD2006-00049]; European
   Union (IP HEROIC); Catalan government (AGAUR); fellowship from the
   Spanish Ministry of Science
FX We thank Luciano Di Croce, CRG, for providing the expression vector for
   histone H3, the CRG ultrasequencing facility and Dr Juan Valcarcel for
   help with the manuscript. The experimental work has been supported by
   grants from the Spanish government (BMC 2003-02902 and 2010-15313;
   CSD2006-00049), the European Union (IP HEROIC) and the Catalan
   government (AGAUR). DR was the recipient of a fellowship from the
   Spanish Ministry of Science.
CR Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004
   Ballaré C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003
   Ballaré C, 2013, MOL CELL, V49, P67, DOI 10.1016/j.molcel.2012.10.019
   BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5
   Beral Valerie, 2003, Lancet, V362, P419
   BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147
   Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5
   Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8
   Chang S, CANC INVEST, V29, P240
   CLARKE CL, 1990, J BIOL CHEM, V265, P12694
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426
   Drobic B, NUCL ACIDS RES, V38, P3196
   Drobic B, 2010, NUCLEIC ACIDS RES, V38, P3196, DOI 10.1093/nar/gkq030
   Foidart JM, 1998, FERTIL STERIL, V69, P963, DOI 10.1016/S0015-0282(98)00042-9
   Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655
   Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914
   Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254
   Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37
   Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25
   Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477
   Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608
   Lochner A, 2006, CARDIOVASC DRUG REV, V24, P261, DOI 10.1111/j.1527-3466.2006.00261.x
   LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266
   Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x
   Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008
   NANDI S, 1958, JNCI-J NATL CANCER I, V21, P1039
   Vicent GP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000567
   Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735
   Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412
   Sancho M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000227
   Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886
   Strutt H, 1999, METH MOL B, V119, P455
   Subtil-Rodríguez A, 2008, MOL CELL BIOL, V28, P3830, DOI 10.1128/MCB.01217-07
   Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302
   Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139
   Vicent GP, GENES DEV, V25, P845
   Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011
   Vicent Guillermo P, 2009, Nucl Recept Signal, V7, pe008, DOI 10.1621/nrs.07008
   WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2
   Weinstein-Oppenheimer CR, 2002, CANCER BIOL THER, V1, P256, DOI 10.4161/cbt.77
   Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002
   WILSON JE, 1972, BIOCHIM BIOPHYS ACTA, V276, P568, DOI 10.1016/0005-2744(72)91022-4
   Wright RHG, 2012, GENE DEV, V26, P1972, DOI 10.1101/gad.193193.112
NR 50
TC 28
Z9 30
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 20
PY 2014
VL 33
IS 12
BP 1570
EP 1580
DI 10.1038/onc.2013.95
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AD4TS
UT WOS:000333244200010
PM 23604116
OA Bronze
DA 2025-01-12
ER

PT J
AU Kumar, S
   Mapa, K
   Maiti, S
AF Kumar, Santosh
   Mapa, Koyeli
   Maiti, Souvik
TI Understanding the Effect of Locked Nucleic Acid and 2′-<i>O</i>-Methyl
   Modification on the Hybridization Thermodynamics of a miRNA-mRNA Pair in
   the Presence and Absence of AfPiwi Protein
SO BIOCHEMISTRY
LA English
DT Article
ID SMALL INTERFERING RNA; ANTISENSE OLIGONUCLEOTIDES; CRYSTAL-STRUCTURE;
   THERAPEUTIC APPLICATIONS; MICRORNA DYSREGULATION; ARGONAUTE PROTEINS;
   TARGET RECOGNITION; GENE-EXPRESSION; SLICER ACTIVITY; BREAST-CANCER
AB miRNAs are some of the key epigenetic regulators of gene expression. They act through hybridization with their target mRNA and modulate the level of respective proteins via different mechanisms. Various cancer conditions are known to be associated with up- and downregulation of the oncogenic and tumor suppressor miRNAs, respectively. The levels of aberrantly expressed oncogenic miRNAs can be downregulated in different ways. Similarly, restoration of tumor suppressor miRNAs to their normal levels can be achieved using miRNA mimics. However, the use of miRNA mimics is limited by their reduced biostability and function. We have studied the hybridization thermodynamics of the miRNA 26a (11-mer, including the seed sequence) guide strand with the mRNA (11-mer) target strand in the absence and presence of AfPiwi protein. We have also inserted locked nucleic acids (LNAs) and 2'-O-methyl-modified nucleotides into the guide strand, in a walk-through manner, to assess their effect on the binding efficiency between guide and target RNA. Insertion of LNA and 2'-O-methyl-modified nucleotides into the guide strand helped to strengthen the binding affinity irrespective of the position of insertion. However, in the presence of AfPiwi protein, these modifications reduced the binding affinity to different extents depending on the position of insertion. Insertion of a modification leads to an increase in the enthalpic contribution with an increased unfavorable entropic contribution, which negatively compensates for the higher favorable enthalpy.
C1 [Kumar, Santosh; Mapa, Koyeli; Maiti, Souvik] CSIR Inst Genom & Integrat Biol, Prote & Struct Biol Unit, Delhi 110007, India.
   [Maiti, Souvik] CSIR Natl Chem Lab, Pune 411008, Maharashtra, India.
C3 Council of Scientific & Industrial Research (CSIR) - India; CSIR -
   Institute of Genomics & Integrative Biology (IGIB); Council of
   Scientific & Industrial Research (CSIR) - India; CSIR - National
   Chemical Laboratory (NCL)
RP Maiti, S (通讯作者)，CSIR Inst Genom & Integrat Biol, Prote & Struct Biol Unit, Mall Rd, Delhi 110007, India.
EM souvik@igib.res.in
RI Kumar, Santosh/ABF-3590-2021
OI Kumar, Santosh/0000-0002-3594-4795; Maiti, Souvik/0000-0001-9897-1419
FU Council of Scientific and Industrial Research (CSIR), Government of
   India [BSC-0123]; CSIR
FX S.M. acknowledges the Council of Scientific and Industrial Research
   (CSIR), Government of India, for financial support (Project BSC-0123).
   SIC acknowledges a senior research fellowship from CSIR.
CR Aboul-Fadl T, 2005, CURR MED CHEM, V12, P2193, DOI 10.2174/0929867054864859
   Almeida R, 2005, TRENDS CELL BIOL, V15, P251, DOI 10.1016/j.tcb.2005.03.006
   Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2
   Brodersen P, 2009, NAT REV MOL CELL BIO, V10, P141, DOI 10.1038/nrm2619
   Chorn G, 2012, RNA, V18, P1796, DOI 10.1261/rna.031278.111
   Corey DR, 2007, J CLIN INVEST, V117, P3615, DOI 10.1172/JCI33483
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019
   Dias N, 2002, MOL CANCER THER, V1, P347
   Doessing H, 2011, MOLECULES, V16, P4511, DOI 10.3390/molecules16064511
   Elkayam E, 2012, CELL, V150, P100, DOI 10.1016/j.cell.2012.05.017
   Elmén J, 2005, NUCLEIC ACIDS RES, V33, P439, DOI 10.1093/nar/gki193
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Gao J, 2011, ONCOL LETT, V2, P1019, DOI 10.3892/ol.2011.413
   Gascon E, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00048
   Ghildiyal M, 2010, RNA, V16, P43, DOI 10.1261/rna.1972910
   Grünweller A, 2003, NUCLEIC ACIDS RES, V31, P3185, DOI 10.1093/nar/gkg409
   Hu HY, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-413
   Hutvagner G, 2008, NAT REV MOL CELL BIO, V9, P22, DOI 10.1038/nrm2321
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Kaur H, 2008, BIOCHEMISTRY-US, V47, P1218, DOI 10.1021/bi700996z
   Kaur H, 2007, CHEM REV, V107, P4672, DOI 10.1021/cr050266u
   Kaur H, 2006, BIOCHEMISTRY-US, V45, P7347, DOI 10.1021/bi060307w
   Landthaler M, 2008, RNA, V14, P2580, DOI 10.1261/rna.1351608
   Leeper NJ, 2011, J CELL PHYSIOL, V226, P1035, DOI 10.1002/jcp.22422
   Li JM, 2012, SAUDI MED J, V33, P24
   Liu XX, 2011, FEBS LETT, V585, P1363, DOI 10.1016/j.febslet.2011.04.018
   Lu M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003420
   McTigue PM, 2004, BIOCHEMISTRY-US, V43, P5388, DOI 10.1021/bi035976d
   Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462
   MONIA BP, 1993, J BIOL CHEM, V268, P14514
   Mook OR, 2007, MOL CANCER THER, V6, P833, DOI 10.1158/1535-7163.MCT-06-0195
   Parker JS, 2009, MOL CELL, V33, P204, DOI 10.1016/j.molcel.2008.12.012
   Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462
   Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488
   Pierce MM, 1999, METHODS, V19, P213, DOI 10.1006/meth.1999.0852
   Pillai RS, 2005, RNA, V11, P1753, DOI 10.1261/rna.2248605
   Rau F, 2011, NAT STRUCT MOL BIOL, V18, P840, DOI 10.1038/nsmb.2067
   Reinhardt Anita, 2012, Frontiers in Genetics, V3, P226, DOI 10.3389/fgene.2012.00226
   Schirle NT, 2012, SCIENCE, V336, P1037, DOI 10.1126/science.1221551
   Soifer HS, 2007, MOL THER, V15, P2070, DOI 10.1038/sj.mt.6300311
   Song JJ, 2006, CURR OPIN STRUC BIOL, V16, P5, DOI 10.1016/j.sbi.2006.01.010
   Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514
   Stein D, 1997, ANTISENSE NUCLEIC A, V7, P151, DOI 10.1089/oli.1.1997.7.151
   Straarup EM, 2010, NUCLEIC ACIDS RES, V38, P7100, DOI 10.1093/nar/gkq457
   Tétreault N, 2013, CLIN BIOCHEM, V46, P842, DOI 10.1016/j.clinbiochem.2013.02.009
   Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406
   Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48
   Uhlmann S, 2012, MOL SYST BIOL, V8, DOI 10.1038/msb.2011.100
   Vester B, 2004, BIOCHEMISTRY-US, V43, P13233, DOI 10.1021/bi0485732
   Voinnet O, 2002, CURR OPIN PLANT BIOL, V5, P444, DOI 10.1016/S1369-5266(02)00291-1
   Wang ZG, 2011, METHODS MOL BIOL, V676, P211, DOI 10.1007/978-1-60761-863-8_15
   Yakovchuk P, 2006, NUCLEIC ACIDS RES, V34, P564, DOI 10.1093/nar/gkj454
   Ye KQ, 2003, NATURE, V426, P874, DOI 10.1038/nature02213
   Yoo BH, 2004, NUCLEIC ACIDS RES, V32, P2008, DOI 10.1093/nar/gkh516
NR 55
TC 27
Z9 30
U1 0
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD MAR 18
PY 2014
VL 53
IS 10
BP 1607
EP 1615
DI 10.1021/bi401677d
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AD4QM
UT WOS:000333235600009
PM 24564489
DA 2025-01-12
ER

PT J
AU Coradini, D
   Boracchi, P
   Oriana, S
   Biganzoli, E
   Ambrogi, F
AF Coradini, Danila
   Boracchi, Patrizia
   Oriana, Saro
   Biganzoli, Elia
   Ambrogi, Federico
TI Cell Identity Disruption in Breast Cancer Precursors
SO ANTICANCER RESEARCH
LA English
DT Article
DE Mammary epithelium; cell identity; atypical ductal hyperplasia; ductal
   carcinoma in situ
ID TRITHORAX GROUP PROTEINS; ESTROGEN-RECEPTOR-ALPHA; MAMMARY-GLAND;
   GENE-EXPRESSION; POLYCOMB; PROLIFERATION; CHROMATIN; EZH2;
   DIFFERENTIATION; MORPHOGENESIS
AB Background: Mammary epithelial cell identity depends on a set of genes epigenetically-regulated by maintenance proteins, the best-characterized of which belong to the Trithorax and Polycomb groups. Perturbations in expression of these proteins may disrupt cell identity and trigger tumor initiation. Materials and Methods: The pattern of expression of a panel of genes involved in control of cell identity and mammary gland remodeling was investigated in two precancerous lesions, atypical ductal hyperplasia (ADH) and ductal carcinoma in situ (DCIS) and compared to the corresponding histologically normal tissue. Results: ADH and DCIS showed a close association in overexpression of Polycomb complex components, silencing of Homeobox A (HOXA) cluster gene, and overexpression of the genes involved in estrogen signaling, specifically, forkhead box A1 (FOXA1) and GATA binding protein 3 (GATA3) pioneer factors, and estrogen receptor-1 (ESR1). Conclusion: Our findings support the hypothesis that disruption of epigenetic control is associated with loss of cell identity and acquisition of a constitutive estrogen-dependent terminally-differentiated luminal phenotype.
C1 [Coradini, Danila; Boracchi, Patrizia; Biganzoli, Elia; Ambrogi, Federico] Univ Milan, Dept Clin & Community Hlth Sci Med Stat Biometry, I-20133 Milan, Italy.
   [Coradini, Danila; Oriana, Saro] Ambrosiana Clin, Senol Ctr, Milan, Italy.
C3 University of Milan
RP Coradini, D (通讯作者)，Univ Milan, Dept Clin & Community Hlth Sci Med Stat Biometry, Via Vanzetti 5, I-20133 Milan, Italy.
EM danila.coradini@yahoo.it
RI Patrizia, Boracchi/AAB-8851-2019; Biganzoli, Elia/J-1678-2012; Ambrogi,
   Federico/D-4294-2015
OI Biganzoli, Elia/0000-0003-1202-5873; Ambrogi,
   Federico/0000-0001-9358-011X; boracchi, patrizia/0000-0001-8506-2005
CR Alajez NM, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.64
   Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530
   Augello MA, 2011, EMBO J, V30, P3885, DOI 10.1038/emboj.2011.340
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bezsonova I, 2009, BIOCHEMISTRY-US, V48, P10542, DOI 10.1021/bi901131u
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542
   Brock HW, 2005, DEV DYNAM, V232, P633, DOI 10.1002/dvdy.20298
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Clarke RB, 1997, CANCER RES, V57, P4987
   Derfoul A, 2011, CARCINOGENESIS, V32, P1607, DOI 10.1093/carcin/bgr184
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011
   Eecichoute J, 2007, CANCER RES, V67, P6477
   El-Rehim DMA, 2004, J PATHOL, V203, P661, DOI 10.1002/path.1559
   Emery LA, 2009, AM J PATHOL, V175, P1292, DOI 10.2353/ajpath.2009.090115
   Ferrari F, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-446
   García-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200
   Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295
   Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107
   Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007
   Inoue H, 2002, J BIOL CHEM, V277, P41674, DOI 10.1074/jbc.M205961200
   Jacobs JJL, 2002, BBA-REV CANCER, V1602, P151, DOI 10.1016/S0304-419X(02)00052-5
   Jeong KW, 2009, J BIOL CHEM, V284, P29298, DOI 10.1074/jbc.M109.037010
   Jones JL, 2003, J PATHOL, V201, P562, DOI 10.1002/path.1483
   Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445
   KENNY AJ, 1989, LANCET, V2, P785
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048
   Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043
   Li X, 2009, AM J PATHOL, V175, P1246, DOI 10.2353/ajpath.2009.090042
   Lonard DM, 2007, MOL CELL, V27, P691, DOI 10.1016/j.molcel.2007.08.012
   Mallepell S, 2006, P NATL ACAD SCI USA, V103, P2196, DOI 10.1073/pnas.0510974103
   Novak P, 2006, CANCER RES, V66, P10664, DOI 10.1158/0008-5472.CAN-06-2761
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Safe S, 2008, J MOL ENDOCRINOL, V41, P263, DOI 10.1677/JME-08-0103
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509
   Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121
   Shi B, 2007, MOL CELL BIOL, V27, P5105, DOI 10.1128/MCB.00162-07
   Tan HN, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-31
   Trotter KW, 2007, MOL CELL ENDOCRINOL, V265, P162, DOI 10.1016/j.mce.2006.12.015
   Vergoulis T, 2012, NUCLEIC ACIDS RES, V40, pD222, DOI 10.1093/nar/gkr1161
   Vermaak D, 2003, CURR OPIN CELL BIOL, V15, P266, DOI 10.1016/S0955-0674(03)00043-7
   WELLINGS SR, 1975, J NATL CANCER I, V55, P231
   Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111
NR 47
TC 1
Z9 1
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAR
PY 2014
VL 34
IS 3
SI SI
BP 1307
EP 1319
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AD6NQ
UT WOS:000333377800034
PM 24596378
DA 2025-01-12
ER

PT J
AU Chu, KO
   Chan, SO
   Pang, CP
   Wang, CC
AF Chu, Kai On
   Chan, Sun-On
   Pang, Chi Pui
   Wang, Chi Chiu
TI Pro-oxidative and Antioxidative Controls and Signaling Modification of
   Polyphenolic Phytochemicals: Contribution to Health Promotion and
   Disease Prevention?
SO JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY
LA English
DT Article
DE phytochemical polyphenols; antioxidation; pro-oxidation; signaling;
   epigenetic
ID GREEN TEA POLYPHENOL; ACTIVATED PROTEIN-KINASE; HYDROXYCINNAMIC
   ACID-DERIVATIVES; NF-KAPPA-B; BREAST-CANCER; ELLAGIC ACID; IN-VITRO;
   (-)-EPIGALLOCATECHIN GALLATE; EPIGALLOCATECHIN GALLATE; CHEMOPREVENTIVE
   POLYPHENOL
AB Polyphenolic phytochemicals (PPs) have been extensively studied as potential nutriceuticals for maintenance of health and treatment of cancer, inflammation, and neurodegeneration. However, the reported beneficial outcomes are inconsistent. The biological activities of PPs have been attributed to their pro-oxidative and antioxidative actions and effects on signaling mechanisms and epigenomic modifications. These diversified properties were described or postulated on the basis of a variety of experimental studies using cell culture and animal models, even though most have not been replicated and results are not validated. This review attempts to give an overview of biological properties of PPs, based on the coherent results from relevant studies, and evaluate critically the experimental conditions and possible artifacts. Complicated molecular mechanisms and multitargeting genomic interactions of PPs are discussed, with a view that reasonable mechanistic propositions are usually obtained from well-designed in vivo studies.
C1 [Chu, Kai On; Pang, Chi Pui] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Kowloon, Hong Kong, Peoples R China.
   [Chu, Kai On; Wang, Chi Chiu] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China.
   [Chan, Sun-On] Chinese Univ Hong Kong, Sch Biomed Sci, Shatin, Hong Kong, Peoples R China.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong; Prince
   of Wales Hospital; Chinese University of Hong Kong
RP Wang, CC (通讯作者)，Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Shatin, Hong Kong, Peoples R China.
EM ccwang@cuhk.edu.hk
RI Pang, Chi/I-5388-2014; Chan, Sun-On/R-6547-2018; wang,
   ronald/C-6541-2014
OI Chan, Sun-On/0000-0002-3221-3786; wang, ronald/0000-0002-3928-7278
CR Abe LT, 2012, J SCI FOOD AGR, V92, P1679, DOI 10.1002/jsfa.5531
   Abusnina A, 2011, MOL NUTR FOOD RES, V55, P1677, DOI 10.1002/mnfr.201100307
   Adhami VM, 2004, CANCER RES, V64, P8715, DOI 10.1158/0008-5472.CAN-04-2840
   Akhlaghi M, 2010, NUTR RES, V30, P32, DOI 10.1016/j.nutres.2009.11.002
   Ali HM, 2013, CHEM CENT J, V7, DOI 10.1186/1752-153X-7-53
   Apak R, 2005, FREE RADICAL RES, V39, P949, DOI 10.1080/10715760500210145
   Aqil F, 2012, NUTR CANCER, V64, P428, DOI 10.1080/01635581.2012.657766
   Armishaw CJ, 2010, J BIOL CHEM, V285, P1809, DOI 10.1074/jbc.M109.071183
   Armour SM, 2009, AGING-US, V1, P515, DOI 10.18632/aging.100056
   Azam S, 2004, TOXICOL IN VITRO, V18, P555, DOI 10.1016/j.tiv.2003.12.012
   Azmi AS, 2005, FEBS LETT, V579, P3131, DOI 10.1016/j.febslet.2005.04.077
   Babich H, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/467305
   Bachmeier BE, 2007, CELL PHYSIOL BIOCHEM, V19, P137, DOI 10.1159/000099202
   Bak MJ, 2012, INT J MOL SCI, V13, P801, DOI 10.3390/ijms13010801
   Berger SJ, 2001, BIOCHEM BIOPH RES CO, V288, P101, DOI 10.1006/bbrc.2001.5736
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Bharrhan S, 2012, INNATE IMMUN-LONDON, V18, P70, DOI 10.1177/1753425910393369
   Bigelow RLH, 2006, ONCOGENE, V25, P1922, DOI 10.1038/sj.onc.1209227
   Bloomer RJ, 2009, OXID MED CELL LONGEV, V2, P19, DOI 10.4161/oxim.2.1.7860
   Bouayed J, 2010, CURR NUTR FOOD SCI, V6, P13, DOI 10.2174/157340110790909608
   Boulay A, 2001, CANCER RES, V61, P2189
   BRANEN AL, 1975, J AM OIL CHEM SOC, V52, P59, DOI 10.1007/BF02901825
   Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x
   Carroll FI, 2009, NEUROPSYCHOPHARMACOL, V34, P251, DOI 10.1038/npp.2008.160
   Celik G, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/358945
   Chacko Sabu M, 2010, Chin Med, V5, P13, DOI 10.1186/1749-8546-5-13
   Chang YF, 2006, NUTR CANCER, V55, P201, DOI 10.1207/s15327914nc5502_12
   Choi JS, 2008, J NUTR, V138, P983, DOI 10.1093/jn/138.6.983
   Chow HHS, 2007, CANCER EPIDEM BIOMAR, V16, P1662, DOI 10.1158/1055-9965.EPI-06-0830
   Chow HHS, 2011, PHARMACOL RES, V64, P105, DOI 10.1016/j.phrs.2011.05.007
   Chu KO, 2010, J AGR FOOD CHEM, V58, P1523, DOI 10.1021/jf9032602
   Chung FL, 2003, J NUTR, V133, p3268S, DOI 10.1093/jn/133.10.3268S
   D'Archivio M, 2010, INT J MOL SCI, V11, P1321, DOI 10.3390/ijms11041321
   Dai J, 2010, MOLECULES, V15, P7313, DOI 10.3390/molecules15107313
   Danila AM, 2007, J AGR FOOD CHEM, V55, P1139, DOI 10.1021/jf062815i
   Dauchet L, 2005, NEUROLOGY, V65, P1193, DOI 10.1212/01.wnl.0000180600.09719.53
   De Marchi U, 2009, BBA-BIOENERGETICS, V1787, P1425, DOI 10.1016/j.bbabio.2009.06.002
   de Pascual-Teresa S, 2010, INT J MOL SCI, V11, P1679, DOI 10.3390/ijms11041679
   Decker EA, 1997, NUTR REV, V55, P396, DOI 10.1111/j.1753-4887.1997.tb01580.x
   Dong ZG, 1997, CANCER RES, V57, P4414
   Du GJ, 2012, NUTRIENTS, V4, P1679, DOI 10.3390/nu4111679
   Durand AC, 2007, J ENZYM INHIB MED CH, V22, P556, DOI 10.1080/14756360701425238
   Eberhardt MV, 2000, NATURE, V405, P903, DOI 10.1038/35016148
   Elahi MM, 2009, OXID MED CELL LONGEV, V2, P259, DOI 10.4161/oxim.2.5.9441
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fujimura Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037942
   Fukumoto LR, 2000, J AGR FOOD CHEM, V48, P3597, DOI 10.1021/jf000220w
   Galati G, 2004, FREE RADICAL BIO MED, V37, P287, DOI 10.1016/j.freeradbiomed.2004.04.034
   Gattuso G, 2007, MOLECULES, V12, P1641, DOI 10.3390/12081641
   Gould K. S., 2006, Flavonoids: chemistry, biochemistry and applications, P397
   Grellier P, 2008, Z NATURFORSCH C, V63, P445
   GU P, 2013, BRIEF BIOINFORM, V15, P984, DOI [DOI 10.1093/BIB/BBT063, 10.1093/bib/bbt063, 10.1093/bib/bbt063.]
   Gundimeda U, 2012, J BIOL CHEM, V287, P34694, DOI 10.1074/jbc.M112.356899
   Gupta S, 2003, ARCH BIOCHEM BIOPHYS, V410, P177, DOI 10.1016/S0003-9861(02)00668-9
   Hakim IA, 2004, CANCER EPIDEM BIOMAR, V13, P242, DOI 10.1158/1055-9965.EPI-03-0193
   Hakimuddin F, 2004, BREAST CANCER RES TR, V85, P65, DOI 10.1023/B:BREA.0000021048.52430.c0
   Halliwell B, 2005, AM J CLIN NUTR, V81, p268S, DOI 10.1093/ajcn/81.1.268S
   Halliwell B, 2006, J NEUROCHEM, V97, P1634, DOI 10.1111/j.1471-4159.2006.03907.x
   Henry-Kirk RA, 2012, J EXP BOT, V63, P5437, DOI 10.1093/jxb/ers193
   Hitchler MJ, 2012, FREE RADICAL BIO MED, V53, P2178, DOI 10.1016/j.freeradbiomed.2012.09.028
   Hodgson JM, 2000, AM J CLIN NUTR, V71, P1103
   Hong J, 2002, CANCER RES, V62, P7241
   Hou Z, 2005, CANCER RES, V65, P8049, DOI 10.1158/0008-5472.CAN-05-0480
   Hu Miao-Lin, 2011, Chang Gung Med J, V34, P449
   Huang J, 2011, CURR DRUG TARGETS, V12, P1925, DOI 10.2174/138945011798184155
   Huang SM, 2006, MOL NUTR FOOD RES, V50, P1129, DOI 10.1002/mnfr.200600075
   Ibanez S, 2012, TOXINS, V4, P228, DOI 10.3390/toxins4040228
   Itagaki S, 2010, FOOD CHEM, V118, P426, DOI 10.1016/j.foodchem.2009.04.103
   ITO N, 1983, JNCI-J NATL CANCER I, V70, P343
   Iwasaki M, 2010, BREAST CANCER RES TR, V124, P827, DOI 10.1007/s10549-010-0916-x
   Ju J, 2005, CANCER RES, V65, P10623, DOI 10.1158/0008-5472.CAN-05-1949
   Ju J, 2007, SEMIN CANCER BIOL, V17, P395, DOI 10.1016/j.semcancer.2007.06.013
   Kang JH, 2005, BIOCHEM PHARMACOL, V69, P1205, DOI 10.1016/j.bcp.2005.01.014
   Kay CD, 2009, MOL NUTR FOOD RES, V53, pS92, DOI 10.1002/mnfr.200800461
   Kebieche M, 2009, EXP TOXICOL PATHOL, V61, P161, DOI 10.1016/j.etp.2008.06.002
   Khan N, 2007, LIFE SCI, V81, P519, DOI 10.1016/j.lfs.2007.06.011
   Khan N, 2009, NUTR CANCER, V61, P836, DOI 10.1080/01635580903285056
   Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478
   Kristinová V, 2009, J AGR FOOD CHEM, V57, P10377, DOI 10.1021/jf901072t
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Kuzuhara T, 2006, J BIOL CHEM, V281, P17446, DOI 10.1074/jbc.M601196200
   Kwon JY, 2012, J BIOL CHEM, V287, P11566, DOI 10.1074/jbc.M111.259721
   Lambert JD, 2010, ARCH BIOCHEM BIOPHYS, V501, P65, DOI 10.1016/j.abb.2010.06.013
   Landete JM, 2012, CRIT REV FOOD SCI, V52, P936, DOI 10.1080/10408398.2010.513779
   Lee JH, 2005, J AGR FOOD CHEM, V53, P6003, DOI 10.1021/jf050468r
   Lee KW, 2004, CRIT REV FOOD SCI, V44, P437, DOI 10.1080/10408690490886674
   Lepiniec L, 2006, ANNU REV PLANT BIOL, V57, P405, DOI 10.1146/annurev.arplant.57.032905.105252
   Li GX, 2010, CARCINOGENESIS, V31, P902, DOI 10.1093/carcin/bgq039
   Li YY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-274
   Lin LZ, 2011, J AGR FOOD CHEM, V59, P12059, DOI 10.1021/jf202556p
   Liu JD, 2001, J CELL BIOCHEM, V83, P631, DOI 10.1002/jcb.1261
   Liu RH, 2003, AM J CLIN NUTR, V78, p517S, DOI 10.1093/ajcn/78.3.517S
   Lu G, 2008, CLIN CANCER RES, V14, P4981, DOI 10.1158/1078-0432.CCR-07-1860
   Lu G, 2006, CANCER RES, V66, P11494, DOI 10.1158/0008-5472.CAN-06-1497
   Malencic D, 2012, J MED FOOD, V15, P89, DOI 10.1089/jmf.2010.0329
   Malireddy S, 2012, ANTIOXID REDOX SIGN, V17, P327, DOI 10.1089/ars.2012.4600
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   Masella R, 2005, J NUTR BIOCHEM, V16, P577, DOI 10.1016/j.jnutbio.2005.05.013
   Maurya DK, 2010, FOOD CHEM TOXICOL, V48, P3369, DOI 10.1016/j.fct.2010.09.006
   Medina-Franco JL, 2013, DRUG DISCOV TODAY, V18, P495, DOI 10.1016/j.drudis.2013.01.008
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Mellor DD, 2013, DIABETIC MED, V30, P478, DOI 10.1111/dme.12030
   Mennen LI, 2005, AM J CLIN NUTR, V81, p326S, DOI 10.1093/ajcn/81.1.326S
   Mittal A, 2003, NEOPLASIA, V5, P555, DOI 10.1016/S1476-5586(03)80039-8
   Moalin M, 2011, MOLECULES, V16, P9636, DOI 10.3390/molecules16119636
   Monagas M, 2003, J AGR FOOD CHEM, V51, P6475, DOI 10.1021/jf030325+
   Moran JF, 1997, FREE RADICAL BIO MED, V22, P861, DOI 10.1016/S0891-5849(96)00426-1
   Na HK, 2008, FOOD CHEM TOXICOL, V46, P1271, DOI 10.1016/j.fct.2007.10.006
   Nakagawa H, 2004, CARCINOGENESIS, V25, P1567, DOI 10.1093/carcin/bgh168
   Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200
   Nandakumar V, 2011, CARCINOGENESIS, V32, P537, DOI 10.1093/carcin/bgq285
   Nemekaite-Ceniene A, 2005, ARCH BIOCHEM BIOPHYS, V441, P182, DOI 10.1016/j.abb.2005.07.002
   Nichols JA, 2010, ARCH DERMATOL RES, V302, P71, DOI 10.1007/s00403-009-1001-3
   Nihal M, 2010, PHARM RES-DORDR, V27, P1103, DOI 10.1007/s11095-010-0054-5
   Om A, 2008, J MED FOOD, V11, P29, DOI 10.1089/jmf.2007.048
   Ososki AL, 2003, PHYTOTHER RES, V17, P845, DOI 10.1002/ptr.1364
   Pan MH, 2007, J AGR FOOD CHEM, V55, P5030, DOI 10.1021/jf070316r
   Pandey KB, 2009, OXID MED CELL LONGEV, V2, P270, DOI 10.4161/oxim.2.5.9498
   Paolini GV, 2006, NAT BIOTECHNOL, V24, P805, DOI 10.1038/nbt1228
   Pinto MDS, 2008, FOOD CHEM, V107, P1629, DOI 10.1016/j.foodchem.2007.10.038
   Priyadarsini KI, 2002, J AGR FOOD CHEM, V50, P2200, DOI 10.1021/jf011275g
   Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805
   Rahim AA, 2014, FOOD CHEM, V147, P262, DOI 10.1016/j.foodchem.2013.09.131
   Rahman K, 2007, CLIN INTERV AGING, V2, P219
   Ran FA, 2013, CELL, V154, P1380, DOI 10.1016/j.cell.2013.08.021
   Rasulev BF, 2005, QSAR COMB SCI, V24, P1056, DOI 10.1002/qsar.200430013
   Raza H, 2005, TOXICOL APPL PHARM, V207, P212, DOI 10.1016/j.taap.2005.01.004
   Reuter S, 2011, GENES NUTR, V6, P93, DOI 10.1007/s12263-011-0222-1
   Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011
   Rietjens IMCM, 2005, MUTAT RES-FUND MOL M, V574, P124, DOI 10.1016/j.mrfmmm.2005.01.028
   Robaszkiewicz A, 2007, CELL BIOL INT, V31, P1245, DOI 10.1016/j.cellbi.2007.04.009
   Rodriguez SK, 2006, INT J CANCER, V118, P1635, DOI 10.1002/ijc.21545
   Rosa EF, 2007, J NEUROPHYSIOL, V98, P1820, DOI 10.1152/jn.01158.2006
   Rugina D., 2008, B UASVM AGR, V65, P1843
   Sang SM, 2005, J AGR FOOD CHEM, V53, P9478, DOI 10.1021/jf0519055
   Scheidt HA, 2004, BBA-BIOMEMBRANES, V1663, P97, DOI 10.1016/j.bbamem.2004.02.004
   Schloms L, 2014, MOL NUTR FOOD RES, V58, P537, DOI 10.1002/mnfr.201300463
   Selassie CD, 2005, J MED CHEM, V48, P7234, DOI 10.1021/jm050567w
   Sen T, 2010, ANTI-CANCER DRUG, V21, P632, DOI 10.1097/CAD.0b013e32833a4385
   Shen GX, 2005, PHARM RES-DORDR, V22, P1805, DOI 10.1007/s11095-005-7546-8
   Sim GS, 2007, ARCH PHARM RES, V30, P290, DOI 10.1007/BF02977608
   Simic A, 2007, MOLECULES, V12, P2327, DOI 10.3390/12102327
   Siow RCM, 2010, MOL ASPECTS MED, V31, P468, DOI 10.1016/j.mam.2010.09.003
   Somerset SM, 2008, NUTR CANCER, V60, P442, DOI 10.1080/01635580802143836
   Soulat T, 2006, BRIT J NUTR, V96, P290, DOI 10.1079/BJN20061818
   Souza CG, 2007, LIFE SCI, V81, P198, DOI 10.1016/j.lfs.2007.05.001
   Stevenson DE, 2007, CELL MOL LIFE SCI, V64, P2900, DOI 10.1007/s00018-007-7237-1
   Suh KS, 2010, CELL BIOL TOXICOL, V26, P189, DOI 10.1007/s10565-009-9137-7
   Tachibana H, 2004, NAT STRUCT MOL BIOL, V11, P380, DOI 10.1038/nsmb743
   Tanaka T, 2010, INT J MOL SCI, V11, P14, DOI 10.3390/ijms11010014
   Thavasi V, 2006, J PHYS CHEM A, V110, P4918, DOI 10.1021/jp057315r
   Toufektsian MC, 2008, J NUTR, V138, P747, DOI 10.1093/jn/138.4.747
   Umeda D, 2005, BIOCHEM BIOPH RES CO, V333, P628, DOI 10.1016/j.bbrc.2005.05.108
   Umesalma S, 2010, BASIC CLIN PHARMACOL, V107, P650, DOI 10.1111/j.1742-7843.2010.00565.x
   Utesch D, 2008, MUTAT RES-GEN TOX EN, V654, P38, DOI 10.1016/j.mrgentox.2008.04.008
   Valcic S, 2000, CHEM RES TOXICOL, V13, P801, DOI 10.1021/tx000080k
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Vallejo F, 2004, J CHROMATOGR A, V1054, P181, DOI 10.1016/j.chroma.2004.05.045
   van Duijnhoven FJB, 2009, AM J CLIN NUTR, V89, P1441, DOI 10.3945/ajcn.2008.27120
   Vauzour D, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/914273
   Vollaard NBJ, 2005, SPORTS MED, V35, P1045, DOI 10.2165/00007256-200535120-00004
   Wahyudi Sianne, 2007, Acta Med Indones, V39, P66
   Wang MF, 2003, J AGR FOOD CHEM, V51, P6132, DOI 10.1021/jf0344587
   Wang YQ, 2011, J MOL MODEL, V17, P1, DOI 10.1007/s00894-010-0689-5
   Wätjen W, 2005, J NUTR, V135, P525, DOI 10.1093/jn/135.3.525
   Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4
   Williams RJ, 2004, FREE RADICAL BIO MED, V36, P838, DOI 10.1016/j.freeradbiomed.2004.01.001
   Williamson MP, 2006, J ALLERGY CLIN IMMUN, V118, P1369, DOI 10.1016/j.jaci.2006.08.016
   Wong CP, 2011, IMMUNOL LETT, V139, P7, DOI 10.1016/j.imlet.2011.04.009
   Wu TY, 2011, AAPS J, V13, P1, DOI 10.1208/s12248-010-9239-4
   Wu XL, 2004, J AGR FOOD CHEM, V52, P7846, DOI 10.1021/jf0486850
   Xiao J, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/185172
   Yang CS, 2008, ASIA PAC J CLIN NUTR, V17, P245
   Yang CS, 2009, NAT REV CANCER, V9, P429, DOI 10.1038/nrc2641
   Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611
   Yang J, 2011, J AGR FOOD CHEM, V59, P11483, DOI 10.1021/jf2024819
   Yi L, 2012, BIOCHIMIE, V94, P2035, DOI 10.1016/j.biochi.2012.05.027
   Yi L, 2011, INT J MOL SCI, V12, P5471, DOI 10.3390/ijms12095471
   Yin JJ, 2012, J AGR FOOD CHEM, V60, P2554, DOI 10.1021/jf204724w
   Yin ST, 2009, N-S ARCH PHARMACOL, V379, P551, DOI 10.1007/s00210-009-0401-4
   Yuan JH, 2007, PHARMACOLOGY, V80, P269, DOI 10.1159/000106447
   Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188
   Zhen MC, 2006, ACTA PHARMACOL SIN, V27, P1600, DOI 10.1111/j.1745-7254.2006.00439.x
   Zhu WG, 2007, MOL CELL NEUROSCI, V34, P689, DOI 10.1016/j.mcn.2007.01.005
NR 184
TC 36
Z9 40
U1 0
U2 57
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0021-8561
EI 1520-5118
J9 J AGR FOOD CHEM
JI J. Agric. Food Chem.
PD MAY 7
PY 2014
VL 62
IS 18
BP 4026
EP 4038
DI 10.1021/jf500080z
PG 13
WC Agriculture, Multidisciplinary; Chemistry, Applied; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Chemistry; Food Science & Technology
GA AH1KH
UT WOS:000335878500021
PM 24779775
DA 2025-01-12
ER

PT J
AU Weissenborn, C
   Ignatov, T
   Poehlmann, A
   Wege, AK
   Costa, SD
   Zenclussen, AC
   Ignatov, A
AF Weissenborn, Christine
   Ignatov, Tanja
   Poehlmann, Angela
   Wege, Anja K.
   Costa, Serban D.
   Zenclussen, Ana Claudia
   Ignatov, Atanas
TI GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer
   cells
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE GPER; GPR30; Breast cancer; Tumor suppressor
ID PROTEIN-COUPLED RECEPTOR-30; ESTROGEN-RECEPTOR; UP-REGULATION; AGONIST
   G-1; GENE-EXPRESSION; GPR30; GROWTH; PROLIFERATION; OVARIAN;
   17-BETA-ESTRADIOL
AB Purpose The orphan, membrane-bound estrogen receptor (GPER) is expressed at high levels in a large fraction of breast cancer patients, and its expression is favorable for patients' survival. We investigated the role of GPER as a potential tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells.
   Methods The effect of GPER agonist G-1 in cell culture was used to determine whether GPER inhibit cell growth. The methylation status of GPER promoter was investigated by methylation-specific PCR.
   Results GPER-specific agonist G-1 inhibited breast cancer cell proliferation in concentration-dependent manner via induction of the cell cycle arrest in M-phase, enhanced phosphorylation of histone 3 and cell apoptosis. Analysis of the methylation status of the GPER promoter in MCF-7 and SK-BR-3 cells revealed that GPER expression is regulated by epigenetic mechanisms and GPER expression is inactivated by promoter methylation. Overall, our results are consistent with our recent findings in triple-negative breast cancer cells, and the cell surface expression of GPER makes it an excellent potential therapeutic target for non-triple-negative breast cancer.
C1 [Weissenborn, Christine; Ignatov, Tanja; Costa, Serban D.; Ignatov, Atanas] Univ Clin Magdeburg, Dept Obstet & Gynecol, D-39108 Magdeburg, Germany.
   [Weissenborn, Christine; Zenclussen, Ana Claudia] Univ Clin Magdeburg, Dept Expt Obstet & Gynaecol, D-39108 Magdeburg, Germany.
   [Poehlmann, Angela] Univ Clin Magdeburg, Dept Pathol, D-39108 Magdeburg, Germany.
   [Wege, Anja K.] Univ Regensburg, Caritas Hosp St Josef, Clin Gynecol & Obstet, D-93053 Regensburg, Germany.
C3 University of Regensburg
RP Ignatov, A (通讯作者)，Univ Clin Magdeburg, Dept Obstet & Gynecol, Gerhart Hauptmann Str 35, D-39108 Magdeburg, Germany.
EM atanas.ignatov@gmail.com
RI Zenclussen, Ana/AAE-8760-2020; Zenclussen, Ana Claudia/G-2186-2013
OI Zenclussen, Ana Claudia/0000-0003-3544-4552
FU Deutsche Krebshilfe
FX This work was supported by Deutsche Krebshilfe to AI.
CR Ahola TM, 2002, ENDOCRINOLOGY, V143, P3376, DOI 10.1210/en.2001-211445
   Ahola TM, 2002, ENDOCRINOLOGY, V143, P4620, DOI 10.1210/en.2002-220492
   Aihara M, 2012, GENE, V501, P118, DOI 10.1016/j.gene.2012.04.029
   Albanito L, 2008, ENDOCRINOLOGY, V149, P3799, DOI 10.1210/en.2008-0117
   Albanito L, 2007, CANCER RES, V67, P1859, DOI 10.1158/0008-5472.CAN-06-2909
   Arias-Pulido H, 2010, BREAST CANCER RES TR, V123, P51, DOI 10.1007/s10549-009-0631-7
   Ariazi EA, 2010, CANCER RES, V70, P1184, DOI 10.1158/0008-5472.CAN-09-3068
   Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775
   Chan QKY, 2010, CELL DEATH DIFFER, V17, P1511, DOI 10.1038/cdd.2010.20
   Chimento A, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.275
   Choi HJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024312
   De Marco P, 2013, ONCOGENE, V32, P678, DOI 10.1038/onc.2012.97
   Dennis MK, 2009, NAT CHEM BIOL, V5, P421, DOI 10.1038/nchembio.168
   Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069
   Du GQ, 2012, BIOCHEM BIOPH RES CO, V420, P343, DOI 10.1016/j.bbrc.2012.02.161
   Esteller M, 2001, CANCER RES, V61, P3225
   Filardo EJ, 2006, CLIN CANCER RES, V12, P6359, DOI 10.1158/1078-0432.CCR-06-0860
   Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649
   Gao F, 2011, ENDOCRINOLOGY, V152, P1434, DOI 10.1210/en.2010-1368
   Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326
   Holm A, 2011, J VASC RES, V48, P327, DOI 10.1159/000322578
   Ignatov A, 2003, BIOCHEM BIOPH RES CO, V311, P329, DOI 10.1016/j.bbrc.2003.10.006
   Ignatov A, 2008, GYNECOL ONCOL, V111, P365, DOI 10.1016/j.ygyno.2008.07.037
   Ignatov A, 2011, BREAST CANCER RES TR, V128, P457, DOI 10.1007/s10549-011-1584-1
   Ignatov A, 2010, BREAST CANCER RES TR, V123, P87, DOI 10.1007/s10549-009-0624-6
   Ignatov A, 2010, CANCER SCI, V101, P321, DOI 10.1111/j.1349-7006.2009.01397.x
   Ignatov T, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-51
   Ignatov T, 2013, CANCER INVEST, V31, P309, DOI 10.3109/07357907.2013.789901
   Kuo Wen-Hung, 2007, Taiwan J Obstet Gynecol, V46, P135, DOI 10.1016/S1028-4559(07)60007-2
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Liu Q, 2009, CHINESE MED J-PEKING, V122, P2763, DOI 10.3760/cma.j.issn.0366-6999.2009.22.017
   Lubig J, 2012, CANCER INVEST, V30, P372, DOI 10.3109/07357907.2012.666690
   Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200
   Osborne C, 2004, ONCOLOGIST, V9, P361, DOI 10.1634/theoncologist.9-4-361
   Payne SR, 2005, CARCINOGENESIS, V26, P2031, DOI 10.1093/carcin/bgi223
   Poola I, 2008, BREAST CANCER-BASIC, V1, P65
   Prossnitz ER, 2008, ANNU REV PHYSIOL, V70, P165, DOI 10.1146/annurev.physiol.70.113006.100518
   Revankar CM, 2005, SCIENCE, V307, P1625, DOI 10.1126/science.1106943
   Ruan SQ, 2012, MOL MED REP, V6, P131, DOI 10.3892/mmr.2012.874
   Ruan SQ, 2012, BIOCHEM BIOPH RES CO, V420, P385, DOI 10.1016/j.bbrc.2012.03.004
   Schumacher A, 2009, J IMMUNOL, V182, P5488, DOI 10.4049/jimmunol.0803177
   Smith HO, 2009, GYNECOL ONCOL, V114, P465, DOI 10.1016/j.ygyno.2009.05.015
   Smith HO, 2007, AM J OBSTET GYNECOL, V196, DOI 10.1016/j.ajog.2007.01.004
   Song SH, 2011, DRUGS, V71, P2391, DOI 10.2165/11596690-000000000-00000
   Teng J, 2008, ENDOCRINOLOGY, V149, P4024, DOI 10.1210/en.2007-1669
   Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064
   Toh WH, 2010, CELL DEATH DIFFER, V17, P787, DOI 10.1038/cdd.2009.181
   Tu G, 2009, TECHNOL CANCER RES T, V8, P231, DOI 10.1177/153303460900800308
   Vivacqua A, 2006, MOL ENDOCRINOL, V20, P631, DOI 10.1210/me.2005-0280
   Vivacqua A, 2012, BREAST CANCER RES TR, V133, P1025, DOI 10.1007/s10549-011-1901-8
   Wang C, 2012, AM J TRANSL RES, V4, P390
NR 51
TC 45
Z9 52
U1 0
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD APR
PY 2014
VL 140
IS 4
BP 663
EP 671
DI 10.1007/s00432-014-1598-2
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AC9SW
UT WOS:000332875700015
PM 24515910
DA 2025-01-12
ER

PT J
AU Thériault, BL
   Basavarajappa, HD
   Lim, H
   Pajovic, S
   Gallie, BL
   Corson, TW
AF Theriault, Brigitte L.
   Basavarajappa, Halesha D.
   Lim, Harvey
   Pajovic, Sanja
   Gallie, Brenda L.
   Corson, Timothy W.
TI Transcriptional and Epigenetic Regulation of <i>KIF14</i> Overexpression
   in Ovarian Cancer
SO PLOS ONE
LA English
DT Article
ID MESSENGER-RNA EXPRESSION; FAMILY-MEMBER 14; HEPATOCELLULAR-CARCINOMA;
   PROGNOSTIC MARKER; SIGNALING PATHWAY; GENE-EXPRESSION; BREAST-CANCER;
   LUNG-CANCER; FACTORS SP1; PROGRESSION
AB KIF14 (kinesin family member 14) is a mitotic kinesin and an important oncogene in several cancers. Tumor KIF14 expression levels are independently predictive of poor outcome, and in cancer cells KIF14 can modulate metastatic behavior by maintaining appropriate levels of cell adhesion and migration proteins at the cell membrane. Thus KIF14 is an exciting potential therapeutic target. Understanding KIF14's regulation in cancer cells is crucial to the development of effective and selective therapies to block its tumorigenic function(s). We previously determined that close to 30% of serous ovarian cancers (OvCa tumors) exhibit low-level genomic gain, indicating one mechanism of KIF14 overexpression in tumors. We now report on transcriptional and epigenetic regulation of KIF14. Through promoter deletion analyses, we identified one cis-regulatory region containing binding sites for Sp1, HSF1 and YY1. siRNA-mediated knockdown of these transcription factors demonstrated endogenous regulation of KIF14 overexpression by Sp1 and YY1, but not HSF1. ChIP experiments confirmed an enrichment of both Sp1 and YY1 binding to the endogenous KIF14 promoter in OvCa cell lines with high KIF14 expression. A strong correlation was seen in primary serous OvCa tumors between Sp1, YY1 and KIF14 expression, further evidence that these transcription factors are important players in KIF14 overexpression. Hypomethylation patterns were observed in primary serous OvCa tumors, suggesting a minor role for promoter methylation in the control of KIF14 gene expression. miRNA expression analysis determined that miR-93, miR-144 and miR-382 had significantly lower levels of expression in primary serous OvCa tumors than normal tissues; treatment of an OvCa cell line with miRNA mimics and inhibitors specifically modulated KIF14 mRNA levels, pointing to potential novel mechanisms of KIF14 overexpression in primary tumors. Our findings reveal multiple mechanisms of KIF14 upregulation in cancer cells, offering new targets for therapeutic interventions to reduce KIF14 in tumors, aiming at improved prognosis.
C1 [Theriault, Brigitte L.; Lim, Harvey; Pajovic, Sanja; Gallie, Brenda L.] Princess Margaret Canc Ctr, Campbell Family Canc Res Inst, Toronto, ON, Canada.
   [Basavarajappa, Halesha D.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Ophthalmol, Eugene & Marilyn Glick Eye Inst, Indianapolis, IN 46202 USA.
   [Basavarajappa, Halesha D.; Corson, Timothy W.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
   [Lim, Harvey; Gallie, Brenda L.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
   [Gallie, Brenda L.] Toronto Western Hosp, Res Inst, Div Visual Sci, Toronto, ON M5T 2S8, Canada.
   [Gallie, Brenda L.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada.
   [Gallie, Brenda L.] Univ Toronto, Dept Ophthalmol, Toronto, ON M5S 1A1, Canada.
   [Corson, Timothy W.] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; Indiana University System; Indiana University
   Bloomington; Indiana University System; Indiana University Bloomington;
   University of Toronto; University of Toronto; University Health Network
   Toronto; University of Toronto; University of Toronto; Indiana
   University System; Indiana University Indianapolis
RP Gallie, BL (通讯作者)，Princess Margaret Canc Ctr, Campbell Family Canc Res Inst, Toronto, ON, Canada.
EM brenda@gallie.ca; tcorson@iupui.edu
RI Basavarajappa, Halesha/V-2038-2019; Corson, Timothy/B-6851-2009
OI Corson, Timothy/0000-0002-1402-7875; BASAVARAJAPPA,
   HALESHA/0000-0002-2840-5937; Gallie, Brenda/0000-0002-9697-9211
FU U.S. Department of Defence [OC080083]; Marsha Rivkin Ovarian Cancer
   Center Scientific Scholar Award; Indiana Clinical and Translational
   Sciences Institute; United States National Institutes of Health,
   National Center for Advancing Translational Sciences, Clinical and
   Translational Sciences Award [TR000163]
FX This work was funded by the U.S. Department of Defence Career
   Development Award; grant #OC080083, and the Marsha Rivkin Ovarian Cancer
   Center Scientific Scholar Award. This work was also supported in part by
   the Indiana Clinical and Translational Sciences Institute funded, in
   part by the United States National Institutes of Health, National Center
   for Advancing Translational Sciences, Clinical and Translational
   Sciences Award (TR000163; TWC). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ahmed SM, 2012, J CELL BIOL, V199, P951, DOI 10.1083/jcb.201206051
   Austen M, 1997, J BIOL CHEM, V272, P1709, DOI 10.1074/jbc.272.3.1709
   Bijron Jonathan G, 2012, Expert Opin Med Diagn, V6, P421, DOI 10.1517/17530059.2012.702105
   Bowles E, 2007, GENE CHROMOSOME CANC, V46, P118, DOI 10.1002/gcc.20383
   Campbell MJ, 2013, ADV EXP MED BIOL, V754, P81, DOI 10.1007/978-1-4419-9967-2_4
   Carleton M, 2006, MOL CELL BIOL, V26, P3853, DOI 10.1128/MCB.26.10.3853-3863.2006
   Chiang YC, 2013, ENDOCR-RELAT CANCER, V20, P213, DOI 10.1530/ERC-12-0117
   Chuang JY, 2009, INT J CANCER, V125, P2066, DOI 10.1002/ijc.24563
   Ciocca DR, 2013, ARCH TOXICOL, V87, P19, DOI 10.1007/s00204-012-0918-z
   Corson TW, 2007, CLIN CANCER RES, V13, P3229, DOI 10.1158/1078-0432.CCR-07-0393
   Corson TW, 2006, INT J CANCER, V119, P1088, DOI 10.1002/ijc.21954
   Corson TW, 2005, ONCOGENE, V24, P4741, DOI 10.1038/sj.onc.1208641
   Davie JR, 2008, ADV ENZYME REGUL, V48, P189, DOI 10.1016/j.advenzreg.2007.11.016
   Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511
   Dimaras H, 2008, HUM MOL GENET, V17, P1363, DOI 10.1093/hmg/ddn024
   Ehrlichova M, 2013, GENOMICS, V102, P96, DOI 10.1016/j.ygeno.2013.03.005
   Filges I, 2013, CLIN GENET
   Fu X, 2012, FEBS LETT, V586, P1279, DOI 10.1016/j.febslet.2012.03.006
   Gruneberg U, 2006, J CELL BIOL, V172, P363, DOI 10.1083/jcb.200511061
   Healy NA, 2012, INT J CANCER, V131, P2215, DOI 10.1002/ijc.27642
   Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
   Ho CM, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-53
   Iwaya T, 2012, CARCINOGENESIS, V33, P2391, DOI 10.1093/carcin/bgs288
   Joung JG, 2013, J AM MED INFORM ASS
   Jun DY, 2008, BBA-GENE REGUL MECH, V1779, P356, DOI 10.1016/j.bbagrm.2008.03.013
   Kim SW, 2007, GENE CHROMOSOME CANC, V46, P1, DOI 10.1002/gcc.20384
   Kim TM, 2008, INT J CANCER, V123, P2808, DOI 10.1002/ijc.23901
   Kong LM, 2010, CANCER SCI, V101, P1463, DOI 10.1111/j.1349-7006.2010.01554.x
   Li L, 2010, ANN ANAT, V192, P275, DOI 10.1016/j.aanat.2010.07.010
   Madhavan J, 2009, MOL VIS, V15, P235
   Malek A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035130
   Markowski J, 2009, J PHYSIOL PHARMACOL, V60, P57
   Markowski J, 2009, EUR ARCH OTO-RHINO-L, V266, P1501, DOI 10.1007/s00405-009-1019-3
   Previdi S, 2010, GYNECOL ONCOL, V118, P182, DOI 10.1016/j.ygyno.2010.03.020
   Renna M, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703778200
   Sarver AL, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-7
   SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0
   Shepherd TG, 2006, NAT PROTOC, V1, P2643, DOI 10.1038/nprot.2006.328
   Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010
   Sriraksa R, 2010, CLIN BIOCHEM, V43, P528, DOI 10.1016/j.clinbiochem.2009.11.005
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Szponar A, 2009, INT J CANCER, V124, P2071, DOI 10.1002/ijc.24180
   Theriault BL, 2012, ATLAS GENETICS CYTOG
   Thériault BL, 2012, INT J CANCER, V130, P1844, DOI 10.1002/ijc.26189
   Thorsen SB, 2012, CANCER J, V18, P275, DOI 10.1097/PPO.0b013e318258b5d6
   Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571
   Wang Q, 2013, CANCER EPIDEMIOL, V37, P79, DOI 10.1016/j.canep.2012.08.011
   Wang YQ, 2013, J OBSTET GYNAECOL RE, V39, P549, DOI 10.1111/j.1447-0756.2012.01979.x
   Yang T, 2013, CANCER SCI, V104, P552, DOI 10.1111/cas.12128
   Yu H, 2010, MOL CELL BIOL, V30, P5071, DOI 10.1128/MCB.00396-10
   Zaman MS, 2012, J OVARIAN RES, V5, DOI 10.1186/1757-2215-5-44
   Zhang Qiang, 2011, Critical Reviews in Oncogenesis, V16, P163
   ZHOU QJ, 1995, J VIROL, V69, P4323, DOI 10.1128/JVI.69.7.4323-4330.1995
NR 54
TC 27
Z9 32
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 13
PY 2014
VL 9
IS 3
AR e91540
DI 10.1371/journal.pone.0091540
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC9JS
UT WOS:000332851300102
PM 24626475
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Fröhlich, LF
   Mrakovcic, M
   Smole, C
   Lahiri, P
   Zatloukal, K
AF Froehlich, Leopold F.
   Mrakovcic, Maria
   Smole, Claudia
   Lahiri, Pooja
   Zatloukal, Kurt
TI Epigenetic Silencing of Apoptosis-Inducing Gene Expression Can Be
   Efficiently Overcome by Combined SAHA and TRAIL Treatment in Uterine
   Sarcoma Cells
SO PLOS ONE
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID;
   BREAST-CANCER CELLS; HDAC INHIBITORS; COMMON HALLMARK; OVARIAN-CANCER;
   CASPASE 8; RESISTANCE; DEATH; APO2L/TRAIL
AB The lack of knowledge about molecular pathology of uterine sarcomas with a representation of 3-7% of all malignant uterine tumors prevents the establishment of effective therapy protocols. Here, we explored advanced therapeutic options to the previously discovered antitumorigenic effects of the histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) by combined treatment with the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo-2L). In addition, we investigated the uterine sarcoma cell lines, MES-SA and ESS-1, regarding the underlying molecular mechanisms of SAHA and TRAIL-induced apoptosis and their resistance towards TRAIL. Compared to single SAHA or TRAIL treatment, the combination of SAHA with TRAIL led to complete cell death of both tumor cell lines after 24 to 48 hours. In contrast to single SAHA treatment, apoptosis occured faster and was more pronounced in ESS-1 cells than in MES-SA cells. Induction of SAHA-and TRAIL-induced apoptosis was accompanied by upregulation of the intrinsic apoptotic pathway via reduction of mitochondrial membrane potential, caspase-3, -6, and -7 activation, and PARP cleavage, but was also found to be partially caspase-independent. Apoptosis resistance was caused by reduced expression of caspase-8 and DR 4/TRAIL-R1 in ESS-1 and MES-SA cells, respectively, due to epigenetic silencing by DNA hypermethylation of gene promoter sequences. Treatment with the demethylating agent 5-Aza-2'-deoxycytidine or gene transfer therefore restored gene expression and increased the sensitivity of both cell lines against TRAIL-induced apoptosis. Our data provide evidence that deregulation of epigenetic silencing by histone acetylation and DNA hypermethylation might play a fundamental role in the origin of uterine sarcomas. Therefore, tumor growth might be efficiently overcome by a cytotoxic combinatorial treatment of HDAC inhibitors with TRAIL.
C1 [Froehlich, Leopold F.; Smole, Claudia; Lahiri, Pooja; Zatloukal, Kurt] Med Univ Graz, Mol Pathol Lab, Graz, Austria.
   [Mrakovcic, Maria] Med Univ Graz, Med Res Ctr, Graz, Austria.
C3 Medical University of Graz; Medical University of Graz
RP Fröhlich, LF (通讯作者)，Med Univ Graz, Mol Pathol Lab, Graz, Austria.
EM leopold.froehlich@medunigraz.at
RI Lahiri, Pooja/AAE-6663-2019
OI Lahiri, Pooja/0000-0002-6305-9451
FU Lore Saldow Research Fund
FX This work was supported by the Lore Saldow Research Fund. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Bae SI, 2008, ONCOGENE, V27, P490, DOI 10.1038/sj.onc.1210655
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Butler LM, 2006, INT J CANCER, V119, P944, DOI 10.1002/ijc.21939
   Carlisi D, 2009, EUR J CANCER, V45, P2425, DOI 10.1016/j.ejca.2009.06.024
   Cichorek M, 2008, DERMATOLOGIA ESTETYC, V10, P1
   Cowling V, 2002, CELL DEATH DIFFER, V9, P1046, DOI 10.1038/sj.cdd.4401065
   D'Angelo E, 2010, GYNECOL ONCOL, V116, P131, DOI 10.1016/j.ygyno.2009.09.023
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Elias A, 2009, CLIN CANCER RES, V15, P5457, DOI 10.1158/1078-0432.CCR-09-1125
   Fandy TE, 2005, NEOPLASIA, V7, P646, DOI 10.1593/neo.04655
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Frew AJ, 2008, P NATL ACAD SCI USA, V105, P11317, DOI 10.1073/pnas.0801868105
   Frew AJ, 2009, CANCER LETT, V280, P125, DOI 10.1016/j.canlet.2009.02.042
   Fröhlich LF, 2007, ENDOCRINOLOGY, V148, P2925, DOI 10.1210/en.2006-1298
   FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827
   Fulda S, 2001, ONCOGENE, V20, P5865, DOI 10.1038/sj.onc.1204750
   Fulda S, 2008, CURR CANCER DRUG TAR, V8, P132, DOI 10.2174/156800908783769355
   Gillenwater AM, 2007, MOL CANCER THER, V6, P2967, DOI 10.1158/1535-7163.MCT-04-0344
   Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309
   Gunawan B, 1998, INT J CANCER, V77, P424, DOI 10.1002/(SICI)1097-0215(19980729)77:3<424::AID-IJC19>3.0.CO;2-7
   Harada K, 2002, CANCER RES, V62, P5897
   HARKER WG, 1983, CANCER RES, V43, P4943
   Horak P, 2005, MOL CANCER RES, V3, P335, DOI 10.1158/1541-7786.MCR-04-0136
   Hrzenjak A, 2008, J PATHOL, V216, P495, DOI 10.1002/path.2434
   Hrzenjak A, 2006, MOL CANCER THER, V5, P2203, DOI 10.1158/1535-7163.MCT-05-0480
   Hrzenjak A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-49
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Kaminskyy VO, 2011, CARCINOGENESIS, V32, P1450, DOI 10.1093/carcin/bgr135
   Krikun G, 2004, ENDOCRINOLOGY, V145, P2291, DOI 10.1210/en.2003-1606
   Kubota T, 1997, NAT GENET, V16, P16, DOI 10.1038/ng0597-16
   Lakshmikanthan V, 2006, INT J CANCER, V119, P221, DOI 10.1002/ijc.21824
   Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397
   LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187
   Li H, 2007, P NATL ACAD SCI USA, V104, P20001, DOI 10.1073/pnas.0709986104
   Lillehammer T, 2007, J GENE MED, V9, P440, DOI 10.1002/jgm.1036
   Lin JQ, 2006, BIOCHEM BIOPH RES CO, V346, P1136, DOI 10.1016/j.bbrc.2006.05.209
   Lubieniecka JM, 2008, CANCER RES, V68, P4303, DOI 10.1158/0008-5472.CAN-08-0092
   MAJOR FJ, 1993, CANCER-AM CANCER SOC, V71, P1702, DOI 10.1002/cncr.2820710440
   Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247
   Martinez R, 2007, CARCINOGENESIS, V28, P1264, DOI 10.1093/carcin/bgm014
   Mrakovcic M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056791
   Nakata S, 2004, ONCOGENE, V23, P6261, DOI 10.1038/sj.onc.1207830
   Oliver FJ, 1998, J BIOL CHEM, V273, P33533, DOI 10.1074/jbc.273.50.33533
   Reichardt P, 2012, ANN ONCOL, V23, P151, DOI 10.1093/annonc/mds359
   Ropero S, 2007, MOL ONCOL, V1, P19, DOI 10.1016/j.molonc.2007.01.001
   Shivapurkar N, 2002, CANCER BIOL THER, V1, P65, DOI 10.4161/cbt.1.1.45
   Sonnemann J, 2007, J CANCER RES CLIN, V133, P847, DOI 10.1007/s00432-007-0227-8
   Sung ES, 2010, APOPTOSIS, V15, P1256, DOI 10.1007/s10495-010-0521-9
   Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135
   Tavassoli F.A., 2003, WHO CLASSIFICATION P, P233
   Teitz T, 2000, NAT MED, V6, P529, DOI 10.1038/75007
   Tomek S, 2004, GYNECOL ONCOL, V94, P107, DOI 10.1016/j.ygyno.2004.04.012
   VALERIOTE F, 1975, CANCER CHEMOTH REP 1, V59, P895
   Wagner JM, 2010, CLIN EPIGENETICS, V1, DOI 10.1007/s13148-010-0012-4
   Wiegmans AP, 2011, CANCER RES, V71, P3603, DOI 10.1158/0008-5472.CAN-10-3289
   Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-32
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
NR 57
TC 20
Z9 23
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 11
PY 2014
VL 9
IS 3
AR e91558
DI 10.1371/journal.pone.0091558
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC9GM
UT WOS:000332842400105
PM 24618889
OA gold, Green Submitted, Green Published
DA 2025-01-12
ER

PT J
AU Yahia, ZA
   Adam, AAM
   Elgizouli, M
   Hussein, A
   Masri, MA
   Kamal, M
   Mohamed, HS
   Alzaki, K
   Elhassan, AM
   Hamad, K
   Ibrahim, ME
AF Yahia, Zeinab A.
   Adam, Ameera A. M.
   Elgizouli, Magdeldin
   Hussein, Ayman
   Masri, Mai A.
   Kamal, Mayada
   Mohamed, Hiba S.
   Alzaki, Kamal
   Elhassan, Ahmed M.
   Hamad, Kamal
   Ibrahim, Muntaser E.
TI Epstein Barr virus: a prime candidate of breast cancer aetiology in
   Sudanese patients
SO INFECTIOUS AGENTS AND CANCER
LA English
DT Article
DE Sudan; Epstein Barr virus (EBV); Breast cancer; DNA methylation
ID NASOPHARYNGEAL CARCINOMA; P53; DNA; EBV; METHYLATION; INFECTION;
   FREQUENCY; TUMORS; GENES
AB Breast cancer is the commonest cancer in Sudanese women. Reported genetic alterations in the form of mutations in tumor suppressors are low in frequencies and could not explain the peculiarities of the diseases including its focal nature. Potential contributors disease aetiology include oncogenic viruses such as Epstein-Barr virus (EBV), an established culprit of nasopharyngeal carcinoma, one of the most frequent cancers in Sudan.
   In this study, DNA was extracted from malignant tissue samples and healthy tumour-free tissue from the same breast. Polymerase chain Reaction (PCR) was used to amplify two genes encoding for EBV viral proteins. The presence of Epstein-Barr virus and its cellular localization was confirmed by in situ hybridization (ISH) for Epstein-Barr encoded small RNAs (EBERs). Given the reported low frequency of mutations in BRCA1 and BRCA2 in Sudanese breast cancer patients, the methylation status of six tumor suppressor genes was investigated using methylation specific PCR. EBV genome was detected in 55.5% (n = 90) of breast cancer tissues as compared to 23% in control tissue samples (p = 0.0001).
   Using ISH, EBV signal was detected in all 18 breast cancer biopsies examined while all five normal breast tissue biopsies tested were negative for EBV. Of six tumour suppressor genes investigated BRCA1, BRCA2, and p14 appeared to be under strong epigenetic silencing.
   In conclusion, we present evidence of a strong association between EBV and breast carcinoma in Sudanese patients, and considerable epigenetic silencing of tumor suppressors that may likely be an outcome or an association with viral oncogenesis.
C1 [Yahia, Zeinab A.; Adam, Ameera A. M.; Elgizouli, Magdeldin; Hussein, Ayman; Masri, Mai A.; Kamal, Mayada; Mohamed, Hiba S.; Elhassan, Ahmed M.; Ibrahim, Muntaser E.] Univ Khartoum, Unit Dis & Div, Inst Endem Dis IEND, Khartoum, Sudan.
   [Alzaki, Kamal; Hamad, Kamal] Univ Khartoum, Fac Med, Khartoum, Sudan.
C3 University of Khartoum; University of Khartoum
RP Ibrahim, ME (通讯作者)，Univ Khartoum, Unit Dis & Div, Inst Endem Dis IEND, Med Campus,POB 102, Khartoum, Sudan.
EM mibrahim@iend.org
RI Ibrahim, Mohammed/LYO-3356-2024; Ahmed, Mohamed/KWU-1585-2024;
   Elgizouli, Magdeldin/ABA-5108-2020
OI Elgizouli, Magdeldin/0000-0001-7424-4938; Mohamed Elhassan,
   Ahmed/0000-0003-0740-0499; Mohamed, Hiba/0000-0003-4227-0212
FU International Agency of Genetic Engineering and Biotechnology (ICGEB)
   [CRP/SUD/10-01]
FX This work received financial support from the International Agency of
   Genetic Engineering and Biotechnology (ICGEB). Project CRP/SUD/10-01).
CR Abdullah Nazik E, 2011, Clin Med Insights Ear Nose Throat, V4, P5, DOI 10.4137/CMENT.S5825
   Abuidris DO, 2008, SAUDI MED J, V29, P962
   Arvey A, 2012, CELL HOST MICROBE, V12, P233, DOI 10.1016/j.chom.2012.06.008
   Benchimol S, BASIC SCI ONCOLOGY 1, P77
   Bereir REH, 2003, GENETICA, V119, P57, DOI 10.1023/A:1024486716497
   Bonnet M, 1999, J NATL CANCER I, V91, P1376, DOI 10.1093/jnci/91.16.1376
   Brink AATP, 2000, J NATL CANCER I, V92, P655, DOI 10.1093/jnci/92.8.655
   Cohen JI, 2000, NEW ENGL J MED, V343, P481, DOI 10.1056/NEJM200008173430707
   Eltahir HA, 2012, MOL BIOL REP, V39, P10833, DOI 10.1007/s11033-012-1978-0
   Eltahir HA, 2012, MOL MED REP, V6, P473, DOI 10.3892/mmr.2012.942
   Esteller M, 2000, CANCER RES, V60, P129
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Fina F, 2001, BRIT J CANCER, V84, P783, DOI 10.1054/bjoc.2000.1672
   GAFFEY MJ, 1993, MODERN PATHOL, V6, P721
   GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0
   Grinstein S, 2002, CANCER RES, V62, P4876
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HIDAYATALLA A, 1983, EUR J CANCER CLIN ON, V19, P705, DOI 10.1016/0277-5379(83)90001-9
   HORIUCHI K, 1994, J CLIN PATHOL, V47, P538, DOI 10.1136/jcp.47.6.538
   Iamaroon A, 2003, ORAL DIS, V9, P14, DOI 10.1034/j.1601-0825.2003.01808.x
   Ishii H, 1997, INT J EXP PATHOL, V78, P123, DOI 10.1046/j.1365-2613.1997.170350.x
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Joshi D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008180
   Khairy GA, 2005, SAUDI MED J, V26, P612
   LABRECQUE LG, 1995, CANCER RES, V55, P39
   Lawson James S, 2010, Cancers (Basel), V2, P752, DOI 10.3390/cancers2020752
   LUQMANI YA, 1995, INT J ONCOL, V6, P899
   Masri MA, 2002, BREAST CANCER RES TR, V71, P145, DOI 10.1023/A:1013807830329
   Mauser A, 2002, J VIROL, V76, P12503, DOI 10.1128/JVI.76.24.12503-12512.2002
   McCall SA, 2001, JNCI-J NATL CANCER I, V93, P148, DOI 10.1093/jnci/93.2.148
   NIEDOBITEK G, 1994, LANCET, V343, P333, DOI 10.1016/S0140-6736(94)91167-3
   Ryan Julie L, 2010, Infect Agent Cancer, V5, P27, DOI 10.1186/1750-9378-5-27
   Thomas M, 1996, ONCOGENE, V13, P471
   Xia L, 2012, GASTROENT RES PRACT, V17, P1
   Xue SA, 2003, BRIT J CANCER, V89, P113, DOI 10.1038/sj.bjc.6601027
   ZURHAUSE.H, 1970, NATURE, V228, P1056, DOI 10.1038/2281056a0
NR 37
TC 48
Z9 49
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-9378
J9 INFECT AGENTS CANCER
JI Infect. Agents Cancer
PD MAR 7
PY 2014
VL 9
AR 9
DI 10.1186/1750-9378-9-9
PG 5
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA AD3SN
UT WOS:000333166500001
PM 24607238
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU De Summa, S
   Pinto, R
   Pilato, B
   Sambiasi, D
   Porcelli, L
   Guida, G
   Mattioli, E
   Paradiso, A
   Merla, G
   Micale, L
   De Nittis, P
   Tommasi, S
AF De Summa, S.
   Pinto, R.
   Pilato, B.
   Sambiasi, D.
   Porcelli, L.
   Guida, G.
   Mattioli, E.
   Paradiso, A.
   Merla, G.
   Micale, L.
   De Nittis, P.
   Tommasi, S.
TI Expression of base excision repair key factors and miR17 in familial and
   sporadic breast cancer
SO CELL DEATH & DISEASE
LA English
DT Article
DE base excision repair; APEX1/REF1; PARP1; miR17; XRCC1; familial breast
   cancer
ID POLY(ADP-RIBOSE) POLYMERASE; COLON-CANCER; DNA-DAMAGE; CELL-LINES;
   BRCA1; ENDONUCLEASE; XRCC1; IDENTIFICATION; INHIBITION; MODELS
AB Understanding of BRCA1/2 interaction with the base excision repair (BER) pathway could improve therapy based on 'synthetic lethality', whose effectiveness is based on homologous recombination deficiency in cells lacking functional BRCA genes. However, poly (ADP-ribose) polymerase (PARP) inhibitors failed in some patients and for this reason we explored BER key enzyme expression. In this study, the expression of BER enzymes (redox factor 1/apurinic-apyrimidinic endonuclease 1 (REF1/ APEX1), NTH endonuclease III-like 1 (NTHL1), 8-oxoguanine DNA glycosylase (OGG1), PARP1) and of the scaffold protein XRCC1 (X-ray repair complementing defective repair in Chinese hamster cells 1) were investigated in familial (BRCA-related and not) and sporadic breast cancer cases. Furthermore, miR17 expression was measured because of its role in the epigenetic regulation of BRCA1. Gene expression was evaluated in BRCA1-mutated cell lines, SUM149PT and SUM1315MO2, and in a BRCA1-proficient triple-negative MDA-MB-231 cell line. A cohort of 27 familial and 16 sporadic breast cancer patients was then examined to confirm results obtained from the cell line model. APEX1/REF1 was found to be upregulated in familial BRCA-wild-type and sporadic cases, indicating this enzyme as a potential therapeutic target. Furthermore, XRCC1 was overexpressed in BRCAX patients; consequently, we suggest to test the effectiveness of inhibitors targeting two different BER components in preclinical studies. XRCC1, which is also involved in the non-homologous end-joining pathway, was found to be downregulated in BRCA2related patients concurrently with no change in PARP1 expression. Interestingly, no difference in PARP1 and miR17 expression was found in BRCA-related and sporadic breast cancer cases. PARP1 and miR17 could therefore be further investigated as molecular biomarkers of 'BRCAness' phenotype, indicating patients which could really benefit from PARP inhibitor therapies.
C1 [De Summa, S.; Pinto, R.; Pilato, B.; Sambiasi, D.; Tommasi, S.] Ist Tumori Giovanni Paolo II, Natl Canc Res Ctr, Mol Genet Lab, I-70124 Bari, Italy.
   [Porcelli, L.] Ist Tumori Giovanni Paolo II, Natl Canc Res Ctr, Preclin & Clin Pharmacol Lab, I-70124 Bari, Italy.
   [Guida, G.] Univ Bari, Sch Med, Dept Med Biochem Med Biol & Med Phys, Bari, Italy.
   [Mattioli, E.] Ist Tumori Giovanni Paolo II, Natl Canc Res Ctr, Anatomopathol Unit, I-70124 Bari, Italy.
   [Paradiso, A.] Ist Tumori Giovanni Paolo II, Natl Canc Res Ctr, Expt Med Oncol Unit, I-70124 Bari, Italy.
   [Merla, G.; Micale, L.; De Nittis, P.] IRCCS Casa Sollievo Sofferenza, Med Genet Unit, San Giovanni Rotondo, Italy.
C3 Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica
   Molecolare (IGM-CNR); IRCCS Istituto Tumori Bari Giovanni Paolo II;
   IRCCS Istituto Tumori Bari Giovanni Paolo II; Universita degli Studi di
   Bari Aldo Moro; IRCCS Istituto Tumori Bari Giovanni Paolo II; IRCCS
   Istituto Tumori Bari Giovanni Paolo II; IRCCS Casa Sollievo Della
   Sofferenza
RP Tommasi, S (通讯作者)，Ist Tumori Giovanni Paolo II, Natl Canc Res Ctr, Mol Genet Lab, Vle Orazio Flacco 65, I-70124 Bari, Italy.
EM s.tommasi@oncologico.bari.it
RI paradiso, angelo/J-9457-2018; merla, giuseppe/K-4627-2012; Mattioli,
   Eliseo/AAC-5018-2022; Micale, Lucia/K-3909-2016; porcelli,
   letizia/AAC-5939-2020; De Nittis, Pasquelena/AAL-8306-2020; Pilato,
   Brunella/AAH-7365-2020; De Summa, Simona/K-2582-2018; Tommasi,
   Stefania/J-6732-2012
OI Guida, Gabriella/0000-0003-2345-2838; De Summa,
   Simona/0000-0001-9607-3754; pilato, brunella/0000-0001-6067-3977; De
   Nittis, Pasquelena/0000-0001-7144-8425; merla,
   giuseppe/0000-0001-5078-928X; Micale, Lucia/0000-0003-3604-194X;
   Porcelli, Letizia/0000-0003-0175-9716; Tommasi,
   Stefania/0000-0002-2157-2978
FU Regione Puglia; Ministry of Health
FX We thank Caroline Oakley for manuscript revision. This work was
   partially funded by Regione Puglia (DIEF 2011) and by RF 2008 Ministry
   of Health.
CR Abbott DW, 1998, J NATL CANCER I, V90, P978, DOI 10.1093/jnci/90.13.978
   Alli E, 2009, CANCER RES, V69, P3589, DOI 10.1158/0008-5472.CAN-08-4016
   BARZILAY G, 1995, NUCLEIC ACIDS RES, V23, P1544, DOI 10.1093/nar/23.9.1544
   Bielas JH, 2006, P NATL ACAD SCI USA, V103, P18238, DOI 10.1073/pnas.0607057103
   Bobola MS, 2001, CLIN CANCER RES, V7, P3510
   Bogliolo M, 2000, ONCOGENE, V19, P5781, DOI 10.1038/sj.onc.1203951
   Chacón RD, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2574
   Chuang HC, 2012, BREAST CANCER RES TR, V134, P649, DOI 10.1007/s10549-012-2106-5
   Dibiase SJ, 2000, CANCER RES, V60, P1245
   Fishel ML, 2007, CLIN CANCER RES, V13, P260, DOI 10.1158/1078-0432.CCR-06-1920
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Gonçalves A, 2011, BREAST CANCER RES TR, V127, P273, DOI 10.1007/s10549-010-1199-y
   Grigoriadis A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-619
   Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953
   Kerr P, 2001, CURR BIOL, V11, pR668, DOI 10.1016/S0960-9822(01)00389-X
   Koukourakis MI, 2001, INT J RADIAT ONCOL, V50, P27, DOI 10.1016/S0360-3016(00)01561-3
   Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148-011-0040-8
   Ladiges WC, 2006, ONCOGENE, V25, P1612, DOI 10.1038/sj.onc.1209370
   Le Page F, 2000, CANCER RES, V60, P5548
   Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Liu LL, 2002, CLIN CANCER RES, V8, P2985
   Luo MH, 2004, ANTICANCER RES, V24, P2127
   Nazarkina ZK, 2007, BIOCHEMISTRY-MOSCOW+, V72, P878, DOI 10.1134/S000629790708010X
   Peasland A, 2011, BRIT J CANCER, V105, P372, DOI 10.1038/bjc.2011.243
   Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
   Puglisi F, 2001, ANTICANCER RES, V21, P4041
   Robertson KA, 2001, CANCER RES, V61, P2220
   Saha T, 2010, J BIOL CHEM, V285, P19092, DOI 10.1074/jbc.M110.104430
   Sultana R, 2013, CANCER RES, V73, P1621, DOI 10.1158/0008-5472.CAN-12-2929
   Taverna P, 2001, MUTAT RES-DNA REPAIR, V485, P269, DOI 10.1016/S0921-8777(01)00076-3
   Thomson B, 2001, J PEDIAT HEMATOL ONC, V23, P234, DOI 10.1097/00043426-200105000-00011
   Tommasi S, 2008, MUTAT RES-FUND MOL M, V644, P64, DOI 10.1016/j.mrfmmm.2008.07.005
   Turner NC, 2007, ONCOGENE, V26, P2126, DOI 10.1038/sj.onc.1210014
   Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3
   Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087
   Walsh T, 2006, JAMA-J AM MED ASSOC, V295, P1379, DOI 10.1001/jama.295.12.1379
   Wang HC, 2003, NUCLEIC ACIDS RES, V31, P5377, DOI 10.1093/nar/gkg728
   Wang Y, 2000, GENE DEV, V14, P927
   Weaver DA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-18
   Wu HH, 2013, ANN SURG ONCOL, V20, pS336, DOI 10.1245/s10434-012-2431-2
   Xu XR, 2009, BREAST CANCER RES TR, V115, P397, DOI 10.1007/s10549-008-0075-5
   Zhong Q, 2002, CANCER RES, V62, P3966
NR 43
TC 17
Z9 18
U1 0
U2 12
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD FEB
PY 2014
VL 5
AR e1076
DI 10.1038/cddis.2014.30
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AC0ZJ
UT WOS:000332223700033
PM 24556691
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Sandhu, R
   Rivenbark, AG
   Mackler, RM
   Livasy, CA
   Coleman, WB
AF Sandhu, Rupninder
   Rivenbark, Ashley G.
   Mackler, Randi M.
   Livasy, Chad A.
   Coleman, William B.
TI Dysregulation of microRNA expression drives aberrant DNA
   hypermethylation in basal-like breast cancer
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE primary breast cancers; epigenetic silencing; microRNA; basal-like
   breast cancers; aberrant DNA hypermethylation
ID LUNG-CANCER; METHYLATION; METHYLTRANSFERASES; 3B; 3A; HYPOMETHYLATION;
   DNMT3B; TUMORS; OVEREXPRESSION; EPIGENETICS
AB Basal-like breast cancers frequently express aberrant DNA hypermethylation associated with concurrent silencing of specific genes secondary to DNMT3b overexpression and DNMT hyperactivity. DNMT3b is known to be post-transcriptionally regulated by microRNAs. The objective of the current study was to determine the role of microRNA dysregulation in the molecular mechanism governing DNMT3b overexpression in primary breast cancers that express aberrant DNA hypermethylation. The expression of microRNAs (miRs) that regulate (miR-29a, miR-29b, miR-29c, miR-148a and miR-148b) or are predicted to regulate DNMT3b (miR-26a, miR-26b, miR-203 and miR-222) were evaluated among 70 primary breast cancers (36 luminal A-like, 13 luminal B-like, 5 HER2-enriched, 16 basal-like) and 18 normal mammoplasty tissues. Significantly reduced expression of miR-29c distinguished basal-like breast cancers from other breast cancer molecular subtypes. The expression of aberrant DNA hypermethylation was determined in a subset of 33 breast cancers (6 luminal A-like, 6 luminal B-like, 5 HER2-enriched and 16 basal-like) through examination of methylation-sensitive biomarker gene expression (CEACAM6, CDH1, CST6, ESR1, GNA11, MUC1, MYB, TFF3 and SCNN1A), 11/33 (33%) cancers exhibited aberrant DNA hypermethylation including 9/16 (56%) basal-like cancers, but only 2/17 (12%) non-basal-like cancers (luminal A-like, n=1; HER2-enriched, n=1). Breast cancers with aberrant DNA hypermethylation express diminished levels of miR-29a, miR-29b, miR-26a, miR-26b, miR-148a and miR-148b compared to cancers lacking aberrant DNA hypermethylation. A total of 7/9 (78%) basal-like breast cancers with aberrant DNA hypermethylation exhibit diminished levels of >= 6 regulatory miRs. The results show that i) reduced expression of miR-29c is characteristic of basal-like breast cancers, ii) miR and methylation-sensitive gene expression patterns identify two subsets of basal-like breast cancers, and iii) the subset of basal-like breast cancers with reduced expression of multiple regulatory miRs express aberrant DNA hypermethylation. Together, these findings strongly suggest that the molecular mechanism governing the DNMT3b-mediated aberrant DNA hypermethylation in primary breast cancer involves the loss of post-transcriptional regulation of DNMT3b by regulatory miRs.
C1 [Sandhu, Rupninder; Rivenbark, Ashley G.; Mackler, Randi M.; Livasy, Chad A.; Coleman, William B.] Univ N Carolina, Dept Pathol & Lab Med, Sch Med, Chapel Hill, NC 27599 USA.
   [Sandhu, Rupninder; Coleman, William B.] Univ N Carolina, UNC Program Translat Med, Sch Med, Chapel Hill, NC 27599 USA.
   [Sandhu, Rupninder; Rivenbark, Ashley G.; Livasy, Chad A.; Coleman, William B.] Univ N Carolina, UNC Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA.
C3 University of North Carolina School of Medicine; University of North
   Carolina; University of North Carolina Chapel Hill; University of North
   Carolina School of Medicine; University of North Carolina; University of
   North Carolina Chapel Hill; University of North Carolina School of
   Medicine; University of North Carolina; University of North Carolina
   Chapel Hill
RP Coleman, WB (通讯作者)，Univ N Carolina, Dept Pathol & Lab Med, Sch Med, 515 Brinkhous Bullitt Bldg,CB 7525, Chapel Hill, NC 27599 USA.
EM wbcolemn@med.unc.edu
OI Kotlar, Randi/0000-0002-2513-6479
FU Susan G. Komen Breast Cancer Foundation [BCTR0100-575]; National Cancer
   Institute (NIH) [CA78343]; Friends for an Earlier Breast Cancer Test;
   UNC Lineberger Comprehensive Cancer Center; University Research Council;
   Medical Alumni Endowment Fund of the University of North Carolina at
   Chapel Hill
FX This study was supported by grants to W.B.C. from the Susan G. Komen
   Breast Cancer Foundation (BCTR0100-575), the National Cancer Institute
   (NIH grant CA78343), Friends for an Earlier Breast Cancer Test
   (Earlier.org), the UNC Lineberger Comprehensive Cancer Center, the
   University Research Council, and the Medical Alumni Endowment Fund of
   the University of North Carolina at Chapel Hill.
CR Ai LB, 2006, CANCER RES, V66, P7899, DOI 10.1158/0008-5472.CAN-06-0576
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Anand S, 2010, NAT MED, V16, P909, DOI 10.1038/nm.2186
   Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031
   Bartel B, 2005, NAT STRUCT MOL BIOL, V12, P569, DOI 10.1038/nsmb0705-569
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baylin S, 2001, Dev Biol (Basel), V106, P85
   Baylin SB, 1998, ADV CANCER RES, V72, P141
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995
   Carleton M, 2007, CELL CYCLE, V6, P2127, DOI 10.4161/cc.6.17.4641
   Corcoran C, 2011, CLIN CHEM, V57, P18, DOI 10.1373/clinchem.2010.150730
   Duursma AM, 2008, RNA, V14, P872, DOI 10.1261/rna.972008
   Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104
   FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6
   Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279
   Garzon R, 2008, BLOOD, V111, P3183, DOI 10.1182/blood-2007-07-098749
   Garzon R, 2009, ANNU REV MED, V60, P167, DOI [10.1146/annurev.med.59.053006.104707, 10.1146/annurev.pathol.4.110807.092222]
   Garzon R, 2009, BLOOD, V113, P6411, DOI 10.1182/blood-2008-07-170589
   Gaudet F, 2003, SCIENCE, V300, P489, DOI 10.1126/science.1083558
   Gaur A, 2007, CANCER RES, V67, P2456, DOI 10.1158/0008-5472.CAN-06-2698
   Giraldez AJ, 2006, SCIENCE, V312, P75, DOI 10.1126/science.1122689
   Girault I, 2003, CLIN CANCER RES, V9, P4415
   Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474
   Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jin F, 2005, GYNECOL ONCOL, V96, P531, DOI 10.1016/j.ygyno.2004.10.039
   Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947
   Kanai Y, 2007, CARCINOGENESIS, V28, P2434, DOI 10.1093/carcin/bgm206
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Lewis CM, 2005, CLIN CANCER RES, V11, P166
   Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528
   Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Melo SA, 2011, FEBS LETT, V585, P2087, DOI 10.1016/j.febslet.2010.08.009
   Miska EA, 2005, CURR OPIN GENET DEV, V15, P563, DOI 10.1016/j.gde.2005.08.005
   Mizuno S, 2001, BLOOD, V97, P1172, DOI 10.1182/blood.V97.5.1172
   Mott JL, 2007, ONCOGENE, V26, P6133, DOI 10.1038/sj.onc.1210436
   Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V
   Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220
   Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pillai RS, 2005, SCIENCE, V309, P1573, DOI 10.1126/science.1115079
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Sandhu R, 2012, INT J ONCOL, V41, P721, DOI 10.3892/ijo.2012.1505
   Sengupta S, 2008, P NATL ACAD SCI USA, V105, P5874, DOI 10.1073/pnas.0801130105
   Sevignani C, 2006, MAMM GENOME, V17, P189, DOI 10.1007/s00335-005-0066-3
   Shen LL, 2002, J NATL CANCER I, V94, P755, DOI 10.1093/jnci/94.10.755
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Toyota M, 1999, CANCER RES, V59, P5438
   Veeck J, 2010, J MAMMARY GLAND BIOL, V15, P5, DOI 10.1007/s10911-010-9165-1
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Wang Y, 2009, J CELL MOL MED, V13, P12, DOI 10.1111/j.1582-4934.2008.00510.x
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
NR 62
TC 63
Z9 69
U1 0
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD FEB
PY 2014
VL 44
IS 2
BP 563
EP 572
DI 10.3892/ijo.2013.2197
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AC7DM
UT WOS:000332687400025
PM 24297604
OA Green Submitted, Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Tu, CY
   Chen, CH
   Hsia, TC
   Hsu, MH
   Wei, YL
   Yu, MC
   Chen, WS
   Hsu, KW
   Yeh, MH
   Liu, LC
   Chen, YJ
   Huang, WC
AF Tu, Chih-Yen
   Chen, Chia-Hung
   Hsia, Te-Chun
   Hsu, Min-Hsiang
   Wei, Ya-Ling
   Yu, Meng-Chieh
   Chen, Wen-Shu
   Hsu, Ke-Wei
   Yeh, Ming-Hsin
   Liu, Liang-Chih
   Chen, Yun-Ju
   Huang, Wei-Chien
TI Trichostatin A Suppresses EGFR Expression through Induction of
   MicroRNA-7 in an HDAC-Independent Manner in Lapatinib-Treated Cells
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID DEACETYLASE INHIBITOR TRICHOSTATIN; BREAST-CANCER; ESTROGEN-RECEPTOR;
   PHASE-II; PLUS PACLITAXEL; GROWTH; DIFFERENTIATION; AMPLIFICATION;
   MONOTHERAPY; RESISTANCE
AB Lapatinib, a dual EGFR/HER2 tyrosine kinase inhibitor, has been shown to improve the survival rate of patients with advanced HER2-positive breast cancers. However, the off-target activity of lapatinib in inducing EGFR expression without tyrosine kinase activity was demonstrated to render HER2-negative breast cancer cells more metastatic, suggesting a limitation to the therapeutic effectiveness of this dual inhibitor in HER2-heterogeneous tumors. Therefore, targeting EGFR expression may be a feasible approach to improve the anticancer efficiency of lapatinib-based therapy. Inhibition of HDAC has been previously reported to epigenetically suppress EGFR protein expression. In this study, however, our data indicated that treatment with HDAC inhibitors trichostatin A (TSA), but not suberoylanilide hydroxamic acid (SAHA) or HDAC siRNA, can attenuate both protein and mRNA expressions of EGFR in lapatinib-treated triple-negative breast cancer cells, suggesting that TSA may suppress EGFR expression independently of HDAC inhibition. Nevertheless, TSA reduced EGFR 3 ' UTR activity and induced the gene expression of microRNA-7, a known EGFR-targeting microRNA. Furthermore, treatment with microRNA-7 inhibitor attenuated TSA-mediated EGFR suppression. These results suggest that TSA induced microRNA-7 expression to downregulate EGFR expression in an HDAC-independent manner.
C1 [Tu, Chih-Yen; Chen, Chia-Hung] China Med Univ & Hosp, Div Pulm & Crit Care Med, Taichung 404, Taiwan.
   [Tu, Chih-Yen; Chen, Chia-Hung; Hsia, Te-Chun; Yu, Meng-Chieh] China Med Univ & Hosp, Dept Internal Med, Taichung 404, Taiwan.
   [Tu, Chih-Yen; Liu, Liang-Chih] China Med Univ, Sch Med, Taichung 404, Taiwan.
   [Tu, Chih-Yen] Natl Chung Hsing Univ, Dept Life Sci, Taichung 402, Taiwan.
   [Chen, Chia-Hung; Hsia, Te-Chun] China Med Univ, Dept Resp Therapy, Taichung 404, Taiwan.
   [Chen, Chia-Hung] China Med Univ, Grad Inst Clin Med Sci, Taichung 404, Taiwan.
   [Hsu, Min-Hsiang; Yu, Meng-Chieh; Huang, Wei-Chien] China Med Univ, Grad Inst Canc Biol, Taichung 404, Taiwan.
   [Wei, Ya-Ling; Chen, Wen-Shu; Huang, Wei-Chien] China Med Univ & Hosp, Ctr Mol Med, Taichung 404, Taiwan.
   [Chen, Wen-Shu] Natl Taiwan Univ, Coll Med, Dept Pharmacol, Taipei 106, Taiwan.
   [Hsu, Ke-Wei] China Med Univ, Dept Biol Sci & Technol, Taichung 404, Taiwan.
   [Yeh, Ming-Hsin] China Med Univ & Hosp, Sect Breast Surg, Taichung 404, Taiwan.
   [Liu, Liang-Chih] China Med Univ & Hosp, Dept Surg, Taichung 404, Taiwan.
   [Chen, Yun-Ju] E Da Hosp, Dept Med Res, Kaohsiung 824, Taiwan.
   [Chen, Yun-Ju] I Shou Univ, Dept Biol Sci & Technol, Kaohsiung 824, Taiwan.
   [Huang, Wei-Chien] China Med Univ, PhD Program Canc Biol & Drug Discovery, Taichung 404, Taiwan.
   [Huang, Wei-Chien] Asia Univ, Dept Biotechnol, Taichung 413, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan; China Medical University Taiwan; National Chung Hsing
   University; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; National Taiwan
   University; China Medical University Taiwan; China Medical University
   Taiwan; China Medical University Hospital - Taiwan; China Medical
   University Taiwan; China Medical University Hospital - Taiwan; E-Da
   Hospital; I Shou University; China Medical University Taiwan; Asia
   University Taiwan
RP Chen, YJ (通讯作者)，E Da Hosp, Dept Med Res, Kaohsiung 824, Taiwan.
EM yjchen0326@isu.edu.tw; whuang@mail.cmu.edu.tw
RI Bau, Da-Tian/KWV-0302-2024; Huang, Wei-Chien/H-3126-2019; Lin,
   Yanting/HJI-4170-2023; Huang, Wei-Chien/D-1740-2012
OI Chen, Chia-Hung/0000-0003-1158-9722; Huang,
   Wei-Chien/0000-0001-6467-8716; Tu, Chih-Yen/0000-0002-8126-6171
FU E-Da Hospital [EDAHT100024, EDAHT100026]; National Science Council of
   Taiwan [NSC 102-2320-B-039-054-MY3, NSC 102-2320-B-039-052, NSC
   101-2911-I-002-303, NSC 101-2320-B-039-049]; China Medical University
   and Hospital [CMU102-S-12]; National Health Research Institutes of
   Taiwan [NHRI-EX103-10329BI]
FX This work was supported by Grants from E-Da Hospital (EDAHT100024,
   EDAHT100026), the National Science Council of Taiwan (NSC
   102-2320-B-039-054-MY3, NSC 102-2320-B-039-052, NSC 101-2911-I-002-303,
   and NSC 101-2320-B-039-049 to W.C.H), China Medical University and
   Hospital (CMU102-S-12 to C.-Y. Tu), and the National Health Research
   Institutes of Taiwan (NHRI-EX103-10329BI to W.-C. Huang).
CR Amir E, 2010, CANCER TREAT REV, V36, P410, DOI 10.1016/j.ctrv.2009.12.012
   Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133
   Bolleyn J, 2011, TOXICOL IN VITRO, V25, P1173, DOI 10.1016/j.tiv.2011.04.013
   Boussen H, 2010, J CLIN ONCOL, V28, P3248, DOI 10.1200/JCO.2009.21.8594
   Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574
   Burstein HJ, 2008, ANN ONCOL, V19, P1068, DOI 10.1093/annonc/mdm601
   Chen YJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3575
   Chen YJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/682380
   Chou C. W., 2011, PLOS ONE, V6
   Dhillon N, 2000, STUDY LAPATINIB COMB
   Downey L, 2010, CLIN CANCER RES, V16, P1281, DOI 10.1158/1078-0432.CCR-09-1643
   Finn RS, 2009, J CLIN ONCOL, V27, P5552, DOI 10.1200/JCO.2008.21.1763
   Finn RS, 2009, J CLIN ONCOL, V27, P3908, DOI 10.1200/JCO.2008.18.1925
   Frassoldati A, 2008, CLIN BREAST CANCER, V8, P97, DOI 10.3816/CBC.2008.n.010
   Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754
   Gilbert RE, 2011, KIDNEY INT, V79, P1312, DOI 10.1038/ki.2011.39
   Guy CT, 1996, J BIOL CHEM, V271, P7673, DOI 10.1074/jbc.271.13.7673
   Herbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041
   Hsia TC, 2013, MOL PHARMACOL, V83, P857, DOI 10.1124/mol.112.082743
   Huang WC, 2011, BIOMEDICINE-TAIWAN, V1, P2, DOI 10.1016/j.biomed.2011.10.001
   Huang WC, 2013, AM J TRANSL RES, V5, P441
   Huber K, 2011, J BIOL CHEM, V286, P22211, DOI 10.1074/jbc.M110.180224
   Humphreys KJ, 2013, MOL CARCINOGEN, V52, P459, DOI 10.1002/mc.21879
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Imesch P, 2009, INT J ONCOL, V35, P631, DOI 10.3892/ijo_00000375
   Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734
   Kim NH, 2011, BIOCHEM BIOPH RES CO, V404, P915, DOI 10.1016/j.bbrc.2010.12.081
   Leary AF, 2010, CLIN CANCER RES, V16, P1486, DOI 10.1158/1078-0432.CCR-09-1764
   Lei WW, 2010, INT J BIOCHEM CELL B, V42, P1489, DOI 10.1016/j.biocel.2010.05.006
   Li X, 2005, CELL, V123, P1267, DOI 10.1016/j.cell.2005.10.040
   Linares A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/856985
   Mayer IA, 2010, CLIN CANCER RES, V16, P1355, DOI 10.1158/1078-0432.CCR-09-3223
   Park SY, 2011, ONCOL REP, V25, P1677, DOI 10.3892/or.2011.1236
   Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103
   Rhodes LV, 2012, ONCOL REP, V27, P10, DOI 10.3892/or.2011.1488
   Richon VM, 1998, P NATL ACAD SCI USA, V95, P3003, DOI 10.1073/pnas.95.6.3003
   Rusnak DW, 2001, MOL CANCER THER, V1, P85
   Rusnak DW, 2001, CANCER RES, V61, P7196
   Saji S, 2005, ONCOGENE, V24, P4531, DOI 10.1038/sj.onc.1208646
   Sharma P., 2000, LAPATINIB WOMEN META
   Siziopikou KP, 2007, BREAST, V16, P104, DOI 10.1016/j.breast.2006.09.003
   Siziopikou KP, 2006, BREAST J, V12, P360, DOI 10.1111/j.1075-122X.2006.00276.x
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Toi M, 2009, BRIT J CANCER, V101, P1676, DOI 10.1038/sj.bjc.6605343
   Valenzuela-Fernández A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003
   Webster RJ, 2009, J BIOL CHEM, V284, P5731, DOI 10.1074/jbc.M804280200
   Zhao ZN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045133
   Zhou Q, 2009, BREAST CANCER RES TR, V117, P443, DOI 10.1007/s10549-008-0148-5
NR 49
TC 16
Z9 16
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PY 2014
VL 2014
AR 168949
DI 10.1155/2014/168949
PG 11
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA AC6JA
UT WOS:000332627100001
PM 24707474
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Ju, TZ
   Aryal, RP
   Kudelka, MR
   Wang, YC
   Cummings, RD
AF Ju, Tongzhong
   Aryal, Rajindra P.
   Kudelka, Matthew R.
   Wang, Yingchun
   Cummings, Richard D.
TI The <i>Cosmc</i> connection to the Tn antigen in cancer
SO CANCER BIOMARKERS
LA English
DT Article
DE Cosmc; T-synthase; Tn antigen; cancer
ID O-LINKED GLYCOSYLATION; N-ACETYLGALACTOSAMINYLTRANSFERASE 6;
   ACETYL-D-GALACTOSAMINE; ALPHA-D-GALACTOSAMINE; POLYPEPTIDE
   GALNAC-TRANSFERASES; THOMSEN-FRIEDENREICH ANTIGEN; SERUM SIALYL TN;
   BREAST-CANCER; SIALOSYL-TN; MONOCLONAL-ANTIBODY
AB The Tn antigen is a tumor-associated carbohydrate antigen that is not normally expressed in peripheral tissues or blood cells. Expression of this antigen, which is found in a majority of human carcinomas of all types, arises from a blockage in the normal O-glycosylation pathway in which glycans are extended from the common precursor GalNAc alpha 1-O-Ser/Thr (Tn antigen). This precursor is generated in the Golgi apparatus on newly synthesized glycoproteins by a family of polypeptide alpha-N-acetylgalactosaminyltransferases (ppGalNAcTs) and then extended to the common core 1 O-glycan Gal beta 1-3GalNAc alpha 1-O-Ser/Thr (T antigen) by a single enzyme termed the T-synthase (core 1 beta 3-galactosyltransferase or C1GalT). Formation of the active form of the T-synthase requires a unique molecular chaperone termed Cosmc, encoded by Cosmc on the X-chromosome (Xq24 in humans, Xc3 in mice). Cosmc resides in the endoplasmic reticulum (ER) and prevents misfolding, aggregation, and proteasome-dependent degradation of newly synthesized T-synthase. Loss of expression of active T-synthase or Cosmc can lead to expression of the Tn antigen, along with its sialylated version Sialyl Tn antigen as observed in several cancers. Both genetic and epigenetic pathways, in addition to potential metabolic regulation, can result in abnormal expression of the Tn antigen. Engineered expression of the Tn antigen by disruption of either C1GalT (T-syn) or Cosmc in mice is associated with a tremendous range of pathologies and engineered expression of the Tn antigen in mouse embryos leads to embryonic death. Studies indicate that many membrane glycoproteins expressing the Tn antigen and/or truncated O-glycans may be dysfunctional, due to degradation and/or misfolding. Thus, expression of normal O-glycans is associated with health and homeostasis whereas truncation of O-glycans, e.g. the Tn and/or Sialyl Tn antigens is associated with cancer and other pathologies.
C1 Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA.
   Emory Univ, Sch Med, Emory Glyc Ctr, Atlanta, GA 30322 USA.
C3 Emory University; Emory University
RP Cummings, RD (通讯作者)，Emory Univ, Sch Med, Dept Biochem, Rollins Res Ctr, 1510 Clifton Rd NE,Room 4001, Atlanta, GA 30322 USA.
EM rdcummi@emory.edu
RI Wang, Yifan/AAF-7282-2019
OI Aryal, Rajindra P/0000-0001-8718-636X; Ju, Tongzhong/0000-0002-4429-1976
FU NCI [U01CA168930]; NCI; NIGMS [R24 GM 098791-01]
FX The work by the authors was supported by NIH Grant U01CA168930 from the
   NCI to RDC and TJ and the general support of the NCI-sponsored Alliance
   of Glycobiologists for Detection of Cancer, and NIH Grant R24 GM
   098791-01 from the NIGMS to RDC for glycan microarray studies of
   antibodies to Oglycan determinants.
CR Abdel-Aal ABM, 2012, J MED CHEM, V55, P6968, DOI 10.1021/jm300822g
   Agnese DM, 2004, ANN SURG ONCOL, V11, P197, DOI 10.1245/ASO.2004.05.010
   Akita K, 2012, INT J GYNECOL CANCER, V22, P531, DOI 10.1097/IGC.0b013e3182473292
   Almaraz RT, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M112.017558
   Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770
   An GY, 2007, J EXP MED, V204, P1417, DOI 10.1084/jem.20061929
   Ando H, 2008, BIOL PHARM BULL, V31, P1739, DOI 10.1248/bpb.31.1739
   Aryal RP, 2012, J BIOL CHEM, V287, P15317, DOI 10.1074/jbc.M111.312587
   Aryal RP, 2010, J BIOL CHEM, V285, P2456, DOI 10.1074/jbc.M109.065169
   Avichezer D, 1997, INT J CANCER, V72, P119, DOI 10.1002/(SICI)1097-0215(19970703)72:1<119::AID-IJC17>3.3.CO;2-5
   Bennett EP, 2012, GLYCOBIOLOGY, V22, P736, DOI 10.1093/glycob/cwr182
   Berger EG, 1999, BBA-MOL BASIS DIS, V1455, P255, DOI 10.1016/S0925-4439(99)00069-1
   Berois N, 2006, J HISTOCHEM CYTOCHEM, V54, P317, DOI 10.1369/jhc.5A6783.2005
   Berriel E, 2005, ONCOL REP, V14, P219
   Bolscher JGM, 2010, CARBOHYD RES, V345, P1998, DOI 10.1016/j.carres.2010.07.022
   Borgert A, 2012, ACS CHEM BIOL, V7, P1031, DOI 10.1021/cb300076s
   Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803
   Brockhausen I, 2001, BIOL CHEM, V382, P219
   BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015
   BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008
   Brockhausen I, 2006, EMBO REP, V7, P599, DOI 10.1038/sj.embor.7400705
   Brooks CL, 2010, P NATL ACAD SCI USA, V107, P10056, DOI 10.1073/pnas.0915176107
   Brooks SA, 2007, ACTA HISTOCHEM, V109, P273, DOI 10.1016/j.acthis.2007.02.009
   Byrd JC, 2004, CANCER METAST REV, V23, P77, DOI 10.1023/A:1025815113599
   Cao Y, 2008, INT J CANCER, V123, P89, DOI 10.1002/ijc.23493
   CARTRON JP, 1979, NATURE, V282, P621, DOI 10.1038/282621a0
   CARTRON JP, 1978, LANCET, V1, P856
   Clarke E, 2012, HUM MUTAT, V33, P1056, DOI 10.1002/humu.22088
   Colcher D, 1999, ANN NY ACAD SCI, V880, P263, DOI 10.1111/j.1749-6632.1999.tb09531.x
   Crew VK, 2008, BRIT J HAEMATOL, V142, P657, DOI 10.1111/j.1365-2141.2008.07215.x
   CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261
   DAHR W, 1975, VOX SANG, V29, P36, DOI 10.1111/j.1423-0410.1975.tb00475.x
   DAHR W, 1974, VOX SANG, V27, P29, DOI 10.1111/j.1423-0410.1974.tb02386.x
   Dall'Olio F, 2012, FRONT BIOSCI-LANDMRK, V17, P670, DOI 10.2741/3951
   DAUSSET J, 1959, BLOOD, V14, P1079, DOI 10.1182/blood.V14.10.1079.1079
   DAVIS CG, 1986, J BIOL CHEM, V261, P2828
   DO SI, 1992, GLYCOBIOLOGY, V2, P345, DOI 10.1093/glycob/2.4.345
   Eheman C, 2012, CANCER-AM CANCER SOC, V118, P2338, DOI 10.1002/cncr.27514
   Fang LY, 2007, J CLIN PHARMACOL, V47, P227, DOI 10.1177/0091270006293758
   Felner KM, 1998, BBA-MOL BASIS DIS, V1406, P115
   FILELLA X, 1992, B CANCER, V79, P271
   Freire T, 2006, INT J CANCER, V119, P1383, DOI 10.1002/ijc.21959
   Freire T, 2011, J BIOL CHEM, V286, P7797, DOI 10.1074/jbc.M110.209742
   Friedenreich V., 1930, THESIS
   Fu JX, 2008, J CLIN INVEST, V118, P3725, DOI 10.1172/JCI36077
   Fu JX, 2011, J CLIN INVEST, V121, P1657, DOI 10.1172/JCI45538
   Gendler SJ, 2001, J MAMMARY GLAND BIOL, V6, P339, DOI 10.1023/A:1011379725811
   Gill DJ, 2011, TRENDS CELL BIOL, V21, P149, DOI 10.1016/j.tcb.2010.11.004
   Gill DJ, 2010, J CELL BIOL, V189, P843, DOI 10.1083/jcb.201003055
   Guadagni F, 1996, CANCER RES, V56, P5293
   Guda K, 2009, P NATL ACAD SCI USA, V106, P12921, DOI 10.1073/pnas.0901454106
   Guo JM, 2004, ONCOLOGY-BASEL, V67, P271, DOI 10.1159/000081328
   Hakomori S, 2001, ADV EXP MED BIOL, V491, P369
   Hakomori SI, 2012, GLYCOCONJUGATE J, V29, P565, DOI 10.1007/s10719-012-9448-4
   Hamilton SR, 2012, MOL ONCOL, V6, P177, DOI 10.1016/j.molonc.2012.02.007
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801
   Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200
   Hassinen A, 2011, J BIOL CHEM, V286, P38329, DOI 10.1074/jbc.M111.277681
   Hassinen A, 2010, J BIOL CHEM, V285, P17771, DOI 10.1074/jbc.M110.103184
   HAYES GR, 1992, GLYCOBIOLOGY, V2, P355, DOI 10.1093/glycob/2.4.355
   HIROHASHI S, 1985, P NATL ACAD SCI USA, V82, P7039, DOI 10.1073/pnas.82.20.7039
   Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251
   Huang ZH, 2012, J AM CHEM SOC, V134, P8730, DOI 10.1021/ja211725s
   Hubert P, 2011, CANCER RES, V71, P5134, DOI 10.1158/0008-5472.CAN-10-4222
   Ichikawa S, 2010, AM J MED GENET A, V152A, P896, DOI 10.1002/ajmg.a.33337
   Ikeda Y, 1995, Eur J Surg Oncol, V21, P168, DOI 10.1016/S0748-7983(95)90369-0
   Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213
   Imada T, 1999, HEPATO-GASTROENTEROL, V46, P208
   INOUE M, 1991, AM J CLIN PATHOL, V96, P711, DOI 10.1093/ajcp/96.6.711
   ITZKOWITZ S, 1991, GASTROENTEROLOGY, V100, P1691, DOI 10.1016/0016-5085(91)90671-7
   ITZKOWITZ SH, 1992, GUT, V33, P518, DOI 10.1136/gut.33.4.518
   ITZKOWITZ SH, 1989, CANCER RES, V49, P197
   JASS JR, 1994, PATHOLOGY, V26, P418, DOI 10.1080/00313029400169112
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Ju TZ, 2008, J CELL BIOL, V182, P531, DOI 10.1083/jcb.200711151
   Ju TZ, 2008, CANCER RES, V68, P1636, DOI 10.1158/0008-5472.CAN-07-2345
   Ju TZ, 2006, GLYCOBIOLOGY, V16, P947, DOI 10.1093/glycob/cwl008
   Ju TZ, 2011, ANGEW CHEM INT EDIT, V50, P1770, DOI 10.1002/anie.201002313
   Ju TZ, 2005, NATURE, V437, P1252, DOI 10.1038/4371252a
   Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199
   Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200
   Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200
   Julien S, 2006, GLYCOBIOLOGY, V16, P54, DOI 10.1093/glycob/cwj033
   Julien S, 2001, GLYCOCONJUGATE J, V18, P883, DOI 10.1023/A:1022200525695
   Kabuss R, 2005, GLYCOBIOLOGY, V15, P905, DOI 10.1093/glycob/cwi085
   Kato K, 2010, GLYCOCONJUGATE J, V27, P267, DOI 10.1007/s10719-009-9275-4
   Kawano-Yamamoto C, 2006, LEUKEMIA RES, V30, P829, DOI 10.1016/j.leukres.2005.10.021
   Kellokumpu S, 2002, FEBS LETT, V516, P217, DOI 10.1016/S0014-5793(02)02535-8
   Kim Evelyn H, 2011, Int J Proteomics, V2011, P601937, DOI 10.1155/2011/601937
   Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129
   KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X
   Kiyohara M, 2012, J BIOL CHEM, V287, P693, DOI 10.1074/jbc.M111.277384
   KJELDSEN T, 1989, VOX SANG, V57, P81, DOI 10.1111/j.1423-0410.1989.tb04990.x
   KJELDSEN T, 1988, CANCER RES, V48, P2214
   KOBAYASHI H, 1991, J CLIN ONCOL, V9, P983, DOI 10.1200/JCO.1991.9.6.983
   KOBAYASHI H, 1992, J CLIN ONCOL, V10, P95, DOI 10.1200/JCO.1992.10.1.95
   Kohsaki T, 2000, J GASTROENTEROL, V35, P840, DOI 10.1007/s005350070021
   Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101
   Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433
   Konska G, 2006, ONCOL REP, V15, P305
   KOZARSKY K, 1988, P NATL ACAD SCI USA, V85, P4335, DOI 10.1073/pnas.85.12.4335
   Kubota T, 2010, ANTICANCER RES, V30, P3397
   Kudo T, 2002, J BIOL CHEM, V277, P47724, DOI 10.1074/jbc.M205839200
   Kumamoto K, 2001, CANCER RES, V61, P4620
   La Thangue NB, 2011, NAT REV CLIN ONCOL, V8, P587, DOI 10.1038/nrclinonc.2011.121
   Lakshminarayanan V, 2012, P NATL ACAD SCI USA, V109, P261, DOI 10.1073/pnas.1115166109
   LASTORIA S, 1992, BIOMED PHARMACOTHER, V46, P453, DOI 10.1016/0753-3322(92)90003-P
   Leppänen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838
   Li Q, 2009, MOL CANCER THER, V8, P971, DOI 10.1158/1535-7163.MCT-08-0934
   Li Z, 2011, BRIT J CANCER, V104, P1882, DOI 10.1038/bjc.2011.166
   Liu J, 2011, MOL MED REP, V4, P1299, DOI 10.3892/mmr.2011.569
   Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078
   Liu YC, 2011, P NATL ACAD SCI USA, V108, P11332, DOI 10.1073/pnas.1107385108
   Loaiza-Bonilla Arturo, 2011, J Med Case Rep, V5, P8, DOI 10.1186/1752-1947-5-8
   Marcos NT, 2003, J HISTOCHEM CYTOCHEM, V51, P761, DOI 10.1177/002215540305100607
   Marcos Nuno T, 2011, Front Biosci (Elite Ed), V3, P1443
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Matsumoto Y, 2012, BIOCHEM BIOPH RES CO, V419, P7, DOI 10.1016/j.bbrc.2012.01.086
   Meany Danni L, 2011, Clin Proteomics, V8, P7, DOI 10.1186/1559-0275-8-7
   Meyts ERD, 2007, VIRCHOWS ARCH, V451, P805, DOI 10.1007/s00428-007-0478-4
   Mitchell BS, 1999, HISTOL HISTOPATHOL, V14, P217, DOI 10.14670/HH-14.217
   MOREAU R, 1957, Bull Mem Soc Med Hop Paris, V73, P569
   Morita N, 2009, BIOSCI TRENDS, V3, P32
   Müller R, 2005, FEBS J, V272, P4295, DOI 10.1111/j.1742-4658.2005.04838.x
   MUROI K, 1994, BLOOD, V83, P84
   Narimatsu Y, 2008, BIOCHEM BIOPH RES CO, V366, P199, DOI 10.1016/j.bbrc.2007.11.121
   NUMATA Y, 1990, BIOCHEM BIOPH RES CO, V170, P981, DOI 10.1016/0006-291X(90)90488-9
   Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019
   OHUCHI N, 1995, SURG TODAY, V25, P244, DOI 10.1007/BF00311535
   Opat AS, 2000, J BIOL CHEM, V275, P11836, DOI 10.1074/jbc.275.16.11836
   Orntoft TF, 1999, ELECTROPHORESIS, V20, P362, DOI 10.1002/(SICI)1522-2683(19990201)20:2<362::AID-ELPS362>3.0.CO;2-V
   ORNTOFT TF, 1990, INT J CANCER, V45, P666, DOI 10.1002/ijc.2910450416
   Park JH, 2011, NEOPLASIA, V13, P320, DOI 10.1593/neo.101440
   Park JH, 2010, CANCER RES, V70, P2759, DOI 10.1158/0008-5472.CAN-09-3911
   Patton S, 1995, BBA-REV BIOMEMBRANES, V1241, P407, DOI 10.1016/0304-4157(95)00014-3
   Peng RQ, 2012, J BIOL CHEM, V287, P14301, DOI 10.1074/jbc.M111.337642
   Peracaula R, 2008, DIS MARKERS, V25, P207, DOI 10.1155/2008/797629
   Phelan CM, 2010, CANCER EPIDEM BIOMAR, V19, P600, DOI 10.1158/1055-9965.EPI-09-0861
   PILLER V, 1990, J BIOL CHEM, V265, P9264
   Reddish MA, 1997, GLYCOCONJUGATE J, V14, P549, DOI 10.1023/A:1018576224062
   REEPMAKER J, 1952, J CLIN PATHOL, V5, P266, DOI 10.1136/jcp.5.3.266
   Rivinoja A, 2009, J CELL PHYSIOL, V220, P144, DOI 10.1002/jcp.21744
   Roberge M, 2006, PROTEIN ENG DES SEL, V19, P141, DOI 10.1093/protein/gzj012
   Rogers BE, 2005, CANCER BIOTHER RADIO, V20, P502, DOI 10.1089/cbr.2005.20.502
   Röttger S, 1998, J CELL SCI, V111, P45
   RUTLEDGE EA, 1994, BLOOD, V83, P580
   Rutledge EA, 1996, J CELL PHYSIOL, V168, P284, DOI 10.1002/(SICI)1097-4652(199608)168:2<284::AID-JCP7>3.3.CO;2-#
   Sabbatini PJ, 2007, CLIN CANCER RES, V13, P4170, DOI 10.1158/1078-0432.CCR-06-2949
   Schachter H., 1992, Glycoconjugates: Composition: Structure, and Function, P263
   Schietinger A, 2006, SCIENCE, V314, P304, DOI 10.1126/science.1129200
   SCHNEIDER U, 1977, INT J CANCER, V19, P621, DOI 10.1002/ijc.2910190505
   SCHUMACHER U, 1994, CANCER-AM CANCER SOC, V74, P3104, DOI 10.1002/1097-0142(19941215)74:12<3104::AID-CNCR2820741207>3.0.CO;2-0
   Scott KL, 2010, CLIN CANCER RES, V16, P2229, DOI 10.1158/1078-0432.CCR-09-1695
   Senapati S, 2008, HISTOL HISTOPATHOL, V23, P1541, DOI 10.14670/HH-23.1541
   Sewell R, 2006, J BIOL CHEM, V281, P3586, DOI 10.1074/jbc.M511826200
   Shen S, 2011, CANCER BIOTHER RADIO, V26, P127, DOI 10.1089/cbr.2010.0864
   Shibao K, 2002, CANCER, V94, P1939, DOI 10.1002/cncr.10423
   Silverman HS, 2001, GLYCOBIOLOGY, V11, P459, DOI 10.1093/glycob/11.6.459
   Slovin SF, 2003, J CLIN ONCOL, V21, P4292, DOI 10.1200/JCO.2003.04.112
   Slovin SF, 2007, CANCER IMMUNOL IMMUN, V56, P1921, DOI 10.1007/s00262-007-0335-y
   SPRINGER GF, 1974, NATURWISSENSCHAFTEN, V61, P457, DOI 10.1007/BF00597216
   SPRINGER GF, 1993, ANN NY ACAD SCI, V690, P355
   SPRINGER GF, 1985, CANCER-AM CANCER SOC, V55, P561, DOI 10.1002/1097-0142(19850201)55:3<561::AID-CNCR2820550315>3.0.CO;2-1
   SPRINGER GF, 1975, J NATL CANCER I, V54, P335
   Springer GF, 1997, J MOL MED, V75, P594, DOI 10.1007/s001090050144
   SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450
   Sun QA, 2011, J BIOL CHEM, V286, P11529, DOI 10.1074/jbc.M110.173591
   TAKAHASHI HK, 1988, CANCER RES, V48, P4361
   Taniuchi K, 2011, ONCOGENE, V30, P4843, DOI 10.1038/onc.2011.194
   Tarp MA, 2008, BBA-GEN SUBJECTS, V1780, P546, DOI 10.1016/j.bbagen.2007.09.010
   Taylor-Papadimitriou J, 1999, BBA-MOL BASIS DIS, V1455, P301, DOI 10.1016/S0925-4439(99)00055-1
   TAYLORPAPADIMITRIOU J, 1994, TRENDS BIOTECHNOL, V12, P227, DOI 10.1016/0167-7799(94)90121-X
   Tenno M, 2002, J BIOL CHEM, V277, P47088, DOI 10.1074/jbc.M207369200
   Terasawa K, 1996, CANCER RES, V56, P2229
   Thornton DJ, 1997, J BIOL CHEM, V272, P9561
   THURNHER M, 1994, GLYCOBIOLOGY, V4, P429, DOI 10.1093/glycob/4.4.429
   THURNHER M, 1993, J CLIN INVEST, V91, P2103, DOI 10.1172/JCI116434
   Tian E, 2009, GLYCOCONJUGATE J, V26, P325, DOI 10.1007/s10719-008-9162-4
   Tsuchiya, 1999, Breast Cancer, V6, P175, DOI 10.1007/BF02967164
   UHLENBRUCK G, 1981, IMMUNOL COMMUN, V10, P251, DOI 10.3109/08820138109093459
   VAINCHENKER W, 1985, J CLIN INVEST, V75, P541, DOI 10.1172/JCI111730
   Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020
   VAVASSEUR F, 1994, EUR J BIOCHEM, V222, P415, DOI 10.1111/j.1432-1033.1994.tb18880.x
   Vázquez-Martín C, 2004, ONCOLOGY-BASEL, V67, P159, DOI 10.1159/000081003
   Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094
   Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627
   Wang YC, 2012, P NATL ACAD SCI USA, V109, P16143, DOI 10.1073/pnas.1208253109
   Wargovich MJ, 2004, APPL IMMUNOHISTO M M, V12, P350, DOI 10.1097/00129039-200412000-00011
   Welinder C, 2011, GLYCOBIOLOGY, V21, P1097, DOI 10.1093/glycob/cwr048
   Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732
   Wu C, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-123
   Wu YM, 2011, CANCER RES, V71, P7270, DOI 10.1158/0008-5472.CAN-11-1161
   Xia BY, 2005, GLYCOBIOLOGY, V15, P747, DOI 10.1093/glycob/cwi061
   Xia L, 2010, P NATL ACAD IN PRESS
   Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112
   XU M, 1989, INT J CANCER, V44, P985, DOI 10.1002/ijc.2910440607
   Yamada K, 2010, NEPHROL DIAL TRANSPL
   Yamamoto S, 2004, PATHOBIOLOGY, V71, P12, DOI 10.1159/000072957
   Yang K, 2008, CANCER RES, V68, P7313, DOI 10.1158/0008-5472.CAN-08-0598
   Yonezawa S, 1997, PATHOL INT, V47, P813, DOI 10.1111/j.1440-1827.1997.tb03713.x
   Yu LG, 2007, J BIOL CHEM, V282, P773, DOI 10.1074/jbc.M606862200
   Yu YK, 2010, INT J PHARMACEUT, V386, P208, DOI 10.1016/j.ijpharm.2009.11.020
   Yuan M, 1989, Zhonghua Bing Li Xue Za Zhi, V18, P211
   Zhang HM, 2010, MOL CELL PROTEOMICS, V9, P635, DOI 10.1074/mcp.M900314-MCP200
   Zou P, 2010, WORLD J SURG ONCOL, V8, DOI 10.1186/1477-7819-8-65
NR 206
TC 114
Z9 138
U1 2
U2 36
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2014
VL 14
IS 1
BP 63
EP 81
DI 10.3233/CBM-130375
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AD2QE
UT WOS:000333079400007
PM 24643043
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Zhang, EB
   Yin, DD
   Sun, M
   Kong, R
   Liu, XH
   You, LH
   Han, L
   Xia, R
   Wang, KM
   Yang, JS
   De, W
   Shu, YQ
   Wang, ZX
AF Zhang, E-b
   Yin, D-d
   Sun, M.
   Kong, R.
   Liu, X-h
   You, L-h
   Han, L.
   Xia, R.
   Wang, K-m
   Yang, J-s
   De, W.
   Shu, Y-q
   Wang, Z-x
TI P53-regulated long non-coding RNA TUG1 affects cell proliferation in
   human non-small cell lung cancer, partly through epigenetically
   regulating HOXB7 expression
SO CELL DEATH & DISEASE
LA English
DT Article
DE p53; TUG1; proliferation; non-small cell lung cancer; HOXB7
ID BREAST-CANCER; CHROMATIN; REVEALS; SURVIVAL; PROTEIN; GENOME;
   DIFFERENTIATION; TRANSCRIPTION; ACTIVATION; SIGNATURE
AB Recently, a novel class of transcripts, long non-coding RNAs (lncRNAs), is being identified at a rapid pace. These RNAs have critical roles in diverse biological processes, including tumorigenesis. Here we report that taurine-upregulated gene 1 (TUG1), a 7.1-kb lncRNA, recruiting and binding to polycomb repressive complex 2 (PRC2), is generally downregulated in non-small cell lung carcinoma (NSCLC) tissues. In a cohort of 192 NSCLC patients, the lower expression of TUG1 was associated with a higher TNM stage and tumor size, as well as poorer overall survival (P < 0.001). Univariate and multivariate analyses revealed that TUG1 expression serves as an independent predictor for overall survival (P<0.001). Further experiments revealed that TUG1 expression was induced by p53, and luciferase and chromatin immunoprecipitation (ChIP) assays confirmed that TUG1 was a direct transcriptional target of p53. TUG1 knockdown significantly promoted the proliferation in vitro and in vivo. Moreover, the lncRNA-mediated regulation of the expression of HOX genes in tumorigenesis and development has been recently receiving increased attention. Interestingly, inhibition of TUG1 could upregulate homeobox B7 (HOXB7) expression; ChIP assays demonstrated that the promoter of HOXB7 locus was bound by EZH2 (enhancer of zeste homolog 2), a key component of PRC2, and was H3K27 trimethylated. This TUG1-mediated growth regulation is in part due to specific modulation of HOXB7, thus participating in AKT and MAPK pathways. Together, these results suggest that p53-regulated TUG1 is a growth regulator, which acts in part through control of HOXB7. The p53/TUG1/PRC2/HOXB7 interaction might serve as targets for NSCLC diagnosis and therapy.
C1 [Zhang, E-b; Sun, M.; Kong, R.; Liu, X-h; You, L-h; Xia, R.; De, W.] Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing 210000, Jiangsu, Peoples R China.
   [Yin, D-d] Southeast Univ, Affiliated Hosp 2, Cent Lab, Nanjing, Jiangsu, Peoples R China.
   [Han, L.; Shu, Y-q] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210000, Jiangsu, Peoples R China.
   [Wang, K-m; Wang, Z-x] Nanjing Med Univ, Affiliated Hosp 2, Dept Oncol, Nanjing 210000, Jiangsu, Peoples R China.
   [Yang, J-s] Nanjing Med Univ, Affiliated Nanjing Hosp, Dept Oncol, Nanjing 210000, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Southeast University - China; Nanjing
   Medical University; Nanjing Medical University; Nanjing Medical
   University
RP De, W (通讯作者)，Nanjing Med Univ, Dept Biochem & Mol Biol, Nanjing 210000, Jiangsu, Peoples R China.
EM dewei@njmu.edu.cn; nanjingyongqianshu@163.com;
   nanjingzhaoxiawang@163.com
RI Shu, Yongqian/ABD-5698-2021
OI zhang, erbao/0000-0002-5752-7976; yin, dandan/0000-0002-2550-5254
FU National Nature Scientific Foundation of China [81070620, 81272601];
   Jiangsu province ordinary university graduate student research
   innovation project [CXZZ13_0562]
FX This research was supported by the National Nature Scientific Foundation
   of China (No. 81070620 and No. 81272601). MS was supported by the
   Jiangsu province ordinary university graduate student research
   innovation project for 2013 (CXZZ13_0562). The costs associated with the
   publication of this article were defrayed in part by the payment of page
   charges.
CR Amaral PP, 2008, SCIENCE, V319, P1787, DOI 10.1126/science.1155472
   Amaral PP, 2008, MAMM GENOME, V19, P454, DOI 10.1007/s00335-008-9136-7
   Kovochich AN, 2013, CANCER-AM CANCER SOC, V119, P529, DOI 10.1002/cncr.27725
   Blackshaw S, 2004, PLOS BIOL, V2, P1411, DOI 10.1371/journal.pbio.0020247
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   di Pietro M, 2012, P NATL ACAD SCI USA, V109, P9077, DOI 10.1073/pnas.1116933109
   Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108
   Ginger MR, 2006, P NATL ACAD SCI USA, V103, P5781, DOI 10.1073/pnas.0600745103
   Goldstraw Peter, 2007, J Thorac Oncol, V2, P706, DOI 10.1097/JTO.0b013e31812f3c1a
   Guil S, 2012, NAT STRUCT MOL BIOL, V19, P664, DOI 10.1038/nsmb.2315
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Han YH, 2013, J SURG ONCOL, V107, P555, DOI 10.1002/jso.23264
   Huarte M, 2010, CELL, V142, P409, DOI 10.1016/j.cell.2010.06.040
   Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848
   Ishii N, 2006, J HUM GENET, V51, P1087, DOI 10.1007/s10038-006-0070-9
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Jin K, 2012, P NATL ACAD SCI USA, V109, P2736, DOI 10.1073/pnas.1018859108
   Ke XS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004687
   Khaitan D, 2011, CANCER RES, V71, P3852, DOI 10.1158/0008-5472.CAN-10-4460
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kotake Y, 2011, ONCOGENE, V30, P1956, DOI 10.1038/onc.2010.568
   Liao WT, 2011, CLIN CANCER RES, V17, P3569, DOI 10.1158/1078-0432.CCR-10-2533
   Liao WT, 2009, CANCER-AM CANCER SOC, V115, P1507, DOI 10.1002/cncr.24128
   Maamar H, 2013, GENE DEV, V27, P1260, DOI 10.1101/gad.217018.113
   Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2
   Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014
   Pearson JC, 2005, NAT REV GENET, V6, P893, DOI 10.1038/nrg1726
   Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826
   Soussi T, 2006, NAT REV CANCER, V6, P83, DOI 10.1038/nrc1783
   Storti P, 2011, LEUKEMIA, V25, P527, DOI 10.1038/leu.2010.270
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819
   Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001
   Wu XY, 2006, CANCER RES, V66, P9527, DOI 10.1158/0008-5472.CAN-05-4470
   Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054
   Young TL, 2005, CURR BIOL, V15, P501, DOI 10.1016/j.cub.2005.02.027
   Yuan SX, 2012, HEPATOLOGY, V56, P2231, DOI 10.1002/hep.25895
   Yuan W, 2012, MOL CARCINOG, V53, P49
   Zhang Q, 2013, ASIAN PAC J CANCER P, V14, P2311, DOI 10.7314/APJCP.2013.14.4.2311
   Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004
NR 46
TC 395
Z9 436
U1 3
U2 86
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY
PY 2014
VL 5
SI SI
AR e1243
DI 10.1038/cddis.2014.201
PG 12
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AI9DN
UT WOS:000337229300043
PM 24853421
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Xie, Q
   Bai, Q
   Zou, LY
   Zhang, QY
   Zhou, Y
   Chang, H
   Yi, L
   Zhu, JD
   Mi, MT
AF Xie, Qi
   Bai, Qian
   Zou, Ling-Yun
   Zhang, Qian-Yong
   Zhou, Yong
   Chang, Hui
   Yi, Long
   Zhu, Jun-Dong
   Mi, Man-Tian
TI Genistein inhibits DNA methylation and increases expression of tumor
   suppressor genes in human breast cancer cells
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID DIETARY POLYPHENOLS; HYPERMETHYLATION; EPIGENETICS; PTEN; EPIGENOMICS;
   PREVENTION; ISOFLAVONE; THERAPY; DISEASE
AB It has been previously demonstrated that genistein exhibits anticancer activity against breast cancer. However, the precise mechanisms underlying the anticancer effect of genistein, in particular the epigenetic basis, remain unclear. In this study, we investigated whether genistein could modulate the DNA methylation status and expression of cancer-related genes in breast cancer cells. We treated MCF-7 and MDA-MB-231 human breast cancer cells with genistein in vitro. We found that genistein decreased the levels of global DNA methylation, DNA methyltransferase (DNMT) activity and expression of DNMT1. Yet, the expression of DNMT3A and DNMT3B showed no significant change. Using molecular modeling, we observed that genistein might directly interact with the catalytic domain of DNMT1, thus competitively inhibiting the binding of hemimethylated DNA to the catalytic domain of DNMT1. Furthermore, genistein decreased DNA methylation in the promoter region of multiple tumor suppressor genes (TSGs) such as ataxia telangiectasia mutated (ATM), adenomatous polyposis coli (APC), phosphatase and tensin homolog (PTEN), mammary serpin peptidase inhibitor (SERPINB5), and increased the mRNA expression of these genes. However, we detected no significant changes in the DNA methylation status or mRNA expression of stratifin (SFN). These results suggest that the anticancer effect of genistein on breast cancer may be partly due to its ability to demethylate and reactivate methylation-silenced TSGs through direct interaction with the DNMT1 catalytic domain and inhibition of DNMT1 expression. (c) 2014 Wiley Periodicals, Inc.
C1 [Xie, Qi; Bai, Qian; Zhang, Qian-Yong; Zhou, Yong; Chang, Hui; Yi, Long; Zhu, Jun-Dong; Mi, Man-Tian] Third Mil Med Univ, Chongqing Key Lab Nutr & Food Safety, Res Ctr Nutr & Food Safety, Dept Nutr & Food Hyg,Coll Mil Prevent Med, Chongqing, Peoples R China.
   [Zou, Ling-Yun] Third Mil Med Univ, Bioinformat Ctr, Dept Nutr & Food Hyg, Chongqing, Peoples R China.
C3 Army Medical University; Army Medical University
RP Zhu, JD (通讯作者)，Third Mil Med Univ, Chongqing Key Lab Nutr & Food Safety, Res Ctr Nutr & Food Safety, Dept Nutr & Food Hyg,Coll Mil Prevent Med, Chongqing, Peoples R China.
EM zjdnfs@126.com; mimt@vip.sina.com
OI Chang, Hui/0000-0001-6693-2570; Xie, Qi/0000-0001-7087-8845
FU National Natural Science Foundation of China (NSFC) [30771793]
FX Supported by: National Natural Science Foundation of China (NSFC), Grant
   number: 30771793.
CR Adjakly M, 2011, EPIGENOMICS-UK, V3, P795, DOI [10.2217/EPI.11.103, 10.2217/epi.11.103]
   Banerjee S, 2008, CANCER LETT, V269, P226, DOI 10.1016/j.canlet.2008.03.052
   Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799
   Billington CJ, 2013, J NUTR, V143, P332, DOI 10.3945/jn.112.168906
   Bosviel R, 2012, OMICS, V16, P235, DOI 10.1089/omi.2011.0105
   Chang H, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3194
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Dampier K, 2001, BRIT J CANCER, V85, P618, DOI 10.1054/bjoc.2001.1980
   Dworkin AM, 2009, SEMIN CANCER BIOL, V19, P165, DOI 10.1016/j.semcancer.2009.02.007
   Esteller M, 2000, CANCER RES, V60, P4366
   Fang MZ, 2007, J NUTR, V137, p223S, DOI 10.1093/jn/137.1.223S
   Fang MZ, 2005, CLIN CANCER RES, V11, P7033, DOI 10.1158/1078-0432.CCR-05-0406
   Fang MZ, 2003, CANCER RES, V63, P7563
   Fattash I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064135
   Feil R, 2012, NAT REV GENET, V13, P97, DOI 10.1038/nrg3142
   Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Issa JP, 2008, CANCER PREV RES, V1, P219, DOI 10.1158/1940-6207.CAPR-08-0029
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045
   Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   King-Batoon A, 2008, ENVIRON MOL MUTAGEN, V49, P36, DOI 10.1002/em.20363
   Li Y, 2010, CURR MED CHEM, V17, P2141, DOI 10.2174/092986710791299966
   Li YY, 2009, INT J CANCER, V125, P286, DOI 10.1002/ijc.24398
   Link A, 2010, BIOCHEM PHARMACOL, V80, P1771, DOI 10.1016/j.bcp.2010.06.036
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Lubecka-Pietruszewska K, 2013, BIOCHEM BIOPH RES CO, V430, P623, DOI 10.1016/j.bbrc.2012.11.103
   Majid S, 2010, CANCER-AM CANCER SOC, V116, P66, DOI 10.1002/cncr.24662
   Medina-Franco JL, 2011, DRUG DISCOV TODAY, V16, P418, DOI 10.1016/j.drudis.2011.02.003
   Meeran SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011457
   Merchant K, 2011, FUNCT FOODS HEALTH D, V1, P91
   Ouyang GL, 2009, CELL BIOL INT, V33, P1237, DOI 10.1016/j.cellbi.2009.08.011
   Polyak K, 2007, J CLIN INVEST, V117, P3155, DOI 10.1172/JCI33295
   Robert MF, 2003, NAT GENET, V33, P61, DOI 10.1038/ng1068
   Siedlecki P, 2003, BIOCHEM BIOPH RES CO, V306, P558, DOI 10.1016/S0006-291X(03)01000-3
   Soria JC, 2002, CLIN CANCER RES, V8, P1178
   Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092
   Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003
   Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-32
   Xie Q, 2013, ASIA PAC J CLIN NUTR, V22, P118, DOI 10.6133/apjcn.2013.22.1.16
NR 43
TC 150
Z9 162
U1 1
U2 64
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD MAY
PY 2014
VL 53
IS 5
BP 422
EP 431
DI 10.1002/gcc.22154
PG 10
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA AC7GC
UT WOS:000332695000006
PM 24532317
DA 2025-01-12
ER

PT J
AU Valencia, RAC
   Martino, DJ
   Saffery, R
   Ellis, JA
AF Valencia, Raul A. Chavez
   Martino, David J.
   Saffery, Richard
   Ellis, Justine A.
TI In vitro exposure of human blood mononuclear cells to active vitamin D
   does not induce substantial change to DNA methylation on a genome-scale
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Vitamin D; Mononuclear cells; 1,25-Dihydroxyvitamin D3; DNA methylation;
   Epigenetics; Infinium
ID BREAST-CANCER CELLS; D DEFICIENCY; GENE; EXPRESSION; DISCORDANCE;
   MICROARRAY; DISEASE; LIFE
AB It is well-established that vitamin D impacts gene regulation via vitamin D response elements (VDREs) across the genome. Recent evidence, primarily at a locus-specific level, suggests that alterations to DNA methylation may also be a relevant mechanism through which vitamin D regulates gene expression. Given the intense interest in vitamin D, particularly as an immune modifier, we sought to examine the impact of vitamin D exposure on the immune cell methylome in vitro. We exposed primary human blood mononuclear cells with up to 100 nM calcitriol for up to 120 h, and measured genome-scale DNA methylation response using the Illumina Infinium HumanMethylation450 beadchip array. We observed that, while the expression of known vitamin D responsive genes was clearly altered by calcitriol exposure, substantial genome-scale changes to DNA methylation were not induced. Our data suggests that, over the exposure period measured, changes to DNA methylation may not be a predominant mechanism through which vitamin D impacts gene expression in human immune cells. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Valencia, Raul A. Chavez; Martino, David J.; Saffery, Richard; Ellis, Justine A.] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia.
   [Valencia, Raul A. Chavez; Martino, David J.; Saffery, Richard; Ellis, Justine A.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia.
C3 Murdoch Children's Research Institute; University of Melbourne
RP Ellis, JA (通讯作者)，Murdoch Childrens Res Inst, 50 Flemington Rd, Parkville, Vic 3052, Australia.
EM raul.chavez@mcri.edu.au; david.martino@mcri.edu.au;
   richard.saffery@mcri.edu.au; justine.ellis@mcri.edu.au
RI Martino, DJ/X-1753-2019; Saffery, Richard/GLS-1976-2022
OI Martino, David/0000-0001-6823-4696; Ellis, Justine/0000-0003-4103-4445;
   Saffery, Richard/0000-0002-9510-4181
FU Australian Research Council Future Fellowship [FT120100253]; National
   Health and Medical Research Council Senior Research Fellowship
   [APP1045161]; National Health and Medical Research Council Early Career
   Fellowship [1072752]; Arthritis Australia & State and Territory
   Affiliate grant (South Australia); Victorian State Government
   Operational Infrastructure support program; Australian Research Council
   [FT120100253] Funding Source: Australian Research Council; National
   Health and Medical Research Council of Australia [1072752] Funding
   Source: NHMRC
FX We thank the volunteers who made the kind donations of blood samples
   that facilitated this work, and Anna Czajko for assisting with blood
   processing. JAE is supported by an Australian Research Council Future
   Fellowship (#FT120100253). RS is supported by a National Health and
   Medical Research Council Senior Research Fellowship (#APP1045161). DJM
   is supported by a National Health and Medical Research Council Early
   Career Fellowship (APP#1072752). RACV is supported by an Arthritis
   Australia & State and Territory Affiliate grant (South Australia). This
   work was supported by the Victorian State Government Operational
   Infrastructure support program.
CR Badenhoop K, 2012, CURR DIABETES REP, V12, P635, DOI 10.1007/s11892-012-0322-3
   Bell CG, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-33
   Chen YA, 2013, EPIGENETICS-US, V8, P203, DOI 10.4161/epi.23470
   Di Rosa M, 2011, IMMUNOLOGY, V134, P123, DOI 10.1111/j.1365-2567.2011.03482.x
   Du P, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-587
   Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80
   Gunta SS, 2013, NAT REV NEPHROL, V9, P337, DOI 10.1038/nrneph.2013.74
   Harvey L, 2010, J STEROID BIOCHEM, V121, P239, DOI 10.1016/j.jsbmb.2010.03.050
   Hewison M, 2012, P NUTR SOC, V71, P50, DOI 10.1017/S0029665111001650
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Jacobsen R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-515
   Januchowski R, 2007, CANCER LETT, V246, P313, DOI 10.1016/j.canlet.2006.03.010
   Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109
   Kasper D., MINFI ANAL ILLUMINA
   Lopes N, 2012, ANTICANCER RES, V32, P249
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Martino D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-5-r42
   Martino DJ, 2011, EPIGENETICS-US, V6, P1085, DOI 10.4161/epi.6.9.16401
   Novakovic B, 2009, J BIOL CHEM, V284, P14838, DOI 10.1074/jbc.M809542200
   Olsen KS, 2013, EUR J CLIN NUTR, V67, P773, DOI 10.1038/ejcn.2013.53
   Rakyan VK, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002300
   Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110
   Rawson JB, 2012, NUTR CANCER, V64, P919, DOI 10.1080/01635581.2012.711418
   Simon KC, 2012, CURR OPIN NEUROL, V25, P246, DOI 10.1097/WCO.0b013e3283533a7e
   Stefanska B, 2012, BRIT J NUTR, V107, P781, DOI 10.1017/S0007114511003631
   Wen HY, 2011, JCR-J CLIN RHEUMATOL, V17, P102, DOI 10.1097/RHU.0b013e31820edd18
   Zhu HD, 2013, J PEDIATR-US, V162, P1004, DOI 10.1016/j.jpeds.2012.10.059
NR 27
TC 18
Z9 18
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAY
PY 2014
VL 141
BP 144
EP 149
DI 10.1016/j.jsbmb.2014.01.018
PG 6
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AG0OJ
UT WOS:000335114500017
PM 24525112
DA 2025-01-12
ER

PT J
AU Bhan, A
   Hussain, I
   Ansari, KI
   Bobzean, SAM
   Perrotti, LI
   Mandal, SS
AF Bhan, Arunoday
   Hussain, Imran
   Ansari, Khairul I.
   Bobzean, Samara A. M.
   Perrotti, Linda I.
   Mandal, Subhrangsu S.
TI Bisphenol-A and diethylstilbestrol exposure induces the expression of
   breast cancer associated long noncoding RNA HOTAIR <i>in vitro</i> and
   <i>in vivo</i>
SO JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Article
DE Endocrine disruption; HOTAIR; LncRNA; Bisphenol A; Diethylstilbestrol;
   Transcriptional regulation; Epigenetics
ID NUCLEAR RECEPTOR SUPERFAMILY; MAMMARY-GLAND DEVELOPMENT; MLL HISTONE
   METHYLASES; ESTROGEN-RECEPTOR; ENDOCRINE DISRUPTORS; GENE-EXPRESSION;
   UTERO EXPOSURE; CRITICAL ROLES; TUMOR-GROWTH; CHROMATIN
AB Antisense transcript, long non-coding RNA HOTAIR is a key player in gene silencing and breast cancer and is transcriptionally regulated by estradiol. Here, we have investigated if HOTAIR expression is misregulated by bisphenol-A (BPA) and diethylstilbestrol (DES). Our findings demonstrate BPA and DES induce HOTAIR expression in cultured human breast cancer cells (MCF7) as well as in vivo in the mammary glands of rat. Luciferase assay showed that HOTAIR promoter estrogen-response-elements (EREs) are induced by BPA and DES. Estrogen-receptors (ERs) and ER-coregulators such as MLL-histone methylases (MLL1 and MLL3) bind to the HOTAIR promoter EREs in the presence of BPA and DES, modify chromatin (histone methylation and acetylation) and lead to gene activation. Knockdown of ERs down-regulated the BPA and DES-induced expression of HOTAIR. In summary, our results demonstrate that BPA and DES exposure alters the epigenetic programming of the HOTAIR promoters leading to its endocrine disruption in vitro and in vivo. Published by Elsevier Ltd.
C1 [Bhan, Arunoday; Hussain, Imran; Ansari, Khairul I.; Mandal, Subhrangsu S.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
   [Bobzean, Samara A. M.; Perrotti, Linda I.] Univ Texas Arlington, Dept Psychol, Arlington, TX 76019 USA.
C3 University of Texas System; University of Texas Arlington; University of
   Texas System; University of Texas Arlington
RP Mandal, SS (通讯作者)，Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
EM smandal@uta.edu
RI Ansari, Khairul/C-9791-2011; bhan, arunoday/F-1066-2011
OI Perrotti, Linda/0000-0002-6297-2572; Hussain, Imran/0000-0003-1563-7656;
   Ansari, Khairul I/0000-0002-9564-2107
FU National Institutes of Health [1R15 ES019129-01, 2R15CA113747-02];
   American Heart Association [0765160Y]; American Heart Association (AHA)
   [0765160Y] Funding Source: American Heart Association (AHA)
FX We thank all the Mandal laboratory members for helpful discussions.
   Research in the Mandal laboratory is supported in part by grants from
   the National Institutes of Health (1R15 ES019129-01 and
   2R15CA113747-02), and the American Heart Association (0765160Y).
CR Adamsson NA, 2008, REPROD TOXICOL, V25, P76, DOI 10.1016/j.reprotox.2007.08.001
   Akbas GE, 2004, J MOL BIOL, V340, P1013, DOI 10.1016/j.jmb.2004.05.052
   Ansari KI, 2013, ONCOGENE, V32, P3359, DOI 10.1038/onc.2012.352
   Ansari KI, 2012, BRIT J CANCER, V107, P315, DOI 10.1038/bjc.2012.263
   Ansari KI, 2013, MOL ENDOCRINOL, V27, P92, DOI 10.1210/me.2012-1147
   Ansari KI, 2012, J MOL ENDOCRINOL, V48, P61, DOI 10.1530/JME-11-0078
   Ansari KI, 2011, J MOL BIOL, V411, P334, DOI 10.1016/j.jmb.2011.05.050
   Ansari KI, 2011, BIOCHEMISTRY-US, V50, P3517, DOI 10.1021/bi102037t
   Ansari KI, 2010, FEBS J, V277, P1790, DOI 10.1111/j.1742-4658.2010.07606.x
   Ansari KI, 2009, FEBS J, V276, P7400, DOI 10.1111/j.1742-4658.2009.07453.x
   Ansari KI, 2009, FRONT BIOSCI-LANDMRK, V14, P3483, DOI 10.2741/3466
   Baba K, 2009, TOXICOL SCI, V108, P344, DOI 10.1093/toxsci/kfp025
   Ben-Jonathan N, 1998, TRENDS ENDOCRIN MET, V9, P124, DOI 10.1016/S1043-2760(98)00029-0
   Betancourt AM, 2010, ENVIRON HEALTH PERSP, V118, P1614, DOI 10.1289/ehp.1002148
   Bhan A, 2013, J MOL BIOL, V425, P3707, DOI 10.1016/j.jmb.2013.01.022
   Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138
   Block K, 2000, FASEB J, V14, P1101, DOI 10.1096/fasebj.14.9.1101
   Bromer JG, 2010, FASEB J, V24, P2273, DOI 10.1096/fj.09-140533
   BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0
   BROWN NM, 1995, ENVIRON HEALTH PERSP, V103, P708, DOI 10.2307/3432863
   Bulynko YA, 2011, BIOCHEMISTRY-US, V50, P313, DOI 10.1021/bi101762x
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Calle EE, 1996, AM J EPIDEMIOL, V144, P645, DOI 10.1093/oxfordjournals.aje.a008976
   Carninci P, 2005, SCIENCE, V309, P1559, DOI 10.1126/science.1112014
   Casals-Casas C, 2011, ANNU REV PHYSIOL, V73, P135, DOI 10.1146/annurev-physiol-012110-142200
   Chen JG, 2006, MOL ENDOCRINOL, V20, P1, DOI 10.1210/me.2005-0192
   Doherty Leo F., 2010, Hormones & Cancer, V1, P146, DOI 10.1007/s12672-010-0015-9
   Dreijerink KMA, 2006, CANCER RES, V66, P4929, DOI 10.1158/0008-5472.CAN-05-4461
   Eilam-Stock T, 2012, BEHAV NEUROSCI, V126, P175, DOI 10.1037/a0025959
   Fenichel P, 2013, ANN ENDOCRINOL-PARIS, V74, P211, DOI 10.1016/j.ando.2013.04.002
   Fenton SE, 2006, ENDOCRINOLOGY, V147, pS18, DOI 10.1210/en.2005-1131
   Geng YJ, 2011, J INT MED RES, V39, P2119, DOI 10.1177/147323001103900608
   Gibert Y, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-4
   GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201
   Grün F, 2010, CURR OPIN ENDOCRINOL, V17, P453, DOI 10.1097/MED.0b013e32833ddea0
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Harries LW, 2012, BIOCHEM SOC T, V40, P902, DOI 10.1042/BST20120020
   He S, 2011, BMC EVOL BIOL, V11, DOI 10.1186/1471-2148-11-102
   Hess JL, 2004, TRENDS MOL MED, V10, P500, DOI 10.1016/j.molmed.2004.08.005
   Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167
   Hwang HM, 2008, SCI TOTAL ENVIRON, V404, P26, DOI 10.1016/j.scitotenv.2008.05.031
   Inagaki T, 2012, ENDOCRINOLOGY, V153, P3357, DOI 10.1210/en.2012-1121
   Ishibashi M, 2013, ONCOL REP, V29, P946, DOI 10.3892/or.2012.2219
   Jacobs MN, 2008, CURR DRUG METAB, V9, P796, DOI 10.2174/138920008786049294
   Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim K, 2013, ONCOGENE, V32, P1616, DOI 10.1038/onc.2012.193
   Kogo R, 2011, CANCER RES, V71, P6320, DOI 10.1158/0008-5472.CAN-11-1021
   KRISHNAN AV, 1993, ENDOCRINOLOGY, V132, P2279, DOI 10.1210/en.132.6.2279
   Lee HR, 2012, INT J MOL MED, V29, P883, DOI 10.3892/ijmm.2012.903
   Lee JS, 2008, CANCER LETT, V267, P189, DOI 10.1016/j.canlet.2008.03.013
   Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856
   Lee JW, 2000, EXP MOL MED, V32, P53, DOI 10.1038/emm.2000.10
   Lee S, 2008, MOL ENDOCRINOL, V22, P1312, DOI 10.1210/me.2008-0012
   Levi F, 1996, EUR J CANCER PREV, V5, P259, DOI 10.1097/00008469-199608000-00006
   Li MWM, 2009, INT J BIOCHEM CELL B, V41, P2302, DOI 10.1016/j.biocel.2009.05.016
   Lonard DM, 2005, TRENDS BIOCHEM SCI, V30, P126, DOI 10.1016/j.tibs.2005.01.001
   Lv XB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063516
   MacLusky NJ, 2005, ENVIRON HEALTH PERSP, V113, P675, DOI 10.1289/ehp.7633
   Mahoney MM, 2010, TOXICOL APPL PHARM, V247, P98, DOI 10.1016/j.taap.2010.05.017
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Markey CM, 2005, BIOL REPROD, V72, P1344, DOI 10.1095/biolreprod.104.036301
   Markey CM, 2001, BIOL REPROD, V65, P1215, DOI 10.1093/biolreprod/65.4.1215
   Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046
   Milhem M.M., 2011, J CANC SCI THER S, VS5
   Muñoz-de-Toro M, 2005, ENDOCRINOLOGY, V146, P4138, DOI 10.1210/en.2005-0340
   Nakagawa T, 2013, BIOCHEM BIOPH RES CO, V436, P319, DOI 10.1016/j.bbrc.2013.05.101
   Nakanishi T, 2008, J TOXICOL SCI, V33, P269, DOI 10.2131/jts.33.269
   Nanjappa MK, 2012, BIOL REPROD, V86, DOI 10.1095/biolreprod.111.095349
   Navas JM, 2008, EXPERT OPIN DRUG MET, V4, P605, DOI [10.1517/17425255.4.5.605, 10.1517/17425255.4.5.605 ]
   Niinuma T, 2012, CANCER RES, V72, P1126, DOI 10.1158/0008-5472.CAN-11-1803
   Niland Courtney N., 2012, Frontiers in Genetics, V3, P25, DOI 10.3389/fgene.2012.00025
   Nilsson S, 2002, CRIT REV EUKAR GENE, V12, P237, DOI 10.1615/CritRevEukaryotGeneExpr.v12.i4.10
   Pan YF, 2011, CHINESE MED J-PEKING, V124, P2378, DOI 10.3760/cma.j.issn.0366-6999.2011.15.023
   Phillips KP, 2008, J TOXICOL ENV HEAL B, V11, P149, DOI 10.1080/00927870701873115
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Qureshi IA, 2010, BRAIN RES, V1338, P20, DOI 10.1016/j.brainres.2010.03.110
   Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022
   Saunders PTK, 1997, ADV EXP MED BIOL, V424, P99
   Schoeters G, 2008, BASIC CLIN PHARMACOL, V102, P168, DOI 10.1111/j.1742-7843.2007.00180.x
   Shrestha B, 2012, FEBS J, V279, P3715, DOI 10.1111/j.1742-4658.2012.08733.x
   Sierra-Miranda M, 2012, MOL BIOCHEM PARASIT, V185, P36, DOI 10.1016/j.molbiopara.2012.06.005
   Sleutels F, 2002, NATURE, V415, P810, DOI 10.1038/415810a
   Smith CC, 2007, FASEB J, V21, P239, DOI 10.1096/fj.06-6635com
   Stangl H, 2002, J ENDOCRINOL, V175, P663, DOI 10.1677/joe.0.1750663
   Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888
   Susiarjo M, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030005
   Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P126, DOI 10.1054/bjoc.2000.1521
   Troisi R, 2007, INT J CANCER, V121, P356, DOI 10.1002/ijc.22631
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Umezawa R, 2009, ENDOCRINOLOGY, V150, P3425, DOI 10.1210/en.2008-1738
   Valekunja UK, 2013, P NATL ACAD SCI USA, V110, P1554, DOI 10.1073/pnas.1214168110
   Vuorinen A, 2013, J STEROID BIOCHEM, V137, P18, DOI 10.1016/j.jsbmb.2013.04.009
   Wang J, 2011, CANCER RES, V71, P7238, DOI 10.1158/0008-5472.CAN-11-0896
   Wang LF, 2010, P NATL ACAD SCI USA, V107, P7317, DOI 10.1073/pnas.1000031107
   Wohlfahrt-Veje C, 2009, CLIN ENDOCRINOL, V71, P459, DOI 10.1111/j.1365-2265.2009.03545.x
   Wolstenholme JT, 2012, ENDOCRINOLOGY, V153, P3828, DOI 10.1210/en.2012-1195
   Xia Tian, 2013, Yichuan, V35, P269, DOI 10.3724/SP.J.1005.2013.00269
   Xu XH, 2012, HORM BEHAV, V62, P480, DOI 10.1016/j.yhbeh.2012.08.005
   Yang Z, 2011, ANN SURG ONCOL, V18, P1243, DOI 10.1245/s10434-011-1581-y
   Yearley EJ, 2008, J MOL STRUCT, V890, P240, DOI 10.1016/j.molstruc.2008.03.053
   Zhuang Y, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-35
NR 102
TC 135
Z9 145
U1 0
U2 83
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-0760
J9 J STEROID BIOCHEM
JI J. Steroid Biochem. Mol. Biol.
PD MAY
PY 2014
VL 141
BP 160
EP 170
DI 10.1016/j.jsbmb.2014.02.002
PG 11
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AG0OJ
UT WOS:000335114500019
PM 24533973
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Ben Gacem, R
   Ben Abdelkrim, O
   Ziadi, S
   Ben Dhiab, M
   Trimeche, M
AF Ben Gacem, Riadh
   Ben Abdelkrim, Olfa
   Ziadi, Sonia
   Ben Dhiab, Myriam
   Trimeche, Mounir
TI Methylation of miR-124a-1, miR-124a-2, and miR-124a-3 genes correlates
   with aggressive and advanced breast cancer disease
SO TUMOR BIOLOGY
LA English
DT Article
DE microRNA; Methylation; Breast cancer
ID DNA METHYLTRANSFERASES; TUMOR-SUPPRESSOR; GASTRIC-CANCER; EXPRESSION;
   MICRORNAS; CELLS; DIFFERENTIATION; OVEREXPRESSION; PHENOTYPE; TARGETS
AB Aberrant DNA methylation on CpG islands is one of the most consistent epigenetic changes in human cancers, and the process of methylation is catalyzed by the DNA methyltransferases DNMT1, DNMT3a, and DNMT3b. Recent reports demonstrate that deregulation of miR-124a, one of the frequently methylated microRNAs in human cancers, is related to carcinogenesis. The aim of this study was to evaluate the frequencies of methylation of the three genomic loci encoding the miR-124a in primary breast cancers and to investigate their relationships with the clinicopathological characteristics of the tumors and with the expression levels of DNMT1, DNMT3a, and DNMT3b. The methylation status of the three genomic loci encoding the miR-124a (miR-124a-1, miR-124a-2, and miR-124a-3) was analyzed in fresh-frozen tumor samples using methylation-specific PCR in a large series of invasive breast ductal carcinomas (n = 60). Results were correlated to several clinicopathological characteristics of the tumors and to the expression levels of DNMT1, DNMT3a, and DNMT3b, determined by immunohistochemistry. Promoter hypermethylation of miR-124a-1, miR-124a-2, and miR-124a-3 was detected in 53.3, 70, and 36.7 % of cases, respectively. Methylation of miR-124a-2 correlated to patients with age higher than 45 years (P = 0.008) and to postmenopausal patients (P = 0.03), whereas methylation of miR-124a-3 correlated significantly to tumor size > 20 mm (P = 0.03). Interestingly, simultaneous methylation of the three genes encoding miR-124a correlated significantly with the presence of lymph node metastasis (P = 0.01) and high mitotic score (P = 0.03). No significant correlation was found between promoter hypermethylation of miR-124a and expression of hormone receptors or HER2/neu. With regard to DNMT expression, no correlation was found between DNMT1 or DNMT3a expression and promoter methylation of any tested microRNA. However, DNMT3b overexpression correlates significantly with the hypermethylation of miR-124a-3 (P = 0.03). Our data indicates that miR-124a-1, miR-124a-2, and miR-124a-3 genes are frequently methylated in breast cancer and play a role in tumor growth and aggressivity.
C1 [Ben Gacem, Riadh; Ben Abdelkrim, Olfa; Ziadi, Sonia; Ben Dhiab, Myriam; Trimeche, Mounir] Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia.
C3 Universite de Sousse; Hopital Farhat Hached
RP Trimeche, M (通讯作者)，Farhat Hached Hosp, Dept Pathol, Sousse 4000, Tunisia.
EM m_trimech@yahoo.fr
FU Ministere de l'Enseignement Superieur, de la Recherche Scientifique et
   Technologie; "Ministere de la Sante" of Tunisia
FX This work was supported by the "Ministere de l'Enseignement Superieur,
   de la Recherche Scientifique et Technologie" and the "Ministere de la
   Sante" of Tunisia.
CR Agirre X, 2009, CANCER RES, V69, P4443, DOI 10.1158/0008-5472.CAN-08-4025
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219
   Ben Gacem R, 2012, CANCER EPIDEMIOL, V36, P190, DOI 10.1016/j.canep.2011.09.001
   Ben Gacem R, 2012, HUM PATHOL, V43, P1731, DOI 10.1016/j.humpath.2011.12.022
   BESTOR TH, 1994, CURR OPIN CELL BIOL, V6, P380, DOI 10.1016/0955-0674(94)90030-2
   Billam M, 2010, BREAST CANCER RES TR, V120, P581, DOI 10.1007/s10549-009-0420-3
   Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658
   Chen XY, 2013, INVEST OPHTH VIS SCI, V54, P2248, DOI 10.1167/iovs.12-10977
   Choi MS, 2003, HUM PATHOL, V34, P11, DOI 10.1053/hupa.2003.5
   Deng GR, 2011, ONCOL LETT, V2, P175, DOI 10.3892/ol.2010.222
   Ding WJ, 2008, DIGEST DIS SCI, V53, P2083, DOI 10.1007/s10620-007-0145-2
   ELSTON CW, 1998, SYSTEMIC PATHOLOGY B, V13, P385
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Esteller M, 2002, ONCOGENE, V21, P5427, DOI 10.1038/sj.onc.1205600
   Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250
   Garzon R, 2006, TRENDS MOL MED, V12, P580, DOI 10.1016/j.molmed.2006.10.006
   Grossel MJ, 2006, J CELL BIOCHEM, V97, P485, DOI 10.1002/jcb.20712
   Hachana M, 2009, BREAST CANCER RES TR, V113, P43, DOI 10.1007/s10549-008-9901-z
   Hammond SM, 2007, NAT GENET, V39, P582, DOI 10.1038/ng0507-582
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383
   Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218
   Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289
   Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6
   Peurala H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026122
   Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124
   Roll JD, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-15
   Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14
   Singal R, 2004, ONCOL REP, V12, P631
   Turek-Plewa J, 2005, CELL MOL BIOL LETT, V10, P631
   Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167
   Wong KY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019027
   Xu Q, 2013, J MOL CELL BIOL, V5, P3, DOI 10.1093/jmcb/mjs049
   Zhou X, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0039011, 10.1371/journal.pone.0043230]
NR 35
TC 37
Z9 41
U1 0
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD MAY
PY 2014
VL 35
IS 5
BP 4047
EP 4056
DI 10.1007/s13277-013-1530-4
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AG9SL
UT WOS:000335759800012
PM 24375250
DA 2025-01-12
ER

PT J
AU Rose, M
   Gaisa, NT
   Antony, P
   Fiedler, D
   Heidenreich, A
   Otto, W
   Denzinger, S
   Bertz, S
   Hartmann, A
   Karl, A
   Knüchel, R
   Dahl, E
AF Rose, Michael
   Gaisa, Nadine T.
   Antony, Pia
   Fiedler, David
   Heidenreich, Axel
   Otto, Wolfgang
   Denzinger, Stefan
   Bertz, Simone
   Hartmann, Arndt
   Karl, Alexander
   Knuechel, Ruth
   Dahl, Edgar
TI Epigenetic inactivation of <i>ITIH5</i> promotes bladder cancer
   progression and predicts early relapse of pT1 high-grade urothelial
   tumours
SO CARCINOGENESIS
LA English
DT Article
ID ALPHA-TRYPSIN INHIBITOR; BREAST-CANCER; HEAVY-CHAIN; FAMILY; EXPRESSION;
   CARCINOMA; GENE; METHYLATION; RECURRENCE; BIOMARKERS
AB Inter-alpha-trypsin inhibitor heavy chain 5 (ITIH5) has been associated with tumour suppression in various cancers. However, its putative role in bladder cancer is completely unknown. Therefore, we initiated a study analysing ITIH5 expression as well as its prognostic and functional impact on human urothelial cancers (UCs). Expression analysis showed a clear down-regulation of ITIH5 mRNA in 61% (n 45) of UCs, especially in muscle-invasive tumours (P < 0.001). ITIH5 loss in UCs was further evident on protein level (65.5%, n 55) as detected by immunohistochemistry. DNA methylation analysis demonstrated tumour-specific ITIH5 promoter methylation in 50% of papillary none-invasive pTa (n 30) and 68% of invasive (n 28) UCs. Aberrant ITIH5 promoter methylation in bladder tumours was tightly linked (P < 0.001) with loss of ITIH5 mRNA expression, which was furthermore functionally confirmed by demethylation analysis in cell lines. Pyrosequencing analysis revealed that ITIH5 promoter hypermethylation was closely associated with progressive bladder cancers. Subsequently, a large cohort (n 120) of clinically challenging pT1 high-grade UC was analysed for ITIH5 expression. Of clinical significance, we found an association between loss of ITIH5 expression and unfavourable prognosis of UC patients without distant metastasis at first diagnosis (recurrence-free survival; hazard ratio: 4.35, P 0.048). Functionally, ITIH5 re-expression in human RT112 bladder cancer cells led to both suppression of cell migration and inhibition of colony spreading. Hence, we provide evidence that down-regulation of ITIH5 by aberrant DNA hypermethylation may provoke invasive phenotypes in human bladder cancer. Moreover, ITIH5 protein might become a prognostic biomarker for relapse risk stratification in high-grade UC patients.
C1 [Rose, Michael; Gaisa, Nadine T.; Antony, Pia; Fiedler, David; Knuechel, Ruth; Dahl, Edgar] Rhein Westfal TH Aachen, Fac Med, Inst Pathol, Mol Oncol Grp, Aachen, Germany.
   [Heidenreich, Axel] Rhein Westfal TH Aachen, Fac Med, Dept Urol, Aachen, Germany.
   [Otto, Wolfgang; Denzinger, Stefan] Univ Regensburg, Caritas St Josef Med Ctr, Dept Urol, D-93053 Regensburg, Germany.
   [Bertz, Simone; Hartmann, Arndt] Univ Hosp Erlangen, Inst Pathol, Erlangen, Germany.
   [Karl, Alexander] Ludwig Maximilians Univ Munchen, Dept Urol, Munich, Germany.
C3 RWTH Aachen University; RWTH Aachen University; University of
   Regensburg; University of Erlangen Nuremberg; University of Munich
RP Dahl, E (通讯作者)，Hosp RWTH Aachen Univ, Inst Pathol, Mol Oncol Grp, Pauwelsstr 30, D-52074 Aachen, Germany.
EM edahl@ukaachen.de
RI Heidenreich, Axel/L-1015-2013
OI Otto, Wolfgang/0000-0003-0523-5442; Gaisa, Nadine/0000-0002-4762-3964
FU START programme of the Medical Faculty of the Rheinisch-Westfalische
   Technische Hochschule (RWTH) Aachen University [149/08]
FX START programme of the Medical Faculty of the Rheinisch-Westfalische
   Technische Hochschule (RWTH) Aachen University (149/08).
CR Aitken KJ, 2009, NAT REV UROL, V6, P596, DOI 10.1038/nrurol.2009.201
   Babjuk M, 2008, EUR UROL, V54, P303, DOI 10.1016/j.eururo.2008.04.051
   Bertz S, 2014, EUR UROL, V65, P218, DOI 10.1016/j.eururo.2012.05.033
   Bost F, 1998, EUR J BIOCHEM, V252, P339, DOI 10.1046/j.1432-1327.1998.2520339.x
   Bourguignon J, 1999, J HISTOCHEM CYTOCHEM, V47, P1625, DOI 10.1177/002215549904701214
   Esteller M, 2007, HUM MOL GENET, V16, pR50, DOI 10.1093/hmg/ddm018
   Hamm A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-25
   Himmelfarb M, 2004, CANCER LETT, V204, P69, DOI 10.1016/j.canlet.2003.09.011
   HUANG L, 1993, J BIOL CHEM, V268, P26725
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kloten V, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3375
   Knowles MA, 2006, CARCINOGENESIS, V27, P361, DOI 10.1093/carcin/bgi310
   Kristiansen G, 2011, J BIOL CHEM, V286, P43417, DOI 10.1074/jbc.M111.227553
   Lu Y, 2011, AM J TRANSL RES, V3, P8
   MASTERS JRW, 1986, CANCER RES, V46, P3630
   Mhawech-Fauceglia P, 2007, BJU INT, V100, P1182, DOI 10.1111/j.1464-410X.2007.07090.x
   Nieder AM, 2005, UROLOGY, V66, P108, DOI 10.1016/j.urology.2005.08.066
   Noetzel E, 2012, ONCOGENE, V31, P2101, DOI 10.1038/onc.2011.403
   Noetzel E, 2010, ONCOGENE, V29, P4814, DOI 10.1038/onc.2010.229
   Obayashi Y, 2008, ONCOL REP, V19, P1245
   Oing C, 2011, CLIN EPIGENETICS, V2, P419, DOI 10.1007/s13148-011-0043-5
   Otto W, 2011, BJU INT, V107, P404, DOI 10.1111/j.1464-410X.2010.09515.x
   Paris S, 2002, INT J CANCER, V97, P615, DOI 10.1002/ijc.10120
   Pita JM, 2009, BRIT J CANCER, V101, P1782, DOI 10.1038/sj.bjc.6605340
   REMMELE W, 1987, PATHOLOGE, V8, P138
   Sahai E, 2005, CURR OPIN GENET DEV, V15, P87, DOI 10.1016/j.gde.2004.12.002
   Salier JP, 1996, BIOCHEM J, V315, P1, DOI 10.1042/bj3150001
   Selbi W, 2006, KIDNEY INT, V70, P1287, DOI 10.1038/sj.ki.5001760
   Shahin O, 2003, J UROLOGY, V169, P96, DOI 10.1016/S0022-5347(05)64044-X
   Stein John P, 2008, Curr Urol Rep, V9, P179, DOI 10.1007/s11934-008-0031-2
   Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200
   van Rhijn BWG, 2009, EUR UROL, V56, P430, DOI 10.1016/j.eururo.2009.06.028
   Veeck J, 2008, ONCOGENE, V27, P865, DOI 10.1038/sj.onc.1210669
   Veeck J, 2008, Pathologe, V29 Suppl 2, P338, DOI 10.1007/s00292-008-1044-9
   Werbowetski-Ogilvie TE, 2006, CANCER RES, V66, P1464, DOI 10.1158/0008-5472.CAN-05-1913
   Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697
   Zhang S, 2013, ONCOL REP, V29, P1819, DOI 10.3892/or.2013.2309
   ZHAO M, 1995, J BIOL CHEM, V270, P26657, DOI 10.1074/jbc.270.44.26657
   Zhuo L, 2008, CONNECT TISSUE RES, V49, P311, DOI 10.1080/03008200802325458
   Zhuo LS, 2004, J BIOL CHEM, V279, P38079, DOI 10.1074/jbc.R300039200
NR 40
TC 40
Z9 42
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD MAR
PY 2014
VL 35
IS 3
BP 727
EP 736
DI 10.1093/carcin/bgt375
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AC7RZ
UT WOS:000332730900023
PM 24265292
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Damania, D
   Subramanian, H
   Backman, V
   Anderson, EC
   Wong, MH
   McCarty, OJT
   Phillips, KG
AF Damania, Dhwanil
   Subramanian, Hariharan
   Backman, Vadim
   Anderson, Eric C.
   Wong, Melissa H.
   McCarty, Owen J. T.
   Phillips, Kevin G.
TI Network signatures of nuclear and cytoplasmic density alterations in a
   model of pre and postmetastatic colorectal cancer
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE colorectal cancer; cancer cell lines; quantitative phase microscopy;
   partial wave spectroscopic microscopy; disorder strength; cell density;
   subcellular architecture; label-free optical microscopy
ID NONITERATIVE PHASE RETRIEVAL; BREAST-CANCER; FIELD CARCINOGENESIS;
   RAMAN-SPECTROSCOPY; DISORDER STRENGTH; EPITHELIAL-CELLS;
   LIGHT-SCATTERING; NANOCYTOLOGY; DIAGNOSIS
AB Cells contributing to the pathogenesis of cancer possess cytoplasmic and nuclear structural alterations that accompany their aberrant genetic, epigenetic, and molecular perturbations. Although it is known that architectural changes in primary and metastatic tumor cells can be quantified through variations in cellular density at the nanometer and micrometer spatial scales, the interdependent relationships among nuclear and cytoplasmic density as a function of tumorigenic potential has not been thoroughly investigated. We present a combined optical approach utilizing quantitative phase microscopy and partial wave spectroscopic microscopy to perform parallel structural characterizations of cellular architecture. Using the isogenic SW480 and SW620 cell lines as a model of pre and postmetastatic transition in colorectal cancer, we demonstrate that nuclear and cytoplasmic nanoscale disorder, micron-scale dry mass content, mean dry mass density, and shape metrics of the dry mass density histogram are uniquely correlated within and across different cellular compartments for a given cell type. The correlations of these physical parameters can be interpreted as networks whose nodal importance and level of connection independence differ according to disease stage. This work demonstrates how optically derived biophysical parameters are linked within and across different cellular compartments during the architectural orchestration of the metastatic phenotype. (C) 2014 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Damania, Dhwanil; Subramanian, Hariharan; Backman, Vadim] Northwestern Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   [Anderson, Eric C.; Wong, Melissa H.; McCarty, Owen J. T.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97239 USA.
   [Wong, Melissa H.; McCarty, Owen J. T.] Oregon Hlth & Sci Univ, Sch Med, Dept Cell & Dev Biol, Portland, OR 97239 USA.
   [Wong, Melissa H.; Phillips, Kevin G.] Oregon Hlth & Sci Univ, Sch Med, Dept Dermatol, Portland, OR 97239 USA.
   [McCarty, Owen J. T.; Phillips, Kevin G.] Oregon Hlth & Sci Univ, Sch Med, Dept Biomed Engn, Portland, OR 97239 USA.
C3 Northwestern University; Oregon Health & Science University; Oregon
   Health & Science University; Oregon Health & Science University; Oregon
   Health & Science University
RP Phillips, KG (通讯作者)，Oregon Hlth & Sci Univ, Sch Med, Dept Dermatol, Portland, OR 97239 USA.
EM phillkev@ohsu.edu
RI Backman, Vadim/B-6689-2009
FU National Institutes of Health [U54CA143906, U54CA143869, R01CA128641,
   R01CA165309]; Physical Sciences in Oncology Young Investigator Award;
   Medical Research Foundation Early Clinical Investigator Award
FX This work was supported by the National Institutes of Health under grant
   nos. U54CA143906 (O.J.T.M, K.G.P.), U54CA143869, R01CA128641,
   R01CA165309 (D.D., V.B., H.S.); a Physical Sciences in Oncology Young
   Investigator Award (D.D., H.S., K.G.P.); and a Medical Research
   Foundation Early Clinical Investigator Award (K.G.P.). D.D. wishes to
   thank Varun Gupta for assistance with PWS measurements.
CR Agus DB, 2013, SCI REP-UK, V3, DOI 10.1038/srep01449
   Allen JE, 2010, CURR COLORECT CANC R, V6, P212, DOI 10.1007/s11888-010-0069-7
   Baker SM, 2012, CELL MOL BIOENG, V5, P488, DOI 10.1007/s12195-012-0249-4
   BARER R, 1952, NATURE, V169, P366, DOI 10.1038/169366b0
   Bishitz Y., 2013, J BIOPHOTONICS
   Bista RK, 2012, BREAST CANCER RES TR, V135, P115, DOI 10.1007/s10549-012-2125-2
   Cerussi A, 2007, P NATL ACAD SCI USA, V104, P4014, DOI 10.1073/pnas.0611058104
   Chen K, 2006, OPT LETT, V31, P2015, DOI 10.1364/OL.31.002015
   Cherkezyan L, 2013, PHYS REV LETT, V111, DOI 10.1103/PhysRevLett.111.033903
   Damania D, 2013, INT J CANCER, V133, P1143, DOI 10.1002/ijc.28122
   Damania D, 2012, CANCER RES, V72, P2720, DOI 10.1158/0008-5472.CAN-11-3807
   Damania D, 2010, BIOPHYS J, V99, P989, DOI 10.1016/j.bpj.2010.05.023
   Frank J, 2011, APPL OPTICS, V50, P427, DOI 10.1364/AO.50.000427
   Frank J, 2010, J OPT SOC AM A, V27, P2244, DOI 10.1364/JOSAA.27.002244
   Girshovitz P, 2012, BIOMED OPT EXPRESS, V3, P1757, DOI 10.1364/BOE.3.001757
   Gurjar RS, 2001, NAT MED, V7, P1245, DOI 10.1038/nm1101-1245
   Haka AS, 2005, P NATL ACAD SCI USA, V102, P12371, DOI 10.1073/pnas.0501390102
   Hewitt RE, 2000, J PATHOL, V192, P446
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Kim YL, 2005, APPL OPTICS, V44, P366, DOI 10.1364/AO.44.000366
   LEIBOVITZ A, 1976, CANCER RES, V36, P4562
   Michor F, 2011, NAT REV CANCER, V11, P657, DOI 10.1038/nrc3092
   Mir M, 2011, P NATL ACAD SCI USA, V108, P13124, DOI 10.1073/pnas.1100506108
   Mourant JR, 1995, LASER SURG MED, V17, P350, DOI 10.1002/lsm.1900170403
   Paganin D, 1998, PHYS REV LETT, V80, P2586, DOI 10.1103/PhysRevLett.80.2586
   Pham HV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055676
   Phillips KG, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00072
   Phillips KG, 2012, PHYS REV LETT, V109, DOI 10.1103/PhysRevLett.109.118105
   Popescu G, 2008, METHOD CELL BIOL, V90, P87, DOI 10.1016/S0091-679X(08)00805-4
   PRADHAN P, 1994, PHYS REV B, V50, P9644, DOI 10.1103/PhysRevB.50.9644
   Preza C., 2012, HDB BIOMEDICAL OPTIC, P483
   Roy HK, 2009, CANCER RES, V69, P4476, DOI 10.1158/0008-5472.CAN-08-4780
   Stypula Y, 2011, GASTROENTEROLOGY, V140, pS765
   Subramanian H, 2009, CANCER RES, V69, P5357, DOI 10.1158/0008-5472.CAN-08-3895
   Subramanian H, 2008, P NATL ACAD SCI USA, V105, P20118, DOI 10.1073/pnas.0804723105
   Terry N, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3631799
   Wang Z, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3656732
   Wax A, 2002, BIOPHYS J, V82, P2256, DOI 10.1016/S0006-3495(02)75571-9
NR 38
TC 16
Z9 19
U1 0
U2 18
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JAN
PY 2014
VL 19
IS 1
AR 016016
DI 10.1117/1.JBO.19.1.016016
PG 11
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
   Medical Imaging
GA AB6IZ
UT WOS:000331892700048
PM 24441943
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Singh, PK
   Preus, L
   Hu, Q
   Yan, L
   Long, MD
   Morrison, CD
   Nesline, M
   Johnson, CS
   Koochekpour, S
   Kohli, M
   Liu, S
   Trump, DL
   Sucheston-Campbell, LE
   Campbell, MJ
AF Singh, Prashant K.
   Preus, Leah
   Hu, Qiang
   Yan, Li
   Long, Mark D.
   Morrison, Carl D.
   Nesline, Mary
   Johnson, Candace S.
   Koochekpour, Shahriar
   Kohli, Manish
   Liu, Song
   Trump, Donald L.
   Sucheston-Campbell, Lara E.
   Campbell, Moray J.
TI Serum microRNA expression patterns that predict early treatment failure
   in prostate cancer patients
SO ONCOTARGET
LA English
DT Article
DE Prostate cancer; microRNA; biochemical progression; miR-103; miR-125b;
   miR-222; cancer epigenetics
ID CIRCULATING MICRORNAS; DOWN-REGULATION; BREAST-CANCER; BIOCHEMICAL
   RECURRENCE; TAMOXIFEN RESISTANCE; TUMOR PROGRESSION; MIR-200 FAMILY;
   GROWTH; PROLIFERATION; METASTASIS
AB We aimed to identify microRNA (miRNA) expression patterns in the serum of prostate cancer (CaP) patients that predict the risk of early treatment failure following radical prostatectomy (RP). Microarray and Q-RT-PCR analyses identified 43 miRNAs as differentiating disease stages within 14 prostate cell lines and reflected publically available patient data. 34 of these miRNA were detectable in the serum of CaP patients. Association with time to biochemical progression was examined in a cohort of CaP patients following RP. A greater than two-fold increase in hazard of biochemical progression associated with altered expression of miR-103, miR-125b and miR-222 (p<.0008) in the serum of CaP patients. Prediction models based on penalized regression analyses showed that the levels of the miRNAs and PSA together were better at detecting false positives than models without miRNAs, for similar level of sensitivity. Analyses of publically available data revealed significant and reciprocal relationships between changes in CpG methylation and miRNA expression patterns suggesting a role for CpG methylation to regulate miRNA. Exploratory validation supported roles for miR-222 and miR-125b to predict progression risk in CaP. The current study established that expression patterns of serum-detectable miRNAs taken at the time of RP are prognostic for men who are at risk of experiencing subsequent early biochemical progression. These non-invasive approaches could be used to augment treatment decisions.
C1 [Singh, Prashant K.; Long, Mark D.; Johnson, Candace S.; Campbell, Moray J.] Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.
   [Preus, Leah; Nesline, Mary; Sucheston-Campbell, Lara E.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA.
   [Hu, Qiang; Yan, Li; Liu, Song] Roswell Pk Canc Inst, Dept Biostat & Bioinformat, Buffalo, NY 14263 USA.
   [Morrison, Carl D.] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.
   [Koochekpour, Shahriar] Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA.
   [Kohli, Manish] Mayo Clin, Dept Med Oncol, Rochester, MN USA.
   [Trump, Donald L.] Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive
   Cancer Center; Roswell Park Comprehensive Cancer Center; Roswell Park
   Comprehensive Cancer Center; Roswell Park Comprehensive Cancer Center;
   Mayo Clinic; Roswell Park Comprehensive Cancer Center
RP Campbell, MJ (通讯作者)，Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA.
EM Lara.Sucheston@RoswellPark.org; Moray.Campbell@RoswellPark.org
RI Campbell, Moray/ABF-1264-2021; SINGH, PRASHANT/K-5405-2014; Kohli,
   Manish/AAN-8862-2021; Hu, Qiang/AAJ-9438-2020
OI Long, Mark/0000-0003-1120-8176; Campbell, Moray/0000-0002-3355-0928
FU University at Buffalo Clinical and Translational Research Center;
   Buffalo Translational Consortium; NCI [CA016056]; Roswell Park Cancer
   Institute DataBank and Biorepository;  [T32 CA009072-38]
FX MJC and LESC acknowledge support of the Pilot Studies program of the
   University at Buffalo Clinical and Translational Research Center and the
   Buffalo Translational Consortium; The NCI Cancer Center Support Grant to
   the Roswell Park Cancer Institute [CA016056]; The Roswell Park Cancer
   Institute DataBank and Biorepository; Support for MDL from T32
   CA009072-38 - Drug Development and Cancer Treatments.
CR Ambrosone CB, 2006, CANCER EPIDEM BIOMAR, V15, P1574, DOI 10.1158/1055-9965.EPI-06-0627
   Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144
   Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696
   [Anonymous], 2004, Stat. Appl. Genet. Mol. Biol., DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]
   Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215
   Bello-DeOcampo D, 2003, CURR DRUG TARGETS, V4, P197, DOI 10.2174/1389450033491118
   Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85
   Brase JC, 2011, INT J CANCER, V128, P608, DOI 10.1002/ijc.25376
   Buyyounouski MK, 2012, J CLIN ONCOL, V30, P1857, DOI 10.1200/JCO.2011.35.1924
   Campbell M. J., 2013, CANCERS IN PRESS
   Ciafrè SA, 2005, BIOCHEM BIOPH RES CO, V334, P1351, DOI 10.1016/j.bbrc.2005.07.030
   Cookson MS, 2007, J UROLOGY, V177, P540, DOI 10.1016/j.juro.2006.10.097
   Cortez MA, 2011, NAT REV CLIN ONCOL, V8, P467, DOI 10.1038/nrclinonc.2011.76
   COX DR, 1972, J R STAT SOC B, V34, P187
   Creighton CJ, 2010, CANCER RES, V70, P1906, DOI 10.1158/0008-5472.CAN-09-3875
   Dai YM, 2011, HEAD NECK-J SCI SPEC, V33, P786, DOI 10.1002/hed.21540
   Di Vizio D, 2012, AM J PATHOL, V181, P1573, DOI 10.1016/j.ajpath.2012.07.030
   Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677
   Felli N, 2005, P NATL ACAD SCI USA, V102, P18081, DOI 10.1073/pnas.0506216102
   Freedland SJ, 2011, CANCER-AM CANCER SOC, V117, P1123, DOI 10.1002/cncr.25477
   Friedman J, 2010, J STAT SOFTW, V33, P1, DOI 10.18637/jss.v033.i01
   Glaser AP, 2012, CURR UROL REP
   Gopal Rao G., 2012, J ANTIMICROB CHEMOTH
   Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Han L, MOL CANC, V9, P252
   Hao JW, 2012, ONCOL REP, V27, P1504, DOI 10.3892/or.2012.1652
   Ignatiadis M, 2007, PHARMACOGENOMICS, V8, P101, DOI 10.2217/14622416.8.1.101
   Keutgen XM, 2012, CLIN CANCER RES, V18, P2032, DOI 10.1158/1078-0432.CCR-11-2487
   Kim A, 2012, J SURG ONCOL
   Koochekpour S, 2004, PROSTATE, V60, P141, DOI 10.1002/pros.20053
   KURIYAMA M, 1980, Cancer Research, V40, P4658
   Lee YS, 2005, J BIOL CHEM, V280, P16635, DOI 10.1074/jbc.M412247200
   Leskelä S, 2011, ENDOCR-RELAT CANCER, V18, P85, DOI 10.1677/ERC-10-0148
   Li N, 2012, FEBS LETT, V586, P722, DOI 10.1016/j.febslet.2012.01.025
   Li QY, 2013, CELL, V152, P633, DOI 10.1016/j.cell.2012.12.034
   Lin D, 2011, J INT MED RES, V39, P1870, DOI 10.1177/147323001103900530
   Ling MT, 2001, J ENDOCRINOL, V170, P287, DOI 10.1677/joe.0.1700287
   Lussier YA, 2012, J AM MED INFORM ASSN, V19, P156, DOI 10.1136/amiajnl-2011-000419
   Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017
   Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304
   Medina R, 2008, CANCER RES, V68, P2773, DOI 10.1158/0008-5472.CAN-07-6754
   Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029
   Mestdagh P, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-r64
   Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Navone NM, 1997, CLIN CANCER RES, V3, P2493
   Nguyen HC., 2012, Prostate
   Nikiforova MN, 2008, J CLIN ENDOCR METAB, V93, P1600, DOI 10.1210/jc.2007-2696
   Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809
   Palma J, 2012, NUCLEIC ACIDS RES, V40, P9125, DOI 10.1093/nar/gks656
   Papaconstantinou IG, 2012, PANCREAS
   Papadopoulos GL, 2009, BIOINFORMATICS, V25, P1991, DOI 10.1093/bioinformatics/btp299
   Pigati L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013515
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Puerta-Gil P, 2012, AM J PATHOL, V180, P1808, DOI 10.1016/j.ajpath.2012.01.034
   Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827
   Schroeder FH, 2009, NEW ENGL J MED, V360, P1320, DOI 10.1056/NEJMoa0810084
   Selth LA, 2013, BRIT J CANCER, V109, P641, DOI 10.1038/bjc.2013.369
   Selth LA, 2012, ENDOCR RELAT CANC
   Selth Luke A, 2013, Methods Mol Biol, V1024, P235, DOI 10.1007/978-1-62703-453-1_19
   Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104
   Simon N, 2011, J STAT SOFTW, V39, P1
   Sita-Lumsden A, 2013, BRIT J CANCER, V108, P1925, DOI 10.1038/bjc.2013.192
   Siva AC, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-17
   Srougi M, 2011, UROL ONCOL
   Sun D, 2013, ONCOGENE
   Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   THALMANN GN, 1994, CANCER RES, V54, P2577
   Thorne JL, 2011, NUCLEIC ACIDS RES, V39, P2045, DOI 10.1093/nar/gkq875
   Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77
   Tsuchiyama K, 2013, PROSTATE, V73, P827, DOI 10.1002/pros.22626
   Valastyan S, 2010, CANCER RES, V70, P5147, DOI 10.1158/0008-5472.CAN-10-0410
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wach S, 2012, INT J CANCER, V130, P611, DOI 10.1002/ijc.26064
   Wang JB, 2010, CANCER LETT, V297, P137, DOI 10.1016/j.canlet.2010.07.018
   Wang L, 2009, CANCER RES, V69, P9490, DOI 10.1158/0008-5472.CAN-09-2183
   WANG MC, 1979, INVEST UROL, V17, P159
   Watahiki A, 2013, INT J MOL SCI, V14, P7757, DOI 10.3390/ijms14047757
   Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950
   Yang XP, 2012, BIORESEARCH OPEN ACC, V1, P55, DOI 10.1089/biores.2012.9903
   Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579
   Yu DQ, 2012, ONCOL LETT, V3, P1221, DOI 10.3892/ol.2012.638
   Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200
NR 85
TC 48
Z9 56
U1 0
U2 10
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PY 2014
VL 5
IS 3
BP 824
EP 840
DI 10.18632/oncotarget.1776
PG 17
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA AC7IK
UT WOS:000332701300022
PM 24583788
OA Green Submitted, Green Published, gold
DA 2025-01-12
ER

PT J
AU Karakoula, K
   Jacques, TS
   Phipps, KP
   Harkness, W
   Thompson, D
   Harding, BN
   Darling, JL
   Warr, TJ
AF Karakoula, Katherine
   Jacques, Thomas S.
   Phipps, Kim P.
   Harkness, William
   Thompson, Dominic
   Harding, Brian N.
   Darling, John L.
   Warr, Tracy J.
TI Epigenetic genome-wide analysis identifies <i>BEX1</i> as a candidate
   tumour suppressor gene in paediatric intracranial ependymoma
SO CANCER LETTERS
LA English
DT Article
DE Paediatric ependymoma; Pharmacological unmasking; 5-Aza-dC; DNA
   methylation; BEX1
ID NEUROTROPHIN RECEPTOR; PROMOTER METHYLATION; DOWN-REGULATION;
   NERVOUS-SYSTEM; BREAST-CANCER; EXPRESSION; CHILDHOOD; PATHWAY; MARKERS;
   GROWTH
AB Promoter hypermethylation and transcriptional silencing is a common epigenetic mechanism of gene inactivation in cancer. To identify targets of epigenetic silencing in paediatric intracranial ependymoma, we used a pharmacological unmasking approach through treatment of 3 ependymoma short-term cell cultures with the demethylating agent 5-Aza-2'-deoxycytidine followed by global expression microarray analysis. We identified 55 candidate epigenetically silenced genes, which are involved in the regulation of apoptosis, Wnt signalling, p53 and cell differentiation. The methylation status of 26 of these genes was further determined by combined bisulfite restriction analysis (COBRA) and genomic sequencing in a cohort of 40 ependymoma samples. The most frequently methylated genes were BEX1 (27/40 cases), BAI2 (20/40), CCND2 (18/40), and CDKN2A (14/40). A high correlation between promoter hypermethylation and decreased gene expression levels was established by real-time quantitative PCR, suggesting the involvement of these genes in ependymoma tumourigenesis. Furthermore, ectopic expression of brain-expressed X-linked 1 (BEX1) in paediatric ependymoma short-term cell cultures significantly suppressed cell proliferation and colony formation. These data suggest that promoter hypermethylation contributes to silencing of target genes in paediatric intracranial ependymoma. Epigenetic inactivation of BEX1 supports its role as a candidate tumour suppressor gene in intracranial ependymoma, and a potential target for novel therapies for ependymoma in children. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Karakoula, Katherine; Darling, John L.; Warr, Tracy J.] Wolverhampton Univ, Sch Appl Sci, Brain Tumour Res Ctr, Wolverhampton WV1 1LY, W Midlands, England.
   [Jacques, Thomas S.] UCL, UCL Inst Child Hlth, Birth Defects Res Ctr, Neural Dev Unit, London WC1E 6BT, England.
   [Jacques, Thomas S.] Children NHS Fdn Trust, Great Ormond St Hosp, Dept Histopathol, London WC1N 3JH, England.
   [Phipps, Kim P.; Harkness, William; Thompson, Dominic] Children NHS Fdn Trust, Great Ormond St Hosp, Dept Neurosurg, London WC1N 3JH, England.
   [Harding, Brian N.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Div Neuropathol, Philadelphia, PA 19104 USA.
C3 University of Wolverhampton; University of London; University College
   London; University of London; University College London; Great Ormond
   Street Hospital for Children NHS Foundation Trust; University of London;
   University College London; Great Ormond Street Hospital for Children NHS
   Foundation Trust; University of Pennsylvania; Pennsylvania Medicine;
   Childrens Hospital of Philadelphia
RP Karakoula, K (通讯作者)，Wolverhampton Univ, Sch Appl Sci, Brain Tumour Res Ctr, City Campus South,Wulfruna St, Wolverhampton WV1 1LY, W Midlands, England.
EM A.Karakoula@wlv.ac.uk
RI Jacques, Thomas/C-2209-2008; Thompson, Dominic/AAS-8814-2020
OI Thompson, Dominic/0000-0002-1114-9869
FU Brain Tumour Charity
FX This work was supported by The Brain Tumour Charity.
CR Alonso ME, 2003, CANCER GENET CYTOGEN, V144, P134, DOI 10.1016/S0165-4608(02)00928-7
   Becker EBE, 2004, J NEUROSCI, V24, P8762, DOI 10.1523/JNEUROSCI.2953-04.2004
   Carter M, 2002, BRIT J CANCER, V86, P929, DOI 10.1038/sj.bjc.6600180
   de Ronde JJ, 2013, BREAST CANCER RES TR, V137, P213, DOI 10.1007/s10549-012-2340-x
   Ding KF, 2009, CARCINOGENESIS, V30, P35, DOI 10.1093/carcin/bgn251
   Drozdov I, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022457
   Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11
   Foltz G, 2006, CANCER RES, V66, P6665, DOI 10.1158/0008-5472.CAN-05-4453
   Gajjar A, 2013, PEDIATR BLOOD CANCER, V60, P1022, DOI 10.1002/pbc.24427
   Garvin JH, 2012, PEDIATR BLOOD CANCER, V59, P1183, DOI 10.1002/pbc.24274
   Gaspar N, 2006, PEDIATR BLOOD CANCER, V46, P604, DOI 10.1002/pbc.20532
   Hawes SE, 2010, LUNG CANCER, V69, P172, DOI 10.1016/j.lungcan.2009.11.002
   HERMAN JG, 1995, CANCER RES, V55, P4525
   Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173
   Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816
   Jost E, 2009, CANCER LETT, V281, P24, DOI 10.1016/j.canlet.2009.02.002
   Kaderali Z, 2009, CHILD NERV SYST, V25, P787, DOI 10.1007/s00381-008-0771-9
   Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208
   Karakoula K, 2008, GENE CHROMOSOME CANC, V47, P1005, DOI 10.1002/gcc.20607
   Kaur B, 2009, CANCER RES, V69, P1212, DOI 10.1158/0008-5472.CAN-08-1166
   Kilday JP, 2012, CLIN CANCER RES, V18, P2001, DOI 10.1158/1078-0432.CCR-11-2489
   Kilday JP, 2009, MOL CANCER RES, V7, P765, DOI 10.1158/1541-7786.MCR-08-0584
   Kim HE, 2010, PIGM CELL MELANOMA R, V23, P845, DOI 10.1111/j.1755-148X.2010.00753.x
   Kleihues P, 2002, J NEUROPATH EXP NEUR, V61, P215, DOI 10.1093/jnen/61.3.215
   Koo JH, 2004, J NEUROCHEM, V90, P102, DOI 10.1111/j.1471-4159.2004.02463.x
   Korshunov A, 2010, J CLIN ONCOL, V28, P3182, DOI 10.1200/JCO.2009.27.3359
   Lewandowicz G.M., 2002, EUR J CANCER, P1955
   Lodygin D, 2005, CANCER RES, V65, P4218, DOI 10.1158/0008-5472.CAN-04-4407
   Mahner S, 2008, BRIT J CANCER, V99, P1269, DOI 10.1038/sj.bjc.6604650
   Makino K, 2010, CHILD NERV SYST, V26, P1029, DOI 10.1007/s00381-010-1126-x
   Mendrzyk F, 2006, CLIN CANCER RES, V12, P2070, DOI 10.1158/1078-0432.CCR-05-2363
   Michalowski MB, 2006, CANCER GENET CYTOGEN, V166, P74, DOI 10.1016/j.cancergencyto.2005.09.004
   Modena P, 2006, J CLIN ONCOL, V24, P5223, DOI 10.1200/JCO.2006.06.3701
   Morris MR, 2011, ONCOGENE, V30, P1390, DOI 10.1038/onc.2010.525
   Mueller W, 2007, ONCOGENE, V26, P583, DOI 10.1038/sj.onc.1209805
   Mukai J, 2000, J BIOL CHEM, V275, P17566, DOI 10.1074/jbc.C000140200
   Ostrow KL, 2009, CLIN CANCER RES, V15, P1184, DOI 10.1158/1078-0432.CCR-08-1304
   Pehlivan M, 2009, LEUKEMIA RES, V33, P1062, DOI 10.1016/j.leukres.2008.11.013
   Qiu J, 2008, LAB INVEST, V88, P910, DOI 10.1038/labinvest.2008.66
   Rogers HA, 2012, ACTA NEUROPATHOL, V123, P711, DOI 10.1007/s00401-011-0904-1
   Rousseau E, 2003, NEUROPATH APPL NEURO, V29, P574, DOI 10.1046/j.0305-1846.2003.00505.x
   Rowther F B, 2012, J Biomol Tech, V23, P1, DOI 10.7171/jbt.12-2301-004
   Sarkar R, 2010, COLORECTAL DIS, V12, P316, DOI 10.1111/j.1463-1318.2009.01829.x
   Sharma MC, 2009, NEUROPATHOLOGY, V29, P148, DOI 10.1111/j.1440-1789.2008.00962.x
   Suarez-Merino B, 2005, NEURO-ONCOLOGY, V7, P20
   Suzuki SO, 2000, MODERN PATHOL, V13, P548, DOI 10.1038/modpathol.3880095
   Vilar M, 2006, EMBO J, V25, P1219, DOI 10.1038/sj.emboj.7601017
   Waha A, 2004, INT J CANCER, V110, P542, DOI 10.1002/ijc.20165
   Witt H, 2011, CANCER CELL, V20, P143, DOI 10.1016/j.ccr.2011.07.007
NR 49
TC 19
Z9 21
U1 0
U2 15
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD APR 28
PY 2014
VL 346
IS 1
BP 34
EP 44
DI 10.1016/j.canlet.2013.12.005
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AE5GY
UT WOS:000334017000005
PM 24333734
DA 2025-01-12
ER

PT J
AU Wen, H
   Li, YY
   Xi, YX
   Jiang, SM
   Stratton, S
   Peng, DN
   Tanaka, K
   Ren, YF
   Xia, Z
   Wu, J
   Li, B
   Barton, MC
   Li, W
   Li, HT
   Shi, XB
AF Wen, Hong
   Li, Yuanyuan
   Xi, Yuanxin
   Jiang, Shiming
   Stratton, Sabrina
   Peng, Danni
   Tanaka, Kaori
   Ren, Yongfeng
   Xia, Zheng
   Wu, Jun
   Li, Bing
   Barton, Michelle C.
   Li, Wei
   Li, Haitao
   Shi, Xiaobing
TI ZMYND11 links histone H3.3K36me3 to transcription elongation and tumour
   suppression
SO NATURE
LA English
DT Article
ID ADENOVIRUS E1A-ASSOCIATED PROTEIN; HIGH-AFFINITY BINDING; PWWP DOMAIN;
   LYSINE 36; PLANT HOMEODOMAIN; H3; RECOGNITION; BS69; METHYLATION;
   MUTATIONS
AB Recognition of modified histones by 'reader' proteins plays a critical role in the regulation of chromatin(1). H3K36 trimethylation (H3K36me3) is deposited onto the nucleosomes in the transcribed regions after RNA polymerase II elongation. In yeast, this mark in turn recruits epigenetic regulators to reset the chromatin to a relatively repressive state, thus suppressing cryptic transcription(2). However, much less is known about the role of H3K36me3 in transcription regulation in mammals. This is further complicated by the transcription-coupled incorporation of the histone variant H3.3 in gene bodies(3). Here we show that the candidate tumour suppressor ZMYND11 specifically recognizes H3K36me3 on H3.3 (H3.3K36me3) and regulates RNA polymerase II elongation. Structural studies show that in addition to the trimethyl-lysine binding by an aromatic cage within the PWWP domain, the H3.3-dependent recognition is mediated by the encapsulation of the H3.3-specific 'Ser 31' residue in a composite pocket formed by the tandem bromo-PWWP domains of ZMYND11. Chromatin immunoprecipitation followed by sequencing shows a genome-wide co-localization of ZMYND11 with H3K36me3 and H3.3 in gene bodies, and its occupancy requires the pre-deposition of H3.3K36me3. Although ZMYND11 is associated with highly expressed genes, it functions as an unconventional transcription corepressor by modulating RNA polymerase II at the elongation stage. ZMYND11 is critical for the repression of a transcriptional program that is essential for tumour cell growth; low expression levels of ZMYND11 in breast cancer patients correlate with worse prognosis. Consistently, overexpression of ZMYND11 suppresses cancer cell growth in vitro and tumour formation in mice. Together, this study identifies ZMYND11 as an H3.3-specific reader of H3K36me3 that links the histone-variant-mediated transcription elongation control to tumour suppression.
C1 [Wen, Hong; Jiang, Shiming; Stratton, Sabrina; Peng, Danni; Tanaka, Kaori; Barton, Michelle C.; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
   [Wen, Hong; Barton, Michelle C.; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Ctr Canc Epigenet, Ctr Genet & Genom, Houston, TX 77030 USA.
   [Wen, Hong; Barton, Michelle C.; Shi, Xiaobing] Univ Texas MD Anderson Canc Ctr, Ctr Stem Cell & Dev Biol, Houston, TX 77030 USA.
   [Li, Yuanyuan; Ren, Yongfeng; Li, Haitao] Tsinghua Univ, Sch Life Sci, Struct Biol Ctr, MOE Key Lab Prot Sci, Beijing 100084, Peoples R China.
   [Li, Yuanyuan; Ren, Yongfeng; Li, Haitao] Tsinghua Univ, Sch Med, Dept Basic Med Sci, Beijing 100084, Peoples R China.
   [Xi, Yuanxin; Xia, Zheng; Li, Wei] Baylor Coll Med, Dept Mol & Cellular Biol, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
   [Wu, Jun; Li, Bing] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
   [Barton, Michelle C.; Shi, Xiaobing] Univ Texas Houston, Grad Sch Biomed Sci, Genes & Dev Grad Program, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   UTMD Anderson Cancer Center; Tsinghua University; Tsinghua University;
   Baylor College of Medicine; University of Texas System; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Health Science Center Houston
RP Shi, XB (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA.
EM hwen@mdanderson.org; WL1@bcm.edu; lht@tsinghua.edu.cn;
   xbshi@mdanderson.org
RI Xing, Puyuan/GMX-3723-2022; Li, Wei/A-8544-2009; Li, Haitao/B-2668-2012;
   Xia, Zheng/F-6561-2014
OI Wen, Hong/0000-0001-8739-4572; Barton, Michelle/0000-0002-4042-1374; Li,
   Haitao/0000-0001-6741-293X; Shi, Xiaobing/0000-0001-5242-8189; Xia,
   Zheng/0000-0003-3364-8324; Li, Wei/0000-0001-9931-5990
FU American Cancer Society [RSG-13-290-01-TBE]; National institutes of
   Health (NIH)/MDACC [CCSG CA016672]; Major State Basic Research
   Development Program in China [2011CB965300]; Program for New Century
   Excellent Talents in University; China Postdoctoral Science Foundation
   [2012M510413]; Kimmel Scholar Award;  [CPRITRP110471];  [Welch G1719]; 
   [NIH R01HG007538];  [NIH R01GM090077];  [Welch I1713]
FX We thank J. Lipsick, Y. Shi, P. Chi, C. D. Allis, D. J. Patel, S. R.
   Dent, J. Tyler, M. Galko, T. Westbrook, M. Lee, T. Yao and E. Guccione
   for comments and reagents. We thank the staff at beamlines 1W2B of the
   Beijing Synchrotron Radiation Facility and BL17U of the Shanghai
   Synchrotron Radiation Facility for their assistance in data collection.
   We thank J. Munch for editing the manuscript. This work was supported by
   grants to X. S. (CPRITRP110471, Welch G1719, American Cancer Society
   RSG-13-290-01-TBE, and National institutes of Health (NIH)/MDACC CCSG
   CA016672), H. L. (The Major State Basic Research Development Program in
   China, 2011CB965300 and Program for New Century Excellent Talents in
   University), W. L. (CPRITRP110471, NIH R01HG007538), B. L. (NIH
   R01GM090077, Welch I1713), Y. L. (China Postdoctoral Science Foundation,
   2012M510413) and H. W. (MD Anderson IRG, Center for Cancer Epigenetics
   pilot grant). W. L. is a recipient of a Duncan Scholar Award and X. S.
   is a recipient of a Kimmel Scholar Award.
CR Abmayr Susan M, 2006, Curr Protoc Pharmacol, VChapter 12, DOI [10.1002/0471142727.mb1201s75, 10.1002/0471141755.ph1203s35]
   Akué-Gédu R, 2009, J MED CHEM, V52, P6369, DOI 10.1021/jm901018f
   Ansieau S, 2003, PATHOL BIOL, V51, P397, DOI 10.1016/S0369-8114(03)00019-1
   Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426
   Boettiger AN, 2009, SCIENCE, V325, P471, DOI 10.1126/science.1173976
   Danko CG, 2013, MOL CELL, V50, P212, DOI 10.1016/j.molcel.2013.02.015
   Dhayalan A, 2010, J BIOL CHEM, V285, P26114, DOI 10.1074/jbc.M109.089433
   Edmunds JW, 2008, EMBO J, V27, P406, DOI 10.1038/sj.emboj.7601967
   Eidahl JO, 2013, NUCLEIC ACIDS RES, V41, P3924, DOI 10.1093/nar/gkt074
   Elsaesser SJ, 2010, CURR OPIN GENET DEV, V20, P110, DOI 10.1016/j.gde.2010.01.003
   Eswaran J, 2009, P NATL ACAD SCI USA, V106, P20198, DOI 10.1073/pnas.0901989106
   Fish PV, 2012, J MED CHEM, V55, P9831, DOI 10.1021/jm3010515
   Goldberg AD, 2010, CELL, V140, P678, DOI 10.1016/j.cell.2010.01.003
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   HATEBOER G, 1995, EMBO J, V14, P3159, DOI 10.1002/j.1460-2075.1995.tb07318.x
   Jin CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409
   Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728
   Kuo AJ, 2011, MOL CELL, V44, P609, DOI 10.1016/j.molcel.2011.08.042
   Ladendorff NE, 2001, ONCOGENE, V20, P125, DOI 10.1038/sj.onc.1204048
   Lewis PW, 2013, SCIENCE, V340, P857, DOI 10.1126/science.1232245
   Li B, 2007, SCIENCE, V316, P1050, DOI 10.1126/science.1139004
   Li YY, 2012, ACTA BIOCH BIOPH SIN, V44, P28, DOI 10.1093/abbs/gmr117
   Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494
   Luo ZJ, 2012, NAT REV MOL CELL BIO, V13, P543, DOI 10.1038/nrm3417
   Méndez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000
   Näär AM, 2001, ANNU REV BIOCHEM, V70, P475, DOI 10.1146/annurev.biochem.70.1.475
   Nechaev S, 2008, CELL CYCLE, V7, P1539, DOI 10.4161/cc.7.11.6006
   Qiu C, 2002, NAT STRUCT BIOL, V9, P217, DOI 10.1038/nsb759
   Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030
   Ray-Gallet D, 2011, MOL CELL, V44, P928, DOI 10.1016/j.molcel.2011.12.006
   Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298
   Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]
   Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835
   Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904
   Simon MD, 2007, CELL, V128, P1003, DOI 10.1016/j.cell.2006.12.041
   Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004
   Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024
   Turnbull WB, 2003, J AM CHEM SOC, V125, P14859, DOI 10.1021/ja036166s
   van Nuland R, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-12
   Venkatesh S, 2012, NATURE, V489, P452, DOI 10.1038/nature11326
   Vezzoli A, 2010, NAT STRUCT MOL BIOL, V17, P617, DOI 10.1038/nsmb.1797
   WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127
   Wei G, 2003, ANTICANCER RES, V23, P2173
   Wen H, 2010, J BIOL CHEM, V285, P9322, DOI 10.1074/jbc.C109.097667
   Wu H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018919
   Zeitlinger J, 2007, NAT GENET, V39, P1512, DOI 10.1038/ng.2007.26
   Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137
NR 49
TC 236
Z9 297
U1 1
U2 109
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD APR 10
PY 2014
VL 508
IS 7495
BP 263
EP +
DI 10.1038/nature13045
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AE4UK
UT WOS:000333979900048
PM 24590075
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Patel, HK
   Siklos, MI
   Abdelkarim, H
   Mendonca, EL
   Vaidya, A
   Petukhov, PA
   Thatcher, GRJ
AF Patel, Hitisha K.
   Siklos, Marton I.
   Abdelkarim, Hazem
   Mendonca, Emma L.
   Vaidya, Aditya
   Petukhov, Pavel A.
   Thatcher, Gregory R. J.
TI A Chimeric SERM-Histone Deacetylase Inhibitor Approach to Breast Cancer
   Therapy
SO CHEMMEDCHEM
LA English
DT Article
DE breast cancer; estrogen receptors; HDAC inhibitors; histone
   deacetylases; SERMs
ID ESTROGEN-RECEPTOR-ALPHA; GENE-EXPRESSION; BIOLOGICAL EVALUATION;
   TRANSCRIPTIONAL ACTIVITY; CELLS; ER; MODULATORS; TAMOXIFEN; POTENT;
   ANTIESTROGENS
AB Breast cancer remains a significant cause of death in women, and few therapeutic options exist for estrogen receptor negative (ER(-)) cancers. Epigenetic reactivation of target genes using histone deacetylase (HDAC) inhibitors has been proposed in ER(-) cancers to resensitize to therapy using selective estrogen receptor modulators (SERMs) that are effective in ER(+) cancer treatment. Based upon preliminary studies in ER(+) and ER(-) breast cancer cells treated with combinations of HDAC inhibitors and SERMs, hybrid drugs, termed SERMostats, were designed with computational guidance. Assay for inhibition of four typeI HDAC isoforms and antagonism of estrogenic activity in two cell lines yielded a SERMostat with 1-3M potency across all targets. The superior hybrid caused significant cell death in ER(-) human breast cancer cells and elicited cell death at the same concentration as the parent SERM in combination treatment and at an earlier time point.
C1 [Patel, Hitisha K.; Siklos, Marton I.; Abdelkarim, Hazem; Mendonca, Emma L.; Vaidya, Aditya; Petukhov, Pavel A.; Thatcher, Gregory R. J.] Univ Illinois, Dept Med Chem & Pharmacognosy, Coll Pharm, UIC, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Thatcher, GRJ (通讯作者)，Univ Illinois, Dept Med Chem & Pharmacognosy, Coll Pharm, UIC, 833 S Wood St, Chicago, IL 60612 USA.
EM thatcher@uic.edu
FU US National Institutes of Health (NIH) [R01 CA102590, R01 CA131970]; US
   NIH [P41 RR001081]
FX The work was supported in part by the US National Institutes of Health
   (NIH) (grant no. R01 CA102590 (GT) and R01 CA131970 (PP)). Molecular
   modeling was in part conducted using the UCSF Chimera package from the
   Resource for Biocomputing, Visualization, and Informatics at the
   University of California, San Francisco (supported by US NIH P41
   RR001081). Huali Dong (University of Illinois at Chicago (UIC), USA) is
   acknowledged for her assistance with the Ishikawa assay.
CR Abdelhamid R, 2011, ACS CHEM NEUROSCI, V2, P256, DOI 10.1021/cn100106a
   Behre H., 2001, Int. PCT Pub., Patent No. [WO/2001/077061 A1, 2001077061]
   Biçaku E, 2008, CANCER RES, V68, P1513, DOI 10.1158/0008-5472.CAN-07-2822
   Bressi JC, 2010, BIOORG MED CHEM LETT, V20, P3142, DOI 10.1016/j.bmcl.2010.03.091
   Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645
   Cameron K. O., 1995, Int. PCT Pub., Patent No. [WO 95/10513, 9510513]
   Chemical Computing Group, 2010, MOL OP ENV
   Chen PC, 2008, BIOORGAN MED CHEM, V16, P4839, DOI 10.1016/j.bmc.2008.03.050
   Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937
   Colombano G, 2010, J MED CHEM, V53, P616, DOI 10.1021/jm9010669
   Dao KL, 2012, BIOCONJUGATE CHEM, V23, P2139, DOI 10.1021/bc300378e
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fischer J, 2012, CHEM BIOL, V19, P963, DOI 10.1016/j.chembiol.2012.05.024
   Fiskus W, 2007, CLIN CANCER RES, V13, P4882, DOI 10.1158/1078-0432.CCR-06-3093
   Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326
   Frasor J, 2006, CANCER RES, V66, P7334, DOI 10.1158/0008-5472.CAN-05-4269
   Giacinti L, 2012, J CELL PHYSIOL, V227, P3426, DOI 10.1002/jcp.24043
   Hall JM, 2001, J BIOL CHEM, V276, P36869, DOI 10.1074/jbc.R100029200
   He R, 2010, J MED CHEM, V53, P1347, DOI 10.1021/jm901667k
   Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6
   Hodges-Gallagher L, 2007, BREAST CANCER RES TR, V105, P297, DOI 10.1007/s10549-006-9459-6
   Irvin WJ, 2008, EUR J CANCER, V44, P2799, DOI 10.1016/j.ejca.2008.09.034
   Jang ER, 2004, ONCOGENE, V23, P1724, DOI 10.1038/sj.onc.1207315
   Jones C. D., 2002, US Patent, Patent No. [US 6,350,884 B1, 6350884]
   Kawai H, 2003, INT J CANCER, V107, P353, DOI 10.1002/ijc.11403
   Keen JC, 2003, BREAST CANCER RES TR, V81, P177, DOI 10.1023/A:1026146524737
   Kirchmair J, 2008, J MED CHEM, V51, P7021, DOI 10.1021/jm8005977
   Kuang C., 2012, Chin. Pat. Appl., Patent No. [CN 102344395 A, 102344395]
   Lapidus RG, 1996, CLIN CANCER RES, V2, P805
   Mahboobi S, 2010, J MED CHEM, V53, P8546, DOI 10.1021/jm100665z
   Manavathi B, 2013, ENDOCR REV, V34, P1, DOI 10.1210/er.2011-1057
   Margueron R, 2004, J MOL ENDOCRINOL, V32, P583, DOI 10.1677/jme.0.0320583
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Munster PN, 2009, BRIT J CANCER, V101, P1044, DOI 10.1038/sj.bjc.6605293
   Neelarapu R, 2011, J MED CHEM, V54, P4350, DOI 10.1021/jm2001025
   Overk CR, 2007, CHEMMEDCHEM, V2, P1520, DOI 10.1002/cmdc.200700104
   Palkowitz AD, 1997, J MED CHEM, V40, P1407, DOI 10.1021/jm970167b
   Peng KW, 2009, ACS CHEM BIOL, V4, P1039, DOI 10.1021/cb9001848
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Qin ZH, 2007, J MED CHEM, V50, P2682, DOI 10.1021/jm070079j
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Roy SS, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/654698
   Santos MDL, 2007, ENDOCR-RELAT CANCER, V14, P1021, DOI 10.1677/ERC-07-0144
   Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Suzuki T, 2009, CHEM PHARM BULL, V57, P897, DOI 10.1248/cpb.57.897
   Thomas S, 2011, BREAST CANCER RES TR, V130, P437, DOI 10.1007/s10549-011-1364-y
   Thomas S, 2009, CANCER LETT, V280, P184, DOI 10.1016/j.canlet.2008.12.026
   Tu ZZ, 2012, MOL CELL BIOCHEM, V366, P111, DOI 10.1007/s11010-012-1288-9
   Vaidya AS, 2012, BIOORG MED CHEM LETT, V22, P5025, DOI 10.1016/j.bmcl.2012.06.017
   Witt O, 2009, CANCER LETT, V277, P8, DOI 10.1016/j.canlet.2008.08.016
   Witter DJ, 2008, BIOORG MED CHEM LETT, V18, P726, DOI 10.1016/j.bmcl.2007.11.047
   Yang XW, 2001, CANCER RES, V61, P7025
   Yang XW, 2000, CANCER RES, V60, P6890
   Yi X, 2008, BIOCHEM PHARMACOL, V75, P1697, DOI 10.1016/j.bcp.2007.10.035
   Zhou Q, 2007, CANCER BIOL THER, V6, P64, DOI 10.4161/cbt.6.1.3549
NR 57
TC 24
Z9 43
U1 0
U2 19
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD MAR
PY 2014
VL 9
IS 3
SI SI
BP 602
EP 613
DI 10.1002/cmdc.201300270
PG 12
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA AB4YI
UT WOS:000331795500018
PM 23956109
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Haenisch, S
   Werk, AN
   Cascorbi, I
AF Haenisch, Sierk
   Werk, Anneke Nina
   Cascorbi, Ingolf
TI MicroRNAs and their relevance to ABC transporters
SO BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
LA English
DT Article
DE ABC transporter; drug resistance; epigenetics; gene regulation; microRNA
ID CANCER RESISTANCE PROTEIN; BREAST-CANCER; DOWN-REGULATION; STEM-CELLS;
   MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; MIR-200 FAMILY; P-GLYCOPROTEIN;
   MDR1/P-GLYCOPROTEIN EXPRESSION; POSTTRANSCRIPTIONAL REGULATION
AB MicroRNAs (miRNAs) are small noncoding RNAs, which regulate the expression of their target genes post-transcriptionally by RNA interference. They are involved in almost all cellular processes, including proliferation, differentiation, apoptosis, cell survival and the maintenance of tissue specificity. Recent findings also suggest that efflux pumps of the ABC (ATP-binding cassette) transporter family are subject to miRNA-mediated gene regulation. Moreover, it seems that ABC transporters are embedded in a concerted and miRNA-guided network of concurrently regulated proteins that mediate altered drug transport and cell survival in changing environmental conditions. In this review, we summarize recent findings of miRNAs interacting with ABC transporters, which have been connected with drug distribution as well as with drug resistance. Additionally, we specify findings of complex miRNA-protein pathways conferring increased drug export and cell survival.
C1 [Haenisch, Sierk; Werk, Anneke Nina; Cascorbi, Ingolf] Univ Hosp Schleswig Holstein, Inst Expt & Clin Pharmacol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Haenisch, S (通讯作者)，Univ Hosp Schleswig Holstein, Inst Expt & Clin Pharmacol, Arnold Heller Str 3,Bldg 30, D-24105 Kiel, Germany.
EM haenisch@pharmakologie.uni-kiel.de
RI Haenisch, Sierk/I-4689-2012; Cascorbi, Ingolf/AAT-1927-2021
OI Cascorbi, Ingolf/0000-0002-2182-9534
CR Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818
   Bao LL, 2012, AM J PATHOL, V180, P2490, DOI 10.1016/j.ajpath.2012.02.024
   Begley DJ, 2004, CURR PHARM DESIGN, V10, P1295, DOI 10.2174/1381612043384844
   Bitarte N, 2011, STEM CELLS, V29, P1661, DOI 10.1002/stem.741
   Borel F, 2012, HEPATOLOGY, V55, P821, DOI 10.1002/hep.24682
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Chen JQ, 2012, MED ONCOL, V29, P2527, DOI 10.1007/s12032-011-0117-4
   Chen KG, 2012, CLIN CANCER RES, V18, P1863, DOI 10.1158/1078-0432.CCR-11-1590
   Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721
   Dietrich CG, 2003, GUT, V52, P1788, DOI 10.1136/gut.52.12.1788
   Feng DD, 2011, J CELL MOL MED, V15, P2164, DOI 10.1111/j.1582-4934.2010.01213.x
   Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103
   Haenisch S, 2012, EPIGENOMICS-UK, V4, P369, DOI [10.2217/epi.12.39, 10.2217/EPI.12.39]
   Haenisch S, 2011, MOL PHARMACOL, V80, P314, DOI 10.1124/mol.110.070714
   Haimeur A, 2004, CURR DRUG METAB, V5, P21, DOI 10.2174/1389200043489199
   Ho RH, 2005, CLIN PHARMACOL THER, V78, P260, DOI 10.1016/j.clpt.2005.05.011
   Hobert O, 2004, TRENDS BIOCHEM SCI, V29, P462, DOI 10.1016/j.tibs.2004.07.001
   Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9
   Ikemura K, 2013, MOL PHARMACOL, V83, P399, DOI 10.1124/mol.112.081844
   Janssen HLA, 2013, NEW ENGL J MED, V368, P1685, DOI 10.1056/NEJMoa1209026
   Jeon HM, 2011, CANCER RES, V71, P3410, DOI 10.1158/0008-5472.CAN-10-3340
   Kipp H, 2002, ANNU REV PHYSIOL, V64, P595, DOI 10.1146/annurev.physiol.64.081501.155793
   Kipp H, 2001, J BIOL CHEM, V276, P7218, DOI 10.1074/jbc.M007794200
   Köhle C, 2009, BIOCHEM PHARMACOL, V77, P689, DOI 10.1016/j.bcp.2008.05.020
   Kong YW, 2012, LANCET ONCOL, V13, pE249, DOI 10.1016/S1470-2045(12)70073-6
   Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021
   Landi D, 2012, MUTAGENESIS, V27, P205, DOI 10.1093/mutage/ger055
   Lee EJ, 2008, RNA, V14, P35, DOI 10.1261/rna.804508
   Li X, 2011, BIOCHEM PHARMACOL, V81, P783, DOI 10.1016/j.bcp.2010.12.018
   Li ZM, 2010, GYNECOL ONCOL, V119, P125, DOI 10.1016/j.ygyno.2010.06.004
   Liang ZX, 2010, BIOCHEM PHARMACOL, V79, P817, DOI 10.1016/j.bcp.2009.10.017
   Liao RX, 2008, J CELL BIOCHEM, V104, P805, DOI 10.1002/jcb.21668
   Lim YY, 2013, J CELL SCI, V126, P2256, DOI 10.1242/jcs.122275
   Liu SJ, 2012, AM J PATHOL, V181, P1823, DOI 10.1016/j.ajpath.2012.07.009
   Mo Wei, 2012, Int J Biochem Mol Biol, V3, P1
   Neilson JR, 2007, GENE DEV, V21, P578, DOI 10.1101/gad.1522907
   Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506
   Pan YZ, 2009, MOL PHARMACOL, V75, P1374, DOI 10.1124/mol.108.054163
   Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608
   Pascussi JM, 2008, ANNU REV PHARMACOL, V48, P1, DOI 10.1146/annurev.pharmtox.47.120505.105349
   Rácz Z, 2011, ACTA PHYSIOL HUNG, V98, P243, DOI 10.1556/APhysiol.98.2011.3.1
   Rukov JL, 2011, TRENDS MOL MED, V17, P412, DOI 10.1016/j.molmed.2011.04.003
   Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104
   Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507
   Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011
   Skalsky RL, 2010, ANNU REV MICROBIOL, V64, P123, DOI 10.1146/annurev.micro.112408.134243
   To KKW, 2008, MOL CELL BIOL, V28, P5147, DOI 10.1128/MCB.00331-08
   To KKW, 2009, MOL CANCER THER, V8, P2959, DOI 10.1158/1535-7163.MCT-09-0292
   Tryndyak VP, 2010, INT J CANCER, V126, P2575, DOI 10.1002/ijc.24972
   Turrini E, 2012, PHARMACOGENET GENOM, V22, P198, DOI 10.1097/FPC.0b013e328350012b
   Uchino K, 2013, JPN J CLIN ONCOL, V43, P596, DOI 10.1093/jjco/hyt052
   van Herwaarden AE, 2006, TRENDS PHARMACOL SCI, V27, P10, DOI 10.1016/j.tips.2005.11.007
   Wang F, 2010, BRIT J CANCER, V103, P567, DOI 10.1038/sj.bjc.6605724
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   Wiemer EAC, 2007, EUR J CANCER, V43, P1529, DOI 10.1016/j.ejca.2007.04.002
   Wittmann J, 2010, BBA-REV CANCER, V1806, P200, DOI 10.1016/j.bbcan.2010.07.002
   Xu K, 2012, BIOCHEM J, V446, P291, DOI 10.1042/BJ20120386
   Xu XT, 2012, BRIT J CANCER, V106, P1320, DOI 10.1038/bjc.2012.88
   Zhang HW, 2010, DIGEST DIS SCI, V55, P2545, DOI 10.1007/s10620-009-1051-6
   Zhao XH, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-55
   Zhao XH, 2010, LEUKEMIA RES, V34, P1078, DOI 10.1016/j.leukres.2009.10.002
   Zhou SF, 2008, XENOBIOTICA, V38, P802, DOI [10.1080/00498250701867889, 10.1080/00498250701867889 ]
   Zhu H, 2008, BIOCHEM PHARMACOL, V76, P582, DOI 10.1016/j.bcp.2008.06.007
   Zhu XL, 2013, ACTA BIOCH BIOPH SIN, V45, P80, DOI 10.1093/abbs/gms099
NR 66
TC 72
Z9 80
U1 3
U2 25
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0306-5251
EI 1365-2125
J9 BRIT J CLIN PHARMACO
JI Br. J. Clin. Pharmacol.
PD APR
PY 2014
VL 77
IS 4
SI SI
BP 587
EP 596
DI 10.1111/bcp.12251
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AD2PF
UT WOS:000333076900002
PM 24645868
OA Bronze, Green Published
DA 2025-01-12
ER

PT J
AU Foedermayr, M
   Sebesta, M
   Rudas, M
   Berghoff, AS
   Promberger, R
   Preusser, M
   Dubsky, P
   Fitzal, F
   Gnant, M
   Steger, GG
   Weltermann, A
   Zielinski, CC
   Zach, O
   Bartsch, R
AF Foedermayr, Mathilde
   Sebesta, Miriam
   Rudas, Margaretha
   Berghoff, Anna S.
   Promberger, Regina
   Preusser, Matthias
   Dubsky, Peter
   Fitzal, Florian
   Gnant, Michael
   Steger, Guenther G.
   Weltermann, Ansgar
   Zielinski, Christoph C.
   Zach, Otto
   Bartsch, Rupert
TI <i>BRCA</i>-<i>1</i> methylation and <i>TP53</i> mutation in
   triple-negative breast cancer patients without pathological complete
   response to taxane-based neoadjuvant chemotherapy
SO CANCER CHEMOTHERAPY AND PHARMACOLOGY
LA English
DT Article
DE BRCA-1 methylation; Breast cancer; Taxane; Neoadjuvant therapy; Triple
   negative breast cancer
ID PREDICTS SENSITIVITY; SURVIVAL; GENE; PROMOTER; METASTASES
AB Introduction Triple-negative breast cancer (TNBC) patients without pathological complete response (pCR) to neoadjuvant chemotherapy have an unfavourable prognosis. TNBC harbouring BRCA-1 germline mutations may be less responsive to taxanes, while sensitivity to DNA-damaging agents is retained. A similar effect was seen in tumours with epigenetic BRCA-1 silencing. Patients without pCR to neoadjuvant chemotherapy consisting of epirubicin plus docetaxel routinely received post-operative CMF at our centre. Here, we investigated the effect of adjuvant CMF in patients with or without BRCA-1 methylation or TP53 mutation.
   Methods DNA was extracted from formalin-fixed paraffin-embedded tissue. For determining BRCA-1 methylation status, quantitative methylation-specific PCR was performed. For the investigation of TP53 mutation status, DNA was PCR amplified and sequenced by Sanger sequencing.
   Results Twenty-four patients were included; BRCA-1 methylation was present in 41.7 %, while TP53 mutations were observed in 66.7 %. At a median follow-up of 27.5 months, 20 % of patients with BRCA-1 methylation had a disease-free survival (DFS) event, as compared to 64.3 % in the non-methylated group (p = 0.0472). Median DFS in the non-methylated group was 16 months and was not reached in the methylated group (n.s.). No association TP53 mutation status with clinical outcome was observed.
   Conclusions Adjuvant CMF is of limited activity in TNBC refractory to taxane-based neoadjuvant chemotherapy. In this population, BRCA-1 methylation was associated with a significant decrease in DFS events suggesting a better prognosis and potentially retained activity of DNA damaging agents.
C1 [Foedermayr, Mathilde; Sebesta, Miriam; Berghoff, Anna S.; Zach, Otto] Acad Teaching Hosp Elisabethinen Linz, Dept Med 1, Linz, Austria.
   [Foedermayr, Mathilde; Berghoff, Anna S.; Promberger, Regina; Preusser, Matthias; Dubsky, Peter; Fitzal, Florian; Gnant, Michael; Steger, Guenther G.; Zielinski, Christoph C.; Bartsch, Rupert] Med Univ Vienna, Comprehens Canc Ctr Vienna, A-1090 Vienna, Austria.
   [Rudas, Margaretha] Med Univ Vienna, Dept Pathol, A-1090 Vienna, Austria.
   [Berghoff, Anna S.] Med Univ Vienna, Inst N eurol, A-1090 Vienna, Austria.
   [Promberger, Regina; Dubsky, Peter; Fitzal, Florian; Gnant, Michael] Med Univ Vienna, Dept Surg, A-1090 Vienna, Austria.
   [Preusser, Matthias; Steger, Guenther G.; Zielinski, Christoph C.; Bartsch, Rupert] Med Univ Vienna, Dept Med 1, Div Clin Oncol, A-1090 Vienna, Austria.
C3 Ordensklinikum Linz Elisabethinen; Medical University of Vienna; Medical
   University of Vienna; Medical University of Vienna; Medical University
   of Vienna; Medical University of Vienna
RP Bartsch, R (通讯作者)，Med Univ Vienna, Dept Med 1, Div Clin Oncol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.
EM rupert.bartsch@meduniwien.ac.at
RI Gnant, Michael/AAN-7054-2020; Preusser, Matthias/C-8530-2011
OI Gnant, Michael/0000-0003-1002-2118; Preusser,
   Matthias/0000-0003-3541-2315; Berghoff, Anna Sophie/0000-0001-9379-6797
FU medical research budget of the Medical University of Vienna
FX This work was supported by the medical research budget of the Medical
   University of Vienna.
CR Berghoff A, 2012, BRIT J CANCER, V106, P440, DOI 10.1038/bjc.2011.597
   Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090
   Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200
   Birgisdottir V, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1522
   Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470-2045(11)70094-8
   Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693
   Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019
   Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
   Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075
   Holstege H, 2009, CANCER RES, V69, P3625, DOI 10.1158/0008-5472.CAN-08-3426
   Ibragimova I, 2011, METHODS MOL BIOL, V780, P277, DOI 10.1007/978-1-61779-270-0_17
   Kriege M, 2012, CANCER-AM CANCER SOC, V118, P899, DOI 10.1002/cncr.26351
   Lee LJ, 2011, CANCER-AM CANCER SOC, V117, P3093, DOI 10.1002/cncr.25911
   Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147
   Lo Nigro C, 2012, BRIT J CANCER, V106, P397, DOI 10.1038/bjc.2011.464
   Pfeifer GP, 2009, HUM GENET, V125, P493, DOI 10.1007/s00439-009-0657-2
   Quinn JE, 2003, CANCER RES, V63, P6221
   Quinn JE, 2007, CLIN CANCER RES, V13, P7413, DOI 10.1158/1078-0432.CCR-07-1083
   Sanchez JA, 2011, INFLAMM BOWEL DIS, V17, P1966, DOI 10.1002/ibd.21526
   Sharma PP, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.e11107
   Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725
   Sorlie T, 2011, EUR J CANCER, V47, pS310, DOI 10.1016/S0959-8049(11)70182-4
   Stefansson OA, 2012, EPIGENETICS-US, V7, P1225, DOI 10.4161/epi.22561
   Steger G, 2009, CANC RES S24, V69
   Steger GG, 2007, J CLIN ONCOL, V25, P2012, DOI 10.1200/JCO.2006.09.1777
   von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595
   Xu Y, 2013, ANN ONCOL, V24, P1498, DOI 10.1093/annonc/mdt011
NR 27
TC 19
Z9 24
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0344-5704
EI 1432-0843
J9 CANCER CHEMOTH PHARM
JI Cancer Chemother. Pharmacol.
PD APR
PY 2014
VL 73
IS 4
BP 771
EP 778
DI 10.1007/s00280-014-2404-1
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA AD7SR
UT WOS:000333467100013
PM 24526178
DA 2025-01-12
ER

PT J
AU Moison, C
   Assemat, F
   Daunay, A
   Tost, J
   Guieysse-Peugeot, AL
   Arimondo, PB
AF Moison, Celine
   Assemat, Fanny
   Daunay, Antoine
   Tost, Joerg
   Guieysse-Peugeot, Anne-Laure
   Arimondo, Paola B.
TI Synergistic chromatin repression of the tumor suppressor gene
   <i>RARB</i> in human prostate cancers
SO EPIGENETICS
LA English
DT Article
DE polycomb protein; EZH2; DNA hypermethylation; prostate cancer; retinoic
   acid receptor beta (RAR beta); H3K27 trimethylation
ID ACID RECEPTOR-BETA; POLYCOMB TARGET GENES; GROUP PROTEIN EZH2; DNA
   METHYLATION; BREAST-CANCER; MESENCHYMAL TRANSITION; CELLS;
   HYPERMETHYLATION; HISTONE; EXPRESSION
AB DNA methylation and polycomb proteins are well-known mediators of epigenetic silencing in mammalian cells. Usually described as mutually exclusive, this statement is today controversial and recent in vitro studies suggest the co-existence of both repressor systems. We addressed this issue in the study of Retinoic Acid Receptor beta (RAR beta), a tumor suppressor gene frequently silenced in prostate cancer. We found that the RAR beta promoter is hypermethylated in all studied prostate tumors and methylation levels are positively correlated with H3K27me3 enrichments. Thus, by using bisulfite conversion and pyrosequencing of immunoprecipitated H3K27me3 chromatin, we demonstrated that DNA methylation and polycomb repression co-exist in vivo at this locus. We found this repressive association in 6/6 patient tumor samples of different Gleason score, suggesting a strong interplay of DNA methylation and EZH2 to silence RAR beta during prostate tumorigenesis.
C1 [Moison, Celine; Assemat, Fanny; Arimondo, Paola B.] CNRS Pierre Fabre, Epigenet Targeting Canc ETaC, Toulouse, France.
   [Moison, Celine; Guieysse-Peugeot, Anne-Laure] CNRS, MNHN, UMR7196, Paris, France.
   [Moison, Celine; Guieysse-Peugeot, Anne-Laure] INSERM, U565, Paris, France.
   [Moison, Celine] Univ Paris 06, Paris, France.
   [Daunay, Antoine; Tost, Joerg] Fondat Jean Dausset, Lab Funct Genom, CEPH, Paris, France.
   [Tost, Joerg] CEA Inst Genom, Ctr Natl Genotypage, Lab Epigenet & Environm, Evry, France.
C3 Centre National de la Recherche Scientifique (CNRS); Museum National
   d'Histoire Naturelle (MNHN); Centre National de la Recherche
   Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Institut
   National de la Sante et de la Recherche Medicale (Inserm); Sorbonne
   Universite; CEA; Universite Paris Saclay
RP Arimondo, PB (通讯作者)，CNRS Pierre Fabre, Epigenet Targeting Canc ETaC, Toulouse, France.
EM paola.arimondo@etac.cnrs.fr
RI Arimondo, Paola/R-9095-2017; Tost, Jorg/H-7129-2019
OI Tost, Jorg/0000-0002-2683-0817
FU ATIP CNRS; Equipe d'Excellence Region Midi-Pyrenees grants; MNERT
   fellowship
FX The authors acknowledge the Service d'Anatomie et Cytologie
   Pathologiques des Hopitaux de Toulouse for the tumor samples. The
   authors thank Slimane Ait-Si-Ali and Julien Pontis (Universite Paris
   Diderot) for their ChIP protocol and Loic Ponger (MNHN, Paris) for
   critical discussions. This work was supported by ATIP CNRS and Equipe
   d'Excellence Region Midi-Pyrenees grants to PBA. CM was recipient of an
   MNERT fellowship.
CR ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7
   Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007
   Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706
   Brinkman AB, 2012, GENOME RES, V22, P1128, DOI 10.1101/gr.133728.111
   Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106
   Gal-Yam EN, 2008, P NATL ACAD SCI USA, V105, P12979, DOI 10.1073/pnas.0806437105
   HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985
   Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669
   Ke XS, 2011, EXP CELL RES, V317, P234, DOI 10.1016/j.yexcr.2010.10.009
   Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204
   Kondo Y, 2008, NAT GENET, V40, P741, DOI 10.1038/ng.159
   Lindroth AM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000145
   Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065
   Moison C, 2013, FASEB J, V27, P1468, DOI 10.1096/fj.12-210971
   Moison C, 2011, BIOCHIMIE, V93, P1731, DOI 10.1016/j.biochi.2011.06.005
   Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972
   Reddington JP, 2014, BIOESSAYS, V36, P134, DOI 10.1002/bies.201300130
   Reddington JP, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-3-r25
   Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950
   SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077
   Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456
   Statham AL, 2012, GENOME RES, V22, P1120, DOI 10.1101/gr.132076.111
   Takeshima H, 2009, GENOME RES, V19, P1974, DOI 10.1101/gr.093310.109
   Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941
   Wu H, 2010, SCIENCE, V329, P444, DOI 10.1126/science.1190485
   Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011
NR 30
TC 27
Z9 30
U1 0
U2 11
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1559-2294
EI 1559-2308
J9 EPIGENETICS-US
JI Epigenetics
PD APR 1
PY 2014
VL 9
IS 4
BP 477
EP 482
DI 10.4161/epi.27869
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AE9DP
UT WOS:000334305100001
PM 24492483
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Caizzi, L
   Ferrero, G
   Cutrupi, S
   Cordero, F
   Ballaré, C
   Miano, V
   Reineri, S
   Ricci, L
   Friard, O
   Testori, A
   Corà, D
   Caselle, M
   Di Croce, L
   De Bortoli, M
AF Caizzi, Livia
   Ferrero, Giulio
   Cutrupi, Santina
   Cordero, Francesca
   Ballare, Cecilia
   Miano, Valentina
   Reineri, Stefania
   Ricci, Laura
   Friard, Olivier
   Testori, Alessandro
   Cora, Davide
   Caselle, Michele
   Di Croce, Luciano
   De Bortoli, Michele
TI Genome-wide activity of unliganded estrogen receptor-α in breast cancer
   cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE chromatin binding; transcriptome; enhancer; pioneer factors; epigenetics
ID ER-ALPHA; TRANSCRIPTION; GENE; BINDING; CHROMATIN; IDENTIFICATION;
   MAINTENANCE; ACTIVATION; EXPRESSION; RESISTANCE
AB Estrogen receptor-alpha (ER alpha) has central role in hormone-dependent breast cancer and its ligand-induced functions have been extensively characterized. However, evidence exists that ER alpha has functions that are independent of ligands. In the present work, we investigated the binding of ER alpha to chromatin in the absence of ligands and its functions on gene regulation. We demonstrated that in MCF7 breast cancer cells unliganded ER alpha binds to more than 4,000 chromatin sites. Unexpectedly, although almost entirely comprised in the larger group of estrogen-induced binding sites, we found that unliganded-ER alpha binding is specifically linked to genes with developmental functions, compared with estrogen-induced binding. Moreover, we found that siRNA-mediated down-regulation of ER alpha in absence of estrogen is accompanied by changes in the expression levels of hundreds of coding and noncoding RNAs. Down-regulated mRNAs showed enrichment in genes related to epithelial cell growth and development. Stable ER alpha down-regulation using shRNA, which caused cell growth arrest, was accompanied by increased H3K27me3 at ER alpha binding sites. Finally, we found that FOXA1 and AP2 gamma binding to several sites is decreased upon ER alpha silencing, suggesting that unliganded ER alpha participates, together with other factors, in the maintenance of the luminal-specific cistrome in breast cancer cells.
C1 [Caizzi, Livia; Ferrero, Giulio; Cutrupi, Santina; Cordero, Francesca; Miano, Valentina; Friard, Olivier; Testori, Alessandro; Cora, Davide; Caselle, Michele; De Bortoli, Michele] Univ Turin, Ctr Mol Syst Biol, I-10043 Turin, Italy.
   [Caizzi, Livia; Reineri, Stefania; Ricci, Laura] Bioind Pk Silvano Fumero, I-10010 Turin, Italy.
   [Caizzi, Livia; Ballare, Cecilia; Di Croce, Luciano] CRG Ctr Genom Regulat, Dept Gene Regulat Stem Cells & Canc, Barcelona 08003, Spain.
   [Ferrero, Giulio; Cutrupi, Santina; Miano, Valentina; De Bortoli, Michele] Univ Turin, Dept Clin & Biol Sci, I-10043 Turin, Italy.
   [Cordero, Francesca] Univ Turin, Dept Comp Sci, I-10149 Turin, Italy.
   [Ballare, Cecilia; Di Croce, Luciano] Univ Pompeu Fabra, Barcelona 08018, Spain.
   [Cora, Davide] Univ Turin, Inst Canc Res & Treatment IRCC, Dept Oncol, I-10060 Turin, Italy.
   [Caselle, Michele] Univ Turin, Dept Phys, I-10125 Turin, Italy.
   [Di Croce, Luciano] ICREA, Barcelona 08010, Spain.
C3 University of Turin; Barcelona Institute of Science & Technology; Pompeu
   Fabra University; Centre de Regulacio Genomica (CRG); University of
   Turin; University of Turin; Pompeu Fabra University; IRCCS Fondazione
   del Piemonte per l'Oncologia; University of Turin; University of Turin;
   ICREA
RP De Bortoli, M (通讯作者)，Univ Turin, Ctr Mol Syst Biol, I-10043 Turin, Italy.
EM michele.debortoli@unito.it
RI Friard, Olivier/ABG-2435-2021; Caselle, Michele/E-3724-2013; Cordero,
   Francesca/AAB-3655-2019; De Bortoli, Michele/B-5418-2013; Caizzi,
   Livia/AAO-2725-2021; cutrupi, santina/AAC-4479-2022; ,
   Alessandro/K-7611-2016; Ferrero, Giulio/B-9838-2014; Di Croce,
   Luciano/E-7759-2015; Ballare, Cecilia/F-2593-2016; MIANO,
   VALENTINA/K-3716-2018
OI CUTRUPI, SANTINA/0000-0002-2358-5852; , Alessandro/0000-0001-6088-730X;
   Ferrero, Giulio/0000-0002-4580-0680; Friard,
   Olivier/0000-0002-0374-9872; Di Croce, Luciano/0000-0003-3488-6228;
   Ballare, Cecilia/0000-0002-9442-807X; MIANO,
   VALENTINA/0000-0002-0260-5885
FU Associazione Italiana per la Ricerca sul Cancro Grant [IG9397]; Italian
   Ministry of Education, University and Research PRIN Grant
   [2008PC9CFW_002]; Fondazione SanPaolo grant GeneRNet; Spanish
   "Ministerio de Educacion y Ciencia" [BFU2010-18692]; Agencia de Gestio
   d'Ajuts Universitaris i de Recerca; International Union against Cancer
   short-term International Cancer Technology Transfer fellowship; ICREA
   Funding Source: Custom
FX We thank all the members of the L.D.C. laboratory for discussions, the
   Center for Genomic Regulation Genomic and Bioinformatic Units, and Dr.
   He and Dr. Liu for providing data. This work was supported by
   Associazione Italiana per la Ricerca sul Cancro Grant IG9397 (to
   M.D.B.); Italian Ministry of Education, University and Research PRIN
   Grant 2008PC9CFW_002 (to M.D.B.); Fondazione SanPaolo grant GeneRNet (to
   M.C.); the Spanish "Ministerio de Educacion y Ciencia" (BFU2010-18692)
   and Agencia de Gestio d'Ajuts Universitaris i de Recerca (L.D.C.); and
   in part by an International Union against Cancer short-term
   International Cancer Technology Transfer fellowship (to L.C.).
CR Aguilar H, 2010, ONCOGENE, V29, P6071, DOI 10.1038/onc.2010.333
   Al Saleh S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020610
   Ballaré C, 2013, MOL CELL, V49, P67, DOI 10.1016/j.molcel.2012.10.019
   Cardamone MD, 2009, P NATL ACAD SCI USA, V106, P7420, DOI 10.1073/pnas.0903033106
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Ceschin DG, 2011, GENE DEV, V25, P1132, DOI 10.1101/gad.619211
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   Cvoro A, 2006, MOL CELL, V21, P555, DOI 10.1016/j.molcel.2006.01.014
   Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293
   Garcia-Bassets I, 2012, CELL CYCLE, V11, P3199, DOI 10.4161/cc.21281
   Green KA, 2007, NAT REV CANCER, V7, P713, DOI 10.1038/nrc2211
   Hah N, 2011, CELL, V145, P622, DOI 10.1016/j.cell.2011.03.042
   He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111
   Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914
   Hewitt SC, 2012, MOL ENDOCRINOL, V26, P887, DOI 10.1210/me.2011-1311
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Joseph R, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.109
   Kwon YS, 2007, P NATL ACAD SCI USA, V104, P4852, DOI 10.1073/pnas.0700715104
   Laganière J, 2005, MOL ENDOCRINOL, V19, P1584, DOI 10.1210/me.2005-0040
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Madak-Erdogan Z, 2011, MOL CELL BIOL, V31, P226, DOI 10.1128/MCB.00821-10
   Maggi A, 2011, BBA-MOL BASIS DIS, V1812, P1054, DOI 10.1016/j.bbadis.2011.05.001
   Magnani L, 2014, MOL CELL ENDOCRINOL, V382, P633, DOI 10.1016/j.mce.2013.04.026
   McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630
   McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342
   Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Orso F, 2004, BIOCHEM J, V377, P429, DOI 10.1042/BJ20031133
   Vicent GP, 2011, GENE DEV, V25, P845, DOI 10.1101/gad.621811
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910
   Strutt H, 1999, METH MOL B, V119, P455
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Testori A, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-400
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   Yu GC, 2010, BIOINFORMATICS, V26, P976, DOI 10.1093/bioinformatics/btq064
   Zhao Y, 2006, MOL ENDOCRINOL, V20, P2187, DOI 10.1210/me.2005-0214
NR 38
TC 65
Z9 71
U1 0
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD APR 1
PY 2014
VL 111
IS 13
BP 4892
EP 4897
DI 10.1073/pnas.1315445111
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AD9IX
UT WOS:000333579700054
PM 24639548
OA Green Published
DA 2025-01-12
ER

PT J
AU Tsujiura, M
   Ichikawa, D
   Konishi, H
   Komatsu, S
   Shiozaki, A
   Otsuji, E
AF Tsujiura, Masahiro
   Ichikawa, Daisuke
   Konishi, Hirotaka
   Komatsu, Shuhei
   Shiozaki, Atsushi
   Otsuji, Eigo
TI Liquid biopsy of gastric cancer patients: Circulating tumor cells and
   cell-free nucleic acids
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
DE Gastric cancer; Biomarker; Liquid biopsy; Circulating tumor cells;
   Cell-free nucleic acids; MicroRNA
ID POLYMERASE-CHAIN-REACTION; METASTATIC BREAST-CANCER; ANTIGEN
   MESSENGER-RNA; LONG NONCODING RNAS; P16 PROMOTER HYPERMETHYLATION;
   MICRORNA EXPRESSION PROFILES; PERIPHERAL-BLOOD; CLINICAL-SIGNIFICANCE;
   MOLECULAR-DETECTION; FREE DNA
AB To improve the clinical outcomes of cancer patients, early detection and accurate monitoring of diseases are necessary. Numerous genetic and epigenetic alterations contribute to oncogenesis and cancer progression, and analyses of these changes have been increasingly utilized for diagnostic, prognostic and therapeutic purposes in malignant diseases including gastric cancer (GC). Surgical and/or biopsy specimens are generally used to understand the tumor-associated alterations; however, those approaches cannot always be performed because of their invasive characteristics and may fail to reflect current tumor dynamics and drug sensitivities, which may change during the therapeutic process. Therefore, the importance of developing a non-invasive biomarker with the ability to monitor real-time tumor dynamics should be emphasized. This concept, so called "liquid biopsy", would provide an ideal therapeutic strategy for an individual cancer patient and would facilitate the development of "tailor- made" cancer management programs. In the blood of cancer patients, the presence and potent utilities of circulating tumor cells (CTCs) and cell-free nucleic acids ( cfNAs) such as DNA, mRNA and microRNA have been recognized, and their clinical relevance is attracting considerable attention. In this review, we discuss recent developments in this research field as well as the relevance and future perspectives of CTCs and cfNAs in cancer patients, especially focusing on GC. (c) 2014 Baishideng Publishing Group Co., Limited. All rights reserved.
C1 [Tsujiura, Masahiro; Ichikawa, Daisuke; Konishi, Hirotaka; Komatsu, Shuhei; Shiozaki, Atsushi; Otsuji, Eigo] Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Kyoto 6028566, Japan.
C3 Kyoto Prefectural University of Medicine
RP Ichikawa, D (通讯作者)，Kyoto Prefectural Univ Med, Dept Surg, Div Digest Surg, Kamigyo Ku, 465 Kajii Cho,Kawaramachihirokoji, Kyoto 6028566, Japan.
EM ichikawa@koto.kpu-m.ac.jp
FU Grants-in-Aid for Scientific Research [23501299] Funding Source: KAKEN
CR Abbaszadegan MR, 2008, WORLD J GASTROENTERO, V14, P2055, DOI 10.3748/wjg.14.2055
   Aihara T, 1997, INT J CANCER, V72, P408, DOI 10.1002/(SICI)1097-0215(19970729)72:3<408::AID-IJC6>3.0.CO;2-T
   Alix-Panabières C, 2007, CLIN CHEM, V53, P537, DOI 10.1373/clinchem.2006.079509
   Alix-Panabières C, 2013, CLIN CHEM, V59, P110, DOI 10.1373/clinchem.2012.194258
   Alix-Panabieres Catherine, 2012, Recent Results Cancer Res, V195, P69, DOI 10.1007/978-3-642-28160-0_6
   Alix-Panabières C, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2326
   Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378
   Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Arigami T, 2011, CANCER SCI, V102, P1019, DOI 10.1111/j.1349-7006.2011.01877.x
   Arita T, 2013, ANTICANCER RES, V33, P3185
   Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108
   Ashworth T. R., 1869, Aust. J. Med, V14, P146
   Balgkouranidou I, 2013, CLIN CHEM LAB MED, V51, P1505, DOI 10.1515/cclm-2012-0320
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bertazza L, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-111
   Cann GM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049144
   Cao WG, 2011, J SURG ONCOL, V103, P110, DOI 10.1002/jso.21777
   Castells A, 1999, J CLIN ONCOL, V17, P578, DOI 10.1200/JCO.1999.17.2.578
   Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014
   Chen L, 2012, DIS MARKERS, V32, P195, DOI [10.1155/2012/473251, 10.3233/DMA-2011-0877]
   Chen XQ, 2000, CLIN CANCER RES, V6, P3823
   Chen Z, 2009, INT J CANCER, V124, P739, DOI 10.1002/ijc.23960
   Choi JJ, 2005, IMMUNOLOGY, V115, P55, DOI 10.1111/j.1365-2567.2005.02130.x
   Coumans FAW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061774
   Coumans FAW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061770
   Cristofanilli M, 2004, NEW ENGL J MED, V351, P781, DOI 10.1056/NEJMoa040766
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
   Cui L, 2011, CLIN BIOCHEM, V44, P1050, DOI 10.1016/j.clinbiochem.2011.06.004
   Danila DC, 2007, CLIN CANCER RES, V13, P7053, DOI 10.1158/1078-0432.CCR-07-1506
   Dardaei L, 2011, CLIN BIOCHEM, V44, P325, DOI 10.1016/j.clinbiochem.2010.11.005
   Dasi F, 2006, ANN NY ACAD SCI, V1075, P204, DOI 10.1196/annals.1368.028
   Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Du WQ, 2009, J CANCER RES CLIN, V135, P1277, DOI 10.1007/s00432-009-0569-5
   Duttagupta R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020769
   Friederichs J, 2005, WORLD J SURG, V29, P422, DOI 10.1007/s00268-004-7662-3
   Funaki NO, 1996, LIFE SCI, V59, P2187, DOI 10.1016/S0024-3205(96)00576-0
   García-Olmo DC, 2010, CANCER RES, V70, P560, DOI 10.1158/0008-5472.CAN-09-3513
   Gevensleben H, 2013, CLIN CANCER RES, V19, P3276, DOI 10.1158/1078-0432.CCR-12-3768
   Ghildiyal M, 2009, NAT REV GENET, V10, P94, DOI 10.1038/nrg2504
   Ghossein RA, 1999, CLIN CANCER RES, V5, P1950
   Gorur A, 2013, MOL BIOL REP, V40, P2091, DOI 10.1007/s11033-012-2267-7
   Hayes DF, 2006, CLIN CANCER RES, V12, P4218, DOI 10.1158/1078-0432.CCR-05-2821
   Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140
   Hibi K, 2011, ANTICANCER RES, V31, P3835
   Hiraiwa K, 2008, ANN SURG ONCOL, V15, P3092, DOI 10.1245/s10434-008-0122-9
   Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964
   Hsieh HB, 2006, BIOSENS BIOELECTRON, V21, P1893, DOI 10.1016/j.bios.2005.12.024
   Ichikawa D, 2004, ANTICANCER RES, V24, P2477
   Ichikawa D, 2012, GASTROENTEROLOGY, V142, P1074, DOI 10.1053/j.gastro.2012.03.008
   Ikeguchi M, 2005, SURG TODAY, V35, P436, DOI 10.1007/s00595-004-2978-z
   Ikoma H, 2007, HEPATO-GASTROENTEROL, V54, P946
   Illert B, 2005, SCAND J GASTROENTERO, V40, P843, DOI 10.1080/00365520510015557
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Kang Y, 2013, INT J CLIN ONCOL, V18, P478, DOI 10.1007/s10147-012-0405-9
   Kanyama Y, 2003, CANCER SCI, V94, P418, DOI 10.1111/j.1349-7006.2003.tb01457.x
   Kim SY, 2013, J MOL DIAGN, V15, P661, DOI 10.1016/j.jmoldx.2013.04.004
   Kita Y, 2009, BRIT J CANCER, V100, P153, DOI 10.1038/sj.bjc.6604806
   Koga T, 2008, HEPATO-GASTROENTEROL, V55, P1131
   Koike H, 2005, HEPATO-GASTROENTEROL, V52, P1293
   Koike H, 2004, J SURG ONCOL, V87, P182, DOI 10.1002/jso.20106
   Kolesnikova EV, 2008, ANN NY ACAD SCI, V1137, P226, DOI 10.1196/annals.1448.009
   Kolodziejczyk P, 2007, BRIT J CANCER, V97, P589, DOI 10.1038/sj.bjc.6603904
   Komatsu S, 2013, ANTICANCER RES, V33, P271
   Konishi H, 2012, BRIT J CANCER, V106, P740, DOI 10.1038/bjc.2011.588
   Kopreski MS, 1999, CLIN CANCER RES, V5, P1961
   Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821
   Krivacic RT, 2004, P NATL ACAD SCI USA, V101, P10501, DOI 10.1073/pnas.0404036101
   Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x
   Leary RJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000702
   Lee HE, 2013, EUR J CANCER, V49, P1448, DOI 10.1016/j.ejca.2012.10.018
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   LEON SA, 1977, CANCER RES, V37, P646
   Leung WK, 2005, BRIT J CANCER, V92, P2190, DOI 10.1038/sj.bjc.6602636
   Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3
   Li C, 2013, J SURG ONCOL, V108, P89, DOI 10.1002/jso.23358
   Li CS, 2009, AAPS J, V11, P747, DOI 10.1208/s12248-009-9145-9
   Li GM, 2008, CELL RES, V18, P1, DOI 10.1038/cr.2008.9
   Ling ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067195
   Liu HS, 2012, CANCER LETT, V316, P196, DOI 10.1016/j.canlet.2011.10.034
   Liu R, 2011, EUR J CANCER, V47, P784, DOI 10.1016/j.ejca.2010.10.025
   Lo KW, 1999, CLIN CHEM, V45, P1292
   Lo YMD, 2001, CLIN CANCER RES, V7, P1856
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Maheswaran S, 2008, NEW ENGL J MED, V359, P366, DOI 10.1056/NEJMoa0800668
   Majima T, 2000, JPN J CLIN ONCOL, V30, P499, DOI 10.1093/jjco/hyd130
   MANDEL P, 1948, CR SOC BIOL, V142, P241
   MAOR D, 1978, CRC CR REV CL LAB SC, V10, P89
   Marrinucci D, 2007, HUM PATHOL, V38, P514, DOI 10.1016/j.humpath.2006.08.027
   Matsusaka S, 2010, CANCER SCI, V101, P1067, DOI 10.1111/j.1349-7006.2010.01492.x
   Mei YP, 2013, CANCER LETT, V336, P46, DOI 10.1016/j.canlet.2013.04.008
   Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521
   Mimori K, 2008, ANN SURG ONCOL, V15, P2934, DOI 10.1245/s10434-008-9916-z
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Miyazono F, 2001, ANN SURG, V233, P189, DOI 10.1097/00000658-200102000-00007
   Mohamed H, 2009, J CHROMATOGR A, V1216, P8289, DOI 10.1016/j.chroma.2009.05.036
   Mori M, 1996, INT J CANCER, V68, P739
   Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   Ng EKO, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022233
   Nishida S, 2000, ANTICANCER RES, V20, P2155
   Noh YH, 2001, EXP MOL MED, V33, P8, DOI 10.1038/emm.2001.2
   Noh YH, 1999, J KOREAN MED SCI, V14, P623, DOI 10.3346/jkms.1999.14.6.623
   Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001
   Pantel K, 2009, NAT REV CLIN ONCOL, V6, P339, DOI 10.1038/nrclinonc.2009.44
   Park JL, 2012, ONCOL LETT, V3, P921, DOI 10.3892/ol.2012.592
   Park KU, 2009, CLIN CHEM LAB MED, V47, P530, DOI 10.1515/CCLM.2009.126
   Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556
   Pisetsky DS, 2007, AUTOIMMUNITY, V40, P281, DOI 10.1080/08916930701358826
   Pituch-Noworolska A, 2007, ANTICANCER RES, V27, P635
   Pritchard CC, 2012, CANCER PREV RES, V5, P492, DOI 10.1158/1940-6207.CAPR-11-0370
   Qiu MZ, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-107
   Raja UM, 2012, ASIAN PAC J CANCER P, V13, P5563, DOI 10.7314/APJCP.2012.13.11.5563
   Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798
   REDDI KK, 1976, P NATL ACAD SCI USA, V73, P2308, DOI 10.1073/pnas.73.7.2308
   Reid G, 2011, CRIT REV ONCOL HEMAT, V80, P193, DOI 10.1016/j.critrevonc.2010.11.004
   Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607
   Ren J, 2000, CANCER, V88, P280
   Riethdorf S, 2007, CLIN CANCER RES, V13, P920, DOI 10.1158/1078-0432.CCR-06-1695
   Saad AA, 2010, ANN SURG ONCOL, V17, P3059, DOI 10.1245/s10434-010-1151-8
   Sai S, 2007, ANTICANCER RES, V27, P2747
   Sakaizawa K, 2012, BRIT J CANCER, V106, P939, DOI 10.1038/bjc.2012.12
   Sakakura C, 2009, ANTICANCER RES, V29, P2619
   Sastre J, 2008, ANN ONCOL, V19, P935, DOI 10.1093/annonc/mdm583
   Saucedo-Zeni N, 2012, INT J ONCOL, V41, P1241, DOI 10.3892/ijo.2012.1557
   Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066
   Seo JH, 2005, AM J CLIN ONCOL-CANC, V28, P24, DOI 10.1097/01.coc.0000139018.47930.a5
   Shaffer DR, 2007, CLIN CANCER RES, V13, P2023, DOI 10.1158/1078-0432.CCR-06-2701
   Shirahata A, 2012, ANTICANCER RES, V32, P791
   Sieuwerts AM, 2011, CLIN CANCER RES, V17, P3600, DOI 10.1158/1078-0432.CCR-11-0255
   Sieuwerts AM, 2009, BREAST CANCER RES TR, V118, P455, DOI 10.1007/s10549-008-0290-0
   Silva JM, 2002, GUT, V50, P530, DOI 10.1136/gut.50.4.530
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Smirnov DA, 2005, CANCER RES, V65, P4993, DOI 10.1158/0008-5472.CAN-04-4330
   Soeth E, 1997, CANCER RES, V57, P3106
   Song MY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033608
   SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67
   Stott SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000403
   Stroun M, 2001, ANN NY ACAD SCI, V945, P258
   Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9
   Sumikura S, 2003, CANCER LETT, V200, P77, DOI 10.1016/S0304-3835(03)00388-4
   Suzuki N, 2008, CLIN CHIM ACTA, V387, P55, DOI 10.1016/j.cca.2007.09.001
   Tan SH, 2007, ONCOL REP, V18, P1225
   Tan SJ, 2009, BIOMED MICRODEVICES, V11, P883, DOI 10.1007/s10544-009-9305-9
   Tani N, 2007, ANTICANCER RES, V27, P1207
   Thompson EW, 2011, NAT MED, V17, P1048, DOI 10.1038/nm.2437
   Trang P, 2008, Oncogene, V27 Suppl 2, pS52, DOI 10.1038/onc.2009.353
   Trejo-Becerril C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052754
   Tsai KW, 2012, GENE CHROMOSOME CANC, V51, P394, DOI 10.1002/gcc.21924
   Tsujiura M, 2010, BRIT J CANCER, V102, P1174, DOI 10.1038/sj.bjc.6605608
   Turchinovich A, 2011, NUCLEIC ACIDS RES, V39, P7223, DOI 10.1093/nar/gkr254
   Uen YH, 2006, CLIN CHIM ACTA, V367, P55, DOI 10.1016/j.cca.2005.11.013
   Valladares-Ayerbes M, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-186
   van de Stolpe A, 2011, CANCER RES, V71, P5955, DOI 10.1158/0008-5472.CAN-11-1254
   van der Gun BTF, 2010, CARCINOGENESIS, V31, P1913, DOI 10.1093/carcin/bgq187
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   VASIOUKHIN V, 1994, BRIT J HAEMATOL, V86, P774, DOI 10.1111/j.1365-2141.1994.tb04828.x
   Vickers KC, 2011, NAT CELL BIOL, V13, P423, DOI 10.1038/ncb2210
   Vona G, 2000, AM J PATHOL, V156, P57, DOI 10.1016/S0002-9440(10)64706-2
   Wang BG, 2003, CANCER RES, V63, P3966
   Wang B, 2012, J CANCER RES CLIN, V138, P1659, DOI 10.1007/s00432-012-1244-9
   Wang M, 2012, MOL MED REP, V5, P1514, DOI 10.3892/mmr.2012.828
   Wang YC, 2008, WORLD J GASTROENTERO, V14, P3074, DOI 10.3748/wjg.14.3074
   WIECZOREK AJ, 1987, CANCER RES, V47, P6407
   WIECZOREK AJ, 1985, P NATL ACAD SCI USA, V82, P3455, DOI 10.1073/pnas.82.10.3455
   Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666
   Wu CH, 2006, DIS MARKERS, V22, P103, DOI 10.1155/2006/281315
   Wu CH, 2006, INT J CANCER, V119, P373, DOI 10.1002/ijc.21856
   Xu WR, 2009, MOL MED REP, V2, P765, DOI 10.3892/mmr_00000170
   Yang F, 2013, J CANCER RES CLIN, V139, P437, DOI 10.1007/s00432-012-1324-x
   Yang F, 2012, FEBS J, V279, P3159, DOI 10.1111/j.1742-4658.2012.08694.x
   Yeh KH, 1998, ANTICANCER RES, V18, P1283
   Yie SM, 2008, ANN SURG ONCOL, V15, P3073, DOI 10.1245/s10434-008-0069-x
   Zernecke A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000610
   Zhang WH, 2012, ONCOL RES, V20, P139, DOI 10.3727/096504012X13522227232156
   Zhang Y, 2010, CANC LETT, V1, P1, DOI DOI 10.1371/J0URNAL.P0NE.0009167]
   Zhang YJ, 2010, MOL CELL, V39, P133, DOI 10.1016/j.molcel.2010.06.010
   Zheng S, 2007, J CHROMATOGR A, V1162, P154, DOI 10.1016/j.chroma.2007.05.064
   Zheng YA, 2011, CLIN BIOCHEM, V44, P1405, DOI 10.1016/j.clinbiochem.2011.09.006
   Zheng YY, 2011, CANCER BIOMARK, V10, P71, DOI 10.3233/CBM-2011-0231
   Zhou H, 2012, BIOMARKERS, V17, P104, DOI 10.3109/1354750X.2011.614961
   Zhou H, 2010, J MOL MED, V88, P709, DOI 10.1007/s00109-010-0617-2
NR 187
TC 52
Z9 57
U1 0
U2 29
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD MAR 28
PY 2014
VL 20
IS 12
BP 3265
EP 3286
DI 10.3748/wjg.v20.i12.3265
PG 22
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA AE0PH
UT WOS:000333667700021
PM 24696609
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Naushad, SM
   Reddy, CA
   Kumaraswami, K
   Divyya, S
   Kotamraju, S
   Gottumukkala, SR
   Digumarti, RR
   Kutala, VK
AF Naushad, Shaik Mohammad
   Reddy, Cheruku Apoorva
   Kumaraswami, Konda
   Divyya, Shree
   Kotamraju, Srigiridhar
   Gottumukkala, Suryanarayana Raju
   Digumarti, Raghunadha Rao
   Kutala, Vijay Kumar
TI Impact of Hyperhomocysteinemia on Breast Cancer Initiation and
   Progression: Epigenetic Perspective
SO CELL BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Epigenetics; Homocysteine; Methionine dependency phenotype; One-carbon
   metabolism
ID METHYLATION-SPECIFIC PCR; ESTROGEN-RECEPTOR-ALPHA; TUMOR-CELL-LINES;
   PROMOTER HYPERMETHYLATION; METHIONINE-DEPENDENCE; HUMAN-LYMPHOCYTES;
   MAMMALIAN-CELLS; BRCA1; DNA; METABOLISM
AB Our recent study showing association of hyperhomocysteinemia and hypomethioninemia in breast cancer and other studies indicating association of hyperhomocysteinemia with metastasis and development of drug resistance in breast cancer cells treated with homocysteine lead us to hypothesize that homocysteine might modulate the expression of certain tumor suppressors, i.e., RASSF1, RAR beta 1, CNND1, BRCA1, and p21, and might influence prognostic markers such as BNIP3 by inducing epigenetic alteration. To demonstrate this hypothesis, we have treated MCF-7 and MDA-MB-231 cells with different doses of homocysteine and observed dose-dependent inhibition of BRCA1 and RASSF1, respectively. In breast cancer tissues, we observed the following expression pattern: BNIP3 > BRCA1 > RAR beta 1 > CCND1 > p21 > RASSF1. Hyperhomocysteinemia was positively associated with BRAC1 hypermethylation both in breast cancer tissue and corresponding peripheral blood. Peripheral blood CpG island methylation of BRCA1 in all types of breast cancer and methylation of RASSF1 in ER/PR-negative breast cancers showed positive correlation with total plasma homocysteine. The methylation of RASSF1 and BRCA1 was associated with breast cancer initiation as well as progression, while BRCA1 methylation was associated with DNA damage. Vitamin B-12 showed inverse association with the methylation at both the loci. RFC1 G80A and cSHMT C1420T variants showed positive association with methylation at both the loci. Genetic variants influencing remethylation step were associated positively with BRCA1 methylation and inversely with RASSF1 methylation. GCPII C1561T variant showed inverse association with BRCA1 methylation. We found good correlation of BRAC1 (r = 0.90) and RASSF1 (0.92) methylation pattern between the breast cancer tissue and the corresponding peripheral blood. To conclude, elevated homocysteine influences methionine dependency phenotype of breast cancer cells and is associated with breast cancer progression by epigenetic modulation of RASSF1 and BRCA1 .
C1 [Naushad, Shaik Mohammad; Reddy, Cheruku Apoorva; Kumaraswami, Konda; Divyya, Shree; Kutala, Vijay Kumar] Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad 500082, Andhra Pradesh, India.
   [Kotamraju, Srigiridhar] Indian Inst Chem Technol, Ctr Chem Biol, Hyderabad 500607, Andhra Pradesh, India.
   [Gottumukkala, Suryanarayana Raju; Digumarti, Raghunadha Rao] Nizams Inst Med Sci, Hyderabad 500082, Andhra Pradesh, India.
C3 Nizam's Institute of Medical Sciences; Council of Scientific &
   Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical
   Technology (IICT); Nizam's Institute of Medical Sciences
RP Kutala, VK (通讯作者)，Nizams Inst Med Sci, Dept Clin Pharmacol & Therapeut, Hyderabad 500082, Andhra Pradesh, India.
EM vijaykutala@gmail.com
RI Digumarti, Raghunadharao/H-4075-2019; Kumaraswami, Konda/HDO-6991-2022;
   Naushad, Shaik Mohammad/C-3094-2012
OI Kutala, Vijay Kumar/0000-0002-7253-8999; Konda,
   Kumaraswami/0000-0003-3984-7295; Naushad, Shaik
   Mohammad/0000-0001-8952-9581; Digumarti,
   Raghunadharao/0000-0003-2876-3475
FU Indian Council of Medical Research (ICMR), New Delhi [5/13/32/2007];
   Department of Biotechnology [BT/PR9637/BRB/10/582/2007]; Department of
   Science and Technology, Government of India; Lady Tata Junior Research
   Fellowship
FX This work was supported by the grant funded by Indian Council of Medical
   Research (ICMR), New Delhi (Ref No. 5/13/32/2007), and Department of
   Biotechnology (BT/PR9637/BRB/10/582/2007). VKK and SGK are recipients of
   Ramanujan Fellowship awarded by Department of Science and Technology,
   Government of India. SD is recipient of Lady Tata Junior Research
   Fellowship.
CR Beetstra S, 2008, CANCER EPIDEM BIOMAR, V17, P2565, DOI 10.1158/1055-9965.EPI-08-0140
   Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691
   CARSON DA, 1983, BIOCHEM BIOPH RES CO, V112, P391, DOI 10.1016/0006-291X(83)91476-6
   Cho YH, 2010, ANTICANCER RES, V30, P2489
   Crott J, 2001, MUTAGENESIS, V16, P317, DOI 10.1093/mutage/16.4.317
   Evron E, 2001, LANCET, V357, P1335, DOI 10.1016/S0140-6736(00)04501-3
   Fackler MJ, 2006, CLIN CANCER RES, V12, P3306, DOI 10.1158/1078-0432.CCR-05-2733
   Fackler MJ, 2004, CANCER RES, V64, P4442, DOI 10.1158/0008-5472.CAN-03-3341
   Gatt A, 2007, INT J LAB HEMATOL, V29, P421, DOI 10.1111/j.1751-553X.2007.00907.x
   HALL CA, 1986, P SOC EXP BIOL MED, V182, P215
   HALPERN BC, 1974, P NATL ACAD SCI USA, V71, P1133, DOI 10.1073/pnas.71.4.1133
   Han SH, 2006, CLIN GENET, V70, P496, DOI 10.1111/j.1399-0004.2006.00717.x
   HOFFMAN RM, 1983, BIOCHIM BIOPHYS ACTA, V738, P49, DOI 10.1016/0304-419X(84)90019-2
   Holstege H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-654
   JAMES SJ, 1989, J NUTR, V119, P661, DOI 10.1093/jn/119.4.661
   Joosse SA, 2011, GENE CHROMOSOME CANC, V50, P71, DOI 10.1002/gcc.20833
   JUDDE JG, 1989, CANCER RES, V49, P4859
   Karray-Chouayekh S, 2010, J CANCER RES CLIN, V136, P203, DOI 10.1007/s00432-009-0649-6
   Kokkinakis DM, 2005, MOL CANCER THER, V4, P1338, DOI 10.1158/1535-7163.MCT-05-0141
   Lee JS, 2010, CANCER BIOL THER, V9, P1017, DOI 10.4161/cbt.9.12.11804
   Mangia A, 2010, ONCOL REP, V23, P1641, DOI 10.3892/or_00000806
   MECHAM JO, 1983, BIOCHEM BIOPH RES CO, V117, P429, DOI 10.1016/0006-291X(83)91218-4
   Mirza S, 2007, LIFE SCI, V81, P280, DOI 10.1016/j.lfs.2007.05.012
   Mohammad NS, 2011, MOL CELL BIOCHEM, V349, P159, DOI 10.1007/s11010-010-0670-8
   MOSCOW JA, 1995, CANCER RES, V55, P3790
   Müller HM, 2003, CANCER RES, V63, P7641
   Naushad SM, 2012, MOL CARCINOGEN, V51, pE32, DOI 10.1002/mc.21830
   Naushad SM, 2012, MOL CELL BIOCHEM, V361, P189, DOI 10.1007/s11010-011-1103-z
   Naushad SM, 2011, CELL BIOCHEM BIOPHYS, V61, P715, DOI 10.1007/s12013-011-9245-x
   Naushad SM, 2011, MOL BIOL REP, V38, P4893, DOI 10.1007/s11033-010-0631-z
   Pepe C, 2007, BREAST CANCER RES TR, V103, P29, DOI 10.1007/s10549-006-9349-y
   Pirouzpanah S, 2010, CANCER CAUSE CONTROL, V21, P2101, DOI 10.1007/s10552-010-9629-z
   Radpour R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016080
   Ryu CS, 2011, TOXICOL APPL PHARM, V255, P94, DOI 10.1016/j.taap.2011.06.004
   Tan EY, 2007, CLIN CANCER RES, V13, P467, DOI 10.1158/1078-0432.CCR-06-1466
   Tischkowitz MD, 2006, CELL CYCLE, V5, P963, DOI 10.4161/cc.5.9.2713
   Wei MJ, 2008, BREAST CANCER RES TR, V111, P113, DOI 10.1007/s10549-007-9766-6
   Widschwendter M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002656
   Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200
   Xue WJ, 2008, J GASTROEN HEPATOL, V23, P1448, DOI 10.1111/j.1440-1746.2007.05067.x
   Zhang W, 2005, CANCER RES, V65, P1554, DOI 10.1158/0008-5472.CAN-04-1554
NR 41
TC 27
Z9 28
U1 0
U2 16
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1085-9195
EI 1559-0283
J9 CELL BIOCHEM BIOPHYS
JI Cell Biochem. Biophys.
PD MAR
PY 2014
VL 68
IS 2
BP 397
EP 406
DI 10.1007/s12013-013-9720-7
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA AB2VW
UT WOS:000331651200017
PM 23934182
DA 2025-01-12
ER

PT J
AU Liu, B
   Tahk, S
   Yee, KM
   Yang, R
   Yang, YH
   Mackie, R
   Hsu, C
   Chernishof, V
   O'Brien, N
   Jin, YS
   Fan, GP
   Lane, TF
   Rao, JY
   Slamon, D
   Shuai, K
AF Liu, Bin
   Tahk, Samuel
   Yee, Kathleen M.
   Yang, Randy
   Yang, Yonghui
   Mackie, Ryan
   Hsu, Cary
   Chernishof, Vasili
   O'Brien, Neil
   Jin, Yusheng
   Fan, Guoping
   Lane, Timothy F.
   Rao, Jianyu
   Slamon, Dennis
   Shuai, Ke
TI PIAS1 Regulates Breast Tumorigenesis through Selective Epigenetic Gene
   Silencing
SO PLOS ONE
LA English
DT Article
ID CYCLIN D2 EXPRESSION; CANCER STEM-CELLS; NF-KAPPA-B; PROMOTER
   HYPERMETHYLATION; TUMOR-SUPPRESSOR; SELF-RENEWAL; WNT5A; METHYLATION;
   PROTEIN; ACTIVATION
AB Epigenetic gene silencing by histone modifications and DNA methylation is essential for cancer development. The molecular mechanism that promotes selective epigenetic changes during tumorigenesis is not understood. We report here that the PIAS1 SUMO ligase is involved in the progression of breast tumorigenesis. Elevated PIAS1 expression was observed in breast tumor samples. PIAS1 knockdown in breast cancer cells reduced the subpopulation of tumor-initiating cells, and inhibited breast tumor growth in vivo. PIAS1 acts by delineating histone modifications and DNA methylation to silence the expression of a subset of clinically relevant genes, including breast cancer DNA methylation signature genes such as cyclin D2 and estrogen receptor, and breast tumor suppressor WNT5A. Our studies identify a novel epigenetic mechanism that regulates breast tumorigenesis through selective gene silencing.
C1 [Liu, Bin; Tahk, Samuel; Yang, Yonghui; Mackie, Ryan; Chernishof, Vasili; O'Brien, Neil; Slamon, Dennis; Shuai, Ke] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA.
   [Yee, Kathleen M.; Yang, Randy; Shuai, Ke] Univ Calif Los Angeles, Dept Biol Chem, Los Angeles, CA 90024 USA.
   [Hsu, Cary] Univ Calif Los Angeles, Dept Gen Surg, Los Angeles, CA USA.
   [Jin, Yusheng; Rao, Jianyu] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA.
   [Fan, Guoping] Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA USA.
   [Lane, Timothy F.] Univ Calif Los Angeles, Dept Obstet & Gynecol, Los Angeles, CA 90024 USA.
C3 University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles;
   University of California System; University of California Los Angeles
RP Liu, B (通讯作者)，Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90024 USA.
EM bliu@ucla.edu; kshuai@mednet.ucla.edu
OI Lane, Timothy F./0000-0002-0210-970X
FU NIH [R01AI063286, R01GM085797]; Margaret E. Early Medical Research
   Trust; UCLA Jonsson Comprehensive Cancer Center; Research Scientist
   Development Award from the NIH [K01 AR52717-01]; UCLA Tumor Immunology
   Training Fellowship; National Cancer Institute [P30CA016042] Funding
   Source: NIH RePORTER
FX This research was supported by grants from the NIH (R01AI063286 and
   R01GM085797), Margaret E. Early Medical Research Trust, and the UCLA
   Jonsson Comprehensive Cancer Center (K.S.). B.L. was supported by a
   Research Scientist Development Award from the NIH (K01 AR52717-01). S.T.
   was supported by a UCLA Tumor Immunology Training Fellowship. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007
   Bin L, 2008, TRENDS PHARMACOL SCI, V29, P505, DOI 10.1016/j.tips.2008.07.008
   Blanc E, 2005, CANCER LETT, V228, P117, DOI 10.1016/j.canlet.2004.11.061
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Connolly R., 2012, J Mammary Gland Biol Neoplasia
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Dedeurwaerder S, 2011, CURR OPIN ONCOL, V23, P559, DOI 10.1097/CCO.0b013e32834bd481
   Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803
   Dontu G, 2005, STEM CELL REV, V1, P207, DOI 10.1385/SCR:1:3:207
   Evron E, 2001, CANCER RES, V61, P2782
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Hautala LC, 2008, INT J CANCER, V123, P2279, DOI 10.1002/ijc.23773
   Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Inoue M, 2005, FEBS LETT, V579, P604, DOI 10.1016/j.febslet.2004.12.030
   Jansson M, 2001, J CELL SCI, V114, P2043
   Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029
   Jönsson M, 2002, CANCER RES, V62, P409
   Jovanovic J, 2010, MOL ONCOL, V4, P242, DOI 10.1016/j.molonc.2010.04.002
   Kakarala M, 2008, J CLIN ONCOL, V26, P2813, DOI 10.1200/JCO.2008.16.3931
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Li LC, 2000, CANCER RES, V60, P702
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Liang HL, 2003, CANCER CELL, V4, P349, DOI 10.1016/S1535-6108(03)00268-X
   Liu B, 2004, NAT IMMUNOL, V5, P891, DOI 10.1038/ni1104
   Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626
   Liu B, 2005, MOL CELL BIOL, V25, P1113, DOI 10.1128/MCB.25.3.1113-1123.2005
   Liu B, 2008, CURR OPIN CELL BIOL, V20, P288, DOI 10.1016/j.ceb.2008.03.014
   Liu B, 2007, CELL, V129, P903, DOI 10.1016/j.cell.2007.03.056
   Liu B, 2010, SCIENCE, V330, P521, DOI 10.1126/science.1193787
   LOKE SL, 1988, AM J PATHOL, V131, P29
   Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835
   Mandelin E, 2003, CANCER RES, V63, P6258
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Mimeault M, 2007, J CELL MOL MED, V11, P981, DOI 10.1111/j.1582-4934.2007.00088.x
   Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998
   Molofsky AV, 2004, CURR OPIN CELL BIOL, V16, P700, DOI 10.1016/j.ceb.2004.09.004
   Olson DJ, 1997, CELL GROWTH DIFFER, V8, P417
   Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Roarty K, 2007, DEVELOPMENT, V134, P3929, DOI 10.1242/dev.008250
   Sakuma M, 2007, CANCER SCI, V98, P380, DOI 10.1111/j.1349-7006.2007.00394.x
   Shuai K, 2005, NAT REV IMMUNOL, V5, P593, DOI 10.1038/nri1667
   Szyf M, 2012, GENOME MED, V4, DOI 10.1186/gm325
   Tahk S, 2007, P NATL ACAD SCI USA, V104, P11643, DOI 10.1073/pnas.0701877104
   Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906
   Wang DL, 2013, P NATL ACAD SCI USA, V110, P5516, DOI 10.1073/pnas.1216596110
   Woodward WA, 2007, P NATL ACAD SCI USA, V104, P618, DOI 10.1073/pnas.0606599104
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
   Ying J, 2007, BLOOD, V110, P4130, DOI 10.1182/blood-2007-06-094870
   Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054
   Yu J, 2003, BRIT J CANCER, V88, P1560, DOI 10.1038/sj.bjc.6600940
NR 52
TC 30
Z9 34
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 24
PY 2014
VL 9
IS 2
AR e89464
DI 10.1371/journal.pone.0089464
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AB6EP
UT WOS:000331880700049
PM 24586797
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Wang, H
   Wang, X
   Hu, R
   Yang, W
   Liao, A
   Zhao, C
   Zhang, J
   Liu, Z
AF Wang, H.
   Wang, X.
   Hu, R.
   Yang, W.
   Liao, A.
   Zhao, C.
   Zhang, J.
   Liu, Z.
TI Methylation of SFRP5 is related to multidrug resistance in leukemia
   cells
SO CANCER GENE THERAPY
LA English
DT Article
DE methylation of SFRP; Wnt; beta-catenin; mdr1; P-glycoprotein; multidrug
   resistance
ID WNT-SIGNALING PATHWAY; CHRONIC LYMPHOCYTIC-LEUKEMIA; FRIZZLED-RELATED
   PROTEIN-5; ACUTE MYELOID-LEUKEMIA; DRUG-RESISTANCE; P-GLYCOPROTEIN;
   EPIGENETIC INACTIVATION; ABC TRANSPORTERS; BREAST-CANCER; IN-VITRO
AB Methylation of secreted frizzle-related protein (SFRP) genes activates Wnt/beta-catenin signaling and promotes tumor development. This study investigated whether SFRP5 gene methylation causes multidrug resistance (MDR) in leukemia through the Wnt/beta-catenin signaling, leading to the upregulation of the mdr1 gene and its product, P-glycoprotein (P-gp). Methylation-specific PCR identified SFRP5 gene methylation in cultured bone mononuclear cells from 7/12 patients with acute leukemia and in four human leukemia cell lines (HL-60, Raji, U937 and KG1a). Western blotting revealed absent SFRP5 protein expression in cells from 5/7 patients with SFRP5 gene methylation and in all cell lines. Treatment with a demethylation agent (DAC) rescued SFRP5 expression. mdr1 mRNA and P-gp protein were detected in cells from 3/5 patients with absent SFRP5, and in the KG1a cell line; these cells also had the highest levels of activated beta-catenin. In cells from these three patients, DAC rescued SFRP5 expression and downregulated mdr1 and P-gp. SFRP5 protein expression was rescued in transgenic KG1a/SFRP5 cells, compared with KG1a/eGFP or untransfected KG1a cells. mdr1 and P-gp in KG1a/SFRP5 cells were downregulated. Doxorubicin IC50 values were significantly lower in KG1a/SFRP5 (0.573 +/- 0.131 mu m) than in KG1a (0.963 +/- 0.115) or KG1a/eGFP (0.917 +/- 0.138) cells (P <0.05). We conclude that SFRP5 gene methylation in leukemia cells activates Wnt/beta-catenin signaling to upregulate mdr1/P-gp expression and cause MDR. Recovery of SFRP5 expression reversed MDR in the KG1a leukemia cell line. Our results suggest that modulating SFRP5 methylation could decrease MDR in leukemia patients.
C1 [Wang, H.; Hu, R.; Yang, W.; Liao, A.; Zhang, J.; Liu, Z.] China Med Univ, Shengjing Hosp, Dept Hematol, Shenyang 110016, Peoples R China.
   [Wang, X.] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang 110016, Peoples R China.
   [Zhao, C.] China Med Univ, Dept Pathophysiol, Shenyang 110016, Peoples R China.
C3 China Medical University; China Medical University; China Medical
   University
RP Liu, Z (通讯作者)，China Med Univ, Shengjing Hosp, Dept Hematol, Shenyang 110016, Peoples R China.
EM liuzhuogangmedsci@126.com
FU National Natural Science Foundation [81100376]
FX This study was supported by the National Natural Science Foundation
   (81100376).
CR Amado NG, 2011, LIFE SCI, V89, P545, DOI 10.1016/j.lfs.2011.05.003
   Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2
   Chen ZS, 2011, FEBS J, V278, P3226, DOI 10.1111/j.1742-4658.2011.08235.x
   Dabdoub A, 2005, J NEUROBIOL, V64, P446, DOI 10.1002/neu.20171
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   El Wakil A, 2011, MOL CELL ENDOCRINOL, V332, P32, DOI 10.1016/j.mce.2010.11.014
   Filipovich A, 2011, EUR J HAEMATOL, V86, P453, DOI 10.1111/j.1600-0609.2011.01592.x
   Finch PW, 1997, P NATL ACAD SCI USA, V94, P6770, DOI 10.1073/pnas.94.13.6770
   Gandhirajan RK, 2010, CURR CANCER DRUG TAR, V10, P716
   Griffiths EA, 2010, LEUKEMIA LYMPHOMA, V51, P1711, DOI 10.3109/10428194.2010.496505
   Ho CM, 2010, EUR J CLIN INVEST, V40, P310, DOI 10.1111/j.1365-2362.2010.02266.x
   Jost E, 2008, BRIT J HAEMATOL, V142, P745, DOI 10.1111/j.1365-2141.2008.07242.x
   Kawakami K, 2011, INT J CANCER, V128, P541, DOI 10.1002/ijc.25357
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1
   Kinoshita T, 2011, HEPATO-GASTROENTEROL, V58, P1051
   Knez L, 2011, LUNG CANCER, V72, P271, DOI 10.1016/j.lungcan.2011.02.014
   Koenderink JB, 2010, TRENDS PARASITOL, V26, P440, DOI 10.1016/j.pt.2010.05.002
   Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012
   Li Y, 2010, CURR MED CHEM, V17, P786, DOI 10.2174/092986710790514507
   Li Y, 2008, GENE DEV, V22, P3050, DOI 10.1101/gad.1687308
   Lim JC, 2008, J NEUROCHEM, V106, P1855, DOI 10.1111/j.1471-4159.2008.05537.x
   Lin YW, 2009, J CANCER RES CLIN, V135, P1665, DOI 10.1007/s00432-009-0613-5
   Liu JB, 2011, WORLD J GASTROENTERO, V17, P4917, DOI 10.3748/wjg.v17.i44.4917
   Liu TH, 2006, CANCER RES, V66, P653, DOI 10.1158/0008-5472.CAN-05-3712
   Montcouquiol M, 2006, ANNU REV NEUROSCI, V29, P363, DOI 10.1146/annurev.neuro.29.051605.112933
   Pan GD, 2009, WORLD J GASTROENTERO, V15, P431, DOI 10.3748/wjg.15.431
   Prosperi JR, 2010, CURR DRUG TARGETS, V11, P1074
   Ravna AW, 2009, MINI-REV MED CHEM, V9, P186, DOI 10.2174/138955709787316065
   Ren YH, 2008, MOL PHARMACEUT, V5, P579, DOI 10.1021/mp800001j
   Román-Gómez J, 2007, BLOOD, V109, P3462, DOI 10.1182/blood-2006-09-047043
   Shekhar MPV, 2011, CURR CANCER DRUG TAR, V11, P613
   Slot AJ, 2011, ESSAYS BIOCHEM, V50, P179, DOI [10.1042/BSE0500179, 10.1042/bse0500179]
   Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083
   Tamaki A, 2011, ESSAYS BIOCHEM, V50, P209, DOI [10.1042/BSE0500209, 10.1042/bse0500209]
   Veeck J, 2008, CARCINOGENESIS, V29, P991, DOI 10.1093/carcin/bgn076
   Verkaar F, 2011, DRUG DISCOV TODAY, V16, P35, DOI 10.1016/j.drudis.2010.11.007
   Wang YY, 2010, ONCOTARGET, V1, P674, DOI 10.18632/oncotarget.201
   Wansleeben C, 2011, DEV DYNAM, V240, P616, DOI 10.1002/dvdy.22564
   Weisberg E, 2010, ONCOGENE, V29, P5120, DOI 10.1038/onc.2010.273
   Yao H, 2011, EXPERT OPIN THER TAR, V15, P873, DOI 10.1517/14728222.2011.577418
   Ye XS, 2009, LEUKEMIA RES, V33, P1114, DOI 10.1016/j.leukres.2008.10.011
NR 41
TC 19
Z9 23
U1 1
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0929-1903
EI 1476-5500
J9 CANCER GENE THER
JI Cancer Gene Ther.
PD FEB
PY 2014
VL 21
IS 2
BP 83
EP 89
DI 10.1038/cgt.2013.87
PG 7
WC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology; Genetics & Heredity;
   Research & Experimental Medicine
GA AB3IN
UT WOS:000331684600007
PM 24434572
OA Bronze
DA 2025-01-12
ER

PT J
AU Lan, VTT
   Thuan, TB
   Thu, MD
   Uyen, NQ
   Ha, NT
   To, TV
AF Vo Thi Thuong Lan
   Ta Bich Thuan
   Doan Minh Thu
   Nguyen Quynh Uyen
   Ngo Thi Ha
   Ta Van To
TI Methylation Profile of <i>BRCA1</i>, <i>RASSF1A</i> and <i>ER</i> in
   Vietnamese Women with Ovarian Cancer
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE Breast cancer 1 (BRCA1); RAS-association domain family member 1
   (RASSF1A); estrogen receptor alpha (ER)
ID CPG ISLAND METHYLATION; PROMOTER METHYLATION; MULTIPLE GENES;
   HYPERMETHYLATION; DIAGNOSIS; BREAST; TUMORS; SERUM; INACTIVATION;
   EPIGENETICS
AB DNA methylation is considered a promising biomarkers for diagnosis of cancer in general and of ovarian cancer in particular. In our study, we validated the accuracy of methylation specific polymerase chain reaction (MSP) to analyze the methylation pattern of BRCA1, RASSF1A and ER in 59 and 10 Vietnamese patients with epithelial ovarian cancer (EOC) and benign ovarian tumors, respectively. We found methylation of BRCA1, RASSF1A and ER in 11/59 (18.6%), 40/59 (67.8%) and 15/59 (25.4%) of EOC cases, while methylation of BRCA1 was only detected in 2/10 (20%) benign ovarian patients. Forty five out of the 59 EOCs (78%) demonstrated methylation at one or more genes. The methylation frequency of RASSF1A was significantly associated with EOC (p<0.0005). No significant association was observed between methylation status of these genes and the clinical and pathological parameters of tumors collected from Vietnamese women suffering from ovarian cancer.
C1 [Vo Thi Thuong Lan; Ta Bich Thuan; Doan Minh Thu] VNU Univ Sci, Fac Biol, Hanoi, Vietnam.
   [Nguyen Quynh Uyen; Ngo Thi Ha] Vietnam Natl Univ, Inst Microbiol & Biotechnol, Hanoi, Vietnam.
   [Ta Van To] Natl Canc Hosp, Dept Pathol & Cytol, Hanoi, Vietnam.
C3 Vietnam National University Hanoi (VNU Hanoi) System; VNU University of
   Science (VNU-HUS); Vietnam National University Hanoi (VNU Hanoi) System
RP Lan, VTT (通讯作者)，VNU Univ Sci, Fac Biol, Hanoi, Vietnam.
EM vothithuonglan@hus.edu.vn
FU Ministry of Science and Technology, Viet Nam [NAFOSTED106.06/ 2010.20,
   KC.04.05/11-15]
FX This study was financially supported by grants (NAFOSTED106.06/ 2010.20
   and KC.04.05/11-15) from the Ministry of Science and Technology, Viet
   Nam.
CR Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175
   Asadollahi R, 2010, GYNECOL ONCOL, V118, P81, DOI 10.1016/j.ygyno.2010.03.015
   Barnholtz-Sloan JS, 2003, AM J OBSTET GYNECOL, V189, P1120, DOI 10.1067/S0002-9378(03)00579-9
   Barton CA, 2008, GYNECOL ONCOL, V109, P129, DOI 10.1016/j.ygyno.2007.12.017
   Bhoo-Pathy N., 2012, PLoS One, V7, pe30995
   BonDurant AE, 2011, GYNECOL ONCOL, V123, P581, DOI 10.1016/j.ygyno.2011.08.029
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Du XL, 2008, INT J GYNECOL CANCER, V18, P660, DOI 10.1111/j.1525-1438.2007.01081.x
   Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564
   Esteller M, 2001, CANCER RES, V61, P3225
   Feng SH, 2011, METHODS MOL BIOL, V733, P223, DOI 10.1007/978-1-61779-089-8_16
   Heichman KA, 2012, CLIN CHEM LAB MED, V50, P1707, DOI 10.1515/cclm-2011-0935
   Heyn H, 2012, NAT REV GENET, V13, P679, DOI 10.1038/nrg3270
   Houshdaran S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009359
   Ibanez de Caceres I, 2004, CANCER RES, V64, P6476
   Kristensen LS, 2009, CLIN CHEM, V55, P1471, DOI 10.1373/clinchem.2008.121962
   Lapidus RG, 1998, CANCER RES, V58, P2515
   Liu LM, 2002, ONCOGENE, V21, P6835, DOI 10.1038/sj.onc.1205814
   Mann Monica, 2011, Cancers (Basel), V3, P1691, DOI 10.3390/cancers3021691
   Matoo AA, 2013, J PIONEER MED SCI, V3, P87
   Mehrotra J, 2004, CLIN CANCER RES, V10, P2052, DOI 10.1158/1078-0432.CCR-03-0514
   Montavon C, 2012, GYNECOL ONCOL, V124, P582, DOI 10.1016/j.ygyno.2011.11.026
   Ozdemir F, 2012, EXP THER MED, V4, P1092, DOI 10.3892/etm.2012.715
   Pan YM, 2010, SCI RES ESSAYS, V5, P3939
   Rathi A, 2002, CLIN CANCER RES, V8, P3324
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Teodoridis JM, 2005, CANCER RES, V65, P8961, DOI 10.1158/0008-5472.CAN-05-1187
   Widschwendter M, 2013, GYNECOL ONCOL, V128, P134, DOI 10.1016/j.ygyno.2012.09.027
   Wiencke JK, 2004, NAT REV CANCER, V4, P79, DOI 10.1038/nrc1257
   Wilcox CB, 2005, CANCER GENET CYTOGEN, V159, P114, DOI 10.1016/j.cancergencyto.2004.12.017
   Wiley A, 2006, CANCER-AM CANCER SOC, V107, P299, DOI 10.1002/cncr.21992
   Zhang Q, 2013, GYNECOL ONCOL, V130, P132, DOI 10.1016/j.ygyno.2013.04.048
NR 32
TC 16
Z9 16
U1 0
U2 0
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2013
VL 14
IS 12
BP 7713
EP 7718
DI 10.7314/APJCP.2013.14.12.7713
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB1CM
UT WOS:000331528900110
PM 24460357
OA gold
DA 2025-01-12
ER

PT J
AU Cheng, C
   Huang, C
   Ma, TT
   Bian, EB
   He, Y
   Zhang, L
   Li, J
AF Cheng, Chang
   Huang, Cheng
   Ma, Tao-Tao
   Bian, Er-Bao
   He, Yong
   Zhang, Lei
   Li, Jun
TI SOCS1 hypermethylation mediated by DNMT1 is associated with
   lipopolysaccharide-induced inflammatory cytokines in macrophages
SO TOXICOLOGY LETTERS
LA English
DT Article
DE RAW264.7 mouse macrophage cell line; Suppressors of cytokine signaling1
   (SOCS1); Hypermethylation; DNA methyltransferase1 (DNMT1);
   Pro-inflammatory cytokines
ID DNA METHYLTRANSFERASE 1; ISLAND METHYLATOR PHENOTYPE; SQUAMOUS-CELL
   CARCINOMA; CANCER-CELLS; BREAST-CANCER; ACTIVATION; SUPPRESSOR;
   EXPRESSION; DISEASE; GENE
AB Macrophages activation which releases the pro-inflammatory cytokines is an essential event in the process of inflammation. SOCS1 has been shown to act as a negative regulator of cytokine signals and plays a key role in the suppression of tissue injury and inflammatory diseases. DNA methylation mediated by specific DNA methyltransferases1 (DNMT1) which contributes to the epigenetic silencing of multiple genes. SOCS1 promoter hypermethylation is by far the best categorized epigenetic change in tumors. Our study with a view to investigate whether the loss of SOCS1 due to SOCS1 promoter methylation was involved in the course of inflammatory cytokines released from lipopolysaccharide (LPS)-stimulated macrophages. Here, we found that treatment of LPS-induced RAW264.7 macrophage cells with the DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-azadC) reduced aberrant promoter hypermethylation of SOCS1 and prevented the loss of the expression of SOCS1 in macrophages which secret inflammatory cytokines. Knockdown of DNMT1 gene not only attenuated the SOCS1 gene promoter methylation but also up-regulated the expression of SOCS1 in activated RAW264.7 cells. Furthermore, silencing of DNMT1 prevented the activation of JAK2/STAT3 pathway in LPS-induced RAW264.7 cells. These studies demonstrated that DNMT1-mediated SOCS1 hypermethylation caused the loss of SOCS1 expression results in negative regulation of activation of the JAK2/STAT3 pathway, and enhanced the release of LPS-induced pro-inflammatory cytokines such as TNF-alpha and IL-6 in macrophages. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Cheng, Chang; Huang, Cheng; Ma, Tao-Tao; Bian, Er-Bao; He, Yong; Zhang, Lei; Li, Jun] Anhui Med Univ, Sch Pharm, Hefei 230032, Anhui, Peoples R China.
   [Cheng, Chang; Huang, Cheng; Ma, Tao-Tao; Bian, Er-Bao; He, Yong; Zhang, Lei; Li, Jun] Anhui Med Univ, Inst Liver Dis, Hefei, Peoples R China.
C3 Anhui Medical University; Anhui Medical University
RP Cheng, C (通讯作者)，Anhui Med Univ, Sch Pharm, Mei Shan Rd, Hefei 230032, Anhui, Peoples R China.
EM chengchang730@gmail.com; lj@ahmu.edu.cn
RI ma, tao/JTS-7892-2023
OI Bian, Erbao/0000-0001-6539-5152; He, Yong/0009-0006-8681-5287
FU National Science Foundation of China [81072686, 81273526]
FX This project was supported by the National Science Foundation of China
   (No. 81072686, 81273526).
CR [Anonymous], IEEE GLOBECOM, DOI DOI 10.1109/GLOCOM.2010.5683628
   Aoyama S, 2012, BIOCHEM BIOPH RES CO, V420, P775, DOI 10.1016/j.bbrc.2012.03.071
   Bian EB, 2012, TOXICOL APPL PHARM, V264, P13, DOI 10.1016/j.taap.2012.06.022
   Capello D, 2013, HEMATOL ONCOL, V31, P22, DOI 10.1002/hon.2010
   Chawla A, 2011, NAT REV IMMUNOL, V11, P738, DOI 10.1038/nri3071
   Cui M, 2010, MED ONCOL, V27, P278, DOI 10.1007/s12032-009-9204-1
   Davey GM, 2006, TISSUE ANTIGENS, V67, P1, DOI 10.1111/j.1399-0039.2005.00532.x
   de Andrés MC, 2011, BIOCHEM BIOPH RES CO, V407, P54, DOI 10.1016/j.bbrc.2011.02.101
   de Geus E.D., 2013, DEV COMP IMMUNOL
   De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013
   Denis H, 2011, EMBO REP, V12, P647, DOI 10.1038/embor.2011.110
   Gagnon J, 2007, CELL SIGNAL, V19, P806, DOI 10.1016/j.cellsig.2006.10.003
   Griffiths EA, 2010, EPIGENETICS-US, V5, P590, DOI 10.4161/epi.5.7.12558
   Guenterberg KD, 2011, CANCER IMMUNOL IMMUN, V60, P1281, DOI 10.1007/s00262-011-1034-2
   Gyorfy Z, 2013, VET IMMUNOL IMMUNOP, V152, P28, DOI 10.1016/j.vetimm.2012.09.020
   Harrison DA., 2012, COLD SPRING HARB PER, V4
   Hashimoto M, 2009, CANCER SCI, V100, P730, DOI 10.1111/j.1349-7006.2009.01098.x
   He SS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027684
   Hirahara K, 2013, J ALLERGY CLIN IMMUN, V131, P1276, DOI 10.1016/j.jaci.2013.03.015
   Huang WL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-309
   Hussain S, 2011, J RECEPT SIG TRANSD, V31, P147, DOI 10.3109/10799893.2011.553836
   Ilangumaran S, 2003, IMMUNOL REV, V192, P196, DOI 10.1034/j.1600-065X.2003.00020.x
   Jo P, 2012, SURGERY, V151, P564, DOI 10.1016/j.surg.2011.08.013
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kar S, 2012, EPIGENETICS-US, V7, P994, DOI 10.4161/epi.21568
   Kim WJ, 2012, CANCER LETT, V320, P65, DOI 10.1016/j.canlet.2012.01.022
   Krifa M, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-30
   Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069
   Lesinski GB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-142
   Li Y, 2012, CARCINOGENESIS, V33, P1889, DOI 10.1093/carcin/bgs214
   Liu GW, 2013, J CELL PHYSIOL, V228, P502, DOI 10.1002/jcp.24157
   Lubecka-Pietruszewska K, 2013, BIOCHEM BIOPH RES CO, V430, P623, DOI 10.1016/j.bbrc.2012.11.103
   Minogue AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-126
   Morita R, 2013, EXP MOL PATHOL, V94, P322, DOI 10.1016/j.yexmp.2012.10.004
   Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Palmer DC, 2009, TRENDS IMMUNOL, V30, P592, DOI 10.1016/j.it.2009.09.009
   Raggi C., 2013, CLIN RES HEPATOL GAS
   Saelee P, 2012, ASIAN PAC J CANCER P, V13, P3489, DOI 10.7314/APJCP.2012.13.7.3489
   Scrivo R, 2011, AUTOIMMUN REV, V10, P369, DOI 10.1016/j.autrev.2010.12.006
   Shibata N, 2009, J LIPID RES, V50, pS277, DOI 10.1194/jlr.R800063-JLR200
   Shlomi T, 2013, NAT CHEM BIOL, V9, P293, DOI 10.1038/nchembio.1234
   Shull AY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058731
   Sobti RC, 2011, CELL ONCOL, V34, P533, DOI 10.1007/s13402-011-0056-2
   Souma Y, 2012, INT J CANCER, V131, P1287, DOI 10.1002/ijc.27350
   Sutherland KD, 2004, ONCOGENE, V23, P7726, DOI 10.1038/sj.onc.1207787
   Svedruzic ZM, 2011, PROG MOL BIOL TRANSL, V101, P221, DOI 10.1016/B978-0-12-387685-0.00006-8
   Tajiri K, 2012, J IMMUNOL, V189, P2043, DOI 10.4049/jimmunol.1103610
   Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464
   Tao H, 2011, TOXICOLOGY, V290, P327, DOI 10.1016/j.tox.2011.10.011
   Um TH, 2011, J HEPATOL, V54, P939, DOI 10.1016/j.jhep.2010.08.021
   Vaissière T, 2008, MUTAT RES-REV MUTAT, V659, P40, DOI 10.1016/j.mrrev.2008.02.004
   Valledor AF, 2010, ADV IMMUNOL, V108, P1, DOI 10.1016/S0065-2776(10)08001_6
   van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136
   Wu CT, 2011, CANCER-AM CANCER SOC, V117, P5221, DOI 10.1002/cncr.26150
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Zhao SL, 2011, DIS ESOPHAGUS, V24, P601, DOI 10.1111/j.1442-2050.2011.01199.x
NR 57
TC 90
Z9 100
U1 2
U2 30
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0378-4274
EI 1879-3169
J9 TOXICOL LETT
JI Toxicol. Lett.
PD MAR 21
PY 2014
VL 225
IS 3
BP 488
EP 497
DI 10.1016/j.toxlet.2013.12.023
PG 10
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA AB3YF
UT WOS:000331725400018
PM 24440346
DA 2025-01-12
ER

PT J
AU Biava, PM
   Nicolini, A
   Ferrari, P
   Carpi, A
   Sell, S
AF Biava, P. M.
   Nicolini, A.
   Ferrari, P.
   Carpi, A.
   Sell, S.
TI A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming
   Focused on Endocrine-Related Cancers
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Article
DE Cancer; cancer stem cells; differentiation factors; embryonic
   microenvironment; epigenetic reprogramming; reprogramming of cancer
   cells; stem cells
ID DIFFERENTIATION STAGE FACTORS; STEM-CELLS; OVARIAN-CANCER; COLON-CANCER;
   IN-VITRO; HEPATOCELLULAR-CARCINOMA; MATURATION ARREST; ZEBRAFISH
   EMBRYOS; PROSTATE-CANCER; SIDE POPULATION
AB The term "cancer cell reprogramming" is used to define any kind of intervention aimed at transforming cancer cells into terminally differentiated cells. Using this approach, new technologies have been applied with different methods for a more systemic approach to cancer treatment. This review reports on advances of these technologies, including our personal contributions, mainly carried out on endocrine-related cancers. Some of the interventions, aimed at reverting cancer cells into a normal phenotype, are based on the evidence that tumor development is suppressed by the embryonic microenvironment. On the basis of this rationale, experiments have been conducted using stem cell differentiation stage factors (SCDSFs) taken at different stages of development of Zebrafish embryos, oocyte extracts, or nave human umbilical cord matrix derived stem cells (UMDSCs). SCDSFs induce significant growth inhibition on different tumor cell lines in vitro, likely because of increases in cell cycle regulatory molecules, such as p53 and pRb. Treatment with these factors activates apoptosis and differentiation related to caspase-3. This is achieved via p73 apoptotic-dependent pathway activation with a concurrent normalization of the E-cadherin and beta-catenin ratio. Extracts from prophase amphibian oocytes could reprogram relevant epigenetic alterations in MCF-7 and HCC1954 breast cancer cell lines, while un-engineered (naive) human UMDSCs attenuated growth of MDA-231 human breast carcinoma cells. A product prepared for human treatments, containing SCDSFs at very low doses, yielded favorable results in breast cancer and in intermediate-advanced hepatocellular carcinoma. Other reprogramming interventions used in the models of breast, prostate and ovarian cancer cell lines are described. Finally, current and future perspectives of this novel technology are discussed and a new hallmark of cancer is suggested: the loss of differentiation of cancer cells.
C1 [Biava, P. M.] Sci Inst Res & Hlth Care IRCCS Multimed Milano, Milan, Italy.
   [Nicolini, A.; Ferrari, P.] Univ Pisa, Dept Internal Med, I-56100 Pisa, Italy.
   [Carpi, A.] Univ Pisa, Dept Reprod & Aging, I-56100 Pisa, Italy.
   [Sell, S.] Albany Coll Pharm, Wadsworth Ctr, Div Translat Med, Albany, NY USA.
   [Sell, S.] SUNY Albany, Albany, NY 12222 USA.
C3 IRCCS Multimedica; University of Pisa; University of Pisa; Albany
   College of Pharmacy & Health Sciences; Wadsworth Center; State
   University of New York (SUNY) System; University at Albany, SUNY
RP Biava, PM (通讯作者)，Sci Inst Res & Care Multimed, Milan, Italy.
EM biava@tiscali.it
RI Nicolini, Antonio/J-1852-2015
OI Biava, Pier Mario/0000-0003-3662-4643; Nicolini,
   Andrea/0000-0002-5178-9510
CR Abollo-Jiménez F, 2010, SEMIN CANCER BIOL, V20, P98, DOI 10.1016/j.semcancer.2010.02.002
   Ailles L, 2009, METHODS MOL BIOL, V568, P175, DOI 10.1007/978-1-59745-280-9_11
   Allegrucci C, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-7
   AYUZAWA R, CANC LETT
   Bae KM, 2010, J UROLOGY, V183, P2045, DOI 10.1016/j.juro.2009.12.092
   Biava P, 2001, J TUMOR MARKER ONCOL, V16, P203
   Biava PM, 2011, CURR PHARM BIOTECHNO, V12, P231
   Biava P.M., 2002, J TUMOR MARKER ONCOL, V17, P55
   Biava P.M., 2005, J TUMOR MARKER ONCOL, V20, P109
   Biava P.M., 2002, J TUMOR MARKER ONCOL, V17, P65
   Biava PM, 2011, CURR PHARM BIOTECHNO, V12, P145
   Biava PM, 2001, J TUMOR MARKER ONCOL, V16, P195
   BIAVA PM, 1988, CANCER LETT, V41, P265
   Biava PM, 1997, J TUMOR MARKER ONCOL, V12, P9
   Biava PM, 2000, J TUMOR MARKER ONCOL, V15, P223
   Biava PM., 2002, J Tumor Marker Oncol, V17, P47
   Bizzarri M, 2011, CURR PHARM BIOTECHNO, V12, P243, DOI 10.2174/138920111794295701
   Bizzarri M., 2002, J TUMOR MARKER ONCOL, V17, P59
   BRENT RL, 1980, TERATOLOGY, V21, P281, DOI 10.1002/tera.1420210304
   BRINSTER RL, 1974, J EXP MED, V140, P1049, DOI 10.1084/jem.140.4.1049
   Brunner M, 2008, J SURG ONCOL, V98, P545, DOI 10.1002/jso.21139
   Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712
   Chen Jian, 2010, Chin J Cancer, V29, P265
   CHEN Z, 2009, J SURG ONCOL, V34, P1201
   Chik F, 2012, ADV EXP MED BIOL, V720, P91, DOI 10.1007/978-1-4614-0254-1_8
   Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734
   COLEMAN WB, 1993, AM J PATHOL, V142, P1373
   Correia M, 2009, HELICOBACTER, V14, P36, DOI 10.1111/j.1523-5378.2009.00696.x
   Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382
   Cubillos-Ruiz JR, 2012, CANCER RES, V72, P1683, DOI 10.1158/0008-5472.CAN-11-3160
   Cucina A, 2006, APOPTOSIS, V11, P1617, DOI 10.1007/s10495-006-8895-4
   D'Anselmi F, 2011, CURR PHARM BIOTECHNO, V12, P261, DOI 10.2174/138920111794295864
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   De Palma M, 2012, MOL ONCOL, V6, P111, DOI 10.1016/j.molonc.2012.01.011
   Di Tomaso T, 2010, CLIN CANCER RES, V16, P800, DOI 10.1158/1078-0432.CCR-09-2730
   Díez-Torre A, 2009, INT J DEV BIOL, V53, P1563, DOI 10.1387/ijdb.093021ad
   EINHORN L, 1983, ONCODEV BIOL MED, V4, P219
   Fong MY, 2010, HISTOL HISTOPATHOL, V25, P113, DOI 10.14670/HH-25.113
   Freeman JA, 2013, BRIEF FUNCT GENOMICS, V12, P46, DOI 10.1093/bfgp/els058
   Gai H, 2010, DIFFERENTIATION, V79, P171, DOI 10.1016/j.diff.2010.01.002
   Ganta C, 2009, CANCER RES, V69, P1815, DOI 10.1158/0008-5472.CAN-08-2750
   GERSCHENSON M, 1986, P NATL ACAD SCI USA, V83, P7307, DOI 10.1073/pnas.83.19.7307
   GOOTWINE E, 1982, NATURE, V299, P63, DOI 10.1038/299063a0
   Gorelik E, 2010, ANTI-CANCER AGENT ME, V10, P164, DOI 10.2174/187152010790909308
   Grzmil M, 2004, INT J ONCOL, V24, P97
   Gulino A, 2009, EMBO MOL MED, V1, P300, DOI 10.1002/emmm.200900042
   Guo YC, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/69141
   Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108
   Hinshelwood RA, 2008, J MOL MED, V86, P1315, DOI 10.1007/s00109-008-0386-3
   Huang S, 2009, SEMIN CELL DEV BIOL, V20, P869, DOI 10.1016/j.semcdb.2009.07.003
   Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375
   Ji JF, 2010, NEUROSURG CLIN N AM, V21, P159, DOI 10.1016/j.nec.2009.08.006
   Joung JY, 2010, J SURG ONCOL, V101, P145, DOI 10.1002/jso.21445
   Kang DH, 2009, J GASTROENTEROL, V44, P372, DOI 10.1007/s00535-009-0006-1
   Katoh M, 2009, INT J MOL MED, V23, P763, DOI 10.3892/ijmm_00000190
   Katoh M, 2009, INT J ONCOL, V34, P1411, DOI 10.3892/ijo_00000269
   Kenny PA, 2003, INT J CANCER, V107, P688, DOI 10.1002/ijc.11491
   Kulesa PM, 2006, P NATL ACAD SCI USA, V103, P3752, DOI 10.1073/pnas.0506977103
   KUNG JW, 2010, J BIOMED BIOTECHNOL, V30, P26
   Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802
   Lang SH, 2010, STEM CELLS DEV, V19, P537, DOI 10.1089/scd.2009.0291
   Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107
   Lawson JC, 2009, BREAST CANCER RES TR, V118, P241, DOI 10.1007/s10549-009-0524-9
   Lee JT, 2006, NAT MED, V12, P882, DOI 10.1038/nm0806-882
   Lee LMJ, 2005, DEV DYNAM, V233, P1560, DOI 10.1002/dvdy.20471
   Lee TKW, 2009, LIVER INT, V29, P955, DOI 10.1111/j.1478-3231.2009.02040.x
   Li L, 2003, CANCER RES, V63, P2733
   Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1
   Liu M, 2013, REPROD SCI, V20, P605, DOI 10.1177/1933719112461183
   Liu T, 2010, ONCOL REP, V23, P1277, DOI 10.3892/or_00000761
   Livraghi T, 2005, ONCOL RES, V15, P399, DOI 10.3727/096504005776449716
   Lo PK, 2008, PHARMACOGENOMICS, V9, P1879, DOI 10.2217/14622416.9.12.1879
   Luo J, 2010, AM J MED SCI, V339, P366, DOI 10.1097/MAJ.0b013e3181cad964
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Marquardt JU, 2010, SEMIN LIVER DIS, V30, P26, DOI 10.1055/s-0030-1247130
   MCKINNELL RG, 1969, SCIENCE, V165, P394, DOI 10.1126/science.165.3891.394
   Mima K, 2013, ONCOL LETT, V5, P149, DOI 10.3892/ol.2012.954
   MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585
   Murphy SK, 2010, ANTI-CANCER AGENT ME, V10, P157, DOI 10.2174/187152010790909272
   NEEDHAM JOSEPH, 1936, PROC ROY SOC MED, V29, P1577
   Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x
   Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977
   Olumi AF, 1999, CANCER RES, V59, P5002
   Onder TT, 2011, GENOME MED, V3, DOI 10.1186/gm256
   PAPAIOANNOU VE, 1975, NATURE, V258, P70, DOI 10.1038/258070a0
   Park SY, 2010, CLIN CANCER RES, V16, P876, DOI 10.1158/1078-0432.CCR-09-1532
   Park YJ, 2011, PROG DRUG RES, V67, P25, DOI 10.1007/978-3-7643-8989-5_2
   Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606
   Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500
   Pierce G.B., 1983, TERATOCARCINOMA STEM, P15
   PIERCE GB, 1979, P NATL ACAD SCI USA, V76, P6649, DOI 10.1073/pnas.76.12.6649
   PIERCE GB, 1982, CANCER RES, V42, P1082
   PIERCE GB, 1983, AM J PATHOL, V113, P115
   PODESTA AH, 1984, P NATL ACAD SCI-BIOL, V81, P7608, DOI 10.1073/pnas.81.23.7608
   POSTOVIT LM, 2008, P NATL ACAD SCI USA, V18, P105
   Puri S, 2010, DEV CELL, V18, P342, DOI 10.1016/j.devcel.2010.02.005
   Quante M, 2009, NAT REV GASTRO HEPAT, V6, P724, DOI 10.1038/nrgastro.2009.195
   Quinn MCJ, 2009, MOL CARCINOGEN, V48, P648, DOI 10.1002/mc.20511
   Rachakatla RS, 2009, FUTURE ONCOL, V5, P1237, DOI 10.2217/FON.09.99
   Rasheed ZA, 2010, JNCI-J NATL CANCER I, V102, P340, DOI 10.1093/jnci/djp535
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507
   Roesler R, 2010, LANCET ONCOL, V11, P225, DOI 10.1016/S1470-2045(09)70404-8
   Ruiz-Vela A, 2009, STEM CELL REV REP, V5, P319, DOI 10.1007/s12015-009-9096-7
   Sato A, 2010, NEUROSURG REV, V33, P175, DOI 10.1007/s10143-010-0239-8
   Schumacker PT, 2011, CANCER CELL, V19, P299, DOI 10.1016/j.ccr.2011.03.001
   Sell S, 2007, Stem Cell Rev, V3, P1, DOI 10.1007/s12015-007-0015-5
   SELL S, 1994, LAB INVEST, V70, P6
   Sell S, 2005, STEM CELL REV, V1, P197, DOI 10.1385/SCR:1:3:197
   Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050
   Spike Benjamin T, 2011, Genes Cancer, V2, P404, DOI 10.1177/1947601911410224
   Spiro SG, 2010, RESPIROLOGY, V15, P44, DOI 10.1111/j.1440-1843.2009.01674.x
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101
   Sullivan JP, 2010, CANCER METAST REV, V29, P61, DOI 10.1007/s10555-010-9216-5
   Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30
   Teperek-Tkacz M, 2011, REPRODUCTION, V142, P621, DOI 10.1530/REP-11-0148
   Thenappan A, 2009, CURR COLORECT CANC R, V5, P209, DOI 10.1007/s11888-009-0029-2
   Tommasi S, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2233
   Tomuleasa C, 2010, J GASTROINTEST LIVER, V19, P61
   Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448
   Tuan L. T., 2006, PROTEOMICS, V6, P3176
   Uppalapati D, 2011, MOL PHARMACEUT, V8, P1549, DOI 10.1021/mp2001582
   Waddington CH, 1935, NATURE, V135, P606, DOI 10.1038/135606a0
   Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231
   WEBB CG, 1984, DEV BIOL, V101, P221, DOI 10.1016/0012-1606(84)90132-5
   WELLS RS, 1986, CANCER RES, V46, P1659
   WESTHOFF B, 2010, P NATL ACAD SCI USA, V87, P457
   Wu W, 2011, METHODS MOL BIOL, V676, P59, DOI 10.1007/978-1-60761-863-8_5
   Wu Wei, 2010, Recent Pat DNA Gene Seq, V4, P40
   Xu T, 2011, PROSTATE, V71, P1390, DOI 10.1002/pros.21355
   Xu T, 2010, MOL CANCER THER, V9, P438, DOI 10.1158/1535-7163.MCT-09-0682
   Xu Yucheng, 2011, Clin Adv Hematol Oncol, V9, P442
   Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107
   Yu CL, 2001, CANCER LETT, V166, P173, DOI 10.1016/S0304-3835(01)00417-7
   Zhang P, 2009, CANCER LETT, V277, P227, DOI 10.1016/j.canlet.2008.12.015
   Zhang QZ, 2010, CANCER LETT, V289, P151, DOI 10.1016/j.canlet.2009.08.010
   Zhang Y, 2011, CELL MOL LIFE SCI, V68, P3557, DOI 10.1007/s00018-011-0808-1
   Zhao TBA, 2010, TRENDS CELL BIOL, V20, P170, DOI 10.1016/j.tcb.2009.12.004
   Zou GM, 2010, ANTI-CANCER AGENT ME, V10, P172, DOI 10.2174/187152010790909263
NR 142
TC 14
Z9 14
U1 0
U2 25
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PD MAR
PY 2014
VL 21
IS 9
BP 1072
EP 1081
DI 10.2174/0929867321666131201143124
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA AA9ZN
UT WOS:000331451700002
PM 24304275
DA 2025-01-12
ER

PT J
AU Yiannakopoulou, EC
AF Yiannakopoulou, Eugenia Ch
TI Green Tea Catechins: Proposed Mechanisms of Action in Breast Cancer
   Focusing on the Interplay Between Survival and Apoptosis
SO ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY
LA English
DT Article
DE Apoptosis; breast cancer; carcinogenesis; EGCG; green tea catechins;
   mechanisms of action
ID EPIGALLOCATECHIN GALLATE; IN-VITRO; CELLS; PREVENTION;
   (-)-EPIGALLOCATECHIN-3-GALLATE; PROLIFERATION; INTERVENTION;
   POLYPHENOLS; SUPPRESSION; TELOMERASE
AB Recent data have shown strong chemopreventive and possibly cancer chemotherapeutic effects of green tea polyphenols against cancer. Despite advances in breast cancer treatment, mortality from breast cancer is still high. Undoubtedly novel treatment strategies are needed for chemoprevention of high risk women and for the treatment of receptor negative breast cancer. Green tea catechins have been shown to inhibit proliferation of breast cancer cells and to block carcinogenesis. This review attempts a critical presentation of the mechanisms of action of green tea catechins in breast cancer. Several mechanisms of action of green tea catechins in breast cancer have been proposed including modulation of extracellular signalling, induction of apoptosis through redox regulation, or through modulation of epigenetic alterations. A number of molecular targets of green tea catechins have been suggested i.e molecular chaperones, telomerase, apoptotic cascade. Although the molecular links among the proposed mechanisms of action of green tea catechins are often missing, it must be emphasized that all the proposed mechanisms indicate that green tea catechins inhibit growth and /or promote apoptosis. It would be interesting if future experimental trials could take into account that green tea catechins are multi-target agents and attempt to link every novel proposed target with the other already proposed targets of green tea catechins.
C1 [Yiannakopoulou, Eugenia Ch] Fac Hlth, Dept Basic Med Lessons, Athens, Greece.
   [Yiannakopoulou, Eugenia Ch] Caring Profess Technol Educ Inst Athens, Athens, Greece.
RP Yiannakopoulou, EC (通讯作者)，Eleutheriou Benizelou 106, Athens 17676, Greece.
EM nyiannak@teiath.gr
CR Alshatwi AA, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-167
   Beltz Lisa Ann, 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P389
   Berletch JB, 2008, J CELL BIOCHEM, V103, P509, DOI 10.1002/jcb.21417
   Bigelow RLH, 2006, ONCOGENE, V25, P1922, DOI 10.1038/sj.onc.1209227
   Cabrera C, 2006, J AM COLL NUTR, V25, P79, DOI 10.1080/07315724.2006.10719518
   Crew KD, 2012, CANCER PREV RES, V5, P1144, DOI 10.1158/1940-6207.CAPR-12-0117
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Friedman M, 2007, J AGR FOOD CHEM, V55, P243, DOI 10.1021/jf062276h
   Hsuuw YD, 2007, ANN NY ACAD SCI, V1095, P428, DOI 10.1196/annals.1397.046
   Kaur S, 2007, J AGR FOOD CHEM, V55, P3378, DOI 10.1021/jf0633342
   Landis-Piwowar KR, 2007, CANCER RES, V67, P4303, DOI 10.1158/0008-5472.CAN-06-4699
   Mann CD, 2009, EUR J CANCER PREV, V18, P13, DOI 10.1097/CEJ.0b013e3282f0c090
   Meeran SM, 2011, CANCER PREV RES, V4, P1243, DOI 10.1158/1940-6207.CAPR-11-0009
   Mittal A, 2004, INT J ONCOL, V24, P703
   Rathore K, 2013, CANCER LETT, V333, P113, DOI 10.1016/j.canlet.2013.01.030
   Rathore K, 2012, MOL CARCINOGEN, V51, P280, DOI 10.1002/mc.20844
   Rathore K, 2012, CARCINOGENESIS, V33, P174, DOI 10.1093/carcin/bgr244
   Roy AM, 2005, MOL CANCER THER, V4, P81
   Sing MF, 2011, EUR J CANCER PREV, V20, P157, DOI 10.1097/CEJ.0b013e3283447497
   Skrzydlewska E, 2002, PHYTOMEDICINE, V9, P232, DOI 10.1078/0944-7113-00119
   Sutherland BA, 2006, J NUTR BIOCHEM, V17, P291, DOI 10.1016/j.jnutbio.2005.10.005
   Thangapazham RL, 2007, CANCER LETT, V245, P232, DOI 10.1016/j.canlet.2006.01.027
   Tran PLCHB, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-276
   Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011
   Vergote D, 2002, BREAST CANCER RES TR, V76, P195, DOI 10.1023/A:1020833410523
   Yang CS, 2011, PHARMACOL RES, V64, P113, DOI 10.1016/j.phrs.2011.03.001
   Yiannakopoulou EC, 2013, FREE RADICAL RES, V47, P667, DOI 10.3109/10715762.2013.819975
   Yuan JM, 2011, PHARMACOL RES, V64, P123, DOI 10.1016/j.phrs.2011.03.002
   Zhao XH, 2006, FRONT BIOSCI-LANDMRK, V11, P2428, DOI 10.2741/1980
NR 29
TC 14
Z9 14
U1 0
U2 34
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1871-5206
EI 1875-5992
J9 ANTI-CANCER AGENT ME
JI Anti-Cancer Agents Med. Chem.
PD FEB
PY 2014
VL 14
IS 2
BP 290
EP 295
DI 10.2174/18715206113136660339
PG 6
WC Oncology; Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA AB0DU
UT WOS:000331462800012
PM 24069935
DA 2025-01-12
ER

PT J
AU Larsen, MJ
   Thomassen, M
   Tan, QH
   Lænkholm, AV
   Bak, M
   Sorensen, KP
   Andersen, MK
   Kruse, TA
   Gerdes, AM
AF Larsen, Martin J.
   Thomassen, Mads
   Tan, Qihua
   Laenkholm, Anne-Vibeke
   Bak, Martin
   Sorensen, Kristina P.
   Andersen, Mette Klarskov
   Kruse, Torben A.
   Gerdes, Anne-Marie
TI RNA profiling reveals familial aggregation of molecular subtypes in
   non-BRCA1/2 breast cancer families
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Hereditary breast and ovarian cancer syndrome; RNA profiling;
   non-BRCA1/2; Gene expression analysis; Microarray analysis; Molecular
   subtypes; Promoter methylation
ID TUMORS; BRCA1; PATTERNS; CLASSIFICATION; PORTRAITS; PREDICTOR;
   MUTATIONS; PATHOLOGY; PROMOTER; LINKAGE
AB Background: In more than 70% of families with a strong history of breast and ovarian cancers, pathogenic mutation in BRCA1 or BRCA2 cannot be identified, even though hereditary factors are expected to be involved. It has been proposed that tumors with similar molecular phenotypes also share similar underlying pathophysiological mechanisms. In the current study, the aim was to investigate if global RNA profiling can be used to identify functional subgroups within breast tumors from families tested negative for BRCA1/2 germline mutations and how these subgroupings relate to different breast cancer patients within the same family.
   Methods: In the current study we analyzed a collection of 70 frozen breast tumor biopsies from a total of 58 families by global RNA profiling and promoter methylation analysis.
   Results: We show that distinct functional subgroupings, similar to the intrinsic molecular breast cancer subtypes, exist among non-BRCA1/2 breast cancers. The distribution of subtypes was markedly different from the distribution found among BRCA1/2 mutation carriers. From 11 breast cancer families, breast tumor biopsies from more than one affected family member were included in the study. Notably, in 8 of these families we found that patients from the same family shared the same tumor subtype, showing a tendency of familial aggregation of tumor subtypes (p-value = 1.7e-3). Using our previously developed BRCA1/2-signatures, we identified 7 non-BRCA1/2 tumors with a BRCA1-like molecular phenotype and provide evidence for epigenetic inactivation of BRCA1 in three of the tumors. In addition, 7 BRCA2-like tumors were found.
   Conclusions: Our finding indicates involvement of hereditary factors in non-BRCA1/2 breast cancer families in which family members may carry genetic susceptibility not just to breast cancer but to a particular subtype of breast cancer. This is the first study to provide a biological link between breast cancers from family members of high-risk non-BRCA1/2 families in a systematic manner, suggesting that future genetic analysis may benefit from subgrouping families into molecularly homogeneous subtypes in order to search for new high penetrance susceptibility genes.
C1 [Larsen, Martin J.; Thomassen, Mads; Tan, Qihua; Sorensen, Kristina P.; Kruse, Torben A.] Odense Univ Hosp, Dept Clin Genet, DK-5000 Odense, Denmark.
   [Larsen, Martin J.; Thomassen, Mads; Sorensen, Kristina P.; Kruse, Torben A.] Univ Southern Denmark, Inst Clin, Odense, Denmark.
   [Tan, Qihua] Univ Southern Denmark, Inst Publ Hlth, Odense, Denmark.
   [Laenkholm, Anne-Vibeke] Slagelse Hosp, Dept Pathol, Slagelse, Denmark.
   [Bak, Martin] Odense Univ Hosp, Dept Pathol, DK-5000 Odense, Denmark.
   [Andersen, Mette Klarskov; Gerdes, Anne-Marie] Copenhagen Univ Hosp, Rigshosp, Dept Clin Genet, Copenhagen, Denmark.
C3 University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; University of Southern Denmark; University of
   Southern Denmark; Odense University Hospital; University of Copenhagen;
   Rigshospitalet
RP Larsen, MJ (通讯作者)，Odense Univ Hosp, Dept Clin Genet, Sdr Blvd 29, DK-5000 Odense, Denmark.
EM martin.larsen@rsyd.dk
RI Larsen, Martin/L-5794-2019; Bak, Martin/D-1392-2012; Tan,
   Qihua/F-1349-2015
OI Gerdes, Anne-Marie/0000-0002-0328-3320; Tan, Qihua/0000-0003-3194-0030;
   Larsen, Martin Jakob/0000-0003-4107-8771; Laenkholm,
   Anne-Vibeke/0000-0003-2166-8686
FU Ministry of the Interior; Ministry of Health; University of Southern
   Denmark; Odense University Hospital; Danish Cancer Society; Danish
   Council for Strategic Research (DBCG-TIBCAT); Dansk Kraeftforsknings
   Fond; Breast Friends; Kobenhavns Universitets fond for kraeftforskning;
   Savvaerksejer Jeppe Juhls og hustru Ovita Juhls Mindelegat; Arvid
   Nilssons Fond; Agnes og Poul Friis Fond; Raimond og Dagmar Ringgard
   Bohns Fond; Fonden til Laegevidenskabens Fremme; Kong Christian IX og
   Dronning Louises Jubilaeumslegat; Ingenior K. A. Rohde og hustrus Legat;
   Snedkermester Sophus Jacobsens og hustru Astrid Jacobsens Fond; Fru
   Astrid Thaysens Legat for Laegevidenskabelig Grundforskning; Helen Rudes
   Fond; Karen A. Tolstrups Fond; A.J. Andersen og Hustrus Fond; Dagmar
   Marshalls Fond; Aase og Ejnar Danielsens Fond; Grosserer M. Brogaard og
   Hustrus Mindefonde; Augustinus Fonden; Familien Hede Nielsens Fond
FX The authors acknowledge Ingrid Hedenfalk and colleagues for making their
   microarray dataset publically available. The work was supported by a
   gift from Heidi Seide Jacobsen and grants from Ministry of the Interior
   and Ministry of Health, University of Southern Denmark, Odense
   University Hospital, Danish Cancer Society, The Danish Council for
   Strategic Research (DBCG-TIBCAT), Dansk Kraeftforsknings Fond, Breast
   Friends, Kobenhavns Universitets fond for kraeftforskning, Savvaerksejer
   Jeppe Juhls og hustru Ovita Juhls Mindelegat, Arvid Nilssons Fond, Agnes
   og Poul Friis Fond, Raimond og Dagmar Ringgard Bohns Fond, Fonden til
   Laegevidenskabens Fremme, Kong Christian IX og Dronning Louises
   Jubilaeumslegat, Ingenior K. A. Rohde og hustrus Legat, Snedkermester
   Sophus Jacobsens og hustru Astrid Jacobsens Fond, Fru Astrid Thaysens
   Legat for Laegevidenskabelig Grundforskning, Helen Rudes Fond, Karen A.
   Tolstrups Fond, A.J. Andersen og Hustrus Fond, Dagmar Marshalls Fond,
   Aase og Ejnar Danielsens Fond, Grosserer M. Brogaard og Hustrus
   Mindefonde, Augustinus Fonden, Familien Hede Nielsens Fond.
CR Alvarez S, 2005, CLIN CANCER RES, V11, P1146
   Arason A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2608
   Collins N, 1997, BRIT J CANCER, V76, P1150, DOI 10.1038/bjc.1997.526
   Didraga MA, 2011, BREAST CANCER RES TR, V130, P425, DOI 10.1007/s10549-011-1357-x
   Eccles SA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3493
   Fernández-Ramires R, 2011, INT J CANCER, V128, P2635, DOI 10.1002/ijc.25603
   Gerdes AM, 2006, CLIN GENET, V69, P171, DOI 10.1111/j.1399-0004.2006.00568.x
   Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801
   Hedenfalk I, 2003, P NATL ACAD SCI USA, V100, P2532, DOI 10.1073/pnas.0533805100
   Hilbers FS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055734
   Honrado E, 2007, MODERN PATHOL, V20, P1298, DOI 10.1038/modpathol.3800969
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Gracia-Aznarez FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055681
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jönsson G, 2012, CANCER RES, V72, P4028, DOI 10.1158/0008-5472.CAN-12-0097
   Jönsson G, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2596
   Joosse SA, 2012, BREAST CANCER RES TR, V132, P379, DOI 10.1007/s10549-010-1016-7
   Joosse SA, 2011, GENE CHROMOSOME CANC, V50, P71, DOI 10.1002/gcc.20833
   Lakhani SR, 2000, CLIN CANCER RES, V6, P782
   Larsen MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064268
   Rosa-Rosa JM, 2009, AM J HUM GENET, V84, P115, DOI 10.1016/j.ajhg.2008.12.013
   Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775
   Melchor L, 2008, ONCOGENE, V27, P3165, DOI 10.1038/sj.onc.1210975
   Melchor L, 2013, HUM GENET, V132, P845, DOI 10.1007/s00439-013-1299-y
   Nagel JHA, 2012, BREAST CANCER RES TR, V132, P439, DOI 10.1007/s10549-011-1588-x
   Oldenburg RA, 2006, CLIN CANCER RES, V12, P1693, DOI 10.1158/1078-0432.CCR-05-2230
   Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Smith P, 2006, GENE CHROMOSOME CANC, V45, P646, DOI 10.1002/gcc.20330
   Snape K, 2012, BREAST CANCER RES TR, V134, P429, DOI 10.1007/s10549-012-2057-x
   Sorlie T, 2003, P NATL ACAD SCI USA, V100, P8418, DOI 10.1073/pnas.0932692100
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Turnbull C, 2008, ANNU REV GENOM HUM G, V9, P321, DOI 10.1146/annurev.genom.9.081307.164339
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Vargas AC, 2011, J MAMMARY GLAND BIOL, V16, P27, DOI 10.1007/s10911-011-9204-6
   Waddell N, 2010, J PATHOL, V221, P452, DOI 10.1002/path.2728
   Waddell N, 2010, BREAST CANCER RES TR, V123, P661, DOI 10.1007/s10549-009-0653-1
   Yu K, 2004, CLIN CANCER RES, V10, P5508, DOI 10.1158/1078-0432.CCR-04-0085
NR 38
TC 15
Z9 15
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD JAN 31
PY 2014
VL 7
AR 9
DI 10.1186/1755-8794-7-9
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AB5HK
UT WOS:000331819300001
PM 24479546
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Petersen, AK
   Zeilinger, S
   Kastenmüller, G
   Römisch-Margl, W
   Brugger, M
   Peters, A
   Meisinger, C
   Strauch, K
   Hengstenberg, C
   Pagel, P
   Huber, F
   Mohney, RP
   Grallert, H
   Illig, T
   Adamski, J
   Waldenberger, M
   Gieger, C
   Suhre, K
AF Petersen, Ann-Kristin
   Zeilinger, Sonja
   Kastenmueller, Gabi
   Roemisch-Margl, Werner
   Brugger, Markus
   Peters, Annette
   Meisinger, Christine
   Strauch, Konstantin
   Hengstenberg, Christian
   Pagel, Philipp
   Huber, Fritz
   Mohney, Robert P.
   Grallert, Harald
   Illig, Thomas
   Adamski, Jerzy
   Waldenberger, Melanie
   Gieger, Christian
   Suhre, Karsten
TI Epigenetics meets metabolomics: an epigenome-wide association study with
   blood serum metabolic traits
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID DNA METHYLATION PATTERNS; QUANTILE NORMALIZATION; MASS-SPECTROMETRY;
   GENETIC-VARIATION; SUBSET-QUANTILE; BREAST-CANCER; PHENOTYPES; ESTROGEN;
   PIPELINE; DISEASE
AB Previously, we reported strong influences of genetic variants on metabolic phenotypes, some of them with clinical relevance. Here, we hypothesize that DNA methylation may have an important and potentially independent effect on human metabolism. To test this hypothesis, we conducted what is to the best of our knowledge the first epigenome-wide association study (EWAS) between DNA methylation and metabolic traits (metabotypes) in human blood. We assess 649 blood metabolic traits from 1814 participants of the Kooperative Gesundheitsforschung in der Region Augsburg (KORA) population study for association with methylation of 457 004 CpG sites, determined on the Infinium HumanMethylation450 BeadChip platform. Using the EWAS approach, we identified two types of methylome-metabotype associations. One type is driven by an underlying genetic effect; the other type is independent of genetic variation and potentially driven by common environmental and life-style-dependent factors. We report eight CpG loci at genome-wide significance that have a genetic variant as confounder (P = 3.9 x 10(-20) to 2.0 x 10(-108), r(2) = 0.036 to 0.221). Seven loci display CpG site-specific associations to metabotypes, but do not exhibit any underlying genetic signals (P = 9.2 x 10(-14) to 2.7 x 10(-27), r(2) = 0.008 to 0.107). We further identify several groups of CpG loci that associate with a same metabotype, such as 4-vinylphenol sulfate and 4-androsten-3-beta, 17-beta-diol disulfate. In these cases, the association between CpG-methylation and metabotype is likely the result of a common external environmental factor, including smoking. Our study shows that analysis of EWAS with large numbers of metabolic traits in large population cohorts are, in principle, feasible. Taken together, our data suggest that DNA methylation plays an important role in regulating human metabolism.
C1 [Petersen, Ann-Kristin; Brugger, Markus; Strauch, Konstantin; Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Genome Anal Ctr, Inst Genet Epidemiol, D-85764 Neuherberg, Germany.
   [Zeilinger, Sonja; Peters, Annette; Grallert, Harald; Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Genome Anal Ctr, Res Unit Mol Epidemiol, D-85764 Neuherberg, Germany.
   [Kastenmueller, Gabi; Roemisch-Margl, Werner; Suhre, Karsten] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Genome Anal Ctr, Inst Bioinformat & Syst Biol, D-85764 Neuherberg, Germany.
   [Peters, Annette; Meisinger, Christine] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Genome Anal Ctr, Inst Epidemiol 2, D-85764 Neuherberg, Germany.
   [Adamski, Jerzy] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Genome Anal Ctr, Inst Expt Genet, D-85764 Neuherberg, Germany.
   [Brugger, Markus; Strauch, Konstantin] Univ Munich, Inst Med Informat Biometry & Epidemiol, D-85764 Neuherberg, Germany.
   [Hengstenberg, Christian] Univ Regensburg, Klin & Poliklin Innere Med 2, D-93053 Regensburg, Germany.
   [Pagel, Philipp; Huber, Fritz] Numares Hlth, D-93053 Regensburg, Germany.
   [Mohney, Robert P.] Metabolon, Res Triangle Pk, NC USA.
   [Illig, Thomas] Hannover Med Sch, Hannover Unified Biobank, D-30625 Hannover, Germany.
   [Adamski, Jerzy] Tech Univ Munich, Lehrstuhl Expt Genet, D-85350 Freising Weihenstephan, Germany.
   [Adamski, Jerzy] German Ctr Diabet Res, D-85764 Neuherberg, Germany.
   [Suhre, Karsten] Qatar Fdn, Weill Cornell Med Coll Qatar, Dept Physiol & Biophys, Doha, Qatar.
C3 Helmholtz Association; Helmholtz-Center Munich - German Research Center
   for Environmental Health; Helmholtz Association; Helmholtz-Center Munich
   - German Research Center for Environmental Health; Helmholtz
   Association; Helmholtz-Center Munich - German Research Center for
   Environmental Health; Helmholtz Association; Helmholtz-Center Munich -
   German Research Center for Environmental Health; Helmholtz Association;
   Helmholtz-Center Munich - German Research Center for Environmental
   Health; University of Munich; University of Regensburg; Metabolon;
   Hannover Medical School; Technical University of Munich; Qatar
   Foundation (QF); Weill Cornell Medical College Qatar
RP Suhre, K (通讯作者)，Qatar Fdn Educ City, Weill Cornell Med Coll Qatar, POB 24144, Doha, Qatar.
EM karsten@suhre.fr
RI Kastenmüller, Gabi/ABF-5987-2020; Hengstenberg, Christian/U-5485-2019;
   Waldenberger, Melanie/B-5355-2014; Suhre, Karsten/AAF-1778-2020; Gieger,
   Christian/A-3083-2013; Meisinger, Christine/B-5358-2014; Peters,
   Annette/A-6117-2011
OI Kunze, Sonja/0000-0002-9685-2675; Adamski, Jerzy/0000-0001-9259-0199;
   Peters, Annette/0000-0001-6645-0985; Gieger,
   Christian/0000-0001-6986-9554; Kastenmuller, Gabi/0000-0002-2368-7322;
   Meisinger, Christa/0000-0002-9026-6544; Suhre,
   Karsten/0000-0001-9638-3912
FU Helmholtz Zentrum Munchen-German Research Center for Environmental
   Health; German Federal Ministry of Education and Research (BMBF)
   [305280]; State of Bavaria; European Union [261433]; BMBF [0315494A,
   03IS2061B]; ENGAGE Exchange and Mobility Program
   [HEALTH-F4-2007-201413]; 'Biomedical Research Program' funds at Weill
   Cornell Medical College in Qatar; Qatar Foundation; Weill Cornell
   Medical College in Qatar;  [DFG/Tr22-Z03]
FX The KORA study was initiated and financed by the Helmholtz Zentrum
   Munchen-German Research Center for Environmental Health, which is funded
   by the German Federal Ministry of Education and Research (BMBF) and by
   the State of Bavaria. This work was supported by the DFG/Tr22-Z03. The
   research leading to these results has also received funding from the
   European Union Seventh Framework Programme (FP7/2007-2013) under grant
   agreement no. 261433 and by the DFG/Tr22-Z03. Part of the metabolomics
   measurements were funded by BMBF grant 0315494A (project SysMBo). A. K.
   P. was supported by the ENGAGE Exchange and Mobility Program
   (HEALTH-F4-2007-201413) and W. R. M. is supported by BMBF grant
   03IS2061B (project Gani_Med). This work was also supported in part by a
   grant from the German Federal Ministry of Education and Research (BMBF)
   to the (FP7-Health-F5-2012) under grant agreement no. 305280 (MIMOmics).
   K. S. is supported by 'Biomedical Research Program' funds at Weill
   Cornell Medical College in Qatar, a program funded by the Qatar
   Foundation. The statements made herein are solely the responsibility of
   the authors. Funding to pay the Open Access publication charges for this
   article was provided by Weill Cornell Medical College in Qatar.
CR Åberg K, 2012, EUR J HUM GENET, V20, P953, DOI 10.1038/ejhg.2012.33
   Bibikova M, 2011, GENOMICS, V98, P288, DOI 10.1016/j.ygeno.2011.07.007
   Buterin T, 2006, CARCINOGENESIS, V27, P1567, DOI [10.1093/carcin/bci339, 10.1093/carcin/bgi339]
   Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445
   Chen WA, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-74
   Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102
   Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110
   Gieger C, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000282
   Illig T, 2010, NAT GENET, V42, P137, DOI 10.1038/ng.507
   Jourdan C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040009
   Koestler DC, 2013, STAT APPL GENET MOL, V12, P225, DOI 10.1515/sagmb-2012-0068
   Krumsiek J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1003005
   Liu Y, 2013, NAT BIOTECHNOL, V31, P142, DOI 10.1038/nbt.2487
   Maksimovic J, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-6-r44
   Manini P, 2003, G Ital Med Lav Ergon, V25 Suppl, P61
   Marabita F, 2013, EPIGENETICS-US, V8, P333, DOI 10.4161/epi.24008
   Menni C., 2013, Int. J. Epid
   Mootha VK, 2010, NAT GENET, V42, P97, DOI 10.1038/ng0210-97
   Parikh H, 2007, PLOS MED, V4, P868, DOI 10.1371/journal.pmed.0040158
   Petersen AK, 2012, HUM MOL GENET, V21, P1433, DOI 10.1093/hmg/ddr580
   Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685
   Possemato R, 2011, NATURE, V476, P346, DOI 10.1038/nature10350
   Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000
   Reinius LE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041361
   Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354
   Suhre K, 2012, NAT REV GENET, V13, P759, DOI 10.1038/nrg3314
   Suhre K, 2011, NATURE, V477, P54, DOI 10.1038/nature10354
   Teschendorff AE, 2013, BIOINFORMATICS, V29, P189, DOI 10.1093/bioinformatics/bts680
   Thompson RF, 2009, BIOINFORMATICS, V25, P2164, DOI 10.1093/bioinformatics/btp382
   Todorova VK, 2011, CANCER CHEMOTH PHARM, V67, P285, DOI 10.1007/s00280-010-1316-y
   Touleimat N, 2012, EPIGENOMICS-UK, V4, P325, DOI [10.2217/EPI.12.21, 10.2217/epi.12.21]
   Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226
   Zeilinger S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063812
NR 33
TC 140
Z9 147
U1 3
U2 40
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 15
PY 2014
VL 23
IS 2
BP 534
EP 545
DI 10.1093/hmg/ddt430
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AA1EX
UT WOS:000330840400021
PM 24014485
OA Green Published, Green Submitted, hybrid
DA 2025-01-12
ER

PT J
AU Stewart, DJ
   Nunez, MI
   Jelinek, J
   Hong, D
   Gupta, S
   Issa, JP
   Wistuba, II
   Kurzrock, R
AF Stewart, David J.
   Nunez, Maria I.
   Jelinek, Jaroslav
   Hong, David
   Gupta, Sanjay
   Issa, Jean-Pierre
   Wistuba, Ignacio I.
   Kurzrock, Razelle
TI Decitabine impact on the endocytosis regulator RhoA, the folate carriers
   RFC1 and FOLR1, and the glucose transporter GLUT4 in human tumors
SO CLINICAL EPIGENETICS
LA English
DT Article
DE Decitabine; RhoA; RFC1; FOLR1; GLUT4; LINE1 methylation; Promoter
   methylation
ID DNA METHYLTRANSFERASE INHIBITOR; CELL LUNG-CANCER; RESPONSE
   RELATIONSHIPS; EPIGENETIC MECHANISMS; CISPLATIN RESISTANCE; PROMOTER
   METHYLATION; DRUG-RESISTANCE; DOWN-REGULATION; MESSENGER-RNA;
   BREAST-CANCER
AB Background: In 31 solid tumor patients treated with the demethylating agent decitabine, we performed tumor biopsies before and after the first cycle of decitabine and used immunohistochemistry (IHC) to assess whether decitabine increased expression of various membrane transporters. Resistance to chemotherapy may arise due to promoter methylation/downregulation of expression of transporters required for drug uptake, and decitabine can reverse resistance in vitro. The endocytosis regulator RhoA, the folate carriers FOLR1 and RFC1, and the glucose transporter GLUT4 were assessed.
   Results: Pre-decitabine RhoA was higher in patients who had received their last therapy >3 months previously than in patients with more recent prior therapy (P = 0.02), and varied inversely with global DNA methylation as assessed by LINE1 methylation (r = -0.58, P = 0.006). Tumor RhoA scores increased with decitabine (P = 0.03), and RFC1 also increased in patients with pre-decitabine scores = 150 (P = 0.004). Change in LINE1 methylation with decitabine did not correlate significantly with change in IHC scores for any transporter assessed. We also assessed methylation of the RFC1 gene (alias SLC19A1). SLC19A1 methylation correlated with tumor LINE1 methylation (r = 0.45, P = 0.02). There was a small (statistically insignificant) decrease in SLC19A1 methylation with decitabine, and there was a trend towards change in SLC19A1 methylation with decitabine correlating with change in LINE1 methylation (r = 0.47, P <0.15). While SLC19A1 methylation did not correlate with RFC1 scores, there was a trend towards an inverse correlation between change in SLC19A1 methylation and change in RFC1 expression (r = -0.45, P = 0.19).
   Conclusions: In conclusion, after decitabine administration, there was increased expression of some (but not other) transporters that may play a role in chemotherapy uptake. Larger patient numbers will be needed to define the extent to which this increased expression is associated with changes in DNA methylation.
C1 [Stewart, David J.; Kurzrock, Razelle] Univ Ottawa, Div Med Oncol, Ottawa Hosp, Ottawa, ON K1H 8L6, Canada.
   [Nunez, Maria I.; Hong, David; Gupta, Sanjay; Wistuba, Ignacio I.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Issa, Jean-Pierre] Temple Univ, Fels Inst Canc Res, Philadelphia, PA 19410 USA.
   [Kurzrock, Razelle] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
C3 University of Ottawa; Ottawa Hospital Research Institute; University of
   Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); Temple University; University of
   California System; University of California San Diego
RP Stewart, DJ (通讯作者)，Univ Ottawa, Div Med Oncol, Ottawa Hosp, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.
EM dstewart@toh.on.ca
RI Jelinek, Jaroslav/O-6876-2019; Kurzrock, Razelle/AAU-9782-2020; Hong,
   David/HKW-1105-2023; Jelinek, Jaroslav/D-2282-2012
OI Issa, Jean-Pierre/0000-0003-2258-5030; Jelinek,
   Jaroslav/0000-0002-2533-0220; Gupta, Sanjay/0000-0001-7001-0130; S.
   Hong, David/0000-0001-8721-1609
FU NIH [UO1 CA062461-10, R21 CA112895-01A1]; Cancer Center Support Grant
   [5-P30 CA16672-32]; Department of Defense [W81XWH-07-1-0306]; MD
   Anderson Cancer Center
FX Supported in part by NIH grants UO1 CA062461-10, R21 CA112895-01A1,
   Cancer Center Support Grant number 5-P30 CA16672-32, and by Department
   of Defense grant number W81XWH-07-1-0306. We would like to thank MD
   Anderson Cancer Center for making funding available for required tumor
   biopsies and would also like to express our appreciation for the help
   and support for this project that we received from the late Dr. Igor
   Espinoza-Delgado while he was at CTEP, NCI. Presented in part at the
   100th annual meeting of the American Association for Cancer Research,
   Denver, CO, April 18 to 22, 2009 and the 45th annual meeting of the
   American Society of Clinical Oncology, Orlando, FL, May 29-June 2, 2009.
CR Baylin SB, 1998, ADV CANCER RES, V72, P141
   Braga E A, 2006, Mol Biol (Mosk), V40, P865
   Chang XF, 2010, CANCER RES, V70, P2870, DOI 10.1158/0008-5472.CAN-09-3427
   Charlet J, 2012, BIOCHEM PHARMACOL, V83, P858, DOI 10.1016/j.bcp.2012.01.009
   Chekhun VF, 2007, MOL CANCER THER, V6, P1089, DOI 10.1158/1535-7163.MCT-06-0663
   Crea F, 2009, MOL CANCER THER, V8, P1964, DOI 10.1158/1535-7163.MCT-09-0027
   Ding L, 2009, BIOL PHARM BULL, V32, P1105, DOI 10.1248/bpb.32.1105
   Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204
   Festuccia C, 2009, ENDOCR-RELAT CANCER, V16, P401, DOI 10.1677/ERC-08-0130
   Finnell RH, 2002, J NUTR, V132, p2457S, DOI 10.1093/jn/132.8.2457S
   Fu SQ, 2011, CANCER-AM CANCER SOC, V117, P1661, DOI 10.1002/cncr.25701
   Ghoshal K, 2007, DRUG TODAY, V43, P395, DOI 10.1358/dot.2007.43.6.1062666
   Gordian E, 2009, ANTICANCER RES, V29, P3207
   Issa JPJ, 2005, J CLIN ONCOL, V23, P3948, DOI 10.1200/JCO.2005.11.981
   Issa JPJ, 2004, BLOOD, V103, P1635, DOI 10.1182/blood-2003-03-0687
   Iwata H, 2011, INT J ONCOL, V38, P1653, DOI 10.3892/ijo.2011.999
   Kane MA, 2004, CANCER DETECT PREV, V29, P46, DOI 10.1016/j.cdp.2004.08.002
   Kantarjian H, 2007, BLOOD, V109, P52, DOI 10.1182/blood-2006-05-021162
   Kantarjian HM, 2007, CANCER-AM CANCER SOC, V109, P1133, DOI 10.1002/cncr.22508
   Kim JS, 2004, CARCINOGENESIS, V25, P2165, DOI 10.1093/carcin/bgh217
   Kroeger H, 2008, BLOOD, V112, P1366, DOI 10.1182/blood-2007-11-126227
   Kumari A, 2009, PANCREATOLOGY, V9, P360, DOI 10.1159/000212094
   Lee TB, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-33
   Li YF, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.08.030
   Liang XJ, 2004, J INORG BIOCHEM, V98, P1599, DOI 10.1016/j.jinorgbio.2004.05.015
   Liu ZG, 2009, CELL BIOL INT, V33, P1111, DOI 10.1016/j.cellbi.2009.07.004
   Orta ML, 2009, MUTAGENESIS, V24, P237, DOI 10.1093/mutage/gep002
   Ma DQ, 2000, BIOCHEM BIOPH RES CO, V279, P891, DOI 10.1006/bbrc.2000.4019
   Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909
   Müerköster SS, 2008, INT J CANCER, V123, P1751, DOI 10.1002/ijc.23703
   Nabilsi NH, 2009, ONCOGENE, V28, P2046, DOI 10.1038/onc.2009.62
   Oki Y, 2007, CRIT REV ONCOL HEMAT, V61, P140, DOI 10.1016/j.critrevonc.2006.07.010
   Onda K, 2012, ANTICANCER RES, V32, P4439
   Piyathilake CJ, 2000, NUTR CANCER, V37, P99, DOI 10.1207/S15327914NC3701_13
   Plumb JA, 2000, CANCER RES, V60, P6039
   Ramachandran K, 2011, ANTICANCER RES, V31, P3757
   Reed K, 2010, PHARMACOGENOMICS J, V10, P489, DOI 10.1038/tpj.2010.1
   Rothem L, 2004, J BIOL CHEM, V279, P374, DOI 10.1074/jbc.M309092200
   José-Eneriz ES, 2009, EUR J CANCER, V45, P1877, DOI 10.1016/j.ejca.2009.04.005
   Shang DH, 2009, CANCER LETT, V278, P82, DOI 10.1016/j.canlet.2008.12.034
   Shen DW, 2004, BRIT J CANCER, V91, P270, DOI 10.1038/sj.bjc.6601956
   Shia J, 2008, HUM PATHOL, V39, P498, DOI 10.1016/j.humpath.2007.09.013
   Stewart DJ, 2007, CRIT REV ONCOL HEMAT, V63, P12, DOI 10.1016/j.critrevonc.2007.02.001
   Stewart DJ, 2007, CANCER TREAT REV, V33, P101, DOI 10.1016/j.ctrv.2006.12.002
   Stewart DJ, 2010, CRIT REV ONCOL HEMAT, V75, P173, DOI 10.1016/j.critrevonc.2009.11.006
   Stewart DJ, 2009, CLIN CANCER RES, V15, P3881, DOI 10.1158/1078-0432.CCR-08-2196
   Stewart DJ, 2009, J CLIN ONCOL, V27, P328, DOI 10.1200/JCO.2008.18.9621
   Stewart DJ, 1996, INVEST NEW DRUG, V14, P115
   Stidley CA, 2010, CANCER RES, V70, P568, DOI 10.1158/0008-5472.CAN-09-3410
   Tanaka T, 2012, ONCOL REP, V27, P1292, DOI 10.3892/or.2012.1628
   Tikoo K, 2009, TOXICOL LETT, V191, P158, DOI 10.1016/j.toxlet.2009.08.018
   Tse KY, 2009, TUMOR BIOL, V30, P93, DOI 10.1159/000218032
   Vijayaraghavalu S, 2012, MOL PHARMACEUT, V9, P2730, DOI 10.1021/mp300281t
   Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032
   Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611
   Zhang Y, 2009, ANTI-CANCER DRUG, V20, P208, DOI 10.1097/CAD.0b013e328322fbaa
   Zhao RB, 2008, MOL PHARMACOL, V74, P854, DOI 10.1124/mol.108.045443
NR 57
TC 8
Z9 10
U1 0
U2 12
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1868-7075
EI 1868-7083
J9 CLIN EPIGENETICS
JI Clin. Epigenetics
PD JAN 9
PY 2014
VL 6
AR 2
DI 10.1186/1868-7083-6-2
PG 9
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA AB7ZO
UT WOS:000332010100001
PM 24401732
OA gold, Green Published
DA 2025-01-12
ER

PT J
AU Shen, L
   Cui, J
   Pang, YX
   Ma, YH
   Liu, PS
AF Shen, Liang
   Cui, Jing
   Pang, Ying-Xin
   Ma, Yan-Hui
   Liu, Pei-Shu
TI 3-Deazaneplanocin A is a Promising Therapeutic Agent for Ovarian Cancer
   Cells
SO ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
LA English
DT Article
DE DZNep; ovarian cancer cells; proliferation; apoptosis; migration
ID EPIGENETIC THERAPY; ALPHA-CATENIN; HISTONE H3; E-CADHERIN; EPITHELIUM;
   EXPRESSION; APOPTOSIS; INHIBITOR; HYDROLASE; ENHANCER
AB Background: Recent studies have shown that 3-deazaneplanocin A (DZNep), a well-known histone methyltransferase inhibitor, disrupts polycomb-repressive complex 2 (PRC2), and induces apoptosis, while inhibiting proliferation and metastasis, in cancer cells, including acute myeloid leukemia, breast cancer and glioblastoma. However, little is known about effects of DZNep on ovarian cancer cells. Materials and Methods: We here therefore studied DZNep-treated A2780 ovarian cancer cells in vitro. Proliferation of ovarian cancer cells under treatment of DZNep was assessed by MTT and apoptosis by flow cytometry. Cell wound healing was applied to detect the migration. Finally, we used q-PCR to assess the migration-related gene, E-cadherin. Results: DZNep could inhibit the proliferation of A2780 and induce apoptosis Furthermore, it inhibited migration and increased the expression of E-cadherin (P<0.05). Conclusion: DZNep is a promising therapeutic agent for ovarian cancer cells, with potential to inhibite proliferation, induce apoptosis and decrease migration.
C1 [Shen, Liang] Shandong Univ, Prov Hosp, Dept Obstet & Gynaecol, Jinan 250100, Shandong, Peoples R China.
   [Shen, Liang; Pang, Ying-Xin; Ma, Yan-Hui; Liu, Pei-Shu] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China.
   [Cui, Jing] Jinan Stomatol Hosp, Dept Oral & Maxillofacial Surg, Jinan, Shandong, Peoples R China.
C3 Shandong University; Shandong University
RP Liu, PS (通讯作者)，Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250100, Shandong, Peoples R China.
EM shenlang007@163.com
CR Bristow RE, 2010, GYNECOL ONCOL, V118, P262, DOI 10.1016/j.ygyno.2010.05.025
   Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Davies BR, 1998, HISTOPATHOLOGY, V32, P69
   GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V135, P688, DOI 10.1016/0006-291X(86)90048-3
   Guo JF, 2011, CANCER SCI, V102, P530, DOI 10.1111/j.1349-7006.2010.01836.x
   Hudson LG, 2008, CLIN EXP METASTAS, V25, P643, DOI 10.1007/s10585-008-9171-5
   Imai T, 2004, HUM PATHOL, V35, P1469, DOI 10.1016/j.humpath.2004.09.014
   Kalushkova A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011483
   Kikuchi J, 2012, LUNG CANCER, V78, P138, DOI 10.1016/j.lungcan.2012.08.003
   Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902
   Landen CN, 2008, J CLIN ONCOL, V26, P995, DOI 10.1200/JCO.2006.07.9970
   LIU S, 1992, ANTIVIR RES, V19, P247, DOI 10.1016/0166-3542(92)90083-H
   Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150
   Rao ZY, 2010, CARCINOGENESIS, V31, P1576, DOI 10.1093/carcin/bgq150
   Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788
   Sasaki D, 2011, HAEMATOL-HEMATOL J, V96, P712, DOI 10.3324/haematol.2010.028605
   Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107
NR 18
TC 6
Z9 7
U1 0
U2 5
PU ASIAN PACIFIC ORGANIZATION CANCER PREVENTION
PI GYEONGGI-DO
PA APJCP HEAD OFFICE, KOREAN NATL CANCER CENTER, 323 ILAN -RO,
   ILSANDONG-GU, GOYANG-SI, GYEONGGI-DO, 410-769, SOUTH KOREA
SN 1513-7368
J9 ASIAN PAC J CANCER P
JI Asian Pac. J. Cancer Prev.
PY 2013
VL 14
IS 5
BP 2915
EP 2918
DI 10.7314/APJCP.2013.14.5.2915
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AB0HU
UT WOS:000331473400038
PM 23803053
OA gold, Green Submitted
DA 2025-01-12
ER

PT J
AU Kim, JH
   Sharma, A
   Dhar, SS
   Lee, SH
   Gu, B
   Chan, CH
   Lin, HK
   Lee, MG
AF Kim, Jae-Hwan
   Sharma, Amrish
   Dhar, Shilpa S.
   Lee, Sung-Hun
   Gu, Bingnan
   Chan, Chia-Hsin
   Lin, Hui-Kuan
   Lee, Min Gyu
TI UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell
   Proliferation and Invasiveness in Breast Cancer Cells
SO CANCER RESEARCH
LA English
DT Article
ID HISTONE LYSINE METHYLATION; DEMETHYLASE UTX; GENE-EXPRESSION;
   PROSTATE-CANCER; INK4A-ARF LOCUS; PROTEIN EZH2; HUMAN GENOME; H3;
   METASTASIS; H3K27ME3
AB Histone methyltransferases and demethylases reversibly modulate histone lysine methylation, which is considered a key epigenetic mark associated with gene regulation. Recently, aberrant regulation of gene expression by histone methylation modifiers has emerged as an important mechanism for tumorigenesis. However, it remains largely unknown how histone methyltransferases and demethylases coregulate transcriptional profiles for cancer cell characteristics. Here, we show that in breast cancer cells, the histone H3 lysine 27 (H3K27) demethylase UTX (also known as KDM6A) positively regulates gene expression programs associated with cell proliferation and invasion. The majority of UTX-controlled genes, including a cohort of oncogenes and prometastatic genes, are coregulated by the H3K4 methyltransferase mixed lineage leukemia 4 (MLL4, also called ALR, KMT2D, and MLL2). UTX interacted with a C-terminal region of MLL4. UTX knockdown resulted in significant decreases in the proliferation and invasiveness of breast cancer cells in vitro and in a mouse xenograft model. Such defective cellular characteristics of UTX-depleted cells were phenocopied by MLL4 knockdown cells. UTX-catalyzed demethylation of trimethylated H3K27 and MLL4-mediated trimethylation at H3K4 occurred interdependently at cotarget genes of UTX and MLL4. Clinically, high levels of UTX or MLL4 were associated with poor prognosis in patients with breast cancer. Taken together, these findings uncover that coordinated regulation of gene expression programs by a histone methyltransferase and a histone demethylase is coupled to the proliferation and invasion of breast cancer cells. (C) 2014 AACR.
C1 [Kim, Jae-Hwan; Sharma, Amrish; Dhar, Shilpa S.; Lee, Sung-Hun; Gu, Bingnan; Chan, Chia-Hsin; Lin, Hui-Kuan; Lee, Min Gyu] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA.
   [Lin, Hui-Kuan; Lee, Min Gyu] Univ Texas Hlth Sci Ctr Houston, Canc Biol Program, Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Lin, Hui-Kuan] China Med Univ, Grad Inst Basic Med Sci, Taichung, Taiwan.
   [Lin, Hui-Kuan] Asia Univ, Dept Biotechnol, Taichung, Taiwan.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; University of Texas Health Science Center Houston; China
   Medical University Taiwan; Asia University Taiwan
RP Lee, MG (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM mglee@mdanderson.org
RI Lee, Ji Hyung/HNI-8824-2023; Chan, Chia-Hsin/AAT-7782-2020
OI Chan, Chia-Hsin/0000-0001-8506-7500
FU NIH [R01 GM095659, R01 CA157919]; Cancer Prevention and Research
   Institute of Texas [RP110183]
FX This work was supported by grants to M. G. Lee from the NIH (R01
   GM095659 and R01 CA157919) and Cancer Prevention and Research Institute
   of Texas (RP110183).
CR Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Berdel B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-516
   Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chaturvedi CP, 2012, P NATL ACAD SCI USA, V109, P18845, DOI 10.1073/pnas.1213951109
   Cho YW, 2007, J BIOL CHEM, V282, P20395, DOI 10.1074/jbc.M701574200
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60
   Dhar SS, 2012, GENE DEV, V26, P2749, DOI 10.1101/gad.203356.112
   Ding L, 2006, CANCER RES, V66, P4095, DOI 10.1158/0008-5472.CAN-05-4300
   Elsheikh SE, 2009, CANCER RES, V69, P3802, DOI 10.1158/0008-5472.CAN-08-3907
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Gong Y, 2011, CANCER-AM CANCER SOC, V117, P5476, DOI 10.1002/cncr.26179
   Hock H, 2012, GENE DEV, V26, P751, DOI 10.1101/gad.191163.112
   Issaeva I, 2007, MOL CELL BIOL, V27, P1889, DOI 10.1128/MCB.01506-06
   Jin CY, 2011, CELL METAB, V14, P161, DOI 10.1016/j.cmet.2011.07.001
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klose RJ, 2007, NAT REV MOL CELL BIO, V8, P307, DOI 10.1038/nrm2143
   Kunju LP, 2011, MODERN PATHOL, V24, P786, DOI 10.1038/modpathol.2011.8
   Lee MG, 2007, SCIENCE, V318, P447, DOI 10.1126/science.1149042
   Lee MG, 2006, MOL CELL BIOL, V26, P6395, DOI 10.1128/MCB.00723-06
   Lee S, 2012, DEV CELL, V22, P25, DOI 10.1016/j.devcel.2011.11.009
   Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324
   Liu JN, 2012, EXP HEMATOL, V40, P487, DOI 10.1016/j.exphem.2012.01.017
   Mansour AA, 2012, NATURE, V488, P409, DOI 10.1038/nature11272
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Miller SA, 2010, MOL CELL, V40, P594, DOI 10.1016/j.molcel.2010.10.028
   Patani N, 2011, ANTICANCER RES, V31, P4115
   Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026
   Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546
   Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014
   Seenundun S, 2010, EMBO J, V29, P1401, DOI 10.1038/emboj.2010.37
   Shen YQ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-470
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shpargel KB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002964
   Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007
   Strahl BD, 1999, P NATL ACAD SCI USA, V96, P14967, DOI 10.1073/pnas.96.26.14967
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   Wang JK, 2010, GENE DEV, V24, P327, DOI 10.1101/gad.1882610
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wei YK, 2008, MOL CARCINOGEN, V47, P701, DOI 10.1002/mc.20413
   Welstead GG, 2012, P NATL ACAD SCI USA, V109, P13004, DOI 10.1073/pnas.1210787109
   Wu J, 2012, ONCOGENE, V31, P333, DOI 10.1038/onc.2011.227
   Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604
NR 50
TC 188
Z9 214
U1 1
U2 34
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 15
PY 2014
VL 74
IS 6
BP 1705
EP 1717
DI 10.1158/0008-5472.CAN-13-1896
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AE2OD
UT WOS:000333811700010
PM 24491801
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-12
ER

PT J
AU Du, L
   Rong, H
   Cheng, Y
   Guo, SY
   Shi, QY
   Jia, XX
   Zhu, HP
   Hao, YC
   Xu, KL
   Zhang, JN
   Jiao, HW
   Zhao, TJ
   Zhang, H
   Chen, CF
   Wang, FY
AF Du, Li
   Rong, Hui
   Cheng, Ying
   Guo, Shiyu
   Shi, Qiaoyun
   Jia, Xiaoxiao
   Zhu, Huapei
   Hao, Yongchang
   Xu, Kailian
   Zhang, Jianing
   Jiao, Hanwei
   Zhao, Tianjing
   Zhang, Hui
   Chen, Chuangfu
   Wang, Fengyang
TI Identification of MicroRNAs Dysregulated in CD14 Gene Silencing RAW264.7
   Macrophage Cells
SO INFLAMMATION
LA English
DT Article
DE CD14; knockdown; RAW264.7; microarray; microRNAs
ID ENDOTOXIN-SHOCK; BREAST-CANCER; LPS; EXPRESSION
AB A cluster of differentiation antigen 14 (CD14) is involved in lipopolysaccharide (LPS)-induced proinflammatory cytokine release and LPS-induced septic shock. MicroRNAs (miRNAs) are short non-coding RNAs that are involved in the epigenetic regulation of cellular process and bacterial infection. Our previous study indicated that siRNA against CD14 effectively inhibited LPS-induced tumor necrosis factor alpha, chemokine (C-X-C motif) ligand 2, interleukin-6 release, and NO production. To identify miRNAs which are affected by CD14 gene silencing and dissect the mechanisms of the attenuating of LPS-induced damaging immune activation more clearly, based on the CD14 knockdown RAW264.7 macrophage cell line established in our previous study, miRNAs expression profiling of CD14 knockdown RAW264.7 cells were analyzed with miRNA microarray and validated by qRT-PCR, the potential targets were predicted and subjected to gene ontology (GO) pathway and biological processes analysis. We demonstrated for the first time that CD14 knockdown significantly changed the expression of 199a-3p, miR-199a-5p, and miR-21-5p in RAW264.7 cells, and significantly enriched GO terms in the predicted target genes of these miRNAs were apoptosis process, immune response, inflammatory response, innate immune response, anti-apoptosis, cytokine production, and cytokine-mediated signaling pathway. These findings may improve our understanding about functional mechanism of miRNAs in the attenuating of LPS-induced damaging immune activation more clearly.
C1 [Du, Li; Rong, Hui; Cheng, Ying; Guo, Shiyu; Shi, Qiaoyun; Jia, Xiaoxiao; Zhu, Huapei; Hao, Yongchang; Xu, Kailian; Zhang, Jianing; Jiao, Hanwei; Zhao, Tianjing; Zhang, Hui; Chen, Chuangfu; Wang, Fengyang] Hainan Univ, Coll Agr, Hainan Key Lab Trop Anim Reprod & Breeding & Epid, Anim Genet Engn Key Lab Haikou, Haidian Isl 570228, Haikou, Peoples R China.
C3 Hainan University
RP Wang, FY (通讯作者)，Hainan Univ, Coll Agr, Hainan Key Lab Trop Anim Reprod & Breeding & Epid, Anim Genet Engn Key Lab Haikou, Haidian Isl 570228, Haikou, Peoples R China.
EM fywang68@hotmail.com
FU National Basic Research Program of China (973 Program) [2010CB530203];
   National High Technology Research and Development Program of China
   [2011AA100302, 2013AA102524]
FX This study was financially supported by the National Basic Research
   Program of China (973 Program) (No. 2010CB530203), the National High
   Technology Research and Development Program of China (No. 2011AA100302),
   and the National High Technology Research and Development Program of
   China (No. 2013AA102524).
CR Bode JG, 2012, CELL SIGNAL, V24, P1185, DOI 10.1016/j.cellsig.2012.01.018
   Cardenas CLL, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003291
   Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903
   Cheng Y, 2012, INFLAMMATION, V35, P1308, DOI 10.1007/s10753-012-9443-8
   Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181
   Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2
   Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839
   Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X
   Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359
   Lei M, 2012, VET MICROBIOL, V160, P362, DOI 10.1016/j.vetmic.2012.05.039
   Liu J, 2003, J BIOL CHEM, V278, P45034, DOI 10.1074/jbc.M306062200
   Mariana L., 2003, RNA, V9, P175
   Maris NA, 2006, EUR RESPIR J, V28, P622, DOI 10.1183/09031936.06.00010806
   Matsuguchi T, 2003, EMBO J, V22, P4455, DOI 10.1093/emboj/cdg438
   Ruggiero T, 2009, FASEB J, V23, P2898, DOI 10.1096/fj.09-131342
   Sanchez-Diaz PC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061622
   Shatseva T, 2011, J CELL SCI, V124, P2826, DOI 10.1242/jcs.077529
   Sheedy FJ, 2008, ANN RHEUM DIS, V67, P50, DOI 10.1136/ard.2008.100289
   Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082
   Triantafilou M, 2000, EUR J BIOCHEM, V267, P2218, DOI 10.1046/j.1432-1327.2000.01222.x
   Zhang S., 2013, ARCH VIROLOGY, VI
   Zhang Y, 2012, NUCLEIC ACIDS RES, V40, P9286, DOI 10.1093/nar/gks667
NR 22
TC 6
Z9 6
U1 0
U2 21
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0360-3997
EI 1573-2576
J9 INFLAMMATION
JI Inflammation
PD FEB
PY 2014
VL 37
IS 1
BP 287
EP 294
DI 10.1007/s10753-013-9739-3
PG 8
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA AA1IK
UT WOS:000330849600034
PM 24062059
DA 2025-01-12
ER

PT J
AU Kahali, B
   Gramling, SJB
   Marquez, SB
   Thompson, K
   Lu, L
   Reisman, D
AF Kahali, B.
   Gramling, S. J. B.
   Marquez, S. B.
   Thompson, K.
   Lu, L.
   Reisman, D.
TI Identifying targets for the restoration and reactivation of BRM
SO ONCOGENE
LA English
DT Article
DE epigenetic; histone transferase; SWI/SNF; histone deacetylase complex;
   tumor suppressor; brahma
ID HUMAN LUNG-CANCER; CHROMATIN-REMODELING FACTOR; II HISTONE DEACETYLASES;
   SWI/SNF COMPLEX; GENE-EXPRESSION; BREAST-CANCER; CELL-LINES;
   TRANSCRIPTIONAL ACTIVITY; RAS MUTATIONS; DNA-BINDING
AB Brahma (BRM) is a novel anticancer gene, which is frequently inactivated in a variety of tumor types. Unlike many anticancer genes, BRM is not mutated, but rather epigenetically silenced. In addition, histone deacetylase complex (HDAC) inhibitors are known to reverse BRM silencing, but they also inactivate it via acetylation of its C-terminus. High-throughput screening has uncovered many compounds that are effective at pharmacologically restoring BRM and thereby inhibit cancer cell growth. As we do not know which specific proteins, if any, regulate BRM, we sought to identify the proteins, which underlie the epigenetic suppression of BRM. By selectively knocking down each HDAC, we found that HDAC3 and HDAC9 regulate BRM expression, whereas HDAC2 controls its acetylation. Similarly, we ectopically overexpressed 21 different histone acetyltransferases and found that KAT6A, KAT6B and KAT7 induce BRM expression, whereas KAT2B and KAT8 induce its acetylation. We also investigated the role of two transcription factors (TFs) linked to either BRM (GATA3) or HDAC9 (MEF2D) expression. Knockdown of either GATA3 and/or MEF2D downregulated HDAC9 and induced BRM. As targets for molecular biotherapy are typically uniquely, or simply differentially expressed in cancer cells, we also determined if any of these proteins are dysregulated. However, by sequencing, no mutations were found in any of these BRM-regulating HDACs, HATs or TFs. We selectively knocked down GATA3, MEF2D, HDAC3 and HDAC9, and found that each gene-specific knockdown induced growth inhibition. We observed that both GATA3 and HDAC9 were greatly overexpressed only in BRM-negative cell lines indicating that HDAC9 may be a good target for therapy. We also found that the mitogen-activated protein (MAP) kinase pathway regulates both BRM acetylation and BRM silencing as MAP kinase pathway inhibitors both induced BRM as well as caused BRM deacetylation. Together, these data identify a cadre of key proteins, which underlie the epigenetic regulation of BRM.
C1 [Kahali, B.; Gramling, S. J. B.; Marquez, S. B.; Thompson, K.; Reisman, D.] Univ Florida, Dept Med, Dept Hematol Oncol, Gainesville, FL 32610 USA.
   [Lu, L.] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Reisman, D (通讯作者)，Univ Florida, Dept Med, Dept Hematol Oncol, Gainesville, FL 32610 USA.
EM dnreisman@ufl.edu
RI Kahali, Bhaskar/N-6398-2018
OI Kahali, Bhaskar/0000-0003-4160-7979
FU  [5R01CA136683-03]
FX We thank Rachel Dresbeck for her time and effort in editing the
   manuscript. This research was supported by 5R01CA136683-03 Identifying
   Agents which Restored BRM expression.
CR Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327
   Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608
   Avvakumov Nikita, 2007, Subcell Biochem, V41, P295
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275
   Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243
   Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431
   Bock VL, 2011, BRIT J DERMATOL, V164, P1221, DOI 10.1111/j.1365-2133.2011.10267.x
   Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621
   Brose MS, 2002, CANCER RES, V62, P6997
   Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1
   Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664
   Califano R, 2012, DRUGS, V72, P28, DOI 10.2165/1163012-S0-000000000-00000
   CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9
   CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
   de Castro-Carpeño J, 2008, CLIN TRANSL ONCOL, V10, P6, DOI 10.1007/s12094-008-0147-3
   DelBove J, 2011, EPIGENETICS-US, V6, P1444, DOI 10.4161/epi.6.12.18492
   DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7
   Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299
   Dwarakanath BS, 2008, INDIAN J MED RES, V128, P13
   Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489
   Gervais C, 2008, LEUKEMIA, V22, P1567, DOI 10.1038/leu.2008.128
   Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514
   Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652
   Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610
   Gordon VS, 2010, ONCOL REV, V4, P89, DOI 10.1007/s12156-010-0040-5
   Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80
   Gramling S, 2011, LETT DRUG DES DISCOV, V8, P93, DOI 10.2174/157018011793663840
   Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200
   Grégoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06
   Haber DA, 2005, COLD SH Q B, V70, P419, DOI 10.1101/sqb.2005.70.043
   Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06
   Hess-Stumpp H, 2005, EUR J CELL BIOL, V84, P109, DOI 10.1016/j.ejcb.2004.12.010
   Ho IC, 2007, CELL MOL IMMUNOL, V4, P15
   Itoh T, 2008, BIOCHEM BIOPH RES CO, V366, P827, DOI 10.1016/j.bbrc.2007.12.026
   KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0
   Konofaos P, 2006, SURG ONCOL, V15, P257, DOI 10.1016/j.suronc.2007.03.004
   Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847
   LAURENT BC, 1993, COLD SPRING HARB SYM, V58, P257, DOI 10.1101/SQB.1993.058.01.030
   Lee JH, 2005, MOL CELLS, V19, P289
   Liu G, 2011, ONCOGENE, V30, P3295, DOI 10.1038/onc.2011.81
   Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005
   Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024
   Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491, DOI 10.4049/jimmunol.178.4.2491
   Marijon H, 2011, B CANCER, V98, P1011, DOI 10.1684/bdc.2011.1379
   Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730
   Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068
   Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395
   Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200
   Moore SDP, 2004, CANCER RES, V64, P5570, DOI 10.1158/0008-5472.CAN-04-0050
   Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x
   Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300
   Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223
   Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999
   MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x
   Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331
   Nakada S, 2001, ANTICANCER RES, V21, P167
   Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200
   Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116
   Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200
   Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367
   Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4
   Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011
   Reisman DN, 2003, CANCER RES, V63, P560
   Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188
   Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263
   Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415
   Sakurai K, 2011, CANCER RES, V71, P1680, DOI 10.1158/0008-5472.CAN-10-2345
   Skov V, 2012, LEUKEMIA LYMPHOMA, V53, P123, DOI 10.3109/10428194.2011.597905
   Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748
   Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200
   Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200
   Strober BE, 1996, MOL CELL BIOL, V16, P1576
   Tagliabue E, 2010, EXPERT OPIN BIOL TH, V10, P711, DOI 10.1517/14712591003689972
   Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605
   Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492
   Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x
   Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117
   Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047
   Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068
   Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200
   Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716
   Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X
   Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004
   Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223
NR 85
TC 43
Z9 47
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 30
PY 2014
VL 33
IS 5
BP 653
EP 664
DI 10.1038/onc.2012.613
PG 12
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AA5GW
UT WOS:000331125100013
PM 23524580
OA Bronze
DA 2025-01-12
ER

PT J
AU Xiang, M
   Birkbak, NJ
   Vafaizadeh, V
   Walker, SR
   Yeh, JE
   Liu, SH
   Kroll, Y
   Boldin, M
   Taganov, K
   Groner, B
   Richardson, AL
   Frank, DA
AF Xiang, Michael
   Birkbak, Nicolai J.
   Vafaizadeh, Vida
   Walker, Sarah R.
   Yeh, Jennifer E.
   Liu, Suhu
   Kroll, Yasmin
   Boldin, Mark
   Taganov, Konstantin
   Groner, Bernd
   Richardson, Andrea L.
   Frank, David A.
TI STAT3 Induction of miR-146b Forms a Feedback Loop to Inhibit the NF-κB
   to IL-6 Signaling Axis and STAT3-Driven Cancer Phenotypes
SO SCIENCE SIGNALING
LA English
DT Article
ID MULTIPLE-MYELOMA CELLS; BREAST-CANCER; EPITHELIAL-CELLS;
   PROSTATE-CANCER; DOWN-REGULATION; EXPRESSION; SUPPRESSES; ACTIVATION;
   PATHWAY; INFLAMMATION
AB Interleukin-6 (IL-6)-mediated activation of signal transducer and activator of transcription 3 (STAT3) is a mechanism by which chronic inflammation can contribute to cancer and is a common oncogenic event. We discovered a pathway, the loss of which is associated with persistent STAT3 activation in human cancer. We found that the gene encoding the tumor suppressor microRNA miR-146b is a direct STAT3 target gene, and its expression was increased in normal breast epithelial cells but decreased in tumor cells. Methylation of the miR-146b promoter, which inhibited STAT3-mediated induction of expression, was increased in primary breast cancers. Moreover, we found that miR-146b inhibited nuclear factor kappa B (NF-kappa B)-dependent production of IL-6, subsequent STAT3 activation, and IL-6/STAT3-driven migration and invasion in breast cancer cells, thereby establishing a negative feedback loop. In addition, higher expression ofmiR-146b was positively correlated with patient survival in breast cancer subtypes with increased IL6 expression and STAT3 phosphorylation. Our results identify an epigenetic mechanism of crosstalk between STAT3 and NF-kappa B relevant to constitutive STAT3 activation in malignancy and the role of inflammation in oncogenesis.
C1 [Xiang, Michael; Walker, Sarah R.; Yeh, Jennifer E.; Liu, Suhu; Kroll, Yasmin; Frank, David A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
   [Birkbak, Nicolai J.; Richardson, Andrea L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
   [Birkbak, Nicolai J.; Walker, Sarah R.; Richardson, Andrea L.; Frank, David A.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
   [Vafaizadeh, Vida; Groner, Bernd] Inst Biomed Res, D-60956 Frankfurt, Germany.
   [Walker, Sarah R.; Frank, David A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02215 USA.
   [Boldin, Mark; Taganov, Konstantin] CALTECH, Div Biol, Pasadena, CA 91125 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Brigham & Women's Hospital; Harvard University; Harvard Medical School;
   Harvard University; Brigham & Women's Hospital; California Institute of
   Technology
RP Frank, DA (通讯作者)，Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
EM david_frank@dfci.harvard.edu
RI Van Loo, Peter/A-3287-2012
OI Yeh, Jennifer/0000-0003-3144-6702; Birkbak, Nicolai/0000-0003-1613-9587;
   Boldin, Mark/0000-0003-4593-0669; Vafaizadeh, Vida/0000-0002-0875-6246
FU National Cancer Institute [R01-CA160979]; Brent Leahey Fund; Breast
   Cancer Research Foundation-American Association for Cancer Research;
   National Institute of General Medical Sciences [T32GM007753, F30
   CA165740-01]
FX Funding: This work was supported by a grant from the National Cancer
   Institute (R01-CA160979), the Brent Leahey Fund, and a Breast Cancer
   Research Foundation-American Association for Cancer Research grant for
   Translational Breast Cancer Research. This work was also supported by
   award numbers T32GM007753 and F30 CA165740-01 from the National
   Institute of General Medical Sciences.
CR Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Battle TE, 2005, BLOOD, V106, P690, DOI 10.1182/blood-2004-11-4273
   Battle TE, 2003, BLOOD, V102, P3016, DOI 10.1182/blood-2002-09-2972
   Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171
   Brock M, 2009, CIRC RES, V104, P1184, DOI 10.1161/CIRCRESAHA.109.197491
   Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5
   CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990
   Dai BB, 2011, CANCER RES, V71, P3658, DOI 10.1158/0008-5472.CAN-10-3647
   Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X
   Dechow TN, 2004, P NATL ACAD SCI USA, V101, P10602, DOI 10.1073/pnas.0404100101
   DiRenzo J, 2002, CANCER RES, V62, P89
   Domingo-Domenech J, 2006, CLIN CANCER RES, V12, P5578, DOI 10.1158/1078-0432.CCR-05-2767
   Ebert MS, 2012, CELL, V149, P515, DOI 10.1016/j.cell.2012.04.005
   Frank DA, 1997, J CLIN INVEST, V100, P3140, DOI 10.1172/JCI119869
   Frank DA, 2007, CANCER LETT, V251, P199, DOI 10.1016/j.canlet.2006.10.017
   Grivennikov S, 2008, CANCER CELL, V13, P7, DOI 10.1016/j.ccr.2007.12.020
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043
   Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Hodge DR, 2005, EUR J CANCER, V41, P2502, DOI 10.1016/j.ejca.2005.08.016
   Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6
   Hou ZB, 2012, MED ONCOL, V29, P886, DOI 10.1007/s12032-011-9862-7
   Hurst DR, 2009, CANCER RES, V69, P1279, DOI 10.1158/0008-5472.CAN-08-3559
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014
   Kanaan Z, 2012, HUM MUTAT, V33, P551, DOI 10.1002/humu.22021
   Katakowski M, 2010, CANCER INVEST, V28, P1024, DOI 10.3109/07357907.2010.512596
   Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008
   Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015
   Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792
   Liang J, 2013, CANCER CELL, V23, P107, DOI 10.1016/j.ccr.2012.11.013
   LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327
   Lin SL, 2008, RNA, V14, P417, DOI 10.1261/rna.874808
   Liu LH, 2011, BIOCHEM BIOPH RES CO, V416, P31, DOI 10.1016/j.bbrc.2011.10.117
   Liu M, 2010, CANCER RES, V70, P10464, DOI 10.1158/0008-5472.CAN-10-0732
   Löffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133
   Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745
   Matsumoto G, 2005, CLIN CANCER RES, V11, P1287
   Ndlovu MN, 2009, MOL CELL BIOL, V29, P5488, DOI 10.1128/MCB.01657-08
   Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173
   Nelson EA, 2008, BLOOD, V112, P5095, DOI 10.1182/blood-2007-12-129718
   Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015
   Sansone P, 2012, J CLIN ONCOL, V30, P1005, DOI 10.1200/JCO.2010.31.8907
   Shao MH, 2011, NUCLEIC ACIDS RES, V39, P4035, DOI 10.1093/nar/gkq1305
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010
   Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775
   Walker SR, 2013, MOL CELL BIOL, V33, P2879, DOI 10.1128/MCB.01620-12
   Walker SR, 2010, MOL PHARMACOL, V78, P903, DOI 10.1124/mol.110.066316
   Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238
   Xia HP, 2009, BRAIN RES, V1269, P158, DOI 10.1016/j.brainres.2009.02.037
   Xiao WH, 2004, PROSTATE, V61, P354, DOI 10.1002/pros.20113
   Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964
   Xu B, 2012, PROSTATE, V72, P1171, DOI 10.1002/pros.22466
   Yang JM, 2012, CANCER RES, V72, P4682, DOI 10.1158/0008-5472.CAN-12-0440
   Zhang MM, 2011, J IMMUNOL, V186, P4716, DOI 10.4049/jimmunol.1002989
NR 59
TC 143
Z9 158
U1 0
U2 23
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD JAN 28
PY 2014
VL 7
IS 310
AR ra11
DI 10.1126/scisignal.2004497
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA AA4QW
UT WOS:000331082000004
PM 24473196
OA Green Submitted, Green Accepted
DA 2025-01-12
ER

PT J
AU Cunha, S
   Lin, YC
   Goossen, EA
   DeVette, CI
   Albertella, MR
   Thomson, S
   Mulvihill, MJ
   Welm, AL
AF Cunha, Stephanie
   Lin, Yi-Chun
   Goossen, Elizabeth A.
   DeVette, Christa I.
   Albertella, Mark R.
   Thomson, Stuart
   Mulvihill, Mark J.
   Welm, Alana L.
TI The RON Receptor Tyrosine Kinase Promotes Metastasis by Triggering
   MBD4-Dependent DNA Methylation Reprogramming
SO CELL REPORTS
LA English
DT Article
ID BREAST-CANCER METASTASIS; GENE-EXPRESSION SIGNATURE; DEMETHYLATION;
   GLYCOSYLASE; GROWTH; MODEL; PROGRESSION; DEAMINATION; ACTIVATION;
   EXCISION
AB Metastasis is the major cause of death in cancer patients, yet the genetic and epigenetic programs that drive metastasis are poorly understood. Here, we report an epigenetic reprogramming pathway that is required for breast cancer metastasis. Concerted differential DNA methylation is initiated by the activation of the RON receptor tyrosine kinase by its ligand, macrophage stimulating protein (MSP). Through PI3K signaling, RON/MSP promotes expression of the G: T mismatch-specific thymine glycosylase MBD4. RON/MSP and MBD4-dependent aberrant DNA methylation results in the misregulation of a specific set of genes. Knockdown of MBD4 reverses methylation at these specific loci and blocks metastasis. We also show that the MBD4 glycosylase catalytic residue is required for RON/MSP-driven metastasis. Analysis of human breast cancers revealed that this epigenetic program is significantly associated with poor clinical outcome. Furthermore, inhibition of Ron kinase activity with a pharmacological agent blocks metastasis of patient-derived breast tumor grafts in vivo.
C1 [Cunha, Stephanie; Lin, Yi-Chun; Goossen, Elizabeth A.; DeVette, Christa I.; Welm, Alana L.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Salt Lake City, UT 84112 USA.
   [Albertella, Mark R.; Thomson, Stuart; Mulvihill, Mark J.] OSI Astellas, Farmingdale, NY 11735 USA.
C3 Utah System of Higher Education; University of Utah; Huntsman Cancer
   Institute
RP Welm, AL (通讯作者)，Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, 2000 Circle Hope, Salt Lake City, UT 84112 USA.
EM alana.welm@hci.utah.edu
OI Albertella, Mark/0000-0003-4406-6135; DeVette,
   Christa/0000-0001-9972-0646
FU DOD; Susan G. Komen for the Cure Career Catalyst Award; Huntsman Cancer
   Institute and Foundation; Cancer Research UK; British Columbia Cancer
   Agency Branch; OSI/Astellas
FX This work was funded by the DOD Breast Cancer Research Program Era of
   Hope Scholar Award (to A.L.W.), a Susan G. Komen for the Cure Career
   Catalyst Award (to A.L.W.), and the Huntsman Cancer Institute and
   Foundation. We utilized the Cancer Center's Microarray and Genomic
   Analysis Shared Resource, the Comparative Oncology Resource, and the
   University of Utah Health Sciences Center Bioinformatics and DNA
   Sequencing core facilities. We thank members of Dr. David Jones' and Dr.
   Bradley Cairns' labs for useful input and for critical reading of the
   manuscript. We thank Brian Dalley for help with genomics, and Darren
   Ames, David Nix, and Brett Milash for assistance with computational data
   analysis. This study makes use of data generated by the Molecular
   Taxonomy of Breast Cancer International Consortium. Funding for that
   project was provided by Cancer Research UK and the British Columbia
   Cancer Agency Branch. M.R.A., S.T., and M.J.M. are former employees of
   OSI/Astellas and hold stock in this company. A.L.W. received funding
   from OSI/Astellas to support work investigating RON inhibitors.
CR Andersen A, 2013, ADV EXP MED BIOL, V754, P167, DOI 10.1007/978-1-4419-9967-2_8
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Chen SS, 2009, P NATL ACAD SCI USA, V106, P13433, DOI 10.1073/pnas.0906455106
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Cortellino S, 2011, CELL, V146, P67, DOI 10.1016/j.cell.2011.06.020
   Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983
   DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Fang F, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001875
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Feng WW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-378
   GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x
   Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   He YF, 2011, SCIENCE, V333, P1303, DOI 10.1126/science.1210944
   Heikkinen T, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3076
   Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843
   Hsu PY, 2013, CANCER CELL, V24, P197, DOI 10.1016/j.ccr.2013.07.007
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   Kretschmann KL, 2010, CURR DRUG TARGETS, V11, P1157
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598
   Liu Xuemei, 2011, Genes Cancer, V2, P753, DOI 10.1177/1947601911421924
   Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Nix DA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-455
   Petronzelli F, 2000, J BIOL CHEM, V275, P32422, DOI 10.1074/jbc.M004535200
   Rai K, 2010, CELL, V142, P930, DOI 10.1016/j.cell.2010.08.030
   Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   RONSIN C, 1993, ONCOGENE, V8, P1195
   Santoro MM, 1996, MOL CELL BIOL, V16, P7072
   Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Steinig AG, 2013, BIOORG MED CHEM LETT, V23, P4381, DOI 10.1016/j.bmcl.2013.05.074
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Suvà ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang MH, 1996, ONCOGENE, V13, P2167
   WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629
   Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104
NR 46
TC 44
Z9 49
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD JAN
PY 2014
VL 6
IS 1
BP 141
EP 154
DI 10.1016/j.celrep.2013.12.010
PG 14
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AA5PX
UT WOS:000331153200014
PM 24388747
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Dillon, LM
   Miller, TW
AF Dillon, Lloye M.
   Miller, Todd W.
TI Therapeutic Targeting of Cancers with Loss of PTEN Function
SO CURRENT DRUG TARGETS
LA English
DT Article
DE Cancer; phosphatase; targeted therapy; tumor; tumor suppressor; PI3K;
   mTOR; synthetic lethal
ID PROTEIN PHOSPHATASE-ACTIVITY; TUMOR-SUPPRESSOR PTEN; PHOSPHOINOSITIDE
   3-KINASE INHIBITOR; TUBEROUS SCLEROSIS COMPLEX; METASTATIC
   BREAST-CANCER; GIANT-CELL ASTROCYTOMAS; I PI3K INHIBITOR; PHASE-I;
   PROSTATE-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE
AB Phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is one of the most frequently disrupted tumor suppressors in cancer. The lipid phosphatase activity of PTEN antagonizes the phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR pathway to repress tumor cell growth and survival. In the nucleus, PTEN promotes chromosome stability and DNA repair. Consequently, loss of PTEN function increases genomic instability. PTEN deficiency is caused by inherited germline mutations, somatic mutations, epigenetic and transcriptional silencing, post-translational modifications, and protein-protein interactions. Given the high frequency of PTEN deficiency across cancer subtypes, therapeutic approaches that exploit PTEN loss-of-function could provide effective treatment strategies. Herein, we discuss therapeutic strategies aimed at cancers with loss of PTEN function, and the challenges involved in treating patients afflicted with such cancers. We review preclinical and clinical findings, and highlight novel strategies under development to target PTENdeficient cancers.
C1 Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Lebanon, NH USA.
   Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Lebanon, NH USA.
C3 Dartmouth College; Norris Cotton Cancer Center; Dartmouth College
RP Miller, TW (通讯作者)，Dartmouth Hitchcock Med Ctr, One Med Ctr Dr HB-7936, Lebanon, NH 03756 USA.
EM Todd.W.Miller@Dartmouth.edu
RI Miller, Todd/GLS-6611-2022
OI Dillon, Lloye/0000-0002-5118-1126
FU NCI [R00CA142899]
FX Funding for this manuscript was supported by NCI R00CA142899.
CR Andre F, 2010, J CLIN ONCOL, V28, P5110, DOI 10.1200/JCO.2009.27.8549
   [Anonymous], 2013, RES DAT 1973 2010
   Apweiler R, 2010, NUCLEIC ACIDS RES, V38, pD142, DOI 10.1093/nar/gkp846
   Ashworth A, 2008, J CLIN ONCOL, V26, P3785, DOI 10.1200/JCO.2008.16.0812
   Banerji S, 2012, NATURE, V486, P405, DOI 10.1038/nature11154
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166
   Bendell JC, 2010, ANN ONCOL, V21, P162
   Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360
   Blando J, 2009, AM J PATHOL, V174, P1869, DOI 10.2353/ajpath.2009.080055
   Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010
   Calvo E, 2012, J CLIN ONCOL S, V30
   Campone M, 2012, J CLIN ONCOL, V30
   Cao C, 2006, CANCER RES, V66, P10040, DOI 10.1158/0008-5472.CAN-06-0802
   Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chang KY, 2011, CLIN CANCER RES, V17, P7116, DOI 10.1158/1078-0432.CCR-11-0796
   Chen HB, 2011, J NEURO-ONCOL, V104, P155, DOI 10.1007/s11060-010-0492-2
   Chen ML, 2006, GENE DEV, V20, P1569, DOI 10.1101/gad.1395006
   Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185
   Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814
   Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T
   Davies DM, 2011, CLIN CANCER RES, V17, P4071, DOI 10.1158/1078-0432.CCR-11-0445
   Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086
   Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538
   Demetri GD, 2013, J CLIN ONCOL, V31, P2485, DOI 10.1200/JCO.2012.45.5766
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Donawho CK, 2007, CLIN CANCER RES, V13, P2728, DOI 10.1158/1078-0432.CCR-06-3039
   Edgar KA, 2010, CANCER RES, V70, P1164, DOI 10.1158/0008-5472.CAN-09-2525
   Elkabets M, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005747
   Escrivà M, 2008, MOL CELL BIOL, V28, P1528, DOI 10.1128/MCB.02061-07
   Espina Virginia, 2009, V520, P89, DOI 10.1007/978-1-60327-811-9_7
   Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885
   Fenton TR, 2012, P NATL ACAD SCI USA, V109, P14164, DOI 10.1073/pnas.1211962109
   Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569
   Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Forster MD, 2011, NAT REV CLIN ONCOL, V8, P302, DOI 10.1038/nrclinonc.2011.42
   Fournier MV, 2009, CANCER RES, V69, P4545, DOI 10.1158/0008-5472.CAN-08-1694
   Franz DN, 2013, LANCET, V381, P125, DOI 10.1016/S0140-6736(12)61134-9
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007
   Garg K, 2012, INT J GYNECOL PATHOL, V31, P48, DOI 10.1097/PGP.0b013e3182230d00
   Garlich JR, 2008, CANCER RES, V68, P206, DOI 10.1158/0008-5472.CAN-07-0669
   Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gil A, 2006, MOL BIOL CELL, V17, P4002, DOI 10.1091/mbc.E06-05-0380
   Glauer J, 2013, BLOOD CANCER J, V3, DOI 10.1038/bcj.2013.37
   Gökmen-Polar Y, 2012, BREAST CANCER RES TR, V136, P673, DOI 10.1007/s10549-012-2298-8
   Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2
   Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389
   Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017
   Gumuskaya B, 2013, PROSTATE CANCER P D, V16, P209, DOI 10.1038/pcan.2013.8
   Hallett L, 2011, CURR MED RES OPIN, V27, P1571, DOI 10.1185/03007995.2011.586687
   Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404
   He LZ, 2010, J CLIN INVEST, V120, P2094, DOI 10.1172/JCI40778
   Hettinger K, 2007, CELL DEATH DIFFER, V14, P218, DOI 10.1038/sj.cdd.4401946
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012
   Hofbauer GFL, 2008, BRIT J DERMATOL, V159, P473, DOI 10.1111/j.1365-2133.2008.08677.x
   Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037
   Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907
   Hui STY, 2008, P NATL ACAD SCI USA, V105, P3921, DOI 10.1073/pnas.0800293105
   Ihle NT, 2004, MOL CANCER THER, V3, P763
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Iyer G, 2013, J CLIN ONCOL, V31, P3133, DOI 10.1200/JCO.2012.46.5740
   Jerusalem G, 2011, BREAST CANCER RES TR, V125, P447, DOI 10.1007/s10549-010-1260-x
   Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659
   Jiang XN, 2010, J BIOL CHEM, V285, P14980, DOI 10.1074/jbc.M109.085696
   Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020
   Kang YH, 2002, LAB INVEST, V82, P285, DOI 10.1038/labinvest.3780422
   Kato M, 2009, NAT CELL BIOL, V11, P881, DOI 10.1038/ncb1897
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Kim J, 2011, BIOORG MED CHEM LETT, V21, P6977, DOI 10.1016/j.bmcl.2011.09.118
   Kim RH, 2005, CANCER CELL, V7, P263, DOI 10.1016/j.ccr.2005.02.010
   King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Komiya T, 2013, J CLIN ONCOL, V31
   Kou XX, 2013, CARCINOGENESIS, V34, P58, DOI 10.1093/carcin/bgs336
   Krop IE, 2013, J CLIN ONCOL S, V30
   Krueger DA, 2010, NEW ENGL J MED, V363, P1801, DOI 10.1056/NEJMoa1001671
   Lee SR, 2002, J BIOL CHEM, V277, P20336, DOI 10.1074/jbc.M111899200
   Leslie NR, 2011, TRENDS PHARMACOL SCI, V32, P131, DOI 10.1016/j.tips.2010.12.005
   Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0
   Li AG, 2006, MOL CELL, V23, P575, DOI 10.1016/j.molcel.2006.06.028
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li YQ, 2008, CANCER RES, V68, P1723, DOI 10.1158/0008-5472.CAN-07-1963
   Liang HY, 2010, IDRUGS, V13, P646
   Lin J, 2013, CLIN CANCER RES, V19, P1760, DOI 10.1158/1078-0432.CCR-12-3072
   Lindhurst MJ, 2011, NEW ENGL J MED, V365, P611, DOI 10.1056/NEJMoa1104017
   Liu XH, 2010, J CLIN INVEST, V120, P2497, DOI 10.1172/JCI42382
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796
   Lu JY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005577
   Ma WW, 2012, CLIN CANCER RES, V18, P2048, DOI 10.1158/1078-0432.CCR-11-2813
   Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017
   Maira SM, 2012, MOL CANCER THER, V11, P317, DOI 10.1158/1535-7163.MCT-11-0474
   Mallon R, 2011, CLIN CANCER RES, V17, P3193, DOI 10.1158/1078-0432.CCR-10-1694
   Markman B, 2012, ANN ONCOL, V23, P2399, DOI 10.1093/annonc/mds011
   Mayer IA, 2011, CANC RES
   McCormack FX, 2011, NEW ENGL J MED, V364, P1595, DOI 10.1056/NEJMoa1100391
   McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295
   McGonigle S, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-4688
   Mendes-Pereira AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047249
   Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041
   Meric-Bernstam F, 2012, CLIN CANCER RES, V18, P1777, DOI 10.1158/1078-0432.CCR-11-2123
   Mester J, 2013, AM J MED GENET C, V163C, P114, DOI 10.1002/ajmg.c.31364
   Miknyoczki S, 2007, MOL CANCER THER, V6, P2290, DOI 10.1158/1535-7163.MCT-07-0062
   Milam MR, 2007, AM J OBSTET GYNECOL, V196, P247, DOI 10.1016/j.ajog.2006.10.872
   Miller TW, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3039
   Miller TW, 2009, CANCER RES, V69, P4192, DOI 10.1158/0008-5472.CAN-09-0042
   Mirmohammadsadegh A, 2006, CANCER RES, V66, P6546, DOI 10.1158/0008-5472.CAN-06-0384
   Molina MA, 2001, CANCER RES, V61, P4744
   Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321
   Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9
   Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nair JS, 2013, ANTICANCER RES, V33, P1307
   Ndubaku CO, 2013, J MED CHEM, V56, P4597, DOI 10.1021/jm4003632
   Negri FV, 2010, BRIT J CANCER, V102, P162, DOI 10.1038/sj.bjc.6605471
   Nguyen TTP, 2011, BREAST CANCER RES TR, V130, P73, DOI 10.1007/s10549-010-1304-2
   Ni J, 2012, CANCER DISCOV, V2, P425, DOI 10.1158/2159-8290.CD-12-0003
   Odriozola L, 2007, J BIOL CHEM, V282, P23306, DOI 10.1074/jbc.M611240200
   Ogilvie-Michie C, 2013, J CLIN ONCOL S, V31
   Ohwada J, 2011, BIOORG MED CHEM LETT, V21, P1767, DOI 10.1016/j.bmcl.2011.01.065
   Okumura K, 2006, J BIOL CHEM, V281, P26562, DOI 10.1074/jbc.M605391200
   Orloff MS, 2008, ONCOGENE, V27, P5387, DOI 10.1038/onc.2008.237
   Perez EA, 2013, J CLIN ONCOL, V31, P2115, DOI 10.1200/JCO.2012.42.2642
   Peyrou M, 2013, J HEPATOL, V59, P420, DOI 10.1016/j.jhep.2013.04.012
   Pezzolesi MG, 2006, AM J HUM GENET, V79, P923, DOI 10.1086/508943
   Pike KG, 2013, BIOORG MED CHEM LETT, V23, P1212, DOI 10.1016/j.bmcl.2013.01.019
   Planchon SM, 2008, J CELL SCI, V121, P249, DOI 10.1242/jcs.022459
   Plummer R, 2013, CANCER CHEMOTH PHARM, V71, P1191, DOI 10.1007/s00280-013-2113-1
   Podsypanina K, 2001, P NATL ACAD SCI USA, V98, P10320, DOI 10.1073/pnas.171060098
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Pressey JG, 2010, PEDIATR BLOOD CANCER, V54, P1035, DOI 10.1002/pbc.22401
   Putz U, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003084
   Qian CG, 2012, CLIN CANCER RES, V18, P4104, DOI 10.1158/1078-0432.CCR-12-0055
   Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106
   Razis E, 2011, BREAST CANCER RES TR, V128, P447, DOI 10.1007/s10549-011-1572-5
   Razis E, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-234
   Reynolds CP, 2013, PEDIATR BLOOD CANCER, V60, P791, DOI 10.1002/pbc.24301
   Ross SH, 2007, CELL SIGNAL, V19, P1521, DOI 10.1016/j.cellsig.2007.01.026
   Russo AL, 2009, CLIN CANCER RES, V15, P607, DOI 10.1158/1078-0432.CCR-08-2079
   Saba NF, 2013, J CLIN ONCOL S, V31
   Sartore-Bianchi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007287
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933
   Shahda S, 2011, J CLIN ONCOL S, V29
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   Shen Y, 2012, WORLD J GASTROENTERO, V18, P2712, DOI [10.3748/wjg.v18121.2712, 10.3748/wjg.v18.i21.2712]
   Shih KC, 2012, J CLIN ONCOL S, V30
   Shoji K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037431
   Silva A, 2008, J CLIN INVEST, V118, P3762, DOI 10.1172/JCI34616
   So LM, 2013, J BIOL CHEM, V288, P5718, DOI 10.1074/jbc.M112.379446
   Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Song MS, 2011, CELL, V144, P187, DOI 10.1016/j.cell.2010.12.020
   Soria JC, 2002, CLIN CANCER RES, V8, P1178
   Spencer A, 2011, PHAS 1 1 TIME IN HUM
   Spoerke JM, 2012, CLIN CANCER RES, V18, P6771, DOI 10.1158/1078-0432.CCR-12-2347
   Stambolic V, 2000, CANCER RES, V60, P3605
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Sutherlin DP, 2011, J MED CHEM, V54, P7579, DOI 10.1021/jm2009327
   Takeda H, 2013, EXP CELL RES, V319, P417, DOI 10.1016/j.yexcr.2012.12.018
   Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614
   Tan MH, 2012, CLIN CANCER RES, V18, P400, DOI 10.1158/1078-0432.CCR-11-2283
   Tanaka H, 2011, CLIN CANCER RES, V17, P3272, DOI 10.1158/1078-0432.CCR-10-2882
   Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Templeton AJ, 2013, EUR UROL, V64, P150, DOI 10.1016/j.eururo.2013.03.040
   Teresi RE, 2006, INT J CANCER, V118, P2390, DOI 10.1002/ijc.21799
   Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138
   Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200
   Trotman LC, 2007, CELL, V128, P141, DOI 10.1016/j.cell.2006.11.040
   Venkatesan AM, 2010, J MED CHEM, V53, P2636, DOI 10.1021/jm901830p
   Wagner AJ, 2010, EJC SUPPL, V8, P123, DOI 10.1016/S1359-6349(10)72096-6
   Wang L, 2007, HEPATOL RES, V37, P389, DOI 10.1111/j.1872-034X.2007.00042.x
   Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039
   Weigelt B, 2013, CLIN CANCER RES, V19, P3533, DOI 10.1158/1078-0432.CCR-12-3815
   Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599
   Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246
   Wiencke JK, 2007, NEURO-ONCOLOGY, V9, P271, DOI 10.1215/15228517-2007-003
   Wu XY, 2000, P NATL ACAD SCI USA, V97, P4233, DOI 10.1073/pnas.97.8.4233
   Xia DR, 2007, J BIOL CHEM, V282, P3507, DOI 10.1074/jbc.M610141200
   Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
   Yin Y, 2008, ONCOGENE, V27, P5443, DOI 10.1038/onc.2008.241
   Yoshimoto M, 2013, MODERN PATHOL, V26, P435, DOI 10.1038/modpathol.2012.162
   Zhang XC, 2012, BIOCHEM J, V444, P457, DOI 10.1042/BJ20120098
NR 194
TC 193
Z9 236
U1 0
U2 19
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-4501
EI 1873-5592
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD JAN
PY 2014
VL 15
IS 1
BP 65
EP 79
DI 10.2174/1389450114666140106100909
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA AA4YY
UT WOS:000331103800006
PM 24387334
OA Green Accepted
DA 2025-01-12
ER

PT J
AU Feng, GX
   Zhang, Y
   Yuan, HS
   Bai, RX
   Zheng, JW
   Zhang, JQ
   Song, MM
AF Feng, Guoxun
   Zhang, Yan
   Yuan, Huisheng
   Bai, Rixing
   Zheng, Jianwei
   Zhang, Jinqian
   Song, Maomin
TI DNA methylation of trefoil factor 1 (TFF1) is associated with the
   tumorigenesis of gastric carcinoma
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE DNA methylation; trefoil factor 1; tumorigenesis; gastric carcinoma
ID PROMOTER HYPERMETHYLATION; HEPATOCELLULAR-CARCINOMA; NORMAL STOMACH;
   BREAST-CANCER; CELL LINEAGE; GENE; PEPTIDES; MUCOSA; EPIGENETICS;
   ADENOCARCINOMA
AB Trefoil factor 1 (TFF1) is a tumor suppressor gene that encodes a peptide belonging to the trefoil factor family of protease-resistant peptides. Although TFF1 expression is frequently lost in gastric carcinomas (GCs), the tumorigenic pathways that are affected have yet to be determined. The aim of the current study was to identify the mechanism(s) by which the TFF1 gene is regulated in gastric carcinogenesis. In this study, TFF1 was shown to be silenced or downregulated in gastric tumor tissue compared with matched non-cancerous tissue. In addition, human gastric cells weakly expressed TFF1. The hypermethylation status in the promoter CpG islands appeared to be correlated with TFF1 expression levels in gastric cell lines or specimen tissue. Further molecular analysis indicated that the CpG islands play a role in the promoter activity of the TFF1 gene. The expression of TFF1 and DNA methylation of its promoter affected cell proliferation and apoptosis. The expression of TFF1 in gastric cell lines was restored with a demethylating agent, 5-azacytidine. Low expression of TFF1 in gastric cell lines and cancer tissue is associated with TP 53. In conclusion, the current study demonstrates that DNA methylation is a key mechanism of silencing TFF1 expression in human gastric cells and TFF1 gene hypermethylation of the CpG islands is a potential biomarker for GC.
C1 [Feng, Guoxun; Yuan, Huisheng; Bai, Rixing; Zheng, Jianwei; Song, Maomin] Capital Med Univ, Beijing Tiantan Hosp, Dept Gen Surg, Beijing 100050, Peoples R China.
   [Zhang, Yan] Chinese PLA, Gen Hosp Beijing Mil Area Command, Dept Ophthalmol, Beijing 100700, Peoples R China.
   [Zhang, Jinqian] Capital Med Univ, Beijing Ditan Hosp, Beijing Key Lab Emerging Infect Dis, Inst Infect Dis, Beijing 100015, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Song, MM (通讯作者)，Capital Med Univ, Beijing Tiantan Hosp, Dept Gen Surg, 6 Tiantan Xili, Beijing 100050, Peoples R China.
EM jingwanghou@yahoo.com.cn
FU National Natural Science Foundation of China [30600524, 81071990,
   81172383, 81201758]
FX This study was supported by grants from the National Natural Science
   Foundation of China (nos. 30600524, 81071990, 81172383 and 81201758).
CR Adrien LR, 2006, CYTOGENET GENOME RES, V114, P16, DOI 10.1159/000091923
   Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P489, DOI 10.1053/gast.1996.v110.pm8566596
   Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x
   Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X
   Baylin SB, 2002, SEMIN CANCER BIOL, V12, P331, DOI 10.1016/S1044-579X(02)00053-6
   Byun DS, 2001, CANCER RES, V61, P7034
   Calnan DP, 1999, J PATHOL, V188, P312, DOI 10.1002/(SICI)1096-9896(199907)188:3<312::AID-PATH360>3.0.CO;2-P
   Carvalho B, 2003, EUR J CANCER, V39, P1222, DOI 10.1016/S0959-8049(03)00177-1
   Carvalho R, 2002, LAB INVEST, V82, P1319, DOI 10.1097/01.LAB.0000029205.76632.A8
   Corte MD, 2006, BREAST CANCER RES TR, V96, P63, DOI 10.1007/s10549-005-9041-7
   DIGNASS A, 1994, J CLIN INVEST, V94, P376, DOI 10.1172/JCI117332
   Feng ZQ, 2011, EXP MOL PATHOL, V91, P569, DOI 10.1016/j.yexmp.2011.06.004
   Fenoglio-Preiser CM, 2003, HUM MUTAT, V21, P258, DOI 10.1002/humu.10180
   Fujimoto J, 2000, CANCER LETT, V149, P125, DOI 10.1016/S0304-3835(99)00349-3
   Herath NI, 2006, J GASTROEN HEPATOL, V21, P15, DOI 10.1111/j.1440-1746.2005.04043.x
   Herceg Z, 2007, MUTAGENESIS, V22, P91, DOI 10.1093/mutage/gel068
   Hur K, 2003, BIOCHEM BIOPH RES CO, V310, P844, DOI 10.1016/j.bbrc.2003.09.095
   Katoh M, 2003, INT J MOL MED, V12, P3
   Lee TL, 2002, CLIN CANCER RES, V8, P1761
   Lefebvre O, 1996, SCIENCE, V274, P259, DOI 10.1126/science.274.5285.259
   Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010
   Li HP, 2005, CELL RES, V15, P262, DOI 10.1038/sj.cr.7290295
   Li LH, 2013, NANOSCALE RES LETT, V8, DOI [10.1186/1556-276X-8-100, 10.1186/1556-276X-8-194]
   Longman RJ, 2000, GUT, V47, P792, DOI 10.1136/gut.47.6.792
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   McChesney PA, 2006, CANCER RES, V66, P1346, DOI 10.1158/0008-5472.CAN-05-3593
   Newton JL, 2000, GUT, V46, P312, DOI 10.1136/gut.46.3.312
   Park WS, 2000, CANCER LETT, V159, P15, DOI 10.1016/S0304-3835(00)00525-5
   Park WS, 2000, GASTROENTEROLOGY, V119, P691, DOI 10.1053/gast.2000.16483
   Pera M, 2001, GUT, V48, P792, DOI 10.1136/gut.48.6.792
   Poulsen SS, 1999, GUT, V45, P516, DOI 10.1136/gut.45.4.516
   RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9
   Ren J, 2000, CANCER, V88, P280
   Ribieras S, 1998, BBA-REV CANCER, V1378, pF61, DOI 10.1016/S0304-419X(98)00016-X
   Ribieras S, 2001, GENE, V266, P67, DOI 10.1016/S0378-1119(01)00380-8
   RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T
   RIO MC, 1988, SCIENCE, V241, P705, DOI 10.1126/science.3041593
   Sankpal NV, 2005, BBA-GENE STRUCT EXPR, V1728, P1, DOI 10.1016/j.bbaexp.2004.12.014
   Sozzi G, 2003, J CLIN ONCOL, V21, P3902, DOI 10.1200/JCO.2003.02.006
   Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991
   Stadtländer CTKH, 1999, CARCINOGENESIS, V20, P2195, DOI 10.1093/carcin/20.12.2195
   Tahara Eiichi, 2004, IARC Sci Publ, P327
   Taupin D, 2001, LAB INVEST, V81, P397, DOI 10.1038/labinvest.3780247
   Thim L, 2005, CELL MOL LIFE SCI, V62, P2956, DOI 10.1007/s00018-005-5484-6
   Tischoff I, 2008, WORLD J GASTROENTERO, V14, P1741, DOI 10.3748/wjg.14.1741
   Tomita H, 2011, GASTROENTEROLOGY, V140, P879, DOI 10.1053/j.gastro.2010.11.037
   Toyota M, 2000, ELECTROPHORESIS, V21, P329, DOI 10.1002/(SICI)1522-2683(20000101)21:2<329::AID-ELPS329>3.0.CO;2-9
   Wang HN, 2012, ONCOL REP, V28, P311, DOI 10.3892/or.2012.1788
   Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890
NR 49
TC 25
Z9 29
U1 0
U2 12
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD JAN
PY 2014
VL 9
IS 1
BP 109
EP 117
DI 10.3892/mmr.2013.1772
PG 9
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AA0KJ
UT WOS:000330783700018
PM 24190027
OA Bronze
DA 2025-01-12
ER

PT J
AU Lee, JY
   Park, MK
   Park, JH
   Lee, HJ
   Shin, DH
   Kang, Y
   Lee, CH
   Kong, G
AF Lee, J-Y
   Park, M. K.
   Park, J-H
   Lee, H. J.
   Shin, D. H.
   Kang, Y.
   Lee, C. H.
   Kong, G.
TI Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal
   transition by ZEB1 and ZEB2 expression through the downregulation of
   miR-205 in breast cancer
SO ONCOGENE
LA English
DT Article
DE Mel-18; miR-205; ZEB1; ZEB2; epithelial-mesenchymal transition; polycomb
ID GROWTH-FACTOR-BETA; TUMOR INVASION; MICRORNAS; BMI-1; CELLS;
   OVEREXPRESSION; REPRESSION; FAMILY
AB The epithelial-mesenchymal transition (EMT) is the pivotal mechanism underlying the initiation of cancer invasion and metastasis. Although Mel-18 has been implicated in several biological processes in cancer, its function in the EMT of human cancers has not yet been studied. Here, we demonstrate that Mel-18 negatively regulates the EMT by epigenetically modulating miR-205. We identified miR-205 as a novel target of Mel-18 using a microRNA microarray analysis and found that Mel-18 increased miR-205 transcription by the inhibition of DNA methyltransferase-mediated DNA methylation of the miR-205 promoter, thereby downregulating its target genes, ZEB1 and ZEB2. Furthermore, the loss of Mel-18 promoted ZEB1- and ZEB2-mediated downregulation of E-cadherin transcription and also enhanced the expression of mesenchymal markers, leading to increased migration and invasion in MCF-7 cells. In MDA-MB-231 cells, Mel-18 overexpression restored E-cadherin expression, resulting in reduced migration and invasion. These effects were reversed by miR-205 overexpression or inhibition. A tumor xenograft with Mel-18 knockdown MCF-7 cells consistently showed increased ZEB1 and ZEB2 expression and decreased E-cadherin expression. Taken together, these results suggest that Mel-18 functions as a tumor suppressor by its novel negative control of the EMT, achieved through regulating the expression of miR-205 and its target genes, ZEB1 and ZEB2.
C1 [Lee, J-Y; Kong, G.] Hanyang Univ, IBBR, Seoul 133791, South Korea.
   [Park, M. K.; Lee, H. J.; Lee, C. H.] Dongguk Univ Seoul, Coll Pharm, Seoul 410820, South Korea.
   [Park, J-H; Shin, D. H.; Kong, G.] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea.
   [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.
C3 Hanyang University; Dongguk University; Hanyang University; Princeton
   University
RP Lee, CH (通讯作者)，Dongguk Univ Seoul, Coll Pharm, Seoul 410820, South Korea.
EM uatheone@gmail.com; gkong@hanyang.ac.kr
OI Kang, Yibin/0000-0002-1626-6730
FU Korea Healthcare Technology RD Project [A101836]; Ministry of Health
   Welfare and Family Affairs; Research Program for New Drug Target
   Discovery [2011-0030173]
FX This study was supported by grants from the Korea Healthcare Technology
   R&D Project (A101836), the Ministry of Health Welfare and Family Affairs
   and the Research Program for New Drug Target Discovery (2011-0030173).
CR Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226
   AuS Leung-Kuen., 2012, Hepatology, V56, P622
   Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807
   Blumenberg M, 2007, CELLS TISSUES ORGANS, V185, P162, DOI 10.1159/000101317
   Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016
   Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368
   Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447
   Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010
   Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681
   Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113
   Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669
   Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570
   Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11
   Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174
   Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084
   Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065
   Negishi M, 2007, BIOCHEM BIOPH RES CO, V353, P992, DOI 10.1016/j.bbrc.2006.12.166
   Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174
   Qian T, 2010, ONCOGENE, V29, P5818, DOI 10.1038/onc.2010.317
   Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907
   Rush Margaret, 2009, Epigenetics, V4, P404
   Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019
   Shin DH, 2011, J CELL PHYSIOL, V226, P1340, DOI 10.1002/jcp.22462
   Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035
   Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005
   Viré E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431
   Wanami LS, 2008, EXP CELL RES, V314, P2448, DOI 10.1016/j.yexcr.2008.05.004
   Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461
   Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015
   Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086
   Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099
NR 44
TC 97
Z9 101
U1 0
U2 20
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAR 6
PY 2014
VL 33
IS 10
BP 1325
EP 1335
DI 10.1038/onc.2013.53
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA AC6KI
UT WOS:000332631100013
PM 23474752
DA 2025-01-12
ER

PT J
AU Faraji, F
   Hu, Y
   Wu, G
   Goldberger, NE
   Walker, RC
   Zhang, JH
   Hunter, KW
AF Faraji, Farhoud
   Hu, Ying
   Wu, Gang
   Goldberger, Natalie E.
   Walker, Renard C.
   Zhang, Jinghui
   Hunter, Kent W.
TI An integrated systems genetics screen reveals the transcriptional
   structure of inherited predisposition to metastatic disease
SO GENOME RESEARCH
LA English
DT Article
ID BREAST-CANCER METASTASIS; TO-MESENCHYMAL TRANSITION; SUPPRESSES
   TUMOR-GROWTH; MAMMARY-TUMOR; CCR4-NOT COMPLEX; HEPATOCELLULAR-CARCINOMA;
   EXPRESSION PROFILES; NETWORK ANALYSIS; DNA METHYLATION; MICRORNA
AB Metastasis is the result of stochastic genomic and epigenetic events leading to gene expression profiles that drive tumor dissemination. Here we exploit the principle that metastatic propensity is modified by the genetic background to generate prognostic gene expression signatures that illuminate regulators of metastasis. We also identify multiple microRNAs whose germline variation is causally linked to tumor progression and metastasis. We employ network analysis of global gene expression profiles in tumors derived from a panel of recombinant inbred mice to identify a network of co-expressed genes centered on Cnot2 that predicts metastasis-free survival. Modulating Cnot2 expression changes tumor cell metastatic potential in vivo, supporting a functional role for Cnot2 in metastasis. SmallRNA sequencing of the same tumor set revealed a negative correlation between expression of the Mir216/217 cluster and tumor progression. Expression quantitative trait locus analysis (eQTL) identified cis-eQTLs at the Mir216/217 locus, indicating that differences in expression may be inherited. Ectopic expression of Mir216/217 in tumor cells suppressed metastasis in vivo. Finally, small RNA sequencing and mRNA expression profiling data were integrated to reveal that miR-3470a/b target a high proportion of network transcripts. In vivo analysis of Mir3470a/b demonstrated that both promote metastasis. Moreover, Mir3470b is a likely regulator of the Cnot2 network as its overexpression down-regulated expression of network hub genes and enhanced metastasis in vivo, phenocopying Cnot2 knockdown. The resulting data from this strategy identify Cnot2 as a novel regulator of metastasis and demonstrate the power of our systems-level approach in identifying modifiers of metastasis.
C1 [Faraji, Farhoud; Goldberger, Natalie E.; Walker, Renard C.; Hunter, Kent W.] NCI, Metastasis Susceptibil Sect, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA.
   [Faraji, Farhoud] St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA.
   [Faraji, Farhoud] Howard Hughes Med Inst, Natl Inst Hlth Res Scholars Program, Chevy Chase, MD 20815 USA.
   [Hu, Ying] NCI, Lab Populat Genet, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
   [Wu, Gang; Zhang, Jinghui] St Jude Childrens Res Hosp, Dept Computat Biol, Memphis, TN 38105 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI); Saint Louis University; National Institutes of Health (NIH) -
   USA; Howard Hughes Medical Institute; National Institutes of Health
   (NIH) - USA; NIH National Cancer Institute (NCI); St Jude Children's
   Research Hospital
RP Hunter, KW (通讯作者)，NCI, Metastasis Susceptibil Sect, Lab Canc Biol & Genet, NIH, Bethesda, MD 20892 USA.
EM hunterk@mail.nih.gov
RI Wu, Gang/M-8012-2014; hu, ying/IVV-6516-2023; Faraji,
   Farhoud/AAG-2417-2019
OI Wu, Gang/0000-0002-1678-5864; Faraji, Farhoud/0000-0001-5078-813X
FU Intramural Research Program of the NIH, National Cancer Institute,
   Center for Cancer Research; Howard Hughes Medical Institute Research
   Scholars Program
FX We thank Jude Alsarraj, Thomas R. Geiger, Jeffrey E. Green, Ngoc-Han Ha,
   and James J. Morrow for critical review of this manuscript and
   stimulating discussion. We thank Dominic Esposito of the Protein
   Expression Laboratory, SAIC-Frederick, for constructing the myc-Cnot2
   expression vector. This research was supported by the Intramural
   Research Program of the NIH, National Cancer Institute, Center for
   Cancer Research and the Howard Hughes Medical Institute Research
   Scholars Program.
CR Ahn HW, 2010, MOL HUM REPROD, V16, P463, DOI 10.1093/molehr/gaq017
   Ali S, 2012, J CELL PHYSIOL, V227, P3373, DOI 10.1002/jcp.24036
   Alsarraj J, 2011, CANCER RES, V71, P3121, DOI 10.1158/0008-5472.CAN-10-4417
   ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Bao LL, 2012, AM J PATHOL, V180, P2490, DOI 10.1016/j.ajpath.2012.02.024
   Behm-Ansmant I, 2006, GENE DEV, V20, P1885, DOI 10.1101/gad.1424106
   Bockhorn J, 2013, BREAST CANCER RES TR, V137, P373, DOI 10.1007/s10549-012-2346-4
   Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112
   Churchill G, 2004, NAT GENET, V36, P1133, DOI 10.1038/ng1104-1133
   COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525
   Collart MA, 2012, GENE, V492, P42, DOI 10.1016/j.gene.2011.09.033
   Crawford NPS, 2008, CLIN EXP METASTAS, V25, P357, DOI 10.1007/s10585-008-9146-6
   Crawford NPS, 2007, PLOS GENET, V3, P2296, DOI 10.1371/journal.pgen.0030214
   Crawford NPS, 2008, P NATL ACAD SCI USA, V105, P6380, DOI 10.1073/pnas.0710331105
   Crawford NPS, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1389
   Das TK, 2013, ONCOGENE, V32, P3184, DOI 10.1038/onc.2012.326
   Deng M, 2011, J CELL SCI, V124, P2997, DOI 10.1242/jcs.085050
   Doss S, 2005, GENOME RES, V15, P681, DOI 10.1101/gr.3216905
   Ein-Dor L, 2006, P NATL ACAD SCI USA, V103, P5923, DOI 10.1073/pnas.0601231103
   Ezzeddine N, 2007, MOL CELL BIOL, V27, P7791, DOI 10.1128/MCB.01254-07
   Faraji F, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002926
   Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608
   FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0
   Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764
   Florl AR, 1999, BRIT J CANCER, V80, P1312, DOI 10.1038/sj.bjc.6690524
   Goldberger N, 2013, CANCER RES, V73, P2671, DOI 10.1158/0008-5472.CAN-12-3513
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954
   Haga CL, 2012, J BIOL CHEM, V287, P42695, DOI 10.1074/jbc.M112.387761
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hsieh SM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2412
   Hu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072287
   Hu Y, 2012, P NATL ACAD SCI USA, V109, P3184, DOI 10.1073/pnas.1117872109
   Hui ABY, 2013, CLIN CANCER RES, V19, P2154, DOI 10.1158/1078-0432.CCR-12-3572
   Hunter KW, 2001, CANCER RES, V61, P8866
   Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111
   Ito K, 2011, GENES CELLS, V16, P368, DOI 10.1111/j.1365-2443.2011.01492.x
   Jahid S, 2012, CANCER DISCOV, V2, P540, DOI 10.1158/2159-8290.CD-11-0267
   Jayne S, 2006, BIOCHEM J, V398, P461, DOI 10.1042/BJ20060406
   Kau P, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-120
   Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011
   Kruk JA, 2011, GENE DEV, V25, P581, DOI 10.1101/gad.2020911
   KUO YZ, 2013, ORAL DIS, DOI DOI 10.1111/0DI.12133
   Lancaster M, 2005, MAMM GENOME, V16, P120, DOI 10.1007/s00335-004-2432-y
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Lau NC, 2009, BIOCHEM J, V422, P443, DOI 10.1042/BJ20090500
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li Ai, 2009, BMC Res Notes, V2, P142, DOI 10.1186/1756-0500-2-142
   Li H, 2013, NEOPLASMA, V60, P511, DOI 10.4149/neo_2013_066
   Li HL, 2013, CARCINOGENESIS, V34, P2145, DOI 10.1093/carcin/bgt158
   Li JP, 2013, MOL CELL BIOCHEM, V380, P277, DOI 10.1007/s11010-013-1682-y
   Li XN, 2013, J BIOL CHEM, V288, P18121, DOI 10.1074/jbc.M113.478560
   Li Y, 2010, CANCER RES, V70, P7894, DOI 10.1158/0008-5472.CAN-10-1675
   Liang SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018409
   Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8
   Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560
   Liu CJ, 2014, INT J CANCER, V134, P811, DOI 10.1002/ijc.28358
   Lukes L, 2009, CANCER RES, V69, P310, DOI 10.1158/0008-5472.CAN-08-3520
   Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3
   Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031
   MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236
   Park YG, 2005, NAT GENET, V37, P1055, DOI 10.1038/ng1635
   Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14
   Pencheva N, 2013, NAT CELL BIOL, V15, P546, DOI 10.1038/ncb2769
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Pillutla RC, 1998, J BIOL CHEM, V273, P21443, DOI 10.1074/jbc.273.34.21443
   Quigley DA, 2009, NATURE, V458, P505, DOI 10.1038/nature07683
   Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Rutnam ZJ, 2012, J CELL SCI, V125, P2075, DOI 10.1242/jcs100818
   Schadt EE, 2003, NATURE, V422, P297, DOI 10.1038/nature01434
   Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206
   Su JZ, 2012, GENOMICS, V99, P10, DOI 10.1016/j.ygeno.2011.10.004
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Takagaki Y, 2000, MOL CELL BIOL, V20, P1515, DOI 10.1128/MCB.20.5.1515-1525.2000
   Takahashi F, 2011, ONCOGENE, V30, P3084, DOI 10.1038/onc.2011.24
   Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Uchino K, 2013, MOL THER, V21, P610, DOI 10.1038/mt.2012.269
   Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047
   Valencia K, 2013, BONE, V52, P532, DOI 10.1016/j.bone.2012.10.033
   van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Winter SF, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002735
   Witkos TM, 2011, CURR MOL MED, V11, P93
   Yang H, 2013, HEPATOLOGY, V58, P205, DOI 10.1002/hep.26315
   Yang HY, 2005, CLIN EXP METASTAS, V22, P593, DOI 10.1007/s10585-005-6244-6
   Yang ZH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065256
   Ying Q, 2011, HEPATOLOGY, V54, P2064, DOI 10.1002/hep.24614
   Zheng XF, 2012, STEM CELLS, V30, P910, DOI 10.1002/stem.1070
   Zhou J, 2011, J SURG ONCOL, V104, P278, DOI 10.1002/jso.21941
NR 93
TC 35
Z9 39
U1 0
U2 19
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1088-9051
EI 1549-5469
J9 GENOME RES
JI Genome Res.
PD FEB
PY 2014
VL 24
IS 2
BP 227
EP 240
DI 10.1101/gr.166223.113
PG 14
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 303TG
UT WOS:000330696800005
PM 24322557
OA Green Published, hybrid
DA 2025-01-12
ER

PT J
AU Kang, HJ
   Lee, MH
   Kang, HL
   Kim, SH
   Ahn, JR
   Na, H
   Na, TY
   Kim, YN
   Seong, JK
   Lee, MO
AF Kang, Hyun-Jin
   Lee, Min-Ho
   Kang, Hae-Lim
   Kim, Sung-Hye
   Ahn, Jung-Ranh
   Na, Hyelin
   Na, Tae-Young
   Kim, Yo Na
   Seong, Je Kyung
   Lee, Mi-Ock
TI Differential Regulation of Estrogen Receptor a Expression in Breast
   Cancer Cells by Metastasis-Associated Protein 1
SO CANCER RESEARCH
LA English
DT Article
ID ER-ALPHA; HISTONE DEACETYLASE; TRANSCRIPTIONAL REPRESSION; ANDROGEN
   RECEPTOR; TUMOR-SUPPRESSOR; GENE-EXPRESSION; VALPROIC ACID; MTA1;
   HETEROZYGOSITY; INHIBITOR
AB Metastasis-associated protein 1 (MTA1) is a component of the nucleosome remodeling and histone deacetylase (HDAC) complex, which plays an important role in progression of breast cancer. Although MTA1 is known as a repressor of the transactivation function of estrogen receptor alpha (ER alpha), its involvement in the epigenetic control of transcription of the ER alpha gene ESR1 has not been studied. Here, we show that silencing of MTA1 reduced the level of expression of ER alpha in ER alpha-positive cells but increased it in ER alpha-negative cells. In both MCF7 and MDA-MB-231, MTA1 was recruited to the region + 146 to + 461 bp downstream of the transcription start site of ESR1 (ERpro315). Proteomics analysis of the MTA1 complex that was pulled down by an oligonucleotide encoding ERpro315 revealed that the transcription factor AP-2 gamma (TFAP2C) and the IFN-gamma-inducible protein 16 (IFI16) were components of the complex. Interestingly, in MCF7, TFAP2C activated the reporter encoding ERpro315 and the level of ER alpha mRNA. By contrast, in MDA-MB-231, IFI16 repressed the promoter activity and silencing of MTA1 increased expression of ER alpha. Importantly, class II HDACs are involved in the MTA1-mediated differential regulation of ER alpha. Finally, an MDA-MB-231-derived cell line that stably expressed shIFI16 or shMTA1 was more susceptible to tamoxifen-induced growth inhibition in in vitro and in vivo experiments. Taken together, our findings suggest that theMTA1-TFAP2C or the MTA1-IFI16 complex may contribute to the epigenetic regulation of ESR1 expression in breast cancer and may determine the chemosensitivity of tumors to tamoxifen therapy in patients with breast cancer. (c) 2014 AACR.
C1 [Kang, Hyun-Jin; Lee, Min-Ho; Kang, Hae-Lim; Kim, Sung-Hye; Ahn, Jung-Ranh; Na, Hyelin; Na, Tae-Young; Lee, Mi-Ock] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea.
   [Kang, Hyun-Jin; Lee, Min-Ho; Kang, Hae-Lim; Kim, Sung-Hye; Ahn, Jung-Ranh; Na, Hyelin; Na, Tae-Young; Lee, Mi-Ock] Seoul Natl Univ, BioMAX Inst, Pharmaceut Sci Res Inst, Seoul 151742, South Korea.
   [Kim, Yo Na; Seong, Je Kyung] Seoul Natl Univ, Coll Vet Med, Plus Program Vet Sci BK21, Seoul 151742, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU)
RP Lee, MO (通讯作者)，Seoul Natl Univ, Coll Pharm, 1 Gwanak Ro, Seoul 151742, South Korea.
EM molee@snu.ac.kr
RI KIM, BYOUNG HYUCK/IRZ-5874-2023; Kim, Sunghoon/AAE-8314-2020; Na,
   Hyelin/K-7303-2016
OI Seong, Je Kyung/0000-0003-1177-6958
FU NRF [2013-003999]; National R&D Program for Cancer Control, Ministry of
   Health Welfare, Korea [1220110]
FX This work was supported by grants from the NRF (2013-003999) and the
   National R&D Program for Cancer Control, Ministry of Health & Welfare,
   Korea (1220110).
CR Alimirah F, 2006, FEBS LETT, V580, P1659, DOI 10.1016/j.febslet.2006.02.015
   Asefa B, 2004, BLOOD CELL MOL DIS, V32, P155, DOI 10.1016/j.bcmd.2003.10.002
   CHEN LC, 1989, P NATL ACAD SCI USA, V86, P7204, DOI 10.1073/pnas.86.18.7204
   Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009
   Cicatiello L, 2010, AM J PATHOL, V176, P2113, DOI 10.2353/ajpath.2010.090837
   Desmedt C, 2007, CLIN CANCER RES, V13, P3207, DOI 10.1158/1078-0432.CCR-06-2765
   Fan J, 2008, J CANCER RES CLIN, V134, P883, DOI 10.1007/s00432-008-0354-x
   Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011
   Ghanta KS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017135
   Gururaj AE, 2006, CELL CYCLE, V5, P1407, DOI 10.4161/cc.5.13.2924
   Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799
   Harvell DME, 2006, ENDOCRINOLOGY, V147, P700, DOI 10.1210/en.2005-0617
   Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006
   Herynk MH, 2004, ENDOCR REV, V25, P869, DOI 10.1210/er.2003-0010
   Hickey TE, 2012, MOL ENDOCRINOL, V26, P1252, DOI 10.1210/me.2012-1107
   Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006
   IWASE H, 1995, BRIT J CANCER, V71, P448, DOI 10.1038/bjc.1995.91
   Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x
   Jiang QM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-60
   Katzenellenbogen BS, 2000, BREAST CANCER RES, V2, P335, DOI 10.1186/bcr78
   KNIGHT WA, 1977, CANCER RES, V37, P4669
   Kos M, 2001, MOL ENDOCRINOL, V15, P2057, DOI 10.1210/me.15.12.2057
   Lee MH, 2012, ONCOGENE, V31, P5099, DOI 10.1038/onc.2012.2
   Lower EE, 2005, BREAST CANCER RES TR, V90, P65, DOI 10.1007/s10549-004-2756-z
   Macaluso M, 2003, ONCOGENE, V22, P3511, DOI 10.1038/sj.onc.1206578
   Manavathi Bramanandam, 2007, Nucl Recept Signal, V5, pe010, DOI 10.1621/nrs.05010
   Martin MD, 2001, CANCER RES, V61, P3578
   McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342
   Molli PR, 2008, ONCOGENE, V27, P1971, DOI 10.1038/sj.onc.1210839
   Munster PN, 2011, BRIT J CANCER, V104, P1828, DOI 10.1038/bjc.2011.156
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   OTTAVIANO YL, 1994, CANCER RES, V54, P2552
   Pinzone JJ, 2004, MOL CELL BIOL, V24, P4605, DOI 10.1128/MCB.24.11.4605-4612.2004
   Reddy SDN, 2012, J BIOL CHEM, V287, P27843, DOI 10.1074/jbc.M112.348474
   Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662
   Schairer C, 2004, JNCI-J NATL CANCER I, V96, P1311, DOI 10.1093/jnci/djh253
   Sharma D, 2006, CANCER RES, V66, P6370, DOI 10.1158/0008-5472.CAN-06-0402
   Sharma D, 2005, MOL ENDOCRINOL, V19, P1740, DOI 10.1210/me.2004-0011
   Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274
   TOH Y, 1994, J BIOL CHEM, V269, P22958
   Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8
   Vesuna F, 2012, ONCOGENE, V31, P3223, DOI 10.1038/onc.2011.483
   Waddell N, 2010, J PATHOL, V221, P452, DOI 10.1002/path.2728
   Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293
   Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807
   Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343
   Yang XW, 2001, CANCER RES, V61, P7025
NR 47
TC 63
Z9 76
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD MAR 1
PY 2014
VL 74
IS 5
BP 1484
EP 1494
DI 10.1158/0008-5472.CAN-13-2020
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AC4FG
UT WOS:000332475900021
PM 24413532
OA Green Submitted
DA 2025-01-12
ER

PT J
AU Menendez, JA
   Alarcón, T
   Joven, J
AF Menendez, Javier A.
   Alarcon, Tomas
   Joven, Jorge
TI Gerometabolites The pseudohypoxic aging side of cancer oncometabolites
SO CELL CYCLE
LA English
DT Article
DE Warburg effect; pseudohypoxia; metabolism; cancer; geroncogenesis; Myc;
   oncometabolites; HIF; aging
ID VHL TUMOR-SUPPRESSOR; AGE-RELATED DISEASES; C-MYC; ALPHA-KETOGLUTARATE;
   CELL-METABOLISM; BREAST-CANCER; PROMOTES DIFFERENTIATION; PROLYL
   HYDROXYLASES; ENERGY-EXPENDITURE; MAMMALIAN TARGET
AB Oncometabolites are defined as small-molecule components (or enantiomers) of normal metabolism whose accumulation causes signaling dysregulation to establish a milieu that initiates carcinogenesis. In a similar manner, we propose the term "gerometabolites" to refer to small-molecule components of normal metabolism whose depletion causes signaling dysregulation to establish a milieu that drives aging. In an investigation of the pathogenic activities of the currently recognized oncometabolites R(-)-2-hydroxyglutarate (2-HG), fumarate, and succinate, which accumulate due to mutations in isocitrate dehydrogenases (IDH), fumarate hydratase (FH), and succinate dehydrogenase (SDH), respectively, we illustrate the fact that metabolic pseudohypoxia, the accumulation of hypoxia-inducible factor (HIF alpha) under normoxic conditions, and the subsequent Warburg-like reprogramming that shifts glucose metabolism from the oxidative pathway to aerobic glycolysis are the same mechanisms through which the decline of the "gerometabolite" nicotinamide adenine dinucleotide (NAD)(+) reversibly disrupts nuclear-mitochondrial communication and contributes to the decline in mitochondrial function with age. From an evolutionary perspective, it is reasonable to view NAD(+)-driven mitochondrial homeostasis as a conserved response to changes in energy supplies and oxygen levels. Similarly, the natural ability of 2-HG to significantly alter epigenetics might reflect an evolutionarily ancient role of certain metabolites to signal for elevated glutamine/glutamate metabolism and/or oxygen deficiency. However, when chronically altered, these responses become conserved causes of aging and cancer. Because HIF alpha-driven pseudohypoxia might drive the overproduction of 2-HG, the intriguing possibility exists that the decline of gerometabolites such as NAD(+) could promote the chronic accumulation of oncometabolites in normal cells during aging. If the sole activation of a Warburg-like metabolic reprogramming in normal tissues might be able to significantly increase the endogenous production of bona fide etiological determinants in cancer, such as oncometabolites, this undesirable trade-off between mitochondrial dysfunction and activation of oncometabolites production might then pave the way for the epigenetic initiation of carcinogenesis in a strictly metabolic-dependent manner. Perhaps it is time to definitely adopt the view that aging and aging diseases including cancer are governed by a pivotal regulatory role of metabolic reprogramming in cell fate decisions.
C1 [Menendez, Javier A.] Catalan Inst Oncol, Metab & Canc Grp, Translat Res Lab, Girona, Spain.
   [Menendez, Javier A.] Girona Biomed Res Inst IDIBGI, Mol Oncol Grp, Girona, Spain.
   [Alarcon, Tomas] CRM, Computat & Math Biol Res Grp, Barcelona, Spain.
   [Joven, Jorge] Univ Rovira & Virgili, IISPV, Unitat Recerca Biomed URB CRB, E-43201 Reus, Spain.
C3 Institut Catala d'Oncologia; Universitat de Girona; Girona University
   Hospital Dr. Josep Trueta; Institut d'Investigacio Biomedica de Girona
   (IDIBGI); Centre de Recerca Matematica (CRM); Universitat Rovira i
   Virgili; Institut d'Investigacio Sanitaria Pere Virgili (IISPV)
RP Menendez, JA (通讯作者)，Catalan Inst Oncol, Metab & Canc Grp, Translat Res Lab, Girona, Spain.
EM jmenendez@iconcologia.net
RI MENENDEZ MENENDEZ, JAVIER ABEL/C-6148-2016; Alarcon, Tomas/D-9083-2013;
   Joven, Jorge/B-3360-2016
OI MENENDEZ MENENDEZ, JAVIER ABEL/0000-0001-8733-4561; Alarcon,
   Tomas/0000-0002-8566-3676; Joven, Jorge/0000-0003-2749-4541
FU Ministerio de Ciencia e Innovacion, Plan Nacional de I+D+I, MICINN,
   Spain [SAF2012-38914]
FX This work was financially supported by the Ministerio de Ciencia e
   Innovacion (SAF2012-38914), Plan Nacional de I+D+I, MICINN, Spain.
CR Adam J, 2014, ONCOGENE, V33, P2547, DOI 10.1038/onc.2013.222
   Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003
   Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200
   Blagosklonny MV, 2013, CELL CYCLE, V12, P3736, DOI 10.4161/cc.27188
   Blagosklonny MV, 2013, AGING-US, V5, P592, DOI 10.18632/aging.100591
   Blagosklonny MV, 2013, CELL CYCLE, V12, P1842, DOI 10.4161/cc.25062
   Blagosklonny MV, 2013, AGING-US, V5, P227, DOI 10.18632/aging.100551
   Blagosklonny MV, 2012, ONCOTARGET, V3, P1711, DOI 10.18632/oncotarget.890
   Blagosklonny MV, 2013, AUTOPHAGY, V9, P260, DOI 10.4161/auto.22783
   Blagosklonny MV, 2012, CANCER BIOL THER, V13, P1349, DOI 10.4161/cbt.22859
   Blagosklonny MV, 2012, AM J PATHOL, V181, P1142, DOI 10.1016/j.ajpath.2012.06.024
   Blagosklonny MV, 2012, AGING-US, V4, P350, DOI 10.18632/aging.100461
   Blagosklonny MV, 2012, AGING-US, V4, P159, DOI 10.18632/aging.100443
   Blagosklonny MV, 2011, ONCOTARGET, V2, P1352
   Blagosklonny MV, 2011, AGING-US, V3, P1130, DOI 10.18632/aging.100422
   Blagosklonny MV, 2011, AGING-US, V3, P1051, DOI 10.18632/aging.100411
   Borodovsky A, 2013, ONCOTARGET, V4, P1737, DOI 10.18632/oncotarget.1408
   Boulahbel H, 2009, BIOCHEM SOC T, V37, P291, DOI 10.1042/BST0370291
   Brière JJ, 2006, AM J PHYSIOL-CELL PH, V291, pC1114, DOI 10.1152/ajpcell.00216.2006
   Brière JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359
   Cairns RA, 2013, CANCER DISCOV, V3, P730, DOI 10.1158/2159-8290.CD-13-0083
   Cantó C, 2010, CELL METAB, V11, P213, DOI 10.1016/j.cmet.2010.02.006
   Cantó C, 2009, NATURE, V458, P1056, DOI 10.1038/nature07813
   Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345
   Carabelli J, 2011, J CELL MOL MED, V15, P1329, DOI 10.1111/j.1582-4934.2010.01128.x
   Caton PW, 2011, DIABETES OBES METAB, V13, P1097, DOI 10.1111/j.1463-1326.2011.01466.x
   Chalkiadaki A, 2012, NAT REV ENDOCRINOL, V8, P287, DOI 10.1038/nrendo.2011.225
   Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43
   Dahia PLM, 2006, ANN NY ACAD SCI, V1073, P208, DOI 10.1196/annals.1353.023
   Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008
   Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274
   Demidenko ZN, 2011, CELL CYCLE, V10, P1557, DOI 10.4161/cc.10.10.15789
   Ece H, 2012, ASIAN PAC J CANCER P, V13, P5143, DOI 10.7314/APJCP.2012.13.10.5143
   Fang IM, 2013, EXP EYE RES, V113, P49, DOI 10.1016/j.exer.2013.05.007
   Favier J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007094
   Folmes CDL, 2013, J CARDIOVASC TRANSL, V6, P10, DOI 10.1007/s12265-012-9431-2
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002
   Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4
   Galluzzi L, 2013, NAT REV DRUG DISCOV, V12, P829, DOI 10.1038/nrd4145
   Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413
   Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037
   Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125
   Haase VH, 2009, CURR PHARM DESIGN, V15, P3895, DOI 10.2174/138161209789649394
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Harada H, 2009, J BIOL CHEM, V284, P5332, DOI 10.1074/jbc.M806653200
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Herold S, 2009, NAT REV CANCER, V9, P441, DOI 10.1038/nrc2640
   Hewitson KS, 2007, J BIOL CHEM, V282, P3293, DOI 10.1074/jbc.M608337200
   Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293
   Iglesias-Bartolome R, 2012, ONCOTARGET, V3, P1061
   Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509
   Khacho M, 2009, FUTURE ONCOL, V5, P85, DOI 10.2217/14796694.5.1.85
   Kim J, 2013, SCIENCE, V340, P558, DOI 10.1126/science.1238523
   Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898
   Krell D, 2013, FUTURE ONCOL, V9, P1923, DOI [10.2217/fon.13.143, 10.2217/FON.13.143]
   Krishnan J, 2012, GENE DEV, V26, P259, DOI 10.1101/gad.180406.111
   Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Lawlor ER, 2006, CANCER RES, V66, P4591, DOI 10.1158/0008-5472.CAN-05-3826
   Leontieva OV, 2012, AGING-US, V4, P899, DOI 10.18632/aging.100528
   Leontieva OV, 2012, CELL CYCLE, V11, P3926, DOI 10.4161/cc.21908
   Leontieva OV, 2012, P NATL ACAD SCI USA, V109, P13314, DOI 10.1073/pnas.1205690109
   Letouzé E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018
   Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005
   Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010
   Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677
   MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06
   Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006
   Mendelsohn AR, 2014, REJUV RES, V17, P62, DOI 10.1089/rej.2014.1546
   Menendez JA, 2013, CELL CYCLE, V12, P1166, DOI 10.4161/cc.24479
   Menendez JA, 2013, CELL CYCLE, V12, P555, DOI 10.4161/cc.23756
   Menssen A, 2012, ONCOTARGET, V3, P112, DOI 10.18632/oncotarget.440
   Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109
   Merksamer PI, 2013, AGING-US, V5, P144, DOI 10.18632/aging.100544
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Mullen AR, 2012, TRENDS ENDOCRIN MET, V23, P552, DOI 10.1016/j.tem.2012.06.009
   Nyengaard JR, 2004, DIABETES, V53, P2931, DOI 10.2337/diabetes.53.11.2931
   Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393
   Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904
   Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234
   Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003
   Ptitsyn A, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-318
   Raimundo N, 2011, TRENDS MOL MED, V17, P641, DOI 10.1016/j.molmed.2011.06.001
   Rohle D, 2013, SCIENCE, V340, P626, DOI 10.1126/science.1236062
   Savino M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022284
   Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022
   Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666
   Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230
   Sodir NM, 2011, GENE DEV, V25, P907, DOI 10.1101/gad.2038411
   Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443
   Soucek L, 2002, CANCER RES, V62, P3507
   Soucek L, 2002, CANCER CELL, V1, P406, DOI 10.1016/S1535-6108(02)00077-6
   Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260
   Soucek L, 2013, GENE DEV, V27, P504, DOI 10.1101/gad.205542.112
   Soucek L, 2010, CURR OPIN GENET DEV, V20, P91, DOI 10.1016/j.gde.2009.11.001
   Sudhagar S, 2011, BRIT J CANCER, V105, P953, DOI 10.1038/bjc.2011.349
   Sullivan LB, 2013, MOL CELL, V51, P236, DOI 10.1016/j.molcel.2013.05.003
   Takiyama Y, 2011, DIABETES, V60, P981, DOI 10.2337/db10-0655
   Terunuma A, 2014, J CLIN INVEST, V124, P398, DOI 10.1172/JCI71180
   Treins C, 2006, BIOCHEM BIOPH RES CO, V342, P1197, DOI 10.1016/j.bbrc.2006.02.088
   Treins C, 2005, MOL ENDOCRINOL, V19, P1304, DOI 10.1210/me.2004-0239
   Turcan S, 2013, ONCOTARGET, V4, P1729, DOI 10.18632/oncotarget.1412
   van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819
   Wang F, 2013, SCIENCE, V340, P622, DOI 10.1126/science.1234769
   Wang Y, 2011, FEBS LETT, V585, P986, DOI 10.1016/j.febslet.2010.11.047
   Ward PS, 2012, ONCOGENE, V31, P2491, DOI 10.1038/onc.2011.416
   Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014
   Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020
   Watson J, 2013, OPEN BIOL, V3, DOI 10.1098/rsob.120144
   Webster BR, 2012, FREE RADICAL BIO MED, V52, P281, DOI 10.1016/j.freeradbiomed.2011.10.484
   Whitfield JR, 2012, CELL MOL LIFE SCI, V69, P931, DOI 10.1007/s00018-011-0860-x
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108
   Woo DK, 2012, AM J PATHOL, V180, P24, DOI 10.1016/j.ajpath.2011.10.003
   Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789
   Wu LE, 2014, CANCER CELL, V25, P12, DOI 10.1016/j.ccr.2013.12.005
   Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014
   Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035
   Yang M, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00085
   Yang M, 2013, J CLIN INVEST, V123, P3652, DOI 10.1172/JCI67228
   Yang M, 2013, CANCER CELL, V23, P709, DOI 10.1016/j.ccr.2013.05.015
   Yuan G, 2008, J CELL PHYSIOL, V217, P674, DOI 10.1002/jcp.21537
   Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167
   Zheng Z, 2012, DIABETES, V61, P217, DOI 10.2337/db11-0416
   Zhong L, 2011, CELL METAB, V13, P621, DOI 10.1016/j.cmet.2011.05.004
NR 125
TC 30
Z9 37
U1 0
U2 16
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4101
EI 1551-4005
J9 CELL CYCLE
JI Cell Cycle
PD MAR 1
PY 2014
VL 13
IS 5
BP 699
EP 709
DI 10.4161/cc.28079
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AE3UQ
UT WOS:000333904200012
PM 24526120
OA Green Published, Bronze
DA 2025-01-12
ER

PT J
AU Cao, J
   Liu, ZZ
   Cheung, WKC
   Zhao, MH
   Chen, SY
   Chan, SW
   Booth, CJ
   Nguyen, DX
   Yan, Q
AF Cao, Jian
   Liu, Zongzhi
   Cheung, William K. C.
   Zhao, Minghui
   Chen, Sophia Y.
   Chan, Siew Wee
   Booth, Carmen J.
   Nguyen, Don X.
   Yan, Qin
TI Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and
   Metastasis
SO CELL REPORTS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; TENASCIN-C; BINDING; GENES;
   EXPRESSION; EZH2; PHOSPHORYLATION; DISSEMINATION; TUMORIGENESIS;
   REPRESSION
AB Metastasis is a major clinical challenge for cancer treatment. Emerging evidence suggests that aberrant epigenetic modifications contribute significantly to tumor formation and progression. However, the drivers and roles of such epigenetic changes in tumor metastasis are still poorly understood. Using bioinformatic analysis of human breast cancer gene-expression data sets, we identified histone demethylase RBP2 as a putative mediator of metastatic progression. By using both human breast cancer cells and genetically engineered mice, we demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple in vivo models. Mechanistically, RBP2 promotes metastasis as a pleiotropic positive regulator of many metastasis genes, including TNC. In addition, RBP2 loss suppresses tumor formation in MMTV-neu transgenic mice. These results suggest that therapeutic targeting of RBP2 is a potential strategy for inhibition of tumor progression and metastasis.
C1 [Cao, Jian; Liu, Zongzhi; Cheung, William K. C.; Zhao, Minghui; Chen, Sophia Y.; Nguyen, Don X.; Yan, Qin] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
   [Chan, Siew Wee] Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, Singapore 138673, Singapore.
   [Booth, Carmen J.] Yale Univ, Sch Med, Comparat Med Sect, New Haven, CT 06520 USA.
C3 Yale University; Agency for Science Technology & Research (A*STAR);
   A*STAR - Institute of Molecular & Cell Biology (IMCB); Yale University
RP Yan, Q (通讯作者)，Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA.
EM qin.yan@yale.edu
RI Cao, Jian/K-2440-2014; Liu, Zongzhi/AAE-1856-2022; Yan, Qin/E-8893-2012
OI Yan, Qin/0000-0003-4077-453X; Cao, Jian/0000-0003-3424-6802;
   /0000-0001-6772-8483
FU Alexander and Margaret Stewart Trust Fellowship; Connecticut Department
   of Public Health Biomedical Research [2013-0201]; American Cancer
   Society Research Scholar Grant [RSG-13-384-01-DMC]; NIH [R01CA166376,
   P30CA16359]
FX We thank members of the Nguyen, Stern, Wajapeyee, and Yan laboratories
   for their kind help and valuable discussions. We thank Dr. Joan Massague
   for providing MDA-MB-231, LM2, 1833, 67NR and 4T1 cells; Dr. Yibin Kang
   for providing 168FARN, 4TO7, and 66cl4 cells; Drs. Lee Cheng-Feng and
   Li-Jung Juan for sharing RBP2 shRNA constructs; Dr. Wanjin Hong for
   sharing the VSVG-RBP2 constructs; Dr. Narendra Wajapeyee for providing
   anti-IGFBP7 antibody; and Dr. Tian Xu for sharing his equipment. This
   work was supported by the Alexander and Margaret Stewart Trust
   Fellowship (to Q.Y.), Connecticut Department of Public Health Biomedical
   Research grant 2013-0201 (to Q.Y.), American Cancer Society Research
   Scholar Grant RSG-13-384-01-DMC (to Q.Y.), NIH grants R01CA166376 (to
   D.X.N.) and P30CA16359 (to the Yale Comprehensive Cancer Center).
CR ASLAKSON CJ, 1992, CANCER RES, V52, P1399
   Benevolenskaya EV, 2005, MOL CELL, V18, P623, DOI 10.1016/j.molcel.2005.05.012
   Beshiri ML, 2012, P NATL ACAD SCI USA, V109, P18499, DOI 10.1073/pnas.1216724109
   Blair LP, 2012, DNA CELL BIOL, V31, pS49, DOI 10.1089/dna.2012.1654
   Blair Lauren P, 2011, Cancers (Basel), V3, P1383, DOI 10.3390/cancers3011383
   Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021
   Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009
   Cao J, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004188
   Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154
   Chan SW, 2001, J BIOL CHEM, V276, P28402, DOI 10.1074/jbc.M100313200
   Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009
   Christensen J, 2007, CELL, V128, P1063, DOI 10.1016/j.cell.2007.02.003
   DEFEOJONES D, 1991, NATURE, V352, P251, DOI 10.1038/352251a0
   DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134
   GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578
   Györffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9
   Hancox RA, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2251
   Hou JL, 2012, AM J TRANSL RES, V4, P247
   Iwase S, 2007, CELL, V128, P1077, DOI 10.1016/j.cell.2007.02.017
   Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6
   KIM YW, 1994, MOL CELL BIOL, V14, P7256, DOI 10.1128/MCB.14.11.7256
   Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100
   Klose RJ, 2007, CELL, V128, P889, DOI 10.1016/j.cell.2007.02.013
   Lee MG, 2007, CELL, V128, P877, DOI 10.1016/j.cell.2007.02.004
   Li L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001221
   Lin WC, 2011, P NATL ACAD SCI USA, V108, P13379, DOI 10.1073/pnas.1110104108
   Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002
   Luo WB, 2012, P NATL ACAD SCI USA, V109, pE3367, DOI 10.1073/pnas.1217394109
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799
   Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104
   Moore HM, 2013, BREAST CANCER RES TR, V138, P741, DOI 10.1007/s10549-013-2498-x
   Nagaharu K, 2011, AM J PATHOL, V178, P754, DOI 10.1016/j.ajpath.2010.10.015
   Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101
   Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Paolicchi E, 2013, CRIT REV ONCOL HEMAT, V86, P97, DOI 10.1016/j.critrevonc.2012.11.008
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Sayegh J, 2013, J BIOL CHEM, V288, P9408, DOI 10.1074/jbc.M112.419861
   Secombe J, 2007, GENE DEV, V21, P537, DOI 10.1101/gad.1523007
   Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tahiliani M, 2007, NATURE, V447, P601, DOI 10.1038/nature05823
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Teng YC, 2013, CANCER RES, V73, P4711, DOI 10.1158/0008-5472.CAN-12-3165
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Tu SJ, 2008, NAT STRUCT MOL BIOL, V15, P419, DOI 10.1038/nsmb.1400
   Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075
   Wang GG, 2009, NATURE, V459, P847, DOI 10.1038/nature08036
   Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050
   Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1
   Yamane K, 2007, MOL CELL, V25, P801, DOI 10.1016/j.molcel.2007.03.001
   Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010
   Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004
NR 58
TC 88
Z9 101
U1 0
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD MAR
PY 2014
VL 6
IS 5
BP 868
EP 877
DI 10.1016/j.celrep.2014.02.004
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA AD2BL
UT WOS:000333037800011
PM 24582965
OA Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Wang, SH
   Li, N
   Wei, Y
   Li, QR
   Yu, ZP
AF Wang, Shao-Hua
   Li, Ning
   Wei, Yao
   Li, Qiu-Rong
   Yu, Ze-Ping
TI ∼- catenin deacetylation is essential for WNT-induced proliferation of
   breast cancer cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE WNT; acetylation; -catenin; P300; breast cancer
ID BETA-CATENIN; NEGATIVE REGULATOR; SIGNALING PATHWAY; ACETYLATION;
   PHOSPHORYLATION; INTERFERON; ACTIVATION; PROTEIN; TARGET; GROWTH
AB Deregulation of the WNT signaling pathway is associated with the development and progression of breast cancer. -catenin mutations have been found to constitutively activate -catenin-T-cell factor (TCF) signaling in other types of cancer. -catenin acetylation regulates -catenin-TCF4 interaction in WNT signaling, but it remains unknown whether the acetylation of -catenin is involved in WNT-induced proliferation of breast cancer cells. In this study, a lower level of acetylated -catenin (K345) was observed in breast cancer tissues. WNT3A stimulated the downregulation of -catenin acetylation and promoted the proliferation of MCF7 cells. The K345Q mutation in -catenin inhibited WNT-induced cell growth and axin2/TCF7 upregulation in breast cancer cells. By contrast, K345R mutants could mimic deacetylated -catenin to generate the WNT-elicited phenotype. Additionally, the acetylation of -catenin may prime -catenin for phosphorylation. Further investigation revealed that the deacetylase HDAC6 was responsible for WNT-induced deacetylation of -catenin in breast cancer cells. In conclusion, the epigenetic modification of -catenin may be essential for WNT signaling in breast cancer progression, and blocking the occurrence of -catenin acetylation may provide a novel therapeutic approach for breast cancer.
C1 [Wang, Shao-Hua; Li, Ning; Wei, Yao; Li, Qiu-Rong; Yu, Ze-Ping] Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, Nanjing 210002, Jiangsu, Peoples R China.
C3 Nanjing University
RP Li, N (通讯作者)，Nanjing Univ, Sch Med, Jinling Hosp, Dept Gen Surg, 305 East Zhongshan Rd, Nanjing 210002, Jiangsu, Peoples R China.
EM lining1106pubsci@163.com
OI Wang, Shaohua/0000-0003-2981-1416
CR Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032
   Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531
   Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561
   Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371
   JEMAL A, 2011, CA-CANCER J CLIN, V61, P69, DOI DOI 10.3322/CAAC.20107
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002
   Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401
   Lévy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004
   Li Y, 2008, J BIOL CHEM, V283, P12686, DOI 10.1074/jbc.C700185200
   Lin YY, 2012, NATURE, V482, P251, DOI 10.1038/nature10804
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Matsuda Y, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2317
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Takahashi-Yanaga F, 2007, J PHARMACOL SCI, V104, P293, DOI 10.1254/jphs.CR0070024
   van Amerongen R, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.135re9
   van de Wetering M, 2001, CANCER RES, V61, P278
   von Kries JP, 2000, NAT STRUCT BIOL, V7, P800
   Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200
   Yang PY, 2010, NAT IMMUNOL, V11, P487, DOI 10.1038/ni.1876
   Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443
   Zhu JZ, 2011, EMBO J, V30, P4838, DOI 10.1038/emboj.2011.351
NR 28
TC 39
Z9 41
U1 0
U2 9
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD MAR
PY 2014
VL 9
IS 3
BP 973
EP 978
DI 10.3892/mmr.2014.1889
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA AC7HO
UT WOS:000332699000032
PM 24401947
OA Bronze
DA 2025-01-12
ER

PT J
AU Parris, TZ
   Kovács, A
   Hajizadeh, S
   Nemes, S
   Semaan, M
   Levin, M
   Karlsson, P
   Helou, K
AF Parris, T. Z.
   Kovacs, A.
   Hajizadeh, S.
   Nemes, S.
   Semaan, M.
   Levin, M.
   Karlsson, P.
   Helou, K.
TI Frequent <i>MYC</i> coamplification and DNA hypomethylation of multiple
   genes on 8q in 8p11-p12-amplified breast carcinomas
SO ONCOGENESIS
LA English
DT Article
DE breast cancer; DNA amplification; DNA methylation; 8p11-p12; MYC
ID COMPARATIVE-GENOMIC-HYBRIDIZATION; TRANSCRIPTION FACTOR; THERAPEUTIC
   TARGET; 8P11-12 AMPLICON; AMPLIFIED GENES; FUSION GENES; CANCER;
   EXPRESSION; METHYLATION; AMPLIFICATION
AB Genetic and epigenetic (DNA methylation, histone modifications, microRNA expression) crosstalk promotes inactivation of tumor suppressor genes or activation of oncogenes by gene loss/hypermethylation or duplications/hypomethylation, respectively. The 8p11-p12 chromosomal region is a hotspot for genomic aberrations (chromosomal rearrangements, amplifications and deletions) in several cancer forms, including breast carcinoma where amplification has been associated with increased proliferation rates and reduced patient survival. Here, an integrative genomics screen (DNA copy number, transcriptional and DNA methylation profiling) performed in 229 primary invasive breast carcinomas identified substantial coamplification of the 8p11-p12 genomic region and the MYC oncogene (8q24.21), as well as aberrant methylation and transcriptional patterns for several genes spanning the 8q12.1-q24.22 genomic region (ENPP2, FABP5, IMPAD1, NDRG1, PLEKHF2, RRM2B, SQLE, TAF2, TATDN1, TRPS1, VPS13B). Taken together, our findings suggest that MYC activity and aberrant DNA methylation may also have a pivotal role in the aggressive tumor phenotype frequently observed in breast carcinomas harboring 8p11-p12 regional amplification.
C1 [Parris, T. Z.; Semaan, M.; Levin, M.; Karlsson, P.; Helou, K.] Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Canc Ctr, Dept Oncol,Inst Clin Sci, S-41390 Gothenburg, Sweden.
   [Kovacs, A.; Hajizadeh, S.] Sahlgrens Univ Hosp, Dept Clin Pathol & Cytol, Gothenburg, Sweden.
   [Nemes, S.] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Div Clin Canc Epidemiol,Dept Oncol, S-41390 Gothenburg, Sweden.
   [Nemes, S.] Sahlgrens Univ Hosp, Western Sweden Hlth Care Reg, Reg Canc Ctr West, Dept Oncol, Gothenburg, Sweden.
C3 University of Gothenburg; Sahlgrenska University Hospital; University of
   Gothenburg; Sahlgrenska University Hospital
RP Parris, TZ (通讯作者)，Univ Gothenburg, Sahlgrenska Acad, Sahlgrenska Canc Ctr, Dept Oncol,Inst Clin Sci, Medicinaregatan 1G,6th Floor, S-41390 Gothenburg, Sweden.
EM toshima.parris@oncology.gu.se
RI Nemes, Szilard/I-3924-2012; Parris, Toshima/Q-5427-2018
OI Karlsson, Per/0000-0003-4841-2672; Nemes, Szilard/0000-0002-4145-1786
FU Swedish Cancer Society; King Gustav V Jubilee Clinic Cancer Research
   Foundation; Wilhelm and Martina Lundgren Research Foundation; Serena
   Ehrenstrom Foundation for Cancer Research/Torsten and Sara Jansson
   Research Foundation; Assar Gabrielsson Research Foundation for Clinical
   Cancer Research; Lars Hierta's Memorial Research Foundation
FX This work was supported by grants from the Swedish Cancer Society (KH),
   King Gustav V Jubilee Clinic Cancer Research Foundation (KH), the
   Wilhelm and Martina Lundgren Research Foundation (TZP), Serena
   Ehrenstrom Foundation for Cancer Research/Torsten and Sara Jansson
   Research Foundation (TZP), Assar Gabrielsson Research Foundation for
   Clinical Cancer Research (TZP) and Lars Hierta's Memorial Research
   Foundation (TZP).
CR Adelaide J, 1998, GENE CHROMOSOME CANC, V22, P186, DOI 10.1002/(SICI)1098-2264(199807)22:3<186::AID-GCC4>3.0.CO;2-S
   An CH, 2012, HUM PATHOL, V43, P40, DOI 10.1016/j.humpath.2010.03.015
   Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465
   Baylin Stephen B, 2012, Proc Am Thorac Soc, V9, P64, DOI 10.1513/pats.201201-001MS
   Bernard-Pierrot I, 2008, CANCER RES, V68, P7165, DOI 10.1158/0008-5472.CAN-08-1360
   Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102
   Boelens MC, 2009, LUNG CANCER, V66, P372, DOI 10.1016/j.lungcan.2009.02.017
   Carson C, 2012, PIGM CELL MELANOMA R, V25, P514, DOI 10.1111/j.1755-148X.2012.01010.x
   Chang GTG, 2004, ENDOCR-RELAT CANCER, V11, P815, DOI 10.1677/erc.1.00853
   Chen Jie Qing, 2011, Hormones & Cancer, V2, P132, DOI 10.1007/s12672-011-0067-5
   Chin SF, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r215
   Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285
   Edgren H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r6
   Esteller M, 2005, ANNU REV PHARMACOL, V45, P629, DOI 10.1146/annurev.pharmtox.45.120403.095832
   Fotovati A, 2011, PATHOL ONCOL RES, V17, P525, DOI 10.1007/s12253-010-9342-y
   Fuks F, 2005, CURR OPIN GENET DEV, V15, P490, DOI 10.1016/j.gde.2005.08.002
   Gal-Yam EN, 2008, ANNU REV MED, V59, P267, DOI 10.1146/annurev.med.59.061606.095816
   Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128
   Gökmen-Polar Y, 2012, BREAST CANCER RES TR, V136, P673, DOI 10.1007/s10549-012-2298-8
   Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304
   Han LL, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-52
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Heard E, 2006, GENE DEV, V20, P1848, DOI 10.1101/gad.1422906
   Helms MW, 2008, BRIT J CANCER, V99, P774, DOI 10.1038/sj.bjc.6604556
   Helou K, 1999, ONCOGENE, V18, P3226, DOI 10.1038/sj.onc.1202658
   Holland DG, 2011, EMBO MOL MED, V3, P167, DOI 10.1002/emmm.201100122
   Hu ZY, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-96
   Huang Y, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2925
   Knuutila S, 1998, AM J PATHOL, V152, P1107
   Kuo ML, 2012, SCI REP-UK, V2, DOI 10.1038/srep00822
   Kwek SS, 2009, ONCOGENE, V28, P1892, DOI 10.1038/onc.2009.34
   Loi S, 2007, J CLIN ONCOL, V25, P1239, DOI 10.1200/JCO.2006.07.1522
   Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504
   Mahmood SF, 2013, AM J PATHOL, V183, P1634, DOI 10.1016/j.ajpath.2013.07.028
   Malkowska M, 2013, BIOCHIMIE, V95, P680, DOI 10.1016/j.biochi.2012.10.024
   Mao XY, 2011, TUMOR BIOL, V32, P1271, DOI 10.1007/s13277-011-0232-z
   Möllerström E, 2010, CANCER GENET CYTOGEN, V198, P79, DOI 10.1016/j.cancergencyto.2009.12.012
   Nagai MA, 2011, BREAST CANCER RES TR, V126, P1, DOI 10.1007/s10549-010-0867-2
   Parris TZ, 2010, CLIN CANCER RES, V16, P3860, DOI 10.1158/1078-0432.CCR-10-0889
   Paterson AL, 2007, GENE CHROMOSOME CANC, V46, P427, DOI 10.1002/gcc.20424
   Roque L, 2004, CANCER GENET CYTOGEN, V149, P58, DOI 10.1016/S0165-4608(03)00284-X
   Schulte I, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-719
   Simon R, 2001, CANCER RES, V61, P4514
   Sircoulomb F, 2011, EMBO MOL MED, V3, P153, DOI 10.1002/emmm.201100121
   Sircoulomb F, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-539
   Sommer EM, 2013, BIOCHEM J, V452, P499, DOI 10.1042/BJ20130342
   Sotiriou C, 2006, JNCI-J NATL CANCER I, V98, P262, DOI 10.1093/jnci/djj052
   THEILLET C, 1993, GENE CHROMOSOME CANC, V7, P219, DOI 10.1002/gcc.2870070407
   Thor AD, 2002, HUM PATHOL, V33, P628, DOI 10.1053/hupa.2002.124034
   Thurn KT, 2013, MOL CANCER THER, V12, P2078, DOI 10.1158/1535-7163.MCT-12-1242
   Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102
   Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746
   Wang D, 2012, BIOINFORMATICS, V28, P729, DOI 10.1093/bioinformatics/bts013
   Williams SV, 2010, GENE CHROMOSOME CANC, V49, P642, DOI 10.1002/gcc.20775
   Yang ZQ, 2006, CANCER RES, V66, P11632, DOI 10.1158/0008-5472.CAN-06-2946
   Yang ZQ, 2010, CANCER RES, V70, P8487, DOI 10.1158/0008-5472.CAN-10-1013
   Zhang X, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072053
NR 57
TC 57
Z9 65
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD MAR
PY 2014
VL 3
AR e95
DI 10.1038/oncsis.2014.8
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AZ8CY
UT WOS:000348443600006
PM 24662924
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Chen, RP
   Zhuge, XJ
   Huang, ZM
   Lu, DY
   Ye, XH
   Chen, C
   Yu, JY
   Lu, GR
AF Chen, Renpin
   Zhuge, Xiaoju
   Huang, Zhiming
   Lu, Deyi
   Ye, Xiaohua
   Chen, Chao
   Yu, Jieyu
   Lu, Guangrong
TI Analysis of SEMA3B methylation and expression patterns in gastric cancer
   tissue and cell lines
SO ONCOLOGY REPORTS
LA English
DT Article
DE SEMA3B; gastric cancer; 5-Aza-2-deoxycytidine; DNA methylation
ID FREQUENT EPIGENETIC INACTIVATION; SEMAPHORIN 3B; LUNG-CANCER; SECRETED
   SEMAPHORINS; CHROMOSOME 3P21.3; BREAST-CANCER; AXON GUIDANCE; REGION;
   HYPERMETHYLATION; IDENTIFICATION
AB The family of semaphorins has been demonstrated to possess tumor suppressor activity, in which semaphorin 3B (SEMA3B) is differentially expressed in several types of tumors. The relationship between SEMA3B expression and its clinical significance in gastric cancer (GC) is currently unclear. In the present study, the expression and methylation status of the SEMA3B gene were detected by quantitative PCR and bisulfite sequencing PCR (BSP). Data indicated that the levels of SEMA3B mRNA decreased in gastric tumor tissues and the methylation status of SEMA3B in the tumor group was higher than the paired normal tissues. By BSP, the SEMA3B gene showed high methylated status which was detected in all 4 cell lines (AGS, BGC-823, MGC-803 and SGC-7901). Treatment of the cells with 5-Aza-2-deoxycytidine revealed clearly elevated mRNA levels of SEMA3B. These results were further confirmed by western blot analysis of Sema3b protein expression. At the same time, increased expression of p53 mRNA in BGC-823, MGC-803 was detected and indicated that p53 may be involved in the regulation of SEMA3B expression in specific genetic background. Downregulation of SEMA3B was negatively correlated with tumor size and N staging in GC (P<0.05). In conclusion, CpG methylation of SEMA3B epigenetically regulates SEMA3B expression during development of GC. Furthermore, 5-Aza-2-deoxycytidine could reverse the hypermethylation status of SEMA3B, which may benefit future studies exploring the application of demethylating agents in clinical usage of GC.
C1 [Chen, Renpin; Zhuge, Xiaoju; Huang, Zhiming; Lu, Deyi; Chen, Chao; Yu, Jieyu] Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Wenzhou 325035, Zhejiang, Peoples R China.
   [Ye, Xiaohua] Jinhua Municipal Cent Hosp, Dept Gastroenterol, Jinhua 321000, Zhejiang, Peoples R China.
   [Lu, Guangrong] Wenzhou Med Univ, Affiliated Hosp 2, Dept Gastroenterol & Hepatol, Wenzhou 325000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University; Wenzhou Medical University
RP Huang, ZM (通讯作者)，Wenzhou Med Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Wenzhou 325035, Zhejiang, Peoples R China.
EM wzhzm123@gmail.com
CR Bernal C, 2008, CLIN CANCER RES, V14, P6264, DOI 10.1158/1078-0432.CCR-07-4522
   Bernal C, 2008, BIOL RES, V41, P303, DOI /S0716-97602008000300007
   Castro-Rivera E, 2004, P NATL ACAD SCI USA, V101, P11432, DOI 10.1073/pnas.0403969101
   Castro-Rivera E, 2008, CANCER RES, V68, P8295, DOI 10.1158/0008-5472.CAN-07-6601
   Chilton JK, 2003, DEV DYNAM, V228, P726, DOI 10.1002/dvdy.10396
   Falk J, 2005, NEURON, V48, P63, DOI 10.1016/j.neuron.2005.08.033
   Giger RJ, 2000, NEURON, V25, P29, DOI 10.1016/S0896-6273(00)80869-7
   Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P29922
   Haiko P, 2008, MOL CELL BIOL, V28, P4843, DOI 10.1128/MCB.02214-07
   Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407
   Koyama N, 2008, ONCOGENE, V27, P6581, DOI 10.1038/onc.2008.263
   Kuroki T, 2003, CANCER RES, V63, P3352
   Li K, 2013, NEOPLASMA, V60, P683, DOI 10.4149/neo_2013_087
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Nawabi H, 2010, GENE DEV, V24, P396, DOI 10.1101/gad.542510
   Ochi K, 2002, NEOPLASIA, V4, P82, DOI 10.1038/sj.neo.7900211
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pronina I V, 2009, Mol Biol (Mosk), V43, P439
   Riquelme E, 2007, CANCER LETT, V250, P100, DOI 10.1016/j.canlet.2006.09.019
   Rivera F, 2007, CANCER TREAT REV, V33, P315, DOI 10.1016/j.ctrv.2007.01.004
   Rolny C, 2008, J EXP MED, V205, P1155, DOI 10.1084/jem.20072509
   Sekido Y, 1996, P NATL ACAD SCI USA, V93, P4120, DOI 10.1073/pnas.93.9.4120
   Soker S, 2002, J CELL BIOCHEM, V85, P357, DOI 10.1002/jcb.10140
   Tamagnone L, 2004, EMBO REP, V5, P356, DOI 10.1038/sj.embor.7400114
   Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944
   Tomizawa Y, 2001, P NATL ACAD SCI USA, V98, P13954, DOI 10.1073/pnas.231490898
   Tse C, 2002, CANCER RES, V62, P542
   Vailaya A, 2005, BIOINFORMATICS, V21, P430, DOI 10.1093/bioinformatics/bti187
   Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408
   Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211
   Zhou XP, 2012, ONCOL REP, V28, P269, DOI 10.3892/or.2012.1796
NR 32
TC 19
Z9 21
U1 0
U2 6
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD MAR
PY 2014
VL 31
IS 3
BP 1211
EP 1218
DI 10.3892/or.2014.2972
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AC7FR
UT WOS:000332693700025
PM 24402303
OA Bronze
DA 2025-01-12
ER

PT J
AU Brglez, V
   Pucer, A
   Pungercar, J
   Lambeau, G
   Petan, T
AF Brglez, Vesna
   Pucer, Anja
   Pungercar, Joze
   Lambeau, Gerard
   Petan, Toni
TI Secreted phospholipases A<sub>2</sub> are differentially expressed and
   epigenetically silenced in human breast cancer cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE DNA methylation; Epigenetics; Histone acetylation; Secreted
   phospholipase A(2); Lipid signalling; Breast cancer
ID EMERGING ROLES; METASTASIS; COLLECTION; PATHWAYS; ENZYMES; PLA2G2A;
   TARGET; LINES
AB Secreted phospholipases A(2) (sPLA(2)s) have recently been associated with several cancers, but their role in breast cancer is unknown. Here we demonstrate that mRNA expression of group IIA, III and X sPLA(2)s differs both in vivo in tumour biopsies and in breast cancer cells in vitro. Their expression is differentially regulated by DNA methylation and histone acetylation and, significantly, all three genes are silenced in aggressive triple negative cells due to both mechanisms. The transcription start site promoter region and the upstream CpG islands, exclusive to the group X sPLA(2) gene, have variable roles in the regulation of sPLA(2) expression. Our results suggest that the differential expression of hGIIA, hGIII and hGX sPLA(2)s in breast cancer cells is a consequence of various degrees of epigenetic silencing due to DNA hypermethylation and histone deacetylation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Brglez, Vesna; Pucer, Anja; Pungercar, Joze; Petan, Toni] Jozef Stefan Inst, Dept Mol & Biomed Sci, SI-1000 Ljubljana, Slovenia.
   [Lambeau, Gerard] CNRS, Inst Pharmacol Mol & Cellulaire, Valbonne, France.
   [Lambeau, Gerard] Univ Nice Sophia Antipolis, UMR 6097, Valbonne, France.
C3 Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute;
   Centre National de la Recherche Scientifique (CNRS); Universite Cote
   d'Azur; Universite Cote d'Azur
RP Petan, T (通讯作者)，Jozef Stefan Inst, Dept Mol & Biomed Sci, Jamova Cesta 39, SI-1000 Ljubljana, Slovenia.
EM toni.petan@ijs.si
RI Petan, Toni/ABA-2506-2021; Lambeau, Gerard/GRJ-5624-2022; Brglez,
   Vesna/L-1382-2015
OI Petan, Toni/0000-0003-1223-2397; Lambeau, Gerard/0000-0002-9239-518X;
   Brglez, Vesna/0000-0002-3357-5017
FU Slovenian Research Agency [P1-0207]; French-Slovene partnership project
   [BI-FR/12-13-PROTEUS-006]; CNRS; Association for International Cancer
   Research; Fondation ARC pour la recherche sur le cancer
FX We are grateful to Dr. Roger H. Pain for critical reading of the
   manuscript, Dr. Borut Jerman for preparation of recombinant hGX, Petra
   Kaferle for assistance with qPCR data analysis and statistics, and
   Christine Payre for preparation of radiolabelled E. coil membranes and
   technical help with E. coli assay and TRFIA. This work was supported by
   grant P1-0207 from the Slovenian Research Agency, by the French-Slovene
   partnership project BI-FR/12-13-PROTEUS-006, and by CNRS, the
   Association for International Cancer Research and the Fondation ARC pour
   la recherche sur le cancer to G.L.
CR Belinsky GS, 2007, MOL CARCINOGEN, V46, P106, DOI 10.1002/mc.20271
   Claerhout S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024662
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Fijneman RJA, 2008, CANCER SCI, V99, P2113, DOI 10.1111/j.1349-7006.2008.00924.x
   Ganesan K, 2008, CANCER RES, V68, P4277, DOI 10.1158/0008-5472.CAN-07-6517
   Grimm C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003250
   Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007
   Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427
   Mannello F, 2008, BREAST CANCER RES TR, V111, P209, DOI 10.1007/s10549-007-9779-1
   Menschikowski M, 2008, NEOPLASIA, V10, P1195, DOI 10.1593/neo.08640
   Menschikowski M, 2008, NEOPLASIA, V10, P279, DOI 10.1593/neo.07965
   Miki Y, 2007, ANTICANCER RES, V27, P1493
   Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4
   Murakami M, 2013, BIOCHIMIE, V95, P43, DOI 10.1016/j.biochi.2012.09.007
   Nelson HH, 2012, EPIGENETICS-US, V7, P559, DOI 10.4161/epi.20219
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Pucer A, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-111
   Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112
   Rodenhiser DI, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2121
   Scott KF, 2010, BIOCHIMIE, V92, P601, DOI 10.1016/j.biochi.2010.03.019
   Surrel F, 2009, MOL PHARMACOL, V76, P778, DOI 10.1124/mol.108.053371
   Ward CS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062610
   YAMASHITA SI, 1994, BRIT J CANCER, V69, P1166, DOI 10.1038/bjc.1994.229
NR 24
TC 26
Z9 29
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 28
PY 2014
VL 445
IS 1
BP 230
EP 235
DI 10.1016/j.bbrc.2014.01.182
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA AC7YE
UT WOS:000332749400040
PM 24508801
DA 2025-01-12
ER

PT J
AU Rani, A
   Greenlaw, R
   Runglall, M
   Jurcevic, S
   John, S
AF Rani, Aradhana
   Greenlaw, Roseanna
   Runglall, Manohursingh
   Jurcevic, Stipo
   John, Susan
TI <i>FRA2</i> Is a STAT5 Target Gene Regulated by IL-2 in Human CD4 T
   Cells
SO PLOS ONE
LA English
DT Article
ID DNASE HYPERSENSITIVE SITES; BINDING-SITES; SOMATIC MUTATIONS; CHROMATIN
   IMMUNOPRECIPITATION; BREAST-CANCER; HUMAN GENOME; TRANSCRIPTION;
   EXPRESSION; RECEPTOR; IDENTIFICATION
AB Signal transducers and activators of transcription 5(STAT5) are cytokine induced signaling proteins, which regulate key immunological processes, such as tolerance induction, maintenance of homeostasis, and CD4 T-effector cell differentiation. In this study, transcriptional targets of STAT5 in CD4 T cells were studied by Chromatin Immunoprecipitation (ChIP). Genomic mapping of the sites cloned and identified in this study revealed the striking observation that the majority of STAT5-binding sites mapped to intergenic (>50 kb upstream) or intronic, rather than promoter proximal regions. Of the 105 STAT5 responsive binding sites identified, 94% contained the canonical (IFN-gamma activation site) GAS motifs. A number of putative target genes identified here are associated with tumor biology. Here, we identified Fos-related antigen 2 (FRA2) as a transcriptional target of IL-2 regulated STAT5. FRA2 is a basic -leucine zipper (bZIP) motif 'Fos' family transcription factor that is part of the AP-1 transcription factor complex and is also known to play a critical role in the progression of human tumours and more recently as a determinant of T cell plasticity. The binding site mapped to an internal intron within the FRA2 gene. The epigenetic architecture of FRA2, characterizes a transcriptionally active promoter as indicated by enrichment for histone methylation marks H3K4me1, H3K4me2, H3K4me3, and transcription/elongation associated marks H2BK5me1 and H4K20me1. FRA2 is regulated by IL-2 in activated CD4 T cells. Consistently, STAT5 bound to GAS sequence in the internal intron of FRA2 and reporter gene assays confirmed IL-2 induced STAT5 binding and transcriptional activation. Furthermore, addition of JAK3 inhibitor (R333) or Daclizumab inhibited the induction in TCR stimulated cells. Taken together, our data suggest that FRA2 is a novel STAT5 target gene, regulated by IL-2 in activated CD4 T cells.
C1 [Rani, Aradhana; Greenlaw, Roseanna; Runglall, Manohursingh; Jurcevic, Stipo] Kings Coll London, Div Transplantat Immunol & Mucosal Biol, London WC2R 2LS, England.
   [John, Susan] Kings Coll London, Dept Immunobiol, London WC2R 2LS, England.
C3 University of London; King's College London; University of London;
   King's College London
RP Jurcevic, S (通讯作者)，Kings Coll London, Div Transplantat Immunol & Mucosal Biol, London WC2R 2LS, England.
EM stipo.jurcevic@kcl.ac.uk; susan.john@kcl.ac.uk
RI Jurcevic, Stipo/JCN-8783-2023; John, Susan/HNP-1340-2023
OI Runglall, Manohursingh/0000-0002-0549-9029; Rani,
   Aradhana/0000-0003-4273-9826; Rani, Aradhana/0000-0001-5334-2723
FU MRC Centre for Transplantation; Wellcome Trust UK [074656/Z/04/Z];
   National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Guy's and St Thomas' NHS Foundation Trust; National Institute
   for Health Research (NIHR) Biomedical Research Centre based at King's
   College London; MRC [G0400197] Funding Source: UKRI
FX The authors would like to acknowledge the support of the MRC Centre for
   Transplantation. This work was supported by Wellcome Trust UK Grant
   074656/Z/04/Z (to S.John.). The research was funded/supported by the
   National Institute for Health Research (NIHR) Biomedical Research Centre
   based at Guy's and St Thomas' NHS Foundation Trust and King's College
   London. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health.
CR Barash I, 2012, CARCINOGENESIS, V33, P2320, DOI 10.1093/carcin/bgs362
   Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009
   Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541
   Berger MF, 2011, NATURE, V470, P214, DOI 10.1038/nature09744
   Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915
   Boyle AP, 2008, CELL, V132, P311, DOI 10.1016/j.cell.2007.12.014
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016
   Clark MJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000832
   Crawford GE, 2006, GENOME RES, V16, P123, DOI 10.1101/gr.4074106
   Crawford GE, 2004, P NATL ACAD SCI USA, V101, P992, DOI 10.1073/pnas.0307540100
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Ehret GB, 2001, J BIOL CHEM, V276, P6675, DOI 10.1074/jbc.M001748200
   Ferbeyre G, 2011, BBA-REV CANCER, V1815, P104, DOI 10.1016/j.bbcan.2010.10.004
   Foletta VC, 1996, IMMUNOL CELL BIOL, V74, P121, DOI 10.1038/icb.1996.17
   Fung MM, 2005, ONCOGENE, V24, P4624, DOI 10.1038/sj.onc.1208507
   Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299
   Gatzka M, 2006, CYTOKINE, V34, P143, DOI 10.1016/j.cyto.2006.04.003
   Greif PA, 2011, LEUKEMIA, V25, P821, DOI 10.1038/leu.2011.19
   Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907
   Hoelbl A, 2010, EMBO MOL MED, V2, P98, DOI 10.1002/emmm.201000062
   Iyer VR, 2001, NATURE, V409, P533, DOI 10.1038/35054095
   John S, 1999, MOL CELL BIOL, V19, P1910
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   LeBaron MJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-6
   Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015
   Liao W, 2008, NAT IMMUNOL, V9, P1288, DOI 10.1038/ni.1656
   Lin JX, 2012, IMMUNITY, V36, P586, DOI 10.1016/j.immuni.2012.02.017
   Lund RJ, 2007, J IMMUNOL, V178, P3648, DOI 10.4049/jimmunol.178.6.3648
   Martone R, 2003, P NATL ACAD SCI USA, V100, P12247, DOI 10.1073/pnas.2135255100
   McDyer JF, 2002, J IMMUNOL, V169, P2736, DOI 10.4049/jimmunol.169.5.2736
   Mi HY, 2013, NUCLEIC ACIDS RES, V41, pD377, DOI 10.1093/nar/gks1118
   Moriggl R, 2005, CANCER CELL, V7, P87, DOI 10.1016/j.ccr.2004.12.010
   Nagy ZS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057326
   Nagy ZS, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-67
   Nakayama T, 2012, ANTICANCER RES, V32, P1367
   Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200
   NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619
   Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Rani A, 2011, J IMMUNOL, V187, P3721, DOI 10.4049/jimmunol.1002354
   Rascle A, 2003, MOL CELL BIOL, V23, P4162, DOI 10.1128/MCB.23.12.4162-4173.2003
   Robertson G, 2007, NAT METHODS, V4, P651, DOI 10.1038/NMETH1068
   Shahbazian MD, 2007, ANNU REV BIOCHEM, V76, P75, DOI 10.1146/annurev.biochem.76.052705.162114
   Soldaini E, 2000, MOL CELL BIOL, V20, P389, DOI 10.1128/MCB.20.1.389-401.2000
   Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013
   Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130
   Totoki Y, 2011, NAT GENET, V43, P464, DOI 10.1038/ng.804
   Velotta JB, 2009, TRANSPLANTATION, V87, P653, DOI 10.1097/TP.0b013e318196110f
   Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018
   Wang ZB, 2008, NAT GENET, V40, P897, DOI 10.1038/ng.154
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
NR 54
TC 12
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 28
PY 2014
VL 9
IS 2
AR e90370
DI 10.1371/journal.pone.0090370
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA AC3DW
UT WOS:000332396200181
PM 24587342
OA Green Published, Green Submitted, Green Accepted, gold
DA 2025-01-12
ER

PT J
AU Ye, XM
   Zhu, HY
   Bai, WD
   Wang, T
   Wang, L
   Chen, Y
   Yang, AG
   Jia, LT
AF Ye, Xing-Ming
   Zhu, Hua-Yu
   Bai, Wen-Dong
   Wang, Ting
   Wang, Lei
   Chen, Ying
   Yang, An-Gang
   Jia, Lin-Tao
TI Epigenetic silencing of miR-375 induces trastuzumab resistance in
   HER2-positive breast cancer by targeting IGF1R
SO BMC CANCER
LA English
DT Article
DE miR-375; Insulin-like growth factor 1 receptor; Trastuzumab resistance;
   erbB2/HER2; Breast cancer
ID MEDIATES RESISTANCE; RECEPTOR; THERAPY; CONTRIBUTES; PROGRESSION;
   ACTIVATION; EXPRESSION; MICRORNAS; MUTATION
AB Background: Resistance to humanized monoclonal erbB2/HER2 antibody, trastuzumab (Herceptin), has become a pivotal obstacle for targeted therapy of HER2-positive breast cancers. The activation of alternative growth factor receptors, in particular, the insulin-like growth factor 1 receptor (IGF1R), represents a common feature of trastuzumab-refractory cells; however, the underlying mechanism remains elusive.
   Methods: Trastuzumab-resistant breast cancer SKBr-3 cells were generated by long-term in vitro culture of SKBr-3 cells in the presence of trastuzumab. Among the differentially expressed microRNAs (miRNAs) screened by microarray analysis, candidate miRNA(s) predicted to target IGF1R was studied for its role in conferring trastuzumab resistance. The mechanism underlying decreased expression of IGF1R-targeted miRNA in refractory cells was also addressed.
   Results: miR-375, which was downregulated and predicted to target IGF1R in trastuzumab-resistant HER2-positive breast cancer cells, could indeed inhibit the cellular luciferase activity in a reporter construct containing the 3 '-UTR of IGF1R. Overexpression of miR-375 restored the sensitivity of cells to trastuzumab, while inhibition of miR-375 conferred trastuzumab resistance on HER2-positive breast cancer cells. Blockade of DNA methylation and histone deacetylation restored the expression of miR-375 in trastuzumab-resistant cells. A reverse correlation between the levels of miR-375 and IGF1R was validated in clinical breast cancers.
   Conclusions: Epigenetic silencing of miR-375 causes the upregulation of IGF1R, which at least partially underlies trastuzumab resistance of breast cancer cells. Our study has implications for miR-375 as a potential target in combination with trastuzumab for treating HER2-positive breast cancers.
C1 [Ye, Xing-Ming; Zhu, Hua-Yu; Wang, Ting; Wang, Lei; Jia, Lin-Tao] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian 710032, Peoples R China.
   [Ye, Xing-Ming; Chen, Ying] Fujian Med Univ, Teaching Hosp, Fujian Prov Canc Hosp, Fuzhou 350014, Peoples R China.
   [Bai, Wen-Dong; Yang, An-Gang] Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China.
C3 Air Force Military Medical University; Fujian Medical University; Air
   Force Military Medical University
RP Yang, AG (通讯作者)，Fourth Mil Med Univ, Dept Immunol, Xian 710032, Peoples R China.
EM agyang@fmmu.edu.cn; jialth@fmmu.edu.cn
OI Bai, Wen-Dong/0000-0003-1873-7900; Jia, Lintao/0000-0001-6329-0453
FU National Basic Research Program of China [2010CB529905]; National
   Natural Sciences Foundation of China [81030045, 81272646]
FX This work was funded by the National Basic Research Program of China
   (No. 2010CB529905), and the National Natural Sciences Foundation of
   China (No. 81030045 and No. 81272646).
CR Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177
   Avnit-Sagi T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005033
   Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Garrett JT, 2011, CANCER BIOL THER, V11, P793, DOI 10.4161/cbt.11.9.15045
   Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887
   Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
   Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538
   GUSTERSON BA, 1992, J CLIN ONCOL, V10, P1049, DOI 10.1200/JCO.1992.10.7.1049
   Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Ichikawa T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031422
   Junttila TT, 2011, BREAST CANCER RES TR, V128, P347, DOI 10.1007/s10549-010-1090-x
   Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178
   Kong KL, 2010, CANCER RES, V70, P8832, DOI 10.1158/0008-5472.CAN-10-0779
   Lagana Alessandro, 2010, J RNAi Gene Silencing, V6, P379
   Le XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041170
   Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852
   Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173
   Morris PG, 2009, EXPERT OPIN PHARMACO, V10, P967, DOI [10.1517/14656560902834961, 10.1517/14656560902834961 ]
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900
   Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841
   Nishimura R, 2008, BREAST CANCER-TOKYO, V15, P57, DOI 10.1007/s12282-007-0014-z
   Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701
   Romanelli RJ, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M704309200
   ROSEN PP, 1995, CANCER, V75, P1320, DOI 10.1002/1097-0142(19950315)75:6<1320::AID-CNCR2820750614>3.0.CO;2-C
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Tamborini E, 2004, GASTROENTEROLOGY, V127, P294, DOI 10.1053/j.gastro.2004.02.021
   Tsukamoto Y, 2010, CANCER RES, V70, P2339, DOI 10.1158/0008-5472.CAN-09-2777
   Ulanet DB, 2010, P NATL ACAD SCI USA, V107, P10791, DOI 10.1073/pnas.0914076107
   Veksler-Lublinsky I, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-249
   Ward A, 2013, ONCOGENE, V32, P1173, DOI 10.1038/onc.2012.128
NR 36
TC 125
Z9 137
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 26
PY 2014
VL 14
AR 134
DI 10.1186/1471-2407-14-134
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA AC4YQ
UT WOS:000332527700005
PM 24571711
OA Green Published, gold
DA 2025-01-12
ER

PT J
AU Nunna, S
   Reinhardt, R
   Ragozin, S
   Jeltsch, A
AF Nunna, Suneetha
   Reinhardt, Richard
   Ragozin, Sergey
   Jeltsch, Albert
TI Targeted Methylation of the Epithelial Cell Adhesion Molecule (EpCAM)
   Promoter to Silence Its Expression in Ovarian Cancer Cells
SO PLOS ONE
LA English
DT Article
ID DNA METHYLATION; EP-CAM; ZINC FINGERS; TRANSCRIPTION FACTORS; EPIGENETIC
   MARKS; BREAST-CANCER; OVEREXPRESSION; CATUMAXOMAB; SELECTION; ANTIGEN
AB The Epithelial Cell Adhesion Molecule (EpCAM) is overexpressed in many cancers including ovarian cancer and EpCAM overexpression correlates with decreased survival of patients. It was the aim of this study to achieve a targeted methylation of the EpCAM promoter and silence EpCAM gene expression using an engineered zinc finger protein that specifically binds the EpCAM promoter fused to the catalytic domain of the Dnmt3a DNA methyltransferase. We show that transient transfection of this construct increased the methylation of the EpCAM promoter in SKOV3 cells from 4-8% in untreated cells to 30%. Up to 48% methylation was observed in stable cell lines which express the chimeric methyltransferase. Control experiments confirmed that the methylation was dependent on the fusion of the Zinc finger and the methyltransferase domains and specific for the target region. The stable cell lines with methylated EpCAM promoter showed a 60-80% reduction of EpCAM expression as determined at mRNA and protein level and exhibited a significantly reduced cell proliferation. Our data indicate that targeted methylation of the EpCAM promoter could be an approach in the therapy of EpCAM overexpressing cancers.
C1 [Nunna, Suneetha; Ragozin, Sergey; Jeltsch, Albert] Univ Stuttgart, Inst Biochem, D-70174 Stuttgart, Germany.
   [Reinhardt, Richard] Max Planck Genomzentrum Koln, Cologne, Germany.
C3 University of Stuttgart; Max Planck Society
RP Jeltsch, A (通讯作者)，Univ Stuttgart, Inst Biochem, D-70174 Stuttgart, Germany.
EM albert.jeltsch@ibc.uni-stuttgart.de
RI ; Jeltsch, Albert/O-7404-2014
OI Reinhardt, Richard/0000-0001-9376-2132; Jeltsch,
   Albert/0000-0001-6113-9290
FU Sander Foundation; DAAD (Deutscher Akademischer Austauschdienst)
FX This work has been supported by the Sander Foundation and the DAAD
   (Deutscher Akademischer Austauschdienst). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985
   Baeuerle PA, 2007, BRIT J CANCER, V96, P417, DOI 10.1038/sj.bjc.6603494
   Barnholtz-Sloan JS, 2003, AM J OBSTET GYNECOL, V189, P1120, DOI 10.1067/S0002-9378(03)00579-9
   Bogdanove AJ, 2011, SCIENCE, V333, P1843, DOI 10.1126/science.1204094
   Bokemeyer C, 2010, EXPERT OPIN BIOL TH, V10, P1259, DOI 10.1517/14712598.2010.504706
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Cedar H, 2012, ANNU REV BIOCHEM, V81, P97, DOI 10.1146/annurev-biochem-052610-091920
   Cermak T, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr218
   CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0
   CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163
   de Groote ML, 2012, NUCLEIC ACIDS RES, V40, P10596, DOI 10.1093/nar/gks863
   Frampton JE, 2012, DRUGS, V72, P1399, DOI 10.2165/11209040-000000000-00000
   Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Gommans WM, 2007, MOL CARCINOGEN, V46, P391, DOI 10.1002/mc.20289
   Heinzelmann-Schwarz VA, 2004, CLIN CANCER RES, V10, P4427, DOI 10.1158/1078-0432.CCR-04-0073
   Holschneider CH, 2000, SEMIN SURG ONCOL, V19, P3, DOI 10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
   JAMIESON AC, 1994, BIOCHEMISTRY-US, V33, P5689, DOI 10.1021/bi00185a004
   Jeltsch A, 2007, APPL MICROBIOL BIOT, V75, P1233, DOI 10.1007/s00253-007-0966-0
   Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Jurkowska RZ, 2010, METHODS MOL BIOL, V649, P149, DOI 10.1007/978-1-60761-753-2_9
   Jurkowska RZ, 2011, CHEMBIOCHEM, V12, P206, DOI 10.1002/cbic.201000195
   Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102
   Köbel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232
   Law JA, 2010, NAT REV GENET, V11, P204, DOI 10.1038/nrg2719
   Li FY, 2007, NUCLEIC ACIDS RES, V35, P100, DOI 10.1093/nar/gkl1035
   Linke R, 2010, MABS-AUSTIN, V2, P129, DOI 10.4161/mabs.2.2.11221
   LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437
   Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525
   Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824
   Mostert B, 2009, CANCER TREAT REV, V35, P463, DOI 10.1016/j.ctrv.2009.03.004
   Münz M, 2004, ONCOGENE, V23, P5748, DOI 10.1038/sj.onc.1207610
   Oberneder R, 2006, EUR J CANCER, V42, P2530, DOI 10.1016/j.ejca.2006.05.029
   Osta WA, 2004, CANCER RES, V64, P5818, DOI 10.1158/0008-5472.CAN-04-0754
   REBAR EJ, 1994, SCIENCE, V263, P671, DOI 10.1126/science.8303274
   Rescigno P, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/852839
   Rivenbark AG, 2012, EPIGENETICS-US, V7, P350, DOI 10.4161/epi.19507
   Rohde C, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-230
   Schwartzberg LS, 2001, CRIT REV ONCOL HEMAT, V40, P17, DOI 10.1016/S1040-8428(01)00131-7
   Seimetz D, 2010, CANCER TREAT REV, V36, P458, DOI 10.1016/j.ctrv.2010.03.001
   Shigdar S, 2011, CANCER SCI, V102, P991, DOI 10.1111/j.1349-7006.2011.01897.x
   Siddique A, 2013, J MOL BIOL, V425, P479, DOI 10.1016/j.jmb.2012.11.038
   Simon M, 2013, EXPERT OPIN DRUG DEL, V10, P451, DOI 10.1517/17425247.2013.759938
   Spizzo G, 2007, CANCER LETT, V246, P253, DOI 10.1016/j.canlet.2006.03.002
   Spizzo G, 2006, GYNECOL ONCOL, V103, P483, DOI 10.1016/j.ygyno.2006.03.035
   Spizzo G, 2011, J CLIN PATHOL, V64, P415, DOI 10.1136/jcp.2011.090274
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Suzuki MM, 2008, NAT REV GENET, V9, P465, DOI 10.1038/nrg2341
   Tai KY, 2007, ONCOGENE, V26, P3989, DOI 10.1038/sj.onc.1210176
   Thiery JP, 1996, J CELL BIOCHEM, V61, P489
   van der Gun BTF, 2013, BRIT J CANCER, V108, P881, DOI 10.1038/bjc.2013.45
   van der Gun BTF, 2011, BRIT J CANCER, V105, P312, DOI 10.1038/bjc.2011.231
   van der Gun BTF, 2008, INT J CANCER, V123, P484, DOI 10.1002/ijc.23476
   van der Gun BTF, 2010, CARCINOGENESIS, V31, P1913, DOI 10.1093/carcin/bgq187
   van der Gun BTF, 2010, BIOCONJUGATE CHEM, V21, P1239, DOI 10.1021/bc1000388
   Varga M, 2004, CLIN CANCER RES, V10, P3131, DOI 10.1158/1078-0432.CCR-03-0528
   Wei SH, 2002, CLIN CANCER RES, V8, P2246
   Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026
   Wimberger P, 2009, ANTICANCER RES, V29, P1787
   Winter MJ, 2003, AM J PATHOL, V163, P2139, DOI 10.1016/S0002-9440(10)63570-5
   WU H, 1995, P NATL ACAD SCI USA, V92, P344, DOI 10.1073/pnas.92.2.344
   Xiang W, 2003, J CANCER RES CLIN, V129, P341, DOI 10.1007/s00432-003-0438-6
   Xu GL, 1997, NAT GENET, V17, P376, DOI 10.1038/ng1297-376
   Zhang Yingying, 2009, V507, P177, DOI 10.1007/978-1-59745-522-0_14
NR 66
TC 53
Z9 60
U1 0
U2 27
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 29
PY 2014
VL 9
IS 1
AR e87703
DI 10.1371/journal.pone.0087703
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 301ZC
UT WOS:000330570000172
PM 24489952
OA Green Published, Green Submitted, gold
DA 2025-01-12
ER

PT J
AU Magnani, L
   Lupien, M
AF Magnani, Luca
   Lupien, Mathieu
TI Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1)
   signaling
SO MOLECULAR AND CELLULAR ENDOCRINOLOGY
LA English
DT Article
DE Epigenetic; Chromatin; Estrogen receptor; Transcriptional regulation;
   Pioneer factor; FOXA1
ID DNASE-I HYPERSENSITIVITY; LONG-RANGE INTERACTION; ER-ALPHA; RESPONSIVE
   PROMOTERS; REGULATORY ELEMENTS; ANDROGEN RECEPTOR; DISTAL ENHANCER;
   PIONEER FACTORS; NONCODING RNAS; CHIP-SEQ
AB The oestrogen receptor alpha (ESR1) is a transcription factor that potentiates the response to diverse stimuli, including oestrogen and growth factors, in various tissue types. Its recruitment to the DNA is directly regulated by the chromatin landscape, inclusive of chromatin compaction and epigenetic modifications. In this review we discuss our current understanding of the interplay between ESR1 signaling and the chromatin landscape. We present how the chromatin landscape primes the lineage-specific response and contributes to stimuli-specific signaling. Finally, we discuss recent efforts to decipher the relationship between genetic and epigenetic as it relates to ESR1 signaling in breast cancer. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Magnani, Luca; Lupien, Mathieu] Univ Hlth Network, Princess Margaret Canc Ctr, Ontario Canc Inst, Toronto, ON, Canada.
   Ontario Inst Canc Res, Toronto, ON, Canada.
   Univ Toronto, Dept Med Biophys, Toronto, ON, Canada.
C3 University of Toronto; University Health Network Toronto; Princess
   Margaret Cancer Centre; University of Toronto; Ontario Institute for
   Cancer Research; University of Toronto
RP Magnani, L (通讯作者)，Univ Hlth Network, Princess Margaret Canc Ctr, Ontario Canc Inst, Toronto, ON, Canada.
EM l.magnani@imperial.ac.uk; mlupien@uhnres.u-toronto.ca
RI Lupien, Mathieu/KFB-6691-2024; magnani, luca/N-1094-2015
OI Lupien, Mathieu/0000-0003-0929-9478; magnani, luca/0000-0002-7534-0785
CR Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426
   Barnett DH, 2008, CANCER RES, V68, P3505, DOI 10.1158/0008-5472.CAN-07-6151
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Bell O, 2011, NAT REV GENET, V12, P554, DOI 10.1038/nrg3017
   Bilu Y, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-12-r103
   Bintu L, 2012, CELL, V151, P738, DOI 10.1016/j.cell.2012.10.009
   Bonneville R., 2012, BIOINFORMATICS, DOI DOI 10.1093/BI0INF0RMATICS/BTS639
   Bourdeau V, 2004, MOL ENDOCRINOL, V18, P1411, DOI 10.1210/me.2003-0441
   Bretschneider N, 2008, MOL ONCOL, V2, P182, DOI 10.1016/j.molonc.2008.05.004
   Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901
   Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008
   Cirillo LA, 2002, MOL CELL, V9, P279, DOI 10.1016/S1097-2765(02)00459-8
   Costa FF, 2010, BIOESSAYS, V32, P599, DOI 10.1002/bies.200900112
   Cowper-Sal-lari R, 2012, NAT GENET, V44, P1191, DOI 10.1038/ng.2416
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746
   Eeckhoute J, 2009, GENOME RES, V19, P372, DOI 10.1101/gr.084582.108
   Ellis MJ, 2012, NATURE, V486, P353, DOI 10.1038/nature11143
   Ernst J, 2011, NATURE, V473, P43, DOI 10.1038/nature09906
   Ernst J, 2010, NAT BIOTECHNOL, V28, P817, DOI 10.1038/nbt.1662
   Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614
   Foulds Charles E, 2010, Mol Endocrinol, V24, P1090, DOI 10.1210/me.2009-0427
   Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497
   Fussner E, 2011, TRENDS BIOCHEM SCI, V36, P1, DOI 10.1016/j.tibs.2010.09.002
   Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038
   Gertz J, 2012, GENOME RES, V22, P2153, DOI 10.1101/gr.135681.111
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672
   Hall JM, 2002, MOL ENDOCRINOL, V16, P469, DOI 10.1210/me.16.3.469
   Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32
   He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111
   He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545
   Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966
   Heintzman ND, 2009, NATURE, V459, P108, DOI 10.1038/nature07829
   Henikoff S, 2011, TRENDS GENET, V27, P389, DOI 10.1016/j.tig.2011.06.006
   Holmes KA, 2012, P NATL ACAD SCI USA, V109, P2748, DOI 10.1073/pnas.1018863108
   Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730
   Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Joshi SR, 2011, MOL ENDOCRINOL, V25, P980, DOI 10.1210/me.2010-0302
   Joshi SR, 2012, NUCLEIC ACIDS RES, V40, P10161, DOI 10.1093/nar/gks815
   Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263
   Kangaspeska S, 2008, NATURE, V452, P112, DOI 10.1038/nature06640
   Kim D, 2010, J BIOL CHEM, V285, P1147, DOI 10.1074/jbc.M109.035865
   KLEINHITPASS L, 1986, CELL, V46, P1053, DOI 10.1016/0092-8674(86)90705-1
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kong SL, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.59
   Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005
   Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331
   Krum SA, 2008, MOL ENDOCRINOL, V22, P2393, DOI 10.1210/me.2008-0100
   KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2
   KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7
   Laganière J, 2005, P NATL ACAD SCI USA, V102, P11651, DOI 10.1073/pnas.0505575102
   Lan X, 2012, NUCLEIC ACIDS RES, V40, P7690, DOI 10.1093/nar/gks501
   Lanz RB, 1999, CELL, V97, P17, DOI 10.1016/S0092-8674(00)80711-4
   Li GL, 2012, CELL, V148, P84, DOI 10.1016/j.cell.2011.12.014
   Li ZY, 2012, CELL, V151, P1608, DOI 10.1016/j.cell.2012.11.018
   Lieberman-Aiden E, 2009, SCIENCE, V326, P289, DOI 10.1126/science.1181369
   Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087
   Liu XF, 2004, J BIOL CHEM, V279, P15050, DOI 10.1074/jbc.M311932200
   Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444
   Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018
   Lupien M, 2010, GENE DEV, V24, P2219, DOI 10.1101/gad.1944810
   Lupien M, 2009, MOL CELL BIOL, V29, P3413, DOI 10.1128/MCB.00020-09
   Magnani L, 2013, P NATL ACAD SCI USA, V110, pE1490, DOI 10.1073/pnas.1219992110
   Magnani L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002368
   Magnani L, 2011, TRENDS GENET, V27, P465, DOI 10.1016/j.tig.2011.07.002
   Métivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6
   Métivier R, 2008, NATURE, V452, P45, DOI 10.1038/nature06544
   Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008
   Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200
   Neph S, 2012, NATURE, V489, P83, DOI 10.1038/nature11212
   Pan YF, 2008, J BIOL CHEM, V283, P32977, DOI 10.1074/jbc.M802024200
   Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674
   Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403
   Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X
   Renoir JM, 2012, STEROIDS, V77, P1249, DOI 10.1016/j.steroids.2012.07.019
   Rodríguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305
   Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730
   Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014
   Sanchez R, 2009, CURR OPIN DRUG DISC, V12, P659
   Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012
   Sanyal A, 2012, NATURE, V489, P109, DOI 10.1038/nature11279
   Schneider R, 2007, GENE DEV, V21, P3027, DOI 10.1101/gad.1604607
   Sérandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110
   Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4
   SHEFFERY M, 1982, P NATL ACAD SCI-BIOL, V79, P1180, DOI 10.1073/pnas.79.4.1180
   Shen Y, 2012, NATURE, V488, P116, DOI 10.1038/nature11243
   Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108
   Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012
   Smale ST, 2010, CURR OPIN GENET DEV, V20, P519, DOI 10.1016/j.gde.2010.06.010
   Smith BC, 2009, BBA-GENE REGUL MECH, V1789, P45, DOI 10.1016/j.bbagrm.2008.06.005
   Song LY, 2011, GENOME RES, V21, P1757, DOI 10.1101/gr.121541.111
   Staynov DZ, 2000, NUCLEIC ACIDS RES, V28, P3092, DOI 10.1093/nar/28.16.3092
   Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017
   Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151
   Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112
   Thurman RE, 2012, NATURE, V489, P75, DOI 10.1038/nature11232
   Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406
   Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028
   Wang J, 2012, GENOME RES, V22, P1798, DOI 10.1101/gr.139105.112
   Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018
   Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056
   Welboren WJ, 2009, EMBO J, V28, P1418, DOI 10.1038/emboj.2009.88
   WINGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879, DOI 10.1093/nar/16.5.1879
   Wright JB, 2010, MOL CELL BIOL, V30, P1411, DOI 10.1128/MCB.01384-09
   Wu JC, 2012, P NATL ACAD SCI USA, V109, P5675, DOI 10.1073/pnas.1114905109
   Wu JI, 2009, CELL, V136, P200, DOI 10.1016/j.cell.2009.01.009
   Xiao R, 2012, MOL ENDOCRINOL, V26, P349, DOI 10.1210/me.2011-1080
   Yap KL, 2011, BIOCHEMISTRY-US, V50, P1966, DOI 10.1021/bi101885m
   Zaret KS, 2011, GENE DEV, V25, P2227, DOI 10.1101/gad.176826.111
   Zhang XY, 2012, GENOME RES, V22, P1437, DOI 10.1101/gr.135665.111
   Zhang XS, 2012, P NATL ACAD SCI USA, V109, P13331, DOI 10.1073/pnas.1203280109
   Zwart W, 2011, EMBO J, V30, P4764, DOI 10.1038/emboj.2011.368
NR 117
TC 39
Z9 43
U1 1
U2 18
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0303-7207
J9 MOL CELL ENDOCRINOL
JI Mol. Cell. Endocrinol.
PD JAN 25
PY 2014
VL 382
IS 1
BP 633
EP 641
DI 10.1016/j.mce.2013.04.026
PG 9
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA 299UQ
UT WOS:000330421600069
PM 23684889
DA 2025-01-12
ER

PT J
AU Lubecka-Pietruszewska, K
   Kaufman-Szymczyk, A
   Stefanska, B
   Cebula-Obrzut, B
   Smolewski, P
   Fabianowska-Majewska, K
AF Lubecka-Pietruszewska, Katarzyna
   Kaufman-Szymczyk, Agnieszka
   Stefanska, Barbara
   Cebula-Obrzut, Barbara
   Smolewski, Piotr
   Fabianowska-Majewska, Krystyna
TI Clofarabine, a novel adenosine analogue, reactivates DNA
   methylation-silenced tumour suppressor genes and inhibits cell growth in
   breast cancer cells
SO EUROPEAN JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE Clofarabine; Epigenetic therapy; Tumour suppressor genes; Promoter
   methylation; Breast cancer
ID ACID-RECEPTOR-BETA; HUMAN LYMPHOBLASTOID-CELLS; RETINOIC-ACID;
   NUCLEOSIDE ANALOGS; TRANSCRIPTIONAL REGULATION; PROMOTER
   HYPERMETHYLATION; METHYLTRANSFERASE 1; MESSENGER-RNA; EXPRESSION; PTEN
AB Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine, CIF) is a second-generation 2'-cleoxyaclenosine analogue that is structurally related to cladribine (2-chloro-2'-deoxyaclenosine, 2CdA) and fludarabine (9-beta-D-arabinosyl-2-fluoroadenine, F-ara-A). It demonstrates potent antitumour activity at much lower doses than parent compounds with high therapeutic efficacy in paediatric blood cancers. Our previous studies in breast cancer cells indicate that 2CdA and F-ara-A are involved in epigenetic regulation of gene transcription. We therefore investigated whether CIF influences methylation and expression of selected tumour suppressor genes, such as adenomatous polyposis coli (APC), phosphatase and tensin homologue (PTEN), and retinoic acid receptor beta 2 (RARbeta2), as well as expression of p53, p21 and DNA methyltransferase 1 (DNMT1) in MCF-7 and MDA-MB-231 breast cancer cell lines with different invasive potential. Promoter methylation and gene expression were estimated using methylation-sensitive restriction analysis (MSRA) and real-time PCR, respectively. CIF demonstrated potent growth inhibitory activity in MCF-7 and MDA-MB-231 cells after 9611 treatment with IC50 determined as equal to 640 nM and 50 nM, respectively. In both breast cancer cell lines, CIF led to hypomethylation and up regulation of APC, PTEN and RARbeta2 as well as increase in p21 expression. Only in non-invasive MCF-7 cells, these changes were associated with down regulation of DNMT1. Our results provide first evidence of CIF implications in epigenetic regulation of transcriptional activity of selected tumour suppressor genes in breast cancer. It seems to be a new important element of CIF anticancer activity and may indicate its potential efficacy in epigenetic therapy of solid tumours, especially at early stages of carcinogenesis. (C) 2013 Elsevier By. All rights reserved
C1 [Lubecka-Pietruszewska, Katarzyna; Kaufman-Szymczyk, Agnieszka; Fabianowska-Majewska, Krystyna] Med Univ Lodz, Dept Biomed Chem, PL-92215 Lodz, Poland.
   [Stefanska, Barbara] Purdue Univ, Dept Nutr Sci, W Lafayette, IN 47907 USA.
   [Stefanska, Barbara] McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada.
   [Cebula-Obrzut, Barbara; Smolewski, Piotr] Med Univ Lodz, Dept Expt Haematol, PL-93510 Lodz, Poland.
C3 Medical University Lodz; Purdue University System; Purdue University;
   McGill University; Medical University Lodz
RP Lubecka-Pietruszewska, K (通讯作者)，Med Univ Lodz, Dept Biomed Chem, 6-8 Mazowiecka St, PL-92215 Lodz, Poland.
EM katarzyna.lubecka-pietruszewska@umed.lodz.pl
RI Lubecka, Katarzyna/S-9731-2016; Kaufman-Szymczyk, Agnieszka/S-9624-2016;
   Stefańska, Barbara/ABD-1161-2021
OI Cebula-Obrzut, Barbara/0000-0002-2689-7130; Smolewski,
   Piotr/0000-0003-2700-3343; Kaufman-Szymczyk,
   Agnieszka/0000-0001-6014-7280; Lubecka-Gajewska,
   Katarzyna/0000-0002-4250-0922
FU National Science Centre in Poland [DEC-2011/01/N/NZ2/01697]; Medical
   University of Lodz [503/6-099-01/503-01]
FX The studies were financed by the National Science Centre in Poland,
   Grant no. DEC-2011/01/N/NZ2/01697, and Medical University of Lodz, Grant
   no. 503/6-099-01/503-01.
CR Alvarez S, 2007, INT J BIOCHEM CELL B, V39, P1406, DOI 10.1016/j.biocel.2007.02.010
   Arapshian A, 2000, ONCOGENE, V19, P4066, DOI 10.1038/sj.onc.1203734
   Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668
   Bigey P, 2000, GENE, V242, P407, DOI 10.1016/S0378-1119(99)00501-6
   Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055
   Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240
   Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2
   Christman JK, 2002, ONCOGENE, V21, P5483, DOI 10.1038/sj.onc.1205699
   Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996
   Connolly R, 2012, J MAMMARY GLAND BIOL, V17, P191, DOI 10.1007/s10911-012-9263-3
   Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151
   De Marzo AM, 1999, CANCER RES, V59, P3855
   Fabianowska-Majewska K, 2006, NUCLEOS NUCLEOT NUCL, V25, P1025, DOI 10.1080/15257770600890640
   Fabianowska-Majewska K, 1998, ADV EXP MED BIOL, V431, P531
   Faderl S, 2005, CANCER-AM CANCER SOC, V103, P1985, DOI 10.1002/cncr.21005
   Galmarini CM, 2008, CURR MED CHEM, V15, P1072, DOI 10.2174/092986708784221449
   García JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062
   Genini D, 2000, BLOOD, V96, P3537
   Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967
   Gu JG, 1998, J CELL BIOL, V143, P1375, DOI 10.1083/jcb.143.5.1375
   Iida T, 2002, GENES CELLS, V7, P997, DOI 10.1046/j.1365-2443.2002.00584.x
   Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631
   Jaiswal AS, 2001, J BIOL CHEM, V276, P18193, DOI 10.1074/jbc.M101298200
   Jänicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357
   Jin Z, 2001, BRIT J CANCER, V85, P69, DOI 10.1054/bjoc.2001.1853
   Khan S, 2004, INT J CANCER, V112, P407, DOI 10.1002/ijc.20447
   Koressaar T, 2007, BIOINFORMATICS, V23, P1289, DOI 10.1093/bioinformatics/btm091
   Krawczyk B, 2006, NUCLEOS NUCLEOT NUCL, V25, P1029, DOI 10.1080/15257770600890764
   Krawczyk B., 2007, NUCLEOS NUCLEOT, V26, P1
   Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172
   Laird PW, 2005, HUM MOL GENET, V14, pR65, DOI 10.1093/hmg/ddi113
   LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M
   Lefebvre B, 2006, MOL ENDOCRINOL, V20, P2109, DOI 10.1210/me.2005-0321
   Lin F, 2000, CANCER RES, V60, P3271
   Liu Y, 1996, MOL CELL BIOL, V16, P1138
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lubecka-Pietruszewska K, 2013, BIOCHEM BIOPH RES CO, V430, P623, DOI 10.1016/j.bbrc.2012.11.103
   Mack GS, 2006, J NATL CANCER I, V98, P1443, DOI 10.1093/jnci/djj447
   Mirzayans R, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/170325
   Mongan NP, 2005, MOL CANCER THER, V4, P477
   MONTGOMERY JA, 1992, J MED CHEM, V35, P397, DOI 10.1021/jm00080a029
   Peterson EJ, 2003, CANCER RES, V63, P6579
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Polakis P, 2000, GENE DEV, V14, P1837
   Potemski P, 2007, HISTOPATHOLOGY, V51, P829, DOI 10.1111/j.1365-2559.2007.02886.x
   Qin WH, 2011, NUCLEUS-PHILA, V2, P392, DOI 10.4161/nucl.2.5.17928
   REICHELOVA V, 1995, J PHARMACEUT BIOMED, V13, P711, DOI 10.1016/0731-7085(95)01325-F
   Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291
   Saldaña-Meyer R, 2011, EPIGENETICS-US, V6, P1068, DOI 10.4161/epi.6.9.16683
   Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S
   Stefanska B, 2012, BRIT J NUTR, V107, P781, DOI 10.1017/S0007114511003631
   Stefanska B, 2010, EUR J PHARMACOL, V638, P47, DOI 10.1016/j.ejphar.2010.04.032
   Szyf M, 2004, BIOCHEM PHARMACOL, V68, P1187, DOI 10.1016/j.bcp.2004.04.030
   Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102
   Takahashi T, 2002, CANCER CHEMOTH PHARM, V50, P193, DOI 10.1007/s00280-002-0472-0
   Untergasser A, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks596
   Valdez BC, 2013, EXP HEMATOL, V41, P719, DOI 10.1016/j.exphem.2013.04.009
   Widschwendter M, 2000, J NATL CANCER I, V92, P826, DOI 10.1093/jnci/92.10.826
   Wyczechowska D, 2003, BIOCHEM PHARMACOL, V65, P219, DOI 10.1016/S0006-2952(02)01486-7
   XIE CX, 1995, CANCER RES, V55, P2847
   Xie KC, 1996, CANCER RES, V56, P3030
   Yang LM, 1997, CANCER RES, V57, P4652
   Yang X, 2001, ENDOCR-RELAT CANCER, V8, P115, DOI 10.1677/erc.0.0080115
   Ying JM, 2004, BLOOD, V103, P743, DOI 10.1182/blood-2003-09-3193
   Zelazowski MJ, 2011, TUMOR BIOL, V32, P551, DOI 10.1007/s13277-010-0150-5
   Zheng SS, 2012, BRIT J NUTR, V108, P998, DOI 10.1017/S0007114511006222
NR 66
TC 25
Z9 27
U1 0
U2 20
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0014-2999
EI 1879-0712
J9 EUR J PHARMACOL
JI Eur. J. Pharmacol.
PD JAN 15
PY 2014
VL 723
BP 276
EP 287
DI 10.1016/j.ejphar.2013.11.021
PG 12
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 302AW
UT WOS:000330574600036
PM 24296317
DA 2025-01-12
ER

PT J
AU Al-Nakhle, H
   Smith, L
   Bell, SM
   Burns, PA
   Cummings, M
   Hanby, AM
   Lane, S
   Parker, MD
   Hughes, TA
   Speirs, V
AF Al-Nakhle, Hakeemah
   Smith, Laura
   Bell, Sandra M.
   Burns, Philip A.
   Cummings, Michele
   Hanby, Andrew M.
   Lane, Sally
   Parker, Marie D.
   Hughes, Thomas A.
   Speirs, Valerie
TI Regulation of estrogen receptor β1 expression in breast cancer by
   epigenetic modification of the 5′ regulatory region
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE breast cancer; ESR2; estrogen receptor 1; methylation; loss of
   heterozygosity
ID ER-BETA; DNA-METHYLATION; PROMOTER HYPERMETHYLATION; PCR ASSAY; PHASE-I;
   GENE; ISOFORMS; TUMOR
AB ER1 is often down-regulated in breast cancer compared to normal breast but mechanisms surrounding this are unclear. We examined whether loss of heterozygosity (LOH) or methylation at ER promoters (0N, 0K) and/or untranslated exon 0N were involved in ER down-regulation in breast cancer tissues and cell lines and if treatment with the de-methylating agent 5-aza-deoxycytidine and/or the histone deacetylase inhibitor Trichostatin A could influence expression in vitro. We found no evidence of correlation between LOH at 14q22-24 (genomic locus containing ER/ESR2), and ER1 expression in primary breast cancers. A negative correlation between ER1 mRNA expression and methylation status was observed for promoter 0N in BT-20, MDA-MB-453 and T47D cells. Promoter 0K was consistently unmethylated. In primary breast tumours, methylation of the untranslated exon 0N, downstream of promoter 0N, but not of promoter 0N itself, correlated with down-regulation of ER. In MDA-MB-453 cells, treatment with 5-aza-deoxycytidine was sufficient to induce ER1 expression from the 0N promoter while in BT-20 both agents were required. Examination of various sites on ESR2 highlighted epigenetic but not genetic regulation of ER1. In particular methylation adjacent to promoter 0N was a key regulatory event for ER1 silencing. A combination of de-methylating agents and histone deacetylase inhibitors fully restored ER1 expression which may offer a novel therapeutic angle for breast cancer management.
C1 [Al-Nakhle, Hakeemah; Smith, Laura; Burns, Philip A.; Cummings, Michele; Hanby, Andrew M.; Parker, Marie D.; Speirs, Valerie] Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England.
   [Bell, Sandra M.; Hughes, Thomas A.] Univ Leeds, Leeds Inst Biomed & Clin Sci, Leeds LS9 7TF, W Yorkshire, England.
   [Lane, Sally] St James Univ Hosp, St Jamess Inst Oncol, Leeds LS9 7TF, W Yorkshire, England.
C3 University of Leeds; University of Leeds; Saint James's University
   Hospital
RP Speirs, V (通讯作者)，Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England.
EM v.speirs@leeds.ac.uk
RI Speirs, Valerie/ABE-7377-2021; Alnakhle, Hakeemah/JAN-5995-2023; Hughes,
   Thomas/O-8031-2015
OI Al-Nakhle, Hakeemah/0000-0002-5311-7072; Bell,
   Sandra/0000-0002-3022-9864; Hughes, Thomas/0000-0003-1169-3386
FU Breast Cancer Campaign; government of Saudi Arabia
FX This study was supported by grants from Breast Cancer Campaign (to V.
   S., T. A. H. and A. M. H.) and the government of Saudi Arabia (H.A.N.).
CR Al-Nakhle H, 2010, CANCER RES, V70, P4778, DOI 10.1158/0008-5472.CAN-09-4104
   Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800
   Bernstein I, 2010, EPIGENETICS-US, V5, P750, DOI 10.4161/epi.5.8.13105
   CAWKWELL L, 1993, BRIT J CANCER, V67, P1262, DOI 10.1038/bjc.1993.236
   Cottrell SE, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh008
   Cummings M, 2009, CELL ONCOL, V31, P467, DOI 10.3233/CLO-2009-0495
   Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258
   Hamilton-Burke W, 2010, AM J PATHOL, V177, P1079, DOI 10.2353/ajpath.2010.090886
   Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821
   Leung Y, 1996, P NATL ACAD SCI USA, V103, P13162
   Matthews Jason, 2003, Mol Interv, V3, P281, DOI 10.1124/mi.3.5.281
   Mirza S, 2012, ANN SURG ONCOL, V19, P3107, DOI 10.1245/s10434-012-2323-5
   Moore JT, 1998, BIOCHEM BIOPH RES CO, V247, P75, DOI 10.1006/bbrc.1998.8738
   Nojima D, 2001, CANCER, V92, P2076, DOI 10.1002/1097-0142(20011015)92:8<2076::AID-CNCR1548>3.0.CO;2-A
   Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088
   Shaaban AM, 2008, CLIN CANCER RES, V14, P5228, DOI 10.1158/1078-0432.CCR-07-4528
   Skliris GP, 2003, J PATHOL, V201, P213, DOI 10.1002/path.1436
   Smith L, 2010, J CELL MOL MED, V14, P2172, DOI 10.1111/j.1582-4934.2009.00867.x
   Smith L, 2010, BIOCHEM J, V429, P283, DOI 10.1042/BJ20100373
   Speirs V, 2002, J CLIN PATHOL, V55, P371, DOI 10.1136/jcp.55.5.371
   Suzuki F, 2008, CANCER SCI, V99, P2365, DOI 10.1111/j.1349-7006.2008.00988.x
   Walton TJ, 2008, PROSTATE, V68, P210, DOI 10.1002/pros.20673
   Xue Q, 2007, BIOL REPROD, V77, P681, DOI 10.1095/biolreprod.107.061804
   Yap OWS, 2009, ANTICANCER RES, V29, P139
   Yeo W, 2012, J CLIN ONCOL, V30, P3361, DOI 10.1200/JCO.2011.41.2395
   Zambrano P, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-44
   Zhai RL, 2009, J SURG RES, V155, P306, DOI 10.1016/j.jss.2008.09.028
   Zhao CY, 2003, ONCOGENE, V22, P7600, DOI 10.1038/sj.onc.1207100
   Zhu XG, 2004, AM J PATHOL, V164, P2003, DOI 10.1016/S0002-9440(10)63760-1
NR 29
TC 15
Z9 16
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
EI 1791-2423
J9 INT J ONCOL
JI Int. J. Oncol.
PD DEC
PY 2013
VL 43
IS 6
BP 2039
EP 2045
DI 10.3892/ijo.2013.2112
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 297AA
UT WOS:000330225800036
PM 24068253
OA Bronze
DA 2025-01-12
ER

PT J
AU Ray, A
   Alalem, M
   Ray, BK
AF Ray, Alpana
   Alalem, Mohamed
   Ray, Bimal K.
TI Loss of Epigenetic Kruppel-like Factor 4 Histone Deacetylase
   (KLF-4-HDAC)-mediated Transcriptional Suppression Is Crucial in
   Increasing Vascular Endothelial Growth Factor (VEGF) Expression in
   Breast Cancer
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ESTROGEN-RECEPTOR-ALPHA; TUMOR-SUPPRESSOR; GENE-EXPRESSION; PROTEIN
   EXPRESSION; DOWN-REGULATION; DNA-BINDING; FACTOR SAF; KLF4; CELLS; SP1
AB Vascular endothelial growth factor (VEGF) is recognized as an important angiogenic factor that promotes angiogenesis in a series of pathological conditions, including cancer, inflammation, and ischemic disorders. We have recently shown that the inflammatory transcription factor SAF-1 is, at least in part, responsible for the marked increase of VEGF levels in breast cancer. Here, we show that SAF-1-mediated induction of VEGF is repressed by KLF-4 transcription factor. KLF-4 is abundantly present in normal breast epithelial cells, but its level is considerably reduced in breast cancer cells and clinical cancer tissues. In the human VEGF promoter, SAF-1- and KLF-4-binding elements are overlapping, whereas SAF-1 induces and KLF-4 suppresses VEGF expression. Ectopic overexpression of KLF-4 and RNAi-mediated inhibition of endogenous KLF-4 supported the role of KLF-4 as a transcriptional repressor of VEGF and an inhibitor of angiogenesis in breast cancer cells. We show that KLF-4 recruits histone deacetylases (HDACs) -2 and -3 at the VEGF promoter. Chronological ChIP assays demonstrated the occupancy of KLF-4, HDAC2, and HDAC3 in the VEGF promoter in normal MCF-10A cells but not in MDA-MB-231 cancer cells. Co-transfection of KLF-4 and HDAC expression plasmids in breast cancer cells results in synergistic repression of VEGF expression and inhibition of angiogenic potential of these carcinoma cells. Together these results identify a new mechanism of VEGF up-regulation in cancer that involves concomitant loss of KLF-4-HDAC-mediated transcriptional repression and active recruitment of SAF-1-mediated transcriptional activation.
C1 [Ray, Alpana; Alalem, Mohamed; Ray, Bimal K.] Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.
C3 University of Missouri System; University of Missouri Columbia
RP Ray, A (通讯作者)，Univ Missouri, Dept Vet Pathobiol, 126A Connaway Hall, Columbia, MO 65211 USA.
EM rayal@missouri.edu; rayb@missouri.edu
RI Alalem, Mohamed/K-9011-2016
OI Alalem, Mohamed/0000-0003-2626-295X
FU United States Army Medical Research and Material Command; College of
   Veterinary Medicine, University of Missouri
FX This work was supported in part by grants from the United States Army
   Medical Research and Material Command and the College of Veterinary
   Medicine, University of Missouri.
CR Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713
   Ai WD, 2004, J BIOL CHEM, V279, P27830
   Ai WD, 2004, J BIOL CHEM, V279, P8684, DOI 10.1074/jbc.M308278200
   Akaogi K, 2009, ONCOGENE, V28, P2894, DOI 10.1038/onc.2009.151
   ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200
   Atkins GB, 2007, CIRC RES, V100, P1686, DOI 10.1161/01.RES.0000267856.00713.0a
   Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bianchi F, 2004, CLIN CANCER RES, V10, P6023, DOI 10.1158/1078-0432.CCR-04-0619
   Bouras T, 2001, CANCER RES, V61, P903
   BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1
   Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev
   Deacon K, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.397042
   Engels K, 1997, J PATHOL, V181, P207
   Evans PM, 2007, J BIOL CHEM, V282, P33994, DOI 10.1074/jbc.M701847200
   Ferrara N, 2002, SEMIN ONCOL, V29, P10, DOI 10.1053/sonc.2002.37264
   FERRARA N, 1995, BREAST CANCER RES TR, V36, P127, DOI 10.1007/BF00666035
   Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   Foster KW, 2000, CANCER RES, V60, P6488
   Hamik A, 2007, J BIOL CHEM, V282, P13769, DOI 10.1074/jbc.M700078200
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Jacobs EJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1400
   Kanai M, 2006, CLIN CANCER RES, V12, P6395, DOI 10.1158/1078-0432.CCR-06-1034
   Kee HJ, 2009, J MOL CELL CARDIOL, V47, P770, DOI 10.1016/j.yjmcc.2009.08.022
   Kumar D, 2009, J BIOL CHEM, V284, P1853, DOI 10.1074/jbc.M806289200
   Li J, 2012, CARCINOGENESIS, V33, P1239, DOI 10.1093/carcin/bgs143
   Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010
   McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009
   Miller KA, 2001, J BIOL CHEM, V276, P42863, DOI 10.1074/jbc.M108130200
   Nagata T., 2012, BREAST CANC IN PRESS
   Ohnishi S, 2003, BIOCHEM BIOPH RES CO, V308, P251, DOI 10.1016/S0006-291X(03)01356-1
   Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003
   Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484
   Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300
   Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327
   Ray A, 2003, J BIOL CHEM, V278, P22586, DOI 10.1074/jbc.M300705200
   Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002
   Ray A, 2002, DNA CELL BIOL, V21, P31, DOI 10.1089/10445490252810294
   Ray A, 1996, MOL CELL BIOL, V16, P1584
   Ray A, 2000, J BIOL CHEM, V275, P39727, DOI 10.1074/jbc.M007907200
   Ray A, 2011, MOL CANCER RES, V9, P1030, DOI 10.1158/1541-7786.MCR-10-0598
   Ray BK, 2007, J IMMUNOL, V178, P1774, DOI 10.4049/jimmunol.178.3.1774
   Ray BK, 1999, DNA CELL BIOL, V18, P65, DOI 10.1089/104454999315637
   Ray BK, 1997, BIOCHEMISTRY-US, V36, P4662, DOI 10.1021/bi9624595
   Rowland BD, 2006, NAT REV CANCER, V6, P11, DOI 10.1038/nrc1780
   Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314
   Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009
   Song J, 2003, INT J MOL MED, V11, P547
   Song YD, 2009, CLIN CANCER RES, V15, P492, DOI 10.1158/1078-0432.CCR-08-1945
   Stoner M, 2000, J BIOL CHEM, V275, P22769, DOI 10.1074/jbc.M002188200
   Stoner M, 2004, ONCOGENE, V23, P1052, DOI 10.1038/sj.onc.1207201
   Thiagalingam S, 2003, ANN NY ACAD SCI, V983, P84, DOI 10.1111/j.1749-6632.2003.tb05964.x
   Thomas-Chollier M, 2008, NUCLEIC ACIDS RES, V36, pW119, DOI 10.1093/nar/gkn304
   Tsutsui H, 1999, BIOCHEM BIOPH RES CO, V262, P198, DOI 10.1006/bbrc.1999.1130
   Van der Auwera I, 2004, CLIN CANCER RES, V10, P7965, DOI 10.1158/1078-0432.CCR-04-0063
   Wade PA, 2001, HUM MOL GENET, V10, P693, DOI 10.1093/hmg/10.7.693
   Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414
   Wang L, 2003, CLIN CANCER RES, V9, P3660
   Wang N, 2002, WORLD J GASTROENTERO, V8, P966, DOI 10.3748/wjg.v8.i6.966
   Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243
   Wei XL, 2007, CANCER RES, V67, P1853, DOI 10.1158/0008-5472.CAN-06-3063
   Wolffe AP, 1996, SCIENCE, V272, P371, DOI 10.1126/science.272.5260.371
   Yancy Haile F, 2007, J Carcinog, V6, P8
   Yasunaga J, 2004, CANCER RES, V64, P6002, DOI 10.1158/0008-5472.CAN-04-1422
   Yoon HS, 2004, J BIOL CHEM, V279, P5035, DOI 10.1074/jbc.M307631200
   Yori JL, 2011, NEOPLASIA, V13, P601, DOI 10.1593/neo.11260
   Yori JL, 2010, J BIOL CHEM, V285, P16854, DOI 10.1074/jbc.M110.114546
   Yoshiji H, 1996, CANCER RES, V56, P2013
   Yu F, 2011, ONCOGENE, V30, P2161, DOI 10.1038/onc.2010.591
   Yu TX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032492
   Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200
NR 72
TC 32
Z9 39
U1 0
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD SEP 20
PY 2013
VL 288
IS 38
BP 27232
EP 27242
DI 10.1074/jbc.M113.481184
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 302IG
UT WOS:000330597300021
PM 23926105
OA Green Published
DA 2025-01-12
ER

EF